PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Reynolds, AB; Kanner, SB; Bouton, AH; Schaller, MD; Weed, SA; Flynn, DC; Parsons, JT				Reynolds, A. B.; Kanner, S. B.; Bouton, A. H.; Schaller, M. D.; Weed, S. A.; Flynn, D. C.; Parsons, J. T.			SRChing for the substrates of Src	ONCOGENE			English	Review						Src; cortactin; p130Cas; FAK; p120-catenin; AFAP1	FOCAL ADHESION KINASE; EPIDERMAL-GROWTH-FACTOR; ACTIN-FILAMENT INTEGRITY; BREAST-CANCER CELLS; CHRONIC MYELOID-LEUKEMIA; RESEARCH-AND-DEVELOPMENT; E-CADHERIN COMPLEXES; ADAPTER PROTEIN CAS; TYROSINE PHOSPHORYLATION; C-SRC	By the mid 1980's, it was clear that the transforming activity of oncogenic Src was linked to the activity of its tyrosine kinase domain and attention turned to identifying substrates, the putative next level of control in the pathway to transformation. Among the first to recognize the potential of phosphotyrosine-specific antibodies, Parsons and colleagues launched a risky shotgun-based approach that led ultimately to the cDNA cloning and functional characterization of many of today's best-known Src substrates (for example, p85-Cortactin, p110-AFAP1, p130Cas, p125FAK and p120-catenin). Two decades and over 6000 citations later, the original goals of the project may be seen as secondary to the enormous impact of these protein substrates in many areas of biology. At the request of the editors, this review is not restricted to the current status of the substrates, but reflects also on the anatomy of the project itself and some of the challenges and decisions encountered along the way.	[Reynolds, A. B.] Vanderbilt Univ, Dept Canc Biol, Nashville, TN 37235 USA; [Kanner, S. B.] Arrowhead Res Corp, Madison, WI USA; [Bouton, A. H.] Univ Virginia, Sch Med, Dept Microbiol, Charlottesville, VA 22908 USA; [Bouton, A. H.] Univ Virginia, Sch Med, Dept Immunol, Charlottesville, VA 22908 USA; [Bouton, A. H.] Univ Virginia, Sch Med, Dept Canc Biol, Charlottesville, VA 22908 USA; [Schaller, M. D.] W Virginia Univ, Sch Med, Dept Biochem, Robert C Byrd Hlth Sci Ctr,HSN 3124, Morgantown, WV USA; [Weed, S. A.] W Virginia Univ, Dept Neurobiol & Anat, Mary Babb Randolph Canc Ctr 1833, Robert C Byrd Hlth Sci Ctr,Sch Med, Morgantown, WV USA; [Flynn, D. C.] Univ Delaware, Coll Hlth Sci, Dept Med Lab Sci, Newark, DE 19716 USA; [Parsons, J. T.] Univ Virginia, Ctr Canc, Dept Microbiol, Charlottesville, VA 22908 USA; [Parsons, J. T.] Univ Virginia, Ctr Canc, Dept Immunol, Charlottesville, VA 22908 USA; [Parsons, J. T.] Univ Virginia, Ctr Canc, Dept Canc Biol, Charlottesville, VA 22908 USA	Vanderbilt University; University of Virginia; University of Virginia; University of Virginia; West Virginia University; West Virginia University; University of Delaware; University of Virginia; University of Virginia; University of Virginia	Flynn, DC (corresponding author), Univ Delaware, Coll Hlth Sci, Newark, DE 19716 USA.	dflynn@udel.edu		Weed, Scott/0000-0001-7033-9999	NIGMS NIH HHS [R01 GM102524] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM102524] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abbott BL, 2012, CLIN THER, V34, P272, DOI 10.1016/j.clinthera.2012.01.009; Ammer AG, 2008, CELL MOTIL CYTOSKEL, V65, P687, DOI 10.1002/cm.20296; Anastasiadis PZ, 2001, CURR OPIN CELL BIOL, V13, P604, DOI 10.1016/S0955-0674(00)00258-1; Anastasiadis PZ, 2000, NAT CELL BIOL, V2, P637, DOI 10.1038/35023588; Artym VV, 2006, CANCER RES, V66, P3034, DOI 10.1158/0008-5472.CAN-05-2177; Avizienyte E, 2002, NAT CELL BIOL, V4, P632, DOI 10.1038/ncb829; Baisden JM, 2001, ONCOGENE, V20, P6435, DOI 10.1038/sj.onc.1204784; Beggs HE, 2003, NEURON, V40, P501, DOI 10.1016/S0896-6273(03)00666-4; Berggren R, 2012, NAT REV DRUG DISCOV, V11, P435, DOI 10.1038/nrd3744; Berwanger B, 2002, CANCER CELL, V2, P377, DOI 10.1016/S1535-6108(02)00179-4; Birukova AA, 2011, EXP CELL RES, V317, P859, DOI 10.1016/j.yexcr.2010.11.011; Boguslavsky S, 2007, P NATL ACAD SCI USA, V104, P10882, DOI 10.1073/pnas.0702731104; Bouton AH, 2001, ONCOGENE, V20, P6448, DOI 10.1038/sj.onc.1204785; Brandt D, 2002, J BIOL CHEM, V277, P20903, DOI 10.1074/jbc.M200946200; Braren R, 2006, J CELL BIOL, V172, P151, DOI 10.1083/jcb.200506184; Brinkman A, 2000, JNCI-J NATL CANCER I, V92, P112, DOI 10.1093/jnci/92.2.112; Bruce-Staskal PJ, 2001, EXP CELL RES, V264, P296, DOI 10.1006/excr.2000.5137; Brunton VG, 2008, CURR OPIN PHARMACOL, V8, P427, DOI 10.1016/j.coph.2008.06.012; Bryce NS, 2005, CURR BIOL, V15, P1276, DOI 10.1016/j.cub.2005.06.043; Burnham MR, 2000, MOL CELL BIOL, V20, P5865, DOI 10.1128/MCB.20.16.5865-5878.2000; Cabodi S, 2006, CANCER RES, V66, P4672, DOI 10.1158/0008-5472.CAN-05-2909; Cabodi S, 2010, NAT REV CANCER, V10, P858, DOI 10.1038/nrc2967; Casamassima A, 1998, J BIOL CHEM, V273, P26149, DOI 10.1074/jbc.273.40.26149; Casamassima A, 1997, J BIOL CHEM, V272, P9363; CHEN HC, 1995, J BIOL CHEM, V270, P16995, DOI 10.1074/jbc.270.28.16995; Cho SY, 2002, J CELL BIOL, V156, P725, DOI 10.1083/jcb.200111032; Cho SY, 2000, J CELL BIOL, V149, P223, DOI 10.1083/jcb.149.1.223; Clark ES, 2007, CANCER RES, V67, P4227, DOI 10.1158/0008-5472.CAN-06-3928; Creedon Helen, 2012, Critical Reviews in Oncogenesis, V17, P145; David E, 2009, NAT REV DRUG DISCOV, V8, P609, DOI 10.1038/nrd2948; Davis MA, 2006, DEV CELL, V10, P21, DOI 10.1016/j.devcel.2005.12.004; Dillon DA, 1998, AM J PATHOL, V152, P75; Dorssers LCJ, 2004, CLIN CANCER RES, V10, P6194, DOI 10.1158/1078-0432.CCR-04-0444; DOWNING JR, 1991, ONCOGENE, V6, P607; Dunn KB, 2010, ANTI-CANCER AGENT ME, V10, P722; Eke I, 2012, J CLIN INVEST, V122, P1529, DOI 10.1172/JCI61350; Ezratty EJ, 2005, NAT CELL BIOL, V7, P581, DOI 10.1038/ncb1262; FLYNN DC, 1995, J BIOL CHEM, V270, P3894, DOI 10.1074/jbc.270.8.3894; FLYNN DC, 1993, MOL CELL BIOL, V13, P7892, DOI 10.1128/MCB.13.12.7892; Forrest AD, 2009, J NEUROSCI RES, V87, P3456, DOI 10.1002/jnr.22022; Frame MC, 2004, J CELL SCI, V117, P989, DOI 10.1242/jcs.01111; Franco SJ, 2004, NAT CELL BIOL, V6, P977, DOI 10.1038/ncb1175; Fromont G, 2007, PROSTATE, V67, P268, DOI 10.1002/pros.20516; FURUTA Y, 1995, ONCOGENE, V11, P1989; Gallick GE, 2012, FUTURE MED CHEM, V4, P107, DOI [10.4155/FMC.11.161, 10.4155/fmc.11.161]; Gatesman A, 2004, MOL CELL BIOL, V24, P7578, DOI 10.1128/MCB.24.17.7578-7597.2004; GLENNEY JR, 1989, J CELL BIOL, V108, P2401, DOI 10.1083/jcb.108.6.2401; GOLDEN A, 1990, J CELL BIOL, V111, P3117, DOI 10.1083/jcb.111.6.3117; GUAN JL, 1991, CELL REGUL, V2, P951, DOI 10.1091/mbc.2.11.951; Guappone AC, 1998, MOL CARCINOGEN, V22, P110, DOI 10.1002/(SICI)1098-2744(199806)22:2<110::AID-MC6>3.0.CO;2-Q; Guappone AC, 1997, MOL CELL BIOCHEM, V175, P243, DOI 10.1023/A:1006840104666; Guerrero Michael S, 2012, Genes Cancer, V3, P371, DOI 10.1177/1947601912458585; Hakim ZS, 2007, MOL CELL BIOL, V27, P5352, DOI 10.1128/MCB.00068-07; Han EKH, 2007, ANTI-CANCER AGENT ME, V7, P681, DOI 10.2174/187152007784111296; Hantschel O, 2012, CANCER RES, V72, P4890, DOI 10.1158/0008-5472.CAN-12-1276; Harte MT, 2000, BBA-MOL CELL RES, V1499, P34, DOI 10.1016/S0167-4889(00)00104-X; Harte MT, 1996, J BIOL CHEM, V271, P13649, DOI 10.1074/jbc.271.23.13649; Hauck CR, 2001, CANCER RES, V61, P7079; HILDEBRAND JD, 1995, MOL BIOL CELL, V6, P637, DOI 10.1091/mbc.6.6.637; Hildebrand JD, 1996, MOL CELL BIOL, V16, P3169; Honda H, 1999, BIOCHEM BIOPH RES CO, V262, P25, DOI 10.1006/bbrc.1999.1162; Hopkins AL, 2008, NAT CHEM BIOL, V4, P682, DOI 10.1038/nchembio.118; Huang W, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036124; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; ILLC D, 1995, NATURE, V377, P539; Iwanicki MP, 2008, J CELL SCI, V121, P895, DOI 10.1242/jcs.020941; KAMPS MP, 1988, ONCOGENE, V2, P305; KANNER SB, 1991, EMBO J, V10, P1689, DOI 10.1002/j.1460-2075.1991.tb07693.x; KANNER SB, 1989, J IMMUNOL METHODS, V120, P115, DOI 10.1016/0022-1759(89)90296-2; KANNER SB, 1991, MOL CELL BIOL, V11, P713, DOI 10.1128/MCB.11.2.713; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; Khan SH, 2011, J BIOMOL STRUCT DYN, V28, P929, DOI 10.1080/07391102.2011.10508619; Kim W, 2004, J BIOL CHEM, V279, P8333, DOI 10.1074/jbc.M312026200; Kirkbride KC, 2011, CELL ADHES MIGR, V5, P187, DOI 10.4161/cam.5.2.14773; Klein EA, 2009, CURR BIOL, V19, P1511, DOI 10.1016/j.cub.2009.07.069; Klemke RL, 1998, J CELL BIOL, V140, P961, DOI 10.1083/jcb.140.4.961; Kopetz S, 2007, CLIN CANCER RES, V13, P7232, DOI 10.1158/1078-0432.CCR-07-1902; KORNBERG LJ, 1991, P NATL ACAD SCI USA, V88, P8392, DOI 10.1073/pnas.88.19.8392; Kowalski JR, 2005, J CELL SCI, V118, P79, DOI 10.1242/jcs.01586; Kurley SJ, 2012, DEVELOPMENT, V139, P1754, DOI 10.1242/dev.072769; Lawson C, 2012, J CELL BIOL, V196, P223, DOI 10.1083/jcb.201108078; Lim Y, 2008, J CELL BIOL, V180, P187, DOI 10.1083/jcb.200708194; Linder S, 2011, ANNU REV CELL DEV BI, V27, P185, DOI 10.1146/annurev-cellbio-092910-154216; Ling K, 2002, NATURE, V420, P89, DOI 10.1038/nature01082; Ma WW, 2011, ANTI-CANCER AGENT ME, V11, P638; Magalhaes MAO, 2011, J CELL BIOL, V195, P903, DOI 10.1083/jcb.201103045; Manley PW, 2010, BBA-PROTEINS PROTEOM, V1804, P445, DOI 10.1016/j.bbapap.2009.11.008; Martinez-Quiles N, 2004, MOL CELL BIOL, V24, P5269, DOI 10.1128/MCB.24.12.5269-5280.2004; Meenderink LM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013412; Midwood KS, 2002, MOL BIOL CELL, V13, P3601, DOI 10.1091/mbc.E02-05-0292; Miyashita Y, 2007, J BIOL CHEM, V282, P11540, DOI 10.1074/jbc.M608351200; Murphy DA, 2011, NAT REV MOL CELL BIO, V12, P413, DOI 10.1038/nrm3141; Nagy T, 2007, J BIOL CHEM, V282, P31766, DOI 10.1074/jbc.M705403200; Nakamoto T, 1997, MOL CELL BIOL, V17, P3884, DOI 10.1128/MCB.17.7.3884; Nakamoto T, 1996, J BIOL CHEM, V271, P8959, DOI 10.1074/jbc.271.15.8959; Nayal A, 2004, CURR OPIN CELL BIOL, V16, P94, DOI 10.1016/j.ceb.2003.11.007; Nick AM, 2011, JNCI-J NATL CANCER I, V103, P1596, DOI 10.1093/jnci/djr372; NOJIMA Y, 1995, J BIOL CHEM, V270, P15398, DOI 10.1074/jbc.270.25.15398; Oser M, 2010, J CELL SCI, V123, P3662, DOI 10.1242/jcs.068163; Oser M, 2009, J CELL BIOL, V186, P571, DOI 10.1083/jcb.200812176; Owen KA, 2007, J CELL BIOL, V179, P1275, DOI 10.1083/jcb.200708093; Pan YR, 2011, J CELL BIOL, V195, P113, DOI 10.1083/jcb.201103016; Parekh A, 2009, CELL ADHES MIGR, V3, P288, DOI 10.4161/cam.3.3.8888; Parsons JT, 2003, J CELL SCI, V116, P1409, DOI 10.1242/jcs.00373; Parsons SJ, 2004, ONCOGENE, V23, P7906, DOI 10.1038/sj.onc.1208160; Paul SM, 2010, NAT REV DRUG DISCOV, V9, P203, DOI 10.1038/nrd3078; PAWSON T, 1981, J VIROL, V40, P665, DOI 10.1128/JVI.40.3.665-672.1981; PEIFER M, 1994, CELL, V76, P789, DOI 10.1016/0092-8674(94)90353-0; Pellicena P, 1998, J BIOL CHEM, V273, P15325, DOI 10.1074/jbc.273.25.15325; Pellicena P, 2001, J BIOL CHEM, V276, P28190, DOI 10.1074/jbc.M100055200; Perez-Moreno M, 2006, CELL, V124, P631, DOI 10.1016/j.cell.2005.11.043; Playford MP, 2008, EXP CELL RES, V314, P3187, DOI 10.1016/j.yexcr.2008.08.010; Ponik SM, 2013, MOL BIOL CELL, V24, P1688, DOI 10.1091/mbc.E12-05-0386; Provenzano PP, 2009, ONCOGENE, V28, P4326, DOI 10.1038/onc.2009.299; Qian Y, 2004, J CELL BIOCHEM, V91, P602, DOI 10.1002/jcb.10725; Qian Y, 2000, EXP CELL RES, V255, P102, DOI 10.1006/excr.1999.4795; Quintas-Cardama A, 2012, DRUG TODAY, V48, P177, DOI 10.1358/dot.2012.48.3.1750274; Radi M, 2013, CURR PHARM BIOTECHNO, V14, P477, DOI 10.2174/138920101405131111103750; Ren XD, 2000, J CELL SCI, V113, P3673; Ren XR, 2001, J CELL BIOL, V152, P971, DOI 10.1083/jcb.152.5.971; Reynolds AB, 2004, ONCOGENE, V23, P7947, DOI 10.1038/sj.onc.1208161; REYNOLDS AB, 1987, EMBO J, V6, P2359, DOI 10.1002/j.1460-2075.1987.tb02512.x; REYNOLDS AB, 1989, MOL CELL BIOL, V9, P629, DOI 10.1128/MCB.9.2.629; REYNOLDS AB, 1994, MOL CELL BIOL, V14, P8333, DOI 10.1128/MCB.14.12.8333; REYNOLDS AB, 1992, ONCOGENE, V7, P2439; Reynolds AB, 2007, BBA-MOL CELL RES, V1773, P2, DOI 10.1016/j.bbamcr.2006.09.019; Rico B, 2004, NAT NEUROSCI, V7, P1059, DOI 10.1038/nn1317; Riggins RB, 2003, J BIOL CHEM, V278, P28264, DOI 10.1074/jbc.M303535200; Riggins RB, 2006, CANCER RES, V66, P7007, DOI 10.1158/0008-5472.CAN-05-3952; Rodrigo JP, 2009, J PATHOL, V217, P516, DOI 10.1002/path.2462; Rodrigo JP, 2000, CLIN CANCER RES, V6, P3177; Rodrigo JP, 2011, CANCER PREV RES, V4, P1333, DOI 10.1158/1940-6207.CAPR-10-0338; Rodriguez FJ, 2012, BBA-REV CANCER, V1826, P23, DOI 10.1016/j.bbcan.2012.03.002; Rothsschild BL, 2006, CANCER RES, V66, P8017, DOI 10.1158/0008-5472.CAN-05-4490; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; Sato K, 2011, MOL BIOL CELL, V22, P3103, DOI 10.1091/mbc.E11-03-0274; Sawada Y, 2006, CELL, V127, P1015, DOI 10.1016/j.cell.2006.09.044; SCHALLER MD, 1993, PROG NUCLEIC ACID RE, V44, P205, DOI 10.1016/S0079-6603(08)60221-4; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; Schaller MD, 2010, J CELL SCI, V123, P1007, DOI 10.1242/jcs.045112; Schnoor M, 2011, J EXP MED, V208, P1721, DOI 10.1084/jem.20101920; Schuh NR, 2010, J BIOL CHEM, V285, P2309, DOI 10.1074/jbc.M109.046631; Schultze A, 2011, ANTI-CANCER AGENT ME, V11, P593, DOI 10.2174/187152011796817727; SCHUURING E, 1992, ONCOGENE, V7, P355; Schwock J, 2010, EXPERT OPIN THER TAR, V14, P77, DOI 10.1517/14728220903460340; Shen TL, 2005, J CELL BIOL, V169, P941, DOI 10.1083/jcb.200411155; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; Smalley-Freed WG, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019880; Smalley-Freed WG, 2010, J CLIN INVEST, V120, P1824, DOI 10.1172/JCI41414; Smith AL, 2012, MOL BIOL CELL, V23, P99, DOI 10.1091/mbc.E11-06-0497; Snyder BN, 2011, EUR J CELL BIOL, V90, P376, DOI 10.1016/j.ejcb.2010.11.016; Stairs DB, 2011, CANCER CELL, V19, P470, DOI 10.1016/j.ccr.2011.02.007; Summy JM, 2000, ONCOGENE, V19, P155, DOI 10.1038/sj.onc.1203265; Ta HQ, 2008, CANCER RES, V68, P8796, DOI 10.1158/0008-5472.CAN-08-2426; Tehrani S, 2007, P NATL ACAD SCI USA, V104, P11933, DOI 10.1073/pnas.0701077104; Thoreson MA, 2002, DIFFERENTIATION, V70, P583, DOI 10.1046/j.1432-0436.2002.700911.x; Thoreson MA, 2000, J CELL BIOL, V148, P189, DOI 10.1083/jcb.148.1.189; Tikhmyanova N, 2010, CELL MOL LIFE SCI, V67, P1025, DOI 10.1007/s00018-009-0213-1; Tilghman RW, 2008, SEMIN CANCER BIOL, V18, P45, DOI 10.1016/j.semcancer.2007.08.002; Timpson P, 2007, CANCER RES, V67, P9304, DOI 10.1158/0008-5472.CAN-07-0798; Tomar A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044041; Tomar A, 2009, CURR OPIN CELL BIOL, V21, P676, DOI 10.1016/j.ceb.2009.05.006; Tomar A, 2009, J CELL SCI, V122, P1852, DOI 10.1242/jcs.046870; Uruno T, 2001, NAT CELL BIOL, V3, P259, DOI 10.1038/35060051; Vallejo-Illarramendi A, 2009, J CLIN INVEST, V119, P2218, DOI 10.1172/JCI38194; van der Flier S, 2000, JNCI-J NATL CANCER I, V92, P120, DOI 10.1093/jnci/92.2.120; Vogt PK, 2012, NAT REV CANCER, V12, P639, DOI 10.1038/nrc3320; Walker VG, 2007, AM J PHYSIOL-CELL PH, V293, pC119, DOI 10.1152/ajpcell.00525.2006; Wang Y, 2012, J CELL BIOL, V196, P375, DOI 10.1083/jcb.201105153; Wang Y, 2011, MOL BIOL CELL, V22, P1529, DOI 10.1091/mbc.E10-09-0785; Weaver AM, 2002, CURR BIOL, V12, P1270, DOI 10.1016/S0960-9822(02)01035-7; Weaver AM, 2001, CURR BIOL, V11, P370, DOI 10.1016/S0960-9822(01)00098-7; Webb DJ, 2004, NAT CELL BIOL, V6, P154, DOI 10.1038/ncb1094; Weed SA, 2000, J CELL BIOL, V151, P29, DOI 10.1083/jcb.151.1.29; Wei L, 2004, J CELL BIOCHEM, V91, P325, DOI 10.1002/jcb.10760; Wells JA, 2007, NATURE, V450, P1001, DOI 10.1038/nature06526; Wildenberg GA, 2006, CELL, V127, P1027, DOI 10.1016/j.cell.2006.09.046; Wilkerson PM, 2013, GENE CHROMOSOME CANC, V52, P333, DOI 10.1002/gcc.22037; Williams JC, 1997, J MOL BIOL, V274, P757, DOI 10.1006/jmbi.1997.1426; WITTE ON, 1980, NATURE, V283, P826, DOI 10.1038/283826a0; WU H, 1991, MOL CELL BIOL, V11, P5113, DOI 10.1128/MCB.11.10.5113; WU H, 1993, J CELL BIOL, V120, P1417, DOI 10.1083/jcb.120.6.1417; Wu XY, 2005, DEV CELL, V9, P185, DOI 10.1016/j.devcel.2005.06.006; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; Yamakita Y, 1999, J CELL BIOL, V144, P315, DOI 10.1083/jcb.144.2.315; Yano H, 2004, J CELL BIOL, V166, P283, DOI 10.1083/jcb.200312013; Yu D, 2010, EXP CELL RES, V316, P848, DOI 10.1016/j.yexcr.2009.11.018; ZHAN X, 1993, J BIOL CHEM, V268, P9611; Zhang J, 2007, J CLIN INVEST, V117, P2962, DOI 10.1172/JCI30710; Zhao X, 2011, ADV DRUG DELIVER REV, V63, P610, DOI 10.1016/j.addr.2010.11.001	191	32	33	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 11	2014	33	37					4537	4547		10.1038/onc.2013.416	http://dx.doi.org/10.1038/onc.2013.416			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AP3UZ	24121272				2022-12-17	WOS:000342004800001
J	Fiore, LS; Ganguly, SS; Sledziona, J; Cibull, ML; Wang, C; Richards, DL; Neltner, JM; Beach, C; McCorkle, JR; Kaetzel, DM; Plattner, R				Fiore, L. S.; Ganguly, S. S.; Sledziona, J.; Cibull, M. L.; Wang, C.; Richards, D. L.; Neltner, J. M.; Beach, C.; McCorkle, J. R.; Kaetzel, D. M.; Plattner, R.			c-Abl and Arg induce cathepsin-mediated lysosomal degradation of the NM23-H1 metastasis suppressor in invasive cancer	ONCOGENE			English	Article						metastasis suppressor; c-Abl; Arg; NM23-H1; cathepsin	MESSENGER-RNA EXPRESSION; TUMOR-CELL MOTILITY; BREAST-CANCER; CYSTEINE CATHEPSINS; ADHERENS JUNCTIONS; TYROSINE KINASES; GENE-EXPRESSION; MELANOMA-CELLS; GROWTH; ENDOCYTOSIS	Metastasis suppressors comprise a growing class of genes whose downregulation triggers metastatic progression. In contrast to tumor suppressors, metastasis suppressors are rarely mutated or deleted, and little is known regarding the mechanisms by which their expression is downregulated. Here, we demonstrate that the metastasis suppressor, NM23-H1, is degraded by lysosomal cysteine cathepsins (L,B), which directly cleave NM23-H1. In addition, activation of c-Abl and Arg oncoproteins induces NM23-H1 degradation in invasive cancer cells by increasing cysteine cathepsin transcription and activation. Moreover, c-Abl activates cathepsins by promoting endosome maturation, which facilitates trafficking of NM23-H1 to the lysosome where it is degraded. Importantly, the invasion- and metastasis-promoting activity of c-Abl/Arg is dependent on their ability to induce NM23-H1 degradation, and the pathway is clinically relevant as c-Abl/Arg activity and NM23-H1 expression are inversely correlated in primary breast cancers and melanomas. Thus, we demonstrate a novel mechanism by which cathepsin expression is upregulated in cancer cells (via Abl kinases). We also identify a novel role for intracellular cathepsins in invasion and metastasis (degradation of a metastasis suppressor). Finally, we identify novel crosstalk between oncogenic and metastasis suppressor pathways, thereby providing mechanistic insight into the process of NM23-H1 loss, which may pave the way for new strategies to restore NM23-H1 expression and block metastatic progression.	[Fiore, L. S.; Ganguly, S. S.; Sledziona, J.; McCorkle, J. R.; Plattner, R.] Univ Kentucky, Sch Med, Dept Mol & Biomed Pharmacol, Lexington, KY 40536 USA; [Cibull, M. L.; Richards, D. L.; Neltner, J. M.] Univ Kentucky, Sch Med, Dept Pathol, Lexington, KY 40536 USA; [Wang, C.] Univ Kentucky, Sch Med, Dept Biostat, Lexington, KY 40536 USA; [Wang, C.] Univ Kentucky, Sch Med, Markey Canc Ctr, Lexington, KY 40536 USA; [Beach, C.] Univ Kentucky, Sch Med, Dept Biochem, Lexington, KY 40536 USA; [Kaetzel, D. M.] Univ Maryland, Sch Med, Dept Mol & Cellular Biol, Baltimore, MD 21201 USA	University of Kentucky; University of Kentucky; University of Kentucky; University of Kentucky; University of Kentucky; University System of Maryland; University of Maryland Baltimore	Plattner, R (corresponding author), Univ Kentucky, Sch Med, Dept Mol & Biomed Pharmacol, Combs Res Bldg,Room 209,800 Rose St, Lexington, KY 40536 USA.	rplat2@uky.edu	McCorkle, Rob/AAH-3759-2019	McCorkle, Rob/0000-0002-5028-8853	NIH/NCI/R01 [CA116784, CA166499]; NIH/NCI; Office of the Vice President for Research; NATIONAL CANCER INSTITUTE [R01CA116784, R01CA159871, R01CA166499, P30CA177558] Funding Source: NIH RePORTER	NIH/NCI/R01(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Office of the Vice President for Research; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank the following individuals for their assistance. Garretson Epperly and James Begley (confocal), Spear/Peterson Labs (qPCR), Jonathan Sims and Divya Srinivasan (cell lysates), Vivek Rangnekar, Suzanne Ridges, Aditi Jain (manuscript review) and Woodrow Friend (Figures 1a and 6d). Mass spectrometry was performed at the University of Kentucky Proteomics Core Facility, which is supported in part by the Office of the Vice President for Research. Edman Degradation was performed at the University of Nebraska Protein Structure Core Facility. This work was supported by NIH/NCI/R01 grants to RP (CA116784, CA166499). Dr Plattner is funded by NIH/NCI. DMK also is funded by NIH/NCI, but this work was not supported by his grants.	Allington TM, 2011, CELLS TISSUES ORGANS, V193, P98, DOI 10.1159/000320163; Allington TM, 2009, FASEB J, V23, P4231, DOI 10.1096/fj.09-138412; Annesley SJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026024; Authier F, 1999, J BIOL CHEM, V274, P33723, DOI 10.1074/jbc.274.47.33723; Balaji K, 2012, J CELL SCI, V125, P5887, DOI 10.1242/jcs.113688; Balint K, 2005, J CLIN INVEST, V115, P3166, DOI 10.1172/JCI25001; Barila D, 1998, NAT GENET, V18, P280, DOI 10.1038/ng0398-280; Bauer B, 2009, CELL MICROBIOL, V11, P156, DOI 10.1111/j.1462-5822.2008.01246.x; Boissan M, 2010, CANCER RES, V70, P7710, DOI 10.1158/0008-5472.CAN-10-1887; Chambers AF, 2009, CANCER RES, V69, P5292, DOI 10.1158/0008-5472.CAN-09-1528; Curtis CD, 2007, CANCER RES, V67, P10600, DOI 10.1158/0008-5472.CAN-07-0055; De Braekeleer E, 2011, EUR J HAEMATOL, V86, P361, DOI 10.1111/j.1600-0609.2011.01586.x; De Wever O, 2010, INT J DEV BIOL, V54, P887, DOI 10.1387/ijdb.092948ow; Easty DJ, 1996, BRIT J CANCER, V74, P109, DOI 10.1038/bjc.1996.323; ENGEL M, 1993, INT J CANCER, V55, P375, DOI 10.1002/ijc.2910550306; Fenyo David, 2007, J Vis Exp, P192, DOI 10.3791/192; Ganguly SS, 2012, ONCOGENE, V31, P1804, DOI 10.1038/onc.2011.361; Ganguly Sourik S, 2012, Genes Cancer, V3, P414, DOI 10.1177/1947601912458586; GOODALL RJ, 1994, PATHOLOGY, V26, P423, DOI 10.1080/00313029400169122; Horak CE, 2008, APMIS, V116, P586, DOI 10.1111/j.1600-0463.2008.01213.x; Horak CE, 2007, CANCER RES, V67, P7238, DOI 10.1158/0008-5472.CAN-07-0962; Hsu T, 2006, J BIOL CHEM, V281, P12069, DOI 10.1074/jbc.M511621200; Huang SY, 2000, CYTOKINES CELL MOL T, V6, P9, DOI 10.1080/13684730050515868; Huotari J, 2011, EMBO J, V30, P3481, DOI 10.1038/emboj.2011.286; Hwang Byung-Gap, 1997, Journal of Korean Medical Science, V12, P514; IIZUKA N, 1995, CANCER RES, V55, P652; Jacob F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059180; Jacob M, 2009, CELL SIGNAL, V21, P1308, DOI 10.1016/j.cellsig.2009.03.016; Krishnan KS, 2001, NEURON, V30, P197, DOI 10.1016/S0896-6273(01)00273-2; Lin LI, 1998, ANTICANCER RES, V18, P541; Lorenzi PL, 2009, MOL CANCER THER, V8, P713, DOI 10.1158/1535-7163.MCT-08-0921; Ma D, 1996, INVEST OPHTH VIS SCI, V37, P2293; Ma DQ, 2004, J BIOL CHEM, V279, P18073, DOI 10.1074/jbc.M400185200; Marshall JC, 2010, EUR J CANCER, V46, P1278, DOI 10.1016/j.ejca.2010.02.042; McDermott WG, 2008, CLIN EXP METASTAS, V25, P131, DOI 10.1007/s10585-007-9128-0; Mesaki K, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019764; MYEROFF LL, 1993, J NATL CANCER I, V85, P147, DOI 10.1093/jnci/85.2.147; Novak M, 2011, N-S ARCH PHARMACOL, V384, P433, DOI 10.1007/s00210-011-0621-2; Palacios F, 2002, NAT CELL BIOL, V4, P929, DOI 10.1038/ncb881; Platta HW, 2011, CURR OPIN CELL BIOL, V23, P393, DOI 10.1016/j.ceb.2011.03.008; Plattner R, 1999, GENE DEV, V13, P2400, DOI 10.1101/gad.13.18.2400; Press B, 1998, J CELL BIOL, V140, P1075, DOI 10.1083/jcb.140.5.1075; Radonic A, 2004, BIOCHEM BIOPH RES CO, V313, P856, DOI 10.1016/j.bbrc.2003.11.177; Rae JM, 2007, BREAST CANCER RES TR, V104, P13, DOI 10.1007/s10549-006-9392-8; Reiser J, 2010, J CLIN INVEST, V120, P3421, DOI 10.1172/JCI42918; Rosenfeld JL, 2001, J CELL SCI, V114, P4499; Rotty JD, 2013, NAT REV MOL CELL BIO, V14, P7, DOI 10.1038/nrm3492; Saha A, 2011, FEBS LETT, V585, P3174, DOI 10.1016/j.febslet.2011.08.007; Sgouros J, 2007, IN VIVO, V21, P519; Sims JT, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055509; Smith SC, 2009, NAT REV CANCER, V9, P253, DOI 10.1038/nrc2594; Sossey-Alaoui K, 2007, J BIOL CHEM, V282, P26257, DOI 10.1074/jbc.M701484200; Srinivasan D, 2008, ONCOGENE, V27, P1095, DOI 10.1038/sj.onc.1210714; Srinivasan D, 2006, CANCER RES, V66, P5648, DOI 10.1158/0008-5472.CAN-06-0734; Srinivasan D, 2009, CELL SIGNAL, V21, P1143, DOI 10.1016/j.cellsig.2009.03.003; Steeg PS, 2008, CLIN CANCER RES, V14, P5006, DOI 10.1158/1078-0432.CCR-08-0238; Taha TA, 2006, FEBS LETT, V580, P6047, DOI 10.1016/j.febslet.2006.09.070; Tanos B, 2006, J BIOL CHEM, V281, P32714, DOI 10.1074/jbc.M603126200; Turk V, 2012, BBA-PROTEINS PROTEOM, V1824, P68, DOI 10.1016/j.bbapap.2011.10.002; Wetzel DM, 2012, MOL CELL BIOL, V32, P3176, DOI 10.1128/MCB.00086-12; Woolworth JA, 2009, MOL CELL BIOL, V29, P4679, DOI 10.1128/MCB.00297-09; Wright PK, 2008, RECENT PAT ANTI-CANC, V3, P137, DOI 10.2174/157489208784638730; Xiong WJ, 2013, DEVELOPMENT, V140, P176, DOI 10.1242/dev.088799; Yogalingam G, 2008, J BIOL CHEM, V283, P35941, DOI 10.1074/jbc.M804543200	65	32	34	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 4	2014	33	36					4508	4520		10.1038/onc.2013.399	http://dx.doi.org/10.1038/onc.2013.399			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AO2MY	24096484	Green Accepted			2022-12-17	WOS:000341158800006
J	Cowling, VH; Turner, SA; Cole, MD				Cowling, V. H.; Turner, S. A.; Cole, M. D.			Burkitt's lymphoma-associated c-Myc mutations converge on a dramatically altered target gene response and implicate Nol5a/Nop56 in oncogenesis	ONCOGENE			English	Article						Myc; lymphoma; mutations; Burkitt's; transcription	N-TERMINAL DOMAIN; RNA-POLYMERASE-I; TRANSACTIVATION DOMAIN; RIBOSOME BIOGENESIS; PROTEIN-SYNTHESIS; CODING REGION; DNA-BINDING; PHOSPHORYLATION; TRANSCRIPTION; EXPRESSION	Burkitt's lymphomas (BLs) acquire consistent point mutations in a conserved domain of Myc, Myc Box I. We report that the enhanced transforming activity of BL-associated Myc mutants can be uncoupled from loss of phosphorylation and increased protein stability. Furthermore, two different BL-associated Myc mutations induced similar gene expression profiles independently of T58 phosphorylation, and these profiles are dramatically different from MycWT. Nol5a/Nop56, which is required for ribosomal RNA methylation, was identified as a gene hyperactivated by the BL-associated Myc mutants. We show that Nol5a is necessary for Myc-induced cell transformation, enhances MycWT-induced cell transformation and increases the size of MycWT-induced tumors. Thus, Nol5a expands the link between Myc-induced regulation of nucleolar target genes, which are rate limiting for cell transformation and tumor growth.	[Cowling, V. H.; Cole, M. D.] Geisel Sch Med Dartmouth, Norris Cotton Canc Ctr, Dept Pharmacol, Lebanon, NH 03756 USA; [Turner, S. A.; Cole, M. D.] Geisel Sch Med Dartmouth, Norris Cotton Canc Ctr, Dept Genet, Lebanon, NH 03756 USA	Dartmouth College; Norris Cotton Cancer Center; Dartmouth College; Norris Cotton Cancer Center	Cole, MD (corresponding author), Geisel Sch Med Dartmouth, Norris Cotton Canc Ctr, Dept Pharmacol, One Med Ctr Dr,Rubin 633, Lebanon, NH 03756 USA.	Michael.D.Cole@dartmouth.edu		Cowling, Victoria/0000-0001-7638-4870	National Cancer Institute [CA055248]; National Institute of General Medical Sciences [T32GM008704]; NATIONAL CANCER INSTITUTE [R01CA080320, R01CA055248, P30CA023108] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008704] Funding Source: NIH RePORTER; MRC [MR/K024213/1, G0700240] Funding Source: UKRI; Medical Research Council [MR/K024213/1, G0700240] Funding Source: researchfish	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Institute of General Medical Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	We thank Steve Hann and Chi Dang for providing cell lines. This project was supported by a grant from the National Cancer Institute (CA055248; MDC) and by Award Number T32GM008704 from the National Institute of General Medical Sciences (SAT). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of General Medical Sciences or the National Institutes of Health.	Adhikary S, 2005, NAT REV MOL CELL BIO, V6, P635, DOI 10.1038/nrm1703; Alawi F, 2007, BIOCHEM BIOPH RES CO, V362, P893, DOI 10.1016/j.bbrc.2007.08.071; ALBERT T, 1994, ONCOGENE, V9, P759; Arabi A, 2005, NAT CELL BIOL, V7, P303, DOI 10.1038/ncb1225; Barna M, 2008, NATURE, V456, P971, DOI 10.1038/nature07449; Benassi B, 2006, MOL CELL, V21, P509, DOI 10.1016/j.molcel.2006.01.009; BHATIA K, 1994, BLOOD, V84, P883; BHATIA K, 1993, NAT GENET, V5, P56, DOI 10.1038/ng0993-56; Bogomolnaya LM, 2004, CURR GENET, V45, P350, DOI 10.1007/s00294-004-0497-5; Boisvert FM, 2007, NAT REV MOL CELL BIO, V8, P574, DOI 10.1038/nrm2184; Boon K, 2001, EMBO J, V20, P1383, DOI 10.1093/emboj/20.6.1383; BRENNSCHEIDT U, 1994, LEUKEMIA, V8, P897; Brown SJ, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-442; Chang DW, 2000, MOL CELL BIOL, V20, P4309, DOI 10.1128/MCB.20.12.4309-4319.2000; CLARK HM, 1994, CANCER RES, V54, P3383; Cowling VH, 2007, MOL CELL BIOL, V27, P2059, DOI 10.1128/MCB.01828-06; Cowling VH, 2006, MOL CELL BIOL, V26, P4226, DOI 10.1128/MCB.01959-05; Dang CV, 2006, SEMIN CANCER BIOL, V16, P253, DOI 10.1016/j.semcancer.2006.07.014; Dave SS, 2006, NEW ENGL J MED, V354, P2431, DOI 10.1056/NEJMoa055759; Fernandez PC, 2003, GENE DEV, V17, P1115, DOI 10.1101/gad.1067003; Gautier T, 1997, MOL CELL BIOL, V17, P7088, DOI 10.1128/MCB.17.12.7088; Gomez-Roman N, 2003, NATURE, V421, P290, DOI 10.1038/nature01327; Goy A, 2006, CANCER CYTOPATHOL, V108, P10, DOI 10.1002/cncr.21500; Grandori C, 2005, NAT CELL BIOL, V7, P311, DOI 10.1038/ncb1224; Grewal SS, 2005, NAT CELL BIOL, V7, P295, DOI 10.1038/ncb1223; Grisendi S, 2006, NAT REV CANCER, V6, P493, DOI 10.1038/nrc1885; Hann SR, 2006, SEMIN CANCER BIOL, V16, P288, DOI 10.1016/j.semcancer.2006.08.004; Hayano T, 2003, J BIOL CHEM, V278, P34309, DOI 10.1074/jbc.M304304200; Hemann MT, 2005, NATURE, V436, P807, DOI 10.1038/nature03845; HENRIKSSON M, 1993, ONCOGENE, V8, P3199; HOANG AT, 1995, MOL CELL BIOL, V15, P4031; JOHNSTON JM, 1991, BLOOD, V78, P2419; Kim S, 2000, P NATL ACAD SCI USA, V97, P11198, DOI 10.1073/pnas.200372597; Li Z, 2013, ONCOGENE, V32, P1988, DOI 10.1038/onc.2012.227; Lin CY, 2012, CELL, V151, P56, DOI 10.1016/j.cell.2012.08.026; Machida YJ, 2006, MOL BIOL CELL, V17, P4837, DOI 10.1091/mbc.E06-04-0340; Mateyak MK, 1997, CELL GROWTH DIFFER, V8, P1039; McMahon SB, 2000, MOL CELL BIOL, V20, P556, DOI 10.1128/MCB.20.2.556-562.2000; Menssen A, 2002, P NATL ACAD SCI USA, V99, P6274, DOI 10.1073/pnas.082005599; Meyer N, 2008, NAT REV CANCER, V8, P976, DOI 10.1038/nrc2231; Newman DR, 2000, RNA, V6, P861, DOI 10.1017/S1355838200992446; Nie ZQ, 2012, CELL, V151, P68, DOI 10.1016/j.cell.2012.08.033; Pandolfi PP, 2004, ONCOGENE, V23, P3134, DOI 10.1038/sj.onc.1207618; Perna D, 2012, ONCOGENE, V31, P1695, DOI 10.1038/onc.2011.359; PULVERER BJ, 1994, ONCOGENE, V9, P59; Ruggero D, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2003477; Schlosser I, 2003, NUCLEIC ACIDS RES, V31, P6148, DOI 10.1093/nar/gkg794; Sears R, 2000, GENE DEV, V14, P2501, DOI 10.1101/gad.836800; Sears RC, 2004, CELL CYCLE, V3, P1133, DOI 10.4161/cc.3.9.1145; Shaffer AL, 2006, IMMUNOL REV, V210, P67, DOI 10.1111/j.0105-2896.2006.00373.x; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Vallat LD, 2007, BLOOD, V109, P3989, DOI 10.1182/blood-2006-09-045377; van Riggelen J, 2010, NAT REV CANCER, V10, P301, DOI 10.1038/nrc2819; Wang XY, 2011, CANCER RES, V71, P925, DOI 10.1158/0008-5472.CAN-10-1032; Warner JR, 2009, MOL CELL, V34, P3, DOI 10.1016/j.molcel.2009.03.006; Watnick RS, 2003, CANCER CELL, V3, P219, DOI 10.1016/S1535-6108(03)00030-8; Watson JD, 2002, J BIOL CHEM, V277, P36921, DOI 10.1074/jbc.M201493200; YANO T, 1993, ONCOGENE, V8, P2741; Yeh E, 2004, NAT CELL BIOL, V6, P308, DOI 10.1038/ncb1110; Yustein JT, 2007, CURR OPIN HEMATOL, V14, P375, DOI 10.1097/MOH.0b013e3281bccdee	60	32	34	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 3	2014	33	27					3519	3527		10.1038/onc.2013.338	http://dx.doi.org/10.1038/onc.2013.338			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AL2FK	24013231	Green Accepted			2022-12-17	WOS:000338941100004
J	Novitskaya, V; Romanska, H; Kordek, R; Potemski, P; Kusinska, R; Parsons, M; Odintsova, E; Berditchevski, F				Novitskaya, V.; Romanska, H.; Kordek, R.; Potemski, P.; Kusinska, R.; Parsons, M.; Odintsova, E.; Berditchevski, F.			Integrin alpha 3 beta 1-CD151 complex regulates dimerization of ErbB2 via RhoA	ONCOGENE			English	Article						tetraspanin; integrin; CD151; breast cancer; ErbB2	BREAST-CANCER CELLS; SELF-ASSOCIATION; LIPID RAFTS; ADHESION; GROWTH; ACTIVATION; PROTEINS; BETA-1-INTEGRIN; PROLIFERATION; TRASTUZUMAB	Integrin alpha 3 beta 1 regulates adhesive interactions of cells with laminins and have a critical role in adhesion-dependent cellular responses. Here, we examined the role of alpha 3 beta 1-integrin in ErbB2-dependent proliferation of breast cancer cells in three-dimensional laminin-rich extracellular matrix (3D lr-ECM). Depletion of alpha 3 beta 1 in ErbB2-overexpressing breast cancer cells suppressed growth and restore cell polarity in 3D lr-ECM. The phenotype of alpha 3 beta 1-depleted cells was reproduced upon depletion of tetraspanin CD151 and mirrored that of the cells treated with Herceptin, an established ErbB2 antagonist. Breast cancer cells expressing the alpha 3 beta 1-CD151 complex have higher steady-state phosphorylation of ErbB2 and show enhanced dimerization of the protein when compared with alpha 3 beta 1-/CD151-depleted cells. Furthermore, Herceptin-dependent dephosphorylation of ErbB2 was only observed in alpha 3 beta 1-CD151-expressing cells. Importantly, the inhibitory activity of Herceptin was more pronounced when cells expressed both alpha 3 beta 1 and CD151. We also found that the level of active RhoA was increased in alpha 3 beta 1- and CD151-depleted cells and that Rho controls dimerization of ErbB2. Expression of alpha 3 beta 1 alone did not have significant prognostic value in patients with invasive ductal carcinoma of the breast. However, expression of alpha 3 beta 1 in combination with CD151 represented a more stringent indicator of poor survival than CD151 alone. Taken together, these results demonstrate that the alpha 3 beta 1-CD151 complex has a critical regulatory role in ErbB2-dependent signalling and thereby may be involved in breast cancer progression.	[Novitskaya, V.; Odintsova, E.; Berditchevski, F.] Univ Birmingham, Sch Canc Sci, Birmingham B15 2TT, W Midlands, England; [Romanska, H.; Kordek, R.; Potemski, P.; Kusinska, R.] Med Univ Lodz, Dept Pathol & Chemotherapy, Lodz, Poland; [Parsons, M.] Kings Coll London, Randall Div Cell & Mol Biophys, London, England	University of Birmingham; Medical University Lodz; University of London; King's College London	Odintsova, E (corresponding author), Univ Birmingham, Sch Canc Sci, Birmingham B15 2TT, W Midlands, England.	e.odintsova@bham.ac.uk; f.berditchevski@bham.ac.uk	Kordek, Radzislaw/S-9616-2016; Parsons, Maddy/B-2203-2013; Mieszkowska, Magdalena/O-6753-2017	Parsons, Maddy/0000-0002-2021-8379; Romanska-Knight, Hanna/0000-0002-2328-710X	WE Dunn Trust, CR UK [C1322/A5705]; Royal Society University Research Fellowship; NCN [2011/01/B/NZ4/04910]	WE Dunn Trust, CR UK; Royal Society University Research Fellowship(Royal Society of London); NCN	We are very grateful to all our colleagues for their generous gifts of the reagents that were used in this study. This work was supported by the WE Dunn Trust, CR UK Grant C1322/A5705 (to FB), Royal Society University Research Fellowship (to MP) and NCN Grant No. 2011/01/B/NZ4/04910 (to RK).	Alexi X, 2011, BIOCHEM SOC T, V39, P568, DOI 10.1042/BST0390568; Arteaga CL, 2012, NAT REV CLIN ONCOL, V9, P16, DOI 10.1038/nrclinonc.2011.177; Bailey Tameka A, 2011, J Carcinog, V10, P28, DOI 10.4103/1477-3163.90442; Baldwin G, 2008, J BIOL CHEM, V283, P35445, DOI 10.1074/jbc.M806394200; Banyard J, 2000, ONCOGENE, V19, P580, DOI 10.1038/sj.onc.1203338; Berditchevski F, 1997, J BIOL CHEM, V272, P29174, DOI 10.1074/jbc.272.46.29174; Berry MG, 2004, EJSO, V30, P484, DOI 10.1016/j.ejso.2004.01.016; Chen LL, 2008, CELL COMMUN ADHES, V15, P317, DOI 10.1080/15419060802428356; Dave B, 2011, J CLIN ONCOL, V29, P166, DOI 10.1200/JCO.2009.27.7814; Deng XY, 2012, NEOPLASIA, V14, P678, DOI 10.1593/neo.12922; Duan L, 2010, J BIOL CHEM, V285, P1555, DOI 10.1074/jbc.M109.057976; Falcioni R, 1997, EXP CELL RES, V236, P76, DOI 10.1006/excr.1997.3695; Ghosh R, 2011, CANCER RES, V71, P1871, DOI 10.1158/0008-5472.CAN-10-1872; Giancotti FG, 2007, TRENDS PHARMACOL SCI, V28, P506, DOI 10.1016/j.tips.2007.08.004; Guo WJ, 2006, CELL, V126, P489, DOI 10.1016/j.cell.2006.05.047; Haenssen KK, 2010, J CELL SCI, V123, P1373, DOI 10.1242/jcs.050906; HEMLER ME, 1983, J IMMUNOL, V131, P334; Hong IK, 2012, J BIOL CHEM, V287, P32027, DOI 10.1074/jbc.M111.314443; Hopkins AM, 2003, J CELL SCI, V116, P725, DOI 10.1242/jcs.00300; Huang C, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2936; Huck L, 2010, P NATL ACAD SCI USA, V107, P15559, DOI 10.1073/pnas.1003034107; Hynes NE, 2009, CURR OPIN CELL BIOL, V21, P177, DOI 10.1016/j.ceb.2008.12.010; Itoh RE, 2002, MOL CELL BIOL, V22, P6582, DOI 10.1128/MCB.22.18.6582-6591.2002; Kazarov AR, 2002, J CELL BIOL, V158, P1299, DOI 10.1083/jcb.200204056; Kwon MJ, 2012, BRIT J CANCER, V106, P923, DOI 10.1038/bjc.2012.11; Lemmon MA, 2009, EXP CELL RES, V315, P638, DOI 10.1016/j.yexcr.2008.10.024; Lesniak D, 2009, CANCER RES, V69, P8620, DOI 10.1158/0008-5472.CAN-09-1591; Malaval C, 2009, CELL SIGNAL, V21, P120, DOI 10.1016/j.cellsig.2008.09.016; Morini M, 2000, INT J CANCER, V87, P336, DOI 10.1002/1097-0215(20000801)87:3<336::AID-IJC5>3.0.CO;2-3; Morton PE, 2011, METHODS MOL BIOL, V769, P403, DOI 10.1007/978-1-61779-207-6_27; Muthuswamy SK, 2001, NAT CELL BIOL, V3, P785, DOI 10.1038/ncb0901-785; Nagy P, 2002, J CELL SCI, V115, P4251, DOI 10.1242/jcs.00118; Novitskaya V, 2010, CANCER RES, V70, P4698, DOI 10.1158/0008-5472.CAN-09-4330; Orr G, 2005, BIOPHYS J, V89, P1362, DOI 10.1529/biophysj.104.056192; Park CC, 2006, CANCER RES, V66, P1526, DOI 10.1158/0008-5472.CAN-05-3071; Parsons M, 2008, J CELL SCI, V121, P265, DOI 10.1242/jcs.018440; Penuel E, 2002, J BIOL CHEM, V277, P28468, DOI 10.1074/jbc.M202510200; Prakash A, 2011, BIOPHYS J, V101, P1949, DOI 10.1016/j.bpj.2011.09.017; Ramirez NE, 2011, J CLIN INVEST, V121, P226, DOI 10.1172/JCI42328; Reim F, 2009, CANCER RES, V69, P8058, DOI 10.1158/0008-5472.CAN-09-0834; Sadej R, 2009, MOL CANCER RES, V7, P787, DOI 10.1158/1541-7786.MCR-08-0574; Sahai E, 2001, EMBO J, V20, P755, DOI 10.1093/emboj/20.4.755; Scales TME, 2013, ONCOGENE, V32, P3965, DOI 10.1038/onc.2012.415; Scaltriti M, 2011, P NATL ACAD SCI USA, V108, P3761, DOI 10.1073/pnas.1014835108; Sharpe S, 2002, BIOCHEMISTRY-US, V41, P2341, DOI 10.1021/bi011340f; Sottocornola E, 2006, FEBS J, V273, P1821, DOI 10.1111/j.1742-4658.2006.05203.x; Stipp CS, 2010, EXPERT REV MOL MED, V12, DOI 10.1017/S1462399409001355; Tachibana I, 1997, J BIOL CHEM, V272, P29181, DOI 10.1074/jbc.272.46.29181; Wang SE, 2009, CANCER RES, V69, P475, DOI 10.1158/0008-5472.CAN-08-2649; Weigelt B, 2010, BREAST CANCER RES TR, V122, P35, DOI 10.1007/s10549-009-0502-2; WEITZMAN JB, 1993, J BIOL CHEM, V268, P8651; Wolff AC, 2007, J CLIN ONCOL, V25, P118, DOI 10.1200/JCO.2006.09.2775; Yang XWH, 2010, CANCER RES, V70, P2256, DOI 10.1158/0008-5472.CAN-09-4032; Zhang F, 2011, BLOOD, V118, P4274, DOI 10.1182/blood-2011-03-339531	54	32	32	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 22	2014	33	21					2779	2789		10.1038/onc.2013.231	http://dx.doi.org/10.1038/onc.2013.231			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AI9EH	23792450				2022-12-17	WOS:000337231700011
J	Wu, K; Liu, J; Tseng, SF; Gore, C; Ning, Z; Sharifi, N; Fazli, L; Gleave, M; Kapur, P; Xiao, G; Sun, X; Oz, OK; Min, W; Alexandrakis, G; Yang, CR; Hsieh, CL; Wu, HC; He, D; Xie, D; Hsieh, JT				Wu, K.; Liu, J.; Tseng, S-F; Gore, C.; Ning, Z.; Sharifi, N.; Fazli, L.; Gleave, M.; Kapur, P.; Xiao, G.; Sun, X.; Oz, O. K.; Min, W.; Alexandrakis, G.; Yang, C-R; Hsieh, C-L; Wu, H-C; He, D.; Xie, D.; Hsieh, J-T			The role of DAB2IP in androgen receptor activation during prostate cancer progression	ONCOGENE			English	Article						prostate cancer; DAB2IP; androgen receptor; Src; genomic pathway	ABERRANT PROMOTER METHYLATION; PROTEIN HDAB2IP GENE; SERINE 81 PHOSPHORYLATION; BREAST-CANCER; CELL-GROWTH; SH3 DOMAINS; TRANSCRIPTION; KINASE; TUMOR; LOCALIZATION	Altered androgen-receptor (AR) expression and/ or constitutively active AR are commonly associated with prostate cancer (PCa) progression. Targeting AR remains a focal point for designing new strategy of PCa therapy. Here, we have shown that DAB2IP, a novel tumor suppressor in PCa, can inhibit AR-mediated cell growth and gene activation in PCa cells via distinct mechanisms. DAB2IP inhibits the genomic pathway by preventing AR nuclear translocation or phosphorylation and suppresses the non-genomic pathway via its unique functional domain to inactivate c-Src. Also, DAB2IP is capable of suppressing AR activation in an androgen-independent manner. In addition, DAB2IP can inhibit several AR splice variants showing constitutive activity in PCa cells. In DAB2IP(-/-)mice, the prostate gland exhibits hyperplastic epithelia, in which AR becomes more active. Consistently, DAB2IP expression inversely correlates with AR activation status particularly in recurrent or metastatic PCa patients. Taken together, DAB2IP is a unique intrinsic AR modulator in normal cells, and likely can be further developed into a therapeutic agent for PCa.	[Wu, K.; Gore, C.; Hsieh, J-T] Univ Texas SW Med Ctr Dallas, Dept Urol, Dallas, TX 75390 USA; [Wu, K.; Ning, Z.; He, D.] Xi An Jiao Tong Univ, Affiliated Hosp 1, Sch Med, Dept Urol, Xian, Shaanxi, Peoples R China; [Liu, J.; Sun, X.; Oz, O. K.] Univ Texas SW Med Ctr Dallas, Dept Radiol, Dallas, TX 75390 USA; [Tseng, S-F; Alexandrakis, G.] Univ Texas Arlington, Dept Bioengn, Arlington, TX 76019 USA; [Sharifi, N.] Univ Texas SW Med Ctr Dallas, Dept Internal Med, Div Hematol Oncol, Dallas, TX 75390 USA; [Fazli, L.; Gleave, M.] Univ British Columbia, Vancouver Prostate Ctr, Vancouver, BC, Canada; [Kapur, P.] Univ Texas SW Med Ctr Dallas, Dept Pathol, Dallas, TX 75390 USA; [Xiao, G.] Univ Texas SW Med Ctr Dallas, Dept Clin Sci, Dallas, TX 75390 USA; [Min, W.] Yale Univ, Sch Med, Interdept Program Vasc Biol & Transplant, New Haven, CT USA; [Min, W.] Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06510 USA; [Yang, C-R; Wu, H-C] China Med Univ Hosp, Dept Urol, Taichung, Taiwan; [Hsieh, C-L; Hsieh, J-T] China Med Univ Hosp, Grad Inst Canc Biol, Taichung, Taiwan; [Hsieh, C-L] China Med Univ Hosp, Ctr Mol Med, Taichung, Taiwan; [Hsieh, C-L] Asia Univ, Dept Biotechnol, Taichung, Taiwan; [Wu, H-C] China Med Univ, Sch Med, Taichung, Taiwan; [Xie, D.] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Canc Res Inst, Dept Gen Surg, Wuhan 430074, Hubei, Peoples R China	University of Texas System; University of Texas Southwestern Medical Center Dallas; Xi'an Jiaotong University; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Arlington; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of British Columbia; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas; Yale University; Yale University; China Medical University Taiwan; China Medical University Hospital - Taiwan; China Medical University Taiwan; China Medical University Hospital - Taiwan; China Medical University Taiwan; China Medical University Hospital - Taiwan; Asia University Taiwan; China Medical University Taiwan; Huazhong University of Science & Technology	Hsieh, JT (corresponding author), Univ Texas SW Med Ctr Dallas, Dept Urol, J8-134,5323 Harry Hines Blvd, Dallas, TX 75390 USA.	dxxie@tjh.tjmu.edu.cn; jt.hsieh@utsouthwestern.edu	Oz, Orhan/GVT-7264-2022	Gleave, Martin/0000-0003-4235-0167	United States Army [W81XWH-04-1-0222 (JTH)]; National Natural Science Foundation of China [NSFC 81202014]	United States Army(United States Department of DefenseUnited States Army); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	We thank Dr Jiang Min for editorial assistant and Rui Li for technical support. This work is supported in part by United States Army Grant W81XWH-04-1-0222 (JTH) and the National Natural Science Foundation of China (NSFC 81202014 to KW).	Araujo JC, 2012, CANCER-AM CANCER SOC, V118, P63, DOI 10.1002/cncr.26204; Brooke GN, 2009, CURR GENOMICS, V10, P18, DOI 10.2174/138920209787581307; Cai HJ, 2011, CANCER RES, V71, P862, DOI 10.1158/0008-5472.CAN-10-1605; Cao WH, 2000, J BIOL CHEM, V275, P38131, DOI 10.1074/jbc.C000592200; Chen H, 2005, J BIOL CHEM, V280, P22437, DOI 10.1074/jbc.M501379200; Chen H, 2003, J BIOL CHEM, V278, P3121, DOI 10.1074/jbc.M208230200; Chen SY, 2012, J BIOL CHEM, V287, P8571, DOI 10.1074/jbc.M111.325290; Craft N, 1999, NAT MED, V5, P280, DOI 10.1038/6495; Debes JD, 2004, NEW ENGL J MED, V351, P1488, DOI 10.1056/NEJMp048178; Dote H, 2004, CLIN CANCER RES, V10, P2082, DOI 10.1158/1078-0432.CCR-03-0236; Dote H, 2005, BRIT J CANCER, V92, P1117, DOI 10.1038/sj.bjc.6602458; Duggan D, 2007, JNCI-J NATL CANCER I, V99, P1836, DOI 10.1093/jnci/djm250; Feldman BJ, 2001, NAT REV CANCER, V1, P34, DOI 10.1038/35094009; Gioeli D, 2006, MOL ENDOCRINOL, V20, P503, DOI 10.1210/me.2005-0351; Gordon V, 2010, MOL ENDOCRINOL, V24, P2267, DOI 10.1210/me.2010-0238; Guo ZY, 2009, CANCER RES, V69, P2305, DOI 10.1158/0008-5472.CAN-08-3795; Harvey JM, 1999, J CLIN ONCOL, V17, P1474, DOI 10.1200/JCO.1999.17.5.1474; Heinlein CA, 2004, ENDOCR REV, V25, P276, DOI 10.1210/er.2002-0032; Hu R, 2009, CANCER RES, V69, P16, DOI 10.1158/0008-5472.CAN-08-2764; Huggins C, 1941, CANCER RES, V1, P293; Kesler CT, 2007, MOL ENDOCRINOL, V21, P2071, DOI 10.1210/me.2007-0240; Mayer BJ, 2001, J CELL SCI, V114, P1253; McKenna NJ, 1999, ENDOCR REV, V20, P321, DOI 10.1210/er.20.3.321; Min J, 2010, NAT MED, V16, P286, DOI 10.1038/nm.2100; Min W, 2008, CIRC RES, V102, P840, DOI 10.1161/CIRCRESAHA.107.168153; Qiu GH, 2007, J HEPATOL, V46, P655, DOI 10.1016/j.jhep.2006.11.012; Shang YF, 2002, MOL CELL, V9, P601, DOI 10.1016/S1097-2765(02)00471-9; Sun SH, 2010, J CLIN INVEST, V120, P2715, DOI 10.1172/JCI41824; Tatarov O, 2009, CLIN CANCER RES, V15, P3540, DOI 10.1158/1078-0432.CCR-08-1857; Verras M, 2004, CANCER RES, V64, P8860, DOI 10.1158/0008-5472.CAN-04-2370; Vidal M, 2001, CRIT REV ONCOL HEMAT, V40, P175, DOI 10.1016/S1040-8428(01)00142-1; VISAKORPI T, 1995, NAT GENET, V9, P401, DOI 10.1038/ng0495-401; Wang QB, 2005, MOL CELL, V19, P631, DOI 10.1016/j.molcel.2005.07.018; Wang QB, 2007, MOL CELL, V27, P380, DOI 10.1016/j.molcel.2007.05.041; Wang Z, 2002, J BIOL CHEM, V277, P12622, DOI 10.1074/jbc.M110568200; Watson PA, 2010, P NATL ACAD SCI USA, V107, P16759, DOI 10.1073/pnas.1012443107; Wen Y, 2000, CANCER RES, V60, P6841; Wright CD, 2008, CIRC RES, V103, P992, DOI 10.1161/CIRCRESAHA.108.176024; Xie DX, 2010, P NATL ACAD SCI USA, V107, P2485, DOI 10.1073/pnas.0908133107; Xie DX, 2009, P NATL ACAD SCI USA, V106, P19878, DOI 10.1073/pnas.0908458106; Yang CS, 2005, MOL CELL BIOL, V25, P1298, DOI 10.1128/MCB.25.4.1298-1308.2005; Yano M, 2005, INT J CANCER, V113, P59, DOI 10.1002/ijc.20531; Yu EY, 2009, CLIN CANCER RES, V15, P7421, DOI 10.1158/1078-0432.CCR-09-1691; Zhou XE, 2010, J BIOL CHEM, V285, P9161, DOI 10.1074/jbc.M109.085779	44	32	36	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 10	2014	33	15					1954	1963		10.1038/onc.2013.143	http://dx.doi.org/10.1038/onc.2013.143			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AE9RK	23604126				2022-12-17	WOS:000334346300008
J	Lu, D; Han, C; Wu, T				Lu, D.; Han, C.; Wu, T.			15-PGDH inhibits hepatocellular carcinoma growth through 15-keto-PGE(2)/PPAR gamma-mediated activation of p21(WAF1/Cip1)	ONCOGENE			English	Article						hepatocellular carcinoma (HCC); 15-hydroxyprostaglandin dehydrogenase (15-PGDH); 15-keto-PGE(2); p21; PPAR gamma; liver	15-HYDROXYPROSTAGLANDIN DEHYDROGENASE EXPRESSION; PCNA BINDING DOMAINS; COLORECTAL-CANCER; TUMOR-SUPPRESSOR; LUNG-CANCER; GASTRIC-CANCER; RENAL-FUNCTION; BETA-CATENIN; FATTY-ACIDS; PPAR-GAMMA	15-Hydroxyprostaglandin dehydrogenase (15-PGDH) is a key enzyme in prostaglandin (PG) metabolism. This study provides important evidence for inhibition of hepatocellular carcinoma (HCC) growth by 15-PGDH through the 15-keto-prostaglandin E-2 (15-keto-PGE(2))/peroxisome proliferator-activated receptor-gamma (PPAR gamma)/p21(WAF1/Cip1) signaling pathway. Forced overexpression of 15-PGDH inhibited HCC cell growth in vitro, whereas knockdown of 15-PGDH enhanced tumor growth parameters. In a tumor xenograft model in severe combined immunodeficiency mice, inoculation of human HCC cells (Huh7) with overexpression of 15-PGDH led to significant inhibition of tumor growth, whereas knockdown of 15-PGDH enhanced tumor growth. In a separate tumor xenograft model in which mouse HCC cells (Hepa1-6) were inoculated into syngeneic C57BL/6 mice, intratumoral injection of adenovirus vector expressing 15-PGDH (pAd-15-PGDH) significantly inhibited xenograft tumor growth. The antitumor effect of 15-PGDH is mediated through its enzymatic product, 15-keto-PGE(2), which serves as an endogenous PPAR gamma ligand. Activation of PPAR gamma by 15-PGDH-derived 15-keto-PGE(2) enhanced the association of PPAR gamma with the p21(WAF1/Cip1) promoter and increased p21 expression and association with cyclin-dependent kinase 2 (CDK2), CDK4 and proliferating cell nuclear antigen. Depletion of p21 by short hairpin RNA reversed 15-PGDH-induced inhibition of HCC cell growth; overexpression of p21 prevented 15-PGDH knockdown-induced tumor cell growth. These results show a key 15-PGDH/15-keto-PGE(2)-mediated activation of PPAR gamma and p21WAF1/Cip1 signaling cascade that regulates hepatocarcinogenesis and tumor progression.	[Lu, D.; Han, C.; Wu, T.] Tulane Univ, Sch Med, Dept Pathol, New Orleans, LA 70112 USA; [Lu, D.; Han, C.; Wu, T.] Tulane Univ, Sch Med, Lab Med, New Orleans, LA 70112 USA; [Lu, D.] Tongji Univ, Sch Life Sci & Technol, Shanghai 200092, Peoples R China	Tulane University; Tulane University; Tongji University	Wu, T (corresponding author), Tulane Univ, Sch Med, Dept Pathol, 1430 Tulane Ave,SL-79, New Orleans, LA 70112 USA.	twu@tulane.edu			National Institutes of Health [CA102325, CA106280, CA134568, DK077776]; NATIONAL CANCER INSTITUTE [R01CA134568, R01CA102325, R01CA106280] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK077776, R01DK077776] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We thank Dr Hsin-Hsiung Tai at the University of Kentucky for providing the 15-PGDH-adenoviral vector. This work was supported by National Institutes of Health grants CA102325, CA106280, CA134568 and DK077776.	Abbas T, 2009, NAT REV CANCER, V9, P400, DOI 10.1038/nrc2657; Backlund MG, 2005, J BIOL CHEM, V280, P3217, DOI 10.1074/jbc.M411221200; Backlund MG, 2008, CANCER RES, V68, P9331, DOI 10.1158/0008-5472.CAN-08-2893; Baron JA, 2006, GASTROENTEROLOGY, V131, P1674, DOI 10.1053/j.gastro.2006.08.079; Bosch-Marce M, 1999, GASTROENTEROLOGY, V116, P1167, DOI 10.1016/S0016-5085(99)70020-X; Breinig M, 2007, CURR PHARM DESIGN, V13, P3305, DOI 10.2174/138161207782360627; Cervello M, 2006, WORLD J GASTROENTERO, V12, P5113; CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; Chou WL, 2007, J BIOL CHEM, V282, P18162, DOI 10.1074/jbc.M702289200; Claria J, 2005, HEPATOLOGY, V41, P579, DOI 10.1002/hep.20595; Couzin J, 2004, SCIENCE, V306, P1673, DOI 10.1126/science.306.5702.1673; Ding YF, 2005, CARCINOGENESIS, V26, P65, DOI 10.1093/carcin/bgh277; Dotto GP, 2000, BBA-REV CANCER, V1471, pM43, DOI 10.1016/S0304-419X(00)00019-6; El-Serag HB, 2012, GASTROENTEROLOGY, V142, P1264, DOI 10.1053/j.gastro.2011.12.061; El-Serag HB, 2011, NEW ENGL J MED, V365, P1118, DOI 10.1056/NEJMra1001683; Eruslanov E, 2009, J IMMUNOL, V182, P7548, DOI 10.4049/jimmunol.0802358; Farazi PA, 2006, NAT REV CANCER, V6, P674, DOI 10.1038/nrc1934; Frank B, 2011, CARCINOGENESIS, V32, P190, DOI 10.1093/carcin/bgq231; Grosser T, 2006, J CLIN INVEST, V116, P4, DOI 10.1172/JCI27291; Huang GS, 2008, CANCER RES, V68, P5040, DOI 10.1158/0008-5472.CAN-07-6575; Jung YS, 2010, CELL SIGNAL, V22, P1003, DOI 10.1016/j.cellsig.2010.01.013; Kaliberova LN, 2009, MOL CANCER THER, V8, P3130, DOI 10.1158/1535-7163.MCT-09-0270; Kawai M, 2010, NAT REV ENDOCRINOL, V6, P629, DOI 10.1038/nrendo.2010.155; Lim K, 2008, CANCER RES, V68, P553, DOI 10.1158/0008-5472.CAN-07-2295; Lim K, 2009, MOL CANCER THER, V8, P3046, DOI 10.1158/1535-7163.MCT-09-0551; Liu ZX, 2008, CARCINOGENESIS, V29, P1219, DOI 10.1093/carcin/bgm297; Llovet JM, 2008, HEPATOLOGY, V48, P1312, DOI 10.1002/hep.22506; LUO Y, 1995, NATURE, V375, P159, DOI 10.1038/375159a0; Moore AE, 2009, CARCINOGENESIS, P30; Myung SJ, 2006, P NATL ACAD SCI USA, V103, P12098, DOI 10.1073/pnas.0603235103; Rousseau D, 1999, ONCOGENE, V18, P4313, DOI 10.1038/sj.onc.1202686; Starostina NG, 2012, TRENDS CELL BIOL, V22, P33, DOI 10.1016/j.tcb.2011.10.004; Tai HH, 2011, CANCER METAST REV, V30, P409, DOI 10.1007/s10555-011-9314-z; Tatsuwaki H, 2010, CANCER SCI, V101, P550, DOI 10.1111/j.1349-7006.2009.01390.x; Thiel A, 2009, CLIN CANCER RES, V15, P4572, DOI 10.1158/1078-0432.CCR-08-2518; Tong M, 2006, CARCINOGENESIS, V27, P2170, DOI 10.1093/carcin/bgl053; Tontonoz P, 2008, ANNU REV BIOCHEM, V77, P289, DOI 10.1146/annurev.biochem.77.061307.091829; Tseng-Rogenski S, 2010, AM J PATHOL, V176, P1462, DOI 10.2353/ajpath.2010.090875; Vanchieri C, 2004, J NATL CANCER I, V96, P1734, DOI 10.1093/jnci/96.23.1734; Wakimoto N, 2008, CANCER RES, V68, P6978, DOI 10.1158/0008-5472.CAN-07-5675; Wolf I, 2006, CANCER RES, V66, P7818, DOI 10.1158/0008-5472.CAN-05-4368; Wu T, 2006, CANCER TREAT REV, V32, P28, DOI 10.1016/j.ctrv.2005.10.004; Yan M, 2009, P NATL ACAD SCI USA, V106, P9409, DOI 10.1073/pnas.0902367106; Yang L, 2007, CANCER RES, V67, P5587, DOI 10.1158/0008-5472.CAN-06-2287	44	32	33	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 27	2014	33	9					1101	1112		10.1038/onc.2013.69	http://dx.doi.org/10.1038/onc.2013.69			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AB6XT	23542179	Green Accepted			2022-12-17	WOS:000331933800004
J	Ogami, K; Hosoda, N; Funakoshi, Y; Hoshino, S				Ogami, K.; Hosoda, N.; Funakoshi, Y.; Hoshino, S.			Antiproliferative protein Tob directly regulates c-myc proto-oncogene expression through cytoplasmic polyadenylation element-binding protein CPEB	ONCOGENE			English	Article						Tob; Caf1; CPEB; mRNA decay; deadenylation	MESSENGER-RNA TRANSLATION; CELL-CYCLE PROGRESSION; POLY(A)-BINDING PROTEIN; GROWTH-FACTORS; DEADENYLASE; IDENTIFICATION; COMPLEX; CAF1; PROLIFERATION; HIPPOCAMPUS	The regulation of mRNA deadenylation constitutes a pivotal mechanism of the post-transcriptional control of gene expression. Here we show that the antiproliferative protein Tob, a component of the Caf1-Ccr4 deadenylase complex, is involved in regulating the expression of the proto-oncogene c-myc. The c-myc mRNA contains cis elements (CPEs) in its 3'-untranslated region (3'-UTR), which are recognized by the cytoplasmic polyadenylation element-binding protein (CPEB). CPEB recruits Caf1 deadenylase through interaction with Tob to form a ternary complex, CPEB-Tob-Caf1, and negatively regulates the expression of c-myc by accelerating the deadenylation and decay of its mRNA. In quiescent cells, c-myc mRNA is destabilized by the trans-acting complex (CPEB-Tob-Caf1), while in cells stimulated by the serum, both Tob and Caf1 are released from CPEB, and c-Myc expression is induced early after stimulation by the stabilization of its mRNA as an 'immediate-early gene'. Collectively, these results indicate that Tob is a key factor in the regulation of c-myc gene expression, which is essential for cell growth. Thus, Tob appears to function in the control of cell growth at least, in part, by regulating the expression of c-myc.	[Ogami, K.; Hosoda, N.; Funakoshi, Y.; Hoshino, S.] Nagoya City Univ, Grad Sch Pharmaceut Sci, Dept Biol Chem, Nagoya, Aichi 4678603, Japan	Nagoya City University	Hoshino, S (corresponding author), Nagoya City Univ, Grad Sch Pharmaceut Sci, Dept Biol Chem, Mizuho Ku, 3-1 Tanabe Dori, Nagoya, Aichi 4678603, Japan.	hoshino@phar.nagoya-cu.ac.jp	Ogami, Koichi/K-1160-2019	Ogami, Koichi/0000-0001-9380-9666; Hoshino, Shinichi/0000-0001-6135-7896	Ministry of Education, Culture, Sports, Science and Technology of Japan [20112006]; Grants-in-Aid for Scientific Research [24770116] Funding Source: KAKEN	Ministry of Education, Culture, Sports, Science and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	We thank A-B Shyu for anti-Caf1 antibody. This work was supported by a Grant-in-Aid for Scientific Research on Innovative Areas 'RNA regulation' (No. 20112006) from the Ministry of Education, Culture, Sports, Science and Technology of Japan.	Arumugam K, 2010, EMBO J, V29, P387, DOI 10.1038/emboj.2009.337; Aslam A, 2009, MOL BIOL CELL, V20, P3840, DOI 10.1091/mbc.E09-02-0146; Barnard DC, 2004, CELL, V119, P641, DOI 10.1016/j.cell.2004.10.029; Belloc E, 2008, NATURE, V452, P1017, DOI 10.1038/nature06809; Bianchin C, 2005, RNA, V11, P487, DOI 10.1261/rna.7135305; BLANCHARD JM, 1985, NATURE, V317, P443, DOI 10.1038/317443a0; Burns DM, 2008, GENE DEV, V22, P3449, DOI 10.1101/gad.1697808; DEAN M, 1986, J BIOL CHEM, V261, P9161; DECKER CJ, 1993, GENE DEV, V7, P1632, DOI 10.1101/gad.7.8.1632; Eckmann CR, 2011, WIRES RNA, V2, P348, DOI 10.1002/wrna.56; ELLIS RE, 1995, GENETICS, V139, P561; Funakoshi Y, 2007, GENE DEV, V21, P3135, DOI 10.1101/gad.1597707; GALLIE DR, 1991, GENE DEV, V5, P2108, DOI 10.1101/gad.5.11.2108; Groisman I, 2002, CELL, V109, P473, DOI 10.1016/S0092-8674(02)00733-X; Groisman I, 2006, GENE DEV, V20, P2701, DOI 10.1101/gad.1438906; Horiuchi M, 2009, J BIOL CHEM, V284, P13244, DOI 10.1074/jbc.M809250200; Hosoda N, 2011, EMBO J, V30, P1311, DOI 10.1038/emboj.2011.37; IIZUKA N, 1994, MOL CELL BIOL, V14, P7322, DOI 10.1128/MCB.14.11.7322; Ikematsu N, 1999, ONCOGENE, V18, P7432, DOI 10.1038/sj.onc.1203193; Jin M, 2005, NEUROSCIENCE, V131, P647, DOI 10.1016/j.neuroscience.2004.10.044; Kerkhoff E, 1998, ONCOGENE, V16, P211, DOI 10.1038/sj.onc.1201520; Kim JH, 2006, MOL CELL, V24, P173, DOI 10.1016/j.molcel.2006.08.016; Kim KC, 2011, J NEUROSCI, V31, P12118, DOI 10.1523/JNEUROSCI.1621-11.2011; KINDY MS, 1986, J BIOL CHEM, V261, P2865; Korner CG, 1998, EMBO J, V17, P5427, DOI 10.1093/emboj/17.18.5427; Macnicol MC, 2010, MOL REPROD DEV, V77, P662, DOI 10.1002/mrd.21191; Maekawa M, 2002, J BIOL CHEM, V277, P37783, DOI 10.1074/jbc.M204506200; Mateyak MK, 1999, MOL CELL BIOL, V19, P4672; Novoa I, 2010, NAT CELL BIOL, V12, P447, DOI 10.1038/ncb2046; Okochi K, 2005, GENES CELLS, V10, P151, DOI 10.1111/j.1365-2443.2005.00826.x; Pique M, 2008, CELL, V132, P434, DOI 10.1016/j.cell.2007.12.038; Ren YG, 2002, J BIOL CHEM, V277, P5982, DOI 10.1074/jbc.M111515200; Ruan L, 2010, J BIOL CHEM, V285, P27624, DOI 10.1074/jbc.M110.138867; Suzuki T, 2002, GENE DEV, V16, P1356, DOI 10.1101/gad.962802; Tzachanis D, 2001, NAT IMMUNOL, V2, P1174, DOI 10.1038/ni730; Uchida N, 2004, J BIOL CHEM, V279, P1383, DOI 10.1074/jbc.M309125200; Viswanathan P, 2004, J BIOL CHEM, V279, P23988, DOI 10.1074/jbc.M402803200; Wang XM, 2006, BIOCHEM BIOPH RES CO, V340, P1023, DOI 10.1016/j.bbrc.2005.12.125; Wang YY, 2008, DEV BIOL, V317, P454, DOI 10.1016/j.ydbio.2008.02.033; Wu L, 1998, NEURON, V21, P1129, DOI 10.1016/S0896-6273(00)80630-3; Wu XY, 2012, GENE, V500, P10, DOI 10.1016/j.gene.2012.03.021; Xiong B, 2006, DEV CELL, V11, P225, DOI 10.1016/j.devcel.2006.06.012; Yamashita A, 2005, NAT STRUCT MOL BIOL, V12, P1054, DOI 10.1038/nsmb1016; Yoshida Y, 2000, CELL, V103, P1085, DOI 10.1016/S0092-8674(00)00211-7; Zearfoss NR, 2008, J NEUROSCI, V28, P8502, DOI 10.1523/JNEUROSCI.1756-08.2008	45	32	35	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2014	33	1					55	64		10.1038/onc.2012.548	http://dx.doi.org/10.1038/onc.2012.548			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	282YU	23178487				2022-12-17	WOS:000329212000007
J	Yeung, CL; Ngo, VN; Grohar, PJ; Arnaldez, FI; Asante, A; Wan, X; Khan, J; Hewitt, SM; Khanna, C; Staudt, LM; Helman, LJ				Yeung, C. L.; Ngo, V. N.; Grohar, P. J.; Arnaldez, F. I.; Asante, A.; Wan, X.; Khan, J.; Hewitt, S. M.; Khanna, C.; Staudt, L. M.; Helman, L. J.			Loss-of-function screen in rhabdomyosarcoma identifies CRKL-YES as a critical signal for tumor growth	ONCOGENE			English	Article						rhabdomyosarcoma; CRKL; SRC; YES; dasatinib	CHRONIC MYELOGENOUS LEUKEMIA; ALVEOLAR RHABDOMYOSARCOMA; CHROMOSOMAL LOCALIZATION; CELLS; CANCER; GENE; PATHWAY; PROTEIN; FUSION; FAMILY	To identify novel signaling pathways necessary for rhabdomyosarcoma (RMS) survival, we performed a loss-of-function screen using an inducible small hairpin RNA (shRNA) library in an alveolar and an embryonal RMS cell line. This screen identified CRKL expression as necessary for growth of alveolar RMS and embryonal RMS both in vitro and in vivo. We also found that CRKL was uniformly highly expressed in both RMS cell lines and tumor tissue. As CRKL is a member of the CRK adapter protein family that contains an SH2 and two SH3 domains and is involved in signal transduction from multiple tyrosine kinase receptors, we evaluated CRKL interaction with multiple tyrosine kinase receptor signaling pathways in RMS cells. While we saw no interaction of CRKL with IGFIR, MET or PI3KAKT/mTOR pathways, we determined that CRKL signaling was associated with SRC family kinase (SFK) signaling, specifically with YES kinase. Inhibition of SFK signaling with dasatinib or another SFK inhibitor, sarcatinib, suppressed RMS cell growth in vitro and in vivo. These data identify CRKL as a novel critical component of RMS growth. This study also demonstrates the use of functional screening to identify a potentially novel therapeutic target and treatment approach for these highly aggressive pediatric cancers.	[Yeung, C. L.; Grohar, P. J.; Arnaldez, F. I.; Asante, A.; Wan, X.; Khan, J.; Khanna, C.; Helman, L. J.] NCI, Pediat Oncol Branch, Ctr Canc Res, Bethesda, MD 20892 USA; [Ngo, V. N.] City Hope Natl Med Ctr, Beckman Res Inst, Div Hematopoiet Stem Cell & Leukemia Res, Duarte, CA 91010 USA; [Hewitt, S. M.] NCI, Ctr Canc Res, Pathol Lab, Bethesda, MD 20892 USA; [Staudt, L. M.] NCI, Metab Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); City of Hope; Beckman Research Institute of City of Hope; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Helman, LJ (corresponding author), NCI, Pediat Oncol Branch, Ctr Canc Res, Bldg 31,Room 3A11, Bethesda, MD 20892 USA.	helmanl@nih.gov	Khan, Javed/P-9157-2014; Staudt, Louis/AAC-5324-2019; Grohar, Patrick/V-2557-2018	Hewitt, Stephen/0000-0001-8283-1788; Ngo, Vu/0000-0002-9501-6990	National Cancer Institute; NATIONAL CANCER INSTITUTE [ZIABC010999, ZIABC010806, ZIABC011007, ZICBC010923, ZIASC006892] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported through funding to the Intramural Research Program of the National Cancer Institute. We would also like to thank the many patients and their families who continue to contribute to and inform our research. We thank Dr Su Young Kim experiments, Elena Kuznetsova, Dr Arnulfo Mendoza, and Dr Melinda G Hollings-head for advice and help with xenograft experiment. We also thank the Children's Oncology Group Soft-Tissue Sarcoma Committee for providing the tissue microarrays for analysis of CRKL expression. We thank Joan Massague for the sharing the Addgene plasmid 26 980.	Arai A, 2006, CELL SIGNAL, V18, P2162, DOI 10.1016/j.cellsig.2006.05.001; Berns K, 2004, NATURE, V428, P431, DOI 10.1038/nature02371; Cheung HW, 2011, CANCER DISCOV, V1, P608, DOI 10.1158/2159-8290.CD-11-0046; DAVIS RJ, 1994, CANCER RES, V54, P2869; Feller SM, 2001, ONCOGENE, V20, P6348, DOI 10.1038/sj.onc.1204779; Guris DL, 2001, NAT GENET, V27, P293, DOI 10.1038/85855; Koval AP, 1998, J BIOL CHEM, V273, P14780, DOI 10.1074/jbc.273.24.14780; Luo B, 2008, P NATL ACAD SCI USA, V105, P20380, DOI 10.1073/pnas.0810485105; MARKOWITZ D, 1988, J VIROL, V62, P1120, DOI 10.1128/JVI.62.4.1120-1124.1988; Ngo VN, 2006, NATURE, V441, P106, DOI 10.1038/nature04687; NICHOLS GL, 1994, BLOOD, V84, P2912; Oberlin O, 2008, J CLIN ONCOL, V26, P2384, DOI 10.1200/JCO.2007.14.7207; ODA T, 1994, J BIOL CHEM, V269, P22925; Sakkab D, 2000, J BIOL CHEM, V275, P10772, DOI 10.1074/jbc.275.15.10772; SCRABLE HJ, 1987, NATURE, V329, P645, DOI 10.1038/329645a0; SHAPIRO DN, 1993, CANCER RES, V53, P5108; Taulli R, 2006, CANCER RES, V66, P4742, DOI 10.1158/0008-5472.CAN-05-4292; TENHOEVE J, 1994, BLOOD, V84, P1731; TENHOEVE J, 1993, ONCOGENE, V8, P2469; Zhang XHF, 2009, CANCER CELL, V16, P67, DOI 10.1016/j.ccr.2009.05.017	20	32	32	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 21	2013	32	47					5429	5438		10.1038/onc.2012.590	http://dx.doi.org/10.1038/onc.2012.590			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	254PM	23318429	Green Published, hybrid			2022-12-17	WOS:000327177600006
J	Zhao, P; Damerow, MS; Stern, P; Liu, AH; Sweet-Cordero, A; Siziopikou, K; Neilson, JR; Sharp, PA; Cheng, C				Zhao, P.; Damerow, M. S.; Stern, P.; Liu, A. H.; Sweet-Cordero, A.; Siziopikou, K.; Neilson, J. R.; Sharp, P. A.; Cheng, C.			CD44 promotes Kras-dependent lung adenocarcinoma	ONCOGENE			English	Article						CD44; Kras; lung adenocarcinoma	BREAST-CANCER CELLS; STEM-CELLS; K-RAS; TUMOR; ACTIVATION; EXPRESSION; IDENTIFICATION; MICE; CARCINOMA	Kras-induced non-small-cell lung adenocarcinoma is the major subtype of lung cancers and is associated with poor prognosis. Using a lung cancer mouse model that expresses a cre-mediated Kras(G12D) mutant, we identified a critical role for the cell surface molecule CD44 in mediating cell proliferation downstream of oncogenic Kras signaling. The deletion of CD44 attenuates lung adenocarcinoma formation and prolongs the survival of these mice. Mechanistically, CD44 is required for the activation of Kras-mediated signaling through the mitogen-activated protein kinase (MAPK) pathway and thus promotes tumor cell proliferation. Together, these results reveal an unrecognized role for CD44 in oncogenic Kras-induced lung adenocarcinoma and suggest that targeting CD44 could be an effective strategy for halting Kras-dependent carcinomas.	[Zhao, P.; Damerow, M. S.; Liu, A. H.; Cheng, C.] Northwestern Univ, Feinberg Sch Med, Robert H Lurie Comprehens Canc Ctr, Dept Med,Div Hematol Oncol, Chicago, IL 60611 USA; [Stern, P.] Sextant Therapeut Inc, Cambridge, MA USA; [Sweet-Cordero, A.] Stanford Univ, Dept Pediat, Sch Med, Canc Biol Program, Stanford, CA 94305 USA; [Siziopikou, K.] Northwestern Univ, Feinberg Sch Med, Dept Pathol, Chicago, IL 60611 USA; [Neilson, J. R.] Baylor Coll Med, Dept Mol Physiol & Biophys, Houston, TX 77030 USA; [Sharp, P. A.] MIT, Koch Inst Integrat Canc Res, Cambridge, MA 02139 USA	Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Feinberg School of Medicine; Robert H. Lurie Comprehensive Cancer Center; Stanford University; Northwestern University; Feinberg School of Medicine; Baylor College of Medicine; Massachusetts Institute of Technology (MIT)	Cheng, C (corresponding author), Northwestern Univ, Feinberg Sch Med, Robert H Lurie Comprehens Canc Ctr, Dept Med, 303 E Super St, Chicago, IL 60611 USA.	chengc@northwestern.edu		Neilson, Joel R./0000-0002-3408-608X; Liu, Angela/0000-0002-2567-0671	NATIONAL CANCER INSTITUTE [K99CA131474, P30CA014051, R00CA131474, P01CA042063] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034277] Funding Source: NIH RePORTER; NCI NIH HHS [K99 CA131474, P30 CA014051, R00 CA131474, P01 CA042063] Funding Source: Medline; NIGMS NIH HHS [R01 GM034277] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Bourguignon LYW, 1997, J BIOL CHEM, V272, P27913, DOI 10.1074/jbc.272.44.27913; Brown RL, 2011, J CLIN INVEST, V121, P1064, DOI 10.1172/JCI44540; Cheng CH, 2006, MOL CELL BIOL, V26, P362, DOI 10.1128/MCB.26.1.362-370.2006; Cheng CH, 2006, GENE DEV, V20, P1715, DOI 10.1101/gad.1430906; Dalerba P, 2007, P NATL ACAD SCI USA, V104, P10158, DOI 10.1073/pnas.0703478104; Davie SA, 2007, TRANSGENIC RES, V16, P193, DOI 10.1007/s11248-006-9056-9; Fillmore C, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1673; Girard L, 2000, CANCER RES, V60, P4894; Godar S, 2008, CELL, V134, P62, DOI 10.1016/j.cell.2008.06.006; Hirata T, 1998, CANCER RES, V58, P1108; Jackson EL, 2001, GENE DEV, V15, P3243, DOI 10.1101/gad.943001; Jin LQ, 2006, NAT MED, V12, P1167, DOI 10.1038/nm1483; Johnson L, 2001, NATURE, V410, P1111, DOI 10.1038/35074129; Kumar MS, 2007, NAT GENET, V39, P673, DOI 10.1038/ng2003; Li CW, 2007, CANCER RES, V67, P1030, DOI 10.1158/0008-5472.CAN-06-2030; Liu R, 2007, NEW ENGL J MED, V356, P217, DOI 10.1056/NEJMoa063994; PENNO MB, 1994, CANCER RES, V54, P1381; Ponta H, 2003, NAT REV MOL CELL BIO, V4, P33, DOI 10.1038/nrm1004; Prince ME, 2007, P NATL ACAD SCI USA, V104, P973, DOI 10.1073/pnas.0610117104; Sherman LS, 2000, J CELL BIOL, V150, P1071, DOI 10.1083/jcb.150.5.1071; SLEBOS RJC, 1990, NEW ENGL J MED, V323, P561, DOI 10.1056/NEJM199008303230902; Weg-Remers S, 2001, EMBO J, V20, P4194, DOI 10.1093/emboj/20.15.4194; Yu WH, 2002, GENE DEV, V16, P307, DOI 10.1101/gad.925702	24	32	34	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 24	2013	32	43					5186	5190		10.1038/onc.2012.542	http://dx.doi.org/10.1038/onc.2012.542			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	240JY	23208496	Green Accepted			2022-12-17	WOS:000326093200006
J	Fritz, V; Benfodda, Z; Henriquet, C; Hure, S; Cristol, JP; Michel, F; Carbonneau, MA; Casas, F; Fajas, L				Fritz, V.; Benfodda, Z.; Henriquet, C.; Hure, S.; Cristol, J-P; Michel, F.; Carbonneau, M-A; Casas, F.; Fajas, L.			Metabolic intervention on lipid synthesis converging pathways abrogates prostate cancer growth	ONCOGENE			English	Article						lipids; cancer; FAS; metabolism; prostate	FATTY-ACID SYNTHASE; PROTEIN-KINASE; MALIC ENZYME; CELLS; INHIBITION; TISSUES; TARGET; AMPK; CYTOTOXICITY; LIPOGENESIS	One of the most conserved features of all cancers is a profound reprogramming of cellular metabolism, favoring biosynthetic processes and limiting catalytic processes. With the acquired knowledge of some of these important changes, we have designed a combination therapy in order to force cancer cells to use a particular metabolic pathway that ultimately results in the accumulation of toxic products. This innovative approach consists of blocking lipid synthesis, at the same time that we force the cell, through the inhibition of AMP-activated kinase, to accumulate toxic intermediates, such as malonyl-coenzyme A (malonyl-CoA) or nicotinamide adenine dinucleotide phosphate. This results in excess of oxidative stress and cancer cell death. Our new therapeutic strategy, based on the manipulation of metabolic pathways, will certainly set up the basis for new upcoming studies defining a new paradigm of cancer treatment.	[Fritz, V.; Hure, S.; Fajas, L.] CNRS, IGMM, Inst Genet Mol Montpellier, F-34293 Montpellier, France; [Fritz, V.; Hure, S.; Fajas, L.] CNRS, UMR5535, F-34293 Montpellier, France; [Fritz, V.; Hure, S.; Fajas, L.] Univ Montpellier 2, Montpellier, France; [Benfodda, Z.] Univ Montpellier 2, IBMM, Inst Biomol Max Mousseron, Lab Acides Amines Peptides & Prot,CNRS UMR5247 CC, Montpellier, France; [Benfodda, Z.] Univ Nimes, Chim Bioorgan Lab, Nimes, France; [Henriquet, C.] Inst Rech Cancerol Montpellier, IRCM, Montpellier, France; [Cristol, J-P; Michel, F.] Ctr Hosp Univ Lapeyronie, Biochim Lab, Montpellier, France; [Cristol, J-P; Michel, F.] Inst Univ Rech Clin, UMR Prevent Malnutr & Pathol Associees 204, Montpellier, France; [Carbonneau, M-A] Inst Univ Rech Clin, UMR NUTRIPASS 204, Montpellier, France; [Casas, F.] INRA, UMR 0866, F-34060 Montpellier, France; [Fajas, L.] Ctr Hosp Reg Univ Montpellier, Montpellier, France; [Fajas, L.] Univ Lausanne, Dept Physiol, Lausanne, Switzerland	Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Montpellier; Universite de Montpellier; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Chemistry (INC); Ecole nationale superieure de chimie de Montpellier; Universite de Montpellier; Universite de Nimes; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; UNICANCER; Institut Regional du Cancer Montpellier / Val d'Aurelle (ICM); Universite de Montpellier; CHU de Montpellier; Institut de Recherche pour le Developpement (IRD); Universite de Montpellier; Institut de Recherche pour le Developpement (IRD); Universite de Montpellier; INRAE; Universite de Montpellier; CHU de Montpellier; University of Lausanne	Fajas, L (corresponding author), CNRS, IGMM, Inst Genet Mol Montpellier, 1919 Route Mende, F-34293 Montpellier, France.	lluis.fajas@unil.ch	Coll, Lluis Fajas/C-8567-2014; BENFODDA, Zohra/P-4355-2017	BENFODDA, Zohra/0000-0001-7574-4977; Francois, Casas/0000-0002-5535-8195; Fajas, Lluis/0000-0002-1283-9503	Ligue Contre le Cancer; Agence Nationale de la Recherche (ANR); Institut National du Cancer (INCA)	Ligue Contre le Cancer(Ligue nationale contre le cancer); Agence Nationale de la Recherche (ANR)(French National Research Agency (ANR)); Institut National du Cancer (INCA)(Institut National du Cancer (INCA) France)	Members of Fajas' lab are acknowledged for support and discussions. This work was supported by grants from Ligue Contre le Cancer, Agence Nationale de la Recherche (ANR) and Institut National du Cancer (INCA).	Brusselmans K, 2005, CANCER RES, V65, P6719, DOI 10.1158/0008-5472.CAN-05-0571; Brusselmans K, 2005, J BIOL CHEM, V280, P5636, DOI 10.1074/jbc.M408177200; Eid AA, 2010, J BIOL CHEM, V285, P37503, DOI 10.1074/jbc.M110.136796; Fogarty S, 2010, BBA-PROTEINS PROTEOM, V1804, P581, DOI 10.1016/j.bbapap.2009.09.012; FOLCH J, 1957, J BIOL CHEM, V226, P497; Fritz V, 2010, ONCOGENE, V29, P4369, DOI 10.1038/onc.2010.182; Fritz V, 2010, MOL CANCER THER, V9, P1740, DOI 10.1158/1535-7163.MCT-09-1064; GEER BW, 1979, BIOCHEM GENET, V17, P867, DOI 10.1007/BF00504309; Huang P, 2000, NATURE, V407, P390, DOI 10.1038/35030140; Kato K, 2002, ONCOGENE, V21, P6082, DOI 10.1038/sj.onc.1205737; Korczynska J, 2004, METABOLISM, V53, P1060, DOI 10.1016/j.metabol.2004.02.015; KUHAJDA FP, 1994, P NATL ACAD SCI USA, V91, P6379, DOI 10.1073/pnas.91.14.6379; Kuhajda FP, 2000, NUTRITION, V16, P202, DOI 10.1016/S0899-9007(99)00266-X; Menendez JA, 2004, INT J ONCOL, V24, P1369; Menendez JA, 2007, NAT REV CANCER, V7, P763, DOI 10.1038/nrc2222; Pizer ES, 2000, CANCER RES, V60, P213; Sarruf DA, 2005, MOL CELL BIOL, V25, P9985, DOI 10.1128/MCB.25.22.9985-9995.2005; Stelmanska E, 2004, ACTA BIOCHIM POL, V51, P805; Swinnen JV, 2006, CURR OPIN CLIN NUTR, V9, P358, DOI 10.1097/01.mco.0000232894.28674.30; Thupari JN, 2001, BIOCHEM BIOPH RES CO, V285, P217, DOI 10.1006/bbrc.2001.5146; Viollet B, 2010, CRIT REV BIOCHEM MOL, V45, P276, DOI 10.3109/10409238.2010.488215; Zhang J, 2008, MOL CARCINOGEN, V47, P974, DOI 10.1002/mc.20450	22	32	32	2	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 17	2013	32	42					5101	5110		10.1038/onc.2012.523	http://dx.doi.org/10.1038/onc.2012.523			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	238IB	23208508	Green Published, hybrid			2022-12-17	WOS:000325937900011
J	Saandi, T; Baraille, F; Derbal-Wolfrom, L; Cattin, AL; Benahmed, F; Martin, E; Cardot, P; Duclos, B; Ribeiro, A; Freund, JN; Duluc, I				Saandi, T.; Baraille, F.; Derbal-Wolfrom, L.; Cattin, A-L; Benahmed, F.; Martin, E.; Cardot, P.; Duclos, B.; Ribeiro, A.; Freund, J-N; Duluc, I.			Regulation of the tumor suppressor homeogene Cdx2 by HNF4 alpha in intestinal cancer	ONCOGENE			English	Article						intestine; hepatocyte nuclear factor; tumor suppressor; homeobox gene	HEPATOCYTE NUCLEAR FACTOR-4-ALPHA; IV GENE-TRANSCRIPTION; HOMEOBOX GENE; COLORECTAL-CANCER; CHROMOSOMAL INSTABILITY; EPITHELIAL-CELLS; GUT DEVELOPMENT; DOWN-REGULATION; MUTANT MICE; EXPRESSION	The gut-specific homeotic transcription factor Cdx2 is a crucial regulator of intestinal development and homeostasis, which is downregulated in colorectal cancers (CRC) and exhibits a tumor suppressor function in the colon. We have previously established that several endodermal transcription factors, including HNF4 alpha and GATA6, are involved in Cdx2 regulation in the normal gut. Here we have studied the role of HNF4 alpha in the mechanism of deregulation of Cdx2 in colon cancers. Crossing Apc(Delta 14/+) mice prone to spontaneous intestinal tumor development with pCdx2-9LacZ transgenic mice containing the LacZ reporter under the control of the 9.3-kb Cdx2 promoter showed that this promoter segment contains sequences recapitulating the decrease of Cdx2 expression in intestinal cancers. Immunohistochemistry revealed that HNF4 alpha, unlike GATA6, exhibited a similar decrease to Cdx2 in genetic (Apc(min/+) and Apc(Delta 14/+)) and chemically induced (Azoxymethane (AOM) treatment) models of intestinal tumors in mice. HNF4 alpha and Cdx2 also exhibited a comparable deregulated pattern in human CRC. Correlated patterns were observed between HNF4 alpha and Cdx2 in several experimental models of human colon cancer cell lines: xenografts in nude mice, wound healing and glucose starvation. Furthermore, Cdx2 decreased by knocking down HNF4 alpha in human colon cancer cells using siRNA and in the colon of mice conditionally knocked out for the Hnf4 alpha gene in the adult intestine (Hnf4 alpha(f/f); VilCre(ERT2) mice). Finally, the conditionally knocked out mice Hnf4 alpha(f/f); VilCre(ERT2) treated with the carcinogen AOM developed colorectal tumors earlier than wild-type mice, as previously reported for mice with a reduced Cdx2 expression. In conclusion, this study provides evidence that the downregulation of HNF4 alpha is an important determinant of the reduced expression of the Cdx2 tumor suppressor gene in intestinal cancers. Consistently, similar to Cdx2, HNF4 alpha exerts a tumor suppressor function in the colon in that its loss of function facilitates tumor progression.	[Saandi, T.; Derbal-Wolfrom, L.; Benahmed, F.; Martin, E.; Duclos, B.; Freund, J-N; Duluc, I.] INSERM, U682, F-67200 Strasbourg, France; [Saandi, T.; Derbal-Wolfrom, L.; Martin, E.; Duclos, B.; Freund, J-N; Duluc, I.] Univ Strasbourg, Fac Med, Strasbourg, France; [Baraille, F.; Cattin, A-L; Cardot, P.; Ribeiro, A.] Ctr Rech Cordeliers, INSERM, UMRS 872, Paris, France; [Baraille, F.; Cattin, A-L; Cardot, P.; Ribeiro, A.] Univ Paris 06, UMRS 872, Paris, France; [Baraille, F.; Cattin, A-L; Cardot, P.; Ribeiro, A.] Univ Paris 05, UMRS 872, Paris, France; [Benahmed, F.] Hosp Special Surg, Autoimmun & Inflammat Program, New York, NY 10021 USA; [Duclos, B.] CHU Strasbourg, Serv Gastroenterol, F-67000 Strasbourg, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; CHU Strasbourg; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Duluc, I (corresponding author), INSERM, U682, 3 Ave Moliere, F-67200 Strasbourg, France.	isabelle.duluc@inserm.fr	Ribeiro, Agnès/Q-9702-2017; Duluc, Isabelle/O-1972-2017; DULUC, Isabelle/AAA-7062-2022; Freund, Jean-Noel/R-4383-2016	Ribeiro, Agnès/0000-0003-2063-6084; Duluc, Isabelle/0000-0001-8396-6385; DULUC, Isabelle/0000-0001-8396-6385; Freund, Jean-Noel/0000-0002-0971-3774	Inserm; Ligue contre le Cancer du Haut-Rhin; Canceropole Grand-Est (France); Association for International Cancer Research (AICR, UK); Departement de Mayotte (France); Canceropole Ile-de-France	Inserm(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission); Ligue contre le Cancer du Haut-Rhin; Canceropole Grand-Est (France); Association for International Cancer Research (AICR, UK); Departement de Mayotte (France); Canceropole Ile-de-France(Region Ile-de-France)	This work was supported by Inserm, Ligue contre le Cancer du Haut-Rhin and the Canceropole Grand-Est (France). TS was funded by the Association for International Cancer Research (AICR, UK) and by the Departement de Mayotte (France), and Fl B by the Canceropole Ile-de-France.	Ahn SH, 2008, INFLAMM BOWEL DIS, V14, P908, DOI 10.1002/ibd.20413; Aoki K, 2003, NAT GENET, V35, P323, DOI 10.1038/ng1265; Archer A, 2005, MOL ENDOCRINOL, V19, P2320, DOI 10.1210/me.2004-0462; Beck F, 1999, P NATL ACAD SCI USA, V96, P7318, DOI 10.1073/pnas.96.13.7318; Benahmed F, 2008, GASTROENTEROLOGY, V135, P1238, DOI 10.1053/j.gastro.2008.06.045; Benahmed F, 2007, AM J PATHOL, V170, P733, DOI 10.2353/ajpath.2007.060696; Bonhomme C, 2008, ONCOGENE, V27, P4497, DOI 10.1038/onc.2008.78; Bonhomme C, 2003, GUT, V52, P1465, DOI 10.1136/gut.52.10.1465; Boyd M, 2009, BMC GASTROENTEROL, V9, DOI 10.1186/1471-230X-9-68; Brabletz T, 2004, CANCER RES, V64, P6973, DOI 10.1158/0008-5472.CAN-04-1132; Calon A, 2007, GUT, V56, P1688, DOI 10.1136/gut.2007.125542; Carriere V, 2005, J BIOL CHEM, V280, P5406, DOI 10.1074/jbc.M408002200; Cattin AL, 2009, MOL CELL BIOL, V29, P6294, DOI 10.1128/MCB.00939-09; Colnot S, 2004, LAB INVEST, V84, P1619, DOI 10.1038/labinvest.3700180; da Costa LT, 1999, ONCOGENE, V18, P5010, DOI 10.1038/sj.onc.1202872; Darsigny M, 2010, CANCER RES, V70, P9423, DOI 10.1158/0008-5472.CAN-10-1697; Drewes T, 1996, MOL CELL BIOL, V16, P925; El Marjou F, 2004, GENESIS, V39, P186, DOI 10.1002/gene.20042; Garrison WD, 2006, GASTROENTEROLOGY, V130, P1207, DOI 10.1053/j.gastro.2006.01.003; Gross I, 2008, ONCOGENE, V27, P107, DOI 10.1038/sj.onc.1210601; Hayhurst GP, 2001, MOL CELL BIOL, V21, P1393, DOI 10.1128/MCB.21.4.1393-1403.2001; Hinoi T, 2001, AM J PATHOL, V159, P2239, DOI 10.1016/S0002-9440(10)63074-X; Kim S, 2002, GASTROENTEROLOGY, V123, P1163, DOI 10.1053/gast.2002.36043; Lazarevich N. L., 2010, Experimental Oncology, V32, P167; Li TG, 2010, J LIPID RES, V51, P832, DOI 10.1194/jlr.M002782; Lorentz O, 1999, ONCOGENE, V18, P87, DOI 10.1038/sj.onc.1202280; Neuville A, 2011, HUM PATHOL, V42, P244, DOI 10.1016/j.humpath.2010.07.003; Parviz F, 2003, NAT GENET, V34, P292, DOI 10.1038/ng1175; SLADEK FM, 1990, GENE DEV, V4, P2353, DOI 10.1101/gad.4.12b.2353; Stringer EJ, 2012, DEVELOPMENT, V139, P465, DOI 10.1242/dev.070722; SU LK, 1992, SCIENCE, V256, P668, DOI 10.1126/science.1350108; Subtil C, 2007, CANCER LETT, V247, P197, DOI 10.1016/j.canlet.2006.04.004; Tanaka T, 2006, INT J CANCER, V118, P25, DOI 10.1002/ijc.21282; Tanaka T, 2006, J PATHOL, V208, P662, DOI 10.1002/path.1928; TARAVIRAS S, 1994, MECH DEVELOP, V48, P67, DOI 10.1016/0925-4773(94)90017-5; Verzi MP, 2010, DEV CELL, V19, P713, DOI 10.1016/j.devcel.2010.10.006	36	32	38	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 8	2013	32	32					3782	3788		10.1038/onc.2012.401	http://dx.doi.org/10.1038/onc.2012.401			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	198EH	22986531	Bronze			2022-12-17	WOS:000322904400012
J	Chen, N; Eritja, N; Lock, R; Debnath, J				Chen, N.; Eritja, N.; Lock, R.; Debnath, J.			Autophagy restricts proliferation driven by oncogenic phosphatidylinositol 3-kinase in three-dimensional culture	ONCOGENE			English	Article						autophagy; oncogenic PI3K; proliferation; 3D culture	SIGNALING PATHWAYS; RAT HEPATOCYTES; CANCER; TUMORIGENESIS; MUTATIONS; BECLIN-1; CELLS; GENE; ACTIVATION; INDUCTION	Autophagy is a tightly regulated lysosomal self-digestion process that can both promote and impede tumorigenesis. Here, we utilize a three-dimensional (3D) culture model to address how interactions between autophagy and the phosphatidylinositol 3-kinase(PI3K)/Akt/mammalian target of rapamycin pathway impact the malignant behavior of cells carrying a tumor-derived, activating mutation in PI3K (PI3K-H1047R). In this model, autophagy simultaneously mediates tumor-suppressive and -promoting functions within individual glandular structures. In 3D culture, constitutive PI3K activation overcomes proliferation arrest and promotes resistance to anoikis in the luminal space, resulting in aberrant structures with filled lumen. Inhibiting autophagy in PI3K-H1047R structures triggers luminal cell apoptosis, resulting in lumen clearance. At the same time, autophagy gene depletion strongly enhances PI3K-H1047R cell proliferation during 3D morphogenesis, revealing an unexpected role for autophagy in restricting proliferation driven by PI3K activation. Intriguingly, overexpression of the autophagy cargo receptor p62/SQSTM1 in PI3K-H1047R cells is sufficient to enhance cell proliferation, activate the extracellular signal-related kinase/mitogen-activated protein kinase pathway and to promote epidermal growth factor-independent proliferation in 3D culture. Overall, these results indicate that autophagy antagonizes specific aspects of oncogenic PI3K transformation, with the loss of autophagy promoting proliferation.	[Chen, N.; Eritja, N.; Lock, R.; Debnath, J.] Univ Calif San Francisco, Dept Pathol, Biomed Sci Grad Program, San Francisco, CA 94143 USA; [Chen, N.; Eritja, N.; Lock, R.; Debnath, J.] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA; [Eritja, N.] Univ Lleida, IRBLleida, Inst Recerca Biomed Lleida, Oncol Pathol Grp, Lleida, Spain	University of California System; University of California San Francisco; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer Center; Institut de Recerca Biomedica - IRB Lleida; Universitat de Lleida	Debnath, J (corresponding author), Univ Calif San Francisco, Dept Pathol, Biomed Sci Grad Program, 513 Parnassus Ave,HSW 450B Box 0502, San Francisco, CA 94143 USA.	Jayanta.Debnath@ucsf.edu	Eritja, Núria/S-3700-2019; Eritja, Nuria/M-1347-2015	Eritja, Núria/0000-0003-2131-7915; Eritja, Nuria/0000-0003-1018-6649; Debnath, Jayanta/0000-0002-8745-4069	NIH [RO1 CA126792, CA126792-S1]; DOD BCRP [W81XWH-11-1-0130]; Spanish Ministry of Health; NATIONAL CANCER INSTITUTE [R01CA126792] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); DOD BCRP(United States Department of Defense); Spanish Ministry of Health(Instituto de Salud Carlos IIISpanish Government); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Drs William Weiss, Qiwen Fan and members of the Debnath lab for critically reading the manuscript, and Drs William Weiss and Terge Johansen for generously providing constructs. Grant support to JD includes the NIH (RO1 CA126792 and ARRA supplement CA126792-S1) and the DOD BCRP (W81XWH-11-1-0130). NE received a Short-Term Stay Fellowship from the Spanish Ministry of Health. RL is a DOD BCRP Predoctoral Scholar (W81XWH-08-1-0759).	Amaravadi RK, 2011, CLIN CANCER RES, V17, P654, DOI 10.1158/1078-0432.CCR-10-2634; Bjorkoy G, 2005, J CELL BIOL, V171, P603, DOI 10.1083/jcb.200507002; Chen N, 2010, FEBS LETT, V584, P1427, DOI 10.1016/j.febslet.2009.12.034; Debnath J, 2005, NAT REV CANCER, V5, P675, DOI 10.1038/nrc1695; Debnath J, 2003, J CELL BIOL, V163, P315, DOI 10.1083/jcb.200304159; Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X; Debnath J, 2002, CELL, V111, P29, DOI 10.1016/S0092-8674(02)01001-2; Debnath J, 2009, METHOD ENZYMOL, V452, P423, DOI 10.1016/S0076-6879(08)03625-2; Engelman JA, 2009, NAT REV CANCER, V9, P550, DOI 10.1038/nrc2664; Fung C, 2008, MOL BIOL CELL, V19, P797, DOI 10.1091/mbc.E07-10-1092; Guo JY, 2011, GENE DEV, V25, P460, DOI 10.1101/gad.2016311; He CC, 2009, ANNU REV GENET, V43, P67, DOI 10.1146/annurev-genet-102808-114910; Inami Y, 2011, J CELL BIOL, V193, P275, DOI 10.1083/jcb.201102031; Isakoff SJ, 2005, CANCER RES, V65, P10992, DOI 10.1158/0008-5472.CAN-05-2612; Janku F, 2011, NAT REV CLIN ONCOL, V8, P528, DOI 10.1038/nrclinonc.2011.71; Kanazawa T, 2004, J BIOL CHEM, V279, P8452, DOI 10.1074/jbc.M306337200; Kang SY, 2005, P NATL ACAD SCI USA, V102, P802, DOI 10.1073/pnas.0408864102; Karantza-Wadsworth V, 2007, GENE DEV, V21, P1621, DOI 10.1101/gad.1565707; Kimmelman AC, 2011, GENE DEV, V25, P1999, DOI 10.1101/gad.17558811; Klionsky DJ, 2008, AUTOPHAGY, V4, P151, DOI 10.4161/auto.5338; Kondo Y, 2005, NAT REV CANCER, V5, P726, DOI 10.1038/nrc1692; Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257; Lock R, 2011, MOL BIOL CELL, V22, P165, DOI 10.1091/mbc.E10-06-0500; Luiken JJFP, 1996, EUR J BIOCHEM, V235, P564; Mathew R, 2007, GENE DEV, V21, P1367, DOI 10.1101/gad.1545107; Mathew R, 2009, CELL, V137, P1062, DOI 10.1016/j.cell.2009.03.048; Moscat J, 2011, CELL, V147, P724, DOI 10.1016/j.cell.2011.10.021; Pankiv S, 2007, J BIOL CHEM, V282, P24131, DOI 10.1074/jbc.M702824200; Petiot A, 2000, J BIOL CHEM, V275, P992, DOI 10.1074/jbc.275.2.992; Qu XP, 2003, J CLIN INVEST, V112, P1809, DOI 10.1172/JCI200320039; Samuels Y, 2004, SCIENCE, V304, P554, DOI 10.1126/science.1096502; Takamura A, 2011, GENE DEV, V25, P795, DOI 10.1101/gad.2016211; Yang SH, 2011, GENE DEV, V25, P717, DOI 10.1101/gad.2016111; Yue ZY, 2003, P NATL ACAD SCI USA, V100, P15077, DOI 10.1073/pnas.2436255100	34	32	32	0	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 16	2013	32	20					2543	2554		10.1038/onc.2012.277	http://dx.doi.org/10.1038/onc.2012.277			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	148UY	22777351	Green Submitted, Green Accepted			2022-12-17	WOS:000319274300006
J	Furcht, CM; Rojas, ARM; Nihalani, D; Lazzara, MJ				Furcht, C. M.; Rojas, A. R. Munoz; Nihalani, D.; Lazzara, M. J.			Diminished functional role and altered localization of SHP2 in non-small cell lung cancer cells with EGFR-activating mutations	ONCOGENE			English	Article						extracellular signal-regulated kinase (ERK); gefitinib; endocytosis; GRB2-associated binder 1 (GAB1)	SIGNAL-REGULATED KINASE; MOLECULAR-MECHANISM; TYROSINE KINASE; GEFITINIB; PHOSPHATASE; SENSITIVITY; MET; PHOSPHORYLATION; RESISTANCE; INHIBITORS	Non-small cell lung cancer (NSCLC) cells harboring activating mutations of the epidermal growth factor receptor (EGFR) tend to display elevated activity of several survival signaling pathways. Surprisingly, these mutations also correlate with reduced phosphorylation of ERK and SHP2, a protein tyrosine phosphatase required for complete ERK activation downstream of most receptor tyrosine kinases. As ERK activity influences cellular response to EGFR inhibition, altered SHP2 function could have a role in the striking response to gefitinib witnessed with EGFR mutation. Here, we demonstrate that impaired SHP2 phosphorylation correlates with diminished SHP2 function in NSCLC cells expressing mutant, versus wild-type, EGFR. In NSCLC cells expressing wild-type EGFR, SHP2 knockdown decreased ERK phosphorylation, basally and in response to gefitinib, and increased cellular sensitivity to gefitinib. In cells expressing EGFR mutants, these effects of SHP2 knockdown were less substantial, but the expression of constitutively active SHP2 reduced cellular sensitivity to gefitinib. In cells expressing EGFR mutants, which do not undergo efficient ligand-mediated endocytosis, SHP2 was basally associated with GRB2-associated binder 1 (GAB1) and EGFR, and SHP2's presence in membrane fractions was dependent on EGFR activity. Whereas EGF promoted a more uniform intracellular distribution of initially centrally localized SHP2 in cells expressing wild-type EGFR, SHP2 was basally evenly distributed and did not redistribute in response to EGF in cells with EGFR mutation. Thus, EGFR mutation may promote association of a fraction of SHP2 at the plasma membrane with adapters that promote SHP2 activity. Consistent with this, SHP2 immunoprecipitated from cells with EGFR mutation was active, and EGF treatment did not change this activity. Overall, our data suggest that a fraction of SHP2 is sequestered at the plasma membrane in cells with EGFR mutation in a way that impedes SHP2's ability to promote ERK activity and identify SHP2 as a potential target for co-inhibition with EGFR in NSCLC.	[Furcht, C. M.; Lazzara, M. J.] Univ Penn, Dept Chem & Biomol Engn, Philadelphia, PA 19104 USA; [Rojas, A. R. Munoz; Lazzara, M. J.] Univ Penn, Dept Bioengn, Philadelphia, PA 19104 USA; [Nihalani, D.] Univ Penn, Dept Med, Renal Electrolyde & Hypertens Div, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania	Lazzara, MJ (corresponding author), Univ Penn, Dept Chem & Biomol Engn, 311A Towne Bldg,220 South 33rd St, Philadelphia, PA 19104 USA.	mlazzara@seas.upenn.edu	nihalani, deepak/AAK-9453-2020	Furcht, Christopher/0000-0002-5403-4914; Munoz-Rojas, Andres R./0000-0002-1251-723X	University of Pennsylvania Cell and Molecular Biology Training Grant [T32 GM-07229]; National Cancer Institute [R25 CA101871-07]; Ashton Foundation; University of Pennsylvania Institute for Regenerative Medicine; Pennsylvania Department of Health; National Institutes of Health through the NIDDK [1R01DK087956]; University of Pennsylvania; NATIONAL CANCER INSTITUTE [R25CA101871] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK087956] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007229] Funding Source: NIH RePORTER	University of Pennsylvania Cell and Molecular Biology Training Grant; National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Ashton Foundation; University of Pennsylvania Institute for Regenerative Medicine; Pennsylvania Department of Health; National Institutes of Health through the NIDDK; University of Pennsylvania; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	CMF was supported in part by the University of Pennsylvania Cell and Molecular Biology Training Grant (T32 GM-07229), grant R25 CA101871-07 from the National Cancer Institute and a fellowship from the Ashton Foundation. AMR received support from the University of Pennsylvania Institute for Regenerative Medicine. This project was funded, in part, under a grant with the Pennsylvania Department of Health. The Department specifically disclaims responsibility for any analyses, interpretations or conclusions. Support for DN was provided by the National Institutes of Health Grant 1R01DK087956 through the NIDDK. This work was also supported in part by laboratory startup funds from the University of Pennsylvania. We thank Dr Ben Neel, Dr Eric Haura, Dr Pasi Janne, Dr Tyler Jacks, Dr Marilyn Farquhar, Dr Gary Nolan, Dr Anil Rustgi and Dr Susan Margulies for generously providing reagents and access to instrumentation. We also thank Ms Gladys Gray Lawrence, Dr Ranganath Parthasarathy, Mr Calixte Monast and Ms Alice Macdonald Walsh for technical assistance.	Akca H, 2006, LUNG CANCER, V54, P25, DOI 10.1016/j.lungcan.2006.06.007; Araki T, 2003, J BIOL CHEM, V278, P41677, DOI 10.1074/jbc.M306461200; Bentires-Alj M, 2004, CANCER RES, V64, P8816, DOI 10.1158/0008-5472.CAN-04-1923; Chan G, 2008, CANCER METAST REV, V27, P179, DOI 10.1007/s10555-008-9126-y; Coldren CD, 2006, MOL CANCER RES, V4, P521, DOI 10.1158/1541-7786.MCR-06-0095; Engelman JA, 2005, P NATL ACAD SCI USA, V102, P3788, DOI 10.1073/pnas.0409773102; Fukuoka M, 2003, J CLIN ONCOL, V21, P2237, DOI 10.1200/JCO.2003.10.038; Gu HH, 2003, TRENDS CELL BIOL, V13, P122, DOI 10.1016/S0962-8924(03)00002-3; Guo A, 2008, P NATL ACAD SCI USA, V105, P692, DOI 10.1073/pnas.0707270105; Hendriks BS, 2006, IEE P SYST BIOL, V153, P457, DOI 10.1049/ip-syb:20050108; Hendriks BS, 2003, CANCER RES, V63, P1130; Hynes NE, 2005, NAT REV CANCER, V5, P341, DOI 10.1038/nrc1609; Kontaridis MI, 2006, J BIOL CHEM, V281, P6785, DOI 10.1074/jbc.M513068200; Lazzara MJ, 2010, CANCER RES, V70, P3843, DOI 10.1158/0008-5472.CAN-09-3421; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Maroun CR, 2000, MOL CELL BIOL, V20, P8513, DOI 10.1128/MCB.20.22.8513-8525.2000; Neel BG, 2003, TRENDS BIOCHEM SCI, V28, P284, DOI 10.1016/S0968-0004(03)00091-4; Offterdinger M, 2008, TRAFFIC, V9, P147, DOI 10.1111/j.1600-0854.2007.00665.x; Paulsen CE, 2012, NAT CHEM BIOL, V8, P57, DOI 10.1038/nchembio.736; Ren Yuan, 2010, Genes Cancer, V1, P994, DOI 10.1177/1947601910395582; Salvi M, 2004, CELL MOL LIFE SCI, V61, P2393, DOI 10.1007/s00018-004-4211-z; Sharma SV, 2007, NAT REV CANCER, V7, P169, DOI 10.1038/nrc2088; Shi ZQ, 2000, MOL CELL BIOL, V20, P1526, DOI 10.1128/MCB.20.5.1526-1536.2000; Sordella R, 2004, SCIENCE, V305, P1163, DOI 10.1126/science.1101637; Turke AB, 2010, CANCER CELL, V17, P77, DOI 10.1016/j.ccr.2009.11.022; Ventura A, 2004, P NATL ACAD SCI USA, V101, P10380, DOI 10.1073/pnas.0403954101; Vieira AV, 1996, SCIENCE, V274, P2086, DOI 10.1126/science.274.5295.2086; Wang SZE, 2006, CANCER CELL, V10, P25, DOI 10.1016/j.ccr.2006.05.023; Wickrema A, 1999, J BIOL CHEM, V274, P24469, DOI 10.1074/jbc.274.35.24469; Yano S, 2008, CANCER RES, V68, P9479, DOI 10.1158/0008-5472.CAN-08-1643; Zhou XD, 2009, J BIOL CHEM, V284, P12226, DOI 10.1074/jbc.M900020200	31	32	35	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY	2013	32	18					2346	2355		10.1038/onc.2012.240	http://dx.doi.org/10.1038/onc.2012.240			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	140VF	22777356	Green Accepted			2022-12-17	WOS:000318683600011
J	Vitolo, MI; Boggs, AE; Whipple, RA; Yoon, JR; Thompson, K; Matrone, MA; Cho, EH; Balzer, EM; Martin, SS				Vitolo, M. I.; Boggs, A. E.; Whipple, R. A.; Yoon, J. R.; Thompson, K.; Matrone, M. A.; Cho, E. H.; Balzer, E. M.; Martin, S. S.			Loss of PTEN induces microtentacles through PI3K-independent activation of cofilin	ONCOGENE			English	Article						PTEN; microtentacle; actin; contractility; cofilin; metastasis	CIRCULATING TUMOR-CELLS; NONMUSCLE MYOSIN-II; LIGHT-CHAIN KINASE; BREAST-CANCER; LIM-KINASE; F-ACTIN; PHOSPHOINOSITIDE-BINDING; PHOSPHATASE SLINGSHOT; INHIBITION; EXPRESSION	Loss of PTEN tumor suppressor enhances metastatic risk in breast cancer, although the underlying mechanisms are poorly defined. We report that homozygous deletion of PTEN in mammary epithelial cells induces tubulin-based microtentacles (McTNs) that facilitate cell reattachment and homotypic aggregation. Treatment with contractility-modulating drugs showed that McTNs in PTEN-/- cells are suppressible by controlling the actin cytoskeleton. Because outward microtubule extension is counteracted by actin cortical contraction, increased activity of actin-severing proteins could release constraints on McTN formation in PTEN-/- cells. One such actin-severing protein, cofilin, is activated in detached PTEN-/- cells that could weaken the actin cortex to promote McTNs. Expression of wild-type cofilin, an activated mutant (S3A), and an inactive mutant (S3E) demonstrated that altering cofilin phosphorylation directly affects McTNs formation. Chemical inhibition of PI3K did not reduce McTNs or inactivate cofilin in PTEN-/- cells. Additionally, knock-in expression of the two most common PI3K-activating mutations observed in human cancer patients did not increase McTNs or activate cofilin. PTEN loss and PI3K activation also caused differential activation of the cofilin regulators, LIM-kinase1 (LIMK) and Slingshot-1L (SSH). Furthermore, McTNs were suppressed and cofilin was inactivated by restoration of PTEN in the PTEN-/- cells, indicating that both the elevation of McTNs and the activation of cofilin are specific results arising from PTEN loss. These data identify a novel mechanism by which PTEN loss could remodel the cortical actin network to facilitate McTNs that promote tumor cell reattachment and aggregation. Using isogenic MCF-10A PTEN-/- and PIK3CA mutants, we have further demonstrated that there are clear differences in activation of cofilin, LIMK and SSH between PTEN loss and PI3K activation, providing a new evidence that these mutations yield distinct cytoskeletal phenotypes, which could have an impact on tumor biology. Oncogene (2013) 32, 2200-2210; doi:10.1038/onc.2012.234; published online 11 June 2012	[Vitolo, M. I.; Boggs, A. E.; Whipple, R. A.; Yoon, J. R.; Thompson, K.; Martin, S. S.] Univ Maryland, Marlene & Stewart Greenebaum NCI Canc Ctr, Baltimore, MD 21201 USA; [Boggs, A. E.; Yoon, J. R.; Martin, S. S.] Univ Maryland, Grad Program Life Sci, Program Mol Med, Baltimore, MD 21201 USA; [Matrone, M. A.] Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA; [Cho, E. H.] Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA; [Balzer, E. M.] Johns Hopkins Univ, Johns Hopkins Inst NanoBioTechnol, Baltimore, MD USA; [Martin, S. S.] Univ Maryland, Sch Med, Dept Physiol, Baltimore, MD 21201 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; Scripps Research Institute; Scripps Research Institute; Johns Hopkins University; University System of Maryland; University of Maryland Baltimore	Martin, SS (corresponding author), Univ Maryland, Sch Med, Dept Physiol, Room 10-29,Bressler Bldg,655 West Baltimore St, Baltimore, MD 21201 USA.	ssmartin@som.umaryland.edu	Cho, Edward/B-3727-2012	Cho, Edward/0000-0002-0278-334X; Vitolo, Michele/0000-0001-8055-9645	Ruth L Kirschstein-National Service Research Award [T32-HL07698]; National Cancer Institute [R01-CA124704]; Susan G Komen Foundation [KG100240]; Era of Hope Scholar award from the Department of Defense [BC100675]; NATIONAL CANCER INSTITUTE [P30CA134274, R01CA154624, R01CA124704] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007698] Funding Source: NIH RePORTER	Ruth L Kirschstein-National Service Research Award(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Susan G Komen Foundation(Susan G. Komen Breast Cancer Foundation); Era of Hope Scholar award from the Department of Defense(United States Department of Defense); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This work was supported by grants from the Ruth L Kirschstein-National Service Research Award, T32-HL07698 (MIV), National Cancer Institute, R01-CA124704 (SSM), Susan G Komen Foundation, KG100240 (SSM) and an Era of Hope Scholar award from the Department of Defense, BC100675 (SSM).	Aguirre-Ghiso JA, 2007, NAT REV CANCER, V7, P834, DOI 10.1038/nrc2256; Asch HL, 1996, CANCER RES, V56, P4841; Balzer EM, 2010, BREAST CANCER RES TR, V121, P65, DOI 10.1007/s10549-009-0457-3; Betapudi V, 2006, CANCER RES, V66, P4725, DOI 10.1158/0008-5472.CAN-05-4236; Cantley LC, 1999, P NATL ACAD SCI USA, V96, P4240, DOI 10.1073/pnas.96.8.4240; Chambers AF, 2002, NAT REV CANCER, V2, P563, DOI 10.1038/nrc865; Clark J, 2011, NAT METHODS, V8, P267, DOI 10.1038/NMETH.1564; Craven SE, 1998, CELL, V93, P495, DOI 10.1016/S0092-8674(00)81179-4; Denu JM, 1996, CELL, V87, P361, DOI 10.1016/S0092-8674(00)81356-2; Di Paolo G, 2006, NATURE, V443, P651, DOI 10.1038/nature05185; Doreian BW, 2009, MOL BIOL CELL, V20, P3142, DOI 10.1091/mbc.E09-03-0197; Edwards DC, 1999, NAT CELL BIOL, V1, P253, DOI 10.1038/12963; Eiseler T, 2009, NAT CELL BIOL, V11, P545, DOI 10.1038/ncb1861; Even-Ram S, 2007, NAT CELL BIOL, V9, P299, DOI 10.1038/ncb1540; Fraley TS, 2005, J BIOL CHEM, V280, P15479, DOI 10.1074/jbc.M500631200; Ghosh M, 2004, SCIENCE, V304, P743, DOI 10.1126/science.1094561; Gilmore AP, 1996, NATURE, V381, P531, DOI 10.1038/381531a0; Glinsky VV, 2003, CANCER RES, V63, P3805; Guck J, 2005, BIOPHYS J, V88, P3689, DOI 10.1529/biophysj.104.045476; Gustin JP, 2009, P NATL ACAD SCI USA, V106, P2835, DOI 10.1073/pnas.0813351106; Hale CM, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007054; Hsieh SHK, 2006, J NEUROSCI, V26, P1006, DOI 10.1523/JNEUROSCI.2806-05.2006; Huang TY, 2006, CURR OPIN CELL BIOL, V18, P26, DOI 10.1016/j.ceb.2005.11.005; Ingber DE, 2003, J CELL SCI, V116, P1157, DOI 10.1242/jcs.00359; Janmey PA, 2004, NAT REV MOL CELL BIO, V5, P658, DOI 10.1038/nrm1434; Janssen EAM, 2007, CELL ONCOL, V29, P25; Kobayashi M, 2006, EMBO J, V25, P713, DOI 10.1038/sj.emboj.7600973; Korb T, 2004, EXP CELL RES, V299, P236, DOI 10.1016/j.yexcr.2004.06.001; Kusano K, 1999, MOL CELL BIOCHEM, V190, P133, DOI 10.1023/A:1006962210692; Liu CR, 2004, CHINESE MED J-PEKING, V117, P213; Maekawa M, 1999, SCIENCE, V285, P895, DOI 10.1126/science.285.5429.895; Martin SS, 2004, BBA-MOL CELL RES, V1692, P145, DOI 10.1016/j.bbamcr.2004.02.008; Matrone MA, 2010, ONCOGENE, V29, P3217, DOI 10.1038/onc.2010.68; Matrone MA, 2010, CANCER RES, V70, P7737, DOI 10.1158/0008-5472.CAN-10-1569; Mehlen P, 2006, NAT REV CANCER, V6, P449, DOI 10.1038/nrc1886; Myers MP, 1997, P NATL ACAD SCI USA, V94, P9052, DOI 10.1073/pnas.94.17.9052; Nagata-Ohashi K, 2004, J CELL BIOL, V165, P465, DOI 10.1083/jcb.200401136; Naumov GN, 2002, CANCER RES, V62, P2162; Nishita M, 2004, J BIOL CHEM, V279, P7193, DOI 10.1074/jbc.M312591200; Ohashi K, 2000, J BIOL CHEM, V275, P3577, DOI 10.1074/jbc.275.5.3577; Okagaki T, 1999, J BIOCHEM-TOKYO, V125, P619, DOI 10.1093/oxfordjournals.jbchem.a022328; Perez-Tenorio G, 2007, CLIN CANCER RES, V13, P3577, DOI 10.1158/1078-0432.CCR-06-1609; Saal LH, 2008, NAT GENET, V40, P102, DOI 10.1038/ng.2007.39; Saal LH, 2007, P NATL ACAD SCI USA, V104, P7564, DOI 10.1073/pnas.0702507104; Schmidt-Kittler O, 2003, P NATL ACAD SCI USA, V100, P7737, DOI 10.1073/pnas.1331931100; Shin DH, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007451; Stemke-Hale K, 2008, CANCER RES, V68, P6084, DOI 10.1158/0008-5472.CAN-07-6854; Tohtong R, 2003, PROSTATE CANCER P D, V6, P212, DOI 10.1038/sj.pcan.4500663; Vicente-Manzanares M, 2009, NAT REV MOL CELL BIO, V10, P778, DOI 10.1038/nrm2786; Vitolo MI, 2009, CANCER RES, V69, P8275, DOI 10.1158/0008-5472.CAN-09-1067; WEISS L, 1992, CANCER METAST REV, V11, P227, DOI 10.1007/BF01307179; Whipple RA, 2008, CANCER RES, V68, P5678, DOI 10.1158/0008-5472.CAN-07-6589; Whipple RA, 2007, EXP CELL RES, V313, P1326, DOI 10.1016/j.yexcr.2007.02.001; Wiggan O, 2012, DEV CELL, V22, P530, DOI 10.1016/j.devcel.2011.12.026; Yamaguchi H, 2005, CURR OPIN CELL BIOL, V17, P559, DOI 10.1016/j.ceb.2005.08.002; Yamamoto M, 2001, J CELL BIOL, V152, P867, DOI 10.1083/jcb.152.5.867; YONEZAWA N, 1990, J BIOL CHEM, V265, P8382; Zschiesche W, 1997, ANTICANCER RES, V17, P561	58	32	33	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 25	2013	32	17					2200	2210		10.1038/onc.2012.234	http://dx.doi.org/10.1038/onc.2012.234			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	132JD	22689060	Green Accepted			2022-12-17	WOS:000318062800009
J	Freije, A; Ceballos, L; Coisy, M; Barnes, L; Rosa, M; De Diego, E; Blanchard, JM; Gandarillas, A				Freije, A.; Ceballos, L.; Coisy, M.; Barnes, L.; Rosa, M.; De Diego, E.; Blanchard, J. M.; Gandarillas, A.			Cyclin E drives human keratinocyte growth into differentiation	ONCOGENE			English	Article						skin; stem cells; DNA damage; MYCER; cell size; endoreplication	DEPENDENT KINASE INHIBITOR; EPIDERMAL STEM-CELLS; XENOPUS EGG EXTRACTS; C-MYC; DNA-DAMAGE; TERMINAL DIFFERENTIATION; INVOLUCRIN SYNTHESIS; CHEMICAL INHIBITORS; CANCER DEVELOPMENT; G2/M TRANSITION	Human epidermis is continuously exposed to environmental mutagenic hazard and is the most frequent target of human cancer. How the epidermis coordinates proliferation with differentiation to maintain homeostasis, even in hyperproliferative conditions, is unclear. For instance, overactivation of the proto-oncogene MYC in keratinocytes stimulates differentiation. Here we explore the cell cycle regulation as proliferating human keratinocytes commit to terminal differentiation upon loss of anchorage or overactivation of MYC. The S-phase of the cell cycle is deregulated as mitotic regulators are inhibited in the onset of differentiation. Experimental inhibition of mitotic kinase cdk1 or kinases of the mitosis spindle checkpoint Aurora B or Polo-like Kinase, triggered keratinocyte terminal differentiation. Furthermore, hyperactivation of the cell cycle by overexpressing the DNA replication regulator Cyclin E induced mitosis failure and differentiation. Inhibition of Cyclin E by shRNAs attenuated the induction of differentiation by MYC. In addition, we present evidence that Cyclin E induces DNA damage and the p53 pathway. The results provide novel clues for the mechanisms committing proliferative keratinocytes to differentiate, with implications for tissue homeostasis maintenance, HPV amplification and tumorigenesis. Oncogene (2012) 31, 5180--5192; doi:10.1038/onc.2012.22; published online 20 February 2012	[Freije, A.; Ceballos, L.; Rosa, M.; Gandarillas, A.] Fdn Marques de Valdecilla IFIMAV FMDV, Res & Training Inst, Cell Cycle Stem Cell Fate & Canc Lab, Santander 39011, Spain; [Freije, A.; Ceballos, L.; Rosa, M.; Gandarillas, A.] Univ Cantabria, Dept Mol Biol, E-39005 Santander, Spain; [Coisy, M.; Barnes, L.; Blanchard, J. M.; Gandarillas, A.] Inst Genet Mol Montpellier CNRS UMPII, Montpellier, France; [De Diego, E.] HUMV, Serv Cirugia Pediat, Santander, Spain; [Gandarillas, A.] Inst Univ Rech Clin, Inserm ADR Languedoc Roussillon, Lab Dermatol Mol, UPRES EA 3754, Montpellier, France	Hospital Universitario Marques de Valdecilla (HUMV); Universidad de Cantabria; Centre National de la Recherche Scientifique (CNRS); Hospital Universitario Marques de Valdecilla (HUMV); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier	Gandarillas, A (corresponding author), Fdn Marques de Valdecilla IFIMAV FMDV, Res & Training Inst, Cell Cycle Stem Cell Fate & Canc Lab, Av Herrera Oria S-N, Santander 39011, Spain.	ifimav.agandarillas@fmdv.org	Rosa-Garrido, Manuel/AAE-4188-2019	Rosa-Garrido, Manuel/0000-0002-2169-3972	ARC (France); INSERM (Spain); ISCIII (Spain); ISCIII; FMDV-IFIMAV; La Ligue contre le cancer (France); Instituto de Salud Carlos III (ISCIII-Programa Regiones Emergentes); Instituto de Salud Carlos III (Fondo de Investigaciones Sanitarias; Spain) [PI080890]	ARC (France); INSERM (Spain); ISCIII (Spain)(Instituto de Salud Carlos III); ISCIII(Instituto de Salud Carlos III); FMDV-IFIMAV; La Ligue contre le cancer (France); Instituto de Salud Carlos III (ISCIII-Programa Regiones Emergentes); Instituto de Salud Carlos III (Fondo de Investigaciones Sanitarias; Spain)(Instituto de Salud Carlos III)	We are especially grateful to Jean-Claude Rossi and Javier Leon for their strong support. We thank Bruno Amati, Pierre Roux and Jonathon Pines for providing DNA constructs, J. Leon for reagents, Anne Blangy, Vjeko Dulic, Veronique Baldin and Thierry Lorca for technical advice, Daniel Fisher for helpful suggestions, Kathy Brooks and Maria Aramburu for technical support at flow cytometry, J. Leon and Philippe Pasero for critical reading of the manuscript, and Anna Solinis and Diana Solinis for reviewing the English writing. Human skin biopsies were provided with consent by St Jean and Hopital La Peronye (Montpellier, France) and by the Chirurgical Paediatric Service of Hospital Marques de Valdecilla (EdD; HMDV, Santander, Spain). MC was a recipient of a predoctoral fellowship from ARC (France). AG belongs to the INSERM (France) and the FMDV-IFIMAV (Spain) and was financially supported by the INSERM and the ISCIII (Spain). AF and LC were employed by FMDV-IFIMAV and supported by the ISCIII, MR was recipient of a postdoctoral contract by the FMDV-IFIMAV. This work was funded by ARC (AG; France), La Ligue contre le cancer (JMB; France), and Instituto de Salud Carlos III (AG; ISCIII-Programa Regiones Emergentes and Fondo de Investigaciones Sanitarias PI080890; Spain).	ADAMS JC, 1989, NATURE, V340, P307, DOI 10.1038/340307a0; BANKSSCHLEGEL S, 1981, J CELL BIOL, V90, P732, DOI 10.1083/jcb.90.3.732; Barr FA, 2004, NAT REV MOL CELL BIO, V5, P429, DOI 10.1038/nrm1401; Beer S, 2004, PLOS BIOL, V2, P1785, DOI 10.1371/journal.pbio.0020332; Ben-Bassat H, 1999, J PHARMACOL EXP THER, V290, P1442; Bester AC, 2011, CELL, V145, P435, DOI 10.1016/j.cell.2011.03.044; Campaner S, 2010, NAT CELL BIOL, V12, P54, DOI 10.1038/ncb2004; Coudreuse D, 2010, NATURE, V468, P1074, DOI 10.1038/nature09543; Dazard JE, 2000, ONCOGENE, V19, P3693, DOI 10.1038/sj.onc.1203695; Dotto GP, 2000, BBA-REV CANCER, V1471, pM43, DOI 10.1016/S0304-419X(00)00019-6; Edgar BA, 2001, CELL, V105, P297, DOI 10.1016/S0092-8674(01)00334-8; Eilers M, 2008, GENE DEV, V22, P2755, DOI 10.1101/gad.1712408; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317; Fernandez-Capetillo O, 2004, DNA REPAIR, V3, P959, DOI 10.1016/j.dnarep.2004.03.024; Fuchs E, 2008, GENE DEV, V22, P976, DOI 10.1101/gad.1645908; Gadea BB, 2005, MOL BIOL CELL, V16, P1305, DOI 10.1091/mbc.E04-10-0891; Gandarillas A, 1997, GENE DEV, V11, P2869, DOI 10.1101/gad.11.21.2869; Gandarillas A, 2000, EXP GERONTOL, V35, P53, DOI 10.1016/S0531-5565(99)00088-1; GANDARILLAS A, 1995, ONCOGENE, V11, P1403; Gandarillas A, 2000, ONCOGENE, V19, P3278, DOI 10.1038/sj.onc.1203630; Garcia P, 2000, ONCOGENE, V19, P1820, DOI 10.1038/sj.onc.1203494; GUADAGNO TM, 1993, SCIENCE, V262, P1572, DOI 10.1126/science.8248807; Halazonetis TD, 2008, SCIENCE, V319, P1352, DOI 10.1126/science.1140735; HANSON KD, 1994, MOL CELL BIOL, V14, P5748, DOI 10.1128/MCB.14.9.5748; Harvat BL, 1998, J CELL SCI, V111, P1185; Hauser P, 2004, MOL CANCER RES, V2, P96; Herold S, 2002, MOL CELL, V10, P509, DOI 10.1016/S1097-2765(02)00633-0; Hurlin PJ, 1995, ONCOGENE, V11, P2487; Iglesias-Ara A, 2010, ONCOGENE, V29, P5579, DOI 10.1038/onc.2010.296; Itahana Koji, 2007, Methods Mol Biol, V371, P21; JANSENDURR P, 1993, P NATL ACAD SCI USA, V90, P3685, DOI 10.1073/pnas.90.8.3685; JONES PH, 1993, CELL, V73, P713, DOI 10.1016/0092-8674(93)90251-K; Kleinberger-Doron N, 1998, EXP CELL RES, V241, P340, DOI 10.1006/excr.1998.4061; Knockaert M, 2002, TRENDS PHARMACOL SCI, V23, P417, DOI 10.1016/S0165-6147(02)02071-0; Krasinska L, 2008, CELL CYCLE, V7, P1702, DOI 10.4161/cc.7.12.6101; Lenart P, 2007, CURR BIOL, V17, P304, DOI 10.1016/j.cub.2006.12.046; Lilly MA, 2005, ONCOGENE, V24, P2765, DOI 10.1038/sj.onc.1208610; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; Medema RH, 1998, ONCOGENE, V16, P431, DOI 10.1038/sj.onc.1201558; Meijer L, 1996, TRENDS CELL BIOL, V6, P393, DOI 10.1016/0962-8924(96)10034-9; Munoz-Alonso MJ, 2012, J CELL PHYSIOL, V227, P2069, DOI 10.1002/jcp.22935; Murray AW, 2004, CELL, V116, P221, DOI 10.1016/S0092-8674(03)01080-8; Noya F, 2001, J VIROL, V75, P6121, DOI 10.1128/JVI.75.13.6121-6134.2001; Paramio JM, 1998, ONCOGENE, V17, P949, DOI 10.1038/sj.onc.1202031; Perez de Castro I, 2008, CURR OPIN PHARMACOL, V8, P375, DOI 10.1016/j.coph.2008.06.013; Planchais S, 1997, PLANT J, V12, P191, DOI 10.1046/j.1365-313X.1997.12010191.x; Planchais S, 2000, FEBS LETT, V476, P78, DOI 10.1016/S0014-5793(00)01675-6; Rheinwald JG., 1989, CELL GROWTH DIVISION, P81; Rosania GR, 1999, P NATL ACAD SCI USA, V96, P4797, DOI 10.1073/pnas.96.9.4797; Schellmann S, 2005, INT J DEV BIOL, V49, P579, DOI 10.1387/ijdb.051983ss; Seoane J, 2002, NATURE, V419, P729, DOI 10.1038/nature01119; Simpson CL, 2010, METHODS MOL BIOL, V585, P127, DOI 10.1007/978-1-60761-380-0_10; SUN TT, 1976, CELL, V9, P511, DOI 10.1016/0092-8674(76)90033-7; Swift LP, 2006, CANCER RES, V66, P4863, DOI 10.1158/0008-5472.CAN-05-3410; Taylor S, 2008, CURR OPIN CELL BIOL, V20, P77, DOI 10.1016/j.ceb.2007.11.008; Taylor WR, 2001, ONCOGENE, V20, P1803, DOI 10.1038/sj.onc.1204252; Ullah Z, 2009, CELL DIV, V4, DOI 10.1186/1747-1028-4-10; Watt FM, 2008, NAT REV CANCER, V8, P234, DOI 10.1038/nrc2328; Watt FM, 2006, CURR OPIN GENET DEV, V16, P518, DOI 10.1016/j.gde.2006.08.006; Watt FM, 2002, EMBO J, V21, P3919, DOI 10.1093/emboj/cdf399; WATT FM, 1981, J CELL BIOL, V90, P738, DOI 10.1083/jcb.90.3.738; Whittaker SR, 2007, CELL CYCLE, V6, P3114, DOI 10.4161/cc.6.24.5142; Yin XY, 2001, CANCER RES, V61, P6487; Zanet J, 2005, J CELL SCI, V118, P1693, DOI 10.1242/jcs.02298; Zanet J, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015701	65	32	33	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC	2012	31	50					5180	5192		10.1038/onc.2012.22	http://dx.doi.org/10.1038/onc.2012.22			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	055WY	22349815				2022-12-17	WOS:000312449800007
J	Macia, A; Gallel, P; Vaquero, M; Gou-Fabregas, M; Santacana, M; Maliszewska, A; Robledo, M; Gardiner, JR; Basson, MA; Matias-Guiu, X; Encinas, M				Macia, A.; Gallel, P.; Vaquero, M.; Gou-Fabregas, M.; Santacana, M.; Maliszewska, A.; Robledo, M.; Gardiner, J. R.; Basson, M. A.; Matias-Guiu, X.; Encinas, M.			Sprouty1 is a candidate tumor-suppressor gene in medullary thyroid carcinoma	ONCOGENE			English	Article						sprouty; medullary thyroid carcinoma; mouse models	RET PROTOONCOGENE; CELLULAR SENESCENCE; KINASE INHIBITOR; GDNF FAMILY; C-CELL; EXPRESSION; GROWTH; MICE; MORPHOGENESIS; PROTEINS	Medullary thyroid carcinoma (MTC) is a malignancy derived from the calcitonin-producing C-cells of the thyroid gland. Oncogenic mutations of the Ret protooncogene are found in all heritable forms of MTC and roughly one half of the sporadic cases. However, several lines of evidence argue for the existence of additional genetic lesions necessary for the development of MTC. Sprouty (Spry) family of genes is composed of four members in mammals (Spry1-4). Some Spry family members have been proposed as candidate tumor-suppressor genes in a variety of cancerous pathologies. In this work, we show that targeted deletion of Spry1 causes C-cell hyperplasia, a precancerous lesion preceding MTC, in young adult mice. Expression of Spry1 restrains proliferation of the MTC-derived cell line, TT. Finally, we found that the Spry1 promoter is frequently methylated in MTC and that Spry1 expression is consequently decreased. These findings identify Spry1 as a candidate tumor- suppressor gene in MTC. Oncogene (2012) 31, 3961-3972; doi:10.1038/onc.2011.556; published online 12 December 2011	[Macia, A.; Vaquero, M.; Gou-Fabregas, M.; Encinas, M.] Univ Lleida, Inst Recerca Biomed Lleida, Dept Expt Med, Lleida, Spain; [Gallel, P.; Santacana, M.; Matias-Guiu, X.] Univ Lleida, Inst Recerca Biomed Lleida, Dept Pathol & Mol Genet, Lleida, Spain; [Maliszewska, A.; Robledo, M.] Spanish Natl Canc Res Ctr CNIO, Hereditary Endocrine Canc Grp, Madrid, Spain; [Maliszewska, A.; Robledo, M.] Ctr Invest Biomed Red Enfermedades Raras CIBERER, Madrid, Spain; [Gardiner, J. R.; Basson, M. A.] Kings Coll London, Dept Craniofacial Dev, London WC2R 2LS, England	Institut de Recerca Biomedica - IRB Lleida; Universitat de Lleida; Institut de Recerca Biomedica - IRB Lleida; Universitat de Lleida; Centro Nacional de Investigaciones Oncologicas (CNIO); CIBER - Centro de Investigacion Biomedica en Red; CIBERER; University of London; King's College London	Encinas, M (corresponding author), Hosp Arnau Vilanova, Lab Invest UdL HUAV, Dept Med Expt, Rovira Roure 80, Lleida 25198, Spain.	mario.encinas@mex.udl.cat	Robledo, Mercedes/O-2230-2013; Encinas, Mario/B-5600-2009; Armengol, Anna Macià/V-2631-2017; matias-guiu, xavier/C-3039-2009; Gou-Fabregas, Myriam/K-1899-2016; Basson, M. Albert/C-5565-2009	Robledo, Mercedes/0000-0001-6256-5902; Encinas, Mario/0000-0003-3509-7431; Armengol, Anna Macià/0000-0001-6038-178X; matias-guiu, xavier/0000-0002-7201-6605; Gou-Fabregas, Myriam/0000-0002-5329-7640; Santacana, Maria/0000-0003-1975-2598; Vaquero Susagna, Marta/0000-0002-3856-6769; Basson, M. Albert/0000-0001-9834-7528	Ministerio de Educacion y Ciencia [BFU2007-67619, BFU2010-17628]; Fundacio La Marato de TV3; Suport als Grups de Recerca from Generalitat de Catalunya [2009 SGR 740]; programa de intensificacion de la investigacion, Instituto Carlos III; Fondo de Investigaciones Sanitarias [PI080883]; Fundacion Mutua Madrilena [AP2775/2008]; Medical Research Council [G0601104]; Tumor Banc Platform of RTICC [RD09/0076/00059]; Universitat de Lleida; Fundacio Alicia Cuello de Merigo;  [2009SGR794];  [RD06/0020/1034]; MRC [G0601104] Funding Source: UKRI	Ministerio de Educacion y Ciencia(Spanish Government); Fundacio La Marato de TV3; Suport als Grups de Recerca from Generalitat de Catalunya; programa de intensificacion de la investigacion, Instituto Carlos III; Fondo de Investigaciones Sanitarias(Instituto de Salud Carlos III); Fundacion Mutua Madrilena(Instituto de Salud Carlos III); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Tumor Banc Platform of RTICC; Universitat de Lleida; Fundacio Alicia Cuello de Merigo; ; ; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	We are grateful to Esteban J Rozen for his initial contribution to the development of this work. We also thank Ana Velasco and Carme Guerris for technical assistance. This work was supported by grants from Ministerio de Educacion y Ciencia (BFU2007-67619 and BFU2010-17628) and Fundacio La Marato de TV3, and funding from Suport als Grups de Recerca (2009 SGR 740) from Generalitat de Catalunya to ME; grants 2009SGR794,RD06/0020/1034 and programa de intensificacion de la investigacion, Instituto Carlos III to XM-G; grants from Fondo de Investigaciones Sanitarias (PI080883) and Fundacion Mutua Madrilena (AP2775/2008) to MR; and from the Medical Research Council (G0601104) to MAB Tumor samples were obtained with the support of Xarxa catalana de Bancs de Tumors, the Tumor Banc Platform of RTICC and RD09/0076/00059. AM is supported by a predoctoral fellowship from Universitat de Lleida and was supported by a fellowship from a Fundacio Alicia Cuello de Merigo. MV was recipient of a 'beca d'introduccio a la recerca fellowship from Universitat de Lleida.	Acton DS, 2000, ONCOGENE, V19, P3121, DOI 10.1038/sj.onc.1203648; Airaksinen MS, 2002, NAT REV NEUROSCI, V3, P383, DOI 10.1038/nrn812; Akeno-Stuart N, 2007, CANCER RES, V67, P6956, DOI 10.1158/0008-5472.CAN-06-4605; Aranda S, 2008, MOL CELL BIOL, V28, P5899, DOI 10.1128/MCB.00394-08; Asai N, 2006, PATHOL INT, V56, P164, DOI 10.1111/j.1440-1827.2006.01942.x; Baloh RH, 2000, CURR OPIN NEUROBIOL, V10, P103, DOI 10.1016/S0959-4388(99)00048-3; Basson MA, 2006, DEV BIOL, V299, P466, DOI 10.1016/j.ydbio.2006.08.051; Basson MA, 2005, DEV CELL, V8, P229, DOI 10.1016/j.devcel.2004.12.004; Cabrita MA, 2008, ANGIOGENESIS, V11, P53, DOI 10.1007/s10456-008-9089-1; Cerrato A, 2009, J MOL ENDOCRINOL, V43, P143, DOI 10.1677/JME-09-0024; Collado M, 2010, NAT REV CANCER, V10, P51, DOI 10.1038/nrc2772; Courtois-Cox S, 2006, CANCER CELL, V10, P459, DOI 10.1016/j.ccr.2006.10.003; Darimipourain M, 2011, PROSTATE CANCER P D, V14, P279, DOI 10.1038/pcan.2011.33; Edwin F, 2009, MOL PHARMACOL, V76, P679, DOI 10.1124/mol.109.055848; Encinas M, 2008, CELL DEATH DIFFER, V15, P1510, DOI 10.1038/cdd.2008.76; Eritja N, 2010, AM J PATHOL, V176, P2722, DOI 10.2353/ajpath.2010.090974; Fagman H, 2010, MOL CELL ENDOCRINOL, V323, P35, DOI 10.1016/j.mce.2009.12.008; Fong CW, 2006, CANCER RES, V66, P2048, DOI 10.1158/0008-5472.CAN-05-1072; Frank MJ, 2009, BLOOD, V113, P2478, DOI 10.1182/blood-2008-05-156943; Fritzsche S, 2006, ENDOCR-RELAT CANCER, V13, P839, DOI 10.1677/erc.1.01190; Gagel RF, 2003, WILLIAMS TXB ENDOCRI, P1717; Gallel P, 2008, HUM PATHOL, V39, P994, DOI 10.1016/j.humpath.2007.11.015; Guy GR, 2009, J ENDOCRINOL, V203, P191, DOI 10.1677/JOE-09-0110; Hacohen N, 1998, CELL, V92, P253, DOI 10.1016/S0092-8674(00)80919-8; Ishida M, 2007, CANCER SCI, V98, P815, DOI 10.1111/j.1349-7006.2007.00457.x; Kawai K, 2000, CANCER RES, V60, P5254; Kwabi-Addo B, 2004, CANCER RES, V64, P4728, DOI 10.1158/0008-5472.CAN-03-3759; Kwabi-Addo B, 2009, EPIGENETICS, V4, P54, DOI 10.4161/epi.4.1.7400; Lanigan F, 2011, ONCOGENE, V30, P2901, DOI 10.1038/onc.2011.34; Li LC, 2002, BIOINFORMATICS, V18, P1427, DOI 10.1093/bioinformatics/18.11.1427; Lin AW, 1998, GENE DEV, V12, P3008, DOI 10.1101/gad.12.19.3008; Litovchick L, 2011, GENE DEV, V25, P801, DOI 10.1101/gad.2034211; Llobet D, 2008, ONCOGENE, V27, P2513, DOI 10.1038/sj.onc.1210924; Majumdar A, 2003, DEVELOPMENT, V130, P3175, DOI 10.1242/dev.00520; Mason JM, 2006, TRENDS CELL BIOL, V16, P45, DOI 10.1016/j.tcb.2005.11.004; Matias-Guiu X, 2004, PATHOLOGY GENETICS T, V8, P86; McKie AB, 2005, ONCOGENE, V24, P2166, DOI 10.1038/sj.onc.1208371; Michiels FM, 1997, P NATL ACAD SCI USA, V94, P3330, DOI 10.1073/pnas.94.7.3330; Michos O, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000809; Plaza-Menacho I, 2006, TRENDS GENET, V22, P627, DOI 10.1016/j.tig.2006.09.005; Prieur A, 2008, CURR OPIN CELL BIOL, V20, P150, DOI 10.1016/j.ceb.2008.01.007; Reynolds L, 2001, ONCOGENE, V20, P3986, DOI 10.1038/sj.onc.1204434; Rozen EJ, 2009, J AM SOC NEPHROL, V20, P255, DOI 10.1681/ASN.2008030267; Santarpia L, 2009, J INTERN MED, V266, P99, DOI 10.1111/j.1365-2796.2009.02112.x; Shamma A, 2009, CANCER CELL, V15, P255, DOI 10.1016/j.ccr.2009.03.001; Smith-Hicks CL, 2000, EMBO J, V19, P612, DOI 10.1093/emboj/19.4.612; TAKAHASHI M, 1985, CELL, V42, P581, DOI 10.1016/0092-8674(85)90115-1; Taketomi T, 2005, NAT NEUROSCI, V8, P855, DOI 10.1038/nn1485; Thum T, 2008, NATURE, V456, P980, DOI 10.1038/nature07511; Velasco A, 2011, HUM PATHOL, V42, P185, DOI 10.1016/j.humpath.2010.08.001; Yaguchi Y, 2009, DEV DYNAM, V238, P2058, DOI 10.1002/dvdy.22013; Ye L, 2008, J CLIN ENDOCR METAB, V93, P4367, DOI 10.1210/jc.2008-0912; Yin L, 2007, INT J CANCER, V121, P292, DOI 10.1002/ijc.22378; Zaremba A, 2011, VIROL J, V8, DOI 10.1186/1743-422X-8-192; Zhu JY, 1998, GENE DEV, V12, P2997, DOI 10.1101/gad.12.19.2997	55	32	33	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2012	31	35					3961	3972		10.1038/onc.2011.556	http://dx.doi.org/10.1038/onc.2011.556			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	999VJ	22158037	Green Accepted, Bronze			2022-12-17	WOS:000308342800005
J	Caino, MC; Lopez-Haber, C; Kim, J; Mochly-Rosen, D; Kazanietz, MG				Caino, M. C.; Lopez-Haber, C.; Kim, J.; Mochly-Rosen, D.; Kazanietz, M. G.			Proteins kinase C epsilon is required for non-small cell lung carcinoma growth and regulates the expression of apoptotic genes	ONCOGENE			English	Article						PKC epsilon; non-small cell lung carcinoma; tumorigenesis; cell survival; apoptotic genes	CANCER CELLS; PKC-EPSILON; INHIBITORS; DEATH; OVEREXPRESSION; ACTIVATION; RECEPTOR; DELTA; SENESCENCE; MUTATIONS	Protein kinase C (PKC)epsilon, a member of the novel PKC family, has key roles in mitogenesis and survival in normal and cancer cells. PKC epsilon is frequently overexpressed in epithelial cancers, particularly in lung cancer. Using a short-hairpin RNA approach, here we established that PKCe is required for non-small cell lung carcinoma (NSCLC) growth in vitro as well as tumor growth when inoculated into athymic mice. Moreover, sustained delivery of a PKC epsilon-selective inhibitor peptide, epsilon V1-2, reduced xenograft growth in mice. Both RNA interference depletion and pharmacological inhibition of PKCe caused a marked elevation in the number of apoptotic cells in NSCLC tumors. PKC epsilon-depleted NSCLC cells show elevated expression of pro-apoptotic proteins of the Bcl2 family, caspase recruitment domain-containing proteins and tumor necrosis factor ligands/receptor superfamily members. Moreover, a Gene Set Enrichment Analysis revealed that a vast majority of the genes changed in PKC epsilon-depleted cells were also deregulated in human NSCLC. Our results strongly suggest that PKC epsilon is required for NSCLC cell survival and maintenance of NSCLC tumor growth. Therefore, PKC epsilon may represent an attractive therapeutic target for NSCLC. Oncogene (2012) 31, 2593-2600; doi:10.1038/onc.2011.428; published online 26 September 2011	[Caino, M. C.; Lopez-Haber, C.; Kazanietz, M. G.] Univ Penn, Sch Med, Dept Pharmacol, Philadelphia, PA 19104 USA; [Kim, J.] Stanford Sch Med, Stanford Comprehens Canc Ctr, Stanford, CA USA; [Mochly-Rosen, D.] Stanford Sch Med, Dept Chem & Syst Biol, Stanford, CA USA	University of Pennsylvania; Stanford University; Stanford University	Kazanietz, MG (corresponding author), Univ Penn, Sch Med, Dept Pharmacol, 1256 BRB 2-3,421 Curie Blvd, Philadelphia, PA 19104 USA.	marcelog@upenn.edu		Kim, Jeewon/0000-0002-1063-0239; Caino, M. Cecilia/0000-0001-8294-8070; Mochly-Rosen, Daria/0000-0002-6691-8733; Lopez Haber, Cynthia/0000-0001-9106-543X	NCI NIH HHS [R01 CA074197] Funding Source: Medline; NHLBI NIH HHS [R01 HL052141] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA074197] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052141] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bae KM, 2007, CANCER RES, V67, P6053, DOI 10.1158/0008-5472.CAN-06-4037; Bain J, 2003, BIOCHEM J, V371, P199, DOI 10.1042/BJ20021535; Bain J, 2007, BIOCHEM J, V408, P297, DOI 10.1042/BJ20070797; BARR LF, 1991, CANCER RES, V51, P5514; Barry OP, 2001, CURR PHARM DESIGN, V7, P1725, DOI 10.2174/1381612013397041; Basu A, 2007, CELL SIGNAL, V19, P1633, DOI 10.1016/j.cellsig.2007.04.008; Begley R, 2004, BIOCHEM BIOPH RES CO, V318, P949, DOI 10.1016/j.bbrc.2004.04.121; Benavides F, 2011, CELL CYCLE, V10, P268, DOI 10.4161/cc.10.2.14469; Bhattacharjee A, 2001, P NATL ACAD SCI USA, V98, P13790, DOI 10.1073/pnas.191502998; Black JD, 2000, FRONT BIOSCI-LANDMRK, V5, pD406, DOI 10.2741/Black; Brodie C, 2003, APOPTOSIS, V8, P19, DOI 10.1023/A:1021640817208; Budas GR, 2007, BIOCHEM SOC T, V35, P1021, DOI 10.1042/BST0351021; Caino MC, 2011, J BIOL CHEM, V286, P11254, DOI 10.1074/jbc.M110.194332; Caino MC, 2009, APOPTOSIS, V14, P392, DOI 10.1007/s10495-009-0316-z; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; Felber M, 2007, PATHOL ONCOL RES, V13, P295, DOI 10.1007/BF02940308; FLEISCHMAN LF, 1986, SCIENCE, V231, P407, DOI 10.1126/science.3001936; Goekjian PG, 2001, EXPERT OPIN INV DRUG, V10, P2117; Gorin MA, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-9; Gray MO, 1997, J BIOL CHEM, V272, P30945, DOI 10.1074/jbc.272.49.30945; Griner EM, 2007, NAT REV CANCER, V7, P281, DOI 10.1038/nrc2110; HAN EKH, 1995, CARCINOGENESIS, V16, P2423, DOI 10.1093/carcin/16.10.2423; HSIAO WLW, 1989, MOL CELL BIOL, V9, P2641, DOI 10.1128/MCB.9.6.2641; Inagaki K, 2005, CIRCULATION, V111, P44, DOI 10.1161/01.CIR.0000151614.22282.F1; Jansen AP, 2001, CANCER RES, V61, P808; Koyanagi T, 2007, J MOL CELL CARDIOL, V43, P517, DOI 10.1016/j.yjmcc.2007.06.003; Lemmon MA, 2010, CELL, V141, P1117, DOI 10.1016/j.cell.2010.06.011; Lu DM, 2006, J BIOL CHEM, V281, P22799, DOI 10.1074/jbc.M603390200; Malumbres M, 2003, NAT REV CANCER, V3, P459, DOI 10.1038/nrc1097; MATYAS GR, 1989, CELL SIGNAL, V1, P395, DOI 10.1016/0898-6568(89)90058-2; McJilton MA, 2003, ONCOGENE, V22, P7958, DOI 10.1038/sj.onc.1206795; MISCHAK H, 1993, J BIOL CHEM, V268, P6090; Mochly-Rosen D, 1998, ADV PHARMACOL, V44, P91, DOI 10.1016/S1054-3589(08)60126-X; Nakagawa M, 2005, J BIOL CHEM, V280, P33926, DOI 10.1074/jbc.M505748200; Okhrimenko H, 2005, CANCER RES, V65, P7301, DOI 10.1158/0008-5472.CAN-05-1064; Oliva JL, 2008, J BIOL CHEM, V283, P5466, DOI 10.1074/jbc.M707576200; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Pao W, 2004, P NATL ACAD SCI USA, V101, P13306, DOI 10.1073/pnas.0405220101; Parker PJ, 2004, J CELL SCI, V117, P131, DOI 10.1242/jcs.00982; Perletti GP, 1996, ONCOGENE, V12, P847; PREISS J, 1986, J BIOL CHEM, V261, P8597; RUSCH V, 1993, CANCER RES, V53, P2379; Sekido Y, 2003, ANNU REV MED, V54, P73, DOI 10.1146/annurev.med.54.101601.152202; Serova M, 2006, SEMIN ONCOL, V33, P466, DOI 10.1053/j.seminoncol.2006.04.009; Slupsky JR, 2007, AM J PATHOL, V170, P745, DOI 10.2353/ajpath.2007.060557; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Toker Alex, 1998, Frontiers in Bioscience, V3, pD1134	47	32	33	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY	2012	31	20					2593	2600		10.1038/onc.2011.428	http://dx.doi.org/10.1038/onc.2011.428			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	944ID	21996750	Green Accepted			2022-12-17	WOS:000304191800009
J	Hsu, T				Hsu, T.			Complex cellular functions of the von Hippel-Lindau tumor suppressor gene: insights from model organisms	ONCOGENE			English	Review						VHL; HIF; model organisms	HYPOXIA-INDUCIBLE FACTOR; VHL GENE; CONDITIONAL INACTIVATION; VASCULAR TUMORS; HIF-ALPHA; PROTEIN; DROSOPHILA; OXYGEN; PVHL; MUTATION	The von Hippel-Lindau tumor suppressor gene (VHL) has attracted intensive interest not only because its mutations predispose carriers to devastating tumors, but also because it is involved in oxygen sensing under physiological conditions. VHL loss-of-function mutations result in organ-specific tumors, such as hemangioblastoma of the central nervous system and renal cell carcinoma, both untreatable with conventional chemotherapies. The VHL protein is best known as an E3 ubiquitin ligase that targets hypoxia-inducible factor-alpha (HIF-alpha), but many diverse, non-canonical cellular functions have also been assigned to VHL, mainly based on studies in cell culture systems. As such, although the HIF-dependent role of VHL is critical, the full spectrum of pathophysiological functions of VHL is still unresolved. Such understanding requires careful cross-referencing with physiologically relevant experimental models. Studies in model systems, such as Caenorhabditis elegans, Drosophila, zebrafish and mouse have provided critical in vivo confirmation of the VHL-HIF pathway, and verification of potentially important cellular functions including microtubule stabilization and epithelial morphogenesis. More recently, animal models have also suggested systemic roles of VHL in hematopoiesis, metabolic homeostasis and inflammation. In this review, the studies performed in model organisms will be summarized and placed in context with existing clinical and in vitro data. Oncogene (2012) 31, 2247-2257; doi:10.1038/onc.2011.442; published online 26 September 2011	Boston Univ, Sch Med, Dept Med, Boston, MA 02118 USA	Boston University	Hsu, T (corresponding author), Boston Univ, Sch Med, Dept Med, 650 Albany St,Rm 440, Boston, MA 02118 USA.	tienh@bu.edu		Hsu, Tien/0000-0003-2308-4297	National Cancer Institute (USA) [RO1CA109860]; NATIONAL CANCER INSTITUTE [R01CA109860] Funding Source: NIH RePORTER	National Cancer Institute (USA)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was funded by the National Cancer Institute (USA) grant (RO1CA109860).	Adryan B, 2000, ONCOGENE, V19, P2803, DOI 10.1038/sj.onc.1203611; Akis N, 2004, KIDNEY INT, V65, P2223, DOI 10.1111/j.1523-1755.2004.00634.x; Alexander A, 2011, FEBS LETT, V585, P952, DOI 10.1016/j.febslet.2011.03.010; Arquier N, 2006, BIOCHEM J, V393, P471, DOI 10.1042/BJ20050675; Aso T, 2000, BIOCHEM BIOPH RES CO, V276, P355, DOI 10.1006/bbrc.2000.3451; Banks RE, 2006, CANCER RES, V66, P2000, DOI 10.1158/0008-5472.CAN-05-3074; Bartolini F, 2006, J CELL SCI, V119, P4155, DOI 10.1242/jcs.03227; Behr M, 2007, NAT CELL BIOL, V9, P847, DOI 10.1038/ncb1611; Berra E, 2003, EMBO J, V22, P4082, DOI 10.1093/emboj/cdg392; Betschinger J, 2005, CURR BIOL, V15, P276, DOI 10.1016/j.cub.2005.01.012; Biju MP, 2004, MOL CELL BIOL, V24, P9038, DOI 10.1128/MCB.24.20.9038-9047.2004; Bilder D, 2003, NAT CELL BIOL, V5, P53, DOI 10.1038/ncb897; Bishop T, 2004, PLOS BIOL, V2, P1549, DOI 10.1371/journal.pbio.0020289; BRAUCH H, 1995, HUM GENET, V95, P551, DOI 10.1007/BF00223868; Brukamp K, 2007, AM J PHYSIOL-RENAL, V293, pF1397, DOI 10.1152/ajprenal.00133.2007; Bushuev VI, 2006, HAEMATOLOGICA, V91, P744; Centanin L, 2008, DEV CELL, V14, P547, DOI 10.1016/j.devcel.2008.01.020; Champion KJ, 2008, CANCER RES, V68, P4649, DOI 10.1158/0008-5472.CAN-07-6003; Cho D, 2007, CLIN CANCER RES, V13, p758S, DOI 10.1158/1078-0432.CCR-06-1986; Clark PE, 2009, KIDNEY INT, V76, P939, DOI 10.1038/ki.2009.296; Colotta F, 2009, CARCINOGENESIS, V30, P1073, DOI 10.1093/carcin/bgp127; Dammai V, 2003, GENE DEV, V17, P2812, DOI 10.1101/gad.1096903; Danilin S, 2009, CARCINOGENESIS, V30, P387, DOI 10.1093/carcin/bgn275; Datta K, 2005, ONCOGENE, V24, P7850, DOI 10.1038/sj.onc.1208912; Doronkin S, 2010, ONCOGENE, V29, P1123, DOI 10.1038/onc.2009.407; Duchek P, 2001, CELL, V107, P17, DOI 10.1016/S0092-8674(01)00502-5; Duchi S, 2010, DEVELOPMENT, V137, P1493, DOI 10.1242/dev.042804; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Esteban MA, 2006, J AM SOC NEPHROL, V17, P1801, DOI 10.1681/ASN.2006020181; Feijoo-Cuaresma M, 2008, J BIOL CHEM, V283, P24982, DOI 10.1074/jbc.M709390200; Frew IJ, 2008, EMBO J, V27, P1747, DOI 10.1038/emboj.2008.96; Frew IJ, 2008, MOL CELL BIOL, V28, P4536, DOI 10.1128/MCB.02132-07; Frew IJ, 2007, CURR OPIN CELL BIOL, V19, P685, DOI 10.1016/j.ceb.2007.10.001; Frew IJ, 2008, SCI SIGNAL, V1, DOI 10.1126/scisignal.124pe30; GAO JZ, 1995, CANCER RES, V55, P743; Ghabrial A, 2003, ANNU REV CELL DEV BI, V19, P623, DOI 10.1146/annurev.cellbio.19.031403.160043; Gnarra JR, 1997, P NATL ACAD SCI USA, V94, P9102, DOI 10.1073/pnas.94.17.9102; Gordeuk VR, 2004, BLOOD, V103, P3924, DOI 10.1182/blood-2003-07-2535; Grivennikov SI, 2010, CELL, V140, P883, DOI 10.1016/j.cell.2010.01.025; Guo Y, 2009, ONCOGENE, V28, P1864, DOI 10.1038/onc.2009.35; Haase VH, 2001, P NATL ACAD SCI USA, V98, P1583, DOI 10.1073/pnas.98.4.1583; Harten SK, 2009, MOL BIOL CELL, V20, P1089, DOI 10.1091/mbc.E08-06-0566; Hergovich A, 2003, NAT CELL BIOL, V5, P64, DOI 10.1038/ncb899; HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700; Hickey MM, 2010, J CLIN INVEST, V120, P827, DOI 10.1172/JCI36362; Higgins DF, 2007, J CLIN INVEST, V117, P3810, DOI 10.1172/JCI30487; Hong SB, 2006, LAB INVEST, V86, P664, DOI 10.1038/labinvest.3700431; Hsouna A, 2010, MOL CELL BIOL, V30, P3779, DOI 10.1128/MCB.01578-09; Hsu T, 2006, J BIOL CHEM, V281, P12069, DOI 10.1074/jbc.M511621200; Hussain SP, 2003, NAT REV CANCER, V3, P276, DOI 10.1038/nrc1046; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Jarecki J, 1999, CELL, V99, P211, DOI 10.1016/S0092-8674(00)81652-9; Kaelin WG, 2005, COLD SH Q B, V70, P159, DOI 10.1101/sqb.2005.70.001; Kaelin WG, 2009, CANCER-AM CANCER SOC, V115, P2262, DOI 10.1002/cncr.24232; Kamura T, 1999, SCIENCE, V284, P657, DOI 10.1126/science.284.5414.657; Kapitsinou PP, 2008, CELL DEATH DIFFER, V15, P650, DOI 10.1038/sj.cdd.4402313; KESSLER PM, 1995, MOL MED, V1, P457, DOI 10.1007/BF03401583; Kim WY, 2004, J CLIN ONCOL, V22, P4991, DOI 10.1200/JCO.2004.05.061; Kimura K, 2008, AM J PHYSIOL-RENAL, V295, pF1023, DOI 10.1152/ajprenal.90209.2008; Kraus S, 2009, CURR OPIN PHARMACOL, V9, P405, DOI 10.1016/j.coph.2009.06.006; Kurban G, 2008, ONCOGENE, V27, P1004, DOI 10.1038/sj.onc.1210709; LATIF F, 1993, SCIENCE, V260, P1317, DOI 10.1126/science.8493574; Lisztwan J, 1999, GENE DEV, V13, P1822, DOI 10.1101/gad.13.14.1822; Lonergan KM, 1998, MOL CELL BIOL, V18, P732, DOI 10.1128/MCB.18.2.732; Lonser RR, 2003, LANCET, V361, P2059, DOI 10.1016/S0140-6736(03)13643-4; Ma WB, 2003, CANCER RES, V63, P5320; Ma XJM, 2009, NAT REV MOL CELL BIO, V10, P307, DOI 10.1038/nrm2672; Maher ER, 2011, EUR J HUM GENET, V19, P617, DOI 10.1038/ejhg.2010.175; Mandriota SJ, 2002, CANCER CELL, V1, P459, DOI 10.1016/S1535-6108(02)00071-5; McDonald JA, 2003, DEVELOPMENT, V130, P3469, DOI 10.1242/dev.00574; Mikhaylova O, 2008, MOL CELL BIOL, V28, P2701, DOI 10.1128/MCB.01231-07; Montell DJ, 2003, NAT REV MOL CELL BIO, V4, P13, DOI 10.1038/nrm1006; Mortimer NT, 2009, DEV BIOL, V329, P294, DOI 10.1016/j.ydbio.2009.03.001; Muller RU, 2009, J AM SOC NEPHROL, V20, P2513, DOI 10.1681/ASN.2009050497; Nallamothu G, 2008, MOL CELL BIOL, V28, P1964, DOI 10.1128/MCB.01743-07; Nallamothu G, 2009, MOL CELL BIOCHEM, V329, P35, DOI 10.1007/s11010-009-0112-7; Ohh M, 1998, MOL CELL, V1, P959, DOI 10.1016/S1097-2765(00)80096-9; Park DM, 2007, PLOS MED, V4, P333, DOI 10.1371/journal.pmed.0040060; Pause A, 1997, P NATL ACAD SCI USA, V94, P2156, DOI 10.1073/pnas.94.6.2156; Pfander D, 2004, DEVELOPMENT, V131, P2497, DOI 10.1242/dev.01138; Rankin EB, 2006, CANCER RES, V66, P2576, DOI 10.1158/0008-5472.CAN-05-3241; Rorth P, 2002, TRENDS CELL BIOL, V12, P325, DOI 10.1016/S0962-8924(02)02311-5; Schermer B, 2006, J CELL BIOL, V175, P547, DOI 10.1083/jcb.200605092; Shen C, 2005, J BIOL CHEM, V280, P20580, DOI 10.1074/jbc.M501894200; Shen HCJ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004897; Smith TG, 2006, PLOS MED, V3, P1178, DOI 10.1371/journal.pmed.0030290; Staller P, 2003, NATURE, V425, P307, DOI 10.1038/nature01874; Stebbins CE, 1999, SCIENCE, V284, P455, DOI 10.1126/science.284.5413.455; Stenmark KR, 2006, CIRC RES, V99, P675, DOI 10.1161/01.RES.0000243584.45145.3f; Suzuki A, 2006, J CELL SCI, V119, P979, DOI 10.1242/jcs.02898; Takubo K, 2010, CELL STEM CELL, V7, P391, DOI 10.1016/j.stem.2010.06.020; Tang N, 2006, MOL CELL BIOL, V26, P2519, DOI 10.1128/MCB.26.7.2519-2530.2006; Thoma CR, 2007, NAT CELL BIOL, V9, P588, DOI 10.1038/ncb1579; Thoma CR, 2009, NAT CELL BIOL, V11, P994, DOI 10.1038/ncb1912; Thomas GV, 2006, NAT MED, V12, P122, DOI 10.1038/nm1337; Tsarouhas V, 2007, DEV CELL, V13, P214, DOI 10.1016/j.devcel.2007.06.008; Uv A, 2003, TRENDS CELL BIOL, V13, P301, DOI 10.1016/S0962-8924(03)00083-7; van der Velden YU, 2011, P NATL ACAD SCI USA, V108, P4358, DOI 10.1073/pnas.1010210108; van Rooijen E, 2010, DIS MODEL MECH, V3, P343, DOI 10.1242/dmm.004036; van Rooijen E, 2009, BLOOD, V113, P6449, DOI 10.1182/blood-2008-07-167890; Vortmeyer AO, 1997, HUM PATHOL, V28, P540, DOI 10.1016/S0046-8177(97)90075-7; Wang Y, 2009, NAT MED, V15, P319, DOI 10.1038/nm.1922; Wilhelm S, 2006, NAT REV DRUG DISCOV, V5, P835, DOI 10.1038/nrd2130; Wingrove JA, 1999, CELL, V98, P105, DOI 10.1016/S0092-8674(00)80610-8; Woodward ER, 2000, GENOMICS, V65, P253, DOI 10.1006/geno.2000.6144; Woolworth JA, 2009, MOL CELL BIOL, V29, P4679, DOI 10.1128/MCB.00297-09; Yamanaka T, 2003, CURR BIOL, V13, P734, DOI 10.1016/S0960-9822(03)00244-6; Yang H, 2007, MOL CELL, V28, P15, DOI 10.1016/j.molcel.2007.09.010; Yaqoob N, 2010, COMP BIOCHEM PHYS A, V156, P475, DOI 10.1016/j.cbpa.2010.03.033; Young AP, 2008, NAT CELL BIOL, V10, P361, DOI 10.1038/ncb1699; Zehetner J, 2008, GENE DEV, V22, P3135, DOI 10.1101/gad.496908; ZLOTOGORA J, 1994, AM J MED GENET, V49, P10, DOI 10.1002/ajmg.1320490104	113	32	36	1	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2012	31	18					2247	2257		10.1038/onc.2011.442	http://dx.doi.org/10.1038/onc.2011.442			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	936SR	21996733	Green Accepted			2022-12-17	WOS:000303610800001
J	Carrascosa, C; Obula, RG; Missiaglia, E; Lehr, HA; Delorenzi, M; Frattini, M; Ruegg, C; Mariotti, A				Carrascosa, C.; Obula, R. G.; Missiaglia, E.; Lehr, H-A; Delorenzi, M.; Frattini, M.; Rueegg, C.; Mariotti, A.			MFG-E8/lactadherin regulates cyclins D1/D3 expression and enhances the tumorigenic potential of mammary epithelial cells	ONCOGENE			English	Article						MFG-E8; mammary tumorigenesis; neoplastic transformation; cyclin D; N-cadherin	MILK-FAT GLOBULE; BREAST-CANCER; N-CADHERIN; PREOPERATIVE CHEMOTHERAPY; MONOCLONAL-ANTIBODIES; ESTROGEN-RECEPTOR; APOPTOTIC CELLS; TUMOR; CARCINOMA; PROTEIN	Milk fat globule-EGF factor 8 (MFG-E8) is a glycoprotein highly expressed in breast cancer that contributes to tumor progression through largely undefined mechanisms. By analyzing publicly available gene expression profiles of breast carcinomas, we found that MFG-E8 is highly expressed in primary and metastatic breast carcinomas, associated with absent estrogen receptor expression. Immunohistochemistry analysis of breast cancer biopsies revealed that MFG-E8 is expressed on the cell membrane as well as in the cytoplasm and nucleus. We also show that increased expression of MFG-E8 in mammary carcinoma cells increases their tumorigenicity in immunodeficient mice, and conversely, its downregulation reduces their in vivo growth. Moreover, expression of MFG-E8 in immortalized mammary epithelial cells promotes their growth and branching in three-dimensional collagen matrices and induces the expression of cyclins D1/D3 and N-cadherin. A mutant protein unable to bind integrins can in part exert these effects, indicating that MFG-E8 function is only partially dependent on integrin activation. We conclude that MFG-E8-dependent signaling stimulates cell proliferation and the acquisition of mesenchymal properties and contributes to mammary carcinoma development. Oncogene (2012) 31, 1521-1532; doi:10.1038/onc.2011.356; published online 15 August 2011	[Carrascosa, C.; Mariotti, A.] Univ Lausanne, Div Expt Oncol, Ctr Pluridisciplinaire Oncol, Lausanne Canc Ctr, CH-1066 Epalinges, Switzerland; [Missiaglia, E.; Delorenzi, M.] Univ Lausanne, Swiss Inst Bioinformat, Lausanne, Switzerland; [Lehr, H-A] CHUV, Inst Pathol, Lausanne, Switzerland; [Delorenzi, M.; Mariotti, A.] Univ Lausanne, Dept Format & Rech, CHUV, Lausanne, Switzerland; [Frattini, M.] Inst Pathol, Lab Mol Diagnost, Locarno, Switzerland; [Rueegg, C.] Univ Fribourg, Dept Med, CH-1700 Fribourg, Switzerland	University of Lausanne; Swiss Institute of Bioinformatics; University of Lausanne; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Fribourg	Mariotti, A (corresponding author), Univ Lausanne, Div Expt Oncol, Ctr Pluridisciplinaire Oncol, Lausanne Canc Ctr, 155 Ch Boveresses,Room D203, CH-1066 Epalinges, Switzerland.	Agnese.Mariotti@unil.ch		missiaglia, edoardo/0000-0001-9221-0117; Mariotti, Agnese/0000-0002-3704-7908	MEDIC Foundation	MEDIC Foundation	This work was supported by a grant from the MEDIC Foundation to AM. We thank J-C Stehle and J Horlbeck of the UNIL Mouse Pathology facility for help with immunohistochemistry, F Botta for help in obtaining the breast carcinoma biopsies, C Brisken for reagents and T Petrova for discussions and support.	Andersen MH, 1997, BIOCHEMISTRY-US, V36, P5441, DOI 10.1021/bi963119m; ASLAKSON CJ, 1992, CANCER RES, V52, P1399; Atabai K, 2005, MOL BIOL CELL, V16, P5528, DOI 10.1091/mbc.E05-02-0128; Ayers M, 2004, J CLIN ONCOL, V22, P2284, DOI 10.1200/JCO.2004.05.166; CERIANI RL, 1982, P NATL ACAD SCI-BIOL, V79, P5420, DOI 10.1073/pnas.79.17.5420; CERIANI RL, 1977, P NATL ACAD SCI USA, V74, P582, DOI 10.1073/pnas.74.2.582; CERIANI RL, 1987, CANCER RES, V47, P532; Cowin P, 2005, CURR OPIN CELL BIOL, V17, P499, DOI 10.1016/j.ceb.2005.08.014; Ensslin MA, 2007, P NATL ACAD SCI USA, V104, P2715, DOI 10.1073/pnas.0610296104; Hanayama R, 2002, NATURE, V417, P182, DOI 10.1038/417182a; Hanayama R, 2005, P NATL ACAD SCI USA, V102, P16886, DOI 10.1073/pnas.0508599102; Hanayama R, 2004, SCIENCE, V304, P1147, DOI 10.1126/science.1094359; Hazan RB, 2000, J CELL BIOL, V148, P779, DOI 10.1083/jcb.148.4.779; Hess KR, 2006, J CLIN ONCOL, V24, P4236, DOI 10.1200/JCO.2006.05.6861; Janda E, 2002, J CELL BIOL, V156, P299, DOI 10.1083/jcb.200109037; Jinushi M, 2008, CANCER RES, V68, P8889, DOI 10.1158/0008-5472.CAN-08-2147; Jinushi M, 2009, J EXP MED, V206, P1317, DOI 10.1084/jem.20082614; Joel PB, 1998, J BIOL CHEM, V273, P13317, DOI 10.1074/jbc.273.21.13317; LAROCCA D, 1991, CANCER RES, V51, P4994; Lee MH, 2003, CANCER METAST REV, V22, P435, DOI 10.1023/A:1023785332315; Lincoln DW, 2003, BREAST CANCER RES TR, V78, P167, DOI 10.1023/A:1022904624054; Loi S, 2007, J CLIN ONCOL, V25, P1239, DOI 10.1200/JCO.2006.07.1522; Miller LD, 2005, P NATL ACAD SCI USA, V102, P13550, DOI 10.1073/pnas.0506230102; Nagi C, 2005, BREAST CANCER RES TR, V94, P225, DOI 10.1007/s10549-005-7727-5; Neutzner M, 2007, CANCER RES, V67, P6777, DOI 10.1158/0008-5472.CAN-07-0165; Oft M, 1996, GENE DEV, V10, P2462, DOI 10.1101/gad.10.19.2462; Oshima K, 1999, BIOCHEM BIOPH RES CO, V254, P522, DOI 10.1006/bbrc.1998.0107; Peintinger F, 2007, CLIN CANCER RES, V13, P4078, DOI 10.1158/1078-0432.CCR-06-2600; PETERSON JA, 1990, HYBRIDOMA, V9, P221, DOI 10.1089/hyb.1990.9.221; Raymond A, 2009, J CELL BIOCHEM, V106, P957, DOI 10.1002/jcb.22076; Roy PG, 2006, BREAST, V15, P718, DOI 10.1016/j.breast.2006.02.005; Russell A, 1999, ONCOGENE, V18, P1983, DOI 10.1038/sj.onc.1202511; Silvestre JS, 2005, NAT MED, V11, P499, DOI 10.1038/nm1233; Suyama K, 2002, CANCER CELL, V2, P301, DOI 10.1016/S1535-6108(02)00150-2; Symmans WF, 2003, CANCER, V97, P2960, DOI 10.1002/cncr.11435; Taubenberger AV, 2010, BIOMATERIALS, V31, P2827, DOI 10.1016/j.biomaterials.2009.12.051; Taylor MR, 1997, DNA CELL BIOL, V16, P861, DOI 10.1089/dna.1997.16.861; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; Yang CW, 2011, CANCER RES, V71, P937, DOI 10.1158/0008-5472.CAN-10-1471; Yu QY, 2001, NATURE, V411, P1017, DOI 10.1038/35082500	40	32	35	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR	2012	31	12					1521	1532		10.1038/onc.2011.356	http://dx.doi.org/10.1038/onc.2011.356			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	916VT	21841820	Green Submitted			2022-12-17	WOS:000302132000005
J	Mao, JH; Wu, D; Kim, IJ; Kang, HC; Wei, G; Climent, J; Kumar, A; Pelorosso, FG; DelRosario, R; Huang, EJ; Balmain, A				Mao, J-H; Wu, D.; Kim, I-J; Kang, H. C.; Wei, G.; Climent, J.; Kumar, A.; Pelorosso, F. G.; DelRosario, R.; Huang, E. J.; Balmain, A.			Hipk2 cooperates with p53 to suppress gamma-ray radiation-induced mouse thymic lymphoma	ONCOGENE			English	Article						Hipk2; p53; radiation; tumorigenesis	INTERACTING PROTEIN KINASE-2; TRANSCRIPTION; TUMORS; GENE	A genome-wide screen for genetic alterations in radiation-induced thymic lymphomas generated from p53+/- and p53-/- mice showed frequent loss of heterozygosity (LOH) on chromosome 6. Fine mapping of these LOH regions revealed three non-overlapping regions, one of which was refined to a 0.2 Mb interval that contained only the gene encoding homeobox-interacting protein kinase 2 (Hipk2). More than 30% of radiation-induced tumors from both p53+/- and p53-/- mice showed heterozygous loss of one Hipk2 allele. Mice carrying a single inactive allele of Hipk2 in the germline were susceptible to induction of tumors by gamma-radiation, but most tumors retained and expressed the wild-type allele, suggesting that Hipk2 is a haploinsufficient tumor suppressor gene for mouse lymphoma development. Heterozygous loss of both Hipk2 and p53 confers strong sensitization to radiation-induced lymphoma. We conclude that Hipk2 is a haploinsufficient lymphoma suppressor gene. Oncogene (2012) 31, 1176-1180; doi:10.1038/onc.2011.306; published online 25 July 2011	[Wu, D.; Kim, I-J; Kang, H. C.; Climent, J.; Kumar, A.; Pelorosso, F. G.; DelRosario, R.; Balmain, A.] Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94158 USA; [Mao, J-H] Univ Calif Berkeley, Lawrence Berkeley Natl Lab, Div Life Sci, Berkeley, CA 94720 USA; [Wei, G.; Huang, E. J.] Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94140 USA; [Wei, G.; Huang, E. J.] Vet Affairs Med Ctr, Pathol Serv 113B, San Francisco, CA 94121 USA	University of California System; University of California San Francisco; UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer Center; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Balmain, A (corresponding author), Helen Diller Family Comprehens Canc Ctr, 1450 3rd St, San Francisco, CA 94158 USA.	abalmain@cc.ucsf.edu	Climent, Joan/O-5877-2017; Mao, Jian-Hua/EIZ-8595-2022; Wei, Grace/GPX-0836-2022; Huang, Eric J./AAH-7997-2019	Climent, Joan/0000-0002-8927-6614; Mao, Jian-Hua/0000-0001-9320-6021; Huang, Eric J./0000-0002-5381-3801	NIH/NCI [U01 CA84244R, 01 CA116481]; DOE [DE-FG02-03ER63630]; Office of Biological and Environmental Research of the US Department of Energy [DE-AC02-05CH11231]; Laboratory Directed Research and Development Program (LDRD); UCSF Genome Analysis Core; Barbara Bass Bakar Chair of Cancer Genetics; NATIONAL CANCER INSTITUTE [R01CA116481, U01CA084244] Funding Source: NIH RePORTER	NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); DOE(United States Department of Energy (DOE)); Office of Biological and Environmental Research of the US Department of Energy(United States Department of Energy (DOE)); Laboratory Directed Research and Development Program (LDRD); UCSF Genome Analysis Core; Barbara Bass Bakar Chair of Cancer Genetics; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	These studies were supported by NIH/NCI grant U01 CA84244 and the DOE (DE-FG02-03ER63630) to AB, and NIH/NCI grant R01 CA116481, Office of Biological and Environmental Research of the US Department of Energy under Contract No DE-AC02-05CH11231 and Laboratory Directed Research and Development Program (LDRD) to JHM. AB acknowledges support from the UCSF Genome Analysis Core and the Barbara Bass Bakar Chair of Cancer Genetics.	Cai WW, 2002, NAT BIOTECHNOL, V20, P393, DOI 10.1038/nbt0402-393; D'Orazi G, 2002, NAT CELL BIOL, V4, P11, DOI 10.1038/ncb714; Dauth I, 2007, CANCER RES, V67, P2274, DOI 10.1158/0008-5472.CAN-06-2884; Deshmukh H, 2008, ONCOGENE, V27, P4745, DOI 10.1038/onc.2008.110; Di Stefano V, 2004, ONCOGENE, V23, P5185, DOI 10.1038/sj.onc.1207656; Hofmann TG, 2002, NAT CELL BIOL, V4, P1, DOI 10.1038/ncb715; Kanei-Ishii C, 2004, J BIOL CHEM, V279, P44582, DOI 10.1074/jbc.M407831200; Li XL, 2007, ONCOGENE, V26, P7231, DOI 10.1038/sj.onc.1210523; Mao JH, 2004, NATURE, V432, P775, DOI 10.1038/nature03155; Mao JH, 2007, CANCER CELL, V11, P161, DOI 10.1016/j.ccr.2006.11.025; Mitelman F, 2010, MITELMAN DATABASE CH; Pierantoni GM, 2007, J CLIN INVEST, V117, P693, DOI 10.1172/JCI29852; Pierantoni GM, 2001, ONCOGENE, V20, P6132, DOI 10.1038/sj.onc.1204635; Pistritto G, 2007, CELL DEATH DIFFER, V14, P1837, DOI 10.1038/sj.cdd.4402186; Trapasso F, 2009, DNA CELL BIOL, V28, P161, DOI 10.1089/dna.2008.0778; Wei GW, 2007, P NATL ACAD SCI USA, V104, P13040, DOI 10.1073/pnas.0703213104; Zhang OH, 2003, CELL, V115, P177, DOI 10.1016/S0092-8674(03)00802-X	17	32	33	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2012	31	9					1176	1180		10.1038/onc.2011.306	http://dx.doi.org/10.1038/onc.2011.306			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	901EW	21785465	Green Published, hybrid, Green Submitted			2022-12-17	WOS:000300945900010
J	Arwert, EN; Mentink, RA; Driskell, RR; Hoste, E; Goldie, SJ; Quist, S; Watt, FM				Arwert, E. N.; Mentink, R. A.; Driskell, R. R.; Hoste, E.; Goldie, S. J.; Quist, S.; Watt, F. M.			Upregulation of CD26 expression in epithelial cells and stromal cells during wound-induced skin tumour formation	ONCOGENE			English	Article						epidermis; MEK1; IL-1 alpha; CD26; dipeptidyl peptidase-4; Sitagliptin	DIPEPTIDYL-PEPTIDASE-IV; ENZYME-ACTIVITY; EPIDERMAL-CELLS; STEM-CELLS; KERATINOCYTES; INHIBITION; DIFFERENTIATION; PROLIFERATION; GLYCOSYLATION; SITAGLIPTIN	We have previously described InvEE transgenic mice in which non-dividing, differentiating epidermal cells express oncogenically activated MAPK kinase 1 (MEK1). Skin wounding triggers tumour formation in InvEE mice via a mechanism that involves epidermal release of IL-1 alpha and attraction of a pro-tumorigenic inflammatory infiltrate. To look for potential effects on the underlying connective tissue, we screened InvEE and wild-type epidermis for differential expression of cytokines and immune modulators. We identified a single protein, CD26 (dipeptidyl peptidase-4). CD26 serum levels were not increased in InvEE mice. In contrast, CD26 was upregulated in keratinocytes expressing mutant MEK1 and in the epithelial compartment of InvEE tumours, where it accumulated at cell-cell borders. CD26 expression was increased in dermal fibroblasts following skin wounding but was downregulated in tumour stroma. CD26 activity was stimulated by calcium-induced intercellular adhesion in keratinocytes, suggesting that the upregulation of CD26 in InvEE epidermis is due to expansion of the differentiated cell layers. IL-1 alpha treatment of dermal fibroblasts stimulated CD26 activity, and therefore epidermal IL-1 alpha release may contribute to the upregulation of CD26 expression in wounded dermis. Pharmacological blockade of CD26, via Sitagliptin, reduced growth of InvEE tumours, while combined inhibition of IL-1 alpha and CD26 delayed tumour onset and reduced tumour incidence. Our results demonstrate that inappropriate activation of MEK1 in the epidermis leads to changes in dermal fibroblasts that, like the skin inflammatory infiltrate, contribute to tumour formation. Oncogene (2012) 31, 992-1000; doi:10.1038/onc.2011.298; published online 18 July 2011	[Arwert, E. N.; Mentink, R. A.; Hoste, E.; Goldie, S. J.; Quist, S.; Watt, F. M.] Li Ka Shing Ctr, Canc Res UK Cambridge Res Inst, Cambridge CB2 0RE, Cambs, England; [Driskell, R. R.; Watt, F. M.] Wellcome Trust Ctr Stem Cell Res, Cambridge, England	Cancer Research UK; CRUK Cambridge Institute; University of Cambridge	Watt, FM (corresponding author), Li Ka Shing Ctr, Canc Res UK Cambridge Res Inst, Robinson Way, Cambridge CB2 0RE, Cambs, England.	Fiona.watt@cancer.org.uk	Quist, Sven R/G-2052-2013; Hoste, Esther/M-9926-2014; Hoste, Esther/AAG-2218-2020; Watt, Fiona/AHB-0226-2022; Quist, Sven R/C-9102-2017	Quist, Sven R/0000-0002-9548-7813; Hoste, Esther/0000-0002-3181-431X; Hoste, Esther/0000-0002-3181-431X; Watt, Fiona/0000-0001-9151-5154; Quist, Sven R/0000-0002-9548-7813; Driskell, Ryan/0000-0001-7673-2564; Arwert, Esther/0000-0001-7475-9704; Mentink, Remco/0000-0003-1005-7767	Cancer Research UK; Dutch Cancer Society; Wellcome Trust; MRC; European Union; Hutchison Whampoa; Cambridge University; Medical Research Council [G0701336, G1100073] Funding Source: researchfish; MRC [G0701336, G1100073] Funding Source: UKRI	Cancer Research UK(Cancer Research UK); Dutch Cancer Society(KWF Kankerbestrijding); Wellcome Trust(Wellcome Trust); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); European Union(European Commission); Hutchison Whampoa; Cambridge University(University of Cambridge); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	We are grateful to Donna Michelle Smith for performing SG chromatography. We acknowledge support from Cancer Research UK, the Dutch Cancer Society (to RM), the Wellcome Trust, the MRC, the European Union, Hutchison Whampoa and Cambridge University.	Aertgeerts K, 2004, PROTEIN SCI, V13, P145, DOI 10.1110/ps.03352504; Ansorge S, 2009, CLIN CHEM LAB MED, V47, P253, DOI 10.1515/CCLM.2009.063; Arwert EN, 2010, P NATL ACAD SCI USA, V107, P19903, DOI 10.1073/pnas.1007404107; Cordero OJ, 2009, CANCER IMMUNOL IMMUN, V58, P1725, DOI 10.1007/s00262-009-0728-1; Deacon CF, 2007, EXPERT OPIN INV DRUG, V16, P533, DOI 10.1517/13543784.16.4.533; Egeblad M, 2010, DEV CELL, V18, P884, DOI 10.1016/j.devcel.2010.05.012; Fan H, 1997, EUR J BIOCHEM, V246, P243, DOI 10.1111/j.1432-1033.1997.00243.x; Hobbs RM, 2004, J INVEST DERMATOL, V123, P503, DOI 10.1111/j.0022-202X.2004.23225.x; Iwata S, 1999, J EXP MED, V190, P301, DOI 10.1084/jem.190.3.301; Jackson EK, 2008, HYPERTENSION, V51, P1637, DOI 10.1161/HYPERTENSIONAHA.108.112532; Jensen KB, 2010, NAT PROTOC, V5, P898, DOI 10.1038/nprot.2010.39; Jones SM, 2006, NAT REV CANCER, V6, P175, DOI 10.1038/nrc1817; Karlsson L, 1999, DEVELOPMENT, V126, P2611; Kim D, 2005, J MED CHEM, V48, P141, DOI 10.1021/jm0493156; KOHL A, 1991, AGENTS ACTIONS, V32, P125, DOI 10.1007/BF01983337; Kraman M, 2010, SCIENCE, V330, P827, DOI 10.1126/science.1195300; Landman GWD, 2010, DIABETES CARE, V33, P322, DOI 10.2337/dc09-1380; Lindsay JR, 2005, DIABETIC MED, V22, P654, DOI 10.1111/j.1464-5491.2005.01461.x; MALEY F, 1989, ANAL BIOCHEM, V180, P195, DOI 10.1016/0003-2697(89)90115-2; Nemoto E, 1999, INFECT IMMUN, V67, P6225; Novelli M, 1996, BRIT J DERMATOL, V134, P1052, DOI 10.1111/j.1365-2133.1996.tb07941.x; Ohnuma K, 2008, TRENDS IMMUNOL, V29, P295, DOI 10.1016/j.it.2008.02.010; Owens DM, 2003, NAT REV CANCER, V3, P444, DOI 10.1038/nrc1096; Pereira DA, 2003, BRAZ J MED BIOL RES, V36, P567, DOI 10.1590/S0100-879X2003000500003; Reinhold D, 1998, FEBS LETT, V428, P100, DOI 10.1016/S0014-5793(98)00502-X; Romero MR, 1999, EXP DERMATOL, V8, P53, DOI 10.1111/j.1600-0625.1999.tb00348.x; Ta NN, 2010, ATHEROSCLEROSIS, V213, P429, DOI 10.1016/j.atherosclerosis.2010.08.064; Takasawa W, 2010, BIOCHEM BIOPH RES CO, V401, P7, DOI 10.1016/j.bbrc.2010.08.112; VIVIER I, 1991, J IMMUNOL, V147, P447; WATT FM, 1984, J CELL BIOL, V98, P16, DOI 10.1083/jcb.98.1.16; Willheim M, 1997, J ALLERGY CLIN IMMUN, V100, P348, DOI 10.1016/S0091-6749(97)70248-3	31	32	34	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2012	31	8					992	1000		10.1038/onc.2011.298	http://dx.doi.org/10.1038/onc.2011.298			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	898BG	21765471				2022-12-17	WOS:000300709700005
J	Lu, D; Han, C; Wu, T				Lu, D.; Han, C.; Wu, T.			Microsomal prostaglandin E synthase-1 promotes hepatocarcinogenesis through activation of a novel EGR1/beta-catenin signaling axis	ONCOGENE			English	Article						microsomal prostaglandin E synthase-1; beta-catenin; early growth response 1; hepatocellular carcinoma; liver	HUMAN HEPATOCELLULAR-CARCINOMA; BETA-CATENIN; CELL-GROWTH; CYCLIN D1; HEPATITIS-B; EXPRESSION; CYCLOOXYGENASE-2; TRANSCRIPTION; COX-2; INHIBITION	Microsomal prostaglandin E synthase-1 (mPGES-1) is a key enzyme that couples with cyclooxygenase-2 (COX-2) for the production of PGE2. Although COX-2 is known to mediate the growth and progression of several human cancers including hepatocellular carcinoma (HCC), the role of mPGES-1 in hepatocarcinogenesis is not well established. This study provides novel evidence for a key role of mPGES-1 in HCC growth and progression. Forced overexpression of mPGES-1 in two HCC cell lines (Hep3B and Huh7) increased tumor cell growth, clonogenic formation, migration and invasion, whereas knockdown of mPGES-1 inhibited these parameters, in vitro. In a mouse tumor xenograft model, mPGES-1 overexpressed cells formed palpable tumors at earlier time points and developed larger tumors when compared with the control (P<0.01); in contrast, mPGES-1 knockdown delayed tumor development and reduced tumor size (P<0.01). Mechanistically, mPGES-1-induced HCC cell proliferation, invasion and migration involve PGE2 production and activation of early growth response 1 (EGR1) and beta-catenin. Specifically, mPGES1-derived PGE2 induces the formation of EGR1-beta-catenin complex, which interacts with T-cell factor 4/lymphoid enhancer factor 1 transcription factors and activates the expression of b-catenin downstream genes. Our findings depict a novel crosstalk between mPGES-1/PGE2 and EGR1/beta-catenin signaling that is critical for hepatocarcinogenesis. Oncogene (2012) 31, 842-857; doi: 10.1038/onc.2011.287; published online 11 July 2011	[Lu, D.; Han, C.; Wu, T.] Tulane Univ, Sch Med, Dept Pathol & Lab Med, New Orleans, LA 70112 USA; [Lu, D.] Tongji Univ, Sch Life Sci & Technol, Shanghai 200092, Peoples R China	Tulane University; Tongji University	Wu, T (corresponding author), Tulane Univ, Sch Med, Dept Pathol & Lab Med, 1430 Tulane Ave,SL-79, New Orleans, LA 70112 USA.	twu@tulane.edu			National Institutes of Health [CA106280, CA102325, CA134568, DK077776, CA137729]; NATIONAL CANCER INSTITUTE [R03CA137729, R01CA102325, R01CA106280, R01CA134568] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK077776, R56DK077776] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work is supported by the National Institutes of Health grants CA106280, CA102325, CA134568 and DK077776 (to TW) and CA137729 (to CH).	Bae SH, 2001, CLIN CANCER RES, V7, P1410; Baron JA, 2006, GASTROENTEROLOGY, V131, P1674, DOI 10.1053/j.gastro.2006.08.079; Bijur GN, 2001, J BIOL CHEM, V276, P37436, DOI 10.1074/jbc.M105725200; Branda M, 2006, HEPATOLOGY, V43, P891, DOI 10.1002/hep.21196; Caspi M, 2008, ONCOGENE, V27, P3546, DOI 10.1038/sj.onc.1211026; Castellone MD, 2005, SCIENCE, V310, P1504, DOI 10.1126/science.1116221; Cheng ASL, 2004, INT J ONCOL, V24, P853; Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018; Couzin J, 2004, SCIENCE, V306, P1673, DOI 10.1126/science.306.5702.1673; DANESCH U, 1994, J BIOL CHEM, V269, P27258; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Dihlmann S, 2005, CARCINOGENESIS, V26, P1503, DOI 10.1093/carcin/bgi120; El-Serag HB, 2004, GASTROENTEROLOGY, V127, pS27, DOI 10.1053/j.gastro.2004.09.013; El-Serag HB, 1999, NEW ENGL J MED, V340, P745, DOI 10.1056/NEJM199903113401001; Farazi PA, 2006, NAT REV CANCER, V6, P674, DOI 10.1038/nrc1934; Giles RH, 2003, BBA-REV CANCER, V1653, P1, DOI 10.1016/S0304-419X(03)00005-2; Gitenay D, 2009, FUTURE ONCOL, V5, P993, DOI [10.2217/fon.09.67, 10.2217/FON.09.67]; Gordon MD, 2006, J BIOL CHEM, V281, P22429, DOI 10.1074/jbc.R600015200; Grosser T, 2006, J CLIN INVEST, V116, P4, DOI 10.1172/JCI27291; Han C, 2006, J CELL PHYSIOL, V207, P261, DOI 10.1002/jcp.20560; Hanaka H, 2009, P NATL ACAD SCI USA, V106, P18757, DOI 10.1073/pnas.0910218106; Henderson BR, 2000, NAT CELL BIOL, V2, P653, DOI 10.1038/35023605; Hoppler S, 2007, J CELL SCI, V120, P385, DOI 10.1242/jcs.03363; Itoh Keiji, 2005, J Biol, V4, P3, DOI 10.1186/jbiol20; Jakobsson PJ, 1999, P NATL ACAD SCI USA, V96, P7220, DOI 10.1073/pnas.96.13.7220; Kamei D, 2010, BIOCHEM J, V425, P361, DOI 10.1042/BJ20090045; Kang YJ, 2007, PROG LIPID RES, V46, P108, DOI 10.1016/j.plipres.2007.01.001; Kapoor M, 2007, J BIOL CHEM, V282, P5356, DOI 10.1074/jbc.M610153200; Koga H, 1999, HEPATOLOGY, V29, P688, DOI 10.1002/hep.510290355; Kondo M, 1999, CLIN CANCER RES, V5, P4005; Lee KH, 2009, CLIN EXP METASTAS, V26, P685, DOI 10.1007/s10585-009-9266-7; Leng J, 2003, HEPATOLOGY, V38, P756, DOI 10.1053/jhep.2003.50380; Lim K, 2008, CANCER RES, V68, P553, DOI 10.1158/0008-5472.CAN-07-2295; Lim K, 2009, MOL CANCER THER, V8, P3046, DOI 10.1158/1535-7163.MCT-09-0551; Llovet JM, 2008, HEPATOLOGY, V48, P1312, DOI 10.1002/hep.22506; Ma JJ, 2009, J BIOL CHEM, V284, P34600, DOI 10.1074/jbc.M109.016246; Merle P, 2004, GASTROENTEROLOGY, V127, P1110, DOI 10.1053/j.gastro.2004.07.009; Monga SPS, 2006, HEPATOLOGY, V43, P401, DOI 10.1002/hep.21110; Moon RT, 2004, NAT REV GENET, V5, P689, DOI 10.1038/nrg1427; Moon Y, 2007, BIOCHEM PHARMACOL, V73, P125, DOI 10.1016/j.bcp.2006.08.017; Morisco C, 2001, J BIOL CHEM, V276, P28586, DOI 10.1074/jbc.M103166200; Murakami M, 2006, CURR PHARM DESIGN, V12, P943, DOI 10.2174/138161206776055912; Murakami M, 2000, J BIOL CHEM, V275, P32783, DOI 10.1074/jbc.M003505200; Ngiam N, 2010, AM J RESP CRIT CARE, V181, P947, DOI 10.1164/rccm.200908-1297OC; Parra E, 2009, ONCOL REP, V22, P1513, DOI 10.3892/or_00000595; Philipp-Staheli J, 2002, CANCER CELL, V1, P355, DOI 10.1016/S1535-6108(02)00054-5; Rahman MA, 2001, CLIN CANCER RES, V7, P1325; Saegusa M, 2004, AM J PATHOL, V164, P1739, DOI 10.1016/S0002-9440(10)63732-7; Saegusa M, 2008, J PATHOL, V216, P521, DOI 10.1002/path.2404; Samuelsson B, 2007, PHARMACOL REV, V59, P207, DOI 10.1124/pr.59.3.1; Satoh S, 2000, NAT GENET, V24, P245, DOI 10.1038/73448; Shao JY, 2005, J BIOL CHEM, V280, P26565, DOI 10.1074/jbc.M413056200; Shiota G, 1999, HEPATO-GASTROENTEROL, V46, P407; Smith WL, 2001, J CLIN INVEST, V107, P1491, DOI 10.1172/JCI13271; Smith WL, 2000, ANNU REV BIOCHEM, V69, P145, DOI 10.1146/annurev.biochem.69.1.145; Stichtenoth DO, 2001, J IMMUNOL, V167, P469, DOI 10.4049/jimmunol.167.1.469; Subbaramaiah K, 2004, J BIOL CHEM, V279, P12647, DOI 10.1074/jbc.M312972200; Takii Y, 2007, LIVER INT, V27, P989, DOI 10.1111/j.1478-3231.2007.01530.x; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Thiel G, 2010, CELL CALCIUM, V47, P397, DOI 10.1016/j.ceca.2010.02.005; Thompson MD, 2007, HEPATOLOGY, V45, P1298, DOI 10.1002/hep.21651; Thoren S, 2003, J BIOL CHEM, V278, P22199, DOI 10.1074/jbc.M303227200; Vanchieri C, 2004, J NATL CANCER I, V96, P1734, DOI 10.1093/jnci/96.23.1734; Virolle T, 2001, NAT CELL BIOL, V3, P1124, DOI 10.1038/ncb1201-1124; Wu T, 2006, CANCER TREAT REV, V32, P28, DOI 10.1016/j.ctrv.2005.10.004; Yu JX, 2009, EMBO J, V28, P21, DOI 10.1038/emboj.2008.238; Zucman-Rossi J, 2006, HEPATOLOGY, V43, P515, DOI 10.1002/hep.21068	67	32	32	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2012	31	7					842	857		10.1038/onc.2011.287	http://dx.doi.org/10.1038/onc.2011.287			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	897BL	21743491	Green Accepted			2022-12-17	WOS:000300615800004
J	Swaminathan, G; Cartwright, CA				Swaminathan, G.; Cartwright, C. A.			Rack1 promotes epithelial cell-cell adhesion by regulating E-cadherin endocytosis	ONCOGENE			English	Article						RACK1; Src; E-cadherin; adhesion; endocytosis; invasion	PROTEIN-TYROSINE-PHOSPHATASE; COLON-CANCER CELLS; SRC FAMILY KINASES; PTP-MU; MESENCHYMAL TRANSITION; CARCINOMA-CELLS; SIGNAL-TRANSDUCTION; MEDIATED ADHESION; CATENIN COMPLEX; DOWN-REGULATION	E-cadherin and its cytoplasmic partners, catenins, mediate epithelial cell-cell adhesion. Disruption of this adhesion allows cancer cells to invade and metastasize. Aberrant activation of the Src tyrosine kinase disrupts cell-cell contacts through an E-cadherin/catenin-dependent mechanism. Previously we showed that Rack1 regulates the growth of colon cells by suppressing Src activity at G(1) and mitotic checkpoints, and in the intrinsic apoptotic and Akt cell survival pathways. Here we show that Rack1, partly by inhibiting Src, promotes cell-cell adhesion and reduces the invasive potential of colon cancer cells. Rack1 stabilizes E-cadherin and catenins at cell-cell contacts by inhibiting the Src phosphorylation of E-cadherin, the ubiquitination of E-cadherin by the E3 ligase Hakai and the endocytosis of E-cadherin. Upon depletion and restoration of extracellular calcium, Rack1 facilitates the re-assembly of E-cadherin-containing cell-cell contacts. Rack1 also blocks HGF-induced endocytosis of E-cadherin, disruption of cell-cell contacts and cell scatter. Our results uncover a novel function of Rack1 in maintaining the junctional homeostasis of intestinal epithelial cells by regulation of the Src- and growth factor-induced endocytosis of E-cadherin. Oncogene (2012) 31, 376-389; doi:10.1038/onc.2011.242; published online 20 June 2011	[Swaminathan, G.; Cartwright, C. A.] Stanford Univ, Dept Med, Stanford, CA 94305 USA	Stanford University	Cartwright, CA (corresponding author), Stanford Univ, Dept Med, M211 Alway Bldg,MC 5187,300 Pasteur Dr, Stanford, CA 94305 USA.	chris.cartwright@stanford.edu			NIH [DK43743]; NIH Digestive Disease Center [DK56339]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK043743, P30DK056339, R01DK043743] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH Digestive Disease Center; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We thank Toufan Parman for performing initial preliminary experiments. We are grateful to Jenny Cheng, James Nelson, Anson Lowe and Manuel Amieva for helpful discussions and reagents. We thank James Nelson for the gift of MDCK cells and the members of the Lipsick laboratory for help with confocal imaging. We thank Jenny Cheng for critical review of the data and the manuscript. This work was supported by the NIH Grant DK43743 (CAC) and the NIH Digestive Disease Center Grant DK56339.	Avizienyte E, 2004, MOL BIOL CELL, V15, P2794, DOI 10.1091/mbc.E03-12-0879; Avizienyte E, 2005, CURR OPIN CELL BIOL, V17, P542, DOI 10.1016/j.ceb.2005.08.007; Avizienyte E, 2002, NAT CELL BIOL, V4, P632, DOI 10.1038/ncb829; BEHRENS J, 1993, J CELL BIOL, V120, P757, DOI 10.1083/jcb.120.3.757; Bertotti A, 2010, CLIN CANCER RES, V16, P3933, DOI 10.1158/1078-0432.CCR-10-0106; Berx G, 2009, CSH PERSPECT BIOL, V1, DOI 10.1101/cshperspect.a003129; Brady-Kalnay SM, 1998, J CELL BIOL, V141, P287, DOI 10.1083/jcb.141.1.287; BRADYKALNAY SM, 1995, J CELL BIOL, V130, P977, DOI 10.1083/jcb.130.4.977; Bryant DM, 2004, TRENDS CELL BIOL, V14, P427, DOI 10.1016/j.tcb.2004.07.007; Chang BY, 1998, MOL CELL BIOL, V18, P3245, DOI 10.1128/MCB.18.6.3245; Chang BY, 2002, ONCOGENE, V21, P7619, DOI 10.1038/sj.onc.1206002; Chang BY, 2001, J BIOL CHEM, V276, P20346, DOI 10.1074/jbc.M101375200; Chattopadhyay N, 2003, J CELL BIOL, V163, P1351, DOI 10.1083/jcb.200306067; Cox EA, 2003, MOL BIOL CELL, V14, P658, DOI 10.1091/mbc.E02-03-0142; Delva E, 2009, TRAFFIC, V10, P259, DOI 10.1111/j.1600-0854.2008.00862.x; Doan AT, 2007, EXP CELL RES, V313, P2667, DOI 10.1016/j.yexcr.2007.05.013; Emaduddin M, 2008, P NATL ACAD SCI USA, V105, P2358, DOI 10.1073/pnas.0712176105; Fan SJ, 2009, J BIOL CHEM, V284, P7561, DOI 10.1074/jbc.M807497200; Fomenkov A, 2004, CELL CYCLE, V3, P1285, DOI 10.4161/cc.3.10.1155; Frame MC, 2004, J CELL SCI, V117, P989, DOI 10.1242/jcs.01111; Fujita Y, 2002, NAT CELL BIOL, V4, P222, DOI 10.1038/ncb758; Gumbiner BM, 2005, NAT REV MOL CELL BIO, V6, P622, DOI 10.1038/nrm1699; Hartsock A, 2008, BBA-BIOMEMBRANES, V1778, P660, DOI 10.1016/j.bbamem.2007.07.012; Hellberg CB, 2002, J BIOL CHEM, V277, P11165, DOI 10.1074/jbc.M112157200; Herynk MH, 2007, J EXP THER ONCOL, V6, P205; Irby RB, 2002, CANCER RES, V62, P2669; Janda E, 2006, ONCOGENE, V25, P7117, DOI 10.1038/sj.onc.1209701; Jeanes A, 2008, ONCOGENE, V27, P6920, DOI 10.1038/onc.2008.343; Kiely PA, 2005, J BIOL CHEM, V280, P7624, DOI 10.1074/jbc.M412889200; Kim JB, 2000, J CELL BIOL, V151, P1193, DOI 10.1083/jcb.151.6.1193; Kowalczyk AP, 2004, CURR OPIN CELL BIOL, V16, P522, DOI 10.1016/j.ceb.2004.07.001; Lai AZ, 2009, TRENDS CELL BIOL, V19, P542, DOI 10.1016/j.tcb.2009.07.002; Leroy C, 2009, CANCER RES, V69, P2279, DOI 10.1158/0008-5472.CAN-08-2354; Li YC, 2009, MOL CELL BIOL, V29, P3953, DOI 10.1128/MCB.00449-09; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; Liu YV, 2007, MOL CELL, V25, P207, DOI 10.1016/j.molcel.2007.01.001; Lu ZM, 2003, CANCER CELL, V4, P499, DOI 10.1016/S1535-6108(03)00304-0; Mamidipudi V, 2007, ONCOGENE, V26, P2914, DOI 10.1038/sj.onc.1210091; Mamidipudi V, 2004, MOL CELL BIOL, V24, P6788, DOI 10.1128/MCB.24.15.6788-6798.2004; Mamidipudi V, 2009, ONCOGENE, V28, P4421, DOI 10.1038/onc.2009.293; McCahill A, 2002, MOL PHARMACOL, V62, P1261, DOI 10.1124/mol.62.6.1261; Mosesson Y, 2008, NAT REV CANCER, V8, P835, DOI 10.1038/nrc2521; Mourton T, 2001, J BIOL CHEM, V276, P14896, DOI 10.1074/jbc.M010823200; Ohgaki R, 2008, J BIOL CHEM, V283, P4417, DOI 10.1074/jbc.M705146200; Orlichenko L, 2009, MOL BIOL CELL, V20, P4140, DOI 10.1091/mbc.E08-10-1043; Owens DW, 2000, MOL BIOL CELL, V11, P51, DOI 10.1091/mbc.11.1.51; Palacios F, 2005, MOL CELL BIOL, V25, P389, DOI 10.1128/MCB.25.1.389-402.2005; Parent A, 2008, TRAFFIC, V9, P394, DOI 10.1111/j.1600-0854.2007.00692.x; Rengifo-Cam W, 2004, ONCOGENE, V23, P289, DOI 10.1038/sj.onc.1207041; Saitoh M, 2009, BIOCHEM BIOPH RES CO, V381, P560, DOI 10.1016/j.bbrc.2009.02.098; Schechtman D, 2001, ONCOGENE, V20, P6339, DOI 10.1038/sj.onc.1204778; Schill NJ, 2009, BIOCHEM J, V418, P247, DOI 10.1042/BJ20081844; Serrels B, 2010, CURR BIOL, V20, P1086, DOI 10.1016/j.cub.2010.04.042; Shen Y, 2008, J BIOL CHEM, V283, P5127, DOI 10.1074/jbc.M703300200; Skoudy A, 1996, BIOCHEM J, V317, P279, DOI 10.1042/bj3170279; Varghese B, 2008, MOL CELL BIOL, V28, P5275, DOI 10.1128/MCB.00350-08; Vomastek T, 2007, MOL CELL BIOL, V27, P8296, DOI 10.1128/MCB.00598-07; Wadhawan A, 2011, CANCER TREAT REV, V37, P234, DOI 10.1016/j.ctrv.2010.08.003; Woodcock SA, 2009, MOL CELL, V33, P639, DOI 10.1016/j.molcel.2009.02.012; Yap AS, 2007, CURR OPIN CELL BIOL, V19, P508, DOI 10.1016/j.ceb.2007.09.008; Yeatman TJ, 2004, NAT REV CANCER, V4, P470, DOI 10.1038/nrc1366	61	32	34	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2012	31	3					376	389		10.1038/onc.2011.242	http://dx.doi.org/10.1038/onc.2011.242			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	882DQ	21685945	Bronze			2022-12-17	WOS:000299542100010
J	Yao, R; Natsume, Y; Saiki, Y; Shioya, H; Takeuchi, K; Yamori, T; Toki, H; Aoki, I; Saga, T; Noda, T				Yao, R.; Natsume, Y.; Saiki, Y.; Shioya, H.; Takeuchi, K.; Yamori, T.; Toki, H.; Aoki, I.; Saga, T.; Noda, T.			Disruption of Tacc3 function leads to in vivo tumor regression	ONCOGENE			English	Article						TACC3; mitosis; spindle; p53; tumor regression	SUPPRESSOR GENE; BREAST-CANCER; COILED-COIL; ZYG-9 FORM; PROTEIN; P53; EXPRESSION; MUTATIONS; CELLS; TAC-1	The formation of the bipolar spindle is responsible for accurate chromosomal segregation during mitosis. The dynamic instability of microtubules has an important role in this process, and has been shown to be an effective target for cancer chemotherapy. Several agents that target non-microtubule mitotic proteins, including the motor protein Eg5, Aurora kinases and Polo-like kinases, are currently being developed as chemotherapeutic drugs. However, because the efficacies of these drugs remain elusive, new molecular targets that have essential roles in tumor cells are desired. Here, we provide in vivo evidence that transforming acidic coiled-coil-3 (Tacc3) is a potential target for cancer chemotherapy. Using MRI, we showed that Tacc3 loss led to the regression of mouse thymic lymphoma in vivo, which was accompanied by massive apoptosis. By contrast, normal tissues, including the thymus, showed no overt abnormalities, despite high Tacc3 expression. in vitro analysis indicated that Tacc3 depletion induced multi-polar spindle formation, which led to mitotic arrest, followed by apoptosis. Similar responses have been observed in Burkitt's lymphoma and T-ALL. These results show that Tacc3 is a vulnerable component of the spindle assembly in lymphoma cells and is a promising cancer chemotherapy target. Oncogene (2012) 31, 135-148; doi:10.1038/onc.2011.235; published online 20 June 2011	[Yao, R.] Japanese Fdn Canc Res, Dept Cell Biol, Inst Canc, Koto Ku, Tokyo 1358550, Japan; [Takeuchi, K.] Japanese Fdn Canc Res, Dept Pathol, Inst Canc, Tokyo 1358550, Japan; [Yamori, T.] Japanese Fdn Canc Res, Div Mol Pharmacol, Ctr Canc Chemotherapy, Tokyo 1358550, Japan; [Toki, H.; Noda, T.] RIKEN, Bioresource Ctr, Team Adv Dev & Evaluat Human Dis Models, Ibaraki, Japan; [Aoki, I.; Saga, T.] Natl Inst Radiol Sci, Diagnost Imaging Program, Mol Imaging Ctr, Chiba 260, Japan	Japanese Foundation for Cancer Research; Japanese Foundation for Cancer Research; Japanese Foundation for Cancer Research; RIKEN; National Institutes for Quantum Science & Technology	Yao, R (corresponding author), Japanese Fdn Canc Res, Dept Cell Biol, Inst Canc, Koto Ku, 3-8-31 Ariake, Tokyo 1358550, Japan.	ryao@jfcr.or.jp	Aoki, Ichio/ABF-7336-2020; Aoki, Ichio/G-2529-2011; Noda, Tetsuo/B-1667-2016; Takeuchi, Kengo/C-3614-2008	Aoki, Ichio/0000-0002-4429-5053; Takeuchi, Kengo/0000-0002-1599-5800	Ministry of Education, Culture, Sports, Science and Technology of Japan	Ministry of Education, Culture, Sports, Science and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT))	We thank T Jacks for providing the R26CreERT2 mice; S Shibata, T Nakahara T Shimomura, S Saito and F Yamagishi for MRI imaging; S Hasegawa for helpful discussions; and Y Terui for the donation of human lymphoma cells. We also thank Y Inoue and T Hirota for critically reading the manuscript. This work was supported by a Grant-in-Aid for cancer research from the Ministry of Education, Culture, Sports, Science and Technology of Japan.	Bamford S, 2004, BRIT J CANCER, V91, P355, DOI 10.1038/sj.bjc.6601894; Barr AR, 2008, MOL CELL BIOL, V28, P7199, DOI 10.1128/MCB.01040-08; Bellanger JM, 2003, CURR BIOL, V13, P1488, DOI 10.1016/S0960-9822(03)00582-7; CHARRASSE S, 1995, EUR J BIOCHEM, V234, P406, DOI 10.1111/j.1432-1033.1995.406_b.x; CHENG J, 1990, MOL CELL BIOL, V10, P5502, DOI 10.1128/MCB.10.10.5502; CHOW VTK, 1993, CANCER LETT, V73, P141, DOI 10.1016/0304-3835(93)90256-9; Cinti C, 2000, ONCOGENE, V19, P5098, DOI 10.1038/sj.onc.1203848; Cullen CF, 2001, NAT CELL BIOL, V3, P637, DOI 10.1038/35083025; D'Assoro AB, 2002, ONCOGENE, V21, P6146, DOI 10.1038/sj.onc.1205772; FARRELL PJ, 1991, EMBO J, V10, P2879, DOI 10.1002/j.1460-2075.1991.tb07837.x; Fielding AB, 2011, ONCOGENE, V30, P521, DOI 10.1038/onc.2010.431; GAIDANO G, 1991, P NATL ACAD SCI USA, V88, P5413, DOI 10.1073/pnas.88.12.5413; Gascoigne KE, 2008, CANCER CELL, V14, P111, DOI 10.1016/j.ccr.2008.07.002; Gergely F, 2003, GENE DEV, V17, P336, DOI 10.1101/gad.245603; Gergely F, 2000, EMBO J, V19, P241, DOI 10.1093/emboj/19.2.241; Gergely F, 2000, P NATL ACAD SCI USA, V97, P14352, DOI 10.1073/pnas.97.26.14352; Harrison Michael R, 2009, Clin Adv Hematol Oncol, V7, P54; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Jackson JR, 2007, NAT REV CANCER, V7, P107, DOI 10.1038/nrc2049; Jacquemier J, 2005, CANCER RES, V65, P767; Janssen K, 2007, BLOOD, V110, P3662, DOI 10.1182/blood-2007-02-073213; Jung CK, 2006, PATHOL INT, V56, P503, DOI 10.1111/j.1440-1827.2006.01998.x; Keen N, 2004, NAT REV CANCER, V4, P927, DOI 10.1038/nrc1502; Kinoshita K, 2005, J CELL BIOL, V170, P1047, DOI 10.1083/jcb.200503023; Kwon M, 2008, GENE DEV, V22, P2189, DOI 10.1101/gad.1700908; Lauffart Brenda, 2005, BMC Womens Health, V5, P8, DOI 10.1186/1472-6874-5-8; Le Bot N, 2003, CURR BIOL, V13, P1499, DOI 10.1016/S0960-9822(03)00577-3; Lee MJ, 2001, NAT CELL BIOL, V3, P643, DOI 10.1038/35083033; Ma XJ, 2003, P NATL ACAD SCI USA, V100, P5974, DOI 10.1073/pnas.0931261100; Oliferenko S, 2002, NAT CELL BIOL, V4, P816, DOI 10.1038/ncb861; Peset I, 2008, TRENDS CELL BIOL, V18, P379, DOI 10.1016/j.tcb.2008.06.005; Piekorz RP, 2002, EMBO J, V21, P653, DOI 10.1093/emboj/21.4.653; Quintyne NJ, 2005, SCIENCE, V307, P127, DOI 10.1126/science.1104905; Sato M, 2004, MOL BIOL CELL, V15, P1609, DOI 10.1091/mbc.e03-11-0837; Schmidt S, 2010, ONCOGENE, V29, P6184, DOI 10.1038/onc.2010.354; Schneider L, 2008, ONCOGENE, V27, P116, DOI 10.1038/sj.onc.1210628; Schneider L, 2007, J BIOL CHEM, V282, P29273, DOI 10.1074/jbc.M704151200; Schuendeln MM, 2004, MOL CELL BIOL, V24, P6403, DOI 10.1128/MCB.24.14.6403-6409.2004; Shamma A, 2009, CANCER CELL, V15, P255, DOI 10.1016/j.ccr.2009.03.001; Srayko M, 2003, CURR BIOL, V13, P1506, DOI 10.1016/S0960-9822(03)00597-9; Strebhardt K, 2006, NAT REV CANCER, V6, P321, DOI 10.1038/nrc1841; Sudakin V, 2007, BIODRUGS, V21, P225, DOI 10.2165/00063030-200721040-00003; Tarapore P, 2002, ONCOGENE, V21, P6234, DOI 10.1038/sj.onc.1205707; Ventura A, 2007, NATURE, V445, P661, DOI 10.1038/nature05541; Yao R, 2007, CANCER SCI, V98, P555, DOI 10.1111/j.1349-7006.2007.00433.x	45	32	32	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2012	31	2					135	148		10.1038/onc.2011.235	http://dx.doi.org/10.1038/onc.2011.235			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	879CN	21685933				2022-12-17	WOS:000299307400001
J	Zhang, B; Qian, D; Ma, HH; Jin, R; Yang, PX; Cai, MY; Liu, YH; Liao, YJ; Deng, HX; Mai, SJ; Zhang, H; Zeng, YX; Lin, MC; Kung, HF; Xie, D; Huang, JJ				Zhang, B.; Qian, D.; Ma, H-H; Jin, R.; Yang, P-X; Cai, M-Y; Liu, Y-H; Liao, Y-J; Deng, H-X; Mai, S-J; Zhang, H.; Zeng, Y-X; Lin, M. C.; Kung, H-F; Xie, D.; Huang, J-J			Anthracyclines disrupt telomere maintenance by telomerase through inducing PinX1 ubiquitination and degradation	ONCOGENE			English	Article						anthracyclines; telomere dysfunction; PinX1; telomerase; cancer	SENSITIZES CANCER-CELLS; REVERSE-TRANSCRIPTASE; MAMMALIAN TELOMERES; DNA-DAMAGE; IN-VIVO; THERAPEUTICS; TRAFFICKING; BIOGENESIS; SHELTERIN; SUBUNIT	Telomere maintenance is essential for cancer growth. Induction of telomere dysfunction, for example, by inhibition of telomeric proteins or telomerase, has been shown to strongly enhance cancer cells' sensitivity to chemotherapies. However, it is not clear whether modulations of telomere maintenance constitute cancer cellular responses to chemotherapies. Furthermore, the manner in which anti-cancer drugs affect telomere function remains unknown. In this study, we show that anthracyclines, a class of anti-cancer drugs widely used in clinical cancer treatments, have an active role in triggering telomere dysfunction specifically in telomerase-positive cancer cells. Anthracyclines interrupt telomere maintenance by telomerase through the down-regulation of PinX1, a protein factor responsible for targeting telomerase onto telomeres, thereby inhibiting telomerase association with telomeres. We further demonstrate that anthracyclines downregulate PinX1 by inducing this protein degradation through the ubiquitin-proteasome-dependent pathway. Our data not only reveal a novel action for anthracyclines as telomerase functional inhibitors but also provide a clue for the development of novel anti-cancer drugs based on telomerase/telomere targeting, which is actively investigated by many current studies. Oncogene (2012) 31, 1-12; doi: 10.1038/onc.2011.214; published online 6 June 2011	[Zhang, B.; Qian, D.; Cai, M-Y; Liao, Y-J; Deng, H-X; Mai, S-J; Zeng, Y-X; Kung, H-F; Xie, D.] Sun Yat Sen Univ, Ctr Canc, State Key Lab Oncol S China, Guangzhou 510060, Guangdong, Peoples R China; [Ma, H-H; Jin, R.; Yang, P-X; Zhang, H.; Huang, J-J] Beijing Inst Biotechnol, Lab Tumor & Mol Biol, Beijing 100850, Peoples R China; [Liu, Y-H] Guangdong Prov Peoples Hosp, Dept Pathol, Guangzhou, Guangdong, Peoples R China; [Lin, M. C.; Kung, H-F] Chinese Univ Hong Kong, State Key Lab Oncol S China, Hong Kong, Hong Kong, Peoples R China	Sun Yat Sen University; Guangdong Academy of Medical Sciences & Guangdong General Hospital; Chinese University of Hong Kong	Xie, D (corresponding author), Sun Yat Sen Univ, Ctr Canc, State Key Lab Oncol S China, Room 634,651 Dongfeng Rd E, Guangzhou 510060, Guangdong, Peoples R China.	hkung@cuhk.edu.hk; xied@mail.sysu.edu.cn; huangjun_j@yahoo.com	mai, sj/HGE-8908-2022; LIAO, YIJI/Z-4902-2019	LIAO, YIJI/0000-0002-0849-4573	Chinese NSFC [30901769, 30771074]; Guangdong National Science Foundation [9451008901002371]; China Postdoctoral Science Foundation [20090450900]; National Basic Research Program (973 program) of China [2010CB912802, 2010CB529404]	Chinese NSFC(National Natural Science Foundation of China (NSFC)); Guangdong National Science Foundation; China Postdoctoral Science Foundation(China Postdoctoral Science Foundation); National Basic Research Program (973 program) of China(National Basic Research Program of China)	This work is supported by grants from the Chinese NSFC (30901769), Guangdong National Science Foundation (9451008901002371) and the China Postdoctoral Science Foundation (20090450900) to B Zhang, and also partially by grants from the National Basic Research Program (973 program) of China (No. 2010CB912802) to H-F Kung and (No. 2010CB529404) to J-J Huang, the Chinese NSFC (30771074) to H Zhang.	Akiyama Y, 2004, ONCOL REP, V11, P871; Autexier C, 1996, TRENDS BIOCHEM SCI, V21, P387, DOI 10.1016/S0968-0004(96)90128-0; Bianchi A, 2008, MOL CELL, V31, P153, DOI 10.1016/j.molcel.2008.06.013; Blackburn EH, 2000, NATURE, V408, P53, DOI 10.1038/35040500; Chang Q, 2004, INT J CANCER, V109, P309, DOI 10.1002/ijc.11689; Collins K, 2000, CURR OPIN CELL BIOL, V12, P378, DOI 10.1016/S0955-0674(00)00103-4; Collins K, 2006, NAT REV MOL CELL BIO, V7, P484, DOI 10.1038/nrm1961; Cong YS, 2002, MICROBIOL MOL BIOL R, V66, P407, DOI 10.1128/MMBR.66.3.407-425.2002; de Lange T, 2005, GENE DEV, V19, P2100, DOI 10.1101/gad.1346005; de Lange T, 1998, SCIENCE, V279, P334, DOI 10.1126/science.279.5349.334; Denchi EL, 2007, NATURE, V448, P1068, DOI 10.1038/nature06065; Gallardo F, 2008, EMBO J, V27, P748, DOI 10.1038/emboj.2008.21; Goueli BS, 2004, MOL CELL BIOL, V24, P25, DOI 10.1128/MCB.24.1.25-35.2004; Harley CB, 2008, NAT REV CANCER, V8, P167, DOI 10.1038/nrc2275; Hawkins GA, 2004, PROSTATE, V60, P298, DOI 10.1002/pros.20075; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Laurent G, 2001, BLOOD, V98, P913, DOI 10.1182/blood.V98.4.913; Lin SY, 2003, CELL, V113, P881, DOI 10.1016/S0092-8674(03)00430-6; Liu Y, 2000, CURR BIOL, V10, P1459, DOI 10.1016/S0960-9822(00)00805-8; Mergny JL, 1998, NAT MED, V4, P1366, DOI 10.1038/3949; Meyerson M, 1997, CELL, V90, P785, DOI 10.1016/S0092-8674(00)80538-3; Minotti G, 2004, PHARMACOL REV, V56, P185, DOI 10.1124/pr.56.2.6; Nakamura M, 2005, HUM GENE THER, V16, P859, DOI 10.1089/hum.2005.16.859; Nugent CI, 1998, GENE DEV, V12, P1073, DOI 10.1101/gad.12.8.1073; Palm W, 2008, ANNU REV GENET, V42, P301, DOI 10.1146/annurev.genet.41.110306.130350; Shay JW, 2006, NAT REV DRUG DISCOV, V5, P577, DOI 10.1038/nrd2081; Small GW, 2003, J PHARMACOL EXP THER, V307, P861, DOI 10.1124/jpet.103.055806; Takai H, 2003, CURR BIOL, V13, P1549, DOI 10.1016/S0960-9822(03)00542-6; Tomlinson RL, 2006, MOL BIOL CELL, V17, P955, DOI 10.1091/mbc.E05-09-0903; Uziel O, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009132; Wang C, 2010, EUR J CELL BIOL, V89, P748, DOI 10.1016/j.ejcb.2010.05.005; Wong JMY, 2002, NAT CELL BIOL, V4, P731, DOI 10.1038/ncb846; Xin HW, 2007, NATURE, V445, P559, DOI 10.1038/nature05469; Zhang B, 2009, CANCER RES, V69, P75, DOI 10.1158/0008-5472.CAN-08-1393; Zhou XZ, 2001, CELL, V107, P347, DOI 10.1016/S0092-8674(01)00538-4	35	32	32	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN	2012	31	1					1	12		10.1038/onc.2011.214	http://dx.doi.org/10.1038/onc.2011.214			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	877JT	21643006				2022-12-17	WOS:000299176200001
J	Wu, Z; Zheng, S; Li, Z; Tan, J; Yu, Q				Wu, Z.; Zheng, S.; Li, Z.; Tan, J.; Yu, Q.			E2F1 suppresses Wnt/beta-catenin activity through transactivation of beta-catenin interacting protein ICAT	ONCOGENE			English	Article						E2F1; Wnt/beta-catenin; ICAT; cancer cells	WNT; PATHWAY; TRANSCRIPTION; TARGET; APOPTOSIS; CANCER; LIFE	Deregulation of the pRb/E2F or Wnt/beta-catenin pathway occurs frequently in human cancers, which is often associated with inappropriate cell proliferation. Although the oncogenic roles of pRb/E2F1 and Wnt/beta-catenin pathways have been well studied, the functional interaction between the two pathways has only recently been characterized. In particular, E2F1 has been recently reported to negatively regulate Wnt/beta-catenin activity in human colorectal cancers, though the mechanism underlying this regulation is not fully understood. Here we provide evidence that beta-catenin interacting protein 1 (CTNNBIP1), also known as ICAT (inhibitor of beta-catenin and TCF4), functions as a crucial node to mediate the cross talk between E2F1 and beta-catenin signaling. We show that ICAT is a direct transcriptional target of E2F1, and that activation of ICAT by E2F1 is required for E2F1 to inhibit beta-catenin activity. This study provides a mechanistic insight into the antagonistic interaction between E2F1 and beta-catenin signaling. Oncogene (2011) 30, 3979-3984; doi:10.1038/onc.2011.129; published online 2 May 2011	[Wu, Z.; Zheng, S.; Li, Z.; Tan, J.; Yu, Q.] ASTAR, Dept Canc Biol & Pharmacol, Genome Inst Singapore, Singapore 138672, Singapore; [Yu, Q.] Natl Univ Singapore, Dept Physiol, Yong Loo Lin Sch Med, Singapore 117548, Singapore	Agency for Science Technology & Research (A*STAR); A*STAR - Genome Institute of Singapore (GIS); National University of Singapore	Yu, Q (corresponding author), ASTAR, Dept Canc Biol & Pharmacol, Genome Inst Singapore, Genome 02-01,60 Biopolis St, Singapore 138672, Singapore.	yuq@gis.a-star.edu.sg		Yu, Qiang/0000-0003-2132-8278	Agency for Science, Technology and Research of Singapore	Agency for Science, Technology and Research of Singapore(Agency for Science Technology & Research (A*STAR))	We thank Dr Kristian Helin (European Institute of Oncology, Milan) for the ER-E2F1 plasmids and Dr Claudio Brancolini for providing the IMR90/E1A cells. This work was supported by the Agency for Science, Technology and Research of Singapore.	Bernards R, 2008, NATURE, V455, P479, DOI 10.1038/455479a; Bracken AP, 2003, EMBO J, V22, P5323, DOI 10.1093/emboj/cdg542; Bramis J, 2004, ANTICANCER RES, V24, P3041; Cadigan KM, 2008, CURR BIOL, V18, pR943, DOI 10.1016/j.cub.2008.08.017; Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018; Firestein R, 2008, NATURE, V455, P547, DOI 10.1038/nature07179; Iaquinta PJ, 2007, CURR OPIN CELL BIOL, V19, P649, DOI 10.1016/j.ceb.2007.10.006; Kim SM, 2009, EXP CELL RES, V315, P943, DOI 10.1016/j.yexcr.2009.01.013; Klaus A, 2008, NAT REV CANCER, V8, P387, DOI 10.1038/nrc2389; Logan CY, 2004, ANNU REV CELL DEV BI, V20, P781, DOI 10.1146/annurev.cellbio.20.010403.113126; Moon RT, 2004, NAT REV GENET, V5, P689, DOI 10.1038/nrg1427; Morris EJ, 2008, NATURE, V455, P552, DOI 10.1038/nature07310; Nahle Z, 2002, NAT CELL BIOL, V4, P859, DOI 10.1038/ncb868; Nevins JR, 2001, HUM MOL GENET, V10, P699, DOI 10.1093/hmg/10.7.699; Polager S, 2008, TRENDS CELL BIOL, V18, P528, DOI 10.1016/j.tcb.2008.08.003; Polakis P, 2007, CURR OPIN GENET DEV, V17, P45, DOI 10.1016/j.gde.2006.12.007; Sherr CJ, 2002, CANCER CELL, V2, P103, DOI 10.1016/S1535-6108(02)00102-2; Tago K, 2000, GENE DEV, V14, P1741; Tan J, 2006, J BIOL CHEM, V281, P10508, DOI 10.1074/jbc.M512719200; Vigo E, 1999, MOL CELL BIOL, V19, P6379; Wu ZL, 2010, CELL DEATH DIFFER, V17, P801, DOI 10.1038/cdd.2009.162; Xie W, 2009, J CELL MOL MED, V13, P1719, DOI 10.1111/j.1582-4934.2008.00423.x; Zhao Y, 2005, P NATL ACAD SCI USA, V102, P16090, DOI 10.1073/pnas.0505585102	23	32	33	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2011	30	37					3979	3984		10.1038/onc.2011.129	http://dx.doi.org/10.1038/onc.2011.129			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	820FG	21532622				2022-12-17	WOS:000294890400007
J	Colombi, M; Molle, KD; Benjamin, D; Rattenbacher-Kiser, K; Schaefer, C; Betz, C; Thiemeyer, A; Regenass, U; Hall, MN; Moroni, C				Colombi, M.; Molle, K. D.; Benjamin, D.; Rattenbacher-Kiser, K.; Schaefer, C.; Betz, C.; Thiemeyer, A.; Regenass, U.; Hall, M. N.; Moroni, C.			Genome-wide shRNA screen reveals increased mitochondrial dependence upon mTORC2 addiction	ONCOGENE			English	Article						shRNA screen; mTOR addiction; IL-3 dependence; mitochondria; drug targets	LENTIVIRAL RNAI LIBRARY; CANCER-CELLS; GLUT4 TRANSLOCATION; PROTEIN; KINASE; EXPRESSION; METABOLISM; GENE; IDENTIFICATION; INHIBITION	Release from growth factor dependence and acquisition of signalling pathway addiction are critical steps in oncogenesis. To identify genes required on mammalian target of rapamycin (mTOR) addiction, we performed a genome-wide short hairpin RNA screen on a v-H-ras-transformed Pten-deficient cell line that displayed two alternative growth modes, interleukin (IL)-3-independent/mTOR-addicted proliferation (transformed growth mode) and IL-3-dependent/mTOR-non-addicted proliferation (normal growth mode). We screened for genes required only in the absence of IL-3 and thus specifically for the transformed growth mode. The top 800 hits from this conditional lethal screen were analyzed in silico and 235 hits were subsequently rescreened in two additional Pten-deficient cell lines to generate a core set of 47 genes. Hits included genes encoding mTOR and the mTOR complex 2 (mTORC2) component rictor and several genes encoding mitochondrial functions including components of the respiratory chain, adenosine triphosphate synthase, the mitochondrial ribosome and mitochondrial fission factor. Small interfering RNA knockdown against a sizeable fraction of these genes triggered apoptosis in human cancer cell lines but not in normal fibroblasts. We conclude that mTORC2-addicted cells require mitochondrial functions that may be novel drug targets in human cancer. Oncogene (2011) 30, 1551-1565; doi: 10.1038/onc.2010.539; published online 20 December 2010	[Colombi, M.; Molle, K. D.; Benjamin, D.; Betz, C.; Thiemeyer, A.; Hall, M. N.; Moroni, C.] Univ Basel, Biozentrum, CH-4056 Basel, Switzerland; [Rattenbacher-Kiser, K.; Schaefer, C.] Univ Basel, Inst Med Microbiol, CH-4056 Basel, Switzerland; [Regenass, U.] Actel Pharmaceut Ltd, Allschwil, Switzerland	University of Basel; University of Basel; Actelion Pharmaceuticals Ltd	Hall, MN (corresponding author), Univ Basel, Biozentrum, Klingelbergstr 70, CH-4056 Basel, Switzerland.	m.hall@unibas.ch; christoph.moroni@unibas.ch	Betz, Charles/B-7444-2008	Betz, Charles/0000-0002-9837-6916; Hall, Michael N/0000-0002-2998-0757	Commission of Technology and Innovation (CTI); Swiss National Science Foundation; Swiss Cancer League; Louis-Jeantet Foundation	Commission of Technology and Innovation (CTI); Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); Swiss Cancer League; Louis-Jeantet Foundation	We thank TW Sturgill for comments and Dr F Wenzel for providing normal human fibroblasts. We acknowledge support from the Commission of Technology and Innovation (CTI) (CM, MNH and UR), the Swiss National Science Foundation (CM and MNH) and the Swiss Cancer League and the Louis-Jeantet Foundation (MNH).	Alto NM, 2002, J CELL BIOL, V158, P659, DOI 10.1083/jcb.200204081; Bandyopadhyay G, 2001, J BIOL CHEM, V276, P35537, DOI 10.1074/jbc.M106042200; Bauer DE, 2004, FASEB J, V18, P1303, DOI 10.1096/fj.03-1001fje; Bentzinger CF, 2008, CELL METAB, V8, P411, DOI 10.1016/j.cmet.2008.10.002; Chiang GG, 2007, TRENDS MOL MED, V13, P433, DOI 10.1016/j.molmed.2007.08.001; Cunningham JT, 2007, NATURE, V450, P736, DOI 10.1038/nature06322; Dang CV, 2010, MOL CELL BIOL, V30, P1300, DOI 10.1128/MCB.01661-09; Fan YJ, 2010, J BIOL CHEM, V285, P7324, DOI 10.1074/jbc.M109.035584; Fantin VR, 2006, ONCOGENE, V25, P4787, DOI 10.1038/sj.onc.1209599; Foster DA, 2007, CANCER RES, V67, P1, DOI 10.1158/0008-5472.CAN-06-3016; Gandre-Babbe S, 2008, MOL BIOL CELL, V19, P2402, DOI 10.1091/mbc.E07-12-1287; Gonez LJ, 2008, MOL MED, V14, P697, DOI 10.2119/2008-00072.Gonez; Grandori C, 1996, EMBO J, V15, P4344, DOI 10.1002/j.1460-2075.1996.tb00808.x; Guertin DA, 2007, CANCER CELL, V12, P9, DOI 10.1016/j.ccr.2007.05.008; Heyward CA, 2008, BMC CELL BIOL, V9, DOI 10.1186/1471-2121-9-25; Hill MM, 1999, MOL CELL BIOL, V19, P7771; Jung HC, 2005, LIFE SCI, V77, P1249, DOI 10.1016/j.lfs.2005.02.009; Kiser KF, 2006, ONCOGENE, V25, P6595, DOI 10.1038/sj.onc.1209673; Lipscomb EA, 2001, J BIOL CHEM, V276, P5085, DOI 10.1074/jbc.M008407200; Luo B, 2008, P NATL ACAD SCI USA, V105, P20380, DOI 10.1073/pnas.0810485105; Luo J, 2009, CELL, V137, P835, DOI 10.1016/j.cell.2009.05.006; Majumder PK, 2004, NAT MED, V10, P594, DOI 10.1038/nm1052; Moffat J, 2006, CELL, V124, P1283, DOI 10.1016/j.cell.2006.01.040; Mueller BA, 2009, CURR PHARM DESIGN, V15, P120, DOI 10.2174/138161209787002933; Murray JT, 2004, BIOCHEM J, V384, P477, DOI 10.1042/BJ20041057; NAIR APK, 1992, ONCOGENE, V7, P1963; Nilsson R, 2009, CELL METAB, V10, P119, DOI 10.1016/j.cmet.2009.06.012; Pagliarini DJ, 2008, CELL, V134, P112, DOI 10.1016/j.cell.2008.06.016; Polak P, 2008, CELL METAB, V8, P399, DOI 10.1016/j.cmet.2008.09.003; Pytel D, 2009, ANTI-CANCER AGENT ME, V9, P66, DOI 10.2174/187152009787047752; Ramanathan A, 2009, P NATL ACAD SCI USA, V106, P22229, DOI 10.1073/pnas.0912074106; Root DE, 2006, NAT METHODS, V3, P715, DOI 10.1038/NMETH924; Sato T, 2010, ONCOGENE, V29, P2746, DOI 10.1038/onc.2010.28; Schieke SM, 2006, J BIOL CHEM, V281, P27643, DOI 10.1074/jbc.M603536200; Schlabach MR, 2008, SCIENCE, V319, P620, DOI 10.1126/science.1149200; Scholl C, 2009, CELL, V137, P821, DOI 10.1016/j.cell.2009.03.017; Solimini NL, 2007, CELL, V130, P986, DOI 10.1016/j.cell.2007.09.007; Soria JC, 2002, CLIN CANCER RES, V8, P1178; Thaimattam R, 2007, CURR PHARM DESIGN, V13, P2751, DOI 10.2174/138161207781757042; van de Wetering M, 2003, EMBO REP, V4, P609, DOI 10.1038/sj.embor.embor865; Wang QH, 1999, MOL CELL BIOL, V19, P4008; Weinberg F, 2010, P NATL ACAD SCI USA, V107, P8788, DOI 10.1073/pnas.1003428107; Weinberg F, 2009, ANN NY ACAD SCI, V1177, P66, DOI 10.1111/j.1749-6632.2009.05039.x; Wise DR, 2008, P NATL ACAD SCI USA, V105, P18782, DOI 10.1073/pnas.0810199105; WITTWER AJ, 1980, P NATL ACAD SCI-BIOL, V77, P4484, DOI 10.1073/pnas.77.8.4484; Wullschleger S, 2006, CELL, V124, P471, DOI 10.1016/j.cell.2006.01.016	46	32	32	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2011	30	13					1551	1565		10.1038/onc.2010.539	http://dx.doi.org/10.1038/onc.2010.539			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	743DU	21170086				2022-12-17	WOS:000288998300006
J	Delston, RB; Matatall, KA; Sun, Y; Onken, MD; Harbour, JW				Delston, R. B.; Matatall, K. A.; Sun, Y.; Onken, M. D.; Harbour, J. W.			p38 phosphorylates Rb on Ser567 by a novel, cell cycle-independent mechanism that triggers Rb-Hdm2 interaction and apoptosis	ONCOGENE			English	Article						apoptosis; p38; phosphorylation; retinoblastoma protein; Hdm2	S-PHASE ENTRY; RETINOBLASTOMA GENE-PRODUCT; TUMOR-SUPPRESSOR; E2F1-INDUCED APOPTOSIS; TRANSCRIPTION FACTOR; DIFFERENTIAL REGULATION; NEURONAL APOPTOSIS; MULTIPLE SITES; FAMILY-MEMBERS; PROTEIN PRB	The retinoblastoma protein (Rb) inhibits both cell division and apoptosis, but the mechanism by which Rb alternatively regulates these divergent outcomes remains poorly understood. Cyclin-dependent kinases (Cdks) promote cell division by phosphorylating and reversibly inactivating Rb by a hierarchical series of phosphorylation events and sequential conformational changes. The stress-regulated mitogen-activated protein kinase p38 also phosphorylates Rb, but it does so in a cell cycle-independent manner that is associated with apoptosis rather than with cell division. Here, we show that p38 phosphorylates Rb by a novel mechanism that is distinct from that of Cdks. p38 bypasses the cell cycle-associated hierarchical phosphorylation and directly phosphorylates Rb on Ser567, which is not phosphorylated during the normal cell cycle. Phosphorylation by p38, but not Cdks, triggers an interaction between Rb and the human homolog of murine double minute 2 (Hdm2), leading to degradation of Rb, release of E2F1 and cell death. These findings provide a mechanistic explanation as to how Rb regulates cell division and apoptosis through different kinases, and reveal how Hdm2 may functionally link the tumor suppressors Rb and p53. Oncogene (2011) 30, 588-599; doi: 10.1038/onc.2010.442; published online 27 September 2010	[Delston, R. B.; Matatall, K. A.; Sun, Y.; Onken, M. D.; Harbour, J. W.] Washington Univ, Sch Med, Dept Ophthalmol & Visual Sci, St Louis, MO 63110 USA	Washington University (WUSTL)	Harbour, JW (corresponding author), Washington Univ, Sch Med, Dept Ophthalmol & Visual Sci, 660 S Euclid Ave,Campus Box 8096, St Louis, MO 63110 USA.	harbour@wustl.edu	Onken, Michael D/H-5620-2013; Harbour, J. William/B-1448-2015	Onken, Michael D/0000-0003-4082-1105; Harbour, J. William/0000-0002-1104-9809	Vision Training Grant [5T32EY013360-09]; NIH [EY013169-09, P30 EY 02687]; Barnes-Jewish Hospital Foundation; Horncrest Foundation; Kling Family Foundation; Research to Prevent Blindness; NATIONAL EYE INSTITUTE [P30EY002687, R01EY013169, T32EY013360] Funding Source: NIH RePORTER	Vision Training Grant; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Barnes-Jewish Hospital Foundation; Horncrest Foundation; Kling Family Foundation; Research to Prevent Blindness(Research to Prevent Blindness (RPB)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))	We thank Doug Dean and members of the Harbour Lab for helpful discussions. This work was supported by the Vision Training Grant 5T32EY013360-09, and grants from the NIH (EY013169-09), the Barnes-Jewish Hospital Foundation, the Horncrest Foundation, The Kling Family Foundation and a Research to Prevent Blindness David F Weeks Professorship. This work was also supported by awards to the Department of Ophthalmology and Visual Sciences at Washington University from a Research to Prevent Blindness Inc. Unrestricted grant, and the NIH Vision Core Grant P30 EY 02687.	ALMASAN A, 1995, P NATL ACAD SCI USA, V92, P5436, DOI 10.1073/pnas.92.12.5436; Askari N, 2009, BIOCHEMISTRY-US, V48, P2497, DOI 10.1021/bi900024v; Bacus SS, 2001, ONCOGENE, V20, P147, DOI 10.1038/sj.onc.1204062; Bowen C, 2002, J BIOL CHEM, V277, P44969, DOI 10.1074/jbc.M202000200; Brown VD, 1999, MOL CELL BIOL, V19, P3246; Chau BN, 2006, PLOS ONE, V1, DOI 10.1371/journal.pone.0000082; Chau BN, 2003, NAT REV CANCER, V3, P130, DOI 10.1038/nrc993; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; Dick FA, 2003, MOL CELL, V12, P639, DOI 10.1016/S1097-2765(03)00344-7; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Elbashir SM, 2001, EMBO J, V20, P6877, DOI 10.1093/emboj/20.23.6877; Enge M, 2009, CANCER CELL, V15, P171, DOI 10.1016/j.ccr.2009.01.019; Ezhevsky SA, 1997, P NATL ACAD SCI USA, V94, P10699, DOI 10.1073/pnas.94.20.10699; Ezhevsky SA, 2001, MOL CELL BIOL, V21, P4773, DOI 10.1128/MCB.21.14.4773-4784.2001; Fattman CL, 1998, CANCER LETT, V130, P103, DOI 10.1016/S0304-3835(98)00121-9; Fattman CL, 2001, ONCOGENE, V20, P2918, DOI 10.1038/sj.onc.1204414; Fattman CL, 1997, J CELL BIOCHEM, V67, P399; Giovanni A, 2000, J BIOL CHEM, V275, P11553, DOI 10.1074/jbc.275.16.11553; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; Hallstrom TC, 2003, P NATL ACAD SCI USA, V100, P10848, DOI 10.1073/pnas.1831408100; Hallstrom TC, 2008, CANCER CELL, V13, P11, DOI 10.1016/j.ccr.2007.11.031; Harbour JW, 2000, NAT CELL BIOL, V2, pE65, DOI 10.1038/35008695; Harbour JW, 1999, CELL, V98, P859, DOI 10.1016/S0092-8674(00)81519-6; Harrington EA, 1998, P NATL ACAD SCI USA, V95, P11945, DOI 10.1073/pnas.95.20.11945; Hauck L, 2002, CIRC RES, V91, P782, DOI 10.1161/01.RES.0000041030.98642.41; Hayashi T, 2000, NEUROPATH APPL NEURO, V26, P390, DOI 10.1046/j.1365-2990.2000.00264.x; Heidkamp MC, 2005, AM J PHYSIOL-CELL PH, V289, pC471, DOI 10.1152/ajpcell.00130.2005; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; Hoglinger GU, 2007, P NATL ACAD SCI USA, V104, P3585, DOI 10.1073/pnas.0611671104; Hou ST, 2002, J BIOL CHEM, V277, P48764, DOI 10.1074/jbc.M206336200; Hsieh JK, 1997, GENE DEV, V11, P1840, DOI 10.1101/gad.11.14.1840; Hsieh JK, 1999, MOL CELL, V3, P181, DOI 10.1016/S1097-2765(00)80309-3; Ianari A, 2009, CANCER CELL, V15, P184, DOI 10.1016/j.ccr.2009.01.026; Irwin M, 2000, NATURE, V407, P645, DOI 10.1038/35036614; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; Kishore R, 2003, CIRC RES, V93, P932, DOI 10.1161/01.RES.0000102400.22370.20; Kitagawa M, 2008, ONCOGENE, V27, P5303, DOI 10.1038/onc.2008.164; Knudsen ES, 1998, GENE DEV, V12, P2278, DOI 10.1101/gad.12.15.2278; Lee C, 2002, GENE DEV, V16, P3199, DOI 10.1101/gad.1046102; Lee EJ, 2003, INT J ONCOL, V23, P503; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; Lee JO, 1998, NATURE, V391, P859, DOI 10.1038/36038; LEES JA, 1991, EMBO J, V10, P4279, DOI 10.1002/j.1460-2075.1991.tb05006.x; Lemaire C, 2005, ONCOGENE, V24, P3297, DOI 10.1038/sj.onc.1208493; LIN BTY, 1991, EMBO J, V10, P857, DOI 10.1002/j.1460-2075.1991.tb08018.x; Liu DX, 2001, CELL TISSUE RES, V305, P217, DOI 10.1007/s004410100396; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; Lundberg AS, 1998, MOL CELL BIOL, V18, P753, DOI 10.1128/MCB.18.2.753; Ma DD, 2003, J BIOL CHEM, V278, P19358, DOI 10.1074/jbc.M301761200; Macleod KF, 1996, EMBO J, V15, P6178, DOI 10.1002/j.1460-2075.1996.tb01006.x; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; MORGENBESSER SD, 1994, NATURE, V371, P72, DOI 10.1038/371072a0; Nath N, 2003, ONCOGENE, V22, P5986, DOI 10.1038/sj.onc.1206843; Nevins JR, 1998, CELL GROWTH DIFFER, V9, P585; O'Hare MJ, 2000, J BIOL CHEM, V275, P25358, DOI 10.1074/jbc.M001725200; Ohba M, 1998, MOL CELL BIOL, V18, P5199, DOI 10.1128/MCB.18.9.5199; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; Park DS, 2000, J NEUROSCI, V20, P3104, DOI 10.1523/JNEUROSCI.20-09-03104.2000; Pillaire MJ, 2000, BIOCHEM BIOPH RES CO, V278, P724, DOI 10.1006/bbrc.2000.3877; Proctor BM, 2008, CIRCULATION, V118, P658, DOI 10.1161/CIRCULATIONAHA.107.734848; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; Ramalho RM, 2004, J NEUROCHEM, V90, P567, DOI 10.1111/j.1471-4159.2004.02517.x; Sdek P, 2005, MOL CELL, V20, P699, DOI 10.1016/j.molcel.2005.10.017; Sdek P, 2004, J BIOL CHEM, V279, P53317, DOI 10.1074/jbc.M406062200; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHAN B, 1994, MOL CELL BIOL, V14, P8166, DOI 10.1128/MCB.14.12.8166; Sherr CJ, 2002, CANCER CELL, V2, P103, DOI 10.1016/S1535-6108(02)00102-2; Stevaux O, 2002, CURR OPIN CELL BIOL, V14, P684, DOI 10.1016/S0955-0674(02)00388-5; Strobeck MW, 2000, ONCOGENE, V19, P1857, DOI 10.1038/sj.onc.1203510; Sun BH, 2010, CELL CYCLE, V9, P1122, DOI 10.4161/cc.9.6.10990; Sun Y, 2005, INVEST OPHTH VIS SCI, V46, P1561, DOI 10.1167/iovs.04-1362; TEMPLETON DJ, 1991, P NATL ACAD SCI USA, V88, P3033, DOI 10.1073/pnas.88.8.3033; Thakur A, 2008, INT J CLIN EXP PATHO, V1, P134; Tsai KY, 1998, MOL CELL, V2, P293, DOI 10.1016/S1097-2765(00)80274-9; Uchida CH, 2005, EMBO J, V24, P160, DOI 10.1038/sj.emboj.7600486; Valentini A, 2007, CANCER BIOL THER, V6, P185, DOI 10.4161/cbt.6.2.3578; von Willebrand M, 2003, CANCER RES, V63, P1420; Wang S, 1999, EMBO J, V18, P1559, DOI 10.1093/emboj/18.6.1559; Wang WH, 2008, J BIOL CHEM, V283, P25455, DOI 10.1074/jbc.M801934200; Wang YB, 1998, J BIOL CHEM, V273, P2161, DOI 10.1074/jbc.273.4.2161; Weber HO, 2005, ONCOGENE, V24, P1965, DOI 10.1038/sj.onc.1208389; Wells J, 2000, MOL CELL BIOL, V20, P5797, DOI 10.1128/MCB.20.16.5797-5807.2000; Wells J, 2003, ONCOGENE, V22, P1445, DOI 10.1038/sj.onc.1206264; Wu LZ, 2003, NATURE, V421, P942, DOI 10.1038/nature01417; XIAO ZX, 1995, NATURE, V375, P694, DOI 10.1038/375694a0; Xu XQ, 2007, GENOME RES, V17, P1550, DOI 10.1101/gr.6783507; Yap DBS, 1999, ONCOGENE, V18, P7681, DOI 10.1038/sj.onc.1202954; Yeste-Velasco M, 2009, NEUROCHEM INT, V54, P99, DOI 10.1016/j.neuint.2008.10.004; Yilmaz S, 1998, Hum Mutat, V12, P434, DOI 10.1002/(SICI)1098-1004(1998)12:6<434::AID-HUMU16>3.3.CO;2-Z; Young AP, 2003, ONCOGENE, V22, P7209, DOI 10.1038/sj.onc.1206804; Young AP, 2004, ONCOGENE, V23, P2587, DOI 10.1038/sj.onc.1207330; Yu BD, 2003, P NATL ACAD SCI USA, V100, P14881, DOI 10.1073/pnas.2431391100; Zagorski WA, 2007, CANCER RES, V67, P8264, DOI 10.1158/0008-5472.CAN-06-4753; Zhang HS, 2000, CELL, V101, P79, DOI 10.1016/S0092-8674(00)80625-X	95	32	33	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2011	30	5					588	599		10.1038/onc.2010.442	http://dx.doi.org/10.1038/onc.2010.442			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	715WG	20871633	Green Accepted			2022-12-17	WOS:000286922300007
J	Alameda, JP; Moreno-Maldonado, R; Navarro, M; Bravo, A; Ramirez, A; Page, A; Jorcano, JL; Fernandez-Acenero, MJ; Casanova, ML				Alameda, J. P.; Moreno-Maldonado, R.; Navarro, M.; Bravo, A.; Ramirez, A.; Page, A.; Jorcano, J. L.; Fernandez-Acenero, M. J.; Casanova, M. L.			An inactivating CYLD mutation promotes skin tumor progression by conferring enhanced proliferative, survival and angiogenic properties to epidermal cancer cells	ONCOGENE			English	Article						CYLD; angiogenesis; skin cancer; tumor progression	NF-KAPPA-B; ENDOTHELIAL GROWTH-FACTOR; MALIGNANT-TRANSFORMATION; EXPRESSION; GENE; ACTIVATION; VEGF; CYLINDROMATOSIS; CARCINOGENESIS; STATE	In this study, we demonstrate that the expression in tumorigenic epidermal cells of a catalytically inactive form of CYLD (CYLDC/S) that mimics the identified mutations of cyld in human tumors and competes with the endogenous CYLD results in enhanced cell proliferation and inhibition of apoptosis; it also stimulates cell migration and induces the expression of angiogenic factors, including vascular endothelial growth factor-A. Altogether, these characteristics indicate an increased oncogenicity of the tumorigenic epidermal CYLDC/S mutant cells in vitro. Moreover, we show the increase in malignancy of epidermal squamous cell carcinomas that express the CYLDC/S transgene in an in vivo xenograft model. Tumors carrying the mutated CYLDC/S exhibit a fast growth, are poorly differentiated and present a robust angiogenesis. CYLDC/S tumors are also characterized by their elevated proliferation rate and decreased apoptosis. In contrast with previous studies showing the development of benign tumors by mutations in the CYLD gene, here we provide evidence that the occurrence of mutations in the CYLD gene in tumorigenic epidermal cells (carrying previous mutations) increases the aggressiveness of carcinomas, mainly through enhancement of the expression of angiogenic factors, having therefore a key role in epidermal cancer malignancy. Oncogene (2010) 29, 6522-6532; doi:10.1038/onc.2010.378; published online 13 September 2010	[Alameda, J. P.; Moreno-Maldonado, R.; Navarro, M.; Ramirez, A.; Page, A.; Jorcano, J. L.; Casanova, M. L.] CIEMAT, Div Epithelial Biomed, E-28040 Madrid, Spain; [Bravo, A.] Univ Santiago de Compostela, Fac Vet, Dept Vet Clin Sci, Lugo, Spain; [Fernandez-Acenero, M. J.] Fdn Jimenez Diaz, Dept Pathol, E-28040 Madrid, Spain	Centro de Investigaciones Energeticas, Medioambientales Tecnologicas; Universidade de Santiago de Compostela	Casanova, ML (corresponding author), CIEMAT, Div Epithelial Biomed, Ave Complutense 22, E-28040 Madrid, Spain.	llanos.casanova@ciemat.es	Ramirez, Angel/A-4800-2018; Navarro, Manuel/S-1496-2019; Moral, Ana María Bravo/AAD-3339-2021	Ramirez, Angel/0000-0001-7745-5108; Navarro, Manuel/0000-0003-1118-8531; Moral, Ana María Bravo/0000-0002-5282-8921; Page, Angustias/0000-0002-0231-8536; Casanova, M. Llanos/0000-0001-7742-8265	Ministerio de Sanidad [PI061233, PI060655]; Ministerio de Educacion y Ciencia [PSE-010000-2008-7]	Ministerio de Sanidad(Instituto de Salud Carlos IIISpanish Government); Ministerio de Educacion y Ciencia(Spanish Government)	We thank Dr R Bernards for providing the CYLD<SUP>C/S</SUP> cDNA; M Isabel de los Santos and Federico Sanchez-Sierra for invaluable assistance in the histological and immunohistochemical analyses; Juan Manuel Luque and Soledad Moreno for technical assistance; and Jesus Martinez, Edilia Almeida and the personnel of the CIEMAT Animal Unit for care of the mice used. This work was funded by grant from the Ministerio de Sanidad (PI061233, PI060655) to MLC and AR respectively and a grant from the Ministerio de Educacion y Ciencia (PSE-010000-2008-7).	Annunziata CM, 2007, CANCER CELL, V12, P115, DOI 10.1016/j.ccr.2007.07.004; Bignell GR, 2000, NAT GENET, V25, P160, DOI 10.1038/76006; Bolontrade MF, 1998, CARCINOGENESIS, V19, P2107, DOI 10.1093/carcin/19.12.2107; Brummelkamp TR, 2003, NATURE, V424, P797, DOI 10.1038/nature01811; Budunova IV, 1999, ONCOGENE, V18, P7423, DOI 10.1038/sj.onc.1203104; Carmeliet P, 2003, NAT MED, V9, P653, DOI 10.1038/nm0603-653; Casanova ML, 2004, FASEB J, V18, P1556, DOI 10.1096/fj.04-1683fje; Casanova ML, 2002, CANCER RES, V62, P3402; Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018; Cogswell PC, 2000, ONCOGENE, V19, P1123, DOI 10.1038/sj.onc.1203412; Costello CM, 2005, PLOS MED, V2, P771, DOI 10.1371/journal.pmed.0020199; Dajee M, 2003, NATURE, V421, P639, DOI 10.1038/nature01283; De Francesco V, 2005, AM J DERMATOPATH, V27, P21, DOI 10.1097/01.dad.0000141548.69423.c7; Derksen PWB, 2004, P NATL ACAD SCI USA, V101, P6122, DOI 10.1073/pnas.0305855101; Detmar M, 2000, J DERMATOL SCI, V24, pS78, DOI 10.1016/S0923-1811(00)00145-6; Detmar M, 2000, J INVEST DERM SYMP P, V5, P20, DOI 10.1046/j.1087-0024.2000.00003.x; Durani BK, 2001, BRIT J DERMATOL, V145, P653, DOI 10.1046/j.1365-2133.2001.04460.x; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317; Farrara N, 2000, CURR OPIN BIOTECH, V11, P617, DOI 10.1016/S0958-1669(00)00153-1; Ferrara N, 2002, NAT REV CANCER, V2, P795, DOI 10.1038/nrc909; Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669; FREDERICKSON RM, 1989, NUCLEIC ACIDS RES, V17, P253, DOI 10.1093/nar/17.1.253; Green DR, 2002, CANCER CELL, V1, P19, DOI 10.1016/S1535-6108(02)00024-7; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hashimoto K, 2004, MODERN PATHOL, V17, P617, DOI 10.1038/modpathol.3800107; Hellerbrand C, 2007, CARCINOGENESIS, V28, P21, DOI 10.1093/carcin/bgl081; Hirai Y, 2004, INT J ONCOL, V24, P977; Jenner MW, 2007, BLOOD, V110, P3291, DOI 10.1182/blood-2007-02-075069; Keats JJ, 2007, CANCER CELL, V12, P131, DOI 10.1016/j.ccr.2007.07.003; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Kovalenko A, 2003, NATURE, V424, P801, DOI 10.1038/nature01802; Larcher F, 1998, ONCOGENE, V17, P303, DOI 10.1038/sj.onc.1201928; Larcher F, 1996, CANCER RES, V56, P5391; Li HC, 2009, J EXP CLIN CANC RES, V28, DOI 10.1186/1756-9966-28-110; Limmer B L, 2001, Tex Med, V97, P56; Massoumi R, 2007, BIOESSAYS, V29, P1203, DOI 10.1002/bies.20677; Massoumi R, 2006, CELL, V125, P665, DOI 10.1016/j.cell.2006.03.041; Massoumi R, 2009, J EXP MED, V206, P221, DOI 10.1084/jem.20082044; Mirones I, 2009, J INVEST DERMATOL, V129, P730, DOI 10.1038/jid.2008.292; Moon RT, 2004, NAT REV GENET, V5, P689, DOI 10.1038/nrg1427; Moreno-Maldonado R, 2008, CELL CYCLE, V7, P2021, DOI 10.4161/cc.7.13.6147; PIERCEALL WE, 1991, MOL CARCINOGEN, V4, P196, DOI 10.1002/mc.2940040306; Qiang YW, 2005, BLOOD, V106, P1786, DOI 10.1182/blood-2005-01-0049; Regamey A, 2003, J EXP MED, V198, P1959, DOI 10.1084/jem.20031187; Ren Q, 2006, CANCER RES, V66, P5209, DOI 10.1158/0008-5472.CAN-05-4158; Scharstuhl A, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006688; Seitz CS, 1998, P NATL ACAD SCI USA, V95, P2307, DOI 10.1073/pnas.95.5.2307; Solovey A, 1999, BLOOD, V93, P3824, DOI 10.1182/blood.V93.11.3824.411k10_3824_3830; SPENCER JM, 1995, ARCH DERMATOL, V131, P796, DOI 10.1001/archderm.131.7.796; Strobel P, 2002, AM J SURG PATHOL, V26, P119, DOI 10.1097/00000478-200201000-00016; Sukhdeo K, 2007, P NATL ACAD SCI USA, V104, P7516, DOI 10.1073/pnas.0610299104; Tauriello DVF, 2010, MOL CELL, V37, P607, DOI 10.1016/j.molcel.2010.01.035; Thornburg NJ, 2003, CANCER RES, V63, P8293; Thurston G, 1998, AM J PATHOL, V153, P1099, DOI 10.1016/S0002-9440(10)65654-4; Trompouki E, 2003, NATURE, V424, P793, DOI 10.1038/nature01803; van Hogerlinden M, 1999, CANCER RES, V59, P3299; WINTER H, 1990, DIFFERENTIATION, V43, P105, DOI 10.1111/j.1432-0436.1990.tb00436.x; ZHANG W, 2010, MED ONCOL, V37, P607; Zhong S, 2007, ONCOGENE, V26, P2621, DOI 10.1038/sj.onc.1210041	59	32	33	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	2010	29	50					6522	6532		10.1038/onc.2010.378	http://dx.doi.org/10.1038/onc.2010.378			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	695OA	20838385				2022-12-17	WOS:000285380200002
J	Lacher, MD; Pincheira, R; Zhu, Z; Camoretti-Mercado, B; Matli, M; Warren, RS; Castro, AF				Lacher, M. D.; Pincheira, R.; Zhu, Z.; Camoretti-Mercado, B.; Matli, M.; Warren, R. S.; Castro, A. F.			Rheb activates AMPK and reduces p27Kip1 levels in Tsc2-null cells via mTORC1-independent mechanisms: implications for cell proliferation and tumorigenesis	ONCOGENE			English	Article						Rheb; p27; AMPK; mTORC1; TSC/LAM; cancer	TUBEROUS SCLEROSIS COMPLEX; PROTEIN-KINASE; MAMMALIAN TARGET; PULMONARY LYMPHANGIOLEIOMYOMATOSIS; CYTOPLASMIC SEQUESTRATION; PROMOTES BINDING; CANCER-THERAPY; NULL-CELLS; PHOSPHORYLATION; TSC2	Tuberous sclerosis complex (TSC) is an autosomally inherited disorder that causes tumors to form in many organs. It is frequently caused by inactivating mutations in the TSC2 tumor-suppressor gene. TSC2 negatively regulates the activity of the GTPase Rheb and thereby inhibits mammalian target of rapamycin complex 1 (mTORC1) signaling. Activation of mTORC1 as a result of lack of TSC2 function is observed in TSC and sporadic lymphangioleiomyomatosis (LAM). TSC2 deficiency has recently been associated with elevated AMP-activated protein kinase (AMPK) activity, which in turn correlated with cytoplasmic localization of p27Kip1 (p27), a negative regulator of cyclin-dependent kinase 2 (Cdk2). How AMPK in the absence of TSC2 is stimulated is not fully understood. In this study, we demonstrate that Rheb activates AMPK and reduces p27 levels in Tsc2-null cells. Importantly, both effects occur largely independent of mTORC1. Furthermore, increased p27 levels following Rheb depletion correlated with reduced Cdk2 activity and cell proliferation in vitro, and with inhibition of tumor formation by Tsc2-null cells in vivo. Taken together, our data suggest that Rheb controls proliferation of TSC2-deficient cells by a mechanism that involves regulation of AMPK and p27, and that Rheb is a potential target for TSC/LAM therapy. Oncogene (2010) 29, 6543-6556; doi:10.1038/onc.2010.393; published online 6 September 2010	[Lacher, M. D.; Castro, A. F.] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA; [Pincheira, R.] Univ Concepcion, Dept Biochem & Mol Biol, Concepcion, Chile; [Zhu, Z.; Matli, M.; Warren, R. S.] Univ Calif San Francisco, Dept Surg, San Francisco, CA 94143 USA; [Camoretti-Mercado, B.] Univ Chicago, Dept Med, Chicago, IL 60637 USA; [Castro, A. F.] Univ Calif San Francisco, Dept Dermatol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer Center; Universidad de Concepcion; University of California System; University of California San Francisco; University of Chicago; University of California System; University of California San Francisco	Castro, AF (corresponding author), Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA.	arcastro@udec.cl	Lacher, Markus D/F-3772-2012	Pincheira, Roxana/0000-0003-4277-5245	Department of Defense (DOD) [DOD TS043006, TS043006]; Academic Senate (UCSF); LAM Foundation; ATS; ALA; Blowitz-Ridgeway Foundation; DOD [TS043006]	Department of Defense (DOD)(United States Department of Defense); Academic Senate (UCSF); LAM Foundation; ATS; ALA; Blowitz-Ridgeway Foundation; DOD(United States Department of Defense)	We are grateful to the NIH-LAM registry, the LAM foundation and especially to the LAM patients for providing LAM specimens. We thank Prema S Idumalla and Xiaochen Yuan for technical assistance, and Drs David Donner and Martin McMahon for review of the paper and suggestions. Special thanks to Pamela Derish at UCSF for editing the paper. We also thank Dr Geoffrey Clark for providing the custom Rheb antibody, Dr Cheryl Walker for the ELT3 cells and Dr David Kwiatkowski for the MEFs Tsc2-/- and Tsc2+/+. This work was supported by grants from the Department of Defense (DOD TS043006) and Academic Senate (UCSF) (AFC), and LAM Foundation, ATS, ALA, and Blowitz-Ridgeway Foundation (BC-M). Zhe Zhu was supported by the DOD TS043006 grant to AFC.	Alkarain A, 2004, BREAST CANCER RES, V6, P13, DOI 10.1186/bcr722; Carsillo T, 2000, P NATL ACAD SCI USA, V97, P6085, DOI 10.1073/pnas.97.11.6085; Castro AF, 2003, J BIOL CHEM, V278, P32493, DOI 10.1074/jbc.C300226200; Cheadle JP, 2000, HUM GENET, V107, P97, DOI 10.1007/s004390000348; Choo AY, 2008, P NATL ACAD SCI USA, V105, P17414, DOI 10.1073/pnas.0809136105; Choo AY, 2006, CANCER CELL, V9, P77, DOI 10.1016/j.ccr.2006.01.021; Dabora SL, 2001, AM J HUM GENET, V68, P64, DOI 10.1086/316951; Easton JB, 2006, ONCOGENE, V25, P6436, DOI 10.1038/sj.onc.1209886; El-Hashemite N, 2003, LANCET, V361, P1348, DOI 10.1016/S0140-6736(03)13044-9; Finlay GA, 2007, CANCER RES, V67, P9878, DOI 10.1158/0008-5472.CAN-07-1394; Fujita N, 2002, J BIOL CHEM, V277, P28706, DOI 10.1074/jbc.M203668200; Garami A, 2003, MOL CELL, V11, P1457, DOI 10.1016/S1097-2765(03)00220-X; Garcia-Martinez JM, 2008, BIOCHEM J, V416, P375, DOI 10.1042/BJ20081668; Gau CL, 2005, MOL CANCER THER, V4, P918, DOI 10.1158/1535-7163.MCT-04-0347; Gottlob K, 2001, GENE DEV, V15, P1406, DOI 10.1101/gad.889901; Gwinn DM, 2008, MOL CELL, V30, P214, DOI 10.1016/j.molcel.2008.03.003; Hahn-Windgassen A, 2005, J BIOL CHEM, V280, P32081, DOI 10.1074/jbc.M502876200; Halayko AJ, 1999, AM J PHYSIOL-LUNG C, V276, pL197, DOI 10.1152/ajplung.1999.276.1.L197; Hong F, 2008, MOL CELL, V30, P701, DOI 10.1016/j.molcel.2008.04.027; HOWE SR, 1995, AM J PATHOL, V146, P1568; Huang J, 2008, BIOCHEM J, V412, P179, DOI 10.1042/BJ20080281; Huang JX, 2009, CANCER RES, V69, P6107, DOI 10.1158/0008-5472.CAN-09-0975; Inoki K, 2003, CELL, V115, P577, DOI 10.1016/S0092-8674(03)00929-2; Inoki K, 2003, GENE DEV, V17, P1829, DOI 10.1101/gad.1110003; Inoki K, 2009, HUM MOL GENET, V18, pR94, DOI 10.1093/hmg/ddp032; Kim J, 2009, CLIN CANCER RES, V15, P81, DOI 10.1158/1078-0432.CCR-08-0170; Kovacic S, 2003, J BIOL CHEM, V278, P39422, DOI 10.1074/jbc.M305371200; Liang JY, 2007, NAT CELL BIOL, V9, P218, DOI 10.1038/ncb1537; Ma L, 2007, CANCER RES, V67, P7106, DOI 10.1158/0008-5472.CAN-06-4798; Manning BD, 2004, J CELL BIOL, V167, P399, DOI 10.1083/jcb.200408161; Park HU, 2009, MOL CANCER THER, V8, P733, DOI 10.1158/1535-7163.MCT-08-0631; Paul E, 2008, NEW ENGL J MED, V358, P190, DOI 10.1056/NEJMe0707153; PlanasSilva MD, 1997, MOL CELL BIOL, V17, P4059, DOI 10.1128/MCB.17.7.4059; Pollizzi K, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-38; Rosner M, 2007, HUM MOL GENET, V16, P1541, DOI 10.1093/hmg/ddm103; Rosner M, 2006, MUTAT RES-REV MUTAT, V613, P10, DOI 10.1016/j.mrrev.2006.03.001; Sarbassov DD, 2006, MOL CELL, V22, P159, DOI 10.1016/j.molcel.2006.03.029; Sato M, 2004, DEV CELL, V6, P458, DOI 10.1016/S1534-5807(04)00103-0; Sato T, 2002, J HUM GENET, V47, P20, DOI 10.1007/s10038-002-8651-8; Shaw RJ, 2006, NATURE, V441, P424, DOI 10.1038/nature04869; Short JD, 2008, CANCER RES, V68, P6496, DOI 10.1158/0008-5472.CAN-07-5756; Short JD, 2010, MOL CARCINOGEN, V49, P429, DOI 10.1002/mc.20613; Tee AR, 2003, CURR BIOL, V13, P1259, DOI 10.1016/S0960-9822(03)00506-2; Thoreen CC, 2009, J BIOL CHEM, V284, P8023, DOI 10.1074/jbc.M900301200; vanSlegtenhorst M, 1997, SCIENCE, V277, P805, DOI 10.1126/science.277.5327.805; Vervoorts J, 2008, CELL MOL LIFE SCI, V65, P3255, DOI 10.1007/s00018-008-8296-7; Viollet B, 2009, FRONT BIOSCI-LANDMRK, V14, P19, DOI 10.2741/3229; Wu FY, 2006, CANCER RES, V66, P2162, DOI 10.1158/0008-5472.CAN-05-3304; Yu JJ, 2009, P NATL ACAD SCI USA, V106, P2635, DOI 10.1073/pnas.0810790106; Zhang BB, 2009, CELL METAB, V9, P407, DOI 10.1016/j.cmet.2009.03.012; Zhang HB, 2003, J CLIN INVEST, V112, P1223, DOI 10.1172/JCI200317222; Zhang Y, 2003, NAT CELL BIOL, V5, P578, DOI 10.1038/ncb999	52	32	33	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	2010	29	50					6543	6556		10.1038/onc.2010.393	http://dx.doi.org/10.1038/onc.2010.393			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	695OA	20818424				2022-12-17	WOS:000285380200004
J	Dhillon, J; Astanehe, A; Lee, C; Fotovati, A; Hu, K; Dunn, SE				Dhillon, J.; Astanehe, A.; Lee, C.; Fotovati, A.; Hu, K.; Dunn, S. E.			The expression of activated Y-box binding protein-1 serine 102 mediates trastuzumab resistance in breast cancer cells by increasing CD44(+) cells	ONCOGENE			English	Article						YB-1; trastuzumab; resistance; CD44; tumor-initiating cells	GROWTH-FACTOR RECEPTOR; MONOCLONAL-ANTIBODY; TUMOR-GROWTH; CHEMOTHERAPY; HER-2; YB-1; EFFICACY; RELAPSE; SAFETY	The development of acquired resistance to trastuzumab remains a prevalent challenge in the treatment of patients whose tumors express human epidermal growth factor 2 (HER2). We previously reported that HER2 overexpressing breast cancers are dependent on Y-box binding protein-1 (YB-1) for growth and survival. As YB-1 is also linked to drug resistance in other types of cancer, we address its possible role in trastuzumab insensitivity. Employing an in vivo model of acquired resistance, we demonstrate that resistant cell lines have elevated levels of P-YB-1(S102) and its activating kinase P-RSK and these levels are sustained following trastuzumab treatment. Further, to demonstrate the importance of YB-1 in mediating drug resistance, the expression of the active mutant YB-1(S102D) rendered the BT474 cell line insensitive to trastuzumab. Questioning the role of tumor-initiating cells (TIC) and their ability to escape cancer therapies, we investigate YB-1's role in inducing the cancer stem cell marker CD44. Notably, the resistant cells express more CD44 mRNA and protein compared with BT474 cells, which correlated with increased mammosphere formation. Expression of YB-1S102D in the BT474 cells increase CD44 protein levels, resulting in enhanced mammosphere formation. Further, exposing BT474 cells to trastuzumab selected for a resistant sub-population enriched for CD44. Conversely, small intefering RNA inhibition of CD44 restored trastuzumab sensitivity in the resistant cell lines. Our findings provide insight on a novel mechanism employed by tumor cells to acquire the ability to escape the effects of trastuzumab and suggest that targeting YB-1 may overcome resistance by eliminating the unresponsive TIC population, rendering the cancer sensitive to therapy. Oncogene (2010) 29, 6294-6300; doi:10.1038/onc.2010.365; published online 30 August 2010	[Dhillon, J.; Astanehe, A.; Lee, C.; Fotovati, A.; Hu, K.; Dunn, S. E.] Univ British Columbia, Dept Paediat, Child & Family Res Inst, Lab Oncogenom Res, Vancouver, BC V5Z 4H4, Canada; [Dhillon, J.; Astanehe, A.; Lee, C.; Dunn, S. E.] Expt Med Program, Dept Med, Vancouver, BC, Canada	Child & Family Research Institute; University of British Columbia	Dunn, SE (corresponding author), Univ British Columbia, Dept Paediat, Child & Family Res Inst, Lab Oncogenom Res, 950 W 28th Ave,Room 3083, Vancouver, BC V5Z 4H4, Canada.	sedunn@interchange.ubc.ca			Canadian Breast Cancer Research Alliance; National Cancer Institute of Canada; Child and Family Research Institute; Canadian Institute of Health Research; Michael Smith Foundation for Health Research	Canadian Breast Cancer Research Alliance; National Cancer Institute of Canada(Canadian Cancer Society (CCS)); Child and Family Research Institute; Canadian Institute of Health Research(Canadian Institutes of Health Research (CIHR)); Michael Smith Foundation for Health Research(Michael Smith Foundation for Health Research)	We thank Spencer Freeman from the Life Sciences Centre, UBC for his assistance with confocal microscopy. This work was supported by the Canadian Breast Cancer Research Alliance and the National Cancer Institute of Canada (SED). JD was a recipient of the Child and Family Research Institute Graduate Studentship and AA was a recipient of Canadian Institute of Health Research MD/PhD and the Michael Smith Foundation for Health Research Studentships.	Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Astanehe A, 2009, ONCOGENE, V28, P2406, DOI 10.1038/onc.2009.81; Bargou RC, 1997, NAT MED, V3, P447, DOI 10.1038/nm0497-447; Cobleigh MA, 1999, J CLIN ONCOL, V17, P2639, DOI 10.1200/JCO.1999.17.9.2639; Finkbeiner MR, 2009, ONCOGENE, V28, P1421, DOI 10.1038/onc.2008.485; Gluz O, 2009, J CLIN ONCOL, V27, P6144, DOI 10.1200/JCO.2008.19.6261; Habibi G, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2156; Korkaya H, 2008, ONCOGENE, V27, P6120, DOI 10.1038/onc.2008.207; Lee C, 2008, CANCER RES, V68, P8661, DOI 10.1158/0008-5472.CAN-08-1082; Li XX, 2008, JNCI-J NATL CANCER I, V100, P672, DOI 10.1093/jnci/djn123; Marangoni E, 2009, BRIT J CANCER, V100, P918, DOI 10.1038/sj.bjc.6604953; Ritter CA, 2007, CLIN CANCER RES, V13, P4909, DOI 10.1158/1078-0432.CCR-07-0701; Sawyers C, 2004, NATURE, V432, P294, DOI 10.1038/nature03095; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Stratford AL, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1767; Stratford AL, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2202; Sutherland BW, 2005, ONCOGENE, V24, P4281, DOI 10.1038/sj.onc.1208590; To K, 2010, CANCER RES, V70, P2840, DOI 10.1158/0008-5472.CAN-09-3155; Vogel CL, 2002, J CLIN ONCOL, V20, P719, DOI 10.1200/JCO.2002.20.3.719; Wu J, 2006, CANCER RES, V66, P4872, DOI 10.1158/0008-5472.CAN-05-3561	21	32	35	2	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV	2010	29	47					6294	6300		10.1038/onc.2010.365	http://dx.doi.org/10.1038/onc.2010.365			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	685CG	20802512				2022-12-17	WOS:000284601700010
J	Oram, SH; Thoms, JAI; Pridans, C; Janes, ME; Kinston, SJ; Anand, S; Landry, JR; Lock, RB; Jayaraman, PS; Huntly, BJ; Pimanda, JE; Gottgens, B				Oram, S. H.; Thoms, J. A. I.; Pridans, C.; Janes, M. E.; Kinston, S. J.; Anand, S.; Landry, J-R; Lock, R. B.; Jayaraman, P-S; Huntly, B. J.; Pimanda, J. E.; Goettgens, B.			A previously unrecognized promoter of LMO2 forms part of a transcriptional regulatory circuit mediating LMO2 expression in a subset of T-acute lymphoblastic leukaemia patients	ONCOGENE			English	Article						LMO2; leukaemia; transcriptional regulation; human; ChIP-on-chip; chromatin immunoprecipitation	LIM-PROTEIN RBTN2; GENE-THERAPY; CELL LEUKEMIA; ETS; ONCOGENE; DOMAIN; ERG; ELEMENTS; SCL; TRANSLOCATIONS	The T-cell oncogene Lim-only 2 (LMO2) critically influences both normal and malignant haematopoiesis. LMO2 is not normally expressed in T cells, yet ectopic expression is seen in the majority of T-acute lymphoblastic leukaemia (T-ALL) patients with specific translocations involving LMO2 in only a subset of these patients. Ectopic lmo2 expression in thymocytes of transgenic mice causes T-ALL, and retroviral vector integration into the LMO2 locus was implicated in the development of clonal T-cell disease in patients undergoing gene therapy. Using array-based chromatin immunoprecipitation, we now demonstrate that in contrast to B-acute lymphoblastic leukaemia, human T-ALL samples largely use promoter elements with little influence from distal enhancers. Active LMO2 promoter elements in T-ALL included a previously unrecognized third promoter, which we demonstrate to be active in cell lines, primary T-ALL patients and transgenic mice. The ETS factors ERG and FLI1 previously implicated in lmo2-dependent mouse models of T-ALL bind to the novel LMO2 promoter in human T-ALL samples, while in return LMO2 binds to blood stem/progenitor enhancers in the FLI1 and ERG gene loci. Moreover, LMO2, ERG and FLI1 all regulate the +1 enhancer of HHEX/PRH, which was recently implicated as a key mediator of early progenitor expansion in LMO2-driven T-ALL. Our data therefore suggest that a self-sustaining triad of LMO2/ERG/FLI1 stabilizes the expression of important mediators of the leukaemic phenotype such as HHEX/PRH. Oncogene (2010) 29, 5796-5808; doi: 10.1038/onc.2010.320; published online 2 August 2010	[Oram, S. H.; Pridans, C.; Kinston, S. J.; Anand, S.; Huntly, B. J.; Goettgens, B.] Univ Cambridge, Dept Haematol, Cambridge Inst Med Res, Cambridge CB2 0XY, England; [Thoms, J. A. I.; Janes, M. E.; Pimanda, J. E.] Univ New S Wales, Lowy Canc Res Ctr, Sydney, NSW, Australia; [Thoms, J. A. I.; Janes, M. E.; Pimanda, J. E.] Univ New S Wales, Prince Wales Clin Sch, Sydney, NSW, Australia; [Landry, J-R] Univ Montreal, Inst Res Immunol & Canc, Montreal, PQ, Canada; [Lock, R. B.] Univ New S Wales, Childrens Canc Inst Australia, Sydney, NSW, Australia; [Jayaraman, P-S] Univ Birmingham, Birmingham Univ Stem Cell Ctr, Birmingham, W Midlands, England	University of Cambridge; University of New South Wales Sydney; University of New South Wales Sydney; Universite de Montreal; Children's Cancer Institute; University of New South Wales Sydney; University of Birmingham	Gottgens, B (corresponding author), Univ Cambridge, Dept Haematol, Cambridge Inst Med Res, Hills Rd, Cambridge CB2 0XY, England.	BG200@CAM.AC.UK	Thoms, Julie/H-6123-2019; Pridans, Clare/AAF-9953-2020; huntly, brian JP/E-6725-2014; Lock, Richard/G-4253-2013	Thoms, Julie/0000-0002-4876-7230; Pridans, Clare/0000-0001-9423-557X; huntly, brian JP/0000-0003-0312-161X; Lock, Richard/0000-0002-3436-9071; Gottgens, Berthold/0000-0001-6302-5705; /0000-0002-6500-9095	Kay Kendall Leukaemia Fund; Medical Research Council; Cancer Research UK; National Health and Research Council of Australia; National Institute for Health Research Cambridge Biomedical Research Centre; Leukaemia and Lymphoma Research UK; Medical Research Council [G116/187, G0800784, G0800784B] Funding Source: researchfish; National Centre for the Replacement [G0900729/1] Funding Source: researchfish; MRC [G0800784, G116/187] Funding Source: UKRI	Kay Kendall Leukaemia Fund; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Cancer Research UK(Cancer Research UK); National Health and Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia); National Institute for Health Research Cambridge Biomedical Research Centre(National Institute for Health Research (NIHR)); Leukaemia and Lymphoma Research UK; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); National Centre for the Replacement; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	We thank the Kay Kendall Leukaemia Fund, Medical Research Council, Cancer Research UK, National Health and Research Council of Australia, the National Institute for Health Research Cambridge Biomedical Research Centre and Leukaemia and Lymphoma Research UK for grant funding. We are grateful to Michelle Hammet and Tina Hamilton for assistance with pronuclear microinjections and to Professor Sally Kinsey, Leeds Teaching Hospitals, for assistance with sourcing patient material.	Appert A, 2009, CANCER RES, V69, P4784, DOI 10.1158/0008-5472.CAN-08-4774; Asnafi V, 2004, BLOOD, V104, P4173, DOI 10.1182/blood-2003-11-3944; Baldus CD, 2007, J CLIN ONCOL, V25, P3739, DOI 10.1200/JCO.2007.11.5253; Baldus CD, 2006, J CLIN ONCOL, V24, P4714, DOI 10.1200/JCO.2006.06.1580; BOEHM T, 1991, P NATL ACAD SCI USA, V88, P4367, DOI 10.1073/pnas.88.10.4367; Bohne A, 2009, LEUKEMIA RES, V33, P817, DOI 10.1016/j.leukres.2008.11.012; Chan WYI, 2007, BLOOD, V109, P1908, DOI 10.1182/blood-2006-05-023226; Chiaretti S, 2004, BLOOD, V103, P2771, DOI 10.1182/blood-2003-09-3243; Crable SC, 2003, BLOOD, V101, P4757, DOI 10.1182/blood-2002-09-2702; CRIST WM, 1993, STEM CELLS, V11, P81, DOI 10.1002/stem.5530110202; Dave UP, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000491; Donaldson IJ, 2005, HUM MOL GENET, V14, P595, DOI 10.1093/hmg/ddi056; Ferrando AA, 2004, BLOOD, V103, P1909, DOI 10.1182/blood-2003-07-2577; Ferrando AA, 2002, CANCER CELL, V1, P75, DOI 10.1016/S1535-6108(02)00018-1; Follows GA, 2006, GENOME RES, V16, P1310, DOI 10.1101/gr.5373606; Garand R, 1993, Recent Results Cancer Res, V131, P283; Gottgens B, 2004, MOL CELL BIOL, V24, P1870, DOI 10.1128/MCB.24.5.1870-1883.2004; Hacein-Bey-Abina S, 2003, SCIENCE, V302, P415, DOI 10.1126/science.1088547; Hacein-Bey-Abina S, 2003, NEW ENGL J MED, V348, P255, DOI 10.1056/NEJM200301163480314; Hacein-Bey-Abina S, 2008, J CLIN INVEST, V118, P3132, DOI 10.1172/JCI35700; Hammond SM, 2005, LEUKEMIA RES, V29, P89, DOI 10.1016/j.leukres.2004.05.013; Howe SJ, 2008, J CLIN INVEST, V118, P3143, DOI 10.1172/JCI35798; Huang XL, 2006, BLOOD, V107, P3153, DOI 10.1182/blood-2005-08-3206; Kadrmas JL, 2004, NAT REV MOL CELL BIO, V5, P920, DOI 10.1038/nrm1499; Kruse EA, 2009, P NATL ACAD SCI USA, V106, P13814, DOI 10.1073/pnas.0906556106; Landry JR, 2009, BLOOD, V113, P5783, DOI 10.1182/blood-2008-11-187757; Landry JR, 2005, BLOOD, V106, P2680, DOI 10.1182/blood-2004-12-4755; LARSON RC, 1995, ONCOGENE, V11, P853; Larson RC, 1996, EMBO J, V15, P1021, DOI 10.1002/j.1460-2075.1996.tb00439.x; Lock RB, 2002, BLOOD, V99, P4100, DOI 10.1182/blood.V99.11.4100; MacArthur BD, 2009, NAT REV MOL CELL BIO, V10, P672, DOI 10.1038/nrm2766; McCormack MP, 2010, SCIENCE, V327, P879, DOI 10.1126/science.1182378; Noy P, 2010, MOL CELL BIOL, V30, P2120, DOI 10.1128/MCB.01511-09; OSADA H, 1995, P NATL ACAD SCI USA, V92, P9585, DOI 10.1073/pnas.92.21.9585; Pimanda JE, 2007, P NATL ACAD SCI USA, V104, P17692, DOI 10.1073/pnas.0707045104; Rabbitts T. H., 1997, Leukemia (Basingstoke), V11, P271; RAIMONDI SC, 2007, ATLAS GENET CYTOGENE, V11, P69; ROYERPOKORA B, 1995, ONCOGENE, V10, P1353; ROYERPOKORA B, 1991, ONCOGENE, V6, P1887; Valge-Archer V, 1998, ONCOGENE, V17, P3199, DOI 10.1038/sj.onc.1202353; van Grotel M, 2008, LEUKEMIA, V22, P124, DOI 10.1038/sj.leu.2404957; Wadman IA, 1997, EMBO J, V16, P3145, DOI 10.1093/emboj/16.11.3145; WARREN AJ, 1994, CELL, V78, P45, DOI 10.1016/0092-8674(94)90571-1; Wilson NK, 2009, BLOOD, V113, P5456, DOI 10.1182/blood-2009-01-200048; Yamada Y, 1998, P NATL ACAD SCI USA, V95, P3890, DOI 10.1073/pnas.95.7.3890; Yeoh EJ, 2002, CANCER CELL, V1, P133, DOI 10.1016/S1535-6108(02)00032-6	46	32	35	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2010	29	43					5796	5808		10.1038/onc.2010.320	http://dx.doi.org/10.1038/onc.2010.320			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	672LY	20676125	Green Published			2022-12-17	WOS:000283586200005
J	Weiss, MB; Vitolo, MI; Mohseni, M; Rosen, DM; Denmeade, SR; Park, BH; Weber, DJ; Bachman, KE				Weiss, M. B.; Vitolo, M. I.; Mohseni, M.; Rosen, D. M.; Denmeade, S. R.; Park, B. H.; Weber, D. J.; Bachman, K. E.			Deletion of p53 in human mammary epithelial cells causes chromosomal instability and altered therapeutic response	ONCOGENE			English	Article						p53; TP53; chromosomal instability; Doxorubicin; MCF-10A	BREAST-CANCER PATIENTS; TUMOR-SUPPRESSOR GENE; COLORECTAL-CANCER; CONTINUOUS-INFUSION; P53-DEFICIENT MICE; IN-VITRO; MUTATIONS; AMPLIFICATION; CHEMOTHERAPY; ANEUPLOIDY	The TP53 tumor suppressor gene is the most commonly mutated gene in human cancers. To evaluate the biological and clinical relevance of p53 loss, human somatic cell gene targeting was used to delete the TP53 gene in the non-tumorigenic epithelial cell line, MCF-10A. In all four p53-/- clones generated, cells acquired the capability for epidermal growth factor-independent growth and were defective in appropriate downstream signaling and cell cycle checkpoints in response to DNA damage. Interestingly, p53 loss induced chromosomal instability leading to features of transformation and the selection of clones with varying phenotypes. For example, p53-deficient clones were heterogeneous in their capacity for anchorage-independent growth and invasion. In addition, and of clinical importance, the cohort of p53-null clones showed sensitivity to chemotherapeutic interventions that varied depending not only on the type of chemotherapeutic agent, but also on the treatment schedule. In conclusion, deletion of the TP53 gene from MCF-10A cells eliminated p53 functions, as well as produced p53-/- clones with varying phenotypes possibly stemming from the distinct chromosomal changes observed. Such a model system will be useful to further understand the cancer-specific phenotypic changes that accompany p53 loss, as well as help to provide future treatment strategies for human malignancies that harbor aberrant p53. Oncogene (2010) 29, 4715-4724; doi:10.1038/onc.2010.220; published online 21 June 2010	[Weiss, M. B.; Vitolo, M. I.; Weber, D. J.; Bachman, K. E.] Univ Maryland, Greenebaum Canc Ctr, Baltimore, MD 21201 USA; [Weiss, M. B.] Univ Maryland, Grad Program Mol Med, Baltimore, MD 21201 USA; [Mohseni, M.] Johns Hopkins Univ, Sch Med, Dept Human Genet, Baltimore, MD USA; [Rosen, D. M.; Denmeade, S. R.; Park, B. H.] Johns Hopkins Univ, Sch Med, Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Dept Oncol, Baltimore, MD USA; [Weber, D. J.; Bachman, K. E.] Univ Maryland, Sch Med, Dept Biochem & Mol Biol, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; Johns Hopkins University; Johns Hopkins University; Johns Hopkins Medicine; University System of Maryland; University of Maryland Baltimore	Bachman, KE (corresponding author), GlaxoSmithKline Inc, Dept Oncol, 1250 S Collegeville Rd,UP1340, Collegeville, PA 19426 USA.	bpark2@jhmi.edu; dweber@umaryland.edu; kurtis.e.bachman@gsk.com	Weber, David J/B-5349-2011	Weber, David J/0000-0002-8824-1110; Vitolo, Michele/0000-0001-8055-9645	NIH [T32DK067872]; Susan G Komen Breast Cancer Foundation [PDF104506]; DOD [BC083057]; Avon Foundation [R01CA109274]; Breast Cancer Research Foundation [R01CA107331, R01GM58888]; Maryland Cigarette Restitution Fund; NATIONAL CANCER INSTITUTE [R01CA107331, R01CA109274] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK067872] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058888] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Susan G Komen Breast Cancer Foundation(Susan G. Komen Breast Cancer Foundation); DOD(United States Department of Defense); Avon Foundation; Breast Cancer Research Foundation; Maryland Cigarette Restitution Fund; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank Dr Fred Bunz for providing TP53 knockout vectors and advice, and Joel Greschock for advice on copy number analysis. This work was supported by: NIH grant T32DK067872 (MBW), Susan G Komen Breast Cancer Foundation PDF104506 (MIV), DOD Breast Cancer Pre-doctoral Training Award BC083057 (MM), The Avon Foundation, R01CA109274, The Breast Cancer Research Foundation (BHP), R01CA107331 and R01GM58888 (DJW) and Maryland Cigarette Restitution Fund (KEB).	Aas T, 1996, NAT MED, V2, P811, DOI 10.1038/nm0796-811; AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; Bachman KE, 2004, CANCER BIOL THER, V3, P221, DOI 10.4161/cbt.3.2.666; BISCHOFF FZ, 1990, CANCER RES, V50, P7979; Bomme L, 2001, INT J CANCER, V92, P816, DOI 10.1002/ijc.1275; Bunz F, 1999, J CLIN INVEST, V104, P263, DOI 10.1172/JCI6863; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Bunz F, 2002, CANCER RES, V62, P1129; Calistri D, 2006, CELL ONCOL, V28, P161; Campomenosi P, 1998, ANAL CELL PATHOL, V17, P1; Chiba S, 2000, EXP CELL RES, V258, P310, DOI 10.1006/excr.2000.4916; Citron ML, 2003, J CLIN ONCOL, V21, P1431, DOI 10.1200/JCO.2003.09.081; Dutt A, 2007, CURR OPIN ONCOL, V19, P43, DOI 10.1097/CCO.0b013e328011a8c1; El-Deiry WS, 1998, SEMIN CANCER BIOL, V8, P345, DOI 10.1006/scbi.1998.0097; Formenti SC, 1997, INT J RADIAT ONCOL, V39, P1059, DOI 10.1016/S0360-3016(97)00506-3; Fukasawa K, 1996, SCIENCE, V271, P1744, DOI 10.1126/science.271.5256.1744; Fukasawa K, 1997, ONCOGENE, V15, P1295, DOI 10.1038/sj.onc.1201482; GREENBLATT MS, 1994, CANCER RES, V54, P4855; Greshock J, 2007, CANCER RES, V67, P10173, DOI 10.1158/0008-5472.CAN-07-2102; Gustin JP, 2009, P NATL ACAD SCI USA, V106, P2835, DOI 10.1073/pnas.0813351106; HARVEY M, 1993, NAT GENET, V5, P225, DOI 10.1038/ng1193-225; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Horn HF, 2007, ONCOGENE, V26, P1306, DOI 10.1038/sj.onc.1210263; Hyman E, 2002, CANCER RES, V62, P6240; Janus F, 1999, CELL MOL LIFE SCI, V55, P12, DOI 10.1007/s000180050266; Konishi H, 2007, CANCER RES, V67, P8460, DOI 10.1158/0008-5472.CAN-07-0108; Korn WM, 1999, GENE CHROMOSOME CANC, V25, P82, DOI 10.1002/(SICI)1098-2264(199906)25:2<82::AID-GCC2>3.0.CO;2-6; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; Lin M, 2004, BIOINFORMATICS, V20, P1233, DOI 10.1093/bioinformatics/bth069; LOTHE RA, 1992, J NATL CANCER I, V84, P1100, DOI 10.1093/jnci/84.14.1100; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; Moon A, 2000, INT J CANCER, V85, P176, DOI 10.1002/(SICI)1097-0215(20000115)85:2<176::AID-IJC5>3.0.CO;2-E; Narayan S, 2004, ONCOGENE, V23, P5880, DOI 10.1038/sj.onc.1207792; Papa V, 1997, J ENDOCRINOL INVEST, V20, P531, DOI 10.1007/BF03348015; Park BH, 2001, P NATL ACAD SCI USA, V98, P2598, DOI 10.1073/pnas.051630998; Park JT, 2006, CANCER RES, V66, P6312, DOI 10.1158/0008-5472.CAN-05-3610; Pollack JR, 2002, P NATL ACAD SCI USA, V99, P12963, DOI 10.1073/pnas.162471999; Riley T, 2008, NAT REV MOL CELL BIO, V9, P402, DOI 10.1038/nrm2395; Rozan S, 1998, INT J CANCER, V79, P27, DOI 10.1002/(SICI)1097-0215(19980220)79:1<27::AID-IJC6>3.3.CO;2-8; Sengelov L, 1997, J CANCER RES CLIN, V123, P565, DOI 10.1007/s004320050106; SOULE HD, 1990, CANCER RES, V50, P6075; THORLACIUS S, 1993, CANCER RES, V53, P1637; Tsafrir D, 2006, CANCER RES, V66, P2129, DOI 10.1158/0008-5472.CAN-05-2569; Varis A, 2003, BRIT J CANCER, V88, P1914, DOI 10.1038/sj.bjc.6600969; Vitolo MI, 2009, CANCER RES, V69, P8275, DOI 10.1158/0008-5472.CAN-09-1067; Wallace-Brodeur RR, 1999, CELL MOL LIFE SCI, V55, P64, DOI 10.1007/s000180050270; Willmarth NE, 2006, J BIOL CHEM, V281, P37728, DOI 10.1074/jbc.M606532200; Wolmark N, 1998, J CLIN ONCOL, V16, P301; YAHANDA AM, 1995, MOL CELL BIOL, V15, P4249	49	32	34	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG	2010	29	33					4715	4724		10.1038/onc.2010.220	http://dx.doi.org/10.1038/onc.2010.220			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	641LK	20562907	Green Accepted			2022-12-17	WOS:000281127400010
J	Fotheringham, JA; Mazzucca, S; Raab-Traub, N				Fotheringham, J. A.; Mazzucca, S.; Raab-Traub, N.			Epstein-Barr virus latent membrane protein-2A-induced Delta Np63 alpha expression is associated with impaired epithelial-cell differentiation	ONCOGENE			English	Article						Epstein-Barr virus; nasopharyngeal carcinoma; differentiation; p63; latent membrane protein 2A	NASOPHARYNGEAL CARCINOMA; PROTEIN 2A; KERATINOCYTE DIFFERENTIATION; UBIQUITIN LIGASE; STEM-CELLS; PY MOTIFS; P63; LMP2A; TRANSCRIPTION; DEGRADATION	Epstein-Barr virus (EBV) is an oncogenic gamma-herpes virus associated with malignancies that develop in both lymphoid and epithelial cells including nasopharyngeal carcinoma (NPC). The EBV protein, latent membrane protein 2A (LMP2A), is expressed in NPC and can modulate epithelial proliferation, transformation and differentiation, and as such may promote malignancy. A key regulator of epithelial-cell differentiation is the transcription factor p63, a member of the p53 family. This study examines the potential contribution of p63 to LMP2A-mediated inhibition of epithelial-cell differentiation. Stable expression of LMP2A increased the protein level and stability of the Delta Np63 alpha isoform and in two epithelial cell lines, LMP2A interacted with Delta Np63 alpha under stable-and transient-expression systems. LMP2A and Delta Np63 alpha were localized to the cytoplasm and nuclear membrane and co-immunoprecipitated in the same fractions. Following induction of epithelial-cell differentiation by calcium, expression of differentiation markers was impaired in both Delta Np63 alpha- and LMP2A-expressing cells. Induction of p63 alpha, association of p63 alpha with LMP2A and impairment of differentiation required the PY and immunoreceptor tyrosine-based activation motif (ITAM) signaling motif of LMP2A. By associating with and being regulated by LMP2A, Delta Np63 alpha may function as a unique regulator of LMP2A effects on epithelial differentiation and contribute to EBV-associated epithelial cancers. Oncogene (2010) 29, 4287-4296; doi:10.1038/onc.2010.175; published online 24 May 2010	[Fotheringham, J. A.; Mazzucca, S.; Raab-Traub, N.] Univ N Carolina, Dept Microbiol & Immunol, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill	Raab-Traub, N (corresponding author), Univ N Carolina, Dept Microbiol & Immunol, Lineberger Comprehens Canc Ctr, 450 West Dr, Chapel Hill, NC 27599 USA.	nrt@med.unc.edu	Ariel, Pablo/AGJ-4118-2022	Mazzucca, Stephanie/0000-0001-6908-0780	National Institutes of Health [CA19014, CA32979, CA103634]; NATIONAL CANCER INSTITUTE [P01CA019014, R01CA032979, R01CA103634] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	The authors gratefully acknowledge Dr M Oren for providing the Delta Np63 alpha plasmid and Dr R Longnecker for providing the LMP2A PY mutant. Funding for this study was provided by the National Institutes of Health grants CA19014, CA32979 and CA103634.	Bamberger C, 2002, J INVEST DERMATOL, V118, P133, DOI 10.1046/j.0022-202x.2001.01649.x; BROOKS L, 1992, J VIROL, V66, P2689, DOI 10.1128/JVI.66.5.2689-2697.1992; Bultema R, 2009, ONCOGENE, V28, P1471, DOI 10.1038/onc.2008.492; BUSSON P, 1992, J VIROL, V66, P3257, DOI 10.1128/JVI.66.5.3257-3262.1992; Candi E, 2008, CELL MOL LIFE SCI, V65, P3126, DOI 10.1007/s00018-008-8119-x; Candi E, 2007, CELL CYCLE, V6, P274, DOI 10.4161/cc.6.3.3797; Deyrieux AF, 2007, CYTOTECHNOLOGY, V54, P77, DOI 10.1007/s10616-007-9076-1; Fukuda M, 2007, J VIROL, V81, P9299, DOI 10.1128/JVI.00537-07; Guo C, 2006, J TRANSL MED, V4, DOI 10.1186/1479-5876-4-23; Ikeda A, 2003, J VIROL, V77, P5529, DOI 10.1128/JVI.77.9.5529-5534.2003; Ikeda M, 2000, VIROLOGY, V268, P178, DOI 10.1006/viro.1999.0166; Ikeda M, 2001, J VIROL, V75, P5711, DOI 10.1128/JVI.75.12.5711-5718.2001; Koster MI, 2004, GENE DEV, V18, P126, DOI 10.1101/gad.1165104; Li YC, 2009, MOL CELL BIOL, V29, P3953, DOI 10.1128/MCB.00449-09; Longnecker R, 2000, EXP CELL RES, V257, P332, DOI 10.1006/excr.2000.4900; Medawar A, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003441; Melino G, 2006, CELL CYCLE, V5, P1735; Merchant M, 2001, Int Rev Immunol, V20, P805, DOI 10.3109/08830180109045591; Morrison JA, 2005, J VIROL, V79, P2375, DOI 10.1128/JVI.79.4.2375-2382.2005; Murray-Zmijewski F, 2006, CELL DEATH DIFFER, V13, P962, DOI 10.1038/sj.cdd.4401914; Ogawa E, 2008, J BIOL CHEM, V283, P34241, DOI 10.1074/jbc.M804101200; Okuyama R, 2007, ONCOGENE, V26, P4478, DOI 10.1038/sj.onc.1210235; Raab-Traub N, 1992, Semin Cancer Biol, V3, P297; Raab-Traub N, 2002, SEMIN CANCER BIOL, V12, P431, DOI 10.1016/S1044579X0200086X; RAABTRAUB N, 1992, INFECT AGENT DIS, V1, P173; Rossi M, 2006, CELL CYCLE, V5, P1816, DOI 10.4161/cc.5.16.2861; Rossi M, 2006, P NATL ACAD SCI USA, V103, P12753, DOI 10.1073/pnas.0603449103; Scholle F, 2000, J VIROL, V74, P10681, DOI 10.1128/JVI.74.22.10681-10689.2000; Testoni B, 2006, NUCLEIC ACIDS RES, V34, P928, DOI 10.1093/nar/gkj477; Truong AB, 2007, CELL CYCLE, V6, P295, DOI 10.4161/cc.6.3.3753; Westfall MD, 2003, MOL CELL BIOL, V23, P2264, DOI 10.1128/MCB.23.7.2264-2276.2003; Winberg G, 2000, MOL CELL BIOL, V20, P8526, DOI 10.1128/MCB.20.22.8526-8535.2000; Wu GJ, 2003, CANCER RES, V63, P2351; Yip YL, 2008, INT J ONCOL, V33, P713, DOI 10.3892/ijo_00000057; Young L S, 1992, Semin Cancer Biol, V3, P273	35	32	32	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL	2010	29	30					4287	4296		10.1038/onc.2010.175	http://dx.doi.org/10.1038/onc.2010.175			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	633ZV	20498633	Green Accepted, Green Submitted			2022-12-17	WOS:000280547900005
J	Guo, G; Qiu, X; Wang, S; Chen, Y; Rothman, PB; Wang, Z; Chen, Y; Wang, G; Chen, JL				Guo, G.; Qiu, X.; Wang, S.; Chen, Y.; Rothman, P. B.; Wang, Z.; Chen, Y.; Wang, G.; Chen, J-L			Oncogenic E17K mutation in the pleckstrin homology domain of AKT1 promotes v-Abl-mediated pre-B-cell transformation and survival of Pim-deficient cells	ONCOGENE			English	Article						AKT1; v-Abl; Pim; mutation; cancer	SERINE/THREONINE KINASE PIM-1; HEMATOPOIETIC-CELLS; LEUKEMIA-CELLS; HUMAN CANCER; DOWNSTREAM; APOPTOSIS; PATHWAY; GROWTH; PHOSPHORYLATION; LEUKEMOGENESIS	Abl-mediated transformation requires the activation of multiple pathways involved in the cellular proliferation and survival, including PI3K/AKT and JAK/STAT-dependent Pim kinases. Recently, the E17K mutation in the AKT1 has been associated with multiple human malignancies and leukemia in mice. However, this mutation has not been identified in Abl-transformed cells. We investigated the presence of the AKT1(E17K) mutation in v-Abl-transformed cell clones. AKT1(E17K) was detected in 3 (2.6%) of 116 specimens examined. To show the involvement of AKT1(E17K) directly in v-Abl-mediated tumorigenesis, we infected bone marrow cells from mice with bicistronic retroviruses encoding v-Abl and either wild-type or the mutant AKT1. Interestingly, we found that E17K mutant greatly increased the v-Abl transformation efficiency as compared with wild-type AKT1. Ectopic expression of E17K mutant increased the expression levels of antiapoptotic protein BCL2 and phosphorylation levels of proapoptotic protein BAD. This correlated with an increased protection from imatinib-induced apoptosis in Abl transformants. Furthermore, AKT1(E17K) promotes survival of the Pim-deficient cells, indicating a functional link between AKT and Pim in v-Abl transformation. In addition, AKT1(E17K) delays loss of Pim-1 and Pim-2 protein levels on v-Abl inactivation, which suggests that there exists reciprocal signaling between AKT and Pim in v-Abl transformants. Oncogene (2010) 29, 3845-3853; doi: 10.1038/onc.2010.149; published online 3 May 2010	[Guo, G.; Qiu, X.; Wang, S.; Chen, Y.; Chen, J-L] Chinese Acad Sci, Inst Microbiol, Key Lab Pathogen Microbiol & Immunol, Beijing 100101, Peoples R China; [Rothman, P. B.] Univ Iowa, Dept Internal Med, Roy J & Lucille A Carver Coll Med, Iowa City, IA 52242 USA; [Wang, Z.; Chen, Y.] China Agr Univ, Coll Anim Med, Dept Cell Biol & Anat, Beijing 100094, Peoples R China; [Wang, G.] Louisiana State Univ, Hlth Sci Ctr, Dept Med & Genet, Gene Therapy Program, New Orleans, LA USA	Chinese Academy of Sciences; Institute of Microbiology, CAS; University of Iowa; China Agricultural University; Louisiana State University System; Louisiana State University Health Sciences Center New Orleans	Chen, JL (corresponding author), Chinese Acad Sci, Inst Microbiol, Key Lab Pathogen Microbiol & Immunol, W Beichen Rd, Beijing 100101, Peoples R China.	chenjl@im.ac.cn	Chen, Ji-Long/AAJ-2134-2021	Chen, Ji-Long/0000-0002-4274-0563; Guo, Guijie/0000-0002-9031-1915	Natural Science Foundation of China [30971476]; National Basic Research Program (973) of China [2009CB918902, 2010CB534004]; Chinese Academy of Sciences	Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Basic Research Program (973) of China(National Basic Research Program of China); Chinese Academy of Sciences(Chinese Academy of Sciences)	We thank members of Chen laboratory for helpful discussions. This work was supported by Natural Science Foundation of China (30971476), National Basic Research Program (973) of China (2009CB918902, 2010CB534004) and Hundreds of Talents Program of Chinese Academy of Sciences 2009-2014.	AHMED NN, 1993, ONCOGENE, V8, P1957; Amaravadi R, 2005, J CLIN INVEST, V115, P2618, DOI 10.1172/JCI26273; Askham JM, 2010, ONCOGENE, V29, P150, DOI 10.1038/onc.2009.315; Bachmann M, 2005, INT J BIOCHEM CELL B, V37, P726, DOI 10.1016/j.biocel.2004.11.005; Banerjee A, 1998, J IMMUNOL, V161, P4611; Bleeker FE, 2008, ONCOGENE, V27, P5648, DOI 10.1038/onc.2008.170; Brugge J, 2007, CANCER CELL, V12, P104, DOI 10.1016/j.ccr.2007.07.014; Carpten JD, 2007, NATURE, V448, P439, DOI 10.1038/nature05933; Chen JL, 2008, BLOOD, V111, P1677, DOI 10.1182/blood-2007-04-083808; Cheng GD, 2005, COLD REG SCI TECHNOL, V42, P169, DOI 10.1016/j.coldregions.2005.01.002; Danial NN, 2000, ONCOGENE, V19, P2523, DOI 10.1038/sj.onc.1203484; Deutsch AJA, 2007, BLOOD, V109, P3500, DOI 10.1182/blood-2006-06-030494; Dhanasekaran SM, 2001, NATURE, V412, P822, DOI 10.1038/35090585; Gong L, 2004, J VIROL, V78, P1636, DOI 10.1128/JVI.78.4.1636-1644.2004; Hammerman PS, 2005, BLOOD, V105, P4477, DOI 10.1182/blood-2004-09-3706; Horita M, 2000, J EXP MED, V191, P977, DOI 10.1084/jem.191.6.977; Horn S, 2008, ONCOGENE, V27, P4096, DOI 10.1038/onc.2008.40; Hu XF, 2009, J CLIN INVEST, V119, P362, DOI 10.1172/JCI33216; Kharas MG, 2008, J CLIN INVEST, V118, P3038, DOI 10.1172/JCI33337; Kharas NG, 2005, CANCER RES, V65, P2047, DOI 10.1158/0008-5472.CAN-04-3888; Kim MS, 2008, BRIT J CANCER, V98, P1533, DOI 10.1038/sj.bjc.6604212; Klejman A, 2002, ONCOGENE, V21, P5868, DOI 10.1038/sj.onc.1205724; Landgraf KE, 2008, BIOCHEMISTRY-US, V47, P12260, DOI 10.1021/bi801683k; Li XH, 2007, NATURE, V447, P1012, DOI 10.1038/nature05861; Mahmoud IS, 2008, BRIT J CANCER, V99, P488, DOI 10.1038/sj.bjc.6604512; Malanga D, 2008, CELL CYCLE, V7, P665, DOI 10.4161/cc.7.5.5485; Manning BD, 2007, CELL, V129, P1261, DOI 10.1016/j.cell.2007.06.009; Mohamedali A, 2008, TECHNOL CANCER RES T, V7, P407, DOI 10.1177/153303460800700509; Muraski JA, 2007, NAT MED, V13, P1467, DOI 10.1038/nm1671; Nieborowska-Skorska M, 2002, BLOOD, V99, P4531, DOI 10.1182/blood.V99.12.4531; Oki S, 2002, BLOOD, V100, P966, DOI 10.1182/blood.V100.3.966; Pasqualucci L, 2001, NATURE, V412, P341, DOI 10.1038/35085588; Riener MO, 2008, BRIT J CANCER, V99, P836, DOI 10.1038/sj.bjc.6604498; Samuels Y, 2005, CANCER CELL, V7, P561, DOI 10.1016/j.ccr.2005.05.014; Shoji K, 2009, BRIT J CANCER, V101, P145, DOI 10.1038/sj.bjc.6605109; Skorski T, 1997, EMBO J, V16, P6151, DOI 10.1093/emboj/16.20.6151; Tao WJ, 2008, ONCOGENE, V27, P3194, DOI 10.1038/sj.onc.1210979; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Zenz T, 2008, BRIT J HAEMATOL, V141, P742, DOI 10.1111/j.1365-2141.2008.07113.x; Zhang F, 2009, CANCER BIOL THER, V8, P846, DOI 10.4161/cbt.8.9.8210; Zilberman DE, 2009, CANCER GENET CYTOGEN, V191, P34, DOI 10.1016/j.cancergencyto.2009.01.009	41	32	33	1	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 1	2010	29	26					3845	3853		10.1038/onc.2010.149	http://dx.doi.org/10.1038/onc.2010.149			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	618VW	20440266				2022-12-17	WOS:000279385200012
J	Zuntini, M; Pedrini, E; Parra, A; Sgariglia, F; Gentile, FV; Pandolfi, M; Alberghini, M; Sangiorgi, L				Zuntini, M.; Pedrini, E.; Parra, A.; Sgariglia, F.; Gentile, F. V.; Pandolfi, M.; Alberghini, M.; Sangiorgi, L.			Genetic models of osteochondroma onset and neoplastic progression: evidence for mechanisms alternative to EXT genes inactivation	ONCOGENE			English	Article						solitary osteochondroma; multiple osteochondroma; chondrosarcoma; EXT genes; tumor suppressor; mutation screening	MULTIPLE EXOSTOSES; NATURAL-HISTORY; MUTATIONS; HETEROZYGOSITY; POINT; LOCI	Osteochondroma, the most common benign bone tumor, may occur as a sporadic lesion or as multiple neoplasms in the context of multiple osteochondromas syndrome. The most severe complication is malignant transformation into peripheral secondary chondrosarcoma. Although both benign conditions have been linked to defects in EXT1 or EXT2 genes, contradictory reports are present in the literature regarding the requirement of their biallelic inactivation for osteochondroma development. A major limitation of these studies is represented by the small number of samples available for the screening. Taking advantage of a large series of tissues, our aim was to contribute to the definition of a genetic model for osteochondromas onset and transformation. EXT genes point mutations and big deletions were analyzed in 64 tissue samples. A double hit was found in 5 out of 35 hereditary cases, 6 out of 16 chondrosarcomas and 2 recurrences; none of the 11 sporadic osteochondromas showed two somatic mutations. Our results clearly indicate that, in most cases, biallelic inactivation of EXT genes does not account for osteochondromas formation; this mechanism should be regarded as a common feature for hereditary osteochondromas transformation and as an event that occurs later in tumor progression of solitary cases. These findings suggest that mechanisms alternative to EXT genetic alteration likely have a role in osteochondromas pathogenesis. Oncogene (2010) 29, 3827-3834; doi: 10.1038/onc.2010.135; published online 26 April 2010	[Zuntini, M.; Pedrini, E.; Parra, A.; Sgariglia, F.; Gentile, F. V.; Pandolfi, M.; Sangiorgi, L.] Ist Ortoped Rizzoli, Dept Med Genet & Skeletal Rare Dis, I-40136 Bologna, Italy; [Alberghini, M.] Ist Ortoped Rizzoli, Dept Anat Pathol & Histol, I-40136 Bologna, Italy	IRCCS Istituto Ortopedico Rizzoli; IRCCS Istituto Ortopedico Rizzoli	Sangiorgi, L (corresponding author), Ist Ortoped Rizzoli, Dept Med Genet & Skeletal Rare Dis, Via Barbiano 1-10, I-40136 Bologna, Italy.	luca.sangiorgi@ior.it	Sangiorgi, Luca/AHI-1694-2022; Parra, Alessandro/C-7967-2019; Pandolfi, Margareth/H-7616-2016; PEDRINI, ELENA/E-6340-2019	Parra, Alessandro/0000-0002-4482-0612; PEDRINI, ELENA/0000-0001-9980-7741; Sangiorgi, Luca/0000-0003-3658-1209	European Project EuroBoNeT	European Project EuroBoNeT	This research was supported by the European Project EuroBoNeT.	Bernard MA, 2001, CELL MOTIL CYTOSKEL, V48, P149, DOI 10.1002/1097-0169(200102)48:2<149::AID-CM1005>3.0.CO;2-3; Bovee JVMG, 1999, GENE CHROMOSOME CANC, V26, P237; Bovee JVMG, 1999, AM J HUM GENET, V65, P689, DOI 10.1086/302532; Bridge JA, 1998, CANCER-AM CANCER SOC, V82, P1657, DOI 10.1002/(SICI)1097-0142(19980501)82:9<1657::AID-CNCR10>3.0.CO;2-3; Cheung PK, 2001, AM J HUM GENET, V69, P55, DOI 10.1086/321278; Essadki B, 2000, Acta Orthop Belg, V66, P146; Farach-Carson MC, 2005, CRIT REV EUKAR GENE, V15, P29, DOI 10.1615/CritRevEukaryotGeneExpr.v15.i1.30; Hall CR, 2002, AM J MED GENET, V112, P1, DOI 10.1002/ajmg.10635; Hameetman L, 2007, JNCI-J NATL CANCER I, V99, P396, DOI 10.1093/jnci/djk067; HECHT JT, 1995, AM J HUM GENET, V56, P1125; HENNEKAM RCM, 1991, J MED GENET, V28, P262, DOI 10.1136/jmg.28.4.262; Huvos A, 1991, BONE TUMORS DIAGNOSI; Jennes I, 2009, HUM MUTAT, V30, P1620, DOI 10.1002/humu.21123; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; Lonie Lorne, 2006, Hum Mutat, V27, P1160, DOI 10.1002/humu.9467; Ludecke HJ, 1997, GENOMICS, V40, P351, DOI 10.1006/geno.1996.4577; McCormick C, 2000, P NATL ACAD SCI USA, V97, P668, DOI 10.1073/pnas.97.2.668; McCormick C, 1998, NAT GENET, V19, P158, DOI 10.1038/514; MERTENS F, 1994, GENE CHROMOSOME CANC, V9, P8, DOI 10.1002/gcc.2870090103; Pedrini E, 2005, HUM MUTAT, V26, DOI 10.1002/humu.9359; Porter DE, 1999, J PATHOL, V188, P119; RASKIND WH, 1995, AM J HUM GENET, V56, P1132; Rohlin A, 2009, HUM MUTAT, V30, P1012, DOI 10.1002/humu.20980; SCHMALE GA, 1994, J BONE JOINT SURG AM, V76A, P986, DOI 10.2106/00004623-199407000-00005; SOLOMON L, 1964, AM J HUM GENET, V16, P351; Springfield DS, 1996, AAOS INSTR COURS LEC, V45, P417; Traeger-Synodinos Joanne, 2006, Molecular Aspects of Medicine, V27, P176, DOI 10.1016/j.mam.2005.12.004; Trebicz-Geffen M, 2008, INT J EXP PATHOL, V89, P321, DOI 10.1111/j.1365-2613.2008.00589.x; WICKLUND CL, 1995, AM J MED GENET, V55, P43, DOI 10.1002/ajmg.1320550113; WU YQ, 1994, HUM MOL GENET, V3, P167, DOI 10.1093/hmg/3.1.167; Wuyts W, 2000, HUM MUTAT, V15, P220, DOI 10.1002/(SICI)1098-1004(200003)15:3<220::AID-HUMU2>3.0.CO;2-K; Wuyts W, 1998, AM J HUM GENET, V62, P346, DOI 10.1086/301726; WUYTS W, 1995, AM J HUM GENET, V57, P382	33	32	32	0	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 1	2010	29	26					3827	3834		10.1038/onc.2010.135	http://dx.doi.org/10.1038/onc.2010.135			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	618VW	20418910				2022-12-17	WOS:000279385200010
J	Pirngruber, J; Johnsen, SA				Pirngruber, J.; Johnsen, S. A.			Induced G1 cell-cycle arrest controls replication-dependent histone mRNA 3 ' end processing through p21, NPAT and CDK9	ONCOGENE			English	Article						P53; CDK; histone; mRNA processing	S-PHASE ENTRY; GENE-EXPRESSION; DNA-DAMAGE; E/CDK2 SUBSTRATE; CAJAL BODIES; TRANSCRIPTION; P53; ACTIVATION; P220(NPAT); PHOSPHORYLATION	Proper cell cycle-dependent expression of replication-dependent histones is essential for packaging of DNA into chromatin during replication. We previously showed that cyclin-dependent kinase-9 (CDK9) controls histone H2B monoubiquitination (H2Bub1) to direct the recruitment of specific mRNA 3' end processing proteins to replication-dependent histone genes and promote proper pre-mRNA 3' end processing. We now show that p53 decreases the expression of the histone-specific transcriptional regulator Nuclear Protein, Ataxia-Telangiectasia Locus (NPAT) by inducing a G1 cell-cycle arrest, thereby affecting E2F-dependent transcription of the NPAT gene. Furthermore, NPAT is essential for histone mRNA 3' end processing and recruits CDK9 to replication-dependent histone genes. Reduced NPAT expression following p53 activation or small interfering RNA knockdown decreases CDK9 recruitment and replication-dependent histone gene transcription but increases the polyadenylation of remaining histone mRNAs. Thus, we present evidence that the induction of a G1 cell-cycle arrest (for example, following p53 accumulation) alters histone mRNA 3' end processing and uncover the first mechanism of a regulated switch in the mode of pre-mRNA 3' end processing during a normal cellular process, which may be altered during tumorigenesis. Oncogene (2010) 29, 2853-2863; doi: 10.1038/onc.2010.42; published online 1 March 2010	[Pirngruber, J.; Johnsen, S. A.] Univ Gottingen, Dept Mol Oncol, Gottingen Ctr Mol Biosci, D-37073 Gottingen, Lower Saxony, Germany	University of Gottingen	Johnsen, SA (corresponding author), Univ Gottingen, Dept Mol Oncol, Gottingen Ctr Mol Biosci, Justus von Liebig Weg 11, D-37073 Gottingen, Lower Saxony, Germany.	sjohnse@gwdg.de	Johnsen, Steven/AAX-2322-2020	Johnsen, Steven/0000-0003-1198-5805	Gottingen Graduate School for Neurosciences and Molecular Biosciences (GGNB); Forschungsforderungsprogramm at the University of Gottingen Medical Center; Deutsche Forschungsgemeinschaft [JO 815/1]	Gottingen Graduate School for Neurosciences and Molecular Biosciences (GGNB); Forschungsforderungsprogramm at the University of Gottingen Medical Center; Deutsche Forschungsgemeinschaft(German Research Foundation (DFG))	We thank J Zhao for graciously providing the NPAT antibody and for helpful advice; O Karpiuk, T Prenzel and A Shchebet for suggestions, discussions and technical help; S Emmert for advice and enabling us to test some interesting medically relevant hypotheses; and M Dobbelstein for advice and extensive scientific discussions regarding the p53/RB/E2F axis. JP was supported by an Excellence Fellowship from the Gottingen Graduate School for Neurosciences and Molecular Biosciences (GGNB). This work was supported by grants from the Forschungsforderungsprogramm at the University of Gottingen Medical Center and the Deutsche Forschungsgemeinschaft (JO 815/1) to SAJ.	Abba MC, 2005, BMC GENOMICS, V6, DOI 10.1186/1471-2164-6-37; Carvajal D, 2005, CANCER RES, V65, P1918, DOI 10.1158/0008-5472.CAN-04-3576; Choi HS, 2005, CANCER RES, V65, P5818, DOI 10.1158/0008-5472.CAN-05-0197; COLLART D, 1991, BIOCHEMISTRY-US, V30, P1610, DOI 10.1021/bi00220a024; Deran M, 2008, MOL CELL BIOL, V28, P435, DOI 10.1128/MCB.00607-07; Gao G, 2003, MOL CELL BIOL, V23, P2821, DOI 10.1128/MCB.23.8.2821-2833.2003; Huen MSY, 2007, CELL, V131, P901, DOI 10.1016/j.cell.2007.09.041; Johnsen SA, 2002, J BIOL CHEM, V277, P30754, DOI 10.1074/jbc.M204812200; KIRSH AL, 1989, GENE DEV, V3, P2172, DOI 10.1101/gad.3.12b.2172; Kranz D, 2008, J CELL BIOL, V182, P197, DOI 10.1083/jcb.200712014; Kranz D, 2006, CANCER RES, V66, P10274, DOI 10.1158/0008-5472.CAN-06-1527; Lemm I, 2006, MOL BIOL CELL, V17, P3221, DOI 10.1091/mbc.E06-03-0247; Lohr K, 2003, J BIOL CHEM, V278, P32507, DOI 10.1074/jbc.M212517200; Ma TL, 2000, GENE DEV, V14, P2298, DOI 10.1101/gad.829500; Mailand N, 2007, CELL, V131, P887, DOI 10.1016/j.cell.2007.09.040; Martinez I, 2007, EUR J CANCER, V43, P415, DOI 10.1016/j.ejca.2006.09.001; Marzluff WF, 2008, NAT REV GENET, V9, P843, DOI 10.1038/nrg2438; Narita T, 2007, MOL CELL, V26, P349, DOI 10.1016/j.molcel.2007.04.011; Pirngruber J, 2009, CELL CYCLE, V8, P3636, DOI 10.4161/cc.8.22.9890; Pirngruber J, 2009, EMBO REP, V10, P894, DOI 10.1038/embor.2009.108; Rappold I, 2001, J CELL BIOL, V153, P613, DOI 10.1083/jcb.153.3.613; Saintigny Y, 2001, EMBO J, V20, P3861, DOI 10.1093/emboj/20.14.3861; Shin S, 2007, CANCER RES, V67, P7572, DOI 10.1158/0008-5472.CAN-06-4652; Simone C, 2002, ONCOGENE, V21, P4158, DOI 10.1038/sj.onc.1205511; Sims RJ, 2007, MOL CELL, V28, P665, DOI 10.1016/j.molcel.2007.11.010; Su C, 2004, EMBO J, V23, P1133, DOI 10.1038/sj.emboj.7600120; Takahashi Y, 2000, GENE DEV, V14, P804; VAIRO G, 1995, GENE DEV, V9, P869, DOI 10.1101/gad.9.7.869; Wagner EJ, 2007, MOL CELL, V28, P692, DOI 10.1016/j.molcel.2007.10.009; Wang HB, 2006, MOL CELL, V22, P383, DOI 10.1016/j.molcel.2006.03.035; Wei Y, 2003, MOL CELL BIOL, V23, P3669, DOI 10.1128/MCB.23.10.3669-3680.2003; Yan B, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-5-r78; Ye X, 2003, MOL CELL BIOL, V23, P8586, DOI 10.1128/MCB.23.23.8586-8600.2003; Zhao HJ, 2004, MOL BIOL CELL, V15, P2523, DOI 10.1091/mbc.E03-11-0786; Zhao JY, 2000, GENE DEV, V14, P2283, DOI 10.1101/gad.827700; Zhao JY, 1998, GENE DEV, V12, P456, DOI 10.1101/gad.12.4.456; ZURHAUSEN H, 1994, ANNU REV MICROBIOL, V48, P427, DOI 10.1146/annurev.micro.48.1.427	37	32	33	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY	2010	29	19					2853	2863		10.1038/onc.2010.42	http://dx.doi.org/10.1038/onc.2010.42			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	595DW	20190802				2022-12-17	WOS:000277591900010
J	Siegel, PM; Muller, WJ				Siegel, P. M.; Muller, W. J.			Transcription factor regulatory networks in mammary epithelial development and tumorigenesis	ONCOGENE			English	Review						mammary gland development; transcription factor networks; STAT; Elf; GATA-3; breast cancer	BREAST-CANCER METASTASIS; LUMINAL CELL FATE; GENE-EXPRESSION; STEM-CELLS; GLAND DEVELOPMENT; C/EBP-DELTA; MOUSE MODEL; IN-VIVO; GATA-3; DIFFERENTIATION	The mouse mammary gland is composed of three epithelial cell types, which include ductal, alveolar and myoepithelial cells. A hierarchy in which the mammary stem cell compartment gives rise to progressively restricted progenitors that ultimately form the luminal (ductal and alveolar) and myoepithelial lineages is now emerging. Although very little is known about the mechanisms controlling the differentiation of the myoepithelial cell lineage, a growing body of work reveals that the luminal cell fate is specified by a network of transcription factors. The precise roles of specific transcription factors in promoting differentiation of luminal progenitors into ductal or alveolar cells are now being elucidated. This review will discuss the importance of these recent observations and place them within the context of other transcription factor networks involved in mammary gland development and tumorigenesis. Oncogene (2010) 29, 2753-2759; doi: 10.1038/onc.2010.43; published online 29 March 2010	[Muller, W. J.] McGill Univ, Dept Biochem, Montreal, PQ H3A 1A3, Canada; McGill Univ, Dept Med, Goodman Canc Ctr, Montreal, PQ H3A 1A3, Canada	McGill University; McGill University	Muller, WJ (corresponding author), McGill Univ, Dept Biochem, 1160 Ave Pins Ouest,Room 516, Montreal, PQ H3A 1A3, Canada.	william.muller@mcgill.ca			National Cancer Institute of Canada/Terry Fox Foundation [017003]	National Cancer Institute of Canada/Terry Fox Foundation	We thank Dr Josie Ursini-Siegel and Rob Annan for their critical reading of the manuscript. Work carried out in the laboratory of Dr WJ Muller was supported by a grant from the National Cancer Institute of Canada/Terry Fox Foundation Program Project Grant (# 017003). PMS is a research scientist of the Canadian Cancer Society and WJM holds a Canada Research Chair in Molecular Oncology.	Asselin-Labat ML, 2008, COLD SH Q B, V73, P469, DOI 10.1101/sqb.2008.73.020; Asselin-Labat ML, 2007, NAT CELL BIOL, V9, P201, DOI 10.1038/ncb1530; Brisken C, 2002, J MAMMARY GLAND BIOL, V7, P39, DOI 10.1023/A:1015718406329; Campbell LL, 2007, CELL CYCLE, V6, P2332, DOI 10.4161/cc.6.19.4914; Chapman RS, 1999, GENE DEV, V13, P2604, DOI 10.1101/gad.13.19.2604; Choi YS, 2009, DEV BIOL, V329, P227, DOI 10.1016/j.ydbio.2009.02.032; Clevenger Charles V, 2003, Breast Dis, V18, P75; Cotarla I, 2004, INT J CANCER, V108, P665, DOI 10.1002/ijc.11619; Dydensborg AB, 2009, ONCOGENE, V28, P2634, DOI 10.1038/onc.2009.126; Eirew P, 2008, NAT MED, V14, P1384, DOI 10.1038/nm.1791; Fang SH, 2009, J SURG RES, V157, P290, DOI 10.1016/j.jss.2008.07.015; Ginestier C, 2007, CELL STEM CELL, V1, P555, DOI 10.1016/j.stem.2007.08.014; Grimm SL, 2003, J MAMMARY GLAND BIOL, V8, P191, DOI 10.1023/A:1025900908026; Guo WJ, 2006, CELL, V126, P489, DOI 10.1016/j.cell.2006.05.047; GUY CT, 1992, MOL CELL BIOL, V12, P954, DOI 10.1128/MCB.12.3.954; Hennessy BT, 2009, CANCER RES, V69, P4116, DOI 10.1158/0008-5472.CAN-08-3441; Herschkowitz JI, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-5-r76; Humphreys RC, 2002, ENDOCRINOLOGY, V143, P3641, DOI 10.1210/en.2002-220224; Jackson-Fisher AJ, 2006, ONCOGENE, V25, P5664, DOI 10.1038/sj.onc.1209574; Jones FE, 1999, J CELL BIOL, V147, P77, DOI 10.1083/jcb.147.1.77; Kouros-Mehr H, 2008, CURR OPIN CELL BIOL, V20, P164, DOI 10.1016/j.ceb.2008.02.003; Kouros-Mehr H, 2008, CANCER CELL, V13, P141, DOI 10.1016/j.ccr.2008.01.011; Kouros-Mehr H, 2006, CELL, V127, P1041, DOI 10.1016/j.cell.2006.09.048; LAMARCA HL, 2010, STEM CELLS; Lim E, 2009, NAT MED, V15, P907, DOI 10.1038/nm.2000; Lin EY, 2003, AM J PATHOL, V163, P2113, DOI 10.1016/S0002-9440(10)63568-7; Liu XW, 1997, GENE DEV, V11, P179, DOI 10.1101/gad.11.2.179; McDaniel SM, 2006, AM J PATHOL, V168, P608, DOI 10.2353/ajpath.2006.050677; Mehra R, 2005, CANCER RES, V65, P11259, DOI 10.1158/0008-5472.CAN-05-2495; Miyoshi K, 2001, J CELL BIOL, V155, P531, DOI 10.1083/jcb.200107065; Molyneux G, 2007, CELL MOL LIFE SCI, V64, P3248, DOI 10.1007/s00018-007-7391-5; Naylor MJ, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1661; Oakes SR, 2008, GENE DEV, V22, P581, DOI 10.1101/gad.1614608; Pensa S, 2009, J MAMMARY GLAND BIOL, V14, P121, DOI 10.1007/s10911-009-9124-x; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Polyak K, 2007, J CLIN INVEST, V117, P3155, DOI 10.1172/JCI33295; Polyak K, 2007, STEM CELL REV, V3, P107, DOI 10.1007/s12015-007-0020-8; Prat A, 2009, NAT MED, V15, P842, DOI 10.1038/nm0809-842; Ranger JJ, 2009, CANCER RES, V69, P6823, DOI 10.1158/0008-5472.CAN-09-1684; Ren SX, 2002, ONCOGENE, V21, P4335, DOI 10.1038/sj.onc.1205484; Schedin P, 2007, J MAMMARY GLAND BIOL, V12, P71, DOI 10.1007/s10911-007-9039-3; Shackleton M, 2006, NATURE, V439, P84, DOI 10.1038/nature04372; Sorlie T, 2003, P NATL ACAD SCI USA, V100, P8418, DOI 10.1073/pnas.0932692100; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Sotiriou C, 2003, P NATL ACAD SCI USA, V100, P10393, DOI 10.1073/pnas.1732912100; Sternlicht MD, 2006, DIFFERENTIATION, V74, P365, DOI 10.1111/j.1432-0436.2006.00105.x; Stingl J, 2006, NATURE, V439, P993, DOI 10.1038/nature04496; Stingl J, 2006, CELL CYCLE, V5, P1519, DOI 10.4161/cc.5.14.2983; Thangaraju M, 2005, DEVELOPMENT, V132, P4675, DOI 10.1242/dev.02050; Tiffen PG, 2008, MOL ENDOCRINOL, V22, P2677, DOI 10.1210/me.2008-0097; Tvorogov D, 2009, J BIOL CHEM, V284, P5582, DOI 10.1074/jbc.M805438200; Visvader JE, 2009, GENE DEV, V23, P2563, DOI 10.1101/gad.1849509; Vomachka AJ, 2000, ONCOGENE, V19, P1077, DOI 10.1038/sj.onc.1203348; Wang S, 2009, P NATL ACAD SCI USA, V106, P151, DOI 10.1073/pnas.0808703105; Yamaji D, 2009, GENE DEV, V23, P2382, DOI 10.1101/gad.1840109; Zhang YJ, 2007, J CELL BIOCHEM, V102, P1256, DOI 10.1002/jcb.21356; Zhou JB, 2007, P NATL ACAD SCI USA, V104, P16158, DOI 10.1073/pnas.0702596104	57	32	34	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY	2010	29	19					2753	2759		10.1038/onc.2010.43	http://dx.doi.org/10.1038/onc.2010.43			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	595DW	20348953				2022-12-17	WOS:000277591900001
J	Murayama-Hosokawa, S; Oda, K; Nakagawa, S; Ishikawa, S; Yamamoto, S; Shoji, K; Ikeda, Y; Uehara, Y; Fukayama, M; McCormick, F; Yano, T; Taketani, Y; Aburatani, H				Murayama-Hosokawa, S.; Oda, K.; Nakagawa, S.; Ishikawa, S.; Yamamoto, S.; Shoji, K.; Ikeda, Y.; Uehara, Y.; Fukayama, M.; McCormick, F.; Yano, T.; Taketani, Y.; Aburatani, H.			Genome-wide single-nucleotide polymorphism arrays in endometrial carcinomas associate extensive chromosomal instability with poor prognosis and unveil frequent chromosomal imbalances involved in the PI3-kinase pathway	ONCOGENE			English	Article						chromosomal instability; microsatellite instability; copy number neutral LOH; homozygous deletions; Ras-PI3K pathway; endometrial carcinoma	ACQUIRED UNIPARENTAL DISOMY; PLECKSTRIN HOMOLOGY DOMAIN; ACUTE MYELOID LEUKEMIAS; RESOLUTION COPY NUMBER; MICROSATELLITE INSTABILITY; OVARIAN-CANCER; MUTATIONS; HETEROZYGOSITY; PIK3CA; GENES	Endometrial cancer is one of the tumor types in which either chromosomal instability (CIN) or microsatellite instability (MSI) may occur. It is known to possess mutations frequently in the Ras-PI3K (phosphatidylinositol 30-kinase) pathway. We performed a comprehensive genomic survey in 31 endometrial carcinomas with paired DNA for chromosomal imbalances (25 by the 50K and 6 by the 250K single-nucleotide polymorphism (SNP) array), and screened 25 of the 31 samples for MSI status and mutational status in the Ras-PI3K pathway genes. We detected five or more copy number changes (classified as CIN-extensive) in 9 (29%), 1 to 4 changes (CIN-intermediate) in 17 (55%) and no changes (CIN-negative) in 5 (16%) tumors. Positive MSI was less common in CIN-extensive tumors (14%), compared with CIN-intermediate/negative tumors (50%), and multivariate analysis showed that CIN-extensive is an independent poor prognostic factor. SNP array analysis unveiled copy number neutral LOH at 54 loci in 13 tumors (42%), including four at the locus of PTEN. In addition to eight (26%) tumors with PTEN deletions, we detected chromosomal imbalances of NF1, K-Ras and PIK3CA in four (13%), four (13%) and six (19%) tumors, respectively. In all, 7 of the 9 CIN-extensive tumors harbor deletions in the loci of PTEN and/or NF1, whereas all the 10 MSI-positive tumors possess PTEN, PIK3CA and/or K-Ras mutations. Our results showed that genomic alterations in the Ras-PI3K pathway are remarkably widespread in endometrial carcinomas, regardless of the type of genomic instability, and suggest that the degree of CIN is a useful biomarker for prognosis in endometrial carcinomas. Oncogene (2010) 29, 1897-1908; doi:10.1038/onc.2009.474; published online 11 January 2010	[Aburatani, H.] Univ Tokyo, Adv Sci & Technol Res Ctr, Genome Sci Div, Meguro Ku, Tokyo 1538904, Japan; [Murayama-Hosokawa, S.; Oda, K.; Nakagawa, S.; Shoji, K.; Ikeda, Y.; Uehara, Y.; Yano, T.; Taketani, Y.] Univ Tokyo, Dept Obstet & Gynecol, Tokyo, Japan; [Ishikawa, S.; Fukayama, M.] Univ Tokyo, Dept Pathol, Tokyo, Japan; [McCormick, F.] Univ Calif San Francisco, UCSF Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA; [McCormick, F.] Univ Calif San Francisco, Canc Res Inst, San Francisco, CA 94143 USA	University of Tokyo; University of Tokyo; University of Tokyo; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer Center; University of California System; University of California San Francisco	Aburatani, H (corresponding author), Univ Tokyo, Adv Sci & Technol Res Ctr, Genome Sci Div, Meguro Ku, Komaba 4-6-1, Tokyo 1538904, Japan.	haburata-tky@umin.ac.jp			Ministry of Education, Science, Sports and Culture [16101006, 17015008]; Ministry of Education, Culture, Sports, Science and Technology of Japan [20014007, 19599005, 21791544, 20018005]; Core Research for Evolutional Science and Technology (CREST); Japan Science and Technology Agency (JST); New Energy and Industrial Technology Development Organization (NEDO) of Japan	Ministry of Education, Science, Sports and Culture(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Ministry of Education, Culture, Sports, Science and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Core Research for Evolutional Science and Technology (CREST)(Core Research for Evolutional Science and Technology (CREST)); Japan Science and Technology Agency (JST)(Japan Science & Technology Agency (JST)); New Energy and Industrial Technology Development Organization (NEDO) of Japan(New Energy and Industrial Technology Development Organization (NEDO))	We thank Hiroko Meguro, Akira Watanabe, Jennifer Okada, Toshiharu Yasugi, Kei Kawana, Takahide Arimoto, Akira Tsuchiya, Osamu Hiraike-Wada, Kenbun Sone, Yuichiro Miyamoto, Haruko Hiraike, Katsuyuki Adachi, Shiho Miura and Ayako Tomio for support and assistance. This work was supported by the Ministry of Education, Science, Sports and Culture Grant Number: Scientific Research (S) 16101006, Scientific Research on Priority Areas 17015008, Ministry of Education, Culture, Sports, Science and Technology of Japan on Priority Area; Grant Number: 20014007, and Core Research for Evolutional Science and Technology (CREST), Japan Science and Technology Agency (JST) (to H Aburatani); by the Grant-in-Aid for Scientific Research (C), Grant Number 19599005 and the Grant-in-Aid for Young Scientists (B), Grant Number 21791544 from the Ministry of Education, Culture, Sports, Science and Technology of Japan (to K Oda); by the Grant-in-Aid for Scientific Research on Priority Areas 'Applied Genomics', Grant Number 20018005, from the Ministry of Education, Culture, Sports, Science and Technology of Japan and Industrial Technology Research Grant Program from New Energy and Industrial Technology Development Organization (NEDO) of Japan (to S Ishikawa).	An HJ, 2004, MODERN PATHOL, V17, P530, DOI 10.1038/modpathol.3800057; Arabi H, 2009, GYNECOL ONCOL, V113, P153, DOI 10.1016/j.ygyno.2009.02.004; Atkin NB, 2001, CYTOGENET CELL GENET, V92, P177, DOI 10.1159/000056898; Bacolod MD, 2009, CANCER RES, V69, P723, DOI 10.1158/0008-5472.CAN-08-3543; Bilbao C, 2006, INT J CANCER, V119, P563, DOI 10.1002/ijc.21862; Black D, 2006, J CLIN ONCOL, V24, P1745, DOI 10.1200/JCO.2005.04.1574; Carpten JD, 2007, NATURE, V448, P439, DOI 10.1038/nature05933; CHENG JQ, 1992, P NATL ACAD SCI USA, V89, P9267, DOI 10.1073/pnas.89.19.9267; Chin L, 2008, NATURE, V455, P1061, DOI 10.1038/nature07385; Choi SW, 2002, CLIN CANCER RES, V8, P2311; Conrad DF, 2006, NAT GENET, V38, P75, DOI 10.1038/ng1697; Doll A, 2008, J STEROID BIOCHEM, V108, P221, DOI 10.1016/j.jsbmb.2007.09.020; Dunbar AJ, 2008, CANCER RES, V68, P10349, DOI 10.1158/0008-5472.CAN-08-2754; ENOMOTO T, 1991, CANCER RES, V51, P5308; Fitzgibbon J, 2005, CANCER RES, V65, P9152, DOI 10.1158/0008-5472.CAN-05-2017; Flotho C, 2007, ONCOGENE, V26, P5816, DOI 10.1038/sj.onc.1210361; Geigl JB, 2008, TRENDS GENET, V24, P64, DOI 10.1016/j.tig.2007.11.006; Gorringe KL, 2008, GENE CHROMOSOME CANC, V47, P933, DOI 10.1002/gcc.20595; Gorringe KL, 2007, CLIN CANCER RES, V13, P4731, DOI 10.1158/1078-0432.CCR-07-0502; Gorringe KL, 2009, GENE CHROMOSOME CANC, V48, P931, DOI 10.1002/gcc.20694; Grady WM, 2004, CANCER METAST REV, V23, P11, DOI 10.1023/A:1025861527711; Hirasawa A, 2003, CLIN CANCER RES, V9, P5675; Ishikawa S, 2005, BIOCHEM BIOPH RES CO, V333, P1309, DOI 10.1016/j.bbrc.2005.06.040; Kawamata N, 2008, BLOOD, V111, P776, DOI 10.1182/blood-2007-05-088310; Komura D, 2006, GENOME RES, V16, P1575, DOI 10.1101/gr.5629106; Kong D, 2008, CANCER SCI, V99, P1734, DOI 10.1111/j.1349-7006.2008.00891.x; Kong DH, 1997, NAT GENET, V17, P143, DOI 10.1038/ng1097-143; Kralovics R, 2005, NEW ENGL J MED, V352, P1779, DOI 10.1056/NEJMoa051113; Kratz CP, 2007, HUM MOL GENET, V16, P374, DOI 10.1093/hmg/ddl458; Levan K, 2006, CYTOGENET GENOME RES, V115, P16, DOI 10.1159/000094796; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Loukola A, 2001, CANCER RES, V61, P4545; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Maira SM, 2009, BIOCHEM SOC T, V37, P265, DOI 10.1042/BST0370265; MCCONNELL JD, 1995, BR J UROL S, V1, P5; Melcher R, 2007, CYTOGENET GENOME RES, V118, P214, DOI 10.1159/000108303; Micci F, 2004, GENE CHROMOSOME CANC, V40, P229, DOI 10.1002/gcc.20038; Midorikawa Y, 2006, ONCOGENE, V25, P5581, DOI 10.1038/sj.onc.1209537; Minaguchi T, 2001, CLIN CANCER RES, V7, P2636; Oda K, 2005, CANCER RES, V65, P10669, DOI 10.1158/0008-5472.CAN-05-2620; Oda K, 2008, CANCER RES, V68, P8127, DOI 10.1158/0008-5472.CAN-08-0755; Onda T, 1997, BRIT J CANCER, V75, P1836, DOI 10.1038/bjc.1997.313; Parkin DM, 2001, LANCET ONCOL, V2, P533, DOI 10.1016/S1470-2045(01)00486-7; Raghavan M, 2005, CANCER RES, V65, P375; Rowan A, 2005, CLIN GASTROENTEROL H, V3, P1115, DOI 10.1016/S1542-3565(05)00618-X; Ryan AJ, 2005, CELL TISSUE RES, V322, P53, DOI 10.1007/s00441-005-1109-5; Salvesen HB, 2009, P NATL ACAD SCI USA, V106, P4834, DOI 10.1073/pnas.0806514106; Samuels Y, 2004, SCIENCE, V304, P554, DOI 10.1126/science.1096502; Shayesteh L, 1999, NAT GENET, V21, P99, DOI 10.1038/5042; Shoji K, 2009, BRIT J CANCER, V101, P145, DOI 10.1038/sj.bjc.6605109; Sirchia SM, 2000, CANCER GENET CYTOGEN, V121, P156, DOI 10.1016/S0165-4608(00)00240-5; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; Suehiro Y, 2000, GENE CHROMOSOME CANC, V29, P75, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1010>3.3.CO;2-T; Tashiro H, 1997, AM J PATHOL, V150, P75; Teh MT, 2005, CANCER RES, V65, P8597, DOI 10.1158/0008-5472.CAN-05-0842; Toda T, 2001, CANCER GENET CYTOGEN, V126, P120, DOI 10.1016/S0165-4608(00)00400-3; Tuna M, 2009, TRENDS MOL MED, V15, P120, DOI 10.1016/j.molmed.2009.01.005; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; Walsh CS, 2008, CLIN CANCER RES, V14, P7645, DOI 10.1158/1078-0432.CCR-08-1291; Weber JC, 2007, INT J CANCER, V120, P524, DOI 10.1002/ijc.22343; Woerner SM, 2003, ONCOGENE, V22, P2226, DOI 10.1038/sj.onc.1206421	62	32	35	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR	2010	29	13					1897	1908		10.1038/onc.2009.474	http://dx.doi.org/10.1038/onc.2009.474			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	577CV	20062086				2022-12-17	WOS:000276199600003
J	Wang, M; Wang, M; Yuan, L; Wu, D; Zhang, Z; Yin, C; Fu, G; Wei, Q; Zhang, Z				Wang, M.; Wang, M.; Yuan, L.; Wu, D.; Zhang, Z.; Yin, C.; Fu, G.; Wei, Q.; Zhang, Z.			A novel XPF-357A > C polymorphism predicts risk and recurrence of bladder cancer	ONCOGENE			English	Article						genetic variation; XPF; bladder cancer; recurrence; molecular epidemiology	EXCISION-REPAIR GENES; DNA-REPAIR; MDM2 PROMOTER; LUNG-CANCER; SUSCEPTIBILITY; PROTEIN; ERCC4; MELANOMA; PATHWAY	Xeroderma pigmentosum group F (XPF) has an essential role in the nucleotide excision repair pathway that removes a wide variety of DNA lesions. We hypothesized that genetic variants in XPF are associated with bladder cancer risk and recurrence. We selected three tagging single nucleotide polymorphisms (tagSNPs) from the HapMap database for the Chinese and genotyped them in a two-stage case-control study to evaluate the association and further examined the functionality of a novel polymorphism in the promoter. The two-stage analysis found that the rs744154 tagSNP in the XPF intron 1, which was linkage disequilibrium with the -357A > C polymorphism in the promoter region, was associated with a protective effect on bladder cancer risk. Electrophoretic mobility shift assay (EMSA) further revealed that the -357C allele decreased the binding ability of transcriptional factors to the XPF promoter. The vector construct containing the -357C allele had a lower luciferase expression than did the -357A allele. The -357C allele in the transcription factor-binding site was also associated with decreased expression levels of both XPF mRNA and protein in bladder cancer tissues. Furthermore, patients with the -357C allele had a shorter overall recurrence-free survival than did patients with the -357A allele. Our results suggest that the XPF promoter -357A > C polymorphism may regulate the expression of XPF and thereby contribute to susceptibility to and prognosis of bladder cancer. Further larger studies with different populations are warranted to confirm these findings. Oncogene (2010) 29, 1920-1928; doi:10.1038/onc.2009.484; published online 11 January 2010	[Wang, M.; Wang, M.; Yuan, L.; Wu, D.; Zhang, Z.] Nanjing Med Univ, Ctr Canc, Dept Mol Toxicol, Nanjing 210029, Peoples R China; [Wang, M.; Wang, M.; Yuan, L.; Wu, D.; Zhang, Z.] Nanjing Med Univ, Ctr Canc, Dept Genet Toxicol, Nanjing 210029, Peoples R China; [Zhang, Z.; Zhang, Z.] Nanjing Med Univ, Ctr Canc, Dept Epidemiol, Nanjing 210029, Peoples R China; [Zhang, Z.; Zhang, Z.] Nanjing Med Univ, Ctr Canc, Dept Biostat, Nanjing 210029, Peoples R China; [Yin, C.] Nanjing Med Univ, Affiliated Hosp 1, Dept Urol, Nanjing 210029, Peoples R China; [Fu, G.] Nanjing Med Univ, Huai An Affiliated Hosp 1, Dept Urol, Huaian, Peoples R China; [Wei, Q.] Univ Texas MD Anderson Canc Ctr, Dept Epidemiol, Houston, TX 77030 USA	Nanjing Medical University; Nanjing Medical University; Nanjing Medical University; Nanjing Medical University; Nanjing Medical University; Nanjing Medical University; University of Texas System; UTMD Anderson Cancer Center	Zhang, Z (corresponding author), Nanjing Med Univ, Dept Mol & Genet Toxicol, Sch Publ Hlth, 140 Hanzhong Rd, Nanjing 210029, Peoples R China.	drzdzhang@gmail.com			National Natural Science Foundation of China [30872084, 30800926, 30972444]; Key Program for Basic Research of Jiangsu Provincial Department of Education [08KJA330001]; 'Qinglan Project' Foundation for the Young Academic Leader of Jiangsu Province; Jiangsu Provincial Graduates Innovative Project [CX08B-183Z]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Key Program for Basic Research of Jiangsu Provincial Department of Education; 'Qinglan Project' Foundation for the Young Academic Leader of Jiangsu Province; Jiangsu Provincial Graduates Innovative Project	This study was partly supported by the National Natural Science Foundation of China (30872084, 30800926 and 30972444), the Key Program for Basic Research of Jiangsu Provincial Department of Education (08KJA330001), 'Qinglan Project' Foundation for the Young Academic Leader of Jiangsu Province (Z Zhang), and Jiangsu Provincial Graduates Innovative Project (CX08B-183Z).	An J, 2007, CANCER EPIDEM BIOMAR, V16, P1633, DOI 10.1158/1055-9965.EPI-07-0252; Berwick M, 2000, JNCI-J NATL CANCER I, V92, P874, DOI 10.1093/jnci/92.11.874; Bond GL, 2004, CELL, V119, P591, DOI 10.1016/j.cell.2004.11.022; Bustin M, 2001, TRENDS BIOCHEM SCI, V26, P152, DOI 10.1016/S0968-0004(00)01777-1; Bustin M, 1996, PROG NUCLEIC ACID RE, V54, P35, DOI 10.1016/S0079-6603(08)60360-8; COHEN SM, 1992, UROL CLIN N AM, V19, P421; Cohen SM, 2000, SCAND J UROL NEPHROL, V34, P105, DOI 10.1080/00365590050509869; de Laat WL, 1998, J BIOL CHEM, V273, P7835, DOI 10.1074/jbc.273.14.7835; Friedberg EC, 2001, NAT REV CANCER, V1, P22, DOI 10.1038/35094000; Frosina G, 2000, EUR J BIOCHEM, V267, P2135, DOI 10.1046/j.1432-1327.2000.01266.x; Garcia-Closas M, 2006, CANCER EPIDEM BIOMAR, V15, P536, DOI 10.1158/1055-9965.EPI-05-0749; Gu J, 2005, CLIN CANCER RES, V11, P1408, DOI 10.1158/1078-0432.CCR-04-1101; Han JL, 2009, BREAST CANCER RES TR, V115, P613, DOI 10.1007/s10549-008-0089-z; Hecht SS, 2002, ENVIRON MOL MUTAGEN, V39, P119, DOI 10.1002/em.10071; Kim WJ, 2008, CANCER SCI, V99, P646, DOI 10.1111/j.1349-7006.2008.00735.x; Kornguth DG, 2005, INT J RADIAT ONCOL, V62, P665, DOI 10.1016/j.ijrobp.2004.11.026; KRAEMER KH, 1994, ARCH DERMATOL, V130, P1018, DOI 10.1001/archderm.130.8.1018; Kruppa M, 2001, MOL CELL, V7, P309, DOI 10.1016/S1097-2765(01)00179-4; Laser H, 2000, P NATL ACAD SCI USA, V97, P13732, DOI 10.1073/pnas.250400997; Lee OKE, 2005, WORLDV EVID-BASED NU, V2, P4, DOI 10.1111/j.1524-475X.2005.04085.x; McWilliams RR, 2008, CANCER RES, V68, P4928, DOI 10.1158/0008-5472.CAN-07-5539; Milne RL, 2006, CANCER RES, V66, P9420, DOI 10.1158/0008-5472.CAN-06-1418; Nyholt DR, 2004, AM J HUM GENET, V74, P765, DOI 10.1086/383251; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; PRYOR WA, 1983, SCIENCE, V220, P425, DOI 10.1126/science.6301009; Shaoa MH, 2008, LUNG CANCER, V60, P332, DOI 10.1016/j.lungcan.2007.10.023; Shen M, 2005, INT J CANCER, V116, P768, DOI 10.1002/ijc.21117; Sijbers AM, 1996, CELL, V86, P811, DOI 10.1016/S0092-8674(00)80155-5; Smith TR, 2003, CANCER EPIDEM BIOMAR, V12, P1200; Stram DO, 2003, HUM HERED, V55, P27, DOI 10.1159/000071807; Sun T, 2007, NAT GENET, V39, P605, DOI 10.1038/ng2030; Theodorescu D, 2003, HISTOL HISTOPATHOL, V18, P259, DOI 10.14670/HH-18.259; TRAVERS AA, 1994, CELL, V77, P167, DOI 10.1016/0092-8674(94)90306-9; Tsodikov OV, 2005, P NATL ACAD SCI USA, V102, P11236, DOI 10.1073/pnas.0504341102; Wang ML, 2008, CLIN CANCER RES, V14, P3633, DOI 10.1158/1078-0432.CCR-07-5155; WATANABE F, 1994, BBA-MOL CELL RES, V1223, P255, DOI 10.1016/0167-4889(94)90234-8; Winsey SL, 2000, CANCER RES, V60, P5612; Wood RD, 2001, SCIENCE, V291, P1284, DOI 10.1126/science.1056154	38	32	35	1	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2010	29	13					1920	1928		10.1038/onc.2009.484	http://dx.doi.org/10.1038/onc.2009.484			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	577CV	20062074				2022-12-17	WOS:000276199600005
J	Ishikawa, F; Miyoshi, H; Nose, K; Shibanuma, M				Ishikawa, F.; Miyoshi, H.; Nose, K.; Shibanuma, M.			Transcriptional induction of MMP-10 by TGF-beta, mediated by activation of MEF2A and downregulation of class IIa HDACs	ONCOGENE			English	Article						TGF-beta; MMP-10; MEF2A; class IIa HDACs	GROWTH-FACTOR-BETA; EPITHELIAL-MESENCHYMAL TRANSITION; MATRIX METALLOPROTEINASES; MYOGENIC DIFFERENTIATION; CELL CARCINOMA; EXPRESSION; CANCER; PROTEIN; GENE; REPRESSES	Transforming growth factor (TGF)-beta regulates the expression of matrix metalloproteinases (MMPs) and components of the extracellular matrix, thereby profoundly affecting the microenvironment of cells including cancerous ones. We studied MMP-10 induction by TGF-beta in mammary epithelial cells and found that the induction was dependent on the myocyte enhancer factor (MEF)-2 transcription factor. TGF-beta upregulated the gene promoter through the MEF2 site, and knockdown of the MEF2A transcription factor negatively affected MMP-10 induction, whereas its overexpression had a positive effect on the induction. In response to TGF-beta, acetylation and concomitant binding of MEF2A to the promoter region increased, thus suggesting a critical role of MEF2A in transactivation of MMP-10 by TGF-beta. Consistent with the fact that class IIa histone deacetylases (HDACs) interact with MEF2 and suppress transcription, knockdown of HDACs increased and their overexpression inhibited MMP-10 expression. Intriguingly, TGF-beta promoted proteasome-dependent degradation of HDACs. Consistent with this, acetylation of core histones was increased around the MEF2 site of the MMP-10 promoter by TGF-beta and alleviated by overexpression of HDACs. Collectively, it is possible that TGF-beta transcriptionally upregulated MMP-10 through activation of MEF2A, concomitant with acetylation of core histones increasing around the promoter, as a consequence of degradation of the class IIa HDACs. Oncogene (2010) 29, 909-919; doi:10.1038/onc.2009.387; published online 23 November 2009	[Ishikawa, F.; Nose, K.; Shibanuma, M.] Showa Univ, Sch Pharm, Dept Canc Cell Biol, Shinagawa Ku, Tokyo 1428555, Japan; [Miyoshi, H.] RIKEN BioResource Ctr, Subteam Manipulat Cell Fate, Tsukuba, Ibaraki, Japan	Showa University; RIKEN	Shibanuma, M (corresponding author), Showa Univ, Sch Pharm, Dept Canc Cell Biol, Shinagawa Ku, Tokyo 1428555, Japan.	smotoko@pharm.showa-u.ac.jp	Miyoshi, Hiroyuki/G-9808-2013		Ministry for Education, Culture Sports, Science and Technology (MEXT) of Japan [19570185]	Ministry for Education, Culture Sports, Science and Technology (MEXT) of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT))	We thank Dr Eric N Olson (University of Texas Southwestern Medical School, Dallas, TX, USA) for his generous gift of the MMP-10 promoter luciferase constructs. We also thank Ms E Kaneko and Ms T Kaneko for contributing to this work as a project for their bachelor's degree. This work was supported in part by a Grant-in-Aid for Scientific Research (C) (19570185) and the High-Technology Research Center Project from the Ministry for Education, Culture Sports, Science and Technology (MEXT) of Japan, and also by the High-Tech Research Centre Project for Private Universities: a matching fund subsidy from MEXT, 2007-2009.	Angelelli C, 2008, NUCLEIC ACIDS RES, V36, P915, DOI 10.1093/nar/gkm1114; Aung PP, 2006, ONCOGENE, V25, P2546, DOI 10.1038/sj.onc.1209279; Bierie B, 2006, NAT REV CANCER, V6, P506, DOI 10.1038/nrc1926; Chakraborti S, 2003, MOL CELL BIOCHEM, V253, P269, DOI 10.1023/A:1026028303196; Chang SR, 2006, CELL, V126, P321, DOI 10.1016/j.cell.2006.05.040; Cho NH, 2004, ONCOGENE, V23, P845, DOI 10.1038/sj.onc.1207140; Clark IA, 2008, INT J BIOCHEM CELL B, V40, P1362, DOI 10.1016/j.biocel.2007.12.006; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; Derynck R, 1998, CELL, V95, P737, DOI 10.1016/S0092-8674(00)81696-7; Gill JH, 2004, NEOPLASIA, V6, P777, DOI 10.1593/neo.04283; Impola U, 2004, J PATHOL, V202, P14, DOI 10.1002/path.1479; Inoue Y, 2008, CANCER SCI, V99, P2107, DOI 10.1111/j.1349-7006.2008.00925.x; Ishikawa F, 2008, EXP CELL RES, V314, P2131, DOI 10.1016/j.yexcr.2008.03.013; Izzi L, 2004, ONCOGENE, V23, P2071, DOI 10.1038/sj.onc.1207412; Jakowlew SB, 2006, CANCER METAST REV, V25, P435, DOI 10.1007/s10555-006-9006-2; Kang JS, 2005, EMBO J, V24, P2543, DOI 10.1038/sj.emboj.7600729; Kanome T, 2007, ONCOGENE, V26, P5991, DOI 10.1038/sj.onc.1210423; Kato Y, 2000, J BIOL CHEM, V275, P18534, DOI 10.1074/jbc.M001573200; Kerkela E, 2001, BRIT J CANCER, V84, P659, DOI 10.1054/bjoc.2000.1634; Kitamura T, 2003, EXP HEMATOL, V31, P1007, DOI 10.1016/j.exphem.2003.07.005; Lemercier C, 2000, J BIOL CHEM, V275, P15594, DOI 10.1074/jbc.M908437199; Levy L, 2005, MOL CELL BIOL, V25, P8108, DOI 10.1128/MCB.25.18.8108-8125.2005; Liu D, 2004, EMBO J, V23, P1557, DOI 10.1038/sj.emboj.7600179; Ma KW, 2005, MOL CELL BIOL, V25, P3575, DOI 10.1128/MCB.25.9.3575-3582.2005; Massague J, 2006, FEBS LETT, V580, P2811, DOI 10.1016/j.febslet.2006.04.033; Mathew R, 2002, CANCER DETECT PREV, V26, P222, DOI 10.1016/S0361-090X(02)00035-1; McKinsey TA, 2002, TRENDS BIOCHEM SCI, V27, P40, DOI 10.1016/S0968-0004(01)02031-X; Miska EA, 1999, EMBO J, V18, P5099, DOI 10.1093/emboj/18.18.5099; Miyata Y, 2007, EUR UROL, V52, P791, DOI 10.1016/j.eururo.2006.12.028; Mori K, 2006, J BIOL CHEM, V281, P22048, DOI 10.1074/jbc.M513111200; Muraoka-Cook RS, 2004, CANCER RES, V64, P9002, DOI 10.1158/0008-5472.CAN-04-2111; Nakamura H, 1998, EUR J BIOCHEM, V253, P67, DOI 10.1046/j.1432-1327.1998.2530067.x; Nelson JD, 2006, NAT PROTOC, V1, P179, DOI 10.1038/nprot.2006.27; Ornatsky OI, 1999, NUCLEIC ACIDS RES, V27, P2646, DOI 10.1093/nar/27.13.2646; Pardali K, 2007, BBA-REV CANCER, V1775, P21, DOI 10.1016/j.bbcan.2006.06.004; Piek E, 2001, J BIOL CHEM, V276, P19945, DOI 10.1074/jbc.M102382200; Quinn ZA, 2001, NUCLEIC ACIDS RES, V29, P732, DOI 10.1093/nar/29.3.732; Ramos-DeSimone N, 1999, J BIOL CHEM, V274, P13066, DOI 10.1074/jbc.274.19.13066; Shalizi A, 2006, SCIENCE, V311, P1012, DOI 10.1126/science.1122513; Sparrow DB, 1999, EMBO J, V18, P5085, DOI 10.1093/emboj/18.18.5085; Thuault S, 2006, J CELL BIOL, V174, P175, DOI 10.1083/jcb.200512110; Weeks BH, 2001, CANCER RES, V61, P7435; WINDSOR LJ, 1993, J BIOL CHEM, V268, P17341; Yang SH, 1999, MOL CELL BIOL, V19, P4028; Zhao M, 1999, MOL CELL BIOL, V19, P21	45	32	32	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 11	2010	29	6					909	919		10.1038/onc.2009.387	http://dx.doi.org/10.1038/onc.2009.387			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	553WP	19935709				2022-12-17	WOS:000274397800013
J	Su, F; Pascal, LE; Xiao, W; Wang, Z				Su, F.; Pascal, L. E.; Xiao, W.; Wang, Z.			Tumor suppressor U19/EAF2 regulates thrombospondin-1 expression via p53	ONCOGENE			English	Article						U19/EAF2; prostate cancer; tumor suppressor; TSP-1; p53	HIPPEL-LINDAU PROTEIN; ELONGATION-FACTOR ELL; PROSTATE-CANCER; GENE; ANGIOGENESIS; GROWTH; CELLS; CARCINOMA; APOPTOSIS; TRANSACTIVATION	Inactivation of U19/EAF2 has been shown previously to lead to tumorigenesis in multiple organs; however, the mechanism of U19/EAF2 tumor suppression remains unclear. In this paper, we report that the expression of an anti-angiogenic protein, thrombospondin-1 (TSP-1) is down-regulated in the prostate and liver of U19/EAF2 knockout mouse. The U19/EAF2 knockout liver displayed increased CD31-positive blood vessels, suggesting that the TSP-1 down-regulation can contribute to increased angiogenesis. TSP-1 is reported to be a p53-target gene and p53 is a known binding partner of ELL, which binds to U19/EAF2. Here, we show that U19/EAF2 can co-localize and co-immunoprecipitate with p53 in transfected cells. In a TSP-1 promoter-driven luciferase reporter assay, p53 transfection suppressed the TSP-1 promoter activity and U19/EAF2 co-transfection blocked the p53 suppression of TSP-1 promoter. However, U19/EAF2 transfection alone had little or no effect on the TSP-1 promoter. The above observations together suggest that U19/EAF2 regulates the expression of TSP-1 via blocking p53 repression of the TSP-1 promoter. Oncogene (2010) 29, 421-431; doi:10.1038/onc.2009.326; published online 12 October 2009	[Su, F.; Pascal, L. E.; Wang, Z.] Univ Pittsburgh, Sch Med, Inst Canc, Dept Urol, Pittsburgh, PA 15232 USA; [Xiao, W.] Chinese Acad Sci, Inst Hydrobiol, Key Lab Biodivers & Conservat Aquat Organisms, Wuhan, Peoples R China; [Wang, Z.] Univ Pittsburgh, Sch Med, Dept Pharmacol & Chem Biol, Pittsburgh, PA 15232 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Chinese Academy of Sciences; Institute of Hydrobiology, CAS; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Wang, Z (corresponding author), Univ Pittsburgh, Sch Med, Inst Canc, Dept Urol, 5200 Ctr Ave,Suite G40, Pittsburgh, PA 15232 USA.	wangz2@upmc.edu	Pascal, Laura E./AAH-5743-2019; Xiao, Wuhan/GLU-7352-2022	Pascal, Laura E./0000-0003-3840-1662; SU, FEI/0000-0001-5834-4074	NIH [R01 CA 120386, R37 DK51993]; Prostate Cancer Specialized Program of Research Excellence (SPORE) [P50 CA90386]; NATIONAL CANCER INSTITUTE [P50CA090386, R01CA120386] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK051193] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Prostate Cancer Specialized Program of Research Excellence (SPORE); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported in part by NIH Grant Number R01 CA 120386, R37 DK51993, and Prostate Cancer Specialized Program of Research Excellence (SPORE), P50 CA90386.	ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Alvarez AA, 2001, GYNECOL ONCOL, V82, P273, DOI 10.1006/gyno.2001.6287; Azam N, 2001, J BIOL CHEM, V276, P2766, DOI 10.1074/jbc.M005626200; Cinatl J, 1999, AM J PATHOL, V155, P285, DOI 10.1016/S0002-9440(10)65122-X; DONOVIEL DB, 1988, J BIOL CHEM, V263, P18590; Duan X, 2008, INT J RADIAT BIOL, V84, P211, DOI 10.1080/09553000801902117; FRAMSON P, 1993, J BIOL CHEM, V268, P4989; Freitas TMC, 2005, EXP MOL PATHOL, V79, P79, DOI 10.1016/j.yexmp.2005.02.006; Harada H, 2003, CANCER LETT, V191, P109, DOI 10.1016/S0304-3835(02)00592-X; Jiang C, 2004, MOL CANCER THER, V3, P877; Kwak C, 2002, BJU INT, V89, P303, DOI 10.1046/j.1464-4096.2001.01417.x; MAEDA K, 1995, BRIT J CANCER, V72, P319, DOI 10.1038/bjc.1995.331; Mitani K, 2000, BIOCHEM BIOPH RES CO, V279, P563, DOI 10.1006/bbrc.2000.3970; Nelius T, 2007, INT J CANCER, V121, P999, DOI 10.1002/ijc.22802; Reiher FK, 2001, J UROLOGY, V165, P2075, DOI 10.1016/S0022-5347(05)66297-0; Ren B, 2006, BBA-REV CANCER, V1765, P178, DOI 10.1016/j.bbcan.2005.11.002; Roe JS, 2006, MOL CELL, V22, P395, DOI 10.1016/j.molcel.2006.04.006; SELFRIDGE J, 1992, SOMAT CELL MOLEC GEN, V18, P325, DOI 10.1007/BF01235756; Shinobu N, 1999, J BIOL CHEM, V274, P17003, DOI 10.1074/jbc.274.24.17003; Simone F, 2003, BLOOD, V101, P2355, DOI 10.1182/blood-2002-06-1664; Tokunaga T, 1998, VIRCHOWS ARCH, V433, P415, DOI 10.1007/s004280050268; Wang Z, 1997, P NATL ACAD SCI USA, V94, P12999, DOI 10.1073/pnas.94.24.12999; Wiederschain D, 2003, MOL CELL BIOL, V23, P4230, DOI 10.1128/MCB.23.12.4230-4246.2003; Xiao W, 2008, ONCOGENE, V27, P1536, DOI 10.1038/sj.onc.1210786; Xiao WH, 2006, PROSTATE, V66, P1, DOI 10.1002/pros.20309; Xiao WH, 2003, CANCER RES, V63, P4698; Xiao WH, 2009, CANCER RES, V69, P2599, DOI 10.1158/0008-5472.CAN-08-2595; Zhou JG, 2009, J BIOL CHEM, V284, P19142, DOI 10.1074/jbc.M109.010439	28	32	34	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 21	2010	29	3					421	431		10.1038/onc.2009.326	http://dx.doi.org/10.1038/onc.2009.326			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	546EO	19826414	Green Accepted			2022-12-17	WOS:000273793200011
J	van Amerongen, R; Nawijn, MC; Lambooij, JP; Proost, N; Jonkers, J; Berns, A				van Amerongen, R.; Nawijn, M. C.; Lambooij, J-P; Proost, N.; Jonkers, J.; Berns, A.			Frat oncoproteins act at the crossroad of canonical and noncanonical Wnt-signaling pathways	ONCOGENE			English	Article						Frat; Gsk3-binding protein; lymphoma-genesis; Diversin; Wnt-signal transduction; planar cell polarity	KINASE-I-EPSILON; CELL POLARITY; PLANAR POLARITY; BETA-CATENIN; AXIN; ACTIVATION; BINDING; LEADS; OVEREXPRESSION; PROTOONCOGENE	Wnt-signal transduction is critical for development and tissue homeostasis in a wide range of animal species and is frequently deregulated in human cancers. Members of the Frat/GBP family of glycogen synthase kinase 3 beta (Gsk3b)binding oncoproteins are recognized as potent activators of the Wnt/beta-catenin pathway in vertebrates. Here, we reveal a novel, Gsk3b-independent function of Frat converging on the activation of JNK and AP-1. Both these have been used as readouts for the noncanonical Frizzled/PCP pathway, which controls polarized cell movements and the establishment of tissue polarity. We find that Frat synergizes with Diversin, the mammalian homolog of the Drosophila PCP protein diego, in the activation of JNK/AP-1 signaling. Importantly, Frat mutants deficient for binding to Gsk3b retain oncogenic activity in vivo, suggesting that Wnt/beta-catenin-independent events contribute to Frat-induced malignant transformation. The observed activities of Frat are reminiscent of the dual function of Dishevelled in the Wnt/beta-catenin and Frizzled/PCP pathways and suggest that Frat may also function to bridge canonical and noncanonical Wnt pathways.	[van Amerongen, R.; Nawijn, M. C.; Lambooij, J-P; Proost, N.; Berns, A.] Netherlands Canc Inst, Div Mol Genet, NL-1066 CX Amsterdam, Netherlands; [van Amerongen, R.; Nawijn, M. C.; Lambooij, J-P; Proost, N.; Berns, A.] Ctr Biomed Genet, Amsterdam, Netherlands; [Jonkers, J.] Netherlands Canc Inst, Div Mol Biol, NL-1066 CX Amsterdam, Netherlands; [Berns, A.] Univ Amsterdam, Acad Med Ctr, NL-1105 AZ Amsterdam, Netherlands	Netherlands Cancer Institute; Netherlands Cancer Institute; University of Amsterdam; Academic Medical Center Amsterdam	Berns, A (corresponding author), Netherlands Canc Inst, Div Mol Genet, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.	a.berns@nki.nl	van Amerongen, Renee/G-2945-2017; van Amerongen, Renee/N-6645-2019; Jonkers, Jos/AAG-3246-2019	van Amerongen, Renee/0000-0002-8808-2092; van Amerongen, Renee/0000-0002-8808-2092; Jonkers, Jos/0000-0002-9264-9792; Nawijn, Martijn/0000-0003-3372-6521	Centre of Biomedical Genetics (CBG)	Centre of Biomedical Genetics (CBG)	We thank Dr Walter Birchmeier, Dr Hans Clevers, Dr Gerald Crabtree, Dr Trevor Dale, Dr Jolita Hendriksen, Dr Rob Michalides, and Dr Rob Wolthuis for providing constructs and reagents and Dr Ping Chen for advice on cochlear dissections. We thank Fina van de Ahe, Sjaak Greven, Loes Rijswijk, and Maaike Voetel for tail vein injections, Hanneke van de Gulden for generating the Frat1<SUP>IAQA</SUP> mutant, and Dr Joaquim Calbo-Angrill for reading of an early version of the manuscript. This work received financial support from the Centre of Biomedical Genetics (CBG).	Bax B, 2001, STRUCTURE, V9, P1143, DOI 10.1016/S0969-2126(01)00679-7; Bilic J, 2007, SCIENCE, V316, P1619, DOI 10.1126/science.1137065; Boutros M, 1998, CELL, V94, P109, DOI 10.1016/S0092-8674(00)81226-X; Carpenter AE, 2006, GENOME BIOL, V7, DOI 10.1186/gb-2006-7-10-r100; Cong F, 2004, MOL CELL BIOL, V24, P2000, DOI 10.1128/MCB.24.5.2000-2011.2004; Etheridge SL, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000259; Fanto M, 2004, J CELL SCI, V117, P527, DOI 10.1242/jcs.00973; Ferkey DM, 2002, J BIOL CHEM, V277, P16147, DOI 10.1074/jbc.M112363200; Fraser E, 2002, J BIOL CHEM, V277, P2176, DOI 10.1074/jbc.M109462200; Habas R, 2003, GENE DEV, V17, P295, DOI 10.1101/gad.1022203; Hamblet NS, 2002, DEVELOPMENT, V129, P5827, DOI 10.1242/dev.00164; Hino S, 2003, J BIOL CHEM, V278, P14066, DOI 10.1074/jbc.M213265200; Hocevar BA, 2003, EMBO J, V22, P3084, DOI 10.1093/emboj/cdg286; Hongisto V, 2003, MOL CELL BIOL, V23, P6027, DOI 10.1128/MCB.23.17.6027-6036.2003; Jones C, 2007, BIOESSAYS, V29, P120, DOI 10.1002/bies.20526; Jonkers J, 1997, EMBO J, V16, P441, DOI 10.1093/emboj/16.3.441; Jonkers J, 1999, MECH DEVELOP, V88, P183, DOI 10.1016/S0925-4773(99)00187-2; Jonkers J, 1999, ONCOGENE, V18, P5982, DOI 10.1038/sj.onc.1202995; Klein TJ, 2006, CURR BIOL, V16, P1337, DOI 10.1016/j.cub.2006.06.030; Klein TJ, 2005, ANNU REV CELL DEV BI, V21, P155, DOI 10.1146/annurev.cellbio.21.012704.132806; Lamprecht MR, 2007, BIOTECHNIQUES, V42, P71, DOI 10.2144/000112257; Li L, 1999, J BIOL CHEM, V274, P129, DOI 10.1074/jbc.274.1.129; Li L, 1999, EMBO J, V18, P4233, DOI 10.1093/emboj/18.15.4233; Maretto S, 2003, P NATL ACAD SCI USA, V100, P3299, DOI 10.1073/pnas.0434590100; Mikkers H, 2002, NAT GENET, V32, P459, DOI 10.1038/ng1102-459b; Moeller H, 2006, P NATL ACAD SCI USA, V103, P15900, DOI 10.1073/pnas.0603808103; Qian D, 2007, DEV BIOL, V306, P121, DOI 10.1016/j.ydbio.2007.03.011; Saitoh T, 2001, INT J ONCOL, V19, P311; Sakanaka C, 2000, RECENT PROG HORM RES, V55, P225; Schwarz-Romond T, 2002, GENE DEV, V16, P2073, DOI 10.1101/gad.230402; Simons M, 2005, NAT GENET, V37, P537, DOI 10.1038/ng1552; Strutt H, 2006, CURR BIOL, V16, P1329, DOI 10.1016/j.cub.2006.04.041; THEISEN H, 1994, DEVELOPMENT, V120, P347; Thomas GM, 1999, FEBS LETT, V458, P247, DOI 10.1016/S0014-5793(99)01161-8; van Amerongen R, 2005, CELL CYCLE, V4, pE89; van Amerongen R, 2005, GENE DEV, V19, P425, DOI 10.1101/gad.326705; van Amerongen R, 2004, J BIOL CHEM, V279, P26967, DOI 10.1074/jbc.M400439200; VANDERLUGT NMT, 1995, EMBO J, V14, P2536, DOI 10.1002/j.1460-2075.1995.tb07251.x; Wallingford JB, 2000, NATURE, V405, P81, DOI 10.1038/35011077; Wang JB, 2006, DEVELOPMENT, V133, P1767, DOI 10.1242/dev.02347; Wang Y, 2006, BRIT J CANCER, V94, P686, DOI 10.1038/sj.bjc.6602988; Wang YS, 2007, DEVELOPMENT, V134, P647, DOI 10.1242/dev.02772; Wang YH, 2006, J NEUROSCI, V26, P2147, DOI 10.1523/JNEUROSCI.4698-05.2005; Wang YH, 2008, INT J CANCER, V123, P561, DOI 10.1002/ijc.23600; Yan D, 2001, P NATL ACAD SCI USA, V98, P3802, DOI 10.1073/pnas.071041898; Yost C, 1998, CELL, V93, P1031, DOI 10.1016/S0092-8674(00)81208-8; Zeng X, 2008, DEVELOPMENT, V135, P367, DOI 10.1242/dev.013540	47	32	32	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 7	2010	29	1					93	104		10.1038/onc.2009.310	http://dx.doi.org/10.1038/onc.2009.310			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	540XE	19802005				2022-12-17	WOS:000273373500009
J	Stylianou, DC; Maur, AAD; Kodack, DP; Henke, RT; Hohn, S; Toretsky, JA; Riegel, AT; Wellstein, A				Stylianou, D. C.; Maur, A. Auf Der; Kodack, D. P.; Henke, R. T.; Hohn, S.; Toretsky, J. A.; Riegel, A. T.; Wellstein, A.			Effect of single-chain antibody targeting of the ligand-binding domain in the anaplastic lymphoma kinase receptor	ONCOGENE			English	Article						ALK; growth factor; PTN; single-chain antibody; tyrosine kinase receptor	TYROSINE-PHOSPHATASE-BETA/ZETA; GROWTH-FACTOR PLEIOTROPHIN; ACTIVATED PROTEIN-KINASE; SULFATE HYBRID CHAINS; NON-HODGKINS-LYMPHOMA; EMBRYONIC PIG BRAIN; MOLECULE HB-GAM; ZETA/RPTP-BETA; PHOSPHATIDYLINOSITOL 3-KINASE; CHONDROITIN/DERMATAN SULFATE	The tyrosine kinase receptor anaplastic lymphoma kinase (ALK) and its ligand, the growth factor pleiotrophin (PTN), are highly expressed during the development of the nervous system and have been implicated in the malignant progression of different tumor types. Here, we describe human single-chain variable fragment (scFv) antibodies that target the ligand-binding domain (LBD) in ALK and show the effect in vitro and in vivo. The ALK LBD was used as a bait in a yeast two-hybdrid system to select human scFv from a library with randomized complementarity-determining region 3 domains. Surface plasmon resonance showed high-affinity binding of the selected scFv. The anti-ALK scFv competed for binding of PTN to ALK in intact cells and inhibited PTN-dependent signal transduction through endogenous ALK. Invasion of an intact endothelial cell monolayer by U87MG human glioblastoma cells was inhibited by the anti-ALK scFv. In addition, the growth of established tumor xenografts in mice was reversed after the induction of the conditional expression of the anti-ALK scFv. In archival malignant brain tumors expression levels of ALK and PTN were found elevated and appear correlated with poor patient survival. This suggests a rate-limiting function of the PTN/ALK interaction that may be exploited therapeutically. Oncogene (2009) 28, 3296-3306; doi:10.1038/onc.2009.184; published online 27 July 2009	[Wellstein, A.] Georgetown Univ, Med Ctr, Lombardi Canc Ctr, Washington, DC 20057 USA; [Maur, A. Auf Der; Hohn, S.] Esbatech AG, Zurich, Switzerland	Georgetown University	Wellstein, A (corresponding author), Georgetown Univ, Med Ctr, Lombardi Canc Ctr, E315 TRB 3970 Reservoir Rd NW, Washington, DC 20057 USA.	wellstea@georgetown.edu	Stylianou, Dora/AAT-1074-2020; Stylianou, Dora/J-2697-2016	Stylianou, Dora/0000-0003-4167-1380; Stylianou, Dora/0000-0003-4167-1380; Wellstein, Anton/0000-0002-0570-4950	National Institute of Health [RO1 CA108440]; NATIONAL CANCER INSTITUTE [R01CA108440, T32CA009686, R01CA071508, P50CA058185, R01CA101811] Funding Source: NIH RePORTER	National Institute of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Drs Emma T Bowden, Angera H Kuo and Gerald E Stoica (Georgetown University) for help with some of the experiments as well as discussions and suggestions. This work was supported by RO1 CA108440 from the National Institute of Health (to AW).	Aricescu AR, 2007, SCIENCE, V317, P1217, DOI 10.1126/science.1144646; AUFDERMAUR A, 2002, J BIOL CHEM, V277, P45075; Bao XF, 2005, J BIOL CHEM, V280, P9180, DOI 10.1074/jbc.M413423200; Bilsland JG, 2008, NEUROPSYCHOPHARMACOL, V33, P685, DOI 10.1038/sj.npp.1301446; Bowden ET, 2002, J BIOL CHEM, V277, P35862, DOI 10.1074/jbc.M203963200; Chang YC, 2006, BIOCHEM BIOPH RES CO, V351, P336, DOI 10.1016/j.bbrc.2006.09.148; Chen HM, 2007, BLOOD, V110, P287, DOI 10.1182/blood-2006-08-042374; Chiarle R, 2008, NAT REV CANCER, V8, P11, DOI 10.1038/nrc2291; CHOTHIA C, 1987, J MOL BIOL, V196, P901, DOI 10.1016/0022-2836(87)90412-8; CHOTHIA C, 1985, J MOL BIOL, V186, P651, DOI 10.1016/0022-2836(85)90137-8; Czubayko F, 1996, P NATL ACAD SCI USA, V93, P14753, DOI 10.1073/pnas.93.25.14753; der Maur AA, 2001, FEBS LETT, V508, P407, DOI 10.1016/S0014-5793(01)03101-5; der Maur Adrian Auf, 2004, Methods (Amsterdam), V34, P215; Duyster J, 2001, ONCOGENE, V20, P5623, DOI 10.1038/sj.onc.1204594; FANG WJ, 1992, J BIOL CHEM, V267, P25889; Freije WA, 2004, CANCER RES, V64, P6503, DOI 10.1158/0008-5472.CAN-04-0452; Grzelinski M, 2006, HUM GENE THER, V17, P751, DOI 10.1089/hum.2006.17.751; Hamma-Kourbali Y, 2008, J CELL PHYSIOL, V214, P250, DOI 10.1002/jcp.21191; Henke RT, 2006, METHODS, V38, P253, DOI 10.1016/j.ymeth.2005.11.013; Ho M, 2006, P NATL ACAD SCI USA, V103, P9637, DOI 10.1073/pnas.0603653103; Iwahara T, 1997, ONCOGENE, V14, P439, DOI 10.1038/sj.onc.1200849; Keese CR, 2002, BIOTECHNIQUES, V33, P842, DOI 10.2144/02334rr01; Kuo AH, 2007, ONCOGENE, V26, P859, DOI 10.1038/sj.onc.1209840; Li FC, 2007, J BIOL CHEM, V282, P2956, DOI 10.1074/jbc.M609296200; Li RS, 2008, MED RES REV, V28, P372, DOI 10.1002/med.20109; LI YS, 1990, SCIENCE, V250, P1690, DOI 10.1126/science.2270483; Lu KV, 2005, J BIOL CHEM, V280, P26953, DOI 10.1074/jbc.M502614200; Maeda N, 1999, J BIOL CHEM, V274, P12474, DOI 10.1074/jbc.274.18.12474; Maeda N, 1996, J BIOL CHEM, V271, P21446, DOI 10.1074/jbc.271.35.21446; Maeda N, 1998, J CELL BIOL, V142, P203, DOI 10.1083/jcb.142.1.203; Mathivet T, 2007, CELL SIGNAL, V19, P2434, DOI 10.1016/j.cellsig.2007.07.011; McCarthy N, 2008, NAT REV CANCER, V8, DOI 10.1038/nrc2305; Meng K, 2000, P NATL ACAD SCI USA, V97, P2603, DOI 10.1073/pnas.020487997; Mentlein R, 2002, J NEUROCHEM, V83, P747, DOI 10.1046/j.1471-4159.2002.01179.x; Mi RF, 2007, P NATL ACAD SCI USA, V104, P4664, DOI 10.1073/pnas.0603243104; MIURA M, 1995, J BIOL CHEM, V270, P22639, DOI 10.1074/jbc.270.38.22639; Moog-Lutz C, 2005, J BIOL CHEM, V280, P26039, DOI 10.1074/jbc.M501972200; MORRIS SW, 1994, SCIENCE, V263, P1281, DOI 10.1126/science.8122112; Morris SW, 1997, ONCOGENE, V14, P2175, DOI 10.1038/sj.onc.1201062; Muramatsu H, 2006, GENES CELLS, V11, P1405, DOI 10.1111/j.1365-2443.2006.01028.x; Owada K, 1999, J NEUROCHEM, V73, P2084; PADLAN EA, 1994, MOL IMMUNOL, V31, P169, DOI 10.1016/0161-5890(94)90001-9; Perez-Pinera P, 2006, P NATL ACAD SCI USA, V103, P17795, DOI 10.1073/pnas.0607299103; Perez-Pinera P, 2007, J BIOL CHEM, V282, P28683, DOI 10.1074/jbc.M704505200; Peria FM, 2007, J NEURO-ONCOL, V84, P255, DOI 10.1007/s11060-007-9379-2; Phillips HS, 2006, CANCER CELL, V9, P157, DOI 10.1016/j.ccr.2006.02.019; Powers C, 2002, J BIOL CHEM, V277, P14153, DOI 10.1074/jbc.M112354200; Powers CJ, 2000, ENDOCR-RELAT CANCER, V7, P165, DOI 10.1677/erc.0.0070165; Qi MS, 2001, J BIOL CHEM, V276, P15868, DOI 10.1074/jbc.M005911200; Rhodes DR, 2004, NEOPLASIA, V6, P1, DOI 10.1016/S1476-5586(04)80047-2; Sakaguchi N, 2003, NEUROSCI RES, V45, P219, DOI 10.1016/S0168-0102(02)00226-2; Schaerer-Brodbeck C, 2004, BIOTECHNIQUES, V37, P202, DOI 10.2144/04372BM05; Shai R, 2003, ONCOGENE, V22, P4918, DOI 10.1038/sj.onc.1206753; Soda M, 2007, NATURE, V448, P561, DOI 10.1038/nature05945; Stoica GE, 2002, J BIOL CHEM, V277, P35990, DOI 10.1074/jbc.M205749200; Stoica GE, 2001, J BIOL CHEM, V276, P16772, DOI 10.1074/jbc.M010660200; Sugahara K, 2007, CURR OPIN STRUC BIOL, V17, P536, DOI 10.1016/j.sbi.2007.08.015; Sun LX, 2006, CANCER CELL, V9, P287, DOI 10.1016/j.ccr.2006.03.003; Tang Y, 2007, J IMMUNOL, V179, P2815, DOI 10.4049/jimmunol.179.5.2815; Weber D, 2000, CANCER RES, V60, P5284; WELLSTEIN A, 1992, J BIOL CHEM, V267, P2582; Zhang N, 1997, J BIOL CHEM, V272, P16733, DOI 10.1074/jbc.272.27.16733; Zou P, 2006, LAB INVEST, V86, P645, DOI 10.1038/labinvest.3700428	63	32	32	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 17	2009	28	37					3296	3306		10.1038/onc.2009.184	http://dx.doi.org/10.1038/onc.2009.184			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	495LS	19633684	Green Accepted			2022-12-17	WOS:000269893700004
J	Lee, CM; Hickey, MM; Sanford, CA; McGuire, CG; Cowey, CL; Simon, MC; Rathmell, WK				Lee, C. M.; Hickey, M. M.; Sanford, C. A.; McGuire, C. G.; Cowey, C. L.; Simon, M. C.; Rathmell, W. K.			VHL Type 2B gene mutation moderates HIF dosage in vitro and in vivo	ONCOGENE			English	Article						von Hippel-Lindau; hypoxia inducible factors; renal cell carcinoma	TUMOR-SUPPRESSOR PROTEIN; HYPOXIA-INDUCIBLE FACTOR; HIPPEL-LINDAU-DISEASE; RENAL-CELL CARCINOMA; ENDOTHELIAL GROWTH-FACTOR; CHUVASH POLYCYTHEMIA; EMBRYONIC LETHALITY; UBIQUITIN LIGASE; VASCULAR TUMORS; BINDING-SITES	Von Hippel-Lindau (VHL) disease is caused by germline mutations in the VHL tumor suppressor gene, with Type 2B missense VHL mutations predisposing to renal cell carcinoma, hemangioblastoma and pheochromocytoma. Type 2B mutant pVHL is predicted to be defective in hypoxia inducible factor (HIF)-alpha regulation. Murine embryonic stem (ES) cells in which the endogenous wildtype Vhl gene was replaced with the representative Type 2B VHL hotspot mutation R167Q (Vhl(2B/2B)) displayed preserved physiological regulation of both HIF factors with slightly greater normoxic dysregulation of HIF-2 alpha. Differentiated Vhl(2B/2B)-derived teratomas overexpressed joint HIF targets Vegf and EglN3 but not the HIF-1 alpha-specific target Pfk1. Vhl(2B/2B) teratomas additionally displayed a growth advantage over Vhl(-/-)-derived teratomas, suggestive of a tight connection between perturbations in the degree and ratio of HIF-1 alpha and HIF-2 alpha stabilization and cell growth. Vhl(2B/2B) mice displayed mid-gestational embryonic lethality, whereas adult Vhl(2B/+) mice exhibited susceptibility to carcinogen-promoted renal neoplasia compared with wild-type littermates at 12 months. Our experiments support a model in which the representative Type 2B R167Q mutant pVhl produces a unique pro. le of HIF dysregulation, thereby promoting tissue-specific effects on cell growth, development and tumor predisposition.	[Lee, C. M.; Sanford, C. A.; McGuire, C. G.; Cowey, C. L.; Rathmell, W. K.] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; [Lee, C. M.; Rathmell, W. K.] Univ N Carolina, Curriculum Genet & Mol Biol, Chapel Hill, NC 27599 USA; [Hickey, M. M.; Simon, M. C.] Univ Penn, Sch Med, Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA; [Hickey, M. M.; Simon, M. C.] Univ Penn, Sch Med, Cell & Mol Biol Grad Grp, Philadelphia, PA 19104 USA; [Hickey, M. M.; Simon, M. C.] Univ Penn, Sch Med, Howard Hughes Med Inst, Philadelphia, PA 19104 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Howard Hughes Medical Institute; University of Pennsylvania	Rathmell, WK (corresponding author), Univ N Carolina, Lineberger Comprehens Canc Ctr, 450 W Dr,Room 21-237,Campus Box 7295, Chapel Hill, NC 27599 USA.	rathmell@med.unc.edu	Simon, Celeste/AAG-3941-2021		V Foundation; American Cancer Society; VHL Family Alliance; NCI [K08098410, R01121781]; Howard Hughes Medical Institute; NIEHS [F30015248]; NATIONAL CANCER INSTITUTE [K08CA098410, R01CA121781] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL066310] Funding Source: NIH RePORTER	V Foundation; American Cancer Society(American Cancer Society); VHL Family Alliance; NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Howard Hughes Medical Institute(Howard Hughes Medical Institute); NIEHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	We thank Dr T Van Dyke and members of her laboratory, Dr I Davis, and Dr WY Kim for many helpful discussions. This work was supported by the V Foundation, the American Cancer Society, the VHL Family Alliance, and the NCI K08098410 and R01121781 (WKR); by the Howard Hughes Medical Institute (MCS, MMH); and by the NIEHS F30015248 (CML).	Alvarez-Silva M, 2003, DEVELOPMENT, V130, P5437, DOI 10.1242/dev.00755; Ang SO, 2002, NAT GENET, V32, P614, DOI 10.1038/ng1019; Banks RE, 2006, CANCER RES, V66, P2000, DOI 10.1158/0008-5472.CAN-05-3074; Bruick RK, 2001, SCIENCE, V294, P1337, DOI 10.1126/science.1066373; Brusselmans K, 2005, J BIOL CHEM, V280, P3493, DOI 10.1074/jbc.M406613200; Carmeliet P, 1998, NATURE, V394, P485, DOI 10.1038/28867; Clifford SC, 2001, HUM MOL GENET, V10, P1029, DOI 10.1093/hmg/10.10.1029; Cockman ME, 2000, J BIOL CHEM, V275, P25733, DOI 10.1074/jbc.M002740200; Covello KL, 2005, CANCER RES, V65, P2277, DOI 10.1158/0008-5472.CAN-04-3246; CROSSEY PA, 1994, HUM MOL GENET, V3, P1303; DUAN DR, 1995, SCIENCE, V269, P1402, DOI 10.1126/science.7660122; Elvert G, 2003, J BIOL CHEM, V278, P7520, DOI 10.1074/jbc.M211298200; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; FOSTER K, 1994, HUM MOL GENET, V3, P2169, DOI 10.1093/hmg/3.12.2169; Gallou C, 2004, HUM MUTAT, V24, P215, DOI 10.1002/humu.20082; Gnarra JR, 1997, P NATL ACAD SCI USA, V94, P9102, DOI 10.1073/pnas.94.17.9102; Haase VH, 2001, P NATL ACAD SCI USA, V98, P1583, DOI 10.1073/pnas.98.4.1583; Hacker KE, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003801; Hickey MM, 2007, J CLIN INVEST, V117, P3879, DOI 10.1172/JCI32614; Hon WC, 2002, NATURE, V417, P975, DOI 10.1038/nature00767; Hu CJ, 2003, MOL CELL BIOL, V23, P9361, DOI 10.1128/MCB.23.24.9361-9374.2003; Hu CJ, 2006, MOL CELL BIOL, V26, P3514, DOI 10.1128/MCB.26.9.3514-3526.2006; Huang JH, 2002, J BIOL CHEM, V277, P39792, DOI 10.1074/jbc.M206955200; Huang LE, 1998, P NATL ACAD SCI USA, V95, P7987, DOI 10.1073/pnas.95.14.7987; Iliopoulos O, 1996, P NATL ACAD SCI USA, V93, P10595, DOI 10.1073/pnas.93.20.10595; ILIOPOULOS O, 1995, NAT MED, V1, P822, DOI 10.1038/nm0895-822; Ivan M, 2002, P NATL ACAD SCI USA, V99, P13459, DOI 10.1073/pnas.192342099; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Iwai K, 1999, P NATL ACAD SCI USA, V96, P12436, DOI 10.1073/pnas.96.22.12436; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Jiang BH, 1996, J BIOL CHEM, V271, P17771, DOI 10.1074/jbc.271.30.17771; Jiang BH, 1997, J BIOL CHEM, V272, P19253, DOI 10.1074/jbc.272.31.19253; Kamura T, 2000, P NATL ACAD SCI USA, V97, P10430, DOI 10.1073/pnas.190332597; Kamura T, 1999, SCIENCE, V284, P657, DOI 10.1126/science.284.5414.657; KIBEL A, 1995, SCIENCE, V269, P1444, DOI 10.1126/science.7660130; Knauth K, 2006, ONCOGENE, V25, P370, DOI 10.1038/sj.onc.1209062; Kobayashi T, 1999, CANCER RES, V59, P1206; Kondo K, 2002, GENE CHROMOSOME CANC, V34, P58, DOI 10.1002/gcc.10054; LATIF F, 1993, SCIENCE, V260, P1317, DOI 10.1126/science.8493574; Le Bras A, 2007, ONCOGENE, V26, P7480, DOI 10.1038/sj.onc.1210566; Li LJ, 2007, MOL CELL BIOL, V27, P5381, DOI 10.1128/MCB.00282-07; Lisztwan J, 1999, GENE DEV, V13, P1822, DOI 10.1101/gad.13.14.1822; Ma WB, 2003, CANCER RES, V63, P5320; Mack FA, 2003, CANCER CELL, V3, P75, DOI 10.1016/S1535-6108(02)00240-4; MAHER ER, 1991, J MED GENET, V28, P443, DOI 10.1136/jmg.28.7.443; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Miller MS, 2004, TOXICOL APPL PHARM, V198, P95, DOI 10.1016/j.taap.2003.07.018; Min JH, 2002, SCIENCE, V296, P1886, DOI 10.1126/science.1073440; NEUMANN HPH, 1991, LANCET, V337, P1052, DOI 10.1016/0140-6736(91)91705-Y; Nickerson ML, 2008, CLIN CANCER RES, V14, P4726, DOI 10.1158/1078-0432.CCR-07-4921; Ohh M, 1999, J CLIN INVEST, V104, P1583, DOI 10.1172/JCI8161; Ohh M, 2000, NAT CELL BIOL, V2, P423, DOI 10.1038/35017054; Pastore YD, 2003, BLOOD, V101, P1591, DOI 10.1182/blood-2002-06-1843; Pause A, 1997, P NATL ACAD SCI USA, V94, P2156, DOI 10.1073/pnas.94.6.2156; Pugh CW, 1997, J BIOL CHEM, V272, P11205; Rathmell WK, 2008, EXPERT REV ANTICANC, V8, P63, DOI 10.1586/14737140.8.1.63; Rathmell WK, 2004, CANCER RES, V64, P8595, DOI 10.1158/0008-5472.CAN-04-1430; Sanchez-Elsner T, 2002, J BIOL CHEM, V277, P43799, DOI 10.1074/jbc.M207160200; Semenza GL, 1996, J BIOL CHEM, V271, P32529, DOI 10.1074/jbc.271.51.32529; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Stebbins CE, 1999, SCIENCE, V284, P455, DOI 10.1126/science.284.5413.455; Tian H, 1997, GENE DEV, V11, P72, DOI 10.1101/gad.11.1.72; Voss AK, 2000, DEVELOPMENT, V127, P1; Williams-Simons L, 1999, TRANSGENIC RES, V8, P253, DOI 10.1023/A:1008994831937; Zbar B, 1996, HUM MUTAT, V8, P348, DOI 10.1002/(SICI)1098-1004(1996)8:4<348::AID-HUMU8>3.3.CO;2-9	65	32	32	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 9	2009	28	14					1694	1705		10.1038/onc.2009.12	http://dx.doi.org/10.1038/onc.2009.12			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	430WQ	19252526	Green Accepted, Green Submitted			2022-12-17	WOS:000265022000004
J	Greenow, KR; Clarke, AR; Jones, RH				Greenow, K. R.; Clarke, A. R.; Jones, R. H.			Chk1 deficiency in the mouse small intestine results in p53-independent crypt death and subsequent intestinal compensation	ONCOGENE			English	Article						Chk1; DNA damage; small intestine; apoptosis; p53	DNA-DAMAGE CHECKPOINT; CELL-DEATH; SERINE 139; CANCER; P53; PHOSPHORYLATION; EXPRESSION; REPLICATION; INHIBITION; INITIATION	Chk1 is a serine/threonine protein kinase that is activated by a wide range of DNA-damaging agents to slow the cell cycle during S phase and G2/M. Abrogation of these cell-cycle checkpoints using Chk1 inhibitors results in hypersensitivity to DNA-damaging agents in vitro and may provide a potential therapeutic tool to sensitize tumour cells in vivo. We have generated a Cre-Lox-based mouse model in which Chk1 can be inducibly deleted from somatic epithelial cells in the adult mouse small intestine and liver. Loss of Chk1 in the liver is tolerated with no apparent phenotype. In contrast, the loss of Chk1 within the small intestine results in immediate DNA damage and high levels of p53-independent apoptosis leading to crypt death. However, the intestine is able to compensate for this death by undergoing complete re-population with Chk1-proficient cells. These data therefore show that Chk1 deficiency is cell lethal, but the intestine can tolerate such lethality at the organ level.	[Greenow, K. R.; Clarke, A. R.; Jones, R. H.] Cardiff Univ, Cardiff Sch Biosci, Cardiff CF10 3US, S Glam, Wales; [Jones, R. H.] Univ Bristol, Dept Cellular & Mol Med, Bristol, Avon, England	Cardiff University; University of Bristol	Jones, RH (corresponding author), Cardiff Univ, Cardiff Sch Biosci, Museum Ave, Cardiff CF10 3US, S Glam, Wales.	jonesrh7@cardiff.ac.uk	Clarke, Alan R/A-6256-2008; clarke, alan r/P-2820-2014	Clarke, Alan/0000-0002-4281-426X	Cancer Research UK; MRC [G0301154] Funding Source: UKRI; Medical Research Council [G0301154] Funding Source: researchfish	Cancer Research UK(Cancer Research UK); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	This study was supported by Cancer Research UK. We thank Mark Bishop, Lucie Pietzka and Derek Scarborough for technical assistance.	Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Bartek J, 2003, CANCER CELL, V3, P421, DOI 10.1016/S1535-6108(03)00110-7; BJERKNES M, 1981, ANAT REC, V199, P565, DOI 10.1002/ar.1091990412; Chen ZH, 2003, MOL CANCER THER, V2, P543; Hapke G, 2001, CANCER METAST REV, V20, P109, DOI 10.1023/A:1013116826788; Ireland H, 2004, GASTROENTEROLOGY, V126, P1236, DOI 10.1053/j.gastro.2004.03.020; Jonkers J, 2001, NAT GENET, V29, P418, DOI 10.1038/ng747; Kawabe T, 2004, MOL CANCER THER, V3, P513; Koniaras K, 2001, ONCOGENE, V20, P7453, DOI 10.1038/sj.onc.1204942; Kramer A, 2004, NAT CELL BIOL, V6, P884, DOI 10.1038/ncb1165; Lam MH, 2004, CANCER CELL, V6, P45, DOI 10.1016/j.ccr.2004.06.015; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Liu QH, 2000, GENE DEV, V14, P1448; Merritt AJ, 1997, ONCOGENE, V14, P2759, DOI 10.1038/sj.onc.1201126; Nyberg KA, 2002, ANNU REV GENET, V36, P617, DOI 10.1146/annurev.genet.36.060402.113540; Robinson HMR, 2006, ONCOGENE, V25, P5359, DOI 10.1038/sj.onc.1209532; Rogakou EP, 2000, J BIOL CHEM, V275, P9390, DOI 10.1074/jbc.275.13.9390; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Sancar A, 2004, ANNU REV BIOCHEM, V73, P39, DOI 10.1146/annurev.biochem.73.011303.073723; Sansom OJ, 2005, ONCOGENE, V24, P8205, DOI 10.1038/sj.onc.1208956; Shibata H, 1997, SCIENCE, V278, P120, DOI 10.1126/science.278.5335.120; Soriano P, 1999, NAT GENET, V21, P70, DOI 10.1038/5007; Syljuasen RG, 2005, MOL CELL BIOL, V25, P3553, DOI 10.1128/MCB.25.9.3553-3562.2005; Takai H, 2000, GENE DEV, V14, P1439; Tse AN, 2007, CLIN CANCER RES, V13, P1955, DOI 10.1158/1078-0432.CCR-06-2793; Wang QZ, 1996, J NATL CANCER I, V88, P956, DOI 10.1093/jnci/88.14.956; Xiao Z, 2003, J BIOL CHEM, V278, P21767, DOI 10.1074/jbc.M300229200; Zachos G, 2003, EMBO J, V22, P713, DOI 10.1093/emboj/cdg060; Zaugg K, 2007, P NATL ACAD SCI USA, V104, P3805, DOI 10.1073/pnas.0611584104	29	32	32	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR	2009	28	11					1443	1453		10.1038/onc.2008.482	http://dx.doi.org/10.1038/onc.2008.482			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	421JE	19169280	Green Accepted			2022-12-17	WOS:000264354400005
J	Saharia, A; Stewart, SA				Saharia, A.; Stewart, S. A.			FEN1 contributes to telomere stability in ALT-positive tumor cells	ONCOGENE			English	Article						telomere; FEN1; genomic stability; ALT	REPLICATION FORK; DNA-REPLICATION; WRN HELICASE; COMPLEX; LENGTH; STRAND; MECHANISM; ENDS; STIMULATION; INHIBITION	Abrogation of telomere stability through loss-of-function mutations in telomere binding proteins contributes to genomic instability and cancer progression. Recently, Flap endonuclease 1 (FEN1) was shown to contribute to telomere stability in human cells that had not yet activated a telomere maintenance mechanism, suggesting that abrogation of FEN1 function influences the transformation process by compromising telomere stability and driving genomic instability. Here, we analyse the telomeres in human cancer cells following FEN1 depletion. We show that FEN1 is required for telomere stability in cells that rely on the alternative lengthening of telomere (ALT) mechanism. Indeed, FEN1 depletion resulted in telomere dysfunction, characterized by formation of telomere dysfunction-induced foci (TIFs) and end-to-end fusions in ALT-positive cells. In contrast, no telomere phenotype was observed in telomerase-positive cells on FEN1 depletion, suggesting that ongoing telomerase activity protected telomeres. In consonance with this, we found that expression of the catalytic component of telomerase (hTERT) but not an inactive allele rescued telomere dysfunction on FEN1 depletion in ALT cells. Our data suggest that mutations that arise in FEN1 affect telomere stability and genome fidelity by promoting telomere fusions and anaphase-bridge-breakage cycles, which further drive genome instability and thereby contribute to the transformation process.	[Stewart, S. A.] Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA; [Saharia, A.; Stewart, S. A.] Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	Stewart, SA (corresponding author), Washington Univ, Sch Med, Dept Cell Biol & Physiol & Med, Campus Box 8228,660 S Euclid Ave, St Louis, MO 63110 USA.	sheila.stewart@cellbiology.wustl.edu	Stewart, Sheila A/C-5213-2012		Sidney Kimmel Foundation for Cancer Research; Edward Mallinckrodt, Jr Foundation; Lucille P Markey Program	Sidney Kimmel Foundation for Cancer Research; Edward Mallinckrodt, Jr Foundation; Lucille P Markey Program	This work was supported by the Sidney Kimmel Foundation for Cancer Research and the Edward Mallinckrodt, Jr Foundation. AS was supported by the Lucille P Markey Program. SAS is a Sidney Kimmel Scholar. We are grateful to Yu Tao for helpwith statistical analyses and members of the Stewart Laboratory for valuable discussions.	Artandi SE, 2000, CURR OPIN GENET DEV, V10, P39, DOI 10.1016/S0959-437X(99)00047-7; Blasco MA, 2005, NAT REV GENET, V6, P611, DOI 10.1038/nrg1656; Branzei D, 2005, CURR OPIN CELL BIOL, V17, P568, DOI 10.1016/j.ceb.2005.09.003; Bryan TM, 1997, NAT MED, V3, P1271, DOI 10.1038/nm1197-1271; Crabbe L, 2004, SCIENCE, V306, P1951, DOI 10.1126/science.1103619; d'Adda di Fagagna F, 2003, NATURE, V426, P194, DOI [10.1038/nature02118, DOI 10.1038/NATURE02118]; de Lange T, 2005, GENE DEV, V19, P2100, DOI 10.1101/gad.1346005; Forstemann K, 2000, NUCLEIC ACIDS RES, V28, P2690, DOI 10.1093/nar/28.14.2690; Fouche N, 2006, NUCLEIC ACIDS RES, V34, P6044, DOI 10.1093/nar/gkl757; Gilson E, 2007, NAT REV MOL CELL BIO, V8, P825, DOI 10.1038/nrm2259; Grobelny JV, 2001, HUM MOL GENET, V10, P1953, DOI 10.1093/hmg/10.18.1953; Hahn WC, 1999, NAT MED, V5, P1164, DOI 10.1038/13495; Hemann MT, 2001, CELL, V107, P67, DOI 10.1016/S0092-8674(01)00504-9; Kikuchi K, 2005, MOL CELL BIOL, V25, P6948, DOI 10.1128/MCB.25.16.6948-6955.2005; Kucherlapati M, 2007, ONCOGENE, V26, P6297, DOI 10.1038/sj.onc.1210453; LI XY, 1995, J BIOL CHEM, V270, P22109, DOI 10.1074/jbc.270.38.22109; Liu D, 2004, J BIOL CHEM, V279, P51338, DOI 10.1074/jbc.M409293200; Londono-Vallejo JA, 2004, CANCER RES, V64, P2324, DOI 10.1158/0008-5472.CAN-03-4035; Marcand S, 1999, EMBO J, V18, P3509, DOI 10.1093/emboj/18.12.3509; Nabetani A, 2004, J BIOL CHEM, V279, P25849, DOI 10.1074/jbc.M312652200; Ohki R, 2004, NUCLEIC ACIDS RES, V32, P1627, DOI 10.1093/nar/gkh309; Ouellette MM, 2000, J BIOL CHEM, V275, P10072, DOI 10.1074/jbc.275.14.10072; Parenteau J, 2002, GENETICS, V162, P1583; Parenteau J, 1999, MOL CELL BIOL, V19, P4143; Perrem K, 2001, MOL CELL BIOL, V21, P3862, DOI 10.1128/MCB.21.12.3862-3875.2001; Prasad R, 2000, J BIOL CHEM, V275, P4460, DOI 10.1074/jbc.275.6.4460; Saharia A, 2008, CURR BIOL, V18, P496, DOI 10.1016/j.cub.2008.02.071; Sharma S, 2004, MOL BIOL CELL, V15, P734, DOI 10.1091/mbc.E03-08-0567; Stewart SA, 2003, NAT GENET, V33, P492, DOI 10.1038/ng1127; Stewart SA, 2002, P NATL ACAD SCI USA, V99, P12606, DOI 10.1073/pnas.182407599; Takai H, 2003, CURR BIOL, V13, P1549, DOI 10.1016/S0960-9822(03)00542-6; Teixeira MT, 2004, CELL, V117, P323, DOI 10.1016/S0092-8674(04)00334-4; Tishkoff DX, 1997, CELL, V88, P253, DOI 10.1016/S0092-8674(00)81846-2; Zheng L, 2005, EMBO REP, V6, P83, DOI 10.1038/sj.embor.7400313; Zheng L, 2007, NAT MED, V13, P812, DOI 10.1038/nm1599	35	32	34	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2009	28	8					1162	1167		10.1038/onc.2008.458	http://dx.doi.org/10.1038/onc.2008.458			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	412KE	19137021				2022-12-17	WOS:000263722900011
J	Chien, J; Narita, K; Rattan, R; Giri, S; Shridhar, R; Staub, J; Beleford, D; Lai, J; Roberts, LR; Molina, J; Kaufmann, SH; Prendergast, GC; Shridhar, V				Chien, J.; Narita, K.; Rattan, R.; Giri, S.; Shridhar, R.; Staub, J.; Beleford, D.; Lai, J.; Roberts, L. R.; Molina, J.; Kaufmann, S. H.; Prendergast, G. C.; Shridhar, V.			A role for candidate tumor-suppressor gene TCEAL7 in the regulation of c-Myc activity, cyclin D1 levels and cellular transformation	ONCOGENE			English	Article						TCEAL7; Myc; cyclin D1; tumor suppressor; transformation	OVARIAN-CARCINOMA CELLS; RNA-POLYMERASE-II; BURKITT-LYMPHOMA; CANCER CELLS; EARLY-STAGE; NETWORK; PROTEIN; FIDELITY; SCREEN; HTRA1	The pathophysiological mechanisms that drive the development and progression of epithelial ovarian cancer remain obscure. Recently, we identified TCEAL7 as a transcriptional regulatory protein often downregulated in epithelial ovarian cancer. However, the biological significance of such downregulation in cancer is not currently known. Here, we show that TCEAL7 is downregulated frequently in many human cancers and that in immortalized human ovarian epithelial cells this event promotes anchorage-independent cell growth. Mechanistic investigations revealed that TCEAL7 associates with cyclin D1 promoter containing Myc E-box sequence and transcriptionally represses cyclin D1 expression. Moreover, downregulation of TCEAL7 promotes DNA-binding activity of Myc-Max, and upregulates the promoter activity of c-Myc-target gene, ornithine decarboxylase (ODC), whereas enhanced expression of TCEAL7 inhibits Myc-induced promoter activity of ODC. Our findings suggest that TCEAL7 may restrict ovarian epithelial cell transformation by limiting Myc activity. These results also suggest a potential, alternative mechanism by which c-Myc activity may be deregulated in cancer by the downregulation of TCEAL7.	[Chien, J.; Rattan, R.; Staub, J.; Beleford, D.; Shridhar, V.] Mayo Clin, Coll Med, Div Expt Pathol, Rochester, MN USA; [Narita, K.] Univ Yamanashi, Fac Med, Dept Anat & Cell Biol, Chuo Yamanashi, Japan; [Giri, S.] Med Univ S Carolina, Children Res Inst, Dept Pediat, Charleston, SC 29425 USA; [Shridhar, R.] Wayne State Univ, Dept Radiat Oncol, Sch Med, Detroit, MI 48202 USA; [Lai, J.; Roberts, L. R.] Mayo Clin, Coll Med, Dept Gastroenterol & Hepatol, Rochester, MN USA; [Molina, J.] Mayo Clin, Coll Med, Dept Med Oncol, Rochester, MN USA; [Kaufmann, S. H.] Mayo Clin, Coll Med, Dept Oncol Res, Rochester, MN USA; [Prendergast, G. C.] Lankenau Inst Med Res, Wynnewood, PA USA	Mayo Clinic; University of Yamanashi; Medical University of South Carolina; Wayne State University; Mayo Clinic; Mayo Clinic; Mayo Clinic; Lankenau Medical Center; Lankenau Institute for Medical Research	Shridhar, V (corresponding author), Mayo Coll Med, Div Expt Pathol, 200 1st St SW,2-46 Stabile, Rochester, MN 55905 USA.	shridhar.vijayalakshmi@mayo.edu	Lai, Jinping/AAZ-6861-2021; Chien, Jeremy/AID-8939-2022; Seal, Sudipta/A-7698-2012; Narita, Keishi/E-3539-2010	Narita, Keishi/0000-0002-7602-8523; Roberts, Lewis/0000-0001-7885-8574; Kaufmann, Scott/0000-0002-4900-7145; Chien, Jeremy/0000-0003-4744-8374	Department of Defense OCRP [W81XWH-04-1-0085]; NATIONAL CANCER INSTITUTE [K12CA090628] Funding Source: NIH RePORTER	Department of Defense OCRP(United States Department of Defense); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This study was funded by Fraternal Order of Eagle to VS, by Department of Defense OCRP W81XWH-04-1-0085 to VS, and by Edith and Bernie Waterman Foundation and the Mayo Foundation to VS.	Baudino TA, 2001, MOL CELL BIOL, V21, P691, DOI 10.1128/MCB.21.3.691-702.2001; Bell DA, 2005, MODERN PATHOL, V18, pS19, DOI 10.1038/modpathol.3800306; Berns K, 2004, NATURE, V428, P431, DOI 10.1038/nature02371; Budhram-Mahadeo VS, 2006, EXPERT OPIN THER TAR, V10, P15, DOI 10.1517/14728222.10.1.15; Chien J, 1999, ONCOGENE, V18, P3376, DOI 10.1038/sj.onc.1202690; Chien J, 2005, ONCOGENE, V24, P5089, DOI 10.1038/sj.onc.1208700; Chien J, 2004, ONCOGENE, V23, P1636, DOI 10.1038/sj.onc.1207271; Chien J, 2006, J CLIN INVEST, V116, P1994, DOI 10.1172/JCI27698; Conover CA, 1998, EXP CELL RES, V238, P439, DOI 10.1006/excr.1997.3861; DALLAFAVERA R, 1982, P NATL ACAD SCI-BIOL, V79, P7824, DOI 10.1073/pnas.79.24.7824; Elliott K, 1999, ONCOGENE, V18, P3564, DOI 10.1038/sj.onc.1202670; Fernandez PC, 2003, GENE DEV, V17, P1115, DOI 10.1101/gad.1067003; Fukumoto M, 2006, PATHOL INT, V56, P233, DOI 10.1111/J.1440-1827.2006.01960.x; GILLETT C, 1994, CANCER RES, V54, P1812; Gomis RR, 2006, CANCER CELL, V10, P203, DOI 10.1016/j.ccr.2006.07.019; Grandori C, 2000, ANNU REV CELL DEV BI, V16, P653, DOI 10.1146/annurev.cellbio.16.1.653; Hall M, 1996, ADV CANCER RES, V68, P67, DOI 10.1016/S0065-230X(08)60352-8; Jeon C, 1996, P NATL ACAD SCI USA, V93, P13677, DOI 10.1073/pnas.93.24.13677; Kalli KR, 2002, ENDOCRINOLOGY, V143, P3259, DOI 10.1210/en.2001-211408; Lamb J, 2003, CELL, V114, P323, DOI 10.1016/S0092-8674(03)00570-1; Massague J, 2005, GENE DEV, V19, P2783, DOI 10.1101/gad.1350705; Nesbit CE, 1999, ONCOGENE, V18, P3004, DOI 10.1038/sj.onc.1202746; Nilsson JA, 2005, CANCER CELL, V7, P433, DOI 10.1016/j.ccr.2005.03.036; Orian A, 2003, GENE DEV, V17, P1101, DOI 10.1101/gad.1066903; Oster SK, 2002, ADV CANCER RES, V84, P81, DOI 10.1016/S0065-230X(02)84004-0; Shridhar V, 2002, CANCER RES, V62, P262; Shridhar V, 2001, CANCER RES, V61, P5895; Staub J, 2007, ONCOGENE, V26, P4969, DOI 10.1038/sj.onc.1210300; TAUB R, 1982, P NATL ACAD SCI-BIOL, V79, P7837, DOI 10.1073/pnas.79.24.7837; Thomas MJ, 1998, CELL, V93, P627, DOI 10.1016/S0092-8674(00)81191-5; Westbrook TF, 2005, CELL, V121, P837, DOI 10.1016/j.cell.2005.03.033; YEH CH, 1995, J BIOL CHEM, V270, P15815, DOI 10.1074/jbc.270.26.15815	32	32	34	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	2008	27	58					7223	7234		10.1038/onc.2008.360	http://dx.doi.org/10.1038/onc.2008.360			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	382FI	18806825	Green Accepted			2022-12-17	WOS:000261590300001
J	Taghavi, P; Verhoeven, E; Jacobs, JJL; Lambooij, JP; Stortelers, C; Tanger, E; Moolenaar, WH; van Lohuizen, M				Taghavi, P.; Verhoeven, E.; Jacobs, J. J. L.; Lambooij, J. P.; Stortelers, C.; Tanger, E.; Moolenaar, W. H.; van Lohuizen, M.			In vitro genetic screen identifies a cooperative role for LPA signaling and c-Myc in cell transformation	ONCOGENE			English	Article						LPA; transformation; screen	PROTEIN-COUPLED RECEPTOR; LYSOPHOSPHATIDIC ACID; TUMOR-SUPPRESSOR; EMBRYO FIBROBLASTS; OVARIAN-CANCER; GROWTH; RAS; KINASE; ACTIVATION; EXPRESSION	c-Myc drives uncontrolled cell proliferation in various human cancers. However, in mouse embryo fibroblasts (MEFs), c-Myc also induces apoptosis by activating the p19Arf tumor suppressor pathway. Tbx2, a transcriptional repressor of p19Arf, can collaborate with c-Myc by suppressing apoptosis. MEFs overexpressing c-Myc and Tbx2 are immortal but not transformed. We have performed an unbiased genetic screen, which identified 12 oncogenes that collaborate with c-Myc and Tbx2 to transform MEFs in vitro. One of them encodes the LPA2 receptor for the lipid growth factor lysophosphatidic acid (LPA). We find that LPA1 and LPA4, but not LPA3, can reproduce the transforming effect of LPA2. Using pharmacological inhibitors, we show that the in vitro cell transformation induced by LPA receptors is dependent on the Gi-linked ERK and PI3K signaling pathways. The transforming ability of LPA1, LPA2 and LPA4 was confirmed by tumor formation assays in vivo and correlated with prolonged ERK1/2 activation in response to LPA. Our results reveal a direct role for LPA receptor signaling in cell transformation and tumorigenesis in conjunction with c-Myc and reduced p19Arf expression. Oncogene (2008) 27, 6806-6816; doi: 10.1038/onc.2008.294;published online 1 September 2008	[Taghavi, P.; Verhoeven, E.; Jacobs, J. J. L.; Lambooij, J. P.; Tanger, E.; van Lohuizen, M.] Netherlands Canc Inst, Div Mol Genet, NL-1066 CX Amsterdam, Netherlands; [Stortelers, C.; Moolenaar, W. H.] Netherlands Canc Inst, Div Cellular Biochem, NL-1066 CX Amsterdam, Netherlands	Netherlands Cancer Institute; Netherlands Cancer Institute	van Lohuizen, M (corresponding author), Netherlands Canc Inst, Div Mol Genet, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.	m.v.lohuizen@nki.nl	Jacobs, Jacqueline/ABA-5652-2020	Jacobs, Jacqueline/0000-0002-7704-4795	Dutch Cancer Society [NKI 2003-2935, NKI 2003-2964]	Dutch Cancer Society(KWF Kankerbestrijding)	We thank Laurens A van Meeteren for LPA receptor plasmids and advice, Wendy Lagcher for technical assistance and Nullin Divecha and Daniel S Peeper for helpful discussions. This study was supported by grants from the Dutch Cancer Society, NKI 2003-2935 (to MvL) and NKI 2003-2964 (to WHM).	Adhikary S, 2005, NAT REV MOL CELL BIO, V6, P635, DOI 10.1038/nrm1703; BENITO M, 1993, GROWTH REGULAT, V3, P172; Boucharaba A, 2004, J CLIN INVEST, V114, P1714, DOI 10.1172/JCI200422123; BOWE MA, 1995, ANNU REV NEUROSCI, V18, P443; Datta A, 2004, J BIOL CHEM, V279, P36698, DOI 10.1074/jbc.M312305200; Ding ZY, 2006, P NATL ACAD SCI USA, V103, P15014, DOI 10.1073/pnas.0606917103; Drayton S, 2003, CANCER CELL, V4, P301, DOI 10.1016/S1535-6108(03)00242-3; Erickson JR, 2001, PROSTAG OTH LIPID M, V64, P63, DOI 10.1016/S0090-6980(01)00100-9; Fu L, 2007, CANCER-AM CANCER SOC, V110, P2672, DOI 10.1002/cncr.23110; Gil J, 2006, NAT REV MOL CELL BIO, V7, P667, DOI 10.1038/nrm1987; HEIDECKER G, 1990, MOL CELL BIOL, V10, P2503, DOI 10.1128/MCB.10.6.2503; Honda K, 1998, J CELL BIOL, V140, P1383, DOI 10.1083/jcb.140.6.1383; Honda K, 2005, GASTROENTEROLOGY, V128, P51, DOI 10.1053/j.gastro.2004.10.004; Huang MC, 2004, ONCOGENE, V23, P122, DOI 10.1038/sj.onc.1206986; Ishii I, 2000, MOL PHARMACOL, V58, P895, DOI 10.1124/mol.58.5.895; Ishii I, 2004, ANNU REV BIOCHEM, V73, P321, DOI 10.1146/annurev.biochem.73.011303.073731; Jacobs JJL, 2000, NAT GENET, V26, P291, DOI 10.1038/81583; Jacobs JJL, 1999, GENE DEV, V13, P2678, DOI 10.1101/gad.13.20.2678; Jaffe AB, 2005, ANNU REV CELL DEV BI, V21, P247, DOI 10.1146/annurev.cellbio.21.020604.150721; Jones SM, 2001, NAT CELL BIOL, V3, P165, DOI 10.1038/35055073; KhosraviFar R, 1996, MOL CELL BIOL, V16, P3923; Koh EY, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/gnf142; Kostenko EV, 2005, J BIOL CHEM, V280, P2807, DOI 10.1074/jbc.M411139200; Krimpenfort P, 2007, NATURE, V448, P943, DOI 10.1038/nature06084; LAND H, 1986, MOL CELL BIOL, V6, P1917, DOI 10.1128/MCB.6.6.1917; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; Lee CW, 2007, J BIOL CHEM, V282, P4310, DOI 10.1074/jbc.M610826200; Lee CW, 2006, J BIOL CHEM, V281, P23589, DOI 10.1074/jbc.M603670200; Lee Z, 2006, CANCER RES, V66, P2740, DOI 10.1158/0008-5472.CAN-05-2947; Lingbeek ME, 2002, J BIOL CHEM, V277, P26120, DOI 10.1074/jbc.M200403200; Mills GB, 2003, NAT REV CANCER, V3, P582, DOI 10.1038/nrc1143; Moolenaar WH, 2004, BIOESSAYS, V26, P870, DOI 10.1002/bies.20081; Noguchi K, 2003, J BIOL CHEM, V278, P25600, DOI 10.1074/jbc.M302648200; O'Regan L, 2007, CELL DIV, V2, DOI 10.1186/1747-1028-2-25; Pasternack SM, 2008, NAT GENET, V40, P329, DOI 10.1038/ng.84; Pietras K, 2003, CANCER CELL, V3, P439, DOI 10.1016/S1535-6108(03)00089-8; Prince S, 2004, CANCER RES, V64, P1669, DOI 10.1158/0008-5472.CAN-03-3286; Qi Y, 2004, NATURE, V431, P712, DOI 10.1038/nature02958; Ramjaun AR, 2007, CELL CYCLE, V6, P2902, DOI 10.4161/cc.6.23.4996; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; Seoane J, 2002, NATURE, V419, P729, DOI 10.1038/nature01119; Sherr CJ, 2006, NAT REV CANCER, V6, P663, DOI 10.1038/nrc1954; Sherr CJ, 2004, CELL, V116, P235, DOI 10.1016/S0092-8674(03)01075-4; Shields JM, 2000, TRENDS CELL BIOL, V10, P147, DOI 10.1016/S0962-8924(00)01740-2; Toyoshima M, 2007, CANCER RES, V67, P5162, DOI 10.1158/0008-5472.CAN-06-2756; van Meeteren LA, 2007, PROG LIPID RES, V46, P145, DOI 10.1016/j.plipres.2007.02.001; Ye XQ, 2005, NATURE, V435, P104, DOI 10.1038/nature03505; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424; Zuber J, 2000, NAT GENET, V24, P144, DOI 10.1038/72799	49	32	36	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 20	2008	27	54					6806	6816		10.1038/onc.2008.294	http://dx.doi.org/10.1038/onc.2008.294			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	375IS	18762810				2022-12-17	WOS:000261108000002
J	Hanashiro, K; Kanai, M; Geng, Y; Sicinski, P; Fukasawa, K				Hanashiro, K.; Kanai, M.; Geng, Y.; Sicinski, P.; Fukasawa, K.			Roles of cyclins A and E in induction of centrosome amplification in p53-compromised cells	ONCOGENE			English	Article						centrosome; cyclin A; cyclin E; CDK2; p53; centrosome amplification	CHROMOSOME INSTABILITY; E OVEREXPRESSION; DNA-SYNTHESIS; P53 MUTATION; CANCER; DUPLICATION; HYPERAMPLIFICATION; ACTIVATION; EXPRESSION; EXPOSURE	Abnormal amplification of centrosomes, which occurs frequently in cancers, leads to high frequencies of mitotic defect and chromosome segregation error, profoundly affecting the rate of tumor progression. Centrosome amplification results primarily from overduplication of centrosomes, and p53 is involved in the regulation of centrosome duplication partly through controlling the activity of cyclin-dependent kinase (CDK) 2-cyclin E, a kinase complex critical for the initiation of centrosome duplication. Thus, loss or mutational inactivation of p53 leads to an increased frequency of centrosome amplification. Moreover, the status of cyclin E greatly influences the frequency of centrosome amplification in cells lacking functional p53. Here, we dissected the roles of CDK2-associating cyclins, namely cyclins E and A, in centrosome amplification in the p53-negative cells. We found that loss of cyclin E was readily compensated by cyclin A for triggering the initiation of centrosome duplication, and thus the centrosome duplication kinetics was not significantly altered in cyclin E-deficient cells. It has been shown that cells lacking functional p53, when arrested in either early S-phase or late G(2) phase, continue to reduplicate centrosomes, resulting in centrosome amplification. In cells arrested in early S phase, cyclin E, but not cyclin A, is important in centrosome amplification, whereas in the absence of cyclin E, cyclin A is important for centrosome amplification. In late G(2)-arrested cells, cyclin A is important in centrosome amplification irrespective of the cyclin E status. These findings advance our understandings of the mechanisms underlying the numeral abnormality of centrosomes and consequential genomic instability associated with loss of p53 function and aberrant expression of cyclins E and A in cancer cells.	[Hanashiro, K.; Kanai, M.; Fukasawa, K.] H Lee Moffitt Canc Ctr & Res Inst, Mol Oncol Program, Tampa, FL 33612 USA; [Geng, Y.; Sicinski, P.] Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA; [Geng, Y.; Sicinski, P.] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA	H Lee Moffitt Cancer Center & Research Institute; Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School	Fukasawa, K (corresponding author), H Lee Moffitt Canc Ctr & Res Inst, Mol Oncol Program, 12902 Magnolia Dr,SRB-2, Tampa, FL 33612 USA.	kenji.fukasawa@mof.tt.org	Kanai, Motomu/J-6807-2016	Kanai, Motomu/0000-0003-1977-7648	National Institutes of Health, USA [CA90522, CA108950]; NATIONAL CANCER INSTITUTE [R01CA090522, R01CA108950] Funding Source: NIH RePORTER	National Institutes of Health, USA(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank C French, A Wilson and M Crowe for technical assistance, and Drs Z Andrysik and S Schwemberger for FACS analysis. This research is supported by the grants from National Institutes of Health, USA (CA90522 to KF and CA108950 to PS).	BALCZON R, 1995, J CELL BIOL, V130, P105, DOI 10.1083/jcb.130.1.105; Bennett RA, 2004, ONCOGENE, V23, P6823, DOI 10.1038/sj.onc.1207561; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Carroll PE, 1999, ONCOGENE, V18, P1935, DOI 10.1038/sj.onc.1202515; Coverley D, 2002, NAT CELL BIOL, V4, P523, DOI 10.1038/ncb813; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; Desdouets C, 1995, Prog Cell Cycle Res, V1, P115; Dodson H, 2004, EMBO J, V23, P3864, DOI 10.1038/sj.emboj.7600393; Fukasawa K, 2005, CANCER LETT, V230, P6, DOI 10.1016/j.canlet.2004.12.028; Fukasawa K, 1996, SCIENCE, V271, P1744, DOI 10.1126/science.271.5256.1744; Fukasawa K, 2007, NAT REV CANCER, V7, P911, DOI 10.1038/nrc2249; Geng Y, 2003, CELL, V114, P431, DOI 10.1016/S0092-8674(03)00645-7; Hinchcliffe EH, 1999, SCIENCE, V283, P851, DOI 10.1126/science.283.5403.851; HOFFMAN BD, 1991, CYTOMETRY, V12, P26, DOI 10.1002/cyto.990120105; Horn HF, 2007, ONCOGENE, V26, P1306, DOI 10.1038/sj.onc.1210263; JOSHI HC, 1994, CURR OPIN CELL BIOL, V6, P55, DOI 10.1016/0955-0674(94)90116-3; Kastan MB, 2004, NATURE, V432, P316, DOI 10.1038/nature03097; Kawamura K, 2006, CANCER SCI, V97, P252, DOI 10.1111/j.1349-7006.2006.00168.x; Kawamura K, 2004, CANCER RES, V64, P4800, DOI 10.1158/0008-5472.CAN-03-3908; Lacey KR, 1999, P NATL ACAD SCI USA, V96, P2817, DOI 10.1073/pnas.96.6.2817; Mussman JG, 2000, ONCOGENE, V19, P1635, DOI 10.1038/sj.onc.1203460; Ossovskaya VS, 1996, P NATL ACAD SCI USA, V93, P10309, DOI 10.1073/pnas.93.19.10309; Pihan GA, 1998, CANCER RES, V58, P3974; Sweeney C, 1996, DEVELOPMENT, V122, P53; Tarapore P, 2001, ONCOGENE, V20, P3173, DOI 10.1038/sj.onc.1204424; Taylor WR, 2001, ONCOGENE, V20, P1803, DOI 10.1038/sj.onc.1204252; Tokuyama Y, 2001, J BIOL CHEM, V276, P21529, DOI 10.1074/jbc.M100014200; Wang XJ, 1998, MOL CARCINOGEN, V23, P185, DOI 10.1002/(SICI)1098-2744(199811)23:3<185::AID-MC7>3.0.CO;2-5; Wong C, 2003, NAT CELL BIOL, V5, P539, DOI 10.1038/ncb993	29	32	33	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 11	2008	27	40					5288	5302		10.1038/onc.2008.161	http://dx.doi.org/10.1038/onc.2008.161			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	346UW	18490919	Green Accepted			2022-12-17	WOS:000259096100002
J	Costoya, JA; Hobbs, RM; Pandolfi, PP				Costoya, J. A.; Hobbs, R. M.; Pandolfi, P. P.			Cyclin-dependent kinase antagonizes promyelocytic leukemia zinc-finger through phosphorylation	ONCOGENE			English	Article						POZ and Kruppel-type zinc finger domains; transcriptional repression; cell cycle; cyclin-dependent kinases; PEST domains; ubiquitination	HEMATOPOIETIC STEM-CELLS; TRANSCRIPTIONAL REPRESSION; PROTEIN PLZF; DNA-BINDING; GERM-CELLS; EXPRESSION; GENE; PROLIFERATION; GROWTH	Acute promyelocytic leukemia is associated with chromosomal translocations that involve the RAR alpha gene and several distinct loci producing a variety of fusion proteins. One such fusion partner is promyelocytic leukemia zinc finger gene ( PLZF), a member of the POK ( POZ and Kruppel) family of transcriptional repressors that is a key developmental regulator, stem cell maintenance factor and tumor suppressor. Overexpression of PLZF has been shown to induce cell cycle arrest at the G(1) to S transition and repress the expression of key pro-proliferative genes such as CCNA2 and MYC. However, given this data suggesting an important growth inhibitory role for PLZF, relatively little is known regarding regulation of its activity. Here we show that the main cyclin-dependent kinase involved at the G1 to S transition ( CDK2) phosphorylates PLZF at two consensus sites found within PEST domains present in the hinge region of the protein. This phosphorylation triggers the ubiquitination and subsequent degradation of PLZF, which impairs PLZF transcriptional repression ability and antagonizes its growth inhibitory effects. This critical mechanism of PLZF regulation may thus be relevant for cell cycle progression during the development and the pathogenesis of human cancer.	[Costoya, J. A.; Hobbs, R. M.; Pandolfi, P. P.] Mem Sloan Kettering Canc Ctr, Dept Pathol, Sloan Kettering Inst, Canc Biol & Genet Program, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center	Pandolfi, PP (corresponding author), Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Canc Genet Program, NRB-1036E,330 Brookline Ave, Boston, MA 02215 USA.	ppandolf@bidmc.harvard.edu	Costoya, Jose A./B-2718-2009; Hobbs, Robin/I-2577-2014	Costoya, Jose A./0000-0003-3691-6419; Hobbs, Robin/0000-0002-3853-2614	NCI NIH HHS [CA-71692] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA071692, R37CA071692] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Barna M, 2002, DEV CELL, V3, P499, DOI 10.1016/S1534-5807(02)00289-7; Barna M, 2000, NAT GENET, V25, P166, DOI 10.1038/76014; BONIFACINO JS, 2000, CURRENT PROTOCOLS CE; BRISSETTE JL, 1991, MOL CELL BIOL, V11, P5364, DOI 10.1128/MCB.11.10.5364; Buaas FW, 2004, NAT GENET, V36, P647, DOI 10.1038/ng1366; Chao TT, 2007, BIOCHEM BIOPH RES CO, V358, P475, DOI 10.1016/j.bbrc.2007.04.157; CHEN Z, 1993, EMBO J, V12, P1161, DOI 10.1002/j.1460-2075.1993.tb05757.x; COOK M, 1995, P NATL ACAD SCI USA, V92, P2249, DOI 10.1073/pnas.92.6.2249; Costoya JA, 2004, NAT GENET, V36, P653, DOI 10.1038/ng1367; Costoya JA, 2001, CURR OPIN HEMATOL, V8, P212, DOI 10.1097/00062752-200107000-00006; Deed RW, 1997, MOL CELL BIOL, V17, P6815, DOI 10.1128/MCB.17.12.6815; Filipponi D, 2007, MOL CELL BIOL, V27, P6770, DOI 10.1128/MCB.00479-07; Guidez F, 2005, MOL CELL BIOL, V25, P5552, DOI 10.1128/MCB.25.13.5552-5566.2005; Hock H, 2004, NATURE, V431, P1002, DOI 10.1038/nature02994; Johnson TK, 1999, J BIOL CHEM, V274, P36741, DOI 10.1074/jbc.274.51.36741; Kang SI, 2003, J BIOL CHEM, V278, P51479, DOI 10.1074/jbc.M309237200; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; Li JY, 1997, J BIOL CHEM, V272, P22447, DOI 10.1074/jbc.272.36.22447; Malumbres M, 2001, NAT REV CANCER, V1, P222, DOI 10.1038/35106065; Nanba D, 2003, J CELL BIOL, V163, P489, DOI 10.1083/jcb.200303017; Niu HF, 1998, GENE DEV, V12, P1953, DOI 10.1101/gad.12.13.1953; Piazza F, 2004, MOL CELL BIOL, V24, P10456, DOI 10.1128/MCB.24.23.10456-10469.2004; Rechsteiner M, 1996, TRENDS BIOCHEM SCI, V21, P267, DOI 10.1016/S0968-0004(96)10031-1; REID A, 1995, BLOOD, V86, P4544, DOI 10.1182/blood.V86.12.4544.bloodjournal86124544; Rogatsky I, 1999, J BIOL CHEM, V274, P22296, DOI 10.1074/jbc.274.32.22296; Senbonmatsu T, 2003, EMBO J, V22, P6471, DOI 10.1093/emboj/cdg637; Shaknovich R, 1998, MOL CELL BIOL, V18, P5533, DOI 10.1128/MCB.18.9.5533; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Ubersax JA, 2007, NAT REV MOL CELL BIO, V8, P530, DOI 10.1038/nrm2203; Yeyati PL, 1999, ONCOGENE, V18, P925, DOI 10.1038/sj.onc.1202375; Zhang JW, 2006, NATURE, V441, P518, DOI 10.1038/nature04747	31	32	32	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 19	2008	27	27					3789	3796		10.1038/onc.2008.7	http://dx.doi.org/10.1038/onc.2008.7			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	315UC	18246121				2022-12-17	WOS:000256904700003
J	Tucker, LA; Zhang, Q; Sheppard, GS; Lou, P; Jiang, F; McKeegan, E; Lesniewski, R; Davidsen, SK; Bell, RL; Wang, J				Tucker, L. A.; Zhang, Q.; Sheppard, G. S.; Lou, P.; Jiang, F.; McKeegan, E.; Lesniewski, R.; Davidsen, S. K.; Bell, R. L.; Wang, J.			Ectopic expression of methionine aminopeptidase-2 causes cell transformation and stimulates proliferation	ONCOGENE			English	Article						MetAP2; transformation; proliferation; IHC	ANGIOGENESIS INHIBITOR; CLINICAL DEVELOPMENT; TNP-470 AGM-1470; GROWTH ARREST; AGENT TNP-470; TUMOR-GROWTH; FUMAGILLIN; PROTEIN; TARGET; CANCER	Methionine aminopeptidase-2 (MetAP2) processes N-terminal methionine from nascent cellular proteins. Inhibition of MetAP2 has been shown to block angiogenesis and suppress tumor growth in preclinical tumor models. However, the biological role of MetAP2 in cancer is not well understood. We examined the effect of three distinct chemical classes of MetAP2 inhibitors on the growth of a panel of human cancer cells in vitro. All MetAP2 inhibitors caused inhibition of tumor cell growth in both anchorage-dependent and, particularly, in anchorage-independent manner. These data prompted us to examine the possible roles of MetAP2 in cancers. Ectopic expression of MetAP2 in NIH-3T3 cells caused transformation, evidenced by the formation of foci in monolayer culture and growth of large colonies in soft agar. Overexpression of MetAP2 in an immortalized bronchial epithelial cell line NL20 accelerated growth. These phenotypes induced by the overexpression of MetAP2 were reversed by the treatment with MetAP2 inhibitors, indicating that the catalytic function of MetAP2 was essential. Accordingly, overexpression of a catalytically inactive MetAP2 resulted in growth retardation of HT1080 tumor cells, suggesting a dominant-negative role of the inactive MetAP2 mutant. Finally, we analysed the expression of MetAP2 in patient cancer samples by immunohistochemistry. Moderate-to-high staining was identified in the majority of breast, colon, lung, ovarian and prostate carcinomas examined. These data suggest that MetAP2 plays an important role in tumor cell growth and may contribute to tumorigenesis.	[Tucker, L. A.; Zhang, Q.; Sheppard, G. S.; Lou, P.; Jiang, F.; McKeegan, E.; Lesniewski, R.; Davidsen, S. K.; Bell, R. L.; Wang, J.] Abbott Labs, GPRD, Canc Res, Abbott Pk, IL 60064 USA	Abbott Laboratories	Wang, J (corresponding author), Abbott Labs, GPRD, Canc Res, R47A,AP9-2124,100 Abbott Pk Rd, Abbott Pk, IL 60064 USA.	jieyi.wang@abbott.com						Arner ESJ, 2006, SEMIN CANCER BIOL, V16, P420, DOI 10.1016/j.semcancer.2006.10.009; Bernier SG, 2005, J CELL BIOCHEM, V95, P1191, DOI 10.1002/jcb.20493; Bradshaw RA, 2002, ESSAYS BIOCHEM, V38, P65, DOI 10.1042/bse0380065; Bradshaw RA, 1998, TRENDS BIOCHEM SCI, V23, P263, DOI 10.1016/S0968-0004(98)01227-4; Castronovo V, 1996, EUR J CANCER, V32A, P2520, DOI 10.1016/S0959-8049(96)00388-7; Catalano A, 2001, AM J PATHOL, V159, P721, DOI 10.1016/S0002-9440(10)61743-9; Datta B, 2000, BIOCHIMIE, V82, P95, DOI 10.1016/S0300-9084(00)00383-7; Datta B, 1999, EXP CELL RES, V246, P376, DOI 10.1006/excr.1998.4313; Griffith EC, 1998, P NATL ACAD SCI USA, V95, P15183, DOI 10.1073/pnas.95.26.15183; Griffith EC, 1997, CHEM BIOL, V4, P461, DOI 10.1016/S1074-5521(97)90198-8; Hannig G, 2006, INT J ONCOL, V28, P955; Hashimoto S, 2004, P NATL ACAD SCI USA, V101, P6647, DOI 10.1073/pnas.0401753101; Homsi J, 2007, EXPERT OPIN THER TAR, V11, P91, DOI 10.1517/14728222.11.1.91; INGBER D, 1990, NATURE, V348, P555, DOI 10.1038/348555a0; Kanno T, 2002, LAB INVEST, V82, P893, DOI 10.1097/01.LAB.0000020419.25365.C4; Kruger EA, 2000, EXPERT OPIN INV DRUG, V9, P1383, DOI 10.1517/13543784.9.6.1383; KUSAKA M, 1994, BRIT J CANCER, V69, P212, DOI 10.1038/bjc.1994.41; Kwon YT, 2002, SCIENCE, V297, P96, DOI 10.1126/science.1069531; Leszczyniecka M, 2006, ONCOGENE, V25, P3471, DOI 10.1038/sj.onc.1209383; Liu SP, 1998, SCIENCE, V282, P1324, DOI 10.1126/science.282.5392.1324; Lowther WT, 2000, BBA-PROTEIN STRUCT M, V1477, P157, DOI 10.1016/S0167-4838(99)00271-X; Menssen A, 2002, P NATL ACAD SCI USA, V99, P6274, DOI 10.1073/pnas.082005599; Mieulet V, 2007, AM J PHYSIOL-CELL PH, V293, pC712, DOI 10.1152/ajpcell.00499.2006; Resh MD, 2004, SUB CELL BIOCHEM, V37, P217; Selvakumar P, 2004, CLIN CANCER RES, V10, P2771, DOI 10.1158/1078-0432.CCR-03-0218; Sheppard GS, 2006, J MED CHEM, V49, P3832, DOI 10.1021/jm0601001; Sin N, 1997, P NATL ACAD SCI USA, V94, P6099, DOI 10.1073/pnas.94.12.6099; Varshavsky A, 2005, TRENDS BIOCHEM SCI, V30, P283, DOI 10.1016/j.tibs.2005.04.005; Vetro JA, 2005, J CELL BIOCHEM, V94, P656, DOI 10.1002/jcb.20285; Wang JY, 2000, J CELL BIOCHEM, V77, P465, DOI 10.1002/(SICI)1097-4644(20000601)77:3<465::AID-JCB11>3.3.CO;2-D; Wang JY, 2003, CANCER RES, V63, P7861; Wang JY, 2003, BIOCHEMISTRY-US, V42, P5035, DOI 10.1021/bi020670c; WU SY, 1993, J BIOL CHEM, V268, P10796; Yang G, 2001, BIOCHEMISTRY-US, V40, P10645, DOI 10.1021/bi010806r; Yeh JRJ, 2006, P NATL ACAD SCI USA, V103, P10379, DOI 10.1073/pnas.0511313103; Yeh JRJ, 2000, P NATL ACAD SCI USA, V97, P12782, DOI 10.1073/pnas.97.23.12782; Zhang Y, 2000, P NATL ACAD SCI USA, V97, P6427, DOI 10.1073/pnas.97.12.6427	37	32	37	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN	2008	27	28					3967	3976		10.1038/onc.2008.14	http://dx.doi.org/10.1038/onc.2008.14			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	318JZ	18264137				2022-12-17	WOS:000257089000008
J	Fu, YN; Yeh, CL; Cheng, HY; Yang, CH; Tsai, SF; Huang, SF; Chen, YR				Fu, Y-N; Yeh, C-L; Cheng, Hh-Y; Yang, C-H; Tsai, S-F; Huang, S-F; Chen, Y-R			EGFR mutants found in non-small cell lung cancer show different levels of sensitivity to suppression of Src: implications in targeting therapy	ONCOGENE			English	Article						EGFR; mutation; src; inhibitor; tyrosine phosphorylation	GROWTH-FACTOR-RECEPTOR; TYROSINE KINASE INHIBITOR; C-SRC; ACQUIRED-RESISTANCE; GEFITINIB TREATMENT; MUTATIONS; DOMAIN; ACTIVATION; PATTERNS; COMPLEX	Mutations in epidermal growth factor receptor (EGFR) kinase domain associate with clinical responses to EGFR inhibitors and are frequently observed in non-small cell lung cancer (NSCLC) patients in East Asian populations. Clinically identified EGFR mutations cause constitutive receptor activation. The activating mechanisms were unclear but appeared to be different among EGFR mutants. We found that EGFR mutants had different sensitivity to an Src inhibitor PP2. S768I and L861Q mutants were less sensitive to Src suppression than others. Mutation at tyrosine 869 (845) residue, an Src phosphorylation site, decreased the phosphorylation levels of wild-type EGFR and other mutants, but not that of S768I and L861Q mutants, suggesting that S768I and L861Q mutants became Src independent for their activation and biological functions. In contrast, cells expressing EGFR-L858R or exon 19 deletion mutants were more sensitive to PP2 than cells expressing wild-type EGFR. Interestingly, EGFR with exon 19-deletion/T790M double mutations, which was resistant to gefitinib, remained sensitive to PP2. Taken together, our data indicate that Src inhibitors might be effective in treating NSCLC harboring specific types of EGFR mutations.	[Fu, Y-N; Yeh, C-L; Cheng, Hh-Y; Yang, C-H; Tsai, S-F; Huang, S-F; Chen, Y-R] Natl Hlth Res Inst, Div Mol Genom Med, Zhunan Town 350, Miaoli Cty, Taiwan; [Tsai, S-F] Natl Yang Ming Univ, Inst Genet Genome Res Ctr, Taipei 112, Taiwan; [Huang, S-F] Chang Gung Mem Hosp, Dept Pathol, Taipei 10591, Taiwan	National Health Research Institutes - Taiwan; National Yang Ming Chiao Tung University; Chang Gung Memorial Hospital	Chen, YR (corresponding author), Natl Hlth Res Inst, Div Mol Genom Med, 35 Keyan Rd, Zhunan Town 350, Miaoli Cty, Taiwan.	yrchen@nhri.org.tw	Chen, Yi-Rong/CAH-7991-2022; Chen, Yi-Rong/CAF-2186-2022; Tsai, Shih-Feng/E-3997-2010; Chen, Yi-Rong/E-3991-2010; Huang, Shiu-Feng Kathy/E-3977-2010	Chen, Yi-Rong/0000-0002-4307-3002; Chen, Yi-Rong/0000-0002-4307-3002; Chen, Yi-Rong/0000-0002-4307-3002; 				Biscardi JS, 1999, J BIOL CHEM, V274, P8335, DOI 10.1074/jbc.274.12.8335; Biscardi JS, 2000, BREAST CANCER RES, V2, P203, DOI 10.1186/bcr55; Burgess AW, 2003, MOL CELL, V12, P541, DOI 10.1016/S1097-2765(03)00350-2; Chen YR, 2006, ONCOGENE, V25, P1205, DOI 10.1038/sj.onc.1209159; Chou TY, 2005, CLIN CANCER RES, V11, P3750, DOI 10.1158/1078-0432.CCR-04-1981; Citri A, 2006, NAT REV MOL CELL BIO, V7, P505, DOI 10.1038/nrm1962; Gazdar AF, 2004, TRENDS MOL MED, V10, P481, DOI 10.1016/j.molmed.2004.08.008; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Herbst RS, 2003, CLIN CANCER RES, V9, P5813; Hsieh MH, 2006, LUNG CANCER-J IASLC, V53, P311, DOI 10.1016/j.lungcan.2006.06.005; Huang SF, 2004, CLIN CANCER RES, V10, P8195, DOI 10.1158/1078-0432.CCR-04-1245; Ishizawar R, 2004, CANCER CELL, V6, P209, DOI 10.1016/j.ccr.2004.09.001; Kobayashi S, 2005, NEW ENGL J MED, V352, P786, DOI 10.1056/NEJMoa044238; Kosaka T, 2004, CANCER RES, V64, P8919, DOI 10.1158/0008-5472.CAN-04-2818; Kwak EL, 2005, P NATL ACAD SCI USA, V102, P7665, DOI 10.1073/pnas.0502860102; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Nakagawa K, 2003, ANN ONCOL, V14, P922, DOI 10.1093/annonc/mdg250; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Pao W, 2005, PLOS MED, V2, P225, DOI 10.1371/journal.pmed.0020073; Pao W, 2004, P NATL ACAD SCI USA, V101, P13306, DOI 10.1073/pnas.0405220101; Shigematsu H, 2005, CANCER RES, V65, P1642, DOI 10.1158/0008-5472.CAN-04-4235; Song LX, 2006, CANCER RES, V66, P5542, DOI 10.1158/0008-5472.CAN-05-4620; Stamos J, 2002, J BIOL CHEM, V277, P46265, DOI 10.1074/jbc.M207135200; STOVER DR, 1995, J BIOL CHEM, V270, P15591, DOI 10.1074/jbc.270.26.15591; Zhang J, 2007, AM J PATHOL, V170, P366, DOI 10.2353/ajpath.2007.060706; Zhang XW, 2006, CELL, V125, P1137, DOI 10.1016/j.cell.2006.05.013	26	32	34	2	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 7	2008	27	7					957	965		10.1038/sj.onc.1210684	http://dx.doi.org/10.1038/sj.onc.1210684			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	259NP	17653080				2022-12-17	WOS:000252946300007
J	Bhattacharyya, R; Noch, EK; Khalili, K				Bhattacharyya, R.; Noch, E. K.; Khalili, K.			A novel role of Rac1 GTPase in JCV T-antigen-mediated beta-catenin stabilization	ONCOGENE			English	Article						beta-catenin; T-antigen; JC virus; Rho; Wnt pathway; medulloblastoma	CELL-ADHESION; BRAIN-TUMORS; RHO; PROTEINS; UBIQUITINATION; LOCALIZATION; INVOLVEMENT; INTERACTS; BINDING; PATHWAY	Wnt signaling follows canonical and non-canonical pathways to regulate a variety of processes during cellular homeostasis and development. The large T-antigen (T-Ag) of the human neurotropic JC virus, has been shown to modulate the Wnt-signaling pathway via interaction with beta-catenin, one of the most important components of the canonical Wnt pathway. Here, we have identified an alternative non-canonical pathway that allows T-Ag to recruit Rac1 for stabilizing beta-catenin by inhibiting its ubiquitin-dependent proteasomal degradation. We demonstrate that inhibition of Rac1 by its dominant negative mutant, RacN17, abrogates T-Ag-mediated stabilization of b-catenin yet exhibits no impact on the transcriptional activity of b-catenin. Results from immunocytochemistry revealed that together with T-Ag, a pool of beta-catenin appears at the cell surface, particularly at the membrane ruffles where active Rac1 is positioned. Interestingly, cooperativity between T-Ag and beta-catenin leads to activation of Rac1, which in turn, stimulates its association with beta-catenin. These observations unravel the interplay between beta-catenin and Rac1 that is initiated by T-Ag and results in stabilization of beta-catenin and its presence in cell membrane ruffles.	[Bhattacharyya, R.; Noch, E. K.; Khalili, K.] Temple Univ, Sch Med, Ctr Neurovirol, Dept Neurosci, Philadelphia, PA 19122 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Khalili, K (corresponding author), Temple Univ, Sch Med, Ctr Neurovirol, Dept Neurosci, Philadelphia, PA 19122 USA.	kkhalili@temple.edu						Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Akiyama T, 2006, ONCOGENE, V25, P7538, DOI 10.1038/sj.onc.1210063; Bachar-Dahan L, 2006, MOL BIOL CELL, V17, P2572, DOI 10.1091/mbc.E06-01-0052; Bhattacharyya R, 2000, J BIOL CHEM, V275, P14992, DOI 10.1074/jbc.M000415200; Bienz M, 2000, CELL, V103, P311, DOI 10.1016/S0092-8674(00)00122-7; BUTEL JS, 1989, ANN NY ACAD SCI, V567, P104, DOI 10.1111/j.1749-6632.1989.tb16463.x; Gan DD, 2004, ONCOGENE, V23, P483, DOI 10.1038/sj.onc.1207018; Hwang SL, 2005, ACTA NEUROCHIR, V147, P551, DOI 10.1007/s00701-005-0515-5; Khalili K, 2006, ADV EXP MED BIOL, V577, P274; Kikuchi A, 2006, EXP MOL MED, V38, P1, DOI 10.1038/emm.2006.1; Malliri A, 2003, CURR OPIN CELL BIOL, V15, P583, DOI 10.1016/S0955-0674(03)00098-X; Mao JH, 1998, J BIOL CHEM, V273, P27118, DOI 10.1074/jbc.273.42.27118; Michaelson D, 2001, J CELL BIOL, V152, P111, DOI 10.1083/jcb.152.1.111; Nusse R, 2005, CELL RES, V15, P28, DOI 10.1038/sj.cr.7290260; Senadheera D, 2001, INT J MOL MED, V8, P127; Shackelford J, 2004, MOL CELL BIOL, V24, P5089, DOI 10.1128/MCB.24.12.5089-5093.2004; Shollar D, 2004, ONCOGENE, V23, P5459, DOI 10.1038/sj.onc.1207728; Welcker M, 2005, J BIOL CHEM, V280, P7654, DOI 10.1074/jbc.M413377200; White MK, 2005, BRAIN RES REV, V50, P69, DOI 10.1016/j.brainresrev.2005.04.007; Wildenberg GA, 2006, CELL, V127, P1027, DOI 10.1016/j.cell.2006.09.046	20	32	32	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 6	2007	26	55					7628	7636		10.1038/sj.onc.1210576	http://dx.doi.org/10.1038/sj.onc.1210576			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	239SK	17637758				2022-12-17	WOS:000251537800004
J	Zhong, Y; Jiang, L; Hiai, H; Toyokuni, S; Yamada, Y				Zhong, Y.; Jiang, L.; Hiai, H.; Toyokuni, S.; Yamada, Y.			Overexpression of a transcription factor LYL1 induces T- and B-cell lymphoma in mice	ONCOGENE			English	Article						LYL1; lymphoma; basic helix-loop-helix transcription factor; E2A; transgenic mice; two-hybrid assay	LOOP-HELIX PROTEINS; ACUTE LYMPHOBLASTIC-LEUKEMIA; TRANSGENIC MICE; SCL GENE; TARGETED DISRUPTION; EXPRESSION; MALIGNANCIES; TAL1; BHLH; IMMUNOGLOBULIN	LYL1, a member of the class II basic helix-loop-helix transcription factors, is aberrantly expressed in a fraction of human T-cell acute lymphoblastic leukemia. Here, we generated transgenic mice ubiquitously overexpressing LYL1 using a construct expressing full-length cDNA driven by a human elongation factor lot promoter. Four independent lines exhibiting high LYL1 expression were established. Of these transgenic mice, 96% displayed loss of hair with a short kinked tail. Furthermore, 30% of them developed malignant lymphoma, with an average latent period of 352 days. In these mice, histological examination revealed tumor cell infiltration in multiple organs and immunohistochemical analysis showed that the infiltrated tumor cells were either CD3 or CD45R/B220-positive; fluorescence-activated cell sorter analysis indicated that each tumor consisted either of mainly CD4, CD8 double-positive T cells or mature B cells; the clonality of LYL1-induced lymphoma was confirmed by T-cell receptor rearrangement and immunoglobulin heavy-chain gene rearrangement analyses. Mammalian two-hybrid analysis and luciferase assay suggested that excess LYL1 blocked the dimerization of E2A and thus inhibited the regulatory activity of E2A on the CD4 promoter. Reverse transcription-polymerase chain reaction results showed that the expression of certain E2A/HEB target genes was downregulated. Taken together, our results provide direct evidence that aberrant expression of LYL1 plays a role in lymphomagenesis.	Kyoto Univ, Grad Sch Med, Dept Pathol & Biol Dis, Sakyo Ku, Kyoto 6068501, Japan; Shiga Med Ctr Adults, Shiga, Japan; Aino Univ, Fac Nursing & Rehabil, Osaka, Japan	Kyoto University	Toyokuni, S (corresponding author), Kyoto Univ, Grad Sch Med, Dept Pathol & Biol Dis, Sakyo Ku, Kyoto 6068501, Japan.	toyokuni@path1.med.kyoto-u.ac.jp; yamada@aino.ac.jp	Toyokuni, Shinya/ABE-7714-2021; Zhong, Yi/K-7419-2012; Toyokuni, Shinya/C-1358-2010	Toyokuni, Shinya/0000-0002-5757-1109; Toyokuni, Shinya/0000-0002-5757-1109				Aplan PD, 1997, EMBO J, V16, P2408, DOI 10.1093/emboj/16.9.2408; BAER R, 1993, SEMIN CANCER BIOL, V4, P341; Bain G, 1997, MOL CELL BIOL, V17, P4782, DOI 10.1128/MCB.17.8.4782; Begley CG, 1999, BLOOD, V93, P2760; Chervinsky DS, 1999, MOL CELL BIOL, V19, P5025; Condorelli GL, 1996, CANCER RES, V56, P5113; Dolcet X, 2005, VIRCHOWS ARCH, V446, P475, DOI 10.1007/s00428-005-1264-9; Ferrando AA, 2003, SEMIN HEMATOL, V40, P274, DOI 10.1016/S0037-1963(03)00195-1; Ferrando AA, 2002, CANCER CELL, V1, P75, DOI 10.1016/S1535-6108(02)00018-1; Ferrier R, 1999, ONCOGENE, V18, P995, DOI 10.1038/sj.onc.1202374; Gilmore TD, 1996, ONCOGENE, V13, P1367; Herblot S, 2000, NAT IMMUNOL, V1, P138, DOI 10.1038/77819; Hjalt T, 2004, INT REV CYTOL, V236, P251, DOI 10.1016/S0074-7696(04)36006-7; HSU HL, 1994, P NATL ACAD SCI USA, V91, P3181, DOI 10.1073/pnas.91.8.3181; Jones S, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-6-226; KUO SS, 1991, ONCOGENE, V6, P961; LARSON RC, 1995, ONCOGENE, V11, P853; Larson RC, 1996, EMBO J, V15, P1021, DOI 10.1002/j.1460-2075.1996.tb00439.x; Lazorchak A, 2005, TRENDS IMMUNOL, V26, P334, DOI 10.1016/j.it.2005.03.011; MALISSEN M, 1984, CELL, V37, P1101, DOI 10.1016/0092-8674(84)90444-6; Massari ME, 2000, MOL CELL BIOL, V20, P429, DOI 10.1128/MCB.20.2.429-440.2000; MELLENTIN JD, 1989, CELL, V58, P77, DOI 10.1016/0092-8674(89)90404-2; Meng YS, 2005, LEUKEMIA, V19, P1941, DOI 10.1038/sj.leu.2403836; Miyamoto A, 1996, MOL CELL BIOL, V16, P2394; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; Murre C, 2005, NAT IMMUNOL, V6, P1079, DOI 10.1038/ni1260; MURRE C, 1994, BBA-GENE STRUCT EXPR, V1218, P129, DOI 10.1016/0167-4781(94)90001-9; O'Neil J, 2004, CANCER CELL, V5, P587, DOI 10.1016/j.ccr.2004.05.023; ROBB L, 1995, P NATL ACAD SCI USA, V92, P7075, DOI 10.1073/pnas.92.15.7075; SAKANO H, 1980, NATURE, V286, P676, DOI 10.1038/286676a0; SAWADA S, 1993, MOL CELL BIOL, V13, P5620, DOI 10.1128/MCB.13.9.5620; SHIVDASANI RA, 1995, NATURE, V373, P432, DOI 10.1038/373432a0; Toyokuni S, 2003, PATHOL INT, V53, P259, DOI 10.1046/j.1320-5463.2003.01465.x; Toyokuni S, 1997, LAB INVEST, V76, P365; VANDONGEN JJM, 1991, CLIN CHIM ACTA, V198, P1; VISVADER J, 1991, ONCOGENE, V6, P187; WADMAN I, 1994, EMBO J, V13, P4831, DOI 10.1002/j.1460-2075.1994.tb06809.x; Wilm B, 1998, P NATL ACAD SCI USA, V95, P8692, DOI 10.1073/pnas.95.15.8692; Wilson V, 2002, GENOME BIOL, V3, DOI [10.1186/gb-2002-3-6-reviews3008, DOI 10.1186/GB-2002-3-6-REVIEWS3008]; XIA Y, 1994, ONCOGENE, V9, P1437; XIA Y, 1991, P NATL ACAD SCI USA, V88, P11416, DOI 10.1073/pnas.88.24.11416; Yan W, 1997, MOL CELL BIOL, V17, P7317, DOI 10.1128/MCB.17.12.7317	42	32	34	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 18	2007	26	48					6937	6947		10.1038/sj.onc.1210494	http://dx.doi.org/10.1038/sj.onc.1210494			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	220WQ	17486074	Green Submitted			2022-12-17	WOS:000250188400009
J	Li, Y; Huang, J; Zhao, YL; He, J; Wang, W; Davies, KE; Nose, V; Xiao, S				Li, Y.; Huang, J.; Zhao, Y-L; He, J.; Wang, W.; Davies, K. E.; Nose, V.; Xiao, S.			UTRN on chromosome 6q24 is mutated in multiple tumors	ONCOGENE			English	Article						tumor suppressor; UTRN; functional screening	DUCHENNE MUSCULAR-DYSTROPHY; SUPPRESSOR GENE; BREAST-CANCER; TERMINAL DOMAIN; UTROPHIN GENE; CELL-LINES; ARM 6Q; TUMORIGENICITY; DELETION; HETEROZYGOSITY	Though deletion of the long arm of chromosome 6 is one of the most common aberrations in tumors, its targeted gene(s) has not been convincingly identified. Using a functional screening approach, we found that UTRN ( which encodes utrophin, a dystrophin-related protein) at 6q24, when expressed in an antisense orientation, induced cellular transformation, consistent with a tumor suppressor role. Northern blot analysis, semiquantitative reverse transcription-polymerase chain reaction (RT-PCR), and gene expression arrays all showed that UTRN expression was downregulated in primary tumors compared with matched normal tissues. Several UTRN neighbor genes were not affected in some tumors with UTRN downregulation, suggesting that UTRN was specifically targeted. RT-PCR, coupled with an in vitro transcription and translation assay, revealed inactivation mutations in 21/62 breast cancers, 4/20 neuroblastomas and 4/15 malignant melanomas. Most of the mutations were deletions involving one or more exons that led to the truncation of utrophin. Splicing errors were found in two cases, and nonsense mutation in one case. Overexpression of a wild-type UTRN in breast cancer cells inhibited tumor cell growth in vitro and reduced their tumor potential in nude mice. Our studies suggest that UTRN is a candidate tumor suppressor gene.	Harbin Inst Technol, Harbin, Peoples R China; Brigham & Womens Hosp, Harvard Med Sch, Dept Pathol, Boston, MA USA; Cornell Univ, Microarray Core Facility, Ithaca, NY USA; Univ Oxford, Dept Biochem, Oxford OX1 2JD, England	Harbin Institute of Technology; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Cornell University; University of Oxford	Xiao, S (corresponding author), Brigham & Womens Hosp, Dept Pathol, 75 Francis St, Boston, MA 02115 USA.	sxiao@rics.bwh.harvard.edu						Abe T, 1999, GENE CHROMOSOME CANC, V25, P60, DOI 10.1002/(SICI)1098-2264(199905)25:1<60::AID-GCC9>3.0.CO;2-Y; Acevedo CM, 2002, CANCER-AM CANCER SOC, V94, P793, DOI 10.1002/cncr.10275; Atkin NB, 1996, CANCER GENET CYTOGEN, V92, P87, DOI 10.1016/S0165-4608(96)00131-8; Barghorn A, 2001, AM J PATHOL, V158, P1903, DOI 10.1016/S0002-9440(10)64658-5; Biroccio A, 2003, ONCOGENE, V22, P6579, DOI 10.1038/sj.onc.1206812; BLAKE DJ, 1995, P NATL ACAD SCI USA, V92, P3697, DOI 10.1073/pnas.92.9.3697; Brault E, 2001, J CELL SCI, V114, P1901; Chappell SA, 1997, BRIT J CANCER, V75, P1324, DOI 10.1038/bjc.1997.224; Deconinck AE, 1997, CELL, V90, P717, DOI 10.1016/S0092-8674(00)80532-2; Fujioka Y, 2001, J BIOL CHEM, V276, P45137, DOI 10.1074/jbc.M106127200; Gutmann DH, 1999, HUM MOL GENET, V8, P267, DOI 10.1093/hmg/8.2.267; Hoffman PJ, 2004, FERTIL STERIL, V82, P639, DOI 10.1016/j.fertnstert.2004.01.047; Hu J, 2001, ONCOGENE, V20, P8042, DOI 10.1038/sj.onc.1204961; Huang LW, 2000, HUM PATHOL, V31, P367, DOI 10.1016/S0046-8177(00)80252-X; Jensen RH, 2003, ANTICANCER RES, V23, P2281; Li LM, 1996, CELL, V85, P319, DOI 10.1016/S0092-8674(00)81111-3; Mertens F, 1997, CANCER RES, V57, P2765; Morris GE, 1998, BIOCHEMISTRY-US, V37, P11117, DOI 10.1021/bi9805137; MOSER H, 1984, HUM GENET, V66, P17, DOI 10.1007/BF00275183; NEGRINI M, 1994, CANCER RES, V54, P1331; Noviello C, 1996, CLIN CANCER RES, V2, P1601; OFFIT K, 1993, BLOOD, V82, P2157; OFFIT K, 1994, BLOOD, V83, P2611, DOI 10.1182/blood.V83.9.2611.bloodjournal8392611; PEARCE M, 1993, HUM MOL GENET, V2, P1765, DOI 10.1093/hmg/2.11.1765; Pozzoli U, 2002, GENETICS, V160, P793; Qu XY, 1998, DNA SEQUENCE, V9, P189, DOI 10.3109/10425179809105206; Rhodes DR, 2004, NEOPLASIA, V6, P1, DOI 10.1016/S1476-5586(04)80047-2; Roque L, 2003, GENE CHROMOSOME CANC, V36, P292, DOI 10.1002/gcc.10146; SCHOFIELD J, 1993, DEV DYNAM, V198, P254, DOI 10.1002/aja.1001980403; Theile M, 1996, ONCOGENE, V13, P677; Tibiletti MB, 2000, CLIN CANCER RES, V6, P1422; Tibiletti MG, 1996, CANCER RES, V56, P4493; Tibiletti MG, 2001, CLIN CANCER RES, V7, P3404; TRENT JM, 1990, SCIENCE, V247, P568, DOI 10.1126/science.2300817; Wan MH, 1999, ONCOGENE, V18, P1545, DOI 10.1038/sj.onc.1202476; WELCH DR, 1994, ONCOGENE, V9, P255; YAMADA H, 1990, ONCOGENE, V5, P1141	37	32	33	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 13	2007	26	42					6220	6228		10.1038/sj.onc.1210432	http://dx.doi.org/10.1038/sj.onc.1210432			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	209PU	17384672				2022-12-17	WOS:000249401300013
J	Gonin-Laurent, N; Hadj-Hamou, NS; Vogt, N; Houdayer, C; Gauthiers-Villars, M; Dehainault, C; Sastre-Garau, X; Chevillard, S; Malfoy, B				Gonin-Laurent, N.; Hadj-Hamou, N. S.; Vogt, N.; Houdayer, C.; Gauthiers-Villars, M.; Dehainault, C.; Sastre-Garau, X.; Chevillard, S.; Malfoy, B.			RB1 and TP53 pathways in radiation-induced sarcomas	ONCOGENE			English	Article						ionising radiation; sarcoma; RB1; TP53; CDKN2A; MDMX	SOLID TUMORS; SOFT-TISSUE; PROMOTER METHYLATION; ORAL-CANCER; P53 PATHWAY; MDM2 GENES; RETINOBLASTOMA; OSTEOSARCOMA; INACTIVATION; EXPRESSION	The tumour suppressor genes, TP53 and RB1, and four genes involved in their regulation, INK4a, ARF, MDM2 and MDMX, were analysed in a series of 36 post-radiotherapy radiation- induced sarcomas. One- third of the tumours developed in patients carrying a germline mutation of RB1 that predisposed them to retinoblastoma and radiation- induced sarcomas. The genetic inactivation of RB1 and/ or TP53 genes was frequently observed in these sarcomas. These inactivations were owing to an interplay between point mutations and losses of large chromosome segments. Radiation- induced somatic mutations were observed in TP53, but not in RB1 or in the four other genes, indicating an early role of TP53 in the radio- sarcomagenesis. RB1 and TP53 genes were biallelically coinactivated in all sarcomas developing in the context of the predisposition, indicating that both genes played a major role in the formation of these sarcomas. In the absence of predisposition, TP53 was biallelically inactivated in one- third of the sarcomas, whereas at least one allele of RB1 was wild type. In both genetic contexts, the TP53 pathway was inactivated by genetic lesions and not by the activation of the ARF / MDM2/ MDMX pathway, as recently shown in retinoblastomas. Together, these findings highlight the intricate tissue- and aetiology-specific relationships between TP53 and RB1 pathways in tumorigenesis.	CNRS, UMR 7147, Paris 05, France; Ctr Rech, Inst Curie, Paris, France; Univ Paris 06, Paris, France; Inst Curie, Dept Genet, Paris, France; Inst Curie, Dept Pathol, Paris, France; DRR, DSV, CEA, Fontenay Aux Roses, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; UDICE-French Research Universities; Sorbonne Universite; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; CEA	Malfoy, B (corresponding author), CNRS, UMR 7147, 26 Rue Ulm, Paris 05, France.	bernard.malfoy@curie.fr	Britzen-Laurent, Nathalie/M-3982-2013	Britzen-Laurent, Nathalie/0000-0002-0494-7117; Chevillard, Sylvie/0000-0001-5889-4041; Sastre-Garau, Xavier/0000-0001-5992-2083				Aerts I, 2004, EUR J CANCER, V40, P1522, DOI 10.1016/j.ejca.2004.03.023; Chatterjee SJ, 2004, J PATHOL, V203, P762, DOI 10.1002/path.1567; Danovi D, 2004, MOL CELL BIOL, V24, P5835, DOI 10.1128/MCB.24.13.5835-5843.2004; Gonin-Laurent N, 2006, CARCINOGENESIS, V27, P1266, DOI 10.1093/carcin/bgi356; Goodrich DW, 2006, ONCOGENE, V25, P5233, DOI 10.1038/sj.onc.1209616; Houdayer C, 2004, HUM MUTAT, V23, P193, DOI 10.1002/humu.10303; Kato MV, 1996, CANCER LETT, V106, P75, DOI 10.1016/0304-3835(96)04305-4; Kawaguchi K, 2006, MODERN PATHOL, V19, P106, DOI 10.1038/modpathol.3800502; Kawaguchi K, 2003, J PATHOL, V201, P487, DOI 10.1002/path.1419; Kawaguchi K, 2002, MODERN PATHOL, V15, P878, DOI 10.1097/01.MP.0000024264.48690.EA; Kleinerman RA, 2005, J CLIN ONCOL, V23, P2272, DOI 10.1200/JCO.2005.05.054; Knudson AG, 2001, NAT REV CANCER, V1, P157, DOI 10.1038/35101031; Laurie NA, 2006, NATURE, V444, P61, DOI 10.1038/nature05194; Lavin MF, 2006, CELL DEATH DIFFER, V13, P941, DOI 10.1038/sj.cdd.4401925; Lefevre SH, 2001, ONCOGENE, V20, P8092, DOI 10.1038/sj.onc.1205009; Marine JC, 2004, CELL CYCLE, V3, P900; Menu-Branthomme A, 2004, INT J CANCER, V110, P87, DOI 10.1002/ijc.20002; Miller CW, 1996, J CANCER RES CLIN, V122, P559, DOI 10.1007/BF01213553; Moysich KB, 2002, LANCET ONCOL, V3, P269, DOI 10.1016/S1470-2045(02)00727-1; PatinoGarcia A, 1997, CANCER GENET CYTOGEN, V98, P50, DOI 10.1016/S0165-4608(96)00397-4; Perucca-Lostanlen D, 2004, GENE CHROMOSOME CANC, V39, P99, DOI 10.1002/gcc.10303; Ramos YFM, 2001, CANCER RES, V61, P1839; Sartor M, 1999, BRIT J CANCER, V80, P79, DOI 10.1038/sj.bjc.6690505; Sharpless NE, 2005, MUTAT RES-FUND MOL M, V576, P22, DOI 10.1016/j.mrfmmm.2004.08.021; Shaw RJ, 2006, BRIT J CANCER, V94, P561, DOI 10.1038/sj.bjc.6602972; Toledo F, 2006, NAT REV CANCER, V6, P909, DOI 10.1038/nrc2012; Travis LB, 2002, ACTA ONCOL, V41, P323, DOI 10.1080/028418602760169361; Tsuchiya T, 2000, CANCER GENET CYTOGEN, V120, P91, DOI 10.1016/S0165-4608(99)00255-1; Wakeford R, 2004, ONCOGENE, V23, P6404, DOI 10.1038/sj.onc.1207896	29	32	33	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP	2007	26	41					6106	6112		10.1038/sj.onc.1210404	http://dx.doi.org/10.1038/sj.onc.1210404			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	207US	17369843				2022-12-17	WOS:000249277200014
J	Kehn, K; Berro, R; Alhaj, A; Bottazzi, M; Yeh, WI; Klase, Z; Van Duyne, R; Fu, S; Kashanchi, F				Kehn, K.; Berro, R.; Alhaj, A.; Bottazzi, M. E.; Yeh, W-I; Klase, Z.; Van Duyne, R.; Fu, S.; Kashanchi, F.			Functional consequences of cyclin D1/BRCA1 interaction in breast cancer cells	ONCOGENE			English	Article						BRCA1; cyclin D1; cdk4; transcription; phosphorylation	ESTROGEN-RECEPTOR; DEPENDENT KINASES; DNA-BINDING; BRCA1; GENE; PHOSPHORYLATION; TRANSCRIPTION; FASCAPLYSIN; INHIBITION; EXPRESSION	The inheritance of one defective BRCA1 or BRCA2 allele predisposes an individual to developing breast and ovarian cancers. BRCA1 is a multifunctional tumor suppressor protein, which through interaction with a vast array of proteins has implications in processes such as cell cycle, transcription, DNA damage response and chromatin remodeling. Conversely, the oncogene, cyclin D1 is overexpressed in about 35% of all breast cancer cases. In this study, we provide detailed analyses on the phosphorylation state of BRCA1 by cyclin D1/cdk4 complexes. In particular, we have identified Ser 632 of BRCA1 as a cyclin D1/cdk4 phosphorylation site in vitro. Using chromatin immunoprecipitation assays, we observed that the inhibition of cyclin D1/cdk4 activity resulted in increased BRC A1 DNA binding at particular promoters in vivo. In addition, we identified multiple novel genes that are bound by BRCA1 in vivo. Collectively, these results indicate that cyclin D1/cdk4- mediated phosphorylation of BRCA1 inhibits the ability of BRCA1 to be recruited to particular promoters in vivo. Therefore, cyclin D1/Cdk4 phosphorylation of BRCA1 could provide a mechanism to interfere with the DNA- dependent activities of BRCA1.	George Washington Univ, Sch Med, Dept Biochem & Mol Biol, Washington, DC 20037 USA; George Washington Univ, Dept Microbiol, Inst Proteom Technol & Applicat, Washington, DC 20037 USA; Inst Genom Res TIGR, Dept Biochem, Rockville, MD USA	George Washington University; George Washington University; J. Craig Venter Institute	Kashanchi, F (corresponding author), George Washington Univ, Sch Med, Dept Biochem & Mol Biol, 2300 Eye St,NW,Ross Hall,Rm 552, Washington, DC 20037 USA.	bcmfxk@gwumc.edu	Kehn-Hall, Kylene/I-5752-2013; Van Duyne, Rachel/I-7365-2019	Bottazzi, Maria Elena/0000-0002-8429-0476; Van Duyne, Rachel/0000-0003-2914-6874	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI043894, R21AI065236] Funding Source: NIH RePORTER; NIAID NIH HHS [AI043894, AI065236] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Aubry C, 2004, CHEM COMMUN, P1696, DOI 10.1039/b406076h; Boulton SJ, 2006, BIOCHEM SOC T, V34, P633, DOI 10.1042/BST0340633; Cable PL, 2003, MOL CARCINOGEN, V38, P85, DOI 10.1002/mc.10148; Chen YM, 1996, CANCER RES, V56, P3168; Coqueret O, 2002, GENE, V299, P35, DOI 10.1016/S0378-1119(02)01055-7; Cortez D, 1999, SCIENCE, V286, P1162, DOI 10.1126/science.286.5442.1162; De La Fuente C, 2000, J VIROL, V74, P7270, DOI 10.1128/JVI.74.16.7270-7283.2000; Fabbro M, 2002, J BIOL CHEM, V277, P21315, DOI 10.1074/jbc.M200769200; Fan SJ, 2002, CANCER RES, V62, P141; Hejna M, 2002, ANN ONCOL, V13, P653, DOI 10.1093/annonc/mdf142; Hillion J, 1997, BLOOD, V90, P3714, DOI 10.1182/blood.V90.9.3714; Katoh M, 2004, INT J ONCOL, V25, P1495; Kehn Kylene, 2004, Retrovirology, V1, P6, DOI 10.1186/1742-4690-1-6; Lacroix M, 2004, BREAST CANCER RES TR, V83, P249, DOI 10.1023/B:BREA.0000014042.54925.cc; Lin L, 2002, CANCER RES, V62, P5273; Mark WY, 2005, J MOL BIOL, V345, P275, DOI 10.1016/j.jmb.2004.10.045; Matsuura I, 2004, NATURE, V430, P226, DOI 10.1038/nature02650; Moisan A, 2006, J BIOL CHEM, V281, P21119, DOI 10.1074/jbc.M600712200; Montminy M, 1996, METABOLISM, V45, P4, DOI 10.1016/S0026-0495(96)90068-2; Mullan PB, 2006, ONCOGENE, V25, P5854, DOI 10.1038/sj.onc.1209872; Nakamura T, 2004, ONCOGENE, V23, P2385, DOI 10.1038/sj.onc.1207392; Pao GM, 2000, P NATL ACAD SCI USA, V97, P1020, DOI 10.1073/pnas.97.3.1020; Paull TT, 2001, P NATL ACAD SCI USA, V98, P6086, DOI 10.1073/pnas.111125998; Rosen ED, 2003, J THROMB HAEMOST, V1, P19, DOI 10.1046/j.1538-7836.2003.00030.x; Rosen EM, 2006, CANCER LETT, V236, P175, DOI 10.1016/j.canlet.2005.04.037; Ruffner H, 1999, MOL CELL BIOL, V19, P4843; Santosh M, 1999, GONDWANA RES, V2, P1, DOI 10.1016/S1342-937X(05)70121-0; Soni R, 2000, BIOCHEM BIOPH RES CO, V275, P877, DOI 10.1006/bbrc.2000.3349; Teh MT, 2002, CANCER RES, V62, P4773; Wang CG, 2005, CANCER RES, V65, P6557, DOI 10.1158/0008-5472.CAN-05-0486; Wang HC, 1997, ONCOGENE, V15, P143, DOI 10.1038/sj.onc.1201252; Zheng L, 2001, P NATL ACAD SCI USA, V98, P9587, DOI 10.1073/pnas.171174298	32	32	34	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 2	2007	26	35					5060	5069		10.1038/sj.onc.1210319	http://dx.doi.org/10.1038/sj.onc.1210319			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	196MT	17334399				2022-12-17	WOS:000248487400004
J	Ma, X; Kalakonda, S; Srinivasula, SM; Reddy, SP; Platanias, LC; Kalvakolanu, DV				Ma, X.; Kalakonda, S.; Srinivasula, S. M.; Reddy, S. P.; Platanias, L. C.; Kalvakolanu, D. V.			GRIM-19 associates with the serine protease HtrA2 for promoting cell death	ONCOGENE			English	Article						cytokines; vitamins; cancer; cell death; growth; suppression	RETINOIC ACID; TUMOR-DEVELOPMENT; CASPASE ACTIVITY; IFN-GAMMA; APOPTOSIS; INHIBITOR; OMI/HTRA2; MITOCHONDRIA; REGULATOR; INTERACTS	We have isolated a novel interferon (IFN)-retinoid regulated cell death regulatory protein genes associated with retinoid-IFN-induced mortality (GRIM)-19 earlier. To understand its mechanism of action, we have employed a yeast-two-hybrid screen and identified serine protease HtrA2 as its binding partner. GRIM-19 physically interacts with HtrA2 and augments cell death in an IFN/all-trans retinoic acid (RA)-dependent manner. In the presence of GRIM-19, the HtrA2-driven destruction of the antiapoptotic protein X-linked inhibitor of apoptosis (XIAP) is augmented. These interactions were disrupted by an human herpes virus-8 (HHV-8)-coded oncoprotein, vIRF1, and conferred resistance to IFN/RA-induced cell death. These data show a critical role of HtrA2 in a cytokine-induced cell death response for the. rst time and its inhibition by a viral protein.	Univ Maryland, Greenbaum Canc Ctr, Dept Microbiol & Immunol, Sch Med, Baltimore, MD 21201 USA; NCI, Lab Immune Cell Biol, Bethesda, MD 20892 USA; Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Environm Hlth Sci, Baltimore, MD USA; Northwestern Univ, Sch Med, Lurie Canc Ctr, Div Hematol & Oncol, Chicago, IL 60611 USA	University System of Maryland; University of Maryland Baltimore; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Northwestern University; Robert H. Lurie Comprehensive Cancer Center	Kalvakolanu, DV (corresponding author), Univ Maryland, Greenbaum Canc Ctr, Dept Microbiol & Immunol, Sch Med, Baltimore, MD 21201 USA.	dkalvako@umaryland.edu			NATIONAL CANCER INSTITUTE [R01CA105005] Funding Source: NIH RePORTER; NCI NIH HHS [CA105005] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Altucci L, 2001, NAT REV CANCER, V1, P181, DOI 10.1038/35106036; Angell JE, 2000, J BIOL CHEM, V275, P33416, DOI 10.1074/jbc.M003929200; CHOMIENNE C, 1990, BLOOD, V76, P1710; DALE TC, 1989, P NATL ACAD SCI USA, V86, P1203, DOI 10.1073/pnas.86.4.1203; Fearnley IM, 2001, J BIOL CHEM, V276, P38345, DOI 10.1074/jbc.C100444200; Gao SJ, 1997, ONCOGENE, V15, P1979, DOI 10.1038/sj.onc.1201571; Gresser I, 2002, CYTOKINE GROWTH F R, V13, P111, DOI 10.1016/S1359-6101(01)00035-1; Gupta S, 2004, J BIOL CHEM, V279, P45844, DOI 10.1074/jbc.M404940200; Hegde R, 2002, J BIOL CHEM, V277, P432, DOI 10.1074/jbc.M109721200; Hu JD, 2002, J INTERF CYTOK RES, V22, P1017, DOI 10.1089/107999002760624242; Ikeda H, 2002, CYTOKINE GROWTH F R, V13, P95, DOI 10.1016/S1359-6101(01)00038-7; Jayachandra S, 1999, P NATL ACAD SCI USA, V96, P11566, DOI 10.1073/pnas.96.20.11566; Jin SK, 2003, GENE DEV, V17, P359, DOI 10.1101/gad.1047003; Kalvakolanu DV, 2004, CYTOKINE GROWTH F R, V15, P169, DOI 10.1016/j.cytogfr.2004.01.002; KALVAKOLANU DV, 2002, ENCY CANC, V2, P511; Kuninaka S, 2005, ONCOGENE, V24, P5287, DOI 10.1038/sj.onc.1208682; Li WY, 2002, NAT STRUCT BIOL, V9, P436, DOI 10.1038/nsb795; Martins LM, 2002, J BIOL CHEM, V277, P439, DOI 10.1074/jbc.M109784200; Seo T, 2002, J VIROL, V76, P8797, DOI 10.1128/JVI.76.17.8797-8807.2002; Shankaran V, 2001, NATURE, V410, P1107, DOI 10.1038/35074122; Stennicke HR, 1999, J BIOL CHEM, V274, P8359, DOI 10.1074/jbc.274.13.8359; Suzuki Y, 2001, MOL CELL, V8, P613, DOI 10.1016/S1097-2765(01)00341-0; van Loo G, 2002, CELL DEATH DIFFER, V9, P20, DOI 10.1038/sj.cdd.4400970; VanderHeiden MG, 1997, CELL, V91, P627, DOI 10.1016/S0092-8674(00)80450-X; Vaux DL, 2003, BIOCHEM BIOPH RES CO, V304, P499, DOI 10.1016/S0006-291X(03)00622-3; Yang QH, 2003, GENE DEV, V17, P1487, DOI 10.1101/gad.1097903; Zhang J, 2003, P NATL ACAD SCI USA, V100, P9342, DOI 10.1073/pnas.1633516100; Zimring JC, 1998, J VIROL, V72, P701, DOI 10.1128/JVI.72.1.701-707.1998	28	32	33	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 19	2007	26	33					4842	4849		10.1038/sj.onc.1210287	http://dx.doi.org/10.1038/sj.onc.1210287			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	191ZL	17297443				2022-12-17	WOS:000248170400009
J	Tews, B; Roerig, P; Hartmann, C; Hahn, M; Felsberg, J; Blaschke, B; Sabel, M; Kunitz, A; Toedt, G; Neben, K; Benner, A; von Deimling, A; Reifenberger, G; Lichter, P				Tews, B.; Roerig, P.; Hartmann, C.; Hahn, M.; Felsberg, J.; Blaschke, B.; Sabel, M.; Kunitz, A.; Toedt, G.; Neben, K.; Benner, A.; von Deimling, A.; Reifenberger, G.; Lichter, P.			Hypermethylation and transcriptional downregulation of the CITED4 gene at 1p34.2 in oligodendroglial tumours with allelic losses on 1p and 19q	ONCOGENE			English	Article						CITED4; gene expression profiling; oligodendroglioma; CpG island; hypermethylation; tumour suppressor gene	PHASE-III TRIAL; ANAPLASTIC OLIGODENDROGLIOMAS; MGMT GENE; EXPRESSION; SUPPRESSOR; CANCER; SURVIVAL; IDENTIFICATION; 19Q13.3; GLIOMAS	Deletions of chromosomal arms 1p and 19q are frequent in oligodendroglial tumours and have been associated with sensitivity to radio- and chemotherapy as well as favourable prognosis. By using microarray-based expression pro. ling, we found that oligodendroglial tumours with 1p and 19q losses showed signi. cantly lower expression of the CBP/p300-interacting transactivator with glutamic acid/ aspartic acid-rich carboxyl-terminal domain 4 gene (CITED4) at 1p34.2 as compared to tumours without 1p and 19q losses. Mutational analysis showed no CITED4 mutations in gliomas. However, 1p and 19q losses as well as low expression of CITED4 transcripts were significantly associated with hypermethylation of the CITED4-associated CpG island. In line with the latter. nding, treatment of CITED4 hypermethylated glioma cell lines with 5-aza-2'-deoxycytidine and trichostatine A resulted in a marked increase of the CITED4 transcript levels. Furthermore, CITED4 hypermethylation was signi. cantly associated with longer recurrence-free and overall survival of patients with oligodendroglial tumours. Taken together, our results indicate that CITED4 is epigenetically silenced in the vast majority of oligodendroglial tumours with 1p and 19q deletions and suggest CITED4 hypermethylation as a novel prognostic marker in oligodendroglioma patients.	Univ Dusseldorf, Dept Neuropathol, D-40225 Dusseldorf, Germany; Deutches Krebsforschungszentrum, Div Mol Genet B060, Heidelberg, Germany; Univ Med Berlin, Charite, Dept Neuropathol, Berlin, Germany; Univ Dusseldorf, Dept Neurosurg, D-4000 Dusseldorf, Germany; Deutches Krebsforschungszentrum, Cent Unit Biostat, C060, Heidelberg, Germany	Heinrich Heine University Dusseldorf; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Heinrich Heine University Dusseldorf	Reifenberger, G (corresponding author), Univ Dusseldorf, Dept Neuropathol, Moorenstr 5, D-40225 Dusseldorf, Germany.	reifenberger@med.uni-duesseldorf.de	von Deimling, Andreas/F-7774-2013; Reifenberger, Guido/AAE-3599-2019; Hartmann, Christian/D-1882-2010	von Deimling, Andreas/0000-0002-5863-540X; 	PHS HHS [01GS0462, 01GS0463, 01GS0460] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Alaminos M, 2005, CANCER RES, V65, P2565, DOI 10.1158/0008-5472.CAN-04-4283; Barbashina V, 2005, CLIN CANCER RES, V11, P1119; Braga D, 2002, CRYSTENGCOMM, V4, P277, DOI 10.1039/b201547a; Cairncross G, 2006, J CLIN ONCOL, V24, P2707, DOI 10.1200/JCO.2005.04.3414; Cairncross JG, 1998, J NATL CANCER I, V90, P1473, DOI 10.1093/jnci/90.19.1473; Dong SM, 2002, INT J CANCER, V98, P370, DOI 10.1002/ijc.10204; Felsberg J, 2004, BRAIN PATHOL, V14, P121, DOI 10.1111/j.1750-3639.2004.tb00044.x; Fox SB, 2004, CANCER RES, V64, P6075, DOI 10.1158/0008-5472.CAN-04-0708; Griffin CA, 2006, J NEUROPATH EXP NEUR, V65, P988, DOI 10.1097/01.jnen.0000235122.98052.8f; Grossman SR, 2001, EUR J BIOCHEM, V268, P2773, DOI 10.1046/j.1432-1327.2001.02226.x; Hegi ME, 2005, NEW ENGL J MED, V352, P997, DOI 10.1056/NEJMoa043331; Iyer NG, 2004, ONCOGENE, V23, P4225, DOI 10.1038/sj.onc.1207118; Jenkins RB, 2006, CANCER RES, V66, P9852, DOI 10.1158/0008-5472.CAN-06-1796; McDonald JM, 2006, CANCER BIOL THER, V5, P300, DOI 10.4161/cbt.5.3.2391; McDonald JM, 2005, MOL CANCER, V4, DOI 10.1186/1476-4598-4-35; Mollemann M, 2005, INT J CANCER, V113, P379, DOI 10.1002/ijc.20575; R Development Core Team, 2005, LANG ENV STAT COMP; Reifenberger G, 2003, J NEUROPATH EXP NEUR, V62, P111, DOI 10.1093/jnen/62.2.111; REIFENBERGER G, 2000, WHO CLASSIFICATION T, P55; Tews B, 2006, INT J CANCER, V119, P792, DOI 10.1002/ijc.21901; Tibshirani R, 2002, P NATL ACAD SCI USA, V99, P6567, DOI 10.1073/pnas.082099299; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; van den Bent MJ, 2006, J CLIN ONCOL, V24, P2715, DOI 10.1200/JCO.2005.04.6078; van den Boom J, 2003, AM J PATHOL, V163, P1033, DOI 10.1016/S0002-9440(10)63463-3; Wolf RM, 2003, GENE DEV, V17, P476, DOI 10.1101/gad.1040003	25	32	33	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2007	26	34					5010	5016		10.1038/sj.onc.1210297	http://dx.doi.org/10.1038/sj.onc.1210297			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	194CV	17311001				2022-12-17	WOS:000248322500013
J	Berenjeno, IM; Nunez, F; Bustelo, XR				Berenjeno, I. M.; Nunez, F.; Bustelo, X. R.			Transcriptomal profiling of the cellular transformation induced by Rho subfamily GTPases	ONCOGENE			English	Article						Rho/Rac GTPases; microarray; proliferation; gene expression; transcription; rock; c-Myc	FACTOR-KAPPA-B; C-MYC; ACTIVATION; EXPRESSION; PROTEINS; KINASES; BIOLOGY; PHOSPHORYLATION; METASTASIS; GADD153	We have used microarray technology to identify the transcriptional targets of Rho subfamily guanosine 5'-triphosphate (GTP)ases in NIH3T3 cells. This analysis indicated that murine fibroblasts transformed by these proteins show similar transcriptomal profiles. Functional annotation of the regulated genes indicate that Rho subfamily GTPases target a wide spectrum of functions, although loci encoding proteins linked to proliferation and DNA synthesis/transcription are upregulated preferentially. Rho proteins promote four main networks of interacting proteins nucleated around E2F, c-Jun, c-Myc and p53. Of those, E2F, c-Jun and c-Myc are essential for the maintenance of cell transformation. Inhibition of Rock, one of the main Rho GTPase targets, leads to small changes in the transcriptome of Rho-transformed cells. Rock inhibition decreases c-myc gene expression without affecting the E2F and c-Jun pathways. Loss-of-function studies demonstrate that c-Myc is important for the blockage of cell-contact inhibition rather than for promoting the proliferation of Rho-transformed cells. However, c-Myc overexpression does not bypass the inhibition of cell transformation induced by Rock blockage, indicating that c-Myc is essential, but not sufficient, for Rock-dependent transformation. These results reveal the complexity of the genetic program orchestrated by the Rho subfamily and pinpoint protein networks that mediate different aspects of the malignant phenotype of Rho-transformed cells.	Univ Salamanca, CSIC, Ctr Invest Canc, E-37007 Salamanca, Spain; Univ Salamanca, CSIC, IBMCC, E-37007 Salamanca, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigacion del Cancer (CIC); CSIC-USAL - Instituto de Biologia Molecular y Celular del Cancer de Salamanca (IBMCC); University of Salamanca; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC-USAL - Instituto de Biologia Molecular y Celular del Cancer de Salamanca (IBMCC); University of Salamanca	Bustelo, XR (corresponding author), Univ Salamanca, CSIC, Ctr Invest Canc, Campus Unamuno, E-37007 Salamanca, Spain.	xbustelo@usal.es	Bustelo, Xose R./A-9526-2010; Bustelo, Xose R./AAD-2081-2022	Bustelo, Xose R./0000-0001-9398-6072; Bustelo, Xose R./0000-0001-9398-6072	NCI NIH HHS [R01 CA073735, 5R01-CA73735-10] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA073735] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Barsyte-Lovejoy D, 2004, ONCOGENE, V23, P3481, DOI 10.1038/sj.onc.1207487; Bolstad BM, 2004, INT REV NEUROBIOL, V60, P25; Budzyn K, 2006, TRENDS PHARMACOL SCI, V27, P97, DOI 10.1016/j.tips.2005.12.002; Calvano SE, 2005, NATURE, V437, P1032, DOI 10.1038/nature03985; Chen CH, 1996, ONCOGENE, V13, P1659; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Gautier L, 2004, BIOINFORMATICS, V20, P307, DOI 10.1093/bioinformatics/btg405; Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80; Hakem A, 2005, GENE DEV, V19, P1974, DOI 10.1101/gad.1310805; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; Jaffe AB, 2005, ANNU REV CELL DEV BI, V21, P247, DOI 10.1146/annurev.cellbio.21.020604.150721; Leng XH, 1997, CURR BIOL, V7, P709, DOI 10.1016/S0960-9822(06)00301-0; Liu AX, 2001, MOL CELL BIOL, V21, P6906, DOI 10.1128/MCB.21.20.6906-6912.2001; Marinissen MJ, 2004, MOL CELL, V14, P29, DOI 10.1016/S1097-2765(04)00153-4; Montaner S, 1998, J BIOL CHEM, V273, P12779, DOI 10.1074/jbc.273.21.12779; Montaner S, 1999, J BIOL CHEM, V274, P8506, DOI 10.1074/jbc.274.13.8506; Parrish Rudolph S, 2004, J Biopharm Stat, V14, P575, DOI 10.1081/BIP-200025650; Perona R, 1997, GENE DEV, V11, P463, DOI 10.1101/gad.11.4.463; Riento K, 2003, NAT REV MOL CELL BIO, V4, P446, DOI 10.1038/nrm1128; Sahai E, 1999, CURR BIOL, V9, P136, DOI 10.1016/S0960-9822(99)80067-0; Schuebel KE, 1998, EMBO J, V17, P6608, DOI 10.1093/emboj/17.22.6608; Simpson KJ, 2004, CANCER RES, V64, P8694, DOI 10.1158/0008-5472.CAN-04-2247; Teramoto H, 2003, ONCOGENE, V22, P2689, DOI 10.1038/sj.onc.1206364; Uehata M, 1997, NATURE, V389, P990, DOI 10.1038/40187; van der Eb A J, 1980, Methods Enzymol, V65, P826; Watnick RS, 2003, CANCER CELL, V3, P219, DOI 10.1016/S1535-6108(03)00030-8; Wheeler AP, 2004, EXP CELL RES, V301, P43, DOI 10.1016/j.yexcr.2004.08.012; Wu M, 2004, BREAST CANCER RES TR, V84, P3, DOI 10.1023/B:BREA.0000018426.76893.21	28	32	32	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 21	2007	26	29					4295	4305		10.1038/sj.onc.1210194	http://dx.doi.org/10.1038/sj.onc.1210194			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	184CY	17213802	Green Accepted, Green Submitted			2022-12-17	WOS:000247619900012
J	Brun, T; Duhamel, DL; He, KHH; Wollheim, CB; Gauthier, BR				Brun, T.; Duhamel, D. L.; He, K. H. Hu; Wollheim, C. B.; Gauthier, B. R.			The transcription factor PAX4 acts as a survival gene in INS-1E insulinoma cells	ONCOGENE			English	Article						RNAi; insulin; Pax4; proliferation; apoptosis; survival	GROWTH-FACTOR; BETA-CELLS; EXPRESSION; DIFFERENTIATION; PROLIFERATION; BETACELLULIN; DYSFUNCTION; SUSCEPTIBILITY; ASSOCIATION; METABOLISM	The paired/homeodomain transcription factor Pax4 is essential for islet beta-cell generation during pancreas development and their survival in adulthood. High Pax4 expression was reported in human insulinomas indicating that deregulation of the gene may be associated with tumorigenesis. We report that rat insulinoma INS-1E cells express 25-fold higher Pax4 mRNA levels than rat islets. In contrast to primary beta-cells, activin A but not betacellulin or glucose induced Pax4 mRNA levels indicating dissociation of Pax4 expression from insulinoma cell proliferation. Short hairpin RNA adenoviral constructs targeted to the paired domain or homeodomain (viPax4PD and viPax4HD) were generated. Pax4 mRNA levels were lowered by 73 and 50% in cells expressing either viPax4PD or viPax4HD. Transcript levels of the Pax4 target gene bcl-xl were reduced by 53 and 47%, whereas Pax6 and Pdx1 mRNA levels were unchanged. viPax4PD-infected cells displayed a twofold increase in spontaneous apoptosis and were more susceptible to cytokine-induced cell death. In contrast, proliferation was unaltered. RNA interference-mediated repression of insulin had no adverse effects on either Pax4 or Pdx1 expression as well as on cell replication or apoptosis. These results indicate that Pax4 is redundant for proliferation of insulinoma cells, whereas it is essential for survival through upregulation of the antiapoptotic gene bcl-xl.	Univ Geneva, Med Ctr, Dept Cell Physiol & Metab, CH-1211 Geneva 4, Switzerland	University of Geneva	Brun, T (corresponding author), Univ Geneva, Med Ctr, Dept Cell Physiol & Metab, CH-1211 Geneva 4, Switzerland.	thierry.brun@medecine.unige.ch; benoit.gauthier@medecine.unige.ch	Gauthier, Benoit R/C-3138-2017	Gauthier, Benoit R/0000-0001-8146-7486; BRUN, Thierry/0000-0002-1659-4283				ASFARI M, 1992, ENDOCRINOLOGY, V130, P167, DOI 10.1210/en.130.1.167; Barker CJ, 2002, AM J PHYSIOL-ENDOC M, V283, pE1113, DOI 10.1152/ajpendo.00088.2002; Bernasconi M, 1996, P NATL ACAD SCI USA, V93, P13164, DOI 10.1073/pnas.93.23.13164; Biason-Lauber A, 2005, DIABETOLOGIA, V48, P900, DOI 10.1007/s00125-005-1723-5; Blasco MA, 2005, NAT REV GENET, V6, P611, DOI 10.1038/nrg1656; Brun T, 2005, DIABETOLOGIA, V48, pA27; Brun T, 2004, J CELL BIOL, V167, P1123, DOI 10.1083/jcb.200405148; Buteau J, 2003, DIABETES, V52, P124, DOI 10.2337/diabetes.52.1.124; Collier Dawn C, 2003, J Appl Clin Med Phys, V4, P17, DOI 10.1120/1.1521271; Collombat P, 2005, DEVELOPMENT, V132, P2969, DOI 10.1242/dev.01870; Dor Y, 2004, NATURE, V429, P41, DOI 10.1038/nature02520; Feng XH, 2005, ANNU REV CELL DEV BI, V21, P659, DOI 10.1146/annurev.cellbio.21.022404.142018; Gauthier B, 1999, ATHEROSCLEROSIS, V142, P301, DOI 10.1016/S0021-9150(98)00245-7; Gauthier BR, 2004, J BIOL CHEM, V279, P31121, DOI 10.1074/jbc.M405030200; Gunton JE, 2005, CELL, V122, P337, DOI 10.1016/j.cell.2005.05.027; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; He SJ, 2005, MOL CANCER THER, V4, P996, DOI 10.1158/1535-7163.MCT-04-0252; Henderson CC, 2005, ONCOGENE, V24, P7120, DOI 10.1038/sj.onc.1208887; Heremans Y, 2002, J CELL BIOL, V159, P303, DOI 10.1083/jcb.200203074; Holm P, 2004, DIABETES, V53, P1584, DOI 10.2337/diabetes.53.6.1584; Hugl SR, 1998, J BIOL CHEM, V273, P17771, DOI 10.1074/jbc.273.28.17771; Huotari MA, 1998, ENDOCRINOLOGY, V139, P1494, DOI 10.1210/en.139.4.1494; Ishihara H, 2003, NAT CELL BIOL, V5, P330, DOI 10.1038/ncb951; Kanatsuka A, 2002, METABOLISM, V51, P1161, DOI 10.1053/meta.2002.34707; Kojima H, 2003, NAT MED, V9, P596, DOI 10.1038/nm867; LI Y, 2006, LEUKEMIA RES, V9, P1547; Margue CM, 2000, ONCOGENE, V19, P2921, DOI 10.1038/sj.onc.1203607; Mauvais-Jarvis F, 2004, HUM MOL GENET, V13, P3151, DOI 10.1093/hmg/ddh341; Merglen A, 2004, ENDOCRINOLOGY, V145, P667, DOI 10.1210/en.2003-1099; Miyamoto T, 2001, BIOCHEM BIOPH RES CO, V282, P34, DOI 10.1006/bbrc.2001.4552; Muratovska A, 2003, ONCOGENE, V22, P7989, DOI 10.1038/sj.onc.1206766; Ostrom L, 2000, DEV BIOL, V219, P250, DOI 10.1006/dbio.2000.9618; Park D, 2006, DEVELOPMENT, V133, P4193, DOI 10.1242/dev.02614; Robson EJD, 2006, NAT REV CANCER, V6, P52, DOI 10.1038/nrc1778; Shima Akihiro, 2003, EMBO Reports, V4, P121, DOI 10.1038/sj.embor.embor743; Shimajiri Y, 2001, DIABETES, V50, P2864, DOI 10.2337/diabetes.50.12.2864; SHING Y, 1993, SCIENCE, V259, P1604, DOI 10.1126/science.8456283; Sledz CA, 2003, NAT CELL BIOL, V5, P834, DOI 10.1038/ncb1038; SosaPineda B, 1997, NATURE, V386, P399, DOI 10.1038/386399a0; Theander-Carrillo C, 2006, J CLIN INVEST, V116, P1983, DOI 10.1172/JCI25811; Theis M, 2004, EXP CELL RES, V294, P18, DOI 10.1016/j.yexcr.2003.09.031; Tokuyama Y, 2006, METABOLISM, V55, P213, DOI 10.1016/j.metabol.2005.08.014; Ueda Y, 2000, FEBS LETT, V480, P101, DOI 10.1016/S0014-5793(00)01914-1; Wang JF, 2004, DEV BIOL, V266, P178, DOI 10.1016/j.ydbio.2003.10.018; Yamaoka T, 2000, DIABETOLOGIA, V43, P332, DOI 10.1007/s001250050051; Zalzman M, 2003, P NATL ACAD SCI USA, V100, P7253, DOI 10.1073/pnas.1136854100; Zhang YQ, 2001, DIABETES, V50, pS10, DOI 10.2337/diabetes.50.2007.S10; Zhou J, 2005, IEEE T INTELL TRANSP, V6, P229, DOI 10.1109/TITS.2005.848359; Zhou YH, 2003, CLIN CANCER RES, V9, P3369	49	32	34	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 21	2007	26	29					4261	4271		10.1038/sj.onc.1210205	http://dx.doi.org/10.1038/sj.onc.1210205			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	184CY	17260022				2022-12-17	WOS:000247619900009
J	Burwell, EA; McCarty, GP; Simpson, LA; Thompson, KA; Loeb, DM				Burwell, E. A.; McCarty, G. P.; Simpson, L. A.; Thompson, K. A.; Loeb, D. M.			Isoforms of Wilms' tumor suppressor gene (WT1) have distinct effects on mammary epithelial cells	ONCOGENE			English	Article						breast cancer; oncogene; epithelial-mesenchymal transition; cell cycle; alternative splicing	BREAST-CANCER; EXPRESSION; DIFFERENTIATION; TRANSCRIPTION; INTERACTS; PRODUCT; TARGET; EXON; DNA	The role of WT1 (Wilm's tumor suppressor gene) in breast cancer is controversial, with evidence for both tumor-promoting and tumor-suppressing activities. In order to address this question, we expressed different WT1 isoforms in the mammary epithelial cell line H16N-2, which does not express endogenous WT1. Cells were stably transfected with either WT1 (- Ex5/ - KTS) or WT1 ( + Ex5/ + KTS) under the control of the inducible metallothionein promoter. Induction of WT1 (- Ex5/ - KTS) upregulated p21, causing a slowing of proliferation and a G2-phase cell cycle arrest. In artificial basement membrane, the WT1 (- Ex5/ - KTS) isoform promoted the appearance of highly organized acinar cellular aggregates. In contrast, WT1 (+ Ex5/ + KTS) had no effect on p21 or proliferation, but rather caused an epithelial-mesenchymal transition and a redistribution of E-cadherin from the cell membrane to the cytoplasm. This isoform also causes the cellular aggregates growing in artificial basement membrane to appear significantly less organized than control cells. Thus, different WT1 isoforms have distinct effects in this cell line, suggesting that depending on the ratio of WT1 isoform expression in mammary epithelial cells, WT1 could function to either promote or suppress a transformed phenotype.	Johns Hopkins Univ, Div Pediat Oncol, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21231 USA	Johns Hopkins University; Johns Hopkins Medicine	Loeb, DM (corresponding author), Johns Hopkins Univ, Div Pediat Oncol, Sidney Kimmel Comprehens Canc Ctr, Bunting Blaustein Canc Res Bldg, Baltimore, MD 21231 USA.	dmloeb@jhmi.edu			NATIONAL CANCER INSTITUTE [T32CA060441] Funding Source: NIH RePORTER; NCI NIH HHS [T32CA60441] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Barlund M, 2000, J NATL CANCER I, V92, P1252, DOI 10.1093/jnci/92.15.1252; Davies RC, 1998, GENE DEV, V12, P3217, DOI 10.1101/gad.12.20.3217; Englert C, 1997, CANCER RES, V57, P1429; HABER DA, 1991, P NATL ACAD SCI USA, V88, P9618, DOI 10.1073/pnas.88.21.9618; Hewitt SM, 1996, ANTICANCER RES, V16, P621; Inoue K, 1998, BLOOD, V91, P2969, DOI 10.1182/blood.V91.8.2969.2969_2969_2976; KOLCH W, 1995, BREAST CANCER RES TR, V36, P139, DOI 10.1007/BF00666036; LARSSON SH, 1995, CELL, V81, P391, DOI 10.1016/0092-8674(95)90392-5; LEMOINE NR, 1992, BRIT J CANCER, V66, P1116, DOI 10.1038/bjc.1992.420; LO HW, 2005, BREAST CANC RES TREA, V95, P1; Loeb DM, 2001, CANCER RES, V61, P921; Loeb DM, 2006, CELL CYCLE, V5, P1249, DOI 10.4161/cc.5.12.2807; Loeb DM, 2003, LEUKEMIA, V17, P965, DOI 10.1038/sj.leu.2402906; Loeb DM, 2002, J BIOL CHEM, V277, P19627, DOI 10.1074/jbc.M201336200; MAHESWARAN S, 1993, P NATL ACAD SCI USA, V90, P5100, DOI 10.1073/pnas.90.11.5100; Miyoshi Y, 2002, CLIN CANCER RES, V8, P1167; Natoli TA, 2002, MOL CELL BIOL, V22, P4433, DOI 10.1128/MCB.22.12.4433-4438.2002; Reizner N, 2005, J MOL ENDOCRINOL, V35, P135, DOI 10.1677/jme.1.01761; Reynolds PA, 2003, GENE DEV, V17, P2094, DOI 10.1101/gad.1110703; Silberstein GB, 1997, P NATL ACAD SCI USA, V94, P8132, DOI 10.1073/pnas.94.15.8132; Udabage L, 2005, EXP CELL RES, V310, P205, DOI 10.1016/j.yexcr.2005.07.026; Velona T, 1999, PEDIATR RES, V45, P658, DOI 10.1203/00006450-199905010-00008; Zapata-Benavides P, 2002, BIOCHEM BIOPH RES CO, V295, P784, DOI 10.1016/S0006-291X(02)00751-9; Zhang TF, 2003, ANTICANCER RES, V23, P3575	24	32	33	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 17	2007	26	23					3423	3430		10.1038/sj.onc.1210127	http://dx.doi.org/10.1038/sj.onc.1210127			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	169GB	17160023				2022-12-17	WOS:000246579600012
J	Cai, C; Chen, SY; Zheng, Z; Omwancha, J; Lin, MF; Balk, SP; Shemshedini, L				Cai, C.; Chen, S-Y; Zheng, Z.; Omwancha, J.; Lin, M-F; Balk, S. P.; Shemshedini, L.			Androgen regulation of soluble guanylyl cyclase alpha 1 mediates prostate cancer cell proliferation	ONCOGENE			English	Article						androgen receptor; soluble guanylyl cyclase; prostate cancer; proliferation	NITRIC-OXIDE; ACID-PHOSPHATASE; GENE-EXPRESSION; RECEPTOR; LNCAP; PROGRESSION; ANTIGEN; INHIBITION; BIOLOGY; DEATH	The growth and progression of prostate cancer are dependent on androgens and androgen receptor (AR), which act by modulating gene expression. Utilizing a gene microarray approach, we have identified the alpha 1-subunit gene of soluble guanylyl cyclase (sGC) as a novel androgen-regulated gene. A heterodimeric cytoplasmic protein composed of one alpha and one beta subunit, sGC mediates the widespread cellular effects of nitric oxide (NO). We report here that, in prostate cancer cells, androgens stimulate the expression of sGC alpha 1. A cloned human sGC alpha 1 promoter is activated by androgen in an AR-dependent manner, suggesting that sGC alpha 1 may be a direct AR target gene. Disruption of sGC alpha 1 expression severely compromises the growth of both androgen-dependent and androgen-independent AR-positive prostate cancer cells. Overexpression of sGC alpha 1 alone is sufficient for stimulating prostate cancer cell proliferation. Interestingly, the major growth effect of sGC alpha 1 is independent of NO and cyclic guanosine monophosphate, a major mediator of the sGC enzyme. These data strongly suggest that sGC alpha 1 acts in prostate cancer via a novel pathway that does not depend on sGC beta 1. Tissue studies show that sGC alpha 1 expression is significantly elevated in advanced prostate cancer. Thus, sGC alpha 1 may be an important mediator of the procarcinogenic effects of androgens.	Univ Toledo, Dept Biol Sci, Toledo, OH 43606 USA; Beth Israel Deaconess Med Ctr, Dept Med, Div Hematol Oncol, Canc Biol Program, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Univ Nebraska, Coll Med, Ctr Med, Dept Biochem & Mol Biol, Omaha, NE 68198 USA	University System of Ohio; University of Toledo; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; University of Nebraska System	Shemshedini, L (corresponding author), Univ Toledo, Dept Biol Sci, 2801 W Bancroft St, Toledo, OH 43606 USA.	lshemsh@utnet.utoledo.edu	Cai, Changmeng/AAE-6835-2020; CHEN, Shaoyong/ABF-3357-2021	Cai, Changmeng/0000-0002-8701-2586				Arnold JT, 2002, ENDOCR-RELAT CANCER, V9, P61, DOI 10.1677/erc.0.0090061; CHANG CS, 1988, SCIENCE, V240, P324, DOI 10.1126/science.3353726; Chen L, 2004, NEW ASTRON, V10, P39, DOI 10.1016/j.newast.2004.04.008; Chen ME, 1998, J BIOL CHEM, V273, P17618, DOI 10.1074/jbc.273.28.17618; CHEN SY, 2006, IN PRESS ONCOGE 0529; Chen ZJ, 2002, CANCER LETT, V177, P181, DOI 10.1016/S0304-3835(01)00788-1; CUNHA GR, 1987, ENDOCR REV, V8, P338, DOI 10.1210/edrv-8-3-338; Eder IE, 2002, CANCER GENE THER, V9, P117, DOI 10.1038/sj.cgt.7700416; GARCIAARENAS R, 1995, MOL CELL ENDOCRINOL, V111, P29, DOI 10.1016/0303-7207(95)03544-H; Han GZ, 2005, P NATL ACAD SCI USA, V102, P1151, DOI 10.1073/pnas.0408925102; Heisler LE, 1997, MOL CELL ENDOCRINOL, V126, P59, DOI 10.1016/S0303-7207(96)03970-6; HOROSZEWICZ JS, 1983, CANCER RES, V43, P1809; Igawa T, 2002, PROSTATE, V50, P222, DOI 10.1002/pros.10054; ISAACS JT, 1994, VITAM HORM, V49, P433; ISAACS JT, 1984, PROSTATE, V5, P545, DOI 10.1002/pros.2990050510; Isaacs JT, 1999, UROL CLIN N AM, V26, P263, DOI 10.1016/S0094-0143(05)70066-5; Jenster G, 1999, SEMIN ONCOL, V26, P407; Jia L, 2003, MOL CANCER RES, V1, P385; Jiang J, 2004, CHINESE MED J-PEKING, V117, P684; KASTNER P, 1995, CELL, V83, P859, DOI 10.1016/0092-8674(95)90202-3; Koksal IT, 2002, PATHOLOGY, V34, P233, DOI 10.1080/00313020220131282; Krumenacker J, 2004, BRAIN RES BULL, V62, P505, DOI 10.1016/S0361-9230(03)00102-3; KRUMENACKER JS, 2001, P NATL ACAD SCI USA, V23, P170; LEE C, 1995, ENDOCRINOLOGY, V136, P796, DOI 10.1210/en.136.2.796; Lin MF, 1998, J BIOL CHEM, V273, P5939, DOI 10.1074/jbc.273.10.5939; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Meehan KL, 2003, FRONT BIOSCI-LANDMRK, V8, pD780, DOI 10.2741/1063; Mimeault M, 2005, PROSTATE, V62, P187, DOI 10.1002/pros.20138; Papandreou CN, 1998, NAT MED, V4, P50, DOI 10.1038/nm0198-050; Postovit LM, 2002, J BIOL CHEM, V277, P35730, DOI 10.1074/jbc.M204529200; Schrammel A, 1996, MOL PHARMACOL, V50, P1; Shenk JL, 2001, J BIOL CHEM, V276, P38472, DOI 10.1074/jbc.M103652200; Sinnaeve P, 2001, CIRC RES, V88, P103, DOI 10.1161/01.RES.88.1.103; Trapman J, 1997, SEMIN CANCER BIOL, V8, P29, DOI 10.1006/scbi.1997.0050; Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075; YOUNG CYF, 1994, ONCOL RES, V6, P203; YUAN SX, 1993, CANCER RES, V53, P1304	37	32	34	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 8	2007	26	11					1606	1615		10.1038/sj.onc.1209956	http://dx.doi.org/10.1038/sj.onc.1209956			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	144FV	16964290				2022-12-17	WOS:000244782500010
J	Hess, F; Estrugo, D; Fischer, A; Belka, C; Cordes, N				Hess, F.; Estrugo, D.; Fischer, A.; Belka, C.; Cordes, N.			Integrin-linked kinase interacts with caspase-9 and-8 in an adhesion-dependent manner for promoting radiation-induced apoptosis in human leukemia cells	ONCOGENE			English	Article						apoptosis; ILK; caspase-8; caspase-9; ECM; radiation	RESISTANCE CAM-DR; LUNG-CANCER CELLS; IN-VITRO; PROTEIN-KINASE; IONIZING-RADIATION; ALPHA-4-BETA-1 INTEGRIN; CD95-INDUCED APOPTOSIS; RNA INTERFERENCE; CYTOTOXIC DRUGS; SURVIVAL	Integrin-mediated adhesion of leukemia cells to extracellular matrix proteins reduces apoptosis following radiation-induced genotoxic injury. To evaluate the role of integrin-linked kinase ( ILK) in this process, HL60 human acute promyelocytic leukemia cells were stably transfected with ILK wild-type or kinase-hyperactive overexpression vectors. Suspension or. bronectin (FN) adhesion cultures were irradiated with X-rays and processed for measurement of apoptosis, mitochondrial transmembrane potential and caspase activation. Adhesion to FN pronouncedly reduced radiation-induced apoptosis of HL60 cells and vector controls. Intriguingly, overexpressed ILK enhanced apoptosis after irradiation by combined activation of caspase-3 through caspase-8 and -9 in irradiated FN cultures. Irradiation of ILK suspension cultures lacked caspase-8 activation, but showed serial cleavage of caspase-9, -3 and poly (ADPribose) polymerase. These findings further characterize the cell death-promoting function of ILK in DNA-damaged cells. Moreover, ILK might represent a potential therapeutic target for innovative chemo- and radiooncological approaches in hematological malignancies.	Tech Univ Dresden, Fac Med, D-01307 Dresden, Germany; Bundeswehr Inst Radiobiol, Munich, Germany; Univ Tubingen, Dept Radiat Oncol, Tubingen, Germany	Technische Universitat Dresden; Eberhard Karls University of Tubingen	Cordes, N (corresponding author), Tech Univ Dresden, Fac Med, Fetscherstasse 74-PF, D-01307 Dresden, Germany.	nils.cordes@oncoray.de		Cordes, Nils/0000-0001-5684-629X				Aoudjit F, 2001, ONCOGENE, V20, P4995, DOI 10.1038/sj.onc.1204554; Attwell S, 2000, ONCOGENE, V19, P3811, DOI 10.1038/sj.onc.1203711; Baker EK, 2003, EXP CELL RES, V290, P177, DOI 10.1016/S0014-4827(03)00342-2; Belka C, 2002, INT J RADIAT BIOL, V78, P643, DOI 10.1080/09553000210137680; Belka C, 2000, ONCOGENE, V19, P1181, DOI 10.1038/sj.onc.1203401; Chanan-Khan Asher, 2004, Curr Treat Options Oncol, V5, P261, DOI 10.1007/s11864-004-0017-3; Cheng EHYA, 2001, MOL CELL, V8, P705, DOI 10.1016/S1097-2765(01)00320-3; Cordes N, 2006, ONCOGENE, V25, P1378, DOI 10.1038/sj.onc.1209164; Cordes N, 2004, STRAHLENTHER ONKOL, V180, P157, DOI 10.1007/s00066-004-1144-2; Cordes N, 2004, CANCER RES, V64, P5683, DOI 10.1158/0008-5472.CAN-04-1056; Cordes N, 2004, INT J RADIAT ONCOL, V58, P453, DOI 10.1016/j.ijrobp.2003.09.069; Cordes N, 2003, BRIT J CANCER, V88, P1470, DOI 10.1038/sj.bjc.6600912; Cordes N, 2003, STRAHLENTHER ONKOL, V179, P337, DOI 10.1007/s00066-003-1074-4; Damiano JS, 2001, LEUKEMIA, V15, P1232, DOI 10.1038/sj.leu.2402179; Damiano JS, 1999, BLOOD, V93, P1658, DOI 10.1182/blood.V93.5.1658; de la Fuente MT, 2002, J LEUKOCYTE BIOL, V71, P495; Duxbury MS, 2005, CLIN CANCER RES, V11, P3433, DOI 10.1158/1078-0432.CCR-04-1510; Eke I, 2006, RADIOTHER ONCOL, V80, P178, DOI 10.1016/j.radonc.2006.07.028; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Finkelstein LD, 2000, BIOCHEM J, V345, P385, DOI 10.1042/0264-6021:3450385; Frisch SM, 2001, CURR OPIN CELL BIOL, V13, P555, DOI 10.1016/S0955-0674(00)00251-9; Gendron S, 2003, J BIOL CHEM, V278, P48633, DOI 10.1074/jbc.M305169200; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Gilmore AP, 2000, J CELL BIOL, V149, P431, DOI 10.1083/jcb.149.2.431; Hannigan GE, 1996, NATURE, V379, P91, DOI 10.1038/379091a0; Hazlehurst LA, 2000, ONCOGENE, V19, P4319, DOI 10.1038/sj.onc.1203782; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; Jan YW, 2004, CELL, V116, P751, DOI 10.1016/S0092-8674(04)00204-1; Kasahara T, 2002, ANTIOXID REDOX SIGN, V4, P491, DOI 10.1089/15230860260196290; Kinbara K, 2003, NAT REV MOL CELL BIO, V4, P767, DOI 10.1038/nrm1229; Kremer CL, 2006, PROSTATE, V66, P88, DOI 10.1002/pros.20316; Legate KR, 2006, NAT REV MOL CELL BIO, V7, P20, DOI 10.1038/nrm1789; Matter ML, 2001, J BIOL CHEM, V276, P27757, DOI 10.1074/jbc.M102014200; Mitra SK, 2005, NAT REV MOL CELL BIO, V6, P56, DOI 10.1038/nrm1549; Nardi V, 2004, CURR OPIN HEMATOL, V11, P35, DOI 10.1097/00062752-200401000-00006; Newton K, 2000, J EXP MED, V191, P195, DOI 10.1084/jem.191.1.195; Persad S, 2001, J BIOL CHEM, V276, P27462, DOI 10.1074/jbc.M102940200; Peter ME, 2003, CELL DEATH DIFFER, V10, P26, DOI 10.1038/sj.cdd.4401186; Riedl SJ, 2004, NAT REV MOL CELL BIO, V5, P897, DOI 10.1038/nrm1496; Seidler J, 2005, RADIOTHER ONCOL, V76, P129, DOI 10.1016/j.radonc.2005.06.018; Sethi T, 1999, NAT MED, V5, P662, DOI 10.1038/9511; Shain KH, 2002, J IMMUNOL, V168, P2544, DOI 10.4049/jimmunol.168.5.2544; Soldatenkov VA, 2000, INT J CANCER, V90, P59, DOI 10.1002/(SICI)1097-0215(20000420)90:2<59::AID-IJC1>3.0.CO;2-4; Stupack DG, 2001, J CELL BIOL, V155, P459, DOI 10.1083/jcb.200106070; Sun EW, 2001, PHARMACOL THERAPEUT, V92, P135, DOI 10.1016/S0163-7258(01)00164-4; Tamagiku Y, 2004, BIOCHEM BIOPH RES CO, V323, P445, DOI 10.1016/j.bbrc.2004.08.115; Zhang H, 2002, CANCER, V95, P896, DOI 10.1002/cncr.10751	47	32	32	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 1	2007	26	10					1372	1384		10.1038/sj.onc.1209947	http://dx.doi.org/10.1038/sj.onc.1209947			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	141DV	16936772				2022-12-17	WOS:000244558800002
J	Rinaldo, F; Li, J; Wang, E; Muders, M; Datta, K				Rinaldo, F.; Li, J.; Wang, E.; Muders, M.; Datta, K.			RalA regulates vascular endothelial growth factor-C (VEGF-C) synthesis in prostate cancer cells during androgen ablation	ONCOGENE			English	Article						RalA; VEGF-C; androgen; reactive oxygen species; prostate cancer	LYMPH-NODE METASTASIS; TUMOR LYMPHANGIOGENESIS; OXIDATIVE STRESS; EPITHELIAL-CELLS; EXPRESSION; RAS; PATHWAY; INVOLVEMENT; ACTIVATION; RECEPTOR-3	Prostate cancer mortality is primarily due to failure to cure patients with metastatic disease. In its early stages, prostate cancer growth is enhanced by androgens. As such, the primary therapy for advanced (locally extensive or metastatic) prostate cancer consists of androgen deprivation therapy by pharmacotherapeutic or surgical means. Eventually, the tumor recurs owing to a transition from androgen-dependence to a highly metastatic and androgen refractory (androgen depletion-independent) phenotype. As the detailed molecular mechanism underlying this transition to a more aggressive phenotype is poorly understood, it has been difficult to develop effective treatments for this advanced stage of the disease. We have previously reported an increase in vascular endothelial growth factor-C (VEGF-C) express ion in human prostate cancer cells after androgen withdrawal. We have also shown increased expression of the androgen receptor coactivator BAG-1L by VEGF-C, suggesting the involvement of this growth factor in transactivation of the androgen receptor, even at low concentrations of androgen. In our present study, we show that androgen deprivation of human prostate carcinoma cells activates the small GTPase, RalA, a molecule important for human oncogenesis. RalA activation leads to VEGF-C upregulation. We also show that elevated levels of intracellular reactive oxygen species in prostate cancer cells under androgen-ablated conditions is the major inducer of RalA activation and VEGF-C synthesis.	Mayo Clin Fdn, Mayo Clin Canc Ctr, Dept Biochem & Mol Biol, Rochester, MN 55905 USA	Mayo Clinic	Datta, K (corresponding author), Mayo Clin Fdn, Mayo Clin Canc Ctr, Dept Biochem & Mol Biol, Gugg 1401B,200 1st St SW, Rochester, MN 55905 USA.	datta.kaustubh@mayo.edu	Muders, Michael/AAU-6443-2020		PHS HHS [1 PSOCA91956-3] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		CHARDIN P, 1986, EMBO J, V5, P2203, DOI 10.1002/j.1460-2075.1986.tb04485.x; Chien YC, 2003, EMBO REP, V4, P800, DOI 10.1038/sj.embor.embor899; Collette J, 2004, INT J CANCER, V112, P190, DOI 10.1002/ijc.20398; De Ruiter ND, 2000, MOL CELL BIOL, V20, P8480, DOI 10.1128/MCB.20.22.8480-8488.2000; DENIS L, 1993, CANCER, V72, P3888, DOI 10.1002/1097-0142(19931215)72:12+<3888::AID-CNCR2820721726>3.0.CO;2-B; Epstein JI, 1996, AM J SURG PATHOL, V20, P286, DOI 10.1097/00000478-199603000-00004; Essers MAG, 2004, EMBO J, V23, P4802, DOI 10.1038/sj.emboj.7600476; Feig LA, 2003, TRENDS CELL BIOL, V13, P419, DOI 10.1016/S0962-8924(03)00152-1; He YL, 2002, J NATL CANCER I, V94, P819, DOI 10.1093/jnci/94.11.819; Isaacs JT, 1999, UROL CLIN N AM, V26, P263, DOI 10.1016/S0094-0143(05)70066-5; Jennbacken K, 2005, PROSTATE, V65, P110, DOI 10.1002/pros.20276; Jia YT, 2004, WORLD J GASTROENTERO, V10, P3261, DOI 10.3748/wjg.v10.i22.3261; Karpanen T, 2001, CANCER RES, V61, P1786; Kimura Y, 2003, ONCOL REP, V10, P1747; KYPRIANOU N, 1990, CANCER RES, V50, P3748; Li JP, 2005, ONCOGENE, V24, P5510, DOI 10.1038/sj.onc.1208693; Lo YYC, 1996, J BIOL CHEM, V271, P15703, DOI 10.1074/jbc.271.26.15703; Mandriota SJ, 2001, EMBO J, V20, P672, DOI 10.1093/emboj/20.4.672; McFall A, 2001, MOL CELL BIOL, V21, P5488, DOI 10.1128/MCB.21.16.5488-5499.2001; Neuchrist C, 2003, HEAD NECK-J SCI SPEC, V25, P464, DOI 10.1002/hed.10235; Oh WK, 1998, J UROLOGY, V160, P1220, DOI 10.1016/S0022-5347(01)62501-1; Pettaway CA, 1996, CLIN CANCER RES, V2, P1627; Sipos B, 2004, AM J PATHOL, V165, P1187, DOI 10.1016/S0002-9440(10)63379-2; Skobe M, 2001, NAT MED, V7, P192, DOI 10.1038/84643; Tam NNC, 2003, AM J PATHOL, V163, P2513, DOI 10.1016/S0002-9440(10)63606-1; Tchevkina E, 2005, ONCOGENE, V24, P329, DOI 10.1038/sj.onc.1208094; Tsurusaki T, 1999, BRIT J CANCER, V80, P309, DOI 10.1038/sj.bjc.6690356; Ulku AS, 2003, MOL CANCER RES, V1, P1077; Urano T, 1996, EMBO J, V15, P810, DOI 10.1002/j.1460-2075.1996.tb00416.x; Zeng YP, 2005, PROSTATE, V65, P222, DOI 10.1002/pros.20288	30	32	32	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2007	26	12					1731	1738		10.1038/sj.onc.1209971	http://dx.doi.org/10.1038/sj.onc.1209971			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	146SS	16964283				2022-12-17	WOS:000244955600007
J	Corral, RS; Iniguez, MA; Duque, J; Lopez-Perez, R; Fresno, M				Corral, R. S.; Iniguez, M. A.; Duque, J.; Lopez-Perez, R.; Fresno, M.			Bombesin induces cyclooxygenase-2 expression through the activation of the nuclear factor of activated T cells and enhances cell migration in Caco-2 colon carcinoma cells	ONCOGENE			English	Article						cyclooxygenase-2; NFAT; bombesin; migration; colon carcinoma	GASTRIN-RELEASING-PEPTIDE; RECEPTOR TYROSINE KINASE; CANCER CELLS; TRANSCRIPTIONAL REGULATION; INVASION; INHIBITION; MOTILITY; GROWTH; NFAT; INDUCTION	Cyclooxygenase-2 (Cox-2), the gastrin-release peptide (GRP) and its cognate receptor (GRP-R) are over-expressed in a significant percentage of colorectal carcinomas and are associated with cell growth, invasiveness and tumor progression. However, a molecular link between all of them in adenocarcinomas has not been established. Here, we show that bombesin (BBS), a GRP homolog, stimulates the expression of Cox-2 mRNA and protein in human colon adenocarcinoma Caco-2 cells, resulting in enhanced release of prostaglandin E-2. These effects were markedly inhibited by the specific BBS antagonist RC-3940-II. BBS promotes the activation of the nuclear factor of activated T cells (NFAT) through a Ca2+/calcineurin (Cn)linked pathway. Upon BBS stimulation, the NFATc1 isoform translocates into the nucleus witha concomitant increase in NFATc1 binding to two specific recognition sites in the promoter region of the Cox-2 gene. Furthermore, inhibition of Cn activity by the immunosuppressive drug cyclosporin A impaired NFAT activation and diminished Cox-2 expression in BBS-stimulated cells. Interestingly, BBS pretreatment strongly enhances the invasive capacity of carcinoma cells, effect which was inhibited by a Cox-2-specific inhibitor. These. findings provide the. first evidence for the involvement of the Ca2+/Cn/NFAT pathway in BBS-mediated induction of genes involved in colon carcinoma invasiveness such as Cox-2.	Univ Autonoma Madrid, CSIC, Ctr Biol Mol Severo Ochoa, E-28049 Madrid, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM)	Fresno, M (corresponding author), Univ Autonoma Madrid, CSIC, Ctr Biol Mol Severo Ochoa, E-28049 Madrid, Spain.	mfresno@cbm.uam.es	Peña, Miguel Angel Iñiguez/J-8518-2012	Peña, Miguel Angel Iñiguez/0000-0001-8262-6119; Lopez-Perez, Ricardo/0000-0001-9495-8604; Fresno Escudero, Manuel/0000-0002-9223-5477				ALBINI A, 1987, CANCER RES, V47, P3239; Aprikian AG, 1997, INT J CANCER, V72, P498, DOI 10.1002/(SICI)1097-0215(19970729)72:3<498::AID-IJC19>3.3.CO;2-P; Boss V, 1996, J BIOL CHEM, V271, P10429, DOI 10.1074/jbc.271.18.10429; Bresalier RS, 2005, NEW ENGL J MED, V352, P1092, DOI 10.1056/NEJMoa050493; CAI RZ, 1994, P NATL ACAD SCI USA, V91, P12664, DOI 10.1073/pnas.91.26.12664; Carroll RE, 2000, MOL PHARMACOL, V58, P601, DOI 10.1124/mol.58.3.601; Carroll RE, 1999, AM J PHYSIOL-GASTR L, V276, pG655, DOI 10.1152/ajpgi.1999.276.3.G655; Chan TA, 2002, LANCET ONCOL, V3, P166, DOI 10.1016/S1470-2045(02)00680-0; Chen M, 2005, ONCOGENE, V24, P5125, DOI 10.1038/sj.onc.1208729; Cheng HF, 2002, J BIOL CHEM, V277, P45638, DOI 10.1074/JBC.m206040200; CUTTITTA F, 1985, NATURE, V316, P823, DOI 10.1038/316823a0; Dixon DA, 2004, CURR PHARM DESIGN, V10, P635, DOI 10.2174/1381612043453171; Duque J, 2005, J BIOL CHEM, V280, P8686, DOI 10.1074/jbc.M413076200; Engle MJ, 1998, J CELL PHYSIOL, V174, P362, DOI 10.1002/(SICI)1097-4652(199803)174:3<362::AID-JCP10>3.0.CO;2-B; Fenwick SW, 2003, GASTROENTEROLOGY, V125, P716, DOI 10.1016/S0016-5085(03)01061-8; Festuccia C, 1998, INT J CANCER, V75, P418, DOI 10.1002/(SICI)1097-0215(19980130)75:3<418::AID-IJC16>3.0.CO;2-4; Festuccia C, 2002, EXP CELL RES, V280, P1, DOI 10.1006/excr.2002.5609; Glover S, 2005, AM J PHYSIOL-GASTR L, V288, pG1274, DOI 10.1152/ajpgi.00108.2004; Guo YS, 2001, J BIOL CHEM, V276, P22941, DOI 10.1074/jbc.M101801200; Gupta RA, 2001, NAT REV CANCER, V1, P11, DOI 10.1038/35094017; Hecht JR, 1997, PROSTAG OTH LIPID M, V54, P757, DOI 10.1016/S0090-6980(97)00162-7; Hellmich MR, 1999, J BIOL CHEM, V274, P23901, DOI 10.1074/jbc.274.34.23901; Hernandez GL, 2001, J EXP MED, V193, P607, DOI 10.1084/jem.193.5.607; Hogan PG, 2003, GENE DEV, V17, P2205, DOI 10.1101/gad.1102703; Holzmann K, 2004, CANCER RES, V64, P4428, DOI 10.1158/0008-5472.CAN-04-0431; Horsley V, 2002, J CELL BIOL, V156, P771, DOI 10.1083/jcb.200111073; Iishi H, 2003, CLIN EXP METASTAS, V20, P555, DOI 10.1023/A:1025883129932; Iniguez MA, 2003, TRENDS MOL MED, V9, P73, DOI 10.1016/S1471-4914(02)00011-4; Iniguez MA, 2000, J BIOL CHEM, V275, P23627, DOI 10.1074/jbc.M001381200; Inoue H, 2002, ARTERIOSCL THROM VAS, V22, P1415, DOI 10.1161/01.ATV.0000028816.13582.13; Jauliac S, 2002, NAT CELL BIOL, V4, P540, DOI 10.1038/ncb816; Jensen JAG, 2001, PEPTIDES, V22, P689, DOI 10.1016/S0196-9781(01)00380-1; Kanashiro CA, 2003, P NATL ACAD SCI USA, V100, P15836, DOI 10.1073/pnas.2536558100; Kawai N, 2002, PROSTAG OTH LIPID M, V68-9, P187, DOI 10.1016/S0090-6980(02)00030-8; Kermorgant S, 2001, CARCINOGENESIS, V22, P1035, DOI 10.1093/carcin/22.7.1035; Lara-Pezzi E, 2002, J CLIN INVEST, V110, P1831, DOI 10.1172/JCI200215887; Levine L, 2003, CANCER RES, V63, P3495; Liu WV, 2003, CANCER RES, V63, P3632; Liu ZM, 2004, J BIOL CHEM, V279, P41218, DOI 10.1074/jbc.M406917200; Luo C, 1996, P NATL ACAD SCI USA, V93, P8907, DOI 10.1073/pnas.93.17.8907; MartinezMartinez S, 1997, MOL CELL BIOL, V17, P6437, DOI 10.1128/MCB.17.11.6437; Munoz-Najar UM, 2006, ONCOGENE, V25, P2379, DOI 10.1038/sj.onc.1209273; Neal JW, 2003, J BIOL CHEM, V278, P17246, DOI 10.1074/jbc.M300528200; NORTHROP JP, 1994, NATURE, V369, P497, DOI 10.1038/369497a0; Oshima M, 1996, CELL, V87, P803, DOI 10.1016/S0092-8674(00)81988-1; Pai R, 2003, FASEB J, V17, P1640, DOI 10.1096/fj.02-1011com; PRESTON SR, 1995, BRIT J CANCER, V71, P1087, DOI 10.1038/bjc.1995.210; Ramsay RG, 2003, INT J IMMUNOPATH PH, V16, P59; Robida AM, 2000, MOL PHARMACOL, V58, P701, DOI 10.1124/mol.58.4.701; Rozengurt E, 2002, EUR J SURG, V168, P23; Ryan FR, 1999, J PHARMACOL EXP THER, V290, P1202; Saurin JC, 2002, CANCER RES, V62, P4829; Saurin JC, 1999, CANCER RES, V59, P962; Shao JY, 2004, J BIOL CHEM, V279, P14287, DOI 10.1074/jbc.M313276200; Shao JY, 2000, J BIOL CHEM, V275, P33951, DOI 10.1074/jbc.M002324200; Singh B, 2005, INT J ONCOL, V26, P1393; Smith WL, 2000, ANNU REV BIOCHEM, V69, P145, DOI 10.1146/annurev.biochem.69.1.145; Sun YJ, 2005, MOL CANCER THER, V4, P51; Tsujii M, 1997, P NATL ACAD SCI USA, V94, P3336, DOI 10.1073/pnas.94.7.3336; Williams CS, 1996, GASTROENTEROLOGY, V111, P1134, DOI 10.1016/S0016-5085(96)70083-5; Yegen BC, 2003, CURR PHARM DESIGN, V9, P1013, DOI 10.2174/1381612033455134; Yiu GK, 2006, J BIOL CHEM, V281, P12210, DOI 10.1074/jbc.M600184200	62	32	33	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2007	26	7					958	969		10.1038/sj.onc.1209856	http://dx.doi.org/10.1038/sj.onc.1209856			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	136SW	16909108	Bronze			2022-12-17	WOS:000244245400002
J	Chen, SL; Lin, ST; Tsai, TC; Hsiao, WC; Tsao, YP				Chen, S-L; Lin, S-T; Tsai, T-C; Hsiao, W-C; Tsao, Y-P			ErbB4 (JM-b/CYT-1)-induced expression and phosphorylation of c-Jun is abrogated by human papillomavirus type 16 E5 protein	ONCOGENE			English	Article						c-jun; ErbB4; HPV-16 E5; phosphorylation; proliferation	EPIDERMAL-GROWTH-FACTOR; NEU DIFFERENTIATION FACTOR; FACTOR RECEPTOR; TRANSCRIPTIONAL ACTIVITY; PRODUCTIVE INTERACTION; TRANSMEMBRANE MUTANTS; GENE-EXPRESSION; MESSENGER-RNA; MICE LACKING; HA-RAS	Human papillomavirus type 16 E5 (HPV-16 E5) is a highly hydrophobic membrane protein with weak-transforming activity, which is associated with ErbB4 receptor in HPV-16-infected cervical lesions. Presently, we investigated the transforming mechanisms of E5 involving ErbB4 signaling. Firstly, we report a role for ErbB4 (JM-b/CYT-1) receptor that activates c-jun gene expression and phosphorylating at Ser63 and Ser73 of the c-Jun protein in ligand-independent and Ras-c-jun NH2-terminal kinase-dependent pathway. Secondly, we show that HPV-16 E5 protein can form a complex with ErbB4 via binding to the extracellular and transmembrane domains of ErbB4 (JM-b/CYT-1). When co-expressing HPV-16 E5 and ErbB4 in cells, E5 can abrogate ErbB4-induced c-Jun protein expression and phosphorylation resulted in increasing cell proliferation compared to ErbB4-expressing cells. The interaction between of HPV-16 E5 and ErbB4 provides more insight into the mechanisms of HPV-16 E5 transformation induction.	Natl Taiwan Univ, Grad Inst Microbiol, Coll Med, Dept Microbiol, Taipei, Taiwan; Natl Def Univ, Natl Def Med Ctr, Dept Microbiol & Immunol, Taipei, Taiwan; Asia Univ, Dept Biotechnol & Bioinformat, Taichung, Taiwan; Mackay Mem Hosp, Dept Ophthalmol, Taipei, Taiwan	National Taiwan University; National Defense Medical Center; National Defense University - Taiwan; Asia University Taiwan; Mackay Memorial Hospital	Chen, SL (corresponding author), Natl Taiwan Univ, Grad Inst Microbiol, Coll Med, Dept Microbiol, 7F,1,Sec 1,Jen Ai Rd, Taipei, Taiwan.	showlic@ha.mc.ntu.edu.tw						Adduci AJ, 1999, J BIOL CHEM, V274, P10249, DOI 10.1074/jbc.274.15.10249; Aqeilan RI, 2005, CANCER RES, V65, P6764, DOI 10.1158/0008-5472.CAN-05-1150; Bacus SS, 1996, AM J PATHOL, V148, P549; BACUS SS, 1994, AM J CLIN PATHOL, V102, pS13; Beerli RR, 1996, J BIOL CHEM, V271, P6071, DOI 10.1074/jbc.271.11.6071; Bouyain S, 2005, P NATL ACAD SCI USA, V102, P15024, DOI 10.1073/pnas.0507591102; Carpenter G, 2003, EXP CELL RES, V284, P66, DOI 10.1016/S0014-4827(02)00100-3; Chang JL, 2001, J BIOMED SCI, V8, P206, DOI 10.1007/BF02256414; Chen SL, 1998, VIROLOGY, V244, P521, DOI 10.1006/viro.1998.9109; Chen XM, 1996, J BIOL CHEM, V271, P7620, DOI 10.1074/jbc.271.13.7620; Clark DE, 2005, J BIOL CHEM, V280, P24175, DOI 10.1074/jbc.M414044200; CULOUSCOU JM, 1995, J BIOL CHEM, V270, P12857, DOI 10.1074/jbc.270.21.12857; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DiMaio D, 2001, ONCOGENE, V20, P7866, DOI 10.1038/sj.onc.1204915; Elenius K, 1997, EMBO J, V16, P1268, DOI 10.1093/emboj/16.6.1268; Elenius K, 1997, J BIOL CHEM, V272, P26761, DOI 10.1074/jbc.272.42.26761; FALLS DL, 1993, CELL, V72, P801, DOI 10.1016/0092-8674(93)90407-H; Gambarotta G, 2004, J BIOL CHEM, V279, P48808, DOI 10.1074/jbc.M408374200; GASSMANN M, 1995, NATURE, V378, P390, DOI 10.1038/378390a0; Golding JP, 2000, NAT CELL BIOL, V2, P103, DOI 10.1038/35000058; Graber HU, 1999, INT J CANCER, V84, P24, DOI 10.1002/(SICI)1097-0215(19990219)84:1<24::AID-IJC5>3.0.CO;2-2; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; GrausPorta D, 1997, EMBO J, V16, P1647, DOI 10.1093/emboj/16.7.1647; Gullick WJ, 2003, J PATHOL, V200, P279, DOI 10.1002/path.1335; HIGASHIYAMA S, 1991, SCIENCE, V251, P936, DOI 10.1126/science.1840698; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; Hsieh CH, 2000, ARCH VIROL, V145, P2273, DOI 10.1007/s007050070020; HWANG ES, 1995, VIROLOGY, V211, P227, DOI 10.1006/viro.1995.1395; Jones FE, 1999, J CELL BIOL, V147, P77, DOI 10.1083/jcb.147.1.77; Jorissen RN, 2003, EXP CELL RES, V284, P31, DOI 10.1016/S0014-4827(02)00098-8; Junttila TT, 2005, CANCER RES, V65, P1384, DOI 10.1158/0008-5472.CAN-04-3150; Kainulainen V, 2000, J BIOL CHEM, V275, P8641, DOI 10.1074/jbc.275.12.8641; Knowlden JM, 1998, ONCOGENE, V17, P1949, DOI 10.1038/sj.onc.1202107; Komuro A, 2003, J BIOL CHEM, V278, P33334, DOI 10.1074/jbc.M305597200; Lai CC, 2005, J VIROL, V79, P1924, DOI 10.1128/JVI.79.3.1924-1929.2005; Lee HJ, 2002, J BIOL CHEM, V277, P6318, DOI 10.1074/jbc.M110371200; Lee SA, 2001, J BIOL CHEM, V276, P11783, DOI 10.1074/jbc.M004517200; Li BS, 2002, EMBO J, V21, P324, DOI 10.1093/emboj/21.3.324; Long WW, 2003, DEVELOPMENT, V130, P5257, DOI 10.1242/dev.00715; Lyne JC, 1997, CANCER J SCI AM, V3, P21; MARCHIONNI MA, 1993, NATURE, V362, P312, DOI 10.1038/362312a0; Memon AA, 2004, BRIT J CANCER, V91, P2034, DOI 10.1038/sj.bjc.6602251; Mendrola JM, 2002, J BIOL CHEM, V277, P4704, DOI 10.1074/jbc.M108681200; Nappi VM, 2002, J BIOL CHEM, V277, P47149, DOI 10.1074/jbc.M209582200; Nappi VM, 2002, J VIROL, V76, P7976, DOI 10.1128/JVI.76.16.7976-7986.2002; Ni CY, 2001, SCIENCE, V294, P2179, DOI 10.1126/science.1065412; PLOWMAN GD, 1993, P NATL ACAD SCI USA, V90, P1746, DOI 10.1073/pnas.90.5.1746; Riese DJ, 1996, ONCOGENE, V12, P345; Rio C, 2000, J BIOL CHEM, V275, P10379, DOI 10.1074/jbc.275.14.10379; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SHING Y, 1993, SCIENCE, V259, P1604, DOI 10.1126/science.8456283; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; SMEAL T, 1994, EMBO J, V13, P6006, DOI 10.1002/j.1460-2075.1994.tb06946.x; Sparkowski J, 1996, J VIROL, V70, P2420, DOI 10.1128/JVI.70.4.2420-2430.1996; Srinivasan R, 1998, J PATHOL, V185, P236, DOI 10.1002/(SICI)1096-9896(199807)185:3<236::AID-PATH118>3.0.CO;2-7; TALOR P, 2006, IN PRESS J CELL 0303; Thomasson M, 2004, ACTA ONCOL, V43, P453, DOI 10.1080/02841860410028574; Tsai TC, 2003, ARCH VIROL, V148, P1445, DOI 10.1007/s00705-003-0111-z; TSAO YP, 1995, CANCER LETT, V95, P201, DOI 10.1016/0304-3835(95)03894-3; Tsao YP, 1996, J VIROL, V70, P7535, DOI 10.1128/JVI.70.11.7535-7539.1996; Vidal GA, 2005, J BIOL CHEM, V280, P19777, DOI 10.1074/jbc.M412457200; Weiss FU, 1997, J CELL PHYSIOL, V173, P187, DOI 10.1002/(SICI)1097-4652(199711)173:2<187::AID-JCP19>3.0.CO;2-D; WEN DZ, 1992, CELL, V69, P559, DOI 10.1016/0092-8674(92)90456-M; Williams CC, 2004, J CELL BIOL, V167, P469, DOI 10.1083/jcb.200403155; Williams SMG, 2005, CANCER RES, V65, P6534, DOI 10.1158/0008-5472.CAN-05-0083; zur Hausen H, 2002, NAT REV CANCER, V2, P342, DOI 10.1038/nrc798	66	32	32	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 4	2007	26	1					42	53		10.1038/sj.onc.1209768	http://dx.doi.org/10.1038/sj.onc.1209768			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	122OO	16819515				2022-12-17	WOS:000243236500005
J	Zhang, JS; Gong, A; Young, CYF				Zhang, J-S; Gong, A.; Young, C. Y. F.			ZNF185, an actin-cytoskeleton-associated growth inhibitory LIM protein in prostate cancer	ONCOGENE			English	Article						LIM domain protein; filamentous actin; prostate cancer; tumor suppressor	GENE; DOMAIN; DIFFERENTIATION; HOMEODOMAIN; TARGETS; EPLIN; CELLS; MOTIF; LOST	We have recently identified ZNF185 as a gene that is downregulated in prostate cancer (PCa), in part via epigenetic alteration, and maybe associated with disease progression. In this study, we cloned the ZNF185 cDNA from normal human prostate tissues and investigated its biological function. We show that ZNF185 is a novel actin-cytoskeleton-associated Lin-l 1, Isl-1 and Mec-3 (LIM) domain-containing protein that localizes to F-actin structures, and is enriched at focal adhesions. We find that the NH2-terminal region, which we designate the actin-targeting domain, facilitates ZNF185 binding to actin ;in vitro and is both necessary and sufficient to mediate actin - cytoskeleton targeting of ZNF185, whereas the LIM domain, which is localized in the COOH-terminus is dispensable for this phenomenon. Interestingly, ectopic expression of full-length ZNF185, but not a mutant lacking the actin-targeting domain, could suppress proliferation and anchorage-independent growth of PCa cells. Together, our data suggest that ZNF185 may function as a tumor-suppressor protein by associating with the actin cytoskeleton.	Mayo Clin & Mayo Fdn, Coll Med, Dept Urol, Rochester, MN 55905 USA	Mayo Clinic	Zhang, JS (corresponding author), Mayo Clin & Mayo Fdn, Coll Med, Dept Urol, 200 1st St SW, Rochester, MN 55905 USA.	zhang.jinsan@mayo.edu			NCI NIH HHS [CA70892, CA91956] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA091956, R01CA070892] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bach I, 2000, MECH DEVELOP, V91, P5, DOI 10.1016/S0925-4773(99)00314-7; Dawid IB, 1998, TRENDS GENET, V14, P156, DOI 10.1016/S0168-9525(98)01424-3; Dhanasekaran SM, 2001, NATURE, V412, P822, DOI 10.1038/35090585; FREYD G, 1990, NATURE, V344, P876, DOI 10.1038/344876a0; Garvalov BK, 2003, J CELL BIOL, V161, P33, DOI 10.1083/jcb.200211015; Gonzalez HE, 2003, ARCH OTOLARYNGOL, V129, P754, DOI 10.1001/archotol.129.7.754; Heiss NS, 1997, GENOMICS, V43, P329, DOI 10.1006/geno.1997.4810; Jemal A, 2006, CA-CANCER J CLIN, V56, P106, DOI 10.3322/canjclin.56.2.106; Kadrmas JL, 2004, NAT REV MOL CELL BIO, V5, P920, DOI 10.1038/nrm1499; KARLSSON O, 1990, NATURE, V344, P879, DOI 10.1038/344879a0; Labouesse M, 2003, CURR BIOL, V13, pR528, DOI 10.1016/S0960-9822(03)00448-2; Luo J, 2001, CANCER RES, V61, P4683; Magee JA, 2001, CANCER RES, V61, P5692; Maul RS, 1999, ONCOGENE, V18, P7838, DOI 10.1038/sj.onc.1203206; Medina PP, 2005, HUM MOL GENET, V14, P973, DOI 10.1093/hmg/ddi091; PAN Y, 2003, CANCER EPIDEM BIOMAR, V8, P769; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; Rubin MA, 2002, JAMA-J AM MED ASSOC, V287, P1662, DOI 10.1001/jama.287.13.1662; Song YH, 2002, MOL BIOL CELL, V13, P1408, DOI 10.1091/mbc.01-08-0414; Sum EYM, 2002, J BIOL CHEM, V277, P7849, DOI 10.1074/jbc.M110603200; Tatarelli C, 2000, GENOMICS, V68, P1, DOI 10.1006/geno.2000.6272; Tobias ES, 2001, ONCOGENE, V20, P2844, DOI 10.1038/sj.onc.1204433; Vanaja DK, 2003, CANCER RES, V63, P3877; Visvader JE, 2001, P NATL ACAD SCI USA, V98, P14452, DOI 10.1073/pnas.251547698; WAY JC, 1988, CELL, V54, P5, DOI 10.1016/0092-8674(88)90174-2; Welsh JB, 2001, CANCER RES, V61, P5974; Wong N, 2005, CLIN CANCER RES, V11, P1319; Xu JF, 1998, NAT GENET, V20, P175, DOI 10.1038/2477; Zhang JS, 2001, MOL CELL BIOL, V21, P5041, DOI 10.1128/MCB.21.15.5041-5049.2001; Zhang JS, 2005, GENE CHROMOSOME CANC, V43, P249, DOI 10.1002/gcc.20188	30	32	39	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 4	2007	26	1					111	122		10.1038/sj.onc.1209769	http://dx.doi.org/10.1038/sj.onc.1209769			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	122OO	16799630				2022-12-17	WOS:000243236500011
J	Jiang, LQ; Feng, X; Zhou, W; Knyazev, PG; Ullrich, A; Chen, Z				Jiang, L. Q.; Feng, X.; Zhou, W.; Knyazev, P. G.; Ullrich, A.; Chen, Z.			Csk-binding protein (Cbp) negatively regulates epidermal growth factor-induced cell transformation by controlling Src activation	ONCOGENE			English	Article						Cbp; EGFR; cell transformation; Src; Csk	GLYCOSPHINGOLIPID-ENRICHED MICRODOMAINS; FAMILY TYROSINE KINASES; C-SRC; FACTOR RECEPTOR; TRANSMEMBRANE ADAPTER; AKT ACTIVATION; BREAST-CANCER; DNA-SYNTHESIS; LIPID RAFTS; PHOSPHORYLATION	Epidermal growth factor receptor (EGFR) and Src tyrosine kinase cooperate in regulating EGFR-mediated cell signaling and promoting cell transformation and tumorigenesis in pathological conditions. Activation of Src is tightly regulated by the C-terminal Src kinase (Csk). The Csk-binding protein (Cbp) is a ubiquitously expressed transmembrane protein. Its functions include suppression of T-cell receptor activation through recruiting Csk and inhibiting Src family kinase (SFK). However, a potential role of Cbp in EGF-induced cell activities has not been investigated. Here, we report that EGF-stimulation-induced Cbp tyrosine phosphorylation followed by Cbp-Csk association, in a SFK-dependent manner. Expression of wild-type (wt) Cbp remarkably suppressed EGF-induced activation of Src, ERK1/2, and Akt-1 enzymes, and NIH3T3 cell transformation, as well as colony formation of a breast cancer cell line (MDAMB468) in soft agar. In contrast, expression of CbpY317F or knockdown endogenous Cbp in NIH3T3 cells by RNA interference significantly enhanced EGF-induced activation of these enzymes and cell transformation. In addition, overexpression of multiple receptor tyrosine kinases (RTKs)-induced Cbp tyrosine phosphorylation. These results demonstrate that Cbp functions as a negative regulator of cell transformation and tumor cell growth through downregulation of Src activation, suggesting that Cbp might be broadly involved in RTKs-activated signaling pathways and tumorigenesis.	Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Biochem & Cell Biol, Key Lab Proteom, Shanghai 200031, Peoples R China; Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Biochem & Cell Biol, SHARF Lab, Shanghai 200031, Peoples R China; Max Planck Inst Biochem, Chinese Acad Sci, Grad Sch, D-82152 Martinsried, Germany; Max Planck Inst Biochem, Dept Mol Biol, D-82152 Martinsried, Germany	Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Max Planck Society; Max Planck Society	Chen, Z (corresponding author), Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Biochem & Cell Biol, Key Lab Proteom, Room 210,Bldg 23,320 Yue Yang Rd, Shanghai 200031, Peoples R China.	zjchen@sibs.ac.cn						Baumeister U, 2005, EMBO J, V24, P1686, DOI 10.1038/sj.emboj.7600647; Baumgartner M, 2003, BLOOD, V101, P1874, DOI 10.1182/blood-2002-02-0456; Biscardi JS, 1998, MOL CARCINOGEN, V21, P261, DOI 10.1002/(SICI)1098-2744(199804)21:4<261::AID-MC5>3.0.CO;2-N; Biscardi JS, 1999, J BIOL CHEM, V274, P8335, DOI 10.1074/jbc.274.12.8335; Bivona TG, 2003, NATURE, V424, P694, DOI 10.1038/nature01806; Brdicka T, 2000, J EXP MED, V191, P1591, DOI 10.1084/jem.191.9.1591; CANCE WG, 1995, BREAST CANCER RES TR, V35, P105, DOI 10.1007/BF00694751; Cao HM, 2004, EXP CELL RES, V294, P159, DOI 10.1016/j.yexcr.2003.11.010; Couet J, 1997, J BIOL CHEM, V272, P6525, DOI 10.1074/jbc.272.10.6525; Davidson D, 2003, MOL CELL BIOL, V23, P2017, DOI 10.1128/MCB.23.6.2017-2028.2003; DeMali KA, 1999, EXP CELL RES, V253, P271, DOI 10.1006/excr.1999.4669; DI FP, 1987, CELL, V51, P1063; Dobenecker MW, 2005, MOL CELL BIOL, V25, P10533, DOI 10.1128/MCB.25.23.10533-10542.2005; Franke TF, 2003, ONCOGENE, V22, P8983, DOI 10.1038/sj.onc.1207115; Ishizawar R, 2004, CANCER CELL, V6, P209, DOI 10.1016/j.ccr.2004.09.001; Ishizawar RC, 2004, J BIOL CHEM, V279, P23773, DOI 10.1074/jbc.M312368200; Jiang TY, 2003, J BIOL CHEM, V278, P15789, DOI 10.1074/jbc.M212525200; Karni R, 1999, ONCOGENE, V18, P4654, DOI 10.1038/sj.onc.1202835; Kassenbrock CK, 2002, J BIOL CHEM, V277, P24967, DOI 10.1074/jbc.M201026200; Kawabuchi M, 2000, NATURE, V404, P999, DOI 10.1038/35010121; Kharitonenkov A, 1997, NATURE, V386, P181, DOI 10.1038/386181a0; Kim YN, 2002, EXP CELL RES, V280, P134, DOI 10.1006/excr.2002.5623; Kong M, 2003, J BIOL CHEM, V278, P5837, DOI 10.1074/jbc.M208286200; Lev DC, 2004, BRIT J CANCER, V91, P795, DOI 10.1038/sj.bjc.6602051; LISANTI MP, 1994, J CELL BIOL, V126, P111, DOI 10.1083/jcb.126.1.111; Lu YL, 2003, J BIOL CHEM, V278, P40057, DOI 10.1074/jbc.M303621200; MAA MC, 1995, P NATL ACAD SCI USA, V92, P6981, DOI 10.1073/pnas.92.15.6981; Mason CS, 1999, EMBO J, V18, P2137, DOI 10.1093/emboj/18.8.2137; Matsuoka H, 2004, J BIOL CHEM, V279, P5975, DOI 10.1074/jbc.M311278200; Nguyen Dao M, 2004, Semin Thorac Cardiovasc Surg, V16, P3, DOI 10.1053/j.semtcvs.2003.12.002; Ohtake H, 2002, J IMMUNOL, V168, P2087, DOI 10.4049/jimmunol.168.5.2087; Okamoto T, 1998, J BIOL CHEM, V273, P5419, DOI 10.1074/jbc.273.10.5419; Olayioye MA, 1999, J BIOL CHEM, V274, P17209, DOI 10.1074/jbc.274.24.17209; Rae JM, 2004, BREAST CANCER RES TR, V83, P99, DOI 10.1023/B:BREA.0000010702.10130.29; ROCHE S, 1995, MOL CELL BIOL, V15, P1102; Shien Tadahiko, 2004, Breast Cancer, V11, P367, DOI 10.1007/BF02968044; Shima T, 2003, P NATL ACAD SCI USA, V100, P14897, DOI 10.1073/pnas.2432139100; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; SMART EJ, 1995, P NATL ACAD SCI USA, V92, P10104, DOI 10.1073/pnas.92.22.10104; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; Tremblay L, 1996, INT J CANCER, V68, P164, DOI 10.1002/(SICI)1097-0215(19961009)68:2<169::AID-IJC4>3.0.CO;2-W; Tsuruda A, 2004, FEBS LETT, V560, P215, DOI 10.1016/S0014-5793(04)00115-2; Van Slyke P, 2005, MOL CELL BIOL, V25, P3831, DOI 10.1128/MCB.25.9.3831-3841.2005; Wang B, 2001, MOL CELL BIOL, V21, P1077, DOI 10.1128/MCB.21.4.1077-1088.2001; WILSON LK, 1989, MOL CELL BIOL, V9, P1536, DOI 10.1128/MCB.9.4.1536; Xu SL, 2005, MOL CELL BIOL, V25, P8486, DOI 10.1128/MCB.25.19.8486-8495.2005; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Yayon A, 1997, ONCOGENE, V14, P2999, DOI 10.1038/sj.onc.1201159; Zhang SQ, 2004, MOL CELL, V13, P341, DOI 10.1016/S1097-2765(04)00050-4	49	32	38	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2006	25	40					5495	5506		10.1038/sj.onc.1209554	http://dx.doi.org/10.1038/sj.onc.1209554			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	082EV	16636672				2022-12-17	WOS:000240370400003
J	Scambia, G; Lovergine, S; Masciullo, V				Scambia, G.; Lovergine, S.; Masciullo, V.			RB family members as predictive and prognostic factors in human cancer	ONCOGENE			English	Review						pRb; pRb2; p130; prognostic factor; predictive factor	RETINOBLASTOMA GENE-PRODUCT; NUCLEAR ANTIGEN-EXPRESSION; PROTEIN EXPRESSION; CYCLIN D1; ALTERED EXPRESSION; DIFFERENTIAL EXPRESSION; REGULATORY PROTEINS; SUSCEPTIBILITY GENE; ABERRANT EXPRESSION; BREAST-CARCINOMA	The retinoblastoma family members - pRb, pRb2/p130 and p107- are tumor suppressor genes involved in controlling four major cellular processes: growth arrest, apoptosis, differentiation and angiogenesis. Molecular genetic studies have identified abnormalities of these tumor suppressor genes in a large proportion of human cancers. These genetic alterations have emerged as significant factors in the pathogenesis and progression of many types of tumors and are therefore likely to provide relevant information to assess risk in cancer patients. There is a pressing clinical need to identify prognostic and predictive factors for patients with cancer, because there is an undeniable importance in being able to determine which patients will have a favorable outcome without further therapy ( prognostic factor) and which will need some additional treatment ( predictive factor). This review examines the predictive and/or prognostic role of each retinoblastoma family member in human cancer.	Temple Univ, Coll Sci & Technol, Sbarro Inst Canc Res & Mol Med, Philadelphia, PA 19122 USA; Univ Cattolica Sacro Cuore, Div Gynecol Oncol, Rome, Italy	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli	Masciullo, V (corresponding author), Temple Univ, Coll Sci & Technol, Sbarro Inst Canc Res & Mol Med, Biolife Sci Bld,Suite 333,1900 N 12th St, Philadelphia, PA 19122 USA.	masciull@temple.edu						Baldi A, 1996, CLIN CANCER RES, V2, P1239; Baldi A, 1997, CLIN CANCER RES, V3, P1691; Barrett MT, 1996, ONCOGENE, V12, P1873; Bartkova J, 1996, CANCER RES, V56, P5475; Benassi MS, 1999, INT J CANCER, V84, P489, DOI 10.1002/(SICI)1097-0215(19991022)84:5<489::AID-IJC7>3.0.CO;2-D; Bianchi S., 1994, Pathologica (Genoa), V86, P146; Bieche I, 2000, MOL CARCINOGEN, V29, P151, DOI 10.1002/1098-2744(200011)29:3<151::AID-MC4>3.3.CO;2-Y; CANCE WG, 1990, NEW ENGL J MED, V323, P1457, DOI 10.1056/NEJM199011223232105; Ceccarelli C, 1998, J CLIN PATHOL, V51, P818, DOI 10.1136/jcp.51.11.818; Chakravarti A, 2003, J CLIN ONCOL, V21, P3328, DOI 10.1200/JCO.2003.12.151; Chan MKM, 1998, GYNECOL ONCOL, V68, P156, DOI 10.1006/gyno.1997.4914; Chen JT, 2001, LUNG CANCER, V31, P163, DOI 10.1016/S0169-5002(00)00191-4; Cinti C, 2000, AM J PATHOL, V156, P751, DOI 10.1016/S0002-9440(10)64941-3; Claudio PP, 2000, CANCER RES, V60, P372; Claudio PP, 2000, CANCER RES, V60, P8; Claudio PP, 2004, CLIN CANCER RES, V10, P3509, DOI 10.1158/1078-0432.CCR-03-0662; Claudio PP, 2002, CLIN CANCER RES, V8, P1808; CLAUDIO PP, 1994, CANCER RES, V54, P5556; CORDONCARDO C, 1992, J NATL CANCER I, V84, P1251, DOI 10.1093/jnci/84.16.1251; Cote RJ, 1998, CANCER RES, V58, P1090; Cui X, 2004, HUM PATHOL, V35, P1189, DOI 10.1016/j.humpath.2004.06.010; D'Andrilli G, 2004, CLIN CANCER RES, V10, P3098, DOI 10.1158/1078-0432.CCR-03-0524; DeLuca A, 1997, NAT MED, V3, P913, DOI 10.1038/nm0897-913; DODSON MK, 1994, CANCER RES, V54, P610; Dokiya F, 1998, ACTA OTO-LARYNGOL, V118, P759; Dong Y, 1997, INT J CANCER, V74, P407, DOI 10.1002/(SICI)1097-0215(19970822)74:4<407::AID-IJC8>3.0.CO;2-Z; Feakins RM, 2003, HUM PATHOL, V34, P1276, DOI 10.1016/j.humpath.2003.07.005; Feugeas O, 1996, J CLIN ONCOL, V14, P467, DOI 10.1200/JCO.1996.14.2.467; Fung Y K, 1992, Cancer Treat Res, V61, P59; GERADTS J, 1994, INT J CANCER, V58, P161, DOI 10.1002/ijc.2910580203; Girod SC, 1998, BRIT J ORAL MAX SURG, V36, P252, DOI 10.1016/S0266-4356(98)90708-2; Goldstein NS, 2000, ANN THORAC SURG, V69, P1648, DOI 10.1016/S0003-4975(00)01269-8; Guenova M, 1999, MODERN PATHOL, V12, P1062; Hashiguchi Y, 2004, HUM PATHOL, V35, P165, DOI 10.1016/j.humpath.2003.07.018; Helin K, 1997, P NATL ACAD SCI USA, V94, P6933, DOI 10.1073/pnas.94.13.6933; HENSEL CH, 1990, CANCER RES, V50, P3067; Hommura F, 1999, BRIT J CANCER, V81, P696, DOI 10.1038/sj.bjc.6690750; Hui AM, 1999, INT J CANCER, V84, P604, DOI 10.1002/(SICI)1097-0215(19991222)84:6<604::AID-IJC11>3.0.CO;2-Y; Ikeguchi M, 2000, J SURG ONCOL, V73, P104, DOI 10.1002/(SICI)1096-9098(200002)73:2<104::AID-JSO9>3.0.CO;2-7; Ishii H, 1997, AM J HEMATOL, V55, P46, DOI 10.1002/(SICI)1096-8652(199705)55:1<46::AID-AJH9>3.0.CO;2-3; Jahnson S, 1998, J UROLOGY, V160, P1291, DOI 10.1016/S0022-5347(01)62518-7; KARPEH MS, 1995, BRIT J CANCER, V72, P986, DOI 10.1038/bjc.1995.447; KIM TM, 1994, CANCER RES, V54, P605; Kusume T, 1999, CLIN CANCER RES, V5, P4152; LAUPACIS A, 1994, JAMA-J AM MED ASSOC, V272, P234, DOI 10.1001/jama.272.3.234; LI WW, 1995, P NATL ACAD SCI USA, V92, P10436, DOI 10.1073/pnas.92.22.10436; LIU Y, 1994, INT J CANCER, V58, P663, DOI 10.1002/ijc.2910580508; LOGOTHETIS CJ, 1992, J NATL CANCER I, V84, P1256, DOI 10.1093/jnci/84.16.1256; Macaluso M, 2003, ONCOGENE, V22, P3511, DOI 10.1038/sj.onc.1206578; Masciullo V, 2000, INT J ONCOL, V17, P897; Massaro-Giordano M, 1999, CLIN CANCER RES, V5, P1455; Milde-Langosch K, 2003, INT J GYNECOL PATHOL, V22, P168, DOI 10.1097/00004347-200304000-00009; Milde-Langosch K, 2001, BRIT J CANCER, V85, P546, DOI 10.1054/bjoc.2001.1923; Minimo C, 1999, PATHOL RES PRACT, V195, P67, DOI 10.1016/S0344-0338(99)80072-7; Mizokami H, 1999, MODERN PATHOL, V12, P47; Morente MM, 1997, BLOOD, V90, P2429; MUNGER K, 1992, CANCER SURV, V12, P197; Nakahara Y, 2000, CANCER LETT, V160, P3, DOI 10.1016/S0304-3835(00)00546-2; Omura K, 1997, J CLIN ONCOL, V15, P3458, DOI 10.1200/JCO.1997.15.12.3458; PIETILAINEN T, 1995, EUR J CANCER, V31A, P329, DOI 10.1016/0959-8049(94)00463-F; Pinto AE, 2005, PATHOLOGY, V37, P45, DOI 10.1080/00313020400011250; Pollack A, 1997, CLIN CANCER RES, V3, P1823; Poller DN, 1997, BRIT J CANCER, V75, P87, DOI 10.1038/bjc.1997.14; Puduvalli VK, 2000, INT J ONCOL, V17, P963; Rolfe KJ, 2001, INT J GYNECOL CANCER, V11, P381, DOI 10.1046/j.1525-1438.2001.01039.x; Russo G, 2005, CLIN CANCER RES, V11, P3265, DOI 10.1158/1078-0432.CCR-04-2508; Salgia R, 1998, J CLIN ONCOL, V16, P1207, DOI 10.1200/JCO.1998.16.3.1207; Sanchez E, 1998, J CLIN ONCOL, V16, P1931, DOI 10.1200/JCO.1998.16.5.1931; Sartor M, 1999, BRIT J CANCER, V80, P79, DOI 10.1038/sj.bjc.6690505; SAWAN A, 1992, J PATHOL, V168, P23, DOI 10.1002/path.1711680105; SCHEMPER M, 1993, STAT MED, V12, P2377, DOI 10.1002/sim.4780122413; Semczuk A, 2000, PATHOL RES PRACT, V196, P41, DOI 10.1016/S0344-0338(00)80020-5; Skomedal H, 1999, GYNECOL ONCOL, V73, P223, DOI 10.1006/gyno.1999.5346; Song Hong Suk, 2005, Korean Journal of Internal Medicine, V20, P1; SPANDIDOS DA, 1992, ANTICANCER RES, V12, P81; SUN Y, 1993, ONCOGENE, V8, P791; Susini T, 2001, HUM PATHOL, V32, P360, DOI 10.1053/hupa.2001.23514; Susini T, 1998, J CLIN ONCOL, V16, P1085, DOI 10.1200/JCO.1998.16.3.1085; Tonini T, 2004, CLIN CANCER RES, V10, P8085, DOI 10.1158/1078-0432.CCR-04-0996; TRUDEL M, 1992, HUM PATHOL, V23, P1388, DOI 10.1016/0046-8177(92)90059-C; WADAYAMA B, 1994, CANCER RES, V54, P3042; Wakasugi E, 1997, J CLIN PATHOL, V50, P407, DOI 10.1136/jcp.50.5.407; WALTHER MM, 1995, J UROLOGY, V153, P2050, DOI 10.1016/S0022-5347(01)67400-7; WEIDE R, 1994, LEUKEMIA, V8, P97; WREDE D, 1991, MOL CARCINOGEN, V4, P171, DOI 10.1002/mc.2940040302; Wurl P, 1999, CANCER LETT, V139, P159, DOI 10.1016/S0304-3835(99)00034-8; Wurl P, 1998, LANGENBECK ARCH SURG, V383, P99, DOI 10.1007/s004230050099; Xu HJ, 1996, CLIN CANCER RES, V2, P1169; XU HJ, 1994, JNCI-J NATL CANCER I, V86, P695, DOI 10.1093/jnci/86.9.695; Yamamoto Y, 1998, ONCOL REP, V5, P447; Zamparelli A, 2001, HUM PATHOL, V32, P4, DOI 10.1053/hupa.2001.20371; Zhang BY, 2006, P NATL ACAD SCI USA, V103, P437, DOI 10.1073/pnas.0510012103; Zojer N, 2000, BLOOD, V95, P1925, DOI 10.1182/blood.V95.6.1925	93	32	34	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 28	2006	25	38					5302	5308		10.1038/sj.onc.1209620	http://dx.doi.org/10.1038/sj.onc.1209620			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	077XD	16936751				2022-12-17	WOS:000240064100016
J	Zhang, Z; Huettner, PC; Nguyen, L; Bidder, M; Funk, MC; Li, J; Rader, JS				Zhang, Z.; Huettner, P. C.; Nguyen, L.; Bidder, M.; Funk, M. C.; Li, J.; Rader, J. S.			Aberrant promoter methylation and silencing of the POU2F3 gene in cervical cancer	ONCOGENE			English	Article						POU2F3; promoter; hypermethylation; cervical cancer	HISTONE DEACETYLASE INHIBITION; HUMAN CHROMOSOME-11; DOMAIN FACTORS; EXPRESSION; TRANSCRIPTION; DIFFERENTIATION; CELLS; HETEROZYGOSITY; DEMETHYLATION; CARCINOMA	POU2F3 (OCT11, Skn-1a) is a keratinocyte-specific POU transcription factor whose expression is tied to squamous epithelial strati. cation. It is also a candidate tumor suppressor gene in cervical cancer (CC) because it lies in a critical loss of heterozygosity region on11q23.3 in that cancer, and its expression is lost in more than 50% of CC tumors and cell lines. We now report that the loss of POU2F3 expression is tied to the hypermethylation of CpG islands in the POU2F3 promoter. Bisulfite sequencing analysis revealed that methylation of specific CpG sites (-287 to -70 bp) correlated with POU2F3 expression, which could be reactivated with a demethylating agent. Combined bisulfite restriction analysis revealed aberrant methylation of the POU2F3 promoter in 18 of 46 (39%) cervical tumors but never in normal epithelium. POU2F3 expression was downregulated and inversely correlated with promoter hypermethylation in 10 out of 11 CC cell lines. Immunohistochemical analysis on a cervical tissue microarray detected POU2F3 protein in the epithelium above the basal layer. As the disease progressed, expression also decreased, especially in invasive squamous cell cancer (70% loss). Thus, aberrant DNA methylation of the CpG island in POU2F3 promoter appears to play a key role in silencing this gene expression in human CC. The results suggested that POU2F3 might be one of the CC-related tumor suppressor genes, which are disrupted by both epigenetic and genetic mechanisms.	Washington Univ, Sch Med, Dept Obstet & Gynecol, Div Gynecol Oncol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	Rader, JS (corresponding author), Washington Univ, Sch Med, Dept Obstet & Gynecol, Div Gynecol Oncol, 4911 Barnes Jewish Hosp Plaza,Campus Box 8064, St Louis, MO 63110 USA.	raderj@wustl.edu	Funk, Margo/AAC-2265-2020		NCI NIH HHS [P30 CA91842, CA94141-04] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA094141, P30CA091842] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSEN B, 1993, SCIENCE, V260, P78, DOI 10.1126/science.7682011; Andersen B, 1997, J BIOL CHEM, V272, P15905, DOI 10.1074/jbc.272.25.15905; Andersen B, 2001, ENDOCR REV, V22, P2, DOI 10.1210/er.22.1.2; Avvakumov N, 2003, ONCOGENE, V22, P3833, DOI 10.1038/sj.onc.1206562; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; Christman JK, 2002, ONCOGENE, V21, P5483, DOI 10.1038/sj.onc.1205699; Davey CS, 2004, NUCLEIC ACIDS RES, V32, P4322, DOI 10.1093/nar/gkh749; Enomoto Y, 2004, ONCOGENE, V23, P5014, DOI 10.1038/sj.onc.1207653; Fischer DF, 1996, MOL CELL BIOL, V16, P5365, DOI 10.1128/mcb.16.10.5365; Gius D, 2004, CANCER CELL, V6, P361, DOI 10.1016/j.ccr.2004.08.029; GOLDSBOROUGH AS, 1993, NUCLEIC ACIDS RES, V21, P127, DOI 10.1093/nar/21.1.127; Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075; Hietala KA, 1997, J PATHOL, V183, P305; Hildesheim J, 2001, J CELL SCI, V114, P1913; HOWLEY PM, 1991, CANCER RES, V51, pS5019; Huettner PC, 1998, HUM PATHOL, V29, P364, DOI 10.1016/S0046-8177(98)90117-4; KOI M, 1989, MOL CARCINOGEN, V2, P12, DOI 10.1002/mc.2940020103; Kononen J, 1998, NAT MED, V4, P844, DOI 10.1038/nm0798-844; Kukimoto I, 2001, J VIROL, V75, P9302, DOI 10.1128/JVI.75.19.9302-9311.2001; Li JD, 2005, GYNECOL ONCOL, V96, P150, DOI 10.1016/j.ygyno.2004.08.050; Nguyen DX, 2004, EMBO J, V23, P1609, DOI 10.1038/sj.emboj.7600176; O'Sullivan MJ, 2001, HUM PATHOL, V32, P475, DOI 10.1053/hupa.2001.24317; Pennings Sari, 2005, Briefings in Functional Genomics & Proteomics, V3, P351, DOI 10.1093/bfgp/3.4.351; Rader JS, 1996, ONCOGENE, V13, P2737; RADER JS, 1990, ONCOGENE, V5, P571; SAXON PJ, 1986, EMBO J, V5, P3461, DOI 10.1002/j.1460-2075.1986.tb04670.x; Suzuki H, 2002, NAT GENET, V31, P141, DOI 10.1038/ng892; YUKAWA K, 1993, GENE, V133, P163; Yukawa K, 1996, J VIROL, V70, P10, DOI 10.1128/JVI.70.1.10-16.1996; Zhang ZY, 2005, GENE CHROMOSOME CANC, V43, P95, DOI 10.1002/gcc.20151	30	32	35	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG	2006	25	39					5436	5445		10.1038/sj.onc.1209530	http://dx.doi.org/10.1038/sj.onc.1209530			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	078ZI	16607278				2022-12-17	WOS:000240144900008
J	Prieto-Sanchez, RM; Berenjeno, IM; Bustelo, XR				Prieto-Sanchez, R. M.; Berenjeno, I. M.; Bustelo, X. R.			Involvement of the Rho/Rac family member RhoG in caveolar endocytosis	ONCOGENE			English	Article						rhoG; caveolin; endocytosis; cholera toxin; vesicle trafficking	LIPID RAFTS; ACTIVATES RAC1; GOLGI-COMPLEX; CHOLERA-TOXIN; DISTINCT; PATHWAY; CDC42; PHAGOCYTOSIS; INTERNALIZATION; TRANSDUCTION	We show here that the GTPase RhoG is involved in caveolar trafficking. Wild-type RhoG moves sequentially to the plasma membrane, intracellular vesicles, and the Golgi apparatus along markers of this endocytic pathway. Such translocation is associated with changes in RhoG GDP/GTP levels and is highly dependent on lipid raft integrity and on the function of the GTPase dynamin2. In addition, the constitutively active RhoG(Q61L) mutant is preferentially located in endocytic vesicles that can be decorated with markers of the caveola-derived endocytic pathway. RhoG(Q61L,) but not the analogous Rac1 mutant protein, affects caveola internalization and the subsequent delivery of endocytic vesicles to the Golgi apparatus. The expression of RhoG/Rac1 chimeric proteins and RhoG(Q61L) effector mutants in cells induces alterations in the internalization of caveolae and severe changes in vesicle structure, respectively. However, the knockdown of endogenous rhoG transcripts using small interfering RNAs does not affect significantly the trafficking of caveola-derived vesicles, suggesting that RhoG function is dispensable for this endocytic process or, alternatively, that its function is compensated by other molecules. Taken together, these observations assign a novel function to RhoG and suggest that caveolar trafficking, as previously shown for other endocytic routes, is modulated by GTPases of the Ras superfamily.	Univ Salamanca, CSIC, IBMCC, E-37007 Salamanca, Spain; Univ Salamanca, CSIC, Red Temat Cooperat Ctr Canc, E-37007 Salamanca, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC-USAL - Instituto de Biologia Molecular y Celular del Cancer de Salamanca (IBMCC); University of Salamanca; Consejo Superior de Investigaciones Cientificas (CSIC); University of Salamanca	Bustelo, XR (corresponding author), Univ Salamanca, CSIC, IBMCC, Campus Unamuno, E-37007 Salamanca, Spain.	xbustelo@usal.es	Bustelo, Xose R./AAD-2081-2022; Bustelo, Xose R./A-9526-2010	Bustelo, Xose R./0000-0001-9398-6072; Bustelo, Xose R./0000-0001-9398-6072	NATIONAL CANCER INSTITUTE [R01CA073735] Funding Source: NIH RePORTER; NCI NIH HHS [5-R01-CA73735-08, R01 CA073735] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Conner SD, 2003, NATURE, V422, P37, DOI 10.1038/nature01451; Cox D, 1997, J EXP MED, V186, P1487, DOI 10.1084/jem.186.9.1487; Di Guglielmo GM, 2003, NAT CELL BIOL, V5, P410, DOI 10.1038/ncb975; Ellis S, 2000, TRENDS CELL BIOL, V10, P85, DOI 10.1016/S0962-8924(99)01710-9; Felberbaum-Corti M, 2003, NAT CELL BIOL, V5, P382, DOI 10.1038/ncb0503-382; Filippi MD, 2004, NAT IMMUNOL, V5, P744, DOI 10.1038/ni1081; Gauthier-Rouviere C, 1998, MOL BIOL CELL, V9, P1379, DOI 10.1091/mbc.9.6.1379; Gonzallez-Gaitan M, 2003, NAT REV MOL CELL BIO, V4, P213, DOI 10.1038/nrm1053; Greenberg S, 1999, J LEUKOCYTE BIOL, V66, P712, DOI 10.1002/jlb.66.5.712; Gruenberg J, 2001, NAT REV MOL CELL BIO, V2, P721, DOI 10.1038/35096054; Henley JR, 1998, J CELL BIOL, V141, P85, DOI 10.1083/jcb.141.1.85; Hoppe AD, 2004, MOL BIOL CELL, V15, P3509, DOI 10.1091/mbc.E03-11-0847; Joneson T, 1996, SCIENCE, V274, P1374, DOI 10.1126/science.274.5291.1374; Katoh H, 2003, NATURE, V424, P461, DOI 10.1038/nature01817; Katoh H, 2000, MOL CELL BIOL, V20, P7378, DOI 10.1128/MCB.20.19.7378-7387.2000; LI GP, 1993, J BIOL CHEM, V268, P24475; Massol P, 1998, EMBO J, V17, P6219, DOI 10.1093/emboj/17.21.6219; May V, 2002, J NEUROSCI, V22, P6980; Nichols B, 2003, J CELL SCI, V116, P4707, DOI 10.1242/jcs.00840; Nichols BJ, 2002, NAT CELL BIOL, V4, P374, DOI 10.1038/ncb787; Nichols BJ, 2001, J CELL BIOL, V153, P529, DOI 10.1083/jcb.153.3.529; Nichols BJ, 2001, TRENDS CELL BIOL, V11, P406, DOI 10.1016/S0962-8924(01)02107-9; Orlandi PA, 1998, J CELL BIOL, V141, P905, DOI 10.1083/jcb.141.4.905; Parton RG, 2003, TRAFFIC, V4, P724, DOI 10.1034/j.1600-0854.2003.00128.x; Pelkmans L, 2005, NATURE, V436, P128, DOI 10.1038/nature03866; Pelkmans L, 2005, NATURE, V436, P78, DOI 10.1038/nature03571; Pelkmans L, 2002, TRAFFIC, V3, P311, DOI 10.1034/j.1600-0854.2002.30501.x; Prieto-Sanchez RM, 2003, J BIOL CHEM, V278, P37916, DOI 10.1074/jbc.M301437200; Sabharanjak S, 2002, DEV CELL, V2, P411, DOI 10.1016/S1534-5807(02)00145-4; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Torgersen ML, 2001, J CELL SCI, V114, P3737; Vignal E, 2001, MOL CELL BIOL, V21, P8022, DOI 10.1128/MCB.21.23.8022-8034.2001; Wennerberg K, 2002, J BIOL CHEM, V277, P47810, DOI 10.1074/jbc.M203816200; Wu WJ, 2000, NATURE, V405, P800, DOI 10.1038/35015585; Zerial M, 2001, NAT REV MOL CELL BIO, V2, P107, DOI 10.1038/35052055	35	32	34	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 18	2006	25	21					2961	2973		10.1038/sj.onc.1209333	http://dx.doi.org/10.1038/sj.onc.1209333			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	048MI	16568096	Green Accepted, Green Submitted			2022-12-17	WOS:000237950800001
J	Warbrick, E				Warbrick, E.			A functional analysis of PCNA-binding peptides derived from protein sequence, interaction screening and rational design	ONCOGENE			English	Article						PCNA; peptides; interaction; screening	CELL NUCLEAR ANTIGEN; DNA-POLYMERASE-DELTA; FISSION YEAST; SCHIZOSACCHAROMYCES-POMBE; REPLICATION; P21; INHIBITOR; PHOSPHORYLATION; GADD45; MOTIF	Proliferating cell nuclear antigen ( PCNA) has no intrinsic enzymatic function, but functions as a sliding platform to mediate protein interactions with the DNA strand. Many proteins interact with PCNA through a small conserved motif with consensus QxxLxxFF. This work uses Schizosaccharomyces pombe and human cells to analyse the function of PCNA- binding peptides. Interacting peptides were identified using two- hybrid screening; one ( pep102) binds directly to a physiologically relevant site on PCNA. The EGFP- pep102 overexpression phenotype is consistent with competitive blocking of PCNA - protein interactions. Various PCNA- binding peptides were all shown to inhibit PCNA function by competitive binding in both human and S. pombe cells as EGFP fusion proteins. The action of a p21( WAF1/ Cip1)- derived peptide was complicated by the presence of additional functional domains and possible post- translational modi. cation. The activity of pep102 was hampered by low expression in both model systems. The peptide derived from rational design ( con1) was stable, highly active in inhibiting PCNA function both S. pombe and human cells and showed a high affinity for PCNA both in vitro and in vivo. These results validate the use of functional screening in yeast to identify peptide aptamers that are functional in mammalian cells; such aptamers provide excellent leads for small molecule antiproliferative therapies.	Univ Dundee, Ninewells Hosp & Med Sch, Dept Surg & Mol Oncol, Dundee DD1 9SY, Scotland	University of Dundee	Warbrick, E (corresponding author), Univ Dundee, Ninewells Hosp & Med Sch, Dept Surg & Mol Oncol, Dundee DD1 9SY, Scotland.	e.warbrick@dundee.ac.uk	Warbrick, Emma/C-6424-2008		Cancer Research UK [A6613] Funding Source: Medline	Cancer Research UK(Cancer Research UK)		Adams PD, 1996, MOL CELL BIOL, V16, P6623; ALKHODAIRY F, 1994, MOL BIOL CELL, V5, P147, DOI 10.1091/mbc.5.2.147; Ausubel F.M., 1993, CURRENT PROTOCOLS MO; Cayrol C, 1998, ONCOGENE, V16, P311, DOI 10.1038/sj.onc.1201543; CHEN IT, 1995, ONCOGENE, V11, P1931; Chuang LSH, 1997, SCIENCE, V277, P1996, DOI 10.1126/science.277.5334.1996; Craven RA, 1998, GENE, V221, P59, DOI 10.1016/S0378-1119(98)00434-X; FLORESROZAS H, 1994, P NATL ACAD SCI USA, V91, P8655, DOI 10.1073/pnas.91.18.8655; Gulbis JM, 1996, CELL, V87, P297, DOI 10.1016/S0092-8674(00)81347-1; HALL PA, 1995, ONCOGENE, V10, P2427; Jonsson ZO, 1997, BIOESSAYS, V19, P967, DOI 10.1002/bies.950191106; Kamb A, 2001, CURR OPIN CHEM BIOL, V5, P74, DOI 10.1016/S1367-5931(00)00160-5; Kelman Z, 1997, ONCOGENE, V14, P629, DOI 10.1038/sj.onc.1200886; Kelman Z, 1998, TRENDS BIOCHEM SCI, V23, P236, DOI 10.1016/S0968-0004(98)01223-7; Kontopidis G, 2005, P NATL ACAD SCI USA, V102, P1871, DOI 10.1073/pnas.0406540102; LEE MG, 1987, NATURE, V327, P31, DOI 10.1038/327031a0; Li Y, 2002, J BIOL CHEM, V277, P11352, DOI 10.1074/jbc.M109062200; MacNeill SA, 1996, EMBO J, V15, P4613, DOI 10.1002/j.1460-2075.1996.tb00839.x; Mattock H, 2001, EXP CELL RES, V265, P242, DOI 10.1006/excr.2001.5181; Mattock H, 2001, EXP CELL RES, V265, P234, DOI 10.1006/excr.2001.5160; Moggs JG, 2000, MOL CELL BIOL, V20, P1206, DOI 10.1128/MCB.20.4.1206-1218.2000; MORENO S, 1991, METHOD ENZYMOL, V194, P795; Otterlei M, 1999, EMBO J, V18, P3834, DOI 10.1093/emboj/18.13.3834; Reynolds N, 2000, EMBO J, V19, P1108, DOI 10.1093/emboj/19.5.1108; Rossig L, 2001, MOL CELL BIOL, V21, P5644, DOI 10.1128/MCB.21.16.5644-5657.2001; SAZER S, 1990, J CELL SCI, V97, P509; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; Tournier S, 1996, MOL BIOL CELL, V7, P651, DOI 10.1091/mbc.7.4.651; Tsurimoto T., 1999, FRONT BIOSCI, V4, P849; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; Warbrick E, 1998, NUCLEIC ACIDS RES, V26, P3925, DOI 10.1093/nar/26.17.3925; WARBRICK E, 1995, CURR BIOL, V5, P275, DOI 10.1016/S0960-9822(95)00058-3; Warbrick E, 2000, BIOESSAYS, V22, P997, DOI 10.1002/1521-1878(200011)22:11<997::AID-BIES6>3.3.CO;2-R; WASEEM NH, 1992, EMBO J, V11, P5111, DOI 10.1002/j.1460-2075.1992.tb05618.x; Xu H, 2001, BIOCHEMISTRY-US, V40, P4512, DOI 10.1021/bi010103+; Xu X, 2001, NAT GENET, V27, P23, DOI 10.1038/83717; YANG MJ, 1995, NUCLEIC ACIDS RES, V23, P1152, DOI 10.1093/nar/23.7.1152; Zheleva DI, 2002, J PEPT RES, V60, P257, DOI 10.1034/j.1399-3011.2002.21014.x; Zheleva DI, 2000, BIOCHEMISTRY-US, V39, P7388, DOI 10.1021/bi992498r	39	32	35	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2006	25	20					2850	2859		10.1038/sj.onc.1209320	http://dx.doi.org/10.1038/sj.onc.1209320			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	041IN	16407840	Green Accepted, Bronze			2022-12-17	WOS:000237448200003
J	Yin, MB; Li, ZR; Toth, K; Cao, S; Durrani, FA; Hapke, G; Bhattacharya, A; Azrak, RG; Frank, C; Rustum, YM				Yin, MB; Li, ZR; Toth, K; Cao, S; Durrani, FA; Hapke, G; Bhattacharya, A; Azrak, RG; Frank, C; Rustum, YM			Potentiation of irinotecan sensitivity by Se-methylselenocysteine in an in vivo tumor model is associated with downregulation of cyclooxygenase-2, inducible nitric oxide synthase, and hypoxia-inducible factor 1 alpha expression, resulting in reduced angiogenesis	ONCOGENE			English	Article						MSC; irinotecan; COX-2; iNOS; HIF-1 alpha; angiogenesis	NF-KAPPA-B; SQUAMOUS-CELL CARCINOMA; COLON-CANCER CELLS; GENE-EXPRESSION; COLORECTAL-CANCER; ENDOTHELIAL-CELLS; MAMMARY-CANCER; NECK-CANCER; MOUSE SKIN; HUMAN HEAD	Until recently, the use of Se-methylselenocysteine ( MSC) as selective modulator of the antitumor activity and selectivity of anticancer drugs including irinotecan, a topoisomerase I poison, had not been evaluated. Therapeutic synergy between MSC and irinotecan was demonstrated by our laboratory in mice bearing human squamous cell carcinoma of the head and neck tumors. In FaDu xenografts, a poorly differentiated tumor-expressing mutant p53, the cure rate was increased from 30% with irinotecan alone to 100% with the combination of irinotecan and MSC. Cellular exposure to cytotoxic concentration of SN-38, the active metabolite of irinotecan (0.1 mu M) alone and in combination with noncytotoxic concentration of MSC (10 mu M) did not result in additional enhancement of chk2 phosphorylation and downregulation of specific DNA replication-associated proteins, cdc6, MCM2, cdc25A, nor increase in PARP cleavage, caspase activation and the 30-300 kb DNA fragmentation induced by SN-38 treatment. MSC did not alter significantly markers associated with apoptosis, nor potentiate irinotecan-induced apoptosis. These results indicate that apoptosis is unlikely to be one of the main mechanism associated with the observed in vivo therapeutic synergy. In contrast, significant downregulation of cyclooxygenase-2 (COX-2) expression and activity was observed in the cells exposed to SN-38 in combination with MSC compared to SN-38 alone. Moreover, the inhibition of PGE(2) production was also observed in the cells treated with the combination as compared with SN-38 alone. Analysis of tumor tissues at 24 h after treatment with synergistic modality of irinotecan and MSC revealed significant downregulation of COX-2, inducible nitric oxide synthase (iNOS) and hypoxia-induced factor-1 alpha expression (HIF 1 alpha). Moreover, decreased micro-vessel density was observed after irinotecan treatment with the addition of MSC. These results suggest that observed therapeutic synergy correlates with the inhibition of neoangiogenesis through the downregulation of COX-2, iNOS and HIF-1 alpha expression.	Roswell Pk Canc Inst, Dept Canc Biol, Buffalo, NY 14263 USA	Roswell Park Cancer Institute	Rustum, YM (corresponding author), Roswell Pk Canc Inst, Dept Canc Biol, Elm & Carlton St, Buffalo, NY 14263 USA.	youcef.rustum@roswellpark.org			NCI NIH HHS [CA65761, CA16056] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016056, R01CA065761] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahn KS, 2005, LIFE SCI, V76, P2315, DOI 10.1016/j.lfs.2004.10.042; Apostolou S, 2004, ONCOGENE, V23, P5032, DOI 10.1038/sj.onc.1207683; Azrak RG, 2004, CLIN CANCER RES, V10, P1121, DOI 10.1158/1078-0432.CCR-0913-3; Bhattacharya A, 2004, CLIN CANCER RES, V10, P8005, DOI 10.1158/1078-0432.CCR-04-1306; Bing RJ, 2001, CLIN CANCER RES, V7, P3385; Bussolati B, 2003, FASEB J, V17, P1159, DOI 10.1096/fj.02-0557fje; Cao SS, 2004, CLIN CANCER RES, V10, P2561, DOI 10.1158/1078-0432.CCR-03-0268; Chang SH, 2004, P NATL ACAD SCI USA, V101, P591, DOI 10.1073/pnas.2535911100; Chapple KS, 2002, J PATHOL, V198, P435, DOI 10.1002/path.1223; Chen YC, 2000, BIOCHEM PHARMACOL, V59, P1445, DOI 10.1016/S0006-2952(00)00255-0; Cherukuri DR, 2005, CANCER BIOL THER, V4, P175; Chun KS, 2004, CARCINOGENESIS, V25, P445, DOI 10.1093/carcin/bgh021; Cianchi F, 2004, CLIN CANCER RES, V10, P2694, DOI 10.1158/1078-0432.CCR-03-0192; Cianchi F, 2001, GASTROENTEROLOGY, V121, P1339, DOI 10.1053/gast.2001.29691; Cianchi F, 2003, AM J PATHOL, V162, P793, DOI 10.1016/S0002-9440(10)63876-X; Collins JA, 1997, J HISTOCHEM CYTOCHEM, V45, P923, DOI 10.1177/002215549704500702; Deregibus MC, 2003, J BIOL CHEM, V278, P18008, DOI 10.1074/jbc.M300711200; Dimmeler S, 2000, CIRC RES, V86, P4, DOI 10.1161/01.RES.86.1.4; Fukumura D, 1998, CELL, V94, P715, DOI 10.1016/S0092-8674(00)81731-6; Gallo O, 2002, BIOCHEM BIOPH RES CO, V299, P517, DOI 10.1016/S0006-291X(02)02683-9; Gallo O, 1998, J NATL CANCER I, V90, P587, DOI 10.1093/jnci/90.8.587; Ganther HE, 1999, CARCINOGENESIS, V20, P1657, DOI 10.1093/carcin/20.9.1657; GIACCIA AJ, 1991, MUTAT RES, V263, P69, DOI 10.1016/0165-7992(91)90062-9; Guo B, 2000, CLIN CANCER RES, V6, P718; Hussain SP, 2004, CANCER RES, V64, P6849, DOI 10.1158/0008-5472.CAN-04-2201; Iniguez MA, 2003, TRENDS MOL MED, V9, P73, DOI 10.1016/S1471-4914(02)00011-4; Ip C, 1999, ANTICANCER RES, V19, P2875; Jiang BB, 2004, J BIOL CHEM, V279, P1323, DOI 10.1074/jbc.M307521200; Jiang C, 1999, MOL CARCINOGEN, V26, P213, DOI 10.1002/(SICI)1098-2744(199912)26:4<213::AID-MC1>3.0.CO;2-Z; Jones MK, 1999, NAT MED, V5, P1418; Jung YJ, 2003, FASEB J, V17, P2115, DOI 10.1096/fj.03-0329fje; Kisley LR, 2002, CANCER RES, V62, P6850; Lando D, 2002, SCIENCE, V295, P858, DOI 10.1126/science.1068592; Liu CH, 2001, J BIOL CHEM, V276, P18563, DOI 10.1074/jbc.M010787200; Lu JX, 2001, NUTR CANCER, V40, P64, DOI 10.1207/S15327914NC401_12; Lu JX, 2001, ADV EXP MED BIOL, V492, P131; Masferrer JL, 2000, CANCER RES, V60, P1306; Maxwell PH, 1997, P NATL ACAD SCI USA, V94, P8104, DOI 10.1073/pnas.94.15.8104; MEDINA D, 1988, PATHOL IMMUNOPATH R, V7, P187, DOI 10.1159/000157115; Merchan JR, 2005, INT J CANCER, V113, P490, DOI 10.1002/ijc.20595; Muller-Decker K, 2002, P NATL ACAD SCI USA, V99, P12483, DOI 10.1073/pnas.192323799; Murakami M, 2003, J BIOL CHEM, V278, P37937, DOI 10.1074/jbc.M305108200; OBERHAMMER F, 1993, EMBO J, V12, P3679, DOI 10.1002/j.1460-2075.1993.tb06042.x; Park SW, 2003, INT J CANCER, V107, P729, DOI 10.1002/ijc.11498; Pichiule P, 2004, J BIOL CHEM, V279, P12171, DOI 10.1074/jbc.M305146200; Rajnakova A, 2001, CANCER LETT, V172, P177, DOI 10.1016/S0304-3835(01)00645-0; Rapisarda A, 2004, CANCER RES, V64, P6845, DOI 10.1158/0008-5472.CAN-04-2116; Reid ME, 2002, CANCER EPIDEM BIOMAR, V11, P1285; SCHWARTZ DC, 1984, CELL, V37, P67, DOI 10.1016/0092-8674(84)90301-5; Surh YJ, 2001, MUTAT RES-FUND MOL M, V480, P243, DOI 10.1016/S0027-5107(01)00183-X; Tsujii M, 1998, CELL, V93, P705, DOI 10.1016/S0092-8674(00)81433-6; Wei DY, 2004, CANCER RES, V64, P2030, DOI 10.1158/0008-5472.CAN-03-1945; Wink DA, 1998, CARCINOGENESIS, V19, P711, DOI 10.1093/carcin/19.5.711; Yin MB, 2004, MOL PHARMACOL, V66, P153, DOI 10.1124/mol.66.1.153; Zhou N, 2003, J BIOL CHEM, V278, P29532, DOI 10.1074/jbc.M301877200; Ziche M, 1997, J CLIN INVEST, V99, P2625, DOI 10.1172/JCI119451; ZICHE M, 1993, BIOCHEM BIOPH RES CO, V192, P1198, DOI 10.1006/bbrc.1993.1543	57	32	35	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2006	25	17					2509	2519		10.1038/sj.onc.1209073	http://dx.doi.org/10.1038/sj.onc.1209073			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	034RJ	16518418				2022-12-17	WOS:000236948000009
J	Radhakrishnan, SK; Gierut, J; Gartel, AL				Radhakrishnan, SK; Gierut, J; Gartel, AL			Multiple alternate p21 transcripts are regulated by p53 in human cells	ONCOGENE			English	Article						p21; alternate transcript; p53; basal transcription	CANCER CELLS; EXPRESSION; PUMA; P21(WAF1/CIP1); APOPTOSIS; STABILITY; MEDIATOR; PROMOTER; BINDING; GENE	The p53 tumor-suppressor is a transcription factor that is stabilized in response to cellular stress leading to growth arrest or apoptosis. p21(WAF1/CIP1) is a major transcriptional target of p53 and it plays a critical role in p53-dependent cell cycle arrest. In this study, we identified multiple alternate human p21 transcripts that have their transcriptional start sites in the direct proximity of the distal p53 response element. These transcripts are upregulated as a result of DNA damage-induced p53 activation. Furthermore, the basal expression of these alternate transcripts is strongly regulated by p53 and they are undetectable in p53-knocked down cells. This is in contrast to classical p21 transcripts, which have reduced, albeit detectable expression levels in the absence of p53. The existence of the alternate transcripts underscores the complexity of the human p21 genomic locus and opens up new avenues for further investigation.	Univ Illinois, Dept Med, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Gartel, AL (corresponding author), Univ Illinois, Dept Med, 840 S Wood St,Room 1041, Chicago, IL 60612 USA.	agartel@uic.edu		Radhakrishnan, Senthil/0000-0002-5211-9498	NCI NIH HHS [CA91146] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R21CA091146] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bartel F, 2002, CANCER CELL, V2, P9, DOI 10.1016/S1535-6108(02)00091-0; Chen B, 2000, CANCER RES, V60, P3290; Chipuk JE, 2003, CANCER CELL, V4, P371, DOI 10.1016/S1535-6108(03)00272-1; Claus R, 2003, ONCOGENE, V22, P6489, DOI 10.1038/sj.onc.1206814; El-Deiry WS, 2003, ONCOGENE, V22, P7486, DOI 10.1038/sj.onc.1206949; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Gartel AL, 2004, ONCOGENE, V23, P8154, DOI 10.1038/sj.onc.1207820; Gartel AL, 1996, P SOC EXP BIOL MED, V213, P138; Gartel AL, 1999, EXP CELL RES, V246, P280, DOI 10.1006/excr.1998.4319; Gartel AL, 2005, CANCER RES, V65, P3980, DOI 10.1158/0008-5472.CAN-04-3995; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Jeffers JR, 2003, CANCER CELL, V4, P321, DOI 10.1016/S1535-6108(03)00244-7; Kaeser MD, 2004, J BIOL CHEM, V279, P7598, DOI 10.1074/jbc.M311732200; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; LOWE SW, 1994, SCIENCE, V266, P807, DOI 10.1126/science.7973635; Mihara M, 2003, MOL CELL, V11, P577, DOI 10.1016/S1097-2765(03)00050-9; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Nozell S, 2002, ONCOGENE, V21, P1285, DOI 10.1038/sj.onc.1205191; Phelps DE, 1998, MOL CELL BIOL, V18, P2334, DOI 10.1128/MCB.18.4.2334; Slee EA, 2004, ONCOGENE, V23, P2809, DOI 10.1038/sj.onc.1207516; Tang H, 1998, J BIOL CHEM, V273, P29156, DOI 10.1074/jbc.273.44.29156; Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097-2765(01)00213-1; Zhu WG, 2003, MOL CELL BIOL, V23, P4056, DOI 10.1128/MCB.23.12.4056-4065.2003	23	32	42	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2006	25	12					1812	1815		10.1038/sj.onc.1209195	http://dx.doi.org/10.1038/sj.onc.1209195			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	021VJ	16261158				2022-12-17	WOS:000236013700013
J	Bartholomeusz, C; Itamochi, H; Nitta, M; Saya, H; Ginsberg, MH; Ueno, NT				Bartholomeusz, C; Itamochi, H; Nitta, M; Saya, H; Ginsberg, MH; Ueno, NT			Antitumor effect of E1A in ovarian cancer by cytoplasmic sequestration of activated ERK by PEA15	ONCOGENE			English	Article						adenovirus type 5 E1A; proliferation; ovarian neoplasms; PEA15; ERK	PROTEIN-KINASE-C; TUMOR SUPPRESSION; HUMAN BREAST; INDUCE APOPTOSIS; ADENOVIRUS-5 E1A; GENE-TRANSFER; CELL-GROWTH; PEA-15; EXPRESSION; TRANSFORMATION	The adenovirus type 5 gene E1A is known to suppress tumorigenicity by transcriptionally downregulating HER-2/neu (HER2) or by inducing apoptosis. We show here that E1A also suppressed the tumorigenicity of the low-HER2-expressing ovarian cancer cell line OVCAR- 3 by decreasing cell proliferation. We further found that the mechanism responsible for this reduced proliferation is the presence of PEA15 (phosphoprotein enriched in astro-cytes), which is upregulated by E1A in ovarian cancer; PEA15 promotes translocation of ERK from the nucleus to the cytoplasm, leading to inhibition of ERK-dependent transcription and proliferation. Indeed, siRNA-mediated knockdown of PEA15 expression in OVCAR-3 stable E1A transfectants resulted in a nuclear accumulation of the active form of ERK, followed by an increase in Elk-1 activity, DNA synthesis, and anchorage-independent growth. Finally, PEA15 by itself suppressed colony formation in breast and ovarian cancer cell lines, in which E1A is known to have antitumor activity. We conclude that part of the antitumor effect of E1A in ovarian cancer results from cytoplasmic sequestration of the activated form of ERK by PEA15.	Univ Texas, MD Anderson Canc Ctr, Dept Blood & Marrow Transplantat, Unit 448, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Breast Canc Translat Res Lab, Houston, TX 77030 USA; Univ Texas, Hlth Sci Ctr, Grad Sch Biomed Sci, Houston, TX USA; Kumamoto Univ, Sch Med, Dept Tumor Genet & Biol, Kumamoto, Japan; Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; University of Texas Health Science Center Houston; Kumamoto University; University of California System; University of California San Diego; University of Texas System; UTMD Anderson Cancer Center	Ueno, NT (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Blood & Marrow Transplantat, Unit 448, 1515 Holcombe Blvd, Houston, TX 77030 USA.	nueno@mdanderson.org	Saya, Hideyuki/J-4325-2013		NCI NIH HHS [CA76450-1, CA16672-27, CA016672-29] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K08CA076450, P30CA016672] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARAUJO H, 1993, J BIOL CHEM, V268, P5911; BERA TK, 1994, P NATL ACAD SCI USA, V91, P9789, DOI 10.1073/pnas.91.21.9789; BYRD PJ, 1988, ONCOGENE, V2, P477; Chang JY, 1997, ONCOGENE, V14, P561, DOI 10.1038/sj.onc.1200861; Condorelli G, 1998, EMBO J, V17, P3858, DOI 10.1093/emboj/17.14.3858; Condorelli G, 1999, ONCOGENE, V18, P4409, DOI 10.1038/sj.onc.1202831; Condorelli G, 2002, J BIOL CHEM, V277, P11013, DOI 10.1074/jbc.M110934200; DANZIGER N, 1995, J NEUROCHEM, V64, P1016; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; Deng J, 1998, ONCOGENE, V17, P2167, DOI 10.1038/sj.onc.1202148; DOUGLAS JL, 1991, ONCOGENE, V6, P2093; Estelles A, 1996, J BIOL CHEM, V271, P14800, DOI 10.1074/jbc.271.25.14800; Estelles A, 1999, DEV BIOL, V216, P16, DOI 10.1006/dbio.1999.9510; Formstecher E, 2001, DEV CELL, V1, P239, DOI 10.1016/S1534-5807(01)00035-1; FREEDMAN VH, 1974, CELL, V3, P355, DOI 10.1016/0092-8674(74)90050-6; FRISCH SM, 1991, P NATL ACAD SCI USA, V88, P9077, DOI 10.1073/pnas.88.20.9077; Frisch SM, 2004, CLIN CANCER RES, V10, P2905, DOI 10.1158/1078-0432.CCR-04-0644; FRISCH SM, 1995, CANCER RES, V55, P5551; Frisch SM, 2002, NAT REV MOL CELL BIO, V3, P441, DOI 10.1038/nrm827; FRISCH SM, 1994, J CELL BIOL, V127, P1085, DOI 10.1083/jcb.127.4.1085; FRISCH SM, 1990, ONCOGENE, V5, P75; Gaumont-Leclerc MF, 2004, J BIOL CHEM, V279, P46802, DOI 10.1074/jbc.M403893200; Gum R, 1996, J BIOL CHEM, V271, P10672, DOI 10.1074/jbc.271.18.10672; Hao CH, 2001, CANCER RES, V61, P1162; Hortobagyi GN, 2001, J CLIN ONCOL, V19, P3422, DOI 10.1200/JCO.2001.19.14.3422; Hwang S, 1997, GENOMICS, V42, P540, DOI 10.1006/geno.1997.4768; Jemal A, 2004, CA-CANCER J CLIN, V54, P8, DOI 10.3322/canjclin.54.1.8; Krueger J, 2005, MOL BIOL CELL, V16, P3552, DOI 10.1091/mbc.E04-11-1007; Kubes M, 1998, J NEUROCHEM, V71, P1307; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; Lee WP, 1999, MOL CELL BIOL, V19, P8075; Mymryk JS, 1996, ONCOGENE, V13, P1581; NELSON CC, 1990, P NATL ACAD SCI USA, V87, P8041, DOI 10.1073/pnas.87.20.8041; Pages G, 1999, SCIENCE, V286, P1374, DOI 10.1126/science.286.5443.1374; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; Ramos JW, 2000, MOL BIOL CELL, V11, P2863, DOI 10.1091/mbc.11.9.2863; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; Renault F, 2003, BIOCHEM PHARMACOL, V66, P1581, DOI 10.1016/S0006-2952(03)00514-8; RENGANAHAN H, 2005, BIOCH J 0526; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; Sebolt-Leopold JS, 1999, NAT MED, V5, P810, DOI 10.1038/10533; Seger YR, 2002, CANCER CELL, V2, P401, DOI 10.1016/S1535-6108(02)00183-6; Shao RP, 2000, CANCER RES, V60, P3123; Shao RP, 1997, J BIOL CHEM, V272, P32739, DOI 10.1074/jbc.272.52.32739; TEODORO JG, 1995, ONCOGENE, V11, P467; Trencia A, 2003, MOL CELL BIOL, V23, P4511, DOI 10.1128/MCB.23.13.4511-4521.2003; Ueno NT, 2000, CLIN CANCER RES, V6, P250; Ueno NT, 1997, ONCOGENE, V15, P953, DOI 10.1038/sj.onc.1201250; Whitehurst AW, 2004, J BIOL CHEM, V279, P12840, DOI 10.1074/jbc.M310031200; Xu FJ, 1999, CLIN CANCER RES, V5, P3653; YAN DH, 1991, ONCOGENE, V6, P343; Yoo GH, 2001, CLIN CANCER RES, V7, P1237; YOUNG KS, 1989, MOL CELL BIOL, V9, P3109, DOI 10.1128/MCB.9.7.3109; YU DH, 1992, ONCOGENE, V7, P2263; YU DH, 1991, MOL CELL BIOL, V11, P1745, DOI 10.1128/MCB.11.3.1745; YU DH, 1993, CANCER RES, V53, P891; YU DH, 1990, P NATL ACAD SCI USA, V87, P4499, DOI 10.1073/pnas.87.12.4499; YU DH, 1995, ONCOGENE, V11, P1383; Zang RY, 2001, INT J GYNECOL CANCER, V11, P18, DOI 10.1046/j.1525-1438.2001.011001018.x; ZHANG YJ, 1995, ONCOGENE, V10, P1947	60	32	34	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2006	25	1					79	90		10.1038/sj.onc.1209014	http://dx.doi.org/10.1038/sj.onc.1209014			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	999QX	16170361				2022-12-17	WOS:000234406400009
J	Katuri, V; Tang, Y; Marshall, B; Rashid, A; Jogunoori, W; Volpe, EA; Sidawy, AN; Evans, S; Blay, J; Gallicano, GI; Reddy, EA; Mishra, L; Mishra, B				Katuri, V; Tang, Y; Marshall, B; Rashid, A; Jogunoori, W; Volpe, EA; Sidawy, AN; Evans, S; Blay, J; Gallicano, GI; Reddy, EA; Mishra, L; Mishra, B			Inactivation of ELF/TGF-beta signaling in human gastrointestinal cancer	ONCOGENE			English	Article						TGF-beta; ELF; Smad4; gastric cancer; E-cadherin; cell adhesion	GROWTH-FACTOR-BETA; E-CADHERIN EXPRESSION; CELL-CELL ADHESION; TGF-BETA; GASTRIC-CANCER; COLORECTAL-CANCER; MICROSATELLITE INSTABILITY; MESENCHYMAL TRANSITION; LIVER DEVELOPMENT; GENE-EXPRESSION	TGF-beta/Smads regulate a wide variety of biological responses through transcriptional regulation of target genes. ELF, a beta-spectrin, plays a key role in the transmission of TGF-beta-mediated transcriptional response through Smads. ELF was originally identified as a key protein involved in endodermal stem/progenitor cells committed to foregut lineage. Also, as a major dynamic adaptor and scaffolding protein, ELF is important for the generation of functionally distinct membranes, protein sorting and the development of polarized differentiated epithelial cells. Disruption of elf results in the loss of Smad3/Smad4 activation and, there fore, a disruption of the TGF-beta pathway. These observations led us to pursue the function of ELF in gastrointestinal (GI) epithelial cell-cell adhesion and tumor suppression. Here, we show a significant loss of ELF and reduced Smad4 expression in human gastric cancer tissue samples. Also, of the six human gastric cancer cell lines examined, three show deficient ELF expression. Furthermore, we demonstrate the rescue of E-cadherin-dependent homophilic cell-cell adhesion by ectopic expression of full-length elf. Our results suggest that ELF has an essential role in tumor suppression in GI cancers.	Georgetown Univ, Dept Surg Sci, Lombardi Canc Ctr, Lab Dev Mol Biol, Washington, DC 20007 USA; Dept Vet Affairs Med Ctr, Washington, DC 20007 USA; Georgetown Univ, Dept Surg, Washington, DC 20007 USA; Univ Texas, MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA; Dalhousie Univ, Dept Pharmacol, Halifax, NS B3H 4R2, Canada; Georgetown Univ, Dept Cell Biol, Washington, DC 20007 USA; Fels Inst Canc Res & Mol Biol, Philadelphia, PA 19140 USA	Georgetown University; Georgetown University; University of Texas System; UTMD Anderson Cancer Center; Dalhousie University; Georgetown University	Mishra, L (corresponding author), Georgetown Univ, Dept Surg Sci, Lombardi Canc Ctr, Lab Dev Mol Biol, Med Dent Bldg NW 210-213,3900 Reservoir Rd, Washington, DC 20007 USA.	lm229@georgeown.edu; bm72@georgetown.edu	Reddy, E. Premkumar/F-6233-2011; Volpe, Eugene A./D-2000-2012; Blay, Jean-Yves/N-3966-2016	Volpe, Eugene A./0000-0002-9128-754X; Blay, Jean-Yves/0000-0001-7190-120X; Mishra, Lopa/0000-0002-6850-0808				Abdollah S, 1997, J BIOL CHEM, V272, P27678, DOI 10.1074/jbc.272.44.27678; Attisano L, 2000, CURR OPIN CELL BIOL, V12, P235, DOI 10.1016/S0955-0674(99)00081-2; BATTEGAY EJ, 1990, CELL, V63, P515, DOI 10.1016/0092-8674(90)90448-N; Behrens J, 1992, Semin Cell Biol, V3, P169; Blobe GC, 2000, NEW ENGL J MED, V342, P1350, DOI 10.1056/NEJM200005043421807; CHEN RH, 1993, SCIENCE, V260, P1335, DOI 10.1126/science.8388126; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; Dong CM, 2000, MOL CELL, V5, P27, DOI 10.1016/S1097-2765(00)80400-1; DORUDI S, 1993, AM J PATHOL, V142, P981; EDWARDS DR, 1987, EMBO J, V6, P1899, DOI 10.1002/j.1460-2075.1987.tb02449.x; Ehrlich JS, 2002, DEV CELL, V3, P259, DOI 10.1016/S1534-5807(02)00216-2; Eppert K, 1996, CELL, V86, P543, DOI 10.1016/S0092-8674(00)80128-2; Fath KR, 1997, J CELL BIOL, V139, P1169, DOI 10.1083/jcb.139.5.1169; Feng XH, 1997, EMBO J, V16, P3912, DOI 10.1093/emboj/16.13.3912; GAMALLO C, 1993, AM J PATHOL, V142, P987; Goggins M, 1998, CANCER RES, V58, P5329; Gold LI, 1999, CRIT REV ONCOGENESIS, V10, P303; Goodman KJ, 2001, EPIDEMIOLOGY, V12, P266, DOI 10.1097/00001648-200103000-00023; Grady WM, 1999, CANCER RES, V59, P320; Guilford P, 1998, NATURE, V392, P402, DOI 10.1038/32918; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Hippo Y, 2002, CANCER RES, V62, P233; IGNOTZ RA, 1987, CELL, V51, P189, DOI 10.1016/0092-8674(87)90146-2; IGNOTZ RA, 1987, J BIOL CHEM, V262, P6443; KERR LD, 1990, CELL, V61, P267, DOI 10.1016/0092-8674(90)90807-Q; Kim JB, 2000, J CELL BIOL, V151, P1193, DOI 10.1083/jcb.151.6.1193; KIMCHI A, 1988, SCIENCE, V240, P196, DOI 10.1126/science.2895499; Kretzschmar M, 1997, GENE DEV, V11, P984, DOI 10.1101/gad.11.8.984; LAIHO M, 1986, J CELL BIOL, V103, P2403, DOI 10.1083/jcb.103.6.2403; LEOF EB, 1986, J CELL PHYSIOL, V127, P83, DOI 10.1002/jcp.1041270111; Lin WC, 2000, ONCOGENE, V19, P5680, DOI 10.1038/sj.onc.1203924; MA TY, 1993, J LAB CLIN MED, V122, P590; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; Mishra L, 1999, ONCOGENE, V18, P353, DOI 10.1038/sj.onc.1202313; Mishra L, 1998, INT J DEV BIOL, V42, P221; Miyaki M, 1999, CANCER RES, V59, P4506; Moses HL, 1996, CURR OPIN GENET DEV, V6, P581, DOI 10.1016/S0959-437X(96)80087-6; Murray PG, 1996, J PATHOL, V178, P44, DOI 10.1002/(SICI)1096-9896(199601)178:1<44::AID-PATH471>3.0.CO;2-0; Nelson WJ, 2004, SCIENCE, V303, P1483, DOI 10.1126/science.1094291; NELSON WJ, 1989, J CELL BIOL, V108, P893, DOI 10.1083/jcb.108.3.893; ODA T, 1994, P NATL ACAD SCI USA, V91, P1858, DOI 10.1073/pnas.91.5.1858; OKA H, 1993, CANCER RES, V53, P1696; Pepper I, 1997, REV MED CHILE, V125, P107; Piepenhagen PA, 1998, MOL BIOL CELL, V9, P3161, DOI 10.1091/mbc.9.11.3161; Powell SM, 1997, CANCER RES, V57, P4221; ROBERTS AB, 1990, TRANSFORMING GROWTH; Rosivatz E, 2002, AM J PATHOL, V161, P1881, DOI 10.1016/S0002-9440(10)64464-1; Ross JS, 2001, CANCER INVEST, V19, P554, DOI 10.1081/CNV-100103852; Schutte M, 1996, CANCER RES, V56, P2527; Setiawan VW, 2001, CANCER CAUSE CONTROL, V12, P673, DOI 10.1023/A:1011261602940; Siegel PM, 2003, NAT REV CANCER, V3, P807, DOI 10.1038/nrc1208; Sporn MB, 1999, MICROBES INFECT, V1, P1251, DOI 10.1016/S1286-4579(99)00260-9; Takaku K, 1999, CANCER RES, V59, P6113; Takaku K, 1998, CELL, V92, P645, DOI 10.1016/S0092-8674(00)81132-0; Tang Y, 2003, SCIENCE, V299, P574, DOI 10.1126/science.1075994; Tang Y, 2002, ONCOGENE, V21, P5255, DOI 10.1038/sj.onc.1205548; Tsukazaki T, 1998, CELL, V95, P779, DOI 10.1016/S0092-8674(00)81701-8; UCHINO S, 1992, CANCER RES, V52, P3099; WALL NA, 1994, CURR OPIN GENET DEV, V4, P517, DOI 10.1016/0959-437X(94)90066-C; Werner M, 2001, J CANCER RES CLIN, V127, P207, DOI 10.1007/s004320000195; Woodford-Richens KL, 2001, P NATL ACAD SCI USA, V98, P9719, DOI 10.1073/pnas.171321498; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; Xiangming C, 2001, CLIN CANCER RES, V7, P277; Xu XL, 2000, ONCOGENE, V19, P1868, DOI 10.1038/sj.onc.1203504; Yokozaki H, 2000, PATHOL INT, V50, P767, DOI 10.1046/j.1440-1827.2000.01117.x; Zhang QP, 2001, J CELL SCI, V114, P4485; Zhang Y, 1997, CURR BIOL, V7, P270, DOI 10.1016/S0960-9822(06)00123-0	68	32	35	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 1	2005	24	54					8012	8024		10.1038/sj.onc.1208946	http://dx.doi.org/10.1038/sj.onc.1208946			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	989EV	16158060				2022-12-17	WOS:000233656600008
J	Steinman, HA; Hoover, KM; Keeler, ML; Sands, AT; Jones, SN				Steinman, HA; Hoover, KM; Keeler, ML; Sands, AT; Jones, SN			Rescue of Mdm4-deficient mice by Mdm2 reveals functional overlap of Mdm2 and Mdm4 in development	ONCOGENE			English	Article						Mdm4; Mdm2; development; tumorigenesis	EMBRYONIC LETHALITY; GROWTH-CHARACTERISTICS; MDM2-DEFICIENT MICE; MDM4-NULL MICE; CELL-GROWTH; P53; APOPTOSIS; DELETION; ABSENCE; DEATH	The Mdm2 and Mdm4 genes are amplified and overexpressed in a variety of human cancers and encode structurally related oncoproteins that bind to the p53 tumor suppressor protein and inhibit p53 activity. Mice deleted for either Mdm2 or Mdm4 die during embryogenesis, and the developmental lethality of either mouse model can be rescued by concomitant deletion of p53. However, the phenotypes of Mdm2 and Mdm4-deficient mice suggest that Mdm2 and Mdm4 play nonoverlapping roles in regulating p53 activity during development, with Mdm2 regulating p53-mediated cell death and Mdm4 regulating p53-mediated inhibition of cell growth. Here, we describe complete rescue of Mdm4-deficient mice by expression of an Mdm2 transgene, and demonstrate that Mdm2 can regulate both p53-mediated apoptosis and inhibition of cell growth in the absence of Mdm4 in primary cells. Furthermore, deletion of Mdm4 enhances the ability of Mdm2 to promote cell growth and tumor formation, indicating that Mdm4 has antioncogenic properties when Mdm2 is overexpressed.	Univ Massachusetts, Sch Med, Dept Cell Biol, Worcester, MA 01655 USA; Univ Massachusetts, Sch Med, Dept Canc Biol, Worcester, MA 01655 USA; Lexicon Genet, The Woodlands, TX 77381 USA	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester; Lexicon Pharmaceuticals	Jones, SN (corresponding author), Univ Massachusetts, Sch Med, Dept Cell Biol, S3-123,55 Lake Ave N, Worcester, MA 01655 USA.	Stephen.jones@umassmed.edu			NATIONAL CANCER INSTITUTE [R56CA077735, R01CA077735] Funding Source: NIH RePORTER; NCI NIH HHS [CA77735] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Attardi LD, 2000, GENE DEV, V14, P704; Chavez-Reyes A, 2003, CANCER RES, V63, P8664; Danovi D, 2004, MOL CELL BIOL, V24, P5835, DOI 10.1128/MCB.24.13.5835-5843.2004; de Rozieres S, 2000, ONCOGENE, V19, P1691, DOI 10.1038/sj.onc.1203468; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Finch RA, 2002, CANCER RES, V62, P3221; Gu JJ, 2002, J BIOL CHEM, V277, P19251, DOI 10.1074/jbc.C200150200; HARVEY M, 1993, ONCOGENE, V8, P2457; Jackson MW, 2000, MOL CELL BIOL, V20, P1001, DOI 10.1128/MCB.20.3.1001-1007.2000; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; Jones SN, 1996, P NATL ACAD SCI USA, V93, P14106, DOI 10.1073/pnas.93.24.14106; Jones SN, 1998, P NATL ACAD SCI USA, V95, P15608, DOI 10.1073/pnas.95.26.15608; LUNA RMD, 1995, NATURE, V378, P203; Luna RMD, 1997, NAT GENET, V16, P336; Mancini F, 2004, J BIOL CHEM, V279, P8169, DOI 10.1074/jbc.M311793200; Michael D, 2002, CURR OPIN GENET DEV, V12, P53, DOI 10.1016/S0959-437X(01)00264-7; Migliorini D, 2002, MOL CELL BIOL, V22, P5527, DOI 10.1128/MCB.22.15.5527-5538.2002; OLINER JD, 1992, NATURE, V358, P15; Parant J, 2001, NAT GENET, V29, P92, DOI 10.1038/ng714; Sharp DA, 1999, J BIOL CHEM, V274, P38189, DOI 10.1074/jbc.274.53.38189; Shvarts A, 1996, EMBO J, V15, P5349, DOI 10.1002/j.1460-2075.1996.tb00919.x; Stad R, 2000, J BIOL CHEM, V275, P28039; Stad R, 2001, EMBO REP, V2, P1029, DOI 10.1093/embo-reports/kve227; Steinman HA, 2004, ONCOGENE, V23, P303, DOI 10.1038/sj.onc.1206925; Steinman HA, 2002, GENESIS, V32, P142, DOI 10.1002/gene.10035; Vousden KH, 2000, CELL, V103, P691, DOI 10.1016/S0092-8674(00)00171-9; Woods DB, 2001, EXP CELL RES, V264, P56, DOI 10.1006/excr.2000.5141	27	32	32	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 24	2005	24	53					7935	7940		10.1038/sj.onc.1208930	http://dx.doi.org/10.1038/sj.onc.1208930			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	986PU	16027727				2022-12-17	WOS:000233463000012
J	Caron, L; Bost, F; Prot, M; Hofman, P; Binetruy, B				Caron, L; Bost, F; Prot, M; Hofman, P; Binetruy, B			A new role for the oncogenic high-mobility group A2 transcription factor in myogenesis of embryonic stem cells	ONCOGENE			English	Article						HMGA2 transcription factor; ES cells; myogenesis	HMGI-C GENE; EXPRESSION; PATHWAY; DIFFERENTIATION; PROTEINS; LIPOMAS	The high mobility group type A-2 (HMGA2) transcription factor is involved in proliferation and differentiation, mainly during embryogenesis. Its activated form (HMGA2/T) presents oncogenic activities both in vivo and in vitro. However, its precise role during embryogenesis is unknown. We investigated its role during the commitment of mouse embryonic stem (ES) cells by constructing cell lines expressing either wild type (wt) or HMGA2/T forms of the gene. Following differentiation, control and wt HMGA2 ES cells did not display myotubes; whereas HMGA2/T ES cell lines massively formed contractile myotubes. Furthermore, as opposed to control cells, HMGA2/T ES cells highly expressed the muscle myosin heavy chain (MHC) marker. Interestingly, in experimental conditions inhibitory for myogenesis, we observed a strong expression of MyoD and myogenin in HMGA2/T cells. By contrast, commitment into adipocyte, neuron, and cardiomyocyte lineages was not affected. Teratocarcinomas induced by HMGA2/T ES cell lines presented numerous skeletal muscle-differentiated tissues that were not observed in wt HMGA2 or control tumours. Finally, rapamycin, an inhibitor of the mTOR kinase, downregulated endogenous HMGA-2 expression and inhibited myogenesis. This effect was prevented by overexpression of exogenous HMGA-2. Our results reveal a novel function of HMGA-2 in skeletal muscle differentiation.	Univ Nice Sophia Antipolis, INSERM, U568, Fac Med, F-06107 Nice, France; Univ Nice Sophia Antipolis, INSERM E0215, Fac Med, F-06107 Nice, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur	Binetruy, B (corresponding author), Univ Nice Sophia Antipolis, INSERM, U568, Fac Med, Ave Valombrose, F-06107 Nice, France.	binetruy@unice.fr	Binetruy, Bernard/AAG-7139-2022; Hofman, Paul/P-7654-2018; Binetruy, Bernard/A-6465-2009; Binetruy, Bernard/AFL-7188-2022; Binetruy, Bernard/S-2062-2019; BOST, Frederic/AAN-4691-2020; Caron, Leslie/AAE-3511-2022	Hofman, Paul/0000-0003-0431-9353; Binetruy, Bernard/0000-0001-8012-7092; BOST, Frederic/0000-0003-4509-4701; Caron, Leslie/0000-0003-4118-2974				Anand A, 2000, NAT GENET, V24, P377, DOI 10.1038/74207; Anisimov SV, 2002, MECH DEVELOP, V117, P25, DOI 10.1016/S0925-4773(02)00177-6; ASHAR HR, 1995, CELL, V82, P57; Baldassarre G, 2001, P NATL ACAD SCI USA, V98, P7970, DOI 10.1073/pnas.141224998; Battista S, 1999, CANCER RES, V59, P4793; Bost F, 2002, BIOCHEM J, V361, P621, DOI 10.1042/0264-6021:3610621; Chieffi P, 2002, ONCOGENE, V21, P3644, DOI 10.1038/sj/onc/1205501; COLMENARES C, 1989, CELL, V59, P293, DOI 10.1016/0092-8674(89)90291-2; Fedele M, 1998, ONCOGENE, V17, P413, DOI 10.1038/sj.onc.1201952; Gao XS, 2002, NAT CELL BIOL, V4, P699, DOI 10.1038/ncb847; Hirning-Folz U, 1998, GENE CHROMOSOME CANC, V23, P350, DOI 10.1002/(SICI)1098-2264(199812)23:4<350::AID-GCC10>3.0.CO;2-E; Hunter DS, 2002, CANCER RES, V62, P3766; Molkentin JD, 1996, CURR OPIN GENET DEV, V6, P445, DOI 10.1016/S0959-437X(96)80066-9; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; Noro B, 2003, BIOCHEMISTRY-US, V42, P4569, DOI 10.1021/bi026605k; Pende M, 2004, MOL CELL BIOL, V24, P3112, DOI 10.1128/MCB.24.8.3112-3124.2004; Reeves R, 2001, BBA-GENE STRUCT EXPR, V1519, P13, DOI 10.1016/S0167-4781(01)00215-9; Reeves R, 1999, METHOD ENZYMOL, V304, P155; Tallini G, 2000, LAB INVEST, V80, P359, DOI 10.1038/labinvest.3780040; Vernochet C, 2002, FEBS LETT, V510, P94, DOI 10.1016/S0014-5793(01)03235-5; Wobus Anna M., 2001, Molecular Aspects of Medicine, V22, P149, DOI 10.1016/S0098-2997(01)00006-1; ZHOU XJ, 1995, NATURE, V376, P771, DOI 10.1038/376771a0; Zhou XJ, 1996, NUCLEIC ACIDS RES, V24, P4071, DOI 10.1093/nar/24.20.4071	23	32	33	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2005	24	41					6281	6291		10.1038/sj.onc.1208781	http://dx.doi.org/10.1038/sj.onc.1208781			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	964JM	16007198				2022-12-17	WOS:000231877100009
J	Volanti, C; Hendrickx, N; Van Lint, J; Matroule, JY; Agostinis, P; Piette, J				Volanti, C; Hendrickx, N; Van Lint, J; Matroule, JY; Agostinis, P; Piette, J			Distinct transduction mechanisms of cyclooxygenase 2 gene activation in tumour cells after photodynamic therapy	ONCOGENE			English	Article						photodynamic therapy; COX-2; NF-kappa B; PI3K; PKC; T24 cells; HeLa cells; pyropheophorbide	NF-KAPPA-B; KINASE-C-ALPHA; RELA/P65 SUBUNIT; NITRIC-OXIDE; APOPTOSIS; AKT; PHOSPHORYLATION; EXPRESSION; PHOTOSENSITIZATION; PHARMACOKINETICS	Photodynamic therapy (PDT) is a minimally invasive treatment for cancer and several noncancerous proliferating cell diseases. PDT relies on the uptake of a photosensitizing compound by the pathologic tissue followed by a selective irradiation with visible light, which leads to oxidative stress-mediated cell death. However, some studies showed that PDT induces the release of proangiogenic factors, such as vascular endothelial growth factor, and/or cyclooxygenase-2 (COX-2), thereby promoting cancer cell regrowth following PDT. In this work, we focused on the molecular mechanisms regulating COX-2 expression after low-dose PDT in two cancer cell lines, namely HeLa and T24. We report that PDT induces COX-2 expression in these cells and this expression is mainly due to nuclear factor kappa B (NF-kappa B)-dependent transcription of cox-2 gene without any post-transcriptional regulation. However, the transduction mechanism leading to NF-kappa B activation and subsequent cox-2 gene transcription differs in both cell types. In T24, NF-kappa B activation occurs through a protein kinase C (PKC)alpha- and phosphoinositide-3-kinase (PI3K)-dependent I kappa B kinase (IKK) complex activation, whereas in HeLa cells, NF-kappa B activation is mediated by PKC- and PI3K-independent IKK complex activation.	Univ Liege, Inst Pathol B23, Lab Virol & Immunol, B-4000 Liege, Belgium; Catholic Univ Louvain, Div Biochem, B-3000 Louvain, Belgium	University of Liege; Universite Catholique Louvain	Piette, J (corresponding author), Univ Liege, Inst Pathol B23, Lab Virol & Immunol, B-4000 Liege, Belgium.	jpiette@ulg.ac.be	Van Lint, Johan/P-9073-2019; Agostinis, Patrizia/AAO-2468-2020; Agostinis, Patrizia/ABI-1177-2020	Agostinis, Patrizia/0000-0003-1314-2115; Van Lint, Johan/0000-0002-0275-571X				BELLNIER DA, 1993, J PHOTOCH PHOTOBIO B, V20, P55, DOI 10.1016/1011-1344(93)80131-R; Bork PM, 1999, PLANTA MED, V65, P297, DOI 10.1055/s-1999-13989; Deane JA, 2004, ANNU REV IMMUNOL, V22, P563, DOI 10.1146/annurev.immunol.22.012703.104721; Dempsey EC, 2000, AM J PHYSIOL-LUNG C, V279, pL429, DOI 10.1152/ajplung.2000.279.3.L429; Dougherty TJ, 1998, JNCI-J NATL CANCER I, V90, P889, DOI 10.1093/jnci/90.12.889; Dougherty TJ, 2002, J CLIN LASER MED SUR, V20, P3, DOI 10.1089/104454702753474931; Ferrario A, 2000, CANCER RES, V60, P4066; Ferrario A, 2002, CANCER RES, V62, P3956; FLATOW U, 1987, INT J CANCER, V40, P240, DOI 10.1002/ijc.2910400220; Gupta RA, 2001, NAT REV CANCER, V1, P11, DOI 10.1038/35094017; Henderson BW, 1997, CANCER RES, V57, P4000; Hendrickx N, 2003, J BIOL CHEM, V278, P52231, DOI 10.1074/jbc.M307591200; Huang WC, 2003, J BIOL CHEM, V278, P9944, DOI 10.1074/jbc.M208521200; Jang BC, 2004, BIOCHEM BIOPH RES CO, V316, P398, DOI 10.1016/j.bbrc.2004.02.060; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Khan KMF, 2004, J BIOL CHEM, V279, P22039, DOI 10.1074/jbc.M312735200; Kim SJ, 2003, BIOCHEM BIOPH RES CO, V303, P206, DOI 10.1016/S0006-291X(03)00305-X; Lallena MJ, 1999, MOL CELL BIOL, V19, P2180; Lasa M, 2000, MOL CELL BIOL, V20, P4265, DOI 10.1128/MCB.20.12.4265-4274.2000; Madrid LV, 2000, MOL CELL BIOL, V20, P1626, DOI 10.1128/MCB.20.5.1626-1638.2000; Madrid LV, 2001, J BIOL CHEM, V276, P18934, DOI 10.1074/jbc.M101103200; Makowski M, 2003, CLIN CANCER RES, V9, P5417; Matroule JY, 2000, ANTIOXID REDOX SIGN, V2, P301, DOI 10.1089/ars.2000.2.2-301; Matroule JY, 1999, J BIOL CHEM, V274, P2988, DOI 10.1074/jbc.274.5.2988; Matroule JY, 2000, METHOD ENZYMOL, V319, P119; Morita I, 2002, PROSTAG OTH LIPID M, V68-9, P165, DOI 10.1016/S0090-6980(02)00029-1; Nemeth JF, 2001, BIOCHEMISTRY-US, V40, P3109, DOI 10.1021/bi002313c; Oleinick NL, 2002, PHOTOCH PHOTOBIO SCI, V1, P1, DOI 10.1039/b108586g; Ozes ON, 1999, NATURE, V401, P82; Payne JT, 1996, LASER SURG MED, V18, P406, DOI 10.1002/(SICI)1096-9101(1996)18:4<406::AID-LSM10>3.3.CO;2-7; Piette J, 2003, BIOCHEM PHARMACOL, V66, P1651, DOI 10.1016/S0006-2952(03)00539-2; Romashkova JA, 1999, NATURE, V401, P86, DOI 10.1038/43474; Sanz L, 1999, EMBO J, V18, P3044, DOI 10.1093/emboj/18.11.3044; Sengupta S, 2003, J BIOL CHEM, V278, P25227, DOI 10.1074/jbc.M301813200; Sizemore N, 1999, MOL CELL BIOL, V19, P4798; Smith WL, 2000, ANNU REV BIOCHEM, V69, P145, DOI 10.1146/annurev.biochem.69.1.145; Storz P, 2003, EMBO J, V22, P109, DOI 10.1093/emboj/cdg009; Taher MM, 2002, IUBMB LIFE, V54, P357, DOI 10.1080/15216540216039; Tang QB, 2001, CANCER RES, V61, P4329; Trushin SA, 2003, MOL CELL BIOL, V23, P7068, DOI 10.1128/MCB.23.19.7068-7081.2003; Tsujii M, 1998, CELL, V93, P705, DOI 10.1016/S0092-8674(00)81433-6; TSUJII M, 1995, CELL, V83, P493, DOI 10.1016/0092-8674(95)90127-2; Vane JR, 1998, ANNU REV PHARMACOL, V38, P97, DOI 10.1146/annurev.pharmtox.38.1.97; Volanti C, 2002, PHOTOCHEM PHOTOBIOL, V75, P36, DOI 10.1562/0031-8655(2002)075<0036:IOOSIN>2.0.CO;2; Wang DM, 1998, J BIOL CHEM, V273, P33027, DOI 10.1074/jbc.273.49.33027	45	32	33	0	9	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 21	2005	24	18					2981	2991		10.1038/sj.onc.1208481	http://dx.doi.org/10.1038/sj.onc.1208481			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	919WY	15735712	Green Published			2022-12-17	WOS:000228649500007
J	Park, S; James, CD				Park, S; James, CD			ECop (EGFR-Coamplifed and overexpressed protein), a novel protein, regulates NF-kappa B transcriptional activity and associated apoptotic response in an I kappa B alpha-dependent manner	ONCOGENE			English	Article						ecop; gene amplificatio; NF-kappa B; I kappa B alpha; apoptosis	HUMAN SARCOMAS; HUMAN GENES; CELL-LINES; REGION; AMPLIFICATION; IDENTIFICATION; CANCER; COAMPLIFICATION; UBIQUITINATION; SENSITIVITY	In the present study, we describe the function of a novel protein, ECop (EGFR-Coamplified and overexpressed protein), in the regulation of NF-kB activity. Ectopic expression of ECop increases NF-kB transcriptional activity by promoting nuclear translocation and DNA binding of NF-kB, and ECop-induced NF-kB activation confers cellular resistance to apoptotic challenge. In ECop knockdown cells, NF-kB transcriptional activity is suppressed due to delayed IkB alpha degradation, which results in a delayed nuclear translocation as well as decreased DNA binding of NF-kB. Suppression of NF-kB activation by ECop knockdown increases cellular susceptibility to apoptosis. These results suggest that ECop is a key regulator of NF-kB signaling, and that high-level, amplification-mediated ECop expression, such as that occurring in tumors with amplified EGFR, could contribute to resistance to apoptosis.	Mayo Fdn & Grad Sch, Tumor Biol Program, Rochester, MN 55905 USA; Mayo Fdn & Grad Sch, Div Expt Pathol, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic	James, CD (corresponding author), Mayo Clin & Mayo Fdn, 200 1st St,SW Hilton Bldg Room 80-D, Rochester, MN USA.	james.david@mayo.edu	James, Charles D/E-2721-2012	James, Charles D/0000-0002-1027-203X				ALBERTS B., 1994, MOL BIOL CELL, P551; Amit S, 2003, SEMIN CANCER BIOL, V13, P15, DOI 10.1016/S1044-579X(02)00096-2; Amler LC, 1996, GENE CHROMOSOME CANC, V15, P134, DOI 10.1002/(SICI)1098-2264(199602)15:2<134::AID-GCC9>3.0.CO;2-4; Anest V, 2003, NATURE, V423, P659, DOI 10.1038/nature01648; BEG AA, 1996, SCIENCE, V274, P784; Birbach A, 2002, J BIOL CHEM, V277, P10842, DOI 10.1074/jbc.M112475200; Eley GD, 2002, NEURO-ONCOLOGY, V4, P86, DOI 10.1093/neuonc/4.2.86; FORUS A, 1993, CELL GROWTH DIFFER, V4, P1065; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Kawai H, 2002, MOL CELL BIOL, V22, P6079, DOI 10.1128/MCB.22.17.6079-6088.2002; KHATIB ZA, 1993, CANCER RES, V53, P5535; KING CR, 1985, SCIENCE, V229, P974, DOI 10.1126/science.2992089; Kucharczak J, 2003, ONCOGENE, V22, P8961, DOI 10.1038/sj.onc.1207230; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Matsuda A, 2003, ONCOGENE, V22, P3307, DOI 10.1038/sj.onc.1206406; Park S, 2003, CANCER RES, V63, P723; SCHUURING E, 1992, ONCOGENE, V7, P355; SCHWAB M, 1983, NATURE, V305, P245, DOI 10.1038/305245a0; Schwab M, 1999, SEMIN CANCER BIOL, V9, P319, DOI 10.1006/scbi.1999.0126; SMITH K, 1993, ONCOGENE, V8, P933; TANIGAMI A, 1992, GENOMICS, V13, P21, DOI 10.1016/0888-7543(92)90196-Y; TOMASETTO C, 1995, GENOMICS, V28, P367, DOI 10.1006/geno.1995.1163; VAN AD, 1996, SCIENCE, V274, P787; Wang XY, 1998, ONCOGENE, V16, P191, DOI 10.1038/sj.onc.1201476; Wei N, 2003, ANNU REV CELL DEV BI, V19, P261, DOI 10.1146/annurev.cellbio.19.111301.112449; Whiteside ST, 1997, SEMIN CANCER BIOL, V8, P75, DOI 10.1006/scbi.1997.0058	28	32	34	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 7	2005	24	15					2495	2502		10.1038/sj.onc.1208496	http://dx.doi.org/10.1038/sj.onc.1208496			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	913UV	15735698				2022-12-17	WOS:000228180600007
J	Agger, K; Santoni-Rugiu, E; Holmberg, C; Karlstrom, O; Helin, K				Agger, K; Santoni-Rugiu, E; Holmberg, C; Karlstrom, O; Helin, K			Conditional E2F1 activation in transgenic mice causes testicular atrophy and dysplasia mimicking human CIS	ONCOGENE			English	Article						E2F; retinoblastoma; testis; apoptosis; neoplasia	E2F-INDUCED S-PHASE; GERM-CELL TUMORS; P53-DEPENDENT APOPTOSIS; DEREGULATED EXPRESSION; RETINOBLASTOMA GENE; FAMILY-MEMBER; DNA-SYNTHESIS; TRANSCRIPTION; P53; PROLIFERATION	E2F1 is a crucial downstream effector of the retinoblastoma protein (pRB) pathway. To address the consequences of short-term increase in E2F1 activity in adult tissues, we generated transgenic mice expressing the human E2F1 protein fused to the oestrogen receptor ( ER) ligand-binding domain. The expression of the ER-E2F1 fusion protein, which is inactive in the absence of 4-hydroxy tamoxifen (OHT), was targeted to the testes. We show that short-term activation of E2F1 results in activation of E2F target genes and apoptosis of germ cells. Consistent with our previously published results, the apoptotic response was independent of p53. Persistent E2F1 activation for 3 weeks led to massive apoptosis and severe testicular atrophy with seminiferous tubules containing only Sertoli cells and clusters of undifferentiated spermatogonia. The latter showed high expression of ER-E2F1 and excessive mitotic activity, including atypical mitoses. In addition, gonocyte-like dysplastic germ cells, resembling carcinoma in situ (CIS) cells in humans, appeared. Our results show that a relatively short period of deregulated E2F1 activity in testicles can induce premalignant changes. Moreover, we demonstrate the feasibility of tissue-specific expression of conditional ER-E2F1 in transgenic mice.	Biotech Res & Innovat Ctr, DK-2100 Copenhagen, Denmark; Univ Copenhagen, Inst Mol Biol, Dept Mol Cell Biol, DK-1353 Copenhagen, Denmark; European Inst Oncol, Dept Expt Oncol, I-20141 Milan, Italy; Univ Copenhagen Hosp, Rigshosp, Dept Pathol, DK-2100 Copenhagen, Denmark	University of Copenhagen; IRCCS European Institute of Oncology (IEO); Rigshospitalet; University of Copenhagen	Helin, K (corresponding author), Biotech Res & Innovat Ctr, Fruebjergvej 3, DK-2100 Copenhagen, Denmark.	kristian.helin@bric.dk	Santoni-Rugiu, Eric/AAH-3368-2020; Holmberg, Christian/L-8011-2014; Helin, Kristian/HDM-8306-2022; Santoni-Rugiu, Eric/H-4913-2019; Helin, Kristian/K-2526-2019	Santoni-Rugiu, Eric/0000-0002-2283-3535; Holmberg, Christian/0000-0001-9224-0543; Helin, Kristian/0000-0003-1975-6097; 				Bartkova J, 2003, APMIS, V111, P252, DOI 10.1034/j.1600-0463.2003.1110129.x; Cam H, 2003, CANCER CELL, V3, P311, DOI 10.1016/S1535-6108(03)00080-1; Cartwright P, 1998, ONCOGENE, V17, P611, DOI 10.1038/sj.onc.1201975; Celeste A, 2002, SCIENCE, V296, P922, DOI 10.1126/science.1069398; Chaganti RSK, 2000, CANCER RES, V60, P1475; Cheville JC, 1998, AM J SURG PATHOL, V22, P1361, DOI 10.1097/00000478-199811000-00006; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; Conner EA, 2000, ONCOGENE, V19, P5054, DOI 10.1038/sj.onc.1203885; de Bruin A, 2003, J BIOL CHEM, V278, P42041, DOI 10.1074/jbc.M308105200; de la Cova C, 2004, CELL, V117, P107, DOI 10.1016/S0092-8674(04)00214-4; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; Di Stefano L, 2003, EMBO J, V22, P6289, DOI 10.1093/emboj/cdg613; Gaubatz S, 1998, P NATL ACAD SCI USA, V95, P9190, DOI 10.1073/pnas.95.16.9190; GAUTIER C, 1989, NUCLEIC ACIDS RES, V17, P8389, DOI 10.1093/nar/17.20.8389; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Hickman ES, 2002, CURR OPIN GENET DEV, V12, P60, DOI 10.1016/S0959-437X(01)00265-9; Holmberg C, 1998, ONCOGENE, V17, P143, DOI 10.1038/sj.onc.1201915; Hsia KT, 2003, DEVELOPMENT, V130, P369, DOI 10.1242/dev.00221; Hsieh JK, 1997, GENE DEV, V11, P1840, DOI 10.1101/gad.11.14.1840; Humbert PO, 2000, MOL CELL, V6, P281, DOI 10.1016/S1097-2765(00)00029-0; Irwin M, 2000, NATURE, V407, P645, DOI 10.1038/35036614; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; Lindeman GJ, 1998, GENE DEV, V12, P1092, DOI 10.1101/gad.12.8.1092; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; Lomazzi M, 2002, NAT GENET, V31, P190, DOI 10.1038/ng891; Lukas J, 1996, MOL CELL BIOL, V16, P1047; MEHTALI M, 1990, GENE, V91, P179, DOI 10.1016/0378-1119(90)90086-7; Meng XJ, 2000, SCIENCE, V287, P1489, DOI 10.1126/science.287.5457.1489; Moreno E, 2004, CELL, V117, P117, DOI 10.1016/S0092-8674(04)00262-4; Morkel M, 1997, NATURE, V390, P567, DOI 10.1038/37507; Moroni MC, 2001, NAT CELL BIOL, V3, P552, DOI 10.1038/35078527; Mostofi FK, 1994, IARC SCI PUBL, V111, P407; Muller H, 2001, GENE DEV, V15, P267, DOI 10.1101/gad.864201; MULLER H, 2000, BIOCHIM BIOPHYS ACTA, V1470, P1; Nikitin AY, 1996, GENE DEV, V10, P1870, DOI 10.1101/gad.10.15.1870; Pan HC, 1998, MOL CELL, V2, P283, DOI 10.1016/S1097-2765(00)80273-7; Phillips AC, 1997, GENE DEV, V11, P1853, DOI 10.1101/gad.11.14.1853; Pierce AM, 1998, ONCOGENE, V16, P1267, DOI 10.1038/sj.onc.1201666; Pierce AM, 1998, P NATL ACAD SCI USA, V95, P8858, DOI 10.1073/pnas.95.15.8858; POON GK, 1995, DRUG METAB DISPOS, V23, P377; Rempel RE, 2000, MOL CELL, V6, P293, DOI 10.1016/S1097-2765(00)00030-7; Sage J, 2003, NATURE, V424, P223, DOI 10.1038/nature01764; Sherr CJ, 2002, CANCER CELL, V2, P103, DOI 10.1016/S1535-6108(02)00102-2; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; Trimarchi JM, 2002, NAT REV MOL CELL BIO, V3, P11, DOI 10.1038/nrm714; Trimarchi JM, 1998, P NATL ACAD SCI USA, V95, P2850, DOI 10.1073/pnas.95.6.2850; Vigo E, 1999, MOL CELL BIOL, V19, P6379; Wu LZ, 2001, NATURE, V414, P457, DOI 10.1038/35106593; Yamasaki L, 1998, NAT GENET, V18, P360, DOI 10.1038/ng0498-360; Zindy F, 2000, MOL CELL BIOL, V20, P372, DOI 10.1128/MCB.20.1.372-378.2000	53	32	33	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 27	2005	24	5					780	789		10.1038/sj.onc.1208248	http://dx.doi.org/10.1038/sj.onc.1208248			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	891JM	15531911				2022-12-17	WOS:000226577100004
J	Tchevkina, E; Agapova, L; Dyakova, N; Martinjuk, A; Komelkov, A; Tatosyan, A				Tchevkina, E; Agapova, L; Dyakova, N; Martinjuk, A; Komelkov, A; Tatosyan, A			The small G-protein RalA stimulates metastasis of transformed cells	ONCOGENE			English	Article						Ras; Ral; metastasis; signal transduction	ROUS-SARCOMA VIRUS; RAS ONCOGENES; CANCER-CELLS; N-RAS; KINASE; TUMORIGENICITY; FIBROBLASTS; GROWTH; ACTIVATION; MECHANISMS	RAS oncogenes play a critical role in oncogenic transformation and metastases formation. Here we show that Ha-ras greatly stimulates spontaneous metastatic activity of transformed cells through the Ras/RalGDS/RalA intracellular signaling pathway. Introduction of RalA alone leads to a drastic increase of metastatic activity of transformed cells. We demonstrate that metastatic ability of cells could be dramatically enhanced by RalA stimulation or, conversely, hampered by RalA suppression. Furthermore, we found that during in vivo selection cells acquire high metastatic properties as a result of endogenous RalA activation. The ability of RalA to induce metastasis was demonstrated in spontaneously transformed as well as in virus transformed fibroblasts.	Russian Acad Med Sci, Canc Res Ctr, Inst Carcinogenesis, Moscow 115478, Russia	Russian Academy of Medical Sciences	Tatosyan, A (corresponding author), Russian Acad Med Sci, Canc Res Ctr, Inst Carcinogenesis, Moscow 115478, Russia.	tatosyan@space.ru	Tchevkina, Elena/R-8909-2019; Komelkov, Andrei/E-4567-2012	Komelkov, Andrei/0000-0003-0766-163X				Bernards R, 2002, NATURE, V418, P823, DOI 10.1038/418823a; BOS JL, 1989, CANCER RES, V49, P4682; CHAMBERS AF, 1993, CRIT REV ONCOGENESIS, V4, P95; Chambers AF, 2002, NAT REV CANCER, V2, P563, DOI 10.1038/nrc865; CHARDIN P, 1986, EMBO J, V5, P2203, DOI 10.1002/j.1460-2075.1986.tb04485.x; Chien YC, 2003, EMBO REP, V4, P800, DOI 10.1038/sj.embor.embor899; DEICHMAN GI, 1989, INT J CANCER, V44, P908, DOI 10.1002/ijc.2910440527; DEICHMAN GI, 1992, INT J CANCER, V51, P903, DOI 10.1002/ijc.2910510612; Deichman GI, 1996, INT J CANCER, V66, P747, DOI 10.1002/(SICI)1097-0215(19960611)66:6<747::AID-IJC7>3.0.CO;2-#; DEICHMAN GI, 1989, INT J CANCER, V44, P904, DOI 10.1002/ijc.2910440526; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; Fidler IJ, 2003, NAT REV CANCER, V3, P453, DOI 10.1038/nrc1098; Gildea JJ, 2002, CANCER RES, V62, P982; Hamad NM, 2002, GENE DEV, V16, P2045, DOI 10.1101/gad.993902; Joneson T, 1996, SCIENCE, V271, P810, DOI 10.1126/science.271.5250.810; KhosraviFar R, 1996, MOL CELL BIOL, V16, P3923; Malumbres M, 2003, NAT REV CANCER, V3, P459, DOI 10.1038/nrc1097; Miller MJ, 1997, J BIOL CHEM, V272, P5600, DOI 10.1074/jbc.272.9.5600; Mizenina O, 2001, J BIOL CHEM, V276, P34006, DOI 10.1074/jbc.M011320200; Moskalenko S, 2002, NAT CELL BIOL, V4, P66, DOI 10.1038/ncb728; Pawlak G, 2002, MOL BIOL CELL, V13, P336, DOI 10.1091/mbc.01-06-0302; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; Sprang SR, 1997, ANNU REV BIOCHEM, V66, P639, DOI 10.1146/annurev.biochem.66.1.639; Suzuki J, 2000, MOL CELL BIOL, V20, P4658, DOI 10.1128/MCB.20.13.4658-4665.2000; TOPOL LZ, 1993, MOL CARCINOGEN, V8, P167, DOI 10.1002/mc.2940080307; Urano T, 1996, EMBO J, V15, P810, DOI 10.1002/j.1460-2075.1996.tb00416.x; Ward Y, 2001, MOL CELL BIOL, V21, P5958, DOI 10.1128/MCB.21.17.5958-5969.2001; Webb CP, 1998, P NATL ACAD SCI USA, V95, P8773, DOI 10.1073/pnas.95.15.8773; White MA, 1996, J BIOL CHEM, V271, P16439, DOI 10.1074/jbc.271.28.16439; Yamazaki Y, 2001, BIOCHEM BIOPH RES CO, V280, P868, DOI 10.1006/bbrc.2000.4233; Yu Y, 2002, ONCOGENE, V21, P7557, DOI 10.1038/sj.onc.1205961	31	32	36	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 13	2005	24	3					329	335		10.1038/sj.onc.1208094	http://dx.doi.org/10.1038/sj.onc.1208094			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	887CH	15467745				2022-12-17	WOS:000226279700004
J	Cavazzoni, A; Petronini, PG; Galetti, M; Roz, L; Andriani, F; Carbognani, P; Rusca, M; Fumarola, C; Alfieri, R; Sozzi, G				Cavazzoni, A; Petronini, PG; Galetti, M; Roz, L; Andriani, F; Carbognani, P; Rusca, M; Fumarola, C; Alfieri, R; Sozzi, G			Dose-dependent effect of FHIT-inducible expression in Calu-1 lung cancer cell line	ONCOGENE			English	Article						FHIT; inducible expression system; proliferation; lung cancer; p21	HISTIDINE TRIAD GENE; SUPPRESSES TUMORIGENICITY; GLUTAMINE DEPRIVATION; TUMOR-SUPPRESSOR; APOPTOSIS; SUSCEPTIBILITY; SURVIVAL; PROTEIN	Abnormalities in the expression of the tumour suppressor fragile histidine triad ( FHIT) gene have been reported in a variety of human tumours, including lung cancer and restoration of its expression in cancer cell lines resulted in the inhibition of proliferation and apoptosis induction. Most of the studies that have assigned a proapoptotic role to the FHIT gene were performed in adenoviral-FHIT-transduced cancer cells expressing high levels of the Fhit protein. The present work was the first study designed to investigate the effects of FHIT gene replacement in a human FHIT-negative non-small-cell lung cancer (NSCLC) cell line (Calu-1) by using a hormone-inducible expression system that allows tight modulation of the transgene expression. Through this approach, we demonstrated that a prolonged induction was required to accumulate the Fhit protein at levels adequate to promote a significant decrease of cell proliferation. Analysis of cell-cycle phase distribution showed an accumulation of cells in the G(0)/G(1) phase and a concomitant decrease in the S phase. Moreover, an upregulation of p21(waf1) transcript was found, which could account for the alteration of the cycling properties of the cells. The growth-inhibitory effects observed were not associated with apoptosis appearance, and although in these conditions the Fhit protein content was higher than in normal bronchial human epithelial cells (NHBE), it was still significantly lower than the level capable of inducing apoptosis in Calu-1 cells after adenoviral-mediated FHIT gene transfer. These results indicate that the tumour suppressor properties of Fhit are strictly related to its expression level and show that the Fhit protein has a dose-dependent antiproliferative effect on the Fhit-negative Calu-1 lung cancer cell line.	Ist Nazl Tumori, Dept Expt Oncol, I-20133 Milan, Italy; Univ Parma, Dept Expt Med, I-43100 Parma, Italy; Univ Parma, Dept Surg, Thorac Surg Unit, I-43100 Parma, Italy	Fondazione IRCCS Istituto Nazionale Tumori Milan; University of Parma; University of Parma	Sozzi, G (corresponding author), Ist Nazl Tumori, Dept Expt Oncol, Via Venezian 1, I-20133 Milan, Italy.	gabriella.sozzi@istitutotumori.mi.it	sozzi, gabriella/G-8259-2011; Andriani, Francesca/D-4898-2017; Galetti, Maricla/AAJ-8927-2020; Alfieri, Roberta R/G-6350-2012; Cavazzoni, Andrea/J-8079-2019; Carbognani, Paolo/AAC-2610-2019; Roz, Luca/AAB-3889-2019; Galetti, Maricla/CAG-4178-2022	sozzi, gabriella/0000-0001-9360-6914; Andriani, Francesca/0000-0002-6178-7789; Galetti, Maricla/0000-0002-8061-8649; Cavazzoni, Andrea/0000-0002-3752-1868; Roz, Luca/0000-0001-5817-7149; Galetti, Maricla/0000-0002-8061-8649				Alfieri RR, 2002, J PHYSIOL-LONDON, V540, P499, DOI 10.1113/jphysiol.2001.013395; Barnes LD, 1996, BIOCHEMISTRY-US, V35, P11529, DOI 10.1021/bi961415t; Dumon KR, 2001, CANCER RES, V61, P4827; FAIRCHILD CR, 2000, P 91 AACR ANN M S FR, V41, P227; Fumarola C, 2001, CELL DEATH DIFFER, V8, P1004, DOI 10.1038/sj.cdd.4400902; Ishii H, 2001, JAMA-J AM MED ASSOC, V286, P2441, DOI 10.1001/jama.286.19.2441; Ishii H, 2001, CANCER RES, V61, P1578; Ji L, 1999, CANCER RES, V59, P3333; Ohta M, 1996, CELL, V84, P587, DOI 10.1016/S0092-8674(00)81034-X; Otterson GA, 1998, J NATL CANCER I, V90, P426, DOI 10.1093/jnci/90.6.426; PETRONINI PG, 1993, BRIT J CANCER, V67, P493, DOI 10.1038/bjc.1993.92; Petronini PG, 1996, J CELL PHYSIOL, V169, P175, DOI 10.1002/(SICI)1097-4652(199610)169:1<175::AID-JCP18>3.0.CO;2-C; Roz L, 2002, P NATL ACAD SCI USA, V99, P3615, DOI 10.1073/pnas.062030799; Roz Luca, 2004, Proceedings of the American Association for Cancer Research Annual Meeting, V45, P1129; Roz Luca, 2003, Proceedings of the American Association for Cancer Research Annual Meeting, V44, P1206; Sard L, 1999, P NATL ACAD SCI USA, V96, P8489, DOI 10.1073/pnas.96.15.8489; Siprashvili Z, 1997, P NATL ACAD SCI USA, V94, P13771, DOI 10.1073/pnas.94.25.13771; Sozzi G, 1998, CANCER RES, V58, P5032; Werner NS, 2000, CANCER RES, V60, P2780; Wu R, 2000, J NATL CANCER I, V92, P338, DOI 10.1093/jnci/92.4.338; Zanesi N, 2001, P NATL ACAD SCI USA, V98, P10250, DOI 10.1073/pnas.191345898	21	32	37	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 4	2004	23	52					8439	8446		10.1038/sj.onc.1207847	http://dx.doi.org/10.1038/sj.onc.1207847			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	867VN	15361849				2022-12-17	WOS:000224870700004
J	Anazawa, Y; Arakawa, H; Nakagawa, H; Nakamura, Y				Anazawa, Y; Arakawa, H; Nakagawa, H; Nakamura, Y			Identification of STAG1 as a key mediator of a p53-dependent apoptotic pathway	ONCOGENE			English	Article						p53; p53-121F; p53 target gene; apoptosis; cDNA microarray; gene therapy	CELL-CYCLE CHECKPOINT; P53 GENE-TRANSFER; POTENTIAL MEDIATOR; DIRECT TARGET; LUNG-CANCER; PROTEIN; MUTATIONS; EXPRESSION; INHIBITOR; KINASES	A mutant version of p53 (p53-121F), in which phenylalanine replaces the 121st serine residue, can induce apoptosis more effectively than wild-type p53 (wt-p53). In view of this observation, we considered that one or more apoptosis-related p53-target genes might be preferentially induced by p53-121F. We carried out cDNA microarray analysis to identify such genes, using mRNAs isolated from LS174T colon-cancer cells infected by adenovirus vectors containing either p53-121F(Ad-p53-121F) or wt-p53 (Ad-p53). The STAG1 gene was one of the transcripts showing higher expression levels in cells infected with Ad-p53-121F as opposed to Ad-wtp53. The encoded product appears to contain a transmembrane domain, and binding motifs for SH3 and WW. In two other cancer cell lines, the expression of STAG1 mRNA was induced in response to various genotoxic stresses in a p53-dependent manner; moreover, enforced expression of STAG1 led to apoptosis in several additional cancer cell lines. Suppression of endogenous STAG1 using the RNA-interference method reduced the apoptotic response, whether induced by Ad-p53-121F or Ad- p53. These results suggest that STAG1, a novel transcriptional target for p53, mediates p53-dependent apoptosis, and might be a good candidate for next-generation gene therapy.	Univ Tokyo, Inst Med Sci, Ctr Human Genome, Mol Med Lab,Minato Ku, Tokyo 1088639, Japan	University of Tokyo	Nakamura, Y (corresponding author), Univ Tokyo, Inst Med Sci, Ctr Human Genome, Mol Med Lab,Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.	yusuke@ims.u-tokyo.ac.jp	Arakawa, Hirofumi/L-3459-2013	Arakawa, Hirofumi/0000-0001-6077-0638				BAKER SJ, 1990, CANCER RES, V50, P7717; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FREEMAN J, 1994, EMBO J, V13, P5393, DOI 10.1002/j.1460-2075.1994.tb06874.x; Furuhata T, 1996, ONCOGENE, V13, P1965; Habib NA, 1999, HUM GENE THER, V10, P2019, DOI 10.1089/10430349950017383; Han HJ, 1998, HUM MOL GENET, V7, P1039, DOI 10.1093/hmg/7.6.1039; HARPER JW, 1993, CELL, V75, P805; Harvey KF, 1998, J BIOL CHEM, V273, P13524, DOI 10.1074/jbc.273.22.13524; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Iiizumi M, 2002, CANCER RES, V62, P1246; Matsuda K, 2002, CANCER RES, V62, P2883; MCGRORY WJ, 1988, VIROLOGY, V163, P614, DOI 10.1016/0042-6822(88)90302-9; Mori T, 2002, NEOPLASIA, V4, P268, DOI 10.1038/sj.neo.7900235; Mori T, 2002, ONCOGENE, V21, P2914, DOI 10.1038/sj.onc.1205459; Murillas R, 2002, J BIOL CHEM, V277, P2897, DOI 10.1074/jbc.M110047200; Ng CC, 1999, GENE CHROMOSOME CANC, V26, P329, DOI 10.1002/(SICI)1098-2264(199912)26:4<329::AID-GCC7>3.0.CO;2-C; Nishimori H, 1997, ONCOGENE, V15, P2145, DOI 10.1038/sj.onc.1201542; Ochi K, 2002, NEOPLASIA, V4, P82, DOI 10.1038/sj.neo.7900211; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; Ono K, 2000, CANCER RES, V60, P5007; Rae FK, 2001, MOL CARCINOGEN, V32, P44, DOI 10.1002/mc.1063; Roth JA, 1996, NAT MED, V2, P985, DOI 10.1038/nm0996-985; Saller E, 1999, EMBO J, V18, P4424, DOI 10.1093/emboj/18.16.4424; Takei Y, 1998, GENE CHROMOSOME CANC, V23, P1; Tanaka H, 2000, NATURE, V404, P42, DOI 10.1038/35003506; Urano T, 1997, CANCER RES, V57, P3281; Weill D, 2000, CHEST, V118, P966, DOI 10.1378/chest.118.4.966; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Yamaguchi T, 2001, CANCER RES, V61, P8256	29	32	33	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 7	2004	23	46					7621	7627		10.1038/sj.onc.1207270	http://dx.doi.org/10.1038/sj.onc.1207270			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	859ZK	15361841				2022-12-17	WOS:000224306700003
J	Haverkos, HW				Haverkos, HW			Viruses, chemicals and co-carcinogenesis	ONCOGENE			English	Article						co-carcinogenesis; oncogenic viruses; chemical carcinogens; cervical cancer; hepatocellular cancer; Kaposi's sarcoma	INVASIVE CERVICAL-CANCER; HERPES-SIMPLEX-VIRUS; HEPATITIS-B-VIRUS; SARCOMA-ASSOCIATED HERPESVIRUS; KAPOSIS-SARCOMA; HUMAN-PAPILLOMAVIRUS; HEPATOCELLULAR-CARCINOMA; RISK-FACTORS; CIGARETTE-SMOKING; INFECTED WOMEN	The etiology of cancers appears to be complex and multifactorial. Peyton Rous and others demonstrated the process of co-carcinogenesis by exposing rabbits to a virus and tars. Epidemiologists have proposed virus-chemical interactions to cause several cancers. For example, one might propose that the etiology of cervical cancer results from a complex interplay between oncogenic viruses and cervical tar exposures through tar-based vaginal douching, cigarette smoking, and/or long-term cooking over wood-burning stoves in poorly ventilated kitchens. Hepatocellular carcinoma may result from the joint effects of viruses and hepatotoxic chemical carcinogens. Kaposi's sarcoma might happen following reciprocal actions of human herpes virus-8 infection, immunosuppression, and chemical exposures, such as nitrite radicals and alumino-silicates. Use of Koch's postulates will not help one prove or disprove a multifactorial causation of disease; new criteria are needed. Delineating the web of causation may lead to additional strategies for prevention and treatment of several cancers.	Walter Reed Army Med Ctr, Dept Med, Infect Dis Serv, Washington, DC 20307 USA	United States Department of Defense; United States Army; Walter Reed National Military Medical Center	Haverkos, HW (corresponding author), 5600 Fishers Lane, Rockville, MD 20857 USA.	haverkosh@cder.fda.gov						ARMSTRONG B, 1992, EPIDEMIOLOGY CANC CE, P11; BARRESINOUSSI F, 1983, SCIENCE, V220, P868, DOI 10.1126/science.6189183; BEASLEY RP, 1981, LANCET, V2, P1129; BEERS FG, 1973, BRIT J CANCER, V27, P473; BERAL V, 1990, LANCET, V335, P123, DOI 10.1016/0140-6736(90)90001-L; BERENBLUM I, 1954, ADV CANCER RES, V2, P129, DOI 10.1016/S0065-230X(08)60493-5; BOSCH FX, 1992, INT J CANCER, V52, P750, DOI 10.1002/ijc.2910520514; BOSCH FX, 1995, JNCI-J NATL CANCER I, V87, P796, DOI 10.1093/jnci/87.11.796; BOSHART M, 1984, EMBO J, V3, P1151, DOI 10.1002/j.1460-2075.1984.tb01944.x; Cannon MJ, 2003, AIDS, V17, P215, DOI 10.1097/00002030-200301240-00012; Carbone M, 2003, ONCOGENE, V22, P5173, DOI 10.1038/sj.onc.1206552; Castle PE, 2002, JNCI-J NATL CANCER I, V94, P1406, DOI 10.1093/jnci/94.18.1406; Chang MH, 1997, NEW ENGL J MED, V336, P1855, DOI 10.1056/NEJM199706263362602; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; Chen CJ, 1997, J GASTROEN HEPATOL, V12, pS294, DOI 10.1111/j.1440-1746.1997.tb00513.x; Chen CJ, 2002, HEPATOLOGY, V36, P1046, DOI 10.1053/jhep.2002.37084; Dal Maso L, 2001, EUR J CANCER, V37, P1188, DOI 10.1016/S0959-8049(01)00120-4; Daling JR, 1996, CANCER EPIDEM BIOMAR, V5, P541; DAY GL, 1994, INT J CANCER, V59, P319, DOI 10.1002/ijc.2910590305; DROTMAN DP, 1995, DERMATOL CLIN, V13, P575, DOI 10.1016/S0733-8635(18)30063-9; DURANREYNALS F, 1957, TEX REP BIOL MED, V15, P306; DURST M, 1983, P NATL ACAD SCI-BIOL, V80, P3812, DOI 10.1073/pnas.80.12.3812; Evans Alfred S., 1990, Annals of Epidemiology, V1, P71; EVANS AS, 1982, YALE J BIOL MED, V55, P193; Ferlay J, 2001, GLOBOCAN 2000 CANC I; Ferrera A, 2000, INT J EPIDEMIOL, V29, P817, DOI 10.1093/ije/29.5.817; FRENKEL N, 1972, P NATL ACAD SCI USA, V69, P3784, DOI 10.1073/pnas.69.12.3784; FRIEDMANKIEN AE, 1989, COLOR ATLAS AIDS; Galloway DA, 2003, LANCET INFECT DIS, V3, P469, DOI 10.1016/S1473-3099(03)00720-5; GARRETT LR, 1993, CARCINOGENESIS, V14, P329, DOI 10.1093/carcin/14.2.329; GILLISON N, 2003, J NCI MONOGR, V31, P57; Hassan MM, 2002, HEPATOLOGY, V36, P1206, DOI 10.1053/jhep.2002.36780; HAUSEN HZ, 1975, BIOCHIM BIOPHYS ACTA, V417, P25, DOI 10.1016/0304-419X(75)90007-4; Haverkos H, 2000, BIOMED PHARMACOTHER, V54, P54, DOI 10.1016/S0753-3322(00)88642-4; HAVERKOS HW, 1994, ENVIRON HEALTH PERSP, V102, P858, DOI 10.2307/3432118; HAVERKOS HW, 1985, SEX TRANSM DIS, V12, P203, DOI 10.1097/00007435-198510000-00007; Haverkos HW, 1996, BIOMED PHARMACOTHER, V50, P318, DOI 10.1016/0753-3322(96)84834-7; Haverkos HW, 2003, BIOMED PHARMACOTHER, V57, P67, DOI 10.1016/S0753-3322(03)00196-3; HAVERKOS HW, 1982, CA-CANCER J CLIN, V32, P330, DOI 10.3322/canjclin.32.6.330; HAVERKOS HW, 1995, GENETICA, V95, P157, DOI 10.1007/BF01435007; HILDESHEIM A, 1991, INT J CANCER, V49, P335, DOI 10.1002/ijc.2910490304; Hildesheim A, 2001, BRIT J CANCER, V84, P1219, DOI 10.1054/bjoc.2001.1779; HO GYF, 1995, JNCI-J NATL CANCER I, V87, P1365, DOI 10.1093/jnci/87.18.1365; Ho GYF, 1998, NEW ENGL J MED, V338, P423, DOI 10.1056/NEJM199802123380703; Holly EA, 1998, AM J PUBLIC HEALTH, V88, P1767, DOI 10.2105/AJPH.88.12.1767; HUANG MH, 1997, NEW ENGL J MED, V336, P1855; Kew MC, 2002, TOXICOLOGY, V181, P35, DOI 10.1016/S0300-483X(02)00251-2; KOUTSKY LA, 1992, NEW ENGL J MED, V327, P1272, DOI 10.1056/NEJM199210293271804; LOMBARD HL, 1950, CANCER, V3, P960, DOI 10.1002/1097-0142(1950)3:6<960::AID-CNCR2820030603>3.0.CO;2-G; MARTIN CM, 1961, SCIENCE, V134, P1985, DOI 10.1126/science.134.3494.1985; MENDIS LN, 1981, INT J CANCER, V27, P669, DOI 10.1002/ijc.2910270514; Ming L, 2002, HEPATOLOGY, V36, P1214, DOI 10.1053/jhep.2002.36366; MIRVISH SS, 1993, ENVIRON MOL MUTAGEN, V21, P247, DOI 10.1002/em.2850210307; MOORE PS, 1995, NEW ENGL J MED, V332, P1181, DOI 10.1056/NEJM199505043321801; Osmond DH, 2002, JAMA-J AM MED ASSOC, V287, P221, DOI 10.1001/jama.287.2.221; Papanicolaou GN, 1941, AM J OBSTET GYNECOL, V42, P193; POPOVIC M, 1984, SCIENCE, V224, P497, DOI 10.1126/science.6200935; Prokopczyk B, 1997, J NATL CANCER I, V89, P868, DOI 10.1093/jnci/89.12.868; ROGERS S, 1951, J EXP MED, V93, P459, DOI 10.1084/jem.93.5.459; ROOTBERNSTEIN RS, 1993, RETHINKING AIDS TRAG, P104; Rothman N, 1997, LANCET, V350, P240, DOI 10.1016/S0140-6736(97)02088-6; ROTKIN ID, 1967, AM J PUBLIC HEALTH N, V57, P815, DOI 10.2105/AJPH.57.5.815; Rous P, 1934, J EXP MED, V60, P741, DOI 10.1084/jem.60.6.741; ROUS P, 1965, NATURE, V207, P457, DOI 10.1038/207457a0; Rous P, 1911, J AMER MED ASSOC, V56, P198; Rous P, 1938, J EXP MED, V67, P399, DOI 10.1084/jem.67.3.399; ROWE PC, 1988, JAMA-J AM MED ASSOC, V260, P3167, DOI 10.1001/jama.260.21.3167; ROWSON KE, 1961, NATURE, V191, P893, DOI 10.1038/191893a0; SALAMAN MH, 1964, BRIT MED BULL, V20, P139, DOI 10.1093/oxfordjournals.bmb.a070307; Smith FR, 1931, AM J OBSTET GYNECOL, V21, P18, DOI 10.1016/S0002-9378(31)90837-5; Smith JS, 2002, JNCI-J NATL CANCER I, V94, P1604, DOI 10.1093/jnci/94.21.1604; SOUTHAM CM, 1963, CANCER RES, V23, P1105; Steckley SL, 2003, BIOMED PHARMACOTHER, V57, P78, DOI 10.1016/S0753-3322(02)00342-6; STOKER M, 1963, NATURE, V200, P756, DOI 10.1038/200756a0; Sun ZT, 1999, HEPATOLOGY, V30, P379, DOI 10.1002/hep.510300204; Sylla A, 1999, MUTAT RES-FUND MOL M, V428, P187, DOI 10.1016/S1383-5742(99)00046-0; TANAKA S, 1962, JNCI-J NATL CANCER I, V29, P711; TANAKA S, 1965, J NATL CANCER I, V34, P441; Tran-Thanh D, 2003, AM J OBSTET GYNECOL, V188, P129, DOI 10.1067/mob.2003.66; Uetake S, 2003, ALCOHOL CLIN EXP RES, V27, p47S, DOI 10.1097/01.ALC.0000079449.47468.B0; Velema JP, 2002, INT J CANCER, V97, P536, DOI 10.1002/ijc.1622; WHITBY D, 1995, LANCET, V346, P799, DOI 10.1016/S0140-6736(95)91619-9; WINKELSTEIN W, 1977, AM J EPIDEMIOL, V106, P257, DOI 10.1093/oxfordjournals.aje.a112460; WINKELSTEIN W, 1977, AM J EPIDEMIOL, V105, P407, DOI 10.1093/oxfordjournals.aje.a112399; ZHURHAUSEN JH, 1975, BIBL HAEMATOL, V43, P569; ZIEGLER JL, 1993, LANCET, V342, P1348, DOI 10.1016/0140-6736(93)92252-O; Ziegler JL, 1997, AIDS, V11, P1619, DOI 10.1097/00002030-199713000-00011; Ziegler JL, 2001, J CLIN VIROL, V20, P127, DOI 10.1016/S1386-6532(00)00137-2; zur Hausen H, 1974, Int J Cancer, V13, P650; Zur Hausen H, 1982, LANCET, V2, P1370, DOI DOI 10.1016/S0140-6736(82)91273-9; ZURHAUSEN H, 1976, CANCER RES, V36, P794; 1996, NIH CONS C APR 1 3, V14, P1	92	32	32	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 23	2004	23	38					6492	6499		10.1038/sj.onc.1207822	http://dx.doi.org/10.1038/sj.onc.1207822			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	848LJ	15322520				2022-12-17	WOS:000223468800014
J	Chen, CF; Goyette, P; Lohnes, D				Chen, CF; Goyette, P; Lohnes, D			RAR gamma acts as a tumor suppressor in mouse keratinocytes	ONCOGENE			English	Article						retinoic acid receptors; Ras; skin tumorigenesis; keratinocytes; squamous cell carcinoma; tumor suppressor	RETINOIC ACID RECEPTOR; TARGETED DISRUPTION; NUCLEAR RECEPTORS; DOWN-REGULATION; CYCLIN D1; BETA 2; SKIN; CELLS; ACTIVATION; EXPRESSION	All-trans retinoic acid (RA), the principal biologically active form of vitamin A, is essential for many developmental process as well as homeostasis in the adult. Many lines of evidence also suggest that RA, acting through the RA receptors (RARs), can also suppress growth of tumors of diverse origin. To assess directly the role of the RARs in a model of epidermal tumorigenesis, we investigated the incidence of tumor formation using keratinocytes lacking specific RAR types. Our data suggest that loss of RARgamma, but not RARalpha, predisposed keratinocytes to v-Ha-Ras-induced squamous cell carcinoma. We also found that ablation of RARgamma, but not RARalpha, abolished RA-induced cell cycle arrest and apoptosis in these keratinocytes. Reconstitution of receptor expression into RAR-null cells restored sensitivity to RA, and reversed the tumorigenic potential of receptor-deficient keratinocytes. These data strongly support a tumor suppressor effect for the RARs, in particular endogenous RARgamma, in murine keratinocytes.	Clin Res Inst Montreal, Montreal, PQ H2W 1R7, Canada; McGill Univ, Div Expt Med, Montreal, PQ H3A 2T5, Canada; Univ Montreal, Dept Mol Biol, Montreal, PQ H3C 3J7, Canada	Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; McGill University; Universite de Montreal	Lohnes, D (corresponding author), Clin Res Inst Montreal, 110 Pine Ave W, Montreal, PQ H2W 1R7, Canada.	lohnesd@ircm.qc.ca						Adnane J, 2000, ONCOGENE, V19, P5338, DOI 10.1038/sj.onc.1203956; Altucci L, 2001, NAT REV CANCER, V1, P181, DOI 10.1038/35106036; Angel P, 1992, Matrix Suppl, V1, P156; Berard J, 1996, FASEB J, V10, P1091, DOI 10.1096/fasebj.10.9.8801172; Borriello A, 2000, ONCOGENE, V19, P51, DOI 10.1038/sj.onc.1203231; Bost F, 2002, BIOCHEM J, V361, P621, DOI 10.1042/0264-6021:3610621; Boudjelal M, 2000, CANCER RES, V60, P2247; BOYLAN JF, 1995, MOL CELL BIOL, V15, P843; Boyle JO, 1999, J NATL CANCER I, V91, P373, DOI 10.1093/jnci/91.4.373; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; Chapellier B, 2002, EMBO J, V21, P3402, DOI 10.1093/emboj/cdf331; CHEN LC, 1995, CANCER LETT, V95, P113, DOI 10.1016/0304-3835(95)03868-W; Chiba H, 1997, MOL CELL BIOL, V17, P3013, DOI 10.1128/MCB.17.6.3013; Chiba H, 1997, J CELL BIOL, V139, P735, DOI 10.1083/jcb.139.3.735; Classon M, 2002, NAT REV CANCER, V2, P910, DOI 10.1038/nrc950; Darwiche N, 1996, CANCER RES, V56, P4942; DARWICHE N, 1995, CANCER RES, V55, P2774; De Luca LM, 1996, NUTR CANCER, V25, P249, DOI 10.1080/01635589609514449; Dimberg A, 2002, BLOOD, V99, P2199, DOI 10.1182/blood.V99.6.2199; Faria TN, 1999, J BIOL CHEM, V274, P26783, DOI 10.1074/jbc.274.38.26783; Fisher GJ, 1996, FASEB J, V10, P1002, DOI 10.1096/fasebj.10.9.8801161; Fontana JA, 2002, LEUKEMIA, V16, P463, DOI 10.1038/sj.leu.2402414; Ghyselinck NB, 1997, INT J DEV BIOL, V41, P425; Gianni M, 2002, J BIOL CHEM, V277, P24859, DOI 10.1074/jbc.C200230200; GIMENEZCONTI I, 1990, CARCINOGENESIS, V11, P1995, DOI 10.1093/carcin/11.11.1995; Goyette P, 2000, J BIOL CHEM, V275, P16497, DOI 10.1074/jbc.M909382199; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hansen LA, 2003, CANCER RES, V63, P5257; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; HOULE B, 1993, P NATL ACAD SCI USA, V90, P985, DOI 10.1073/pnas.90.3.985; Houle M, 2000, MOL CELL BIOL, V20, P6579, DOI 10.1128/MCB.20.17.6579-6586.2000; Huang CS, 1997, P NATL ACAD SCI USA, V94, P5826, DOI 10.1073/pnas.94.11.5826; Jochum W, 2001, ONCOGENE, V20, P2401, DOI 10.1038/sj.onc.1204389; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; KASTNER P, 1995, CELL, V83, P859, DOI 10.1016/0092-8674(95)90202-3; Katz ME, 1997, CURR OPIN GENET DEV, V7, P75, DOI 10.1016/S0959-437X(97)80112-8; KhosraviFar R, 1996, MOL CELL BIOL, V16, P3923; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Klaassen I, 2001, INT J CANCER, V92, P661, DOI 10.1002/1097-0215(20010601)92:5<661::AID-IJC1251>3.0.CO;2-O; KUENG W, 1989, ANAL BIOCHEM, V182, P16, DOI 10.1016/0003-2697(89)90710-0; KUMAR R, 1994, CARCINOGENESIS, V15, P701, DOI 10.1093/carcin/15.4.701; Langenfeld J, 1997, P NATL ACAD SCI USA, V94, P12070, DOI 10.1073/pnas.94.22.12070; LARCHER F, 1992, MOL CARCINOGEN, V6, P112, DOI 10.1002/mc.2940060206; Le Q, 2000, ONCOGENE, V19, P1457, DOI 10.1038/sj.onc.1203436; Lee HY, 1999, MOL CELL BIOL, V19, P1973; Liu M, 1996, J BIOL CHEM, V271, P31723, DOI 10.1074/jbc.271.49.31723; LOHNES D, 1994, DEVELOPMENT, V120, P2723; LOHNES D, 1993, CELL, V73, P643, DOI 10.1016/0092-8674(93)90246-M; LUFKIN T, 1993, P NATL ACAD SCI USA, V90, P7225, DOI 10.1073/pnas.90.15.7225; MARKS R, 1995, CANCER-AM CANCER SOC, V75, P607, DOI 10.1002/1097-0142(19950115)75:2+<607::AID-CNCR2820751402>3.0.CO;2-8; Mehta K, 2003, J BIOL REG HOMEOS AG, V17, P1; MENDELSOHN C, 1994, DEVELOPMENT, V120, P2749; Mittnacht S, 1998, CURR OPIN GENET DEV, V8, P21, DOI 10.1016/S0959-437X(98)80057-9; Moller MB, 2000, LEUKEMIA LYMPHOMA, V39, P19, DOI 10.3109/10428190009053535; Naderi S, 1999, BLOOD, V94, P1348, DOI 10.1182/blood.V94.4.1348.416k29_1348_1358; NELSON KG, 1982, CANCER RES, V42, P4176; Nevins JR, 2001, HUM MOL GENET, V10, P699, DOI 10.1093/hmg/10.7.699; Oridate N, 1996, ONCOGENE, V12, P2019; Pepper C, 2002, EUR J HAEMATOL, V69, P227, DOI 10.1034/j.1600-0609.2002.02799.x; Philipp J, 1999, ONCOGENE, V18, P4689, DOI 10.1038/sj.onc.1202840; Robles AI, 1998, GENE DEV, V12, P2469, DOI 10.1101/gad.12.16.2469; Rommel C, 1998, CURR OPIN GENET DEV, V8, P412, DOI 10.1016/S0959-437X(98)80111-1; ROOP DR, 1986, NATURE, V323, P822, DOI 10.1038/323822a0; Ross SA, 2000, PHYSIOL REV, V80, P1021, DOI 10.1152/physrev.2000.80.3.1021; Sebolt-Leopold JS, 2000, ONCOGENE, V19, P6594, DOI 10.1038/sj.onc.1204083; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; SHEIKH MS, 1994, J BIOL CHEM, V269, P21440; Stevaux O, 2002, CURR OPIN CELL BIOL, V14, P684, DOI 10.1016/S0955-0674(02)00388-5; Sun SY, 2002, CRIT REV ONCOL HEMAT, V41, P41, DOI 10.1016/S1040-8428(01)00144-5; TANEJA R, 1995, P NATL ACAD SCI USA, V92, P7854, DOI 10.1073/pnas.92.17.7854; Taneja R, 1996, P NATL ACAD SCI USA, V93, P6197, DOI 10.1073/pnas.93.12.6197; Topley GI, 1999, P NATL ACAD SCI USA, V96, P9089, DOI 10.1073/pnas.96.16.9089; Wang ZQ, 1999, NAT MED, V5, P418, DOI 10.1038/7417; Webb CP, 1998, P NATL ACAD SCI USA, V95, P8773, DOI 10.1073/pnas.95.15.8773; Wei LN, 2003, ANNU REV PHARMACOL, V43, P47, DOI 10.1146/annurev.pharmtox.43.100901.140301; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Weinstein IB, 2002, SCIENCE, V297, P63, DOI 10.1126/science.1073096; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; Wu JM, 2001, APOPTOSIS, V6, P377, DOI 10.1023/A:1011342220621; Xu L, 1999, CURR OPIN GENET DEV, V9, P140, DOI 10.1016/S0959-437X(99)80021-5; Xu XC, 2001, CANCER RES, V61, P4306; Yen A, 1999, IN VITRO CELL DEV-AN, V35, P527; Young MR, 1999, P NATL ACAD SCI USA, V96, P9827, DOI 10.1073/pnas.96.17.9827; Yuspa SH, 1996, JOURNAL OF INVESTIGATIVE DERMATOLOGY SYMPOSIUM PROCEEDINGS, VOL 1, NO 2, APRIL 1996, P147; Zhang DM, 2001, ONCOGENE, V20, P7935, DOI 10.1038/sj.onc.1204971; ZHANG LX, 1995, J BIOL CHEM, V270, P6022, DOI 10.1074/jbc.270.11.6022	86	32	37	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 8	2004	23	31					5350	5359		10.1038/sj.onc.1207682	http://dx.doi.org/10.1038/sj.onc.1207682			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	835NX	15094780				2022-12-17	WOS:000222491600010
J	Pakakasama, S; Chen, TTL; Frawley, W; Muller, CY; Douglass, EC; Lee, R; Pollock, BH; Tomlinson, GE				Pakakasama, S; Chen, TTL; Frawley, W; Muller, CY; Douglass, EC; Lee, R; Pollock, BH; Tomlinson, GE			CCND1 polymorphism and age of onset of hepatoblastoma	ONCOGENE			English	Article						hepatoblastoma; cyclin D1; CCND1 childhood cancer	CYCLIN D1 POLYMORPHISM; BETA-CATENIN GENE; COLORECTAL-CANCER; SOMATIC MUTATIONS; APC GENE; RISK	Cyclin D1, encoded by the gene CCND1, is a major regulator of the cell cycle transition from G1 phase to S phase. A CCND1 polymorphism (G to A) at codon 242, the boundary of exon 4 and intron 4, affects splicing such that exon 5 is not expressed in the A allele. Since exon 5 is involved in rapid turnover, the variant cyclin D1 corresponding to the A allele may have a longer half-life. A previous study demonstrated that in families with hereditary nonpolyposis colorectal cancer, the age of onset of colorectal cancer varied according to variation at this polymorphic site. We examined this CCND1 polymorphism in a series hepatoblastoma, a childhood liver cancer that shares other molecular features with colon cancer. We determined in an analysis of 84 children with hepatoblastoma that the G/A exon 4 polymorphism in CCND1 is correlated with the age of onset of hepatoblastomas. The A/A genotype is associated with an earlier age of onset compared to the G/A or G/G genotype. The median age of patients with the G/G genotype was 22 months, compared to 17 months in patients with the G/A genotype and 11 months for the A/A genotype. These findings suggest that the CCND1 A polymorphism may contribute to tumor development in children with hepatoblastoma.	Univ Texas, SW Med Ctr, Dept Pediat, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, Dallas, TX USA; Univ Texas, SW Med Ctr, Acad Comp Serv, Dallas, TX USA; Temple Univ, St Christophers Hosp, Dept Pediat, Philadelphia, PA 19122 USA; Univ Texas, Hlth Sci Ctr, Ctr Biostat & Epidemiol, San Antonio, TX USA; Univ Texas, SW Med Ctr, Dept Obstet Gynecol, Dallas, TX USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Tomlinson, GE (corresponding author), Univ Texas, SW Med Ctr, Dept Pediat, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	gail.tomlinson@utsouthwestern.edu	Tomlinson, Gail/AAR-9776-2020		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL053917] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-53917] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BETTICHER DC, 1995, ONCOGENE, V11, P1005; BULTERYS M, 1999, HEPATIC TUMORS CANC; DeBaun MR, 1998, J PEDIATR-US, V132, P398, DOI 10.1016/S0022-3476(98)70008-3; Donnellan R, 1998, J CLIN PATHOL-MOL PA, V51, P1; Hollander M., 1999, NONPARAMETRIC STAT M; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; Jeng YM, 2000, CANCER LETT, V152, P45, DOI 10.1016/S0304-3835(99)00433-4; Koch A, 1999, CANCER RES, V59, P269; Kong SM, 2001, JNCI-J NATL CANCER I, V93, P1106, DOI 10.1093/jnci/93.14.1106; Kong SM, 2000, CANCER RES, V60, P249; KURAHASHI H, 1995, CANCER RES, V55, P5007; Matthias C, 1998, CLIN CANCER RES, V4, P2411; McKay JA, 2000, INT J CANCER, V88, P77, DOI 10.1002/1097-0215(20001001)88:1<77::AID-IJC12>3.0.CO;2-O; Oda H, 1996, CANCER RES, V56, P3320; ORITA M, 1989, P NATL ACAD SCI USA, V86, P2766, DOI 10.1073/pnas.86.8.2766; Sawa H, 1998, ONCOGENE, V16, P1701, DOI 10.1038/sj.onc.1201691; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Takayasu H, 2001, CLIN CANCER RES, V7, P901	19	32	34	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 10	2004	23	27					4789	4792		10.1038/sj.onc.1207499	http://dx.doi.org/10.1038/sj.onc.1207499			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	825ZX	15133490				2022-12-17	WOS:000221799200014
J	Chen, XY; Huang, LM; Kung, HJ; Ann, DK; Shih, HM				Chen, XY; Huang, LM; Kung, HJ; Ann, DK; Shih, HM			The role of tyrosine kinase Etk/Bmx in EGF-induced apoptosis of MDA-MB-468 breast cancer cells	ONCOGENE			English	Article						Etk kinase; EGF-induced apoptosis; Statl activation	EPIDERMAL-GROWTH-FACTOR; FACTOR RECEPTOR GENE; FOCAL ADHESION KINASE; X-LINKED AGAMMAGLOBULINEMIA; TEC FAMILY; PHOSPHATIDYLINOSITOL 3'-KINASE; MEDIATED APOPTOSIS; SIGNALING PATHWAY; FACTOR-ALPHA; PH-DOMAIN	Etk/Bmx, a member of the Tec family of tyrosine kinases, mediates various signaling pathways and confers several cellular functions. In the present study, we have explored the functional role of Etk in mediating EGF-induced apoptosis, using MDA-MB-468 cell line as a model. We first demonstrated that EGF treatment induces Etk tyrosine phosphorylation in both HeLa and MDA-MB468 cells. Overexpression of Etk by recombinant adenovirus in MDA-MB-468 cells potentiates the extent of EGF-induced cell apoptosis. The observed Etk-enhanced MDA-MB-468 cell apoptosis is associated with the Stat1 activation, as demonstrated by electrophoresis mobility shift assays and reporter gene assays. By contrast, a kinase domain deletion mutant EtkDeltaK, functioning as a dominant-negative mutant, ameliorates EGF- induced Stat1 activation and apoptosis in MDA-MB-468 cells. To explore whether the activated Etk alone is sufficient for inducing apoptosis, a conditionally activated Etk (DeltaEtk-ER), a chimeric fusion protein of PH domain-truncated Etk and ligand-binding domain of estrogen receptor, was introduced into MDA-MB-468 cells. Upon beta-estradiol ligand activation, the DeltaEtk-ER could stimulate Stat1 activity and confer cell apoptosis independent of EGF treatment. Taken together, our findings indicate that Etk is a downstream signaling molecule of EGF receptor and suggest that Etk activation is essential for transducing the EGF- induced apoptotic signaling.	Natl Hlth Res Inst, Div Mol & Genom Med, Taipei 11529, Taiwan; Natl Def Med Ctr, Grad Inst Life Sci, Taipei, Taiwan; Univ Calif Davis, Ctr Canc, Sacramento, CA 95817 USA; Univ So Calif, Dept Mol Pharmacol & Toxicol, Los Angeles, CA 90033 USA	National Health Research Institutes - Taiwan; National Defense Medical Center; University of California System; University of California Davis; University of Southern California	Shih, HM (corresponding author), Natl Hlth Res Inst, Div Mol & Genom Med, 128,Sec2,Yen Chiu Yuan RD, Taipei 11529, Taiwan.	shihh@nhri.org.tw	Shih, Hsiu-Ming/S-7023-2018; Kung, Hsing-Jien/C-7651-2013		NCI NIH HHS [CA39207] Funding Source: Medline; NIDCR NIH HHS [R01 DE10742, DE14183] Funding Source: Medline; PHS HHS [91574] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA039207, R01CA039207] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE010742] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE014183] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Anderson JS, 1996, P NATL ACAD SCI USA, V93, P10966, DOI 10.1073/pnas.93.20.10966; ARMSTRONG DK, 1994, CANCER RES, V54, P5280; August A, 2002, INT J BIOCHEM CELL B, V34, P1184, DOI 10.1016/S1357-2725(02)00068-7; Bagheri-Yarmand R, 2001, J BIOL CHEM, V276, P29403, DOI 10.1074/jbc.M103129200; Berclaz G, 2001, INT J ONCOL, V19, P1155; Bromberg JF, 1998, CELL GROWTH DIFFER, V9, P505; Bunnell SC, 2000, J BIOL CHEM, V275, P2219, DOI 10.1074/jbc.275.3.2219; Chau CH, 2002, ONCOGENE, V21, P8817, DOI 10.1038/sj.onc.1206032; Chen RY, 2001, NAT CELL BIOL, V3, P439, DOI 10.1038/35074500; Chin YE, 1997, MOL CELL BIOL, V17, P5328, DOI 10.1128/MCB.17.9.5328; COSTA S, 1988, LANCET, V2, P1258; Czar MJ, 2001, BIOCHEM SOC T, V29, P863, DOI 10.1042/0300-5127:0290863; DEPALAZZO IEG, 1993, CANCER RES, V53, P3217; DERYNCK R, 1987, CANCER RES, V47, P707; Ekman N, 2000, ONCOGENE, V19, P4151, DOI 10.1038/sj.onc.1203763; EKSTRAND AJ, 1991, CANCER RES, V51, P2164; FILMUS J, 1985, BIOCHEM BIOPH RES CO, V128, P898, DOI 10.1016/0006-291X(85)90131-7; Gulli LF, 1996, CELL GROWTH DIFFER, V7, P173; Hognason T, 2001, FEBS LETT, V491, P9, DOI 10.1016/S0014-5793(01)02166-4; Hsueh RC, 2000, ADV IMMUNOL, V75, P283, DOI 10.1016/S0065-2776(00)75007-3; Ibrahim SO, 1997, ANTICANCER RES, V17, P4539; Islam TC, 2000, J GENE MED, V2, P204; Jorissen RN, 2003, EXP CELL RES, V284, P31, DOI 10.1016/S0014-4827(02)00098-8; Jui HY, 2000, J BIOL CHEM, V275, P41124, DOI 10.1074/jbc.M007772200; KERNER JD, 1995, IMMUNITY, V3, P301, DOI 10.1016/1074-7613(95)90115-9; KHAN WN, 1995, IMMUNITY, V3, P283, DOI 10.1016/1074-7613(95)90114-0; KIKUCHI A, 1990, BRIT J DERMATOL, V123, P49, DOI 10.1111/j.1365-2133.1990.tb01823.x; Lee LF, 2001, MOL CELL BIOL, V21, P8385, DOI 10.1128/MCB.21.24.8385-8397.2001; Lewis CM, 2001, CURR OPIN IMMUNOL, V13, P317, DOI 10.1016/S0952-7915(00)00221-1; Lu ZM, 2001, MOL CELL BIOL, V21, P4016, DOI 10.1128/MCB.21.12.4016-4031.2001; MAA MC, 1995, P NATL ACAD SCI USA, V92, P6981, DOI 10.1073/pnas.92.15.6981; MANO H, 1995, BLOOD, V85, P343; MATSUDA T, 1995, BLOOD, V85, P627, DOI 10.1182/blood.V85.3.627.bloodjournal853627; MERLINO GT, 1985, J CLIN INVEST, V75, P1077, DOI 10.1172/JCI111770; Miller AT, 2002, CURR OPIN IMMUNOL, V14, P331, DOI 10.1016/S0952-7915(02)00345-X; Misra UK, 1998, CELL SIGNAL, V10, P441, DOI 10.1016/S0898-6568(97)00171-X; Pan S, 2002, MOL CELL BIOL, V22, P7512, DOI 10.1128/MCB.22.21.7512-7523.2002; Price JT, 1999, CANCER RES, V59, P5475; Qiu Y, 1998, P NATL ACAD SCI USA, V95, P3644, DOI 10.1073/pnas.95.7.3644; Qiu Y, 2000, ONCOGENE, V19, P5651, DOI 10.1038/sj.onc.1203958; Rajantie I, 2001, MOL CELL BIOL, V21, P4647, DOI 10.1128/MCB.21.14.4647-4655.2001; Ramsauer K, 2002, P NATL ACAD SCI USA, V99, P12859, DOI 10.1073/pnas.192264999; RO J, 1988, CANCER RES, V48, P161; Robinson D, 1996, P NATL ACAD SCI USA, V93, P5958, DOI 10.1073/pnas.93.12.5958; SAINSBURY JRC, 1988, BRIT J CANCER, V58, P458, DOI 10.1038/bjc.1988.240; Satterthwaite AB, 1998, SEMIN IMMUNOL, V10, P309, DOI 10.1006/smim.1998.0123; Sieg DJ, 2000, NAT CELL BIOL, V2, P249, DOI 10.1038/35010517; Smith CIE, 2001, BIOESSAYS, V23, P436, DOI 10.1002/bies.1062; Stephanou A, 2002, FASEB J, V16, P1841, DOI 10.1096/fj.02-0150fje; Stephanou A, 2001, J BIOL CHEM, V276, P28340, DOI 10.1074/jbc.M101177200; Suhardja A, 2003, MICROSC RES TECHNIQ, V60, P70, DOI 10.1002/jemt.10245; TAMAGNONE L, 1994, ONCOGENE, V9, P3683; TANG B, 1994, MOL CELL BIOL, V14, P8432, DOI 10.1128/MCB.14.12.8432; Thomas T, 1999, J CELL PHYSIOL, V179, P257, DOI 10.1002/(SICI)1097-4652(199906)179:3<257::AID-JCP3>3.0.CO;2-4; Tsai YT, 2000, MOL CELL BIOL, V20, P2043, DOI 10.1128/MCB.20.6.2043-2054.2000; Tsang DK, 1999, INT J ONCOL, V15, P519; TSUKADA S, 1993, CELL, V72, P279, DOI 10.1016/0092-8674(93)90667-F; Uckun FM, 1996, SCIENCE, V273, P1096, DOI 10.1126/science.273.5278.1096; Vignais ML, 1999, MOL CELL BIOL, V19, P3727; Vihinen M, 2000, FRONT BIOSCI-LANDMRK, V5, pD917, DOI 10.2741/vihinen; Wells A, 1999, INT J BIOCHEM CELL B, V31, P637, DOI 10.1016/S1357-2725(99)00015-1; Wen X, 1999, J BIOL CHEM, V274, P38204, DOI 10.1074/jbc.274.53.38204; WONG AJ, 1987, P NATL ACAD SCI USA, V84, P6899, DOI 10.1073/pnas.84.19.6899; Wu YM, 2001, J BIOL CHEM, V276, P17672, DOI 10.1074/jbc.M010964200; XU YH, 1984, P NATL ACAD SCI-BIOL, V81, P7308, DOI 10.1073/pnas.81.23.7308; Xue LY, 1999, ONCOGENE, V18, P3391, DOI 10.1038/sj.onc.1202687; Yart A, 2001, J BIOL CHEM, V276, P8856, DOI 10.1074/jbc.M006966200	67	32	36	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 11	2004	23	10					1854	1862		10.1038/sj.onc.1207308	http://dx.doi.org/10.1038/sj.onc.1207308			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	801XV	14676838				2022-12-17	WOS:000220129500007
J	Ko, JS; Shin, SM; Oh, YM; Lee, YS; Ryoo, ZY; Lee, YH; Na, DS; Kim, JW				Ko, JS; Shin, SM; Oh, YM; Lee, YS; Ryoo, ZY; Lee, YH; Na, DS; Kim, JW			Transgenic mouse model for breast cancer: induction of breast cancer in novel oncogene HCCR-2 transgenic mice	ONCOGENE			English	Article						breast cancer; HCCR-2; p53; transgenic mouse	EMBRYO FIBROBLASTS; C-MYC; IDENTIFICATION; AMPLIFICATION; INVOLVEMENT; GENES; CELLS; DNA	Transgenic mice containing novel oncogene HCCR-2 were generated to analyse the phenotype and to characterize the role of HCCR-2 in cellular events. Mice transgenic for HCCR-2 developed breast cancers and metastasis. The level of p53 in HCCR-2 transgenic mice was elevated in most tissues including breast, brain, heart, lung, liver, stomach, kidney, spleen, and lymph node. We examined whether stabilized p53 is functional in HCCR-2 transgenic mice. Defective induction of p53 responsive genes including p21(WAF1), MDM2, and bax indicates that stabilized p53 in HCCR-2 transgenic mice exists in an inactive form. These results suggest that HCCR-2 represents an oncoprotein that is related to breast cancer development and regulation of the p53 tumor suppressor.	Catholic Univ Korea, Coll Med, Mol Genet Lab, Seoul 137040, South Korea; Univ Ulsan, Coll Med, Asan Inst Life Sci, Seoul 138736, South Korea; Univ Ulsan, Coll Med, Dept Internal Med, Seoul 138736, South Korea; Catholic Univ Korea, Coll Med, Dept Obstet & Gynecol, Seoul 137040, South Korea; Catholic Univ Korea, Coll Med, Dept Clin Pathol, Seoul 137040, South Korea; Catholic Univ Korea, Coll Med, Lab Anim Sci, Seoul 137040, South Korea; Yeungnam Univ, Coll Med, Dept Biochem & Mol Biol, Taegu 705717, South Korea; Univ Ulsan, Coll Med, Dept Biochem & Mol Biol, Seoul 138736, South Korea	Catholic University of Korea; University of Ulsan; University of Ulsan; Catholic University of Korea; Catholic University of Korea; Catholic University of Korea; Yeungnam University; University of Ulsan	Kim, JW (corresponding author), Catholic Univ Korea, Coll Med, Mol Genet Lab, Seoul 137040, South Korea.	jinwoo@catholic.ac.kr	RYOO, ZAEYOUNG/AAQ-1573-2020					BERNS EMJJ, 1992, CANCER RES, V52, P1107; BIRRER MJ, 1988, MOL CELL BIOL, V8, P2668, DOI 10.1128/MCB.8.6.2668; BYRNE JA, 1995, CANCER RES, V55, P2896; Deininger MWN, 1997, BLOOD, V90, P3691, DOI 10.1182/blood.V90.9.3691; Dickson C, 2000, ONCOGENE, V19, P1097, DOI 10.1038/sj.onc.1203267; GALAKTIONOV K, 1995, SCIENCE, V269, P1575, DOI 10.1126/science.7667636; GORDON JW, 1980, P NATL ACAD SCI-BIOL, V77, P7380, DOI 10.1073/pnas.77.12.7380; Kim J, 1996, AM J PHYSIOL-RENAL, V270, pF575, DOI 10.1152/ajprenal.1996.270.4.F575; Ko J, 2003, ONCOGENE, V22, P4679, DOI 10.1038/sj.onc.1206624; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; MIKI T, 1989, GENE, V83, P137, DOI 10.1016/0378-1119(89)90411-3; NEBERT DW, 1991, MUTAT RES, V247, P267, DOI 10.1016/0027-5107(91)90022-G; NOWELL PC, 1976, SCIENCE, V194, P23, DOI 10.1126/science.959840; OTTENHOFFKALFF AE, 1992, CANCER RES, V52, P4773; Proux V, 1996, J BIOL CHEM, V271, P30790, DOI 10.1074/jbc.271.48.30790; Sambrook J., 1989, MOL CLONING LAB MANU, V2nd; SCHUURING E, 1992, CANCER RES, V52, P5229; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; Smith JB, 1998, J NATL CANCER I, V90, P1146, DOI 10.1093/jnci/90.15.1146	19	32	45	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 11	2004	23	10					1950	1953		10.1038/sj.onc.1207356	http://dx.doi.org/10.1038/sj.onc.1207356			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	801XV	14691448				2022-12-17	WOS:000220129500017
J	Gerard, A; Favre, C; Garcon, F; Nemorin, JG; Duplay, P; Pastor, S; Collette, Y; Olive, D; Nunes, JA				Gerard, A; Favre, C; Garcon, F; Nemorin, JG; Duplay, P; Pastor, S; Collette, Y; Olive, D; Nunes, JA			Functional interaction of RasGAP-binding proteins Dok-1 and Dok-2 with the Tec protein tyrosine kinase	ONCOGENE			English	Article						Dok adaptor proteins; Tec tyrosine kinase; signal transduction; tumor suppressors; T cells	CHRONIC MYELOGENOUS LEUKEMIA; CELL ANTIGEN RECEPTOR; T-CELLS; P62(DOK); FAMILY; PHOSPHORYLATION; RECRUITMENT; ABL	The Dok adaptor family of proteins binding to RasGAP, consisting of Dok-1 and Dok-2, are critical regulators in cell proliferation. These molecules are partners and/or substrates of different protein tyrosine kinases considered as oncoproteins. Here, we show that Dok-1 and Dok-2 are the major tyrosine-phosphorylated proteins associated to Tec, a protein tyrosine kinase expressed in T cells. Furthermore, we evaluate the effect of Dok-1 or Dok-2 on Tec-mediated signalling pathways in T cells. Here, we provide evidence that Dok-1 and Dok-2 proteins are involved in a negative feedback regulation of Tec via a downregulation of its tyrosine phosphorylation and downstream signalling pathways including the Ras pathway. Either Dok-1 or Dok-2 therefore represents a mean of potent retrograde control for protein tyrosine kinase signalling, and then possibly of tumor development.	Univ Mediterranee, Inst Canc & Immunol Marseille, INSERM, U119, F-13009 Marseille, France; Univ Quebec, Inst Armand Frappier, Inst Natl Rech Sci, Laval, PQ, Canada	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; University of Quebec; Institut national de la recherche scientifique (INRS)	Nunes, JA (corresponding author), Univ Mediterranee, Inst Canc & Immunol Marseille, INSERM, U119, 27 Bd Lei Roure, F-13009 Marseille, France.	nunes@marseille.inserm.fr	COLLETTE, Yves/F-2270-2013; NUNES, Jacques A/F-4952-2013	COLLETTE, Yves/0000-0001-5359-7099; NUNES, Jacques A/0000-0003-4865-0400				Bhat A, 1998, J BIOL CHEM, V273, P32360, DOI 10.1074/jbc.273.48.32360; Carpino N, 1997, CELL, V88, P197, DOI 10.1016/S0092-8674(00)81840-1; CLARKSON B, 1993, LEUKEMIA, V7, P1683; Di Cristofano A, 1998, J BIOL CHEM, V273, P4827, DOI 10.1074/jbc.273.9.4827; Di Cristofano A, 2001, J EXP MED, V194, P275, DOI 10.1084/jem.194.3.275; Gugasyan R, 2002, J CELL BIOL, V158, P115, DOI 10.1083/jcb.200112066; Guy GR, 2002, CELL SIGNAL, V14, P11, DOI 10.1016/S0898-6568(01)00227-3; IZQUIERDO M, 1993, J EXP MED, V178, P1199, DOI 10.1084/jem.178.4.1199; Jones N, 1999, CURR BIOL, V9, P1057, DOI 10.1016/S0960-9822(99)80458-8; Liang XQ, 2002, J BIOL CHEM, V277, P13732, DOI 10.1074/jbc.M200277200; Master Z, 2003, J BIOL CHEM, V278, P30170, DOI 10.1074/jbc.M301339200; Miller AT, 2002, CURR OPIN IMMUNOL, V14, P331, DOI 10.1016/S0952-7915(02)00345-X; Nelms K, 1998, IMMUNITY, V9, P13, DOI 10.1016/S1074-7613(00)80584-1; Nemorin JG, 2000, J BIOL CHEM, V275, P14590, DOI 10.1074/jbc.275.19.14590; Nemorin JG, 2001, J IMMUNOL, V166, P4408, DOI 10.4049/jimmunol.166.7.4408; Nunes JA, 1996, J BIOL CHEM, V271, P1591, DOI 10.1074/jbc.271.3.1591; Shah K, 2002, CHEM BIOL, V9, P35, DOI 10.1016/S1074-5521(02)00086-8; van Dijk TB, 2000, BLOOD, V96, P3406; Yamanashi Y, 2000, GENE DEV, V14, P11; Yang WC, 2000, INT IMMUNOL, V12, P1547, DOI 10.1093/intimm/12.11.1547; Yang WC, 1999, J BIOL CHEM, V274, P607, DOI 10.1074/jbc.274.2.607; Yang WC, 2000, IMMUNITY, V12, P373, DOI 10.1016/S1074-7613(00)80189-2; Yoshida K, 2000, J BIOL CHEM, V275, P24945, DOI 10.1074/jbc.M909012199	23	32	34	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 26	2004	23	8					1594	1598		10.1038/sj.onc.1207283	http://dx.doi.org/10.1038/sj.onc.1207283			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	778BP	14647425				2022-12-17	WOS:000189219500013
J	Eszlinger, M; Krohn, K; Frenzel, R; Kropf, S; Tonjes, A; Paschke, R				Eszlinger, M; Krohn, K; Frenzel, R; Kropf, S; Tonjes, A; Paschke, R			Gene expression analysis reveals evidence for inactivation of the TGF-beta signaling cascade in autonomously functioning thyroid nodules	ONCOGENE			English	Article						thyroid; TSH receptor; signal transduction; transforming growth factor beta 1; sialyltransferase 1	GROWTH-FACTOR-BETA; HUMAN THYROTROPIN RECEPTOR; TSH RECEPTOR; MUTATIONS; CELLS; COLD; PROLIFERATION; MECHANISM; ADENOMAS; PATHWAY	Molecular eventsthat lead to the development of autonomously functioning thyroid nodules (AFTNs) are somatic mutations of the thyrotropin receptor (TSHR) in approximately 60% of the nodules and less frequently, somatic mutations in the G(s)alpha protein. However, AFTNs without known mutations indicate that other causes remain to be identified. Moreover, the impact of constitutively activating TSHR mutations on the signal transduction network of the thyroid epithelial cell is unknown. We therefore investigated gene expression in 15 AFTNs and their surrounding tissue using Affymetrix GeneChips. Most prominently, data analysis revealed a changed pattern of gene expression in the TGF-beta signaling cascade and 25 differentially regulated genes in AFTNs, including thyroid peroxidase, type I iodothyronine deiodinase and sialyltransferase ( SIAT) 1. Strikingly coexpression of SIAT 1 and TSHR in COS-7 cells increased TSH binding and cell surface expression of the TSHR. Moreover, differences in gene expression patterns for AFTNs with and without TSHR mutations indicate specific alterations of signal transduction in AFTNs without TSHR mutations. These results suggest that AFTNs with TSHR mutations harbor further mechanisms of forward stimulation. Furthermore, they give important leads to elucidate the molecular etiology of AFTNs without TSHR mutations.	Univ Leipzig, Dept Med 3, D-04103 Leipzig, Germany; Interdisciplinary Ctr Clin Res, D-04103 Leipzig, Germany; Univ Magdeburg, Inst Biometr & Med Informat, D-39120 Magdeburg, Germany	Leipzig University; Otto von Guericke University	Paschke, R (corresponding author), Univ Leipzig, Dept Med 3, Ph Rosenthal Str 27, D-04103 Leipzig, Germany.	pasr@medizin.uni-leipzig.de		Eszlinger, Markus/0000-0002-4732-2934				Arturi F, 1998, EXP CLIN ENDOCR DIAB, V106, P234, DOI 10.1055/s-0029-1211982; Biebermann H, 1998, FASEB J, V12, P1461, DOI 10.1096/fasebj.12.14.1461; COLLETTA G, 1989, CANCER RES, V49, P3457; Coyle P, 2002, CELL MOL LIFE SCI, V59, P627, DOI 10.1007/s00018-002-8454-2; Dahlquist KD, 2002, NAT GENET, V31, P19, DOI 10.1038/ng0502-19; Depoortere F, 2000, MOL BIOL CELL, V11, P1061, DOI 10.1091/mbc.11.3.1061; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Eszlinger M, 2001, J CLIN ENDOCR METAB, V86, P4834, DOI 10.1210/jc.86.10.4834; Eszlinger M, 2001, THYROID, V11, P125, DOI 10.1089/105072501300042767; Fuhrer D, 1999, THYROID, V9, P757, DOI 10.1089/thy.1999.9.757; Gartner R, 1997, THYROID, V7, P633, DOI 10.1089/thy.1997.7.633; Grande M, 2002, J CELL SCI, V115, P4227, DOI 10.1242/jcs.00091; GRUBECKLOEBENSTEIN B, 1989, J CLIN INVEST, V83, P764, DOI 10.1172/JCI113955; Hedinger C, 1988, HISTOLOGICAL TYPING; Huang Y, 2001, P NATL ACAD SCI USA, V98, P15044, DOI 10.1073/pnas.251547398; Kretzschmar M, 1999, GENE DEV, V13, P804, DOI 10.1101/gad.13.7.804; Kretzschmar M, 1997, NATURE, V389, P618, DOI 10.1038/39348; Krohn K, 1999, THYROID, V9, P241, DOI 10.1089/thy.1999.9.241; LIBERT F, 1989, BIOCHEM BIOPH RES CO, V165, P1250, DOI 10.1016/0006-291X(89)92736-8; LOPEZCASILLAS F, 1993, CELL, V73, P1435, DOI 10.1016/0092-8674(93)90368-Z; Lutz M, 2002, CELL SIGNAL, V14, P977, DOI 10.1016/S0898-6568(02)00058-X; Miyazono K, 1997, INT J HEMATOL, V65, P97; Neumann S, 2001, MOL ENDOCRINOL, V15, P1294, DOI 10.1210/me.15.8.1294; Oda Y, 1999, J CLIN ENDOCR METAB, V84, P2119, DOI 10.1210/jc.84.6.2119; PANG XP, 1992, ENDOCRINOLOGY, V131, P45, DOI 10.1210/en.131.1.45; Park ES, 2000, MOL ENDOCRINOL, V14, P662, DOI 10.1210/mend.14.5.0458; PARMA J, 1993, NATURE, V365, P649, DOI 10.1038/365649a0; Paschke R, 1997, NEW ENGL J MED, V337, P1675, DOI 10.1056/NEJM199712043372307; Ribeiro-Neto F, 2002, P NATL ACAD SCI USA, V99, P5418, DOI 10.1073/pnas.082122499; SANDROCK D, 1993, ACTA ENDOCRINOL-COP, V128, P51, DOI 10.1530/acta.0.1280051; Schoneberg T, 1996, EMBO J, V15, P1283, DOI 10.1002/j.1460-2075.1996.tb00470.x; TATON M, 1993, MOL CELL ENDOCRINOL, V95, P13, DOI 10.1016/0303-7207(93)90024-E; Trulzsch B, 1999, BIOTECHNIQUES, V27, P266, DOI 10.2144/99272bm10; Trulzsch B, 2001, J MOL MED, V78, P684, DOI 10.1007/s001090000170; TSUSHIMA T, 1988, ENDOCRINOLOGY, V123, P1187, DOI 10.1210/endo-123-2-1187; Vanvooren V, 2001, EUR J ENDOCRINOL, V144, P605, DOI 10.1530/eje.0.1440605; Vicencio AG, 2002, J APPL PHYSIOL, V93, P1123, DOI 10.1152/japplphysiol.00031.2002; Voigt C, 2000, FEBS LETT, V486, P208, DOI 10.1016/S0014-5793(00)02302-4; Westfall P.H., 1993, RESAMPLING BASED MUL; Wonerow P, 2000, CLIN ENDOCRINOL, V53, P461, DOI 10.1046/j.1365-2265.2000.01119.x; Wonerow P, 1998, J BIOL CHEM, V273, P7900, DOI 10.1074/jbc.273.14.7900; ZHANG K, 1990, SCIENCE, V249, P162, DOI 10.1126/science.2115210	42	32	39	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 22	2004	23	3					795	804		10.1038/sj.onc.1207186	http://dx.doi.org/10.1038/sj.onc.1207186			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	765VK	14737114				2022-12-17	WOS:000188304900018
J	Pendino, F; Dudognon, C; Delhommeau, F; Sahraoui, T; Flexor, M; Bennaceur-Griscelli, A; Lanotte, M; Segal-Bendirdjian, E				Pendino, F; Dudognon, C; Delhommeau, F; Sahraoui, T; Flexor, M; Bennaceur-Griscelli, A; Lanotte, M; Segal-Bendirdjian, E			Retinoic acid receptor alpha and retinoid-X receptor-specific agonists synergistically target telomerase expression and induce tumor cell death	ONCOGENE			English	Article						telomerase; hTERT; retinoids; RAR; RXR; nuclear receptors	ACUTE PROMYELOCYTIC LEUKEMIA; CATALYTIC SUBUNIT GENE; SELECTIVE RETINOIDS; CANCER-THERAPY; RNA COMPONENT; IDENTIFICATION; MATURATION; RESISTANCE; LINE; NB4	Retinoids modulate growth and differentiation of cancer cells through activation of gene transcription via the nuclear retinoic-acid receptors (RAR) and retinoid-X receptors (RXR). Their use in differentiation therapy of acute promyelocytic leukemia (APL) represents a model concept for reprogramming cancer cells. However, they also regulate antiproliferative genes whose functions do not mechanistically concur to this program. Recently, we have shown that, independently of maturation, a long-term all-trans retinoic acid (ATRA) treatment of the maturation-resistant APL cell line (NB4-LR1) represses telomerase (hTERT), leading to telomere shortening and death. Using retinoid-receptor-specific agonists, we demonstrate herein that cross-talk between RARalpha and RXR dual-liganded to their respective agonists resulted in strong synergistic downregulation of hTERT and subsequent cell death. Importantly, unlike ATRA, this synergy was obtained at very low agonist concentrations and occurred in other ATRA maturation-resistant APL cells. These findings provide the first demonstration that dual-liganded RXR and RARalpha signaling should allow efficient targeting of telomerase in differentiation-resistant tumor cells. Such a combination therapy might hold promise in clinic to avoid side effects of ATRA whose administration can indiscriminately activate all RARs. Given the tissue-specific expression of RARs, a tissue-selective therapy targeting telomerase in tumor cells by synthetic agonists can be envisioned.	Hop St Louis, INSERM, U496, Inst Hematol, F-75475 Paris 10, France; Inst Gustave Roussy, INSERM, U362, F-94800 Villejuif, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Gustave Roussy	Segal-Bendirdjian, E (corresponding author), Hop St Louis, INSERM, U496, Inst Hematol, 1 Ave Claude Vellefaux, F-75475 Paris 10, France.	esegal@jupiter.chu-stlouis.fr	PENDINO, Frederic/G-6630-2017	bennaceur griscelli, annelise/0000-0002-3557-4499; Delhommeau, Francois/0000-0002-4915-0734; Segal-Bendirdjian, Evelyne/0000-0001-9813-4880				AMOS B, 1990, METHOD ENZYMOL, V190, P217; BERNARD BA, 1992, BIOCHEM BIOPH RES CO, V186, P977, DOI 10.1016/0006-291X(92)90842-9; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; Chen JY, 1996, NATURE, V382, P819, DOI 10.1038/382819a0; Chou WC, 2001, J CLIN INVEST, V108, P1541, DOI 10.1172/JCI200114064; DE LUCA LM, 1991, FASEB J, V5, P2924; DELESCLUSE C, 1991, MOL PHARMACOL, V40, P556; Duprez E, 2000, LEUKEMIA, V14, P255, DOI 10.1038/sj.leu.2401683; DUPREZ E, 1992, LEUKEMIA, V6, P1281; Fenaux P, 2001, SEMIN HEMATOL, V38, P13, DOI 10.1053/shem.2001.20862; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; Gallagher RE, 2002, LEUKEMIA, V16, P1940, DOI 10.1038/sj.leu.2402719; Germain P, 2002, NATURE, V415, P187, DOI 10.1038/415187a; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; GUDAS LJ, 1994, J BIOL CHEM, V269, P15399; Hahn WC, 1999, NAT MED, V5, P1164, DOI 10.1038/13495; Helder MN, 2002, CANCER INVEST, V20, P82, DOI 10.1081/CNV-120000370; Kilian A, 1997, HUM MOL GENET, V6, P2011, DOI 10.1093/hmg/6.12.2011; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; LANOTTE M, 1991, BLOOD, V77, P1080; LEHMANN JM, 1991, CANCER RES, V51, P4804; LEHMANN JM, 1992, SCIENCE, V258, P1944, DOI 10.1126/science.1335166; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Mergny JL, 2002, NUCLEIC ACIDS RES, V30, P839, DOI 10.1093/nar/30.4.839; Meyerson M, 1997, CELL, V90, P785, DOI 10.1016/S0092-8674(00)80538-3; Miller VA, 1997, J CLIN ONCOL, V15, P790, DOI 10.1200/JCO.1997.15.2.790; MORIN GB, 1989, CELL, V59, P521, DOI 10.1016/0092-8674(89)90035-4; Pendino F, 2002, LEUKEMIA, V16, P826, DOI 10.1038/sj.leu.2402470; Pendino F, 2001, P NATL ACAD SCI USA, V98, P6662, DOI 10.1073/pnas.111464998; ROY DY, 1995, MOL CELL BIOL, V15, P6481; RUCHAUD S, 1994, P NATL ACAD SCI USA, V91, P8428, DOI 10.1073/pnas.91.18.8428; SMITH MA, 1992, J CLIN ONCOL, V10, P839, DOI 10.1200/JCO.1992.10.5.839; Sun SY, 2000, CLIN CANCER RES, V6, P1563; URBACH J, 1994, BIOCHEM J, V299, P459, DOI 10.1042/bj2990459; Van heusden J, 1998, BRIT J CANCER, V77, P26, DOI 10.1038/bjc.1998.5; Weinberg RA, 1998, NATURE, V396, P23, DOI 10.1038/23825; Weinrich SL, 1997, NAT GENET, V17, P498, DOI 10.1038/ng1297-498; Xu D, 1996, LEUKEMIA, V10, P1354; Xu DW, 2000, BLOOD, V96, P4313, DOI 10.1182/blood.V96.13.4313.h8004313_4313_4318; Zusi FC, 2002, DRUG DISCOV TODAY, V7, P1165, DOI 10.1016/S1359-6446(02)02526-6	40	32	33	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 11	2003	22	57					9142	9150		10.1038/sj.onc.1207093	http://dx.doi.org/10.1038/sj.onc.1207093			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	752FJ	14668795				2022-12-17	WOS:000187149100004
J	Das, S; El-Deiry, WS; Somasundaram, K				Das, S; El-Deiry, WS; Somasundaram, K			Efficient growth inhibition of HPV 16 E6-expressing cells by an adenovirus-expressing p53 homologue p73 beta	ONCOGENE			English	Article						p53; p73; human papilloma virus; cervical cancer; E6; gene therapy	HUMAN-PAPILLOMAVIRUS; DNA-BINDING; GENE; APOPTOSIS; DEGRADATION; SUPPRESSION; CARCINOMA; PROMOTES; PROTEIN; ARREST	Tumor suppressor p53 functions are downregulated in most cervical cancers, because the product of human papilloma virus (HPV) oncogene E6 binds to and inactivates p53 by promoting its degradation. p73, a p53 homologue, is similar to p53 in structure and function but yet not degraded by HPV E6 gene product. In this study, we have developed a replication-deficient recombinant adenovirus, which expresses p73beta (Ad-p73). Infection of human cancer cells with Ad-p73 results in several fold increase of p73beta levels as well as its known target genes like p21(WAF1/CIP1). Ad-p73-infected cells showed reduced cellular DNA synthesis, arrest in G1 phase of cell cycle and induction of apoptosis. Ad-p73 inhibited the growth of cancer cells of different types. More importantly, Ad-p73 inhibited the growth of cell tines carrying HPV E6 gene, which was introduced by stable integration, more efficiently in comparison to an Ad-p53. Furthermore, Ad-p73 also inhibited the growth of HeLa cells, a cell line derived from cervical cancer, very efficiently. The ability of Ad-p73 to inhibit the growth of HPV E6-expressing cells and HeLa cells correlated with the stable expression of functional p73 in the presence of E6. These results suggest that Ad-p73 could be used as a potential gene therapy agent against cervical cancer.	Indian Inst Sci, Dept Microbiol & Cell Biol, Bangalore 560012, Karnataka, India; Univ Penn, Sch Med, Howard Hughes Med Inst, Philadelphia, PA 19104 USA	Indian Institute of Science (IISC) - Bangalore; Howard Hughes Medical Institute; University of Pennsylvania	Somasundaram, K (corresponding author), Indian Inst Sci, Dept Microbiol & Cell Biol, Bangalore 560012, Karnataka, India.	skumar@mcbl.iisc.ernet.in	El-Deiry, Wafik/AAJ-6080-2020	El-Deiry, Wafik/0000-0002-9577-8266; Das, Sanjeev/0000-0002-3594-1033				BeerRomero P, 1997, ONCOGENE, V14, P595, DOI 10.1038/sj.onc.1200872; Blagosklonny MV, 1996, INT J CANCER, V67, P386, DOI 10.1002/(SICI)1097-0215(19960729)67:3<386::AID-IJC13>3.0.CO;2-6; BRINTON LA, 1992, EPIDEMIOLOGY CERVICA, P3; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Greenlee RT, 2001, CA-CANCER J CLIN, V51, P15, DOI 10.3322/canjclin.51.1.15; Hamada K, 1996, CANCER RES, V56, P3047; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Huh WK, 2001, GYNECOL ONCOL, V83, P370, DOI 10.1006/gyno.2001.6403; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Kamijo T, 1998, P NATL ACAD SCI USA, V95, P8292, DOI 10.1073/pnas.95.14.8292; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; LECHNER MS, 1994, J VIROL, V68, P4262, DOI 10.1128/JVI.68.7.4262-4273.1994; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LUNGU O, 1995, OBSTET GYNECOL, V85, P337, DOI 10.1016/0029-7844(94)00399-X; Marin MC, 1998, MOL CELL BIOL, V18, P6316, DOI 10.1128/MCB.18.11.6316; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; Orlow I, 1999, AM J PATHOL, V155, P105, DOI 10.1016/S0002-9440(10)65105-X; Prabhu NS, 1996, CLIN CANCER RES, V2, P1221; Prabhu NS, 1998, INT J ONCOL, V13, P5; Qu WM, 1997, J CLIN MICROBIOL, V35, P1304, DOI 10.1128/JCM.35.6.1304-1310.1997; ROSE PG, 2000, COMBINED MODALITY TR; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; Somasundaram K, 1999, ONCOGENE, V18, P6605, DOI 10.1038/sj.onc.1203284; Somasundaram K, 1996, P NATL ACAD SCI USA, V93, P3088, DOI 10.1073/pnas.93.7.3088; Somasundaram K, 1997, ONCOGENE, V14, P1047, DOI 10.1038/sj.onc.1201002; Storey A, 1998, NATURE, V393, P229, DOI 10.1038/30400; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Takimoto R, 2002, CANCER BIOL THER, V1, P177, DOI 10.4161/cbt.65; Tsao YP, 1999, J VIROL, V73, P4983, DOI 10.1128/JVI.73.6.4983-4990.1999; Yatabe N, 2002, CANCER GENE THER, V9, P624, DOI 10.1038/sj.cgt.7700479; Zeng YX, 1997, NAT GENET, V15, P78, DOI 10.1038/ng0197-78; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4	36	32	35	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 20	2003	22	52					8394	8402		10.1038/sj.onc.1206908	http://dx.doi.org/10.1038/sj.onc.1206908			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	744UB	14627980				2022-12-17	WOS:000186650300003
J	Nath, N; Wang, S; Betts, V; Knudsen, E; Chellappan, S				Nath, N; Wang, S; Betts, V; Knudsen, E; Chellappan, S			Apoptotic and mitogenic stimuli inactivate Rb by differential utilization of p38 and cyclin-dependent kinases	ONCOGENE			English	Article						Fas; p38; E2F1; cyclins; cdk	S-PHASE ENTRY; RETINOBLASTOMA PROTEIN; TRANSCRIPTION FACTOR; HISTONE DEACETYLASE; CELL-PROLIFERATION; RB/E2F PATHWAY; E2F PROTEINS; EXPRESSION; ACTIVATION; BINDING	Inactivation of the retinoblastoma (Rb) tumor suppressor protein is essential for the G1/S transition during mammalian cell cycle progression. Although Rb is inactivated by phosphorylation by cyclins D and E and their associated kinases during cell cycle progression, we find that Rb is inactivated upon apoptotic stimulation by Fas through the mediation of p38 kinase, independent of cyclins and cyclin-dependent kinases (cdks). Inactivation by p38 kinase coincided with increased phosphorylation of Rb leading to dissociation of E2F and increased transcriptional activity; such p38-mediated changes in Rb function occurred only during Fas stimulation but not mitogenic progression. p38 kinase targets Rb preferentially and had minimal effects on p107 and had no effect on p130 function. We also find that phosphorylation site mutants of Rb (PSM7LP and PSM9-Rb) that cannot be inactivated by cdks can be targeted by Fas and p38 kinase, suggesting that Rb inactivation by these kinases is biochemically and functionally distinct. It appears that Rb inactivation is achieved by different kinase cascades in response to mitogenic and apoptotic signals.	Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Dept Interdisciplinary Oncol, Tampa, FL 33612 USA	H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida	Chellappan, S (corresponding author), Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Dept Interdisciplinary Oncol, 12902 Magnolia Dr, Tampa, FL 33612 USA.	Chellasp@moffitt.usf.edu			NATIONAL CANCER INSTITUTE [R01CA063136] Funding Source: NIH RePORTER; NCI NIH HHS [CA63136] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams PD, 1996, CURR TOP MICROBIOL, V208, P79; ADAMS PD, 1995, SEMIN CANCER BIOL, V6, P99, DOI 10.1006/scbi.1995.0013; Asano M, 1996, GENE DEV, V10, P1422, DOI 10.1101/gad.10.11.1422; Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; CHELLAPPAN S, 1992, P NATL ACAD SCI USA, V89, P4549, DOI 10.1073/pnas.89.10.4549; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; Chen WD, 1997, ONCOGENE, V14, P1243, DOI 10.1038/sj.onc.1201096; DeGregori J, 1997, P NATL ACAD SCI USA, V94, P7245, DOI 10.1073/pnas.94.14.7245; DEGREGORI J, 1995, GENE DEV, V9, P2873, DOI 10.1101/gad.9.23.2873; Dou QP, 1997, J CELL BIOCHEM, V64, P586; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; Harbour JW, 2000, GENE DEV, V14, P2393, DOI 10.1101/gad.813200; Harbour JW, 2000, NAT CELL BIOL, V2, pE65, DOI 10.1038/35008695; Harbour JW, 1999, CELL, V98, P859, DOI 10.1016/S0092-8674(00)81519-6; Helin K, 1998, CURR OPIN GENET DEV, V8, P28, DOI 10.1016/S0959-437X(98)80058-0; Hou ST, 2000, J NEUROCHEM, V75, P91, DOI 10.1046/j.1471-4159.2000.0750091.x; Hsieh JK, 1997, GENE DEV, V11, P1840, DOI 10.1101/gad.11.14.1840; Irwin M, 2000, NATURE, V407, P645, DOI 10.1038/35036614; Ishida S, 2001, MOL CELL BIOL, V21, P4684, DOI 10.1128/MCB.21.14.4684-4699.2001; Juo P, 1997, MOL CELL BIOL, V17, P24, DOI 10.1128/MCB.17.1.24; Knudsen ES, 1996, J BIOL CHEM, V271, P8313, DOI 10.1074/jbc.271.14.8313; Knudsen ES, 1997, MOL CELL BIOL, V17, P5771, DOI 10.1128/MCB.17.10.5771; Lee JO, 1998, NATURE, V391, P859, DOI 10.1038/36038; Lissy NA, 2000, NATURE, V407, P642, DOI 10.1038/35036608; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; Moroni MC, 2001, NAT CELL BIOL, V3, P552, DOI 10.1038/35078527; Muller H, 2000, BBA-REV CANCER, V1470, pM1, DOI 10.1016/S0304-419X(99)00030-X; Muller H, 2001, GENE DEV, V15, P267, DOI 10.1101/gad.864201; Nath N, 1999, J IMMUNOL, V162, P5351; Nevins JR, 2001, HUM MOL GENET, V10, P699, DOI 10.1093/hmg/10.7.699; Nevins JR, 1998, CELL GROWTH DIFFER, V9, P585; NEVINS JR, 1992, SCIENCE, V258, P424; Phillips AC, 2001, APOPTOSIS, V6, P173, DOI 10.1023/A:1011332625740; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; Ren B, 2002, GENE DEV, V16, P245, DOI 10.1101/gad.949802; SHAN B, 1994, MOL CELL BIOL, V14, P8166, DOI 10.1128/MCB.14.12.8166; Sherr Charles J., 1994, Trends in Cell Biology, V4, P15, DOI 10.1016/0962-8924(94)90033-7; Takahashi Y, 2000, GENE DEV, V14, P804; Tan XQ, 1998, TRENDS CELL BIOL, V8, P116, DOI 10.1016/S0962-8924(97)01208-7; Tan XQ, 1997, J BIOL CHEM, V272, P9613; Taya Y, 1997, TRENDS BIOCHEM SCI, V22, P14, DOI 10.1016/S0968-0004(96)10070-0; Wang JYJ, 1997, CURR OPIN GENET DEV, V7, P39, DOI 10.1016/S0959-437X(97)80107-4; Wang S, 1999, EMBO J, V18, P1559, DOI 10.1093/emboj/18.6.1559; Wang S, 1998, MOL CELL BIOL, V18, P7487, DOI 10.1128/MCB.18.12.7487; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; Yang HL, 2000, CLIN CANCER RES, V6, P1579	50	32	35	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 4	2003	22	38					5986	5994		10.1038/sj.onc.1206843	http://dx.doi.org/10.1038/sj.onc.1206843			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	718GY	12955077				2022-12-17	WOS:000185137800007
J	Chen, DY; Xu, LG; Chen, L; Li, LX; Zhai, ZH; Shu, HB				Chen, DY; Xu, LG; Chen, L; Li, LX; Zhai, ZH; Shu, HB			NIK is a component of the EGF/heregulin receptor signaling complexes	ONCOGENE			English	Article						NIK; EGF; Grb7; NF-kappa B; signaling	NF-KAPPA-B; GROWTH-FACTOR RECEPTOR; LYMPHOTOXIN-BETA-RECEPTOR; FOCAL ADHESION KINASE; SRC HOMOLOGY 2; ADAPTER PROTEIN; INTERACTING PROTEIN; BINDING-PROTEIN; GRB7 FAMILY; ACTIVATION	Nuclear factor kappaB-inducing kinase (NIK) is a member of the MAP kinase kinase kinase family that was first identified as a component of the TNF-R1-induced NF-kappaB activation pathway (TNF, tumor necrosis factor; nuclear factor kappaB, NF-kappaB). Gene knockout study, however, suggests that NIK is dispensable for TNF-R1- but required for lymphotoxin-beta receptor-induced NF-kappaB activation. A NIK kinase inactive mutant is a potent inhibitor of NF-kappaB activation triggered by various stimuli, suggesting that NIK is involved in a broad range of NF-kappaB activation pathways. To unambiguously identify signaling pathways that NIK participates in, we screened antibody arrays for proteins that are associated with NIK. This effort identified ErbB4, one of the EGF/heregulin receptors, and Grb7, an adapter protein associated with ErbB4 (ErbB, epidermal growth factor receptor family protein; EGF, epidermal growth factor; Grb, growth factor receptor bound). Coimmunoprecipitation experiments demonstrated that NIK interacted with Grb7, as well as Grb10 and Grb14, but not Grb2. Domain mapping experiments indicated that the central GM domain of Grb7 was sufficient for its interaction with NIK. Coimmunoprecipitation experiments also indicated that Grb7 and NIK could be simultaneously recruited into signaling complexes of all known EGF/heregulin receptors, including EGFR, ErbB2, ErbB3, and ErbB4. In reporter gene assays, NIK could potentiate Grb7, ErbB2/ErbB4, and EGF-induced NF-kappaB activation. A NIK kinase inactive mutant could block ErbB2/ErbB4 and EGF-induced NF-kappaB activation. Moreover, EGF/heregulin receptors activated NF-kappaB in wild-type, but not NIK-/- embryonic fibroblasts. Our findings suggest that NIK is a component of the EGF/heregulin receptor signaling complexes and involved in NF-kappaB activation triggered by these receptors.	Univ Colorado, Hlth Sci Ctr, Dept Immunol, Natl Jewish Med & Res Ctr, Denver, CO 80206 USA; Peking Univ, Dept Cell Biol & Genet, Coll Life Sci, Beijing 100871, Peoples R China	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Peking University	Shu, HB (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Immunol, Natl Jewish Med & Res Ctr, 1400 Jackson St,K516C, Denver, CO 80206 USA.	shuh@njc.org		Xu, Liangguo/0000-0003-1991-2889	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI049992] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI49992-01] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Akiyama N, 1997, CANCER RES, V57, P3548; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Bereziat V, 2002, J BIOL CHEM, V277, P4845, DOI 10.1074/jbc.M106574200; Biswas DK, 2000, P NATL ACAD SCI USA, V97, P8542, DOI 10.1073/pnas.97.15.8542; Chen DY, 2002, J BIOL CHEM, V277, P15985, DOI 10.1074/jbc.M108675200; Daly RJ, 1998, CELL SIGNAL, V10, P613, DOI 10.1016/S0898-6568(98)00022-9; Daly RJ, 1996, J BIOL CHEM, V271, P12502, DOI 10.1074/jbc.271.21.12502; Dong LQ, 1997, J BIOL CHEM, V272, P29104, DOI 10.1074/jbc.272.46.29104; Fiddes RJ, 1998, J BIOL CHEM, V273, P7717, DOI 10.1074/jbc.273.13.7717; Forster RE, 1998, P NATL ACAD SCI USA, V95, P15815, DOI 10.1073/pnas.95.26.15815; Frantz JD, 1997, J BIOL CHEM, V272, P2659, DOI 10.1074/jbc.272.5.2659; Habib AA, 2001, J BIOL CHEM, V276, P8865, DOI 10.1074/jbc.M008458200; Han DC, 2000, J BIOL CHEM, V275, P28911, DOI 10.1074/jbc.M001997200; Han DC, 1999, J BIOL CHEM, V274, P24425, DOI 10.1074/jbc.274.34.24425; Han DC, 2001, ONCOGENE, V20, P6315, DOI 10.1038/sj.onc.1204775; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; Hoffmann M, 1998, CANCER IMMUNOL IMMUN, V47, P167, DOI 10.1007/s002620050517; Jahn T, 2002, MOL CELL BIOL, V22, P979, DOI 10.1128/MCB.22.4.979-991.2002; JANES PW, 1997, J BIOL CHEM, V274, P30896; Lee H, 2000, MOL ENDOCRINOL, V14, P1750, DOI 10.1210/me.14.11.1750; Lin X, 1998, MOL CELL BIOL, V18, P5899, DOI 10.1128/MCB.18.10.5899; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Lyons RJ, 2001, J BIOL CHEM, V276, P17172, DOI 10.1074/jbc.M009756200; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; MARGOLIS B, 1992, P NATL ACAD SCI USA, V89, P8894, DOI 10.1073/pnas.89.19.8894; Matsushima A, 2001, J EXP MED, V193, P631, DOI 10.1084/jem.193.5.631; Nantel A, 1999, J BIOL CHEM, V274, P35719, DOI 10.1074/jbc.274.50.35719; Nantel A, 1998, J BIOL CHEM, V273, P10475, DOI 10.1074/jbc.273.17.10475; Obata H, 1996, BIOCHEM BIOPH RES CO, V224, P27, DOI 10.1006/bbrc.1996.0979; OOI J, 1995, ONCOGENE, V10, P1621; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; Reilly JF, 2000, J BIOL CHEM, V275, P7771, DOI 10.1074/jbc.275.11.7771; Sambrook J., 1989, MOL CLONING LAB MANU, V2nd; STEIN D, 1994, EMBO J, V13, P1331, DOI 10.1002/j.1460-2075.1994.tb06386.x; Sun L, 1998, ONCOGENE, V16, P2095, DOI 10.1038/sj.onc.1201731; Tanaka S, 1997, CANCER RES, V57, P28; Tanaka S, 1998, J CLIN INVEST, V102, P821, DOI 10.1172/JCI2921; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; Vayssiere B, 2000, FEBS LETT, V467, P91, DOI 10.1016/S0014-5793(99)01530-6; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Yin L, 2001, SCIENCE, V291, P2162, DOI 10.1126/science.1058453	41	32	36	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 10	2003	22	28					4348	4355		10.1038/sj.onc.1206532	http://dx.doi.org/10.1038/sj.onc.1206532			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	698BZ	12853971				2022-12-17	WOS:000183978900004
J	He, Q; Montalbano, J; Corcoran, C; Jin, WX; Huang, Y; Sheikh, MS				He, Q; Montalbano, J; Corcoran, C; Jin, WX; Huang, Y; Sheikh, MS			Effect of Bax deficiency on death receptor 5 and mitochondrial pathways during endoplasmic reticulum calcium pool depletion-induced apoptosis	ONCOGENE			English	Article						thapsigargin; Apo2L/TRAIL; death receptor 5; caspases; Bax; cytochrome c	PROSTATE-CANCER CELLS; CYTOCHROME-C; RELEASE; THAPSIGARGIN; SULINDAC; CYTOSOL; LIGAND; AGENTS; COLON	Thapsigargin (TG), by inducing perturbations in cellular Ca2+ homeostasis, can induce apoptosis, but the molecular mechanisms remain to be fully elucidated. We have recently reported that TG-induced apoptosis appears to involve the DR5-dependent apoptotic pathway that cross talks with the mitochondrial pathway via TG-induced Bid cleavage. In this study, we have utilized Bax-proficient and -deficient HCT116 human colon cancer cells to investigate the effect of Bax deficiency on TG-induced apoptosis and TG regulation of the DR5 and mitochondrial pathways. Our results indicate that Bax-deficient cells are less sensitive to undergo apoptosis following TG treatment. Our results further demonstrate that TG-induced apoptosis is coupled with DR5 upregulation and caspases 8 and 3 activation, as well as Bid cleavage in both Bax-proficient and -deficient cells, although caspase 3 activation was reduced in Bax-deficient cells. TG also promoted the release of cytochrome c into cytosol and caspase 9 activation in Bax-proficient cells but not in Bax-deficient cells. These findings suggest that although Bax is not absolutely required for death receptor (DR)-dependent signals, it appears to be a key molecule in TG-regulated mitochondrial events. Bax-deficient cells were relatively more resistant to Apo2L/TRAIL than the Bax-proficient counterparts. However, the combination of Apo2L/TRAIL and TG was more effective in mediating apoptosis in both Bax-proficient. and -deficient cells and that was coupled with activation of caspases 8 and 3. Although both agents in combination also induced cytochrome c release into cytosol and caspase 9 activation in Bax-proficient cells, these events were abrogated in Bax-deficient cells. Our results thus suggest that the combination of Apo2L/TRAIL and TG appears to bypass the Bax deficiency-induced defects in the mitochondrial (intrinsic) pathway by engaging the DR5-dependent apoptotic signals (extrinsic pathway).	SUNY Upstate Med Univ, Dept Pharmacol, Syracuse, NY 13210 USA	State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center	Sheikh, MS (corresponding author), SUNY Upstate Med Univ, Dept Pharmacol, Syracuse, NY 13210 USA.				NATIONAL CANCER INSTITUTE [R21CA089043] Funding Source: NIH RePORTER; NCI NIH HHS [CA89043] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Boya P, 2002, CELL DEATH DIFFER, V9, P465, DOI 10.1038/sj.cdd.4401006; Burns TF, 2001, J BIOL CHEM, V276, P37879; Deng YB, 2002, GENE DEV, V16, P33, DOI 10.1101/gad.949602; Foyouzi-Youssefi R, 2000, P NATL ACAD SCI USA, V97, P5723, DOI 10.1073/pnas.97.11.5723; FURUYA Y, 1994, CANCER RES, V54, P6167; He Q, 2002, ONCOGENE, V21, P6032, DOI 10.1038/sj.onc.1205897; He Q, 2002, ONCOGENE, V21, P2623, DOI 10.1038/sj.onc.1205345; Hsu YT, 1997, P NATL ACAD SCI USA, V94, P3668, DOI 10.1073/pnas.94.8.3668; Huang Y, 2001, CANCER RES, V61, P6918; Jin ZY, 2002, CELL CYCLE, V1, P82, DOI 10.4161/cc.1.1.104; Johnstone RW, 2002, CELL, V108, P153, DOI 10.1016/S0092-8674(02)00625-6; Kim BC, 2002, J BIOL CHEM, V277, P31381, DOI 10.1074/jbc.M203465200; Krebs J, 1998, BIOMETALS, V11, P375, DOI 10.1023/A:1009226316146; LeBlanc H, 2002, NAT MED, V8, P274, DOI 10.1038/nm0302-274; Mikhailov V, 2003, J BIOL CHEM, V278, P5367, DOI 10.1074/jbc.M203392200; Murphy AN, 1996, P NATL ACAD SCI USA, V93, P9893, DOI 10.1073/pnas.93.18.9893; Nechushtan A, 1999, EMBO J, V18, P2330, DOI 10.1093/emboj/18.9.2330; Nicholson DW, 2000, NATURE, V407, P810, DOI 10.1038/35037747; Nutt LK, 2002, J BIOL CHEM, V277, P20301, DOI 10.1074/jbc.M201604200; Nutt LK, 2002, J BIOL CHEM, V277, P9219, DOI 10.1074/jbc.M106817200; Reed JC, 2002, NAT REV DRUG DISCOV, V1, P111, DOI 10.1038/nrd726; SAGARA Y, 1991, J BIOL CHEM, V266, P13503; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; Shimizu S, 1998, P NATL ACAD SCI USA, V95, P1455, DOI 10.1073/pnas.95.4.1455; Tombal B, 2002, CELL DEATH DIFFER, V9, P561, DOI 10.1038/sj.cdd.4400999; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Wang XD, 2001, GENE DEV, V15, P2922; Wertz IE, 2000, J BIOL CHEM, V275, P11470, DOI 10.1074/jbc.275.15.11470; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; YANG E, 1996, BLOOD, V88, P368; Zhang L, 2000, SCIENCE, V290, P989, DOI 10.1126/science.290.5493.989	32	32	34	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 1	2003	22	17					2674	2679		10.1038/sj.onc.1206363	http://dx.doi.org/10.1038/sj.onc.1206363			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	673FF	12730681				2022-12-17	WOS:000182569000015
J	Ko, JK; Lee, MJ; Cho, SH; Cho, JA; Lee, BY; Koh, JS; Lee, SS; Shim, YH; Kim, CW				Ko, JK; Lee, MJ; Cho, SH; Cho, JA; Lee, BY; Koh, JS; Lee, SS; Shim, YH; Kim, CW			Bfl-1S, a novel alternative splice variant of Bfl-1, localizes in the nucleus via its C-terminus and prevents cell death	ONCOGENE			English	Article						Bfl-1S; Bcl-2 family; alternative splice; apoptosis; Molt-4; nuclear localization	BCL-2 FAMILY MEMBER; TUMOR-NECROSIS-FACTOR; MEDIATED APOPTOSIS; UP-REGULATION; YEAST-CELLS; B-CELLS; A1; EXPRESSION; HOMOLOG; PROTEIN	Bfl-1 is an antiapoptotic Bcl-2 family member and a mouse A1 homologue. The mouse A1 has been reported to have three isoforms, but little is known about human Bfl-1. By reverse-transcriptase polymerase chain reaction analysis, we have identified Bfl-1S (short form), an alternative splice variant of Bfl-1. The Bfl-1S primary sequence contains four conserved Bcl-2 homology (BH) domains and a positive-charged C-terminus containing KKRK amino acids. The expression of Bfl-1S mRNA was detected predominantly in normal lymph nodes and in B-lymphoid leukemia cells. Confocal microscopic analysis using green fluorescence protein fusion proteins demonstrated that Bfl-1S is localized in the nucleus by its C-terminus as an intrinsic nuclear localization sequence. Bfl-1S acts as an antiapoptotic agent in coexpression experiments with Bax, a proapoptotic molecule. The expression of Bfl-1S provided significant resistance against staurosporine (STS) treatments in Molt-4 human T-leukemia cells. Bfl-1S also significantly inhibited the cleavage of Bid, and of caspases 3 and 8 against STS treatment. These results indicate that Bfl-1S is a novel human Bcl-2 family member that possesses antiapoptotic function.	Seoul Natl Univ, Coll Med, Inst Canc Res, Dept Pathol,Ghongno Gu, Seoul 110799, South Korea; Inst iNtRON Biotechnol, Seoul, South Korea; Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Neurol, Boston, MA 02115 USA; Korea Canc Ctr Hosp, Lab Expt Pathol, Seoul, South Korea; Konkuk Univ, Dept Biol Sci, Seoul, South Korea	Seoul National University (SNU); Harvard University; Brigham & Women's Hospital; Harvard Medical School; National Cancer Center - Korea (NCC); Konkuk University	Kim, CW (corresponding author), Seoul Natl Univ, Coll Med, Inst Canc Res, Dept Pathol,Ghongno Gu, 28 Yongon Dong, Seoul 110799, South Korea.		Kim, Chul-Woo/F-7008-2011; Shim, Yhong-Hee/D-6691-2011	Shim, Yhong-Hee/0000-0002-8660-4176				BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; Chao DT, 1998, ANNU REV IMMUNOL, V16, P395, DOI 10.1146/annurev.immunol.16.1.395; Cheng QW, 2000, ONCOGENE, V19, P4936, DOI 10.1038/sj.onc.1203861; Cheung KJ, 2001, EXP CELL RES, V268, P1, DOI 10.1006/excr.2001.5258; CHOI SS, 1995, ONCOGENE, V11, P1693; D'Sa-Eipper C, 1998, ONCOGENE, V16, P3105, DOI 10.1038/sj.onc.1201851; DSaEipper C, 1996, CANCER RES, V56, P3879; Duriez PJ, 2000, J BIOL CHEM, V275, P18099, DOI 10.1074/jbc.M908925199; Ha SH, 2002, CANCER RES, V62, P1275; Han JH, 1998, MOL CELL BIOL, V18, P6052, DOI 10.1128/MCB.18.10.6052; Han ZY, 1999, MOL CELL BIOL, V19, P1381; Hatakeyama S, 1998, INT IMMUNOL, V10, P631, DOI 10.1093/intimm/10.5.631; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; Holmgreen SP, 1999, CELL DEATH DIFFER, V6, P525, DOI 10.1038/sj.cdd.4400519; Jung-Ha H, 1998, HUM PATHOL, V29, P723, DOI 10.1016/S0046-8177(98)90282-9; Karsan A, 1996, J BIOL CHEM, V271, P27201, DOI 10.1074/jbc.271.44.27201; Karsan A, 1996, BLOOD, V87, P3089, DOI 10.1182/blood.V87.8.3089.bloodjournal8783089; Kasof GM, 1999, MOL CELL BIOL, V19, P4390; KEPLER TB, 1993, IMMUNOL TODAY, V14, P412, DOI 10.1016/0167-5699(93)90145-B; Lee HH, 1999, P NATL ACAD SCI USA, V96, P9136, DOI 10.1073/pnas.96.16.9136; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Perez D, 1998, J CELL BIOL, V141, P1255, DOI 10.1083/jcb.141.5.1255; Priault M, 1999, FEBS LETT, V443, P225, DOI 10.1016/S0014-5793(98)01661-5; Rao L, 1997, ONCOGENE, V15, P1587, DOI 10.1038/sj.onc.1201323; Reed JC, 1998, ONCOGENE, V17, P3225, DOI 10.1038/sj.onc.1202591; Shim YH, 2000, INT J HEMATOL, V72, P484; Somogyi RD, 2001, CELL DEATH DIFFER, V8, P785, DOI 10.1038/sj.cdd.4400879; Tomayko MM, 1998, J IMMUNOL, V160, P107; Wang CY, 1999, MOL CELL BIOL, V19, P5923; WANG L, 1994, CELL, V78, P739, DOI 10.1016/S0092-8674(94)90422-7; Werner AB, 2002, J BIOL CHEM, V277, P22781, DOI 10.1074/jbc.M201469200; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0; Zhang H, 2000, J BIOL CHEM, V275, P11092, DOI 10.1074/jbc.275.15.11092; Zong WX, 1999, GENE DEV, V13, P382, DOI 10.1101/gad.13.4.382	35	32	33	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 24	2003	22	16					2457	2465		10.1038/sj.onc.1206274	http://dx.doi.org/10.1038/sj.onc.1206274			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	670AD	12717423				2022-12-17	WOS:000182383500009
J	Baumann, S; Hess, J; Eichhorst, ST; Krueger, A; Angel, P; Krammer, PH; Kirchhoff, S				Baumann, S; Hess, J; Eichhorst, ST; Krueger, A; Angel, P; Krammer, PH; Kirchhoff, S			An unexpected role for FosB in activation-induced cell death of T cells	ONCOGENE			English	Article						activation-induced cell death; CD95 ligand; AP-1; T cells	FAS-LIGAND EXPRESSION; NF-KAPPA-B; INDUCED APOPTOSIS; TRANSCRIPTION FACTORS; GENE-EXPRESSION; CARCINOMA CELLS; CYCLOSPORINE-A; UP-REGULATION; C-FOS; PROMOTER	The CD95 (APO-1/Fas) system plays a major role in induction of apoptosis in lymphoid and nonlymphoid tissues. The CD95 (APO-1/Fas) ligand (CD95L) is induced in response to a variety of signals including TCR/CD3 stimulation or application of chemotherapeutic drugs. Here we report that an AP-1 site located in the 5' untranslated region of the CD95L gene is required for TCR/CD3-mediated induction of the human CD95L promoter. Electrophoretic mobility shift assays using nuclear extracts of Jurkat T cells as well as TCR/CD3-restimulated primary human T cells demonstrated specific binding of AP-1, predominantly composed of c-Jun and FosB, to this sequence. Ectopic expression of transdominant negative Jun mutants strongly reduced CD95L promoter activity and activation-induced cell death (AICD), confirming the functional significance of FosB/c-Jun binding. Thus, our results demonstrate an important novel function for FosB dimerized with c-Jun in TCR/CD3-mediated AICD in human T cells.	German Canc Res Ctr, Div Immunogenet, D-69120 Heidelberg, Germany; Tumor Immunol Program, D-69120 Heidelberg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ)	Krammer, PH (corresponding author), German Canc Res Ctr, Div Immunogenet, G0300,Neuenheimer Feld 280, D-69120 Heidelberg, Germany.		Krueger, Andreas/M-9769-2019; Piris, Miguel A/AAP-1445-2020; Hess, Jochen/ABE-1144-2021; Krueger, Andreas/B-9427-2009	Krueger, Andreas/0000-0001-7873-7334; Piris, Miguel A/0000-0001-5839-3634; Hess, Jochen/0000-0003-3493-1711; Krueger, Andreas/0000-0001-7873-7334				ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Chow WA, 2000, J IMMUNOL, V164, P3512, DOI 10.4049/jimmunol.164.7.3512; COCKERILL GW, 1995, BLOOD, V86, P2689; Crabtree GR, 1999, CELL, V96, P611, DOI 10.1016/S0092-8674(00)80571-1; DHEIN J, 1995, NATURE, V373, P438, DOI 10.1038/373438a0; Eichhorst ST, 2000, MOL CELL BIOL, V20, P7826, DOI 10.1128/MCB.20.20.7826-7837.2000; Faris M, 1998, J IMMUNOL, V160, P134; Friesen C, 1996, NAT MED, V2, P574, DOI 10.1038/nm0596-574; Hafezi F, 1997, NAT MED, V3, P346, DOI 10.1038/nm0397-346; Harwood FG, 2000, J BIOL CHEM, V275, P10023, DOI 10.1074/jbc.275.14.10023; Holtz-Heppelmann CJ, 1998, J BIOL CHEM, V273, P4416, DOI 10.1074/jbc.273.8.4416; Ivanov VN, 1997, J BIOL CHEM, V272, P8558; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Kasibhatla S, 1998, MOL CELL, V1, P543, DOI 10.1016/S1097-2765(00)80054-4; Kasibhatla S, 1999, J BIOL CHEM, V274, P987, DOI 10.1074/jbc.274.2.987; Kirchhoff S, 2000, J IMMUNOL, V165, P6293, DOI 10.4049/jimmunol.165.11.6293; Kolbus A, 2000, MOL CELL BIOL, V20, P575, DOI 10.1128/MCB.20.2.575-582.2000; Li-Weber M, 2000, EUR J IMMUNOL, V30, P661, DOI 10.1002/1521-4141(200002)30:2<661::AID-IMMU661>3.3.CO;2-C; Li-Weber M, 1998, EUR J IMMUNOL, V28, P2373, DOI 10.1002/(SICI)1521-4141(199808)28:08<2373::AID-IMMU2373>3.0.CO;2-T; Li-Weber M, 1999, EUR J IMMUNOL, V29, P3017, DOI 10.1002/(SICI)1521-4141(199909)29:09<3017::AID-IMMU3017>3.0.CO;2-R; Lidwell K, 2000, J NEUROSCI RES, V62, P427, DOI 10.1002/1097-4547(20001101)62:3<427::AID-JNR13>3.0.CO;2-O; Macian F, 2000, EMBO J, V19, P4783, DOI 10.1093/emboj/19.17.4783; Matsui K, 2000, J IMMUNOL, V164, P3002, DOI 10.4049/jimmunol.164.6.3002; Mittelstadt PR, 1998, MOL CELL BIOL, V18, P3744, DOI 10.1128/MCB.18.7.3744; Mittelstadt PR, 1999, J BIOL CHEM, V274, P3222, DOI 10.1074/jbc.274.5.3222; Norian LA, 1998, J IMMUNOL, V161, P1078; Passegue E, 2000, EMBO J, V19, P2969, DOI 10.1093/emboj/19.12.2969; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; Rivera I, 1998, J BIOL CHEM, V273, P22382, DOI 10.1074/jbc.273.35.22382; ROONEY JW, 1995, IMMUNITY, V2, P473, DOI 10.1016/1074-7613(95)90028-4; Schmitz I, 2000, INT J BIOCHEM CELL B, V32, P1123, DOI 10.1016/S1357-2725(00)00048-0; STEIN B, 1993, EMBO J, V12, P3879, DOI 10.1002/j.1460-2075.1993.tb06066.x; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; Weitzman JB, 2000, MOL CELL, V6, P1109, DOI 10.1016/S1097-2765(00)00109-X; Yamamura Y, 2000, J BIOL CHEM, V275, P36295, DOI 10.1074/jbc.M006023200; Zhang J, 2000, J EXP MED, V191, P1017, DOI 10.1084/jem.191.6.1017	37	32	33	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 6	2003	22	9					1333	1339		10.1038/sj.onc.1206126	http://dx.doi.org/10.1038/sj.onc.1206126			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	652CA	12618758				2022-12-17	WOS:000181360900007
J	Klingelhofer, J; Troyanovsky, RB; Laur, OY; Troyanovsky, S				Klingelhofer, J; Troyanovsky, RB; Laur, OY; Troyanovsky, S			Exchange of catenins in cadherin-catenin complex	ONCOGENE			English	Article						cadherin; catenins; APC; adhesion	APC TUMOR-SUPPRESSOR; BETA-CATENIN; CELL-ADHESION; TYROSINE PHOSPHORYLATION; FUNCTIONAL-ANALYSIS; ALPHA-CATENIN; DROSOPHILA; BINDING; LOCALIZATION; JUNCTIONS	beta-Catenin is an intracellular multifunctional protein. In complex with the transmembrane adhesive receptor E-cadherin, it becomes plasma membrane-associated and mediates intercellular adhesion. A cytosolic pool of beta-catenin interacts with DNA-binding proteins and participates in signal transduction. To reveal the possible cross-talk between these two pools, we studied whether beta-catenin is exchanged between its free and cadherin-bound states. We found that pulse-labeled beta-catenin replaces the beta-catenin bound to the cell surface prebiotinylated E-cadherin immediately after synthesis. Approximately 25% of all pulse-labeled beta-catenin destined for E-cadherin associates with this protein via this mechanism. The rest of the newly synthesized beta-catenin arrives at the plasma membrane in a complex with the E-cadherin precursor. Immediately after arrival, this beta-catenin pool is transferred to the prebiotinylated E-cadherin. beta-Catenin released from E-cadherin may participate in new exchange cycles. This beta-catenin exchange is strongly affected in cells that contain mutations in the tumor suppressor gene APC. This process may contribute significantly to both cell-cell adhesion and beta-catenin-dependent signaling.	Washington Univ, Sch Med, Div Dermatol, St Louis, MO 63110 USA	Washington University (WUSTL)	Troyanovsky, S (corresponding author), Washington Univ, Sch Med, Div Dermatol, Campus Box 8123,660 S Euclid Ave, St Louis, MO 63110 USA.		Klingelhöfer, Jörg/C-1676-2013		NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR045254] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR44106-04, AR45254-01] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Aono S, 1999, J CELL BIOL, V145, P551, DOI 10.1083/jcb.145.3.551; Balsamo J, 1996, J CELL BIOL, V134, P801, DOI 10.1083/jcb.134.3.801; Bienz M, 1999, CURR OPIN GENET DEV, V9, P595, DOI 10.1016/S0959-437X(99)00016-7; Chitaev NA, 1998, J CELL BIOL, V142, P837, DOI 10.1083/jcb.142.3.837; Gottardi CJ, 2001, J CELL BIOL, V153, P1049, DOI 10.1083/jcb.153.5.1049; Hamada F, 2002, NAT CELL BIOL, V4, P208, DOI 10.1038/ncb755; HEASMAN J, 1994, CELL, V79, P791, DOI 10.1016/0092-8674(94)90069-8; HINCK L, 1994, J CELL BIOL, V125, P1327, DOI 10.1083/jcb.125.6.1327; Ilyas M, 1997, P NATL ACAD SCI USA, V94, P10330, DOI 10.1073/pnas.94.19.10330; Kaibuchi K, 1999, CURR OPIN CELL BIOL, V11, P591, DOI 10.1016/S0955-0674(99)00014-9; KINCH MS, 1995, J CELL BIOL, V130, P461, DOI 10.1083/jcb.130.2.461; Klingelhofer J, 2002, MOL CELL BIOL, V22, P7449, DOI 10.1128/MCB.22.21.7449-7458.2002; KLYMKOWSKY MW, 1995, CELL, V83, P5, DOI 10.1016/0092-8674(95)90226-0; Laur OY, 2002, ARCH BIOCHEM BIOPHYS, V400, P141, DOI 10.1006/abbi.2002.2774; McCartney BM, 2001, NAT CELL BIOL, V3, P933, DOI 10.1038/ncb1001-933; NAGAFUCHI A, 1994, J CELL BIOL, V127, P235, DOI 10.1083/jcb.127.1.235; Orsulic S, 1999, J CELL SCI, V112, P1237; OZAWA M, 1992, J CELL BIOL, V116, P989, DOI 10.1083/jcb.116.4.989; Ozawa M, 1998, J BIOL CHEM, V273, P6166, DOI 10.1074/jbc.273.11.6166; Peifer M, 2000, SCIENCE, V287, P1606, DOI 10.1126/science.287.5458.1606; Piedra J, 2001, J BIOL CHEM, V276, P20436, DOI 10.1074/jbc.M100194200; Provost E, 1999, CURR OPIN CELL BIOL, V11, P567, DOI 10.1016/S0955-0674(99)00015-0; Rosin-Arbesfeld R, 2001, EMBO J, V20, P5929, DOI 10.1093/emboj/20.21.5929; Sanson B, 1996, NATURE, V383, P627, DOI 10.1038/383627a0; Schmelz M, 1998, CELL TISSUE RES, V294, P11, DOI 10.1007/s004410051152; Troyanovsky RB, 1996, J CELL SCI, V109, P3069; Yap AS, 1997, ANNU REV CELL DEV BI, V13, P119, DOI 10.1146/annurev.cellbio.13.1.119	27	32	32	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 27	2003	22	8					1181	1188		10.1038/sj.onc.1206245	http://dx.doi.org/10.1038/sj.onc.1206245			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	650EK	12606944				2022-12-17	WOS:000181249700006
J	Neiman, PE; Grbic, JJ; Polony, TS; Kimmel, R; Bowers, SJ; Delrow, J; Beemon, KL				Neiman, PE; Grbic, JJ; Polony, TS; Kimmel, R; Bowers, SJ; Delrow, J; Beemon, KL			Functional genomic analysis reveals distinct neoplastic phenotypes associated with c-myb mutation in the bursa of Fabricius	ONCOGENE			English	Article						c-myb; c-myc; bursa of farbricius; lymphomas; cDNA microarray	AVIAN-LEUKOSIS VIRUS; B-CELL LYMPHOMA; GENE-EXPRESSION; PROMOTER INSERTION; RAPID INDUCTION; MYELOID TUMORS; BALB/C MICE; ACTIVATION; ONCOGENE; PROTEINS	Avian retroviral integration into the c-myb locus is casually associated with the development of lymphomas in the bursa of Farbricius of chickens; these arise with a shorter latency than bursal lymphomas caused by deregulation of c-myc. This study indicates that c-myb mutation in embryonic bursal precursors leads to an oligoclonal population of developing bursal follicles, showing a variable propensity to form a novel lesion, the neoplastic follicle (NF). About half of such bursas rapidly developed lymphomas. Detection of changes in gene expression, during the development of neoplasms, was carried out by cDNA microarray analysis. The transcriptional signature of lymphomas with mutant c-myb was more limited than, and only partially shared with, those of bursal lymphomas caused by Myc or Rel oncogenes. The c-myb-associated lymphomas frequently showed overexpression of c-myc and altered expression of other genes involved in cell cycle control and proliferation-related signal transduction. Oligoclonal, NF-containing bursas lacked detectable c-myc overexpression and demonstrated a pattern of gene expression distinct from that of normal bursa and partially shared with the short-latency lymphomas. This functional genomic analysis uncovered several different pathways of lymphomagenesis by oncogenic transcription factors acting in a B-cell lineage.	Fred Hutchinson Canc Res Ctr, Div Basic Sci, Seattle, WA 98109 USA; Fred Hutchinson Canc Res Ctr, Div Human Biol, Seattle, WA 98109 USA; Univ Washington, Dept Med, Seattle, WA 98195 USA; Univ Washington, Dept Pathol, Seattle, WA 98195 USA; Johns Hopkins Univ, Dept Biol, Baltimore, MD 21218 USA	Fred Hutchinson Cancer Center; Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Johns Hopkins University	Neiman, PE (corresponding author), Fred Hutchinson Canc Res Ctr, Div Basic Sci, 1124 Columbia St, Seattle, WA 98109 USA.				NCI NIH HHS [R01 CA20068, R01 CA48746] Funding Source: Medline; NIGMS NIH HHS [T32 GM007231] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA020068, R01CA048746] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007231] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abdrakhmanov I, 2000, GENOME RES, V10, P2062, DOI 10.1101/gr.10.12.2062; BABA TW, 1985, P NATL ACAD SCI USA, V82, P213, DOI 10.1073/pnas.82.1.213; BARTH CF, 1988, MOL CELL BIOL, V8, P5358, DOI 10.1128/MCB.8.12.5358; Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; Brandvold KA, 2000, ONCOGENE, V19, P2780, DOI 10.1038/sj.onc.1203589; Brandvold KA, 2001, ONCOGENE, V20, P3226, DOI 10.1038/sj.onc.1204431; Clurman BE, 1998, P NATL ACAD SCI USA, V95, P15158, DOI 10.1073/pnas.95.26.15158; CLURMAN BE, 1989, MOL CELL BIOL, V9, P2657, DOI 10.1128/MCB.9.6.2657; COOPER MD, 1960, HISTOGENESIS J NATT, V41, P373; ECKERT EA, 1951, J NATL CANCER I, V12, P447; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Goitsuka R, 1997, J IMMUNOL, V159, P3126; GONDA TJ, 1987, J VIROL, V61, P2754, DOI 10.1128/JVI.61.9.2754-2763.1987; Gong M, 1998, J VIROL, V72, P5517, DOI 10.1128/JVI.72.7.5517-5525.1998; Grandori C, 2000, ANNU REV CELL DEV BI, V16, P653, DOI 10.1146/annurev.cellbio.16.1.653; Guarguaglini G, 2000, CELL GROWTH DIFFER, V11, P455; HAYWARD WS, 1981, NATURE, V290, P475, DOI 10.1038/290475a0; Irwin MS, 2001, APOPTOSIS, V6, P17, DOI 10.1023/A:1009663809458; Jackers P, 1996, ONCOGENE, V13, P495; Jiang WP, 1997, J VIROL, V71, P6526, DOI 10.1128/JVI.71.9.6526-6533.1997; KANTER MR, 1988, J VIROL, V62, P1423, DOI 10.1128/JVI.62.4.1423-1432.1988; Kramer ER, 2000, MOL BIOL CELL, V11, P1555, DOI 10.1091/mbc.11.5.1555; Kuersten S, 2001, TRENDS CELL BIOL, V11, P497, DOI 10.1016/S0962-8924(01)02144-4; LEPRINCE D, 1983, NATURE, V306, P395, DOI 10.1038/306395a0; Marshall AJ, 2000, J EXP MED, V191, P1319, DOI 10.1084/jem.191.8.1319; MuziFalconi M, 1995, P NATL ACAD SCI USA, V92, P12475, DOI 10.1073/pnas.92.26.12475; NASONBURCHENAL K, 1993, P NATL ACAD SCI USA, V90, P1619, DOI 10.1073/pnas.90.4.1619; NEEL BG, 1981, CELL, V23, P323, DOI 10.1016/0092-8674(81)90128-8; NEIMAN P, 1985, P NATL ACAD SCI USA, V82, P222, DOI 10.1073/pnas.82.1.222; NEIMAN P, 1980, J VIROL, V34, P178, DOI 10.1128/JVI.34.1.178-186.1980; NEIMAN PE, 1991, P NATL ACAD SCI USA, V88, P5857, DOI 10.1073/pnas.88.13.5857; NEIMAN PE, 1994, ADV IMMUNOL, V56, P467, DOI 10.1016/S0065-2776(08)60457-5; Neiman PE, 2001, P NATL ACAD SCI USA, V98, P6378, DOI 10.1073/pnas.111144898; Ness SA, 1996, BBA-REV CANCER, V1288, pF123, DOI 10.1016/S0304-419X(96)00027-3; Ouspenski II, 1998, EXP CELL RES, V244, P171, DOI 10.1006/excr.1998.4174; PAYNE GS, 1981, CELL, V23, P311, DOI 10.1016/0092-8674(81)90127-6; Petersen BO, 2000, GENE DEV, V14, P2330, DOI 10.1101/gad.832500; Pfleger CM, 2001, GENE DEV, V15, P2396, DOI 10.1101/gad.918201; PIZER E, 1989, J VIROL, V63, P1630, DOI 10.1128/JVI.63.4.1630-1640.1989; PIZER ES, 1992, J VIROL, V66, P512, DOI 10.1128/JVI.66.1.512-523.1992; PRICHARD CC, 2001, P NATL ACAD SCI USA, V98, P13266; Sauer K, 2001, J BIOL CHEM, V276, P45207, DOI 10.1074/jbc.M106811200; Schmidt M, 2000, MOL CELL BIOL, V20, P1970, DOI 10.1128/MCB.20.6.1970-1981.2000; SHENONG GL, 1986, IN PRESS MOL CELL BI, V6, P2756; SHENONG GLC, 1986, MOL CELL BIOL, V6, P380, DOI 10.1128/MCB.6.2.380; SHENONG GLC, 1987, J VIROL, V61, P3721, DOI 10.1128/JVI.61.12.3721-3725.1987; Smith MR, 1997, J VIROL, V71, P6534, DOI 10.1128/JVI.71.9.6534-6540.1997; Sudo T, 2001, EMBO J, V20, P6499, DOI 10.1093/emboj/20.22.6499; THOMPSON CB, 1987, CELL, V51, P371, DOI 10.1016/0092-8674(87)90633-7; Tirunagaru VG, 2000, GENOMICS, V66, P144, DOI 10.1006/geno.2000.6189; WOLFF L, 1988, J IMMUNOL, V141, P681	51	32	33	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 20	2003	22	7					1073	1086		10.1038/sj.onc.1206070	http://dx.doi.org/10.1038/sj.onc.1206070			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	644PB	12592394				2022-12-17	WOS:000180926100013
J	Li, JX; Ma, CL; Huang, Y; Luo, H; Huang, CS				Li, JX; Ma, CL; Huang, Y; Luo, H; Huang, CS			Differential requirement of EGF receptor and its tyrosine kinase for AP-1 transactivation induced by EGF and TPA	ONCOGENE			English	Article						EGF; TPA; AP-1; kinase and signal transduction	GROWTH-FACTOR RECEPTOR; ACTIVATED PROTEIN-KINASE; CELL-TRANSFORMATION; MECHANISMS; EXPRESSION; BINDING; FAMILY; CANCER; DOMAIN; RAF	The transcription factor activator protein-1 (AP-1) has been implicated in a large variety of biological processes including cell differentiation, proliferation, apoptosis and oncogenic transformation. It is thought that the 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced AP-1 activity is because of the activation of the PKC/MAPK/AP-1 pathway, although the detailed molecular mechanism has not been fully characterized. The tyrosine kinases of epidermal growth factor receptor (EGFR) lie at the head of a complex of signal transduction cascade that modulates cell proliferation, survival, adhesion, migration and differentiation. Currently, little is known about whether EGFR or its tyrosine kinase is necessary for TPA-induced AP-1 activation. In the present study, we investigated this issue using a well-characterized mouse fibroblast B82 cell line, which is devoid of the EGFR, and its stable transfectants with either wild-type EGFR (B82L) or tyrosine kinase-deficient EGFR (mutation at Lys-721) (B82M721). We demonstrated that the TPA or epidermal growth factor (EGF) induced AP-1 activation in the B82L cells that express wild-type EGFR, but not in the B82 cell, whereas autophosphorylation at tyrosine(1173) of EGFR in B82L cells was only induced by EGF, but not TPA. The expression of tyrosine kinase-deficient EGFR (mutation at Lys-721) (B82M721) resulted in deficiency of AP-1 induction in cellular response to EGF, while TPA treatment led to fully AP-1 activation. Furthermore, the mutation at Lys-721 of EGFR resulted in impairing of EGFR autophosphorylation at tyrosinell(1173) induced by EGF. Based on these results, we conclude that TPA-induced AP-1 activation requires the basal level-EGFR protein, but not EGFR tyrosine kinase and EGFR autophosphorylation at tyrosine(1173), whereas both EGFR tyrosine kinase and EGFR autophosphorylation at Y-1173 play a critical role in EGF-induced AP-1 activation.	NYU, Sch Med, Nelson Inst Environm Med, Tuxedo Pk, NY 10987 USA; W Virginia Univ, Dept Microbiol Immunol & Cell Biol, Morgantown, WV 26506 USA	New York University; West Virginia University	Huang, CS (corresponding author), NYU, Sch Med, Nelson Inst Environm Med, 57 Old Forge Rd, Tuxedo Pk, NY 10987 USA.	chuanshu@env.med.nyu.edu		Huang, Chuanshu/0000-0003-4133-5096; Luo, Jia/0000-0002-6968-3618	NCI NIH HHS [CA 16087] Funding Source: Medline; NIEHS NIH HHS [ES 00260] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016087] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000260] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Baker VL, 1998, PLACENTA, V19, P475, DOI 10.1016/S0143-4004(98)91040-2; BLUMBERG PM, 1991, MOL CARCINOGEN, V4, P339, DOI 10.1002/mc.2940040502; Carpenter G, 1999, J CELL BIOL, V146, P697, DOI 10.1083/jcb.146.4.697; Chen NY, 2001, J BIOL CHEM, V276, P46722, DOI 10.1074/jbc.M107156200; CHEN WS, 1987, NATURE, V328, P820, DOI 10.1038/328820a0; Ciardiello F, 2000, DRUGS, V60, P25, DOI 10.2165/00003495-200060001-00003; Gschwind A, 2001, ONCOGENE, V20, P1594, DOI 10.1038/sj.onc.1204192; Gulliford T, 1999, CELL SIGNAL, V11, P245, DOI 10.1016/S0898-6568(98)00058-8; Hackel PO, 1999, CURR OPIN CELL BIOL, V11, P184, DOI 10.1016/S0955-0674(99)80024-6; Huang CS, 1997, P NATL ACAD SCI USA, V94, P5826, DOI 10.1073/pnas.94.11.5826; Huang CS, 1999, J BIOL CHEM, V274, P29672, DOI 10.1074/jbc.274.42.29672; Huang CS, 1997, CANCER RES, V57, P2873; Huang CS, 1997, J BIOL CHEM, V272, P4187, DOI 10.1074/jbc.272.7.4187; Huang CS, 1996, J BIOL CHEM, V271, P31262, DOI 10.1074/jbc.271.49.31262; Huang CS, 1996, MOL CELL BIOL, V16, P6427; Huang CS, 1997, J BIOL CHEM, V272, P26325, DOI 10.1074/jbc.272.42.26325; Huang CS, 1997, ONCOGENE, V14, P1945, DOI 10.1038/sj.onc.1201056; Huang CS, 1998, P NATL ACAD SCI USA, V95, P156, DOI 10.1073/pnas.95.1.156; Huang CS, 1999, ONCOGENE, V18, P2828, DOI 10.1038/sj.onc.1202639; Jochum W, 2001, ONCOGENE, V20, P2401, DOI 10.1038/sj.onc.1204389; Kong ANT, 2001, MUTAT RES-FUND MOL M, V480, P231, DOI 10.1016/S0027-5107(01)00182-8; LIN CR, 1986, CELL, V44, P839, DOI 10.1016/0092-8674(86)90006-1; Mendelsohn J, 2000, ONCOGENE, V19, P6550, DOI 10.1038/sj.onc.1204082; Moghal N, 1999, CURR OPIN CELL BIOL, V11, P190, DOI 10.1016/S0955-0674(99)80025-8; Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260; PRYWES R, 1986, EMBO J, V5, P2179, DOI 10.1002/j.1460-2075.1986.tb04482.x; SCHAAP D, 1993, J BIOL CHEM, V268, P20232; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Schwartz MA, 1999, CURR OPIN CELL BIOL, V11, P197, DOI 10.1016/S0955-0674(99)80026-X; Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383; Simon MA, 2000, CELL, V103, P13, DOI 10.1016/S0092-8674(00)00100-8; SLAGA TJ, 1982, J CELL BIOCHEM, V18, P99, DOI 10.1002/jcb.1982.240180109; TROPPMAIR J, 1994, J BIOL CHEM, V269, P7030; Watts RG, 1998, ONCOGENE, V17, P3493, DOI 10.1038/sj.onc.1202259; Wells A, 1999, INT J BIOCHEM CELL B, V31, P637, DOI 10.1016/S1357-2725(99)00015-1; XIAN WJ, 1995, CELL GROWTH DIFFER, V6, P1447; Yarden Y, 2001, EUR J CANCER, V37, pS3; Young MR, 1999, P NATL ACAD SCI USA, V96, P9827, DOI 10.1073/pnas.96.17.9827	38	32	32	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 16	2003	22	2					211	219		10.1038/sj.onc.1206102	http://dx.doi.org/10.1038/sj.onc.1206102			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	634CL	12527890				2022-12-17	WOS:000180322400006
J	Kwong, KY; Zou, YY; Day, CP; Hung, MC				Kwong, KY; Zou, YY; Day, CP; Hung, MC			The suppression of colon cancer cell growth in nude mice by targeting beta-catenin/TCF pathway	ONCOGENE			English	Article						APC; beta-catenin; Tcf; colon cancer; adenovirus; thymidine kinase	CYCLIN D1; MUTATIONS; EXPRESSION; TUMOR; GENE; APC	The adenomatous polyposis coli (APC) or beta-catenin genes are frequently mutated in colorectal cancers, leading to activation of downstream genes with beta-catenin/T-cell factor (Tcf)-responsive promoters. We have developed a gene therapy approach selectively targeting colorectal cancer cells in which beta-catenin/Tcf4 pathway is activated by using a recombinant adenovirus AdTOP-CMV-TK, which carries a herpes simplex virus thymidine kinase gene (HSV TK) under the control of a beta-catenin/Tcf-response promoter linking to a minimum CMV promoter. AdTOP-CMV-TK and ganciclovir (GCV) treatment significantly suppressed the growth of human DLD-1 colon cancer cells in nude mice. Furthermore, no significant tumor suppression effect was observed in human hepatoma cell line SK-HEP-1, in which the beta-catenin/Tcf pathway is not activated, as a control experiment. In summary, we demonstrated the selective targeting of colorectal cancers with activated beta-catenin by AdTOP-CMV-TK and GCV treatment in animal models, as well as its therapeutic potential for colon cancer metastasized to liver.	Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Hung, MC (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, 1515 Holcombe Blvd, Houston, TX 77030 USA.		Hung, Mien-Chie/ABD-5911-2021	Hung, Mien-Chie/0000-0003-4317-4740				Bienz M, 2000, CELL, V103, P311, DOI 10.1016/S0092-8674(00)00122-7; Chan EF, 1999, NAT GENET, V21, P410, DOI 10.1038/7747; Chen RH, 2001, CANCER RES, V61, P4445; Crawford HC, 1999, ONCOGENE, V18, P2883, DOI 10.1038/sj.onc.1202627; de La Coste A, 1998, P NATL ACAD SCI USA, V95, P8847; Goss KH, 2000, J CLIN ONCOL, V18, P1967, DOI 10.1200/JCO.2000.18.9.1967; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Lin SY, 2000, P NATL ACAD SCI USA, V97, P4262, DOI 10.1073/pnas.060025397; MELTON RG, 1999, ENZYME PRODRUG STRAT, P216; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Polakis P, 2000, GENE DEV, V14, P1837; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884	15	32	36	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 28	2002	21	54					8340	8346		10.1038/sj.onc.1206050	http://dx.doi.org/10.1038/sj.onc.1206050			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	616VK	12447697				2022-12-17	WOS:000179323900012
J	Peschiaroli, A; Figliola, R; Coltella, L; Strom, A; Valentini, A; D'Agnano, I; Maione, R				Peschiaroli, A; Figliola, R; Coltella, L; Strom, A; Valentini, A; D'Agnano, I; Maione, R			MyoD induces apoptosis in the absence of RB function through a p21(WAF1)-dependent re-localization of cyclin/cdk complexes to the nucleus	ONCOGENE			English	Article						apoptosis; cyclin-cdk; MyoD; p21; retinoblastoma	CELL-CYCLE ARREST; T-EXPRESSING MYOBLASTS; SKELETAL-MUSCLE CELLS; TERMINAL DIFFERENTIATION; RETINOBLASTOMA PROTEIN; GENE-EXPRESSION; KINASE-ACTIVITY; CDK INHIBITORS; MYOGENIC DIFFERENTIATION; MYOCYTE DIFFERENTIATION	During differentiation of skeletal myoblasts, MyoD promotes growth arrest through the induction of the cdk inhibitor p21 and the accumulation of hypophosphorylated RB protein. Myoblasts lacking RB function fail to accomplish full differentiation and undergo apoptosis. Here we show that exogenous MyoD induces apoptosis in several cell backgrounds sharing RB inactivation. This process is associated with increased levels of cell cycle-driving proteins and aberrant cell cycle progression. The inability of MyoD to induce apoptosis in a p21-null background, highlights a requirement of p21 in RB-regulated apoptosis during myogenesis. This pro-apoptotic function of p21 cannot be exerted by simple p21 over-expression, but requires the co-operation of MyoD. We also suggest that the essential aspect of p21 activity involved in such a process is related to its ability to induce the nuclear accumulation and aberrant activity of cyclin/cdk complexes. These results establish a novel link between MyoD, p21 and RB during myogenesis, providing new insights into the antagonism between muscle differentiation and loss of RB function.	Univ Roma La Sapienza, Ist Pasteur, Fdn Cenci Bolognetti,Sez Genet Mol, Dipartimento Biotecnol Cellulari & Ematol, I-00161 Rome, Italy; CNR, Ist Tecnol Biomed, I-00137 Rome, Italy	Fondazione Cenci Bolognetti; Sapienza University Rome; Consiglio Nazionale delle Ricerche (CNR); Istituto di Tecnologie Biomediche (ITB-CNR)	Maione, R (corresponding author), Univ Roma La Sapienza, Ist Pasteur, Fdn Cenci Bolognetti,Sez Genet Mol, Dipartimento Biotecnol Cellulari & Ematol, Piazzale Aldo Moro 5, I-00161 Rome, Italy.		Coltella, Luana/AAA-5263-2020; D'Agnano, Igea/AAR-7282-2020	PESCHIAROLI, ANGELO/0000-0001-6311-2382; D'Agnano, Igea/0000-0002-2646-9224				Bates S, 1998, ONCOGENE, V17, P1691, DOI 10.1038/sj.onc.1202104; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Cenciarelli C, 1999, MOL CELL BIOL, V19, P5203; Chen YNP, 1999, P NATL ACAD SCI USA, V96, P4325, DOI 10.1073/pnas.96.8.4325; Cheng T, 2000, SCIENCE, V287, P1804, DOI 10.1126/science.287.5459.1804; Cho SY, 2001, J BIOL CHEM, V276, P33533, DOI 10.1074/jbc.M102906200; CRESCENZI M, 1990, P NATL ACAD SCI USA, V87, P8442, DOI 10.1073/pnas.87.21.8442; D'Agnano I, 1998, ENVIRON MOL MUTAGEN, V32, P56, DOI 10.1002/(SICI)1098-2280(1998)32:1<56::AID-EM7>3.0.CO;2-9; D'Agnano I, 2001, ONCOGENE, V20, P2814, DOI 10.1038/sj.onc.1204392; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; de la Serna IL, 2001, J BIOL CHEM, V276, P41486, DOI 10.1074/jbc.M107281200; Dotto GP, 2000, BBA-REV CANCER, V1471, pM43, DOI 10.1016/S0304-419X(00)00019-6; Dulic V, 1998, MOL CELL BIOL, V18, P546, DOI 10.1128/MCB.18.1.546; Fimia GM, 1998, MOL BIOL CELL, V9, P1449, DOI 10.1091/mbc.9.6.1449; Furuno N, 1999, J CELL BIOL, V147, P295, DOI 10.1083/jcb.147.2.295; Gorospe M, 1997, ONCOGENE, V14, P929, DOI 10.1038/sj.onc.1200897; Gottifredi V, 1999, J CELL SCI, V112, P2397; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; Guadagno TM, 1996, CELL, V84, P73, DOI 10.1016/S0092-8674(00)80994-0; Guo K, 1997, J BIOL CHEM, V272, P791, DOI 10.1074/jbc.272.2.791; GUO K, 1995, MOL CELL BIOL, V15, P3823; Guo M, 1999, CURR OPIN CELL BIOL, V11, P745, DOI 10.1016/S0955-0674(99)00046-0; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HU JS, 1990, J BIOL CHEM, V265, P7914; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; Jiang Z, 2000, DEV BIOL, V227, P28, DOI 10.1006/dbio.2000.9892; Krek W, 1995, CELL, V83, P1149, DOI 10.1016/0092-8674(95)90141-8; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; Lawlor MA, 2000, MOL CELL BIOL, V20, P8983, DOI 10.1128/MCB.20.23.8983-8995.2000; LUO Y, 1995, NATURE, V375, P159, DOI 10.1038/375159a0; MAIONE R, 1994, CELL GROWTH DIFFER, V5, P231; Maione R, 1997, BBA-REV CANCER, V1332, pM19, DOI 10.1016/S0304-419X(96)00036-4; MARTELLI F, 1994, ONCOGENE, V9, P3579; Meijer L, 1997, EUR J BIOCHEM, V243, P527, DOI 10.1111/j.1432-1033.1997.t01-2-00527.x; Meikrantz W, 1996, J BIOL CHEM, V271, P10205, DOI 10.1074/jbc.271.17.10205; Missero C, 1996, GENE DEV, V10, P3065, DOI 10.1101/gad.10.23.3065; Naya FJ, 1999, CURR OPIN CELL BIOL, V11, P683, DOI 10.1016/S0955-0674(99)00036-8; Niculescu AB, 1998, MOL CELL BIOL, V18, P629, DOI 10.1128/MCB.18.1.629; Novitch BG, 1999, CURR BIOL, V9, P449, DOI 10.1016/S0960-9822(99)80210-3; Novitch BG, 1996, J CELL BIOL, V135, P441, DOI 10.1083/jcb.135.2.441; PAGANO M, 1993, J CELL BIOL, V121, P101, DOI 10.1083/jcb.121.1.101; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Phillips AC, 1999, MOL CELL, V4, P771, DOI 10.1016/S1097-2765(00)80387-1; Poluha W, 1996, MOL CELL BIOL, V16, P1335; Puri PL, 2000, J CELL PHYSIOL, V185, P155, DOI 10.1002/1097-4652(200011)185:2<155::AID-JCP1>3.0.CO;2-Z; Puri PL, 1997, EMBO J, V16, P369, DOI 10.1093/emboj/16.2.369; Schreiber M, 1999, ONCOGENE, V18, P1663, DOI 10.1038/sj.onc.1202466; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; SHI L, 1994, SCIENCE, V263, P1143, DOI 10.1126/science.8108732; SORRENTINO V, 1990, NATURE, V345, P813, DOI 10.1038/345813a0; Taylor WR, 2001, ONCOGENE, V20, P1803, DOI 10.1038/sj.onc.1204252; Tedesco D, 2001, EXP CELL RES, V269, P301, DOI 10.1006/excr.2001.5318; Tsao YP, 1999, J VIROL, V73, P4983, DOI 10.1128/JVI.73.6.4983-4990.1999; Wang J, 1996, SCIENCE, V273, P359, DOI 10.1126/science.273.5273.359; Wang J, 1997, CANCER RES, V57, P351; Wei Q, 2001, FEBS LETT, V490, P171, DOI 10.1016/S0014-5793(01)02120-2; WEINTRAUB H, 1989, P NATL ACAD SCI USA, V86, P5434, DOI 10.1073/pnas.86.14.5434; WEINTRAUB H, 1993, CELL, V75, P1241, DOI 10.1016/0092-8674(93)90610-3; Yang J, 1999, TRENDS CELL BIOL, V9, P207, DOI 10.1016/S0962-8924(99)01577-9; Zacksenhaus E, 1996, GENE DEV, V10, P3051, DOI 10.1101/gad.10.23.3051; Zhang JM, 1999, EMBO J, V18, P6983, DOI 10.1093/emboj/18.24.6983; Zhang PM, 1997, NATURE, V387, P151, DOI 10.1038/387151a0; Zhang PM, 1999, GENE DEV, V13, P213, DOI 10.1101/gad.13.2.213	66	32	32	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 21	2002	21	53					8114	8127		10.1038/sj.onc.1206010	http://dx.doi.org/10.1038/sj.onc.1206010			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	615DW	12444547				2022-12-17	WOS:000179231400005
J	Perren, A; Barghorn, A; Schmid, S; Saremaslani, P; Roth, J; Heitz, PU; Komminoth, P				Perren, A; Barghorn, A; Schmid, S; Saremaslani, P; Roth, J; Heitz, PU; Komminoth, P			Absence of somatic SDHD mutations in sporadic neuroendocrine tumors and detection of two germline variants in paraganglioma patients	ONCOGENE			English	Article						SDHD; endocrine tumors; mutation; allelic loss	COMPARATIVE GENOMIC HYBRIDIZATION; PANCREATIC ENDOCRINE TUMORS; COMPLEX-II GENE; SUPPRESSOR GENE; HEREDITARY PARAGANGLIOMA; CARCINOID-TUMORS; HETEROZYGOSITY; CHROMOSOME-11; PHEOCHROMOCYTOMA; OXIDOREDUCTASE	Allelic loss of the long arm of chromosome 11 is frequent in neuroendocrine tumors (NET) of different organs. However, the MEN1 gene on 11q13 is mutated only in a subset of NET and allelic losses on 11q frequently extend to the telomere. In this genetic region lies the tumor suppressor gene SDHD which is associated with hereditary paragangliomas (PGL1). We sought to determine whether SDHD plays a role in the development of sporadic NET. By mutation and deletion analysis of SDHD we were unable to detect any SDHD mutation in 45 NET of the lung, gastrointestinal tract, pancreas or parathyroid. However, we found allelic deletions in 20 to 50% of all tumors but parathyroid adenomas. Furthermore, we found heterozygous germline variants in 2/8 paragangliomas. A first case of variant c.149 A > G (H50R) was found in a patient with an extra-adrenal pheochromocytoma, the other variant c.34 G > A (G12S) in a patient with a paratracheal paraganglioma, C-cell hyperplasia of the thyroid and hyperplasia of ACTH-producing cells of the pituitary gland. Both variants were absent in 93 controls. Our results demonstrate that somatic SDHD mutations are rare in sporadic NET. However, LOH alone could lead to a complete loss of function since SDHD is an imprinted gene. Furthermore, we describe two germline variants possibly causing hereditary paragangliomas.	Univ Zurich Hosp, Dept Pathol, CH-8091 Zurich, Switzerland; Inst Pathol, CH-5404 Baden, Switzerland	University of Zurich; University Zurich Hospital	Perren, A (corresponding author), Univ Zurich Hosp, Dept Pathol, Schmelzbergstr 12, CH-8091 Zurich, Switzerland.		Perren, Aurel/A-9383-2018; Perren, Aurel/N-5979-2019	Perren, Aurel/0000-0002-6819-6092; Perren, Aurel/0000-0002-6819-6092				Badenhop RF, 2001, GENE CHROMOSOME CANC, V31, P255, DOI 10.1002/gcc.1142; Baysal BE, 2000, SCIENCE, V287, P848, DOI 10.1126/science.287.5454.848; Baysal BE, 1999, HUM GENET, V104, P219, DOI 10.1007/s004390050939; Chakrabarti R, 1998, GENE CHROMOSOME CANC, V22, P130, DOI 10.1002/(SICI)1098-2264(199806)22:2<130::AID-GCC7>3.0.CO;2-Y; D'Adda T, 1999, LAB INVEST, V79, P671; Dannenberg H, 2000, AM J PATHOL, V157, P353, DOI 10.1016/S0002-9440(10)64547-6; EUBANKS PJ, 1994, AM J SURG, V167, P180, DOI 10.1016/0002-9610(94)90071-X; Farnebo F, 1997, HUM GENET, V99, P342, DOI 10.1007/s004390050369; Farnebo F, 1999, J CLIN ENDOCR METAB, V84, P3775, DOI 10.1210/jc.84.10.3775; FRIEDMAN E, 1992, CANCER RES, V52, P6804; Gimm O, 2000, CANCER RES, V60, P6822; Gortz B, 1999, AM J PATHOL, V154, P429, DOI 10.1016/S0002-9440(10)65289-3; Hagerhall C, 1997, BBA-BIOENERGETICS, V1320, P107, DOI 10.1016/S0005-2728(97)00019-4; Hirawake H, 1999, BBA-BIOENERGETICS, V1412, P295, DOI 10.1016/S0005-2728(99)00071-7; Iwasaki H, 1996, INT SURG, V81, P71; Jakobovitz G, 1996, J CLIN ENDOCR METAB, V81, P3164; Koehler CM, 2000, FEBS LETT, V476, P27, DOI 10.1016/S0014-5793(00)01664-1; KOMMINOTH P, 1994, AM J PATHOL, V145, P922; Malik K, 2000, CANCER RES, V60, P2356; Perren A, 1998, J PATHOL, V186, P363; Petzmann S, 2001, HUM PATHOL, V32, P333, DOI 10.1053/hupa.2001.22762; Pfanner N, 2000, CURR BIOL, V10, pR412, DOI 10.1016/S0960-9822(00)00507-8; Rigaud G, 2001, CANCER RES, V61, P285; Scheffler IE, 1998, PROG NUCLEIC ACID RE, V60, P267, DOI 10.1016/S0079-6603(08)60895-8; Speel EJM, 1999, AM J PATHOL, V155, P1787, DOI 10.1016/S0002-9440(10)65495-8; VANDERMEY AGL, 1989, LANCET, V2, P1291; Walch AK, 1998, AM J PATHOL, V153, P1089, DOI 10.1016/S0002-9440(10)65653-2; Zhao JM, 2000, AM J PATHOL, V157, P1431, DOI 10.1016/S0002-9440(10)64780-3	28	32	36	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 24	2002	21	49					7605	7608		10.1038/sj.onc.1205812	http://dx.doi.org/10.1038/sj.onc.1205812			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	604JX	12386824				2022-12-17	WOS:000178618200017
J	Yang, HP; Reddy, TR; Truong, KT; Suhasini, M; Wong-Staal, F				Yang, HP; Reddy, TR; Truong, KT; Suhasini, M; Wong-Staal, F			Functional interaction of Sam68 and heterogeneous nuclear ribonucleoprotein K	ONCOGENE			English	Article						Sam68; hnRNP K; RRE; CT element; protein - protein interaction	HUMAN-IMMUNODEFICIENCY-VIRUS; FAMILY TYROSINE KINASES; RNA HELICASE-A; HNRNP-K; BINDING-PROTEIN; MESSENGER-RNA; DOMAIN; SRC; IDENTIFICATION; LOCALIZATION	Sam68 is a target of the c-Src tyrosine kinase. We previously showed that overexpression of Sam68 functionally substitutes for, as well as synergies with, HIV-1 Rev in Rev-response element (RRE)-mediated gene expression and virus replication. Here we describe the identification of heterogeneous nuclear ribonucleoprotein K (hnRNP K) as a protein that specifically interacts with Sam68 in vitro and in vivo. HnRNP K did not bind to RRE-RNA directly, but formed a super complex with Sam68 and RRE in vitro. RNase treatment did not change the strength of binding of hnRNP K to Sam68. We demonstrated that hnRNP K significantly inhibited Sam68-mediated, but not Rev-mediated, RRE-dependent gene expression. We further showed that Sam68, but not a non-functional mutant Sam68p21, inhibited transcriptional activation of CT element by hnRNP K. Interestingly, the Sam68p21 with a single amino acid substitution in the nuclear localization domain exhibited less affinity for hnRNP K in vitro. We propose that the direct interaction of Sam68 and hnRNP K adversely affect the activities of both proteins in signal transduction pathways of both transcriptional and post-transcriptional events.	Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; Wayne State Univ, Sch Med, Dept Immunol & Microbiol, Detroit, MI 48201 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; Wayne State University	Wong-Staal, F (corresponding author), Univ Calif San Diego, Dept Biol, Stein Clin Res Bldg, La Jolla, CA 92093 USA.	fwongstaal@ucsd.edu			NIAID NIH HHS [AI46240] Funding Source: Medline; NIGMS NIH HHS [GM05089] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI046240] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARGRAVES WS, 1990, J CELL BIOL, V111, P3155, DOI 10.1083/jcb.111.6.3155; Bomsztyk K, 1997, FEBS LETT, V403, P113, DOI 10.1016/S0014-5793(97)00041-0; BRAY M, 1994, P NATL ACAD SCI USA, V91, P1256, DOI 10.1073/pnas.91.4.1256; Chen TP, 1997, MOL CELL BIOL, V17, P5707, DOI 10.1128/MCB.17.10.5707; Chen TP, 1999, MOL BIOL CELL, V10, P3015, DOI 10.1091/mbc.10.9.3015; Denisenko ON, 1996, J BIOL CHEM, V271, P27701, DOI 10.1074/jbc.271.44.27701; FUMAGALLI S, 1994, NATURE, V368, P871, DOI 10.1038/368871a0; Fusaki N, 1997, J BIOL CHEM, V272, P6214, DOI 10.1074/jbc.272.10.6214; Harfmann AM, 1999, MOL BIOL CELL, V10, P3909, DOI 10.1091/mbc.10.11.3909; Huang YQ, 1999, EMBO J, V18, P1642, DOI 10.1093/emboj/18.6.1642; Ishidate T, 1997, FEBS LETT, V409, P237, DOI 10.1016/S0014-5793(97)00455-9; JONES AR, 1995, GENE DEV, V9, P1491, DOI 10.1101/gad.9.12.1491; Lee MH, 1996, J BIOL CHEM, V271, P3420; Lin Q, 1997, J BIOL CHEM, V272, P27274, DOI 10.1074/jbc.272.43.27274; MATUNIS MJ, 1992, MOL CELL BIOL, V12, P164, DOI 10.1128/MCB.12.1.164; McBride AE, 1998, EXP CELL RES, V241, P84, DOI 10.1006/excr.1998.4047; Miau LH, 1998, J BIOL CHEM, V273, P10784, DOI 10.1074/jbc.273.17.10784; Michael WM, 1997, EMBO J, V16, P3587, DOI 10.1093/emboj/16.12.3587; Michelotti EF, 1996, MOL CELL BIOL, V16, P2350, DOI 10.1128/mcb.16.5.2350; Reddy TR, 2000, ONCOGENE, V19, P4071, DOI 10.1038/sj.onc.1203749; Reddy TR, 2000, ONCOGENE, V19, P3570, DOI 10.1038/sj.onc.1203676; Reddy TR, 2000, ONCOGENE, V19, P3110, DOI 10.1038/sj.onc.1203637; Reddy TR, 1999, NAT MED, V5, P635, DOI 10.1038/9479; REICH E, 1962, P NATL ACAD SCI USA, V48, P1238, DOI 10.1073/pnas.48.7.1238; Renz A, 1996, NUCLEIC ACIDS RES, V24, P843, DOI 10.1093/nar/24.5.843; Resnick RJ, 1997, ONCOGENE, V15, P1247, DOI 10.1038/sj.onc.1201289; RICHARD S, 1995, MOL CELL BIOL, V15, P186, DOI 10.1128/MCB.15.1.186; Sambrook J., 1989, MOL CLONING LAB MANU, V2nd; Shnyreva M, 2000, J BIOL CHEM, V275, P15498, DOI 10.1074/jbc.275.20.15498; SIOMI H, 1994, CELL, V77, P33, DOI 10.1016/0092-8674(94)90232-1; SIOMI H, 1993, NUCLEIC ACIDS RES, V21, P1193, DOI 10.1093/nar/21.5.1193; TAYLOR SJ, 1995, J BIOL CHEM, V270, P10120, DOI 10.1074/jbc.270.17.10120; TAYLOR SJ, 1994, NATURE, V368, P867, DOI 10.1038/368867a0; TOMONAGA T, 1995, J BIOL CHEM, V270, P4875, DOI 10.1074/jbc.270.9.4875; VANSEUNINGEN I, 1995, BIOCHEMISTRY-US, V34, P5644, DOI 10.1021/bi00016a040; Weighardt F, 1999, J CELL SCI, V112, P1465; Westberg C, 2000, J BIOL CHEM, V275, P21396, DOI 10.1074/jbc.M909887199; Yang JP, 1999, ONCOGENE, V18, P5177, DOI 10.1038/sj.onc.1202904; Yang JP, 1999, J BIOL CHEM, V274, P15662, DOI 10.1074/jbc.274.22.15662	39	32	34	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 17	2002	21	47					7187	7194		10.1038/sj.onc.1205759	http://dx.doi.org/10.1038/sj.onc.1205759			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	602KN	12370808				2022-12-17	WOS:000178504600006
J	Gallagher, RCJ; Hay, T; Meniel, V; Naughton, C; Anderson, TJ; Shibata, H; Ito, M; Clevers, H; Noda, T; Sansom, OJ; Mason, JO; Clarke, AR				Gallagher, RCJ; Hay, T; Meniel, V; Naughton, C; Anderson, TJ; Shibata, H; Ito, M; Clevers, H; Noda, T; Sansom, OJ; Mason, JO; Clarke, AR			Inactivation of Apc perturbs mammary development, but only directly results in acanthoma in the context of Tcf-1 deficiency	ONCOGENE			English	Article						Apc; Tcf-1; mammary; acanthoma; cre	BETA-CATENIN; CYCLIN D1; BREAST-CANCER; GENE; EXPRESSION; GLAND; PROTEIN; TARGET; TUMORIGENESIS; HYPERPLASIA	Apc (adenomatous polyposis colt) encodes a tumour suppressor gene that is mutated in the majority of colorectal cancers. Recent evidence has also implicated Apc mutations in the aetiology of breast tumours. Ape is a component of the canonical Wnt signal transduction pathway, of which one target is Tcf-1. In the mouse, mutations of both Ape and Tcf-1 have been implicated in mammary tumorigenesis. We have conditionally inactivated Apc in both the presence and absence of Tcf-1 to examine the function of these genes in both normal and neoplastic development. Mice harbouring mammary-specific mutations in Apc show markedly delayed development of the mammary ductal network. During lactation, the mice develop multiple metaplastic growths which, surprisingly, do not spontaneously progress to neoplasia up to a year following their induction. However, additional deficiency of Tcf-1 completely blocks normal mammary development and results in acanthoma.	Cardiff Univ, Dept Biol Sci, Cardiff CF10 3US, S Glam, Wales; Univ Edinburgh, Sch Med, Dept Biomed Sci, Edinburgh EH8 9AG, Midlothian, Scotland; Univ Edinburgh, Sch Med, Dept Pathol, Edinburgh EH8 9AG, Midlothian, Scotland; Inst Canc Res, Dept Cell Biol, Toshima Ku, Tokyo 170, Japan; Univ Med Ctr, Ctr Biomed Genet, Utrecht, Netherlands; Univ Med Ctr, Dept Immunol, Utrecht, Netherlands	Cardiff University; University of Edinburgh; University of Edinburgh; Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center	Clarke, AR (corresponding author), Cardiff Univ, Dept Biol Sci, Cardiff CF10 3US, S Glam, Wales.	ClarkeAR@cf.ac.uk	Clarke, Alan R/A-6256-2008; Mason, John O/A-1926-2010; clarke, alan r/P-2820-2014; Noda, Tetsuo/B-1667-2016	Mason, John O/0000-0002-0489-2400; Naughton, Catherine/0000-0002-9576-5983; Sansom, Owen J./0000-0001-9540-3010; Clarke, Alan/0000-0002-4281-426X	Biotechnology and Biological Sciences Research Council [G06054] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		Bienz M, 2000, CELL, V103, P311, DOI 10.1016/S0092-8674(00)00122-7; BRADBURY JM, 1995, DEV BIOL, V170, P553, DOI 10.1006/dbio.1995.1236; Brisken C, 1998, P NATL ACAD SCI USA, V95, P5076, DOI 10.1073/pnas.95.9.5076; Brisken C, 2000, GENE DEV, V14, P650; Bukholm IK, 2000, J PATHOL, V190, P15; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; Callahan R, 2000, ONCOGENE, V19, P992, DOI 10.1038/sj.onc.1203276; Cardiff RD, 2000, ONCOGENE, V19, P968, DOI 10.1038/sj.onc.1203277; Chapman RS, 1999, GENE DEV, V13, P2604, DOI 10.1101/gad.13.19.2604; EDWARDS PAW, 1992, ONCOGENE, V7, P2041; Fearnhead NS, 2001, HUM MOL GENET, V10, P721, DOI 10.1093/hmg/10.7.721; Furuuchi K, 2000, AM J PATHOL, V156, P1997, DOI 10.1016/S0002-9440(10)65072-9; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; GU H, 1994, SCIENCE, V265, P103, DOI 10.1126/science.8016642; Guger KA, 2000, DEV BIOL, V223, P441, DOI 10.1006/dbio.2000.9770; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; He TC, 1999, CELL, V99, P335, DOI 10.1016/S0092-8674(00)81664-5; Ho KYK, 1999, HISTOPATHOLOGY, V35, P249; Imbert A, 2001, J CELL BIOL, V153, P555, DOI 10.1083/jcb.153.3.555; Ishitani T, 1999, NATURE, V399, P798, DOI 10.1038/21674; Jin Z, 2001, BRIT J CANCER, V85, P69, DOI 10.1054/bjoc.2001.1853; KASHIWABA M, 1994, J CANCER RES CLIN, V120, P727, DOI 10.1007/BF01194271; Kordon EC, 1998, DEVELOPMENT, V125, P1921; Lane TF, 1997, ONCOGENE, V15, P2133, DOI 10.1038/sj.onc.1201593; Lin SY, 2000, P NATL ACAD SCI USA, V97, P4262, DOI 10.1073/pnas.060025397; Michaelson JS, 2001, ONCOGENE, V20, P5093, DOI 10.1038/sj.onc.1204586; Midgley CA, 1997, J PATHOL, V181, P426; Miyoshi K, 2002, P NATL ACAD SCI USA, V99, P219, DOI 10.1073/pnas.012414099; MOSER AR, 1995, DEV DYNAM, V203, P422, DOI 10.1002/aja.1002030405; MOSER AR, 1993, P NATL ACAD SCI USA, V90, P8977, DOI 10.1073/pnas.90.19.8977; Moser AR, 2001, CANCER RES, V61, P3480; Nathke IS, 1996, J CELL BIOL, V134, P165, DOI 10.1083/jcb.134.1.165; NUSSE R, 1982, CELL, V31, P99, DOI 10.1016/0092-8674(82)90409-3; Polakis P, 2000, GENE DEV, V14, P1837; Pollack AL, 1997, J CELL BIOL, V137, P1651, DOI 10.1083/jcb.137.7.1651; Roose J, 1999, BBA-REV CANCER, V1424, pM23, DOI 10.1016/S0304-419X(99)00026-8; Roose J, 1998, NATURE, V395, P608, DOI 10.1038/26989; Roose J, 1999, SCIENCE, V285, P1923, DOI 10.1126/science.285.5435.1923; Schlosshauer PW, 2000, CARCINOGENESIS, V21, P1453, DOI 10.1093/carcin/21.7.1453; Selbert S, 1998, TRANSGENIC RES, V7, P387, DOI 10.1023/A:1008848304391; Shibata H, 1997, SCIENCE, V278, P120, DOI 10.1126/science.278.5335.120; Shimizu H, 1997, CELL GROWTH DIFFER, V8, P1349; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Smits R, 1999, GENE DEV, V13, P1309, DOI 10.1101/gad.13.10.1309; Soriano P, 1999, NAT GENET, V21, P70, DOI 10.1038/5007; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; THOMPSON AM, 1993, BRIT J CANCER, V68, P64, DOI 10.1038/bjc.1993.287; TSUKAMOTO AS, 1988, CELL, V55, P619, DOI 10.1016/0092-8674(88)90220-6; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; Woodage T, 1998, NAT GENET, V20, P62, DOI 10.1038/1722; Yu QY, 2001, NATURE, V411, P1017, DOI 10.1038/35082500	51	32	34	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 19	2002	21	42					6446	6457		10.1038/sj.onc.1205892	http://dx.doi.org/10.1038/sj.onc.1205892			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	592FD	12226748				2022-12-17	WOS:000177925300005
J	Malanchi, I; Caldeira, S; Krutzfeldt, M; Giarre, M; Alunni-Fabbroni, M; Tommasino, M				Malanchi, I; Caldeira, S; Krutzfeldt, M; Giarre, M; Alunni-Fabbroni, M; Tommasino, M			Identification of a novel activity of human papillomavirus type 16 E6 protein in deregulating the G1/S transition	ONCOGENE			English	Article						HPV; E6; G1/S transition	CELL-CYCLE REGULATION; RETINOBLASTOMA-PROTEIN; E7 ONCOPROTEIN; INHIBITOR P27(KIP1); GROWTH ARREST; GENE-PRODUCT; S-PHASE; C-MYC; BINDING; PATHWAY	In this study we show that E6 of human papillomavirus has the ability to deregulate the cell cycle G1/S transition. In rodent immortalized fibroblasts (NIH3T3) serum deprivation or over-expression of the cyclin-dependent kinase inhibitors, p16(INK4a) or p27(KIP1), leads to G1 cell cycle arrest. HPV16 E6 overcomes the antiproliferative signals, gaining the ability to drive serum-deprived and p16(INK4a) or p27(KIP1) over-expressing cells into S phase. E6 protein from the benign HPV type 1 displays a similar activity to HPV16 E6 to deregulate the G1/S transition. Thus, this activity appears to be conserved between E6 proteins from non-oncogenic and oncogenic HPV types. Furthermore, we show that HPV16 E6 is not able to circumvent a G1 arrest imposed by pRb mutant in which all CDK phosphorylation sites have been mutated. These data indicate that the viral protein acts upstream of pRb and its mechanism in promoting cell cycle progression is dependent on pRb phosphorylation. In summary, this study describes a novel biological function of HPV E6 and shows that the S phase entry, required for viral DNA replication, is not exclusively controlled by E7, but that E6 also is involved in this event.	Deutsch Krebsforschungszentrum, Angew Tumorvirol, D-69120 Heidelberg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ)	Tommasino, M (corresponding author), Deutsch Krebsforschungszentrum, Angew Tumorvirol, INF 242, D-69120 Heidelberg, Germany.		Caldeira, Sandra/Y-3652-2019	Caldeira, Sandra/0000-0002-6057-5979				Alevizopoulos K, 1997, EMBO J, V16, P5322, DOI 10.1093/emboj/16.17.5322; Alunni-Fabbroni M, 2000, ONCOGENE, V19, P2277, DOI 10.1038/sj.onc.1203570; Botz J, 1996, MOL CELL BIOL, V16, P3401; Boyer SN, 1996, CANCER RES, V56, P4620; Caldeira S, 2000, ONCOGENE, V19, P821, DOI 10.1038/sj.onc.1203375; CICCOLINI F, 1994, ONCOGENE, V9, P2342; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; Elbel M, 1997, VIROLOGY, V239, P132, DOI 10.1006/viro.1997.8860; GAGE JR, 1990, J VIROL, V64, P723, DOI 10.1128/JVI.64.2.723-730.1990; Giarre M, 2001, J VIROL, V75, P4705, DOI 10.1128/JVI.75.10.4705-4712.2001; Jones DL, 1997, J VIROL, V71, P2905, DOI 10.1128/JVI.71.4.2905-2912.1997; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; Lukas J, 1997, GENE DEV, V11, P1479, DOI 10.1101/gad.11.11.1479; Mann DJ, 1996, CURR BIOL, V6, P474, DOI 10.1016/S0960-9822(02)00515-8; Martin LG, 1998, J VIROL, V72, P975, DOI 10.1128/JVI.72.2.975-985.1998; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Morris EJ, 2001, ADV CANCER RES, V82, P1, DOI 10.1016/S0065-230X(01)82001-7; MUNGER K, 1989, EMBO J, V8, P4099, DOI 10.1002/j.1460-2075.1989.tb08594.x; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; SCHMITT A, 1994, J VIROL, V68, P7051, DOI 10.1128/JVI.68.11.7051-7059.1994; SCHULZE A, 1995, P NATL ACAD SCI USA, V92, P11264, DOI 10.1073/pnas.92.24.11264; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Thomas M, 1999, ONCOGENE, V18, P7690, DOI 10.1038/sj.onc.1202953; TOMMASINO M, 1997, E7 PROTEIN HUMAN PAP; Vlach J, 1996, EMBO J, V15, P6595, DOI 10.1002/j.1460-2075.1996.tb01050.x; ZERFASS K, 1995, J VIROL, V69, P6389, DOI 10.1128/JVI.69.10.6389-6399.1995; ZerfassThome K, 1996, ONCOGENE, V13, P2323; zur Hausen H, 2000, JNCI-J NATL CANCER I, V92, P690, DOI 10.1093/jnci/92.9.690; Zwerschke W, 2000, ADV CANCER RES, V78, P1	30	32	32	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 22	2002	21	37					5665	5672		10.1038/sj.onc.1205617	http://dx.doi.org/10.1038/sj.onc.1205617			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	584JL	12173036				2022-12-17	WOS:000177463400001
J	Srivatsan, ES; Chakrabarti, R; Zainabadi, K; Pack, SD; Benyamini, P; Mendonca, MS; Yang, PK; Kang, K; Motamedi, D; Sawicki, MP; Zhuang, ZP; Jesudasan, RA; Bengtsson, U; Sun, C; Roe, BA; Stanbridge, EJ; Wilczynski, SP; Redpath, JL				Srivatsan, ES; Chakrabarti, R; Zainabadi, K; Pack, SD; Benyamini, P; Mendonca, MS; Yang, PK; Kang, K; Motamedi, D; Sawicki, MP; Zhuang, ZP; Jesudasan, RA; Bengtsson, U; Sun, C; Roe, BA; Stanbridge, EJ; Wilczynski, SP; Redpath, JL			Localization of deletion to a 300 Kb interval of chromosome 11q13 in cervical cancer	ONCOGENE			English	Article						cervical cancer; tumor suppressor gene; chromosome 11q13; loss of heterozygosity; fluorescence in situ hybridization; homozygous deletion	TUMOR-SUPPRESSOR GENE; CARCINOMA CELL-LINES; HELA-CELLS; FRAGILE SITE; HOMOZYGOUS DELETIONS; ENDOCRINE TUMORS; UTERINE CERVIX; BAND 11Q13; FHIT GENE; MEN1	Previous molecular genetic studies on HeLa cell (a cervical cancer cell line) derived non-tumorigenic and tumorigenic hybrids have localized a tumor suppressor gene to the long arm of chromosome 11. Analysis of cervical cancer cell lines using chromosome 11 specific probes showed deletion and translocation of 11q13 sequences in five out of eight cell lines. Fluorescence in situ hybridization (FISH), using 11q13 specific probes, has shown interstitial deletion of 11q13 sequences in the HeLa cells. In order to determine whether 11q13 deletions occur in primary cervical tumors, we analysed 36 tumors using 20 different microsatellite and RFLP markers. Semi automated fluorescein based allelotyping was performed to identify loss of heterozygosity (LOH) in tumors. The results showed allelic loss in 17 (47%) tumors. Three different regions of loss, one near MEN1, the second near D11S913, and the third near INT2 locus were observed. The smallest region of deletion overlap at the D11S913 locus was localized to a 300 Kb distance between D11S4908 and D11S5023. Fluorescence in situ hybridization (FISH), using 11q13 specific cosmid and BAC (bacterial artificial chromosome) probes, confirmed allelic deletion in the tumors. PCR analysis further identified homozygous deletion of 11q13 sequences in a primary tumor, in HeLa cells and in two HeLa cell derived tumorigenic hybrid cell lines. The homozygous deletion in the cell lines was mapped to a 5.7 kb sequence of 11q13. We hypothesize therefore that a putative cervical cancer tumor suppressor gene exists within the 300 kb of chromosome 11q13.	Univ Calif Los Angeles, Sch Med, VAGLAHS, Dept Surg, Los Angeles, CA 90073 USA; Natl Inst Neurol Disorders & Stroke, Surg Neurol Branch, NIH, Bethesda, MD 20892 USA; Indiana Univ, Sch Med, Dept Radiat Oncol, Indianapolis, IN 46202 USA; Univ Calif Irvine, Calif Coll Med, Dept Radiat Oncol, Irvine, CA 92697 USA; Univ Oklahoma, Dept Chem & Biochem, Norman, OK 73019 USA; Univ Calif Irvine, Calif Coll Med, Dept Microbiol & Mol Genet, Irvine, CA 92697 USA; City Hope Natl Med Ctr, Dept Anat Pathol, Duarte, CA 91010 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); Indiana University System; Indiana University-Purdue University Indianapolis; University of California System; University of California Irvine; University of Oklahoma System; University of Oklahoma - Norman; University of California System; University of California Irvine; City of Hope	Srivatsan, ES (corresponding author), Univ Calif Los Angeles, Sch Med, VAGLAHS, Dept Surg, 10H2,11301 Wilshire Blvd, Los Angeles, CA 90073 USA.	esrivats@ucla.edu	Jesudasan, Rachel/AHE-4743-2022; Pack, Svetlana D./C-2020-2014	Jesudasan, Rachel/0000-0001-9459-832X; Pack, Svetlana D./0000-0003-3256-6626	NCI NIH HHS [CA39312, CA19401] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA039312, R55CA039312, R37CA019401, R01CA019401] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [Z01NS002991] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Allen DG, 2000, BRIT J CANCER, V83, P1659, DOI 10.1054/bjoc.2000.1509; ATKIN NB, 1990, CANCER GENET CYTOGEN, V44, P229, DOI 10.1016/0165-4608(90)90052-C; Bednarek AK, 2001, CANCER RES, V61, P8068; Boldog F, 1997, HUM MOL GENET, V6, P193, DOI 10.1093/hmg/6.2.193; Chakrabarti R, 1998, GENE CHROMOSOME CANC, V22, P130, DOI 10.1002/(SICI)1098-2264(199806)22:2<130::AID-GCC7>3.0.CO;2-Y; Chandrasekharappa SC, 1997, SCIENCE, V276, P404, DOI 10.1126/science.276.5311.404; Cheng Y, 2002, GENE CHROMOSOME CANC, V34, P97, DOI 10.1002/gcc.10048; Coquelle A, 1997, CELL, V89, P215, DOI 10.1016/S0092-8674(00)80201-9; Courseaux A, 1996, GENOMICS, V37, P354, DOI 10.1006/geno.1996.0570; Greenspan DL, 1997, CANCER RES, V57, P4692; Guo ZM, 1998, ANTICANCER RES, V18, P707; Guru SC, 1997, GENOMICS, V42, P436, DOI 10.1006/geno.1997.4783; HAMPTON GM, 1994, P NATL ACAD SCI USA, V91, P6953, DOI 10.1073/pnas.91.15.6953; HAUSEN HZ, 1991, VIROLOGY, V184, P9, DOI 10.1016/0042-6822(91)90816-T; Heselmeyer K, 1997, GENE CHROMOSOME CANC, V19, P233, DOI 10.1002/(SICI)1098-2264(199708)19:4<233::AID-GCC5>3.0.CO;2-Y; Heselmeyer K, 1996, P NATL ACAD SCI USA, V93, P479, DOI 10.1073/pnas.93.1.479; Horikawa I, 1995, CANCER GENET CYTOGEN, V85, P97, DOI 10.1016/0165-4608(95)00147-6; Ishii H, 2001, CANCER RES, V61, P1578; JESUDASAN RA, 1995, AM J HUM GENET, V56, P705; JESUDASAN RA, 1994, ANTICANCER RES, V14, P1727; KOI M, 1989, MOL CARCINOGEN, V2, P12, DOI 10.1002/mc.2940020103; Landis SH, 1998, CA-CANCER J CLIN, V48, P6, DOI 10.3322/canjclin.48.1.6; Liaw KL, 1999, J NATL CANCER I, V91, P954, DOI 10.1093/jnci/91.11.954; Macville M, 1999, CANCER RES, V59, P141; Mao L, 1998, J NATL CANCER I, V90, P412, DOI 10.1093/jnci/90.6.412; MISRA BC, 1989, AM J HUM GENET, V45, P565; MITRA AB, 1994, CANCER RES, V54, P4481; MONK BJ, 1994, DIAGN MOL PATHOL, V3, P283, DOI 10.1097/00019606-199412000-00012; Muliokandov MR, 1996, CANCER RES, V56, P197; OCADIZ R, 1987, CANCER RES, V47, P4173; Ohta M, 1996, CELL, V84, P587, DOI 10.1016/S0092-8674(00)81034-X; Panagopoulos I, 1997, GENE CHROMOSOME CANC, V19, P215, DOI 10.1002/(SICI)1098-2264(199708)19:4<215::AID-GCC2>3.0.CO;2-#; Perucca-Lostanlen D, 1997, CYTOGENET CELL GENET, V79, P88, DOI 10.1159/000134689; Prezant TR, 1998, J CLIN ENDOCR METAB, V83, P1388, DOI 10.1210/jc.83.4.1388; Pulido HA, 2000, CANCER RES, V60, P6677; Ramesh R, 2001, MOL THER, V3, P337, DOI 10.1006/mthe.2001.0266; Richards RI, 2001, TRENDS GENET, V17, P339, DOI 10.1016/S0168-9525(01)02303-4; Ried K, 2000, HUM MOL GENET, V9, P1651, DOI 10.1093/hmg/9.11.1651; RIOU G, 1988, ONCOGENE, V3, P329; SAXON PJ, 1986, EMBO J, V5, P3461, DOI 10.1002/j.1460-2075.1986.tb04670.x; Shuster MI, 2000, GENE CHROMOSOME CANC, V28, P153, DOI 10.1002/(SICI)1098-2264(200006)28:2<153::AID-GCC4>3.0.CO;2-9; SIPRASHVILI Z, 1997, CANCER RES, V57, P5207; Sozzi G, 1997, CANCER RES, V57, P5207; SREEKANTAIAH C, 1987, GYNECOL ONCOL, V28, P337, DOI 10.1016/0090-8258(87)90181-8; SRIVATSAN ES, 1993, GENE CHROMOSOME CANC, V7, P32, DOI 10.1002/gcc.2870070106; SRIVATSAN ES, 1991, AM J HUM GENET, V49, P868; Srivatsan ES, 2000, GENE CHROMOSOME CANC, V29, P157, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1024>3.0.CO;2-P; STANBRIDGE EJ, 1976, NATURE, V260, P17, DOI 10.1038/260017a0; STOLER MH, 1992, HUM PATHOL, V23, P117, DOI 10.1016/0046-8177(92)90232-R; Tanaka C, 1998, J CLIN ENDOCR METAB, V83, P2631, DOI 10.1210/jc.83.8.2631; Venugopalan M, 1998, CANCER GENET CYTOGEN, V104, P124, DOI 10.1016/S0165-4608(97)00461-5; Wang EH, 1998, CANCER RES, V58, P4417; Wood TF, 1996, GENOMICS, V38, P166, DOI 10.1006/geno.1996.0612; Zhuang ZP, 1997, CANCER RES, V57, P4682; ZHUANG ZP, 1995, CANCER RES, V55, P467	55	32	33	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 15	2002	21	36					5631	5642		10.1038/sj.onc.1205698	http://dx.doi.org/10.1038/sj.onc.1205698			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	583ZM	12165862				2022-12-17	WOS:000177442000013
J	Kim, SS; Chae, HS; Bach, JH; Lee, MW; Kim, KY; Lee, WB; Jung, YM; Bonventre, JV; Suh, YH				Kim, SS; Chae, HS; Bach, JH; Lee, MW; Kim, KY; Lee, WB; Jung, YM; Bonventre, JV; Suh, YH			P53 mediates ceramide-induced apoptosis in SKN-SH cells	ONCOGENE			English	Article						p53; apoptosis; ceramide; Bcl-2; Bax; caspase	PC12 CELLS; FACTOR WITHDRAWAL; NEURONAL DEATH; BCL-2; BAX; ACTIVATION; PROTEIN; DISTINCT; PATHWAY; HETERODIMERIZES	Ceramide induces apoptotic cell death in a dose- and time-dependent manner in neuroblastoma SKN-SH cells. Pretreatment with caspase inhibitors blocks cell death, suggesting that a set of caspase activities including caspase 1, as well as caspase 3, are involved in ceramide-induced apoptosis in SKN-SH cells. Treatment with a caspase inhibitor 3 h after ceramide addition did not inhibit cell death, although caspase activity was substantially reduced. Ceramide-induced apoptosis is accompanied by accumulation of p53 followed by an increase of Bax and decrease of Bcl-2 levels. Inhibition of p53 expression with p53 antisense oligonucleotides inhibits apoptosis and prevents the increase in Bax and decrease in Bcl-2. Furthermore, pretreatment with p53 antisense oligonucleotides markedly inhibits the induction of caspase activity. These results suggest that p53 regulates the ratio Bcl-2/Bax and the expression/activation of caspases during ceramide-induced apoptosis in SKN-SH cells. Caspase inhibition did not alter the expression of p53, Bcl-2 and Bax. Thus ceramide-induced reduction in the Bcl-2/Bax ratio, increase in caspase activity, and apoptosis is dependent upon increases in cellular p53 levels which play a critical role in the regulation of apoptotic cell death.	Chung Ang Univ, Coll Med, Dept Anat, BioGrand Inc,MRC, Seoul 156756, South Korea; NIH, Biomed Brain Res Ctr, Seoul 122701, South Korea; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA; Seoul Natl Univ, Coll Med, Dept Pharmacol,Neurosci Res Inst,MRC, Natl Creat Res Initiat Ctr Alzheimers Dementia, Seoul 110799, South Korea	Chung Ang University; Chung Ang University Hospital; Korea Centers for Disease Control & Prevention (KCDC); Korea National Institute of Health (KNIH); Harvard University; Harvard Medical School; Seoul National University (SNU)	Bonventre, JV (corresponding author), Massachusetts Gen Hosp E, Suite 4002,149 13th St, Charlestown, MA 02129 USA.	joseph_bonventre@hms.harvard.edu	Suh, Yoo-Hun/J-2761-2012		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK039773, P01DK038452, R01DK039773] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS010828, P50NS010828] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK38452, DK39773] Funding Source: Medline; NINDS NIH HHS [NS10828] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Ali ST, 1997, BIOCHEM J, V325, P321, DOI 10.1042/bj3250321; Allouche M, 1997, ONCOGENE, V14, P1837, DOI 10.1038/sj.onc.1201023; Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; Anjum R, 1998, FEBS LETT, V439, P81, DOI 10.1016/S0014-5793(98)01343-X; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brugg B, 1996, J NEUROCHEM, V66, P733; Choisy-Rossi C, 1998, TOXICOL LETT, V103, P491, DOI 10.1016/S0378-4274(98)00238-0; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; Dbaibo GS, 1998, J CLIN INVEST, V102, P329, DOI 10.1172/JCI1180; EIZENBERG O, 1995, EMBO J, V14, P1136, DOI 10.1002/j.1460-2075.1995.tb07097.x; El-Assaad W, 1998, BIOCHEM J, V336, P735, DOI 10.1042/bj3360735; FranceLanord V, 1997, J NEUROCHEM, V69, P1612; Friedlander RM, 1997, J EXP MED, V185, P933, DOI 10.1084/jem.185.5.933; GRAEBER TG, 1994, MOL CELL BIOL, V14, P6264, DOI 10.1128/MCB.14.9.6264; Han JH, 1996, GENE DEV, V10, P461, DOI 10.1101/gad.10.4.461; Hartfield PJ, 1998, J NEUROCHEM, V71, P161; Hartfield PJ, 1997, FEBS LETT, V401, P148, DOI 10.1016/S0014-5793(96)01460-3; Haupt Y, 1996, EMBO J, V15, P1596, DOI 10.1002/j.1460-2075.1996.tb00504.x; JOHNSON EM, 1993, ANNU REV NEUROSCI, V16, P31, DOI 10.1146/annurev.ne.16.030193.000335; Kim SS, 1997, BIOCHEM BIOPH RES CO, V237, P583, DOI 10.1006/bbrc.1997.7133; KNUDSON CM, 1995, SCIENCE, V270, P96, DOI 10.1126/science.270.5233.96; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lightle SA, 2000, MECH AGEING DEV, V120, P111, DOI 10.1016/S0047-6374(00)00191-3; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; Mathias S, 1998, BIOCHEM J, V335, P465, DOI 10.1042/bj3350465; MESNER PW, 1992, J CELL BIOL, V119, P1669, DOI 10.1083/jcb.119.6.1669; Mizushima N, 1996, FEBS LETT, V395, P267, DOI 10.1016/0014-5793(96)01050-2; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; SEDLAK TW, 1995, P NATL ACAD SCI USA, V92, P7834, DOI 10.1073/pnas.92.17.7834; SELVAKUMARAN M, 1994, ONCOGENE, V9, P1791; Thornberry NA, 1997, BRIT MED BULL, V53, P478; Venable ME, 1995, J BIOL CHEM, V270, P30701, DOI 10.1074/jbc.270.51.30701; Wieder T, 1997, FEBS LETT, V411, P260, DOI 10.1016/S0014-5793(97)00717-5; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; Zha HB, 1996, J BIOL CHEM, V271, P7440, DOI 10.1074/jbc.271.13.7440; Zhang JD, 1996, P NATL ACAD SCI USA, V93, P5325, DOI 10.1073/pnas.93.11.5325	38	32	42	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 21	2002	21	13					2020	2028	PII 10.1038/sj/onc/1205037	10.1038/sj.onc.1205037	http://dx.doi.org/10.1038/sj.onc.1205037			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	538QR	11960374				2022-12-17	WOS:000174827000008
J	Huang, JM; Kirk, B; Favis, R; Soussi, T; Paty, P; Cao, WG; Barany, F				Huang, JM; Kirk, B; Favis, R; Soussi, T; Paty, P; Cao, WG; Barany, F			An endonuclease/ligase based mutation scanning method especially suited for analysis of neoplastic tissue	ONCOGENE			English	Article						mutation detection; endonuclease V; thermostable ligase; mismatch recognition	SINGLE-NUCLEOTIDE POLYMORPHISMS; DEOXYINOSINE-SPECIFIC ENDONUCLEASE; ENZYME MISMATCH CLEAVAGE; HIPPEL-LINDAU-DISEASE; RAS POINT MUTATIONS; K-RAS; GERMLINE MUTATIONS; CARRIER FREQUENCY; CHEMICAL CLEAVAGE; SENSITIVE METHOD	Knowledge of inherited and sporadic mutations in known and candidate cancer genes may influence clinical decisions. We have developed a mutation scanning method that combines thermostable EndonucleaseV (Endo V) and DNA ligase. Variant and wild-type PCR amplicons are generated using fluorescently labeled primers, and heteroduplexed. Thermotoga maritima (Tma) EndoV recognizes and primarily cleaves heteroduplex DNA one base 3' to the mismatch, as well as nicking matched DNA at low levels. Thermus species (Tsp.) AK16D DNA ligase reseals the background nicks to create a highly sensitive and specific assay. The fragment mobility on a DNA sequencing gel reveals the approximate position of the mutation. This method identified 31/35 and 8/8 unique point mutations and insertions/deletions, respectively, in the p53, VHL, K-ras, APC, BRCA1, and BRCA2 genes. The method has the sensitivity to detect K-ras mutations diluted 1 :20 with wildtype DNA, a p53 mutation in a 1.7 kb amplicon, and unknown p53 mutations in pooled DNA samples. EndoV/Ligase mutation scanning combined with PCR/LDR/Universal array proved superior to automated DNA sequencing for detecting p53 mutations in colon tumors. This technique is well suited for scanning low-frequency mutations in pooled samples and for analysing tumor DNA containing a minority of the unknown mutation.	Cornell Univ, Joan & Sanford I Weill Med Coll, Strang Canc Prevent Ctr, Hearst Microbiol Res Ctr,Dept Microbiol, New York, NY 10021 USA; Inst Curie, Lab Genotoxicol Tumeurs, F-75248 Paris, France; Mem Sloan Kettering Canc Ctr, Dept Surg, Colorectal Serv, New York, NY 10021 USA	Cornell University; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Memorial Sloan Kettering Cancer Center	Barany, F (corresponding author), Cornell Univ, Joan & Sanford I Weill Med Coll, Strang Canc Prevent Ctr, Hearst Microbiol Res Ctr,Dept Microbiol, Box 62,Room B-406,1300 York Ave, New York, NY 10021 USA.	barany@med.cornell.edu		soussi, thierry/0000-0001-8184-3293	NATIONAL CANCER INSTITUTE [R01CA081467, P01CA065930] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA81467, P01-CA65930] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abeliovich D, 1997, AM J HUM GENET, V60, P505; Ahrendt SA, 1999, P NATL ACAD SCI USA, V96, P7382, DOI 10.1073/pnas.96.13.7382; Aurelio ON, 1998, CANCER RES, V58, P2190; Aurelio ON, 2000, MOL CELL BIOL, V20, P770, DOI 10.1128/MCB.20.3.770-778.2000; Beller U, 1997, GYNECOL ONCOL, V67, P123, DOI 10.1006/gyno.1997.4844; Berman DB, 1996, CANCER RES, V56, P3409; Broll R, 1999, EUR J CANCER, V35, P1083, DOI 10.1016/S0959-8049(99)00058-1; Bunz F, 1999, J CLIN INVEST, V104, P263, DOI 10.1172/JCI6863; Cargill M, 1999, NAT GENET, V22, P231, DOI 10.1038/10290; Chen F, 1996, J MED GENET, V33, P716, DOI 10.1136/jmg.33.8.716; CHEN J, 1994, ENV HLTH PERSPECT, V3, P227; COTTON RGH, 1988, P NATL ACAD SCI USA, V85, P4397, DOI 10.1073/pnas.85.12.4397; DAMERON KM, 1994, SCIENCE, V265, P1582, DOI 10.1126/science.7521539; Fahy E, 1997, NUCLEIC ACIDS RES, V25, P3102, DOI 10.1093/nar/25.15.3102; Favis R, 2000, NAT BIOTECHNOL, V18, P561, DOI 10.1038/75452; FODDE R, 1994, HUM MUTAT, V3, P83, DOI 10.1002/humu.1380030202; Foster BA, 1999, SCIENCE, V286, P2507, DOI 10.1126/science.286.5449.2507; Gerry NP, 1999, J MOL BIOL, V292, P251, DOI 10.1006/jmbi.1999.3063; Giunta C, 1996, DIAGN MOL PATHOL, V5, P265, DOI 10.1097/00019606-199612000-00007; GULDBERG P, 1994, NUCLEIC ACIDS RES, V22, P880, DOI 10.1093/nar/22.5.880; Hacia JG, 1999, NAT GENET, V21, P42, DOI 10.1038/4469; Hacia JG, 1996, NAT GENET, V14, P441, DOI 10.1038/ng1296-441; Halushka MK, 1999, NAT GENET, V22, P239, DOI 10.1038/10297; Hansen Lise Lotte, 1995, P275; HARIS II, 1994, PCR METH APPL, V3, P268; Hayashi K, 1991, PCR Methods Appl, V1, P34; Heide I, 1997, EUR J CANCER, V33, P1314, DOI 10.1016/S0959-8049(97)00118-4; Henke W, 1997, NUCLEIC ACIDS RES, V25, P3957, DOI 10.1093/nar/25.19.3957; Huang JM, 2001, BIOCHEMISTRY-US, V40, P8738, DOI 10.1021/bi010183h; INNIS MA, 1988, P NATL ACAD SCI USA, V85, P9436, DOI 10.1073/pnas.85.24.9436; Khanna M, 1999, ONCOGENE, V18, P27, DOI 10.1038/sj.onc.1202291; KHRAPKO K, 1994, NUCLEIC ACIDS RES, V22, P364, DOI 10.1093/nar/22.3.364; KORN SH, 1993, J CLIN PATHOL, V46, P621, DOI 10.1136/jcp.46.7.621; Laken SJ, 1997, NAT GENET, V17, P79, DOI 10.1038/ng0997-79; Libutti SK, 2000, SURGERY, V128, P1022, DOI 10.1067/msy.2000.110239; Liu J, 2000, MUTAT RES-DNA REPAIR, V461, P169, DOI 10.1016/S0921-8777(00)00054-9; LIU Q, 1995, BIOTECHNIQUES, V18, P470; Makino R, 1992, PCR Methods Appl, V2, P10; Mohr VH, 2000, AM J PATHOL, V157, P1615, DOI 10.1016/S0002-9440(10)64799-2; MYERS RM, 1985, SCIENCE, V230, P1242, DOI 10.1126/science.4071043; Oddoux C, 1996, NAT GENET, V14, P188, DOI 10.1038/ng1096-188; Oleykowski CA, 1998, NUCLEIC ACIDS RES, V26, P4597, DOI 10.1093/nar/26.20.4597; PERUCHO M, 1989, CANCER CEL, V7, P137; POMP D, 1991, BIOTECHNIQUES, V10, P58; Prives C, 1999, J PATHOL, V187, P112; REES WA, 1993, BIOCHEMISTRY-US, V32, P137, DOI 10.1021/bi00052a019; RIDANPAA M, 1993, HUM MOL GENET, V2, P639, DOI 10.1093/hmg/2.6.639; RIDANPAA M, 1995, MUTAT RES-ENVIR MUTA, V334, P357, DOI 10.1016/0165-1161(95)90073-X; Risch N, 1996, SCIENCE, V273, P1516, DOI 10.1126/science.273.5281.1516; Roa BB, 1996, NAT GENET, V14, P185, DOI 10.1038/ng1096-185; SARKAR G, 1992, GENOMICS, V13, P441, DOI 10.1016/0888-7543(92)90266-U; Sgambati MT, 2000, AM J HUM GENET, V66, P84, DOI 10.1086/302726; Soussi T, 2001, NAT REV CANCER, V1, P233, DOI 10.1038/35106009; Stephens JC, 2001, SCIENCE, V293, P489, DOI 10.1126/science.1059431; Stolle C, 1998, HUM MUTAT, V12, P417, DOI 10.1002/(SICI)1098-1004(1998)12:6<417::AID-HUMU8>3.0.CO;2-K; STRUEWING JP, 1995, NAT GENET, V11, P198, DOI 10.1038/ng1095-198; Struewing JP, 1997, NEW ENGL J MED, V336, P1401, DOI 10.1056/NEJM199705153362001; SUZUKI Y, 1990, ONCOGENE, V5, P1037; TABOR S, 1995, P NATL ACAD SCI USA, V92, P6339, DOI 10.1073/pnas.92.14.6339; Taylor GR, 1999, ELECTROPHORESIS, V20, P1125, DOI 10.1002/(SICI)1522-2683(19990101)20:6<1125::AID-ELPS1125>3.0.CO;2-O; Thiagalingam S, 2001, P NATL ACAD SCI USA, V98, P2698, DOI 10.1073/pnas.051625398; Tong J, 1999, NUCLEIC ACIDS RES, V27, P788, DOI 10.1093/nar/27.3.788; Tortola S, 1999, J CLIN ONCOL, V17, P1375, DOI 10.1200/JCO.1999.17.5.1375; Underhill PA, 1996, P NATL ACAD SCI USA, V93, P196, DOI 10.1073/pnas.93.1.196; Walther MM, 1999, J UROLOGY, V162, P659, DOI 10.1097/00005392-199909010-00004; Wang DG, 1998, SCIENCE, V280, P1077, DOI 10.1126/science.280.5366.1077; Wang YC, 1998, ONCOGENE, V17, P1923, DOI 10.1038/sj.onc.1202113; Webley KM, 2000, J PATHOL, V191, P361; WINTER E, 1985, P NATL ACAD SCI USA, V82, P7575, DOI 10.1073/pnas.82.22.7575; Xu JF, 1996, CARCINOGENESIS, V17, P321; Yan H, 2000, NATURE, V403, P723, DOI 10.1038/35001659; YAO M, 1994, ANN NY ACAD SCI, V726, P315, DOI 10.1111/j.1749-6632.1994.tb52837.x; YAO M, 1994, J BIOL CHEM, V269, P31390; Yen H, 2000, SCIENCE, V289, P1890; YOUIL R, 1995, P NATL ACAD SCI USA, V92, P87, DOI 10.1073/pnas.92.1.87; Zirvi M, 1999, NUCLEIC ACIDS RES, V27, DOI 10.1093/nar/27.24.e40; Zou ZQ, 2000, J BIOL CHEM, V275, P6051, DOI 10.1074/jbc.275.9.6051	77	32	39	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 14	2002	21	12					1909	1921		10.1038/sj.onc.1205109	http://dx.doi.org/10.1038/sj.onc.1205109			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	529DJ	11896624				2022-12-17	WOS:000174284500014
J	Agazie, Y; Ischenko, I; Hayman, M				Agazie, Y; Ischenko, I; Hayman, M			Concomitant activation of the PI3K-Akt and the Ras-ERK signaling pathways is essential for transformation by the V-SEA tyrosine kinase oncogene	ONCOGENE			English	Article						V-SEA; oncogene; Ras-ERK; PI3K-Akt; transformation	AVIAN ERYTHROBLASTOSIS VIRUS; GROWTH-FACTOR RECEPTORS; PROTEIN-KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; MET RECEPTOR; PHOSPHOINOSITIDE 3-KINASE; CELL-TRANSFORMATION; CATALYTIC SUBUNIT; DOCKING SITE; MAP KINASE	V-SEA is the transforming component of S13 Avian Erythroblastosis Retrovirus that causes erythroblastosis and anemia in chicken. Like all members in the family (MET, RON, SEA), its cytosolic domain possesses two tyrosine autophosphorylation sites in the tandemly arranged bidentate motif that serve as docking sites for SH2 domain-containing proteins. Here, we investigated phosphotyrosine-dependent activation of signaling pathways and their significance in V-SEA-induced transformation and/or proliferation. We demonstrated that V-SEA activates the PI3K-Akt signaling pathway primarily in Y557- and secondarily in Y564-dependent manner. V-SEA was also shown to induce the tyrosine phosphorylation of the Gab2 protein, leading to PI3K association and thus providing an alternative route for PI3K activation. On the other hand, activation of the Ras-ERK pathway is primarily via Y564 and secondarily via Y557. A dominant-negative form of Ras inhibited V-SEA-induced ERK phosphorylation in concentration dependent manner suggesting the importance of the Grb2-Ras signaling axis in V-SEA-induced ERK activation. The biological significance of activation of the PI3K-Akt and the Ras-ERK pathways in V-SEA-induced transformation was analysed in the V-SEARATI and V-SEA-3T3 cell lines by employing specific inhibitors, LV294002 and PD98059 compounds. Both the PD and LY compounds inhibited cell growth, but only the PD compound caused reversion of the transformed phenotype. In addition, both compounds inhibited focal colony formation by the transformants in soft agar. Thus, transformation by the V-SEA oncogene is a function of the concomitant activation of, at least, the PI3K-Akt and Ras-ERK signaling pathways that regulate cell growth and morphology.	SUNY Stony Brook, Dept Mol Genet & Microbiol, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Hayman, M (corresponding author), SUNY Stony Brook, Dept Mol Genet & Microbiol, Stony Brook, NY 11794 USA.	mhayman@ms.cc.sunysb.edu						Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Anderson KE, 1998, CURR BIOL, V8, P684, DOI 10.1016/S0960-9822(98)70274-X; Anderson MJ, 1998, GENOMICS, V47, P187, DOI 10.1006/geno.1997.5122; Aoki M, 2000, J BIOL CHEM, V275, P6267, DOI 10.1074/jbc.275.9.6267; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; Bardelli A, 1999, ONCOGENE, V18, P1139, DOI 10.1038/sj.onc.1202607; Borlado LR, 2000, FASEB J, V14, P895; BORNFELDT KE, 1991, DIABETOLOGIA, V34, P307, DOI 10.1007/BF00405001; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; Chang HW, 1997, SCIENCE, V276, P1848, DOI 10.1126/science.276.5320.1848; COOPER CS, 1984, NATURE, V311, P29, DOI 10.1038/311029a0; Corbalan-Garcia S, 1998, MOL CELL BIOL, V18, P880, DOI 10.1128/MCB.18.2.880; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; Datta SR, 2000, MOL CELL, V6, P41, DOI 10.1016/S1097-2765(00)00006-X; END P, 1993, J BIOL CHEM, V268, P10066; Fan SJ, 2000, ONCOGENE, V19, P2212, DOI 10.1038/sj.onc.1203566; Fixman ED, 1996, J BIOL CHEM, V271, P13116, DOI 10.1074/jbc.271.22.13116; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GRAZIANI A, 1991, J BIOL CHEM, V266, P22087; GRECO A, 1992, ONCOGENE, V7, P237; Gu HH, 2000, MOL CELL BIOL, V20, P7109, DOI 10.1128/MCB.20.19.7109-7120.2000; HAYMAN MJ, 1985, P NATL ACAD SCI USA, V82, P8237, DOI 10.1073/pnas.82.23.8237; Hibi M, 2000, LEUKEMIA LYMPHOMA, V37, P299, DOI 10.3109/10428190009089430; HUFF JL, 1993, P NATL ACAD SCI USA, V90, P6140, DOI 10.1073/pnas.90.13.6140; Iwama A, 1996, EMBO J, V15, P5866, DOI 10.1002/j.1460-2075.1996.tb00973.x; Jiang BH, 2000, P NATL ACAD SCI USA, V97, P1749, DOI 10.1073/pnas.040560897; Jimenez C, 1998, EMBO J, V17, P743, DOI 10.1093/emboj/17.3.743; Kennedy SG, 1999, MOL CELL BIOL, V19, P5800; KNIGHT J, 1990, VIROLOGY, V178, P232, DOI 10.1016/0042-6822(90)90398-B; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; Maroun CR, 1999, MOL CELL BIOL, V19, P1784; MORIMOTO AM, 1994, J VIROL, V68, P1837, DOI 10.1128/JVI.68.3.1837-1842.1994; Nishida K, 1999, BLOOD, V93, P1809, DOI 10.1182/blood.V93.6.1809.406k35_1809_1816; Park CY, 1999, J BIOL CHEM, V274, P7583, DOI 10.1074/jbc.274.11.7583; PARK M, 1986, CELL, V45, P895, DOI 10.1016/0092-8674(86)90564-7; PARK M, 1984, PNAS, V84, P6379; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PONZETTO C, 1993, MOL CELL BIOL, V13, P4600, DOI 10.1128/MCB.13.8.4600; Ponzetto C, 1996, J BIOL CHEM, V271, P14119, DOI 10.1074/jbc.271.24.14119; Potempa S, 1998, MOL BIOL CELL, V9, P2185, DOI 10.1091/mbc.9.8.2185; Reed JC, 1998, ONCOGENE, V17, P3225, DOI 10.1038/sj.onc.1202591; RORDORFNIKOLIC T, 1995, J BIOL CHEM, V270, P3662, DOI 10.1074/jbc.270.8.3662; Royal I, 2000, MOL BIOL CELL, V11, P1709, DOI 10.1091/mbc.11.5.1709; Schaeper U, 2000, J CELL BIOL, V149, P1419, DOI 10.1083/jcb.149.7.1419; SMITH DR, 1989, P NATL ACAD SCI USA, V86, P5291, DOI 10.1073/pnas.86.14.5291; Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710; Tang XW, 2000, J BIOL CHEM, V275, P13142, DOI 10.1074/jbc.275.17.13142; Tulasne D, 1999, MOL BIOL CELL, V10, P551, DOI 10.1091/mbc.10.3.551; Wahl RC, 1999, J BIOL CHEM, V274, P26361, DOI 10.1074/jbc.274.37.26361; WHITMAN M, 1985, NATURE, V315, P239, DOI 10.1038/315239a0; Wickrema A, 1999, J BIOL CHEM, V274, P24469, DOI 10.1074/jbc.274.35.24469; Zhao CM, 1999, J BIOL CHEM, V274, P19649, DOI 10.1074/jbc.274.28.19649	54	32	33	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 24	2002	21	5					697	707		10.1038/sj.onc.1205115	http://dx.doi.org/10.1038/sj.onc.1205115			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	514FB	11850798				2022-12-17	WOS:000173427000001
J	Spalding, AC; Jotte, RM; Scheinman, RI; Geraci, MW; Clarke, P; Tyler, KL; Johnson, GL				Spalding, AC; Jotte, RM; Scheinman, RI; Geraci, MW; Clarke, P; Tyler, KL; Johnson, GL			TRAIL and inhibitors of apoptosis are opposing determinants for NF-kappa B-dependent, genotoxin-induced apoptosis of cancer cells	ONCOGENE			English	Article						TRAIL; IAP; NF-kappa B; apoptosis; chemotherapy	PACLITAXEL-INDUCED APOPTOSIS; INTESTINAL TREFOIL FACTOR; NECROSIS-FACTOR-ALPHA; ZINC FINGER PROTEIN; CYTOCHROME-C; TRANSCRIPTIONAL ACTIVATION; FORKHEAD PROTEINS; DECOY RECEPTORS; DEATH RECEPTORS; EXPRESSION	Opposing pro- and anti-apoptotic actions of TRAIL and the inhibitors of apoptosis (IAPs) contribute to the cell's decision to survive or die. We demonstrate that in H157 human lung carcinoma cells, etoposide and doxorubicin induce the NF-kappaB-dependent expression of both pro- and anti-apoptotic proteins including TRAIL and its death receptor, DR5, and IAPs. Inhibition of NF-kappaB activation in H157 cells in response to genotoxin resulted in loss of cell surface expression of TRAIL and DR5, aggressive growth and chemotherapy resistance of tumors in nude mice. Similar to the paracrine TRAIL response in H157 cells, the sensitivity of normal lung and breast epithelium and carcinomas to undergo genotoxin-induced apoptosis correlates strongly with cell surface expression of TRAIL. Suppression of TRAIL signaling by expression of the TRAIL decoy receptor, DeR1, confers chemo-resistance to cancer cells. These findings demonstrate that TRAIL signaling via its death receptors is a significant contributor to genotoxin-induced apoptosis in human epithelial carcinomas.	Univ Colorado, Hlth Sci Ctr, Dept Pharmacol, SOM,Canc Ctr, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Ctr Canc, Dept Med, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Ctr Canc, Dept Neurol, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Ctr Canc, Sch Pharm, Denver, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Johnson, GL (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Pharmacol, SOM,Canc Ctr, C236,Room 2809,4200 E 9th Ave, Denver, CO 80262 USA.		Tyler, Kenneth L./J-2420-2019	Tyler, Kenneth L./0000-0003-3294-5888				Altucci L, 2001, NAT MED, V7, P680, DOI 10.1038/89050; Ashkenazi A, 1999, CURR OPIN CELL BIOL, V11, P255, DOI 10.1016/S0955-0674(99)80034-9; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Basu S, 1998, BIOCHEM BIOPH RES CO, V247, P79, DOI 10.1006/bbrc.1998.8741; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Chaudhary PM, 1997, IMMUNITY, V7, P821, DOI 10.1016/S1074-7613(00)80400-8; Chen YH, 2000, BIOCHEM BIOPH RES CO, V274, P576, DOI 10.1006/bbrc.2000.3176; Chu ZL, 1997, P NATL ACAD SCI USA, V94, P10057, DOI 10.1073/pnas.94.19.10057; Clarke P, 2000, J VIROL, V74, P8135, DOI 10.1128/JVI.74.17.8135-8139.2000; Cooper JT, 1996, J BIOL CHEM, V271, P18068, DOI 10.1074/jbc.271.30.18068; Fisher MJ, 2001, CLIN CANCER RES, V7, P1688; Gibson SB, 2000, MOL CELL BIOL, V20, P205, DOI 10.1128/MCB.20.1.205-212.2000; HAN JY, 2001, P ASCO, V20; Hellqvist M, 1996, J BIOL CHEM, V271, P4482; Jones PL, 1997, MOL CELL BIOL, V17, P6970, DOI 10.1128/MCB.17.12.6970; Jurgensmeier JM, 1998, P NATL ACAD SCI USA, V95, P4997, DOI 10.1073/pnas.95.9.4997; Kasibhatla S, 1998, MOL CELL, V1, P543, DOI 10.1016/S1097-2765(00)80054-4; Kaufmann SH, 2000, EXP CELL RES, V256, P42, DOI 10.1006/excr.2000.4838; KRIKOS A, 1992, J BIOL CHEM, V267, P17971; Lee SH, 1999, CANCER RES, V59, P5683; Lee SH, 2001, ONCOGENE, V20, P399, DOI 10.1038/sj.onc.1204103; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Mahlapuu M, 1998, DEV BIOL, V202, P183, DOI 10.1006/dbio.1998.9010; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nakamura M, 2000, ACTA NEUROPATHOL, V99, P1, DOI 10.1007/PL00007399; OPIPARI AW, 1992, J BIOL CHEM, V267, P12424; Ozoren N, 2000, INT J ONCOL, V16, P917; Pai SI, 1998, CANCER RES, V58, P3513; PIERROU S, 1994, EMBO J, V13, P5002, DOI 10.1002/j.1460-2075.1994.tb06827.x; Ravi R, 2001, NAT CELL BIOL, V3, P409, DOI 10.1038/35070096; Sakai T, 2001, NAT MED, V7, P324, DOI 10.1038/85471; Schneider P, 1997, FEBS LETT, V416, P329, DOI 10.1016/S0014-5793(97)01231-3; Sedger LM, 1999, J IMMUNOL, V163, P920; Sheridan JP, 1997, SCIENCE, V277, P818, DOI 10.1126/science.277.5327.818; Srivastava RK, 1999, P NATL ACAD SCI USA, V96, P3775, DOI 10.1073/pnas.96.7.3775; Strobel T, 1996, P NATL ACAD SCI USA, V93, P14094, DOI 10.1073/pnas.93.24.14094; SUEMORI S, 1991, P NATL ACAD SCI USA, V88, P11017, DOI 10.1073/pnas.88.24.11017; Sun XM, 1999, J BIOL CHEM, V274, P5053, DOI 10.1074/jbc.274.8.5053; Taupin DR, 2000, P NATL ACAD SCI USA, V97, P799, DOI 10.1073/pnas.97.2.799; THIM L, 1989, FEBS LETT, V250, P85, DOI 10.1016/0014-5793(89)80690-8; Tzung SP, 2001, NAT CELL BIOL, V3, P183, DOI 10.1038/35055095; VERHAEGEN S, 1995, BIOCHEM PHARMACOL, V50, P1021, DOI 10.1016/0006-2952(95)00233-P; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Wang SW, 1999, ANN CLIN LAB SCI, V29, P192; Wu WG, 2000, ANTICANCER RES, V20, P4525; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; ZHANG ZH, 1995, P NATL ACAD SCI USA, V92, P6161, DOI 10.1073/pnas.92.13.6161; Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549	50	32	33	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 10	2002	21	2					260	271		10.1038/sj.onc.1205048	http://dx.doi.org/10.1038/sj.onc.1205048			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	507KG	11803469				2022-12-17	WOS:000173026200010
J	Acquaviva, C; Brockly, F; Ferrara, P; Bossis, G; Salvat, C; Jariel-Encontre, I; Piechaczyk, M				Acquaviva, C; Brockly, F; Ferrara, P; Bossis, G; Salvat, C; Jariel-Encontre, I; Piechaczyk, M			Identification of a C-terminal tripeptide motif involved in the control of rapid proteasomal degradation of c-Fos proto-oncoprotein during the G(0)-to-S phase transition	ONCOGENE			English	Article						c-Fos; oncogene; protein degradation; proteasome; PEST motif	KAPPA-B-ALPHA; IN-VIVO; TRANSCRIPTION FACTORS; INSTABILITY DETERMINANTS; TRANSFORMING ACTIVITY; MEDIATED PROTEOLYSIS; G0-TO-G1 TRANSITION; MOUSE FIBROBLASTS; PEST SEQUENCES; 26S PROTEASOME	c-Fos proto-oncoprotein is rapidly and transiently expressed in cells undergoing the G(0)-to-S phase transition in response to stimulation for growth by serum. Under these conditions, the rapid decay of the protein occurring after induction is accounted for by efficient recognition and degradation by the proteasome. PEST motifs are sequences rich in Pro, Glu, Asp, Ser and Thr which have been proposed to constitute protein instability determinants. c-Fos contains three such motifs, one of which comprises the C-terminal 20 amino acids and has already been proposed to be the major determinant of c-Fos instability. Using site-directed mutagenesis and an expression system reproducing c-fos gene transient expression in transfected cells, we have analysed the turnover of c-Fos mutants deleted of the various PEST sequences in synchronized mouse embryo fibroblasts. Our data showed no role for the two internal PEST motifs in c-Fos instability. However, deletion of the C-terminal PEST region led to only a twofold stabilization of the protein. Taken together, these data indicate that c-Fos instability during the G0-to-S phase transition is governed by a major non-PEST destabilizer and a C-terminal degradation-accelerating element. Further dissection of c-Fos C-terminal region showed that the degradation-accelerating effect is not contributed by the whole PEST sequence but by a short PTL tripeptide which cannot be considered as a PEST motif and which can act in the absence of any PEST environment. Interestingly, the PTL motif is conserved in other members of the fos multigene family. Nevertheless, its contribution to protein instability is restricted to c-Fos suggesting that the mechanisms whereby the various Fos proteins are broken down are, at least partially, different. MAP kinases-mediated phosphorylation of two serines close to PTL, which are both phosphorylated all over the G(0)-to-S phase transition, have been proposed by others to stabilize c-Fos protein significantly. We, however, showed that the PTL motif does not exert its effect by counteracting a stabilizing effect of these phosphorylations under our experimental conditions.	Inst Genet Mol, CNRS, UMR 5535, IFR 24, F-34293 Montpellier 05, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Montpellier	Piechaczyk, M (corresponding author), Inst Genet Mol, CNRS, UMR 5535, IFR 24, 1919 route de Mende, F-34293 Montpellier 05, France.	piechaczyk@igm.cnrs-mop.fr	Acquaviva, Claire/N-4306-2017; PIECHACZYK, Marc/E-7896-2013	Acquaviva, Claire/0000-0002-0227-9813; PIECHACZYK, Marc/0000-0003-1367-2597; bossis, guillaume/0000-0002-3349-8250				ABATE C, 1990, CELL GROWTH DIFFER, V1, P455; Acquaviva C, 2001, ONCOGENE, V20, P942, DOI 10.1038/sj.onc.1204155; Angel P. E., 1994, FOS JUN FAMILIES TRA; Aniento F, 1996, FEBS LETT, V390, P47, DOI 10.1016/0014-5793(96)00625-4; Bies J, 1999, J VIROL, V73, P2038, DOI 10.1128/JVI.73.3.2038-2044.1999; Boudjelal M, 2000, CANCER RES, V60, P2247; BROWN HJ, 1995, EMBO J, V14, P124, DOI 10.1002/j.1460-2075.1995.tb06982.x; Carillo S, 1996, BIOCHEM J, V313, P245, DOI 10.1042/bj3130245; CARILLO S, 1994, ONCOGENE, V9, P1679; Chen RH, 1996, ONCOGENE, V12, P1493; Ciechanover A, 2000, BIOESSAYS, V22, P442, DOI 10.1002/(SICI)1521-1878(200005)22:5<442::AID-BIES6>3.0.CO;2-Q; Ciechanover A, 2000, J CELL BIOCHEM, P40; Coffino P, 1998, UBIQUITIN BIOL CELL, P411; CURRAN T, 1984, VIROLOGY, V135, P218, DOI 10.1016/0042-6822(84)90132-6; CURRAN T, 1984, CELL, V36, P259; Curran T, 1988, ONCOGENE HDB, P307; Fleming JV, 2000, MOL CELL BIOL, V20, P4932, DOI 10.1128/MCB.20.13.4932-4947.2000; GHODA L, 1992, MOL CELL BIOL, V12, P2178, DOI 10.1128/MCB.12.5.2178; Harlow, 1999, USING ANTIBODIES LAB; He HL, 1998, J BIOL CHEM, V273, P25015, DOI 10.1074/jbc.273.39.25015; HermidaMatsumoto ML, 1996, J BIOL CHEM, V271, P4930; HIRAI S, 1991, FEBS LETT, V287, P57, DOI 10.1016/0014-5793(91)80015-U; HOCHSTRASSER M, 1988, UBIQUITIN BIOL CELL; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Kornitzer D, 2000, J CELL PHYSIOL, V182, P1, DOI 10.1002/(SICI)1097-4652(200001)182:1<1::AID-JCP1>3.0.CO;2-V; KOVARY K, 1992, MOL CELL BIOL, V12, P5015, DOI 10.1128/MCB.12.11.5015; KOVARY K, 1991, MOL CELL BIOL, V11, P2451, DOI 10.1128/MCB.11.5.2451; Krappmann D, 1996, EMBO J, V15, P6716, DOI 10.1002/j.1460-2075.1996.tb01061.x; LAEMMLI EK, 1971, NATURE, V227, P6800; Lallemand D, 1997, ONCOGENE, V14, P819, DOI 10.1038/sj.onc.1200901; Langenfeld J, 1997, P NATL ACAD SCI USA, V94, P12070, DOI 10.1073/pnas.94.22.12070; Li XQ, 1998, J BIOL CHEM, V273, P34970, DOI 10.1074/jbc.273.52.34970; MATSUI M, 1990, ONCOGENE, V5, P249; MIAO GG, 1994, MOL CELL BIOL, V14, P4295, DOI 10.1128/MCB.14.6.4295; Mils V, 1997, ONCOGENE, V14, P1555, DOI 10.1038/sj.onc.1200991; MOLINARI M, 1995, J BIOL CHEM, V270, P2032, DOI 10.1074/jbc.270.5.2032; Musti AM, 1996, BIOL CHEM, V377, P619, DOI 10.1515/bchm3.1996.377.10.619; OKAZAKI K, 1995, EMBO J, V14, P5048, DOI 10.1002/j.1460-2075.1995.tb00187.x; Penrose KJ, 2000, J VIROL, V74, P6031, DOI 10.1128/JVI.74.13.6031-6038.2000; PETERS JM, 1998, UBIQUITIN BIOL CELL; PIECHACZYK M, 1994, CRIT REV ONCOL HEMAT, V17, P93, DOI 10.1016/1040-8428(94)90021-3; RECH J, 1989, NUCLEIC ACIDS RES, V17, P2874, DOI 10.1093/nar/17.7.2874; Rechsteiner M, 1996, TRENDS BIOCHEM SCI, V21, P267, DOI 10.1016/S0968-0004(96)10031-1; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; ROUX P, 1990, CELL, V63, P341, DOI 10.1016/0092-8674(90)90167-D; ROUX P, 1994, C FOS C JUN FAMILIES, P87; Salvat C, 1999, MOL BIOL REP, V26, P45, DOI 10.1023/A:1006960021281; Salvat C, 1998, ONCOGENE, V17, P327, DOI 10.1038/sj.onc.1201922; Salvat C, 2000, EUR J BIOCHEM, V267, P3712, DOI 10.1046/j.1432-1327.2000.01404.x; Sambrook J., 1989, MOL CLONING; Schoonbroodt S, 2000, J IMMUNOL, V164, P4292, DOI 10.4049/jimmunol.164.8.4292; SCHUERMANN M, 1991, ONCOGENE, V6, P567; Sheaff RJ, 2000, MOL CELL, V5, P403, DOI 10.1016/S1097-2765(00)80435-9; Shumway SD, 1999, J BIOL CHEM, V274, P30874, DOI 10.1074/jbc.274.43.30874; STANCOVSKI I, 1995, MOL CELL BIOL, V15, P7106; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; TSURUMI C, 1995, MOL CELL BIOL, V15, P5682; Verma R, 2000, CELL, V101, P341, DOI 10.1016/S0092-8674(00)80843-0; VEYRUNE JL, 1995, ONCOGENE, V11, P2127; Wang WL, 1996, P NATL ACAD SCI USA, V93, P8236, DOI 10.1073/pnas.93.16.8236; WATT F, 1993, NUCLEIC ACIDS RES, V21, P5092, DOI 10.1093/nar/21.22.5092; Wilkinson KD, 2000, SEMIN CELL DEV BIOL, V11, P141, DOI 10.1006/scdb.2000.0164; Wisdom R, 1999, EXP CELL RES, V253, P180, DOI 10.1006/excr.1999.4685; Xu WD, 2000, EXP CELL RES, V255, P135, DOI 10.1006/excr.2000.4803	64	32	32	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 8	2001	20	51					7563	7572		10.1038/sj.onc.1204880	http://dx.doi.org/10.1038/sj.onc.1204880			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	489DN	11709728				2022-12-17	WOS:000171976900013
J	Benoit, G; Roussel, M; Pendino, F; Segal-Bendirdjian, E; Lanotte, M				Benoit, G; Roussel, M; Pendino, F; Segal-Bendirdjian, E; Lanotte, M			Orchestration of multiple arrays of signal cross-talk and combinatorial interactions for maturation and cell death: another vision of t(15;17) preleukemic blast and APL-cell maturation	ONCOGENE			English	Review						APL; maturation; cell death; ATRA; cyclic AMP; 'rexinoids'; RXR signaling; cross-talk	ACUTE PROMYELOCYTIC LEUKEMIA; TRANS-RETINOIC ACID; PML-RAR-ALPHA; COLONY-STIMULATING FACTOR; ARSENIC TRIOXIDE AS2O3; ACUTE MYELOID-LEUKEMIA; ONCOGENIC TRANSCRIPTION FACTORS; LEUKOCYTE ALKALINE-PHOSPHATASE; BONE-MARROW TRANSPLANTATION; POLYMERASE CHAIN-REACTION	Despite intensive molecular biology investigations over the past 10 years, and an important breakthrough on how PML-RAR alpha, the fusion protein resulting from t(15;17), can alter RAR alpha and PML functions, no definitive views on how leukemia is generated and by what mechanism(s) the normal phenotype is restored, are yet available. 'Resistances' to pharmacological levels of all-traps-retinoic acid (ATRA) have been observed in experimental in vivo and in vitro models. In this review, we emphasize the key role played by signal cross-talk for both normal and neoplastic hemopoiesis. After an overview of reported experimental data on APL-cell maturation and apoptosis, we apply our current knowledge on signaling pathways to underline those which might generate signal cross-talks. The design of biological models suitable to decipher the integration of signal cross-talks at the transcriptional level should be our first priority today, to generate some realistic therapeutic approaches After 'Ten Years of Molecular APL', we still know very little about how the disease develops and how effective medicines work.	Hop St Louis, Ctr G Hayem, INSERM U 496, F-75010 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Lanotte, M (corresponding author), Hop St Louis, Ctr G Hayem, INSERM U 496, 1 Ave Claude Vellefaux, F-75010 Paris, France.	mlanotte@chu-stlouis.fr	PENDINO, Frederic/G-6630-2017	Segal-Bendirdjian, Evelyne/0000-0001-9813-4880; BENOIT, Gerard/0000-0001-9462-6570				ADAMS JM, 1992, CANCER SURV, V15, P119; AHN MJ, 1995, ONCOGENE, V10, P2307; Albanell J, 1996, CANCER RES, V56, P1503; Alcalay M, 1998, MOL CELL BIOL, V18, P1084, DOI 10.1128/MCB.18.2.1084; Allouche M, 2000, BLOOD, V96, P1187, DOI 10.1182/blood.V96.3.1187.015k01_1187_1190; Allouche Michele, 1995, Progress in Growth Factor Research, V6, P35, DOI 10.1016/0955-2235(95)00041-0; Allsopp RC, 2001, J EXP MED, V193, P917, DOI 10.1084/jem.193.8.917; Altabef M, 1996, EMBO J, V15, P2707, DOI 10.1002/j.1460-2075.1996.tb00631.x; Arnould C, 1999, HUM MOL GENET, V8, P1741, DOI 10.1093/hmg/8.9.1741; Benoit G, 1999, EMBO J, V18, P7011, DOI 10.1093/emboj/18.24.7011; Benoit GR, 2001, MOL ENDOCRINOL, V15, P1154, DOI 10.1210/me.15.7.1154; Bergstrom SK, 1998, J PEDIAT HEMATOL ONC, V20, P545, DOI 10.1097/00043426-199811000-00006; Berry DM, 1999, ENDOCRINOLOGY, V140, P4779, DOI 10.1210/en.140.10.4779; BHATIA M, 1994, LEUKEMIA, V8, P1744; Bhatia M, 1996, EXP CELL RES, V222, P61, DOI 10.1006/excr.1996.0008; Blalock WL, 1999, LEUKEMIA, V13, P1109, DOI 10.1038/sj.leu.2401493; Blobel GA, 2000, BLOOD, V95, P745, DOI 10.1182/blood.V95.3.745.003k05_745_755; BOLLAG W, 1994, J CELL BIOCHEM, V56, P427, DOI 10.1002/jcb.240560402; BORROW J, 1990, SCIENCE, V249, P1577, DOI 10.1126/science.2218500; BREITMAN TR, 1981, BLOOD, V57, P1000; BREITMAN TR, 1980, P NATL ACAD SCI-BIOL, V77, P2936, DOI 10.1073/pnas.77.5.2936; Breitschopf K, 2001, FEBS LETT, V493, P21, DOI 10.1016/S0014-5793(01)02272-4; Brendel C, 2000, LEUKEMIA, V14, P1711, DOI 10.1038/sj.leu.2401907; Brown D, 1997, P NATL ACAD SCI USA, V94, P2551, DOI 10.1073/pnas.94.6.2551; Brown DC, 1999, BRIT J HAEMATOL, V107, P86, DOI 10.1046/j.1365-2141.1999.01671.x; BUDEL LM, 1993, J BIOL CHEM, V268, P10154; BURGER C, 1994, J CELL SCI, V107, P2047; Cai X, 2000, LEUKEMIA, V14, P262, DOI 10.1038/sj.leu.2401650; Charrad RS, 1999, NAT MED, V5, P669, DOI 10.1038/9518; Chelbi-Alix MK, 1999, LEUKEMIA, V13, P1167, DOI 10.1038/sj.leu.2401469; ChelbiAlix MK, 1995, LEUKEMIA, V9, P2027; Chen GQ, 1997, BLOOD, V89, P3345; Chen GQ, 1996, BLOOD, V88, P1052; CHEN HM, 1995, BLOOD, V85, P2918, DOI 10.1182/blood.V85.10.2918.bloodjournal85102918; CHEN Z, 1993, EMBO J, V12, P1161, DOI 10.1002/j.1460-2075.1993.tb05757.x; Ciullo I, 2001, ONCOGENE, V20, P1186, DOI 10.1038/sj.onc.1204219; Clark BR, 1995, ANN NY ACAD SCI, V770, P70, DOI 10.1111/j.1749-6632.1995.tb31044.x; Classon M, 2000, SEMIN CANCER BIOL, V10, P393, DOI 10.1006/scbi.2000.0338; COREY SJ, 1994, LEUKEMIA, V8, P1350; Crans HN, 2001, LEUKEMIA, V15, P313, DOI 10.1038/sj.leu.2402033; Dai J, 1999, BLOOD, V93, P268, DOI 10.1182/blood.V93.1.268.401a21_268_277; DALTON WT, 1988, BLOOD, V71, P242; De Cesare D, 2000, PROG NUCLEIC ACID RE, V64, P343, DOI 10.1016/S0079-6603(00)64009-6; DERMIME S, 1993, BLOOD, V82, P1573; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; Dexter T M, 1984, Prog Clin Biol Res, V148, P13; Douer D, 2000, LEUKEMIA, V14, P874, DOI 10.1038/sj.leu.2401772; DUBOIS C, 1994, LEUKEMIA, V8, P1750; DUBOIS C, 1994, BLOOD, V83, P3264; Duprez E, 2000, LEUKEMIA, V14, P255, DOI 10.1038/sj.leu.2401683; Duprez E, 1996, ONCOGENE, V12, P2451; DUPREZ E, 1992, LEUKEMIA, V6, P1281; Edwards RH, 1999, AM J CLIN PATHOL, V112, P819; El Marjou M, 2000, LEUKEMIA, V14, P2118; Elstner E, 1997, J CLIN INVEST, V99, P349, DOI 10.1172/JCI119164; Fenaux P, 1997, SEMIN ONCOL, V24, P92; Fenaux P, 2000, LEUKEMIA, V14, P1371, DOI 10.1038/sj.leu.2401859; Fenaux P, 2001, SEMIN HEMATOL, V38, P13, DOI 10.1053/shem.2001.20862; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; Ferrero D, 2001, LEUKEMIA, V15, P422, DOI 10.1038/sj.leu.2402038; FONTANA JA, 1987, J NATL CANCER I, V78, P1107; GABERT J, 1989, LANCET, V2, P1125; Gaboli M, 1998, LEUKEMIA LYMPHOMA, V30, P11, DOI 10.3109/10428199809050925; GALLAGHER R, 1979, BLOOD, V54, P713; GALLAGHER RE, 1987, LEUKEMIA RES, V11, P609, DOI 10.1016/0145-2126(87)90033-6; Garattini E, 1998, LEUKEMIA LYMPHOMA, V30, P467, DOI 10.3109/10428199809057559; GIANNI M, 1995, BLOOD, V85, P3619, DOI 10.1182/blood.V85.12.3619.bloodjournal85123619; Gianni M, 1997, BLOOD, V89, P1001, DOI 10.1182/blood.V89.3.1001; GIANNI M, 1994, BLOOD, V83, P1909; Gianni M, 1998, BLOOD, V91, P4300, DOI 10.1182/blood.V91.11.4300.411k41_4300_4310; Grisolano JL, 1997, BLOOD, V89, P376, DOI 10.1182/blood.V89.2.376; Grolleau A, 2000, LEUKEMIA, V14, P1909, DOI 10.1038/sj.leu.2401904; Grotzinger T, 1996, J BIOL CHEM, V271, P25253, DOI 10.1074/jbc.271.41.25253; GUIDEZ F, 1994, LEUKEMIA, V8, P312; HAFNER S, 1994, MOL CELL BIOL, V14, P6696; Hansen LA, 2000, CARCINOGENESIS, V21, P1271, DOI 10.1093/carcin/21.7.1271; He LZ, 1997, P NATL ACAD SCI USA, V94, P5302, DOI 10.1073/pnas.94.10.5302; Hida T, 2001, JPN J PHARMACOL, V85, P60, DOI 10.1254/jjp.85.60; HOHMANN P, 1989, INT J CANCER, V43, P863, DOI 10.1002/ijc.2910430521; Honkakoski P, 2000, BIOCHEM J, V347, P321, DOI 10.1042/0264-6021:3470321; Hsu HC, 1999, EUR J HAEMATOL, V63, P11; HSU HC, 1993, LEUKEMIA, V7, P458; HSU HC, 1996, CHUNG HUA I HSUEH TS, V57, P93; HU ZB, 1993, LEUKEMIA, V7, P1817; HUANG ME, 1988, BLOOD, V72, P567, DOI 10.1182/blood.V72.2.567.567; Idres N, 2001, CANCER RES, V61, P700; Introna M, 1999, LEUKEMIA, V13, P1301, DOI 10.1038/sj.leu.2401492; Ismair MG, 1998, LEUKEMIA, V12, P1136, DOI 10.1038/sj.leu.2401042; James SY, 1999, GEN PHARMACOL, V32, P143, DOI 10.1016/S0306-3623(98)00098-6; Jansen JH, 2001, SEMIN HEMATOL, V38, P37, DOI 10.1053/shem.2001.20864; Jing YK, 2001, BLOOD, V97, P264, DOI 10.1182/blood.V97.1.264; Kang SS, 1999, J BIOL CHEM, V274, P13085, DOI 10.1074/jbc.274.19.13085; Katayama N, 1998, AM J HEMATOL, V58, P31, DOI 10.1002/(SICI)1096-8652(199805)58:1<31::AID-AJH6>3.0.CO;2-1; KHANNAGUPTA A, 1994, BLOOD, V84, P294; KHAZAIE K, 1994, P NATL ACAD SCI USA, V91, P7430, DOI 10.1073/pnas.91.16.7430; Kihara H, 1998, INT J ONCOL, V12, P629; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kitamura K, 2000, BRIT J HAEMATOL, V108, P696, DOI 10.1046/j.1365-2141.2000.01933.x; Kitamura K, 2000, LEUKEMIA, V14, P1743, DOI 10.1038/sj.leu.2401900; Kiyoi H, 1997, LEUKEMIA, V11, P1447, DOI 10.1038/sj.leu.2400756; KLEIN G, 1995, EXPERIENTIA, V51, P914, DOI 10.1007/BF01921741; Ko BS, 1999, LEUKEMIA, V13, P1406, DOI 10.1038/sj.leu.2401495; Kogan SC, 1999, ONCOGENE, V18, P5261, DOI 10.1038/sj.onc.1202996; Koken MHM, 1999, ONCOGENE, V18, P1113, DOI 10.1038/sj.onc.1202414; KOKEN MHM, 1995, ONCOGENE, V10, P1315; Kolquist KA, 1998, NAT GENET, V19, P182, DOI 10.1038/554; Kosugi H, 1999, LEUKEMIA, V13, P1316, DOI 10.1038/sj.leu.2401508; Lallemand-Breitenbach V, 1999, J EXP MED, V189, P1043, DOI 10.1084/jem.189.7.1043; LANOTTE M, 1991, BLOOD, V77, P1080; LAZZARINO M, 1995, BRIT J HAEMATOL, V90, P928, DOI 10.1111/j.1365-2141.1995.tb05217.x; Lee HY, 1999, MOL CELL BIOL, V19, P1973; LEID M, 1992, TRENDS BIOCHEM SCI, V17, P427, DOI 10.1016/0968-0004(92)90014-Z; LEROY P, 1991, P NATL ACAD SCI USA, V88, P10138, DOI 10.1073/pnas.88.22.10138; Liu JP, 1999, FASEB J, V13, P2091, DOI 10.1096/fasebj.13.15.2091; Liu M, 1996, J BIOL CHEM, V271, P31723, DOI 10.1074/jbc.271.49.31723; Look AT, 1997, SCIENCE, V278, P1059, DOI 10.1126/science.278.5340.1059; Marchetti M, 1996, BRIT J HAEMATOL, V93, P360, DOI 10.1046/j.1365-2141.1996.4911029.x; Marill J, 2000, MOL PHARMACOL, V58, P1341, DOI 10.1124/mol.58.6.1341; MARSHALL M, 1995, MOL REPROD DEV, V42, P493, DOI 10.1002/mrd.1080420418; MARTINTHOUVENIN V, 1992, J CELL PHYSIOL, V153, P95, DOI 10.1002/jcp.1041530113; Matikainen S, 1997, CELL GROWTH DIFFER, V8, P687; MATIKAINEN S, 1994, CELL GROWTH DIFFER, V5, P975; Matikainen S, 1996, BLOOD, V88, P114; Mayani H, 1996, LEUKEMIA, V10, P1041; MCCANN SR, 1994, LEUKEMIA, V8, pS133; McCubrey JA, 2000, LEUKEMIA, V14, P9, DOI 10.1038/sj.leu.2401657; Melnick A, 1999, BLOOD, V93, P3167, DOI 10.1182/blood.V93.10.3167.410k44_3167_3215; Metcalf D, 1998, BLOOD, V92, P345, DOI 10.1182/blood.V92.2.345b.Con2_345_347; Meyerson M, 2000, J CLIN ONCOL, V18, P2626, DOI 10.1200/JCO.2000.18.13.2626; Meyerson M, 1997, CELL, V90, P785, DOI 10.1016/S0092-8674(00)80538-3; Misiti S, 2000, MOL CELL BIOL, V20, P3764, DOI 10.1128/MCB.20.11.3764-3771.2000; Miura D, 1999, FEBS LETT, V460, P297, DOI 10.1016/S0014-5793(99)01347-2; Moqattash S, 1998, P SOC EXP BIOL MED, V219, P8; Morgan MA, 2001, BLOOD, V97, P1823, DOI 10.1182/blood.V97.6.1823; Morosetti R, 1997, BLOOD, V90, P2591, DOI 10.1182/blood.V90.7.2591.2591_2591_2600; Mu ZM, 1997, CARCINOGENESIS, V18, P2063, DOI 10.1093/carcin/18.11.2063; MU ZM, 1994, MOL CELL BIOL, V14, P6858, DOI 10.1128/MCB.14.10.6858; Muller S, 1998, EMBO J, V17, P61, DOI 10.1093/emboj/17.1.61; Muller S, 1998, BLOOD, V92, P4308, DOI 10.1182/blood.V92.11.4308.423k36_4308_4316; Nakamura M, 2001, J CELL PHYSIOL, V187, P392, DOI 10.1002/jcp.1087; NasonBurchenal K, 1996, BLOOD, V88, P3926, DOI 10.1182/blood.V88.10.3926.bloodjournal88103926; NasonBurchenal K, 1997, DIFFERENTIATION, V61, P321, DOI 10.1046/j.1432-0436.1997.6150321.x; NATHAN C, 1991, J CELL BIOL, V113, P981, DOI 10.1083/jcb.113.5.981; NUCIFORA G, 1994, LEUKEMIA LYMPHOMA, V14, P353, DOI 10.3109/10428199409049690; Ohsawa M, 2000, LEUKEMIA, V14, P941, DOI 10.1038/sj.leu.2401755; OLSSON IL, 1982, CANCER RES, V42, P3928; Omay SB, 1996, BLOOD, V87, P2947, DOI 10.1182/blood.V87.7.2947.bloodjournal8772947; ORKIN SH, 1995, CURR OPIN CELL BIOL, V7, P870, DOI 10.1016/0955-0674(95)80072-7; PAUL CC, 1995, BLOOD, V86, P3737, DOI 10.1182/blood.V86.10.3737.bloodjournal86103737; Paulson R F, 1995, Semin Immunol, V7, P267, DOI 10.1006/smim.1995.0031; Pelicano L, 1999, ONCOGENE, V18, P3944, DOI 10.1038/sj.onc.1202802; Pelicano L, 1997, ONCOGENE, V15, P2349, DOI 10.1038/sj.onc.1201410; Pendino F, 2001, P NATL ACAD SCI USA, V98, P6662, DOI 10.1073/pnas.111464998; Peschel C, 1996, LEUKEMIA LYMPHOMA, V22, P129, DOI 10.3109/10428199609074370; Prosper F, 2001, J LEUKOCYTE BIOL, V69, P307; Quenech'Du N, 1998, LEUKEMIA, V12, P1829, DOI 10.1038/sj.leu.2401171; Radich J P, 1999, Rev Immunogenet, V1, P265; Redner RL, 1997, LEUKEMIA, V11, P1014, DOI 10.1038/sj.leu.2400661; ROCHETTEEGLY C, 1995, MOL ENDOCRINOL, V9, P860, DOI 10.1210/me.9.7.860; Rosenfeld C, 2000, LEUKEMIA, V14, P2, DOI 10.1038/sj.leu.2401618; RUCHAUD S, 1994, P NATL ACAD SCI USA, V91, P8428, DOI 10.1073/pnas.91.18.8428; Savickiene J, 1997, ANTICANCER RES, V17, P285; Scheele JS, 2000, CELL MOL LIFE SCI, V57, P1950, DOI 10.1007/PL00000675; Shao WL, 1998, J NATL CANCER I, V90, P124, DOI 10.1093/jnci/90.2.124; Shen ZX, 1997, BLOOD, V89, P3354, DOI 10.1182/blood.V89.9.3354; Shivdasani RA, 1996, BLOOD, V87, P4025, DOI 10.1182/blood.V87.10.4025.bloodjournal87104025; SMELAND EB, 1994, BLOOD, V84, P2940, DOI 10.1182/blood.V84.9.2940.bloodjournal8492940; So CW, 2000, LEUKEMIA, V14, P77, DOI 10.1038/sj.leu.2401643; Song XD, 1999, LEUKEMIA, V13, P275, DOI 10.1038/sj.leu.2401261; Stadler M, 1995, ONCOGENE, V11, P2565; Sternsdorf T, 1999, MOL CELL BIOL, V19, P5170; STONE R M, 1992, Current Opinion in Oncology, V4, P33, DOI 10.1097/00001622-199202000-00006; Stone RM, 1997, LEUKEMIA RES, V21, P399, DOI 10.1016/S0145-2126(96)00123-3; STONE RM, 1988, BLOOD, V72, P208; STONE RM, 1988, BLOOD, V71, P690; TALPAZ M, 1994, J CLIN INVEST, V94, P1383, DOI 10.1172/JCI117473; TESTA NG, 1989, ENVIRON HEALTH PERSP, V82, P51, DOI 10.2307/3430761; TESTA U, 1994, CANCER RES, V54, P4508; Thomas X, 2000, LEUKEMIA, V14, P1006, DOI 10.1038/sj.leu.2401800; TKATCH LS, 1995, J LEUKOCYTE BIOL, V57, P964, DOI 10.1002/jlb.57.6.964; Toba K, 1998, EXP HEMATOL, V26, P135; Torok-Storb B, 1999, ANN NY ACAD SCI, V872, P164, DOI 10.1111/j.1749-6632.1999.tb08461.x; Touhami M, 1999, BRIT J HAEMATOL, V104, P706, DOI 10.1046/j.1365-2141.1999.01235.x; Truran L, 1998, LEUKEMIA RES, V22, P241, DOI 10.1016/S0145-2126(97)00179-3; VAHDAT L, 1994, BLOOD, V84, P3843, DOI 10.1182/blood.V84.11.3843.bloodjournal84113843; Verbeek W, 2001, LEUKEMIA, V15, P103, DOI 10.1038/sj.leu.2401995; Vereecque R, 2000, GENE THER, V7, P1312, DOI 10.1038/sj.gt.3301228; Verheijen MHG, 1999, J BIOL CHEM, V274, P1487, DOI 10.1074/jbc.274.3.1487; Ward AC, 2000, LEUKEMIA, V14, P973, DOI 10.1038/sj.leu.2401808; Wells RA, 1996, LEUKEMIA, V10, P735; White JA, 1997, J BIOL CHEM, V272, P18538, DOI 10.1074/jbc.272.30.18538; Wiernik PH, 1996, CANCER, V78, P2510, DOI 10.1002/(SICI)1097-0142(19961215)78:12<2510::AID-CNCR10>3.0.CO;2-Z; WOLBACH SB, 1978, NUTR REV, V36, P16; Xu DW, 2000, ONCOGENE, V19, P5123, DOI 10.1038/sj.onc.1203890; Zang CB, 2000, J CANCER RES CLIN, V126, P33, DOI 10.1007/PL00008462; ZIPORI D, 1990, CANCER CELL-MON REV, V2, P205	196	32	34	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 29	2001	20	49					7161	7177		10.1038/sj.onc.1204760	http://dx.doi.org/10.1038/sj.onc.1204760			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	487TM	11704845				2022-12-17	WOS:000171891900005
J	Sorby, M; Sandstrom, J; Ostman, A				Sorby, M; Sandstrom, J; Ostman, A			An extracellular ligand increases the specific activity of the receptor-like protein tyrosine phosphatase DEP-1	ONCOGENE			English	Article						DEP-1; Matrigel (TM); protein tyrosine phosphatase	T-CELL ACTIVATION; HOMOPHILIC BINDING; EXPRESSION; CD148; BETA; PHOSPHORYLATION; DIMERIZATION; GROWTH; ALPHA; INHIBITION	Cellular growth, differentiation and migration is regulated by protein tyrosine phosphorylation. Receptor-like protein tyrosine phosphatases are thus likely to be key regulators of vital cellular processes. The regulation of these enzymes is in general poorly understood. Ligands have been identified only for a small subset of the receptor-like protein tyrosine phosphatases and in no case has upregulation of the specific activity by extracellular ligands been demonstrated. Prompted by earlier findings of ligands for receptor-like protein tyrosine phosphatases in extracellular matrix we investigated if Matrigel (TM), a preparation of extracellular matrix proteins, contained modulators of the specific activity of the receptor-like protein tyrosine phosphatase DEP-1. Matrigel (TM) stimulation of cells increased the specific activity of immunoprecipitated DEP-1. Also, incubation of immunoprecipitated DEP-1 with Matrigel (TM) led to an increase in DEP-1 activity, which was blocked by soluble DEP-1 extracellular domain. Finally, immunoprecipitated Delta ECD-DEP-1, a mutant form of DEP-1 lacking most of the extracellular domain, failed to respond to Matrigel (TM) stimulation. These experiments identify Matrigel (TM) as a source of DEP-1 agonist(s) and provide the first evidence for upregulation of the specific activity of receptor-like protein tyrosine phosphatases by extracellular ligands.	Ludwig Inst Canc Res, S-75124 Uppsala, Sweden	Ludwig Institute for Cancer Research	Ostman, A (corresponding author), Ludwig Inst Canc Res, Box 595, S-75124 Uppsala, Sweden.							Autschbach F, 1999, TISSUE ANTIGENS, V54, P485, DOI 10.1034/j.1399-0039.1999.540506.x; BARNEA G, 1994, J BIOL CHEM, V269, P14349; Bilwes AM, 1996, NATURE, V382, P555, DOI 10.1038/382555a0; Borges LG, 1996, CIRC RES, V79, P570, DOI 10.1161/01.RES.79.3.570; BRADYKALNAY SM, 1995, CURR OPIN CELL BIOL, V7, P650, DOI 10.1016/0955-0674(95)80106-5; BRADYKALNAY SM, 1993, J CELL BIOL, V122, P961, DOI 10.1083/jcb.122.4.961; de la Fuente-Garcia MA, 1998, BLOOD, V91, P2800, DOI 10.1182/blood.V91.8.2800.2800_2800_2809; GEBBINK MFBG, 1993, J BIOL CHEM, V268, P16101; HONDA H, 1994, BLOOD, V84, P4186, DOI 10.1182/blood.V84.12.4186.bloodjournal84124186; Jiang GL, 1999, NATURE, V401, P606, DOI 10.1038/44170; Keane MM, 1996, CANCER RES, V56, P4236; Kovalenko M, 2000, J BIOL CHEM, V275, P16219, DOI 10.1074/jbc.275.21.16219; Leppanen O, 2000, BIOCHEMISTRY-US, V39, P2370, DOI 10.1021/bi9919192; Majeti R, 1998, SCIENCE, V279, P88, DOI 10.1126/science.279.5347.88; Martelli ML, 1998, EXP CELL RES, V245, P195, DOI 10.1006/excr.1998.4257; Meng K, 2000, P NATL ACAD SCI USA, V97, P2603, DOI 10.1073/pnas.020487997; O'Grady P, 1998, J CELL BIOL, V141, P1675, DOI 10.1083/jcb.141.7.1675; OSTMAN A, 1994, P NATL ACAD SCI USA, V91, P9680, DOI 10.1073/pnas.91.21.9680; PELES E, 1995, CELL, V82, P251, DOI 10.1016/0092-8674(95)90312-7; SAP J, 1994, MOL CELL BIOL, V14, P1; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; STOVER DR, 1994, MOL CELL BIOL, V14, P5523, DOI 10.1128/MCB.14.8.5523; STOVER DR, 1991, P NATL ACAD SCI USA, V88, P7704, DOI 10.1073/pnas.88.17.7704; STREULI M, 1989, P NATL ACAD SCI USA, V86, P8698, DOI 10.1073/pnas.86.22.8698; Suzuki E, 2000, J BIOL CHEM, V275, P3637, DOI 10.1074/jbc.275.5.3637; Tangye SG, 1998, J IMMUNOL, V161, P3249; Tangye SG, 1998, J IMMUNOL, V161, P3803; Trapasso F, 2000, MOL CELL BIOL, V20, P9236, DOI 10.1128/MCB.20.24.9236-9246.2000; TRUETT MA, 1985, DNA-J MOLEC CELL BIO, V4, P333, DOI 10.1089/dna.1985.4.333; Van Vactor D, 1998, CURR OPIN CELL BIOL, V10, P174, DOI 10.1016/S0955-0674(98)80139-7; Wang Y, 1999, J BIOL CHEM, V274, P7454, DOI 10.1074/jbc.274.11.7454; Zeng L, 1999, J CELL BIOL, V147, P707, DOI 10.1083/jcb.147.4.707; Zhang L, 1997, EXP CELL RES, V235, P62, DOI 10.1006/excr.1997.3659	33	32	34	0	4	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 23	2001	20	37					5219	5224		10.1038/sj.onc.1204581	http://dx.doi.org/10.1038/sj.onc.1204581			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	463EN	11526512				2022-12-17	WOS:000170464000017
J	Kim, JJ; Yang, JS; Nottingham, LK; Tang, WX; Dang, K; Manson, KH; Wyand, MS; Wilson, DM; Weiner, DB				Kim, JJ; Yang, JS; Nottingham, LK; Tang, WX; Dang, K; Manson, KH; Wyand, MS; Wilson, DM; Weiner, DB			Induction of immune responses and safety profiles in rhesus macaques immunized with a DNA vaccine expressing human prostate specific antigen	ONCOGENE			English	Article						prostate specific antigen; DNA vaccines; prostate cancer; immune responses; rhesus macaques	RADIATION-THERAPY; CANCER; CELLS; PSA; IMMUNOTHERAPY; TRIAL	Prostate specific antigen (PSA) is a widely used marker for prostate cancer, which is secreted by normal prostate cells at low levels, but is produced more substantially by cancer cells. We have previously reported on the use of a DNA vaccine construct that encodes for human PSA gene to elicit host immune responses against cells producing PSA. DNA immunization strategy delivers DNA constructs encoding for a specific immunogen into the host, who becomes the in vivo protein source for the production of antigen. This antigen then is the focus of the resulting immune response. In this study, we examine the induction of immune responses and safety profiles in rhesus macaques immunized with DNA-based PSA vaccine. We observed induction of PSA-specific humoral response as well as positive PSA-specific lymphoproliferative (LPA) response in the vaccinated macaques. We also observed that the stimulated T cells from the PSA-immunized rhesus macaques produced higher levels of Th1 type cytokine IFN-gamma than the control vector immunized animals. On the other hand, DNA immunization did not result in any adverse effects in the immunized macaques, as indicated by complete blood counts, leukocyte differentials and hepatic and renal chemistries. The macaques appeared healthy, without any physical signs of toxicity throughout the observation period. In addition, we did not observe any adverse effect on the vaccination site. The apparent safety and immunogenecity of DNA immunization in this study suggest that further evaluation of this vaccination strategy is warranted.	Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA; Viral Genomix Inc, Philadelphia, PA 19104 USA; Inst Human Gene Therapy, Philadelphia, PA 19104 USA; Primedica Mason Labs, Worcester, MA USA; Wistar Inst Anat & Biol, Philadelphia, PA 19104 USA	University of Pennsylvania; The Wistar Institute	Weiner, DB (corresponding author), Univ Penn, Dept Pathol & Lab Med, 505 Stellar Chance,422 Curie Blvd, Philadelphia, PA 19104 USA.	dbweiner@mail.med.upenn.edu	Weiner, David B/H-8579-2014					ARMBRUSTER DA, 1993, CLIN CHEM, V39, P181; BORING CC, 1994, CA-CANCER J CLIN, V44, P7, DOI 10.3322/canjclin.44.1.7; Boyer JD, 1997, NAT MED, V3, P526, DOI 10.1038/nm0597-526; Boyer JD, 1999, CLIN IMMUNOL, V90, P100, DOI 10.1006/clim.1998.4616; CLERICI M, 1993, SCIENCE, V262, P1721, DOI 10.1126/science.7903123; CONRY RM, 1994, CANCER RES, V54, P1164; Conry RM, 1998, CLIN CANCER RES, V4, P2903; D'Amico AV, 1998, CANCER, V82, P334, DOI 10.1002/(SICI)1097-0142(19980115)82:2<342::AID-CNCR14>3.0.CO;2-Z; Eder JP, 2000, CLIN CANCER RES, V6, P1632; Garnick MB, 1998, SCI AM, V279, P74, DOI 10.1038/scientificamerican1298-74; Godley PA, 1999, CANCER DETECT PREV, V23, P316, DOI 10.1046/j.1525-1500.1999.99033.x; HODGE JW, 1995, INT J CANCER, V63, P231, DOI 10.1002/ijc.2910630215; JIAO SS, 1992, HUM GENE THER, V3, P21, DOI 10.1089/hum.1992.3.1-21; KELLEY JR, 1998, GENE THER MOL BIOL, V2, P14; Kim JJ, 1998, ONCOGENE, V17, P3125, DOI 10.1038/sj.onc.1201736; Kim JJ, 1998, J CLIN INVEST, V102, P1112, DOI 10.1172/JCI3986; LABRIE F, 1992, J UROLOGY, V151, P1283; Lekutis C, 1997, J IMMUNOL, V158, P4471; Letvin NL, 1997, P NATL ACAD SCI USA, V94, P9378, DOI 10.1073/pnas.94.17.9378; Lotze MT, 1997, ADV EXP MED BIOL, V417, P551; MacGregor RR, 1998, J INFECT DIS, V178, P92, DOI 10.1086/515613; Malkowicz SB, 1998, HEMATOL ONCOL CLIN N, V12, P649, DOI 10.1016/S0889-8588(05)70013-7; Murphy G, 1996, PROSTATE, V29, P371; ODONNELL PD, 1989, J UROLOGY, V142, P1227, DOI 10.1016/S0022-5347(17)39038-9; Porgador A, 1996, J IMMUNOL, V156, P2918; Rosenberg ES, 1997, SCIENCE, V278, P1447, DOI 10.1126/science.278.5342.1447; SANDA MG, 1994, J UROLOGY, V151, P622, DOI 10.1016/S0022-5347(17)35032-2; SEDER RA, 1994, ANNU REV IMMUNOL, V12, P635, DOI 10.1146/annurev.iy.12.040194.003223; Small EJ, 2000, CURR OPIN ONCOL, V12, P265, DOI 10.1097/00001622-200005000-00014; Smith BF, 1998, GENE THER, V5, P865, DOI 10.1038/sj.gt.3300675; Stenman UH, 1999, SEMIN CANCER BIOL, V9, P83, DOI 10.1006/scbi.1998.0086; Tjoa B, 1996, PROSTATE, V28, P65; Tuting T, 1997, J MOL MED-JMM, V75, P478, DOI 10.1007/s001090050133; VIEWEG J, 1994, CANCER RES, V54, P1760; WANG MC, 1982, METHOD CANCER RES, V19, P179; Wang RB, 1998, SCIENCE, V282, P476, DOI 10.1126/science.282.5388.476; WATT KWK, 1986, P NATL ACAD SCI USA, V83, P3166, DOI 10.1073/pnas.83.10.3166; ZAGARS GK, 1995, UROLOGY, V45, P476, DOI 10.1016/S0090-4295(99)80019-3	38	32	35	0	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 27	2001	20	33					4497	4506		10.1038/sj.onc.1204542	http://dx.doi.org/10.1038/sj.onc.1204542			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	456GN	11494145				2022-12-17	WOS:000170074900007
J	Shi, YJ; Simmons, MN; Seki, T; Oh, SP; Sugrue, SP				Shi, YJ; Simmons, MN; Seki, T; Oh, SP; Sugrue, SP			Change in gene expression subsequent to induction of Pnn/DRS/memA: increase in p21(cip1/waf1)	ONCOGENE			English	Article						Pnn; cell migration; cell cycle progression; p21(cip1/waf1); RhoA; MMP-7; MIC-1	CELL-CYCLE ARREST; METALLOPROTEINASE MATRILYSIN MMP-7; MACROPHAGE INHIBITORY CYTOKINE; TRANSCRIPTION FACTOR SNAIL; E-CADHERIN EXPRESSION; TGF-BETA SUPERFAMILY; C-MYC; MATRIX METALLOPROTEINASES; DESMOSOMAL PROTEIN; DNA-REPLICATION	Pnn (PNN) is a nuclear and cell adhesion-related protein. Previous work has suggested that Pnn/DRS/memA is a potential tumor suppressor involved in the regulation of cell adhesion and cell migration. Using the ecdysone-inducible mammalian expression system, a stable inducible GFP-tagged human Pnn gene (PNNGFP) expressing 293 cell line was created (EcR293-PNNGFP), Cells induced to express PNNGFP not only exhibited increased cell-cell adhesion but also exhibited changes in cell growth and cell cycle progression. cDNA array analyses, together with real time PCR, revealed that the effects of exogenously expressed Pnn on cellular behavior may be linked to the regulation of the expression of specific subset genes. This subset includes cell cycle-related genes such as p21(cip1/waf1), CDK4, CPR2; cell migration and invasion regulatory genes such as RhoA, CDK5, TIMP-1, MMP-7, and EMMPRIN; and MIC-1, Concordant with previous observations of Pnn-induced phenotype changes, genes coding for epithelial associated processes and cell division controls were elevated, while those coding for increased cell motility and cellular reorganizations were downregulated. We utilized p21 promoter-luciferase reporter constructs and demonstrated that a marked stimulation of p21 promoter activity in 293 cells correlated with increased Pnn expression, Taken together, these data indicate that Pnn may participate in the regulation of gene expression, thereby, positively promoting cell-cell adhesion, and negatively affecting cell migration and cell proliferation.	Univ Florida, Coll Med, Dept Anat & Cell Biol, Gainesville, FL 32610 USA; Univ Florida, Coll Med, Dept Physiol, Gainesville, FL 32610 USA	State University System of Florida; University of Florida; State University System of Florida; University of Florida	Sugrue, SP (corresponding author), Univ Florida, Coll Med, Dept Anat & Cell Biol, Archer Rd, Gainesville, FL 32610 USA.	sugrue@anatomy.med.ufl.edu			NEI NIH HHS [EY07883] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY007883] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Aberle H, 1996, J CELL BIOCHEM, V61, P514, DOI 10.1002/(SICI)1097-4644(19960616)61:4<514::AID-JCB4>3.0.CO;2-R; Adachi Y, 1998, INT J ONCOL, V13, P1031; Adachi Y, 1999, GUT, V45, P252, DOI 10.1136/gut.45.2.252; Balda MS, 2000, EMBO J, V19, P2024, DOI 10.1093/emboj/19.9.2024; Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; Bauskin AR, 2000, EMBO J, V19, P2212, DOI 10.1093/emboj/19.10.2212; Ben-Ze'ev A, 1998, CURR OPIN CELL BIOL, V10, P629, DOI 10.1016/S0955-0674(98)80039-2; Berditchevski F, 1997, J BIOL CHEM, V272, P29174, DOI 10.1074/jbc.272.46.29174; BISWAS C, 1995, CANCER RES, V55, P434; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; Bootcov MR, 1997, P NATL ACAD SCI USA, V94, P11514, DOI 10.1073/pnas.94.21.11514; Bordador LC, 2000, INT J CANCER, V85, P347, DOI 10.1002/(SICI)1097-0215(20000201)85:3<347::AID-IJC9>3.3.CO;2-R; Bramhall SR, 1997, J PATHOL, V182, P347, DOI 10.1002/(SICI)1096-9896(199707)182:3<347::AID-PATH848>3.0.CO;2-J; Brandner JM, 1997, DIFFERENTIATION, V62, P119, DOI 10.1046/j.1432-0436.1997.6230119.x; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Claassen GF, 2000, P NATL ACAD SCI USA, V97, P9498, DOI 10.1073/pnas.150006697; Criqui-Filipe P, 1999, EMBO J, V18, P3392, DOI 10.1093/emboj/18.12.3392; Dang CV, 1999, MOL CELL BIOL, V19, P1; DeCastro R, 1996, J INVEST DERMATOL, V106, P1260, DOI 10.1111/1523-1747.ep12348959; Degen WGJ, 1999, BBA-GENE STRUCT EXPR, V1444, P384, DOI 10.1016/S0167-4781(99)00012-3; Edwards MC, 1997, GENETICS, V147, P1063; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Fang F, 1996, SCIENCE, V271, P499, DOI 10.1126/science.271.5248.499; Fischer RS, 1998, VIROLOGY, V249, P427, DOI 10.1006/viro.1998.9337; Frisch SM, 1997, BIOESSAYS, V19, P705, DOI 10.1002/bies.950190811; FRISCH SM, 1994, J CELL BIOL, V127, P1085, DOI 10.1083/jcb.127.4.1085; Grooteclaes ML, 2000, ONCOGENE, V19, P3823, DOI 10.1038/sj.onc.1203721; Guo HM, 1998, GENE, V220, P99, DOI 10.1016/S0378-1119(98)00400-4; GUO K, 1995, MOL CELL BIOL, V15, P3823; Harada K, 2000, ORAL ONCOL, V36, P3, DOI 10.1016/S1368-8375(99)00049-4; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Hecht A, 2000, EMBO J, V19, P1839, DOI 10.1093/emboj/19.8.1839; Hoover KB, 1998, AM J PATHOL, V153, P1767, DOI 10.1016/S0002-9440(10)65691-X; JONES N, 1995, CURR TOP MICROBIOL, V199, P59; KANAI Y, 1994, MOLECULAR AND CELLULAR BASIS FOR CELL TO CELL INTERACTION: ITS SIGNIFICANCE IN CANCER, P51; Kannan K, 2000, FEBS LETT, V470, P77, DOI 10.1016/S0014-5793(00)01291-6; Kitaura H, 2000, J BIOL CHEM, V275, P10477, DOI 10.1074/jbc.275.14.10477; Kwon YT, 2000, CURR BIOL, V10, P363, DOI 10.1016/S0960-9822(00)00411-5; Mann B, 1999, P NATL ACAD SCI USA, V96, P1603, DOI 10.1073/pnas.96.4.1603; Moll I, 1997, J INVEST DERMATOL, V108, P139, DOI 10.1111/1523-1747.ep12332388; Moorman JP, 1999, ONCOGENE, V18, P47, DOI 10.1038/sj.onc.1202262; Mueller S, 2000, CANCER RES, V60, P156; Nibu Y, 1998, SCIENCE, V280, P101, DOI 10.1126/science.280.5360.101; Niculescu AB, 1998, MOL CELL BIOL, V18, P629, DOI 10.1128/MCB.18.1.629; O'Connor KL, 2000, J CELL BIOL, V148, P253, DOI 10.1083/jcb.148.2.253; Orend G, 1998, ONCOGENE, V16, P2575, DOI 10.1038/sj.onc.1201791; OUYANG P, 1992, J CELL BIOL, V118, P1477, DOI 10.1083/jcb.118.6.1477; Perou CM, 1999, P NATL ACAD SCI USA, V96, P9212, DOI 10.1073/pnas.96.16.9212; Pin OY, 1999, BIOCHEM BIOPH RES CO, V263, P192, DOI 10.1006/bbrc.1999.1353; Pin OY, 1996, J CELL BIOL, V135, P1027, DOI 10.1083/jcb.135.4.1027; Rorke EA, 2000, EXP CELL RES, V259, P149, DOI 10.1006/excr.2000.4953; Ross DT, 2000, NAT GENET, V24, P227, DOI 10.1038/73432; Sander EE, 1999, EUR J CANCER, V35, P1302, DOI 10.1016/S0959-8049(99)00145-8; SHEIKH MS, 1994, ONCOGENE, V9, P3407; SHERR CJ, 1995, TRENDS BIOCHEM SCI, V20, P187, DOI 10.1016/S0968-0004(00)89005-2; Shi YJ, 2000, ONCOGENE, V19, P289, DOI 10.1038/sj.onc.1203328; Shi YJ, 2000, INVEST OPHTH VIS SCI, V41, P1337; Simcha I, 1998, J CELL BIOL, V141, P1433, DOI 10.1083/jcb.141.6.1433; Snowden AW, 2000, MOL CELL BIOL, V20, P2676, DOI 10.1128/MCB.20.8.2676-2686.2000; St Croix B, 1998, J CELL BIOL, V142, P557, DOI 10.1083/jcb.142.2.557; Takemaru KI, 2000, J CELL BIOL, V149, P249, DOI 10.1083/jcb.149.2.249; Tanimoto H, 1999, TUMOR BIOL, V20, P88, DOI 10.1159/000030051; Wu RC, 1997, J BIOL CHEM, V272, P29091, DOI 10.1074/jbc.272.46.29091; YAMAMOTO H, 1995, J CLIN LAB ANAL, V9, P297, DOI 10.1002/jcla.1860090504	64	32	34	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 5	2001	20	30					4007	4018		10.1038/sj.onc.1204507	http://dx.doi.org/10.1038/sj.onc.1204507			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	449JM	11494129				2022-12-17	WOS:000169681500009
J	Chan, TL; Yuen, ST; Ho, JWC; Chan, ASY; Kwan, KD; Chung, LP; Lam, PWY; Tse, CW; Leung, SY				Chan, TL; Yuen, ST; Ho, JWC; Chan, ASY; Kwan, KD; Chung, LP; Lam, PWY; Tse, CW; Leung, SY			A novel germline 1.8-kb deletion of hMLH1 mimicking alternative splicing: a founder mutation in the Chinese population	ONCOGENE			English	Article						hMLH1; germline mutation; intragenic deletion; alternative splicing; HNPCC syndrome	NONPOLYPOSIS COLORECTAL-CANCER; DNA MISMATCH REPAIR; HEREDITARY COLON-CANCER; MLH1 MESSENGER-RNA; MICROSATELLITE INSTABILITY; GENE-MUTATIONS; YOUNG-PATIENTS; HMSH2; MSH2; FAMILIES	We have previously reported that there is a high incidence of microsatellite instability (MSI) and germline mismatch repair gene mutation in colorectal cancer arising from young Hong Kong Chinese, Most of the germline mutations involve hMSH2, which is different from the mutation spectrum in the Western population. It is well known that alternative splicing is common in hMLH1, which complicates RNA based mutation detection methods. In contrast, large deletions in hMLH1, commonly observed in some ethnic groups, tend to escape detection by exon-by-exon direct DNA sequencing. Here we report the detection of a novel germline 1.8 kb deletion involving exon 11 of hMLH1 in a local hereditary non-polyposis colorectal cancer family. This mutation generates a mRNA transcript with deletion of exons 10-11, which is indistinguishable from one of the most common and predominant hMLH1 splice variants, A diagnostic test based on PCR of the breakpoint region led to the identification of an additional young colorectal cancer patient with this mutation. Haplotype analysis suggests that they may share a common ancestral mutation. Our results caution investigators in the interpretation of alternative splicing and have important implications for the design of hMLH1 mutation detection strategy in the Chinese population. Oncogene (2001) 20, 2976-2981.	Univ Hong Kong, Queen Mary Hosp, Dept Pathol, Hong Kong, Hong Kong, Peoples R China; Univ Hong Kong, Queen Mary Hosp, Hereditary Gastrointestinal Canc Registry, Hong Kong, Hong Kong, Peoples R China; Queen Elizabeth Hosp, Dept Surg, Kowloon, Hong Kong, Peoples R China; Queen Elizabeth Hosp, Dept Pathol, Kowloon, Hong Kong, Peoples R China	University of Hong Kong; University of Hong Kong	Leung, SY (corresponding author), Univ Hong Kong, Queen Mary Hosp, Dept Pathol, Pokfulam Rd, Hong Kong, Hong Kong, Peoples R China.		Chung, Lap Ping/C-4258-2009; Leung, Suet Yi/C-4340-2009; Yuen, Siu/K-6311-2014; Leung, Suet Yi/T-9620-2019	Leung, Suet Yi/0000-0001-8614-4619				AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; Akiyama Y, 1997, CANCER RES, V57, P3920; Bapat BV, 1999, HUM GENET, V104, P167, DOI 10.1007/s004390050931; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; BUERSTEDDE JM, 1995, J MED GENET, V32, P909, DOI 10.1136/jmg.32.11.909; Chan TL, 1999, JNCI-J NATL CANCER I, V91, P1221, DOI 10.1093/jnci/91.14.1221; Charbonnier F, 2000, CANCER RES, V60, P2760; CHARBONNIER F, 1995, CANCER RES, V55, P1839; DRUMMOND JT, 1995, SCIENCE, V268, P1909, DOI 10.1126/science.7604264; Farrington SM, 1998, AM J HUM GENET, V63, P749, DOI 10.1086/301996; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; Froggatt NJ, 1996, J MED GENET, V33, P726, DOI 10.1136/jmg.33.9.726; Ho JWC, 2000, INT J CANCER, V89, P356, DOI 10.1002/1097-0215(20000720)89:4<356::AID-IJC7>3.0.CO;2-J; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; KohonenCorish M, 1996, AM J HUM GENET, V59, P818; Lamberti C, 1999, GUT, V44, P839, DOI 10.1136/gut.44.6.839; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; Leung SY, 1998, AM J PATHOL, V153, P1181, DOI 10.1016/S0002-9440(10)65662-3; Leung SY, 1999, CANCER RES, V59, P159; Liu B, 1996, NAT MED, V2, P169, DOI 10.1038/nm0296-169; LIU B, 1995, NAT MED, V1, P348, DOI 10.1038/nm0495-348; Mauillon JL, 1996, CANCER RES, V56, P5728; MIYAKI M, 1995, J MOL MED-JMM, V73, P515; Miyaki M, 1997, NAT GENET, V17, P271, DOI 10.1038/ng1197-271; Moslein G, 1996, HUM MOL GENET, V5, P1245, DOI 10.1093/hmg/5.9.1245; NICOLAIDES NC, 1994, NATURE, V371, P75, DOI 10.1038/371075a0; NYSTROMLAHTI M, 1995, NAT MED, V1, P1203, DOI 10.1038/nm1195-1203; NystromLahti M, 1996, HUM MOL GENET, V5, P763, DOI 10.1093/hmg/5.6.763; Palmer E, 1998, CHEM BRIT, V34, P27; PALOMBO F, 1995, SCIENCE, V268, P1912, DOI 10.1126/science.7604265; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; Peltomaki P, 1997, GASTROENTEROLOGY, V113, P1146, DOI 10.1053/gast.1997.v113.pm9322509; Schuelke M, 2000, NAT BIOTECHNOL, V18, P233, DOI 10.1038/72708; Stelter A, 2000, INT FED INFO PROC, V51, P43; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; Viel A, 1997, GENE CHROMOSOME CANC, V18, P8, DOI 10.1002/(SICI)1098-2264(199701)18:1<8::AID-GCC2>3.0.CO;2-7; Weber TK, 1997, CANCER RES, V57, P3798; WIJNEN J, 1995, AM J HUM GENET, V56, P1060; Wijnen J, 1998, NAT GENET, V20, P326, DOI 10.1038/3795; Wijnen J, 1996, AM J HUM GENET, V58, P300; Yuen ST, 1997, BRIT J CANCER, V76, P1610, DOI 10.1038/bjc.1997.605	41	32	33	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 24	2001	20	23					2976	2981		10.1038/sj.onc.1204376	http://dx.doi.org/10.1038/sj.onc.1204376			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	435VA	11420710				2022-12-17	WOS:000168901800013
J	Fluge, O; Haugen, DRF; Akslen, LA; Marstad, A; Santoro, M; Fusco, A; Varhaug, JE; Lillehaug, JR				Fluge, O; Haugen, DRF; Akslen, LA; Marstad, A; Santoro, M; Fusco, A; Varhaug, JE; Lillehaug, JR			Expression and alternative splicing of c-ret RNA in papillary thyroid carcinomas	ONCOGENE			English	Article						ret; RNA splicing; ret/ptc; thyroid carcinoma	RET/PTC ONCOGENE ACTIVATION; TYROSINE KINASE; 3'-SPLICING VARIANTS; SIGNAL-TRANSDUCTION; HUMAN KIDNEY; PROTOONCOGENE; RECEPTOR; MUTATIONS; GENE; PHENOTYPES	Somatic rearrangements of the ret receptor tyrosine kinase have been consistently reported in papillary thyroid carcinomas (PTC), It is unclear whether the expression of wild-type c-ret may also be implicated in thyroid tumorigenesis, We studied ret mRNA expression in PTC from Norwegian patients. Using RT-PCR, wild-type ret mRNA was detected in all of 22 PTC and in a PTC cell line. c-ret mRNA was clearly overexpressed in PTC as compared to non-neoplastic thyroid tissue. Hybridization using ret exon DNA dot blot arrays and complex cDNA probes confirmed expression of ret RNA in thyroid biopsies. In accordance with the RNA data, Western immunoblotting showed evidence of wildtype Ret protein in PTC, Rearrangements generating the ret/PTC oncogenes co-existed with c-ret mRNA in PTC, Multiple alternative ret splicing variants were detected in PTC, Four novel I et splicing events were found in the region encoding the extracellular domain. The open reading frames of these transcripts were all in-frame with the Ret tyrosine kinase domain. In the central ret mRNA region encoding the cystein-rich, transmembrane, and main tyrosine kinase domains, no evidence of alternative splicing was detected. Two alternative splice events were detected in the I ct mRNA encoding the C-terminal part of Ret protein harboring tyrosine residues important for Ret signaling, excluding exon 19, or retaining intron 19, respectively. Ribonuclease protection assays confirmed the presence of I et alternative splicing events in thyroid biopsies. We conclude that in addition to ret/PTC rearrangements, wild-type c-ret mRNA and alternatively spliced ret transcripts are present in PTC, Transcriptional up-regulation and post-transcriptional mechanisms of c-l et RNA processing may contribute to differences in expression of Ret protein observed in PTC compared to non-neoplastic thyroid tissue.	Univ Bergen, Dept Mol Biol, N-5020 Bergen, Norway; Univ Bergen, Haukeland Hosp, Dept Oncol, N-5021 Bergen, Norway; Univ Bergen, Haukeland Hosp, Gade Inst, Dept Pathol, N-5021 Bergen, Norway; CNR, Ctr Endocrinol & Oncol Sperimentale, I-80131 Naples, Italy; Univ Catanzaro, Fac Med & Chirurg, Dipartimento Med Sperimentale & Clin, I-88100 Catanzaro, Italy; Univ Bergen, Haukeland Hosp, Dept Surg, N-5021 Bergen, Norway	University of Bergen; University of Bergen; Haukeland University Hospital; University of Bergen; Haukeland University Hospital; Consiglio Nazionale delle Ricerche (CNR); Magna Graecia University of Catanzaro; University of Bergen; Haukeland University Hospital	Fluge, O (corresponding author), Univ Bergen, Dept Mol Biol, Thormohlens Gt 55, N-5020 Bergen, Norway.		Akslen, Lars A./AAG-6097-2021; Haugen, Dagny R. Faksvåg/AAX-7989-2021; Akslen, Lars A/C-1202-2017	Akslen, Lars A./0000-0003-2710-9543; Akslen, Lars A/0000-0003-2710-9543; Haugen, Dagny Faksvag/0000-0002-8592-4995; Fusco, Alfredo/0000-0003-3332-5197				Airaksinen MS, 1999, MOL CELL NEUROSCI, V13, P313, DOI 10.1006/mcne.1999.0754; ATTIE T, 1995, HUM MOL GENET, V4, P1381, DOI 10.1093/hmg/4.8.1381; Bunone G, 2000, CANCER RES, V60, P2845; Carson-Walter EB, 1998, ONCOGENE, V17, P367, DOI 10.1038/sj.onc.1201938; CECCHERINI I, 1993, BIOCHEM BIOPH RES CO, V196, P1288, DOI 10.1006/bbrc.1993.2392; de Nigris F, 1998, CANCER RES, V58, P4745; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; Fluge O, 2000, INT J CANCER, V87, P763, DOI 10.1002/1097-0215(20000915)87:6<763::AID-IJC1>3.0.CO;2-T; ISHIZAKA Y, 1992, ONCOGENE, V7, P1441; Ivanchuk SM, 1998, ONCOGENE, V16, P991, DOI 10.1038/sj.onc.1201622; Ivanchuk SM, 1997, ONCOGENE, V14, P1811, DOI 10.1038/sj.onc.1201016; KWOK JBJ, 1993, ONCOGENE, V8, P2575; Lam AKY, 1998, HUM PATHOL, V29, P565, DOI 10.1016/S0046-8177(98)80004-X; Landsvater RM, 1996, HUM GENET, V97, P11, DOI 10.1007/BF00218825; Learoyd DL, 1998, J CLIN ENDOCR METAB, V83, P3631, DOI 10.1210/jc.83.10.3631; LORENZO MJ, 1995, ONCOGENE, V10, P1377; Lorenzo MJ, 1997, ONCOGENE, V14, P763, DOI 10.1038/sj.onc.1200894; MULLIGAN LM, 1994, HUM MOL GENET, V3, P2163, DOI 10.1093/hmg/3.12.2163; MYERS SM, 1995, ONCOGENE, V11, P2039; Nikiforov YE, 1997, CANCER RES, V57, P1690; SANTORO M, 1993, BRIT J CANCER, V68, P460, DOI 10.1038/bjc.1993.370; SANTORO M, 1994, MOL CELL BIOL, V14, P663, DOI 10.1128/MCB.14.1.663; Santoro M, 1999, BIOCHIMIE, V81, P397, DOI 10.1016/S0300-9084(99)80087-X; TAHIRA T, 1990, ONCOGENE, V5, P97; TAKAHASHI M, 1989, ONCOGENE, V4, P805; TAKAHASHI M, 1988, ONCOGENE, V3, P571; Tallini G, 1998, CLIN CANCER RES, V4, P287; Treanor JJS, 1996, NATURE, V382, P80, DOI 10.1038/382080a0; van Weering DHJ, 1998, RECENT RES CANCER, V154, P271; VIGLIETTO G, 1995, ONCOGENE, V11, P1207; Visser M, 1996, BRIT J HAEMATOL, V94, P236, DOI 10.1046/j.1365-2141.1996.d01-1789.x; Williams GH, 1996, BRIT J CANCER, V74, P585, DOI 10.1038/bjc.1996.405; Wilson KF, 1999, J BIOL CHEM, V274, P4166, DOI 10.1074/jbc.274.7.4166; Wirtschafter A, 1997, LARYNGOSCOPE, V107, P95, DOI 10.1097/00005537-199701000-00019; XING SH, 1994, BIOCHEM BIOPH RES CO, V205, P1526, DOI 10.1006/bbrc.1994.2840	35	32	33	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 15	2001	20	7					885	892		10.1038/sj.onc.1204161	http://dx.doi.org/10.1038/sj.onc.1204161			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	401JL	11314023				2022-12-17	WOS:000166924400013
J	Baross-Francis, A; Makhani, N; Liskay, RM; Jirik, FR				Baross-Francis, A; Makhani, N; Liskay, RM; Jirik, FR			Elevated mutant frequencies and increased C : G -> T : A transitions in Mlh1(-/-) versus Pms2(-/-) murine small intestinal epithelial cells	ONCOGENE			English	Article						DNA mismatch repair; Mlh1; Pms2; transgenic; lacI	DNA MISMATCH REPAIR; COLORECTAL-CANCER; MICROSATELLITE INSTABILITY; PROMOTER METHYLATION; TRANSGENIC MICE; GENE PMS2; LACI GENE; MUTATIONS; MLH1; HMLH1	Mutations in DNA mismatch repair (MMR) genes are associated with increased genomic instability and susceptibility to cancer. Mice rendered deficient in either Mlh1 or Pms2 as a result of gene targeting are prone to tumorigenesis, particularly, lymphomas, In addition, although Mlh1(-/-) mice also develop small intestinal adenomas and adenocarcinomas, Pms2(-/-) animals remain free of such tumors. To establish whether this phenotypic dichotomy might he associated with quantitative and/or qualitative difference in genomic instability in these mice, we determined small intestinal epithelial cell DNA mutant frequency and mutation using a transgenic lambda -phage lacI reporter Mutant frequencies obtained from both Mlh1(-/-) and Pms2(-/-) mice revealed elevations of 18 and 13-fold, respectively, as compared to their wild-type littermates. interestingly, we found that C:G-->T:A transitions, were significantly elevated in MlH1 (/-) mice, accounting in large measure for the 1.5-fold lacI mutant frequency increase seen in these animals, We hypothesize that the increased level of C:G-->T:A mutations may explain, in part, why Mlh1(-/) mice, but not Pms2(-/-) mice, develop small intestinal tumors, Furthermore, the difference in the lacI mutational spectrum of Mlh1 and Pms2(-/-) mice suggests that other MutL-like heterodimers may play important roles in the repair of G : T mispairs arising within murine small intestinal epithelial cells.	Univ British Columbia, Ctr Mol Med & Therapeut, Vancouver, BC V5Z 4H4, Canada; Univ British Columbia, Dept Med, Vancouver, BC V5Z 4H4, Canada; Oregon Hlth Sci Univ, Dept Med & Mol Genet, Portland, OR 97201 USA	University of British Columbia; University of British Columbia; Oregon Health & Science University	Jirik, FR (corresponding author), Univ British Columbia, Ctr Mol Med & Therapeut, Vancouver, BC V5Z 4H4, Canada.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032741] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM32741] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Andrew SE, 1996, MUTAT RES-FUND MOL M, V357, P57, DOI 10.1016/0027-5107(96)00080-2; Baker SM, 1996, NAT GENET, V13, P336, DOI 10.1038/ng0796-336; BAKER SM, 1995, CELL, V82, P309, DOI 10.1016/0092-8674(95)90318-6; de Boer JG, 1998, GENETICS, V148, P1441; DEBOER J, 1999, BIG BLUE WEBSITE; Di Cristofano A, 1998, NAT GENET, V19, P348, DOI 10.1038/1235; Dogliotti E, 1996, CARCINOGENESIS, V17, P2113, DOI 10.1093/carcin/17.10.2113; Edelmann W, 1997, CELL, V91, P467, DOI 10.1016/S0092-8674(00)80433-X; Flores-Rozas H, 1998, P NATL ACAD SCI USA, V95, P12404, DOI 10.1073/pnas.95.21.12404; Guerrette S, 1999, J BIOL CHEM, V274, P6336, DOI 10.1074/jbc.274.10.6336; Herman JG, 1998, P NATL ACAD SCI USA, V95, P6870, DOI 10.1073/pnas.95.12.6870; Heyer J, 1999, ONCOGENE, V18, P5325, DOI 10.1038/sj.onc.1203036; Huang J, 1996, P NATL ACAD SCI USA, V93, P9049, DOI 10.1073/pnas.93.17.9049; Jiricny J, 1998, MUTAT RES-DNA REPAIR, V409, P107, DOI 10.1016/S0921-8777(98)00056-1; Kato T, 1998, MUTAT RES-FUND MOL M, V422, P279, DOI 10.1016/S0027-5107(98)00208-5; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; KOHLER SW, 1991, P NATL ACAD SCI USA, V88, P7958, DOI 10.1073/pnas.88.18.7958; KOHLER SW, 1990, GENET ANAL-BIOMOL E, V7, P212, DOI 10.1016/0735-0651(90)90003-X; KOLODNER RD, 1995, TRENDS BIOCHEM SCI, V20, P397, DOI 10.1016/S0968-0004(00)89087-8; Kolodner RD, 1999, CURR OPIN GENET DEV, V9, P89, DOI 10.1016/S0959-437X(99)80013-6; LAZAR V, 1994, HUM MOL GENET, V3, P2257, DOI 10.1093/hmg/3.12.2257; Leung SY, 1999, CANCER RES, V59, P159; Lipkin SM, 2000, NAT GENET, V24, P27, DOI 10.1038/71643; Lynch ED, 1997, AM J HUM GENET, V61, P1254, DOI 10.1086/301639; Marra G, 1999, BIOCHEM J, V338, P1, DOI 10.1042/0264-6021:3380001; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; Narayanan L, 1997, P NATL ACAD SCI USA, V94, P3122, DOI 10.1073/pnas.94.7.3122; Olschwang S, 1997, P NATL ACAD SCI USA, V94, P12122, DOI 10.1073/pnas.94.22.12122; Prolla TA, 1998, CURR OPIN CELL BIOL, V10, P311, DOI 10.1016/S0955-0674(98)80005-7; Prolla TA, 1998, NAT GENET, V18, P276, DOI 10.1038/ng0398-276; PROLLA TA, 1994, SCIENCE, V265, P1091, DOI 10.1126/science.8066446; Raschle M, 1999, J BIOL CHEM, V274, P32368, DOI 10.1074/jbc.274.45.32368; Ricciardone MD, 1999, CANCER RES, V59, P290; Simpkins SB, 1999, HUM MOL GENET, V8, P661, DOI 10.1093/hmg/8.4.661; Suzuki A, 1998, CURR BIOL, V8, P1169, DOI 10.1016/S0960-9822(07)00488-5; Toft NJ, 1998, J PATHOL, V185, P123; Wang Q, 1999, HUM GENET, V105, P79, DOI 10.1007/s004390051067; Wang Q, 1999, CANCER RES, V59, P294; Wheeler JMD, 1999, P NATL ACAD SCI USA, V96, P10296, DOI 10.1073/pnas.96.18.10296; Yang Y, 1999, MOL GEN GENET, V261, P777, DOI 10.1007/s004380050021; Yao X, 1999, P NATL ACAD SCI USA, V96, P6850, DOI 10.1073/pnas.96.12.6850	41	32	32	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 1	2001	20	5					619	625		10.1038/sj.onc.1204138	http://dx.doi.org/10.1038/sj.onc.1204138			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	398KE	11313994				2022-12-17	WOS:000166755000009
J	Foos, G; Hauser, CA				Foos, G; Hauser, CA			Altered Ets transcription factor activity in prostate tumor cells inhibits anchorage-independent growth, survival, and invasiveness	ONCOGENE			English	Article						prostate cancer; Ets2 overexpression; dominant negative Ets2; transformation	MEDIATED CELLULAR-TRANSFORMATION; COLON-CANCER CELLS; ANDROGEN RECEPTOR; INDUCED APOPTOSIS; GENE-EXPRESSION; CARCINOMA CELLS; RAS; ACTIVATION; PROTEIN; LINES	The Ets family of transcription factors are important downstream targets in cellular transformation, as altering Ets activity has been found to reverse the transformed phenotype of Ras transformed mouse fibroblasts and of several human tumor cell lines. To determine whether Ets factors are important targets in the largely uncharacterized aberrant signaling in prostate cancer, we have altered Ets activity in the prostate tumor cell line PPC-1, by stable expression of either full-length Ets2, or a dominant inhibitor of Ets activity, the Ets2 DNA binding domain (Ets2DBD). Analysis of multiple independent clonal cell lines revealed that expression of either Ets2 or the Ets2DBD inhibited the anchorage-independent growth of PPC-1 cells up to 20-fold. In contrast to our previous findings with Ras-transformed NIH3T3 cells, PPC-1 cell lines expressing either Ets2 or the EtsDBD exhibited slower attached cell growth, increased Ets-dependent gene expression, and up to a 10-fold increase in apoptotic cell death. The p21(cip) gene was identified as a potential target of altered Ets signaling. Interestingly, the two distinct Ets2 constructs had strikingly different effects on in vitro invasiveness. Expression of the Ets2DBD almost completely blocked PPC-1 cell invasion through Matrigel, whereas overexpression of full-length Ets2 did not inhibit invasion. Overall, these results demonstrate that the balance of Ets factor activity can regulate multiple aspects of the transformed phenotype of PPC-1 prostate tumor cells, including anchorage-independent growth, survival, and invasiveness.	La Jolla Canc Res Ctr, Burnham Inst, La Jolla, CA 92037 USA	Sanford Burnham Prebys Medical Discovery Institute	Hauser, CA (corresponding author), La Jolla Canc Res Ctr, Burnham Inst, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.				NATIONAL CANCER INSTITUTE [R01CA063130, R01CA074547] Funding Source: NIH RePORTER; NCI NIH HHS [CA63130, CA74547] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Beier F, 1999, J BIOL CHEM, V274, P30273, DOI 10.1074/jbc.274.42.30273; Borden P, 1997, CRIT REV EUKAR GENE, V7, P159, DOI 10.1615/CritRevEukarGeneExpr.v7.i1-2.90; BORNER MM, 1995, CANCER RES, V55, P2122; BROTHMAN AR, 1989, INT J CANCER, V44, P898, DOI 10.1002/ijc.2910440525; BROTHMAN AR, 1991, J UROLOGY, V145, P1088, DOI 10.1016/S0022-5347(17)38540-3; CHEN G, 1995, EXP CELL RES, V221, P55, DOI 10.1006/excr.1995.1351; CHEN TR, 1993, CYTOGENET CELL GENET, V62, P183, DOI 10.1159/000133468; Chen ZQ, 1997, CANCER RES, V57, P2013; CLARK GJ, 1995, METHOD ENZYMOL, V255, P395; Crawford HC, 1996, ENZYME PROTEIN, V49, P20, DOI 10.1159/000468614; Delannoy-Courdent A, 1998, J CELL SCI, V111, P1521; Dittmer J, 1998, BBA-REV CANCER, V1377, pF1, DOI 10.1016/S0304-419X(97)00039-5; Foos G, 1998, J BIOL CHEM, V273, P18871, DOI 10.1074/jbc.273.30.18871; Funaoka K, 1997, BIOCHEM BIOPH RES CO, V236, P79, DOI 10.1006/bbrc.1997.6909; Galang CK, 1996, J BIOL CHEM, V271, P7992, DOI 10.1074/jbc.271.14.7992; GALANG CK, 1994, ONCOGENE, V9, P2913; GHYSDAEL J, 1997, ONCOGENES TRANSCRIPT, V1, P29; Graves BJ, 1998, ADV CANCER RES, V75, P1, DOI 10.1016/S0065-230X(08)60738-1; GUMERLOCK PH, 1991, CANCER RES, V51, P1632; HAUSER CA, 1995, METHOD ENZYMOL, V255, P412; Huang CC, 1997, ONCOGENE, V15, P851, DOI 10.1038/sj.onc.1201408; HUNCHAREK M, 1995, CANCER EPIDEM BIOMAR, V4, P681; Konishi N, 1997, PROSTATE, V30, P53; Kurada P, 1998, CELL, V95, P319, DOI 10.1016/S0092-8674(00)81764-X; LANGER SJ, 1992, MOL CELL BIOL, V12, P5355, DOI 10.1128/MCB.12.12.5355; Li RH, 1999, P NATL ACAD SCI USA, V96, P3876, DOI 10.1073/pnas.96.7.3876; Liu AY, 1997, PROSTATE, V30, P145, DOI 10.1002/(SICI)1097-0045(19970215)30:3<145::AID-PROS1>3.0.CO;2-L; McCarthy SA, 1997, MOL CELL BIOL, V17, P2401, DOI 10.1128/MCB.17.5.2401; Rees S, 1996, BIOTECHNIQUES, V20, P102; Royai R, 1996, SEMIN ONCOL, V23, P35; Sapi E, 1998, CANCER RES, V58, P1027; Schneikert J, 1996, J BIOL CHEM, V271, P23907, DOI 10.1074/jbc.271.39.23907; Sementchenko VI, 1998, ONCOGENE, V17, P2883, DOI 10.1038/sj.onc.1202220; Sevilla L, 1999, MOL CELL BIOL, V19, P2624; Shao NS, 1998, ONCOGENE, V17, P527, DOI 10.1038/sj.onc.1201931; Shi XB, 1996, WORLD J UROL, V14, P318, DOI 10.1007/BF00184605; SUZUKI H, 1995, P NATL ACAD SCI USA, V92, P4442, DOI 10.1073/pnas.92.10.4442; Wasilenko WJ, 1996, INT J CANCER, V68, P259, DOI 10.1002/(SICI)1097-0215(19961009)68:2<259::AID-IJC20>3.0.CO;2-4; Wasylyk B, 1998, TRENDS BIOCHEM SCI, V23, P213, DOI 10.1016/S0968-0004(98)01211-0; WASYLYK C, 1989, EMBO J, V8, P3371, DOI 10.1002/j.1460-2075.1989.tb08500.x; WASYLYK C, 1994, ONCOGENE, V9, P3665; Webber MM, 1997, PROSTATE, V30, P58; Woods D, 1997, MOL CELL BIOL, V17, P5598, DOI 10.1128/MCB.17.9.5598; Yamada T, 1997, BLOOD, V89, P1383, DOI 10.1182/blood.V89.4.1383; Yang BS, 1996, MOL CELL BIOL, V16, P538; Zeng YX, 1997, NAT GENET, V15, P78, DOI 10.1038/ng0197-78; Zhang M, 1997, P NATL ACAD SCI USA, V94, P5673, DOI 10.1073/pnas.94.11.5673	47	32	33	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 16	2000	19	48					5507	5516		10.1038/sj.onc.1203946	http://dx.doi.org/10.1038/sj.onc.1203946			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	375JQ	11114728				2022-12-17	WOS:000165396100011
J	Brachat, A; Pierrat, B; Brungger, A; Heim, J				Brachat, A; Pierrat, B; Brungger, A; Heim, J			Comparative microarray analysis of gene expression during apoptosis-induction by growth factor deprivation or protein kinase C inhibition	ONCOGENE			English	Article						apoptosis; microarray; interleukin-3; protein kinase C; staurosporine	PROGRAMMED CELL-DEATH; NF-KAPPA-B; TRANSCRIPTION FACTOR; PROTEOLYTIC ACTIVATION; MEDIATED APOPTOSIS; MOUSE SKIN; IN-VIVO; T-CELLS; SURVIVAL; RECEPTOR	The transcriptional response of mouse pro-B cells to two different apoptotic stimuli was investigated. First, interleukin3 (IL-3) deprivation was used to trigger programmed cell death in IL-3 dependent FL5.12 cells, Alternatively, cells were treated with the protein kinase C (PKC) inhibitor staurosporine, The temporal pattern of gene expression was followed with cDNA microarrays, covering over 8700 different mouse cDNA sequences corresponding to approximately 7900 unique genes. Messenger RNA levels of 315 genes mere found to be regulated by more than twofold upon IL-3 removal, while 125 genes reacted to staurosporine treatment. Cross-comparison revealed an intersection of 34 genes similarly regulated in both pathways and thus representing candidates for common apoptosis regulators, For many expressed sequence tags (ESTs) our data suggest for the first time functions in the control of apoptosis, stress response or the cell cycle. IL-3 removal led to the repression of genes required for proliferation and to the induction of genes, linked to apoptotic and signaling pathways. Staurosporine caused predominantly activation of genes, some of which had previously been described to be involved in inflammation. Our findings indicate that cellular responses to both apoptotic stimuli influence various physiological pathways which had not previously been known to be linked.	Novartis Pharma AG, Mol & Cellular Biol Senior Sci Expert Lab, CH-4002 Basel, Switzerland; Novartis Pharma AG, Oncol Res, CH-4002 Basel, Switzerland	Novartis; Novartis	Heim, J (corresponding author), Novartis Pharma AG, Mol & Cellular Biol Senior Sci Expert Lab, K-125-13-16, CH-4002 Basel, Switzerland.			Brachat, Arndt/0000-0001-5768-3429				BERTRAND R, 1994, EXP CELL RES, V211, P314, DOI 10.1006/excr.1994.1093; Besancon F, 1998, P NATL ACAD SCI USA, V95, P8081, DOI 10.1073/pnas.95.14.8081; BLANDINO G, 1995, ONCOGENE, V10, P731; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; CHOWDHURY K, 1988, NUCLEIC ACIDS RES, V16, P9995, DOI 10.1093/nar/16.21.9995; CHUBATSU LS, 1993, BIOCHEM J, V291, P193, DOI 10.1042/bj2910193; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; De Valck D, 1999, ONCOGENE, V18, P4182, DOI 10.1038/sj.onc.1202787; Denhardt DT, 1998, J CELL BIOCHEM, P92, DOI 10.1002/(SICI)1097-4644(1998)72:30/31+<92::AID-JCB13>3.0.CO;2-A; Dupressoir A, 1999, J BIOL CHEM, V274, P31068, DOI 10.1074/jbc.274.43.31068; ELLIS HM, 1986, CELL, V44, P817, DOI 10.1016/0092-8674(86)90004-8; Emoto Y, 1995, EMBO J, V14, P6148, DOI 10.1002/j.1460-2075.1995.tb00305.x; Galvin JP, 1999, J IMMUNOL, V162, P5345; Germain M, 1999, J BIOL CHEM, V274, P28379, DOI 10.1074/jbc.274.40.28379; Ghayur T, 1996, J EXP MED, V184, P2399, DOI 10.1084/jem.184.6.2399; Gottlieb E, 1998, EMBO J, V17, P3587, DOI 10.1093/emboj/17.13.3587; Grummt I, 1999, PROG NUCLEIC ACID RE, V62, P109; GUPTA AK, 1988, J INVEST DERMATOL, V91, P486, DOI 10.1111/1523-1747.ep12476635; Hamilton GS, 1998, J MED CHEM, V41, P5119, DOI 10.1021/jm980307x; Hartigan J.A., 1975, CLUSTERING ALGORITHM; Hesselgesser J, 1998, CURR BIOL, V8, P595, DOI 10.1016/S0960-9822(98)70230-1; Heyworth C, 1999, GENE DEV, V13, P1847, DOI 10.1101/gad.13.14.1847; Hisaeda H, 1997, J IMMUNOL, V159, P2375; Ikushima S, 1997, P NATL ACAD SCI USA, V94, P2609, DOI 10.1073/pnas.94.6.2609; INGLIS JD, 1991, GENE, V106, P213, DOI 10.1016/0378-1119(91)90201-L; Inukai T, 1999, MOL CELL, V4, P343, DOI 10.1016/S1097-2765(00)80336-6; Jiang SN, 1999, J BIOL CHEM, V274, P29905, DOI 10.1074/jbc.274.42.29905; Kasibhatla S, 1998, MOL CELL, V1, P543, DOI 10.1016/S1097-2765(00)80054-4; Kataoka M, 1997, J BIOL CHEM, V272, P18209, DOI 10.1074/jbc.272.29.18209; Kerkhoff C, 1998, BBA-MOL CELL RES, V1448, P200, DOI 10.1016/S0167-4889(98)00144-X; KHANNA KK, 1993, ONCOGENE, V8, P3307; KIMURA H, 1995, NUCLEIC ACIDS RES, V23, P2097, DOI 10.1093/nar/23.12.2097; Kume K, 1997, BIOCHEM BIOPH RES CO, V237, P663, DOI 10.1006/bbrc.1997.7214; LAROSA FA, 1994, MOL CELL BIOL, V14, P1039, DOI 10.1128/MCB.14.2.1039; Lentsch AB, 1999, CLIN CHEM LAB MED, V37, P205, DOI 10.1515/CCLM.1999.038; Li FZ, 1999, CANCER RES, V59, P3143; LOTSCHER E, 1990, NUCLEIC ACIDS RES, V18, P7153, DOI 10.1093/nar/18.23.7153; MARTIN SJ, 1990, J IMMUNOL, V145, P1859; Matsumoto A, 1997, BLOOD, V89, P3148, DOI 10.1182/blood.V89.9.3148; MICHELOTTI EF, 1995, J BIOL CHEM, V270, P9494, DOI 10.1074/jbc.270.16.9494; MIYASHITA T, 1995, CELL, V80, P293; Mizuki K, 1998, EUR J BIOCHEM, V251, P573, DOI 10.1046/j.1432-1327.1998.2510573.x; MOOLENAAR WH, 1990, CIBA F SYMP, V150, P99; Mui ALF, 1996, EMBO J, V15, P2425, DOI 10.1002/j.1460-2075.1996.tb00600.x; Oliver FJ, 1996, BIOCHEM J, V316, P421, DOI 10.1042/bj3160421; Oliver FJ, 1997, J BIOL CHEM, V272, P10624; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; PATARCA R, 1988, P NATL ACAD SCI USA, V85, P2733, DOI 10.1073/pnas.85.8.2733; Paumen MB, 1997, J BIOL CHEM, V272, P3324, DOI 10.1074/jbc.272.6.3324; Perillo NL, 1998, J MOL MED, V76, P402, DOI 10.1007/s001090050232; Persons DA, 1999, BLOOD, V93, P488, DOI 10.1182/blood.V93.2.488.402k17_488_499; Pierrat B, 1998, J BIOL CHEM, V273, P29661, DOI 10.1074/jbc.273.45.29661; Rabinovich GA, 1999, CELL DEATH DIFFER, V6, P711, DOI 10.1038/sj.cdd.4400535; Reynolds NJ, 1997, ARCH DERMATOL RES, V289, P540, DOI 10.1007/s004030050236; Rickers A, 1999, EUR J BIOCHEM, V261, P269, DOI 10.1046/j.1432-1327.1999.00273.x; Rosenfeld ME, 1998, SEMIN REPROD ENDOCR, V16, P249, DOI 10.1055/s-2007-1016285; Rouault JP, 1998, J BIOL CHEM, V273, P22563, DOI 10.1074/jbc.273.35.22563; Rouault JP, 1996, NAT GENET, V14, P482, DOI 10.1038/ng1296-482; Scatena M, 1998, J CELL BIOL, V141, P1083, DOI 10.1083/jcb.141.4.1083; SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467; Schena M, 1996, P NATL ACAD SCI USA, V93, P10614, DOI 10.1073/pnas.93.20.10614; Simpkins C, 1998, J SURG RES, V75, P30, DOI 10.1006/jsre.1997.5241; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; Sun HB, 1998, P NATL ACAD SCI USA, V95, P13555, DOI 10.1073/pnas.95.23.13555; TANAKA Y, 1993, NATURE, V361, P79, DOI 10.1038/361079a0; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; TSAI FY, 1994, NATURE, V371, P221, DOI 10.1038/371221a0; Urbanowicz-Kachnowicz I, 1999, INT J CANCER, V82, P98, DOI 10.1002/(SICI)1097-0215(19990702)82:1<98::AID-IJC17>3.0.CO;2-A; Vainberg IE, 1998, CELL, V93, P863, DOI 10.1016/S0092-8674(00)81446-4; Wada J, 1997, J CLIN INVEST, V99, P2452, DOI 10.1172/JCI119429; Wada J, 1997, J BIOL CHEM, V272, P6078, DOI 10.1074/jbc.272.9.6078; Wu M, 1996, MOL CELL BIOL, V16, P5015; Wu YQ, 1999, CYTOKINE, V11, P523, DOI 10.1006/cyto.1998.0436; Xiao YQ, 1999, BBA-MOL CELL RES, V1450, P155, DOI 10.1016/S0167-4889(99)00042-7; Yaron A, 1998, NATURE, V396, P590, DOI 10.1038/25159; Zhang H, 1999, INT J ONCOL, V14, P113; Zhang HC, 1996, PROSTATE, V29, P69; Zhou JH, 1998, BIOCHEM BIOPH RES CO, V242, P502, DOI 10.1006/bbrc.1997.7993	79	32	32	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 19	2000	19	44					5073	5082		10.1038/sj.onc.1203882	http://dx.doi.org/10.1038/sj.onc.1203882			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	365CD	11042695				2022-12-17	WOS:000089930100004
J	Vial, E; Perez, S; Castellazzi, M				Vial, E; Perez, S; Castellazzi, M			Transcriptional control of SPARC by v-Jun and other members of the AP1 family of transcription factors	ONCOGENE			English	Article						v-Jun; Fra2; ATF2; Maf; AP1; SPARC promoter; chick embryo fibroblasts; cell transformation	RAT EMBRYO FIBROBLASTS; C-JUN; CELLULAR-TRANSFORMATION; NEOPLASTIC PROGRESSION; OSTEONECTIN PROMOTER; EXTRACELLULAR-MATRIX; GENE-EXPRESSION; CYSTEINE SPARC; AP-1 FUNCTION; BONE-CELLS	Transformation of chick embryo fibroblasts by the v-Jun oncoprotein correlates with a down-regulation of the extracellular matrix protein SPARC and repression of the corresponding mRNA, Alteration in SPARC expression has been repeatedly reported in human cancers of various origin, and is thought to contribute to the remodeling of the extracellular matrix during neoplastic progression, Transcriptional control of SPARC is poorly understood, We show here that (i) v-Jun-mediated repression of the endogenous SPARC gene is enhanced by Fra2 but alleviated by ATF2, Fra2 and ATF2 being the two major partners of v-Jun in the transformed cells; (ii) high basal activity as well as repression by v-Jun and modulation by Fra2 and ATF2 is restricted to a small proximal fragment (-124/+16) of the chicken SPARC promoter; (iii) the activity of this minimal promoter is modulated by all the AP1 family members known in chickens (c-Jun and JunD; c-Fos and Fra2; ATF2; c-Maf, MafA, and MafB), Taken together these data demonstrate that, at least in avian primary cells, SPARC expression is under the control of the AP1 transcription factor. Further studies with the minimal (-124/+16) promoter fragment are needed to understand how this control takes place at the molecular level.	Ecole Normale Super Lyon, INSERM, U412, Unite Virol Humaine, F-69364 Lyon 07, France	Ecole Normale Superieure de Lyon (ENS de LYON); Institut National de la Sante et de la Recherche Medicale (Inserm)	Castellazzi, M (corresponding author), Ecole Normale Super Lyon, INSERM, U412, Unite Virol Humaine, 46 Allee Italie, F-69364 Lyon 07, France.							ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; BENJAMIN T, 1990, VIROLOGY, V1, P317; Benkhelifa S, 1998, ONCOGENE, V17, P247, DOI 10.1038/sj.onc.1201898; BORNSTEIN P, 1995, J CELL BIOL, V130, P503, DOI 10.1083/jcb.130.3.503; CASTELLAZZI M, 1990, ONCOGENE, V5, P1541; Dejong V, 1999, ONCOGENE, V18, P3143, DOI 10.1038/sj.onc.1202654; DZIADEK M, 1986, EUR J BIOCHEM, V161, P455, DOI 10.1111/j.1432-1033.1986.tb10466.x; Gao MH, 1996, CANCER RES, V56, P4229; Graham JD, 1997, EUR J CANCER, V33, P1654, DOI 10.1016/S0959-8049(97)00182-2; Hafner M, 1995, MATRIX BIOL, V14, P733, DOI 10.1016/S0945-053X(05)80016-2; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; Huguier S, 1998, MOL CELL BIOL, V18, P7020, DOI 10.1128/MCB.18.12.7020; IBARAKI K, 1993, GENE, V130, P225, DOI 10.1016/0378-1119(93)90423-Z; JOVE R, 1987, ANNU REV CELL BIOL, V3, P31, DOI 10.1146/annurev.cellbio.3.1.31; JURDIC P, 1995, ONCOGENE, V11, P1699; Kardassis D, 1999, J BIOL CHEM, V274, P29572, DOI 10.1074/jbc.274.41.29572; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; KATAOKA K, 1993, J VIROL, V67, P2133, DOI 10.1128/JVI.67.4.2133-2141.1993; KATAOKA K, 1994, MOL CELL BIOL, V14, P7581, DOI 10.1128/MCB.14.11.7581; Kilbey A, 1996, ONCOGENE, V12, P2409; Kraemer M, 1999, CELL GROWTH DIFFER, V10, P193; Kumar AP, 1997, NUCLEIC ACIDS RES, V25, P2012, DOI 10.1093/nar/25.10.2012; Ledda F, 1997, J INVEST DERMATOL, V108, P210, DOI 10.1111/1523-1747.ep12334263; MAEKAWA T, 1989, EMBO J, V8, P2023, DOI 10.1002/j.1460-2075.1989.tb03610.x; MASON IJ, 1986, EMBO J, V5, P1465, DOI 10.1002/j.1460-2075.1986.tb04383.x; MASON IJ, 1986, EMBO J, V5, P1831, DOI 10.1002/j.1460-2075.1986.tb04434.x; MCVEY JH, 1988, J BIOL CHEM, V263, P11111; METTOUCHI A, 1994, EMBO J, V13, P5668, DOI 10.1002/j.1460-2075.1994.tb06905.x; Mok SC, 1996, ONCOGENE, V12, P1895; Motohashi H, 1997, NUCLEIC ACIDS RES, V25, P2953, DOI 10.1093/nar/25.15.2953; Murakami M, 1999, CELL GROWTH DIFFER, V10, P333; NISHIZAWA M, 1989, P NATL ACAD SCI USA, V86, P7711, DOI 10.1073/pnas.86.20.7711; NOMURA S, 1989, J BIOL CHEM, V264, P12201; PORTE H, 1995, INT J CANCER, V64, P70, DOI 10.1002/ijc.2910640114; Reed MJ, 1996, CURR TOP MICROBIOL, V213, P81; SAGE H, 1984, J BIOL CHEM, V259, P3993; SONOBE MH, 1995, ONCOGENE, V10, P689; SUZUKI T, 1994, J VIROL, V68, P3527, DOI 10.1128/JVI.68.6.3527-3535.1994; TERMINE JD, 1981, CELL, V26, P99, DOI 10.1016/0092-8674(81)90037-4; TIMPL R, 1993, MOL CELLULAR ASPECTS, P211; Ungefroren H, 1998, J BIOL CHEM, V273, P29230, DOI 10.1074/jbc.273.44.29230; van Dam H, 1998, GENE DEV, V12, P1227, DOI 10.1101/gad.12.8.1227; Vandel L, 1996, MOL CELL BIOL, V16, P1881; Vial E, 2000, ONCOGENE, V19, P1772, DOI 10.1038/sj.onc.1203493; VOGT PK, 1994, FOS JUN FAMILIES TRA, P203; WRANA JL, 1991, EUR J BIOCHEM, V197, P519, DOI 10.1111/j.1432-1033.1991.tb15940.x; YOUNG MF, 1989, J BIOL CHEM, V264, P450	48	32	32	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 12	2000	19	43					5020	5029		10.1038/sj.onc.1203867	http://dx.doi.org/10.1038/sj.onc.1203867			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	363KF	11042689	Bronze			2022-12-17	WOS:000089834300009
J	Kang, BS; French, OG; Sando, JJ; Hahn, CS				Kang, BS; French, OG; Sando, JJ; Hahn, CS			Activation-dependent degradation of protein kinase C eta	ONCOGENE			English	Article						protein kinase C; down-regulation; proteolysis; phorbol ester; ubiquitin; proteasome	MOUSE THYMOMA CELLS; DOWN-REGULATION; EXPRESSION VECTORS; COUPLED RECEPTOR; UP-REGULATION; BETA-II; PHOSPHORYLATION; APOPTOSIS; INACTIVATION; PATHWAY	Prolonged activation of protein kinase Cs (PKCs) by long-term treatment of cells with phorbol ester tumor promoters down-regulates the expression of many PKCs, To investigate the molecular mechanisms involved in the down-regulation of PKC eta, we expressed the novel PKCs eta and theta and various mutant forms in baby hamster kidney cells. Upon overexpression, constitutively active PKC eta, but not wild type or kinase-dead PKC eta, underwent rapid degradation to generate several lower molecular weight polypeptides. When co-expressed with active kinases, kinase-dead PKC eta with a pseudosubstrate site mutation designed to give an active conformation was dawn-regulated while the wild type PKC eta was not. These results suggest requirements for kinase activity and an active conformation for down-regulation of PKC eta. Treatment with the proteasome inhibitors N-Ac-Leu-Leu-norleucinal and lactacystin led to accumulation of PKC eta proteolytic products and potentially ubiquitinated forms, While wild type PKC eta localizes mostly to the detergent-soluble fraction of the cell, a significant portion of full-length constitutively active PKC eta and of kinase-dead, active conformation PKC eta were found in the detergent-insoluble fraction. Several proteolytic fragments of constitutively active PKC eta also were found in the detergent insoluble fraction. These full-length and proteolytic fragments of PKC eta in the detergent-insoluble fraction accumulated further in the presence of proteasome inhibitors. These data suggest that active conformation PKC eta accumulates in the detergent-insoluble compartment, is degraded by proteolysis in the presence of kinase activity, and that the cleavage products undergo further degradation via ubiquitin-mediated degradation in the proteasome.	Univ Virginia, Hlth Sci Ctr, Beirne Carter Ctr Immunol Res, Dept Microbiol, Charlottesville, VA 22908 USA; Univ Virginia, Hlth Sci Ctr, Beirne Carter Ctr Immunol Res, Dept Anesthesiol, Charlottesville, VA 22908 USA	University of Virginia; University of Virginia	Hahn, CS (corresponding author), Univ Virginia, Hlth Sci Ctr, Beirne Carter Ctr Immunol Res, Dept Microbiol, Box MR4-4012, Charlottesville, VA 22908 USA.				NIGMS NIH HHS [GM54572, GM31184] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054572, R01GM031184] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bobak D, 1997, ONCOGENE, V15, P2179, DOI 10.1038/sj.onc.1201396; Bornancin F, 1996, CURR BIOL, V6, P1114, DOI 10.1016/S0960-9822(02)70678-7; Bornancin F, 1997, J BIOL CHEM, V272, P3544, DOI 10.1074/jbc.272.6.3544; BREDENBEEK PJ, 1993, J VIROL, V67, P6439, DOI 10.1128/JVI.67.11.6439-6446.1993; Chen CC, 1997, FEBS LETT, V412, P30, DOI 10.1016/S0014-5793(97)00697-2; Datta R, 1997, J BIOL CHEM, V272, P20317, DOI 10.1074/jbc.272.33.20317; Datta R, 1997, J BIOL CHEM, V272, P1965, DOI 10.1074/jbc.272.3.1965; DEKKER LV, 1994, TRENDS BIOCHEM SCI, V19, P73, DOI 10.1016/0968-0004(94)90038-8; Edwards AS, 1997, J BIOL CHEM, V272, P18382, DOI 10.1074/jbc.272.29.18382; Edwards AS, 1999, J BIOL CHEM, V274, P6461, DOI 10.1074/jbc.274.10.6461; Feng X, 1998, J BIOL CHEM, V273, P26870, DOI 10.1074/jbc.273.41.26870; Feng X, 1998, J BIOL CHEM, V273, P10755, DOI 10.1074/jbc.273.17.10755; FREISEWINKEL I, 1991, FEBS LETT, V280, P262, DOI 10.1016/0014-5793(91)80307-O; GOODE NT, 1994, MOL BIOL CELL, V5, P907, DOI 10.1091/mbc.5.8.907; GOODE NT, 1995, J BIOL CHEM, V270, P2669, DOI 10.1074/jbc.270.6.2669; GREIF H, 1992, MOL CELL BIOL, V12, P1304, DOI 10.1128/MCB.12.3.1304; HAHN CS, 1992, P NATL ACAD SCI USA, V89, P2679, DOI 10.1073/pnas.89.7.2679; Hansra G, 1999, BIOCHEM J, V342, P337, DOI 10.1042/0264-6021:3420337; HONG DH, 1995, BBA-MOL CELL RES, V1267, P45, DOI 10.1016/0167-4889(95)00024-M; Jeffers M, 1997, MOL CELL BIOL, V17, P799, DOI 10.1128/MCB.17.2.799; KISHIMOTO A, 1989, J BIOL CHEM, V264, P4088; Lee HW, 1996, AM J PHYSIOL-CELL PH, V271, pC304, DOI 10.1152/ajpcell.1996.271.1.C304; Lee HW, 1997, MOL PHARMACOL, V51, P439; Lu ZM, 1998, MOL CELL BIOL, V18, P839, DOI 10.1128/MCB.18.2.839; Mellor H, 1998, BIOCHEM J, V332, P281, DOI 10.1042/bj3320281; Moorman JP, 1999, ONCOGENE, V18, P47, DOI 10.1038/sj.onc.1202262; Moorman JP, 1996, J IMMUNOL, V156, P4146; Murakami A, 1996, J INVEST DERMATOL, V106, P790, DOI 10.1111/1523-1747.ep12346391; Newton AC, 1997, CURR OPIN CELL BIOL, V9, P161, DOI 10.1016/S0955-0674(97)80058-0; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; PARKER PJ, 1995, BIOCHEM SOC T, V23, P153, DOI 10.1042/bst0230153; PEARS C, 1991, FEBS LETT, V284, P120, DOI 10.1016/0014-5793(91)80776-Y; PONTREMOLI S, 1988, J BIOL CHEM, V263, P1915; Resnick MS, 1998, J BIOL CHEM, V273, P27654, DOI 10.1074/jbc.273.42.27654; Resnick MS, 1997, CANCER RES, V57, P2209; Roth AF, 1996, J CELL BIOL, V134, P661, DOI 10.1083/jcb.134.3.661; Terrell J, 1998, MOL CELL, V1, P193, DOI 10.1016/S1097-2765(00)80020-9	37	32	33	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 31	2000	19	37					4263	4272		10.1038/sj.onc.1203779	http://dx.doi.org/10.1038/sj.onc.1203779			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	349FL	10980600				2022-12-17	WOS:000089032900009
J	Kovar, H; Jug, G; Printz, D; Bartl, S; Schmid, G; Wesierska-Gadek, J				Kovar, H; Jug, G; Printz, D; Bartl, S; Schmid, G; Wesierska-Gadek, J			Characterization of distinct consecutive phases in non-genotoxic p53-induced apoptosis of Ewing tumor cells and the rate-limiting role of caspase 8	ONCOGENE			English	Article						Ewing tumors; p53; caspase S; transcription; early phase; apoptosis; PIG-3; TRAIL	IRRADIATION-INDUCED APOPTOSIS; TEMPERATURE-SENSITIVE MUTANT; ZINC-FINGER PROTEIN; BCL-X-L; CYTOCHROME-C; TRANSCRIPTIONAL ACTIVATION; HUMAN P53; P53-DEPENDENT APOPTOSIS; P53-MEDIATED APOPTOSIS; MEDIATED APOPTOSIS	To dissect the p53-dependent apoptotic pathway events following induction of temperature sensitive (ts) p53val138 were studied in a Ewing tumor cell line. Transcriptional deregulation of p53 targets first observable after 1 h at 32 degrees C preceded activation of caspases and the break-down of mitochondrial respiratory activity. Activation of caspases was first observed 4 h after p53 induction. Using peptide inhibitors we identified activation of caspase 8 upstream of caspases-9 and -3. Although the caspase 8 specific inhibitor z-IETD.fmk did not affect translocation of BAX to the mitochondrial membrane and cytochrome C release it almost completely blocked cleavage of the prototype caspase substrate PARP and DNA fragmentation while enforcing mitochondrial depolarization and production of reactive oxygene species (ROS). Activation of caspase 8 did not involve death-domain receptor signaling. Expression of BCL2 only partially suppressed caspase activation but blocked apoptosis, Replacement of the N-terminus of p53val138 by the related VP16 transactivation domain created a ts p53 with a tanscriptional activity indistinguishable from p53val138 until the time of caspase activation. However, the VP16-p53 fusion failed to trigger caspases and subsequent induction of the ROS producing gene pig3 paralleled by complete loss of apoptotic activity. These results indicate that p53-dependent transcriptional deregulation, triggering of the caspase cascade and the mitochondrial break-down occur in a timely ordered sequence coordinated by the genuine p53 amino terminus and suggest caspase 8 and PIG3 as key regulatory elements in this process.	St Anna Childrens Hosp, Childrens Canc Res Inst, A-1090 Vienna, Austria; Univ Vienna, Canc Res Inst, A-1090 Vienna, Austria	Saint Anna Children's Hospital; University of Vienna	Kovar, H (corresponding author), St Anna Childrens Hosp, Childrens Canc Res Inst, Kinderspitalgasse 6, A-1090 Vienna, Austria.			Kovar, Heinrich/0000-0001-6873-9109				Antonsson B, 1997, SCIENCE, V277, P370, DOI 10.1126/science.277.5324.370; Aragane Y, 1998, J CELL BIOL, V140, P171, DOI 10.1083/jcb.140.1.171; Attardi LD, 1996, EMBO J, V15, P3693, DOI 10.1002/j.1460-2075.1996.tb00739.x; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; Bennett M, 1998, SCIENCE, V282, P290, DOI 10.1126/science.282.5387.290; Bodmer JL, 2000, NAT CELL BIOL, V2, P241, DOI 10.1038/35008667; Bossy-Wetzel E, 1999, J BIOL CHEM, V274, P17484, DOI 10.1074/jbc.274.25.17484; Buckbinder L, 1997, P NATL ACAD SCI USA, V94, P7868, DOI 10.1073/pnas.94.15.7868; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; FernandesAlnemri T, 1996, P NATL ACAD SCI USA, V93, P7464, DOI 10.1073/pnas.93.15.7464; FISKUM G, 1980, P NATL ACAD SCI-BIOL, V77, P3430, DOI 10.1073/pnas.77.6.3430; Friedlander P, 1996, MOL CELL BIOL, V16, P4961; Fuchs EJ, 1997, CANCER RES, V57, P2550; Fulda S, 1998, CELL DEATH DIFFER, V5, P884, DOI 10.1038/sj.cdd.4400419; Gao CF, 1999, JPN J CANCER RES, V90, P180, DOI 10.1111/j.1349-7006.1999.tb00731.x; Gross A, 1998, EMBO J, V17, P3878, DOI 10.1093/emboj/17.14.3878; Hakem R, 1998, CELL, V94, P339, DOI 10.1016/S0092-8674(00)81477-4; HAUPT Y, 1995, ONCOGENE, V10, P1563; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; HIRANO Y, 1995, ONCOGENE, V10, P1879; Hsu YT, 1997, P NATL ACAD SCI USA, V94, P3668, DOI 10.1073/pnas.94.8.3668; Hu YM, 1998, P NATL ACAD SCI USA, V95, P4386, DOI 10.1073/pnas.95.8.4386; Israeli D, 1997, EMBO J, V16, P4384, DOI 10.1093/emboj/16.14.4384; Juo P, 1998, CURR BIOL, V8, P1001, DOI 10.1016/S0960-9822(07)00420-4; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; KOVAR H, 1993, ONCOGENE, V8, P2683; Kovar H, 1996, CELL GROWTH DIFFER, V7, P429; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; MIYASHITA T, 1995, CELL, V80, P293; Muller M, 1998, EUR CYTOKINE NETW, V9, P685; OWENSCHAUB LB, 1995, MOL CELL BIOL, V15, P3032; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; PRASAD SC, 1990, CANCER RES, V50, P38; Roemer K, 1996, ONCOGENE, V12, P2069; SABBATINI P, 1995, GENE DEV, V9, P2184, DOI 10.1101/gad.9.17.2184; Sabbatini P, 1997, CELL GROWTH DIFFER, V8, P643; Salvesen GS, 1999, P NATL ACAD SCI USA, V96, P10964, DOI 10.1073/pnas.96.20.10964; Scaffidi C, 1999, J BIOL CHEM, V274, P22532, DOI 10.1074/jbc.274.32.22532; Sheikh MS, 1998, ONCOGENE, V17, P2555, DOI 10.1038/sj.onc.1202292; Sheikh MS, 1998, CANCER RES, V58, P1593; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; Soengas MS, 1999, SCIENCE, V284, P156, DOI 10.1126/science.284.5411.156; Song QZ, 1999, EMBO J, V18, P167, DOI 10.1093/emboj/18.1.167; Takimoto R, 2000, ONCOGENE, V19, P1735, DOI 10.1038/sj.onc.1203489; Theis S, 1997, INT J CANCER, V71, P858; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; THUT CJ, 1995, SCIENCE, V267, P100, DOI 10.1126/science.7809597; Unger T, 1999, ONCOGENE, V18, P3205, DOI 10.1038/sj.onc.1202656; VarmehZiaie S, 1997, ONCOGENE, V15, P2699, DOI 10.1038/sj.onc.1201454; Venot C, 1998, EMBO J, V17, P4668, DOI 10.1093/emboj/17.16.4668; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; Wu GS, 1997, NAT GENET, V17, P141, DOI 10.1038/ng1097-141; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Zhan QM, 1999, ONCOGENE, V18, P297, DOI 10.1038/sj.onc.1202310; Zhu JH, 1999, ONCOGENE, V18, P2149, DOI 10.1038/sj.onc.1202533	59	32	32	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 24	2000	19	36					4096	4107		10.1038/sj.onc.1203780	http://dx.doi.org/10.1038/sj.onc.1203780			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	347XU	10962570				2022-12-17	WOS:000088955100003
J	Matsuzaki, T; Aisaki, K; Yamamura, Y; Noda, M; Ikawa, Y				Matsuzaki, T; Aisaki, K; Yamamura, Y; Noda, M; Ikawa, Y			Induction of erythroid differentiation by inhibition of Ras/ERK pathway in a Friend murine leukemia cell line	ONCOGENE			English	Article						Friend leukemia cell; EPO-induced differentiation; Ras/ERK pathway	MOUSE ERYTHROLEUKEMIA-CELLS; SIGNAL-TRANSDUCTION PATHWAY; PROTEIN-KINASE CASCADE; P38 MAP KINASE; ERYTHROPOIETIN RECEPTOR; TYROSINE PHOSPHORYLATION; PHOSPHATIDYLINOSITOL 3-KINASE; GENE-EXPRESSION; ACTIVATION; JAK2	The role of Ras and MAP kinases (MAPKs) in the regulation of erythroid differentiation was studied using a cell line (SKT6) derived from Friend virus (Anemic strain)-induced murine erythroleukemia. This cell line undergoes differentiation in vitro in response to erythropoietin (EPO) or other chemical inducers such as dimethylsulfoxide (DMSO), When a constitutively active ras mutant (ras12V) was expressed in SKT6 cells, EPO-induced differentiation was inhibited. Conversely, a dominant negative I au mutant (ras17N) induced differentiation even in the absence of EPO, suggesting that the basal Ras activity is essential for the maintenance of the undifferentiated phenotype and proliferative potential in this cell line. Rapid inactivation of ERK was observed after expression of ras17N. Slow but significant inactivation of ERR was also observed during EPO-induced differentiation. Furthermore, overexpression of a constitutively active mutant of ERK-activating kinase (MAPKK) was found to suppress erythroid differentiation, while pharmacological inhibition of MAPKK induced differentiation. These findings suggest that down-regulation of Ras/ERK signaling pathway may be an essential event in EPO-induced erythroid differentiation in this system.	Tokyo Med & Dent Univ, Dept Retroviral Regulat, Div Med Res, Bunkyo Ku, Tokyo 1138519, Japan; Japan Sci & Technol Corp, CREST, Honcho, Saitama 3320012, Japan; Kyoto Univ, Grad Sch Med, Dept Mol Oncol, Sakyo Ku, Kyoto 6068501, Japan	Tokyo Medical & Dental University (TMDU); Japan Science & Technology Agency (JST); Kyoto University	Ikawa, Y (corresponding author), Tokyo Med & Dent Univ, Dept Retroviral Regulat, Div Med Res, Bunkyo Ku, 1-5-45 Yushima, Tokyo 1138519, Japan.			Matsuzaki, Tomoko/0000-0002-9878-0433				Aisaki K, 1999, JPN J CANCER RES, V90, P171, DOI 10.1111/j.1349-7006.1999.tb00730.x; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; CARROLL MP, 1994, J BIOL CHEM, V269, P1249; DAMEN JE, 1993, BLOOD, V81, P3204; DAMEN JE, 1993, BLOOD, V82, P2296; DAMEN JE, 1995, J BIOL CHEM, V270, P23402, DOI 10.1074/jbc.270.40.23402; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Dumont FJ, 1998, J IMMUNOL, V160, P2579; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; Fukuda M, 1997, J BIOL CHEM, V272, P32642, DOI 10.1074/jbc.272.51.32642; GOBERT S, 1995, EUR J BIOCHEM, V234, P75, DOI 10.1111/j.1432-1033.1995.075_c.x; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; HE TC, 1995, J BIOL CHEM, V270, P11055, DOI 10.1074/jbc.270.19.11055; IKUTA K, 1990, CELL, V62, P863, DOI 10.1016/0092-8674(90)90262-D; Iwatsuki K, 1997, J BIOL CHEM, V272, P8149, DOI 10.1074/jbc.272.13.8149; JOHNSON P, 1993, MOL CELL BIOL, V13, P1456, DOI 10.1128/MCB.13.3.1456; Kang CD, 1999, EXP MOL MED, V31, P76, DOI 10.1038/emm.1999.13; Kato MV, 1997, BLOOD, V90, P1373, DOI 10.1182/blood.V90.4.1373.1373_1373_1378; KIMURA K, 1994, J BIOL CHEM, V269, P18961; Kirken RA, 1997, J BIOL CHEM, V272, P15459, DOI 10.1074/jbc.272.24.15459; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; Klingmuller U, 1997, EUR J BIOCHEM, V249, P637, DOI 10.1111/j.1432-1033.1997.t01-1-00637.x; Kume T, 1996, J BIOL CHEM, V271, P30916, DOI 10.1074/jbc.271.48.30916; KURAMOCHI S, 1991, BIOCHEM BIOPH RES CO, V181, P1103, DOI 10.1016/0006-291X(91)92052-L; KURAMOCHI S, 1990, EUR J BIOCHEM, V193, P163, DOI 10.1111/j.1432-1033.1990.tb19318.x; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; Lu Q, 1998, MOL CELL BIOL, V18, P3257, DOI 10.1128/MCB.18.6.3257; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MIURA Y, 1994, J BIOL CHEM, V269, P29962; Muszynski KW, 1998, J VIROL, V72, P919, DOI 10.1128/JVI.72.2.919-925.1998; Nagata Y, 1999, BLOOD, V94, P853, DOI 10.1182/blood.V94.3.853.415a12_853_863; Nagata Y, 1997, BLOOD, V90, P929, DOI 10.1182/blood.V90.3.929.929_929_934; Nagata Y, 1998, BLOOD, V92, P1859, DOI 10.1182/blood.V92.6.1859.418k37_1859_1869; Neubauer H, 1998, CELL, V93, P397, DOI 10.1016/S0092-8674(00)81168-X; Parganas E, 1998, CELL, V93, P385, DOI 10.1016/S0092-8674(00)81167-8; Quelle FW, 1996, MOL CELL BIOL, V16, P1622; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Sawyer ST, 1996, J BIOL CHEM, V271, P32430, DOI 10.1074/jbc.271.50.32430; Sharlow ER, 1997, BLOOD, V90, P2175, DOI 10.1182/blood.V90.6.2175.2175_2175_2187; SHOCKETT P, 1995, P NATL ACAD SCI USA, V92, P6522, DOI 10.1073/pnas.92.14.6522; Tilbrook PA, 1996, CELL GROWTH DIFFER, V7, P511; TODOKORO K, 1994, BIOCHEM BIOPH RES CO, V203, P1912, DOI 10.1006/bbrc.1994.2411; TODOKORO K, 1988, BIOCHIM BIOPHYS ACTA, V943, P326, DOI 10.1016/0005-2736(88)90564-0; TODOKORO K, 1987, P NATL ACAD SCI USA, V84, P4126, DOI 10.1073/pnas.84.12.4126; TORTI M, 1992, J BIOL CHEM, V267, P8293; Uckun FM, 1998, BIOCHEM PHARMACOL, V56, P683, DOI 10.1016/S0006-2952(98)00122-1; Wakao H, 1997, BIOCHEM BIOPH RES CO, V234, P198, DOI 10.1006/bbrc.1997.6486; WATANABE T, 1992, J BIOL CHEM, V267, P17116; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; XU X, 1995, JPN J CANCER RES, V86, P284, DOI 10.1111/j.1349-7006.1995.tb03052.x; Yamamura Y, 1998, MOL CELL BIOL, V18, P1172, DOI 10.1128/MCB.18.3.1172	52	32	33	1	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 16	2000	19	12					1500	1508		10.1038/sj.onc.1203461	http://dx.doi.org/10.1038/sj.onc.1203461			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	297XN	10734309				2022-12-17	WOS:000086108100002
J	Stroeken, PJM; van Rijthoven, EAM; de Boer, E; Geerts, D; Roos, E				Stroeken, PJM; van Rijthoven, EAM; de Boer, E; Geerts, D; Roos, E			Cytoplasmic domain mutants of beta 1 integrin, expressed in beta 1-knockout lymphoma cells, have distinct effects on adhesion, invasion and metastasis	ONCOGENE			English	Article						integrin cytoplasmic domains; dissemination; lymphoid cells; migration	MEDIATED TYROSINE PHOSPHORYLATION; HUMAN T-CELLS; PHOSPHATIDYLINOSITOL 3-KINASE; BETA(1) INTEGRIN; ACTIVATION; SUBUNIT; REQUIREMENT; MODULATION; MIGRATION; PROTEIN	Structural requirements for beta 1 integrin cytoplasmic domain functions in adhesion, migration and signaling have been studied mainly for fibroblasts in vitro. The relevance for beta 1-dependent in vivo migration of lymphoid cells has not been assessed. To study this, we transfected beta 1 mutants into beta 1-deficient double knockout (DKO) ESb lymphoma cells, and tested the capacity of the cells to metastasize to Li,er and spleen. This was compared to alpha 4 beta 1-dependent invasion into cell monolayers in vitro and Mn2+-induced adhesion to fibronectin, Deletion of the five C-terminal residues or mutation of both threonines T788 and T789 to alanines blocked invasion and metastasis and greatly reduced adhesion, in line with known in vitro effects. However, mutations of the NP motif tyrosines had unexpected consequences. A Y783F mutation had no effect at all, but a Y783,795F double mutation strongly reduced Mn2+-induced adhesion, whereas it had limited effects on invasion and metastasis. Furthermore, cells expressing a beta 1/beta 2 chimeric subunit, which contains phenylalanines in the NPXY/F motifs, adhered poorly but invasion and metastasis was fully restored to the same levels as for cells expressing wild-type beta 1. We conclude that part of the functions of the beta 1 cytoplasmic domain that are required for adhesion are not essential for beta 1-dependent invasion and metastasis.	Netherlands Canc Inst, Div Cell Biol, NL-1066 CX Amsterdam, Netherlands	Netherlands Cancer Institute	Roos, E (corresponding author), Netherlands Canc Inst, Div Cell Biol, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.		Geerts, Dirk/K-8260-2015	Geerts, Dirk/0000-0002-6386-8187				Baggiolini M, 1998, NATURE, V392, P565, DOI 10.1038/33340; Blystone SD, 1997, J BIOL CHEM, V272, P28757, DOI 10.1074/jbc.272.45.28757; Chang DD, 1997, J CELL BIOL, V138, P1149, DOI 10.1083/jcb.138.5.1149; Driessens MHE, 1997, EXP CELL RES, V231, P242, DOI 10.1006/excr.1996.3463; Faisst AM, 1998, DEV DYNAM, V212, P293, DOI 10.1002/(SICI)1097-0177(199806)212:2<293::AID-AJA14>3.0.CO;2-5; FILARDO EJ, 1995, J CELL BIOL, V130, P441, DOI 10.1083/jcb.130.2.441; Finkelstein LD, 1997, J IMMUNOL, V159, P5355; Grignani F, 1998, CANCER RES, V58, P14; HIBBS ML, 1991, J EXP MED, V174, P1227, DOI 10.1084/jem.174.5.1227; Hunter AJ, 1997, J IMMUNOL, V159, P4806; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Jenkins AL, 1998, J BIOL CHEM, V273, P13878, DOI 10.1074/jbc.273.22.13878; Keely P, 1998, TRENDS CELL BIOL, V8, P101, DOI 10.1016/S0962-8924(97)01219-1; Kinsella TM, 1996, HUM GENE THER, V7, P1405, DOI 10.1089/hum.1996.7.12-1405; Klemke RL, 1998, J CELL BIOL, V140, P961, DOI 10.1083/jcb.140.4.961; Kolanus W, 1996, CELL, V86, P233, DOI 10.1016/S0092-8674(00)80095-1; Liliental J, 1998, J BIOL CHEM, V273, P2379, DOI 10.1074/jbc.273.4.2379; Lub M, 1997, MOL BIOL CELL, V8, P719, DOI 10.1091/mbc.8.4.719; Mastrangelo AM, 1999, J CELL SCI, V112, P217; MICHIELS F, 2000, IN PRESS METHODS ENZ; PETER K, 1995, J EXP MED, V181, P315, DOI 10.1084/jem.181.1.315; PIETRANGELI CE, 1988, EUR J IMMUNOL, V18, P863, DOI 10.1002/eji.1830180606; Retta SF, 1998, MOL BIOL CELL, V9, P715, DOI 10.1091/mbc.9.4.715; Romzek NC, 1998, MOL BIOL CELL, V9, P2715, DOI 10.1091/mbc.9.10.2715; ROOSSIEN FF, 1989, J CELL BIOL, V108, P1979, DOI 10.1083/jcb.108.5.1979; Sakai T, 1998, J CELL BIOL, V141, P527, DOI 10.1083/jcb.141.2.527; Sakai T, 1998, J BIOL CHEM, V273, P19378, DOI 10.1074/jbc.273.31.19378; Schaapveld RQJ, 1998, J CELL BIOL, V142, P271, DOI 10.1083/jcb.142.1.271; SCHIRRMACHER V, 1979, INT J CANCER, V23, P245, DOI 10.1002/ijc.2910230216; Schlaepfer DD, 1998, TRENDS CELL BIOL, V8, P151, DOI 10.1016/S0962-8924(97)01172-0; Shimizu Y, 1995, J CELL BIOL, V131, P1867, DOI 10.1083/jcb.131.6.1867; Stroeken PJM, 1998, CANCER RES, V58, P1569; Valmu L, 1999, BIOCHEM J, V339, P119, DOI 10.1042/0264-6021:3390119; VALMU L, 1995, J IMMUNOL, V155, P1175; Weber C, 1997, J IMMUNOL, V159, P3968; WEISS L, 1963, AM J ANAT, V113, P51, DOI 10.1002/aja.1001130106; Wennerberg K, 1996, J CELL BIOL, V132, P227, DOI 10.1083/jcb.132.1.227; Wennerberg K, 1998, J CELL SCI, V111, P1117; Zell T, 1996, J IMMUNOL, V156, P883; Zhang XA, 1999, J BIOL CHEM, V274, P11, DOI 10.1074/jbc.274.1.11	40	32	32	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 24	2000	19	9					1232	1238		10.1038/sj.onc.1203423	http://dx.doi.org/10.1038/sj.onc.1203423			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	288MX	10713712				2022-12-17	WOS:000085567800014
J	Ivanov, VN; Kehrl, JH; Ronai, Z				Ivanov, VN; Kehrl, JH; Ronai, Z			Role of TRAF2/GCK in melanoma sensitivity to UV-induced apoptosis	ONCOGENE			English	Article						TRAF2; GCK; NF-kappa B; melanoma; apoptosis; UV-irradiation	NF-KAPPA-B; RECEPTOR-ASSOCIATED FACTOR-2; FAS LIGAND EXPRESSION; FACTOR TNF RECEPTOR-1; TERMINAL KINASE; SIGNAL-TRANSDUCTION; INDUCED ACTIVATION; CELL-DEATH; T-CELLS; PATHWAYS	Radiation resistance is a hallmark of human melanoma, and yet mechanisms underlying this resistance are not well understood. We recently established the role of ATF2 in this process, suggesting that stress kinases, which contribute to regulation of ATF2 stability and activity, play an important role in the acquisition of such resistance. Here we demonstrate that changes in the expression and respective activities of TRAF2/GCK occur during melanoma development and regulate its sensitivity to UV-induced apoptosis, Comparing early- and late-stage melanoma cells revealed low expression of TRAF2 and GCK in early-stage melanoma, which coincided with poor resistance to UV-induced, TNF-mediated apoptosis; forced expression of GCK alone or in combination with TRAF2 efficiently increased JNK and NF-kappa B activities, which coincided with increased protection against apoptosis, Conversely, forced expression of the dominant negative form of TRAF2 or GCK in late-stage melanoma cells reduced NF-kappa B activity and decreased Fas expression, resulting in a lower degree of UV-induced, Fas-mediated cell death. Our results illustrate a mechanism in which protection from, or promotion of, UV-induced melanoma cell death depends on the nature of the apoptotic cascade (TNF or Fas) and on the availability of TRAF2/GCK, whose expression increases during melanoma progression.	CUNY Mt Sinai Sch Med, Ruttenberg Canc Ctr, New York, NY 10029 USA; NIH, Immunoregulat Lab, Bethesda, MD 20892 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; National Institutes of Health (NIH) - USA	Ronai, Z (corresponding author), CUNY Mt Sinai Sch Med, Ruttenberg Canc Ctr, 1425 Madison Ave,Room 15-20, New York, NY 10029 USA.		Ivanov, Vladimir N/A-3081-2008; Kehrl, John/AAE-6292-2019	Ivanov, Vladimir N/0000-0003-3091-9774; RONAI, ZEEV/0000-0002-3859-0400; Kehrl, John/0000-0002-6526-159X	NCI NIH HHS [CA 51995] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA051995, R29CA051995] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000739] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Arch RH, 1998, GENE DEV, V12, P2821, DOI 10.1101/gad.12.18.2821; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Bakker TR, 1999, INT J CANCER, V80, P320; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Brenner B, 1997, J BIOL CHEM, V272, P22173, DOI 10.1074/jbc.272.35.22173; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; Carpentier I, 1998, FEBS LETT, V425, P195, DOI 10.1016/S0014-5793(98)00226-9; Chan H, 1999, MOL CELL BIOL, V19, P2098, DOI 10.1128/mcb.19.3.2098; Chaudhuri A, 1999, BIOCHEM BIOPH RES CO, V256, P620, DOI 10.1006/bbrc.1999.0385; Deak JC, 1998, P NATL ACAD SCI USA, V95, P5595, DOI 10.1073/pnas.95.10.5595; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Faris M, 1998, J IMMUNOL, V160, P134; Faris M, 1998, MOL CELL BIOL, V18, P5414, DOI 10.1128/MCB.18.9.5414; Fuchs SY, 1999, ONCOGENE, V18, P2039, DOI 10.1038/sj.onc.1202760; Fuchs SY, 1998, P NATL ACAD SCI USA, V95, P10541, DOI 10.1073/pnas.95.18.10541; Galibert L, 1998, J BIOL CHEM, V273, P34120, DOI 10.1074/jbc.273.51.34120; Goillot E, 1997, P NATL ACAD SCI USA, V94, P3302, DOI 10.1073/pnas.94.7.3302; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Huang CS, 1999, J BIOL CHEM, V274, P12229, DOI 10.1074/jbc.274.18.12229; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; Ivanov VN, 1999, J BIOL CHEM, V274, P14079, DOI 10.1074/jbc.274.20.14079; IVANOV VN, 1995, INT IMMUNOL, V7, P1709, DOI 10.1093/intimm/7.11.1709; Kasibhatla S, 1998, MOL CELL, V1, P543, DOI 10.1016/S1097-2765(00)80054-4; Kelliher MA, 1998, IMMUNITY, V8, P297, DOI 10.1016/S1074-7613(00)80535-X; Kyriakis JM, 1999, J BIOL CHEM, V274, P5259, DOI 10.1074/jbc.274.9.5259; Lee FS, 1998, P NATL ACAD SCI USA, V95, P9319, DOI 10.1073/pnas.95.16.9319; Lee SY, 1997, IMMUNITY, V7, P703, DOI 10.1016/S1074-7613(00)80390-8; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lin X, 1998, MOL CELL BIOL, V18, P5899, DOI 10.1128/MCB.18.10.5899; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Maniatis T, 1999, GENE DEV, V13, P505, DOI 10.1101/gad.13.5.505; Meier F., 1998, FRONT BIOSCI J VIS L, V3, P1005, DOI [10.2741/a341, DOI 10.2741/A341]; Minden A, 1997, BBA-REV CANCER, V1333, pF85, DOI 10.1016/S0304-419X(97)00018-8; Moretti S, 1999, INT J CANCER, V84, P160, DOI 10.1002/(SICI)1097-0215(19990420)84:2<160::AID-IJC12>3.3.CO;2-I; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Natoli G, 1998, J BIOL CHEM, V273, P31262, DOI 10.1074/jbc.273.47.31262; Natoli G, 1998, BIOCHEM PHARMACOL, V56, P915, DOI 10.1016/S0006-2952(98)00154-3; Natoli G, 1997, SCIENCE, V275, P200, DOI 10.1126/science.275.5297.200; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Nishitoh H, 1998, MOL CELL, V2, P389, DOI 10.1016/S1097-2765(00)80283-X; Peli J, 1999, EMBO J, V18, P1824, DOI 10.1093/emboj/18.7.1824; Reinhard C, 1997, EMBO J, V16, P1080, DOI 10.1093/emboj/16.5.1080; Relaix F, 1998, NAT GENET, V18, P287, DOI 10.1038/ng0398-287; Ronai Z, 1998, ONCOGENE, V16, P523, DOI 10.1038/sj.onc.1201566; Satyamoorthy K, 1997, MELANOMA RES, V7, pS35; Shi CS, 1999, J IMMUNOL, V163, P3279; Shi CS, 1997, J BIOL CHEM, V272, P32102, DOI 10.1074/jbc.272.51.32102; Song HY, 1997, P NATL ACAD SCI USA, V94, P9792, DOI 10.1073/pnas.94.18.9792; Sprecher E, 1999, J CUTAN PATHOL, V26, P72, DOI 10.1111/j.1600-0560.1999.tb01805.x; Tan PL, 1999, MOL CELL, V3, P527, DOI 10.1016/S1097-2765(00)80481-5; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Ting AT, 1996, EMBO J, V15, P6189, DOI 10.1002/j.1460-2075.1996.tb01007.x; Tobin D, 1998, P NATL ACAD SCI USA, V95, P565, DOI 10.1073/pnas.95.2.565; van Dam H, 1998, GENE DEV, V12, P1227, DOI 10.1101/gad.12.8.1227; Yang XL, 1997, CELL, V89, P1067, DOI 10.1016/S0092-8674(00)80294-9; Yang YM, 1996, ONCOGENE, V12, P2223; Yeh WC, 1997, IMMUNITY, V7, P715, DOI 10.1016/S1074-7613(00)80391-X; Yuasa T, 1998, J BIOL CHEM, V273, P22681, DOI 10.1074/jbc.273.35.22681; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7	61	32	33	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 17	2000	19	7					933	942		10.1038/sj.onc.1203415	http://dx.doi.org/10.1038/sj.onc.1203415			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	288MW	10702802	Green Published			2022-12-17	WOS:000085567700011
J	Barrientes, S; Cooke, C; Goodrich, DW				Barrientes, S; Cooke, C; Goodrich, DW			Glutamic acid mutagenesis of retinoblastoma protein phosphorylation sites has diverse effects on function	ONCOGENE			English	Article						retinoblastoma; phosphorylation; cyclin-dependent kinase; mutagenesis	CYCLIN-DEPENDENT KINASE; GENE-PRODUCT PRB; CELL-CYCLE; S-PHASE; TRANSCRIPTIONAL REPRESSION; ECTOPIC EXPRESSION; TERMINAL REGION; T-ANTIGEN; BINDING; E2F	The retinoblastoma tumor suppressor gene (Rb) has many functions within the cell including regulation of transcription, differentiation, apoptosis, and the cell cycle. Regulation of these functions is mediated by phosphorylation at as many as 16 cyclin-dependent kinase (CDK) phosphorylation sites in vivo. The contribution of these sites to the regulation of the various Rb functions is not well understood. To characterize the effect of phosphorylation at these sites, we systematically mutagenized the serines or threonines to glutamic acid. Thirty-five mutants with different combinations of modified phosphorylation sites were assayed for their ability to arrest the cell cycle and for their potential to induce differentiation. Only the most highly substituted mutants failed to arrest cell cycle progression, However, mutants with as few as four modified phosphorylation sites were unable to promote differentiation. Other mutants had increased activity in this assay. We conclude that modification of Rb phosphorylation sites can increase or decrease protein activity, that different Rb functions can be regulated independently by distinct combinations of sites, and that the effects of modification at any one site are context dependent.	Univ Texas, MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Goodrich, DW (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Canc Biol, 1515 Holcombe Blvd,Box 108, Houston, TX 77030 USA.				NATIONAL CANCER INSTITUTE [R01CA070292] Funding Source: NIH RePORTER; NCI NIH HHS [CA-70292-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BREMNER R, 1995, MOL CELL BIOL, V15, P3256; Brown VD, 1999, MOL CELL BIOL, V19, P3246; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; Chen DS, 1999, MOL CELL BIOL, V19, P1002; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; Chew YP, 1998, ONCOGENE, V17, P2177, DOI 10.1038/sj.onc.1202443; ConnellCrowley L, 1997, MOL BIOL CELL, V8, P287, DOI 10.1091/mbc.8.2.287; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; DUCOMMUN B, 1991, EMBO J, V10, P3311, DOI 10.1002/j.1460-2075.1991.tb04895.x; DURFEE T, 1994, J CELL BIOL, V127, P609, DOI 10.1083/jcb.127.3.609; ENGEL K, 1995, J BIOL CHEM, V270, P27213, DOI 10.1074/jbc.270.45.27213; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; GOODRICH DW, 1990, CANCER SURV, V9, P529; HAMEL PA, 1992, ONCOGENE, V7, P693; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HU QJ, 1990, EMBO J, V9, P1147, DOI 10.1002/j.1460-2075.1990.tb08221.x; HUANG S, 1992, DNA CELL BIOL, V11, P539, DOI 10.1089/dna.1992.11.539; HUANG S, 1990, EMBO J, V9, P1815, DOI 10.1002/j.1460-2075.1990.tb08306.x; INOUE A, 1995, J BIOL CHEM, V270, P22571, DOI 10.1074/jbc.270.38.22571; KATO J, 1993, GENE DEV, V7, P331; Knauf U, 1996, GENE DEV, V10, P2782, DOI 10.1101/gad.10.21.2782; Knudsen ES, 1996, J BIOL CHEM, V271, P8313, DOI 10.1074/jbc.271.14.8313; Knudsen ES, 1998, GENE DEV, V12, P2278, DOI 10.1101/gad.12.15.2278; Knudsen ES, 1997, MOL CELL BIOL, V17, P5771, DOI 10.1128/MCB.17.10.5771; Lee JO, 1998, NATURE, V391, P859, DOI 10.1038/36038; LEES JA, 1991, EMBO J, V10, P4279, DOI 10.1002/j.1460-2075.1991.tb05006.x; Leng XH, 1997, CURR BIOL, V7, P709, DOI 10.1016/S0960-9822(06)00301-0; LIN BTY, 1991, EMBO J, V10, P857, DOI 10.1002/j.1460-2075.1991.tb08018.x; Lukas J, 1997, GENE DEV, V11, P1479, DOI 10.1101/gad.11.11.1479; MACIEJEWSKI PM, 1995, J BIOL CHEM, V270, P27661, DOI 10.1074/jbc.270.46.27661; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; PEARSON RB, 1995, EMBO J, V14, P5279, DOI 10.1002/j.1460-2075.1995.tb00212.x; QIN XQ, 1992, GENE DEV, V6, P953, DOI 10.1101/gad.6.6.953; Riley DJ, 1997, MOL CELL BIOL, V17, P7342, DOI 10.1128/MCB.17.12.7342; SELLERS WR, 1995, P NATL ACAD SCI USA, V92, P11544, DOI 10.1073/pnas.92.25.11544; Sellers WR, 1998, GENE DEV, V12, P95, DOI 10.1101/gad.12.1.95; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Smith EJ, 1998, CELL GROWTH DIFFER, V9, P297; Sterner JM, 1998, MOL CELL BIOL, V18, P2748, DOI 10.1128/MCB.18.5.2748; SUZUKITAKAHASHI I, 1995, ONCOGENE, V10, P1691; TAYA Y, 1989, BIOCHEM BIOPH RES CO, V164, P580, DOI 10.1016/0006-291X(89)91759-2; WEINBERG RA, 1990, TRENDS BIOCHEM SCI, V15, P199, DOI 10.1016/0968-0004(90)90162-5; WELCH PJ, 1993, CELL, V75, P779, DOI 10.1016/0092-8674(93)90497-E; WIGLER M, 1979, CELL, V16, P777, DOI 10.1016/0092-8674(79)90093-X; Yang YD, 1998, J BIOL CHEM, V273, P15946, DOI 10.1074/jbc.273.26.15946	47	32	32	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 27	2000	19	4					562	570		10.1038/sj.onc.1203332	http://dx.doi.org/10.1038/sj.onc.1203332			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	280LL	10698526				2022-12-17	WOS:000085104200010
J	Nass, SJ; Ferguson, AT; El-Ashry, D; Nelson, WG; Davidson, NE				Nass, SJ; Ferguson, AT; El-Ashry, D; Nelson, WG; Davidson, NE			Expression of DNA methyl-transferase (DMT) and the cell cycle in human breast cancer cells	ONCOGENE			English	Article						breast cancer; estrogen receptor; DNA methylation; S phase; p21	RECEPTOR GENE-EXPRESSION; ESTROGEN-RECEPTOR; SIGNALING PATHWAY; METHYLTRANSFERASE; GROWTH; CARCINOGENESIS; PROGRESSION; ISLANDS; TARGET	Estrogen receptor (ER)-negative breast cancer cells display extensive methylation of the ER gene CpG island and elevated DNA methyltransferase (DMT) expression compared to ER-positive cells. The present study demonstrates that DMT protein levels tightly correlate with S phase fraction in ER-positive cells, whereas ER-negative cells express DMT throughout the cell cycle. In addition, levels of p21(CIP1), which disrupts DMT binding to PCNA, are inversely correlated with DMT levels, Therefore increased DMT expression in ER-negative cells is not simply due to elevated S-phase fraction, but rather to more complex changes that allow cells to escape normal cell cycle-dependent controls on DMT expression. Because ER-negative breast tumors often have activated growth factor pathways, the impact of these pathways on DMT expression was examined in ER-positive cells. Stable transfection with fibroblast growth factors (FGFs) 1 and 4 led to increased DMT expression that could not be accounted for by a shift in S phase fraction. Elevated DMT protein expression in FGF-transfectants was accompanied by a significant decrease in p21, again suggesting a reciprocal relationship between these two proteins. However, acquisition of an estrogen-independent phenotype, even in conjunction with elevated DMT levels, was not sufficient to promote ER gene silencing via methylation, These results indicate that multiple steps are required for de novo methylation of the ER CpG island.	Johns Hopkins Univ, Sch Med, Ctr Oncol, Baltimore, MD 21231 USA; Georgetown Univ, Lombardi Canc Ctr, Washington, DC 20007 USA	Johns Hopkins University; Johns Hopkins Medicine; Georgetown University	Davidson, NE (corresponding author), Johns Hopkins Univ, Sch Med, Ctr Oncol, 422 N Bond St, Baltimore, MD 21231 USA.			Nass, Sharyl/0000-0001-5874-5337				Araujo FD, 1998, MOL CELL BIOL, V18, P3475, DOI 10.1128/MCB.18.6.3475; Bakin AV, 1999, SCIENCE, V283, P387, DOI 10.1126/science.283.5400.387; Belinsky SA, 1996, P NATL ACAD SCI USA, V93, P4045, DOI 10.1073/pnas.93.9.4045; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; Chuang LSH, 1997, SCIENCE, V277, P1996, DOI 10.1126/science.277.5334.1996; Clarke M, 1998, LANCET, V351, P1451; CLARKE R, 1994, BREAST CANCER RES TR, V31, P237, DOI 10.1007/BF00666157; COUNTS JL, 1995, CELL, V83, P13, DOI 10.1016/0092-8674(95)90228-7; DICKSON RB, 1995, ENDOCR REV, V16, P559, DOI 10.1210/er.16.5.559; ElAshry D, 1997, ONCOGENE, V15, P423, DOI 10.1038/sj.onc.1201198; FERGUSON AT, 1995, CANCER RES, V55, P2279; Ferguson AT, 1997, J BIOL CHEM, V272, P32260, DOI 10.1074/jbc.272.51.32260; FILMUS J, 1985, BIOCHEM BIOPH RES CO, V128, P898, DOI 10.1016/0006-291X(85)90131-7; Kass SU, 1997, TRENDS GENET, V13, P444, DOI 10.1016/S0168-9525(97)01268-7; KERN FG, 1994, BREAST CANCER RES TR, V31, P153, DOI 10.1007/BF00666149; KRAUS MH, 1984, P NATL ACAD SCI-BIOL, V81, P5384, DOI 10.1073/pnas.81.17.5384; Laird PW, 1996, ANNU REV GENET, V30, P441, DOI 10.1146/annurev.genet.30.1.441; Lapidus RG, 1998, CANCER RES, V58, P2515; Lapidus RG, 1996, CLIN CANCER RES, V2, P805; Lapidus RG, 1998, J MAMMARY GLAND BIOL, V3, P85, DOI 10.1023/A:1018778403001; Lee PJ, 1996, P NATL ACAD SCI USA, V93, P10366, DOI 10.1073/pnas.93.19.10366; MACLEOD AR, 1995, J BIOL CHEM, V270, P11327, DOI 10.1074/jbc.270.19.11327; Maki CG, 1997, MOL CELL BIOL, V17, P355, DOI 10.1128/MCB.17.1.355; MCGUIRE WL, 1978, SEMIN ONCOL, V5, P428; MIYOSHI E, 1993, CARCINOGENESIS, V14, P603, DOI 10.1093/carcin/14.4.603; OTTAVIANO YL, 1994, CANCER RES, V54, P2552; ROULEAU J, 1995, J BIOL CHEM, V270, P1595, DOI 10.1074/jbc.270.4.1595; SAMAAN NA, 1981, CANCER, V47, P554, DOI 10.1002/1097-0142(19810201)47:3<554::AID-CNCR2820470322>3.0.CO;2-W; SZYF M, 1985, J BIOL CHEM, V260, P8653; SZYF M, 1991, J BIOL CHEM, V266, P10027; Vertino PM, 1996, MOL CELL BIOL, V16, P4555, DOI 10.1128/mcb.16.8.4555; VICKER PJ, 1988, MOL ENDOCRINOL, V2, P866; VINDELOV LL, 1983, CYTOMETRY, V3, P323, DOI 10.1002/cyto.990030503; WU JJ, 1993, P NATL ACAD SCI USA, V90, P8891, DOI 10.1073/pnas.90.19.8891	34	32	34	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 9	1999	18	52					7453	7461		10.1038/sj.onc.1203138	http://dx.doi.org/10.1038/sj.onc.1203138			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	263HQ	10602504				2022-12-17	WOS:000084119600006
J	Bannasch, D; Weis, I; Schwab, M				Bannasch, D; Weis, I; Schwab, M			Nmi protein interacts with regions that differ between MycN and Myc and is localized in the cytoplasm of neuroblastoma cells in contrast to nuclear MycN	ONCOGENE			English	Article						protein-protein interactions; two-hybrid; Max; immunofluorescence; Ga14 DNA binding domain; amplification	C-MYC; N-MYC; TRANSCRIPTIONAL ACTIVATION; DNA-BINDING; NEURO-BLASTOMA; IN-VIVO; MAX; GENE; EXPRESSION; AMPLIFICATION	Myc family proteins play an important role in cellular processes such as proliferation, differentiation, apoptosis and transformation. A number of interaction partners of Myc have been identified, such as Max, p107, TBP, YY1, Miz-1, AP-2 and Nmi. Both Max and Nmi also bind to MycN. In contrast to the well defined binding of Max to Myc family proteins the interaction of Nmi with Myc or MycN is only poorly characterized. By employing the yeast two-hybrid system we have mapped the regions of MycN and Myc responsible for binding to Nmi. For MycN exclusively a central region mediates binding to Nmi. In contrast, for Myc a C-terminal portion of the protein, and possibly also a central part, is involved in Nmi interaction. Nmi does not interact with Max and has no transactivation capabilities in yeast, suggesting that Nmi alone is not a transcriptional activator in mammalian cells. Immunofluorescence demonstrates that both in 293 embryonic kidney cells and in Kelly neuroblastoma cells all detectable ectopically expressed Nmi is localized in the cytoplasm, in part in a punctate, granular pattern. MycN, which is highly expressed in Kelly cells consequent to amplification, appears to be localized exclusively in the nuclei. This directly demonstrates that in the same cell at least the major proportion of MycN and Nmi is localized in different cellular compartments. This result is confirmed by the finding that endogenous Nmi, which is expressed in Kelly cells only after stimulation with interferon gamma, is detected exclusively in the cytoplasm of these cells. Therefore only a very small amount of MycN and Nmi is likely to be involved in MycN/Nmi interaction in vivo.	Deutsch Krebsforschungszentrum, Div Cytogenet H0400, D-69120 Heidelberg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ)	Schwab, M (corresponding author), Deutsch Krebsforschungszentrum, Div Cytogenet H0400, Neuenheimer Feld 280, D-69120 Heidelberg, Germany.							ALEXANDROVA N, 1995, MOL CELL BIOL, V15, P5188; AMATI B, 1992, NATURE, V359, P423, DOI 10.1038/359423a0; AMIN C, 1993, MOL CELL BIOL, V13, P383, DOI 10.1128/MCB.13.1.383; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; BANNASCH D, 1999, IN PRESS PLASMID, V42; Bao JX, 1996, ONCOGENE, V12, P2171; BEIJERSBERGEN RL, 1994, EMBO J, V13, P4080, DOI 10.1002/j.1460-2075.1994.tb06725.x; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLACKWOOD EM, 1992, GENE DEV, V6, P71, DOI 10.1101/gad.6.1.71; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; Bush A, 1998, GENE DEV, V12, P3797, DOI 10.1101/gad.12.24.3797; CERNI C, 1995, ONCOGENE, V11, P587; Cheng SWG, 1999, NAT GENET, V22, P102, DOI 10.1038/8811; DEPINHO RA, 1991, ADV CANCER RES, V57, P1; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; Facchini LM, 1998, FASEB J, V12, P633, DOI 10.1096/fasebj.12.9.633; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; GAUBATZ S, 1994, MOL CELL BIOL, V14, P3853, DOI 10.1128/MCB.14.6.3853; GAUBATZ S, 1995, EMBO J, V14, P1508, DOI 10.1002/j.1460-2075.1995.tb07137.x; GRANDORI C, 1998, TIBS, V22, P177; GU W, 1994, SCIENCE, V264, P251, DOI 10.1126/science.8146655; GU W, 1993, P NATL ACAD SCI USA, V90, P2935, DOI 10.1073/pnas.90.7.2935; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; HURLIN PJ, 1995, EMBO J, V14, P5646, DOI 10.1002/j.1460-2075.1995.tb00252.x; Ingvarsson S, 1990, Semin Cancer Biol, V1, P359; Kalenik JL, 1997, NUCLEIC ACIDS RES, V25, P843, DOI 10.1093/nar/25.4.843; KERKHOFF E, 1991, P NATL ACAD SCI USA, V88, P4323, DOI 10.1073/pnas.88.10.4323; KHANNA R, 1995, MICROBIOL REV, V59, P387, DOI 10.1128/MMBR.59.3.387-405.1995; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; Lebrun SJ, 1998, J INTERF CYTOK RES, V18, P767, DOI 10.1089/jir.1998.18.767; LECH K, 1988, CELL, V52, P179, DOI 10.1016/0092-8674(88)90506-5; LEE WH, 1984, NATURE, V309, P458, DOI 10.1038/309458a0; MAHESWARAN S, 1994, MOL CELL BIOL, V14, P1147, DOI 10.1128/MCB.14.2.1147; Mateyak MK, 1997, CELL GROWTH DIFFER, V8, P1039; McMahon SB, 1998, CELL, V94, P363, DOI 10.1016/S0092-8674(00)81479-8; NAU MM, 1986, P NATL ACAD SCI USA, V83, P1092, DOI 10.1073/pnas.83.4.1092; NERLOV C, 1995, EMBO J, V14, P4318, DOI 10.1002/j.1460-2075.1995.tb00106.x; Peukert K, 1997, EMBO J, V16, P5672, DOI 10.1093/emboj/16.18.5672; PRENDERGAST GC, 1991, SCIENCE, V251, P186, DOI 10.1126/science.1987636; Sakamuro D, 1996, NAT GENET, V14, P69, DOI 10.1038/ng0996-69; Schreiber-Agus N, 1998, BIOESSAYS, V20, P808, DOI 10.1002/(SICI)1521-1878(199810)20:10<808::AID-BIES6>3.0.CO;2-U; SCHWAB M, 1983, NATURE, V305, P245, DOI 10.1038/305245a0; SCHWAB M, 1984, P NATL ACAD SCI-BIOL, V81, P4940, DOI 10.1073/pnas.81.15.4940; Schwab M, 1998, BIOESSAYS, V20, P473, DOI 10.1002/(SICI)1521-1878(199806)20:6<473::AID-BIES5>3.3.CO;2-N; SCHWAB M, 1988, ONCOGENE HDB, P381; Shrivastava A, 1996, P NATL ACAD SCI USA, V93, P10638, DOI 10.1073/pnas.93.20.10638; VANLOHUIZEN M, 1989, EMBO J, V8, P133, DOI 10.1002/j.1460-2075.1989.tb03357.x; WAGNER AJ, 1993, CELL GROWTH DIFFER, V4, P879; WAKAMATSU Y, 1993, NEURON, V10, P1, DOI 10.1016/0896-6273(93)90236-K; Wang Q, 1998, ONCOGENE, V17, P1939, DOI 10.1038/sj.onc.1202403; WENZEL A, 1991, EMBO J, V10, P3703, DOI 10.1002/j.1460-2075.1991.tb04938.x; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A; Zhu MH, 1999, CELL, V96, P121, DOI 10.1016/S0092-8674(00)80965-4; ZIMMERMAN KA, 1986, NATURE, V319, P780, DOI 10.1038/319780a0	54	32	33	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 18	1999	18	48					6810	6817		10.1038/sj.onc.1203090	http://dx.doi.org/10.1038/sj.onc.1203090			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	257QA	10597290				2022-12-17	WOS:000083792000024
J	Thant, AA; Sein, TT; Liu, EB; Machida, K; Kikkawa, F; Koike, T; Seiki, M; Matsuda, S; Hamaguchi, M				Thant, AA; Sein, TT; Liu, EB; Machida, K; Kikkawa, F; Koike, T; Seiki, M; Matsuda, S; Hamaguchi, M			Ras pathway is required for the activation of MMP-2 secretion and for the invasion of src-transformed 3Y1	ONCOGENE			English	Article						Ras; v-Src; matrix metalloproteinase-2; invasion; signaling pathway	ROUS-SARCOMA VIRUS; V-SRC; MATRIX METALLOPROTEINASES; TYROSINE PHOSPHORYLATION; CELL-TRANSFORMATION; STAT3 ACTIVATION; INFECTED CELLS; MESSENGER-RNA; GENE-PRODUCT; TUMOR-CELLS	To search for the signaling pathway critical for tumor invasion, we examined the effects of dominant negative ras (S17N ras) expression on the activation of matrix metalloproteinase-2 (MMP-2) in spc-transformed 3Y1, SR3Y1, under the control of conditionally inducible promoter. In SR3Y1 clones transfected with S17N pas, augmented secretion and proteolytic activation of MMP-2 were dramatically suppressed by S17N Ras expression, while tyrosine phosphorylation of cellular proteins was not suppressed. We found that invasiveness of SR3Y1 cells assayed by the modified Boyden Chamber method was strongly suppressed by S17N Ras expression. In contrast, cell morphology reverted partially and glucose uptake remained unchanged by S17N Ras expression. In addition, treatment of SR3Y1 with manumycin A, a potent inhibitor of Ras farnesyltransferase, strongly suppressed both augmented secretion and proteolytic activation of MMP-2. Contrary, treatment of SR3Y1 with wortmannin or TPA showed no clear effect on MMP-2 activation. Thus, these results strongly suggest that Ras-signaling, but neither P13 kinase- nor protein kinase C-signalings, plays a critical role in activation of MMP-2 and, subsequently, in the invasiveness of src-transformed cells.	Nagoya Univ, Sch Med, Dept Mol Pathogenesis, Showa Ku, Nagoya, Aichi 4668550, Japan; Nagoya Univ, Sch Med, Dept Obstet & Gynecol, Showa Ku, Nagoya, Aichi 4668550, Japan; Univ Tokyo, Inst Med Sci, Dept Canc Cell Res, Minato Ku, Tokyo 1088639, Japan	Nagoya University; Nagoya University; University of Tokyo	Hamaguchi, M (corresponding author), Nagoya Univ, Sch Med, Dept Mol Pathogenesis, Showa Ku, 65 Tsurumai Cho, Nagoya, Aichi 4668550, Japan.		KIKKAWA, Fumitaka/I-7341-2014; Seiki, Motoharu/K-9443-2015					Aftab DT, 1997, P NATL ACAD SCI USA, V94, P3028, DOI 10.1073/pnas.94.7.3028; ALBINI A, 1987, CANCER RES, V47, P3239; Bromberg JF, 1998, MOL CELL BIOL, V18, P2553, DOI 10.1128/MCB.18.5.2553; BURR JG, 1980, P NATL ACAD SCI-BIOL, V77, P3484, DOI 10.1073/pnas.77.6.3484; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; Cao XM, 1996, MOL CELL BIOL, V16, P1595; Chang HW, 1997, SCIENCE, V276, P1848, DOI 10.1126/science.276.5320.1848; COLLETT MS, 1978, P NATL ACAD SCI USA, V75, P2021, DOI 10.1073/pnas.75.4.2021; COLLIER IE, 1988, J BIOL CHEM, V263, P6579; DECLUE JE, 1991, MOL CELL BIOL, V11, P2819, DOI 10.1128/MCB.11.5.2819; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FUKUI Y, 1989, MOL CELL BIOL, V9, P1651, DOI 10.1128/MCB.9.4.1651; HAMAGUCHI M, 1987, P NATL ACAD SCI USA, V84, P2312, DOI 10.1073/pnas.84.8.2312; HAMAGUCHI M, 1993, EMBO J, V12, P307, DOI 10.1002/j.1460-2075.1993.tb05658.x; HAMAGUCHI M, 1990, MOL CELL BIOL, V10, P830, DOI 10.1128/MCB.10.2.830; HAMAGUCHI M, 1988, MOL CELL BIOL, V8, P3035, DOI 10.1128/MCB.8.8.3035; HAMAGUCHI M, 1995, ONCOGENE, V10, P1037; HAMAGUCHI M, 1993, ONCOGENE, V8, P559; HANAFUSA H, 1977, COMPREHENSIVE VIROLO, V10, P401; HATANAKA M, 1970, VIROLOGY, V41, P647, DOI 10.1016/0042-6822(70)90429-0; Kataoka M, 1996, INT J ONCOL, V8, P773; KAWAI S, 1980, J VIROL, V34, P772, DOI 10.1128/JVI.34.3.772-776.1980; KAWAI S, 1971, VIROLOGY, V46, P470, DOI 10.1016/0042-6822(71)90047-X; Klein NP, 1997, MOL CELL BIOL, V17, P6427, DOI 10.1128/MCB.17.11.6427; LEVINSON AD, 1978, CELL, V15, P561, DOI 10.1016/0092-8674(78)90024-7; LIOTTA LA, 1986, CANCER RES, V46, P1; MATRISIAN LM, 1990, TRENDS GENET, V6, P121, DOI 10.1016/0168-9525(90)90126-Q; MULLINS DE, 1983, BIOCHIM BIOPHYS ACTA, V695, P177, DOI 10.1016/0304-419X(83)90011-2; NORI M, 1991, MOL CELL BIOL, V11, P2812, DOI 10.1128/MCB.11.5.2812; OHTANI H, 1995, JPN J CANCER RES, V86, P833, DOI 10.1111/j.1349-7006.1995.tb03093.x; OKADA A, 1995, P NATL ACAD SCI USA, V92, P2730, DOI 10.1073/pnas.92.7.2730; PYKE C, 1992, CANCER RES, V52, P1336; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; STETLERSTEVENSON WG, 1989, J BIOL CHEM, V264, P1353; TAMANOI F, 1993, TRENDS BIOCHEM SCI, V18, P349, DOI 10.1016/0968-0004(93)90072-U; Thant AA, 1997, FEBS LETT, V406, P28, DOI 10.1016/S0014-5793(97)00230-5; Turkson J, 1998, MOL CELL BIOL, V18, P2545, DOI 10.1128/MCB.18.5.2545; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705; XIAO HY, 1995, INT J ONCOL, V6, P405; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555; ZANG Q, 1995, CELL GROWTH DIFFER, V6, P1367	42	32	32	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 11	1999	18	47					6555	6563		10.1038/sj.onc.1203049	http://dx.doi.org/10.1038/sj.onc.1203049			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	256CW	10597259	Bronze			2022-12-17	WOS:000083709200019
J	Trautwein, C; Will, M; Kubicka, S; Rakemann, T; Flemming, P; Manns, MP				Trautwein, C; Will, M; Kubicka, S; Rakemann, T; Flemming, P; Manns, MP			2-acetaminofluorene blocks cell cycle progression after hepatectomy by p21 induction and lack of Cyclin E expression	ONCOGENE			English	Article						2-acetaminofluorene; hepatectomy; liver regeneration; cell cycle progression; P21; Cyclin E	LIVER STEM-CELLS; RETINOBLASTOMA PROTEIN; OVAL CELLS; DEPENDENT KINASES; G(1) ARREST; TRANSCRIPTION FACTORS; REGENERATING LIVER; GENE-TRANSCRIPTION; DOWN-REGULATION; GROWTH	In the Solt-Faber model DENA and 2-Acetaminofluorene (AAF) treatment combined with hepatectomy induces hepatocellular carcinoma in rats. In this model AAF blocks proliferation of hepatocytes, while oval cells restore liver mass. Here we studied the molecular mechanism involved in blocking AAF-dependent cell cycle progression of hepatocytes. AAF inhibits cell proliferation of hepatocytes shown by the lack of Cyclin E expression before the G1/S phase restriction point. Immunfluorescence studies revealed that Cyclin E positive signals mere restricted to oval cells, while hepatocytes remained negative. Additionally, AAF treatment induces strong nuclear p53 expression which is associated with increased p21 mRNA levels. Inhibition of active Cyclin/CdK (cyclin dependent kinase) complexes is reflected in AAF-treated animals by decreased RE expression and phosphorylation. The decrease in RE expression and phosphorylation, which is essential in triggering DNA synthesis and Cyclin A expression, leads to a deficiency in transcriptionally active E2F complex formation after hepatectomy. Thus, two molecular explanations are evident to account for AAF-dependent cell cycle progression of hepatocytes in vivo: first, induction of p53 expression which leads to higher p21 mRNA levels, and second, a lack of Cyclin E expression at the G1/S phase restriction point after hepatectomy.	Med Hsch Hannover, Dept Gastroenterol & Hepatol, D-30625 Hannover, Germany; Med Hsch Hannover, Dept Pathol, D-30625 Hannover, Germany	Hannover Medical School; Hannover Medical School	Trautwein, C (corresponding author), Med Hsch Hannover, Dept Gastroenterol & Hepatol, Carl-Neuberg-Str 1, D-30625 Hannover, Germany.							Albrecht JH, 1998, ONCOGENE, V16, P2141, DOI 10.1038/sj.onc.1201728; Albrecht JH, 1997, HEPATOLOGY, V25, P557, DOI 10.1002/hep.510250311; Alison MR, 1996, CELL PROLIFERAT, V29, P373, DOI 10.1111/j.1365-2184.1996.tb00982.x; ALMASAN A, 1995, P NATL ACAD SCI USA, V92, P5436, DOI 10.1073/pnas.92.12.5436; ARROYO M, 1992, NUCLEIC ACIDS RES, V20, P5947, DOI 10.1093/nar/20.22.5947; Bisgaard HC, 1996, HEPATOLOGY, V23, P62, DOI 10.1002/hep.510230110; Bock CT, 1997, GASTROENTEROLOGY, V113, P1976, DOI 10.1016/S0016-5085(97)70018-0; CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; CHIOU K, 1994, MOL CELL BIOL, V15, P2556; CHOWDARY DR, 1994, MOL CELL BIOL, V14, P1997, DOI 10.1128/MCB.14.3.1997; Cressman DE, 1996, SCIENCE, V274, P1379, DOI 10.1126/science.274.5291.1379; CRESSMAN DE, 1995, HEPATOLOGY, V21, P1443, DOI 10.1016/0270-9139(95)90068-3; DEGREGORI J, 1995, GENE DEV, V9, P2873, DOI 10.1101/gad.9.23.2873; DYNLACHT BD, 1994, GENE DEV, V8, P1772, DOI 10.1101/gad.8.15.1772; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELLEDGE SJ, 1991, EMBO J, V10, P2653, DOI 10.1002/j.1460-2075.1991.tb07808.x; EVARTS RP, 1987, CARCINOGENESIS, V8, P1737, DOI 10.1093/carcin/8.11.1737; FARIS RA, 1991, CANCER RES, V51, P1308; Fausto N, 1990, CURR OPIN CELL BIOL, V2, P1036, DOI 10.1016/0955-0674(90)90153-6; FU XX, 1988, J VIROL, V62, P3422, DOI 10.1128/JVI.62.9.3422-3430.1988; GANNON JV, 1990, EMBO J, V9, P15905; GRANA X, 1995, ONCOGENE, V11, P211; GRISHAM JW, 1962, CANCER RES, V22, P842; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; Herrera RE, 1996, MOL CELL BIOL, V16, P2402; Ikeda M, 1996, P NATL ACAD SCI USA, V93, P3215, DOI 10.1073/pnas.93.8.3215; KASTAN MB, 1991, CANCER RES, V51, P6304; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; LEES JA, 1993, MOL CELL BIOL, V13, P7813, DOI 10.1128/MCB.13.12.7813; Linke SP, 1997, ONCOGENE, V15, P337, DOI 10.1038/sj.onc.1201200; Livneh E, 1997, EUR J BIOCHEM, V248, P1, DOI 10.1111/j.1432-1033.1997.t01-4-00001.x; Michalopoulos GK, 1997, SCIENCE, V276, P60, DOI 10.1126/science.276.5309.60; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Nasmyth K, 1996, SCIENCE, V274, P1643, DOI 10.1126/science.274.5293.1643; Niehof M, 1997, MOL CELL BIOL, V17, P3600, DOI 10.1128/MCB.17.7.3600; Nishida N, 1997, HISTOL HISTOPATHOL, V12, P1019; Ohtani K, 1995, P NATL ACAD SCI USA, V92, P12146, DOI 10.1073/pnas.92.26.12146; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; Petersen BE, 1998, HEPATOLOGY, V27, P433, DOI 10.1002/hep.510270218; SCHIRMACHER P, 1993, VIRCHOWS ARCH B, V63, P71, DOI 10.1007/BF02899246; Schnier JB, 1996, P NATL ACAD SCI USA, V93, P5941, DOI 10.1073/pnas.93.12.5941; SELL S, 1994, MODERN PATHOL, V7, P105; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SIGAL HS, 1992, AM J PHYSIOL, V26, pG139; SLANSKY JE, 1993, MOL CELL BIOL, V13, P1610, DOI 10.1128/MCB.13.3.1610; SOLT D, 1976, NATURE, V263, P701, DOI 10.1038/263701a0; TEWARI M, 1992, MOL CELL BIOL, V12, P2898, DOI 10.1128/MCB.12.6.2898; THORGEIRSSON SS, 1993, AM J PATHOL, V142, P1331; Trautwein C, 1996, J BIOL CHEM, V271, P22262, DOI 10.1074/jbc.271.36.22262; TRAUTWEIN C, 1993, NATURE, V364, P544, DOI 10.1038/364544a0; Trautwein C, 1996, GASTROENTEROLOGY, V110, P1854, DOI 10.1053/gast.1996.v110.pm8964411; Trautwein C, 1998, J CLIN INVEST, V101, P1960, DOI 10.1172/JCI504; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Wu H, 1996, GENE DEV, V10, P245, DOI 10.1101/gad.10.3.245; XU GF, 1995, P NATL ACAD SCI USA, V92, P1357, DOI 10.1073/pnas.92.5.1357; Yamada Y, 1997, P NATL ACAD SCI USA, V94, P1441, DOI 10.1073/pnas.94.4.1441	59	32	32	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 11	1999	18	47					6443	6453		10.1038/sj.onc.1203045	http://dx.doi.org/10.1038/sj.onc.1203045			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	256CW	10597246				2022-12-17	WOS:000083709200006
J	Craig, AL; Blaydes, JP; Burch, LR; Thompson, AM; Hupp, TR				Craig, AL; Blaydes, JP; Burch, LR; Thompson, AM; Hupp, TR			Dephosphorylation of p53 at Ser20 after cellular exposure to low levels of non-ionizing radiation	ONCOGENE			English	Article						p53; transcription; kinase; radiation; phosphorylation	DNA-BINDING FUNCTION; WILD-TYPE P53; PROTEIN; PHOSPHORYLATION; CELLS; DAMAGE; MDM2; TRANSCRIPTION; STABILITY; ACTIVATE	Induction of the transactivation function of p53 after cellular irradiation was studied under conditions in which upstream signaling events modulating p53 activation were uncoupled from those regulating stabilization. This investigation prompted the discovery of a novel radiation-responsive kinase pathway targeting Ser20 that results in the masking of the DO-1 epitope in undamaged cells. Unmasking of the DO-1 epitope via dephosphorylation occurs in response to low doses of nonionizing radiation. Our data show that phosphorylation at Ser20 reduces binding of the mdm2 protein, suggesting that a function of the Ser20-kinase pathway may be to produce a stable pool of inactive p53 in undamaged cells which can be readily activated after cellular injury. Phospho-specific monoclonal antibodies were used to determine whether the Ser20 signaling pathway is coupled to the Ser15 and Ser392 radiation-responsive kinase pathways. These results demonstrated that: (1) dephosphorylation at Ser20 is co-ordinated with an increased steady-state phosphorylation at Ser392 after irradiation, without p53 protein stabilization, and (2) stabilization of p53 protein can occur without Ser15 phosphorylation at higher doses of radiation. These data show that the Ser20 and Ser392 phosphorylation sites are both targeted by an integrated network of signaling pathways which is acutely sensitive to radiation injury.	Univ Dundee, Dundee Canc Res Inst, Dept Mol & Cellular Pathol, Dundee DD1 9SY, Scotland; Univ Dundee, Dundee Canc Res Inst, Dept Mol Oncol, Dundee DD1 9SY, Scotland; Univ Dundee, Dundee Canc Res Inst, Dept Surg, Dundee DD1 9SY, Scotland	University of Dundee; University of Dundee; University of Dundee	Hupp, TR (corresponding author), Univ Dundee, Dundee Canc Res Inst, Dept Mol & Cellular Pathol, Dundee DD1 9SY, Scotland.		Blaydes, Jeremy/AAC-6939-2019	Blaydes, Jeremy/0000-0001-8525-0209				Berns EMJJ, 1998, J CLIN ONCOL, V16, P121, DOI 10.1200/JCO.1998.16.1.121; Blaydes JP, 1997, ONCOGENE, V14, P1859, DOI 10.1038/sj.onc.1201018; Blaydes JP, 1998, ONCOGENE, V17, P1045, DOI 10.1038/sj.onc.1202014; BOND J, 1999, IN PRESS ONCOGENE; Bottger A, 1997, CURR BIOL, V7, P860, DOI 10.1016/S0960-9822(06)00374-5; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cairns CA, 1998, EMBO J, V17, P3112, DOI 10.1093/emboj/17.11.3112; Chesnokov I, 1996, MOL CELL BIOL, V16, P7084; DOVER R, 1994, J CELL SCI, V107, P1181; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HUPP TR, 1995, CELL, V83, P237, DOI 10.1016/0092-8674(95)90165-5; HUPP TR, 1995, J BIOL CHEM, V270, P18165, DOI 10.1074/jbc.270.30.18165; HUPP TR, 1994, COLD SPRING HARB SYM, V59, P195, DOI 10.1101/SQB.1994.059.01.024; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; KASTAN MB, 1991, CANCER RES, V51, P6304; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Kussie PH, 1996, SCIENCE, V274, P948, DOI 10.1126/science.274.5289.948; Lambert PF, 1998, J BIOL CHEM, V273, P33048, DOI 10.1074/jbc.273.49.33048; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; Lutzker SG, 1996, NAT MED, V2, P804, DOI 10.1038/nm0796-804; Midgley CA, 1997, ONCOGENE, V15, P1179, DOI 10.1038/sj.onc.1201459; Oren M, 1996, BBA-REV CANCER, V1288, pR13, DOI 10.1016/S0304-419X(96)00030-3; Pise-Masison CA, 1998, J VIROL, V72, P6348, DOI 10.1128/JVI.72.8.6348-6355.1998; Ravera MW, 1998, ONCOGENE, V16, P1993, DOI 10.1038/sj.onc.1201717; Sakaguchi K, 1997, BIOCHEMISTRY-US, V36, P10117, DOI 10.1021/bi970759w; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; Soussi T, 1996, J MOL BIOL, V260, P623, DOI 10.1006/jmbi.1996.0425; STEPHEN CW, 1995, J MOL BIOL, V248, P58, DOI 10.1006/jmbi.1995.0202; THOMPSON AM, 1998, BRIT J SURG, V82, P210; Unger T, 1999, EMBO J, V18, P1805, DOI 10.1093/emboj/18.7.1805; Van Der Geer P., 1993, PROTEIN PHOSPHORYLAT, P31; Venkatachalam S, 1998, EMBO J, V17, P4657, DOI 10.1093/emboj/17.16.4657; VOJTESEK B, 1995, ONCOGENE, V10, P389; Waterman MJF, 1998, NAT GENET, V19, P175, DOI 10.1038/542; YEARGIN J, 1995, CURR BIOL, V5, P423, DOI 10.1016/S0960-9822(95)00083-2	36	32	33	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 4	1999	18	46					6305	6312		10.1038/sj.onc.1203085	http://dx.doi.org/10.1038/sj.onc.1203085			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	260DK	10597229				2022-12-17	WOS:000083934100014
J	Shack, S; Gorospe, M; Fawcett, TW; Hudgins, WR; Holbrook, NJ				Shack, S; Gorospe, M; Fawcett, TW; Hudgins, WR; Holbrook, NJ			Activation of the cholesterol pathway and Ras maturation in response to stress	ONCOGENE			English	Article						cholesterol; 3-hydroxy-3-methylglutaryl-CoA reductase; ras; stress	MAP KINASE KINASE; PROTEIN-KINASE; P21RAS ISOPRENYLATION; CELLS; TRANSFORMATION; PRENYLATION; EXPRESSION; INHIBITOR; REDUCTASE; PLANTS	All cells depend on sterols and isoprenoids derived from mevalonate (MVA) for growth, differentiation, and maintenance of homeostatic functions. In plants, environmental insults like heat and sunlight trigger the synthesis of isoprene, also derived from MVA, and this phenomenon has been associated with enhanced tolerance to heat. Here, we show that in human prostate adenocarcinoma PC-3M cells heat shock leads to activation of the MVA pathway. This is characterized by a dose- and time-dependent elevation in 3-hydroxy3methylglutaryl-coenzyme A reductase (HMGR) activity; enhanced sterol and isoprenoid synthesis, and increased protein prenylation, Furthermore, prenylation and subsequent membrane localization of Ras, a central player in cell signaling, was rapidly induced following heat stress. These effects were dose-dependent, augmented with repeated insults, and were prevented by culturing cells in the presence of lovastatin, a competitive inhibitor of HMGR, Enhanced Ras maturation by heat stress was also associated with a heightened activation of extracellular signal-regulated kinase (ERK), a key mediator of both mitogenic and stress signaling pathways, in response to subsequent growth factor stimulation. Thus, activation of the MVA pathway may constitute an important adaptive host response to stress, and have significant implications to carcinogenesis.	NIA, Gerontol Res Ctr, Biol Chem Lab, Cell Stress & Aging Sect,NIH, Baltimore, MD 21224 USA; NCI, Med Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Holbrook, NJ (corresponding author), NIA, Gerontol Res Ctr, Biol Chem Lab, Cell Stress & Aging Sect,NIH, 5600 Nathan Shock Dr,Box 12, Baltimore, MD 21224 USA.							ALBERTS AW, 1980, P NATL ACAD SCI-BIOL, V77, P3957, DOI 10.1073/pnas.77.7.3957; BACH TJ, 1995, LIPIDS, V30, P191, DOI 10.1007/BF02537822; Bernhard EJ, 1998, CANCER RES, V58, P1754; BUCHER NLR, 1958, J BIOL CHEM, V234, P262; CASEY PJ, 1992, J LIPID RES, V33, P1731; CORTON JM, 1994, CURR BIOL, V4, P315, DOI 10.1016/S0960-9822(00)00070-1; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; FUJII H, 1982, BIOCHIM BIOPHYS ACTA, V712, P716; Gadbut AP, 1997, EMBO J, V16, P7250, DOI 10.1093/emboj/16.24.7250; GIBBS JB, 1994, CELL, V77, P175, DOI 10.1016/0092-8674(94)90308-5; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; GRUNLER J, 1994, BBA-LIPID LIPID MET, V1212, P259, DOI 10.1016/0005-2760(94)90200-3; Guyton KZ, 1996, CANCER RES, V56, P3480; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HARDIE DG, 1997, EUR J BIOCHEM, V246, P258; HORIE M, 1993, BIOCHEM PHARMACOL, V46, P297, DOI 10.1016/0006-2952(93)90418-V; KHAN SG, 1994, J INVEST DERMATOL, V102, P754, DOI 10.1111/1523-1747.ep12377020; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; KRITCHEVSKY D, 1958, CHOLESTEROL, P139; Kyriakis JM, 1996, J BIOL CHEM, V271, P24313, DOI 10.1074/jbc.271.40.24313; Larner J, 1998, AM J CLIN ONCOL-CANC, V21, P579, DOI 10.1097/00000421-199812000-00010; LARSON TR, 1995, J ENDOUROL, V9, P339, DOI 10.1089/end.1995.9.339; Madersbacher S, 1998, PROSTATE, V37, P174; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARSHALL CJ, 1993, SCIENCE, V259, P1865, DOI 10.1126/science.8456312; MILLER AC, 1993, INT J CANCER, V53, P302, DOI 10.1002/ijc.2910530222; MILLER AC, 1995, INT J CANCER, V60, P249; Moriyama T, 1998, J BIOL CHEM, V273, P22037, DOI 10.1074/jbc.273.34.22037; MUMBY SM, 1990, P NATL ACAD SCI USA, V87, P5873, DOI 10.1073/pnas.87.15.5873; OKAZAKI K, 1995, ONCOGENE, V10, P1149; SAMID D, 1991, RADIAT RES, V126, P244, DOI 10.2307/3577825; SERVADIO C, 1991, UROLOGY, V38, P307, DOI 10.1016/0090-4295(91)80140-3; SERVATIUS RJ, 1993, PHYSIOL BEHAV, V53, P1101, DOI 10.1016/0031-9384(93)90365-M; SHAPIRO DJ, 1974, BIOCHIM BIOPHYS ACTA, V370, P369, DOI 10.1016/0005-2744(74)90098-9; SHARKEY TD, 1995, NATURE, V374, P769, DOI 10.1038/374769a0; Sharkey TD, 1996, ENDEAVOUR, V20, P74, DOI 10.1016/0160-9327(96)10014-4; Siddiqui AA, 1998, J BIOL CHEM, V273, P3712, DOI 10.1074/jbc.273.6.3712; SIPERSTEIN MD, 1995, ADV EXP MED BIOL, V369, P155; SKLAR MD, 1988, SCIENCE, V239, P645, DOI 10.1126/science.3277276; STERMER BA, 1994, J LIPID RES, V35, P1133; TILBROOK PA, 1995, ONCOGENE, V10, P805; Yasuda M, 1932, J CLIN INVEST, V11, P677, DOI 10.1172/JCI100442	43	32	32	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 28	1999	18	44					6021	6028		10.1038/sj.onc.1203002	http://dx.doi.org/10.1038/sj.onc.1203002			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	249XU	10557091				2022-12-17	WOS:000083359100008
J	Shridhar, V; Staub, J; Huntley, B; Cliby, W; Jenkins, R; Pass, HI; Hartmann, L; Smith, DI				Shridhar, V; Staub, J; Huntley, B; Cliby, W; Jenkins, R; Pass, HI; Hartmann, L; Smith, DI			A novel region of deletion on chromosome 6q23.3 spanning less than 500 Kb in high grade invasive epithelial ovarian cancer	ONCOGENE			English	Article						6q23.3 loss; invasive epithelial ovarian cancer; tumor suppressor	TUMOR-SUPPRESSOR GENE; BREAST CARCINOMAS; MULTIPLE REGIONS; FREQUENT LOSS; FRAGILE SITE; ARM 6Q; HETEROZYGOSITY; LOCI; IDENTIFICATION; MELANOMA	Detailed deletion mapping of chromosome 6q sequences in invasive ovarian tumors have implicated several broad regions involving 6q14- 16, 6q21 -23, 6q25 -26, and the telomeric portion in band 6q27 as regions of frequent loss in this malignancy. In order to define regions of loss involved in the development of ovarian cancer, we used 23 polymorphic markers on 6q to examine allelic loss in 25 high-grade, late stage ovarian tumors. Four nonoverlapping deletion regions were observed: (1) at 6q21-22.3 (D6S301-D6S292); (2) within a 1 cM region at 23.2-23.3 between markers D6S978-D6S1637 (at D6S311); (3) at 6q26 (between markers D6S411-D6S1277) and (4) at 6q27 with the markers D6S297 and D6S193. The highest region of loss was observed with marker D6S311 (lost in 17 of 19 informative cases, 89%) in 6q23.3, followed by D6S977 and D6S1637 (71 and 55%, respectively). The average fractional allele loss in the high-grade tumors was around 35%. Previous reports have shown 6q27 as the region of most frequent loss in invasive ovarian cancer. However, our results indicate a novel region in 6q23.3 (spanning less than 500 Kb distance between the markers) with the highest loss, implicating this region of chromosome 6q to harbor a putative tumor suppressor gene involved in the development of invasive epithelial ovarian cancer.	Mayo Clin & Mayo Fdn, Dept Expt Pathol & Lab Med, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Med Oncol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Div Gynecol Surg, Rochester, MN 55905 USA; Wayne State Univ, Sch Med, Dept Surg, Detroit, MI 48201 USA; Karmanos Canc Inst, Detroit, MI USA	Mayo Clinic; Mayo Clinic; Mayo Clinic; Wayne State University; Barbara Ann Karmanos Cancer Institute	Smith, DI (corresponding author), Mayo Clin & Mayo Fdn, Dept Expt Pathol & Lab Med, 200 1st St SW, Rochester, MN 55905 USA.			Pass, Harvey/0000-0003-3222-3471	NCI NIH HHS [CA48031] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA048031] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abdollahi A, 1997, ONCOGENE, V14, P1973, DOI 10.1038/sj.onc.1201034; Banga SS, 1997, ONCOGENE, V14, P313, DOI 10.1038/sj.onc.1200842; Bell DW, 1997, CANCER RES, V57, P4057; CANNISTRA SA, 1993, NEW ENGL J MED, V329, P1550, DOI 10.1056/NEJM199311183292108; Chappell SA, 1997, BRIT J CANCER, V75, P1324, DOI 10.1038/bjc.1997.224; CHURCH SL, 1993, P NATL ACAD SCI USA, V90, P3113, DOI 10.1073/pnas.90.7.3113; CLIBY W, 1993, CANCER RES, V53, P2393; Colitti CV, 1998, ONCOGENE, V16, P555, DOI 10.1038/sj.onc.1201523; Collins A, 1996, P NATL ACAD SCI USA, V93, P14771, DOI 10.1073/pnas.93.25.14771; Cooke IE, 1996, GENE CHROMOSOME CANC, V15, P223, DOI 10.1002/(SICI)1098-2264(199604)15:4<223::AID-GCC4>3.3.CO;2-4; Cooney KA, 1996, CANCER RES, V56, P4150; DODSON MK, 1993, CANCER RES, V53, P4456; FOULKES WD, 1993, BRIT J CANCER, V67, P551, DOI 10.1038/bjc.1993.101; Guan XY, 1996, BLOOD, V88, P1418, DOI 10.1182/blood.V88.4.1418.bloodjournal8841418; Hauptschein RS, 1998, GENOMICS, V50, P170, DOI 10.1006/geno.1998.5321; HENDERSON BE, 1991, SCIENCE, V254, P1131, DOI 10.1126/science.1957166; Jiang XX, 1996, CANCER RES, V56, P3534; Landis SH, 1998, CA-CANCER J CLIN, V48, P6, DOI 10.3322/canjclin.48.1.6; LEARY JA, 1993, INT J GYNECOL CANCER, V3, P293, DOI 10.1046/j.1525-1438.1993.03050293.x; LEE JH, 1990, CANCER RES, V50, P2724; MORELLI C, 1997, CANCER RES, V57, P4152; ORPHANOS V, 1995, BRIT J CANCER, V71, P666, DOI 10.1038/bjc.1995.132; QUIMADO L, 1995, GENES CHROMOSOM CANC, V14, P28; RODABAUGH KJ, 1995, CANCER RES, V55, P2169; SAITO S, 1992, CANCER RES, V52, P5815; Saito S, 1996, CANCER RES, V56, P5586; SANDHU AK, 1994, P NATL ACAD SCI USA, V91, P5498, DOI 10.1073/pnas.91.12.5498; Sheng ZM, 1996, BRIT J CANCER, V73, P144, DOI 10.1038/bjc.1996.27; Shridhar R, 1996, CANCER RES, V56, P4347; Shridhar V, 1997, ONCOGENE, V14, P1269, DOI 10.1038/sj.onc.1201100; SHRIDHAR V, 1994, CANCER RES, V54, P2084; Theile M, 1996, ONCOGENE, V13, P677; Tibiletti MG, 1998, ONCOGENE, V16, P1639, DOI 10.1038/sj.onc.1201654; WALKER GJ, 1994, INT J CANCER, V58, P203, DOI 10.1002/ijc.2910580210; WANG ND, 1993, GENOMICS, V17, P341, DOI 10.1006/geno.1993.1330	35	32	33	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 1	1999	18	26					3913	3918		10.1038/sj.onc.1202756	http://dx.doi.org/10.1038/sj.onc.1202756			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	211QK	10445856				2022-12-17	WOS:000081171700014
J	Velcich, A; Corner, G; Palumbo, L; Augenlicht, L				Velcich, A; Corner, G; Palumbo, L; Augenlicht, L			Altered phenotype of HT29 colonic adenocarcinoma cells following expression of the DCC gene	ONCOGENE			English	Article						DCC; MUC2 expression; colon cancer	TUMOR-SUPPRESSOR GENE; INTESTINAL MUCIN GENE; II COLORECTAL-CANCER; CARCINOMA CELLS; MESSENGER-RNA; ALLELIC LOSS; CHROMOSOME 18Q; MUTANT MICE; DIFFERENTIATION; APOPTOSIS	On 18q, frequently deleted in late stage colorectal cancers, a gene, Deleted in Colon Cancer (DCC), has been identified and postulated to play a role as a tumor suppressor gene. DCC is retained in the majority of mucinous tumors, which produce high levels of mucins, and seems to be preferentially expressed in intestinal goblet cells. To investigate whether DCC is related to mucin expression and can modulate the transformed phenotype, we introduced a full-length DCC cDNA into HT29 cells, which can be induced in vitro to express MUC2, the gene that encodes the major colonic mucin, Expression of DCC did not modulate constitutive or induced expression of MUC2, nor did DCC induce a mature goblet cell phenotype, However, HT29 clones expressing high and low levels of DCC protein showed a significant decrease in cell proliferation and tumorigenicity. Furthermore, increased shedding and an elevated rate of spontaneous apoptosis were associated with higher levels of expression of DCC, In summary, while restoration of DCC expression in a human colon carcinoma cell line did not influence expression of differentiation markers, DCC expression did affect the growth and tumorigenic properties of the cells suggesting that DCC can modulate the malignant phenotype of colon cancer.	Montefiore Med Ctr, Albert Einstein Canc Ctr, Dept Oncol, Bronx, NY 10467 USA	Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine	Velcich, A (corresponding author), Montefiore Med Ctr, Albert Einstein Canc Ctr, Dept Oncol, 111 E 210th St, Bronx, NY 10467 USA.				NCI NIH HHS [CA-68965, CA-55913] Funding Source: Medline; PHS HHS [P30-13330] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA068965, R29CA055913] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AUGENLICHT LH, 1991, P NATL ACAD SCI USA, V88, P3286, DOI 10.1073/pnas.88.8.3286; BEDI A, 1995, CANCER RES, V55, P1811; BURSCH W, 1990, CARCINOGENESIS, V11, P847, DOI 10.1093/carcin/11.5.847; Carethers JM, 1998, GASTROENTEROLOGY, V114, P1188, DOI 10.1016/S0016-5085(98)70424-X; Chan SSY, 1996, CELL, V87, P187, DOI 10.1016/S0092-8674(00)81337-9; CHANG SK, 1994, GASTROENTEROLOGY, V107, P28, DOI 10.1016/0016-5085(94)90057-4; CHO KR, 1994, GENOMICS, V19, P525, DOI 10.1006/geno.1994.1102; CHO KR, 1995, CURR OPIN GENET DEV, V5, P72, DOI 10.1016/S0959-437X(95)90056-X; COLONY PC, 1983, DEV BIOL, V97, P349, DOI 10.1016/0012-1606(83)90092-1; COLONY PC, 1989, CELL MOL BIOL COLON, P1; Derynck R, 1996, CELL, V87, P173, DOI 10.1016/S0092-8674(00)81335-5; Eppert K, 1996, CELL, V86, P543, DOI 10.1016/S0092-8674(00)80128-2; Fazeli A, 1997, NATURE, V386, P796, DOI 10.1038/386796a0; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Fearon ER, 1996, BBA-REV CANCER, V1288, pM17, DOI 10.1016/0304-419X(96)00023-6; GENDLER SJ, 1995, ANNU REV PHYSIOL, V57, P607, DOI 10.1146/annurev.ph.57.030195.003135; Gotley DC, 1996, ONCOGENE, V13, P787; GUM JR, 1994, J BIOL CHEM, V269, P2440; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; HEDRICK L, 1994, GENE DEV, V8, P1174, DOI 10.1101/gad.8.10.1174; HEERDT BG, 1994, CANCER RES, V54, P3288; Heerdt BG, 1996, CELL GROWTH DIFFER, V7, P101; ITOH F, 1993, INT J CANCER, V53, P260, DOI 10.1002/ijc.2910530215; JEN J, 1994, NEW ENGL J MED, V331, P213, DOI 10.1056/NEJM199407283310401; KeinoMasu K, 1996, CELL, V87, P175, DOI 10.1016/S0092-8674(00)81336-7; KIM SH, 1993, J CELL BIOL, V123, P877, DOI 10.1083/jcb.123.4.877; KLINGELHUTZ AJ, 1995, ONCOGENE, V10, P1581; Kolodziej PA, 1996, CELL, V87, P197, DOI 10.1016/S0092-8674(00)81338-0; LABOISSE CL, 1989, CELL MOL BIOL COLON, P28; Martinez-Lopez E, 1998, GASTROENTEROLOGY, V114, P1180, DOI 10.1016/S0016-5085(98)70423-8; Mehlen P, 1998, NATURE, V395, P801, DOI 10.1038/27441; MOSER AR, 1990, SCIENCE, V247, P322, DOI 10.1126/science.2296722; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; OOKAWA K, 1993, INT J CANCER, V53, P382, DOI 10.1002/ijc.2910530307; PIERCEALL WE, 1994, J CELL BIOL, V124, P1017, DOI 10.1083/jcb.124.6.1017; REALE MA, 1994, CANCER RES, V54, P4493; Reale MA, 1996, CLIN CANCER RES, V2, P1097; Reyes-Mugica M, 1998, LAB INVEST, V78, P669; REYESMUGICA M, 1997, CANCER RES, P382; RIEFERCHRIST KM, 1997, FRONT BIOSCI, V15, P438; Riggins GJ, 1996, NAT GENET, V13, P347, DOI 10.1038/ng0796-347; SCHAEFFER WI, 1976, CANCER LETT, V1, P259; Shibata D, 1996, NEW ENGL J MED, V335, P1727, DOI 10.1056/NEJM199612053352303; Shoemaker AR, 1997, CANCER RES, V57, P1999; Smits R, 1997, CARCINOGENESIS, V18, P321, DOI 10.1093/carcin/18.2.321; Takaku K, 1998, CELL, V92, P645, DOI 10.1016/S0092-8674(00)81132-0; TANAKA K, 1991, NATURE, V349, P340, DOI 10.1038/349340a0; Thiagalingam S, 1996, NAT GENET, V13, P343, DOI 10.1038/ng0796-343; Velcich A, 1997, J BIOL CHEM, V272, P7968, DOI 10.1074/jbc.272.12.7968; VELCICH A, 1993, J BIOL CHEM, V268, P13956; VELCICH A, 1995, CELL GROWTH DIFFER, V6, P749; VIELMETTER J, 1994, J CELL BIOL, V127, P2009, DOI 10.1083/jcb.127.6.2009; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; Zhang L, 1997, SCIENCE, V276, P1268, DOI 10.1126/science.276.5316.1268; Zhu YA, 1998, CELL, V94, P703, DOI 10.1016/S0092-8674(00)81730-4	56	32	35	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 22	1999	18	16					2599	2606		10.1038/sj.onc.1202610	http://dx.doi.org/10.1038/sj.onc.1202610			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	189LU	10353603				2022-12-17	WOS:000079907100007
J	Abdel-Rahman, WM; Georgiades, IB; Curtis, LJ; Arends, MJ; Wyllie, AH				Abdel-Rahman, WM; Georgiades, IB; Curtis, LJ; Arends, MJ; Wyllie, AH			Role of BAX mutations in mismatch repair-deficient colorectal carcinogenesis	ONCOGENE			English	Article						BAX; colorectal cancer; RER; mismatch repair	TUMOR-SUPPRESSOR P53; TGF-BETA RECEPTOR; MICROSATELLITE INSTABILITY; COLON-CANCER; IN-VIVO; GENE; BCL-2; PROGRESSION; CARCINOMAS; PHENOTYPE	BAX gene mutations occur in approximately 50% of RER+ colorectal cancers. To determine the role of these mutations in tumour progression we analysed multiple different tumour sites from RER+ colorectal cancers for BAX mutations. Sixty colorectal carcinomas were analysed for microsatellite instability at loci BAT-26, L-myc, TGF beta RII, D13S160 and D2S123. Twelve out of 60 tumours (20%) were RER+, Forty-five different tumour sites from the 12 RER+ carcinomas were analysed for BAX mutations at the [(G)8] tract in exon 3, Six out of 12 (50%) RER+ tumours showed BAX mutations, four of which showed a homogenous pattern of such mutations detected in all tumour sites. In the other two cases, BAX mutations were present in some but not all tumour sites sampled from the same patient. In contrast, TGF beta RII mutations were found in 9/12 cases (75%) and in each of these were present in all the sampled sites. Two cases showed neither BAX nor TGF beta RII mutation. These data suggest that mutations in TGF beta RII may occur at a very early stage in tumour progression, perhaps in the founder clone. BAX mutations, however, are clearly not necessary for formation of the founder clone and can occur for the first time later in tumour progression.	Univ Edinburgh, Western Gen Hosp, Mol Med Ctr, Sir Alastair Currie CRC Labs, Edinburgh EH4 2XU, Midlothian, Scotland	University of Edinburgh	Wyllie, AH (corresponding author), Univ Cambridge, Dept Pathol, Tennis Court Rd, Cambridge CB2 1QP, England.			Abdel-Rahman, Wael/0000-0002-2149-1043				AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; Brown R, 1997, BRIT MED BULL, V53, P466; Bubb VJ, 1996, ONCOGENE, V12, P2641; Chung YJ, 1997, ONCOGENE, V15, P1719, DOI 10.1038/sj.onc.1201343; GOELZ SE, 1985, BIOCHEM BIOPH RES CO, V130, P118, DOI 10.1016/0006-291X(85)90390-0; Hoang JM, 1997, CANCER RES, V57, P300; Huang J, 1996, P NATL ACAD SCI USA, V93, P9049, DOI 10.1073/pnas.93.17.9049; JACOBY RF, 1995, GASTROENTEROLOGY, V109, P73, DOI 10.1016/0016-5085(95)90270-8; Kroemer G, 1997, NAT MED, V3, P614, DOI 10.1038/nm0697-614; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, ONCOGENE, V9, P1799; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Ouyang H, 1998, CLIN CANCER RES, V4, P1071; PARSONS R, 1995, CANCER RES, V55, P5548; Rampino N, 1997, SCIENCE, V275, P967, DOI 10.1126/science.275.5302.967; Samowitz WS, 1997, AM J PATHOL, V151, P33; THIBODEAU SN, 1993, AM J HUM GENET, V53, P1; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; Yagi OK, 1998, GASTROENTEROLOGY, V114, P268, DOI 10.1016/S0016-5085(98)70477-9; Yamamoto H, 1998, CANCER RES, V58, P997; YOUNG J, 1995, GENE CHROMOSOME CANC, V12, P251, DOI 10.1002/gcc.2870120403; Zhou XP, 1998, GENE CHROMOSOME CANC, V21, P101, DOI 10.1002/(SICI)1098-2264(199802)21:2<101::AID-GCC4>3.0.CO;2-4	24	32	34	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 25	1999	18	12					2139	2142		10.1038/sj.onc.1202589	http://dx.doi.org/10.1038/sj.onc.1202589			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	179TX	10321738				2022-12-17	WOS:000079346200011
J	Takita, J; Hayashi, Y; Nakajima, T; Adachi, J; Tanaka, T; Yamaguchi, N; Ogawa, Y; Hanada, R; Yamamoto, K; Yokota, J				Takita, J; Hayashi, Y; Nakajima, T; Adachi, J; Tanaka, T; Yamaguchi, N; Ogawa, Y; Hanada, R; Yamamoto, K; Yokota, J			The p16 (CDKN2A) gene is involved in the growth of neuroblastoma cells and its expression is associated with prognosis of neuroblastoma patients	ONCOGENE			English	Article						p16; neuroblastoma; G1 arrest; methylation; prognosis	N-MYC AMPLIFICATION; DISEASE STAGE; HUMAN GLIOMA; LUNG-CANCER; ARREST; SUPPRESSION; P16(INK4A); MUTATIONS; ARM	We previously reported that loss of heterozygosity (LOH) on chromosome 9p21 correlates with poor prognosis of neuroblastoma and the p16 gene is not expressed in approximately two thirds of neuroblastoma cell lines. Here we demonstrated that p16 expression was induced by 5-aza-2-deoxycytidine treatment in cell lines with 5' CpG island methylation but not in cell lines without methylation. Furthermore, the cell cycle of neuroblastoma cell lines significantly delayed with accumulation of cells in G1 phase by transfection of a wild-type p16 expression vector. These results indicate that p16 is inactivated in part by DNA methylation and its expression is involved in the growth of neuroblastoma cells in vitro, To assess the biological and clinical significance of p16 expression in primary tumors, we undertook immunohistochemical analysis in 74 paraffin sections of neuroblastomas. p16 protein was undetectable in 45 of 74 cases (61%) and lack of p16 expression significantly correlated with poor prognosis of patients and advanced stage of the disease. There was no correlation between loss of p16 expression and N-myc amplification in these tumors. These results indicate that inactivation of the p16 gene is involved in the progression of neuroblastoma independently of N-myc amplification.	Natl Canc Ctr, Res Inst, Div Biol, Chuo Ku, Tokyo 104, Japan; Natl Canc Ctr, Res Inst, Canc Informat & Epidemiol Div, Chuo Ku, Tokyo 104, Japan; Univ Tokyo, Fac Med, Dept Pediat, Bunkyo Ku, Tokyo 113, Japan; Gunma Univ, Sch Med, Dept Pathol, Maebashi, Gumma 371, Japan; Natl Kure Hosp, Clin Pediat Res Div, Kure 737, Japan; Saitama Childrens Med Ctr, Div Pathol, Iwatsuki, Saitama 339, Japan; Saitama Childrens Med Ctr, Div Hematol Oncol, Iwatsuki, Saitama 339, Japan	National Cancer Center - Japan; National Cancer Center - Japan; University of Tokyo; Gunma University; Saitama Children's Medical Center; Saitama Children's Medical Center	Yokota, J (corresponding author), Natl Canc Ctr, Res Inst, Div Biol, Chuo Ku, 1-1 Tsukiji 5-Chome, Tokyo 104, Japan.							Adachi J, 1997, INT J ONCOL, V10, P33; Arap W, 1997, ONCOGENE, V14, P603, DOI 10.1038/sj.onc.1200870; ARAP W, 1995, CANCER RES, V55, P1351; BELTINGER CP, 1995, CANCER RES, V55, P2053; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; BRODEUR GM, 1995, PRINCIPLES PRACTICE, P739; Burns KL, 1998, J NEUROPATH EXP NEUR, V57, P122, DOI 10.1097/00005072-199802000-00003; EVANS AE, 1971, CANCER, V27, P374, DOI 10.1002/1097-0142(197102)27:2<374::AID-CNCR2820270221>3.0.CO;2-G; Fueyo J, 1996, ONCOGENE, V12, P103; KRATZKE RA, 1995, J NATL CANCER I, V87, P1870, DOI 10.1093/jnci/87.24.1870; MATTHAY KTK, 1995, CA-CANCER J CLIN, V45, P179, DOI 10.3322/canjclin.45.3.179; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; NAKAGAWA K, 1995, ONCOGENE, V11, P1843; NAKAGAWARA A, 1992, CANCER RES, V52, P1364; NAKAGAWARA A, 1993, NEW ENGL J MED, V328, P847, DOI 10.1056/NEJM199303253281205; OTTERSON GA, 1995, ONCOGENE, V11, P1211; QUELLE DE, 1995, CELL, V83, P993; REED JA, 1995, CANCER RES, V55, P2731; SCHLEIERMACHER G, 1994, GENE CHROMOSOME CANC, V10, P275, DOI 10.1002/gcc.2870100409; TAKEDA O, 1994, GENE CHROMOSOME CANC, V10, P30, DOI 10.1002/gcc.2870100106; TAKITA J, 1995, ONCOGENE, V11, P1829; Takita J, 1997, CANCER RES, V57, P907; TANAKA T, 1995, CANCER-AM CANCER SOC, V76, P1086, DOI 10.1002/1097-0142(19950915)76:6<1086::AID-CNCR2820760625>3.0.CO;2-8; TONINI GP, 1993, EUR J CANCER, V29A, P802, DOI 10.1016/S0959-8049(05)80412-5; TSUDA T, 1987, CANCER, V60, P820, DOI 10.1002/1097-0142(19870815)60:4<820::AID-CNCR2820600418>3.0.CO;2-Y; Wu Q, 1996, INT J CANCER, V65, P840, DOI 10.1002/(SICI)1097-0215(19960315)65:6<840::AID-IJC22>3.0.CO;2-6	26	32	34	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 17	1998	17	24					3137	3143		10.1038/sj.onc.1202232	http://dx.doi.org/10.1038/sj.onc.1202232			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	147VF	9872329				2022-12-17	WOS:000077517400007
J	Wu, SJ; Zhang, DM; Zhang, ZP; Soprano, DR; Soprano, KJ				Wu, SJ; Zhang, DM; Zhang, ZP; Soprano, DR; Soprano, KJ			Critical role of both retinoid nuclear receptors and retinoid-X-receptors in mediating growth inhibition of ovarian cancer cells by all-trans retinoic acid	ONCOGENE			English	Article						retinoids; RAR; RXR; ovarian carcinoma; LacSwitch	BREAST-CARCINOMA CELLS; ADENOCARCINOMA CELLS; CYCLE PROGRESSION; MESSENGER-RNA; SENSITIVE METHOD; THYROID-HORMONE; PROTEIN COMPLEX; LINES; PROLIFERATION; EXPRESSION	Retinoids have been shown to inhibit the growth of a number of human tumor cells, including several ovarian adenocarcinoma cell lines. All-trams retinoic acid (RA) is an effective growth suppressor of CA-OV3 cells but not SK-OV3 cells. Since the effects of RA are known to be mediated via the nuclear receptors (RARs and RXRs), we initially compared levels of the various RARs and RXRs in the CA-OV3 and SK-OV3 cell lines. The RA resistant SK-OV3 cells expressed reduced levels of RAR-alpha and RXR-alpha. Furthermore, induction of RAR-alpha by RA was impaired in the RA resistant SK-OV3 cells as was RARE binding and RARE-dependent transcriptional activity. These results suggested that changes in the amounts and/or activity of RARs and/or RXR-alpha could determine the growth response of ovarian tumor cells to RA. This was confirmed by modulating the levels of RARs and RXR-alpha in the SK-OV3 cells using the LacSwitch(TM) inducible expression system. Stably transfected clones of RA resistant SK-OV3 cells exhibited a significant inhibition of growth by RA treatment when RAR-alpha was induced. Overexpression of both RAR-alpha and RXR-alpha resulted in a level of growth inhibition nearly equal to that exhibited by the RA sensitive CA-OV3 cell line. Similar results were obtained when a combination of RXR-alpha and either RAR-beta or RAR-gamma was overexpressed in SK-OV3 cells. Our results show that the nuclear receptors and RXR-alpha play a critical role in mediating growth suppression by RA in ovarian cancer cells.	Temple Univ, Sch Med, Dept Microbiol & Immunol, Philadelphia, PA 19140 USA; Temple Univ, Sch Med, Dept Biochem, Philadelphia, PA 19140 USA; Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, Philadelphia, PA 19140 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Soprano, KJ (corresponding author), Temple Univ, Sch Med, Dept Microbiol & Immunol, 3400 N Broad St, Philadelphia, PA 19140 USA.				NCI NIH HHS [CA 64945] Funding Source: Medline; NICHD NIH HHS [HD 27556] Funding Source: Medline; NIDDK NIH HHS [DK 49045] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R55HD027556, R01HD027556] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA064945] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK049045] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BERG K, 1990, APMIS, V98, P156, DOI 10.1111/j.1699-0463.1990.tb01016.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CALIARO MJ, 1994, INT J CANCER, V56, P743, DOI 10.1002/ijc.2910560522; CARMICHAEL J, 1987, CANCER RES, V47, P936; CARTER R, 1991, ONCOGENE, V6, P229; COSENZA SC, 1988, J BIOL CHEM, V263, P12751; DAWSON MI, 1995, CANCER RES, V55, P4446; DE LUCA LM, 1991, FASEB J, V5, P2924; EUSTICE DC, 1991, BIOTECHNIQUES, V11, P739; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FANJUL A, 1994, NATURE, V372, P107, DOI 10.1038/372107a0; FONTANA JA, 1988, EXP CELL BIOL, V56, P254; FONTANA JA, 1990, CANCER RES, V50, P1997; FONTANA JA, 1987, EXP CELL BIOL, V55, P136; FORMELLI F, 1993, CANCER RES, V53, P5374; GRUNT TW, 1991, J CELL SCI, V100, P657; GRUNT TW, 1992, J CELL SCI, V103, P501; GUDAS LJ, 1992, CELL GROWTH DIFFER, V3, P655; Gudas Lorraine J., 1994, P443; HARANT H, 1993, BRIT J CANCER, V68, P530, DOI 10.1038/bjc.1993.381; HARNISH DC, 1992, DEV DYNAM, V194, P239, DOI 10.1002/aja.1001940309; HERMANN T, 1992, MOL ENDOCRINOL, V6, P1153, DOI 10.1210/me.6.7.1153; Hoskins WJ, 1995, J CELL BIOCHEM, P189; KOGA M, 1991, J STEROID BIOCHEM, V39, P455, DOI 10.1016/0960-0760(91)90238-Z; LACROIX A, 1980, J CLIN INVEST, V65, P586, DOI 10.1172/JCI109703; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; Liu Y, 1996, MOL CELL BIOL, V16, P1138; LOHNES D, 1994, DEVELOPMENT, V120, P2723; LOHNES D, 1992, J CELL SCI, P69; LOTAN R, 1990, METHOD ENZYMOL, V190, P100; LOTAN R, 1980, BIOCHIM BIOPHYS ACTA, V605, P33, DOI 10.1016/0304-419X(80)90021-9; LOTAN R, 1979, CANCER RES, V39, P1014; Mangelsdorf David J., 1994, P319; MARTH C, 1985, J NATL CANCER I, V75, P871, DOI 10.1093/jnci/75.5.871; MARTH C, 1993, J STEROID BIOCHEM, V47, P123, DOI 10.1016/0960-0760(93)90065-5; MCGUIRE WP, 1995, J CLIN ONCOL, V13, P1589, DOI 10.1200/JCO.1995.13.7.1589; NAGPAL S, 1995, J BIOL CHEM, V270, P923, DOI 10.1074/jbc.270.2.923; OMALLEY B, 1990, MOL ENDOCRINOL, V4, P363, DOI 10.1210/mend-4-3-363; ORTH K, 1994, P NATL ACAD SCI USA, V91, P9495, DOI 10.1073/pnas.91.20.9495; OWEN TA, 1987, J BIOL CHEM, V262, P15111; OWEN TA, 1989, J CELL PHYSIOL, V139, P424, DOI 10.1002/jcp.1041390227; OZOLS RF, 1995, SEMIN ONCOL, V22, P61; PELLEGRINI R, 1995, CELL GROWTH DIFFER, V6, P863; PENA A, 1993, J BIOL CHEM, V268, P27277; RAPPOLEE DA, 1989, J CELL BIOCHEM, V39, P1, DOI 10.1002/jcb.240390102; ROMAN SD, 1992, CANCER RES, V52, P2236; ROMAN SD, 1993, CANCER RES, V53, P5940; ROWINSKY EK, 1991, J CLIN ONCOL, V9, P1692, DOI 10.1200/JCO.1991.9.9.1692; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; SHAO ZM, 1995, ONCOGENE, V11, P493; SHAO ZM, 1994, INT J ONCOL, V4, P859; SHEIKH MS, 1994, J BIOL CHEM, V269, P21440; Soprano DR, 1996, ONCOGENE, V12, P577; SOPRANO DR, 1994, MECH DEVELOP, V45, P243, DOI 10.1016/0925-4773(94)90011-6; SOPRANO KJ, 1987, MOL CELL BIOCHEM, V75, P61, DOI 10.1007/BF00231609; SPORN MB, 1991, MOL ENDOCRINOL, V5, P3, DOI 10.1210/mend-5-1-3; THOMAS P, 1980, P NATL ACAD SCI USA, V77, P54205; TOSCANI A, 1987, ANAL BIOCHEM, V165, P309, DOI 10.1016/0003-2697(87)90274-0; UEDA H, 1980, CANCER-AM CANCER SOC, V46, P2203, DOI 10.1002/1097-0142(19801115)46:10<2203::AID-CNCR2820461017>3.0.CO;2-A; VANDERBURG B, 1995, MOL CELL ENDOCRINOL, V112, P143, DOI 10.1016/0303-7207(95)03600-C; VANDERBURG B, 1993, MOL CELL ENDOCRINOL, V91, P149, DOI 10.1016/0303-7207(93)90267-N; WETHERALL NT, 1986, EUR J CANCER CLIN ON, V22, P53, DOI 10.1016/0277-5379(86)90342-1; Wilcken NRC, 1996, CELL GROWTH DIFFER, V7, P65; WINGO PA, 1995, CA-CANCER J CLIN, V45, P8, DOI 10.3322/canjclin.45.1.8; WU S, 1998, IN PRESS J CELL BIOC; Wu SJ, 1996, ONCOGENE, V12, P621; Wu SJ, 1997, EXP CELL RES, V237, P118, DOI 10.1006/excr.1997.3769; Wu SJ, 1997, EXP CELL RES, V232, P277, DOI 10.1006/excr.1997.3495; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0; ZHAO ZR, 1995, EXP CELL RES, V219, P555, DOI 10.1006/excr.1995.1264	70	32	33	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 3	1998	17	22					2839	2849		10.1038/sj.onc.1202208	http://dx.doi.org/10.1038/sj.onc.1202208			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	143ZA	9879990				2022-12-17	WOS:000077286400004
J	Berg, KL; Carlberg, K; Rohrschneider, LR; Siminovitch, KA; Stanley, ER				Berg, KL; Carlberg, K; Rohrschneider, LR; Siminovitch, KA; Stanley, ER			The major SHP-1-binding, tyrosine-phosphorylated protein in macrophages is a member of the KIR/LIR family and an SHP-1 substrate	ONCOGENE			English	Article						macrophage; SHP-1; KIR; LIR-1; PIR-B; PTP	CELL INHIBITORY RECEPTORS; MOTH-EATEN MICE; B-CELLS; PHOSPHATASE; STIMULATION; EXPRESSION; GROWTH; PTP1C	The SH2 domain-containing cytoplasmic protein tyrosine phosphatase, SHP-1, negatively regulates hematopoietic cell signaling, SHP-1 is associated with a tyrosine phosphorylated, plasma membrane-spanning glycoprotein, pp130, in colony stimulating factor-1 stimulated or unstimulated macrophages, This association is phosphotyrosine dependent and is mediated by the amino-terminal SH2 domain of SHP-1, pp130 behaves as a substrate of SHP-1 in vitro and is hyperphosphorylated on tyrosine in SHP-1 deficient macrophages from viable-motheaten mice. Co-immunoprecipitation data indicate that pp130 is the product of the mouse p91/PIR-B gene that encodes a member of the killer cell inhibitory receptor (KIR)/leukocyte immunoglobulin-like receptor (LIR) family. By analogy to the KIRs, p91/PIR-B may represent a novel class of macrophage receptors which act to suppress macrophage activation. These observations identify SHP-1 interactions with and regulation of p91/PIR-B as a potential mechanism for inhibiting the signaling cascades linking extracellular stimuli to macrophage activation and/or development.	Albert Einstein Coll Med, Dept Dev & Mol Biol, Bronx, NY 10461 USA; Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA; Univ Toronto, Dept Med, Toronto, ON, Canada; Univ Toronto, Dept Immunol, Toronto, ON, Canada; Univ Toronto, Dept Mol & Med Genet, Toronto, ON, Canada; Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada	Yeshiva University; Albert Einstein College of Medicine; Fred Hutchinson Cancer Center; University of Toronto; University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute	Stanley, ER (corresponding author), Albert Einstein Coll Med, Dept Dev & Mol Biol, Bronx, NY 10461 USA.		Siminovitch, Katherine/K-1475-2013; Stanley, Evan R/J-9154-2013	Stanley, Evan R/0000-0002-2910-2065	NATIONAL CANCER INSTITUTE [T32CA009173, R37CA026504, R01CA026504] Funding Source: NIH RePORTER; NCI NIH HHS [CA 26504, 5 T32 CA09173] Funding Source: Medline; PHS HHS [P30-13330] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BIGNON JS, 1994, CLIN IMMUNOL IMMUNOP, V73, P168, DOI 10.1006/clin.1994.1185; Burshtyn DN, 1996, IMMUNITY, V4, P77, DOI 10.1016/S1074-7613(00)80300-3; BUSCHER D, 1993, ONCOGENE, V8, P3323; Chen HE, 1996, MOL CELL BIOL, V16, P3685, DOI 10.1128/mcb.16.7.3685; Cosman D, 1997, IMMUNITY, V7, P273, DOI 10.1016/S1074-7613(00)80529-4; Hayami K, 1997, J BIOL CHEM, V272, P7320, DOI 10.1074/jbc.272.11.7320; Hof P, 1998, CELL, V92, P441, DOI 10.1016/S0092-8674(00)80938-1; HUBBARD AL, 1975, J CELL BIOL, V64, P438, DOI 10.1083/jcb.64.2.438; Kharitonenkov A, 1997, NATURE, V386, P181, DOI 10.1038/386181a0; KOO GC, 1993, J IMMUNOL, V151, P6733; KOZLOWSKI M, 1993, J EXP MED, V178, P2157, DOI 10.1084/jem.178.6.2157; Kubagawa H, 1997, P NATL ACAD SCI USA, V94, P5261, DOI 10.1073/pnas.94.10.5261; Kuroiwa A, 1998, J BIOL CHEM, V273, P1070, DOI 10.1074/jbc.273.2.1070; LI W, 1991, J BIOL CHEM, V266, P6808; Meyaard L, 1997, IMMUNITY, V7, P283, DOI 10.1016/S1074-7613(00)80530-0; Neel BG, 1997, CURR OPIN CELL BIOL, V9, P193, DOI 10.1016/S0955-0674(97)80063-4; Pei DH, 1996, P NATL ACAD SCI USA, V93, P1141, DOI 10.1073/pnas.93.3.1141; Siminovitch KA, 1998, SEMIN IMMUNOL, V10, P329, DOI 10.1006/smim.1998.0125; Somani AK, 1997, J BIOL CHEM, V272, P21113, DOI 10.1074/jbc.272.34.21113; STANLEY ER, 1994, CYTOKINE HDB, P387; STANLEY ER, 1990, METHOD MOL BIOL, P299; Unkeless JC, 1997, CURR OPIN IMMUNOL, V9, P338, DOI 10.1016/S0952-7915(97)80079-9; Wagtmann N, 1997, CURR BIOL, V7, P615, DOI 10.1016/S0960-9822(06)00263-6; Wang Y, 1996, J BIOL CHEM, V271, P17, DOI 10.1074/jbc.271.1.17; YEUNG YG, 1992, J BIOL CHEM, V267, P23447; YI TL, 1993, MOL CELL BIOL, V13, P3350, DOI 10.1128/MCB.13.6.3350; Yokoyama WM, 1997, J EXP MED, V186, P1803, DOI 10.1084/jem.186.11.1803; Yu CCK, 1996, J EXP MED, V183, P371, DOI 10.1084/jem.183.2.371	28	32	36	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 12	1998	17	19					2535	2541		10.1038/sj.onc.1202203	http://dx.doi.org/10.1038/sj.onc.1202203			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	137QQ	9824165				2022-12-17	WOS:000076927300014
J	Strobel, T; Tai, YT; Korsmeyer, S; Cannistra, SA				Strobel, T; Tai, YT; Korsmeyer, S; Cannistra, SA			BAD partly reverses paclitaxel resistance in human ovarian cancer cells	ONCOGENE			English	Article						apoptosis; BAD; drug resistance; paclitaxel; ovarian cancer	INDUCED APOPTOSIS; IN-VIVO; BCL-2 PHOSPHORYLATION; NEUROBLASTOMA-CELLS; MYELOID-LEUKEMIA; BCL-X(L); DEATH; TAXOL; EXPRESSION; OVEREXPRESSION	Although paclitaxel is an important chemotherapy agent for the treatment of patients with epithelial ovarian cancer, its utility is significantly limited by the frequent development of drug resistance, Recent evidence suggests that resistance to chemotherapy may be partly related to defects in the apoptotic pathway. In this study me have investigated whether enhancement of apoptotic pathway function through stable expression of the BAD protein is capable of sensitizing human epithelial ovarian cancer cells to the effects of chemotherapy. Expression of HA-BAD in sis separate clonal transfectants from two different ovarian cancer cell lines was found to significantly enhance the cytotoxic effects of paclitaxel, vincristine, and, to a lesser extent, etoposide, Enhancement of paclitaxel-induced apoptosis in HA-BAD-expressing clones was demonstrated by trypan blue exclusion, clonogenic cell assay, and flow cytometric evaluation. Importantly, this effect was associated with binding of HA-BAD to BCL-x(L) and concomitant disruption of BAX:BCL-x(L) interaction. Taken together, these data suggest that the development of small molecules which mimic the effects of BAD may represent a new class of drugs capable of preventing or reversing resistance to chemotherapy agents such as paclitaxel.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA; Washington Univ, Sch Med, Howard Hughes Med Inst, Div Mol Oncol, St Louis, MO 63110 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Howard Hughes Medical Institute; Washington University (WUSTL)	Cannistra, SA (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Adult Oncol, 44 Binney St, Boston, MA 02115 USA.				NCI NIH HHS [CA60670] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA060670] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARCECI RJ, 1993, BLOOD, V81, P2215; Blagosklonny MV, 1996, CANCER RES, V56, P1851; CABRAL FR, 1983, J CELL BIOL, V97, P22, DOI 10.1083/jcb.97.1.22; CANNISTRA SA, 1985, BLOOD, V65, P414; CANNISTRA SA, 1993, NEW ENGL J MED, V329, P1550, DOI 10.1056/NEJM199311183292108; CANNISTRA SA, 1993, CANCER RES, V53, P3830; CHAO DT, 1995, J EXP MED, V182, P821, DOI 10.1084/jem.182.3.821; Cheng EHY, 1996, NATURE, V379, P554, DOI 10.1038/379554a0; DATTA R, 1995, CELL GROWTH DIFFER, V6, P363; DOLE MG, 1995, CANCER RES, V55, P2576; Dole MG, 1996, CANCER RES, V56, P5734; Dumontet C, 1996, CANCER RES, V56, P1091; FISHER DE, 1994, CELL, V78, P539, DOI 10.1016/0092-8674(94)90518-5; Haber M, 1995, J BIOL CHEM, V270, P31269, DOI 10.1074/jbc.270.52.31269; Haldar S, 1996, CANCER RES, V56, P1253; Horwitz S B, 1994, Ann Oncol, V5 Suppl 6, pS3; Ibrado AM, 1996, CELL GROWTH DIFFER, V7, P1087; Ibrado AM, 1997, CANCER RES, V57, P1109; Ito T, 1997, J BIOL CHEM, V272, P11671, DOI 10.1074/jbc.272.18.11671; IZQUIERDO MA, 1995, JNCI-J NATL CANCER I, V87, P1230; Knudson CM, 1997, NAT GENET, V16, P358, DOI 10.1038/ng0897-358; KOOPMAN G, 1994, BLOOD, V84, P1415, DOI 10.1182/blood.V84.5.1415.1415; LOWE SW, 1994, SCIENCE, V266, P807, DOI 10.1126/science.7973635; McGuire WP, 1996, NEW ENGL J MED, V334, P1, DOI 10.1056/NEJM199601043340101; MINN AJ, 1995, BLOOD, V86, P1903, DOI 10.1182/blood.V86.5.1903.bloodjournal8651903; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; SEDLAK TW, 1995, P NATL ACAD SCI USA, V92, P7834, DOI 10.1073/pnas.92.17.7834; Strobel T, 1997, CANCER RES, V57, P1228; Strobel T, 1996, P NATL ACAD SCI USA, V93, P14094, DOI 10.1073/pnas.93.24.14094; Strobel T, 1997, ONCOGENE, V14, P2753, DOI 10.1038/sj.onc.1201132; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; Yang E, 1996, BLOOD, V88, P386, DOI 10.1182/blood.V88.2.386.bloodjournal882386; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0; Zha HB, 1996, J BIOL CHEM, V271, P7440, DOI 10.1074/jbc.271.13.7440; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zha JP, 1997, J BIOL CHEM, V272, P24101, DOI 10.1074/jbc.272.39.24101	37	32	34	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 12	1998	17	19					2419	2427		10.1038/sj.onc.1202180	http://dx.doi.org/10.1038/sj.onc.1202180			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	137QQ	9824152				2022-12-17	WOS:000076927300001
J	Rodriguez-Puebla, ML; LaCava, M; Gimenez-Conti, IB; Johnson, DG; Conti, CJ				Rodriguez-Puebla, ML; LaCava, M; Gimenez-Conti, IB; Johnson, DG; Conti, CJ			Deregulated expression of cell-cycle proteins during premalignant progression in SENCAR mouse skin	ONCOGENE			English	Article						cyclins; cell-cycle; tumor progression; papilloma; squamous cell carcinoma	RETINOBLASTOMA GENE-PRODUCT; DEPENDENT KINASE INHIBITORS; E2F TRANSCRIPTION FACTOR; TUMOR-SUPPRESSOR GENE; HARVEY-RAS ONCOGENE; D-CDK COMPLEXES; GROWTH SUPPRESSION; SQUAMOUS-CELL; ALTERED EXPRESSION; TRANSGENIC MICE	It is now evident that several genes encoding regulatory activities that control the mammalian cell cycle, particularly some that control the progression of quiescent cells through G1 and into S phase, are targets for alterations that underlie the development of neoplasms. Here, we made a sequential study of alterations in cell cycle protein expression and complex formation among cyclin, cyclin dependent kinases (CDKs) and CDK inhibitors (CKIs) during premalignant progression in SENCAR mouse skin tumors. Changes in the level of expression were observed in positive (cyclin DI, D2, and E2F family members) and negative regulators (p16(Ink4a), p57(Kip2)) Of the cell cycle. Also, we observed the formation of cyclin/CDK/CKI complexes. The amounts of these proteins and complexes increased substantially at specific times during promotion but not during malignant conversion to carcinomas. These data show that deregulation of growth control occurs in benign tumors and that subsequent mutations not involved cell-cycle regulation are probably necessary to induce invasive behavior.	Univ Texas, Md Anderson Canc Ctr, Div Sci Pk Res, Smithville, TX 78957 USA	University of Texas System; UTMD Anderson Cancer Center	Conti, CJ (corresponding author), Univ Texas, Md Anderson Canc Ctr, Div Sci Pk Res, Smithville, TX 78957 USA.			Johnson, David/0000-0002-6223-1790	NCI NIH HHS [CA 57596, CA 42157, CA 16672] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016672, R01CA042157, P01CA057596] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALDAZ CM, 1989, MOL CARCINOGEN, V2, P22, DOI 10.1002/mc.2940020104; ALDAZ CM, 1987, P NATL ACAD SCI USA, V84, P2029, DOI 10.1073/pnas.84.7.2029; BAGCHI S, 1991, CELL, V65, P1063, DOI 10.1016/0092-8674(91)90558-G; BALMAIN A, 1983, NATURE, V303, P72, DOI 10.1038/303072a0; BANDARA LR, 1991, NATURE, V352, P249, DOI 10.1038/352249a0; BARTKOVA J, 1995, CANCER RES, V55, P949; BARTKOVA J, 1995, ONCOGENE, V10, P775; BATES S, 1994, ONCOGENE, V9, P1633; BIANCHI AB, 1993, ONCOGENE, V8, P1127; BIANCHI AB, 1991, P NATL ACAD SCI USA, V88, P7590, DOI 10.1073/pnas.88.17.7590; BIANCHI AB, 1990, P NATL ACAD SCI USA, V87, P6902, DOI 10.1073/pnas.87.17.6902; BIZUB D, 1986, P NATL ACAD SCI USA, V83, P6048, DOI 10.1073/pnas.83.16.6048; BURNS FJ, 1978, CARCINOGENESIS, V2, P91; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; COBRINIK D, 1993, GENE DEV, V7, P2392, DOI 10.1101/gad.7.12a.2392; DeGregori J, 1997, P NATL ACAD SCI USA, V94, P7245, DOI 10.1073/pnas.94.14.7245; DEMERS GW, 1994, P NATL ACAD SCI USA, V91, P4382, DOI 10.1073/pnas.91.10.4382; DYSON N, 1993, J VIROL, V67, P7641, DOI 10.1128/JVI.67.12.7641-7647.1993; FRIXEN UH, 1991, J CELL BIOL, V113, P173, DOI 10.1083/jcb.113.1.173; FUKUDA M, 1978, CELL TISSUE KINET, V11, P611, DOI 10.1111/j.1365-2184.1978.tb00834.x; GIANCOTTI FG, 1990, CELL, V60, P849, DOI 10.1016/0092-8674(90)90098-Y; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HATADA I, 1995, NAT GENET, V11, P204, DOI 10.1038/ng1095-204; HIEBERT SW, 1993, MOL CELL BIOL, V13, P3384, DOI 10.1128/MCB.13.6.3384; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; HIRAI H, 1995, MOL CELL BIOL, V15, P2672; HIRAMA T, 1995, BLOOD, V86, P841; Hurford RK, 1997, GENE DEV, V11, P1447, DOI 10.1101/gad.11.11.1447; Jadayel DM, 1997, LEUKEMIA, V11, P64, DOI 10.1038/sj.leu.2400555; JIANG W, 1993, P NATL ACAD SCI USA, V90, P9026, DOI 10.1073/pnas.90.19.9026; JOHNSON DG, 1994, P NATL ACAD SCI USA, V91, P12823, DOI 10.1073/pnas.91.26.12823; JOHNSON DG, 1995, ONCOGENE, V11, P1685; KOIKE M, 1994, BIOCHEM BIOPH RES CO, V201, P673, DOI 10.1006/bbrc.1994.1753; LAMMIE GA, 1991, ONCOGENE, V6, P439; Lilischkis R, 1996, INT J CANCER, V66, P249, DOI 10.1002/(SICI)1097-0215(19960410)66:2<249::AID-IJC19>3.0.CO;2-7; LINARDOPOULOS S, 1995, CANCER RES, V55, P5168; Lukas J, 1996, MOL CELL BIOL, V16, P1047; Missero C, 1996, GENE DEV, V10, P3065, DOI 10.1101/gad.10.23.3065; MITSUNAGA SI, 1995, CARCINOGENESIS, V16, P1629, DOI 10.1093/carcin/16.7.1629; MOOLGAVKAR SH, 1981, J NATL CANCER I, V66, P1037, DOI 10.1093/jnci/66.6.1037; MORI T, 1994, CANCER RES, V54, P3396; MUSGROVE EA, 1995, INT J CANCER, V63, P584, DOI 10.1002/ijc.2910630420; PARRY D, 1995, EMBO J, V14, P503, DOI 10.1002/j.1460-2075.1995.tb07026.x; POTTER VR, 1981, CARCINOGENESIS, V2, P1375, DOI 10.1093/carcin/2.12.1375; QIAN YY, 1992, MOL CELL BIOL, V12, P5363, DOI 10.1128/MCB.12.12.5363; QIN XQ, 1992, GENE DEV, V6, P953, DOI 10.1101/gad.6.6.953; ROBELS AI, 1995, CARCINOGENESIS, V16, P781, DOI 10.1093/carcin/16.4.781; Robles AI, 1996, P NATL ACAD SCI USA, V93, P7634, DOI 10.1073/pnas.93.15.7634; Rodriguez-Puebla ML, 1998, CELL GROWTH DIFFER, V9, P31; ROOP DR, 1986, NATURE, V323, P822, DOI 10.1038/323822a0; SCHMIDT EE, 1994, CANCER RES, V54, P6321; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SGAMBATO A, 1995, CARCINOGENESIS, V16, P2193, DOI 10.1093/carcin/16.9.2193; SHAPIRO GI, 1995, CANCER RES, V55, P505; SHERR CJ, 1995, TRENDS BIOCHEM SCI, V20, P187, DOI 10.1016/S0968-0004(00)89005-2; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SINGH P, 1994, EMBO J, V13, P3329, DOI 10.1002/j.1460-2075.1994.tb06635.x; SLAGA T J, 1989, P1; Taniguchi T, 1997, ONCOGENE, V14, P1201, DOI 10.1038/sj.onc.1200934; TENNENBAUM T, 1992, CANCER RES, V52, P2966; VAN DJ, 1991, AM J PATHOL, V138, P1165; Wang A, 1996, J CANCER RES CLIN, V122, P122, DOI 10.1007/BF01226270; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; Weinberg WC, 1997, ONCOGENE, V15, P685, DOI 10.1038/sj.onc.1201230; WEINSTATSASLOW D, 1995, NAT MED, V1, P1257, DOI 10.1038/nm1295-1257; Xiong Y, 1996, Biochim Biophys Acta, V1288, P01; Yamasaki L, 1996, CELL, V85, P537, DOI 10.1016/S0092-8674(00)81254-4; YUSPA SH, 1990, ENVIRON HEALTH PERSP, V88, P193; Zhang SY, 1997, MOL CARCINOGEN, V18, P142, DOI 10.1002/(SICI)1098-2744(199703)18:3<142::AID-MC3>3.3.CO;2-J; ZHANG SY, 1994, CANCER RES, V54, P5050	72	32	32	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 29	1998	17	17					2251	2258		10.1038/sj.onc.1202131	http://dx.doi.org/10.1038/sj.onc.1202131			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	133QX	9811455				2022-12-17	WOS:000076698200010
J	von Brevern, M; Hollstein, MC; Risk, JM; Garde, J; Bennett, WP; Harris, CC; Muehlbauer, KR; Field, JK				von Brevern, M; Hollstein, MC; Risk, JM; Garde, J; Bennett, WP; Harris, CC; Muehlbauer, KR; Field, JK			Loss of heterozygosity in sporadic oesophageal tumors in the tylosis oesophageal cancer (TOC) gene region of chromosome 17q	ONCOGENE			English	Article						tylosis; loss of heterozygosity; oesophageal cancer	ESOPHAGEAL CANCER; PALMOPLANTAR KERATODERMA; P53 GENE; CARCINOMA; ALLELOTYPE; MUTATIONS	From the genotyping of UK and US tylotic families with a high risk of oesophageal cancer we have previously localized the tylosis-associated cancer susceptibility gene (TOC gene, tylosis oesophageal cancer gene) to a 1 cM region on the long arm of chromosome 17 (Kelsell et al,, 1996), In the present study we investigated loss of heterozygosity (LOH) patterns of 35 sporadic squamous cell carcinomas of the oesophagus using six polymorphic microsatellite markers encompassing this locus. Twenty-four of the 35 cases (69%) revealed LOH at one or more loci. Deletion was most frequently observed with the marker D17S801 (64% LOH, informative cases), which shows significant linkage to the TOC locus. The LOH analysis in sporadic oesophageal cancer we report here is thus consistent with the hypothesis that the tylosis oesophageal cancer susceptibility gene is also involved in the pathogenesis of a proportion of sporadic squamous cell carcinomas of the oesophagus.	Univ Liverpool, Dept Clin Dent Sci, Mol Genet & Oncol Grp, Liverpool L69 3BX, Merseyside, England; Deutsch Krebsforschungszentrum, German Canc Res Ctr, D-69120 Heidelberg, Germany; NCI, Human Carcinogenesis Lab, Bethesda, MD 20892 USA; Roy Castle Int Ctr Lung Canc Res, Liverpool L3 4TA, Merseyside, England	University of Liverpool; Helmholtz Association; German Cancer Research Center (DKFZ); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Field, JK (corresponding author), Univ Liverpool, Dept Clin Dent Sci, Mol Genet & Oncol Grp, Liverpool L69 3BX, Merseyside, England.		Field, John K./AAD-5674-2020	Field, John K./0000-0003-3951-6365				AOKI T, 1994, GENE CHROMOSOME CANC, V10, P177, DOI 10.1002/gcc.2870100305; BENNETT WP, 1991, ONCOGENE, V6, P1779; Dib C, 1996, NATURE, V380, P152, DOI 10.1038/380152a0; Ellis A, 1994, Eur J Cancer B Oral Oncol, V30B, P102, DOI 10.1016/0964-1955(94)90061-2; HENNIES HC, 1995, GENOMICS, V29, P537, DOI 10.1006/geno.1995.9971; Hollstein M, 1996, NUCLEIC ACIDS RES, V24, P141, DOI 10.1093/nar/24.1.141; HOLLSTEIN MC, 1990, P NATL ACAD SCI USA, V87, P9958, DOI 10.1073/pnas.87.24.9958; *J HOPK U, 1990, GDBTM HUM GEN DAT VE; Kelsell DP, 1996, HUM MOL GENET, V5, P857, DOI 10.1093/hmg/5.6.857; Montesano R, 1996, INT J CANCER, V69, P225, DOI 10.1002/(SICI)1097-0215(19960621)69:3<225::AID-IJC13>3.0.CO;2-6; MORI T, 1994, CANCER RES, V54, P1638; MUNOZ N, 1994, EUR J GASTROEN HEPAT, V6, P649, DOI 10.1097/00042737-199408000-00002; RISK JM, 1994, NAT GENET, V8, P319, DOI 10.1038/ng1294-319; SHIBAGAKI I, 1994, CANCER RES, V54, P2996; Stevens HP, 1996, ARCH DERMATOL, V132, P640, DOI 10.1001/archderm.132.6.640; TOMATIS L, 1990, IARC SCI PUBLICATION, V100; vonBrevern MC, 1996, CANCER RES, V56, P4917	17	32	32	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 22	1998	17	16					2101	2105		10.1038/sj.onc.1202139	http://dx.doi.org/10.1038/sj.onc.1202139			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	130VK	9798681				2022-12-17	WOS:000076540900009
J	Gomez, J; Martinez, C; Gonzalez, A; Garcia, A; Rebollo, A				Gomez, J; Martinez, C; Gonzalez, A; Garcia, A; Rebollo, A			The Bcl-2 gene is differentially regulated by IL-2 and IL-4: role of the transcription factor NF-AT	ONCOGENE			English	Article						Bcl-2; calcineurin; IL-4; IL-2; NF-AT	PROTEIN-KINASE-C; HUMAN INTERLEUKIN-2 RECEPTOR; T-CELL LINE; CYCLOSPORINE-A; B-CELLS; SIGNAL-TRANSDUCTION; MOLECULAR-CLONING; HIGH-AFFINITY; GAMMA-CHAIN; EXPRESSION	The murine TS1 alpha beta T cell line expresses the anti-apoptotic protein Bcl-2 upon IL-2 stimulation, whereas IL-4-mediated growth of this cell line proceeds in the absence of Bcl-2 expression. In addition, IL-4 stimulation inhibits Bcl-2 expression and modulates its mRNA level. IL-2-induced DNA binding activity for these transcription factors is sensitive to phosphatidylinositol 3 kinase inhibitor wortmannin and to Rho inhibitor Clostridium difficile toxin B, which inhibit IL-2-induced Bcl-2 expression. IVF-AT transcription factor appears to be the most important in the control Bcl-2 expression, since inhibition of the calcium-calmodulin-dependent phosphatase calcineurin, which regulates NF-AT activity, downregulates Bcl-2 expression in IL-2-stimulated cells, Constitutive expression of this phosphatase also upregulates Bcl-2 expression in IL-4-stimulated cells. In addition, a dominant negative NF-AT expression vector downregulates Bcl-2 expression in IL-2-stimulated cells. These results suggest that IL-2 induction of Bcl-2 expression may be directly or indirectly mediated by NF-AT.	Univ Autonoma Madrid, Ctr Nacl Biotecnol, Dept Immunol & Oncol, E-28049 Madrid, Spain; Inst Pasteur, Grp Dev Cellulaire, F-75015 Paris, France	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Rebollo, A (corresponding author), Univ Autonoma Madrid, Ctr Nacl Biotecnol, Dept Immunol & Oncol, Campus Cantoblanco, E-28049 Madrid, Spain.		Rebollo, Angelita/P-2118-2017	Rebollo, Angelita/0000-0002-1293-9686				Akbar AN, 1996, EUR J IMMUNOL, V26, P294, DOI 10.1002/eji.1830260204; BROOME HE, 1995, IMMUNOLOGY, V84, P375; BROOME HE, 1995, J IMMUNOL, V155, P2311; CHENLEVY Z, 1989, MOL CELL BIOL, V9, P701, DOI 10.1128/MCB.9.2.701; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; Cohen SBA, 1997, IMMUNOLOGY, V92, P1, DOI 10.1046/j.1365-2567.1997.00348.x; COSMAN D, 1984, NATURE, V312, P768, DOI 10.1038/312768a0; DEJONG D, 1994, CANCER RES, V54, P256; DENG G, 1993, P NATL ACAD SCI USA, V90, P2189, DOI 10.1073/pnas.90.6.2189; EMMEL EA, 1989, SCIENCE, V246, P1617, DOI 10.1126/science.2595372; FIERING S, 1990, GENE DEV, V4, P1824; FLANAGAN WM, 1991, NATURE, V352, P803, DOI 10.1038/352803a0; GOMEZ J, 1994, EXP CELL RES, V213, P178, DOI 10.1006/excr.1994.1188; Gomez J, 1997, J IMMUNOL, V158, P1516; Gomez J, 1997, EUR J IMMUNOL, V27, P1610, DOI 10.1002/eji.1830270704; Gomez J, 1997, EUR J IMMUNOL, V27, P2793, DOI 10.1002/eji.1830271108; GOMEZ J, 1995, EXP CELL RES, V218, P105, DOI 10.1006/excr.1995.1136; GOMEZ J, 1995, EUR J IMMUNOL, V25, P2673, DOI 10.1002/eji.1830250941; GOMEZ J, 1996, J IMMUNOL, V157, P2772; GREENLUND LJS, 1995, NEURON, V15, P649, DOI 10.1016/0896-6273(95)90153-1; HANADA M, 1993, CANCER RES, V53, P4978; HATAKEYAMA M, 1989, SCIENCE, V244, P551, DOI 10.1126/science.2785715; HENDERSON S, 1991, CELL, V65, P1107, DOI 10.1016/0092-8674(91)90007-L; Herrmann JL, 1997, EXP CELL RES, V237, P101, DOI 10.1006/excr.1997.3737; Hodge MR, 1996, IMMUNITY, V4, P397, DOI 10.1016/S1074-7613(00)80253-8; HOEY T, 1995, IMMUNITY, V2, P461, DOI 10.1016/1074-7613(95)90027-6; IVANOV VN, 1995, INT IMMUNOL, V7, P1709, DOI 10.1093/intimm/7.11.1709; JAIN JN, 1995, J BIOL CHEM, V270, P4138, DOI 10.1074/jbc.270.8.4138; Katoh S, 1997, NEUROSCI LETT, V232, P71, DOI 10.1016/S0304-3940(97)00582-X; KATSUMATA M, 1992, P NATL ACAD SCI USA, V89, P11376, DOI 10.1073/pnas.89.23.11376; KORSMEYER SJ, 1992, IMMUNOL TODAY, V13, P285, DOI 10.1016/0167-5699(92)90037-8; KRAJEWSKI S, 1993, CANCER RES, V53, P47017; LEONARD WJ, 1984, NATURE, V311, P626, DOI 10.1038/311626a0; Linette GP, 1996, P NATL ACAD SCI USA, V93, P9545, DOI 10.1073/pnas.93.18.9545; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; MAKOVER D, 1991, ONCOGENE, V6, P455; MANIATIS T, 1989, MOL CLONING LAB HDB; MASUDA ES, 1995, MOL CELL BIOL, V15, P2697; MATTILA PS, 1990, EMBO J, V9, P4425, DOI 10.1002/j.1460-2075.1990.tb07893.x; Merry DE, 1997, ANNU REV NEUROSCI, V20, P245, DOI 10.1146/annurev.neuro.20.1.245; MINAMI Y, 1995, CURR OPIN CELL BIOL, V7, P156, DOI 10.1016/0955-0674(95)80023-9; MINER JN, 1991, TRENDS BIOCHEM SCI, V16, P423, DOI 10.1016/0968-0004(91)90168-U; MIYAZAKI T, 1995, CELL, V81, P223, DOI 10.1016/0092-8674(95)90332-1; MONAGHAN P, 1992, J HISTOCHEM CYTOCHEM, V40, P1819, DOI 10.1177/40.12.1453000; NIKAIDO T, 1984, NATURE, V311, P631, DOI 10.1038/311631a0; NORTHROP JP, 1994, NATURE, V369, P497, DOI 10.1038/369497a0; NUNEZ G, 1994, IMMUNOL TODAY, V15, P582, DOI 10.1016/0167-5699(94)90221-6; NUNEZ G, 1990, J IMMUNOL, V144, P3602; OLIVER FJ, 1993, BIOCHEM BIOPH RES CO, V194, P126, DOI 10.1006/bbrc.1993.1794; PITTON C, 1993, CYTOKINE, V5, P362, DOI 10.1016/1043-4666(93)90069-H; RANDAK C, 1990, EMBO J, V9, P2529, DOI 10.1002/j.1460-2075.1990.tb07433.x; RAO A, 1994, IMMUNOL TODAY, V15, P274, DOI 10.1016/0167-5699(94)90007-8; Rebollo A, 1996, ADV IMMUNOL, V63, P127, DOI 10.1016/S0065-2776(08)60856-1; REBOLLO A, 1995, CYTOKINE, V7, P277, DOI 10.1006/cyto.1995.0033; REED JC, 1987, SCIENCE, V236, P1295, DOI 10.1126/science.3495884; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; RINAUDO MS, 1995, BLOOD, V86, P80, DOI 10.1182/blood.V86.1.80.bloodjournal86180; ROONEY JW, 1995, IMMUNITY, V2, P473, DOI 10.1016/1074-7613(95)90028-4; RUFF VA, 1995, J BIOL CHEM, V270, P22602, DOI 10.1074/jbc.270.38.22602; SCHWARTZ LM, 1993, IMMUNOL TODAY, V14, P582, DOI 10.1016/0167-5699(93)90197-S; Sekiya M, 1997, BIOCHEM BIOPH RES CO, V239, P401, DOI 10.1006/bbrc.1997.7478; SELVAKUMARAN M, 1994, MOL CELL BIOL, V14, P2352, DOI 10.1128/MCB.14.4.2352; SENTMAN CL, 1991, CELL, V67, P878; SHAW KTY, 1995, P NATL ACAD SCI USA, V92, P11205, DOI 10.1073/pnas.92.24.11205; Shibasaki F, 1997, NATURE, V386, P728, DOI 10.1038/386728a0; SMITH KA, 1984, ANNU REV IMMUNOL, V2, P319, DOI 10.1146/annurev.immunol.2.1.319; STRASSER A, 1991, CELL, V67, P889, DOI 10.1016/0092-8674(91)90362-3; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; SUN XJ, 1995, NATURE, V377, P173, DOI 10.1038/377173a0; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; TAKESHITA T, 1992, SCIENCE, V257, P379, DOI 10.1126/science.1631559; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; WELLER M, 1995, J CLIN INVEST, V95, P2633, DOI 10.1172/JCI117965; WYLLIE AH, 1995, CURR OPIN GENET DEV, V5, P97, DOI 10.1016/S0959-437X(95)90060-8	74	32	33	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 10	1998	17	10					1235	1243		10.1038/sj.onc.1202049	http://dx.doi.org/10.1038/sj.onc.1202049			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	117VL	9771966				2022-12-17	WOS:000075803300005
J	Ferguson, AT; Lapidus, RG; Davidson, NE				Ferguson, AT; Lapidus, RG; Davidson, NE			Demethylation of the progesterone receptor CpG island is not required for progesterone receptor gene expression	ONCOGENE			English	Article						breast cancer; CpG island; DNA methylation; estrogen receptor; histone acetyltransferase; progesterone receptor	BREAST-CANCER CELLS; TUMOR-SUPPRESSOR GENE; DNA METHYLATION; BINDING-PROTEIN; ESTROGEN-RECEPTOR; TRANSCRIPTION; SEQUENCE; INACTIVATION	Progesterone receptor (PR) is an estrogen-stimulated gene which has a CpG island that is heavily methylated in a significant fraction of estrogen receptor (ER)negative/PR-negative human breast cancers and cell lines, including MDA-MB-231 cells. Treatment of MDA-MB-231 cells with the demethylating agent, 5-aza-2'-deoxycytidine (deoxyC) led to demethylation and expression of ER and PR, However, simultaneous treatment with antiestrogen prevented PR transcription, suggesting that demethylation of PR alone is not sufficient to reactivate the PR gene. To examine the effects of ER on the methylation status of the PR CpG island, we stably transfected MDA-MB-231 cells with an inducible expression vector for ER, Surprisingly, in two cell clones, we found that induction of PR gene expression by ligand-bound ER does not require demethylation of the PR CpG island. In contrast, induction of PR transcription was inhibited by blocking the interaction of ER with SRC-1A, a coactivator of ER function. For the first time, we show that a transcription factor with the potential to remodel heterochromatin can activate gene expression without altering the methylation status of the CpG island. These results raise the possibility that demethylation and histone acetylation are distinct but complementary mechanisms for destabilizing heterochromatin and activating transcription.	Johns Hopkins Univ, Sch Med, Ctr Oncol, Baltimore, MD 21231 USA	Johns Hopkins University; Johns Hopkins Medicine	Davidson, NE (corresponding author), Johns Hopkins Univ, Sch Med, Ctr Oncol, 422 N Bond St, Baltimore, MD 21231 USA.							ABRAHAM SE, 1993, ONCOGENE, V8, P1639; BAYLIN SB, 1991, CANCER CELL-MON REV, V3, P383; Beato M, 1996, J STEROID BIOCHEM, V56, P47, DOI 10.1016/0960-0760(95)00223-5; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; COMB M, 1990, NUCLEIC ACIDS RES, V18, P3975, DOI 10.1093/nar/18.13.3975; FERGUSON AT, 1995, CANCER RES, V55, P2279; Graham JD, 1995, J BIOL CHEM, V270, P30693, DOI 10.1074/jbc.270.51.30693; HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700; HERMAN JG, 1995, CANCER RES, V55, P4525; Hsieh CL, 1997, MOL CELL BIOL, V17, P5897, DOI 10.1128/MCB.17.10.5897; HSIEH CL, 1994, MOL CELL BIOL, V14, P5487, DOI 10.1128/MCB.14.8.5487; IGUCHIARIGA SMM, 1989, GENE DEV, V3, P612, DOI 10.1101/gad.3.5.612; Jenster G, 1997, P NATL ACAD SCI USA, V94, P7879, DOI 10.1073/pnas.94.15.7879; JIANG SY, 1992, JNCI-J NATL CANCER I, V84, P580, DOI 10.1093/jnci/84.8.580; KASS SU, 1993, MOL CELL BIOL, V13, P7372, DOI 10.1128/MCB.13.12.7372; KASTNER P, 1990, EMBO J, V9, P1603, DOI 10.1002/j.1460-2075.1990.tb08280.x; Kee BL, 1996, J BIOL CHEM, V271, P2373, DOI 10.1074/jbc.271.5.2373; KLEMPNAUER KH, 1993, ONCOGENE, V8, P111; Korzus E, 1998, SCIENCE, V279, P703, DOI 10.1126/science.279.5351.703; Lapidus RG, 1996, CLIN CANCER RES, V2, P805; LEVINE A, 1993, J BIOL CHEM, V268, P21754; LEWIS JD, 1992, CELL, V69, P905, DOI 10.1016/0092-8674(92)90610-O; LI E, 1993, NATURE, V366, P362, DOI 10.1038/366362a0; MCGUIRE WL, 1978, SEMIN ONCOL, V5, P428; MEEHAN RR, 1989, CELL, V58, P499, DOI 10.1016/0092-8674(89)90430-3; MEEHAN RR, 1992, NUCLEIC ACIDS RES, V20, P5085, DOI 10.1093/nar/20.19.5085; MOHANDAS T, 1981, SCIENCE, V211, P393, DOI 10.1126/science.6164095; Morin PJ, 1996, P NATL ACAD SCI USA, V93, P7950, DOI 10.1073/pnas.93.15.7950; OHTANIFUJITA N, 1993, ONCOGENE, V8, P1063; ONATE SA, 1995, SCIENCE, V270, P1354; OTTAVIANO YL, 1994, CANCER RES, V54, P2552; PRENDERGAST GC, 1991, SCIENCE, V251, P186, DOI 10.1126/science.1987636; RIDEOUT WM, 1994, MOL CELL BIOL, V14, P6143, DOI 10.1128/MCB.14.9.6143; Smith CL, 1996, P NATL ACAD SCI USA, V93, P8884, DOI 10.1073/pnas.93.17.8884; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; XING LP, 1995, J BIOL CHEM, V270, P17488, DOI 10.1074/jbc.270.29.17488; YOSHIURA K, 1995, P NATL ACAD SCI USA, V92, P7416, DOI 10.1073/pnas.92.16.7416	37	32	34	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 6	1998	17	5					577	583		10.1038/sj.onc.1201961	http://dx.doi.org/10.1038/sj.onc.1201961			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	107EZ	9704923				2022-12-17	WOS:000075195300005
J	Pierce, A; Owen-Lynch, PJ; Spooncer, E; Dexter, TM; Whetton, AD				Pierce, A; Owen-Lynch, PJ; Spooncer, E; Dexter, TM; Whetton, AD			P210 Bcr-Abl expression in a primitive multipotent haematopoietic cell line models the development of chronic myeloid leukaemia	ONCOGENE			English	Article						Bcr-Abl; chronic myeloid leukaemia; stem cell line	CHRONIC MYELOGENOUS LEUKEMIA; TYROSINE KINASE-ACTIVITY; PHILADELPHIA-CHROMOSOME; TRANSFORMATION; GROWTH; PROTEIN; GENE; PROLIFERATION; INTERLEUKIN-3; CONSEQUENCES	Chronic myeloid leukaemia (CML) is a clonal disorder of the pluripotent haemopoietic stem cell, the hallmark of which is the constitutively activated Bcr-Abl protein tyrosine kinase. During the initial chronic phase of CML the primitive multipotent leukaemic progenitor cells remain growth factor dependant and are capable of producing terminally differentiated cells. Although the available evidence suggests that Bcr-Abl directly affects signalling pathways involved in controlling the development of primitive haemopoietic progenitors the identification of the specific biological consequences of Bcr - Abl activity in these progenitors has been hampered by the lack of suitable systems modelling CML, By transfecting the multipotent haemopoietic cell line FDCP-Mix with a temperature sensitive mutant of Bcr-Abl we have developed the first working model that mirrors the chronic phase of CML, FDCP-Mix cells expressing Bcr-Abl tyrosine kinase activity remain growth factor dependent and retain their ability to differentiate. Normal neutrophilic cells are formed in response to CSF and GM-CSF, In addition, the transfected FDCP-Mix cells grown at the permissive temperature for Bcr-Abl tyrosine kinase activity display enhanced survival and proliferation in low concentrations of growth factor, These findings are consistent with the initial subtle changes seen in CML progenitor cells during the chronic phase and confirm that Bcr-Abl effects are context specific, i.e, they depend on the origin and developmental potential of the transfected cells, This questions the significance of studies in non-haemopoietic and differentiation blocked haemopoietic cells.	Univ Manchester, Leukaemia Res Fund Cellular Dev Unit, Manchester M60 1QD, Lancs, England; Univ Manchester, Dept Biomol Sci, Manchester M60 1QD, Lancs, England; Christie Hosp NHS Trust, Paterson Inst Canc Res, Dept Expt Haematol, Manchester M20 9BX, Lancs, England	University of Manchester; University of Manchester; Christie NHS Foundation Trust; Christie Hospital; Paterson Institute for Cancer Research	Whetton, AD (corresponding author), Univ Manchester, Leukaemia Res Fund Cellular Dev Unit, Sackville St, Manchester M60 1QD, Lancs, England.			WHETTON, ANTHONY D/0000-0002-1098-3878; Owen-Lynch, Penelope Jane/0000-0002-5928-2327; Pierce, Andrew/0000-0001-5995-2469				BEDI A, 1994, BLOOD, V83, P2038; CARLESSO N, 1994, ONCOGENE, V9, P149; CLARKSON B, 1993, LEUKEMIA, V7, P1683; COTTER TG, 1995, LEUKEMIA LYMPHOMA, V18, P231, DOI 10.3109/10428199509059612; DALEY GQ, 1988, P NATL ACAD SCI USA, V85, P9312, DOI 10.1073/pnas.85.23.9312; DALEY GQ, 1991, P NATL ACAD SCI USA, V88, P11335, DOI 10.1073/pnas.88.24.11335; DALEY GQ, 1991, ADV CANCER RES, V57, P151; Eaves C, 1985, Prog Clin Biol Res, V184, P403; EAVES C, 1994, BLOOD CELLS, V20, P83; GISHIZKY ML, 1992, SCIENCE, V256, P836, DOI 10.1126/science.1375394; Gotoh A, 1997, Curr Opin Hematol, V4, P3; Hariharan I K, 1988, Oncogene Res, V3, P387; Heyworth CM, 1990, GROWTH FACTORS, V2, P197, DOI 10.3109/08977199009071506; KABAROWSKI JHS, 1994, EMBO J, V13, P5887, DOI 10.1002/j.1460-2075.1994.tb06934.x; KONOPKA JB, 1984, CELL, V37, P1035, DOI 10.1016/0092-8674(84)90438-0; LAKER C, 1987, P NATL ACAD SCI USA, V84, P8458, DOI 10.1073/pnas.84.23.8458; LANEUVILLE P, 1992, BLOOD, V80, P1788; LANEUVILLE P, 1991, ONCOGENE, V6, P275; LUGO TG, 1990, SCIENCE, V247, P1079, DOI 10.1126/science.2408149; MARKOWITZ D, 1988, VIROLOGY, V167, P400, DOI 10.1016/S0042-6822(88)90101-8; MATULONIS U, 1993, EXP HEMATOL, V21, P1460; MCLAUGHLIN J, 1987, P NATL ACAD SCI USA, V84, P6558, DOI 10.1073/pnas.84.18.6558; RASKIND WH, 1987, ADV CANCER RES, V49, P127, DOI 10.1016/S0065-230X(08)60796-4; SAWYERS CL, 1993, LEUKEMIA LYMPHOMA, V11, P101, DOI 10.3109/10428199309064268; SCHERLE PA, 1990, P NATL ACAD SCI USA, V87, P1908, DOI 10.1073/pnas.87.5.1908; SPOONCER E, 1994, LEUKEMIA, V8, P620; SPOONCER E, 1986, DIFFERENTIATION, V31, P111, DOI 10.1111/j.1432-0436.1986.tb00391.x; WANG J Y J, 1992, Current Biology, V2, P70, DOI 10.1016/0960-9822(92)90198-J; WETZLER M, 1993, LEUKEMIA LYMPHOMA, V11, P47, DOI 10.3109/10428199309047863; YOUNG JC, 1988, MOL CELL BIOL, V8, P4079, DOI 10.1128/MCB.8.10.4079	30	32	32	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 6	1998	17	5					667	672		10.1038/sj.onc.1201969	http://dx.doi.org/10.1038/sj.onc.1201969			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	107EZ	9704934				2022-12-17	WOS:000075195300016
J	Kilbey, A; Bartholomew, C				Kilbey, A; Bartholomew, C			Evi-1 ZF1 DNA binding activity and a second distinct transcriptional repressor region are both required for optimal transformation of Rat1 fibroblasts	ONCOGENE			English	Article						Evi-1; transcriptional repression; leukaemogenesis	ZINC-FINGER GENE; MYELOID-LEUKEMIA; PROTEIN; EXPRESSION; SEQUENCE; ACTIVATION; CELL; IDENTIFICATION; DOMAIN; FAMILY	The Evi-1 gene encodes a zinc finger transcriptional repressor protein that normally plays a role in development and is frequently activated in myeloid leukaemias, Evi-1 has two distinct DNA binding domains, ZF1 and ZF2, and a defined repressor domain but the function of the remainder of the molecule is unknown. The ZF2 and repressor domains have been shown to be required for transformation and we show here that ZF1 is also required. An alternative splice variant of Evi-1, designated Delta 324, encodes a protein which lacks a portion of the ZF1 DNA binding domain and the intervening amino acids 239-514 (designated IR) located between ZF1 and the repressor domain, We show that Delta 324 can neither bind ZF1, repress transcription through this site nor transform Rat1 fibroblasts, Reconstitution studies demonstrate that the defect in Delta 324 is partially complemented by recreating the ZF1 DNA binding activity. However, full function also requires the IR region which has transcriptional repressor activity. This study shows therefore, that ZF1, ZF2 and repressor domains and the IR region all contribute to the transformation efficiency of the Evi-1 protein.	Beatson Inst Canc Res, CRC, Beatson Labs, Glasgow, Lanark, Scotland	Beatson Institute	Bartholomew, C (corresponding author), Beatson Inst Canc Res, CRC, Beatson Labs, Garscube Estate,Switchback Rd, Glasgow, Lanark, Scotland.							Bartholomew C, 1997, ONCOGENE, V14, P569, DOI 10.1038/sj.onc.1200864; BARTHOLOMEW C, 1994, ONCOGENE, V9, P939; BERGERON D, 1992, VIROLOGY, V191, P661, DOI 10.1016/0042-6822(92)90241-G; BORDEREAUX D, 1990, ONCOGENE, V5, P925; Brooks DJ, 1996, BRIT J CANCER, V74, P1518, DOI 10.1038/bjc.1996.583; COWELL IG, 1994, TRENDS BIOCHEM SCI, V19, P38, DOI 10.1016/0968-0004(94)90172-4; DELWEL R, 1993, MOL CELL BIOL, V13, P4291, DOI 10.1128/MCB.13.7.4291; Fears S, 1996, P NATL ACAD SCI USA, V93, P1642, DOI 10.1073/pnas.93.4.1642; FUNABIKI T, 1994, ONCOGENE, V9, P1575; HOLLENBERG SM, 1995, MOL CELL BIOL, V15, P3813; Hoyt PR, 1997, MECH DEVELOP, V65, P55, DOI 10.1016/S0925-4773(97)00057-9; KREIDER BL, 1993, P NATL ACAD SCI USA, V90, P6454, DOI 10.1073/pnas.90.14.6454; KUROKAWA M, 1995, ONCOGENE, V11, P833; LICHT JD, 1993, P NATL ACAD SCI USA, V90, P11361, DOI 10.1073/pnas.90.23.11361; MATSUGI T, 1990, MOL CELL BIOL, V10, P1259, DOI 10.1128/MCB.10.3.1259; MITANI K, 1994, EMBO J, V13, P504, DOI 10.1002/j.1460-2075.1994.tb06288.x; MORISHITA K, 1990, ONCOGENE, V5, P963; MORISHITA K, 1992, MOL CELL BIOL, V12, P183, DOI 10.1128/MCB.12.1.183; MORISHITA K, 1992, P NATL ACAD SCI USA, V89, P3937, DOI 10.1073/pnas.89.9.3937; MORISHITA K, 1988, CELL, V54, P831, DOI 10.1016/S0092-8674(88)91175-0; Ogawa S, 1996, ONCOGENE, V13, P183; SHI Y, 1991, CELL, V67, P377, DOI 10.1016/0092-8674(91)90189-6; Soderholm J, 1997, LEUKEMIA, V11, P352, DOI 10.1038/sj.leu.2400584; Suzukawa K, 1997, GENOMICS, V42, P356, DOI 10.1006/geno.1997.4732	24	32	34	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 30	1998	16	17					2287	2291		10.1038/sj.onc.1201732	http://dx.doi.org/10.1038/sj.onc.1201732			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZK226	9619838				2022-12-17	WOS:000073298000014
J	Tamada, M; Hu, CD; Kariya, K; Okada, T; Kataoka, T				Tamada, M; Hu, CD; Kariya, K; Okada, T; Kataoka, T			Membrane recruitment of Raf-1 is not the only function of Ras in Raf-1 activation	ONCOGENE			English	Article						Ras; Raf-1; membrane translocation	PLASMA-MEMBRANE; PROTEIN-KINASE; SIGNAL-TRANSDUCTION; HA-RAS; P21; PHOSPHORYLATION; EXPRESSION; MECHANISM; P21(RAS); DOMAINS	Pas interacts with Raf-1 and stimulates its kinase activity, which results in activation of the mitogen-activated protein (MAP) kinase cascade. It has been proposed that the main function of Ras in Raf-1 activation is to recruit Raf-1 to the plasma membrane, where a separate activation event such as phosphorylation takes place, Here, we examined the activities of various mutants of human Ha-Pas to induce membrane translocation of Raf-1 and to activate Raf-1 in vivo. Overexpression of an activator region mutant Ha-Ras(V45E) in COS7 cells induced membrane translocation of Raf-1 as effectively as wild-type Ha-Ras. However, the activity of this mutant to activate Raf-1 and extracellular signal-regulated kinase-2 (ERK2) was attenuated by approximately 70% compared to that of wild-type Ha-Pas. The decrease in the specific activity was further demonstrated by measuring the activity of the Ha-Ras(V45E)-associated Raf-1 purified from the membrane fraction. These results imply that the association of Pas with Raf-1 has another important consequence, presumably dependent on the interaction between its activator region and Raf-1, than the simple recruitment of Raf-1 to the plasma membrane.	KOBE UNIV,SCH MED,DEPT PHYSIOL 2,CHUO KU,KOBE,HYOGO 650,JAPAN	Kobe University								Akasaka K, 1996, J BIOL CHEM, V271, P5353, DOI 10.1074/jbc.271.10.5353; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P279, DOI 10.1016/0968-0004(94)90005-1; BRTVA TR, 1995, J BIOL CHEM, V270, P9809, DOI 10.1074/jbc.270.17.9809; Cai H, 1997, MOL CELL BIOL, V17, P732, DOI 10.1128/MCB.17.2.732; CASEY PJ, 1994, CURR OPIN CELL BIOL, V6, P219, DOI 10.1016/0955-0674(94)90139-2; DAUM G, 1994, TRENDS BIOCHEM SCI, V19, P474, DOI 10.1016/0968-0004(94)90133-3; DENT P, 1995, MOL CELL BIOL, V15, P4125; Drugan JK, 1996, J BIOL CHEM, V271, P233, DOI 10.1074/jbc.271.1.233; FABIAN JR, 1994, P NATL ACAD SCI USA, V91, P5982, DOI 10.1073/pnas.91.13.5982; FABIAN JR, 1993, MOL CELL BIOL, V13, P7170, DOI 10.1128/MCB.13.11.7170; Farrar MA, 1996, NATURE, V383, P178, DOI 10.1038/383178a0; Ferrier AF, 1997, J BIOL CHEM, V272, P2136; FUJITAYOSHIGAKI J, 1995, J BIOL CHEM, V270, P4661, DOI 10.1074/jbc.270.9.4661; HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O; Hu CD, 1995, J BIOL CHEM, V270, P30274, DOI 10.1074/jbc.270.51.30274; KIKUCHI A, 1994, J BIOL CHEM, V269, P20054; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; Luo ZJ, 1997, MOL CELL BIOL, V17, P46, DOI 10.1128/MCB.17.1.46; Luo ZJ, 1996, NATURE, V383, P181, DOI 10.1038/383181a0; MARSHALL MS, 1993, TRENDS BIOCHEM SCI, V18, P250, DOI 10.1016/0968-0004(93)90175-M; MILBURN MV, 1990, SCIENCE, V247, P939, DOI 10.1126/science.2406906; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Mineo C, 1997, J BIOL CHEM, V272, P10345; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; PATRIOTIS C, 1994, P NATL ACAD SCI USA, V91, P9755, DOI 10.1073/pnas.91.21.9755; Shinkai M, 1996, BIOCHEM BIOPH RES CO, V223, P729, DOI 10.1006/bbrc.1996.0964; SHIROUZU M, 1994, ONCOGENE, V9, P2153; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; WILLIAMS NG, 1992, P NATL ACAD SCI USA, V89, P2922, DOI 10.1073/pnas.89.7.2922; WILLUMSEN BM, 1984, EMBO J, V3, P2581, DOI 10.1002/j.1460-2075.1984.tb02177.x; YAO B, 1995, NATURE, V378, P307, DOI 10.1038/378307a0; Zhang YH, 1997, CELL, V89, P63, DOI 10.1016/S0092-8674(00)80183-X	36	32	32	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 11	1997	15	24					2959	2964		10.1038/sj.onc.1201582	http://dx.doi.org/10.1038/sj.onc.1201582			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YK377	9416839				2022-12-17	WOS:A1997YK37700008
J	Ji, C; Marnett, LJ; Pietenpol, JA				Ji, C; Marnett, LJ; Pietenpol, JA			Cell cycle re-entry following chemically-induced cell cycle synchronization leads to elevated p53 and p21 protein levels	ONCOGENE			English	Article						p53; p21; cell cycle synchronization; mimosine; aphidicolin	P53-INDEPENDENT PATHWAY; HUMAN FIBROBLASTS; GROWTH ARREST; DNA-SYNTHESIS; DIFFERENTIATION; MIMOSINE; CHECKPOINTS; SUPPRESSION; IRRADIATION; INHIBITION	Mimosine (MIM) and aphidicolin (APH) are two agents frequently used in tissue culture-based experiments to achieve cell synchronization at late G1 and S phases. Following MIM or APH treatment of human cancer cell lines, a reversible growth arrest in late G1 and S phases of the cell cycle was correlated with moderate increases in p53 and p21 protein levels. Both p53-dependent and -independent increases in p21 were observed following treatment with either agent. However, a striking increase in p21 protein levels and a continuous elevation in both p53 and p21 protein levels were observed over 48 h after cells re-entered the cell cycle following the chemically-induced synchronization. In addition, the increase in p21 protein levels typically seen following treatment of cells with DNA damaging agents, was enhanced when cells were treated with genotoxic agents following MIM or APH synchronization. These findings suggest that caution should be exercised when interpreting results from experiments using cell synchronization agents, in particular, studies designed to investigate p53- and p21-regulatory pathways.	VANDERBILT UNIV,SCH MED,CTR MOL TOXICOL,DEPT BIOCHEM,NASHVILLE,TN 37232; VANDERBILT UNIV,SCH MED,CTR MOL TOXICOL,DEPT CHEM,NASHVILLE,TN 37232; VANDERBILT UNIV,SCH MED,VANDERBILT CANC CTR,NASHVILLE,TN 37232	Vanderbilt University; Vanderbilt University; Vanderbilt University				Li, Tao/0000-0003-3831-901X	NCI NIH HHS [CA68485, CA47479, CA68450] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA047479, P30CA068485] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; Alpan RS, 1996, CELL GROWTH DIFFER, V7, P893; CHUAN J, 1997, P AM ASSOC CANC RES, V38, P1324; DAI YM, 1994, VIROLOGY, V205, P210, DOI 10.1006/viro.1994.1636; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; GILBERT DM, 1995, J BIOL CHEM, V270, P9597, DOI 10.1074/jbc.270.16.9597; HARPER JW, 1993, CELL, V75, P805; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; JANERO DR, 1990, FREE RADICAL BIO MED, V9, P515, DOI 10.1016/0891-5849(90)90131-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KASTAN MB, 1995, ENV HLTH PERSPECT, V5, P55; KATO JY, 1993, P NATL ACAD SCI USA, V90, P11513, DOI 10.1073/pnas.90.24.11513; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LAVIN MF, 1994, INT J RADIAT BIOL, V66, pS151; Linke SP, 1996, GENE DEV, V10, P934, DOI 10.1101/gad.10.8.934; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; Pietenpol JA, 1996, P NATL ACAD SCI USA, V93, P8390, DOI 10.1073/pnas.93.16.8390; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; RUSSO T, 1995, J BIOL CHEM, V270, P29386, DOI 10.1074/jbc.270.49.29386; STEINMAN RA, 1994, ONCOGENE, V9, P3389; STEWART N, 1995, ONCOGENE, V10, P109; WANG TSF, 1991, ANNU REV BIOCHEM, V60, P513, DOI 10.1146/annurev.biochem.60.1.513; ZHANG W, 1995, CANCER RES, V55, P668	27	32	32	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 27	1997	15	22					2749	2753		10.1038/sj.onc.1201441	http://dx.doi.org/10.1038/sj.onc.1201441			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YH468	9401002				2022-12-17	WOS:A1997YH46800013
J	Kroll, M; Conconi, M; Desterro, MJP; Marin, A; Thomas, D; Friguet, B; Hay, RT; Virelizier, JL; ArenzanaSeisdedos, F; Rodriguez, MS				Kroll, M; Conconi, M; Desterro, MJP; Marin, A; Thomas, D; Friguet, B; Hay, RT; Virelizier, JL; ArenzanaSeisdedos, F; Rodriguez, MS			The carboxy-terminus of I kappa B alpha determines susceptibility to degradation by the catalytic core of the proteasome	ONCOGENE			English	Article						I kappa B alpha; carboxy-terminus; NF-kappa B; 20S proteasome	CASEIN KINASE-II; SIGNAL-INDUCED DEGRADATION; CONSTITUTIVE PHOSPHORYLATION; INDUCIBLE DEGRADATION; TRANSCRIPTION FACTORS; PROTEIN-DEGRADATION; INDUCED APOPTOSIS; PRECURSOR P105; DNA-BINDING; ACTIVATION	The Rel/NF-kappa B family of transcription factors controls the expression of a wide variety of genes that are implicated in immune and inflammatory responses and cellular proliferation. Disregulation of NF-kappa B is associated with cellular transformation and the maintenance of a high anti-apoptotic threshold in transformed cells. NF-kappa B activity is in turn regulated by its sequestration in the cytoplasm by the inhibitor I kappa B. I kappa B alpha, the most abundant and well-characterized member of the I kappa B multiprotein family, is rapidly degraded in response to multiple physiologic stimuli. In the present study we show that not only the amino-terminus, but also the carboxy-terminus of I kappa B alpha contain transferable signals that must be simultaneously present in an unrelated protein to render it susceptible to activation-induced, proteasome-mediated degradation. We show here that I kappa B alpha amino-terminal modifications occur independently of the carboxy-terminus. Moreover, we present evidence indicating a critical role far the carboxy-terminal region in facilitating proteolysis by the catalytic core of the proteasome. When incubated with 20S proteasome extracted from rat liver, I kappa B alpha was quickly degraded while a deletion mutant lacking the carboxy-terminus was resistant to proteolysis. Likewise, chimeric proteins of beta-galactosidase with the I kappa B alpha carboxy-terminus were degraded in vitro independently of the presence of the I kappa B alpha amino-terminus, whereas chimeric proteins lacking the I kappa B alpha carboxy-terminus were stable. Our results identify the carboxy-terminus of I kappa B alpha as a domain critical for degradation through interaction with an as yet unidentified component of the proteasome.	INST PASTEUR,UNITE IMMUNOL VIRALE,F-75724 PARIS 15,FRANCE; INST PASTEUR,UNITE BIOCHIM CELLULAIRE,F-75724 PARIS 15,FRANCE; UNIV ST ANDREWS,SCH BIOL & MED SCI,ST ANDREWS KY16 9AL,FIFE,SCOTLAND	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; University of St Andrews			Hay, Ronald/S-3233-2019; Arenzana-Seisdedos, Fernando/E-5835-2016; Hay, Ronald T/F-9338-2011	Hay, Ronald/0000-0001-7113-9024; Hay, Ronald T/0000-0001-7113-9024; Desterro, Joana/0000-0002-6359-7233; Friguet, Bertrand/0000-0001-8085-1961				ALKALAY I, 1995, MOL CELL BIOL, V15, P1294; Aoki T, 1996, ONCOGENE, V12, P1159; ARENZANASEISDEDOS F, 1995, MOL CELL BIOL, V15, P2689; ArenzanaSeisdedos F, 1997, J CELL SCI, V110, P369; BACHMAIR A, 1986, SCIENCE, V234, P179, DOI 10.1126/science.3018930; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Baldi L, 1996, J BIOL CHEM, V271, P376, DOI 10.1074/jbc.271.1.376; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BARROGA CF, 1995, P NATL ACAD SCI USA, V92, P7637, DOI 10.1073/pnas.92.17.7637; Beauparlant P, 1996, J BIOL CHEM, V271, P10690, DOI 10.1074/jbc.271.18.10690; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BEG AA, 1993, GENE DEV, V7, P2064, DOI 10.1101/gad.7.11.2064; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; Brown K, 1997, MOL CELL BIOL, V17, P3021, DOI 10.1128/MCB.17.6.3021; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; CHIAO PJ, 1994, P NATL ACAD SCI USA, V91, P28, DOI 10.1073/pnas.91.1.28; Conconi M, 1996, ARCH BIOCHEM BIOPHYS, V331, P232, DOI 10.1006/abbi.1996.0303; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; DEVERAUX Q, 1994, J BIOL CHEM, V269, P7059; DiDonato J, 1996, MOL CELL BIOL, V16, P1295; DIDONATO JA, 1995, MOL CELL BIOL, V15, P1302; FEHRENTZ JA, 1985, INT J PEPT PROT RES, V26, P236; FINCO TS, 1994, P NATL ACAD SCI USA, V91, P11884, DOI 10.1073/pnas.91.25.11884; FRIGUET B, 1994, ARCH BIOCHEM BIOPHYS, V311, P168, DOI 10.1006/abbi.1994.1222; GILMORE TD, 1993, TRENDS GENET, V9, P427, DOI 10.1016/0168-9525(93)90106-R; HANKE T, 1992, J GEN VIROL, V73, P653, DOI 10.1099/0022-1317-73-3-653; HATADA EN, 1993, EMBO J, V12, P2781, DOI 10.1002/j.1460-2075.1993.tb05939.x; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; HOCHSTRASSER M, 1990, CELL, V61, P697, DOI 10.1016/0092-8674(90)90481-S; JAFFRAY E, 1995, MOL CELL BIOL, V15, P2166; Janosch P, 1996, J BIOL CHEM, V271, P13868, DOI 10.1074/jbc.271.23.13868; LEBAIL O, 1993, EMBO J, V12, P5043, DOI 10.1002/j.1460-2075.1993.tb06197.x; LI CCH, 1995, BIOCHEM BIOPH RES CO, V215, P292, DOI 10.1006/bbrc.1995.2465; LIN RT, 1995, J BIOL CHEM, V270, P3123, DOI 10.1074/jbc.270.7.3123; Lin RT, 1996, MOL CELL BIOL, V16, P1401; MATTHEWS JR, 1995, INT J BIOCHEM CELL B, V27, P865, DOI 10.1016/1357-2725(95)00071-V; McElhinny JA, 1996, MOL CELL BIOL, V16, P899; MELLITS KH, 1993, NUCLEIC ACIDS RES, V21, P5059, DOI 10.1093/nar/21.22.5059; MIYAMOTO S, 1994, P NATL ACAD SCI USA, V91, P12740, DOI 10.1073/pnas.91.26.12740; NAUMANN M, 1993, EMBO J, V12, P213, DOI 10.1002/j.1460-2075.1993.tb05647.x; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; Rechsteiner M, 1996, TRENDS BIOCHEM SCI, V21, P267, DOI 10.1016/S0968-0004(96)10031-1; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; Rodriguez MS, 1996, ONCOGENE, V12, P2425; RODRIGUEZ MS, 1995, MOL CELL BIOL, V15, P2413; Roff M, 1996, J BIOL CHEM, V271, P7844, DOI 10.1074/jbc.271.13.7844; ROGERS SW, 1986, BIOMED BIOCHIM ACTA, V45, P1611; ROULSTON A, 1995, MICROBIOL REV, V59, P481, DOI 10.1128/MMBR.59.3.481-505.1995; SCHERER DC, 1995, P NATL ACAD SCI USA, V92, P11259, DOI 10.1073/pnas.92.24.11259; Schwarz EM, 1996, MOL CELL BIOL, V16, P3554; Soddu S, 1996, J CELL BIOL, V134, P193, DOI 10.1083/jcb.134.1.193; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; SUN SC, 1994, MOL CELL BIOL, V14, P7377, DOI 10.1128/MCB.14.11.7377; Sun SC, 1996, MOL CELL BIOL, V16, P1058; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; TRAENCKNER EBM, 1994, EMBO J, V13, P5433, DOI 10.1002/j.1460-2075.1994.tb06878.x; VanAntwerp DJ, 1996, MOL CELL BIOL, V16, P6037; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; VARSHAVSKY A, 1992, CELL, V69, P725, DOI 10.1016/0092-8674(92)90285-K; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; WHITESIDE ST, 1995, MOL CELL BIOL, V15, P5339; Wu M, 1996, EMBO J, V15, P4682, DOI 10.1002/j.1460-2075.1996.tb00845.x; YAGLOM J, 1995, MOL CELL BIOL, V15, P731; Zhong HH, 1997, CELL, V89, P413, DOI 10.1016/S0092-8674(00)80222-6	66	32	33	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 9	1997	15	15					1841	1850		10.1038/sj.onc.1201560	http://dx.doi.org/10.1038/sj.onc.1201560			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XZ725	9362451				2022-12-17	WOS:A1997XZ72500011
J	Komatsu, M; Li, HO; Tsutsui, H; Itakura, K; Matsumura, M; Yokoyama, KK				Komatsu, M; Li, HO; Tsutsui, H; Itakura, K; Matsumura, M; Yokoyama, KK			MAZ, a Myc-associated zinc finger protein, is essential for the ME1a1-mediated expression of the c-myc gene during neuroectodermal differentiation of P19 cells	ONCOGENE			English	Article						MAZ; c-myc; ME1a1 site; gene expression	ERYTHROLEUKEMIA-CELLS; PROMOTER ACTIVITY; RETINOIC ACID; TRANSCRIPTION; LINE; COMMITMENT; SITE; E1A; PROLIFERATION; SEQUENCES	To investigate whether MAZ (Myc-associated zinc finger protein) affects the expression of the c-myc gene during the retinoic acid-induced (RA-induced) neuroectodermal differentiation of P19 embryonal carcinoma (EC) cells, we introduced a CAT reporter construct, human c-myc promoter/CAT (pMyc2CAT), and a mutant CAT derivative that lacked an ME1a1 site (pMyc1CAT) into P19EC cells tp monitor the promoter activity of the c-myc gene, The expression of CAT in pMyc2CAT-transformed cells declined fivefold after 24 h in the presence of RA, returned to the normal level within 48 h, and decreased again to below 20% of the normal level after 96 h. By contrast, the expression of CAT in pMyc1CAT-transformed cells did not return to the normal level after 48 h in the presence of RA, In addition, an electrophoretic mobility shift assay (EMSA) with ME1a1 DNA as probe demonstrated that the kinetics of the DNA-binding activity of MAZ were closely correlated with the changes in the expression of CAT from the c-myc promoter/CAT gene during the differentiation of P19EC cells, Taken together, these results suggest that MAZ plays a key role in the transient increase in the expression of the c-myc gene after 48 h of exposure to RA during the neuroectodermal differentiation of P19EC cells.	RIKEN, TSUKUBA LIFE SCI CTR, TSUKUBA, IBARAKI 305, JAPAN; CITY HOPE NATL MED CTR, BECKMAN RES INST, DEPT MOL GENET, DUARTE, CA 91010 USA; UNIV TSUKUBA, INST APPL BIOCHEM, TSUKUBA, IBARAKI 305, JAPAN	RIKEN; City of Hope; Beckman Research Institute of City of Hope; University of Tsukuba			Komatsu, Masaaki/B-8321-2011	Komatsu, Masaaki/0000-0001-7672-7722				ASHFIELD R, 1994, EMBO J, V13, P5656, DOI 10.1002/j.1460-2075.1994.tb06904.x; ASSELIN C, 1989, ONCOGENE, V4, P549; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BOSSONE SA, 1992, P NATL SCI US, V89, P11498; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; COPPOLA JA, 1986, NATURE, V320, P760, DOI 10.1038/320760a0; DESJARDINS E, 1993, MOL CELL BIOL, V13, P5710, DOI 10.1128/MCB.13.9.5710; DMITROVSKY E, 1986, NATURE, V322, P748, DOI 10.1038/322748a0; DUNCAN DD, 1995, MOL CELL BIOL, V15, P3179; EDWARDS MKS, 1983, DEV BIOL, V98, P187, DOI 10.1016/0012-1606(83)90348-2; EDWARDS MKS, 1983, MOL CELL BIOL, V3, P2280, DOI 10.1128/MCB.3.12.2280; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; HALL DJ, 1990, ONCOGENE, V5, P47; HOLT JT, 1988, MOL CELL BIOL, V8, P963, DOI 10.1128/MCB.8.2.963; JONESVILLENEUVE EMV, 1982, J CELL BIOL, V94, P253, DOI 10.1083/jcb.94.2.253; KAUFMANN SH, 1987, ANAL BIOCHEM, V161, P89, DOI 10.1016/0003-2697(87)90656-7; Kawasaki H, 1996, NUCLEIC ACIDS RES, V24, P3010, DOI 10.1093/nar/24.15.3010; KENNEDY GC, 1992, P NATL ACAD SCI USA, V89, P11498, DOI 10.1073/pnas.89.23.11498; KITABAYASHI I, 1992, EMBO J, V11, P167, DOI 10.1002/j.1460-2075.1992.tb05039.x; KITABAYASHI I, 1991, NUCLEIC ACIDS RES, V19, P649, DOI 10.1093/nar/19.3.649; KOVESDI I, 1986, CELL, V45, P219, DOI 10.1016/0092-8674(86)90386-7; KUME TU, 1988, J MOL BIOL, V202, P779, DOI 10.1016/0022-2836(88)90558-X; LACHMAN HM, 1986, P NATL ACAD SCI USA, V83, P6480, DOI 10.1073/pnas.83.17.6480; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; MCBURNEY MW, 1982, NATURE, V299, P165, DOI 10.1038/299165a0; MOBERG KH, 1992, ONCOGENE, V7, P411; MOBERG KH, 1991, J CELL PHYSIOL, V148, P75, DOI 10.1002/jcp.1041480110; Parks CL, 1996, J BIOL CHEM, V271, P4417; PROCHOWNIK EV, 1986, NATURE, V322, P848, DOI 10.1038/322848a0; PYRC J, 1994, INT J ONCOL, V5, P1085; PYRC JJ, 1992, BIOCHEMISTRY-US, V31, P4102, DOI 10.1021/bi00131a029; Sambrook D.J., 1989, MOL CLONING LAB MANU; SCHMITT-NEY M, 1991, MOL CELL BIOL, V11, P3745, DOI 10.1128/MCB.11.7.3745; SPENCER CA, 1991, ADV CANCER RES, V56, P1; STARNAUD R, 1988, ONCOGENE, V3, P553; Tsutsui H, 1996, BIOCHEM BIOPH RES CO, V226, P801, DOI 10.1006/bbrc.1996.1432; ULLOA L, 1993, EMBO J, V12, P1633, DOI 10.1002/j.1460-2075.1993.tb05808.x; WICKSTROM EL, 1988, P NATL ACAD SCI USA, V85, P1028, DOI 10.1073/pnas.85.4.1028; WONG KK, 1995, MOL CELL BIOL, V15, P6535; Ye JP, 1996, MOL CELL BIOL, V16, P157; YOKOYAMA K, 1987, P NATL ACAD SCI USA, V84, P7363, DOI 10.1073/pnas.84.21.7363	41	32	32	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 4	1997	15	10					1123	1131		10.1038/sj.onc.1201283	http://dx.doi.org/10.1038/sj.onc.1201283			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XU991	9294605				2022-12-17	WOS:A1997XU99100001
J	Narducci, MG; Virgilio, L; Engiles, JB; Buchberg, AM; Billips, L; Facchiano, A; Croce, CM; Russo, G; Rothstein, JL				Narducci, MG; Virgilio, L; Engiles, JB; Buchberg, AM; Billips, L; Facchiano, A; Croce, CM; Russo, G; Rothstein, JL			The murine Tcl1 oncogene: embryonic and lymphoid cell expression	ONCOGENE			English	Article						ATM; ataxia-telangiectasia; TCL1; chronic lymphocytic leukemia; MTCP1; T-PLL	T-PROLYMPHOCYTIC LEUKEMIA; ATAXIA-TELANGIECTASIA; MOLECULAR ANALYSIS; CHROMOSOME; GENE; TRANSLOCATIONS; LOCUS; BREAKPOINT; RECEPTOR; PATIENT	In human leukemias and lymphomas nonrandom chromosomal rearrangements cause changes in cell growth and/or survival in such a way as to promote malignancy, The detailed study of the biochemical and genetic pathways altered in human cancer requires the identification or development of models to allow the study and manipulation of cancer gene function, Recently, the breakpoint gene TCL1, involved in chromosome translocations observed mostly in mature T-cell proliferations and chronic lymphocytic leukemias (CLL), was isolated and characterized, and showed to be part of a new gene family of proteins involved in these tumors, The murine Tcl1 gene, is similar in sequence to the murine and human MTCP1 gene also involved in T cell leukemias, The murine Tcl1 gene was shown to reside on mouse chromosome 12 in a region syntenic to human chromosome 14, Furthermore, we show that the murine Tcl1 gene is expressed early in mouse embryonic development and demonstrates expression in fetal hematopoietic organs as well as in immature T and B cells, Characterization of the murine Tcl1 gene will help in developing a mouse model of CLL and would provide the best opportunity to study and decipher the role of TCL1 in malignant transformation.	THOMAS JEFFERSON MED COL,KIMMEL CANC INST,DEPT MICROBIOL IMMUNOL,PHILADELPHIA,PA 19107; IRCCS,IST DERMOPAT IMMACOLATA,I-00167 ROME,ITALY; THOMAS JEFFERSON MED COL,KIMMEL CANC INST,DEPT OTOLARYNGOL HEAD & NECK SURG,PHILADELPHIA,PA 19107; UNIV ALABAMA,HOWARD HUGHES MED INST,BIRMINGHAM,AL 35294	Jefferson University; IRCCS Istituto Dermopatico dell'Immacolata (IDI); Jefferson University; Howard Hughes Medical Institute; University of Alabama System; University of Alabama Birmingham			Engiles, Julie/K-1916-2015; Facchiano, Antonio/K-5984-2016; Facchiano, Antonio/J-4744-2012; Young, Richard A/F-6495-2012; Russo, Giandomenico/K-9566-2016; Narducci, Maria Grazia/L-3093-2018	Engiles, Julie/0000-0001-9057-2093; Facchiano, Antonio/0000-0002-4243-2392; Facchiano, Antonio/0000-0002-4243-2392; Young, Richard A/0000-0001-8855-8647; Russo, Giandomenico/0000-0002-7718-9687; Narducci, Maria Grazia/0000-0002-9066-186X; Narducci, Maria Grazia/0000-0002-8877-4611; Buchberg, Arthur/0000-0002-0543-5631	NCI NIH HHS [CA-56336, CA-39869, CA-21124] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA021124] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ausubel FM., 2006, ENZYMATIC MANIPULATI; BAER R, 1987, P NATL ACAD SCI USA, V84, P9069, DOI 10.1073/pnas.84.24.9069; Barlow C, 1996, CELL, V86, P159, DOI 10.1016/S0092-8674(00)80086-0; BERTNESS VL, 1990, CANCER GENET CYTOGEN, V44, P47, DOI 10.1016/0165-4608(90)90196-H; BRITOBABAPULLE V, 1991, CANCER GENET CYTOGEN, V55, P1, DOI 10.1016/0165-4608(91)90228-M; BRUNNING RD, 1991, BLOOD, V78, P3111; CALZONE FJ, 1987, METHOD ENZYMOL, V152, P611; CHEN CYA, 1994, MOL CELL BIOL, V14, P416, DOI 10.1128/MCB.14.1.416; CIMINO G, 1991, CANCER RES, V51, P6712; CLEARY ML, 1991, CELL, V66, P619, DOI 10.1016/0092-8674(91)90105-8; CROCE CM, 1985, SCIENCE, V227, P1044, DOI 10.1126/science.3919442; CROCE CM, 1991, ORIGINS OF HUMAN CANCER, P527; DIETRICH W, 1992, GENETICS, V131, P423; Freeman SJ, 1990, POSTIMPLANTATION MAM, P249; FU TB, 1994, CANCER RES, V54, P6297; Green MC., 1989, GENETIC VARIANTS STR, P12; HEIM S, 1987, CANC CYTOGENETICS; HIGGINS DG, 1989, COMPUT APPL BIOSCI, V5, P151; ISOBE M, 1985, SCIENCE, V228, P580, DOI 10.1126/science.3983641; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Madani A, 1996, BLOOD, V87, P1923; MENGLEGAW L, 1987, EMBO J, V6, P2273, DOI 10.1002/j.1460-2075.1987.tb02501.x; NADEAU JH, 1992, MAMM GENOME, V3, P480, DOI 10.1007/BF00778825; NAGASAKA M, 1983, BLOOD, V61, P1174; NARDUCCI MG, 1995, BLOOD, V86, P2358, DOI 10.1182/blood.V86.6.2358.bloodjournal8662358; ROTHSTEIN JL, 1993, METHOD ENZYMOL, V225, P587; ROTHSTEIN JL, 1992, GENE DEV, V6, P1190, DOI 10.1101/gad.6.7.1190; ROWLEY JD, 1992, GENE CHROMOSOME CANC, V5, P264, DOI 10.1002/gcc.2870050316; ROWLEY JD, 1990, P NATL ACAD SCI USA, V87, P9358, DOI 10.1073/pnas.87.23.9358; RUSSO G, 1988, CELL, V53, P137, DOI 10.1016/0092-8674(88)90495-3; RUSSO G, 1989, P NATL ACAD SCI USA, V86, P602, DOI 10.1073/pnas.86.2.602; Sambrook J, 1989, MOL CLONING LAB MANU; SAVAGE PD, 1988, CYTOGENET CELL GENET, V49, P289, DOI 10.1159/000132680; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; STAATS J, 1981, MOUSE BIOCH RES, P177; STERN MH, 1993, ONCOGENE, V8, P2475; TAYLOR AM, 1992, ATAXIA TELANGIECTASI, P53; VIRGILIO L, 1994, P NATL ACAD SCI USA, V91, P12530, DOI 10.1073/pnas.91.26.12530; VIRGILIO L, 1993, P NATL ACAD SCI USA, V90, P925; WEI S, 1990, CANCER GENET CYTOGEN, V46, P1, DOI 10.1016/0165-4608(90)90002-R; White T.J., 1990, PCR PROTOCOLS GUIDE, P315, DOI [10.1016/0307-4412(91), DOI 10.1016/0307-4412(91)]; WOLF FW, 1994, J BIOL CHEM, V269, P3633	42	32	34	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 21	1997	15	8					919	926		10.1038/sj.onc.1201246	http://dx.doi.org/10.1038/sj.onc.1201246			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XR767	9285687				2022-12-17	WOS:A1997XR76700005
J	Hipp, ML; Bauer, G				Hipp, ML; Bauer, G			Intercellular induction of apoptosis in transformed cells does not depend on p53	ONCOGENE			English	Article						apoptosis; p53; TGF-beta	WILD-TYPE P53; BETA-INDUCED ELIMINATION; DNA STRAND BREAKS; TUMOR-SUPPRESSOR; TGF-BETA; P53-DEPENDENT APOPTOSIS; INDEPENDENT PATHWAYS; BCL-2 PROTEINS; CYCLE CONTROL; IN-VIVO	Transformed fibroblast from p53 null/null mice were tested for their sensitivity to intercellular induction of apoptosis by TGF-beta-treated nontransformed cells. They were found to be as sensitive as p53-positive transformed cells. Based on morphological criteria, detection of chromatin condensation and DNA strand breaks, death of p53-negative transformed cells was due to apoptosis. p53-negative nontransformed cells were as efficient in the induction of apoptosis in transformed cells as p53-positive nontransformed cells. These data show that intercellular induction of apoptosis in transformed cells does not depend on functional p53. Therefore it may be assumed that mutations of p53 or modulation of its concentration are without relevance for this particular aspect of control of oncogenesis.	UNIV FREIBURG,ABT VIROL,INST MED MIKROBIOL & HYG,D-79104 FREIBURG,GERMANY	University of Freiburg								BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BAND V, 1993, EMBO J, V12, P1847, DOI 10.1002/j.1460-2075.1993.tb05833.x; BASSLER D, 1997, IN PRESS EXP CELL RE; BAUER G, 1982, J BIOL CHEM, V257, P1405; BAUER G, 1995, INT J ONCOL, V6, P1227; Bauer G, 1996, HISTOL HISTOPATHOL, V11, P237; BECK E, 1997, IN PRESS EXP CELL RE; BRONNER MP, 1995, AM J PATHOL, V146, P20; CHIOU SK, 1994, MOL CELL BIOL, V14, P2556, DOI 10.1128/MCB.14.4.2556; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; Descalzo AM, 1997, INT J ONCOL, V10, P765; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; ELEIRY WS, 1994, CANCER RES, V54, P1169; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FRITSCHE M, 1993, ONCOGENE, V8, P307; GAUKROGER JM, 1993, J GEN VIROL, V74, P2275, DOI 10.1099/0022-1317-74-10-2275; GORCZYCA W, 1993, CANCER RES, V53, P1945; GOTTLIEB E, 1994, EMBO J, V13, P1368, DOI 10.1002/j.1460-2075.1994.tb06390.x; GOTZ C, 1995, INT J ONCOL, V6, P1129; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; GREENBLATT MS, 1994, CANCER RES, V54, P4855; GU ZM, 1994, ONCOGENE, V9, P629; Hackenjos K, 1996, ONCOL REP, V3, P27; HAVRE PA, 1995, CANCER RES, V55, P4420; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; JURGENSMEIER JM, 1994, CANCER RES, V54, P393; JURGENSMEIER JM, 1997, IN PRESS INT J CANC; Kinzler KW, 1996, NATURE, V379, P19, DOI 10.1038/379019a0; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; Langer C, 1996, EXP CELL RES, V222, P117, DOI 10.1006/excr.1996.0015; LIEBERMANN DA, 1995, ONCOGENE, V11, P199; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; Melchinger W, 1996, INT J ONCOL, V9, P927; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MIYASHITA T, 1994, ONCOGENE, V9, P1799; MYASHITA T, 1995, CELL, V80, P293; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; PAN HC, 1995, GENE DEV, V9, P2157, DOI 10.1101/gad.9.17.2157; Panse J, 1997, CARCINOGENESIS, V18, P259, DOI 10.1093/carcin/18.2.259; PICHT G, 1995, EXP CELL RES, V218, P71, DOI 10.1006/excr.1995.1132; RADINSKY R, 1994, ONCOGENE, V9, P1877; RAMQVIST T, 1993, ONCOGENE, V8, P1495; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; SABBATINI P, 1995, MOL CELL BIOL, V15, P1060; SCHAEFER D, 1995, INT J CANCER, V60, P520, DOI 10.1002/ijc.2910600416; STRASSER A, 1994, CELL, V79, P329, DOI 10.1016/0092-8674(94)90201-1; SUBRAMANIAN T, 1995, CELL GROWTH DIFFER, V6, P131; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; WEHRLE I, 1994, INT J ONCOL, V5, P1341; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; YONISHROUACH E, 1993, MOL CELL BIOL, V13, P1415, DOI 10.1128/MCB.13.3.1415	60	32	34	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 14	1997	15	7					791	797		10.1038/sj.onc.1201247	http://dx.doi.org/10.1038/sj.onc.1201247			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XQ117	9266965				2022-12-17	WOS:A1997XQ11700005
J	Jiang, JG; Chen, QY; Bell, A; Zarnegar, R				Jiang, JG; Chen, QY; Bell, A; Zarnegar, R			Transcriptional regulation of the hepatocyte growth factor (HGF) gene by the Sp family of transcription factors	ONCOGENE			English	Article						hepatocyte growth factor (HGF); transcription; promoter; SP1; SP3	FACTOR-SCATTER-FACTOR; C-MET PROTOONCOGENE; FACTOR/SCATTER FACTOR; EPITHELIAL-CELLS; HEPATOPOIETIN-A; MESSENGER-RNA; EXPRESSION; RECEPTOR; PROMOTER; ACTIVATION	In this study, we have localized an enhancer element in the 5'-flanking region of the HGF gene promoter and have identified its functional transcriptional factors. Through transient transfection of NIH3T3 fibroblast cells and gel mobility shift assays, the functional binding site was localized to a short region (-318 to -303 bp from the transcription start site) which has a CTCCC sequence. This motif is also conserved in the human HGF promoter and acts as a binding site for the Sp family of transcription factors. In the presence of NIH3T3 nuclear protein extracts, this enhancer region formed specific DNA-protein complexes which were totally abrogated by excess amounts of consensus Spl oligonucleotide. In gel mobility supershift assays, anti-Sp1 and anti-Sp3 antibodies specifically recognized these complexes as was evident by their slower migration. Site-specific mutation of this binding motif resulted in total loss of Sp1 and Sp3 binding and a concomitant loss of enhancer function within the context of the HGF promoter. Furthermore, in transient cotransfection assays, overexpression of Sp1 and/or Sp3 stimulated HGF promoter activity independently and additively through binding to the Sp1 binding site in the HGF gene promoter region. DNaseI hypersensitive analysis of freshly isolated nuclei from NIH3T3 cells revealed that five hypersensitive sites (HSS) are present within the 2 kb region immediately upstream of the HGF promoter. One of these sites was mapped to position -0.3 kb from the transcription start site. These data show that both Sp1 and Sp3 transcription factors upregulate HGF promoter activity by binding to the Sp1 binding site at position -318 to -303 bp in the HGF gene promoter.	UNIV PITTSBURGH,SCH MED,DEPT PATHOL,DIV CELLULAR & MOL PATHOL,PITTSBURGH,PA 15261	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh			Jiang, Jie-Gen/K-3845-2019		NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES006109] Funding Source: NIH RePORTER; NIEHS NIH HHS [R01ES06109] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; ARAVAMUDAN B, 1993, BIOCHEM BIOPH RES CO, V195, P346, DOI 10.1006/bbrc.1993.2050; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; BURATOWSKI S, 1995, SCIENCE, V270, P1773, DOI 10.1126/science.270.5243.1773; BURKOWITZ EA, 1996, ONCOGENE, V12, P1991; BUSSOLINO F, 1992, J CELL BIOL, V119, P629, DOI 10.1083/jcb.119.3.629; CHI TH, 1995, NATURE, V377, P254, DOI 10.1038/377254a0; DEFRANCES MC, 1992, DEVELOPMENT, V116, P388; DENNIG J, 1995, J BIOL CHEM, V270, P12737, DOI 10.1074/jbc.270.21.12737; EBERT M, 1994, CANCER RES, V54, P5775; FISCHER KD, 1993, J BIOL CHEM, V268, P23915; GHERARDI E, 1989, P NATL ACAD SCI USA, V86, P5844, DOI 10.1073/pnas.86.15.5844; GIDONI D, 1984, NATURE, V312, P409, DOI 10.1038/312409a0; GOLDBERG ID, 1995, EPITHELIAL MESENCHYM; GUALBERTO A, 1995, J BIOL CHEM, V270, P19680, DOI 10.1074/jbc.270.34.19680; HAGEN G, 1992, NUCLEIC ACIDS RES, V20, P5519, DOI 10.1093/nar/20.21.5519; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; Hino M, 1996, BRIT J CANCER, V73, P119, DOI 10.1038/bjc.1996.22; Jeffers M, 1996, ONCOGENE, V13, P853; Jiang JG, 1997, J BIOL CHEM, V272, P3928, DOI 10.1074/jbc.272.7.3928; JUNG W, 1994, J CELL BIOL, V126, P485, DOI 10.1083/jcb.126.2.485; KADONAGA JT, 1986, TRENDS BIOCHEM SCI, V11, P20, DOI 10.1016/0968-0004(86)90226-4; KINGSLEY C, 1992, MOL CELL BIOL, V12, P4251, DOI 10.1128/MCB.12.10.4251; KONO S, 1992, BIOCHEM BIOPH RES CO, V186, P991, DOI 10.1016/0006-291X(92)90844-B; Liang YX, 1996, J BIOL CHEM, V271, P11792, DOI 10.1074/jbc.271.20.11792; Lin SY, 1996, MOL CELL BIOL, V16, P1668; LINDROOS PM, 1991, HEPATOLOGY, V13, P743, DOI 10.1002/hep.1840130422; LIU YH, 1994, J BIOL CHEM, V269, P4152; Maier JAM, 1996, INT J CANCER, V65, P168, DOI 10.1002/(SICI)1097-0215(19960117)65:2<168::AID-IJC7>3.0.CO;2-X; MATSUMOTO K, 1991, EXP CELL RES, V196, P114, DOI 10.1016/0014-4827(91)90462-4; Matsumoto K, 1996, J BIOCHEM-TOKYO, V119, P591; MERIKA M, 1995, MOL CELL BIOL, V15, P2437; MIYAZAWA K, 1991, BIOCHEMISTRY-US, V30, P9170, DOI 10.1021/bi00102a007; MONTESANO R, 1991, CELL, V67, P901, DOI 10.1016/0092-8674(91)90363-4; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; OKAJIMA A, 1993, EUR J BIOCHEM, V213, P113, DOI 10.1111/j.1432-1033.1993.tb17740.x; PLASCHKESCHLUTTER A, 1995, J BIOL CHEM, V270, P830, DOI 10.1074/jbc.270.2.830; RONG S, 1993, CANCER RES, V53, P5355; RONG S, 1994, P NATL ACAD SCI USA, V91, P4731, DOI 10.1073/pnas.91.11.4731; Rosen EM, 1996, INT J CANCER, V67, P248, DOI 10.1002/(SICI)1097-0215(19960717)67:2<248::AID-IJC16>3.0.CO;2-7; ROSEN EM, 1990, P SOC EXP BIOL MED, V195, P34; ROSEN EM, 1994, J CELL BIOL, V127, P1783, DOI 10.1083/jcb.127.6.1783; RUBIN JS, 1991, P NATL ACAD SCI USA, V88, P415, DOI 10.1073/pnas.88.2.415; RUBIN JS, 1993, BIOCHIM BIOPHYS ACTA, V1155, P357, DOI 10.1016/0304-419X(93)90015-5; SAFFER JD, 1990, GENE DEV, V4, P659, DOI 10.1101/gad.4.4.659; SAUER F, 1995, SCIENCE, V270, P1825, DOI 10.1126/science.270.5243.1825; SCHMIDT C, 1995, NATURE, V373, P699, DOI 10.1038/373699a0; SETO E, 1993, NATURE, V365, P462, DOI 10.1038/365462a0; SONNENBERG E, 1993, J CELL BIOL, V123, P223, DOI 10.1083/jcb.123.1.223; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; STOKER M, 1991, FEBS LETT, V291, P229; Takayama H, 1996, P NATL ACAD SCI USA, V93, P5866, DOI 10.1073/pnas.93.12.5866; TSARFATY I, 1994, SCIENCE, V263, P98, DOI 10.1126/science.7505952; UEHARA Y, 1995, NATURE, V373, P702, DOI 10.1038/373702a0; UEHARA Y, 1992, J CELL BIOL, V117, P889, DOI 10.1083/jcb.117.4.889; WAGNER S, 1994, CURR OPIN CELL BIOL, V6, P410, DOI 10.1016/0955-0674(94)90034-5; WEIDNER KM, 1990, J CELL BIOL, V111, P2097, DOI 10.1083/jcb.111.5.2097; ZARNEGAR R, 1995, J CELL BIOL, V129, P1177, DOI 10.1083/jcb.129.5.1177; ZARNEGAR R, 1989, CANCER RES, V49, P3314; Zarnegar R., 1995, V74, P33	60	32	34	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 26	1997	14	25					3039	3049		10.1038/sj.onc.1201152	http://dx.doi.org/10.1038/sj.onc.1201152			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XG100	9223667				2022-12-17	WOS:A1997XG10000006
J	Urich, M; Senften, M; Shaw, PE; BallmerHofer, K				Urich, M; Senften, M; Shaw, PE; BallmerHofer, K			A role for the small GTPase Rac in polyomavirus middle-T antigen-mediated activation of the serum response element and in cell transformation	ONCOGENE			English	Article						polyomavirus; middle-T; cell transformation; serum response element; transcription; fos	ACTIN STRESS FIBERS; MAP KINASE KINASE; C-FOS PROMOTER; TUMOR-ANTIGEN; PROTEIN-KINASE; GROWTH-FACTOR; PHOSPHATIDYLINOSITOL 3-KINASE; TYROSINE PHOSPHORYLATION; TRANSCRIPTIONAL ACTIVITY; PLASMA-MEMBRANE	The oncogenic proteins encoded by papovaviruses, the tumor antigens, have been extensively used as model systems to study mitogenic signaling and cell transformation, These proteins stimulate cell growth in cultured cells and induce tumors in virus infected or transgenic animals, One of these proteins, polyomavirus middle-T, acts like a constitutively activated tyrosine growth factor receptor, Middle-T recruits several cellular enzymes into a multifunctional complex located at cellular membranes, This results in the activation of cellular enzymes involved in the regulation of cell signaling, like tyrosine kinases of the Src family, a phosphatidylinositol 3-kinase and a GDP/GTP exchange factor for Ras, These activities are all required for stimulation of cell growth by middle-T and activate members of the MAP kinase family, Here we investigate the role of T antigen-activated pathways in the stimulation of transcription of immediate early genes, These genes are essential for progression of resting cells into S phase, Our data show that Rho family GTPases play an essential role in cell transformation by middle-T. Furthermore, we demonstrate that the c-fos promoter is activated by two Pas-initiated signaling cascades, One is Raf-dependent and requires binding of SHC and PI 3-kinase to the middle-T complex, This pathway signals via ternary complex factor (TCF) to the serum response element (SRE) of the c-fos promoter, Signaling to TCF by Raf also depends on functional Pac, but not CDC42, as demonstrated in luciferase reporter assays with an ETS domain-containing promoter, The second pathway is Raf-independent, does not require SHC but functional PI 3-kinase, and transduces signals via Pac to serum response factor (SRF), Microinjection of dominant negative Rad blocks nuclear translocation of ERK1 in middle-T-expressing cells, This lends support to the idea that the two signaling cascades initiated by Pas show crosstalk at the level of MAP kinase-mediated signaling to nuclear transcription factors.	FRIEDRICH MIESCHER INST,CH-4002 BASEL,SWITZERLAND; UNIV NOTTINGHAM,QUEENS MED CTR,DEPT BIOCHEM,NOTTINGHAM NG7 2UH,ENGLAND	Friedrich Miescher Institute for Biomedical Research; University of Nottingham				Ballmer-Hofer, Kurt/0000-0002-3800-9129; SHAW, Peter/0000-0002-2598-4283				Besser D, 1995, ONCOGENE, V11, P2383; CAMPBELL KS, 1994, P NATL ACAD SCI USA, V91, P6344, DOI 10.1073/pnas.91.14.6344; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; COURTNEIDGE SA, 1986, CANCER SURV, V5, P173; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DILWORTH SM, 1994, NATURE, V367, P87, DOI 10.1038/367087a0; Dilworth Stephen M., 1995, Trends in Microbiology, V3, P31, DOI 10.1016/S0966-842X(00)88866-6; FREED E, 1994, SCIENCE, V265, P1713, DOI 10.1126/science.8085158; FROST JA, 1994, MOL CELL BIOL, V14, P6244, DOI 10.1128/MCB.14.9.6244; FU H, 1994, SCIENCE, V266, P126, DOI 10.1126/science.7939632; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; HILL CS, 1993, CELL, V73, P395, DOI 10.1016/0092-8674(93)90238-L; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; IRIE K, 1994, SCIENCE, V265, P1716, DOI 10.1126/science.8085159; JANKNECHT R, 1995, CARCINOGENESIS, V16, P443, DOI 10.1093/carcin/16.3.443; JELINEK MA, 1992, ONCOGENE, V7, P1687; Joneson T, 1996, SCIENCE, V271, P810, DOI 10.1126/science.271.5250.810; KAPELLER R, 1994, BIOESSAYS, V16, P565, DOI 10.1002/bies.950160810; KORTENJANN M, 1994, MOL CELL BIOL, V14, P4815, DOI 10.1128/MCB.14.7.4815; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LI SF, 1995, EMBO J, V14, P685, DOI 10.1002/j.1460-2075.1995.tb07047.x; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARAIS R, 1995, EMBO J, V14, P3136, DOI 10.1002/j.1460-2075.1995.tb07316.x; MCCORMICK F, 1994, CURR OPIN GENET DEV, V4, P71, DOI 10.1016/0959-437X(94)90093-0; Messerschmitt A, 1996, J GEN VIROL, V77, P17, DOI 10.1099/0022-1317-77-1-17; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MORAN E, 1993, CURR OPIN GENET DEV, V3, P63, DOI 10.1016/S0959-437X(05)80342-9; NEVINS JR, 1994, CURR OPIN GENET DEV, V4, P130, DOI 10.1016/0959-437X(94)90101-5; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; NORMAN C, 1988, CELL, V55, P989, DOI 10.1016/0092-8674(88)90244-9; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; PALLAS DC, 1994, SCIENCE, V265, P535, DOI 10.1126/science.8036498; PALLAS DC, 1990, CELL, V60, P167, DOI 10.1016/0092-8674(90)90726-U; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; RASSOULZADEGAN M, 1982, NATURE, V300, P713, DOI 10.1038/300713a0; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SHAW PE, 1989, CELL, V56, P563, DOI 10.1016/0092-8674(89)90579-5; SONTAG E, 1993, CELL, V75, P887, DOI 10.1016/0092-8674(93)90533-V; SRINIVAS S, 1994, P NATL ACAD SCI USA, V91, P10064, DOI 10.1073/pnas.91.21.10064; SU W, 1995, J BIOL CHEM, V270, P12331, DOI 10.1074/jbc.270.21.12331; Tooze J, 1980, DNA TUMOR VIRUSES; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; URICH M, 1995, J BIOL CHEM, V270, P29286, DOI 10.1074/jbc.270.49.29286; VARTICOVSKI L, 1994, BBA-MOL BASIS DIS, V1226, P1, DOI 10.1016/0925-4439(94)90051-5; WALTER G, 1990, P NATL ACAD SCI USA, V87, P2521, DOI 10.1073/pnas.87.7.2521; WHITMAN M, 1985, NATURE, V315, P239, DOI 10.1038/315239a0	54	32	34	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR 13	1997	14	10					1235	1241		10.1038/sj.onc.1200982	http://dx.doi.org/10.1038/sj.onc.1200982			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WM782	9121774				2022-12-17	WOS:A1997WM78200014
J	Trecca, D; Guerrini, L; Fracchiolla, NS; Pomati, M; Baldini, L; Maiolo, AT; Neri, A				Trecca, D; Guerrini, L; Fracchiolla, NS; Pomati, M; Baldini, L; Maiolo, AT; Neri, A			Identification of a tumor-associated mutant form of the NF-kappa B RelA gene with reduced DNA-binding and transactivating activities	ONCOGENE			English	Article						NF-kappa B; RelA; transcriptional activity; lymphoid malignancies	P65 SUBUNIT; TRANSCRIPTION FACTOR; LYMPHOID MALIGNANCIES; ANTISENSE INHIBITION; MULTIPLE-MYELOMA; MAMMALIAN-CELLS; C-REL; ACTIVATION; EXPRESSION; PROTEINS	Alterations of NF-kappa B family members have been found to be associated with various forms of lymphoid malignancies. In order to determine whether alterations of the RelA gene are involved in lymphomagenesis, we analysed a large and representative panel (200 cases) of such tumors. Southern blot analysis did not reveal any rearrangements or locus amplification, suggesting that structural alterations of the RelA gene may represent rare events in lymphoid neoplasia. By means of PCR-SSCP analysis, we were able to identify a single point mutation leading to amino acid substitution (codon 494, Glu-Asp) in the transactivating (TA) domain in one case of multiple myeloma. The mutated allele was expressed in the pathological bone marrow sample but not in the peripheral blood cells of the patient. We demonstrate that the RelA protein carrying this specific mutation (called RelA(494D)) has less transactivating ability than the normal RelA protein. Interestingly, the mutated protein has a lower affinity for kappa B binding sites both as a homodimer or in association with the NFKB1/p50 subunit. Transfection experiments using a Ga14-RelA(494D) fusion protein indicated that the mutation does not alter the intrinsic transactivating ability of the TA domain of ReLA. Furthermore, in vitro translated RelA(494D) is able to dimerize efficiently with other NF-kappa B members, such as p50, cREL and I kappa B alpha. Our data therefore suggest that this mutation may alter the specific structural conformation needed for the DNA interaction of RelA, and provide insights into the amino acid sequences involved in mediating the biological activities of RelA.	UNIV MILAN,OSPED MAGGIORE,SERV EMATOL,IST SCI MED,IRCCS,LAB EMATOL SPERIMENTALE & GENET MOL,I-20122 MILAN,ITALY; UNIV MILAN,DIPARTIMENTO GENET & BIOL MICROORGANISMI,MILAN,ITALY	IRCCS Ca Granda Ospedale Maggiore Policlinico; University of Milan; University of Milan			Neri, Antonino/I-9690-2014; Fracchiolla, Nicola Stefano/K-1915-2015	Neri, Antonino/0000-0001-9047-5912; Fracchiolla, Nicola Stefano/0000-0002-5356-8690; Critelli, Salvatore/0000-0001-7325-0228; Baldini, Luca/0000-0003-2964-9981; Fracchiolla, Nicola/0000-0002-8982-8079				BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BALLARD DW, 1988, SCIENCE, V241, P1652, DOI 10.1126/science.2843985; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; BLAIR WS, 1994, MOL CELL BIOL, V14, P7226, DOI 10.1128/MCB.14.11.7226; BOSE HR, 1992, BIOCHIM BIOPHYS ACTA, V1114, P1, DOI 10.1016/0304-419X(92)90002-G; CHANG CC, 1994, ONCOGENE, V9, P923; DELOUKAS P, 1993, HUM MOL GENET, V2, P1895, DOI 10.1093/hmg/2.11.1895; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FRACCHIOLLA NS, 1993, ONCOGENE, V8, P2839; GANCHI PA, 1992, MOL BIOL CELL, V3, P1339, DOI 10.1091/mbc.3.12.1339; GILMORE TD, 1991, TRENDS GENET, V7, P318, DOI 10.1016/0168-9525(91)90421-L; GRECO A, 1992, ONCOGENE, V7, P237; GRILLI M, 1993, INT REV CYTOL, V143, P1; GRIMM S, 1994, ONCOGENE, V9, P2391; HANSEN SK, 1994, J BIOL CHEM, V269, P22230; HANSEN SK, 1992, EMBO J, V11, P205, DOI 10.1002/j.1460-2075.1992.tb05043.x; HIGGINS KA, 1993, P NATL ACAD SCI USA, V90, P9901, DOI 10.1073/pnas.90.21.9901; Houldsworth J, 1996, BLOOD, V87, P25; IKEDA T, 1993, GENE, V133, P237, DOI 10.1016/0378-1119(93)90645-J; KITAJIMA I, 1992, SCIENCE, V258, P1792, DOI 10.1126/science.1299224; LAI JL, 1995, BLOOD, V85, P2490, DOI 10.1182/blood.V85.9.2490.bloodjournal8592490; LIOU HC, 1994, MOL CELL BIOL, V14, P5349, DOI 10.1128/MCB.14.8.5349; LOMBARDI L, 1995, NUCLEIC ACIDS RES, V23, P2328, DOI 10.1093/nar/23.12.2328; LU D, 1991, ONCOGENE, V6, P1235; MATHEW S, 1993, ONCOGENE, V8, P191; MIGLIAZZA A, 1994, BLOOD, V84, P3850, DOI 10.1182/blood.V84.11.3850.bloodjournal84113850; MOORE PA, 1993, MOL CELL BIOL, V13, P1666, DOI 10.1128/MCB.13.3.1666; MOTOKURA T, 1993, CURR OPIN GENET DEV, V3, P5, DOI 10.1016/S0959-437X(05)80334-X; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; NARAYANAN R, 1992, SCIENCE, V256, P367, DOI 10.1126/science.256.5055.367; NERI A, 1991, CELL, V67, P1075, DOI 10.1016/0092-8674(91)90285-7; NERI A, 1993, BLOOD, V81, P128; NOLAN GP, 1994, CELL, V77, P795, DOI 10.1016/0092-8674(94)90126-0; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; OHNO H, 1990, CELL, V60, P991, DOI 10.1016/0092-8674(90)90347-H; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; RUBEN SM, 1992, MOL CELL BIOL, V12, P444, DOI 10.1128/MCB.12.2.444; RUBEN SM, 1991, SCIENCE, V251, P1490, DOI 10.1126/science.2006423; SADOWSKI I, 1989, NUCLEIC ACIDS RES, V17, P7539, DOI 10.1093/nar/17.18.7539; Sambrook J, 1989, MOL CLONING LAB MANU; SCHMITZ ML, 1991, EMBO J, V10, P3805, DOI 10.1002/j.1460-2075.1991.tb04950.x; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; SOKOLOSKI JA, 1993, BLOOD, V82, P625; VANDENBERGHE H, 1979, CANCER, V44, P179; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723	45	32	32	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB 20	1997	14	7					791	799		10.1038/sj.onc.1200895	http://dx.doi.org/10.1038/sj.onc.1200895			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WJ112	9047386				2022-12-17	WOS:A1997WJ11200005
J	Horton, LE; Templeton, DJ				Horton, LE; Templeton, DJ			The cyclin box and C-terminus of cyclins A and E specify CDK activation and substrate specificity	ONCOGENE			English	Article						cell cycle; cyclins; cyclin dependent kinase; lamin B	RETINOBLASTOMA GENE-PRODUCT; PROTEIN-KINASE; CELL-CYCLE; DEPENDENT KINASE-2; CRYSTAL-STRUCTURE; S-PHASE; BINDING; CDC2; PHOSPHORYLATION; EXPRESSION	The cyclins and their catalytic partners, the Cyclin Dependent Kinases (CDKs), are essential for progression through the cell cycle. Cyclin/kinase complexes containing cyclins A or E are active primarily in Late G(1) to S phase and both have been shown to phosphorylate histone H1 and the retinoblastoma gene product (pRb) in vitro. Despite these similarities, cyclins A and E display differences in CDK activation and substrate specificity. We find that in vitro, cyclin E/CDK2 and cyclin A/CDK2 phosphorylate histone H1 similarly but only cyclin A/CDK2 phosphorylates lamin B. While both cyclin A and cyclin E bind CDK1 efficiently, only cyclin A activates CDK1 kinase activity. Using chimeric proteins between cyclins A and E we find that both the cyclin box and C-terminus of cyclins A and E are required for CDK binding, activation and targeting of substrate specificity.	CASE WESTERN RESERVE UNIV,SCH MED,INST PATHOL,CLEVELAND,OH 44106; CASE WESTERN RESERVE UNIV,SCH MED,CELL BIOL PROGRAM,CLEVELAND,OH 44106	Case Western Reserve University; Case Western Reserve University			Templeton, Dennis J/F-7695-2011		NCI NIH HHS [CA-55719] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA055719] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		DEBONDT HL, 1993, NATURE, V363, P595, DOI 10.1038/363595a0; DESAI D, 1995, MOL CELL BIOL, V15, P345, DOI 10.1128/MCB.15.1.345; DUCOMMUN B, 1991, EMBO J, V10, P3311, DOI 10.1002/j.1460-2075.1991.tb04895.x; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; DYNLACHT BD, 1994, GENE DEV, V8, P1772, DOI 10.1101/gad.8.15.1772; ELLEDGE SJ, 1991, EMBO J, V10, P2653, DOI 10.1002/j.1460-2075.1991.tb07808.x; ELLEDGE SJ, 1992, P NATL ACAD SCI USA, V89, P2907, DOI 10.1073/pnas.89.7.2907; ELROYSTEIN O, 1989, P NATL ACAD SCI USA, V86, P6126, DOI 10.1073/pnas.86.16.6126; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FANG F, 1991, CELL, V66, P731, DOI 10.1016/0092-8674(91)90117-H; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HORTON LE, 1995, CELL GROWTH DIFFER, V6, P395; Hunt T, 1989, CURR OPIN CELL BIOL, V1, P268, DOI 10.1016/0955-0674(89)90099-9; Hunt T, 1991, Semin Cell Biol, V2, P213; JEFFREY PD, 1995, NATURE, V376, P313, DOI 10.1038/376313a0; KOBAYASHI H, 1992, MOL BIOL CELL, V3, P1279, DOI 10.1091/mbc.3.11.1279; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; LEES EM, 1993, MOL CELL BIOL, V13, P1194, DOI 10.1128/MCB.13.2.1194; MARSHALL CJ, 1994, NATURE, V367, P24; McKeon F, 1991, CURR OPIN CELL BIOL, V3, P82, DOI 10.1016/0955-0674(91)90169-Y; MOSS B, 1990, NATURE, V348, P91, DOI 10.1038/348091a0; NAYSMITH K, 1993, CURR OPIN CELL BIOL, V5, P166; NUGENT JHA, 1991, J CELL SCI, V99, P669; PAGANO M, 1993, J CELL BIOL, V121, P101, DOI 10.1083/jcb.121.1.101; Pines J, 1991, Trends Cell Biol, V1, P117, DOI 10.1016/0962-8924(91)90116-Q; PINES J, 1994, EMBO J, V13, P3772, DOI 10.1002/j.1460-2075.1994.tb06688.x; PINES J, 1993, TRENDS BIOCHEM SCI, V18, P195, DOI 10.1016/0968-0004(93)90185-P; QIAN YY, 1992, MOL CELL BIOL, V12, P5363, DOI 10.1128/MCB.12.12.5363; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; RESNITZKY D, 1995, MOL CELL BIOL, V15, P4347; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; ROSE JK, 1991, BIOTECHNIQUES, V10, P520; ROSENBLATT J, 1992, P NATL ACAD SCI USA, V89, P2824, DOI 10.1073/pnas.89.7.2824; ROY LM, 1991, J CELL BIOL, V113, P507, DOI 10.1083/jcb.113.3.507; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; Solomon MJ, 1993, CURR OPIN CELL BIOL, V5, P180, DOI 10.1016/0955-0674(93)90100-5; TAYLOR SS, 1993, TRENDS BIOCHEM SCI, V18, P84, DOI 10.1016/0968-0004(93)80001-R; TEMPLETON DJ, 1991, P NATL ACAD SCI USA, V88, P3033, DOI 10.1073/pnas.88.8.3033; TEMPLETON DJ, 1992, MOL CELL BIOL, V12, P435, DOI 10.1128/MCB.12.2.435; TSAI LH, 1993, ONCOGENE, V8, P1593; UCHIDA S, 1990, MOL CELL BIOL, V10, P577, DOI 10.1128/MCB.10.2.577; WANG Y, 1995, NATURE, V376, P88, DOI 10.1038/376088a0; ZHANG FM, 1993, J MOL BIOL, V233, P550, DOI 10.1006/jmbi.1993.1532; ZHENG JH, 1993, BIOCHEMISTRY-US, V32, P2154, DOI 10.1021/bi00060a005	47	32	33	2	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 30	1997	14	4					491	498		10.1038/sj.onc.1200851	http://dx.doi.org/10.1038/sj.onc.1200851			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WE364	9053846				2022-12-17	WOS:A1997WE36400012
J	Thomas, M; Massimi, P; Banks, L				Thomas, M; Massimi, P; Banks, L			HPV-18 E6 inhibits p53 DNA binding activity regardless of the oligomeric state of p53 or the exact p53 recognition sequence	ONCOGENE			English	Article						p53; HPV; DNA binding; TBP	WILD-TYPE P53; HUMAN PAPILLOMAVIRUS TYPE-16; CYCLIN-DEPENDENT KINASES; CARCINOMA CELL-LINES; C-TERMINAL DOMAIN; TRANSCRIPTIONAL ACTIVATION; GENE-EXPRESSION; IN-VITRO; GROWTH ARREST; MUTANT P53	The E6 proteins of the oncogenic-associated human papillomavirus types 16 (HPV-16) and 18 (HPV-18) function by interfering with the normal cell cycle control mechanisms, particularly those controlled by p53. HPV E6 is able to interfere with p53 function by preventing its binding to DNA target sequences and also by labelling p53 for ubiquitin-mediated degradation. We have previously reported that certain p53 mutants, defective in oligomerisation, vary in their susceptibility to E6-directed labelling for ubiquitin-mediated degradation. In this paper we report that the strength of p53's binding to DNA is dependent upon the precise target sequence, but that E6 is able to disrupt each complex. We also report the binding of different oligomeric forms of p53 to different DNA sequences and correlate this with in vivo transcriptional activity and demonstrate the susceptibility of that DNA binding to disruption by E6. Finally we show that the ability of p53 to bind to TBP is a function of its oligomeric state and correlates in part with its ability to transrepress but not with its ability to transactivate.			Thomas, M (corresponding author), INT CTR GENET ENGN & BIOTECHNOL, PADRICIANO 99, I-34012 TRIESTE, ITALY.							AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; ALONIGRINSTEIN R, 1995, EMBO J, V14, P1392, DOI 10.1002/j.1460-2075.1995.tb07125.x; BANKS L, 1986, EUR J BIOCHEM, V159, P529, DOI 10.1111/j.1432-1033.1986.tb09919.x; BARAK Y, 1994, GENE DEV, V8, P1739, DOI 10.1101/gad.8.15.1739; CHEN XB, 1993, GENE DEV, V7, P1837, DOI 10.1101/gad.7.10.1837; CLORE GM, 1994, SCIENCE, V265, P386, DOI 10.1126/science.8023159; CROOK T, 1991, ONCOGENE, V6, P873; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELDEIRY WS, 1995, CANCER RES, V55, P2910; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; HAINAUT P, 1993, CANCER RES, V53, P4469; HARPER JW, 1993, CELL, V75, P805; Hecker D, 1996, ONCOGENE, V12, P953; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P4918, DOI 10.1128/MCB.13.8.4918; HUIBREGTSE JM, 1991, EMBO J, V10, P4129, DOI 10.1002/j.1460-2075.1991.tb04990.x; HUPP TR, 1995, CELL, V83, P237, DOI 10.1016/0092-8674(95)90165-5; HUPP TR, 1993, NUCLEIC ACIDS RES, V21, P3167, DOI 10.1093/nar/21.14.3167; JAYARAMAN L, 1995, CELL, V81, P1021, DOI 10.1016/S0092-8674(05)80007-8; JUVEN T, 1993, ONCOGENE, V8, P3411; KEMP CJ, 1993, CELL, V74, P813, DOI 10.1016/0092-8674(93)90461-X; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KESSIS TD, 1993, P NATL ACAD SCI USA, V90, P3988, DOI 10.1073/pnas.90.9.3988; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LECHNER MS, 1992, EMBO J, V11, P3045, DOI 10.1002/j.1460-2075.1992.tb05375.x; LECHNER MS, 1994, J VIROL, V68, P4262, DOI 10.1128/JVI.68.7.4262-4273.1994; LEE S, 1995, CELL, V81, P1013, DOI 10.1016/S0092-8674(05)80006-6; LIN D, 1992, P NATL ACAD SCI USA, V89, P9210, DOI 10.1073/pnas.89.19.9210; LIU X, 1995, MOL CELL BIOL, V15, P6474; LIU X, 1993, MOL CELL BIOL, V13, P3291, DOI 10.1128/MCB.13.6.3291; MACK DH, 1993, NATURE, V363, P281, DOI 10.1038/363281a0; MARSTON NJ, 1995, ONCOGENE, V10, P1709; MATLASHEWSKI G, 1987, EMBO J, V6, P1741, DOI 10.1002/j.1460-2075.1987.tb02426.x; MEDCALF EA, 1993, ONCOGENE, V8, P2847; MIETZ JA, 1992, EMBO J, V11, P5013, DOI 10.1002/j.1460-2075.1992.tb05608.x; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; MOLINARI M, 1995, ONCOGENE, V10, P1849; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; PELLEGATA NS, 1995, ONCOGENE, V11, P337; PIM D, 1994, ONCOGENE, V9, P1869; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SHAULIAN E, 1995, ONCOGENE, V10, P671; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; Shaw P, 1996, ONCOGENE, V12, P921; STEWART N, 1995, ONCOGENE, V10, P109; STURZBECHER HW, 1992, ONCOGENE, V7, P1513; SUBLER MA, 1992, J VIROL, V66, P4757, DOI 10.1128/JVI.66.8.4757-4762.1992; TARUNINA M, 1993, ONCOGENE, V8, P3165; THOMAS M, 1995, ONCOGENE, V10, P261; THUKRAL SK, 1995, MOL CELL BIOL, V15, P5196; TRUANT R, 1993, J BIOL CHEM, V268, P2284; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WANG Y, 1995, NATURE, V376, P88, DOI 10.1038/376088a0; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143; ZHANG W, 1994, ONCOGENE, V9, P2513	68	32	32	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 1	1996	13	3					471	480						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VB328	8760288				2022-12-17	WOS:A1996VB32800004
J	Sun, XF; Johannsson, O; Hakansson, S; Sellberg, G; Nordenskjold, B; Olsson, H; Borg, A				Sun, XF; Johannsson, O; Hakansson, S; Sellberg, G; Nordenskjold, B; Olsson, H; Borg, A			A novel p53 germline alteration identified in a late onset breast cancer kindred	ONCOGENE			English	Article						p53; germline mutation; familial breast cancer; Li-Fraumeni syndrome	LI-FRAUMENI SYNDROME; TP53 MUTATIONS; OVARIAN-CANCER; GENE-MUTATIONS; FAMILIES; PREVALENCE; RATES	Germline mutations in the p53 tumor suppressor gene are associated with the Li-Fraumeni syndrome, characterized by childhood sarcoma, leukemia and early onset breast cancer and has occasionally been found also in familial breast-ovarian cancer. Most mutations found are of missense type and located in the central region of the gene (exons 5 to 8). In the present study, a germline p53 alteration was identified in a late onset breast cancer family (kindred Lund 5; mean age 58 years) using single stranded conformation polymorphism and sequence analysis. The mutation (a CCG to CTG transition) at codon 82 in exon 4, resulting in a proline to leucine substitution, has not previously been reported and was not present in a control set of 60 healthy individuals. Three of five woman with breast cancer (45, 57 and 65 years) were carriers of the alteration. Loss of heterozygosity at the p53 locus was not seen in the primary tumors of these women, but appeared as a partial loss of the wildtype allele in subsequent recurrent lesions of two gene carriers. The family manifested no linkage to the p53 gene (a two-point LOD-score of -0.41), and has previously also been excluded for linkage to the BRCA1 and BRCA2 loci, as well as being carrier of a BRCA1 germline mutation. Although it seems unlikely that the p53 germline mutation is the major cause of disease predisposition in Lund 5, the data suggest that some p53 alteration may confer a subtle influence on breast cancer development and progression.	LINKOPING UNIV HOSP,DEPT ONCOL,S-58185 LINKOPING,SWEDEN; UNIV LUND HOSP,DEPT ONCOL,S-22185 LUND,SWEDEN	Linkoping University; Lund University; Skane University Hospital				Olsson, Hakan/0000-0002-8794-9635				BIRCH JM, 1994, CANCER RES, V54, P1298; BORRESEN AL, 1992, CANCER RES, V52, P3234; BORRESEN AL, 1995, GENE CHROMOSOME CANC, V14, P71, DOI 10.1002/gcc.2870140113; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CORNELIS RS, 1995, GENE CHROMOSOME CANC, V13, P203, DOI 10.1002/gcc.2870130310; EASTON DF, 1993, AM J HUM GENET, V52, P678; FREBOURG T, 1995, AM J HUM GENET, V56, P608; HARTMANN A, 1995, ONCOGENE, V10, P681; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Johannsson O, 1996, AM J HUM GENET, V58, P441; JOLLY KW, 1994, ONCOGENE, V9, P97; JONES MH, 1992, GENE CHROMOSOME CANC, V5, P89, DOI 10.1002/gcc.2870050113; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MALKIN D, 1994, BBA-REV CANCER, V1198, P197, DOI 10.1016/0304-419X(94)90014-0; PROSSER J, 1992, BRIT J CANCER, V65, P527, DOI 10.1038/bjc.1992.109; PROSSER J, 1991, BRIT J CANCER, V63, P181, DOI 10.1038/bjc.1991.44; RUSSO CL, 1994, MED PEDIATR ONCOL, V23, P354, DOI 10.1002/mpo.2950230407; SIDRANSKY D, 1992, CANCER RES, V52, P2984; SLINGERLAND JM, 1993, EMBO J, V12, P1029, DOI 10.1002/j.1460-2075.1993.tb05744.x; SOUSSI T, 1990, ONCOGENE, V5, P945; TOGUCHIDA J, 1992, NEW ENGL J MED, V326, P1301, DOI 10.1056/NEJM199205143262001; TORNALETTI S, 1995, ONCOGENE, V10, P1493; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WARREN W, 1992, ONCOGENE, V7, P1043; WOOSTER R, 1994, SCIENCE, V265, P2088, DOI 10.1126/science.8091231	26	32	32	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 18	1996	13	2					407	411						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VA252	8710380				2022-12-17	WOS:A1996VA25200020
J	Kilbey, A; Black, EJ; Unlu, M; Gillespie, DAF				Kilbey, A; Black, EJ; Unlu, M; Gillespie, DAF			The v-Jun oncoprotein replaces p39 c-Jun as the predominant AP-1 constituent in ASV17-transformed fibroblasts: Implications for SAPK/JNK-mediated signal transduction	ONCOGENE			English	Article						v-Jun; AP-1; transformation; SAPK/JNK	CHICKEN-EMBRYO FIBROBLASTS; DNA-BINDING ACTIVITY; TRANSCRIPTIONAL ACTIVATION; MOUSE FIBROBLASTS; G0-TO-G1 TRANSITION; LEUCINE ZIPPER; FOS PROTEINS; TRANSFORMATION; DOMAIN; INVITRO	We have investigated the expression of Jun family proteins and composition of AP-I in chicken embryo fibroblasts before and after transformation by the v-Jun oncoprotein of ASV17, We show that p39 c-Jun is the predominant Jun family protein expressed in normal fibroblasts, and that heterodimers of c-Jun and Fos-related partners (Fra's) account for the majority of the AP-1 DNA binding activity, Unexpectedly, because ASV17-transformed fibroblasts do not express p39 c-Jun, v-Jun replaces c-Jun as the predominant AP-1 constituent in association with similar or identical Fra's, This substitution has little effect on the overall level of TRE-specific DNA binding activity, however it results in a profound reduction in TRE-dependent component of AP-1; whilst agonists of SAPK/JNK kinases trigger transient N-terminal phosphorylation of c-Jun in normal fibroblasts, no corresponding modification of v-Jun occurs in ASV17-transformed cells. Because SAPK/JNK-mediated phosphorylation is thought to regulate c-Jun transcriptional activity and thereby cellular gene expression in response to extracellular signals, we propose that subversion of this signal transduction process by v-Jun is likely to contribute to oncogenesis by ASV17.	BEATSON INST CANC RES,CANC RES CAMPAIGN BEATSON LABS,GLASGOW G61 1BD,LANARK,SCOTLAND	Beatson Institute			Gillespie, David/R-4771-2019	Gillespie, David/0000-0002-6338-0544				Abate C, 1990, Semin Cancer Biol, V1, P19; ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; BAICHWAL VR, 1990, CELL, V63, P815, DOI 10.1016/0092-8674(90)90147-7; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BLACK EJ, 1994, ONCOGENE, V9, P2363; BLACK EJ, 1991, ONCOGENE, V6, P1949; BOHMANN D, 1989, CELL, V59, P709, DOI 10.1016/0092-8674(89)90017-2; BOHMANN D, 1994, CELL, V78, P973, DOI 10.1016/0092-8674(94)90273-9; BOS TJ, 1990, GENE DEV, V4, P1677, DOI 10.1101/gad.4.10.1677; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; CATLING AD, 1993, ONCOGENE, V8, P1875; CROUCH DH, 1990, ONCOGENE, V5, P683; DAI TN, 1995, ONCOGENE, V10, P849; DEAN DC, 1989, MOL CELL BIOL, V9, P1489; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; FRAME MC, 1991, ONCOGENE, V6, P205; GOLDSTONE SD, 1994, ONCOGENE, V9, P2305; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HAAS S, 1995, CARCINOGENESIS, V16, P985, DOI 10.1093/carcin/16.5.985; HADMAN M, 1993, ONCOGENE, V8, P1895; HAVARSTEIN LS, 1992, P NATL ACAD SCI USA, V89, P618, DOI 10.1073/pnas.89.2.618; HAWKER KL, 1993, J VIROL, V67, P5487, DOI 10.1128/JVI.67.9.5487-5495.1993; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HILBERG F, 1993, NATURE, V365, P179, DOI 10.1038/365179a0; JOHNSON RS, 1993, GENE DEV, V7, P1309, DOI 10.1101/gad.7.7b.1309; KARIN MJ, BIOL CHEM, V270, P16483; KATAOKA K, 1994, MOL CELL BIOL, V14, P700, DOI 10.1128/MCB.14.1.700; KOVARY K, 1992, MOL CELL BIOL, V12, P5015, DOI 10.1128/MCB.12.11.5015; KOVARY K, 1991, MOL CELL BIOL, V11, P4466, DOI 10.1128/MCB.11.9.4466; KOVARY K, 1991, MOL CELL BIOL, V11, P2451, DOI 10.1128/MCB.11.5.2451; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LANDSCHULZ WH, 1988, GENE DEV, V2, P786, DOI 10.1101/gad.2.7.786; LAROCCA SA, 1994, ONCOGENE, V9, P3499; LIN AN, 1992, CELL, V70, P777, DOI 10.1016/0092-8674(92)90311-Y; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MASOOD K, 1993, J NEUROCHEM, V61, P160, DOI 10.1111/j.1471-4159.1993.tb03551.x; MATRISIAN LM, 1986, MOL CELL BIOL, V6, P1679, DOI 10.1128/MCB.6.5.1679; MINDEN A, 1994, MOL CELL BIOL, V14, P6683, DOI 10.1128/MCB.14.10.6683; MORGAN IM, 1993, ONCOGENE, V8, P1135; MORGAN IM, 1992, ONCOGENE, V7, P1119; NISHIMURA T, 1988, ONCOGENE, V3, P659; PFARR CM, 1994, CELL, V76, P747, DOI 10.1016/0092-8674(94)90513-4; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; RYSECK RP, 1988, NATURE, V334, P535, DOI 10.1038/334535a0; SCHUTTE J, 1989, P NATL ACAD SCI USA, V86, P2257, DOI 10.1073/pnas.86.7.2257; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; SMEAL T, 1994, EMBO J, V13, P6006, DOI 10.1002/j.1460-2075.1994.tb06946.x; SUZUKI T, 1994, J VIROL, V68, P3527, DOI 10.1128/JVI.68.6.3527-3535.1994; SUZUKI T, 1991, JPN J CANCER RES, V82, P58, DOI 10.1111/j.1349-7006.1991.tb01746.x; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; VANDAM H, 1995, EMBO J, V14, P1798, DOI 10.1002/j.1460-2075.1995.tb07168.x; VOSATKA RJ, 1989, J CELL PHYSIOL, V138, P493, DOI 10.1002/jcp.1041380308	54	32	32	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 6	1996	12	11					2409	2418						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UQ220	8649782				2022-12-17	WOS:A1996UQ22000019
J	Thick, J; Metcalfe, JA; Mak, YF; Beatty, D; Minegishi, M; Dyer, MJS; Lucas, G; Taylor, AMR				Thick, J; Metcalfe, JA; Mak, YF; Beatty, D; Minegishi, M; Dyer, MJS; Lucas, G; Taylor, AMR			Expression of either the TCL1 oncogene, or transcripts from its homologue MTCP1/c6.1B, in leukaemic and non-leukaemic T cells from ataxia telangiectasia patients	ONCOGENE			English	Article						ataxia telangiectasia; MTCP1; TCL1; leukaemia	CHRONIC LYMPHOCYTIC-LEUKEMIA; MOLECULAR ANALYSIS; CHAIN LOCUS; TRANSLOCATION; BREAKPOINT; GENE	Patients with the recessively inherited disorder ataxia telangiectasia (A-T) have a high level of specific chromosome translocations which can be easily observed in peripheral T cells and show a greatly increased predisposition to leukaemia/lymphoma, mainly of T cell origin, Some translocation cells proliferate into a large clone and may develop into T cell prolymphocytic leukaemia (T-PLL), By the time of diagnosis of T-PLL, the clone contains many more genetic changes in the form of additional translocations, T-PLL is also seen in non-A-T individuals where expression of either TCL1 (at 14q32) or the c6.1B/MTCP1 A1 transcript (at-Xq28) has been demonstrated in just a few instances, We show here, that expression of TCL1 occurs in leukaemic T cells from A-T patients with chromosome 14 rearrangements, Expression of TCL1 also occurs in the preleukaemic clone cells of A-T patients containing the primary translocation alone, Some expression of TCL1 could also be detected in randomly selected A-T patients without large cytogenetic clones and without any evidence of leukaemic change, We also show that expression of the B1 transcript from a second gene, MTCP1, occurred at a relatively high level only in two T-PLL tumours from A-T patients with t(X;14) translocations whereas the MTCP1/A1 transcript is much more widely expressed in both tumour and non tumour cells of A-T and non-A-T individuals.	UNIV BIRMINGHAM,SCH MED,INST CANC STUDIES,BIRMINGHAM B15 2TJ,W MIDLANDS,ENGLAND; UNIV CAPE TOWN,RED CROSS WAR MEM CHILDRENS HOSP,DEPT PAEDIAT & CHILD HLTH,RONDEBOSCH 7700,SOUTH AFRICA; TOHOKU UNIV,TB & CANC RES INST,DEPT PAEDIAT,SENDAI,MIYAGI 980,JAPAN; ROYAL CANC HOSP,CANC RES INST,SUTTON SM2 5NG,SURREY,ENGLAND; UNIV WALES COLL CARDIFF,DEPT HAEMATOL,CARDIFF CF4 4XN,S GLAM,WALES	University of Birmingham; University of Cape Town; Tohoku University; University of London; Institute of Cancer Research - UK; Cardiff University			Dyer, Martin/F-2691-2014	Dyer, Martin/0000-0002-5033-2236				BAER R, 1987, P NATL ACAD SCI USA, V84, P9069, DOI 10.1073/pnas.84.24.9069; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; DAVEY MP, 1988, P NATL ACAD SCI USA, V85, P9287, DOI 10.1073/pnas.85.23.9287; FISCH P, 1993, ONCOGENE, V8, P3271; FU TB, 1994, CANCER RES, V54, P6297; GAW LM, 1987, EMBO J, V6, P2273; MADANI A, 1995, ONCOGENE, V10, P2259; MENGLEGAW L, 1988, P NATL ACAD SCI USA, V85, P9171, DOI 10.1073/pnas.85.23.9171; MINEGISHI M, 1991, LEUKEMIA, V5, P88; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; RUSSO G, 1988, CELL, V53, P137, DOI 10.1016/0092-8674(88)90495-3; RUSSO G, 1989, P NATL ACAD SCI USA, V86, P602, DOI 10.1073/pnas.86.2.602; Sedgwick R, 1991, HDB CLIN NEUROLOGY, P347; SHERRINGTON PD, 1994, ONCOGENE, V9, P2377; SOULIER J, 1994, ONCOGENE, V9, P3565; Sparkes R.S., 1980, CANCER GENET CYTOGEN, V1, P329; STERN MH, 1993, ONCOGENE, V8, P2475; TAYLOR AMR, 1992, BRIT J CANCER, V66, P5, DOI 10.1038/bjc.1992.208; TAYLOR AMR, 1986, INT J CANCER, V37, P511, DOI 10.1002/ijc.2910370407; TAYLOR AMR, 1992, LEUKEMIA, V6, P961; TAYLOR AMR, 1982, ATAXIA TELANGIECTASI, P53; THICK J, 1994, LEUKEMIA, V8, P564; THICK J, 1992, GENE CHROMOSOME CANC, V5, P321, DOI 10.1002/gcc.2870050407; VIRGILIO L, 1994, P NATL ACAD SCI USA, V91, P12530, DOI 10.1073/pnas.91.26.12530; VIRGILIO L, 1993, P NATL ACAD SCI USA, V90, P9275, DOI 10.1073/pnas.90.20.9275	25	32	34	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 18	1996	12	2					379	386						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TR538	8570215				2022-12-17	WOS:A1996TR53800017
J	Kamano, H; Burk, B; NobenTrauth, K; Klempnauer, KH				Kamano, H; Burk, B; NobenTrauth, K; Klempnauer, KH			Differential splicing of the mouse B-myb gene	ONCOGENE			English	Article						B-myb; differential splicing; transactivation; heat shock promotor	C-MYB; V-MYB; A-MYB; MOLECULAR-CLONING; TRANS-ACTIVATION; MAMMALIAN-CELLS; HUMAN HSP70; EXPRESSION; ONCOGENE; PROLIFERATION	The myb gene family consists of three members, the c-myb proto-oncogene and two myb-related genes (A-myb and B-myb), all of which encode nuclear DNA-binding proteins. Unlike c-myb, which plays a critical role in hematopoietic cells, B-myb is expressed in a large spectrum of hematopoietic as well as non-homatopoietic cells and has been implicated in the control of cell proliferation. The isolation of B-myb cDNA clones from several species has shown that B-myb shares limited homology to the so-called exon 9A of the c-myb gene. This exon is involved in differential splicing as only a subfraction of c-myb mRNA contains exon 9A sequences. The presence in the B-myb cDNA of a sequence related to the exon 9A of c-myb has prompted us to investigate whether B-myb mRNA is also spliced differentially. We here show that B-myb mRNAs containing or lacking exon 9A related sequences are present in many cell types. In contrast to c-myb, where RNA containing the exon 9A constitutes only a minor mRNA fraction, B-myb RNA containing the exon 9A related sequences is the major mRNA form, The proteins encoded by the two B-myb mRNA species are unable to activate promoters to which they bind. Curiously, both B-myb proteins differ in their ability to activate the HSP70 promoter by a myb binding-site independent mechanism; B-myb protein containing exon 9A related aminoacid sequences activates the HSP70 promoter much more potently than the B-myb protein which lacks these sequences. Our results suggest that differential splicing may be a general feature of the members of the myb family and provide first evidence for functional differences of the splice variants.	MAX PLANCK INST IMMUNOBIOL,HANS SPEMANN LAB,D-79108 FREIBURG,GERMANY	Max Planck Society								ALESSANDRO A, 1987, P NATL ACAD SCI USA, V84, P1794; ARSURA M, 1992, BLOOD, V79, P2708; BOUWMEESTER T, 1992, MECH DEVELOP, V37, P57, DOI 10.1016/0925-4773(92)90015-C; BURK O, 1991, EMBO J, V10, P3731; CHEN JZ, 1993, P NATL ACAD SCI USA, V90, P4528, DOI 10.1073/pnas.90.10.4528; CLARKE MF, 1988, MOL CELL BIOL, V8, P884, DOI 10.1128/MCB.8.2.884; DASGUPTA P, 1989, ONCOGENE, V4, P1419; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DUDEK H, 1989, ONCOGENE, V4, P1061; FARRAR JJ, 1980, J IMMUNOL, V125, P2555; FOOS G, 1994, ONCOGENE, V9, P2481; FOOS G, 1993, ONCOGENE, V8, P1775; FOOS G, 1992, EMBO J, V11, P4619, DOI 10.1002/j.1460-2075.1992.tb05564.x; GEWIRTZ AM, 1989, SCIENCE, V245, P180, DOI 10.1126/science.2665077; GEWIRTZ AM, 1988, SCIENCE, V242, P1303, DOI 10.1126/science.2461588; GOLAY J, 1991, BLOOD, V77, P149; GOLAY J, 1994, ONCOGENE, V9, P2469; Graf T, 1992, CURR OPIN GENET DEV, V2, P249, DOI 10.1016/S0959-437X(05)80281-3; IBANEZ CE, 1990, MOL CELL BIOL, V10, P2285, DOI 10.1128/MCB.10.5.2285; IGLESIAS A, 1991, EMBO J, V10, P2147, DOI 10.1002/j.1460-2075.1991.tb07749.x; JAIN VK, 1991, ANAL BIOCHEM, V199, P119, DOI 10.1016/0003-2697(91)90278-2; KIM KJ, 1979, J IMMUNOL, V122, P549; KLEMPNAUER KH, 1989, GENE DEV, V3, P1582, DOI 10.1101/gad.3.10.1582; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; LAM EWF, 1992, ONCOGENE, V7, P1185; LIN D, 1994, P NATL ACAD SCI USA, V91, P10079, DOI 10.1073/pnas.91.21.10079; LUSCHER B, 1990, GENE DEV, V4, P2235, DOI 10.1101/gad.4.12b.2235; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; MCMAHON J, 1988, ONCOGENE, V3, P717; METTUS RV, 1994, ONCOGENE, V9, P3077; MILARSKI KL, 1986, P NATL ACAD SCI USA, V83, P9517, DOI 10.1073/pnas.83.24.9517; MIZGUCHI G, 1990, J BIOL CHEM, V265, P9280; MOSCOVICI C, 1977, CELL, V11, P95, DOI 10.1016/0092-8674(77)90320-8; MUSCENSKI ML, 1991, CELL, V65, P677; NAKAGOSHI H, 1993, J BIOL CHEM, V268, P14161; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; NISHINA Y, 1989, NUCLEIC ACIDS RES, V17, P107, DOI 10.1093/nar/17.1.107; NOMURA N, 1988, NUCLEIC ACIDS RES, V16, P11075, DOI 10.1093/nar/16.23.11075; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; OI VT, 1983, P NATL ACAD SCI-BIOL, V80, P825, DOI 10.1073/pnas.80.3.825; PATULEIA MC, 1967, CANCER RES, V67, P726; RETH MG, 1985, NATURE, V317, P353, DOI 10.1038/317353a0; ROBERTSON E, 1986, NATURE, V323, P445, DOI 10.1038/323445a0; ROSSON D, 1987, P NATL ACAD SCI USA, V84, P3171, DOI 10.1073/pnas.84.10.3171; SADOWSKI I, 1989, NUCLEIC ACIDS RES, V17, P7539, DOI 10.1093/nar/17.18.7539; SALA A, 1992, P NATL ACAD SCI USA, V89, P10415, DOI 10.1073/pnas.89.21.10415; SCHUUR ER, 1993, ONCOGENE, V8, P1839; SHENONG GLC, 1987, EMBO J, V6, P4035, DOI 10.1002/j.1460-2075.1987.tb02748.x; SHENONG GLC, 1989, MOL CELL BIOL, V9, P5456, DOI 10.1128/MCB.9.12.5456; SHENONG GLC, 1990, BIOCHIM BIOPHYS ACTA, V1032, P39, DOI 10.1016/0304-419X(90)90011-O; SLEEMAN JP, 1993, ONCOGENE, V8, P1931; Tavassoli M, 1983, BONE MARROW STRUCTUR; TODOKORO K, 1988, P NATL ACAD SCI USA, V85, P8900, DOI 10.1073/pnas.85.23.8900; TRAUTH K, 1994, EMBO J, V13, P5994, DOI 10.1002/j.1460-2075.1994.tb06945.x; WATSON RJ, 1993, NUCLEIC ACIDS RES, V21, P267, DOI 10.1093/nar/21.2.267; WESTON K, 1989, CELL, V58, P85, DOI 10.1016/0092-8674(89)90405-4; WILLIAMS RL, 1988, CELL, V52, P121; YAFFE D, 1977, NATURE, V270, P725, DOI 10.1038/270725a0	58	32	32	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 21	1995	11	12					2575	2582						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TP188	8545114				2022-12-17	WOS:A1995TP18800013
J	Connor, RJ; Pasquale, EB				Connor, RJ; Pasquale, EB			Genomic organization and alternatively processed forms of Cek5, a receptor protein-tyrosine kinase of the Eph subfamily	ONCOGENE			English	Article						exon-intron structure; alternative splicing; alternative polyadenylation; domain structure; gene family	GROWTH-FACTOR-RECEPTOR; FACTOR-I RECEPTOR; INSULIN-RECEPTOR; MESSENGER-RNA; GENE; IDENTIFICATION; EXPRESSION; EVOLUTION; ENCODES; LIGAND	The genomic organization of Cek5, a receptor tyrosine kinase of the Eph subfamily, was elucidated utilizing a strategy involving PCR amplification of Cek5 genomic DNA, Cek5 is the first Eph-related kinase for which the exon-intron structure of the entire coding region has been determined, The Cek5 gene spans over 35 kb and comprises at least 16 exons, The exon-intron structure of Cek5 can be correlated with the proposed domain structure of the Eph subfamily, with the exception of an Ig motif in the extracellular domain, Intron positions in the Cek5 gene coincide with the locations of the deletions, substitutions, or insertions that have been described in a number of Eph-related kinases. This suggests that alternative processing plays a major role in generating the structural variability observed in the Eph subfamily. Consistent with this hypothesis, analysis of the Cek5 gene indicated that: (i) a variant form of Cek5 containing an insertion in the juxtamembrane region (Cek5+) arises through the use of alternative 5' splice sites, and (ii) a soluble form of Cek5 comprising only the extracellular domain (Cek5s) may exist, which originates by alternative polyadenylation. RT-PCR analysis and RNase protection assays revealed the expression of both Cek5+ and Cek5s at various stages of chicken development.	LA JOLLA CANC RES FDN, LA JOLLA, CA 92037 USA	Sanford Burnham Prebys Medical Discovery Institute					NCI NIH HHS [CA56721] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA056721] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABBOTT AM, 1992, J BIOL CHEM, V267, P10759; AGNES F, 1994, GENE, V145, P283, DOI 10.1016/0378-1119(94)90021-3; ANDRE C, 1992, ONCOGENE, V7, P685; BARTLEY TD, 1994, NATURE, V368, P558, DOI 10.1038/368558a0; BECKER N, 1994, MECH DEVELOP, V47, P3, DOI 10.1016/0925-4773(94)90091-4; BECKMANN MP, 1994, EMBO J, V13, P3757, DOI 10.1002/j.1460-2075.1994.tb06685.x; BENNETT BD, 1995, P NATL ACAD SCI USA, V92, P1866, DOI 10.1073/pnas.92.6.1866; BLAKE CCF, 1985, INT REV CYTOL, V93, P149, DOI 10.1016/S0074-7696(08)61374-1; Bork P, 1992, CURR OPIN STRUC BIOL, V2, P413; BRAMBILLA R, 1995, EMBO J, V14, P3116, DOI 10.1002/j.1460-2075.1995.tb07314.x; CECCHERINI I, 1993, BIOCHEM BIOPH RES CO, V196, P1288, DOI 10.1006/bbrc.1993.2392; CHAN J, 1991, ONCOGENE, V6, P1057; CHENG HJ, 1994, CELL, V79, P157, DOI 10.1016/0092-8674(94)90408-1; CIOSSEK T, 1995, ONCOGENE, V10, P97; CLEVELAND DW, 1980, CELL, V20, P95, DOI 10.1016/0092-8674(80)90238-X; DAVIS C G, 1990, New Biologist, V2, P410; DAVIS S, 1994, SCIENCE, V266, P816, DOI 10.1126/science.7973638; DOOLITTLE RF, 1992, PROTEIN SCI, V1, P191; DOWNING JR, 1989, MOL CELL BIOL, V9, P2890, DOI 10.1128/MCB.9.7.2890; DOWNWARD J, 1985, J BIOL CHEM, V260, P4538; FEENER EP, 1993, J BIOL CHEM, V268, P11256; FLICKINGER TW, 1992, MOL CELL BIOL, V12, P883, DOI 10.1128/MCB.12.2.883; GANDINO L, 1994, J BIOL CHEM, V269, P1815; HENKEMEYER M, 1994, ONCOGENE, V9, P1001; JOHNSON DE, 1991, MOL CELL BIOL, V11, P4627, DOI 10.1128/MCB.11.9.4627; KAVANAUGH WM, 1995, SCIENCE, V268, P1177, DOI 10.1126/science.7539155; KENDALL RL, 1993, P NATL ACAD SCI USA, V90, P10705, DOI 10.1073/pnas.90.22.10705; KIYOKAWA E, 1994, CANCER RES, V54, P3645; KORHONEN J, 1994, ONCOGENE, V9, P395; KOZLOSKY CJ, 1995, ONCOGENE, V10, P299; LEE CC, 1994, J BIOL CHEM, V269, P19457; LI Y, 1994, MOL CELL BIOL, V14, P7660, DOI 10.1128/MCB.14.11.7660; MAISONPIERRE PC, 1993, ONCOGENE, V8, P3277; MARU Y, 1988, MOL CELL BIOL, V8, P3770, DOI 10.1128/MCB.8.9.3770; MCKEOWN M, 1992, ANNU REV CELL BIOL, V8, P133, DOI 10.1146/annurev.cb.08.110192.001025; Moore DD, 1995, GLOB MOB SURV; MORI S, 1993, EMBO J, V12, P2257, DOI 10.1002/j.1460-2075.1993.tb05879.x; NIETO MA, 1992, DEVELOPMENT, V116, P1137; OBRYAN JP, 1991, MOL CELL BIOL, V11, P5016, DOI 10.1128/MCB.11.10.5016; OGRADY P, 1994, J BIOL CHEM, V269, P25193; PAJUSOLA K, 1993, ONCOGENE, V8, P2931; PASQUALE EB, 1991, CELL REGUL, V2, P523, DOI 10.1091/mbc.2.7.523; PASQUALE EB, 1994, DEV BIOL, V163, P491, DOI 10.1006/dbio.1994.1165; PASQUALE EB, 1992, J NEUROSCI, V12, P3956; Patthy L, 1991, CURR OPIN STRUC BIOL, V1, P351, DOI 10.1016/0959-440X(91)90033-P; PETCH LA, 1990, MOL CELL BIOL, V10, P2973, DOI 10.1128/MCB.10.6.2973; ROGERS JH, 1989, TRENDS GENET, V5, P213, DOI 10.1016/0168-9525(89)90084-X; ROUER E, 1989, GENE, V84, P105, DOI 10.1016/0378-1119(89)90144-3; SAJJADI FG, 1993, ONCOGENE, V8, P1807; SAJJADI FG, 1991, NEW BIOL, V3, P769; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHULZ AS, 1993, ONCOGENE, V8, P509; SCHWARZBAUER JE, 1987, EMBO J, V6, P2573, DOI 10.1002/j.1460-2075.1987.tb02547.x; SEGATTO O, 1991, MOL CELL BIOL, V11, P3191, DOI 10.1128/MCB.11.6.3191; SEINO S, 1989, P NATL ACAD SCI USA, V86, P114, DOI 10.1073/pnas.86.1.114; SEMBA K, 1985, P NATL ACAD SCI USA, V82, P6497, DOI 10.1073/pnas.82.19.6497; SHAO HN, 1994, J BIOL CHEM, V269, P26606; SIEVER DA, 1994, GENE, V148, P219, DOI 10.1016/0378-1119(94)90692-0; SMITH CWJ, 1989, ANNU REV GENET, V23, P527, DOI 10.1146/annurev.genet.23.1.527; SOANS C, 1994, ONCOGENE, V9, P3353; STAUBS PA, 1994, J BIOL CHEM, V269, P27186; SUDHOF TC, 1985, SCIENCE, V228, P893, DOI 10.1126/science.3873704; TUZI NL, 1994, BRIT J CANCER, V69, P417, DOI 10.1038/bjc.1994.77; VALENZUELA DM, 1995, ONCOGENE, V10, P1573; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; WINSLOW JW, 1995, NEURON, V14, P973, DOI 10.1016/0896-6273(95)90335-6; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	68	32	32	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 7	1995	11	11					2429	2438						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TK702	8570195				2022-12-17	WOS:A1995TK70200028
J	UZAWA, N; YOSHIDA, MA; OSHIMURA, M; IKEUCHI, T				UZAWA, N; YOSHIDA, MA; OSHIMURA, M; IKEUCHI, T			SUPPRESSION OF TUMORIGENICITY IN 3 DIFFERENT CELL-LINES OF HUMAN ORAL SQUAMOUS-CELL CARCINOMA BY INTRODUCTION OF CHROMOSOME 3P VIA MICROCELL-MEDIATED CHROMOSOME TRANSFER	ONCOGENE			English	Article						CHROMOSOME 3; SQUAMOUS CELL CARCINOMA; MICROCELL FUSION; ORAL CANCER; TUMOR SUPPRESSOR GENE	SHORT ARM; LUNG-CANCER; RAS ONCOGENE; ALLELIC LOSS; HEAD; HETEROZYGOSITY; FREQUENCY; DELETION; REGIONS; TUMORS	It has been suggested that loss of the short arm of chromosome 3 is one of the most frequent abnormalities in human head and neck cancers including oral squamous cell carcinomas (SCC) and that one or more putative tumor suppressor gene(s) which may contribute to the initiation and/or progression of these tumors might be located on chromosome 3p. In this study, we examined the effects of introducing human chromosome 3 or 7 by microcell hybridization on the tumor-associated phenotypes of three different human oral SCC cell lines, HSC-2, HSC-3 and HSC-4. Transfer of a single chromosome 3p completely suppressed the tumorigenicity of all three parental cell lines, which showed a significant decrease in growth rate in vitro and morphological changes. In contrast, transfer of chromosome 7 had no effect on HSC-2 and HSC-4 cells, although it suppressed the tumorigenicity of HSC-3 cells without modifying their in vitro growth properties. Our findings provide additional confirmatory evidence that loss or inactivation of putative tumor suppressor gene(s) present on chromosome 3p might be primarily involved in the development of human oral SCC. The possibility that chromosome 7 may carry another tumor suppressor gene(s) is also discussed.	TOKYO MED & DENT UNIV,FAC DENT,DEPT ORAL & MAXILLOFACIAL SURG 1,BUNKYO KU,TOKYO 113,JAPAN; TOTTORI UNIV,FAC MED,SCH LIFE SCI,DEPT MOLEC & CELL GENET,YONAGO,TOTTORI 683,JAPAN	Tokyo Medical & Dental University (TMDU); Tottori University	UZAWA, N (corresponding author), TOKYO MED & DENT UNIV,MED RES INST,DEPT CYTOGENET,BUNKYO KU,1-5-45 YUSHIMA,TOKYO 113,JAPAN.							BERENSON JR, 1989, ONCOGENE, V4, P111; BRAUCH H, 1987, NEW ENGL J MED, V317, P1109, DOI 10.1056/NEJM198710293171803; CHANG SE, 1991, INT J CANCER, V48, P409, DOI 10.1002/ijc.2910480318; COWAN JM, 1992, J NATL CANCER I, V84, P793, DOI 10.1093/jnci/84.10.793; DEVILEE P, 1989, GENOMICS, V5, P554, DOI 10.1016/0888-7543(89)90023-2; DRABKIN H, 1988, P NATL ACAD SCI USA, V85, P9258, DOI 10.1073/pnas.85.23.9258; EHLEN T, 1990, ONCOGENE, V5, P219; ELNAGGAR AK, 1993, CANCER, V72, P881, DOI 10.1002/1097-0142(19930801)72:3<881::AID-CNCR2820720337>3.0.CO;2-Q; FIELD JK, 1989, ONCOGENE, V4, P1463; FIELD JK, 1987, J ORAL PATHOL MED, V16, P97, DOI 10.1111/j.1600-0714.1987.tb01474.x; HANSEN MF, 1987, CANCER RES, V47, P5518; HARRIS H, 1988, CANCER RES, V48, P3302; HEO DS, 1989, CANCER RES, V49, P5167; HIBI K, 1992, ONCOGENE, V7, P445; JIN YS, 1993, ORAL ONCOL, V29B, P257, DOI 10.1016/0964-1955(93)90045-G; KILLARY AM, 1992, P NATL ACAD SCI USA, V89, P10877, DOI 10.1073/pnas.89.22.10877; KLEIN G, 1987, SCIENCE, V238, P1539, DOI 10.1126/science.3317834; KOI M, 1989, MOL CARCINOGEN, V2, P12, DOI 10.1002/mc.2940020103; KOVACS G, 1993, ADV CANCER RES, V62, P89, DOI 10.1016/S0065-230X(08)60316-4; LARGEY JS, 1994, ORAL SURG ORAL MED O, V77, P260, DOI 10.1016/0030-4220(94)90295-X; LATIF F, 1992, CANCER RES, V52, P1451; LOTHE RA, 1989, GENOMICS, V5, P134, DOI 10.1016/0888-7543(89)90097-9; MAESTRO R, 1993, CANCER RES, V53, P5775; MOMOSE F, 1989, J ORAL PATHOL MED, V18, P391, DOI 10.1111/j.1600-0714.1989.tb01570.x; MORITA R, 1991, CANCER RES, V51, P820; NAWROZ H, 1994, CANCER RES, V54, P1152; NAYLOR SL, 1987, NATURE, V329, P451, DOI 10.1038/329451a0; ONO T, 1993, JPN J GENET, V68, P617, DOI 10.1266/jjg.68.617; OSHIMURA M, 1990, J CELL BIOCHEM, V42, P135, DOI 10.1002/jcb.240420304; PARKIN DM, 1988, INT J CANCER, V41, P184, DOI 10.1002/ijc.2910410205; RABBITTS P, 1989, GENE CHROMOSOME CANC, V1, P95, DOI 10.1002/gcc.2870010115; RUMSBY G, 1990, BRIT J CANCER, V61, P365, DOI 10.1038/bjc.1990.80; SAKAI E, 1992, INT J CANCER, V52, P867, DOI 10.1002/ijc.2910520606; SANDBERG AA, 1988, CANCER RES, V48, P1049; SARANATH D, 1991, BRIT J CANCER, V63, P573, DOI 10.1038/bjc.1991.133; SATO T, 1991, CANCER RES, V51, P5794; SATOH H, 1993, MOL CARCINOGEN, V7, P157, DOI 10.1002/mc.2940070306; SAXON PJ, 1986, EMBO J, V15, P3461; SHIMIZU M, 1990, ONCOGENE, V5, P185; SOMERS KD, 1990, ONCOGENE, V5, P915; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STANBRIDGE EJ, 1990, ANNU REV GENET, V24, P615; TAKAHASHI E, 1992, GENOMICS, V13, P1047, DOI 10.1016/0888-7543(92)90018-N; TANAKA K, 1991, NATURE, V349, P340, DOI 10.1038/349340a0; TORY K, 1992, GENOMICS, V13, P275, DOI 10.1016/0888-7543(92)90243-L; TRENT JM, 1990, SCIENCE, V247, P568, DOI 10.1126/science.2300817; UZAWA K, 1994, INT J CANCER, V58, P814, DOI 10.1002/ijc.2910580611; WU CL, 1994, CANCER RES, V54, P6484; YAMADA H, 1990, ONCOGENE, V5, P1141; YAMAMOTO T, 1986, CANCER RES, V46, P414; YOKOTA J, 1987, P NATL ACAD SCI USA, V84, P9252, DOI 10.1073/pnas.84.24.9252; YOKOTA J, 1989, CANCER RES, V49, P3598; YOSHIDA MA, 1986, CANCER RES, V46, P2139; YOSHIDA MA, 1994, MOL CARCINOGEN, V9, P114, DOI 10.1002/mc.2940090303; ZBAR B, 1987, NATURE, V327, P721, DOI 10.1038/327721a0	55	32	33	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	NOV 16	1995	11	10					1997	2004						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TF297	7478518				2022-12-17	WOS:A1995TF29700009
J	MIRZAYANS, R; FAMULSKI, KS; ENNS, L; FRASER, M; PATERSON, MC				MIRZAYANS, R; FAMULSKI, KS; ENNS, L; FRASER, M; PATERSON, MC			CHARACTERIZATION OF THE SIGNAL-TRANSDUCTION PATHWAY MEDIATING GAMMA-RAY-INDUCED INHIBITION OF DNA-SYNTHESIS IN HUMAN-CELLS - INDIRECT EVIDENCE FOR INVOLVEMENT OF CALMODULIN BUT NOT PROTEIN-KINASE-C NOR P53	ONCOGENE			English	Article						RADIORESISTANT DNA SYNTHESIS; ATAXIA-TELANGIECTASIA; LI-FRAUMENI SYNDROME; CALMODULIN; PROTEIN KINASE C; P53	ATAXIA-TELANGIECTASIA CELLS; LI-FRAUMENI SYNDROME; WILD-TYPE P53; IONIZING-RADIATION; 4-NITROQUINOLINE 1-OXIDE; MUTANT P53; STAUROSPORINE; HYPERSENSITIVITY; COMPLEMENTATION; REPLICATION	Cultured cells from patients inheriting the rare cancer-prone and radiotherapy-sensitive disorder ataxia-telangiectasia (A-T) exhibit anomalies in cell. cycle control and protein kinase C (PKC)-mediated upregulation of p53 protein following exposure to ionizing radiation. It remains unclear, however, as to whether this irregularity in a p53-dependent signal transduction pathway controlling the G(1)/S checkpoint is causally linked to the most consistent molecular hallmark. of A-T - namely, marked attenuation in the inhibition of replicative DNA synthesis at early times (less than or equal to 2 h) after irradiation [radioresistant DNA synthesis (RDS)]. We report here that treatment of normal human fibroblast strains with inhibitors of calmodulin (CaM) (i.e. W7 and W13) and CaM-dependent protein kinases II and IV (i.e. KN62) prior to radiation exposure elicits an 'A-T-like' RDS phenotype, whereas treatment with PKC inhibitors (e.g. staurosporine) does not produce this response. Moreover, at 1 h post-gamma irradiation A-T fibroblasts undergo normal induction of p53 protein while exhibiting the RDS trait. At later times (e.g. 4 h) following irradiation, however, these A-T cells contain abnormally low levels of p53 protein, as do their lymphoblastoid cell line counterparts during the entire post-gamma ray incubation period. On the other hand, human cells which either lack the p53 gene completely (i.e. HL60 leukemia cells) or harbor a germline mutation in the gene (i.e. Li-Frauneni syndrome cells) shut down their DNA replication machinery normally upon sustaining radiation damage. We thus conclude that the transitory delay in DNA; synthesis routinely experienced by human cells in the face of radiation injury is mediated through a CaM-dependent regulatory cascade which involves neither PKC nor p53 protein. Accordingly, A-T cells appear to be malfunctional in at least two distinct radiation-responsive signalling pathways, one regulating the G(1)/S checkpoint and governed by p53 and PKC and another controlling passage through S phase and requiring CaM.	CROSS CANC INST,ONCOL MOLEC PROGRAM,EDMONTON,AB T6G 1Z2,CANADA; UNIV ALBERTA,DEPT ONCOL,EDMONTON,AB T6G 1Z2,CANADA	University of Alberta; University of Alberta			Famulski, Konrad/J-8685-2012					BACHS O, 1994, CELL CALCIUM, V16, P289, DOI 10.1016/0143-4160(94)90092-2; BEAMISH H, 1994, INT J RADIAT BIOL, V65, P175, DOI 10.1080/09553009414550211; BEAMISH H, 1994, RADIAT RES, V138, pS130, DOI 10.2307/3578780; CHAFOULEAS JG, 1984, SCIENCE, V224, P1346, DOI 10.1126/science.6203171; CHEN PC, 1978, NATURE, V274, P484, DOI 10.1038/274484a0; CLEAVER JE, 1990, RADIAT RES, V124, P294, DOI 10.2307/3577842; ENSLEN H, 1994, J BIOL CHEM, V269, P15520; GANGULY A, 1992, BIOCHEM BIOPH RES CO, V182, P254, DOI 10.1016/S0006-291X(05)80138-X; GATTI RA, 1991, MEDICINE, V70, P99, DOI 10.1097/00005792-199103000-00003; HANAWALT P, 1985, ATAXIA TELANGIECTASI, P67; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; HIDAKA H, 1984, BIOCHEMISTRY-US, V23, P5036, DOI 10.1021/bi00316a032; HIDAKA H, 1979, MOL PHARMACOL, V15, P49; HIDAKA H, 1984, P NATL ACAD SCI USA, V78, P4354; HOULDSWORTH J, 1980, NUCLEIC ACIDS RES, V8, P3709, DOI 10.1093/nar/8.16.3709; JASPERS NGJ, 1988, CYTOGENET CELL GENET, V49, P259, DOI 10.1159/000132673; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KHANNA KK, 1993, ONCOGENE, V8, P3307; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LAMB JR, 1989, INT J RADIAT BIOL, V56, P125, DOI 10.1080/09553008914551271; LAVIN MF, 1993, NATO ASI SERIES H, V77, P235; LEHMANN AR, 1979, CANCER RES, V39, P4237; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MARX J, 1994, SCIENCE, V266, P1321, DOI 10.1126/science.7973719; MEANS AR, 1994, FEBS LETT, V347, P1, DOI 10.1016/0014-5793(94)00492-7; MIRZAYANS R, 1989, CANCER RES, V49, P5523; MIRZAYANS R, 1991, CARCINOGENESIS, V12, P19, DOI 10.1093/carcin/12.1.19; MIRZAYANS R, 1995, 86TH ANN M AM ASS CA, P172; MURNANE JP, 1982, P NATL ACAD SCI-BIOL, V79, P1960, DOI 10.1073/pnas.79.6.1960; Murray A., 1993, CELL CYCLE INTRO; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; OBRIAN CA, 1990, J NATL CANCER I, V82, P1734, DOI 10.1093/jnci/82.22.1734; PAINTER RB, 1980, P NATL ACAD SCI-BIOL, V77, P7315, DOI 10.1073/pnas.77.12.7315; PAINTER RB, 1986, INT J RADIAT BIOL, V49, P771; PALCIC B, 1990, BIOINSTRUMENTATION D, P923; PATERSON MC, 1994, 3RD MCGILL U C REG E; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; RUEGG UT, 1989, TRENDS PHARMACOL SCI, V10, P218, DOI 10.1016/0165-6147(89)90263-0; SCHNEIDE.EL, 1974, EXP CELL RES, V84, P311, DOI 10.1016/0014-4827(74)90411-X; Sedgwick R, 1991, HDB CLIN NEUROLOGY, P347; SHUNG B, 1994, MUTAT RES, V307, P43, DOI 10.1016/0027-5107(94)90276-3; SRIVASTAVA S, 1993, ONCOGENE, V8, P2449; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; SRIVASTAVA S, 1993, CANCER RES, V53, P4452; TOKUMITSU H, 1990, J BIOL CHEM, V265, P4315; WANG Y, 1993, CANCER RES, V53, P1213; WRIGHT CD, 1986, BIOCHEM BIOPH RES CO, V135, P749, DOI 10.1016/0006-291X(86)90992-7; YOUNG BR, 1989, HUM GENET, V82, P113, DOI 10.1007/BF00284040; ZHUKOVSKAYA N, 1994, CARCINOGENESIS, V15, P2189, DOI 10.1093/carcin/15.10.2189	50	32	32	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	OCT 19	1995	11	8					1597	1605						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TC535	7478584				2022-12-17	WOS:A1995TC53500018
J	XUAN, JW; CHIN, JL; GUO, YZ; CHAMBERS, AF; FINKELMAN, MA; CLARKE, MW				XUAN, JW; CHIN, JL; GUO, YZ; CHAMBERS, AF; FINKELMAN, MA; CLARKE, MW			ALTERNATIVE SPLICING OF PSP94 (PROSTATIC SECRETORY PROTEIN OF 94 AMINO-ACIDS) MESSENGER-RNA IN PROSTATE TISSUE	ONCOGENE			English	Article						PROSTATE TUMOR; PSP94 (PROSTATIC SECRETORY PROTEIN OF 94 AMINO ACIDS); ALTERNATIVE SPLICING; CDNA SEQUENCE	INHIBIN-LIKE MATERIAL; HUMAN SEMINAL PLASMA; HUMAN BETA-MICROSEMINOPROTEIN; CARCINOMA CELL-LINES; MOLECULAR-CLONING; RHESUS-MONKEY; SEQUENCE; PEPTIDE; GENE; EXPRESSION	While performing reverse transcriptase-polymerase chain reaction (RT-PCR) analysis of total mRNA from prostate cancer specimens, two forms of PSP94 cDNA were detected, RT-PCR products were analysed by Southern blotting and probing with exon-specific oligonucleotides, In the short form of PSP94 mRNA, designated as PSP57, exon III was found to be deleted, The two mRNA forms were confirmed by cloning and sequencing of the RT-PCR products and were found to result from alternative splicing, The alternatively spliced form, PSP57, was characterized by sequence analysis, PSP94 and PSP57 possess identical exons I and II, including identical secretion signal peptide and the 5' untranslated sequences, PSP57 has a frame-shifted exon IV and encodes a putative 57 amino acid protein with a navel, highly basic C-terminus of 41 amino acids, PSP57 mRNA was detected in other urogenital tissues (kidney, bladder) and in most tumor cell lines tested, but was not detectable in other tissues such as breast and lung, In prostate tumor cell lines, PSP57 mRNA was aberrantly spliced and localized in the nuclear fraction of the cell, Our results suggest the possible existence of a novel PSP protein that originates from alternative splicing of PSP94 mRNA in urogenital tissues.	UNIV WESTERN ONTARIO,DEPT SURG,DIV UROL,LONDON,ON N6A 5C1,CANADA; UNIV WESTERN ONTARIO,DEPT ONCOL,LONDON,ON N6A 5C1,CANADA; UNIV WESTERN ONTARIO,LONDON REG CANC CTR,LONDON,ON N6A 5C1,CANADA; UNIV WESTERN ONTARIO,DEPT MICROBIOL & IMMUNOL,LONDON,ON N6A 5C1,CANADA; PROCYON BIOPHARMA INC,LONDON,ON N6L 1A8,CANADA	Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario)			Chambers, Ann F/L-6285-2015	Chambers, Ann F/0000-0002-9509-5123				ABRAHAMSSON PA, 1988, PROSTATE, V12, P39, DOI 10.1002/pros.2990120106; AKIYAMA K, 1985, BIOCHIM BIOPHYS ACTA, V829, P288, DOI 10.1016/0167-4838(85)90200-6; ALPERT G, 1992, J INFECT DIS, V165, P494, DOI 10.1093/infdis/165.3.494; BRAR A, 1988, J ANDROL, V99, P253; DOCTOR VM, 1986, BRIT J CANCER, V53, P547, DOI 10.1038/bjc.1986.85; DUBE JY, 1987, J UROLOGY, V138, P883, DOI 10.1016/S0022-5347(17)43408-2; DUBE JY, 1987, J ANDROL, V8, P182; FISHER CJ, 1994, CRIT CARE MED, V22, P553, DOI 10.1097/00003246-199404000-00008; FOA C, 1977, CANCER RES, V37, P3957; GARDE S, 1993, PROSTATE, V22, P225, DOI 10.1002/pros.2990220305; GARDE SV, 1993, CANCER LETT, V70, P159, DOI 10.1016/0304-3835(93)90226-Y; GREEN CB, 1990, BIOCHEM BIOPH RES CO, V167, P1184, DOI 10.1016/0006-291X(90)90648-7; HARA M, 1989, J LAB CLIN MED, V113, P541; KHARBANDA K, 1990, PROSTATE, V16, P163, DOI 10.1002/pros.2990160207; KHARBANDA K, 1991, PROSTATE, V18, P59, DOI 10.1002/pros.2990180106; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIANG ZG, 1991, BIOCHEM BIOPH RES CO, V180, P356, DOI 10.1016/S0006-291X(05)81300-2; LIU AY, 1993, CANCER LETT, V74, P91, DOI 10.1016/0304-3835(93)90049-F; LOKESHWAR BL, 1993, CANCER RES, V53, P4855; MANIATIS T, 1991, SCIENCE, V251, P33, DOI 10.1126/science.1824726; MARRA MM, 1992, J IMMUNOL, V144, P662; MBIKAY M, 1987, DNA-J MOLEC CELL BIO, V6, P23, DOI 10.1089/dna.1987.6.23; MUNDLE SD, 1993, CELL BIOL INT, V17, P587, DOI 10.1006/cbir.1993.1103; MUTA T, 1987, J BIOCHEM-TOKYO, V101, P1321, DOI 10.1093/oxfordjournals.jbchem.a121999; NOLET S, 1991, GENOMICS, V9, P775, DOI 10.1016/0888-7543(91)90375-O; NOLET S, 1991, BIOCHIM BIOPHYS ACTA, V1089, P247, DOI 10.1016/0167-4781(91)90016-F; PRICE JE, 1990, CANCER RES, V50, P717; SAMBROOK J, 1969, MOL CLONING LABORATO; SCHONWETTER BS, 1995, SCIENCE, V267, P1645, DOI 10.1126/science.7886453; SEIDAH NG, 1984, FEBS LETT, V175, P349, DOI 10.1016/0014-5793(84)80766-8; SHETH AR, 1991, PERSPECTIVE PRIMATES, P235; SHETH AR, 1988, PROGR ENDOCRINOLOGY, P301; SHETH NA, 1987, CANCER LETT, V36, P93, DOI 10.1016/0304-3835(87)90106-6; SHETH NA, 1987, INHIBINS, V2, P109; SMITH CWJ, 1989, ANNU REV GENET, V23, P527, DOI 10.1146/annurev.genet.23.1.527; STARR L, 1992, BIOTECHNIQUES, V13, P612; TENI TR, 1988, CANCER LETT, V43, P9, DOI 10.1016/0304-3835(88)90205-4; ULVSBACK M, 1989, BIOCHEM BIOPH RES CO, V164, P1310, DOI 10.1016/0006-291X(89)91812-3; ULVSBACK M, 1991, GENOMICS, V11, P920, DOI 10.1016/0888-7543(91)90015-7; XUAN JW, 1994, GENOMICS, V20, P129, DOI 10.1006/geno.1994.1139; XUAN JW, 1994, J CELL BIOCHEM, V54, P247, DOI 10.1002/jcb.240540213	41	32	37	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	SEP 21	1995	11	6					1041	1047						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RX180	7566962				2022-12-17	WOS:A1995RX18000005
J	BLAYDES, JP; SCHLUMBERGER, M; WYNFORDTHOMAS, D; WYLLIE, FS				BLAYDES, JP; SCHLUMBERGER, M; WYNFORDTHOMAS, D; WYLLIE, FS			INTERACTION BETWEEN P53 AND TGF-BETA-1 IN CONTROL OF EPITHELIAL-CELL PROLIFERATION	ONCOGENE			English	Article						P53; TGF-BETA; RAS; THYROID; IMMORTALIZATION	TRANSFORMING GROWTH-FACTOR; MONOCLONAL-ANTIBODIES; FACTOR-BETA; MURINE KERATINOCYTES; MUTANT P53; TGF-BETA; LARGE-T; RAS ONCOGENE; EXPRESSION; CARCINOMA	Although loss of sensitivity to transforming growth factor beta (TGF beta) may be a key step in the escape of epithelial tumours from normal growth control, the intracellular signals determining responsiveness remain controversial, particularly the role of p53. We have investigated this question using thyroid epithelial lines as a model. We analysed (i) human thyroid cancer cell lines having either wild-type (wt) or mutant p53; (ii) rat thyroid lines derived by spontaneous immortalisation following introduction of mutant H-ras, which exhibit high levels of wt p53 but loss of p53-mediated cell-cycle control. Loss of response to TGF beta 1 was found in all human lines bearing mutant p53, and in the majority of the functionally equivalent rat lines, consistent with a role of wt p53 in mediating response, However, introduction of a dominant negative p53 mutant into TGF beta 1 responsive human lines containing wt p53 did not reduce responsiveness, demonstrating that p53 function is not necessary for TGF beta 1 response. On the other hand, expression of a temperature-sensitive (ts) p53 gene in a partially-responsive rat line demonstrated a highly significant modulation of TGF beta response, which fell from 65% inhibition of H-3-thymidine labelling index at 32.5 degrees C (wt p53 conformation) to only 14% at 37.5 degrees C (mutant conformation), The results suggest that p53 and TGF beta generate separate but interacting inhibitory signals, i.e. that p53 modulates but does not mediate TGF beta response. This conclusion explains previous conflicting data and is consistent with current models of cell cycle control by multiple inhibitors of cyclin-dependent kinases.	UNIV WALES COLL MED,DEPT PATHOL,THYROID TUMOUR BIOL RES GRP,CANC RES CAMPAIGN,CARDIFF CF4 4XN,S GLAM,WALES; INST GUSTAVE ROUSSY,F-94805 VILLEJUIF,FRANCE	Cardiff University; UNICANCER; Gustave Roussy			Blaydes, Jeremy/AAC-6939-2019	Blaydes, Jeremy/0000-0001-8525-0209				ANTONINI P, 1993, CANCER GENET CYTOGEN, V67, P117, DOI 10.1016/0165-4608(93)90163-G; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BALL RK, 1984, EMBO J, V3, P1485, DOI 10.1002/j.1460-2075.1984.tb02000.x; BANKS L, 1986, EUR J BIOCHEM, V159, P529, DOI 10.1111/j.1432-1033.1986.tb09919.x; BOND J, 1992, MOL CARCINOGEN, V5, P129, DOI 10.1002/mc.2940050208; BRASH DE, 1987, MOL CELL BIOL, V7, P2031, DOI 10.1128/MCB.7.5.2031; BURNS JS, 1989, BRIT J CANCER, V59, P755, DOI 10.1038/bjc.1989.158; BURNS JS, 1992, MOL CARCINOGEN, V6, P129, DOI 10.1002/mc.2940060208; COMPERE SJ, 1989, MOL CELL BIOL, V9, P6, DOI 10.1128/MCB.9.1.6; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELIYAHU D, 1985, NATURE, V316, P158, DOI 10.1038/316158a0; ESTOUR B, 1989, VIRCHOWS ARCH B, V57, P167, DOI 10.1007/BF02899078; EWEN ME, 1993, CELL, V74, P1009, DOI 10.1016/0092-8674(93)90723-4; FYNAN TM, 1993, CRIT REV ONCOGENESIS, V4, P493; GANNON JV, 1991, NATURE, V349, P802; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GERWIN BI, 1992, P NATL ACAD SCI USA, V89, P2759, DOI 10.1073/pnas.89.7.2759; GORETZKI PE, 1989, ANN ENDOCRINOL, V50, P145; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HARPER JW, 1993, CELL, V75, P805; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KORMAN AJ, 1987, P NATL ACAD SCI USA, V84, P2150, DOI 10.1073/pnas.84.8.2150; LANE DP, 1994, INT J CANCER, V57, P623, DOI 10.1002/ijc.2910570502; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LANE EB, 1982, J CELL BIOL, V92, P665, DOI 10.1083/jcb.92.3.665; LU X, 1992, CELL, V70, P153, DOI 10.1016/0092-8674(92)90541-J; MACDONALD RJ, 1987, GUIDE MOL CLONING TE, P219; MANNING AM, 1991, ONCOGENE, V6, P1471; MASUI T, 1986, P NATL ACAD SCI USA, V83, P2438, DOI 10.1073/pnas.83.8.2438; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; MORRIS JC, 1988, ENDOCRINOLOGY, V123, P1385, DOI 10.1210/endo-123-3-1385; ONG G, 1991, ONCOGENE, V6, P761; PIETENPOL JA, 1990, CELL, V61, P777, DOI 10.1016/0092-8674(90)90188-K; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; REISS M, 1990, CANCER RES, V50, P6641; REISS M, 1993, CANCER RES, V53, P899; REISS M, 1989, J INVEST DERMATOL, V93, P136, DOI 10.1111/1523-1747.ep12277384; SHIPLEY GD, 1986, CANCER RES, V43, P5915; SOUSSI T, 1988, NUCLEIC ACIDS RES, V16, P11384, DOI 10.1093/nar/16.23.11384; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; WEISSMAN B, 1985, MOL CELL BIOL, V5, P3386, DOI 10.1128/MCB.5.12.3386; WILLIAMS AC, 1994, ONCOGENE, V9, P1479; WILLIAMS DW, 1989, THYROID TUMOURS MOL, P57; WILLIAMS NW, 1989, EXP CELL RES, V184, P316, DOI 10.1016/0014-4827(89)90331-5; WRIGHT PA, 1991, ONCOGENE, V6, P1693; WU SP, 1992, J CELL BIOL, V116, P187, DOI 10.1083/jcb.116.1.187; WYLLIE FS, 1993, MOL CARCINOGEN, V7, P83, DOI 10.1002/mc.2940070205; WYLLIE FS, 1991, MOL CELL ENDOCRINOL, V76, P13, DOI 10.1016/0303-7207(91)90255-Q; WYLLIE FS, IN PRESS ONCOGENE; YEWDELL JW, 1986, J VIROL, V59, P444, DOI 10.1128/JVI.59.2.444-452.1986; ZENTELLA A, 1991, MOL CELL BIOL, V11, P4952, DOI 10.1128/MCB.11.10.4952	52	32	32	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JAN 19	1995	10	2					307	317						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QC624	7838530				2022-12-17	WOS:A1995QC62400010
J	HIGASHITSUJI, H; ARII, S; FURUTANI, M; IMAMURA, M; KANEKO, Y; TAKENAWA, J; NAKAYAMA, H; FUJITA, J				HIGASHITSUJI, H; ARII, S; FURUTANI, M; IMAMURA, M; KANEKO, Y; TAKENAWA, J; NAKAYAMA, H; FUJITA, J			ENHANCED EXPRESSION OF MULTIPLE PROTEIN-TYROSINE PHOSPHATASES IN THE REGENERATING MOUSE-LIVER - ISOLATION OF PTP-RL10, A NOVEL CYTOPLASMIC-TYPE PHOSPHATASE WITH SEQUENCE HOMOLOGY TO CYTOSKELETAL PROTEIN-4.1	ONCOGENE			English	Note						PARTIAL HEPATECTOMY; LIVER REGENERATION; PROTEIN TYROSINE PHOSPHATASE; PTP-RL10, EZRIN; BAND 4.1	IMMEDIATE-EARLY GENE; MOLECULAR-CLONING; CDNA SEQUENCE; RECEPTOR; FAMILY; IDENTIFICATION; GROWTH; MEMBER; EZRIN; BAND-4.1	To elucidate the role that protein tyrosine phosphatases (PTPs) may play in liver regeneration, PTPs expressed in the mouse liver after partial hepatectomy (PH) were investigated by a PCR-based cloning method, Sequencing of 115 cDNA clones identified 10 different sequences including MPTP (T cell PTP), PTP-1B, PTP-P19, mR-PTP mu, R-PTP alpha, PTP NE-3 (PTP-P1), R-PTP-kappa and the murine homologue of human LAR, The remaining two sequences, PTP-RL9 and PTP-RL10, encoded novel PTPs. PTP-RL10 cDNA contained an open reading frame of 1176 amino acids with no apparent membrane-spanning region. The amino-terminal region had sequence homology to those of human erythrocyte protein 4.1 and ezrin, cytoskeletal proteins. In the regenerating liver, the levels of five PTP gene mRNAs (MPTP, PTP-P19, R-PTP alpha, LAR homologue, and PTP-RL9) increased within 6h, decreased to the normal level by 24h, and increased again at 48 to 72 h after PH, The levels of PTP-1B and R-PTP-kappa mRNAs peaked within 6 h, decreased gradually, and returned to the normal level by 168 h after PH, In contrast, the levels of two PTP mRNAs (mR-PTP mu and PTP-RL10) peaked at 48 to 72 h, and returned to the normal level by 168 h after PH, No expression of PTP NE-3 was detected in the liver by Northern blotting, The differential expression of multiple PTPs during the prereplicative and post-replicative stages of liver regeneration suggests that PTPs are involved in the regulation of growth and differentiation of liver cells.	KYOTO UNIV,FAC MED,DEPT SURG 1,SAKYO KU,KYOTO 606,JAPAN; KYOTO UNIV,FAC MED,DEPT CLIN MOLEC BIOL,SAKYO KU,KYOTO 606,JAPAN	Kyoto University; Kyoto University								BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; BOEHM T, 1993, ONCOGENE, V8, P1385; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; BUCHER NLR, 1963, INT REV CYTOL, V15, P245, DOI 10.1016/S0074-7696(08)61119-5; CHARBONNEAU H, 1989, P NATL ACAD SCI USA, V86, P5252, DOI 10.1073/pnas.86.14.5252; CHARBONNEAU H, 1992, ANNU REV CELL BIOL, V8, P463, DOI 10.1146/annurev.cellbio.8.1.463; CHARLES CH, 1992, ONCOGENE, V7, P187; CHARLES CH, 1993, P NATL ACAD SCI USA, V90, P5292, DOI 10.1073/pnas.90.11.5292; CHERNOFF J, 1990, P NATL ACAD SCI USA, V87, P2735, DOI 10.1073/pnas.87.7.2735; CONBOY J, 1986, P NATL ACAD SCI USA, V83, P9512, DOI 10.1073/pnas.83.24.9512; COOL DE, 1989, P NATL ACAD SCI USA, V86, P5257, DOI 10.1073/pnas.86.14.5257; CORREAS I, 1986, J BIOL CHEM, V261, P3362; DIAMOND RH, 1994, MOL CELL BIOL, V14, P3752, DOI 10.1128/MCB.14.6.3752; FAUSTO N, 1989, LAB INVEST, V60, P4; FAUSTO N, 1990, HEPATOLOGY TXB LIVER, P49; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; FUNAYAMA N, 1991, J CELL BIOL, V115, P1039, DOI 10.1083/jcb.115.4.1039; GEBBINK MFBG, 1991, FEBS LETT, V290, P123, DOI 10.1016/0014-5793(91)81241-Y; GOULD KL, 1989, EMBO J, V8, P4133, DOI 10.1002/j.1460-2075.1989.tb08598.x; GRISHAM JW, 1962, CANCER RES, V22, P842; GU MX, 1991, P NATL ACAD SCI USA, V88, P5867, DOI 10.1073/pnas.88.13.5867; HERTOG JD, 1992, BIOCHEM BIOPH RES CO, V184, P1241; Higgins GM, 1931, ARCH PATHOL, V12, P186; HUNTER T, 1989, CELL, V58, P1013, DOI 10.1016/0092-8674(89)90496-0; JIANG YP, 1993, MOL CELL BIOL, V13, P2942, DOI 10.1128/MCB.13.5.2942; KANEKO Y, 1993, BIOCHEM BIOPH RES CO, V197, P625, DOI 10.1006/bbrc.1993.2525; KRUEGER NX, 1990, EMBO J, V9, P3241, DOI 10.1002/j.1460-2075.1990.tb07523.x; LANKES WT, 1991, P NATL ACAD SCI USA, V88, P8297, DOI 10.1073/pnas.88.19.8297; MAEKAWA K, 1994, FEBS LETT, V337, P200, DOI 10.1016/0014-5793(94)80273-4; MARCHUK D, 1991, NUCLEIC ACIDS RES, V19, P1154, DOI 10.1093/nar/19.5.1154; MATTHEWS RJ, 1990, P NATL ACAD SCI USA, V87, P4444, DOI 10.1073/pnas.87.12.4444; MICHALOPOULOS GK, 1990, FASEB J, V4, P176, DOI 10.1096/fasebj.4.2.2404819; MIYASAKA H, 1992, BIOCHEM BIOPH RES CO, V185, P818, DOI 10.1016/0006-291X(92)91700-Z; MOLLER NPH, 1994, P NATL ACAD SCI USA, V91, P7477, DOI 10.1073/pnas.91.16.7477; MOSINGER B, 1992, P NATL ACAD SCI USA, V89, P499, DOI 10.1073/pnas.89.2.499; PAN MG, 1993, J BIOL CHEM, V268, P19284; ROULEAU GA, 1993, NATURE, V363, P515, DOI 10.1038/363515a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAP J, 1990, P NATL ACAD SCI USA, V87, P6112, DOI 10.1073/pnas.87.16.6112; SCHEPENS J, 1992, MOL BIOL REP, V16, P241, DOI 10.1007/BF00419663; STRAIN AJ, 1994, EXP CELL RES, V210, P253, DOI 10.1006/excr.1994.1037; STREULI M, 1988, J EXP MED, V168, P1553; TAKEKAWA M, 1992, BIOCHEM BIOPH RES CO, V189, P1223, DOI 10.1016/0006-291X(92)92335-U; TROFATTER JA, 1993, CELL, V72, P791, DOI 10.1016/0092-8674(93)90406-G; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WALTON KM, 1993, NEURON, V11, P387, DOI 10.1016/0896-6273(93)90193-U; WILGENBUS KK, 1993, GENOMICS, V16, P199, DOI 10.1006/geno.1993.1159; YANG Q, 1993, J BIOL CHEM, V268, P6622; YANG Q, 1991, P NATL ACAD SCI USA, V88, P5949, DOI 10.1073/pnas.88.14.5949; YI TL, 1991, BLOOD, V78, P2222; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; ZHENG XM, 1992, NATURE, V359, P336, DOI 10.1038/359336a0	52	32	34	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JAN 19	1995	10	2					407	414						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QC624	7838537				2022-12-17	WOS:A1995QC62400021
J	HUANG, F; HSU, S; YAN, ZF; WINAWER, S; FRIEDMAN, E				HUANG, F; HSU, S; YAN, ZF; WINAWER, S; FRIEDMAN, E			THE CAPACITY FOR GROWTH-STIMULATION BY TGF-BETA-1 SEEN ONLY IN ADVANCED COLON CANCERS CANNOT BE ASCRIBED TO MUTATIONS IN APC, DCC, P53 OR RAS	ONCOGENE			English	Note							HEXAMETHYLENE BISACETAMIDE; COLORECTAL TUMORIGENESIS; CARCINOMA CELLS; GENE-MUTATIONS; DIFFERENTIATION; IDENTIFICATION; FACTOR-BETA-1; EXPRESSION; ONCOGENES; CHROMOSOME-5Q21	Human colon cancer development is associated with the accumulation of mutations and deletions in the suppressor genes DCC, APC and p53 and mutations in the dominant oncogene K-ras, with loss of wild type alleles. In earlier studies we had observed that about half of the resected human colon cancers placed into primary culture were growth stimulated by TGF beta 1. This group included the more advanced cancers which were either poorly differentiated primary-site cancers or metastases. In contract, the more differentiated colon cancers were inhibited or unaffected by TGF beta 1, indicating that a switch fn response to TGF beta 1 occurs during colon cancer progression. Different sublines of the HT29 colon carcinoma cell line model the resected cancers, responding to TGF beta 1 by proliferation, inhibition or no growth modulation. The current study shows that while the poorly differentiated, TGF beta 1-stimulated sublines are most tumorigenic, all the sublines have the same spectrum of mutations: truncating mutations in both APC (adenomatous polyposis coli) alleles, no activated vas genes, mutated and thus overexpressed p53, and very low expression of DCC compared to normal colon cells. Genes other than the four already implicated in colon carcinoma evolution are responsible for the mitogenic response to TGF beta 1 found in the more advanced cancers.	MEM SLOAN KETTERING CANC CTR,NEW YORK,NY 10021	Memorial Sloan Kettering Cancer Center					NCI NIH HHS [IT32CAO9628] Funding Source: Medline; PHS HHS [R0145783, R0150645] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009628] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BOS JL, 1987, NATURE, V327, P293, DOI 10.1038/327293a0; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FEARON ER, 1987, SCIENCE, V238, P193, DOI 10.1126/science.2889267; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FORRESTER K, 1987, NATURE, V327, P298, DOI 10.1038/327298a0; GIBBS JB, 1990, J BIOL CHEM, V265, P20437; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; HAFEZ MM, 1990, CELL GROWTH DIFFER, V1, P617; HAFEZ MM, 1992, CELL GROWTH DIFFER, V3, P753; HSU S, 1994, CELL GROWTH DIFFER, V5, P267; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; LAWLOR KG, 1992, CELL GROWTH DIFFER, V3, P609; NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563; POWELL SM, 1992, NATURE, V359, P235, DOI 10.1038/359235a0; RODRIGUES NR, 1990, P NATL ACAD SCI USA, V87, P7555, DOI 10.1073/pnas.87.19.7555; SCHROY P, 1990, CANCER RES, V50, P261; SCHROY PC, 1988, CANCER RES, V48, P5487; SMITH KJ, 1993, P NATL ACAD SCI USA, V90, P2846, DOI 10.1073/pnas.90.7.2846; SWEET RW, 1984, NATURE, V311, P273, DOI 10.1038/311273a0; VERLAANDEVRIES M, 1986, GENE, V50, P313, DOI 10.1016/0378-1119(86)90335-5; VOGELSTEIN B, 1989, SCIENCE, V244, P207, DOI 10.1126/science.2565047; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; YAN ZF, 1993, CELL GROWTH DIFFER, V4, P785; YAN ZF, 1994, J BIOL CHEM, V269, P13231; YAN ZF, 1992, ONCOGENE, V7, P801	26	32	32	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1994	9	12					3701	3706						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PT392	7970729				2022-12-17	WOS:A1994PT39200035
J	YAMASHIRO, S; URANO, T; SHIKU, H; FURUKAWA, K				YAMASHIRO, S; URANO, T; SHIKU, H; FURUKAWA, K			ALTERATION OF NM23 GENE-EXPRESSION DURING THE INDUCED-DIFFERENTIATION OF HUMAN LEUKEMIA-CELL LINES	ONCOGENE			English	Article							NUCLEOSIDE DIPHOSPHATE KINASE; TUMOR-METASTASIS; PROTEINS; DROSOPHILA; IDENTIFICATION; SURFACE	The nm23-H1 gene is regarded as a human homologue of the mouse nm23 gene, which was expressed in a nonmetastatic subline of mouse melanoma K-1735. The expression levels of nm23-H1 mRNA and the levels of protein during induced differentiation of human leukemia cell lines were analysed. mRNA levels of the megakaryoblastic leukemia line MEG-O1, which were induced to differentiate into megakaryocyte by TPA, decreased rapidly from 2 days after the start of treatment and became almost undetectable at day 4. Similar downregulation of nm23-H1 mRNA was also observed in the induced differentiation of the promyelocytic leukemia line HL-60 by TPA, or DMSO into monocyte-macrophage lineage or granulocytes, respectively. The amount of Nm23-H1 protein was analysed by Western immune-blot analysis using mouse antiserum raised against a recombinant fusion protein with glutathione S-transferase. The amount of Nm23-H1 protein also decreased during the induced differentiation of these leukemia cell lines. On the other hand, in the differentiation of the erythroleukemia line K562 by hemin, levels of both mRNA and protein of Nm23-H1 elevated transiently, then reduced to the original level. When MEG-01 and K562 were stably transfected with nm23-H1 cDNA, MEG-O1 transfectants showed reduced sensitivity to the induction of differentiation, whereas K562 transfectants were better induced to synthesize hemoglobin than controls. These findings suggest the possibility that Nm23-H1 protein plays an important role to maintain the proliferation of immature leukemic cells in MEG-O1 and HL-60, but it may also play a role in the early stage of K562 differentiation, possibly in the different manner.	NAGASAKI UNIV,SCH MED,DEPT ONCOL,NAGASAKI 852,JAPAN	Nagasaki University				Urano, Takeshi/0000-0003-3383-3554				Agarwal R P, 1978, Methods Enzymol, V51, P376; BEVILACQUA G, 1989, CANCER RES, V49, P5185; BIGGS J, 1988, GENE DEV, V2, P1333, DOI 10.1101/gad.2.10.1333; BIGGS J, 1990, CELL, V63, P933, DOI 10.1016/0092-8674(90)90496-2; CIOE L, 1981, CANCER RES, V41, P237; HAYASHI K, 1986, ACTA HAEMATOL-BASEL, V75, P141, DOI 10.1159/000206107; KARASUYAMA H, 1990, J EXP MED, V172, P969, DOI 10.1084/jem.172.3.969; KIMURA N, 1988, J BIOL CHEM, V263, P4647; KIMURA N, 1990, BIOCHEM BIOPH RES CO, V168, P99, DOI 10.1016/0006-291X(90)91680-Q; LACOMBE ML, 1990, J BIOL CHEM, V265, P10012; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Maniatis T, 1989, DECONTAMINATION DILU; NICKERSON JA, 1984, J BIOL CHEM, V259, P1297; OGURA M, 1985, BLOOD, V66, P1384; OKABEKADO J, 1992, BIOCHEM BIOPH RES CO, V182, P987, DOI 10.1016/0006-291X(92)91829-F; POSTEL EH, 1993, SCIENCE, V261, P478, DOI 10.1126/science.8392752; SORSCHER SM, 1993, BIOCHEM BIOPH RES CO, V195, P336, DOI 10.1006/bbrc.1993.2049; STAHL JA, 1991, CANCER RES, V51, P445; STEEG PS, 1988, J NATL CANCER I, V80, P200, DOI 10.1093/jnci/80.3.200; STEEG PS, 1989, CANCER METASTASIS, P48; TOKUNAGA Y, 1993, INT J CANCER, V55, P66, DOI 10.1002/ijc.2910550113; URANO T, 1993, ONCOGENE, V8, P1371; URANO T, 1992, INT J ONCOL, V1, P425; WALLET V, 1990, J NATL CANCER I, V82, P1199, DOI 10.1093/jnci/82.14.1199; YAMASHIRO S, 1993, LEUKEMIA RES, V17, P129, DOI 10.1016/0145-2126(93)90057-R	26	32	36	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1994	9	9					2461	2468						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PC054	8058309				2022-12-17	WOS:A1994PC05400005
J	NAMCIU, S; LIEBERMAN, MA; STAVNEZER, E				NAMCIU, S; LIEBERMAN, MA; STAVNEZER, E			INDUCTION OF THE C-SKI PROTOONCOGENE BY PHORBOL ESTER CORRELATES WITH INDUCTION OF MEGAKARYOCYTE DIFFERENTIATION	ONCOGENE			English	Article							LEUKEMIA-CELL-LINE; HEL CELLS; EXPRESSION; PHENOTYPE; SEQUENCE; PRODUCT; CULTURE; GROWTH; MUSCLE; GENE	Overexpression of v-ski blocks the terminal differentiation of chicken erythroblasts, and in cooperation with v-sea causes transformation of these cells, indicating that c-ski may play a role in regulating either proliferation or differentiation in hematopoietic cells. We examined c-ski expression in four different myeloid cell lines which can be induced to differentiate by exposure to phorbol 12-myristate 13-acetate (PMA). Two of the cell lines are multipotent and have the ability to differentiate into either erythrocytes or megakaryocytes (K562 and HEL cells), one cell line differentiates exclusively into megakaryocytes (CHRF-288-11), and the fourth cell line differentiates into either monocytes or granulocytes (HL-60). Our findings indicate that c-ski mRNA is up regulated by PMA only in those cell lines which respond by differentiating along the megakaryocyte lineage. The extent of differentiation and the observed increase in c-ski mRNA levels are positively correlated with the PMA concentration used to induce differentiation. Experiments in which CHRF-288-11 cells were treated with the protein kinase C (PKC) activator bryostatin 1 indicate that c-ski mRNA induction is not a general effect of PKC activation. The results strongly suggest that c-ski expression is correlated with megakaryocyte maturation.	UNIV CINCINNATI,COLL MED,DEPT MOLEC GENET,CINCINNATI,OH 45267; UNIV CINCINNATI,COLL MED,DEPT BIOCHEM,CINCINNATI,OH 45267; UNIV CINCINNATI,COLL MED,DEPT MICROBIOL,CINCINNATI,OH 45267	University of Cincinnati; University of Cincinnati; University of Cincinnati					NATIONAL CANCER INSTITUTE [R01CA043600] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [T32ES007250] Funding Source: NIH RePORTER; NCI NIH HHS [CA43600] Funding Source: Medline; NIEHS NIH HHS [T32-ES07250] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; BERKOW RL, 1985, BIOCHEM BIOPH RES CO, V131, P1109, DOI 10.1016/0006-291X(85)90205-0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; COLLINS SJ, 1977, NATURE, V270, P347, DOI 10.1038/270347a0; COLMENARES C, 1991, J VIROL, V65, P4929, DOI 10.1128/JVI.65.9.4929-4935.1991; COLMENARES C, 1989, CELL, V59, P293, DOI 10.1016/0092-8674(89)90291-2; DANIELSON PE, 1988, DNA-J MOLEC CELL BIO, V7, P261, DOI 10.1089/dna.1988.7.261; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FRENCH BT, 1990, CANCER CHEMOTH PHARM, V27, P171, DOI 10.1007/BF00685709; FUGMAN DA, 1990, BLOOD, V75, P1252; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HOCEVAR BA, 1992, J CELL SCI, V101, P671; HOFFMAN R, 1989, BLOOD, V74, P1196; KABNOUDIAS A, 1992, EXP HEMATOL, V20, P43; LARSEN J, 1992, ONCOGENE, V7, P1903; LI Y, 1986, J VIROL, V57, P1065, DOI 10.1128/JVI.57.3.1065-1072.1986; LONG MW, 1990, J CLIN INVEST, V85, P1072, DOI 10.1172/JCI114538; LOZZIO BB, 1981, P SOC EXP BIOL MED, V166, P546; LOZZIO CB, 1975, BLOOD, V45, P321, DOI 10.1182/blood.V45.3.321.321; MARTIN P, 1982, SCIENCE, V216, P1233, DOI 10.1126/science.6177045; MCKINNON RD, 1987, MOL CELL BIOL, V7, P2148, DOI 10.1128/MCB.7.6.2148; MCMASTER GK, 1977, P NATL ACAD SCI USA, V74, P4835, DOI 10.1073/pnas.74.11.4835; MILNER RM, 1983, NUCLEIC ACIDS RES, V11, P4597; MURRAY NR, 1993, J BIOL CHEM, V268, P15847; NAGASE T, 1990, NUCLEIC ACIDS RES, V18, P337, DOI 10.1093/nar/18.2.337; NOMURA N, 1989, NUCLEIC ACIDS RES, V17, P5489, DOI 10.1093/nar/17.14.5489; PAPAYANNOPOULOU T, 1987, BLOOD, V70, P1764; PRASAD VS, 1991, J IMMUNOL, V147, P4200; ROVERA G, 1979, P NATL ACAD SCI USA, V76, P2779, DOI 10.1073/pnas.76.6.2779; STAEHELI P, 1989, MOL CELL BIOL, V9, P4038; STAVNEZER E, 1989, MOL CELL BIOL, V9, P4038, DOI 10.1128/MCB.9.9.4038; SUTRAVE P, 1989, MOL CELL BIOL, V9, P4046, DOI 10.1128/MCB.9.9.4046; SUTRAVE P, 1990, GENE DEV, V4, P1462, DOI 10.1101/gad.4.9.1462; TAKAHASHI T, 1991, BRIT J HAEMATOL, V78, P480, DOI 10.1111/j.1365-2141.1991.tb04476.x; TETTEROO PAT, 1984, LEUKEMIA RES, V8, P197, DOI 10.1016/0145-2126(84)90143-7	36	32	32	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1994	9	5					1407	1416						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NH401	8152801				2022-12-17	WOS:A1994NH40100012
J	BASSETSEGUIN, N; DEMOLY, P; MOLES, JP; TESNIERES, A; GAUTHIERROUVIERE, C; RICHARD, S; BLANCHARD, JM; GUILHOU, JJ				BASSETSEGUIN, N; DEMOLY, P; MOLES, JP; TESNIERES, A; GAUTHIERROUVIERE, C; RICHARD, S; BLANCHARD, JM; GUILHOU, JJ			COMPARATIVE-ANALYSIS OF CELLULAR AND TISSULAR EXPRESSION OF C-FOS IN HUMAN KERATINOCYTES - EVIDENCE OF ITS ROLE IN CELL-DIFFERENTIATION	ONCOGENE			English	Article							PROTOONCOGENE EXPRESSION; GENE-TRANSCRIPTION; PROTO-ONCOGENE; ONC GENES; ACTIVATION; CALCIUM; GROWTH; MOUSE; SKIN; FIBROBLASTS	Recent studies on normal and pathological skin have suggested a role of the c-fos proto-oncogene in keratinocyte differentiation. To further elucidate this question we have used keratinocyte and skin culture models to study in vitro regulation of c-fos expression and attempted to correlate it with the keratinocyte maturation process. Our results show that c-fos expression is prolonged in keratinocyte monolayers both at the mRNA and protein level. Extracellular calcium which stimulate keratinocyte differentiation is able to induce c-fos expression in the presence of growth factors. However this c-fas expression cannot be maintained by these factors as seen in normal human skin in vivo. Conversely, spontaneous expression of c-fos can be seen in reconstituted skin when the neo-epidermis has completed its differentiation. All these data strongly support a role of c-fos as a switch between the early and late phases of keratinocyte differentiation allowing them to be definitively committed to their elimination process. Additionally, a differential regulation of c-fos seems to exist between keratinocyte culture and reconstituted epidermis, suggesting that tissular and serum factors are involved in the prolonged c-fos expression observed in human epidermis.	SERV PNEUMOL,CNRS,UMR 9942,MONTPELLIER,FRANCE; CNRS,UMR 9942,INSERM,U249,MONTPELLIER,FRANCE; INST GENET MOLEC,CNRS,UMR 9942,MONTPELLIER,FRANCE	Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Centre National de la Recherche Scientifique (CNRS)	BASSETSEGUIN, N (corresponding author), DERMATOL MOLEC LAB,CNRS,UMR 9942,MONTPELLIER,FRANCE.		Molès, Jean-Pierre/M-2286-2017; Demoly, Pascal/Y-9938-2019; Richard, Sylvain/C-9695-2016	Molès, Jean-Pierre/0000-0002-6863-6350; Demoly, Pascal/0000-0001-7827-7964; GAUTHIER-ROUVIERE, Cecile/0000-0002-8364-3882; Richard, Sylvain/0000-0001-9460-6705				BASSET N, 1987, DERMATOLOGICA, V175, P296, DOI 10.1159/000248838; BASSETSEGUIN N, 1990, J INVEST DERMATOL, V94, P418, DOI 10.1111/1523-1747.ep12874493; BASSETSEGUIN N, 1991, J INVEST DERMATOL, V97, P672, DOI 10.1111/1523-1747.ep12483807; BASSETSEGUIN N, 1990, DIFFERENTIATION, V44, P232, DOI 10.1111/j.1432-0436.1990.tb00622.x; BELL E, 1983, J INVEST DERMATOL, V81, pS2, DOI 10.1111/1523-1747.ep12539993; BRIATA P, 1993, EXP CELL RES, V204, P136, DOI 10.1006/excr.1993.1018; COLLART MA, 1991, MOL CELL BIOL, V11, P2826, DOI 10.1128/MCB.11.5.2826; COULOMB B, 1986, BRIT J DERMATOL, V114, P91, DOI 10.1111/j.1365-2133.1986.tb02783.x; CURRAN T, 1986, P NATL ACAD SCI USA, V83, P8521, DOI 10.1073/pnas.83.22.8521; FISHER C, 1991, DEVELOPMENT, V111, P253; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; GAUTHIERROUVIERE C, 1990, EMBO J, V9, P171, DOI 10.1002/j.1460-2075.1990.tb08093.x; GREEN H, 1979, P NATL ACAD SCI USA, V76, P5665, DOI 10.1073/pnas.76.11.5665; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; MECHTI N, 1991, MOL CELL BIOL, V11, P2832, DOI 10.1128/MCB.11.5.2832; MULLER R, 1982, NATURE, V299, P640, DOI 10.1038/299640a0; MULLER R, 1983, NATURE, V304, P454, DOI 10.1038/304454a0; MULLER R, 1984, EMBO J, V3, P1887, DOI 10.1002/j.1460-2075.1984.tb02063.x; MULLER R, 1983, EMBO J, V2, P679, DOI 10.1002/j.1460-2075.1983.tb01484.x; MULLER R, 1986, EMBO J, V3, P311; OSHIMA RG, 1990, GENE DEV, V4, P835, DOI 10.1101/gad.4.5.835; PANTERNE B, 1992, ONCOGENE, V7, P2341; PRUNIERAS M, 1979, J INVEST DERMATOL, V73, P135, DOI 10.1111/1523-1747.ep12556751; SASSONECORSI P, 1987, NATURE, V326, P507, DOI 10.1038/326507a0; SHENG M, 1988, MOL CELL BIOL, V8, P2787, DOI 10.1128/MCB.8.7.2787; SHENG M, 1990, NEURON, V4, P571, DOI 10.1016/0896-6273(90)90115-V; SMEYNE RJ, 1993, NATURE, V363, P166, DOI 10.1038/363166a0; SPIEGELMAN BM, 1988, J CELL BIOL, V107, P829, DOI 10.1083/jcb.107.3.829; TAKAHASHI H, 1993, J INVEST DERMATOL, V100, P10, DOI 10.1111/1523-1747.ep12349867; TINOIS E, 1987, ARCH DERMATOL RES, V279, P241, DOI 10.1007/BF00417322; VERRIER B, 1986, EMBO J, V5, P913, DOI 10.1002/j.1460-2075.1986.tb04303.x	31	32	32	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1994	9	3					765	771						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW551	8108118				2022-12-17	WOS:A1994MW55100011
J	GHOSH, PK; ANDERSON, J; COHEN, N; TAKESHITA, K; ATWEH, GF; LEBOWITZ, P				GHOSH, PK; ANDERSON, J; COHEN, N; TAKESHITA, K; ATWEH, GF; LEBOWITZ, P			EXPRESSION OF THE LEUKEMIA-ASSOCIATED GENE, P18, IN NORMAL AND MALIGNANT-TISSUES - INACTIVATION OF EXPRESSION IN A PATIENT WITH CLEAVED B-CELL LYMPHOMA LEUKEMIA	ONCOGENE			English	Note							GROWTH ARREST; PHORBOL ESTER; PHOSPHOPROTEIN; DIFFERENTIATION; PHOSPHORYLATION; IDENTIFICATION; CHROMOSOME-1; CONSERVATION; STATHMIN; LIGHT	p18 is a well conserved gene coding for an 18 kDa cytosolic phosphoprotein. Although the function of p18 is unknown, it is suspected of playing a role in regulation of cell proliferation or the proliferation-differentiation switch. Here we have found p18 mRNA expression highest in testis, brain, thymus and a multipotent hematopoietic stem cell line and lowest in liver. p18 was also expressed vigorously in all but one of 85 diverse tumor cell lines and primary human malignant specimens examined. In five primary tumors, expression was substantially elevated with respect to expression in contiguous normal tissue. Expression in chronic phase chronic myelogenous leukemia cells was far greater than in normal blood cells and increased with progression of disease. In liver material, the highest level of p18 was found in a primary hepatoblastoma, a stem cell tumor, whereas a benign adenoma demonstrated very low level expression. Cells from a cleaved B cell lymphoma/leukemia failed to express p18 whereas 18 specimens from other B lymphoid malignancies, including a second cleaved cell malignancy, expressed p18 at substantial levels. These data are consistent with p18 playing a role in control of cell proliferation in at least certain tissues. The questions arise if high level p18 expression in certain malignancies may play a primary role in driving cell proliferation or, based on chromosomal localization and inactivation of p18 expression in one lymphoma, if p18 may act as a tumor suppressor.	YALE UNIV,SCH MED,HEMATOL SECT,333 CEDAR ST,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,DEPT INTERNAL MED,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,GASTROENTEROL SECT,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,CTR COMPREHENS CANC,NEW HAVEN,CT 06510; CUNY MT SINAI SCH MED,DEPT MED,HEMATOL SECT,NEW YORK,NY 10029	Yale University; Yale University; Yale University; Yale University; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai								BALE SJ, 1989, NEW ENGL J MED, V320, P1367, DOI 10.1056/NEJM198905253202102; BORIES D, 1989, CELL, V59, P959, DOI 10.1016/0092-8674(89)90752-6; BRAVERMAN R, 1986, J BIOL CHEM, V261, P14342; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; COOPER HL, 1989, J IMMUNOL, V143, P956; DOYE V, 1989, J BIOL CHEM, V264, P12134; DRACOPOLI NC, 1989, P NATL ACAD SCI USA, V86, P4614, DOI 10.1073/pnas.86.12.4614; FERRUCCI JT, 1990, BILIARY LITHOTRIPSY, V2, P1; FEUERSTEIN N, 1984, J BIOL CHEM, V259, P2782; FONG C, 1989, P NATL ACAD SCI USA, V86, P3756; HANASH S, 1989, BLOOD S1, V74, pA347; HANASH SM, 1988, J BIOL CHEM, V263, P12813; KOPPEL J, 1990, J BIOL CHEM, V265, P3703; LUSCHER B, 1990, GENE DEV, V4, P2235, DOI 10.1101/gad.4.12b.2235; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; MATHEW CGP, 1987, NATURE, V328, P524, DOI 10.1038/328524a0; SCHMID P, 1991, DEVELOPMENT, V113, P857; SCHUBART UK, 1989, DNA-J MOLEC CELL BIO, V8, P389, DOI 10.1089/dna.1.1989.8.389; ZHU XX, 1989, J BIOL CHEM, V264, P14556	19	32	32	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1993	8	10					2869	2872						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LX343	8397372				2022-12-17	WOS:A1993LX34300032
J	SOWERBY, SJ; KENNEDY, MA; FITZGERALD, PH; MORRIS, CM				SOWERBY, SJ; KENNEDY, MA; FITZGERALD, PH; MORRIS, CM			DNA-SEQUENCE ANALYSIS OF THE MAJOR BREAKPOINT CLUSTER REGION OF THE BCR GENE REARRANGED IN PHILADELPHIA-POSITIVE HUMAN LEUKEMIAS	ONCOGENE			English	Note							ACUTE LYMPHOBLASTIC-LEUKEMIA; CHRONIC MYELOID-LEUKEMIA; 1ST INTRON; ALU SEQUENCES; ABL GENES; TRANSLOCATION; CHROMOSOME; CONSENSUS; INSERTION; PATIENT	We sought sequence characteristics that might explain the apparent high recombination frequency of the 5-kb BgIII segment containing M-bcr exons 1, 2 and 3, and the intron to exon 4. An Alu sequence (subfamily Sx), in 5' --> 3' orientation, lay in the middle of a 3-kb region that contains the great majority of Philadelphia chromosome breakpoint sites. The breakpoint of only one out of five chronic myeloid leukemia patients, for whom the BCR breakpoint site had been sequenced, was located within this Alu. Other features of interest for recombination were a 51-bp AT-rich region close to the 3' end, six hypervariable minisatellite consensus octamers, GC[A/T]GG[A/T]GG, six lymphoid recombinase heptamer signal sequences, one nonamer and a 16-bp inverted repeat. Dot matrix comparisons of the 5-kb M-bcr sequence with a 3-kb m-bcr2 segment showed significant homology only in corresponding Alu sequences.	CHRISTCHURCH HOSP,CHRISTCHURCH SCH MED,DEPT PATHOL,CYTOGENET & MOLEC ONCOL UNIT,CHRISTCHURCH,NEW ZEALAND	Christchurch Hospital New Zealand; University of Otago			Morris, Christine/G-1690-2011; Sowerby, Stephen J/G-7601-2011; Kennedy, Martin A/A-4942-2008	Kennedy, Martin A/0000-0002-6445-8526				BOEHM T, 1989, EMBO J, V8, P2621, DOI 10.1002/j.1460-2075.1989.tb08402.x; BOEHM T, 1989, EUR J BIOCHEM, V185, P1, DOI 10.1111/j.1432-1033.1989.tb15074.x; CHEN SJ, 1989, NUCLEIC ACIDS RES, V17, P7631, DOI 10.1093/nar/17.19.7631; CHEN SJ, 1988, LEUKEMIA, V2, P634; CHEN SJ, 1989, ONCOGENE, V4, P195; CHEN SJ, 1989, BLOOD, V73, P1312; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; DEKLEIN A, 1986, NUCLEIC ACIDS RES, V14, P7071, DOI 10.1093/nar/14.17.7071; DIEKMANN D, 1991, NATURE, V351, P400, DOI 10.1038/351400a0; FITZGERALD PH, 1991, CANCER GENET CYTOGEN, V55, P129, DOI 10.1016/0165-4608(91)90248-S; GALLI I, 1992, NUCLEIC ACIDS RES, V20, P3333, DOI 10.1093/nar/20.13.3333; HEISTERKAMP N, 1990, NATURE, V344, P251, DOI 10.1038/344251a0; HEISTERKAMP N, 1985, NATURE, V315, P758, DOI 10.1038/315758a0; HEISTERKAMP N, 1988, NUCLEIC ACIDS RES, V16, P10069, DOI 10.1093/nar/16.21.10069; HEISTERKAMP N, 1985, NATURE, V317, P559, DOI 10.1038/317559b0; HERMANS A, 1987, CELL, V51, P33, DOI 10.1016/0092-8674(87)90007-9; HOFMANN JFX, 1991, CELL, V64, P951, DOI 10.1016/0092-8674(91)90319-T; HOLZMAN D, 1991, SCIENCE, V254, P1728, DOI 10.1126/science.1662411; HUEBNER K, 1989, CANCER RES, V49, P4071; JURKA J, 1991, J MOL EVOL, V32, P105, DOI 10.1007/BF02515383; KELLIHER MA, 1990, P NATL ACAD SCI USA, V87, P6649, DOI 10.1073/pnas.87.17.6649; KROWCZYNSKA AM, 1990, NUCLEIC ACIDS RES, V18, P1121, DOI 10.1093/nar/18.5.1121; LEFRANC MP, 1986, CELL, V45, P237, DOI 10.1016/0092-8674(86)90388-0; MATSUOKA M, 1991, SCIENCE, V254, P81, DOI 10.1126/science.1925563; MILLS KI, 1991, BLOOD, V78, P1155; MORRIS CM, 1991, BLOOD, V78, P1078; MURATANI K, 1991, P NATL ACAD SCI USA, V88, P11315, DOI 10.1073/pnas.88.24.11315; PAPADOPOULOS PC, 1990, GENE CHROMOSOME CANC, V1, P233, DOI 10.1002/gcc.2870010308; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; TRAVERS AA, 1990, CELL, V60, P177, DOI 10.1016/0092-8674(90)90729-X; VANDERFELTZ MJM, 1989, NUCLEIC ACIDS RES, V17, P1, DOI 10.1093/nar/17.1.1; WALLACE MR, 1991, NATURE, V353, P864, DOI 10.1038/353864a0	32	32	32	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1993	8	6					1679	1683						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LE064	8502487				2022-12-17	WOS:A1993LE06400033
J	DANIEL, J; SPIEGELMAN, GB; WEEKS, G				DANIEL, J; SPIEGELMAN, GB; WEEKS, G			CHARACTERIZATION OF A 3RD RAS GENE, RASB, THAT IS EXPRESSED THROUGHOUT THE GROWTH AND DEVELOPMENT OF DICTYOSTELIUM-DISCOIDEUM	ONCOGENE			English	Article							VULVAR INDUCTION; CELL-LINE; PROTEIN; BINDING; FAMILY; CDNAS; MICROINJECTION; TRANSFORMATION; IDENTIFICATION; SEQUENCES	Previous reports have indicated that the cellular slime mold Dictyostelium discoideum possesses two ras genes (rasG and rasD) and one rap gene (rap1). All three genes are developmentally regulated, with each showing a different pattern of transcription during the Dictyostelium life cycle. To establish whether there are additional ras or rap genes in Dictyostelium, we used -degenerate oligonucleotide primers to the highly conserved GTP-binding domains and both ras- and rap-unique sequences to amplify products from cDNA using the polymerase chain reaction (PCR). No additional rap genes were amplified, but a fragment whose nucleotide sequence predicted a novel ras gene was isolated. Using this PCR product as a probe, a full-length cDNA clone was isolated and sequenced. Its deduced amino acid sequence predicted a 197 amino acid protein that is 71% and 68% identical to RasG and RasD respectively. The new ras gene contains the conserved Ras-specific effector domain, the conserved binding site for the Ras-specific Y13-259 monoclonal antibody, and shows greater sequence similarity to the human H-Ras protein than to any other mammalian Ras protein. In view of this high level of identity to the ras gene subfamily, we have designated this gene rasB. Northern blot analysis has shown that rasB is developmentally regulated with maximum levels of a single 950-bp message detected during vegetative growth and the first 8 h of development.	UNIV BRITISH COLUMBIA,DEPT MICROBIOL,VANCOUVER V6T 1Z3,BC,CANADA; UNIV BRITISH COLUMBIA,DEPT MED GENET,VANCOUVER V6T 1Z3,BC,CANADA	University of British Columbia; University of British Columbia								BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BEITEL GJ, 1990, NATURE, V348, P503, DOI 10.1038/348503a0; BONNER JT, 1947, J EXP ZOOL, V106, P1, DOI 10.1002/jez.1401060102; CAPON DJ, 1983, NATURE, V302, P33, DOI 10.1038/302033a0; CHARDIN P, 1986, EMBO J, V5, P2203, DOI 10.1002/j.1460-2075.1986.tb04485.x; CHARDIN P, 1989, NUCLEIC ACIDS RES, V17, P4380, DOI 10.1093/nar/17.11.4380; CHARDIN P, 1989, EMBO J, V8, P1087, DOI 10.1002/j.1460-2075.1989.tb03477.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; COCUCCI SM, 1970, J CELL BIOL, V45, P399, DOI 10.1083/jcb.45.2.399; DRIVAS GT, 1990, MOL CELL BIOL, V10, P1793, DOI 10.1128/MCB.10.4.1793; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FERAMISCO JR, 1984, CELL, V38, P109, DOI 10.1016/0092-8674(84)90531-2; FURTH ME, 1982, J VIROL, V43, P294, DOI 10.1128/JVI.43.1.294-304.1982; GOUD B, 1988, CELL, V53, P753, DOI 10.1016/0092-8674(88)90093-1; HAN M, 1990, CELL, V63, P921, DOI 10.1016/0092-8674(90)90495-Z; HARIHARAN IK, 1991, CELL, V67, P717, DOI 10.1016/0092-8674(91)90066-8; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; KRISTENSEN T, 1987, NUCLEIC ACIDS RES, V15, P5507, DOI 10.1093/nar/15.14.5507; LOOMIS WF, 1982, DEV DICTYOSTELIUM DI; LOWE DG, 1987, CELL, V48, P137, DOI 10.1016/0092-8674(87)90364-3; LUDERUS MEE, 1988, J CELL SCI, V90, P701; Maniatis T., 1982, MOL CLONING; MAUDAULE P, 1985, CELL, V41, P31; MIYAKE S, 1990, EMBO J, V9, P1417, DOI 10.1002/j.1460-2075.1990.tb08257.x; NODA M, 1985, NATURE, V318, P73, DOI 10.1038/318073a0; PIZON V, 1988, ONCOGENE, V3, P201; REYMOND CD, 1986, NATURE, V323, P340, DOI 10.1038/323340a0; REYMOND CD, 1984, CELL, V39, P141, DOI 10.1016/0092-8674(84)90199-5; ROBBINS SM, 1990, NUCLEIC ACIDS RES, V18, P5265, DOI 10.1093/nar/18.17.5265; ROBBINS SM, 1989, P NATL ACAD SCI USA, V86, P938, DOI 10.1073/pnas.86.3.938; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANTOS E, 1989, FASEB J, V3, P2151, DOI 10.1096/fasebj.3.10.2666231; SAXE SA, 1990, MOL CELL BIOL, V10, P2367, DOI 10.1128/MCB.10.5.2367; SEEBURG PH, 1984, NATURE, V312, P71, DOI 10.1038/312071a0; SIGAL IS, 1986, P NATL ACAD SCI USA, V83, P4725, DOI 10.1073/pnas.83.13.4725; STACEY DW, 1984, NATURE, V310, P508, DOI 10.1038/310508a0; THIERY R, 1992, IN PRESS BIOCH CELL; TOUCHOT N, 1987, P NATL ACAD SCI USA, V84, P8210, DOI 10.1073/pnas.84.23.8210; VALENCIA A, 1991, BIOCHEMISTRY-US, V30, P4637, DOI 10.1021/bi00233a001; VANHAASTERT PJM, 1987, P NATL ACAD SCI USA, V84, P4905	40	32	33	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1993	8	4					1041	1047						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KT220	8455930				2022-12-17	WOS:A1993KT22000028
J	MING, L; NAN, Z; HO, AD				MING, L; NAN, Z; HO, AD			GENOMIC ORGANIZATION OF THE PUTATIVE HUMAN HOMEOBOX PROTOONCOGENE HOX-11 (TCL-3) AND ITS ENDOGENOUS EXPRESSION IN T-CELLS	ONCOGENE			English	Article								The HOX-11 (TCL-3) gene, which is abnormally expressed in the leukemic cells of some patients with T-cell acute lymphoblastic leukemia, is a new member of the homeobox gene family. It is structurally altered by the t(10;14) chromosomal translocation, resulting in head-to-tail juxtaposition of HOX-11 with the T-cell receptor delta-chain gene. In order to understand the normal functions of HOX-11 and its role in T-cell leukemia, we have determined the exon-intron structure of the HOX-11 gene. By using oligonucleotide primers flanking an intron of the HOX-11 gene, we have developed a quantitative reverse transcription-polymerase chain reaction (RT-PCR) assay for the expression of HOX-11. We detected HOX-11 expression in multiple cell lineages including normal T cells and two T-cell lines in which the HOX-11 gene appeared to be unaltered in structure. Our results suggest that deregulation of the endogenous expression of HOX-11 in normal T cells represents an essential step towards the formation of this type of T-cell leukemia.	UNIV OTTAWA, DEPT MED, OTTAWA K1N 6N5, ONTARIO, CANADA	University of Ottawa	MING, L (corresponding author), UNIV OTTAWA, NE ONTARIO REG CANC CTR, 41 RAMSEY LAKE RD, SUDBURY P3E 5J1, ONTARIO, CANADA.							BOEHM T, 1991, ONCOGENE, V6, P695; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; CLEARY ML, 1991, CELL, V66, P619, DOI 10.1016/0092-8674(91)90105-8; CROCE CM, 1991, CANCER RES, V51, pS5015; FINGER LR, 1986, SCIENCE, V234, P982, DOI 10.1126/science.3490692; GEHRING WJ, 1990, TRENDS GENET, V6, P323, DOI 10.1016/0168-9525(90)90253-3; GREEN AR, 1991, ONCOGENE, V6, P475; HATANO M, 1991, SCIENCE, V253, P79, DOI 10.1126/science.1676542; KENNEDY MA, 1991, P NATL ACAD SCI USA, V88, P8900, DOI 10.1073/pnas.88.20.8900; KESSEL M, 1990, SCIENCE, V249, P374, DOI 10.1126/science.1974085; KONGSUWAN K, 1988, EMBO J, V7, P2131, DOI 10.1002/j.1460-2075.1988.tb03052.x; LU M, 1991, EMBO J, V10, P2905, DOI 10.1002/j.1460-2075.1991.tb07840.x; MCGUIRE EA, 1991, BLOOD, V77, P599; NOWELL PC, 1988, FASEB J, V2, P3054, DOI 10.1096/fasebj.2.15.3056765; PEVERALI FA, 1990, DIFFERENTIATION, V45, P61, DOI 10.1111/j.1432-0436.1990.tb00458.x; ROWLEY JD, 1982, SCIENCE, V216, P749, DOI 10.1126/science.7079737; ROYERPOKORA B, 1991, ONCOGENE, V6, P1887; SCHUGHART K, 1988, BRIT J CANCER, V58, P9; SCOTT MP, 1989, BIOCHIM BIOPHYS ACTA, V989, P25, DOI 10.1016/0304-419X(89)90033-4; SHEN WF, 1989, P NATL ACAD SCI USA, V86, P8536, DOI 10.1073/pnas.86.21.8536; VISVADER J, 1991, ONCOGENE, V6, P187; ZUTTER M, 1990, P NATL ACAD SCI USA, V87, P3161, DOI 10.1073/pnas.87.8.3161	22	32	33	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	1992	7	7					1325	1330						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HZ971	1352396				2022-12-17	WOS:A1992HZ97100010
J	JUCKER, M; ROEBROEK, AJM; MAUTNER, J; KOCH, K; EICK, D; DIEHL, V; VANDEVEN, WJM; TESCH, H				JUCKER, M; ROEBROEK, AJM; MAUTNER, J; KOCH, K; EICK, D; DIEHL, V; VANDEVEN, WJM; TESCH, H			EXPRESSION OF TRUNCATED TRANSCRIPTS OF THE PROTOONCOGENE C-FPS/FES IN HUMAN LYMPHOMA AND LYMPHOID LEUKEMIA-CELL LINES	ONCOGENE			English	Article							FUJINAMI SARCOMA-VIRUS; CHRONIC MYELOGENOUS LEUKEMIA; TYROSINE KINASE-ACTIVITY; HODGKINS-DISEASE; BURKITTS-LYMPHOMA; TRANSFORMING GENE; ANTIGEN RECEPTOR; TRANSGENIC MICE; FPS PROTEIN; DIFFERENTIATION	The human c-fps/fes proto-oncogene is expressed as a transcript of about 3.0 kb in both normal and leukemic myeloid cells. We have detected truncated c-fps/fes transcripts of about 0.9 kb in a panel of human lymphoma and lymphoid leukemia cell lines, but not in normal untransformed hematopoietic cells. Analysis of the chromatin structure of the c-fps/fes gene revealed DNAase I-hypersensitive sites in the 5' region of the gene and in exon 16. The presence and absence of these sites correlates with the expression of the 3.0 kb and 0.9 kb c-fps/fes RNAs respectively. The truncated transcripts initiate at two distinct sites within exon 16 of the c-fps/fes gene. The genomic region 5' to the transcription initiation sites is G + C rich but does not contain typical promoter consensus sequences. Sequence analysis of a cDNA clone of the truncated c-fps/fes transcripts did not reveal any point mutation and the truncated transcripts are normally spliced using the regular splice donor and acceptor sites. A putative open reading frame encompasses the phosphotransfer motif and the autophosphorylation site of the fps/fes kinase domain. In vitro transcription/translation of a cDNA clone corresponding to the truncated c-fps/fes transcripts revealed a protein of 17 kDa. There are no translocations or rearrangements in or around the c-fps/fes gene in cell lines which express the truncated c-fps/fes transcripts. This alternative transcription of c-fps/fes may indicate a novel activation process of this proto-oncogene.	UNIV COLOGNE,MED KLIN 1,JOSEPH STELZMANNSTR 9,W-5000 COLOGNE 41,GERMANY; CATHOLIC UNIV LEUVEN,CTR HUMAN GENET,MOLEC ONCOL SECT,B-3000 LOUVAIN,BELGIUM; GESELL STRAHLEN & UMWELTFORSCH MBH,FORSCHUNGSZENTRUM UMWELT & GESUNDHEIT,INST MED MOLEK BIOL,W-8000 MUNICH,GERMANY	University of Cologne; KU Leuven								ALCALAY M, 1990, ONCOGENE, V5, P267; ARRUSHDI A, 1983, SCIENCE, V222, P390, DOI 10.1126/science.6414084; BERNARD O, 1983, EMBO J, V2, P2375, DOI 10.1002/j.1460-2075.1983.tb01749.x; BERNHEIM A, 1981, CANCER GENET CYTOGEN, V3, P307, DOI 10.1016/0165-4608(81)90039-X; BERNHEIM A, 1983, CANCER GENET CYTOGEN, V8, P223, DOI 10.1016/0165-4608(83)90138-3; CARMIER JF, 1986, CELL, V44, P159, DOI 10.1016/0092-8674(86)90494-0; CLARK SS, 1987, SCIENCE, V235, P85, DOI 10.1126/science.3541203; COLLINS SJ, 1977, NATURE, V270, P347, DOI 10.1038/270347a0; COLLINS SJ, 1984, SCIENCE, V225, P72, DOI 10.1126/science.6587568; DUBY AD, 1986, P NATL ACAD SCI USA, V83, P4890, DOI 10.1073/pnas.83.13.4890; DYNYN WS, 1983, CELL, V35, P79; EICK D, 1985, EMBO J, V4, P3717, DOI 10.1002/j.1460-2075.1985.tb04140.x; FAINSTEIN E, 1987, NATURE, V330, P386, DOI 10.1038/330386a0; FALK MH, 1987, INT J CANCER, V40, P262, DOI 10.1002/ijc.2910400223; FELDMAN RA, 1989, J VIROL, V63, P5469, DOI 10.1128/JVI.63.12.5469-5474.1989; FELDMAN RA, 1985, P NATL ACAD SCI USA, V82, P2379, DOI 10.1073/pnas.82.8.2379; FELDMAN RA, 1987, ONCOGENE RES, V1, P441; FELDMAN RA, 1980, CELL, V22, P757, DOI 10.1016/0092-8674(80)90552-8; FERRARI S, 1985, BRIT J HAEMATOL, V59, P21, DOI 10.1111/j.1365-2141.1985.tb02959.x; FISCHMAN K, 1990, MOL CELL BIOL, V10, P146, DOI 10.1128/MCB.10.1.146; FOLEY GE, 1965, CANCER, V18, P522, DOI 10.1002/1097-0142(196504)18:4<522::AID-CNCR2820180418>3.0.CO;2-J; FONATSCH C, 1982, INT J CANCER, V30, P321, DOI 10.1002/ijc.2910300311; FONATSCH C, 1986, CANCER GENET CYTOGEN, V20, P39, DOI 10.1016/0165-4608(86)90106-8; GALE RP, 1984, P NATL ACAD SCI-BIOL, V81, P5648, DOI 10.1073/pnas.81.18.5648; GARDNER MB, 1970, NATURE, V226, P807, DOI 10.1038/226807a0; GREER P, 1990, MOL CELL BIOL, V10, P2521, DOI 10.1128/MCB.10.6.2521; GREER PA, 1988, MOL CELL BIOL, V8, P578, DOI 10.1128/MCB.8.2.578; HANAFUSA T, 1980, P NATL ACAD SCI-BIOL, V77, P3009, DOI 10.1073/pnas.77.5.3009; HARPER ME, 1983, NATURE, V304, P169, DOI 10.1038/304169a0; JONES DB, 1985, HEMATOL ONCOL, V3, P133, DOI 10.1002/hon.2900030205; JUCKER M, 1990, HEMATOL ONCOL, V8, P191, DOI 10.1002/hon.2900080404; Kamesaki H, 1989, Recent Results Cancer Res, V117, P83; KAMESAKI H, 1986, BLOOD, V68, P285; KOCH K, 1990, NUCLEIC ACIDS RES, V18, P5918, DOI 10.1093/nar/18.19.5918; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; KOZAK M, 1984, NATURE, V308, P241, DOI 10.1038/308241a0; LEE WH, 1980, P NATL ACAD SCI-BIOL, V77, P2018, DOI 10.1073/pnas.77.4.2018; LENOIR GM, 1982, NATURE, V298, P474, DOI 10.1038/298474a0; LENOIR GM, 1985, IARC SCI PUBL, V60, P309; MACDONALD I, 1985, MOL CELL BIOL, V5, P2543, DOI 10.1128/MCB.5.10.2543; MARTINZANCA D, 1986, NATURE, V319, P743, DOI 10.1038/319743a0; MOOS M, 1983, EMBO J, V2, P757, DOI 10.1002/j.1460-2075.1983.tb01496.x; MORAN MF, 1988, ONCOGENE, V3, P665; PARK M, 1986, CELL, V45, P95; PAULES RS, 1988, ONCOGENE, V3, P59; PAWSON T, 1980, CELL, V22, P767, DOI 10.1016/0092-8674(80)90553-X; ROEBROEK AJM, 1986, MOL BIOL REP, V11, P117, DOI 10.1007/BF00364823; ROEBROEK AJM, 1985, EMBO J, V4, P2897, DOI 10.1002/j.1460-2075.1985.tb04020.x; ROTH MS, 1988, BLOOD, V71, P1744; SADOWSKI I, 1987, ONCOGENE, V1, P181; SAMARUT J, 1985, MOL CELL BIOL, V5, P1067, DOI 10.1128/MCB.5.5.1067; SAVELYEVA L, 1988, CANCER GENET CYTOGEN, V34, P63, DOI 10.1016/0165-4608(88)90170-7; SCHAADT M, 1988, Cancer Reviews, V10, P108; SCHWENK HU, 1975, BLUT, V31, P299, DOI 10.1007/BF01634146; SHACKELFORD DA, 1987, J IMMUNOL, V138, P613; SNYDER SP, 1969, NATURE, V221, P1074, DOI 10.1038/2211074a0; VANBOKHOVEN A, 1991, IN PRESS MOL BIOL RE; VANDEVEN WJM, 1990, MOL BIOL REP, V14, P265, DOI 10.1007/BF00429896; YEE SP, 1989, MOL CELL BIOL, V9, P5491, DOI 10.1128/MCB.9.12.5491; YU G, 1989, J BIOL CHEM, V264, P10276; ZIEGLER A, 1987, J CLIN CHEM CLIN BIO, V25, P578	61	32	32	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1992	7	5					943	952						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HP642	1373879				2022-12-17	WOS:A1992HP64200014
J	LICHTENBERG, U; QUINTRELL, N; BISHOP, JM				LICHTENBERG, U; QUINTRELL, N; BISHOP, JM			HUMAN PROTEIN-TYROSINE KINASE GENE HCK - EXPRESSION AND STRUCTURAL-ANALYSIS OF THE PROMOTER REGION	ONCOGENE			English	Article							PROMYELOCYTIC LEUKEMIA-CELLS; SV40 T-ANTIGEN; HEMATOPOIETIC-CELLS; FGR PROTOONCOGENE; MAMMALIAN-CELLS; LCK GENE; DIFFERENTIATION; LINE; SEQUENCE; HL-60	The vertebrate gene HCK encodes a protein-tyrosine kinase that is closely related to the product of the proto-oncogene SRC. HCK is expressed principally in monocytic and granulocytic hematopoietic cells, in coordination with differentiation of these cells. Here we report an initial description of the mechanisms by which expression of human HCK is controlled. Induction of the gene during differentiation was manifested by an increase in the steady-state levels of HCK RNA and protein product. The accumulation of RNA apparently resulted from modulation of transcription itself, since no change occurred in the stability of the transcripts. Transcription initiated at multiple sites, clustered c. 145 nucleotides upstream of the first intron of HCK. The sequence of 660 bp upstream of the major initiation site was determined, revealing candidate binding sites for Sp1 and AP-2 transcription factors, but neither TATA nor CAAT elements. Comparison to the same region of the mouse hck locus showed five small regions of similarity, only two of which were topographically analogous between the two sequences. It appears that expression of HCK is regulated primarily through control of transcription, but the mechanisms by which tissue-specific expression and increase of transcription during differentiation are achieved remain to be explored.	UNIV CALIF SAN FRANCISCO, GEORGE WILLIAMS HOOPER FDN, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco	LICHTENBERG, U (corresponding author), UNIV CALIF SAN FRANCISCO, DEPT MICROBIOL & IMMUNOL, SAN FRANCISCO, CA 94143 USA.				NATIONAL CANCER INSTITUTE [R35CA044338] Funding Source: NIH RePORTER; NCI NIH HHS [CA 44338] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAHAM KM, 1991, J EXP MED, V173, P1421, DOI 10.1084/jem.173.6.1421; ADLER HT, 1988, J VIROL, V62, P4113, DOI 10.1128/JVI.62.11.4113-4122.1988; AMREIN KE, 1988, P NATL ACAD SCI USA, V85, P4247, DOI 10.1073/pnas.85.12.4247; BARNEKOW A, 1986, EMBO J, V5, P701, DOI 10.1002/j.1460-2075.1986.tb04270.x; BERNARDS A, 1990, EMBO J, V9, P2279, DOI 10.1002/j.1460-2075.1990.tb07399.x; BIGGIN MD, 1983, P NATL ACAD SCI-BIOL, V80, P3963, DOI 10.1073/pnas.80.13.3963; BOLEN JB, 1989, TRENDS BIOCHEM SCI, V14, P404, DOI 10.1016/0968-0004(89)90288-0; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COLLINS SJ, 1977, NATURE, V270, P347, DOI 10.1038/270347a0; COLLINS SJ, 1980, INT J CANCER, V25, P213, DOI 10.1002/ijc.2910250208; COLLINS SJ, 1978, P NATL ACAD SCI USA, V75, P2458, DOI 10.1073/pnas.75.5.2458; COLLINS SJ, 1987, BLOOD, V70, P1233; COOKE M P, 1989, New Biologist, V1, P66; Cooper J.A, 1990, PEPT PROT PHOSPH, P85; COTTON PC, 1983, MOL CELL BIOL, V3, P1157, DOI 10.1128/MCB.3.6.1157; DALTON WT, 1988, BLOOD, V71, P242; DANI C, 1984, P NATL ACAD SCI-BIOL, V81, P7046, DOI 10.1073/pnas.81.22.7046; DYMECKI SM, 1990, SCIENCE, V247, P332, DOI 10.1126/science.2404338; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; EISEMAN E, 1990, CANCER CELL-MON REV, V2, P303; GALLAGHER R, 1979, BLOOD, V54, P713; GARVIN AM, 1990, INT IMMUNOL, V2, P173, DOI 10.1093/intimm/2.2.173; GARVIN AM, 1988, MOL CELL BIOL, V8, P3058, DOI 10.1128/MCB.8.8.3058; GEE CE, 1986, P NATL ACAD SCI USA, V83, P5131, DOI 10.1073/pnas.83.14.5131; GOLDEN A, 1986, P NATL ACAD SCI USA, V83, P852, DOI 10.1073/pnas.83.4.852; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HOLTZMAN DA, 1987, P NATL ACAD SCI USA, V84, P8325, DOI 10.1073/pnas.84.23.8325; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; KLAUSNER RD, 1991, CELL, V64, P875, DOI 10.1016/0092-8674(91)90310-U; LEY TJ, 1989, MOL CELL BIOL, V9, P92, DOI 10.1128/MCB.9.1.92; LOCK P, 1991, MOL CELL BIOL, V11, P4363, DOI 10.1128/MCB.11.9.4363; LOCK P, 1990, MOL CELL BIOL, V10, P4603, DOI 10.1128/MCB.10.9.4603; LOZZIO CB, 1975, BLOOD, V45, P321, DOI 10.1182/blood.V45.3.321.321; MARTH JD, 1988, MOL CELL BIOL, V8, P540, DOI 10.1128/MCB.8.2.540; MARTH JD, 1985, CELL, V43, P393, DOI 10.1016/0092-8674(85)90169-2; MIKKO J, 1979, NATURE, V279, P605; MITCHELL PJ, 1987, CELL, V50, P847, DOI 10.1016/0092-8674(87)90512-5; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; NOTARIO V, 1989, J CELL BIOL, V109, P3129, DOI 10.1083/jcb.109.6.3129; PATEL M, 1990, ONCOGENE, V5, P201; PERLMUTTER R M, 1988, Biochimica et Biophysica Acta, V948, P245; QUINTRELL N, 1987, MOL CELL BIOL, V7, P2267, DOI 10.1128/MCB.7.6.2267; ROVERA G, 1979, P NATL ACAD SCI USA, V76, P2779, DOI 10.1073/pnas.76.6.2779; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J., 1989, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARIS CJM, 1991, EMBO J, V10, P655, DOI 10.1002/j.1460-2075.1991.tb07994.x; SHAPIRO MB, 1987, NUCLEIC ACIDS RES, V15, P7155, DOI 10.1093/nar/15.17.7155; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SORGE LK, 1984, CELL, V36, P249, DOI 10.1016/0092-8674(84)90218-6; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; SUNDSTROM C, 1976, INT J CANCER, V17, P565, DOI 10.1002/ijc.2910170504; TAKADERA T, 1989, MOL CELL BIOL, V9, P2173, DOI 10.1128/MCB.9.5.2173; TARELLA C, 1982, CANCER RES, V42, P445; WILDIN RS, 1991, J EXP MED, V173, P383, DOI 10.1084/jem.173.2.383; WILLMAN CL, 1987, P NATL ACAD SCI USA, V84, P4480, DOI 10.1073/pnas.84.13.4480; WILLMAN CL, 1991, BLOOD, V77, P726; ZIEGLER SF, 1991, ONCOGENE, V6, P283; ZIEGLER SF, 1988, J EXP MED, V168, P1801, DOI 10.1084/jem.168.5.1801; ZIEGLER SF, 1987, MOL CELL BIOL, V7, P2276, DOI 10.1128/MCB.7.6.2276; ZIEGLER SF, 1989, MOL CELL BIOL, V9, P2724, DOI 10.1128/MCB.9.6.2724; ZINN K, 1983, CELL, V34, P865, DOI 10.1016/0092-8674(83)90544-5	62	32	33	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	1992	7	5					849	858						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HP642	1373873				2022-12-17	WOS:A1992HP64200003
J	NAKANO, T; GRAF, T				NAKANO, T; GRAF, T			IDENTIFICATION OF GENES DIFFERENTIALLY EXPRESSED IN 2 TYPES OF V-MYB-TRANSFORMED AVIAN MYELOMONOCYTIC CELLS	ONCOGENE			English	Article							AMINO-ACID-SEQUENCE; CALCIUM-BINDING PROTEINS; LEUKEMIA-VIRUS; C-MYB; GROWTH-FACTOR; ETS ONCOGENE; TARGET-CELLS; EGG-WHITE; DNA; TRANSCRIPTION	In an earlier study we found that different forms of the v-myb oncogene transform myeloid cells which resemble either monoblasts [when v-myb of avian myeloblastosis virus (AMV) was used] or promyelocytes [when a point mutant in v-myb of AMV was used; Introna, M., Golay, J., Frampton J., Nakano, T., Ness, S.A. & Graf, T. (1990). Cell, 63, 1287-1297]. In the present study we have searched for genes expressed in AMV mutant-transformed promyelocytes that are not expressed in AMV-transformed monoblasts using a differential screening approach. Eight different genes were identified among more than 500 differentially expressed clones. The most abundant of these was the previously identified myb-regulated mim-1 gene. The others were found to encode a small calcium-binding (MRP-like) protein; the p20K protein; goose-type lysozyme; a ribonuclease A/angiogenin-related protein; and three non-identified proteins. Although these genes appear to be rather lineage restricted, their expression varied in different subtypes of transformed myelomonocytic cells, and only two of them (goose lysozyme and ribonuclease) showed a similar expression pattern in normal promyelocytes and macrophages, suggesting an aberrant gene regulation in the transformed cells. Co-transfection experiments of a reporter construct containing the promoter of the ribonuclease A-related gene indicated that this promoter is regulated by the v-Myb oncoprotein without the involvement of Myb-specific binding sequences.	EUROPEAN MOLEC BIOL LAB,DIFFERENTIAT PROGRAMME,MEYERHOFSTR 1,W-6900 HEIDELBERG,GERMANY	European Molecular Biology Laboratory (EMBL)			Graf, Thomas/B-4252-2015	Graf, Thomas/0000-0003-2774-4117				ALMENDRAL JM, 1988, MOL CELL BIOL, V8, P2140, DOI 10.1128/MCB.8.5.2140; BARTLETT JA, 1986, BIOTECHNIQUES, V4, P208; BEDARD PA, 1989, MOL CELL BIOL, V9, P1371, DOI 10.1128/MCB.9.3.1371; BEDARD PA, 1987, MOL CELL BIOL, V7, P1450, DOI 10.1128/MCB.7.4.1450; BEINTEMA JJ, 1985, EUR J BIOCHEM, V153, P305, DOI 10.1111/j.1432-1033.1985.tb09301.x; BEUG H, 1984, CELL, V39, P579, DOI 10.1016/0092-8674(84)90465-3; BEUG H, 1987, GENE DEV, V1, P277, DOI 10.1101/gad.1.3.277; BEUG H, 1982, EMBO J, V1, P1069, DOI 10.1002/j.1460-2075.1982.tb01298.x; BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; BISTER K, 1982, P NATL ACAD SCI-BIOL, V79, P3677, DOI 10.1073/pnas.79.12.3677; BONNEROT C, 1987, P NATL ACAD SCI USA, V84, P6795, DOI 10.1073/pnas.84.19.6795; BOYLE WJ, 1984, P NATL ACAD SCI USA, V84, P6795; CARSANA A, 1988, NUCLEIC ACIDS RES, V16, P5491, DOI 10.1093/nar/16.12.5491; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DURBAN EM, 1981, P NATL ACAD SCI-BIOL, V78, P3600, DOI 10.1073/pnas.78.6.3600; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GOLAY J, 1988, CELL, V55, P1147, DOI 10.1016/0092-8674(88)90259-0; GRAF T, 1973, VIROLOGY, V54, P398, DOI 10.1016/0042-6822(73)90152-9; GRAF T, 1981, EXP CELL RES, V131, P331, DOI 10.1016/0014-4827(81)90236-6; HERBOMEL P, 1984, CELL, V39, P653, DOI 10.1016/0092-8674(84)90472-0; HUYNH TV, 1985, DNA CLONING PRACTICA, V1; INTRONA M, 1990, CELL, V63, P1287, DOI 10.1016/0092-8674(90)90424-D; ISOBE T, 1978, EUR J BIOCHEM, V89, P379, DOI 10.1111/j.1432-1033.1978.tb12539.x; KLEMPNAUER KH, 1989, GENE DEV, V3, P1582, DOI 10.1101/gad.3.10.1582; KLEMPNAUER KH, 1983, CELL, V33, P345, DOI 10.1016/0092-8674(83)90416-6; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; KURACHI K, 1985, BIOCHEMISTRY-US, V24, P5494, DOI 10.1021/bi00341a032; KUWANO R, 1986, FEBS LETT, V202, P87; LAGASSE E, 1988, MOL CELL BIOL, V8, P2402, DOI 10.1128/MCB.8.6.2402; LEPRINCE D, 1983, NATURE, V306, P395, DOI 10.1038/306395a0; LEUTZ A, 1984, EMBO J, V3, P3191, DOI 10.1002/j.1460-2075.1984.tb02278.x; MOSCOVICI C, 1982, ADV VIRAL ONCOLOGY O, V1; NESS SA, 1987, CELL, V51, P41, DOI 10.1016/0092-8674(87)90008-0; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; NUNN M, 1989, NATURE, V306, P391; ODINK K, 1987, NATURE, V330, P80, DOI 10.1038/330080a0; QUEVA C, 1992, IN PRESS DEVELOPMENT; ROUSSEL M, 1979, NATURE, V281, P452, DOI 10.1038/281452a0; SAKURA H, 1989, P NATL ACAD SCI USA, V86, P5758, DOI 10.1073/pnas.86.15.5758; Sambrook J., 1989, MOL CLONING LAB MANU; SHOENTGEN F, 1982, EUR J BIOCHEM, V123, P489; SIMPSON RJ, 1980, BIOCHEMISTRY-US, V19, P1814, DOI 10.1021/bi00550a013; SIMPSON RJ, 1983, BIOCHIM BIOPHYS ACTA, V744, P349, DOI 10.1016/0167-4838(83)90210-8; VENNSTROM B, 1982, CELL, V28, P135, DOI 10.1016/0092-8674(82)90383-X; WESTON K, 1989, CELL, V58, P85, DOI 10.1016/0092-8674(89)90405-4; ZENKE M, 1988, CELL, V52, P107, DOI 10.1016/0092-8674(88)90535-1	48	32	38	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1992	7	3					527	534						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HK005	1549365				2022-12-17	WOS:A1992HK00500019
J	SHIROUZU, M; FUJITAYOSHIGAKI, J; ITO, Y; KOIDE, H; NISHIMURA, S; YOKOYAMA, S				SHIROUZU, M; FUJITAYOSHIGAKI, J; ITO, Y; KOIDE, H; NISHIMURA, S; YOKOYAMA, S			A GLUTAMIC-ACID RESIDUE AT POSITION-31 OF RAS PROTEIN IS ESSENTIAL TO THE SIGNAL TRANSDUCTION FOR NEURITE OUTGROWTH OF PC12 CELLS AND THE STIMULATION OF GTPASE ACTIVITY BY GAPRAS	ONCOGENE			English	Article							PUTATIVE EFFECTOR DOMAIN; ACTIVATING PROTEIN; GENE-PRODUCT; SACCHAROMYCES-CEREVISIAE; ONCOGENE PROTEIN; CATALYTIC DOMAIN; BINDING DOMAIN; RAS-P21 GTPASE; BOVINE BRAIN; P21 GTPASE	The roles of residues at positions 23-31 adjacent to the 'effector region' and residues at positions 61-65 in a phosphoryl binding loop of the human c-Ha-ras protein were studied by changing each residue of the normal (Gly-12 type) and oncogenic (Val-12 type) Ras proteins to the corresponding residue of the K-rev-1 protein. Firstly, the signal-transducing activities of the mutant Ras proteins of Val-12 type were examined by analysis of their ability to induce neurite outgrowth of phaeochromocytoma (PC12) cells upon expression of the mutant ras gene. Thus, replacement of Glu-31 by Lys was found to impair the signal-transducing activity of the oncogenic Ras protein. Furthermore, it was shown that expression of the Gly-12 --> Val/Glu-31 --> Lys mutant Ras protein in PC12 cells suppresses neurite outgrowth induced either by microinjection of the oncogenic Ras protein or by addition of nerve growth factor to the medium. As for the Glu-31 --> Lys mutant Ras protein (Gly-12 type), the GTPase activity in the presence of GTPase-activating protein for Ras (GAP(Ras)) is much lower than that of the normal Ras protein, whereas the intrinsic GTPase activity is nearly the same as that of the normal Ras protein. Therefore, Gly-31 is one of the determinants for the signal transduction and the correct interaction with GAP(Ras) on the other hand, the GTPase activity of the Gln-61 --> Thr mutant Ras protein (Gly-12 type) is negligibly low both in the absence and in the presence of GAP(Ras).	UNIV TOKYO,FAC SCI,DEPT BIOPHYS & BIOCHEM,BUNKYO KU,TOKYO 113,JAPAN; NATL CANC CTR,RES INST,DIV BIOL,CHUO KU,TOKYO 104,JAPAN	University of Tokyo; National Cancer Center - Japan			Ito, Yutaka/P-2604-2015; Koide, Hiroshi/E-9000-2011; Yokoyama, Shigeyuki/N-6911-2015; Shirouzu, Mikako/A-6521-2016; Yoshigaki, Junko/AAE-6702-2020	Ito, Yutaka/0000-0002-1030-4660; Yokoyama, Shigeyuki/0000-0003-3133-7338; Koide, Hiroshi/0000-0001-5916-3179				ADARI H, 1988, SCIENCE, V240, P518, DOI 10.1126/science.2833817; BALLESTER R, 1990, CELL, V63, P851, DOI 10.1016/0092-8674(90)90151-4; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; CAI H, 1990, MOL CELL BIOL, V10, P5314, DOI 10.1128/MCB.10.10.5314; CALES C, 1988, NATURE, V332, P548, DOI 10.1038/332548a0; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; DEVOS AM, 1988, SCIENCE, V239, P888, DOI 10.1126/science.2448879; FARNSWORTH CL, 1991, CELL, V64, P625, DOI 10.1016/0092-8674(91)90246-U; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FIELD J, 1987, MOL CELL BIOL, V7, P2128, DOI 10.1128/MCB.7.6.2128; Frech M, 1990, SCIENCE, V249, P169, DOI 10.1126/science.2164710; GIBBS JB, 1989, P NATL ACAD SCI USA, V86, P6630, DOI 10.1073/pnas.86.17.6630; GIBBS JB, 1988, P NATL ACAD SCI USA, V85, P5026, DOI 10.1073/pnas.85.14.5026; HA JM, 1989, BIOCHEMISTRY-US, V28, P8411, DOI 10.1021/bi00447a021; HAGAG N, 1986, NATURE, V319, P680, DOI 10.1038/319680a0; HART PA, 1990, ONCOGENE, V5, P1099; HATA Y, 1990, J BIOL CHEM, V265, P7104; HATATANAKA A, 1989, BIOCHEMISTRY-US, V28, P9550, DOI 10.1021/bi00450a045; KANAI T, 1987, JPN J CANCER RES, V78, P1314; KAWATA M, 1988, J BIOL CHEM, V263, P18965; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; MARSHALL MS, 1989, EMBO J, V8, P1105, DOI 10.1002/j.1460-2075.1989.tb03480.x; MARTIN GA, 1990, CELL, V63, P843, DOI 10.1016/0092-8674(90)90150-D; MARUTA H, 1991, J BIOL CHEM, V266, P11661; MCCORMICK F, 1989, CELL, V56, P5, DOI 10.1016/0092-8674(89)90976-8; MILBURN MV, 1990, SCIENCE, V247, P939, DOI 10.1126/science.2406906; MIURA K, 1986, JPN J CANCER RES, V77, P45; NODA M, 1985, NATURE, V318, P73, DOI 10.1038/318073a0; PAI EF, 1989, NATURE, V341, P209, DOI 10.1038/341209a0; PIZON V, 1988, ONCOGENE, V3, P201; POWERS S, 1989, MOL CELL BIOL, V9, P390, DOI 10.1128/MCB.9.2.390; SATOH T, 1991, P NATL ACAD SCI USA, V88, P3314, DOI 10.1073/pnas.88.8.3314; SATOH T, 1987, MOL CELL BIOL, V7, P4553, DOI 10.1128/MCB.7.12.4553; SCHLICHTING I, 1990, BIOCHEMISTRY-US, V29, P504, DOI 10.1021/bi00454a026; SIGAL IS, 1986, P NATL ACAD SCI USA, V83, P4725, DOI 10.1073/pnas.83.13.4725; STONE JC, 1988, MOL CELL BIOL, V8, P3565, DOI 10.1128/MCB.8.8.3565; SZERBERENYI J, 1990, MOL CELL BIOL, V10, P5324; TRAHEY M, 1988, SCIENCE, V242, P1697, DOI 10.1126/science.3201259; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; WILLUMSEN BM, 1986, MOL CELL BIOL, V6, P2646, DOI 10.1128/MCB.6.7.2646; XU GF, 1990, CELL, V63, P835, DOI 10.1016/0092-8674(90)90149-9; ZHANG K, 1990, SCIENCE, V249, P162, DOI 10.1126/science.2115210	44	32	32	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1992	7	3					475	480						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HK005	1549361				2022-12-17	WOS:A1992HK00500011
J	HARTL, M; HUTCHINS, JT; VOGT, PK				HARTL, M; HUTCHINS, JT; VOGT, PK			THE CHICKEN JUND GENE AND ITS PRODUCT	ONCOGENE			English	Article							C-JUN; PROTO-ONCOGENE; SEQUENCES; FOS; REGULATOR; FRAGMENTS; PROTEINS; MEMBER; FAMILY	We have isolated and characterized the chicken junD gene. It does not contain an intron; its upstream regulatory sequences lack the AP-1-binding site seen in c-jun but include two CRE elements. Downstream untranslated sequences do not show the destabilizing signal ATTTA. The amino acid sequence of the chicken JunD protein is closely related to that of mouse JunD in the dimerization and DNA contact surfaces of the carboxy-terminal region; additional homologies to mouse JunD are seen in acidic and amphipathic amino-terminal domains. Chicken JunD contains stretches of oligoglycines, alanines and prolines, possibly acting as hinges that connect functionally distinct domains of the protein. Chicken junD is broadly expressed at low basal levels in differentiated tissues and at somewhat higher levels in cultured fibroblasts. The cDNA clone of junD was transcribed and translated in vitro. The resulting JunD protein migrates in between 40 and 50 kDa in an SDS gel and can be precipitated with an antibody prepared against a polypeptide consisting of the carboxy-terminal 100 amino acids of mouse c-Jun.	UNIV SO CALIF,SCH MED,DEPT MICROBIOL,LOS ANGELES,CA 90033; NORRIS CANC CTR,LOS ANGELES,CA 90033	University of Southern California			Hartl, Markus/O-4655-2014; Vogt, Peter K./R-7547-2019	Hartl, Markus/0000-0001-7447-5920; Vogt, Peter K./0000-0002-4519-7500	NATIONAL CANCER INSTITUTE [R35CA042564] Funding Source: NIH RePORTER; NCI NIH HHS [CA42564] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; BALL AR, 1988, COLD SPRING HARB SYM, V53, P687, DOI 10.1101/SQB.1988.053.01.078; BIRNSTIEL ML, 1985, CELL, V41, P349, DOI 10.1016/S0092-8674(85)80007-6; BOS TJ, 1989, ONCOGENE, V4, P123; BOS TJ, 1990, GENE DEV, V4, P1677, DOI 10.1101/gad.4.10.1677; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; CURRAN T, 1987, ONCOGENE, V2, P79; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; KIMMEL SL, 1987, METHODS ENZYMOLOGY, V152; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Maniatis T, 1989, DECONTAMINATION DILU; MCKNIGHT S, 1986, CELL, V46, P795, DOI 10.1016/0092-8674(86)90061-9; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; NISHIMURA T, 1988, ONCOGENE, V3, P659; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; SAP J, 1986, NATURE, V324, P635, DOI 10.1038/324635a0; SCHUTTE J, 1989, CELL, V59, P987, DOI 10.1016/0092-8674(89)90755-1; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SINGH H, 1986, NATURE, V319, P144; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0	24	32	34	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1991	6	9					1623	1631						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX274	1923529				2022-12-17	WOS:A1991GX27400018
J	BERGER, I; SHAUL, Y				BERGER, I; SHAUL, Y			STRUCTURE AND FUNCTION OF HUMAN JUN-D	ONCOGENE			English	Article							B VIRUS ENHANCER; C-JUN; TRANSCRIPTIONAL ACTIVATION; TRANS-ACTIVATOR; V-JUN; GENE; BINDING; AP-1; FOS; EXPRESSION	A jun related cDNA and its corresponding genomic fragment were cloned from human cells and sequenced. Polymerase chain reaction analysis showed that this gene is the human homologue of the mouse jun-D gene despite the fact that the degree of amino acid sequence conservation between the two is much poorer (77.3%) than that found between the homologues of c-jun and jun-B (95-98%). The product of this gene binds an AP-1 site and upon cotransfection stimulates the activity of a promoter that bears an AP-1 site. The level of activation is comparable to that of v-jun and the activity of both is further stimulated by v-fos. Deletion mutants of the gene that lack the best conserved region in the activating domain are poorly active. However, our data suggest that the activating domain is not confined exclusively to the conserved regions. Interestingly, at high concentrations human jun-D displays decreased activity which cannot be explained by a simple self squelching model.			BERGER, I (corresponding author), WEIZMANN INST SCI, DEPT MOLEC GENET & VIROL, IL-76100 REHOVOT, ISRAEL.							ANGEL P, 1989, New Biologist, V1, P35; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; BENLEVY R, 1989, MOL CELL BIOL, V9, P1804, DOI 10.1128/MCB.9.4.1804; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BOHMANN D, 1989, CELL, V59, P709, DOI 10.1016/0092-8674(89)90017-2; BUSCH SJ, 1990, TRENDS GENET, V6, P36, DOI 10.1016/0168-9525(90)90071-D; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; DIKSTEIN R, 1990, MOL CELL BIOL, V10, P4427, DOI 10.1128/MCB.10.8.4427; FAKTOR O, 1990, ONCOGENE, V5, P867; GILL G, 1988, NATURE, V334, P721, DOI 10.1038/334721a0; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; HIRAI SI, 1990, ONCOGENE, V5, P39; LAMPH WW, 1988, NATURE, V334, P629, DOI 10.1038/334629a0; LANDSCHULZ WH, 1988, GENE DEV, V2, P786, DOI 10.1101/gad.2.7.786; MARTIN KJ, 1990, NATURE, V346, P147, DOI 10.1038/346147a0; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; PTASHNE M, 1990, NATURE, V346, P329, DOI 10.1038/346329a0; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; RYSECK RP, 1988, NATURE, V334, P535, DOI 10.1038/334535a0; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHUTTE J, 1989, P NATL ACAD SCI USA, V86, P2257, DOI 10.1073/pnas.86.7.2257; SCHUTTE J, 1989, CELL, V59, P987, DOI 10.1016/0092-8674(89)90755-1; SHAUL Y, 1984, J VIROL, V51, P776, DOI 10.1128/JVI.51.3.776-787.1984; SINGH H, 1986, NATURE, V319, P154, DOI 10.1038/319154a0; STRUHL K, 1988, NATURE, V332, P649, DOI 10.1038/332649a0; TRIEZENBERG SJ, 1988, GENE DEV, V2, P718, DOI 10.1101/gad.2.6.718; YANG-YEN H-F, 1990, New Biologist, V2, P351	31	32	33	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	1991	6	4					561	566						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FR939	1903194				2022-12-17	WOS:A1991FR93900009
J	STRAWHECKER, JM; BETZ, NA; NEADES, RY; HOUSER, W; PELLING, JC				STRAWHECKER, JM; BETZ, NA; NEADES, RY; HOUSER, W; PELLING, JC			BINDING OF THE 97KDA GLUCOCORTICOID RECEPTOR TO THE 5' UPSTREAM FLANKING REGION OF THE MOUSE C-HA-RAS ONCOGENE	ONCOGENE			English	Article									UNIV NEBRASKA,MED CTR,DEPT BIOCHEM,OMAHA,NE 68105	University of Nebraska System; University of Nebraska Medical Center	STRAWHECKER, JM (corresponding author), UNIV NEBRASKA,MED CTR,EPPLEY INST RES CANC & ALLIED DIS,42ND & DEWEY AVE,OMAHA,NE 68105, USA.				NATIONAL CANCER INSTITUTE [K04CA001382, P30CA036727, R01CA040847] Funding Source: NIH RePORTER; NCI NIH HHS [K04-CA 01382, CA40847, CA36727] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BROWN K, 1988, MOL CARCINOGEN, V1, P161, DOI 10.1002/mc.2940010304; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; GORMAN C, 1985, DNA CLONING PRACTICA, V2, P143; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GUERTIN M, 1983, BIOCHEMISTRY-US, V22, P4296, DOI 10.1021/bi00287a021; HOUSLEY PR, 1983, J BIOL CHEM, V258, P4630; HUANG AL, 1981, CELL, V27, P245, DOI 10.1016/0092-8674(81)90408-6; KARIN M, 1984, NATURE, V308, P513, DOI 10.1038/308513a0; KO MSH, 1989, DNA-J MOLEC CELL BIO, V8, P127, DOI 10.1089/dna.1.1989.8.127; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAIMINS LA, 1982, P NATL ACAD SCI-BIOL, V79, P6453, DOI 10.1073/pnas.79.21.6453; MATHIS JM, 1989, ARCH BIOCHEM BIOPHYS, V269, P93, DOI 10.1016/0003-9861(89)90090-8; MIKSICEK R, 1986, CELL, V46, P283, DOI 10.1016/0092-8674(86)90745-2; OIKARINEN J, 1981, BIOCHEM J, V198, P519, DOI 10.1042/bj1980519; OSTROWSKI MC, 1984, EMBO J, V3, P1891, DOI 10.1002/j.1460-2075.1984.tb02064.x; PAYVAR F, 1983, CELL, V35, P381, DOI 10.1016/0092-8674(83)90171-X; PELLING JC, 1987, CARCINOGENESIS, V8, P1481, DOI 10.1093/carcin/8.10.1481; POTTER E, 1981, P NATL ACAD SCI-BIOL, V78, P6662, DOI 10.1073/pnas.78.11.6662; QUINTANILLA M, 1986, NATURE, V322, P78, DOI 10.1038/322078a0; SCHEIDEREIT C, 1983, NATURE, V304, P749, DOI 10.1038/304749a0; SCHEIDEREIT C, 1984, P NATL ACAD SCI-BIOL, V81, P3029, DOI 10.1073/pnas.81.10.3029; SILVA CM, 1987, P NATL ACAD SCI USA, V84, P1744, DOI 10.1073/pnas.84.7.1744; Slaga T J, 1980, Carcinog Compr Surv, V5, P111; TIENRUNGROJ W, 1987, J BIOL CHEM, V262, P6992; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; YAMAMOTO KR, 1985, ANNU REV GENET, V19, P209, DOI 10.1146/annurev.genet.19.1.209; YUSPA SH, 1974, EXP CELL RES, V86, P95, DOI 10.1016/0014-4827(74)90653-3	28	32	32	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1989	4	11					1317	1322						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AX659	2682459				2022-12-17	WOS:A1989AX65900007
J	PENDERGAST, AM; CLARK, R; KAWASAKI, ES; MCCORMICK, FP; WITTE, ON				PENDERGAST, AM; CLARK, R; KAWASAKI, ES; MCCORMICK, FP; WITTE, ON			BACULOVIRUS EXPRESSION OF FUNCTIONAL P210 BCR-ABL ONCOGENE PRODUCT	ONCOGENE			English	Article									UNIV CALIF LOS ANGELES,INST MOLEC BIOL,405 HILGARD AVE,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,DEPT MICROBIOL,LOS ANGELES,CA 90024; CETUS CORP,DEPT MOLEC BIOL,EMERYVILLE,CA 94608; HOWARD HUGHES MED INST,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; Howard Hughes Medical Institute				Pendergast, Ann Marie/0000-0002-1250-6880				BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; CLARK SS, 1988, SCIENCE, V239, P775, DOI 10.1126/science.3422516; CLARKE CF, 1988, MOL CELL BIOL, V8, P1206, DOI 10.1128/MCB.8.3.1206; COLLINS SJ, 1984, SCIENCE, V225, P72, DOI 10.1126/science.6587568; COURTNEIDGE SA, 1983, NATURE, V303, P435, DOI 10.1038/303435a0; DALEY GQ, 1987, SCIENCE, V237, P532, DOI 10.1126/science.2440107; DAVIS RL, 1985, MOL CELL BIOL, V5, P204, DOI 10.1128/MCB.5.1.204; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; FERGUSON B, 1985, J BIOL CHEM, V260, P3652; FOULKES JG, 1985, J BIOL CHEM, V260, P8070; GREENFIELD C, 1988, EMBO J, V7, P139, DOI 10.1002/j.1460-2075.1988.tb02793.x; GROFFEN J, 1984, CELL, V36, P93, DOI 10.1016/0092-8674(84)90077-1; GROSVELD G, 1986, MOL CELL BIOL, V6, P607, DOI 10.1128/MCB.6.2.607; HERRERA R, 1988, J BIOL CHEM, V263, P5560; HINDS PW, 1987, MOL CELL BIOL, V7, P2863, DOI 10.1128/MCB.7.8.2863; HUNTER T, 1986, ENZYMES, V17, P191; JEANG KT, 1987, J VIROL, V61, P1761, DOI 10.1128/JVI.61.5.1761-1764.1987; KONOPKA JB, 1984, CELL, V37, P1035, DOI 10.1016/0092-8674(84)90438-0; KONOPKA JB, 1985, MOL CELL BIOL, V5, P3116, DOI 10.1128/MCB.5.11.3116; LOZZIO CB, 1975, BLOOD, V45, P321, DOI 10.1182/blood.V45.3.321.321; LUCKOW VA, 1988, BIO-TECHNOL, V6, P47, DOI 10.1038/nbt0188-47; MAIORELLA B, 1988, IN PRESS BIOTECHNOLO; MCLAUGHLIN J, 1987, P NATL ACAD SCI USA, V84, P6558, DOI 10.1073/pnas.84.18.6558; MESMASSON AM, 1986, P NATL ACAD SCI USA, V83, P9768, DOI 10.1073/pnas.83.24.9768; MIYAMOTO C, 1985, MOL CELL BIOL, V5, P2860, DOI 10.1128/MCB.5.10.2860; MURPHY CI, 1988, J VIROL, V62, P2951, DOI 10.1128/JVI.62.8.2951-2959.1988; NOWELL PC, 1960, SCIENCE, V132, P1497; OLLO R, 1987, P NATL ACAD SCI USA, V84, P5700, DOI 10.1073/pnas.84.16.5700; RICE WC, 1987, J VIROL, V61, P1712, DOI 10.1128/JVI.61.5.1712-1716.1987; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; SASSONECORSI P, 1988, CELL, V54, P553, DOI 10.1016/0092-8674(88)90077-3; SCHNEIDER C, 1982, J BIOL CHEM, V257, P766; SHTIVELMAN E, 1986, CELL, V47, P277, DOI 10.1016/0092-8674(86)90450-2; SHTIVELMAN E, 1985, NATURE, V315, P550, DOI 10.1038/315550a0; SMITH GE, 1983, MOL CELL BIOL, V3, P2156, DOI 10.1128/MCB.3.12.2156; SMITH GE, 1985, P NATL ACAD SCI USA, V82, P8404, DOI 10.1073/pnas.82.24.8404; Summers MD, 1987, TEXAS AGR EXPT STATI; WANG JYJ, 1985, J BIOL CHEM, V260, P64; YOUNG JC, 1988, MOL CELL BIOL, V8, P4079, DOI 10.1128/MCB.8.10.4079; ZIEGLER SF, 1981, CELL, V27, P477, DOI 10.1016/0092-8674(81)90389-5	41	32	36	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1989	4	6					759	766						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AA660	2499863				2022-12-17	WOS:A1989AA66000012
J	RAO, VN; MODI, WS; DRABKIN, HD; PATTERSON, D; OBRIEN, SJ; PAPAS, TS; REDDY, ESP				RAO, VN; MODI, WS; DRABKIN, HD; PATTERSON, D; OBRIEN, SJ; PAPAS, TS; REDDY, ESP			THE HUMAN ERG GENE MAPS TO CHROMOSOME-21, BAND-Q22 - RELATIONSHIP TO THE 8-21 TRANSLOCATION OF ACUTE MYELOGENOUS LEUKEMIA	ONCOGENE			English	Article									NCI,MOLEC ONCOL LAB,FREDERICK,MD 21701; NCI,VIRAL CARCINOGENESIS LAB,FREDERICK,MD 21701; ELEANOR ROOSEVELT INST CANC RES,DENVER,CO 80262; UNIV COLORADO,CTR CANC,DENVER,CO 80262; NCI,PROGRAM RESOURCES INC,FREDERICK,MD 21701	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Colorado System; University of Colorado Denver; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			OBRIEN, STEPHEN/ABD-1346-2020	OBRIEN, STEPHEN/0000-0001-7857-0757	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD017449] Funding Source: NIH RePORTER; NIA NIH HHS [AG00029] Funding Source: Medline; NICHD NIH HHS [HD17449] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		CANAANI E, 1984, LANCET, V1, P593; COLLINS SJ, 1984, SCIENCE, V225, P72, DOI 10.1126/science.6587568; CROCE CM, 1987, CELL, V49, P155, DOI 10.1016/0092-8674(87)90552-6; DALLAFAVERA R, 1982, P NATL ACAD SCI-BIOL, V79, P7824, DOI 10.1073/pnas.79.24.7824; DIAZ MO, 1986, SCIENCE, V231, P265, DOI 10.1126/science.3455787; DRABKIN HA, 1985, P NATL ACAD SCI USA, V82, P464, DOI 10.1073/pnas.82.2.464; EVANS DIK, 1972, LANCET, V2, P1322; JONES C, 1981, SOMAT CELL GENET, V7, P399, DOI 10.1007/BF01542985; KIRKILIONIS AJ, 1986, J PEDIATR-US, V108, P793, DOI 10.1016/S0022-3476(86)81077-0; LEPRINCE D, 1983, NATURE, V306, P395, DOI 10.1038/306395a0; LESCHOT NJ, 1981, HUM GENET, V57, P220, DOI 10.1007/BF00282029; Maniatis T., 1982, MOL CLONING; MODI WS, 1987, GENE ANAL TECH, V4, P75; NUNN MF, 1983, NATURE, V306, P391, DOI 10.1038/306391a0; OBRIEN SJ, 1983, NATURE, V302, P839, DOI 10.1038/302839a0; OBRIEN SJ, 1983, NATURE, V303, P74, DOI 10.1038/303074a0; PELLICI PG, 1986, P NATL ACAD SCI USA, V83, P2984; RAO VN, 1987, ONCOGENE RES, V2, P95; RAO VN, 1987, SCIENCE, V237, P635, DOI 10.1126/science.3299708; REDDY ESP, 1987, P NATL ACAD SCI USA, V84, P6131, DOI 10.1073/pnas.84.17.6131; REDDY ESP, 1988, IN PRESS ONCOGENE RE; ROVIGATTI U, 1986, SCIENCE, V232, P398, DOI 10.1126/science.3457468; ROWLEY JD, 1982, SCIENCE, V216, P749, DOI 10.1126/science.7079737; SACCHI N, 1986, SCIENCE, V231, P379, DOI 10.1126/science.3941901; SHOWE LC, 1987, P NATL ACAD SCI USA, V84, P2824, DOI 10.1073/pnas.84.9.2824; SHTIVELMAN E, 1985, NATURE, V315, P550, DOI 10.1038/315550a0; SINET PM, 1976, EXP CELL RES, V97, P47, DOI 10.1016/0014-4827(76)90653-4; TAUB R, 1982, P NATL ACAD SCI-BIOL, V79, P7837, DOI 10.1073/pnas.79.24.7837; WATSON DK, 1985, P NATL ACAD SCI USA, V82, P7294, DOI 10.1073/pnas.82.21.7294; WATSON DK, 1986, P NATL ACAD SCI USA, V83, P1792, DOI 10.1073/pnas.83.6.1792; YUNIS JJ, 1983, SCIENCE, V221, P227, DOI 10.1126/science.6336310	31	32	33	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1988	3	5					497	500						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	R5163	3274086				2022-12-17	WOS:A1988R516300002
J	MAUELER, W; RAULF, F; SCHARTL, M				MAUELER, W; RAULF, F; SCHARTL, M			EXPRESSION OF PROTO-ONCOGENES IN EMBRYONIC, ADULT, AND TRANSFORMED TISSUE OF XIPHOPHORUS (TELEOSTEI-POECILIIDAE)	ONCOGENE			English	Article											MAUELER, W (corresponding author), MAX PLANCK INST BIOCHEM,GENTECHNOL ARBEITSGRP MOLEK EMBRYOL,KLOPFERSPITZ 18A,D-8033 MARTINSRIED,FED REP GER.			Schartl, Manfred/0000-0001-9882-5948				ALBINO AP, 1984, NATURE, V308, P69, DOI 10.1038/308069a0; ANDERS A, 1978, BIOCHIM BIOPHYS ACTA, V516, P61, DOI 10.1016/0304-419X(78)90004-5; Anders A., 1973, P33; ANDERS F, 1984, ADV CANCER RES, V42, P191, DOI 10.1016/S0065-230X(08)60459-5; BARNEKOW A, 1987, CANCER RES, V47, P235; BARNEKOW A, 1982, CANCER RES, V42, P2429; BETSHOLTZ C, 1986, NATURE, V320, P695, DOI 10.1038/320695a0; BISHOP JM, 1986, J CELL PHYSIOL, V4, P1; BRUGGE J, 1987, GENE DEV, V1, P287, DOI 10.1101/gad.1.3.287; COLLINS T, 1985, NATURE, V316, P748, DOI 10.1038/316748a0; COTTON PC, 1983, MOL CELL BIOL, V3, P1157, DOI 10.1128/MCB.3.6.1157; DELORBE WJ, 1980, J VIROL, V36, P50, DOI 10.1128/JVI.36.1.50-61.1980; ELLIS RW, 1980, J VIROL, V36, P408, DOI 10.1128/JVI.36.2.408-420.1980; FRIEND SF, 1987, IN PRESS P NATL ACAD; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; FULTS DW, 1985, MOL CELL BIOL, V5, P27, DOI 10.1128/MCB.5.1.27; FURTH ME, 1987, ONCOGENE, V1, P47; GELMANN EP, 1981, P NATL ACAD SCI-BIOL, V78, P3373, DOI 10.1073/pnas.78.6.3373; GESSLER M, 1984, BIOSCIENCE REP, V4, P757, DOI 10.1007/BF01128817; GOFF SP, 1980, CELL, V22, P777, DOI 10.1016/0092-8674(80)90554-1; GONDA TJ, 1982, MOL CELL BIOL, V2, P617, DOI 10.1128/MCB.2.6.617; GOUSTIN AS, 1985, CELL, V41, P301, DOI 10.1016/0092-8674(85)90083-2; GUSTERSON B, 1984, CELL BIOL INT REP, V8, P649, DOI 10.1016/0309-1651(84)90045-6; HALL A, 1983, NATURE, V303, P396, DOI 10.1038/303396a0; IGARASHI H, 1987, ONCOGENE, V1, P79; JACOB L, 1987, CELL, V50, P215, DOI 10.1016/0092-8674(87)90217-0; JANSEN HW, 1983, EMBO J, V2, P1969, DOI 10.1002/j.1460-2075.1983.tb01686.x; Kallman K.D., 1975, P81; KHANDJIAN EW, 1986, MOL BIOL REP, V11, P105; KITAMURA N, 1982, NATURE, V297, P205, DOI 10.1038/297205a0; KNUDSON AG, 1985, CANCER RES, V45, P1437; KRAUS MH, 1987, EMBO J, V6, P605, DOI 10.1002/j.1460-2075.1987.tb04797.x; KUHN C, 1979, IN VITRO CELL DEV B, V15, P537, DOI 10.1007/BF02618156; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033; LEMEUR M, 1981, CELL, V23, P561, DOI 10.1016/0092-8674(81)90152-5; LEOF EB, 1986, P NATL ACAD SCI USA, V83, P2453, DOI 10.1073/pnas.83.8.2453; LEV Z, 1985, MOL CELL BIOL, V5, P1540, DOI 10.1128/MCB.5.6.1540; LEV Z, 1986, BIOCHIM BIOPHYS ACTA, V867, P144, DOI 10.1016/0167-4781(86)90074-6; LYNCH HT, 1985, PIGMENT CELL, P691; MANIATIS T, 1982, MOL CLONING LABORATO; MARTINET Y, 1986, NATURE, V319, P158, DOI 10.1038/319158a0; MARTINEZ R, 1987, SCIENCE, V237, P411, DOI 10.1126/science.2440106; MECHLER BM, 1985, EMBO J, V4, P1551, DOI 10.1002/j.1460-2075.1985.tb03816.x; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MULLER R, 1986, TRENDS BIOCHEM SCI, V11, P129, DOI 10.1016/0968-0004(86)90066-6; MULLER R, 1982, NATURE, V299, P640, DOI 10.1038/299640a0; MULLER R, 1984, CURR TOP MICROBIOL, V112, P73; MULLER R, 1983, COLD SPRING HARBOR C, V10, P451; NEMOTO N, 1987, J CANCER RES CLIN, V113, P56, DOI 10.1007/BF00389967; OHARA B, 1986, CYTOGENET CELL GENET, V43, P97, DOI 10.1159/000132303; PADUA RA, 1985, MOL CELL BIOL, V5, P582, DOI 10.1128/MCB.5.3.582; PAWSON T, 1985, MOL CELL BIOL, V5, P33, DOI 10.1128/MCB.5.1.33; REED KC, 1985, NUCLEIC ACIDS RES, V13, P7207, DOI 10.1093/nar/13.20.7207; RHODES AR, 1983, J AM ACAD DERMATOL, V9, P563, DOI 10.1016/S0190-9622(83)70171-4; SCHARTL M, 1985, INT J CANCER, V36, P199, DOI 10.1002/ijc.2910360212; SCHARTL M, 1984, DEV BIOL, V105, P415, DOI 10.1016/0012-1606(84)90298-7; SCHARTL M, 1982, CANCER RES, V42, P4222; SCHARTL M, 1988, IN PRESS PIGMENT CEL, V8; SCHARTL M, 1988, IN PRESS GENETICS; SEFTON BM, 1985, TRENDS GENET, V1, P306, DOI 10.1016/0168-9525(85)90120-9; SEJERSEN T, 1986, P NATL ACAD SCI USA, V83, P6844, DOI 10.1073/pnas.83.18.6844; SEKIYA T, 1985, JPN J CANCER RES, V76, P555; SHEINESS DK, 1980, VIROLOGY, V105, P415, DOI 10.1016/0042-6822(80)90042-2; SIMON MA, 1985, CELL, V42, P831, DOI 10.1016/0092-8674(85)90279-X; SLAMON DJ, 1984, P NATL ACAD SCI-BIOL, V81, P7141, DOI 10.1073/pnas.81.22.7141; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SPANDIDOS DA, 1985, ANTICANCER RES, V5, P221; TATOSYAN AG, 1985, INT J CANCER, V35, P731, DOI 10.1002/ijc.2910350606; TAVOLGA WN, 1949, B AM MUS NAT HIST, V164, P161; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; VARDIMON L, 1986, MOL CELL BIOL, V6, P4109, DOI 10.1128/MCB.6.11.4109; VENNSTROM B, 1982, CELL, V28, P135, DOI 10.1016/0092-8674(82)90383-X; VENNSTROM B, 1980, J VIROL, V36, P375; WAKAMATSU Y, 1984, DEV GROWTH DIFFER, V26, P503; WANG JYJ, 1983, MOL CELL BIOL, V3, P773, DOI 10.1128/MCB.3.5.773; WEINBERG RA, 1986, J CLIN ONCOL, V4, P1293, DOI 10.1200/JCO.1986.4.9.1293; WESTERMARK B, 1986, P NATL ACAD SCI USA, V83, P7197, DOI 10.1073/pnas.83.19.7197; WESTIN EH, 1982, P NATL ACAD SCI-BIOL, V79, P2490, DOI 10.1073/pnas.79.8.2490; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0	80	32	33	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1988	2	5					421	430						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	N4348	3374960				2022-12-17	WOS:A1988N434800002
J	BEREBBI, M; DANDOLO, L; HASSOUN, J; BERNARD, AM; BLANGY, D				BEREBBI, M; DANDOLO, L; HASSOUN, J; BERNARD, AM; BLANGY, D			SPECIFIC TISSUE TARGETING OF POLYOMA-VIRUS ONCOGENICITY IN ATHYMIC NUDE-MICE	ONCOGENE			English	Article									UNIV PIERRE & MARIE CURIE,INST RECH SCI CANC,VIRUS ONCOGENES LAB,EQUIPE RECH 272,BP 8,F-94802 VILLEJUIF,FRANCE; INST J PAOLI I CALMETTES,ANAT PATHOL LAB,F-13009 MARSEILLE,FRANCE; CNRS,JE,F-13009 MARSEILLE,FRANCE	UDICE-French Research Universities; Sorbonne Universite; UNICANCER; Institut Paoli-Calmette (IPC); Centre National de la Recherche Scientifique (CNRS)								ALLISON AC, 1974, NATURE, V252, P746, DOI 10.1038/252746a0; AMATI P, 1985, CELL, V43, P561, DOI 10.1016/0092-8674(85)90225-9; ARYA SK, 1982, J GEN VIROL, V63, P405, DOI 10.1099/0022-1317-63-2-405; ARYA SK, 1982, J GEN VIROL, V58, P107, DOI 10.1099/0022-1317-58-1-107; ASSELIN C, 1983, MOL CELL BIOL, V3, P1451, DOI 10.1128/MCB.3.8.1451; Azzopardi JG., 1979, PROBLEMS BREAST PATH, V1st edn; DANDOLO L, 1983, J VIROL, V47, P55, DOI 10.1128/JVI.47.1.55-64.1983; DANDOLO L, 1984, MOL CELL BIOL, V4, P317, DOI 10.1128/MCB.4.2.317; DAWE CJ, 1987, AM J PATHOL, V127, P243; DAWE CJ, 1959, J NATL CANCER I, V23, P717; DAWE CLYDE J., 1960, NATL CANCER INST MONOGR, V4, P67; EDDY BE, 1969, VIROL MONOGR, V7, P1; FLANAGAN SP, 1966, GENET RES, V8, P295, DOI 10.1017/S0016672300010168; FREUND R, 1987, J VIROL, V61, P2232, DOI 10.1128/JVI.61.7.2232-2239.1987; Fried M, 1975, Cold Spring Harb Symp Quant Biol, V39 Pt 1, P45; GIOVANELLA BC, 1985, ADV CANCER RES, V44, P69, DOI 10.1016/S0065-230X(08)60026-3; Herberman R B, 1978, Adv Cancer Res, V27, P305; HERBERMAN RB, 1975, INT J CANCER, V16, P216, DOI 10.1002/ijc.2910160204; HERBOMEL P, 1984, CELL, V39, P653, DOI 10.1016/0092-8674(84)90472-0; HERRINGGILLAM E, 1985, VIRUS RES, V4, P1, DOI 10.1016/0168-1702(85)90016-4; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; ISRAEL MA, 1980, J BIOL CHEM, V255, P3798; KATINKA M, 1980, CELL, V20, P393, DOI 10.1016/0092-8674(80)90625-X; KATINKA M, 1981, NATURE, V290, P720, DOI 10.1038/290720a0; MELIN F, 1985, EMBO J, V4, P1799, DOI 10.1002/j.1460-2075.1985.tb03853.x; MELIN F, 1985, J VIROL, V53, P862, DOI 10.1128/JVI.53.3.862-866.1985; Morris D. W., 1987, ADV VIRAL ONCOL, V7, P123; Pantelouris E M, 1973, Differentiation, V1, P437, DOI 10.1111/j.1432-0436.1973.tb00143.x; PANTELOURIS EM, 1968, NATURE, V217, P370, DOI 10.1038/217370a0; RABSON AS, 1963, J NATL CANCER I, V30, P367; RICHIE JP, 1981, J NATL CANCER I, V62, P761; SOMPAYRAC LM, 1981, P NATL ACAD SCI-BIOL, V78, P7575, DOI 10.1073/pnas.78.12.7575; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STEWART SE, 1957, VIROLOGY, V3, P380, DOI 10.1016/0042-6822(57)90100-9; STUTMAN O, 1975, J IMMUNOL, V114, P1213; VANDEPUTTE M, 1974, INT J CANCER, V14, P445, DOI 10.1002/ijc.2910140404; VASSEUR M, 1980, P NATL ACAD SCI-BIOL, V77, P1068, DOI 10.1073/pnas.77.2.1068; VASSEUR M, 1982, J VIROL, V43, P800, DOI 10.1128/JVI.43.3.800-808.1982	38	32	32	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1988	2	2					149	156						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	M0860	2835724				2022-12-17	WOS:A1988M086000008
J	EVA, A; VECCHIO, G; DIAMOND, M; TRONICK, SR; RON, D; COOPER, GM; AARONSON, SA				EVA, A; VECCHIO, G; DIAMOND, M; TRONICK, SR; RON, D; COOPER, GM; AARONSON, SA			INDEPENDENTLY ACTIVATED DBL-ONCOGENES EXHIBIT SIMILAR YET DISTINCT STRUCTURAL ALTERATIONS	ONCOGENE			English	Article									HARVARD UNIV,SCH MED,DANA FARBER CANC INST,BOSTON,MA 02115	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	EVA, A (corresponding author), NCI,CELLULAR & MOLEC BIOL LAB,BLDG 37,ROOM 1E24,BETHESDA,MD 20892, USA.		Eva, Alessandra/J-8268-2016	Eva, Alessandra/0000-0003-2949-078X				ADAMS SL, 1977, P NATL ACAD SCI USA, V74, P3399, DOI 10.1073/pnas.74.8.3399; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BIRCHMEIER C, 1986, MOL CELL BIOL, V6, P3109, DOI 10.1128/MCB.6.9.3109; COOPER CS, 1984, CANCER RES, V44, P1; Cox RA., 1968, METHODS ENZYMOL, V12, P120, DOI 10.1016/0076-6879(67)12123-X; EVA A, 1985, NATURE, V316, P273, DOI 10.1038/316273a0; EVA A, 1983, P NATL ACAD SCI-BIOL, V80, P4926, DOI 10.1073/pnas.80.16.4926; FASANO O, 1984, MOL CELL BIOL, V4, P1695, DOI 10.1128/MCB.4.9.1695; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; KONAPKA JB, 1984, CELL, V37, P1035; LANE MA, 1982, CELL, V28, P873, DOI 10.1016/0092-8674(82)90066-6; LEDER P, 1983, SCIENCE, V222, P765, DOI 10.1126/science.6356357; MARTINZANCA D, 1986, NATURE, V319, P743, DOI 10.1038/319743a0; PADUA RA, 1984, NATURE, V311, P671, DOI 10.1038/311671a0; PARK M, 1986, CELL, V45, P895, DOI 10.1016/0092-8674(86)90564-7; SHIMIZU K, 1985, P NATL ACAD SCI USA, V82, P5641, DOI 10.1073/pnas.82.17.5641; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SRIVASTAVA SK, 1986, P NATL ACAD SCI USA, V83, P8868, DOI 10.1073/pnas.83.23.8868; STANTON VP, 1987, MOL CELL BIOL, V7, P1171, DOI 10.1128/MCB.7.3.1171; TAKAHASHI M, 1985, CELL, V42, P581, DOI 10.1016/0092-8674(85)90115-1; TAKAHASHI M, 1987, MOL CELL BIOL, V7, P1378, DOI 10.1128/MCB.7.4.1378; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VARMUS HE, 1984, ANNU REV GENET, V18, P553; YOUNG D, 1986, CELL, V45, P711, DOI 10.1016/0092-8674(86)90785-3	25	32	32	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene		1987	1	4					355	360						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	K7483	3330779				2022-12-17	WOS:A1987K748300003
J	INOUE, K; IKAWA, S; SEMBA, K; SUKEGAWA, J; YAMAMOTO, T; TOYOSHIMA, K				INOUE, K; IKAWA, S; SEMBA, K; SUKEGAWA, J; YAMAMOTO, T; TOYOSHIMA, K			ISOLATION AND SEQUENCING OF CDNA CLONES HOMOLOGOUS TO THE V-FGR ONCOGENE FROM A HUMAN LYMPHOCYTE-B CELL-LINE, IM-9	ONCOGENE			English	Note									UNIV TOKYO,INST MED SCI,DEPT ONCOL,4-6-1 SHIROKANEDAI,MINATO KU,TOKYO 108,JAPAN	University of Tokyo			井川, 俊太郎/L-5911-2015					ANDERSON SK, 1985, MOL CELL BIOL, V5, P1122, DOI 10.1128/MCB.5.5.1122; BUSS JE, 1985, J VIROL, V53, P7, DOI 10.1128/JVI.53.1.7-12.1985; CHEAH MSC, 1986, NATURE, V319, P238, DOI 10.1038/319238a0; COLLETT MS, 1979, J VIROL, V29, P770, DOI 10.1128/JVI.29.2.770-781.1979; DOWNWARD J, 1984, NATURE, V307, P521, DOI 10.1038/307521a0; FAHEY JL, 1971, ANN NY ACAD SCI, V190, P221, DOI 10.1111/j.1749-6632.1971.tb13537.x; GOULD KL, 1985, CELL, V42, P849, DOI 10.1016/0092-8674(85)90281-8; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.bi.54.070185.004341; KAWAKAMI T, 1986, MOL CELL BIOL, V6, P4195, DOI 10.1128/MCB.6.12.4195; KOZAK M, 1984, NATURE, V308, P241, DOI 10.1038/308241a0; MANIATIS T, 1978, CELL, V15, P687, DOI 10.1016/0092-8674(78)90036-3; MARTH JD, 1985, CELL, V43, P393, DOI 10.1016/0092-8674(85)90169-2; NAHARRO G, 1984, SCIENCE, V223, P63, DOI 10.1126/science.6318314; NAHARRO G, 1983, J VIROL, V47, P611, DOI 10.1128/JVI.47.3.611-619.1983; NISHIZAWA M, 1985, JPN J CANCER RES, V76, P155; NISHIZAWA M, 1986, MOL CELL BIOL, V6, P511, DOI 10.1128/MCB.6.2.511; PARKER RC, 1985, MOL CELL BIOL, V5, P831, DOI 10.1128/MCB.5.4.831; QUINTRELL N, 1987, MOL CELL BIOL, V7, P2256; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEMBA K, 1986, P NATL ACAD SCI USA, V83, P5459, DOI 10.1073/pnas.83.15.5459; SHERR CJ, 1985, CELL, V41, P665, DOI 10.1016/S0092-8674(85)80047-7; SUKEGAWA J, 1987, MOL CELL BIOL, V7, P41, DOI 10.1128/MCB.7.1.41; TAKEYA T, 1983, CELL, V32, P881, DOI 10.1016/0092-8674(83)90073-9; TANAKA A, 1987, MOL CELL BIOL, V7, P943; TRONICK SR, 1985, P NATL ACAD SCI USA, V82, P6595, DOI 10.1073/pnas.82.19.6595; VIEIRA J, IN PRESS METHODS ENZ; YAMAMOTO T, 1983, CELL, V35, P71, DOI 10.1016/0092-8674(83)90209-X; YAMANASHI Y, 1987, MOL CELL BIOL, V7, P237, DOI 10.1128/MCB.7.1.237; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; ZIEGLER SF, 1987, MOL CELL BIOL, V7, P2276, DOI 10.1128/MCB.7.6.2276	30	32	35	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene		1987	1	3					301	304						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	J9705	3330776				2022-12-17	WOS:A1987J970500011
J	Li, XL; Su, X; Liu, R; Pan, YS; Fang, JK; Cao, LJ; Feng, C; Shang, QW; Chen, YJ; Shao, CS; Shi, YF				Li, Xiaolei; Su, Xiao; Liu, Rui; Pan, Yongsha; Fang, Jiankai; Cao, Lijuan; Feng, Chao; Shang, Qianwen; Chen, Yongjing; Shao, Changshun; Shi, Yufang			HDAC inhibition potentiates anti-tumor activity of macrophages and enhances anti-PD-L1-mediated tumor suppression	ONCOGENE			English	Article								Despite the widespread use of the blockade of immune checkpoints, for a significant number of cancer patients, these therapies have proven ineffective, presumably due to the immunosuppressive nature of the tumor microenvironment (TME). Critical drivers of immune escape in the TME include tumor-associated macrophages (TAMs) and myeloid-derived suppressor cells (MDSCs), which not only mediate immune suppression, but also facilitate metastatic dissemination and impart resistance to immunotherapies. Thus, strategies that convert them into tumor fighters may offer great therapeutic potential. In this study, we evaluated whether pharmacologic modulation of macrophage phenotype by HDAC inhibitors (HDACi) could produce an anti-tumor effect. We demonstrated that low-dose HDACi trichostatin-A (TSA) markedly reshaped the tumor immune microenvironment by modulating the suppressive activity of infiltrating macrophages and inhibiting the recruitment of MDSCs in various tumors. These actions, in turn, augmented anti-tumor immune responses and further enhanced anti-tumor effects of immunotherapies. HDAC inhibition, however, also upregulated PD-L1, thereby limiting the beneficial therapeutic effects. Indeed, combining low-dose TSA with anti-PD-L1 in this model significantly enhanced the durability of tumor reduction and prolonged survival of tumor-bearing mice, compared with the effect of either treatment alone. These data introduce HDAC inhibition as a potential means to harness the anti-tumor potential of macrophages in cancer therapy.	[Li, Xiaolei; Su, Xiao; Liu, Rui; Pan, Yongsha; Fang, Jiankai; Cao, Lijuan; Feng, Chao; Shang, Qianwen; Chen, Yongjing; Shao, Changshun; Shi, Yufang] Soochow Univ, Affiliated Hosp 1, State Key Lab Radiat Med & Protect, Inst Translat Med,Med Coll, Suzhou 215123, Jiangsu, Peoples R China	Soochow University - China	Shao, CS; Shi, YF (corresponding author), Soochow Univ, Affiliated Hosp 1, State Key Lab Radiat Med & Protect, Inst Translat Med,Med Coll, Suzhou 215123, Jiangsu, Peoples R China.	shaoc@suda.edu.cn; yfshi@suda.edu.cn	Shao, Changshun/AAD-8977-2022; li, Xiaolei/V-1383-2019; Shi, Yufang/AAE-4431-2020	Shao, Changshun/0000-0003-2618-9342; li, Xiaolei/0000-0002-2697-6496; Shi, Yufang/0000-0001-8964-319X	National Natural Science Foundation of China [81930085, 81672797, 81530043]; National Key R&D Program of China [2018YFA0107500]; State Key Laboratory of Radiation Medicine and Protection, Soochow University [GZN1201804, GZN1201903]; Natural Science Foundation of the Jiangsu Higher Education Institutions of China [20KJB180005]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Key R&D Program of China; State Key Laboratory of Radiation Medicine and Protection, Soochow University; Natural Science Foundation of the Jiangsu Higher Education Institutions of China(National Natural Science Foundation of China (NSFC))	This work was supported by grants from the National Natural Science Foundation of China (81930085, 81672797, and 81530043), National Key R&D Program of China (2018YFA0107500), State Key Laboratory of Radiation Medicine and Protection, Soochow University (GZN1201804 and GZN1201903), and The Natural Science Foundation of the Jiangsu Higher Education Institutions of China (20KJB180005).	Amit I, 2016, NAT IMMUNOL, V17, P18, DOI 10.1038/ni.3325; Armeanu S, 2005, CANCER RES, V65, P6321, DOI 10.1158/0008-5472.CAN-04-4252; Azad N, 2013, NAT REV CLIN ONCOL, V10, P256, DOI 10.1038/nrclinonc.2013.42; Butowski N, 2016, NEURO-ONCOLOGY, V18, P557, DOI 10.1093/neuonc/nov245; Cao K, 2015, ONCOGENE, V34, P5960, DOI 10.1038/onc.2015.46; Christiansen AJ, 2011, P NATL ACAD SCI USA, V108, P4141, DOI 10.1073/pnas.1011037108; Cittera E, 2007, J IMMUNOL, V178, P6616, DOI 10.4049/jimmunol.178.10.6616; Coussens LM, 2011, CSH PERSPECT BIOL, V3, DOI 10.1101/cshperspect.a003285; Cui SN, 2019, INT IMMUNOPHARMACOL, V77, DOI 10.1016/j.intimp.2019.105973; Demaria O, 2019, NATURE, V574, P45, DOI 10.1038/s41586-019-1593-5; Flores-Toro JA, 2020, P NATL ACAD SCI USA, V117, P1129, DOI 10.1073/pnas.1910856117; Franklin RA, 2014, SCIENCE, V344, P921, DOI 10.1126/science.1252510; Ghoneim HE, 2017, CELL, V170, DOI 10.1016/j.cell.2017.06.007; Gul N, 2015, CANCER RES, V75, P5008, DOI 10.1158/0008-5472.CAN-15-1330; Guerriero JL, 2017, NATURE, V543, P428, DOI 10.1038/nature21409; Gul N, 2014, J CLIN INVEST, V124, P812, DOI 10.1172/JCI66776; Halili MA, 2010, J LEUKOCYTE BIOL, V87, P1103, DOI 10.1189/jlb.0509363; Henning AN, 2018, NAT REV IMMUNOL, V18, P340, DOI 10.1038/nri.2017.146; Ino Y, 2013, BRIT J CANCER, V108, P914, DOI 10.1038/bjc.2013.32; Kim YD, 2020, J CANCER, V11, P4059, DOI 10.7150/jca.44622; Klug F, 2013, CANCER CELL, V24, P589, DOI 10.1016/j.ccr.2013.09.014; Laengle J, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2019-000195; Li XL, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1102-3; Li XL, 2019, CELL MOL IMMUNOL, V16, P28, DOI 10.1038/s41423-018-0086-z; Li XL, 2018, J HEMATOL ONCOL, V11, DOI 10.1186/s13045-018-0578-4; Lin H, 2018, J CLIN INVEST, V128, P805, DOI 10.1172/JCI96113; Lu ZH, 2020, NATURE, V579, P284, DOI 10.1038/s41586-020-2054-x; Mantovani A, 2017, NAT REV CLIN ONCOL, V14, P399, DOI 10.1038/nrclinonc.2016.217; Marvel D, 2015, J CLIN INVEST, V125, P3356, DOI 10.1172/JCI80005; Medrek C, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-306; Minucci S, 2006, NAT REV CANCER, V6, P38, DOI 10.1038/nrc1779; Morel D, 2020, NAT REV CLIN ONCOL, V17, P91, DOI 10.1038/s41571-019-0267-4; Murray PJ, 2014, IMMUNITY, V41, P14, DOI 10.1016/j.immuni.2014.06.008; Nguyen A, 2018, CELL REP, V24, P642, DOI 10.1016/j.celrep.2018.06.040; Noy R, 2014, IMMUNITY, V41, P49, DOI 10.1016/j.immuni.2014.06.010; Nywening TM, 2018, GUT, V67, P1112, DOI 10.1136/gutjnl-2017-313738; Orillion A, 2017, CLIN CANCER RES, V23, P5187, DOI 10.1158/1078-0432.CCR-17-0741; Philip M, 2017, NATURE, V545, P452, DOI 10.1038/nature22367; Pollard JW, 2009, NAT REV IMMUNOL, V9, P259, DOI 10.1038/nri2528; Pucci F, 2009, BLOOD, V114, P901, DOI 10.1182/blood-2009-01-200931; Pyonteck SM, 2013, NAT MED, V19, P1264, DOI 10.1038/nm.3337; Rodriguez PC, 2003, J IMMUNOL, V171, P1232, DOI 10.4049/jimmunol.171.3.1232; Romano E, 2015, P NATL ACAD SCI USA, V112, P6140, DOI 10.1073/pnas.1417320112; Saeed S, 2014, SCIENCE, V345, P1578, DOI 10.1126/science.1251086; Simpson TR, 2013, J EXP MED, V210, P1695, DOI 10.1084/jem.20130579; Skov S, 2005, CANCER RES, V65, P11136, DOI 10.1158/0008-5472.CAN-05-0599; Sun SC, 2017, NAT REV IMMUNOL, V17, P545, DOI 10.1038/nri.2017.52; Tang HD, 2018, J CLIN INVEST, V128, P580, DOI 10.1172/JCI96061; Topper MJ, 2020, NAT REV CLIN ONCOL, V17, P75, DOI 10.1038/s41571-019-0266-5; Ugel S, 2015, J CLIN INVEST, V125, P3365, DOI 10.1172/JCI80006; Van Dyken SJ, 2013, ANNU REV IMMUNOL, V31, P317, DOI 10.1146/annurev-immunol-032712-095906; VANROOIJEN N, 1988, VIRCHOWS ARCH B, V54, P241; Xie ZQ, 2020, ONCOIMMUNOLOGY, V9, DOI 10.1080/2162402X.2020.1734268; Xiong HZ, 2019, CANCER RES, V79, P1493, DOI 10.1158/0008-5472.CAN-18-3208; Yau HL, 2019, TRENDS CELL BIOL, V29, P31, DOI 10.1016/j.tcb.2018.07.006	55	31	31	4	26	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 10	2021	40	10					1836	1850		10.1038/s41388-020-01636-x	http://dx.doi.org/10.1038/s41388-020-01636-x		FEB 2021	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QU6VJ	33564072	Green Published, hybrid			2022-12-17	WOS:000616489100003
J	Tan, XX; Sivakumar, S; Bednarsch, J; Wiltberger, G; Kather, JN; Niehues, J; de Vos-Geelen, J; Valkenburg-van Iersel, L; Kintsler, S; Roeth, A; Hao, GS; Lang, S; Coolsen, ME; den Dulk, M; Aberle, MR; Koolen, J; Gaisa, NT; Damink, SWMO; Neumann, UP; Heij, LR				Tan, Xiuxiang; Sivakumar, Shivan; Bednarsch, Jan; Wiltberger, Georg; Kather, Jakob Nikolas; Niehues, Jan; de Vos-Geelen, Judith; Valkenburg-van Iersel, Liselot; Kintsler, Svetlana; Roeth, Anjali; Hao, Guangshan; Lang, Sven; Coolsen, Marielle E.; den Dulk, Marcel; Aberle, Merel R.; Koolen, Jarne; Gaisa, Nadine T.; Olde Damink, Steven W. M.; Neumann, Ulf P.; Heij, Lara R.			Nerve fibers in the tumor microenvironment in neurotropic cancer-pancreatic cancer and cholangiocarcinoma	ONCOGENE			English	Review							MUSCARINIC ACETYLCHOLINE-RECEPTOR; PREDICTS POOR-PROGNOSIS; PERINEURAL INVASION; GROWTH-FACTOR; INTRAHEPATIC CHOLANGIOCARCINOMA; CLINICAL-SIGNIFICANCE; STELLATE CELLS; EXPRESSION; NEUROGENESIS; PROGRESSION	Pancreatic ductal adenocarcinoma (PDAC) and cholangiocarcinoma (CCA) are both deadly cancers and they share many biological features besides their close anatomical location. One of the main histological features is neurotropism, which results in frequent perineural invasion. The underlying mechanism of cancer cells favoring growth by and through the nerve fibers is not fully understood. In this review, we provide knowledge of these cancers with frequent perineural invasion. We discuss nerve fiber crosstalk with the main different components of the tumor microenvironment (TME), the immune cells, and the fibroblasts. Also, we discuss the crosstalk between the nerve fibers and the cancer. We highlight the shared signaling pathways of the mechanisms behind perineural invasion in PDAC and CCA. Hereby we have focussed on signaling neurotransmitters and neuropeptides which may be a target for future therapies. Furthermore, we have summarized retrospective results of the previous literature about nerve fibers in PDAC and CCA patients. We provide our point of view in the potential for nerve fibers to be used as powerful biomarker for prognosis, as a tool to stratify patients for therapy or as a target in a (combination) therapy. Taking the presence of nerves into account can potentially change the field of personalized care in these neurotropic cancers.	[Tan, Xiuxiang; Coolsen, Marielle E.; den Dulk, Marcel; Koolen, Jarne; Olde Damink, Steven W. M.; Neumann, Ulf P.; Heij, Lara R.] Maastricht Univ, Med Ctr, Dept Surg, Maastricht, Netherlands; [Tan, Xiuxiang; Bednarsch, Jan; Wiltberger, Georg; Roeth, Anjali; Lang, Sven; Olde Damink, Steven W. M.; Neumann, Ulf P.; Heij, Lara R.] RWTH Aachen Univ Hosp, Dept Gen Gastrointestinal Hepatobiliary & Transpl, Aachen, Germany; [Tan, Xiuxiang; Roeth, Anjali; Aberle, Merel R.; Olde Damink, Steven W. M.] Maastricht Univ, NUTRIM Sch Nutr & Translat Res Metab, Maastricht, Netherlands; [Sivakumar, Shivan] Univ Oxford, Dept Oncol, Oxford, England; [Sivakumar, Shivan] Univ Oxford, Kennedy Inst Rheumatol, Oxford, England; [Kather, Jakob Nikolas; Niehues, Jan] Univ Hosp RWTH Aachen, Dept Med 3, Aachen, Germany; [de Vos-Geelen, Judith; Valkenburg-van Iersel, Liselot] Maastricht Univ, Med Ctr, GROW Sch Oncol & Dev Biol, Div Med Oncol,Dept Internal Med, Maastricht, Netherlands; [Kintsler, Svetlana; Gaisa, Nadine T.; Heij, Lara R.] Univ Hosp RWTH Aachen, Inst Pathol, Aachen, Germany; [Hao, Guangshan] Univ Hosp RWTH Aachen, Translat Neurosurg & Neurobiol, Aachen, Germany	Maastricht University; RWTH Aachen University; RWTH Aachen University Hospital; Maastricht University; Maastricht University Medical Centre (MUMC); University of Oxford; University of Oxford; RWTH Aachen University; RWTH Aachen University Hospital; Maastricht University; RWTH Aachen University; RWTH Aachen University Hospital; RWTH Aachen University; RWTH Aachen University Hospital	Heij, LR (corresponding author), Maastricht Univ, Med Ctr, Dept Surg, Maastricht, Netherlands.; Heij, LR (corresponding author), RWTH Aachen Univ Hosp, Dept Gen Gastrointestinal Hepatobiliary & Transpl, Aachen, Germany.; Heij, LR (corresponding author), Univ Hosp RWTH Aachen, Inst Pathol, Aachen, Germany.	lheij@ukaachen.de	Kather, Jakob Nikolas/D-4279-2015; Heij, Lara/AAU-2792-2020; Tan, Xiuxiang/GRX-8703-2022; hao, guangshan/HGC-8867-2022	Kather, Jakob Nikolas/0000-0002-3730-5348; Heij, Lara/0000-0002-0602-3356; Tan, Xiuxiang/0000-0001-6782-9137; Olde Damink, Steven/0000-0002-5202-9345; de Vos-Geelen, Judith/0000-0003-2578-1766; Aberle, Merel/0000-0003-1990-1784	China Scholarship Council [201806210074]	China Scholarship Council(China Scholarship Council)	X. Tan was funded by China Scholarship Council (Grantnumber: 201806210074). Open Access funding enabled and organized by Projekt DEAL.	Al-Shalan HAM, 2019, CELL TISSUE RES, V378, P239, DOI 10.1007/s00441-019-03052-4; Albo D, 2011, CANCER-AM CANCER SOC, V117, P4834, DOI 10.1002/cncr.26117; Aloe L, 2016, J EXP CLIN CANC RES, V35, DOI 10.1186/s13046-016-0395-y; Amit M, 2020, NATURE, V578, P449, DOI 10.1038/s41586-020-1996-3; Amonyingcharoen S, 2015, INT J ONCOL, V46, P2317, DOI 10.3892/ijo.2015.2939; Apte MV, 2013, GASTROENTEROLOGY, V144, P1210, DOI 10.1053/j.gastro.2012.11.037; Ayala GE, 2008, CLIN CANCER RES, V14, P7593, DOI 10.1158/1078-0432.CCR-08-1164; Babic T, 2016, PANCREAPEDIA EXOCRIN, P1, DOI [10.3998/panc.2016.27, DOI 10.3998/PANC.2016.27]; Bai H, 2011, CARCINOGENESIS, V32, P1689, DOI 10.1093/carcin/bgr191; Bapat AA, 2011, NAT REV CANCER, V11, P695, DOI 10.1038/nrc3131; Barbieri A, 2015, INT J ONCOL, V47, P527, DOI 10.3892/ijo.2015.3038; Barron TI, 2011, J CLIN ONCOL, V29, P2635, DOI 10.1200/JCO.2010.33.5422; BATSAKIS JG, 1985, ANN OTO RHINOL LARYN, V94, P426; Bertuccio P, 2019, J HEPATOL, V71, P104, DOI 10.1016/j.jhep.2019.03.013; BOCKMAN DE, 1994, GASTROENTEROLOGY, V107, P219, DOI 10.1016/0016-5085(94)90080-9; Campbell K, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10269-y; Ceyhan GO, 2010, ANN SURG, V251, P923, DOI 10.1097/SLA.0b013e3181d974d4; Ceyhan GO, 2009, GASTROENTEROLOGY, V136, P177, DOI 10.1053/j.gastro.2008.09.029; Chatterjee D, 2012, AM J SURG PATHOL, V36, P409, DOI 10.1097/PAS.0b013e31824104c5; Chen SH, 2019, AM J CANCER RES, V9, P1; Chesne J, 2019, MUCOSAL IMMUNOL, V12, P10, DOI 10.1038/s41385-018-0063-y; Cirri P, 2011, AM J CANCER RES, V1, P482; Coulouarn C, 2014, J HEPATOL, V60, P1306, DOI 10.1016/j.jhep.2014.02.003; Dang NN, 2016, BIOMED REP, V4, P515, DOI 10.3892/br.2016.625; Demir IE, 2015, NAT REV GASTRO HEPAT, V12, P649, DOI 10.1038/nrgastro.2015.166; Demir Ihsan Ekin, 2010, Cancers (Basel), V2, P1513, DOI 10.3390/cancers2031513; Eichmann A, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008910; Farrow B, 2008, J SURG RES, V149, P319, DOI 10.1016/j.jss.2007.12.757; Feng YJ, 2012, HEPATOB PANCREAT DIS, V11, P418, DOI 10.1016/S1499-3872(12)60201-X; Fisher SB, 2012, HPB, V14, P514, DOI 10.1111/j.1477-2574.2012.00489.x; FOLKMAN J, 1989, NATURE, V339, P58, DOI 10.1038/339058a0; Franchitto A, 2013, ANN TRANSL MED, V1, DOI 10.3978/j.issn.2305-5839.2012.10.03; Gasparini G, 2019, CANCERS, V11, DOI 10.3390/cancers11070893; Gigliozzi A, 2004, GASTROENTEROLOGY, V127, P1198, DOI 10.1053/j.gastro.2004.06.023; Godinho-Silva C, 2019, ANNU REV IMMUNOL, V37, P19, DOI 10.1146/annurev-immunol-042718-041812; Gritsenko PG, 2012, J PATHOL, V226, P185, DOI 10.1002/path.3031; Grytli HH, 2014, EUR UROL, V65, P635, DOI 10.1016/j.eururo.2013.01.007; Hondermarck H, 2018, TRENDS CANCER, V4, P93, DOI 10.1016/j.trecan.2017.11.008; Huang D, 2014, MEDICINE, V93, DOI 10.1097/MD.0000000000000172; Iwasaki T, 2019, CANCER SCI, V110, P1491, DOI 10.1111/cas.13975; Jobling P, 2015, CANCER RES, V75, P1777, DOI 10.1158/0008-5472.CAN-14-3180; Joyce JA, 2015, SCIENCE, V348, P74, DOI 10.1126/science.aaa6204; Kamiya A, 2019, NAT NEUROSCI, V22, P1289, DOI 10.1038/s41593-019-0430-3; Kanno N, 2002, HEPATOLOGY, V35, P1329, DOI 10.1053/jhep.2002.33330; Khan SA, 2019, LIVER INT, V39, P19, DOI 10.1111/liv.14095; Kim-Fuchs C, 2014, BRAIN BEHAV IMMUN, V40, P40, DOI 10.1016/j.bbi.2014.02.019; Lenz J, 2011, J GASTROINTEST LIVER, V20, P389; Li WJ, 2019, FRONT NEUROSCI-SWITZ, V13, DOI 10.3389/fnins.2019.00021; Liang DK, 2016, BBA-REV CANCER, V1865, P111, DOI 10.1016/j.bbcan.2016.01.002; Liebig C, 2009, CANCER-AM CANCER SOC, V115, P3379, DOI 10.1002/cncr.24396; Liu Bin, 2002, Hepatobiliary Pancreat Dis Int, V1, P469; Liu H, 2012, CURR PHARM DESIGN, V18, P2395, DOI 10.2174/13816128112092395; Liu HP, 1998, CELL TISSUE RES, V294, P227, DOI 10.1007/s004410051172; Liu TY, 2019, FRONT CELL DEV BIOL, V7, DOI 10.3389/fcell.2019.00060; Ma J, 2008, J GASTROEN HEPATOL, V23, P1852, DOI 10.1111/j.1440-1746.2008.05579.x; Maatta M, 2000, CLIN CANCER RES, V6, P2726; Magnon C, 2013, SCIENCE, V341, P143, DOI 10.1126/science.1236361; Maisonneuve P, 2019, PRESSE MED, V48, pE113, DOI 10.1016/j.lpm.2019.02.030; March B, 2020, NAT REV UROL, V17, P119, DOI 10.1038/s41585-019-0274-3; Martinez AK, 2017, AM J PATHOL, V187, P1093, DOI 10.1016/j.ajpath.2017.01.011; Mauffrey P, 2019, NATURE, V569, P672, DOI 10.1038/s41586-019-1219-y; Mavros MN, 2014, JAMA SURG, V149, P565, DOI 10.1001/jamasurg.2013.5137; McClements S, 2019, LIVER CANC MECH MANA, P179; Mignini F, 2014, INT J MOL MED, V33, P1392, DOI 10.3892/ijmm.2014.1709; Mizuno K, 2017, HEPATOL RES, V47, P160, DOI 10.1111/hepr.12760; Molloy Niamh H, 2011, Cancers (Basel), V3, P510, DOI 10.3390/cancers3010510; Momi N, 2013, ONCOGENE, V32, P1384, DOI 10.1038/onc.2012.163; Monje M, 2020, CELL, V181, P219, DOI 10.1016/j.cell.2020.03.034; Nakao A, 1996, PANCREAS, V12, P357, DOI 10.1097/00006676-199605000-00006; O'Donnell J, 2012, NEUROCHEM RES, V37, P2496, DOI 10.1007/s11064-012-0818-x; Preston Marnie, 2011, Front Biosci (Schol Ed), V3, P1165; Pundavela J, 2015, MOL ONCOL, V9, P1626, DOI 10.1016/j.molonc.2015.05.001; Rahib L, 2014, CANCER RES, V74, P2913, DOI 10.1158/0008-5472.CAN-14-0155; Raju B, 2007, NEUROSCIENCE, V149, P715, DOI 10.1016/j.neuroscience.2007.07.048; Ren K, 2020, CLIN ANAT, V33, P630, DOI 10.1002/ca.23470; Renz BW, 2018, CANCER DISCOV, V8, P1458, DOI 10.1158/2159-8290.CD-18-0046; Renz BW, 2018, CANCER CELL, V33, P75, DOI 10.1016/j.ccell.2017.11.007; Rodriguez-Diaz R, 2014, BEST PRACT RES CL EN, V28, P745, DOI 10.1016/j.beem.2014.05.002; Roux PP, 2002, PROG NEUROBIOL, V67, P203, DOI 10.1016/S0301-0082(02)00016-3; Roy R, 2009, J CLIN ONCOL, V27, P5287, DOI 10.1200/JCO.2009.23.5556; Saloman JL, 2018, PANCREAS, V47, P856, DOI 10.1097/MPA.0000000000001090; Saloman JL, 2016, P NATL ACAD SCI USA, V113, P3078, DOI 10.1073/pnas.1512603113; Schecterson LC, 2010, DEV NEUROBIOL, V70, P332, DOI 10.1002/dneu.20767; Sha M, 2019, BBA-REV CANCER, V1872, P66, DOI 10.1016/j.bbcan.2019.05.005; Shao JX, 2016, THORAC CANCER, V7, P588, DOI 10.1111/1759-7714.12374; Shen FZ, 2010, J EXP CLIN CANC RES, V29, DOI 10.1186/1756-9966-29-24; Shimada K, 2011, PANCREAS, V40, P464, DOI 10.1097/MPA.0b013e31820b5d37; Shirai K, 2008, WORLD J SURG, V32, P2395, DOI 10.1007/s00268-008-9726-2; Sinha S, 2017, CANCER RES, V77, P1868, DOI 10.1158/0008-5472.CAN-16-0899-T; Soto-Tinoco E, 2016, EXP PHYSIOL, V101, P1463, DOI 10.1113/EP085560; Thome JJC, 2016, NAT MED, V22, P72, DOI 10.1038/nm.4008; Ulrich R, 2005, DEV NEUROSCI-BASEL, V27, P408, DOI 10.1159/000088455; Veiga-Fernandes H, 2017, NAT IMMUNOL, V18, P116, DOI 10.1038/ni.3634; Veiga-Fernandes H, 2016, CELL, V165, P801, DOI 10.1016/j.cell.2016.04.041; Xu LB, 2010, WORLD J SURG, V34, P1039, DOI 10.1007/s00268-010-0417-4; Yamada Y, 2012, RADIOLOGY, V263, P419, DOI 10.1148/radiol.12111024; Yang XQ, 2014, WORLD J GASTROENTERO, V20, P4076, DOI 10.3748/wjg.v20.i14.4076; Yu M, 2012, CANCER CELL, V21, P327, DOI 10.1016/j.ccr.2012.03.002; Yue XJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062024; Zahalka AH, 2020, NAT REV CANCER, V20, P143, DOI 10.1038/s41568-019-0237-2; Zahalka AH, 2017, SCIENCE, V358, P321, DOI 10.1126/science.aah5072; Zareba P, 2017, CANCER EPIDEM BIOMAR, V26, P719, DOI 10.1158/1055-9965.EPI-16-0237; Zhang LF, 2016, ONCOTARGETS THER, V9, P6719, DOI 10.2147/OTT.S111382; Zhang LF, 2016, CHINESE J CANCER RES, V28, P180, DOI 10.21147/j.issn.1000-9604.2016.02.05; Zhao CM, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3009569; Zuo HD, 2012, WORLD J RADIOL, V4, P36, DOI 10.4329/wjr.v4.i2.36	106	31	32	13	24	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 4	2021	40	5					899	908		10.1038/s41388-020-01578-4	http://dx.doi.org/10.1038/s41388-020-01578-4		DEC 2020	10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QC5NB	33288884	hybrid, Green Published			2022-12-17	WOS:000599011200001
J	Wang, FX; Lau, JKC; Yu, J				Wang, Feixue; Lau, Jennie Ka Ching; Yu, Jun			The role of natural killer cell in gastrointestinal cancer: killer or helper	ONCOGENE			English	Review							NK CELLS; COLORECTAL-CANCER; HEPATOCELLULAR-CARCINOMA; TUMOR-CELLS; IN-VIVO; PHASE-I; CYTOTOXIC ACTIVITY; ANTITUMOR-ACTIVITY; ADOPTIVE TRANSFER; PERIPHERAL-BLOOD	Gastrointestinal cancer is one of the leading health problems worldwide, with a high morbidity and mortality. To date, harnessing both the innate and adaptive immune system against cancer provides a selective and effective therapeutic strategy for patients. As a first line defense against cancer, natural killer (NK) cells can swiftly target and lyse tumor cells without prior activation. In addition to its pivotal role in innate immunity, NK cells also play unique roles in the adaptive immune system as it enhance anti-tumor adaptive immune responses through secretion of cytokines and retaining an immunological memory. All these characteristics make NK cell a promising anti-cancer agent for patients. In spite of scarce infiltration and impaired function of NK cells in tumors, and the fact that tumors easily develop resistant mechanisms to evade the attacks from endogenous NK cells, multiple strategies have been developed to boost anti-tumor effect of NK cells and abolish tumor resistance. Some examples include adoptive transfer of NK cells after ex vivo activation and expansion; restoration of NK cell function using immune checkpoint inhibitors, and monoclonal antibody or cytokine treatment. Preclinical data have shown encouraging results, suggesting that NK cells hold great potential in cancer therapy. In this review, we discuss NK cells' cytotoxicity and modulation function in GI cancer and the current application in clinical therapy.	[Wang, Feixue; Yu, Jun] Chinese Univ Hong Kong, Inst Digest Dis, Li Ka Shing Inst Hlth Sci, CUHK Shenzhen Res Inst,Dept Med & Therapeut,State, Hong Kong, Peoples R China; [Lau, Jennie Ka Ching] Chinese Univ Hong Kong, SHHO Coll, Fac Med, Hong Kong, Peoples R China	Chinese University of Hong Kong; Chinese University of Hong Kong	Yu, J (corresponding author), Chinese Univ Hong Kong, Inst Digest Dis, Li Ka Shing Inst Hlth Sci, CUHK Shenzhen Res Inst,Dept Med & Therapeut,State, Hong Kong, Peoples R China.	junyu@cuhk.edu.hk	Jun, Yu/D-8569-2015	Jun, Yu/0000-0001-5008-2153	RGC-CRF Hong Kong [C4041-17GF, C7026-18G]; RGC Theme-based Research Scheme Hong Kong [T12-703/19-R]	RGC-CRF Hong Kong; RGC Theme-based Research Scheme Hong Kong	The project was supported by RGC-CRF Hong Kong (C4041-17GF; C7026-18G); RGC Theme-based Research Scheme Hong Kong (T12-703/19-R).	Acoba JD, 2017, PHASE IB II STUDY AL, V35, pTPS510; ALBINI A, 2017, ANN ONCOL S, V28, pvi11, DOI DOI 10.1093/annonc/mdx422.028; Ames E, 2015, J IMMUNOL, V195, P4010, DOI 10.4049/jimmunol.1500447; Andre P, 2018, CELL, V175, P1731, DOI 10.1016/j.cell.2018.10.014; Ardolino M, 2014, J CLIN INVEST, V124, P4781, DOI 10.1172/JCI74337; Baginska J, 2013, P NATL ACAD SCI USA, V110, P17450, DOI 10.1073/pnas.1304790110; Bald T, 2020, NAT IMMUNOL, V21, P835, DOI 10.1038/s41590-020-0728-z; BARLOZZARI T, 1983, J IMMUNOL, V131, P1024; Barry KC, 2018, NAT MED, V24, P1178, DOI 10.1038/s41591-018-0085-8; Berchem G, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2015.1062968; Bjordahl R, 2018, CANCER RES, V78, DOI 10.1158/1538-7445.AM2018-3576; Bottcher JP, 2018, CELL, V172, P1022, DOI 10.1016/j.cell.2018.01.004; Brackett CM, 2016, P NATL ACAD SCI USA, V113, pE874, DOI 10.1073/pnas.1521359113; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Bruno A, 2018, FASEB J, V32, P5365, DOI 10.1096/fj.201701103R; Calmeiro J, 2018, HIGHLIGHTING ROLE DC, P25; Chen SS, 2016, ONCOL LETT, V12, P1868, DOI 10.3892/ol.2016.4835; David JM, 2018, CANCER RES, V78, DOI 10.1158/1538-7445.AM2018-3821; de Andrade LF, 2018, SCIENCE, V359, P1537, DOI 10.1126/science.aao0505; Deauvieau F, 2015, INT J CANCER, V136, P1085, DOI 10.1002/ijc.29087; Dogra P, 2020, CELL, V180, P749, DOI 10.1016/j.cell.2020.01.022; Dotan E, 2017, J CLIN ONCOL, V35, P3338, DOI 10.1200/JCO.2017.73.9011; Duan XH, 2011, MED ONCOL, V28, P466, DOI 10.1007/s12032-010-9480-9; Dubois S, 2017, CANCER IMMUNOL RES, V5, P929, DOI 10.1158/2326-6066.CIR-17-0279; Dupaul-Chicoine J, 2015, IMMUNITY, V43, P751, DOI 10.1016/j.immuni.2015.08.013; Easom NJW, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01009; Ferlazzo G, 2004, J IMMUNOL, V172, P1333, DOI 10.4049/jimmunol.172.3.1333; Freud AG, 2017, IMMUNITY, V47, P820, DOI 10.1016/j.immuni.2017.10.008; Geller MA, 2011, CYTOTHERAPY, V13, P98, DOI 10.3109/14653249.2010.515582; Gharagozloo M, 2015, BRATISL MED J, V116, P296, DOI 10.4149/BLL_2015_056; Halama N, 2011, CLIN CANCER RES, V17, P678, DOI 10.1158/1078-0432.CCR-10-2173; Han B, 2018, J IMMUNOL RES, V2018, DOI 10.1155/2018/6248590; Harmon C, 2019, CANCER IMMUNOL RES, V7, P335, DOI 10.1158/2326-6066.CIR-18-0481; He H, 2016, SCI REP-UK, V6, DOI 10.1038/srep27711; Hermanson DL, 2016, STEM CELLS, V34, P93, DOI 10.1002/stem.2230; Hoechst B, 2009, HEPATOLOGY, V50, P799, DOI 10.1002/hep.23054; Hsu J, 2018, J CLIN INVEST, V128, P4654, DOI 10.1172/JCI99317; Imai K, 2000, LANCET, V356, P1795, DOI 10.1016/S0140-6736(00)03231-1; Ishikawa T, 2018, INT J CANCER, V142, P2599, DOI 10.1002/ijc.31285; Jinushi M, 2005, J HEPATOL, V43, P1013, DOI 10.1016/j.jhep.2005.05.026; Jobin G, 2017, GASTROENTEROLOGY, V153, P980, DOI 10.1053/j.gastro.2017.06.009; KARRE K, 1986, NATURE, V319, P675, DOI 10.1038/319675a0; KIESSLING R, 1975, EUR J IMMUNOL, V5, P112, DOI 10.1002/eji.1830050208; Kim HR, 2004, CANCER IMMUNOL IMMUN, V53, P461, DOI 10.1007/s00262-003-0461-0; Kono K, 2002, CANCER RES, V62, P5813; Krause SW, 2004, CLIN CANCER RES, V10, P3699, DOI 10.1158/1078-0432.CCR-03-0683; Langhans B, 2015, J HEPATOL, V62, P398, DOI 10.1016/j.jhep.2014.08.038; Lanier LL, 2001, NAT IMMUNOL, V2, P23, DOI 10.1038/83130; LANIER LL, 1989, NATURE, V342, P803, DOI 10.1038/342803a0; Li HJ, 2018, GUT, V67, P2035, DOI 10.1136/gutjnl-2017-314098; Li LY, 2018, CYTOTHERAPY, V20, P134, DOI 10.1016/j.jcyt.2017.09.009; Li TJ, 2012, CANCER LETT, V318, P154, DOI 10.1016/j.canlet.2011.12.020; Li Y, 2018, CELL STEM CELL, V23, P181, DOI 10.1016/j.stem.2018.06.002; Liu EL, 2020, NEW ENGL J MED, V382, P545, DOI 10.1056/NEJMoa1910607; Liu Y, 2017, ONCOGENE, V36, P6143, DOI 10.1038/onc.2017.209; Lopez-Soto A, 2017, CANCER CELL, V32, P135, DOI 10.1016/j.ccell.2017.06.009; Lu CG, 2020, MOL IMMUNOL, V122, P200, DOI 10.1016/j.molimm.2020.04.016; Malmberg KJ, 2017, SEMIN IMMUNOL, V31, P20, DOI 10.1016/j.smim.2017.08.002; Mantovani S, 2019, HEPATOLOGY, V69, P1165, DOI 10.1002/hep.30235; Margolin K, 2018, CLIN CANCER RES, V24, P5552, DOI 10.1158/1078-0432.CCR-18-0945; Martin-Fontecha A, 2004, NAT IMMUNOL, V5, P1260, DOI 10.1038/ni1138; Mimura K, 2014, INT J CANCER, V135, P1390, DOI 10.1002/ijc.28780; Mocikat R, 2003, IMMUNITY, V19, P561, DOI 10.1016/S1074-7613(03)00264-4; Morvan MG, 2016, NAT REV CANCER, V16, P7, DOI 10.1038/nrc.2015.5; Oppenheim DE, 2014, BRIT J CANCER, V110, P1221, DOI 10.1038/bjc.2014.35; Pernot S, 2020, GASTRIC CANCER, V23, P73, DOI 10.1007/s10120-019-00983-3; Pinho MJ, 2011, CELL COMMUN ADHES, V18, P45, DOI 10.3109/15419061.2011.610911; ROBERTSON MJ, 1990, BLOOD, V76, P2421; Rothe A, 2014, INT J CANCER, V134, P2829, DOI 10.1002/ijc.28609; Royal RE, 2010, J IMMUNOTHER, V33, P828, DOI 10.1097/CJI.0b013e3181eec14c; Sakamoto N, 2015, J TRANSL MED, V13, DOI 10.1186/s12967-015-0632-8; Schirrmann T, 2002, CANCER GENE THER, V9, P390, DOI 10.1038/sj.cgt.7700453; Schmohl JU, 2016, TARGET ONCOL, V11, P353, DOI 10.1007/s11523-015-0391-8; Schmohl JU, 2017, CANCER RES TREAT, V49, P1140, DOI 10.4143/crt.2016.491; Screpanti V, 2005, MOL IMMUNOL, V42, P495, DOI 10.1016/j.molimm.2004.07.033; Rocca YS, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00413; Spiegel A, 2016, CANCER DISCOV, V6, P630, DOI 10.1158/2159-8290.CD-15-1157; Sun HY, 2019, HEPATOLOGY, V70, P168, DOI 10.1002/hep.30347; Sun JC, 2011, NAT REV IMMUNOL, V11, P645, DOI 10.1038/nri3044; Takeda K, 2001, NAT MED, V7, P94, DOI 10.1038/83416; Tam YK, 2003, CYTOTHERAPY, V5, P259, DOI 10.1080/14653240310001523; Trotta AM, 2016, CANCER IMMUNOL RES, V4, P366, DOI 10.1158/2326-6066.CIR-15-0184; Vallera DA, 2016, CLIN CANCER RES, V22, P3440, DOI 10.1158/1078-0432.CCR-15-2710; Vallera DA, 2013, CANCER BIOTHER RADIO, V28, P274, DOI 10.1089/cbr.2012.1329; van Hall T, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0761-3; Viry E, 2014, AUTOPHAGY, V10, P173, DOI 10.4161/auto.26924; Vivier E, 2011, SCIENCE, V331, DOI 10.1126/science.1198687; Wallin RPA, 2003, EUR J IMMUNOL, V33, P2727, DOI 10.1002/eji.200324070; Wang L, 2017, CELL PHYSIOL BIOCHEM, V44, P1038, DOI 10.1159/000485404; Wang W, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00368; Woll PS, 2009, BLOOD, V113, P6094, DOI 10.1182/blood-2008-06-165225; Xiao L, 2019, MOL THER, V27, P1114, DOI 10.1016/j.ymthe.2019.03.011; Xu C, 2019, HUM GENE THER, V30, P459, DOI 10.1089/hum.2018.011; Yang Y, 2016, CANCER IMMUNOL RES, V4, P215, DOI 10.1158/2326-6066.CIR-15-0118; Zhang Q, 2018, J IMMUNOL RES, V2018, DOI 10.1155/2018/4263520; Zhang Q, 2018, NAT IMMUNOL, V19, P723, DOI 10.1038/s41590-018-0132-0; Zhao JJ, 2014, SCI REP-UK, V4, DOI 10.1038/srep05177; Zhou XM, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02821; Zhu Ling-Yan, 2009, Ai Zheng, V28, P1198	99	31	31	1	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 28	2021	40	4					717	730		10.1038/s41388-020-01561-z	http://dx.doi.org/10.1038/s41388-020-01561-z		DEC 2020	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QA4GO	33262461	Green Published, hybrid			2022-12-17	WOS:000595928700001
J	Yu, L; Dong, L; Li, H; Liu, ZJ; Luo, Z; Duan, GJ; Dai, XT; Lin, ZH				Yu, Le; Dong, Ling; Li, Hui; Liu, Zhaojian; Luo, Zhong; Duan, Guangjie; Dai, Xiaotian; Lin, Zhenghong			Ubiquitination-mediated degradation of SIRT1 by SMURF2 suppresses CRC cell proliferation and tumorigenesis	ONCOGENE			English	Article							DEPENDENT DEGRADATION; DEACETYLASE ACTIVITY; CANCER STATISTICS; PROTEIN SIR2; LIGASE; TRANSCRIPTION; ACTIVATION; REPRESSION; REGULATOR; INTERACTS	The NAD-dependent deacetylase sirtuin 1 (SIRT1), a member of the mammalian sirtuin family, plays a pivotal role in deacetylating histone and nonhistone proteins. Recently, it has been reported that SIRT1 is upregulated in various kinds of tumors and is associated with cell growth and metastasis. However, the factors and molecular mechanism regulating its cellular levels remain to be clarified. Here, we reported that the E3 ubiquitin ligase SMURF2 interacts with SIRT1 and mediates its ubiquitination and degradation. Depletion of SMURF2 leads to SIRT1 upregulation and induces the tumor formation and growth of colorectal cancer in vitro and in vivo. Furthermore, we show a negative correlation between SIRT1 and SMURF2 expression in human colorectal cancer. Thus, we propose a novel mechanism of colorectal tumorigenesis via SIRT1 regulation by SMURF2, which could potentially give rise to a new strategy for the treatment of colorectal cancer.	[Yu, Le; Dong, Ling; Li, Hui; Luo, Zhong; Lin, Zhenghong] Chongqing Univ, Sch Life Sci, Chongqing 401331, Peoples R China; [Liu, Zhaojian] Shandong Univ, Dept Cell Biol, Sch Med, Jinan 250012, Peoples R China; [Duan, Guangjie; Dai, Xiaotian] Third Mil Med Univ, Dept Pulmonol, Southwest Hosp, Chongqing 400038, Peoples R China	Chongqing University; Shandong University; Army Medical University	Lin, ZH (corresponding author), Chongqing Univ, Sch Life Sci, Chongqing 401331, Peoples R China.; Dai, XT (corresponding author), Third Mil Med Univ, Dept Pulmonol, Southwest Hosp, Chongqing 400038, Peoples R China.	daixt1973@163.com; zhenghonglin@cqu.edu.cn	, Owen/AHE-6976-2022; Luo, Zhong/AAU-2225-2020	Luo, Zhong/0000-0002-9019-3314; Lin, Zhenghong/0000-0002-6354-0042	National Natural Science Foundation of China [31571454, 31801181]; 61st Batch of China Postdoctoral Science Fund [2017M610588]; Special Fund for Postdoctoral Research Projects of Chongqing City [Xm2017080]; Fundamental Research Funds for the Central Universities [106112017CDJQJ298833]; Key Laboratory for Experimental Teratology of the Ministry of Education of Shandong University	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); 61st Batch of China Postdoctoral Science Fund; Special Fund for Postdoctoral Research Projects of Chongqing City; Fundamental Research Funds for the Central Universities(Fundamental Research Funds for the Central Universities); Key Laboratory for Experimental Teratology of the Ministry of Education of Shandong University	The National Natural Science Foundation of China (Grant Nos. 31571454 and 31801181), the 61st Batch of China Postdoctoral Science Fund (Grant No. 2017M610588), the Special Fund for Postdoctoral Research Projects of Chongqing City (Grant No. Xm2017080), the Fundamental Research Funds for the Central Universities (Project No. 106112017CDJQJ298833), and the funding from Key Laboratory for Experimental Teratology of the Ministry of Education of Shandong University supported this study. We also thank the Analytical and Testing Center of Chongqing University for confocal fluorescence microscopy assistance.	Behrouzfar K, 2017, CELL BIOCHEM FUNCT, V35, P327, DOI 10.1002/cbf.3279; Blank M, 2012, NAT MED, V18, P227, DOI 10.1038/nm.2596; Bouras T, 2005, J BIOL CHEM, V280, P10264, DOI 10.1074/jbc.M408748200; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Brooks CL, 2009, NAT REV CANCER, V9, P123, DOI 10.1038/nrc2562; Brunet A, 2004, SCIENCE, V303, P2011, DOI 10.1126/science.1094637; Cha B, 2015, MOL CELLS, V38, P723, DOI 10.14348/molcells.2015.0113; Chen J, 2011, CANCER RES, V71, P4138, DOI 10.1158/0008-5472.CAN-10-4274; Chen WQ, 2016, CA-CANCER J CLIN, V66, P115, DOI 10.3322/caac.21338; Cheng FF, 2016, CANCER LETT, V375, P274, DOI 10.1016/j.canlet.2016.03.010; Dong L, 2018, ONCOGENE, V37, P2702, DOI 10.1038/s41388-018-0137-z; Elangovan S, 2011, CANCER RES, V71, P6654, DOI 10.1158/0008-5472.CAN-11-1446; Elias D, 2015, ANN SURG, V261, P157, DOI 10.1097/SLA.0000000000000582; Fukunaga E, 2008, J BIOL CHEM, V283, P35660, DOI 10.1074/jbc.M710496200; Haigis MC, 2010, ANNU REV PATHOL-MECH, V5, P253, DOI 10.1146/annurev.pathol.4.110807.092250; Huffman DM, 2007, CANCER RES, V67, P6612, DOI 10.1158/0008-5472.CAN-07-0085; Imai S, 2000, NATURE, V403, P795, DOI 10.1038/35001622; Jeong HM, 2014, BBA-MOL CELL RES, V1843, P2005, DOI 10.1016/j.bbamcr.2014.04.023; Jeong J, 2007, EXP MOL MED, V39, P8, DOI 10.1038/emm.2007.2; Kavsak P, 2000, MOL CELL, V6, P1365, DOI 10.1016/S1097-2765(00)00134-9; Kim EJ, 2007, MOL CELL, V28, P277, DOI 10.1016/j.molcel.2007.08.030; Landry J, 2000, P NATL ACAD SCI USA, V97, P5807, DOI 10.1073/pnas.110148297; Lee IH, 2008, P NATL ACAD SCI USA, V105, P3374, DOI 10.1073/pnas.0712145105; Lee YS, 2019, ASTROPHYS SPACE SCI, V364, DOI 10.1007/s10509-019-3691-0; Li LS, 2013, CLIN EXP MED, V13, P109, DOI 10.1007/s10238-012-0186-5; Li Y, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00299-9; Lin X, 2000, J BIOL CHEM, V275, P36818, DOI 10.1074/jbc.C000580200; Lin ZH, 2012, MOL CELL, V46, P484, DOI 10.1016/j.molcel.2012.03.024; Liu GT, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-67; Menssen A, 2012, P NATL ACAD SCI USA, V109, pE187, DOI 10.1073/pnas.1105304109; Mertins P, 2013, NAT METHODS, V10, P634, DOI 10.1038/nmeth.2518; Miller KD, 2016, CA-CANCER J CLIN, V66, P271, DOI 10.3322/caac.21349; Nemoto S, 2005, J BIOL CHEM, V280, P16456, DOI 10.1074/jbc.M501485200; Olmos Y, 2011, DRUG RESIST UPDATE, V14, P35, DOI 10.1016/j.drup.2010.12.001; Ramkumar C, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3598; Smith JS, 2000, P NATL ACAD SCI USA, V97, P6658, DOI 10.1073/pnas.97.12.6658; Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262; Vaquero A, 2004, MOL CELL, V16, P93, DOI 10.1016/j.molcel.2004.08.031; Vaziri H, 2001, CELL, V107, P149, DOI 10.1016/S0092-8674(01)00527-X; Wang CG, 2006, NAT CELL BIOL, V8, P1025, DOI 10.1038/ncb1468; Wang RH, 2008, CANCER CELL, V14, P312, DOI 10.1016/j.ccr.2008.09.001; Wiesner S, 2007, CELL, V130, P651, DOI 10.1016/j.cell.2007.06.050; Wilking MJ, 2014, ARCH BIOCHEM BIOPHYS, V563, P94, DOI 10.1016/j.abb.2014.04.001; Wong S, 2007, BIOCHEM J, V407, P451, DOI 10.1042/BJ20070151; Yamakuchi M, 2008, P NATL ACAD SCI USA, V105, P13421, DOI 10.1073/pnas.0801613105; Yang YH, 2007, NAT CELL BIOL, V9, P1253, DOI 10.1038/ncb1645; Yeung F, 2004, EMBO J, V23, P2369, DOI 10.1038/sj.emboj.7600244; Yu L, 2019, CANCER LETT, V448, P40, DOI 10.1016/j.canlet.2019.01.039; Zhang R, 2010, J BIOL CHEM, V285, P7097, DOI 10.1074/jbc.M109.038604; Zhang Y, 2001, P NATL ACAD SCI USA, V98, P974, DOI 10.1073/pnas.98.3.974; Zhang Y, 2009, ONCOGENE, V28, P445, DOI 10.1038/onc.2008.388	51	31	31	2	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2020	39	22					4450	4464		10.1038/s41388-020-1298-0	http://dx.doi.org/10.1038/s41388-020-1298-0		MAY 2020	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LR9IT	32361710				2022-12-17	WOS:000530258200001
J	Sundqvist, A; Vasilaki, E; Voytyuk, O; Bai, Y; Morikawa, M; Moustakas, A; Miyazono, K; Heldin, CH; ten Dijke, P; van Dam, H				Sundqvist, Anders; Vasilaki, Eleftheria; Voytyuk, Oleksandr; Bai, Yu; Morikawa, Masato; Moustakas, Aristidis; Miyazono, Kohei; Heldin, Carl-Henrik; ten Dijke, Peter; van Dam, Hans			TGF beta and EGF signaling orchestrates the AP-1-and p63 transcriptional regulation of breast cancer invasiveness	ONCOGENE			English	Article							NETWORK; TARGET; CELLS; FRA-1; CHEMOSENSITIVITY; EVOLUTION; PATHWAYS; PROTEIN; FOS	Activator protein (AP)-1 transcription factors are essential elements of the pro-oncogenic functions of transforming growth factor-beta (TGF beta)-SMAD signaling. Here we show that in multiple HER2+ and/or EGFR+ breast cancer cell lines these AP-1-dependent tumorigenic properties of TGF beta critically rely on epidermal growth factor receptor (EGFR) activation and expression of the Delta N isoform of transcriptional regulator p63. EGFR and Delta Np63 enabled and/or potentiated the activation of a subset of TGF beta-inducible invasion/migration-associated genes, e.g., ITGA2, LAMB3, and WNT7A/B, and enhanced the recruitment of SMAD2/3 to these genes. The TGF beta- and EGF-induced binding of SMAD2/3 and JUNB to these gene loci was accompanied by p63-SMAD2/3 and p63-JUNB complex formation. p63 and EGFR were also found to strongly potentiate TGF beta induction of AP-1 proteins and, in particular, FOS family members. Ectopic overexpression of FOS could counteract the decrease in TGF beta-induced gene activation after p63 depletion. p63 is also involved in the transcriptional regulation of heparin binding (HB)-EGF and EGFR genes, thereby establishing a self-amplification loop that facilitates and empowers the pro-invasive functions of TGF beta. These cooperative pro-oncogenic functions of EGFR, AP-1, p63, and TGF beta were efficiently inhibited by clinically relevant chemical inhibitors. Our findings may, therefore, be of importance for therapy of patients with breast cancers with an activated EGFR-RAS-RAF pathway.	[Sundqvist, Anders; Vasilaki, Eleftheria; Voytyuk, Oleksandr; Bai, Yu; Moustakas, Aristidis; Miyazono, Kohei; Heldin, Carl-Henrik; ten Dijke, Peter] Uppsala Univ, Sci Life Lab, Dept Med Biochem & Microbiol, SE-75123 Uppsala, Sweden; [Morikawa, Masato; Miyazono, Kohei] Univ Tokyo, Grad Sch Med, Dept Mol Pathol, Tokyo 1130033, Japan; [ten Dijke, Peter; van Dam, Hans] Leiden Univ, Med Ctr, Oncode Inst, Dept Cell & Chem Biol, NL-2300 RC Leiden, Netherlands	Uppsala University; University of Tokyo; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Sundqvist, A (corresponding author), Uppsala Univ, Sci Life Lab, Dept Med Biochem & Microbiol, SE-75123 Uppsala, Sweden.; van Dam, H (corresponding author), Leiden Univ, Med Ctr, Oncode Inst, Dept Cell & Chem Biol, NL-2300 RC Leiden, Netherlands.	anders.sundqvist@imbim.uu.se; vdam@lumc.nl	Dijke, Peter ten/AAG-4660-2021; Morikawa, Masato/D-1932-2011; Vasilaki, Eleftheria/AAY-6392-2020	Dijke, Peter ten/0000-0002-7234-342X; Morikawa, Masato/0000-0002-6191-7176; van Dam, Hans/0000-0002-8307-4325	Swedish Cancer Foundation [2016/468, 2018/439]; Swedish Research Council [2015-02757]; European Research Council [787472]; Cancer Genomics Centre Netherlands (CGC.NL)	Swedish Cancer Foundation; Swedish Research Council(Swedish Research CouncilEuropean Commission); European Research Council(European Research Council (ERC)European Commission); Cancer Genomics Centre Netherlands (CGC.NL)	S We thank our colleagues, in particular Maria Tsioumpekou, for valuable discussion. David Baker and David van IJzendoorn for the Flag-FOS lentiviral vector. The HCC-1954 cells were kindly provided by Otavia L. Caballero and Andrew J.G. Simpson, Ludwig Cancer Research, New York, USA, and the HCC1937 and HCC202 cells by SE Le Devedec, Leiden Academic Center for Drug Research, Leiden, the Netherlands. This work was supported by the Swedish Cancer Foundation (2016/468 to PtD, 2018/439 to KM); Swedish Research Council (2015-02757 to C-HH); European Research Council (787472 to C-HH); and Cancer Genomics Centre Netherlands (CGC.NL to PtD).	Akhurst RJ, 2015, SCI SIGNAL, V8, DOI 10.1126/scisignal.aad0416; Ali R, 2017, SIGNAL TRANSDUCT TAR, V2, DOI 10.1038/sigtrans.2016.42; Baan B, 2010, MOL CELL PROTEOMICS, V9, P1982, DOI 10.1074/mcp.M110.000943; Bakiri L, 2015, CELL DEATH DIFFER, V22, P336, DOI 10.1038/cdd.2014.157; Belguise K, 2005, ONCOGENE, V24, P1434, DOI 10.1038/sj.onc.1208312; Bhola NE, 2013, J CLIN INVEST, V123, P1348, DOI 10.1172/JCI65416; Buckley NE, 2011, CANCER RES, V71, P1933, DOI 10.1158/0008-5472.CAN-10-2717; Carroll DK, 2006, NAT CELL BIOL, V8, P551, DOI 10.1038/ncb1420; Chen YL, 2018, CELL MOL LIFE SCI, V75, P965, DOI 10.1007/s00018-017-2666-y; Chow A, 2011, J MAMMARY GLAND BIOL, V16, P81, DOI 10.1007/s10911-011-9206-4; David CJ, 2018, NAT REV MOL CELL BIO, V19, P419, DOI 10.1038/s41580-018-0007-0; Dawson PJ, 1996, AM J PATHOL, V148, P313; Derynck R, 2019, SCI SIGNAL, V12, DOI 10.1126/scisignal.aav5183; Desmet CJ, 2013, P NATL ACAD SCI USA, V110, P5139, DOI 10.1073/pnas.1222085110; Dhillon AS, 2015, ONCOGENE, V34, P4421, DOI 10.1038/onc.2014.374; Durchdewald M, 2009, HISTOL HISTOPATHOL, V24, P14451, DOI 10.14670/HH-24.1451; Eferl R, 2003, NAT REV CANCER, V3, P859, DOI 10.1038/nrc1209; Eferl R, 2003, CELL, V112, P181, DOI 10.1016/S0092-8674(03)00042-4; Ellis MJ, 2012, NATURE, V486, P353, DOI 10.1038/nature11143; Gatti V, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20112683; Gatti V, 2018, ONCOGENESIS, V7, DOI 10.1038/s41389-018-0073-3; Hess J, 2004, J CELL SCI, V117, P5965, DOI 10.1242/jcs.01589; Hill CS, 2016, CSH PERSPECT BIOL, V8, DOI 10.1101/cshperspect.a022079; Hu LS, 2017, P NATL ACAD SCI USA, V114, pE3964, DOI 10.1073/pnas.1617816114; Huang F, 2018, CANCER RES, V78, P6073, DOI 10.1158/0008-5472.CAN-18-0136; Huang SD, 2012, CELL, V151, P937, DOI 10.1016/j.cell.2012.10.035; Ikushima H, 2012, CELL TISSUE RES, V347, P37, DOI 10.1007/s00441-011-1179-5; Katsuno Y, 2013, CURR OPIN ONCOL, V25, P76, DOI 10.1097/CCO.0b013e32835b6371; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Koinuma D, 2009, MOL CELL BIOL, V29, P172, DOI 10.1128/MCB.01038-08; Kurrey NK, 2009, STEM CELLS, V27, P2059, DOI 10.1002/stem.154; Lemmon MA, 2010, CELL, V141, P1117, DOI 10.1016/j.cell.2010.06.011; Leong CO, 2007, J CLIN INVEST, V117, P1370, DOI 10.1172/JCI30866; Lopez-Bergami P, 2010, NAT REV CANCER, V10, P65, DOI 10.1038/nrc2681; Lu D, 2012, CANCER RES, V72, P3451, DOI 10.1158/0008-5472.CAN-11-2536; Madrigal P, 2018, TRENDS CELL BIOL, V28, P509, DOI 10.1016/j.tcb.2018.04.009; Massague J, 2012, NAT REV MOL CELL BIO, V13, P616, DOI 10.1038/nrm3434; Moses HL, 2016, CSH PERSPECT BIOL, V8, DOI 10.1101/cshperspect.a021865; Ozanne BW, 2007, ONCOGENE, V26, P1, DOI 10.1038/sj.onc.1209759; ROBERTS AB, 1982, NATURE, V295, P417, DOI 10.1038/295417a0; Shah SP, 2012, NATURE, V486, P395, DOI 10.1038/nature10933; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; Shaulian E, 2010, CELL SIGNAL, V22, P894, DOI 10.1016/j.cellsig.2009.12.008; SOULE HD, 1990, CANCER RES, V50, P6075; Stephens PJ, 2012, NATURE, V486, P400, DOI 10.1038/nature11017; Subramanian D, 2015, J BIOL CHEM, V290, P18636, DOI 10.1074/jbc.M115.636548; Sundqvist A, 2013, ONCOGENE, V32, P3606, DOI 10.1038/onc.2012.370; Sundqvist A, 2018, NUCLEIC ACIDS RES, V46, P1180, DOI 10.1093/nar/gkx1190; Sundqvist A, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3066; Tam WL, 2013, CANCER CELL, V24, P347, DOI 10.1016/j.ccr.2013.08.005; van IJzendoorn DGP, 2017, J BIOL CHEM, V292, P21282, DOI 10.1074/jbc.C117.815845; van Staalduinen J, 2018, ONCOGENE, V37, P6195, DOI 10.1038/s41388-018-0378-x; Vasilaki E, 2016, SCI SIGNAL, V9, DOI 10.1126/scisignal.aag3232; Vierbuchen T, 2017, MOL CELL, V68, P1067, DOI 10.1016/j.molcel.2017.11.026; Wagner EF, 2009, NAT REV CANCER, V9, P537, DOI 10.1038/nrc2694; Wiercinska E, 2011, BREAST CANCER RES TR, V128, P657, DOI 10.1007/s10549-010-1147-x; Wilson CA, 2005, BREAST CANCER RES, V7, pR1058, DOI 10.1186/bcr1343; Xue Z, 2018, CELL RES, V28, P719, DOI 10.1038/s41422-018-0044-4; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814	59	31	32	3	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2020	39	22					4436	4449		10.1038/s41388-020-1299-z	http://dx.doi.org/10.1038/s41388-020-1299-z		APR 2020	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LR9IT	32350443	Green Published, hybrid			2022-12-17	WOS:000529589900002
J	Guan, YF; Huang, QL; Ai, YL; Chen, QT; Zhao, WX; Wang, XM; Wu, Q; Chen, HZ				Guan, Yun-feng; Huang, Qiao-ling; Ai, Yuan-li; Chen, Qi-tao; Zhao, Wen-xiu; Wang, Xiao-min; Wu, Qiao; Chen, Hang-zi			Nur77-activated lncRNA WFDC21P attenuates hepatocarcinogenesis via modulating glycolysis	ONCOGENE			English	Article							LONG NONCODING RNAS; NUCLEAR RECEPTOR TR3; PYRUVATE-KINASE M2; HEPATOCELLULAR-CARCINOMA; GLUCOSE-METABOLISM; CANCER; PHOSPHOFRUCTOKINASE; EXPRESSION; ISOFORM	Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related mortality worldwide. Orphan nuclear receptor Nur77, which is low expressed in HCC, functions as a tumor suppressor to suppress HCC. However, the detailed mechanism is still not well understood. Here, we demonstrate that Nur77 could inhibit HCC development via transcriptional activation of the lncRNA WAP four-disulfide core domain 21 pseudogene (WFDC21P). Nur77 binds to its response elements on the WFDC21P promoter to directly induce WFDC21P transcription, which inhibits HCC cell proliferation, tumor growth, and tumor metastasis both in vitro and in vivo. In clinical HCC samples, WFDC21P expression positively correlated with that of Nur77, and the loss of WFDC21P is associated with worse prognosis. Mechanistically, WFDC21P could inhibit glycolysis by simultaneously interacting with PFKP and PKM2, two key enzymes in glycolysis. These interactions not only abrogate the tetramer formation of PFKP to impede its catalytic activity but also prevent the nuclear translocation of PKM2 to suppress its function as a transcriptional coactivator. Cytosporone-B (Csn-B), an agonist for Nur77, could stimulate WFDC21P expression and suppress HCC in a WFDC21P-dependent manner. Therefore, our study reveals a new HCC suppressor and connects the glycolytic remodeling of HCC with the Nur77-WFDC21P-PFKP/PKM2 axis.	[Guan, Yun-feng; Huang, Qiao-ling; Ai, Yuan-li; Chen, Qi-tao; Wu, Qiao; Chen, Hang-zi] Xiamen Univ, Innovat Ctr Cell Signaling Network, Sch Life Sci, State Key Lab Cellular Stress Biol, Xiamen 361102, Fujian, Peoples R China; [Zhao, Wen-xiu; Wang, Xiao-min] Xiamen Univ, Zhong Shan Hosp, Fujian Prov Key Lab Chron Liver Dis & Hepatocellu, Xiamen 361005, Fujian, Peoples R China	Xiamen University; Xiamen University	Chen, HZ (corresponding author), Xiamen Univ, Innovat Ctr Cell Signaling Network, Sch Life Sci, State Key Lab Cellular Stress Biol, Xiamen 361102, Fujian, Peoples R China.	Chenhz@xmu.edu.cn		Chen, Hang-zi/0000-0002-4827-2182	National Natural Science Fund of China; Ministry of Science and Technology of China [31822013, 31871434, U1405224, 81672695, 2017YFA0504502]; Fundamental Research Funds for the Central Universities of China [20720190083]	National Natural Science Fund of China(National Natural Science Foundation of China (NSFC)); Ministry of Science and Technology of China(Ministry of Science and Technology, China); Fundamental Research Funds for the Central Universities of China(Fundamental Research Funds for the Central Universities)	We thank Dr Hui-ying Huang for her assistance with the metabolites detection using NMR magnet system. This work was supported by grants from the National Natural Science Fund of China and the Ministry of Science and Technology of China (31822013, 31871434, U1405224, 81672695, and 2017YFA0504502), the Fundamental Research Funds for the Central Universities of China (20720190083).	Allen AE, 2018, CANCER CELL, V33, P337, DOI 10.1016/j.ccell.2018.02.008; Anastasiou D, 2011, SCIENCE, V334, P1278, DOI 10.1126/science.1211485; Atianand MK, 2017, ANNU REV IMMUNOL, V35, P177, DOI 10.1146/annurev-immunol-041015-055459; Beard JA, 2015, CELL SIGNAL, V27, P257, DOI 10.1016/j.cellsig.2014.11.009; Beyoglu D, 2013, J HEPATOL, V59, P842, DOI 10.1016/j.jhep.2013.05.030; Bian XL, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14420; Chen HZ, 2012, ONCOGENE, V31, P2876, DOI 10.1038/onc.2011.463; Chen HZ, 2012, GUT, V61, P714, DOI 10.1136/gutjnl-2011-300783; Chen X, 2016, CELL RES, V26, P1007, DOI 10.1038/cr.2016.100; Cho SD, 2007, CANCER RES, V67, P674, DOI 10.1158/0008-5472.CAN-06-2907; Christofk HR, 2008, NATURE, V452, P230, DOI 10.1038/nature06734; DUNAWAY GA, 1988, BIOCHEM J, V251, P677, DOI 10.1042/bj2510677; Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210; Fu WM, 2015, J HEPATOL, V63, P886, DOI 10.1016/j.jhep.2015.05.016; Han YH, 2006, ONCOGENE, V25, P2974, DOI 10.1038/sj.onc.1209358; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hay N, 2016, NAT REV CANCER, V16, P635, DOI 10.1038/nrc.2016.77; Huarte M, 2015, NAT MED, V21, P1253, DOI 10.1038/nm.3981; Hung CL, 2014, P NATL ACAD SCI USA, V111, P18697, DOI 10.1073/pnas.1415669112; Jiang SH, 2017, NATURE, V544, P460, DOI 10.1038/nature22032; Klingenberg M, 2017, J HEPATOL, V67, P603, DOI 10.1016/j.jhep.2017.04.009; Kong L, 2007, NUCLEIC ACIDS RES, V35, pW345, DOI 10.1093/nar/gkm391; Kopp F, 2018, CELL, V172, P393, DOI 10.1016/j.cell.2018.01.011; Li XX, 2018, MOL CELL, V69, P480, DOI 10.1016/j.molcel.2018.01.001; Lin MF, 2011, BIOINFORMATICS, V27, pI275, DOI 10.1093/bioinformatics/btr209; Luo WB, 2011, CELL, V145, P732, DOI 10.1016/j.cell.2011.03.054; Mazurek S, 2011, INT J BIOCHEM CELL B, V43, P969, DOI 10.1016/j.biocel.2010.02.005; Mor I, 2011, COLD SH Q B, V76, P211, DOI 10.1101/sqb.2011.76.010868; Morita M, 2018, CANCER CELL, V33, P355, DOI 10.1016/j.ccell.2018.02.004; Orom UA, 2010, CELL, V143, P46, DOI 10.1016/j.cell.2010.09.001; Park YY, 2013, HEPATOLOGY, V58, P182, DOI 10.1002/hep.26310; Pawlak A, 2015, STEROIDS, V95, P1, DOI 10.1016/j.steroids.2014.12.020; Safe S, 2016, J STEROID BIOCHEM, V157, P48, DOI 10.1016/j.jsbmb.2015.04.016; Safe S, 2014, MOL ENDOCRINOL, V28, P157, DOI 10.1210/me.2013-1291; Schmitt AM, 2016, CANCER CELL, V29, P452, DOI 10.1016/j.ccell.2016.03.010; Takahashi K, 2014, HEPATOLOGY, V60, P744, DOI 10.1002/hep.27043; Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262; Tsai MC, 2010, SCIENCE, V329, P689, DOI 10.1126/science.1192002; VORA S, 1983, HUM GENET, V63, P374, DOI 10.1007/BF00274765; Wang HJ, 2014, P NATL ACAD SCI USA, V111, P279, DOI 10.1073/pnas.1311249111; Wang WJ, 2014, NAT CHEM BIOL, V10, P133, DOI [10.1038/NCHEMBIO.1406, 10.1038/nchembio.1406]; Webb BA, 2015, NATURE, V523, P111, DOI 10.1038/nature14405; Wong N, 2015, CANCER LETT, V356, P184, DOI 10.1016/j.canlet.2014.01.031; Yang F, 2014, MOL CELL, V53, P88, DOI 10.1016/j.molcel.2013.11.004; Yang H, 2011, HEPATOLOGY, V53, P865, DOI 10.1002/hep.24101; Yang JD, 2010, NAT REV GASTRO HEPAT, V7, P448, DOI 10.1038/nrgastro.2010.100; Yao LM, 2012, CARCINOGENESIS, V33, P301, DOI 10.1093/carcin/bgr287; Yi W, 2012, SCIENCE, V337, P975, DOI 10.1126/science.1222278; Yoon JH, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3939; Yuan JH, 2017, NAT CELL BIOL, V19, P820, DOI 10.1038/ncb3538; Zhan YP, 2008, NAT CHEM BIOL, V4, P548, DOI 10.1038/nchembio.106; Zhao XY, 2015, TRENDS BIOCHEM SCI, V40, P586, DOI 10.1016/j.tibs.2015.08.002	52	31	32	5	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2020	39	11					2408	2423		10.1038/s41388-020-1158-y	http://dx.doi.org/10.1038/s41388-020-1158-y		JAN 2020	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KU0ZS	31959898	Green Published, hybrid			2022-12-17	WOS:000508322900001
J	Prokhorova, EA; Egorshina, AY; Zhivotovsky, B; Kopeina, GS				Prokhorova, Evgeniia A.; Egorshina, Aleksandra Yu.; Zhivotovsky, Boris; Kopeina, Gelina S.			The DNA-damage response and nuclear events as regulators of nonapoptotic forms of cell death	ONCOGENE			English	Review							POLY(ADP-RIBOSE) PAR POLYMER; PREMATURE SENESCENCE SIPS; DOMAIN-LIKE PROTEIN; 2 DISTINCT MODES; MITOTIC CATASTROPHE; TUMOR-SUPPRESSOR; MOLECULAR-MECHANISMS; GENOTOXIC STRESS; ONCOGENIC RAS; AUTOPHAGY	The maintenance of genome stability is essential for the cell as the integrity of genomic information guaranties reproduction of a whole organism. DNA damage occurring in response to different natural and nonnatural stimuli (errors in DNA replication, UV radiation, chemical agents, etc.) is normally detected by special cellular machinery that induces DNA repair. However, further accumulation of genetic lesions drives the activation of cell death to eliminate cells with defective genome. This particular feature is used for targeting fast-proliferating tumor cells during chemo-, radio-, and immunotherapy. Among different cell death modalities induced by DNA damage, apoptosis is the best studied. Nevertheless, nonapoptotic cell death and adaptive stress responses are also activated following genotoxic stress and play a crucial role in the outcome of anticancer therapy. Here, we provide an overview of nonapoptotic cell death pathways induced by DNA damage and discuss their interplay with cellular senescence, mitotic catastrophe, and autophagy.	[Prokhorova, Evgeniia A.; Egorshina, Aleksandra Yu.; Zhivotovsky, Boris; Kopeina, Gelina S.] Moscow MV Lomonosov State Univ, Fac Fundamental Med, Moscow 119991, Russia; [Zhivotovsky, Boris] Karolinska Inst, Inst Environm Med, Div Toxicol, Box 210, S-17177 Stockholm, Sweden; [Prokhorova, Evgeniia A.] Univ Oxford, Sir William Dunn Sch Pathol, Oxford OX1 3RE, England	Lomonosov Moscow State University; Karolinska Institutet; University of Oxford	Zhivotovsky, B; Kopeina, GS (corresponding author), Moscow MV Lomonosov State Univ, Fac Fundamental Med, Moscow 119991, Russia.; Zhivotovsky, B (corresponding author), Karolinska Inst, Inst Environm Med, Div Toxicol, Box 210, S-17177 Stockholm, Sweden.	Boris.Zhivotovsky@ki.se; lirroster@gmail.com	Kopeina, Gelina/AAD-5713-2022; Egorshina, Aleksandra/AAM-7411-2020; Zhivotovsky, Boris/A-4346-2014	Egorshina, Aleksandra/0000-0001-7818-1161; Prokhorova, Evgeniia/0000-0002-5467-5586; Zhivotovsky, Boris/0000-0002-2238-3482; Gelina, Kopeina/0000-0002-7143-6923	Russian Science Foundation [19-15-00125]; Russian Foundation for Basic Research [18-29-09005, 18-015-00211]; Swedish Cancer Society; Swedish Childhood Cancer Foundation; Stockholm Cancer Society	Russian Science Foundation(Russian Science Foundation (RSF)); Russian Foundation for Basic Research(Russian Foundation for Basic Research (RFBR)); Swedish Cancer Society(Swedish Cancer Society); Swedish Childhood Cancer Foundation(European Commission); Stockholm Cancer Society	This work was supported by the Grant from the Russian Science Foundation (19-15-00125). The work in the authors' laboratories is also supported by the Grants from the Russian Foundation for Basic Research (18-29-09005, 18-015-00211), the Swedish and Stockholm Cancer Societies and the Swedish Childhood Cancer Foundation. We apologize to those authors whose primary works could not be cited owing to space limitations.	Acosta JC, 2012, TRENDS CELL BIOL, V22, P211, DOI 10.1016/j.tcb.2011.11.006; Alano CC, 2010, J NEUROSCI, V30, P2967, DOI 10.1523/JNEUROSCI.5552-09.2010; Allocati N, 2012, EXP CELL RES, V318, P1285, DOI 10.1016/j.yexcr.2012.01.023; Allsopp RC, 1996, EXP GERONTOL, V31, P235, DOI 10.1016/0531-5565(95)02008-X; Andersen JL, 2009, EMBO J, V28, P3216, DOI 10.1038/emboj.2009.253; Andrabi SA, 2006, P NATL ACAD SCI USA, V103, P18308, DOI 10.1073/pnas.0606526103; Andrabi SA, 2014, P NATL ACAD SCI USA, V111, P10209, DOI 10.1073/pnas.1405158111; Andrabi SA, 2011, NAT MED, V17, P692, DOI 10.1038/nm.2387; Bae H, 2011, MOL CANCER RES, V9, P1232, DOI 10.1158/1541-7786.MCR-11-0098; Baek SH, 2013, MOL CELLS, V36, P258, DOI 10.1007/s10059-013-0172-0; Batchelor E, 2008, MOL CELL, V30, P277, DOI 10.1016/j.molcel.2008.03.016; Bergsbaken T, 2009, NAT REV MICROBIOL, V7, P99, DOI 10.1038/nrmicro2070; Bianchi-Smiraglia A, 2012, CELL CYCLE, V11, P4147, DOI 10.4161/cc.22589; Biton S, 2011, CELL, V145, P92, DOI 10.1016/j.cell.2011.02.023; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Brown JM, 1999, CANCER RES, V59, P1391; Brunyanszki A, 2016, FREE RADICAL BIO MED, V100, P257, DOI 10.1016/j.freeradbiomed.2016.02.024; Campisi J, 2013, ANNU REV PHYSIOL, V75, P685, DOI 10.1146/annurev-physiol-030212-183653; Castedo M, 2004, ONCOGENE, V23, P4362, DOI 10.1038/sj.onc.1207572; Castedo M, 2006, EMBO J, V25, P2584, DOI 10.1038/sj.emboj.7601127; Chen JH, 2015, AUTOPHAGY, V11, P239, DOI 10.1080/15548627.2015.1009767; Chen NC, 2016, SCI REP-UK, V6, DOI 10.1038/srep20417; Chen X, 2014, CELL RES, V24, P105, DOI 10.1038/cr.2013.171; Chen ZB, 2005, NATURE, V436, P725, DOI 10.1038/nature03918; Chen Z, 2009, BBA-BIOENERGETICS, V1787, P553, DOI 10.1016/j.bbabio.2009.03.003; Chiu LY, 2011, BIOCHEM PHARMACOL, V81, P459, DOI 10.1016/j.bcp.2010.10.016; Christmann M, 2013, NUCLEIC ACIDS RES, V41, P8403, DOI 10.1093/nar/gkt635; Christofferson DE, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.64; Ciccia A, 2010, MOL CELL, V40, P179, DOI 10.1016/j.molcel.2010.09.019; Colicchia V, 2017, ONCOGENE, V36, P4682, DOI 10.1038/onc.2017.40; Dantzer F, 2004, MOL CELL BIOL, V24, P1595, DOI 10.1128/MCB.24.4.1595-1607.2004; Dashzeveg N, 2015, CANCER LETT, V367, P108, DOI 10.1016/j.canlet.2015.07.019; de Stanchina E, 2004, MOL CELL, V13, P523, DOI 10.1016/S1097-2765(04)00062-0; Degterev A, 2005, NAT CHEM BIOL, V1, P112, DOI 10.1038/nchembio711; Delgado-Camprubi M, 2016, CELL DEATH DIFFER, V1, P1; Denchi EL, 2007, NATURE, V448, P1068, DOI 10.1038/nature06065; Denisenko TV, 2016, DRUG RESIST UPDATE, V24, P1, DOI 10.1016/j.drup.2015.11.002; di Fagagna FD, 2008, NAT REV CANCER, V8, P512, DOI 10.1038/nrc2440; Di Micco R, 2006, NATURE, V444, P638, DOI 10.1038/nature05327; Dixon SJ, 2012, CELL, V149, P1060, DOI 10.1016/j.cell.2012.03.042; Dolle C, 2013, FEBS J, V280, P3530, DOI 10.1111/febs.12304; Dolle C, 2010, CELL MOL LIFE SCI, V67, P433, DOI 10.1007/s00018-009-0190-4; Douglas DL, 2014, J CELL SCI, V127, P4134, DOI 10.1242/jcs.128009; Duursma AM, 2013, MOL CELL, V50, P116, DOI 10.1016/j.molcel.2013.03.006; Eapen VV, 2017, P NATL ACAD SCI USA, V114, pE1158, DOI 10.1073/pnas.1614364114; Eom YW, 2005, ONCOGENE, V24, P4765, DOI 10.1038/sj.onc.1208627; Erdelyi K, 2009, FASEB J, V23, P3553, DOI 10.1096/fj.09-133264; Fatokun AA, 2014, BRIT J PHARMACOL, V171, P2000, DOI 10.1111/bph.12416; Feoktistova M, 2011, MOL CELL, V43, P449, DOI 10.1016/j.molcel.2011.06.011; Ferbeyre G, 2000, GENE DEV, V14, P2015; Fouquerel E, 2014, CELL REP, V8, P1819, DOI 10.1016/j.celrep.2014.08.036; Gagne JP, 2008, NUCLEIC ACIDS RES, V36, P6959, DOI 10.1093/nar/gkn771; Galluzzi L, 2015, CELL DEATH DIFFER, V22, P1237, DOI 10.1038/cdd.2015.54; Galluzzi L, 2012, CELL DEATH DIFFER, V19, P107, DOI 10.1038/cdd.2011.96; Galluzzi L, 2018, CELL DEATH DIFFER, V25, P486, DOI 10.1038/s41418-017-0012-4; Gao RJ, 2007, BIOMED ENVIRON SCI, V20, P189; Griffith JD, 1999, CELL, V97, P503, DOI 10.1016/S0092-8674(00)80760-6; Guo WJ, 2011, CANCER LETT, V312, P55, DOI 10.1016/j.canlet.2011.07.024; Haldar S, 2015, J BIOL CHEM, V290, P6574, DOI 10.1074/jbc.M114.617886; Hanson B, 2016, CANCER BIOL THER, V17, P899, DOI 10.1080/15384047.2016.1210732; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HAYFLICK L, 1965, EXP CELL RES, V37, P614, DOI 10.1016/0014-4827(65)90211-9; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; He L, 2007, NATURE, V447, P1130, DOI 10.1038/nature05939; He Y, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20071562; He Y, 2019, MOL CANCER RES, V17, P1129, DOI 10.1158/1541-7786.MCR-18-1306; Hildebrand JM, 2014, P NATL ACAD SCI USA, V111, P15072, DOI 10.1073/pnas.1408987111; Huang Y, 2005, CANCER RES, V65, P7446, DOI 10.1158/0008-5472.CAN-04-4267; Jakhar R, 2018, MOL CANCER RES, V16, P1625, DOI 10.1158/1541-7786.MCR-18-0024; Jang KH, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2016.437; Janssen A, 2009, P NATL ACAD SCI USA, V106, P19108, DOI 10.1073/pnas.0904343106; Jeong NY, 2012, INT J ONCOL, V40, P1949, DOI 10.3892/ijo.2012.1401; Jiang L, 2015, NATURE, V520, P57, DOI 10.1038/nature14344; Jing L, 2018, CANCER LETT, V414, P136, DOI 10.1016/j.canlet.2017.10.047; Kang C, 2016, AUTOPHAGY, V12, P898, DOI 10.1080/15548627.2015.1121361; Kang C, 2015, SCIENCE, V349, DOI 10.1126/science.aaa5612; Karakashev S, 2017, CELL REP, V21, P3398, DOI 10.1016/j.celrep.2017.11.095; Karlseder J, 2004, PLOS BIOL, V2, P1150, DOI 10.1371/journal.pbio.0020240; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Kim J, 2011, NAT CELL BIOL, V13, P132, DOI 10.1038/ncb2152; Klionsky DJ, 2016, AUTOPHAGY, V12, P1, DOI 10.1080/15548627.2015.1100356; Knizhnik AV, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055665; Koh DW, 2004, P NATL ACAD SCI USA, V101, P17699, DOI 10.1073/pnas.0406182101; KUNZ C, 1995, NUCLEIC ACIDS RES, V23, P3710, DOI 10.1093/nar/23.18.3710; Kwok M, 2016, BLOOD, V127, P582, DOI 10.1182/blood-2015-05-644872; LASTER SM, 1988, J IMMUNOL, V141, P2629; Lee AC, 1999, J BIOL CHEM, V274, P7936, DOI 10.1074/jbc.274.12.7936; Lee IH, 2008, P NATL ACAD SCI USA, V105, P3374, DOI 10.1073/pnas.0712145105; Lee SY, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.266; Lescarbeau RS, 2016, MOL CANCER THER, V15, P1332, DOI [10.1158/1535-7163.MCT-15-0692-T, 10.1158/1535-7163.MCT-15-0692]; Li TY, 2012, CELL, V149, P1269, DOI 10.1016/j.cell.2012.04.026; Lin SY, 2018, AUTOPHAGY, V14, P778, DOI 10.1080/15548627.2017.1386359; Linkermann A, 2013, P NATL ACAD SCI USA, V110, P12024, DOI 10.1073/pnas.1305538110; Liu MD, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06556-9; Liu XX, 2011, FEBS LETT, V585, P1363, DOI 10.1016/j.febslet.2011.04.018; Lu JV, 2012, IMMUNOL REV, V249, P205, DOI 10.1111/j.1600-065X.2012.01147.x; Ma K, 2017, AUTOPHAGY, V13, P579, DOI 10.1080/15548627.2016.1272742; Mannava S, 2013, AM J PATHOL, V182, P142, DOI 10.1016/j.ajpath.2012.09.011; Rodriguez-Vargas JM, 2012, CELL RES, V22, P1181, DOI 10.1038/cr.2012.70; Manzl C, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.470; Maskey D, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3130; Matt S, 2016, CELL MOL LIFE SCI, V73, P2829, DOI 10.1007/s00018-016-2130-4; Menon MB, 2018, TRENDS BIOCHEM SCI, V43, P170, DOI 10.1016/j.tibs.2017.12.002; Mohammad RM, 2015, SEMIN CANCER BIOL, V35, pS78, DOI 10.1016/j.semcancer.2015.03.001; Morselli E, 2011, CELL CYCLE, V10, P2763, DOI 10.4161/cc.10.16.16868; Munoz-Gomez JA, 2009, AUTOPHAGY, V5, P61, DOI 10.4161/auto.5.1.7272; Nardella C, 2011, NAT REV CANCER, V11, P503, DOI 10.1038/nrc3057; Niere M, 2008, MOL CELL BIOL, V28, P814, DOI 10.1128/MCB.01766-07; Oberst A, 2011, NATURE, V471, P363, DOI 10.1038/nature09852; Okamura H, 2008, J CELL BIOCHEM, V103, P1488, DOI 10.1002/jcb.21537; Orlotti NI, 2012, AUTOPHAGY, V8, P1185, DOI 10.4161/auto.20519; Pietkiewicz S, 2015, J IMMUNOL METHODS, V423, P99, DOI 10.1016/j.jim.2015.04.025; Pietrobono S, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-017-0142-0; Pietrocola F, 2013, SEMIN CANCER BIOL, V23, P310, DOI 10.1016/j.semcancer.2013.05.008; Polo SE, 2011, GENE DEV, V25, P409, DOI 10.1101/gad.2021311; Prokhorova EA, 2015, CELL MOL LIFE SCI, V72, P4593, DOI 10.1007/s00018-015-2031-y; Qian YJ, 2008, J BIOL CHEM, V283, P2896, DOI 10.1074/jbc.M708624200; Qian Yingjuan, 2013, Methods Mol Biol, V965, P37, DOI 10.1007/978-1-62703-239-1_3; Qin SH, 2018, WORLD J CLIN ONCOL, V9, P180, DOI 10.5306/wjco.v9.i8.180; Rao SG, 2016, TRENDS CANCER, V2, P676, DOI 10.1016/j.trecan.2016.10.001; Reinhardt HC, 2009, CURR OPIN CELL BIOL, V21, P245, DOI 10.1016/j.ceb.2009.01.018; Roninson IB, 2001, DRUG RESIST UPDATE, V4, P303, DOI 10.1054/drup.2001.0213; Salama R, 2014, GENE DEV, V28, P99, DOI 10.1101/gad.235184.113; Samali Afshin, 2010, Int J Cell Biol, V2010, P245803, DOI 10.1155/2010/245803; Sapkota GP, 2002, BIOCHEM J, V368, P507, DOI 10.1042/BJ20021284; Sedic M, 2008, MOL CANCER THER, V7, P2121, DOI 10.1158/1535-7163.MCT-07-2261; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Sidi S, 2008, CELL, V133, P864, DOI 10.1016/j.cell.2008.03.037; Singh K, 2012, AUTOPHAGY, V8, P236, DOI 10.4161/auto.8.2.18600; SKALKA M, 1976, FEBS LETT, V72, P271, DOI 10.1016/0014-5793(76)80984-2; Sorokina IV, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-14901-z; Spriggs KA, 2010, MOL CELL, V40, P228, DOI 10.1016/j.molcel.2010.09.028; Suzuki K, 2003, ONCOGENE, V22, P6988, DOI 10.1038/sj.onc.1206881; Suzuki M, 2008, J RADIAT RES, V49, P105, DOI 10.1269/jrr.07081; Tait SWG, 2014, J CELL SCI, V127, P2135, DOI 10.1242/jcs.093575; Tenev T, 2011, MOL CELL, V43, P432, DOI 10.1016/j.molcel.2011.06.006; Tomasini R, 2008, GENE DEV, V22, P2677, DOI 10.1101/gad.1695308; Tomasini R, 2009, P NATL ACAD SCI USA, V106, P797, DOI 10.1073/pnas.0812096106; Toussaint O, 2000, EXP GERONTOL, V35, P927, DOI 10.1016/S0531-5565(00)00180-7; Vakifahmetoglu H, 2008, CELL DEATH DIFFER, V15, P555, DOI 10.1038/sj.cdd.4402286; Vanden Berghe T, 2014, NAT REV MOL CELL BIO, V15, P134, DOI 10.1038/nrm3737; Vandenabeele P, 2010, NAT REV MOL CELL BIO, V11, P700, DOI 10.1038/nrm2970; Vanpouille-Box C, 2018, CANCER CELL, V34, P361, DOI 10.1016/j.ccell.2018.05.013; Vaseva AV, 2012, CELL, V149, P1536, DOI 10.1016/j.cell.2012.05.014; Velarde MC, 2013, INTERD TOP GERONTOL, V38, P17, DOI 10.1159/000343572; Vernier M, 2011, GENE DEV, V25, P41, DOI 10.1101/gad.1975111; Vitale I, 2011, NAT REV MOL CELL BIO, V12, P384, DOI 10.1038/nrm3115; von Moltke J, 2012, NATURE, V490, P107, DOI 10.1038/nature11351; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; Wang HY, 2014, MOL CELL, V54, P133, DOI 10.1016/j.molcel.2014.03.003; Wang L, 2019, PLOS PATHOG, V15, DOI 10.1371/journal.ppat.1007541; Wang YN, 2016, MOL CELL, V63, P34, DOI 10.1016/j.molcel.2016.05.027; Wang YF, 2016, SCIENCE, V354, DOI 10.1126/science.aad6872; Wang YF, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2000902; Wang YF, 2009, J NEUROCHEM, V110, P687, DOI 10.1111/j.1471-4159.2009.06167.x; Wei YJ, 2008, AUTOPHAGY, V4, P949, DOI 10.4161/auto.6788; Xu YF, 2017, CELL SIGNAL, V31, P112, DOI 10.1016/j.cellsig.2017.01.004; Ying WH, 2003, BIOCHEM BIOPH RES CO, V308, P809, DOI 10.1016/S0006-291X(03)01483-9; Ying WH, 2002, J CEREBR BLOOD F MET, V22, P774, DOI 10.1097/00004647-200207000-00002; Yoon S, 2016, CELL DEATH DIFFER, V23, P253, DOI 10.1038/cdd.2015.92; Young ARJ, 2009, GENE DEV, V23, P798, DOI 10.1101/gad.519709; Yu SW, 2006, P NATL ACAD SCI USA, V103, P18314, DOI 10.1073/pnas.0606528103; Yun M, 2009, MOL CANCER RES, V7, P371, DOI 10.1158/1541-7786.MCR-08-0056; Zamaraev AV, 2018, INT J BIOCHEM CELL B, V102, P101, DOI 10.1016/j.biocel.2018.07.006; Zhang FJ, 2014, TOXICOL SCI, V140, P118, DOI 10.1093/toxsci/kfu073; Zhang T, 2016, NAT MED, V22, P175, DOI 10.1038/nm.4017; Zhang XD, 2010, ACTA PHARMACOL SIN, V31, P1208, DOI 10.1038/aps.2010.151	167	31	31	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2020	39	1					1	16		10.1038/s41388-019-0980-6	http://dx.doi.org/10.1038/s41388-019-0980-6			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KG3NM	31462710				2022-12-17	WOS:000509849200001
J	Tang, K; Yu, YD; Zhu, LY; Xu, PW; Chen, J; Ma, JW; Zhang, HF; Fang, HQ; Sun, WW; Zhou, L; Wei, KK; Li, F; Lv, JD; Xie, J; Liu, YY; Huang, B				Tang, Ke; Yu, Yuandong; Zhu, Liyan; Xu, Pingwei; Chen, Jie; Ma, Jingwei; Zhang, Huafeng; Fang, Haiqing; Sun, Weiwei; Zhou, Li; Wei, Keke; Li, Fei; Lv, Jiadi; Xie, Jing; Liu, Yuying; Huang, Bo			Hypoxia-reprogrammed tricarboxylic acid cycle promotes the growth of human breast tumorigenic cells	ONCOGENE			English	Article							CANCER STEM-CELLS; TUMOR-REPOPULATING CELLS; MITOCHONDRIAL ROS; PHOSPHOENOLPYRUVATE CARBOXYKINASE; METASTASIS; HETEROGENEITY; ANGIOGENESIS; MAINTENANCE; METABOLISM; ADAPTATION	Clinical applications of antiangiogenic agents profoundly affect tumor cell behaviors via the resultant hypoxia. To date, how the hypoxia regulates tumor cells remains unclear. Here, we show that hypoxia promotes the growth of human breast tumorigenic cells that repopulate tumors [tumor-repopulating cells (TRCs)] in vitro and in vivo. This stimulating effect is ascribed to hypoxia-induced reactive oxygen species (ROS) that activates Akt and NF-kappa B, dependent on the attenuated tricarboxylic acid (TCA) cycle. We find that fumarate is accumulated in the TCA cycle of hypoxic TRCs, leading to glutathione succination, NADPH/NADP(+) decrease, and an increase in ROS levels. Mechanistically, hypoxia-increased HIF-1 alpha transcriptionally downregulates the expression of mitochondrial phosphoenolpyruvate carboxykinase (PCK2), leading to TCA cycle attenuation and fumarate accumulation. These findings reveal that hypoxia-reprogrammed TCA cycle promotes human breast TRCs growth via a HIF-1 alpha-downregulated PCK2 pathway, implying a need for a combination of an antiangiogenic therapy with an antioxidant modulator.	[Tang, Ke; Yu, Yuandong; Zhu, Liyan; Xu, Pingwei; Chen, Jie; Ma, Jingwei; Zhang, Huafeng; Fang, Haiqing; Sun, Weiwei; Zhou, Li; Wei, Keke; Li, Fei; Huang, Bo] Huazhong Univ Sci & Technol, Tongji Med Coll, Dept Biochem & Mol Biol, Wuhan 430030, Hubei, Peoples R China; [Lv, Jiadi; Xie, Jing; Liu, Yuying; Huang, Bo] Chinese Acad Med Sci & Peking Union Med Coll, Dept Immunol, Inst Basic Med Sci, Beijing 100005, Peoples R China; [Lv, Jiadi; Xie, Jing; Liu, Yuying; Huang, Bo] Chinese Acad Med Sci & Peking Union Med Coll, State Key Lab Med Mol Biol, Beijing 100005, Peoples R China; [Liu, Yuying; Huang, Bo] Chinese Acad Med Sci, Clin Immunol Ctr, Beijing 100005, Peoples R China	Huazhong University of Science & Technology; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; Chinese Academy of Medical Sciences - Peking Union Medical College	Huang, B (corresponding author), Huazhong Univ Sci & Technol, Tongji Med Coll, Dept Biochem & Mol Biol, Wuhan 430030, Hubei, Peoples R China.; Huang, B (corresponding author), Chinese Acad Med Sci & Peking Union Med Coll, Dept Immunol, Inst Basic Med Sci, Beijing 100005, Peoples R China.; Huang, B (corresponding author), Chinese Acad Med Sci & Peking Union Med Coll, State Key Lab Med Mol Biol, Beijing 100005, Peoples R China.; Huang, B (corresponding author), Chinese Acad Med Sci, Clin Immunol Ctr, Beijing 100005, Peoples R China.	tjhuangbo@hotmail.com	Liu, Yuying/ABD-9637-2021	Liu, Yuying/0000-0003-2182-7210	National Natural Science Foundation of China [81788101, 81530080, 81601366]; CAMS Initiative for Innovative Medicine [2016-I2M-1-007]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); CAMS Initiative for Innovative Medicine	This work was supported by National Natural Science Foundation of China (81788101, 81530080, and 81601366), CAMS Initiative for Innovative Medicine (2016-I2M-1-007).	Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Alderson NL, 2006, ARCH BIOCHEM BIOPHYS, V450, P1, DOI 10.1016/j.abb.2006.03.005; Bell EL, 2011, ONCOGENE, V30, P2986, DOI 10.1038/onc.2011.37; Bertout JA, 2008, NAT REV CANCER, V8, P967, DOI 10.1038/nrc2540; Brooks MD, 2015, CELL STEM CELL, V17, P260, DOI 10.1016/j.stem.2015.08.014; Bruna A, 2016, CELL, V167, P260, DOI 10.1016/j.cell.2016.08.041; Chaffer CL, 2011, P NATL ACAD SCI USA, V108, P7950, DOI 10.1073/pnas.1102454108; Chua YL, 2010, J BIOL CHEM, V285, P31277, DOI 10.1074/jbc.M110.158485; Clevers H, 2011, NAT MED, V17, P313, DOI 10.1038/nm.2304; Conley SJ, 2012, P NATL ACAD SCI USA, V109, P2784, DOI 10.1073/pnas.1018866109; Dieter SM, 2011, CELL STEM CELL, V9, P357, DOI 10.1016/j.stem.2011.08.010; Garcia-Perez C, 2012, P NATL ACAD SCI USA, V109, P4497, DOI 10.1073/pnas.1118244109; Ghajar CM, 2015, NAT REV CANCER, V15, P238, DOI 10.1038/nrc3910; Gilkes DM, 2014, NAT REV CANCER, V14, P430, DOI 10.1038/nrc3726; Hitosugi T, 2011, MOL CELL, V44, P864, DOI 10.1016/j.molcel.2011.10.015; Hou HG, 2016, MED GAS RES, V6, P138, DOI 10.4103/2045-9912.191359; Koren S, 2015, MOL CELL, V60, P537, DOI 10.1016/j.molcel.2015.10.031; Lee CU, 2015, ANGEW CHEM INT EDIT, V54, P13796, DOI 10.1002/anie.201506338; Li Y, 2015, CANCER RES, V75, P1191, DOI 10.1158/0008-5472.CAN-14-2615; Liou GY, 2010, FREE RADICAL RES, V44, P479, DOI 10.3109/10715761003667554; Liu J, 2012, NAT MATER, V11, P734, DOI [10.1038/NMAT3361, 10.1038/nmat3361]; Liu YY, 2018, CANCER CELL, V33, P480, DOI 10.1016/j.ccell.2018.02.005; Liu YY, 2018, J CLIN INVEST, V128, P1057, DOI 10.1172/JCI96329; Lou YM, 2011, CANCER RES, V71, P3364, DOI 10.1158/0008-5472.CAN-10-4261; Luo S, 2017, ONCOGENE, V36, P3609, DOI 10.1038/onc.2016.520; Ma RH, 2018, NAT CELL BIOL, V20, P21, DOI 10.1038/s41556-017-0002-2; Magee JA, 2012, CANCER CELL, V21, P283, DOI 10.1016/j.ccr.2012.03.003; Man JH, 2018, CELL STEM CELL, V22, P104, DOI 10.1016/j.stem.2017.10.005; McIntyre A, 2012, CLIN CANCER RES, V18, P3100, DOI 10.1158/1078-0432.CCR-11-1877; Medema JP, 2013, NAT CELL BIOL, V15, P338, DOI 10.1038/ncb2717; Montagner M, 2012, NATURE, V487, P380, DOI 10.1038/nature11207; Muz B, 2015, HYPOXIA, V3, P83, DOI 10.2147/HP.S93413; Olcina MM, 2016, ONCOGENE, V35, P793, DOI 10.1038/onc.2015.134; Ostergaard L, 2013, CANCER RES, V73, P5618, DOI 10.1158/0008-5472.CAN-13-0964; Papandreou I, 2006, CELL METAB, V3, P187, DOI 10.1016/j.cmet.2006.01.012; Sabharwal SS, 2014, NAT REV CANCER, V14, P709, DOI 10.1038/nrc3803; Samanta D, 2016, CANCER RES, V76, P4430, DOI 10.1158/0008-5472.CAN-16-0530; Semenza GL, 2017, EMBO J, V36, P252, DOI 10.15252/embj.201695204; Shadel GS, 2015, CELL, V163, P560, DOI 10.1016/j.cell.2015.10.001; Sullivan LB, 2014, CANCER METAB, V2, DOI 10.1186/2049-3002-2-17; Sullivan LB, 2013, MOL CELL, V51, P236, DOI 10.1016/j.molcel.2013.05.003; Vincent EE, 2015, MOL CELL, V60, P195, DOI 10.1016/j.molcel.2015.08.013; Weyemi U, 2012, ONCOGENE, V31, P1117, DOI 10.1038/onc.2011.327; Wilson WR, 2011, NAT REV CANCER, V11, P393, DOI 10.1038/nrc3064; Wong CCL, 2011, P NATL ACAD SCI USA, V108, P16369, DOI 10.1073/pnas.1113483108; Xing F, 2011, ONCOGENE, V30, P4075, DOI 10.1038/onc.2011.122; Yang CD, 2014, MOL CELL, V56, P414, DOI 10.1016/j.molcel.2014.09.025; Zheng L, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7001	48	31	33	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 31	2019	38	44					6970	6984		10.1038/s41388-019-0932-1	http://dx.doi.org/10.1038/s41388-019-0932-1			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JJ1AO	31409901	hybrid			2022-12-17	WOS:000493892900002
J	Nakagawa, M; Nakatani, F; Matsunaga, H; Seki, T; Endo, M; Ogawara, Y; Machida, Y; Katsumoto, T; Yamagata, K; Hattori, A; Fujita, S; Aikawa, Y; Ishikawa, T; Soga, T; Kawai, A; Chuman, H; Yokoyama, N; Fukushima, S; Yahiro, K; Kimura, A; Shimada, E; Hirose, T; Fujiwara, T; Setsu, N; Matsumoto, Y; Iwamoto, Y; Nakashima, Y; Kitabayashi, I				Nakagawa, Makoto; Nakatani, Fumihiko; Matsunaga, Hironori; Seki, Takahiko; Endo, Makoto; Ogawara, Yoko; Machida, Yukino; Katsumoto, Takuo; Yamagata, Kazutsune; Hattori, Ayuna; Fujita, Shuhei; Aikawa, Yukiko; Ishikawa, Takamasa; Soga, Tomoyoshi; Kawai, Akira; Chuman, Hirokazu; Yokoyama, Nobuhiko; Fukushima, Suguru; Yahiro, Kenichiro; Kimura, Atsushi; Shimada, Eijiro; Hirose, Takeshi; Fujiwara, Toshifumi; Setsu, Nokitaka; Matsumoto, Yoshihiro; Iwamoto, Yukihide; Nakashima, Yasuharu; Kitabayashi, Issay			Selective inhibition of mutant IDH1 by DS-1001b ameliorates aberrant histone modifications and impairs tumor activity in chondrosarcoma	ONCOGENE			English	Article							SOFT-TISSUE SARCOMA; OPEN-LABEL; ONCOMETABOLITE 2-HYDROXYGLUTARATE; OLLIER DISEASE; MUTATIONS; DIFFERENTIATION; CHEMOTHERAPY; SUFFICIENT; EXPRESSION; ENASIDENIB	Chondrosarcoma is the second most common malignant bone tumor. It is characterized by low vascularity and an abundant extracellular matrix, which confer these tumors resistance to chemotherapy and radiotherapy. There are currently no effective treatment options for relapsed or dedifferentiated chondrosarcoma, and new targeted therapies need to be identified. Isocitrate dehydrogenase (IDH) mutations, which are detected in similar to 50% of chondrosarcoma patients, contribute to malignant transformation by catalyzing the production of 2-hydroxyglutarate (2-HG), a competitive inhibitor of alpha-ketoglutarate-dependent dioxygenases. Mutant IDH inhibitors are therefore potential novel anticancer drugs in IDH mutant tumors. Here, we examined the efficacy of the inhibition of mutant IDH1 as an antitumor approach in chondrosarcoma cells in vitro and in vivo, and investigated the association between the IDH mutation and chondrosarcoma cells. DS-1001b, a novel, orally bioavailable, selective mutant IDH1 inhibitor, impaired the proliferation of chondrosarcoma cells with IDH1 mutations in vitro and in vivo, and decreased 2-HG levels. RNA-seq analysis showed that inhibition of mutant IDH1 promoted chondrocyte differentiation in the conventional chondrosarcoma L835 cell line and caused cell cycle arrest in the dedifferentiated JJ012 cell line. Mutant IDH1-mediated modulation of SOX9 and CDKN1C expression regulated chondrosarcoma tumor progression, and DS-1001b upregulated the expression of these genes via a common mechanism involving the demethylation of H3K9me3. DS-1001b treatment reversed the epigenetic changes caused by aberrant histone modifications. The present data strongly suggest that inhibition of mutant IDH1 is a promising therapeutic approach in chondrosarcoma, particularly for the treatment of relapsed or dedifferentiated chondrosarcoma.	[Nakagawa, Makoto; Ogawara, Yoko; Machida, Yukino; Katsumoto, Takuo; Yamagata, Kazutsune; Hattori, Ayuna; Fujita, Shuhei; Aikawa, Yukiko; Kitabayashi, Issay] Natl Canc Ctr, Div Hematol Malignancy, Tokyo, Japan; [Nakagawa, Makoto; Endo, Makoto; Yokoyama, Nobuhiko; Fukushima, Suguru; Yahiro, Kenichiro; Kimura, Atsushi; Shimada, Eijiro; Hirose, Takeshi; Fujiwara, Toshifumi; Setsu, Nokitaka; Matsumoto, Yoshihiro; Nakashima, Yasuharu] Kyushu Univ, Grad Sch Med Sci, Dept Orthopaed Surg, Fukuoka, Fukuoka, Japan; [Nakagawa, Makoto; Nakatani, Fumihiko; Kawai, Akira] Natl Canc Ctr, Div Musculoskeletal Oncol, Tokyo, Japan; [Matsunaga, Hironori; Seki, Takahiko] Daiichi Sankyo Co Ltd, Oncol Labs, Tokyo, Japan; [Ishikawa, Takamasa; Soga, Tomoyoshi] Keio Univ, Inst Adv Biosci, Yamagata, Japan; [Chuman, Hirokazu] Katai Orthopaed Internal Med Hosp, Div Orthopaed Surg, Fukuoka, Fukuoka, Japan; [Iwamoto, Yukihide] Kyushu Rosai Hosp, Div Orthopaed Surg, Fukuoka, Fukuoka, Japan	National Cancer Center - Japan; Kyushu University; National Cancer Center - Japan; Daiichi Sankyo Company Limited; Keio University	Kitabayashi, I (corresponding author), Natl Canc Ctr, Div Hematol Malignancy, Tokyo, Japan.	ikitabay@ncc.go.jp	Endo, Makoto/K-2896-2012	Endo, Makoto/0000-0002-7956-2190; Nakagawa, Makoto/0000-0001-8243-7705; Kitabayashi, Issay/0000-0002-8409-0407; Hirose, Takeshi/0000-0003-1588-9757	Foundation for Promotion of Cancer Research (FPCR); Acceleration Transformative Research for Medical Innovation from the Japan Agency for Medical Research and Development; National Cancer Center Research and Development Fund	Foundation for Promotion of Cancer Research (FPCR); Acceleration Transformative Research for Medical Innovation from the Japan Agency for Medical Research and Development(Japan Agency for Medical Research and Development (AMED)); National Cancer Center Research and Development Fund(National Cancer Center - Japan)	We wish to thank Dr Joel A. Block, Dr Judith V.M. G. Bovee, and Dr A. Ogose for providing important cell lines. We thank Yutaka Shima, Yuki Kagiyama, and Emi Takamatsu-Ichihara for expert advice and technical support. This work was supported by a Grant from Foundation for Promotion of Cancer Research (FPCR) (F.N.). IK was funded by Acceleration Transformative Research for Medical Innovation from the Japan Agency for Medical Research and Development and by the National Cancer Center Research and Development Fund.	Amary MF, 2011, NAT GENET, V43, P1262, DOI 10.1038/ng.994; Amary MF, 2011, J PATHOL, V224, P334, DOI 10.1002/path.2913; Amatangelo MD, 2017, BLOOD, V130, P732, DOI 10.1182/blood-2017-04-779447; Andreou D, 2011, ACTA ORTHOP, V82, P749, DOI 10.3109/17453674.2011.636668; Borger DR, 2012, ONCOLOGIST, V17, P72, DOI 10.1634/theoncologist.2011-0386; Cairns RA, 2012, BLOOD, V119, P1901, DOI 10.1182/blood-2011-11-391748; Chowdhury R, 2011, EMBO REP, V12, P463, DOI 10.1038/embor.2011.43; Clark JCM, 2010, CANCER CELL INT, V10, DOI 10.1186/1475-2867-10-20; Endo M, 2015, MODERN PATHOL, V28, P587, DOI 10.1038/modpathol.2014.155; Figueroa ME, 2010, CANCER CELL, V18, P553, DOI 10.1016/j.ccr.2010.11.015; Ghert MA, 2001, ONCOLOGY-BASEL, V61, P306, DOI 10.1159/000055338; Giuffrida AY, 2009, J BONE JOINT SURG AM, V91A, P1063, DOI 10.2106/JBJS.H.00416; Hirata M, 2015, P NATL ACAD SCI USA, V112, P2829, DOI 10.1073/pnas.1424400112; Hogendoorn P, 2013, WHO CLASSIFICATION T, V4, P264; Italiano A, 2013, ANN ONCOL, V24, P2916, DOI 10.1093/annonc/mdt374; Jin Y, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126956; Kawai A, 2015, LANCET ONCOL, V16, P406, DOI 10.1016/S1470-2045(15)70098-7; Koivunen P, 2012, NATURE, V483, P485, DOI 10.1038/nature10898; Kudo N, 2007, VIRCHOWS ARCH, V451, P691, DOI 10.1007/s00428-007-0426-3; Li L., 2015, J OCEAN WIND ENERGY, V2, P1, DOI DOI 10.1371/J0URNAL.P0NE.0133813; Losman JA, 2013, SCIENCE, V339, P1621, DOI 10.1126/science.1231677; Lu C, 2013, GENE DEV, V27, P1986, DOI 10.1101/gad.226753.113; Lu C, 2012, NATURE, V483, P474, DOI 10.1038/nature10860; Mardis ER, 2009, NEW ENGL J MED, V361, P1058, DOI 10.1056/NEJMoa0903840; Mitchell AD, 2000, J BONE JOINT SURG BR, V82B, P55, DOI 10.1302/0301-620X.82B1.9020; Ogawara Y, 2015, CANCER RES, V75, P2005, DOI 10.1158/0008-5472.CAN-14-2200; Pansuriya TC, 2011, NAT GENET, V43, P1256, DOI 10.1038/ng.1004; Parsons DW, 2008, SCIENCE, V321, P1807, DOI 10.1126/science.1164382; Perut F, 2018, J ORTHOP RES, V36, P2305, DOI 10.1002/jor.23880; Pollack SM, 2018, J CLIN ONCOL, V36, P125, DOI 10.1200/JCO.2017.75.1610; Pollack SM, 2017, J IMMUNOTHER, V40, P302, DOI 10.1097/CJI.0000000000000183; Polychronidou G, 2017, FUTURE ONCOL, V13, P637, DOI 10.2217/fon-2016-0226; Pusch S, 2017, ACTA NEUROPATHOL, V133, P629, DOI 10.1007/s00401-017-1677-y; Rohle D, 2013, SCIENCE, V340, P626, DOI 10.1126/science.1236062; Sasaki M, 2012, GENE DEV, V26, P2038, DOI 10.1101/gad.198200.112; Schoffski P, 2016, LANCET, V387, P1629, DOI 10.1016/S0140-6736(15)01283-0; Stein EM, 2017, BLOOD, V130, P722, DOI 10.1182/blood-2017-04-779405; Streitbuerger A, 2012, J BONE JOINT SURG BR, V94B, P122, DOI 10.1302/0301-620X.94B1.26876; Suijker J, 2015, ONCOTARGET, V6, P12505, DOI 10.18632/oncotarget.3723; Tap WD, 2016, LANCET, V388, P488, DOI 10.1016/S0140-6736(16)30587-6; Tawbi HA, 2017, LANCET ONCOL, V18, P1493, DOI 10.1016/S1470-2045(17)30624-1; van der Graaf WTA, 2012, LANCET, V379, P1879, DOI 10.1016/S0140-6736(12)60651-5; van Oosterwijk JG, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-375; Ward PS, 2010, CANCER CELL, V17, P225, DOI 10.1016/j.ccr.2010.01.020; Xu W, 2011, CANCER CELL, V19, P17, DOI 10.1016/j.ccr.2010.12.014; Yen K, 2017, CANCER DISCOV, V7, P478, DOI 10.1158/2159-8290.CD-16-1034; Zhao SM, 2009, SCIENCE, V324, P261, DOI 10.1126/science.1170944	47	31	32	1	12	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 17	2019	38	42					6835	6849		10.1038/s41388-019-0929-9	http://dx.doi.org/10.1038/s41388-019-0929-9			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JE5UU	31406254	hybrid			2022-12-17	WOS:000490758200003
J	Cui, YM; Wu, XQ; Lin, CY; Zhang, X; Ye, LP; Ren, LL; Chen, M; Yang, MSZ; Li, Y; Li, MF; Li, J; Guan, J; Song, LB				Cui, Yanmei; Wu, Xianqiu; Lin, Chuyong; Zhang, Xin; Ye, Liping; Ren, Liangliang; Chen, Min; Yang, Meisongzhu; Li, Yue; Li, Mengfeng; Li, Jun; Guan, Jian; Song, Libing			AKIP1 promotes early recurrence of hepatocellular carcinoma through activating the Wnt/beta-catenin/CBP signaling pathway	ONCOGENE			English	Article							APC TUMOR-SUPPRESSOR; PROTEIN-KINASE-A; BETA-CATENIN; CELL-LINE; CANCER; PHOSPHORYLATION; MUTATIONS; ASSOCIATION; CLONES; GENES	The early recurrence of hepatocellular carcinoma (HCC) is the main obstacle for long-term survival of patients. Wnt/beta-catenin signaling has been involved in the development and progression of HCC. However, the molecular changes that link Wnt/beta-catenin activation and HCC early recurrence remain poorly understood. Here we identified AKIP1 as a binding partner of beta-catenin. AKIP1 interacted with and sustained beta-catenin in the nuclear by blocking its interaction with adenomatous polyposis coli protein (APC). Moreover, AKIP1 enhanced the protein kinase A catalytic subunit (PKAc)-mediated phosphorylation of beta-catenin, leading to recruitment of cyclic AMP response element-binding protein (CBP) and activation of beta-catenin downstream transcription. Increased AKIP1 expression was observed in HCC clinical samples and correlated with early recurrence and poor prognosis of HCC. AKIP1 promoted invasion and colony outgrowth in vitro and increased intrahepatic and lung metastasis in vivo. Treatment with a CBP inhibitor ICG-001 effectively inhibited the metastatic progression of HCC tumors that had elevated AKIP1 in both cell line and patient-derived xenograft mouse models. Our findings not only establish AKIP1 as a novel regulator of Wnt/beta-catenin signaling as well as HCC early recurrence but also highlight targeting the AKIP1/beta-catenin/CBP axis as attractive therapies for combating HCC metastatic relapse.	[Cui, Yanmei; Wu, Xianqiu; Lin, Chuyong; Zhang, Xin; Ye, Liping; Ren, Liangliang; Li, Yue; Song, Libing] Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, Dept Expt Res, State Key Lab Oncol Southern China,Canc Ctr, Guangzhou 510060, Guangdong, Peoples R China; [Cui, Yanmei] Sun Yat Sen Univ, Affiliated Hosp 6, Guangdong Inst Gastroenterol, Guangdong Prov Key Lab Colorectal & Pelv Floor Di, Guangzhou 510655, Guangdong, Peoples R China; [Chen, Min; Guan, Jian] Sourthern Med Univ, Nanfang Hosp, Dept Radiat Oncol, Guangzhou 510515, Guangdong, Peoples R China; [Yang, Meisongzhu; Li, Jun] Sun Yat Sen Univ, Zhongshan Sch Med, Dept Biochem, Guangzhou 510080, Guangdong, Peoples R China; [Li, Mengfeng] Sun Yat Sen Univ, Zhongshan Sch Med, Dept Microbiol, Guangzhou 510080, Guangdong, Peoples R China	State Key Lab Oncology South China; Sun Yat Sen University; Sun Yat Sen University; Southern Medical University - China; Sun Yat Sen University; Sun Yat Sen University	Song, LB (corresponding author), Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, Dept Expt Res, State Key Lab Oncol Southern China,Canc Ctr, Guangzhou 510060, Guangdong, Peoples R China.; Guan, J (corresponding author), Sourthern Med Univ, Nanfang Hosp, Dept Radiat Oncol, Guangzhou 510515, Guangdong, Peoples R China.; Li, J (corresponding author), Sun Yat Sen Univ, Zhongshan Sch Med, Dept Biochem, Guangzhou 510080, Guangdong, Peoples R China.	lijun37@mail.sysu.edu.cn; guanjian5461@163.com; songlb@sysucc.org.cn	Ren, Liangliang/AAR-6436-2020; Song, LB/AAL-1968-2020; Lin, Chuyong/AAA-9931-2020; Zhang, Xin/C-2464-2017	Lin, Chuyong/0000-0003-4887-5386; Zhang, Xin/0000-0001-6036-2685	Natural Science Foundation of China [81572688, 81872386, 81530082, 81773106, 91740118, 81830082, 91740119, 91529301, 81621004, 81472546]; Natural Science Foundation of Guangdong Province [2016A030308002, 2018B030311060, 2018B030311009]; Science and Technology Program of Guangzhou [201504010015]; Guangzhou Science and Technology Plan Projects [201803010098]; Fundamental Research Funds for the Central Universities [17ykjc02]	Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Guangdong Province(National Natural Science Foundation of Guangdong Province); Science and Technology Program of Guangzhou; Guangzhou Science and Technology Plan Projects; Fundamental Research Funds for the Central Universities(Fundamental Research Funds for the Central Universities)	This work was supported by The Natural Science Foundation of China (Nos. 81572688, 81872386, 81530082, 81773106, 91740118, 81830082, 91740119, 91529301, 81621004, 81472546); The Natural Science Foundation of Guangdong Province (Nos. 2016A030308002, 2018B030311060, 2018B030311009); The Science and Technology Program of Guangzhou (201504010015); Guangzhou Science and Technology Plan Projects (201803010098); and The Fundamental Research Funds for the Central Universities [No. 17ykjc02].	Anastas JN, 2013, NAT REV CANCER, V13, P11, DOI 10.1038/nrc3419; Anson M, 2012, J CLIN INVEST, V122, P586, DOI 10.1172/JCI43937; Arce L, 2006, ONCOGENE, V25, P7492, DOI 10.1038/sj.onc.1210056; Chen JX, 2016, GUT, V65, P1522, DOI 10.1136/gutjnl-2015-310625; Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018; Cui YM, 2015, ONCOGENE, V34, P4379, DOI 10.1038/onc.2014.368; Dema A, 2016, J BIOL CHEM, V291, P19618, DOI 10.1074/jbc.M116.738047; El-Serag HB, 2011, NEW ENGL J MED, V365, P1118, DOI 10.1056/NEJMra1001683; Emami KH, 2004, P NATL ACAD SCI USA, V101, P12682, DOI 10.1073/pnas.0404875101; Farazi PA, 2006, NAT REV CANCER, V6, P674, DOI 10.1038/nrc1934; Forner A, 2012, LANCET, V379, P1245, DOI 10.1016/S0140-6736(11)61347-0; Gang EJ, 2014, ONCOGENE, V33, P2169, DOI 10.1038/onc.2013.169; Gao N, 2008, J BIOL CHEM, V283, P7834, DOI 10.1074/jbc.M710285200; Guichard C, 2012, NAT GENET, V44, P694, DOI 10.1038/ng.2256; Hecht A, 2000, EMBO J, V19, P1839, DOI 10.1093/emboj/19.8.1839; Henderson BR, 2000, NAT CELL BIOL, V2, P653, DOI 10.1038/35023605; Hoshida Y, 2009, CANCER RES, V69, P7385, DOI 10.1158/0008-5472.CAN-09-1089; Huang H, 1999, AM J PATHOL, V155, P1795, DOI 10.1016/S0002-9440(10)65496-X; Imamura H, 2003, J HEPATOL, V38, P200, DOI 10.1016/S0168-8278(02)00360-4; Kitching R, 2003, BBA-GENE STRUCT EXPR, V1625, P116, DOI 10.1016/S0167-4781(02)00562-6; Laurent-Puig P, 2001, GASTROENTEROLOGY, V120, P1763, DOI 10.1053/gast.2001.24798; Li CC, 2016, P NATL ACAD SCI USA, V113, P5946, DOI 10.1073/pnas.1601918113; Li Y, 2001, WORLD J GASTROENTERO, V7, P630; Lin C, 2015, ONCOGENE, V34, P332, DOI 10.1038/onc.2013.559; Ma D, 2018, EXP CELL RES, V362, P142, DOI 10.1016/j.yexcr.2017.11.011; Marquardt JU, 2014, CANCER CELL, V25, P550, DOI 10.1016/j.ccr.2014.04.002; Moon RT, 2004, NAT REV GENET, V5, P689, DOI 10.1038/nrg1427; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Nagaraj AB, 2015, ONCOTARGET, V6, P23720, DOI 10.18632/oncotarget.4690; Nguyen DX, 2009, CELL, V138, P51, DOI 10.1016/j.cell.2009.04.030; Pez F, 2013, J HEPATOL, V59, P1107, DOI 10.1016/j.jhep.2013.07.001; Rosin-Arbesfeld R, 2000, NATURE, V406, P1009, DOI 10.1038/35023016; Sasaki Y, 2006, ANN SURG, V244, P771, DOI 10.1097/01.sla.0000225126.56483.b3; Sastri M, 2005, P NATL ACAD SCI USA, V102, P349, DOI 10.1073/pnas.0408608102; SU LK, 1993, SCIENCE, V262, P1734, DOI 10.1126/science.8259519; Takemaru KI, 2000, J CELL BIOL, V149, P249, DOI 10.1083/jcb.149.2.249; Taurin S, 2006, J BIOL CHEM, V281, P9971, DOI 10.1074/jbc.M508778200; Tian J, 1999, BRIT J CANCER, V81, P814, DOI 10.1038/sj.bjc.6690769; Valenta T, 2012, EMBO J, V31, P2714, DOI 10.1038/emboj.2012.150; Wang WH, 2016, NEOPLASIA, V18, P711, DOI 10.1016/j.neo.2016.10.004; Wend P, 2013, EMBO J, V32, P1977, DOI 10.1038/emboj.2013.127; Xing Y, 2004, MOL CELL, V15, P523, DOI 10.1016/j.molcel.2004.08.001	42	31	33	3	25	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 4	2019	38	27					5516	5529		10.1038/s41388-019-0807-5	http://dx.doi.org/10.1038/s41388-019-0807-5			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IG5KR	30936461				2022-12-17	WOS:000473842500013
J	Williams, KC; Cepeda, MA; Javed, S; Searle, K; Parkins, KM; Makela, AV; Hamilton, AM; Soukhtehzari, S; Kim, Y; Tuck, AB; Ronald, JA; Foster, PJ; Chambers, AF; Leong, HS				Williams, Karla C.; Cepeda, Mario A.; Javed, Sumreen; Searle, Karlee; Parkins, Katie M.; Makela, Ashley V.; Hamilton, Amanda M.; Soukhtehzari, Sepideh; Kim, Yohan; Tuck, Alan B.; Ronald, John A.; Foster, Paula J.; Chambers, Ann F.; Leong, Hon S.			Invadopodia are chemosensing protrusions that guide cancer cell extravasation to promote brain tropism in metastasis	ONCOGENE			English	Article							BREAST-CANCER; THERAPEUTIC TARGET; LIGHT-CHAIN; PROSTATE-CANCER; IN-VIVO; PHOSPHORYLATION; INVASION; KINASE; PAK1; ACTIVATION	Invadopodia are cell protrusions that mediate cancer cell extravasation but the microenvironmental cues and signaling factors that induce invadopodia formation during extravasation remain unclear. Using intravital imaging and loss of function experiments, we determined invadopodia contain receptors involved in chemotaxis, namely GABA receptor and EGFR. These chemotaxis capabilities are mediated in part by PAK1 which controls invadopodia responsiveness to ligands such as GABA and EGF via assembly, stability, and turnover of invadopodia in vivo. PAK1 knockdown rendered cells unresponsive to chemotactic stimuli present in the stroma, resulting in dramatically lower rates of cancer cell extravasation and metastatic colony formation compared to stimulated cancer cells. In an experimental mouse model of brain metastasis, inhibition of PAK1 significantly reduced overall tumor burden and reduced the average size of brain metastases. In summary, invadopodia contain chemotaxis receptors that can respond to microenvironmental cues to guide cancer cell extravasation, and when PAK1 is depleted, brain tropism of metastatic breast cancer cells is significantly reduced, blocking secondary colony growth at sites otherwise permissive for metastatic outgrowth.	[Williams, Karla C.; Cepeda, Mario A.; Searle, Karlee; Kim, Yohan; Leong, Hon S.] Western Univ, Schulich Sch Med & Dent, Dept Surg, Div Urol, London, ON, Canada; [Williams, Karla C.; Cepeda, Mario A.; Leong, Hon S.] Lawson Hlth Res Inst, Translat Prostate Canc Res Lab, London, ON, Canada; [Williams, Karla C.; Tuck, Alan B.; Chambers, Ann F.] Lawson Hlth Res Inst, Translat Breast Canc Res Unit, London, ON, Canada; [Williams, Karla C.; Javed, Sumreen; Searle, Karlee; Soukhtehzari, Sepideh] Univ British Columbia, Fac Pharmaceut Sci, Vancouver, BC, Canada; [Cepeda, Mario A.; Leong, Hon S.] Mayo Clin, Dept Urol, Rochester, MN 55905 USA; [Parkins, Katie M.; Makela, Ashley V.; Hamilton, Amanda M.; Ronald, John A.; Foster, Paula J.] Western Univ, Schulich Sch Med & Dent, Dept Med Biophys, London, ON, Canada; [Parkins, Katie M.; Makela, Ashley V.; Hamilton, Amanda M.; Ronald, John A.; Foster, Paula J.] Western Univ, Robarts Res Inst, London, ON, Canada; [Tuck, Alan B.; Chambers, Ann F.] Western Univ, Schulich Sch Med & Dent, Dept Oncol, London, ON, Canada; [Tuck, Alan B.; Chambers, Ann F.] Western Univ, Schulich Sch Med & Dent, Dept Pathol & Lab Med, London, ON, Canada	Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario); University of British Columbia; Mayo Clinic; Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario)	Williams, KC; Leong, HS (corresponding author), Western Univ, Schulich Sch Med & Dent, Dept Surg, Div Urol, London, ON, Canada.; Williams, KC; Leong, HS (corresponding author), Lawson Hlth Res Inst, Translat Prostate Canc Res Lab, London, ON, Canada.; Williams, KC (corresponding author), Lawson Hlth Res Inst, Translat Breast Canc Res Unit, London, ON, Canada.; Williams, KC (corresponding author), Univ British Columbia, Fac Pharmaceut Sci, Vancouver, BC, Canada.; Leong, HS (corresponding author), Mayo Clin, Dept Urol, Rochester, MN 55905 USA.	karla.williams@ubc.ca; leong.hon@mayo.edu	Ronald, John A/B-7123-2008	Ronald, John A/0000-0003-3665-173X; Leong, Hon/0000-0001-7801-1402; Williams, Karla/0000-0003-2954-2869	OICR High Impact Grant [SPS 0613-03]; Movember/PCC Rising Star Grants [RS-2013-55, RS-2016-1011]; CIHR Postdoctoral Fellowship [140880]; Breast Cancer Society of Canada	OICR High Impact Grant; Movember/PCC Rising Star Grants; CIHR Postdoctoral Fellowship(Canadian Institutes of Health Research (CIHR)); Breast Cancer Society of Canada	This work was supported by an OICR High Impact Grant (SPS 0613-03), Movember/PCC Rising Star Grants (RS-2013-55 and RS-2016-1011) awarded to H.S.L., CIHR Postdoctoral Fellowship (140880) awarded to K.C.W., and the Breast Cancer Society of Canada (K.C.W., K.P., A.M.).	Artym VV, 2015, J CELL BIOL, V208, P331, DOI 10.1083/jcb.201405099; Artym Vira V., 2009, V522, P211, DOI 10.1007/978-1-59745-413-1_15; Badowski C, 2008, MOL BIOL CELL, V19, P633, DOI 10.1091/mbc.E06-01-0088; BAND V, 1990, CANCER RES, V50, P7351; Barry DJ, 2015, J CELL BIOL, V209, P163, DOI 10.1083/jcb.201501081; Beach JR, 2011, BMC CELL BIOL, V12, DOI 10.1186/1471-2121-12-52; Bowden ET, 1999, ONCOGENE, V18, P4440, DOI 10.1038/sj.onc.1202827; Burger KL, 2014, PROSTATE, V74, P134, DOI 10.1002/pros.22735; Calle Y, 2006, J CELL SCI, V119, P2375, DOI 10.1242/jcs.02939; Cepeda MA, 2016, MOL CANCER, V15, DOI 10.1186/s12943-016-0547-x; Chambers AF, 2002, NAT REV CANCER, V2, P563, DOI 10.1038/nrc865; Chew TL, 1998, J MUSCLE RES CELL M, V19, P839, DOI 10.1023/A:1005417926585; Coniglio SJ, 2008, MOL CELL BIOL, V28, P4162, DOI 10.1128/MCB.01532-07; Edwards DC, 1999, NAT CELL BIOL, V1, P253, DOI 10.1038/12963; Gligorijevic B, 2012, J CELL SCI, V125, P724, DOI 10.1242/jcs.092726; Goicoechea SM, 2017, J CELL SCI, V130, P1064, DOI 10.1242/jcs.195552; Heyn C, 2006, MAGN RESON MED, V56, P1001, DOI 10.1002/mrm.21029; Jeannot P, 2017, ELIFE, V6, DOI [10.7554/eLife.22207, 10.7554/eLife.22207.001]; Kienast Y, 2010, NAT MED, V16, P116, DOI 10.1038/nm.2072; Kim Y, 2016, NAT PROTOC, V11, P937, DOI 10.1038/nprot.2016.050; KOOP S, 1995, CANCER RES, V55, P2520; Koop S, 1996, P NATL ACAD SCI USA, V93, P11080, DOI 10.1073/pnas.93.20.11080; Leong HS, 2014, CELL REP, V8, P1558, DOI 10.1016/j.celrep.2014.07.050; Li Z, 2003, CELL, V114, P215, DOI 10.1016/S0092-8674(03)00559-2; Lohmer LL, 2016, PLOS GENET, V12, DOI 10.1371/journal.pgen.1005786; Lohmer LL, 2014, CELL ADHES MIGR, V8, P246, DOI 10.4161/cam.28406; MORRIS VL, 1994, CLIN EXP METASTAS, V12, P357, DOI 10.1007/BF01755879; Moshfegh Y, 2014, NAT CELL BIOL, V16, P571, DOI 10.1038/ncb2972; Murphy DA, 2011, NAT REV MOL CELL BIO, V12, P413, DOI 10.1038/nrm3141; Murrell DH, 2015, TRANSL ONCOL, V8, P176, DOI 10.1016/j.tranon.2015.03.009; Neman J, 2014, P NATL ACAD SCI USA, V111, P984, DOI 10.1073/pnas.1322098111; Nicholas NS, 2016, ONCOTARGET, V7, P70881, DOI 10.18632/oncotarget.12282; Parkins KM, 2016, SCI REP-UK, V6, DOI 10.1038/srep35889; Sanders LC, 1999, SCIENCE, V283, P2083, DOI 10.1126/science.283.5410.2083; Sells MA, 1999, J CELL BIOL, V145, P837, DOI 10.1083/jcb.145.4.837; Sharma VP, 2013, CURR BIOL, V23, P2079, DOI 10.1016/j.cub.2013.08.044; Sizemore GM, 2014, J BIOL CHEM, V289, P24102, DOI 10.1074/jbc.M114.593582; Souter LH, 2010, LAB INVEST, V90, P1247, DOI 10.1038/labinvest.2010.97; Steffen A, 2008, CURR BIOL, V18, P926, DOI 10.1016/j.cub.2008.05.044; Stoletov K, 2015, EXPERT REV ANTICANC, V15, P733, DOI 10.1586/14737140.2015.1058711; Stoletov K, 2014, AM J CLIN EXP UROL, V2, P45; Stylli SS, 2009, J CELL SCI, V122, P2727, DOI 10.1242/jcs.046680; Takizawa N, 2002, BIOCHEM BIOPH RES CO, V297, P773, DOI 10.1016/S0006-291X(02)02302-1; van den Dries K, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2402; Viaud J, 2009, MOL CANCER THER, V8, P2559, DOI 10.1158/1535-7163.MCT-09-0102; Williams KC, 2016, CONVERG SCI PHYS ONC, V2, DOI 10.1088/2057-1739/2/2/023001; Williams KC, 2014, MOL BIOL CELL, V25, P2061, DOI 10.1091/mbc.E13-10-0582; Williams KC, 2014, J CELL SCI, V127, P1712, DOI 10.1242/jcs.134734; Wirth A, 2003, J PHYSIOL-LONDON, V549, P489, DOI 10.1113/jphysiol.2002.033167; Yamaguchi H, 2005, J CELL BIOL, V168, P441, DOI 10.1083/jcb.200407076; Yamauchi K, 2006, CANCER RES, V66, P4208, DOI 10.1158/0008-5472.CAN-05-3927; Zhang QB, 2010, INT J CANCER, V126, P2534, DOI 10.1002/ijc.24979; 2006, CANCER RES, V66, P3034, DOI DOI 10.1158/0008-5472.CAN-05-2177	53	31	31	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 9	2019	38	19					3598	3615		10.1038/s41388-018-0667-4	http://dx.doi.org/10.1038/s41388-018-0667-4			18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HX4OU	30651600	hybrid, Green Published			2022-12-17	WOS:000467379600004
J	Khan, I; Spencer-Smith, R; O'Bryan, JP				Khan, Imran; Spencer-Smith, Russell; O'Bryan, John P.			Targeting the alpha 4-alpha 5 dimerization interface of K-RAS inhibits tumor formation in vivo	ONCOGENE			English	Article							FORMS DIMERS; H-RAS; N-RAS; PROTEINS; KRAS; GAPS; GEFS	RAS genes are the most commonly mutated oncogenes in human cancers. Despite tremendous efforts over the past several decades, however, RAS-specific inhibitors remain elusive. Thus, targeting RAS remains a highly sought-after goal of cancer research. Previously, we have reported a new approach to inhibit RAS-dependent signaling and transformation in vitro by targeting the alpha 4-alpha 5 dimerization interface with a novel RAS-specific monobody termed NS1. Expression of NS1 inhibits oncogenic K-RAS and H-RAS signaling and transformation in vitro. Here, we evaluated the efficacy of targeting RAS dimerization as an approach to inhibit tumor formation in vivo. Using a doxycycline (DOX)-regulated NS1 expression system, we demonstrate that DOX-induced NS1 inhibited oncogenic K-RAS-driven tumor growth in vivo. Furthermore, we observed context-specific effects of NS1 on RAS-mediated signaling in 2D vs 3D growth conditions. Finally, our results highlight the potential therapeutic efficacy of targeting the alpha 4-alpha 5 dimerization interface as an approach to inhibit RAS-driven tumors in vivo.	[Khan, Imran; Spencer-Smith, Russell; O'Bryan, John P.] Univ Illinois, Canc Ctr, Dept Pharmacol, Chicago, IL 60612 USA; [Khan, Imran; Spencer-Smith, Russell; O'Bryan, John P.] Jesse Brown VA Med Ctr, Chicago, IL 60612 USA; [Khan, Imran; O'Bryan, John P.] Med Univ South Carolina, Hollings Canc Ctr, Dept Cell & Mol Pharmacol & Expt Therapeut, Charleston, SC 29425 USA; [Khan, Imran; O'Bryan, John P.] Ralph H Johnson VA Med Ctr, Charleston, SC 29401 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; US Department of Veterans Affairs; Veterans Health Administration (VHA); Jesse Brown VA Medical Center; Medical University of South Carolina; US Department of Veterans Affairs; Veterans Health Administration (VHA); Ralph H Johnson VA Medical Center	O'Bryan, JP (corresponding author), Univ Illinois, Canc Ctr, Dept Pharmacol, Chicago, IL 60612 USA.; O'Bryan, JP (corresponding author), Jesse Brown VA Med Ctr, Chicago, IL 60612 USA.; O'Bryan, JP (corresponding author), Med Univ South Carolina, Hollings Canc Ctr, Dept Cell & Mol Pharmacol & Expt Therapeut, Charleston, SC 29425 USA.; O'Bryan, JP (corresponding author), Ralph H Johnson VA Med Ctr, Charleston, SC 29401 USA.	obryanjo@musc.edu		Spencer-Smith, Russell/0000-0002-8865-0520; O'Bryan, John/0000-0001-5386-1080	NIH [CA192822, CA212608, CA201717]; US Department of Veterans Affairs Biomedical Laboratory Research and Development Service [1I01BX002095]; NATIONAL CANCER INSTITUTE [R01CA212608, R21CA201717, F31CA192822] Funding Source: NIH RePORTER; Veterans Affairs [I01BX002095] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); US Department of Veterans Affairs Biomedical Laboratory Research and Development Service; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Veterans Affairs(US Department of Veterans Affairs)	The authors wish to thank Drs. Andrei Karginov, Todd Waldman, Gregory Thatcher, Bernard Weisman, and Robert Winn for providing various cell lines. In addition, we wish to thank Drs. Shohei Koide and Andrei Karginov along with the O'Bryan and Karginov labs for many helpful discussions. R.S.S. was supported by an NIH F31 Predoctoral Award (CA192822). This work was supported in part by a Merit Review Award (1I01BX002095) from the US Department of Veterans Affairs Biomedical Laboratory Research and Development Service and NIH awards (CA212608 and CA201717) to J.P.O. The contents of this article do not represent the views of the U.S. Department of Veterans Affairs or the United States Government.	Ambrogio C, 2018, CELL, V172, P857, DOI 10.1016/j.cell.2017.12.020; Cherfils J, 2013, PHYSIOL REV, V93, P269, DOI 10.1152/physrev.00003.2012; Chung JK, 2018, BIOPHYS J, V114, P137, DOI 10.1016/j.bpj.2017.10.042; CLARK GJ, 1995, METHOD ENZYMOL, V255, P395; Cox AD, 2014, NAT REV DRUG DISCOV, V13, P828, DOI 10.1038/nrd4389; Cox Adrienne D, 2010, Small GTPases, V1, P2; Guldenhaupt J, 2012, BIOPHYS J, V103, P1585, DOI 10.1016/j.bpj.2012.08.043; Janes MR, 2018, CELL, V172, P578, DOI 10.1016/j.cell.2018.01.006; Karnoub AE, 2008, NAT REV MOL CELL BIO, V9, P517, DOI 10.1038/nrm2438; Kim JS, 2004, CANCER RES, V64, P1932, DOI 10.1158/0008-5472.CAN-03-3862; Kovrigina EA, 2015, BIOPHYS J, V109, P1000, DOI 10.1016/j.bpj.2015.07.020; LERNER EC, 1995, J BIOL CHEM, V270, P26770, DOI 10.1074/jbc.270.45.26770; Lin WC, 2014, P NATL ACAD SCI USA, V111, P2996, DOI 10.1073/pnas.1321155111; Muzumdar MD, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00942-5; Nan XL, 2015, P NATL ACAD SCI USA, V112, P7996, DOI 10.1073/pnas.1509123112; Ostrem JM, 2013, NATURE, V503, P548, DOI 10.1038/nature12796; Plowman SJ, 2005, P NATL ACAD SCI USA, V102, P15500, DOI 10.1073/pnas.0504114102; Porter AG, 1999, CELL DEATH DIFFER, V6, P99, DOI 10.1038/sj.cdd.4400476; Santos E, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2005318; Simanshu DK, 2017, CELL, V170, P17, DOI 10.1016/j.cell.2017.06.009; Spencer-Smith R, 2019, SEMIN CANCER BIOL, V54, P138, DOI 10.1016/j.semcancer.2017.12.005; Spencer-Smith Russell, 2019, Small GTPases, V10, P378, DOI 10.1080/21541248.2017.1333188; Spencer-Smith R, 2017, NAT CHEM BIOL, V13, P62, DOI [10.1038/NCHEMBIO.2231, 10.1038/nchembio.2231]; Vartanian S, 2013, J BIOL CHEM, V288, P2403, DOI 10.1074/jbc.M112.394130; Vigil D, 2010, NAT REV CANCER, V10, P842, DOI 10.1038/nrc2960; Whyte DB, 1997, J BIOL CHEM, V272, P14459, DOI 10.1074/jbc.272.22.14459	26	31	31	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 18	2019	38	16					2984	2993		10.1038/s41388-018-0636-y	http://dx.doi.org/10.1038/s41388-018-0636-y			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HU3IV	30573767	Green Accepted			2022-12-17	WOS:000465167600008
J	Jia, YF; Gu, DS; Wan, J; Yu, BQ; Zhang, XL; Chiorean, EG; Wang, YS; Xie, JW				Jia, Yanfei; Gu, Dongsheng; Wan, Jun; Yu, Beiqin; Zhang, Xiaoli; Chiorean, E. Gabriela; Wang, Yunshan; Xie, Jingwu			The role of GLI-SOX2 signaling axis for gemcitabine resistance in pancreatic cancer	ONCOGENE			English	Article							STEM-CELLS; HEDGEHOG PATHWAY; PROMOTES; INHIBITION; IDENTIFICATION; CHEMOTHERAPY; ACTIVATION; GROWTH; EXPRESSION; TRIAL	Pancreatic cancer, mostly pancreatic ductal adenocarcinomas (PDAC), is one of the most lethal cancers, with a dismal median survival around 8 months. PDAC is notoriously resistant to chemotherapy. Thus far, numerous attempts using novel targeted therapies and immunotherapies yielded limited clinical benefits for pancreatic cancer patients. It is hoped that delineating the molecular mechanisms underlying drug resistance in pancreatic cancer may provide novel therapeutic options. Using acquired gemcitabine resistant pancreatic cell lines, we revealed an important role of the GLI-SOX2 signaling axis for regulation of gemcitabine sensitivity in vitro and in animal models. Down-regulation of GLI transcriptional factors (GLI1 or GLI2), but not SMO signaling inhibition, reduces tumor sphere formation, a characteristics of tumor initiating cell (TIC). Down-regulation of GLI transcription factors also decreased expression of TIC marker CD24. Similarly, high SOX2 expression is associated with gemcitabine resistance whereas down-regulation of SOX2 sensitizes pancreatic cancer cells to gemcitabine treatment. We further revealed that elevated SOX2 expression is associated with an increase in GLI1 or GLI2 expression. Our ChIP assay revealed that GLI proteins are associated with a putative Gli binding site within the SOX2 promoter, suggesting a more direct regulation of SOX2 by GLI transcription factors. The relevance of our findings to human disease was revealed in human cancer specimens. We found that high SOX2 protein expression is associated with frequent tumor relapse and poor survival in stage II PDAC patients (all of them underwent gemcitabine treatment), indicating that reduced SOX2 expression or down-regulation of GLI transcription factors may be effective in sensitizing pancreatic cancer cells to gemcitabine treatment.	[Jia, Yanfei; Wang, Yunshan] Shandong Univ, Cent Lab, Jinan Cent Hosp, Jinan, Shandong, Peoples R China; [Jia, Yanfei; Gu, Dongsheng; Yu, Beiqin; Zhang, Xiaoli; Xie, Jingwu] Indiana Univ Sch Med, Dept Pediat, Wells Ctr Pediat Res, Indianapolis, IN 46202 USA; [Wan, Jun] Indiana Univ, Simon Canc Ctr, Dept Mol & Med Genet, Indianapolis, IN 46202 USA; [Yu, Beiqin] Shanghai Jiao Tong Univ, Shanghai Key Lab Gastr Neoplasms, Shanghai Inst Digest Surg, Ruijin Hosp,Sch Med, Shanghai 200025, Peoples R China; [Chiorean, E. Gabriela] Univ Washington, Div Med Oncol, 825 Eastlake Ave E,G4-833, Seattle, WA 98109 USA; [Chiorean, E. Gabriela] Fred Hutchinson Canc Res Ctr, 825 Eastlake Ave E,G4-833, Seattle, WA 98109 USA	Shandong First Medical University & Shandong Academy of Medical Sciences; Shandong University; Indiana University System; Indiana University Bloomington; Indiana University System; Indiana University-Purdue University Indianapolis; Shanghai Jiao Tong University; University of Washington; University of Washington Seattle; Fred Hutchinson Cancer Center	Wang, YS (corresponding author), Shandong Univ, Cent Lab, Jinan Cent Hosp, Jinan, Shandong, Peoples R China.; Xie, JW (corresponding author), Indiana Univ Sch Med, Dept Pediat, Wells Ctr Pediat Res, Indianapolis, IN 46202 USA.	w_yunshan@126.com; jinxie@iu.edu	Xin, Xiaofei/N-4518-2018; Liu, Bingya/GMW-5655-2022; Xie, J/AAR-7259-2020; Wan, Jun/AAN-1337-2020	Xin, Xiaofei/0000-0002-7618-0808; Wan, Jun/0000-0001-9286-6562; xie, jingwu/0000-0002-3674-332X	Department of Pediatrics; Well Center for Pediatric Research; Jeff Gordon Research Laboratory; AGA; Healthcare Initiatives, Inc.; CTSI Indiana; Walther Cancer Foundation; Riley Foundation for Children; National Natural Science Foundation of China [31671468, 81602593]; Shandong Provincial Natural Science Foundation of China [ZR2015HM018];  [NIH-R01-155086]; NATIONAL CANCER INSTITUTE [R01CA155086] Funding Source: NIH RePORTER	Department of Pediatrics; Well Center for Pediatric Research; Jeff Gordon Research Laboratory; AGA; Healthcare Initiatives, Inc.; CTSI Indiana; Walther Cancer Foundation; Riley Foundation for Children; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Shandong Provincial Natural Science Foundation of China(Natural Science Foundation of Shandong Province); ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank you Professor Keping Xie and Dr. Zizheng Dong for help with cell line generation, and generous support from the Department of Pediatrics, The Well Center for Pediatric Research, Jeff Gordon Research Laboratory, AGA, Healthcare Initiatives, Inc., and CTSI Indiana. The bioinformatics data analysis was performed in collaboration with the Collaborative Core for Cancer Bioinformatics (C3B) shared by Indiana University Simon Cancer Center and Purdue University Center for Cancer Research with support from the Walther Cancer Foundation. This work was supported by the following grants and foundations: NIH-R01-155086; Riley Foundation for Children; National Natural Science Foundation of China (No. 31671468 and 81602593), Shandong Provincial Natural Science Foundation of China (ZR2015HM018).	Abel EV, 2013, GASTROENTEROLOGY, V144, P1241, DOI 10.1053/j.gastro.2013.01.072; Athar M, 2004, CANCER RES, V64, P7545, DOI 10.1158/0008-5472.CAN-04-1393; Boehme KA, 2016, INT J ONCOL, V48, P801, DOI 10.3892/ijo.2015.3293; Bruns Christiane J., 1999, Neoplasia (New York), V1, P50, DOI 10.1038/sj.neo.7900005; Cao X, 2012, ONCOGENE, V31, P104, DOI 10.1038/onc.2011.219; Catenacci DVT, 2015, J CLIN ONCOL, V33, P4284, DOI 10.1200/JCO.2015.62.8719; Chen T, 2012, CELL RES, V22, P248, DOI 10.1038/cr.2011.109; Chen WJ, 2013, HEPATO-GASTROENTEROL, V60, P949, DOI 10.5754/hge12881; Cheung HOL, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000405; Fan QP, 2014, CANCER RES, V74, P471, DOI 10.1158/0008-5472.CAN-13-2134-T; Frenzel A, 2009, APOPTOSIS, V14, P584, DOI 10.1007/s10495-008-0300-z; Fukamachi H, 2011, CANCER SCI, V102, P1313, DOI 10.1111/j.1349-7006.2011.01947.x; Goldman J, 2015, CLIN CANCER RES, V21, P1002, DOI 10.1158/1078-0432.CCR-14-1234; Gu DS, 2013, MOL CANCER THER, V12, P1038, DOI 10.1158/1535-7163.MCT-12-1030; GUDJONSSON B, 1987, CANCER, V60, P2284, DOI 10.1002/1097-0142(19871101)60:9<2284::AID-CNCR2820600930>3.0.CO;2-V; He J, 2006, J BIOL CHEM, V281, P35598, DOI 10.1074/jbc.C600200200; Hong SP, 2009, INT J CANCER, V125, P2323, DOI 10.1002/ijc.24573; Huang SH, 2006, CARCINOGENESIS, V27, P1334, DOI 10.1093/carcin/bgi378; Ishimoto T, 2011, CANCER CELL, V19, P387, DOI 10.1016/j.ccr.2011.01.038; Jeon HM, 2011, CANCER RES, V71, P3410, DOI 10.1158/0008-5472.CAN-10-3340; Jiang J, 2012, ONCOGENE, V31, P671, DOI 10.1038/onc.2011.282; Julian LM, 2017, CURR OPIN GENET DEV, V46, P24, DOI 10.1016/j.gde.2017.06.005; Justilien V, 2015, CLIN CANCER RES, V21, P505, DOI 10.1158/1078-0432.CCR-14-0507; Kim EJ, 2014, CLIN CANCER RES, V20, P5937, DOI 10.1158/1078-0432.CCR-14-1269; Kim J, 2013, CANCER CELL, V23, P23, DOI 10.1016/j.ccr.2012.11.017; Lauressergues E, 2016, PHARMACOL RES PERSPE, V4, DOI 10.1002/prp2.214; Lauth M, 2007, P NATL ACAD SCI USA, V104, P8455, DOI 10.1073/pnas.0609699104; Li CW, 2007, CANCER RES, V67, P1030, DOI 10.1158/0008-5472.CAN-06-2030; Liu Hailan, 2011, Chin J Cancer, V30, P13; LoRusso PM, 2011, CLIN CANCER RES, V17, P2502, DOI 10.1158/1078-0432.CCR-10-2745; Ma XL, 2006, INT J CANCER, V118, P139, DOI 10.1002/ijc.21295; Mondesire WH, 2004, CLIN CANCER RES, V10, P7031, DOI 10.1158/1078-0432.CCR-04-0361; Mu P, 2017, SCIENCE, V355, P84, DOI 10.1126/science.aah4307; O'Neil BH, 2015, ANN ONCOL, V26, P2505, DOI 10.1093/annonc/mdv477; Olive KP, 2009, SCIENCE, V324, P1457, DOI 10.1126/science.1171362; Peter Marcus E, 2004, Biochem J, V382, pe1; Piva M, 2014, EMBO MOL MED, V6, P66, DOI 10.1002/emmm.201303411; Platzbecker U, 2017, J CLIN ONCOL, V35, P605, DOI 10.1200/JCO.2016.67.1982; Rahib L, 2016, JAMA ONCOL, V2, P1209, DOI 10.1001/jamaoncol.2016.0585; Rahib L, 2014, CANCER RES, V74, P2913, DOI 10.1158/0008-5472.CAN-14-0155; Rassouli FB, 2016, TUMOR BIOL, V37, P7, DOI 10.1007/s13277-015-4155-y; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; Schniewind B, 2004, INT J CANCER, V109, P182, DOI 10.1002/ijc.11679; Shimokawa T, 2008, J BIOL CHEM, V283, P14345, DOI 10.1074/jbc.M800299200; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; Stacy AE, 2013, MOL PHARMACOL, V84, P655, DOI 10.1124/mol.113.088609; Taipale J, 2001, NATURE, V411, P349, DOI 10.1038/35077219; Takebe N, 2015, NAT REV CLIN ONCOL, V12, P445, DOI 10.1038/nrclinonc.2015.61; Tesei A, 2002, CLIN CANCER RES, V8, P233; Vogelzang NJ, 2012, J CLIN ONCOL, V30, P88, DOI 10.1200/JCO.2011.40.1919; Von Hoff DD, 2013, NEW ENGL J MED, V369, P1691, DOI 10.1056/NEJMoa1304369; Wang T, 2011, BRIT J CANCER, V105, P658, DOI 10.1038/bjc.2011.287; Weiswald LB, 2015, NEOPLASIA, V17, P1, DOI 10.1016/j.neo.2014.12.004; Yang DG, 2013, ACTA HAEMATOL-BASEL, V130, P260, DOI 10.1159/000351603; Yang L, 2010, ONCOGENE, V29, P469, DOI 10.1038/onc.2009.392; Yu BQ, 2017, ONCOTARGET, V8, P27412, DOI 10.18632/oncotarget.16174; Zhang LN, 2017, CELL BIOSCI, V7, DOI 10.1186/s13578-017-0145-7; Zhang ZL, 2016, CANCER LETT, V382, P53, DOI 10.1016/j.canlet.2016.08.023; Zhao D, 2013, CANCER CELL, V23, P464, DOI 10.1016/j.ccr.2013.02.005; Zhao HQ, 2017, J CELL MOL MED, V21, P2055, DOI 10.1111/jcmm.13126	60	31	33	0	10	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 7	2019	38	10					1764	1777		10.1038/s41388-018-0553-0	http://dx.doi.org/10.1038/s41388-018-0553-0			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HN8DD	30382189	Green Published, Green Accepted, hybrid, Green Submitted			2022-12-17	WOS:000460423800014
J	Xiang, SS; Wang, Z; Ye, YY; Zhang, F; Li, HF; Yang, Y; Miao, HJ; Liang, HB; Zhang, YJ; Jiang, L; Hu, YP; Zheng, L; Liu, XY; Liu, YB				Xiang, Shanshan; Wang, Zheng; Ye, Yuanyuan; Zhang, Fei; Li, Huaifeng; Yang, Yang; Miao, Huijie; Liang, Haibin; Zhang, Yijian; Jiang, Lin; Hu, Yunping; Zheng, Lei; Liu, Xiyong; Liu, Yingbin			E2F1 and E2F7 differentially regulate KPNA2 to promote the development of gallbladder cancer	ONCOGENE			English	Article							TRANSCRIPTION FACTOR; KARYOPHERIN ALPHA-2; CELL-PROLIFERATION; PROGNOSTIC MARKER; FAMILY-MEMBERS; DNA-DAMAGE; PROTEIN; DP-1; IDENTIFICATION; LOCALIZATION	Karyopherin alpha 2 (KPNA2) is a nuclear import factor that is elevated in multiple cancers. However, its molecular regulation at the transcriptional levels is poorly understood. Here we found that KPNA2 was significantly upregulated in gallbladder cancer (GBC), and the increased levels were correlated with short survival of patients. Gene knocking down of KPNA2 inhibited tumor cell proliferation and migration in vitro as well as xenografted tumor development in vivo. A typical transcription factor E2F1 associated with its DNA-binding partner DP1 bond to the promoter region of KPNA2 and induced KPNA2 expression. In contrast, an atypical transcription factor E2F7 competed against DP1 and blocked E2F1-induced KPNA2 gene activation. Mutation of the dimerization residues of E2F7 or DNA-binding domain of E2F1 abolished the suppressive effects of E2F7 on KPNA2 gene expression. In addition, KPNA2 mediated nuclear localization of E2F1 and E2F7, where they in turn controlled KPNA2 expression. Taken together, our data provided mechanistic insights into divergently transcriptional regulation of KPNA2, thus pointing to KPNA2 as a potential target for cancer therapy.	[Xiang, Shanshan; Wang, Zheng; Ye, Yuanyuan; Zhang, Fei; Li, Huaifeng; Yang, Yang; Miao, Huijie; Liang, Haibin; Zhang, Yijian; Jiang, Lin; Hu, Yunping; Liu, Yingbin] Shanghai Jiao Tong Univ, Dept Gen Surg, Xinhua Hosp, Sch Med, 1665 Kongjiang Rd, Shanghai 200092, Peoples R China; [Xiang, Shanshan; Wang, Zheng; Ye, Yuanyuan; Zhang, Fei; Li, Huaifeng; Yang, Yang; Miao, Huijie; Liang, Haibin; Zhang, Yijian; Jiang, Lin; Hu, Yunping; Liu, Yingbin] Shanghai Key Lab Biliary Tract Dis Res, 1665 Kongjiang Rd, Shanghai 200092, Peoples R China; [Xiang, Shanshan; Wang, Zheng; Ye, Yuanyuan; Zhang, Fei; Li, Huaifeng; Yang, Yang; Miao, Huijie; Liang, Haibin; Zhang, Yijian; Jiang, Lin; Hu, Yunping; Liu, Yingbin] Shanghai Res Ctr Biliary Tract Dis, 1665 Kongjiang Rd, Shanghai 200092, Peoples R China; [Zheng, Lei] Johns Hopkins Univ, Sch Med, Dept Oncol, Baltimore, MD 21205 USA; [Liu, Xiyong] City Hope Comprehens Canc Ctr, Dept Mol Pharmacol, Duarte, CA USA	Shanghai Jiao Tong University; Johns Hopkins University; City of Hope	Liu, YB (corresponding author), Shanghai Jiao Tong Univ, Dept Gen Surg, Xinhua Hosp, Sch Med, 1665 Kongjiang Rd, Shanghai 200092, Peoples R China.; Liu, YB (corresponding author), Shanghai Key Lab Biliary Tract Dis Res, 1665 Kongjiang Rd, Shanghai 200092, Peoples R China.; Liu, YB (corresponding author), Shanghai Res Ctr Biliary Tract Dis, 1665 Kongjiang Rd, Shanghai 200092, Peoples R China.	liuyingbin@xinhuamed.com.cn	LIU, YING/GZL-7252-2022; Liu, Yingbin/AAI-1919-2020	Liu, Yingbin/0000-0001-6110-0185	Shanghai Key Laboratory of Biliary Tract Disease Research Foundation [17DZ2260200]; National Natural Science Foundation of China [91440203, 31620103910, 31601021, 81773043]; Precision Medicine Research Program of Shanghai Jiao Tong University School of Medicine [15ZH4003, DKY201507]; development fund for Shanghai talents [201608]	Shanghai Key Laboratory of Biliary Tract Disease Research Foundation; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Precision Medicine Research Program of Shanghai Jiao Tong University School of Medicine; development fund for Shanghai talents	This study was supported by Shanghai Key Laboratory of Biliary Tract Disease Research Foundation (17DZ2260200), the National Natural Science Foundation of China (No. 91440203, 31620103910, 31601021, 81773043), the development fund for Shanghai talents (No. 201608), and the Precision Medicine Research Program of Shanghai Jiao Tong University School of Medicine (No. 15ZH4003, DKY201507). We sincerely thank Professor Shao Rong from Shanghai Jiao Tong University School of Medicine for substantially editing the manuscript and offering constructive suggestions; and A.M. Sieuwerts from Erasmus MC, Dong Qiongzhu from Fudan University for the help.	Alshareeda AT, 2015, BRIT J CANCER, V112, P1929, DOI 10.1038/bjc.2015.165; Araki K, 2003, ONCOGENE, V22, P7632, DOI 10.1038/sj.onc.1206840; BANDARA LR, 1993, EMBO J, V12, P4317, DOI 10.1002/j.1460-2075.1993.tb06116.x; Chen CX, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000912; Chong JL, 2009, NATURE, V462, P930, DOI 10.1038/nature08677; Christiansen A, 2013, CANCER LETT, V331, P18, DOI 10.1016/j.canlet.2012.12.013; Crosby ME, 2004, CANCER BIOL THER, V3, P1208, DOI 10.4161/cbt.3.12.1494; Dahl E, 2006, CLIN CANCER RES, V12, P3950, DOI 10.1158/1078-0432.CCR-05-2090; de Bruin A, 2003, J BIOL CHEM, V278, P42041, DOI 10.1074/jbc.M308105200; DeGregori J, 2006, CURR MOL MED, V6, P739; Di Stefano L, 2003, EMBO J, V22, P6289, DOI 10.1093/emboj/cdg613; Endo-Munoz L, 2009, CANCER RES, V69, P1800, DOI 10.1158/0008-5472.CAN-08-2725; Gao J, 2010, NATURE, V466, P1105, DOI 10.1038/nature09271; Gorlich D, 1998, EMBO J, V17, P2721, DOI 10.1093/emboj/17.10.2721; HELIN K, 1993, GENE DEV, V7, P1850, DOI 10.1101/gad.7.10.1850; Hu ZY, 2014, J EXP CLIN CANC RES, V33, DOI 10.1186/s13046-014-0061-1; Huang L, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.256; Ishida H, 2005, J BIOL CHEM, V280, P24642, DOI 10.1074/jbc.M500189200; Kanthan R, 2015, J ONCOL, V2015, DOI 10.1155/2015/967472; Korah J, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.146; Lammens T, 2009, TRENDS CELL BIOL, V19, P111, DOI 10.1016/j.tcb.2009.01.002; Lee BK, 2011, NUCLEIC ACIDS RES, V39, P3558, DOI 10.1093/nar/gkq1313; Lee EK, 2010, NAT STRUCT MOL BIOL, V17, P732, DOI 10.1038/nsmb.1815; Li J, 2008, DEV CELL, V14, P62, DOI 10.1016/j.devcel.2007.10.017; Li ML, 2017, CANCER LETT, V391, P20, DOI 10.1016/j.canlet.2016.12.027; Li ML, 2014, NAT GENET, V46, P872, DOI 10.1038/ng.3030; Liang HB, 2017, CELL PHYSIOL BIOCHEM, V41, P2117, DOI 10.1159/000475454; Lin WC, 2001, GENE DEV, V15, P1833; Liu BY, 2013, J BIOL CHEM, V288, P24581, DOI 10.1074/jbc.M113.467506; Logan N, 2004, ONCOGENE, V23, P5138, DOI 10.1038/sj.onc.1207649; Martinez-Balbas MA, 2000, EMBO J, V19, P662, DOI 10.1093/emboj/19.4.662; Moon NS, 2005, DEV CELL, V9, P463, DOI 10.1016/j.devcel.2005.08.015; Sakai M, 2010, ANTICANCER RES, V30, P851; Shu YJ, 2017, CELL DEATH DIFFER, V24, P445, DOI 10.1038/cdd.2016.146; Trimarchi JM, 2002, NAT REV MOL CELL BIO, V3, P11, DOI 10.1038/nrm714; Tseng SF, 2005, J BIOL CHEM, V280, P39594, DOI 10.1074/jbc.M508425200; van der Watt PJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027723; Wang B, 2004, J BIOL CHEM, V279, P54140, DOI 10.1074/jbc.M410493200; Wang CI, 2012, MOL CELL PROTEOMICS, V11, P1105, DOI 10.1074/mcp.M111.016592; Winnepenninckx VR, 2006, JNCI-J NATL CANCER I, V98, P472, DOI 10.1093/jnci/djj103; Wu XS, 2017, EMBO REP, V18, P1837, DOI 10.15252/embr.201744147; Ye YY, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0444-x; Zannini L, 2003, J BIOL CHEM, V278, P42346, DOI 10.1074/jbc.M303304200; Zeng HM, 2018, LANCET GLOB HEALTH, V6, pE555, DOI 10.1016/S2214-109X(18)30127-X	44	31	33	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 21	2019	38	8					1269	1281		10.1038/s41388-018-0494-7	http://dx.doi.org/10.1038/s41388-018-0494-7			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HM1XR	30254209				2022-12-17	WOS:000459249800009
J	Yuan, XT; Mu, NN; Wang, N; Straat, K; Sofiadis, A; Guo, YX; Stenman, A; Li, KL; Cheng, GH; Zhang, L; Kong, F; Ekblad, L; Wennerberg, J; Nilsson, IL; Juhlin, CC; Larsson, C; Xu, DW				Yuan, Xiaotian; Mu, Ninni; Wang, Na; Straat, Klas; Sofiadis, Anastasios; Guo, Yanxia; Stenman, Adam; Li, Kailin; Cheng, Guanghui; Zhang, Lu; Kong, Feng; Ekblad, Lars; Wennerberg, Johan; Nilsson, Inga-Lena; Juhlin, C. Christofer; Larsson, Catharina; Xu, Dawei			GABPA inhibits invasion/metastasis in papillary thyroid carcinoma by regulating DICER1 expression	ONCOGENE			English	Article							TERT PROMOTER MUTATIONS; TRANSCRIPTION FACTOR; ETS FAMILY; CANCER; TELOMERASE; BRAF; COEXISTENCE; GENES	The ETS family transcription factor GABPA is suggested as an oncogenic element, which is further supported by the recent reporting of it as the sole ETS member to activate the mutant TERT promoter in thyroid carcinomas (TC). However, it remains unclear how GABPA contributes to TC pathogenesis. The present study is designed to address this issue. TERT expression was significantly diminished in TERT promoter-mutated TC cells upon GABPA inhibition. Surprisingly, GABPA depletion led to robustly increased cellular invasion independently of TERT promoter mutations and TERT expression. DICER1, a component of the microRNA machinery, was identified as a downstream effector of GABPA. GABPA facilitated Dicer1 transcription while its depletion reduced Dicer1 expression. The mutation of the GABPA binding site in the DICER1 promoter led to diminished basal levels of DICER1 promoter activity and abolishment of GABPA-stimulated promoter activity as well. The forced DICER1 expression abrogated the invasiveness of GABPA-depleted TC cells. Consistently, the analyses of 93 patients with papillary thyroid carcinoma (PTC) revealed a positive correlation between GABPA and DICER1 expression. GABPA expression was negatively associated with TERT expression and promoter mutations, in contrast to published observations in cancer cell lines. Lower GABPA expression was associated with distant metastasis and shorter overall/disease-free survival in PTC patients. Similar results were obtained for PTC cases in the TCGA dataset. In addition, a positive correlation between GABPA and DICER1 expression was seen in multiple types of malignancies. Taken together, despite its stimulatory effect on the mutant TERT promoter and telomerase activation, GABPA may itself act as a tumor suppressor rather than an oncogenic factor to inhibit invasion/metastasis in TCs and be a useful predictor for patient outcomes.	[Yuan, Xiaotian] Shandong Univ, Reprod Ctr, Jinan 250013, Shandong, Peoples R China; [Yuan, Xiaotian; Straat, Klas; Guo, Yanxia; Xu, Dawei] Karolinska Inst, Karolinska Univ Hosp CMM, Dept Med Solna, SE-17176 Stockholm, Sweden; [Mu, Ninni; Wang, Na; Sofiadis, Anastasios; Stenman, Adam; Juhlin, C. Christofer; Larsson, Catharina] Karolinska Inst, Karolinska Univ Hosp CCK, Dept Oncol Pathol, SE-17176 Stockholm, Sweden; [Guo, Yanxia; Li, Kailin; Cheng, Guanghui; Zhang, Lu; Kong, Feng] Shandong Univ, Hosp 2, Cent Res Lab, Jinan 250033, Shandong, Peoples R China; [Ekblad, Lars] Lund Univ, Fac Med, Dept Clin Sci Lund, Div Oncol & Pathol, Lund, Sweden; [Wennerberg, Johan] Lund Univ, Skane Univ Hosp, Dept Clin Sci Lund, Div Otorhinolaryngol Head & Neck Surg, Lund, Sweden; [Nilsson, Inga-Lena] Karolinska Inst, Karolinska Univ Hosp, Dept Mol Med & Surg, SE-17176 Stockholm, Sweden	Shandong University; Karolinska Institutet; Karolinska Institutet; Karolinska University Hospital; Shandong University; Lund University; Lund University; Skane University Hospital; Karolinska Institutet; Karolinska University Hospital	Xu, DW (corresponding author), Karolinska Inst, Karolinska Univ Hosp CMM, Dept Med Solna, SE-17176 Stockholm, Sweden.; Larsson, C (corresponding author), Karolinska Inst, Karolinska Univ Hosp CCK, Dept Oncol Pathol, SE-17176 Stockholm, Sweden.	Catharina.Larsson@ki.se; Dawei.Xu@ki.se	Li, Kai/HCI-8860-2022; Stenman, Adam/AAI-3866-2021; yuan, xiaotian/AAN-6330-2020; Juhlin, Carl Christofer/C-1125-2016; Ekblad, Lars/O-8932-2014	Stenman, Adam/0000-0003-3248-7629; yuan, xiaotian/0000-0002-1501-518X; Juhlin, Carl Christofer/0000-0002-5945-9081; Ekblad, Lars/0000-0003-0152-786X; Xu, Dawei/0000-0003-3141-4524; Zhang, Lu/0000-0002-1580-6774; Nilsson, Inga-Lena/0000-0002-8966-3729	Swedish Cancer Society; Cancer Society in Stockholm; Stockholm County Council; Karolinska Institutet; Shandong Provincial Natural Science Foundation, China [2016ZDJS07A09]	Swedish Cancer Society(Swedish Cancer Society); Cancer Society in Stockholm; Stockholm County Council(Stockholm County Council); Karolinska Institutet(Karolinska Institutet); Shandong Provincial Natural Science Foundation, China(Natural Science Foundation of Shandong Province)	We thank Dr. J.K., Dr. J.F. Costello (University of California, San Francisco) for the TERT promoter reporters, Ms. L. Ahnfalk for excellent assistance in tumor tissue collection, Dr. B. Guan for evaluation of tumor colonies in mouse lung, and E. Berg (Karolinska Institutet) for expert consultations in the statistical analyses. The study was supported by grants from the Swedish Cancer Society, the Cancer Society in Stockholm, Stockholm County Council and Karolinska Institutet, and Shandong Provincial Natural Science Foundation, China (2016ZDJS07A09).	[Anonymous], 2016, J CLIN INVEST, DOI DOI 10.1172/JCI85271; Bell RJA, 2015, SCIENCE, V348, P1036, DOI 10.1126/science.aab0015; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Ding DQ, 2013, FASEB J, V27, P4375, DOI 10.1096/fj.13-230904; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Grant GD, 2013, MOL BIOL CELL, V24, P3634, DOI 10.1091/mbc.E13-05-0264; Horn S, 2013, SCIENCE, V339, P959, DOI 10.1126/science.1230062; Huang FW, 2013, SCIENCE, V339, P957, DOI 10.1126/science.1229259; Jafarnejad SM, 2013, ONCOGENE, V32, P2131, DOI 10.1038/onc.2012.239; Kitahara CM, 2016, NAT REV ENDOCRINOL, V12, P646, DOI 10.1038/nrendo.2016.110; Kumar MS, 2009, GENE DEV, V23, P2700, DOI 10.1101/gad.1848209; Landa I, 2013, J CLIN ENDOCR METAB, V98, pE1562, DOI 10.1210/jc.2013-2383; Lee JJ, 2007, THYROID, V17, P289, DOI 10.1089/thy.2006.0246; Lee SE, 2016, THYROID, V26, P901, DOI 10.1089/thy.2015.0488; Lewis KA, 2016, FRONT GENET, V7, DOI 10.3389/fgene.2016.00083; Liu RY, 2016, ENDOCR-RELAT CANCER, V23, pR143, DOI 10.1530/ERC-15-0533; Liu T, 2014, ONCOGENE, V33, P4978, DOI 10.1038/onc.2013.446; Liu TT, 2016, GENES-BASEL, V7, DOI 10.3390/genes7070038; Liu Z, 2013, ONCOGENE, V32, P4203, DOI 10.1038/onc.2012.441; Lloyd R., 2017, WHO CLASSIFICATION T, V4th; Martello G, 2010, CELL, V141, P1195, DOI 10.1016/j.cell.2010.05.017; Melo M, 2017, J CLIN ENDOCR METAB, V102, P1898, DOI 10.1210/jc.2016-2785; Melo M, 2015, J CLIN ONCOL, V33, P667, DOI 10.1200/JCO.2014.59.4614; Molinaro E, 2017, NAT REV ENDOCRINOL, V13, P644, DOI 10.1038/nrendo.2017.76; Odrowaz Z, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049892; Pacini F, 2011, NAT REV ENDOCRINOL, V7, P420, DOI 10.1038/nrendo.2011.52; Pestana A, 2017, J MOL ENDOCRINOL, V58, pR129, DOI 10.1530/JME-16-0195; Prazeres H, 2011, ONCOGENE, V30, P1302, DOI 10.1038/onc.2010.512; Ramirez-Moya J, 2018, ONCOGENE, V37, P3369, DOI 10.1038/s41388-017-0088-9; Rupaimoole R, 2016, ONCOGENE, V35, P4312, DOI 10.1038/onc.2015.492; Rupaimoole R, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6202; Saretzki G, 2014, CURR PHARM DESIGN, V20, P6386, DOI 10.2174/1381612820666140630095606; Schweppe RE, 2013, J CLIN ENDOCR METAB, V98, P956, DOI 10.1210/jc.2012-4182; Sharma NL, 2014, NUCLEIC ACIDS RES, V42, P6256, DOI 10.1093/nar/gku281; Sizemore GM, 2017, NAT REV CANCER, V17, P337, DOI 10.1038/nrc.2017.20; Song YS, 2016, CANCER-AM CANCER SOC, V122, P1370, DOI 10.1002/cncr.29934; Stern JL, 2015, GENE DEV, V29, P2219, DOI 10.1101/gad.269498.115; To SKY, 2017, ONCOGENE, V36, P5927, DOI 10.1038/onc.2017.185; van den Beucken T, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6203; Vinagre J, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3185; Wang N, 2014, CANCER-AM CANCER SOC, V120, P2965, DOI 10.1002/cncr.28800; Woodward EL, 2017, ENDOCR-RELAT CANCER, V24, P209, DOI 10.1530/ERC-16-0522; Xing MZ, 2014, J CLIN ONCOL, V32, P2718, DOI 10.1200/JCO.2014.55.5094; Yang ZF, 2013, P NATL ACAD SCI USA, V110, P2312, DOI 10.1073/pnas.1212904110; Yu JY, 2018, CANCER LETT, V434, P33, DOI 10.1016/j.canlet.2018.07.013; Zhang K, 2017, CANCER RES, V77, P2534, DOI 10.1158/0008-5472.CAN-16-1887; Zhang L, 2017, J CLIN INVEST, V127, P2159, DOI 10.1172/JCI90077; ZHANG S, 2017, BMC CANCER, V17	48	31	31	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 14	2019	38	7					965	979		10.1038/s41388-018-0483-x	http://dx.doi.org/10.1038/s41388-018-0483-x			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HL3OH	30181547				2022-12-17	WOS:000458624900004
J	Bao, Y; Wang, ZX; Liu, B; Lu, X; Xiong, Y; Shi, JZ; Li, P; Chen, JM; Zhang, ZQ; Chen, M; Wang, LH; Wu, ZJ				Bao, Yi; Wang, Zhixiang; Liu, Bing; Lu, Xin; Xiong, Ying; Shi, Jiazi; Li, Peng; Chen, Junming; Zhang, Zongqin; Chen, Ming; Wang, Linhui; Wu, Zhenjie			A feed-forward loop between nuclear translocation of CXCR4 and HIF-1 alpha promotes renal cell carcinoma metastasis	ONCOGENE			English	Article							CHEMOKINE RECEPTOR CXCR4; BREAST-CANCER; EXPRESSION; HYPOXIA; SDF-1-ALPHA; BIOLOGY; SDF-1	CXC chemokine receptor 4 (CXCR4) has been suggested to play a critical role in cancer metastasis. Some studies have described CXCR4 nuclear localization in metastatic lesions of renal cell carcinoma (RCC), which has been suggested to be correlated with cancer metastasis. However, the underlying mechanism and clinical significance of CXCR4 nuclear localization remains unknown. Here, we show that CXCR4 nuclear localization is more likely to occur in RCC tissues, especially in metastases, and is associated with poor prognosis. CXCR4 nuclear localization requires its nuclear localization sequence (NLS, residues 146-RPRK-149). After the mutation of NLS in CXCR4, CXCR4 nuclear localization in RCC cells is lost. Nuclear localization of CXCR4 promoted RCC tumorigenicity both in vitro and in vivo. Mechanistically, we found that CXCR4 and hypoxia-inducible factor-1 alpha (HIF-1 alpha) colocalized in RCC cells and interacted with each other. Moreover, CXCR4 nuclear localization promoted nuclear accumulation of HIF-1 alpha, thereby promoting the expression of genes downstream of HIF-1 alpha. Reciprocally, nuclear HIF-1 alpha promoted CXCR4 transcription, thus forming a feed-forward loop. Subcellular CXCR4 and HIF-1 alpha expression levels were independent adverse prognostic factors and could be combined with TNM stage to generate a predictive nomogram of the clinical outcome of patients with RCC. Therefore, our findings indicate that CXCR4 nuclear translocation plays a critical role in RCC metastasis and may serve as a prognostic biomarker and potential therapeutic target.	[Bao, Yi; Liu, Bing; Xiong, Ying; Shi, Jiazi; Li, Peng; Chen, Junming; Zhang, Zongqin; Chen, Ming; Wang, Linhui; Wu, Zhenjie] Second Mil Med Univ, Changzheng Hosp, Dept Urol, Shanghai 200003, Peoples R China; [Wang, Zhixiang] 458th Hosp PLA, Dept Urol, Guangzhou 510602, Guangdong, Peoples R China; [Lu, Xin] Second Mil Med Univ, Changhai Hosp, Dept Urol, Shanghai 200433, Peoples R China; [Li, Peng] 153 Hosp PLA, Dept Urol, Zhengzhou 450042, Henan, Peoples R China; [Chen, Junming] Chinese Peoples Armed Police Forces, Dept Urol, Henan Prov Corps Hosp, Zhengzhou 450052, Henan, Peoples R China	Naval Medical University; Naval Medical University	Wang, LH; Wu, ZJ (corresponding author), Second Mil Med Univ, Changzheng Hosp, Dept Urol, Shanghai 200003, Peoples R China.	wanglinhui@smmu.edu.cn; wuzhenjie17@smmu.edu.cn	Wu, Zhenjie/GRJ-0184-2022; wang, lin/GSE-3040-2022; wang, lili/HDL-7210-2022; wang, lin/HHM-2225-2022	Wu, Zhenjie/0000-0002-6487-5207; 	National Natural Science Foundation of China [81272817, 81874093, 81572521, 81730073]; Leading Talent Project of Shanghai [2013046]; Translation and Application of Precise Medicine of Second Military Medical University [2017JZ22]; Youth Talent Sailing Programme of Shanghai Science and Technology Committee [16YF1403600]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Leading Talent Project of Shanghai; Translation and Application of Precise Medicine of Second Military Medical University; Youth Talent Sailing Programme of Shanghai Science and Technology Committee	We thank Dr. Taoyong Chen for valuable comments and expert technical support. This study was supported by the National Natural Science Foundation of China (81272817, 81874093, 81572521 and 81730073), the Leading Talent Project of Shanghai (2013046), the Translation and Application of Precise Medicine of Second Military Medical University (No. 2017JZ22) (to L.W.); the Youth Talent Sailing Programme of Shanghai Science and Technology Committee (16YF1403600) (to Z.W.).	Brocato J, 2014, MOL PHARMACOL, V85, P651, DOI 10.1124/mol.113.089623; Busillo JM, 2007, BBA-BIOMEMBRANES, V1768, P952, DOI 10.1016/j.bbamem.2006.11.002; Cabioglu N, 2007, ANN ONCOL, V18, P1021, DOI 10.1093/annonc/mdm060; Cabioglu N, 2005, CLIN EXP METASTAS, V22, P39, DOI 10.1007/s10585-005-3222-y; Capitanio U, 2016, LANCET, V387, P894, DOI 10.1016/S0140-6736(15)00046-X; Caruz A, 1998, FEBS LETT, V426, P271, DOI 10.1016/S0014-5793(98)00359-7; Choudhry H, 2018, CELL METAB, V27, P281, DOI 10.1016/j.cmet.2017.10.005; Don-Salu-Hewage AS, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057194; Figlin RA, 1999, J UROLOGY, V161, P381, DOI 10.1016/S0022-5347(01)61897-4; Gong J, 2016, ASIAN J UROL, V3, P286, DOI 10.1016/j.ajur.2016.08.006; Han MZ, 2014, TUMOR BIOL, V35, P4589, DOI 10.1007/s13277-013-1603-4; He X, 2010, PATHOL RES PRACT, V206, P712, DOI 10.1016/j.prp.2010.05.003; Kizaka-Kondoh S, 2009, ADV DRUG DELIVER REV, V61, P623, DOI 10.1016/j.addr.2009.01.006; Marechal R, 2009, BRIT J CANCER, V100, P1444, DOI 10.1038/sj.bjc.6605020; Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016; Murphy PM, 2000, PHARMACOL REV, V52, P145; Nikkhoo B, 2014, J ONCOL, V2014, DOI 10.1155/2014/808012; Pan JD, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-56; Schioppa T, 2003, J EXP MED, V198, P1391, DOI 10.1084/jem.20030267; Shannon AM, 2003, CANCER TREAT REV, V29, P297, DOI 10.1016/S0305-7372(03)00003-3; Siegel RL, 2015, CA-CANCER J CLIN, V65, P5, DOI 10.3322/caac.21254; Signoret N, 1997, J CELL BIOL, V139, P651, DOI 10.1083/jcb.139.3.651; Singh D, 2017, CELL BIOSCI, V7, DOI 10.1186/s13578-017-0190-2; Staller P, 2003, NATURE, V425, P307, DOI 10.1038/nature01874; Sun WD, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-05685-3; Vila-Coro AJ, 1999, FASEB J, V13, P1699, DOI 10.1096/fasebj.13.13.1699; Wang LH, 2009, ONCOL REP, V22, P1333, DOI 10.3892/or_00000572; Wang LH, 2009, CLIN EXP METASTAS, V26, P1049, DOI 10.1007/s10585-009-9294-3; Wang SC, 2010, INT J COLORECTAL DIS, V25, P1185, DOI 10.1007/s00384-010-0999-1; Xu ZP, 2016, ONCOL REP, V36, P2681, DOI 10.3892/or.2016.5082; Yoshitake N, 2008, BRIT J CANCER, V98, P1682, DOI 10.1038/sj.bjc.6604363; Zagzag D, 2006, LAB INVEST, V86, P1221, DOI 10.1038/labinvest.3700482	32	31	31	2	20	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 7	2019	38	6					881	895		10.1038/s41388-018-0452-4	http://dx.doi.org/10.1038/s41388-018-0452-4			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HK5LC	30177838	hybrid, Green Published			2022-12-17	WOS:000458006300009
J	Lin, MC; Chien, PH; Wu, HY; Chen, ST; Juan, HF; Lou, PJ; Huang, MC				Lin, Mei-Chun; Chien, Pin-Hui; Wu, Hsin-Yi; Chen, Syue-Ting; Juan, Hsueh-Fen; Lou, Pei-Jen; Huang, Min-Chuan			C1GALT1 predicts poor prognosis and is a potential therapeutic target in head and neck cancer	ONCOGENE			English	Article							MOLECULAR CHAPERONE COSMC; CELL LUNG-CANCER; O-GLYCOSYLATION; HEPATOCELLULAR-CARCINOMA; PROSTATE-CANCER; EGF RECEPTOR; ITRACONAZOLE; GROWTH; DIMERIZATION; ANGIOGENESIS	Core 1 beta 1,3-galactosyltransferase (C1GALT1) controls the crucial step of GalNAc-type O-glycosylation and is overexpressed in various human malignancies. However, its role in head and neck squamous cell carcinoma (HNSCC) remains unclear. Here we demonstrate that C1GALT1 expression is upregulated in HNSCC tumors and is associated with adverse clinicopathologic features. Moreover, high C1GALT1 expression predicts poor disease-free and overall survivals. C1GALT1 overexpression enhances HNSCC cell viability, migration, and invasion, which can be reversed by erlotinib. Silencing of C1GALT1 suppresses the malignant behavior both in vitro and in vivo. Mass spectrometry and lectin pull-down assays demonstrate that C1GALT1 modifies O-glycans on EGFR. Blocking O-glycan elongation on EGFR by C1GALT1 knockdown decreases EGF-EGFR binding affinity and inhibits EGFR signaling, thereby suppressing malignant phenotypes. Using molecular docking simulations, we identify itraconazole as a C1GALT1 inhibitor that directly binds C1GALT1 and promotes its proteasomal degradation, leading to significant blockade of C1GALT1-mediated effects in HNSCC cells in vitro and in vivo. Collectively, our findings demonstrate a critical role of O-glycosylation in HNSCC progression and highlight the therapeutic potential of targeting C1GALT1 in HNSCC treatment.	[Lin, Mei-Chun; Chien, Pin-Hui] Natl Taiwan Univ Hosp, Hsin Chu Branch, Dept Otolaryngol, Hsinchu, Taiwan; [Lin, Mei-Chun] Natl Taiwan Univ, Canc Ctr, Taipei, Taiwan; [Wu, Hsin-Yi] Natl Taiwan Univ, Instrumentat Ctr, Taipei, Taiwan; [Chen, Syue-Ting; Huang, Min-Chuan] Natl Taiwan Univ, Grad Inst Anat & Cell Biol, Coll Med, Taipei, Taiwan; [Juan, Hsueh-Fen] Natl Taiwan Univ, Grad Inst Biomed Elect & Bioinformat, Dept Life Sci, Taipei, Taiwan; [Lou, Pei-Jen] Natl Taiwan Univ Hosp & Coll Med, Dept Otolaryngol, Taipei, Taiwan	National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University; National Taiwan University; National Taiwan University; National Taiwan University; National Taiwan University Hospital	Huang, MC (corresponding author), Natl Taiwan Univ, Grad Inst Anat & Cell Biol, Coll Med, Taipei, Taiwan.; Lou, PJ (corresponding author), Natl Taiwan Univ Hosp & Coll Med, Dept Otolaryngol, Taipei, Taiwan.	pjlou@ntu.edu.tw; mchuang@ntu.edu.tw		LOU, PEI-JEN/0000-0002-3383-8593; HUANG, MIN-CHUAN/0000-0002-0704-3447	National Taiwan University Hospital, Hsinchu Branch [HCH104-045, 106-HCH067]; Ministry of Science and Technology, R.O.C. [104-2320-B-002-068-MY3, 103-2314-B-002-082-MY2, 106-2923-B-002-003-MY3, 105-2314-B-002-203-MY2]; Academia Sinica, Taiwan Head and Neck Cancer Biosignature	National Taiwan University Hospital, Hsinchu Branch; Ministry of Science and Technology, R.O.C.; Academia Sinica, Taiwan Head and Neck Cancer Biosignature	We thank Chia-Hsien Lee for help in homology modeling and docking simulation. This study was supported by the National Taiwan University Hospital, Hsinchu Branch, HCH104-045, 106-HCH067 (M.-C.L.) and Ministry of Science and Technology, R.O.C. 104-2320-B-002-068-MY3 (M.-C.H.), 103-2314-B-002-082-MY2, 106-2923-B-002-003-MY3 (P.-J.L.), 105-2314-B-002-203-MY2 (M.-C.L.), and the Academia Sinica, Taiwan Head and Neck Cancer Biosignature (P.-J.L.).	Aftab BT, 2011, CANCER RES, V71, P6764, DOI 10.1158/0008-5472.CAN-11-0691; Antonarakis ES, 2013, ONCOLOGIST, V18, P163, DOI 10.1634/theoncologist.2012-314; Aryal RP, 2014, J BIOL CHEM, V289, P11630, DOI 10.1074/jbc.M114.555870; Bannert N, 2001, J EXP MED, V194, P1661, DOI 10.1084/jem.194.11.1661; Bennett EP, 2012, GLYCOBIOLOGY, V22, P736, DOI 10.1093/glycob/cwr182; Chen BZ, 2016, MOL CANCER THER, V15, P866, DOI 10.1158/1535-7163.MCT-15-0729-T; Chou CH, 2015, ONCOTARGET, V6, P6123, DOI 10.18632/oncotarget.3045; Gerken TA, 2011, J BIOL CHEM, V286, P14493, DOI 10.1074/jbc.M111.218701; Haddad RI, 2008, NEW ENGL J MED, V359, P1143, DOI 10.1056/NEJMra0707975; Hakomori S, 2002, P NATL ACAD SCI USA, V99, P10231, DOI 10.1073/pnas.172380699; Harris KA, 2002, J UROLOGY, V168, P542, DOI 10.1016/S0022-5347(05)64675-7; HOLMES EH, 1987, J BIOL CHEM, V262, P11331; Hung JS, 2014, ONCOTARGET, V5, P2096, DOI 10.18632/oncotarget.1815; Ju TZ, 2002, P NATL ACAD SCI USA, V99, P16613, DOI 10.1073/pnas.262438199; Kannagi R, 2008, BBA-GEN SUBJECTS, V1780, P525, DOI 10.1016/j.bbagen.2007.10.007; Kim J, 2010, CANCER CELL, V17, P388, DOI 10.1016/j.ccr.2010.02.027; King SL, 2017, BLOOD ADV, V1, P429, DOI 10.1182/bloodadvances.2016002121; Kong Y, 2015, GLYCOBIOLOGY, V25, P55, DOI 10.1093/glycob/cwu089; Leemans CR, 2018, NAT REV CANCER, V18, P269, DOI 10.1038/nrc.2018.11; Leemans CR, 2011, NAT REV CANCER, V11, P9, DOI 10.1038/nrc2982; Li SQ, 2005, CANCER CELL, V7, P301, DOI 10.1016/j.ccr.2005.03.003; Liang GZ, 2017, ONCOTARGET, V8, P28510, DOI 10.18632/oncotarget.15324; Lin MC, 2014, ORAL ONCOL, V50, P478, DOI 10.1016/j.oraloncology.2014.02.003; Nguyen-Tan PF, 2014, J CLIN ONCOL, V32, P3858, DOI 10.1200/JCO.2014.55.3925; Pinho SS, 2015, NAT REV CANCER, V15, P540, DOI 10.1038/nrc3982; Rudin CM, 2013, J THORAC ONCOL, V8, P619, DOI 10.1097/JTO.0b013e31828c3950; Schachter H, 2000, GLYCOCONJUGATE J, V17, P465; Schlessinger J, 2002, CELL, V110, P669, DOI 10.1016/S0092-8674(02)00966-2; Steentoft C, 2013, EMBO J, V32, P1478, DOI 10.1038/emboj.2013.79; Tarp MA, 2008, BBA-GEN SUBJECTS, V1780, P546, DOI 10.1016/j.bbagen.2007.09.010; Ten Hagen KG, 2003, GLYCOBIOLOGY, V13, p1R, DOI 10.1093/glycob/cwg007; Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262; Tsai CH, 2016, CANCER RES, V76, P5756, DOI 10.1158/0008-5472.CAN-16-0641; Tsubamoto H, 2014, ANTICANCER RES, V34, P2481; Vermorken JB, 2008, NEW ENGL J MED, V359, P1116, DOI 10.1056/NEJMoa0802656; Wu YM, 2013, CANCER RES, V73, P5580, DOI 10.1158/0008-5472.CAN-13-0869; Wu YM, 2011, CANCER RES, V71, P7270, DOI 10.1158/0008-5472.CAN-11-1161; Xia LJ, 2004, J CELL BIOL, V164, P451, DOI 10.1083/jcb.200311112; Yokota M, 1997, HISTOCHEM J, V29, P555, DOI 10.1023/A:1026475926033	39	31	32	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 25	2018	37	43					5780	5793		10.1038/s41388-018-0375-0	http://dx.doi.org/10.1038/s41388-018-0375-0			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GY1KL	29930379	Green Published, hybrid			2022-12-17	WOS:000448288200006
J	Bruggeman, JW; Koster, J; Lodder, P; Repping, S; Hamer, G				Bruggeman, Jan Willem; Koster, Jan; Lodder, Paul; Repping, Sjoerd; Hamer, Geert			Massive expression of germ cell-specific genes is a hallmark of cancer and a potential target for novel treatment development	ONCOGENE			English	Article							CANCER/TESTIS-ANTIGEN; MESSENGER-RNA; IDENTIFICATION; DATABASE	Cancer cells have been found to frequently express genes that are normally restricted to the testis, often referred to as cancer/testis (CT) antigens or genes. Because germ cell-specific antigens are not recognized as "self" by the innate immune system, CT-genes have previously been suggested as ideal candidate targets for cancer therapy. The use of CT-genes in cancer therapy has thus far been unsuccessful, most likely because their identification has relied on gene expression in whole testis, including the testicular somatic cells, precluding the detection of true germ cell-specific genes. By comparing the transcriptomes of micro-dissected germ cell subtypes, representing the main developmental stages of human spermatogenesis, with the publicly accessible transcriptomes of 2617 samples from 49 different healthy somatic tissues and 9232 samples from 33 tumor types, we here discover hundreds of true germ cell-specific cancer expressed genes. Strikingly, we found these germ cell cancer genes (GC-genes) to be widely expressed in all analyzed tumors. Many GC-genes appeared to be involved in processes that are likely to actively promote tumor viability, proliferation and metastasis. Targeting these true GC-genes thus has the potential to inhibit tumor growth with infertility being the only possible side effect. Moreover, we identified a subset of GC-genes that are not expressed in spermatogonial stem cells. Targeting of this GC-gene subset is predicted to only lead to temporary infertility, as untargeted spermatogonial stem cells can recover spermatogenesis after treatment. Our GC-gene dataset enables improved understanding of tumor biology and provides multiple novel targets for cancer treatment.	[Bruggeman, Jan Willem; Lodder, Paul; Repping, Sjoerd; Hamer, Geert] Univ Amsterdam, Acad Med Ctr, Amsterdam Res Inst Reprod & Dev, Ctr Reprod Med, Amsterdam, Netherlands; [Koster, Jan] Univ Amsterdam, Acad Med Ctr, Dept Oncogen, Amsterdam, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; Vrije Universiteit Amsterdam	Hamer, G (corresponding author), Univ Amsterdam, Acad Med Ctr, Amsterdam Res Inst Reprod & Dev, Ctr Reprod Med, Amsterdam, Netherlands.	g.hamer@amc.uva.nl	Koster, Jan/C-5934-2008	Koster, Jan/0000-0002-0890-7585; Bruggeman, Jan Willem/0000-0003-1901-4720; Hamer, Geert/0000-0002-9583-6796	ZonMw VIDI [91796362]; AMC Fellowship; People Programme (Marie Curie Actions) of the European Union's Seventh Framework Programme [CIG 293765]	ZonMw VIDI(Netherlands Organization for Health Research and Development); AMC Fellowship; People Programme (Marie Curie Actions) of the European Union's Seventh Framework Programme	This work was financed by ZonMw VIDI-grant 91796362 to SR and; an AMC Fellowship and The People Programme (Marie Curie Actions) of the European Union's Seventh Framework Programme (CIG 293765) to GH.	Almeida LG, 2009, NUCLEIC ACIDS RES, V37, pD816, DOI 10.1093/nar/gkn673; Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; Chen YT, 2005, P NATL ACAD SCI USA, V102, P7940, DOI 10.1073/pnas.0502583102; Dawkins R., 1976, SELFISH GENE; Gjerstorff MF, 2015, ONCOTARGET, V6, P15772, DOI 10.18632/oncotarget.4694; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hofmann O, 2008, P NATL ACAD SCI USA, V105, P20422, DOI 10.1073/pnas.0810777105; Huang DW, 2007, NUCLEIC ACIDS RES, V35, pW169, DOI 10.1093/nar/gkm415; Jan SZ, 2017, DEVELOPMENT, V144, P3659, DOI 10.1242/dev.152413; Jan SZ, 2012, BBA-MOL BASIS DIS, V1822, P1838, DOI 10.1016/j.bbadis.2012.02.008; JANITZ M, 1994, MOL REPROD DEV, V38, P231, DOI 10.1002/mrd.1080380215; Jungbluth Achim A, 2007, Cancer Immun, V7, P15; KIRKWOOD TBL, 1979, PROC R SOC SER B-BIO, V205, P531, DOI 10.1098/rspb.1979.0083; Koster J, 2015, CANCER RES, V75, DOI 10.1158/1538-7445.TRANSCAGEN-A2-45; Lonsdale J, 2013, NAT GENET, V45, P580, DOI 10.1038/ng.2653; Maxfield KE, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9840; Nielsen AY, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17060890; Scanlan MJ, 2002, INT J CANCER, V98, P485, DOI 10.1002/ijc.10276; Simpson AJG, 2005, NAT REV CANCER, V5, P615, DOI 10.1038/nrc1669; Uhlen M, 2015, SCIENCE, V347, DOI 10.1126/science.1260419; Vincent MD, 2011, ADV CANCER RES, V112, P283, DOI 10.1016/B978-0-12-387688-1.00010-7; Wang C, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10499; Whitehurst AW, 2014, ANNU REV PHARMACOL, V54, P251, DOI 10.1146/annurev-pharmtox-011112-140326; Yokoe T, 2008, CANCER RES, V68, P1074, DOI 10.1158/0008-5472.CAN-07-0964	25	31	31	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 18	2018	37	42					5694	5700		10.1038/s41388-018-0357-2	http://dx.doi.org/10.1038/s41388-018-0357-2			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX3JJ	29907769	Green Submitted, Green Published, hybrid			2022-12-17	WOS:000447619100008
J	Zhang, Y; Zhou, XX; Li, Y; Xu, YY; Lu, K; Li, PP; Wang, X				Zhang, Ya; Zhou, Xiangxiang; Li, Ying; Xu, Yangyang; Lu, Kang; Li, Peipei; Wang, Xin			Inhibition of maternal embryonic leucine zipper kinase with OTSSP167 displays potent anti-leukemic effects in chronic lymphocytic leukemia	ONCOGENE			English	Article							GLIOMA STEM-CELLS; LARGE GENE LISTS; CANCER CELLS; JNK/MITOCHONDRIAL PATHWAY; HEPATOCELLULAR-CARCINOMA; IBRUTINIB RESISTANCE; EXPRESSION SIGNATURE; DISEASE PROGRESSION; MELK EXPRESSION; LUNG-CANCER	TP53 pathway defects contributed to therapy resistance and adverse clinical outcome in chronic lymphocytic leukemia (CLL), which represents an unmet clinical need with few therapeutic options. Maternal embryonic leucine zipper kinase (MELK) is a novel oncogene, which plays crucial roles in mitotic progression and stem cell maintenance. OTSSP167, an orally administrated inhibitor targeting MELK, is currently in a phase I/II clinical trial in patients with advanced breast cancer and acute myeloid leukemia. Yet, no investigation has been elucidated to date regarding the oncogenic role of MELK and effects of OTSSP167 in chronic lymphocytic leukemia (CLL). Previous studies confirmed MELK inhibition abrogated cancer cell survival via p53 signaling pathway. Thus, we aimed to determine the biological function of MELK and therapeutic potential of OTSSP167 in CLL. Herein, MELK over-expression was observed in CLL cells, and correlated with higher WBC count, advanced stage, elevated LDH, increased beta 2-MG level, unmutated IGHV, positive ZAP-70, deletion of 17p13 and inferior prognosis of CLL patients. In accordance with functional enrichment analyses in gene expression profiling, CLL cells with depletion or inhibition of MELK exhibited impaired cell proliferation, enhanced fast-onset apoptosis, induced G2/M arrest, attenuated cell chemotaxis and promoted sensitivity to fludarabine and ibrutinib. However, gain-of-function assay showed increased cell proliferation and cell chemotaxis. In addition, OTSSP167 treatment reduced phosphorylation of AKT and ERK1/2. It decreased FoxM1 phosphorylation, expression of FoxM1, cyclin B1 and CDK1, while up-regulating p53 and p21 expression. Taken together, MELK served as a candidate of therapeutic target in CLL. OTSSP167 exhibits potent anti-tumor activities in CLL cells, highlighting a novel molecule-based strategy for leukemic interventions.	[Zhang, Ya; Zhou, Xiangxiang; Li, Ying; Xu, Yangyang; Lu, Kang; Li, Peipei; Wang, Xin] Shandong Univ, Dept Hematol, Shandong Prov Hosp, Jinan 250021, Shandong, Peoples R China; [Wang, Xin] Shandong Univ, Sch Med, Jinan 250012, Shandong, Peoples R China	Shandong First Medical University & Shandong Academy of Medical Sciences; Shandong University; Shandong University	Wang, X (corresponding author), Shandong Univ, Dept Hematol, Shandong Prov Hosp, Jinan 250021, Shandong, Peoples R China.; Wang, X (corresponding author), Shandong Univ, Sch Med, Jinan 250012, Shandong, Peoples R China.	xinw@sdu.edu.cn			National Natural Science Foundation [81270598, 81473486, 81770210]; Key Research and Development Program of Shandong Province [2018CXGC1213, 2016GSF201029]; Natural Science Foundation of Shandong Province [ZR2012HZ003]; Technology Development Projects of Shandong Province [2014GSF118021]; Program of Shandong Medical Leading Talent; Taishan Scholar Foundation of Shandong Province	National Natural Science Foundation(National Natural Science Foundation of China (NSFC)); Key Research and Development Program of Shandong Province; Natural Science Foundation of Shandong Province(Natural Science Foundation of Shandong Province); Technology Development Projects of Shandong Province; Program of Shandong Medical Leading Talent; Taishan Scholar Foundation of Shandong Province	This study was partly supported by: National Natural Science Foundation (No. 81270598, No. 81473486, No. 81770210), Key Research and Development Program of Shandong Province (No. 2018CXGC1213, No. 2016GSF201029), Natural Science Foundation of Shandong Province (No. ZR2012HZ003), Technology Development Projects of Shandong Province (No. 2014GSF118021), Program of Shandong Medical Leading Talent, and Taishan Scholar Foundation of Shandong Province.	Alachkar H, 2014, ONCOTARGET, V5, P12371, DOI 10.18632/oncotarget.2642; Beke L, 2015, BIOSCIENCE REP, V35, DOI 10.1042/BSR20150194; Bolomsky A, 2018, HAEMATOLOGICA, V103, P325, DOI 10.3324/haematol.2017.172973; Buchner M, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7471; Choi S, 2011, BIOCHEM BIOPH RES CO, V412, P207, DOI 10.1016/j.bbrc.2011.07.060; Chuang HY, 2012, BLOOD, V120, P2639, DOI 10.1182/blood-2012-03-416461; Chung S, 2016, ONCOTARGET, V7, P18171, DOI 10.18632/oncotarget.7685; Chung SY, 2012, ONCOTARGET, V3, P1629; Ciccone M, 2014, CANCER CELL, V26, P770, DOI 10.1016/j.ccell.2014.10.020; Cui J, 2016, ONCOGENE, V35, P4708, DOI 10.1038/onc.2016.14; Davezac N, 2002, ONCOGENE, V21, P7630, DOI 10.1038/sj.onc.1205870; Du T, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-100; Ghia P, 2016, LANCET ONCOL, V17, P1342, DOI 10.1016/S1470-2045(16)30442-9; Giuliano CJ, 2018, ELIFE, V7, DOI 10.7554/eLife.32838; Gu CY, 2013, STEM CELLS, V31, P870, DOI 10.1002/stem.1322; Haferlach T, 2010, J CLIN ONCOL, V28, P2529, DOI 10.1200/JCO.2009.23.4732; Halasi M, 2013, MOL CANCER THER, V12, P245, DOI 10.1158/1535-7163.MCT-12-0712; Hallek M, 2008, BLOOD, V111, P5446, DOI 10.1182/blood-2007-06-093906; Hasegawa K, 2018, J IMMUNOTHER, V41, P201, DOI 10.1097/CJI.0000000000000214; Herold T, 2011, LEUKEMIA, V25, P1639, DOI 10.1038/leu.2011.125; Herold T, 2013, LEUKEMIA LYMPHOMA, V54, P1652, DOI 10.3109/10428194.2012.753445; Hiwatashi K, 2016, ANTICANCER RES, V36, P5183, DOI 10.21873/anticanres.11088; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Huang DW, 2009, NUCLEIC ACIDS RES, V37, P1, DOI 10.1093/nar/gkn923; Huang HT, 2017, ELIFE, V6, DOI 10.7554/eLife.26693; Inoue H, 2016, ONCOTARGET, V7, P13621, DOI 10.18632/oncotarget.7297; Janostiak R, 2017, CELL REP, V21, P2829, DOI 10.1016/j.celrep.2017.11.033; Ji WB, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0153518; Joshi K, 2013, STEM CELLS, V31, P1051, DOI 10.1002/stem.1358; Jurmeister S, 2018, EMBO MOL MED, V10, DOI 10.15252/emmm.201708274; Kaur V, 2017, ANN HEMATOL, V96, P1175, DOI 10.1007/s00277-017-2973-2; Khan I, 2017, LEUKEMIA, V31, P251, DOI 10.1038/leu.2016.270; Khongkow P, 2016, ONCOGENE, V35, P990, DOI 10.1038/onc.2015.152; Kim SH, 2015, STEM CELL REP, V4, P226, DOI 10.1016/j.stemcr.2014.12.006; Klaeger S, 2017, SCIENCE, V358, DOI 10.1126/science.aan4368; Kohler RS, 2017, GYNECOL ONCOL, V145, P159, DOI 10.1016/j.ygyno.2017.02.016; Kohlmann A, 2008, BRIT J HAEMATOL, V142, P802, DOI 10.1111/j.1365-2141.2008.07261.x; Komarova NL, 2014, P NATL ACAD SCI USA, V111, P13906, DOI 10.1073/pnas.1409362111; Krishnan A, 2017, J CELL BIOCHEM, V118, P797, DOI 10.1002/jcb.25754; Kwok CTD, 2016, STEM CELL RES, V16, P651, DOI 10.1016/j.scr.2016.03.007; Lenz G, 2017, J CLIN ONCOL, V35, P1451, DOI 10.1200/JCO.2016.72.0102; Li PP, 2015, MED ONCOL, V32, DOI 10.1007/s12032-014-0479-5; Li S, 2016, ONCOTARGET, V7, P6266, DOI 10.18632/oncotarget.6673; Lin A, 2017, ELIFE, V6, DOI 10.7554/eLife.24179; Liu Y, 2015, NEOPLASMA, V62, P61, DOI 10.4149/neo_2015_008; Longo PG, 2007, LEUKEMIA, V21, P110, DOI 10.1038/sj.leu.2404417; Lu K, 2015, CANCER LETT, V359, P250, DOI 10.1016/j.canlet.2015.01.021; Lu K, 2012, J HEMATOL ONCOL, V5, DOI 10.1186/1756-8722-5-55; Matsuda T, 2017, ONCOTARGET, V8, P57938, DOI 10.18632/oncotarget.18488; Mertens D, 2017, BLOOD, V129, P1407, DOI 10.1182/blood-2017-01-761536; Mootha VK, 2003, NAT GENET, V34, P267, DOI 10.1038/ng1180; Motiwala T, 2015, LEUKEMIA, V29, P1350, DOI 10.1038/leu.2014.341; Mraz M, 2014, BLOOD, V124, P84, DOI 10.1182/blood-2013-09-527234; Nilsson D, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1001037; Parikh SA, 2016, SEMIN ONCOL, V43, P233, DOI 10.1053/j.seminoncol.2016.02.009; Pickard MR, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2350; Raychaudhuri P, 2011, CANCER RES, V71, P4329, DOI 10.1158/0008-5472.CAN-11-0640; Simon M, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0172832; Speers C, 2016, CLIN CANCER RES, V22, P5864, DOI 10.1158/1078-0432.CCR-15-2711; Stefka AT, 2016, BLOOD CANCER J, V6, DOI 10.1038/bcj.2016.71; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Sullivan C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051277; Svirnovski A. I., 2010, Experimental Oncology, V32, P258; Trojani A, 2012, CANCER BIOMARK, V11, P15, DOI 10.3233/CBM-2012-0259; Wang K, 2016, ACTA BIOCH BIOPH SIN, V48, P804, DOI 10.1093/abbs/gmw072; Wang YB, 2014, ELIFE, V3, DOI 10.7554/eLife.01763; Wiestner A, 2015, HAEMATOLOGICA, V100, P1495, DOI 10.3324/haematol.2014.119123; Xia HP, 2016, CANCER LETT, V383, P85, DOI 10.1016/j.canlet.2016.09.017; Zhou XX, 2017, J HEMATOL ONCOL, V10, DOI 10.1186/s13045-017-0391-5	69	31	31	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 11	2018	37	41					5520	5533		10.1038/s41388-018-0333-x	http://dx.doi.org/10.1038/s41388-018-0333-x			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GW5QO	29895969				2022-12-17	WOS:000446991200004
J	Amin, MKBA; Shimizu, A; Zankov, DP; Sato, A; Kurita, S; Ito, M; Maeda, T; Yoshida, T; Sakaue, T; Higashiyama, S; Kawauchi, A; Ogita, H				Amin, Mohammad Khusni B. Ahmat; Shimizu, Akio; Zankov, Dimitar P.; Sato, Akira; Kurita, Souichi; Ito, Masami; Maeda, Toshinaga; Yoshida, Tetsuya; Sakaue, Tomohisa; Higashiyama, Shigeki; Kawauchi, Akihiro; Ogita, Hisakazu			Epithelial membrane protein 1 promotes tumor metastasis by enhancing cell migration via copine-III and Rac1	ONCOGENE			English	Article							PHOSPHOLIPID-BINDING PROTEINS; PROSTATE-CANCER; THERAPEUTIC TARGET; SUPPRESSOR GENE; GROWTH; EMP1; MICROENVIRONMENT; ANGIOGENESIS; RECEPTOR; CD151	Tumor metastasis is the most common cause of cancer death. Elucidation of the mechanism of tumor metastasis is therefore important in the development of novel, effective anti-cancer therapies to reduce cancer mortality. Interaction between cancer cells and surrounding stromal cells in the tumor microenvironment is a key factor in tumor metastasis. Using a co-culture assay system with human prostate cancer LNCaP cells and primary human prostate stromal cells, we identified epithelial membrane protein 1 (EMP1) as a gene with elevated expression in the cancer cells. The orthotopic injection of LNCaP cells overexpressing EMP1 (EMP1-LNCaP cells) into the prostate of nude mice induced lymph node and lung metastases, while that of control LNCaP cells did not. EMP1-LNCaP cells had higher cell motility and Racl activity than control LNCaP cells. These results were also observed in other lines of cancer cells. We newly identified copine-III as an intracellular binding partner of EMP1. Knockdown of copine-III attenuated the increased cell motility and Rac1 activity in EMP1-LNCaP cells. Reduced cell motility and Rac1 activity following knockdown of copine-III in EMP1-LNCaP cells were recovered by reexpression of wild-type copine-III, but not of a copine-III mutant incapable of interacting with EMP1, suggesting the importance of the EMP1-copine-III interaction. Phosphorylated and activated Src and a Rac guanine nucleotide exchange factor Vav2 were found to be involved in the EMP1-induced enhancement of cell motility and Rac1 activation. Moreover, EMP1 was highly expressed in prostate cancer samples obtained from patients with higher Gleason score. These results demonstrate that upregulation of EMP1 significantly increases cancer cell migration that leads to tumor metastasis, suggesting that EMP1 may play an essential role as a positive regulator of tumor metastasis.	[Amin, Mohammad Khusni B. Ahmat; Shimizu, Akio; Zankov, Dimitar P.; Sato, Akira; Kurita, Souichi; Ito, Masami; Maeda, Toshinaga; Ogita, Hisakazu] Shiga Univ Med Sci, Div Mol Med Biochem, Dept Biochem & Mol Biol, Otsu, Shiga, Japan; [Yoshida, Tetsuya; Kawauchi, Akihiro] Shiga Univ Med Sci, Dept Urol, Otsu, Shiga, Japan; [Sakaue, Tomohisa; Higashiyama, Shigeki] Ehime Univ, Div Cell Growth & Tumor Regulat, Proteosci Ctr PROS, Toon, Japan; [Sakaue, Tomohisa] Ehime Univ, Grad Sch Med, Dept Cardiovasc & Thorac Surg, Toon, Japan; [Higashiyama, Shigeki] Ehime Univ, Grad Sch Med, Dept Biochem & Mol Genet, Toon, Japan	Shiga University of Medical Science; Shiga University of Medical Science; Ehime University; Ehime University; Ehime University	Ogita, H (corresponding author), Shiga Univ Med Sci, Div Mol Med Biochem, Dept Biochem & Mol Biol, Otsu, Shiga, Japan.	hogita@belle.shiga-med.ac.jp	Ahmat Amin, Mohammad Khusni Bin/C-7336-2012; Ogita, Hisakazu/AAE-4416-2020	Ahmat Amin, Mohammad Khusni Bin/0000-0002-1948-4071; Ogita, Hisakazu/0000-0001-6750-1668	Japan Society for the Promotion of Science; Uehara Memorial Foundation; Takeda Science Foundation; Naito Foundation; Ichiro Kanehara Foundation	Japan Society for the Promotion of Science(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Uehara Memorial Foundation(Uehara Memorial Foundation); Takeda Science Foundation(Takeda Science Foundation (TSF)); Naito Foundation(Naito Memorial Foundation); Ichiro Kanehara Foundation	We thank Mr. Takefumi Yamamoto, Mr. Akifumi Morinaga, Mr. Akihiro Nishida, Ms. Xiaoling Pang, and Ms. Nor Idayu A. Rahman at Shiga University of Medical Science for their excellent technical assistance in this study. This study was supported by Grants-in-aid for Scientific Research KAKENHI from Japan Society for the Promotion of Science, The Uehara Memorial Foundation, Takeda Science Foundation, The Naito Foundation, and The Ichiro Kanehara Foundation.	Aries IM, 2014, LEUKEMIA, V28, P1828, DOI 10.1038/leu.2014.80; Banyard J, 1998, CANCER METAST REV, V17, P449, DOI 10.1023/A:1006150007710; Ben-Porath I, 1998, GENOMICS, V49, P443, DOI 10.1006/geno.1998.5238; Bid HK, 2013, MOL CANCER THER, V12, P1925, DOI 10.1158/1535-7163.MCT-13-0164; Borsig L, 2014, ONCOGENE, V33, P3217, DOI 10.1038/onc.2013.272; Caudell EG, 2000, BIOCHEMISTRY-US, V39, P13034, DOI 10.1021/bi001250v; Chen J, 2012, ADV CANCER RES, V114, P1, DOI 10.1016/B978-0-12-386503-8.00001-6; Cifuentes FF, 2015, ONCOL LETT, V10, P2142, DOI 10.3892/ol.2015.3522; Creutz CE, 1998, J BIOL CHEM, V273, P1393, DOI 10.1074/jbc.273.3.1393; Detchokul S, 2014, ONCOL REP, V31, P241, DOI 10.3892/or.2013.2823; Fischer M, 2011, CANCER RES, V71, P1520, DOI 10.1158/0008-5472.CAN-10-2817; Fu MY, 2010, CLIN CANCER RES, V16, P3954, DOI 10.1158/1078-0432.CCR-10-0368; Fukumoto Y, 2011, J BIOL CHEM, V286, P43537, DOI 10.1074/jbc.M111.308858; Fumoto S, 2009, CANCER LETT, V274, P25, DOI 10.1016/j.canlet.2008.08.021; Goicoechea SM, 2014, CELL ADHES MIGR, V8, P535, DOI 10.4161/cam.28721; Goubran HA, 2014, CANCER GROWTH METAST, V7, P9, DOI 10.4137/CGM.S11285; Gupta S, 2017, FRONT ONCOL, V7, DOI 10.3389/fonc.2017.00068; Heinrich C, 2010, ONCOGENE, V29, P1598, DOI 10.1038/onc.2009.456; Hirsch FR, 2003, J CLIN ONCOL, V21, P3798, DOI 10.1200/JCO.2003.11.069; Jain A, 2005, P NATL ACAD SCI USA, V102, P11858, DOI 10.1073/pnas.0502113102; Joyce JA, 2009, NAT REV CANCER, V9, P239, DOI 10.1038/nrc2618; Karlou M, 2010, NAT REV UROL, V7, P494, DOI 10.1038/nrurol.2010.134; Lopez-Lago M, 2000, MOL CELL BIOL, V20, P1678, DOI 10.1128/MCB.20.5.1678-1691.2000; Majima T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068134; Martin TA, 2013, TISSUE BARRIERS, V1, DOI 10.4161/tisb.26518; Mbeunkui F, 2009, CANCER CHEMOTH PHARM, V63, P571, DOI 10.1007/s00280-008-0881-9; Mitsuhashi Y, 2012, HISTOPATHOLOGY, V60, P826, DOI 10.1111/j.1365-2559.2011.04158.x; Narumiya S, 1996, J BIOCHEM-TOKYO, V120, P215; Pang XL, 2016, HYPERTENSION, V68, P630, DOI 10.1161/HYPERTENSIONAHA.116.07357; Qin Y, 2017, J NEURO-ONCOL, V134, P29, DOI 10.1007/s11060-017-2507-8; Qin Y, 2014, J BIOL CHEM, V289, P13974, DOI 10.1074/jbc.M113.543728; Rhodes DR, 2004, NEOPLASIA, V6, P1, DOI 10.1016/S1476-5586(04)80047-2; Scott Andrew M, 2012, Cancer Immun, V12, P14; Sleeman JP, 2011, INT J CANCER, V128, P2511, DOI 10.1002/ijc.26027; Sun GG, 2014, TUMOR BIOL, V35, P3185, DOI 10.1007/s13277-013-1416-5; TAYLOR V, 1995, J BIOL CHEM, V270, P28824, DOI 10.1074/jbc.270.48.28824; Thomas G, 2008, NAT GENET, V40, P310, DOI 10.1038/ng.91; Tomsig JL, 2002, CELL MOL LIFE SCI, V59, P1467, DOI 10.1007/s00018-002-8522-7; Uemura H, 2005, MOL CANCER THER, V4, P1699, DOI 10.1158/1535-7163.MCT-04-0295; Voss MA, 2011, BRIT J CANCER, V104, P1611, DOI 10.1038/bjc.2011.80; Wan LL, 2013, NAT MED, V19, P1450, DOI 10.1038/nm.3391; Wang YW, 2017, BBA-REV CANCER, V1868, P199, DOI 10.1016/j.bbcan.2017.04.004; Wang YW, 2014, J UROLOGY, V192, P242, DOI 10.1016/j.juro.2013.12.001; Wang YW, 2005, LAB INVEST, V85, P1392, DOI 10.1038/labinvest.3700335; Whiteside TL, 2008, ONCOGENE, V27, P5904, DOI 10.1038/onc.2008.271; Xue Q, 2013, EXP MOL PATHOL, V95, P313, DOI 10.1016/j.yexmp.2013.07.001; Yang XWH, 2008, CANCER RES, V68, P3204, DOI 10.1158/0008-5472.CAN-07-2949; Yoshida A, 2015, BIOL OPEN, V4, P1063, DOI 10.1242/bio.010918; Zankov DP, 2017, SCI REP-UK, V7, DOI 10.1038/srep39335; Zarzynska JM, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/141747	50	31	31	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 4	2018	37	40					5416	5434		10.1038/s41388-018-0286-0	http://dx.doi.org/10.1038/s41388-018-0286-0			19	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GV7MY	29867202	hybrid, Green Published			2022-12-17	WOS:000446312900004
J	Liao, CP; Lin, TP; Li, PC; Geary, LA; Chen, K; Vaikari, VP; Wu, JB; Lin, CH; Gross, ME; Shih, JC				Liao, Chun-Peng; Lin, Tzu-Ping; Li, Pei-Chuan; Geary, Lauren A.; Chen, Kevin; Vaikari, Vijaya Pooja; Wu, Jason Boyang; Lin, Chi-Hung; Gross, Mitchell E.; Shih, Jean C.			Loss of MAOA in epithelia inhibits adenocarcinoma development, cell proliferation and cancer stem cells in prostate	ONCOGENE			English	Article							MONOAMINE-OXIDASE-A; PTEN; MICE; IDENTIFICATION; TUMORIGENESIS; MAINTENANCE; PROGRESSION; FIBROBLASTS; HIF-1-ALPHA; GENERATION	Monoamine oxidase A (MAOA) is a mitochondrial enzyme, which degrades monoamine neurotransmitters and dietary amines and produces H2O2. Recent studies have shown increased MAOA expression in prostate cancer (PCa), glioma, and classical Hodgkin lymphoma. However, the biological function of MAOA in cancer development remains unknown. In this study, we investigated the role of MAOA in the development of prostate adenocarcinoma by creating a prostate-specific Pten/MAOA knockout (KO) mouse model, in which MAOA-floxP mouse was crossed with the conditional Pten KO PCa mouse that develops invasive PCa. In contrast to Pten KO mice, age-matched Pten/MAOA KO mice exhibited a significant decrease in both prostate size and the incidence of invasive cancer. We observed a significant decline in AKT phosphorylation and Ki67 expression in Pten/MAOA KO mice, which reduced epithelial cell growth and proliferation. As cancer stem cells (CSCs) are required for tumor initiation and growth, we investigated expression of OCT4 and NANOG in the setting of decreased MAOA expression. We found that both OCT4 and NANOG were significantly attenuated in the prostate epithelia of Pten/MAOA KO mice compared to Pten KO mice, which was confirmed with targeted knockdown of MAOA with a short-hairpin(sh) vector targeting MAOA compared to cells transfected with a control vector. Expression of other markers associated with the a stem cell phenotype, including CD44, alpha 2 beta 1, and CD133 as well as HIF-1 alpha(+)CD44(+) stem cells were all decreased in shMAOA PCa cells compared with empty vector-transfected control cells. We also found spheroid formation ability in PCa cells was decreased when endogenous MAOA was suppressed by siRNA or MAOA inhibitor clorgyline in a colony formation assay. Using the TCGA database, elevatedMAOA expression was associated with reduced Pten levels in high Gleason grade in patient samples. Further, we found that Pten-positive PCa cells were more resistant to clorgyline treatments than Pten-null cells in tumorigenicity and stemness. Taken together, these studies suggest that MAOA expression promotes PCa development by increasing cell proliferation and CSCs and highlights the potential use of MAOA inhibitors for the treatment of PCa.	[Liao, Chun-Peng; Lin, Tzu-Ping; Li, Pei-Chuan; Geary, Lauren A.; Chen, Kevin; Vaikari, Vijaya Pooja; Shih, Jean C.] Univ Southern Calif, Sch Pharm, Dept Pharmacol & Pharmaceut Sci, Los Angeles, CA 90089 USA; [Liao, Chun-Peng; Lin, Tzu-Ping; Li, Pei-Chuan; Geary, Lauren A.; Chen, Kevin; Vaikari, Vijaya Pooja; Shih, Jean C.] USC, Taiwan Ctr Translat Res, Los Angeles, CA 90089 USA; [Liao, Chun-Peng; Gross, Mitchell E.] Univ Southern Calif, Keck Sch Med, Lawrence J Ellison Inst Transformat Med, Los Angeles, CA 90033 USA; [Lin, Tzu-Ping; Lin, Chi-Hung] Natl Yang Ming Univ, Sch Med, Inst Clin Med, Taipei 11221, WA, Taiwan; [Wu, Jason Boyang] Washington State Univ, Coll Pharm, Dept Pharmaceut Sci, Spokane, WA 99210 USA; [Gross, Mitchell E.; Shih, Jean C.] Univ Southern Calif, Keck Sch Med, Norris Comprehens Canc Ctr, Los Angeles, CA 90089 USA; [Shih, Jean C.] Univ Southern Calif, Keck Sch Med, Dept Cell & Neurobiol, Los Angeles, CA 90089 USA; [Shih, Jean C.] Taipei Med Univ, Coll Pharm, Taipei 11031, Taiwan	University of Southern California; University of Southern California; University of Southern California; National Yang Ming Chiao Tung University; Washington State University; University of Southern California; University of Southern California; Taipei Medical University	Shih, JC (corresponding author), Univ Southern Calif, Sch Pharm, Dept Pharmacol & Pharmaceut Sci, Los Angeles, CA 90089 USA.; Shih, JC (corresponding author), USC, Taiwan Ctr Translat Res, Los Angeles, CA 90089 USA.; Shih, JC (corresponding author), Univ Southern Calif, Keck Sch Med, Norris Comprehens Canc Ctr, Los Angeles, CA 90089 USA.; Shih, JC (corresponding author), Univ Southern Calif, Keck Sch Med, Dept Cell & Neurobiol, Los Angeles, CA 90089 USA.; Shih, JC (corresponding author), Taipei Med Univ, Coll Pharm, Taipei 11031, Taiwan.	jcshih@usc.edu	Vaikari, Vijaya/GRR-4324-2022; Vaikari, Vijaya/ABH-2110-2021; Chen, Kevin/GYU-8963-2022	Vaikari, Vijaya/0000-0001-9175-3558; Liao, Chun-Peng/0000-0001-8920-4322	Department of Defense Prostate Cancer Research Program [W81XWH-12-1-0282]; Daniel Tsai Family Fund; Boyd and Elsie Welin Professorship	Department of Defense Prostate Cancer Research Program(United States Department of Defense); Daniel Tsai Family Fund; Boyd and Elsie Welin Professorship	This work was supported by the Department of Defense Prostate Cancer Research Program grant W81XWH-12-1-0282, the Daniel Tsai Family Fund, and the Boyd and Elsie Welin Professorship (to JCS). The content is solely the responsibility of the authors and does not necessarily represent the official views of the Department of Defense or other funding agency.	Abeshouse A, 2015, CELL, V163, P1011, DOI 10.1016/j.cell.2015.10.025; Adisetiyo H, 2014, J CELL PHYSIOL, V229, P1170, DOI 10.1002/jcp.24546; Adisetiyo H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069484; Al-Hajj M, 2004, CURR OPIN GENET DEV, V14, P43, DOI 10.1016/j.gde.2003.11.007; Alimonti A, 2010, NAT GENET, V42, P454, DOI 10.1038/ng.556; BACH AWJ, 1988, P NATL ACAD SCI USA, V85, P4934, DOI 10.1073/pnas.85.13.4934; Bortolato M, 2011, NEUROPSYCHOPHARMACOL, V36, P2674, DOI 10.1038/npp.2011.157; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chalhoub N, 2009, ANNU REV PATHOL-MECH, V4, P127, DOI 10.1146/annurev.pathol.4.110807.092311; Collins AT, 2005, CANCER RES, V65, P10946, DOI 10.1158/0008-5472.CAN-05-2018; Dawood S, 2014, ONCOLOGY-NY, V28, P1101; Dillon LM, 2014, CURR DRUG TARGETS, V15, P65, DOI 10.2174/1389450114666140106100909; Dubrovska A, 2009, P NATL ACAD SCI USA, V106, P268, DOI 10.1073/pnas.0810956106; Epstein JI, 2016, EUR UROL, V69, P428, DOI 10.1016/j.eururo.2015.06.046; Forristal CE, 2015, LEUKEMIA, V29, P1366, DOI 10.1038/leu.2015.8; Fu Y, 2008, P NATL ACAD SCI USA, V105, P19444, DOI 10.1073/pnas.0807691105; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Goldstein AS, 2010, SCIENCE, V329, P568, DOI 10.1126/science.1189992; GOTTOWIK J, 1993, FEBS LETT, V317, P152, DOI 10.1016/0014-5793(93)81512-X; Gu GY, 2007, CANCER RES, V67, P4807, DOI 10.1158/0008-5472.CAN-06-4608; Kushal S, 2016, ONCOTARGET, V7, P13842, DOI 10.18632/oncotarget.7283; Lawson DA, 2005, COLD SH Q B, V70, P187, DOI 10.1101/sqb.2005.70.003; Leong KG, 2008, NATURE, V456, P804, DOI 10.1038/nature07427; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Li PC, 2017, J PATHOL, V243, P220, DOI 10.1002/path.4944; Liao CP, 2007, CANCER RES, V67, P7525, DOI 10.1158/0008-5472.CAN-07-0668; Liao Chun-Peng, 2010, Hormones & Cancer, V1, P297, DOI 10.1007/s12672-010-0051-5; Liao CP, 2010, CANCER RES, V70, P7294, DOI 10.1158/0008-5472.CAN-09-3982; Ma JC, 2002, J BIOCHEM, V131, P107, DOI 10.1093/oxfordjournals.jbchem.a003064; Nikitin AY, 2007, HISTOL HISTOPATHOL, V22, P1043, DOI 10.14670/HH-22.1043; Oliveira DSM, 2016, BOSNIAN J BASIC MED, V16, P8, DOI 10.17305/bjbms.2016.917; Peehl DM, 2008, J UROLOGY, V180, P2206, DOI 10.1016/j.juro.2008.07.019; Pfeiffer MJ, 2010, EUR UROL, V57, P246, DOI 10.1016/j.eururo.2009.01.015; Sahlberg SH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094621; Shih JC, 1999, ANNU REV NEUROSCI, V22, P197, DOI 10.1146/annurev.neuro.22.1.197; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; Singh C, 2013, P NATL ACAD SCI USA, V110, P12816, DOI 10.1073/pnas.1308037110; Sun H, 1999, P NATL ACAD SCI USA, V96, P6199, DOI 10.1073/pnas.96.11.6199; Takubo K, 2010, CELL STEM CELL, V7, P391, DOI 10.1016/j.stem.2010.06.020; Tan BT, 2006, LAB INVEST, V86, P1203, DOI 10.1038/labinvest.3700488; Ting MC, 2012, DIS MODEL MECH, V5, P366, DOI 10.1242/dmm.008458; True L, 2006, P NATL ACAD SCI USA, V103, P10991, DOI 10.1073/pnas.0603678103; Tuominen VJ, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2615; van den Berg DLC, 2010, CELL STEM CELL, V6, P369, DOI 10.1016/j.stem.2010.02.014; Vlietstra RJ, 1998, CANCER RES, V58, P2720; Wang SY, 2003, CANCER CELL, V4, P209, DOI 10.1016/S1535-6108(03)00215-0; Wu JB, 2015, J AM CHEM SOC, V137, P2366, DOI 10.1021/ja512613j; Wu JB, 2014, J CLIN INVEST, V124, P2891, DOI 10.1172/JCI70982; Wu XT, 2001, MECH DEVELOP, V101, P61, DOI 10.1016/S0925-4773(00)00551-7; Xu S, 2015, BRIT J CANCER, V113, P242, DOI 10.1038/bjc.2015.228	50	31	32	2	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 20	2018	37	38					5175	5190		10.1038/s41388-018-0325-x	http://dx.doi.org/10.1038/s41388-018-0325-x			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GU2IP	29844571	Green Accepted			2022-12-17	WOS:000445093100003
J	Li, D; Chen, YJ; Mei, H; Jiao, WJ; Song, HJ; Ye, L; Fang, EH; Wang, XJ; Yang, F; Huang, K; Zheng, LD; Tong, QS				Li, Dan; Chen, Yajun; Mei, Hong; Jiao, Wanju; Song, Huajie; Ye, Lin; Fang, Erhu; Wang, Xiaojing; Yang, Feng; Huang, Kai; Zheng, Liduan; Tong, Qiangsong			Ets-1 promoter-associated noncoding RNA regulates the NONO/ERG/Ets-1 axis to drive gastric cancer progression	ONCOGENE			English	Article							TRANSCRIPTION FACTOR; NEUROBLASTOMA-CELLS; TUMOR-SUPPRESSOR; MESSENGER-RNA; PROTEIN NONO; METASTASIS; EXPRESSION; ANGIOGENESIS; INVASION; GENE	Emerging studies have indicated the essential functions of long noncoding RNAs (lncRNAs) during cancer progression. However, whether lncRNAs contribute to the upregulation of v-ets erythroblastosis virus E26 oncogene homolog 1 (Ets-1), an established oncogenic protein facilitating tumor invasion and metastasis, in gastric cancer remains elusive. Herein, we identified Ets-1 promoter-associated noncoding RNA (pancEts-1) as a novel lncRNA associated with the gastric cancer progression via mining of publicly available datasets and rapid amplification of cDNA ends. RNA pull-down, RNA immunoprecipitation, in vitro binding, and RNA electrophoretic mobility shift assays indicated the binding of pancEts-1 to non-POU domain containing octamer binding (NONO) protein. Mechanistically, pancEts-1 facilitated the physical interaction between NONO and Ets related gene (ERG), resulting in increased ERG transactivation and transcription of Ets-1 associated with gastric cancer progression. In addition, pancEts-1 facilitated the growth and aggressiveness of gastric cancer cells via interacting with NONO. In gastric cancer tissues, pancEts-1, NONO, and ERG were upregulated and significantly correlated with Ets-1 levels. High levels of pancEts-1, NONO, ERG, or Ets-1 were respectively associated with poor survival of gastric cancer patients, whereas simultaneous expression of all of them (HR = 3.012, P = 0.105) was not an independent prognostic factor for predicting clinical outcome. Overall, these results demonstrate that lncRNA pancEts-1 exhibits oncogenic properties that drive the progression of gastric cancer via regulating the NONO/ERG/Ets-1 axis.	[Li, Dan; Mei, Hong; Song, Huajie; Ye, Lin; Fang, Erhu; Wang, Xiaojing; Yang, Feng; Tong, Qiangsong] Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Dept Surg, 1277 Jiefang Ave, Wuhan 430022, Hubei, Peoples R China; [Chen, Yajun; Jiao, Wanju; Zheng, Liduan] Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Dept Pathol, 1277 Jiefang Ave, Wuhan 430022, Hubei, Peoples R China; [Huang, Kai; Zheng, Liduan; Tong, Qiangsong] Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Clin Ctr Human Genom Res, 1277 Jiefang Ave, Wuhan 430022, Hubei, Peoples R China	Huazhong University of Science & Technology; Huazhong University of Science & Technology; Huazhong University of Science & Technology	Tong, QS (corresponding author), Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Dept Surg, 1277 Jiefang Ave, Wuhan 430022, Hubei, Peoples R China.; Zheng, LD (corresponding author), Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Dept Pathol, 1277 Jiefang Ave, Wuhan 430022, Hubei, Peoples R China.; Zheng, LD; Tong, QS (corresponding author), Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Clin Ctr Human Genom Res, 1277 Jiefang Ave, Wuhan 430022, Hubei, Peoples R China.	ld_zheng@hotmail.com; qs_tong@hotmail.com	Tong, Qiangsong/B-4500-2014	Tong, Qiangsong/0000-0002-2615-6404; Zheng, Liduan/0000-0001-5566-673X	National Natural Science Foundation of China [81772967, 81773094, 81672500, 81572423, 81402408, 81402301, 81472363, 81372667, 81272779]; Natural Science Foundation of Hubei Province [2014CFA012]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Hubei Province(Natural Science Foundation of Hubei Province)	We appreciate Dr. Jean-Yves Masson for construct gifts. This work was granted by National Natural Science Foundation of China (81772967, 81773094, 81672500, 81572423, 81402408, 81402301, 81472363, 81372667, 81272779), and Natural Science Foundation of Hubei Province (2014CFA012).	Adamo P, 2016, ONCOGENE, V35, P403, DOI 10.1038/onc.2015.109; Behrens P, 2001, J PATHOL, V194, P43, DOI 10.1002/path.844; CHEN JH, 1993, ONCOGENE, V8, P133; Chen ZR, 2016, J CLIN INVEST, V126, P2267, DOI 10.1172/JCI85250; CHUMAKOV AM, 1993, J VIROL, V67, P2421, DOI 10.1128/JVI.67.4.2421-2425.1993; Davidson B, 2001, CLIN CANCER RES, V7, P551; Dittmer J, 2015, SEMIN CANCER BIOL, V35, P20, DOI 10.1016/j.semcancer.2015.09.010; Dong XS, 2007, MOL CELL BIOL, V27, P4863, DOI 10.1128/MCB.02144-06; Dong XS, 2009, MOL ENDOCRINOL, V23, P1147, DOI 10.1210/me.2008-0357; Duraes C, 2014, VIRCHOWS ARCH, V464, P367, DOI 10.1007/s00428-013-1533-y; Fujimoto J, 2002, ANN ONCOL, V13, P1598, DOI 10.1093/annonc/mdf248; Gu CH, 2010, GENOMICS, V95, P278, DOI 10.1016/j.ygeno.2010.02.005; Gupta S, 2010, CANCER RES, V70, P6735, DOI 10.1158/0008-5472.CAN-10-0244; Hallier M, 1996, J BIOL CHEM, V271, P11177, DOI 10.1074/jbc.271.19.11177; HART AH, 1995, ONCOGENE, V10, P1423; Ishiguro H, 2003, INT J CANCER, V105, P26, DOI 10.1002/ijc.11021; Jiang GS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031379; Kabbout M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100693; Kitange G, 2000, CANCER, V89, P2292, DOI 10.1002/1097-0142(20001201)89:11<2292::AID-CNCR18>3.0.CO;2-0; Krietsch J, 2012, NUCLEIC ACIDS RES, V40, P10287, DOI 10.1093/nar/gks798; Leshem O, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021650; Li D, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0320-6; Li D, 2013, ONCOTARGET, V4, P2021, DOI 10.18632/oncotarget.1579; Li Y, 2017, CANCER LETT, V395, P31, DOI 10.1016/j.canlet.2017.02.035; Liu PY, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/dju113; Liu YY, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-02254-6; Mathur M, 2001, MOL CELL BIOL, V21, P2298, DOI 10.1128/MCB.21.7.2298-2311.2001; McLaughlin F, 2001, BLOOD, V98, P3332, DOI 10.1182/blood.V98.12.3332; Meadows SM, 2011, SEMIN CELL DEV BIOL, V22, P976, DOI 10.1016/j.semcdb.2011.09.009; Michel AM, 2014, NUCLEIC ACIDS RES, V42, pD859, DOI 10.1093/nar/gkt1035; Naito S, 2002, BIOCHEM BIOPH RES CO, V291, P130, DOI 10.1006/bbrc.2002.6418; Pham DH, 2017, HUM MOL GENET, V26, P2042, DOI 10.1093/hmg/ddx094; Schiffnery S, 2011, CARCINOGENESIS, V32, P1176, DOI 10.1093/carcin/bgr103; Shav-Tal Y, 2002, FEBS LETT, V531, P109, DOI 10.1016/S0014-5793(02)03447-6; Singh AK, 2011, J BIOL CHEM, V286, P21961, DOI 10.1074/jbc.M111.238238; Szasz AM, 2016, ONCOTARGET, V7, P49322, DOI 10.18632/oncotarget.10337; Takai N, 2002, INT J MOL MED, V9, P287; Terry MB, 2002, SEMIN RADIAT ONCOL, V12, P111, DOI 10.1053/srao.30814; Tokuhara K, 2003, INT SURG, V88, P25; Tsofack SP, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-145; Wang L, 2013, NUCLEIC ACIDS RES, V41, DOI 10.1093/nar/gkt006; Wang ZQ, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.143; Wei JR, 2014, CANCER CELL INT, V14, DOI 10.1186/1475-2867-14-22; Xiang X, 2015, CANCER LETT, V359, P187, DOI 10.1016/j.canlet.2015.01.008; Xu TP, 2014, J HEMATOL ONCOL, V7, DOI 10.1186/s13045-014-0063-7; Yadav SP, 2014, HUM MOL GENET, V23, P2132, DOI 10.1093/hmg/ddt609; Yamaguchi E, 2007, TOHOKU J EXP MED, V213, P41, DOI 10.1620/tjem.213.41; Yamauchi T, 2012, BIOCHEM BIOPH RES CO, V425, P711, DOI 10.1016/j.bbrc.2012.07.103; Yang P, 2016, ONCOTARGET, V7, P42183, DOI 10.18632/oncotarget.9741; Zhang H, 2014, ONCOGENE, V33, P387, DOI 10.1038/onc.2012.574; Zhang HY, 2012, MOL CANCER THER, V11, P1454, DOI 10.1158/1535-7163.MCT-12-0001; Zhang Y, 2011, CANCER RES, V71, P3552, DOI 10.1158/0008-5472.CAN-10-2435; Zhao X, 2016, ONCOGENE, V35, P3565, DOI 10.1038/onc.2015.422; Zheng LD, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.293; Zheng LD, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055719; Zheng LD, 2013, MOL CANCER RES, V11, P182, DOI 10.1158/1541-7786.MCR-12-0534; Zheng LD, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-74; Zheng LD, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-33	58	31	33	3	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 30	2018	37	35					4871	4886		10.1038/s41388-018-0302-4	http://dx.doi.org/10.1038/s41388-018-0302-4			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GS0BA	29773901	hybrid, Green Published			2022-12-17	WOS:000443146000008
J	Reyes-Uribe, P; Adrianzen-Ruesta, MP; Deng, Z; Echevarria-Vargas, I; Mender, I; Saheb, S; Liu, Q; Altieri, DC; Murphy, ME; Shay, JW; Lieberman, PM; Villanueva, J				Reyes-Uribe, Patricia; Adrianzen-Ruesta, Maria Paz; Deng, Zhong; Echevarria-Vargas, Ileabett; Mender, Ilgen; Saheb, Steven; Liu, Qin; Altieri, Dario C.; Murphy, Maureen E.; Shay, Jerry W.; Lieberman, Paul M.; Villanueva, Jessie			Exploiting TERT dependency as a therapeutic strategy for NRAS-mutant melanoma	ONCOGENE			English	Article							TELOMERASE REVERSE-TRANSCRIPTASE; INHIBITOR IMETELSTAT; DNA-DAMAGE; PROMOTER MUTATIONS; RESISTANCE; CANCER; CELLS; INDUCTION; ACTIVATION; PATHWAYS	Targeting RAS is one of the greatest challenges in cancer therapy. Oncogenic mutations in NRAS are present in over 25% of melanomas and patients whose tumors harbor NRAS mutations have limited therapeutic options and poor prognosis. Thus far, there are no clinical agents available to effectively target NRAS or any other RAS oncogene. An alternative approach is to identify and target critical tumor vulnerabilities or non-oncogene addictions that are essential for tumor survival. We investigated the consequences of NRAS blockade in NRAS-mutant melanoma and show that decreased expression of the telomerase catalytic subunit, TERT, is a major consequence. TERT silencing or treatment of NRAS-mutant melanoma with the telomerase-dependent telomere uncapping agent, 6-thio-2'-deoxyguanosine (6-thio-dG), led to rapid cell death, along with evidence of both telomeric and non-telomeric DNA damage, increased ROS levels, and upregulation of a mitochondrial antioxidant adaptive response. Combining 6-thio-dG with the mitochondrial inhibitor Gamitrinib attenuated this adaptive response and more effectively suppressed NRAS-mutant melanoma. Our study uncovers a robust dependency of NRAS-mutant melanoma on TERT, and provides proof-of-principle for a new combination strategy to combat this class of tumors, which could be expanded to other tumor types.	[Reyes-Uribe, Patricia; Adrianzen-Ruesta, Maria Paz; Echevarria-Vargas, Ileabett; Saheb, Steven; Liu, Qin; Murphy, Maureen E.; Villanueva, Jessie] Wistar Inst Anat & Biol, Mol & Cellular Oncogenesis Program, 3601 Spruce St, Philadelphia, PA 19104 USA; [Deng, Zhong; Lieberman, Paul M.] Wistar Inst Anat & Biol, Gene Express & Regulat Program, 3601 Spruce St, Philadelphia, PA 19104 USA; [Mender, Ilgen; Shay, Jerry W.] Univ Texas Southwestern Med Ctr Dallas, Dept Cell Biol, Dallas, TX 75390 USA; [Altieri, Dario C.] Wistar Inst Anat & Biol, Immunol Microenvironm & Metastasis Program, 3601 Spruce St, Philadelphia, PA 19104 USA; [Villanueva, Jessie] Wistar Inst Anat & Biol, Melanoma Res Ctr, 3601 Spruce St, Philadelphia, PA 19104 USA	The Wistar Institute; The Wistar Institute; University of Texas System; University of Texas Southwestern Medical Center Dallas; The Wistar Institute; The Wistar Institute	Villanueva, J (corresponding author), Wistar Inst Anat & Biol, Mol & Cellular Oncogenesis Program, 3601 Spruce St, Philadelphia, PA 19104 USA.; Villanueva, J (corresponding author), Wistar Inst Anat & Biol, Melanoma Res Ctr, 3601 Spruce St, Philadelphia, PA 19104 USA.	jvillanueva@wistar.org		Liu, Qin/0000-0001-9964-580X; MENDER, ILGEN/0000-0002-7552-2618	NIH [R01CA215733, K01CA175269, P01CA114046, P50CA174523]; American Cancer Society; V Foundation for Cancer Research; Melanoma Research Alliance; Melanoma Research Foundation; Martha Rogers Trust; NCI NRSA Cancer Biology Training Grant [T32 CA009171]; Worldwide Cancer Research [15-0338]; Pennsylvania Department of Health; Cancer Center Support Grant (CCSG) [P30CA010815]; NATIONAL CANCER INSTITUTE [P01CA025874, R35CA220446, R01CA215733, P30CA010815, R01CA139319, P50CA174523, R01CA140652, K01CA175269, P01CA140043, T32CA009171, P01CA114046] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Cancer Society(American Cancer Society); V Foundation for Cancer Research; Melanoma Research Alliance; Melanoma Research Foundation; Martha Rogers Trust; NCI NRSA Cancer Biology Training Grant; Worldwide Cancer Research; Pennsylvania Department of Health; Cancer Center Support Grant (CCSG); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Work in our laboratory is supported by NIH grants R01CA215733, K01CA175269, P01CA114046, P50CA174523, the American Cancer Society, the V Foundation for Cancer Research, the Melanoma Research Alliance, the Melanoma Research Foundation, and the Martha Rogers Trust. IEV was supported by NCI NRSA T32 CA009171 Cancer Biology Training Grant to the Wistar Institute, and Z.D. is supported by Worldwide Cancer Research (15-0338). This project was funded, in part, under a grant with the Pennsylvania Department of Health. The Department specifically disclaims responsibility for any analyses, interpretations or conclusions. Support for shared resources utilized in this study was provided by Cancer Center Support Grant (CCSG) P30CA010815 to the Wistar Institute.	Artandi SE, 2010, CARCINOGENESIS, V31, P9, DOI 10.1093/carcin/bgp268; Baerlocher GM, 2015, NEW ENGL J MED, V373, P920, DOI 10.1056/NEJMoa1503479; Bagheri S, 2006, P NATL ACAD SCI USA, V103, P11306, DOI 10.1073/pnas.0510085103; Bryan C, 2015, STRUCTURE, V23, P1934, DOI 10.1016/j.str.2015.08.006; Ceccarelli M, 2016, CELL, V164, P550, DOI 10.1016/j.cell.2015.12.028; Chae YC, 2012, CANCER CELL, V22, P331, DOI 10.1016/j.ccr.2012.07.015; Chiba K, 2017, SCIENCE, V357, P1416, DOI 10.1126/science.aao0535; Choi JK, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.0040010; Damm K, 2001, EMBO J, V20, P6958, DOI 10.1093/emboj/20.24.6958; Easty DJ, 2011, PIGM CELL MELANOMA R, V24, P446, DOI 10.1111/j.1755-148X.2011.00836.x; Fleisig HB, 2016, ONCOGENE, V35, P218, DOI 10.1038/onc.2015.75; Garcia-Beccaria M, 2015, EMBO MOL MED, V7, P930, DOI 10.15252/emmm.201404497; Greider CW, 1998, P NATL ACAD SCI USA, V95, P90, DOI 10.1073/pnas.95.1.90; Griewank KG, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/dju246; Gupta R, 2014, P NATL ACAD SCI USA, V111, pE3062, DOI 10.1073/pnas.1411370111; Haq R, 2013, CANCER CELL, V23, P302, DOI 10.1016/j.ccr.2013.02.003; Hayward NK, 2017, NATURE, V545, P175, DOI 10.1038/nature22071; Santos JH, 2006, HUM MOL GENET, V15, P1757, DOI 10.1093/hmg/ddl098; Hodis E, 2012, CELL, V150, P251, DOI 10.1016/j.cell.2012.06.024; Horn S, 2013, SCIENCE, V339, P959, DOI 10.1126/science.1230062; Hrdlickova R, 2012, MOL CELL BIOL, V32, P4283, DOI 10.1128/MCB.00550-12; Hu J, 2012, CELL, V148, P651, DOI 10.1016/j.cell.2011.12.028; Huang FW, 2013, SCIENCE, V339, P957, DOI 10.1126/science.1229259; Indran IR, 2011, CANCER RES, V71, P266, DOI 10.1158/0008-5472.CAN-10-1588; Jafri MA, 2016, GENOME MED, V8, DOI 10.1186/s13073-016-0324-x; Jakob JA, 2012, CANCER-AM CANCER SOC, V118, P4014, DOI 10.1002/cncr.26724; Johnson DB, 2015, CURR TREAT OPTION ON, V16, DOI 10.1007/s11864-015-0330-z; Johnson DB, 2014, CLIN CANCER RES, V20, P4186, DOI 10.1158/1078-0432.CCR-13-3270; Joseph I, 2010, CANCER RES, V70, P9494, DOI 10.1158/0008-5472.CAN-10-0233; Kang BH, 2010, CLIN CANCER RES, V16, P4779, DOI 10.1158/1078-0432.CCR-10-1818; Koh CM, 2015, J CLIN INVEST, V125, P2109, DOI 10.1172/JCI79134; Kops GJPL, 2002, NATURE, V419, P316, DOI 10.1038/nature01036; Kovalenko OA, 2010, AGING CELL, V9, P203, DOI 10.1111/j.1474-9726.2010.00551.x; Li YH, 2016, P NATL ACAD SCI USA, V113, P14402, DOI 10.1073/pnas.1611106113; Li YH, 2014, CANCER RES, V74, P1639, DOI 10.1158/0008-5472.CAN-13-3568; Listerman I, 2013, CANCER RES, V73, P2817, DOI 10.1158/0008-5472.CAN-12-3082; Maertens O, 2013, CANCER DISCOV, V3, P338, DOI 10.1158/2159-8290.CD-12-0313; Martinez P, 2011, NAT REV CANCER, V11, P161, DOI 10.1038/nrc3025; Masutomi K, 2005, P NATL ACAD SCI USA, V102, P8222, DOI 10.1073/pnas.0503095102; Mender I, 2015, BIO PROTOC, V5; Mender I, 2015, CANCER DISCOV, V5, P82, DOI 10.1158/2159-8290.CD-14-0609; Nazarian R, 2010, NATURE, V468, P973, DOI 10.1038/nature09626; Nissan MH, 2014, CANCER RES, V74, P2340, DOI 10.1158/0008-5472.CAN-13-2625; Nosrati M, 2004, CLIN CANCER RES, V10, P4983, DOI 10.1158/1078-0432.CCR-04-0134; Olmos Y, 2009, J BIOL CHEM, V284, P14476, DOI 10.1074/jbc.M807397200; Postow MA, 2017, LANCET ONCOL, V18, P414, DOI 10.1016/S1470-2045(17)30172-9; Puri N, 2004, FASEB J, V18, P1373, DOI 10.1096/fj.04-1774com; Queisser A, 2013, CANCER GENET-NY, V206, P374, DOI 10.1016/j.cancergen.2013.10.001; Roesch A, 2013, CANCER CELL, V23, P811, DOI 10.1016/j.ccr.2013.05.003; Sarin KY, 2005, NATURE, V436, P1048, DOI 10.1038/nature03836; Sharma NK, 2012, NUCLEIC ACIDS RES, V40, P712, DOI 10.1093/nar/gkr758; Shay JW, 2016, CANCER DISCOV, V6, P584, DOI 10.1158/2159-8290.CD-16-0062; Shin KH, 2004, CLIN CANCER RES, V10, P2551, DOI 10.1158/1078-0432.CCR-0669-3; Siegelin MD, 2011, J CLIN INVEST, V121, P1349, DOI 10.1172/JCI44855; Smith LL, 2003, NAT CELL BIOL, V5, P474, DOI 10.1038/ncb985; Tefferi A, 2015, NEW ENGL J MED, V373, P908, DOI 10.1056/NEJMoa1310523; Vallarelli AF, 2016, ONCOTARGET, V7, P53127, DOI 10.18632/oncotarget.10634; Van Allen EM, 2014, CANCER DISCOV, V4, P94, DOI 10.1158/2159-8290.CD-13-0617; Viceconte N, 2017, CELL REP, V19, P2529, DOI 10.1016/j.celrep.2017.05.046; Villanueva J, 2010, CANCER CELL, V18, P683, DOI 10.1016/j.ccr.2010.11.023; Wong DJL, 2016, CANCER TREAT RES, V167, P251, DOI 10.1007/978-3-319-22539-5_10; Zhang G, 2016, J CLIN INVEST, V126, P1834, DOI 10.1172/JCI82661	62	31	32	3	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 26	2018	37	30					4058	4072		10.1038/s41388-018-0247-7	http://dx.doi.org/10.1038/s41388-018-0247-7			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GO2YI	29695835	Green Published, hybrid, Green Accepted			2022-12-17	WOS:000439847000002
J	Blanchette-Farra, N; Kita, D; Konstorum, A; Tesfay, L; Lemler, D; Hegde, P; Claffey, KP; Torti, FM; Torti, SV				Blanchette-Farra, Nicole; Kita, Daniel; Konstorum, Anna; Tesfay, Lia; Lemler, David; Hegde, Poornima; Claffey, Kevin P.; Torti, Frank M.; Torti, Suzy V.			Contribution of three-dimensional architecture and tumor-associated fibroblasts to hepcidin regulation in breast cancer	ONCOGENE			English	Article							GENE-EXPRESSION PATTERNS; TGF-BETA SUPERFAMILY; TRANSFERRIN RECEPTOR; EPITHELIAL-CELLS; IRON-METABOLISM; MOLECULAR PORTRAITS; ACTIVATION; PROTEIN; GROWTH; STAT3	Hepcidin is a peptide hormone that negatively regulates iron efflux and plays an important role in controlling the growth of breast tumors. In patients with breast cancer, the combined expression of hepcidin and its membrane target, ferroportin, predict disease outcome. However, mechanisms that control hepcidin expression in breast cancer cells remain largely unknown. Here, we use three-dimensional breast cancer spheroids derived from cell lines and breast cancer patients to probe mechanisms of hepcidin regulation in breast cancer. We observe that the extent of hepcidin induction and pathways of its regulation are markedly changed in breast cancer cells grown in three dimensions. In monolayer culture, BMPs, particularly BMP6, regulate hepcidin transcription. When breast cancer cells are grown as spheroids, there is a > 10-fold induction in hepcidin transcripts. Microarray analysis combined with knockdown experiments reveal that GDF-15 is the primary mediator of this change. The increase in hepcidin as breast cells develop a three-dimensional architecture increases intracellular iron, as indicated by an increase in the iron storage protein ferritin. Immunohistochemical staining of human breast tumors confirms that both GDF-15 and hepcidin are expressed in breast cancer specimens. Further, levels of GDF-15 are significantly correlated with levels of hepcidin at both the mRNA and protein level in patient samples, consistent with a role for GDF-15 in control of hepcidin in human breast tumors. Inclusion of tumor-associated fibroblasts in breast cancer spheroids further induces hepcidin. This induction is mediated by fibroblast-dependent secretion of IL-6. Breast cancer cells grown as spheroids are uniquely receptive to IL-6-dependent induction of hepcidin by tumor-associated fibroblasts, since IL6 does not induce hepcidin in cells grown as monolayers. Collectively, our results suggest a new paradigm for tumormediated control of iron through the control of hepcidin by tumor architecture and the breast tumor microenvironment.	[Blanchette-Farra, Nicole; Tesfay, Lia; Lemler, David; Torti, Suzy V.] Univ Connecticut, Hlth Ctr, Dept Mol Biol & Biophys, Farmington, CT 06030 USA; [Kita, Daniel; Claffey, Kevin P.] Univ Connecticut, Hlth Ctr, Dept Cell Biol, Farmington, CT 06030 USA; [Konstorum, Anna] Univ Connecticut, Hlth Ctr, Ctr Quantitat Med, Farmington, CT 06030 USA; [Hegde, Poornima] Univ Connecticut, Hlth Ctr, Dept Pathol, Farmington, CT USA; [Torti, Frank M.] Univ Connecticut, Hlth Ctr, Dept Med, Farmington, CT USA; [Kita, Daniel] Alex Pharmaceut, New Haven, CT USA; [Lemler, David] North Carolina State Univ, Dept Mol Biomed Sci, Raleigh, NC USA	University of Connecticut; University of Connecticut; University of Connecticut; University of Connecticut; University of Connecticut; University of North Carolina; North Carolina State University	Torti, SV (corresponding author), Univ Connecticut, Hlth Ctr, Dept Mol Biol & Biophys, Farmington, CT 06030 USA.	storti@uchc.edu	Lemler, David/GZG-4253-2022		NCI [R01CA188025, R01CA171101, F32CA214030]; NATIONAL CANCER INSTITUTE [F32CA214030, R01CA188025, R01CA171101] Funding Source: NIH RePORTER	NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported in part by NCI R01CA188025 (SVT), NCI R01CA171101 (FMT), and NCI F32CA214030 (AK). We thank Li Chen and Drs. Nathaniel Dyment and David Rowe for assistance in image acquisition, Tara L Arvedson (Amgen, Thousand Oaks, CA) for a generous gift of anti-ferroportin antibody and Xiaohong Wang for her assistance in histological sectioning.	Abboud S, 2000, J BIOL CHEM, V275, P19906, DOI 10.1074/jbc.M000713200; Aboussekhra A, 2011, INT J DEV BIOL, V55, P841, DOI 10.1387/ijdb.113362aa; Allinen M, 2004, CANCER CELL, V6, P17, DOI 10.1016/j.ccr.2004.06.010; Andriopoulos B, 2009, NAT GENET, V41, P482, DOI 10.1038/ng.335; Arman A, 2003, ADV EXP MED BIOL, V534, P297; Arosio P, 2010, BBA-GEN SUBJECTS, V1800, P783, DOI 10.1016/j.bbagen.2010.02.005; Babitt JL, 2007, J CLIN INVEST, V117, P1933, DOI 10.1172/JCI31342; BISSELL MJ, 1982, J THEOR BIOL, V99, P31, DOI 10.1016/0022-5193(82)90388-5; Bootcov MR, 1997, P NATL ACAD SCI USA, V94, P11514, DOI 10.1073/pnas.94.21.11514; Bruzzese F, 2014, CANCER RES, V74, P3408, DOI 10.1158/0008-5472.CAN-13-2259; CALDENHOVEN E, 1995, J BIOL CHEM, V270, P25778, DOI 10.1074/jbc.270.43.25778; Coloff JL, 2016, CELL METAB, V23, P867, DOI 10.1016/j.cmet.2016.03.016; Cooke KS, 2013, BLOOD, V122, P3054, DOI 10.1182/blood-2013-06-505792; Daniels TR, 2012, BBA-GEN SUBJECTS, V1820, P291, DOI 10.1016/j.bbagen.2011.07.016; Debnath J, 2005, NAT REV CANCER, V5, P675, DOI 10.1038/nrc1695; Donovan A, 2000, NATURE, V403, P776, DOI 10.1038/35001596; Fairlie WD, 1999, J LEUKOCYTE BIOL, V65, P2, DOI 10.1002/jlb.65.1.2; Francia G, 2004, MOL CELL BIOL, V24, P6837, DOI 10.1128/mcb.24.15.6837-6849.2004; Garcia R, 2001, ONCOGENE, V20, P2499, DOI 10.1038/sj.onc.1204349; Hanahan D, 2012, CANCER CELL, V21, P309, DOI 10.1016/j.ccr.2012.02.022; HENTZE MW, 1987, SCIENCE, V238, P1570, DOI 10.1126/science.3685996; Horning JL, 2008, MOL PHARMACEUT, V5, P849, DOI 10.1021/mp800047v; Howlader N, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/dju055; Kenny PA, 2007, MOL ONCOL, V1, P84, DOI 10.1016/j.molonc.2007.02.004; Kim JB, 2004, BREAST CANCER RES TR, V85, P281, DOI 10.1023/B:BREA.0000025418.88785.2b; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Lee GY, 2007, NAT METHODS, V4, P359, DOI 10.1038/NMETH1015; Lee P, 2005, P NATL ACAD SCI USA, V102, P1906, DOI 10.1073/pnas.0409808102; Li C, 2016, ONCOTARGET, V7, P860, DOI 10.18632/oncotarget.6205; Li YL, 2017, ONCOTARGET, V8, P1508, DOI 10.18632/oncotarget.13649; Liu XF, 2017, NAT PROTOC, V12, P439, DOI 10.1038/nprot.2016.174; Liu XF, 2012, AM J PATHOL, V180, P599, DOI 10.1016/j.ajpath.2011.10.036; Longati P, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-95; Marques O, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2228-y; Martin KJ, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002994; McKie AT, 2000, MOL CELL, V5, P299, DOI 10.1016/S1097-2765(00)80425-6; Meynard D, 2009, NAT GENET, V41, P478, DOI 10.1038/ng.320; Nath S, 2016, PHARMACOL THERAPEUT, V163, P94, DOI 10.1016/j.pharmthera.2016.03.013; Nemeth E, 2004, SCIENCE, V306, P2090, DOI 10.1126/science.1104742; Nguyen DH, QUANTIFYING CHROMOGE, DOI [10.1038/protex.2013.097, DOI 10.1038/PROTEX.2013.097]; Nieman MT, 1999, J CELL BIOL, V147, P631, DOI 10.1083/jcb.147.3.631; Park YJ, 2010, BMB REP, V43, P91, DOI 10.5483/BMBRep.2010.43.2.091; Perou CM, 1999, P NATL ACAD SCI USA, V96, P9212, DOI 10.1073/pnas.96.16.9212; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Pickl M, 2009, ONCOGENE, V28, P461, DOI 10.1038/onc.2008.394; Pinnix ZK, 2010, SCI TRANSL MED, V2; Riedl A, 2017, J CELL SCI, V130, P203, DOI 10.1242/jcs.188102; Saias L, 2015, CANCER RES, V75, P2426, DOI 10.1158/0008-5472.CAN-14-3534; Sasahara A, 2017, ONCOTARGET, V8, P24869, DOI 10.18632/oncotarget.15276; Schafer ZT, 2009, NATURE, V461, P109, DOI 10.1038/nature08268; Schober A, 2001, J COMP NEUROL, V439, P32, DOI 10.1002/cne.1333; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; SOULE HD, 1973, J NATL CANCER I, V51, P1409, DOI 10.1093/jnci/51.5.1409; Tanno T, 2007, NAT MED, V13, P1096, DOI 10.1038/nm1629; Tesfay L, 2015, CANCER RES, V75, P2254, DOI 10.1158/0008-5472.CAN-14-2465; Theil EC, 2016, ACCOUNTS CHEM RES, V49, P784, DOI 10.1021/ar500469e; TONIK SE, 1986, BREAST CANCER RES TR, V7, P71, DOI 10.1007/BF01806791; Torti FM, 2002, BLOOD, V99, P3505, DOI 10.1182/blood.V99.10.3505; Wang W, 2014, CANCER RES, V74, P497, DOI 10.1158/0008-5472.CAN-13-1224; Weigelt B, 2008, SEMIN CANCER BIOL, V18, P311, DOI 10.1016/j.semcancer.2008.03.013; Welsh JB, 2003, P NATL ACAD SCI USA, V100, P3410, DOI 10.1073/pnas.0530278100; Whiteside TL, 2008, ONCOGENE, V27, P5904, DOI 10.1038/onc.2008.271; Wilkinson J, 2003, ADV ENZYME REGUL, V43, P135, DOI 10.1016/S0065-2571(02)00037-7; WINAND FJ, 2014, J MOL BIOMARK DIAGN, V5, P199; Wrana JL, 2000, CELL, V100, P189, DOI 10.1016/S0092-8674(00)81556-1; WRBA F, 1986, VIRCHOWS ARCH A, V410, P69, DOI 10.1007/BF00710908; Wrighting DM, 2006, BLOOD, V108, P3204, DOI 10.1182/blood-2006-06-027631; Yalcin Mehmet Muhittin, 2016, J Diabetes Res, V2016, P1240843, DOI 10.1155/2016/1240843; Yang CH, 1998, P NATL ACAD SCI USA, V95, P5568, DOI 10.1073/pnas.95.10.5568; Yilmaz H, 2016, INDIAN J HEMATOL BLO, V32, P221, DOI 10.1007/s12288-015-0551-0; Yu M, 2012, MOL CELL BIOL, V32, P3913, DOI 10.1128/MCB.00068-12; Zhang SP, 2014, CELL SIGNAL, V26, P2539, DOI 10.1016/j.cellsig.2014.07.029	72	31	31	2	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 19	2018	37	29					4013	4032		10.1038/s41388-018-0243-y	http://dx.doi.org/10.1038/s41388-018-0243-y			20	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GN5LP	29695834	Green Accepted			2022-12-17	WOS:000439101300008
J	Crossland, DL; Denning, WL; Ang, S; Olivares, S; Mi, TJ; Switzer, K; Singh, H; Huls, H; Gold, KS; Glisson, BS; Cooper, LJ; Heymach, JV				Crossland, Denise L.; Denning, Warren L.; Ang, Sonny; Olivares, Simon; Mi, Tiejuan; Switzer, Kirsten; Singh, Harjeet; Huls, Helen; Gold, Kate S.; Glisson, Bonnie S.; Cooper, Laurence J.; Heymach, John V.			Antitumor activity of CD56-chimeric antigen receptor T cells in neuroblastoma and SCLC models	ONCOGENE			English	Article							ANTIBODY-DRUG CONJUGATE; LUNG-CANCER; LORVOTUZUMAB MERTANSINE; IMPROVED SURVIVAL; HU ANTIBODIES; PHASE 1/2; EXPRESSION; SYSTEM; TRANSACTIVATOR; PEMBROLIZUMAB	The CD56 antigen (NCAM-1) is highly expressed on several malignancies with neuronal or neuroendocrine differentiation, including small-cell lung cancer and neuroblastoma, tumor types for which new therapeutic options are needed. We hypothesized that CD56-specific chimeric antigen receptor (CAR) T cells could target and eliminate CD56-positive malignancies. Sleeping Beauty transposon-generated CD56R-CAR T cells exhibited a beta T-cell receptors, released antitumor cytokines upon co-culture with CD56(+) tumor targets, demonstrated a lack of fratricide, and expression of cytolytic function in the presence of CD56(+) stimulation. The CD56R-CAR(+) T cells are capable of killing CD56(+) neuroblastoma, glioma, and SCLC tumor cells in in vitro co-cultures and when tested against CD56(+) human xenograft neuroblastoma models and SCLC models, CD56R-CAR(+) T cells were able to inhibit tumor growth in vivo. These results indicate that CD56-CARs merit further investigation as a potential treatment for CD56(+) malignancies.	[Crossland, Denise L.; Olivares, Simon; Mi, Tiejuan; Switzer, Kirsten; Singh, Harjeet; Huls, Helen; Cooper, Laurence J.] UT MD Anderson Canc Ctr, Div Pediat, Houston, TX USA; [Denning, Warren L.; Glisson, Bonnie S.; Heymach, John V.] UT MD Anderson Canc Ctr, Thorac Head & Neck Med Oncol, Houston, TX 77030 USA; [Ang, Sonny] UT MD Anderson Canc Ctr, Stem Cell Transplantat, Houston, TX USA; [Huls, Helen] Intrexon, Germantown, MD USA; [Gold, Kate S.] Univ Calif San Diego, Moores Canc Ctr, La Jolla, CA 92093 USA; [Cooper, Laurence J.] ZIOPHARM Oncol Inc, Boston, MA USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of California System; University of California San Diego	Heymach, JV (corresponding author), UT MD Anderson Canc Ctr, Thorac Head & Neck Med Oncol, Houston, TX 77030 USA.	jheymach@mdanderson.org	Heymach, John/AAG-2361-2019	Heymach, John/0000-0001-9068-8942; Denning, Warren/0000-0003-0781-4288	Cancer Center Core Grant [CA16672]; RO1 [CA124782, CA120956, CA141303]; P01 [CA148600]; SPORES [CA100632, CA136411, CA00632]; Albert J Ward Foundation; Alex's Lemonade Stand Foundation; Burroughs Wellcome Fund; Cancer Prevention and Research Institute of Texas; Charles B. Goddard Foundation of Texas; CLL Global Research Foundation; Energy Transfer Partners; Estate of Noelan L. Bibler; Gillson Longenbaugh Foundation; Harry T. Mangurian, Jr., Fund for Leukemia Immunotherapy; Khalifa Bin Zayed Al Nahyan Foundation; Kleberg Foundation; Leukemia and Lymphoma Society; Lung Cancer Research Foundation; Lung Cancer Moon Shot; Lymphoma Research Foundation; Miller Foundation; National Foundation for Cancer Research; NIH Cancer Center Support Grant Pediatric Cancer Research Foundation [CA016672]; Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy; University of Texas MD Anderson Cancer Center Sister Institution Network Fund; University of Texas Moon Shot Fund; University of Texas Southwestern Medical Center [5 P50 CA070907]; University of Texas MD Anderson Cancer Center NIH Lung SPORE Grant [5 P50 CA070907]; William Lawrence and Blanche Hughes Children's Foundation	Cancer Center Core Grant; RO1(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); P01; SPORES; Albert J Ward Foundation; Alex's Lemonade Stand Foundation; Burroughs Wellcome Fund(Burroughs Wellcome Fund); Cancer Prevention and Research Institute of Texas; Charles B. Goddard Foundation of Texas; CLL Global Research Foundation; Energy Transfer Partners; Estate of Noelan L. Bibler; Gillson Longenbaugh Foundation; Harry T. Mangurian, Jr., Fund for Leukemia Immunotherapy; Khalifa Bin Zayed Al Nahyan Foundation; Kleberg Foundation; Leukemia and Lymphoma Society(Leukemia and Lymphoma Society); Lung Cancer Research Foundation; Lung Cancer Moon Shot; Lymphoma Research Foundation; Miller Foundation; National Foundation for Cancer Research; NIH Cancer Center Support Grant Pediatric Cancer Research Foundation; Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy; University of Texas MD Anderson Cancer Center Sister Institution Network Fund; University of Texas Moon Shot Fund; University of Texas Southwestern Medical Center; University of Texas MD Anderson Cancer Center NIH Lung SPORE Grant; William Lawrence and Blanche Hughes Children's Foundation	We thank the flow cytometry and cellular imaging core facilities at MD Anderson. This study was funded by Cancer Center Core Grant (CA16672); RO1 (CA124782, CA120956, CA141303, CA141303); P01 (CA148600); SPORES (CA100632, CA136411, CA00632); Albert J Ward Foundation; Alex's Lemonade Stand Foundation; Burroughs Wellcome Fund; Cancer Prevention and Research Institute of Texas; Charles B. Goddard Foundation of Texas; CLL Global Research Foundation; Energy Transfer Partners; Estate of Noelan L. Bibler; Gillson Longenbaugh Foundation; Harry T. Mangurian, Jr., Fund for Leukemia Immunotherapy; Khalifa Bin Zayed Al Nahyan Foundation; Kleberg Foundation; Leukemia and Lymphoma Society; Lung Cancer Research Foundation; Lung Cancer Moon Shot; Lymphoma Research Foundation; Miller Foundation; Mr. Herb Simons; Mr. and Mrs. Joe H. Scales; Mr. Thomas Scott; National Foundation for Cancer Research; NIH Cancer Center Support Grant (CA016672) Pediatric Cancer Research Foundation; Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy; University of Texas MD Anderson Cancer Center Sister Institution Network Fund and Moon Shot Fund; The University of Texas Southwestern Medical Center and The University of Texas MD Anderson Cancer Center NIH Lung SPORE Grant (5 P50 CA070907); William Lawrence and Blanche Hughes Children's Foundation. Publication under the Creative Commons CC-BY license is not required.	Antonia SJ, 2016, LANCET ONCOL, V17, P883, DOI 10.1016/S1470-2045(16)30098-5; Bruns M, 2016, ONCOTARGET, V7, P64543, DOI 10.18632/oncotarget.11620; Chen HL, 1996, NAT GENET, V13, P210, DOI 10.1038/ng0696-210; DALMAU J, 1995, CANCER, V75, P99, DOI 10.1002/1097-0142(19950101)75:1<99::AID-CNCR2820750117>3.0.CO;2-I; de Braud F., 2015, J IMMUNOTHER CANCER, V3, pP376, DOI DOI 10.1186/2051-1426-3-S2-P376; DOYLE A, 1985, J EXP MED, V161, P1135, DOI 10.1084/jem.161.5.1135; Fedorov VD, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3006597; Feng Y, 2016, MABS-AUSTIN, V8, P799, DOI 10.1080/19420862.2016.1155014; FISK B, 1994, LYMPHOKINE CYTOK RES, V13, P125; Garon EB, 2015, NEW ENGL J MED, V372, P2018, DOI 10.1056/NEJMoa1501824; Graus F, 1997, J CLIN ONCOL, V15, P2866, DOI 10.1200/JCO.1997.15.8.2866; Jena B, 2010, BLOOD, V116, P1035, DOI 10.1182/blood-2010-01-043737; Kazarian M, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-33; Kelly-Rogers J, 2006, HUM IMMUNOL, V67, P863, DOI 10.1016/j.humimm.2006.08.292; Larkin J, 2015, NEW ENGL J MED, V373, P23, DOI [10.1056/NEJMoa1504030, 10.1056/NEJMc1509660]; Michielsen AJ, 2012, MOL CANCER THER, V11, P1829, DOI 10.1158/1535-7163.MCT-12-0162; Morsut L, 2016, CELL, V164, P780, DOI 10.1016/j.cell.2016.01.012; Noble A, 2006, BLOOD, V107, P4475, DOI 10.1182/blood-2005-10-3994; Ohkawa T, 2001, IMMUNOLOGY, V103, P281, DOI 10.1046/j.1365-2567.2001.01248.x; Ott PA, 2017, J CLIN ONCOL, V35, P3823, DOI 10.1200/JCO.2017.72.5069; Page DB, 2014, ANNU REV MED, V65, P185, DOI 10.1146/annurev-med-092012-112807; Pittet MJ, 2000, J IMMUNOL, V164, P1148, DOI 10.4049/jimmunol.164.3.1148; Roellecke K, 2016, GENE THER, V23, P615, DOI 10.1038/gt.2016.38; Ryan SO, 2010, CANCER RES, V70, P5788, DOI 10.1158/0008-5472.CAN-09-4519; Sakemura R, 2016, CANCER IMMUNOL RES, V4, P658, DOI 10.1158/2326-6066.CIR-16-0043; Schreiber RD, 2011, SCIENCE, V331, P1565, DOI 10.1126/science.1203486; Shah MH, 2016, INVEST NEW DRUG, V34, P290, DOI 10.1007/s10637-016-0336-9; Singh H, 2008, CANCER RES, V68, P2961, DOI 10.1158/0008-5472.CAN-07-5600; Singh H, 2011, CANCER RES, V71, P3516, DOI 10.1158/0008-5472.CAN-10-3843; Socinski MA, 2017, CLIN LUNG CANCER, V18, P68, DOI 10.1016/j.cllc.2016.09.002; Whiteman KR, 2014, MABS-AUSTIN, V6, P556, DOI 10.4161/mabs.27756; WINTER SF, 1993, J NATL CANCER I, V85, P2012, DOI 10.1093/jnci/85.24.2012; Yazawa T, 2002, AM J PATHOL, V161, P291, DOI 10.1016/S0002-9440(10)64181-8; Yoshihama S, 2016, P NATL ACAD SCI USA, V113, P5999, DOI 10.1073/pnas.1602069113; Yu AL, 2010, NEW ENGL J MED, V363, P1324, DOI 10.1056/NEJMoa0911123; Zaretsky JM, 2016, NEW ENGL J MED, V375, P819, DOI 10.1056/NEJMoa1604958	36	31	33	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 5	2018	37	27					3686	3697		10.1038/s41388-018-0187-2	http://dx.doi.org/10.1038/s41388-018-0187-2			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GM3CM	29622795				2022-12-17	WOS:000437975200006
J	Kullmann, L; Krahn, MP				Kullmann, Lars; Krahn, Michael P.			Controlling the master-upstream regulation of the tumor suppressor LKB1	ONCOGENE			English	Review							PEUTZ-JEGHERS-SYNDROME; ACTIVATED PROTEIN-KINASE; LKB1-AMPK SIGNALING PATHWAY; HEMATOPOIETIC STEM-CELLS; ENDOTHELIAL-CELLS; ENERGY-METABOLISM; AMPK ACTIVATION; BREAST-CANCER; LUNG-CANCER; IN-VIVO	The tumor suppressor LKB1 is an essential serine/threonine kinase, which regulates various cellular processes such as cell metabolism, cell proliferation, cell polarity, and cell migration. Germline mutations in the STK11 gene (encoding LKB1) are the cause of the Peutz-Jeghers syndrome, which is characterized by benign polyps in the intestine and a higher risk for the patients to develop intestinal and extraintestinal tumors. Moreover, mutations and misregulation of LKB1 have been reported to occur in most types of tumors and are among the most common aberrations in lung cancer. LKB1 activates several downstream kinases of the AMPK family by direct phosphorylation in the T-loop. In particular the activation of AMPK upon energetic stress has been intensively analyzed in various diseases, including cancer to induce a metabolic switch from anabolism towards catabolism to regulate energy homeostasis and cell survival. In contrast, the regulation of LKB1 itself has long been only poorly understood. Only in the last years, several proteins and posttranslational modifications of LKB1 have been analyzed to control its localization, activity and recognition of substrates. Here, we summarize the current knowledge about the upstream regulation of LKB1, which is important for the understanding of the pathogenesis of many types of tumors.	[Kullmann, Lars; Krahn, Michael P.] Univ Hosp Munster, Internal Med D, Domagkstr 3a, D-48149 Munster, Germany	University of Munster	Krahn, MP (corresponding author), Univ Hosp Munster, Internal Med D, Domagkstr 3a, D-48149 Munster, Germany.	Michael.Krahn@ukmuenster.de	Krahn, Michael/AAD-4476-2022	Krahn, Michael/0000-0001-7718-9890	German Research Foundation (DFG) [SFB1348-A5]	German Research Foundation (DFG)(German Research Foundation (DFG))	This work was supported by the German Research Foundation (DFG, SFB1348-A5).	Alessi DR, 2006, ANNU REV BIOCHEM, V75, P137, DOI 10.1146/annurev.biochem.75.103004.142702; Alexander A, 2010, P NATL ACAD SCI USA, V107, P4153, DOI 10.1073/pnas.0913860107; Amin N, 2009, P NATL ACAD SCI USA, V106, P8941, DOI 10.1073/pnas.0812469106; Avtanski DB, 2015, ONCOTARGET, V6, P29947, DOI 10.18632/oncotarget.4937; Baas AF, 2003, EMBO J, V22, P3062, DOI 10.1093/emboj/cdg292; Bai B, 2016, ONCOTARGET, V7, P39065, DOI 10.18632/oncotarget.9687; Bai Y, 2012, FEBS LETT, V586, P1111, DOI 10.1016/j.febslet.2012.03.018; Barbier-Torres L, 2015, ONCOTARGET, V6, P2509, DOI 10.18632/oncotarget.3191; Bardeesy N, 2002, NATURE, V419, P162, DOI 10.1038/nature01045; Barnes AP, 2007, CELL, V129, P549, DOI 10.1016/j.cell.2007.03.025; BARTKOVA J, 1994, INT J CANCER, V57, P353, DOI 10.1002/ijc.2910570311; Benton R, 2003, CELL, V115, P691, DOI 10.1016/S0092-8674(03)00938-3; Boudeau J, 2004, J CELL SCI, V117, P6365, DOI 10.1242/jcs.01571; Boudeau J, 2003, EMBO J, V22, P5102, DOI 10.1093/emboj/cdg490; Boudeau J, 2003, BIOCHEM J, V370, P849, DOI 10.1042/BJ20021813; Bright NJ, 2008, J BIOL CHEM, V283, P14946, DOI 10.1074/jbc.M710381200; Bultot L, 2009, FEBS LETT, V583, P25, DOI 10.1016/j.febslet.2008.11.022; Busch AM, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-211; Calamaras TD, 2015, FREE RADICAL BIO MED, V82, P137, DOI 10.1016/j.freeradbiomed.2015.01.007; Calamaras TD, 2012, J BIOL CHEM, V287, P42400, DOI 10.1074/jbc.M112.385831; Carretero J, 2004, ONCOGENE, V23, P4037, DOI 10.1038/sj.onc.1207502; Casimiro MC, 2017, CANCER RES, V77, P3391, DOI 10.1158/0008-5472.CAN-16-0425; Chen BZ, 2009, NAT CHEM BIOL, V5, P100, DOI 10.1038/nchembio.137; Chen J, 2017, ELIFE, V6, DOI 10.7554/eLife.31268; Cidlinsky N, 2016, CELL ONCOL, V39, P389, DOI 10.1007/s13402-016-0290-8; Collins SP, 2000, BIOCHEM J, V345, P673, DOI 10.1042/0264-6021:3450673; Courchet J, 2013, CELL, V153, P1510, DOI 10.1016/j.cell.2013.05.021; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Denison FC, 2009, J BIOL CHEM, V284, P67, DOI 10.1074/jbc.M806153200; Dogliotti G, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15747; Dolinsky VW, 2009, CIRCULATION, V119, P1643, DOI 10.1161/CIRCULATIONAHA.108.787440; Dorfman J, 2008, MOL BIOL CELL, V19, P1614, DOI 10.1091/mbc.E07-05-0454; Fogarty S, 2009, J BIOL CHEM, V284, P77, DOI 10.1074/jbc.M806152200; Gan BY, 2010, NATURE, V468, P701, DOI 10.1038/nature09595; Gaude H, 2012, ONCOGENE, V31, P1582, DOI 10.1038/onc.2011.342; Geiss-Friedlander R, 2007, NAT REV MOL CELL BIO, V8, P947, DOI 10.1038/nrm2293; George SHL, 2016, ONCOGENE, V35, P59, DOI 10.1038/onc.2015.62; Gill RK, 2011, ONCOGENE, V30, P3784, DOI 10.1038/onc.2011.98; Granot Z, 2009, CELL METAB, V10, P296, DOI 10.1016/j.cmet.2009.08.010; Guldberg P, 1999, ONCOGENE, V18, P1777, DOI 10.1038/sj.onc.1202486; Gurumurthy S, 2010, NATURE, V468, P659, DOI 10.1038/nature09572; Hearle N, 2006, CLIN CANCER RES, V12, P3209, DOI 10.1158/1078-0432.CCR-06-0083; Hemminki A, 1998, NATURE, V391, P184, DOI 10.1038/34432; Hou XY, 2008, J BIOL CHEM, V283, P20015, DOI 10.1074/jbc.M802187200; Houde VP, 2014, BIOCHEM J, V458, P41, DOI 10.1042/BJ20131324; Huang SMA, 2009, NATURE, V461, P614, DOI 10.1038/nature08356; Huo YL, 2014, NAT CELL BIOL, V16, P526, DOI 10.1038/ncb2969; Ikeda Y, 2009, J BIOL CHEM, V284, P35839, DOI 10.1074/jbc.M109.057273; Inoki K, 2003, CELL, V115, P577, DOI 10.1016/S0092-8674(03)00929-2; Jaleel M, 2005, FEBS LETT, V579, P1417, DOI 10.1016/j.febslet.2005.01.042; Jansen M, 2009, PHYSIOL REV, V89, P777, DOI 10.1152/physrev.00026.2008; Jishage K, 2002, P NATL ACAD SCI USA, V99, P8903, DOI 10.1073/pnas.122254599; Karuman P, 2001, MOL CELL, V7, P1307, DOI 10.1016/S1097-2765(01)00258-1; Konen J, 2016, MOL BIOL CELL, V27, P1069, DOI 10.1091/mbc.E15-08-0569; Korsse SE, 2013, CARCINOGENESIS, V34, P1611, DOI 10.1093/carcin/bgt068; Lai DM, 2012, CELL REPROGRAM, V14, P164, DOI 10.1089/cell.2011.0068; Lan F, 2008, J BIOL CHEM, V283, P27628, DOI 10.1074/jbc.M805711200; Lee JH, 2007, NATURE, V447, P1017, DOI 10.1038/nature05828; Lee SW, 2015, MOL CELL, V57, P1022, DOI 10.1016/j.molcel.2015.01.015; Li TY, 2017, BIOCHEM BIOPH RES CO, V482, P1037, DOI 10.1016/j.bbrc.2016.11.154; Liu L, 2012, AM J TRANSL RES, V4, P175; Liu ZY, 2015, J BIOL CHEM, V290, P19011, DOI 10.1074/jbc.M115.649210; Lizcano JM, 2004, EMBO J, V23, P833, DOI 10.1038/sj.emboj.7600110; MACMICKING JD, 1995, CELL, V81, P641, DOI 10.1016/0092-8674(95)90085-3; Mali VR, 2014, FREE RADICAL RES, V48, P251, DOI 10.3109/10715762.2013.864761; Martin SG, 2003, NATURE, V421, P379, DOI 10.1038/nature01296; Matsumoto S, 2007, ONCOGENE, V26, P5911, DOI 10.1038/sj.onc.1210418; McGarrity TJ, 2000, AM J GASTROENTEROL, V95, P596; Mehenni H, 1998, AM J HUM GENET, V63, P1641, DOI 10.1086/302159; Miyoshi H, 2002, CANCER RES, V62, P2261; Morton JP, 2010, GASTROENTEROLOGY, V139, P586, DOI 10.1053/j.gastro.2010.04.055; Nagalingam A, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3128; Nakada D, 2010, NATURE, V468, P653, DOI 10.1038/nature09571; Nezu J, 1999, BIOCHEM BIOPH RES CO, V261, P750, DOI 10.1006/bbrc.1999.1047; Nony P, 2003, ONCOGENE, V22, P9165, DOI 10.1038/sj.onc.1207179; O'Farrell F, 2017, NAT CELL BIOL, V19, P1412, DOI 10.1038/ncb3631; Price NL, 2012, CELL METAB, V15, P675, DOI 10.1016/j.cmet.2012.04.003; Ritho J, 2015, CELL REP, V12, P734, DOI 10.1016/j.celrep.2015.07.002; Rossi DJ, 2002, P NATL ACAD SCI USA, V99, P12327, DOI 10.1073/pnas.192301399; Rowan A, 1999, J INVEST DERMATOL, V112, P509, DOI 10.1046/j.1523-1747.1999.00551.x; Sanchez-Cespedes M, 2002, CANCER RES, V62, P3659; Sapkota GP, 2002, BIOCHEM J, V368, P507, DOI 10.1042/BJ20021284; Sapkota GP, 2002, BIOCHEM J, V362, P481, DOI 10.1042/0264-6021:3620481; Sapkota GP, 2001, J BIOL CHEM, V276, P19469, DOI 10.1074/jbc.M009953200; Schaur R. J., 2003, Molecular Aspects of Medicine, V24, P149, DOI 10.1016/S0098-2997(03)00009-8; Sebbagh M, 2009, CURR BIOL, V19, P37, DOI 10.1016/j.cub.2008.11.033; Sengupta S, 2017, ONCOGENE, V36, P5709, DOI 10.1038/onc.2017.164; Seo MS, 2015, TOXICOL APPL PHARM, V284, P113, DOI 10.1016/j.taap.2015.02.020; Shackelford DB, 2013, CANCER CELL, V23, P143, DOI 10.1016/j.ccr.2012.12.008; Shaw RJ, 2004, CANCER CELL, V6, P91, DOI 10.1016/j.ccr.2004.06.007; Shelly M, 2007, CELL, V129, P565, DOI 10.1016/j.cell.2007.04.012; Shen YAA, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5991; Shen Z, 2002, CLIN CANCER RES, V8, P2085; Smith DP, 1999, HUM MOL GENET, V8, P1479, DOI 10.1093/hmg/8.8.1479; Song P, 2008, J BIOL CHEM, V283, P12446, DOI 10.1074/jbc.M708208200; Stewart DJ, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/djt356; Su JY, 1996, J BIOL CHEM, V271, P14430, DOI 10.1074/jbc.271.24.14430; Tanaka T, 1999, CANCER RES, V59, P2041; Tang XQ, 2017, CIRCULATION, V136, P2051, DOI 10.1161/CIRCULATIONAHA.117.028728; Tanwar PS, 2014, CARCINOGENESIS, V35, P546, DOI 10.1093/carcin/bgt357; Tortelote GG, 2017, CELL SIGNAL, V40, P30, DOI 10.1016/j.cellsig.2017.08.008; Towler MC, 2008, BIOCHEM J, V416, P1, DOI 10.1042/BJ20081447; Walz HA, 2010, J BIOL CHEM, V285, P14101, DOI 10.1074/jbc.M110.110536; Wei CJ, 2005, CANCER RES, V65, P11297, DOI 10.1158/0008-5472.CAN-05-0716; Wilkinson S, 2017, SCI REP-UK, V7, DOI 10.1038/srep40929; Wingo SN, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005137; Woods A, 2003, CURR BIOL, V13, P2004, DOI 10.1016/j.cub.2003.10.031; Xie Z, 2008, CIRCULATION, V117, P952, DOI 10.1161/CIRCULATIONAHA.107.744490; Xie ZL, 2009, MOL CELL BIOL, V29, P3582, DOI 10.1128/MCB.01417-08; Xie ZL, 2006, J BIOL CHEM, V281, P6366, DOI 10.1074/jbc.M511178200; Yang WL, 2010, ONCOGENE, V29, P4493, DOI 10.1038/onc.2010.190; Ylikorkala A, 1999, HUM MOL GENET, V8, P45, DOI 10.1093/hmg/8.1.45; Zeqiraj E, 2009, SCIENCE, V326, P1707, DOI 10.1126/science.1178377; Zhang CS, 2017, NATURE, V548, P112, DOI 10.1038/nature23275; Zhang CS, 2014, CELL METAB, V20, P526, DOI 10.1016/j.cmet.2014.06.014; Zhang WC, 2014, CIRCULATION, V129, P1428, DOI 10.1161/CIRCULATIONAHA.113.004146; Zhang YL, 2013, CELL METAB, V18, P546, DOI 10.1016/j.cmet.2013.09.005; Zheng B, 2009, MOL CELL, V33, P237, DOI 10.1016/j.molcel.2008.12.026; Zheng X, 2018, ONCOGENE, V37, P502, DOI 10.1038/onc.2017.354; Zhu H, 2013, J BIOL CHEM, V288, P16495, DOI 10.1074/jbc.M112.443580; Zu Y, 2010, CIRC RES, V106, P1384, DOI 10.1161/CIRCRESAHA.109.215483	121	31	32	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2018	37	23					3045	3057		10.1038/s41388-018-0145-z	http://dx.doi.org/10.1038/s41388-018-0145-z			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GI6VO	29540834				2022-12-17	WOS:000434641400001
J	Guo, PY; Wang, Y; Dai, CX; Tao, CL; Wu, F; Xie, XZ; Yu, HT; Zhu, QD; Li, JJ; Ye, LY; Yu, FX; Shan, YF; Yu, ZP; Dhanasekaran, R; Zheng, RY; Chen, G				Guo, Pengyi; Wang, Yi; Dai, Chunxiu; Tao, Chonglin; Wu, Fang; Xie, Xiaozai; Yu, Haitao; Zhu, Qiandong; Li, Junjian; Ye, Longyun; Yu, Fuxiang; Shan, Yunfeng; Yu, Zhengping; Dhanasekaran, Renumathy; Zheng, Rongyuan; Chen, Gang			Ribosomal protein S15a promotes tumor angiogenesis via enhancing Wnt/beta-catenin-induced FGF18 expression in hepatocellular carcinoma	ONCOGENE			English	Article							GROWTH-FACTOR-BETA; VIRUS-X PROTEIN; DOWN-REGULATION; CELL-PROLIFERATION; COLORECTAL-CANCER; IN-VITRO; GENES; TRANSFORMATION; MUTATIONS; LEUKEMIA	Ribosomal protein s15a (RPS15A) plays a promotive role in the mRNA/ribosome interactions during early translation. Our previous study has found that inhibiting RPS15A expression can decrease proliferation and induce cell cycle arrest in hepatocellular carcinoma (HCC) cell lines. However, the mechanism underlying the involvement of RPS15A in HCC pathogenesis and the clinical significance of RPS15A expression remain unclear. In this study, an evaluation of RPS15A expression in 110 surgically resected HCCs and matched tumor-adjacent normal tissues revealed an overexpression of RPS15A in HCC, which was correlated with worse survival. In addition, tumor tissue with higher RPS15A expression demonstrated a higher microvascular density (MVD). Subsequently, two HCC cell lines, Huh7 (low-level constitutive RPS15A expression) and HepG2 (high RPS15A expression) were used to further evaluate the role of RPS15A in angiogenesis. The co-culture experiment of HCC cells with endothelial cells revealed that the induced overexpression of RPS15A in Huh7 cells increased the angiogenic potential of HUVEC in a paracrine fashion; conversely, knockdown of RPS15A in HepG2 cells showed an opposite effect. Further analysis indicated that RPS15A modulated FGF signaling by enhancing Wnt/beta-catenin-mediated FGF18 expression in HCC cells. FGF18, in turn, through binding to its FGFR3 receptor on endothelial cells, can activate the AKT and ERK pathway and promotes angiogenesis in a tumor microenvironment. Our in vivo experiment further confirmed that inhibition of RPS15A expression in HCC xenografts dramatically hindered tumor growth and inhibited tumor angiogenesis. Together, our findings suggest that RPS15A promotes angiogenesis in HCCs by enhancing Wnt/beta-catenin induced FGF18 expression. The RPS15A/FGF18 pathway may be a rational target for anti-angiogenic therapy of HCC.	[Guo, Pengyi; Tao, Chonglin; Xie, Xiaozai; Yu, Haitao; Zhu, Qiandong; Li, Junjian; Ye, Longyun; Yu, Fuxiang; Shan, Yunfeng; Yu, Zhengping; Chen, Gang] Wenzhou Med Univ, Affiliated Hosp 1, Dept Hepatobiliary Surg, Wenzhou 2, Zhejiang, Peoples R China; [Wang, Yi] Wenzhou Med Univ, Res Ctr Evidence Based Med & Clin Epidemiol, Sch Publ Hlth & Management, Wenzhou, Zhejiang, Peoples R China; [Dai, Chunxiu] Wenzhou Med Univ, Affiliated Hosp 1, Dept Tradit Chinese Med, Wenzhou, Zhejiang, Peoples R China; [Wu, Fang] Wenzhou Med Univ, Affiliated Hosp 1, Dept Gastroenterol, Wenzhou, Zhejiang, Peoples R China; [Dhanasekaran, Renumathy] Stanford Univ, Div Gastroenterol & Hepatol, Palo Alto, CA 94304 USA; [Zheng, Rongyuan] Wenzhou Med Univ, Affiliated Hosp 1, Dept Neurol, Wenzhou, Zhejiang, Peoples R China	Wenzhou Medical University; Wenzhou Medical University; Wenzhou Medical University; Wenzhou Medical University; Stanford University; Wenzhou Medical University	Chen, G (corresponding author), Wenzhou Med Univ, Affiliated Hosp 1, Dept Hepatobiliary Surg, Wenzhou 2, Zhejiang, Peoples R China.; Zheng, RY (corresponding author), Wenzhou Med Univ, Affiliated Hosp 1, Dept Neurol, Wenzhou, Zhejiang, Peoples R China.	zhengry@aliyun.com; cg_2188@hotmail.com	dhanasekaran, renumathy/B-3300-2014	dhanasekaran, renumathy/0000-0001-8819-7511	Natural Science Foundation of Zhejiang Province [LY17H160047]; National Natural Science Foundation of China [81201953]; Research Found for the Doctoral Fund of Ministry of Education of China [20113321120003]	Natural Science Foundation of Zhejiang Province(Natural Science Foundation of Zhejiang Province); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Research Found for the Doctoral Fund of Ministry of Education of China(Ministry of Education, China)	This work was supported by the grants from the Natural Science Foundation of Zhejiang Province (LY17H160047), the National Natural Science Foundation of China (81201953), the Research Found for the Doctoral Fund of Ministry of Education of China (20113321120003).	Akiyama N, 2000, MOL CELL BIOL, V20, P3266, DOI 10.1128/MCB.20.9.3266-3273.2000; Amsterdam A, 2004, PLOS BIOL, V2, P690, DOI 10.1371/journal.pbio.0020139; Antoine M, 2006, BIOCHEM BIOPH RES CO, V346, P224, DOI 10.1016/j.bbrc.2006.05.105; Berns H, 2000, FASEB J, V14, P2549, DOI 10.1096/fj.99-1038com; Bertram J, 1998, EUR J CANCER, V34, P731, DOI 10.1016/S0959-8049(97)10081-8; Carli A, 2012, EUR CELLS MATER, V24, P107, DOI 10.22203/eCM.v024a08; Carmeliet P, 2011, NATURE, V473, P298, DOI 10.1038/nature10144; Chen JW, 2016, INT J ONCOL, V48, P1628, DOI 10.3892/ijo.2016.3366; Cinque L, 2015, NATURE, V528, P272, DOI 10.1038/nature16063; De Keersmaecker K, 2013, NAT GENET, V45, P186, DOI 10.1038/ng.2508; de las Heras-Rubio A, 2014, CANCER METAST REV, V33, P115, DOI 10.1007/s10555-013-9460-6; Fancello L, 2017, ONCOTARGET, V8, P14462, DOI 10.18632/oncotarget.14895; Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210; Gauglhofer C, 2011, HEPATOLOGY, V53, P854, DOI 10.1002/hep.24099; Goudarzi KM, 2016, INT J ONCOL, V48, P1313, DOI 10.3892/ijo.2016.3387; Harmes DC, 2003, ONCOGENE, V22, P7607, DOI 10.1038/sj.onc.1207129; Hofman IJF, 2017, LEUKEMIA, V31, P1706, DOI 10.1038/leu.2016.370; Hsieh A, 2011, CANCER LETT, V300, P162, DOI 10.1016/j.canlet.2010.09.018; Jones DT, 2013, DIS MODEL MECH, V6, P115, DOI 10.1242/dmm.009183; Kapoun AM, 2004, CIRC RES, V94, P453, DOI 10.1161/01.RES.0000117070.86556.9F; Kumar P, 2016, GENE DEV, V30, P1573, DOI 10.1101/gad.282418.116; Landau DA, 2015, NATURE, V526, P525, DOI 10.1038/nature15395; LAVOIE C, 1994, J BIOL CHEM, V269, P14625; Lee DK, 2001, GENE DEV, V15, P455, DOI 10.1101/gad.856201; Lee JS, 2006, NAT MED, V12, P410, DOI 10.1038/nm1377; Lian ZR, 2004, MOL CARCINOGEN, V40, P34, DOI 10.1002/mc.20012; Lim KH, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022258; Lim S, 2013, P NATL ACAD SCI USA, V110, pE2298, DOI 10.1073/pnas.1301838110; Liu J, 2006, ONCOGENE, V25, P1008, DOI 10.1038/sj.onc.1209138; Liu WG, 2000, NAT GENET, V26, P146, DOI 10.1038/79859; Ljungstrom V, 2016, BLOOD, V127, P1007, DOI 10.1182/blood-2015-10-674572; Llovet JM, 2008, NEW ENGL J MED, V359, P378, DOI 10.1056/NEJMoa0708857; Perdu J, 2001, HUM MUTAT, V17, DOI 10.1002/1098-1004(2001)17:1<74::AID-HUMU14>3.0.CO;2-F; Rao SY, 2012, BLOOD, V120, P3764, DOI 10.1182/blood-2012-03-415349; Reinhold MI, 2007, J BIOL CHEM, V282, P3653, DOI 10.1074/jbc.M608995200; Ronca R, 2015, EXPERT OPIN THER TAR, V19, P1361, DOI 10.1517/14728222.2015.1062475; Ruptier C, 2011, ONCOGENE, V30, P4656, DOI 10.1038/onc.2011.171; Shie JL, 2000, AM J PHYSIOL-GASTR L, V279, pG806, DOI 10.1152/ajpgi.2000.279.4.G806; Shimokawa T, 2003, CANCER RES, V63, P6116; Shukla SK, 2012, FEBS J, V279, P3859, DOI 10.1111/j.1742-4658.2012.08745.x; SLOVAK ML, 1995, CANCER RES, V55, P4214; Uechi T, 2001, GENOMICS, V72, P223, DOI 10.1006/geno.2000.6470; Wang CM, 2015, HEPATOLOGY, V61, P200, DOI 10.1002/hep.27396; Wang F, 2011, CANCER SCI, V102, P2007, DOI 10.1111/j.1349-7006.2011.02065.x; Xu MY, 2014, GENE, V536, P84, DOI 10.1016/j.gene.2013.11.075; Xu Q, 2012, NUCLEIC ACIDS RES, V40, P761, DOI 10.1093/nar/gkr730; Zhang C, 2014, CANCER BIOTHER RADIO, V29, P451, DOI 10.1089/cbr.2014.1698; Zhao XM, 2015, TUMOR BIOL, V36, P6733, DOI 10.1007/s13277-015-3371-9	48	31	33	2	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2018	37	9					1220	1236		10.1038/s41388-017-0017-y	http://dx.doi.org/10.1038/s41388-017-0017-y			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FY0MK	29242604				2022-12-17	WOS:000426505400007
J	Huang, TT; Zhou, YH; Zhang, JL; Wong, CC; Li, WL; Kwan, JSH; Yang, R; Chan, AKY; Dong, YJ; Wu, F; Zhang, B; Cheung, AHK; Wu, WKK; Chen, ASL; Yu, J; Wong, N; Kang, W; To, KF				Huang, Tingting; Zhou, Yuhang; Zhang, Jinglin; Wong, Chi Chun; Li, Weilin; Kwan, Johnny S. H.; Yang, Rui; Chan, Aden K. Y.; Dong, Yujuan; Wu, Feng; Zhang, Bin; Cheung, Alvin H. K.; Wu, William K. K.; Chen, Alfred S. L.; Yu, Jun; Wong, Nathalie; Kang, Wei; To, Ka Fai			SRGAP1, a crucial target of miR-340 and miR-124, functions as a potential oncogene in gastric tumorigenesis	ONCOGENE			English	Article							RHO-GTPASES; BREAST-CANCER; PATHWAY; CARCINOGENESIS; MIGRATION; PROTEINS; PROMOTES; GROWTH; SLIT; ROBO	Slit-Robo GTPase-activating protein 1 (SRGAP1) functions as a GAP for Rho-family GTPases and downstream of Slit-Robo signaling. We aim to investigate the biological function of SRGAP1 and reveal its regulation by deregulated microRNAs (miRNAs) in gastric cancer (GC). mRNA and protein expression of SRGAP1 were examined by quantitative reverse transcription PCR (qRT-PCR) and western blot. The biological role of SRGAP1 was demonstrated through siRNA-mediated knockdown experiments. The regulation of SRGAP1 by miR-340 and miR-124 was confirmed by western blot, dual luciferase activity assays and rescue experiments. SRGAP1 is overexpressed in 9 out of 12 (75.0%) GC cell lines. In primary GC samples from TCGA cohort, SRGAP1 shows gene amplification in 5/258 (1.9%) of cases and its mRNA expression demonstrates a positive correlation with copy number gain. Knockdown of SRGAP1 in GC cells suppressed cell proliferation, reduced colony formation, and significantly inhibited cell invasion and migration. Luciferase reporter assays revealed that SRGAP1 knockdown significantly inhibited Wnt/beta-catenin pathway. In addition, SRGAP1 was found to be a direct target of two tumor-suppressive miRNAs, miR-340 and miR-124. Concordantly, these two miRNAs were downregulated in primary gastric tumors and these decreasing levels w5ere associated with poor outcomes. Expression of miR-340 and SRGAP1 displayed a reverse relationship in primary samples and re-expressed SRGAP1, rescued the anti-cancer effects of miR-340. Taken together, these data strongly suggest that, apart from gene amplification and mutation, the activation of SRGAP1 in GC is partly due to the downregulation of tumor-suppressive miRNAs, miR-340 and miR-124. Thus SRGAP1 is overexpressed in gastric carcinogenesis and plays an oncogenic role through activating Wnt/beta-catenin pathway.	[Huang, Tingting; Zhou, Yuhang; Zhang, Jinglin; Kwan, Johnny S. H.; Yang, Rui; Chan, Aden K. Y.; Wu, Feng; Cheung, Alvin H. K.; Wong, Nathalie; Kang, Wei; To, Ka Fai] Chinese Univ Hong Kong, Prince Wales Hosp, State Key Lab Oncol South China, Dept Anat & Cellular Pathol, Hong Kong, Hong Kong, Peoples R China; [Huang, Tingting; Zhou, Yuhang; Zhang, Jinglin; Wong, Chi Chun; Li, Weilin; Dong, Yujuan; Wu, William K. K.; Yu, Jun; Kang, Wei; To, Ka Fai] Chinese Univ Hong Kong, Partner State Key Lab Digest Dis, Inst Digest Dis, Hong Kong, Hong Kong, Peoples R China; [Huang, Tingting; Zhou, Yuhang; Zhang, Jinglin; Wong, Nathalie; Kang, Wei; To, Ka Fai] Chinese Univ Hong Kong, Sir YK Pao Canc Ctr, Li Ka Shing Inst Hlth Sci, Hong Kong, Hong Kong, Peoples R China; [Huang, Tingting; Chen, Alfred S. L.; Yu, Jun; Kang, Wei; To, Ka Fai] Chinese Univ Hong Kong, Shenzhen Res Inst, Shenzhen, Peoples R China; [Zhang, Bin] Nanjing Univ, Med Sch, Affiliated Drum Tower Hosp, Dept Gastroenterol, Nanjing, Jiangsu, Peoples R China; [Wu, William K. K.] Chinese Univ Hong Kong, Dept Anaesthesia & Intens Care, Hong Kong, Hong Kong, Peoples R China; [Chen, Alfred S. L.] Chinese Univ Hong Kong, Sch Biomed Sci, Hong Kong, Hong Kong, Peoples R China; [Yu, Jun] Chinese Univ Hong Kong, Dept Med & Therapeut, Hong Kong, Hong Kong, Peoples R China	Chinese University of Hong Kong; Prince of Wales Hospital; State Key Lab Oncology South China; Chinese University of Hong Kong; Chinese University of Hong Kong; Chinese University of Hong Kong, Shenzhen; Nanjing University; Chinese University of Hong Kong; Chinese University of Hong Kong; Chinese University of Hong Kong	Kang, W; To, KF (corresponding author), Chinese Univ Hong Kong, Prince Wales Hosp, State Key Lab Oncol South China, Dept Anat & Cellular Pathol, Hong Kong, Hong Kong, Peoples R China.; Kang, W; To, KF (corresponding author), Chinese Univ Hong Kong, Partner State Key Lab Digest Dis, Inst Digest Dis, Hong Kong, Hong Kong, Peoples R China.; Kang, W; To, KF (corresponding author), Chinese Univ Hong Kong, Sir YK Pao Canc Ctr, Li Ka Shing Inst Hlth Sci, Hong Kong, Hong Kong, Peoples R China.; Kang, W; To, KF (corresponding author), Chinese Univ Hong Kong, Shenzhen Res Inst, Shenzhen, Peoples R China.	weikang@cuhk.edu.hk; kfto@cuhk.edu.hk	Dong, Yujuan/AAS-3467-2021; Wong, Chi Chun/C-4636-2016; Li, Weilin/ABG-9032-2021; KANG, Wei/C-5451-2016; Wu, William K.K./A-3277-2009; Cheng, Alfred SL/C-3327-2014; Jun, Yu/D-8569-2015; Chan, Aden, Ka-yin/I-2535-2015	KANG, Wei/0000-0002-4651-677X; Wu, William K.K./0000-0002-5662-5240; Cheng, Alfred SL/0000-0003-2345-6951; Cheung, Alvin Ho-Kwan/0000-0002-3913-8117; Jun, Yu/0000-0001-5008-2153; Chan, Aden, Ka-yin/0000-0001-9176-963X	General Research Fund (RGC) from The Research Grants Council of Hong Kong [CUHK14114414, CUHK14110016]	General Research Fund (RGC) from The Research Grants Council of Hong Kong	We acknowledge the TCGA Research Network (http://cancergcnome.nih.gov/), The UCSC Cancer Genomics Browser (https://genome-cancer.uese.edu/), and NCI Center for Cancer Genomics Office (http://gdc.nci.nih.gov/) for providing the gastric cancer data set and analysis. This study is supported by General Research Fund (RGC Reference No. CUHK14114414 and CUHK14110016) from The Research Grants Council of Hong Kong. We also acknowledge the technical support from Core Utilities of Cancer Genomics and Pathobiology of Department of Anatomical and Cellular Pathology, The Chinese University of Hong Kong.	Bass AJ, 2014, NATURE, V513, P202, DOI 10.1038/nature13480; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chen KX, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5682; Chia NY, 2015, GUT, V64, P707, DOI 10.1136/gutjnl-2013-306596; Coutinho-Budd J, 2012, J CELL SCI, V125, P3390, DOI 10.1242/jcs.098962; Cui JA, 2011, NUCLEIC ACIDS RES, V39, P1197, DOI 10.1093/nar/gkq960; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Fernandez S, 2015, ONCOGENE, V34, P3240, DOI 10.1038/onc.2014.267; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Hall A, 2005, BIOCHEM SOC T, V33, P891, DOI 10.1042/BST0330891; He HL, 2013, J CLIN ENDOCR METAB, V98, pE973, DOI 10.1210/jc.2012-3823; Heasman SJ, 2008, NAT REV MOL CELL BIO, V9, P690, DOI 10.1038/nrm2476; Huang TT, 2016, MOL CANCER, V15, DOI 10.1186/s12943-016-0493-7; Huang TT, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1984-4; Itoh T, 2005, DEV CELL, V9, P791, DOI 10.1016/j.devcel.2005.11.005; Kang W, 2016, WORLD J GASTROENTERO, V22, P1279, DOI 10.3748/wjg.v22.i3.1279; Kang W, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0323-3; Kang W, 2014, J TRANSL MED, V12, DOI 10.1186/s12967-014-0281-3; Kang W, 2014, J TRANSL MED, V12, DOI 10.1186/1479-5876-12-80; Kang W, 2011, CLIN CANCER RES, V17, P2130, DOI 10.1158/1078-0432.CCR-10-2467; Kutys ML, 2014, NAT CELL BIOL, V16, P909, DOI 10.1038/ncb3026; Li WT, 2014, TUMOR BIOL, V35, P10897, DOI 10.1007/s13277-014-2402-2; Lin R, 1999, J BIOL CHEM, V274, P23633, DOI 10.1074/jbc.274.33.23633; Liu S., 2015, COMPUT MATH METHODS, V2015, P1, DOI DOI 10.1155/2015/913726); Mason FM, 2011, J BIOL CHEM, V286, P6577, DOI 10.1074/jbc.M110.190397; Neukomm LJ, 2011, NAT CELL BIOL, V13, P79, DOI 10.1038/ncb2138; Peng XH, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-186; Qian ZL, 2014, GENE CHROMOSOME CANC, V53, P883, DOI 10.1002/gcc.22196; Shi L, 2014, ASIAN PAC J CANCER P, V15, P10439, DOI 10.7314/APJCP.2014.15.23.10439; Shi ZM, 2014, NEURO-ONCOLOGY, V16, P1341, DOI 10.1093/neuonc/nou084; Soderling SH, 2002, NAT CELL BIOL, V4, P970, DOI 10.1038/ncb886; Strong AMP, 2014, ARCH BIOCHEM BIOPHYS, V563, P118, DOI 10.1016/j.abb.2014.07.012; Tcherkezian J, 2007, BIOL CELL, V99, P67, DOI 10.1042/BC20060086; Weiner OD, 2006, PLOS BIOL, V4, P186, DOI 10.1371/journal.pbio.0040038; Wong K, 2001, CELL, V107, P209, DOI 10.1016/S0092-8674(01)00530-X; Wu ZS, 2011, CANCER-AM CANCER SOC, V117, P2842, DOI 10.1002/cncr.25860; Yamashita D, 2015, CANCER RES, V75, P1123, DOI 10.1158/0008-5472.CAN-14-0938; Yamazaki D, 2013, MOL BIOL CELL, V24, P3393, DOI 10.1091/mbc.E13-04-0178; Yang Y, 2006, EXP CELL RES, V312, P2379, DOI 10.1016/j.yexcr.2006.04.001; Ypsilanti AR, 2010, DEVELOPMENT, V137, P1939, DOI 10.1242/dev.044511; Zandvakili I, 2017, ONCOGENE, V36, P3213, DOI 10.1038/onc.2016.473; Zehentmayr F, 2016, CLIN EPIGENETICS, V8, DOI 10.1186/s13148-016-0198-1; Zhang QQ, 2015, ONCOTARGET, V6, P3123, DOI 10.18632/oncotarget.3060; Zhang T, 2014, ACTA BIOCH BIOPH SIN, V46, P1072, DOI 10.1093/abbs/gmu105; Zheng F, 2012, GUT, V61, P278, DOI 10.1136/gut.2011.239145; Zhou WJ, 2011, CELL RES, V21, P609, DOI 10.1038/cr.2011.17; Zhou X, 2013, BIOCHEM BIOPH RES CO, V437, P653, DOI 10.1016/j.bbrc.2013.07.033; Zhou Y, 2017, ONCOGENE, V36, P6518, DOI 10.1038/onc.2017.257; Zhou YH, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0647-2	49	31	33	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2018	37	9					1159	1174		10.1038/s41388-017-0029-7	http://dx.doi.org/10.1038/s41388-017-0029-7			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FY0MK	29234151	Green Published, hybrid			2022-12-17	WOS:000426505400003
J	Qi, M; Jiao, M; Li, X; Hu, J; Wang, L; Zou, Y; Zhao, M; Zhang, R; Liu, H; Mi, J; Zhang, L; Liu, L; Gong, Y; Han, B				Qi, M.; Jiao, M.; Li, X.; Hu, J.; Wang, L.; Zou, Y.; Zhao, M.; Zhang, R.; Liu, H.; Mi, J.; Zhang, L.; Liu, L.; Gong, Y.; Han, B.			CUL4B promotes gastric cancer invasion and metastasis-involvement of upregulation of HER2	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; PROSTATE-CANCER; TUMORIGENESIS; PROGRESSION; CARCINOMA; MICRORNAS; PATHWAY	Cullin 4B (CUL4B) is a scaffold protein overexpressed in several solid malignancies. It is known to silence tumor suppressor through post-transcriptional manner. However, its clinical significance and underlying molecular mechanisms in gastric cancer (GC) remain largely unknown. In this study, we found that CUL4B was significantly overexpressed in GC tissues and its overexpression was correlated with lymph node metastasis and poor prognosis. Through gain-and loss-of-function experiments, we showed that CUL4B promotes GC cell invasion and epithelial-mesenchymal transition (EMT) in vitro, as well as tumor growth and metastasis in vivo. Mechanistically, we identified HER2 as a downstream target gene of CUL4B in GC. CUL4B unregulated HER2 expression via transcriptionally repressing miR-125a. Intriguingly, HER2 inhibitors significantly reversed CUL4B-induced EMT in vitro and partially blocked GC metastasis in tumor xenografts with CUL4B overexpression. Finally, we suggested the involvement of the PI3K/AKT pathway in CUL4B-induced HER2 upregulation in GC. In all, we proposed a model for a CUL4B-miR-125a-HER2 oncoprotein axis, which provided novel insight into how HER2 was activated and contributed to GC progression and metastasis.	[Qi, M.; Jiao, M.; Li, X.; Hu, J.; Zou, Y.; Zhao, M.; Zhang, R.; Liu, H.; Mi, J.; Zhang, L.; Gong, Y.; Han, B.] Shandong Univ, QiLu Med Coll, Sch Basic Med Sci, Key Lab Expt Teratol,Minist Educ, Jinan 250012, Shandong, Peoples R China; [Qi, M.; Jiao, M.; Li, X.; Hu, J.; Zhao, M.; Zhang, R.; Liu, H.; Zhang, L.; Han, B.] Shandong Univ, QiLu Med Coll, Sch Basic Med Sci, Dept Pathol, Jinan 250012, Shandong, Peoples R China; [Qi, M.; Liu, L.; Han, B.] Shandong Univ, Dept Pathol, Qilu Hosp, Jinan, Shandong, Peoples R China; [Li, X.] Binzhou Peoples Hosp, Dept Pathol, Binzhou, Peoples R China; [Wang, L.] Shandong Acad Med Sci, Res Ctr Med Biotechnol, Key Lab Rare & Uncommon Dis Shandong Prov, Jinan, Shandong, Peoples R China; [Zou, Y.; Mi, J.; Gong, Y.] Shandong Univ, QiLu Med Coll, Sch Basic Med Sci, Key Lab Expt Teratol,Minist Educ, Jinan 250012, Shandong, Peoples R China; [Zou, Y.; Mi, J.; Gong, Y.] Shandong Univ, QiLu Med Coll, Sch Basic Med Sci, Dept Mol Med & Genet, Jinan 250012, Shandong, Peoples R China; [Zhao, M.] Binzhou Med Coll, Affiliated Hosp, Dept Pathol, Binzhou, Peoples R China; [Zhang, R.] Xintai Tradit Chinese Med Hosp, Dept Pathol, Tai An, Shandong, Peoples R China	Shandong University; Shandong University; Shandong University; Shandong First Medical University & Shandong Academy of Medical Sciences; University of Jinan; Shandong University; Shandong University; Binzhou Medical University	Han, B (corresponding author), Shandong Univ, QiLu Med Coll, Sch Basic Med Sci, Key Lab Expt Teratol,Minist Educ, Jinan 250012, Shandong, Peoples R China.; Han, B (corresponding author), Shandong Univ, QiLu Med Coll, Sch Basic Med Sci, Dept Pathol, Jinan 250012, Shandong, Peoples R China.	boh@sdu.edu.cn			National Natural Science Foundation of China [81672554, 81472417, 31371369, 31671427]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	We thank Baichun Jiang for technical assistance. This work was supported by National Natural Science Foundation of China (Grants No. 81672554 and 81472417 to BH, 31371369 and 31671427 to YZ).	Bang YJ, 2010, LANCET, V376, P1302; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997; Chen RS, 2009, ONCOGENE, V28, P599, DOI 10.1038/onc.2008.414; Gravalos C, 2008, ANN ONCOL, V19, P1523, DOI 10.1093/annonc/mdn169; Guarino M, 2007, PATHOLOGY, V39, P305, DOI 10.1080/00313020701329914; Hu HL, 2012, CANCER CELL, V22, P781, DOI 10.1016/j.ccr.2012.10.024; Jackson S, 2009, TRENDS BIOCHEM SCI, V34, P562, DOI 10.1016/j.tibs.2009.07.002; Ji QH, 2014, J CELL SCI, V127, P4679, DOI 10.1242/jcs.154245; Jiang T, 2013, MED ONCOL, V30, DOI 10.1007/s12032-013-0534-7; Kong YW, 2012, LANCET ONCOL, V13, pE249, DOI 10.1016/S1470-2045(12)70073-6; Lee J, 2012, FRONT ONCOL, V2, DOI 10.3389/fonc.2012.00021; Lin CH, 2016, ONCOTARGET, V7, P39680, DOI 10.18632/oncotarget.9444; Liu HT, 2016, TUMOR BIOL, V37, P15383, DOI 10.1007/s13277-016-5436-9; Liu HT, 2015, ONCOTARGET, V6, P37467, DOI 10.18632/oncotarget.6059; Mi J, 2017, MOL ONCOL, V11, P305, DOI 10.1002/1878-0261.12038; Mirzaei H, 2016, CURR MED CHEM, V23, P4135, DOI 10.2174/0929867323666160818093854; Nishida N, 2011, CLIN CANCER RES, V17, P2725, DOI 10.1158/1078-0432.CCR-10-2132; Pencheva N, 2013, NAT CELL BIOL, V15, P546, DOI 10.1038/ncb2769; Petroski MD, 2005, NAT REV MOL CELL BIO, V6, P9, DOI 10.1038/nrm1547; Qi M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0084959; Shan YQ, 2015, CANCER GENE THER, V22, P101, DOI 10.1038/cgt.2014.61; Stern HM, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3001539; Sukawa Y, 2014, DIGESTION, V89, P12, DOI 10.1159/000356201; Van Cutsem E, 2016, LANCET, V388, P2654, DOI 10.1016/S0140-6736(16)30354-3; Van Cutsem E, 2015, GASTRIC CANCER, V18, P476, DOI 10.1007/s10120-014-0402-y; Wang CN, 2014, PROSTATE, V74, P689, DOI 10.1002/pros.22787; Wang L, 2015, ONCOTARGET, V6, P35978, DOI 10.18632/oncotarget.5427; Wang L, 2014, PROSTATE, V74, P647, DOI 10.1002/pros.22783; Yang Y, 2015, ONCOGENE, V34, P104, DOI 10.1038/onc.2013.522; Yuan JP, 2015, J PATHOL, V235, P784, DOI 10.1002/path.4492; Zhang C.J., 2016, BIOENERG OPEN ACCESS, V5, P1; Zou YX, 2009, J BIOL CHEM, V284, P33320, DOI 10.1074/jbc.M109.050427	33	31	34	3	10	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 22	2018	37	8					1075	1085		10.1038/onc.2017.380	http://dx.doi.org/10.1038/onc.2017.380			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FX2QD	29106389				2022-12-17	WOS:000425905700010
J	Li, XX; Zhang, HS; Xu, YM; Zhang, RJ; Chen, Y; Fan, L; Qin, YQ; Liu, Y; Li, M; Fang, J				Li, X-X; Zhang, H-S; Xu, Y-M; Zhang, R-J; Chen, Y.; Fan, L.; Qin, Y-Q; Liu, Y.; Li, M.; Fang, J.			Knockdown of IRE1 alpha inhibits colonic tumorigenesis through decreasing beta-catenin and IRE1 alpha targeting suppresses colon cancer cells	ONCOGENE			English	Article							UNFOLDED PROTEIN RESPONSE; ENDOPLASMIC-RETICULUM STRESS; TO-MESENCHYMAL TRANSITION; ER STRESS; STEM-CELLS; EPITHELIAL-CELLS; BREAST-CANCER; CYCLIN D1; WNT; PHOSPHORYLATION	The endoplasmic reticulum (ER) stress occurs frequently in cancers. The unfolded protein response (UPR) is activated to cope with ER stress. This has generated widespread interest in targeting UPR as therapeutic strategies. Inositol-requiring transmembrane kinase/endonuclease 1 alpha (IRE1 alpha), an ER stress sensor, is a key component of UPR. However, the role of IRE1 alpha in tumorigenesis remains unclear. The purpose of this work is to investigate the role of IRE1 alpha in colon cancer and to determine whether IRE1 alpha could serve as a target for therapy. We found that knockdown of IRE1 alpha suppressed the proliferation of colon cancer cells in vitro and xenograft growth in vivo. Inhibition of expression of IRE1 alpha decreased stemness of colon cancer stem cells (CSCs) and attenuated growth of intestinal organoids. Genetic ablation of IRE1 alpha prevented the colitis-associated colonic tumorigenesis in mice. The mechanistic study indicates that knockdown of IRE1 alpha repressed the expression of beta-catenin, a key factor that drives colonic tumorigenesis, through activating pancreatic ER kinase/eukaryotic translation initiation factor 2 alpha signaling. We found that the IRE1a-specific inhibitor 4 mu 8C could suppress the production of beta-catenin, inhibited the proliferation of colon cancer cells, repressed colon CSCs and prevented xenograft growth. The results suggest that IRE1a has a critical role in colonic tumorigenesis and IRE1 alpha targeting might be a strategy for treatment of colon cancers.	[Li, X-X; Zhang, H-S; Xu, Y-M; Zhang, R-J; Chen, Y.; Fan, L.; Qin, Y-Q; Fang, J.] Univ Chinese Acad Sci, Shanghai Inst Biol Sci, Chinese Acad Sci, Key Lab Food Safety Res,Inst Nutrit Sci, 320 Yue Yang Rd, Shanghai 200031, Peoples R China; [Liu, Y.] Wuhan Univ, Coll Life Sci, Wuhan, Hubei, Peoples R China; [Li, M.] Univ Oklahoma, Hlth Sci Ctr, Oklahoma City, OK USA	Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; University of Chinese Academy of Sciences, CAS; Wuhan University; University of Oklahoma System; University of Oklahoma Health Sciences Center	Fang, J (corresponding author), Univ Chinese Acad Sci, Shanghai Inst Biol Sci, Chinese Acad Sci, Key Lab Food Safety Res,Inst Nutrit Sci, 320 Yue Yang Rd, Shanghai 200031, Peoples R China.	jfang@sibs.ac.cn			STCSM [16JC1406100]; NSFC [31270829, 31470769, 31670785]; Chinese Academy of Sciences [XDA08030300, KFJ-EW-STS-099]; CAS/SAFEA	STCSM(Science & Technology Commission of Shanghai Municipality (STCSM)); NSFC(National Natural Science Foundation of China (NSFC)); Chinese Academy of Sciences(Chinese Academy of Sciences); CAS/SAFEA(Chinese Academy of Sciences)	This work was funded by STCSM (16JC1406100), NSFC (31270829, 31470769, 31670785), Chinese Academy of Sciences (XDA08030300, KFJ-EW-STS-099) and CAS/SAFEA International Partnership Program for Creative Research Teams. We thank Dr Xie for kindly providing the vectors.	Anastas JN, 2013, NAT REV CANCER, V13, P11, DOI 10.1038/nrc3419; Brewer JW, 2000, P NATL ACAD SCI USA, V97, P12625, DOI 10.1073/pnas.220247197; Brewer JW, 1999, P NATL ACAD SCI USA, V96, P8505, DOI 10.1073/pnas.96.15.8505; Carrasco DR, 2007, CANCER CELL, V11, P349, DOI 10.1016/j.ccr.2007.02.015; Chen X, 2014, NATURE, V508, P103, DOI 10.1038/nature13119; Chevet E, 2015, CANCER DISCOV, V5, P586, DOI 10.1158/2159-8290.CD-14-1490; Clarke HJ, 2014, CANCER CELL, V25, P563, DOI 10.1016/j.ccr.2014.03.015; COX JS, 1993, CELL, V73, P1197, DOI 10.1016/0092-8674(93)90648-A; Cross BCS, 2012, P NATL ACAD SCI USA, V109, pE869, DOI 10.1073/pnas.1115623109; Feng YX, 2014, CANCER DISCOV, V4, P702, DOI 10.1158/2159-8290.CD-13-0945; Gomez BP, 2007, FASEB J, V21, P4013, DOI 10.1096/fj.06-7990com; Greenman C, 2007, NATURE, V446, P153, DOI 10.1038/nature05610; Hart LS, 2012, J CLIN INVEST, V122, P4621, DOI 10.1172/JCI62973; Heijmans J, 2013, CELL REP, V3, P1128, DOI 10.1016/j.celrep.2013.02.031; Hetz C, 2012, NAT REV MOL CELL BIO, V13, P89, DOI 10.1038/nrm3270; Holland JD, 2013, CURR OPIN CELL BIOL, V25, P254, DOI 10.1016/j.ceb.2013.01.004; Jiang DD, 2015, SEMIN CANCER BIOL, V33, P48, DOI 10.1016/j.semcancer.2015.04.010; Klaus A, 2008, NAT REV CANCER, V8, P387, DOI 10.1038/nrc2389; Lien WH, 2014, GENE DEV, V28, P1517, DOI 10.1101/gad.244772.114; Llado V, 2015, CELL REP, V10, P740, DOI 10.1016/j.celrep.2015.01.007; Ma YJ, 2004, NAT REV CANCER, V4, P966, DOI 10.1038/nrc1505; Mao T, 2011, P NATL ACAD SCI USA, V108, P15852, DOI 10.1073/pnas.1107394108; Mimura N, 2012, BLOOD, V119, P5772, DOI 10.1182/blood-2011-07-366633; MORI K, 1993, CELL, V74, P743; Nagelkerke A, 2014, BBA-REV CANCER, V1846, P277, DOI 10.1016/j.bbcan.2014.07.006; Niederreiter L, 2013, J EXP MED, V210, P2041, DOI 10.1084/jem.20122341; Oakes SA, 2015, ANNU REV PATHOL-MECH, V10, P173, DOI 10.1146/annurev-pathol-012513-104649; Papandreou I, 2011, BLOOD, V117, P1311, DOI 10.1182/blood-2010-08-303099; Qiu YF, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2000514; Reya T, 2005, NATURE, V434, P843, DOI 10.1038/nature03319; Ron D, 2007, NAT REV MOL CELL BIO, V8, P519, DOI 10.1038/nrm2199; Rosekrans SL, 2015, GUT, V64, P195, DOI 10.1136/gutjnl-2013-306347; Sano R, 2013, BBA-MOL CELL RES, V1833, P3460, DOI 10.1016/j.bbamcr.2013.06.028; Sato Toshiro, 2013, Methods Mol Biol, V945, P319, DOI 10.1007/978-1-62703-125-7_19; Sato T, 2009, NATURE, V459, P262, DOI 10.1038/nature07935; Tanjore H, 2011, J BIOL CHEM, V286, P30972, DOI 10.1074/jbc.M110.181164; Thomas SE, 2013, J BIOL CHEM, V288, P7606, DOI 10.1074/jbc.M112.424655; Todd DJ, 2008, NAT REV IMMUNOL, V8, P663, DOI 10.1038/nri2359; Ulianich L, 2008, J CELL SCI, V121, P477, DOI 10.1242/jcs.017202; Vermeulen L, 2010, NAT CELL BIOL, V12, P468, DOI 10.1038/ncb2048; Wang M, 2016, NATURE, V529, P326, DOI 10.1038/nature17041; Wang M, 2014, NAT REV CANCER, V14, P581, DOI 10.1038/nrc3800; Xue J, 2010, GASTROENTEROLOGY, V138, P606, DOI 10.1053/j.gastro.2009.09.049; Zhang F, 2006, J BIOL CHEM, V281, P30036, DOI 10.1074/jbc.M604674200; Zhang HS, 2015, J BIOL CHEM, V290, P15327, DOI 10.1074/jbc.M114.633560; Zhang HS, 2012, J BIOL CHEM, V287, P44164, DOI 10.1074/jbc.M112.401521; Zhao WT, 2013, J BIOL CHEM, V288, P16588, DOI 10.1074/jbc.M113.455121	47	31	32	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 30	2017	36	48					6738	6746		10.1038/onc.2017.284	http://dx.doi.org/10.1038/onc.2017.284			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FO4AJ	28825721				2022-12-17	WOS:000416780800008
J	Guerrero, PA; Tchaicha, JH; Chen, Z; Morales, JE; McCarty, N; Wang, Q; Sulman, EP; Fuller, G; Lang, FF; Rao, G; McCarty, JH				Guerrero, P. A.; Tchaicha, J. H.; Chen, Z.; Morales, J. E.; McCarty, N.; Wang, Q.; Sulman, E. P.; Fuller, G.; Lang, F. F.; Rao, G.; McCarty, J. H.			Glioblastoma stem cells exploit the alpha v beta 8 integrin-TGF beta 1 signaling axis to drive tumor initiation and progression	ONCOGENE			English	Article							GROWTH-FACTOR-BETA; ANTI-VEGF THERAPY; TGF-BETA; INTEGRIN ALPHA-V-BETA-8; ANTIANGIOGENIC THERAPY; CEREBRAL-HEMORRHAGE; SELF-RENEWAL; BRAIN; CANCER; EXPRESSION	Glioblastoma (GBM) is a primary brain cancer that contains populations of stem-like cancer cells (GSCs) that home to specialized perivascular niches. GSC interactions with their niche influence self-renewal, differentiation and drug resistance, although the pathways underlying these events remain largely unknown. Here, we report that the integrin alpha v beta 8 and its latent transforming growth factor beta 1 (TGF beta 1) protein ligand have central roles in promoting niche co-option and GBM initiation. alpha v beta 8 integrin is highly expressed in GSCs and is essential for self-renewal and lineage commitment in vitro. Fractionation of beta 8(high) cells from freshly resected human GBM samples also reveals a requirement for this integrin in tumorigenesis in vivo. Whole-transcriptome sequencing reveals that alpha v beta 8 integrin regulates tumor development, in part, by driving TGF beta 1-induced DNA replication and mitotic checkpoint progression. Collectively, these data identify the av beta 8 integrin-TGF beta 1 signaling axis as crucial for exploitation of the perivascular niche and identify potential therapeutic targets for inhibiting tumor growth and progression in patients with GBM.	[Guerrero, P. A.; Tchaicha, J. H.; Chen, Z.; Morales, J. E.; Lang, F. F.; Rao, G.; McCarty, J. H.] Univ Texas MD Anderson Canc Ctr, Dept Neurosurg, 1515 Holcombe Blvd,Unit 1004, Houston, TX 77030 USA; [McCarty, N.] Univ Texas Hlth Sci Ctr Houston, Brown Inst Mol Med, Houston, TX 77030 USA; [Wang, Q.; Sulman, E. P.] Univ Texas MD Anderson Canc Ctr, Dept Radiat Oncol, Houston, TX 77030 USA; [Wang, Q.; Sulman, E. P.] Univ Texas MD Anderson Canc Ctr, Dept Genom Med, Houston, TX 77030 USA; [Sulman, E. P.] Univ Texas MD Anderson Canc Ctr, Dept Translat Mol Pathol, Houston, TX 77030 USA; [Fuller, G.] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; University of Texas Health Science Center Houston; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	McCarty, JH (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Neurosurg, 1515 Holcombe Blvd,Unit 1004, Houston, TX 77030 USA.	jhmccarty@mdanderson.org		Sulman, Erik/0000-0003-4933-9120	NIH/NINDS [R01NS0 7635, R01NS078402]; Cancer Prevention and Research Institute of Texas [RP140411]; NIH/NCI SPORE in Brain Cancer [P50CA127001]; NATIONAL CANCER INSTITUTE [P30CA016672, P50CA127001] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS078402, R01NS094615, R01NS087635] Funding Source: NIH RePORTER	NIH/NINDS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); Cancer Prevention and Research Institute of Texas; NIH/NCI SPORE in Brain Cancer; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	We would like to thank colleagues in the M.D. Anderson Neurosurgery department for providing freshly resected human samples. This work was supported by grants to JHM from NIH/NINDS (R01NS0 7635 and R01NS078402), the Cancer Prevention and Research Institute of Texas (RP140411), and in part by an NIH/NCI SPORE in Brain Cancer (P50CA127001).	Allinson KR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039336; Anido J, 2010, CANCER CELL, V18, P655, DOI 10.1016/j.ccr.2010.10.023; Arnold TD, 2014, DEVELOPMENT, V141, P4489, DOI 10.1242/dev.107193; Arnold TD, 2012, J NEUROSCI, V32, P1197, DOI 10.1523/JNEUROSCI.5648-11.2012; Arrillaga-Romany I, 2014, EXPERT OPIN INV DRUG, V23, P199, DOI 10.1517/13543784.2014.856880; Bao SD, 2006, NATURE, V444, P756, DOI 10.1038/nature05236; Batchelor TT, 2014, CLIN CANCER RES, V20, P5612, DOI 10.1158/1078-0432.CCR-14-0834; Bergers G, 2008, NAT REV CANCER, V8, P592, DOI 10.1038/nrc2442; Bruna A, 2007, CANCER CELL, V11, P147, DOI 10.1016/j.ccr.2006.11.023; Cambier S, 2005, AM J PATHOL, V166, P1883, DOI 10.1016/S0002-9440(10)62497-2; Chaffer CL, 2011, P NATL ACAD SCI USA, V108, P7950, DOI 10.1073/pnas.1102454108; Cheerathodi M, 2016, MOL CANCER RES, V14, P1277, DOI 10.1158/1541-7786.MCR-16-0251; Dardiotis E, 2017, NEUROMOL MED, V19, P69, DOI 10.1007/s12017-016-8429-3; Delamarre E, 2009, AM J PATHOL, V175, P844, DOI 10.2353/ajpath.2009.080920; Ding Y, 2013, CANCER DISCOV, V3, P198, DOI 10.1158/2159-8290.CD-12-0353; Ellis LM, 2009, NATURE, V458, P290, DOI 10.1038/458290a; Fang L, 2011, ONCOGENE, V30, P806, DOI 10.1038/onc.2010.465; Ferrara N, 2004, NAT REV DRUG DISCOV, V3, P391, DOI 10.1038/nrd1381; Frei K, 2015, ONCOTARGET, V6, P5963, DOI 10.18632/oncotarget.3467; Gilbert MR, 2012, J NEURO-ONCOL, V106, P147, DOI 10.1007/s11060-011-0650-1; Gilbertson RJ, 2007, NAT REV CANCER, V7, P733, DOI 10.1038/nrc2246; Hamidi H, 2016, BRIT J CANCER, V115, P1017, DOI 10.1038/bjc.2016.312; Hirota S, 2015, DEVELOPMENT, V142, P4363, DOI 10.1242/dev.113746; Hirota S, 2011, DEVELOPMENT, V138, P5157, DOI 10.1242/dev.069153; Huang JJ, 2016, BIOCHEM SOC T, V44, P1441, DOI 10.1042/BST20160065; Hynes RO, 2009, SCIENCE, V326, P1216, DOI 10.1126/science.1176009; Jahangiri A, 2013, CLIN CANCER RES, V19, P1773, DOI 10.1158/1078-0432.CCR-12-1281; Jain RK, 2007, NAT REV NEUROSCI, V8, P610, DOI 10.1038/nrn2175; Kanamori M, 2004, CANCER RES, V64, P2751, DOI 10.1158/0008-5472.CAN-03-3354; Lathia JD, 2015, GENE DEV, V29, P1203, DOI 10.1101/gad.261982.115; Lathia JD, 2010, CELL STEM CELL, V6, P421, DOI 10.1016/j.stem.2010.02.018; Lee HS, 2015, MOL CELL BIOL, V35, P1401, DOI 10.1128/MCB.00112-15; Llaguno SA, 2009, CANCER CELL, V15, P45, DOI 10.1016/j.ccr.2008.12.006; Lu KV, 2012, CANCER CELL, V22, P21, DOI 10.1016/j.ccr.2012.05.037; Ma L, 2016, TRANSL STROKE RES, V7, P488, DOI 10.1007/s12975-016-0478-2; Massague J, 2008, CELL, V134, P215, DOI 10.1016/j.cell.2008.07.001; McCarty JH, 2002, MOL CELL BIOL, V22, P7667, DOI 10.1128/MCB.22.21.7667-7677.2002; McCarty JH, 2013, CLIN CANCER RES, V19, P1631, DOI 10.1158/1078-0432.CCR-13-0051; McCarty JH, 2009, CURR OPIN HEMATOL, V16, P209, DOI 10.1097/MOH.0b013e32832a07eb; Ming XY, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13568; Mobley AK, 2011, GLIA, V59, P1579, DOI 10.1002/glia.21199; Mobley AK, 2009, J CELL SCI, V122, P1842, DOI 10.1242/jcs.043257; Nakajima H, 2008, J CELL BIOL, V181, P89, DOI 10.1083/jcb.200708176; Nguyen HL, 2011, LAB INVEST, V91, P1554, DOI 10.1038/labinvest.2011.124; NISHIMURA SL, 1994, J BIOL CHEM, V269, P28708; Nyati S, 2015, SCI SIGNAL, V8, DOI 10.1126/scisignal.2005379; Patel AP, 2014, SCIENCE, V344, P1396, DOI 10.1126/science.1254257; Penuelas S, 2009, CANCER CELL, V15, P315, DOI 10.1016/j.ccr.2009.02.011; Piao Y, 2013, CLIN CANCER RES, V19, P4392, DOI 10.1158/1078-0432.CCR-12-1557; Proctor JM, 2005, J NEUROSCI, V25, P9940, DOI 10.1523/JNEUROSCI.3467-05.2005; Reyes SB, 2013, MOL BIOL CELL, V24, P474, DOI 10.1091/mbc.E12-07-0521; Robertson IB, 2016, COLD SPRING HARB PER, V8, P6; Rojas A, 2009, BBA-MOL CELL RES, V1793, P1165, DOI 10.1016/j.bbamcr.2009.02.001; Sanai N, 2005, NEW ENGL J MED, V353, P811, DOI 10.1056/NEJMra043666; Sathyan P, 2015, J NEUROSCI, V35, P15097, DOI 10.1523/JNEUROSCI.1265-15.2015; Schittenhelm J, 2013, INT J CLIN EXP PATHO, V6, P2719; Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128; Su H, 2010, AM J PATHOL, V176, P1018, DOI 10.2353/ajpath.2010.090453; Tchaicha JH, 2010, ONCOGENE, V29, P4460, DOI 10.1038/onc.2010.199; Tchaicha JH, 2011, CANCER RES, V71, P6371, DOI 10.1158/0008-5472.CAN-11-0991; Toledo CM, 2015, CELL REP, V13, P2425, DOI 10.1016/j.celrep.2015.11.021; Upadhyaya M, 2012, HUM MUTAT, V33, P763, DOI 10.1002/humu.22044; Vaillant F, 2008, CANCER RES, V68, P7711, DOI 10.1158/0008-5472.CAN-08-1949; VENSTROM K, 1995, MOL BIOL CELL, V6, P419, DOI 10.1091/mbc.6.4.419; Wee B, 2016, SCI REP-UK, V6, DOI 10.1038/srep25956; Wei J, 2010, CLIN CANCER RES, V16, P461, DOI 10.1158/1078-0432.CCR-09-1983; Weis SM, 2011, CSH PERSPECT MED, V1, DOI 10.1101/cshperspect.a006478; Worthington JJ, 2011, TRENDS BIOCHEM SCI, V36, P47, DOI 10.1016/j.tibs.2010.08.002; Zheng HW, 2008, NATURE, V455, P1129, DOI 10.1038/nature07443	69	31	31	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 23	2017	36	47					6568	6580		10.1038/onc.2017.248	http://dx.doi.org/10.1038/onc.2017.248			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FN5LN	28783169	Green Accepted			2022-12-17	WOS:000416049200006
J	Shahi, P; Wang, CY; Chou, J; Hagerling, C; Velozo, HG; Ruderisch, A; Yu, Y; Lai, MD; Werb, Z				Shahi, P.; Wang, C-Y; Chou, J.; Hagerling, C.; Velozo, H. Gonzalez; Ruderisch, A.; Yu, Y.; Lai, M-D; Werb, Z.			GATA3 targets semaphorin 3B in mammary epithelial cells to suppress breast cancer progression and metastasis	ONCOGENE			English	Article							LUNG-CANCER; CHROMOSOME 3P21.3; LIM-KINASE; EXPRESSION; GROWTH; DIFFERENTIATION; REGULATOR; MORPHOGENESIS; NEUROPILIN-1; RECEPTORS	Semaphorin 3B (SEMA3B) is a secreted axonal guidance molecule that is expressed during development and throughout adulthood. Recently, SEMA3B has emerged as a tumor suppressor in non-neuronal cells. Here, we show that SEMA3B is a direct target of GATA3 transcriptional activity. GATA3 is a key transcription factor that regulates genes involved in mammary luminal cell differentiation and tumor suppression. We show that GATA3 relies on SEMA3B for suppression of tumor growth. Loss of SEMA3B renders GATA3 inactive and promotes aggressive breast cancer development. Overexpression of SEMA3B in cells lacking GATA3 induces a GATA3-like phenotype and higher levels of SEMA3B are associated with better cancer patient prognosis. Moreover, SEMA3B interferes with activation of LIM kinases (LIMK1 and LIMK2) to abrogate breast cancer progression. Our data provide new insights into the role of SEMA3B in mammary gland and provides a new branch of GATA3 signaling that is pivotal for inhibition of breast cancer progression and metastasis.	[Shahi, P.; Wang, C-Y; Chou, J.; Hagerling, C.; Velozo, H. Gonzalez; Ruderisch, A.; Yu, Y.; Werb, Z.] Univ Calif San Francisco, Dept Anat, 513 Parnassus Ave,BOX 0452, San Francisco, CA 94143 USA; [Shahi, P.; Wang, C-Y; Chou, J.; Hagerling, C.; Velozo, H. Gonzalez; Ruderisch, A.; Yu, Y.; Werb, Z.] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, 513 Parnassus Ave,BOX 0452, San Francisco, CA 94143 USA; [Shahi, P.] Univ Calif San Francisco, Dept Bioengn & Therapeut Sci, San Francisco, CA 94143 USA; [Wang, C-Y; Lai, M-D] Natl Cheng Kung Univ, Coll Med, Inst Basic Med Sci, Dept Biochem & Mol Biol, Tainan, Taiwan	University of California System; University of California San Francisco; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer Center; University of California System; University of California San Francisco; National Cheng Kung University	Werb, Z (corresponding author), Univ Calif San Francisco, Dept Anat, 513 Parnassus Ave,BOX 0452, San Francisco, CA 94143 USA.; Werb, Z (corresponding author), Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, 513 Parnassus Ave,BOX 0452, San Francisco, CA 94143 USA.	zena.werb@ucsf.edu	Lai, Ming-Derg/M-8028-2014	Wang, Chih-Yang/0000-0002-4137-5074	National Cancer Institute [R01 CA129523, R01 CA190851]; Institutional National Research Service Award [T32 CA108462]; Ministry of Science and Technology, Taiwan [104-2917-I-006-002]; Tegger Foundation; Wenner-Gren Foundations; Sweden-America Foundation; Swedish Society of Medicine; Swedish Society for Medical Research; Becas Chile Scholarship; NATIONAL CANCER INSTITUTE [R01CA129523, R01CA190851, T32CA108462] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Institutional National Research Service Award(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Ministry of Science and Technology, Taiwan(Ministry of Science and Technology, Taiwan); Tegger Foundation; Wenner-Gren Foundations; Sweden-America Foundation; Swedish Society of Medicine; Swedish Society for Medical Research; Becas Chile Scholarship; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We acknowledge Dr Gera Neufeld for providing the SEMA3B overexpression DNA construct. We thank Dr Luca Tamagnone for his generous gift of lentiviral SEMA3B short hairpin RNA constructs. We thank Elena Atamaniuc for technical assistance. This study was supported by funds from the National Cancer Institute (R01 CA129523 and R01 CA190851 to ZW); PS was supported by an Institutional National Research Service Award (T32 CA108462); C-YW was supported by a grant from the Ministry of Science and Technology, Taiwan (104-2917-I-006-002); CH was supported by funds from the Tegger Foundation, Wenner-Gren Foundations, Sweden-America Foundation, Swedish Society of Medicine and Swedish Society for Medical Research; and HGV was supported by a Becas Chile Scholarship.	Aguirre-Gamboa R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074250; Asselin-Labat ML, 2007, NAT CELL BIOL, V9, P201, DOI 10.1038/ncb1530; Bagheri-Yarmand R, 2006, INT J CANCER, V118, P2703, DOI 10.1002/ijc.21650; Ballard MS, 2015, CELL REP, V13, P290, DOI 10.1016/j.celrep.2015.09.006; Bernatchez PN, 2002, J CELL BIOCHEM, V85, P629, DOI 10.1002/jcb.10155; Bertucci F, 2000, HUM MOL GENET, V9, P2981, DOI 10.1093/hmg/9.20.2981; Brose K, 1999, CELL, V96, P795, DOI 10.1016/S0092-8674(00)80590-5; Castro-Rivera E, 2004, P NATL ACAD SCI USA, V101, P11432, DOI 10.1073/pnas.0403969101; Castro-Rivera E, 2008, CANCER RES, V68, P8295, DOI 10.1158/0008-5472.CAN-07-6601; Chou J, 2013, NAT CELL BIOL, V15, P201, DOI 10.1038/ncb2672; Driessens MHE, 2001, CURR BIOL, V11, P339, DOI 10.1016/S0960-9822(01)00092-6; Du F, 2015, MED RES REV, V35, P1300, DOI 10.1002/med.21362; Dydensborg AB, 2009, ONCOGENE, V28, P2634, DOI 10.1038/onc.2009.126; Edwards DC, 1999, NAT CELL BIOL, V1, P253, DOI 10.1038/12963; Falk J, 2005, NEURON, V48, P63, DOI 10.1016/j.neuron.2005.08.033; Finak G, 2008, NAT MED, V14, P518, DOI 10.1038/nm1764; Hall C, 2001, J BIOL CHEM, V276, P43482, DOI 10.1074/jbc.C100455200; Hoch RV, 1999, INT J CANCER, V84, P122; Home P, 2009, J BIOL CHEM, V284, P28729, DOI 10.1074/jbc.M109.016840; Jiang YZ, 2014, CANCER-AM CANCER SOC, V120, P1329, DOI 10.1002/cncr.28566; Jin Z, 1997, J NEUROSCI, V17, P6256; Johnson EO, 2012, J CELL SCI, V125, P1204, DOI 10.1242/jcs.092304; Kaufman CK, 2003, GENE DEV, V17, P2108, DOI 10.1101/gad.1115203; KO LJ, 1993, MOL CELL BIOL, V13, P4011, DOI 10.1128/MCB.13.7.4011; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Kouros-Mehr H, 2008, CURR OPIN CELL BIOL, V20, P164, DOI 10.1016/j.ceb.2008.02.003; Kouros-Mehr H, 2008, CANCER CELL, V13, P141, DOI 10.1016/j.ccr.2008.01.011; Kouros-Mehr H, 2006, CELL, V127, P1041, DOI 10.1016/j.cell.2006.09.048; Kruger RR, 2005, NAT REV MOL CELL BIO, V6, P789, DOI 10.1038/nrm1740; Kuroki T, 2003, CANCER RES, V63, P3352; Lagoutte E, 2016, SCI REP-UK, V6, DOI 10.1038/srep24925; LUO YL, 1993, CELL, V75, P217, DOI 10.1016/0092-8674(93)80064-L; Macias H, 2011, DEV CELL, V20, P827, DOI 10.1016/j.devcel.2011.05.012; Marlow R, 2008, CANCER RES, V68, P7819, DOI 10.1158/0008-5472.CAN-08-1357; McConnell BV, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-75; Mehra R, 2005, CANCER RES, V65, P11259, DOI 10.1158/0008-5472.CAN-05-2495; Neufeld G, 2008, NAT REV CANCER, V8, P632, DOI 10.1038/nrc2404; Ohashi K, 2000, J BIOL CHEM, V275, P3577, DOI 10.1074/jbc.275.5.3577; Rhodes DR, 2004, NEOPLASIA, V6, P1, DOI 10.1016/S1476-5586(04)80047-2; Sekido Y, 1996, P NATL ACAD SCI USA, V93, P4120, DOI 10.1073/pnas.93.9.4120; Sellheyer K, 2010, J CUTAN PATHOL, V37, P357, DOI 10.1111/j.1600-0560.2009.01416.x; Shea KF, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003398; Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6; Staton CA, 2011, HISTOPATHOLOGY, V59, P274, DOI 10.1111/j.1365-2559.2011.03922.x; Tomizawa Y, 2001, P NATL ACAD SCI USA, V98, P13954, DOI 10.1073/pnas.231490898; Tse C, 2002, CANCER RES, V62, P542; Turner LJ, 2004, J BIOL CHEM, V279, P33199, DOI 10.1074/jbc.M402943200; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; Wang KH, 1999, CELL, V96, P771, DOI 10.1016/S0092-8674(00)80588-7; Wilson BJ, 2008, MOL CANCER, V7, DOI 10.1186/1476-4598-7-49; Yagi R, 2011, INT IMMUNOL, V23, P415, DOI 10.1093/intimm/dxr029	51	31	35	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 5	2017	36	40					5567	5575		10.1038/onc.2017.165	http://dx.doi.org/10.1038/onc.2017.165			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FI8ZW	28581515	Green Accepted, Green Submitted			2022-12-17	WOS:000412293600002
J	Yu, L; Liang, Y; Cao, X; Wang, X; Gao, H; Lin, SY; Schiff, R; Wang, XS; Li, K				Yu, L.; Liang, Y.; Cao, X.; Wang, X.; Gao, H.; Lin, S-Y; Schiff, R.; Wang, X-S; Li, K.			Identification of MYST3 as a novel epigenetic activator of ER alpha frequently amplified in breast cancer	ONCOGENE			English	Article							ESTROGEN-RECEPTOR-ALPHA; ACUTE MYELOID-LEUKEMIA; HOX GENE-EXPRESSION; HISTONE ACETYLTRANSFERASE; ENDOCRINE RESISTANCE; THERAPEUTIC TARGET; 8P11-P12 AMPLICON; CELL-LINES; STEM-CELLS; MOZ	Estrogen receptor a (ERa) is a master driver of a vast majority of breast cancers. Breast cancer cells often develop resistance to endocrine therapy via restoration of the ERa activity through survival pathways. Thus identifying the epigenetic activator of ERa that can be targeted to block ERa gene expression is a critical topic of endocrine therapy. Here, integrative genomic analysis identified MYST3 as a potential oncogene target that is frequently amplified in breast cancer. MYST3 is involved in histone acetylation via its histone acetyltransferase domain (HAT) and, as a result, activates gene expression by altering chromatin structure. We found that MYST3 was amplified in 11% and/or overexpressed in 15% of breast tumors, and overexpression of MYST3 correlated with worse clinical outcome in estrogen receptor+ (ER+) breast cancers. Interestingly, MYST3 depletion drastically inhibited proliferation in MYST3-high, ER+ breast cancer cells, but not in benign breast epithelial cells or in MYST3-low breast cancer cells. Importantly, we discovered that knocking down MYST3 resulted in profound reduction of ERa expression, while ectopic expression of MYST3 had the reversed effect. Chromatin immunoprecipitation revealed that MYST3 binds to the proximal promoter region of ERa gene, and inactivating mutations in its HAT domain abolished its ability to regulate ERa, suggesting MYST3 functioning as a histone acetyltransferase that activates ERa promoter. Furthermore, MYST3 inhibition with inducible MYST3 shRNAs potently attenuated breast tumor growth in mice. Together, this study identifies the first histone acetyltransferase that activates ERa expression which may be potentially targeted to block ERa at transcriptional level.	[Yu, L.; Liang, Y.; Gao, H.; Li, K.] Baylor Coll Med, Michael E DeBakey Dept Surg, Houston, TX 77030 USA; [Liang, Y.; Cao, X.; Schiff, R.; Wang, X-S] Baylor Coll Med, Lester & Sue Smith Breast Ctr, Houston, TX 77030 USA; [Cao, X.; Wang, X.; Schiff, R.; Wang, X-S] Baylor Coll Med, Dan L Duncan Canc Ctr, Houston, TX 77030 USA; [Cao, X.; Wang, X.; Schiff, R.; Wang, X-S] Baylor Coll Med, Dept Med, Houston, TX 77030 USA; [Cao, X.; Wang, X.; Wang, X-S] Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; [Wang, X.; Wang, X-S] Univ Pittsburgh, Inst Canc, Pittsburgh, PA USA; [Wang, X.; Wang, X-S] Univ Pittsburgh, Dept Pathol, Pittsburgh, PA USA; [Lin, S-Y] Univ Texas MD Anderson Canc Ctr, Dept Syst Biol, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Texas System; UTMD Anderson Cancer Center	Wang, XS (corresponding author), Univ Pittsburgh, Inst Canc, Hillman Canc Ctr, Res Pavil,5117 Ctr Ave,Room G5a, Pittsburgh, PA 15213 USA.; Li, K (corresponding author), Baylor Coll Med, ABBR, Dept Surg, One Baylor Plaza, Houston, TX 77030 USA.	wangx13@pitt.edu; kli@bcm.edu			National Institutes of Health [CA161513, CA155151, CA181368, CA183976]; Dan L. Duncan Cancer Center at Baylor College of Medicine; Susan G. Komen foundation [PDF15333523, CDMRP W81XWH-13-1-0201]; Susan G. Komen for the cure grants Promise grant [PG12221410]; NIH SPORE Grants [P50 CA058183, CA186784-01]; NIH Cancer Center Grant [P30CA125123]; Breast Cancer Research Foundation; Cancer Prevention Research Institute of Texas [CPRIT RP140102, CRPIT RP130310]; Cancer Research UK; British Columbia Cancer Agency Branch; NATIONAL CANCER INSTITUTE [P50CA058183, R01CA181368, P30CA125123, P50CA186784, R01CA183976, R01CA155151, R21CA161513] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Dan L. Duncan Cancer Center at Baylor College of Medicine; Susan G. Komen foundation(Susan G. Komen Breast Cancer Foundation); Susan G. Komen for the cure grants Promise grant; NIH SPORE Grants; NIH Cancer Center Grant; Breast Cancer Research Foundation; Cancer Prevention Research Institute of Texas; Cancer Research UK(Cancer Research UK); British Columbia Cancer Agency Branch; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by grants from the National Institutes of Health (KL, CA161513, CA155151; X-SW, CA181368 & CA183976), a Pilot Project Grant from the Dan L. Duncan Cancer Center at Baylor College of Medicine (KL), Susan G. Komen foundation PDF15333523 (XW), CDMRP W81XWH-13-1-0201(X-XC). This study was partly supported by the Susan G. Komen for the cure grants Promise grant PG12221410 (RS), NIH SPORE Grants P50 CA058183 (RS) and CA186784-01 (RS), and Cancer Center Grant P30CA125123 (RS), Breast Cancer Research Foundation (RS), Cancer Prevention Research Institute of Texas (RS, CPRIT RP140102) and SYL, CRPIT RP130310. We also thank Dr. Ana Rodriguez from the Research Core Team at Michael E. DeBakey Department of Surgery, Baylor College of Medicine for editing of this manuscript. The results published here are in part based upon data generated by TCGA (dbGaP accession: phs000178.v6.p6). This study also makes use of data generated by the Molecular Taxonomy of Breast Cancer International Consortium (funding for that project was provided by Cancer Research UK and the British Columbia Cancer Agency Branch).	Agochiya M, 1999, ONCOGENE, V18, P5646, DOI 10.1038/sj.onc.1202957; Avvakumov N, 2007, ONCOGENE, V26, P5395, DOI 10.1038/sj.onc.1210608; Bernard-Pierrot I, 2008, CANCER RES, V68, P7165, DOI 10.1158/0008-5472.CAN-08-1360; Borrow J, 1996, NAT GENET, V14, P33, DOI 10.1038/ng0996-33; Bristow CAP, 2003, NUCLEIC ACIDS RES, V31, P2735, DOI 10.1093/nar/gkg401; Carlson S, 2014, J CELL PHYSIOL, V229, P1571, DOI 10.1002/jcp.24617; Chen X, 2002, NUCLEIC ACIDS RES, V30, P412, DOI 10.1093/nar/30.1.412; Collins HM, 2006, J BIOL CHEM, V281, P17124, DOI 10.1074/jbc.M602633200; Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983; Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X; Deguchi K, 2003, CANCER CELL, V3, P259, DOI 10.1016/S1535-6108(03)00051-5; Ellison-Zelski SJ, 2009, MOL CELL BIOL, V29, P4949, DOI 10.1128/MCB.00383-09; Esteyries S, 2008, LEUKEMIA, V22, P663, DOI 10.1038/sj.leu.2404930; Feng Q, 2014, CELL RES, V24, P809, DOI 10.1038/cr.2014.71; Georgiakaki M, 2006, MOL ENDOCRINOL, V20, P2122, DOI 10.1210/me.2005-0149; Hervouet E, 2013, EPIGENETICS-US, V8, P237, DOI 10.4161/epi.23790; Ignatiadis M, 2013, NAT REV CLIN ONCOL, V10, P494, DOI 10.1038/nrclinonc.2013.124; Jeong KW, 2011, NAT STRUCT MOL BIOL, V18, P1358, DOI 10.1038/nsmb.2153; Kim MY, 2006, MOL ENDOCRINOL, V20, P1479, DOI 10.1210/me.2005-0531; Kim MY, 2001, EMBO J, V20, P6084, DOI 10.1093/emboj/20.21.6084; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Kwek SS, 2009, ONCOGENE, V28, P1892, DOI 10.1038/onc.2009.34; Manning G, 2002, SCIENCE, V298, P1912, DOI 10.1126/science.1075762; Musgrove EA, 2009, NAT REV CANCER, V9, P631, DOI 10.1038/nrc2713; Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008; Osborne CK, 2011, ANNU REV MED, V62, P233, DOI 10.1146/annurev-med-070909-182917; Paggetti J, 2010, ONCOGENE, V29, P5019, DOI 10.1038/onc.2010.254; Perez-Campo FM, 2014, STEM CELLS, V32, P1591, DOI 10.1002/stem.1606; Santarius T, 2010, NAT REV CANCER, V10, P59, DOI 10.1038/nrc2771; Sheikh BN, 2015, ONCOGENE, V34, P5807, DOI 10.1038/onc.2015.33; Thomas C, 2011, NAT REV CANCER, V11, P597, DOI 10.1038/nrc3093; Turner-Ivey B, 2014, NEOPLASIA, V16, P644, DOI 10.1016/j.neo.2014.07.007; Voss AK, 2009, DEV CELL, V17, P674, DOI 10.1016/j.devcel.2009.10.006; Wang CG, 2001, J BIOL CHEM, V276, P18375, DOI 10.1074/jbc.M100800200; Wang XS, 2009, NAT BIOTECHNOL, V27, P1005, DOI 10.1038/nbt.1584; Wishart DS, 2006, NUCLEIC ACIDS RES, V34, pD668, DOI 10.1093/nar/gkj067; Yang XJ, 2007, ONCOGENE, V26, P5408, DOI 10.1038/sj.onc.1210609; Yang ZQ, 2006, CANCER RES, V66, P11632, DOI 10.1158/0008-5472.CAN-06-2946; Yang ZQ, 2004, CANCER GENET CYTOGEN, V155, P57, DOI 10.1016/j.cancergencyto.2004.03.013; Zhang XZ, 2016, PROCEEDINGS 2016 IEEE INTERNATIONAL CONFERENCE ON INDUSTRIAL TECHNOLOGY (ICIT), P2016, DOI 10.1109/ICIT.2016.7475077	40	31	32	3	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 18	2017	36	20					2910	2918		10.1038/onc.2016.433	http://dx.doi.org/10.1038/onc.2016.433			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EV3ZM	27893709	Green Accepted, Green Published, hybrid			2022-12-17	WOS:000401697800013
J	van Andel, H; Kocemba, KA; de Haan-Kramer, A; Mellink, CH; Piwowar, M; Broijl, A; van Duin, M; Sonneveld, P; Maurice, MM; Kersten, MJ; Spaargaren, M; Pals, ST				van Andel, H.; Kocemba, K. A.; de Haan-Kramer, A.; Mellink, C. H.; Piwowar, M.; Broijl, A.; van Duin, M.; Sonneveld, P.; Maurice, M. M.; Kersten, M. J.; Spaargaren, M.; Pals, S. T.			Loss of CYLD expression unleashes Wnt signaling in multiple myeloma and is associated with aggressive disease	ONCOGENE			English	Article							TUMOR-SUPPRESSOR CYLD; EPIGENETIC DYSREGULATION; PATHWAY; ENZYME; PROLIFERATION; PATHOGENESIS; ACTIVATION; MUTATIONS; RECEPTORS; APOPTOSIS	Deletion or mutation of the gene encoding the deubiquitinating enzyme CYLD is a common genomic aberration in multiple myeloma (MM). However, the functional consequence of CYLD loss and the mechanism underlying its putative role as a tumor suppressor gene in the pathogenesis of MM has not been established. Here, we show that CYLD expression is highly variable in myeloma cell lines and primary MMs and that low CYLD expression is associated with disease progression from monoclonal gammopathy of undetermined significance to MM, and with poor overall and progression free-survival of MM patients. Functional assays revealed that CYLD represses MM cell proliferation and survival. Furthermore, CYLD acts as a negative regulator of NF-kappa B and Wnt/beta-catenin signaling and loss of CYLD sensitizes MM cells to NF-kappa B-stimuli and Wnt ligands. Interestingly, in primary MMs, low CYLD expression strongly correlated with a proliferative and Wnt signaling-gene expression signature, but not with an NF kappa B target gene signature. Altogether, our findings identify CYLD as a negative regulator of NF-kappa B and Wnt/beta-catenin signaling in MM and indicate that loss of CYLD enhances MM aggressiveness through Wnt pathway activation. Thus, targeting the Wnt pathway could be a promising therapeutic strategy in MM with loss of CYLD activity.	[van Andel, H.; Kocemba, K. A.; de Haan-Kramer, A.; Spaargaren, M.; Pals, S. T.] Univ Amsterdam, Acad Med Ctr, Dept Pathol, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands; [van Andel, H.; Kocemba, K. A.; de Haan-Kramer, A.; Kersten, M. J.; Spaargaren, M.; Pals, S. T.] Univ Amsterdam, Acad Med Ctr, Lymphoma & Myeloma Ctr Amsterdam LYMMCARE, Amsterdam, Netherlands; [Kocemba, K. A.] Jagiellonian Univ, Dept Med Biochem, Med Coll, Krakow, Poland; [Mellink, C. H.] Univ Amsterdam, Acad Med Ctr, Dept Clin Genet, Amsterdam, Netherlands; [Piwowar, M.] Jagiellonian Univ, Dept Bioinformat & Telemed, Med Coll, Krakow, Poland; [Broijl, A.; van Duin, M.; Sonneveld, P.] Erasmus MC, Dept Hematol, Rotterdam, Netherlands; [Maurice, M. M.] Univ MC Utrecht, Dept Cell Biol, Utrecht, Netherlands; [Kersten, M. J.] Univ Amsterdam, Acad Med Ctr, Dept Hematol, Amsterdam, Netherlands	University of Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; Jagiellonian University; Collegium Medicum Jagiellonian University; University of Amsterdam; Academic Medical Center Amsterdam; Vrije Universiteit Amsterdam; Jagiellonian University; Collegium Medicum Jagiellonian University; Erasmus University Rotterdam; Erasmus MC; Utrecht University; Utrecht University Medical Center; University of Amsterdam; Academic Medical Center Amsterdam	Pals, ST (corresponding author), Univ Amsterdam, Acad Med Ctr, Dept Pathol, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands.	s.t.pals@amc.uva.nl	kocemba, kinga/AAE-2305-2019; Kocemba, Kinga/AAE-6520-2021; Spaargaren, Marcel/AAU-1298-2021; Piwowar, Monika Weronika/L-5452-2013	kocemba, kinga/0000-0002-7119-2412; Spaargaren, Marcel/0000-0002-3135-5109; Maurice, Madelon/0000-0001-6885-5361; Pals, Steven/0000-0002-1419-0939; Piwowar, Monika Weronika/0000-0003-4645-8730	Dutch Cancer Society; EU-FP7 OVER-MYR	Dutch Cancer Society(KWF Kankerbestrijding); EU-FP7 OVER-MYR	This study was supported by grants from the Dutch Cancer Society and EU-FP7 OVER-MYR.	An CH, 2010, PATHOLOGY, V42, P583, DOI 10.3109/00313025.2010.508735; Annunziata CM, 2007, CANCER CELL, V12, P115, DOI 10.1016/j.ccr.2007.07.004; Bignell GR, 2000, NAT GENET, V25, P160, DOI 10.1038/76006; Brummelkamp TR, 2003, NATURE, V424, P797, DOI 10.1038/nature01811; Carmon KS, 2011, P NATL ACAD SCI USA, V108, P11452, DOI 10.1073/pnas.1106083108; Chim CS, 2007, LEUKEMIA, V21, P2527, DOI 10.1038/sj.leu.2404939; de Lau W, 2011, NATURE, V476, P293, DOI 10.1038/nature10337; Derksen PWB, 2004, P NATL ACAD SCI USA, V101, P6122, DOI 10.1073/pnas.0305855101; Dutta-Simmons J, 2009, BLOOD, V114, P2699, DOI 10.1182/blood-2008-12-194290; Espinosa L, 2010, CANCER CELL, V18, P268, DOI 10.1016/j.ccr.2010.08.006; Hellerbrand C, 2007, CARCINOGENESIS, V28, P21, DOI 10.1093/carcin/bgl081; Hideshima T, 2007, NAT REV CANCER, V7, P585, DOI 10.1038/nrc2189; Hutti JE, 2009, MOL CELL, V34, P461, DOI 10.1016/j.molcel.2009.04.031; Iliopoulos D, 2010, MOL CELL, V39, P493, DOI 10.1016/j.molcel.2010.07.023; Jenner MW, 2007, BLOOD, V110, P3291, DOI 10.1182/blood-2007-02-075069; Jost E, 2009, CANCER LETT, V281, P24, DOI 10.1016/j.canlet.2009.02.002; Keats JJ, 2007, CANCER CELL, V12, P131, DOI 10.1016/j.ccr.2007.07.003; Kocemba KA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030359; Kovalenko A, 2003, NATURE, V424, P801, DOI 10.1038/nature01802; Kuehl WM, 2012, J CLIN INVEST, V122, P3456, DOI 10.1172/JCI61188; Kumar S, 2012, BLOOD, V119, P2100, DOI 10.1182/blood-2011-11-390658; Lawasut P, 2013, SEMIN ONCOL, V40, P537, DOI 10.1053/j.seminoncol.2013.07.010; Lim JH, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1776; Lohr JG, 2014, CANCER CELL, V25, P91, DOI 10.1016/j.ccr.2013.12.015; Massoumi R, 2006, CELL, V125, P665, DOI 10.1016/j.cell.2006.03.041; Massoumi R, 2011, FUTURE ONCOL, V7, P285, DOI 10.2217/FON.10.187; Massoumi R, 2009, J EXP MED, V206, P221, DOI 10.1084/jem.20082044; Morgan GJ, 2012, NAT REV CANCER, V12, P335, DOI 10.1038/nrc3257; Mulligan G, 2007, BLOOD, V109, P3177, DOI 10.1182/blood-2006-09-044974; Rajan N, 2014, ONCOTARGET, V5, P12126, DOI 10.18632/oncotarget.2573; Reiley WW, 2007, J EXP MED, V204, P1475, DOI 10.1084/jem.20062694; Sanjana NE, 2014, NAT METHODS, V11, P783, DOI 10.1038/nmeth.3047; Smith EM, 2015, ONCOTARGET, V6, P17314, DOI 10.18632/oncotarget.1168; Sonneveld P, 2012, J CLIN ONCOL, V30, P2946, DOI 10.1200/JCO.2011.39.6820; Sukhdeo K, 2007, P NATL ACAD SCI USA, V104, P7516, DOI 10.1073/pnas.0610299104; Takada K, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003808; Tauriello DVF, 2010, MOL CELL, V37, P607, DOI 10.1016/j.molcel.2010.01.035; Van den Berg DJ, 1998, BLOOD, V92, P3189, DOI 10.1182/blood.V92.9.3189.421k45_3189_3202; Walker BA, 2015, J CLIN ONCOL, V33, P3911, DOI 10.1200/JCO.2014.59.1503; Winterhalter C, 2014, BIOINFORMATICS, V30, P1029, DOI 10.1093/bioinformatics/btt732; Wright A, 2007, DEV CELL, V13, P705, DOI 10.1016/j.devcel.2007.09.007; Zhan F, 2006, BLOOD, V108, P2020, DOI 10.1182/blood-2005-11-013458	42	31	32	1	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 13	2017	36	15					2105	2115		10.1038/onc.2016.368	http://dx.doi.org/10.1038/onc.2016.368			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ES8DK	27775078				2022-12-17	WOS:000399782500007
J	Thurlings, I; Martinez-Lopez, LM; Westendorp, B; Zijp, M; Kuiper, R; Tooten, P; Kent, LN; Leone, G; Vos, HJ; Burgering, B; de Bruin, A				Thurlings, I.; Martinez-Lopez, L. M.; Westendorp, B.; Zijp, M.; Kuiper, R.; Tooten, P.; Kent, L. N.; Leone, G.; Vos, H. J.; Burgering, B.; de Bruin, A.			Synergistic functions of E2F7 and E2F8 are critical to suppress stress-induced skin cancer	ONCOGENE			English	Article							FAMILY-MEMBER; CELL-PROLIFERATION; ATYPICAL E2FS; DNA-REPAIR; TARGET; P53; DIFFERENTIATION; TRANSCRIPTION; ORGANIZATION; EXPRESSION	E2F transcription factors are important regulators of the cell cycle, and unrestrained activation of E2F-dependent transcription is considered to be an important driver of tumor formation and progression. Although highly expressed in normal skin and skin cancer, the role of the atypical E2Fs, E2F7 and E2F8, in keratinocyte homeostasis, regeneration and tumorigenesis is unknown. Surprisingly, keratinocyte-specific deletion of E2F7 and E2F8 in mice did not interfere with skin development and wound healing. However, the rate for successful isolation and establishment of E2f7/8-deficient primary keratinocyte cultures was much higher than for wild-type keratinocytes. Moreover, E2f7/8-deficient primary keratinocytes proliferate more efficiently under stress conditions, such as low/high confluence or DNA damage. Application of in vivo stress using the DMBA/TPA skin carcinogenesis protocol revealed that combined inactivation of E2f7/8 enhanced tumorigenesis and accelerated malignant progression. Loss of atypical E2Fs resulted in increased expression of E2F target genes, including E2f1. Additional loss of E2f1 did not rescue, but worsened skin tumorigenesis. We show that loss of E2F7/8 triggers apoptosis via induction of E2F1 in response to stress, indicating that the tumor-promoting effect of E2F7/8 inactivation can be partially compensated via E2F1-dependent apoptosis. Importantly, E2F7/8 repressed a large set of E2F target genes that are highly expressed in human patients with skin cancer. Together, our studies demonstrate that atypical E2Fs act as tumor suppressors, most likely via transcriptional repression of cell cycle genes in response to stress.	[Thurlings, I.; Martinez-Lopez, L. M.; Westendorp, B.; Zijp, M.; Kuiper, R.; Tooten, P.; de Bruin, A.] Univ Utrecht, Fac Vet Med, Dept Pathol, Yalelaan 1, NL-3584 CL Utrecht, Netherlands; [Kent, L. N.; Leone, G.] Ohio State Univ, Ctr Comprehens Canc, Dept Mol Virol Immunol Med Genet, Columbus, OH 43210 USA; [Vos, H. J.; Burgering, B.] Univ Med Ctr Utrecht, Mol Canc Res, Utrecht, Netherlands; [de Bruin, A.] Univ Groningen, Univ Med Ctr Groningen, Dept Pediat, Div Mol Genet, Groningen, Netherlands; [Kuiper, R.] Karolinska Univ Hosp Huddinge, Karolinska Inst, Dept Lab Med, S-17177 Stockholm, Sweden	Utrecht University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; Utrecht University; Utrecht University Medical Center; University of Groningen; Karolinska Institutet; Karolinska University Hospital	de Bruin, A (corresponding author), Univ Utrecht, Fac Vet Med, Dept Pathol, Yalelaan 1, NL-3584 CL Utrecht, Netherlands.	a.debruin@uu.nl	de Bruin, Alain/AAL-9195-2020	Kuiper, Raoul/0000-0001-5645-2389; Kent, Lindsey N./0000-0003-4990-8477; Westendorp, Bart/0000-0003-1043-3638; Vos, Harmjan/0000-0002-4696-6068	Dutch Cancer Society [UU2013-5777]; Netherlands Organization of Scientific Research [NWO-ALW:843.11.002]; NATIONAL CANCER INSTITUTE [R01CA121275] Funding Source: NIH RePORTER	Dutch Cancer Society(KWF Kankerbestrijding); Netherlands Organization of Scientific Research(Netherlands Organization for Scientific Research (NWO)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was financially supported by a Dutch Cancer Society grant (KWF: UU2013-5777) to BW and AdB, and the Netherlands Organization of Scientific Research (NWO-ALW:843.11.002). We like to thank M Greenberg (Duke University Medical Center, USA) for kindly providing the E2f1 conventional knockout mice, and R Caldelari (University of Berne, Switzerland) for technical assistance and advice with the keratinocyte isolations. We are also thankful for the technical support by Elsbeth van Liere and Ronald Molenbeek (Utrecht University, The Netherlands).	Abel EL, 2009, NAT PROTOC, V4, P1350, DOI 10.1038/nprot.2009.120; Aksoy O, 2012, GENE DEV, V26, P1546, DOI 10.1101/gad.196238.112; Biswas AK, 2012, CANCER RES, V72, P13, DOI 10.1158/0008-5472.CAN-11-2196; Biswas AK, 2014, CANCER RES, V74, P3369, DOI 10.1158/0008-5472.CAN-13-3216; Boekhout M, 2016, EMBO REP, V17, P414, DOI 10.15252/embr.201540984; Caldelari R, 2010, METHODS MOL BIOL, V633, P125, DOI 10.1007/978-1-59745-019-5_10; Carnevale J, 2012, MOL CELL BIOL, V32, P900, DOI 10.1128/MCB.06286-11; Carvajal LA, 2012, GENE DEV, V26, P1533, DOI 10.1101/gad.184911.111; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; Chen HZ, 2012, NAT CELL BIOL, V14, P1192, DOI 10.1038/ncb2595; Chen HZ, 2009, NAT REV CANCER, V9, P785, DOI 10.1038/nrc2696; Christensen J, 2005, NUCLEIC ACIDS RES, V33, P5458, DOI 10.1093/nar/gki855; Cohen M, 2013, CELL CYCLE, V12, P2992, DOI 10.4161/cc.26030; Costa C, 2013, ONCOGENE, V32, P2937, DOI 10.1038/onc.2012.316; D'Souza SJA, 2002, J BIOL CHEM, V277, P10626, DOI 10.1074/jbc.M111956200; de Bruin A, 2003, J BIOL CHEM, V278, P42041, DOI 10.1074/jbc.M308105200; DeGregori J, 1997, P NATL ACAD SCI USA, V94, P7245, DOI 10.1073/pnas.94.14.7245; Deng Q, 2010, CANCER RES, V70, P782, DOI 10.1158/0008-5472.CAN-09-3082; Di Micco R, 2006, NATURE, V444, P638, DOI 10.1038/nature05327; Di Stefano L, 2003, EMBO J, V22, P6289, DOI 10.1093/emboj/cdg613; Endo-Munoz L, 2009, CANCER RES, V69, P1800, DOI 10.1158/0008-5472.CAN-08-2725; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hande KR, 1998, EUR J CANCER, V34, P1514, DOI 10.1016/S0959-8049(98)00228-7; Hazar-Rethinam M, 2015, CLIN CANCER RES, V21, P417, DOI 10.1158/1078-0432.CCR-14-1962; Hazar-Rethinam M, 2011, J INVEST DERMATOL, V131, P1077, DOI 10.1038/jid.2010.430; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Johnson DG, 2006, CURR MOL MED, V6, P731; Kim C, 2014, EMBO MOL MED, V6, P970, DOI 10.15252/emmm.201303541; Li J, 2008, DEV CELL, V14, P62, DOI 10.1016/j.devcel.2007.10.017; Logan N, 2005, ONCOGENE, V24, P5000, DOI 10.1038/sj.onc.1208703; Logan N, 2004, ONCOGENE, V23, P5138, DOI 10.1038/sj.onc.1207649; Maiti B, 2005, J BIOL CHEM, V280, P18211, DOI 10.1074/jbc.M501410200; Ouseph MM, 2012, DEV CELL, V22, P849, DOI 10.1016/j.devcel.2012.01.013; Pandit SK, 2012, NAT CELL BIOL, V14, P1181, DOI 10.1038/ncb2585; Park S-A, 2015, JNCI-J NATL CANCER I, V107, P1; Pediconi N, 2003, NAT CELL BIOL, V5, P552, DOI 10.1038/ncb998; Polager S, 2009, NAT REV CANCER, V9, P738, DOI 10.1038/nrc2718; Reimer D, 2007, CLIN CANCER RES, V13, P144, DOI 10.1158/1078-0432.CCR-06-0780; Riker AI, 2008, BMC MED GENOMICS, V1, DOI 10.1186/1755-8794-1-13; Rounbehler RJ, 2002, CANCER RES, V62, P3276; Salvatori B, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.151; Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/NMETH.2019, 10.1038/nmeth.2019]; Schmidt-Supprian M, 2007, NAT IMMUNOL, V8, P665, DOI 10.1038/ni0707-665; Silver DP, 2001, MOL CELL, V8, P233, DOI 10.1016/S1097-2765(01)00295-7; Tsai SY, 2008, NATURE, V454, P1137, DOI 10.1038/nature07066; Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-7-research0034; Westendorp B, 2012, NUCLEIC ACIDS RES, V40, P3511, DOI 10.1093/nar/gkr1203; Zalmas LP, 2008, EMBO REP, V9, P252, DOI 10.1038/sj.embor.7401158; Zalmas LP, 2013, CELL CYCLE, V12, P3037, DOI 10.4161/cc.26078	49	31	32	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 9	2017	36	6					829	839		10.1038/onc.2016.251	http://dx.doi.org/10.1038/onc.2016.251			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EK8IX	27452520	Green Published, hybrid			2022-12-17	WOS:000394168200010
J	Zhang, X; Zhang, L; Du, Y; Zheng, H; Zhang, P; Sun, Y; Wang, Y; Chen, J; Ding, P; Wang, N; Yang, C; Huang, T; Yao, X; Qiao, Q; Gu, H; Cai, G; Cai, S; Zhou, X; Hu, W				Zhang, X.; Zhang, L.; Du, Y.; Zheng, H.; Zhang, P.; Sun, Y.; Wang, Y.; Chen, J.; Ding, P.; Wang, N.; Yang, C.; Huang, T.; Yao, X.; Qiao, Q.; Gu, H.; Cai, G.; Cai, S.; Zhou, X.; Hu, W.			A novel FOXM1 isoform, FOXM1D, promotes epithelial-mesenchymal transition and metastasis through ROCKs activation in colorectal cancer	ONCOGENE			English	Article							FORKHEAD BOX M1; RHO-ASSOCIATED KINASE; COILED-COILS; TARGET; TUMORIGENESIS; TRANSCRIPTION; PROGRESSION; INHIBITION; EXPRESSION; INVASION	Epithelial-mesenchymal transition (EMT) is a critical event in metastasis of colorectal cancer (CRC). Rho/ROCKs signaling has a pivotal role in orchestrating actin cytoskeleton, leading to EMT and cancer invasion. However, the underlying mechanisms for ROCKs activation are not fully understood. Here, we identified FOXM1D, a novel isoform of Forkhead box M1 (FOXM1) that has a pivotal role in ROCKs activation by directly interacting with coiled-coil region of ROCK2. FOXM1D overexpression significantly polymerizes actin assembly and impairs E-cadherin expression, resulting in EMT and metastasis in xenograft mouse model and knockdown of FOXM1D has the opposite effect. Moreover, a high FOXM1D level correlates closely with clinical CRC metastasis. FOXM1D-induced ROCKs activation could be abrogated by the ROCKs inhibitors Y-27632 and fasudil. These observations indicate that the FOXM1D-ROCK2 interaction is crucial for Rho/ROCKs signaling and provide novel insight into actin cytoskeleton regulation and therapeutic potential for CRC metastasis.	[Zhang, X.; Zhang, L.; Du, Y.; Zhang, P.; Sun, Y.; Chen, J.; Ding, P.; Wang, N.; Qiao, Q.; Gu, H.; Hu, W.] Fudan Univ, Shanghai Canc Ctr, Collaborat Innovat Ctr Canc Med, Shanghai Med Coll, Shanghai, Peoples R China; [Zhang, X.; Zhang, L.; Du, Y.; Zhang, P.; Sun, Y.; Chen, J.; Ding, P.; Wang, N.; Qiao, Q.; Gu, H.; Hu, W.] Fudan Univ, Shanghai Med Coll, Dept Oncol, Shanghai 200032, Peoples R China; [Zheng, H.; Wang, Y.; Cai, G.; Cai, S.] Fudan Univ, Shanghai Med Coll, Dept Colorectal Surg, Shanghai, Peoples R China; [Yang, C.; Zhou, X.] Second Mil Med Univ, Changzheng Hosp, Shanghai, Peoples R China; [Huang, T.; Yao, X.] Shanghai Tenth Peoples Hosp, Dept Urol, Shanghai, Peoples R China; [Hu, W.] Fudan Univ, Shanghai Med Coll, Dept Immunol, Shanghai, Peoples R China	Fudan University; Fudan University; Fudan University; Naval Medical University; Fudan University	Hu, W (corresponding author), Fudan Univ, Shanghai Canc Ctr, Inst Canc, 270 Dongan Rd, Shanghai 200032, Peoples R China.	weiguohu@fudan.edu.cn	Hu, Weiguo/AAP-2239-2021; Zhang, Long/HCI-5197-2022	Hu, Weiguo/0000-0002-7397-6800; Chen, Jianfeng/0000-0002-4182-145X	Major State Basic Research Development Program of China [2013CB910802]; National Natural Science Foundation of China [81171910, 81372258]; Program for Professor of Special Appointment (Eastern Scholar) at Shanghai Institutions of Higher Learning	Major State Basic Research Development Program of China(National Basic Research Program of China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Program for Professor of Special Appointment (Eastern Scholar) at Shanghai Institutions of Higher Learning	This research was supported by the Major State Basic Research Development Program of China (2013CB910802), the National Natural Science Foundation of China (81171910, 81372258) and the Program for Professor of Special Appointment (Eastern Scholar) at Shanghai Institutions of Higher Learning to WH. We thank Professor Thomas M Roberts (DFCI, Harvard Medical School) and Professor Hua Lu (Department of Biochemistry and Molecular Biology, Tulane University) for scientific suggestions and critical reading of this manuscript. We are also grateful to Dr Yuhu Xin for assistance with confocal microscopy; to Mrs Ping Zhang for assistance with flow cytometry; to Dr Yi Qin, who provided the pCMV-C-FLAG and pCMV-C-HA plasmids; to Professor Yanhui Xu, who kindly provided the modified pGEX-6P-1 plasmid; and to Professor Shenglin Huang, who provided the p-pLVX-IRES-Neo and pwpxl-eGFP-2A-CBGr99 lentiviral vectors; to Dr Fangning Wan for advices on statistics and revision of manuscript.	Bao B, 2011, J CELL BIOCHEM, V112, P2296, DOI 10.1002/jcb.23150; Burkhard P, 2001, TRENDS CELL BIOL, V11, P82, DOI 10.1016/S0962-8924(00)01898-5; Chaffer CL, 2011, SCIENCE, V331, P1559, DOI 10.1126/science.1203543; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Feng JH, 1999, J BIOL CHEM, V274, P3744, DOI 10.1074/jbc.274.6.3744; Halasi M, 2013, MOL CANCER THER, V12, P245, DOI 10.1158/1535-7163.MCT-12-0712; Halasi M, 2009, CELL CYCLE, V8, P1966, DOI 10.4161/cc.8.12.8708; Itoh K, 1999, NAT MED, V5, P221, DOI 10.1038/5587; Kalin TV, 2011, CELL CYCLE, V10, P396, DOI 10.4161/cc.10.3.14709; Kim YH, 2014, J FOOD SAFETY, V34, P1, DOI 10.1111/jfs.12088; Lamouille S, 2014, NAT REV MOL CELL BIO, V15, P178, DOI 10.1038/nrm3758; Lee JM, 2006, J CELL BIOL, V172, P973, DOI 10.1083/jcb.200601018; Liu J, 2008, EURASIP J ADV SIG PR, DOI 10.1155/2008/162587; Liu MG, 2006, CANCER RES, V66, P3593, DOI 10.1158/0008-5472.CAN-05-2912; Liu PY, 2008, METHOD ENZYMOL, V439, P181, DOI 10.1016/S0076-6879(07)00414-4; Liu X, 2015, FUTURE ONCOL, V11, P2911, DOI 10.2217/fon.15.235; Ma RYM, 2005, J CELL SCI, V118, P795, DOI 10.1242/jcs.01657; Morgan-Fisher M, 2013, J HISTOCHEM CYTOCHEM, V61, P185, DOI 10.1369/0022155412470834; Myatt SS, 2007, NAT REV CANCER, V7, P847, DOI 10.1038/nrc2223; Park H, 2011, J HIGH ENERGY PHYS, DOI [10.1155/2011/485173, 10.1007/JHEP10(2011)092]; Parry DAD, 2008, J STRUCT BIOL, V163, P258, DOI 10.1016/j.jsb.2008.01.016; Rajput A, 2008, J SURG RES, V147, P276, DOI 10.1016/j.jss.2007.04.021; Rath N, 2012, EMBO REP, V13, P900, DOI 10.1038/embor.2012.127; Raychaudhuri P, 2011, CANCER RES, V71, P4329, DOI 10.1158/0008-5472.CAN-11-0640; Riento K, 2003, NAT REV MOL CELL BIO, V4, P446, DOI 10.1038/nrm1128; Rohaly G, 2005, CELL, V122, P21, DOI 10.1016/j.cell.2005.04.032; Sebbagh M, 2005, J EXP MED, V201, P465, DOI 10.1084/jem.20031877; Shi JW, 2013, CELL CYCLE, V12, P1119, DOI 10.4161/cc.24164; Siegel R, 2014, CA-CANCER J CLIN, V64, P9, DOI 10.3322/caac.21208; Sun LC, 2011, AM J PATHOL, V179, P380, DOI 10.1016/j.ajpath.2011.03.046; Teh MT, 2012, FRONT ONCOL, V2, DOI 10.3389/fonc.2012.00146; Tseng William, 2007, J Vis Exp, P484, DOI 10.3791/484; Wang IC, 2005, MOL CELL BIOL, V25, P10875, DOI 10.1128/MCB.25.24.10875-10894.2005; Wang Y., 2014, INT J DISTRIB SENS N, V2014, P9, DOI DOI 10.1371/J0URNAL.P0NE.0110024; Wang ZW, 2007, CANCER RES, V67, P8293, DOI 10.1158/0008-5472.CAN-07-1265; Wierstra I, 2013, ADV CANCER RES, V119, P191, DOI 10.1016/B978-0-12-407190-2.00016-2; Xue JF, 2014, J CLIN INVEST, V124, P564, DOI 10.1172/JCI71104; Yang C, 2013, CANCER LETT, V340, P104, DOI 10.1016/j.canlet.2013.07.004; Ye HG, 1997, MOL CELL BIOL, V17, P1626, DOI 10.1128/MCB.17.3.1626; Ying H, 2006, MOL CANCER THER, V5, P2158, DOI 10.1158/1535-7163.MCT-05-0440; Zhang J, 2013, CANCER DISCOV, V3, P1228, DOI 10.1158/2159-8290.CD-13-0253; Zhang N, 2011, CANCER CELL, V20, P427, DOI 10.1016/j.ccr.2011.08.016	42	31	35	3	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 9	2017	36	6					807	819		10.1038/onc.2016.249	http://dx.doi.org/10.1038/onc.2016.249			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EK8IX	27399334	hybrid, Green Published			2022-12-17	WOS:000394168200008
J	Daly, C; Castanaro, C; Zhang, W; Zhang, Q; Wei, Y; Ni, M; Young, TM; Zhang, L; Burova, E; Thurston, G				Daly, C.; Castanaro, C.; Zhang, W.; Zhang, Q.; Wei, Y.; Ni, M.; Young, T. M.; Zhang, L.; Burova, E.; Thurston, G.			FGFR3-TACC3 fusion proteins act as naturally occurring drivers of tumor resistance by functionally substituting for EGFR/ERK signaling	ONCOGENE			English	Article							COMPARATIVE GENOMIC ANALYSIS; SQUAMOUS-CELL CARCINOMA; ACQUIRED-RESISTANCE; COLORECTAL-CANCER; GENE FUSIONS; LUNG-CANCER; CETUXIMAB; GROWTH; HEAD; ANTIBODY	The epidermal growth factor receptor (EGFR) is a clinically validated target in head and neck squamous cell carcinoma (HNSCC), where EGFR-blocking antibodies are approved for first-line treatment. However, as with other targeted therapies, intrinsic/acquired resistance mechanisms limit efficacy. In the FaDu HNSCC xenograft model, we show that combined blockade of EGFR and ERBB3 promotes rapid tumor regression, followed by the eventual outgrowth of resistant cells. RNA sequencing revealed that resistant cells express FGFR3-TACC3 fusion proteins, which were validated as drivers of the resistant phenotype by several approaches, including CRISPR-mediated inactivation of FGFR3-TACC3 fusion genes. Interestingly, analysis of signaling in resistant cell lines demonstrated that FGFR3-TACC3 fusion proteins promote resistance by preferentially substituting for EGFR/RAS/ERK signaling rather than ERBB3/PI3K/AKT signaling. Furthermore, although FGFR3-TACC3 fusion proteins promote resistance of additional EGFR-dependent HNSCC and lung cancer cell lines to EGFR blockade, they are unable to compensate for inhibition of PI3K signaling in PIK3CA-mutant HNSCC cell lines. Validation of FGFR3-TACC3 fusion proteins as endogenous drivers of resistance in our screen provides strong evidence that these fusions are capable of substituting for EGFR signaling. Thus, FGFR3-TACC3 fusion proteins may represent a novel mechanism of acquired resistance in EGFR-dependent cancers of multiple cell lineages.	[Daly, C.; Castanaro, C.; Zhang, W.; Zhang, Q.; Wei, Y.; Ni, M.; Young, T. M.; Zhang, L.; Burova, E.; Thurston, G.] Regeneron Pharmaceut Inc, 777 Old Saw Mill River Rd, Tarrytown, NY 10591 USA; [Zhang, Q.] Genentech Inc, 1 DNA Way, San Francisco, CA 94080 USA	Regeneron; Roche Holding; Genentech	Daly, C (corresponding author), Regeneron Pharmaceut Inc, Dept Oncol, 777 Old Saw Mill River Rd, Tarrytown, NY 10591 USA.	christopher.daly@regeneron.com		Daly, Christopher/0000-0003-3800-8174	Regeneron Pharmaceuticals Inc.	Regeneron Pharmaceuticals Inc.(Regeneron)	We thank Elizabeth Pasnikowski, Chandrika Taduriyasas, Jennifer Espert and David D'Ambrosio for technical assistance and Neil Stahl and George Yancopoulos for helpful comments and suggestions. All research was fully supported by Regeneron Pharmaceuticals Inc.	Arteaga CL, 2014, CANCER CELL, V25, P282, DOI 10.1016/j.ccr.2014.02.025; Bonner JA, 2006, NEW ENGL J MED, V354, P567, DOI 10.1056/NEJMoa053422; Capelletti M, 2014, CLIN CANCER RES, V20, P6551, DOI 10.1158/1078-0432.CCR-14-1337; Chong CR, 2013, NAT MED, V19, P1389, DOI 10.1038/nm.3388; Crystal AS, 2014, SCIENCE, V346, P1480, DOI 10.1126/science.1254721; Cunningham D, 2004, NEW ENGL J MED, V351, P337, DOI 10.1056/NEJMoa033025; di Martino E, 2009, ONCOGENE, V28, P4306, DOI 10.1038/onc.2009.280; Di Stefano AL, 2015, CLIN CANCER RES, V21, P3307, DOI 10.1158/1078-0432.CCR-14-2199; Engelman JA, 2005, P NATL ACAD SCI USA, V102, P3788, DOI 10.1073/pnas.0409773102; Gala K, 2014, CLIN CANCER RES, V20, P1410, DOI 10.1158/1078-0432.CCR-13-1549; Garner AP, 2013, CANCER RES, V73, P6024, DOI 10.1158/0008-5472.CAN-13-1198; Gaykalova DA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093102; Helsten T, 2016, CLIN CANCER RES, V22, P259, DOI 10.1158/1078-0432.CCR-14-3212; Herrera-Abreu MT, 2013, CANCER DISCOV, V3, P1058, DOI 10.1158/2159-8290.CD-12-0569; Holbro T, 2003, P NATL ACAD SCI USA, V100, P8933, DOI 10.1073/pnas.1537685100; Huang S, 2013, CANCER RES, V73, P824, DOI 10.1158/0008-5472.CAN-12-1611; Jebar AH, 2005, ONCOGENE, V24, P5218, DOI 10.1038/sj.onc.1208705; Jiang N, 2014, MOL CANCER THER, V13, P1826, DOI 10.1158/1535-7163.MCT-13-1093; Jonker DJ, 2007, NEW ENGL J MED, V357, P2040, DOI 10.1056/NEJMoa071834; Juanpere N, 2012, HUM PATHOL, V43, P1573, DOI 10.1016/j.humpath.2011.10.026; Kim Y, 2014, J CLIN ONCOL, V32, P121, DOI 10.1200/JCO.2013.50.8556; Knowles MA, 2008, FUTURE ONCOL, V4, P71, DOI 10.2217/14796694.4.1.71; Lamont FR, 2011, BRIT J CANCER, V104, P75, DOI 10.1038/sj.bjc.6606016; Lawrence MS, 2015, NATURE, V517, P576, DOI 10.1038/nature14129; LoRusso P, 2013, CLIN CANCER RES, V19, P3078, DOI 10.1158/1078-0432.CCR-12-3051; Marshall ME, 2011, CLIN CANCER RES, V17, P5016, DOI 10.1158/1078-0432.CCR-11-0050; Mirschberger C, 2013, CANCER RES, V73, P5183, DOI 10.1158/0008-5472.CAN-13-0099; Misale S, 2014, CANCER DISCOV, V4, P1269, DOI 10.1158/2159-8290.CD-14-0462; Nelson KN, 2016, MOL CANCER RES, V14, P458, DOI 10.1158/1541-7786.MCR-15-0497; Oliveras-Ferraros C, 2012, BRIT J CANCER, V106, P1406, DOI 10.1038/bjc.2012.103; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Parker BC, 2013, J CLIN INVEST, V123, P855, DOI 10.1172/JCI67144; Sander JD, 2014, NAT BIOTECHNOL, V32, P347, DOI 10.1038/nbt.2842; Schaefer G, 2011, CANCER CELL, V20, P472, DOI 10.1016/j.ccr.2011.09.003; Schoeberl B, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000352; Seiwert TY, 2015, CLIN CANCER RES, V21, P632, DOI 10.1158/1078-0432.CCR-13-3310; Shalem O, 2014, SCIENCE, V343, P84, DOI 10.1126/science.1247005; Sharma SV, 2007, NAT REV CANCER, V7, P169, DOI 10.1038/nrc2088; Singh D, 2012, SCIENCE, V337, P1231, DOI 10.1126/science.1220834; SOLTOFF SP, 1994, MOL CELL BIOL, V14, P3550, DOI 10.1128/MCB.14.6.3550; Stransky N, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5846; [王如松 Wang Rusong], 2014, [生态学报, Acta Ecologica Sinica], V34, P1; Ware Kathryn E, 2010, PLoS One, V5, pe14117, DOI 10.1371/journal.pone.0014117; Williams SV, 2013, HUM MOL GENET, V22, P795, DOI 10.1093/hmg/dds486; Wu YM, 2013, CANCER DISCOV, V3, P636, DOI 10.1158/2159-8290.CD-13-0050; Yuan L, 2014, CANCER BIOL THER, V15, P1613, DOI 10.4161/15384047.2014.961874; Zhang L, 2014, MOL CANCER THER, V13, P1345, DOI 10.1158/1535-7163.MCT-13-1033	47	31	37	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 26	2017	36	4					471	481		10.1038/onc.2016.216	http://dx.doi.org/10.1038/onc.2016.216			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EK8II	27345413	Green Published, hybrid			2022-12-17	WOS:000394166700004
J	Martin, PL; Yin, JJ; Seng, V; Casey, O; Corey, E; Morrissey, C; Simpson, RM; Kelly, K				Martin, P. L.; Yin, J-J; Seng, V.; Casey, O.; Corey, E.; Morrissey, C.; Simpson, R. M.; Kelly, K.			Androgen deprivation leads to increased carbohydrate metabolism and hexokinase 2-mediated survival in Pten/Tp53-deficient prostate cancer	ONCOGENE			English	Article							MITOCHONDRIAL HEXOKINASES; MASS-SPECTROMETRY; PTEN; APOPTOSIS; GROWTH; AKT; MECHANISMS; RESISTANCE; TRANSITION; DELETION	Prostate cancer is characterized by a dependence upon androgen receptor (AR) signaling, and androgen deprivation therapy (ADT) is the accepted treatment for progressive prostate cancer. Although ADT is usually initially effective, acquired resistance termed castrate-resistant prostate cancer (CRPC) develops. PTEN and TP53 are two of the most commonly deleted or mutated genes in prostate cancer, the compound loss of which is enriched in CRPC. To interrogate the metabolic alterations associated with survival following ADT, we used an orthotopic model of Pten/Tp53 null prostate cancer. Metabolite profiles and associated regulators were compared in tumors from androgen-intact mice and in tumors surviving castration. AR inhibition led to changes in the levels of glycolysis and tricarboxylic acid (TCA) cycle pathway intermediates. As anticipated for inhibitory reciprocal feedback between AR and PI3K/AKT signaling pathways, pAKT levels were increased in androgen-deprived tumors. Elevated mitochondrial hexokinase 2 (HK2) levels and enzyme activities also were observed in androgen-deprived tumors, consistent with pAKT-dependent HK2 protein induction and mitochondrial association. Competitive inhibition of HK2-mitochondrial binding in prostate cancer cells led to decreased viability. These data argue for AKT-associated HK2-mediated metabolic reprogramming and mitochondrial association in PI3K-driven prostate cancer as one survival mechanism downstream of AR inhibition.	[Martin, P. L.; Yin, J-J; Seng, V.; Casey, O.; Kelly, K.] NCI, Lab Genitourinary Canc Pathogenesis, Ctr Canc Res, NIH, Bldg 37,Room 1068 A, Bethesda, MD 20892 USA; [Corey, E.; Morrissey, C.] Univ Washington, Dept Urol, Seattle, WA 98195 USA; [Simpson, R. M.] NCI, Lab Canc Biol & Genet, Ctr Canc Res, NIH, Bethesda, MD 20892 USA; [Martin, P. L.] Medimmune, Gaithersburg, MD USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Washington; University of Washington Seattle; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); AstraZeneca; Medimmune	Kelly, K (corresponding author), NCI, Lab Genitourinary Canc Pathogenesis, Ctr Canc Res, NIH, Bldg 37,Room 1068 A, Bethesda, MD 20892 USA.	kellyka@mail.nih.gov			Intramural Research Program; Center for Cancer Research; NCI; Pacific Northwest Prostate Cancer SPORE [P50CA97186]; PO1 NIH [PO1CA085859]; Richard M. LUCAS Foundation; NATIONAL CANCER INSTITUTE [P50CA097186, P01CA085859, ZIGBC010931] Funding Source: NIH RePORTER	Intramural Research Program; Center for Cancer Research(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Pacific Northwest Prostate Cancer SPORE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PO1 NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Richard M. LUCAS Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We appreciated the patients and their families who participated in the Prostate Cancer Donor Program. We thank the investigators Drs Robert Vessella, Celestia Higano, Bruce Montgomery, Evan Yu, Peter Nelson, Paul Lange, Martine Roudier and Lawrence True for their contributions to the University of Washington Medical Center Prostate Cancer Donor Rapid Autopsy Program. This research was supported by the Intramural Research Program, Center for Cancer Research, NCI and by the Pacific Northwest Prostate Cancer SPORE (P50CA97186), the PO1 NIH grant (PO1CA085859) and the Richard M. LUCAS Foundation.	Abeshouse A, 2015, CELL, V163, P1011, DOI 10.1016/j.cell.2015.10.025; Abou-Kheir W, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026112; Agarwal S., 2015, CELL REP; American Cancer Society, 2015, CANC FACTS FIG 2015; ARORA KK, 1988, J BIOL CHEM, V263, P17422; Arzoine L, 2009, J BIOL CHEM, V284, P3946, DOI 10.1074/jbc.M803614200; Bonizzi G, 2012, TRENDS MOL MED, V18, P6, DOI 10.1016/j.molmed.2011.08.002; Carver BS, 2011, CANCER CELL, V19, P575, DOI 10.1016/j.ccr.2011.04.008; Chaux A, 2012, MODERN PATHOL, V25, P1543, DOI 10.1038/modpathol.2012.104; Chiara F, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001852; Costello LC, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-17; Craft N, 1999, CANCER RES, V59, P5030; Evans AM, 2009, ANAL CHEM, V81, P6656, DOI 10.1021/ac901536h; Ferraldeschi R, 2015, ONCOGENE, V34, P1745, DOI 10.1038/onc.2014.115; Gao H, 2006, CANCER RES, V66, P7929, DOI 10.1158/0008-5472.CAN-06-1637; Gottlob K, 2001, GENE DEV, V15, P1406, DOI 10.1101/gad.889901; Grasso CS, 2012, NATURE, V487, P239, DOI 10.1038/nature11125; Gundem G, 2015, NATURE, V520, P353, DOI 10.1038/nature14347; Hong MKH, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7605; Jadvar H, 2013, J NUCL MED, V54, P1685, DOI 10.2967/jnumed.113.126094; Jiao J, 2007, CANCER RES, V67, P6083, DOI 10.1158/0008-5472.CAN-06-4202; Kami K, 2013, METABOLOMICS, V9, P444, DOI 10.1007/s11306-012-0452-2; Kruiswijk F, 2015, NAT REV MOL CELL BIO, V16, P393, DOI 10.1038/nrm4007; Lotan TL, 2011, CLIN CANCER RES, V17, P6563, DOI 10.1158/1078-0432.CCR-11-1244; Lunardi A, 2013, NAT GENET, V45, P747, DOI 10.1038/ng.2650; Majewski N, 2004, MOL CELL, V16, P819, DOI 10.1016/j.molcel.2004.11.014; Majewski N, 2004, MOL CELL BIOL, V24, P730, DOI 10.1128/MCB.24.2.730-740.2004; Martin P, 2011, AM J PATHOL, V179, P422, DOI 10.1016/j.ajpath.2011.03.035; Massie CE, 2011, EMBO J, V30, P2719, DOI 10.1038/emboj.2011.158; McCall P, 2008, BRIT J CANCER, V99, P1296, DOI 10.1038/sj.bjc.6604680; McDunn JE, 2013, PROSTATE, V73, P1547, DOI 10.1002/pros.22704; Morrissey C, 2013, J BONE MINER RES, V28, P333, DOI 10.1002/jbmr.1749; Mulholland DJ, 2011, CANCER CELL, V19, P792, DOI 10.1016/j.ccr.2011.05.006; Pastorino JG, 2002, J BIOL CHEM, V277, P7610, DOI 10.1074/jbc.M109950200; Patra KC, 2013, CANCER CELL, V24, P213, DOI 10.1016/j.ccr.2013.06.014; Priolo C, 2014, CANCER RES, V74, P7198, DOI 10.1158/0008-5472.CAN-14-1490; Roberts DJ, 2015, CELL DEATH DIFFER, V22, P364, DOI 10.1038/cdd.2014.208; Robey RB, 2006, ONCOGENE, V25, P4683, DOI 10.1038/sj.onc.1209595; Robinson D, 2015, CELL, V161, P1215, DOI 10.1016/j.cell.2015.05.001; Roudier MP, 2003, HUM PATHOL, V34, P646, DOI 10.1016/S0046-8177(03)00190-4; Shah RB, 2004, CANCER RES, V64, P9209, DOI 10.1158/0008-5472.CAN-04-2442; Sircar K, 2009, J PATHOL, V218, P505, DOI 10.1002/path.2559; Stenman K, 2011, BIOMARK INSIGHTS, V6, P39, DOI 10.4137/BMI.S6794; Sun Y, 2012, NAT MED, V18, P1359, DOI 10.1038/nm.2890; Swanson MG, 2003, MAGN RESON MED, V50, P944, DOI 10.1002/mrm.10614; Terry S, 2006, PROSTATE, V66, P1100, DOI 10.1002/pros.20446; Toivanen R, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005688; Wang L, 2014, CELL REP, V8, P1461, DOI 10.1016/j.celrep.2014.07.053; Watson PA, 2015, NAT REV CANCER, V15, P701, DOI 10.1038/nrc4016; Wu RX, 2012, EMBO MOL MED, V4, P633, DOI 10.1002/emmm.201200240; Zadra G, 2013, BBA-MOL CELL BIOL L, V1831, P1518, DOI 10.1016/j.bbalip.2013.03.010; Zong Y, 2013, NAT REV UROL, V10, P90, DOI [10.1038/nrurol.2012.237, 10.1038/nruro1.2012.237]	52	31	32	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 26	2017	36	4					525	533		10.1038/onc.2016.223	http://dx.doi.org/10.1038/onc.2016.223			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EK8II	27375016	Green Accepted			2022-12-17	WOS:000394166700009
J	Wang, Y; Justilien, V; Brennan, KI; Jamieson, L; Murray, NR; Fields, AP				Wang, Y.; Justilien, V.; Brennan, K. I.; Jamieson, L.; Murray, N. R.; Fields, A. P.			PKC iota regulates nuclear YAP1 localization and ovarian cancer tumorigenesis	ONCOGENE			English	Article							PROTEIN-KINASE-C; POOR-PROGNOSIS; ONCOGENE; OVERREPRESENTATION; OVEREXPRESSION; PROLIFERATION; EXPRESSION; ANGIOMOTIN; PHENOTYPE; EFFECTOR	Atypical protein kinase C iota (PKC iota) is an oncogene in lung and ovarian cancer. The PKC iota gene PRKCI is targeted for frequent tumorspecific copy number gain (CNG) in both lung squamous cell carcinoma (LSCC) and ovarian serous carcinoma (OSC). We recently demonstrated that in LSCC cells PRKCI CNG functions to drive transformed growth and tumorigenicity by activating PKC iota-dependent cell autonomous Hedgehog (Hh) signaling. Here, we assessed whether OSC cells harboring PRKCI CNG exhibit similar PKC iota-dependent Hh signaling. Surprisingly, we find that whereas PKC iota is required for the transformed growth of OSC cells harboring PRKCI CNG, these cells do not exhibit PKC iota-dependent Hh signaling or Hh-dependent proliferation. Rather, transformed growth of OSC cells is regulated by PKC iota-dependent nuclear localization of the oncogenic transcription factor, YAP1. Lentiviral shRNA-mediated knockdown (KD) of PKC iota leads to decreased nuclear YAP1 and increased YAP1 binding to angiomotin (AMOT), which sequesters YAP1 in the cytoplasm. Biochemical analysis reveals that PKC iota directly phosphorylates AMOT at a unique site, Thr750, whose phosphorylation inhibits YAP1 binding. Pharmacologic inhibition of PKC iota decreases YAP1 nuclear localization and blocks OSC tumor growth in vitro and in vivo. Immunohistochemical analysis reveals a strong positive correlation between tumor PKC iota expression and nuclear YAP1 in primary OSC tumor samples, indicating the clinical relevance of PKC iota-YAP1 signaling. Our results uncover a novel PKC iota-AMOT-YAP1 signaling axis that promotes OSC tumor growth, and provide a rationale for therapeutic targeting of this pathway for treatment of OSC.	[Wang, Y.; Justilien, V.; Brennan, K. I.; Jamieson, L.; Murray, N. R.; Fields, A. P.] Mayo Clin, Coll Med, Dept Canc Biol, Jacksonville, FL 32224 USA	Mayo Clinic	Murray, NR; Fields, AP (corresponding author), Mayo Clin Florida, Dept Canc Biol, Griffin Canc Res Bldg,Rm 212,4500 San Pablo Rd, Jacksonville, FL 32224 USA.	fields.alan@mayo.edu			Mayo Clinic Specialized Program in Research Excellence (SPORE) grant from the National Institutes of Health [CA136393]; Ovarian Cancer Research Fund; National Cancer Institute [R21 CA204938-01, R01 CA081436-18]; George Haub Family Career Development Award; NATIONAL CANCER INSTITUTE [R01CA081436, P50CA136393, R21CA204938] Funding Source: NIH RePORTER	Mayo Clinic Specialized Program in Research Excellence (SPORE) grant from the National Institutes of Health; Ovarian Cancer Research Fund; National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); George Haub Family Career Development Award; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Kim Kalli and the Mayo Clinic Ovarian SPORE Tissue shared resource for ovarian cancer tissue microarrays, The Mayo Clinic Cytogenetics Core for FISH analysis, Ms Brandy Edenfield for tissue processing and immunohistochemical staining, and Kayla Lewis, Capella Weems and Dr Christelle Colin Cassin for technical assistance. This research was supported by the Mayo Clinic Specialized Program in Research Excellence (SPORE) grant CA136393 from the National Institutes of Health (APF is a Project Leader on this grant), a post-doctoral fellowship award from the Ovarian Cancer Research Fund to YW, National Cancer Institute grants R21 CA204938-01 (to VJ) and R01 CA081436-18 (to APF), and the George Haub Family Career Development Award (to VJ). APF is the Monica Flynn Jacoby Professor of Cancer Research, an endowment fund that provides partial support for his research program.	Algeciras-Schimnich A, 2010, CLIN CHEM, V56, P391, DOI 10.1373/clinchem.2009.134015; Ali SA, 2016, CANCER CELL, V29, P367, DOI 10.1016/j.ccell.2016.02.012; Archibald A, 2015, MOL BIOL CELL, V26, P3578, DOI 10.1091/mbc.E15-05-0265; Arnold N, 1996, GENE CHROMOSOME CANC, V16, P46, DOI 10.1002/(SICI)1098-2264(199605)16:1<46::AID-GCC7>3.0.CO;2-3; Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003; Butler AM, 2015, ONCOTARGET, V6, P15297, DOI 10.18632/oncotarget.3812; Chan SW, 2011, J BIOL CHEM, V286, P7018, DOI 10.1074/jbc.C110.212621; Ciriello G, 2013, NAT GENET, V45, P1127, DOI 10.1038/ng.2762; Domcke S, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3126; Eder AM, 2005, P NATL ACAD SCI USA, V102, P12519, DOI 10.1073/pnas.0505641102; Fields AP, 2007, PHARMACOL RES, V55, P487, DOI 10.1016/j.phrs.2007.04.015; Fields Alan P, 2003, Methods Mol Biol, V233, P519; Fields AP, 2008, ADV ENZYME REGUL, V48, P166, DOI 10.1016/j.advenzreg.2007.11.014; Frederick LA, 2008, ONCOGENE, V27, P4841, DOI 10.1038/onc.2008.119; Hall CA, 2010, CANCER RES, V70, P8517, DOI 10.1158/0008-5472.CAN-10-1242; Haverty PM, 2009, BMC MED GENOMICS, V2, DOI 10.1186/1755-8794-2-21; Hsu YL, 2015, ONCOGENE, V34, P4056, DOI 10.1038/onc.2014.333; Jatoi A, 2015, ONCOLOGY-BASEL, V88, P208, DOI 10.1159/000369257; Jeong GO, 2013, CELL PHYSIOL BIOCHEM, V32, P253, DOI 10.1159/000354434; Justilien V, 2014, CANCER CELL, V25, P139, DOI 10.1016/j.ccr.2014.01.008; Justilien V, 2011, J BIOL CHEM, V286, P8149, DOI 10.1074/jbc.M110.196113; Korkmaz T, 2016, CRIT REV ONCOL HEMAT, V98, P180, DOI 10.1016/j.critrevonc.2015.10.006; Llado V, 2015, CELL REP, V10, P740, DOI 10.1016/j.celrep.2015.01.007; Martin LP, 2009, SEMIN ONCOL, V36, P112, DOI 10.1053/j.seminoncol.2008.12.003; Moleirinho S, 2014, FEBS LETT, V588, P2693, DOI 10.1016/j.febslet.2014.02.006; Murray NR, 2011, J CELL PHYSIOL, V226, P879, DOI 10.1002/jcp.22463; Parker PJ, 2014, BIOCHEM PHARMACOL, V88, P1, DOI 10.1016/j.bcp.2013.10.023; Petrucelli N, 2010, GENET MED, V12, P245, DOI 10.1097/GIM.0b013e3181d38f2f; Regala RP, 2005, CANCER RES, V65, P8905, DOI 10.1158/0008-5472.CAN-05-2372; Regala RP, 2005, J BIOL CHEM, V280, P31109, DOI 10.1074/jbc.M505402200; Rho SB, 2009, BIOTECHNOL LETT, V31, P23, DOI 10.1007/s10529-008-9845-8; Shen HM, 2014, MED ONCOL, V31, DOI 10.1007/s12032-014-0117-2; Siegel RL, 2015, CA-CANCER J CLIN, V65, P5, DOI 10.3322/caac.21254; Sonoda G, 1997, GENE CHROMOSOME CANC, V20, P320; Sugita M, 2000, CANCER GENET CYTOGEN, V117, P9, DOI 10.1016/S0165-4608(99)00135-1; Wang Y, 2013, MOL CANCER RES, V11, P1624, DOI 10.1158/1541-7786.MCR-13-0371-T; Yi CL, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004060; Zhang L, 2006, CANCER RES, V66, P4627, DOI 10.1158/0008-5472.CAN-05-4527; Zhang X, 2011, ONCOGENE, V30, P2810, DOI 10.1038/onc.2011.8	39	31	36	2	12	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 26	2017	36	4					534	545		10.1038/onc.2016.224	http://dx.doi.org/10.1038/onc.2016.224			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EK8II	27321186	Green Accepted			2022-12-17	WOS:000394166700010
J	Iltzsche, F; Simon, K; Stopp, S; Pattschull, G; Francke, S; Wolter, P; Hauser, S; Murphy, DJ; Garcia, P; Rosenwald, A; Gaubatz, S				Iltzsche, F.; Simon, K.; Stopp, S.; Pattschull, G.; Francke, S.; Wolter, P.; Hauser, S.; Murphy, D. J.; Garcia, P.; Rosenwald, A.; Gaubatz, S.			An important role for Myb-MuvB and its target gene KIF23 in a mouse model of lung adenocarcinoma	ONCOGENE			English	Article							B-MYB; IN-VIVO; K-RAS; CHROMOSOMAL INSTABILITY; EXPRESSION PROFILES; MOTOR PROTEINS; G(2)/M GENES; CANCER; COMPLEX; TRANSCRIPTION	The conserved Myb-MuvB (MMB) multiprotein complex has an important role in transcriptional activation of mitotic genes. MMB target genes are overexpressed in several different cancer types and their elevated expression is associated with an advanced tumor state and a poor prognosis. This suggests that MMB could contribute to tumorigenesis by mediating overexpression of mitotic genes. However, although MMB has been extensively characterized biochemically, the requirement for MMB in tumorigenesis in vivo has not been investigated. Here we demonstrate.that MMB is required for tumor formation in a mouse model of lung cancer driven by oncogenic K-RAS. We also identify a requirement for the mitotic kinesin KIF23, a key target gene of MMB, in tumorigenesis. RNA interference-mediated depletion of KIF23 inhibited lung tumor formation in vivo and induced apoptosis in lung cancer cell lines. Our results suggest that inhibition of KIF23 could be a strategy for treatment of lung cancer.	[Iltzsche, F.; Simon, K.; Stopp, S.; Pattschull, G.; Francke, S.; Wolter, P.; Hauser, S.; Gaubatz, S.] Univ Wurzburg, Theodor Boveri Inst, Dept Physiol Chem, Bioctr, Wurzburg, Germany; [Murphy, D. J.] Univ Glasgow, Inst Canc Sci, Glasgow, Lanark, Scotland; [Murphy, D. J.] CRUK Beatson Inst, Glasgow, Lanark, Scotland; [Garcia, P.] Univ Birmingham, Inst Biomed Res, Coll Med & Dent Sci, Birmingham, W Midlands, England; [Rosenwald, A.; Gaubatz, S.] Univ Wurzburg, Comprehens Canc Ctr Mainfranken, Wurzburg, Germany; [Rosenwald, A.] Univ Wurzburg, Inst Pathol, Wurzburg, Germany	University of Wurzburg; University of Glasgow; Beatson Institute; University of Birmingham; University of Wurzburg; University of Wurzburg	Gaubatz, S (corresponding author), Univ Wurzburg, Theodor Boveri Inst, Bioctr, Hubland, D-97074 Wurzburg, Bavaria, Germany.	stefan.gaubatz@biozentrum.uni-wuerzburg.de	Garcia, Paloma/AFO-2595-2022; Murphy, Daniel/V-1079-2019	Murphy, Daniel/0000-0002-5538-5468; Gaubatz, Stefan/0000-0001-8751-4191; Garcia, Paloma/0000-0001-5582-8575	Deutsche Krebshilfe [110928]; Sander Stiftung [2015.038.1]; DFG [GA 575/5-2]	Deutsche Krebshilfe(Deutsche Krebshilfe); Sander Stiftung; DFG(German Research Foundation (DFG))	We thank Tyler Jacks, Anton Berns, Roger Watson, Geert Carmeliet, Thorsten Stiewe and Andras Nagy for reagents, and Sabine Roth and Susi Spahr for excellent technical help. We thank all members of the laboratory for their suggestions and critical reading of the manuscript. This work was supported by grants from the Deutsche Krebshilfe (110928), Sander Stiftung (2015.038.1) and DFG (GA 575/5-2) towards SG.	Bakhoum SF, 2012, J CLIN INVEST, V122, P1138, DOI 10.1172/JCI59954; Basseres DS, 2010, CANCER RES, V70, P3537, DOI 10.1158/0008-5472.CAN-09-4290; Bowman BM, 2015, SCI SIGNAL, V8, DOI 10.1126/scisignal.2005607; Carter SL, 2006, NAT GENET, V38, P1043, DOI 10.1038/ng1861; Cellurale C, 2011, MOL CELL BIOL, V31, P1565, DOI 10.1128/MCB.01122-10; Cheng WY, 2013, PLOS COMPUT BIOL, V9, DOI 10.1371/journal.pcbi.1002920; Chibon F, 2010, NAT MED, V16, P781, DOI 10.1038/nm.2174; Diaz-Rodriguez E, 2008, P NATL ACAD SCI USA, V105, P16719, DOI 10.1073/pnas.0803504105; DuPage M, 2009, NAT PROTOC, V4, P1064, DOI 10.1038/nprot.2009.95; Esterlechner J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062882; Feldser DM, 2010, NATURE, V468, P572, DOI 10.1038/nature09535; Fischer M, 2016, NUCLEIC ACIDS RES, V44, P164, DOI 10.1093/nar/gkv927; Fischer M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063187; Garcia P, 2005, GENESIS, V43, P189, DOI 10.1002/gene.20170; Glotzer M, 2009, NAT REV MOL CELL BIO, V10, P9, DOI 10.1038/nrm2609; Gyorffy B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082241; Hernando E, 2004, NATURE, V430, P797, DOI 10.1038/nature02820; Hirokawa N, 2009, NAT REV MOL CELL BIO, V10, P682, DOI 10.1038/nrm2774; Huszar D, 2009, CANCER METAST REV, V28, P197, DOI 10.1007/s10555-009-9185-8; Jackson EL, 2005, CANCER RES, V65, P10280, DOI 10.1158/0008-5472.CAN-05-2193; Jackson EL, 2001, GENE DEV, V15, P3243, DOI 10.1101/gad.943001; Kissil JL, 2007, CANCER RES, V67, P8089, DOI 10.1158/0008-5472.CAN-07-2300; Knight AS, 2009, ONCOGENE, V28, P1737, DOI 10.1038/onc.2009.22; Litovchick L, 2007, MOL CELL, V26, P539, DOI 10.1016/j.molcel.2007.04.015; Mannefeld M, 2009, CANCER RES, V69, P4073, DOI 10.1158/0008-5472.CAN-08-4156; Marino S, 2000, GENE DEV, V14, P994; Meerbrey KL, 2011, P NATL ACAD SCI USA, V108, P3665, DOI 10.1073/pnas.1019736108; Menssen A, 2007, CELL CYCLE, V6, P339, DOI 10.4161/cc.6.3.3808; Murphy DJ, 2008, CANCER CELL, V14, P447, DOI 10.1016/j.ccr.2008.10.018; Novak A, 2000, GENESIS, V28, P147, DOI 10.1002/1526-968X(200011/12)28:3/4<147::AID-GENE90>3.0.CO;2-G; Osterloh L, 2007, EMBO J, V26, P144, DOI 10.1038/sj.emboj.7601478; Quaas M, 2012, CELL CYCLE, V11, P4661, DOI 10.4161/cc.22917; Raemaekers T, 2003, J CELL BIOL, V162, P1017, DOI 10.1083/jcb.200302129; Rath O, 2012, NAT REV CANCER, V12, P527, DOI 10.1038/nrc3310; Reichert N, 2010, MOL CELL BIOL, V30, P2896, DOI 10.1128/MCB.00028-10; Sadasivam S, 2013, NAT REV CANCER, V13, P585, DOI 10.1038/nrc3556; Sadasivam S, 2012, GENE DEV, V26, P474, DOI 10.1101/gad.181933.111; Saville MK, 1998, ONCOGENE, V17, P2679, DOI 10.1038/sj.onc.1202503; Schmit F, 2007, CELL CYCLE, V6, P1903, DOI 10.4161/cc.6.15.4512; Sotillo R, 2007, CANCER CELL, V11, P9, DOI 10.1016/j.ccr.2006.10.019; Takahashi S, 2012, J NEURO-ONCOL, V106, P519, DOI 10.1007/s11060-011-0706-2; Tanaka Y, 1999, J BIOL CHEM, V274, P28067, DOI 10.1074/jbc.274.40.28067; Tavner F, 2007, ONCOGENE, V26, P2727, DOI 10.1038/sj.onc.1210087; Tetreault MP, 2013, NAT REV CANCER, V13, P701, DOI 10.1038/nrc3582; Tiscornia G, 2006, NAT PROTOC, V1, P241, DOI 10.1038/nprot.2006.37; Valk K, 2010, ONCOLOGY-BASEL, V79, P283, DOI 10.1159/000322116; White EA, 2012, CYTOSKELETON, V69, P882, DOI 10.1002/cm.21065; Winter GE, 2015, SCIENCE, V348, P1376, DOI 10.1126/science.aab1433	48	31	33	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 5	2017	36	1					110	121		10.1038/onc.2016.181	http://dx.doi.org/10.1038/onc.2016.181			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EK6XJ	27212033	Green Published, Green Accepted			2022-12-17	WOS:000394069100010
J	Graziano, S; Johnston, R; Deng, O; Zhang, J; Gonzalo, S				Graziano, S.; Johnston, R.; Deng, O.; Zhang, J.; Gonzalo, S.			Vitamin D/vitamin D receptor axis regulates DNA repair during oncogene-induced senescence	ONCOGENE			English	Article							CATHEPSIN-L EXPRESSION; A-TYPE LAMINS; HOMOLOGOUS RECOMBINATION; BREAST-CANCER; DAMAGE RESPONSE; POLY(ADP-RIBOSE) POLYMERASE; GENOMIC INSTABILITY; CYSTEINE CATHEPSINS; CELLULAR SENESCENCE; CRITICAL MEDIATOR	Oncogenic Ras expression is associated with activation of the DNA damage response (DDR) pathway, as evidenced by elevated DNA damage, primarily DNA double-strand breaks (DSBs), and activation of DNA damage checkpoints, which in primary human cells leads to entry into senescence. DDR activation is viewed as a physiological barrier against uncontrolled proliferation in oncogenic Ras-expressing cells, and arises in response to genotoxic stress due to the production of reactive oxygen species that damage DNA and to hyper-replication stress. Although oncogene-induced senescence (OIS) is considered a tumor suppressor mechanism, the accumulation of DNA damage in senescent cells is thought to cause genomic instability, eventually allowing secondary hits in the genome that promote tumorigenesis. To date, the molecular mechanisms behind DNA repair defects during OIS remain poorly understood. Here, we show that oncogenic Ras expression in human primary cells results in the downregulation of BRCA1 and 53BP1, two key factors in DNA DSB repair by homologous recombination and non-homologous end joining, respectively. As a consequence, Ras-induced senescent cells are hindered in their ability to recruit BRCA1 and 53BP1 to DNA damage sites. Whereas BRCA1 is downregulated at transcripts levels, 53BP1 loss is caused by activation of cathepsin L-mediated degradation of 53BP1 protein. Moreover, we discovered a marked downregulation of vitamin D receptor (VDR) during OIS, and a role for the vitamin D/VDR axis regulating the levels of these DNA repair factors during OIS. This study reveals a new functional relationship between the oncogene Ras, the vitamin D/VDR axis and the expression of DNA repair factors, in the context of OIS. The observed deficiencies in DNA repair factors in senescent cells could contribute to the genomic instability that allows senescence bypass and tumorigenesis.	[Graziano, S.; Johnston, R.; Gonzalo, S.] St Louis Univ, Sch Med, Edward A Doisy Dept Biochem & Mol Biol, 1100S Grand Ave, St Louis, MO 63104 USA; [Deng, O.; Zhang, J.] Case Western Reserve Univ, Sch Med, Dept Radiat Oncol, Cleveland, OH 44106 USA	Saint Louis University; Case Western Reserve University	Gonzalo, S (corresponding author), St Louis Univ, Sch Med, Edward A Doisy Dept Biochem & Mol Biol, 1100S Grand Ave, St Louis, MO 63104 USA.	sgonzalo@slu.edu	Gonzalo, Susana/T-8275-2019	Graziano, Simona/0000-0003-2661-1240; Gonzalo, Susana/0000-0001-9631-1206; Johnston, Rachel/0000-0002-6738-813X; Deng, Ou/0000-0002-9933-1832	NATIONAL CANCER INSTITUTE [R01CA154625] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM094513] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA154625] Funding Source: Medline; NIGMS NIH HHS [R01 GM094513] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aird KM, 2013, CELL REP, V3, P1252, DOI 10.1016/j.celrep.2013.03.004; Aly A, 2011, J MOL CELL BIOL, V3, P66, DOI 10.1093/jmcb/mjq055; Bartek J, 2007, ONCOGENE, V26, P7773, DOI 10.1038/sj.onc.1210881; Bartkova J, 2006, NATURE, V444, P633, DOI 10.1038/nature05268; Bouwman P, 2010, NAT STRUCT MOL BIOL, V17, P688, DOI 10.1038/nsmb.1831; Bunting SF, 2010, CELL, V141, P243, DOI 10.1016/j.cell.2010.03.012; Campbell MJ, 2000, ONCOGENE, V19, P5091, DOI 10.1038/sj.onc.1203888; Campisi J, 2005, SCIENCE, V309, P886, DOI 10.1126/science.1116801; Campisi J, 2005, CELL, V120, P513, DOI 10.1016/j.cell.2005.02.003; Cao L, 2009, MOL CELL, V35, P534, DOI 10.1016/j.molcel.2009.06.037; Carey LA, 2006, JAMA-J AM MED ASSOC, V295, P2492, DOI 10.1001/jama.295.21.2492; Collado M, 2010, NAT REV CANCER, V10, P51, DOI 10.1038/nrc2772; Collette J, 2004, INT J CANCER, V112, P190, DOI 10.1002/ijc.20398; Croke M, 2013, CELL CYCLE, V12, P3629, DOI 10.4161/cc.26582; Deeb KK, 2007, NAT REV CANCER, V7, P684, DOI 10.1038/nrc2196; Deng CH, 2009, MOL ENDOCRINOL, V23, P226, DOI 10.1210/me.2008-0075; DENHARDT DT, 1987, ONCOGENE, V2, P55; Di Micco R, 2006, NATURE, V444, P638, DOI 10.1038/nature05327; Di Micco R, 2011, NAT CELL BIOL, V13, P292, DOI 10.1038/ncb2170; Dusso AS, 2005, AM J PHYSIOL-RENAL, V289, pF8, DOI 10.1152/ajprenal.00336.2004; Farmer H, 2005, NATURE, V434, P917, DOI 10.1038/nature03445; Fong PC, 2009, NEW ENGL J MED, V361, P123, DOI 10.1056/NEJMoa0900212; Gocheva V, 2007, CELL CYCLE, V6, P60, DOI 10.4161/cc.6.1.3669; Gonzalez-Suarez I, 2011, EMBO J, V30, P3383, DOI 10.1038/emboj.2011.225; Gonzalez-Suarez I, 2009, EMBO J, V28, P2414, DOI 10.1038/emboj.2009.196; Gonzalo S, 2014, J STEROID BIOCHEM, V144, P59, DOI 10.1016/j.jsbmb.2013.09.009; Gorgoulis VG, 2005, NATURE, V434, P907, DOI 10.1038/nature03485; Goulet B, 2007, MOL CANCER RES, V5, P899, DOI 10.1158/1541-7786.MCR-07-0160; Grotsky DA, 2013, J CELL BIOL, V200, P187, DOI 10.1083/jcb.201204053; Haussler MR, 2013, CALCIFIED TISSUE INT, V92, P77, DOI 10.1007/s00223-012-9619-0; Helleday T, 2005, CELL CYCLE, V4, P1176, DOI 10.4161/cc.4.9.2031; Jaspers JE, 2013, CANCER DISCOV, V3, P68, DOI 10.1158/2159-8290.CD-12-0049; Jedeszko C, 2004, BIOL CHEM, V385, P1017, DOI 10.1515/BC.2004.132; Kass EM, 2010, CANCER CELL, V17, P423, DOI 10.1016/j.ccr.2010.04.021; King MC, 2003, SCIENCE, V302, P643, DOI 10.1126/science.1088759; Klein HL, 2008, DNA REPAIR, V7, P686, DOI 10.1016/j.dnarep.2007.12.008; Lee AC, 1999, J BIOL CHEM, V274, P7936, DOI 10.1074/jbc.274.12.7936; Lowndes NF, 2010, DNA REPAIR, V9, P1112, DOI 10.1016/j.dnarep.2010.07.012; Mallette FA, 2007, GENE DEV, V21, P43, DOI 10.1101/gad.1487307; Mannava S, 2013, AM J PATHOL, V182, P142, DOI 10.1016/j.ajpath.2012.09.011; Mao ZY, 2012, P NATL ACAD SCI USA, V109, P11800, DOI 10.1073/pnas.1200583109; Morales JC, 2003, J BIOL CHEM, V278, P14971, DOI 10.1074/jbc.M212484200; Narvaez CJ, 2014, FRONT PHYSIOL, V5, DOI 10.3389/fphys.2014.00213; Nesby-O'Dell S, 2002, AM J CLIN NUTR, V76, P187, DOI 10.1093/ajcn/76.1.187; Redwood AB, 2011, CELL CYCLE, V10, P3652, DOI 10.4161/cc.10.21.18201; Redwood AB, 2011, CELL CYCLE, V10, P2549, DOI 10.4161/cc.10.15.16531; Rottenberg S, 2008, P NATL ACAD SCI USA, V105, P17079, DOI 10.1073/pnas.0806092105; Rozenchan PB, 2004, J STEROID BIOCHEM, V92, P89, DOI 10.1016/j.jsbmb.2004.05.007; Salomon DG, 2014, J NEURO-ONCOL, V118, P49, DOI 10.1007/s11060-014-1416-3; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Skrzydlewska E, 2005, WORLD J GASTROENTERO, V11, P1251, DOI 10.3748/wjg.v11.i9.1251; Srinivasan M, 2011, J STEROID BIOCHEM, V123, P30, DOI 10.1016/j.jsbmb.2010.10.002; Suram A, 2012, EMBO J, V31, P2839, DOI 10.1038/emboj.2012.132; Taber LM, 2009, J NUTR BIOCHEM, V20, P629, DOI 10.1016/j.jnutbio.2008.06.008; Tu ZG, 2013, CELL CYCLE, V12, P1653, DOI 10.4161/cc.24986; Tu ZG, 2011, DEV CELL, V21, P1077, DOI 10.1016/j.devcel.2011.10.010; Urbanelli L, 2010, MOL CELL BIOCHEM, V343, P49, DOI 10.1007/s11010-010-0497-3; Weyemi U, 2012, ONCOGENE, V31, P1117, DOI 10.1038/onc.2011.327; Yao S, 2013, J STEROID BIOCHEM, V136, P337, DOI 10.1016/j.jsbmb.2012.09.010; Yuan SSF, 2003, MUTAT RES-FUND MOL M, V525, P85, DOI 10.1016/S0027-5107(03)00009-5; Zhang JR, 2005, NAT STRUCT MOL BIOL, V12, P902, DOI 10.1038/nsmb991	61	31	31	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 13	2016	35	41					5362	5376		10.1038/onc.2016.77	http://dx.doi.org/10.1038/onc.2016.77			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EA5QU	27041576	Green Accepted			2022-12-17	WOS:000386677800003
J	Na, TY; Ka, NL; Rhee, H; Kyeong, D; Kim, MH; Seong, JK; Park, YN; Lee, MO				Na, T-Y; Ka, N-L; Rhee, H.; Kyeong, D.; Kim, M-H; Seong, J. K.; Park, Y. N.; Lee, M-O			Interaction of hepatitis B virus X protein with PARP1 results in inhibition of DNA repair in hepatocellular carcinoma	ONCOGENE			English	Article							POLY(ADP-RIBOSE) POLYMERASE; DAMAGE RESPONSE; EXCISION-REPAIR; LIVER-CANCER; CHROMATIN; CELLS; TRANSCRIPTION; ACCUMULATION; INVOLVEMENT; INVASION	Hepatitis B virus X protein (HBx) contributes to the development of hepatocellular carcinoma (HCC), probably by regulating activities of many host or viral proteins through protein-protein interactions. In this study, we identified poly(ADP-ribose) polymerase (PARP1), a crucial factor in DNA repair, as an HBx-interacting protein using a proteomics approach. Coimmunoprecipitation and proximity ligation assays confirmed the binding and colocalization of HBx and PARP1 in the nucleus. The carboxyl-terminus of HBx protein bound to the catalytic domain of PARP1, and this binding reduced the enzymatic activity of PARP1 in both in vitro and in vivo assays. HBx interrupted the binding of PARP1 to Sirt6, which catalyzes the mono-ADP-ribosylation required for DNA repair. Consistently, overexpression of HBx inhibited the clearance of gamma H2AX DNA repair foci generated under oxidative stress in Chang liver cells. Recruitment of the DNA repair complex to the site-specific double-strand breaks was inhibited in the presence of HBx, when measured by laser microirradiation assay and damage-specific chromatin immunoprecipitation assays. Consequently, HBx increased signs of DNA damage such as accumulation of 8-hydroxy-2'-deoxyguanosine and comet formation, which were reversed by overexpression of PARP1 and/or Sirt6. Finally, the interaction between PARP1 and Sirt6 was markedly lower in the livers of HBx-transgenic mice and specimens obtained from HCC patients to compare with the corresponding control. Our data suggest that the physical interaction of HBx and PARP1 accelerates DNA damage by inhibiting recruitment of the DNA repair complex to the damaged DNA sites, which may lead to the onset of hepatocarcinogenesis.	[Na, T-Y; Ka, N-L; Kim, M-H; Lee, M-O] Seoul Natl Univ, Coll Pharm, San 56-1 Sillim Dong, Seoul 151742, South Korea; [Na, T-Y; Ka, N-L; Kim, M-H; Lee, M-O] Seoul Natl Univ, Bio MAX Inst, Seoul, South Korea; [Rhee, H.; Park, Y. N.] Yonsei Univ, Coll Med, Integrated Genom Res Ctr Metab Regulat, Dept Pathol, Seoul, South Korea; [Kyeong, D.; Seong, J. K.] Seoul Natl Univ, Interdisciplinary Program Bioinformat, Coll Vet Med, Seoul, South Korea; [Kyeong, D.; Seong, J. K.] Seoul Natl Univ, Program Canc Biol, Seoul, South Korea; [Kyeong, D.; Seong, J. K.] Korea Mouse Phenotyping Ctr, Seoul, South Korea; [Park, Y. N.] Yonsei Univ, Coll Med, Severance Biomed Sci Inst, Seoul, South Korea	Seoul National University (SNU); Seoul National University (SNU); Yonsei University; Yonsei University Health System; Seoul National University (SNU); Seoul National University (SNU); Yonsei University; Yonsei University Health System	Lee, MO (corresponding author), Seoul Natl Univ, Coll Pharm, San 56-1 Sillim Dong, Seoul 151742, South Korea.	molee@snu.ac.kr	Rhee, Hyungjin/T-7619-2019	Park, Young Nyun/0000-0003-0357-7967; Seong, Je Kyung/0000-0003-1177-6958; Kyung, Dongsoo/0000-0003-2910-0120; Rhee, Hyungjin/0000-0001-7759-4458	National R&D Program for Cancer Control, Ministry of Health Welfare, Korea [1220110]; Bio & Medical Technology Development Program [2012M3A9B6055338];  [NRF-2014R1A2A1A10052265]	National R&D Program for Cancer Control, Ministry of Health Welfare, Korea(Ministry of Health & Welfare (MOHW), Republic of Korea); Bio & Medical Technology Development Program; 	This work was supported by grants from NRF-2014R1A2A1A10052265, the National R&D Program for Cancer Control, Ministry of Health & Welfare, Korea (1220110) and the Bio & Medical Technology Development Program (2012M3A9B6055338).	Abd Elmageed ZY, 2012, CELL SIGNAL, V24, P1, DOI 10.1016/j.cellsig.2011.07.019; Becker SA, 1998, J VIROL, V72, P266, DOI 10.1128/JVI.72.1.266-272.1998; Bolukbas C, 2005, BMC INFECT DIS, V5, DOI 10.1186/1471-2334-5-95; Bosch FX, 2004, GASTROENTEROLOGY, V127, pS5, DOI 10.1053/j.gastro.2004.09.011; Dandri M, 2002, HEPATOLOGY, V35, P217, DOI 10.1053/jhep.2002.30203; Dantzer F, 1999, BIOCHIMIE, V81, P69, DOI 10.1016/S0300-9084(99)80040-6; deMurcia JM, 1997, P NATL ACAD SCI USA, V94, P7303, DOI 10.1073/pnas.94.14.7303; Deng BA, 2015, GENE, V571, P292, DOI 10.1016/j.gene.2015.06.083; Di Giammartino DC, 2013, MOL CELL, V49, P7, DOI 10.1016/j.molcel.2012.11.005; Fujita N, 2008, J VIRAL HEPATITIS, V15, P498, DOI 10.1111/j.1365-2893.2008.00972.x; Gehrke R, 2004, DIGESTION, V70, P117, DOI 10.1159/000080930; Higgs MR, 2014, J GEN VIROL, V95, P991, DOI 10.1099/vir.0.059485-0; Hoare J, 2001, J MED VIROL, V64, P419, DOI 10.1002/jmv.1067; Iizuka N, 2006, J CANCER RES CLIN, V132, P473, DOI 10.1007/s00432-006-0094-8; Jackson SP, 2009, NATURE, V461, P1071, DOI 10.1038/nature08467; Jia L, 1999, INT J CANCER, V80, P875, DOI 10.1002/(SICI)1097-0215(19990315)80:6<875::AID-IJC13>3.0.CO;2-Z; Kaidi A, 2010, SCIENCE, V329, P1348, DOI 10.1126/science.1192049; Kew MC, 2011, J GASTROEN HEPATOL, V26, P144, DOI 10.1111/j.1440-1746.2010.06546.x; Ko HL, 2011, HEPATOLOGY, V54, P1190, DOI 10.1002/hep.24502; Kraus WL, 2008, CURR OPIN CELL BIOL, V20, P294, DOI 10.1016/j.ceb.2008.03.006; Lara-Pezzi E, 2001, ONCOGENE, V20, P3323, DOI 10.1038/sj.onc.1204451; Lee MH, 2012, ONCOGENE, V31, P5099, DOI 10.1038/onc.2012.2; Lee NS, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10463; LEE TH, 1995, J VIROL, V69, P1107, DOI 10.1128/JVI.69.2.1107-1114.1995; Liu HO, 2012, CANCER SCI, V103, P2072, DOI 10.1111/cas.12017; Lonn P, 2010, MOL CELL, V40, P521, DOI 10.1016/j.molcel.2010.10.029; Lu H, 2011, J BIOL CHEM, V286, P20335, DOI 10.1074/jbc.M110.215632; Mao ZY, 2011, SCIENCE, V332, P1443, DOI 10.1126/science.1202723; Marquardt JU, 2013, HEPATOLOGY, V58, P1054, DOI 10.1002/hep.26413; Maul RS, 2003, J CELL BIOL, V160, P399, DOI 10.1083/jcb.200212057; McCord RA, 2009, AGING-US, V1, P109, DOI 10.18632/aging.100011; Min LH, 2012, NAT CELL BIOL, V14, P1203, DOI 10.1038/ncb2590; Min S, 2014, CELL CYCLE, V13, P666, DOI 10.4161/cc.27548; Na TY, 2009, HEPATOLOGY, V49, P1122, DOI 10.1002/hep.22740; Ng SA, 2011, J GASTROENTEROL, V46, P974, DOI 10.1007/s00535-011-0415-9; Nomura F, 2000, J GASTROEN HEPATOL, V15, P529, DOI 10.1046/j.1440-1746.2000.02193.x; PATERLINI P, 1995, HEPATOLOGY, V21, P313, DOI 10.1002/hep.1840210208; Piskunova Tatiana S, 2008, Curr Gerontol Geriatr Res, P754190, DOI 10.1155/2008/754190; Qadri I, 2011, BMC MICROBIOL, V11, DOI 10.1186/1471-2180-11-48; Sala A, 2008, PLOS BIOL, V6, P2329, DOI 10.1371/journal.pbio.0060252; Seluanov A, 2004, P NATL ACAD SCI USA, V101, P7624, DOI 10.1073/pnas.0400726101; Shimizu S, 2004, ONCOL REP, V12, P821; SHIMODA R, 1994, CANCER RES, V54, P3171; Sousa FG, 2012, CARCINOGENESIS, V33, P1433, DOI 10.1093/carcin/bgs132; Srisuttee R, 2012, ONCOL REP, V28, P276, DOI 10.3892/or.2012.1798; Toiber D, 2013, MOL CELL, V51, P454, DOI 10.1016/j.molcel.2013.06.018; van de Klundert MAA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048940; van Gent DC, 2001, NAT REV GENET, V2, P196, DOI 10.1038/35056049; Weber KL, 2007, J CELL SCI, V120, P3625, DOI 10.1242/jcs.011445; Xu C, 2014, CANCER LETT, V345, P216, DOI 10.1016/j.canlet.2013.08.035; Yoo YG, 2004, FEBS LETT, V577, P121, DOI 10.1016/j.febslet.2004.10.004; Zhang ZG, 2014, MOL MED REP, V9, P882, DOI 10.3892/mmr.2013.1879	52	31	32	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 13	2016	35	41					5435	5445		10.1038/onc.2016.82	http://dx.doi.org/10.1038/onc.2016.82			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EA5QU	27041572				2022-12-17	WOS:000386677800009
J	Fluckiger, A; Dumont, A; Derangere, V; Rebe, C; de Rosny, C; Causse, S; Thomas, C; Apetoh, L; Hichami, A; Ghiringhelli, F; Rialland, M				Fluckiger, A.; Dumont, A.; Derangere, V.; Rebe, C.; de Rosny, C.; Causse, S.; Thomas, C.; Apetoh, L.; Hichami, A.; Ghiringhelli, F.; Rialland, M.			Inhibition of colon cancer growth by docosahexaenoic acid involves autocrine production of TNF alpha	ONCOGENE			English	Article							POLYUNSATURATED FATTY-ACIDS; TUMOR-NECROSIS-FACTOR; ACTIVATED PROTEIN-KINASE; PREVENTS BREAST-CANCER; CELL-PROLIFERATION; TUMORICIDAL ACTION; LIPID-METABOLISM; GENE-EXPRESSION; RIP1 KINASE; NF-KAPPAB	The omega-3 polyunsaturated fatty acid docosahexaenoic acid (DHA) has anti-inflammatory and anti-cancer properties. Among pro-inflammatory mediators, tumor necrosis factor a (TNF alpha) plays a paradoxical role in cancer biology with induction of cancer cell death or survival depending on the cellular context. The objective of the study was to evaluate the role of TNFa in DHA-mediated tumor growth inhibition and colon cancer cell death. The treatment of human colorectal cancer cells, HCT-116 and HCT-8 cells, with DHA triggered apoptosis in autocrine TNF alpha-dependent manner. We demonstrated that DHA-induced increased content of TNF alpha mRNA occurred through a post-transcriptional regulation via the down-regulation of microRNA-21 (miR-21) expression. Treatment with DHA led to nuclear accumulation of Foxo3a that bounds to the miR-21 promoter triggering its transcriptional repression. Moreover, inhibition of RIP1 kinase and AMP-activated protein kinase a reduced Foxo3a nuclear-cytoplasmic shuttling and subsequent increase of TNFa expression through a decrease of miR-21 expression in DHA-treated colon cancer cells. Finally, we were able to show in HCT-116 xenograft tumor-bearing nude mice that a DHA-enriched diet induced a decrease of human miR-21 expression and an increase of human TNF alpha mRNA expression limiting tumor growth in a cancer cell-derived TNF alpha dependent manner. Altogether, the present work highlights a novel mechanism for anti-cancer action of DHA involving colon cancer cell death mediated through autocrine action of TNF alpha.	[Fluckiger, A.; Dumont, A.; Derangere, V.; Rebe, C.; de Rosny, C.; Causse, S.; Thomas, C.; Apetoh, L.; Hichami, A.; Ghiringhelli, F.; Rialland, M.] INSERM, UMR 866, Dijon, France; [Fluckiger, A.; Dumont, A.; de Rosny, C.; Thomas, C.; Hichami, A.; Rialland, M.] Univ Bourgogne, UFR Sci Vie Terre & Environm, Dijon, France; [Derangere, V.; Causse, S.; Apetoh, L.; Ghiringhelli, F.] Univ Bourgogne, UFR Sci Sante, Dijon, France; [Rebe, C.; Apetoh, L.; Ghiringhelli, F.] Ctr Georges Francois Leclerc, Dijon, France	Institut Agro; AgroSup Dijon; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Bourgogne; Universite de Bourgogne; Universite de Bourgogne; UNICANCER; Centre Georges-Francois Leclerc	Rialland, M (corresponding author), Univ Bourgogne, INSERM, UMR 866, 6 Bd Gabriel, F-21000 Dijon, Bourgogne, France.	mickael.rialland@u-bourgogne.fr	Thomas, charles/C-7130-2019; Causse, Sebastien Zwe/AAZ-7365-2021; REBE, Cédric/AAD-4316-2019; Apetoh, Lionel/AIC-2384-2022	Thomas, charles/0000-0001-9998-6698; REBE, Cédric/0000-0001-8831-145X; Apetoh, Lionel/0000-0002-2774-438X; Causse, Sebastien/0000-0003-3246-3491; ghiringhelli, francois/0000-0002-5465-8305; Rialland, Mickael/0000-0001-9693-9351	Ligue contre le cancer comite Grand-Est; French Government grant [ANR-11-LABX-0021]	Ligue contre le cancer comite Grand-Est; French Government grant	The authors would like to thank the lipidomic plateform and the flow cytometry plateform facilities of Universite de Bourgogne. The present work was supported by Ligue contre le cancer comite Grand-Est and by a French Government grant managed by the French National Research Agency under the program 'Investissements d'Avenir' with reference ANR-11-LABX-0021 (Lipstic Labex).	Al-Zoubi M, 2013, CELL CYCLE, V12, P480, DOI 10.4161/cc.23370; ANTI M, 1992, GASTROENTEROLOGY, V103, P883, DOI 10.1016/0016-5085(92)90021-P; ANTI M, 1994, GASTROENTEROLOGY, V107, P1709, DOI 10.1016/0016-5085(94)90811-7; BALKWILL FR, 1986, CANCER RES, V46, P3990; Bansal T, 2010, P NATL ACAD SCI USA, V107, P228, DOI 10.1073/pnas.0906112107; BARTOLI GM, 1993, MOL ASPECTS MED, V14, P247, DOI 10.1016/0098-2997(93)90011-2; Bartoli R, 2000, GUT, V46, P191, DOI 10.1136/gut.46.2.191; Bathen TF, 2008, ANTICANCER RES, V28, P3717; Beaugerie L, 2015, NEW ENGL J MED, V372, P1441, DOI 10.1056/NEJMra1403718; BEGIN ME, 1986, JNCI-J NATL CANCER I, V77, P1053; BEGIN ME, 1986, PROG LIPID RES, V25, P573, DOI 10.1016/0163-7827(86)90116-5; BEGIN ME, 1985, PROSTA LEUKOTR MED, V19, P177, DOI 10.1016/0262-1746(85)90084-8; Berger H, 2013, CANCER RES, V73, P3578, DOI 10.1158/0008-5472.CAN-12-4018; Biton S, 2011, CELL, V145, P92, DOI 10.1016/j.cell.2011.02.023; Brenner H, 2014, LANCET, V383, P1490, DOI 10.1016/S0140-6736(13)61649-9; Calviello G, 2004, CARCINOGENESIS, V25, P2303, DOI 10.1093/carcin/bgh265; Calviello G, 2007, CARCINOGENESIS, V28, P1202, DOI 10.1093/carcin/bgl254; Cardaci S, 2012, J CELL SCI, V125, P2115, DOI 10.1242/jcs.095216; Chen Z, 2014, ONCOGENE, V33, P4548, DOI 10.1038/onc.2013.402; Chiacchiera F, 2010, CELL CYCLE, V9, P1091, DOI 10.4161/cc.9.6.11035; Chou CC, 2014, CANCER RES, V74, P4783, DOI 10.1158/0008-5472.CAN-14-0135; Christofferson DE, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.64; Chung H, 2015, ONCOGENE, V34, P3504, DOI 10.1038/onc.2014.283; Cianchi F, 2008, CLIN CANCER RES, V14, P7691, DOI 10.1158/1078-0432.CCR-08-0799; Cockbain AJ, 2012, GUT, V61, P135, DOI 10.1136/gut.2010.233718; DAS UN, 1991, CANCER LETT, V56, P235, DOI 10.1016/0304-3835(91)90008-6; Ding WQ, 2007, MOL CANCER THER, V6, P1467, DOI 10.1158/1535-7163.MCT-06-0608; Else PL, 2015, BBA-BIOMEMBRANES, V1848, P417, DOI 10.1016/j.bbamem.2014.10.039; Farago N, 2011, LIPIDS HEALTH DIS, V10, DOI 10.1186/1476-511X-10-173; Gattolliat CH, 2015, EUR J CANCER, V51, P409, DOI 10.1016/j.ejca.2014.12.007; Gil-Zamorano J, 2014, J NUTR, V144, P575, DOI 10.3945/jn.113.189050; Giros A, 2009, CANCER PREV RES, V2, P732, DOI 10.1158/1940-6207.CAPR-08-0197; Gravaghi C, 2011, J NUTR BIOCHEM, V22, P360, DOI 10.1016/j.jnutbio.2010.03.003; Greer EL, 2007, J BIOL CHEM, V282, P30107, DOI 10.1074/jbc.M705325200; Gu ZN, 2013, CARCINOGENESIS, V34, P1968, DOI 10.1093/carcin/bgt147; Iliopoulos D, 2010, MOL CELL, V39, P493, DOI 10.1016/j.molcel.2010.07.023; Jasperson KW, 2010, GASTROENTEROLOGY, V138, P2044, DOI 10.1053/j.gastro.2010.01.054; Jung SN, 2008, CARCINOGENESIS, V29, P713, DOI 10.1093/carcin/bgn032; Kreeger PK, 2009, CANCER RES, V69, P8191, DOI 10.1158/0008-5472.CAN-09-1921; Krzystek-Korpacka M, 2013, CANCER LETT, V337, P107, DOI 10.1016/j.canlet.2013.05.033; Bin L, 2008, WORLD J GASTROENTERO, V14, P2434, DOI 10.3748/wjg.14.2434; Maihofner C, 2003, CARCINOGENESIS, V24, P665, DOI 10.1093/carcin/bgg006; Martinasso G, 2007, PPAR RES, V2007, DOI 10.1155/2007/93416; Monjazeb AM, 2006, CARCINOGENESIS, V27, P1950, DOI 10.1093/carcin/bgl023; NAYLOR MS, 1990, CANCER RES, V50, P4436; O'Donnell MA, 2011, NAT CELL BIOL, V13, P1437, DOI 10.1038/ncb2362; Ofengeim D, 2013, NAT REV MOL CELL BIO, V14, P727, DOI 10.1038/nrm3683; Petersen SL, 2007, CANCER CELL, V12, P445, DOI 10.1016/j.ccr.2007.08.029; Pierre AS, 2013, BBA-MOL CELL BIOL L, V1831, P759, DOI 10.1016/j.bbalip.2013.01.005; Popivanova BK, 2008, J CLIN INVEST, V118, P560, DOI [10.1172/JC132453, 10.1172/JCI32453]; Schetter AJ, 2009, CLIN CANCER RES, V15, P5878, DOI 10.1158/1078-0432.CCR-09-0627; Seiler A, 2008, CELL METAB, V8, P237, DOI 10.1016/j.cmet.2008.07.005; Shalini S, 2015, CELL DEATH DIFFER, V22, P526, DOI 10.1038/cdd.2014.216; Shime H, 2012, P NATL ACAD SCI USA, V109, P2066, DOI 10.1073/pnas.1113099109; Sun H, 2008, CANCER RES, V68, P2912, DOI 10.1158/0008-5472.CAN-07-2305; van Kouwenhove M, 2011, NAT REV CANCER, V11, P644, DOI 10.1038/nrc3107; Varga T, 2011, BBA-MOL BASIS DIS, V1812, P1007, DOI 10.1016/j.bbadis.2011.02.014; Verbeke H, 2010, HUM PATHOL, V41, P990, DOI 10.1016/j.humpath.2009.09.021; Wang K, 2010, J BIOL CHEM, V285, P16958, DOI 10.1074/jbc.M109.093005; Wang P, 2009, CELL DEATH DIFFER, V16, P1192, DOI 10.1038/cdd.2009.51; Yao L, 2015, CANCER RES, V75, P1388, DOI 10.1158/0008-5472.CAN-14-2561; Yu HN, 2015, ARCH MED SCI, V11, P282, DOI 10.5114/aoms.2015.50962; Yu XF, 2015, ONCOTARGET, V6, P1995, DOI 10.18632/oncotarget.3038; Zhang XM, 2012, CANCER RES, V72, P4707, DOI 10.1158/0008-5472.CAN-12-0639; Zhou R, 2010, NUCLEIC ACIDS RES, V38, P3222, DOI 10.1093/nar/gkq056; Zins K, 2007, CANCER RES, V67, P1038, DOI 10.1158/0008-5472.CAN-06-2295; Zou ZQ, 2013, J LIPID RES, V54, P3453, DOI 10.1194/jlr.M042754	67	31	33	0	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 1	2016	35	35					4611	4622		10.1038/onc.2015.523	http://dx.doi.org/10.1038/onc.2015.523			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DU6PE	26853468				2022-12-17	WOS:000382336300007
J	Bognar, MK; Vincendeau, M; Erdmann, T; Seeholzer, T; Grau, M; Linnemann, JR; Ruland, J; Scheel, CH; Lenz, P; Ott, G; Lenz, G; Hauck, SM; Krappmann, D				Bognar, M. K.; Vincendeau, M.; Erdmann, T.; Seeholzer, T.; Grau, M.; Linnemann, J. R.; Ruland, J.; Scheel, C. H.; Lenz, P.; Ott, G.; Lenz, G.; Hauck, S. M.; Krappmann, D.			Oncogenic CARMA1 couples NF-kappa B and beta-catenin signaling in diffuse large B-cell lymphomas	ONCOGENE			English	Article							GLYCOGEN-SYNTHASE KINASE-3; RNA INTERFERENCE; INTESTINAL TUMORIGENESIS; CARD11 MUTATIONS; ABC-DLBCL; ACTIVATION; INHIBITION; EXPRESSION; IMMUNITY; CANCER	Constitutive activation of the antiapoptotic nuclear factor-kappa B (NF-kappa B) signaling pathway is a hallmark of the activated B-cell-like (ABC) subtype of diffuse large B-cell lymphomas (DLBCL). Recurrent oncogenic mutations are found in the scaffold protein CARMA1 (CARD11) that connects B-cell receptor (BCR) signaling to the canonical NF-kappa B pathway. We asked how far additional downstream processes are activated and contribute to the oncogenic potential of DLBCL-derived CARMA1 mutants. To this end, we expressed oncogenic CARMA1 in the NF-kappa B negative DLBCL lymphoma cell line BJAB. By a proteomic approach we identified recruitment of beta-catenin and its destruction complex consisting of APC, AXIN1, CK1a and GSK3 beta to oncogenic CARMA1. Recruitment of the beta-catenin destruction complex was independent of CARMA1-BCL10-MALT1 complex formation or constitutive NF-kappa B activation and promoted the stabilization of beta-catenin. The beta-catenin destruction complex was also recruited to CARMA1 in ABC DLBCL cell lines, which coincided with elevated beta-catenin expression. In line, beta-catenin was frequently detected in non-GCB DLBCL biopsies that rely on chronic BCR signaling. Increased beta-catenin amounts alone were not sufficient to induce classical WNT target gene signatures, but could augment TCF/LEF-dependent transcriptional activation in response to WNT signaling. In conjunction with NF-kappa B, beta-catenin enhanced expression of immunosuppressive interleukin-10 and suppressed antitumoral CCL3, indicating that beta-catenin can induce a favorable tumor microenvironment. Thus, parallel activation of NF-kappa B and beta-catenin signaling by gain-of-function mutations in CARMA1 augments WNT stimulation and is required for regulating the expression of distinct NF-kappa B target genes to trigger cell-intrinsic and extrinsic processes that promote DLBCL lymphomagenesis.	[Bognar, M. K.; Vincendeau, M.; Seeholzer, T.; Krappmann, D.] Helmholtz Zentrum Munchen, German Res Ctr Environm Hlth, Inst Mol Toxicol & Pharmacol, Res Unit Cellular Signal Integrat, Ingolstaedter Landstr 1, D-85764 Neuherberg, Bayern, Germany; [Erdmann, T.; Grau, M.; Lenz, G.] Univ Hosp Munster, Dept Med A, Translat Oncol, Albert Schweitzer Campus 1, Munster, Germany; [Erdmann, T.; Lenz, G.] Cluster Excellence EXC 1003, Cells Mot, Munster, Germany; [Grau, M.; Lenz, P.] Univ Marburg, Dept Phys, Marburg, Germany; [Linnemann, J. R.; Scheel, C. H.] Helmholtz Zentrum Munchen, Inst Stem Cell Res, German Res Ctr Environm Hlth, Neuherberg, Germany; [Ruland, J.] Tech Univ Munich, Klinikum Rechts Isar, Inst Klin Chem & Pathobiochem, Munich, Germany; [Ruland, J.] German Canc Consortium DKTK, Heidelberg, Germany; [Ruland, J.] German Ctr Infect Res DZIF, Partner Site Munich, Munich, Germany; [Ott, G.] Robert Bosch Krankenhaus, Dr Margarete Fischer Bosch Inst Clin Pharmacol, Dept Clin Pathol, Stuttgart, Germany; [Hauck, S. M.] Helmholtz Zentrum Munchen, German Res Ctr Environm Hlth, Res Unit Prot Sci, Neuherberg, Germany	Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; University of Munster; Philipps University Marburg; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Technical University of Munich; Helmholtz Association; German Cancer Research Center (DKFZ); German Center for Infection Research; Bosch; Robert Bosch Krankenhaus; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health	Krappmann, D (corresponding author), Helmholtz Zentrum Munchen, German Res Ctr Environm Hlth, Inst Mol Toxicol & Pharmacol, Res Unit Cellular Signal Integrat, Ingolstaedter Landstr 1, D-85764 Neuherberg, Bayern, Germany.	daniel.krappmann@helmholtz-muenchen.de	Krappmann, Daniel/ABF-4038-2021; Vincendeau, Michelle/AAD-4320-2022; Hauck, Stefanie/B-3300-2013; Krappmann, Daniel/AAT-4354-2021; Ruland, Jürgen/Q-6680-2018	Krappmann, Daniel/0000-0001-7640-3234; Hauck, Stefanie/0000-0002-1630-6827; Krappmann, Daniel/0000-0001-7640-3234; Ruland, Jürgen/0000-0002-8381-3597; Seeholzer, Thomas/0000-0002-1115-3358; Lenz, Peter/0000-0001-7705-3950; Grau, Michael/0000-0003-1909-0133	Deutsche Krebshilfe; Else Krner-Fresenius-Stiftung; Swiss National Science Foundation (Sinergia grant); Deutsche Forschungsgemeinschaft (DFG) [EXC 1003]; Philipps-University Marburg (Doctoral Scholarship); Deutsche Krebshilfe [109434]	Deutsche Krebshilfe(Deutsche Krebshilfe); Else Krner-Fresenius-Stiftung; Swiss National Science Foundation (Sinergia grant)(Swiss National Science Foundation (SNSF)); Deutsche Forschungsgemeinschaft (DFG)(German Research Foundation (DFG)); Philipps-University Marburg (Doctoral Scholarship); Deutsche Krebshilfe(Deutsche Krebshilfe)	We thank Bernhard Kloo for support. The following material was kindly provided by: pMD2.G (Addgene # 12259), psPAX2 (Addgene # 12260), pLVTHM (Addgene # 12247) and pLV-tTRKRAB-red (Addgene # 12250) from Didier Trono; TCF/LEF luciferase reporter from Roel Nusse (Addgene # 24307). Support: Deutsche Krebshilfe, Else Krner-Fresenius-Stiftung, Swiss National Science Foundation (Sinergia grant), Deutsche Forschungsgemeinschaft (DFG EXC 1003) to GL; Philipps-University Marburg (Doctoral Scholarship) to MG; Deutsche Krebshilfe (# 109434) to DK.	Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501; Anastas JN, 2013, NAT REV CANCER, V13, P11, DOI 10.1038/nrc3419; Barrett T, 2013, NUCLEIC ACIDS RES, V41, pD991, DOI 10.1093/nar/gks1193; Bidere N, 2009, NATURE, V458, P92, DOI 10.1038/nature07613; Chin M, 2009, ONCOGENE, V28, P2100, DOI 10.1038/onc.2009.74; Christian SL, 2002, J IMMUNOL, V169, P758, DOI 10.4049/jimmunol.169.2.758; Clevers H, 2012, CELL, V149, P1192, DOI 10.1016/j.cell.2012.05.012; Compagno M, 2009, NATURE, V459, P717, DOI 10.1038/nature07968; Davis RE, 2010, NATURE, V463, P88, DOI 10.1038/nature08638; Deng JO, 2002, CANCER CELL, V2, P323, DOI 10.1016/S1535-6108(02)00154-X; Eitelhuber AC, 2011, EMBO J, V30, P594, DOI 10.1038/emboj.2010.331; Etet PFS, 2013, BBA-REV CANCER, V1835, P1, DOI 10.1016/j.bbcan.2012.08.002; Fu CM, 2015, P NATL ACAD SCI USA, V112, P2823, DOI 10.1073/pnas.1414167112; Fuerer C, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009370; Ge XL, 2012, MOL MED REP, V5, P1433, DOI 10.3892/mmr.2012.835; Gloeckner CJ, 2007, PROTEOMICS, V7, P4228, DOI 10.1002/pmic.200700038; Hadian K, 2011, J BIOL CHEM, V286, P26107, DOI 10.1074/jbc.M111.233163; Hans CP, 2004, BLOOD, V103, P275, DOI 10.1182/blood-2003-05-1545; Harlin H, 2009, CANCER RES, V69, P3077, DOI 10.1158/0008-5472.CAN-08-2281; Heuberger J, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a002915; Jeelall YS, 2012, J EXP MED, V209, P1907, DOI 10.1084/jem.20112744; Koch R, 2014, BLOOD, V123, P2189, DOI 10.1182/blood-2013-08-523886; Labbe E, 2007, CANCER RES, V67, P75, DOI 10.1158/0008-5472.CAN-06-2559; Lam LT, 2008, BLOOD, V111, P3701, DOI 10.1182/blood-2007-09-111948; Lam LT, 2008, P NATL ACAD SCI USA, V105, P20798, DOI 10.1073/pnas.0806491106; Lamason RL, 2010, BIOCHEMISTRY-US, V49, P8240, DOI 10.1021/bi101052d; Lenz G, 2008, SCIENCE, V319, P1676, DOI 10.1126/science.1153629; Li SW, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042775; Li VSW, 2012, CELL, V149, P1245, DOI 10.1016/j.cell.2012.05.002; Lovatt M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012794; Nagel D, 2014, ONCOGENE, V33, P5655, DOI 10.1038/onc.2013.565; Nagel D, 2012, CANCER CELL, V22, P825, DOI 10.1016/j.ccr.2012.11.002; Nakashima E, 1996, PHARMACEUT RES, V13, P1896, DOI 10.1023/A:1016057830271; Naylor TL, 2011, CANCER RES, V71, P2643, DOI 10.1158/0008-5472.CAN-10-2525; Ngo VN, 2006, NATURE, V441, P106, DOI 10.1038/nature04687; Ngo VN, 2011, NATURE, V470, P115, DOI 10.1038/nature09671; Nogai H, 2013, BLOOD, V122, P2242, DOI 10.1182/blood-2013-06-508028; Pasqualucci L, 2011, NAT GENET, V43, P830, DOI 10.1038/ng.892; Paul S, 2012, IMMUNITY, V36, P947, DOI 10.1016/j.immuni.2012.04.008; Ramakrishna E, 2009, CANCER RES, V69, P1448, DOI 10.1158/0008-5472.CAN-08-1160; Rawlings DJ, 2006, NAT REV IMMUNOL, V6, P799, DOI 10.1038/nri1944; Ryves WJ, 2001, BIOCHEM BIOPH RES CO, V280, P720, DOI 10.1006/bbrc.2000.4169; Scharschmidt E, 2004, MOL CELL BIOL, V24, P3860, DOI 10.1128/MCB.24.9.3860-3873.2004; Schimmack G, 2014, CELL COMMUN SIGNAL, V12, DOI 10.1186/s12964-014-0049-7; Schwitalla S, 2013, CELL, V152, P25, DOI 10.1016/j.cell.2012.12.012; Sommer K, 2005, IMMUNITY, V23, P561, DOI 10.1016/j.immuni.2005.09.014; Spranger S, 2015, NATURE, V523, P231, DOI 10.1038/nature14404; Staudt LM, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a000109; Tandon B, 2011, MODERN PATHOL, V24, P1433, DOI 10.1038/modpathol.2011.103; Willert Jennifer, 2002, BMC Dev Biol, V2, P8, DOI 10.1186/1471-213X-2-8; Wilson WH, 2015, NAT MED, V21, P922, DOI 10.1038/nm.3884; Wiznerowicz M, 2003, J VIROL, V77, P8957, DOI 10.1128/JVI.77.16.8957-8951.2003; Yaguchi T, 2012, J IMMUNOL, V189, P2110, DOI 10.4049/jimmunol.1102282; Yang YB, 2012, CANCER CELL, V21, P723, DOI 10.1016/j.ccr.2012.05.024	54	31	32	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2016	35	32					4269	4281		10.1038/onc.2015.493	http://dx.doi.org/10.1038/onc.2015.493			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DU3YY	26776161	hybrid, Green Published			2022-12-17	WOS:000382149800011
J	Wang, Q; Liu, P; Spangle, JM; Von, T; Roberts, TM; Lin, NU; Krop, IE; Winer, EP; Zhao, JJ				Wang, Q.; Liu, P.; Spangle, J. M.; Von, T.; Roberts, T. M.; Lin, N. U.; Krop, I. E.; Winer, E. P.; Zhao, J. J.			PI3K-p110 alpha mediates resistance to HER2-targeted therapy in HER2+, PTEN-deficient breast cancers	ONCOGENE			English	Article							P110-ALPHA ISOFORM; PI3K; PIK3CA; TUMORIGENESIS; TRASTUZUMAB; INHIBITION; RECEPTORS; P110-BETA; TUMORS; METASTASIS	Human epidermal growth factor receptor-2 (HER2) amplification/overexpression (HER2+) frequently co-occurs with PI3K pathway activation in breast tumors. PI3K signaling is most often activated by PIK3CA mutation or PTEN loss, which frequently results in sensitivity to p110 alpha or p110 beta inhibitors, respectively. To examine the p110 isoform dependence in HER2+, PTEN-deficient tumors, we generated genetic mouse models of breast tumors driven by concurrent Her2 activation and Pten loss coupled with deletion of p110 alpha or p110 beta. Ablation of p110 alpha, but not p110 beta, significantly impaired the development of Her2+/Pten-null tumors in mice. We further show that p110 alpha primarily mediates oncogenic signaling in HER2+/PTEN-deficient human cancers while p110 beta conditionally mediates PI3K/AKT signaling only upon HER2 inhibition. Combined HER2 and p110 alpha inhibition effectively reduced PI3K/AKT signaling and growth of cancer cells both in vitro and in vivo. Addition of the p110 beta inhibitor to dual HER2 and p110 alpha inhibition induced tumor regression in a xenograft model of HER2+/PTEN-deficient human cancers. Together, our data suggest that combined inhibition of HER2 and p110 alpha/beta may serve as a potent and durable therapeutic regimen for the treatment of HER2+, PTEN-deficient breast tumors.	[Wang, Q.; Liu, P.; Spangle, J. M.; Von, T.; Roberts, T. M.; Zhao, J. J.] Dana Farber Canc Inst, Dept Canc Biol, 450 Brookline Ave,Smith 936B, Boston, MA 02115 USA; [Wang, Q.; Spangle, J. M.; Von, T.; Roberts, T. M.; Zhao, J. J.] Harvard Med Sch, Dept Biol Chem & Mol Pharmacol, Boston, MA USA; [Liu, P.] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Ctr Canc, Wuhan, Peoples R China; [Lin, N. U.; Krop, I. E.; Winer, E. P.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA; [Wang, Q.] Med Univ South Carolina, Dept Pathol & Lab Med, Charleston, SC 29425 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; Huazhong University of Science & Technology; Harvard University; Dana-Farber Cancer Institute; Medical University of South Carolina	Zhao, JJ (corresponding author), Dana Farber Canc Inst, Dept Canc Biol, 450 Brookline Ave,Smith 936B, Boston, MA 02115 USA.	jean_zhao@dfci.harvard.edu			Department of Pathology and Laboratory Medicine, Medical University of South Carolina; Susan G. Komen Breast Cancer Foundation [CCR 12225834]; Breast Cancer Research Foundation; NIH grants [CA187918, CA172461-01, 1P50CA168504]; NATIONAL CANCER INSTITUTE [R01CA172461, R01CA187918, P50CA168504] Funding Source: NIH RePORTER	Department of Pathology and Laboratory Medicine, Medical University of South Carolina; Susan G. Komen Breast Cancer Foundation(Susan G. Komen Breast Cancer Foundation); Breast Cancer Research Foundation; NIH grants(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Roderick Bronson and the Dana-Farber/Harvard Cancer Center Rodent Histopathology Core for histopathological analyses. MMTV-NIC mice were provided by W Muller (McGill University). Floxed Pten mice were provided by H Wu (UCLA). This work was supported by start-up fund from Department of Pathology and Laboratory Medicine, Medical University of South Carolina (QW), the Susan G. Komen Breast Cancer Foundation CCR 12225834 (IEK), the Breast Cancer Research Foundation (NUL, EPW, JJZ), NIH grants CA187918 (TMR and JJZ), CA172461-01 (JJZ) and 1P50CA168504 (TMR, IEK, EPW, NUL and JJZ).	Blackwell KL, 2010, J CLIN ONCOL, V28, P1124, DOI 10.1200/JCO.2008.21.4437; Costa C, 2015, CANCER CELL, V27, P97, DOI 10.1016/j.ccell.2014.11.007; Eichhorn PJA, 2008, CANCER RES, V68, P9221, DOI 10.1158/0008-5472.CAN-08-1740; Esteva FJ, 2010, AM J PATHOL, V177, P1647, DOI 10.2353/ajpath.2010.090885; Fruman DA, 2014, NAT REV DRUG DISCOV, V13, P140, DOI 10.1038/nrd4204; Graupera M, 2008, NATURE, V453, P662, DOI 10.1038/nature06892; Guillermet-Guibert J, 2008, P NATL ACAD SCI USA, V105, P8292, DOI 10.1073/pnas.0707761105; Hanker AB, 2013, P NATL ACAD SCI USA, V110, P14372, DOI 10.1073/pnas.1303204110; Hudis CA, 2007, NEW ENGL J MED, V357, P39, DOI 10.1056/NEJMra043186; Hynes NE, 2005, NAT REV CANCER, V5, P341, DOI 10.1038/nrc1609; Jia SD, 2008, NATURE, V454, P776, DOI 10.1038/nature07091; Juric D, 2012, CANCER RES, V72, P1; Juric D, 2013, CANCER RES, V73, P6; Lesche R, 2002, GENESIS, V32, P148, DOI 10.1002/gene.10036; Nagata Y, 2004, CANCER CELL, V6, P117, DOI 10.1016/j.ccr.2004.06.022; Saal LH, 2005, CANCER RES, V65, P2554, DOI 10.1158/0008-5472-CAN-04-3913; Schade B, 2009, J BIOL CHEM, V284, P19018, DOI 10.1074/jbc.M109.018937; Schmit F, 2014, P NATL ACAD SCI USA, V111, P6395, DOI 10.1073/pnas.1323004111; Schwartz S, 2015, CANCER CELL, V27, P109, DOI 10.1016/j.ccell.2014.11.008; Stemke-Hale K, 2008, CANCER RES, V68, P6084, DOI 10.1158/0008-5472.CAN-07-6854; Ursini-Siegel J, 2008, EMBO J, V27, P910, DOI 10.1038/emboj.2008.22; Utermark T, 2012, GENE DEV, V26, P1573, DOI 10.1101/gad.191973.112; Vanhaesebroeck B, 2014, CANCER CELL, V25, P269, DOI 10.1016/j.ccr.2014.02.012; Vanhaesebroeck B, 2010, NAT REV MOL CELL BIO, V11, P329, DOI 10.1038/nrm2882; Wee S, 2008, P NATL ACAD SCI USA, V105, P13057, DOI 10.1073/pnas.0802655105; Yuan TL, 2008, ONCOGENE, V27, P5497, DOI 10.1038/onc.2008.245; Zhao JJ, 2006, P NATL ACAD SCI USA, V103, P16296, DOI 10.1073/pnas.0607899103	27	31	31	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 7	2016	35	27					3607	3612		10.1038/onc.2015.406	http://dx.doi.org/10.1038/onc.2015.406			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DR0UD	26500061	Green Accepted			2022-12-17	WOS:000379621500013
J	Garibaldi, F; Falcone, E; Trisciuoglio, D; Colombo, T; Lisek, K; Walerych, D; Del Sal, G; Paci, P; Bossi, G; Piaggio, G; Gurtner, A				Garibaldi, F.; Falcone, E.; Trisciuoglio, D.; Colombo, T.; Lisek, K.; Walerych, D.; Del Sal, G.; Paci, P.; Bossi, G.; Piaggio, G.; Gurtner, A.			Mutant p53 inhibits miRNA biogenesis by interfering with the microprocessor complex	ONCOGENE			English	Article							MICRORNA BIOGENESIS; CELL-PROLIFERATION; CANCER; GAIN; EXPRESSION; PROTEINS; RNA; SUPPRESSES; MECHANISMS; MIGRATION	Downregulation of microRNAs (miRNAs) is commonly observed in cancers and promotes tumorigenesis suggesting that miRNAs may function as tumor suppressors. However, the mechanism through which miRNAs are regulated in cancer, and the connection between oncogenes and miRNA biogenesis remain poorly understood. The TP53 tumor-suppressor gene is mutated in half of human cancers resulting in an oncogene with gain-of-function activities. Here we demonstrate that mutant p53 (mutp53) oncoproteins modulate the biogenesis of a subset of miRNAs in cancer cells inhibiting their post-transcriptional maturation. Interestingly, among these miRNAs several are also downregulated in human tumors. By confocal, co-immunoprecipitation and RNA-chromatin immunoprecipitation experiments, we show that endogenous mutp53 binds and sequesters RNA helicases p72/82 from the microprocessor complex, interfering with Drosha-pri-miRNAs association. In agreement with this, the overexpression of p72 leads to an increase of mature miRNAs levels. Moreover, functional experiments demonstrate the oncosuppressive role of mutp53-dependent miRNAs (miR-517a, -519a, -218, -105). Our study highlights a previously undescribed mechanism by which mutp53 interferes with Drosha-p72/82 association leading, at least in part, to miRNA deregulation observed in cancer.	[Garibaldi, F.; Falcone, E.; Trisciuoglio, D.; Bossi, G.; Piaggio, G.; Gurtner, A.] Regina Elena Inst Canc Res, Translat Res Area, Dept Res Adv Diagnost & Technol Innovat, Rome, Italy; [Colombo, T.; Paci, P.] CNR, Inst Syst Anal & Comp Sci Antonio Ruberti, Rome, Italy; [Colombo, T.; Paci, P.] SysBio Ctr Syst Biol, Rome, Italy; [Lisek, K.; Walerych, D.; Del Sal, G.] Area Sci Pk Padriciano, Lab Nazl CIB, Trieste, Italy; [Lisek, K.; Del Sal, G.] Univ Trieste, Dipartimento Sci Vita, Trieste, Italy; [Bossi, G.] Regina Elena Inst Canc Res, Lab Med Phys & Expert Syst, Dept Res Adv Diagnost & Technol Innovat, Rome, Italy	IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; Consiglio Nazionale delle Ricerche (CNR); Istituto di Analisi dei Sistemi ed Informatica "Antonio Ruberti" (IASI-CNR); University of Trieste; IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena	Bossi, G; Piaggio, G; Gurtner, A (corresponding author), Regina Elena Inst Canc Res, Translat Res Area, Via Elio Chianesi 53, I-00144 Rome, Italy.	bossi@ifo.it; piaggio@ifo.it; gurtner@ifo.it	Piaggio, Giulia/AAD-7336-2022; Piaggio, Giulia/J-7214-2018; Bossi, Gianluca/B-9394-2017; gurtner, aymone/AAB-8843-2020; Bossi, Gianluca/ABH-6846-2020; trisciuoglio, daniela/AAL-4002-2021; Lisek, Kamil/J-5785-2016; Gurtner, Aymone/J-7217-2018; Colombo, Teresa/P-2959-2018; Trisciuoglio, Daniela/H-2131-2016	Piaggio, Giulia/0000-0003-2114-1892; Bossi, Gianluca/0000-0002-2947-1063; gurtner, aymone/0000-0002-7661-9059; Bossi, Gianluca/0000-0002-2947-1063; Lisek, Kamil/0000-0002-2406-8830; Gurtner, Aymone/0000-0002-7661-9059; Colombo, Teresa/0000-0003-2415-7507; Walerych, Dawid/0000-0002-8440-1375; Trisciuoglio, Daniela/0000-0002-7007-7914; DEL SAL, GIANNINO/0000-0003-2185-6003	Fondazione Umberto Veronesi Fellowship; FEBS postdoctoral fellowship; AIRC [MFAG 11752, IG 13234, 10016]; Italian Ministry of Health	Fondazione Umberto Veronesi Fellowship(Fondazione Umberto Veronesi); FEBS postdoctoral fellowship; AIRC(Fondazione AIRC per la ricerca sul cancro); Italian Ministry of Health(Ministry of Health, Italy)	We thank Dr Vittorio Sartorelli for the p72 expression vector, Dr Silvia Bacchetti and Silvia Soddu for interesting discussions on the manuscript, Maria Pia Gentileschi for technical advice, Daniela Bona for secretary assistance. Aymone Gurtner and Gianluca Bossi were supported by a Fondazione Umberto Veronesi Fellowship; Dawid Walerych was a recipient of the FEBS postdoctoral fellowship. This work has been supported by grant from AIRC to AG (MFAG 11752); from AIRC to GP (IG 13234); from AIRC (Special Program Molecular Clinical Oncology '5 per mille') (grant no. 10016) to GDS and from Italian Ministry of Health to GDS.	Abdelmohsen K, 2010, CELL CYCLE, V9, P1354, DOI 10.4161/cc.9.7.11164; Adorno M, 2009, CELL, V137, P87, DOI 10.1016/j.cell.2009.01.039; Bates GJ, 2005, EMBO J, V24, P543, DOI 10.1038/sj.emboj.7600550; Borralho PM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023787; Bossi G, 2006, ONCOGENE, V25, P304, DOI 10.1038/sj.onc.1209026; Bossi G, 2008, CELL CYCLE, V7, P1870, DOI 10.4161/cc.7.12.6161; Braicu C, 2013, MOL CELL BIOCHEM, V381, P61, DOI 10.1007/s11010-013-1688-5; Brosh R, 2009, NAT REV CANCER, V9, P701, DOI 10.1038/nrc2693; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Bushati N, 2007, ANNU REV CELL DEV BI, V23, P175, DOI 10.1146/annurev.cellbio.23.090506.123406; Carleton M, 2007, CELL CYCLE, V6, P2127, DOI 10.4161/cc.6.17.4641; Cha ST, 2010, CANCER RES, V70, P2675, DOI 10.1158/0008-5472.CAN-09-2448; Chang TC, 2007, MOL CELL, V26, P745, DOI 10.1016/j.molcel.2007.05.010; Davis BN, 2008, NATURE, V454, P56, DOI 10.1038/nature07086; Di Agostino S, 2006, CANCER CELL, V10, P191, DOI 10.1016/j.ccr.2006.08.013; Donehower LA, 2009, NAT REV CANCER, V9, P830, DOI 10.1038/nrc2731; Dong P, 2013, ONCOGENE, V32, P3286, DOI 10.1038/onc.2012.334; Donzelli S, 2012, CELL DEATH DIFFER, V19, P1038, DOI 10.1038/cdd.2011.190; Fabbri M, 2007, EXPERT OPIN BIOL TH, V7, P1009, DOI 10.1517/14712598.7.7.1009; Feng XL, 2014, CANCER LETT, V344, P166, DOI 10.1016/j.canlet.2013.11.004; Fuller-Pace FV, 2013, BBA-GENE REGUL MECH, V1829, P756, DOI 10.1016/j.bbagrm.2013.03.004; Fuller-Pace FV, 2011, FUTURE ONCOL, V7, P239, DOI 10.2217/FON.11.1; Gaiddon C, 2001, MOL CELL BIOL, V21, P1874, DOI 10.1128/MCB.21.5.1874-1887.2001; Garufi A, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.163; Girardini JE, 2011, CANCER CELL, V20, P79, DOI 10.1016/j.ccr.2011.06.004; Gostissa M, 2004, J BIOL CHEM, V279, P48013, DOI 10.1074/jbc.M310801200; Gregory RI, 2004, NATURE, V432, P235, DOI 10.1038/nature03120; Gurtner A, 2010, J BIOL CHEM, V285, P14160, DOI 10.1074/jbc.M109.094813; Ha M, 2014, NAT REV MOL CELL BIO, V15, P509, DOI 10.1038/nrm3838; Hermeking H, 2012, NAT REV CANCER, V12, P613, DOI 10.1038/nrc3318; Kawai S, 2012, J CELL BIOL, V197, P201, DOI 10.1083/jcb.201110008; Kumar MS, 2007, NAT GENET, V39, P673, DOI 10.1038/ng2003; Liu RF, 2013, CANCER LETT, V329, P164, DOI 10.1016/j.canlet.2012.10.027; Lujambio A, 2012, NATURE, V482, P347, DOI 10.1038/nature10888; Marasa BS, 2010, AGING-US, V2, P333, DOI 10.18632/aging.100159; Masciarelli S, 2014, ONCOGENE, V33, P1601, DOI 10.1038/onc.2013.106; Mori M, 2014, CELL, V156, P893, DOI 10.1016/j.cell.2013.12.043; Muller PAJ, 2014, CANCER CELL, V25, P304, DOI 10.1016/j.ccr.2014.01.021; Muller PAJ, 2014, J BIOL CHEM, V289, P122, DOI 10.1074/jbc.M113.502138; Neilsen PM, 2013, ONCOGENE, V32, P2992, DOI 10.1038/onc.2012.305; Nohata N, 2012, ONCOTARGET, V3, P9; Pinho FG, 2013, CANCER RES, V73, P5936, DOI 10.1158/0008-5472.CAN-13-0158; Subramanian M, 2015, ONCOGENE, V34, P1094, DOI 10.1038/onc.2014.46; Suzuki HI, 2009, NATURE, V460, P529, DOI 10.1038/nature08199; Thomson JM, 2006, GENE DEV, V20, P2202, DOI 10.1101/gad.1444406; Tie J, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000879; Trisciuoglio D, 2012, CLIN CANCER RES, V18, P475, DOI 10.1158/1078-0432.CCR-11-0579; Tu YY, 2013, CANCER RES, V73, P6046, DOI 10.1158/0008-5472.CAN-13-0358; Ubertini V, 2015, ONCOGENE, V34, P2493, DOI 10.1038/onc.2014.191; Uhlmann-Schiffler H, 2002, J BIOL CHEM, V277, P1066, DOI 10.1074/jbc.M107535200; van Kouwenhove M, 2011, NAT REV CANCER, V11, P644, DOI 10.1038/nrc3107; Wang W, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.97; Weinstein JN, 2013, NAT GENET, V45, P1113, DOI 10.1038/ng.2764; Winter J, 2009, NAT CELL BIOL, V11, P228, DOI 10.1038/ncb0309-228; Wiznerowicz M, 2003, J VIROL, V77, P8957, DOI 10.1128/JVI.77.16.8957-8951.2003; Wu LF, 2011, FEBS LETT, V585, P1322, DOI 10.1016/j.febslet.2011.03.067; Yamakuchi M, 2010, P NATL ACAD SCI USA, V107, P6334, DOI 10.1073/pnas.0911082107; Yoshitomi T, 2011, ONCOL REP, V25, P1661, DOI 10.3892/or.2011.1253; Zhang J, 2013, ONCOGENE, V32, P61, DOI 10.1038/onc.2012.28; Zhang MX, 2012, FEBS LETT, V586, P3508, DOI 10.1016/j.febslet.2012.08.007	60	31	32	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2016	35	29					3760	3770		10.1038/onc.2016.51	http://dx.doi.org/10.1038/onc.2016.51			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DS4LS	26996669				2022-12-17	WOS:000380753200002
J	Barbachano, A; Fernandez-Barral, A; Pereira, F; Segura, MF; Ordonez-Moran, P; Pau, ECD; Gonzalez-Sancho, JM; Hanniford, D; Martinez, N; Costales-Carrera, A; Real, FX; Palmer, HG; Rojas, JM; Hernando, E; Munoz, A				Barbachano, A.; Fernandez-Barral, A.; Pereira, F.; Segura, M. F.; Ordonez-Moran, P.; Carrillo-de Santa Pau, E.; Gonzalez-Sancho, J. M.; Hanniford, D.; Martinez, N.; Costales-Carrera, A.; Real, F. X.; Palmer, H. G.; Rojas, J. M.; Hernando, E.; Munoz, A.			SPROUTY-2 represses the epithelial phenotype of colon carcinoma cells via upregulation of ZEB1 mediated by ETS1 and miR-200/miR-150	ONCOGENE			English	Article							ACTIVATED PROTEIN-KINASE; MESENCHYMAL TRANSITION; DOWN-REGULATION; CANCER-CELLS; MIR-200 FAMILY; BETA-CATENIN; EPIGENETIC INACTIVATION; TRANSCRIPTION FACTOR; COLORECTAL-CANCER; GENE-EXPRESSION	SPROUTY-2 (SPRY2) is a modulator of tyrosine kinase receptor signaling with receptor-and cell type-dependent inhibitory or enhancing effects. Studies on the action of SPRY2 in major cancers are conflicting and its role remains unclear. Here we have dissected SPRY2 action in human colon cancer. Global transcriptomic analyses show that SPRY2 downregulates genes encoding tight junction proteins such as claudin-7 and occludin and other cell-to-cell and cell-to-matrix adhesion molecules in human SW480-ADH colon carcinoma cells. Moreover, SPRY2 represses LLGL2/HUGL2, PATJ1/INADL and ST14, main regulators of the polarized epithelial phenotype, and ESRP1, an epithelial-to-mesenchymal transition (EMT) inhibitor. A key action of SPRY2 is the upregulation of the major EMT inducer ZEB1, as these effects are reversed by ZEB1 knock-down by means of RNA interference. Consistently, we found an inverse correlation between the expression level of claudin-7 and those of SPRY2 and ZEB1 in human colon tumors. Mechanistically, ZEB1 upregulation by SPRY2 results from the combined induction of ETS1 transcription factor and the repression of microRNAs (miR-200 family, miR-150) that target ZEB1 RNA. Moreover, SPRY2 increased AKT activation by epidermal growth factor, whereas AKT and also Src inhibition reduced the induction of ZEB1. Altogether, these data suggest that AKT and Src are implicated in SPRY2 action. Collectively, these results show a tumorigenic role of SPRY2 in colon cancer that is based on the dysregulation of tight junction and epithelial polarity master genes via upregulation of ZEB1. The dissection of the mechanism of action of SPRY2 in colon cancer cells is important to understand the upregulation of this gene in a subset of patients with this neoplasia that have poor prognosis.	[Barbachano, A.; Fernandez-Barral, A.; Pereira, F.; Ordonez-Moran, P.; Gonzalez-Sancho, J. M.; Costales-Carrera, A.; Munoz, A.] Univ Autonoma Madrid, CSIC, Inst Invest Biomed Alberto Sols, Dept Canc Biol, Madrid, Spain; [Segura, M. F.; Hanniford, D.; Hernando, E.] NYU, Sch Med, Dept Pathol, New York, NY USA; [Carrillo-de Santa Pau, E.; Real, F. X.] CSIC, Epithelial Carcinogenesis Grp, Madrid, Spain; [Martinez, N.] Inst Salud Carlos III, Unidad Func Invest Enfermedades Cron, Unidad Biol Celular, Madrid, Spain; [Real, F. X.] Univ Pompeu Fabra, Dept Expt & Hlth Sci, Barcelona, Spain; [Palmer, H. G.] Vall dHebron Inst Oncol, Stem Cells & Canc Grp, Barcelona, Spain; [Segura, M. F.] Vall dHebron Inst Recerca VHIR, E-08035 Barcelona, Spain; [Ordonez-Moran, P.] Ecole Polytech Fed Lausanne, Canc Stem Cell Lab, CH-1015 Lausanne, Switzerland	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); New York University; Consejo Superior de Investigaciones Cientificas (CSIC); Instituto de Salud Carlos III; Unidad Funcional de Investigacion de Enfermedades Cronicas (UFIEC); Pompeu Fabra University; Vall d'Hebron Institut d'Oncologia (VHIO); Autonomous University of Barcelona; Hospital Universitari Vall d'Hebron; Vall d'Hebron Institut de Recerca (VHIR); Swiss Federal Institutes of Technology Domain; Ecole Polytechnique Federale de Lausanne	Munoz, A (corresponding author), Univ Autonoma Madrid, CSIC, Inst Invest Biomed Alberto Sols, Madrid 28029, Spain.	amunoz@iib.uam.es	Barbachano, Antonio/O-7731-2015; Arribas, Francisco X Real/H-5275-2015; Munoz, Alberto/O-6393-2014; Rojas, José M/D-3718-2018; Gonzalez-Sancho, Jose/AAA-6010-2019; Palmer, Héctor G./AAG-8332-2019; Costales, ALba/F-2773-2017; de Santa Pau, Enrique Carrillo/AAV-7544-2021; Segura, Miguel F/J-4749-2013; Miquel, Josep Maria/AAG-3508-2019; Rojas, José M./AAA-3354-2021; Hanniford, Douglas/AAS-1480-2020; Fernández-Barral, Asunión/O-8133-2015; Ordonez-Moran, Paloma/B-6371-2016; Hanniford, Doug/M-8251-2014	Barbachano, Antonio/0000-0002-1248-5143; Arribas, Francisco X Real/0000-0001-9501-498X; Munoz, Alberto/0000-0003-3890-4251; Rojas, José M/0000-0002-5383-3482; Gonzalez-Sancho, Jose/0000-0001-5875-1964; Costales, ALba/0000-0002-9075-1646; de Santa Pau, Enrique Carrillo/0000-0002-2310-2267; Segura, Miguel F/0000-0003-0916-3618; Rojas, José M./0000-0002-7547-2825; Fernández-Barral, Asunión/0000-0002-1278-4645; Ordonez-Moran, Paloma/0000-0001-7688-1252; Hernando, Eva/0000-0003-1023-0312; Palmer, Hector/0000-0002-9823-5638; Pires Pereira, Fabio/0000-0002-9991-2805; Hanniford, Doug/0000-0001-6790-8441	FEDER-Instituto de Salud Carlos III [RD12/0036/0021, RD12/0036/0034, RD12/0036/0016, RD12/0036/0012, RD06/0020/0003, PS09/00562, PI13/00703]; Comunidad de Madrid [S2010/BMD-2344 Colomics2]; Fundacion Cientifica de la Asociacion Espanola contra el Cancer; US Department of Defense [CA093471, CA110602]; National Institutes of Health/National Cancer Institute [1R01CA155234-01]; National Institutes of Health/National Institute of Arthritis and Musculoskeletal and Skin Diseases [1R21AR062239-01]; Melanoma Research Alliance; Ministerio de Economia y Competitividad of Spain; Fondo Europeo de Desarrollo Regional (FEDER) [SAF2013-43468-R, SAF2011-29530]; NATIONAL CANCER INSTITUTE [R01CA155234] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R21AR062239] Funding Source: NIH RePORTER	FEDER-Instituto de Salud Carlos III(Instituto de Salud Carlos III); Comunidad de Madrid(Comunidad de Madrid); Fundacion Cientifica de la Asociacion Espanola contra el Cancer; US Department of Defense(United States Department of Defense); National Institutes of Health/National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Institutes of Health/National Institute of Arthritis and Musculoskeletal and Skin Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); Melanoma Research Alliance; Ministerio de Economia y Competitividad of Spain(Spanish Government); Fondo Europeo de Desarrollo Regional (FEDER)(European CommissionSpanish Government); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	We thank Drs G Goodall, T Brabletz and A Garcia de Herreros for kindly providing us reagents, T Martinez and X Langa for technical assistance and Robin Rycroft for help with the English manuscript. This study was supported by the Ministerio de Economia y Competitividad of Spain and Fondo Europeo de Desarrollo Regional (FEDER) (grant SAF2013-43468-R to AM, SAF2011-29530 to FXR); FEDER-Instituto de Salud Carlos III (RD12/0036/0021 to AM and JMR, RD12/0036/0034 to FXR, RD12/0036/0016 to MS, RD12/0036/0012 to HGP, RD06/0020/0003, PS09/00562 and PI13/00703 to JMR); Comunidad de Madrid (S2010/BMD-2344 Colomics2 to AM); Fundacion Cientifica de la Asociacion Espanola contra el Cancer (to JMR); US Department of Defense (CA093471 and CA110602 to EH); National Institutes of Health/National Cancer Institute (1R01CA155234-01 to EH); National Institutes of Health/National Institute of Arthritis and Musculoskeletal and Skin Diseases (1R21AR062239-01 to EH); and the Melanoma Research Alliance (to EH).	Aguilera O, 2007, CARCINOGENESIS, V28, P1877, DOI 10.1093/carcin/bgm094; Aigner K, 2007, ONCOGENE, V26, P6979, DOI 10.1038/sj.onc.1210508; [Anonymous], 2010, R LANG ENV STAT COMP; Barbachano A, 2010, ONCOGENE, V29, P4800, DOI 10.1038/onc.2010.225; Benjamini Y, 2001, BEHAV BRAIN RES, V125, P279, DOI 10.1016/S0166-4328(01)00297-2; Bloethner S, 2005, CARCINOGENESIS, V26, P1224, DOI 10.1093/carcin/bgi066; Bornholdt J, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-65; Bracken CP, 2008, CANCER RES, V68, P7846, DOI 10.1158/0008-5472.CAN-08-1942; Brown RL, 2011, J CLIN INVEST, V121, P1064, DOI 10.1172/JCI44540; Burk U, 2008, EMBO REP, V9, P582, DOI 10.1038/embor.2008.74; Buzza MS, 2010, P NATL ACAD SCI USA, V107, P4200, DOI 10.1073/pnas.0903923107; Cabrita MA, 2008, ANGIOGENESIS, V11, P53, DOI 10.1007/s10456-008-9089-1; Darido C, 2008, CANCER RES, V68, P4258, DOI 10.1158/0008-5472.CAN-07-5805; DaSilva J, 2006, MOL CELL BIOL, V26, P1898, DOI 10.1128/MCB.26.5.1898-1907.2006; Dave N, 2011, J BIOL CHEM, V286, DOI 10.1074/jbc.M110.168625; de Alvaro C, 2005, MOL BIOL CELL, V16, P4454, DOI 10.1091/mbc.E05-05-0419; Dhawan P, 2005, J CLIN INVEST, V115, P1765, DOI 10.1172/JCI24543; Edwin F, 2010, J BIOL CHEM, V285, P255, DOI 10.1074/jbc.M109.030882; Egan JE, 2002, P NATL ACAD SCI USA, V99, P6041, DOI 10.1073/pnas.052090899; Faratian D, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023772; Feng YH, 2011, CANCER BIOL THER, V11, P111, DOI 10.4161/cbt.11.1.13965; Fong CW, 2006, CANCER RES, V66, P2048, DOI 10.1158/0008-5472.CAN-05-1072; Frank MJ, 2009, BLOOD, V113, P2478, DOI 10.1182/blood-2008-05-156943; Gemmill RM, 2011, CANCER LETT, V300, P66, DOI 10.1016/j.canlet.2010.09.007; Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80; Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722; Guy GR, 2003, J CELL SCI, V116, P3061, DOI 10.1242/jcs.00652; Haglund K, 2005, EMBO REP, V6, P635, DOI 10.1038/sj.embor.7400453; Holgren C, 2010, ONCOGENE, V29, P5241, DOI 10.1038/onc.2010.264; Horiguchi K, 2012, ONCOGENE, V31, P3190, DOI 10.1038/onc.2011.493; Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249; Kohno Y, 2006, J BIOL CHEM, V281, P38941, DOI 10.1074/jbc.M608389200; Korpal M, 2008, J BIOL CHEM, V283, P14910, DOI 10.1074/jbc.C800074200; Lee MH, 2008, J CELL SCI, V121, P1141, DOI 10.1242/jcs.016634; Lei ZL, 2012, DEV BIOL, V371, P136, DOI 10.1016/j.ydbio.2012.07.005; Li X, 2004, J CELL SCI, V117, P6007, DOI 10.1242/jcs.01519; List K, 2009, AM J PATHOL, V175, P1453, DOI 10.2353/ajpath.2009.090240; Martin-Belmonte F, 2012, NAT REV CANCER, V12, P23, DOI 10.1038/nrc3169; Masoumi-Moghaddam S, 2014, CANCER METAST REV, V33, P695, DOI 10.1007/s10555-014-9497-1; McKie AB, 2005, ONCOGENE, V24, P2166, DOI 10.1038/sj.onc.1208371; Merikallio H, 2011, J CLIN PATHOL, V64, P136, DOI 10.1136/jcp.2010.086678; Nakayama F, 2008, PATHOBIOLOGY, V75, P177, DOI 10.1159/000124978; Ono H, 2012, ONCOGENE, V31, P4923, DOI 10.1038/onc.2011.646; Ordonez-Moran P, 2014, ONCOGENE, V33, P1975, DOI 10.1038/onc.2013.140; Ozaki K, 2005, J CELL SCI, V118, P5861, DOI 10.1242/jcs.02711; Punzon I, 2004, BLOOD, V103, P580, DOI 10.1182/blood-2003-07-2298; Rhodes DR, 2004, NEOPLASIA, V6, P1, DOI 10.1016/S1476-5586(04)80047-2; Risueno A, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-221; Rubin C, 2003, CURR BIOL, V13, P297, DOI 10.1016/S0960-9822(03)00053-8; Sanchez A, 2008, ONCOGENE, V27, P4969, DOI 10.1038/onc.2008.129; Silva-Vargas V, 2005, DEV CELL, V9, P121, DOI 10.1016/j.devcel.2005.04.013; Spaderna S, 2008, CANCER RES, V68, P537, DOI 10.1158/0008-5472.CAN-07-5682; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Swat A, 2009, MOL CELL BIOL, V29, P3332, DOI 10.1128/MCB.01955-08; Tenbaum SP, 2012, NAT MED, V18, P892, DOI 10.1038/nm.2772; Tsavachidou D, 2004, CANCER RES, V64, P5556, DOI 10.1158/0008-5472.CAN-04-1669; van der Gun BTF, 2013, BRIT J CANCER, V108, P881, DOI 10.1038/bjc.2013.45; Warzecha CC, 2012, SEMIN CANCER BIOL, V22, P417, DOI 10.1016/j.semcancer.2012.04.003; Watanabe T, 2011, EUR J CANCER, V47, P1946, DOI 10.1016/j.ejca.2011.03.029; Wong ESM, 2002, EMBO J, V21, P4796, DOI 10.1093/emboj/cdf493; Wu CJ, 2013, J BIOL CHEM, V288, P12253, DOI 10.1074/jbc.M113.457499	61	31	34	0	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 9	2016	35	23					2991	3003		10.1038/onc.2015.366	http://dx.doi.org/10.1038/onc.2015.366			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DO0NB	26455323	Green Accepted, Green Submitted			2022-12-17	WOS:000377474500005
J	Gkouskou, KK; Ioannou, M; Pavlopoulos, GA; Georgila, K; Siganou, A; Nikolaidis, G; Kanellis, DC; Moore, S; Papadakis, KA; Kardassis, D; Iliopoulos, I; McDyer, FA; Drakos, E; Eliopoulos, AG				Gkouskou, K. K.; Ioannou, M.; Pavlopoulos, G. A.; Georgila, K.; Siganou, A.; Nikolaidis, G.; Kanellis, D. C.; Moore, S.; Papadakis, K. A.; Kardassis, D.; Iliopoulos, I.; McDyer, F. A.; Drakos, E.; Eliopoulos, A. G.			Apolipoprotein A-I inhibits experimental colitis and colitis-propelled carcinogenesis	ONCOGENE			English	Article							INFLAMMATORY-BOWEL-DISEASE; ULCERATIVE-COLITIS; TUMOR-DEVELOPMENT; MIMETIC PEPTIDES; MOUSE MODELS; COLON-CANCER; PROGRESSION; MICE; IL-6; EXPRESSION	In both humans with long-standing ulcerative colitis and mouse models of colitis-associated carcinogenesis (CAC), tumors develop predominantly in the distal part of the large intestine but the biological basis of this intriguing pathology remains unknown. Herein we report intrinsic differences in gene expression between proximal and distal colon in the mouse, which are augmented during dextran sodium sulfate (DSS)/azoxymethane (AOM)-induced CAC. Functional enrichment of differentially expressed genes identified discrete biological pathways operating in proximal vs distal intestine and revealed a cluster of genes involved in lipid metabolism to be associated with the disease-resistant proximal colon. Guided by this finding, we have further interrogated the expression and function of one of these genes, apolipoprotein A-I (ApoA-I), a major component of high-density lipoprotein. We show that ApoA-I is expressed at higher levels in the proximal compared with the distal part of the colon and its ablation in mice results in exaggerated DSS-induced colitis and disruption of epithelial architecture in larger areas of the large intestine. Conversely, treatment with an ApoA-I mimetic peptide ameliorated the phenotypic, histopathological and inflammatory manifestations of the disease. Genetic interference with ApoA-I levels in vivo impacted on the number, size and distribution of AOM/DSS-induced colon tumors. Mechanistically, ApoA-I was found to modulate signal transducer and activator of transcription 3 (STAT3) and nuclear factor-kappa B activation in response to the bacterial product lipopolysaccharide with concomitant impairment in the production of the pathogenic cytokine interleukin-6. Collectively, these data demonstrate a novel protective role for ApoA-I in colitis and CAC and unravel an unprecedented link between lipid metabolic processes and intestinal pathologies.	[Gkouskou, K. K.; Georgila, K.; Siganou, A.; Nikolaidis, G.; Kanellis, D. C.; Eliopoulos, A. G.] Univ Crete, Sch Med, Mol & Cellular Biol Lab, Div Basic Sci, Iraklion 71003, Crete, Greece; [Ioannou, M.; Kardassis, D.; Eliopoulos, A. G.] Fdn Res & Technol Hellas FORTH, Inst Mol Biol & Biotechnol, Iraklion, Greece; [Pavlopoulos, G. A.; Iliopoulos, I.] Univ Crete, Sch Med, Div Basic Sci, Bioinformat & Computat Biol Lab, Iraklion 71003, Crete, Greece; [Moore, S.; McDyer, F. A.] Almac Diagnost, Craigavon, North Ireland; [Papadakis, K. A.] Univ Crete, Sch Med, Dept Gastroenterol, Iraklion 71003, Crete, Greece; [Papadakis, K. A.] Mayo Clin, Div Gastroenterol & Hepatol, Rochester, MN USA; [Kardassis, D.] Univ Crete, Sch Med, Div Basic Sci, Lab Biochem, Iraklion 71003, Crete, Greece; [Drakos, E.] Univ Crete, Sch Med, Dept Pathol, Iraklion 71003, Crete, Greece	University of Crete; University of Crete; University of Crete; Mayo Clinic; University of Crete; University of Crete	Eliopoulos, AG (corresponding author), Univ Crete, Sch Med, Mol & Cellular Biol Lab, Div Basic Sci, Iraklion 71003, Crete, Greece.	eliopag@med.uoc.gr	Gkouskou, Kalliopi/AAY-4666-2021; Kanellis, Dimitrios/AHB-0318-2022; Pavlopoulos, Georgios A./L-7544-2017; ELIOPOULOS, ARISTIDES/R-9449-2018; ELIOPOULOS, ARISTIDES/ABI-6632-2020	Kanellis, Dimitrios/0000-0001-8690-2010; Pavlopoulos, Georgios A./0000-0002-4577-8276; ELIOPOULOS, ARISTIDES/0000-0002-6403-6761; ELIOPOULOS, ARISTIDES/0000-0002-6403-6761	European Commission (EC) [223151]; Almac Diagnostics; EC [285948]	European Commission (EC)(European CommissionEuropean Commission Joint Research Centre); Almac Diagnostics; EC(European CommissionEuropean Commission Joint Research Centre)	We thank Dimitra Vyrla (University of Crete Medical School), Triantafyllos Liloglou (University of Liverpool) and Maria Denis (Biomedcode Hellas SA) for helpful discussions. This work was supported by the European Commission (EC) research program Inflammation and Cancer Research in Europe (INFLA-CARE; EC contract number 223151) to AGE and Almac Diagnostics and the EC REGPOT support program Translational Potential (TransPOT; EC contract number 285948) to AGE, KP, II and DK.	Basque JR, 1998, J CELL BIOCHEM, V70, P354, DOI 10.1002/(SICI)1097-4644(19980901)70:3<354::AID-JCB9>3.3.CO;2-8; Becker C, 2004, IMMUNITY, V21, P491, DOI 10.1016/j.immuni.2004.07.020; Bernstein CN, 2001, CANCER-AM CANCER SOC, V91, P854, DOI 10.1002/1097-0142(20010215)91:4<854::AID-CNCR1073>3.0.CO;2-Z; Bersudsky M, 2014, GUT, V63, P598, DOI 10.1136/gutjnl-2012-303329; Bollrath J, 2009, EMBO REP, V10, P1314, DOI 10.1038/embor.2009.243; Bollrath J, 2009, CANCER CELL, V15, P91, DOI 10.1016/j.ccr.2009.01.002; Bonn V, 2002, ATHEROSCLEROSIS, V163, P59; Brunham LR, 2006, J CLIN INVEST, V116, P1052, DOI 10.1172/JCI27352; CHOI PM, 1993, GASTROENTEROLOGY, V104, P666, DOI 10.1016/0016-5085(93)90455-L; COOPER HS, 1993, LAB INVEST, V69, P238; Cooper HS, 2000, CARCINOGENESIS, V21, P757, DOI 10.1093/carcin/21.4.757; Danese S, 2010, ONCOGENE, V29, P3313, DOI 10.1038/onc.2010.109; Dieleman LA, 1998, CLIN EXP IMMUNOL, V114, P385; Do RQ, 2014, EMBO MOL MED, V6, P1215, DOI 10.15252/emmm.201404000; Eaden JA, 2001, GUT, V48, P526, DOI 10.1136/gut.48.4.526; Eyking A, 2011, GASTROENTEROLOGY, V141, P2154, DOI 10.1053/j.gastro.2011.08.043; Fukata M, 2007, GASTROENTEROLOGY, V133, P1869, DOI 10.1053/j.gastro.2007.09.008; Gkirtzimanaki K, 2013, P NATL ACAD SCI USA, V110, pE1470, DOI 10.1073/pnas.1215938110; Gkouskou KK, 2014, FRONT CELL INFECT MI, V4, DOI 10.3389/fcimb.2014.00028; Goldstone R, 2012, INFLAMM BOWEL DIS, V18, P832, DOI 10.1002/ibd.21809; Goldstone R, 2011, GASTROINTEST ENDOSC, V74, P1087, DOI 10.1016/j.gie.2011.06.028; Greenhill CJ, 2011, J IMMUNOL, V186, P1199, DOI 10.4049/jimmunol.1002971; Grivennikov S, 2009, CANCER CELL, V15, P103, DOI 10.1016/j.ccr.2009.01.001; Gupta H, 2005, CIRC RES, V97, P236, DOI 10.1161/01.RES.0000176530.66400.48; Gupta J, 2014, CANCER CELL, V25, P484, DOI 10.1016/j.ccr.2014.02.019; Haberman Y, 2014, J CLIN INVEST, V124, P3617, DOI 10.1172/JCI75436; Haghpassand M, 2001, J CLIN INVEST, V108, P1315, DOI 10.1172/JCI200112810; Kanagarajan N, 2008, INFLAMM RES, V57, P34, DOI 10.1007/s00011-007-6177-4; Laroui H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032084; Ma J, 2004, ACTA BIOCH BIOPH SIN, V36, P419, DOI 10.1093/abbs/36.6.419; Mahler M, 1998, AM J PHYSIOL-GASTR L, V274, pG544, DOI 10.1152/ajpgi.1998.274.3.G544; Maloy KJ, 2011, NATURE, V474, P298, DOI 10.1038/nature10208; MILLER JCE, 1983, P NATL ACAD SCI-BIOL, V80, P1511, DOI 10.1073/pnas.80.6.1511; Mudter J, 2007, INFLAMM BOWEL DIS, V13, P1016, DOI 10.1002/ibd.20148; Navab M, 2005, CIRC RES, V97, P1085, DOI 10.1161/01.RES.0000194558.86099.ba; Navab M, 2005, ARTERIOSCL THROM VAS, V25, P1426, DOI 10.1161/01.ATV.0000167412.98221.1a; Navab M, 2002, CIRCULATION, V105, P290, DOI 10.1161/hc0302.103711; Navab M, 2006, NAT CLIN PRACT CARD, V3, P540, DOI 10.1038/ncpcardio0661; Neufert C, 2007, NAT PROTOC, V2, P1998, DOI 10.1038/nprot.2007.279; Okayasu I, 1996, GUT, V39, P87, DOI 10.1136/gut.39.1.87; OKAYASU I, 1990, GASTROENTEROLOGY, V98, P694, DOI 10.1016/0016-5085(90)90290-H; Ou JS, 2005, CIRC RES, V97, P1190, DOI 10.1161/01.RES.0000190634.60042.cb; Poynter JN, 2005, NEW ENGL J MED, V352, P2184, DOI 10.1056/NEJMoa043792; Ramasamy I, 2014, CLIN CHEM LAB MED, V52, P1695, DOI 10.1515/cclm-2013-0358; Rubin DC, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00107; Smythies LE, 2010, AM J PHYSIOL-CELL PH, V298, pC1538, DOI 10.1152/ajpcell.00467.2009; Su F, 2012, MOL CANCER THER, V11, P1311, DOI 10.1158/1535-7163.MCT-11-0905; Su F, 2010, P NATL ACAD SCI USA, V107, P19997, DOI 10.1073/pnas.1009010107; Toft NJ, 1999, P NATL ACAD SCI USA, V96, P3911, DOI 10.1073/pnas.96.7.3911; van Duijnhoven FJB, 2011, GUT, V60, P1094, DOI 10.1136/gut.2010.225011; Williams KL, 2001, GASTROENTEROLOGY, V120, P925, DOI 10.1053/gast.2001.22470; WU AL, 1979, J BIOL CHEM, V254, P7316; Yan YT, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006073	53	31	31	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 12	2016	35	19					2496	2505		10.1038/onc.2015.307	http://dx.doi.org/10.1038/onc.2015.307			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DM2GQ	26279300	Bronze			2022-12-17	WOS:000376165500008
J	Zhang, J; Gao, Q; Zhou, Y; Dier, U; Hempel, N; Hochwald, SN				Zhang, J.; Gao, Q.; Zhou, Y.; Dier, U.; Hempel, N.; Hochwald, S. N.			Focal adhesion kinase-promoted tumor glucose metabolism is associated with a shift of mitochondrial respiration to glycolysis	ONCOGENE			English	Article							PANCREATIC-CANCER CELLS; GROWTH-FACTOR-I; FAK; PROLIFERATION; INHIBITION; ACTIVATION; MIGRATION; COMPLEX; IGF-1R	Cancer cells often gains a growth advantage by taking up glucose at a high rate and undergoing aerobic glycolysis through intrinsic cellular factors that reprogram glucose metabolism. Focal adhesion kinase (FAK), a key transmitter of growth factor and anchorage stimulation, is aberrantly overexpressed or activated in most solid tumors, including pancreatic ductal adenocarcinomas (PDACs). We determined whether FAK can act as an intrinsic driver to promote aerobic glycolysis and tumorigenesis. FAK inhibition decreases and overexpression increases intracellular glucose levels during unfavorable conditions, including growth factor deficiency and cell detachment. Amplex glucose assay, fluorescence and carbon-13 tracing studies demonstrate that FAK promotes glucose consumption and glucose-to-lactate conversion. Extracellular flux analysis indicates that FAK enhances glycolysis and decreases mitochondrial respiration. FAK increases key glycolytic proteins, including enolase, pyruvate kinase M2 (PKM2), lactate dehydrogenase and monocarboxylate transporter. Furthermore, active/tyrosine-phosphorylated FAK directly binds to PKM2 and promotes PKM2-mediated glycolysis. On the other hand, FAK-decreased levels of mitochondrial complex I can result in reduced oxidative phosphorylation (OXPHOS). Attenuation of FAK-enhanced glycolysis re-sensitizes cancer cells to growth factor withdrawal, decreases cell viability and reduces growth of tumor xenografts. These observations, for the first time, establish a vital role of FAK in cancer glucose metabolism through alterations in the OXPHOS-to-glycolysis balance. Broadly targeting the common phenotype of aerobic glycolysis and more specifically FAK-reprogrammed glucose metabolism will disrupt the bioenergetic and biosynthetic supply for uncontrolled growth of tumors, particularly glycolytic PDAC.	[Zhang, J.; Gao, Q.; Zhou, Y.; Hochwald, S. N.] Roswell Pk Canc Inst, Dept Surg Oncol, Elm & Carlton St, Buffalo, NY 14263 USA; [Dier, U.; Hempel, N.] SUNY Coll Nanoscale Sci & Engn, Nanobiosci Constellat, Albany, NY USA	Roswell Park Cancer Institute; SUNY Polytechnic Institute	Hochwald, SN (corresponding author), Roswell Pk Canc Inst, Dept Surg Oncol, Elm & Carlton St, Buffalo, NY 14263 USA.	steven.hochwald@roswellpark.org	Hempel, Nadine/F-1700-2014	Hempel, Nadine/0000-0002-5574-8783	NIH (National Institute of Mental Health) from the National Cancer Institute [R00CA143229]; NATIONAL CANCER INSTITUTE [R00CA143229, P30CA016056] Funding Source: NIH RePORTER	NIH (National Institute of Mental Health) from the National Cancer Institute; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	UD and NH are supported by an NIH (National Institute of Mental Health) grant R00CA143229 from the National Cancer Institute.	Andersson S, 2009, BIOCHEM BIOPH RES CO, V387, P36, DOI 10.1016/j.bbrc.2009.06.088; Arbet-Engels C, 1999, FEBS LETT, V454, P252, DOI 10.1016/S0014-5793(99)00815-7; Blum R, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.38; Chen J, 2003, AM J PATHOL, V162, P1283, DOI 10.1016/S0002-9440(10)63924-7; Christofk HR, 2008, NATURE, V452, P181, DOI 10.1038/nature06667; Cui JJ, 2014, CLIN CANCER RES, V20, P2595, DOI 10.1158/1078-0432.CCR-13-2407; Diaz-Ramos A, 2012, J BIOMED BIOTECHNOL, DOI 10.1155/2012/156795; Doudna JA, 2014, SCIENCE, V346, P1077, DOI 10.1126/science.1258096; Frame MC, 2010, NAT REV MOL CELL BIO, V11, P802, DOI 10.1038/nrm2996; Hecker TP, 2004, ONCOGENE, V23, P3962, DOI 10.1038/sj.onc.1207541; Jiao YC, 2011, SCIENCE, V331, P1199, DOI 10.1126/science.1200609; Jones S, 2008, SCIENCE, V321, P1801, DOI 10.1126/science.1164368; Keshari KR, 2013, CANCER RES, V73, P529, DOI 10.1158/0008-5472.CAN-12-3461; Konstantinidou G, 2013, CANCER DISCOV, V3, P444, DOI 10.1158/2159-8290.CD-12-0388; Lee HZ, 2004, LIFE SCI, V74, P2085, DOI 10.1016/j.lfs.2003.06.046; Lee SH, 2011, J CELL PHYSIOL, V226, P1850, DOI 10.1002/jcp.22510; Lim SK, 2012, CLIN EXP METASTAS, V29, P901, DOI 10.1007/s10585-012-9479-z; Mikuriya K, 2007, INT J ONCOL, V30, P849; Muller G, 2001, BIOCHEMISTRY-US, V40, P14603, DOI 10.1021/bi0108352; Muller G, 2000, MOL CELL BIOL, V20, P4708, DOI 10.1128/MCB.20.13.4708-4723.2000; Peng X, 2006, J CLIN INVEST, V116, P217, DOI 10.1172/JCI24497; Santidrian AF, 2013, J CLIN INVEST, V123, P1068, DOI 10.1172/JCI64264; Schultze A, 2011, ANTI-CANCER AGENT ME, V11, P593, DOI 10.2174/187152011796817727; Serrels A, 2012, INT J CANCER, V131, P287, DOI 10.1002/ijc.26351; Shang YL, 2008, MOL CANCER THER, V7, P2599, DOI 10.1158/1535-7163.MCT-07-2401; Sudhakaran PR, 2009, GLYCOCONJUGATE J, V26, P697, DOI 10.1007/s10719-008-9188-7; Tomaino B, 2011, J PROTEOME RES, V10, P105, DOI 10.1021/pr100213b; Tornatore TF, 2011, AM J PHYSIOL-HEART C, V300, pH902, DOI 10.1152/ajpheart.00319.2010; Ucar DA, 2013, ANTI-CANCER AGENT ME, V13, P595; Walker-Samuel S, 2013, NAT MED, V19, P1067, DOI 10.1038/nm.3252; Ward KK, 2013, CLIN EXP METASTAS, V30, P579, DOI 10.1007/s10585-012-9562-5; ZHANG C, 1994, J BIOL CHEM, V269, P25247; Zhang JL, 2014, CELL CYCLE, V13, P3143, DOI 10.4161/15384101.2014.949550; Zhang JL, 2014, PHARMACOL THERAPEUT, V142, P154, DOI 10.1016/j.pharmthera.2013.12.003; Zheng DH, 2010, MOL CARCINOGEN, V49, P200, DOI 10.1002/mc.20590; Zheng DH, 2009, BIOCHEM BIOPH RES CO, V388, P301, DOI 10.1016/j.bbrc.2009.07.156; Zhu J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087904	37	31	31	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 14	2016	35	15					1926	1942		10.1038/onc.2015.256	http://dx.doi.org/10.1038/onc.2015.256			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DJ2CC	26119934	Green Accepted			2022-12-17	WOS:000374010300006
J	Zhu, G; Li, X; Guo, B; Ke, Q; Dong, M; Li, F				Zhu, G.; Li, X.; Guo, B.; Ke, Q.; Dong, M.; Li, F.			PAK5-mediated E47 phosphorylation promotes epithelial-mesenchymal transition and metastasis of colon cancer	ONCOGENE			English	Article							COLORECTAL-CANCER; E-CADHERIN; TRANSCRIPTION FACTORS; GASTRIC-CANCER; DOWN-REGULATION; CELL-ADHESION; E2A PROTEINS; KINASE; MIGRATION; INVASION	The p21-activated kinase 5 (PAK5) is overexpressed in advanced cancer and the transcription factor E47 is a direct repressor of E-cadherin and inducer of epithelial-mesenchymal transition (EMT). However, the relationship between PAK5 and E47 has not been explored. In this study, we found that PAK5-mediated E47 phosphorylation promoted EMT in advanced colon cancer. PAK5 interacted with E47 and phosphorylated E47 on Ser39 under hepatocyte growth factor (HGF) stimulation, which decreased cell-cell cohesion, increased cell migration and invasion in vitro and promoted metastasis in a xenograft model. Furthermore, phosphorylation of E47 facilitated its accumulating in nucleus in an importin a-dependent manner, and enhanced E47 binding to E-cadherin promoter directly, leading to inhibition of E-cadherin transcription. In contrast, PAK5-knockdown resulted in blockage of HGF-induced E47 phosphorylation, attenuated association of E47 with importin a and decreased E47 binding to E-cadherin promoter. In addition, we demonstrated a close correlation between PAK5 and phospho-Ser39 E47 expression in colon cancer specimens. More importantly, high expression of phospho-E47 was associated with an aggressive phenotype of colon cancer and nuclear phospho-E47 staining was found in certain cases of colon cancer with metastasis. Collectively, E47 is a novel substrate of PAK5, and PAK5-mediated phosphorylation of E47 promotes EMT and metastasis of colon cancer, suggesting that phosphorylated E47 on Ser39 may be a potential therapeutic target in progressive colon cancer.	China Med Univ, Dept Cell Biol, Key Lab Cell Biol, Minist Publ Hlth, Shenyang 110122, Peoples R China; China Med Univ, Key Lab Med Cell Biol, Minist Educ, Shenyang 110122, Peoples R China; Hangzhou Normal Univ, Sch Med, Dept Diagnost, Hangzhou, Zhejiang, Peoples R China; China Med Univ, Hosp 1, Gastrointestinal Surg, Dept Gen Surg, Shenyang 110122, Peoples R China	China Medical University; China Medical University; Hangzhou Normal University; China Medical University	Li, F (corresponding author), China Med Univ, Dept Cell Biol, Key Lab Cell Biol, Minist Publ Hlth,Shenyang North New Area, 77 Puhe Rd, Shenyang 110122, Peoples R China.; Li, F (corresponding author), China Med Univ, Key Lab Med Cell Biol, Minist Educ, 77 Puhe Rd, Shenyang 110122, Peoples R China.	fli@mail.cmu.edu.cn		Li, Feng/0000-0001-5868-7456	National Natural Science Foundation of China [90813038, 31371424, 31171360, 31000627, 81201659, 81230077]; Ministry of Education of China [20102104110016, IRT 13101]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Ministry of Education of China(Ministry of Education, China)	We are grateful to Drs Stephen J Brandt and Akira Kato for providing essential expression vectors. We also thank Dr Funan Liu for technical assistance. This work was supported by grants from the National Natural Science Foundation of China (Nos 90813038, 31371424, 31171360, 31000627, 81201659 and 81230077), Doctoral fund of Ministry of Education of China (No. 20102104110016) and Ministry of Education of China (IRT 13101).	BERCHUCK A, 1989, CANCER RES, V49, P2091; Chen XS, 2012, J NEUROSCI RES, V90, P925, DOI 10.1002/jnr.22826; Chiaro C, 2012, BIOCHEM BIOPH RES CO, V428, P121, DOI 10.1016/j.bbrc.2012.10.018; Cochrane SW, 2009, BLOOD, V113, P1016, DOI 10.1182/blood-2008-06-164996; Coma S, 2010, CANCER RES, V70, P3823, DOI 10.1158/0008-5472.CAN-09-3048; Fang ZP, 2014, ACTA PHARMACOL SIN, V35, P82, DOI 10.1038/aps.2013.31; Fawdar S, 2013, P NATL ACAD SCI USA, V110, P12426, DOI 10.1073/pnas.1305207110; Giroux V, 2009, PANCREATOLOGY, V9, P738, DOI 10.1159/000199435; Gong W, 2009, INT J CANCER, V125, P548, DOI 10.1002/ijc.24428; Gu J, 2013, FEBS J, V280, P46, DOI 10.1111/febs.12048; Guo Q, 2014, ONCOGENE, V33, P3277, DOI 10.1038/onc.2013.296; He H, 2013, BBA-MOL CELL RES, V1833, P33, DOI 10.1016/j.bbamcr.2012.10.015; Hwang-Verslues WW, 2011, ONCOGENE, V30, P2463, DOI 10.1038/onc.2010.618; Johnson SE, 1996, MOL CELL BIOL, V16, P1604; Le Bras GF, 2012, CELL ADHES MIGR, V6, P365, DOI 10.4161/cam.21326; Lee SH, 2011, MOL CANCER RES, V9, P782, DOI 10.1158/1541-7786.MCR-10-0535; Li XD, 2010, EXPERT OPIN THER TAR, V14, P419, DOI 10.1517/14728221003642019; Li XD, 2010, INT J BIOCHEM CELL B, V42, P70, DOI 10.1016/j.biocel.2009.09.008; Li Y, 2012, BBA-MOL CELL RES, V1823, P465, DOI 10.1016/j.bbamcr.2011.11.013; Lingbeck JM, 2005, ONCOGENE, V24, P6376, DOI 10.1038/sj.onc.1208789; Lluis F, 2005, EMBO J, V24, P974, DOI 10.1038/sj.emboj.7600528; Loboda A, 2011, BMC MED GENOMICS, V4, DOI 10.1186/1755-8794-4-9; Mehmood R, 2011, MOL BIOL CELL, V22, P3715, DOI 10.1091/mbc.E10-10-0809; Moreno-Bueno G, 2006, CANCER RES, V66, P9543, DOI 10.1158/0008-5472.CAN-06-0479; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; OGO A, 1995, J BIOL CHEM, V270, P25340, DOI 10.1074/jbc.270.43.25340; Patel D, 2012, BIOCHEM BIOPH RES CO, V422, P146, DOI 10.1016/j.bbrc.2012.04.126; Peinado H, 2004, J CELL SCI, V117, P2827, DOI 10.1242/jcs.01145; Perez-Moreno MA, 2001, J BIOL CHEM, V276, P27424, DOI 10.1074/jbc.M100827200; Royal I, 2000, MOL BIOL CELL, V11, P1709, DOI 10.1091/mbc.11.5.1709; Schmitz R, 2012, NATURE, V490, P116, DOI 10.1038/nature11378; Shao YG, 2010, NUCLEIC ACIDS RES, V38, P2813, DOI 10.1093/nar/gkq006; Shapira S, 2014, CURR MED CHEM, V21, P2410, DOI 10.2174/0929867321666140205134616; Slattery C, 2008, INT J BIOCHEM CELL B, V40, P1431, DOI 10.1016/j.biocel.2007.05.014; Slattery C, 2006, FEBS LETT, V580, P4021, DOI 10.1016/j.febslet.2006.06.039; Sloan SR, 1996, MOL CELL BIOL, V16, P6900; Spender LC, 2014, CANCER MANAG RES, V6, P27, DOI 10.2147/CMAR.S37745; Teachenor R, 2012, MOL CELL BIOL, V32, P1671, DOI 10.1128/MCB.06452-11; Teng Y, 2014, CLIN EXP METASTAS, V31, P367, DOI 10.1007/s10585-013-9621-6; Tijchon E, 2013, LEUKEMIA, V27, P541, DOI 10.1038/leu.2012.293; Wang X, 2010, TUMOR BIOL, V31, P575, DOI 10.1007/s13277-010-0071-3; Wang XX, 2013, TUMOR BIOL, V34, P2721, DOI 10.1007/s13277-013-0824-x; Wells CM, 2002, J CELL SCI, V115, P3947, DOI 10.1242/jcs.00080; Whale A, 2011, FRONT BIOSCI-LANDMRK, V16, P849, DOI 10.2741/3724; Zhao HC, 2013, J TRANSL MED, V11, DOI 10.1186/1479-5876-11-317	45	31	33	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 14	2016	35	15					1943	1954		10.1038/onc.2015.259	http://dx.doi.org/10.1038/onc.2015.259			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DJ2CC	26212009				2022-12-17	WOS:000374010300007
J	Stacer, AC; Fenner, J; Cavnar, SP; Xiao, A; Zhao, S; Chang, SL; Salomonnson, A; Luker, KE; Luker, GD				Stacer, A. C.; Fenner, J.; Cavnar, S. P.; Xiao, A.; Zhao, S.; Chang, S. L.; Salomonnson, A.; Luker, K. E.; Luker, G. D.			Endothelial CXCR7 regulates breast cancer metastasis	ONCOGENE			English	Article							CHEMOKINE RECEPTOR CXCR4; CXCL12 ISOFORMS; TUMOR-GROWTH; IN-VIVO; EXPRESSION; CELLS; INHIBITION; MIGRATION; LUNG; PROGNOSIS	Atypical chemokine receptor CXCR7 (ACKR3) functions as a scavenger receptor for chemokine CXCL12, a molecule that promotes multiple steps in tumor growth and metastasis in breast cancer and multiple other malignancies. Although normal vascular endothelium expresses low levels of CXCR7, marked upregulation of CXCR7 occurs in tumor vasculature in breast cancer and other tumors. To investigate effects of endothelial CXCR7 in breast cancer, we conditionally deleted this receptor from vascular endothelium of adult mice, generating CXCR7(Delta END/Delta END) animals. CXCR7(Delta END/Delta END) mice appeared phenotypically normal, although these animals exhibited a modest 35 +/- 3% increase in plasma CXCL12 as compared with control. Using two different syngeneic, orthotopic tumor implant models of breast cancer, we discovered that CXCR7(Delta END/Delta END) mice had significantly greater local recurrence of cancer following resection, elevated numbers of circulating tumor cells and more spontaneous metastases. CXCR7(Delta END/Delta END) mice also showed greater experimental metastases following intracardiac injection of cancer cells. These results establish that endothelial CXCR7 limits breast cancer metastasis at multiple steps in the metastatic cascade, advancing understanding of CXCL12 pathways in tumor environments and informing ongoing drug development targeting CXCR7 in cancer.	[Stacer, A. C.; Fenner, J.; Xiao, A.; Salomonnson, A.; Luker, K. E.; Luker, G. D.] Univ Michigan, Sch Med, Dept Radiol, Ctr Mol Imaging, Ann Arbor, MI USA; [Stacer, A. C.; Fenner, J.; Cavnar, S. P.; Xiao, A.; Zhao, S.; Chang, S. L.; Salomonnson, A.; Luker, K. E.; Luker, G. D.] Univ Michigan, Coll Engn, 109 Zina Pitcher Pl,A526 BSRB, Ann Arbor, MI 48109 USA; [Cavnar, S. P.; Luker, G. D.] Univ Michigan, Sch Med, Dept Biomed Engn, 109 Zina Pitcher Pl,A526 BSRB, Ann Arbor, MI 48109 USA; [Zhao, S.] Univ Michigan, Sch Med, Dept Radiat Oncol, Ann Arbor, MI USA; [Chang, S. L.] Univ Michigan, Sch Med, Dept Chem Engn, Ann Arbor, MI USA; [Luker, G. D.] Univ Michigan, Sch Med, Dept Microbiol & Immunol, 109 Zina Pitcher Pl,A526 BSRB, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Luker, GD (corresponding author), Univ Michigan, Coll Engn, 109 Zina Pitcher Pl,A526 BSRB, Ann Arbor, MI 48109 USA.; Luker, GD (corresponding author), Univ Michigan, Sch Med, Dept Biomed Engn, 109 Zina Pitcher Pl,A526 BSRB, Ann Arbor, MI 48109 USA.; Luker, GD (corresponding author), Univ Michigan, Sch Med, Dept Microbiol & Immunol, 109 Zina Pitcher Pl,A526 BSRB, Ann Arbor, MI 48109 USA.; Luker, GD (corresponding author), Univ Michigan, Sch Med, Dept Radiol, 109 Zina Pitcher Pl,A526 BSRB, Ann Arbor, MI 48109 USA.	gluker@umich.edu	zhao, shuangling/HCI-6255-2022	luker, gary/0000-0001-6832-2581	United States National Institute of Health [R21CA182333, R01CA136553, R01CA142750, R01CA170198, P50CA093990]; NATIONAL CANCER INSTITUTE [R21CA182333, P50CA093990, P01CA085878, R01CA136553, R01CA170198, R01CA142750] Funding Source: NIH RePORTER	United States National Institute of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Mark Penfold and ChemoCentryx for CXCR7 loxP mice and antibody 11G8. Dr Jun-Lin Guan provided SCL Cre<SUP>ERT</SUP> through courteous permission of Dr Glenn Begley. We thank Dr Aaron Robida from the University of Michigan Flow Cytometry Core for assistance. Research was supported by United States National Institute of Health grants R21CA182333, R01CA136553, R01CA142750, R01CA170198 and P50CA093990.	Akashi T, 2008, CANCER SCI, V99, P539, DOI 10.1111/j.1349-7006.2007.00712.x; Allinen M, 2004, CANCER CELL, V6, P17, DOI 10.1016/j.ccr.2004.06.010; Sanchez-Alcaniz JA, 2011, NEURON, V69, P77, DOI 10.1016/j.neuron.2010.12.006; Balkwill F, 2004, NAT REV CANCER, V4, P540, DOI 10.1038/nrc1388; Berahovich RD, 2014, IMMUNOLOGY, V141, P111, DOI 10.1111/imm.12176; Boldajipour B, 2008, CELL, V132, P463, DOI 10.1016/j.cell.2007.12.034; Burns JM, 2006, J EXP MED, V203, P2201, DOI 10.1084/jem.20052144; Casanovas O, 2005, CANCER CELL, V8, P299, DOI 10.1016/j.ccr.2005.09.005; Cavnar SP, 2014, INTEGR BIOL-UK, V6, P564, DOI 10.1039/c4ib00015c; Coleman RE, 2006, CLIN CANCER RES, V12, p6243S, DOI 10.1158/1078-0432.CCR-06-0931; Cruz-Orengo L, 2011, J EXP MED, V208, P327, DOI 10.1084/jem.20102010; Cullen M, 2009, CANCER RES, V69, P6021, DOI 10.1158/0008-5472.CAN-09-1086; D'Alterio C, 2010, CURR CANCER DRUG TAR, V10, P772, DOI 10.2174/156800910793605839; D'Alterio C, 2014, INT J CANCER, V135, P379, DOI 10.1002/ijc.28689; Dang SP, 2013, CLIN DEV IMMUNOL, DOI 10.1155/2013/712561; Ding BS, 2014, NATURE, V505, P97, DOI 10.1038/nature12681; Dona E, 2013, NATURE, V503, P285, DOI 10.1038/nature12635; Ewens A, 2005, ANTICANCER RES, V25, P3905; Fenner J, 2014, SCI REP-UK, V4, DOI 10.1038/srep05512; Gerrits H, 2008, GENESIS, V46, P235, DOI 10.1002/dvg.20387; Goguet-Surmenian E, 2013, BRIT J CANCER, V109, P1579, DOI 10.1038/bjc.2013.482; Gothert JR, 2005, BLOOD, V105, P2724, DOI 10.1182/blood-2004-08-3037; Guillemot E, 2012, BRIT J CANCER, V107, P1944, DOI 10.1038/bjc.2012.503; Hoellenriegel J, 2014, BLOOD, V123, P1032, DOI 10.1182/blood-2013-03-493924; Kitamura T, 2015, NAT REV IMMUNOL, V15, P73, DOI 10.1038/nri3789; Kochetkova M, 2009, CELL DEATH DIFFER, V16, P664, DOI 10.1038/cdd.2008.190; Liao Y, 2001, P NATL ACAD SCI USA, V98, P9989, DOI 10.1073/pnas.171305298; Liberman J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043665; Luker GD, 2003, NAT MED, V9, P969, DOI 10.1038/nm894; Luker K, 2012, ONCOGENE, V31, P4570, DOI DOI 10.1038/0NC.2011.633; Luker KE, 2010, ONCOGENE, V29, P4599, DOI 10.1038/onc.2010.212; Madden SL, 2004, AM J PATHOL, V165, P601, DOI 10.1016/S0002-9440(10)63324-X; Maishi N, 2012, PATHOL INT, V62, P309, DOI 10.1111/j.1440-1827.2012.02792.x; Miao Z, 2007, P NATL ACAD SCI USA, V104, P15735, DOI 10.1073/pnas.0610444104; Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016; Nanda A, 2006, P NATL ACAD SCI USA, V103, P3351, DOI 10.1073/pnas.0511306103; Orimo A, 2005, CELL, V121, P335, DOI 10.1016/j.cell.2005.02.034; Potter SM, 2009, BREAST CANCER RES TR, V115, P279, DOI 10.1007/s10549-008-0078-2; Raggo C, 2005, CANCER RES, V65, P5084, DOI 10.1158/0008-5472.CAN-04-2822; Ray P, 2012, INT J BIOCHEM CELL B, V44, P669, DOI 10.1016/j.biocel.2012.01.007; Salomonnson E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0051500; Sierro F, 2007, P NATL ACAD SCI USA, V104, P14759, DOI 10.1073/pnas.0702229104; Singh S, 2010, BRIT J CANCER, V103, P1671, DOI 10.1038/sj.bjc.6605968; Smith MCP, 2004, CANCER RES, V64, P8604, DOI 10.1158/0008-5472.CAN-04-1844; Suarez Y, 2008, P NATL ACAD SCI USA, V105, P14082, DOI 10.1073/pnas.0804597105; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Sun YN, 2014, TUMOR BIOL, V35, P7765, DOI 10.1007/s13277-014-1816-1; Tachezy M, 2013, J TRANSL MED, V11, DOI 10.1186/1479-5876-11-238; Teicher BA, 2010, CLIN CANCER RES, V16, P2927, DOI 10.1158/1078-0432.CCR-09-2329; Totonchy JE, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069828; Venkiteswaran G, 2013, CELL, V155, P674, DOI 10.1016/j.cell.2013.09.046; Wald O, 2013, THERANOSTICS, V3, P26, DOI 10.7150/thno.4922; Walters MJ, 2014, BRIT J CANCER, V110, P1179, DOI 10.1038/bjc.2013.830; Walters MJ, 2013, IMMUNOL LETT, V151, P44, DOI 10.1016/j.imlet.2013.01.006; Wang JH, 2008, J BIOL CHEM, V283, P4283, DOI 10.1074/jbc.M707465200; Wang YL, 2011, NEURON, V69, P61, DOI 10.1016/j.neuron.2010.12.005; Xu TP, 2013, CANCER EPIDEMIOL, V37, P725, DOI 10.1016/j.canep.2013.04.017; Xue TC, 2012, EXP THER MED, V3, P117, DOI 10.3892/etm.2011.358; Yao X, 2011, J INT MED RES, V39, P1253, DOI 10.1177/147323001103900413; Yokoyama K, 2008, BIOORGAN MED CHEM, V16, P7021, DOI 10.1016/j.bmc.2008.05.036; Zabel BA, 2009, J IMMUNOL, V183, P3204, DOI 10.4049/jimmunol.0900269; Zhang XHF, 2013, CELL, V154, P1060, DOI 10.1016/j.cell.2013.07.036; Zhao S, 2014, TRANSL ONCOL, V7, P429, DOI 10.1016/j.tranon.2014.04.001	63	31	32	1	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 31	2016	35	13					1716	1724		10.1038/onc.2015.236	http://dx.doi.org/10.1038/onc.2015.236			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DH8RP	26119946	Green Accepted			2022-12-17	WOS:000373064200010
J	Yang, E; Cisowski, J; Nguyen, N; O'Callaghan, K; Xu, J; Agarwal, A; Kuliopulos, A; Covic, L				Yang, E.; Cisowski, J.; Nguyen, N.; O'Callaghan, K.; Xu, J.; Agarwal, A.; Kuliopulos, A.; Covic, L.			Dysregulated protease activated receptor 1 (PAR1) promotes metastatic phenotype in breast cancer through HMGA2	ONCOGENE			English	Article							CELL-PENETRATING PEPDUCINS; THROMBIN-RECEPTOR; MESENCHYMAL TRANSITIONS; EXPRESSION; TRANSCRIPTION; INVASION; DIFFERENTIATION; INTERVENTION; PROGRESSION; COOPERATION	As the majority of patients with basal-like breast carcinoma present with invasive, metastatic disease that do not respond to available therapies, it is essential to identify new therapeutic targets that impact invasion and metastasis. Protease-activated receptor 1 (PAR1), a G-protein coupled receptor has been shown to act as an oncogene, but underlying mechanisms are not well understood. Here, we show that ectopic expression of functionally active PAR1 in MCF-7 cells induced a hormone-refractory, invasive phenotype representative of advanced basal-like breast carcinoma that readily formed metastatic lesions in lungs of mice. PAR1 was found to globally upregulate mesenchymal markers, including vimentin, a direct target of PAR1, and downregulate the epithelial markers including E-cadherin, as well as estrogen receptor. In contrast, non-signaling PAR1 mutant receptor did not lead to an invasive, hormone refractory phenotype. PAR1 expression increased spheroid formation and the level of stemness markers and self-renewal capacity in human breast cancer cells. We identified HMGA2 (high mobility group A2) as an important regulator of PAR1-mediated invasion. Inhibition of PAR1 signaling suppresses HMGA2-driven invasion in breast cancer cells. HMGA2 gene and protein are highly expressed in metastatic breast cancer cells. Overall, our results show that PAR1/HMGA2 pathway may present a novel therapeutic target.	[Yang, E.; Cisowski, J.; Nguyen, N.; O'Callaghan, K.; Xu, J.; Agarwal, A.; Kuliopulos, A.; Covic, L.] Tufts Med Ctr, Mol Oncol Res Inst, Boston, MA USA; [Yang, E.; Kuliopulos, A.; Covic, L.] Dept Biochem, Boston, MA USA; [Yang, E.; Kuliopulos, A.; Covic, L.] Tufts Med Ctr, Boston, MA USA; [Kuliopulos, A.; Covic, L.] Tufts Med Ctr, Div Hematol Oncol, Boston, MA USA; [Kuliopulos, A.; Covic, L.] Tufts Med Ctr, Dept Med, Boston, MA USA	Tufts Medical Center; Tufts Medical Center; Tufts Medical Center; Tufts Medical Center	Covic, L (corresponding author), Tufts Med Ctr, Mol Oncol Res Inst, Div Hematol Oncol, Box 7510,750 Washington St, Boston, MA 02111 USA.	lcovic@tuftsmedicalcenter.org			NIH [CA104406, CA122992, HL64701]; Susan G. Komen [BCTR0706763]; Diane Connolly-Zaniboni Research Scholarship; NNDS [P30 NS047243]; Aid for Cancer Research, Boston, MA	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Susan G. Komen(Susan G. Komen Breast Cancer Foundation); Diane Connolly-Zaniboni Research Scholarship; NNDS; Aid for Cancer Research, Boston, MA	We thank Vishal Trivedi, Chris Parkin, Akiko Hata, Larry Feig and Anna Wronski for their expert advice and Ryan Stevenson for critically reading the manuscript. The microarray analysis was carried out in the Genomics Core of the Tufts Center for Neuroscience Research, Tufts University School of Medicine (supported by NNDS - P30 NS047243). This work was supported by NIH grants CA104406 (LC), Susan G. Komen BCTR0706763, Diane Connolly-Zaniboni Research Scholarship (LC) and a fellowship from Aid for Cancer Research, Boston, MA (EY) by NIH CA122992, HL64701 (to AK).	Agarwal A, 2008, MOL CANCER THER, V7, P2746, DOI 10.1158/1535-7163.MCT-08-0177; Aigner K, 2007, ONCOGENE, V26, P6979, DOI 10.1038/sj.onc.1210508; Becker RC, 2009, LANCET, V373, P919, DOI 10.1016/S0140-6736(09)60230-0; Bergers G, 2000, NAT CELL BIOL, V2, P737, DOI 10.1038/35036374; Boire A, 2005, CELL, V120, P303, DOI 10.1016/j.cell.2004.12.018; Bolos V, 2003, J CELL SCI, V116, P499, DOI 10.1242/jcs.00224; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Chen JQ, 2009, BBA-REV CANCER, V1796, P162, DOI 10.1016/j.bbcan.2009.06.003; Cisowski J, 2011, AM J PATHOL, V179, P513, DOI 10.1016/j.ajpath.2011.03.025; Cleynen I, 2007, MOL CANCER RES, V5, P363, DOI 10.1158/1541-7786.MCR-06-0331; Covic L, 2000, BIOCHEMISTRY-US, V39, P5458, DOI 10.1021/bi9927078; Covic L, 2002, NAT MED, V8, P1161, DOI 10.1038/nm760; Even-Ram S, 1998, NAT MED, V4, P909, DOI 10.1038/nm0898-909; Even-Ram SC, 2001, J BIOL CHEM, V276, P10952, DOI 10.1074/jbc.M007027200; Ferguson M, 2003, NUCLEIC ACIDS RES, V31, P3123, DOI 10.1093/nar/gkg403; Fillmore CM, 2010, P NATL ACAD SCI USA, V107, P21737, DOI 10.1073/pnas.1007863107; Hatziapostolou M, 2008, CANCER RES, V68, P1851, DOI 10.1158/0008-5472.CAN-07-5793; Henrikson KP, 1999, BRIT J CANCER, V79, P401, DOI 10.1038/sj.bjc.6690063; Kamath L, 2001, CANCER RES, V61, P5933; Korkola JE, 2003, CANCER RES, V63, P7167; Kuliopulos A, 1999, BIOCHEMISTRY-US, V38, P4572, DOI 10.1021/bi9824792; Kumar MS, 2014, NATURE, V505, P212, DOI 10.1038/nature12785; Lahat G, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010105; Li Y, 2014, CANCER LETT, V355, P130, DOI 10.1016/j.canlet.2014.09.007; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Martin CB, 2001, ONCOGENE, V20, P1953, DOI 10.1038/sj.onc.1204281; Medeiros F, 2007, GENE CHROMOSOME CANC, V46, P981, DOI 10.1002/gcc.20483; Morrow DA, 2012, NEW ENGL J MED, V366, P1404, DOI 10.1056/NEJMoa1200933; NELSON WJ, 1983, MOL CELL BIOL, V3, P1146, DOI 10.1128/MCB.3.6.1146; Nguyen N, 2006, CANCER RES, V66, P2658, DOI 10.1158/0008-5472.CAN-05-2082; Nierodzik ML, 1998, BLOOD, V92, P3694, DOI 10.1182/blood.V92.10.3694.422k40_3694_3700; Pegoraro S, 2013, ONCOTARGET, V4, P1293, DOI 10.18632/oncotarget.1136; Peluso S, 2010, BREAST CARE, V5, P81, DOI 10.1159/000297717; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Reeves R, 2010, BBA-GENE REGUL MECH, V1799, P3, DOI 10.1016/j.bbagrm.2009.09.001; Rudroff C, 2002, CLIN EXP METASTAS, V19, P181, DOI 10.1023/A:1014598904644; Salah Z, 2005, FASEB J, V19, P62, DOI 10.1096/fj.04-2386com; Salah Z, 2012, FASEB J, V26, P2031, DOI 10.1096/fj.11-194704; Satelli A, 2011, CELL MOL LIFE SCI, V68, P3033, DOI 10.1007/s00018-011-0735-1; Sgarra R, 2010, BBA-GENE REGUL MECH, V1799, P37, DOI 10.1016/j.bbagrm.2009.08.009; Sheen YS, 2015, J INVEST DERMATOL, V135, P1065, DOI 10.1038/jid.2014.480; Slofstra SH, 2007, BLOOD, V110, P3176, DOI 10.1182/blood-2007-02-075440; Sun JM, 2005, EXP CELL RES, V302, P96, DOI 10.1016/j.yexcr.2004.08.015; Tallini G, 1999, ADV ANAT PATHOL, V6, P237, DOI 10.1097/00125480-199909000-00001; Tallini G, 1997, AM J PATHOL, V151, P37; Tellez C, 2003, ONCOGENE, V22, P3130, DOI 10.1038/sj.onc.1206453; Thiery JP, 2006, NAT REV MOL CELL BIO, V7, P131, DOI 10.1038/nrm1835; Thuault S, 2008, J BIOL CHEM, V283, P33437, DOI 10.1074/jbc.M802016200; Tricoci P, 2012, NEW ENGL J MED, V366, P20, DOI 10.1056/NEJMoa1109719; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; WHITEHEAD I, 1995, MOL CELL BIOL, V15, P704; Xi YN, 2014, ASIAN PAC J TROP MED, V7, P289, DOI 10.1016/S1995-7645(14)60040-7; Yang E, 2009, CANCER RES, V69, P6223, DOI 10.1158/0008-5472.CAN-09-0187; Zhang P, 2012, CIRCULATION, V126, P83, DOI 10.1161/CIRCULATIONAHA.112.091918	54	31	31	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 24	2016	35	12					1529	1540		10.1038/onc.2015.217	http://dx.doi.org/10.1038/onc.2015.217			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DH8RJ	26165842	Green Accepted			2022-12-17	WOS:000373063600006
J	Fan, H; Zhang, H; Pascuzzi, PE; Andrisani, O				Fan, H.; Zhang, H.; Pascuzzi, P. E.; Andrisani, O.			Hepatitis B virus X protein induces EpCAM expression via active DNA demethylation directed by RelA in complex with EZH2 and TET2	ONCOGENE			English	Article							NF-KAPPA-B; POSITIVE HEPATOCELLULAR-CARCINOMA; LIVER-CANCER PROGRESSION; HEPATOCYTE CELL-LINES; GENE-EXPRESSION; TARGET GENES; TRANSGENIC MICE; MAMMALIAN DNA; ANTIGEN EPCAM; EP-CAM	Chronic hepatitis B virus (HBV) infection is a major risk factor for developing hepatocellular carcinoma (HCC), and HBV X protein (HBx) acts as cofactor in hepatocarcinogenesis. In liver tumors from animals modeling HBx- and HBV-mediated hepatocarcinogenesis, downregulation of chromatin regulating proteins SUZ12 and ZNF198 induces expression of several genes, including epithelial cell adhesion molecule (EpCAM). EpCAM upregulation occurs in HBV-mediated HCCs and hepatic cancer stem cells, by a mechanism not understood. Herein we demonstrate HBx induces EpCAM expression via active DNA demethylation. In hepatocytes, EpCAM is silenced by polycomb repressive complex 2 (PRC2) and ZNF198/LSD1/Co-REST/HDAC1 chromatin-modifying complexes. Cells with stable knockdown of SUZ12, an essential PRC2 subunit, upon HBx expression demethylate a CpG dinucleotide located adjacent to NF-kappa B/RelA half-site. This NF-kappa B/RelA site is in a CpG island downstream from EpCAM transcriptional start site (-155). Chromatin immunoprecipitation (ChIP) assays demonstrate HBx-dependent RelA occupancy of NF-kappa B half-site, whereas RelA knockdown suppresses CpG demethylation and EpCAM expression. Tumor necrosis factor-alpha activates RelA, propagating demethylation to nearby CpG sites, shown by sodium bisulfite sequencing. ReIA-dependent demethylation occurring upon HBx expression requires methyltrasferase EZH2, TET2 a key factor in cytosine demethylation and inactive DNMT3L, shown by knockdown assays and sodium bisulfite sequencing. Co-immunoprecipitations and sequential ChIP assays demonstrate that RelA in the presence of HBx forms a complex with EZH2, TET2 and DNMT3L, although the role of DNMT3L remains to be understood. Interestingly, the human EpCAM gene also has a CpG island downstream from its TSS, and a NF-kappa B-binding site flanked by CpGs. HepG2 cells derived from human HCC exhibit demethylation of these NF-kappa B-flanking CpG sites, and HBV replication propagates demethylation to nearby CpG sites. DLK1, another PRC2 target gene, also upregulated in HBV-mediated HCCs, is demethylated in liver tumors at CpG dinucleotides flanking the NF-kappa B-binding sequence, supporting that this active DNA demethylation mechanism functions during oncogenic transformation.	[Fan, H.; Zhang, H.; Andrisani, O.] Purdue Univ, Dept Basic Med Sci, 205A Hansen Bldg,201 South Univ St, W Lafayette, IN 47907 USA; [Fan, H.; Zhang, H.; Andrisani, O.] Purdue Univ, Dept Purdue, Ctr Canc Res, W Lafayette, IN 47907 USA; [Pascuzzi, P. E.] Purdue Univ, Purdue Univ Lib, W Lafayette, IN 47907 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus; Purdue University System; Purdue University; Purdue University West Lafayette Campus; Purdue University System; Purdue University; Purdue University West Lafayette Campus	Andrisani, O (corresponding author), Purdue Univ, Dept Basic Med Sci, 205A Hansen Bldg,201 South Univ St, W Lafayette, IN 47907 USA.	andrisao@purdue.edu	Pascuzzi, Pete/T-5378-2019	Andrisani, Ourania/0000-0002-6230-0303; Pascuzzi, Pete/0000-0002-9316-4404	NIH [DK044533, P30CA023168]; NATIONAL CANCER INSTITUTE [P30CA023168] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK044533, R01DK044533] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported by NIH grant DK044533 to OA. Shared Resources (flow cytometry and DNA sequencing) are supported by NIH grant P30CA023168 to Purdue Cancer Research Center. The authors thank Dr R Hullinger for critical review of the manuscript.	Andrisani OM, 1999, INT J ONCOL, V15, P373; Baud V, 2009, NAT REV DRUG DISCOV, V8, P33, DOI 10.1038/nrd2781; BEASLEY RP, 1981, LANCET, V2, P1129; Bouchard MJ, 2004, J VIROL, V78, P12725, DOI 10.1128/JVI.78.23.12725-12734.2004; Boyault S, 2007, HEPATOLOGY, V45, P42, DOI 10.1002/hep.21467; Bracken AP, 2006, GENE DEV, V20, P1123, DOI 10.1101/gad.381706; Cartron Pierre-Francois, 2013, Genes Cancer, V4, P235, DOI 10.1177/1947601913489020; Chang CJ, 2012, BRIT J CANCER, V106, P243, DOI 10.1038/bjc.2011.551; Chaves-Perez A, 2013, ONCOGENE, V32, P641, DOI 10.1038/onc.2012.75; Chen YQ, 1998, NAT STRUCT BIOL, V5, P67, DOI 10.1038/nsb0198-67; Chen YQ, 2000, STRUCT FOLD DES, V8, P419, DOI 10.1016/S0969-2126(00)00123-4; de Boer CJ, 1999, J PATHOL, V188, P201, DOI 10.1002/(SICI)1096-9896(199906)188:2<201::AID-PATH339>3.0.CO;2-8; de la Rica L, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-9-r99; Delatte B, 2014, EMBO J, V33, P1198, DOI 10.15252/embj.201488290; Denis H, 2011, EMBO REP, V12, P647, DOI 10.1038/embor.2011.110; Fujiki K, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3262; Gautier L, 2004, BIOINFORMATICS, V20, P307, DOI 10.1093/bioinformatics/btg405; Gocke CB, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003255; Hachmeister M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071836; Haring M, 2007, PLANT METHODS, V3, DOI 10.1186/1746-4811-3-11; Kim E, 2013, CANCER CELL, V23, P839, DOI 10.1016/j.ccr.2013.04.008; Ko M, 2013, NATURE, V497, P122, DOI 10.1038/nature12052; Kriaucionis S, 2009, SCIENCE, V324, P929, DOI 10.1126/science.1169786; Ladner SK, 1997, ANTIMICROB AGENTS CH, V41, P1715, DOI 10.1128/AAC.41.8.1715; Lee HJ, 2014, CELL STEM CELL, V14, P710, DOI 10.1016/j.stem.2014.05.008; Lee ST, 2011, MOL CELL, V43, P798, DOI 10.1016/j.molcel.2011.08.011; Li LC, 2002, BIOINFORMATICS, V18, P1427, DOI 10.1093/bioinformatics/18.11.1427; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lu T, 2013, P NATL ACAD SCI USA, V110, P13510, DOI 10.1073/pnas.1311770110; Madden CR, 2001, J VIROL, V75, P3851, DOI 10.1128/JVI.75.8.3851-3858.2001; Maetzel D, 2009, NAT CELL BIOL, V11, P162, DOI 10.1038/ncb1824; Margueron R, 2011, NATURE, V469, P343, DOI 10.1038/nature09784; Meissner A, 2008, NATURE, V454, P766, DOI 10.1038/nature07107; Meissner A, 2011, CELL STEM CELL, V9, P388, DOI 10.1016/j.stem.2011.10.014; Munz M, 2004, ONCOGENE, V23, P5748, DOI 10.1038/sj.onc.1207610; Munz M, 2009, CANCER RES, V69, P5627, DOI 10.1158/0008-5472.CAN-09-0654; Nakamoto Y, 1997, J IMMUNOL, V158, P5692; Neri F, 2013, CELL, V155, P121, DOI 10.1016/j.cell.2013.08.056; Ning BF, 2014, HEPATOLOGY, V60, P1607, DOI 10.1002/hep.27177; RCore Team, 2014, R LANG ENV STAT COMP; Schmelzer E, 2007, J EXP MED, V204, P1973, DOI 10.1084/jem.20061603; Schnell U, 2013, BBA-BIOMEMBRANES, V1828, P1989, DOI 10.1016/j.bbamem.2013.04.018; Studach L, 2010, J BIOL CHEM, V285, P30282, DOI 10.1074/jbc.M109.093963; Studach LL, 2012, HEPATOLOGY, V56, P1240, DOI 10.1002/hep.25781; Studach LL, 2009, HEPATOLOGY, V50, P414, DOI 10.1002/hep.22996; Su F, 1996, J VIROL, V70, P4558, DOI 10.1128/JVI.70.7.4558-4566.1996; Sun L, 2013, STEM CELLS, V31, P1454, DOI 10.1002/stem.1394; Tahiliani M, 2009, SCIENCE, V324, P930, DOI 10.1126/science.1170116; Tanaka M, 2009, MECH DEVELOP, V126, P665, DOI 10.1016/j.mod.2009.06.939; Tarn C, 1999, J BIOL CHEM, V274, P2327, DOI 10.1074/jbc.274.4.2327; Terradillos O, 1997, ONCOGENE, V14, P395, DOI 10.1038/sj.onc.1200850; Tsai MC, 2010, SCIENCE, V329, P689, DOI 10.1126/science.1192002; van der Gun BTF, 2011, BRIT J CANCER, V105, P312, DOI 10.1038/bjc.2011.231; Vire E, 2006, NATURE, V439, P871, DOI 10.1038/nature04431; Wang VYF, 2012, CELL REP, V2, P824, DOI 10.1016/j.celrep.2012.08.042; Wang WH, 2011, HEPATOLOGY, V53, P1137, DOI 10.1002/hep.24163; Weber M, 2007, NAT GENET, V39, P457, DOI 10.1038/ng1990; Went P, 2006, BRIT J CANCER, V94, P128, DOI 10.1038/sj.bjc.6602924; WU JC, 1994, P NATL ACAD SCI USA, V91, P674, DOI 10.1073/pnas.91.2.674; Yamashita T, 2009, GASTROENTEROLOGY, V136, P1012, DOI 10.1053/j.gastro.2008.12.004; Zeng SS, 2014, J HEPATOL, V60, P127, DOI 10.1016/j.jhep.2013.08.024; Zhang H, CANC RES IN PRESS; ZOULIM F, 1994, J VIROL, V68, P2026, DOI 10.1128/JVI.68.3.2026-2030.1994	63	31	35	2	30	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 11	2016	35	6					715	726		10.1038/onc.2015.122	http://dx.doi.org/10.1038/onc.2015.122			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DE0RF	25893293	Green Accepted			2022-12-17	WOS:000370331300005
J	Mortusewicz, O; Evers, B; Helleday, T				Mortusewicz, O.; Evers, B.; Helleday, T.			PC4 promotes genome stability and DNA repair through binding of ssDNA at DNA damage sites	ONCOGENE			English	Article							DOUBLE-STRAND BREAKS; TRANSCRIPTIONAL COACTIVATOR PC4; ONCOGENE-INDUCED SENESCENCE; MAMMALIAN-CELLS; HOMOLOGOUS RECOMBINATION; REPLICATION FORKS; FRAGILE SITES; COFACTOR PC4; RPA; ACTIVATION	The transcriptional cofactor PC4 is an ancient single-strand DNA (ssDNA)-binding protein that has a homologue in bacteriophage TS where it is likely the elusive replicative ssDNA-binding protein. We hypothesize that human PC4 has retained functions in ssDNA binding to stabilize replication forks and prevent genome instability in mammalian cells, Here we demonstrate that PC4 is recruited to hydroxyurea (HU)-stalled replication forks, which is dependent on active transcription and its ssDNA-binding ability. Interestingly, we demonstrate that ssDNA binding by PC4 is critical to suppress spontaneous DNA damage and promote cellular survival. PC4 accumulation co-localizes with replication protein A (RPA) at stalled forks and is increased upon RPA depletion, demonstrating compensatory functions in ssDNA binding. Depletion of PC4 not only results in defective resolution of HU-induced DNA damage but also significantly reduces homologous recombination repair efficiency. Altogether, our results indicate that PC4 has similar functions to RPA in binding ssDNA to promote genome stability, especially at sites of replication transcription collisions,	[Mortusewicz, O.; Evers, B.; Helleday, T.] Karolinska Inst, Dept Med Biochem & Biophys, Div Translat Med & Chem Biol, Sci Life Lab, Box 1031, S-17121 Stockholm, Sweden; [Evers, B.] Netherlands Canc Inst, Div Mol Carcinogenesis, Amsterdam, Netherlands	Karolinska Institutet; Netherlands Cancer Institute	Mortusewicz, O; Helleday, T (corresponding author), Karolinska Inst, Dept Med Biochem & Biophys, Div Translat Med & Chem Biol, Sci Life Lab, Box 1031, S-17121 Stockholm, Sweden.	oliver.mortusewicz@scilifelab.se; thomas.helleday@scilifelab.se		Helleday, Thomas/0000-0002-7384-092X	Swedish Research Council; Swedish Cancer Society; EMBO LTF [O.M. 451-2010]; Dutch Cancer Society (BE); Torsten and Ragnar Soderberg Foundation; AXA foundation; Goran Gustafsson Foundation	Swedish Research Council(Swedish Research CouncilEuropean Commission); Swedish Cancer Society(Swedish Cancer Society); EMBO LTF(European Molecular Biology Organization (EMBO)); Dutch Cancer Society (BE); Torsten and Ragnar Soderberg Foundation; AXA foundation; Goran Gustafsson Foundation	We would like to express our gratitude to Annette Medhurst and Songmin Ying for help with the fibre assay, Guy Kingham for assistance on the DR-GFP assay and to Mick Woodcock for support with the FACS analysis. This project was supported by the Swedish Research Council, Swedish Cancer Society, EMBO LTF (O.M. 451-2010), Dutch Cancer Society (BE), the Torsten and Ragnar Soderberg Foundation, AXA foundation and the Goran Gustafsson Foundation.	Alabert C, 2014, NAT CELL BIOL, V16, P281, DOI 10.1038/ncb2918; Arnaudeau C, 2001, J MOL BIOL, V307, P1235, DOI 10.1006/jmbi.2001.4564; Aymard F, 2014, NAT STRUCT MOL BIOL, V21, P366, DOI 10.1038/nsmb.2796; Barlow JH, 2013, CELL, V152, P620, DOI 10.1016/j.cell.2013.01.006; Bartkova J, 2006, NATURE, V444, P633, DOI 10.1038/nature05268; Batta K, 2009, J MOL BIOL, V385, P788, DOI 10.1016/j.jmb.2008.11.008; Brandsen J, 1997, NAT STRUCT BIOL, V4, P900, DOI 10.1038/nsb1197-900; Das C, 2006, MOL CELL BIOL, V26, P8303, DOI 10.1128/MCB.00887-06; Di Micco R, 2006, NATURE, V444, P638, DOI 10.1038/nature05327; Feijoo C, 2001, J CELL BIOL, V154, P913, DOI 10.1083/jcb.200104099; GE H, 1994, CELL, V78, P513, DOI 10.1016/0092-8674(94)90428-6; KAISER K, 1995, EMBO J, V14, P3520, DOI 10.1002/j.1460-2075.1995.tb07358.x; KRETZSCHMAR M, 1994, CELL, V78, P525, DOI 10.1016/0092-8674(94)90429-4; Lundin C, 2003, J MOL BIOL, V328, P521, DOI 10.1016/S0022-2836(03)00313-9; Mortusewicz O, 2013, EMBO J, V32, P493, DOI 10.1038/emboj.2013.20; Mortusewicz O, 2008, J CELL BIOL, V183, P769, DOI 10.1083/jcb.200808097; Pan ZQ, 1996, J BIOL CHEM, V271, P22111, DOI 10.1074/jbc.271.36.22111; Petermann E, 2010, MOL CELL, V37, P492, DOI 10.1016/j.molcel.2010.01.021; Pierce AJ, 1999, GENE DEV, V13, P2633, DOI 10.1101/gad.13.20.2633; Sakaguchi K, 2009, FEBS J, V276, P943, DOI 10.1111/j.1742-4658.2008.06841.x; Steigemann B, 2013, J MOL BIOL, V425, P4125, DOI 10.1016/j.jmb.2013.09.001; Suzuki K, 2011, NAT PROTOC, V6, P134, DOI 10.1038/nprot.2010.183; Toledo LI, 2013, CELL, V155, P1088, DOI 10.1016/j.cell.2013.10.043; Vassin VM, 2009, J CELL SCI, V122, P4070, DOI 10.1242/jcs.053702; Wang JY, 2004, MOL CELL BIOL, V24, P6084, DOI 10.1128/MCB.24.13.6084-6093.2004; Werten S, 2006, NAT STRUCT MOL BIOL, V13, P181, DOI 10.1038/nsmb1044; Werten S, 1998, EMBO J, V17, P5103, DOI 10.1093/emboj/17.17.5103; Yu LJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058015; Zou L, 2003, SCIENCE, V300, P1542, DOI 10.1126/science.1083430	29	31	31	4	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 11	2016	35	6					761	770		10.1038/onc.2015.135	http://dx.doi.org/10.1038/onc.2015.135			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DE0RF	25961912				2022-12-17	WOS:000370331300009
J	Seviourig, EG; Sehgal, V; Lu, Y; Luo, Z; Moss, T; Zhang, F; Hill, SM; Liu, W; Maiti, SN; Cooper, L; Azencot, R; Lopez-Berestein, G; Rodriguez-Aguayo, C; Roopaimoole, R; Pecot, CV; Sood, AK; Mukherjee, S; Gray, JW; Mills, G; Ram, P				Seviourig, E. G.; Sehgal, V.; Lu, Y.; Luo, Z.; Moss, T.; Zhang, F.; Hill, S. M.; Liu, W.; Maiti, S. N.; Cooper, L.; Azencot, R.; Lopez-Berestein, G.; Rodriguez-Aguayo, C.; Roopaimoole, R.; Pecot, C. V.; Sood, A. K.; Mukherjee, S.; Gray, J. W.; Mills, G. B.; Ram, P. T.			Functional proteomics identifies miRNAs to target a p27/Myc/phospho-Rb signature in breast and ovarian cancer	ONCOGENE			English	Article							DEPENDENT KINASE INHIBITOR; C-MYC; HEPATOCELLULAR-CARCINOMA; CELL-PROLIFERATION; MICRO RNAS; MIR-124; EXPRESSION; GENE; ACTIVATION; P27(KIP1)	The myc oncogene is overexpressed in almost half of all breast and ovarian cancers, but attempts at therapeutic interventions against myc have proven to be challenging. Myc regulates multiple biological processes, including the cell cycle, and as such is associated with cell proliferation and tumor progression. We identified a protein signature of high myc, low p27 and high phospho-Rb significantly correlated with poor patient survival in breast and ovarian cancers. Screening of a miRNA library by functional proteomics in multiple cell lines and integration of data from patient tumors revealed a panel of five microRNAs (miRNAs) (miR-124, miR-365, miR-34b*, miR-18a and miR-506) as potential tumor suppressors capable of reversing the p27/myc/phospho-Rb protein signature. Mechanistic studies revealed an RNA-activation function of miR-124 resulting in direct induction of p27 protein levels by binding to and inducing transcription on the p27 promoter region leading to a subsequent G1 arrest. Additionally, in vivo studies utilizing a xenograft model demonstrated that nanoparticle-mediated delivery of miR-124 could reduce tumor growth and sensitize cells to etoposide, suggesting a clinical application of miRNAs as therapeutics to target the functional effect of myc on tumor growth.	[Seviourig, E. G.; Sehgal, V.; Lu, Y.; Luo, Z.; Moss, T.; Zhang, F.; Mills, G. B.; Ram, P. T.] Univ Texas MD Anderson Canc Ctr, Dept Syst Biol, 1515 Holcombe Blvd, Houston, TX 77030 USA; [Hill, S. M.] Cambridge Inst Publ Hlth, MRC Biostat Unit, Cambridge, England; [Liu, W.] UTMDACC, Dept Bioinformat & Computat Biol, Houston, TX USA; [Maiti, S. N.] UTMDACC, Dept Pediat, Houston, TX USA; [Azencot, R.] Univ Houston, Dept Math, Houston, TX 77204 USA; [Lopez-Berestein, G.; Rodriguez-Aguayo, C.; Roopaimoole, R.] UTMDACC, Dept Expt Therapeut, Houston, TX USA; [Lopez-Berestein, G.] UTMDACC, Ctr RNA Interference & Noncoding RNA, Houston, TX USA; [Pecot, C. V.] UTMDACC, Div Canc Med, Houston, TX USA; [Sood, A. K.] UTMDACC, Dept Gynecol Oncol, Houston, TX USA; [Gray, J. W.] Oregon Hlth & Sci Univ, Dept Biomed Engn, Portland, OR USA	University of Texas System; UTMD Anderson Cancer Center; MRC Biostatistics Unit; University of Cambridge; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Houston System; University of Houston; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Oregon Health & Science University	Ram, P (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Syst Biol, 1515 Holcombe Blvd, Houston, TX 77030 USA.	pram@mdandcrson.org	rupaimoole, rajesha/K-3272-2016; Sood, Anoop Kumar/A-7344-2013	rupaimoole, rajesha/0000-0002-4795-7921; Sood, Anoop Kumar/0000-0001-5702-4108; RODRIGUEZ-AGUAYO, CRISTIAN/0000-0002-7880-7723; Ram, Prahlad/0000-0003-4739-3166; Seviour, Elena/0000-0003-2885-4246	NIH/NCI ICBP grant [U54-CA112970]; Blanton Davis Foundation; Odessy Fellowship (MDACC); CCBTP training grant from the CPRIT; NATIONAL CANCER INSTITUTE [U54CA112970, P30CA016672, P50CA083639] Funding Source: NIH RePORTER	NIH/NCI ICBP grant; Blanton Davis Foundation; Odessy Fellowship (MDACC); CCBTP training grant from the CPRIT; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	All the data reported are presented and available in the Supplementary Materials. The work presented here was funded by an NIH/NCI ICBP grant U54-CA112970 to JWG (Project 1 Co-PI SM, Project 2 PI-JWG, Project 4 Co-PI's PTR and GBM) and the Blanton Davis Foundation. TM is partly funded by the Odessy Fellowship (MDACC) and ZL and VS are funded by the CCBTP training grant from the CPRIT.	Akbani R, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4887; Bell D, 2011, NATURE, V474, P609, DOI 10.1038/nature10166; Cao XW, 2007, GENE DEV, V21, P531, DOI 10.1101/gad.1519207; Chandramohan V, 2008, J CELL BIOCHEM, V104, P2091, DOI 10.1002/jcb.21765; Chin L, 2008, NATURE, V455, P1061, DOI 10.1038/nature07385; Coller HA, 2000, P NATL ACAD SCI USA, V97, P3260, DOI 10.1073/pnas.97.7.3260; DeGregori J, 2004, J CELL SCI, V117, P3411, DOI 10.1242/jcs.01189; Evan G, 2012, SCIENCE, V335, P293, DOI 10.1126/science.1217819; Fabian MR, 2012, NAT STRUCT MOL BIOL, V19, P586, DOI 10.1038/nsmb.2296; Gao P, 2009, NATURE, V458, P762, DOI 10.1038/nature07823; Hammerman PS, 2012, NATURE, V489, P519, DOI 10.1038/nature11404; Hazlehurst LA, 2001, BLOOD, V98, P1897, DOI 10.1182/blood.V98.6.1897; Hodkinson PS, 2006, CELL DEATH DIFFER, V13, P1776, DOI 10.1038/sj.cdd.4401849; Hoyt DG, 1996, CANCER RES, V56, P4146; Hunt S, 2011, FEBS LETT, V585, P187, DOI 10.1016/j.febslet.2010.11.038; Janowski BA, 2007, NAT CHEM BIOL, V3, P166, DOI 10.1038/nchembio860; Jopling CL, 2005, SCIENCE, V309, P1577, DOI 10.1126/science.1113329; Kang SS, 2014, PROSTATE, V74, P1095, DOI 10.1002/pros.22822; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Lai EC, 2002, NAT GENET, V30, P363, DOI 10.1038/ng865; Lang QB, 2012, BIOCHEM BIOPH RES CO, V426, P247, DOI 10.1016/j.bbrc.2012.08.075; Li CX, 2006, CELL CYCLE, V5, P2103, DOI 10.4161/cc.5.18.3192; Li LC, 2006, P NATL ACAD SCI USA, V103, P17337, DOI 10.1073/pnas.0607015103; Li YF, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00058; Liang YJ, 2013, CARCINOGENESIS, V34, P713, DOI 10.1093/carcin/bgs383; Lu Y, 2011, ONCOGENE, V30, P4567, DOI 10.1038/onc.2011.164; Lu YX, 2013, BIOCHEM BIOPH RES CO, V441, P873, DOI 10.1016/j.bbrc.2013.10.157; Luo ZH, 2013, CARCINOGENESIS, V34, P415, DOI 10.1093/carcin/bgs329; Mendell JT, 2012, CELL, V148, P1172, DOI 10.1016/j.cell.2012.02.005; Miller DM, 2012, CLIN CANCER RES, V18, P5546, DOI 10.1158/1078-0432.CCR-12-0977; Mouw JK, 2014, NAT MED, V20, P360, DOI 10.1038/nm.3497; Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252; Nam EJ, 2008, CLIN CANCER RES, V14, P2690, DOI 10.1158/1078-0432.CCR-07-1731; Obaya AJ, 1999, ONCOGENE, V18, P2934, DOI 10.1038/sj.onc.1202749; Pecot CV, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3427; Place RF, 2008, P NATL ACAD SCI USA, V105, P1608, DOI 10.1073/pnas.0707594105; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; Schmidt EV, 1999, ONCOGENE, V18, P2988, DOI 10.1038/sj.onc.1202751; Shi XB, 2013, ONCOGENE, V32, P4130, DOI 10.1038/onc.2012.425; Shiio Y, 2002, EMBO J, V21, P5088, DOI 10.1093/emboj/cdf525; Szymaski M, 2003, INT REV CYTOL, V231, P197, DOI 10.1016/S0074-7696(03)31005-8; Toyoshima M, 2012, P NATL ACAD SCI USA, V109, P9545, DOI 10.1073/pnas.1121119109; Wei J, 2013, CANCER RES, V73, P3913, DOI 10.1158/0008-5472.CAN-12-4318; Xia HP, 2012, J BIOL CHEM, V287, P9962, DOI 10.1074/jbc.M111.332627; Xia JT, 2012, J PATHOL, V227, P470, DOI 10.1002/path.4030; Xu XL, 2014, ANN THORAC SURG, V97, P1037, DOI 10.1016/j.athoracsur.2013.10.042; Yang W, 2001, ONCOGENE, V20, P1688, DOI 10.1038/sj.onc.1204245; Zeng Y, 2002, MOL CELL, V9, P1327, DOI 10.1016/S1097-2765(02)00541-5; Zhang H, 2002, CANCER, V95, P896, DOI 10.1002/cncr.10751; Zhang JH, 2013, INT J BUS SOC RES, V3, P124; Zheng F, 2012, GUT, V61, P278, DOI 10.1136/gut.2011.239145	51	31	33	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 11	2016	35	6					691	701		10.1038/onc.2014.469	http://dx.doi.org/10.1038/onc.2014.469			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DE0RF	25639871	Green Published, Green Accepted, hybrid			2022-12-17	WOS:000370331300003
J	Hu, F; Deng, X; Yang, X; Jin, H; Gu, D; Lv, X; Wang, C; Zhang, Y; Huo, X; Shen, Q; Luo, Q; Zhao, F; Ge, T; Zhao, F; Chu, W; Shu, H; Yao, M; Fan, J; Qin, W				Hu, F.; Deng, X.; Yang, X.; Jin, H.; Gu, D.; Lv, X.; Wang, C.; Zhang, Y.; Huo, X.; Shen, Q.; Luo, Q.; Zhao, F.; Ge, T.; Zhao, F.; Chu, W.; Shu, H.; Yao, M.; Fan, J.; Qin, W.			Hypoxia upregulates Rab11-family interacting protein 4 through HIF-1 alpha to promote the metastasis of hepatocellular carcinoma	ONCOGENE			English	Article							INDUCIBLE FACTORS; RAB11; TARGET; PRAS40; AKT; DIFFERENTIATION; PROLIFERATION; MECHANISMS; TRANSPORT; FAMILY	Hypoxic microenvironment is a powerful driving force for the invasion and metastasis of hepatocellular carcinoma (HCC). Hypoxia-inducible factor 1 alpha (HIF-1 alpha), as a crucial regulator of transcriptional responses to hypoxia, induces the expression of multiple target genes involved in different steps of HCC metastatic process. It is critical to find target genes associated with metastasis under hypoxia for shedding new light on molecular mechanism of HCC metastasis. In this study, we uncovered that hypoxia could induce the upregulation of Rab11-family interacting protein 4 (Rab11-FIP4) and activation of Rab11-FIP4 promoter by HIF-1a. The overexpression of Rab11-FIP4 significantly enhanced the mobility and invasiveness of HCC cells in vitro, also contributed to distant lung metastasis in vivo, whereas silencing of Rab11-FIP4 decreased the ability of migration and invasion in HCC cells in vitro and suppressed lung metastasis in vivo. Rab11-FIP4 facilitated HCC metastasis through the phosphorylation of PRAS40, which was regulated by mTOR. Furthermore, the expression level of Rab11-FIP4 was significantly increased in HCC tissues and high expression of Rab11-FIP4 was closely correlated with vascular invasion and poor prognosis in HCC patients. A markedly positive correlation between the expression of Rab11-FIP4 and HIF-1 alpha was observed in HCC tissues and combination of Rab11-FIP4 and HIF-1 alpha was a more valuable predictor of poor prognosis for HCC patients. In conclusion, Rab11-FIP4 is a target gene of HIF-1 alpha and has a pro-metastatic role in HCC, suggesting that Rab11-FIP4 may be a promising candidate target for HCC treatment.	[Hu, F.; Deng, X.; Ge, T.] Fudan Univ, Shanghai Med Coll, Shanghai 200433, Peoples R China; [Hu, F.; Deng, X.; Jin, H.; Gu, D.; Wang, C.; Zhang, Y.; Huo, X.; Shen, Q.; Luo, Q.; Ge, T.; Zhao, F.; Chu, W.; Shu, H.; Yao, M.; Qin, W.] Shanghai Jiao Tong Univ, Sch Med, Renji Hosp, State Key Lab Oncogenes & Related Genes,Shanghai, Shanghai 200032, Peoples R China; [Yang, X.; Fan, J.] Zhongshan Hosp, Chinese Minist Educ, Liver Canc Inst, Key Lab Carcinogenesis & Canc Invas, Shanghai, Peoples R China; [Yang, X.; Fan, J.] Fudan Univ, Shanghai Med Coll, Shanghai 200433, Peoples R China; [Gu, D.] Guangdong Med Coll, Dept Pathophysiol, Dongguan, Peoples R China; [Lv, X.; Zhao, F.] Nantong Univ, Coll Med, Basic Med Res Ctr, Nantong, Peoples R China	Fudan University; Shanghai Jiao Tong University; Fudan University; Fudan University; Guangdong Medical University; Nantong University	Qin, W (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Renji Hosp, State Key Lab Oncogenes & Related Genes,Shanghai, 25 Ln 2200 Xie Tu Rd, Shanghai 200032, Peoples R China.	jiafan99@yahoo.com; wxqin@sjtu.edu.cn		Xu, Changlong/0000-0001-7104-9029	National Key Sci-Tech Special Project of China [2012ZX10002011-004]; National Natural Science Foundation of China [81201627, 81371883]; Shanghai Municipal Program of International Cooperation in Science and Technology [12410709800]; Research Fund for the Doctoral Program of Higher Education of China [20120073110091]; Key Basic Research Program of Shanghai Committee of Science and Technology [11JC1412201]; State Key Laboratory of Oncogenes and Related Genes [91-1201, 91-1305]; Doctoral Innovation Fund of Shanghai Jiao Tong University School of Medicine [BXJ201243]; Key Discipline and Specialty Foundation of Shanghai Municipal Commission of Health and Family Planning	National Key Sci-Tech Special Project of China; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Shanghai Municipal Program of International Cooperation in Science and Technology; Research Fund for the Doctoral Program of Higher Education of China(Research Fund for the Doctoral Program of Higher Education of China (RFDP)Specialized Research Fund for the Doctoral Program of Higher Education (SRFDP)); Key Basic Research Program of Shanghai Committee of Science and Technology; State Key Laboratory of Oncogenes and Related Genes; Doctoral Innovation Fund of Shanghai Jiao Tong University School of Medicine; Key Discipline and Specialty Foundation of Shanghai Municipal Commission of Health and Family Planning	This work was supported by grants from National Key Sci-Tech Special Project of China (2012ZX10002011-004), National Natural Science Foundation of China (81201627 and 81371883), Shanghai Municipal Program of International Cooperation in Science and Technology (12410709800), Research Fund for the Doctoral Program of Higher Education of China (20120073110091), Key Basic Research Program of Shanghai Committee of Science and Technology (11JC1412201), Grant from the State Key Laboratory of Oncogenes and Related Genes (91-1201, 91-1305), Doctoral Innovation Fund of Shanghai Jiao Tong University School of Medicine (BXJ201243) and Key Discipline and Specialty Foundation of Shanghai Municipal Commission of Health and Family Planning.	Aravalli RN, 2008, HEPATOLOGY, V48, P2047, DOI 10.1002/hep.22580; Bertout JA, 2008, NAT REV CANCER, V8, P967, DOI 10.1038/nrc2540; Chen W, 1998, MOL BIOL CELL, V9, P3241, DOI 10.1091/mbc.9.11.3241; Deneka M, 2002, NAT CELL BIOL, V4, pE33, DOI 10.1038/ncb0202-e33; Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516; Fielding AB, 2005, EMBO J, V24, P3389, DOI 10.1038/sj.emboj.7600803; Forner A, 2012, LANCET, V379, P1245, DOI 10.1016/S0140-6736(11)61347-0; Hernandez-Gea V, 2013, GASTROENTEROLOGY, V144, P512, DOI 10.1053/j.gastro.2013.01.002; Horgan CP, 2009, BIOCHEM SOC T, V37, P1032, DOI 10.1042/BST0371032; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI [10.3322/caac.20107, 10.3322/caac.20115]; Krzyzaniak MA, 2009, TRAFFIC, V10, P1439, DOI 10.1111/j.1600-0854.2009.00967.x; Lee JW, 2004, EXP MOL MED, V36, P1, DOI 10.1038/emm.2004.1; Majmundar AJ, 2010, MOL CELL, V40, P294, DOI 10.1016/j.molcel.2010.09.022; Maxwell PH, 2001, CURR OPIN GENET DEV, V11, P293, DOI 10.1016/S0959-437X(00)00193-3; Meyers JM, 2002, J BIOL CHEM, V277, P49003, DOI 10.1074/jbc.M205728200; Muto A, 2006, DEV BIOL, V292, P90, DOI 10.1016/j.ydbio.2005.12.050; Muto A, 2007, DEV DYNAM, V236, P214, DOI 10.1002/dvdy.21009; Nagase T, 2001, DNA RES, V8, P319, DOI 10.1093/dnares/8.6.319; Nascimento Emmani B. M., 2009, Archives of Physiology and Biochemistry, V115, P163, DOI 10.1080/13813450902988580; Oshiro N, 2007, J BIOL CHEM, V282, P20329, DOI 10.1074/jbc.M702636200; Portolani N, 2006, ANN SURG, V243, P229, DOI 10.1097/01.sla.0000197706.21803.a1; Prekeris R, 2001, J BIOL CHEM, V276, P38966, DOI 10.1074/jbc.M106133200; Semenza GL, 2010, ONCOGENE, V29, P625, DOI 10.1038/onc.2009.441; Semenza GL, 2001, CURR OPIN CELL BIOL, V13, P167, DOI 10.1016/S0955-0674(00)00194-0; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Semenza GL, 2012, TRENDS PHARMACOL SCI, V33, P207, DOI 10.1016/j.tips.2012.01.005; Sullivan R, 2007, CANCER METAST REV, V26, P319, DOI 10.1007/s10555-007-9062-2; Ullrich O, 1996, J CELL BIOL, V135, P913, DOI 10.1083/jcb.135.4.913; Vander Haar E, 2007, NAT CELL BIOL, V9, P316, DOI 10.1038/ncb1547; Wallace DM, 2002, BIOCHEM BIOPH RES CO, V292, P909, DOI 10.1006/bbrc.2002.6736; Wallace DME, 2002, BIOCHEM BIOPH RES CO, V299, P770, DOI 10.1016/S0006-291X(02)02720-1; Wilcke M, 2000, J CELL BIOL, V151, P1207, DOI 10.1083/jcb.151.6.1207; Wiza C, 2012, AM J PHYSIOL-ENDOC M, V302, pE1453, DOI 10.1152/ajpendo.00660.2011; Wu MZ, 2011, MOL CELL, V43, P811, DOI 10.1016/j.molcel.2011.07.012; Wu XZ, 2007, J GASTROEN HEPATOL, V22, P1178, DOI 10.1111/j.1440-1746.2007.04997.x; Xiong XX, 2014, NEUROBIOL DIS, V66, P43, DOI 10.1016/j.nbd.2014.02.006	37	31	34	0	10	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 3	2015	34	49					6007	6017		10.1038/onc.2015.49	http://dx.doi.org/10.1038/onc.2015.49			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CY0RO	25745995				2022-12-17	WOS:000366113500007
J	Yang, Y; Gorzelanny, C; Bauer, AT; Halter, N; Komljenovic, D; Bauerle, T; Borsig, L; Roblek, M; Schneider, SW				Yang, Y.; Gorzelanny, C.; Bauer, A. T.; Halter, N.; Komljenovic, D.; Baeuerle, T.; Borsig, L.; Roblek, M.; Schneider, S. W.			Nuclear heparanase-1 activity suppresses melanoma progression via its DNA-binding affinity	ONCOGENE			English	Article							NF-KAPPA-B; AGGRESSIVE TUMOR PHENOTYPE; ENDOTHELIAL GROWTH-FACTOR; CELL INVASION; NUDE-MICE; RECIPROCAL REGULATION; CLINICAL-SIGNIFICANCE; VASCULAR ENDOTHELIUM; CANCER METASTASIS; CERVICAL-CANCER	Heparanase-1 (HPSE) plays a pivotal role in structural remodeling of the ECM and the glycocalyx, thus conferring protumorigenic, proangiogenic and prometastatic properties to many cancer entities. In addition to its extracellular function, recent studies suggest an intracellular activity of HPSE with a largely unknown significance during tumor progression. Therefore, we investigated the relevance of the dual functions of HPSE to malignant melanoma in vitro, as well as in different mouse melanoma models based on the intradermal or intravenous injection of melanoma cells. Consistent with its extracellular action, an HPSE deficiency led to a reduced shedding of the glycocalyx accompanied by a reduced availability of vascular endothelial growth factor, affecting tumor growth and vascularization. In contrast, we measured an elevated expression of the protumorigenic factors pentraxin-3, tissue factor, TNF-alpha and most prominently, MMP-9, upon HPSE knockdown. In vivo, an HPSE deficiency was related to increased lymph node metastasis. Since the inhibition of its extracellular function with heparin was unable to block the gene regulatory impact of HPSE, we proposed an intracellular mechanism. Immunostaining revealed a counter-staining of HPSE and NF-kappa B in the nucleus, suggesting a close relationship between both proteins. This finding was further supported by the discovery of a direct charge-driven molecular interaction between HPSE and DNA by using atomic force microscopy and a co-precipitation approach. Our findings are novel and point towards a dual function for HPSE in malignant melanoma with a protumorigenic extracellular activity and a tumor-suppressive nuclear action. The identification of molecular strategies to shuttle extracellular HPSE into the nuclei of cancer cells could provide new therapeutic options.	[Yang, Y.; Gorzelanny, C.; Bauer, A. T.; Halter, N.; Schneider, S. W.] Heidelberg Univ, Med Fac Mannheim, Dept Dermatol Expt Dermatol, D-68167 Mannheim, Germany; [Komljenovic, D.] German Canc Res Ctr, Div Med Phys Radiol, Heidelberg, Germany; [Baeuerle, T.] Univ Hosp Erlangen, Inst Radiol, Erlangen, Germany; [Borsig, L.; Roblek, M.] Univ Zurich, Inst Physiol, Zurich, Switzerland; [Borsig, L.; Roblek, M.] Univ Zurich, Zurich Ctr Integrat Human Physiol, Zurich, Switzerland	Ruprecht Karls University Heidelberg; Helmholtz Association; German Cancer Research Center (DKFZ); University of Erlangen Nuremberg; University of Zurich; University of Zurich; Zurich Center Integrative Human Physiology (ZIHP)	Schneider, SW (corresponding author), Heidelberg Univ, Med Fac Mannheim, Dept Dermatol Expt Dermatol, Theodor Kutzer Ufer 1-3, D-68167 Mannheim, Germany.	stefan.schneider@medma.uni-heidelberg.de		Borsig, Lubor/0000-0003-2263-9545; Bauerle, Tobias/0000-0002-0206-6199	Deutsche Forschungsgemeinschaft [SFB/Transregio 23]	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG))	We thank Katja Oehme for the excellent technical help and advice in dynamic contrast-enhanced magnetic resonance imaging experiments. We acknowledge Prof. Viktor Umansky (Skin Cancer Unit, German Cancer Research Center (DKFZ), Heidelberg and Department of Dermatology, Venereology and Allergology, University Medical Center Mannheim, Ruprecht-Karl University of Heidelberg, Mannheim, Germany) for providing a melanoma cell line from ret transgenic mice. This work was supported by the Deutsche Forschungsgemeinschaft within the SFB/Transregio 23 (project A9 to SWS, project Z1 to DK).	Andela VB, 2000, CANCER RES, V60, P6557; AUBERT C, 1980, J NATL CANCER I, V64, P1029; Barash U, 2010, FEBS J, V277, P3890, DOI 10.1111/j.1742-4658.2010.07799.x; Basile A, 1997, J BIOL CHEM, V272, P8172, DOI 10.1074/jbc.272.13.8172; Bauer AT, 2010, J CEREBR BLOOD F MET, V30, P837, DOI 10.1038/jcbfm.2009.248; Bond M, 1998, FEBS LETT, V435, P29, DOI 10.1016/S0014-5793(98)01034-5; Borczuk AC, 2008, ONCOGENE, V27, P557, DOI 10.1038/sj.onc.1210662; Boyango I, 2014, CANCER RES, V74, P4504, DOI 10.1158/0008-5472.CAN-13-2962; BRIX G, 1991, J COMPUT ASSIST TOMO, V15, P621, DOI 10.1097/00004728-199107000-00018; Cao HJ, 2005, WORLD J GASTROENTERO, V11, P903, DOI 10.3748/wjg.v11.i6.903; Carrer A, 2012, CANCER RES, V72, P6371, DOI 10.1158/0008-5472.CAN-12-0762; Cohen-Kaplan V, 2012, J BIOL CHEM, V287, P6668, DOI 10.1074/jbc.M111.271346; Coward WR, 2002, J IMMUNOL, V169, P5287, DOI 10.4049/jimmunol.169.9.5287; Desch A, 2012, AM J PATHOL, V181, P693, DOI 10.1016/j.ajpath.2012.04.012; Doweck I, 2006, NEOPLASIA, V8, P1055, DOI 10.1593/neo.06577; Elkin M, 2001, FASEB J, V15, P1661, DOI 10.1096/fj.00-0895fje; Fairbrother WJ, 1998, STRUCT FOLD DES, V6, P637, DOI 10.1016/S0969-2126(98)00065-3; Farina AR, 1999, CELL GROWTH DIFFER, V10, P353; GEKLE M, 1994, PFLUG ARCH EUR J PHY, V428, P157, DOI 10.1007/BF00374853; Gingis-Velitski S, 2004, J BIOL CHEM, V279, P23536, DOI 10.1074/jbc.M400554200; Goerge T, 2006, CANCER RES, V66, P7766, DOI 10.1158/0008-5472.CAN-05-3897; Gorzelanny C, 2007, BIOMACROMOLECULES, V8, P3035, DOI 10.1021/bm0703214; HART IR, 1979, AM J PATHOL, V97, P587; Hong X, 2012, INT J ONCOL, V40, P494, DOI 10.3892/ijo.2011.1229; Hostettler N, 2007, FASEB J, V21, P3562, DOI 10.1096/fj.07-8450com; Ilan N, 2006, INT J BIOCHEM CELL B, V38, P2018, DOI 10.1016/j.biocel.2006.06.004; Jain RK, 2001, NAT MED, V7, P987, DOI 10.1038/nm0901-987; Kashani-Sabet M, 2004, J CLIN ONCOL, V22, P617, DOI 10.1200/JCO.2004.06.047; Kelly T, 2003, CANCER RES, V63, P8749; Kerk N, 2010, J INVEST DERMATOL, V130, P2259, DOI 10.1038/jid.2010.136; Liu XY, 2013, INT J BIOL SCI, V9, P564, DOI 10.7150/ijbs.5425; Liu XY, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038659; Ludwig T, 2002, AM J PHYSIOL-RENAL, V283, pF319, DOI 10.1152/ajprenal.00327.2001; Merz M, 2011, EUR J CANCER, V47, P277, DOI 10.1016/j.ejca.2010.08.019; Micheau O, 2003, CELL, V114, P181, DOI 10.1016/S0092-8674(03)00521-X; Murphy G, 2008, MOL ASPECTS MED, V29, P290, DOI 10.1016/j.mam.2008.05.002; Niwa Y, 2001, CLIN CANCER RES, V7, P285; OETH PA, 1994, MOL CELL BIOL, V14, P3772, DOI 10.1128/MCB.14.6.3772; Purushothaman A, 2008, J BIOL CHEM, V283, P32628, DOI 10.1074/jbc.M806266200; Purushothaman A, 2011, J BIOL CHEM, V286, P30377, DOI 10.1074/jbc.M111.254789; Roy M, 2005, NEOPLASIA, V7, P253, DOI 10.1593/neo.04493; Roy M, 2009, J CELL BIOCHEM, V106, P200, DOI 10.1002/jcb.22005; Sato T, 2004, J SURG ONCOL, V87, P174, DOI 10.1002/jso.20097; Schnaeker EM, 2004, CANCER RES, V64, P8924, DOI 10.1158/0008-5472.CAN-04-0324; Schubert SY, 2004, LAB INVEST, V84, P535, DOI 10.1038/labinvest.3700084; Shinyo Y, 2003, ANN ONCOL, V14, P1505, DOI 10.1093/annonc/mdg407; Strozyk EA, 2014, EXP DERMATOL, V23, P670, DOI 10.1111/exd.12505; VANMUIJEN GNP, 1991, INT J CANCER, V48, P85; VANMUIJEN GNP, 1991, CLIN EXP METASTAS, V9, P259, DOI 10.1007/BF01753729; VLODAVSKY I, 1994, INVAS METAST, V14, P290; Vlodavsky I, 1996, CANCER METAST REV, V15, P177, DOI 10.1007/BF00437470; Vlodavsky I, 2006, PATHOPHYSIOL HAEMO T, V35, P116, DOI 10.1159/000093553; Wu WJ, 2010, ONCOL REP, V23, P255, DOI 10.3892/or_00000631; Zak J, 2000, PFLUG ARCH EUR J PHY, V440, P179, DOI 10.1007/s004240000282; Zcharia E, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005181; Zetser A, 2006, CANCER RES, V66, P1455, DOI 10.1158/0008-5472.CAN-05-1811; Zhao F, 2009, CLIN CANCER RES, V15, P4382, DOI 10.1158/1078-0432.CCR-09-0399; Zong F, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007346	58	31	33	1	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 19	2015	34	47					5832	5842		10.1038/onc.2015.40	http://dx.doi.org/10.1038/onc.2015.40			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CW5KV	25745999	Green Accepted			2022-12-17	WOS:000365035200006
J	Sanchez-Tillo, E; de Barrios, O; Valls, E; Darling, DS; Castells, A; Postigo, A				Sanchez-Tillo, E.; de Barrios, O.; Valls, E.; Darling, D. S.; Castells, A.; Postigo, A.			ZEB1 and TCF4 reciprocally modulate their transcriptional activities to regulate Wnt target gene expression	ONCOGENE			English	Article							APC TUMOR-SUPPRESSOR; VITAMIN-D-RECEPTOR; BETA-CATENIN; MESENCHYMAL TRANSITION; COLORECTAL-CANCER; COREPRESSOR CTBP; E-CADHERIN; REPRESSION; ACTIVATION; INVASIVENESS	The canonical Wnt pathway (TCF4/beta-catenin) has important roles during normal differentiation and in disease. Some Wnt functions depend on signaling gradients requiring the pathway to be tightly regulated. A key Wnt target is the transcription factor ZEB1 whose expression by cancer cells promotes tumor invasiveness by repressing the expression of epithelial specification markers and activating mesenchymal genes, including a number of Wnt targets such as LAMC2 and uPA. The ability of ZEB1 to activate/repress its target genes depends on its recruitment of corepressors (CtBP, BRG1) or coactivators (p300) although conditions under which ZEB1 binds these cofactors are not elucidated. Here, we show that TCF4 and ZEB1 reciprocally modulate each other's transcriptional activity: ZEB1 enhances TCF4/beta-catenin-mediated transcription and, in turn, Wnt signaling switches ZEB1 from a repressor into an activator. In colorectal cancer (CRC) cells with active Wnt signaling, ZEB1 enhances transcriptional activation of LAMC2 and uPA by TCF4/beta-catenin. However, in CRC cells with inactive Wnt, ZEB1 represses both genes. Reciprocal modulation of ZEB1 and TCF4 activities involves their binding to DNA and mutual interaction. Wnt signaling turns ZEB1 into an activator by replacing binding of CtBP/BRG1 in favor of p300. Using a mouse model of Wnt-induced intestinal tumorigenesis, we found that downregulation of ZEB1 reduces the expression of LAMC2 in vivo. These results identify a mechanism through which Wnt and ZEB1 transcriptional activities are modulated, offering new approaches in cancer therapy.	[Sanchez-Tillo, E.; de Barrios, O.; Valls, E.; Postigo, A.] IDIBAPS, Dept Hematol & Oncol, Grp Transcript Regulat Gene Express, Barcelona, Spain; [Darling, D. S.] Univ Louisville, Dept Oral Immunol & Infect Dis, Louisville, KY 40292 USA; [Darling, D. S.] Univ Louisville, Ctr Genet & Mol Med, Louisville, KY 40292 USA; [Castells, A.] Hosp Clin Barcelona, Inst Metab & Digest Dis, Barcelona, Spain; [Castells, A.; Postigo, A.] Carlos III Hlth Inst ISCIII, Biomed Res Networking Ctr Hepat & Digest Dis CIBE, Gastrointestinal & Pancreat Oncol Team, Barcelona, Spain; [Postigo, A.] Univ Louisville, James Graham Brown Canc Ctr, Louisville, KY 40292 USA; [Postigo, A.] ICREA, Barcelona, Spain	University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; University of Louisville; University of Louisville; University of Barcelona; Hospital Clinic de Barcelona; CIBER - Centro de Investigacion Biomedica en Red; CIBEREHD; University of Louisville; ICREA	Postigo, A (corresponding author), Univ Barcelona, Sch Med, Dept Hematol & Oncol, IDIBAPS,Grp Transcript Regulat Gene Express, Cellex 1B,Casanova 143, E-08036 Barcelona, Spain.	idib412@clinic.ub.es	Darling, Douglas S/D-4573-2009; de Barrios, Oriol/AAO-6319-2021; Castells, Antoni/ABC-1002-2021	Castells, Antoni/0000-0001-8431-2033; Postigo, Antonio/0000-0003-4605-2634; de Barrios, Oriol/0000-0001-5076-1455; Darling, Douglas/0000-0002-9039-1169	Fundacio La Marato de TV3 [201330.10]; Ministry of Economy and Competitiveness [BFU2010-15163, SAF2014-52874-R]; Leukemia Research Foundation; Academy of Medical and Health Sciences of Catalonia; Balearic Islands, Avon Cosmetics S.A.U. (ACSAU); Catalan Agency for Management of University and Research Grants [AGAUR, 2014-SGR-475]; European Commission of the European Union; Olga Torres Foundation; La Caixa Foundation (LCF); Spanish Association Against Cancer; LCF; CIBERehd; ACSAU; Miguel Servet contract from Instituto de Salud Carlos III [MS13/00200]; Ministry of Education, Culture and Sports (FPU Program) [AP2010-5489]; ICREA Funding Source: Custom	Fundacio La Marato de TV3; Ministry of Economy and Competitiveness; Leukemia Research Foundation; Academy of Medical and Health Sciences of Catalonia; Balearic Islands, Avon Cosmetics S.A.U. (ACSAU); Catalan Agency for Management of University and Research Grants; European Commission of the European Union; Olga Torres Foundation; La Caixa Foundation (LCF); Spanish Association Against Cancer; LCF; CIBERehd; ACSAU; Miguel Servet contract from Instituto de Salud Carlos III(Instituto de Salud Carlos III); Ministry of Education, Culture and Sports (FPU Program); ICREA(ICREA)	We are grateful to all researchers who provided us with reagents (see Materials and Methods and Supplementary Materials and Methods) and apologize to those whose work was cited indirectly through reviews owing to space limitations. This work was developed in the Centre de Recerca Biomedica Cellex at IDIBAPS. The different parts of this study were independently funded by grants to AP from Fundacio La Marato de TV3 (201330.10), Ministry of Economy and Competitiveness (BFU2010-15163 and SAF2014-52874-R), Leukemia Research Foundation, Academy of Medical and Health Sciences of Catalonia and the Balearic Islands, Avon Cosmetics S.A.U. (ACSAU), Catalan Agency for Management of University and Research Grants (AGAUR, 2014-SGR-475), European Commission of the European Union, Olga Torres Foundation, La Caixa Foundation (LCF), Spanish Association Against Cancer. EST's salary was subsequently funded by grants from LCF, CIBERehd, ACSAU, and a Miguel Servet contract (MS13/00200) from Instituto de Salud Carlos III. OdB is recipient of a PhD scholarship from the Ministry of Education, Culture and Sports (FPU Program, AP2010-5489).	Aigner K, 2007, ONCOGENE, V26, P6979, DOI 10.1038/sj.onc.1210508; Barker N, 1999, AM J PATHOL, V154, P29, DOI 10.1016/S0002-9440(10)65247-9; Battaglioli E, 2002, J BIOL CHEM, V277, P41038, DOI 10.1074/jbc.M205691200; Brabletz T, 2001, P NATL ACAD SCI USA, V98, P10356, DOI 10.1073/pnas.171610498; Chinnadurai G, 2009, CANCER RES, V69, P731, DOI 10.1158/0008-5472.CAN-08-3349; Clevers H, 2012, CELL, V149, P1192, DOI 10.1016/j.cell.2012.05.012; Daniels DL, 2005, NAT STRUCT MOL BIOL, V12, P364, DOI 10.1038/nsmb912; Dano K, 2005, THROMB HAEMOSTASIS, V93, P676, DOI 10.1160/TH05-01-0054; Gilles C, 2003, CANCER RES, V63, P2658; Gradl D, 1999, MOL CELL BIOL, V19, P5576; Hiendlmeyer E, 2004, CANCER RES, V64, P1209, DOI 10.1158/0008-5472.CAN-3627-2; Hlubek F, 2001, CANCER RES, V61, P8089; Hlubek F, 2007, INT J CANCER, V121, P1941, DOI 10.1002/ijc.22916; Hu MC, 2005, DEVELOPMENT, V132, P215, DOI 10.1242/dev.01573; Kiecker C, 2001, DEVELOPMENT, V128, P4189; Koshikawa N, 2000, J CELL BIOL, V148, P615, DOI 10.1083/jcb.148.3.615; Lamouille S, 2014, NAT REV MOL CELL BIO, V15, P178, DOI 10.1038/nrm3758; Leclerc D, 2004, J CELL BIOCHEM, V93, P1242, DOI 10.1002/jcb.20236; Lien WH, 2014, GENE DEV, V28, P1517, DOI 10.1101/gad.244772.114; Luis TC, 2011, CELL STEM CELL, V9, P345, DOI 10.1016/j.stem.2011.07.017; Maretto S, 2003, P NATL ACAD SCI USA, V100, P3299, DOI 10.1073/pnas.0434590100; Markowitz SD, 2009, NEW ENGL J MED, V361, P2449, DOI 10.1056/NEJMra0804588; Memezawa A, 2007, ONCOGENE, V26, P5038, DOI 10.1038/sj.onc.1210320; Moore AC, 2008, MOL CELL BIOL, V28, P977, DOI 10.1128/MCB.01242-07; MOSER AR, 1990, SCIENCE, V247, P322, DOI 10.1126/science.2296722; Nateri AS, 2005, NATURE, V437, P281, DOI 10.1038/nature03914; Palmer HG, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001483; Pena C, 2006, INT J CANCER, V119, P2098, DOI 10.1002/ijc.22083; Perissi V, 2010, NAT REV GENET, V11, P109, DOI 10.1038/nrg2736; Postigo AA, 2003, EMBO J, V22, P2453, DOI 10.1093/emboj/cdg226; Postigo AA, 2003, EMBO J, V22, P2443, DOI 10.1093/emboj/cdg225; Postigo AA, 1997, EMBO J, V16, P3924, DOI 10.1093/emboj/16.13.3924; Postigo AA, 1999, P NATL ACAD SCI USA, V96, P6683, DOI 10.1073/pnas.96.12.6683; Rosin-Arbesfeld R, 2000, NATURE, V406, P1009, DOI 10.1038/35023016; Sanchez-Tillo E, 2010, ONCOGENE, V29, P3490, DOI 10.1038/onc.2010.102; Sanchez-Tillo E, 2013, CLIN CANCER RES, V19, P1071, DOI 10.1158/1078-0432.CCR-12-2675; Sanchez-Tillo E, 2012, CELL MOL LIFE SCI, V69, P3429, DOI 10.1007/s00018-012-1122-2; Sanchez-Tillo E, 2011, P NATL ACAD SCI USA, V108, P19204, DOI 10.1073/pnas.1108977108; Sanchez-Tillo E, 2011, AM J CANCER RES, V1, P897; Sierra J, 2006, GENE DEV, V20, P586, DOI 10.1101/gad.1385806; Siles L, 2013, MOL CELL BIOL, V33, P1368, DOI 10.1128/MCB.01259-12; Sinner D, 2004, DEVELOPMENT, V131, P3069, DOI 10.1242/dev.01176; Spaderna S, 2006, GASTROENTEROLOGY, V131, P830, DOI 10.1053/j.gastro.2006.06.016; Takagi T, 1998, DEVELOPMENT, V125, P21; Vermeulen L, 2010, NAT CELL BIOL, V12, P468, DOI 10.1038/ncb2048; Verzi MP, 2010, P NATL ACAD SCI USA, V107, P15157, DOI 10.1073/pnas.1003822107; Wang JX, 2007, NATURE, V446, P882, DOI 10.1038/nature05671; Yuan Y, 2014, BIORESOURCE TECHNOL, V174, P1, DOI 10.1016/j.biortech.2014.07.104; Zhang OH, 2003, CELL, V115, P177, DOI 10.1016/S0092-8674(03)00802-X	49	31	33	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 12	2015	34	46					5760	5770		10.1038/onc.2015.352	http://dx.doi.org/10.1038/onc.2015.352			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CV9GC	26387539				2022-12-17	WOS:000364594600008
J	Bikkavilli, RK; Avasarala, S; Van Scoyk, M; Arcaroli, J; Brzezinski, C; Zhang, W; Edwards, M; Rathinam, MKK; Zhou, T; Tauler, J; Borowicz, S; Lussier, Y; Parr, BA; Cool, CD; Winn, RA				Bikkavilli, R. K.; Avasarala, S.; Van Scoyk, M.; Arcaroli, J.; Brzezinski, C.; Zhang, W.; Edwards, M. G.; Rathinam, M. K. K.; Zhou, T.; Tauler, J.; Borowicz, S.; Lussier, Y. A.; Parr, B. A.; Cool, C. D.; Winn, R. A.			Wnt7a is a novel inducer of beta-catenin-independent tumor-suppressive cellular senescence in lung cancer	ONCOGENE			English	Article							ATYPICAL ADENOMATOUS HYPERPLASIA; ONCOGENIC RAS; CELLS; SKP2; ACTIVATION; INACTIVATION; ACCUMULATION; PROGRESSION; REGULATOR; LIGASE	Cellular senescence is an initial barrier for carcinogenesis. However, the signaling mechanisms that trigger cellular senescence are incompletely understood, particularly in vivo. Here we identify Wnt7a as a novel upstream inducer of cellular senescence. In two different mouse strains (C57Bl/6J and FVB/NJ), we show that the loss of Wnt7a is a major contributing factor for increased lung tumorigenesis owing to reduced cellular senescence, and not reduced apoptosis, or autophagy. Wnt7a-null mice under de novo conditions and in both the strains display E-cadherin-to-N-cadherin switch, reduced expression of cellular senescence markers and reduced expression of senescence-associated secretory phenotype, indicating a genetic predisposition of these mice to increased carcinogen-induced lung tumorigenesis. Interestingly, Wnt7a induced an alternate senescence pathway, which was independent of beta-catenin, and distinct from that of classical oncogene-induced senescence mediated by the well-known p16(INK4a) and p19(ARF) pathways. Mechanistically, Wnt7a induced cellular senescence via inactivation of S-phase kinase-associated protein 2, an important alternate regulator of cellular senescence. Additionally, we identified Iloprost, a prostacyclin analog, which initiates downstream signaling cascades similar to that of Wnt7a, as a novel inducer of cellular senescence, presenting potential future clinical translational strategies. Thus pro-senescence therapies using either Wnt7a or its mimic, Iloprost, might represent a new class of therapeutic treatments for lung cancer.	[Bikkavilli, R. K.; Avasarala, S.; Van Scoyk, M.; Brzezinski, C.; Rathinam, M. K. K.; Zhou, T.; Tauler, J.; Winn, R. A.] Univ Illinois, Dept Pulm Crit Care Sleep & Allergy, Chicago, IL USA; [Arcaroli, J.] Univ Colorado, Sch Med, Div Med Oncol, Aurora, CO USA; [Zhang, W.] Univ Illinois, Coll Med, Dept Pediat, Chicago, IL USA; [Edwards, M. G.] Univ Colorado, Sch Med, Div Pulm Sci & Crit Care Med, Aurora, CO USA; [Edwards, M. G.] Univ Illinois, Coll Med, Dept Hematol & Oncol, Chicago, IL USA; [Lussier, Y. A.] Univ Arizona, Ctr Canc, Tucson, AZ USA; [Parr, B. A.] Albany State Univ, Ctr Funct Gen, Rensselaer, NY USA; [Cool, C. D.] Univ Colorado, Sch Med, Dept Pathol, Aurora, CO USA; [Winn, R. A.] Jesse Brown Vet Affairs Med Ctr, Chicago, IL USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Arizona; University of Colorado System; University of Colorado Anschutz Medical Campus; US Department of Veterans Affairs; Veterans Health Administration (VHA); Jesse Brown VA Medical Center	Winn, RA (corresponding author), Univ Illinois, Dept Pulm Crit Care Sleep & Allergy, Coll Med Res Bldg, Chicago, IL USA.	rwinn@uic.edu	Lussier, Yves/N-4891-2017	Lussier, Yves/0000-0001-9854-1005	US Department of Veterans Affairs; NIH [R01CA138528]; NATIONAL CANCER INSTITUTE [P50CA058187, P30CA046934, R01CA138528] Funding Source: NIH RePORTER	US Department of Veterans Affairs(US Department of Veterans Affairs); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We are immensely grateful to Dr Judith Campisi (Buck Institute for Research on Aging) for her critical reading of this manuscript. We thank Dr Bifeng Gao, Katrina Diener and Dr Ken Jones of the Genomics and Microarray core, University of Colorado Denver, for their expert help in RNA sequencing. We also thank Dr Meredith Tennis, Dr Lora Wilson, Marybeth Sechler and Nicole Kelley for their helpful suggestions on this manuscript. This study was supported by a Merit Award from the US Department of Veterans Affairs and NIH grants R01CA138528 to RW.	Alimonti A, 2010, J CLIN INVEST, V120, P681, DOI 10.1172/JCI40535; Angers S, 2009, NAT REV MOL CELL BIO, V10, P468, DOI 10.1038/nrm2717; Baek KH, 2013, J CLIN INVEST, V123, P4375, DOI 10.1172/JCI67465; Bikkavilli RK, 2008, J CELL SCI, V121, P3598, DOI 10.1242/jcs.032854; Bitler BG, 2011, CANCER RES, V71, P6184, DOI 10.1158/0008-5472.CAN-11-1341; Braig M, 2005, NATURE, V436, P660, DOI 10.1038/nature03841; Bringold F, 2000, EXP GERONTOL, V35, P317, DOI 10.1016/S0531-5565(00)00083-8; Campisi J, 2005, SCIENCE, V309, P886, DOI 10.1126/science.1116801; Campisi J, 2013, ANNU REV PHYSIOL, V75, P685, DOI 10.1146/annurev-physiol-030212-183653; Chan CH, 2014, CELL CYCLE, V13, P679, DOI 10.4161/cc.27853; Chan CH, 2013, CELL, V154, P556, DOI 10.1016/j.cell.2013.06.048; Chang J, 2007, J BIOL CHEM, V282, P30938, DOI 10.1074/jbc.M702391200; Collado M, 2005, NATURE, V436, P642, DOI 10.1038/436642a; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; Jho EH, 2002, MOL CELL BIOL, V22, P1172, DOI 10.1128/MCB.22.4.1172-1183.2002; Ji Lin, 2005, Future Oncol, V1, P79, DOI 10.1517/14796694.1.1.79; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Keith RL, 2004, CANCER RES, V64, P5897, DOI 10.1158/0008-5472.CAN-04-1070; Keith RL, 2011, CANCER PREV RES, V4, P793, DOI 10.1158/1940-6207.CAPR-11-0057; Keith RL, 2010, LUNG CANCER, V70, P37, DOI 10.1016/j.lungcan.2010.01.004; Kondratov AG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047012; Kuilman T, 2010, GENE DEV, V24, P2463, DOI 10.1101/gad.1971610; Malbon CC, 2005, NAT REV MOL CELL BIO, V6, P689, DOI 10.1038/nrm1716; Malbon CC, 2004, FRONT BIOSCI-LANDMRK, V9, P1048, DOI 10.2741/1308; Malumbres M, 2000, MOL CELL BIOL, V20, P2915, DOI 10.1128/MCB.20.8.2915-2925.2000; Mikels A, 2009, J BIOL CHEM, V284, P30167, DOI 10.1074/jbc.M109.041715; Mori M, 2001, MODERN PATHOL, V14, P72, DOI 10.1038/modpathol.3880259; Nakayama K, 2000, EMBO J, V19, P2069, DOI 10.1093/emboj/19.9.2069; Nomori H, 2001, JPN J CLIN ONCOL, V31, P514, DOI 10.1093/jjco/hye103; Orjalo AV, 2009, P NATL ACAD SCI USA, V106, P17031, DOI 10.1073/pnas.0905299106; Parr BA, 1998, DEV BIOL, V202, P228, DOI 10.1006/dbio.1998.9007; Polakis P, 1999, CURR OPIN GENET DEV, V9, P15, DOI 10.1016/S0959-437X(99)80003-3; Polakis P, 2000, GENE DEV, V14, P1837; Polakis P, 2007, CURR OPIN GENET DEV, V17, P45, DOI 10.1016/j.gde.2006.12.007; Roberson RS, 2005, CANCER RES, V65, P2795, DOI 10.1158/0008-5472.CAN-04-1270; Rodier Francis, 2013, Methods Mol Biol, V965, P165, DOI 10.1007/978-1-62703-239-1_10; Rodier F, 2011, J CELL BIOL, V192, P547, DOI 10.1083/jcb.201009094; Romanov VS, 2010, CELL CYCLE, V9, P3945, DOI 10.4161/cc.9.19.13160; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Sharpless NE, 2001, NATURE, V413, P86, DOI 10.1038/35092592; Shigemitsu K, 2001, ONCOGENE, V20, P4249, DOI 10.1038/sj.onc.1204557; Tang YX, 2009, MOL CANCER THER, V8, P458, DOI 10.1158/1535-7163.MCT-08-0885; te Poele RH, 2002, CANCER RES, V62, P1876; Tennis M, 2010, NEOPLASIA, V12, P244, DOI 10.1593/neo.91690; Tennis MA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032921; Ueda M, 2001, BRIT J CANCER, V85, P64, DOI 10.1054/bjoc.2001.1863; Vikis Haris G, 2013, Front Biosci (Elite Ed), V5, P939; Wang GC, 2012, CHIN J CANCER, V31, P169, DOI 10.5732/cjc.011.10319; Wang HY, 2003, SCIENCE, V300, P1529, DOI 10.1126/science.1085259; Wang IC, 2005, MOL CELL BIOL, V25, P10875, DOI 10.1128/MCB.25.24.10875-10894.2005; Widelitz R, 2005, GROWTH FACTORS, V23, P111, DOI 10.1080/08977190500125746; Winn RA, 2005, J BIOL CHEM, V280, P19625, DOI 10.1074/jbc.M409392200; Winn RA, 2006, J BIOL CHEM, V281, P26943, DOI 10.1074/jbc.M604145200	55	31	34	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 16	2015	34	42					5317	5328		10.1038/onc.2015.2	http://dx.doi.org/10.1038/onc.2015.2			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CU4EI	25728679	hybrid, Green Accepted, Green Published			2022-12-17	WOS:000363479200002
J	Rivero, S; Ceballos-Chavez, M; Bhattacharya, SS; Reyes, JC				Rivero, S.; Ceballos-Chavez, M.; Bhattacharya, S. S.; Reyes, J. C.			HMG20A is required for SNAI1-mediated epithelial to mesenchymal transition	ONCOGENE			English	Article							E-CADHERIN REPRESSION; CELL-MIGRATION; EXPRESSION; COMPLEX; LSD1; SNAIL; TRANSCRIPTION; MELANOMA; COREST; GENES	HMG20A is a high mobility group (HMG) domain containing protein homologous to HMG20B, a core subunit of the Lys-specific demethylase 1/REST co-repressor 1 (LSD1-CoREST) histone demethylase complex. Here, we show that HMG20A can replace HMG20B and, therefore, they are mutually exclusive subunits of the complex. Both proteins interact through a coiled-coil domain with BHC80, another subunit of the LSD1-CoREST complex. To investigate the functional differences between the two proteins, we performed transcriptomic analysis of HMG20A-and HMG20B-depleted cells. Analysis of the misregulated genes in HMG20A-knockdown cells evidenced a high proportion of genes related to the epithelial-to-mesenchymal transition (EMT) process. EMT occurs during embryonic development or during the course of malignant cancer progression and consists in the dynamic and reversible transitions between epithelial and mesenchymal phenotypes. We show that HMG20A together with LSD1 are required for SNAI1-dependent repression of epithelial genes and for (transforming growth factor beta) TGF-beta-triggered EMT. Importantly, HMG20A-depleted cells displayed reduced binding of LSD1 to epithelial gene promoters and increased methylation of lysine 4 of histone H3, suggesting a role of HMG20A in recruiting or in stabilizing the complex at the chromatin. SNAI1 and the TGF-beta-related transcription factor SMAD4 were found to be associated with the LSD1-CoREST complex containing HMG20A. Furthermore, we show that HMG20A-depleted cells displayed reduced motility and invasion activity. Finally, we show that expression of HMG20A correlates positively with mesenchymal markers and negatively with epithelial markers in human tumor samples. Taken together, our data demonstrate that HMG20A is essential for the mesenchymal phenotype.	[Rivero, S.; Ceballos-Chavez, M.; Reyes, J. C.] CSIC, Dept Mol Biol, Ctr Andaluz Biol Mol & Med Regenerat CABIMER, Seville 41092, Spain; [Bhattacharya, S. S.] Ctr Andaluz Biol Mol & Med Regenerat CABIMER, Cell Therapy & Regenerat Med Dept, Seville, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); Universidad Pablo de Olavide; University of Sevilla; CSIC - Centro Andaluz de Biologia Molecular y Medicina Regenerativa (CABIMER); Consejo Superior de Investigaciones Cientificas (CSIC); Universidad Pablo de Olavide; University of Sevilla; CSIC - Centro Andaluz de Biologia Molecular y Medicina Regenerativa (CABIMER)	Reyes, JC (corresponding author), CSIC, Dept Mol Biol, CABIMER, Ave Americo Vespucio, Seville 41092, Spain.	jose.reyes@cabimer.es	Reyes, Jose C/K-3699-2014	Reyes, Jose C/0000-0002-8042-5142; Rivero, Sabrina/0000-0001-6359-1432	Spanish Ministry of Economy and Competitiveness [BFU-2011-23442]; Juan de la Cierva; Junta de Andalucia [P09-CTS-04967]	Spanish Ministry of Economy and Competitiveness(Spanish Government); Juan de la Cierva(Instituto de Salud Carlos III); Junta de Andalucia(Junta de Andalucia)	We thank L Sumoy, T Baba, A Garcia de Herreros and J Lu for reagents and plasmids. We thank Dr M Garcia-Dominguez and Dr JA Pintor-Toro for critical reading of the manuscript. We thank E Andujar and M Perez from the CABIMER Genomic Unit for microarray expression analysis. The results published here are in part based upon data generated by the TCGA Research Network: http://cancergenome.nih.gov/. This work was funded by the Spanish Ministry of Economy and Competitiveness [BFU-2011-23442 to JCR] and a Juan de la Cierva grant to SR and by Junta de Andalucia (P09-CTS-04967 to SSB).	Nieto MA, 2013, SCIENCE, V342, P708, DOI 10.1126/science.1234850; Nieto MA, 2011, ANNU REV CELL DEV BI, V27, P347, DOI 10.1146/annurev-cellbio-092910-154036; Barbera MJ, 2004, ONCOGENE, V23, P7345, DOI 10.1038/sj.onc.1207990; Barbieri CE, 2012, NAT GENET, V44, P685, DOI 10.1038/ng.2279; Barrallo-Gimeno A, 2005, DEVELOPMENT, V132, P3151, DOI 10.1242/dev.01907; Barretina J, 2010, NAT GENET, V42, P715, DOI 10.1038/ng.619; Ceballos-Chavez M, 2012, P NATL ACAD SCI US; Colland F, 2004, GENOME RES, V14, P1324, DOI 10.1101/gr.2334104; Creighton CJ, 2013, NATURE, V499, P43, DOI 10.1038/nature12222; Dong CF, 2012, J CLIN INVEST, V122, P1469, DOI 10.1172/JCI57349; Ferrari-Amorotti G, 2013, CANCER RES, V73, P235, DOI 10.1158/0008-5472.CAN-12-1739; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Gordon GJ, 2005, AM J PATHOL, V166, P1827, DOI 10.1016/S0002-9440(10)62492-3; Hakimi MA, 2002, P NATL ACAD SCI USA, V99, P7420, DOI 10.1073/pnas.112008599; Hazan RB, 2000, J CELL BIOL, V148, P779, DOI 10.1083/jcb.148.4.779; Herranz N, 2008, MOL CELL BIOL, V28, P4772, DOI 10.1128/MCB.00323-08; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Irizarry RA, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng015; Iwase S, 2004, BIOCHEM BIOPH RES CO, V322, P601, DOI 10.1016/j.bbrc.2004.07.163; Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104; Lamouille S, 2014, NAT REV MOL CELL BIO, V15, P178, DOI 10.1038/nrm3758; Lee MG, 2005, NATURE, V437, P432, DOI 10.1038/nature04021; Liang CC, 2007, NAT PROTOC, V2, P329, DOI 10.1038/nprot.2007.30; Lim S, 2010, CARCINOGENESIS, V31, P512, DOI 10.1093/carcin/bgp324; Lin T, 2010, ONCOGENE, V29, P4896, DOI 10.1038/onc.2010.234; Lin YW, 2010, EMBO J, V29, P1803, DOI 10.1038/emboj.2010.63; Marmorstein LY, 2001, CELL, V104, P247, DOI 10.1016/S0092-8674(01)00209-4; Massague J, 2012, NAT REV MOL CELL BIO, V13, P616, DOI 10.1038/nrm3434; McDonald OG, 2011, NAT STRUCT MOL BIOL, V18, P867, DOI 10.1038/nsmb.2084; McKay BS, 1997, EXP EYE RES, V65, P661, DOI 10.1006/exer.1997.0374; Metzger E, 2005, NATURE, V437, P436, DOI 10.1038/nature04020; MIETTINEN PJ, 1994, J CELL BIOL, V127, P2021, DOI 10.1083/jcb.127.6.2021; Millanes-Romero A, 2013, MOL CELL, V52, P746, DOI 10.1016/j.molcel.2013.10.015; Onder TT, 2008, CANCER RES, V68, P3645, DOI 10.1158/0008-5472.CAN-07-2938; Peng HM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0014750; Radisky DC, 2005, NATURE, V436, P123, DOI 10.1038/nature03688; Rhodes DR, 2004, NEOPLASIA, V6, P1, DOI 10.1016/S1476-5586(04)80047-2; Riker AI, 2008, BMC MED GENOMICS, V1, DOI 10.1186/1755-8794-1-13; Saleque S, 2007, MOL CELL, V27, P562, DOI 10.1016/j.molcel.2007.06.039; Sanges R, 2007, BIOINFORMATICS, V23, P3406, DOI 10.1093/bioinformatics/btm469; Shi YJ, 2005, MOL CELL, V19, P857, DOI 10.1016/j.molcel.2005.08.027; Shi YJ, 2004, CELL, V119, P941, DOI 10.1016/j.cell.2004.12.012; Shi YJ, 2003, NATURE, V422, P735, DOI 10.1038/nature01550; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Subtil-Rodriguez A, 2010, EMBO REP, V11, P751, DOI 10.1038/embor.2010.131; Sumoy L, 2000, CYTOGENET CELL GENET, V88, P62, DOI 10.1159/000015486; Talantov D, 2005, CLIN CANCER RES, V11, P7234, DOI 10.1158/1078-0432.CCR-05-0683; Tam WL, 2013, NAT MED, V19, P1438, DOI 10.1038/nm.3336; Taube JH, 2010, P NATL ACAD SCI USA, V107, P15449, DOI 10.1073/pnas.1004900107; Tsai JH, 2013, GENE DEV, V27, P2192, DOI 10.1101/gad.225334.113; Vincent T, 2009, NAT CELL BIOL, V11, P943, DOI 10.1038/ncb1905; Wang Y, 2009, CELL, V138, P660, DOI 10.1016/j.cell.2009.05.050; Wu CY, 2012, TRENDS GENET, V28, P454, DOI 10.1016/j.tig.2012.05.005; Wynder C, 2005, NAT CELL BIOL, V7, P1113, DOI 10.1038/ncb1312; Xu J, 2009, CELL RES, V19, P156, DOI 10.1038/cr.2009.5; Xu L, 2008, MOL CANCER RES, V6, P760, DOI 10.1158/1541-7786.MCR-07-0344; Yilmaz M, 2010, MOL CANCER RES, V8, P629, DOI 10.1158/1541-7786.MCR-10-0139; Yilmaz M, 2009, CANCER METAST REV, V28, P15, DOI 10.1007/s10555-008-9169-0; You A, 2001, P NATL ACAD SCI USA, V98, P1454, DOI 10.1073/pnas.98.4.1454	59	31	32	3	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 8	2015	34	41					5264	5276		10.1038/onc.2014.446	http://dx.doi.org/10.1038/onc.2014.446			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CT1QL	25639869				2022-12-17	WOS:000362575400006
J	Chen, J; Lan, T; Zhang, W; Dong, L; Kang, N; Zhang, S; Fu, M; Liu, B; Liu, K; Zhang, C; Hou, J; Zhan, Q				Chen, J.; Lan, T.; Zhang, W.; Dong, L.; Kang, N.; Zhang, S.; Fu, M.; Liu, B.; Liu, K.; Zhang, C.; Hou, J.; Zhan, Q.			Platelet-activating factor receptor-mediated PI3K/AKT activation contributes to the malignant development of esophageal squamous cell carcinoma	ONCOGENE			English	Article							FOCAL ADHESION KINASE; GROWTH-FACTOR-RECEPTOR; PROTEIN-COUPLED RECEPTORS; BREAST-CANCER CELLS; VEIN ENDOTHELIAL-CELLS; FACTOR PAF; PHOSPHATIDYLINOSITOL 3-KINASE; SPHINGOSINE 1-PHOSPHATE; LYSOPHOSPHATIDIC ACID; OPIOID RECEPTORS	Esophageal squamous cell carcinoma (ESCC) is one of the most common malignancies worldwide and occurs at a relatively high frequency in China, yet the mechanisms underlying its devastating outcome remain unclear. Here we report that platelet-activating factor receptor (PAFR), a type of G-protein-coupled receptor, was upregulated in ESCC tumors and cell lines, compared with controls; PAFR levels were positively correlated with ESCC clinical stages and survival time. Overexpression of PAFR promoted the malignant development of ESCC in vitro and in vivo, whereas depletion of PAFR suppressed these effects. Interestingly, PAFR was observed to activate PI3K/AKT (phosphatidylinositol 3-kinase/AKT) through the upregulation of FAK kinase activity. AKT-triggered nuclear factor-kappa B transcriptionally activated PAFR expression. This mutual positive regulation between PAFR and AKT was required for the aggressiveness of ESCC cells both in vitro and in vivo. Furthermore, treating mice bearing ESCC tumors with cholesterolconjugated PAFR small interfering RNA effectively inhibited tumor progression and the expression of AKT-mediated oncogenic proteins. Taken together, we made the first demonstration that dysregulation of PAFR and the positive regulatory loop between PAFR and pAKT contribute to malignant progression of ESCC.	[Chen, J.; Lan, T.; Zhang, W.; Dong, L.; Kang, N.; Zhang, S.; Fu, M.; Zhan, Q.] Chinese Acad Med Sci, State Key Lab Mol Oncol, Canc Inst & Hosp, Beijing 100021, Peoples R China; [Chen, J.; Lan, T.; Zhang, W.; Dong, L.; Kang, N.; Zhang, S.; Fu, M.; Zhan, Q.] Peking Union Med Coll, Beijing 100021, Peoples R China; [Lan, T.] Capital Med Univ, Dept Neurosurg, Beijing Sanbo Brain Hosp, Beijing, Peoples R China; [Liu, B.] Guangdong Pharmaceut Univ, Dept Pharmacol, Sch Pharm, Guangzhou, Guangdong, Peoples R China; [Liu, K.] Tsinghua Univ, Natl Key Lab Med Mol Biol, Inst Basic Med Sci, Peking Union Med Coll, Beijing 100084, Peoples R China; [Liu, K.] Chinese Acad Med Sci, Beijing 100730, Peoples R China; [Zhang, C.; Hou, J.] China Acad Chinese Med Sci, Xiyuan Hosp, Inst Basic Med Sci, Beijing, Peoples R China	Chinese Academy of Medical Sciences - Peking Union Medical College; Cancer Institute & Hospital - CAMS; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; Capital Medical University; Guangdong Pharmaceutical University; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; Institute of Basic Medical Sciences - CAMS; Tsinghua University; Chinese Academy of Medical Sciences - Peking Union Medical College; China Academy of Chinese Medical Sciences; Xiyuan Hospital, CACMS	Zhan, Q (corresponding author), Chinese Acad Med Sci, State Key Lab Mol Oncol, Canc Inst & Hosp, Beijing 100021, Peoples R China.	zhanqimin@pumc.edu.cn	Lan, Ting/GWV-2392-2022		National 973 Program [2015CB553904]; National Natural Fund of China [81021061, 81230047]; China Postdoctoral Science Foundation [2013M530555]	National 973 Program(National Basic Research Program of China); National Natural Fund of China; China Postdoctoral Science Foundation(China Postdoctoral Science Foundation)	The ESCC cell lines (KYSE180, KYSE140, KYSE150, KYSE30, KYSE410, KYSE450 and KYSE510) were generously provided by Dr Shemada of Kyoto University. This work is supported by the National 973 Program (2015CB553904), National Natural Fund of China (81021061 and 81230047) and China Postdoctoral Science Foundation (2013M530555).	Andl CD, 2003, J BIOL CHEM, V278, P1824, DOI 10.1074/jbc.M209148200; Aponte M, 2008, CANCER RES, V68, P5839, DOI 10.1158/0008-5472.CAN-07-5771; Asanuma H, 2005, CANCER RES, V65, P11018, DOI 10.1158/0008-5472.CAN-05-0491; Boire A, 2005, CELL, V120, P303, DOI 10.1016/j.cell.2004.12.018; Cellai C, 2006, BRIT J CANCER, V94, P1637, DOI 10.1038/sj.bjc.6603156; Chen HC, 1996, J BIOL CHEM, V271, P26329, DOI 10.1074/jbc.271.42.26329; Chen J, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.312; Chen ML, 2012, CANCER EPIDEM BIOMAR, V21, P1126, DOI 10.1158/1055-9965.EPI-12-0020; Denizot Y, 2001, LUNG CANCER-J IASLC, V33, P195, DOI 10.1016/S0169-5002(01)00197-0; Deo DD, 2004, J BIOL CHEM, V279, P3497, DOI 10.1074/jbc.M304497200; Deo DD, 2002, J BIOL CHEM, V277, P21237, DOI 10.1074/jbc.M110955200; Ding YZ, 2003, CLIN CANCER RES, V9, P3406; Dorsam RT, 2007, NAT REV CANCER, V7, P79, DOI 10.1038/nrc2069; Dulinska-Litewka J, 2013, CURR MED CHEM, V20, P144; Engelman JA, 2009, NAT REV CANCER, V9, P550, DOI 10.1038/nrc2664; Feng GJ, 2003, J BIOL CHEM, V278, P33400, DOI 10.1074/jbc.M305866200; Gibbs TC, 2009, PROSTATE, V69, P1493, DOI 10.1002/pros.20994; Haribabu B, 1999, J BIOL CHEM, V274, P37087, DOI 10.1074/jbc.274.52.37087; HEON SK, 2006, CANCER RES, V66, P4681; Hu H, 2013, CANCER CELL, V22, P781; Kamangar F, 2006, J CLIN ONCOL, V24, P2137, DOI 10.1200/JCO.2005.05.2308; Kato M, 2002, J IMMUNOL, V169, P5252, DOI 10.4049/jimmunol.169.9.5252; Keane MP, 2004, J IMMUNOL, V172, P2853, DOI 10.4049/jimmunol.172.5.2853; Kim Won Ho, 1993, Yonsei Medical Journal, V34, P45; Lango MN, 2002, J NATL CANCER I, V94, P375; Lee Z, 2006, CANCER RES, V66, P2740, DOI 10.1158/0008-5472.CAN-05-2947; Li JX, 2004, CANCER RES, V64, P94, DOI 10.1158/0008-5472.CAN-03-0737; Li Y, 2009, DIS ESOPHAGUS, V22, P664, DOI 10.1111/j.1442-2050.2008.00928.x; Liu X, 2008, J PHARMACOL EXP THER, V326, P69, DOI 10.1124/jpet.107.134528; Marques SA, 2002, J PHARMACOL EXP THER, V300, P1026, DOI 10.1124/jpet.300.3.1026; Mitra SK, 2005, NAT REV MOL CELL BIO, V6, P56, DOI 10.1038/nrm1549; MUTOH H, 1994, BIOCHEM BIOPH RES CO, V205, P1137, DOI 10.1006/bbrc.1994.2784; Quint P, 2013, J BIOL CHEM, V288, P5398, DOI 10.1074/jbc.M112.413583; Rosato A, 2006, INT J CANCER, V119, P1717, DOI 10.1002/ijc.21923; Rozengurt E, 2007, J CELL PHYSIOL, V213, P589, DOI 10.1002/jcp.21246; Sahu RP, 2012, CARCINOGENESIS, V33, P694, DOI 10.1093/carcin/bgr322; Senga T, 2003, BLOOD, V101, P1185, DOI 10.1182/blood-2002-06-1881; SHINOZAKI K, 1994, LIFE SCI, V54, P429, DOI 10.1016/0024-3205(94)00701-2; Soldi R, 1996, ONCOGENE, V13, P515; Stokes JB, 2011, MOL CANCER THER, V10, P2135, DOI 10.1158/1535-7163.MCT-11-0261; Sud N, 2006, CANCER LETT, V233, P265, DOI 10.1016/j.canlet.2005.03.018; Suzuki A, 2004, MOL CELL BIOL, V24, P3526, DOI 10.1128/MCB.24.8.3526-3535.2004; Tanigawa N, 1997, CANCER, V79, P220; vanBiesen T, 1996, J BIOL CHEM, V271, P1266, DOI 10.1074/jbc.271.3.1266; VENABLE ME, 1993, J LIPID RES, V34, P691; Walsh CT, 2008, MOL INTERV, V8, P165, DOI 10.1124/mi.8.4.8; Wang DX, 1999, J BIOL CHEM, V274, P22081, DOI 10.1074/jbc.274.31.22081; Zhou WL, 2007, AM J PHYSIOL-HEART C, V292, pH2773, DOI 10.1152/ajpheart.01018.2006	48	31	35	1	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 1	2015	34	40					5114	5127		10.1038/onc.2014.434	http://dx.doi.org/10.1038/onc.2014.434			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CS6ZP	25639872				2022-12-17	WOS:000362233400002
J	Zhao, X; Parpart, S; Takai, A; Roessler, S; Budhu, A; Yu, Z; Blank, M; Zhang, YE; Jia, HL; Ye, QH; Qin, LX; Tang, ZY; Thorgeirsson, SS; Wang, XW				Zhao, X.; Parpart, S.; Takai, A.; Roessler, S.; Budhu, A.; Yu, Z.; Blank, M.; Zhang, Y. E.; Jia, H-L; Ye, Q-H; Qin, L-X; Tang, Z-Y; Thorgeirsson, S. S.; Wang, X. W.			Integrative genomics identifies YY1AP1 as an oncogenic driver in EpCAM(+) AFP(+) hepatocellular carcinoma	ONCOGENE			English	Article							H2B UBIQUITYLATION; SOMATIC MUTATIONS; H3 METHYLATION; CANCER; TUMOR; PREDICTION; GENES; CLASSIFICATION; PROGRESSION; LANDSCAPE	Identification of key drivers and new therapeutic targets is important given the poor prognosis for hepatocellular carcinoma (HCC) patients, particularly those ineligible for surgical resection or liver transplant. However, the approach to identify such driver genes is facing significant challenges due to the genomically heterogenous nature of HCC. Here we tested whether the integrative genomic profiling of a well-defined HCC subset that is classified by an extreme EpCAM(+) AFP(+) gene expression signature and associated with poor prognosis, all attributes of a stem cell-like phenotype, could uncover survival-related driver genes in HCC. Following transcriptomic analysis of the well-defined HCC cases, a Gene Set Enrichment Analysis coupled with genomic copy number alteration assessment revealed that YY1-associated protein 1 (YY1AP1) is a critical oncoprotein specifically activated in EpCAM(+) AFP+ HCC. YY1AP1 silencing eliminates oncogene addiction by altering the chromatin landscape and triggering massive apoptosis in vitro and tumor suppression in vivo. YY1AP1 expression promotes HCC proliferation and is required for the maintenance of stem cell features. We revealed that YY1AP1 cooperates with YY1 to alter the chromatin landscape and activate transcription of stemness regulators. Thus YY1AP1 may serve as a key molecular target for EpCAM(+) AFP(+) HCC subtype. Our results demonstrate the feasibility and power of a new strategy by utilizing well-defined patient samples and integrative genomics to uncover critical pathways linked to HCC subtypes with prognostic impact.	[Zhao, X.; Parpart, S.; Takai, A.; Roessler, S.; Budhu, A.; Yu, Z.; Wang, X. W.] NCI, Human Carcinogenesis Lab, Ctr Canc Res, Bethesda, MD 20892 USA; [Blank, M.; Zhang, Y. E.] NCI, Lab Cellular & Mol Biol, Ctr Canc Res, Bethesda, MD 20892 USA; [Jia, H-L; Ye, Q-H; Qin, L-X; Tang, Z-Y] Fudan Univ, Liver Canc Inst, Shanghai 200433, Peoples R China; [Thorgeirsson, S. S.] NCI, Lab Expt Carcinogenesis, Ctr Canc Res, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Fudan University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Wang, XW (corresponding author), NCI, Human Carcinogenesis Lab, Liver Carcinogenesis Sect, Ctr Canc Res, Bldg 37,Room 3044A,37 Convent Dr, Bethesda, MD 20892 USA.	xw3u@nih.gov	Zhao, Xuelian/Q-1370-2017; Roessler, Stephanie/J-8432-2019; Wang, Xin Wei/B-6162-2009; Zhang, Ying E/G-3657-2015	Zhao, Xuelian/0000-0003-2964-3184; Roessler, Stephanie/0000-0002-5333-5942; Wang, Xin Wei/0000-0001-9735-606X; Zhang, Ying E/0000-0003-2753-7601	Intramural Research Grants of the Center for Cancer Research; US National Cancer Institute [Z01 BC 010313, Z01 BC 010877, Z01 BC 010876]; NATIONAL CANCER INSTITUTE [ZIABC011168, Z01BC010313, Z01BC010877, Z01BC010876] Funding Source: NIH RePORTER	Intramural Research Grants of the Center for Cancer Research; US National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Curtis Harris for critical reading of the manuscript, Dr Zheng-Gang Liu for advice on apoptosis study, Dominic Esposito at the Advanced Technology Program of SAIC-Frederick, Inc., for the help in designing the Tet-C2 inducible construct and Liver Tissue Cell Distribution System (LTCDS) at the University of Minnesota (Minneapolis, MN, USA) for generous donation of normal liver specimens. We also thank Karen Yarrick for the bibliographic assistance. This work was supported by the Intramural Research Grants of the Center for Cancer Research and the US National Cancer Institute Z01 BC 010313, Z01 BC 010877 and Z01 BC 010876.	Beroukhim R, 2010, NATURE, V463, P899, DOI 10.1038/nature08822; Boyault S, 2007, HEPATOLOGY, V45, P42, DOI 10.1002/hep.21467; Budhu A, 2006, CANCER CELL, V10, P99, DOI 10.1016/j.ccr.2006.06.016; Budhu A, 2013, GASTROENTEROLOGY, V144, P1066, DOI 10.1053/j.gastro.2013.01.054; Cuddapah S, 2011, MOL CELL BIOL, V31, P700, DOI 10.1128/MCB.00740-10; Forbes SA, 2011, NUCLEIC ACIDS RES, V39, pD945, DOI 10.1093/nar/gkq929; Gerlinger M, 2012, NEW ENGL J MED, V366, P883, DOI 10.1056/NEJMoa1113205; Guichard C, 2012, NAT GENET, V44, P694, DOI 10.1038/ng.2256; Guo MZ, 2004, CLIN CANCER RES, V10, P5131, DOI 10.1158/1078-0432.CCR-03-0763; Hammerman PS, 2012, NATURE, V489, P519, DOI 10.1038/nature11404; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hoshida Y, 2009, CANCER RES, V69, P7385, DOI 10.1158/0008-5472.CAN-09-1089; Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI [10.3322/caac.20107, 10.3322/caac.20115]; Ji JF, 2012, SEMIN ONCOL, V39, P461, DOI 10.1053/j.seminoncol.2012.05.011; Ji JF, 2009, HEPATOLOGY, V50, P472, DOI 10.1002/hep.22989; Kim J, 2009, CELL, V137, P459, DOI 10.1016/j.cell.2009.02.027; Kizer KO, 2005, MOL CELL BIOL, V25, P3305, DOI 10.1128/MCB.25.8.3305-3316.2005; Kuryshev VY, 2006, GENOMICS, V88, P143, DOI 10.1016/j.ygeno.2006.02.002; Laribee RN, 2005, CURR BIOL, V15, P1487, DOI 10.1016/j.cub.2005.07.028; Laurent-Puig P, 2001, GASTROENTEROLOGY, V120, P1763, DOI 10.1053/gast.2001.24798; Lee JS, 2006, NAT MED, V12, P410, DOI 10.1038/nm1377; Lee JS, 2004, HEPATOLOGY, V40, P667, DOI 10.1002/hep.20375; Lee JS, 2007, CELL, V131, P1084, DOI 10.1016/j.cell.2007.09.046; Llovet JM, 2008, NEW ENGL J MED, V359, P378, DOI 10.1056/NEJMoa0708857; Oishi N, 2012, HEPATOLOGY, V56, P1792, DOI 10.1002/hep.25890; Roessler S, 2012, GASTROENTEROLOGY, V142, P957, DOI 10.1053/j.gastro.2011.12.039; Roessler S, 2010, CANCER RES, V70, P10202, DOI 10.1158/0008-5472.CAN-10-2607; Rotili Dante, 2011, Genes Cancer, V2, P663, DOI 10.1177/1947601911417976; Sankpal NV, 2009, CANCER RES, V69, P753, DOI 10.1158/0008-5472.CAN-08-2708; Siegel R, 2013, CA-CANCER J CLIN, V63, P11, DOI 10.3322/caac.21166; Stephens PJ, 2012, NATURE, V486, P400, DOI 10.1038/nature11017; Stratton MR, 2009, NATURE, V458, P719, DOI 10.1038/nature07943; Sun ZW, 2002, NATURE, V418, P104, DOI 10.1038/nature00883; The Cancer Genome Atlas Network, 2012, NATURE, V487, P330, DOI [DOI 10.1038/NATURE11252, 10.1038/nature11252]; Wang CY, 2004, J BIOL CHEM, V279, P17750, DOI 10.1074/jbc.M310532200; Weinstein IB, 2002, SCIENCE, V297, P63, DOI 10.1126/science.1073096; Yamashita T, 2008, CANCER RES, V68, P1451, DOI 10.1158/0008-5472.CAN-07-6013; Yamashita T, 2007, CANCER RES, V67, P10831, DOI 10.1158/0008-5472.CAN-07-0908; Yamashita T, 2013, J CLIN INVEST, V123, P1911, DOI 10.1172/JCI66024; Yamashita T, 2009, GASTROENTEROLOGY, V136, P1012, DOI 10.1053/j.gastro.2008.12.004; Yang EB, 1997, CANCER LETT, V117, P93, DOI 10.1016/S0304-3835(97)00206-1; Ye QH, 2003, NAT MED, V9, P416, DOI 10.1038/nm843; Zhang K, 2005, CLIN CANCER RES, V11, P7532, DOI 10.1158/1078-0432.CCR-05-0400; Zhou XD, 2001, CANCER-AM CANCER SOC, V91, P1479, DOI 10.1002/1097-0142(20010415)91:8<1479::AID-CNCR1155>3.0.CO;2-0	44	31	34	0	14	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 24	2015	34	39					5095	5104		10.1038/onc.2014.438	http://dx.doi.org/10.1038/onc.2014.438			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CR9RC	25597408	Green Accepted			2022-12-17	WOS:000361693300009
J	Singleton, DC; Rouhi, P; Zois, CE; Haider, S; Li, JL; Kessler, BM; Cao, Y; Harris, AL				Singleton, D. C.; Rouhi, P.; Zois, C. E.; Haider, S.; Li, J-L; Kessler, B. M.; Cao, Y.; Harris, A. L.			Hypoxic regulation of RIOK3 is a major mechanism for cancer cell invasion and metastasis	ONCOGENE			English	Article							BREAST-CANCER; MIGRATING CELLS; CYTOPLASMIC MATURATION; ACTIN DYNAMICS; HIF-1-ALPHA; ACTIVATION; CARCINOMA; HIF-2-ALPHA; PHENOTYPE; NETWORKS	Hypoxia is a common feature of locally advanced breast cancers that is associated with increased metastasis and poorer survival. Stabilisation of hypoxia-inducible factor-1 alpha (HIF1 alpha) in tumours causes transcriptional changes in numerous genes that function at distinct stages of the metastatic cascade. We demonstrate that expression of RIOK3 (RIght Open reading frame kinase 3) was increased during hypoxic exposure in an HIF1 alpha-dependent manner. RIOK3 was localised to distinct cytoplasmic aggregates in normoxic cells and underwent redistribution to the leading edge of the cell in hypoxia with a corresponding change in the organisation of the actin cytoskeleton. Depletion of RIOK3 expression caused MDA-MB-231 to become elongated and this morphological change was due to a loss of protraction at the trailing edge of the cell. This phenotypic change resulted in reduced cell migration in two-dimensional cultures and inhibition of cell invasion through three-dimensional extracellular matrix. Proteomic analysis identified interactions of RIOK3 with actin and several actin-binding factors including tropomyosins (TPM3 and TPM4) and tropomodulin 3. Depletion of RIOK3 in cells resulted in fewer and less organised actin filaments. Analysis of these filaments showed reduced association of TPM3, particularly during hypoxia, suggesting that RIOK3 regulates actin filament specialisation. RIOK3 depletion reduced the dissemination of MDA-MB-231 cells in both a zebrafish model of systemic metastasis and a mouse model of pulmonary metastasis. These findings demonstrate that RIOK3 is necessary for maintaining actin cytoskeletal organisation required for migration and invasion, biological processes that are necessary for hypoxia-driven metastasis.	[Singleton, D. C.; Zois, C. E.; Haider, S.; Li, J-L; Harris, A. L.] Univ Oxford, John Radcliffe Hosp, Weatherall Inst Mol Med, Dept Oncol, Oxford OX3 9DS, England; [Rouhi, P.; Cao, Y.] Karolinska Inst, Dept Microbiol Tumor & Cell Biol, Stockholm, Sweden; [Kessler, B. M.] Univ Oxford, Nuffield Dept Med, Target Discovery Inst, Oxford OX3 9DS, England; [Cao, Y.] Linkoping Univ, Dept Med & Hlth Sci, Linkoping, Sweden; [Cao, Y.] Univ Leicester, Dept Cardiovasc Sci, Leicester, Leics, England; [Cao, Y.] Glenfield Hosp, NIHR Leicester Cardiovasc Biomed Res Unit, Leicester, Leics, England	University of Oxford; Karolinska Institutet; University of Oxford; Linkoping University; University of Leicester; University Hospitals of Leicester NHS Trust; University of Leicester; Glenfield Hospital	Harris, AL (corresponding author), Univ Oxford, John Radcliffe Hosp, Weatherall Inst Mol Med, Dept Oncol, Oxford OX3 9DS, England.	aharris.lab@imm.ox.ac.uk	Kessler, Benedikt/AAY-8614-2021; Harris, Adrian L/ABA-3343-2020	Kessler, Benedikt/0000-0002-8160-2446; Harris, Adrian L/0000-0003-1376-8409	European Commission Metoxia [222741]; British Columbia Cancer Agency Branch; Cancer Research UK; Cancer Research UK [16466, 11359] Funding Source: researchfish; National Institute for Health Research [NF-SI-0611-10163] Funding Source: researchfish	European Commission Metoxia; British Columbia Cancer Agency Branch; Cancer Research UK(Cancer Research UK); Cancer Research UK(Cancer Research UK); National Institute for Health Research(National Institute for Health Research (NIHR))	European Commission Metoxia Grant No. 222741 (D Singleton, P Rouhi, Y Cao, A Harris), Cancer Research UK (A Harris, C Zois, S Haider, J Li), Breast Cancer Research Foundation (A Harris) and Oxford NIHR Biomedical Research Centre (B Kessler). This study makes use of data generated by the Molecular Taxonomy of Breast Cancer International Consortium, which was funded by Cancer Research UK and the British Columbia Cancer Agency Branch.	Agus DB, 2013, SCI REP-UK, V3, DOI 10.1038/srep01449; Alcoser SY, 2011, BMC BIOTECHNOL, V11, DOI 10.1186/1472-6750-11-124; Baumas K, 2012, RNA BIOL, V9, DOI [10.4161/rna.9.2.18810, 10.4161/rna.18810]; Buffa FM, 2010, BRIT J CANCER, V102, P428, DOI 10.1038/sj.bjc.6605450; Carroll VA, 2006, CANCER RES, V66, P6264, DOI 10.1158/0008-5472.CAN-05-2519; Cramer LP, 2013, CURR OPIN CELL BIOL, V25, P591, DOI 10.1016/j.ceb.2013.05.001; Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983; Dales JP, 2005, INT J CANCER, V116, P734, DOI 10.1002/ijc.20984; Elias AD, 2010, AM J CLIN ONCOL-CANC, V33, P637, DOI 10.1097/COC.0b013e3181b8afcf; Erler JT, 2006, NATURE, V440, P1222, DOI 10.1038/nature04695; Fournier MF, 2010, J CELL BIOL, V188, P287, DOI 10.1083/jcb.200906139; Gilkes DM, 2013, CANCER RES, V73, P3285, DOI 10.1158/0008-5472.CAN-12-3963; Gupton SL, 2005, J CELL BIOL, V168, P619, DOI 10.1083/jcb.200406063; Hu CJ, 2003, MOL CELL BIOL, V23, P9361, DOI 10.1128/MCB.23.24.9361-9374.2003; Imai T, 2003, AM J PATHOL, V163, P1437, DOI 10.1016/S0002-9440(10)63501-8; Insall RH, 2009, DEV CELL, V17, P310, DOI 10.1016/j.devcel.2009.08.012; Kimmelman AC, 2008, P NATL ACAD SCI USA, V105, P19372, DOI 10.1073/pnas.0809966105; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Koch A, 2010, EUR J CELL BIOL, V89, P184, DOI 10.1016/j.ejcb.2009.11.024; Lammermann T, 2008, NATURE, V453, P51, DOI 10.1038/nature06887; LaRonde-LeBlanc N, 2005, J BIOL CHEM, V280, P37297, DOI 10.1074/jbc.R500013200; Mackeen MM, 2010, J PROTEOME RES, V9, P4082, DOI 10.1021/pr100269b; Meijering E, 2012, METHOD ENZYMOL, V504, P183, DOI 10.1016/B978-0-12-391857-4.00009-4; Munoz-Najar UM, 2006, ONCOGENE, V25, P2379, DOI 10.1038/sj.onc.1209273; Pennacchietti S, 2003, CANCER CELL, V3, P347, DOI 10.1016/S1535-6108(03)00085-0; Poincloux R, 2011, P NATL ACAD SCI USA, V108, P1943, DOI 10.1073/pnas.1010396108; Ponti A, 2004, SCIENCE, V305, P1782, DOI 10.1126/science.1100533; Raval RR, 2005, MOL CELL BIOL, V25, P5675, DOI 10.1128/MCB.25.13.5675-5686.2005; Rouhi P, 2010, NAT PROTOC, V5, P1911, DOI 10.1038/nprot.2010.150; Rundqvist H, 2010, CURR TOP MICROBIOL, V345, P121, DOI 10.1007/82_2010_77; Rzymski T, 2010, ONCOGENE, V29, P4424, DOI 10.1038/onc.2010.191; Semenza GL, 2012, CELL, V148, P399, DOI 10.1016/j.cell.2012.01.021; Sims D, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-10-r104; Tojkander S, 2011, CURR BIOL, V21, P539, DOI 10.1016/j.cub.2011.03.007; Vaupel P, 2007, ANTIOXID REDOX SIGN, V9, P1221, DOI 10.1089/ars.2007.1628; Weber KL, 2007, J CELL SCI, V120, P3625, DOI 10.1242/jcs.011445; Weidemann A, 2013, CELL COMMUN SIGNAL, V11, DOI 10.1186/1478-811X-11-80; Widmann B, 2012, MOL BIOL CELL, V23, P22, DOI 10.1091/mbc.E11-07-0639; Yamamoto Y, 2008, BREAST CANCER RES TR, V110, P465, DOI 10.1007/s10549-007-9742-1; Zemp I, 2009, J CELL BIOL, V185, P1167, DOI 10.1083/jcb.200904048; Zhang H, 2012, ONCOGENE, V31, P1757, DOI 10.1038/onc.2011.365	41	31	32	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 3	2015	34	36					4713	4722		10.1038/onc.2014.396	http://dx.doi.org/10.1038/onc.2014.396			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CQ9JU	25486436	Green Accepted, Green Submitted			2022-12-17	WOS:000360931500005
J	Pathiraja, TN; Thakkar, KN; Jiang, S; Stratton, S; Liu, Z; Gagea, M; Shi, X; Shah, PK; Phan, L; Lee, MH; Andersen, J; Stampfer, M; Barton, MC				Pathiraja, T. N.; Thakkar, K. N.; Jiang, S.; Stratton, S.; Liu, Z.; Gagea, M.; Shi, X.; Shah, P. K.; Phan, L.; Lee, M-H; Andersen, J.; Stampfer, M.; Barton, M. C.			TRIM24 links glucose metabolism with transformation of human mammary epithelial cells	ONCOGENE			English	Article							BREAST-CANCER; GENE-EXPRESSION; TUMOR SUPPRESSORS; P53 FUNCTION; PROLIFERATION; GROWTH; WARBURG; LINES; IMMORTALIZATION; INACTIVATION	Tripartite motif 24 protein (TRIM24) is a plant homeodomain/bromodomain histone reader, recently associated with poor overall survival of breast-cancer patients. At a molecular level, TRIM24 is a negative regulator of p53 levels and a co-activator of estrogen receptor. However, the role of TRIM24 in breast tumorigenesis remains largely unknown. We used an isogenic human mammary epithelial cell (HMEC) culture model, derived from reduction mammoplasty tissue, and found that ectopic expression of TRIM24 in immortalized HMECs (TRIM24 iHMECs) greatly increased cellular proliferation and induced malignant transformation. Subcutaneous injection of TRIM24 iHMECs in nude mice led to growth of intermediate to high-grade tumors in 60-70% of mice. Molecular analysis of TRIM24 iHMECs revealed a glycolytic and tricarboxylic acid cycle gene signature, alongside increased glucose uptake and activated aerobic glycolysis. Collectively, these results identify a role for TRIM24 in breast tumorigenesis through reprogramming of glucose metabolism in HMECs, further supporting TRIM24 as a viable therapeutic target in breast cancer.	[Pathiraja, T. N.; Thakkar, K. N.; Jiang, S.; Stratton, S.; Liu, Z.; Barton, M. C.] Univ Texas MD Anderson Canc Ctr, Ctr Stem Cell & Dev Biol, Ctr Canc Epigenet, Dept Biochem & Mol Biol, Houston, TX 77030 USA; [Gagea, M.] Univ Texas MD Anderson Canc Ctr, Dept Vet Med & Surg, Houston, TX 77030 USA; [Shi, X.; Shah, P. K.; Andersen, J.] Univ Texas MD Anderson Canc Ctr, Inst Appl Canc Sci, Houston, TX 77030 USA; [Phan, L.; Lee, M-H] Univ Texas MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA; [Stampfer, M.] Univ Calif Berkeley, Lawrence Berkeley Natl Lab, Div Life Sci, Berkeley, CA 94720 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley	Barton, MC (corresponding author), Univ Texas MD Anderson Canc Ctr, Ctr Stem Cell & Dev Biol, Ctr Canc Epigenet, Dept Biochem & Mol Biol, 1515 Holcombe Blvd,Houston 207, Houston, TX 77030 USA.	mbarton@mdanderson.org	Liu, Zhiming/GXG-6785-2022	THAKKAR, KAUSHIK/0000-0002-4900-3371; Barton, Michelle/0000-0002-4042-1374; Lee, Mong-Hong/0000-0001-8675-8215; Shi, Xiaobing/0000-0001-5242-8189	Cancer Prevention and Research Initiative of Texas [RP100602]; Center for Cancer Epigenetics scholarship; MD Anderson Cancer Center Support Grant [CA016672]; NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK056338] Funding Source: NIH RePORTER	Cancer Prevention and Research Initiative of Texas; Center for Cancer Epigenetics scholarship; MD Anderson Cancer Center Support Grant; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We thank Abhinav Jain and Srikanth Appikonda for helpful discussions. Zeynep Coban and Kadir Akdemir for help with Bioinformatic analyses. Lindsey Minter and Joseph Taube for help with Xenograft experiments. This research is supported by grant RP100602 from the Cancer Prevention and Research Initiative of Texas to MCB, the Center for Cancer Epigenetics scholarship to KNT and in part by the MD Anderson Cancer Center Support Grant CA016672.	Allred DC, 1998, MODERN PATHOL, V11, P155; Allton K, 2009, P NATL ACAD SCI USA, V106, P11612, DOI 10.1073/pnas.0813177106; Arteaga CL, 2012, NAT REV CLIN ONCOL, V9, P16, DOI 10.1038/nrclinonc.2011.177; Brenner AJ, 1998, ONCOGENE, V17, P199, DOI 10.1038/sj.onc.1201919; Campeau E, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006529; Chambon M, 2011, AM J PATHOL, V178, P1461, DOI 10.1016/j.ajpath.2010.12.026; Chen JQ, 2012, BBA-REV CANCER, V1826, P370, DOI 10.1016/j.bbcan.2012.06.004; Chen MQ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025564; DeBerardinis RJ, 2008, CELL METAB, V7, P11, DOI 10.1016/j.cmet.2007.10.002; Dennis G, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-9-r60; Diers AR, 2012, BIOCHEM J, V444, P561, DOI 10.1042/BJ20120294; Ferrick DA, 2008, DRUG DISCOV TODAY, V13, P268, DOI 10.1016/j.drudis.2007.12.008; Fritz V, 2010, ONCOGENE, V29, P4369, DOI 10.1038/onc.2010.182; Gao P, 2009, NATURE, V458, P762, DOI 10.1038/nature07823; Garbe JC, 2007, CELL CYCLE, V6, P1927, DOI 10.4161/cc.6.15.4519; Garbe JC, 2009, CANCER RES, V69, P7557, DOI 10.1158/0008-5472.CAN-09-0270; Geiss GK, 2008, NAT BIOTECHNOL, V26, P317, DOI 10.1038/nbt1385; Goel A, 2003, J BIOL CHEM, V278, P15333, DOI 10.1074/jbc.M300608200; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hatakeyama S, 2011, NAT REV CANCER, V11, P792, DOI 10.1038/nrc3139; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; Hsu PP, 2008, CELL, V134, P703, DOI 10.1016/j.cell.2008.08.021; Jain AK, 2012, PLOS BIOL, V10, DOI 10.1371/journal.pbio.1001268; Jones RG, 2009, GENE DEV, V23, P537, DOI 10.1101/gad.1756509; Jose C, 2011, BBA-BIOENERGETICS, V1807, P552, DOI 10.1016/j.bbabio.2010.10.012; Koppenol WH, 2011, NAT REV CANCER, V11, P325, DOI 10.1038/nrc3038; Kroemer G, 2008, CANCER CELL, V13, P472, DOI 10.1016/j.ccr.2008.05.005; Lee E, 2013, NEOPLASIA, V15, P112, DOI 10.1593/neo.121638; Lim HY, 2011, MITOCHONDRION, V11, P437, DOI 10.1016/j.mito.2010.12.015; Lv L, 2011, MOL CELL, V42, P719, DOI 10.1016/j.molcel.2011.04.025; Milke L, 2013, CARCINOGENESIS, V34, P850, DOI 10.1093/carcin/bgs387; Moreno-Sanchez R, 2007, FEBS J, V274, P1393, DOI 10.1111/j.1742-4658.2007.05686.x; Novak P, 2009, CANCER RES, V69, P5251, DOI 10.1158/0008-5472.CAN-08-4977; Parker JS, 2009, J CLIN ONCOL, V27, P1160, DOI 10.1200/JCO.2008.18.1370; PIERCE JH, 1991, ONCOGENE, V6, P1189; Schulze A, 2012, NATURE, V491, P364, DOI 10.1038/nature11706; Scott DA, 2011, J BIOL CHEM, V286, P42626, DOI 10.1074/jbc.M111.282046; Smolkova K, 2011, INT J BIOCHEM CELL B, V43, P950, DOI 10.1016/j.biocel.2010.05.003; Stampfer MR, 2003, ONCOGENE, V22, P5238, DOI 10.1038/sj.onc.1206667; Stampfer MR, 2003, CANCER LETT, V194, P199, DOI 10.1016/S0304-3835(02)00707-3; Stampfer MR, 2000, J MAMMARY GLAND BIOL, V5, P365, DOI 10.1023/A:1009525827514; STAMPFER MR, 1985, P NATL ACAD SCI USA, V82, P2394, DOI 10.1073/pnas.82.8.2394; Stampfer MR, 2013, CELL MOL BIOL BREAST, P323, DOI [10.1007/978-1-62703-634-4_15, DOI 10.1007/978-1-62703-634-4_15]; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Tsai WW, 2010, NATURE, V468, P927, DOI 10.1038/nature09542; Vazquez F, 2013, CANCER CELL, V23, P287, DOI 10.1016/j.ccr.2012.11.020; Ward PS, 2012, CANCER CELL, V21, P297, DOI 10.1016/j.ccr.2012.02.014; Wen H, 2014, NATURE, V508, P263, DOI 10.1038/nature13045; Werner H, 2012, LANCET ONCOL, V13, pE537, DOI 10.1016/S1470-2045(12)70362-5; Xu W, 2011, CANCER CELL, V19, P17, DOI 10.1016/j.ccr.2010.12.014; Zaugg K, 2011, GENE DEV, V25, P1041, DOI 10.1101/gad.1987211; Zhao JJ, 2005, P NATL ACAD SCI USA, V102, P18443, DOI 10.1073/pnas.0508988102; Zheng J, 2012, ONCOL LETT, V4, P1151, DOI 10.3892/ol.2012.928; Zhu CW, 2011, CLIN DEV IMMUNOL, P1, DOI 10.1155/2011/920146	54	31	33	2	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 28	2015	34	22					2836	2845		10.1038/onc.2014.220	http://dx.doi.org/10.1038/onc.2014.220			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CJ2OM	25065590	Green Accepted, Green Published			2022-12-17	WOS:000355324300003
J	Faye, MD; Beug, ST; Graber, TE; Earl, N; Xiang, X; Wild, B; Langlois, S; Michaud, J; Cowan, KN; Korneluk, RG; Holcik, M				Faye, M. D.; Beug, S. T.; Graber, T. E.; Earl, N.; Xiang, X.; Wild, B.; Langlois, S.; Michaud, J.; Cowan, K. N.; Korneluk, R. G.; Holcik, M.			IGF2BP1 controls cell death and drug resistance in rhabdomyosarcomas by regulating translation of cIAP1	ONCOGENE			English	Article							RNA-BINDING PROTEINS; ENDOPLASMIC-RETICULUM STRESS; ALPHA-DEPENDENT APOPTOSIS; LIGAND-INDUCED APOPTOSIS; RIBOSOME ENTRY SITES; NF-KAPPA-B; MESSENGER-RNA; SMAC MIMETICS; TNF; CANCER	Rhabdomyosarcoma (RMS), a neoplasm characterised by undifferentiated myoblasts, is the most common soft tissue tumour of childhood. Although aggressive treatment of RMS could provide long-term benefit, resistance to current therapies is an ongoing problem. We report here that insulin-like growth factor 2-binding protein 1 (IGF2BP1), an oncofetal protein, is expressed in RMS patient-derived cell lines and in primary tumours where it drives translation of the cellular inhibitor of apoptosis 1 (cIAP1), a key regulator of the nuclear factor-kappa B signalling pathway and of caspase-8-mediated cell death. We demonstrate that reducing the levels of cIAP1 in RMS, either by IGF2BP1 knockdown or by IAP antagonists, sensitises these cells to tumour necrosis factor-alpha-mediated cell death. Finally, we show that targeting cIAP1 by IAP antagonists delays RMS tumour growth and improve survival in mice. Our results identify IGF2BP1 as a critical translational regulator of cIAP1-mediated apoptotic resistance in RMS and advocate for the combined use of IAP antagonists and tumour necrosis factor-a as a therapeutic approach for this type of cancer.	[Faye, M. D.; Beug, S. T.; Graber, T. E.; Earl, N.; Xiang, X.; Wild, B.; Langlois, S.; Cowan, K. N.; Korneluk, R. G.; Holcik, M.] Childrens Hosp Eastern Ontario, Apoptosis Res Ctr, Res Inst, Ottawa, ON K1H 8L1, Canada; [Faye, M. D.; Korneluk, R. G.; Holcik, M.] Univ Ottawa, Dept Biochem Microbiol & Immunol, Ottawa, ON, Canada; [Xiang, X.; Wild, B.; Cowan, K. N.] Univ Ottawa, Dept Cellular & Mol Med, Ottawa, ON, Canada; [Langlois, S.; Cowan, K. N.] Univ Ottawa, Dept Surg, Ottawa, ON, Canada; [Michaud, J.] Univ Ottawa, Dept Pathol & Lab Med, Ottawa, ON, Canada; [Korneluk, R. G.; Holcik, M.] Univ Ottawa, Dept Pediat, Ottawa, ON K1N 6N5, Canada	University of Ottawa; Children's Hospital of Eastern Ontario; University of Ottawa; University of Ottawa; University of Ottawa; University of Ottawa; University of Ottawa	Holcik, M (corresponding author), Childrens Hosp Eastern Ontario, Apoptosis Res Ctr, Res Inst, 401 Smyth Rd, Ottawa, ON K1H 8L1, Canada.	martin@arc.cheo.ca	Graber, Tyson/K-9385-2019; Holcik, Martin/AAC-6660-2019	Graber, Tyson/0000-0002-5337-3404; Holcik, Martin/0000-0002-1922-5299; Xiang, Xiao/0000-0002-3969-1668; Cowan, Kyle/0000-0003-0109-7716	Canadian Institutes of Health Research [FRN 74740]; Cancer Research Society (CRS); Vanier Canada Graduate Scholarship; Frederick Banting Graduate Scholarship Doctoral Award; Charles Best Canada Graduate Scholarship Doctoral Award	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Cancer Research Society (CRS); Vanier Canada Graduate Scholarship; Frederick Banting Graduate Scholarship Doctoral Award; Charles Best Canada Graduate Scholarship Doctoral Award	We thank the members of the Apoptosis Research Centre and Dr Eric LaCasse in particular for critical discussions. We are grateful to Novartis Pharmaceuticals for providing LCL161 compound and Dr P Houghton (Department of Hematology-Oncology, St Jude Children's Research Hospital, Memphis, TN, USA) for the gift of RMS cell lines. This work forms part of the PhD dissertation of MDF and was supported by an operating grant from the Canadian Institutes of Health Research (FRN 74740) and Cancer Research Society (CRS) to MH. MDF was supported by the Vanier Canada Graduate Scholarship. TEG was supported by the Frederick Banting and Charles Best Canada Graduate Scholarships Doctoral Award.	Baird SD, 2007, NUCLEIC ACIDS RES, V35, P4664, DOI 10.1093/nar/gkm483; Basit F, 2012, J BIOL CHEM, V287, P38767, DOI 10.1074/jbc.M112.398966; Bell JL, 2013, CELL MOL LIFE SCI, V70, P2657, DOI 10.1007/s00018-012-1186-z; Bertrand MJM, 2008, MOL CELL, V30, P689, DOI 10.1016/j.molcel.2008.05.014; Beug ST, 2014, NAT BIOTECHNOL, V32, P182, DOI 10.1038/nbt.2806; Dai N, 2013, GENE DEV, V27, P301, DOI 10.1101/gad.209130.112; Dai N, 2011, GENE DEV, V25, P1159, DOI 10.1101/gad.2042311; Farina KL, 2003, J CELL BIOL, V160, P77, DOI 10.1083/jcb.200206003; Faye MD, 2013, MOL CELL BIOL, V33, P307, DOI 10.1128/MCB.00546-12; Finlay D, 2013, MOL CANC THERAP; Fotin-Mleczek M, 2002, J CELL SCI, V115, P2757; Fulda S, 2012, SARCOMA, V2012; Graber TE, 2010, CELL DEATH DIFFER, V17, P719, DOI 10.1038/cdd.2009.164; Gyrd-Hansen M, 2010, NAT REV CANCER, V10, P561, DOI 10.1038/nrc2889; Hafner M, 2010, CELL, V141, P129, DOI 10.1016/j.cell.2010.03.009; Hansen TVO, 2004, MOL CELL BIOL, V24, P4448, DOI 10.1128/MCB.24.10.4448-4464.2004; Holcik M, 2005, NAT REV MOL CELL BIO, V6, P318, DOI 10.1038/nrm1618; Holcik M, 2002, BMC GENOMICS, V3, DOI 10.1186/1471-2164-3-5; Houghton PJ, 2012, PEDIATR BLOOD CANCER, V58, P636, DOI 10.1002/pbc.23167; Huh WW, 2010, CURR ONCOL REP, V12, P402, DOI 10.1007/s11912-010-0130-3; Huttelmaier S, 2005, NATURE, V438, P512, DOI 10.1038/nature04115; Izeradjene K, 2004, CANCER RES, V64, P8036, DOI 10.1158/0008-5472.CAN-04-0762; Izeradjene K, 2004, CLIN CANCER RES, V10, P6650, DOI 10.1158/1078-0432.CCR-04-0576; Jonson L, 2007, MOL CELL PROTEOMICS, V6, P798, DOI 10.1074/mcp.M600346-MCP200; King HA, 2010, BIOCHEM SOC T, V38, P1581, DOI 10.1042/BST0381581; LaCasse EC, 1998, ONCOGENE, V17, P3247, DOI 10.1038/sj.onc.1202569; Lewis SM, 2008, NUCLEIC ACIDS RES, V36, P168, DOI 10.1093/nar/gkm1007; Li L, 2004, SCIENCE, V305, P1471, DOI 10.1126/science.1098231; Mongroo PS, 2011, CANCER RES, V71, P2172, DOI 10.1158/0008-5472.CAN-10-3295; Nielsen J, 1999, MOL CELL BIOL, V19, P1262; Petak I, 2000, CLIN CANCER RES, V6, P4119; Petersen SL, 2007, CANCER CELL, V12, P445, DOI 10.1016/j.ccr.2007.08.029; Pommier Y, 2004, ONCOGENE, V23, P2934, DOI 10.1038/sj.onc.1207515; Ross AF, 1997, MOL CELL BIOL, V17, P2158, DOI 10.1128/MCB.17.4.2158; Saab R, 2011, CURR TOP DEV BIOL, V94, P197, DOI 10.1016/B978-0-12-380916-2.00007-3; Stohr N, 2006, J CELL BIOL, V175, P527, DOI 10.1083/jcb.200608071; Stohr N, 2012, GENE DEV, V26, P176, DOI 10.1101/gad.177642.111; Tessier CR, 2004, CANCER RES, V64, P209, DOI 10.1158/0008-5472.CAN-03-2927; Vagner S, 2001, EMBO REP, V2, P893, DOI 10.1093/embo-reports/kve208; Van Eden ME, 2004, RNA, V10, P469, DOI 10.1261/rna.5156804; Varfolomeev E, 2007, CELL, V131, P669, DOI 10.1016/j.cell.2007.10.030; Vikesaa J, 2006, EMBO J, V25, P1456, DOI 10.1038/sj.emboj.7601039; Vince JE, 2007, CELL, V131, P682, DOI 10.1016/j.cell.2007.10.037; Warnakulasuriyarachchi D, 2004, J BIOL CHEM, V279, P17148, DOI 10.1074/jbc.M308737200; Weidensdorfer D, 2009, RNA, V15, P104, DOI 10.1261/rna.1175909; Weingartner M, 2002, J BIOL CHEM, V277, P34853, DOI 10.1074/jbc.M205149200; Weinlich S, 2009, RNA, V15, P1528, DOI 10.1261/rna.1578409; Weisberg E, 2010, LEUKEMIA, V24, P2100, DOI 10.1038/leu.2010.212; Yaniv K, 2002, GENE, V287, P49, DOI 10.1016/S0378-1119(01)00866-6; Yisraeli JK, 2005, BIOL CELL, V97, P87	50	31	32	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 19	2015	34	12					1532	1541		10.1038/onc.2014.90	http://dx.doi.org/10.1038/onc.2014.90			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CD9KI	24704827				2022-12-17	WOS:000351416800006
J	de la Cruz-Herrera, CF; Campagna, M; Lang, V; Gonzalez-Santamaria, JD; Marcos-Villar, L; Rodriguez, MS; Vidal, A; Collado, M; Rivas, C				de la Cruz-Herrera, C. F.; Campagna, M.; Lang, V.; del Carmen Gonzalez-Santamaria, J.; Marcos-Villar, L.; Rodriguez, M. S.; Vidal, A.; Collado, M.; Rivas, C.			SUMOylation regulates AKT1 activity	ONCOGENE			English	Article							PROTEIN-KINASE B; HEAT-SHOCK; ONCOGENIC TRANSFORMATION; QUANTITATIVE PROTEOMICS; SUMO-1 MODIFICATION; NIH3T3 CELLS; ACTIVATION; PATHWAY; PHOSPHORYLATION; PML	Serine threonine kinase AKT has a central role in the cell, controlling survival, proliferation, metabolism and angiogenesis. Deregulation of its activity underlies a wide range of pathological situations, including cancer. Here we show that AKT is post-translationally modified by the small ubiquitin-like modifier (SUMO) protein. Interestingly, neither SUMO conjugation nor activation of SUMOylated AKT is regulated by the classical AKT targeting to the cell membrane or by the phosphoinositide 3-kinase pathway. We demonstrate that SUMO induces the activation of AKT, whereas, conversely, down-modulation of the SUMO machinery diminishes AKT activation and cell proliferation. Furthermore, an AKT SUMOylation mutant shows reduced activation, and decreased anti-apoptotic and pro-tumoral activities in comparison with the wild-type protein. These results identify SUMO as a novel key regulator of AKT phosphorylation and activity.	[de la Cruz-Herrera, C. F.; Campagna, M.; del Carmen Gonzalez-Santamaria, J.; Marcos-Villar, L.; Rivas, C.] CSIC, Ctr Nacl Biotecnol, Dept Mol & Cellular Biol, Madrid 28049, Spain; [Lang, V.; Rodriguez, M. S.] Ubiquitylat & Canc Mol Biol Lab, Inbiomed, San Sebastian, Gipuzkoa, Spain; [Vidal, A.] Univ Santiago de Compostela, Inst Invest Sanitarias IDIS, Dept Fisiol, Santiago De Compostela, Spain; [Vidal, A.; Rivas, C.] Univ Santiago de Compostela, Inst Invest Sanitarias IDIS, Ctr Invest Med Mol CIMUS, Santiago De Compostela, Spain; [Collado, M.] Complexo Hosp Univ Santiago de Compostela CHUS, SERGAS, Inst Invest Sanit Santiago Compostela, Santiago De Compostela, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB); Universidade de Santiago de Compostela; Universidade de Santiago de Compostela; Complexo Hospitalario Universitario de Santiago de Compostela	Rivas, C (corresponding author), CSIC, Ctr Nacl Biotecnol, Dept Mol & Cellular Biol, Darwin 3,Campus Univ Autonoma Madrid, Madrid 28049, Spain.	crivas@cnb.csic.es	Rivas, Carmen/L-3162-2017; Santamaria, Jose Gonzalez/AAN-1044-2020; Rivas, Carmen/AAB-6278-2019; RODRIGUEZ, Manuel S./D-5439-2018; Santamaría, José González/Q-2439-2015; Collado, Manuel/K-8140-2014; Vidal, Anxo/B-5010-2015	Rivas, Carmen/0000-0002-0518-7199; Rivas, Carmen/0000-0002-0518-7199; Santamaría, José González/0000-0003-1244-3477; Collado, Manuel/0000-0002-0330-0880; Vidal, Anxo/0000-0002-0866-4202; de la Cruz-Herrera, Carlos/0000-0002-7493-5154	Juan de la Cierva Programme; La Caixa fellowship;  [BFU-2011-27064]	Juan de la Cierva Programme; La Caixa fellowship(La Caixa Foundation); 	We thank Dr William R Sellers who deposited AKT plamids at Addgene. Funding at the laboratory of CR is provided by BFU-2011-27064. LM-V is supported by Juan de la Cierva Programme. CFC-H is supported by La Caixa fellowship. MC is an investigator of the Miguel Servet Program.	Alessi DR, 1998, CURR OPIN GENET DEV, V8, P55, DOI 10.1016/S0959-437X(98)80062-2; Bang OS, 2000, BIOCHEM BIOPH RES CO, V278, P306, DOI 10.1006/bbrc.2000.3805; Bawa-Khalfe Tasneem, 2010, Genes Cancer, V1, P748; Bossis G, 2006, CELL DIV, V1, DOI 10.1186/1747-1028-1-13; Brodbeck D, 1999, J BIOL CHEM, V274, P9133, DOI 10.1074/jbc.274.14.9133; Calleja Veronique, 2009, J Chem Biol, V2, P11, DOI 10.1007/s12154-009-0016-8; Campagna M, 2011, CELL DEATH DIFFER, V18, P72, DOI 10.1038/cdd.2010.77; Desterro JMP, 1998, MOL CELL, V2, P233, DOI 10.1016/S1097-2765(00)80133-1; Flotho A, 2013, ANNU REV BIOCHEM, V82, P357, DOI 10.1146/annurev-biochem-061909-093311; Golebiowski F, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000282; Gonzalez-Santamaria J, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.135; Hay RT, 2005, MOL CELL, V18, P1, DOI 10.1016/j.molcel.2005.03.012; Hietakangas V, 2003, MOL CELL BIOL, V23, P2953, DOI 10.1128/MCB.23.8.2953-2968.2003; Hong YL, 2001, J BIOL CHEM, V276, P40263, DOI 10.1074/jbc.M104714200; Hsieh AC, 2004, NUCLEIC ACIDS RES, V32, P893, DOI 10.1093/nar/gkh238; Johnson ES, 2004, ANNU REV BIOCHEM, V73, P355, DOI 10.1146/annurev.biochem.73.011303.074118; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; Laine J, 2000, MOL CELL, V6, P395, DOI 10.1016/S1097-2765(00)00039-3; Lallemand-Breitenbach V, 2008, NAT CELL BIOL, V10, P547, DOI 10.1038/ncb1717; Liu XS, 2004, ANTICANCER RES, V24, P2697; Mao Y, 2000, J BIOL CHEM, V275, P26066, DOI 10.1074/jbc.M001831200; Marcos-Villar L, 2009, J VIROL, V83, P8849, DOI 10.1128/JVI.00339-09; Matic I, 2008, MOL CELL PROTEOMICS, V7, P132, DOI 10.1074/mcp.M700173-MCP200; Miller MJ, 2013, MOL CELL PROTEOMICS, V12, P449, DOI 10.1074/mcp.M112.025056; Nguyen H, 1999, MOL CELL BIOL, V19, P1190; Ramaswamy S, 1999, P NATL ACAD SCI USA, V96, P2110, DOI 10.1073/pnas.96.5.2110; Sakoda H, 2003, J BIOL CHEM, V278, P25802, DOI 10.1074/jbc.M301127200; Sato S, 2000, P NATL ACAD SCI USA, V97, P10832, DOI 10.1073/pnas.170276797; Steinacher R, 2005, CURR BIOL, V15, P616, DOI 10.1016/j.cub.2005.02.054; Sun M, 2001, AM J PATHOL, V159, P431, DOI 10.1016/S0002-9440(10)61714-2; Tatham MH, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001484; Testa JR, 2005, ONCOGENE, V24, P7391, DOI 10.1038/sj.onc.1209100; Trotman LC, 2006, NATURE, V441, P523, DOI 10.1038/nature04809; Vertegaal ACO, 2006, MOL CELL PROTEOMICS, V5, P2298, DOI 10.1074/mcp.M600212-MCP200; Warfel NA, 2011, J BIOL CHEM, V286, P39122, DOI 10.1074/jbc.M111.278747; Yoshihara T, 2013, ACTA PHYSIOL, V207, P416, DOI 10.1111/apha.12040	36	31	31	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 12	2015	34	11					1442	1450		10.1038/onc.2014.48	http://dx.doi.org/10.1038/onc.2014.48			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CD1AR	24704831	Green Published			2022-12-17	WOS:000350806500010
J	Liu, Z; Zhan, Y; Tu, Y; Chen, K; Liu, Z; Wu, C				Liu, Z.; Zhan, Y.; Tu, Y.; Chen, K.; Liu, Z.; Wu, C.			PDZ and LIM domain protein 1(PDLIM1)/CLP36 promotes breast cancer cell migration, invasion and metastasis through interaction with alpha-actinin	ONCOGENE			English	Article							RHO-GTPASES; GENE AMPLIFICATION; STRESS FIBERS; ADHESION; CLP36; ALPHA-ACTININ-1; MOTILITY; ACTIVATION; EXPRESSION; MIGFILIN	Increased CLP36 expression has been found to be closely associated with breast cancer progression. However, whether and how it contributes to malignant behavior of breast cancer cells were not known. We show here that CLP36 is critical for promoting breast cancer cell migration and invasion in vitro and metastasis in vivo, whereas it is dispensable for breast cell proliferation and anchorage-independent growth in vitro and tumor growth in vivo. CLP36 interacted with both alpha-actinin-1 and -4 in breast cancer cells. Depletion of either alpha-actinin-1 or -4 inhibited breast cancer cell migration. Furthermore, mutations inhibiting the a-actinin-binding activity abolished the ability of CLP36 to promote breast cancer cell migration. Finally, depletion of CLP36 or disruption of the CLP36-alpha-actinin complex in breast cancer cells substantially inhibited Cdc42 activation, cell polarization and migration. Our results identify CLP36 as an important regulator of breast cancer cell migration and metastasis, and shed light on how increased CLP36 expression contributes to the progression of breast cancer.	[Liu, Z.; Tu, Y.; Chen, K.; Wu, C.] Univ Pittsburgh, Dept Pathol, Sch Med, Pittsburgh, PA 15261 USA; [Zhan, Y.; Liu, Z.] Chinese Acad Med Sci, Peking Union Med Coll, Canc Inst & Hosp, State Key Lab Mol Oncol, Beijing 100730, Peoples R China; [Wu, C.] Univ Pittsburgh, Inst Canc, Pittsburgh, PA USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Chinese Academy of Medical Sciences - Peking Union Medical College; Cancer Institute & Hospital - CAMS; Peking Union Medical College; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Wu, C (corresponding author), Univ Pittsburgh, Dept Pathol, Sch Med, 3550 Terrace St,707B Scaife Hall, Pittsburgh, PA 15261 USA.	carywu@pitt.edu			NIH [GM65188]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM065188] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported by NIH Grant GM65188 to CW.	Bauer K, 2000, BLOOD, V96, P4236; Bouzahzah B, 2001, MOL MED, V7, P816, DOI 10.1007/BF03401974; Cardiff RD, 2000, ONCOGENE, V19, P968, DOI 10.1038/sj.onc.1203277; Etienne-Manneville S, 2004, J CELL SCI, V117, P1291, DOI 10.1242/jcs.01115; Fritz G, 2002, BRIT J CANCER, V87, P635, DOI 10.1038/sj.bjc.6600510; Fritz G, 1999, INT J CANCER, V81, P682, DOI 10.1002/(SICI)1097-0215(19990531)81:5<682::AID-IJC2>3.0.CO;2-B; Honda K, 1998, J CELL BIOL, V140, P1383, DOI 10.1083/jcb.140.6.1383; Honda K, 2005, GASTROENTEROLOGY, V128, P51, DOI 10.1053/j.gastro.2004.10.004; Johnson E, 2010, J BIOL CHEM, V285, P29491, DOI 10.1074/jbc.M110.136770; Kikuchi S, 2008, CLIN CANCER RES, V14, P5348, DOI 10.1158/1078-0432.CCR-08-0075; Klaavuniemi T, 2004, J BIOL CHEM, V279, P26402, DOI 10.1074/jbc.M401871200; Liu ZM, 2011, J BIOL CHEM, V286, P30795, DOI 10.1074/jbc.M111.255984; Miyazaki K, 2012, EXP CELL RES, V318, P1716, DOI 10.1016/j.yexcr.2012.05.006; Nobes CD, 1999, J CELL BIOL, V144, P1235, DOI 10.1083/jcb.144.6.1235; Pichot CS, 2010, CANCER RES, V70, P8347, DOI 10.1158/0008-5472.CAN-09-4149; Pitteri SJ, 2011, CANCER RES, V71, P5090, DOI 10.1158/0008-5472.CAN-11-0568; Quick Q, 2010, EXP CELL RES, V316, P1137, DOI 10.1016/j.yexcr.2010.02.011; Shao H, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013921; Shi XH, 2008, MOL CANCER RES, V6, P715, DOI 10.1158/1541-7786.MCR-07-2026; Shi XH, 2007, J BIOL CHEM, V282, P20455, DOI 10.1074/jbc.M611680200; Tamura N, 2007, BIOCHEM BIOPH RES CO, V364, P589, DOI 10.1016/j.bbrc.2007.10.064; Tu YZ, 2003, CELL, V113, P37, DOI 10.1016/S0092-8674(03)00163-6; Tu YZ, 2001, J CELL BIOL, V153, P585, DOI 10.1083/jcb.153.3.585; Uehara N, 2008, MOL CANCER RES, V6, P186, DOI 10.1158/1541-7786.MCR-07-0254; Vallenius T, 2004, EXP CELL RES, V293, P117, DOI 10.1016/j.yexcr.2003.09.004; Vallenius T, 2000, J BIOL CHEM, V275, P11100, DOI 10.1074/jbc.275.15.11100; Velthuis AJWT, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000189; Yamaguchi H, 2005, J CELL BIOL, V168, P441, DOI 10.1083/jcb.200407076; Yamamoto S, 2009, MODERN PATHOL, V22, P499, DOI 10.1038/modpathol.2008.234; Zhang YJ, 2006, J BIOL CHEM, V281, P12397, DOI 10.1074/jbc.M512107200	30	31	33	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 5	2015	34	10					1300	1311		10.1038/onc.2014.64	http://dx.doi.org/10.1038/onc.2014.64			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CC9JX	24662836	Green Accepted			2022-12-17	WOS:000350687100010
J	Bickeboller, M; Tagscherer, KE; Kloor, M; Jansen, L; Chang-Claude, J; Brenner, H; Hoffmeister, M; Toth, C; Schirmacher, P; Roth, W; Blaker, H				Bickeboeller, M.; Tagscherer, K. E.; Kloor, M.; Jansen, L.; Chang-Claude, J.; Brenner, H.; Hoffmeister, M.; Toth, C.; Schirmacher, P.; Roth, W.; Blaeker, H.			Functional characterization of the tumor-suppressor MARCKS in colorectal cancer and its association with survival	ONCOGENE			English	Article							PROTEIN-KINASE-C; APOPTOSIS-INDUCING LIGAND; PROMINENT CELLULAR SUBSTRATE; MICROSATELLITE INSTABILITY; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; PLASMA-MEMBRANE; MELANOMA-CELLS; DIFFERENTIAL EXPRESSION; CALMODULIN-BINDING; EFFECTOR DOMAIN	The myristoylated alanine-rich C-kinase substrate (MARCKS) acts as a tumor suppressor in a variety of human neoplasms. In colorectal cancers (CRCs), MARCKS has been shown to be a preferential target of mutational inactivation in tumors following the microsatellite instability (MSI-H) pathway but little is known about its impact on intestinal carcinogenesis. To investigate the relevance of MARCKS inactivation in more detail, we analyzed 926 MSI-typed CRCs for MARCKS expression by immunohistochemistry and studied the functional consequences of MARCKS depletion in colorectal cancer cell lines. We found that loss of MARCKS expression was not restricted to MSI-H cancers but also occurred in microsatellite stable (MSS) tumors, where it was associated with an adverse outcome regarding overall survival, cancer-specific and disease-free survival (P = 0.002, P = 0.0018, P = 0.0001, respectively; univariate analysis). In MARCKS-positive MSS colon cancer cell lines (SW480 and SW707) small interfering RNA (siRNA)-mediated knockdown of MARCKS conferred resistance to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis. This was accompanied by the downregulation of the TRAIL receptors DR4 and DR5 at the cell surface and activation of AKT signaling. Inhibition of AKT signaling and transient overexpression of wild-type MARCKS, but not of MARCKS lacking the effector domain (ED), abolished the anti-apoptotic effect. In conclusion, our data show that inactivation of MARCKS is common in CRCs and is associated with adverse outcome in MSS cancers. The finding that MARCKS acts as a mediator of apoptosis in MSS CRC cells adds a novel tumor-suppressing function to the so far established roles of MARCKS in cell motility and proliferation and can explain the prognostic effect of MARCKS depletion in MSS CRC.	[Bickeboeller, M.; Tagscherer, K. E.; Roth, W.] German Canc Res Ctr, Div Mol Tumor Pathol, Heidelberg, Germany; [Bickeboeller, M.; Tagscherer, K. E.; Toth, C.; Schirmacher, P.; Roth, W.] Heidelberg Univ, Inst Pathol, Dept Gen Pathol, Heidelberg, Germany; [Kloor, M.] Heidelberg Univ, Inst Pathol, Dept Appl Tumor Biol, Heidelberg, Germany; [Jansen, L.; Brenner, H.; Hoffmeister, M.] German Canc Res Ctr, Div Clin Epidemiol & Aging Res, Heidelberg, Germany; [Chang-Claude, J.] German Canc Res Ctr, Unit Genet Epidemiol, Div Canc Epidemiol, Heidelberg, Germany; [Blaeker, H.] Univ Hosp Charite, Inst Pathol, Dept Gen Pathol, D-10117 Berlin, Germany	Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg; Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ); Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Blaker, H (corresponding author), Univ Hosp Charite, Inst Pathol, Dept Gen Pathol, Campus Mitte,Charitepl 1, D-10117 Berlin, Germany.	hendrik.blaeker@charite.de	Hoffmeister, Michael/T-7187-2019; Hoffmeister, Michael/AAB-2321-2022; Brenner, Hermann/B-4627-2017; Hoffmeister, Michael/B-5745-2012; Brenner, Hermann/ABE-6383-2020; Tagscherer, Katrin/AAS-3809-2021; Jansen, Lina/D-7255-2016	Hoffmeister, Michael/0000-0002-8307-3197; Hoffmeister, Michael/0000-0002-8307-3197; Brenner, Hermann/0000-0002-6129-1572; Hoffmeister, Michael/0000-0002-8307-3197; Brenner, Hermann/0000-0002-6129-1572; Tagscherer, Katrin/0000-0002-0657-6399; Jansen, Lina/0000-0001-8004-4940	German Research Council (Deutsche Forschungsgemeinschaft) [BL554/3-2, BR 1704/6-1, BR 1704/6-3, BR 1704/6-4, CH 390 117/1-1]; German Federal Ministry of Education and Research [01KH0404, 01ER0814]; Interdisciplinary Research Program of the National Center for Tumor Diseases (NCT), Heidelberg, Germany	German Research Council (Deutsche Forschungsgemeinschaft)(German Research Foundation (DFG)); German Federal Ministry of Education and Research(Federal Ministry of Education & Research (BMBF)); Interdisciplinary Research Program of the National Center for Tumor Diseases (NCT), Heidelberg, Germany	We thank the study participants and the interviewers who collected the data. We also greatly appreciate the help of the hospitals, pathology departments and cooperating institutions in recruiting patients for this study and providing tumor samples. We thank Jutta Richter, Ute Handte-Daub, Bettina Walter, Barbara Schreiber and Marina Gernold for their excellent technical assistance. H Blaker has been supported by a grant from the German Research Council (Deutsche Forschungsgemeinschaft; grant number: BL554/3-2). The DACHS study was supported by grants from the German Research Council (Deutsche Forschungsgemeinschaft, grant numbers BR 1704/6-1, BR 1704/6-3, BR 1704/6-4 and CH 390 117/1-1), the German Federal Ministry of Education and Research (grant numbers 01KH0404 and 01ER0814), and the Interdisciplinary Research Program of the National Center for Tumor Diseases (NCT), Heidelberg, Germany.	ALBERT KA, 1987, P NATL ACAD SCI USA, V84, P7046, DOI 10.1073/pnas.84.20.7046; Arbuzova A, 2002, BIOCHEM J, V362, P1, DOI 10.1042/0264-6021:3620001; Bennett M, 1998, SCIENCE, V282, P290, DOI 10.1126/science.282.5387.290; Brenner H, 2011, ANN INTERN MED, V154, P22, DOI 10.7326/0003-4819-154-1-201101040-00004; Brooks G, 1996, CARCINOGENESIS, V17, P683, DOI 10.1093/carcin/17.4.683; Castro F, 2013, INT J CANCER, V132, P308, DOI 10.1002/ijc.27675; Chen XY, 2010, CELL SIGNAL, V22, P1097, DOI 10.1016/j.cellsig.2010.03.003; Cho SJ, 2001, BIOCHEM BIOPH RES CO, V283, P273, DOI 10.1006/bbrc.2001.4773; Estrada-Bernal A, 2009, J CELL SCI, V122, P2300, DOI 10.1242/jcs.047860; Fassl A, 2012, ONCOGENE, V31, P4698, DOI 10.1038/onc.2011.615; Findeisen P, 2005, CANCER RES, V65, P8072, DOI 10.1158/0008-5472.CAN-04-4146; Glaser M, 1996, J BIOL CHEM, V271, P26187, DOI 10.1074/jbc.271.42.26187; GRAFF JM, 1991, J BIOL CHEM, V266, P14390; GRAFF JM, 1989, J BIOL CHEM, V264, P21818; GRAFF JM, 1989, J BIOL CHEM, V264, P11912; HARLAN DM, 1991, J BIOL CHEM, V266, P14399; Hoffmeister M, 2013, CANCER EPIDEM BIOMAR, V22, P2303, DOI 10.1158/1055-9965.EPI-13-0239; Holz RW, 2000, J BIOL CHEM, V275, P17878, DOI 10.1074/jbc.M000925200; Honing S, 2005, MOL CELL, V18, P519, DOI 10.1016/j.molcel.2005.04.019; Jarboe JS, 2012, CLIN CANCER RES, V18, P3030, DOI 10.1158/1078-0432.CCR-11-3091; Johnstone RW, 2008, NAT REV CANCER, V8, P782, DOI 10.1038/nrc2465; Jones SJ, 1999, J IMMUNOL, V162, P1042; JOSEPH CK, 1992, J BIOL CHEM, V267, P1327; Kim NG, 2002, ONCOGENE, V21, P5081, DOI 10.1038/sj.onc.1205703; Koh KH, 2005, LAB INVEST, V85, P1130, DOI 10.1038/labinvest.3700315; Kriegl L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051654; Laux T, 2000, J CELL BIOL, V149, P1455, DOI 10.1083/jcb.149.7.1455; Li YH, 2001, J BIOL CHEM, V276, P40982, DOI 10.1074/jbc.M105614200; Lilla C, 2006, CANCER EPIDEM BIOMAR, V15, P99, DOI 10.1158/1055-9965.EPI-05-0618; Michel S, 2010, MOL CARCINOGEN, V49, P175, DOI 10.1002/mc.20587; Miura K, 2002, MOL CELL, V9, P109, DOI 10.1016/S1097-2765(02)00428-8; Morash SC, 2005, NEUROCHEM RES, V30, P1353, DOI 10.1007/s11064-005-8220-6; Morton LA, 2013, ACS CHEM BIOL, V8, P218, DOI 10.1021/cb300429e; Myat MM, 1997, CURR BIOL, V7, P611, DOI 10.1016/S0960-9822(06)00262-4; Nie ZZ, 2006, CURR BIOL, V16, P130, DOI 10.1016/j.cub.2005.11.069; Peuhu E, 2010, ONCOGENE, V29, P898, DOI 10.1038/onc.2009.386; Rombouts K, 2013, CANCER LETT, V333, P244, DOI 10.1016/j.canlet.2013.01.040; ROSE SD, 1994, J NEUROCHEM, V63, P2314; Rudolph A, 2012, BRIT J CANCER, V107, P831, DOI 10.1038/bjc.2012.323; Schmitt M, 2009, NUCLEIC ACIDS RES, V37, DOI 10.1093/nar/gkp581; SEYKORA JT, 1991, P NATL ACAD SCI USA, V88, P2505, DOI 10.1073/pnas.88.6.2505; Shin N, 2011, INT J CANCER, V128, P2872, DOI 10.1002/ijc.25641; SIMEK SL, 1989, P NATL ACAD SCI USA, V86, P7410, DOI 10.1073/pnas.86.19.7410; Simova S, 2008, APOPTOSIS, V13, P423, DOI 10.1007/s10495-007-0171-8; Smyth MJ, 2001, J EXP MED, V193, P661, DOI 10.1084/jem.193.6.661; STUMPO DJ, 1989, P NATL ACAD SCI USA, V86, P4012, DOI 10.1073/pnas.86.11.4012; Su R, 2010, NEUROSCI BULL, V26, P338, DOI 10.1007/s12264-010-0131-0; Sundaram M, 2004, BIOCHEM CELL BIOL, V82, P191, DOI 10.1139/o03-087; Takeda K, 2002, J EXP MED, V195, P161, DOI 10.1084/jem.20011171; Techasen A, 2010, CANCER SCI, V101, P658, DOI 10.1111/j.1349-7006.2009.01427.x; Wang JY, 2002, J BIOL CHEM, V277, P34401, DOI 10.1074/jbc.M203954200; Woerner SM, 2005, ONCOGENE, V24, P2525, DOI 10.1038/sj.onc.1208456; WOLFMAN A, 1987, J BIOL CHEM, V262, P16546; Yamaguchi T, 2006, DIS COLON RECTUM, V49, P399, DOI 10.1007/s10350-005-0293-4; Zhang XD, 2000, J IMMUNOL, V164, P3961, DOI 10.4049/jimmunol.164.8.3961; Zhu YM, 2005, CANCER RES, V65, P4520, DOI 10.1158/0008-5472.CAN-04-4506	56	31	31	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 26	2015	34	9					1150	1159		10.1038/onc.2014.40	http://dx.doi.org/10.1038/onc.2014.40			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CC1RY	24662837				2022-12-17	WOS:000350122100008
J	Eberlein, C; Rooney, C; Ross, SJ; Farren, M; Weir, HM; Barry, ST				Eberlein, C.; Rooney, C.; Ross, S. J.; Farren, M.; Weir, H. M.; Barry, S. T.			E-Cadherin and EpCAM expression by NSCLC tumour cells associate with normal fibroblast activation through a pathway initiated by integrin alpha v beta 6 and maintained through TGF beta signalling	ONCOGENE			English	Article						NSCLC; stroma; CAF; integrin; alpha v beta 6; TGF beta	CARCINOMA-ASSOCIATED-FIBROBLASTS; GROWTH-FACTOR-BETA; STROMAL MYOFIBROBLASTS; CANCER; INHIBITION; INVASION; KINASE; INTEGRIN-ALPHA-V-BETA-6; SIGNATURE; RECEPTOR	Fibroblasts in the tumour stroma (cancer-associated fibroblasts) influence tumour progression and response to therapeutics; little is known about the mechanisms through which the tumour cell co-opts a normal fibroblast. To study the activation of fibroblasts by tumour cells, a panel of non-small cell lung cancer (NSCLC) cell lines and normal human dermal fibroblasts were co-cultured. A subset of the NSCLC cells induced an activated cancer-associated fibroblast-like fibroblast phenotype defined by induction of fibroblast alpha-smooth muscle actin expression. Tumour cells that activated fibroblasts were associated with E-Cadherin and EpCAM expression and expression of integrin alpha v beta 6. Co-culture of activating tumour cells with fibroblasts resulted in induction of transcripts associated with tumour cell invasion and growth, TGF beta 1 and TGFBR1, SERPINE-1, BMP6, SPHK1 and MMP9. Fibroblast activation was inhibited by an alpha v beta 6/8 integrin blocking antibody (264RAD) and a small molecule inhibitor of the TGF-beta type I receptor activin-like kinase (ALK5) (SB431542), demonstrating that transactivation of the TGF beta pathway initiates fibroblast activation. Both integrin and ALK5 antagonists inhibited initiation. Only ALK5 was effective when added after 3 days of co-culture. This suggests that although activation is alpha v beta 6-dependent, once fibroblasts are activated alternative TGF beta pathway regulators maintain an activation loop. In co-culture activating cells had reduced sensitivity to selumetinib, AZD8931 and afatinib compared with mono-culture. In contrast, non-activating cells were insensitive to selumetinib and AZD8931 in both mono-culture and co-culture. In conclusion NSCLC cell lines, positive for E-Cadherin, EpCAM and alpha v beta 6 expression, activate normal fibroblasts through alpha v beta 6/TGF beta signalling in vitro, and influence both gene expression and response to therapeutic agents.	[Eberlein, C.; Rooney, C.; Ross, S. J.; Farren, M.; Weir, H. M.; Barry, S. T.] AstraZeneca, Oncol iMED, Macclesfield SK10 4TG, Cheshire, England	AstraZeneca	Barry, ST (corresponding author), AstraZeneca, Oncol iMED, Alderley Pk, Macclesfield SK10 4TG, Cheshire, England.	Simon.T.Barry@astrazeneca.com						Aluwihare P, 2009, J CELL SCI, V122, P227, DOI 10.1242/jcs.035246; Bremnes RM, 2011, J THORAC ONCOL, V6, P209, DOI 10.1097/JTO.0b013e3181f8a1bd; Brentnall TA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030219; Cardone A, 1997, PANMINERVA MED, V39, P174; Cascone T, 2011, J CLIN INVEST, V121, P1313, DOI 10.1172/JCI42405; Eberlein C, 2013, ONCOGENE, V32, P4406, DOI 10.1038/onc.2012.460; Egeblad M, 2010, DEV CELL, V18, P884, DOI 10.1016/j.devcel.2010.05.012; Farmer P, 2009, NAT MED, V15, P68, DOI 10.1038/nm.1908; Folkes AJ, 2008, J MED CHEM, V51, P5522, DOI 10.1021/jm800295d; Gaggioli C, 2007, NAT CELL BIOL, V9, P1392, DOI 10.1038/ncb1658; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hickinson DM, 2010, CLIN CANCER RES, V16, P1159, DOI 10.1158/1078-0432.CCR-09-2353; Horan GS, 2008, AM J RESP CRIT CARE, V177, P56, DOI 10.1164/rccm.200706-805OC; Inman GJ, 2002, MOL PHARMACOL, V62, P65, DOI 10.1124/mol.62.1.65; Joyce JA, 2009, NAT REV CANCER, V9, P239, DOI 10.1038/nrc2618; Kalluri R, 2006, NAT REV CANCER, V6, P392, DOI 10.1038/nrc1877; Kano MR, 2007, P NATL ACAD SCI USA, V104, P3460, DOI 10.1073/pnas.0611660104; Kojima Y, 2010, P NATL ACAD SCI USA, V107, P20009, DOI 10.1073/pnas.1013805107; Lebret SC, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1656; Lewis MP, 2004, BRIT J CANCER, V90, P822, DOI 10.1038/sj.bjc.6601611; Maeshima AM, 2002, CANCER, V95, P2546, DOI 10.1002/cncr.11006; Marsh D, 2008, CANCER RES, V68, P3295, DOI 10.1158/0008-5472.CAN-08-0174; Marsh D, 2011, J PATHOL, V223, P470, DOI 10.1002/path.2830; McMillin DW, 2010, NAT MED, V16, P483, DOI 10.1038/nm.2112; Mink SR, 2010, MOL CANCER RES, V8, P809, DOI 10.1158/1541-7786.MCR-09-0460; Minkovsky N, 2008, CURR OPIN INVEST DR, V9, P1336; Munger JS, 1999, CELL, V96, P319, DOI 10.1016/S0092-8674(00)80545-0; Navab R, 2011, P NATL ACAD SCI USA, V108, P7160, DOI 10.1073/pnas.1014506108; Olive KP, 2009, SCIENCE, V324, P1457, DOI 10.1126/science.1171362; Orimo A, 2005, CELL, V121, P335, DOI 10.1016/j.cell.2005.02.034; Popov Y, 2008, J HEPATOL, V48, P453, DOI 10.1016/j.jhep.2007.11.021; Provenzano PP, 2012, CANCER CELL, V21, P418, DOI 10.1016/j.ccr.2012.01.007; Puthawala K, 2008, AM J RESP CRIT CARE, V177, P82, DOI 10.1164/rccm.200706-806OC; Rasanen K, 2010, EXP CELL RES, V316, P2713, DOI 10.1016/j.yexcr.2010.04.032; RONNOVJESSEN L, 1993, LAB INVEST, V68, P696; RonnovJessen L, 1996, PHYSIOL REV, V76, P69, DOI 10.1152/physrev.1996.76.1.69; Ross S, 2008, INT J BIOCHEM CELL B, V40, P383, DOI 10.1016/j.biocel.2007.09.006; Schiller M, 2004, J DERMATOL SCI, V35, P83, DOI 10.1016/j.jdermsci.2003.12.006; Singh A, 2009, CANCER CELL, V15, P489, DOI 10.1016/j.ccr.2009.03.022; Straussman R, 2012, NATURE, V487, P500, DOI 10.1038/nature11183; Surowiak P, 2006, FOLIA HISTOCHEM CYTO, V44, P111; Thomas GJ, 2001, J INVEST DERMATOL, V117, P67, DOI 10.1046/j.0022-202x.2001.01379.x; Tothill RW, 2008, CLIN CANCER RES, V14, P5198, DOI 10.1158/1078-0432.CCR-08-0196; Varga J, 2002, ARTHRITIS RHEUM-US, V46, P1703, DOI 10.1002/art.10413; Yazhou C, 2004, TUMOR BIOL, V25, P290, DOI 10.1159/000081394; Yeh TC, 2007, CLIN CANCER RES, V13, P1576, DOI 10.1158/1078-0432.CCR-06-1150; Zieba A, 2012, MOL CELL PROTEOMICS, V11, DOI 10.1074/mcp.M111.013482	47	31	33	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 5	2015	34	6					704	716		10.1038/onc.2013.600	http://dx.doi.org/10.1038/onc.2013.600			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CA4DG	24488011				2022-12-17	WOS:000348853800004
J	Labidi-Galy, SI; Clauss, A; Ng, V; Duraisamy, S; Elias, KM; Piao, HY; Bilal, E; Davidowitz, RA; Lu, Y; Badalian-Very, G; Gyorffy, B; Kang, UB; Ficarro, S; Ganesan, S; Mills, GB; Marto, JA; Drapkin, R				Labidi-Galy, S. I.; Clauss, A.; Ng, V.; Duraisamy, S.; Elias, K. M.; Piao, H-Y; Bilal, E.; Davidowitz, R. A.; Lu, Y.; Badalian-Very, G.; Gyoerffy, B.; Kang, U-B; Ficarro, S.; Ganesan, S.; Mills, G. B.; Marto, J. A.; Drapkin, R.			Elafin drives poor outcome in high-grade serous ovarian cancers and basal-like breast tumors	ONCOGENE			English	Article						elafin; ovarian cancer; basal-like breast cancer; mitogen; MAP kinase	MAMMARY EPITHELIAL-CELLS; VERSUS-HOST-DISEASE; GENOMIC INSTABILITY; MICROARRAY DATA; EXPRESSION; PROTEIN; VALIDATION; SURVIVAL; GENES; HE-4	High-grade serous ovarian carcinoma (HGSOC) and basal-like breast cancer (BLBC) share many features including TP53 mutations, genomic instability and poor prognosis. We recently reported that Elafin is overexpressed by HGSOC and is associated with poor overall survival. Here, we confirm that Elafin overexpression is associated with shorter survival in 1000 HGSOC patients. Elafin confers a proliferative advantage to tumor cells through the activation of the MAP kinase pathway. This mitogenic effect can be neutralized by RNA interference, specific antibodies and a MEK inhibitor. Elafin expression in patient-derived samples was also associated with chemoresistance and strongly correlates with bcl-xL expression. We extended these findings into the examination of 1100 primary breast tumors and six breast cancer cell lines. We observed that Elafin is overexpressed and secreted specifically by BLBC tumors and cell lines, leading to a similar mitogenic effect through activation of the MAP kinase pathway. Here too, Elafin overexpression is associated with poor overall survival, suggesting that it may serve as a biomarker and therapeutic target in this setting.	[Labidi-Galy, S. I.; Clauss, A.; Ng, V.; Duraisamy, S.; Elias, K. M.; Piao, H-Y; Badalian-Very, G.; Drapkin, R.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA; [Labidi-Galy, S. I.; Clauss, A.; Duraisamy, S.; Elias, K. M.; Badalian-Very, G.; Kang, U-B; Ficarro, S.; Marto, J. A.; Drapkin, R.] Harvard Univ, Sch Med, Boston, MA USA; [Elias, K. M.] Brigham & Womens Hosp, Div Gynecol Oncol, Boston, MA 02115 USA; [Bilal, E.; Ganesan, S.] Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Canc Inst New Jersey, New Brunswick, NJ USA; [Davidowitz, R. A.] Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA USA; [Lu, Y.; Mills, G. B.] Univ Texas MD Anderson Canc Ctr, Dept Syst Biol, Houston, TX 77030 USA; [Gyoerffy, B.] Hungarian Acad Sci, Res Lab Pediat & Nephrol, Budapest, Hungary; [Kang, U-B; Ficarro, S.; Marto, J. A.] Dana Farber Canc Inst, Blais Prote Ctr, Boston, MA 02215 USA; [Drapkin, R.] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers Cancer Institute of New Jersey; Harvard University; Harvard Medical School; University of Texas System; UTMD Anderson Cancer Center; Hungarian Academy of Sciences; Harvard University; Dana-Farber Cancer Institute; Harvard University; Brigham & Women's Hospital	Drapkin, R (corresponding author), Dana Farber Canc Inst, Dept Med Oncol, JF215D,450 Brookline Ave, Boston, MA 02215 USA.	ronny_drapkin@dfci.harvard.edu	Drapkin, Ronny/E-9944-2016; Labidi-Galy, Intidhar/AAG-3915-2021; Badalian-Very, Gayane/GLN-6049-2022; Gyorffy, Balazs/AAA-9135-2021; labidi-galy, sana intidhar/A-4163-2017	Drapkin, Ronny/0000-0002-6912-6977; Gyorffy, Balazs/0000-0002-5772-3766; Elias, Kevin/0000-0003-1502-5553; labidi-galy, sana intidhar/0000-0002-0824-3475; Clauss, Adam/0000-0002-6381-324X	NIH/NCI SPORE in OC [OC P50-CA105009, U01 CA-152990, R21 CA-156021]; NIH/NINDS [P01 NS047572]; Honorable Tina Brozman 'Tina's Wish' Foundation; Dr Miriam and Sheldon G. Adelson Medical Research Foundation; Robert and Debra First Fund; Gamel Family Fund; Ovarian Cancer Research Fund; Madeline Franchi Ovations for the Cure Fund; Mary Kay Foundation; Sandy Rollman Ovarian Cancer Foundation; Dana-Farber Cancer Institute (DFCI) Strategic Initiative; Executive Council of the Cancer Foundation; New Jersey Commission on Cancer Research; Arthur Sachs/Fulbright/Harvard; La Fondation Philippe; La Fondation de France-Recherche clinique en cancerologie-Aide a la mobilite des chercheurs; NATIONAL CANCER INSTITUTE [P50CA105009, R21CA156021, U01CA152990, P30CA016672] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS047572] Funding Source: NIH RePORTER	NIH/NCI SPORE in OC; NIH/NINDS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); Honorable Tina Brozman 'Tina's Wish' Foundation; Dr Miriam and Sheldon G. Adelson Medical Research Foundation; Robert and Debra First Fund; Gamel Family Fund; Ovarian Cancer Research Fund; Madeline Franchi Ovations for the Cure Fund; Mary Kay Foundation; Sandy Rollman Ovarian Cancer Foundation; Dana-Farber Cancer Institute (DFCI) Strategic Initiative; Executive Council of the Cancer Foundation; New Jersey Commission on Cancer Research; Arthur Sachs/Fulbright/Harvard; La Fondation Philippe; La Fondation de France-Recherche clinique en cancerologie-Aide a la mobilite des chercheurs; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	The authors thank Dr Michelle Hirsch for critical review of the manuscript, Laura Selfors of biocomputing analyzes of the RPPA data, and members of the Drapkin laboratory for fruitful discussions. This work was supported by the NIH/NCI SPORE in OC P50-CA105009 (RD), U01 CA-152990 (RD), R21 CA-156021 (RD); NIH/NINDS P01 NS047572 (JM), the Honorable Tina Brozman 'Tina's Wish' Foundation (JM, RD), the Dr Miriam and Sheldon G. Adelson Medical Research Foundation (GBM and RD), The Robert and Debra First Fund (RD), The Gamel Family Fund (RD), the Ovarian Cancer Research Fund (RD), The Madeline Franchi Ovations for the Cure Fund (AC), the Mary Kay Foundation (RD), the Sandy Rollman Ovarian Cancer Foundation (RD), the Dana-Farber Cancer Institute (DFCI) Strategic Initiative (JM), the Executive Council of the Cancer Foundation (SG), and the New Jersey Commission on Cancer Research (SG). SILG is a recipient of grants from Arthur Sachs/Fulbright/Harvard, La Fondation Philippe and La Fondation de France-'Recherche clinique en cancerologie-Aide a la mobilite des chercheurs'.	Askenazi M, 2010, PROTEOMICS, V10, P1880, DOI 10.1002/pmic.200900723; Aung G, 2011, J DERMATOL SCI, V63, P128, DOI 10.1016/j.jdermsci.2011.04.014; Bittner M., EXPRESSION PROJECT O; Bouchard D, 2006, LANCET ONCOL, V7, P167, DOI 10.1016/S1470-2045(06)70579-4; Cancer Genome Atlas Research Network, 2011, Nature, V474, P609, DOI 10.1038/nature10166; Caruso JA, 2010, CANCER RES, V70, P7125, DOI 10.1158/0008-5472.CAN-10-1547; Chin L, 2008, NATURE, V455, P1061, DOI 10.1038/nature07385; Clauss A, 2002, BIOCHEM J, V368, P233, DOI 10.1042/BJ20020869; Clauss A, 2010, NEOPLASIA, V12, P161, DOI 10.1593/neo.91542; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Dent R, 2007, CLIN CANCER RES, V13, P4429, DOI 10.1158/1078-0432.CCR-06-3045; Desmedt C, 2007, CLIN CANCER RES, V13, P3207, DOI 10.1158/1078-0432.CCR-06-2765; Doucet A, 2007, BIOCHEM J, V405, P455, DOI 10.1042/BJ20070020; Drapkin R, 2005, CANCER RES, V65, P2162, DOI 10.1158/0008-5472.CAN-04-3924; Etemadmoghadam D, 2009, CLIN CANCER RES, V15, P1417, DOI 10.1158/1078-0432.CCR-08-1564; Ficarro SB, 2011, MOL CELL PROTEOMICS, V10, DOI 10.1074/mcp.O111.011064; Gautier L, 2004, BIOINFORMATICS, V20, P307, DOI 10.1093/bioinformatics/btg405; Ghosh M, 2010, IMMUNOLOGY, V129, P207, DOI 10.1111/j.1365-2567.2009.03165.x; Gyorffy B, 2012, ENDOCR-RELAT CANCER, V19, P197, DOI 10.1530/ERC-11-0329; Gyorffy B, 2010, BREAST CANCER RES TR, V123, P725, DOI 10.1007/s10549-009-0674-9; Haibe-Kains B, 2012, JNCI-J NATL CANCER I, V104, P311, DOI 10.1093/jnci/djr545; Hellstrom I, 2003, CANCER RES, V63, P3695; Hennessy Bryan T, 2010, Clin Proteomics, V6, P129, DOI 10.1007/s12014-010-9055-y; Hodge C, 1998, J BIOL CHEM, V273, P31327, DOI 10.1074/jbc.273.47.31327; Huper G, 2007, CANCER RES, V67, P2990, DOI 10.1158/0008-5472.CAN-06-4065; Jemal A, 2011, CA-CANCER J CLIN, V61, P133, DOI [10.3322/caac.20073, 10.3322/caac.20105]; Jinawath N, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011198; Karst AM, 2011, P NATL ACAD SCI USA, V108, P7547, DOI 10.1073/pnas.1017300108; Karst AM, 2010, J ONCOL, V2010, DOI 10.1155/2010/932371; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Kulasingam V, 2007, MOL CELL PROTEOMICS, V6, P1997, DOI 10.1074/mcp.M600465-MCP200; Kwei KA, 2010, MOL ONCOL, V4, P255, DOI 10.1016/j.molonc.2010.04.001; Levanon K, 2010, ONCOGENE, V29, P1103, DOI 10.1038/onc.2009.402; Levanon K, 2008, J CLIN ONCOL, V26, P5284, DOI 10.1200/JCO.2008.18.1107; Levine JE, 2012, BLOOD, V119, P3854, DOI 10.1182/blood-2012-01-403063; Li QY, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015031; Lundwall A, 2002, BIOCHEM BIOPH RES CO, V290, P452, DOI 10.1006/bbrc.2001.6224; Manie E, 2009, CANCER RES, V69, P663, DOI 10.1158/0008-5472.CAN-08-1560; Mavaddat N, 2012, CANCER EPIDEM BIOMAR, V21, P134, DOI 10.1158/1055-9965.EPI-11-0775; Moore RG, 2009, GYNECOL ONCOL, V112, P40, DOI 10.1016/j.ygyno.2008.08.031; Morton S, 2004, FEBS LETT, V572, P177, DOI 10.1016/j.febslet.2004.07.031; Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008; Paczesny S, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000406; Pawitan Y, 2005, BREAST CANCER RES, V7, pR953, DOI 10.1186/bcr1325; Pazaiti A, 2011, WOMENS HEALTH, V7, P181, DOI [10.2217/whe.11.5, 10.2217/WHE.11.5]; Pfundt R, 1996, J CLIN INVEST, V98, P1389, DOI 10.1172/JCI118926; Rakha EA, 2008, J CLIN ONCOL, V26, P2568, DOI 10.1200/JCO.2007.13.1748; Richardson AL, 2006, CANCER CELL, V9, P121, DOI 10.1016/j.ccr.2006.01.013; Saidi A, 2008, INT J CANCER, V122, P2187, DOI 10.1002/ijc.23313; Saldanha AJ, 2004, BIOINFORMATICS, V20, P3246, DOI 10.1093/bioinformatics/bth349; Schmidt M, 2008, CANCER RES, V68, P5405, DOI 10.1158/0008-5472.CAN-07-5206; Shaw L, 2011, BIOCHEM SOC T, V39, P1450, DOI 10.1042/BST0391450; Tibes R, 2006, MOL CANCER THER, V5, P2512, DOI 10.1158/1535-7163.MCT-06-0334; Vermeer PD, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030447; Verrier T, 2012, INT J BIOCHEM CELL B, V44, P1377, DOI 10.1016/j.biocel.2012.05.007; Wang YX, 2005, LANCET, V365, P671, DOI 10.1016/S0140-6736(05)17947-1; Wang ZGC, 2012, CLIN CANCER RES, V18, P5806, DOI 10.1158/1078-0432.CCR-12-0857; Wei HF, 2012, GYNECOL ONCOL, V125, P727, DOI 10.1016/j.ygyno.2012.03.018; Wickham H, 2009, USE R, P1, DOI 10.1007/978-0-387-98141-3_1; Williams J, 2005, GYNECOL ONCOL, V96, P287, DOI 10.1016/j.ygyno.2004.10.026; Williams SE, 2006, CLIN SCI, V110, P21, DOI 10.1042/CS20050115; Yokota T, 2007, CANCER RES, V67, P11272, DOI 10.1158/0008-5472.CAN-07-2322; ZHANG M, 1995, CANCER RES, V55, P2537	63	31	31	0	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 15	2015	34	3					299	309		10.1038/onc.2013.562	http://dx.doi.org/10.1038/onc.2013.562			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AZ3RY	24469047	Green Accepted, Green Submitted			2022-12-17	WOS:000348145500004
J	Hou, Y; Gao, J; Xu, H; Xu, Y; Zhang, Z; Xu, Q; Zhang, C				Hou, Y.; Gao, J.; Xu, H.; Xu, Y.; Zhang, Z.; Xu, Q.; Zhang, C.			PPAR gamma E3 ubiquitin ligase regulates MUC1-C oncoprotein stability	ONCOGENE			English	Article						PPAR gamma; MUC1-C; ubiquitin; degradation; ubiquitination; cancer	NF-KAPPA-B; RECEPTOR-GAMMA; COLON-CANCER; CELLS; TRANSCRIPTION; EXPRESSION; DEGRADATION; ACTIVATION; LIGANDS; DOMAIN	MUC1-C oncoprotein is associated with colon, breast, ovarian, lung and pancreatic cancers. MUC1-C interacts with intracellular proteins to elicit signaling cascades that induce cell proliferation and tumor growth. Here we report that peroxisome proliferator-activated receptor gamma (PPAR gamma), an E3 ubiquitin ligase, is an inhibitor of MUC1-C-mediated cell proliferation. PPAR gamma does so by binding to and inducing MUC1-C proteasome-dependent degradation that was independent of PPAR gamma transcriptional activity. Lys134 residue was found to be critically important for PPAR gamma-mediated MUC1-C degradation, as it terminated MUC1-C-mediated cell proliferation. These findings demonstrate PPAR gamma induces MUC1-C ubiquitination and degradation that is critical to terminate MUC1-C signaling pathway-elicited cancer.	[Hou, Y.; Gao, J.; Xu, H.; Xu, Y.; Zhang, Z.; Xu, Q.; Zhang, C.] Jiangsu Univ, Inst Life Sci, Zhenjiang 212013, Jiangsu, Peoples R China	Jiangsu University	Hou, Y (corresponding author), Jiangsu Univ, Inst Life Sci, Zhenjiang 212013, Jiangsu, Peoples R China.	houyz@mail.ujs.edu.cn	hou, YONGZHONG/K-7771-2013	xu, qinggang/0000-0002-8659-7041; Hou, Yongzhong/0000-0003-2019-8686	Jiangsu Province Natural Science Foundation [SBK201320232]; Start Fund of University of JiangSu [12JDG071]	Jiangsu Province Natural Science Foundation(Natural Science Foundation of Jiangsu Province); Start Fund of University of JiangSu	This work was supported by Jiangsu Province Natural Science Foundation (SBK201320232) and Start Fund of University of JiangSu (12JDG071).	Ahmad R, 2007, NAT CELL BIOL, V9, P1419, DOI 10.1038/ncb1661; Ahmad R, 2012, J BIOL CHEM, V287, P20866, DOI 10.1074/jbc.M112.357293; Ahmad R, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001426; Ahmad R, 2009, CANCER RES, V69, P7013, DOI 10.1158/0008-5472.CAN-09-0523; Berger Joel, 2002, Diabetes Technol Ther, V4, P163, DOI 10.1089/15209150260007381; Carson DD, 2008, SCI SIGNAL, V1, DOI 10.1126/scisignal.127pe35; Cascio S, 2011, J BIOL CHEM, V286, P42248, DOI 10.1074/jbc.M111.297630; Deshaies RJ, 2009, ANNU REV BIOCHEM, V78, P399, DOI 10.1146/annurev.biochem.78.101807.093809; Gendler SJ, 2001, J MAMMARY GLAND BIOL, V6, P339, DOI 10.1023/A:1011379725811; Girnun GD, 2007, CANCER CELL, V11, P395, DOI 10.1016/j.ccr.2007.02.025; Heaney AP, 2003, J CLIN INVEST, V111, P1381, DOI 10.1172/JCI200316575; Hou Y, 2014, ONCOGENE, V33, P1997, DOI 10.1038/onc.2013.135; Hou YZ, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms2270; Hou YZ, 2010, J BIOL CHEM, V285, P35497, DOI 10.1074/jbc.M109.066035; Huang L, 2005, CANCER RES, V65, P10413, DOI 10.1158/0008-5472.CAN-05-2474; Joazeiro CAP, 2000, CELL, V102, P549, DOI 10.1016/S0092-8674(00)00077-5; Kufe DW, 2008, CANCER BIOL THER, V7, P81, DOI 10.4161/cbt.7.1.5631; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; Li Y, 2003, CANCER BIOL THER, V2, P187, DOI 10.4161/cbt.2.2.282; Mukherjee R, 1997, J BIOL CHEM, V272, P8071, DOI 10.1074/jbc.272.12.8071; Ogino S, 2009, GASTROENTEROLOGY, V136, P1242, DOI 10.1053/j.gastro.2008.12.048; Park YS, 2012, AM J PHYSIOL-GASTR L, V303, pG765, DOI 10.1152/ajpgi.00023.2012; Park YS, 2012, AM J PHYSIOL-LUNG C, V302, P1679, DOI 10.1152/ajplung.00360.2011; Pascual G, 2005, NATURE, V437, P759, DOI 10.1038/nature03988; Raina D, 2006, EMBO J, V25, P3774, DOI 10.1038/sj.emboj.7601263; Ruan H, 2003, J BIOL CHEM, V278, P28181, DOI 10.1074/jbc.M303141200; Sarraf P, 1999, MOL CELL, V3, P799, DOI 10.1016/S1097-2765(01)80012-5; Shalom-Barak T, 2004, MOL CELL BIOL, V24, P10661, DOI 10.1128/MCB.24.24.10661-10669.2004; Shimada T, 2002, GUT, V50, P658, DOI 10.1136/gut.50.5.658; Straus DS, 2007, TRENDS IMMUNOL, V28, P551, DOI 10.1016/j.it.2007.09.003; Uchida Y, 2013, CANCER BIOL THER, V14, P127, DOI 10.4161/cbt.22634; Wang P, 2010, MOL ENDOCRINOL, V24, P1368, DOI 10.1210/me.2009-0221; Wei XL, 2005, CANCER CELL, V7, P167, DOI 10.1016/j.ccr.2005.01.008	33	31	32	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 4	2014	33	49					5619	5625		10.1038/onc.2013.504	http://dx.doi.org/10.1038/onc.2013.504			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AW1ZW	24292674				2022-12-17	WOS:000346088700006
J	Qi, J; Dong, Z; Liu, J; Zhang, JT				Qi, J.; Dong, Z.; Liu, J.; Zhang, J-T			EIF3i promotes colon oncogenesis by regulating COX-2 protein synthesis and beta-catenin activation	ONCOGENE			English	Article						eIF3i; COX-2; beta-catenin; translational control; colon cancer; RNA-binding	INTESTINAL-CELL DIFFERENTIATION; INITIATION-FACTOR EIF3; TRANSLATIONAL CONTROL; MESSENGER-RNA; CANCER; EXPRESSION; SUBUNITS; CYCLOOXYGENASE-2; REVEALS; GROWTH	Translational control of gene expression has recently been recognized as an important mechanism controlling cell proliferation and oncogenesis, and it mainly occurs in the initiation step of protein synthesis that involves multiple eukaryotic initiation factors (eIFs). Many eIFs have been found to have aberrant expression in human tumors and the aberrant expression may contribute to oncogenesis. However, how these previously considered house-keeping proteins are potentially oncogenic remains elusive. In this study, we investigated the expression of eIF3i in human colon cancers, tested its contribution to colon oncogenesis and determined the mechanism of eIF3i action in colon oncogenesis. We found that eIF3i expression was upregulated in both human colon adenocarcinoma and adenoma polyps as well as in model inducible colon tumorigenic cell lines. Overexpression of ectopic eIF3i in intestinal epithelial cells causes oncogenesis by directly upregulating the synthesis of cyclooxygenase-2 (COX-2) protein and activates the beta-catenin/T-cell factor 4 signaling pathway that mediates the oncogenic function of eIF3i. Together, we conclude that eIF3i is a proto-oncogene that drives colon oncogenesis by translationally upregulating COX-2 and activating the beta-catenin signaling pathway. These findings imply that proto-oncogenic eIFs likely exert their tumorigenic function by regulating/altering the synthesis level of downstream tumor suppressor or oncogenes.	Indiana Univ Sch Med, Dept Pharmacol & Toxicol, Indianapolis, IN 46202 USA; Indiana Univ Sch Med, IU Simon Canc Ctr, Indianapolis, IN 46202 USA	Indiana University System; Indiana University Bloomington; Indiana University System; Indiana University Bloomington	Zhang, JT (corresponding author), Indiana Univ Sch Med, IU Simon Canc Ctr, Dept Pharmacol & Toxicol, 980 W Walnut St,R3-C510, Indianapolis, IN 46202 USA.	jianzhan@iupui.edu	Zhang, Jian-Ting/L-8334-2015	Zhang, Jian-Ting/0000-0002-2803-9914	NIH grant [R01 CA94961]; NATIONAL CANCER INSTITUTE [R01CA094961] Funding Source: NIH RePORTER	NIH grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Hongmiao Sheng for the generous gift of the rat intestinal epithelial cell lines. This work was supported in part by a NIH grant R01 CA94961 (JTZ).	Ahlemann M, 2006, MOL CARCINOGEN, V45, P957, DOI 10.1002/mc.20269; Asano K, 1998, J BIOL CHEM, V273, P18573, DOI 10.1074/jbc.273.29.18573; Bernardini S, 1997, BIOCHEM BIOPH RES CO, V234, P278, DOI 10.1006/bbrc.1997.6626; Block KL, 1998, J BIOL CHEM, V273, P31901, DOI 10.1074/jbc.273.48.31901; Castellone MD, 2005, SCIENCE, V310, P1504, DOI 10.1126/science.1116221; Ding QM, 1998, AM J PHYSIOL-CELL PH, V275, pC1193, DOI 10.1152/ajpcell.1998.275.5.C1193; Dixon DA, 2000, J BIOL CHEM, V275, P11750, DOI 10.1074/jbc.275.16.11750; Dong ZZ, 2006, CRIT REV ONCOL HEMAT, V59, P169, DOI 10.1016/j.critrevonc.2006.03.005; Dong ZZ, 2009, EXP CELL RES, V315, P1889, DOI 10.1016/j.yexcr.2009.03.009; Dong ZZ, 2004, ONCOGENE, V23, P3790, DOI 10.1038/sj.onc.1207465; Dong ZZ, 2003, MOL BIOL CELL, V14, P3942, DOI 10.1091/mbc.E02-12-0784; Gray SG, 2000, INT J MOL MED, V5, P33; Greenhough A, 2009, CARCINOGENESIS, V30, P377, DOI 10.1093/carcin/bgp014; Gupta RA, 2001, NAT REV CANCER, V1, P11, DOI 10.1038/35094017; Herrmannova A, 2012, NUCLEIC ACIDS RES, V40, P2294, DOI 10.1093/nar/gkr765; Kikuchi A, 2003, CANCER SCI, V94, P225, DOI 10.1111/j.1349-7006.2003.tb01424.x; Kuroda T, 2006, CANCER RES, V66, P10127, DOI 10.1158/0008-5472.CAN-06-2744; Liu RY, 2011, ONCOGENE, V30, P4814, DOI 10.1038/onc.2011.189; Liu Y, 2006, CANCER RES, V66, P3248, DOI 10.1158/0008-5472.CAN-05-3801; Liu ZQ, 2007, DIFFERENTIATION, V75, P652, DOI 10.1111/j.1432-0436.2007.00165.x; Markowitz AJ, 1995, AM J PHYSIOL-GASTR L, V269, pG925, DOI 10.1152/ajpgi.1995.269.6.G925; Markowitz SD, 2009, NEW ENGL J MED, V361, P2449, DOI 10.1056/NEJMra0804588; Masutani M, 2007, EMBO J, V26, P3373, DOI 10.1038/sj.emboj.7601765; MATHEWS MB, 2007, TRANSLATIONAL CONTRO; Matsuda S, 2000, CANCER RES, V60, P13; Phan L, 2001, EMBO J, V20, P2954, DOI 10.1093/emboj/20.11.2954; PINTO M, 1983, BIOL CELL, V47, P323; Rauch J, 2004, BIOCHEM BIOPH RES CO, V323, P156, DOI 10.1016/j.bbrc.2004.08.071; SCHNEIDER RJ, 2007, TRANSLATIONAL CONTRO, P401; Shao JY, 2005, J BIOL CHEM, V280, P26565, DOI 10.1074/jbc.M413056200; Sheng HM, 2000, J BIOL CHEM, V275, P6628, DOI 10.1074/jbc.275.9.6628; Sheng HM, 2001, CANCER RES, V61, P2670; Wang Y, 2013, ADV CIV ENG, V2013, DOI 10.1155/2013/189105; Yin JY, 2013, CARCINOGENESIS, V34, P1224, DOI 10.1093/carcin/bgt052; Yin JY, 2011, CLIN CANCER RES, V17, P4600, DOI 10.1158/1078-0432.CCR-10-2591; Yin JY, 2011, BIOSCIENCE REP, V31, P1, DOI 10.1042/BSR20100077; Zhang LL, 2007, J BIOL CHEM, V282, P5790, DOI 10.1074/jbc.M606284200; Zhou M, 2008, P NATL ACAD SCI USA, V105, P18139, DOI 10.1073/pnas.0801313105; Zweibaum A, 1989, ADAPTATION DEV GASTR, P103	39	31	31	0	11	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 7	2014	33	32					4156	4163		10.1038/onc.2013.397	http://dx.doi.org/10.1038/onc.2013.397			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AN4YK	24056964	Green Submitted, Green Accepted			2022-12-17	WOS:000340595700006
J	Mei, Y; Zhang, P; Zuo, H; Clark, D; Xia, R; Li, J; Liu, Z; Mao, L				Mei, Y.; Zhang, P.; Zuo, H.; Clark, D.; Xia, R.; Li, J.; Liu, Z.; Mao, L.			Ebp1 activates podoplanin expression and contributes to oral tumorigenesis	ONCOGENE			English	Article						EBP1; podoplanin; oral; tumorigenesis	BINDING-PROTEIN EBP1; ECTOPIC EXPRESSION; CANCER; ERBB3; LYMPHANGIOGENESIS; PROGRESSION; METASTASIS; CARCINOMAS; INVASION; ANTIGEN	Podoplanin is highly expressed in human cancers. However, mechanisms regulating podoplanin expression remain elusive. Here we show that podoplanin promotes tumorigenesis of oral squamous cell carcinoma (OSCC) and precancerous cells both in vitro and in vivo, and the ErbB3-binding protein-1 (Ebp1) can be activated in oral tumorigenesis and can serve as a transcriptional activator to drive podoplanin expression in the malignant progression. Most of the OSCC cell lines have no detectable podoplanin protein in low-density cultures. However, the protein becomes detectable in high-density cultures and is required for in-vivo tumor formation of OSCC and oral premalignancies. In a high-density culture condition, podoplanin expression can be triggered at both mRNA and protein levels. In this condition, we showed that Ebp1 is upregulated, translocated from the cytoplasm to the nucleus and binds to the podoplanin promoter to result in a dramatic increase of podoplanin mRNA and protein. Ebp1 downregulation significantly reduced podoplanin expression levels in OSCC cells with a decreased anchorage-dependent growth, invasion and wound healing. Conversely, Ebp1 overexpression enhanced these malignant features through podoplanin upregulation both in vitro and in vivo. In 81 patients with oral premalignant lesions, we found that Ebp1 expression is strongly related to OSCC development. We conclude that Ebp1 has a key role in the upregulation of podoplanin and may contribute to oral tumorigenesis.	[Mei, Y.; Zuo, H.; Clark, D.; Mao, L.] Univ Maryland, Sch Dent, Dept Oncol & Diagnost Sci, Baltimore, MD 21201 USA; [Zhang, P.; Xia, R.; Li, J.] Shanghai Jiao Tong Univ, Sch Med, Peoples Hosp 9,Sch Stomatoloty, Dept Oral & Maxillofacial Surg,Shanghai Key Lab S, Shanghai, Peoples R China; [Zhang, P.; Xia, R.; Li, J.] Shanghai Jiao Tong Univ, Sch Med, Peoples Hosp 9,Sch Stomatoloty, Dept Oral & Maxillofacial Surg,Shanghai Res Inst, Shanghai, Peoples R China; [Liu, Z.; Mao, L.] Univ Maryland, Marlene & Stewart Greenebaum Canc Ctr, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore; Shanghai Jiao Tong University; Shanghai Jiao Tong University; University System of Maryland; University of Maryland Baltimore	Mao, L (corresponding author), Univ Maryland, Sch Dent, Dept Oncol & Diagnost Sci, 650 W Baltimore St,Room 7259, Baltimore, MD 21201 USA.	lmao@umaryland.edu		Clark, David/0000-0003-0527-8469				Cortez MA, 2010, GENE CHROMOSOME CANC, V49, P981, DOI 10.1002/gcc.20808; Darnell JE, 2002, NAT REV CANCER, V2, P740, DOI 10.1038/nrc906; de Sousa SF, 2012, APPL IMMUNOHISTO M M, V20, P588, DOI 10.1097/PAI.0b013e31824bb3ea; Funayama A, 2011, PATHOBIOLOGY, V78, P171, DOI 10.1159/000324926; Hamburger AW, 2008, J MAMMARY GLAND BIOL, V13, P225, DOI 10.1007/s10911-008-9077-5; Hantusch B, 2007, BMC MOL BIOL, V8, DOI 10.1186/1471-2199-8-20; Honma M, 2012, J DERMATOL SCI, V65, P134, DOI 10.1016/j.jdermsci.2011.11.011; Huber GF, 2011, INT J CANCER, V129, P1404, DOI 10.1002/ijc.25795; Hwang YS, 2012, CARCINOGENESIS, V33, P2135, DOI 10.1093/carcin/bgs258; Inoue H, 2012, TUMOR BIOL, V33, P183, DOI 10.1007/s13277-011-0261-7; Kawaguchi H, 2008, J CLIN ONCOL, V26, P354, DOI 10.1200/JCO.2007.13.4072; Kim CK, 2010, CANCER RES, V70, P9730, DOI 10.1158/0008-5472.CAN-10-1882; Kreppel M, 2012, ORAL DIS, V18, P692, DOI 10.1111/j.1601-0825.2012.01927.x; Kunita A, 2011, AM J PATHOL, V179, P1041, DOI 10.1016/j.ajpath.2011.04.027; Lessor TJ, 2000, J CELL PHYSIOL, V183, P321, DOI 10.1002/(SICI)1097-4652(200006)183:3<321::AID-JCP4>3.0.CO;2-O; Martin-Villar E, 2009, INT J BIOCHEM CELL B, V41, P1421, DOI 10.1016/j.biocel.2008.12.010; Mashhadiabbas F, 2012, OR SURG OR MED OR PA, V114, P240, DOI 10.1016/j.oooo.2012.04.009; Mei Y, 2008, NEUROSCIENCE, V151, P771, DOI 10.1016/j.neuroscience.2007.10.057; Mei YP, 2012, ONCOGENE, V31, P2794, DOI 10.1038/onc.2011.449; Monie TP, 2007, EMBO J, V26, P3936, DOI 10.1038/sj.emboj.7601817; Neph S, 2012, CELL, V150, P1274, DOI 10.1016/j.cell.2012.04.040; Ohta M, 2013, ORAL ONCOL, V49, P20, DOI 10.1016/j.oraloncology.2012.06.017; Peterziel H, 2012, NEURO-ONCOLOGY, V14, P426, DOI 10.1093/neuonc/nos055; Raica M, 2008, ANTICANCER RES, V28, P2997; Scholl FG, 2000, LAB INVEST, V80, P1749, DOI 10.1038/labinvest.3780185; Shen YQ, 2010, J BIOL CHEM, V285, P9649, DOI 10.1074/jbc.M109.047696; Shimamura Y, 2011, ACTA HISTOCHEM CYTOC, V44, P239, DOI 10.1267/ahc.11032; Tammela T, 2010, CELL, V140, P460, DOI 10.1016/j.cell.2010.01.045; Wicki A, 2006, CANCER CELL, V9, P261, DOI 10.1016/j.ccr.2006.03.010; Wicki A, 2007, BRIT J CANCER, V96, P1, DOI 10.1038/sj.bjc.6603518; Yuan P, 2006, CANCER, V107, P563, DOI 10.1002/cncr.22061; Zhang YX, 2010, CANCER RES, V70, P240, DOI 10.1158/0008-5472.CAN-09-2904; Zhang YX, 2005, NUCLEIC ACIDS RES, V33, P6024, DOI 10.1093/nar/gki903; Zhou X, 2010, J CANCER RES CLIN, V136, P891, DOI 10.1007/s00432-009-0730-1	34	31	33	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 17	2014	33	29					3839	3850		10.1038/onc.2013.354	http://dx.doi.org/10.1038/onc.2013.354			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AL8MU	23975429				2022-12-17	WOS:000339394100010
J	Guo, H; Gao, M; Lu, Y; Liang, J; Lorenzi, PL; Bai, S; Hawke, DH; Li, J; Dogruluk, T; Scott, KL; Jonasch, E; Mills, GB; Ding, Z				Guo, H.; Gao, M.; Lu, Y.; Liang, J.; Lorenzi, P. L.; Bai, S.; Hawke, D. H.; Li, J.; Dogruluk, T.; Scott, K. L.; Jonasch, E.; Mills, G. B.; Ding, Z.			Coordinate phosphorylation of multiple residues on single AKT1 and AKT2 molecules	ONCOGENE			English	Article						AKT; phosphorylation; NIA	PROTEIN-KINASE-B; RICTOR-MTOR COMPLEX; MEMBRANE LOCALIZATION; CANCER CELLS; ACTIVATION; AKT/PKB; GROWTH; ROLES; DOWNSTREAM; STABILITY	Aberrant AKT activation is prevalent across multiple human cancer lineages providing an important new target for therapy. Twenty-two independent phosphorylation sites have been identified on specific AKT isoforms likely contributing to differential isoform regulation. However, the mechanisms regulating phosphorylation of individual AKT isoform molecules have not been elucidated because of the lack of robust approaches able to assess phosphorylation of multiple sites on a single AKT molecule. Using a nanofluidic proteomic immunoassay (NIA), consisting of isoelectric focusing followed by sensitive chemiluminescence detection, we demonstrate that under basal and ligand-induced conditions that the pattern of phosphorylation events is markedly different between AKT1 and AKT2. Indeed, there are at least 12 AKT1 peaks and at least 5 AKT2 peaks consistent with complex combinations of phosphorylation of different sites on individual AKT molecules. Following insulin stimulation, AKT1 was phosphorylated at Thr308 in the T-loop and Ser473 in the hydrophobic domain. In contrast, AKT2 was only phosphorylated at the equivalent sites (Thr309 and Ser474) at low levels. Further, Thr308 and Ser473 phosphorylation occurred predominantly on the same AKT1 molecules, whereas Thr309 and Ser474 were phosphorylated primarily on different AKT2 molecules. Although basal AKT2 phosphorylation was sensitive to inhibition of phosphatidylinositol 3-kinase (PI3K), basal AKT1 phosphorylation was essentially resistant. PI3K inhibition decreased pThr451 on AKT2 but not pThr450 on AKT1. Thus, NIA technology provides an ability to characterize coordinate phosphorylation of individual AKT molecules providing important information about AKT isoform-specific phosphorylation, which is required for optimal development and implementation of drugs targeting aberrant AKT activation.	[Guo, H.; Gao, M.; Lu, Y.; Liang, J.; Li, J.; Mills, G. B.; Ding, Z.] Univ Texas MD Anderson Canc Ctr, Dept Syst Biol, Houston, TX 77030 USA; [Lorenzi, P. L.] Univ Texas MD Anderson Canc Ctr, Dept Bioinformat & Computat Biol, Houston, TX 77030 USA; [Bai, S.; Jonasch, E.] Univ Texas MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, Houston, TX 77030 USA; [Hawke, D. H.] Univ Texas MD Anderson Canc Ctr, Dept Mol Pathol, Houston, TX 77030 USA; [Dogruluk, T.; Scott, K. L.] Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Baylor College of Medicine	Mills, GB (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Syst Biol, 1515 Holcombe Blvd, Houston, TX 77030 USA.	gmills@mdanderson.org; zding@mdanderson.org		Dogruluk, Turgut/0000-0002-9212-9471	National Institutes of Health (NIH) [5R21CA126700]; University of Texas MD Anderson Cancer Center Kidney Cancer Multidisciplinary Research Program; AstraZeneca; Clinical Proteomic Tumor Analysis Consortium (CPTAC) [U24 CA126477, U24 CA126479, U54 CA112970]; NCI CCSG [P30 CA016672]; NATIONAL CANCER INSTITUTE [U01CA168394, R21CA126700, U24CA126477, U24CA126479, U54CA112970, P30CA016672] Funding Source: NIH RePORTER	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); University of Texas MD Anderson Cancer Center Kidney Cancer Multidisciplinary Research Program; AstraZeneca(AstraZeneca); Clinical Proteomic Tumor Analysis Consortium (CPTAC); NCI CCSG; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Bert Vogelstein for providing HCT116 wt and knockout cell lines. The work is supported by National Institutes of Health (NIH) grant 5R21CA126700, a grant from the University of Texas MD Anderson Cancer Center Kidney Cancer Multidisciplinary Research Program, and research support from AstraZeneca to ZD, and the Clinical Proteomic Tumor Analysis Consortium (CPTAC) grants (U24 CA126477, U24 CA126479, and U54 CA112970) to GBM and NCI CCSG grant (P30 CA016672).	Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Andjelkovic M, 1997, J BIOL CHEM, V272, P31515, DOI 10.1074/jbc.272.50.31515; BJELLQVIST B, 1993, ELECTROPHORESIS, V14, P1023, DOI 10.1002/elps.11501401163; Bouzakri K, 2006, CELL METAB, V4, P89, DOI 10.1016/j.cmet.2006.04.008; Bozulic L, 2008, MOL CELL, V30, P203, DOI 10.1016/j.molcel.2008.02.024; Brazil DP, 2004, TRENDS BIOCHEM SCI, V29, P233, DOI 10.1016/j.tibs.2004.03.006; Brognard J, 2007, MOL CELL, V25, P917, DOI 10.1016/j.molcel.2007.02.017; Chin YR, 2010, MOL CELL, V38, P333, DOI 10.1016/j.molcel.2010.02.031; Dillon RL, 2009, CANCER RES, V69, P5057, DOI 10.1158/0008-5472.CAN-08-4287; Ding ZY, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009910; Endersby R, 2011, CANCER RES, V71, P4106, DOI 10.1158/0008-5472.CAN-10-3597; Ericson K, 2010, P NATL ACAD SCI USA, V107, P2598, DOI 10.1073/pnas.0914018107; Facchinetti V, 2008, EMBO J, V27, P1932, DOI 10.1038/emboj.2008.120; Fan AC, 2009, NAT MED, V15, P566, DOI 10.1038/nm.1903; Gao DM, 2009, NAT CELL BIOL, V11, P397, DOI 10.1038/ncb1847; Gonzalez E, 2009, P NATL ACAD SCI USA, V106, P7004, DOI 10.1073/pnas.0901933106; Hennessy BT, 2005, NAT REV DRUG DISCOV, V4, P988, DOI 10.1038/nrd1902; Hornbeck PV, 2012, NUCLEIC ACIDS RES, V40, pD261, DOI 10.1093/nar/gkr1122; Jacinto E, 2006, CELL, V127, P125, DOI 10.1016/j.cell.2006.08.033; Mahajan K, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009646; Manning BD, 2007, CELL, V129, P1261, DOI 10.1016/j.cell.2007.06.009; Mao ML, 2000, BIOCHEM J, V352, P475, DOI 10.1042/0264-6021:3520475; Oh WJ, 2010, EMBO J, V29, P3939, DOI 10.1038/emboj.2010.271; Powell DJ, 2003, MOL CELL BIOL, V23, P7794, DOI 10.1128/MCB.23.21.7794-7808.2003; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Sundaresan NR, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001465; Yang WL, 2009, SCIENCE, V325, P1134, DOI 10.1126/science.1175065	28	31	34	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 26	2014	33	26					3463	3472		10.1038/onc.2013.301	http://dx.doi.org/10.1038/onc.2013.301			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AK9WM	23912456	Green Accepted			2022-12-17	WOS:000338779300013
J	Kasar, S; Underbayev, C; Yuan, Y; Hanlon, M; Aly, S; Khan, H; Chang, V; Batish, M; Gavrilova, T; Badiane, F; Degheidy, H; Marti, G; Raveche, E				Kasar, S.; Underbayev, C.; Yuan, Y.; Hanlon, M.; Aly, S.; Khan, H.; Chang, V.; Batish, M.; Gavrilova, T.; Badiane, F.; Degheidy, H.; Marti, G.; Raveche, E.			Therapeutic implications of activation of the host gene (Dleu2) promoter for miR-15a/16-1 in chronic lymphocytic leukemia	ONCOGENE			English	Article						miR-15a/16-1; BSAP; HDAC inhibitor; CLL; NZB	HISTONE DEACETYLASE INHIBITOR; ZEALAND BLACK MOUSE; MALIGNANT B-1 CELLS; TRANSCRIPTION FACTOR; MULTIPLE-MYELOMA; MANTLE CELL; B-CELLS; PAX5; 13Q14; EXPRESSION	Genetic lesions and other regulatory events lead to silencing of the 13q14 locus in a majority of chronic lymphocytic leukemia (CLL) patients. This locus encodes a pair of critical proapoptotic microRNAs, miR-15a/16-1. Decreased levels of miR-15a/16-1 are critical for the increased survival exhibited by CLL cells. Similarly, in a de novo murine model of CLL, the NZB strain, germline-encoded regulation of the syntenic region resulted in decreased miR-15a/16-1. In this paper, we have identified additional molecular mechanisms regulating miR-15a/16-1 levels and have shown that the transcription factor BSAP (B-cell-specific activator protein) directly interacts with Dleu2, the host gene containing the miR-15a/16-1 loci, and by negative regulation of the Dleu2 promoter, results in repression of miR-15a/16-1 expression. CLL patient B-cell expression levels of BSAP were increased compared with control sources of B cells. With the use of small interfering RNA-mediated repression, the levels of BSAP were decreased in vitro in the NZB-derived malignant B-1 cell line, LNC, and in ex vivo CLL patient peripheral blood mononuclear cells (PBMCs). BSAP knockdown led to an increase in the expression of miR-15a/16-1 and an increase in apoptosis, and a cell cycle arrest in both the cell line and patient PBMCs. Moreover, using Dleu2 promoter analysis by chromatin immunoprecipitation assay, we have shown that BSAP directly interacts with the Dleu2 promoter. Derepression of the Dleu2 promoter via inhibition of histone deacetylation combined with BSAP knockdown increased miR-15a/16-1 expression, and also increased malignant B-cell death. In summary, therapy targeting enhanced host gene Dleu2 transcription may augment CLL therapy.	[Kasar, S.; Underbayev, C.; Hanlon, M.; Aly, S.; Khan, H.; Chang, V.; Batish, M.; Gavrilova, T.; Badiane, F.; Raveche, E.] Univ Med & Dent New Jersey, New Jersey Med Sch, Newark, NJ 07103 USA; [Yuan, Y.] NIH, Bethesda, MD 20892 USA; [Chang, V.] Vet Affairs New Jersey Hlth Care Syst, E Orange, NJ USA; [Degheidy, H.; Marti, G.] OSEL CDRH FDA, White Oak, MD USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; National Institutes of Health (NIH) - USA; US Food & Drug Administration (FDA)	Raveche, E (corresponding author), Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Pathol, 185S Orange Ave,MSB C-512, Newark, NJ 07103 USA.	batishmo@njms.rutgers.edu; raveches@njms.rutgers.edu	Underbayev, Chingiz/J-2970-2019; Batish, Mona/AAG-8296-2019	Batish, Mona/0000-0001-9039-6149; Chang, Victor/0000-0003-3640-7235	NSF/FDA/SIR [1238375]; NIH [R01CA12926]; Early Independence Award [1DP5OD012160-01]; UMDNJ-NJMS Flow Cytometry Core; NATIONAL CANCER INSTITUTE [R01CA129826] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH [DP5OD012160] Funding Source: NIH RePORTER	NSF/FDA/SIR; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Early Independence Award; UMDNJ-NJMS Flow Cytometry Core; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This work was supported by NSF/FDA/SIR No. 1238375 and NIH R01CA12926 (ESR). Early Independence Award # 1DP5OD012160-01 (MB). We thank the UMDNJ-NJMS Flow Cytometry Core for their support.	Barneda-Zahonero B, 2012, MOL ONCOL, V6, P579, DOI 10.1016/j.molonc.2012.07.003; Batish M, 2012, P NATL ACAD SCI USA, V109, P4645, DOI 10.1073/pnas.1111226109; Batish M, 2011, METHODS MOL BIOL, V714, P3, DOI 10.1007/978-1-61779-005-8_1; Bottcher S, 2012, J CLIN ONCOL, V30, P980, DOI 10.1200/JCO.2011.36.9348; Bougel S, 2010, J PATHOL, V220, P87, DOI 10.1002/path.2620; Calin GA, 2002, P NATL ACAD SCI USA, V99, P15524, DOI 10.1073/pnas.242606799; Calin GA, 2005, NEW ENGL J MED, V353, P1793, DOI 10.1056/NEJMoa050995; Calin GA, 2008, P NATL ACAD SCI USA, V105, P5166, DOI 10.1073/pnas.0800121105; Campo E, 2011, BLOOD, V117, P5019, DOI 10.1182/blood-2011-01-293050; Chang H, 2004, LEUKEMIA LYMPHOMA, V45, P965, DOI 10.1080/10428190310001638832; Chang TC, 2008, NAT GENET, V40, P43, DOI 10.1038/ng.2007.30; Chen L.-J., 2007, Experimental Oncology, V29, P116; Chong SY, 2001, CANCER IMMUNOL IMMUN, V50, P41, DOI 10.1007/s002620000165; Chung EY, 2012, J CLIN INVEST, V122, P2257, DOI 10.1172/JCI45851; Chung EY, 2008, CANCER BIOL THER, V7, P1758, DOI 10.4161/cbt.7.11.6722; Cimmino A, 2005, P NATL ACAD SCI USA, V102, P13944, DOI 10.1073/pnas.0506654102; Cobaleda C, 2007, NAT IMMUNOL, V8, P463, DOI 10.1038/ni1454; Corcoran MM, 1998, BLOOD, V91, P1382, DOI 10.1182/blood.V91.4.1382; Crapoulet N, 2011, ANTI-CANCER AGENT ME, V11, P643, DOI 10.2174/187152011796817637; Dohner H, 2000, NEW ENGL J MED, V343, P1910, DOI 10.1056/NEJM200012283432602; Dubovsky JA, 2011, LEUKEMIA RES, V35, P394, DOI 10.1016/j.leukres.2010.08.001; El-Khoury V, 2010, MOL CANCER THER, V9, P1349, DOI 10.1158/1535-7163.MCT-09-1000; Firtina S, 2012, LEUKEMIA RES, V36, P87, DOI 10.1016/j.leukres.2011.07.017; Hamada T, 1998, BRIT J HAEMATOL, V102, P691; Hanlon K, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007169; Humphrey RW, 2011, JNCI-J NATL CANCER I, V103, P1222, DOI 10.1093/jnci/djr246; Kanteti R, 2009, LAB INVEST, V89, P301, DOI 10.1038/labinvest.2008.168; Kasar S, 2012, GENES IMMUN, V13, P109, DOI 10.1038/gene.2011.58; Kasinski AL, 2011, NAT REV CANCER, V11, P849, DOI 10.1038/nrc3166; Khan O, 2012, IMMUNOL CELL BIOL, V90, P85, DOI 10.1038/icb.2011.100; Klein U, 2010, CANCER CELL, V17, P28, DOI 10.1016/j.ccr.2009.11.019; Krenacs L, 1998, BLOOD, V92, P1308, DOI 10.1182/blood.V92.4.1308.416k32_1308_1316; Kubetzko FBB, 2004, CARCINOGENESIS, V25, P1839, DOI 10.1093/carcin/bgh190; Lanasa MC, 2011, LEUKEMIA, V25, P1459, DOI 10.1038/leu.2011.117; Laurie CC, 2012, NAT GENET, V44, P642, DOI 10.1038/ng.2271; Lucas DM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010941; Medvedovic J, 2011, ADV IMMUNOL, V111, P179, DOI 10.1016/B978-0-12-385991-4.00005-2; Mertens D, 2009, LEUKEMIA LYMPHOMA, V50, P502, DOI 10.1080/10428190902763509; Migliazza A, 2001, BLOOD, V97, P2098, DOI 10.1182/blood.V97.7.2098; Montserrat E, 2008, BLOOD, V112, P924, DOI 10.1182/blood-2008-05-155721; O'Brien P, 2011, CANCER RES, V71, P7345, DOI 10.1158/0008-5472.CAN-11-1874; Palamarchuk A, 2010, BLOOD, V115, P3916, DOI 10.1182/blood-2009-10-249367; PENG BH, 1994, J IMMUNOL, V153, P1869; Perez-Perarnau A, 2011, EPIGENETICS-US, V6, P1228, DOI 10.4161/epi.6.10.17200; Piller GJ, 2001, BRIT J HAEMATOL, V112, P282, DOI 10.1046/j.1365-2141.2001.02411.x; Poppe B, 2005, GENE CHROMOSOME CANC, V44, P218, DOI 10.1002/gcc.20214; Proulx M, 2010, INT J HEMATOL, V92, P451, DOI 10.1007/s12185-010-0691-9; Ramalingam SS, 2009, J THORAC ONCOL, V4, P97, DOI 10.1097/JTO.0b013e318191520c; Raveche ES, 2007, BLOOD, V109, P5079, DOI 10.1182/blood-2007-02-071225; ROBERTSON LE, 1992, BLOOD, V80, P29; Robichaud GA, 2008, NUCLEIC ACIDS RES, V36, P4609, DOI 10.1093/nar/gkn432; Rodriguez A, 2004, GENOME RES, V14, P1902, DOI 10.1101/gr.2722704; Salerno E, 2010, CYTOM PART B-CLIN CY, V78B, pS98, DOI 10.1002/cyto.b.20544; Salerno E, 2009, MOL CANCER THER, V8, P2684, DOI 10.1158/1535-7163.MCT-09-0127; Sampath D, 2012, BLOOD, V119, P1162, DOI 10.1182/blood-2011-05-351510; Scaglione BJ, 2007, BRIT J HAEMATOL, V139, P645, DOI 10.1111/j.1365-2141.2007.06851.x; Siegel D, 2009, J HEMATOL ONCOL, V2, DOI 10.1186/1756-8722-2-31; Stathis A, 2011, CLIN CANCER RES, V17, P1582, DOI 10.1158/1078-0432.CCR-10-1893; Thelander EF, 2007, LEUKEMIA RES, V31, P1219, DOI 10.1016/j.leukres.2006.10.022; Van Damme M, 2012, EPIGENETICS-US, V7, P1403, DOI 10.4161/epi.22674; Wang JC, 2011, ONCOLOGY-BASEL, V81, P325, DOI 10.1159/000334577; Yu D, 2003, BLOOD, V101, P1950, DOI 10.1182/blood-2002-06-1797; Zhang M, 1998, ONCOL REP, V5, P23; Zhang M, 2001, EXP CELL RES, V264, P233, DOI 10.1006/excr.2000.5122; Zhang X, 2012, ONCOGENE, V31, P3002, DOI 10.1038/onc.2011.470; Zhao HW, 2009, BLOOD, V113, P505, DOI 10.1182/blood-2008-01-136218	66	31	32	2	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 19	2014	33	25					3307	3315		10.1038/onc.2013.291	http://dx.doi.org/10.1038/onc.2013.291			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AK5DA	23995789	Green Accepted			2022-12-17	WOS:000338443400010
J	Kennedy, CL; Najdovska, M; Tye, H; McLeod, L; Yu, L; Jarnicki, A; Bhathal, PS; Putoczki, T; Ernst, M; Jenkins, BJ				Kennedy, C. L.; Najdovska, M.; Tye, H.; McLeod, L.; Yu, L.; Jarnicki, A.; Bhathal, P. S.; Putoczki, T.; Ernst, M.; Jenkins, B. J.			Differential role of MyD88 and Mal/TIRAP in TLR2-mediated gastric tumourigenesis	ONCOGENE			English	Article						gastric cancer; TLR2; MyD88; Mal/TIRAP	INNATE IMMUNITY; HELICOBACTER-PYLORI; MUTANT MICE; INFLAMMATION; CANCER; STAT3; TLR2; ACTIVATION; SUSCEPTIBILITY; POLYMORPHISM	Signalling by the toll-like receptor (TLR) family of pathogen recognition receptors has emerged as a key molecular component in the pathogenesis of an increasing number of inflammatory-related cancers, among which gastric cancer rates as the second most lethal cancer world-wide. The myeloid differentiation factor 88 (MyD88) adapter molecule has a critical role in mediating innate immune signalling by members of the TLR and interleukin (IL)-1 families, and has been associated with either pro-or antitumourigenic responses in various cancer models. However, little is known about the in vivo role of MyD88 adapter-like (Mal)/TIR-domain containing adapter protein (TIRAP), which is restricted to facilitating TLR4 and TLR2 signalling. To interrogate the role of these innate immune signalling components in gastric tumourigenesis, here we have employed the spontaneous gastric cancer gp130(F/F) mouse model, in which TLR2 promotes the growth of gastric tumours. Genetic ablation of Myd88 in gp130(F/F) mice suppressed tumourigenesis and was associated with increased apoptosis and reduced proliferation in the gastric tumour epithelium, comparable to that observed previously upon deletion of Tlr2 in gp130(F/F) mice. By contrast, the tumour burden in gp130(F/F):Mal(-/-) mice was equivalent to their gp130F/F littermates. At the molecular level, suppressed tumourigenesis in gp130(F/F):Myd88(-/-) mice correlated with reduced expression and activation of TLR2-regulated protumourigenic genes and signalling pathways, respectively. Consistent with the previously defined non-essential role for TLR2 in gastric tumour inflammation, the extent of inflammatory cell infiltrates in gastric tumours from gp130(F/F):Mal(-/-) and gp130(F/F):Myd88(-/-) mice remained unaltered compared with gp130(F/F) mice. Collectively, our data reveal a differential, but inflammation-independent, requirement for Mal and MyD88 during TLR2-promoted gastric tumourigenesis.	[Kennedy, C. L.; Najdovska, M.; Tye, H.; McLeod, L.; Yu, L.; Jenkins, B. J.] Monash Univ, Monash Inst Med Res, Ctr Innate Immun & Infect Dis, Clayton, Vic 3168, Australia; [Jarnicki, A.; Putoczki, T.; Ernst, M.] Royal Melbourne Hosp, Ludwig Inst Canc Res, Parkville, Vic 3050, Australia; [Bhathal, P. S.] Univ Melbourne, Dept Pathol, Melbourne, Vic, Australia	Monash University; Ludwig Institute for Cancer Research; Royal Melbourne Hospital; University of Melbourne	Jenkins, BJ (corresponding author), Monash Univ, Monash Inst Med Res, Ctr Innate Immun & Infect Dis, 27-31 Wright St, Clayton, Vic 3168, Australia.	Brendan.Jenkins@monash.edu	Ernst, Matthias/D-5111-2012	Ernst, Matthias/0000-0002-6399-1177; Kennedy, Catherine/0000-0001-6359-6161; Jenkins, Brendan/0000-0002-7552-4656	Association for International Cancer Research (UK); Cancer Council of Victoria (Australia); National Health and Medical Research Council (Australia); Victorian Government of Australia; Sylvia and Charles Viertel Foundation	Association for International Cancer Research (UK); Cancer Council of Victoria (Australia)(Canadian Institutes of Health Research (CIHR)Cancer Council Victoria); National Health and Medical Research Council (Australia)(National Health and Medical Research Council (NHMRC) of Australia); Victorian Government of Australia; Sylvia and Charles Viertel Foundation	This study was supported by research grants from the Association for International Cancer Research (UK), the Cancer Council of Victoria (Australia) and the National Health and Medical Research Council (Australia), as well as the Operational Infrastructure Support Program by the Victorian Government of Australia. BJ Jenkins is supported by a Senior Medical Research Fellowship awarded by the Sylvia and Charles Viertel Foundation.	Arbibe L, 2000, NAT IMMUNOL, V1, P533, DOI 10.1038/82797; Bollrath J, 2009, CANCER CELL, V15, P91, DOI 10.1016/j.ccr.2009.01.002; Cole LE, 2010, J LEUKOCYTE BIOL, V87, P275, DOI 10.1189/jlb.0909619; Coste I, 2010, J CLIN INVEST, V120, P3663, DOI 10.1172/JCI42771; Ernst M, 2008, J CLIN INVEST, V118, P1727, DOI 10.1172/JCI34944; Greenhill CJ, 2011, J IMMUNOL, V186, P1199, DOI 10.4049/jimmunol.1002971; Grivennikov SI, 2012, NATURE, V491, P254, DOI 10.1038/nature11465; Hoebe K, 2006, ADV IMMUNOL, V91, P175, DOI 10.1016/S0065-2776(06)91005-0; Hold GL, 2007, GASTROENTEROLOGY, V132, P905, DOI 10.1053/j.gastro.2006.12.026; Hutchinson E, 2012, NAT REV IMMUNOL, V12, P681, DOI 10.1038/nri3304; Jenkins BJ, 2005, NAT MED, V11, P845, DOI 10.1038/nm1282; Kawai T, 2010, NAT IMMUNOL, V11, P373, DOI 10.1038/ni.1863; Kennedy CL, 2011, J PATHOL, V225, P255, DOI 10.1002/path.2933; Kenny EF, 2009, J IMMUNOL, V183, P3642, DOI 10.4049/jimmunol.0901140; Mandell L, 2004, INFECT IMMUN, V72, P6446, DOI 10.1128/IAI.72.11.6446-6454.2004; Milne AN, 2009, HUM GENET, V126, P615, DOI 10.1007/s00439-009-0722-x; Naugler WE, 2007, SCIENCE, V317, P121, DOI 10.1126/science.1140485; Rakoff-Nahoum S, 2007, SCIENCE, V317, P124, DOI 10.1126/science.1140488; Salcedo R, 2010, J EXP MED, V207, P1625, DOI 10.1084/jem.20100199; Schiechl G, 2011, J CLIN INVEST, V121, P1692, DOI 10.1172/JCI42540; Shen YN, 2010, INFECT IMMUN, V78, P2857, DOI 10.1128/IAI.01138-09; Sierra SS, 2009, EMBO J, V28, P2018, DOI 10.1038/emboj.2009.158; Swann JB, 2008, P NATL ACAD SCI USA, V105, P652, DOI 10.1073/pnas.0708594105; Tahara T, 2007, CANCER SCI, V98, P1790, DOI 10.1111/j.1349-7006.2007.00590.x; Tye H, 2012, CANCER CELL, V22, P466, DOI 10.1016/j.ccr.2012.08.010; Uemura N, 2001, NEW ENGL J MED, V345, P784, DOI 10.1056/NEJMoa001999; Uno K, 2007, AM J PHYSIOL-GASTR L, V293, pG1004, DOI 10.1152/ajpgi.00096.2007; Uronis JM, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006026; Yamamoto M, 2002, NATURE, V420, P324, DOI 10.1038/nature01182	29	31	34	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 8	2014	33	19					2540	2546		10.1038/onc.2013.205	http://dx.doi.org/10.1038/onc.2013.205			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AH3OK	23728346				2022-12-17	WOS:000336033600014
J	Palla, AR; Piazzolla, D; Abad, M; Li, H; Dominguez, O; Schonthaler, HB; Wagner, EF; Serrano, M				Palla, A. R.; Piazzolla, D.; Abad, M.; Li, H.; Dominguez, O.; Schonthaler, H. B.; Wagner, E. F.; Serrano, M.			Reprogramming activity of NANOGP8, a NANOG family member widely expressed in cancer	ONCOGENE			English	Article						NANOG; NANOGP8; cancer; reprogramming; pluripotency	PLURIPOTENT STEM-CELLS; DIFFERENTIATION; GENE; PROMOTES; ES	NANOG is a key transcription factor for pluripotency in embryonic stem cells. The analysis of NANOG in human cells is confounded by the presence of multiple and highly similar paralogs. In particular, there are three paralogs encoding full-length proteins, namely, NANOG1, NANOG2 and NANOGP8, and at least eight additional paralogs that do not encode full-length NANOG proteins. Here, we have examined NANOG family expression in human embryonic stem cells (hESCs) and in human cancer cell lines using a multi-NANOG PCR that amplifies the three functional paralogs and most of the non-functional ones. As anticipated, we found that hESCs express large amounts of NANOG1 and, interestingly, they also express NANOG2. In contrast, most human cancer cells tested express NANOGP8 and the non-coding paralogs NANOGP4 and NANOGP5. Notably, in some cancer cell lines, the NANOG protein levels produced by NANOGP8 are comparable to those produced by NANOG1 in pluripotent cells. Finally, we show that NANOGP8 is as active as NANOG1 in the reprogramming of human and murine fibroblasts into induced pluripotent stem cells. These results show that cancer-associated NANOGP8 can contribute to promote de-differentiation and/or cellular plasticity.	[Palla, A. R.; Piazzolla, D.; Abad, M.; Li, H.; Serrano, M.] Spanish Natl Canc Res Ctr CNIO, Tumour Suppress Grp, Mol Oncol Programme, E-28029 Madrid, Spain; [Dominguez, O.] Spanish Natl Canc Res Ctr CNIO, Genom Core Unit, Biotechnol Programme, E-28029 Madrid, Spain; [Schonthaler, H. B.; Wagner, E. F.] Spanish Natl Canc Res Ctr CNIO, F BBVA CNIO Canc Cell Biol Programme, Genes Dev & Dis Grp, Madrid, Spain	Centro Nacional de Investigaciones Oncologicas (CNIO); Centro Nacional de Investigaciones Oncologicas (CNIO); Centro Nacional de Investigaciones Oncologicas (CNIO)	Serrano, M (corresponding author), Spanish Natl Canc Res Ctr CNIO, 3 Melchor Fernandez Almagro St, E-28029 Madrid, Spain.	mserrano@cnio.es	Schönthaler, Helia/AAG-4767-2021; Abad, Maria/I-3911-2015; Serrano, Manuel/H-2634-2015; Abad, Maria/AAI-2366-2019; Dominguez, Orlando/M-7515-2018; Vivancos, Ana/AAG-8331-2019	Abad, Maria/0000-0002-1462-2498; Serrano, Manuel/0000-0001-7177-9312; Abad, Maria/0000-0002-1462-2498; Wagner, Erwin F/0000-0001-7872-0196; Vivancos, Ana/0000-0003-2888-6512; Palla, Adelaida/0000-0003-2695-9335	FPI Program of the Spanish Department of Science (MINECO); EMBO Long-Term Fellowship; 'Ramon y Cajal' Program (MINECO); CNIO; MINECO (SAF); European Union (ERC); Regional Government of Madrid; Botin Foundation; Ramon Areces Foundation; AXA Foundation; F-BBVA	FPI Program of the Spanish Department of Science (MINECO); EMBO Long-Term Fellowship(European Molecular Biology Organization (EMBO)); 'Ramon y Cajal' Program (MINECO); CNIO; MINECO (SAF); European Union (ERC)(European Research Council (ERC)European Commission); Regional Government of Madrid; Botin Foundation; Ramon Areces Foundation; AXA Foundation; F-BBVA(BBVA Foundation)	We are grateful to Dr Maria S Soengas (CNIO) for providing us with human primary fibroblasts and to Dr Miguel A Piris (CNIO) for providing us with all the human cancer cell lines. ARP is supported by the FPI Program of the Spanish Department of Science (MINECO). DP was funded by an EMBO Long-Term Fellowship. HL is supported by the 'Ramon y Cajal' Program (MINECO). Work in the laboratory of MS is funded by the CNIO and by grants from the MINECO (SAF), the European Union (ERC Advanced Grant), the Regional Government of Madrid, the Botin Foundation, the Ramon Areces Foundation and the AXA Foundation. Work in the laboratory of EFW is supported by grants from F-BBVA and the European Union (ERC Advanced Grant).	Ambady S, 2010, INT J DEV BIOL, V54, P1743, DOI 10.1387/ijdb.103192sa; Booth HAF, 2004, GENOMICS, V84, P229, DOI 10.1016/j.ygeno.2004.02.014; Carey BW, 2009, P NATL ACAD SCI USA, V106, P157, DOI 10.1073/pnas.0811426106; Chambers I, 2003, CELL, V113, P643, DOI 10.1016/S0092-8674(03)00392-1; Chambers I, 2009, DEVELOPMENT, V136, P2311, DOI 10.1242/dev.024398; Chang DF, 2009, STEM CELLS, V27, P812, DOI 10.1634/stemcells.2008-0657; Do HJ, 2009, J CELL BIOCHEM, V106, P1079, DOI 10.1002/jcb.22089; Eberle I, 2010, NUCLEIC ACIDS RES, V38, P5384, DOI 10.1093/nar/gkq307; Fujita J, 2008, CELL STEM CELL, V2, P595, DOI 10.1016/j.stem.2008.04.001; Grigoriadis AE, 2010, BLOOD, V115, P2769, DOI 10.1182/blood-2009-07-234690; Hanna J, 2009, NATURE, V462, P595, DOI 10.1038/nature08592; Hochedlinger K, 2005, CELL, V121, P465, DOI 10.1016/j.cell.2005.02.018; Ishiguro T, 2012, BIOCHEM BIOPH RES CO, V418, P199, DOI 10.1016/j.bbrc.2011.10.123; Jeter CR, 2011, ONCOGENE, V30, P3833, DOI 10.1038/onc.2011.114; Jeter CR, 2009, STEM CELLS, V27, P993, DOI 10.1002/stem.29; Kim JS, 2005, EXP MOL MED, V37, P601, DOI 10.1038/emm.2005.73; Lowry WE, 2008, P NATL ACAD SCI USA, V105, P2883, DOI 10.1073/pnas.0711983105; Mitsui K, 2003, CELL, V113, P631, DOI 10.1016/S0092-8674(03)00393-3; Moretto-Zita M, 2010, P NATL ACAD SCI USA, V107, P13312, DOI 10.1073/pnas.1005847107; Pan GJ, 2005, J BIOL CHEM, V280, P1401, DOI 10.1074/jbc.M407847200; Ramakrishna S, 2011, STEM CELLS DEV, V20, P1512, DOI 10.1089/scd.2010.0410; Silva J, 2009, CELL, V138, P722, DOI 10.1016/j.cell.2009.07.039; Silva J, 2008, PLOS BIOL, V6, P2237, DOI 10.1371/journal.pbio.0060253; Suva ML, 2013, SCIENCE, V339, P1567, DOI 10.1126/science.1230184; Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019; Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024; Theunissen TW, 2011, DEVELOPMENT, V138, P4853, DOI 10.1242/dev.068775; Uchino K, 2012, EXP CELL RES, V318, P1799, DOI 10.1016/j.yexcr.2012.04.011; Wang SH, 2003, GENE EXPR PATTERNS, V3, P99, DOI 10.1016/S1567-133X(03)00005-X; Ying QL, 2008, NATURE, V453, P519, DOI 10.1038/nature06968; Yu JY, 2007, SCIENCE, V318, P1917, DOI 10.1126/science.1151526; Zbinden M, 2010, EMBO J, V29, P2659, DOI 10.1038/emboj.2010.137; Zhang J, 2013, ONCOGENE, V32, P4397, DOI 10.1038/onc.2012.461; Zhang JY, 2010, ONCOL LETT, V1, P457, DOI 10.3892/ol_00000081; Zhang JY, 2006, FEBS J, V273, P1723, DOI 10.1111/j.1742-4658.2006.05186.x	35	31	34	0	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 8	2014	33	19					2513	2519		10.1038/onc.2013.196	http://dx.doi.org/10.1038/onc.2013.196			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AH3OK	23752184				2022-12-17	WOS:000336033600011
J	Lee, SH; Bae, SC; Kim, KW; Lee, YM				Lee, S. H.; Bae, S. C.; Kim, K. W.; Lee, Y. M.			RUNX3 inhibits hypoxia-inducible factor-1 alpha protein stability by interacting with prolyl hydroxylases in gastric cancer cells	ONCOGENE			English	Article						RUNX3; hypoxia; HIF-1 alpha; prolyl hydroxylase; angiogenesis	HIPPEL-LINDAU PROTEIN; TUMOR-SUPPRESSOR; FACTOR 1-ALPHA; KINASE PHOSPHORYLATES; GENE-EXPRESSION; GROWTH-FACTOR; ANGIOGENESIS; OXYGEN; METASTASIS; PATHWAY	RUNX3 is silenced by histone modification and hypoxia-inducible factor (HIF)-1 alpha is stabilized under hypoxia, but little is known of cross-talk between RUNX3 and HIF-1 alpha under hypoxia. In the present study, the authors investigated the effect of RUNX3 on HIF-1 alpha stability in gastric cancer cells. RUNX3 overexpression was found to downregulate HIF-1 alpha stability under normoxic and hypoxic conditions. Furthermore, the activity of a luciferase reporter containing five copies of vascular endothelial growth factor (VEGF) promoter hypoxia-responsive element (5 x HRE) and the amount of secreted VEGF, were diminished in RUNX3-expressing but increased in RUNX3-knockdown cells. When expression of RUNX3 was recovered using epigenetic reagents the expressions of HIF-1 alpha and VEGF were clearly suppressed under hypoxic conditions. RUNX3 also significantly attenuated the half-life of HIF-1 alpha protein, and induced the cytosolic localization and ubiquitination of HIF-1 alpha. In addition, RUNX3 directly interacted with the C-terminal activation domain of HIF-1 alpha and prolyl hydroxylase (PHD) 2 and enhanced the interaction between HIF-1 alpha and PHD2, which potentiated proline hydroxylation and promoted the degradation of HIF-1 alpha. Furthermore, RUNX3 overexpression significantly inhibited hypoxia-induced angiogenesis in vitro and in vivo. Taken together, these results suggest that RUNX3 destabilizes HIF-1 alpha protein by promoting the proline hydroxylation of HIF-1 alpha through binding to HIF-1 alpha/PHD2. RUNX3 appears to be a novel suppressor of HIF-1 alpha and of hypoxia-mediated angiogenesis in gastric cancer cells.	[Lee, S. H.] Kyungpook Natl Univ, Coll Nat Sci, Sch Life Sci & Biotechnol, Taegu 702701, South Korea; [Bae, S. C.] Chungbook Natl Univ, Sch Med, Chongju, South Korea; [Kim, K. W.] Seoul Natl Univ, Coll Pharm, Seoul, South Korea; [Lee, S. H.; Lee, Y. M.] Kyungpook Natl Univ, Coll Pharm, Taegu 702701, South Korea; [Lee, S. H.; Lee, Y. M.] Kyungpook Natl Univ, Res Inst Pharmaceut Sci, Taegu 702701, South Korea	Kyungpook National University; Seoul National University (SNU); Kyungpook National University; Kyungpook National University	Lee, YM (corresponding author), Kyungpook Natl Univ, Coll Pharm, Taegu 702701, South Korea.	lym@knu.ac.kr	Kim, Kyu Won/AAJ-7213-2020		National Research Foundation grant from the Basic Research Lab program [2012-028835]; National Research Foundation grant from Mid-career Researcher Program [2010-0026741]; Korean Ministry of Education, Science Technology (MEST)	National Research Foundation grant from the Basic Research Lab program; National Research Foundation grant from Mid-career Researcher Program; Korean Ministry of Education, Science Technology (MEST)(Ministry of Education, Science & Technology (MEST), Republic of Korea)	This work was supported by a National Research Foundation grant from the Basic Research Lab program (2012-028835) and from Mid-career Researcher Program (2010-0026741) funded by the Korean Ministry of Education, Science Technology (MEST).	An WG, 1998, NATURE, V392, P405, DOI 10.1038/32925; Bae MK, 2005, CANCER RES, V65, P2520, DOI 10.1158/0008-5472.CAN-03-2735; Cao YH, 2007, ADV CANCER RES, V97, P203, DOI 10.1016/S0065-230X(06)97009-2; Chan DA, 2005, MOL CELL BIOL, V25, P6415, DOI 10.1128/MCB.25.15.6415-6426.2005; Chang CC, 2011, J ORAL PATHOL MED, V40, P567, DOI 10.1111/j.1600-0714.2011.01009.x; Chuang LSH, 2010, ONCOGENE, V29, P2605, DOI 10.1038/onc.2010.88; Corish P, 1999, PROTEIN ENG, V12, P1035, DOI 10.1093/protein/12.12.1035; Coulon C, 2010, ARTERIOSCL THROM VAS, V30, P2331, DOI 10.1161/ATVBAHA.110.214106; Ellis L, 2009, CANCER LETT, V280, P145, DOI 10.1016/j.canlet.2008.11.012; FOLKMAN J, 1990, JNCI-J NATL CANCER I, V82, P4, DOI 10.1093/jnci/82.1.4; Fujita N, 2012, J BIOL CHEM, V287, P16975, DOI 10.1074/jbc.M111.334466; Goh YM, 2010, J BIOL CHEM, V285, P10122, DOI 10.1074/jbc.M109.071381; Guo WH, 2002, ONCOGENE, V21, P8351, DOI 10.1038/sj.onc.1206037; Hagen T, 2003, SCIENCE, V302, P1975, DOI 10.1126/science.1088805; Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704; Isobe T, 2012, INT J CLIN ONCOL; Ito K, 2005, CANCER RES, V65, P7743, DOI 10.1158/0008-5472.CAN-05-0743; Ito Y, 2008, ADV CANCER RES, V99, P33, DOI 10.1016/S0065-230X(07)99002-8; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jeong CH, 2005, INT J ONCOL, V26, P211; Jeong JW, 2002, CELL, V111, P709, DOI 10.1016/S0092-8674(02)01085-1; Kaelin WG, 2008, MOL CELL, V30, P393, DOI 10.1016/j.molcel.2008.04.009; Kim HR, 2008, J CELL BIOCHEM, V105, P1048, DOI 10.1002/jcb.21906; Kim JH, 2009, J CELL BIOCHEM, V107, P557, DOI 10.1002/jcb.22157; Kim MS, 2001, NAT MED, V7, P437, DOI 10.1038/86507; Lau QC, 2006, CANCER RES, V66, P6512, DOI 10.1158/0008-5472.CAN-06-0369; Lee MN, 2010, J NATL CANCER I, V102, P426, DOI 10.1093/jnci/djq026; Lee SH, 2009, ONCOGENE, V28, P184, DOI 10.1038/onc.2008.377; Li QL, 2002, CELL, V109, P113, DOI 10.1016/S0092-8674(02)00690-6; Lund AH, 2002, CANCER CELL, V1, P213, DOI 10.1016/S1535-6108(02)00049-1; Masson N, 2001, EMBO J, V20, P5197, DOI 10.1093/emboj/20.18.5197; Nakase Y, 2005, BRIT J CANCER, V92, P562, DOI 10.1038/sj.bjc.6602372; Ohh M, 2000, NAT CELL BIOL, V2, P423, DOI 10.1038/35017054; Peng ZH, 2006, CLIN CANCER RES, V12, P6386, DOI 10.1158/1078-0432.CCR-05-2359; Poon E, 2009, EXPERT REV MOL MED, V11, DOI 10.1017/S1462399409001173; Pore N, 2006, MOL CANCER RES, V4, P471, DOI 10.1158/1541-7786.MCR-05-0234; Salceda S, 1997, J BIOL CHEM, V272, P22642, DOI 10.1074/jbc.272.36.22642; Semenza GL, 2003, ANNU REV MED, V54, P17, DOI 10.1146/annurev.med.54.101601.152418; Semenza GL, 2000, CANCER METAST REV, V19, P59, DOI 10.1023/A:1026544214667; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Stiehl DP, 2006, J BIOL CHEM, V281, P23482, DOI 10.1074/jbc.M601719200; Takeda K, 2009, ARTERIOSCL THROM VAS, V29, P2132, DOI 10.1161/ATVBAHA.109.196071; Wei DY, 2005, CANCER RES, V65, P4809, DOI 10.1158/0008-5472.CAN-04-3741; Yano T, 2006, MOL CELL BIOL, V26, P4474, DOI 10.1128/MCB.01926-05; Zhang YQ, 2007, MED SCI MONITOR, V13, pRA175; Zhong H, 2000, CANCER RES, V60, P1541	46	31	33	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 13	2014	33	11					1458	1467		10.1038/onc.2013.76	http://dx.doi.org/10.1038/onc.2013.76			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AD0SD	23542169				2022-12-17	WOS:000332943500013
J	Harte, MT; Gorski, JJ; Savage, KI; Purcell, JW; Barros, EW; Burn, PM; McFarlane, C; Mullan, PB; Kennedy, RD; Perkins, ND; Harkin, DP				Harte, M. T.; Gorski, J. J.; Savage, K. I.; Purcell, J. W.; Barros, E. W.; Burn, P. M.; McFarlane, C.; Mullan, P. B.; Kennedy, R. D.; Perkins, N. D.; Harkin, D. P.			NF-kappa B is a critical mediator of BRCA1-induced chemoresistance	ONCOGENE			English	Article						BRCA1; NF-kappa B; DNA damage; apoptosis	DOUBLE-STRAND BREAKS; DNA-REPAIR; BRCA1; CANCER; ACTIVATION; EXPRESSION; SUBUNIT; CHEMOTHERAPY; APOPTOSIS; COMPLEX	BRCA1 mediates resistance to apoptosis in response to DNA-damaging agents, causing BRCA1 wild-type tumours to be significantly more resistant to DNA damage than their mutant counterparts. In this study, we demonstrate that following treatment with the DNA-damaging agents, etoposide or camptothecin, BRCA1 is required for the activation of nuclear factor-kappa B (NF-kappa B), and that BRCA1 and NF-kappa B cooperate to regulate the expression of the NF-kappa B antiapoptotic targets BCL2 and XIAP. We show that BRCA1 and the NF-kappa B subunit p65/RelA associate constitutively, whereas the p50 NF-kappa B subunit associates with BRCA1 only upon DNA damage treatment. Consistent with this BRCA1 and p65 are present constitutively on the promoters of BCL2 and XIAP, whereas p50 is recruited to these promoters only in damage treated cells. Importantly, we demonstrate that the recruitment of p50 onto the promoters of BCL2 and XIAP is dependent upon BRCA1, but independent of its NF-kappa B partner subunit p65. The functional relevance of NF-kappa B activation by BRCA1 in response to etoposide and camptothecin is demonstrated by the significantly reduced survival of BRCA1 wild-type cells upon NF-kappa B inhibition. This study identifies a novel BRCA1-p50 complex, and demonstrates for the first time that NF-kappa B is required for BRCA1-mediated resistance to DNA damage. It reveals a functional interdependence between BRCA1 and NF-kappa B, further elucidating the role played by NF-kappa B in mediating cellular resistance of BRCA1 wild-type tumours to DNA-damaging agents.	[Harte, M. T.; Gorski, J. J.; Savage, K. I.; Barros, E. W.; Burn, P. M.; McFarlane, C.; Mullan, P. B.; Kennedy, R. D.; Harkin, D. P.] Queens Univ Belfast, Ctr Canc Res & Cell Biol, Belfast BT9 7BL, Antrim, North Ireland; [Purcell, J. W.] Abbott Biotherapeut, Global Pharmaceut Res & Dev, Biol Technol, Redwood City, CA USA; [Perkins, N. D.] Newcastle Univ, Sch Med, Inst Cell & Mol Biosci, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England	Queens University Belfast; Newcastle University - UK	Harte, MT (corresponding author), Queens Univ Belfast, Ctr Canc Res & Cell Biol, Lisburn Rd, Belfast BT9 7BL, Antrim, North Ireland.	m.harte@qub.ac.uk; d.harkin@qub.ac.uk	Kennedy, Richard/J-3489-2012	Kennedy, Richard/0000-0003-4737-6163; Savage, Kienan/0000-0002-4898-899X	Medical Research Council; Cancer Research UK; Cancer Focus Northern Ireland; Action Cancer; Medical Research Council [G0600267] Funding Source: researchfish; MRC [G0600267] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Cancer Research UK(Cancer Research UK); Cancer Focus Northern Ireland; Action Cancer; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	We thank Dr Stephen McMahon for help with statistical analysis of survival curves. This study was supported by Medical Research Council (M. T Harte and D. P Harkin); Cancer Research UK (KI Savage, JJ Gorski, P Burn, E Barros and DP Harkin); Cancer Focus Northern Ireland (KI Savage); Action Cancer (J.P Purcell).	Barre B, 2007, EMBO J, V26, P4841, DOI 10.1038/sj.emboj.7601899; Benezra M, 2003, J BIOL CHEM, V278, P26333, DOI 10.1074/jbc.M303076200; Bochar DA, 2000, CELL, V102, P257, DOI 10.1016/S0092-8674(00)00030-1; Chapppuis PO, 2002, J MED GENET, V39, P608, DOI 10.1136/jmg.39.8.608; DiDonato JA, 2012, IMMUNOL REV, V246, P379, DOI 10.1111/j.1600-065X.2012.01099.x; Farmer H, 2005, NATURE, V434, P917, DOI 10.1038/nature03445; Franken NAP, 2006, NAT PROTOC, V1, P2315, DOI 10.1038/nprot.2006.339; Freneaux P, 2000, BRIT J CANCER, V83, P1318, DOI 10.1054/bjoc.2000.1438; Gorski JJ, 2011, NUCLEIC ACIDS RES, V39, P9536, DOI 10.1093/nar/gkr679; Gorski JJ, 2010, BREAST CANCER RES TR, V122, P721, DOI 10.1007/s10549-009-0565-0; Habraken Y, 2003, ONCOGENE, V22, P6090, DOI 10.1038/sj.onc.1206893; Habraken Y, 2006, BIOCHEM PHARMACOL, V72, P1132, DOI 10.1016/j.bcp.2006.07.015; Harkin DP, 1999, CELL, V97, P575, DOI 10.1016/S0092-8674(00)80769-2; Harte MT, 2010, CANCER RES, V70, P2538, DOI 10.1158/0008-5472.CAN-09-2089; Hartman AR, 2002, NAT GENET, V32, P180, DOI 10.1038/ng953; Hayden MS, 2008, CELL, V132, P344, DOI 10.1016/j.cell.2008.01.020; Hosey AM, 2007, J NATL CANCER I, V99, P1683, DOI 10.1093/jnci/djm207; Huen MSY, 2010, NAT REV MOL CELL BIO, V11, P138, DOI 10.1038/nrm2831; Kennedy RD, 2005, CANCER RES, V65, P10265, DOI 10.1158/0008-5472.CAN-05-1841; Kirova YM, 2005, EUR J CANCER, V41, P2304, DOI 10.1016/j.ejca.2005.02.037; McCool KW, 2012, IMMUNOL REV, V246, P311, DOI 10.1111/j.1600-065X.2012.01101.x; McEachern KA, 2003, J CELL BIOCHEM, V89, P120, DOI 10.1002/jcb.10487; Mullan PB, 2006, ONCOGENE, V25, P5854, DOI 10.1038/sj.onc.1209872; Mullan PB, 2006, BBA-REV CANCER, V1766, P205, DOI 10.1016/j.bbcan.2006.07.001; Mullan PB, 2005, ONCOGENE, V24, P5492, DOI 10.1038/sj.onc.1208698; Nakanishi C, 2005, NAT REV CANCER, V5, P297, DOI 10.1038/nrc1588; Perkins ND, 2007, NAT REV MOL CELL BIO, V8, P49, DOI 10.1038/nrm2083; Perkins ND, 2012, NAT REV CANCER, V12, P121, DOI 10.1038/nrc3204; Quinn JE, 2003, CANCER RES, V63, P6221; Quinn JE, 2007, CLIN CANCER RES, V13, P7413, DOI 10.1158/1078-0432.CCR-07-1083; Roy R, 2012, NAT REV CANCER, V12, P68, DOI 10.1038/nrc3181; Sabatel H, 2011, BIOCHEM PHARMACOL, V82, P1371, DOI 10.1016/j.bcp.2011.07.105; Schumm K, 2006, EMBO J, V25, P4820, DOI 10.1038/sj.emboj.7601343; Stilmann M, 2009, MOL CELL, V36, P365, DOI 10.1016/j.molcel.2009.09.032; Treszezamsky AD, 2007, CANCER RES, V67, P7078, DOI 10.1158/0008-5472.CAN-07-0601; Volcic M, 2012, NUCLEIC ACIDS RES, V40, P181, DOI 10.1093/nar/gkr687; Wang JX, 2009, EMBO REP, V10, P1272, DOI 10.1038/embor.2009.197	37	31	34	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 6	2014	33	6					713	723		10.1038/onc.2013.10	http://dx.doi.org/10.1038/onc.2013.10			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AA5IL	23435429	Green Accepted			2022-12-17	WOS:000331129200006
J	Munugalavadla, V; Mariathasan, S; Slaga, D; Du, C; Berry, L; Del Rosario, G; Yan, Y; Boe, M; Sun, L; Friedman, LS; Chesi, M; Bergsagel, PL; Ebens, A				Munugalavadla, V.; Mariathasan, S.; Slaga, D.; Du, C.; Berry, L.; Del Rosario, G.; Yan, Y.; Boe, M.; Sun, L.; Friedman, L. S.; Chesi, M.; Bergsagel, P. Leif; Ebens, A.			The PI3K inhibitor GDC-0941 combines with existing clinical regimens for superior activity in multiple myeloma	ONCOGENE			English	Article						GDC-0941; PI3K; multiple myeloma; FoxO3A	ORALLY BIOAVAILABLE INHIBITOR; TARGET; IDENTIFICATION; RAPAMYCIN; PATHWAY; GROWTH; POTENT; KINASE	The phosphatidylinositol 3'-kinase (PI3K) pathway is dysregulated in multiple myeloma (MM); we therefore tested a highly selective class I PI3K inhibitor, GDC-0941, for anti-myeloma activity. Functional and mechanistic studies were first performed in MM cell lines, then extended to primary MM patient samples cultured in vitro. GDC-0941 was then assessed as a single agent and in various combinations in myeloma tumor xenograft models. We show p110 alpha and beta are the predominant PI3K catalytic subunits in MM and that a highly selective class I PI3K inhibitor, GDC-0941, has robust activity as a single agent to induce cell cycle arrest and apoptosis of both MM cell lines and patient myeloma cells. Mechanistic studies revealed an induction of cell cycle arrest at G(0)/G(1), with decreased phospho-FoxO1/3a levels, decreased cyclin D1 and c-myc expression, and an increase in the cell cycle inhibitor, p27kip. Induction of apoptosis correlated with increased expression of the pro-apoptotic BH3-only protein BIM, cleaved caspase 3 and cleaved poly (ADP-ribose) polymerase (PARP). In vitro, GDC-0941 synergized with dexamethasone (Dex) and lenalidomide (combination index values of 0.3-0.4 and 0.4-0.8, respectively); in vivo GDC-0941 has anti-myeloma activity and significantly increases the activity of the standard of care agents in several murine xenograft tumor models (additional tumor growth inhibition of 37-53% (Dex) and 22-72% (lenalidomide)). These data provide a clear therapeutic hypothesis for the inhibition of PI3K and provide a rationale for clinical development of GDC-0941 in myeloma.	[Munugalavadla, V.; Mariathasan, S.; Slaga, D.; Du, C.; Berry, L.; Del Rosario, G.; Sun, L.; Friedman, L. S.; Ebens, A.] Genentech Inc, Dept Canc Immunotherapy & Hematol, San Francisco, CA 94080 USA; [Yan, Y.; Boe, M.] Genentech Inc, Dept Oncol Biomarker Dev, San Francisco, CA 94080 USA; [Chesi, M.; Bergsagel, P. Leif] Mayo Clin, Dept Med, Ctr Comprehens Canc, Scottsdale, AZ USA	Roche Holding; Genentech; Roche Holding; Genentech; Mayo Clinic; Mayo Clinic Phoenix	Munugalavadla, V (corresponding author), Genentech Inc, Dept Canc Immunotherapy & Hematol, 1 DNA Way,MS 231C,Room 14-3166, San Francisco, CA 94080 USA.	veerendm@gene.com	Bergsagel, Peter Leif/A-7842-2011; Du, Changchun/AAW-6540-2020	Bergsagel, Peter Leif/0000-0003-1523-7388; 				Anderson KC, 2011, ANNU REV PATHOL-MECH, V6, P249, DOI 10.1146/annurev-pathol-011110-130249; Bain J, 2007, BIOCHEM J, V408, P297, DOI 10.1042/BJ20070797; Baumann P, 2009, EXP CELL RES, V315, P485, DOI 10.1016/j.yexcr.2008.11.007; Chanan-Khan AA, BR J HAEMATOL, V151, P3; CHOU TC, 1984, ADV ENZYME REGUL, V22, P27, DOI 10.1016/0065-2571(84)90007-4; Dib Amel, 2008, J Natl Cancer Inst Monogr, P25, DOI 10.1093/jncimonographs/lgn011; Drexler HG, 2000, LEUKEMIA RES, V24, P681, DOI 10.1016/S0145-2126(99)00195-2; Ebens A, 2010, ASH ANN M, V116, P3001; Feldman ME, CURR TOP MICROBIOL I, V347, P241; Folkes AJ, 2008, J MED CHEM, V51, P5522, DOI 10.1021/jm800295d; Gera J, 2011, LEUKEMIA LYMPHOMA, V52, P1857, DOI 10.3109/10428194.2011.580478; Harvey R Donald, 2007, Future Oncol, V3, P639, DOI 10.2217/14796694.3.6.639; Hoang B, 2010, BLOOD, V116, P4560, DOI 10.1182/blood-2010-05-285726; Ikeda H, 2010, BLOOD, V116, P1460, DOI 10.1182/blood-2009-06-222943; Ismail SI, 2010, LEUKEMIA RES, V34, P824, DOI 10.1016/j.leukres.2009.11.018; Jou ST, 2002, MOL CELL BIOL, V22, P8580, DOI 10.1128/MCB.22.24.8580-8591.2002; Kawauchi K, 2009, ANTI-CANCER AGENT ME, V9, P1024, DOI 10.2174/187152009789377772; Kawauchi K, 2009, ANTI-CANCER AGENT ME, V9, P550, DOI 10.2174/187152009788451851; Khwaja A, CURR TOP MICROBIOL I, V347, P169; Kyle RA, 2004, NEW ENGL J MED, V351, P1860, DOI 10.1056/NEJMra041875; Kyle RA, 2009, CLIN LYMPHOMA MYELOM, V9, P278, DOI 10.3816/CLM.2009.n.056; Lee T, 2008, PLOS COMPUT BIOL, V4, DOI 10.1371/journal.pcbi.1000013; McMillin DW, 2009, CANCER RES, V69, P5835, DOI 10.1158/0008-5472.CAN-08-4285; Munugalavadla V, 2010, ASH ANN M, V116, P4084; Munugalavadla V, 2008, MOL CELL BIOL, V28, P7182, DOI 10.1128/MCB.00920-08; O'Brien C, CLIN CANC RES, V16, P3670; Peterson TR, 2009, CELL, V137, P873, DOI 10.1016/j.cell.2009.03.046; Podar K, 2009, LEUKEMIA, V23, P10, DOI 10.1038/leu.2008.259; Rahmani M, 2009, BLOOD, V114, P4507, DOI 10.1182/blood-2008-09-177881; Rajkurnar SV, 2007, BEST PRACT RES CL HA, V20, P665, DOI 10.1016/j.beha.2007.10.002; Raynaud FI, 2009, MOL CANCER THER, V8, P1725, DOI 10.1158/1535-7163.MCT-08-1200; Yasui H, 2006, BRIT J HAEMATOL, V132, P385, DOI 10.1111/j.1365-2141.2005.05860.x; Zhang J, 2003, ONCOGENE, V22, P6289, DOI 10.1038/sj.onc.1206718; Zhao L, 2004, CLIN CANCER RES, V10, P7994, DOI 10.1158/1078-0432.CCR-04-1087; Zollinger A, 2008, BLOOD, V112, P3403, DOI 10.1182/blood-2007-11-119362	35	31	34	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 16	2014	33	3					316	325		10.1038/onc.2012.594	http://dx.doi.org/10.1038/onc.2012.594			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	296VR	23318440				2022-12-17	WOS:000330214000006
J	Stebbing, J; Filipovic, A; Giamas, G				Stebbing, J.; Filipovic, A.; Giamas, G.			Claudin-1 as a promoter of EMT in hepatocellular carcinoma	ONCOGENE			English	Editorial Material						Claudin-1; hepatocellular cancer; invasion; Ras; ERK; c-Abl	CANCER; PROTEINS; THERAPY	Claudins are integral structural and functional components of apical cell adhesions (tight junctions). Loss of such adhesions has been associated with malignant transformation, a process most often accompanied by a concomitant loss of claudin expression. A growing body of evidence reveals the highly contextual upregulation of claudin expression in certain cancer types, and moreover their relevance in promoting cancer cell invasion and metastatic progression. In this issue of Oncogene, Suh et al. reported on claudin-1 expression in hepatocellular carcinoma (HCC), including its role as a promoter of the epithelial - to - mesenchymal transition via the c-Abl/Raf/Ras/ERK signaling pathway. Considering the limited therapeutic options in HCC, evaluation of its role as a target merits further investigation.	[Stebbing, J.; Filipovic, A.; Giamas, G.] Univ London Imperial Coll Sci Technol & Med, Div Surg & Canc, London W12 ONN, England	Imperial College London	Giamas, G (corresponding author), Univ London Imperial Coll Sci Technol & Med, Div Surg & Canc, Du Cane Rd,ICTEM Bldg, London W12 ONN, England.	g.giamas@imperial.ac.uk	Giamas, Georgios/AAP-3487-2021	Stebbing, Justin/0000-0002-1117-6947; Giamas, Georgios/0000-0002-4417-2707	Cancer Research UK Funding Source: Medline; Department of Health [NIHR-RP-011-053] Funding Source: Medline; Cancer Research UK [14549] Funding Source: researchfish; National Institute for Health Research [NIHR-RP-011-053] Funding Source: researchfish	Cancer Research UK(Cancer Research UK); Department of Health; Cancer Research UK(Cancer Research UK); National Institute for Health Research(National Institute for Health Research (NIHR))		Cervello M, 2012, ONCOTARGET, V3, P236, DOI 10.18632/oncotarget.466; Dhawan P, 2005, J CLIN INVEST, V115, P1765, DOI 10.1172/JCI24543; Morin PJ, 2005, CANCER RES, V65, P9603, DOI 10.1158/0008-5472.CAN-05-2782; Myal Y, 2010, J BIOMED BIOTECHNOL, DOI 10.1155/2010/956897; Roxburgh P, 2008, ADV THER, V25, P1089, DOI 10.1007/s12325-008-0113-z; Singh AB, 2010, J ONCOL, V2010, DOI 10.1155/2010/541957; Suh Y, 2013, ONCOGENE, V32, P4873, DOI 10.1038/onc.2012.505; Suzuki H, 2012, ANN NY ACAD SCI, V1258, P65, DOI 10.1111/j.1749-6632.2012.06503.x; Tabaries S, 2012, MOL CELL BIOL, V32, P2979, DOI 10.1128/MCB.00299-12; Turksen K, 2011, BBA-REV CANCER, V1816, P73, DOI 10.1016/j.bbcan.2011.04.001; Yoon CH, 2010, J BIOL CHEM, V285, P226, DOI 10.1074/jbc.M109.054189	11	31	32	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 10	2013	32	41					4871	4872		10.1038/onc.2012.591	http://dx.doi.org/10.1038/onc.2012.591			2	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	235KQ	23318416				2022-12-17	WOS:000325717800002
J	Li, N; Du, ZX; Zong, ZH; Liu, BQ; Li, C; Zhang, Q; Wang, HQ				Li, N.; Du, Z-X; Zong, Z-H; Liu, B-Q; Li, C.; Zhang, Q.; Wang, H-Q			PKC delta-mediated phosphorylation of BAG3 at Ser187 site induces epithelial - mesenchymal transition and enhances invasiveness in thyroid cancer FRO cells	ONCOGENE			English	Article						BAG3; PKC delta; EMT; invasion	PROTEIN-KINASE-C; ACTIVATION MECHANISMS; QUALITY CONTROL; PHORBOL ESTER; BETA-CATENIN; APOPTOSIS; EXPRESSION; MIGRATION; PATHWAY; STRESS	Protein kinase C delta (PKC delta) is a serine (Ser)/threonine kinase, which regulates numerous cellular processes, including proliferation, differentiation, migration and apoptosis. In the current study, Chinese hamster ovary cells were transfected with either a constitutively activated PKCd or a dominant negative PKC delta, phosphoprotein enrichment, two-dimensional difference gel electrophoresis and mass spectrometry was combined to globally identified candidates of PKC delta cascade. We found that Bcl-2 associated athanogene 3 (BAG3) was one of the targets of PKC delta cascade, and BAG3 interacted with PKC delta in vivo. In addition, we clarified that BAG3 was phosphorylate at Ser187 site in a PKC delta-dependent manner in vivo. BAG3 has been implicated in multiple cellular functions, including proliferation, differentiation, apoptosis, migration, invasion, macroautophagy and so on. We generated wild-type (WT)-, Ser187Ala (S187A)- or Ser187Asp (S187D)-BAG3 stably expressing FRO cells, and noticed that phosphorylation state of BAG3 influenced FRO morphology. Finally, for the first time, we showed that BAG3 was implicated in epithelial - mesenchymal transition (EMT) procedure, and phosphorylation state at Ser187 site had a critical role in EMT regulation by BAG3. Collectively, the current study indicates that BAG3 is a novel substrate of PKC delta, and PKC delta-mediated phosphorylation of BAG3 is implicated in EMT and invasiveness of thyroid cancer cells.	[Li, N.; Zong, Z-H; Liu, B-Q; Li, C.; Zhang, Q.; Wang, H-Q] China Med Univ, Dept Biochem & Mol Biol, Shenyang 110001, Liaoning, Peoples R China; [Li, N.; Wang, H-Q] China Med Univ, Minist Publ Hlth, Key Lab Cell Biol, Shenyang 110001, Liaoning, Peoples R China; [Li, N.; Wang, H-Q] China Med Univ, Minist Educ, Key Lab Med Cell Biol, Shenyang 110001, Liaoning, Peoples R China; [Du, Z-X] China Med Univ, Affiliated Hosp 1, Dept Endocrinol & Metab, Shenyang 110001, Liaoning, Peoples R China	China Medical University; China Medical University; China Medical University; China Medical University	Wang, HQ (corresponding author), China Med Univ, Dept Biochem & Mol Biol, 92 Beier, Shenyang 110001, Liaoning, Peoples R China.	wanghq_doctor@hotmail.com			National Natural Science Foundation of China [31070697, 31170727]; Program for LNET [LJQ2011083]; Foundation of Liaoning Educational Committee [L2010561]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Program for LNET; Foundation of Liaoning Educational Committee	This work was supported by National Natural Science Foundation of China (31070697 and 31170727), Program for LNET (LJQ2011083) and Foundation of Liaoning Educational Committee (L2010561) to H- Q Wang.	Arias AM, 2001, CELL, V105, P425, DOI 10.1016/S0092-8674(01)00365-8; Bozdogan O, 2005, TUMORI J, V91, P539, DOI 10.1177/030089160509100615; Brabletz T, 1998, PATHOL RES PRACT, V194, P701, DOI 10.1016/S0344-0338(98)80129-5; Carra S, 2008, J BIOL CHEM, V283, P1437, DOI 10.1074/jbc.M706304200; Carra S, 2009, AUTOPHAGY, V5, P428, DOI 10.4161/auto.5.3.7894; Carra S, 2009, J BIOL CHEM, V284, P5523, DOI 10.1074/jbc.M807440200; Chiappetta G, 2007, J CLIN ENDOCR METAB, V92, P1159, DOI 10.1210/jc.2006-1712; Doong H, 2002, CANCER LETT, V188, P25, DOI 10.1016/S0304-3835(02)00456-1; Doong H, 2000, ONCOGENE, V19, P4385, DOI 10.1038/sj.onc.1203797; Du ZX, 2008, BIOCHEM BIOPH RES CO, V369, P894, DOI 10.1016/j.bbrc.2008.02.112; Du ZX, 2011, J CLIN ENDOCR METAB, V96, pE763, DOI 10.1210/jc.2010-2642; Du ZX, 2009, J CELL PHYSIOL, V218, P631, DOI 10.1002/jcp.21634; Fan JH, 2006, J INVEST DERMATOL, V126, P1233, DOI 10.1038/sj.jid.5700149; Gamerdinger M, 2011, J MOL MED, V89, P1175, DOI 10.1007/s00109-011-0795-6; Gamerdinger M, 2009, EMBO J, V28, P889, DOI 10.1038/emboj.2009.29; Gavert N, 2007, J CELL BIOCHEM, V102, P820, DOI 10.1002/jcb.21505; Haynes J, MOL BIOL CELL, V22, P4750; Huber MA, 2005, CURR OPIN CELL BIOL, V17, P548, DOI 10.1016/j.ceb.2005.08.001; Hugo H, 2007, J CELL PHYSIOL, V213, P374, DOI 10.1002/jcp.21223; Humphries MJ, 2006, J BIOL CHEM, V281, P9728, DOI 10.1074/jbc.M507851200; Iwasaki M, 2007, CANCER RES, V67, P10252, DOI 10.1158/0008-5472.CAN-07-0618; Kassis JN, 2006, EXP CELL RES, V312, P2962, DOI 10.1016/j.yexcr.2006.05.023; Kikkawa U, 2002, J BIOCHEM, V132, P831, DOI 10.1093/oxfordjournals.jbchem.a003294; Lee JH, 1999, ONCOGENE, V18, P6183, DOI 10.1038/sj.onc.1203043; Li CH, 2003, FASEB J, V17, P2106, DOI 10.1096/fj.03-0150fje; Liao Q, 2001, FEBS LETT, V503, P151, DOI 10.1016/S0014-5793(01)02728-4; Liu P, 2009, FEBS LETT, V583, P401, DOI 10.1016/j.febslet.2008.12.032; MISCHAK H, 1993, J BIOL CHEM, V268, P20110; Mitsiades CS, 2006, BLOOD, V107, P1092, DOI 10.1182/blood-2005-03-1158; Newton AC, 1997, CURR OPIN CELL BIOL, V9, P161, DOI 10.1016/S0955-0674(97)80058-0; Pagliuca MG, 2003, FEBS LETT, V541, P11, DOI 10.1016/S0014-5793(03)00274-6; Romano MF, 2003, CANCER BIOL THER, V2, P508, DOI 10.4161/cbt.2.5.524; Romano MF, 2003, CELL DEATH DIFFER, V10, P383, DOI 10.1038/sj.cdd.4401167; Rosati A, 2007, INT J BIOCHEM CELL B, V39, P1337, DOI 10.1016/j.biocel.2007.03.007; Rosati A, 2007, J CELL PHYSIOL, V210, P676, DOI 10.1002/jcp.20865; Shi J, 2008, BLOOD, V111, P1309, DOI 10.1182/blood-2007-03-078535; Steinberg SF, 2004, BIOCHEM J, V384, P449, DOI 10.1042/BJ20040704; Suzuki M, 2011, CANCER LETT, V303, P65, DOI 10.1016/j.canlet.2011.01.019; Takayama S, 1999, J BIOL CHEM, V274, P781, DOI 10.1074/jbc.274.2.781; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; WATANABE T, 1992, P NATL ACAD SCI USA, V89, P10159, DOI 10.1073/pnas.89.21.10159; Yook JI, 2006, NAT CELL BIOL, V8, P1398, DOI 10.1038/ncb1508; Zeisberg M, 2009, J CLIN INVEST, V119, P1429, DOI 10.1172/JCI36183	43	31	33	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 19	2013	32	38					4539	4548		10.1038/onc.2012.466	http://dx.doi.org/10.1038/onc.2012.466			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	223SW	23108398				2022-12-17	WOS:000324831300009
J	Aoki, I; Higuchi, M; Gotoh, Y				Aoki, I.; Higuchi, M.; Gotoh, Y.			NEDDylation controls the target specificity of E2F1 and apoptosis induction	ONCOGENE			English	Article						apoptosis; cell cycle; E2F transcription factor; post-translational modification; NEDD8	DNA-DAMAGE; FAMILY-MEMBERS; CELL-CYCLE; TRANSCRIPTION; P73; NEDD8; DEGRADATION; ACTIVATION; PROTEINS; CHECKPOINT	The transcription factor E2F1 has pivotal roles in both cell proliferation and cell death, and is an important molecular target in cancer. Under proliferative conditions E2F1 induces the expression of genes that promote cell cycle progression, such as E2F2, whereas under proapoptotic conditions E2F1 induces expression of genes such as p73 that lead to apoptosis. The mechanism by which the apoptotic function of E2F1 is activated remains unclear, however. We now show that members of the E2F family are covalently conjugated with the ubiquitin-like modifier NEDD8. Overexpression of SENP8, a NEDD8-specific cysteine protease, resulted in deNEDDylation of E2F1 and promoted its transactivation activity at the p73 gene but not at the E2F2 gene. Knockdown of SENP8, on the other hand, attenuated p73 expression and apoptosis induced by E2F1 or by DNA damage. SENP8 also promoted the interaction between E2F1 and its cofactor Microcephalin 1, which is required for p73 induction. These results suggest that NEDDylation is a molecular trigger that modifies the target specificity of E2F1, and could have important implications for E2F1 regulation of apoptosis.	[Aoki, I.; Higuchi, M.; Gotoh, Y.] Univ Tokyo, Inst Mol & Cellular Biosci, Tokyo 1130032, Japan	University of Tokyo	Gotoh, Y (corresponding author), Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, 1-1-1 Yayoi, Tokyo 1130032, Japan.	ygotoh@iam.u-tokyo.ac.jp	Aoki, Ichiro/J-6578-2012	Aoki, Ichiro/0000-0001-5756-2723	Ministry of Education, Culture, Sports, Science and Technology (MEXT) of Japan; CREST from the Japan Science and Technology Agency; Global COE Program (Integrative Life Science Based on the Study of Biosignaling Mechanisms), MEXT, Japan; Grants-in-Aid for Scientific Research [22123003] Funding Source: KAKEN	Ministry of Education, Culture, Sports, Science and Technology (MEXT) of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); CREST from the Japan Science and Technology Agency(Core Research for Evolutional Science and Technology (CREST)); Global COE Program (Integrative Life Science Based on the Study of Biosignaling Mechanisms), MEXT, Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	We thank Dr Elizabeth Nigh and colleagues for critical reading of the manuscript. This work was supported by Grants-in-Aid for Scientific Research (A) from the Ministry of Education, Culture, Sports, Science and Technology (MEXT) of Japan, and by CREST from the Japan Science and Technology Agency. This work was also supported in part by the Global COE Program (Integrative Life Science Based on the Study of Biosignaling Mechanisms), MEXT, Japan.	Biswas SC, 2005, J NEUROSCI, V25, P8349, DOI 10.1523/JNEUROSCI.1570-05.2005; Chen DN, 2009, NATURE, V462, P925, DOI 10.1038/nature08544; Chong JL, 2009, NATURE, V462, P930, DOI 10.1038/nature08677; DeGregori J, 2006, CURR MOL MED, V6, P739; Denchi EL, 2005, EMBO REP, V6, P661, DOI 10.1038/sj.embor.7400452; Engels IH, 2009, ANAL BIOCHEM, V390, P85, DOI 10.1016/j.ab.2009.03.035; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; Gao F, 2006, NAT CELL BIOL, V8, P1171, DOI 10.1038/ncb1483; Hallstrom TC, 2006, GENE DEV, V20, P613, DOI 10.1101/gad.1345006; Hallstrom TC, 2003, P NATL ACAD SCI USA, V100, P10848, DOI 10.1073/pnas.1831408100; Hateboer G, 1996, GENE DEV, V10, P2960, DOI 10.1101/gad.10.23.2960; Hershko T, 2004, J BIOL CHEM, V279, P8627, DOI 10.1074/jbc.M312866200; Hofmann F, 1996, GENE DEV, V10, P2949, DOI 10.1101/gad.10.23.2949; Hughes TA, 2005, BIOCHEM BIOPH RES CO, V329, P1267, DOI 10.1016/j.bbrc.2005.02.102; Iaquinta PJ, 2007, CURR OPIN CELL BIOL, V19, P649, DOI 10.1016/j.ceb.2007.10.006; Inari A, 2004, J BIOL CHEM, V279, P30830, DOI 10.1074/jbc.M402403200; Irwin M, 2000, NATURE, V407, P645, DOI 10.1038/35036614; Lin WC, 2001, GENE DEV, V15, P1833; Lissy NA, 2000, NATURE, V407, P642, DOI 10.1038/35036608; Martinez LA, 2010, MOL CELL BIOL, V30, P524, DOI 10.1128/MCB.00938-09; Martinez-Balbas MA, 2000, EMBO J, V19, P662, DOI 10.1093/emboj/19.4.662; Marzio G, 2000, J BIOL CHEM, V275, P10887, DOI 10.1074/jbc.275.15.10887; Morita S, 2000, GENE THER, V7, P1063, DOI 10.1038/sj.gt.3301206; Moroni MC, 2001, NAT CELL BIOL, V3, P552, DOI 10.1038/35078527; Morris EJ, 2008, NATURE, V455, P552, DOI 10.1038/nature07310; Nahle Z, 2002, NAT CELL BIOL, V4, P859, DOI 10.1038/ncb868; Pediconi N, 2003, NAT CELL BIOL, V5, P552, DOI 10.1038/ncb998; Polager S, 2008, TRENDS CELL BIOL, V18, P528, DOI 10.1016/j.tcb.2008.08.003; Rabut G, 2008, EMBO REP, V9, P969, DOI 10.1038/embor.2008.183; Rizos H, 2005, CELL CYCLE, V4, P597, DOI 10.4161/cc.4.4.1588; Rogoff HA, 2004, MOL CELL BIOL, V24, P2968, DOI 10.1128/MCB.24.7.2968-2977.2004; Rowland BD, 2006, CELL, V127, P871, DOI 10.1016/j.cell.2006.11.019; Soucy TA, 2009, NATURE, V458, P732, DOI 10.1038/nature07884; Stevens C, 2003, NAT CELL BIOL, V5, P401, DOI 10.1038/ncb974; Stickle NH, 2004, MOL CELL BIOL, V24, P3251, DOI 10.1128/MCB.24.8.3251-3261.2004; Stiewe T, 2000, NAT GENET, V26, P464, DOI 10.1038/82617; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; Urist M, 2004, GENE DEV, V18, P3041, DOI 10.1101/gad.1221004; van den Heuvel S, 2008, NAT REV MOL CELL BIO, V9, P713, DOI 10.1038/nrm2469; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Wang B, 2004, J BIOL CHEM, V279, P54140, DOI 10.1074/jbc.M410493200; Watson IR, 2010, ONCOGENE, V29, P297, DOI 10.1038/onc.2009.314; Watson IR, 2006, J BIOL CHEM, V281, P34096, DOI 10.1074/jbc.M603654200; Wu LZ, 2001, NATURE, V414, P457, DOI 10.1038/35106593; Wu S, 2008, BIOCHEM BIOPH RES CO, V365, P75, DOI 10.1016/j.bbrc.2007.10.145; Xirodimas DP, 2008, EMBO REP, V9, P280, DOI 10.1038/embor.2008.10; Xirodimas DP, 2004, CELL, V118, P83, DOI 10.1016/j.cell.2004.06.016; Yamasaki L, 1996, CELL, V85, P537, DOI 10.1016/S0092-8674(00)81254-4; Yang SZ, 2008, EMBO REP, V9, P907, DOI 10.1038/embor.2008.128	49	31	34	1	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 22	2013	32	34					3954	3964		10.1038/onc.2012.428	http://dx.doi.org/10.1038/onc.2012.428			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	209IC	23001041				2022-12-17	WOS:000323748100004
J	Kim, SJ; Lee, Y; Kim, NY; Hwang, Y; Hwang, B; Min, JK; Koh, SS				Kim, S. J.; Lee, Y.; Kim, N. Y.; Hwang, Y.; Hwang, B.; Min, J-K; Koh, S. S.			Pancreatic adenocarcinoma upregulated factor, a novel endothelial activator, promotes angiogenesis and vascular permeability	ONCOGENE			English	Article						PAUF; angiogenesis; vascular permeability; CXCR4	GROWTH-FACTOR; HIGH EXPRESSION; POOR-PROGNOSIS; CANCER CELLS; VE-CADHERIN; IN-VITRO; METASTASIS; PAUF; CONSEQUENCES; JUNCTIONS	Pancreatic adenocarcinoma upregulated factor (PAUF) was recently reported to be a metastasis factor for pancreatic cancer cells. Here, we demonstrate a novel role for PAUF as a potent endothelial activator, promoting both angiogenesis and vascular permeability. Overexpression of PAUF in a mouse pancreatic cancer model resulted in increased tumor vascularity. Recombinant PAUF (rPAUF) enhanced proliferation, migration and capillary-like tube formation of human endothelial cells (ECs), consistently with increased neovascularization in vivo. rPAUF also increased endothelial permeability through the disruption of vascular endothelial-cadherin-facilitated cell-cell junctions in vitro and induced vascular leakage in mouse skin. These effects were attenuated upon treatment with an antibody against PAUF. Moreover, PAUF evoked a time-and dose-dependent activation of extracellular signal-regulated kinase (ERK) 1/2, AKT and endothelial NO synthase (eNOS) in ECs, which are closely linked to rPAUF-induced angiogenesis. Finally, rPAUF upregulated the expression of C-X-C chemokine receptor 4 (CXCR4) in ECs and potentiated the in vitro and in vivo EC angiogenic responses to stromal cell-derived factor-1 (SDF-1), a ligand for CXCR4. Taken together, these data demonstrate that PAUF has a novel function in promoting angiogenesis and vascular permeability. Our findings suggest new possibilities for PAUF's role in the pathogenesis of angiogenesis-dependent diseases.	[Kim, S. J.; Lee, Y.; Kim, N. Y.; Hwang, Y.; Hwang, B.; Min, J-K; Koh, S. S.] Korea Res Inst Biosci & Biotechnol, Immunotherapy Res Ctr, Taejon 305806, South Korea; [Kim, S. J.; Kim, N. Y.; Hwang, Y.; Koh, S. S.] Univ Sci & Technol, Dept Funct Genom, Taejon, South Korea; [Hwang, Y.; Hwang, B.] Univ Sci & Technol, Dept Biomol Sci, Taejon, South Korea	Korea Research Institute of Bioscience & Biotechnology (KRIBB)	Min, JK (corresponding author), Korea Res Inst Biosci & Biotechnol, Immunotherapy Res Ctr, 125 Gwahak Ro, Taejon 305806, South Korea.	jekmin@kribb.re.kr; sskoh@kribb.re.kr		Min, Jeong-Ki/0000-0003-4924-8739	National Research Foundation of Korea [2011-0015073, 2011-0016309]; Ministry of Education, Science and Technology; Inno-Project of the Korea Research Institute of Bioscience and Biotechnology; Korea Research Council of Fundamental Science and Technology (National Agenda Project)	National Research Foundation of Korea(National Research Foundation of Korea); Ministry of Education, Science and Technology(Ministry of Education, Science & Technology (MEST), Republic of Korea); Inno-Project of the Korea Research Institute of Bioscience and Biotechnology; Korea Research Council of Fundamental Science and Technology (National Agenda Project)	This work was supported by grants from the National Research Foundation of Korea (2011-0015073 and 2011-0016309), funded by the Ministry of Education, Science and Technology and a grant from the Inno-Project of the Korea Research Institute of Bioscience and Biotechnology and a grant from the Korea Research Council of Fundamental Science and Technology (National Agenda Project).	Akira S, 2004, NAT REV IMMUNOL, V4, P499, DOI 10.1038/nri1391; Alagappan VKT, 2005, CELL BIOCHEM BIOPHYS, V43, P119, DOI 10.1385/CBB:43:1:119; Bazzoni G, 2004, PHYSIOL REV, V84, P869, DOI 10.1152/physrev.00035.2003; Bergers G, 2003, NAT REV CANCER, V3, P401, DOI 10.1038/nrc1093; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; Cui K, 2011, J SURG RES, V171, P143, DOI 10.1016/j.jss.2010.03.001; Dejana E, 2008, J CELL SCI, V121, P2115, DOI 10.1242/jcs.017897; Dvorak HF, 2002, J CLIN ONCOL, V20, P4368, DOI 10.1200/JCO.2002.10.088; Esser S, 1998, J CELL SCI, V111, P1853; Ferrara N, 2005, NATURE, V438, P967, DOI 10.1038/nature04483; Fukumura D, 1997, AM J PATHOL, V150, P713; Grote K, 2010, BLOOD, V115, P2543, DOI 10.1182/blood-2009-05-224402; Hordijk PL, 1999, J CELL SCI, V112, P1915; Ikeda N, 1999, BRIT J CANCER, V79, P1553, DOI 10.1038/sj.bjc.6690248; Itakura J, 1997, CLIN CANCER RES, V3, P1309; Jia ZL, 2007, CANCER RES, V67, P4878, DOI 10.1158/0008-5472.CAN-06-3494; Kanagawa M, 2011, BIOCHEM BIOPH RES CO, V404, P201, DOI 10.1016/j.bbrc.2010.11.093; Kim SA, 2009, CANCER SCI, V100, P828, DOI 10.1111/j.1349-7006.2009.01106.x; Korc M, 1998, Surg Oncol Clin N Am, V7, P25; Korc M, 2003, MOL CANCER, V2, P1; Kryczek I, 2005, AM J REPROD IMMUNOL, V54, P270, DOI 10.1111/j.1600-0897.2005.00307.x; Lee Y, 2010, ONCOGENE, V29, P56, DOI 10.1038/onc.2009.298; Lee Y, 2011, EXP MOL MED, V43, P291, DOI 10.3858/emm.2011.43.5.030; Marin V, 2001, J IMMUNOL METHODS, V254, P183, DOI 10.1016/S0022-1759(01)00408-2; Mirshahi F, 2000, THROMB RES, V99, P587, DOI 10.1016/S0049-3848(00)00292-9; Nagy JA, 2007, ANNU REV PATHOL-MECH, V2, P251, DOI 10.1146/annurev.pathol.2.010506.134925; Niedergethmann M, 2002, PANCREAS, V25, P122, DOI 10.1097/00006676-200208000-00002; Park HD, 2011, ONCOGENE, V30, P201, DOI 10.1038/onc.2010.401; Petit I, 2007, TRENDS IMMUNOL, V28, P299, DOI 10.1016/j.it.2007.05.007; Pyun BJ, 2008, CANCER RES, V68, P227, DOI 10.1158/0008-5472.CAN-07-2799; Seo Y, 2000, CANCER, V88, P2239, DOI 10.1002/(SICI)1097-0142(20000515)88:10<2239::AID-CNCR6>3.0.CO;2-V; Steeg PS, 2006, NAT MED, V12, P895, DOI 10.1038/nm1469; Thurston G, 2000, NAT MED, V6, P460, DOI 10.1038/74725; Voronov E, 2003, P NATL ACAD SCI USA, V100, P2645, DOI 10.1073/pnas.0437939100; Wang Z, 2008, BRIT J CANCER, V99, P1695, DOI 10.1038/sj.bjc.6604745; Weis SM, 2005, NATURE, V437, P497, DOI 10.1038/nature03987; West XZ, 2010, NATURE, V467, P972, DOI 10.1038/nature09421; Whipple C, 2008, LANGENBECK ARCH SURG, V393, P901, DOI 10.1007/s00423-008-0280-z; Wong HH, 2009, NAT REV GASTRO HEPAT, V6, P412, DOI 10.1038/nrgastro.2009.89; Wright TJ, 2002, EXP CELL RES, V280, P159, DOI 10.1006/excr.2002.5636; Xie KP, 2006, CYTOKINE GROWTH F R, V17, P147, DOI 10.1016/j.cytogfr.2006.01.002; Zetter BR, 1998, ANNU REV MED, V49, P407, DOI 10.1146/annurev.med.49.1.407	42	31	33	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 1	2013	32	31					3638	3647		10.1038/onc.2012.366	http://dx.doi.org/10.1038/onc.2012.366			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	194MW	22907431				2022-12-17	WOS:000322638400008
J	Kasper, S; Breitenbuecher, F; Reis, H; Brandau, S; Worm, K; Kohler, J; Paul, A; Trarbach, T; Schmid, KW; Schuler, M				Kasper, S.; Breitenbuecher, F.; Reis, H.; Brandau, S.; Worm, K.; Koehler, J.; Paul, A.; Trarbach, T.; Schmid, K. W.; Schuler, M.			Oncogenic RAS simultaneously protects against anti-EGFR antibody-dependent cellular cytotoxicity and EGFR signaling blockade	ONCOGENE			English	Article						cetuximab; colorectal cancer; RAS; ADCC; anti-EGFR antibodies; BCL-XL	GROWTH-FACTOR RECEPTOR; BCL-2 FAMILY PROTEINS; PLUS CETUXIMAB; LUNG-CANCER; APOPTOSIS; EXPRESSION; RESISTANCE; MUTATIONS; INHIBITOR; DEFECTS	Monoclonal antibodies against the epidermal growth factor receptor (EGFR) are effective cancer therapeutics, but tumors harboring RAS mutations are resistant. To functionally dissect RAS-mediated resistance, we have studied clinically approved anti-EGFR antibodies, cetuximab and panitumumab, in cancer models. Both antibodies were equally cytotoxic in vitro. However, cetuximab, which also triggers antibody-dependent cellular cytotoxicity (ADCC), was more effective than panitumumab in vivo. Oncogenic RAS neutralized the activity of both antibodies in vivo. Mechanistically, RAS upregulated BCL-XL in cancer cell lines and in primary colorectal cancers. Suppression of BCL-XL by short hairpin RNA or treatment with a BH3 mimetic overcame RAS-mediated antibody resistance. In conclusion, RAS-mutant tumors escape anti-EGFR antibody-mediated receptor blockade as well as ADCC in vivo. Pharmacological targeting of RAS effectors can restore sensitivity to antibody therapy.	[Kasper, S.; Breitenbuecher, F.; Koehler, J.; Trarbach, T.; Schuler, M.] Univ Duisburg Essen, West German Canc Ctr, Dept Med Oncol, Univ Hosp Essen, D-45147 Essen, Germany; [Reis, H.; Worm, K.; Schmid, K. W.] Univ Duisburg Essen, West German Canc Ctr, Dept Pathol & Neuropathol, Univ Hosp Essen, D-45147 Essen, Germany; [Brandau, S.] Univ Duisburg Essen, West German Canc Ctr, Dept Otorhinolaryngol, Univ Hosp Essen, D-45147 Essen, Germany; [Paul, A.] Univ Duisburg Essen, West German Canc Ctr, Dept Gen Visceral & Transplant Surg, Univ Hosp Essen, D-45147 Essen, Germany	University of Duisburg Essen; University of Duisburg Essen; University of Duisburg Essen; University of Duisburg Essen	Schuler, M (corresponding author), Univ Duisburg Essen, West German Canc Ctr, Dept Med Oncol, Univ Hosp Essen, Hufelandstr 55, D-45147 Essen, Germany.	martin.schuler@uk-essen.de	Reis, Henning/AAX-9545-2020; Trarbach, Tanja/F-4944-2019; Kasper, Stefan/I-4521-2015; Köhler, Jens/AAK-1541-2021	Reis, Henning/0000-0003-1373-5295; Trarbach, Tanja/0000-0002-1275-4040; Kasper, Stefan/0000-0002-5947-8733; Brandau, Sven/0000-0002-2702-4163	Merck Serono; Amgen; Wilhelm Sander-Stiftung [2005.136.3]; Deutsche Forschungsgemeinschaft [SCHU 1541/5-1]; Mercator Research Center Ruhr-MERCUR [An-2011-0031]; CESAR Research Fellowship; Wiedenfeld-Stiftung; IFORES program of the Medical Faculty of the University Duisburg-Essen; Pathology and Molecular Pathology Laboratories, University Hospital Essen	Merck Serono(Merck & Company); Amgen(Amgen); Wilhelm Sander-Stiftung; Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Mercator Research Center Ruhr-MERCUR; CESAR Research Fellowship; Wiedenfeld-Stiftung; IFORES program of the Medical Faculty of the University Duisburg-Essen; Pathology and Molecular Pathology Laboratories, University Hospital Essen	Martin Schuler has served as consultant to Amgen; Tanja Trarbach has received research funding, consulting and speaker honoraria from Merck Serono and Amgen. The other authors declare no conflict of interest.; We thank Sandra Hoffarth, Sarah-Luise Stergar, Kirsten Bruderek, Jeannette Markowetz, Anna Even, Miriam Backs, Ali Sak, Sabine Harde and the staff of the Central Animal Facility, and the Pathology and Molecular Pathology Laboratories, University Hospital Essen, for their support. Robert Coffey, Roman Thomas, Hyatt Balke-Want, Scott W Lowe, Gary P Nolan and Abbott are acknowledged for providing reagents. This work was funded by grants from the Wilhelm Sander-Stiftung (2005.136.3, MS), the Deutsche Forschungsgemeinschaft (SCHU 1541/5-1, MS), Mercator Research Center Ruhr-MERCUR (An-2011-0031, SK) a CESAR Research Fellowship (SK), the Wiedenfeld-Stiftung (SK) and the IFORES program of the Medical Faculty of the University Duisburg-Essen (MS).	Amado RG, 2008, J CLIN ONCOL, V26, P1626, DOI 10.1200/JCO.2007.14.7116; Barriere J, 2009, J CLIN ONCOL, V27; Bibeau F, 2009, J CLIN ONCOL, V27, P1122, DOI 10.1200/JCO.2008.18.0463; Bokemeyer C, 2009, J CLIN ONCOL, V27, P663, DOI 10.1200/JCO.2008.20.8397; Bonner JA, 2006, NEW ENGL J MED, V354, P567, DOI 10.1056/NEJMoa053422; Cunningham D, 2004, NEW ENGL J MED, V351, P337, DOI 10.1056/NEJMoa033025; De Roock W, 2010, LANCET ONCOL, V11, P753, DOI 10.1016/S1470-2045(10)70130-3; Haehnel PS, 2008, CANCER RES, V68, P3899, DOI 10.1158/0008-5472.CAN-07-6286; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hara M, 2008, CANCER SCI, V99, P1471, DOI 10.1111/j.1349-7006.2008.00821.x; Huber C, 2005, CELL DEATH DIFFER, V12, P317, DOI 10.1038/sj.cdd.4401563; Jonker DJ, 2007, NEW ENGL J MED, V357, P2040, DOI 10.1056/NEJMoa071834; KAGI D, 1994, NATURE, V369, P31, DOI 10.1038/369031a0; Karapetis CS, 2008, NEW ENGL J MED, V359, P1757, DOI 10.1056/NEJMoa0804385; Kasper S, 2012, BLOOD CANCER J, V2, DOI 10.1038/bcj.2012.5; KNUDSON CM, 1995, SCIENCE, V270, P96, DOI 10.1126/science.270.5233.96; Kurai J, 2007, CLIN CANCER RES, V13, P1552, DOI 10.1158/1078-0432.CCR-06-1726; Marques CA, 2008, BLOOD, V111, P1413, DOI 10.1182/blood-2007-05-089458; MAYER A, 1993, CANCER, V71, P2454, DOI 10.1002/1097-0142(19930415)71:8<2454::AID-CNCR2820710805>3.0.CO;2-2; Oltersdorf T, 2005, NATURE, V435, P677, DOI 10.1038/nature03579; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Piloto O, 2006, CANCER RES, V66, P4843, DOI 10.1158/0008-5472.CAN-06-0018; Ravi R, 2006, CANCER RES, V66, P1730, DOI 10.1158/0008-5472.CAN-05-3377; REMMELE W, 1987, PATHOLOGE, V8, P138; Schneider-Merck T, 2010, J IMMUNOL, V184, P512, DOI 10.4049/jimmunol.0900847; Schuler M, 2003, CELL DEATH DIFFER, V10, P451, DOI 10.1038/sj.cdd.4401180; SHULTZ LD, 1995, J IMMUNOL, V154, P180; STRASSER A, 1990, CURR TOP MICROBIOL, V166, P175; Van Cutsem E, 2007, J CLIN ONCOL, V25, P1658, DOI 10.1200/JCO.2006.08.1620; Van Cutsem E, 2009, NEW ENGL J MED, V360, P1408, DOI 10.1056/NEJMoa0805019; van Delft MF, 2006, CANCER CELL, V10, P389, DOI 10.1016/j.ccr.2006.08.027; Vermorken JB, 2008, NEW ENGL J MED, V359, P1116, DOI 10.1056/NEJMoa0802656; Wesarg E, 2007, INT J CANCER, V121, P2387, DOI 10.1002/ijc.22977; Yoshida H, 1998, CELL, V94, P739, DOI 10.1016/S0092-8674(00)81733-X	34	31	31	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 6	2013	32	23					2873	2881		10.1038/onc.2012.302	http://dx.doi.org/10.1038/onc.2012.302			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	163WR	22797062				2022-12-17	WOS:000320369100007
J	Bai, F; Smith, MD; Chan, HL; Pei, XH				Bai, F.; Smith, M. D.; Chan, H. L.; Pei, X-H			Germline mutation of Brca1 alters the fate of mammary luminal cells and causes luminal-to-basal mammary tumor transformation	ONCOGENE			English	Article						Brca1; luminal progenitor; basal-like tumor	SUPPRESSOR GENE BRCA1; BREAST-CANCER; ESTROGEN-RECEPTOR; CDK INHIBITORS; EPITHELIAL PROGENITORS; MOLECULAR ANALYSIS; P18(INK4C); EXPRESSION; CYCLE; DIFFERENTIATION	Breast cancer developed in familial BRCA1 mutation carriers bears striking similarities to sporadic basal-like breast tumors. The mechanism underlying the function of BRCA1 in suppressing basal-like breast cancer remains unclear. We previously reported that the deletion of p18(Ink4c) (p18), an inhibitor of G1 cyclin Ds-dependent CDK4 and CDK6, stimulates mammary luminal progenitor cell proliferation and leads to spontaneous luminal tumor development. We report here that germline mutation of Brca1 in p18-deficient mice blocks the increase of luminal progenitor cells, impairs luminal gene expression and promotes malignant transformation of mammary tumors. Instead of the luminal mammary tumors developed in p18 single-mutant mice, mammary tumors developed in the p18; Brca1 mice, similar to breast cancer developed in familial BRCA1 carriers, exhibited extensive basal-like features and lost the remaining wild-type allele of Brca1. These results reveal distinct functions of the RB and BRCA1 pathways in suppressing luminal and basal-like mammary tumors, respectively. These results also suggest a novel mechanism-causing luminal-to-basal transformation-for the development of basal-like breast cancer in familial BRCA1 carriers and establish a unique mouse model for developing therapeutic strategies to target both luminal and basal-like breast cancers.	[Bai, F.; Chan, H. L.; Pei, X-H] Univ Miami, Miller Sch Med, Dept Surg, Mol Oncol Program, Miami, FL 33136 USA; [Smith, M. D.] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; [Pei, X-H] Univ Miami, Miller Sch Med, Sylvester Comprehens Canc Ctr, Miami, FL 33136 USA	University of Miami; University of North Carolina; University of North Carolina Chapel Hill; University of Miami	Pei, XH (corresponding author), Univ Miami, Miller Sch Med, Dept Surg, Mol Oncol Program, 1550 NW 10th Ave, Miami, FL 33136 USA.	xhpei@med.miami.edu	Pei, Xin-Hai/P-1812-2014	pei, xin-hai/0000-0001-6441-1691; Chan, Ho Lam/0000-0001-9799-0618	DOD Idea Award [W81XWH-101-0302]; University of Miami Miller School of Medicine	DOD Idea Award; University of Miami Miller School of Medicine	This project was initiated at the Department of Biochemistry and Biophysics, University of North Carolina at Chapel Hill. We thank Dr Yue Xiong for his invaluable support, discussion and critical reading of the manuscript, Dr Beverly Koller for providing Brca1 germline mutant mice and Drs Anthony Capobianco and Xiangxi Xu for discussions. This study was supported in part by a DOD Idea Award (W81XWH-101-0302) and startup funds from the University of Miami Miller School of Medicine to XHP.	Althuis MD, 2004, CANCER EPIDEM BIOMAR, V13, P1558; Arnes JB, 2005, CLIN CANCER RES, V11, P4003, DOI 10.1158/1078-0432.CCR-04-2064; Bai F, 2003, MOL CELL BIOL, V23, P1269, DOI 10.1128/MCB.23.4.1269-1277.2003; Bai F, 2007, MOL CELL BIOL, V27, P1495, DOI 10.1128/MCB.01764-06; Bai F, 2006, MOL CELL BIOL, V26, P4564, DOI 10.1128/MCB.00266-06; Bennett LM, 2000, CANCER RES, V60, P3461; Bernardo GM, 2010, DEVELOPMENT, V137, P2045, DOI 10.1242/dev.043299; Bignell GR, 2010, NATURE, V463, P893, DOI 10.1038/nature08768; Brzovic PS, 2003, P NATL ACAD SCI USA, V100, P5646, DOI 10.1073/pnas.0836054100; Buckley NE, 2012, STEM CELL REV REP, V8, P982, DOI 10.1007/s12015-012-9354-y; Cao L, 2003, GENE DEV, V17, P201, DOI 10.1101/gad.1050003; Cao L, 2006, EMBO J, V25, P2167, DOI 10.1038/sj.emboj.7601115; Deng CX, 2000, ONCOGENE, V19, P1059, DOI 10.1038/sj.onc.1203269; Drost RM, 2009, BRIT J CANCER, V101, P1651, DOI 10.1038/sj.bjc.6605350; Foulkes WD, 2004, CANCER RES, V64, P830, DOI 10.1158/0008-5472.CAN-03-2970; Foulkes WD, 2004, J MED GENET, V41, P1, DOI 10.1136/jmg.2003.013805; Franklin DS, 1998, GENE DEV, V12, P2899, DOI 10.1101/gad.12.18.2899; Furuta S, 2005, P NATL ACAD SCI USA, V102, P9176, DOI 10.1073/pnas.0503793102; Gorski JJ, 2010, BREAST CANCER RES TR, V122, P721, DOI 10.1007/s10549-009-0565-0; Gowen LC, 1996, NAT GENET, V12, P191, DOI 10.1038/ng0296-191; Hakem R, 1996, CELL, V85, P1009, DOI 10.1016/S0092-8674(00)81302-1; Harte MT, 2010, CANCER RES, V70, P2538, DOI 10.1158/0008-5472.CAN-09-2089; Hashizume R, 2001, J BIOL CHEM, V276, P14537, DOI 10.1074/jbc.C000881200; Herschkowitz JI, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-5-r76; Herschkowitz JI, 2012, P NATL ACAD SCI USA, V109, P2778, DOI 10.1073/pnas.1018862108; Honrado E, 2005, MODERN PATHOL, V18, P1305, DOI 10.1038/modpathol.3800453; Hosey AM, 2007, J NATL CANCER I, V99, P1683, DOI 10.1093/jnci/djm207; Kitagawa M, 1996, EMBO J, V15, P7060, DOI 10.1002/j.1460-2075.1996.tb01097.x; Kubista M, 2002, ONCOGENE, V21, P4747, DOI 10.1038/sj.onc.1205580; Lakhani SR, 2005, CLIN CANCER RES, V11, P5175, DOI 10.1158/1078-0432.CCR-04-2424; LANE TF, 1995, GENE DEV, V9, P2712, DOI 10.1101/gad.9.21.2712; Lapointe J, 1996, CANCER RES, V56, P4586; LARUE L, 1994, P NATL ACAD SCI USA, V91, P8263, DOI 10.1073/pnas.91.17.8263; Lee YH, 2011, GENE DEV, V25, P176, DOI 10.1101/gad.1975811; Leone PE, 2008, CLIN CANCER RES, V14, P6033, DOI 10.1158/1078-0432.CCR-08-0347; Lim E, 2009, NAT MED, V15, P907, DOI 10.1038/nm.2000; Liu S, 2008, P NATL ACAD SCI USA, V105, P1680, DOI 10.1073/pnas.0711613105; MARQUIS ST, 1995, NAT GENET, V11, P17, DOI 10.1038/ng0995-17; Molyneux G, 2010, CELL STEM CELL, V7, P403, DOI 10.1016/j.stem.2010.07.010; Mullan PB, 2006, ONCOGENE, V25, P5854, DOI 10.1038/sj.onc.1209872; Pei XH, 2005, ONCOGENE, V24, P2787, DOI 10.1038/sj.onc.1208611; Pei XH, 2007, CANCER RES, V67, P3162, DOI 10.1158/0008-5472.CAN-06-4517; Pei XH, 2009, CANCER CELL, V15, P389, DOI 10.1016/j.ccr.2009.03.004; Polyak K, 2009, NAT REV CANCER, V9, P265, DOI 10.1038/nrc2620; Proia TA, 2011, CELL STEM CELL, V8, P149, DOI 10.1016/j.stem.2010.12.007; Rajan JV, 1996, P NATL ACAD SCI USA, V93, P13078, DOI 10.1073/pnas.93.23.13078; Ramsey MR, 2007, CANCER RES, V67, P4732, DOI 10.1158/0008-5472.CAN-06-3437; Ribeiro-Silva A, 2005, HISTOPATHOLOGY, V47, P458, DOI 10.1111/j.1365-2559.2005.02249.x; Rosen EM, 2006, CANCER LETT, V236, P175, DOI 10.1016/j.canlet.2005.04.037; Shackleton M, 2006, NATURE, V439, P84, DOI 10.1038/nature04372; Shakya R, 2011, SCIENCE, V334, P525, DOI 10.1126/science.1209909; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Sleeman KE, 2007, J CELL BIOL, V176, P19, DOI 10.1083/jcb.200604065; Smart CE, 2011, ONCOGENE, V30, P1597, DOI 10.1038/onc.2010.538; Smart CE, 2008, BREAST CANCER RES TR, V112, P237, DOI 10.1007/s10549-007-9859-2; Somasundaram K, 1997, NATURE, V389, P187, DOI 10.1038/38291; Spirin KS, 1997, INT J ONCOL, V11, P737; Stingl J, 2006, NATURE, V439, P993, DOI 10.1038/nature04496; Stingl J, 2005, J MAMMARY GLAND BIOL, V10, P49, DOI 10.1007/s10911-005-2540-7; Suspitsin EN, 2011, BREAST CANCER-TOKYO, V18, P137, DOI 10.1007/s12282-009-0105-0; Tkocz D, 2012, ONCOGENE, V31, P3667, DOI 10.1038/onc.2011.531; Van Keymeulen A, 2011, NATURE, V479, P189, DOI 10.1038/nature10573; Wiedemeyer R, 2008, CANCER CELL, V13, P355, DOI 10.1016/j.ccr.2008.02.010; Williamson EA, 2006, ONCOGENE, V25, P1391, DOI 10.1038/sj.onc.1209170; Wright MH, 2008, MOL CANCER, V7, DOI 10.1186/1476-4598-7-29; Xu XL, 1999, NAT GENET, V22, P37, DOI 10.1038/8743; Xu XL, 2001, NAT GENET, V28, P266, DOI 10.1038/90108; Yamaji D, 2009, GENE DEV, V23, P2382, DOI 10.1101/gad.1840109; Zarkowska T, 1997, ONCOGENE, V14, P249, DOI 10.1038/sj.onc.1200824; Zindy F, 2003, CANCER RES, V63, P5420	70	31	31	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 30	2013	32	22					2715	2725		10.1038/onc.2012.293	http://dx.doi.org/10.1038/onc.2012.293			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	156FU	22777348				2022-12-17	WOS:000319808000003
J	Qian, X; Hulit, J; Suyama, K; Eugenin, EA; Belbin, TJ; Loudig, O; Smirnova, T; Zhou, ZN; Segall, J; Locker, J; Phillips, GR; Norton, L; Hazan, RB				Qian, X.; Hulit, J.; Suyama, K.; Eugenin, E. A.; Belbin, T. J.; Loudig, O.; Smirnova, T.; Zhou, Z. N.; Segall, J.; Locker, J.; Phillips, G. R.; Norton, L.; Hazan, R. B.			p21CIP1 mediates reciprocal switching between proliferation and invasion during metastasis	ONCOGENE			English	Article						cell cycle; p21CIP1; cyclin E; cytoskeleton; invasion; metastasis; breast cancer	BREAST-CANCER; CELL-MIGRATION; N-CADHERIN; GENOMIC INSTABILITY; RHO GTPASES; EXPRESSION; P21(WAF1/CIP1); P21(CIP1); RAS; INHIBITION	Cell proliferation and invasion are critical for malignant progression, yet how these processes relate to each other and whether they regulate one another during metastasis is unknown. We show that invasiveness of breast cancer cells is associated with growth arrest due to p21CIP1 upregulation. Knockdown of p21CIP1 increases cell proliferation and suppresses invasion. Since p21CIP1 acts to inhibit cyclin E during cell-cycle progression, we demonstrated that a constitutively active form of cyclin E had similar effects to p21CIP1 inhibition resulting in enhanced cell growth and suppressed invasiveness. We tested these findings in vivo in the Polyoma middle T mammary tumor model in which p21CIP1 was deleted. p21CIP1 knockout mice exhibited dramatic suppression of metastasis, independent of tumor growth, which was rescued by p21CIP1. Metastasis suppression by p21CIP1 ablation was associated with striking cytoskeletal reorganization leading to a non-invasive and highly proliferative state. Thus, p21CIP1 regulates metastasis by mediating reciprocal switching between invasion and proliferation.	[Qian, X.; Hulit, J.; Suyama, K.; Eugenin, E. A.; Belbin, T. J.; Loudig, O.; Locker, J.; Hazan, R. B.] Albert Einstein Coll Med, Dept Pathol, Bronx, NY 10463 USA; [Smirnova, T.; Zhou, Z. N.; Segall, J.] Albert Einstein Coll Med, Dept Anat & Struct Biol, Bronx, NY 10463 USA; [Phillips, G. R.] Mt Sinai Sch Med, Dept Neurosci, New York, NY USA; [Norton, L.] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10021 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Icahn School of Medicine at Mount Sinai; Memorial Sloan Kettering Cancer Center	Hazan, RB (corresponding author), Albert Einstein Coll Med, Dept Pathol, 1300 Morris Pk Ave,F529S, Bronx, NY 10463 USA.	rachel.hazan@einstein.yu.edu	qian, xia/L-1616-2013; Qian, Xia/D-8255-2014	Norton, Larry/0000-0003-3701-9250	National Cancer Institute grant [1R01 CA135061-01A1]; Breast Cancer Research Foundation; Susan G Komen foundation; NATIONAL CANCER INSTITUTE [R01CA135061] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH096625, K01MH076679] Funding Source: NIH RePORTER	National Cancer Institute grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Breast Cancer Research Foundation; Susan G Komen foundation(Susan G. Komen Breast Cancer Foundation); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))	We thank Dr Larry Herbst for his expert advice on animal studies. We thank the analytical imaging facility at AECOM for assistance with imaging. This work was supported by grants from National Cancer Institute grant (1R01 CA135061-01A1) and the Breast Cancer Research Foundation (RB Hazan). James Hulit was supported by the Susan G Komen foundation.	Bearss DJ, 2002, CANCER RES, V62, P2077; Bedrosian I, 2004, ONCOGENE, V23, P2648, DOI 10.1038/sj.onc.1207408; Besson A, 2004, GENE DEV, V18, P862, DOI 10.1101/gad.1185504; Besson A, 2004, NAT REV CANCER, V4, P948, DOI 10.1038/nrc1501; Charames GS, 2003, CURR MOL MED, V3, P589, DOI 10.2174/1566524033479456; Cheng T, 2000, SCIENCE, V287, P1804, DOI 10.1126/science.287.5459.1804; Cheng XY, 2010, BIOCHEM BIOPH RES CO, V403, P103, DOI 10.1016/j.bbrc.2010.10.126; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; Donegan WL, 1997, CA-CANCER J CLIN, V47, P28, DOI 10.3322/canjclin.47.1.28; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FLORESROZAS H, 1994, P NATL ACAD SCI USA, V91, P8655, DOI 10.1073/pnas.91.18.8655; GUY CT, 1992, MOL CELL BIOL, V12, P954, DOI 10.1128/MCB.12.3.954; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; HARPER JW, 1993, CELL, V75, P805; Hazan RB, 2000, J CELL BIOL, V148, P779, DOI 10.1083/jcb.148.4.779; Hulit J, 2007, CANCER RES, V67, P3106, DOI 10.1158/0008-5472.CAN-06-3401; Jaffe AB, 2005, ANNU REV CELL DEV BI, V21, P247, DOI 10.1146/annurev.cellbio.21.020604.150721; Jaffe AB, 2002, ADV CANCER RES, V84, P57, DOI 10.1016/S0065-230X(02)84003-9; Joyce JA, 2009, NAT REV CANCER, V9, P239, DOI 10.1038/nrc2618; Kim MY, 2009, CELL, V139, P1315, DOI 10.1016/j.cell.2009.11.025; Lee S, 2004, J BIOL CHEM, V279, P1885, DOI 10.1074/jbc.M306968200; Lin EY, 2003, AM J PATHOL, V163, P2113, DOI 10.1016/S0002-9440(10)63568-7; Liu MR, 2009, P NATL ACAD SCI USA, V106, P19035, DOI 10.1073/pnas.0910009106; Minn AJ, 2005, NATURE, V436, P518, DOI 10.1038/nature03799; Negrini S, 2010, NAT REV MOL CELL BIO, V11, P220, DOI 10.1038/nrm2858; Norton L, 2006, NAT MED, V12, P875, DOI 10.1038/nm0806-875; Suyama K, 2002, CANCER CELL, V2, P301, DOI 10.1016/S1535-6108(02)00150-2; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Vega S, 2004, GENE DEV, V18, P1131, DOI 10.1101/gad.294104; Wang WG, 2004, CANCER RES, V64, P8585, DOI 10.1158/0008-5472.CAN-04-1136; Winters ZE, 2003, BREAST CANCER RES, V5, pR242, DOI 10.1186/bcr654; Wyckoff J, 2004, CANCER RES, V64, P7022, DOI 10.1158/0008-5472.CAN-04-1449; Wyckoff JB, 2000, CANCER RES, V60, P5401; Yang WC, 2001, CANCER RES, V61, P6297; Yang WT, 2003, CANCER, V98, P1123, DOI 10.1002/cncr.11625	37	31	32	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2013	32	18					2292	2303		10.1038/onc.2012.249	http://dx.doi.org/10.1038/onc.2012.249			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	140VF	22751124	Green Accepted			2022-12-17	WOS:000318683600006
J	Su, B; Gao, L; Meng, F; Guo, LW; Rothschild, J; Gelman, IH				Su, B.; Gao, L.; Meng, F.; Guo, L-W; Rothschild, J.; Gelman, I. H.			Adhesion-mediated cytoskeletal remodeling is controlled by the direct scaffolding of Src from FAK complexes to lipid rafts by SSeCKS/AKAP12	ONCOGENE			English	Article						Src; SSeCKS/Gravin/AKAP12; FAK; caveolin-1; adhesion; actin-based cytoskeleton	RECEPTOR TYROSINE KINASES; GROWTH-FACTOR RECEPTOR; HUMAN COLON-CANCER; C-SRC; ONCOGENIC TRANSFORMATION; SIGNAL-TRANSDUCTION; PROSTATE-CANCER; CELL-MIGRATION; BREAST-CANCER; IN-VIVO	Metastatic cell migration and invasion are regulated by altered adhesion-mediated signaling to the actin-based cytoskeleton via activated Src-FAK complexes. Src-suppressed C-kinase substrate (SSeCKS, the rodent orthologue of human Gravin/AKAP12), whose expression is downregulated by oncogenic Src and in many human cancers, antagonizes oncogenic Src pathways including those driving neovascularization at metastatic sites, metastatic cell motility and invasiveness. This is likely manifested through its function as a scaffolder of F-actin and signaling proteins such as cyclins, calmodulin, protein kinase C and A. Here we show that in contrast to its ability to inhibit haptotaxis, SSeCKS increased prostate cancer cell adhesion to fibronectin and type I collagen in a FAK-dependent manner, correlating with a relative increase in FAK(poY397) levels. In contrast, SSeCKS suppressed adhesion-induced Src activation (Src(poY416)) and phosphorylation of FAK at Y925, a known Src substrate site. SSeCKS also induced increased cell spreading, cell flattening, integrin beta 1 clustering and formation of mature focal adhesion plaques. An in silico analysis identified a Src-binding domain on SSeCKS(aa 153-166) that is homologous to the Src-binding domain of caveolin-1, and this region is required for SSeCKS-Src interaction, for SSeCKS-enhanced Src activity and sequestration to lipid rafts and for SSeCKS-enhanced adhesion of MAT-LyLu and CWR22Rv1 prostate cancer cells. Our data suggest a model in which SSeCKS suppresses oncogenic motility by sequestering Src to caveolin-rich lipid rafts, thereby disengaging Src from FAK-associated adhesion and signaling complexes. Oncogene (2013) 32, 2016-2026; doi:10.1038/onc.2012.218; published online 18 June 2012	[Su, B.; Gao, L.; Rothschild, J.; Gelman, I. H.] Roswell Pk Canc Inst, Dept Canc Genet, Buffalo, NY 14263 USA; [Meng, F.] SUNY Buffalo, Dept Physiol & Biophys, Buffalo, NY 14260 USA; [Guo, L-W] Natl Ctr Toxicol Res, Jefferson, AR 72079 USA	Roswell Park Cancer Institute; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; US Food & Drug Administration (FDA)	Gelman, IH (corresponding author), Roswell Pk Canc Inst, Dept Canc Genet, Elm & Carlton St,CGP L2-309, Buffalo, NY 14263 USA.	irwin.gelman@roswellpark.org			NIH/NCI [CA94108, CA116430]; DoD [PC074228, PC101210]; NCI Comprehensive Cancer funds [P30-CA016056]; NATIONAL CANCER INSTITUTE [R55CA094108, R01CA116430, R01CA094108, P30CA016056] Funding Source: NIH RePORTER	NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); DoD(United States Department of Defense); NCI Comprehensive Cancer funds; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Toru Ouchi and Eugene Kandel for critical review of the manuscript, Kalle Saksela and Bruce Mayer for discussions on SH3 interactions and Bruce Mayer, Y Peter Wang and Tom Parsons for reagents. This work is supported by grants (IHG) CA94108, CA116430 (NIH/NCI), PC074228, PC101210 (DoD) and, in part, through NCI Comprehensive Cancer funds (P30-CA016056).	Akakura S, 2010, CELL CYCLE, V9, P4656, DOI 10.4161/cc.9.23.13974; Aoki M, 1998, P NATL ACAD SCI USA, V95, P14950, DOI 10.1073/pnas.95.25.14950; Bild AH, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2344; Biscardi JS, 1999, ADV CANCER RES, V76, P61; BOS JL, 1989, CANCER RES, V49, P4682; Brunton VG, 2008, CURR OPIN PHARMACOL, V8, P427, DOI 10.1016/j.coph.2008.06.012; Brunton VG, 2005, CANCER RES, V65, P1335, DOI 10.1158/0008-5472.CAN-04-1949; Bu Y, 2007, J BIOL CHEM, V282, P26725, DOI 10.1074/jbc.M702885200; CROSS FR, 1984, MOL CELL BIOL, V4, P1834, DOI 10.1128/MCB.4.9.1834; Damsky CH, 1991, CURR OPIN CELL BIOL, V3, P777, DOI 10.1016/0955-0674(91)90049-5; del Pozo MA, 2005, NAT CELL BIOL, V7, P901, DOI 10.1038/ncb1293; Eliceiri BP, 1999, MOL CELL, V4, P915, DOI 10.1016/S1097-2765(00)80221-X; Frame MC, 2004, J CELL SCI, V117, P989, DOI 10.1242/jcs.01111; Gelman IH, 2006, MOL CANCER RES, V4, P151, DOI 10.1158/1541-7786.MCR-05-0252; Gelman IH, 1998, CELL MOTIL CYTOSKEL, V41, P1; Gelman Irwin H, 2011, Front Biosci (Elite Ed), V3, P801; Gelman Irwin H, 2010, Genes Cancer, V1, P1147, DOI 10.1177/1947601910392984; GLENNEY JR, 1989, J BIOL CHEM, V264, P20163; Guo LW, 2011, J BIOL CHEM, V286, P38356, DOI 10.1074/jbc.M111.258830; Hiscox S, 2006, ENDOCR-RELAT CANCER, V13, pS53, DOI 10.1677/erc.1.01297; HUMPHRIES MJ, 1998, CURRENT PROTOCOLS CE; Iiizumi M, 2008, BBA-REV CANCER, V1786, P87, DOI 10.1016/j.bbcan.2008.07.002; ILLC D, 1995, NATURE, V377, P539; Irby RB, 1999, NAT GENET, V21, P187, DOI 10.1038/5971; Ischenko I, 2008, ONCOGENE, V27, P7212, DOI 10.1038/onc.2008.326; Kumar A, 2011, P NATL ACAD SCI USA, V108, P17087, DOI 10.1073/pnas.1108745108; Kumar CC, 1998, ONCOGENE, V17, P1365, DOI 10.1038/sj.onc.1202172; Li SW, 1996, J BIOL CHEM, V271, P29182, DOI 10.1074/jbc.271.46.29182; Li SW, 1996, J BIOL CHEM, V271, P3863; Lin XY, 1997, CANCER RES, V57, P2304; Lin XY, 1996, J BIOL CHEM, V271, P28430, DOI 10.1074/jbc.271.45.28430; MACCALMAN CD, 1994, CLIN EXP METASTAS, V12, P101, DOI 10.1007/BF01753976; Malek RL, 2002, ONCOGENE, V21, P7256, DOI 10.1038/sj.onc.1205900; Mao WG, 1997, ONCOGENE, V15, P3083, DOI 10.1038/sj.onc.1201496; Martin GS, 2001, NAT REV MOL CELL BIO, V2, P467, DOI 10.1038/35073094; Meng FJ, 2012, J CELL SCI, V125, P743, DOI 10.1242/jcs.093104; MILLIGAN G, 1995, TRENDS BIOCHEM SCI, V20, P181, DOI 10.1016/S0968-0004(00)89004-0; Mitra SK, 2006, ONCOGENE, V25, P5969, DOI 10.1038/sj.onc.1209588; Mitra SK, 2006, CURR OPIN CELL BIOL, V18, P516, DOI 10.1016/j.ceb.2006.08.011; Mizejewski GJ, 1999, P SOC EXP BIOL MED, V222, P124, DOI 10.1046/j.1525-1373.1999.d01-122.x; Moissoglu K, 2003, J BIOL CHEM, V278, P47946, DOI 10.1074/jbc.M302720200; Navarro A, 2004, FASEB J, V18, P1801, DOI 10.1096/fj.04-2516rev; Nethe M, 2011, CELL ADHES MIGR, V5, P59, DOI 10.4161/cam.5.1.13702; Oneyama C, 2008, MOL CELL, V30, P426, DOI 10.1016/j.molcel.2008.03.026; Ory DS, 1996, P NATL ACAD SCI USA, V93, P11400, DOI 10.1073/pnas.93.21.11400; Patra SK, 2008, BBA-REV CANCER, V1785, P182, DOI 10.1016/j.bbcan.2007.11.002; Playford MP, 2004, ONCOGENE, V23, P7928, DOI 10.1038/sj.onc.1208080; Pollard TD, 2003, CELL, V112, P453, DOI 10.1016/S0092-8674(03)00120-X; Razani B, 2002, PHARMACOL REV, V54, P431, DOI 10.1124/pr.54.3.431; RESH MD, 1994, CELL, V76, P411, DOI 10.1016/0092-8674(94)90104-X; Richardson A, 1997, MOL CELL BIOL, V17, P6906, DOI 10.1128/MCB.17.12.6906; Ross SH, 2011, J CELL SCI, V124, P1808, DOI 10.1242/jcs.079830; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; SCHALLER MD, 1993, MOL CELL BIOL, V13, P785, DOI 10.1128/MCB.13.2.785; Schlaepfer DD, 1999, PROG BIOPHYS MOL BIO, V71, P435, DOI 10.1016/S0079-6107(98)00052-2; Schlaepfer DD, 1996, MOL CELL BIOL, V16, P5623; Seong JY, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1414; Seong JH, 2009, CHEM BIOL, V16, P48, DOI 10.1016/j.chembiol.2008.11.007; Shaul PW, 1998, AM J PHYSIOL-LUNG C, V275, pL843, DOI 10.1152/ajplung.1998.275.5.L843; Sieg DJ, 1999, J CELL SCI, V112, P2677; Song KS, 1997, CELL MOL BIOL, V43, P293; Sturge J, 2011, NAT REV CLIN ONCOL, V8, P357, DOI 10.1038/nrclinonc.2011.67; Su B, 2006, CANCER RES, V66, P5599, DOI 10.1158/0008-5472.CAN-05-4123; Su B, 2010, J BIOL CHEM, V285, P4578, DOI 10.1074/jbc.M109.073494; Sverdlov M, 2007, J CELL MOL MED, V11, P1239, DOI 10.1111/j.1582-4934.2007.00127.x; Tao JC, 2007, J BIOL CHEM, V282, P6597, DOI 10.1074/jbc.M608927200; Trevino JG, 2006, AM J PATHOL, V168, P962, DOI 10.2353/ajpath.2006.050570; Wanaski SP, 2003, BIOCHEMISTRY-US, V42, P42, DOI 10.1021/bi012097n; Williams TM, 2005, AM J PHYSIOL-CELL PH, V288, pC494, DOI 10.1152/ajpcell.00458.2004; Xia W, 2001, CANCER RES, V61, P5644; Xia W, 2002, EXP CELL RES, V277, P139, DOI 10.1006/excr.2002.5560; Yan XH, 2009, EXP CELL RES, V315, P1247, DOI 10.1016/j.yexcr.2008.12.026; Yeo MG, 2006, MOL CELL BIOL, V26, P4399, DOI 10.1128/MCB.01147-05; Yilmaz M, 2009, CANCER METAST REV, V28, P15, DOI 10.1007/s10555-008-9169-0; Yoshida T, 2010, CANCER SCI, V101, P167, DOI 10.1111/j.1349-7006.2009.01368.x; Zhao J, 2009, CANCER METAST REV, V28, P35, DOI 10.1007/s10555-008-9165-4	76	31	31	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 18	2013	32	16					2016	2026		10.1038/onc.2012.218	http://dx.doi.org/10.1038/onc.2012.218			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	130LY	22710722	Green Accepted			2022-12-17	WOS:000317919900003
J	Ye, Y; Tian, H; Lange, AR; Yearsley, K; Robertson, FM; Barsky, SH				Ye, Y.; Tian, H.; Lange, A. R.; Yearsley, K.; Robertson, F. M.; Barsky, S. H.			The genesis and unique properties of the lymphovascular tumor embolus are because of calpain-regulated proteolysis of E-cadherin	ONCOGENE			English	Article						calpain-mediated proteolysis; E-cadherin fragments; spheroidgenesis; lymphovascular emboli	INFLAMMATORY BREAST-CANCER; P120 CATENIN; BETA-CATENIN; DOWN-REGULATION; CELL-ADHESION; CLEAVAGE; PROTEINS; GTPASE; GROWTH; DOMAIN	The genesis and unique properties of the lymphovascular tumor embolus are poorly understood largely because of the absence of an experimental model that specifically reflects this important step of tumor progression. The lymphovascular tumor embolus is a blastocyst-like structure resistant to chemotherapy, efficient at metastasis and overexpressing E-cadherin (E-cad). Conventional dogma has regarded E-cad as a metastasis-suppressor gene involved in epithelial-mesenchymal transition. However, within the lymphovascular embolus, E-cad and its proteolytic processing by calpain and other proteases have a dominant oncogenic rather than suppressive role in metastasis formation and tumor cell survival. Studies using a human xenograft model of inflammatory breast cancer, MARY-X, demonstrated the equivalence of xenograft-generated spheroids with lymphovascular emboli in vivo with both structures demonstrating E-cad overexpression and specific proteolytic processing. Western blot revealed full-length (FL) E-cad (120 kDa) and four fragments: E-cad/NTF1 (100 kDa), E-cad/NTF2 (95 kDa), E-cad/NTF3 (85 kDa) and E-cad/NTF4 (80 kDa). Compared with MARY-X, only E-cad/NTF1 was present in the spheroids. E-cad/NTF1 was produced by calpain, E-cad/NTF2 by gamma-secretase and E-cad/NTF3 by a matrix metalloproteinase (MMP). Spheroidgenesis and lymphovascular emboli formation are the direct result of calpain-mediated cleavage of E-cad and the generation of E-cad/NTF1 from membrane-associated E-cad rather than the de novo presence of either E-cad/NTF1 or E-cad/CTF1. E-cad/NTF1 retained the p120ctn-binding site but lost both the beta-catenin and alpha-binding sites, facilitating its disassembly from traditional cadherin-based adherens junctions and its 360 degrees distribution around the embolus. This calpain-mediated proteolysis of E-cad generates the formation of the lymphovascular embolus and is responsible for its unique properties of increased homotypic adhesion, apoptosis resistance and budding. Oncogene (2013) 32, 1702-1713; doi:10.1038/onc.2012.180; published online 14 May 2012	[Ye, Y.; Tian, H.; Lange, A. R.; Barsky, S. H.] Univ Nevada, Sch Med, Dept Pathol, Reno, NV 89557 USA; [Yearsley, K.] Ohio State Univ, Dept Pathol, Columbus, OH 43210 USA; [Robertson, F. M.] Univ Texas MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA; [Robertson, F. M.] Univ Texas MD Anderson Canc Ctr, Morgan Welch Inflammatory Breast Canc Res Program, Houston, TX 77030 USA; [Barsky, S. H.] Whittemore Peterson Inst, Reno, NV USA; [Barsky, S. H.] Nevada Canc Inst, Las Vegas, NV USA	Nevada System of Higher Education (NSHE); University of Nevada Reno; University System of Ohio; Ohio State University; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of California System; University of California San Diego	Barsky, SH (corresponding author), Univ Nevada, Sch Med, Dept Pathol, Whittemore Peterson Inst, 1 Manville Med Bldg,Reno 0350, Reno, NV 89557 USA.	sbarsky@medicine.nevada.edu			Department of Defense Breast Cancer Research Program [BC990959, BC024258, BC053405]; American Airlines-Susan G Komen for the Cure Promise [KG081287-02]; University of Nevada Vasco A Salvadorini Endowment	Department of Defense Breast Cancer Research Program(United States Department of Defense); American Airlines-Susan G Komen for the Cure Promise(Susan G. Komen Breast Cancer Foundation); University of Nevada Vasco A Salvadorini Endowment	We thank Dr John J Hasenau, Dr Walter F Mandeville, Patricia L Atkins and Jared H Smith of Laboratory Animal Medicine for their veterinarian and technical assistance with the maintenance of the MARY-X xenografts. This work was supported by the Department of Defense Breast Cancer Research Program Grants BC990959, BC024258 and BC053405, the American Airlines-Susan G Komen for the Cure Promise Grant KG081287-02 and the University of Nevada Vasco A Salvadorini Endowment.	Alattia JR, 1997, FEBS LETT, V417, P405, DOI 10.1016/S0014-5793(97)01333-1; Albini A, 2010, CURR OPIN CELL BIOL, V22, P677, DOI 10.1016/j.ceb.2010.08.017; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Beronja S, 2005, J CELL BIOL, V169, P635, DOI 10.1083/jcb.200410081; Berx G, 2001, BREAST CANCER RES, V3, P289, DOI 10.1186/bcr309; Bryant DM, 2004, TRENDS CELL BIOL, V14, P427, DOI 10.1016/j.tcb.2004.07.007; Chen XY, 2003, J CELL BIOL, V163, P547, DOI 10.1083/jcb.200305137; Chun J, 2009, CELL HOST MICROBE, V5, P47, DOI 10.1016/j.chom.2008.11.009; Davis MA, 2003, J CELL BIOL, V163, P525, DOI 10.1083/jcb.200307111; Edinger AL, 2003, DEV CELL, V5, P571, DOI 10.1016/S1534-5807(03)00291-0; FENG Y, 1995, J CELL BIOL, V131, P1435, DOI 10.1083/jcb.131.6.1435; Ferber EC, 2008, J BIOL CHEM, V283, P12691, DOI 10.1074/jbc.M708887200; Franco SJ, 2005, J CELL SCI, V118, P3829, DOI 10.1242/jcs.02562; Goll DE, 2003, PHYSIOL REV, V83, P731, DOI 10.1152/physrev.00029.2002; GOPALAKRISHNA R, 1985, ANAL BIOCHEM, V148, P413, DOI 10.1016/0003-2697(85)90247-7; GOPALAKRISHNA R, 1986, J BIOL CHEM, V261, P13936; Gumbiner BM, 2000, J CELL BIOL, V148, P399, DOI 10.1083/jcb.148.3.399; Hajra KM, 2002, CANCER RES, V62, P1613; Hammond DE, 2003, MOL BIOL CELL, V14, P1346, DOI 10.1091/mbc.E02-09-0578; Herren B, 1998, MOL BIOL CELL, V9, P1589, DOI 10.1091/mbc.9.6.1589; Ireton RC, 2002, J CELL BIOL, V159, P465, DOI 10.1083/jcb.200205115; Ito K, 1999, ONCOGENE, V18, P7080, DOI 10.1038/sj.onc.1203191; Kanazawa C, 2003, BIOCHEM BIOPH RES CO, V309, P848, DOI 10.1016/j.bbrc.2003.08.078; Koch AW, 1997, BIOCHEMISTRY-US, V36, P7697, DOI 10.1021/bi9705624; Langevin J, 2005, DEV CELL, V9, P365, DOI 10.1016/j.devcel.2005.07.013; Le Roy C, 2005, NAT REV MOL CELL BIO, V6, P112, DOI 10.1038/nrm1571; Lebart MC, 2006, FEBS J, V273, P3415, DOI 10.1111/j.1742-4658.2006.05350.x; Lombaerts M, 2006, BRIT J CANCER, V94, P661, DOI 10.1038/sj.bjc.6602996; Marambaud P, 2002, EMBO J, V21, P1948, DOI 10.1093/emboj/21.8.1948; Messaritou G, 2009, J CELL SCI, V122, P4042, DOI 10.1242/jcs.044305; NGUYEN M, 1993, NATURE, V365, P267, DOI 10.1038/365267a0; Palacios F, 2005, MOL CELL BIOL, V25, P389, DOI 10.1128/MCB.25.1.389-402.2005; Quigley JP, 1998, CELL, V94, P281, DOI 10.1016/S0092-8674(00)81470-1; Rios-Doria J, 2003, J BIOL CHEM, V278, P1372, DOI 10.1074/jbc.M208772200; Robertson FM, 2010, J BIOMOL SCREEN, V15, P820, DOI 10.1177/1087057110376541; SHIH C, 1982, CELL, V29, P161, DOI 10.1016/0092-8674(82)90100-3; Silvera D, 2009, CELL CYCLE, V8, P3091, DOI 10.4161/cc.8.19.9637; Silvera D, 2009, NAT CELL BIOL, V11, P903, DOI 10.1038/ncb1900; Steinhusen U, 2001, J BIOL CHEM, V276, P4972, DOI 10.1074/jbc.M006102200; Tomlinson JS, 2001, CANCER RES, V61, P5231; Toyoshima M, 2007, CANCER RES, V67, P5162, DOI 10.1158/0008-5472.CAN-06-2756; Vallorosi CJ, 2000, J BIOL CHEM, V275, P3328, DOI 10.1074/jbc.275.5.3328; van IJzendoorn SCD, 2006, J CELL SCI, V119, P1679, DOI 10.1242/jcs.02948; Vitelli R, 1997, J BIOL CHEM, V272, P4391, DOI 10.1074/jbc.272.7.4391; Wakabayashi T, 2008, PHYSIOLOGY, V23, P194, DOI 10.1152/physiol.00009.2008; Wells A, 2005, INT REV CYTOL, V245, P1, DOI 10.1016/S0074-7696(05)45001-9; Xiao KY, 2003, J CELL BIOL, V163, P535, DOI 10.1083/jcb.200306001; Xiao Y, 2011, ONCOGENE, V30, P287, DOI 10.1038/onc.2010.405; Xiao Y, 2008, AM J PATHOL, V173, P561, DOI 10.2353/ajpath.2008.071214; Ye Y, 2010, ANTICANCER RES, V30, P3903; Zhang XM, 2004, J BIOL CHEM, V279, P43027, DOI 10.1074/jbc.M402264200	51	31	35	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 28	2013	32	13					1702	1713		10.1038/onc.2012.180	http://dx.doi.org/10.1038/onc.2012.180			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	116AY	22580607				2022-12-17	WOS:000316855800010
J	Ross, RL; Askham, JM; Knowles, MA				Ross, R. L.; Askham, J. M.; Knowles, M. A.			PIK3CA mutation spectrum in urothelial carcinoma reflects cell context-dependent signaling and phenotypic outputs	ONCOGENE			English	Article						PIK3CA; PI3K signaling; bladder cancer; urothelium	BLADDER-CANCER; HIGH-FREQUENCY; N-CADHERIN; GENE; KINASE; P110-ALPHA; EXPRESSION; GROWTH; DOMAIN; FGFR3	Although activating mutations of PIK3CA are frequent in urothelial carcinoma (UC), no information is available on their specific effects in urothelial cells or the basis for the observed mutation spectrum, which has a large excess of helical domain mutations. We investigated the phenotypic and signaling consequences of hotspot and UC-specific rare PIK3CA mutations in immortalized normal human urothelial cells (NHUC) and mouse fibroblasts (NIH3T3). Our results indicate that in NHUC, rare mutant forms and all three hotspot mutant forms of PIK3CA can activate the PI3K/AKT pathway. The relative frequency at which helical domain and kinase domain mutations are found in UC is related to their potency in inducing signaling downstream of AKT and to the phenotypic effects induced in this cell type (E545K>E542K>H1047R). Helical domain mutations E542K and E545K conferred a significant proliferative advantage at confluence and under conditions of nutrient depletion, and increased cellular resistance to anoikis. Both helical and kinase domain mutants induced increased NHUC cell motility and migration towards a chemoattractant, though no significant differences were found between the mutant forms. In NIH3T3 cells, the kinase domain mutant H1047R induced high levels of AKT activation, but helical domain mutants were significantly less potent and this was reflected in their relative abilities to confer anchorage-independent growth. Our findings indicate that the effects of mutant PIK3CA are both cell type- and mutation-specific. Helical domain mutations in PIK3CA may confer a selective advantage in the urotheliunn in vivo by overcoming normal contact-mediated inhibitory signals and allowing proliferation in nutrient-limiting conditions. Mutant forms of PIK3CA may also stimulate intraepithelial cell movement, which could contribute to spread of cells within the urothelium. Oncogene (2013) 32, 768-776; doi:10.1038/onc.2012.87; published online 19 March 2012	[Ross, R. L.; Askham, J. M.; Knowles, M. A.] St James Univ Hosp, Canc Res UK Clin Ctr, Leeds Inst Mol Med, Sect Expt Oncol, Leeds LS9 7TF, W Yorkshire, England; [Askham, J. M.] Univ Leeds, Mol Epidemiol Unit, Leeds Inst Genet Hlth & Therapeut, LIGHT Labs, Leeds, W Yorkshire, England	Cancer Research UK; Saint James's University Hospital; University of Leeds; University of Leeds	Knowles, MA (corresponding author), St James Univ Hosp, Canc Res UK Clin Ctr, Leeds Inst Mol Med, Sect Expt Oncol, Beckett St, Leeds LS9 7TF, W Yorkshire, England.	m.a.knowles@leeds.ac.uk		Knowles, Margaret/0000-0002-9363-8657	Medical Research Council; University of Leeds	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); University of Leeds	This work was funded by a PhD studentship from the Medical Research Council, awarded via the University of Leeds.	Askham JM, 2010, ONCOGENE, V29, P150, DOI 10.1038/onc.2009.315; Bachman KE, 2004, CANCER BIOL THER, V3, P772, DOI 10.4161/cbt.3.8.994; Broderick DK, 2004, CANCER RES, V64, P5048, DOI 10.1158/0008-5472.CAN-04-1170; Cain RJ, 2009, BIOL CELL, V101, P13, DOI 10.1042/BC20080079; Campbell IG, 2004, CANCER RES, V64, P7678, DOI 10.1158/0008-5472.CAN-04-2933; Carson JD, 2008, BIOCHEM J, V409, P519, DOI 10.1042/BJ20070681; Chapman EJ, 2006, ONCOGENE, V25, P5037, DOI 10.1038/sj.onc.1209513; Chaussade C, 2009, BIOCHEM BIOPH RES CO, V381, P577, DOI 10.1016/j.bbrc.2009.02.081; di Martino E, 2009, ONCOGENE, V28, P4306, DOI 10.1038/onc.2009.280; Fu Z, 2003, P NATL ACAD SCI USA, V100, P3275, DOI 10.1073/pnas.0535975100; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Guo XN, 2007, CANCER RES, V67, P5851, DOI 10.1158/0008-5472.CAN-07-0049; Gustin JP, 2009, P NATL ACAD SCI USA, V106, P2835, DOI 10.1073/pnas.0813351106; Gymnopoulos M, 2007, P NATL ACAD SCI USA, V104, P5569, DOI 10.1073/pnas.0701005104; Huang CH, 2007, SCIENCE, V318, P1744, DOI 10.1126/science.1150799; Ikenoue T, 2005, CANCER RES, V65, P4562, DOI 10.1158/0008-5472.CAN-04-4114; Isakoff SJ, 2005, CANCER RES, V65, P10992, DOI 10.1158/0008-5472.CAN-05-2612; Jaiswal BS, 2009, CANCER CELL, V16, P463, DOI 10.1016/j.ccr.2009.10.016; Knowles MA, 2006, CARCINOGENESIS, V27, P361, DOI 10.1093/carcin/bgi310; Kompier LC, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013821; Lopez-Knowles E, 2006, CANCER RES, V66, P7401, DOI 10.1158/0008-5472.CAN-06-1182; Mandelker D, 2009, P NATL ACAD SCI USA, V106, P16996, DOI 10.1073/pnas.0908444106; Murugan AK, 2008, INT J ONCOL, V32, P101; Pang H, 2009, CANCER RES, V69, P8868, DOI 10.1158/0008-5472.CAN-09-1968; Platt FM, 2009, CLIN CANCER RES, V15, P6008, DOI 10.1158/1078-0432.CCR-09-0898; Rieger-Christ KM, 2007, J CELL BIOCHEM, V102, P377, DOI 10.1002/jcb.21299; Rieger-Christ KM, 2004, ONCOGENE, V23, P4745, DOI 10.1038/sj.onc.1207629; Samuels Y, 2005, CANCER CELL, V7, P561, DOI 10.1016/j.ccr.2005.05.014; Samuels Y, 2004, SCIENCE, V304, P554, DOI 10.1126/science.1096502; Samuels Y, 2006, CURR OPIN ONCOL, V18, P77, DOI 10.1097/01.cco.0000198021.99347.b9; Shekar SC, 2005, J BIOL CHEM, V280, P27850, DOI 10.1074/jbc.M506005200; Shin JJ, 2004, ARCH OTOLARYNGOL, V130, P68, DOI 10.1001/archotol.130.1.68; Sjodahl G, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018583; SOULE HD, 1990, CANCER RES, V50, P6075; Sun M, 2001, AM J PATHOL, V159, P431, DOI 10.1016/S0002-9440(10)61714-2; Theodorescu D, 1998, CELL GROWTH DIFFER, V9, P919; Tomlinson D, 2007, ONCOGENE, V26, P5889, DOI 10.1038/sj.onc.1210399; Tomlinson DC, 2007, J PATHOL, V213, P91, DOI 10.1002/path.2207; Wu X, 2004, BJU INT, V93, P143, DOI 10.1111/j.1464-410X.2004.04574.x; Yu JH, 1998, MOL CELL BIOL, V18, P1379, DOI 10.1128/MCB.18.3.1379; Zhang HJ, 2008, BREAST CANCER RES TR, V112, P217, DOI 10.1007/s10549-007-9847-6; Zhao JJ, 2005, P NATL ACAD SCI USA, V102, P18443, DOI 10.1073/pnas.0508988102; Zhao L, 2008, P NATL ACAD SCI USA, V105, P2652, DOI 10.1073/pnas.0712169105	43	31	34	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 7	2013	32	6					768	776		10.1038/onc.2012.87	http://dx.doi.org/10.1038/onc.2012.87			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	101AF	22430209				2022-12-17	WOS:000315746700010
J	Wu, J; Lee, SW; Zhang, X; Han, F; Kwan, SY; Yuan, X; Yang, WL; Jeong, YS; Rezaeian, AH; Gao, Y; Zeng, YX; Lin, HK				Wu, J.; Lee, S-W; Zhang, X.; Han, F.; Kwan, S-Y; Yuan, X.; Yang, W-L; Jeong, Y. S.; Rezaeian, A. H.; Gao, Y.; Zeng, Y-X; Lin, H-K			Foxo3a transcription factor is a negative regulator of Skp2 and Skp2 SCF complex	ONCOGENE			English	Article						Foxo3a; Skp2 SCF complex; ubiquitination	CDK INHIBITOR P27; CELL-CYCLE; UBIQUITIN LIGASE; PROMOTES TUMORIGENESIS; DEPENDENT REGULATION; CANCER PROGRESSION; DEGRADATION; P27(KIP1); SENESCENCE; EXPRESSION	Skp2 (S-phase kinase-associated protein-2) SCF complex displays E3 ligase activity and oncogenic activity by regulating protein ubiquitination and degradation, in turn regulating cell cycle entry, senescence and tumorigenesis. The maintenance of the integrity of Skp2 SCF complex is critical for its E3 ligase activity. The Skp2 F-box protein is a rate-limiting step and key factor in this complex, which binds to its protein substrates and triggers ubiquitination and degradation of its substrates. Skp2 is found to be overexpressed in numerous human cancers, which has an important role in tumorigenesis. The molecular mechanism by which the function of Skp2 and Skp2 SCF complex is regulated remains largely unknown. Here we show that Foxo3a transcription factor is a novel and negative regulator of Skp2 SCF complex. Foxo3a is found to be a transcriptional repressor of Skp2 gene expression by directly binding to the Skp2 promoter, thereby inhibiting Skp2 protein expression. Surprisingly, we found for the first time that Foxo3a also displays a transcription-independent activity by directly interacting with Skp2 and disrupting Skp2 SCF complex formation, in turn inhibiting Skp2 SCF E3 ligase activity and promoting p27 stability. Finally, we show that the oncogenic activity of Skp2 is repressed by Foxo3a overexpression. Our results not only reveal novel insights into how Skp2 SCF complex is regulated, but also establish a new role for Foxo3a in tumor suppression through a transcription-dependent and independent manner. Oncogene (2013) 32, 78-85; doi:10.1038/onc.2012.26; published online 6 February 2012	[Wu, J.; Lee, S-W; Zhang, X.; Han, F.; Kwan, S-Y; Yuan, X.; Yang, W-L; Jeong, Y. S.; Rezaeian, A. H.; Gao, Y.; Lin, H-K] Univ Texas MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA; [Wu, J.; Zeng, Y-X] Sun Yat Sen Univ Canc Ctr, Dept Expt Res, Guangzhou, Guangdong, Peoples R China; [Wu, J.; Zeng, Y-X] Sun Yat Sen Univ Canc Ctr, State Key Lab Oncol S China, Guangzhou, Guangdong, Peoples R China; [Lee, S-W; Zhang, X.; Han, F.; Kwan, S-Y; Yang, W-L; Jeong, Y. S.; Gao, Y.; Lin, H-K] Univ Texas Grad Sch Biomed Sci Houston, Houston, TX USA; [Wu, J.] Guangzhou Med Univ, Canc Hosp, Canc Ctr, Guangzhou, Guangdong, Peoples R China	University of Texas System; UTMD Anderson Cancer Center; Sun Yat Sen University; Sun Yat Sen University; Guangzhou Medical University	Lin, HK (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA.	hklin@mdanderson.org	Yang, Wei-Lei/E-2598-2012; Rezaeian, Abdol-Hossein/AAV-6900-2021; kwan, suet yan/AAH-3974-2020	Zhang, Xian/0000-0001-9674-7886	MD Anderson Trust Scholar Fund; National Cancer Institute's Prostate Cancer Specialized Program of Research Excellence (SPORE) development grant at the MD Anderson Cancer Center; NIH; CPRIT; DOD; NATIONAL CANCER INSTITUTE [R01CA149321, P50CA140388, R01CA136787] Funding Source: NIH RePORTER	MD Anderson Trust Scholar Fund; National Cancer Institute's Prostate Cancer Specialized Program of Research Excellence (SPORE) development grant at the MD Anderson Cancer Center; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); CPRIT; DOD(United States Department of Defense); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Drs ME Greenberg, WR Sellers, VA Boussiotis and D Bohmann for providing the reagents. We are grateful to Dr Lin's lab members for their insightful comments and suggestions. We extend our special thanks to S Zhang and Dr Z Han for their technical support. This work was supported by the MD Anderson Trust Scholar Fund, the National Cancer Institute's Prostate Cancer Specialized Program of Research Excellence (SPORE) development grant at the MD Anderson Cancer Center, NIH RO1 grants, CPRIT grant, and DOD New Investigator Award to HKL.	Appleman LJ, 2006, CELL CYCLE, V5, P2123, DOI 10.4161/cc.5.18.3139; Barre B, 2007, EMBO J, V26, P4841, DOI 10.1038/sj.emboj.7601899; Bashir T, 2004, NATURE, V428, P190, DOI 10.1038/nature02330; Bloom J, 2003, SEMIN CANCER BIOL, V13, P41, DOI 10.1016/S1044-579X(02)00098-6; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Chan CH, 2011, J MOL MED, V89, P857, DOI 10.1007/s00109-011-0766-y; Chan CH, 2010, THESCIENTIFICWORLDJO, V10, P1001, DOI 10.1100/tsw.2010.89; Chan CH, 2010, NAT CELL BIOL, V12, P457, DOI 10.1038/ncb2047; Chu IM, 2008, NAT REV CANCER, V8, P253, DOI 10.1038/nrc2347; Dansen TB, 2008, TRENDS CELL BIOL, V18, P421, DOI 10.1016/j.tcb.2008.07.004; Gao DM, 2009, NAT CELL BIOL, V11, P397, DOI 10.1038/ncb1847; Hershko DD, 2008, CANCER-AM CANCER SOC, V112, P1415, DOI 10.1002/cncr.23317; Hu MCT, 2004, CELL, V117, P225, DOI 10.1016/S0092-8674(04)00302-2; Huang H, 2005, P NATL ACAD SCI USA, V102, P1649, DOI 10.1073/pnas.0406789102; Imaki H, 2003, CANCER RES, V63, P4607; Jonason JH, 2007, CELL CYCLE, V6, P951, DOI 10.4161/cc.6.8.4104; Lin HK, 2004, NATURE, V431, P205, DOI 10.1038/nature02783; Lin HK, 2010, NATURE, V464, P374, DOI 10.1038/nature08815; Lin HK, 2009, NAT CELL BIOL, V11, P420, DOI 10.1038/ncb1849; Liu JD, 2002, MOL CELL, V10, P1511, DOI 10.1016/S1097-2765(02)00783-9; Majumder PK, 2008, CANCER CELL, V14, P146, DOI 10.1016/j.ccr.2008.06.002; Mamillapalli R, 2001, CURR BIOL, V11, P263, DOI 10.1016/S0960-9822(01)00065-3; Medema RH, 2000, NATURE, V404, P782, DOI 10.1038/35008115; Nakayama K, 2000, EMBO J, V19, P2069, DOI 10.1093/emboj/19.9.2069; Nakayama K, 2004, DEV CELL, V6, P661, DOI 10.1016/S1534-5807(04)00131-5; Nakayama KI, 2005, SEMIN CELL DEV BIOL, V16, P323, DOI 10.1016/j.semcdb.2005.02.010; Paik JH, 2007, CELL, V128, P309, DOI 10.1016/j.cell.2006.12.029; Reichert M, 2007, CANCER RES, V67, P4149, DOI 10.1158/0008-5472.CAN-06-4484; Sarmento LM, 2005, J EXP MED, V202, P157, DOI 10.1084/jem.20050559; Schneider G, 2006, EMBO J, V25, P3801, DOI 10.1038/sj.emboj.7601259; Sicinski P, 2007, GENE DEV, V21, P1703, DOI 10.1101/gad.1583207; Tran H, 2002, SCIENCE, V296, P530, DOI 10.1126/science.1068712; van Duijn PW, 2006, PROSTATE, V66, P749, DOI 10.1002/pros.20398; Wang F, 2012, ONCOGENE, V31, P1546, DOI 10.1038/onc.2011.347; Wang HB, 2010, NAT GENET, V42, P83, DOI 10.1038/ng.498; Wang IC, 2005, MOL CELL BIOL, V25, P10875, DOI 10.1128/MCB.25.24.10875-10894.2005; Wei W, 2004, NATURE, V428, P194, DOI 10.1038/nature02381; Yang JY, 2008, NAT CELL BIOL, V10, P138, DOI 10.1038/ncb1676; Yang JY, 2009, CLIN CANCER RES, V15, P752, DOI 10.1158/1078-0432.CCR-08-0124; Yang WL, 2009, SCIENCE, V325, P1134, DOI 10.1126/science.1175065; Young AP, 2008, NAT CELL BIOL, V10, P361, DOI 10.1038/ncb1699; Zhang L, 2006, ONCOGENE, V25, P2615, DOI 10.1038/sj.onc.1209286; Zheng JY, 2002, MOL CELL, V10, P1519, DOI 10.1016/S1097-2765(02)00784-0; Zuo T, 2007, J CLIN INVEST, V117, P3765, DOI 10.1172/JCI32538	44	31	33	1	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN	2013	32	1					78	85		10.1038/onc.2012.26	http://dx.doi.org/10.1038/onc.2012.26			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	063VG	22310285	Green Accepted			2022-12-17	WOS:000313029500008
J	Kang, JM; Park, S; Kim, SJ; Hong, HY; Jeong, J; Kim, HS; Kim, SJ				Kang, J. M.; Park, S.; Kim, S. J.; Hong, H. Y.; Jeong, J.; Kim, H-S; Kim, S-J			CBL enhances breast tumor formation by inhibiting tumor suppressive activity of TGF-beta signaling	ONCOGENE			English	Article						TGF-beta; smad; CBL; breast cancer; tumorigenesis	GROWTH-FACTOR-BETA; ACQUIRED UNIPARENTAL DISOMY; II RECEPTOR; C-CBL; CANCER CELLS; TYROSINE KINASES; NUCLEAR IMPORT; SMAD3; MUTATIONS; TRANSCRIPTION	Casitas B-lineage lymphoma (CBL) protein family functions as multifunctional adaptor proteins and E3 ubiquitin ligases that are implicated as regulators of signaling in various cell types. Recent discovery revealed mutations of proto-oncogenic CBL in the linker region and RING finger domain in human acute myeloid neoplasm, and these transforming mutations induced carcinogenesis. However, the adaptor function of CBL mediated signaling pathway during tumorigenesis has not been well characterized. Here, we show that CBL is highly expressed in breast cancer cells and significantly inhibits transforming growth factor-beta (TGF-beta) tumor suppressive activity. Knockdown of CBL expression resulted in the increased expression of TGF-beta target genes, PAI-I and CDK inhibitors such as p15(INK4b) and p21(Cip1). Furthermore, we demonstrate that CBL is frequently overexpressed in human breast cancer tissues, and the loss of CBL decreases the tumorigenic activity of breast cancer cells in vivo. CBL directly binds to Smad3 through its proline-rich motif, thereby preventing Smad3 from interacting with Smad4 and blocking nuclear translocation of Smad3. CBL-b, one of CBL protein family, also interacted with Smad3 and knockdown of both CBL and CBL-b further enhanced TGF-beta transcriptional activity. Our findings provide evidence for a previously undescribed mechanism by which oncogenic CBL can block TGF-beta tumor suppressor activity. Oncogene (2012) 31, 5123-5131; doi:10.1038/onc.2012.18; published online 6 February 2012	[Kang, J. M.; Park, S.; Kim, S. J.; Kim, S-J] CHA Univ, Dept Biomed Sci, Seoul 135081, South Korea; [Hong, H. Y.; Kim, S-J] Gachon Univ Med & Sci, Lee Gil Ya Canc & Diabet Inst, Lab Cell Regulat & Carcinogenesis, Inchon, South Korea; [Jeong, J.] Yonsei Univ, Coll Med, Gangnam Severance Hosp, Dept Surg, Seoul, South Korea; [Kim, H-S; Kim, S-J] Case Western Reserve Univ, Rainbow Babies & Childrens Hosp, Dept Pediat, Cleveland, OH 44106 USA	Pochon Cha University; Gachon University; Yonsei University; Yonsei University Health System; Case Western Reserve University; Case Western Reserve University Hospital; University Hospitals of Cleveland; Rainbow Babies & Children's Hospital	Kim, SJ (corresponding author), CHA Univ, Dept Biomed Sci, 605 Yeoksam 1 Dong, Seoul 135081, South Korea.	kimsj@cha.ac.kr		Kim, Staci J./0000-0001-9932-255X; Kang, Jin Muk/0000-0002-7949-9160	National Research Foundation grant of Korea [20090081756, 2011-0014281]; Korea government	National Research Foundation grant of Korea(National Research Foundation of Korea); Korea government(Korean Government)	This work was supported by a National Research Foundation grant of Korea (20090081756 and 2011-0014281) funded by the Korea government. We thank H Kim, W Joo, Y Kim and J Park for their technical supporting.	Bisogna M, 2001, CANCER GENET CYTOGEN, V125, P131, DOI 10.1016/S0165-4608(00)00367-8; Chacko BM, 2004, MOL CELL, V15, P813, DOI 10.1016/j.molcel.2004.07.016; Chipuk JE, 2002, J BIOL CHEM, V277, P1240, DOI 10.1074/jbc.M108855200; Dunbar AJ, 2008, CANCER RES, V68, P10349, DOI 10.1158/0008-5472.CAN-08-2754; Falanga V, 2004, WOUND REPAIR REGEN, V12, P320, DOI 10.1111/j.1067-1927.2004.012316.x; Grand FH, 2009, BLOOD, V113, P6182, DOI 10.1182/blood-2008-12-194548; Hansson MD, 2008, ANAL BIOCHEM, V375, P373, DOI 10.1016/j.ab.2007.12.005; Inoue Y, 2009, J CELL BIOCHEM, V108, P285, DOI 10.1002/jcb.22252; Jin W, 2005, P NATL ACAD SCI USA, V102, P16239, DOI 10.1073/pnas.0503137102; Jin W, 2007, CANCER RES, V67, P9869, DOI 10.1158/0008-5472.CAN-07-0436; Jin W, 2010, CARCINOGENESIS, V31, P1939, DOI 10.1093/carcin/bgq180; Knight JF, 2008, BRIT J CANCER, V99, P1849, DOI 10.1038/sj.bjc.6604774; Komuro A, 2004, ONCOGENE, V23, P6914, DOI 10.1038/sj.onc.1207885; Lahn M, 2006, SMAD SIGNAL TRANSDUC, P415; Lee BI, 2001, CANCER RES, V61, P931; Lee DK, 2002, J BIOL CHEM, V277, P38557, DOI 10.1074/jbc.M206786200; Li LY, 2004, MOL CELL BIOL, V24, P856, DOI 10.1128/MCB.24.2.856-864.2004; Loh ML, 2009, BLOOD, V114, P1859, DOI 10.1182/blood-2009-01-198416; Markowitz Sanford D., 1996, Cytokine and Growth Factor Reviews, V7, P93, DOI 10.1016/1359-6101(96)00001-9; Massague J, 2005, GENE DEV, V19, P2783, DOI 10.1101/gad.1350705; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; Massague J, 2008, CELL, V134, P215, DOI 10.1016/j.cell.2008.07.001; PARK KC, 1994, P NATL ACAD SCI USA, V91, P8772, DOI 10.1073/pnas.91.19.8772; Pennock S, 2008, MOL CELL BIOL, V28, P3020, DOI 10.1128/MCB.01809-07; Sanada M, 2009, NATURE, V460, P904, DOI 10.1038/nature08240; Schmidt MHH, 2005, NAT REV MOL CELL BIO, V6, P907, DOI 10.1038/nrm1762; Tan YHC, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008972; Thien CBF, 2001, NAT REV MOL CELL BIO, V2, P294, DOI 10.1038/35067100; Wan M, 2005, AM J PATHOL, V166, P1379, DOI 10.1016/S0002-9440(10)62356-5; Xu L, 2002, MOL CELL, V10, P271, DOI 10.1016/S1097-2765(02)00586-5; Xu L, 2000, NAT CELL BIOL, V2, P559, DOI 10.1038/35019649; Xu L, 2003, J BIOL CHEM, V278, P42569, DOI 10.1074/jbc.M307601200	32	31	34	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC	2012	31	50					5123	5131		10.1038/onc.2012.18	http://dx.doi.org/10.1038/onc.2012.18			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	055WY	22310290				2022-12-17	WOS:000312449800001
J	Chuang, JY; Wang, SA; Yang, WB; Yang, HC; Hung, CY; Su, TP; Chang, WC; Hung, JJ				Chuang, J-Y; Wang, S-A; Yang, W-B; Yang, H-C; Hung, C-Y; Su, T-P; Chang, W-C; Hung, J-J			Sp1 phosphorylation by cyclin-dependent kinase 1/cyclin B1 represses its DNA-binding activity during mitosis in cancer cells	ONCOGENE			English	Article						Sp1; CDK1; PP2A; myosin; mitosis	TRANSCRIPTION FACTOR SP1; GENE-TRANSCRIPTION; HEAT-SHOCK; PROTEIN; EXPRESSION; PROMOTER; OVEREXPRESSION; ACTIVATION; STABILITY; FACTOR-1	Sp1 is important for the transcription of many genes. Our previous studies have shown that Sp1 is degraded in normal cell, but it is preserved in cancer cells during mitosis and exists a priori in the daughter cells, ready to engage in gene transcription and thereby contributes to the proliferation and survival of cancer cells. The mechanism by which Sp1 is preserved in cancer cells during mitosis remains unknown. In this study, we observed that Sp1 strongly colocalized with cyclin-dependent kinase 1 (CDK1)/cyclin B1 during mitosis. Moreover, we showed that Sp1 is a novel mitotic substrate of CDK1/cyclin B1 and is phosphorylated by it at Thr 739 before the onset of mitosis. Phospho-Sp1 reduced its DNA-binding ability and facilitated the chromatin condensation process during mitosis. Mutation of Thr739 to alanine resulted in Sp1 remaining in the chromosomes, delayed cell-cycle progression, and eventually led to apoptosis. Screening of Sp1-associated proteins during mitosis by using liquid chromatography/mass spectrometry indicated the tethering of Sp1 to myosin/F-actin. Furthermore, phospho-Sp1 and myosin/F-actin appeared to exist as a congregated ring at the periphery of the chromosome. However, at the end of mitosis and the beginning of interphase, Sp1 was dephosphorylated by PP2A and returned to the chromatin. These results indicate that cancer cells use CDK1 and PP2A to regulate the movement of Sp1 in and out of the chromosomes during cell-cycle progression, which may benefit cancer-cell proliferation. Oncogene (2012) 31, 4946-4959; doi:10.1038/onc.2011.649; published online 23 January 2012	[Chuang, J-Y; Wang, S-A; Yang, W-B; Yang, H-C; Hung, J-J] Natl Cheng Kung Univ, Inst Bioinformat & Biosignal Transduct, Coll Biosci & Biotechnol, Tainan 701, Taiwan; [Hung, C-Y; Chang, W-C; Hung, J-J] Natl Cheng Kung Univ, Coll Med, Inst Med, Tainan 70101, Taiwan; [Su, T-P] Natl Inst Drug Abuse, NIH, Baltimore, MD USA; [Chang, W-C; Hung, J-J] Dept Pharmacol, Tainan, Taiwan; [Chang, W-C; Hung, J-J] Natl Cheng Kung Univ, Ctr Infect Dis & Signal Transduct, Tainan 701, Taiwan; [Chang, W-C] Taipei Med Univ, Coll Med, Grad Inst Med Sci, Taipei, Taiwan	National Cheng Kung University; National Cheng Kung University; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); NIH National Institute on Drug Abuse (NIDA); National Cheng Kung University; Taipei Medical University	Hung, JJ (corresponding author), Natl Cheng Kung Univ, Inst Bioinformat & Biosignal Transduct, Coll Biosci & Biotechnol, Tainan 701, Taiwan.	petehung@mail.ncku.edu.tw	Yang, Wen-Bin/AAO-3593-2021	Yang, Wen-Bin/0000-0002-6497-4176; Wang, Shao-an/0000-0002-5473-4195	National Cheng Kung University project of the Program for Promoting Academic Excellence and Developing World Class Research Centers; National Science Council, Taiwan [NSC 97-2320-B-006-016-MY3, NSC 97-2311-B-006-002-MY3]; NATIONAL INSTITUTE ON DRUG ABUSE [ZIADA000206] Funding Source: NIH RePORTER	National Cheng Kung University project of the Program for Promoting Academic Excellence and Developing World Class Research Centers; National Science Council, Taiwan(Ministry of Science and Technology, Taiwan); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)	This work was supported by the National Cheng Kung University project of the Program for Promoting Academic Excellence and Developing World Class Research Centers, together with grants NSC 97-2320-B-006-016-MY3 and NSC 97-2311-B-006-002-MY3 obtained from the National Science Council, Taiwan.	Abdelrahim M, 2004, CANCER RES, V64, P6740, DOI 10.1158/0008-5472.CAN-04-0713; Armstrong SA, 1997, J BIOL CHEM, V272, P13489, DOI 10.1074/jbc.272.21.13489; Benasciutti E, 2004, BLOOD, V104, P256, DOI 10.1182/blood-2003-08-2661; Bonello MR, 2004, J BIOL CHEM, V279, P2377, DOI 10.1074/jbc.M308254200; Boulon S, 2002, MOL CELL BIOL, V22, P7769, DOI 10.1128/MCB.22.22.7769-7779.2002; Chang LK, 2005, NUCLEIC ACIDS RES, V33, P6528, DOI 10.1093/nar/gki956; Chiefari E, 2002, BMC CANCER, V2, DOI 10.1186/1471-2407-2-35; Chu SJ, 2005, GENE, V348, P1, DOI 10.1016/j.gene.2005.01.013; Chuang JY, 2008, MOL BIOL CELL, V19, P1139, DOI 10.1091/mbc.E07-09-0881; Chuang JY, 2011, BIOCHEM BIOPH RES CO, V407, P587, DOI 10.1016/j.bbrc.2011.03.068; Chuang JY, 2009, INT J CANCER, V125, P2066, DOI 10.1002/ijc.24563; Guo T, 2010, CIRC RES, V106, P1743, DOI 10.1161/CIRCRESAHA.110.219816; Han I, 1997, MOL CELL BIOL, V17, P2550, DOI 10.1128/MCB.17.5.2550; He B, 1998, MOL CELL BIOL, V18, P6624, DOI 10.1128/MCB.18.11.6624; He SH, 2006, J CELL SCI, V119, P1063, DOI 10.1242/jcs.02829; Hosoi Y, 2004, INT J ONCOL, V25, P461; Hung JJ, 2006, MOL CELL BIOL, V26, P1770, DOI 10.1128/MCB.26.5.1770-1785.2006; Kugimiya F, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000837; Li L, 2010, ANN ANAT, V192, P275, DOI 10.1016/j.aanat.2010.07.010; Lou Z, 2005, CANCER RES, V65, P1007; Lu KP, 2007, NAT REV MOL CELL BIO, V8, P904, DOI 10.1038/nrm2261; Mertens-Talcott SU, 2007, CANCER RES, V67, P11001, DOI 10.1158/0008-5472.CAN-07-2416; Milanini-Mongiat J, 2002, J BIOL CHEM, V277, P20631, DOI 10.1074/jbc.M201753200; Safe S, 2005, EUR J CANCER, V41, P2438, DOI 10.1016/j.ejca.2005.08.006; Saxena UH, 2010, J BIOL CHEM, V285, P31139, DOI 10.1074/jbc.M109.078808; Strebhardt K, 2010, NAT REV DRUG DISCOV, V9, P643, DOI 10.1038/nrd3184; Tan NY, 2009, MOL CELL BIOL, V29, P2483, DOI 10.1128/MCB.01828-08; Wang LW, 2003, CLIN CANCER RES, V9, P6371; Wang YT, 2008, J MOL BIOL, V380, P869, DOI 10.1016/j.jmb.2008.05.043; Wang YT, 2011, J MOL BIOL, V414, P1, DOI 10.1016/j.jmb.2011.09.027; Xavier IJ, 2000, J BIOL CHEM, V275, P29147, DOI 10.1074/jbc.M002169200	31	31	32	0	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV	2012	31	47					4946	4959		10.1038/onc.2011.649	http://dx.doi.org/10.1038/onc.2011.649			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	041VU	22266860	Green Accepted			2022-12-17	WOS:000311430200006
J	Hromas, R; Williamson, EA; Fnu, S; Lee, YJ; Park, SJ; Beck, BD; You, JS; Laitao, A; Nickoloff, JA; Lee, SH				Hromas, R.; Williamson, E. A.; Fnu, S.; Lee, Y-J; Park, S-J; Beck, B. D.; You, J-S; Laitao, A.; Nickoloff, J. A.; Lee, S-H			Chk1 phosphorylation of Metnase enhances DNA repair but inhibits replication fork restart	ONCOGENE			English	Article						Chk1; Metnase; SETMAR; phosphorylation; DNA repair; replication fork	TRANSPOSASE DOMAIN; IONIZING-RADIATION; PROTEIN-KINASE; CHROMATIN IMMUNOPRECIPITATION; BIOCHEMICAL-CHARACTERIZATION; CHROMOSOME DECATENATION; ATM KINASE; SET; DAMAGE; CELLS	Chk1 both arrests replication forks and enhances repair of DNA damage by phosphorylating downstream effectors. Although there has been a concerted effort to identify effectors of Chk1 activity, underlying mechanisms of effector action are still being identified. Metnase (also called SETMAR) is a SET and transposase domain protein that promotes both DNA double-strand break (DSB) repair and restart of stalled replication forks. In this study, we show that Metnase is phosphorylated only on Ser495 (S495) in vivo in response to DNA damage by ionizing radiation. Chk1 is the major mediator of this phosphorylation event. We had previously shown that wild-type (wt) Metnase associates with chromatin near DSBs and methylates histone H3 Lys36. Here we show that a Ser495Ala (S495A) Metnase mutant, which is not phosphorylated by Chk1, is defective in DSB-induced chromatin association. The S495A mutant also fails to enhance repair of an induced DSB when compared with wt Metnase. Interestingly, the S495A mutant demonstrated increased restart of stalled replication forks compared with wt Metnase. Thus, phosphorylation of Metnase S495 differentiates between these two functions, enhancing DSB repair and repressing replication fork restart. In summary, these data lend insight into the mechanism by which Chk1 enhances repair of DNA damage while at the same time repressing stalled replication fork restart. Oncogene (2012) 31, 4245-4254; doi:10.1038/onc.2011.586; published online 9 January 2012	[Hromas, R.; Williamson, E. A.; Fnu, S.] Univ Florida, Dept Med, Gainesville, FL 32610 USA; [Hromas, R.; Williamson, E. A.; Fnu, S.] Shands Hlth Care Syst, Gainesville, FL USA; [Lee, Y-J; Park, S-J; Beck, B. D.; You, J-S; Lee, S-H] Indiana Univ, Med Ctr, Ctr Canc, Dept Biochem Mol Biol & Med, Indianapolis, IN USA; [Laitao, A.] Univ Sao Paulo, Inst Quim Sao Carlos, Grp Estudos Quim Med Prod Nat NEQUIMED PN, Sao Carlos, SP, Brazil; [Nickoloff, J. A.] Colorado State Univ, Dept Environm & Radiol Hlth Sci, Ft Collins, CO 80523 USA	State University System of Florida; University of Florida; State University System of Florida; University of Florida; Indiana University System; Indiana University-Purdue University Indianapolis; Universidade de Sao Paulo; Colorado State University	Hromas, R (corresponding author), Univ Florida, Dept Med, 1600 SW Archer Rd, Gainesville, FL 32610 USA.	robert.hromas@medicine.ufl.edu; slee@ipui.edu	Leitao, Andrei/B-7942-2012	Leitao, Andrei/0000-0002-6601-6609	NIH [CA92111, CA151367, NIDDK 1 T32 DK 0719-15, R01 GM084020, R01 CA100862, R01 CA102283, R01 HL075783, R01 CA139429]; IU Cancer Center; Walther Oncology Center; APRC [CA100862]; Leukemia and Lymphoma Society SCOR [7388-06]; NATIONAL CANCER INSTITUTE [R01CA139429, R01CA100862, R01CA102283, R01CA151367] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL075783] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM084020] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); IU Cancer Center; Walther Oncology Center; APRC; Leukemia and Lymphoma Society SCOR(Leukemia and Lymphoma Society); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We would like to thank Dr H Chun for providing purified ATM kinase. This research was supported by grants from NIH (CA92111 and CA151367 to S-HL), the IU Cancer Center and the Walther Oncology Center. BDB was supported by NIH predoctoral training grant (NIDDK 1 T32 DK 0719-15). We acknowledge K Valerie for the kind gift of the adenovirus I-SceI system, the support of NIH R01 GM084020 and NIH R01 CA100862 (J.N.), an APRC supplement CA100862 (JN and RH), NIH R01 CA102283 (RH), NIH R01 HL075783 (RH), NIH R01 CA139429 (RH), and the Leukemia and Lymphoma Society SCOR 7388-06 (RH).	Arnold Konstantin, 2009, Journal of Structural and Functional Genomics, V10, P1, DOI 10.1007/s10969-008-9048-5; Bartek J, 2003, CANCER CELL, V3, P421, DOI 10.1016/S1535-6108(03)00110-7; Beck BD, 2011, BIOCHEMISTRY-US, V50, P4360, DOI 10.1021/bi200333k; Brzeska H, 1997, P NATL ACAD SCI USA, V94, P1092, DOI 10.1073/pnas.94.4.1092; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Cordaux R, 2006, P NATL ACAD SCI USA, V103, P8101, DOI 10.1073/pnas.0601161103; De Haro LP, 2010, NUCLEIC ACIDS RES, V38, P5681, DOI 10.1093/nar/gkq339; Donzelli M, 2003, EMBO REP, V4, P671, DOI 10.1038/sj.embor.embor887; Feng JJ, 2009, MOL CELL BIOL, V29, P5696, DOI 10.1128/MCB.00191-09; Firulli Beth A., 2004, Biol Proced Online, V6, P16, DOI 10.1251/bpo69; Fnu S, 2011, P NATL ACAD SCI USA, V108, P540, DOI 10.1073/pnas.1013571108; Goodwin KD, 2010, BIOCHEMISTRY-US, V49, P5705, DOI 10.1021/bi100171x; Hromas R, 2008, DNA REPAIR, V7, P1927, DOI 10.1016/j.dnarep.2008.08.002; Jordan IK, 2006, P NATL ACAD SCI USA, V103, P7941, DOI 10.1073/pnas.0602656103; Kastan MB, 2001, NATURE, V410, P766, DOI 10.1038/35071218; Kim JS, 2005, J CELL BIOL, V170, P341, DOI 10.1083/jcb.200411083; Kim ST, 1999, J BIOL CHEM, V274, P37538, DOI 10.1074/jbc.274.53.37538; Lee SH, 2005, P NATL ACAD SCI USA, V102, P18075, DOI 10.1073/pnas.0503676102; Lee YJ, 2006, CARCINOGENESIS, V27, P446, DOI 10.1093/carcin/bgi254; Lees-Miller SP, 2003, BIOCHIMIE, V85, P1161, DOI 10.1016/j.biochi.2003.10.011; Leung-Pineda V, 2006, MOL CELL BIOL, V26, P7529, DOI 10.1128/MCB.00447-06; Liu DX, 2007, MOL CELL BIOL, V27, P1125, DOI 10.1128/MCB.01899-06; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; O'Neill T, 2002, J BIOL CHEM, V277, P16102, DOI 10.1074/jbc.M111705200; Petermann E, 2010, MOL CELL, V37, P492, DOI 10.1016/j.molcel.2010.01.021; Reyland ME, 2009, FRONT BIOSCI-LANDMRK, V14, P2386, DOI 10.2741/3385; Robertson HM, 1997, GENE, V205, P203, DOI 10.1016/S0378-1119(97)00472-1; Roig J, 1999, J BIOL CHEM, V274, P31119, DOI 10.1074/jbc.274.44.31119; Roman Y, 2007, BIOCHEMISTRY-US, V46, P11369, DOI 10.1021/bi7005477; Valerie K, 2003, ONCOGENE, V22, P5792, DOI 10.1038/sj.onc.1206679; Wang HC, 2001, CANCER RES, V61, P270; Weinmann AS, 2001, MOL CELL BIOL, V21, P6820, DOI 10.1128/MCB.21.20.6820-6832.2001; Weinmann AS, 2002, METHODS, V26, P37, DOI 10.1016/S1046-2023(02)00006-3; Wilkes MC, 2003, MOL CELL BIOL, V23, P8878, DOI 10.1128/MCB.23.23.8878-8889.2003; Williamson EA, 2008, NUCLEIC ACIDS RES, V36, P5822, DOI 10.1093/nar/gkn560; Wray J, 2010, CANCER GENET CYTOGEN, V200, P184, DOI 10.1016/j.cancergencyto.2010.04.011; Wray J, 2009, BLOOD, V114, P1852, DOI 10.1182/blood-2008-08-175760; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005	38	31	32	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP	2012	31	38					4245	4254		10.1038/onc.2011.586	http://dx.doi.org/10.1038/onc.2011.586			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	008SC	22231448	Green Accepted			2022-12-17	WOS:000308975800007
J	Lubbe, SJ; Pittman, AM; Olver, B; Lloyd, A; Vijayakrishnan, J; Naranjo, S; Dobbins, S; Broderick, P; Gomez-Skarmeta, JL; Houlston, RS				Lubbe, S. J.; Pittman, A. M.; Olver, B.; Lloyd, A.; Vijayakrishnan, J.; Naranjo, S.; Dobbins, S.; Broderick, P.; Gomez-Skarmeta, J. L.; Houlston, R. S.			The 14q22.2 colorectal cancer variant rs4444235 shows cis-acting regulation of BMP4	ONCOGENE			English	Article						bone morphogenetic protein-4; colorectal cancer; cis-regulatory	GENOME-WIDE ASSOCIATION; SUSCEPTIBILITY LOCI; GENE-EXPRESSION; CHROMOSOMAL INSTABILITY; GEL-ELECTROPHORESIS; RISK; COMMON; 8Q24; SCAN; PREDISPOSITION	Common genetic variation at human 14q22.2 tagged by rs4444235 is significantly associated with colorectal cancer (CRC) risk. Re-sequencing was used to comprehensively annotate the 17kb region of strong linkage disequilibrium encompassing rs4444235. Through bioinformatic analyses using H3K4Me1, H3K4Me3, and DNase-I hypersensitivity chromatin signatures and evolutionary conservation we identified seven candidate disease-causing single-nucleotide polymorphisms mapping to six regions within the 17-kb region predicted to have regulatory potential. Reporter gene studies of these regions demonstrated that the element to which rs4444235 maps acts as an allele-specific transcriptional enhancer. Allele-specific expression studies in CRC cell lines heterozygous for rs4444235 showed significantly increased expression of bone morphogenetic protein-4 (BMP4) associated with the risk allele (P<0.001). These data provide evidence for a functional basis for the non-coding risk variant rs4444235 at 14q22.2 and emphasizes the importance of genetic variation in the BMP pathway genes as determinants of CRC risk. Oncogene (2012) 31, 3777-3784; doi:10.1038/onc.2011.564; published online 12 December 2011	[Lubbe, S. J.; Pittman, A. M.; Olver, B.; Lloyd, A.; Vijayakrishnan, J.; Dobbins, S.; Broderick, P.; Houlston, R. S.] Inst Canc Res, Sect Canc Genet, Sutton SM2 5NG, Surrey, England; [Naranjo, S.; Gomez-Skarmeta, J. L.] CSIC UPO, Ctr Andaluz Biol Desarrollo, Seville, Spain	University of London; Institute of Cancer Research - UK; Consejo Superior de Investigaciones Cientificas (CSIC); Universidad Pablo de Olavide; CSIC - Andalusian Center for Developmental Biology (CABD)	Houlston, RS (corresponding author), Inst Canc Res, Sect Canc Genet, Sutton SM2 5NG, Surrey, England.	Richard.houlston@icr.ac.uk	Naranjo, Silvia/P-9845-2016; Pittman, Alan/AAP-2534-2020; Pittman, Alan M/D-6231-2012; Gomez-Skarmeta, Jose Luis/B-5268-2014; Lubbe, Steven/L-8261-2013	Naranjo, Silvia/0000-0002-4529-3332; Pittman, Alan/0000-0002-8112-2987; Pittman, Alan M/0000-0002-8112-2987; Gomez-Skarmeta, Jose Luis/0000-0001-5125-4332; Lubbe, Steven/0000-0002-7103-6671; Houlston, Richard/0000-0002-5268-0242; Broderick, Peter/0000-0002-8348-5829; Vijayakrishnan, Jayaram/0000-0002-8284-2249	National Health Service (NHS); Bobby Moore Fund; Spanish Ministry of Education and Science [BFU2010-14839, CSD2007-00008]; Junta de Andalucia [CVI-3488]; PhD studentship from Cancer Research UK; European Union Seventh Framework Programme (FP7) [258236]	National Health Service (NHS); Bobby Moore Fund; Spanish Ministry of Education and Science(Spanish Government); Junta de Andalucia(Junta de Andalucia); PhD studentship from Cancer Research UK; European Union Seventh Framework Programme (FP7)	We acknowledge the National Health Service (NHS) funding to the National Institute for Health Research (NIHR) Biomedical Research Centre. Finally, we are grateful to all patients and individuals for participation. Cancer Research UK (C1298/A8362 supported by the Bobby Moore Fund) provided principal funding for the study. JLG-S acknowledges grants from the Spanish Ministry of Education and Science (BFU2010-14839 and CSD2007-00008) and Junta de Andalucia (CVI-3488). SJL is in receipt of a PhD studentship from Cancer Research UK. The research leading to these results has received funding from the European Union Seventh Framework Programme (FP7/207-2013) under grant no. 258236, FP7 collaborative project SYSCOL.	Aaltonen L, 2007, CLIN CANCER RES, V13, P356, DOI 10.1158/1078-0432.CCR-06-1256; Abdel-Rahman WM, 2001, P NATL ACAD SCI USA, V98, P2538, DOI 10.1073/pnas.041603298; Broderick P, 2007, NAT GENET, V39, P1315, DOI 10.1038/ng.2007.18; Deng HY, 2007, EXP CELL RES, V313, P1033, DOI 10.1016/j.yexcr.2006.12.020; Eisen T, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-244; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; Gaasenbeek M, 2006, CANCER RES, V66, P3471, DOI 10.1158/0008-5472.CAN-05-3285; GARNER MM, 1981, NUCLEIC ACIDS RES, V9, P3047, DOI 10.1093/nar/9.13.3047; Gomez-Skarmeta JL, 2006, DEV DYNAM, V235, P870, DOI 10.1002/dvdy.20659; He XC, 2004, NAT GENET, V36, P1117, DOI 10.1038/ng1430; Heinemeyer T, 1998, NUCLEIC ACIDS RES, V26, P362, DOI 10.1093/nar/26.1.362; Houlston RS, 2010, NAT GENET, V42, P973, DOI 10.1038/ng.670; Houlston RS, 2008, NAT GENET, V40, P1426, DOI 10.1038/ng.262; Jaeger E, 2008, NAT GENET, V40, P26, DOI 10.1038/ng.2007.41; Kawi K, 2002, GENE CHROMOSOME CANC, V34, P1, DOI 10.1002/gcc.10003; Kosinski C, 2007, P NATL ACAD SCI USA, V104, P15418, DOI 10.1073/pnas.0707210104; Lichtenstein P, 2000, NEW ENGL J MED, V343, P78, DOI 10.1056/NEJM200007133430201; Liu CT, 1996, CRIT REV ONCOGENESIS, V7, P101, DOI 10.1615/CritRevOncog.v7.i1-2.70; Lo HS, 2003, GENOME RES, V13, P1855, DOI 10.1101/gr.1006603; Lubbe SJ, 2009, J CLIN ONCOL, V27, P2238, DOI 10.1200/JCO.2008.20.3364; Milani L, 2007, NUCLEIC ACIDS RES, V35, DOI 10.1093/nar/gkl1152; Palin K, 2006, NAT PROTOC, V1, P368, DOI 10.1038/nprot.2006.56; Penegar S, 2007, BRIT J CANCER, V97, P1305, DOI 10.1038/sj.bjc.6603997; Pittman AM, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001126; Pittman AM, 2009, GENOME RES, V19, P987, DOI 10.1101/gr.092668.109; Polakis P, 2000, GENE DEV, V14, P1837; Pomerantz MM, 2009, NAT GENET, V41, P882, DOI 10.1038/ng.403; Pregizer S, 2009, CYTOKINE GROWTH F R, V20, P509, DOI 10.1016/j.cytogfr.2009.10.011; Takash W, 2001, NUCLEIC ACIDS RES, V29, P4274, DOI 10.1093/nar/29.21.4274; Tenesa A, 2008, NAT GENET, V40, P631, DOI 10.1038/ng.133; Tomlinson I, 2007, NAT GENET, V39, P984, DOI 10.1038/ng2085; Tomlinson IPM, 2008, NAT GENET, V40, P623, DOI 10.1038/ng.111; Tomlinson IPM, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002105; Tsushimi T, 2001, CANCER GENET CYTOGEN, V126, P34, DOI 10.1016/S0165-4608(00)00391-5; Tuupanen S, 2009, NAT GENET, V41, P885, DOI 10.1038/ng.406; Zanke BW, 2007, NAT GENET, V39, P989, DOI 10.1038/ng2089	36	31	31	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2012	31	33					3777	3784		10.1038/onc.2011.564	http://dx.doi.org/10.1038/onc.2011.564			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	994IU	22158048				2022-12-17	WOS:000307924900004
J	Chang, CY; Lin, SC; Su, WH; Ho, CM; Jou, YS				Chang, C-Y; Lin, S-C; Su, W-H; Ho, C-M; Jou, Y-S			Somatic LMCD1 mutations promoted cell migration and tumor metastasis in hepatocellular carcinoma	ONCOGENE			English	Article						somatic mutations; LMCD1; LIM domain; metastasis; hepatocellular carcinoma	FOCAL ADHESION PROTEIN; BREAST-CANCER CELLS; LIM DOMAIN GENE; LOCALIZATION; GROWTH; ACTIN; ONCOGENES; TES; HYPERMETHYLATION; IDENTIFICATION	Common genetic alteration in cancer genomes is implicated for embracing an aberrant cancer gene participated in tumor progression. In this study, we identified a somatic mutated LIM and cysteine-rich domains-1 (LMCD1) as a putative metastatic oncogene in human hepatocellular carcinoma (HCC) using integrated genomic approaches. In addition to revealing genomic amplification and gene upregulation, we identified recurrent E135K (3/48 cases) mutations in HCC tissues and K237R mutation in the PLC/PRF/5 HCC cell line. Expression of mutant LMCD1 E135K or K237R reduced the stress fiber assembly, increased cortical actin accumulation and induced lamellipodial extension. Consistently, these mutations enhanced cell migration and showed activation of the Rac1-signaling pathway. Inhibition of the LMCD1/Rac1 pathway by an LMCD1 short-hairpin RNA (shLMCD1) or the Rac1 inhibitor NSC23766 suppressed the mutation-mediated lamellipodial protrusion and cell migration. In PLC/PRF/5 cells with endogenous K237R mutation, cell migration was enhanced by estrogen-induced LMCD1 expression but reversed by shLMCD1 treatment. Moreover, overexpression of LMCD1 E135K mutation significantly promoted systemic lung metastasis in a murine tail vein injection model. Together, our results suggest that LMCD1 mutations are potential oncogenic events in HCC metastasis to promote cell migration through the Rac1-signaling pathway. Oncogene (2012) 31, 2640-2652; doi:10.1038/onc.2011.440; published online 26 September 2011	[Chang, C-Y; Lin, S-C; Jou, Y-S] Acad Sinica, Inst Biomed Sci, Taipei 11529, Taiwan; [Chang, C-Y; Jou, Y-S] Natl Def Med Ctr, Grad Inst Life Sci, Taipei, Taiwan; [Su, W-H] Chang Gung Univ, Chang Gung Mol Med Res Ctr, Grad Inst Biomed Sci, Dept Biomed Sci, Tao Yuan, Taiwan; [Ho, C-M] Natl Chiao Tung Univ, Inst Bioinformat, Hsinchu, Taiwan; [Ho, C-M; Jou, Y-S] Acad Sinica, Bioinformat Program, Taiwan Int Grad Program, Taipei 115, Taiwan	Academia Sinica - Taiwan; National Defense Medical Center; Chang Gung Memorial Hospital; Chang Gung University; National Yang Ming Chiao Tung University; Academia Sinica - Taiwan	Jou, YS (corresponding author), Acad Sinica, Inst Biomed Sci, 128 Acad Rd,Sect 2, Taipei 11529, Taiwan.	jou@ibms.sinica.edu.tw	Jou, Yuh-Shan/O-5921-2018	Jou, Yuh-Shan/0000-0001-5090-3732; Su, Wen-Hui/0000-0003-1037-4615	National Science Council, Taiwan [NSC98-3112-B-001-004, NSC98-3112-B-001-031, NSC99-3112-B-001-019]	National Science Council, Taiwan(Ministry of Science and Technology, Taiwan)	We thank Dr Pei-Jer Chen and Dr Ding-Shinn Chen at School of Medicine, National Taiwan University, for helpful discussions and advice on the work. We also thank the core facilities from National Research Program for Genomic Medicine, National Science Council, Taiwan, including the National Genotyping Center, for their service in SNP genotyping and the National RNAi Core facility for providing shRNAs. Financial Support: This work was funded by the National Research Program for Genomic Medicine of the National Science Council, Taiwan, through grant numbers NSC98-3112-B-001-004, NSC98-3112-B-001-031 and NSC99-3112-B-001-019.	Aoyama M, 2005, CANCER RES, V65, P4587, DOI 10.1158/0008-5472.CAN-04-4630; Arber S, 1998, NATURE, V393, P805, DOI 10.1038/31729; Bagheri-Yarmand R, 2006, INT J CANCER, V118, P2703, DOI 10.1002/ijc.21650; Barrientos T, 2007, J BIOL CHEM, V282, P8393, DOI 10.1074/jbc.M607549200; Bespalova IN, 2000, GENOMICS, V63, P69, DOI 10.1006/geno.1999.6049; BOEHM T, 1991, P NATL ACAD SCI USA, V88, P4367, DOI 10.1073/pnas.88.10.4367; CHALLEN C, 1992, J HEPATOL, V14, P342, DOI 10.1016/0168-8278(92)90181-N; Chen CF, 2010, HEPATOLOGY, V52, P1690, DOI 10.1002/hep.23847; Cheng AL, 2009, LANCET ONCOL, V10, P25, DOI 10.1016/S1470-2045(08)70285-7; Coutts AS, 2003, J CELL SCI, V116, P897, DOI 10.1242/jcs.00278; de La Coste A, 1998, P NATL ACAD SCI USA, V95, P8847; DESOUZA AT, 1995, NAT GENET, V11, P447, DOI 10.1038/ng1295-447; Dudek P, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001859; Farazi PA, 2006, NAT REV CANCER, V6, P674, DOI 10.1038/nrc1934; Gao Y, 2004, P NATL ACAD SCI USA, V101, P7618, DOI 10.1073/pnas.0307512101; Gramantieri L, 2007, CANCER RES, V67, P6092, DOI 10.1158/0008-5472.CAN-06-4607; Griffith E, 2005, CELL MOTIL CYTOSKEL, V60, P140, DOI 10.1002/cm.20052; Grise F, 2009, BBA-REV CANCER, V1795, P137, DOI 10.1016/j.bbcan.2008.12.003; Grunewald TGP, 2007, BRIT J CANCER, V96, P296, DOI 10.1038/sj.bjc.6603545; Harvell DME, 2006, ENDOCRINOLOGY, V147, P700, DOI 10.1210/en.2005-0617; Imbeaud S, 2010, SEMIN LIVER DIS, V30, P75, DOI 10.1055/s-0030-1247134; Jagadeeswaran R, 2008, CANCER RES, V68, P132, DOI 10.1158/0008-5472.CAN-07-1998; Jou YS, 2004, CANCER RES, V64, P3030, DOI 10.1158/0008-5472.CAN-03-2320; Kadrmas JL, 2004, NAT REV MOL CELL BIO, V5, P920, DOI 10.1038/nrm1499; KANAI T, 1987, CANCER, V60, P810, DOI 10.1002/1097-0142(19870815)60:4<810::AID-CNCR2820600417>3.0.CO;2-1; Kang SM, 2000, CANCER RES, V60, P5296; Khurana T, 2002, PROTOPLASMA, V219, P1, DOI 10.1007/s007090200000; Knuutila S, 1999, AM J PATHOL, V155, P683, DOI 10.1016/S0002-9440(10)65166-8; Kusano N, 1999, HEPATOLOGY, V29, P1858, DOI 10.1002/hep.510290636; Liu CY, 2009, J PATHOL, V219, P222, DOI 10.1002/path.2589; Llovet JM, 2008, NEW ENGL J MED, V359, P378, DOI 10.1056/NEJMoa0708857; Matsuda Y, 1999, GASTROENTEROLOGY, V116, P394, DOI 10.1016/S0016-5085(99)70137-X; Meng FY, 2007, GASTROENTEROLOGY, V133, P647, DOI 10.1053/j.gastro.2007.05.022; Mueller W, 2007, ONCOGENE, V26, P583, DOI 10.1038/sj.onc.1209805; Murata H, 2004, LAB INVEST, V84, P1050, DOI 10.1038/labinvest.3700118; Niketeghad F, 2001, BRIT J CANCER, V85, P697, DOI 10.1054/bjoc.2001.1963; OZTURK M, 1991, LANCET, V338, P1356, DOI 10.1016/0140-6736(91)92236-U; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; Pratt SJ, 2005, J CELL BIOL, V168, P813, DOI 10.1083/jcb.200406083; Rath N, 2005, MOL CELL BIOL, V25, P8864, DOI 10.1128/MCB.25.20.8864-8873.2005; Satoh S, 2000, NAT GENET, V24, P245, DOI 10.1038/73448; Tobias ES, 2001, ONCOGENE, V20, P2844, DOI 10.1038/sj.onc.1204433; Visvader JE, 2001, P NATL ACAD SCI USA, V98, P14452, DOI 10.1073/pnas.251547698; Wang G, 2001, GENE CHROMOSOME CANC, V31, P221, DOI 10.1002/gcc.1138; Yakicier MC, 1999, ONCOGENE, V18, P4879, DOI 10.1038/sj.onc.1202866; Yao YJ, 1999, ONCOGENE, V18, P3181, DOI 10.1038/sj.onc.1202659; Yoshida T, 2010, CANCER INFORM, V9, P147; Zheng Q, 2007, BIOL CELL, V99, P489, DOI 10.1042/BC20060126	48	31	31	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY	2012	31	21					2640	2652		10.1038/onc.2011.440	http://dx.doi.org/10.1038/onc.2011.440			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	948SS	21996735				2022-12-17	WOS:000304523500004
J	Gurzov, EN; Barthson, J; Marhfour, I; Ortis, F; Naamane, N; Igoillo-Esteve, M; Gysemans, C; Mathieu, C; Kitajima, S; Marchetti, P; Orntoft, TF; Bakiri, L; Wagner, EF; Eizirik, DL				Gurzov, E. N.; Barthson, J.; Marhfour, I.; Ortis, F.; Naamane, N.; Igoillo-Esteve, M.; Gysemans, C.; Mathieu, C.; Kitajima, S.; Marchetti, P.; Orntoft, T. F.; Bakiri, L.; Wagner, E. F.; Eizirik, D. L.			Pancreatic beta-cells activate a JunB/ATF3-dependent survival pathway during inflammation	ONCOGENE			English	Article						type 1 diabetes; pancreatic beta cells; JunB; ATF3; apoptosis	ENDOPLASMIC-RETICULUM STRESS; ADAPTIVE-RESPONSE GENE; ER STRESS; APOPTOSIS; JUNB; ATF3; EXPRESSION; DEATH; CYTOKINES; MICE	Destruction of insulin-producing pancreatic beta-cells by local autoimmune inflammation is a hallmark of type 1 diabetes. Histochemical analysis of pancreases from non-obese diabetic mice indicated activation of the transcription factor JunB/AP-1 (activator protein-1) after autoimmune infiltration of the islets. In vitro studies demonstrated that the cytokines tumor necrosis factor (TNF)-alpha and interferon (IFN)-gamma induce JunB expression as a protective mechanism against apoptosis in both human and rodent beta-cells. The gene network affected was studied by microarray analysis showing that JunB regulates nearly 20% of the cytokine-modified beta-cell genes, including the transcription factor ATF3. Direct transcriptional induction of ATF3 by JunB is a key event for beta-cell survival after TNF-alpha + IFN-gamma treatment. Moreover, pharmacological upregulation of JunB/ATF3 via increased cAMP protected rodent primary beta-cells and human islet cells against pro-inflammatory mediators. These results were confirmed in genetically modified islets derived from Ubi-JunB transgenic mice. Our findings identify ATF3 as a novel downstream target of JunB in the survival mechanism of beta-cells under inflammatory stress. Oncogene (2012) 31, 1723-1732; doi:10.1038/onc.2011.353; published online 15 August 2011	[Gurzov, E. N.; Barthson, J.; Marhfour, I.; Ortis, F.; Naamane, N.; Igoillo-Esteve, M.; Eizirik, D. L.] Univ Libre Bruxelles, Expt Med Lab, B-1070 Brussels, Belgium; [Gysemans, C.; Mathieu, C.] Katholieke Univ Leuven, Fac Med, Lab Expt Med Endocrinol LEGENDO, Louvain, Belgium; [Kitajima, S.] Tokyo Med & Dent Univ, Med Res Inst, Sch Biomed Sci, Dept Biochem Genet, Tokyo, Japan; [Kitajima, S.] Tokyo Med & Dent Univ, Sch Biomed Sci, Lab Genome Struct & Regulat, Tokyo, Japan; [Marchetti, P.] Univ Pisa, Osped Cisanello, Metab Unit, Dept Endocrinol & Metab, Pisa, Italy; [Orntoft, T. F.] CMO Aros Appl Biotechnol AS, Aarhus, Denmark; [Orntoft, T. F.] Aarhus Univ Hosp, Dept Mol Med, DK-8000 Aarhus, Denmark; [Bakiri, L.; Wagner, E. F.] Banco Bilbao Vizcaya Argentaria BBVA Fdn, Canc Cell Biol Programme, CNIO, Madrid, Spain	Universite Libre de Bruxelles; KU Leuven; Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU); University of Pisa; Aarhus University; Centro Nacional de Investigaciones Oncologicas (CNIO)	Gurzov, EN (corresponding author), Univ Libre Bruxelles, Expt Med Lab, Route Lennik 808,CP-618, B-1070 Brussels, Belgium.	egurzov@ulb.ac.be; deizirik@ulb.ac.be	Bakiri, Latifa/N-5780-2014; Marchetti, Piero/J-7439-2013; Ortis, Fernanda/K-7917-2014; Bakiri, Latifa/AAP-1674-2020; mathieu, chantal/ABD-5505-2021; Ortis, Fernanda/M-7190-2019	Marchetti, Piero/0000-0003-4907-0635; mathieu, chantal/0000-0002-4055-5233; gysemans, conny/0000-0003-3559-6089; Ortis, Fernanda/0000-0002-9551-2839; bakiri, latifa/0000-0002-6300-2420; Gurzov, Esteban/0000-0003-4642-0273; Igoillo-Esteve, Mariana/0000-0002-3264-7912; Wagner, Erwin F/0000-0001-7872-0196	Communaute Francaise de Belgique-Actions de Recherche Concertees (ARC); Fonds National de la Recherche Scientifique (FNRS) Belgium; Belgium Program on Interuniversity Poles of Attraction [IUAP P6/40]; Juvenile Diabetes Research Foundation International (JDRFI) [17-2009-106]; European Union (European Community); EMBO; FWO Vlaanderen	Communaute Francaise de Belgique-Actions de Recherche Concertees (ARC); Fonds National de la Recherche Scientifique (FNRS) Belgium(Fonds de la Recherche Scientifique - FNRS); Belgium Program on Interuniversity Poles of Attraction; Juvenile Diabetes Research Foundation International (JDRFI)(Juvenile Diabetes Research Foundation); European Union (European Community)(European Commission); EMBO(European Molecular Biology Organization (EMBO)); FWO Vlaanderen(FWO)	We thank MA Neef, G Vandenbroeck, M Urbain, R Makhnas, AE Musuaya and S Mertens of the Laboratory of Experimental Medicine (Universite Libre de Bruxelles, Brussels, Belgium) for excellent technical support, and Drs L Marselli and L Ladriere for help with human islet preparations. This work was supported by grants from the Communaute Francaise de Belgique-Actions de Recherche Concertees (ARC), Fonds National de la Recherche Scientifique (FNRS) Belgium, the Belgium Program on Interuniversity Poles of Attraction initiated by the Belgium State (IUAP P6/40), the Juvenile Diabetes Research Foundation International (JDRFI Grant 17-2009-106) and the European Union (project Naimit, in the Framework Programme 7 of the European Community). ENG was supported by an EMBO long-term fellowship. CG and CM were supported by a postdoctoral and senior clinical scholarship from the FWO Vlaanderen, respectively.	Allagnat F, 2011, CELL DEATH DIFFER, V18, P328, DOI 10.1038/cdd.2010.105; Borchers AT, 2010, AUTOIMMUN REV, V9, pA355, DOI 10.1016/j.autrev.2009.12.003; Bosi E, 2010, J CLIN ENDOCR METAB, V95, P2607, DOI 10.1210/jc.2009-2741; Cardozo AK, 2005, DIABETES, V54, P452, DOI 10.2337/diabetes.54.2.452; Carrington EM, 2009, DIABETES, V58, P2316, DOI 10.2337/db08-1602; Colli ML, 2010, HUM MOL GENET, V19, P135, DOI 10.1093/hmg/ddp474; Cunha DA, 2008, J CELL SCI, V121, P2308, DOI 10.1242/jcs.026062; Cunha DA, 2009, DIABETES, V58, P2851, DOI 10.2337/db09-0685; Eferl R, 2003, NAT REV CANCER, V3, P859, DOI 10.1038/nrc1209; Eizirik DL, 2009, NAT REV ENDOCRINOL, V5, P219, DOI 10.1038/nrendo.2009.21; Eizirik DL, 2001, DIABETOLOGIA, V44, P2115, DOI 10.1007/s001250100021; Galluzzi L, 2009, CELL DEATH DIFFER, V16, P1093, DOI 10.1038/cdd.2009.44; Gurzov EN, 2009, CELL DEATH DIFFER, V16, P1539, DOI 10.1038/cdd.2009.99; Gurzov EN, 2010, J BIOL CHEM, V285, P19910, DOI 10.1074/jbc.M110.122374; Gurzov EN, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003030; Heimberg H, 2001, DIABETES, V50, P2219, DOI 10.2337/diabetes.50.10.2219; Jiang HY, 2004, MOL CELL BIOL, V24, P1365, DOI 10.1128/MCB.24.3.1365-1377.2004; Kim KH, 2010, NUCLEIC ACIDS RES, V38, P48, DOI 10.1093/nar/gkp865; KOBIERSKI LA, 1991, P NATL ACAD SCI USA, V88, P10222, DOI 10.1073/pnas.88.22.10222; Kouskouti A, 2005, EMBO J, V24, P347, DOI 10.1038/sj.emboj.7600516; Kutlu B, 2003, DIABETES, V52, P2701, DOI 10.2337/diabetes.52.11.2701; Lupi R, 2002, DIABETES, V51, P1437, DOI 10.2337/diabetes.51.5.1437; Maida A, 2008, ENDOCRINOLOGY, V149, P5670, DOI 10.1210/en.2008-0336; Matsuoka T, 2010, DIABETES, V59, P1709, DOI 10.2337/db08-0693; Meixner A, 2008, NAT CELL BIOL, V10, P1003, DOI 10.1038/ncb1761; Moore F, 2011, J BIOL CHEM, V286, P929, DOI 10.1074/jbc.M110.162131; Moore F, 2009, DIABETES, V58, P1283, DOI 10.2337/db08-1510; PEREZALBUERNE ED, 1993, P NATL ACAD SCI USA, V90, P11960, DOI 10.1073/pnas.90.24.11960; Pflegerl P, 2009, P NATL ACAD SCI USA, V106, P20423, DOI 10.1073/pnas.0910371106; PIPELEERS DG, 1985, ENDOCRINOLOGY, V117, P806, DOI 10.1210/endo-117-3-806; Salameh A, 2010, J BIOL CHEM, V285, P23094, DOI 10.1074/jbc.M109.087221; Schmidt D, 2007, EMBO J, V26, P710, DOI 10.1038/sj.emboj.7601539; Schorpp M, 1996, NUCLEIC ACIDS RES, V24, P1787, DOI 10.1093/nar/24.9.1787; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; Tamura K, 2005, EMBO J, V24, P2590, DOI 10.1038/sj.emboj.7600742; Thompson MR, 2009, J MOL MED, V87, P1053, DOI 10.1007/s00109-009-0520-x; Wu XW, 2010, NATURE, V465, P368, DOI 10.1038/nature08996; Zenz R, 2005, NATURE, V437, P369, DOI 10.1038/nature03963; Zmuda EJ, 2010, DIABETOLOGIA, V53, P1438, DOI 10.1007/s00125-010-1696-x; Zmuda EJ, 2010, MOL ENDOCRINOL, V24, P1423, DOI 10.1210/me.2009-0463	40	31	31	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR	2012	31	13					1723	1732		10.1038/onc.2011.353	http://dx.doi.org/10.1038/onc.2011.353			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	918EF	21841823				2022-12-17	WOS:000302231400010
J	Tho, LM; Libertini, S; Rampling, R; Sansom, O; Gillespie, DA				Tho, L. M.; Libertini, S.; Rampling, R.; Sansom, O.; Gillespie, D. A.			Chk1 is essential for chemical carcinogen-induced mouse skin tumorigenesis	ONCOGENE			English	Article						checkpoints; carcinogenesis; DNA damage; genome stability; apoptosis; senescence	ONCOGENE-INDUCED SENESCENCE; DNA-DAMAGE; STEM-CELLS; TUMOR-FORMATION; HAIR FOLLICLE; CANCER; CHECKPOINT; EPIDERMIS; MICE; ATR	Chk1 is a key regulator of DNA damage checkpoint responses and genome stability in eukaryotes. To better understand how checkpoint proficiency relates to cancer development, we investigated the effects of genetic ablation of Chk1 in the mouse skin on tumors induced by chemical carcinogens. We found that homozygous deletion of Chk1 immediately before carcinogen exposure strongly suppressed benign tumor (papilloma) formation, and that the few, small lesions that formed in the ablated skin always retained Chk1 expression. Remarkably, Chk1 deletion rapidly triggered spontaneous cell proliferation, gamma-H2AX staining and apoptosis within the hair follicle, a principal site of origin for carcinogen-induced tumors. At later times, the ablated skin was progressively repopulated by non-recombined Chk1-expressing cells and ultimately normal sensitivity to tumor induction was restored when carcinogen treatment was delayed. In marked contrast, papillomas formed normally in Chk1 hemizygous skin but showed an increased propensity to progress to carcinoma. Thus, complete loss of Chk1 is incompatible with epithelial tumorigenesis, whereas partial loss of function (haploinsufficiency) fosters benign malignant tumor progression. Oncogene (2012) 31, 1366-1375; doi:10.1038/onc.2011.326; published online 1 August 2011	[Tho, L. M.; Libertini, S.; Sansom, O.; Gillespie, D. A.] Univ Glasgow, Beatson Inst Canc Res, Glasgow G61 1BD, Lanark, Scotland; [Tho, L. M.; Rampling, R.; Sansom, O.; Gillespie, D. A.] Univ Glasgow, Coll Med Vet & Life Sci, Glasgow G61 1BD, Lanark, Scotland	Beatson Institute; University of Glasgow; University of Glasgow	Gillespie, DA (corresponding author), Univ Glasgow, Beatson Inst Canc Res, Garscube Estate,Switchback Rd, Glasgow G61 1BD, Lanark, Scotland.	d.gillespie@beatson.gla.ac.uk	Tho, Lye Mun/A-1232-2011; Tho, Lye Mun/X-1745-2019; Gillespie, David/R-4771-2019; Libertini, Silvana/A-3531-2011	Gillespie, David/0000-0002-6338-0544; Libertini, Silvana/0000-0003-2633-1564; Sansom, Owen J./0000-0001-9540-3010	Cancer Research UK (CR-UK); Marie Curie EU; Royal College of Radiologists; CRUK: Royal College of Radiologists; Marie Curie fellowship; Cancer Research UK [12481] Funding Source: researchfish	Cancer Research UK (CR-UK)(Cancer Research UK); Marie Curie EU(European Commission); Royal College of Radiologists; CRUK: Royal College of Radiologists; Marie Curie fellowship(European Commission); Cancer Research UK(Cancer Research UK)	We thank Cancer Research UK (CR-UK), Marie Curie EU and the Royal College of Radiologists for financial support, Drs S Elledge, J Rosen and M Lam for the kind gift of reagents, as well as Dr G Inman for constructive comments on the manuscript. LMT was the recipient of a joint CRUK: Royal College of Radiologists fellowship and SL was the recipient of a Marie Curie fellowship.	Abel EL, 2009, NAT PROTOC, V4, P1350, DOI 10.1038/nprot.2009.120; Ashwell S, 2008, EXPERT OPIN INV DRUG, V17, P1331, DOI [10.1517/13543784.17.9.1331, 10.1517/13543784.17.9.1331 ]; Bartek J, 2003, CANCER CELL, V3, P421, DOI 10.1016/S1535-6108(03)00110-7; Bartkova J, 2006, NATURE, V444, P633, DOI 10.1038/nature05268; Bolderson E, 2009, CLIN CANCER RES, V15, P6314, DOI 10.1158/1078-0432.CCR-09-0096; Braun KM, 2003, DEVELOPMENT, V130, P5241, DOI 10.1242/dev.00703; Di Micco R, 2006, NATURE, V444, P638, DOI 10.1038/nature05327; Fishler T, 2010, ONCOGENE, V29, P4007, DOI 10.1038/onc.2010.163; Greenow KR, 2009, ONCOGENE, V28, P1443, DOI 10.1038/onc.2008.482; Hoeijmakers JHJ, 2009, NEW ENGL J MED, V361, P1475, DOI 10.1056/NEJMra0804615; Indra AK, 1999, NUCLEIC ACIDS RES, V27, P4324, DOI 10.1093/nar/27.22.4324; Jaks V, 2008, NAT GENET, V40, P1291, DOI 10.1038/ng.239; Kangsamaksin T, 2007, MOL CARCINOGEN, V46, P579, DOI 10.1002/mc.20355; Kemp CJ, 2005, SEMIN CANCER BIOL, V15, P460, DOI 10.1016/j.semcancer.2005.06.003; Lam MH, 2004, CANCER CELL, V6, P45, DOI 10.1016/j.ccr.2004.06.015; Li LH, 2010, SCIENCE, V327, P542, DOI 10.1126/science.1180794; Liu QH, 2000, GENE DEV, V14, P1448; McLean GW, 2004, GENE DEV, V18, P2998, DOI 10.1101/gad.316304; Mulherkar R, 2003, ONCOGENE, V22, P1936, DOI 10.1038/sj.onc.1206229; Niida H, 2010, EMBO J, V29, P3558, DOI 10.1038/emboj.2010.218; Snippert HJ, 2010, SCIENCE, V327, P1385, DOI 10.1126/science.1184733; Syljuasen RG, 2005, MOL CELL BIOL, V25, P3553, DOI 10.1128/MCB.25.9.3553-3562.2005; Takai H, 2000, GENE DEV, V14, P1439; Toledo LI, 2008, GENE DEV, V22, P297, DOI 10.1101/gad.452308; Vogelstein B, 2004, NAT MED, V10, P789, DOI 10.1038/nm1087; Zaugg K, 2007, P NATL ACAD SCI USA, V104, P3805, DOI 10.1073/pnas.0611584104	26	31	33	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR	2012	31	11					1366	1375		10.1038/onc.2011.326	http://dx.doi.org/10.1038/onc.2011.326			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	912FL	21804609				2022-12-17	WOS:000301780000004
J	Li, C; Fan, S; Owonikoko, TK; Khuri, FR; Sun, SY; Li, R				Li, C.; Fan, S.; Owonikoko, T. K.; Khuri, F. R.; Sun, S-Y; Li, R.			Oncogenic role of EAPII in lung cancer development and its activation of the MAPK-ERK pathway	ONCOGENE			English	Article						EAPII; MAPK-ERK pathway; NSCLC	RECEPTOR-ASSOCIATED FACTORS; NONSMALL CELL; CYCLIN D1; TTRAP; GENE; EXPRESSION; PROTEIN; ETS1; MYC; AMPLIFICATION	Cancer progression involves multiple complex and interdependent steps, including progressive proliferation, angiogenesis and metastases. The complexity of these processes requires a comprehensive elucidation of the integrated signaling networks for better understanding. EAPII interacts with multiple cancer-related proteins, but its biological significance in cancer development remains unknown. In this report we identified the elevated level of EAPII protein in non-small-cell lung carcinoma (NSCLC) patients and NSCLC cell lines in culture. The oncogenic role of EAPII in lung cancer development was demonstrated using NSCLC cells with genetic manipulations that influence EAPII expression: EAPII overexpression increases proliferation of NSCLC cells with an accelerated transition of cell cycle and facilitates xenograft tumor growth in vivo; EAPII knockdown results in apoptosis of NSCLC cells and reduces xenograft tumor formation. To further explore the mechanism of EAPII's oncogenic role in lung cancer development and to elucidate the potential signaling pathway(s) that EAPII may impact, we employed antibody array to investigate the alternation of the major signaling pathways in NSCLC cells with altered EAPII level. We found that EAPII overexpression significantly activated Raf1 and ERK1/2, but not c-Jun N-terminal kinase and p38 pathways. Consistently, the protein and mRNA levels of MYC and cyclin D1, which are targets of the mitogen-activated protein kinase/extracellular signal-regulated kinase (MAPK-ERK) pathway, are significantly increased by EAPII overexpression. Taken together, we demonstrated that EAPII is an oncogenic factor and the activation of MAPK-ERK signaling pathway by EAPII may contribute to lung cancer development. Oncogene (2011) 30, 3802-3812; doi:10.1038/onc.2011.94; published online 11 April 2011	[Li, C.; Fan, S.; Owonikoko, T. K.; Khuri, F. R.; Sun, S-Y; Li, R.] Emory Univ, Sch Med, Dept Hematol & Med Oncol, Winship Canc Inst, Atlanta, GA 30322 USA	Emory University	Li, R (corresponding author), Emory Univ, Sch Med, Dept Hematol & Med Oncol, Winship Canc Inst, Room 4090,1365C Clifton Rd, Atlanta, GA 30322 USA.	ssun@emory.edu; r.li@emory.edu	Khuri, Fadlo R./AAU-4942-2020; Owonikoko, Taofeek/C-3012-2011	Khuri, Fadlo R./0000-0002-8638-7618; Owonikoko, Taofeek/0000-0002-7724-7728	National Institutes of Health [K22CA109577, RO1CA118450]; Department of Hematology and Medical Oncology, Emory University; NATIONAL CANCER INSTITUTE [R01CA118450, K23CA164015, K22CA109577] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Department of Hematology and Medical Oncology, Emory University; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Drs JD Minna (University of Texas Southwestern Medical Center, Dallas) and R Lotan (University of Texas MD Anderson Cancer Center, Houston) for providing HBEC3KT and BEAS2B cell lines and Biomolecular Computing Resource (BIMCORE) at the Emory University School of Medicine for assistance with antibody array analysis. This work was supported in part by National Institutes of Health grants K22CA109577 (RL) and RO1CA118450 (SYS), a start-up fund from the Department of Hematology and Medical Oncology, Emory University (RL).	Aktas H, 1997, MOL CELL BIOL, V17, P3850, DOI 10.1128/MCB.17.7.3850; Blanco R, 2009, HUM MUTAT, V30, P1199, DOI 10.1002/humu.21028; Borczuk Alain C, 2009, Proc Am Thorac Soc, V6, P152, DOI 10.1513/pats.200807-076LC; Chang F, 2003, LEUKEMIA, V17, P1263, DOI 10.1038/sj.leu.2402945; Eilers M, 2008, GENE DEV, V22, P2755, DOI 10.1101/gad.1712408; Esguerra CV, 2007, DEVELOPMENT, V134, P4381, DOI 10.1242/dev.000026; Fernandez-Capetillo O, 2004, DNA REPAIR, V3, P959, DOI 10.1016/j.dnarep.2004.03.024; Gautschi O, 2007, LUNG CANCER, V55, P1, DOI 10.1016/j.lungcan.2006.09.024; Hubner A, 2006, DEV CELL, V11, P752, DOI 10.1016/j.devcel.2006.11.006; Johnson L, 2001, NATURE, V410, P1111, DOI 10.1038/35074129; Karnoub AE, 2008, NAT REV MOL CELL BIO, V9, P517, DOI 10.1038/nrm2438; KAUFMANN SH, 1993, CANCER RES, V53, P3976; Lallemand-Breitenbach V, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a000661; Ledesma FC, 2009, NATURE, V461, P674, DOI 10.1038/nature08444; Lee HY, 2008, ARTERIOSCL THROM VAS, V28, P112, DOI 10.1161/ATVBAHA.107.153304; Lee JT, 2010, CELL CYCLE, V9, P857, DOI 10.4161/cc.9.5.11175; Li CY, 2010, J BIOL CHEM, V285, P16096, DOI 10.1074/jbc.M109.072694; Li RH, 1999, P NATL ACAD SCI USA, V96, P3876, DOI 10.1073/pnas.96.7.3876; LITTLE CD, 1983, NATURE, V306, P194, DOI 10.1038/306194a0; Lois C, 2002, SCIENCE, V295, P868, DOI 10.1126/science.1067081; Mitani S, 2001, CLIN EXP MED, V1, P105, DOI 10.1007/s10238-001-8020-5; Molina JR, 2008, MAYO CLIN PROC, V83, P584, DOI 10.4065/83.5.584; Nagakubo D, 1997, BIOCHEM BIOPH RES CO, V231, P509, DOI 10.1006/bbrc.1997.6132; Pei HP, 2005, CANCER RES, V65, P7205, DOI 10.1158/0008-5472.CAN-04-3566; Pei HP, 2003, ONCOGENE, V22, P2699, DOI 10.1038/sj.onc.1206374; Pype S, 2000, J BIOL CHEM, V275, P18586, DOI 10.1074/jbc.M000531200; Rapp UR, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006029; Rodrigues-Lima F, 2001, BIOCHEM BIOPH RES CO, V285, P1274, DOI 10.1006/bbrc.2001.5328; Salomoni P, 2009, CELL DEATH DIFFER, V16, P1083, DOI 10.1038/cdd.2009.63; Sanchez-Cespedes M, 2009, CLIN TRANSL ONCOL, V11, P263, DOI 10.1007/s12094-009-0353-7; SCHAUER IE, 1994, P NATL ACAD SCI USA, V91, P7827, DOI 10.1073/pnas.91.16.7827; Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73; Singhal S, 2008, LUNG CANCER, V60, P313, DOI 10.1016/j.lungcan.2008.03.007; Wang XR, 2008, CANCER RES, V68, P7409, DOI 10.1158/0008-5472.CAN-08-1522; Weinstein IB, 2008, CANCER RES, V68, P3077, DOI 10.1158/0008-5472.CAN-07-3293; Xu GL, 2008, BIOCHEM BIOPH RES CO, V375, P395, DOI 10.1016/j.bbrc.2008.08.023; Zhang Zheng-Bin, 2007, Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi, V25, P654; Zucchelli S, 2009, CELL DEATH DIFFER, V16, P428, DOI 10.1038/cdd.2008.169	38	31	33	1	13	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2011	30	35					3802	3812		10.1038/onc.2011.94	http://dx.doi.org/10.1038/onc.2011.94			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	814TZ	21478903	Green Published, hybrid			2022-12-17	WOS:000294481400007
J	Chen, R; Liliental, JE; Kowalski, PE; Lu, Q; Cohen, SN				Chen, R.; Liliental, J. E.; Kowalski, P. E.; Lu, Q.; Cohen, S. N.			Regulation of transcription of hypoxia-inducible factor-1 alpha (HIF-1 alpha) by heat shock factors HSF2 and HSF4	ONCOGENE			English	Article						heat shock factor; heat shock element; angiogenesis; HSE; VEGF; HIF-1 alpha	ENDOTHELIAL GROWTH-FACTOR; PROTEOTOXIC STRESS; FACTOR FAMILY; RESPONSE ELEMENT; LENS DEVELOPMENT; EXPRESSION; CELLS; GENE; INDUCTION; PROMOTER	Hypoxia-inducible factor-1 alpha (HIF-1 alpha) is a principal regulator of angiogenesis and other cellular responses to hypoxic stress in both normal and tumor cells. To identify novel mechanisms that regulate expression of HIF-1 alpha, we designed a genome-wide screen for expressed sequence tags (ESTs) that when transcribed in the antisense direction increase production of the HIF-1 alpha target, vascular endothelial growth factor (VEGF), in human breast cancer cells. We discovered that heat shock factor (HSF) proteins 2 and 4-which previously have been implicated in the control of multiple genes that modulate cell growth and differentiation and protect against effects of environmental and cellular stresses-function together to maintain a steady state level of HIF-1 alpha transcription and VEGF production in these cells. We show both HSFs bind to discontinuous heat shock element (HSE) sequences we identified in the HIF-1 alpha promoter region and that downregulation of either HSF activates transcription of HIF-1 alpha. We further demonstrate that HSF2 and HSF4 displace each other from HSF/HSE complexes in the HIF-1 alpha promoter so that HIF-1 alpha transcription is also activated by overexpression of either HSFs. These results argue that HSF2 and HSF4 regulate transcription of HIF-1 alpha and that a critical balance between these HSF is required to maintain HIF-alpha expression in a repressed state. Our findings reveal a previously unsuspected role for HSFs in control of VEGF and other genes activated by canonical HIF-1 alpha-mediated signaling. Oncogene (2011) 30, 2570-2580; doi:10.1038/onc.2010.623; published online 24 January 2011	[Chen, R.; Liliental, J. E.; Kowalski, P. E.; Lu, Q.; Cohen, S. N.] Stanford Univ, Dept Genet, Sch Med, Stanford, CA 94305 USA; [Cohen, S. N.] Stanford Univ, Dept Med, Sch Med, Stanford, CA 94305 USA	Stanford University; Stanford University	Cohen, SN (corresponding author), Stanford Univ, Dept Genet, Sch Med, 300 Pasteur Dr, Stanford, CA 94305 USA.	sncohen@stanford.edu			Kwoh-Ting Li Professorship; National Foundation for Cancer Research (NFCR)	Kwoh-Ting Li Professorship; National Foundation for Cancer Research (NFCR)	The study was supported by funds from the Kwoh-Ting Li Professorship to SNC, and by a grant from the National Foundation for Cancer Research (NFCR) to SNC.	Akerfelt M, 2008, P NATL ACAD SCI USA, V105, P11224, DOI 10.1073/pnas.0800620105; Akerfelt M, 2007, ANN NY ACAD SCI, V1113, P15, DOI 10.1196/annals.1391.005; Bos R, 2001, JNCI-J NATL CANCER I, V93, P309, DOI 10.1093/jnci/93.4.309; Brahimi-Horn MC, 2007, BIOCHEM PHARMACOL, V73, P450, DOI 10.1016/j.bcp.2006.10.013; Busca R, 2005, J CELL BIOL, V170, P49, DOI 10.1083/jcb.200501067; Chang YH, 2006, GENE DEV, V20, P836, DOI 10.1101/gad.366906; Chi NC, 2004, CARDIOVASC RES, V61, P437, DOI 10.1016/j.cardiores.2003.11.033; Fraisl P, 2009, DEV CELL, V16, P167, DOI 10.1016/j.devcel.2009.01.003; Fujimoto M, 2004, EMBO J, V23, P4297, DOI 10.1038/sj.emboj.7600435; Fujimoto M, 2008, J BIOL CHEM, V283, P29961, DOI 10.1074/jbc.M804629200; Fujimoto M, 2010, FEBS J, V277, P4112, DOI 10.1111/j.1742-4658.2010.07827.x; Fukumura D, 1998, CELL, V94, P715, DOI 10.1016/S0092-8674(00)81731-6; Isaacs JS, 2002, J BIOL CHEM, V277, P29936, DOI 10.1074/jbc.M204733200; Jiang BH, 1997, CANCER RES, V57, P5328; Loison F, 2006, BIOCHEM J, V395, P223, DOI 10.1042/BJ20051190; Lu Q, 2004, P NATL ACAD SCI USA, V101, P17246, DOI 10.1073/pnas.0407794101; Mathew A, 2001, MOL CELL BIOL, V21, P7163, DOI 10.1128/MCB.21.21.7163-7171.2001; Mazure NM, 1996, CANCER RES, V56, P3436; Mazure NM, 1997, BLOOD, V90, P3322, DOI 10.1182/blood.V90.9.3322; Min JN, 2004, GENESIS, V40, P205, DOI 10.1002/gene.20087; Minet E, 1999, FEBS LETT, V460, P251, DOI 10.1016/S0014-5793(99)01359-9; Morimoto RI, 2008, GENE DEV, V22, P1427, DOI 10.1101/gad.1657108; Murphy LA, 2008, EXP CELL RES, V314, P2224, DOI 10.1016/j.yexcr.2008.04.015; Nakai A, 1997, MOL CELL BIOL, V17, P469, DOI 10.1128/MCB.17.1.469; Nardinocchi L, 2009, BBA-MOL CELL RES, V1793, P368, DOI 10.1016/j.bbamcr.2008.10.013; Ng YS, 2006, EXP CELL RES, V312, P527, DOI 10.1016/j.yexcr.2005.11.008; Olenyuk BZ, 2004, P NATL ACAD SCI USA, V101, P16768, DOI 10.1073/pnas.0407617101; Ostling P, 2007, J BIOL CHEM, V282, P7077, DOI 10.1074/jbc.M607556200; Page EL, 2002, J BIOL CHEM, V277, P48403, DOI 10.1074/jbc.M209114200; Pipinikas C, 2008, BIOMARKERS, V13, P680, DOI 10.1080/13547500802591992 ; Pirkkala L, 2001, FASEB J, V15, P1118, DOI 10.1096/fj00-0294rev; Pore N, 2004, MOL BIOL CELL, V15, P4841, DOI 10.1091/mbc.E04-05-0374; Pouyssegur J, 2006, NATURE, V441, P437, DOI 10.1038/nature04871; Sandqvist A, 2009, MOL BIOL CELL, V20, P1340, DOI 10.1091/mbc.E08-08-0864; Schafer C, 1999, AM J PHYSIOL-CELL PH, V277, pC1032; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Somasundaram T, 2004, J BIOL CHEM, V279, P44497, DOI 10.1074/jbc.M405813200; Tsuzuki Y, 2000, CANCER RES, V60, P6248; Wartenberg M, 2001, FASEB J, V15, P995, DOI 10.1096/fj.00-0350com; Xing HY, 2005, SCIENCE, V307, P421, DOI 10.1126/science.1106478; Yamamoto N, 2009, FEBS J, V276, P1962, DOI 10.1111/j.1742-4658.2009.06923.x; Zhang J, 2008, J BIOL CHEM, V283, P7464, DOI 10.1074/jbc.M707122200; Zhang Y, 2001, J CELL BIOCHEM, V82, P692, DOI 10.1002/jcb.1191	43	31	31	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN	2011	30	22					2570	2580		10.1038/onc.2010.623	http://dx.doi.org/10.1038/onc.2010.623			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	771ZE	21258402				2022-12-17	WOS:000291198400008
J	Zhi, HY; Hou, SW; Li, RS; Basir, Z; Xiang, Q; Szabo, A; Chen, G				Zhi, H-Y; Hou, S-W; Li, R-S; Basir, Z.; Xiang, Q.; Szabo, A.; Chen, G.			PTPH1 cooperates with vitamin D receptor to stimulate breast cancer growth through their mutual stabilization	ONCOGENE			English	Article						PTPH1; VDR; VDR cytoplasmic translocation; mutual stabilization; breast cancer	PROTEIN-TYROSINE-PHOSPHATASE; RETINOID-X-RECEPTOR; ESTROGEN-RECEPTOR; NUCLEAR IMPORT; EXPRESSION; CELLS; TRANSFORMATION; ACTIVATION; RAS; 1B	Tyrosine phosphorylation is tightly regulated by protein tyrosine kinases (PTKs) and protein tyrosine phosphatases (PTPs), and has a critical role in malignant transformation and progression. Although PTKs have a well-established role in regulating breast cancer growth, contribution of PTPs remains mostly unknown. Here, we report that the tyrosine phosphatase PTPH1 stimulates breast cancer growth through regulating vitamin D receptor (VDR) expression. PTPH1 was shown to be overexpressed in 49% of primary breast cancer and levels of its protein expression positively correlate with the clinic metastasis, suggesting its oncogenic activity. Indeed, PTPH1 promotes breast cancer growth by a mechanism independent of its phosphatase activity, but dependent of its stimulatory effect on the nuclear receptor VDR protein expression and depletion of induced VDR abolishes the PTPH1 oncogenic activity. Additional analyses showed that PTPH1 binds VDR and increases its cytoplasmic accumulation, leading to their mutual stabilization and stable expression of a nuclear localization-deficient VDR abolishes the growth-inhibitory activity of the receptor independent of 1,25-dihydroxyvitamin D3. These results reveal a new paradigm in which a PTP may stimulate breast cancer growth through increasing cytoplasmic translocation of a nuclear receptor, leading to their mutual stabilization. Oncogene (2011) 30, 1706-1715; doi:10.1038/onc.2010.543; published online 29 November 2010	[Zhi, H-Y; Hou, S-W; Chen, G.] Med Coll Wisconsin, Dept Pharmacol & Toxicol, Milwaukee, WI 53226 USA; [Li, R-S; Basir, Z.] Med Coll Wisconsin, Dept Pathol, Milwaukee, WI 53226 USA; [Xiang, Q.; Szabo, A.] Med Coll Wisconsin, Div Biostat, Milwaukee, WI 53226 USA; [Chen, G.] Zablocki Vet Affairs Med Ctr, Res Serv, Milwaukee, WI USA	Medical College of Wisconsin; Medical College of Wisconsin; Medical College of Wisconsin	Chen, G (corresponding author), Med Coll Wisconsin, Dept Pharmacol & Toxicol, 8701 Watertown Plank Rd, Milwaukee, WI 53226 USA.	gchen@mcw.edu	Szabo, Aniko/F-9656-2012	Szabo, Aniko/0000-0002-8129-0614	National Institutes of Health [2R01 CA91576]; Department of Veterans Affairs; Cancer Center of Medical College of Wisconsin; NATIONAL CANCER INSTITUTE [R01CA091576] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Department of Veterans Affairs(US Department of Veterans Affairs); Cancer Center of Medical College of Wisconsin; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This study was supported by grants from National Institutes of Health (2R01 CA91576), Department of Veterans Affairs (Merit Review), and Cancer Center of Medical College of Wisconsin (GC). We thank Drs Nicholas K Tonks, JoEllen Welsh, Jiahuai Han, Leonard Freedman, David Shapiro, Lawrence A Donehower and Carol E Lange for providing various reagents that made this work possible. We also appreciate Justin Reitsman and Dr Xiaomei Qi for the technical support and Chen's lab members for suggestions and discussions.	Ardini E, 2000, ONCOGENE, V19, P4979, DOI 10.1038/sj.onc.1203869; Arias-Romero LE, 2009, CANCER RES, V69, P4582, DOI 10.1158/0008-5472.CAN-08-4001; Bentires-Alj M, 2007, CANCER RES, V67, P2420, DOI 10.1158/0008-5472.CAN-06-4610; BROWNSHIMER S, 1992, CANCER RES, V52, P478; Bulavin DV, 2004, NAT GENET, V36, P343, DOI 10.1038/ng1317; Campbell MJ, 2000, ONCOGENE, V19, P5091, DOI 10.1038/sj.onc.1203888; CHEN G, 1994, BIOCHEM PHARMACOL, V47, P1079, DOI 10.1016/0006-2952(94)90420-0; Conzen SD, 2008, MOL ENDOCRINOL, V22, P2215, DOI 10.1210/me.2007-0421; Garay E, 2007, J CELL PHYSIOL, V213, P816, DOI 10.1002/jcp.21150; Hou SW, 2010, CANCER RES, V70, P2901, DOI 10.1158/0008-5472.CAN-09-3229; Kim S, 2005, J BONE MINER RES, V20, P305, DOI 10.1359/JBMR.041112; Korkola JE, 2003, CANCER RES, V63, P7167; Kure S, 2009, CANCER EPIDEM BIOMAR, V18, P2765, DOI 10.1158/1055-9965.EPI-09-0490; Lange CA, 2000, P NATL ACAD SCI USA, V97, P1032, DOI 10.1073/pnas.97.3.1032; Li QP, 2007, J BIOL CHEM, V282, P1544, DOI 10.1074/jbc.M604052200; Liu F, 1998, MOL CELL BIOL, V18, P250, DOI 10.1128/MCB.18.1.250; Loesch M, 2010, J BIOL CHEM, V285, P15149, DOI 10.1074/jbc.M110.105429; Lu XB, 2005, GENE DEV, V19, P1162, DOI 10.1101/gad.1291305; Maruyama R, 2006, CANCER RES, V66, P4574, DOI 10.1158/0008-5472.CAN-05-2562; Menezes RJ, 2008, CANCER EPIDEM BIOMAR, V17, P1104, DOI 10.1158/1055-9965.EPI-07-2713; MHUIRCHEARTAIGH JN, 2006, BRIT J SURG, V95, P827; Obrero M, 2002, J BIOL CHEM, V277, P45695, DOI 10.1074/jbc.M208092200; Ostman A, 2006, NAT REV CANCER, V6, P307, DOI 10.1038/nrc1837; Prufer K, 2002, MOL ENDOCRINOL, V16, P961, DOI 10.1210/me.16.5.961; Prufer K, 2002, MOL ENDOCRINOL, V16, P1738, DOI 10.1210/me.2001-0345; Prufer K, 2000, J BIOL CHEM, V275, P41114, DOI 10.1074/jbc.M003791200; Qi XM, 2006, CANCER RES, V66, P7540, DOI 10.1158/0008-5472.CAN-05-4639; Qi XM, 2004, J BIOL CHEM, V279, P6769, DOI 10.1074/jbc.M311492200; Qi XM, 2002, J BIOL CHEM, V277, P25884, DOI 10.1074/jbc.M203039200; Racz A, 1999, J BIOL CHEM, V274, P19352, DOI 10.1074/jbc.274.27.19352; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Tang J, 2005, J BIOL CHEM, V280, P23910, DOI 10.1074/jbc.M500699200; Wang ZH, 2004, SCIENCE, V304, P1164, DOI 10.1126/science.1096096; Ward JO, 2001, BLOOD, V98, P3290, DOI 10.1182/blood.V98.12.3290; WIENER JR, 1994, J NATL CANCER I, V86, P372, DOI 10.1093/jnci/86.5.372; Yang LM, 2001, J CELL PHYSIOL, V188, P383, DOI 10.1002/jcp.1125; YANG Q, 1991, P NATL ACAD SCI USA, V88, P5949, DOI 10.1073/pnas.88.14.5949; Yasmin R, 2005, J BIOL CHEM, V280, P40152, DOI 10.1074/jbc.M507708200; Yip SS, 2000, INT J CANCER, V88, P363, DOI 10.1002/1097-0215(20001101)88:3<363::AID-IJC7>3.0.CO;2-4; Yu DH, 2000, ONCOGENE, V19, P6115, DOI 10.1038/sj.onc.1203972; Zhang SH, 1999, J BIOL CHEM, V274, P17806, DOI 10.1074/jbc.274.25.17806; Zinser GM, 2003, MOL CELL ENDOCRINOL, V200, P67, DOI 10.1016/S0303-7207(02)00416-1	42	31	34	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2011	30	14					1706	1715		10.1038/onc.2010.543	http://dx.doi.org/10.1038/onc.2010.543			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	746IS	21119599	Green Accepted			2022-12-17	WOS:000289239400008
J	Chen, TH; Chan, PC; Chen, CL; Chen, HC				Chen, T-H; Chan, P-C; Chen, C-L; Chen, H-C			Phosphorylation of focal adhesion kinase on tyrosine 194 by Met leads to its activation through relief of autoinhibition	ONCOGENE			English	Article						FAK; Met; RTK; FERM; autoinhibition	GROWTH-FACTOR; FERM DOMAIN; IN-VITRO; PROTEIN; IDENTIFICATION; PP125(FAK); CELLS; FAK; ASSOCIATION; PP60(SRC)	Focal adhesion kinase (FAK) has a crucial role in integration of signals from integrins and growth factor receptors. In this study, we demonstrate that growth factor receptors including hepatocyte growth factor receptor Met, epidermal growth factor receptor, and platelet-derived growth factor receptor directly phosphorylate FAK on Tyr194 in the FERM domain (band 4.1 and ezrin/radixin/moesin homology domain). Upon binding to Met or phosphoinositides, FAK may undergo conformational changes, which renders Tyr194 accessible for phosphorylation. Substitution of Tyr194 with Phe significantly suppresses the activation of FAK by Met. In contrast, substitution of Tyr194 with Glu (Y194E substitution) leads to constitutive activation of FAK. The phosphorylation of FAK on Tyr194 may cause conformational changes in the FERM domain, which disrupts the intramolecular inhibitory interaction between the FERM and kinase domains of FAK. Moreover, substitution of the basic residues in the (216)KAKTLRK(222) patch in the FERM domain with Ala antagonizes the effect of the Y194E substitution on FAK activation, thus suggesting that the interactions between the phosphorylated Tyr194 and the basic resides in the (216)KAKTLRK(222) patch may allow FAK to be activated through relief of its autoinhibition. Collectively, this study provides the first example to explain how FAK is activated by receptor tyrosine kinases. Oncogene (2011) 30, 153-166; doi:10.1038/onc.2010.398; published online 30 August 2010	[Chen, T-H; Chen, C-L; Chen, H-C] Natl Chung Hsing Univ, Dept Life Sci, Taichung 40227, Taiwan; [Chan, P-C; Chen, H-C] Natl Chung Hsing Univ, Grad Inst Biomed Sci, Taichung 40227, Taiwan; [Chen, H-C] China Med Univ, Dept Nutr, Taichung, Taiwan	National Chung Hsing University; National Chung Hsing University; China Medical University Taiwan	Chen, HC (corresponding author), Natl Chung Hsing Univ, Dept Life Sci, 250 Kuo Kuang Rd, Taichung 40227, Taiwan.	hcchen@nchu.edu.tw			National Science Council, Taiwan [NSC97-3112-B-005-001, NSC97-2628-B-005-001-MY3]; National Health Research Institutes, Taiwan [NHRI-EX97-9730BI]	National Science Council, Taiwan(Ministry of Science and Technology, Taiwan); National Health Research Institutes, Taiwan(National Health Research Institutes - Taiwan)	This work is supported by Grants NSC97-3112-B-005-001 and NSC97-2628-B-005-001-MY3 from the National Science Council, Taiwan and NHRI-EX97-9730BI from the National Health Research Institutes, Taiwan.	Cai XM, 2008, MOL CELL BIOL, V28, P201, DOI 10.1128/MCB.01324-07; CALALB MB, 1995, MOL CELL BIOL, V15, P954; Chan PC, 2002, J BIOL CHEM, V277, P50373, DOI 10.1074/jbc.M204691200; Chen HC, 1998, J BIOL CHEM, V273, P25777, DOI 10.1074/jbc.273.40.25777; Chen LM, 2000, J NEUROSCI, V20, P3776, DOI 10.1523/JNEUROSCI.20-10-03776.2000; Chen RY, 2001, NAT CELL BIOL, V3, P439, DOI 10.1038/35074500; Chen SY, 2006, MOL CELL BIOL, V26, P5155, DOI 10.1128/MCB.02186-05; COBB BS, 1994, MOL CELL BIOL, V14, P147, DOI 10.1128/MCB.14.1.147; Cohen LA, 2005, J BIOL CHEM, V280, P8197, DOI 10.1074/jbc.M412021200; Cooper LA, 2003, MOL CELL BIOL, V23, P8030, DOI 10.1128/MCB.23.22.8030-8041.2003; Dunty JM, 2004, MOL CELL BIOL, V24, P5353, DOI 10.1128/MCB.24.12.5353-5368.2004; EIDE BL, 1995, MOL CELL BIOL, V15, P2819; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; HANKS SK, 1992, P NATL ACAD SCI USA, V89, P8487, DOI 10.1073/pnas.89.18.8487; HILDEBRAND JD, 1993, J CELL BIOL, V123, P993, DOI 10.1083/jcb.123.4.993; Jacamo RO, 2005, BIOCHEM BIOPH RES CO, V334, P1299, DOI 10.1016/j.bbrc.2005.07.034; Lai JF, 2000, J BIOL CHEM, V275, P7474, DOI 10.1074/jbc.275.11.7474; Lehr S, 1999, BIOCHEMISTRY-US, V38, P151, DOI 10.1021/bi9818265; Lehr S, 2000, BIOCHEMISTRY-US, V39, P10898, DOI 10.1021/bi000982k; Lietha D, 2007, CELL, V129, P1177, DOI 10.1016/j.cell.2007.05.041; MATSUMOTO K, 1994, J BIOL CHEM, V269, P31807; McLean GW, 2005, NAT REV CANCER, V5, P505, DOI 10.1038/nrc1647; Mitra SK, 2005, NAT REV MOL CELL BIO, V6, P56, DOI 10.1038/nrm1549; Poullet P, 2001, J BIOL CHEM, V276, P37686, DOI 10.1074/jbc.M106175200; RANKIN S, 1994, J BIOL CHEM, V269, P704; SCHALLER MD, 1995, J CELL BIOL, V130, P1181, DOI 10.1083/jcb.130.5.1181; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; Serrels B, 2007, NAT CELL BIOL, V9, P1046, DOI 10.1038/ncb1626; Sieg DJ, 2000, NAT CELL BIOL, V2, P249, DOI 10.1038/35010517; XING Z, 1994, MOL BIOL CELL, V5, P413, DOI 10.1091/mbc.5.4.413	31	31	31	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2011	30	2					153	166		10.1038/onc.2010.398	http://dx.doi.org/10.1038/onc.2010.398			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	709LG	20802513				2022-12-17	WOS:000286438900004
J	Li, X; Martinez-Ferrer, M; Botta, V; Uwamariya, C; Banerjee, J; Bhowmick, NA				Li, X.; Martinez-Ferrer, M.; Botta, V.; Uwamariya, C.; Banerjee, J.; Bhowmick, N. A.			Epithelial Hic-5/ARA55 expression contributes to prostate tumorigenesis and castrate responsiveness	ONCOGENE			English	Article						Hic-5/ARA55; c-myc; AR; TGF-beta; prostate cancer; castration	GROWTH-FACTOR-BETA; ANDROGEN RECEPTOR COACTIVATORS; CANCER CELLS; CELLULAR SENESCENCE; TUMOR PROGRESSION; SIGNALING AXIS; STROMAL CELLS; LIM PROTEIN; C-MYC; HIC-5	Stromal-epithelial interactions dictate prostate tumorigenesis and response to castration. Hydrogen peroxide-inducible clone 5 (Hic-5/ARA55) is a transforming growth factor-beta (TGF-beta)-induced coactivator of androgen receptor (AR) expressed in the prostate stroma. Interestingly, following castration, we identified epithelial expression of Hic-5/ARA55 in mouse and human prostate tissues. To determine the role of epithelial Hic-5 in prostate cancer progression and castration responsiveness, we compared LNCaP cells having Hic-5 stably expressed with the parental LNCaP cells following tissue recombination xenografts with mouse prostate stromal cells. We previously identified knocking out prostate stromal TGF-beta signaling potentiated castrate-resistant prostate tumors, in a Wnt-dependent manner. The LNCaP chimeric tumors containing prostate fibroblasts conditionally knocked out for the TGF-beta type II receptor (Tgfbr2-KO) resulted in larger, more invasive, and castration-resistant tumors compared those with floxed (control) stromal cells. However, the LNCaP-Hic5 associated with Tgfbr2-KO fibroblasts generated chimeric tumors with reduced tumor volume, lack of invasion and restored castration dependence. Neutralization of canonical Wnt signaling is shown to reduce prostate tumor size and restore regression following castration. Thus, we hypothesized that epithelial Hic-5/ARA55 expression negatively regulated Wnt signaling. The mechanism of the Hic-5/ARA55 effects on castration was determined by analysis of the c-myc promoter. C-myc luciferase reporter activity suggested Hic-5/ARA55 expression inhibited c-myc activity by beta-catenin. Sequential ChIP analysis indicated beta-catenin and T-cell-specific 4 (TCF4) bound the endogenous c-myc promoter in the absence of Hic-5 expression. However, the formation of a TCF4/Hic-5 repressor complex inhibited c-myc promoter activity, by excluding beta-catenin binding with TCF4 on the promoter. The data indicate Hic-5/ARA55 expression in response to castration-enabled epithelial regression through the repression of c-myc gene at the chromatin level. Oncogene (2011) 30, 167-177; doi:10.1038/onc.2010.400; published online 6 September 2010	[Bhowmick, N. A.] Cedars Sinai Med Ctr, Urooncol Res Program, Samuel Oschin Comprehens Canc Inst, Los Angeles, CA 90048 USA; [Bhowmick, N. A.] Cedars Sinai Med Ctr, Dept Med, Los Angeles, CA 90048 USA; [Li, X.; Martinez-Ferrer, M.; Botta, V.; Uwamariya, C.; Banerjee, J.] Vanderbilt Univ, Sch Med, Vanderbilt Ingram Canc Ctr, Nashville, TN 37212 USA; [Li, X.; Martinez-Ferrer, M.; Botta, V.; Uwamariya, C.; Banerjee, J.] Vanderbilt Univ, Sch Med, Dept Urol Surg, Nashville, TN 37212 USA	Cedars Sinai Medical Center; Cedars Sinai Medical Center; Vanderbilt University; Vanderbilt University	Bhowmick, NA (corresponding author), Cedars Sinai Med Ctr, Urooncol Res Program, Samuel Oschin Comprehens Canc Inst, 8750 Beverly Blvd,Atrium 103, Los Angeles, CA 90048 USA.	bhowmickn@cshs.org	Bhowmick, Neil/AAA-7302-2019	Bhowmick, Neil/0000-0001-8747-5989; , Xiaohong/0000-0001-5074-193X	Department of Defense [DAMD17-02-1-0063, PC081246]; NIH [CA108646, CA126505]; NATIONAL CANCER INSTITUTE [U54CA126505, R01CA108646] Funding Source: NIH RePORTER	Department of Defense(United States Department of Defense); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Drs Robert Matusik, Roger Jackson and Veronica Placencio for help in the preparation of this paper. The work was supported through Department of Defense (DAMD17-02-1-0063, PC081246) and NIH grants (CA108646, CA126505). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Cancer Institute or the National Institutes of Health.	Ayala G, 2003, CLIN CANCER RES, V9, P4792; Bhowmick NA, 2004, SCIENCE, V303, P848, DOI 10.1126/science.1090922; Chesire DR, 2002, ONCOGENE, V21, P8453, DOI 10.1038/sj.onc.1206049; Chung LWK, 2005, J UROLOGY, V173, P10, DOI 10.1097/01.ju.0000141582.15218.10; Cunha GR, 2008, DIFFERENTIATION, V76, P578, DOI 10.1111/j.1432-0436.2008.00290.x; Drori S, 2005, GENE DEV, V19, P362, DOI 10.1101/gad.1240705; Fujimoto N, 1999, J BIOL CHEM, V274, P8316, DOI 10.1074/jbc.274.12.8316; Fujimoto N, 2001, UROLOGY, V58, P289, DOI 10.1016/S0090-4295(01)01117-7; Fujimoto N, 2007, CANCER INVEST, V25, P32, DOI 10.1080/07357900601130698; Ghogomu SM, 2006, J BIOL CHEM, V281, P1755, DOI 10.1074/jbc.M505869200; GLEAVE M, 1991, CANCER RES, V51, P3753; Guerrero-Santoro J, 2004, J CELL BIOCHEM, V92, P810, DOI 10.1002/jcb.20109; Guo YP, 1999, CANCER RES, V59, P1366; Gurel B, 2008, MODERN PATHOL, V21, p159A; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Heitzer MD, 2007, STEROIDS, V72, P218, DOI 10.1016/j.steroids.2006.11.010; Heitzer MD, 2006, CANCER RES, V66, P7326, DOI 10.1158/0008-5472.CAN-05-2379; Hwang RF, 2008, CANCER RES, V68, P918, DOI 10.1158/0008-5472.CAN-07-5714; Jakowlew SB, 1997, ANTICANCER RES, V17, P1849; Jemal A, 2009, CA-CANCER J CLIN, V59, P225, DOI 10.3322/caac.20006; Johansson A, 2007, PROSTATE, V67, P1664, DOI 10.1002/pros.20657; Kass L, 2007, INT J BIOCHEM CELL B, V39, P1987, DOI 10.1016/j.biocel.2007.06.025; Kaur M, 2010, NEOPLASIA, V12, P415, DOI 10.1593/neo.10188; Kurita T, 2001, CELL DEATH DIFFER, V8, P192, DOI 10.1038/sj.cdd.4400797; Kwok WK, 2005, CANCER RES, V65, P5153, DOI 10.1158/0008-5472.CAN-04-3785; KYPRIANOU N, 1989, MOL ENDOCRINOL, V3, P1515, DOI 10.1210/mend-3-10-1515; Lee SE, 2000, ANTICANCER RES, V20, P417; Li X, 2008, ONCOGENE, V27, P7118, DOI 10.1038/onc.2008.293; Litvinov IV, 2006, P NATL ACAD SCI USA, V103, P15085, DOI 10.1073/pnas.0603057103; Litvinov IV, 2006, PROSTATE, V66, P1329, DOI 10.1002/pros.20483; Lu WY, 2009, EUR J PHARMACOL, V602, P8, DOI 10.1016/j.ejphar.2008.10.053; Mestayer C, 2003, PROSTATE, V56, P192, DOI 10.1002/pros.10229; Miyoshi Y, 2003, PROSTATE, V56, P280, DOI 10.1002/pros.10262; Moon Randall T, 2005, Sci STKE, V2005, pcm1; MUIR GH, 1994, BRIT J CANCER, V69, P130, DOI 10.1038/bjc.1994.21; Mukaratirwa S, 2005, INT J EXP PATHOL, V86, P219, DOI 10.1111/j.0959-9673.2005.00425.x; Mulholland DJ, 2003, ONCOGENE, V22, P5602, DOI 10.1038/sj.onc.1206802; Niu YJ, 2008, P NATL ACAD SCI USA, V105, P12182, DOI 10.1073/pnas.0804700105; Placencio VR, 2008, CANCER RES, V68, P4709, DOI 10.1158/0008-5472.CAN-07-6289; Rahman MM, 2003, P NATL ACAD SCI USA, V100, P5124, DOI 10.1073/pnas.0530097100; Schweizer L, 2008, BMC CELL BIOL, V9, DOI 10.1186/1471-2121-9-4; Shibanuma M, 2004, J CELL BIOCHEM, V91, P633, DOI 10.1002/jcb.10754; SHIBANUMA M, 1994, J BIOL CHEM, V269, P26767; Taylor RA, 2008, CURR CANCER DRUG TAR, V8, P490, DOI 10.2174/156800908785699351; Thomas SM, 1999, J CELL SCI, V112, P181; Truica CI, 2000, CANCER RES, V60, P4709; Tumbarello DA, 2007, J CELL PHYSIOL, V211, P736, DOI 10.1002/jcp.20991; UKE E, 1983, J UROLOGY, V129, P171, DOI 10.1016/S0022-5347(17)51976-X; Wang G, 2008, CANCER RES, V68, P9918, DOI 10.1158/0008-5472.CAN-08-1718; Wang H, 2005, J BIOL CHEM, V280, P5154, DOI 10.1074/jbc.M411575200; Wang H, 2008, ONCOGENE, V27, P6791, DOI 10.1038/onc.2008.291; Zhang J, 2000, MOL CARCINOGEN, V27, P177, DOI 10.1002/(SICI)1098-2744(200003)27:3<177::AID-MC4>3.3.CO;2-J; Zhu ML, 2008, PROSTATE, V68, P287, DOI 10.1002/pros.20698	53	31	32	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2011	30	2					167	177		10.1038/onc.2010.400	http://dx.doi.org/10.1038/onc.2010.400			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	709LG	20818421	hybrid, Green Published			2022-12-17	WOS:000286438900005
J	De Vita, S; Canzonetta, C; Mulligan, C; Delom, F; Groet, J; Baldo, C; Vanes, L; Dagna-Bricarelli, F; Hoischen, A; Veltman, J; Fisher, EMC; Tybulewicz, VLJ; Nizetic, D				De Vita, S.; Canzonetta, C.; Mulligan, C.; Delom, F.; Groet, J.; Baldo, C.; Vanes, L.; Dagna-Bricarelli, F.; Hoischen, A.; Veltman, J.; Fisher, E. M. C.; Tybulewicz, V. L. J.; Nizetic, D.			Trisomic dose of several chromosome 21 genes perturbs haematopoietic stem and progenitor cell differentiation in Down's syndrome	ONCOGENE			English	Article						chromosome 21; trisomy 21; gene expression; Down's syndrome; leukaemia; mouse models	ACUTE LYMPHOBLASTIC LEUKEMIAS; IN-VITRO DIFFERENTIATION; MEGAKARYOBLASTIC LEUKEMIA; TRANSCRIPTION FACTOR; MOUSE MODEL; MYELOID PROGENITOR; ACQUIRED MUTATIONS; FETAL LIVER; EXPRESSION; TRANSIENT	Children with Down's syndrome (DS) have 20-50-fold higher incidence of all leukaemias (lymphoid and myeloid), for reasons not understood. As incidence of many solid tumours is much lower in DS, we speculated that disturbed early haematopoietic differentiation could be the cause of increased leukaemia risk. If a common mechanism is behind the risk of both major leukaemia types, it would have to arise before the bifurcation to myeloid and lymphoid lineages. Using the transchromosomic system (mouse embryonic stem cells (ESCs)) bearing an extra human chromosome 21 (HSA21)) we analyzed the early stages of haematopoietic commitment (mesodermal colony formation) in vitro. We observed that trisomy 21 (T21) causes increased production of haemogenic endothelial cells, haematopoietic stem cell precursors and increased colony forming potential, with significantly increased immature progenitors. Transchromosomic colonies showed increased expression of Gata-2, c-Kit and Tie-2. A panel of partial T21 ESCs allowed us to assign these effects to HSA21 sub-regions, mapped by 3.5 kbp-resolution tiling arrays. The Gata-2 increase on one side, and c-Kit and Tie-2 increases on the other, could be attributed to two different, non-overlapping HSA21 regions. Using human-specific small interfering RNA silencing, we could demonstrate that an extra copy of RUNX1, but not ETS-2 or ERG, causes an increase in Tie-2/c-Kit levels. Finally, we detected significantly increased levels of RUNX1, C-KIT and PU.1 in human foetal livers with T21. We conclude that overdose of more than one HSA21 gene contributes to the disturbance of early haematopoiesis in DS, and that one of the contributors is RUNX1. As the observed T21-driven hyperproduction of multipotential immature precursors precedes the bifurcation to lymphoid and myeloid lineages, we speculate that this could create conditions of increased chance for acquisition of pre-leukaemogenic rearrangements/mutations in both lymphoid and myeloid lineages foetal haematopoiesis, contributing to the increased risk of both leukaemia types in DS. Oncogene (2010) 29, 6102-6114; doi:10.1038/onc.2010.351; published online 9 August 2010	[De Vita, S.; Canzonetta, C.; Mulligan, C.; Delom, F.; Groet, J.; Nizetic, D.] Queen Mary Univ London, Blizard Inst Cell & Mol Sci, Barts & London Sch Med & Dent, Ctr Paediat, London, England; [Baldo, C.; Dagna-Bricarelli, F.] Galliera Hosp, Human Genet Lab, Genoa, Italy; [Vanes, L.; Tybulewicz, V. L. J.] MRC Natl Inst Med Res, London, England; [Hoischen, A.; Veltman, J.] Radboud Univ Nijmegen, Med Ctr, Dept Human Genet, NL-6525 ED Nijmegen, Netherlands; [Fisher, E. M. C.] UCL Inst Neurol, Dept Neurodegenerat Dis, London, England	University of London; Queen Mary University London; Ente Ospedaliero Ospedali Galliera; MRC National Institute for Medical Research; Radboud University Nijmegen; University of London; University College London	Nizetic, D (corresponding author), Barts & London Queen Marys Sch Med & Dent, Ctr Paediat, Blizard Inst Cell & Mol Sci, 4 Newark St, London E1 2AT, England.	d.nizetic@qmul.ac.uk	Nizetic, Dean/F-9509-2015; Hoischen, Alexander/D-1282-2013; Baldo, Chiara/AAB-1435-2020; Veltman, Joris A/F-5128-2010; Delom, Frederic/J-2782-2014; Hoischen, Alexander/AGF-7293-2022; Fisher, Elizabeth MC/C-2168-2008	Hoischen, Alexander/0000-0002-8072-4476; Baldo, Chiara/0000-0001-7508-3953; Veltman, Joris A/0000-0002-3218-8250; Delom, Frederic/0000-0002-4600-7633; Hoischen, Alexander/0000-0002-8072-4476; Fisher, Elizabeth MC/0000-0003-2850-9936; Canzonetta, Claudia/0000-0002-8928-5537; Nizetic, Dean/0000-0001-5486-5761	EU Commission; Leukaemia Research Fund-UK [05075, 06003]; Italian Telethon [GTB07001]; MRC [U117527252]; MRC [MC_U117527252, G0601056] Funding Source: UKRI; Medical Research Council [MC_U117527252, G0601056] Funding Source: researchfish	EU Commission(European CommissionEuropean Commission Joint Research Centre); Leukaemia Research Fund-UK; Italian Telethon(Fondazione Telethon); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	We thank Gary Warnes for help with FACS analysis and Mike Kirwan for technical advice. This work was supported by the 'Aneuploidy' Grant from Framework Programme 6 from the EU Commission, and by the Gordon Piller Studentship (05075) and the specialist programme Grant (06003) from the Leukaemia Research Fund-UK. For FL material, we thank the MRC-Foetal Tissue Bank, and The Galliera Genetic Bank-'Telethon Genetic Biobank Network', which is supported by Italian Telethon Grants (Project no. GTB07001). We would also like to thank MRC funding number U117527252.	Akashi K, 2000, NATURE, V404, P193, DOI 10.1038/35004599; Al-Kasim F, 2002, J PEDIAT HEMATOL ONC, V24, P9, DOI 10.1097/00043426-200201000-00004; Alford KA, 2010, BLOOD, V115, P2928, DOI 10.1182/blood-2009-06-227629; Bahn S, 2002, LANCET, V359, P310, DOI 10.1016/S0140-6736(02)07497-4; Bercovich D, 2008, LANCET, V372, P1484, DOI 10.1016/S0140-6736(08)61341-0; Broxmeyer HE, 2003, P NATL ACAD SCI USA, V100, P645, DOI 10.1073/pnas.0237086100; Cai ZL, 2000, IMMUNITY, V13, P423, DOI 10.1016/S1074-7613(00)00042-X; Canzonetta C, 2008, AM J HUM GENET, V83, P388, DOI 10.1016/j.ajhg.2008.08.012; Carmichael CL, 2009, BLOOD, V113, P1929, DOI 10.1182/blood-2008-06-161422; Cavani S, 1998, BRIT J HAEMATOL, V103, P213, DOI 10.1046/j.1365-2141.1998.00924.x; Chen MJ, 2009, NATURE, V457, P887, DOI 10.1038/nature07619; Choi K, 1998, DEVELOPMENT, V125, P725; Chou ST, 2008, BLOOD, V112, P4503, DOI 10.1182/blood-2008-05-157859; De Vita S, 2008, BRIT J HAEMATOL, V143, P300, DOI 10.1111/j.1365-2141.2008.07332.x; Delom F, 2007, CELL DEATH DIFFER, V14, P586, DOI 10.1038/sj.cdd.4402012; Era T, 2000, BLOOD, V95, P870, DOI 10.1182/blood.V95.3.870.003k44_870_878; Eto K, 2003, METHOD ENZYMOL, V365, P142; Forestier E, 2008, BLOOD, V111, P1575, DOI 10.1182/blood-2007-09-114231; Groet J, 2003, LANCET, V361, P1617, DOI 10.1016/S0140-6736(03)13266-7; Hasle H, 2000, LANCET, V355, P165, DOI 10.1016/S0140-6736(99)05264-2; Hernandez D, 1999, HUM MOL GENET, V8, P923, DOI 10.1093/hmg/8.5.923; Hertzberg L, 2010, BLOOD, V115, P1006, DOI 10.1182/blood-2009-08-235408; Hitzler JK, 2005, NAT REV CANCER, V5, P11, DOI 10.1038/nrc1525; Jaffredo T, 2005, EXP HEMATOL, V33, P1029, DOI 10.1016/j.exphem.2005.06.005; Kearney L, 2009, BLOOD, V113, P646, DOI 10.1182/blood-2008-08-170928; Kirsammer G, 2008, BLOOD, V111, P767, DOI 10.1182/blood-2007-04-085670; Kitajima K, 2003, METHOD ENZYMOL, V365, P72; Kitajima K, 2006, BLOOD, V107, P1857, DOI 10.1182/blood-2005-06-2527; Kitajima K, 2002, EMBO J, V21, P3060, DOI 10.1093/emboj/cdf301; Klusmann JH, 2010, GENE DEV, V24, P478, DOI 10.1101/gad.1856210; Korbel JO, 2009, P NATL ACAD SCI USA, V106, P12031, DOI 10.1073/pnas.0813248106; KRIVIT W, 1957, AMA J DIS CHILD, V94, P289, DOI 10.1001/archpedi.1957.04030040075012; Lancrin C, 2009, NATURE, V457, P892, DOI 10.1038/nature07679; Lepagnol-Bestel AM, 2009, HUM MOL GENET, V18, P1405, DOI 10.1093/hmg/ddp047; Levanon D, 2004, ONCOGENE, V23, P4211, DOI 10.1038/sj.onc.1207670; Li Z, 2005, NAT GENET, V37, P613, DOI 10.1038/ng1566; Lugus JJ, 2007, DEVELOPMENT, V134, P393, DOI 10.1242/dev.02731; Lugus JJ, 2009, BLOOD, V113, P563, DOI 10.1182/blood-2008-06-162750; Lundin C, 2009, BRIT J HAEMATOL, V146, P113, DOI 10.1111/j.1365-2141.2009.07689.x; Malinge S, 2009, BLOOD, V113, P2619, DOI 10.1182/blood-2008-11-163501; McElwaine S, 2004, BRIT J HAEMATOL, V125, P729, DOI 10.1111/j.1365-2141.2004.04982.x; Mensah A, 2007, BMC DEV BIOL, V7, DOI 10.1186/1471-213X-7-131; NAKANO T, 1994, SCIENCE, V265, P1098, DOI 10.1126/science.8066449; Ng AP, 2010, BLOOD, V115, P3966, DOI 10.1182/blood-2009-09-242107; NIIKAWA N, 1991, HUM GENET, V87, P561; Nottingham WT, 2007, BLOOD, V110, P4188, DOI 10.1182/blood-2007-07-100883; O'Connell RM, 2008, J EXP MED, V205, P585, DOI 10.1084/jem.20072108; Ohta T, 1996, AM J HUM GENET, V58, P544; Olson LE, 2004, DEV DYNAM, V230, P581, DOI 10.1002/dvdy.20079; Park C, 2005, EXP HEMATOL, V33, P965, DOI 10.1016/j.exphem.2005.06.003; Park IH, 2008, CELL, V134, P877, DOI 10.1016/j.cell.2008.07.041; Prandini P, 2007, AM J HUM GENET, V81, P252, DOI 10.1086/519248; Rainis L, 2005, CANCER RES, V65, P7596, DOI 10.1158/0008-5472.CAN-05-0147; Rainis L, 2003, BLOOD, V102, P981, DOI 10.1182/blood-2002-11-3599; Russell LJ, 2009, BLOOD, V114, P2688, DOI 10.1182/blood-2009-03-208397; Sakai E, 2009, EXP HEMATOL, V37, P334, DOI 10.1016/j.exphem.2008.11.007; Salek-Ardakani S, 2009, CANCER RES, V69, P4665, DOI 10.1158/0008-5472.CAN-09-0075; Satge D, 1998, CANCER RES, V58, P448; Shalaby F, 1997, CELL, V89, P981, DOI 10.1016/S0092-8674(00)80283-4; SHEN JJ, 1995, AM J HUM GENET, V56, P915; Stankiewicz MJ, 2009, BLOOD, V113, P3337, DOI 10.1182/blood-2008-08-174813; Sussan TE, 2008, NATURE, V451, P73, DOI 10.1038/nature06446; Taub JW, 2002, J PEDIAT HEMATOL ONC, V24, P6, DOI 10.1097/00043426-200201000-00003; Teyssier-Le Discorde M, 1999, BRIT J HAEMATOL, V107, P247, DOI 10.1046/j.1365-2141.1999.01725.x; Toki T, 2005, BLOOD, V105, P3100, DOI 10.1182/blood-2004-07-2826; Toki T, 2009, LEUKEMIA, V23, P95, DOI 10.1038/leu.2008.267; Tunstall-Pedoe O, 2008, BLOOD, V112, P4507, DOI 10.1182/blood-2008-04-152967; Wang Y, 2009, MOL CELL PROTEOMICS, V8, P585, DOI 10.1074/mcp.M800256-MCP200; Wechsler J, 2002, NAT GENET, V32, P148, DOI 10.1038/ng955; Yanagida M, 2005, ONCOGENE, V24, P4477, DOI 10.1038/sj.onc.1208675; Yang QH, 2002, LANCET, V359, P1019, DOI 10.1016/S0140-6736(02)08092-3; ZIPURSKY A, 1994, LEUKEMIA RES, V18, P163, DOI 10.1016/0145-2126(94)90111-2; Zovein AC, 2008, CELL STEM CELL, V3, P625, DOI 10.1016/j.stem.2008.09.018	73	31	32	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2010	29	46					6102	6114		10.1038/onc.2010.351	http://dx.doi.org/10.1038/onc.2010.351			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	681XD	20697343	hybrid, Green Published			2022-12-17	WOS:000284356500003
J	Tchaicha, JH; Mobley, AK; Hossain, MG; Aldape, KD; McCarty, JH				Tchaicha, J. H.; Mobley, A. K.; Hossain, M. G.; Aldape, K. D.; McCarty, J. H.			A mosaic mouse model of astrocytoma identifies alpha v beta 8 integrin as a negative regulator of tumor angiogenesis	ONCOGENE			English	Article						glioma; glioblastoma multiforme; itgav; itgb8; TGF beta; astrocyte	GROWTH-FACTOR RECEPTOR; ALPHA-V INTEGRINS; NEURAL STEM-CELL; NEUROVASCULAR DEVELOPMENT; GLIOBLASTOMA-MULTIFORME; RADIAL GLIA; FACTOR-BETA; IN-VITRO; ACTIVATION; GLIOMA	Angiogenesis involves a complex set of cell-cell and cell-extracellular matrix (ECM) interactions that coordinately promote and inhibit blood vessel growth and sprouting. Although many factors that promote angiogenesis have been characterized, the identities and mechanisms of action of endogenous inhibitors of angiogenesis remain unclear. Furthermore, little is known about how cancer cells selectively circumvent the actions of these inhibitors to promote pathological angiogenesis, a requisite event for tumor progression. Using mosaic mouse models of the malignant brain cancer, astrocytoma, we report that tumor cells induce pathological angiogenesis by suppressing expression of the ECM protein receptor alpha v beta 8 integrin. Diminished integrin expression in astrocytoma cells leads to reduced activation of latent TGF beta s, resulting in impaired TGF beta receptor signaling in tumor-associated endothelial cells. These data reveal that astrocytoma cells manipulate their angiogenic balance by selectively suppressing avb8 integrin expression and function. Finally, these results show that an adhesion and signaling axis normally involved in developmental brain angiogenesis is pathologically exploited in adult brain tumors. Oncogene (2010) 29, 4460-4472; doi: 10.1038/onc.2010.199; published online 7 June 2010	[McCarty, J. H.] Univ Texas Houston, MD Anderson Canc Ctr, Dept Canc Biol, Unit 173, Houston, TX 77030 USA; [Aldape, K. D.] Univ Texas Houston, MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA	University of Texas System; University of Texas Health Science Center Houston; UTMD Anderson Cancer Center; University of Texas System; University of Texas Health Science Center Houston; UTMD Anderson Cancer Center	McCarty, JH (corresponding author), Univ Texas Houston, MD Anderson Canc Ctr, Dept Canc Biol, Unit 173, 1515 Holcombe Blvd, Houston, TX 77030 USA.	jhmccarty@mdanderson.org			National Institutes of Neurological Disease and Stroke [R01NS059876]; National Cancer Institute [P50CA127001, CA-16672]; Ellison Medical Foundation [AG-NS-0324-06]; NATIONAL CANCER INSTITUTE [P50CA127001, P30CA016672] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS059876] Funding Source: NIH RePORTER	National Institutes of Neurological Disease and Stroke; National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Ellison Medical Foundation(Lawrence Ellison Foundation); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	We thank Dr Nami McCarty for providing assistance with FACS analysis and Dr Russell Pieper for generously providing E6/E7 and <SUP>G12V</SUP>H-Ras plasmids. This research was supported by grants awarded to JHM from the National Institutes of Neurological Disease and Stroke (R01NS059876), the National Cancer Institute (P50CA127001) and the Ellison Medical Foundation (AG-NS-0324-06). This work was also supported in part by a National Cancer Institute core grant (CA-16672) awarded to The University of Texas MD Anderson Cancer Center.	ABE M, 1994, ANAL BIOCHEM, V216, P276, DOI 10.1006/abio.1994.1042; Adams RH, 2007, NAT REV MOL CELL BIO, V8, P464, DOI 10.1038/nrm2183; Bachoo RM, 2002, CANCER CELL, V1, P269, DOI 10.1016/S1535-6108(02)00046-6; Bao SD, 2006, NATURE, V444, P756, DOI 10.1038/nature05236; Bao SD, 2006, CANCER RES, V66, P7843, DOI 10.1158/0008-5472.CAN-06-1010; Bautch VL, 2009, CELL ADHES MIGR, V3, P199, DOI 10.4161/cam.3.2.8397; Benjamin LE, 1997, P NATL ACAD SCI USA, V94, P8761, DOI 10.1073/pnas.94.16.8761; BOGLER O, 1995, CANCER RES, V55, P2746; Calabrese C, 2007, CANCER CELL, V11, P69, DOI 10.1016/j.ccr.2006.11.020; Cambier S, 2005, AM J PATHOL, V166, P1883, DOI 10.1016/S0002-9440(10)62497-2; Cheng SY, 1997, P NATL ACAD SCI USA, V94, P12081, DOI 10.1073/pnas.94.22.12081; Cheng SY, 1996, P NATL ACAD SCI USA, V93, P8502, DOI 10.1073/pnas.93.16.8502; Desgrosellier JS, 2010, NAT REV CANCER, V10, P9, DOI 10.1038/nrc2748; Furnari FB, 2007, GENE DEV, V21, P2683, DOI 10.1101/gad.1596707; Holland EC, 2000, NAT GENET, V25, P55, DOI 10.1038/75596; Ishii N, 1999, BRAIN PATHOL, V9, P469, DOI 10.1111/j.1750-3639.1999.tb00536.x; Jain RK, 2007, NAT REV NEUROSCI, V8, P610, DOI 10.1038/nrn2175; Kanamori M, 2004, CANCER RES, V64, P2751, DOI 10.1158/0008-5472.CAN-03-3354; Kaur B, 2004, J NEURO-ONCOL, V70, P229, DOI 10.1007/s11060-004-2752-5; Llaguno SA, 2009, CANCER CELL, V15, P45, DOI 10.1016/j.ccr.2008.12.006; Massague J, 2008, CELL, V134, P215, DOI 10.1016/j.cell.2008.07.001; McCarty JH, 2005, P NATL ACAD SCI USA, V102, P13479, DOI 10.1073/pnas.0506068102; McCarty JH, 2005, DEVELOPMENT, V132, P165, DOI 10.1242/dev.01551; McCarty JH, 2002, MOL CELL BIOL, V22, P7667, DOI 10.1128/MCB.22.21.7667-7677.2002; McCarty JH, 2008, AM J PATHOL, V172, P1740, DOI 10.2353/ajpath.2008.070700; McCarty JH, 2009, CELL ADHES MIGR, V3, P211, DOI 10.4161/cam.3.2.7767; McCarty JH, 2009, CURR OPIN HEMATOL, V16, P209, DOI 10.1097/MOH.0b013e32832a07eb; Milner R, 2001, MOL CELL NEUROSCI, V18, P108, DOI 10.1006/mcne.2001.1003; Mobley AK, 2009, J CELL SCI, V122, P1842, DOI 10.1242/jcs.043257; Mori T, 2005, CURR TOP DEV BIOL, V69, P67, DOI 10.1016/S0070-2153(05)69004-7; Mu ZY, 2008, MECH DEVELOP, V125, P508, DOI 10.1016/j.mod.2008.01.003; O'Brien CA, 2007, NATURE, V445, P106, DOI 10.1038/nature05372; Petersen M, 2010, ONCOGENE, V29, P1351, DOI 10.1038/onc.2009.426; Proctor JM, 2005, J NEUROSCI, V25, P9940, DOI 10.1523/JNEUROSCI.3467-05.2005; Ramsauer M, 2007, J CELL SCI, V120, P1810, DOI 10.1242/jcs.003533; Riemenschneider MJ, 2005, AM J PATHOL, V167, P1379, DOI 10.1016/S0002-9440(10)61225-4; Rietze RL, 2006, METHOD ENZYMOL, V419, P3, DOI 10.1016/S0076-6879(06)19001-1; Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128; Skuli N, 2009, CANCER RES, V69, P3308, DOI 10.1158/0008-5472.CAN-08-2158; Sonoda Y, 2003, CANCER RES, V63, P1962; Sonoda Y, 2001, CANCER RES, V61, P4956; Sonoda Y, 2001, CANCER RES, V61, P6674; Stipursky J, 2007, GLIA, V55, P1023, DOI 10.1002/glia.20522; Uchida N, 2000, P NATL ACAD SCI USA, V97, P14720, DOI 10.1073/pnas.97.26.14720; Uhrbom L, 2002, CANCER RES, V62, P5551; Zheng HW, 2008, NATURE, V455, P1129, DOI 10.1038/nature07443; Zhu JW, 2002, DEVELOPMENT, V129, P2891	47	31	31	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 5	2010	29	31					4460	4472		10.1038/onc.2010.199	http://dx.doi.org/10.1038/onc.2010.199			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	634DG	20531304	Green Accepted			2022-12-17	WOS:000280559100009
J	Lecomte, S; Desmots, F; Le Masson, F; Le Goff, P; Michel, D; Christians, ES; Le Drean, Y				Lecomte, S.; Desmots, F.; Le Masson, F.; Le Goff, P.; Michel, D.; Christians, E. S.; Le Drean, Y.			Roles of heat shock factor 1 and 2 in response to proteasome inhibition: consequence on p53 stability	ONCOGENE			English	Article						heat shock factor; MG132; proteasome; gankyrin; p53	TRANSCRIPTION FACTOR-1; EXPRESSION; GENE; ACTIVATION; STRESS; SYSTEM; DISRUPTION; RESISTANCE; APOPTOSIS; PROTEINS	A single heat shock factor (HSF), mediating the heat shock response, exists from yeast to Drosophila, whereas several related HSFs have been found in mammals. This raises the question of the specific or redundant functions of the different members of the HSF family and in particular of HSF1 and HSF2, which are both ubiquitously expressed. Using immortalized mouse embryonic fibroblasts (iMEFs) derived from wild-type, Hsf1(-/-), Hsf2(-/-) or double-mutant mice, we observed the distinctive behaviors of these mutants with respect to proteasome inhibition. This proteotoxic stress reduces to the same extent the viability of Hsf1(-/-)- and Hsf2(-/-)-deficient cells, but through different underlying mechanisms. Contrary to Hsf2(-/-) cells, Hsf1(-/-) cells are unable to induce pro-survival heat shock protein expression. Conversely, proteasome activity is lower in Hsf2(-/-) cells and the expression of some proteasome subunits, such as Psmb5 and gankyrin, is decreased. As gankyrin is an oncoprotein involved in p53 degradation, we analyzed the status of p53 in HSF-deficient iMEFs and observed that it was strongly stabilized in Hsf2(-/-) cells. This study points a new role for HSF2 in the regulation of protein degradation and suggests that pan-HSF inhibitors could be valuable tools to reduce chemoresistance to proteasome inhibition observed in cancer therapy. Oncogene ( 2010) 29, 4216-4224; doi: 10.1038/onc.2010.171; published online 24 May 2010	[Lecomte, S.; Desmots, F.; Le Goff, P.; Michel, D.; Le Drean, Y.] Univ Rennes 1, IFR Genom Fonct Agron & Sante 140, CNRS, UMR 6026, F-35042 Rennes, France; [Le Masson, F.; Christians, E. S.] Univ Toulouse 3, CNRS, UMR 5547, Ctr Dev Biol, F-31062 Toulouse, France	Centre National de la Recherche Scientifique (CNRS); Universite de Rennes 1; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Toulouse; Universite Toulouse III - Paul Sabatier	Le Drean, Y (corresponding author), Univ Rennes 1, IFR Genom Fonct Agron & Sante 140, CNRS, UMR 6026, Bat 13,Campus Beaulieu, F-35042 Rennes, France.	yves.le-drean@univ-rennes1.fr	LE GOFF, PASCALE/K-1842-2015; Lecomte, Sylvain/K-1745-2015; Le Dréan, Yves/L-4822-2015	LE GOFF, PASCALE/0000-0002-3931-2197; 	Canceropole Grand Ouest; CNRS; French Ministry of Higher Education and Research (MENRT); 'Association pour la Recherche sur le Cancer' (ARC)	Canceropole Grand Ouest; CNRS(Centre National de la Recherche Scientifique (CNRS)); French Ministry of Higher Education and Research (MENRT); 'Association pour la Recherche sur le Cancer' (ARC)(Fondation ARC pour la Recherche sur le Cancer)	This work was supported by Canceropole Grand Ouest and CNRS. SL and FLM were supported by a fellowship from the French Ministry of Higher Education and Research (MENRT), and FD by a fellowship from the 'Association pour la Recherche sur le Cancer' (ARC). We thank Dr V Mezger (UMR CNRS 7216, Paris, France) for the gift of immortalized MEFs, and V Noel for the help in in silico analysis. We also thank Frederic Percevault for the establishment of a stable clone expressing HSF2 from Hsf2<SUP>-/-</SUP> iMEFs.	Akerfelt M, 2007, ANN NY ACAD SCI, V1113, P15, DOI 10.1196/annals.1391.005; Beere HM, 2000, NAT CELL BIOL, V2, P469, DOI 10.1038/35019501; Beere HM, 2005, J CLIN INVEST, V115, P2633, DOI 10.1172/JCI26471; Bruey JM, 2000, NAT CELL BIOL, V2, P645, DOI 10.1038/35023595; Bush KT, 1997, J BIOL CHEM, V272, P9086; Busse A, 2008, CANCER, V112, P659, DOI 10.1002/cncr.23224; Cantalupo PG, 2009, VIROLOGY, V386, P183, DOI 10.1016/j.virol.2008.12.038; Dai C, 2007, CELL, V130, P1005, DOI 10.1016/j.cell.2007.07.020; Dantuma NP, 2000, NAT BIOTECHNOL, V18, P538, DOI 10.1038/75406; Fuchs D, 2008, J CELL BIOCHEM, V103, P270, DOI 10.1002/jcb.21405; Hahn JS, 2006, MOL MICROBIOL, V60, P240, DOI 10.1111/j.1365-2958.2006.05097.x; Hellemans J, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-2-r19; Higashitsuji H, 2005, CANCER CELL, V8, P75, DOI 10.1016/j.ccr.2005.06.006; Higashitsuji H, 2000, NAT MED, V6, P96, DOI 10.1038/71600; Homma S, 2007, J NEUROSCI, V27, P7974, DOI 10.1523/JNEUROSCI.0006-07.2007; Jin XJ, 2009, J CELL BIOCHEM, V107, P504, DOI 10.1002/jcb.22151; Kawazoe Y, 1998, EUR J BIOCHEM, V255, P356, DOI 10.1046/j.1432-1327.1998.2550356.x; Kisselev AF, 2005, METHOD ENZYMOL, V398, P364, DOI 10.1016/S0076-6879(05)98030-0; KROEGER PE, 1994, MOL CELL BIOL, V14, P7592, DOI 10.1128/MCB.14.11.7592; Loison F, 2006, BIOCHEM J, V395, P223, DOI 10.1042/BJ20051190; McMillan DR, 1998, J BIOL CHEM, V273, P7523, DOI 10.1074/jbc.273.13.7523; McMillan DR, 2002, MOL CELL BIOL, V22, P8005, DOI 10.1128/MCB.22.22.8005-8014.2002; Meiners S, 2003, J BIOL CHEM, V278, P21517, DOI 10.1074/jbc.M301032200; Muratani M, 2003, NAT REV MOL CELL BIO, V4, P192, DOI 10.1038/nrm1049; Nencioni A, 2007, LEUKEMIA, V21, P30, DOI 10.1038/sj.leu.2404444; Oerlemans R, 2008, BLOOD, V112, P2489, DOI 10.1182/blood-2007-08-104950; Ostling P, 2007, J BIOL CHEM, V282, P7077, DOI 10.1074/jbc.M607556200; Paul S, 2008, BIOESSAYS, V30, P1172, DOI 10.1002/bies.20852; Pickart CM, 2004, NAT REV MOL CELL BIO, V5, P177, DOI 10.1038/nrm1336; Pipas JM, 2001, SEMIN CANCER BIOL, V11, P23, DOI 10.1006/scbi.2000.0343; Pirkkala L, 2001, FASEB J, V15, P1118, DOI 10.1096/fj00-0294rev; Pirkkala L, 2000, MOL CELL BIOL, V20, P2670, DOI 10.1128/MCB.20.8.2670-2675.2000; Ruckrich T, 2009, LEUKEMIA, V23, P1098, DOI 10.1038/leu.2009.8; Sandqvist A, 2009, MOL BIOL CELL, V20, P1340, DOI 10.1091/mbc.E08-08-0864; Sato Y, 2009, BIOCHEM BIOPH RES CO, V378, P795, DOI 10.1016/j.bbrc.2008.11.125; Schwartz AL, 1999, ANNU REV MED, V50, P57; SISTONEN L, 1992, MOL CELL BIOL, V12, P4104, DOI 10.1128/MCB.12.9.4104; Taylor DM, 2005, CELL STRESS CHAPERON, V10, P230, DOI 10.1379/CSC-119R.1; Trinklein ND, 2004, MOL BIOL CELL, V15, P1254, DOI 10.1091/mbc.E03-10-0738; Tsirigotis M, 2001, BIOTECHNIQUES, V31, P120, DOI 10.2144/01311rr03; Twombly R, 2003, J NATL CANCER I, V95, P845, DOI 10.1093/jnci/95.12.845; Wilkerson DC, 2007, CELL STRESS CHAPERON, V12, P283, DOI 10.1379/CSC-250.1; Xing HY, 2005, SCIENCE, V307, P421, DOI 10.1126/science.1106478; Yamamoto N, 2009, FEBS J, V276, P1962, DOI 10.1111/j.1742-4658.2009.06923.x; Zaarur N, 2006, CANCER RES, V66, P1783, DOI 10.1158/0008-5472.CAN-05-3692	45	31	32	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 22	2010	29	29					4216	4224		10.1038/onc.2010.171	http://dx.doi.org/10.1038/onc.2010.171			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	628VL	20498630	Green Submitted			2022-12-17	WOS:000280151500009
J	Lin, Y; Chen, NT; Shih, YP; Liao, YC; Xue, L; Lo, SH				Lin, Y.; Chen, N-T; Shih, Y-P; Liao, Y-C; Xue, L.; Lo, S. H.			DLC2 modulates angiogenic responses in vascular endothelial cells by regulating cell attachment and migration	ONCOGENE			English	Article						DLC2; RhoGAP; tumor suppressor; angiogenesis	GTPASE-ACTIVATING PROTEIN; TUMOR-SUPPRESSOR; HEPATOCELLULAR-CARCINOMA; LIVER; CANCER; EXPRESSION; GROWTH; LOCALIZATION; INHIBITION; RHOGAP	Deleted in liver cancer 1 (DLC1) is a RhoGTPase activation protein-containing tumor suppressor that associates with various types of cancer. Although DLC2 shares a similar domain structure with that of DLC1, the function of DLC2 is not well characterized. Here, we describe the expression and ablation of DLC2 in mice using a reporter-knockout approach. DLC2 is expressed in several tissues and in endothelial cells (ECs) of blood vessels. Although ECs and blood vessels show no histological abnormalities and mice appear overall healthy, DLC2-mutant mice display enhanced angiogenic responses induced by matrigel and by tumor cells. Silencing of DLC2 in human ECs has reduced cell attachment, increased migration, and tube formation. These changes are rescued by silencing of RhoA, suggesting that the process is RhoA pathway dependent. These results indicate that DLC2 is not required for mouse development and normal vessel formation, but may protect mouse from unwanted angiogenesis induced by, for example, tumor cells. Oncogene (2010) 29, 3010-3016; doi:10.1038/onc.2010.54; published online 8 March 2010	[Lin, Y.; Chen, N-T; Shih, Y-P; Liao, Y-C; Lo, S. H.] Univ Calif Davis, Dept Biochem & Mol Med, Sacramento, CA 95817 USA; [Lin, Y.; Xue, L.] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Pathol, Guangzhou 510275, Guangdong, Peoples R China	University of California System; University of California Davis; Sun Yat Sen University	Lo, SH (corresponding author), Univ Calif Davis, Dept Biochem & Mol Med, 4635 2nd Ave,Room 3002, Sacramento, CA 95817 USA.	shlo@ucdavis.edu	Hsiao, Wei-Hung/B-9931-2013; Liao, Yi-Chun/H-2383-2014	Liao, Yi-Chun/0000-0002-0399-0201; Lo, Su Hao/0000-0002-2675-9387	National Institutes of Health [CA102537]; NATIONAL CANCER INSTITUTE [R01CA102537, R56CA102537] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank the Knockout Mouse Project Repository for DLC2 ES cells. This work is supported in part by grants from the National Institutes of Health (CA102537) to SHL.	Ching YP, 2003, J BIOL CHEM, V278, P10824, DOI 10.1074/jbc.M208310200; Durkin ME, 2007, ONCOGENE, V26, P4580, DOI 10.1038/sj.onc.1210244; Durkin ME, 2007, J CELL MOL MED, V11, P1185, DOI 10.1111/j.1582-4934.2007.00098.x; Durkin ME, 2005, FEBS LETT, V579, P1191, DOI 10.1016/j.febslet.2004.12.090; Durkin ME, 2002, GENE, V288, P119, DOI 10.1016/S0378-1119(02)00462-6; Leung THY, 2005, P NATL ACAD SCI USA, V102, P15207, DOI 10.1073/pnas.0504501102; Li XR, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-205; Liao YC, 2008, CANCER RES, V68, P7718, DOI 10.1158/0008-5472.CAN-08-2042; Liao YC, 2008, INT J BIOCHEM CELL B, V40, P843, DOI 10.1016/j.biocel.2007.04.008; Liao YC, 2007, J CELL BIOL, V176, P43, DOI 10.1083/jcb.200608015; Masson V, 2004, FASEB J, V18, P234, DOI 10.1096/fj.04-2140fje; Qian XL, 2007, P NATL ACAD SCI USA, V104, P9012, DOI 10.1073/pnas.0703033104; Testa G, 2004, GENESIS, V38, P151, DOI 10.1002/gene.20012; Ullmannova V, 2006, INT J ONCOL, V29, P1127; Xue W, 2008, GENE DEV, V22, P1439, DOI 10.1101/gad.1672608; Yau TO, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006566; Yuan BZ, 1998, CANCER RES, V58, P2196	17	31	32	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2010	29	20					3010	3016		10.1038/onc.2010.54	http://dx.doi.org/10.1038/onc.2010.54			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	599DM	20208559	Green Accepted, Green Submitted			2022-12-17	WOS:000277890400011
J	Osanai, M; Sawada, N; Lee, GH				Osanai, M.; Sawada, N.; Lee, G-H			Oncogenic and cell survival properties of the retinoic acid metabolizing enzyme, CYP26A1	ONCOGENE			English	Article						vitamin A; retinoic acid; CYP26A1; apoptosis; tumorigenesis	VITAMIN-A-DEFICIENCY; HUMAN BREAST; DIFFERENTIATION; EXPRESSION; APOPTOSIS	Vitamin A deficiency (VAD) is associated with increased susceptibility to carcinogenesis in animal models and elevated risk for a number of human cancers. Here, we found that CYP26A1, the gene encoding a cytochrome P450 enzyme specifically involved in metabolic inactivation of retinoic acid (RA), the most active vitamin A derivative, is highly expressed in 42% (27/65) of primary breast cancers. We also showed that enhanced expression of CYP26A1 suppresses cellular responses to anoikis and consequently promotes anchorage-independent growth. This transformed phenotype was sufficient to markedly increase tumorigenic and metastatic potential. Suppression of CYP26A1 significantly reversed the CYP26A1-mediated oncogenic characteristics, suggesting a direct link between intracellular RA status and tumorigenicity. Our observations provide strong evidence for oncogenic and cell survival properties of CYP26A1 in carcinogenesis, and suggest mechanisms whereby VAD might promote cancer development. Oncogene (2010) 29, 1135-1144; doi: 10.1038/onc.2009.414; published online 23 November 2009	[Osanai, M.] Kochi Univ, Sch Med, Dept Pathol, Nanko Ku, Kochi 7838505, Japan; [Sawada, N.] Sapporo Med Univ, Sch Med, Dept Pathol, Sapporo, Hokkaido, Japan	Kochi University; Sapporo Medical University	Osanai, M (corresponding author), Kochi Univ, Sch Med, Dept Pathol, Nanko Ku, Oko Cho, Kochi 7838505, Japan.	osanaim@kochi-u.ac.jp			Japan Society for the Promotion of Science	Japan Society for the Promotion of Science(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science)	This study was supported by a Grant-in-Aid for Scientific Research from the Japan Society for the Promotion of Science. We thank doctors at the Department of Surgical Pathology for providing archival formalin-fixed, paraffin-embedded tissue specimens and for their pathological diagnoses, and doctors at the Department of Surgical Oncology and Gastroenterological Surgery for scientific cooperation by providing surgically resected materials in patients with breast cancer, as well as the Animal Care Facility (Sapporo Medical University School of Medicine, Sapporo, Japan).	Abu-Abed S, 2001, GENE DEV, V15, P226, DOI 10.1101/gad.855001; Altucci L, 2001, NAT REV CANCER, V1, P181, DOI 10.1038/35106036; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; Chang CL, 2008, ONCOGENE, V27, P2951, DOI 10.1038/sj.onc.1210969; ELLIOTT BE, 1988, CANCER RES, V48, P7237; Evan GI, 2001, NATURE, V411, P342, DOI 10.1038/35077213; Fenaux P, 1997, NEW ENGL J MED, V337, P1076, DOI 10.1056/NEJM199710093371509; French AL, 2000, J INFECT DIS, V182, P1084, DOI 10.1086/315816; Gozani Or, 2002, Nature Cell Biology, V4, pE159, DOI 10.1038/ncb0602-e159; Kizaki M, 1997, LEUKEMIA LYMPHOMA, V25, P427, DOI 10.3109/10428199709039029; Lotan R, 1996, FASEB J, V10, P1031, DOI 10.1096/fasebj.10.9.8801164; Loudig O, 2005, BIOCHEM J, V392, P241, DOI 10.1042/BJ20050874; Loudig O, 2000, MOL ENDOCRINOL, V14, P1483, DOI 10.1210/me.14.9.1483; Osanai M, 2005, MOL PHARMACOL, V67, P1808, DOI 10.1124/mol.104.005769; Osanai M, 2006, CANCER RES, V66, P9125, DOI 10.1158/0008-5472.CAN-06-1864; Petkovich PM, 2001, J AM ACAD DERMATOL, V45, pS136, DOI 10.1067/mjd.2001.113715; Shelton DN, 2006, CANCER RES, V66, P7571, DOI 10.1158/0008-5472.CAN-06-1067; Sobin, 2009, UICC TNM CLASSIFICAT; Sonneveld E, 1998, CELL GROWTH DIFFER, V9, P629; Tavassoli FA, 2003, WHO CLASSIFICATION T; Van Heusden J, 1998, BRIT J CANCER, V77, P1229, DOI 10.1038/bjc.1998.207; Wang ZQ, 1999, NAT MED, V5, P418, DOI 10.1038/7417; White JA, 1997, J BIOL CHEM, V272, P18538, DOI 10.1074/jbc.272.30.18538; Wolbach SB, 1925, J EXP MED, V42, P753, DOI 10.1084/jem.42.6.753	24	31	32	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 25	2010	29	8					1135	1144		10.1038/onc.2009.414	http://dx.doi.org/10.1038/onc.2009.414			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	560ON	19935721	Green Submitted			2022-12-17	WOS:000274912100005
J	Oh, SM; Liu, Z; Okada, M; Jang, SW; Liu, X; Chan, CB; Luo, H; Ye, K				Oh, S-M; Liu, Z.; Okada, M.; Jang, S-W; Liu, X.; Chan, C-B; Luo, H.; Ye, K.			Ebp1 sumoylation, regulated by TLS/FUS E3 ligase, is required for its anti-proliferative activity	ONCOGENE			English	Article						Ebp1; TLS/FUS; sumoylation; cell proliferation	HUMAN MYELOID-LEUKEMIA; BINDING-PROTEIN EBP1; ONCOGENIC TRANSFORMATION; DNA-DAMAGE; TRANSCRIPTIONAL ACTIVATION; CHROMOSOMAL TRANSLOCATION; SUBCELLULAR-LOCALIZATION; CELL-PROLIFERATION; GENOMIC STRUCTURE; CHIMERIC PROTEIN	Ebp1, an ErbB3 receptor-binding protein, inhibits cell proliferation and acts as a putative tumor suppressor. Ebp1 translocates into the nucleus and functions as a transcription co-repressor for E2F-1. Here, we show that Ebp1 p42 isoform can be sumoylated on both K93 and K298 residues, which mediate its nuclear translocation and are required for its anti-proliferative activity. We find that translocation in liposarcoma (TLS)/FUS, an RNA-binding nuclear protein that is involved in pre-mRNA processing and nucleocytoplasmic shuttling, has Sumo1 E3 ligase activity for Ebp1 p42. Ebp1 directly binds TLS/FUS, which is regulated by genotoxic stress-triggered phosphorylation on Ebp1. Ebp1 sumoylation facilitates its nucleolar distribution and protein stability. Overexpression of TLS enhances Ebp1 sumoylation, whereas depletion of TLS abolishes Ebp1 sumoylation. Moreover, unsumoylated Ebp1 mutants fail to suppress E2F-1-regulated transcription, resulting in loss of its anti-proliferation activity. Hence, TLS-mediated sumoylation is required for Ebp1 transcriptional repressive activity. Oncogene (2010) 29, 1017-1030; doi:10.1038/onc.2009.411; published online 30 November 2009	[Oh, S-M; Liu, Z.; Okada, M.; Jang, S-W; Liu, X.; Chan, C-B; Ye, K.] Emory Univ, Dept Pathol & Lab Med, Sch Med, Atlanta, GA 30322 USA; [Luo, H.] Harvard Univ, Sch Med, Dept Pathol & Lab Med, Boston, MA USA; [Luo, H.] Childrens Hosp, Boston, MA 02115 USA	Emory University; Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital	Ye, K (corresponding author), Emory Univ, Dept Pathol & Lab Med, Sch Med, Room 145,Whitehead Bldg,615 Michael St, Atlanta, GA 30322 USA.	kye@emory.edu			National Institute of Health [CA127119]; NATIONAL CANCER INSTITUTE [R01CA127119] Funding Source: NIH RePORTER	National Institute of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work is supported by grants from the National Institute of Health (RO1, CA127119) to K Ye. We thank Dr Yang Liu at Medical Research Service (VA Puget Sound Health Care System, Seattle, WA, USA) for TLS constructs.	Ahn JY, 2006, EMBO J, V25, P2083, DOI 10.1038/sj.emboj.7601111; Aman P, 1996, GENOMICS, V37, P1, DOI 10.1006/geno.1996.0513; Andersen JS, 2005, NATURE, V433, P77, DOI 10.1038/nature03207; Bae SH, 2004, BIOCHEM BIOPH RES CO, V324, P394, DOI 10.1016/j.bbrc.2004.09.068; Bossis G, 2005, MOL CELL BIOL, V25, P6964, DOI 10.1128/MCB.25.16.6964-6979.2005; CROZAT A, 1993, NATURE, V363, P640, DOI 10.1038/363640a0; Falini B, 2007, HAEMATOLOGICA, V92, P519, DOI 10.3324/haematol.11007; Gill G, 2005, CURR OPIN GENET DEV, V15, P536, DOI 10.1016/j.gde.2005.07.004; Grisendi S, 2005, NATURE, V437, P147, DOI 10.1038/nature03915; Hay RT, 2001, TRENDS BIOCHEM SCI, V26, P332, DOI 10.1016/S0968-0004(01)01849-7; Hicks GG, 2000, NAT GENET, V24, P175, DOI 10.1038/72842; Hochstrasser M, 2001, CELL, V107, P5, DOI 10.1016/S0092-8674(01)00519-0; Huen MS, 2008, CELL RES, V18, P8, DOI 10.1038/cr.2007.109; Inoue Y, 2007, EMBO J, V26, P2083, DOI 10.1038/sj.emboj.7601652; Jackson PK, 2001, GENE DEV, V15, P3053, DOI 10.1101/gad.955501; Kuroda M, 1997, AM J PATHOL, V151, P735; Kuroda M, 2000, EMBO J, V19, P453, DOI 10.1093/emboj/19.3.453; Lee CD, 2008, PROTEIN SCI, V17, P1241, DOI 10.1110/ps.035188.108; Liu X, 2007, P NATL ACAD SCI USA, V104, P9679, DOI 10.1073/pnas.0701806104; Liu ZX, 2006, P NATL ACAD SCI USA, V103, P10917, DOI 10.1073/pnas.0602923103; Meek DW, 1998, CELL SIGNAL, V10, P159, DOI 10.1016/S0898-6568(97)00119-8; Morohoshi F, 1998, GENE, V221, P191, DOI 10.1016/S0378-1119(98)00463-6; Muller S, 2001, NAT REV MOL CELL BIO, V2, P202, DOI 10.1038/35056591; Nakagawa K, 1997, J HISTOCHEM CYTOCHEM, V45, P41, DOI 10.1177/002215549704500106; Okada M, 2007, J BIOL CHEM, V282, P36744, DOI 10.1074/jbc.M706169200; PANAKHOVA KG, 1995, BIOL MEMBRANY, V12, P16; Perrotti D, 2000, MOL CELL BIOL, V20, P6159, DOI 10.1128/MCB.20.16.6159-6169.2000; PRASAD DDK, 1994, ONCOGENE, V9, P3717; RABBITTS TH, 1993, NAT GENET, V4, P175, DOI 10.1038/ng0693-175; RADOMSKI N, 1995, EXP CELL RES, V220, P434, DOI 10.1006/excr.1995.1335; Rodriguez MS, 2001, J BIOL CHEM, V276, P12654, DOI 10.1074/jbc.M009476200; Ron D, 1997, CURR TOP MICROBIOL, V220, P131; SANCHEZGARCIA I, 1994, P NATL ACAD SCI USA, V91, P7869, DOI 10.1073/pnas.91.17.7869; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; SHIMIZU K, 1993, P NATL ACAD SCI USA, V90, P10280, DOI 10.1073/pnas.90.21.10280; Squatrito M, 2004, ONCOGENE, V23, P4454, DOI 10.1038/sj.onc.1207579; Watts FZ, 2006, DNA REPAIR, V5, P399, DOI 10.1016/j.dnarep.2005.11.002; Wei F, 2007, J BIOL CHEM, V282, P21551, DOI 10.1074/jbc.M611041200; Xia XM, 2001, J CELL PHYSIOL, V187, P209, DOI 10.1002/jcp.1075; Yoo JY, 2000, BRIT J CANCER, V82, P683; Yu YC, 2007, INT J CANCER, V120, P1909, DOI 10.1002/ijc.22541; Zhang YX, 2005, P NATL ACAD SCI USA, V102, P9890, DOI 10.1073/pnas.0503829102; Zhang YX, 2003, NUCLEIC ACIDS RES, V31, P2168, DOI 10.1093/nar/gkg318; ZINSZNER H, 1994, GENE DEV, V8, P2513, DOI 10.1101/gad.8.21.2513; Zinszner H, 1997, ONCOGENE, V14, P451, DOI 10.1038/sj.onc.1200854; Zinszner H, 1997, J CELL SCI, V110, P1741	46	31	33	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 18	2010	29	7					1017	1030		10.1038/onc.2009.411	http://dx.doi.org/10.1038/onc.2009.411			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	556PV	19946338	Green Accepted, Green Submitted			2022-12-17	WOS:000274604400008
J	Chan, IH; Privalsky, ML				Chan, I. H.; Privalsky, M. L.			Thyroid hormone receptor mutants implicated in human hepatocellular carcinoma display an altered target gene repertoire	ONCOGENE			English	Article						hepatocellular carcinoma; thyroid hormone receptors; gene expression; mutant; dominant negative	AVIAN ERYTHROBLASTOSIS VIRUS; V-ERBA; NUCLEAR RECEPTORS; MOLECULAR-BASIS; RETINOIC ACID; HIGH-AFFINITY; HUMAN CANCER; HEPG2 CELLS; C-ERBA; RESISTANCE	Thyroid hormone receptors (TRs) are hormone-regulated transcription factors that control multiple aspects of normal physiology and development. Mutations in TRs have been identified at high frequency in certain cancers, including human hepatocellular carcinomas (HCCs). The majority of HCC-TR mutants bear lesions within their DNA recognition domains, and we have hypothesized that these lesions change the mutant receptors' target gene repertoire in a way crucial to their function as oncoproteins. Using stable cell transformants and expression array analysis, we determined that mutant TRs isolated from two different HCCs do, as hypothesized, display a target gene repertoire distinct from that of their normal TR progenitors. Only a subset of genes regulated by wild-type TRs was regulated by the corresponding HCC-TR mutants. More surprisingly, the HCC-TR mutants also gained the ability to regulate additional target genes not recognized by the wild-type receptors, and were not simply restricted to repression, but could also activate a subset of their target genes. We conclude that the TR mutants isolated from HCC have sustained multiple alterations from their normal progenitors that include not only changes in their transcriptional outputs, but also changes in the genes they target; both are likely to contribute to neoplasia. Oncogene (2009) 28, 4162-4174; doi: 10.1038/onc.2009.265; published online 14 September 2009	[Chan, I. H.; Privalsky, M. L.] Univ Calif Davis, Dept Microbiol, Coll Biol Sci, Davis, CA 95616 USA	University of California System; University of California Davis	Privalsky, ML (corresponding author), Univ Calif Davis, Dept Microbiol, Coll Biol Sci, 1 Shields Ave, Davis, CA 95616 USA.	mlprivalsky@ucdavis.edu	Chan, Ivan/B-7922-2010	Chan, Ivan/0000-0003-2834-2574	Public Health Service/National Cancer Institute [R37-CA53394]; UC Davis Cancer Center Gene Expression Resource [NCI P30-CA93373]; National Institute of General Medical Sciences [T32-GM007377]; NATIONAL CANCER INSTITUTE [P30CA093373, R37CA053394] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007377] Funding Source: NIH RePORTER	Public Health Service/National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)United States Public Health Service); UC Davis Cancer Center Gene Expression Resource; National Institute of General Medical Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We are extremely grateful to Liming Liu for excellent technical assistance, Michael L Goodson for expert assistance in analysis of the array data, and Elsie L Campbell for helpful discussions. This work was supported by the Public Health Service/National Cancer Institute award R37-CA53394 and by the UC Davis Cancer Center Gene Expression Resource (NCI P30-CA93373). IHC was supported in part by a PHS predoctoral training award, T32-GM007377, from the National Institute of General Medical Sciences.	BARLOW C, 1994, EMBO J, V13, P4241, DOI 10.1002/j.1460-2075.1994.tb06744.x; Berghagen H, 2002, J BIOL CHEM, V277, P49517, DOI 10.1074/jbc.M209546200; BONDE BG, 1990, J VIROL, V64, P1314, DOI 10.1128/JVI.64.3.1314-1320.1990; Brent G A, 2000, Rev Endocr Metab Disord, V1, P27, DOI 10.1023/A:1010056202122; Buchholz DR, 2006, GEN COMP ENDOCR, V145, P1, DOI 10.1016/j.ygcen.2005.07.009; Chamba A, 1996, J CLIN ENDOCR METAB, V81, P360, DOI 10.1210/jc.81.1.360; Chan IH, 2006, ONCOGENE, V25, P3576, DOI 10.1038/sj.onc.1209389; CHEN HW, 1993, MOL CELL BIOL, V13, P2366, DOI 10.1128/MCB.13.4.2366; Cheng S Y, 2000, Rev Endocr Metab Disord, V1, P9, DOI 10.1023/A:1010052101214; Cheng SY, 2005, TRENDS ENDOCRIN MET, V16, P176, DOI 10.1016/j.tem.2005.03.008; Cheng SY, 2003, MOL CELL ENDOCRINOL, V213, P23, DOI 10.1016/j.mce.2003.10.051; DAMM K, 1989, NATURE, V339, P593, DOI 10.1038/339593a0; DARBY IA, 1991, IN VITRO CELL DEV B, V27, P21, DOI 10.1007/BF02630890; DeGroot LJ, 1996, ANN INTERN MED, V125, P623, DOI 10.7326/0003-4819-125-7-199610010-00022; DESBOIS C, 1991, CELL, V67, P731, DOI 10.1016/0092-8674(91)90068-A; Flamant F, 2006, PHARMACOL REV, V58, P705, DOI 10.1124/pr.58.4.3; Furumoto H, 2005, MOL CELL BIOL, V25, P124, DOI 10.1128/MCB.25.1.124-135.2005; Furuya F, 2006, P NATL ACAD SCI USA, V103, P1780, DOI 10.1073/pnas.0510849103; Garcia-Silva S, 2004, MOL CELL BIOL, V24, P7514, DOI 10.1128/MCB.24.17.7514-7523.2004; Gonzalez-Sancho JM, 2003, CANCER LETT, V192, P121, DOI 10.1016/S0304-3835(02)00614-6; GRAF T, 1983, CELL, V34, P7, DOI 10.1016/0092-8674(83)90130-7; Harvey CB, 2002, THYROID, V12, P441, DOI 10.1089/105072502760143791; Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249; Kamiya Y, 2002, CARCINOGENESIS, V23, P25, DOI 10.1093/carcin/23.1.25; KATZ RW, 1993, J BIOL CHEM, V268, P19392; Kopp P, 1996, P SOC EXP BIOL MED, V211, P49; Lazar MA, 2003, J CLIN INVEST, V112, P497, DOI 10.1172/JCI200319479; LAZAR MA, 1993, ENDOCR REV, V14, P184, DOI 10.1210/er.14.2.184; Lee AY, 2004, BIOCHEM BIOPH RES CO, V323, P1246, DOI 10.1016/j.bbrc.2004.09.001; Lin KH, 1997, ENDOCRINOLOGY, V138, P5308, DOI 10.1210/en.138.12.5308; Lin KH, 1996, ENDOCRINOLOGY, V137, P4073, DOI 10.1210/en.137.10.4073; Lin KH, 1999, MOL CARCINOGEN, V26, P53, DOI 10.1002/(SICI)1098-2744(199909)26:1<53::AID-MC7>3.0.CO;2-Z; Martinez-Iglesias O, 2009, CANCER RES, V69, P501, DOI 10.1158/0008-5472.CAN-08-2198; Matsushita A, 2007, MOL ENDOCRINOL, V21, P865, DOI 10.1210/me.2006-0208; Meyer T, 1997, J BIOL CHEM, V272, P21090, DOI 10.1074/jbc.272.34.21090; Mikheev AM, 2008, BREAST CANCER RES TR, V112, P263, DOI 10.1007/s10549-007-9867-2; Miller LD, 2001, MOL CELL BIOL, V21, P6626, DOI 10.1128/MCB.21.19.6626-6639.2001; Murata Y, 1998, Nagoya J Med Sci, V61, P103; Nygard M, 2003, MOL ENDOCRINOL, V17, P79, DOI 10.1210/me.2002-0107; PRIVALSKY ML, 1992, BIOCHIM BIOPHYS ACTA, V1114, P51, DOI 10.1016/0304-419X(92)90006-K; PRIVALSKY ML, 2008, THRYOID HORMONE RECE; Puzianowska-Kuznicka M, 2002, J CLIN ENDOCR METAB, V87, P1120, DOI 10.1210/jc.87.3.1120; Ramachandran V, 2008, CANCER RES, V68, P7811, DOI 10.1158/0008-5472.CAN-08-1320; RASTINEJAD F, 1995, NATURE, V375, P203, DOI 10.1038/375203a0; REFETOFF S, 1993, CLIN LAB MED, V13, P563, DOI 10.1016/S0272-2712(18)30426-8; REFETOFF S, 1993, ENDOCR REV, V14, P348, DOI 10.1210/er.14.3.348; Reich M, 2006, NAT GENET, V38, P500, DOI 10.1038/ng0506-500; Ricciardelli C, 2009, CANCER METAST REV, V28, P233, DOI 10.1007/s10555-009-9182-y; Rietveld LEG, 2001, ONCOGENE, V20, P3100, DOI 10.1038/sj.onc.1204335; Rosen MD, 2009, MOL ENDOCRINOL, V23, P1183, DOI 10.1210/me.2009-0126; SAP J, 1986, NATURE, V324, P635, DOI 10.1038/324635a0; SHARIF M, 1991, CELL, V66, P885, DOI 10.1016/0092-8674(91)90435-2; SHARIF M, 1992, ONCOGENE, V7, P953; Smyth G. K., 2004, STAT APPL GENET MOL, V3, DOI [10.2202/1544-6115.1027, DOI 10.2202/1544-6115.1027, 10.2202/1544-6115.1027/MACHINEREADABLECITATION/RIS]; Starr DB, 1996, GENE DEV, V10, P1271, DOI 10.1101/gad.10.10.1271; Tagami T, 1997, MOL CELL BIOL, V17, P2642, DOI 10.1128/MCB.17.5.2642; THERIAULT A, 1992, BIOCHEM BIOPH RES CO, V186, P617, DOI 10.1016/0006-291X(92)90791-I; Tsai CC, 2004, VITAM HORM, V68, P93; Uht Rosalie M, 2004, Nucl Recept, V2, P2, DOI 10.1186/1478-1336-2-2; Vadlamudi RK, 2003, CANCER METAST REV, V22, P385, DOI 10.1023/A:1023729130497; Ventura-Holman T, 2008, GENE, V425, P23, DOI 10.1016/j.gene.2008.08.006; Vogelstein B, 2004, NAT MED, V10, P789, DOI 10.1038/nm1087; WEINBERGER C, 1986, NATURE, V324, P641, DOI 10.1038/324641a0; Yen PM, 2001, PHYSIOL REV, V81, P1097, DOI 10.1152/physrev.2001.81.3.1097; Yen PM, 2003, J ENDOCRINOL INVEST, V26, P780, DOI 10.1007/BF03347365; Yen PM, 2003, TRENDS ENDOCRIN MET, V14, P327, DOI 10.1016/S1043-2760(03)00114-0; ZENKE M, 1990, CELL, V61, P1035, DOI 10.1016/0092-8674(90)90068-P; Zhang JS, 2000, ANNU REV PHYSIOL, V62, P439, DOI 10.1146/annurev.physiol.62.1.439; Zhang LP, 2005, CANCER RES, V65, P457	69	31	32	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 26	2009	28	47					4162	4174		10.1038/onc.2009.265	http://dx.doi.org/10.1038/onc.2009.265			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	534DQ	19749797	Green Accepted			2022-12-17	WOS:000272876100003
J	Krumschnabel, G; Manzl, C; Villunger, A				Krumschnabel, G.; Manzl, C.; Villunger, A.			Caspase-2: killer, savior and safeguard-emerging versatile roles for an ill-defined caspase	ONCOGENE			English	Review						caspase; apoptosis; DNA repair; tumor suppression	DNA-DAMAGE; APOPTOSIS; ACTIVATION; COMPLEX; DEATH; MICE; DIFFERENTIATION; PIDDOSOME; STRESS	Despite the early discovery of caspase-2, its physiological function has long remained an enigma. A number of recent publications now suggest not just one, but multiple functions, including roles in apoptosis, DNA repair and tumor suppression. How can one enzyme have so many talents? Considering the diversity of interaction partners and the specific mode of pro-apoptotic action proposed in these studies, caspase-2 might in fact represent a primordial protease serving numerous pathways, established before the advent of a more elaborate functionally diversified caspases system. Oncogene (2009) 28, 3093-3096; doi: 10.1038/onc.2009.173; published online 6 July 2009	[Krumschnabel, G.; Manzl, C.; Villunger, A.] Innsbruck Med Univ, Div Dev Immunol, Bioctr, A-6020 Innsbruck, Austria	Medical University of Innsbruck	Villunger, A (corresponding author), Innsbruck Med Univ, Div Dev Immunol, Bioctr, A-6020 Innsbruck, Austria.	Gerhard.krumschnabel@i-med.ac.at; andreas.villunger@i-med.ac.at	Krumschnabel, Gerhard/E-3694-2010	Krumschnabel, Gerhard/0000-0003-0804-1248	Austrian Science Fund [Y212-B13, SFB021]; EU; Tyrolean Science Fund (TWF)	Austrian Science Fund(Austrian Science Fund (FWF)); EU(European Commission); Tyrolean Science Fund (TWF)	The work in our laboratory is supported by fellowships and grants from the Austrian Science Fund (Y212-B13, SFB021, MCBO), EU-FP6 (ApopTrain) and the Tyrolean Science Fund (TWF). We apologize to the many scientists in this field whose excellent research was not cited but was only referred to indirectly through reviews.	Arama E, 2003, DEV CELL, V4, P687, DOI 10.1016/S1534-5807(03)00120-5; Bergeron L, 1998, GENE DEV, V12, P1304, DOI 10.1101/gad.12.9.1304; Braga M, 2008, APOPTOSIS, V13, P822, DOI 10.1007/s10495-008-0216-7; de Botton S, 2002, BLOOD, V100, P1310, DOI 10.1182/blood-2002-03-0686; Ditzel M, 2008, MOL CELL, V32, P540, DOI 10.1016/j.molcel.2008.09.025; Duan H, 1997, NATURE, V385, P86, DOI 10.1038/385086a0; Gonzalvez F, 2008, J CELL BIOL, V183, P681, DOI 10.1083/jcb.200803129; Ho LH, 2009, P NATL ACAD SCI USA, V106, P5336, DOI 10.1073/pnas.0811928106; Krumschnabel G, 2009, CELL DEATH DIFFER, V16, P195, DOI 10.1038/cdd.2008.170; KUMAR S, 1992, BIOCHEM BIOPH RES CO, V185, P1155, DOI 10.1016/0006-291X(92)91747-E; Lamkanfi M, 2007, CELL DEATH DIFFER, V14, P44, DOI 10.1038/sj.cdd.4402047; Lavrik IN, 2006, BLOOD, V108, P559, DOI 10.1182/blood-2005-07-007096; Li J, 2008, ONCOGENE, V27, P6194, DOI 10.1038/onc.2008.297; Mancini M, 2000, J CELL BIOL, V149, P603, DOI 10.1083/jcb.149.3.603; Nutt LK, 2005, CELL, V123, P89, DOI 10.1016/j.cell.2005.07.032; Olsson M, 2009, ONCOGENE, V28, P1949, DOI 10.1038/onc.2009.36; Samraj AK, 2007, MOL BIOL CELL, V18, P84, DOI 10.1091/mbc.E06-04-0263; Scott CL, 2004, J CELL BIOL, V164, P89, DOI 10.1083/jcb.200310041; Shi MG, 2009, CELL, V136, P508, DOI 10.1016/j.cell.2008.12.021; Sidi S, 2008, CELL, V133, P864, DOI 10.1016/j.cell.2008.03.037; Tinel A, 2004, SCIENCE, V304, P843, DOI 10.1126/science.1095432; Yi CH, 2009, DEV CELL, V16, P21, DOI 10.1016/j.devcel.2008.12.012; Zhang YP, 2007, MECH AGEING DEV, V128, P213, DOI 10.1016/j.mad.2006.11.030; Zhivotovsky B, 2006, CARCINOGENESIS, V27, P1939, DOI 10.1093/carcin/bgl035	24	31	32	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2009	28	35					3093	3096		10.1038/onc.2009.173	http://dx.doi.org/10.1038/onc.2009.173			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	490QC	19581929	Green Accepted			2022-12-17	WOS:000269515100001
J	Jones, RA; Campbell, CI; Wood, GA; Petrik, JJ; Moorehead, RA				Jones, R. A.; Campbell, C. I.; Wood, G. A.; Petrik, J. J.; Moorehead, R. A.			Reversibility and recurrence of IGF-IR-induced mammary tumors	ONCOGENE			English	Article						insulin-like growth factor; mammary tumorigenesis; tumor recurrence; epithelial to mesenchymal transition; tumor dormancy	GROWTH-FACTOR-I; HUMAN-BREAST-CANCER; MONOCLONAL-ANTIBODY; TRANSCRIPTIONAL REPRESSOR; TRANSGENIC MICE; FACTOR RECEPTOR; MESSENGER-RNA; GENE-EXPRESSION; KINASE-ACTIVITY; SOLID TUMORS	The type-I insulin-like growth factor receptor (IGF-IR) is frequently overexpressed in breast cancer and therapeutic agents targeting IGF-IR are currently in development. The ultimate success of anti-IGF-IR therapies will depend on the extent to which established tumors remain dependent upon IGF-IR signaling for sustained growth. To investigate the potential benefits and pitfalls of targeting IGF-IR, we used a doxycycline inducible mouse model of IGF-IR initiated breast cancer. We found that downregulation of IGF-IR results in tumor-size-dependent regression to an undetectable state. Partially regressed tumors almost always resumed growth in the absence of doxycycline and a proportion of tumors that regressed to an undetectable state ultimately recurred. This reemergence of tumor growth in the absence of doxycycline was facilitated by IGF-IR-dependent and IGF-IR-independent mechanisms. Tumor escape from IGF-IR dependence was associated with an epithelial to mesenchymal transition and upregulation of transcriptional repressors of E-cadherin. These results suggest that tumors initiated by IGF-IR have the ability to become independent of this initiating oncogene, and IGF-IR independence is associated with characteristics consistent with an epithelial to mesenchymal transition. Oncogene (2009) 28, 2152-2162; doi: 10.1038/onc.2009.79; published online 20 April 2009	[Jones, R. A.; Campbell, C. I.; Petrik, J. J.; Moorehead, R. A.] Univ Guelph, Ontario Vet Coll, Dept Biomed Sci, Guelph, ON N1G 2W1, Canada; [Wood, G. A.] Univ Guelph, Ontario Vet Coll, Dept Pathobiol, Guelph, ON N1G 2W1, Canada	University of Guelph; University of Guelph	Moorehead, RA (corresponding author), Univ Guelph, Ontario Vet Coll, Dept Biomed Sci, Guelph, ON N1G 2W1, Canada.	rmoorehe@uoguelph.ca	Wood, Geoffrey/ABB-2052-2021	Wood, Geoffrey/0000-0003-1756-8607; , Roger/0000-0001-9539-6295; Jones, Robert/0000-0001-7665-9301	Canadian Institutes of Health Research; Canadian Breast Cancer Research Alliance; Ontario Graduate Scholarships	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Canadian Breast Cancer Research Alliance; Ontario Graduate Scholarships(Ontario Graduate Scholarship)	We thank Katrina Watson, Helen Coates and Michelle Ross for excellent technical assistance. This work was supported by operating grants from the Canadian Institutes of Health Research, the Canadian Breast Cancer Research Alliance, the Cancer Research Society as well as a New Investigator Salary Award from the Canadian Institutes of Health Research (RA Moorehead) and Ontario Graduate Scholarships (RA Jones and CI Campbell).	Aguirre-Ghiso JA, 2007, NAT REV CANCER, V7, P834, DOI 10.1038/nrc2256; Ali S, 2002, NAT REV CANCER, V2, P101, DOI 10.1038/nrc721; ARTEAGA CL, 1989, J CLIN INVEST, V84, P1418, DOI 10.1172/JCI114315; BATES P, 1995, BRIT J CANCER, V72, P1189, DOI 10.1038/bjc.1995.484; Boxer RB, 2004, CANCER CELL, V6, P577, DOI 10.1016/j.ccr.2004.10.013; Burtrum D, 2003, CANCER RES, V63, P8912; Carboni JM, 2005, CANCER RES, V65, P3781, DOI 10.1158/0008-5472.CAN-04-4602; Chaffer CL, 2006, CANCER RES, V66, P11271, DOI 10.1158/0008-5472.CAN-06-2044; Chernicky CL, 2000, CANCER GENE THER, V7, P384, DOI 10.1038/sj.cgt.7700126; D'Cruz CM, 2001, NAT MED, V7, P235, DOI 10.1038/84691; Debies MT, 2008, J CLIN INVEST, V118, P51, DOI 10.1172/JCI33320; Divisova J, 2006, BREAST CANCER RES TR, V98, P315, DOI 10.1007/s10549-006-9168-1; Dunn SE, 1998, CANCER RES, V58, P3353; Eger A, 2005, ONCOGENE, V24, P2375, DOI 10.1038/sj.onc.1208429; Feng Y, 2006, MOL CANCER THER, V5, P114, DOI 10.1158/1535-7163.MCT-05-0252; Giani C, 1996, BREAST CANCER RES TR, V41, P43, DOI 10.1007/BF01807035; Goetsch L, 2005, INT J CANCER, V113, P316, DOI 10.1002/ijc.20543; Gunther EJ, 2003, GENE DEV, V17, P488, DOI 10.1101/gad.1051603; Hadsell DL, 2000, ONCOGENE, V19, P889, DOI 10.1038/sj.onc.1203386; Haluska P, 2007, CLIN CANCER RES, V13, P5834, DOI 10.1158/1078-0432.CCR-07-1118; Hankinson SE, 1998, LANCET, V351, P1393, DOI 10.1016/S0140-6736(97)10384-1; Hudis CA, 2007, NEW ENGL J MED, V357, P39, DOI 10.1056/NEJMra043186; Hugo H, 2007, J CELL PHYSIOL, V213, P374, DOI 10.1002/jcp.21223; Jones RA, 2007, ONCOGENE, V26, P1636, DOI 10.1038/sj.onc.1209955; Jones RA, 2008, MOL CANCER RES, V6, P819, DOI 10.1158/1541-7786.MCR-07-2157; Kato M, 2007, P NATL ACAD SCI USA, V104, P3432, DOI 10.1073/pnas.0611192104; Kurebayashi Junichi, 2007, Breast Cancer, V14, P200, DOI 10.2325/jbcs.954; LeRoith D, 2003, CANCER LETT, V195, P127, DOI 10.1016/S0304-3835(03)00159-9; Linnerth NM, 2005, INT J CANCER, V114, P977, DOI 10.1002/ijc.20814; Lu YH, 2001, JNCI-J NATL CANCER I, V93, P1852, DOI 10.1093/jnci/93.24.1852; Mitsiades CS, 2004, CANCER CELL, V5, P221, DOI 10.1016/S1535-6108(04)00050-9; Moody SE, 2005, CANCER CELL, V8, P197, DOI 10.1016/j.ccr.2005.07.009; Moody SE, 2002, CANCER CELL, V2, P451, DOI 10.1016/S1535-6108(02)00212-X; Nahta R, 2007, ONCOGENE, V26, P3637, DOI 10.1038/sj.onc.1210379; Nichols KD, 2008, BIOCHEM PHARMACOL, V75, P1230, DOI 10.1016/j.bcp.2007.10.032; PAIK S, 1992, BREAST CANCER RES TR, V22, P31, DOI 10.1007/BF01833331; Parisot JP, 1999, BRIT J CANCER, V79, P693, DOI 10.1038/sj.bjc.6690112; Pattyn F, 2006, NUCLEIC ACIDS RES, V34, pD684, DOI 10.1093/nar/gkj155; Peinado H, 2007, NAT REV CANCER, V7, P415, DOI 10.1038/nrc2131; Podsypanina K, 2008, P NATL ACAD SCI USA, V105, P5242, DOI 10.1073/pnas.0801197105; Pollak MN, 2004, NAT REV CANCER, V4, P505, DOI 10.1038/nrc1387; Pravtcheva DD, 1998, J EXP ZOOL, V281, P43, DOI 10.1002/(SICI)1097-010X(19980501)281:1<43::AID-JEZ7>3.3.CO;2-3; Renehan AG, 2004, LANCET, V363, P1346, DOI 10.1016/S0140-6736(04)16044-3; Resnik JL, 1998, CANCER RES, V58, P1159; Rowinsky EK, 2007, CLIN CANCER RES, V13, p5549S, DOI 10.1158/1078-0432.CCR-07-1109; SINGER C, 1995, CANCER RES, V55, P2448; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; Surmacz E, 2000, J MAMMARY GLAND BIOL, V5, P95, DOI 10.1023/A:1009523501499; Vesuna F, 2008, BIOCHEM BIOPH RES CO, V367, P235, DOI 10.1016/j.bbrc.2007.11.151; Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006; YEE D, 1988, CANCER RES, V48, P6691; YEE D, 1989, MOL ENDOCRINOL, V3, P509, DOI 10.1210/mend-3-3-509	52	31	35	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 28	2009	28	21					2152	2162		10.1038/onc.2009.79	http://dx.doi.org/10.1038/onc.2009.79			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	451DQ	19377512				2022-12-17	WOS:000266451300004
J	Laitem, C; Leprivier, G; Choul-Li, S; Begue, A; Monte, D; Larsimont, D; Dumont, P; Duterque-Coquillaud, M; Aumercier, M				Laitem, C.; Leprivier, G.; Choul-Li, S.; Begue, A.; Monte, D.; Larsimont, D.; Dumont, P.; Duterque-Coquillaud, M.; Aumercier, M.			Ets-1 p27: a novel Ets-1 isoform with dominant-negative effects on the transcriptional properties and the subcellular localization of Ets-1 p51	ONCOGENE			English	Article						Ets-1; transcriptional regulation; subcellular localization; dominant-negative isoform; alternative splicing	ALTERNATIVELY SPLICED ISOFORMS; MESSENGER-RNA; DNA-BINDING; STROMELYSIN PROMOTER; ENDOTHELIAL-CELLS; EXPRESSION; PROTEIN; GENE; PROTOONCOGENE; CARCINOMA	The transcription factor Ets-1 is implicated in various physiological processes and invasive pathologies. We identified a novel variant of ets-1, ets-1 Delta(III-VI), resulting from the alternative splicing of exons III to VI. This variant encodes a 27 kDa isoform, named Ets-1 p27. Ets-1 p27 lacks the threonine-38 residue, the Pointed domain and the transactivation domain, all of which are required for the transactivation of Ets-1 target genes. Both inhibitory domains surrounding the DNA-binding domain are conserved, suggesting that Ets-1 p27, like the full-length Ets-1 p51 isoform, is autoinhibited for DNA binding. We showed that Ets-1 p27 binds DNA in the same way as Ets-1 p51 does and that it acts both at a transcriptional and a subcellular localization level, thereby constituting a dual-acting dominant negative of Ets-1 p51. Ets-1 p27 blocks Ets-1 p51-mediated transactivation of target genes and induces the translocation of Ets-1 p51 from the nucleus to the cytoplasm. Furthermore, Ets-1 p27 overexpression represses the tumor properties of MDA-MB-231 mammary carcinoma cells in correlation with the known implication of Ets-1 in various cellular mechanisms. Thus the dual-acting dominant-negative function of Ets-1 p27 gives to the Ets-1 p27/Ets-1 p51 ratio a determining effect on cell fate. Oncogene (2009) 28, 2087-2099; doi:10.1038/onc.2009.72; published online 20 April 2009	[Laitem, C.; Leprivier, G.; Choul-Li, S.; Begue, A.; Monte, D.; Dumont, P.; Duterque-Coquillaud, M.; Aumercier, M.] Univ Lille 1, Inst Pasteur Lille, Inst Biol Lille, CNRS,UMR 8161, F-59021 Lille, France; [Laitem, C.; Leprivier, G.; Choul-Li, S.; Begue, A.; Monte, D.; Dumont, P.; Duterque-Coquillaud, M.; Aumercier, M.] Univ Lille 2, IFR 142, Lille, France; [Larsimont, D.] Inst Jules Bordet, Dept Pathol, B-1000 Brussels, Belgium	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Universite de Lille; Universite de Lille - ISITE; Universite de Lille; Institut Jules Bordet; Universite Catholique Louvain; Cliniques Universitaires Saint-Luc	Aumercier, M (corresponding author), Univ Lille 1, Inst Pasteur Lille, Inst Biol Lille, CNRS,UMR 8161, 1 Rue Prof Calmette,BP 447, F-59021 Lille, France.	marc.aumercier@ibl.fr	CHOUL-LI, Souhaila/ABA-2431-2020	CHOUL-LI, Souhaila/0000-0003-0682-4214; monte, didier/0000-0002-0613-6203; Duterque-Coquillaud, Martine/0000-0003-3943-5629	Centre National de la Recherche Scientifique (CNRS); la Ligue contre le Cancer- Comite du Pas-de-Calais; Fondation pour la Recherche Medicale-Comite Nord-Pas-de-Calais (FRM)	Centre National de la Recherche Scientifique (CNRS)(Centre National de la Recherche Scientifique (CNRS)); la Ligue contre le Cancer- Comite du Pas-de-Calais; Fondation pour la Recherche Medicale-Comite Nord-Pas-de-Calais (FRM)(Fondation pour la Recherche Medicale)	We thank Isabelle Roland, Anne-Claire Flourens, Nathalie Tomavo and Arnaud Legrand for technical assistance, and Dr Yvan de Launoit for stimulating discussions. We thank the Microscopy Facility of the Institut Pasteur de Lille Campus. This work was supported by the Centre National de la Recherche Scientifique (CNRS) and by grants from la Ligue contre le Cancer- Comite du Pas-de-Calais and from the Fondation pour la Recherche Medicale-Comite Nord-Pas-de-Calais (FRM). The Ministere de la Recherche et de l'Enseignement Superieur provided a student fellowship to Clelia Laitem. La Ligue contre le Cancer provided a student fellowship to Gabriel Leprivier. The CNRS and the Conseil Regional du Nord-Pas-de-Calais provided a PhD fellowship (BDI) to Souhaila Choul-li.	Alipov G, 2005, HISTOPATHOLOGY, V46, P202, DOI 10.1111/j.1365-2559.2005.02059.x; Araud T, 2007, NUCLEIC ACIDS RES, V35, P4649, DOI 10.1093/nar/gkm482; Baillat D, 2006, ONCOGENE, V25, P5764, DOI 10.1038/sj.onc.1209583; Baillat D, 2002, J BIOL CHEM, V277, P29386, DOI 10.1074/jbc.M200088200; Baillat D, 2009, BIOCHEM BIOPH RES CO, V378, P213, DOI 10.1016/j.bbrc.2008.11.035; BUTTICE G, 1993, J BIOL CHEM, V268, P7196; Cho JY, 2004, J BIOL CHEM, V279, P19512, DOI 10.1074/jbc.M309074200; Coutte L, 1999, ONCOGENE, V18, P6278, DOI 10.1038/sj.onc.1203020; Cowley DO, 2000, GENE DEV, V14, P366; De Haro L, 2005, GENOMICS, V85, P493, DOI 10.1016/j.ygeno.2004.12.003; de Nigris F, 2001, CANCER RES, V61, P2267; Dittmer Jurgen, 2003, Mol Cancer, V2, P29, DOI 10.1186/1476-4598-2-29; FISHER RJ, 1994, PROTEIN SCI, V3, P257; Foulds CE, 2004, MOL CELL BIOL, V24, P10954, DOI 10.1128/MCB.24.24.10954-10964.2004; Hewett PW, 2001, INT J BIOCHEM CELL B, V33, P347, DOI 10.1016/S1357-2725(01)00022-X; HIGASHINO F, 1995, ONCOGENE, V10, P1461; Higuchi T, 2007, MOL CELL BIOL, V27, P3353, DOI 10.1128/MCB.01871-06; Jayaraman G, 1999, J BIOL CHEM, V274, P17342, DOI 10.1074/jbc.274.24.17342; John SA, 2008, J BIOL CHEM, V283, P951, DOI 10.1074/jbc.M705262200; JORCYK CL, 1991, ONCOGENE, V6, P523; Katayama S, 2005, HISTOL HISTOPATHOL, V20, P119, DOI 10.14670/HH-20.119; Kherrouche Z, 2006, BIOCHEM J, V396, P547, DOI 10.1042/BJ20051981; Kita D, 2001, CANCER RES, V61, P7985; Kitange G, 1999, MODERN PATHOL, V12, P618; KOIZUMI S, 1990, ONCOGENE, V5, P675; Laitem C, 2008, PROTEIN EXPRES PURIF, V62, P53, DOI 10.1016/j.pep.2008.06.010; Lee GM, 2005, J BIOL CHEM, V280, P7088, DOI 10.1074/jbc.M410722200; Lei WL, 2007, AM J PHYSIOL-LUNG C, V293, pL1359, DOI 10.1152/ajplung.00130.2007; Li B, 2007, FRONT BIOSCI-LANDMRK, V12, P2269, DOI 10.2741/2229; Li RH, 1999, P NATL ACAD SCI USA, V96, P3876, DOI 10.1073/pnas.96.7.3876; Lulli V, 2006, CELL DEATH DIFFER, V13, P1064, DOI 10.1038/sj.cdd.4401811; Maroulakou IG, 2000, ONCOGENE, V19, P6432, DOI 10.1038/sj.onc.1204039; Mylona EE, 2006, CANCER DETECT PREV, V30, P111, DOI 10.1016/j.cdp.2006.03.006; Nakayama T, 2001, MODERN PATHOL, V14, P415, DOI 10.1038/modpathol.3880328; O'Leary DA, 2005, GENE, V344, P79, DOI 10.1016/j.gene.2004.09.031; POGNONEC P, 1990, ONCOGENE, V5, P603; Pufall MA, 2002, ANNU REV CELL DEV BI, V18, P421, DOI 10.1146/annurev.cellbio.18.031502.133614; Raffetseder U, 2004, KIDNEY INT, V66, P622, DOI 10.1111/j.1523-1755.2004.00782.x; RayGallet D, 1996, BIOCHEM BIOPH RES CO, V223, P257, DOI 10.1006/bbrc.1996.0881; Redlich K, 2001, ARTHRITIS RHEUM, V44, P266, DOI 10.1002/1529-0131(200102)44:2<266::AID-ANR43>3.3.CO;2-7; ROWE A, 1992, EXP CELL RES, V202, P199, DOI 10.1016/0014-4827(92)90420-D; Sarrazin S, 2000, MOL CELL BIOL, V20, P2959, DOI 10.1128/MCB.20.9.2959-2969.2000; Sasaki A, 2004, BIOCHEM BIOPH RES CO, V317, P1128, DOI 10.1016/j.bbrc.2004.03.172; Seidel JJ, 2002, GENE DEV, V16, P127, DOI 10.1101/gad.950902; Shin C, 2004, NAT REV MOL CELL BIO, V5, P727, DOI 10.1038/nrm1467; Smith CWJ, 2000, TRENDS BIOCHEM SCI, V25, P381, DOI 10.1016/S0968-0004(00)01604-2; Stamm S, 2005, GENE, V344, P1, DOI 10.1016/j.gene.2004.10.022; Takai N, 2000, CANCER, V89, P2059, DOI 10.1002/1097-0142(20001115)89:10<2059::AID-CNCR5>3.0.CO;2-3; Takai N, 2006, GYNECOL OBSTET INVES, V61, P15, DOI 10.1159/000087855; Takai N, 2002, INT J MOL MED, V9, P287; Taniguchi H, 2007, INT J CANCER, V121, P1609, DOI 10.1002/ijc.22870; Teruyama K, 2001, J CELL PHYSIOL, V188, P243, DOI 10.1002/jcp.1112; Valter MM, 1999, CANCER RES, V59, P5608; WASYLYK C, 1991, EMBO J, V10, P1127, DOI 10.1002/j.1460-2075.1991.tb08053.x	54	31	33	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 21	2009	28	20					2087	2099		10.1038/onc.2009.72	http://dx.doi.org/10.1038/onc.2009.72			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	448BI	19377509				2022-12-17	WOS:000266235800003
J	Ciarapica, R; Annibali, D; Raimondi, L; Savino, M; Nasi, S; Rota, R				Ciarapica, R.; Annibali, D.; Raimondi, L.; Savino, M.; Nasi, S.; Rota, R.			Targeting Id protein interactions by an engineered HLH domain induces human neuroblastoma cell differentiation	ONCOGENE			English	Article						HLH domain; Id proteins; neuroblastoma; differentiation	HELIX-LOOP-HELIX; NEGATIVE AUTOREGULATION; RETINOBLASTOMA PROTEIN; SELF-RENEWAL; CYCLE ARREST; EXPRESSION; CANCER; PROLIFERATION; TRANSCRIPTION; TUMORS	Inhibitor of DNA-binding (Id) proteins prevent cell differentiation, promote growth and sustain tumour development. They do so by binding to E proteins and other transcription factors through the helix-loop-helix (HLH) domain, and inhibiting transcription. This makes HLH-mediated Id protein interactions an appealing therapeutic target. We have used the dominant interfering HLH dimerization mutant 13I to model the impact of Id inhibition in two human neuroblastoma cell lines: LA-N-5, similar to immature neuroblasts, and SH-EP, resembling more immature precursor cells. We have validated 13I as an Id inhibitor by showing that it selectively binds to Ids, impairs complex formation with RB, and relieves repression of E protein-activated transcription. Id inactivation by 13I enhances LA-N-5 neural features and causes SH-EP cells to acquire neuronal morphology, express neuronal proteins such as N-CAMand NF-160, proliferate more slowly, and become responsive to retinoic acid. Concomitantly, 13I augments the cell-cycle inhibitor p27(Kip1) and reduces the angiogenic factor vascular endothelial growth factor. These effects are Id specific, being counteracted by Id overexpression. Furthermore, 13I strongly impairs tumorigenic properties in agar colony formation and cell invasion assays. Targeting Id dimerization may therefore be effective for triggering differentiation and restraining neuroblastoma cell tumorigenicity.	[Ciarapica, R.; Raimondi, L.; Rota, R.] Osped Pediat Bambino Gesu, Angiogenesis Lab, I-00165 Rome, Italy; [Annibali, D.; Savino, M.; Nasi, S.] CNR, Ist Biol & Patol Mol, Rome, Italy	IRCCS Bambino Gesu; Consiglio Nazionale delle Ricerche (CNR); Istituto di Biologia e Patologia Molecolari (IBPM-CNR)	Rota, R (corresponding author), Osped Pediat Bambino Gesu, Angiogenesis Lab, Piazza S Onofrio 4, I-00165 Rome, Italy.	sergio.nasi@uniroma1.it; rota@opbg.net	Raimondi, Lavinia/K-4085-2016; Annibali, Daniela/AAE-3004-2019; Rota, Rossella/AAB-2497-2019; Annibali, Daniela/AAC-5270-2019	Raimondi, Lavinia/0000-0001-9394-2002; Rota, Rossella/0000-0002-9408-7711; Annibali, Daniela/0000-0001-8413-7669				Bai G, 2007, DEV CELL, V13, P283, DOI 10.1016/j.devcel.2007.05.014; Bergmann E, 2001, INT J CANCER, V95, P176, DOI 10.1002/1097-0215(20010520)95:3<176::AID-IJC1030>3.3.CO;2-Q; Brodeur GM, 2003, NAT REV CANCER, V3, P203, DOI 10.1038/nrc1014; Chassot AA, 2007, ONCOGENE, V26, P5772, DOI 10.1038/sj.onc.1210386; Ciarapica R, 2003, J BIOL CHEM, V278, P12182, DOI 10.1074/jbc.M211991200; CICCARONE V, 1989, CANCER RES, V49, P219; COHEN PS, 1988, AM J PATHOL, V131, P391; Santos MDL, 2007, MOL CANCER THER, V6, P1425, DOI 10.1158/1535-7163.MCT-06-0623; Farah MH, 2000, DEVELOPMENT, V127, P693; Henke E, 2008, NAT BIOTECHNOL, V26, P91, DOI 10.1038/nbt1366; Hirata H, 2002, SCIENCE, V298, P840, DOI 10.1126/science.1074560; IAVARONE A, 1994, GENE DEV, V8, P1270, DOI 10.1101/gad.8.11.1270; Iavarone A, 2006, TRENDS MOL MED, V12, P588, DOI 10.1016/j.molmed.2006.10.007; Jankovic V, 2007, P NATL ACAD SCI USA, V104, P1260, DOI 10.1073/pnas.0607894104; Jogi A, 2002, J BIOL CHEM, V277, P9118, DOI 10.1074/jbc.M107713200; Kondo M, 2004, CELL DEATH DIFFER, V11, P1092, DOI 10.1038/sj.cdd.4401467; Lasorella A, 2000, NATURE, V407, P592, DOI 10.1038/35036504; Lasorella A, 2005, MOL CELL BIOL, V25, P3563, DOI 10.1128/MCB.25.9.3563-3574.2005; Li YJ, 2007, J AM SOC NEPHROL, V18, P449, DOI 10.1681/ASN.2006030236; Liu YH, 2004, MOL CELL BIOL, V24, P2662, DOI 10.1128/MCB.24.7.2662-2672.2004; Lofstedt T, 2004, J BIOL CHEM, V279, P39223, DOI 10.1074/jbc.M402904200; Lyden D, 1999, NATURE, V401, P670, DOI 10.1038/44334; Ohtani N, 2001, NATURE, V409, P1067, DOI 10.1038/35059131; PENN LJZ, 1990, EMBO J, V9, P1113, DOI 10.1002/j.1460-2075.1990.tb08217.x; Perk J, 2005, NAT REV CANCER, V5, P603, DOI 10.1038/nrc1673; Reynolds CP, 2003, CANCER LETT, V197, P185, DOI 10.1016/S0304-3835(03)00108-3; Roberts EC, 2001, MOL CELL BIOL, V21, P524, DOI 10.1128/MCB.21.2.524-533.2001; Rothschild G, 2006, MOL CELL BIOL, V26, P4351, DOI 10.1128/MCB.01743-05; Ruzinova MB, 2003, TRENDS CELL BIOL, V13, P410, DOI 10.1016/S0962-8924(03)00147-8; Sakurai D, 2004, J IMMUNOL, V173, P5801, DOI 10.4049/jimmunol.173.9.5801; Schwab M, 2004, CANCER LETT, V204, P179, DOI 10.1016/S0304-3835(03)00454-3; Soucek L, 1998, ONCOGENE, V17, P2463, DOI 10.1038/sj.onc.1202199; Soucek L, 2008, NATURE, V455, P679, DOI 10.1038/nature07260; Tanaka T, 2007, EMBO J, V26, P3250, DOI 10.1038/sj.emboj.7601744; Toschi E, 2000, J INVEST DERMATOL, V114, P1188, DOI 10.1046/j.1523-1747.2000.00000.x; Vandeputte DAA, 2002, GLIA, V38, P329, DOI 10.1002/glia.10076; Vandesompele J, 2003, ONCOGENE, V22, P456, DOI 10.1038/sj.onc.1206148; Voigt A, 2000, CELL ADHES COMMUN, V7, P423, DOI 10.3109/15419060009109023; Wainwright LJ, 2001, P NATL ACAD SCI USA, V98, P9396, DOI 10.1073/pnas.161288698; Wiercinska E, 2006, HEPATOLOGY, V43, P1032, DOI 10.1002/hep.21135; Ying QL, 2003, CELL, V115, P281, DOI 10.1016/S0092-8674(03)00847-X	41	31	31	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 30	2009	28	17					1881	1891		10.1038/onc.2009.56	http://dx.doi.org/10.1038/onc.2009.56			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	439PX	19330020				2022-12-17	WOS:000265640600001
J	Robert, I; Aussems, M; Keutgens, A; Zhang, X; Hennuy, B; Viatour, P; Vanstraelen, G; Merville, MP; Chapelle, JP; de Leval, L; Lambert, F; Dejardin, E; Gothot, A; Chariot, A				Robert, I.; Aussems, M.; Keutgens, A.; Zhang, X.; Hennuy, B.; Viatour, P.; Vanstraelen, G.; Merville, M-P; Chapelle, J-P; de Leval, L.; Lambert, F.; Dejardin, E.; Gothot, A.; Chariot, A.			Matrix Metalloproteinase-9 gene induction by a truncated oncogenic NF-kappa B2 protein involves the recruitment of MLL1 and MLL2 H3K4 histone methyltransferase complexes	ONCOGENE			English	Article						NF-kappa B; MMP9; H3K4 HMT; p100	NF-KAPPA-B; CHRONIC LYMPHOCYTIC-LEUKEMIA; REED-STERNBERG CELLS; SIGNALING PATHWAYS; SACCHAROMYCES-CEREVISIAE; LYSINE-4 METHYLATION; MULTIPLE-MYELOMA; LYMPHOMA-CELLS; ACTIVE GENES; ALPHA-GENE	Constitutive nuclear factor (NF)-kappa Ba ctivation in haematological malignancies is caused in several cases by loss of function mutations within the coding sequence of NF-kappa B inhibitory molecules such as I kappa B alpha or p100. Hut-78, a truncated form of p100, constitutively generates p52 and contributes to the development of T-cell lymphomas but the molecular mechanism underlying this oncogenic potential remains unclear. We show here that MMP9 gene expression is induced through the alternative NF-kappa B-activating pathway in fibroblasts and also on Hut-78 or p52 overexpression in fibroblasts as well as in lymphoma cells. p52 is critical for Hut-78-mediated MMP9 gene induction as a Hut-78 mutant as well as other truncated NF-kappa B2 proteins that are not processed into p52 failed to induce the expression of this metalloproteinase. Conversely, MMP9 gene expression is impaired in p52-depleted HUT-78 cells. Interestingly, MLL1 and MLL2 H3K4 methyltransferase complexes are tethered by p52 on the MMP9 but not on the I kappa B alpha promoter, and the H3K4 trimethyltransferase activity recruited on the MMP9 promoter is impaired in p52-depleted HUT-78 cells. Moreover, MLL1 and MLL2 are associated with Hut-78 in a native chromatin-enriched extract. Thus, we identified a molecular mechanism by which the recruitment of a H3K4 histone methyltransferase complex on the promoter of a NF-kappa B-dependent gene induces its expression and potentially the invasive potential of lymphoma cells harbouring constitutive activity of the alternative NF-kappa B-activating pathway.	[Chariot, A.] Univ Liege, CHU Sart Tilman, Lab Chem Med,Interdisciplinary Cluster Appl Genop, Unit Signal Transduct,GIGA R,Tour GIGA, B-4000 Liege, Belgium; [Robert, I.; Aussems, M.; Keutgens, A.; Zhang, X.; Viatour, P.; Merville, M-P; Chapelle, J-P; Dejardin, E.; Chariot, A.] Univ Liege, CHU Sart Tilman, GIGA Signal Transduct, B-4000 Liege, Belgium; [Hennuy, B.] Univ Liege, CHU Sart Tilman, GIGA Transcript Facil, B-4000 Liege, Belgium; [Vanstraelen, G.; Gothot, A.] Univ Liege, CHU Sart Tilman, Dept Med Hematol, B-4000 Liege, Belgium; [de Leval, L.] Univ Liege, CHU Sart Tilman, Dept Pathol, B-4000 Liege, Belgium; [Lambert, F.] Univ Liege, CHU Sart Tilman, Lab Human Genet, B-4000 Liege, Belgium; [Dejardin, E.] Univ Liege, CHU Sart Tilman, Lab Virol & Immunol, B-4000 Liege, Belgium	University of Liege; University of Liege; University of Liege; University of Liege; University of Liege; University of Liege; University of Liege	Chariot, A (corresponding author), Univ Liege, CHU Sart Tilman, Lab Chem Med,Interdisciplinary Cluster Appl Genop, Unit Signal Transduct,GIGA R,Tour GIGA, 2 B34, B-4000 Liege, Belgium.	Alain.chariot@ulg.ac.be	de Leval, Laurence/M-4889-2017; Dejardin, Emmanuel/AAE-9076-2021	de Leval, Laurence/0000-0003-3994-516X; Chariot, Alain/0000-0002-1691-4347	University of Liege (ULg); FNRS; TELEVIE; Belgian Federation against Cancer; Belgian State, Science Policy Office [IAP6/18]	University of Liege (ULg)(University of Liege); FNRS(Fonds de la Recherche Scientifique - FNRS); TELEVIE; Belgian Federation against Cancer; Belgian State, Science Policy Office(Belgian Federal Science Policy Office)	We are gratefulto F Fuks for helpful discussions, to M Pasparakis, Y St-Pierre and R Weil for the gifts of wild-type and NEMO-deficient mouse embryonic fibroblasts, the 164T2 cell line and the anti-NEMO antibody, respectively. We also thank Dr J-H Lee, Dr DG Skalnik and Dr C van Lint for the gift of expression plasmids. M- PM, LdeL and AC are Senior Research Associates whereas ED is Research Associate at the Belgian National fund for Research ('FNRS'). IR and XZ are 'TELEVIE' Research Assistants whereas MA and AK are 'FNRS' Research Assistants. This work was supported by grants from the University of Liege ( ULg), FNRS, TELEVIE, the Belgian Federation against Cancer, the IAP6/18 (funded by the Interuniversity Attraction Poles Programme, initiated by the Belgian State, Science Policy Office), the 'Centre Antireux and Fonds Leon Fredeericq (Faculty of Medicine, ULg).	Allis CD, 2007, CELL, V131, P633, DOI 10.1016/j.cell.2007.10.039; Annunziata CM, 2007, CANCER CELL, V12, P115, DOI 10.1016/j.ccr.2007.07.004; Aoudjit F, 1998, BLOOD, V91, P623, DOI 10.1182/blood.V91.2.623.623_623_629; Aygun O, 2008, P NATL ACAD SCI USA, V105, P8580, DOI 10.1073/pnas.0804424105; Berger SL, 2007, NATURE, V447, P407, DOI 10.1038/nature05915; Bhaumik SR, 2007, NAT STRUCT MOL BIOL, V14, P1008, DOI 10.1038/nsmb1337; Bonizzi G, 2004, TRENDS IMMUNOL, V25, P280, DOI 10.1016/j.it.2004.03.008; BOURS V, 1993, CELL, V72, P729, DOI 10.1016/0092-8674(93)90401-B; Briggs SD, 2001, GENE DEV, V15, P3286, DOI 10.1101/gad.940201; Cabannes E, 1999, ONCOGENE, V18, P3063, DOI 10.1038/sj.onc.1202893; CHANG CC, 1995, MOL CELL BIOL, V15, P5180; Claudio E, 2002, NAT IMMUNOL, V3, P958, DOI 10.1038/ni842; Coope HJ, 2002, EMBO J, V21, P5375, DOI 10.1093/emboj/cdf542; Courtois G, 2006, ONCOGENE, V25, P6831, DOI 10.1038/sj.onc.1209939; De Santa F, 2007, CELL, V130, P1083, DOI 10.1016/j.cell.2007.08.019; Dejardin E, 2002, IMMUNITY, V17, P525, DOI 10.1016/S1074-7613(02)00423-5; Derudder E, 2003, BIOCHEM BIOPH RES CO, V308, P744, DOI 10.1016/S0006-291X(03)01474-8; Emmerich F, 1999, BLOOD, V94, P3129, DOI 10.1182/blood.V94.9.3129.421k03_3129_3134; Epinat JC, 2000, ONCOGENE, V19, P599, DOI 10.1038/sj.onc.1203376; FRACCHIOLLA NS, 1993, ONCOGENE, V8, P2839; Glaser S, 2006, DEVELOPMENT, V133, P1423, DOI 10.1242/dev.02302; Hayden MS, 2008, CELL, V132, P344, DOI 10.1016/j.cell.2008.01.020; Heissig B, 2003, CURR OPIN HEMATOL, V10, P136, DOI 10.1097/00062752-200303000-00007; Hughes CM, 2004, MOL CELL, V13, P587, DOI 10.1016/S1097-2765(04)00081-4; Ishikawa H, 1997, J EXP MED, V186, P999, DOI 10.1084/jem.186.7.999; Jost PJ, 2007, BLOOD, V109, P2700, DOI 10.1182/blood-2006-07-025809; Jungnickel B, 2000, J EXP MED, V191, P395, DOI 10.1084/jem.191.2.395; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Keats JJ, 2007, CANCER CELL, V12, P131, DOI 10.1016/j.ccr.2007.07.003; Keutgens A, 2006, BIOCHEM PHARMACOL, V72, P1069, DOI 10.1016/j.bcp.2006.06.011; Kim KE, 2000, ONCOGENE, V19, P1334, DOI 10.1038/sj.onc.1203432; Klose RJ, 2007, CELL, V128, P889, DOI 10.1016/j.cell.2007.02.013; Klose RJ, 2006, NAT REV GENET, V7, P715, DOI 10.1038/nrg1945; Kouskouti A, 2005, EMBO J, V24, P347, DOI 10.1038/sj.emboj.7600516; Lalancette M, 2000, BLOOD, V95, P314, DOI 10.1182/blood.V95.1.314.001k32_314_319; Li QT, 2002, NAT REV IMMUNOL, V2, P725, DOI 10.1038/nri910; MCKEITHAN TW, 1987, P NATL ACAD SCI USA, V84, P9257, DOI 10.1073/pnas.84.24.9257; Miller T, 2001, P NATL ACAD SCI USA, V98, P12902, DOI 10.1073/pnas.231473398; Mori N, 2002, BLOOD, V99, P1341, DOI 10.1182/blood.V99.4.1341; Nagy PL, 2002, P NATL ACAD SCI USA, V99, P90, DOI 10.1073/pnas.221596698; NERI A, 1991, CELL, V67, P1075, DOI 10.1016/0092-8674(91)90285-7; Noma K, 2002, P NATL ACAD SCI USA, V99, P16438, DOI 10.1073/pnas.182436399; Perkins ND, 2007, NAT REV MOL CELL BIO, V8, P49, DOI 10.1038/nrm2083; Qing GL, 2007, P NATL ACAD SCI USA, V104, P5324, DOI 10.1073/pnas.0609914104; Redondo-Munoz J, 2006, BLOOD, V108, P3143, DOI 10.1182/blood-2006-03-007294; Ruthenburg AJ, 2007, MOL CELL, V25, P15, DOI 10.1016/j.molcel.2006.12.014; Saitoh Y, 2008, BLOOD, V111, P5118, DOI 10.1182/blood-2007-09-110635; Sakata K, 2004, CANCER, V100, P356, DOI 10.1002/cncr.11905; Santos-Rosa H, 2002, NATURE, V419, P407, DOI 10.1038/nature01080; Shilatifard A, 2006, ANNU REV BIOCHEM, V75, P243, DOI 10.1146/annurev.biochem.75.103004.142422; Shim JH, 2005, GENE DEV, V19, P2668, DOI 10.1101/gad.1360605; Siebenlist U, 2005, NAT REV IMMUNOL, V5, P435, DOI 10.1038/nri1629; Srivastava AK, 2007, J BIOL CHEM, V282, P35113, DOI 10.1074/jbc.M705329200; THAKUR S, 1994, ONCOGENE, V9, P2335; Viatour P, 2004, MOL CELL, V16, P35, DOI 10.1016/j.molcel.2004.09.004; Viatour P, 2003, J BIOL CHEM, V278, P46541, DOI 10.1074/jbc.M306381200; Wang Z, 2008, J BIOL CHEM, V283, P10698, DOI 10.1074/jbc.M800806200; Xiao GT, 2001, MOL CELL, V7, P401, DOI 10.1016/S1097-2765(01)00187-3; Yoshizaki T, 1998, P NATL ACAD SCI USA, V95, P3621, DOI 10.1073/pnas.95.7.3621; Zhang BC, 2007, BLOOD, V110, P743, DOI 10.1182/blood-2006-11-058446; ZHANG JD, 1994, ONCOGENE, V9, P1931	61	31	32	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2009	28	13					1626	1638		10.1038/onc.2009.6	http://dx.doi.org/10.1038/onc.2009.6			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	427LJ	19219072	Green Published			2022-12-17	WOS:000264780500007
J	Ristriani, T; Fournane, S; Orfanoudakis, G; Trave, G; Masson, M				Ristriani, T.; Fournane, S.; Orfanoudakis, G.; Trave, G.; Masson, M.			A single-codon mutation converts HPV16 E6 oncoprotein into a potential tumor suppressor, which induces p53-dependent senescence of HPV-positive HeLa cervical cancer cells	ONCOGENE			English	Article						human papillomavirus; cervical cancer; E6 oncoprotein; senescence; p53 protein	HUMAN-PAPILLOMAVIRUS TYPE-16; CARCINOMA-CELLS; BIOPHYSICAL CHARACTERIZATION; GENE-EXPRESSION; PROTEIN; DEGRADATION; APOPTOSIS; DOMAIN; P53; DNA	High-risk mucosal human papillomaviruses (HPV), mainly HPV16 and HPV18, are implicated in cervical carcinogenesis. HPV16 E6 oncoprotein binds and often targets for degradation numerous cell proteins, including the tumor suppressor p53 and several PDZ domain proteins. Here, we show that a single-point mutation, F47R, is sufficient to convert the HPV16 E6 oncoprotein into a suppressor of HPV-positive HeLa cervical cancer cells proliferation. The E6 F47R mutant is defective for polyubiquitination and subsequent degradation of p53. When expressed in HPV-positive cervical cancer cells, E6 F47R acts as a dominant negative mutant by counteracting the p53 degradation activity of endogenous E6 and restoring high p53 protein levels. Moreover, the prolonged expression of E6 F47R leads to suppression of HeLa cells proliferation through the induction of premature senescence. This phenotype is independent on the PDZ-binding activity of E6. F47R-senescent HeLa cells exhibit a sustained expression of p53, hMDM2 and p21CIP proteins and a reduced expression of endogenous HPV18 E6 protein. Finally, small interfering RNAs directed against p53 counteract the effect of E6 F47R expression, indicating that E6 F47R-induced cellular senescence is strongly dependent on p53 signaling pathway.	[Ristriani, T.; Fournane, S.; Orfanoudakis, G.; Trave, G.; Masson, M.] CNRS, ESBS, Equipe Oncoprot, UMR 7175, F-67412 Illkirch Graffenstaden, Bas Rhin, France	Centre National de la Recherche Scientifique (CNRS)	Masson, M (corresponding author), CNRS, ESBS, Equipe Oncoprot, UMR 7175, Blvd Sebastien Brant,BP10413, F-67412 Illkirch Graffenstaden, Bas Rhin, France.	gtrave@titus.u-strasbg.fr; masson@esbs.u-strasbg.fr	TRAVE, Gilles/P-8577-2016		University of Strasbourg; CNRS; Association de Recherche contre le Cancer (ARC); Ligue Nationale Contre le Cancer; Canceropole Grand-EST (INCA)	University of Strasbourg; CNRS(Centre National de la Recherche Scientifique (CNRS)); Association de Recherche contre le Cancer (ARC)(Fondation ARC pour la Recherche sur le Cancer); Ligue Nationale Contre le Cancer(Ligue nationale contre le cancer); Canceropole Grand-EST (INCA)(Institut National du Cancer (INCA) France)	We thank F Hoppe-Seyler for providing HeLa cells, H Zentgraf for the antibody 18E7C, G de Murcia for the PARP antibody and Arbor Vita Corp. (USA) for the HPV18 E6 antibody. We thank E Weiss, A-P Sibler, A-S Rinaldi and B Chatton for helpful discussions. This study was supported by the University of Strasbourg, CNRS, Association de Recherche contre le Cancer (ARC), Ligue Nationale Contre le Cancer. TR and SF were supported by the Canceropole Grand-EST (INCA).	Bernard B, 2003, BIOL CELL, V95, P17, DOI 10.1016/S0248-4900(02)01220-0; Butz K, 2003, ONCOGENE, V22, P5938, DOI 10.1038/sj.onc.1206894; Courtete J, 2007, MOL CANCER THER, V6, P1728, DOI 10.1158/1535-7163.MCT-06-0808; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Griffin H, 2006, J MOL BIOL, V355, P360, DOI 10.1016/j.jmb.2005.10.077; Hall AHS, 2003, J VIROL, V77, P6066, DOI 10.1128/JVI.77.10.6066-6069.2003; Horner SM, 2004, J VIROL, V78, P4063, DOI 10.1128/JVI.78.8.4063-4073.2004; HUIBREGTSE JM, 1991, EMBO J, V10, P4129, DOI 10.1002/j.1460-2075.1991.tb04990.x; Johung K, 2007, J VIROL, V81, P2102, DOI 10.1128/JVI.02348-06; Lagrange M, 2007, BIOCHEM BIOPH RES CO, V361, P487, DOI 10.1016/j.bbrc.2007.07.040; Lee CJ, 2002, EXP CELL RES, V277, P173, DOI 10.1006/excr.2002.5554; Lipari F, 2001, BIOCHEMISTRY-US, V40, P1196, DOI 10.1021/bi001837+; Liu Y, 1999, J VIROL, V73, P7297, DOI 10.1128/JVI.73.9.7297-7307.1999; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Massimi P, 2004, ONCOGENE, V23, P8033, DOI 10.1038/sj.onc.1207977; Masson M, 2003, J GEN VIROL, V84, P2099, DOI 10.1099/vir.0.18961-0; Nomine Y, 2006, MOL CELL, V21, P665, DOI 10.1016/j.molcel.2006.01.024; Nomine Y, 2003, BIOCHEMISTRY-US, V42, P4909, DOI 10.1021/bi026980c; Nomine Y, 2001, PROTEIN EXPRES PURIF, V23, P22, DOI 10.1006/prep.2001.1451; Nomine Y, 2001, PROTEIN ENG, V14, P297, DOI 10.1093/protein/14.4.297; Ristriani T, 2000, J MOL BIOL, V296, P1189, DOI 10.1006/jmbi.2000.3527; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; Stewart D, 2004, J GEN VIROL, V85, P1419, DOI 10.1099/vir.0.19679-0; Talis AL, 1998, J BIOL CHEM, V273, P6439, DOI 10.1074/jbc.273.11.6439; Tang S, 2006, J VIROL, V80, P4249, DOI 10.1128/JVI.80.9.4249-4263.2006; Topffer S, 2007, J GEN VIROL, V88, P2956, DOI 10.1099/vir.0.83123-0; Veldman T, 2001, J VIROL, V75, P4467, DOI 10.1128/JVI.75.9.4467-4472.2001; VOUSDEN K, 1993, FASEB J, V7, P872, DOI 10.1096/fasebj.7.10.8393818; Wells SI, 2000, EMBO J, V19, P5762, DOI 10.1093/emboj/19.21.5762; Zanier K, 2007, PROTEIN EXPRES PURIF, V51, P59, DOI 10.1016/j.pep.2006.07.029; zurHausen H, 1996, BBA-REV CANCER, V1288, pF55	31	31	35	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 5	2009	28	5					762	772		10.1038/onc.2008.422	http://dx.doi.org/10.1038/onc.2008.422			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	403IN	19015633				2022-12-17	WOS:000263076400013
J	Wang, T; Chen, YH; Hong, H; Zeng, Y; Zhang, J; Lu, JP; Jeansonne, B; Lu, Q				Wang, T.; Chen, Y-H; Hong, H.; Zeng, Y.; Zhang, J.; Lu, J-P; Jeansonne, B.; Lu, Q.			Increased nucleotide polymorphic changes in the 5 '-untranslated region of delta-catenin (CTNND2) gene in prostate cancer	ONCOGENE			English	Article						single-strand conformation polymorphism; single nucleotide polymorphism; 5 '-UTR mutation; methylation; gene amplification	CARCINOMA-CELL-LINE; DU-CHAT SYNDROME; E-CADHERIN; EXPRESSION; PROTEIN; JUNCTION; PAX6; PCR; OVEREXPRESSION; IDENTIFICATION	Cancer pathogenesis involves multiple genetic and epigenetic alterations, which result in oncogenic changes in gene expression. delta-Catenin (CTNND2) is overexpressed in cancer, although the mechanisms of its upregulation are highly variable. Here we report that in prostate cancer, the methylation of CpG islands in the delta-catenin promoter was not a primary regulatory event. There was also no delta-catenin gene amplification. However, using the single-strand conformation polymorphism analysis, we observed the increased nucleotide changes in the 5'-untranslated region of delta-catenin gene in human prostate cancer. At least one such change (-9 G>A) is a true somatic point mutation associated with a high Gleason's score, poorly differentiated prostatic adenocarcinoma. Laser capture microdissection coupled with PCR analyses detected the mutation only in cancerous but not in the adjacent benign prostatic tissues. Using chimeric genes encoding the luciferase reporter, we found that this mutation, but not a random mutation or a mutation that disrupts an upstream open reading frame, resulted in a remarkably higher expression and enzyme activity. This mutation did not affect transcriptional efficiency, suggesting that it promotes delta-catenin translation. This is the first report of delta-catenin gene mutation in cancer and supports the notion that multiple mechanisms contribute to its increased expression in carcinogenesis.	[Wang, T.; Chen, Y-H; Zeng, Y.; Zhang, J.; Lu, J-P; Jeansonne, B.; Lu, Q.] E Carolina Univ, Brody Sch Med, Dept Anat & Cell Biol, Greenville, NC 27834 USA; [Hong, H.] E Carolina Univ, Brody Sch Med, Dept Pathol & Lab Med, Greenville, NC 27834 USA; [Lu, Q.] E Carolina Univ, Brody Sch Med, Leo Jenkins Canc Ctr, Greenville, NC 27834 USA; [Wang, T.] Capital Med Univ, Dept Oncol, Beijing, Peoples R China	University of North Carolina; East Carolina University; University of North Carolina; East Carolina University; University of North Carolina; East Carolina University; Capital Medical University	Lu, Q (corresponding author), E Carolina Univ, Brody Sch Med, Dept Anat & Cell Biol, 7N84 Brody Sci Bldg,600 Moye Blvd, Greenville, NC 27834 USA.	luq@ecu.edu	Lu, Jianping/AFL-6811-2022	Lu, Jianping/0000-0001-9601-0040	NIH; NCI [CA111891]; Department of Defense [PC040569]; NATIONAL CANCER INSTITUTE [R01CA111891] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Department of Defense(United States Department of Defense); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Melissa Clark and GW Lanford for excellent technical assistance, and Lu laboratory members for many helpful discussions. This study was supported in part by NIH/NCI (CA111891) and the Department of Defense (PC040569) grants (QL).	Burger MJ, 2002, INT J CANCER, V100, P228, DOI 10.1002/ijc.10468; Cervera M, 2005, AM J MED GENET A, V136A, P381, DOI 10.1002/ajmg.a.30791; Duparc RH, 2006, DEV BIOL, V300, P647, DOI 10.1016/j.ydbio.2006.07.045; Fatima S, 2006, INT J MOL MED, V17, P159; Griffin E, 2001, NAT MED, V7, P840, DOI 10.1038/89969; Ho C, 2000, J COMP NEUROL, V420, P261; HOROSZEWICZ JS, 1983, CANCER RES, V43, P1809; Huang FY, 2006, GYNECOL ONCOL, V103, P219, DOI 10.1016/j.ygyno.2006.02.028; KAIGHN ME, 1979, INVEST UROL, V17, P16; Kim K, 2008, BIOCHEM BIOPH RES CO, V369, P414, DOI 10.1016/j.bbrc.2008.02.069; Kindich R, 2005, CLIN CHEM, V51, P649, DOI 10.1373/clinchem.2004.045013; Lang D, 2008, MOL CARCINOGEN, V47, P148, DOI 10.1002/mc.20375; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lu Q, 2005, HUM PATHOL, V36, P1037, DOI 10.1016/j.humpath.2005.07.012; Lu Q, 1999, J CELL BIOL, V144, P519, DOI 10.1083/jcb.144.3.519; Marinescu RC, 1999, AM J MED GENET, V86, P66, DOI 10.1002/(SICI)1096-8628(19990903)86:1<66::AID-AJMG13>3.0.CO;2-N; Mayes DA, 2006, CANCER RES, V66, P9809, DOI 10.1158/0008-5472.CAN-05-3877; Medina M, 2000, GENOMICS, V63, P157, DOI 10.1006/geno.1999.6090; Murthy SK, 2005, ARCH PATHOL LAB MED, V129, P39; Nakayama S, 2001, INT J CANCER, V93, P667, DOI 10.1002/ijc.1386; Paffenholz R, 1997, DIFFERENTIATION, V61, P293, DOI 10.1046/j.1432-0436.1997.6150293.x; Paffenholz R, 1999, EXP CELL RES, V250, P452, DOI 10.1006/excr.1999.4534; PRETLOW TG, 1993, J NATL CANCER I, V85, P394, DOI 10.1093/jnci/85.5.394; Ren B, 2006, ONCOGENE, V25, P1090, DOI 10.1038/sj.onc.1209134; Signori E, 2001, ONCOGENE, V20, P4596, DOI 10.1038/sj.onc.1204620; Sramkoski RM, 1999, IN VITRO CELL DEV-AN, V35, P403; STONE KR, 1978, INT J CANCER, V21, P274, DOI 10.1002/ijc.2910210305; Tanahashi H, 1999, NEUROREPORT, V10, P563, DOI 10.1097/00001756-199902250-00022; UMBAS R, 1994, CANCER RES, V54, P3929; WEIJERMAN PC, 1994, CANCER RES, V54, P5579; Zhang HT, 2004, CLIN CANCER RES, V10, P2359, DOI 10.1158/1078-0432.CCR-0959-3; Zheng M, 2004, AM J PATHOL, V165, P63, DOI 10.1016/S0002-9440(10)63275-0; Zhou JH, 1997, NEUROREPORT, V8, P2085, DOI 10.1097/00001756-199705260-00054	33	31	34	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 29	2009	28	4					555	564		10.1038/onc.2008.399	http://dx.doi.org/10.1038/onc.2008.399			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	400KM	18978817	Green Accepted, Green Submitted			2022-12-17	WOS:000262866500009
J	McKinnon, CM; Lygoe, KA; Skelton, L; Mitter, R; Mellor, H				McKinnon, C. M.; Lygoe, K. A.; Skelton, L.; Mitter, R.; Mellor, H.			The atypical Rho GTPase RhoBTB2 is required for expression of the chemokine CXCL14 in normal and cancerous epithelial cells	ONCOGENE			English	Article						Rho GTPase; BTB domain; microarray; cancer; tumor microenvironment; chemokine	MUTATION ANALYSIS; DENDRITIC CELLS; BREAST-CANCER; PROBE LEVEL; IN-VIVO; DBC2; GENE; BRAK; CANDIDATE; TISSUE	The Rho family of small GTPases control cell migration, cell invasion and cell cycle. Many of these processes are perturbed in cancer and several family members show altered expression in a number of tumor types. RhoBTB2/DBC2 is an atypical member of this family of signaling proteins, containing two BTB domains in addition to its conserved Rho GTPase domain. RhoBTB2 is mutated, deleted or silenced in a large percentage of breast and lung cancers; however, the functional consequences of this loss are unclear. Here we use RNA interference in primary human epithelial cells to mimic the loss of RhoBTB2 seen in cancer cells. Through microarray analysis of global gene expression, we show that loss of RhoBTB2 results in downregulation of CXCL14 - a chemokine that controls leukocyte migration and angiogenesis, and whose expression is lost through unknown mechanisms in a wide range of epithelial cancers. Loss of RhoBTB2 expression correlates with loss of CXCL14 secretion by head and neck squamous cell carcinoma cell lines, whereas reintroduction of RhoBTB2 restores CXCL14 secretion. Our studies identify CXCL14 as a gene target of RhoBTB2 and support downregulation of CXCL14 as a functional outcome of RhoBTB2 loss in cancer. Oncogene (2008) 27, 6856 - 6865; doi: 10.1038/onc.2008.317;published online 1 September 2008	[McKinnon, C. M.; Lygoe, K. A.; Skelton, L.; Mellor, H.] Univ Bristol, Dept Biochem, Sch Med Sci, Bristol BS8 1TD, Avon, England; [Mitter, R.] Canc Res UK, London, England	University of Bristol; Cancer Research UK	Mellor, H (corresponding author), Univ Bristol, Dept Biochem, Sch Med Sci, Bristol BS8 1TD, Avon, England.	h.mellor@bris.ac.uk		Mitter, Richard/0000-0002-1279-3760; Mellor, Harry/0000-0003-3894-0623	Cancer Research UK	Cancer Research UK(Cancer Research UK)	We thank Ian Paterson for providing the HNSCC cell lines and Adrian Thrasher for the provision of lentiviral reagents. We particularly thank James Doherty, who provided initial analysis of the microarray data. This work was supported by a grant awarded to HM by Cancer Research UK.	Aspenstrom P, 2004, BIOCHEM J, V377, P327, DOI 10.1042/BJ20031041; BARDWELL VJ, 1994, GENE DEV, V8, P1664, DOI 10.1101/gad.8.14.1664; Beder LB, 2006, J CANCER RES CLIN, V132, P19, DOI 10.1007/s00432-005-0033-0; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Chang FK, 2006, J MOL BIOL, V364, P302, DOI 10.1016/j.jmb.2006.09.026; Clark EA, 2000, NATURE, V406, P532, DOI 10.1038/35020106; Demaison C, 2002, HUM GENE THER, V13, P803, DOI 10.1089/10430340252898984; Frederick MJ, 2000, AM J PATHOL, V156, P1937, DOI 10.1016/S0002-9440(10)65067-5; Gautier L, 2004, BIOINFORMATICS, V20, P307, DOI 10.1093/bioinformatics/btg405; Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80; Hamaguchi M, 2002, P NATL ACAD SCI USA, V99, P13647, DOI 10.1073/pnas.212516099; Hromas R, 1999, BIOCHEM BIOPH RES CO, V255, P703, DOI 10.1006/bbrc.1999.0257; Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249; Kelly KF, 2006, TRENDS CELL BIOL, V16, P578, DOI 10.1016/j.tcb.2006.09.003; Knowles MA, 2005, CANCER LETT, V225, P121, DOI 10.1016/j.canlet.2004.10.047; Kobayashi A, 2004, MOL CELL BIOL, V24, P7130, DOI 10.1128/MCB.24.16.7130-7139.2004; Kurth I, 2001, J EXP MED, V194, P855, DOI 10.1084/jem.194.6.855; Ohadi M, 2007, ACTA ONCOL, V46, P770, DOI 10.1080/02841860601047752; Pasqualucci L, 2003, LEUKEMIA LYMPHOMA, V44, pS5, DOI 10.1080/10428190310001621588; Perez-Torrado R, 2006, BIOESSAYS, V28, P1194, DOI 10.1002/bies.20500; Prime S, 2004, J PATHOL, V203, P927, DOI 10.1002/path.1603; Ramos S, 2002, GENE, V298, P147, DOI 10.1016/S0378-1119(02)00980-0; Redner RL, 2002, LEUKEMIA, V16, P1927, DOI 10.1038/sj.leu.2402720; Ridley AJ, 2004, BREAST CANCER RES TR, V84, P13, DOI 10.1023/B:BREA.0000018423.47497.c6; Ridley AJ, 2006, TRENDS CELL BIOL, V16, P522, DOI 10.1016/j.tcb.2006.08.006; Rivero F, 2001, NUCLEIC ACIDS RES, V29, P1068, DOI 10.1093/nar/29.5.1068; Sahai E, 2002, NAT REV CANCER, V2, P133, DOI 10.1038/nrc725; Schaerli P, 2005, IMMUNITY, V23, P331, DOI 10.1016/j.immuni.2005.08.012; Schwarze SR, 2002, J BIOL CHEM, V277, P14877, DOI 10.1074/jbc.M200373200; Shellenberger TD, 2004, CANCER RES, V64, P8262, DOI 10.1158/0008-5472.CAN-04-2056; Shurin GV, 2005, J IMMUNOL, V174, P5490, DOI 10.4049/jimmunol.174.9.5490; Siripurapu V, 2005, J MOL BIOL, V346, P83, DOI 10.1016/j.jmb.2004.11.043; Smyth GK, 2005, STAT BIOL HEALTH, P397, DOI 10.1007/0-387-29362-0_23; Starnes T, 2006, EXP HEMATOL, V34, P1101, DOI 10.1016/j.exphem.2006.05.015; Wilkins A, 2004, GENE DEV, V18, P856, DOI 10.1101/gad.1177904; Yang L, 2004, ADV CANCER RES, V92, P13, DOI 10.1016/S0065-230X(04)92002-7	36	31	31	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 20	2008	27	54					6856	6865		10.1038/onc.2008.317	http://dx.doi.org/10.1038/onc.2008.317			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	375IS	18762809				2022-12-17	WOS:000261108000006
J	Pene-Dumitrescu, T; Peterson, LF; Donato, NJ; Smithgall, TE				Pene-Dumitrescu, T.; Peterson, L. F.; Donato, N. J.; Smithgall, T. E.			An inhibitor-resistant mutant of Hck protects CML cells against the antiproliferative and apoptotic effects of the broad-spectrum Src family kinase inhibitor A-419259	ONCOGENE			English	Article						Bcr-Abl; CML; Hck; Stat5; pyrrolo-pyrimidine; Src-family kinase inhibitor	CHRONIC MYELOGENOUS LEUKEMIA; BCR-ABL ONCOGENE; CHRONIC MYELOID-LEUKEMIA; TYROSINE KINASE; IMATINIB MESYLATE; SH3 DOMAIN; PHOSPHATIDYLINOSITOL 3-KINASE; PHILADELPHIA-CHROMOSOME; LYMPHOBLASTIC-LEUKEMIA; HEMATOPOIETIC-CELLS	Chronic myelogenous leukemia (CML) is driven by Bcr-Abl, a constitutively active protein-tyrosine kinase that stimulates proliferation and survival of myeloid progenitors. Global inhibition of myeloid Src family kinase (SFK) activity with the broad-spectrum pyrrolo-pyrimidine inhibitor, A-419259, blocks proliferation and induces apoptosis in CML cell lines, suggesting that transformation by Bcr-Abl requires SFK activity. However, the contribution of Hck and other individual SFKs to Bcr-Abl signaling is less clear. Here, we developed an A-419259-resistant mutant of Hck by replacing the gatekeeper residue (Thr-338; c-Src numbering) in the inhibitor-binding site with a bulkier methionine residue (Hck-T338M). This substitution reduced Hck sensitivity to A-419259 by more than 30-fold without significantly affecting kinase activity in vitro. Expression of Hck-T338M protected K-562 CML cells and Bcr-Abl-transformed TF-1 myeloid cells from the apoptotic and antiproliferative effects of A-419259. These effects correlated with persistence of Hck-T338M kinase activity in the presence of the compound, and were accompanied by sustained Erk and Stat5 activation. In contrast, control cells expressing equivalent levels of wild-type Hck retained sensitivity to the inhibitor. We also show for the first time that A-419259 induces cell-cycle arrest and apoptosis in primary CD34(+) CML cells with equal potency to imatinib. These data suggest that Hck has a nonredundant function as a key downstream signaling partner for Bcr-Abl and may represent a potential drug target in CML.	[Pene-Dumitrescu, T.; Smithgall, T. E.] Univ Pittsburgh, Sch Med, Dept Mol Genet & Biochem, Pittsburgh, PA 15261 USA; [Peterson, L. F.; Donato, N. J.] Univ Michigan, Dept Internal Med, Div Hematol Oncol, Ann Arbor, MI 48109 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Michigan System; University of Michigan	Smithgall, TE (corresponding author), Univ Pittsburgh, Sch Med, Dept Mol Genet & Biochem, E1240 Biomed Sci Tower, Pittsburgh, PA 15261 USA.	tsmithga@pitt.edu			National Institutes of Health [CA101828, GM077629]; NATIONAL CANCER INSTITUTE [R01CA101828] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM077629] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported by grants from the National Institutes of Health (CA101828 and GM077629 to TES). We thank Dr David Calderwood of the Abbott Bioresearch Center for the generous gift of the Src family kinase inhibitor, A-419259 and Dr Elisabeth Buchdunger of Novartis, Inc. for providing imatinib mesylate.	Abram CL, 2000, EXP CELL RES, V254, P1, DOI 10.1006/excr.1999.4732; BEN-NERIAH Y, 1986, SCIENCE, V233, P212, DOI 10.1126/science.3460176; Bhatia R, 2003, BLOOD, V101, P4701, DOI 10.1182/blood-2002-09-2780; Bishop AC, 2000, NATURE, V407, P395, DOI 10.1038/35030148; Blencke S, 2004, CHEM BIOL, V11, P691, DOI 10.1016/j.chembiol.2004.02.029; Blencke S, 2003, J BIOL CHEM, V278, P15435, DOI 10.1074/jbc.M211158200; Boggon TJ, 2004, ONCOGENE, V23, P7918, DOI 10.1038/sj.onc.1208081; Briggs SD, 1997, J BIOL CHEM, V272, P17899, DOI 10.1074/jbc.272.29.17899; Briggs SD, 1999, J BIOL CHEM, V274, P26579, DOI 10.1074/jbc.274.37.26579; Carlesso N, 1996, J EXP MED, V183, P811, DOI 10.1084/jem.183.3.811; Cools J, 2003, NEW ENGL J MED, V348, P1201, DOI 10.1056/NEJMoa025217; Copland M, 2006, BLOOD, V107, P4532, DOI 10.1182/blood-2005-07-2947; Cortes J, 2004, BLOOD, V104, P2204, DOI 10.1182/blood-2004-04-1335; Dai Y, 2004, J BIOL CHEM, V279, P34227, DOI 10.1074/jbc.M402290200; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; DanhauserRiedl S, 1996, CANCER RES, V56, P3589; Das J, 2006, J MED CHEM, V49, P6819, DOI 10.1021/jm060727j; de Groot Rolf P., 2000, Molecular Cell Biology Research Communications, V3, P299, DOI 10.1006/mcbr.2000.0231; Donato NJ, 2004, CANCER RES, V64, P672, DOI 10.1158/0008-5472.CAN-03-1484; Eyers PA, 1998, CHEM BIOL, V5, P321, DOI 10.1016/S1074-5521(98)90170-3; Gesbert F, 2000, BLOOD, V96, P2269, DOI 10.1182/blood.V96.6.2269.h8002269_2269_2276; GOGA A, 1995, CELL, V82, P981, DOI 10.1016/0092-8674(95)90277-5; Gorre ME, 2001, SCIENCE, V293, P876, DOI 10.1126/science.1062538; HARRISONFINDIK D, 1995, ONCOGENE, V10, P1385; Holtz MS, 2005, LEUKEMIA, V19, P1034, DOI 10.1038/sj.leu.2403724; Hoover RR, 2001, ONCOGENE, V20, P5826, DOI 10.1038/sj.onc.1204549; Hu YG, 2004, NAT GENET, V36, P453, DOI 10.1038/ng1343; Kantarjian H, 2002, NEW ENGL J MED, V346, P645, DOI 10.1056/NEJMoa011573; Kantarjian HM, 2007, CLIN CANCER RES, V13, P1089, DOI 10.1158/1078-0432.CCR-06-2147; KELLIHER MA, 1990, P NATL ACAD SCI USA, V87, P6649, DOI 10.1073/pnas.87.17.6649; KITAMURA T, 1989, J CELL PHYSIOL, V140, P323, DOI 10.1002/jcp.1041400219; Klejman A, 2002, EMBO J, V21, P5766, DOI 10.1093/emboj/cdf562; Kobayashi S, 2005, NEW ENGL J MED, V352, P786, DOI 10.1056/NEJMoa044238; Lerner EC, 2005, J BIOL CHEM, V280, P40832, DOI 10.1074/jbc.M508782200; Lerner EC, 2002, NAT STRUCT BIOL, V9, P365, DOI 10.1038/nsb782; Lionberger JM, 2000, J BIOL CHEM, V275, P18581, DOI 10.1074/jbc.C000126200; Liu Y, 1998, BIOORGAN MED CHEM, V6, P1219, DOI 10.1016/S0968-0896(98)00099-6; Liu Y, 1999, CHEM BIOL, V6, P671, DOI 10.1016/S1074-5521(99)80118-5; LUGO TG, 1989, MOL CELL BIOL, V9, P1263, DOI 10.1128/MCB.9.3.1263; Martinelli G, 2005, LEUKEMIA, V19, P1872, DOI 10.1038/sj.leu.2403950; Mauro MJ, 2004, LEUKEMIA RES, V28, pS71, DOI 10.1016/j.leukres.2003.10.017; MCLAUGHLIN J, 1987, P NATL ACAD SCI USA, V84, P6558, DOI 10.1073/pnas.84.18.6558; Melnick JS, 2006, P NATL ACAD SCI USA, V103, P3153, DOI 10.1073/pnas.0511292103; Meyn MA, 2006, J BIOL CHEM, V281, P30907, DOI 10.1074/jbc.M605902200; Million RP, 2000, BLOOD, V96, P664; Nakajima A, 2001, LEUKEMIA, V15, P989, DOI 10.1038/sj.leu.2402137; Neshat MS, 2000, MOL CELL BIOL, V20, P1179, DOI 10.1128/MCB.20.4.1179-1186.2000; Olivieri A, 2007, ANN ONCOL, V18, P42, DOI 10.1093/annonc/mdm223; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/0092-8674(93)90689-N; Porter M, 2000, J BIOL CHEM, V275, P2721, DOI 10.1074/jbc.275.4.2721; Ptasznik A, 2004, NAT MED, V10, P1187, DOI 10.1038/nm1127; Raffel GD, 1996, J BIOL CHEM, V271, P4640; Ren RB, 2002, ONCOGENE, V21, P8629, DOI 10.1038/sj.onc.1206090; ROWLEY JD, 1973, NATURE, V243, P290, DOI 10.1038/243290a0; Sattler M, 2002, CANCER CELL, V1, P479, DOI 10.1016/S1535-6108(02)00074-0; Sattler M, 1996, ONCOGENE, V12, P839; Sawyers CL, 1999, NEW ENGL J MED, V340, P1330, DOI 10.1056/NEJM199904293401706; Schindler T, 1999, MOL CELL, V3, P639, DOI 10.1016/S1097-2765(00)80357-3; Schreiner SJ, 2002, J BIOL CHEM, V277, P45680, DOI 10.1074/jbc.M204255200; Shuai K, 1996, ONCOGENE, V13, P247; Skorski T, 1997, EMBO J, V16, P6151, DOI 10.1093/emboj/16.20.6151; Smith KM, 2003, MOL CELL, V12, P27, DOI 10.1016/S1097-2765(03)00274-0; Tamborini E, 2004, GASTROENTEROLOGY, V127, P294, DOI 10.1053/j.gastro.2004.02.021; Trible RP, 2006, J BIOL CHEM, V281, P27029, DOI 10.1074/jbc.M601128200; Warmuth M, 1997, J BIOL CHEM, V272, P33260, DOI 10.1074/jbc.272.52.33260; Wilson MB, 2002, ONCOGENE, V21, P8075, DOI 10.1038/sj.onc.1206008; Wu J, 2008, J NATL CANCER I, V100, P926, DOI 10.1093/jnci/djn188; Xu WQ, 1999, MOL CELL, V3, P629, DOI 10.1016/S1097-2765(00)80356-1; Zhang XW, 2001, MOL CELL BIOL, V21, P840, DOI 10.1128/MCB.21.3.840-853.2001; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	70	31	37	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2008	27	56					7055	7069		10.1038/onc.2008.330	http://dx.doi.org/10.1038/onc.2008.330			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	376PQ	18794796	Green Accepted			2022-12-17	WOS:000261195900001
J	Hossain, MS; Ozaki, T; Wang, H; Nakagawa, A; Takenobu, H; Ohira, M; Kamijo, T; Nakagawara, A				Hossain, M. S.; Ozaki, T.; Wang, H.; Nakagawa, A.; Takenobu, H.; Ohira, M.; Kamijo, T.; Nakagawara, A.			N-MYC promotes cell proliferation through a direct transactivation of neuronal leucine-rich repeat protein-1(NLRR1) gene in neuroblastoma	ONCOGENE			English	Article						c-myc; neuroblastoma; N-MYC; NLRR1; proliferation; transactivation	MOUSE NERVOUS-SYSTEM; DNA-BINDING; EXPRESSION; PROTEIN; ONCOGENE; ZIPPER; AMPLIFICATION; ASSOCIATION; PROGRESSION; ACTIVATION	Neuronal leucine-rich repeat protein-1(NLRR1) gene encodes a type I transmembrane protein with unknown function. We have previously described that NLRR1 gene is highly expressed in unfavorable neuroblastomas as compared with favorable tumors and its higher expression levels correlate significantly with poor clinical outcome. In this study, we have found that NLRR1 gene is one of direct target genes for N-MYC and its gene product contributes to N-MYC-dependent growth promotion in neuroblastoma. Expression levels of NLRR1 were significantly associated with those of N-MYC in various neuroblastoma cell lines as well as primary neuroblastoma tissues. Indeed, enforced expression of N-MYC resulted in a remarkable induction of the endogenous NLRR1. Consistent with these results, we have identified two functional E-boxes within the promoter region and intron 1 of NLRR1 gene. Intriguingly, c-myc also transactivated NLRR1 gene. Enforced expression of NLRR1 promoted cell proliferation and rendered cells resistant to serum deprivation. In support with these observations, small-interfering RNA-mediated knock-down of the endogenous NLRR1-reduced growth rate and sensitized cells to serum starvation. Collectively, our present findings provide a novel insight into understanding molecular mechanisms behind aggressive neuroblastoma with N-MYC amplification.	[Hossain, M. S.; Ozaki, T.; Wang, H.; Takenobu, H.; Ohira, M.; Kamijo, T.; Nakagawara, A.] Chiba Canc Ctr, Res Inst, Div Biochem, Chuoh Ku, Chiba 2608717, Japan; [Hossain, M. S.; Ozaki, T.; Nakagawara, A.] Chiba Univ, Grad Sch Med, Dept Mol Biol & Oncol, Chiba, Japan; [Wang, H.] China Med Univ, ShengJing Hosp, Dept Pediat, Shenyang, Peoples R China; [Nakagawa, A.] Natl Ctr Child Hlth & Dev, Dept Pathol, Tokyo, Japan	Chiba Cancer Center; Chiba University; China Medical University; National Center for Child Health & Development - Japan	Nakagawara, A (corresponding author), Chiba Canc Ctr, Res Inst, Div Biochem, Chuoh Ku, 666-2 Nitona, Chiba 2608717, Japan.	akiranak@chiba-cc.jp			Ministry of Health, Labour and Welfare; Ministry of Education, Culture, Sports, Science and Technology, Japan; Uehara Memorial Foundation; Hisamitsu Pharmaceutical Co	Ministry of Health, Labour and Welfare(Ministry of Health, Labour and Welfare, Japan); Ministry of Education, Culture, Sports, Science and Technology, Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Uehara Memorial Foundation(Uehara Memorial Foundation); Hisamitsu Pharmaceutical Co	We are grateful to Dr M Schwab for providing the expression plasmid for N-MYC. We thank Ms Y Nakamura for technical assistance. This work was supported in part by a Grant-in-Aid from the Ministry of Health, Labour and Welfare for Third Term Comprehensive Control Research for Cancer, a Grant-in-Aid for Scientific Research on Priority Areas from the Ministry of Education, Culture, Sports, Science and Technology, Japan, a Grant-in-Aid for Scientific Research from Japan Society for the Promotion of Science, Uehara Memorial Foundation and Hisamitsu Pharmaceutical Co.	ALEX R, 1992, NUCLEIC ACIDS RES, V20, P2257, DOI 10.1093/nar/20.9.2257; Bando T, 2005, MOL CELL BIOL, V25, P4166, DOI 10.1128/MCB.25.10.4166-4175.2005; BERNARDS R, 1986, CELL, V47, P667, DOI 10.1016/0092-8674(86)90509-X; Blackwood EM, 1992, CURR OPIN GENET DEV, V2, P227, DOI 10.1016/S0959-437X(05)80278-3; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; Boon K, 2001, EMBO J, V20, P1383, DOI 10.1093/emboj/20.6.1383; BRODEUR GM, 1992, AM J PEDIAT HEMATOL, V14, P111; Degterev A, 2003, ONCOGENE, V22, P8543, DOI 10.1038/sj.onc.1207107; Fukamachi K, 2002, J BIOL CHEM, V277, P43549, DOI 10.1074/jbc.C200502200; Hamano S, 2004, INT J ONCOL, V24, P1457; KOHL NE, 1983, CELL, V35, P359, DOI 10.1016/0092-8674(83)90169-1; KOUZARIDES T, 1988, NATURE, V336, P646, DOI 10.1038/336646a0; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; Lasorella A, 2000, NATURE, V407, P592, DOI 10.1038/35036504; Lutz W, 1996, ONCOGENE, V13, P803; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; NEGRONI A, 1991, CELL GROWTH DIFFER, V2, P511; SCHWAB M, 1983, NATURE, V305, P245, DOI 10.1038/305245a0; SEEGER RC, 1985, NEW ENGL J MED, V313, P1111, DOI 10.1056/NEJM198510313131802; Slack A, 2005, P NATL ACAD SCI USA, V102, P731, DOI 10.1073/pnas.0405495102; Taguchi A, 1996, MOL BRAIN RES, V35, P31, DOI 10.1016/0169-328X(95)00178-U; Taniguchi H, 1996, MOL BRAIN RES, V36, P45, DOI 10.1016/0169-328X(95)00243-L; TORRES R, 1992, Current Opinion in Cell Biology, V4, P468, DOI 10.1016/0955-0674(92)90013-3; Truscott M, 2007, J BIOL CHEM, V282, P30216, DOI 10.1074/jbc.M702328200; Wang J, 1998, GENE DEV, V12, P1769, DOI 10.1101/gad.12.12.1769; Weiss WA, 1997, EMBO J, V16, P2985, DOI 10.1093/emboj/16.11.2985	26	31	34	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 9	2008	27	46					6075	6082		10.1038/onc.2008.200	http://dx.doi.org/10.1038/onc.2008.200			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	358BO	18591937				2022-12-17	WOS:000259891600010
J	Carbone, M; Rossi, MN; Cavaldesi, M; Notari, A; Amati, P; Maione, R				Carbone, M.; Rossi, M. N.; Cavaldesi, M.; Notari, A.; Amati, P.; Maione, R.			Poly(ADP-ribosyl)ation is implicated in the G0-G1 transition of resting cells	ONCOGENE			English	Article						c-Fos; c-Myc; G0 exit; poly(ADP-ribosyl)ation	MESSENGER-RNA LEVELS; RIBOSE POLYMERASE; GROWTH-FACTORS; TRANSCRIPTION; EXPRESSION; DIFFERENTIATION; MITOGENESIS; ACTIVATION; DOMAINS; BINDING	Poly(ADP-ribosyl)ation, catalysed by a family of poly (ADP-ribose) polymerases (PARPs), plays an important role in a large variety of physiological processes, including cell proliferation, but its role in cell cycle progression is not yet completely defined. As reported here, the examination of early times following serum stimulation of quiescent fibroblasts suggests that poly(ADP-ribosyl) ation is necessary for the transition from the G0 phase to the G1 phase. We show that PARP activity is involved in this step through the regulation of immediate-early response genes, such as c-Fos and c-Myc. This is supported by the finding that exogenous Myc expression substantially restores cell cycle reactivation in the absence of polymer synthesis. Furthermore, using RNA interference, we show that PARP-1 is the PARP family member playing the most prominent role in the upregulation of c-Fos and c-Myc during G0-G1 transition. We report that even in lectin-stimulated peripheral blood mononucleated cells, the inhibition of PARP activity interferes with the upregulation of immediate-early genes and delays the induction of proliferation, suggesting a general role for PARP-1 in linking growth factor signaling with cell cycle entry.	[Amati, P.; Maione, R.] Univ Roma La Sapienza, Dept Cellular Biotechnol & Haematol, Mol Genet Sect, Pasteur Inst Fdn Cenci Bolognetti, I-00161 Rome, Italy	Sapienza University Rome	Amati, P (corresponding author), Univ Roma La Sapienza, Dept Cellular Biotechnol & Haematol, Mol Genet Sect, Pasteur Inst Fdn Cenci Bolognetti, Viale Regina Elena 324, I-00161 Rome, Italy.	amati@bce.uniroma1.it; maione@bce.uniroma1.it	Rossi, Marianna Nicoletta/S-5083-2019	Rossi, Marianna Nicoletta/0000-0003-4485-7738	Associazione Italiana per la Ricerca sul Cancro (AIRC) [4179]; AIRC/FIRC	Associazione Italiana per la Ricerca sul Cancro (AIRC)(Fondazione AIRC per la ricerca sul cancro); AIRC/FIRC(Fondazione AIRC per la ricerca sul cancro)	We thank Dr M Crescenzi for human FB 1329 cells, Professor G Palmieri for purified PBMCs and Dr B Amati for the c-MycER-expressing cells and for helpful suggestions. We are grateful to Professor P Caiafa for useful discussions on the 'PARP world'. This work was supported by Grant no. 4179 from Associazione Italiana per la Ricerca sul Cancro (AIRC). MC was supported by a fellowship from AIRC/FIRC.	ALMENDRAL JM, 1988, MOL CELL BIOL, V8, P2140, DOI 10.1128/MCB.8.5.2140; BLANCHARD JM, 1985, NATURE, V317, P443, DOI 10.1038/317443a0; BRAVO R, 1990, CELL GROWTH DIFFER, V1, P305; Carbone M, 2006, J MOL BIOL, V363, P773, DOI 10.1016/j.jmb.2006.05.077; CESARONE CF, 1990, BIOCHIM BIOPHYS ACTA, V1087, P241, DOI 10.1016/0167-4781(90)90211-J; Cohen-Armon M, 2007, MOL CELL, V25, P297, DOI 10.1016/j.molcel.2006.12.012; D'Amours D, 1999, BIOCHEM J, V342, P249, DOI 10.1042/0264-6021:3420249; DEAN M, 1986, J BIOL CHEM, V261, P9161; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; Homburg S, 2000, J CELL BIOL, V150, P293, DOI 10.1083/jcb.150.2.293; ITTEL ME, 1983, BIOCHEM BIOPH RES CO, V116, P428, DOI 10.1016/0006-291X(83)90541-7; Jagtap P, 2005, NAT REV DRUG DISCOV, V4, P421, DOI 10.1038/nrd1718; Jagtap P, 2002, CRIT CARE MED, V30, P1071, DOI 10.1097/00003246-200205000-00019; JOHNSTONE AP, 1982, NATURE, V300, P368, DOI 10.1038/300368a0; Jones SM, 2001, NAT CELL BIOL, V3, P165, DOI 10.1038/35055073; Jones SM, 2001, FEBS LETT, V490, P110, DOI 10.1016/S0014-5793(01)02113-5; Kauppinen TM, 2006, P NATL ACAD SCI USA, V103, P7136, DOI 10.1073/pnas.0508606103; Kraus WL, 2003, CELL, V113, P677, DOI 10.1016/S0092-8674(03)00433-1; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; MARINI M, 1989, FEBS LETT, V253, P146, DOI 10.1016/0014-5793(89)80948-2; Marshall C, 1999, CURR OPIN CELL BIOL, V11, P732, DOI 10.1016/S0955-0674(99)00044-7; MENEGAZZI M, 1992, FEBS LETT, V297, P59, DOI 10.1016/0014-5793(92)80327-D; Olabisi OA, 2008, MOL CELL BIOL, V28, P2860, DOI 10.1128/MCB.01746-07; REED JC, 1986, P NATL ACAD SCI USA, V83, P3982, DOI 10.1073/pnas.83.11.3982; Rouleau M, 2004, J CELL SCI, V117, P815, DOI 10.1242/jcs.01080; Schreiber V, 2006, NAT REV MOL CELL BIO, V7, P517, DOI 10.1038/nrm1963; Sears RC, 2002, J BIOL CHEM, V277, P11617, DOI 10.1074/jbc.R100063200; Shieh WM, 1998, J BIOL CHEM, V273, P30069, DOI 10.1074/jbc.273.46.30069; Simbulan-Rosenthal CM, 1999, ONCOGENE, V18, P5015, DOI 10.1038/sj.onc.1202900; Simbulan-Rosenthal CM, 2003, ONCOGENE, V22, P8460, DOI 10.1038/sj.onc.1206897; SimbulanRosenthal CM, 1996, BIOCHEMISTRY-US, V35, P11622, DOI 10.1021/bi953010z; Treitinger, 1999, Braz J Infect Dis, V3, P1; Valdor R, 2008, MOL IMMUNOL, V45, P1863, DOI 10.1016/j.molimm.2007.10.044; WEIN KH, 1993, BIOCHIM BIOPHYS ACTA, V1176, P69, DOI 10.1016/0167-4889(93)90179-S	34	31	32	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2008	27	47					6083	6092		10.1038/onc.2008.221	http://dx.doi.org/10.1038/onc.2008.221			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	360UJ	18663363				2022-12-17	WOS:000260083100001
J	Eelen, G; Bempt, IV; Verlinden, L; Drijkoningen, M; Smeets, A; Neven, P; Christiaens, MR; Marchal, K; Bouillon, R; Verstuyf, A				Eelen, G.; Bempt, I. Vanden; Verlinden, L.; Drijkoningen, M.; Smeets, A.; Neven, P.; Christiaens, M. R.; Marchal, K.; Bouillon, R.; Verstuyf, A.			Expression of the BRCA1-interacting protein Brip1/BACH1/FANCJ is driven by E2F and correlates with human breast cancer malignancy	ONCOGENE			English	Article						Brip1; breast cancer; E2F; vitamin D; high grade; HER-2	FANCONI-ANEMIA; MOLECULAR PORTRAITS; DNA-REPLICATION; HELICASE BRIP1; TARGET GENES; SUSCEPTIBILITY; BACH1; TRANSCRIPTION; CARCINOMAS; MUTATIONS	Mutations in the BRCA1-interacting DEAH helicase Brip1 confer an increased risk of breast cancer. In the present study we aimed to unravel the transcriptional control of Brip1 and to determine its expression levels in a set of 101 primary invasive breast carcinomas. Transcription of Brip1 was found to be cell growth-related and controlled by the E2F/retinoblastoma (Rb) pathway through a conserved E2F-responsive site. Repression of Brip1 expression by the cell growth-inhibiting compound 1 alpha,25-dihydroxyvitamin D(3) depended on this same E2F-responsive site. In spite of its role as a tumor suppressor, both quantitative reverse transcriptase-PCR analyses and immunohistochemical stainings showed significantly elevated Brip1 expression levels in grade 3 tumors as compared to grade 1 or 2 carcinomas. Furthermore, increased Brip1 transcript levels were found in tumors with an estrogen receptor-negative, progesterone receptor-negative or HER-2-positive status. In conclusion, these data show that Brip1 is a genuine target gene for the E2F/Rb pathway and that elevated expression levels of Brip1 are detected in primary invasive breast carcinomas with unfavorable characteristics.	[Eelen, G.; Verlinden, L.; Verstuyf, A.] Katholieke Univ Leuven, LEGENDO, B-3000 Leuven, Belgium; [Bempt, I. Vanden; Drijkoningen, M.] Katholieke Univ Leuven, Univ Hosp, Dept Pathol, B-3000 Leuven, Belgium; [Drijkoningen, M.; Smeets, A.; Neven, P.; Christiaens, M. R.] Katholieke Univ Leuven, Univ Hosp, Multidisciplinary Breast Ctr, B-3000 Leuven, Belgium; [Marchal, K.] Katholieke Univ Leuven, CMPG, ESAT, B-3000 Leuven, Belgium	KU Leuven; KU Leuven; KU Leuven; KU Leuven	Verstuyf, A (corresponding author), Katholieke Univ Leuven, LEGENDO, 9th Floor,Bus 902,Herestr 49, B-3000 Leuven, Belgium.	mieke.verstuyf@med.kuleuven.be	Marchal, Kathleen/O-7936-2017; smeets, ann/AAP-9191-2020; Vanden Bempt, Isabelle/AAH-2501-2022; Marchal, Kathleen/B-5001-2013; Vanden Bempt, Isabelle/AFM-0163-2022; Verlinden, Lieve/E-6517-2011	Marchal, Kathleen/0000-0002-2169-4588; Vanden Bempt, Isabelle/0000-0002-3433-555X; Marchal, Kathleen/0000-0002-2169-4588; Vanden Bempt, Isabelle/0000-0002-3433-555X; Verstuyf, Annemieke/0000-0003-3193-2698; Verlinden, Lieve/0000-0002-9621-3662				Bracken AP, 2004, TRENDS BIOCHEM SCI, V29, P409, DOI 10.1016/j.tibs.2004.06.006; Bridge WL, 2005, NAT GENET, V37, P953, DOI 10.1038/ng1627; Cantor S, 2004, P NATL ACAD SCI USA, V101, P2357, DOI 10.1073/pnas.0308717101; Cantor SB, 2001, CELL, V105, P149, DOI 10.1016/S0092-8674(01)00304-X; Chin K, 2006, CANCER CELL, V10, P529, DOI 10.1016/j.ccr.2006.10.009; D'Andrea AD, 2003, NAT REV CANCER, V3, P23, DOI 10.1038/nrc970; Eelen G, 2007, CURR MED CHEM, V14, P1893; Eelen G, 2004, J STEROID BIOCHEM, V89-90, P405, DOI 10.1016/j.jsbmb.2004.03.008; Eelen G, 2004, J BONE MINER RES, V19, P133, DOI 10.1359/JBMR.0301204; Fridlyand J, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-96; Giangrande PH, 2004, GENE DEV, V18, P2941, DOI 10.1101/gad.1239304; ISHIDA R, 1982, CANCER RES, V42, P4000; Levitus M, 2005, NAT GENET, V37, P934, DOI 10.1038/ng1625; Levran O, 2005, NAT GENET, V37, P931, DOI 10.1038/ng1624; Litman R, 2005, CANCER CELL, V8, P255, DOI 10.1016/j.ccr.2005.08.004; Paris PL, 2004, HUM MOL GENET, V13, P1303, DOI 10.1093/hmg/ddh155; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Pharoah PDP, 2002, NAT GENET, V31, P33, DOI 10.1038/ng853; POLL EHA, 1982, HUM GENET, V61, P228, DOI 10.1007/BF00296447; Raemaekers T, 2003, J CELL BIOL, V162, P1017, DOI 10.1083/jcb.200302129; Saiz AD, 2002, J PATHOL, V198, P157, DOI 10.1002/path.1185; Seal S, 2006, NAT GENET, V38, P1239, DOI 10.1038/ng1902; Sinclair CS, 2003, BREAST CANCER RES TR, V78, P313, DOI 10.1023/A:1023081624133; Sorlie T, 2004, EUR J CANCER, V40, P2667, DOI 10.1016/j.ejca.2004.08.021; Verlinden L, 2005, J BIOL CHEM, V280, P37319, DOI 10.1074/jbc.M503587200; Verlinden L, 2007, CANCER RES, V67, P6574, DOI 10.1158/0008-5472.CAN-06-3545; Whitfield ML, 2006, NAT REV CANCER, V6, P99, DOI 10.1038/nrc1802; Yan Z, 1998, P NATL ACAD SCI USA, V95, P3603, DOI 10.1073/pnas.95.7.3603; Yang L, 2007, LEUKEMIA, V21, P868, DOI 10.1038/sj.leu.2404624; Yu XC, 2003, SCIENCE, V302, P639, DOI 10.1126/science.1088753; Zacharatos P, 2004, J PATHOL, V203, P744, DOI 10.1002/path.1582; Zhang SY, 2000, CANCER EPIDEM BIOMAR, V9, P395	32	31	32	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL	2008	27	30					4233	4241		10.1038/onc.2008.51	http://dx.doi.org/10.1038/onc.2008.51			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	324DB	18345034	Green Published			2022-12-17	WOS:000257496800010
J	Han, X; Saito, H; Miki, Y; Nakanishi, A				Han, X.; Saito, H.; Miki, Y.; Nakanishi, A.			A CRM1-mediated nuclear export signal governs cytoplasmic localization of BRCA2 and is essential for centrosomal localization of BRCA2	ONCOGENE			English	Article						breast cancer; BRCA2; nuclear export; centrosome; leptomycin B; microinjection	SUSCEPTIBILITY GENE BRCA2; CANCER SUSCEPTIBILITY; NUCLEOCYTOPLASMIC TRANSPORT; PHOSPHORYLATION; PROTEIN; GENOME; CRM1	Germ-line mutations of the BRCA2 gene cause inherited susceptibility to breast and ovarian cancers. BRCA2 contains two nuclear localization signals, predominantly localizes in the nucleus and plays significant roles in DNA double-strand break repair. Recently, we reported that BRCA2 localizes to the centrosomes during the S and early M phases of the cell cycle. In this study, for the first time, we identified a functional nuclear export sequence (NES1; (1383)DLSDLTFLEVA(1393)) in BRCA2. The green fluorescent protein (GFP)-NES1 fusion protein was localized in the cytoplasm and could be blocked by the chromosomal region maintenance 1-specific export inhibitor leptomycin B. Mutation of a leucine residue in the NES1 motif to alanine (L1384A) resulted in both cytoplasmic and nuclear localization of the GFP-NES1 fusion protein and a nuclear accumulation of ectopic full-length BRCA2-FLAG. Moreover, treatment of cells with leptomycin B decreased centrosomal localization of BRCA2. Finally, by microinjection of an anti-BRCA2 antibody into the cytoplasm of HeLa S3 cells, we found that depletion of normal BRCA2 proteins in the cytoplasm leads to centrosome amplification and binucleated cells. Our results suggest that disruption of the NES function by genetic changes results in deregulation of BRCA2 export, which ultimately leads to centrosome disorder.	[Han, X.; Miki, Y.] Tokyo Med & Dent Univ, Dept Mol Genet, Med Res Inst, Bunkyo Ku, Tokyo 1138510, Japan; [Han, X.] Yanbiann Univ, Coll Med, Dept Prevent Med, Yanji, Peoples R China; [Saito, H.; Miki, Y.; Nakanishi, A.] Japanese Fdn Canc Res, Inst Canc, Dept Genet Diag, Tokyo 170, Japan; [Nakanishi, A.] Univ Tokyo, Inst Med Sci, Tokyo, Japan	Tokyo Medical & Dental University (TMDU); Yanbian University; Japanese Foundation for Cancer Research; University of Tokyo	Miki, Y (corresponding author), Tokyo Med & Dent Univ, Dept Mol Genet, Med Res Inst, Bunkyo Ku, 1-5-45 Yushima, Tokyo 1138510, Japan.	miki.mgen@mri.tmd.ac.jp						Bednenko J, 2003, TRAFFIC, V4, P127, DOI 10.1034/j.1600-0854.2003.00109.x; Daniels MJ, 2004, SCIENCE, V306, P876, DOI 10.1126/science.1102574; Esashi F, 2005, NATURE, V434, P598, DOI 10.1038/nature03404; Fabbro M, 2003, EXP CELL RES, V282, P59, DOI 10.1016/S0014-4827(02)00019-8; Fukuda M, 1997, NATURE, V390, P308, DOI 10.1038/36894; Gorlich D, 1999, ANNU REV CELL DEV BI, V15, P607, DOI 10.1146/annurev.cellbio.15.1.607; Kudo N, 1998, EXP CELL RES, V242, P540, DOI 10.1006/excr.1998.4136; Nakanishi A, 2007, BIOCHEM BIOPH RES CO, V355, P34, DOI 10.1016/j.bbrc.2007.01.100; Spain BH, 1999, P NATL ACAD SCI USA, V96, P13920, DOI 10.1073/pnas.96.24.13920; Taagepera S, 1998, P NATL ACAD SCI USA, V95, P7457, DOI 10.1073/pnas.95.13.7457; Thompson ME, 2005, J BIOL CHEM, V280, P21854, DOI 10.1074/jbc.M502676200; Tutt A, 1999, CURR BIOL, V9, P1107, DOI 10.1016/S0960-9822(99)80479-5; Venkitaraman AR, 2002, CELL, V108, P171, DOI 10.1016/S0092-8674(02)00615-3; Wang W, 2005, NAT CELL BIOL, V7, P823, DOI 10.1038/ncb1282; Weis K, 2003, CELL, V112, P441, DOI 10.1016/S0092-8674(03)00082-5; Wong AKC, 1997, J BIOL CHEM, V272, P31941, DOI 10.1074/jbc.272.51.31941; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0; Wu KJ, 2005, CANCER RES, V65, P417; Yang HJ, 2005, NATURE, V433, P653, DOI 10.1038/nature03234; Yano K, 2000, BIOCHEM BIOPH RES CO, V270, P171, DOI 10.1006/bbrc.2000.2392; Zhang YP, 2001, SCIENCE, V292, P1910, DOI 10.1126/science.1058637	21	31	31	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 8	2008	27	21					2969	2977		10.1038/sj.onc.1210968	http://dx.doi.org/10.1038/sj.onc.1210968			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	298IP	18059333				2022-12-17	WOS:000255681700004
J	Pearce, VP; Sherrell, J; Lou, Z; Kopelovich, L; Wright, WE; Shay, JW				Pearce, V. P.; Sherrell, J.; Lou, Z.; Kopelovich, L.; Wright, W. E.; Shay, J. W.			Immortalization of epithelial progenitor cells mediated by resveratrol	ONCOGENE			English	Article						telomerase; p53; progesterone; breast epithelial; aging	BREAST-CANCER CELLS; TELOMERASE ACTIVITY; IN-VITRO; P53 PROTEIN; ACTIVATION; EXPRESSION; NEUROBLASTOMA; LOCALIZATION; MAINTENANCE; SENESCENCE	Within the hierarchy of epithelial stem cells, normal progenitor cells may express regulated telomerase during renewal cycles of proliferation and differentiation. Discontinuous telomerase activity may promote increased renewal capacity of progenitor cells, while deregulated/ continuous telomerase activity may promote immortalization when differentiation and/ or senescent pathways are compromised. In the present work, we show that resveratrol activates, while progesterone inactivates, continuous telomerase activity within 24 h in subpopulations of human Li - Fraumeni syndrome- derived breast epithelial cells. Resveratrol results in immortalization of mixed progenitor cells with mutant p53, but not human epithelial cells with wild type p53. Our results demonstrate the potential for renewing progenitor cells with mutant p53 to immortalize after continuous telomerase expression when exposed to certain environmental compounds. Understanding the effects of telomerase modulators on endogenous telomerase activity in progenitor cells is relevant to the role of immortalization in the initiation and progression of cancer subtypes.	[Pearce, V. P.; Lou, Z.; Wright, W. E.; Shay, J. W.] Univ Texas SW Med Ctr Dallas, Dept Cell Biol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA; [Pearce, V. P.] Univ N Texas, Dept Pharmacol & Neurosci, UNT Hlth Sci Ctr Ft Worth, Ft Worth, TX USA; [Sherrell, J.] Univ Arizona, Sch Dent, Phoenix, AZ USA; [Kopelovich, L.] NCI, Div Canc Prevent, Bethesda, MD 20892 USA	University of Texas System; University of Texas Southwestern Medical Center Dallas; University of North Texas System; University of North Texas Health Science Center; University of Arizona; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Shay, JW (corresponding author), Univ Texas SW Med Ctr Dallas, Dept Cell Biol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	Jerry.Shay@UTSouthwestern.edu	Shay, Jerry W/F-7878-2011		DIVISION OF CANCER PREVENTION AND CONTROL [N01CN005106] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R03CA075907, P50CA070907] Funding Source: NIH RePORTER; NCI NIH HHS [P50 CA070907, P50 CA75907, N01CN43301, N01-CN43301, CN-05106] Funding Source: Medline	DIVISION OF CANCER PREVENTION AND CONTROL(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bankfalvi A, 2004, MODERN PATHOL, V17, P1051, DOI 10.1038/modpathol.3800082; Bayne S, 2005, MOL CELL ENDOCRINOL, V240, P11, DOI 10.1016/j.mce.2005.05.009; Bhat KPL, 2002, ANN NY ACAD SCI, V957, P210, DOI 10.1111/j.1749-6632.2002.tb02918.x; Bhat KPL, 2001, ANTIOXID REDOX SIGN, V3, P1041, DOI 10.1089/152308601317203567; Campisi J, 2005, CELL, V120, P513, DOI 10.1016/j.cell.2005.02.003; Conneely OM, 2003, J MAMMARY GLAND BIOL, V8, P205, DOI 10.1023/A:1025952924864; Counter CM, 1998, P NATL ACAD SCI USA, V95, P14723, DOI 10.1073/pnas.95.25.14723; Dimri G, 2005, BREAST CANCER RES, V7, P171, DOI 10.1186/bcr1275; Dong CK, 2005, CRIT REV ONCOL HEMAT, V54, P85, DOI 10.1016/j.critrevonc.2004.12.005; Dong ZG, 2003, MUTAT RES-FUND MOL M, V523, P145, DOI 10.1016/S0027-5107(02)00330-5; Fridriksdottir AJR, 2005, J MAMMARY GLAND BIOL, V10, P61, DOI 10.1007/s10911-005-2541-6; Gusman J, 2001, CARCINOGENESIS, V22, P1111, DOI 10.1093/carcin/22.8.1111; Hahn WC, 2004, CANCER CELL, V6, P215, DOI 10.1016/j.ccr.2004.09.007; Holt SE, 1999, J CELL PHYSIOL, V180, P10, DOI 10.1002/(SICI)1097-4652(199907)180:1<10::AID-JCP2>3.0.CO;2-D; Kim H, 2002, BIOCHEM J, V365, P765, DOI 10.1042/BJ20011848; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Lanzilli G, 2006, INT J ONCOL, V28, P641; Le Corre L, 2005, MOL NUTR FOOD RES, V49, P462, DOI 10.1002/mnfr.200400094; Lebeau J, 2002, ANTICANCER RES, V22, P2161; Leonhardt SA, 2002, EXP BIOL MED, V227, P969, DOI 10.1177/153537020222701104; Leslie KK, 2005, GYNECOL ONCOL, V96, P32, DOI 10.1016/j.ygyno.2004.09.057; Li XT, 2003, J BIOL CHEM, V278, P39261, DOI 10.1074/jbc.R300024200; Lim CS, 1999, MOL ENDOCRINOL, V13, P366, DOI 10.1210/me.13.3.366; Masutomi K, 2003, CANCER LETT, V194, P163, DOI 10.1016/S0304-3835(02)00703-6; Masutomi K, 2003, CELL, V114, P241, DOI 10.1016/S0092-8674(03)00550-6; Miloso M, 1999, NEUROSCI LETT, V264, P141, DOI 10.1016/S0304-3940(99)00194-9; Moll UM, 1996, MOL CELL BIOL, V16, P1126; Mote PA, 2002, BREAST CANCER RES TR, V72, P163, DOI 10.1023/A:1014820500738; Nikolaev AY, 2003, CELL, V112, P29, DOI 10.1016/S0092-8674(02)01255-2; Ostermeyer AG, 1996, P NATL ACAD SCI USA, V93, P15190, DOI 10.1073/pnas.93.26.15190; Petersen OW, 2003, CELL PROLIFERAT, V36, P33, DOI 10.1046/j.1365-2184.36.s.1.4.x; Rambhatla L., 2001, J BIOMED BIOTECHNOL, V1, P28, DOI DOI 10.1155/S1110724301000079; Saeki Y, 1997, J MOL MED-JMM, V75, P50, DOI 10.1007/s001090050086; SHAY JW, 1995, MOL CELL BIOL, V15, P425, DOI 10.1128/MCB.15.1.425; Shay JW, 2005, CARCINOGENESIS, V26, P867, DOI 10.1093/carcin/bgh296; Signorelli P, 2005, J NUTR BIOCHEM, V16, P449, DOI 10.1016/j.jnutbio.2005.01.017; Stampfer MR, 2003, ONCOGENE, V22, P5238, DOI 10.1038/sj.onc.1206667; Stingl J, 2005, J MAMMARY GLAND BIOL, V10, P49, DOI 10.1007/s10911-005-2540-7; Sun W, 1999, CANCER RES, V59, P6118; Tabata Y, 2002, J STEROID BIOCHEM, V82, P217, DOI 10.1016/S0960-0760(02)00157-7; Tanaka M, 1998, AM J PATHOL, V153, P1985, DOI 10.1016/S0002-9440(10)65712-4; TRASK DK, 1990, P NATL ACAD SCI USA, V87, P2319, DOI 10.1073/pnas.87.6.2319; Wang Z, 2000, CANCER RES, V60, P5376; Williams CD, 2001, J CLIN ENDOCR METAB, V86, P3912, DOI 10.1210/jc.86.8.3912; Yaswen P, 2002, INT J BIOCHEM CELL B, V34, P1382, DOI 10.1016/S1357-2725(02)00047-X; Yu CC, 2001, BIOCHEM J, V355, P459, DOI 10.1042/0264-6021:3550459; Zhivotovsky B, 2004, NAT REV MOL CELL BIO, V5, P752, DOI 10.1038/nrm1443	47	31	32	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 10	2008	27	17					2365	2374		10.1038/sj.onc.1210886	http://dx.doi.org/10.1038/sj.onc.1210886			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	286KN	17968319	Green Accepted			2022-12-17	WOS:000254844900001
J	Sales, KJ; Boddy, SC; Jabbour, HN				Sales, K. J.; Boddy, S. C.; Jabbour, H. N.			F-prostanoid receptor alters adhesion, morphology and migration of endometrial adenocarcinoma cells	ONCOGENE			English	Article						PGF(2 alpha); FP receptor; focal adhesions; morphology; migration; chemotaxis	GONADOTROPIN-RELEASING-HORMONE; ACTIVATED PROTEIN-KINASE; GROWTH-FACTOR RECEPTOR; N-TERMINAL KINASE; C-SRC; TYROSINE PHOSPHORYLATION; CYCLOOXYGENASE ENZYMES; SIGNAL-TRANSDUCTION; COUPLED RECEPTORS; EXPRESSION	Cellular adhesion to extracellular matrix is a central phenomenon for the maintenance of tissue integrity and cellular movement. Collectively, these processes are regulated by a fine- tuned balance between the formation and loosening of adhesive contacts, a process involving integrins, and the elevation and diminution of cytoplasmic signalling molecules. We demonstrate that prostaglandin ( PG) F-2 alpha stimulation rapidly increases the capacity of Ishikawa cells stably expressing the F- prostanoid receptor ( FPS) to adhere to vitronectin. Coincident with this elevation in matrix adhesion, we demonstrate a profound PGF(2 alpha)- induced alteration in cytoskeletal remodelling, characterized by polymerization of the actin cytoskeleton and recruitment of focal adhesion kinase at focal adhesions and enhanced cell migration. Moreover, we show that these PGF2a- induced alterations in adhesion and morphology on vitronectin and migration could be abolished by cultivating FPS cells in the presence of integrin alpha v beta 3 antibody or alpha v beta 3- directed tetrapeptide arg - gly - asp - ser or inhibition of FP receptor signalling with the FP receptor antagonist, chemical disruptors of the phospholipase C-beta, protein kinase A, c- Src and epidermal growth factor receptor kinase pathways or inhibition of the monomeric G proteins Rho, Rac and CDC42. These results reveal a mechanism by which prostanoids regulate cell movement, which may be relevant to pathologies of the endometrium.	[Sales, K. J.; Boddy, S. C.; Jabbour, H. N.] Queens Med Res Inst, MRC, MRC Human Reprod Sci Unit, Edinburgh EH16 4TJ, Midlothian, Scotland	University of Edinburgh	Jabbour, HN (corresponding author), Queens Med Res Inst, MRC, MRC Human Reprod Sci Unit, 47 Little France Crescent,Old Dalkeith Rd, Edinburgh EH16 4TJ, Midlothian, Scotland.	h.jabbour@hrsu.mrc.ac.uk		Sales, Kurt/0000-0002-9880-5143	Medical Research Council [MC_U127684438, U.1276.00.004.00002.01/2(61014)] Funding Source: Medline; MRC [MC_U127684438] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Benard O, 2001, J BIOL CHEM, V276, P4554, DOI 10.1074/jbc.M006995200; Brakebusch C, 2002, J CLIN INVEST, V109, P999, DOI 10.1172/JCI200215468; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; Cruet S, 1999, GYNECOL ONCOL, V75, P254, DOI 10.1006/gyno.1999.5572; Damsky CH, 1991, CURR OPIN CELL BIOL, V3, P777, DOI 10.1016/0955-0674(91)90049-5; Daub H, 1997, EMBO J, V16, P7032, DOI 10.1093/emboj/16.23.7032; Davidson L, 2004, J BIOL CHEM, V279, P11906, DOI 10.1074/jbc.M310784200; Davidson L, 2004, J BIOL CHEM, V279, P1980, DOI 10.1074/jbc.M309827200; Del Pozo MA, 2002, NAT CELL BIOL, V4, P232, DOI 10.1038/ncb759; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; Fujino H, 2000, J BIOL CHEM, V275, P29907, DOI 10.1074/jbc.M003467200; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Griffin BW, 1999, J PHARMACOL EXP THER, V290, P1278; Harris D, 2002, ENDOCRINOLOGY, V143, P1018, DOI 10.1210/en.143.3.1018; Hynes RO, 2002, NAT MED, V8, P918, DOI 10.1038/nm0902-918; Jaaro H, 1997, P NATL ACAD SCI USA, V94, P3742, DOI 10.1073/pnas.94.8.3742; Jabbour HN, 2005, ENDOCRINOLOGY, V146, P4657, DOI 10.1210/en.2005-0804; Jabbour HN, 2004, TRENDS ENDOCRIN MET, V15, P398, DOI 10.1016/j.tem.2004.08.006; LEFKOWITZ RJ, 1993, CELL, V74, P409, DOI 10.1016/0092-8674(93)80042-D; LESSEY BA, 1994, J CLIN ENDOCR METAB, V79, P643, DOI 10.1210/jc.79.2.643; Levi NL, 1998, MOL ENDOCRINOL, V12, P815, DOI 10.1210/me.12.6.815; Liapis H, 1997, HUM PATHOL, V28, P443, DOI 10.1016/S0046-8177(97)90033-2; LUMSDEN MA, 1983, BRIT J OBSTET GYNAEC, V90, P1135, DOI 10.1111/j.1471-0528.1983.tb06460.x; LUNDSTROM V, 1978, AM J OBSTET GYNECOL, V130, P640, DOI 10.1016/0002-9378(78)90320-4; Luttrell LM, 1999, CURR OPIN CELL BIOL, V11, P177, DOI 10.1016/S0955-0674(99)80023-4; Luttrell LM, 1997, ADV SEC MESS PHOSPH, V31, P263; MORINO N, 1995, J BIOL CHEM, V270, P269, DOI 10.1074/jbc.270.1.269; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Pierce KL, 1999, J BIOL CHEM, V274, P35944, DOI 10.1074/jbc.274.50.35944; PREISSNER KT, 1991, ANNU REV CELL BIOL, V7, P275, DOI 10.1146/annurev.cb.07.110191.001423; RodriguezFernandez JL, 1996, J BIOL CHEM, V271, P27895, DOI 10.1074/jbc.271.44.27895; Sales KJ, 2004, MOL ENDOCRINOL, V18, P1533, DOI 10.1210/me.2004-0022; Sales KJ, 2005, CANCER RES, V65, P7707, DOI 10.1158/0008-5472.CAN-05-0101; Sales KJ, 2003, PROSTAG OTH LIPID M, V71, P97, DOI 10.1016/S1098-8823(03)00050-9; Sales KJ, 2004, J CLIN ENDOCR METAB, V89, P986, DOI 10.1210/jc.2003-031434; Sales KJ, 2003, REPRODUCTION, V126, P559, DOI 10.1530/rep.0.1260559; Sales KJ, 2007, ENDOCRINOLOGY, V148, P3635, DOI 10.1210/en.2006-1517; Schlaepfer DD, 1997, J BIOL CHEM, V272, P13189, DOI 10.1074/jbc.272.20.13189; SEGER R, 1994, J BIOL CHEM, V269, P25699; SINGH EJ, 1975, AM J OBSTET GYNECOL, V121, P1003, DOI 10.1016/0002-9378(75)90927-8; Slack BE, 1998, P NATL ACAD SCI USA, V95, P7281, DOI 10.1073/pnas.95.13.7281; WEINER TM, 1993, LANCET, V342, P1024, DOI 10.1016/0140-6736(93)92881-S; Wozniak MA, 2004, BBA-MOL CELL RES, V1692, P103, DOI 10.1016/j.bbamcr.2004.04.007	43	31	33	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 10	2008	27	17					2466	2477		10.1038/sj.onc.1210883	http://dx.doi.org/10.1038/sj.onc.1210883			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	286KN	17968320	Green Accepted			2022-12-17	WOS:000254844900011
J	He, Q; Luo, X; Jin, W; Huang, Y; Reddy, MVR; Reddy, EP; Sheikh, MS				He, Q.; Luo, X.; Jin, W.; Huang, Y.; Reddy, M. V. R.; Reddy, E. P.; Sheikh, M. S.			Celecoxib and a novel COX-2 inhibitor ON09310 upregulate death receptor 5 expression via GADD153/CHOP	ONCOGENE			English	Article						COX-2 inhibitors; TRAIL; death receptor 5; prostate cancer; colon cancer	ENDOPLASMIC-RETICULUM STRESS; INDUCED APOPTOSIS; CYCLOOXYGENASE-2; CANCER; ADENOCARCINOMAS; CARCINOMA; CELLS; SULINDAC; PATHWAY; COLON	Cyclooxygenase-2 (COX-2) inhibitors are promising anticancer agents but their long-term use at high doses is associated with adverse cardiovascular events. The molecular mechanisms underlying the anticancer or toxic cardiovascular effects of COX-2 inhibitors remain unknown. Here we report that COX-2-selective celecoxib and a novel COX-2 inhibitor ON09310 upregulate death receptor 5 (DR5) and cooperate with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), the ligand for DR5, to induce apoptosis in COX-2-positive and -negative cancer cells. We also show that both agents engage GADD153/CHOP to transcriptionally upregulate DR5 expression; GADD153/CHOP is a C/EBP homologous transcription factor implicated in cellular stress response and apoptosis. Based on our results, we propose that (1) these agents appear to mediate their effects, at least in part, by engaging GADD153/CHOP to activate DR5-dependent apoptotic pathway and (2) their regulation of GADD153/CHOP and DR5 expression appears to occur independent of their COX2 inhibitory effects. Our results also indicate that ON09310 is generally more potent than celecoxib and, at lower concentration, strongly cooperates with TRAIL to induce apoptosis. Taken together, our findings form the basis for future in-depth studies to further explore the utility of TRAIL and/or agonistic anti-DR5 antibodies in combination with low-dose COX-2 inhibitors as a rational approach for cancer prevention and treatment.	[He, Q.; Luo, X.; Jin, W.; Huang, Y.; Sheikh, M. S.] SUNY Upstate Med Univ, Dept Pharmacol, Syracuse, NY 13210 USA; [Reddy, M. V. R.; Reddy, E. P.] Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, Philadelphia, PA 19122 USA	State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Sheikh, MS (corresponding author), SUNY Upstate Med Univ, Dept Pharmacol, 750 E Adams St, Syracuse, NY 13210 USA.	sheikhm@upstate.edu	Reddy, E. Premkumar/F-6233-2011		NATIONAL CANCER INSTITUTE [R01CA109820, R01CA086945] Funding Source: NIH RePORTER; NCI NIH HHS [CA 109820, CA86945] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		EBERHART CE, 1994, GASTROENTEROLOGY, V107, P1183, DOI 10.1016/0016-5085(94)90246-1; Grosser T, 2006, J CLIN INVEST, V116, P4, DOI 10.1172/JCI27291; Gupta S, 2000, PROSTATE, V42, P73, DOI 10.1002/(SICI)1097-0045(20000101)42:1<73::AID-PROS9>3.0.CO;2-G; He Q, 2002, ONCOGENE, V21, P6032, DOI 10.1038/sj.onc.1205897; He Q, 2002, ONCOGENE, V21, P2623, DOI 10.1038/sj.onc.1205345; Hida T, 1998, CANCER RES, V58, P3761; Huang Y, 2001, CANCER RES, V61, P6918; HUANG Y, 2006, TOXICOL APPL PH 1216; Liu XG, 2004, JNCI-J NATL CANCER I, V96, P1769, DOI 10.1093/jnci/djh322; Marnett LJ, 2002, ANNU REV PHARMACOL, V42, P55, DOI 10.1146/annurev.pharmtox.42.082301.164620; Oyadomari S, 2004, CELL DEATH DIFFER, V11, P381, DOI 10.1038/sj.cdd.4401373; Prescott SM, 2000, BBA-REV CANCER, V1470, pM69, DOI 10.1016/S0304-419X(00)00006-8; REDDY EP, 2002, Patent No. 6376519423; Ristimaki A, 1997, CANCER RES, V57, P1276; Williams CS, 1999, ONCOGENE, V18, P7908, DOI 10.1038/sj.onc.1203286; Wilson KT, 1998, CANCER RES, V58, P2929; Yamaguchi H, 2004, J BIOL CHEM, V279, P45495, DOI 10.1074/jbc.M406933200; Zimmermann KC, 1999, CANCER RES, V59, P198	18	31	32	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR	2008	27	18					2656	2660		10.1038/sj.onc.1210894	http://dx.doi.org/10.1038/sj.onc.1210894			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	289LW	17968315				2022-12-17	WOS:000255057000015
J	Shin, DH; Li, SH; Chun, YS; Huang, LE; Kim, MS; Park, JW				Shin, D. H.; Li, S. H.; Chun, Y-S; Huang, L. E.; Kim, M-S; Park, J-W			CITED2 mediates the paradoxical responses of HIF-1 alpha to proteasome inhibition	ONCOGENE			English	Article						hIF-1 alpha; CITED2; proteasome inhibition; p300 co-activator	HYPOXIA-INDUCIBLE FACTOR-1-ALPHA; MELANOCYTE-SPECIFIC GENE; TRANSCRIPTIONAL ACTIVITY; PROTEIN; HIF-1; EXPRESSION; REGULATOR; P300/CBP; GROWTH; MRG1	Hypoxia-inducible factor-1 alpha (HIF-1 alpha) is destabilized via the ubiquitin-proteasome system. Thus HIF-1 alpha expression is robustly upregulated by proteasome inhibition, but paradoxically its activity is reduced. In the present study, we investigated the mechanism underlying the paradoxical response of HIF-1 alpha to proteasome inhibition. In both Hep3B and HEK293 cells, a proteasome inhibitor MG132 noticeably attenuated hypoxic induction of erythropoietin and VEGF mRNAs. MG132 inactivated HIF-1 alpha C-terminal transactivation domain (CAD), independently of factor inhibiting HIF-1 (FIH) and inhibited p300 recruitment by HIF-1 alpha. We next tested the possibility that CITED2 is involved in the HIF-1 inactivation. CITED2 was found to be degraded via the ubiquitin-proteasome system and thus was stabilized by proteasome inhibition. Both the activity and the p300 binding of HIF-1 alpha were inhibited by CITED2 expression and recovered by CITED2 siRNA in the presence of MG132. These results suggest that CITED2 is stabilized by proteasome inhibition and inactivates HIF-1 by interfering with the HIF-1 alpha-p300 interaction. This may be an important mode-of-action for proteasome inhibition-based cancer therapy.	[Shin, D. H.; Li, S. H.; Kim, M-S; Park, J-W] Seoul Natl Univ, Coll Med, Dept Pharmacol, Seoul 11079, South Korea; [Chun, Y-S] Seoul Natl Univ, Coll Med, Dept Physiol, Seoul 11079, South Korea; [Chun, Y-S] Seoul Natl Univ, Coll Med, Canc Res Inst, Seoul, South Korea; [Huang, L. E.] Univ Utah, Sch Med, Dept Neurosurg, Salt Lake City, UT USA	Seoul National University (SNU); Seoul National University (SNU); Seoul National University (SNU); Utah System of Higher Education; University of Utah	Park, JW (corresponding author), Seoul Natl Univ, Coll Med, Dept Pharmacol, 28 Yongon Dong, Seoul 11079, South Korea.	parkjw@snu.ac.kr	Park, Jong-Wan/J-2758-2012	Huang, Eric/0000-0002-6444-1708				Adams J, 2004, NAT REV CANCER, V4, P349, DOI 10.1038/nrc1361; Arany Z, 1996, P NATL ACAD SCI USA, V93, P12969, DOI 10.1073/pnas.93.23.12969; Bhattacharya S, 1999, GENE DEV, V13, P64, DOI 10.1101/gad.13.1.64; Birle DC, 2007, CANCER RES, V67, P1735, DOI 10.1158/0008-5472.CAN-06-2722; Braganca J, 2003, J BIOL CHEM, V278, P16021, DOI 10.1074/jbc.M208144200; Chou YT, 2006, J BIOL CHEM, V281, P18451, DOI 10.1074/jbc.M601720200; Chun YS, 2002, BIOCHEM J, V362, P71, DOI 10.1042/0264-6021:3620071; Dunwoodie SL, 1998, MECH DEVELOP, V72, P27, DOI 10.1016/S0925-4773(98)00011-2; Freedman SJ, 2003, NAT STRUCT BIOL, V10, P504, DOI 10.1038/nsb936; Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704; Kallio PJ, 1999, J BIOL CHEM, V274, P6519, DOI 10.1074/jbc.274.10.6519; Kaluz S, 2006, MOL CELL BIOL, V26, P5895, DOI 10.1128/MCB.00552-06; Koshiji M, 2005, MOL CELL, V17, P793, DOI 10.1016/j.molcel.2005.02.015; Lando D, 2002, GENE DEV, V16, P1466, DOI 10.1101/gad.991402; Liao D, 2007, CANCER RES, V67, P563, DOI 10.1158/0008-5472.CAN-06-2701; Sasabe E, 2007, INT J CANCER, V120, P268, DOI 10.1002/ijc.22294; Schofield CJ, 2004, NAT REV MOL CELL BIO, V5, P343, DOI 10.1038/nrm1366; Shioda T, 1996, P NATL ACAD SCI USA, V93, P12298, DOI 10.1073/pnas.93.22.12298; Sun HB, 1998, P NATL ACAD SCI USA, V95, P13555, DOI 10.1073/pnas.95.23.13555; Xu B, 2007, DEV BIOL, V301, P130, DOI 10.1016/j.ydbio.2006.08.072; Yeo EJ, 2006, BLOOD, V107, P916, DOI 10.1182/blood-2005-06-2564; Yin Z, 2002, P NATL ACAD SCI USA, V99, P10488, DOI 10.1073/pnas.162371799	22	31	32	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR	2008	27	13					1939	1944		10.1038/sj.onc.1210826	http://dx.doi.org/10.1038/sj.onc.1210826			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	276NZ	17906695				2022-12-17	WOS:000254150600013
J	Engelmann, A; Speidel, D; Bornkamm, GW; Deppert, W; Stocking, C				Engelmann, A.; Speidel, D.; Bornkamm, G. W.; Deppert, W.; Stocking, C.			Gadd45 beta is a pro-survival factor associated with stress-resistant tumors	ONCOGENE			English	Article						B-cell lymphoma; MYC; p53; Bcl-x(L); retroviral insertional mutagenesis; stress-resistance	NF-KAPPA-B; MYC TRANSGENIC MICE; CELL-DEATH; INDUCED APOPTOSIS; INSERTIONAL MUTAGENESIS; HEMATOPOIETIC-CELLS; SIGNALING PATHWAYS; GROWTH-ARREST; IDENTIFICATION; FIBROBLASTS	Tumors that acquire resistance against death stimuli constitute a severe problem in the context of cancer therapy. To determine genetic alterations that favor the development of stress-resistant tumors in vivo, we took advantage of polyclonal tumors generated after retroviral infection of newborn E lambda-MYC mice, in which the retroviral integration acts as a mutagen to enhance tumor progression. Tumor cells were cultivated ex vivo and exposed to gamma-irradiation prior to their transplantation into syngenic recipients, thereby providing a strong selective pressure for pro-survival mutations. Secondary tumors developing from stress-resistant tumor stem cells were analysed for retroviral integration sites to reveal candidate genes whose dysregulation confer survival. In addition to the gene encoding the antiapoptotic Bcl-x(L) protein, we identified the gadd45b locus to be a novel common integration site in these tumors, leading to enhanced expression. In accord with a thus far undocumented role of Gadd45 beta in tumorigenesis, we showed that NIH3T3 cells overexpressing Gadd45 beta form tumors in NOD/SCID mice. Interestingly and differently to other known 'classical' antiapoptotic factors, high Gadd45b levels did not protect against MYC-, UV- or gamma-irradiation-induced apoptosis, but conferred a strong and specific survival advantage to serum withdrawal.	[Engelmann, A.; Speidel, D.; Deppert, W.; Stocking, C.] Heinrich Pette Inst, D-20206 Hamburg, Germany; [Bornkamm, G. W.] GSF Forschungszentrum Umwelt & Gesundheit, Inst Klin Mol Biol & Tumorgenet, Munich, Germany	Heinrich Pette Institute; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health	Stocking, C (corresponding author), Heinrich Pette Inst, POB 201652, D-20206 Hamburg, Germany.	stocking@hpi.uni-hamburg.de	Speidel, Daniel/I-4244-2012					Baxter EW, 1996, J VIROL, V70, P2095, DOI 10.1128/JVI.70.4.2095-2100.1996; Bernier J, 2004, NAT REV CANCER, V4, P737, DOI 10.1038/nrc1451; Blyth K, 2000, ONCOGENE, V19, P773, DOI 10.1038/sj.onc.1203321; Chabner BA, 2005, NAT REV CANCER, V5, P65, DOI 10.1038/nrc1529; Das S, 2005, J BIOL CHEM, V280, P23748, DOI 10.1074/jbc.M412837200; De Smaele E, 2001, NATURE, V414, P308, DOI 10.1038/35104560; Gupta M, 2005, ONCOGENE, V24, P7170, DOI 10.1038/sj.onc.1208847; Gupta M, 2006, J BIOL CHEM, V281, P17552, DOI 10.1074/jbc.M600950200; HAUPT Y, 1991, CELL, V65, P753, DOI 10.1016/0092-8674(91)90383-A; Heinrichs S, 2003, ONCOGENE, V22, P555, DOI 10.1038/sj.onc.1206138; Hwang HC, 2002, P NATL ACAD SCI USA, V99, P11293, DOI 10.1073/pnas.162356099; Johnstone RW, 2002, CELL, V108, P153, DOI 10.1016/S0092-8674(02)00625-6; Kovalchuk AL, 2000, J EXP MED, V192, P1183, DOI 10.1084/jem.192.8.1183; Kroemer G, 2005, NAT REV CANCER, V5, P886, DOI 10.1038/nrc1738; Krug U, 2002, ONCOGENE, V21, P3475, DOI 10.1038/sj.onc.1205322; Kues Wilfried A., 2002, Cloning and Stem Cells, V4, P231, DOI 10.1089/15362300260339511; Leicht M, 2003, MOL CELL BIOCHEM, V251, P119, DOI 10.1023/A:1025446302759; Liebermann DA, 2002, ONCOGENE, V21, P3391, DOI 10.1038/sj.onc.1205312; Lindsten T, 2003, J NEUROSCI, V23, P11112; Mikkers H, 2003, ADV CANCER RES, V88, P53, DOI 10.1016/S0065-230X(03)88304-5; Mikkers H, 2002, NAT GENET, V32, P459, DOI 10.1038/ng1102-459b; Okada H, 2004, NAT REV CANCER, V4, P592, DOI 10.1038/nrc1412; Packham G, 1998, GENE DEV, V12, P2475, DOI 10.1101/gad.12.16.2475; Paddenberg R, 2001, EUR J CELL BIOL, V80, P366, DOI 10.1078/0171-9335-00166; POIRIER Y, 1988, J VIROL, V62, P3985, DOI 10.1128/JVI.62.11.3985-3992.1988; Schmidt M, 2001, HUM GENE THER, V12, P743, DOI 10.1089/104303401750148649; Schwieger M, 2002, J EXP MED, V196, P1227, DOI 10.1084/jem.20020824; SELVAKUMARAN M, 1994, MOL CELL BIOL, V14, P2352, DOI 10.1128/MCB.14.4.2352; Shimizu S, 2004, NAT CELL BIOL, V6, P1221, DOI 10.1038/ncb1192; Simm A, 1997, J CELL SCI, V110, P819; Speidel D, 2006, ONCOGENE, V25, P940, DOI 10.1038/sj.onc.1209126; Stewart M, 2002, J VIROL, V76, P4364, DOI 10.1128/JVI.76.9.4364-4369.2002; Tsujimoto Y, 2003, J CELL PHYSIOL, V195, P158, DOI 10.1002/jcp.10254; VANDERLUGT NMT, 1995, EMBO J, V14, P2536, DOI 10.1002/j.1460-2075.1995.tb07251.x; VANLOHUIZEN M, 1991, CELL, V65, P737, DOI 10.1016/0092-8674(91)90382-9; Yoo JY, 2003, J BIOL CHEM, V278, P43001, DOI 10.1074/jbc.M307869200; Zazzeroni F, 2003, BLOOD, V102, P3270, DOI 10.1182/blood-2003-03-0689; Zerbini LF, 2004, P NATL ACAD SCI USA, V101, P13618, DOI 10.1073/pnas.0402069101	38	31	33	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 28	2008	27	10					1429	1438		10.1038/sj.onc.1210772	http://dx.doi.org/10.1038/sj.onc.1210772			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	267ZR	17891184				2022-12-17	WOS:000253548200010
J	Kurata, K; Yanagisawa, R; Ohira, M; Kitagawa, M; Nakagawara, A; Kamijo, T				Kurata, K.; Yanagisawa, R.; Ohira, M.; Kitagawa, M.; Nakagawara, A.; Kamijo, T.			Stress via p53 pathway causes apoptosis by mitochondrial Noxa upregulation in doxorubicin-treated neuroblastoma cells	ONCOGENE			English	Article						neuroblastoma; p53; noxa; mitochondria; apoptosis	WILD-TYPE P53; DNA-DAMAGE; IN-VIVO; P53-DEPENDENT APOPTOSIS; CYTOPLASMIC SEQUESTRATION; MOLECULAR-CLONING; EXPRESSION; DEATH; PROTEINS; GENE	In this study, we employed a panel of cell lines to determine whether p53-dependent cell death in neuroblastoma (NB) cells is caused by apoptotic cellular function, and we further studied the molecular mechanism of apoptosis induced via the p53-dependent pathway. We obtained evidence that a type of p53-dependent stress, doxorubicin (Doxo) administration, causes accumulation of p53 in the nucleus of NB cells and phosphorylation of several serine residues in both Doxo-sensitive and -resistant cell lines. Upregulation of p53-downstream molecules in cells and upregulation of Noxa in the mitochondrial fraction were observed only in Doxo-sensitive NB cells. Significance of Noxa in the Doxo-induced NB cell death was confirmed by Noxa-knockdown experiments. Mitochondrial dysfunction, including cytochrome-c release and membrane potential disregulation, occurred and resulted in the activation of the intrinsic caspase pathway. However, in the Doxo-resistant cells, the accumulation in the nucleus and phosphorylation of p53 did not induce p53-downstream p21(Cip1/Waf1) expression and the Noxa upregulation, resulting in the retention of the mitochondrial homeostasis. Taken together, these findings indicate that the p53 pathway seems to play a crucial role in NB cell death by Noxa regulation in mitochondria, and inhibition of the induction of p53-downstream effectors may regulate drug resistance of NB cells.	[Ohira, M.; Nakagawara, A.; Kamijo, T.] Chiba Canc Ctr Res Inst, Div Biochem, Chuoh Ku, Chiba 2608717, Japan; [Kurata, K.; Yanagisawa, R.; Kamijo, T.] Shinshu Univ, Sch Med, Dept Pediat, Nagano, Japan; [Kitagawa, M.] Hamamatsu Univ Sch Med, Dept Biochem, Shizuoka, Japan	Chiba Cancer Center; Shinshu University; Hamamatsu University School of Medicine	Kamijo, T (corresponding author), Chiba Canc Ctr Res Inst, Div Biochem, Chuoh Ku, 666-2 Nitona, Chiba 2608717, Japan.	tkamijo@chiba-cc.jp						Aleyasin H, 2004, J NEUROSCI, V24, P2963, DOI 10.1523/JNEUROSCI.0155-04.2004; Bell E, 2006, CELL CYCLE, V5, P2639, DOI 10.4161/cc.5.22.3443; Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7; Green DR, 2000, CELL, V102, P1, DOI 10.1016/S0092-8674(00)00003-9; Hempel G, 2002, CANCER CHEMOTH PHARM, V49, P133, DOI 10.1007/s00280-001-0392-4; HIJIKATA M, 1990, J VIROL, V64, P4632, DOI 10.1128/JVI.64.10.4632-4639.1990; Hopkins-Donaldson S, 2002, ONCOGENE, V21, P6132, DOI 10.1038/sj.onc.1205879; Hudson CD, 2005, J BIOL CHEM, V280, P11851, DOI 10.1074/jbc.M408679200; Isaacs JS, 2001, J BIOL CHEM, V276, P18497, DOI 10.1074/jbc.M100638200; KAMIJO T, 1993, J BIOL CHEM, V268, P26452; Keshelava N, 2001, CANCER RES, V61, P6185; Kiryu-Seo S, 2005, J NEUROSCI, V25, P1442, DOI 10.1523/JNEUROSCI.4041-04.2005; Komarova EA, 1997, EMBO J, V16, P1391, DOI 10.1093/emboj/16.6.1391; Lee SJ, 2005, J BIOL CHEM, V280, P5781, DOI 10.1074/jbc.M411224200; Letai A, 2002, CANCER CELL, V2, P183, DOI 10.1016/S1535-6108(02)00127-7; LOWE SW, 1994, SCIENCE, V266, P807, DOI 10.1126/science.7973635; Machida T, 2006, ONCOGENE, V25, P1931, DOI 10.1038/sj.onc.1209225; Matthay KK, 1998, J CLIN ONCOL, V16, P1256, DOI 10.1200/JCO.1998.16.4.1256; MOLL UM, 1995, P NATL ACAD SCI USA, V92, P4407, DOI 10.1073/pnas.92.10.4407; Moll UM, 1996, MOL CELL BIOL, V16, P1126; Nakazawa Y, 2003, J BIOL CHEM, V278, P27888, DOI 10.1074/jbc.M300510200; Obexer P, 2007, CELL DEATH DIFFER, V14, P534, DOI 10.1038/sj.cdd.4402017; ODA E, 2003, SCIENCE, V17, P1053; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; Ohtani S, 2004, MOL CANCER THER, V3, P93; Oren M, 1999, J BIOL CHEM, V274, P36031, DOI 10.1074/jbc.274.51.36031; Paull A, 2005, MOL VIS, V11, P328; Qin JZ, 2004, MOL CANCER THER, V3, P895; Shen Y, 2001, ADV CANCER RES, V82, P55, DOI 10.1016/S0065-230X(01)82002-9; Shibue T, 2003, GENE DEV, V17, P2233, DOI 10.1101/gad.1103603; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Tweddle DA, 2003, CANCER LETT, V197, P93, DOI 10.1016/S0304-3835(03)00088-0; Tweddle DA, 2001, CANCER RES, V61, P8; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Wolff A, 2001, ONCOGENE, V20, P1307, DOI 10.1038/sj.onc.1204251; Wong HK, 2005, MOL CELL BIOL, V25, P8732, DOI 10.1128/MCB.25.19.8732-8747.2005; Yakovlev AG, 2004, J BIOL CHEM, V279, P28367, DOI 10.1074/jbc.M313526200	37	31	32	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 31	2008	27	6					741	754		10.1038/sj.onc.1210672	http://dx.doi.org/10.1038/sj.onc.1210672			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	258QZ	17653088				2022-12-17	WOS:000252884500003
J	Ichikawa, T; Suenaga, Y; Koda, T; Ozaki, T; Nakagawara, A				Ichikawa, T.; Suenaga, Y.; Koda, T.; Ozaki, T.; Nakagawara, A.			TAp63-dependent induction of growth differentiation factor 15 (GDF15) plays a critical role in the regulation of keratinocyte differentiation	ONCOGENE			English	Article						TAp63; GDF15; keratinocyte; differentiation	TGF-BETA SUPERFAMILY; MACROPHAGE INHIBITORY CYTOKINE-1; PROSTATE-DERIVED FACTOR; CANCER CELL-GROWTH; EPIDERMAL MORPHOGENESIS; TARGET GENE; P53 HOMOLOG; P63; MEMBER; EXPRESSION	Since p63-deficient mice display severe defects in formation of epidermis, p63 has been considered to be a multi-isoform p53 family member essential for epidermal development. However, it is still unclear how p63 could contribute to keratinocyte differentiation. In the present study, we have found that TAp63 alpha is induced in association with the upregulation and a secretion of growth differentiation factor 15 (GDF15) during the keratinocyte differentiation of HaCaT cells bearing p53 mutation. Short interference RNA-mediated knockdown of the endogenous TAp63 resulted in a remarkable reduction of GDF15. Luciferase reporter assay and reverse transcription-PCR analysis demonstrated that enforced expression of TAp63 alpha significantly increases the luciferase activity driven by GDF15 promoter and the expression of GDF15. Consistent with these results, the proximal p53/p63-binding site within the GDF15 promoter region was required for the TAp63 alpha-mediated transcriptional activation of GDF15, and TAp63 alpha was recruited onto this site. Furthermore, siRNA-mediated knockdown of the endogenous GDF15 permitted cell growth and inhibited the expression of the differentiation markers such as keratin 10 and involucrin in response to differentiation stimuli. Taken together, our present results provide a novel insight into understanding the molecular mechanisms behind TAp63 alpha-mediated keratinocyte differentiation.	[Ichikawa, T.; Suenaga, Y.; Ozaki, T.; Nakagawara, A.] Chiba Canc Res Inst, Div Biochem, Chuoh Ku, Chiba 2608717, Japan; [Ichikawa, T.; Koda, T.] Hisamitsu Pharmaceut Co Inc, Res Ctr Funct Genom, Chiba, Japan; [Suenaga, Y.; Ozaki, T.; Nakagawara, A.] Chiba Univ, Grad Sch Med, Dept Mol Biol & Oncol, Chiba, Japan	Chiba Cancer Center; Hisamitsu Pharmaceutical Co Ltd; Chiba University	Nakagawara, A (corresponding author), Chiba Canc Res Inst, Div Biochem, Chuoh Ku, 666-2 Nitona, Chiba 2608717, Japan.	akiranak@chiba-cc.jp		Suenaga, Yusuke/0000-0001-6902-5386				Agarwal MK, 2006, P NATL ACAD SCI USA, V103, P16278, DOI 10.1073/pnas.0607210103; Ago T, 2006, CIRC RES, V98, P294, DOI 10.1161/01.RES.0000207919.83894.9d; Baek SJ, 2002, CARCINOGENESIS, V23, P425, DOI 10.1093/carcin/23.3.425; Baek SJ, 2001, MOL PHARMACOL, V59, P901, DOI 10.1124/mol.59.4.901; Bauskin AR, 2006, CANCER RES, V66, P4983, DOI 10.1158/0008-5472.CAN-05-4067; Bootcov MR, 1997, P NATL ACAD SCI USA, V94, P11514, DOI 10.1073/pnas.94.21.11514; Bottner M, 1999, CELL TISSUE RES, V297, P103, DOI 10.1007/s004410051337; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; Bourdon JC, 2005, GENE DEV, V19, P2122, DOI 10.1101/gad.1339905; Candi E, 2006, CELL DEATH DIFFER, V13, P1037, DOI 10.1038/sj.cdd.4401926; Candi E, 2006, J CELL SCI, V119, P4617, DOI 10.1242/jcs.03265; De Laurenzi V, 2000, BIOCHEM BIOPH RES CO, V273, P342, DOI 10.1006/bbrc.2000.2932; Hromas R, 1997, BBA-GENE STRUCT EXPR, V1354, P40, DOI 10.1016/S0167-4781(97)00122-X; Ikawa S, 1999, CELL DEATH DIFFER, V6, P1154, DOI 10.1038/sj.cdd.4400631; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; King KE, 2006, CARCINOGENESIS, V27, P53, DOI 10.1093/carcin/bgi200; Koster MI, 2007, CELL CYCLE, V6, P269, DOI 10.4161/cc.6.3.3792; Koster MI, 2004, GENE DEV, V18, P126, DOI 10.1101/gad.1165104; Koster MI, 2006, DEV BIOL, V289, P253, DOI 10.1016/j.ydbio.2005.10.041; Lambert JR, 2006, J CELL PHYSIOL, V208, P566, DOI 10.1002/jcp.20692; Lapi E, 2006, ONCOGENE, V25, P3628, DOI 10.1038/sj.onc.1209401; LEHMAN TA, 1993, CARCINOGENESIS, V14, P833, DOI 10.1093/carcin/14.5.833; Li PX, 2000, J BIOL CHEM, V275, P20127, DOI 10.1074/jbc.M909580199; Mills AA, 1999, NATURE, V398, P708, DOI 10.1038/19531; Nazarova N, 2004, INT J CANCER, V112, P951, DOI 10.1002/ijc.20510; Osada M, 2005, MOL CELL BIOL, V25, P6077, DOI 10.1128/MCB.25.14.6077-6089.2005; Osada M, 2007, BIOCHEM BIOPH RES CO, V354, P913, DOI 10.1016/j.bbrc.2007.01.089; Paralkar VM, 1998, J BIOL CHEM, V273, P13760, DOI 10.1074/jbc.273.22.13760; Roninson IB, 2003, CANCER RES, V63, P2705; Tan MJ, 2000, P NATL ACAD SCI USA, V97, P109, DOI 10.1073/pnas.97.1.109; Uchida K, 2003, J CELL BIOCHEM, V88, P394, DOI 10.1002/jcb.10327; Yang A, 2000, NAT REV MOL CELL BIO, V1, P199, DOI 10.1038/35043127; Yang A, 1999, NATURE, V398, P714, DOI 10.1038/19539; Yang A, 2000, NATURE, V404, P99, DOI 10.1038/35003607; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0	35	31	31	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 17	2008	27	4					409	420		10.1038/sj.onc.1210658	http://dx.doi.org/10.1038/sj.onc.1210658			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	252DU	17637746				2022-12-17	WOS:000252426100001
J	Sommer, P; Le Rouzic, P; Gillingham, H; Berry, A; Kayahara, M; Huynh, T; White, A; Ray, DW				Sommer, P.; Le Rouzic, P.; Gillingham, H.; Berry, A.; Kayahara, M.; Huynh, T.; White, A.; Ray, D. W.			Glucocorticoid receptor overexpression exerts an antisurvival effect on human small cell lung cancer cells	ONCOGENE			English	Article						glucocorticoids; glucocorticoid receptor; small cell lung cancer	NF-KAPPA-B; GENE-EXPRESSION; PROOPIOMELANOCORTIN GENE; MICROARRAY ANALYSIS; INDUCED APOPTOSIS; MOLECULAR-BASIS; CYCLE ARREST; DNA-BINDING; GROWTH; DEXAMETHASONE	Small cell lung cancer ( SCLC) is an aggressive tumour with an abysmal prognosis. These cancers are characteristically resistant to glucocorticoid ( Gc) action, owing to impaired expression of the glucocorticoid receptor ( GR). We identified reduced GR expression in human SCLC cell lines, compared to a non-SCLC cell line. The SCLC cells also showed no Gc inhibition of proliferation, in contrast to non-SCLC cells. Retroviral overexpression of GR resulted in significantly increased cell death, which was partially blocked by the GR antagonist, RU486. Indeed, in cells sorted for GR expression, there was rapid, near complete loss of live cells by 72 h, in contrast to control cells that proliferated as expected. Flow cytometry using Annexin V revealed that cell death was by apoptosis. In addition, confocal analysis of fixed cells showed that cells overexpressing GR displayed a significant increase in fragmenting apoptotic nuclei. Microarray studies showed that transgenic GR expression upregulated the proapoptotic genes, BAD and BAX. We have, therefore, identified a profound apoptotic effect of GR in SCLC cells, which may explain the low levels of endogenous GR in SCLC cells. Understanding how GR overexpression leads to apoptotic cell death in SCLC cells may uncover new therapeutic strategies.	Univ Manchester, Fac Med & Human Sci, Dept Med, Ctr Mol Med, Manchester M13 9PT, Lancs, England; Univ Manchester, Endocrine Sci Res Grp, Manchester M13 9PT, Lancs, England; Univ Manchester, Fac Life Sci, Manchester M13 9PT, Lancs, England	University of Manchester; University of Manchester; University of Manchester	White, A (corresponding author), Univ Manchester, Fac Med & Human Sci, Dept Med, Ctr Mol Med, Stopford Bldg,Oxford Rd, Manchester M13 9PT, Lancs, England.	anne.white@manchester.ac.uk; david.w.ray@manchester.ac.uk	Zeef, Leo/D-6922-2011; White, Anne/G-7717-2015; Sommer, Paula/E-9454-2010; White, Anne/C-3753-2011	White, Anne/0000-0002-7686-2884; Kayahara, Midori/0000-0002-2967-1786; Ray, David/0000-0002-4739-6773; Smethurst, Helen/0000-0003-1234-7936	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Baldi P, 2001, BIOINFORMATICS, V17, P509, DOI 10.1093/bioinformatics/17.6.509; Bolstad BM, 2003, BIOINFORMATICS, V19, P185, DOI 10.1093/bioinformatics/19.2.185; BRAUNSCHWEIGER PG, 1983, CANCER RES, V43, P4757; CLARK AJL, 1990, J CLIN ENDOCR METAB, V70, P485, DOI 10.1210/jcem-70-2-485; COLE TJ, 1995, GENE DEV, V9, P1608, DOI 10.1101/gad.9.13.1608; CROSBY SR, 1988, J CLIN ENDOCR METAB, V67, P1272, DOI 10.1210/jcem-67-6-1272; Donn R, 2007, FASEB J, V21, P402, DOI 10.1096/fj.06-7236com; Doucas V, 2000, P NATL ACAD SCI USA, V97, P11893, DOI 10.1073/pnas.220413297; FARRELL WE, 1993, J MOL ENDOCRINOL, V10, P25, DOI 10.1677/jme.0.0100025; Galon J, 2002, FASEB J, V16, P61, DOI 10.1096/fj.01-0245com; Garside H, 2004, J BIOL CHEM, V279, P50050, DOI 10.1074/jbc.M407309200; GOYA L, 1993, MOL ENDOCRINOL, V7, P1121, DOI 10.1210/me.7.9.1121; HARMON JM, 1979, J CELL PHYSIOL, V98, P267, DOI 10.1002/jcp.1040980203; Hernandez J, 2000, CYTOKINE, V12, P791, DOI 10.1006/cyto.1999.0629; Herr I, 2003, CANCER RES, V63, P3112; Hofmann J, 1995, EUR J CANCER, V31A, P2053, DOI 10.1016/0959-8049(95)00431-9; Jackman DM, 2005, LANCET, V366, P1385, DOI 10.1016/S0140-6736(05)67569-1; Kim CFB, 2005, CELL, V121, P823, DOI 10.1016/j.cell.2005.03.032; Kim YH, 2006, ONCOGENE, V25, P130, DOI 10.1038/sj.onc.1208997; Kofler R, 2000, HISTOCHEM CELL BIOL, V114, P1; Leis H, 2004, MOL ENDOCRINOL, V18, P303, DOI 10.1210/me.2003-0350; Li C, 2001, P NATL ACAD SCI USA, V98, P31, DOI 10.1073/pnas.011404098; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lu YS, 2005, WORLD J GASTROENTERO, V11, P6373, DOI 10.3748/wjg.v11.i40.6373; Mathieu M, 1999, GENE THER, V6, P245, DOI 10.1038/sj.gt.3300814; Minna JD, 2003, CANCER CELL, V4, P163, DOI 10.1016/S1535-6108(03)00221-6; Mitelman F, 2000, MUTAT RES-REV MUTAT, V462, P247, DOI 10.1016/S1383-5742(00)00006-5; Mok CL, 1999, J EXP MED, V189, P575, DOI 10.1084/jem.189.3.575; Mortenson MM, 2005, LUNG CANCER, V49, P163, DOI 10.1016/j.lungcan.2005.01.006; NORMAN J, 1994, J SURG RES, V57, P33, DOI 10.1006/jsre.1994.1105; NORMAN MR, 1977, CANCER RES, V37, P3785; Pang D, 2004, BREAST CANCER RES TR, V88, pS27; RAY DW, 1994, J CLIN INVEST, V93, P1625, DOI 10.1172/JCI117143; Ray DW, 1996, CANCER RES, V56, P3276; Reichardt HM, 1998, CELL, V93, P531, DOI 10.1016/S0092-8674(00)81183-6; Rogatsky I, 1999, MOL CELL BIOL, V19, P5036; Rogatsky I, 1997, MOL CELL BIOL, V17, P3181, DOI 10.1128/MCB.17.6.3181; SANCHEZ I, 1993, CELL GROWTH DIFFER, V4, P215; Schmidt S, 2004, CELL DEATH DIFFER, V11, pS45, DOI 10.1038/sj.cdd.4401456; Tamura K, 2002, J HUM GENET, V47, P348, DOI 10.1007/s100380200048; Wang Z, 2003, J BIOL CHEM, V278, P50897, DOI 10.1074/jbc.M310297200; WHITE A, 1990, BAILLIERE CLIN ENDOC, V4, P1, DOI 10.1016/S0950-351X(05)80313-1; WHITE A, 1993, CLIN ENDOCRINOL, V39, P131, DOI 10.1111/j.1365-2265.1993.tb01765.x; Witschi H, 2005, INHAL TOXICOL, V17, P119, DOI 10.1080/08958370590899712; Wu W, 2004, CANCER RES, V64, P1757, DOI 10.1158/0008-5472.CAN-03-2546; Zhu XY, 2004, J STEROID BIOCHEM, V92, P375, DOI 10.1016/j.jsbmb.2004.07.010	46	31	32	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 1	2007	26	50					7111	7121		10.1038/sj.onc.1210524	http://dx.doi.org/10.1038/sj.onc.1210524			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	228GF	17496926				2022-12-17	WOS:000250715000005
J	Dairkee, SH; Nicolau, M; Sayeed, A; Champion, S; Ji, Y; Moore, DH; Yong, B; Meng, Z; Jeffrey, SS				Dairkee, S. H.; Nicolau, M.; Sayeed, A.; Champion, S.; Ji, Y.; Moore, D. H.; Yong, B.; Meng, Z.; Jeffrey, S. S.			Oxidative stress pathways highlighted in tumor cell immortalization: association with breast cancer outcome	ONCOGENE			English	Article						primary tumor culture; telomerase ( hTERT); gene expression	GENE-EXPRESSION SIGNATURE; LENS EPITHELIAL-CELLS; HUMAN FIBROBLASTS; TELOMERASE; GROWTH; HTERT; APOPTOSIS; PATTERNS; RECEPTOR; BINDING	An improved understanding of cell immortalization and its manifestation in clinical tumors could facilitate novel therapeutic approaches. However, only rare tumor cells, which maintain telomerase expression in vitro, immortalize spontaneously. By expression-profiling analyses of limited-life primary breast tumor cultures pre- and post-hTERT transduction, and spontaneously immortalized breast cancer cell lines, we identified a common signature characteristic of tumor cell immortalization. A predominant feature of this immortalization signature ( ImmSig) was the significant overexpression of oxidoreductase genes. In contrast to epithelial cells derived from low histologic grade primary tumors, which required hTERT transduction for the acquisition of ImmSig, spontaneously immortalizing high-grade tumor cultures displayed similar molecular changes independent of exogenous hTERT. Silencing the hTERT gene reversed ImmSig expression, increased cellular reactive oxygen species levels, altered mitochondrial membrane potential and induced apoptotic and proliferation changes in immortalized cells. In clinical breast cancer samples, cell-proliferation-pathway genes were significantly associated with ImmSig. In these cases, ImmSig expression itself was inversely correlated with patient survival ( P = 0), and was particularly relevant to the outcome of estrogen receptor-positive tumors. Our data support the notion that ImmSig assists in surmounting normal barriers related to oxidative and replicative stress response. Targeting a subset of aggressive breast cancers by reversing ImmSig components could be a practical therapeutic strategy.	Calif Pacific Med Ctr, Res Inst, San Francisco, CA 94107 USA; Stanford Univ, Sch Med, Dept Surg, Stanford, CA 94305 USA	California Pacific Medical Center; California Pacific Medical Center Research Institute; Stanford University	Dairkee, SH (corresponding author), Calif Pacific Med Ctr, Res Inst, 475 Brannan St, San Francisco, CA 94107 USA.	dairkes@sutterhealth.org; ssj@stanford.edu	Dairkee, Shanaz Hashmi/D-6743-2012	Jeffrey, Stefanie/0000-0003-4478-2764; Dairkee, Shanaz/0000-0002-2073-9684	NCI NIH HHS [R01 CA109325, U01 CA85129] Funding Source: Medline; NHGRI NIH HHS [K01 HG00030] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U01CA085129, R01CA109325] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [K01HG000030] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		Ben-Porath I, 2005, INT J BIOCHEM CELL B, V37, P961, DOI 10.1016/j.biocel.2004.10.013; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Boyle EI, 2004, BIOINFORMATICS, V20, P3710, DOI 10.1093/bioinformatics/bth456; Chang HY, 2005, P NATL ACAD SCI USA, V102, P3738, DOI 10.1073/pnas.0409462102; Chen QM, 1998, BIOCHEM J, V332, P43, DOI 10.1042/bj3320043; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; DAIRKEE SH, 1995, CANCER RES, V55, P2516; Dairkee SH, 2004, BMC GENOMICS, V5, DOI 10.1186/1471-2164-5-47; Dairkee SH, 1997, CANCER RES, V57, P1590; Dudognon C, 2004, ONCOGENE, V23, P7469, DOI 10.1038/sj.onc.1208029; Elkak A E, 2005, J Carcinog, V4, P17, DOI 10.1186/1477-3163-4-17; Kurz DJ, 2004, J CELL SCI, V117, P2417, DOI 10.1242/jcs.01097; Li Z, 1998, CANCER RES, V58, P5271; Liang XS, 1998, MOL CELL ENDOCRINOL, V146, P151, DOI 10.1016/S0303-7207(98)00161-0; Ma XJ, 2004, CANCER CELL, V5, P607, DOI 10.1016/j.ccr.2004.05.015; Masutomi K, 2005, P NATL ACAD SCI USA, V102, P8222, DOI 10.1073/pnas.0503095102; MICHIELS C, 1990, J CELL PHYSIOL, V144, P295, DOI 10.1002/jcp.1041440216; Paik S, 2004, NEW ENGL J MED, V351, P2817, DOI 10.1056/NEJMoa041588; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Schiff R, 2000, J NATL CANCER I, V92, P1926, DOI 10.1093/jnci/92.23.1926; Serrano M, 2001, CURR OPIN CELL BIOL, V13, P748, DOI 10.1016/S0955-0674(00)00278-7; Shami PJ, 1998, LEUKEMIA, V12, P1461, DOI 10.1038/sj.leu.2401131; Smith LL, 2003, NAT CELL BIOL, V5, P474, DOI 10.1038/ncb985; Sorlie T, 2003, P NATL ACAD SCI USA, V100, P8418, DOI 10.1073/pnas.0932692100; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Sotiriou C, 2006, JNCI-J NATL CANCER I, V98, P262, DOI 10.1093/jnci/djj052; Stampfer MR, 2001, P NATL ACAD SCI USA, V98, P4498, DOI 10.1073/pnas.071483998; Storz P, 2005, FRONT BIOSCI-LANDMRK, V10, P1881, DOI 10.2741/1667; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; Wang J, 2005, J BIOL CHEM, V280, P22776, DOI 10.1074/jbc.M500032200; Wu YL, 2006, J CELL SCI, V119, P2797, DOI 10.1242/jcs.03001; Xiang H, 2002, ONCOGENE, V21, P3784, DOI 10.1038/sj.onc.1205455; Zhang PS, 2003, FASEB J, V17, P767, DOI 10.1096/fj.02-0603fje	35	31	32	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 20	2007	26	43					6269	6279		10.1038/sj.onc.1210452	http://dx.doi.org/10.1038/sj.onc.1210452			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	212GW	17471242				2022-12-17	WOS:000249583300003
J	Schavolt, KL; Pietenpol, JA				Schavolt, K. L.; Pietenpol, J. A.			p53 and Delta Np63 alpha differentially bind and regulate target genes involved in cell cycle arrest, DNA repair and apoptosis	ONCOGENE			English	Article						p21; 14-3-36; p48; p53R2; Noxa; Fas/APO1	IN-VIVO; PROMOTER; DAMAGE; P63; FAMILY; PHOSPHORYLATION; 14-3-3-SIGMA; EPITHELIUM; INHIBITOR; MEDIATOR	The mechanism by which the p53 family of proteins coordinately regulates select target genes after various types of cell stress is not well understood. To further de. ne factors that dictate regulation of target genes, we examined the binding of p53, Delta Np63 alpha and RNA polymerase II (pol II) to the regulatory regions of select target genes in primary human epidermal keratinocytes (HEKs) using chromatin immunoprecipitation. In rapidly proliferating cells, we observed constitutive binding of DNp63a and varying levels of p53 binding, to consensus sites in target genes involved in cell cycle arrest, DNA repair and apoptosis. Following genotoxic stress, p53 occupancy increased whereas DNp63a occupancy decreased at the majority of binding sites examined. Microarray analysis of transcripts isolated from HEKs ectopically expressing p53 and DNp63a revealed an inverse regulation of select target genes by the two family members. Collectively, our results suggest that DNp63a can function as a repressor of select p53 target genes involved in growth arrest, DNA repair and apoptosis, and that the location of the p53 consensus binding site(s) in a target gene may dictate whether pol II is constitutively bound in proliferating cells.	Vanderbilt Univ, Sch Med, Ctr Mol Toxicol, Dept Biochem, Nashville, TN USA	Vanderbilt University	Pietenpol, JA (corresponding author), Vanderbilt Ingram Canc Ctr, Nashville, TN 37232 USA.	j.pietenpol@vanderbilt.edu			NCI NIH HHS [CA70856, CA68485, CA105436] Funding Source: Medline; NIEHS NIH HHS [ES00267, T32 ES0702] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA068485, R01CA105436, R01CA070856] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000267] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Appella E, 2001, EUR J BIOCHEM, V268, P2764, DOI 10.1046/j.1432-1327.2001.02225.x; Bakkers J, 2002, DEV CELL, V2, P617, DOI 10.1016/S1534-5807(02)00163-6; Barbieri CE, 2005, CANCER RES, V65, P2314, DOI 10.1158/0008-5472.CAN-04-3449; Barbieri CE, 2006, CANCER RES, V66, P7589, DOI 10.1158/0008-5472.CAN-06-2020; Beretta C, 2005, CELL CYCLE, V4, P1625, DOI 10.4161/cc.4.11.2135; Bode AM, 2004, NAT REV CANCER, V4, P793, DOI 10.1038/nrc1455; Dohn M, 2001, ONCOGENE, V20, P3193, DOI 10.1038/sj.onc.1204427; Dumaz N, 1999, EMBO J, V18, P7002, DOI 10.1093/emboj/18.24.7002; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Espinosa JM, 2003, MOL CELL, V12, P1015, DOI 10.1016/S1097-2765(03)00359-9; Harms K, 2004, CELL MOL LIFE SCI, V61, P822, DOI 10.1007/s00018-003-3304-4; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; Ihrie RA, 2005, CELL, V120, P843, DOI 10.1016/j.cell.2005.01.008; Jacobs WB, 2005, NEURON, V48, P743, DOI 10.1016/j.neuron.2005.10.027; Kaeser MD, 2002, P NATL ACAD SCI USA, V99, P95, DOI 10.1073/pnas.012283399; Kaeser MD, 2004, ONCOGENE, V23, P4007, DOI 10.1038/sj.onc.1207536; Lambert PF, 1998, J BIOL CHEM, V273, P33048, DOI 10.1074/jbc.273.49.33048; Muller M, 1998, J EXP MED, V188, P2033, DOI 10.1084/jem.188.11.2033; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Qian H, 2002, ONCOGENE, V21, P7901, DOI 10.1038/sj.onc.1205974; Sasaki Y, 2005, ONCOGENE, V24, P5131, DOI 10.1038/sj.onc.1208695; Szak ST, 2001, MOL CELL BIOL, V21, P3375, DOI 10.1128/MCB.21.10.3375-3386.2001; Tan T, 2002, MOL CELL BIOL, V22, P3247, DOI 10.1128/MCB.22.10.3247-3254.2002; Tanaka H, 2000, NATURE, V404, P42, DOI 10.1038/35003506; Weinberg RL, 2005, J MOL BIOL, V348, P589, DOI 10.1016/j.jmb.2005.03.014; Westfall MD, 2004, CARCINOGENESIS, V25, P857, DOI 10.1093/carcin/bgh148; Westfall MD, 2003, MOL CELL BIOL, V23, P2264, DOI 10.1128/MCB.23.7.2264-2276.2003; ZAUBERMAN A, 1995, NUCLEIC ACIDS RES, V23, P2584, DOI 10.1093/nar/23.14.2584	28	31	32	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 13	2007	26	42					6125	6132		10.1038/sj.onc.1210441	http://dx.doi.org/10.1038/sj.onc.1210441			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	209PU	17404570				2022-12-17	WOS:000249401300002
J	Lauth, M; Bergstrom, A; Toftgard, R				Lauth, M.; Bergstrom, A.; Toftgard, R.			Phorbol esters inhibit the Hedgehog signalling pathway downstream of Suppressor of Fused, but upstream of Gli	ONCOGENE			English	Article						hedgehog signalling; phorbol ester; protein kinase C	BASAL-CELL CARCINOMA; PROTEIN-KINASE-A; TRANSCRIPTIONAL ACTIVITY; BETA-TRCP; EXPRESSION; UBIQUITINATION; TRANSFORMATION; FIBROBLASTS; DEGRADATION; MODULATION	The developmentally important Hedgehog ( Hh) signal transduction pathway, which has recently been implicated in several forms of cancer, is subject to regulation by several protein kinases. Here, we address the role of protein kinase Cd in pathway inhibition and show that cellular depletion or pharmacological inhibition of this kinase isoform results in a blockade of signalling between Suppressor of Fused and the Gli transcription factors. We further provide evidence that the observed pathway inhibition is independent of primary cilia and the mitogen- activated protein kinase kinase ( Mek1) kinase. These. findings allowed for the rapid dissection of downstream Hh pathway activation mechanisms in human tumour cells and demonstrate a surprising variation in how cells can activate signalling in a ligand- and receptor-independent manner.	Karolinska Inst, Dept Biosci & Nutr, SE-14157 Huddinge, Sweden	Karolinska Institutet	Lauth, M (corresponding author), Karolinska Inst, Dept Biosci & Nutr, Novum Res Pk,Halsovagen 7, SE-14157 Huddinge, Sweden.	matthias.lauth@biosci.ki.se						Beachy PA, 2004, NATURE, V432, P324, DOI 10.1038/nature03100; Bhatia N, 2006, J BIOL CHEM, V281, P19320, DOI 10.1074/jbc.M513203200; Chen JK, 2002, P NATL ACAD SCI USA, V99, P14071, DOI 10.1073/pnas.182542899; Eichberger T, 2006, GENOMICS, V87, P616, DOI 10.1016/j.ygeno.2005.12.003; Frank-Kamenetsky Maria, 2002, J Biol, V1, P10, DOI 10.1186/1475-4924-1-10; GSCHWENDT M, 1994, BIOCHEM BIOPH RES CO, V199, P93, DOI 10.1006/bbrc.1994.1199; Haycraft CJ, 2005, PLOS GENET, V1, P480, DOI 10.1371/journal.pgen.0010053; Huangfu DW, 2003, NATURE, V426, P83, DOI 10.1038/nature02061; Kaesler S, 2000, BIOL CHEM, V381, P545, DOI 10.1515/BC.2000.070; Karhadkar SS, 2004, NATURE, V431, P707, DOI 10.1038/nature02962; Kasper M, 2006, MOL CELL BIOL, V26, P6283, DOI 10.1128/MCB.02317-05; Kogerman P, 1999, NAT CELL BIOL, V1, P312, DOI 10.1038/13031; Liu QY, 2000, CANCER LETT, V153, P13, DOI 10.1016/S0304-3835(99)00417-6; Liu WS, 1998, CELL SIGNAL, V10, P529, DOI 10.1016/S0898-6568(98)00012-6; Mao JH, 2002, J BIOL CHEM, V277, P35156, DOI 10.1074/jbc.M206743200; Neill GW, 2003, CANCER RES, V63, P4692; Ohno S, 2002, J BIOCHEM, V132, P509, DOI 10.1093/oxfordjournals.jbchem.a003249; OKAZAKI K, 1995, ONCOGENE, V10, P1149; Pan Y, 2006, MOL CELL BIOL, V26, P3365, DOI 10.1128/MCB.26.9.3365-3377.2006; Regl G, 2002, ONCOGENE, V21, P5529, DOI 10.1038/sj.onc.1205748; Riobo NA, 2006, P NATL ACAD SCI USA, V103, P4505, DOI 10.1073/pnas.0504337103; Riobo NA, 2006, CANCER RES, V66, P839, DOI 10.1158/0008-5472.CAN-05-2539; Sanchez P, 2004, P NATL ACAD SCI USA, V101, P12561, DOI 10.1073/pnas.0404956101; Sasaki H, 1997, DEVELOPMENT, V124, P1313; Schneider L, 2005, CURR BIOL, V15, P1861, DOI 10.1016/j.cub.2005.09.012; Sheng T, 2006, J BIOL CHEM, V281, P9, DOI 10.1074/jbc.C500300200; Svard J, 2006, DEV CELL, V10, P187, DOI 10.1016/j.devcel.2005.12.013; Taipale J, 2000, NATURE, V406, P1005, DOI 10.1038/35023008; Tempe D, 2006, MOL CELL BIOL, V26, P4316, DOI 10.1128/MCB.02183-05; Wang BW, 2006, P NATL ACAD SCI USA, V103, P33, DOI 10.1073/pnas.0509927103	30	31	32	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 2	2007	26	35					5163	5168		10.1038/sj.onc.1210321	http://dx.doi.org/10.1038/sj.onc.1210321			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	196MT	17310984				2022-12-17	WOS:000248487400015
J	de Feraudy, S; Limoli, CL; Gledzinski, E; Karentz, D; Marti, TM; Feeney, L; Cleaver, JE				de Feraudy, S.; Limoli, C. L.; Gledzinski, E.; Karentz, D.; Marti, T. M.; Feeney, L.; Cleaver, J. E.			Pol eta is required for DNA replication during nucleotide deprivation by hydroxyurea	ONCOGENE			English	Article						pol eta; H2AX; hydroxyurea	DOUBLE-STRAND BREAKS; S PHASE CHECKPOINT; POLYMERASE-ETA; HOMOLOGOUS RECOMBINATION; HISTONE H2AX; ARREST; MECHANISM; PHOSPHORYLATION; SENSITIVITY; INHIBITION	Hydroxyurea reduces DNA replication by nucleotide deprivation, whereas UV damage generates DNA photoproducts that directly block replication fork progression. We show that the low fidelity class Y polymerase Pol eta is recruited to proliferating cell nuclear antigen at replication forks both by hydroxyurea and UV light. Under nucleotide deprivation, Pol I allows cells to accumulate at the G1/S boundary by facilitating slow S-phase progression and promotes apoptosis. Normal cells consequently enter apoptosis at a faster rate than Pol eta-deficient cells. Coincident with hydroxyurea-induced S-phase delay, Pol eta-deficient cells undergo more replication fork breakage and accumulate more foci of the Mre11/Rad50/Nbs1 complex and phosphorylated histone H2AX. We conclude that under conditions of nucleotide deprivation, Pol eta is required for S-phase progression but is proapoptotic. However, as Pol eta is reported to require higher nucleotide concentrations than class B replicative polymerases, its recruitment by hydroxyurea requires it to function under suboptimal conditions. Our results suggest that hydr-oxyurea-induced apoptosis occurs at the G1/S boundary and that initiation of the S-phase requires greater nucleotide concentrations than does S-phase progression.	Univ Calif San Francisco, UCSF Canc Ctr, Auerback Melanoma Lab, San Francisco, CA 94143 USA; Univ Calif Irvine, Dept Radiat Oncol, Irvine, CA USA; Univ Calif San Francisco, Dept Biol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; UCSF Medical Center; University of California System; University of California Irvine; University of California System; University of California San Francisco	Cleaver, JE (corresponding author), Univ Calif San Francisco, UCSF Canc Ctr, Auerback Melanoma Lab, Room N431, San Francisco, CA 94143 USA.	jcleaver@cc.ucsf.edu	Marti, Thomas/AAW-5232-2020; Limoli, Charles/AAW-1748-2020	Marti, Thomas/0000-0003-3005-220X; Limoli, Charles/0000-0002-1321-4142	NIEHS NIH HHS [1 RO1 ES 8061] Funding Source: Medline; NINDS NIH HHS [5R01NS052781] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES008061] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS052781] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Arnaudeau C, 2000, MUTAT RES-DNA REPAIR, V461, P221, DOI 10.1016/S0921-8777(00)00052-5; Arnaudeau C, 2001, J MOL BIOL, V307, P1235, DOI 10.1006/jmbi.2001.4564; Broughton BC, 2002, P NATL ACAD SCI USA, V99, P815, DOI 10.1073/pnas.022473899; Burgers PMJ, 2001, J BIOL CHEM, V276, P43487, DOI 10.1074/jbc.R100056200; Carter G L, 1989, Cancer Commun, V1, P13; Cleaver JE, 1999, CANCER RES, V59, P1102; Cleaver JE, 2002, DNA REPAIR, V1, P41, DOI 10.1016/S1568-7864(01)00004-0; Cordonnier AM, 1999, MOL CELL BIOL, V19, P2206; Feijoo C, 2001, J CELL BIOL, V154, P913, DOI 10.1083/jcb.200104099; Furuta T, 2003, J BIOL CHEM, V278, P20303, DOI 10.1074/jbc.M300198200; Halicka HD, 2005, CELL CYCLE, V4, P339; Hammond EM, 2003, MUTAT RES-FUND MOL M, V532, P205, DOI 10.1016/j.mrfmmm.2003.08.017; Johnson RE, 1999, SCIENCE, V285, P263, DOI 10.1126/science.285.5425.263; Kannouche P, 2001, GENE DEV, V15, P158, DOI 10.1101/gad.187501; Limoli CL, 2005, ONCOGENE, V24, P3708, DOI 10.1038/sj.onc.1208515; Limoli CL, 2002, MUTAT RES-FUND MOL M, V510, P121, DOI 10.1016/S0027-5107(02)00257-9; Limoli CL, 2002, P NATL ACAD SCI USA, V99, P233, DOI 10.1073/pnas.231611798; Limoli CL, 2000, P NATL ACAD SCI USA, V97, P7939, DOI 10.1073/pnas.130182897; Masutani C, 1999, NATURE, V399, P700, DOI 10.1038/21447; O'Driscoll M, 2003, NAT GENET, V33, P497, DOI 10.1038/ng1129; Robison JG, 2004, J BIOL CHEM, V279, P34802, DOI 10.1074/jbc.M404750200; Saintigny Y, 2001, EMBO J, V20, P3861, DOI 10.1093/emboj/20.14.3861; Thakur M, 2001, GENE CHROMOSOME CANC, V32, P222, DOI 10.1002/gcc.1186; Ward IM, 2001, J BIOL CHEM, V276, P47759, DOI 10.1074/jbc.C100569200; Washington MT, 2003, MOL CELL BIOL, V23, P8316, DOI 10.1128/MCB.23.22.8316-8322.2003	25	31	31	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2007	26	39					5713	5721		10.1038/sj.onc.1210385	http://dx.doi.org/10.1038/sj.onc.1210385			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	202EP	17369853				2022-12-17	WOS:000248885100003
J	Darwish, H; Cho, JM; Loignon, M; Alaoui-Jamali, MA				Darwish, H.; Cho, J. M.; Loignon, M.; Alaoui-Jamali, M. A.			Overexpression of SERTAD3, a putative oncogene located within the 19q13 amplicon, induces E2F activity and promotes tumor growth	ONCOGENE			English	Article						SERTAD; 19q13; cell cycle; oncogenesis; E2F	DNA-SEQUENCES; BREAST-CANCER; CELL-LINES; OVARIAN-CANCER; C-MYC; GENE; AMPLIFICATION; PROTEIN; IDENTIFICATION; TRANSFORMATION	The amplified region of chromosome 19q13.1-13.2 has been associated with several cancers. The well-characterized oncogene AKT2 is located in this amplicon. Two members of the same gene family (SERTAD1 and SERTAD3) are also located within this region. We report herein the genomic structure and potential functions of SERTAD3. SERTAD3 has two transcript variants with short mRNA half-lives, and one of the variants is tightly regulated throughout G1 and S phases of the cell cycle. Overexpression of SERTAD3 induces cell transformation in vitro and tumor formation in mice, whereas inhibition of SERTAD3 by small interfering RNA (siRNA) results in a reduction in cell growth rate. Furthermore, luciferase assays based on E2F-1 binding indicate that SERTAD3 increases the activity of E2F, which is reduced by inhibition of SERTAD3 by siRNA. Together, our data support that SERTAD3 contributes to oncogenesis, at least in part, via an E2F-dependent mechanism.	Sir Mortimer B Davis Jewish Hosp, Lady Davis Inst Med Res, Fac Med, Dept Oncol, Montreal, PQ H3T 1E2, Canada; McGill Univ, Sir Mortimer B Davis Jewish Gen Hosp, Segal Comprehens Canc Ctr, Montreal, PQ H3T 1E2, Canada; Sir Mortimer B Davis Jewish Hosp, Lady Davis Inst Med Res, Fac Med, Dept Med, Montreal, PQ H3T 1E2, Canada	Lady Davis Institute; McGill University; McGill University; Lady Davis Institute; McGill University	Alaoui-Jamali, MA (corresponding author), Sir Mortimer B Davis Jewish Hosp, Lady Davis Inst Med Res, Fac Med, Dept Med, Room E534,3755 Cote St Catherine, Montreal, PQ H3T 1E2, Canada.	moulay.alaoui-jamali@mcgill.ca						Abdullah JM, 2001, BLOOD CELL MOL DIS, V27, P667, DOI 10.1006/bcmd.2001.0434; Alarcon-Vargas D, 2004, J BIOL CHEM, V279, P5008, DOI 10.1074/jbc.M312054200; ALITALO K, 1983, P NATL ACAD SCI-BIOL, V80, P1707, DOI 10.1073/pnas.80.6.1707; BARKER PE, 1982, CANCER GENET CYTOGEN, V5, P81, DOI 10.1016/0165-4608(82)90043-7; Beghini A, 2003, ONCOGENE, V22, P2581, DOI 10.1038/sj.onc.1206336; Bicher A, 1997, GYNECOL ONCOL, V66, P36, DOI 10.1006/gyno.1997.4709; Bienz M, 2006, TRENDS BIOCHEM SCI, V31, P35, DOI 10.1016/j.tibs.2005.11.001; Calgaro S, 2002, GENETICS, V160, P547; Cho JM, 2000, NUCLEIC ACIDS RES, V28, P3478, DOI 10.1093/nar/28.18.3478; Curtis LJ, 1998, GENOMICS, V53, P42, DOI 10.1006/geno.1998.5405; Gupta S, 2003, VIROLOGY, V317, P155, DOI 10.1016/j.virol.2003.08.008; Hiemstra J L, 1994, Prog Clin Biol Res, V385, P51; Hoglund M, 1998, GENE CHROMOSOME CANC, V21, P8; Hsu SIH, 2001, EMBO J, V20, P2273, DOI 10.1093/emboj/20.9.2273; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Loignon M, 2002, CARCINOGENESIS, V23, P35, DOI 10.1093/carcin/23.1.35; Luoh SW, 2002, CANCER GENET CYTOGEN, V136, P43, DOI 10.1016/S0165-4608(01)00657-4; Marchio A, 1997, GENE CHROMOSOME CANC, V18, P59, DOI 10.1002/(SICI)1098-2264(199701)18:1<59::AID-GCC7>3.3.CO;2-N; Miwa W, 1996, BIOCHEM BIOPH RES CO, V225, P968, DOI 10.1006/bbrc.1996.1280; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; MULERIS M, 1995, GENE CHROMOSOME CANC, V14, P155, DOI 10.1002/gcc.2870140302; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; Ormandy CJ, 2003, BREAST CANCER RES TR, V78, P323, DOI 10.1023/A:1023033708204; Petersen I, 1997, BRIT J CANCER, V75, P79, DOI 10.1038/bjc.1997.13; REIFENBERGER G, 1993, CANCER RES, V53, P2736; Ross JS, 1999, SEMIN CANCER BIOL, V9, P125, DOI 10.1006/scbi.1998.0083; SCHNEIDER SS, 1992, MOL CELL BIOL, V12, P5563, DOI 10.1128/MCB.12.12.5563; SHILOH Y, 1986, CANCER RES, V46, P5297; Sieber OM, 2003, NAT REV CANCER, V3, P701, DOI 10.1038/nrc1170; SINGH P, 1994, EMBO J, V13, P3329, DOI 10.1002/j.1460-2075.1994.tb06635.x; Sugimoto M, 1999, GENE DEV, V13, P3027, DOI 10.1101/gad.13.22.3027; Tang TCM, 2002, CANCER RES, V62, P7157; Thompson G, 1996, J GEOM PHYS, V19, P1, DOI 10.1016/0393-0440(95)00014-3; Wang ZJ, 1999, BRIT J CANCER, V80, P70, DOI 10.1038/sj.bjc.6690323; Yang Xiao-He, 1995, Gene Expression, V4, P195; Yen L, 2002, MOL BIOL CELL, V13, P4029, DOI 10.1091/mbc.e02-02-0084; Zaharieva BM, 2003, J PATHOL, V201, P603, DOI 10.1002/path.1481	37	31	32	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 21	2007	26	29					4319	4328		10.1038/sj.onc.1210195	http://dx.doi.org/10.1038/sj.onc.1210195			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	184CY	17260023				2022-12-17	WOS:000247619900014
J	Luo, F; Brooks, DG; Ye, H; Hamoudi, R; Poulogiannis, G; Patek, CE; Winton, DJ; Arends, MJ				Luo, F.; Brooks, D. G.; Ye, H.; Hamoudi, R.; Poulogiannis, G.; Patek, C. E.; Winton, D. J.; Arends, M. J.			Conditional expression of mutated K-ras accelerates intestinal tumorigenesis in Msh2-deficient mice	ONCOGENE			English	Article						K-ras; cre-LoxP; intestine; tumour; mouse	COLORECTAL-CANCER; MOUSE MODELS; MISMATCH REPAIR; GENE-EXPRESSION; BETA-CATENIN; ACTIVATION; MUTATIONS; APOPTOSIS; ONCOGENE; TUMORS	K- ras mutation occurs in 40 - 50% of human colorectal adenomas and carcinomas, but its contribution to intestinal tumorigenesis in vivo is K-ras mutation occurs in 40-50% of human colorectal adenomas and carcinomas, but its contribution to intestinal tumorigenesis in vivo is unclear. We developed K-ras(V12) transgenic mice that were crossed with Ah-Cre mice to generate K-ras(V12)/Cre mice, which showed beta-naphthofla. avone- (i)nduction of Cre- mediated LoxP recombination that activated intestinal expression of K-ras(V12) 4A and 4B transcripts and proteins. Only very occasional intestinal adenomas were observed in beta-naphtho. flavonetreated K-ras(V12)/Cre mice aged up to 2 years, suggesting that mutated K-ras expression alone does not signifi. cantly initiate intestinal tumourigenesis. To investigate the effects of mutated K-ras on DNA mismatch repair (MMR)-deficient intestinal tumour formation, these mice were crossed with Msh2(-/-) mice to generate K-ras(V12)/ Cre/ Msh2(-/-) offspring. After beta-naphtho. flavone treatment, K- ras(V12)/ Cre/ Msh2(-/-) mice showed reduced average life-span of 17.3 +/- 5.0 weeks from 26.9 +/- 6.8 (control Msh2(-/-) mice) ( P < 0.01). They demonstrated increased adenomas in the small intestine from 1.41 ( Msh2(-/-) controls) to 7.75 per mouse (increased. fivefold, P < 0.01). In the large intestine, very few adenomas were found in Msh2(-/-) 2 mice ( 0.13 per mouse) whereas K- ras(V12)/Cre/ Msh2(-/-) mice produced 2.70 ade nomas per mouse (increased 20-fold, P < 0.01). Over 80% adenomas from K- ras(V12)/Cre/Msh2(-/-) mice showed transgene recombination with expression of K-ras(V12) 4A and 4B transcripts and proteins. Sequencing of endogenous murine K-ras showed mutations in two out of 10 tumours examined from Msh2(-/-) mice, but no mutations in 17 tumours from K-ras(V12)/ Cre/ Msh2(-/-) mice. Expression of K-ras(V12) in tumours caused activation of the mitogen-activated protein kinase and Akt/protein kinase B signaling pathways, demonstrated by phosphorylation of p44MAPK, Akt and GSK3 beta, as well as transcriptional upregulation of Pem, Tcl-1 and Trap1a genes (known targets of K-ras(V12) expression in stem cells). Thus, mutated K-ras cooperates synergistically with MMR de. ficiency to accelerate intestinal tumorigenesis, particularly in the large intestine.	Univ Cambridge, Addenbrookes Hosp, Dept Pathol, Cambridge CB2 2Q, England; Univ Edinburgh, Western Gen Hosp, Sir Alastair Currie Canc Res UK Lab, Mol Med Ctr, Edinburgh, Midlothian, Scotland; Univ Cambridge, Cambridge Inst Med Res, Dept Oncol, Cambridge, England	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; University of Edinburgh; University of Cambridge	Arends, MJ (corresponding author), Univ Cambridge, Addenbrookes Hosp, Dept Pathol, Box 235,Hills Rd, Cambridge CB2 2Q, England.	mja40@cam.ac.uk	Poulogiannis, George/AAY-2210-2021; Luo, Feijun/B-1424-2012; Luo, Feijun/AAF-5708-2019; Poulogiannis, George/AAE-1966-2019	Luo, Feijun/0000-0001-7489-544X; Poulogiannis, George/0000-0002-0529-8614; Luo, Feijun/0000-0003-1951-4071; Hamoudi, Rifat/0000-0002-1402-0868	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Al-Aynati MM, 2004, CLIN CANCER RES, V10, P1235, DOI 10.1158/1078-0432.CCR-03-0087; Andreyev HJN, 2001, BRIT J CANCER, V85, P692, DOI 10.1054/bjoc.2001.1964; ARENDS MJ, 1994, AM J PATHOL, V144, P1045; ARENDS MJ, 1993, BRIT J CANCER, V68, P1127, DOI 10.1038/bjc.1993.492; ARENDS MJ, 2004, KEY ADV EFFECTIVE MA, P25; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; Brooks DG, 2001, ONCOGENE, V20, P2144, DOI 10.1038/sj.onc.1204309; CAPON DJ, 1983, NATURE, V304, P507, DOI 10.1038/304507a0; Caulin C, 2004, CANCER RES, V64, P5054, DOI 10.1158/0008-5472.CAN-04-1488; de Wind N, 1998, CANCER RES, V58, P248; DEWIND N, 1995, CELL, V82, P321, DOI 10.1016/0092-8674(95)90319-4; Dinulescu DM, 2005, NAT MED, V11, P63, DOI 10.1038/nm1173; FEARON ER, 1987, SCIENCE, V238, P193, DOI 10.1126/science.2889267; Frayling IM, 2005, MOL DIAGNOSTICS CLIN, P375; Guerra C, 2003, CANCER CELL, V4, P111, DOI 10.1016/S1535-6108(03)00191-0; Ireland H, 2004, GASTROENTEROLOGY, V126, P1236, DOI 10.1053/j.gastro.2004.03.020; Jackson EL, 2001, GENE DEV, V15, P3243, DOI 10.1101/gad.943001; James RM, 2003, MOL CANCER RES, V1, P820; Janssen KP, 2005, BBA-REV CANCER, V1756, P145, DOI 10.1016/j.bbcan.2005.07.004; Janssen KP, 2002, GASTROENTEROLOGY, V123, P492, DOI 10.1053/gast.2002.34786; Jiricny J, 2000, CURR OPIN GENET DEV, V10, P157, DOI 10.1016/S0959-437X(00)00066-6; Johnson L, 2001, NATURE, V410, P1111, DOI 10.1038/35074129; KIM SH, 1993, J CELL BIOL, V123, P877, DOI 10.1083/jcb.123.4.877; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; LUO F, 2007, UNPUB BMC GENOMICS; Malumbres M, 2003, NAT REV CANCER, V3, P459, DOI 10.1038/nrc1097; Meuwissen R, 2001, ONCOGENE, V20, P6551, DOI 10.1038/sj.onc.1204837; Morris RG, 1996, J PATHOL, V180, P357; Otori K, 1997, GUT, V40, P660, DOI 10.1136/gut.40.5.660; Plowman SJ, 2006, J EXP CLIN CANC RES, V25, P259; Plowman SJ, 2006, EXP CELL RES, V312, P16, DOI 10.1016/j.yexcr.2005.10.004; Plowman SJ, 2003, MOL CELL BIOL, V23, P9245, DOI 10.1128/MCB.23.24.9245-9250.2003; Qian JY, 2005, CANCER RES, V65, P5045, DOI 10.1158/0008-5472.CAN-04-3208; Reitmair AH, 1996, CANCER RES, V56, P3842; REITMAIR AH, 1995, NAT GENET, V11, P64, DOI 10.1038/ng0995-64; Sansom OJ, 2006, P NATL ACAD SCI USA, V103, P14122, DOI 10.1073/pnas.0604130103; Shivapurkar N, 1997, CANCER LETT, V115, P39, DOI 10.1016/S0304-3835(97)04709-5; SPANDIDOS DA, 1984, NATURE, V310, P469, DOI 10.1038/310469a0; Toft NJ, 1998, J PATHOL, V185, P123; Toft NJ, 2002, ONCOGENE, V21, P6299, DOI 10.1038/sj.onc.1205727; Toft NJ, 1999, P NATL ACAD SCI USA, V96, P3911, DOI 10.1073/pnas.96.7.3911; Tuveson DA, 2004, CANCER CELL, V5, P375, DOI 10.1016/S1535-6108(04)00085-6; Yamada S, 2005, INT J CANCER, V113, P1015, DOI 10.1002/ijc.20666; Zhu CQ, 2004, CLIN CANCER RES, V10, P1984, DOI 10.1158/1078-0432.CCR-03-0470	44	31	34	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2007	26	30					4415	4427		10.1038/sj.onc.1210231	http://dx.doi.org/10.1038/sj.onc.1210231			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	184CZ	17297472				2022-12-17	WOS:000247620000009
J	Portal, MM; Ferrero, GO; Caputto, BL				Portal, M. M.; Ferrero, G. O.; Caputto, B. L.			N-terminal c-Fos tyrosine phosphorylation regulates c-Fos/ER association and c-Fos-dependent phospholipid synthesis activation	ONCOGENE			English	Article						cytoplasmic c-Fos; phospholipid synthesis regulation; c-Fos/endoplasmic reticulum association; c-Fos-regulated lipid metabolism; c-Fos tyr phosphorylation; tyr-phosphorylation	TRANSCRIPTIONAL ACTIVATION; GENE-EXPRESSION; JUN; PROTEINS; BINDING; KINASE; CELLS; LIGHT; AP-1; DEGRADATION	c-Fos dephosphorylated on tyrosine (c-Fos), a component of the activator protein-1 (AP-1) family of transcription factors, is expressed at very low levels in resting cells. However, its expression is rapidly upregulated in cells undergoing G(0) to S phase transition leading to AP-1-dependent gene transcription responses. In addition, cytoplasmic c-Fos associates to the endoplasmic reticulum (ER) membranes and activates phospholipid synthesis during cell growth and differentiation. Herein, it is shown that in T98G cells, c-Fos/ER association and consequently phospholipid synthesis activation is regulated by the phosphorylated state of c-Fos tyrosine (tyr) residues. The small amount of c-Fos present in quiescent T98G cells is tyr-phosphorylated and not ER-membrane bound. In growing cells, it is dephosphorylated, associated to ER membranes and promotes phospholipid synthesis activation. Impairing tyr-dephosphorylation abrogates phospholipid synthesis activation and reduces proliferation rates to those of quiescent cells. Substitution of tyr residues 10, 30, 106 and 337 evidence tyr 10 and 30 as relevant for this regulatory phenomenon. It is concluded that phosphorylation of tyr residues 10 and 30 of c-Fos regulate the rate of synthesis of phospholipids by regulating c-Fos/ER association.	Univ Nacl Cordoba, Fac Ciencias Quim, Dept Quim Biol, CIQUIBIC,CONICET, RA-5000 Cordoba, Argentina	National University of Cordoba	Caputto, BL (corresponding author), Univ Nacl Cordoba, Fac Ciencias Quim, Dept Quim Biol, CIQUIBIC,CONICET, Pabellon Argentina,Ciudad Univ, RA-5000 Cordoba, Argentina.	bcaputto@dqb.fcq.unc.edu.ar		PORTAL, Maximiliano/0000-0002-2884-6900				ABATE C, 1993, P NATL ACAD SCI USA, V90, P6766, DOI 10.1073/pnas.90.14.6766; Acquaviva C, 2001, ONCOGENE, V20, P942, DOI 10.1038/sj.onc.1204155; ALITALO R, 1990, BLOOD, V75, P1974; ALLEGRETTO EA, 1990, J CELL BIOCHEM, V42, P193, DOI 10.1002/jcb.240420403; Blom N, 1999, J MOL BIOL, V294, P1351, DOI 10.1006/jmbi.1999.3310; Borioli GA, 2005, BBA-BIOMEMBRANES, V1668, P41, DOI 10.1016/j.bbamem.2004.11.007; Borioli GA, 2004, FEBS LETT, V570, P82, DOI 10.1016/j.febslet.2004.06.033; Borioli GA, 2001, BIOCHEM BIOPH RES CO, V280, P9, DOI 10.1006/bbrc.2000.4081; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bussolino DF, 2001, FASEB J, V15, P556; Bussolino DF, 1998, MOL BRAIN RES, V58, P10, DOI 10.1016/S0169-328X(98)00065-5; Coronella-Wood J, 2004, J BIOL CHEM, V279, P33567, DOI 10.1074/jbc.M404013200; CURRAN T, 1987, BIOESSAYS, V7, P255, DOI 10.1002/bies.950070606; Gil GA, 2004, MOL BIOL CELL, V15, P1881, DOI 10.1091/mbc.E03-09-0705; GIUS D, 1990, MOL CELL BIOL, V10, P4243, DOI 10.1128/MCB.10.8.4243; GUIDO ME, 1990, J NEUROCHEM, V55, P1855, DOI 10.1111/j.1471-4159.1990.tb05768.x; Guido ME, 1996, J NEUROSCI RES, V43, P93, DOI 10.1002/jnr.490430112; Herdegen T, 1998, BRAIN RES REV, V28, P370, DOI 10.1016/S0165-0173(98)00018-6; Jacobs D, 1999, GENE DEV, V13, P163, DOI 10.1101/gad.13.2.163; Kaludov NK, 1996, P NATL ACAD SCI USA, V93, P4465, DOI 10.1073/pnas.93.9.4465; KARIN M, 1994, CURR OPIN CELL BIOL, V6, P415, DOI 10.1016/0955-0674(94)90035-3; MEDEMA RH, 1991, J BIOL CHEM, V266, P21186; Monje P, 2003, MOL CELL BIOL, V23, P7030, DOI 10.1128/MCB.23.19.7030-7043.2003; OKAZAKI K, 1995, EMBO J, V14, P5048, DOI 10.1002/j.1460-2075.1995.tb00187.x; Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383; Stork PJS, 2002, CELL CYCLE, V1, P315, DOI 10.4161/cc.1.5.145; Tanos T, 2005, J BIOL CHEM, V280, P18842, DOI 10.1074/jbc.M500620200; TSURUMI C, 1995, MOL CELL BIOL, V15, P5682; Zerpa GAD, 1999, J NEUROCHEM, V73, P1228, DOI 10.1046/j.1471-4159.1999.0731228.x	29	31	32	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY	2007	26	24					3551	3558		10.1038/sj.onc.1210137	http://dx.doi.org/10.1038/sj.onc.1210137			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	172JC	17160021				2022-12-17	WOS:000246799200011
J	Cho, DH; Lee, HJ; Kim, HJ; Hong, SH; Pyo, JO; Cho, C; Jung, YK				Cho, D.-H.; Lee, H.-J.; Kim, H.-J.; Hong, S.-H.; Pyo, J.-O.; Cho, C.; Jung, Y.-K.			Suppression of hypoxic cell death by APIP-induced sustained activation of AKT and ERK1/2	ONCOGENE			English	Article						APIP; hypoxia; ERK1/2; AKT; caspase-9	GLUCOSE-METABOLISM; PHOSPHORYLATION; INHIBITION; CASPASE-9; PROTEIN; PATHWAY; TARGET	Apaf-1-interacting protein (APIP) was previously isolated as an inhibitor of mitochondrial cell death interacting with Apaf-1. Here, we report a hypoxia-selective antiapoptotic activity of APIP that induces the activation of AKT and extracellular signal-regulated kinase (ERK) 1/2. Stable expression of APIP in C2C12 (C2C12/APIP) cells suppressed cell death induced by hypoxia and etoposide. Unlike etoposide, however, APIP induces the sustained activation of AKT and ERK1/2 and the phosphorylation of caspase-9 during hypoxia. Inhibition of AKT and ERK1/2 activation by the treatments with phosphatidylinositol 3'-kinase and mitogen-activated protein kinase kinase (MEK) 1/2 inhibitors sensitized C2C12/APIP cells to hypoxic cell death and abolished the hypoxia-induced phosphorylation of caspase-9. Further, overexpression of phosphorylation-mimic caspase-9 mutants (caspase-9-T125E and caspase-9-S196D), but not phosphorylation-defective caspase-9 mutants (caspase-9-T125A and caspase-9-S196A), effectively suppressed hypoxia-induced death of C2C12 cells. These results elucidate a novel Apaf-1-independent antiapoptotic activity of APIP during hypoxic cell death, inducing the sustained activation of AKT and ERK1/2 and leading to caspase- 9 phosphorylation.	Seoul Natl Univ, Sch Biol Sci, Bio Max Inst, Seoul 151747, South Korea; Gwangju Inst Sci & Technol, Dept Life Sci, Kwangju, South Korea	Seoul National University (SNU); Gwangju Institute of Science & Technology (GIST)	Jung, YK (corresponding author), Seoul Natl Univ, Sch Biol Sci, Bio Max Inst, Seoul 151747, South Korea.	ykjung@snu.ac.kr	Lee, Ho-June/D-8855-2014	Lee, Ho-June/0000-0002-7019-2533; Jung, Yong-Keun/0000-0002-9686-3120				Allan LA, 2003, NAT CELL BIOL, V5, P647, DOI 10.1038/ncb1005; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Chen EY, 2001, CANCER RES, V61, P2429; Chen J, 2003, AM J PATHOL, V162, P1283, DOI 10.1016/S0002-9440(10)63924-7; Cho DH, 2004, J BIOL CHEM, V279, P39942, DOI 10.1074/jbc.M405747200; Dang CV, 1999, TRENDS BIOCHEM SCI, V24, P68, DOI 10.1016/S0968-0004(98)01344-9; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Du KY, 1998, J BIOL CHEM, V273, P32377, DOI 10.1074/jbc.273.49.32377; Jiang ZJ, 2002, BIOCHEM BIOPH RES CO, V294, P726, DOI 10.1016/S0006-291X(02)00540-5; Le Gall M, 2000, MOL BIOL CELL, V11, P1103, DOI 10.1091/mbc.11.3.1103; Mottet D, 2003, J CELL PHYSIOL, V194, P30, DOI 10.1002/jcp.10176; Romashkova JA, 1999, NATURE, V401, P86, DOI 10.1038/43474; Rytomaa M, 2000, ONCOGENE, V19, P4461, DOI 10.1038/sj.onc.1203805; Yanez AJ, 2005, J CELL PHYSIOL, V202, P743, DOI 10.1002/jcp.20183	14	31	32	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 26	2007	26	19					2809	2814		10.1038/sj.onc.1210080	http://dx.doi.org/10.1038/sj.onc.1210080			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	164CP	17086211				2022-12-17	WOS:000246210600016
J	Tavner, F; Frampton, J; Watson, RJ				Tavner, F.; Frampton, J.; Watson, R. J.			Targeting an E2F site in the mouse genome prevents promoter silencing in quiescent and post-mitotic cells	ONCOGENE			English	Article						B-myb promoter; cell cycle; E2F; gene silencing	B-MYB TRANSCRIPTION; IN-VIVO; CYCLE REGULATION; REGULATED EXPRESSION; REPRESSION; ACTIVATION; PRB; PHOSPHORYLATION; SENESCENCE; OCCUPATION	Previous studies have shown that the cell cycle-regulated B-myb promoter contains a conserved E2F binding site that is critical for repressing transcription in quiescent cells. To investigate its significance for permanent promoter silencing, we have inactivated this binding site in the mouse genome. Mice homozygous for the mutant B-myb(mE2F) allele were fully viable, however, B-myb transcription was derepressed during quiescence in mouse embryo fibroblasts (MEFs) derived from mutant animals. Moreover, it was found that mutation of the E2F site resulted in abnormal maintenance of B-myb expression in senescent MEFs and in differentiated brain tissue. These findings therefore reveal a direct and primary role for repressive E2F complexes in silencing gene expression in post-mitotic cells. Analysis of histone modifications at the promoter showed that histone H3 lysine 9 was constitutively acetylated throughout the cell cycle in homozygous mutant MEFs. This mouse system is the first description of an E2F site mutation in situ and will facilitate the study of E2F function in vivo.	Univ London Imperial Coll Sci Technol & Med, Fac Med, Dept Virol, London W2 1PG, England; Univ Birmingham, Sch Med, Inst Biomed Res, Birmingham B15 2TT, W Midlands, England	Imperial College London; University of Birmingham	Watson, RJ (corresponding author), Univ London Imperial Coll Sci Technol & Med, Fac Med, Dept Virol, St Marys Campus,Norfolk Pl, London W2 1PG, England.	r.watson@imperial.ac.uk						Attwooll C, 2004, EMBO J, V23, P4709, DOI 10.1038/sj.emboj.7600481; Bennett JD, 1996, ONCOGENE, V13, P1073; Catchpole S, 2002, J BIOL CHEM, V277, P39015, DOI 10.1074/jbc.M202960200; Cobrinik D, 2005, ONCOGENE, V24, P2796, DOI 10.1038/sj.onc.1208619; Gaubatz S, 2000, MOL CELL, V6, P729, DOI 10.1016/S1097-2765(00)00071-X; Hurford RK, 1997, GENE DEV, V11, P1447, DOI 10.1101/gad.11.11.1447; Joaquin M, 2003, CELL MOL LIFE SCI, V60, P2389, DOI 10.1007/s00018-003-3037-4; LAM EWF, 1992, ONCOGENE, V7, P1885; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; Lane S, 1997, ONCOGENE, V14, P2445, DOI 10.1038/sj.onc.1201086; Liu DX, 2001, NEURON, V32, P425, DOI 10.1016/S0896-6273(01)00495-0; Maehara K, 2005, J CELL BIOL, V168, P553, DOI 10.1083/jcb.200411093; Margueron R, 2005, CURR OPIN GENET DEV, V15, P163, DOI 10.1016/j.gde.2005.01.005; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Nagy AG, 2003, MANIPULATING MOUSE G; Narita M, 2003, CELL, V113, P703, DOI 10.1016/S0092-8674(03)00401-X; Nielsen SJ, 2001, NATURE, V412, P561, DOI 10.1038/35087620; Rayman JB, 2002, GENE DEV, V16, P933, DOI 10.1101/gad.969202; Robinson C, 1996, ONCOGENE, V12, P1855; Rowland BD, 2002, CANCER CELL, V2, P55, DOI 10.1016/S1535-6108(02)00085-5; Sala A, 1997, P NATL ACAD SCI USA, V94, P532, DOI 10.1073/pnas.94.2.532; Sitzmann J, 1996, ONCOGENE, V12, P1889; Takahashi Y, 2000, GENE DEV, V14, P804; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299; Wells J, 2000, MOL CELL BIOL, V20, P5797, DOI 10.1128/MCB.20.16.5797-5807.2000; Ziebold U, 1997, CURR BIOL, V7, P253, DOI 10.1016/S0960-9822(06)00121-7; Zwicker J, 1996, SCIENCE, V271, P1595, DOI 10.1126/science.271.5255.1595	27	31	31	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 26	2007	26	19					2727	2735		10.1038/sj.onc.1210087	http://dx.doi.org/10.1038/sj.onc.1210087			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	164CP	17072340				2022-12-17	WOS:000246210600007
J	Janssen, K; Hofmann, TG; Jans, DA; Hay, RT; Schulze-Osthoff, K; Fischer, U				Janssen, K.; Hofmann, T. G.; Jans, D. A.; Hay, R. T.; Schulze-Osthoff, K.; Fischer, U.			Apoptin is modified by SUMO conjugation and targeted to promyelocytic leukemia protein nuclear bodies	ONCOGENE			English	Article						apoptin; apoptosis; PML; SUMO; HipK2	CHICKEN-ANEMIA-VIRUS; INDUCED CELL-DEATH; INDUCED APOPTOSIS; GENE-THERAPY; P53 ACTIVITY; TUMOR-CELLS; PML; ACCUMULATION; SUPPRESSOR; EXPRESSION	Apoptin, a protein of the chicken anemia virus (CAV), represents a novel potential anticancer therapeutic, because it induces apoptotic death specifically in tumor but not normal cells. The cellular localization appears to be crucial for apoptin's selective toxicity. In normal cells apoptin remains in the cytoplasm, whereas in transformed cells it migrates into the nucleus and kills the cell. However, the manner by which apoptin is able to distinguish between tumor and normal cells is unknown. Here, we report for the first time that apoptin interacts directly with the promyelocytic leukemia protein (PML) in tumor cells and accumulates in PML nuclear bodies (NBs), which are involved in apoptosis induction and viral replication. We also demonstrate that apoptin is sumoylated and that a sumoylation-deficient apoptin mutant is no longer recruited to PML-NBs, but localizes in the nuclear matrix. This mutant fails to bind PML, but can still induce apoptosis as efficiently as wild-type apoptin. Moreover, apoptin kills also PML-/- cells and promyelocytic leukemia cells with defective PML expression. Our results therefore suggest that apoptin kills tumor cells independently of PML and sumoylation, however, the interaction of apoptin with PML and small ubiquitin-like modifier (SUMO) proteins might be relevant for CAV replication.	Univ Dusseldorf, Inst Mol Med, D-40225 Dusseldorf, Germany; Deutsch Krebsforschungszentrum, Res Grp Cellular Senescence, D-6900 Heidelberg, Germany; Monash Univ, Dept Biochem & Mol Biol, Nucl Signaling Lab, Clayton, Vic 3168, Australia; Univ Dundee, Sch Life Sci, Div Gene Regulat & Express, Dundee DD1 4HN, Scotland	Heinrich Heine University Dusseldorf; Helmholtz Association; German Cancer Research Center (DKFZ); Monash University; University of Dundee	Fischer, U (corresponding author), Univ Dusseldorf, Inst Mol Med, Bldg 23-12,Univ Str 1, D-40225 Dusseldorf, Germany.	Ute.Fischer@uni-duesseldorf.de	Schulze-Osthoff, Klaus/N-9025-2013; Hay, Ronald/S-3233-2019; Hay, Ronald T/F-9338-2011	Schulze-Osthoff, Klaus/0000-0003-1443-2720; Hay, Ronald/0000-0001-7113-9024; Hay, Ronald T/0000-0001-7113-9024; Jans, David/0000-0001-5115-4745				Adair BM, 2000, DEV COMP IMMUNOL, V24, P247, DOI 10.1016/S0145-305X(99)00076-2; Bernardi R, 2003, ONCOGENE, V22, P9048, DOI 10.1038/sj.onc.1207106; Burek M, 2006, ONCOGENE, V25, P2213, DOI 10.1038/sj.onc.1209258; Chen A, 2006, J CELL BIOCHEM, V98, P895, DOI 10.1002/jcb.20703; Danen-van Oorschot AAAM, 2003, J BIOL CHEM, V278, P27729, DOI 10.1074/jbc.M303114200; DanenVanOorschot AAAM, 1997, P NATL ACAD SCI USA, V94, P5843; Dellaire G, 2004, BIOESSAYS, V26, P963, DOI 10.1002/bies.20089; Engels IH, 2005, MOL CELL BIOL, V25, P2808, DOI 10.1128/MCB.25.7.2808-2818.2005; Everett RD, 2001, ONCOGENE, V20, P7266, DOI 10.1038/sj.onc.1204759; Fischer U, 2005, PHARMACOL REV, V57, P187, DOI 10.1124/pr.57.2.6; Fischer U, 2005, ONCOGENE, V24, P1231, DOI 10.1038/sj.onc.1208290; Fogal V, 2000, EMBO J, V19, P6185, DOI 10.1093/emboj/19.22.6185; Girdwood D, 2003, MOL CELL, V11, P1043, DOI 10.1016/S1097-2765(03)00141-2; Guelen L, 2004, ONCOGENE, V23, P1153, DOI 10.1038/sj.onc.1207224; Gurrieri C, 2004, JNCI-J NATL CANCER I, V96, P269, DOI 10.1093/jnci/djh043; Hay RT, 2005, MOL CELL, V18, P1, DOI 10.1016/j.molcel.2005.03.012; Hofmann TG, 2003, CELL DEATH DIFFER, V10, P1290, DOI 10.1038/sj.cdd.4401313; Hofmann TG, 2002, NAT CELL BIOL, V4, P1, DOI 10.1038/ncb715; Ishov AM, 1996, J CELL BIOL, V134, P815, DOI 10.1083/jcb.134.4.815; Johnson ES, 2004, ANNU REV BIOCHEM, V73, P355, DOI 10.1146/annurev.biochem.73.011303.074118; Kamitani T, 1998, J BIOL CHEM, V273, P26675, DOI 10.1074/jbc.273.41.26675; KOKEN MHM, 1995, ONCOGENE, V10, P1315; Leliveld SR, 2003, EUR J BIOCHEM, V270, P3619, DOI 10.1046/j.1432-1033.2003.03750.x; Leliveld SR, 2003, J BIOL CHEM, V278, P9042, DOI 10.1074/jbc.M210803200; Muller S, 2001, NAT REV MOL CELL BIO, V2, P202, DOI 10.1038/35056591; NOTEBORN MHM, 1994, J VIROL, V68, P346, DOI 10.1128/JVI.68.1.346-351.1994; Oro C, 2004, CURR DRUG TARGETS, V5, P179, DOI 10.2174/1389450043490631; Peters MA, 2006, J GEN VIROL, V87, P823, DOI 10.1099/vir.0.81468-0; Piazza F, 2001, ONCOGENE, V20, P7216, DOI 10.1038/sj.onc.1204855; Pichler A, 2002, CELL, V108, P109, DOI 10.1016/S0092-8674(01)00633-X; Pietersen AM, 1999, GENE THER, V6, P882, DOI 10.1038/sj.gt.3300876; Poon IH, 2005, CANCER RES, V65, P7059, DOI 10.1158/0008-5472.CAN-05-1370; Poon IKH, 2005, J VIROL, V79, P1339, DOI 10.1128/JVI.79.2.1339-1341.2005; Regad T, 2001, ONCOGENE, V20, P7274, DOI 10.1038/sj.onc.1204854; Renshaw RW, 1996, J VIROL, V70, P8872, DOI 10.1128/JVI.70.12.8872-8878.1996; Rodriguez MS, 2001, J BIOL CHEM, V276, P12654, DOI 10.1074/jbc.M009476200; Rohn JL, 2002, J BIOL CHEM, V277, P50820, DOI 10.1074/jbc.M208557200; Ryu SW, 2000, BIOCHEM BIOPH RES CO, V279, P6, DOI 10.1006/bbrc.2000.3882; Schoop RAL, 2004, INT J CANCER, V109, P38, DOI 10.1002/ijc.11675; Song J, 2005, J BIOL CHEM, V280, P40122, DOI 10.1074/jbc.M507059200; Steffan JS, 2004, SCIENCE, V304, P100, DOI 10.1126/science.1092194; Tatham MH, 2001, J BIOL CHEM, V276, P35368, DOI 10.1074/jbc.M104214200; Tavassoli M, 2005, APOPTOSIS, V10, P717, DOI 10.1007/s10495-005-0930-3; van der Eb MM, 2002, CANCER GENE THER, V9, P53, DOI 10.1038/sj.cgt.7700397; Wang ZG, 1998, NAT GENET, V20, P266, DOI 10.1038/3073; Wang ZG, 1998, SCIENCE, V279, P1547; Xirodimas DP, 2002, FEBS LETT, V528, P207, DOI 10.1016/S0014-5793(02)03310-0; Zhang YH, 1999, CANCER RES, V59, P3010; Zhuang SM, 1995, CARCINOGENESIS, V16, P2939, DOI 10.1093/carcin/16.12.2939	49	31	33	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 8	2007	26	11					1557	1566		10.1038/sj.onc.1209923	http://dx.doi.org/10.1038/sj.onc.1209923			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	144FV	16924230				2022-12-17	WOS:000244782500005
J	La Ferla-Bruhl, K; Westhoff, MA; Karl, S; Kasperczyk, H; Zwacka, RM; Debatin, KM; Fulda, S				La Ferla-Bruehl, K.; Westhoff, M. A.; Karl, S.; Kasperczyk, H.; Zwacka, R. M.; Debatin, K. M.; Fulda, S.			NF-kappa B-independent sensitization of glioblastoma cells for TRAIL-induced apoptosis by proteasome inhibition	ONCOGENE			English	Article						NF-kappa B; TRAIL; cytotoxic drugs; apoptosis; proteasome inhibition	CANCER-CELLS; GENE-EXPRESSION; BETULINIC ACID; LIGAND TRAIL; ACTIVATION; GROWTH; DEATH; RESISTANCE; THERAPY; POTENTIATION	The transcription factor nuclear factor-kappaB (NF-kappa B) is a key regulator of stress-induced transcriptional activation and has been implicated in mediating primary or acquired apoptosis resistance in various cancers. In the present study, we therefore investigated the role of NF-kappa B in regulating apoptosis in malignant glioma, a prototypic tumor refractory to current treatment approaches. Here, we report that constitutive NF-KB DNA-binding activity was tow or moderate in eight different glioblastoma cell fines compared to Hodgkin's lymphoma cells, known to harbor aberrant constitutive NF-kappa B activity. Specific inhibition of NF-kappa B by overexpression of inhibitor of kappa B (I kappa B)a superrepressor did not enhance spontaneous apoptosis of glioblastoma cells. Also, overexpression of I kappa B alpha superrepressor had no significant impact on apoptosis induced by two prototypic classes of apoptotic stimuli, that is, chemotherapeutic drugs or death-inducing ligands such as TNF-related apoptosis inducing ligand (TRAIL), which are known to trigger NF-kappa B activation as part of a cellular stress response. Similarly, inhibition of NF-kappa B by the proteasome inhibitor MG132 did not increase doxorubicin (Doxo)-induced apoptosis of glioblastoma cells, although it prevented DNA binding of NF-kappa B complexes in response to Doxo. Interestingly, proteasome inhibition significantly sensitized glioblastoma cells for TRAIL-induced apoptosis. These findings indicate that the characteristic antiapoptotic function of NF-KB reported for many cancers is not a primary feature of glioblastoma and thus, specific NF-KB inhibition may not be effective for chemosensitization of glioblastoma. Instead, proteasome inhibitors, which enhanced TRAIL-induced apoptosis in an NF-kappa B-independent manner, may open new perspectives to increase the efficacy of TRAIL-based regimens	Univ Childrens Hosp, D-89075 Ulm, Germany; Univ Ulm, Div Gene Therapy, Ulm, Germany	Ulm University; University of Hamburg; University Medical Center Hamburg-Eppendorf; Ulm University	Fulda, S (corresponding author), Univ Childrens Hosp, Eythstr 24, D-89075 Ulm, Germany.	simone.fulda@uniklinik-ulm.de	Fulda, Simone/D-5864-2011; Westhoff, Mike-Andrew/ABA-9272-2021; Debatin, Klaus-Michael/J-9704-2014	Westhoff, Mike-Andrew/0000-0003-3256-7100; Debatin, Klaus-Michael/0000-0002-8397-1886; Fulda, Simone/0000-0002-0459-6417; Zwacka, Ralf/0000-0003-2821-0387				ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Baumann B, 2002, J BIOL CHEM, V277, P44791, DOI 10.1074/jbc.M208003200; Bentires-Alj M, 1999, CANCER RES, V59, P811; Biswas DK, 2000, P NATL ACAD SCI USA, V97, P8542, DOI 10.1073/pnas.97.15.8542; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Campbell KJ, 2004, MOL CELL, V13, P853, DOI 10.1016/S1097-2765(04)00131-5; Darnell JE, 2002, NAT REV CANCER, V2, P740, DOI 10.1038/nrc906; Denk A, 2001, J BIOL CHEM, V276, P28451, DOI 10.1074/jbc.M102698200; Fulda S, 1997, CANCER RES, V57, P4956; Gurney JG, 2001, CURR OPIN ONCOL, V13, P160, DOI 10.1097/00001622-200105000-00005; Hayashi S, 2001, NEUROL MED-CHIR, V41, P187, DOI 10.2176/nmc.41.187; Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704; He Q, 2004, ONCOGENE, V23, P2554, DOI 10.1038/sj.onc.1207351; Hermisson M, 2003, CELL DEATH DIFFER, V10, P1078, DOI 10.1038/sj.cdd.4401269; Hinz M, 2001, BLOOD, V97, P2798, DOI 10.1182/blood.V97.9.2798; Huang S, 2000, CLIN CANCER RES, V6, P2573; Jeremias I, 1998, EUR CYTOKINE NETW, V9, P687; Jiang YX, 2001, ONCOGENE, V20, P2254, DOI 10.1038/sj.onc.1204293; Johnson TR, 2003, ONCOGENE, V22, P4953, DOI 10.1038/sj.onc.1206656; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; Karin M, 2004, NAT REV DRUG DISCOV, V3, P17, DOI 10.1038/nrd1279; Kasperczyk H, 2005, ONCOGENE, V24, P6945, DOI 10.1038/sj.onc.1208842; Kasuga C, 2004, CANCER SCI, V95, P840, DOI 10.1111/j.1349-7006.2004.tb02191.x; Kim S, 2004, CELL MOL LIFE SCI, V61, P1075, DOI 10.1007/s00018-004-3477-5; Lashinger LM, 2005, CANCER RES, V65, P4902, DOI 10.1158/0008-5472.CAN-04-3701; Leverkus M, 2003, MOL CELL BIOL, V23, P777, DOI 10.1128/MCB.23.3.777-790.2003; Mathas S, 2002, EMBO J, V21, P4104, DOI 10.1093/emboj/cdf389; Nagai S, 2002, J NEUROSURG, V96, P909, DOI 10.3171/jns.2002.96.5.0909; Nencioni A, 2005, CLIN CANCER RES, V11, P4259, DOI 10.1158/1078-0432.CCR-04-2496; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Nikrad M, 2005, MOL CANCER THER, V4, P443; Paull TT, 2000, CURR BIOL, V10, P886, DOI 10.1016/S0960-9822(00)00610-2; Sayers TJ, 2003, BLOOD, V102, P303, DOI 10.1182/blood-2002-09-2975; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang HM, 2004, LAB INVEST, V84, P941, DOI 10.1038/labinvest.3700123; Wang WX, 1999, CLIN CANCER RES, V5, P119; Weaver KD, 2003, J NEURO-ONCOL, V61, P187, DOI 10.1023/A:1022554824129; Yin D, 2005, ONCOGENE, V24, P344, DOI 10.1038/sj.onc.1208225; Zwacka RM, 2000, J GENE MED, V2, P334, DOI 10.1002/1521-2254(200009/10)2:5<334::AID-JGM129>3.0.CO;2-Q	39	31	31	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 25	2007	26	4					571	582		10.1038/sj.onc.1209841	http://dx.doi.org/10.1038/sj.onc.1209841			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	129LS	16909119				2022-12-17	WOS:000243731600009
J	Lee, HJ; Yun, CH; Lim, SH; Kim, BC; Baik, KG; Kim, JM; Kim, WH; Kim, SJ				Lee, H-J; Yun, C-H; Lim, S. H.; Kim, B-C; Baik, K. G.; Kim, J-M; Kim, W-H; Kim, S-J			SRF is a nuclear repressor of Smad3-mediated TGF-beta signaling	ONCOGENE			English	Article						SRF; TGF-beta; Smad; signaling; transcription; suppression	SERUM RESPONSE FACTOR; GROWTH-FACTOR-BETA; CELL-CYCLE ARREST; DNA-BINDING ACTIVITY; PHOSPHORYLATION SITES; CDK INHIBITOR; C-MYC; TRANSFORMING GROWTH-FACTOR-BETA-1; TRANSCRIPTIONAL ACTIVATORS; RECEPTOR COMPLEX	Serum response factor (SRF) is a widely expressed transcription factor involved in immediate-early and tissue-specific gene expression, cell proliferation and differentiation. We defined a new role of SRF as a nuclear repressor of the tumor growth factor beta 1 (TGF-beta 1) growth-inhibitory signal during cell proliferation. We show that SRF significantly inhibits the TGF-beta 1/Smad-dependent transcription by associating with Smad3. SRF causes resistance to the TGF-beta 1 cytostatic response by directly repressing the Smad transcriptional activity and Smad binding to DNA. Furthermore, we demonstrated that overexpression of SRF markedly decreases the level of Smad3 complex binding to the promoters of Smad3 target genes, p15(INK4b) and p21(Cip1). This leads to the inhibition of expression of TGF-beta 1-responsive genes. SRF therefore acts as a nuclear repressor of Smad3-mediated TGF-beta 1 signaling.	NCI, Lab Cell Regulat & Carcinogenesis, Bethesda, MD 20892 USA; KRIBB, Div Mol Therapeut, Taejon, South Korea; Korea Adv Inst Sci & Technol, Dept Biol Sci, Taejon 305701, South Korea; Kangweon Natl Univ, Div Life Sci, Chunchon, South Korea; Seoul Natl Univ, Coll Med, Canc Res Inst, Seoul, South Korea	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Korea Research Institute of Bioscience & Biotechnology (KRIBB); Korea Advanced Institute of Science & Technology (KAIST); Kangwon National University; Seoul National University (SNU)	Kim, SJ (corresponding author), NCI, Lab Cell Regulat & Carcinogenesis, Bethesda, MD 20892 USA.	kims@mail.nih.gov	Kim, Wooho/G-3703-2011	Lim, Seunghwan/0000-0001-8920-0890	Intramural NIH HHS Funding Source: Medline; NATIONAL CANCER INSTITUTE [Z01BC005617] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAHAM SE, 1992, MOL BIOL CELL, V3, P655, DOI 10.1091/mbc.3.6.655; ALEXANDROW MG, 1995, P NATL ACAD SCI USA, V92, P3239, DOI 10.1073/pnas.92.8.3239; CARCAMO J, 1995, MOL CELL BIOL, V15, P1573; Chai J, 2002, J PHYSIOL PHARMACOL, V53, P147; Claassen GF, 2000, P NATL ACAD SCI USA, V97, P9498, DOI 10.1073/pnas.150006697; DANIELPOUR D, 1990, J BIOL CHEM, V265, P6973; DATTO MB, 1995, P NATL ACAD SCI USA, V92, P5545, DOI 10.1073/pnas.92.12.5545; de Caestecker MP, 2000, JNCI-J NATL CANCER I, V92, P1388, DOI 10.1093/jnci/92.17.1388; Depoortere F, 2000, MOL BIOL CELL, V11, P1061, DOI 10.1091/mbc.11.3.1061; Derynck R, 1998, CELL, V95, P737, DOI 10.1016/S0092-8674(00)81696-7; EWEN ME, 1993, CELL, V74, P1009, DOI 10.1016/0092-8674(93)90723-4; Feng XH, 2000, EMBO J, V19, P5178, DOI 10.1093/emboj/19.19.5178; Feng XH, 2002, MOL CELL, V9, P133, DOI 10.1016/S1097-2765(01)00430-0; GARRIGUEANTAR L, 1995, J IMMUNOL METHODS, V186, P267, DOI 10.1016/0022-1759(95)00151-Y; GENG Y, 1993, P NATL ACAD SCI USA, V90, P10315, DOI 10.1073/pnas.90.21.10315; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; Iavarone A, 1997, NATURE, V387, P417; Iyer D, 2006, P NATL ACAD SCI USA, V103, P4516, DOI 10.1073/pnas.0505338103; Iyer D, 2003, BIOCHEMISTRY-US, V42, P7477, DOI 10.1021/bi030045n; JANKNECHT R, 1992, EMBO J, V11, P1045, DOI 10.1002/j.1460-2075.1992.tb05143.x; JOHANSEN FE, 1993, MOL CELL BIOL, V13, P4640, DOI 10.1128/MCB.13.8.4640; Kang SH, 1999, BRIT J CANCER, V80, P1144, DOI 10.1038/sj.bjc.6690478; Kim BC, 2004, MOL CELL BIOL, V24, P2251, DOI 10.1128/MCB.24.6.2251-2262.2004; KIM JH, 1994, J BIOL CHEM, V269, P13740; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; Lee DK, 2002, J BIOL CHEM, V277, P38557, DOI 10.1074/jbc.M206786200; Lee HJ, 2004, J BIOL CHEM, V279, P2666, DOI 10.1074/jbc.M310591200; Lee MH, 2003, CANCER METAST REV, V22, P435, DOI 10.1023/A:1023785332315; LIU SH, 1993, J BIOL CHEM, V268, P21147; Mack CP, 1999, CIRC RES, V84, P852; MANAK JR, 1991, MOL CELL BIOL, V11, P3652, DOI 10.1128/MCB.11.7.3652; Massague J, 2000, GENE DEV, V14, P627; Miano JM, 2003, J MOL CELL CARDIOL, V35, P577, DOI 10.1016/S0022-2828(03)00110-X; Moustakas A, 1998, P NATL ACAD SCI USA, V95, P6733, DOI 10.1073/pnas.95.12.6733; NORMAN C, 1988, CELL, V55, P989, DOI 10.1016/0092-8674(88)90244-9; Paradis P, 1996, J BIOL CHEM, V271, P10827, DOI 10.1074/jbc.271.18.10827; Pardali K, 2000, J BIOL CHEM, V275, P29244, DOI 10.1074/jbc.M909467199; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; Psichari E, 2002, J BIOL CHEM, V277, P29490, DOI 10.1074/jbc.M112368200; Qiu P, 2003, J MOL CELL CARDIOL, V35, P1407, DOI 10.1016/j.yjmcc.2003.09.002; RIVERA VM, 1993, MOL CELL BIOL, V13, P6260, DOI 10.1128/MCB.13.10.6260; Schratt G, 2001, MOL CELL BIOL, V21, P2933, DOI 10.1128/MCB.21.8.2933-2943.2001; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Sotiropoulos A, 1999, CELL, V98, P159, DOI 10.1016/S0092-8674(00)81011-9; TREISMAN R, 1995, EMBO J, V14, P4905, DOI 10.1002/j.1460-2075.1995.tb00173.x; TREISMAN R, 1992, TRENDS BIOCHEM SCI, V17, P423, DOI 10.1016/0968-0004(92)90013-Y; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; Warner BJ, 1999, MOL CELL BIOL, V19, P5913; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; Wrana JL, 2000, CYTOKINE GROWTH F R, V11, P5, DOI 10.1016/S1359-6101(99)00024-6; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1	51	31	32	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN	2007	26	2					173	185		10.1038/sj.onc.1209774	http://dx.doi.org/10.1038/sj.onc.1209774			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	124VM	16819512				2022-12-17	WOS:000243398300002
J	Motamed-Khorasani, A; Jurisica, I; Letarte, M; Shaw, PA; Parkes, RK; Zhang, X; Evangelou, A; Rosen, B; Murphy, KJ; Brown, TJ				Motamed-Khorasani, A.; Jurisica, I.; Letarte, M.; Shaw, P. A.; Parkes, R. K.; Zhang, X.; Evangelou, A.; Rosen, B.; Murphy, K. J.; Brown, T. J.			Differentially androgen-modulated genes in ovarian epithelial cells from BRCA mutation carriers and control patients predict ovarian cancer survival and disease progression	ONCOGENE			English	Article						ovarian cancer; androgen; BRCA1; BRCA2; BACH2; acetylcholinesterase	PROTEIN-INTERACTION NETWORK; MESSENGER-RNA EXPRESSION; SIGNALING PATHWAY; CONSTITUTIVE ACTIVATION; PROGESTERONE-RECEPTORS; SURFACE EPITHELIUM; BREAST; TUMORS; CARCINOMA; BETA	Epidemiological studies have implicated androgens in the etiology and progression of epithelial ovarian cancer. We previously reported that some androgen responses were dysregulated in malignant ovarian epithelial cells relative to control, non-malignant ovarian surface epithelial (OSE) cells. Moreover, dysregulated androgen responses were observed in OSE cells derived from patients with germline BRCA-1 or -2 mutations (OSEb), which account for the majority of familial ovarian cancer predisposition, and such altered responses may be involved in ovarian carcinogenesis or progression. In the present study, gene expression pro. ling using cDNA microarrays identified 17 genes differentially expressed in response to continuous androgen exposure in OSEb cells and ovarian cancer cells as compared to OSE cells derived from control patients. A subset of these differentially affected genes was selected and verified by quantitative real-time reverse transcription -polymerase chain reaction. Six of the gene products mapped to the OPHID protein -protein interaction database, and five were networked within two interacting partners. Basic leucine zipper transcription factor 2 (BACH2) and acetylcholinesterase (ACHE), which were upregulated by androgen in OSEb cells relative to OSE cells, were further investigated using an ovarian cancer tissue microarray from a separate set of 149 clinical samples. Both cytoplasmic ACHE and BACH2 immunostaining were significantly increased in ovarian cancer relative to benign cases. High levels of cytoplasmic ACHE staining correlated with decreased survival, whereas nuclear BACH2 staining correlated with decreased time to disease recurrence. The finding that products of genes differentially responsive to androgen in OSEb cells may predict survival and disease progression supports a role for altered androgen effects in ovarian cancer. In addition to BACH2 and ACHE, this study highlights a set of potentially functionally related genes for further investigation in ovarian cancer.	Mt Sinai Hosp, Dept Obstet & Gynecol, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada; Univ Toronto, Dept Physiol, Toronto, ON M5G 1X8, Canada; Univ Hlth Network, Princess Margaret Hosp, Ontario Canc Inst, Div Signaling Biol, Toronto, ON, Canada; Univ Toronto, Dept Comp Sci, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON M5G 1X8, Canada; Univ Toronto, Hosp Sick Children, Canc Res Program, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Obstet & Gynecol, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Immunol, Toronto, ON M5G 1X8, Canada; Univ Toronto, Univ Hlth Network, Princess Margaret Hosp, Div Pathol,Ontario Canc Inst, Toronto, ON M5G 1X8, Canada; Univ Toronto, Univ Hlth Network, Princess Margaret Hosp, Ontario Canc Inst,Div Gynecol Oncol, Toronto, ON M5G 1X8, Canada	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre	Brown, TJ (corresponding author), Mt Sinai Hosp, Dept Obstet & Gynecol, Samuel Lunenfeld Res Inst, Room 876,600 Univ Ave, Toronto, ON M5G 1X5, Canada.	brown@mshri.on.ca	Brown, Theodore J./E-2192-2013	Brown, Theodore J./0000-0002-3074-4516				Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; AUERSPERG N, 1994, LAB INVEST, V71, P510; Auersperg N, 1997, J CELL PHYSIOL, V173, P261, DOI 10.1002/(SICI)1097-4652(199711)173:2<261::AID-JCP32>3.0.CO;2-G; Barrios-Rodiles M, 2005, SCIENCE, V307, P1621, DOI 10.1126/science.1105776; Beheshti B, 2003, NEOPLASIA, V5, P53, DOI 10.1016/S1476-5586(03)80017-9; Brown KR, 2005, BIOINFORMATICS, V21, P2076, DOI 10.1093/bioinformatics/bti273; Buchholz TA, 2002, INT J CANCER, V97, P557, DOI 10.1002/ijc.10109; Camp RL, 2000, LAB INVEST, V80, P1943, DOI 10.1038/labinvest.3780204; Cardillo MR, 1998, J EXP CLIN CANC RES, V17, P231; CHADHA S, 1993, HUM PATHOL, V24, P90, DOI 10.1016/0046-8177(93)90067-Q; CRAMER DW, 1983, JNCI-J NATL CANCER I, V71, P717; Deng CX, 2000, BIOESSAYS, V22, P728; EASTON DF, 1995, AM J HUM GENET, V56, P265; Edmondson R, 2002, BRIT J CANCER, V86, P879, DOI 10.1038/sj.bjc.6600154; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Evangelou A, 2003, CANCER RES, V63, P2416; Evangelou A, 2000, CANCER RES, V60, P929; Ford D, 1998, AM J HUM GENET, V62, P676, DOI 10.1086/301749; Foss DL, 1998, ANIM BIOTECHNOL, V9, P67, DOI 10.1080/10495399809525893; GRAY RJ, 1992, J AM STAT ASSOC, V87, P942, DOI 10.2307/2290630; Hage JJ, 2000, GYNECOL ONCOL, V76, P413, DOI 10.1006/gyno.1999.5720; HELZLSOUER KJ, 1995, JAMA-J AM MED ASSOC, V274, P1926, DOI 10.1001/jama.274.24.1926; Hirashima Y, 2003, J BIOL CHEM, V278, P26793, DOI 10.1074/jbc.M212187200; HIRTE HW, 1992, GYNECOL ONCOL, V44, P223, DOI 10.1016/0090-8258(92)90046-L; Hu W, 2000, ANTICANCER RES, V20, P729; Huang M, 2000, GYNECOL ONCOL, V79, P67, DOI 10.1006/gyno.2000.5931; Imaoka S, 2001, CANCER LETT, V166, P119, DOI 10.1016/S0304-3835(00)00572-3; Isern J, 2003, BIOCHEM BIOPH RES CO, V307, P139, DOI 10.1016/S0006-291X(03)01081-7; Johnson G, 2000, INT J DEV NEUROSCI, V18, P781, DOI 10.1016/S0736-5748(00)00049-6; Johnson G, 2000, APPL BIOCHEM BIOTECH, V83, P131, DOI 10.1385/ABAB:83:1-3:131; Jones RB, 2006, NATURE, V439, P168, DOI 10.1038/nature04177; Kanehisa M, 2002, NUCLEIC ACIDS RES, V30, P42, DOI 10.1093/nar/30.1.42; King MC, 2003, SCIENCE, V302, P643, DOI 10.1126/science.1088759; Kobayashi A, 2000, MOL CELL BIOL, V20, P1733, DOI 10.1128/MCB.20.5.1733-1746.2000; Kohonen T., 2001, SELF ORG MAPS, P501; KRUK PA, 1994, EXP CELL RES, V215, P97, DOI 10.1006/excr.1994.1320; KUHNEL R, 1987, J STEROID BIOCHEM, V26, P393, DOI 10.1016/0022-4731(87)90106-3; KUHNEL R, 1988, ANTICANCER RES, V8, P281; Lau KM, 1999, P NATL ACAD SCI USA, V96, P5722, DOI 10.1073/pnas.96.10.5722; Li AJ, 2005, CANCER EPIDEM BIOMAR, V14, P2919, DOI 10.1158/1055-9965.EPI-05-0540; Li AJ, 2003, CLIN CANCER RES, V9, P3667; LINSLEY PS, 1986, CANCER RES, V46, P6380; Lu J, 2002, ACTA BIOCH BIOPH SIN, V34, P95; Lutz LB, 2003, MOL ENDOCRINOL, V17, P1106, DOI 10.1210/me.2003-0032; Marks A, 1999, BRIT J CANCER, V80, P569, DOI 10.1038/sj.bjc.6690393; Modugno F, 2001, ANN EPIDEMIOL, V11, P568, DOI 10.1016/S1047-2797(01)00213-7; Muto A, 2002, J BIOL CHEM, V277, P20724, DOI 10.1074/jbc.M112003200; Nishimoto A, 2005, CANCER RES, V65, P6701, DOI 10.1158/0008-5472.CAN-05-0130; OTASEK D, 2006, SIAM C DAT MIN 22 AP, P1; Park JJ, 2000, CANCER RES, V60, P5946; Pfaffl MW, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.9.e36; Rask K, 2003, BRIT J CANCER, V89, P1298, DOI 10.1038/sj.bjc.6601265; Revankar CM, 2005, SCIENCE, V307, P1625, DOI 10.1126/science.1106943; Risch HA, 1998, JNCI-J NATL CANCER I, V90, P1774, DOI 10.1093/jnci/90.23.1774; Robertson DM, 2004, ENDOCR-RELAT CANCER, V11, P35, DOI 10.1677/erc.0.0110035; Rual JF, 2005, NATURE, V437, P1173, DOI 10.1038/nature04209; Schildkraut JM, 1996, OBSTET GYNECOL, V88, P554, DOI 10.1016/0029-7844(96)00226-8; Scully R, 2000, NATURE, V408, P429, DOI 10.1038/35044000; Scully RE, 1995, J CELL BIOCHEM, P208; Shaw PA, 2001, GYNECOL ONCOL, V80, P132, DOI 10.1006/gyno.2000.6068; Shin S, 2003, P NATL ACAD SCI USA, V100, P7201, DOI 10.1073/pnas.1132020100; Steinmetz R, 2004, MOL ENDOCRINOL, V18, P2570, DOI 10.1210/me.2004-0082; Stelzl U, 2005, CELL, V122, P957, DOI 10.1016/j.cell.2005.08.029; SULTAN M, 2002, BIOINFORMATICS, V18, P111; Thellin O, 1999, J BIOTECHNOL, V75, P291, DOI 10.1016/S0168-1656(99)00163-7; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Venkitaraman AR, 2002, CELL, V108, P171, DOI 10.1016/S0092-8674(02)00615-3; Vidal CJ, 2005, CHEM-BIOL INTERACT, V157, P227, DOI 10.1016/j.cbi.2005.10.035; Windmill KF, 1997, MUTAT RES-FUND MOL M, V376, P153, DOI 10.1016/S0027-5107(97)00038-9; Yang LV, 2001, MECH DEVELOP, V104, P105, DOI 10.1016/S0925-4773(01)00376-8; Yeh SY, 2000, P NATL ACAD SCI USA, V97, P11256, DOI 10.1073/pnas.190353897; ZAKUT H, 1990, J CLIN INVEST, V86, P900, DOI 10.1172/JCI114791	73	31	32	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2007	26	2					198	214		10.1038/sj.onc.1209773	http://dx.doi.org/10.1038/sj.onc.1209773			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	124VM	16832351				2022-12-17	WOS:000243398300004
J	Vidal, GA; Clark, DE; Marrero, L; Jones, FE				Vidal, G. A.; Clark, D. E.; Marrero, L.; Jones, F. E.			A constitutively active ERBB4/HER4 allele with enhanced transcriptional coactivation and cell-killing activities	ONCOGENE			English	Article						EGFR-family; STAT5A; apoptosis; nuclear translocation; transactivation	TYROSINE KINASE-ACTIVITY; GROWTH-FACTOR RECEPTOR; BREAST-CANCER; NEU ONCOGENE; TRANSMEMBRANE DOMAIN; POINT MUTATION; MAMMARY-GLAND; EXPRESSION; PROTEIN; ACTIVATION	In the normal breast, ERBB4 regulates epithelial differentiation and functions as a nuclear chaperone for signal transducer and activator of transcription (STAT) 5A, thereby stimulating milk-gene expression. In addition, ERBB4 functions as a proapoptotic protein, suppressing the growth of malignant cells. We hypothesize that these ERBB4 activities can be marshaled to suppress the growth of breast tumors. To this end, we have created an ERBB4 allele harboring an activating transmembrane mutation (ERBB4-CA) by substituting isoleucine 658 for glutamic acid. This base substitution forms a valine-glutamic acidglycine activation domain first identified in oncogenic ERBB2/HER2/Neu. Ectopic expression of ERBB4-CA in HEK293T cells resulted in a fivefold increase in receptor tyrosine phosphorylation. Functionally, ERBB4-CA exhibited higher levels of nuclear translocation than wild-type ERBB4, leading to significantly enhanced ERBB4-induced STAT5A simulation of the beta-casein promoter. Activated ERBB4 has been demonstrated to induce cell killing of breast tumor cells. Significantly, ERBB4-CA potentiated the proapoptotic function of ERBB4 in each breast, prostate and ovarian cancer cell line tested. Untransformed cell lines were resistant to both ERBB4 and ERBB4-CA-mediated apoptosis underscoring the potential utility of active ERBB4 signaling for the therapeutic intervention of human cancer.	Tulane Univ, Hlth Sci Ctr, Tulane Canc Ctr, Dept Biochem, New Orleans, LA 70112 USA; Tulane Univ, Hlth Sci Ctr, Dept Struct & Cellular Biol, Tulane Canc Ctr, New Orleans, LA 70112 USA; Louisiana State Univ, Hlth Sci Ctr, Gene Therapy Program, Morphol & Imaging Core Lab, New Orleans, LA 70112 USA	Tulane University; Tulane University; Louisiana State University System; Louisiana State University Health Sciences Center New Orleans	Jones, FE (corresponding author), Tulane Univ, Hlth Sci Ctr, Tulane Canc Ctr, Dept Biochem, 1430 Tulane Ave, New Orleans, LA 70112 USA.	fjones@tulane.edu		Vidal, Gregory/0000-0003-3325-6224	NATIONAL CANCER INSTITUTE [R01CA096717, R01CA095783] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA95783, R01 CA96717] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARGMANN CI, 1988, P NATL ACAD SCI USA, V85, P5394, DOI 10.1073/pnas.85.15.5394; BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; Barnes NLP, 2005, CLIN CANCER RES, V11, P2163, DOI 10.1158/1078-0432.CCR-04-1633; Burke CL, 1997, ONCOGENE, V14, P687, DOI 10.1038/sj.onc.1200873; Clark DE, 2005, J BIOL CHEM, V280, P24175, DOI 10.1074/jbc.M414044200; Jones FE, 1999, J CELL BIOL, V147, P77, DOI 10.1083/jcb.147.1.77; Jones FE, 2003, CELL CYCLE, V2, P555, DOI 10.4161/cc.2.6.598; Kew TY, 2000, BRIT J CANCER, V82, P1163, DOI 10.1054/bjoc.1999.1057; Long WW, 2003, DEVELOPMENT, V130, P5257, DOI 10.1242/dev.00715; MILOSO M, 1995, J BIOL CHEM, V270, P19557, DOI 10.1074/jbc.270.33.19557; Naresh A, 2006, CANCER RES, V66, P6412, DOI 10.1158/0008-5472.CAN-05-2368; Ni CY, 2001, SCIENCE, V294, P2179, DOI 10.1126/science.1065412; SEGATTO O, 1988, MOL CELL BIOL, V8, P5570, DOI 10.1128/MCB.8.12.5570; Srinivasan R, 1998, J PATHOL, V185, P236, DOI 10.1002/(SICI)1096-9896(199807)185:3<236::AID-PATH118>3.0.CO;2-7; STERN DF, 1988, MOL CELL BIOL, V8, P3969, DOI 10.1128/MCB.8.9.3969; Tidcombe H, 2003, P NATL ACAD SCI USA, V100, P8281, DOI 10.1073/pnas.1436402100; Vidal GA, 2005, J BIOL CHEM, V280, P19777, DOI 10.1074/jbc.M412457200; WEINER DB, 1989, NATURE, V339, P230, DOI 10.1038/339230a0; Williams CC, 2004, J CELL BIOL, V167, P469, DOI 10.1083/jcb.200403155; Witton CJ, 2003, J PATHOL, V200, P290, DOI 10.1002/path.1370; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073	21	31	33	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN	2007	26	3					462	466		10.1038/sj.onc.1209794	http://dx.doi.org/10.1038/sj.onc.1209794			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	126VQ	16832345				2022-12-17	WOS:000243544000015
J	Watari, A; Takaki, K; Higashiyama, S; Li, Y; Satomi, Y; Takao, T; Tanemura, A; Yamaguchi, Y; Katayama, I; Shimakage, M; Miyashiro, I; Takami, K; Kodama, K; Yutsudo, M				Watari, A.; Takaki, K.; Higashiyama, S.; Li, Y.; Satomi, Y.; Takao, T.; Tanemura, A.; Yamaguchi, Y.; Katayama, I.; Shimakage, M.; Miyashiro, I.; Takami, K.; Kodama, K.; Yutsudo, M.			Suppression of tumorigenicity, but not anchorage independence, of human cancer cells by new candidate tumor suppressor gene CapG	ONCOGENE			English	Article						CapG; tumor suppressor gene; multistep tumorigenesis; gastric cancer; lung cancer	GELSOLIN; PROTEIN; EXPRESSION	Previously, we isolated a series of cell lines from a human diploid fibroblast lineage as a model for multistep tumorigenesis in humans. After passaging a single LT-transfected fibroblast clone, differently progressed cell lines were obtained, including immortalized, anchorage-independent and tumorigenic cell lines. In the present paper, we analysed the gene expression profiles of these model cell lines, and observed that expression of the CapG protein was lost in the tumorigenic cell line. To examine the possibility that loss of CapG protein expression was required for tumorigenic progression, we transfected CapG cDNA into the tumorigenic cell line and tested for tumor-forming ability in nude mice. Results showed that ectopic expression of CapG suppressed tumorigenicity, but not growth in soft agar or liquid medium. We also found that certain cancer cell lines including stomach cancer, lung cancer and melanoma had also lost CapG expression. One such cancer cell line AZ521 also became non-tumorigenic after the introduction of CapG cDNA. Moreover, we showed that CapG expression was repressed in small-cell lung cancer tissues. Together, our findings indicated that CapG is a new tumor suppressor gene involved in the tumorigenic progression of certain cancers.	Osaka Univ, Res Inst Microbial Dis, Suita, Osaka 5650871, Japan; Osaka Univ, Inst Prot Res, Suita, Osaka 5650871, Japan; Osaka Univ, Grad Sch Med, Suita, Osaka 5650871, Japan; Osaka Natl Hosp, Chuo, Osaka, Japan; Osaka Med Ctr Canc & Cardiovasc Dis, Higashinari, Osaka, Japan	Osaka University; Osaka University; Osaka University; Osaka National Hospital; Osaka Medical Center for Cancer & Cardiovascular Diseases	Yutsudo, M (corresponding author), Osaka Univ, Res Inst Microbial Dis, 3-1 Yamadaoka, Suita, Osaka 5650871, Japan.	yutsudo@biken.osaka-u.ac.jp	Yamaguchi, Yuji/B-9312-2008; Yamaguchi, Yuji/X-6681-2019	Satomi, Yoshinori/0000-0002-8991-1040; Yamaguchi, Yuji/0000-0003-4338-2662				Akagi T, 2000, P NATL ACAD SCI USA, V97, P7290, DOI 10.1073/pnas.140210297; DABIRI GA, 1992, J BIOL CHEM, V267, P16545; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; De Corte V, 2004, J CELL SCI, V117, P5283, DOI 10.1242/jcs.01410; Hahn WC, 2002, NAT REV CANCER, V2, P331, DOI 10.1038/nrc795; Lal A, 1999, CANCER RES, V59, P5403; Oka K, 1999, GENE CHROMOSOME CANC, V26, P47, DOI 10.1002/(SICI)1098-2264(199909)26:1<47::AID-GCC7>3.0.CO;2-8; Pellieux C, 2003, J BIOL CHEM, V278, P29136, DOI 10.1074/jbc.M300598200; PRENDERGAST GC, 1991, EMBO J, V10, P757, DOI 10.1002/j.1460-2075.1991.tb08007.x; Rajagopalan H, 2002, NATURE, V418, P934, DOI 10.1038/418934a; Rajagopalan H, 2003, NAT REV CANCER, V3, P695, DOI 10.1038/nrc1165; Sagawa N, 2003, BRIT J CANCER, V88, P606, DOI 10.1038/sj.bjc.6600739; Silacci P, 2004, CELL MOL LIFE SCI, V61, P2614, DOI 10.1007/s00018-004-4225-6; TANAKA M, 1995, CANCER RES, V55, P3228; Van Ginkel PR, 1998, BBA-MOL CELL RES, V1448, P290, DOI 10.1016/S0167-4889(98)00133-5; YU FX, 1990, SCIENCE, V250, P1413, DOI 10.1126/science.2255912	16	31	31	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2006	25	56					7373	7380		10.1038/sj.onc.1209732	http://dx.doi.org/10.1038/sj.onc.1209732			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	110ZE	16767159				2022-12-17	WOS:000242419100006
J	Chen, H; Li, M; Campbell, RA; Burkhardt, K; Zhu, D; Li, SG; Lee, HJ; Wang, C; Zeng, Z; Gordon, MS; Bonavida, B; Berenson, JR				Chen, H.; Li, M.; Campbell, R. A.; Burkhardt, K.; Zhu, D.; Li, S. G.; Lee, H. J.; Wang, C.; Zeng, Z.; Gordon, M. S.; Bonavida, B.; Berenson, J. R.			Interference with nuclear factor kappa B and c-Jun NH2-terminal kinase signaling by TRAF6C small interfering RNA inhibits myeloma cell proliferation and enhances apoptosis	ONCOGENE			English	Article						TRAF6; multiple myeloma; NF-kappa B; JNK; proliferation; apoptosis	TUMOR-NECROSIS-FACTOR; HUMAN MULTIPLE-MYELOMA; MARROW STROMAL CELLS; BONE-MARROW; DEFECTIVE INTERLEUKIN-1; INDUCE APOPTOSIS; ACTIVATION; MECHANISM; PATHWAYS; RECEPTOR	The tumor necrosis factor receptor (TNFR)-associated factor ( TRAF) family of six adaptor proteins (TRAF1-6) links the TNFR superfamily to the nuclear factor kappa B (NF-kappa B) and activator protein-1 (AP-1) transcriptional activators. Unlike other TRAFs, TRAF6 is also involved in Toll-like/interleukin (IL)-1 receptor (TIR) signal transduction. Thus, inhibition of TRAF6 function could interrupt both CD40 ( TNFR family) and IL-1 growth signals, pathways critical to myeloma proliferation. To block TRAF6-mediated IL-1 signaling, we constructed small interfering RNA ( siRNA) against TRAF6. We found that siRNA targeting the TRAF6 C-terminal (siTRAF6C) receptor interaction domain specifically reduced only TRAF6 protein expression, without affecting TRAF2 or 5 levels, and substantially interfered with IL-1-induced NF-kappa B and c-Jun/AP-1 activation. Inhibition by siTRAF6C was concentration-dependent. SiTRAF6C also significantly reduced myeloma proliferation and enhanced apoptosis in a similar dose-dependent fashion in vitro. More importantly, marked siTRAF6C growth inhibition was detected in vivo when these cells were implanted into the bone marrow of irradiated normal mice. In contrast, introduction of siRNA derived from the TRAF6 Zn-finger domain or an irrelevant siRNA construct failed to alter cell growth or cell death. These studies suggest that TRAF6 may be a new molecular target to block cell signal transduction important for the survival and proliferation of multiple myeloma cells.	Inst Myeloma & Bone Canc Res, W Hollywood, CA 90069 USA; Amgen Inc, Thousand Oaks, CA 91320 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Childrens Hosp, Boston, MA 02115 USA; Univ Calif Los Angeles, Geffen Sch Med, Dept Pathol & Lab Med, Los Angeles, CA USA; Cedars Sinai Med Ctr, Dept Neurosurg, Los Angeles, CA 90048 USA; Univ Calif Los Angeles, Geffen Sch Med, Dept Microbiol Immunol & Mol Genet, Los Angeles, CA USA	Amgen; Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard Medical School; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Berenson, JR (corresponding author), Inst Myeloma & Bone Canc Res, 9201 W Sunset Blvd,Ste 300, W Hollywood, CA 90069 USA.	jberenson@imbcr.org						Aderem A, 2000, NATURE, V406, P782, DOI 10.1038/35021228; Armstrong AP, 2002, J BIOL CHEM, V277, P44347, DOI 10.1074/jbc.M202009200; Berenson JR, 2002, BLOOD, V99, P3163, DOI 10.1182/blood.V99.9.3163; Berenson JR, 2001, SEMIN ONCOL, V28, P626, DOI 10.1053/sonc.2001.29542; Bharti AC, 2004, J BIOL CHEM, V279, P6065, DOI 10.1074/jbc.M308062200; Callander NS, 2001, SEMIN HEMATOL, V38, P276, DOI 10.1053/shem.2001.26007; Cao Z, 1999, COLD SPRING HARB SYM, V64, P473, DOI 10.1101/sqb.1999.64.473; Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0; Chatterjee M, 2004, BLOOD, V104, P3712, DOI 10.1182/blood-2004-04-1670; CHENG GH, 1995, SCIENCE, V267, P1494, DOI 10.1126/science.7533327; Chung JY, 2002, J CELL SCI, V115, P679; Corso A, 2005, CANCER, V104, P118, DOI 10.1002/cncr.21104; Eferl R, 2003, NAT REV CANCER, V3, P859, DOI 10.1038/nrc1209; Feng X, 2005, IUBMB LIFE, V57, P389, DOI 10.1080/15216540500137669; Inoue J, 2000, EXP CELL RES, V254, P14, DOI 10.1006/excr.1999.4733; Kobayashi N, 2001, EMBO J, V20, P1271, DOI 10.1093/emboj/20.6.1271; Lomaga MA, 1999, GENE DEV, V13, P1015, DOI 10.1101/gad.13.8.1015; Ma MH, 2003, CLIN CANCER RES, V9, P1136; Naito A, 1999, GENES CELLS, V4, P353, DOI 10.1046/j.1365-2443.1999.00265.x; Nakanishi C, 2005, NAT REV CANCER, V5, P297, DOI 10.1038/nrc1588; Pagnucco G, 2004, ANN NY ACAD SCI, V1028, P390, DOI 10.1196/annals.1322.047; Sanda T, 2005, CLIN CANCER RES, V11, P1974, DOI 10.1158/1078-0432.CCR-04-1936; Sinha SK, 2002, J BIOL CHEM, V277, P44953, DOI 10.1074/jbc.M207923200; Tai YT, 2005, CANCER RES, V65, P5898, DOI 10.1158/0008-5472.CAN-04-4125; Takeuchi M, 1996, J BIOL CHEM, V271, P19935, DOI 10.1074/jbc.271.33.19935; Teoh G, 2000, BLOOD, V95, P1039, DOI 10.1182/blood.V95.3.1039.003k02_1039_1046; Vincent T, 2005, LEUKEMIA LYMPHOMA, V46, P803, DOI 10.1080/10428190500051448; Yaccoby S, 2004, CANCER RES, V64, P2016, DOI 10.1158/0008-5472.CAN-03-1131; Ye H, 2002, NATURE, V418, P443, DOI 10.1038/nature00888	29	31	38	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 19	2006	25	49					6520	6527		10.1038/sj.onc.1209653	http://dx.doi.org/10.1038/sj.onc.1209653			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	096RS	16702955				2022-12-17	WOS:000241395100008
J	Wani, AA; Sharma, N; Shouche, YS; Bapat, SA				Wani, A. A.; Sharma, N.; Shouche, Y. S.; Bapat, S. A.			Nuclear-mitochondrial genomic profiling reveals a pattern of evolution in epithelial ovarian tumor stem cells	ONCOGENE			English	Article						ovarian cancer; tumor stem cells; mtDNA; CREBBP; mutational profiling	TRANSCRIPTIONAL COACTIVATOR CBP; RUBINSTEIN-TAYBI-SYNDROME; DNA; CANCER; IDENTIFICATION; PROGRESSION; ACTIVATION; MUTATIONS; ACETYLATION; BROMODOMAIN	Analyses of genome orthologs in cancer on the background of tumor heterogeneity, coupled with the recent identification that the tumor propagating capacity resides within a very small fraction of cells ( the tumor stem cells-TSCs), has not been achieved. Here, we describe a strategy to explore genetic drift in the mitochondrial genome accompanying varying stem cell dynamics in epithelial ovarian cancer. A major and novel outcome is the identification of a specific mutant mitochondrial DNA pro. le associated with the TSC lineage that is drastically different from the germ line pro. le. This pro. le, however, is often camouflaged in the primary tumor, and sometimes may not be detected even after metastases, questioning the validity of whole tumor pro. ling towards determining individual prognosis. Continuing mutagenesis in subsets with a mutant mitochondrial genome could result in transformation through a cooperative effect with nuclear genes - a representative example in our study is a tumor suppressor gene viz. cAMP responsive element binding binding protein. This specific pro. le could be a critical predisposing step undertaken by a normal stem cell to overcome a tightly regulated mutation rate and DNA repair in its evolution towards tumorigenesis. Our findings suggest that varying stem cell dynamics and mutagenesis de. ne TSC progression that may clinically translate into increasing tumor aggression with serious implications for prognosis.	Natl Ctr Cell Sci, Pune 411007, Maharashtra, India	Department of Biotechnology (DBT) India; National Centre for Cell Science, Pune (NCCS)	Bapat, SA (corresponding author), Natl Ctr Cell Sci, NCCS Complex,Pune Univ Campus,Ganeskkhind, Pune 411007, Maharashtra, India.	sabapat@nccs.res.in	Bapat, Sharmila/AGU-4130-2022; SHOUCHE, YOGESH/C-1231-2009; Sharma, Neeti/L-6282-2019	Bapat, Sharmila/0000-0002-9557-2233; Sharma, Neeti/0000-0002-4457-5717				Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Alonso A, 2005, J CLIN PATHOL, V58, P83, DOI 10.1136/jcp.2004.017673; Andrews RM, 1999, NAT GENET, V23, P147, DOI 10.1038/13779; Bapat SA, 2005, CANCER RES, V65, P3025, DOI 10.1158/0008-5472.CAN-04-3931; Beckman RA, 2005, GENETICS, V171, P2123, DOI 10.1534/genetics.105.040840; Bonnet D, 1997, NAT MED, V3, P730, DOI 10.1038/nm0797-730; Calabrese P, 2004, AM J PATHOL, V164, P1337, DOI 10.1016/S0002-9440(10)63220-8; Choi JH, 2000, BIOINFORMATICS, V16, P1056, DOI 10.1093/bioinformatics/16.11.1056; Coller HA, 2005, MUTAT RES-FUND MOL M, V578, P256, DOI 10.1016/j.mrfmmm.2005.05.014; Costanzo A, 2002, MOL CELL, V9, P175, DOI 10.1016/S1097-2765(02)00431-8; Deng Z, 2003, MOL CELL BIOL, V23, P2633, DOI 10.1128/MCB.23.8.2633-2644.2003; Dhalluin C, 1999, NATURE, V399, P491, DOI 10.1038/20974; Feinberg AP, 2006, NAT REV GENET, V7, P21, DOI 10.1038/nrg1748; Felsenstein J., 1993, PHYLIP PHYLOGENY INF; Florian S, 2006, LEUKEMIA LYMPHOMA, V47, P207, DOI 10.1080/10428190500272507; Goodman RH, 2000, GENE DEV, V14, P1553; Grossman SR, 2001, EUR J BIOCHEM, V268, P2773, DOI 10.1046/j.1432-1327.2001.02226.x; Hayashida K, 2005, CELL BIOL INT, V29, P472, DOI 10.1016/j.cellbi.2004.09.016; Kitabayashi I, 2001, EMBO J, V20, P7184, DOI 10.1093/emboj/20.24.7184; Knudson AG, 1996, J CANCER RES CLIN, V122, P135, DOI 10.1007/BF01366952; Kung AL, 2000, GENE DEV, V14, P272; Michor F, 2004, NAT REV CANCER, V4, P197, DOI 10.1038/nrc1295; *MITOMAP, 2005, HUM MIT GEN DAT; Murata T, 2001, HUM MOL GENET, V10, P1071, DOI 10.1093/hmg/10.10.1071; O'Brien TW, 2005, GENE, V354, P147, DOI 10.1016/j.gene.2005.03.026; Pakendorf B, 2005, ANNU REV GENOM HUM G, V6, P165, DOI 10.1146/annurev.genom.6.080604.162249; Palanichamy MG, 2004, AM J HUM GENET, V75, P966, DOI 10.1086/425871; Parfait B, 1998, BIOCHEM BIOPH RES CO, V247, P57, DOI 10.1006/bbrc.1998.8666; PETRIJ F, 1995, NATURE, V376, P348, DOI 10.1038/376348a0; Rieder MJ, 1998, NUCLEIC ACIDS RES, V26, P967, DOI 10.1093/nar/26.4.967; Schmid M, 2004, CYTOGENET GENOME RES, V104, P277, DOI 10.1159/000077502; Shigeno K, 2004, CANCER LETT, V213, P11, DOI 10.1016/S0304-3835(03)00442-7; Shin MG, 2004, BLOOD, V103, P553, DOI 10.1182/blood-2003-05-1724; SIDRANSKY D, 1992, NATURE, V355, P846, DOI 10.1038/355846a0; Singh KK, 2005, GENE, V354, P140, DOI 10.1016/j.gene.2005.03.027; Singh SK, 2003, CANCER RES, V63, P5821; van Tilborg AAG, 2000, HUM MOL GENET, V9, P2973, DOI 10.1093/hmg/9.20.2973	37	31	33	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 12	2006	25	47					6336	6344		10.1038/sj.onc.1209649	http://dx.doi.org/10.1038/sj.onc.1209649			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	094CY	16732329				2022-12-17	WOS:000241218200010
J	Macip, S; Kosoy, A; Lee, SW; O'Connell, MJ; Aaronson, SA				Macip, S.; Kosoy, A.; Lee, S. W.; O'Connell, M. J.; Aaronson, S. A.			Oxidative stress induces a prolonged but reversible arrest in p53-null cancer cells, involving a Chk1-dependent G(2) checkpoint	ONCOGENE			English	Article						senescence; p53; ROS; Chk1; checkpoints	DNA-DAMAGE CHECKPOINT; LACKING FUNCTIONAL P53; STRAND BREAK REPAIR; HUMAN FIBROBLASTS; TUMOR-CELLS; REPLICATIVE SENESCENCE; GROWTH ARREST; IN-VIVO; PREMATURE SENESCENCE; CELLULAR SENESCENCE	Reactive oxygen species (ROS), the principal mediators of oxidative stress, induce responses suchas apoptosis or permanent growth arrest/senescence in normal cells. Moreover, p53 activation itself contributes to ROS accumulation. Here we show that treatment of p53-null cancer cells with sublethal concentrations of ROS triggered an arrest with some morphological similarities to cellular senescence. Different from a classical senescent arrest in G(1), the ROS-induced arrest was predominantly in the G(2) phase of the cell cycle, and its establishment depended at least in part on an intact Chk1-dependent checkpoint. Chk1 remained phosphorylated only during the repair of double strand DNA breaks, after which Chk1 was inactivated, the G2 arrest was suppressed, and some cells recovered their ability to proliferate. Inhibition of Chk1 by an RNAi approach resulted in an increase in cell death in p53-null cells, showing that the Chk1-dependent G2 checkpoint protected cells that lacked a functional p53 pathway from oxidative stress. It has been proposed that the induction of a senescent-like phenotype by antineoplastic agents can contribute therapeutic efficacy. Our results indicate that oxidative stress-induced growth arrest of p53-null tumor cells cannot be equated with effective therapy owing to its reversibility and supports the concept that targeting Chk1 may enhance the effects of DNA-damaging agents on cancer progression in such tumors.	Mt Sinai Sch Med, Dept Oncol Sci, New York, NY 10029 USA; Harvard Univ, Sch Med, Massachusetts Gen Hosp, Harvard Cutaneous Biol Res Ctr, Charlestown, MA USA	Icahn School of Medicine at Mount Sinai; Harvard University; Massachusetts General Hospital	Aaronson, SA (corresponding author), Mt Sinai Sch Med, Dept Oncol Sci, 1 Gustave L Levy Pl,Box 1130, New York, NY 10029 USA.	stuart.aaronson@mssm.edu	Macip, Salvador/S-6358-2019; Macip, Salvador/P-4233-2019; Macip, Salvador/K-5985-2014	Macip, Salvador/0000-0003-1963-8840; 	NATIONAL CANCER INSTITUTE [R01CA085214, R01CA100076, R01CA078356, R01CA082211, R56CA100076] Funding Source: NIH RePORTER; NCI NIH HHS [CA85214, CA82211, CA80058, CA78356, CA100076] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALLSOPP RC, 1992, P NATL ACAD SCI USA, V89, P10114, DOI 10.1073/pnas.89.21.10114; Aubry JP, 1999, CYTOMETRY, V37, P197, DOI 10.1002/(SICI)1097-0320(19991101)37:3<197::AID-CYTO6>3.0.CO;2-L; Bai JX, 2003, J BIOL CHEM, V278, P4660, DOI 10.1074/jbc.M206273200; Bakkenist CJ, 2004, CELL, V118, P9, DOI 10.1016/j.cell.2004.06.023; Bakondi E, 2003, J INVEST DERMATOL, V121, P88, DOI 10.1046/j.1523-1747.2003.12329.x; Bartek J, 2001, NAT REV MOL CELL BIO, V2, P877, DOI 10.1038/35103059; Bartek J, 2003, CANCER CELL, V3, P421, DOI 10.1016/S1535-6108(03)00110-7; Bartkowiak D, 1999, CYTOMETRY, V37, P191, DOI 10.1002/(SICI)1097-0320(19991101)37:3<191::AID-CYTO5>3.0.CO;2-U; Barzilai A, 2004, DNA REPAIR, V3, P1109, DOI 10.1016/j.dnarep.2004.03.002; Caldini R, 1998, MECH AGEING DEV, V105, P137, DOI 10.1016/S0047-6374(98)00085-2; Campisi J, 2001, EXP GERONTOL, V36, P1619, DOI 10.1016/S0531-5565(01)00160-7; Castedo M, 2004, ONCOGENE, V23, P2825, DOI 10.1038/sj.onc.1207528; Chang BD, 1999, CANCER RES, V59, P3761; CHEN Q, 1995, P NATL ACAD SCI USA, V92, P4337, DOI 10.1073/pnas.92.10.4337; CHEN Q, 1994, P NATL ACAD SCI USA, V91, P4130, DOI 10.1073/pnas.91.10.4130; Chen QM, 1998, BIOCHEM J, V332, P43, DOI 10.1042/bj3320043; Chiu CC, 2005, CANCER LETT, V223, P249, DOI 10.1016/j.canlet.2004.10.049; CLOPTON DA, 1995, BIOCHEM BIOPH RES CO, V210, P189, DOI 10.1006/bbrc.1995.1645; Curman D, 2001, J BIOL CHEM, V276, P17914, DOI 10.1074/jbc.M100728200; Davies KJA, 1999, IUBMB LIFE, V48, P41, DOI 10.1080/152165499307404; de Magalhaes JP, 2004, EXP GERONTOL, V39, P1379, DOI 10.1016/j.exger.2004.06.004; de Vries HI, 2005, J CELL SCI, V118, P1833, DOI 10.1242/jcs.02309; Dean RT, 1997, BIOCHEM J, V324, P1; den Elzen N, 2004, CELL CYCLE, V3, P529; den Elzen NR, 2004, EMBO J, V23, P908, DOI 10.1038/sj.emboj.7600105; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Dumont P, 2000, FREE RADICAL BIO MED, V28, P361, DOI 10.1016/S0891-5849(99)00249-X; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Fang L, 1999, ONCOGENE, V18, P2789, DOI 10.1038/sj.onc.1202615; Fernandez-Capetillo O, 2004, DNA REPAIR, V3, P959, DOI 10.1016/j.dnarep.2004.03.024; Finkel T, 2000, NATURE, V408, P239, DOI 10.1038/35041687; Foster ER, 2005, FEBS J, V272, P3231, DOI 10.1111/j.1742-4658.2005.04741.x; Garber K, 2005, J NATL CANCER I, V97, P1026, DOI 10.1093/jnci/dji224; Gewirtz DA, 1999, BIOCHEM PHARMACOL, V57, P727, DOI 10.1016/S0006-2952(98)00307-4; GREENBLATT MS, 1994, CANCER RES, V54, P4855; Hammond EM, 2003, J BIOL CHEM, V278, P12207, DOI 10.1074/jbc.M212360200; Hampton MB, 1998, TOXICOL LETT, V103, P355, DOI 10.1016/S0378-4274(98)00333-6; Hara E, 1996, MOL CELL BIOL, V16, P859; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; Ho CC, 2005, EXP CELL RES, V304, P1, DOI 10.1016/j.yexcr.2004.10.016; Hwang ES, 2002, MECH AGEING DEV, V123, P1681, DOI 10.1016/S0047-6374(02)00102-1; Irani K, 1997, SCIENCE, V275, P1649, DOI 10.1126/science.275.5306.1649; Jackson JR, 2000, CANCER RES, V60, P566; Jallepalli PV, 2003, J BIOL CHEM, V278, P20475, DOI 10.1074/jbc.M213159200; Kaneko Y, 1999, ONCOGENE, V18, P3673, DOI 10.1038/sj.onc.1202706; KASTAN MB, 1991, CANCER RES, V51, P6304; KAUFMANN WK, 1995, CANCER RES, V55, P7; Koniaras K, 2001, ONCOGENE, V20, P7453, DOI 10.1038/sj.onc.1204942; Latif C, 2004, J CELL SCI, V117, P3489, DOI 10.1242/jcs.01204; Lee AC, 1999, J BIOL CHEM, V274, P7936, DOI 10.1074/jbc.274.12.7936; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Liu QH, 2000, GENE DEV, V14, P1448; Long H, 2003, CELL PHYSIOL BIOCHEM, V13, P401, DOI 10.1159/000075128; Macip S, 2003, MOL CELL BIOL, V23, P8576, DOI 10.1128/MCB.23.23.8576-8585.2003; Mason DX, 2004, ONCOGENE, V23, P9238, DOI 10.1038/sj.onc.1208172; Nelms BE, 1998, SCIENCE, V280, P590, DOI 10.1126/science.280.5363.590; O'Connell MJ, 2005, J CELL SCI, V118, P1, DOI 10.1242/jcs.01626; ORR WC, 1994, SCIENCE, V263, P1128, DOI 10.1126/science.8108730; Renschler MF, 2004, EUR J CANCER, V40, P1934, DOI 10.1016/j.ejca.2004.02.031; RILEY PA, 1994, INT J RADIAT BIOL, V65, P27, DOI 10.1080/09553009414550041; Roberson RS, 2005, CANCER RES, V65, P2795, DOI 10.1158/0008-5472.CAN-04-1270; Robles SJ, 1998, ONCOGENE, V16, P1113, DOI 10.1038/sj.onc.1201862; Roninson IB, 2003, CANCER RES, V63, P2705; Roninson IB, 2001, DRUG RESIST UPDATE, V4, P303, DOI 10.1054/drup.2001.0213; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Shackelford RE, 2001, J BIOL CHEM, V276, P21951, DOI 10.1074/jbc.M011303200; Shiloh Y, 2001, ADV CANCER RES, V83, P209, DOI 10.1016/S0065-230X(01)83007-4; Smith JR, 1996, SCIENCE, V273, P63, DOI 10.1126/science.273.5271.63; Sugrue MM, 1997, P NATL ACAD SCI USA, V94, P9648, DOI 10.1073/pnas.94.18.9648; Sun XG, 2000, J BIOL CHEM, V275, P17237, DOI 10.1074/jbc.C000099200; Takai H, 2002, EMBO J, V21, P5195, DOI 10.1093/emboj/cdf506; te Poele RH, 2002, CANCER RES, V62, P1876; VOGELSTEIN B, 1990, NATURE, V348, P681, DOI 10.1038/348681a0; VONZGLINICKI T, 1995, EXP CELL RES, V220, P186, DOI 10.1006/excr.1995.1305; Zamzami N, 1998, ONCOGENE, V16, P1055, DOI 10.1038/sj.onc.1201864; Zhang L, 2000, SCIENCE, V290, P989, DOI 10.1126/science.290.5493.989; Zhao H, 2002, P NATL ACAD SCI USA, V99, P14795, DOI 10.1073/pnas.182557299; Zhou BBS, 2004, NAT REV CANCER, V4, P216, DOI 10.1038/nrc1296; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005; Zhu JY, 1998, GENE DEV, V12, P2997, DOI 10.1101/gad.12.19.2997	81	31	31	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 5	2006	25	45					6037	6047		10.1038/sj.onc.1209629	http://dx.doi.org/10.1038/sj.onc.1209629			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	092MN	16652144				2022-12-17	WOS:000241101200001
J	Mise, N; Drosten, M; Racek, T; Tannapfel, A; Putzer, BM				Mise, N.; Drosten, M.; Racek, T.; Tannapfel, A.; Puetzer, B. M.			Evaluation of potential mechanisms underlying genotype-phenotype correlations in multiple endocrine neoplasia type 2	ONCOGENE			English	Article						RET receptor tyrosine kinase; RET protooncogene mutations; multiple endocrine neoplasia type 2 (MEN 2); genotype-phenotype correlation	MEDULLARY-THYROID CARCINOMA; RET TYROSINE KINASE; SIGNALING COMPLEXES; HUMAN CANCER; CYCLIN-E; IN-VIVO; MEN 2A; C-CELL; PROTOONCOGENE; MUTATIONS	Distinct dominant activating mutations in the RET protooncogene are responsible for the development of multiple endocrine neoplasia type 2 (MEN 2). Concise examination of the mutated codons led to the detection of a striking genotype-phenotype correlation between the mutated codon and the MEN 2 phenotype in terms of onset and aggressiveness of the disease, suggesting that manifestation and clinical progression is conditioned by the type of mutation. To gain insight into the molecular basis for this genotype-phenotype correlation, we analysed the impact of common and rare mutations identified in MEN 2A (C609Y, C634R), MEN 2B (A883F, M918T) and familial medullary thyroid carcinoma (Y791F) patients on several aspects of cell transformation, including proliferation, apoptosis, anchorage-independent growth and signaling. We found that tumor cells arising from distinct extracellular or intracellular MEN 2 mutations clearly differ in their proliferation properties owing to the activation of different molecular pathways, but importantly, also in resistance to apoptosis. Whereas MEN 2A mutants resulted in accelerated cell proliferation, MEN 2B-RET mutants significantly enhanced suppression of apoptosis, which may account, at least partially, for some of the clinical differences in MEN 2 patients.	Univ Rostock, Dept Vectorol & Expt Gene Therapy, Biomed Res Ctr, D-18055 Rostock, Germany; Univ Leipzig, Sch Med, Dept Pathol, D-7010 Leipzig, Germany	University of Rostock; Leipzig University	Putzer, BM (corresponding author), Univ Rostock, Dept Vectorol & Expt Gene Therapy, Biomed Res Ctr, Schillingallee 69, D-18055 Rostock, Germany.	brigitte.puetzer@med.uni-rostock.de		Drosten, Matthias/0000-0002-3205-456X				Airaksinen MS, 2002, NAT REV NEUROSCI, V3, P383, DOI 10.1038/nrn812; Arighi E, 2005, CYTOKINE GROWTH F R, V16, P441, DOI 10.1016/j.cytogfr.2005.05.010; Asai N, 1996, J BIOL CHEM, V271, P17644, DOI 10.1074/jbc.271.30.17644; ASAI N, 1995, MOL CELL BIOL, V15, P1613; Besset V, 2000, J BIOL CHEM, V275, P39159, DOI 10.1074/jbc.M006908200; Bocciardi R, 1997, ONCOGENE, V15, P2257, DOI 10.1038/sj.onc.1201413; CARLSON KM, 1994, P NATL ACAD SCI USA, V91, P1579, DOI 10.1073/pnas.91.4.1579; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; DONISKELLER H, 1993, HUM MOL GENET, V2, P851, DOI 10.1093/hmg/2.7.851; Drosten M, 2004, JNCI-J NATL CANCER I, V96, P1231, DOI 10.1093/jnci/djh226; Durbec PL, 1996, DEVELOPMENT, V122, P349; EDERY P, 1994, NATURE, V367, P378, DOI 10.1038/367378a0; Freche B, 2005, J BIOL CHEM, V280, P36584, DOI 10.1074/jbc.M505707200; Gimm O, 2002, SURGERY, V132, P952, DOI 10.1067/msy.2002.128559; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hansford JR, 2000, J MED GENET, V37, P817, DOI 10.1136/jmg.37.11.817; Hess P, 2002, NAT GENET, V32, P201, DOI 10.1038/ng946; HOFSTRA RMW, 1994, NATURE, V367, P375, DOI 10.1038/367375a0; Ichihara M, 2004, CANCER LETT, V204, P197, DOI 10.1016/S0304-3835(03)00456-7; IWAMOTO T, 1993, ONCOGENE, V8, P1087; Jijiwa M, 2004, MOL CELL BIOL, V24, P8026, DOI 10.1128/MCB.24.18.8026-8036.2004; Kurokawa K, 2003, J INTERN MED, V253, P627, DOI 10.1046/j.1365-2796.2003.01167.x; Le Hir H, 2000, ONCOLOGY-BASEL, V58, P311, DOI 10.1159/000012118; Manie S, 2001, TRENDS GENET, V17, P580, DOI 10.1016/S0168-9525(01)02420-9; Marshall GM, 1997, CANCER RES, V57, P5399; Marx SJ, 2005, NAT REV CANCER, V5, P367, DOI 10.1038/nrc1610; Menacho IP, 2005, CANCER RES, V65, P1729, DOI 10.1158/0008-5472.CAN-04-2363; Meng XJ, 2000, SCIENCE, V287, P1489, DOI 10.1126/science.287.5457.1489; Moroy T, 2004, INT J BIOCHEM CELL B, V36, P1424, DOI 10.1016/S1357-2725(03)00432-1; MULLIGAN LM, 1993, NATURE, V363, P458, DOI 10.1038/363458a0; Murakami H, 2002, J BIOL CHEM, V277, P32781, DOI 10.1074/jbc.M202336200; Reynolds L, 2001, ONCOGENE, V20, P3986, DOI 10.1038/sj.onc.1204434; Salvatore D, 2001, CANCER RES, V61, P1426; Santoro M, 2004, CELL MOL LIFE SCI, V61, P2954, DOI 10.1007/s00018-004-4276-8; SANTORO M, 1995, SCIENCE, V267, P381, DOI 10.1126/science.7824936; SCHUCHARDT A, 1994, NATURE, V367, P380, DOI 10.1038/367380a0; Segouffin-Cariou C, 2000, J BIOL CHEM, V275, P3568, DOI 10.1074/jbc.275.5.3568; Smith-Hicks CL, 2000, EMBO J, V19, P612, DOI 10.1093/emboj/19.4.612; Takahashi M, 2001, CYTOKINE GROWTH F R, V12, P361, DOI 10.1016/S1359-6101(01)00012-0; Takahashi M, 1998, J INTERN MED, V243, P509; Thimmaiah KN, 2005, J BIOL CHEM, V280, P31924, DOI 10.1074/jbc.M507057200; Tsui-Pierchala BA, 2002, J BIOL CHEM, V277, P34618, DOI 10.1074/jbc.M203580200; Vitale G, 2001, CANCER-AM CANCER SOC, V91, P1797, DOI 10.1002/1097-0142(20010501)91:9<1797::AID-CNCR1199>3.0.CO;2-P; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Watanabe T, 2002, AM J PATHOL, V161, P249, DOI 10.1016/S0002-9440(10)64176-4; Welcker M, 2003, MOL CELL, V12, P381, DOI 10.1016/S1097-2765(03)00287-9; Yip L, 2003, ARCH SURG-CHICAGO, V138, P409, DOI 10.1001/archsurg.138.4.409	47	31	33	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT	2006	25	50					6637	6647		10.1038/sj.onc.1209669	http://dx.doi.org/10.1038/sj.onc.1209669			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	099CI	16715139				2022-12-17	WOS:000241569700008
J	Hayashi, T; Kobayashi, Y; Kohsaka, S; Sano, K				Hayashi, T.; Kobayashi, Y.; Kohsaka, S.; Sano, K.			The mutation in the ATP-binding region of JAK1, identified in human uterine leiomyosarcomas, results in defective interferon-gamma inducibility of TAP1 and LMP2	ONCOGENE			English	Article						LMP2; JAK1; IFN-gamma; uterus; leiomyosarcoma	MHC CLASS-I; NF-KAPPA-B; IFN-GAMMA; EXPRESSION; GENES; COMPLEX; IMMUNOSURVEILLANCE; PATHWAYS; SUBUNITS; TUMORS	The presentation of human leukocyte antigens (HLA) class I requires the coordinated expression of numerous components involved in antigen presentation. Tumor cells may alter the antigen presentation by HLA class I, allowing them to evade antitumor immunity. In many cases, the lack of antigen presentation can be attributed to the downregulation of genes needed for antigen processing, such as the transporters associated with antigen processing ( TAP) 1, and the proteasomal component, low molecular weight proteins (LMP) 2. The TAP1 and LMP2 genes are transcribed from a shared bidirectional promoter containing an interferon (IFN)-gamma-response factor element; thus, the IFN-gamma-signal strongly induces both TAP1 and LMP2 expression. Low molecular weight proteins2-deficient mice exhibited the development of uterine leiomyosarcomas. Here, the differential responsiveness to IFN-gamma of the SKN human uterine leiomyosarcomas cell line was investigated. We now identify the G871E mutation in the ATP-binding region of Janus kinases 1, suggesting that the loss of TAP1 and LMP2 induction is a defect in the earliest steps of the IFN-gamma-signal pathway, resulting in the inability of SKN cells to upregulate the antigen-processing pathway. Understanding the mechanisms by which these tumors circumvent cytokine signalling, thereby evading antitumor-specific immunity, would greatly aid the efficacy of immunotherapy for treating uterine leiomyosarcomas.	Shinshu Univ, Sch Med, Dept Immunol & Infect Dis, Nagano 3908621, Japan; Shinshu Univ Hosp, Dept Lab Med, Nagano, Japan	Shinshu University; Shinshu University	Hayashi, T (corresponding author), Shinshu Univ, Sch Med, Dept Immunol & Infect Dis, 3-1-1 Asahi, Nagano 3908621, Japan.	takuma-h@sch.md.shinshu-u.ac.jp						Atkins D, 2004, INT J CANCER, V109, P265, DOI 10.1002/ijc.11681; BELICH MP, 1994, CURR BIOL, V4, P769, DOI 10.1016/S0960-9822(00)00174-3; Brucet M, 2004, GENES IMMUN, V5, P26, DOI 10.1038/sj.gene.6364035; Cabrera CM, 2003, TISSUE ANTIGENS, V61, P211, DOI 10.1034/j.1399-0039.2003.00020.x; Chatterjee-Kishore M, 2000, EMBO J, V19, P4111, DOI 10.1093/emboj/19.15.4111; Dovhey SE, 2000, CANCER RES, V60, P5789; DRISCOLL J, 1993, NATURE, V365, P262, DOI 10.1038/365262a0; Dunn GP, 2002, NAT IMMUNOL, V3, P991, DOI 10.1038/ni1102-991; GACZYNSKA M, 1993, NATURE, V365, P264, DOI 10.1038/365264a0; Garrido F, 1997, IMMUNOL TODAY, V18, P89, DOI 10.1016/S0167-5699(96)10075-X; Groettrup M, 1997, P NATL ACAD SCI USA, V94, P8970, DOI 10.1073/pnas.94.17.8970; HARADA H, 1993, SCIENCE, V259, P971, DOI 10.1126/science.8438157; Hayashi T, 2002, CANCER RES, V62, P24; HAYASHI T, 1993, J BIOL CHEM, V268, P26790; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; Ihle JN, 2001, CURR OPIN CELL BIOL, V13, P211, DOI 10.1016/S0955-0674(00)00199-X; Kaplan DH, 1998, P NATL ACAD SCI USA, V95, P7556, DOI 10.1073/pnas.95.13.7556; LEISER AL, 2005, GYNECOL ONCOL; Leitao MM, 2004, CANCER-AM CANCER SOC, V101, P1455, DOI 10.1002/cncr.20521; Maniatis T, 1999, GENE DEV, V13, P505, DOI 10.1101/gad.13.5.505; Miyagi T, 2003, J GASTROEN HEPATOL, V18, P32, DOI 10.1046/j.1440-1746.2003.02921.x; MOMBURG F, 1994, CURR OPIN IMMUNOL, V6, P32, DOI 10.1016/0952-7915(94)90030-2; MOMBURG F, 1994, NATURE, V367, P648, DOI 10.1038/367648a0; O'Shea JJ, 2002, CELL, V109, pS121, DOI 10.1016/S0092-8674(02)00701-8; Platanias LC, 2005, NAT REV IMMUNOL, V5, P375, DOI 10.1038/nri1604; Ramana CV, 2002, TRENDS IMMUNOL, V23, P96, DOI 10.1016/S1471-4906(01)02118-4; Raspollini MR, 2005, GYNECOL ONCOL, V98, P334, DOI 10.1016/j.ygyno.2004.09.035; Seliger B, 2000, IMMUNOL TODAY, V21, P455, DOI 10.1016/S0167-5699(00)01692-3; Sexl V, 2003, BLOOD, V101, P4937, DOI 10.1182/blood-2001-11-0142; Shankaran V, 2001, NATURE, V410, P1107, DOI 10.1038/35074122; Singal DP, 1996, IMMUNOL LETT, V50, P149, DOI 10.1016/0165-2478(96)02531-X; VAN KL, 1994, IMMUNITY, V1, P533; White LC, 1996, IMMUNITY, V5, P365, DOI 10.1016/S1074-7613(00)80262-9; WRIGHT KL, 1995, J EXP MED, V181, P1459, DOI 10.1084/jem.181.4.1459	34	31	37	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 6	2006	25	29					4016	4026		10.1038/sj.onc.1209434	http://dx.doi.org/10.1038/sj.onc.1209434			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	060KZ	16474838				2022-12-17	WOS:000238802400002
J	Coleman, ML; Densham, RM; Croft, DR; Olson, MF				Coleman, ML; Densham, RM; Croft, DR; Olson, MF			Stability of p21(Waf1)/(Cip1) CDK inhibitor protein is responsive to RhoA- mediated regulation of the actin cytoskeleton	ONCOGENE			English	Article						signal transduction; cellular; molecular and tumour biology; guanine nucleotide binding proteins and effectors	CELL-CYCLE PROGRESSION; HMG-COA REDUCTASE; SIGNALING PATHWAYS; C-JUN; MORPHOGENESIS CHECKPOINT; RETINOBLASTOMA PROTEIN; INDUCED PROLIFERATION; KINASE-ACTIVITY; GROWTH-FACTORS; G1 PHASE	The proto-oncogene Ras GTPase stimulates transcription of p21(Waf1/Cip1) (p21), which is repressed by the RhoA GTPase. We previously showed that Ras also elevates p21 protein levels by reducing its proteasome-mediated degradation. Therefore, we investigated whether RhoA also influenced p21 protein degradation. Pulse-chase analysis of p21 protein stability revealed that inhibitors of Rho function, which disrupt filamentous actin (F-actin), drastically slowed p21 degradation. Direct F-actin disruption mimicked Rho inhibition to stabilize p21. We found that Rho inhibition, or F-actin disruption, activated the JNK stress-activated protein kinase, and that interfering with JNK signalling, but not p38, abrogated p21 stabilization by Rho inhibition or F-actin-disrupting drugs. In addition, Ras-transformation led to increased constitutive JNK activity that contributed to the elevated p21 protein levels. These data suggest that p21 stability is influenced by a mechanism that monitors F-actin downstream of Rho, and which acts through a pathway involving activation of JNK. These results may have significant implications for therapies that target Rho-signalling pathways to induce p21-mediated cell-cycle arrest.	Beatson Inst Canc Res, Glasgow G61 1BD, Lanark, Scotland; Wellcome Trust Ctr Human Genet, Oxford, England	Beatson Institute; University of Oxford; Wellcome Centre for Human Genetics	Olson, MF (corresponding author), Beatson Inst Canc Res, Garscube Estate,Switchback Rd, Glasgow G61 1BD, Lanark, Scotland.	m.olson@beatson.gla.ac.uk	Coleman, Mathew L/C-1676-2014; Densham, Ruth/AAO-1971-2020; Olson, Michael/ABA-4240-2021; Olson, Michael F/A-3240-2011	Coleman, Mathew L/0000-0001-6020-9023; Densham, Ruth/0000-0003-4490-2842; Olson, Michael/0000-0003-3428-3507; 	NCI NIH HHS [R01 CA030721] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA030721] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adnane J, 1998, MOL CELL BIOL, V18, P6962, DOI 10.1128/MCB.18.12.6962; AKTORIES K, 1992, CURR TOP MICROBIOL, V175, P115; Assoian RK, 1997, CURR OPIN CELL BIOL, V9, P93, DOI 10.1016/S0955-0674(97)80157-3; Beltman J, 1999, J BIOL CHEM, V274, P3772, DOI 10.1074/jbc.274.6.3772; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; Bergo MO, 2004, J CLIN INVEST, V113, P539, DOI 10.1172/JCI200418829; Besson A, 2004, GENE DEV, V18, P862, DOI 10.1101/gad.1185504; Bohmer RM, 1996, MOL BIOL CELL, V7, P101; Bottazzi ME, 1999, J CELL BIOL, V146, P1255, DOI 10.1083/jcb.146.6.1255; CHARDIN P, 1989, EMBO J, V8, P1087, DOI 10.1002/j.1460-2075.1989.tb03477.x; Coleman ML, 2004, NAT REV MOL CELL BIO, V5, P355, DOI 10.1038/nrm1365; Coleman ML, 2001, NAT CELL BIOL, V3, P339, DOI 10.1038/35070009; Coleman ML, 2003, EMBO J, V22, P2036, DOI 10.1093/emboj/cdg189; Danesh FR, 2002, P NATL ACAD SCI USA, V99, P8301, DOI 10.1073/pnas.122228799; Denoyelle C, 2003, CELL SIGNAL, V15, P327, DOI 10.1016/S0898-6568(02)00124-9; Denoyelle C, 2001, CARCINOGENESIS, V22, P1139, DOI 10.1093/carcin/22.8.1139; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Escote X, 2004, NAT CELL BIOL, V6, P997, DOI 10.1038/ncb1174; Fang F, 1996, SCIENCE, V271, P499, DOI 10.1126/science.271.5248.499; Fuchs SY, 1998, ONCOGENE, V17, P1483, DOI 10.1038/sj.onc.1202184; Han SW, 2005, CANCER LETT, V219, P71, DOI 10.1016/j.canlet.2004.07.040; Harrison JC, 2001, NAT CELL BIOL, V3, P417, DOI 10.1038/35070104; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; Huang S, 2002, EXP CELL RES, V275, P255, DOI 10.1006/excr.2002.5504; Itoh K, 1999, NAT MED, V5, P221, DOI 10.1038/5587; Kim GY, 2002, J BIOL CHEM, V277, P29792, DOI 10.1074/jbc.M201299200; Lee S, 2004, J BIOL CHEM, V279, P1885, DOI 10.1074/jbc.M306968200; Lew DJ, 2003, CURR OPIN CELL BIOL, V15, P648, DOI 10.1016/j.ceb.2003.09.001; Liberto M, 2002, ONCOGENE, V21, P1590, DOI 10.1038/sj.onc.1205242; Lloyd AC, 1997, GENE DEV, V11, P663, DOI 10.1101/gad.11.5.663; MCCARTHY SA, 1995, GENE DEV, V9, P1953, DOI 10.1101/gad.9.16.1953; Meier R, 1996, EUR J BIOCHEM, V236, P796, DOI 10.1111/j.1432-1033.1996.00796.x; Muda M, 1996, J BIOL CHEM, V271, P27205, DOI 10.1074/jbc.271.44.27205; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; Olson MF, 1998, NATURE, V394, P295, DOI 10.1038/28425; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; Pumiglia KM, 1997, P NATL ACAD SCI USA, V94, P448, DOI 10.1073/pnas.94.2.448; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; Reshetnikova G, 2000, EXP CELL RES, V259, P35, DOI 10.1006/excr.2000.4966; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Riento K, 2003, NAT REV MOL CELL BIO, V4, P446, DOI 10.1038/nrm1128; Sahai E, 2001, EMBO J, V20, P755, DOI 10.1093/emboj/20.4.755; Sahai E, 2002, NAT REV CANCER, V2, P133, DOI 10.1038/nrc725; SAMPATH P, 1991, BIOCHEMISTRY-US, V30, P1973, DOI 10.1021/bi00221a034; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SPECTOR I, 1983, SCIENCE, V219, P493, DOI 10.1126/science.6681676; Subbaramaiah K, 2000, J BIOL CHEM, V275, P14838, DOI 10.1074/jbc.275.20.14838; Tanaka H, 2002, J CELL BIOL, V158, P321, DOI 10.1083/jcb.200202071; Uehata M, 1997, NATURE, V389, P990, DOI 10.1038/40187; Walker K, 2005, CURR OPIN GENET DEV, V15, P62, DOI 10.1016/j.gde.2004.11.001; Woods D, 1997, MOL CELL BIOL, V17, P5598, DOI 10.1128/MCB.17.9.5598; Yokoo T, 2003, J BIOL CHEM, V278, P52919, DOI 10.1074/jbc.M309334200; Yujiri T, 1999, J BIOL CHEM, V274, P12605, DOI 10.1074/jbc.274.18.12605; Zhu XY, 1996, J CELL BIOL, V133, P391, DOI 10.1083/jcb.133.2.391	56	31	34	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 4	2006	25	19					2708	2716		10.1038/sj.onc.1209322	http://dx.doi.org/10.1038/sj.onc.1209322			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	039AW	16407839				2022-12-17	WOS:000237272900002
J	Majid, SM; Liss, AS; You, M; Bose, HR				Majid, SM; Liss, AS; You, M; Bose, HR			The suppression of SH3BGRL is important for v-Rel-mediated transformation	ONCOGENE			English	Article						v-rel; NF-kappa B; SH3BGRL; SH3BGR; transformation	NF-KAPPA-B; HUMAN PROSTATE-CANCER; C-REL; RETICULOENDOTHELIOSIS VIRUS; DNA-BINDING; BREAST-CANCER; ANDROGEN-INDEPENDENCE; MOLECULAR ALTERATIONS; TRANSCRIPTION FACTORS; SELECTIVE ACTIVATION	The v-rel oncogene is the most efficient transforming member of the Rel/NF-kappa B family of transcription factors. v-Rel induces avian and mammalian lymphoid cell tumors and transforms chicken embryo fibroblasts in culture by the aberrant regulation of genes under the control of Rel/NF-kappa B proteins. Here we report that the expression of SH3BGRL, a member of the SH3BGR (SH3 domain-binding glutamicacid-rich) family of proteins, is down-regulated in v-Rel-expressing fibroblasts, lymphoid cells, and splenic tumor cells. Chromatin immunoprecipitation experiments demonstrated that v-Rel binds to the sh3bgrl promoter in transformed cells. Coexpression of SH3BGRL with v-Rel in primary splenic lymphocytes reduced the number of colonies formed by 76%. Mutations in the predicted SH3-binding domain of SH3BGRL abolished the suppressive effect on v-Rel transformation and resulted in colony numbers comparable to those formed by v-Rel alone. However, mutations in the predicted EVH1-binding domain of SH3BGRL only had a modest effect on suppression of v-Rel transformation. This study provides the first example of a gene that is down-regulated in v-Rel-expressing cells that also plays a role in v-Rel transformation.	Univ Texas, Inst Mol & Cellular Biol, Sect Mol Genet & Microbiol, Austin, TX 78712 USA; Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Pathol, Boston, MA 02115 USA	University of Texas System; University of Texas Austin; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Bose, HR (corresponding author), Univ Texas, Inst Mol & Cellular Biol, Sect Mol Genet & Microbiol, 1 Univ Stn A5000, Austin, TX 78712 USA.	bose@mail.utexas.edu	Liss, Andrew/L-9696-2019		NCI NIH HHS [CA33192] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA033192] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKIYAMA Y, 1974, BIKEN J, V17, P105; BABA TW, 1985, VIROLOGY, V144, P139, DOI 10.1016/0042-6822(85)90312-5; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Ball LJ, 2002, FEBS LETT, V513, P45, DOI 10.1016/S0014-5793(01)03291-4; BARTH CF, 1990, J VIROL, V64, P6054, DOI 10.1128/JVI.64.12.6054-6062.1990; Barzik M, 2001, J MOL BIOL, V309, P155, DOI 10.1006/jmbi.2001.4640; Berleth ES, 2000, INT J IMMUNOPHARMACO, V22, P1137, DOI 10.1016/S0192-0561(00)00071-0; Berleth ES, 1999, CANCER RES, V59, P5497; Bonizzi G, 2004, TRENDS IMMUNOL, V25, P280, DOI 10.1016/j.it.2004.03.008; BOSE HR, 1992, BIOCHIM BIOPHYS ACTA, V1114, P1, DOI 10.1016/0304-419X(92)90002-G; BULL P, 1990, MOL CELL BIOL, V10, P5473, DOI 10.1128/MCB.10.10.5473; Cao YX, 2003, J MAMMARY GLAND BIOL, V8, P215, DOI 10.1023/A:1025905008934; Carrasco D, 1996, EMBO J, V15, P3640, DOI 10.1002/j.1460-2075.1996.tb00733.x; Cesareni G, 2002, FEBS LETT, V513, P38, DOI 10.1016/S0014-5793(01)03307-5; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Chen F, 2001, AM J PATHOL, V159, P387, DOI 10.1016/S0002-9440(10)61708-7; CHENG Q, 1994, J BIOL CHEM, V269, P13551; CHIAO PJ, 1994, P NATL ACAD SCI USA, V91, P28, DOI 10.1073/pnas.91.1.28; Cogswell PC, 2000, ONCOGENE, V19, P1123, DOI 10.1038/sj.onc.1203412; Deindl E, 2001, BIOTECHNIQUES, V31, P1250, DOI 10.2144/01316bm04; Denk A, 2000, CYTOKINE GROWTH F R, V11, P303, DOI 10.1016/S1359-6101(00)00009-5; DOUGHERTY JP, 1986, MOL CELL BIOL, V6, P4387, DOI 10.1128/MCB.6.12.4387; DYER RB, 1995, BIOTECHNIQUES, V19, P192; Egeo A, 1998, BIOCHEM BIOPH RES CO, V247, P302, DOI 10.1006/bbrc.1998.8763; FRANKLIN RB, 1977, VIROLOGY, V83, P313, DOI 10.1016/0042-6822(77)90176-3; Fujii M, 1996, ONCOGENE, V12, P2193; Gasparian AV, 2002, J CELL SCI, V115, P141; Gilmore TD, 1999, ONCOGENE, V18, P6925, DOI 10.1038/sj.onc.1203222; GILMORE TD, 1995, FRONTIERS MOL BIOL E, P104; Grabs D, 1997, J BIOL CHEM, V272, P13419, DOI 10.1074/jbc.272.20.13419; Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704; Henn AD, 2001, FASEB J, V15, P1315, DOI 10.1096/fj.00-0543fje; HRDLICKOVA R, 1995, J VIROL, V69, P403; HRDLICKOVA R, 1995, J VIROL, V69, P3369; HRDLICKOVA R, 1994, J VIROL, V68, P308; Hrdlickova R, 2001, MOL CELL BIOL, V21, P6369; KABRUN N, 1991, P NATL ACAD SCI USA, V88, P1783, DOI 10.1073/pnas.88.5.1783; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; KERR LD, 1991, GENE DEV, V5, P1464, DOI 10.1101/gad.5.8.1464; Kralova J, 1998, MOL CELL BIOL, V18, P2997, DOI 10.1128/MCB.18.5.2997; Kralova J, 2002, J VIROL, V76, P11960, DOI 10.1128/JVI.76.23.11960-11970.2002; Kralova J, 1996, ONCOGENE, V12, P2595; Lee RM, 1999, GENE DEV, V13, P718, DOI 10.1101/gad.13.6.718; Li QT, 2002, NAT REV IMMUNOL, V2, P725, DOI 10.1038/nri910; Liss AS, 2002, J VIROL, V76, P4928, DOI 10.1128/JVI.76.10.4928-4939.2002; Madrid Lee V, 2003, Methods Mol Biol, V223, P523; Mayer BJ, 2001, J CELL SCI, V114, P1253; Mazzocco M, 2002, GENE, V291, P233, DOI 10.1016/S0378-1119(02)00602-9; Mazzocco M, 2001, BIOCHEM BIOPH RES CO, V285, P540, DOI 10.1006/bbrc.2001.5169; Mecham BH, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh071; MOORE BE, 1988, VIROLOGY, V162, P377, DOI 10.1016/0042-6822(88)90478-3; MOORE PA, 1993, MOL CELL BIOL, V13, P1666, DOI 10.1128/MCB.13.3.1666; MOSCOVICI C, 1998, EXPRESSION DIFFERNTI, P435; Nehyba J, 2002, MOL CELL BIOL, V22, P3942, DOI 10.1128/MCB.22.11.3942-3957.2002; Nelson DM, 1998, HUM GENE THER, V9, P2401, DOI 10.1089/hum.1998.9.16-2401; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Petrenko O, 1997, ONCOGENE, V15, P1671, DOI 10.1038/sj.onc.1201334; PETSKO G, 2002, CURRENT PROTOCOLS BI; RAO A, 1990, CANCER RES, V50, P4764; Romieu-Mourez R, 2003, MOL CELL BIOL, V23, P5738, DOI 10.1128/MCB.23.16.5738-5754.2003; Sachdev S, 1998, MOL CELL BIOL, V18, P5445, DOI 10.1128/MCB.18.9.5445; Sambrook J., 1989, MOL CLONING LAB MANU, V2nd; SARKAR S, 1993, ONCOGENE, V8, P2245; Scartezzini P, 1997, HUM GENET, V99, P387, DOI 10.1007/s004390050377; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHATZLE JD, 1995, J VIROL, V69, P5383, DOI 10.1128/JVI.69.9.5383-5390.1995; SCHWARTZ RC, 1988, VIROLOGY, V165, P182, DOI 10.1016/0042-6822(88)90671-X; Shi XB, 2004, PROSTATE, V60, P257, DOI 10.1002/pros.20039; Sovak MA, 1997, J CLIN INVEST, V100, P2952, DOI 10.1172/JCI119848; STEPHENS RM, 1983, P NATL ACAD SCI-BIOL, V80, P6229, DOI 10.1073/pnas.80.20.6229; Suh J, 2004, J CELL BIOCHEM, V91, P100, DOI 10.1002/jcb.10729; Suh JH, 2002, PROSTATE, V52, P183, DOI 10.1002/pros.10082; Thalmann GN, 2000, PROSTATE, V44, P91; Tong AHY, 2001, SCIENCE, V294, P2364, DOI 10.1126/science.1065810; Tu JC, 1998, NEURON, V21, P717, DOI 10.1016/S0896-6273(00)80589-9; WHITE DW, 1995, ONCOGENE, V10, P857; WILHELMSEN KC, 1984, J VIROL, V52, P172, DOI 10.1128/JVI.52.1.172-182.1984; You MJ, 1998, METHODS, V16, P373, DOI 10.1006/meth.1998.0692; Zhang GQ, 1996, ONCOGENE, V12, P1153; ZHANG GQ, 1995, MOL CELL BIOL, V15, P1806; Zhou JR, 2004, INT J CANCER, V110, P800, DOI 10.1002/ijc.20206; Zong WX, 1997, ONCOGENE, V15, P971, DOI 10.1038/sj.onc.1201266	82	31	31	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2006	25	5					756	768		10.1038/sj.onc.1209107	http://dx.doi.org/10.1038/sj.onc.1209107			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	008VM	16186799				2022-12-17	WOS:000235068800011
J	Christmann, M; Tomicic, MT; Origer, J; Kaina, B				Christmann, M; Tomicic, MT; Origer, J; Kaina, B			Fen1 is induced p53 dependently and involved in the recovery from UV- light-induced replication inhibition	ONCOGENE			English	Article						DNA repair; inducible response; UV sensitivity	REPAIR PROTEINS MSH2; BASE EXCISION-REPAIR; DNA-DAMAGE; FLAP ENDONUCLEASE-1; C-FOS; MOUSE CELLS; S-PHASE; PHOSPHORYLATION; RADIATION; FIBROBLASTS	Mouse embryonic fibroblasts (MEFs) that lack p53 are hypersensitive to the cytotoxic and genotoxic effect of ultraviolet (UV-C) light. They also display a defect in the recovery from UV-C-induced DNA replication inhibition. An enzyme involved in processing stalled DNA replication forks is flap endonuclease 1 (Fen1). Gene expression pro. ling of UV-C-irradiated MEFs revealed fen1 to be upregulated, which was confirmed by RT-PCR and Western blot experiments. Increased Fen1 levels upon UV-C exposure are due to transcriptional activation, as revealed by inhibitor studies. Fen1 induction was dose- and time-dependent; it occurred on protein level already 3 h after irradiation. Induction of Fen1 by UV-C requires p53 since it was observed in p53 wild-type (wt) but not in p53 null (p53-/-) fibroblasts. Fen1 upregulation paralleled the increase in p53 protein level in replicating wt cells, whereas in nonreplicating cells both Fen1 and p53 were not induced by UV-C. The mouse fen1 promoter was cloned and shown to harbor a p53 consensus sequence to which p53 binds. In cotransfection experiments, p53 stimulated the expression of a fen1 promoter-reporter construct. Transgenic expression of Fen1 in p53 null cells attenuated UV-C light-induced DNA replication inhibition, supporting the hypothesis that Fen1 induction is involved in the recovery of cells from DNA damage.	Univ Mainz, Dept Toxicol, D-55131 Mainz, Germany	Johannes Gutenberg University of Mainz	Kaina, B (corresponding author), Univ Mainz, Dept Toxicol, Obere Zahlbacher Str 67, D-55131 Mainz, Germany.	kaina@uni-mainz.de	Kaina, Bernd/AAE-4692-2020; Tomicic, Maja/S-1377-2019	Tomicic, Maja/0000-0001-9289-4168				Bae SH, 2001, NATURE, V412, P456, DOI 10.1038/35086609; Bartek J, 2004, NAT REV MOL CELL BIO, V5, P792, DOI 10.1038/nrm1493; CHAN GL, 1985, BIOCHEMISTRY-US, V24, P5723, DOI 10.1021/bi00342a006; Chehab NH, 1999, P NATL ACAD SCI USA, V96, P13777, DOI 10.1073/pnas.96.24.13777; Christmann M, 2002, NUCLEIC ACIDS RES, V30, P1959, DOI 10.1093/nar/30.9.1959; Christmann M, 2000, J BIOL CHEM, V275, P36256, DOI 10.1074/jbc.M005377200; Christmann M, 2003, TOXICOLOGY, V193, P3, DOI 10.1016/S0300-483X(03)00287-7; Cistulli CA, 1998, CANCER RES, V58, P1993; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; Gottifredi V, 2001, P NATL ACAD SCI USA, V98, P1036, DOI 10.1073/pnas.021282898; Grombacher T, 1998, ONCOGENE, V17, P845, DOI 10.1038/sj.onc.1202000; HAAS S, 1995, CARCINOGENESIS, V16, P985, DOI 10.1093/carcin/16.5.985; HARRINGTON JJ, 1994, EMBO J, V13, P1235, DOI 10.1002/j.1460-2075.1994.tb06373.x; Hawkins DS, 1996, CANCER RES, V56, P892; Henneke G, 2003, ONCOGENE, V22, P4301, DOI 10.1038/sj.onc.1206606; Janus F, 1999, CELL MOL LIFE SCI, V55, P12, DOI 10.1007/s000180050266; KASTAN MB, 1991, CANCER RES, V51, P6304; Khosravi R, 1999, P NATL ACAD SCI USA, V96, P14973, DOI 10.1073/pnas.96.26.14973; Kim IS, 1998, EXP MOL MED, V30, P252, DOI 10.1038/emm.1998.37; Klungland A, 1997, EMBO J, V16, P3341, DOI 10.1093/emboj/16.11.3341; Lackinger D, 2001, MUTAGENESIS, V16, P233, DOI 10.1093/mutage/16.3.233; Lackinger D, 2000, MUTAT RES-FUND MOL M, V457, P113, DOI 10.1016/S0027-5107(00)00133-0; Lakin ND, 1999, ONCOGENE, V18, P7644, DOI 10.1038/sj.onc.1203015; Larsen E, 2003, MOL CELL BIOL, V23, P5346, DOI 10.1128/MCB.23.15.5346-5353.2003; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; Prasad R, 2000, J BIOL CHEM, V275, P4460, DOI 10.1074/jbc.275.6.4460; Prost S, 1998, J BIOL CHEM, V273, P33327, DOI 10.1074/jbc.273.50.33327; Ruggiero BL, 2004, J BIOL CHEM, V279, P23088, DOI 10.1074/jbc.M313170200; Rumbaugh JA, 1999, J BIOL CHEM, V274, P14602, DOI 10.1074/jbc.274.21.14602; Sharma S, 2004, MOL BIOL CELL, V15, P734, DOI 10.1091/mbc.E03-08-0567; Shi BS, 2001, ACTA BIOCH BIOPH SIN, V33, P309; Shibata Y, 2002, J BIOL CHEM, V277, P746, DOI 10.1074/jbc.M109461200; Smith ML, 2000, MOL CELL BIOL, V20, P3705, DOI 10.1128/MCB.20.10.3705-3714.2000; Tomicic MT, 2003, MOL PHARMACOL, V63, P439, DOI 10.1124/mol.63.2.439; Warbrick E, 1998, J PATHOL, V186, P319; Zheng L, 2005, EMBO REP, V6, P83, DOI 10.1038/sj.embor.7400313	36	31	33	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 15	2005	24	56					8304	8313		10.1038/sj.onc.1208994	http://dx.doi.org/10.1038/sj.onc.1208994			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	993LV	16103874				2022-12-17	WOS:000233956500009
J	Scholz, C; Richter, A; Lehmann, M; Schulze-Osthoff, K; Dorken, B; Daniel, PT				Scholz, C; Richter, A; Lehmann, M; Schulze-Osthoff, K; Dorken, B; Daniel, PT			Arsenic trioxide induces regulated, death receptor-independent cell death through a Bcl-2-controlled pathway	ONCOGENE			English	Article						arsenic trioxide; apoptosis; caspase-8; FADD; death receptor; CD95/Fas	ACUTE PROMYELOCYTIC LEUKEMIA; DRUG-INDUCED APOPTOSIS; CD95/FAS RECEPTOR; CYCLE ARREST; ACTIVATION; CASPASE-8; INDUCTION; BCL-2; MANNER; LINES	Arsenic trioxide (As2O3, arsenite) efficiently kills cells from various hematologic malignancies and has successfully been employed especially for the treatment of acute promyelocytic leukemia. There and in lymphoid cells, we demonstrated that As2O3 induces cell death in a caspase-2- and -9-independent fashion. Here, we address a potential role of death receptor signaling through the FADD/caspase-8 death-inducing signaling complex in As2O3-induced cell death. In detail, we demonstrate that As2O3 induces cell death independently of caspase-8 or FADD and cannot be blocked by disruption of CD95/Fas receptor ligand interaction. Unlike in death receptor ligation-induced apoptosis, As2O3-induced cell death was not blocked by the broad-spectrum caspase inhibitor z-VAD-fmk or the caspase-8-specific inhibitor z- IETD-fmk. Nevertheless, As2O3-induced cell death occurred in a regulated manner and was abrogated upon Bcl-2 overexpression. In contrast, As2O3-induced cell demise was neither blocked by the caspase-9 inhibitor z-LEHD-fmk nor substantially inhibited through the expression of a dominant negative caspase-9 mutant. Altogether our data demonstrate that As2O3-induced cell death occurs independently of the extrinsic death receptor pathway of apoptosis. Cell death proceeds entirely via an intrinsic, Bcl-2-controlled mitochondrial pathway that does, however, not rely on caspase-9.	Humboldt Univ, Med Ctr, Dept Hematol Oncol & Tumor Immunol, Berlin, Germany; Univ Dusseldorf, Inst Mol Med, D-4000 Dusseldorf, Germany; Max Delbruck Ctr Mol Med, D-13125 Berlin, Germany	Humboldt University of Berlin; Heinrich Heine University Dusseldorf; Helmholtz Association; Max Delbruck Center for Molecular Medicine	Daniel, PT (corresponding author), Charite Univ, Campus Virchow Klinikum, Med Ctr, Augustenburger Platz 1, D-13353 Berlin, Germany.	pdaniel@mdc-berlin.de	Scholz, Christian W/Q-2778-2017; Lehmann, Mario/G-6090-2016; Schulze-Osthoff, Klaus/N-9025-2013	Scholz, Christian W/0000-0001-6260-4086; Lehmann, Mario/0000-0001-8284-5071; Schulze-Osthoff, Klaus/0000-0003-1443-2720				Akao Y, 1998, BRIT J HAEMATOL, V102, P1055, DOI 10.1046/j.1365-2141.1998.00869.x; Belka C, 2003, ONCOGENE, V22, P176, DOI 10.1038/sj.onc.1206103; Belka C, 2000, ONCOGENE, V19, P1181, DOI 10.1038/sj.onc.1203401; Boatright KM, 2003, MOL CELL, V11, P529, DOI 10.1016/S1097-2765(03)00051-0; Chandra D, 2004, MOL CELL BIOL, V24, P6592, DOI 10.1128/mcb.24.15.6592-6607.2004; Daniel PT, 2003, ESSAYS BIOCHEM, V39, P73, DOI 10.1042/bse0390073; Daniel PT, 1998, BLOOD, V92, P4750, DOI 10.1182/blood.V92.12.4750.424k34_4750_4757; Daniel PT, 2001, LEUKEMIA, V15, P1022, DOI 10.1038/sj.leu.2402169; DHEIN J, 1992, J IMMUNOL, V149, P3166; Engels IH, 2000, ONCOGENE, V19, P4563, DOI 10.1038/sj.onc.1203824; Fischer U, 2003, CELL DEATH DIFFER, V10, P76, DOI 10.1038/sj.cdd.4401160; Hemmati PG, 2002, ONCOGENE, V21, P3149, DOI 10.1038/sj.onc.1205458; Hossain K, 2000, J IMMUNOL, V165, P4290, DOI 10.4049/jimmunol.165.8.4290; Jendrossek V, 2003, FASEB J, V17, P1547, DOI 10.1096/fj.02-0947fje; Jendrossek V, 2003, ONCOGENE, V22, P2621, DOI 10.1038/sj.onc.1206355; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; Kischkel FC, 2000, IMMUNITY, V12, P611, DOI 10.1016/S1074-7613(00)80212-5; Kitamura K, 2000, LEUKEMIA, V14, P1743, DOI 10.1038/sj.leu.2401900; Klopfer A, 2004, ONCOGENE, V23, P9408, DOI 10.1038/sj.onc.1207975; Larochette N, 1999, EXP CELL RES, V249, P413, DOI 10.1006/excr.1999.4519; Liu Q, 2003, BLOOD, V101, P4078, DOI 10.1182/blood-2002-10-3231; Niu C, 1999, BLOOD, V94, P3315, DOI 10.1182/blood.V94.10.3315.422k16_3315_3324; Perkins C, 2000, BLOOD, V95, P1014, DOI 10.1182/blood.V95.3.1014.003k04_1014_1022; Peter ME, 2003, CELL DEATH DIFFER, V10, P26, DOI 10.1038/sj.cdd.4401186; Rudner J, 2005, ONCOGENE, V24, P130, DOI 10.1038/sj.onc.1208191; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Scholz C, 2005, ONCOGENE, V24, P1904, DOI 10.1038/sj.onc.1208233; Shen ZX, 1997, BLOOD, V89, P3354, DOI 10.1182/blood.V89.9.3354; Sohn D, 2005, J BIOL CHEM, V280, P5267, DOI 10.1074/jbc.M408585200; Soignet SL, 1998, NEW ENGL J MED, V339, P1341, DOI 10.1056/NEJM199811053391901; VERMES I, 1995, J IMMUNOL METHODS, V184, P39, DOI 10.1016/0022-1759(95)00072-I; von Haefen C, 2003, ONCOGENE, V22, P2236, DOI 10.1038/sj.onc.1206280; von Haefen C, 2004, ONCOGENE, V23, P8320, DOI 10.1038/sj.onc.1207971; Wang ZG, 1998, BLOOD, V92, P1497, DOI 10.1182/blood.V92.5.1497.417k41_1497_1504; Weinmann M, 2004, ONCOGENE, V23, P3757, DOI 10.1038/sj.onc.1207481; Wieder T, 2001, BLOOD, V97, P1378, DOI 10.1182/blood.V97.5.1378; Woo SH, 2004, INT J CANCER, V112, P596, DOI 10.1002/ijc.20433; Zhang W, 1998, LEUKEMIA, V12, P1383, DOI 10.1038/sj.leu.2401112; Zhu JB, 2003, ONCOL REP, V10, P705; Zhu XH, 1999, J NATL CANCER I, V91, P772, DOI 10.1093/jnci/91.9.772	40	31	36	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 27	2005	24	47					7031	7042		10.1038/sj.onc.1208868	http://dx.doi.org/10.1038/sj.onc.1208868			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	977WC	16007134				2022-12-17	WOS:000232833200005
J	Ishikawa, H; Tsuyama, N; Liu, SQ; Abroun, S; Li, FJ; Otsuyama, I; Zheng, X; Ma, Z; Maki, Y; Iqbal, MS; Obata, M; Kawano, MM				Ishikawa, H; Tsuyama, N; Liu, SQ; Abroun, S; Li, FJ; Otsuyama, I; Zheng, X; Ma, Z; Maki, Y; Iqbal, MS; Obata, M; Kawano, MM			Accelerated proliferation of myeloma cells by interleukin-6 cooperating with fibroblast growth factor receptor 3-mediated signals	ONCOGENE			English	Article						cell proliferation; ERK1/2; FGFR3; IL-6; myeloma; STAT3	MULTIPLE-MYELOMA; CHROMOSOMAL TRANSLOCATION; SERINE PHOSPHORYLATION; STAT3; EXPRESSION; GENE; FAMILY; IL-6; ESTABLISHMENT; TRANSCRIPTION	Interleukin-6 (IL-6) is a cytokine that regulates the proliferation of some tumor cells including multiple myeloma (MM). Ectopic expression of fibroblast growth factor receptor 3 (FGFR3) associated with the chromosomal translocation, t(4;14)(p16.3;q32), is frequently found in MM, and therefore, has been implicated in the neoplastic transformation of this disease. Here, we show that IL-6 together with FGF enhanced proliferation of a myeloma cell line, KMS-11 carrying t(4;14)(p16.3;q32) and the FGFR3-transfected U266 myeloma cell line which ectopically expressed FGFR3 but responded to neither IL-6 nor FGF alone. In KMS-11, IL-6 activated signal transducer and activator of transcription 3 (STAT3) while FGF activated extracellular signal-regulated kinase 1/2 (ERK1/2) and phosphatidylinositol (PI)-3 kinase. As both MEK inhibitors and a PI 3-kinase inhibitor abolished the effect of IL-6 and FGF, the activation of both the ERK1/2 and PI 3-kinase signaling cascades is essential for the proliferation of KMS-11 enhanced by IL-6 and FGF. Furthermore, the FGF-induced activation of ERK1/2 contributed to the serine phosphorylation of STAT3, suggesting that the signaling crosstalk between the cytokine receptor, IL-6 receptor alpha/gp130 and the growth factor receptor tyrosine kinase, FGFR3. The se results indicate that FGFR3 plays a crucial role in the accelerated proliferation of MM carrying t(4;14)(p16.3;q32).	Yamaguchi Univ, Lab Cellular Signal Anal, Dept Bio Signal Anal, Grad Sch Med, Ube, Yamaguchi 7558505, Japan	Yamaguchi University	Ishikawa, H (corresponding author), Yamaguchi Univ, Lab Cellular Signal Anal, Dept Bio Signal Anal, Grad Sch Med, Ube, Yamaguchi 7558505, Japan.	hishika@yamaguchi-u.ac.jp	ABROUN, SAEID/GPF-5006-2022					Abroun S, 2004, BLOOD, V103, P2291, DOI 10.1182/blood-2003-07-2187; Avet-Loiseau H, 1998, CANCER RES, V58, P5640; Bergsagel PL, 2001, ONCOGENE, V20, P5611, DOI 10.1038/sj.onc.1204641; Chesi M, 1998, BLOOD, V92, P3025, DOI 10.1182/blood.V92.9.3025.421k53_3025_3034; Chesi M, 1997, NAT GENET, V16, P260, DOI 10.1038/ng0797-260; Chesi M, 2001, BLOOD, V97, P729, DOI 10.1182/blood.V97.3.729; Chesi M, 1998, BLOOD, V91, P4457, DOI 10.1182/blood.V91.12.4457.412k48_4457_4463; Chung JK, 1997, MOL CELL BIOL, V17, P6508, DOI 10.1128/MCB.17.11.6508; Duarte RF, 2000, BLOOD, V96, P3422; Fujii R, 1999, BRIT J HAEMATOL, V105, P131, DOI 10.1046/j.1365-2141.1999.01281.x; Fukada T, 1996, IMMUNITY, V5, P449, DOI 10.1016/S1074-7613(00)80501-4; Hirano T, 2000, ONCOGENE, V19, P2548, DOI 10.1038/sj.onc.1203551; Hirano Toshio, 1997, Cytokine and Growth Factor Reviews, V8, P241, DOI 10.1016/S1359-6101(98)80005-1; Iida S, 1997, NAT GENET, V17, P226, DOI 10.1038/ng1097-226; Ishikawa H, 2002, BLOOD, V99, P2172, DOI 10.1182/blood.V99.6.2172; KAWANO M, 1988, NATURE, V332, P83, DOI 10.1038/332083a0; KEEGAN K, 1991, P NATL ACAD SCI USA, V88, P1095, DOI 10.1073/pnas.88.4.1095; Kiuchi N, 1999, J EXP MED, V189, P63, DOI 10.1084/jem.189.1.63; KLINT P, 1999, FRONT BIOSCI, V4, P165; Mahmoud MS, 1998, BLOOD, V92, P3887, DOI 10.1182/blood.V92.10.3887.422a48_3887_3897; Malgeri U, 2000, CANCER RES, V60, P4058; NAMBA M, 1989, IN VITRO CELL DEV B, V25, P723; Onishi M, 1998, MOL CELL BIOL, V18, P3871, DOI 10.1128/MCB.18.7.3871; Otsuki T, 1998, INT J ONCOL, V12, P545; Plowright EE, 2000, BLOOD, V95, P992, DOI 10.1182/blood.V95.3.992.003k29_992_998; Richelda R, 1997, BLOOD, V90, P4062, DOI 10.1182/blood.V90.10.4062; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; ZHANG XK, 1995, SCIENCE, V267, P1990, DOI 10.1126/science.7701321	28	31	48	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2005	24	41					6328	6332		10.1038/sj.onc.1208782	http://dx.doi.org/10.1038/sj.onc.1208782			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	964JM	15940250				2022-12-17	WOS:000231877100014
J	Mercer, K; Giblett, S; Oakden, A; Brown, J; Marais, R; Pritchard, C				Mercer, K; Giblett, S; Oakden, A; Brown, J; Marais, R; Pritchard, C			A-Raf and Raf-1 work together to influence transient ERK phosphorylation and Gl/S cell cycle progression	ONCOGENE			English	Article						A-Raf; Raf-1; knockout; ERK activation; cell cycle; c-Fos; cyclin D1	SIGNAL-TRANSDUCTION PATHWAYS; MAP KINASE CASCADE; B-RAF; PROTEIN-KINASE; INDUCED APOPTOSIS; G(1) PHASE; ACTIVATION; EXPRESSION; D1; FIBROBLASTS	The Raf/MEK/ERK ( extracellular regulated kinase) signal transduction pathway controls the ability of cells to respond to proliferative, apoptotic, migratory and differentiation signals. We have investigated the combined contribution of A-Raf and Raf-1 isotypes to signalling through this pathway by generating mice with knockout mutations of both A-raf and raf-1 genes. Double knockout (DKO) mice have a more severe phenotype than single null mutations of either gene, dying in embryogenesis at E10.5. The DKO embryos show no changes in apoptosis, but staining for Ki67 indicates a generalized reduction in proliferation. DKO mouse embryonic fibroblasts (MEFs) exhibit a delayed ability to enter S phase of the cell cycle. This is associated with a reduction in levels of transiently induced MEK and ERK phosphorylation and reduced expression of c-Fos and cyclin Dl. Levels of sustained ERK phosphorylation are not significantly altered. Thus, Raf-1 and A-Raf have a combined role in controlling physiological transient ERK activation and in maintenance of cell cycle progression at its usual rate.	Univ Leicester, Dept Biochem, Leicester LE1 7RH, Leics, England; Univ Leicester, Div Biomed Sci, Leicester LE1 7RH, Leics, England; Inst Canc Res, London SW3 6JB, England	University of Leicester; University of Leicester; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK	Pritchard, C (corresponding author), Univ Leicester, Dept Biochem, Adrian Bldg,Univ Rd, Leicester LE1 7RH, Leics, England.	cap8@le.ac.uk		Marais, Richard/0000-0001-7484-4183; Pritchard, Catrin/0000-0003-1859-4487	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; Avruch J, 2001, RECENT PROG HORM RES, V56, P127, DOI 10.1210/rp.56.1.127; Baccarini M, 2002, CELL DEATH DIFFER, V9, P783, DOI 10.1038/sj.cdd.4401070; Balmanno K, 1999, ONCOGENE, V18, P3085, DOI 10.1038/sj.onc.1202647; Basu S, 1998, J BIOL CHEM, V273, P30419, DOI 10.1074/jbc.273.46.30419; Blagosklonny MV, 1997, CANCER RES, V57, P130; Blagosklonny MV, 1996, CANCER RES, V56, P1851; Brown JR, 1998, MOL CELL BIOL, V18, P5609, DOI 10.1128/MCB.18.9.5609; Chen Z, 2001, CHEM REV, V101, P2449, DOI 10.1021/cr000241p; Chong H, 2003, CELL SIGNAL, V15, P463, DOI 10.1016/S0898-6568(02)00139-0; Chong H, 2001, EMBO J, V20, P3716, DOI 10.1093/emboj/20.14.3716; Cook SJ, 1999, MOL CELL BIOL, V19, P330; Cook SJ, 1996, BIOCHEM J, V320, P237, DOI 10.1042/bj3200237; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Dhillon AS, 2002, ARCH BIOCHEM BIOPHYS, V404, P3, DOI 10.1016/S0003-9861(02)00244-8; Dhillon AS, 2002, EMBO J, V21, P64, DOI 10.1093/emboj/21.1.64; HERBER B, 1994, ONCOGENE, V9, P1295; Hindley A, 2002, J CELL SCI, V115, P1575; Huser M, 2001, EMBO J, V20, P1940, DOI 10.1093/emboj/20.8.1940; Jesenberger V, 2001, J EXP MED, V193, P353, DOI 10.1084/jem.193.3.353; JIANG W, 1993, ONCOGENE, V8, P3447; KARASARIDES M, 2004, ONCOGENE, V21, P21; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Kerkhoff E, 1997, MOL CELL BIOL, V17, P2576, DOI 10.1128/MCB.17.5.2576; Kerkhoff E, 1998, ONCOGENE, V17, P1457, DOI 10.1038/sj.onc.1202185; Kimura ET, 2003, CANCER RES, V63, P1454; Kolch W, 2000, BIOCHEM J, V351, P289, DOI 10.1042/0264-6021:3510289; KOVARY K, 1992, MOL CELL BIOL, V12, P5015, DOI 10.1128/MCB.12.11.5015; KOVARY K, 1991, MOL CELL BIOL, V11, P4466, DOI 10.1128/MCB.11.9.4466; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; Luckett JCA, 2000, CELL GROWTH DIFFER, V11, P163; Marais R, 1997, J BIOL CHEM, V272, P4378, DOI 10.1074/jbc.272.7.4378; Marais R, 1996, CANCER SURV, V27, P101; MARAIS R, 1995, EMBO J, V14, P3136, DOI 10.1002/j.1460-2075.1995.tb07316.x; Marshall C, 1999, CURR OPIN CELL BIOL, V11, P732, DOI 10.1016/S0955-0674(99)00044-7; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Mason CS, 1999, EMBO J, V18, P2137, DOI 10.1093/emboj/18.8.2137; Mercer K, 2002, ONCOGENE, V21, P347, DOI 10.1038/sj.onc.1205101; Mercer KE, 2003, BBA-REV CANCER, V1653, P25, DOI 10.1016/S0304-419X(03)00016-7; MIAO GG, 1994, MOL CELL BIOL, V14, P4295, DOI 10.1128/MCB.14.6.4295; Mikula M, 2001, EMBO J, V20, P1952, DOI 10.1093/emboj/20.8.1952; Murphy LO, 2002, NAT CELL BIOL, V4, P556, DOI 10.1038/ncb822; Ory S, 2003, CURR BIOL, V13, P1356, DOI 10.1016/S0960-9822(03)00535-9; Pritchard CA, 2004, MOL CELL BIOL, V24, P5937, DOI 10.1128/MCB.24.13.5937-5952.2004; Pritchard CA, 1996, CURR BIOL, V6, P614, DOI 10.1016/S0960-9822(02)00548-1; PRITCHARD CA, 1995, MOL CELL BIOL, V15, P6430; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; SAMUELS ML, 1993, MOL CELL BIOL, V13, P6241, DOI 10.1128/MCB.13.10.6241; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; Squires MS, 2002, BIOCHEM J, V366, P673, DOI 10.1042/BJ20020372; Stacey DW, 2003, CURR OPIN CELL BIOL, V15, P158, DOI 10.1016/S0955-0674(03)00008-5; Stevaux O, 2002, CURR OPIN CELL BIOL, V14, P684, DOI 10.1016/S0955-0674(02)00388-5; STORM SM, 1990, ONCOGENE, V5, P345; VOURETCRAVIARI V, 1993, BIOCHEM J, V289, P209, DOI 10.1042/bj2890209; Wan PTC, 2004, CELL, V116, P855, DOI 10.1016/S0092-8674(04)00215-6; Weber JD, 1997, BIOCHEM J, V326, P61, DOI 10.1042/bj3260061; Whitmarsh AJ, 1996, J MOL MED-JMM, V74, P589, DOI 10.1007/s001090050063; Wojnowski L, 2000, MECH DEVELOP, V91, P97, DOI 10.1016/S0925-4773(99)00276-2; WON KA, 1992, P NATL ACAD SCI USA, V89, P9910, DOI 10.1073/pnas.89.20.9910; Woods D, 1997, MOL CELL BIOL, V17, P5598, DOI 10.1128/MCB.17.9.5598; Zhang BH, 2000, EMBO J, V19, P5429, DOI 10.1093/emboj/19.20.5429; Zhang BH, 2001, J BIOL CHEM, V276, P31620, DOI 10.1074/jbc.M102808200	63	31	33	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2005	24	33					5207	5217		10.1038/sj.onc.1208707	http://dx.doi.org/10.1038/sj.onc.1208707			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	951XB	15856007				2022-12-17	WOS:000230964600007
J	Taki, T; Akiyama, M; Saito, S; Ono, R; Taniwaki, M; Kato, Y; Yuza, Y; Eto, Y; Hayashi, Y				Taki, T; Akiyama, M; Saito, S; Ono, R; Taniwaki, M; Kato, Y; Yuza, Y; Eto, Y; Hayashi, Y			The MYO1F, unconventional myosin type 1F, gene is fused to MLL in infant acute monocytic leukemia with a complex translocation involving chromosomes 7, 11, 19 and 22	ONCOGENE			English	Article						MLL; MYO1F; acute monocytic leukemia; chromosometrans location	ACUTE MYELOID-LEUKEMIA; ACUTE LYMPHOBLASTIC-LEUKEMIA; INTENSIVE CHEMOTHERAPY; DROSOPHILA-TRITHORAX; HEAVY-CHAIN; HRX-ENL; FUSION; DOMAIN; 11Q23; REARRANGEMENTS	We analysed a complex translocation involving chromosomes 7, 11, 19 and 22 in infant acute monocytic leukemia, and identified that the MLL gene on 11q23 was fused to the unconventional myosin type 1F, MYO1F, gene on 19p13.2-13.3. MYO1F consists of at least 28 exons and was predicted to encode a 1098-amino-acid with an N-terminal head domain containing both ATP-binding and actin-binding sequences, a neck domain with a single IQ motif, and a tail with TH1, TH2 and SH3 domains. Northern blot analysis of RNAs prepared from multiple tissues showed that the expression of approximately 4-kb transcripts appeared constant in most tissues examined. However, MYO1F was expressed in only three of 22 leukemic cell lines. The MLL-MYO1F fusion protein contains almost the entire MYO1F, however, C-terminal MYO1F has neither the transactivation domain nor the dimerization domain found in various MLL fusion partners. Further analysis of this novel type of MLL fusion protein would provide new insights into leukemogenesis. MYO1F is the fourth partner gene of MLL on 19p13. At the cytogenetic level, it may be difficult to distinguish MLL-ENL, MLL-ELL, MLL-EEN and MLL-MYO1F fusions created by t(11;19)(q23;p13), and it is likely that cases of t(11;19) lacking a known fusion gene may result in this gene fusion.	Gunma Childrens Med Ctr, Div Hematol Oncol, Gunma 3778577, Japan; Kyoto Prefectural Univ, Med Grad Sch Med SCi, Dept Mol Lab Med, Kamigyo Ku, Kyoto 6028566, Japan; Jikei Univ, Sch Med, Dept Pediat, Minato Ku, Tokyo 1058461, Japan; Jikei Univ, Sch Med, Inst DNA Med, Minato Ku, Tokyo 1058461, Japan; Univ Tokyo, Inst Med Sci, Div Hematopoiet Factors, Minato Ku, Tokyo 1088639, Japan	Gunma Children's Medical Centre; Kyoto Prefectural University; Jikei University; Jikei University; University of Tokyo	Hayashi, Y (corresponding author), Gunma Childrens Med Ctr, Div Hematol Oncol, 799 Shimohakoda, Gunma 3778577, Japan.	hayashiy-tky@umin.ac.jp						Armstrong SA, 2002, NAT GENET, V30, P41, DOI 10.1038/ng765; BEVERLOO HB, 1995, CANCER RES, V55, P4220; Biondi A, 2000, BLOOD, V96, P24, DOI 10.1182/blood.V96.1.24; Bloomfield CD, 2002, GENE CHROMOSOME CANC, V33, P362, DOI 10.1002/gcc.10046; Chen AH, 2001, ARCH OTOLARYNGOL, V127, P921, DOI 10.1001/archotol.127.8.921; Chinwalla V, 2003, ONCOGENE, V22, P1400, DOI 10.1038/sj.onc.1206273; Crozet F, 1997, GENOMICS, V40, P332, DOI 10.1006/geno.1996.4526; Daser A, 2004, GENE DEV, V18, P965, DOI 10.1101/gad.1195504; DiMartino JF, 2002, BLOOD, V99, P3780, DOI 10.1182/blood.V99.10.3780; Eguchi M, 2004, BLOOD, V103, P3876, DOI 10.1182/blood-2003-11-3817; Fu JF, 2003, GENE CHROMOSOME CANC, V38, P253, DOI 10.1002/gcc.10272; GU Y, 1992, CELL, V71, P701, DOI 10.1016/0092-8674(92)90603-A; Hasson T, 1996, GENOMICS, V36, P431, DOI 10.1006/geno.1996.0488; Hayashi Y, 2000, SEMIN HEMATOL, V37, P368, DOI 10.1016/S0037-1963(00)90017-9; Hayashi Y, 2003, INT J HEMATOL, V78, P414, DOI 10.1007/BF02983813; Hiwatari M, 2003, ONCOGENE, V22, P2851, DOI 10.1038/sj.onc.1206389; Hsu K, 2003, CANCER CELL, V4, P81, DOI 10.1016/S1535-6108(03)00192-2; HUNGER SP, 1993, BLOOD, V81, P3197; Kawasaki H, 2001, BLOOD, V98, P3589, DOI 10.1182/blood.V98.13.3589; Kosaka Y, 2004, BLOOD, V104, P3527, DOI 10.1182/blood-2004-04-1390; Lamant L, 2003, GENE CHROMOSOME CANC, V37, P427, DOI 10.1002/gcc.10232; Lavau C, 1997, EMBO J, V16, P4226, DOI 10.1093/emboj/16.14.4226; Liu H, 2004, ONCOGENE, V23, P3385, DOI 10.1038/sj.onc.1207402; LIU P, 1993, SCIENCE, V261, P1041, DOI 10.1126/science.8351518; Look AT, 1997, SCIENCE, V278, P1059, DOI 10.1126/science.278.5340.1059; Luo RT, 2001, MOL CELL BIOL, V21, P5678, DOI 10.1128/MCB.21.16.5678-5687.2001; Martin ME, 2003, CANCER CELL, V4, P197, DOI 10.1016/S1535-6108(03)00214-9; Megonigal MD, 2000, P NATL ACAD SCI USA, V97, P9597, DOI 10.1073/pnas.150241797; MITANI K, 1995, BLOOD, V85, P2017, DOI 10.1182/blood.V85.8.2017.bloodjournal8582017; Nishioka M, 2002, P NATL ACAD SCI USA, V99, P12269, DOI 10.1073/pnas.192445899; Oliver TN, 1999, CELL MOL LIFE SCI, V56, P243, DOI 10.1007/s000180050426; Ono R, 2002, CANCER RES, V62, P333; Ono R, 2002, CANCER RES, V62, P4075; Rowley JD, 1998, ANNU REV GENET, V32, P495, DOI 10.1146/annurev.genet.32.1.495; Shibuya N, 2001, GENE CHROMOSOME CANC, V32, P1, DOI 10.1002/gcc.1160; Shilatifard A, 1996, SCIENCE, V271, P1873, DOI 10.1126/science.271.5257.1873; Slany RK, 1998, MOL CELL BIOL, V18, P122, DOI 10.1128/MCB.18.1.122; Slater DJ, 2002, ONCOGENE, V21, P4706, DOI 10.1038/sj.onc.1205572; So CW, 1997, P NATL ACAD SCI USA, V94, P2563, DOI 10.1073/pnas.94.6.2563; So CW, 2003, CANCER CELL, V4, P99, DOI 10.1016/S1535-6108(03)00188-0; So CW, 2002, MOL CELL BIOL, V22, P6542, DOI 10.1128/MCB.22.18.6542-6552.2002; Soldati T, 2003, TRAFFIC, V4, P358, DOI 10.1034/j.1600-0854.2003.t01-1-00095.x; Taketani T, 2004, BLOOD, V103, P1085, DOI 10.1182/blood-2003-02-0418; Taki T, 1996, ONCOGENE, V13, P2121; THIRMAN MJ, 1994, P NATL ACAD SCI USA, V91, P12110, DOI 10.1073/pnas.91.25.12110; TKACHUK DC, 1992, CELL, V71, P691, DOI 10.1016/0092-8674(92)90602-9; Tsutsumi S, 2003, CANCER RES, V63, P4882; ZIEMINVANDERPOEL S, 1991, P NATL ACAD SCI USA, V88, P10735, DOI 10.1073/pnas.88.23.10735	48	31	31	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2005	24	33					5191	5197		10.1038/sj.onc.1208711	http://dx.doi.org/10.1038/sj.onc.1208711			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	951XB	15897884				2022-12-17	WOS:000230964600005
J	Chen, LL; Sabripour, M; Wu, EF; Prieto, VG; Fuller, G; Frazier, ML				Chen, LL; Sabripour, M; Wu, EF; Prieto, VG; Fuller, G; Frazier, ML			A mutation-created novel intra-exonic pre-mRNA splice site causes constitutive activation of KIT in human gastrointestinal stromal tumors	ONCOGENE			English	Article						intra-exonic pre-mRNA splicing; aberrant pre-mRNA splicing; KIT mutation; KIT; gastrointestinal stromal tumor	RECEPTOR TYROSINE KINASE; OF-FUNCTION MUTATIONS; C-KIT; MISSENSE MUTATIONS; GENE; MECHANISM; NONSENSE; AUTOINHIBITION; INHIBITION; EXPRESSION	We report a new mechanism of aberrant pre-mRNA splicing resulting in constitutive activation of a mis-spliced oncoprotein (KIT) leading to malignancy(gastrointestinal stromal tumor) in contrast to loss of function of mis-spliced proteins resulting in diverse human diseases in the literature. The mechanisms of three consecutive molecular events, deletion of noncoding and coding regions encompassing the 30 authentic splice site, creation of a novel intra-exonic pre-mRNA 30 splice acceptor site leading to in-frame loss of 27 nucleotides ( nine amino acids; Lys550-Lys558), and the mechanism of constitutive activation of the mis-spliced KIT are elucidated. Loss of a peptide in a critical location unleashed the protein from autoinhibition ( as evidenced by three-dimensional structural analysis), causing KIT to become constitutively activated and resulting in the GIST phenotype. We also demonstrated that only one of the following two exonic splicing enhancers is sufficient for inclusion of the KIT exon 11 in vivo: AACCCATGT ( nucleotides 2 - 10 from the 50 end, which are recognized by SC35, SRp55, and SF2/ASF) or GGTTGTTGAGG ( nucleotides 27 - 37 from the 50 end, which are recognized by SC35 and SRp55), suggestive of exonic enhancer redundancy.	Univ Texas, MD Anderson Canc Ctr, Dept Sarcoma, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Epidemiol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA; Univ Texas, Grad Sch Biomed Sci, Program Human & Mol Genet, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System	Chen, LL (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Sarcoma, 1515 Holcombe Blvd, Houston, TX 77030 USA.	llchen@mdanderson.org	Pillay, Nischalan/F-9536-2012	Fuller, Gregory/0000-0001-9447-2647	NATIONAL CANCER INSTITUTE [R25CA057730, U01CA070172, P30CA016672] Funding Source: NIH RePORTER; NCI NIH HHS [U01-CA70172-01, R25 CA57730, CA16672, N0-CM-17003] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Allander SV, 2001, CANCER RES, V61, P8624; Aznarez I, 2003, HUM MOL GENET, V12, P2031, DOI 10.1093/hmg/ddg215; Black DL, 2003, ANNU REV BIOCHEM, V72, P291, DOI 10.1146/annurev.biochem.72.121801.161720; Buratti E, 2003, TRENDS MOL MED, V9, P229, DOI 10.1016/S1471-4914(03)00072-8; Cartegni L, 2002, NAT REV GENET, V3, P285, DOI 10.1038/nrg775; Cartegni L, 2003, NUCLEIC ACIDS RES, V31, P3568, DOI 10.1093/nar/gkg616; Chang PM, 2003, MOL CELL BIOL, V23, P3067, DOI 10.1128/MCB.23.9.3067-3078.2003; Chen LL, 2004, CANCER RES, V64, P5913, DOI 10.1158/0008-5472.CAN-04-0085; Colapietro P, 2003, HUM GENET, V113, P551, DOI 10.1007/s00439-003-1009-2; Corless CL, 2004, J MOL DIAGN, V6, P366, DOI 10.1016/S1525-1578(10)60533-8; CROSIER PS, 1993, BLOOD, V82, P1151; Di Blasi C, 2001, BRAIN, V124, P698, DOI 10.1093/brain/124.4.698; Goldstrohm AC, 2001, GENE, V277, P31, DOI 10.1016/S0378-1119(01)00695-3; Gorlov IP, 2003, AM J HUM GENET, V73, P1157, DOI 10.1086/378819; Graveley BR, 2002, CELL, V109, P409, DOI 10.1016/S0092-8674(02)00750-X; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Hammes A, 2001, CELL, V106, P319, DOI 10.1016/S0092-8674(01)00453-6; Harland M, 2001, HUM MOL GENET, V10, P2679, DOI 10.1093/hmg/10.23.2679; Heinrich MC, 2003, SCIENCE, V299, P708, DOI 10.1126/science.1079666; Heinrich MC, 2003, J CLIN ONCOL, V21, P4342, DOI 10.1200/JCO.2003.04.190; Hirota S, 1998, SCIENCE, V279, P577, DOI 10.1126/science.279.5350.577; Hirota S, 2003, GASTROENTEROLOGY, V125, P660, DOI 10.1016/S0016-5085(03)01046-1; Isozaki K, 2000, AM J PATHOL, V157, P1581, DOI 10.1016/S0002-9440(10)64795-5; Jurica MS, 2003, MOL CELL, V12, P5, DOI 10.1016/S1097-2765(03)00270-3; Kinoshita K, 2003, J GASTROEN HEPATOL, V18, P147, DOI 10.1046/j.1440-1746.2003.02911.x; Koh JS, 2004, HISTOL HISTOPATHOL, V19, P565, DOI 10.14670/HH-19.565; Ladd AN, 2002, GENOME BIOL, V3; Liu HX, 2001, NAT GENET, V27, P55, DOI 10.1038/83762; Ma YS, 1999, J BIOL CHEM, V274, P13399, DOI 10.1074/jbc.274.19.13399; Modrek B, 2002, NAT GENET, V30, P13, DOI 10.1038/ng0102-13; Mol CD, 2004, J BIOL CHEM, V279, P31655, DOI 10.1074/jbc.M403319200; Namour F, 2003, BRIT J HAEMATOL, V123, P915, DOI 10.1046/j.1365-2141.2003.04685.x; NELSON KK, 1990, P NATL ACAD SCI USA, V87, P6253, DOI 10.1073/pnas.87.16.6253; Pagani F, 2002, NAT GENET, V30, P426, DOI 10.1038/ng858; Pagani F, 2004, NAT REV GENET, V5, P389, DOI 10.1038/nrg1327; Roca X, 2003, NUCLEIC ACIDS RES, V31, P6321, DOI 10.1093/nar/gkg830; Sandberg AA, 2002, CANCER GENET CYTOGEN, V135, P1, DOI 10.1016/S0165-4608(02)00546-0; Smith CWJ, 2000, TRENDS BIOCHEM SCI, V25, P381, DOI 10.1016/S0968-0004(00)01604-2; Sommer G, 2003, P NATL ACAD SCI USA, V100, P6706, DOI 10.1073/pnas.1037763100; Syrris P, 2002, HUM MUTAT, V20, DOI 10.1002/humu.9057; Taniguchi M, 1999, CANCER RES, V59, P4297; Wagner EJ, 2001, MOL CELL BIOL, V21, P3281, DOI 10.1128/MCB.21.10.3281-3288.2001; ZHU WM, 1994, LEUKEMIA LYMPHOMA, V12, P441, DOI 10.3109/10428199409073786	43	31	32	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 16	2005	24	26					4271	4280		10.1038/sj.onc.1208587	http://dx.doi.org/10.1038/sj.onc.1208587			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	935WY	15824741				2022-12-17	WOS:000229815300010
J	Nonaka, M; Horie, R; Itoh, K; Watanabe, T; Yamamoto, N; Yamaoka, S				Nonaka, M; Horie, R; Itoh, K; Watanabe, T; Yamamoto, N; Yamaoka, S			Aberrant NF-kappa B2/p52 expression in Hodgkin/Reed-Sternberg cells and CD30-transformed rat fibroblasts	ONCOGENE			English	Article						Hodgkin/Reed-Sternberg cells; CD30; NF-kappa B2; IKK	NF-KAPPA-B; DISEASE TUMOR-CELLS; SIGNAL-TRANSDUCTION; GENE-EXPRESSION; LATENT MEMBRANE-PROTEIN-1; CONSTITUTIVE ACTIVATION; KINASE-ACTIVITY; LEUKEMIA-VIRUS; LYMPHOMA; P100	Overexpression of CD30 and constitutive nuclear factor-kappa B (NF-kappa B) activation are hallmarks of the malignant Hodgkin Reed-Sternberg (H-RS) cells. Previous investigations have demonstrated that both proliferation and survival of H-RS cells require constitutive NF-kappa B activity, which is comprised of the p50 and RekA subunits. We report here enhanced expression of NF-kappa B2/p52 and ReIB-containing NF-kappa B DNA-binding activity in Epstein-Barr virus-negative H-RS cells. Kinetic studies revealed that a proteasome inhibitor MG132 induced p100 accumulation with reduced p52 expression in H-RS cells, suggesting proteasome-dependent processing of p100. In addition, treatment with a protein synthesis inhibitor cycloheximide rapidly downregulated inhibitor of NF-kappa B (I kappa B) kinase activity in H-RS cells. We also demonstrate that overexpression of CD30 in rat fibroblasts at levels comparable to those in H-RS cells results in constitutive I kappa B kinase activation, proteasome-dependent p100 processing, and NF-kappa B-dependent cell transformation. Our results thus indicate that CD30 triggers the noncanonical NF-kappa B activation pathway, and suggest that deregulated CD30 signaling contributes to the neoplastic features of H-RS cells.	Tokyo Med & Dent Univ, Grad Sch Med, Dept Mol Virol, Tokyo 1138510, Japan; Kitasato Univ, Sch Med, Dept Internal Med 4, Kanagawa, Japan; Toho Univ, Sch Med, Dept Pathol 2, Tokyo, Japan; Univ Tokyo, Inst Med Sci, Dept Canc Res, Div Pathol, Tokyo, Japan	Tokyo Medical & Dental University (TMDU); Kitasato University; Toho University; University of Tokyo	Yamaoka, S (corresponding author), Tokyo Med & Dent Univ, Grad Sch Med, Dept Mol Virol, 1-5-45 Bunkyo Ku, Tokyo 1138510, Japan.	shojmmb@tmd.ac.jp						Annunziata CM, 2000, BLOOD, V96, P2841; Atkinson PGP, 2003, J BIOL CHEM, V278, P51134, DOI 10.1074/jbc.M304771200; Bargou RC, 1997, J CLIN INVEST, V100, P2961, DOI 10.1172/JCI119849; Barth TFE, 2003, BLOOD, V101, P3681, DOI 10.1182/blood-2002-08-2577; Ben-Neriah Y, 2004, EMBO REP, V5, P668, DOI 10.1038/sj.embor.7400187; Cabannes E, 1999, ONCOGENE, V18, P3063, DOI 10.1038/sj.onc.1202893; CARBONE A, 1995, BLOOD, V85, P780, DOI 10.1182/blood.V85.3.780.bloodjournal853780; Chen LF, 2004, NAT REV MOL CELL BIO, V5, P392, DOI 10.1038/nrm1368; Chinanonwait N, 2002, FEBS LETT, V531, P553, DOI 10.1016/S0014-5793(02)03618-9; Claudio E, 2002, NAT IMMUNOL, V3, P958, DOI 10.1038/ni842; Cogswell PC, 2000, ONCOGENE, V19, P1123, DOI 10.1038/sj.onc.1203412; Coope HJ, 2002, EMBO J, V21, P5375, DOI 10.1093/emboj/cdf542; Dejardin E, 1999, ONCOGENE, V18, P2567, DOI 10.1038/sj.onc.1202599; Dejardin E, 2002, IMMUNITY, V17, P525, DOI 10.1016/S1074-7613(02)00423-5; Derudder E, 2003, J BIOL CHEM, V278, P23278, DOI 10.1074/jbc.M300106200; Eliopoulos AG, 2003, ONCOGENE, V22, P7557, DOI 10.1038/sj.onc.1207120; Emmerich F, 2003, J PATHOL, V201, P413, DOI 10.1002/path.1454; Fiumara P, 2001, BLOOD, V98, P2784, DOI 10.1182/blood.V98.9.2784; Hanada K, 1996, J LEUKOCYTE BIOL, V60, P181, DOI 10.1002/jlb.60.2.181; Hinz M, 2002, J EXP MED, V196, P605, DOI 10.1084/jem.20020062; Hironaka N, 2004, NEOPLASIA, V6, P266, DOI 10.1593/neo.03388; Horie R, 2004, CANCER CELL, V5, P353, DOI 10.1016/S1535-6108(04)00084-4; Horie R, 2003, INT J HEMATOL, V77, P37, DOI 10.1007/BF02982601; Horie R, 2002, ONCOGENE, V21, P2493, DOI 10.1038/sj.onc.1205337; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Hubinger G, 2004, EXP HEMATOL, V32, P382, DOI 10.1016/j.exphem.2004.01.003; Joos S, 2002, BLOOD, V99, P1381, DOI 10.1182/blood.V99.4.1381; Kawakami Y, 1997, P NATL ACAD SCI USA, V94, P3938, DOI 10.1073/pnas.94.8.3938; Kayagaki N, 2002, IMMUNITY, V17, P515, DOI 10.1016/S1074-7613(02)00425-9; Krappmann D, 1999, ONCOGENE, V18, P943, DOI 10.1038/sj.onc.1202351; Kuppers R, 2003, J CLIN INVEST, V111, P529, DOI 10.1172/JC1200316624; Li QT, 2002, NAT REV IMMUNOL, V2, P725, DOI 10.1038/nri910; Liao GX, 2004, J BIOL CHEM, V279, P26243, DOI 10.1074/jbc.M403286200; Makris C, 2002, MOL CELL BIOL, V22, P6573, DOI 10.1128/MCB.22.18.6573-6581.2002; Martin-Subero JI, 2002, BLOOD, V99, P1474, DOI 10.1182/blood.V99.4.1474; Mathas S, 2003, BLOOD, V102, P1028, DOI 10.1182/blood-2002-04-1154; Mori N, 2000, BLOOD, V95, P3915; Morita S, 2000, GENE THER, V7, P1063, DOI 10.1038/sj.gt.3301206; Muller JR, 2003, J BIOL CHEM, V278, P12006, DOI 10.1074/jbc.M210768200; MUNOZ E, 1994, J VIROL, V68, P8035; Novack DV, 2003, J EXP MED, V198, P771, DOI 10.1084/jem.20030116; Opat S, 2001, AUTOIMMUNITY, V33, P45, DOI 10.3109/08916930108994109; Saito N, 2003, J BIOL CHEM, V278, P46565, DOI 10.1074/jbc.M302549200; Saitoh T, 2003, J BIOL CHEM, V278, P36005, DOI 10.1074/jbc.M304266200; Schneider C, 2002, LEUKEMIA LYMPHOMA, V43, P1355, DOI 10.1080/10428190290033288; Skinnider BF, 2002, BLOOD, V99, P4283, DOI 10.1182/blood-2002-01-0099; Solan NJ, 2002, J BIOL CHEM, V277, P1405, DOI 10.1074/jbc.M109619200; Stein H, 2000, BLOOD, V96, P3681; SUGAMURA K, 1984, INT J CANCER, V34, P221, DOI 10.1002/ijc.2910340213; Takahashi Y, 2001, J VIROL, V75, P6748, DOI 10.1128/JVI.75.15.6748-6757.2001; Thomas RK, 2004, LANCET ONCOL, V5, P11, DOI 10.1016/S1470-2045(03)01319-6; WHITESIDE ST, 1995, MOL CELL BIOL, V15, P5339; Xiao GT, 2001, EMBO J, V20, P6805, DOI 10.1093/emboj/20.23.6805; Yamaoka S, 1996, EMBO J, V15, P873, DOI 10.1002/j.1460-2075.1996.tb00422.x; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; Zheng B, 2003, BLOOD, V102, P1019, DOI 10.1182/blood-2002-11-3507	56	31	34	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 2	2005	24	24					3976	3986		10.1038/sj.onc.1208564	http://dx.doi.org/10.1038/sj.onc.1208564			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	930RY	15782119				2022-12-17	WOS:000229435300013
J	Sturniolo, MT; Chandraratna, RAS; Eckert, RL				Sturniolo, MT; Chandraratna, RAS; Eckert, RL			A novel transglutaminase activator forms a complex with type 1 transglutaminase	ONCOGENE			English	Article						involucrin; transglutaminase; TIG3; keratinocyte; epidermis	HUMAN EPIDERMAL-KERATINOCYTES; MEMBRANE ANCHORAGE REGION; TUMOR-SUPPRESSOR PROTEIN; INVOLUCRIN CROSS-LINKING; TISSUE TRANSGLUTAMINASE; CALCIUM-IONS; CORNIFIED ENVELOPE; GENE-EXPRESSION; CELL-DIFFERENTIATION; BARRIER FUNCTION	Type I transglutaminase is a plasma membrane-anchored intracellular protein-protein crosslinking enzyme that is responsible for assembly of the keratinocyte cornified envelope during terminal keratinocyte differentiation. We recently described a novel protein, TIG3, that when expressed in keratinocytes causes increased transglutaminase activity and keratinocyte cell death. However, the mechanism of activation of transglutaminase by TIG3 is not known. W e now extend our previous study and show that full-length TIG3 forms a complex with type I transglutaminase that is demonstrated by TIG3-transglutaminase co-precipitation. We also demonstrate that treating TIG3-expressing cells with monodansyl cadaverine, a competitive transglutaminase substrate, attenuates the TIG3-dependent response, suggesting that transglutaminase is an important mediator of TIG3 action. These findings suggest that TIG3 forms a complex with transglutaminase resulting in transglutaminase activation and that transglutaminase activity is required for the TIG3-dependent biological response.	Case Western Reserve Univ, Sch Med, Dept Physiol & Biophys, Cleveland, OH 44106 USA; Allergan Pharmaceut Inc, Retinoid Res, Dept Biol & Chem, Irvine, CA 92713 USA; Case Western Reserve Univ, Sch Med, Dept Dermatol, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Biochem, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Reprod Biol, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Oncol, Cleveland, OH 44106 USA	Case Western Reserve University; AbbVie; Allergan; Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; Case Western Reserve University	Eckert, RL (corresponding author), Case Western Reserve Univ, Sch Med, Dept Physiol & Biophys, Room E532,2109 Adelbert Rd, Cleveland, OH 44106 USA.	rle2@po.cwru.edu			NCI NIH HHS [P30 CA134274, P30 CA43703] Funding Source: Medline; NIAMS NIH HHS [AR39750] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA134274, P30CA043703] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P30AR039750] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Ahvazi B, 2003, EXP MOL MED, V35, P228, DOI 10.1038/emm.2003.31; Ahvazi B, 2003, J BIOL CHEM, V278, P23834, DOI 10.1074/jbc.M301162200; Ahvazi B, 2002, EMBO J, V21, P2055, DOI 10.1093/emboj/21.9.2055; BANKSSCHLEGEL S, 1981, J CELL BIOL, V90, P732, DOI 10.1083/jcb.90.3.732; Bikle DD, 2001, MOL CELL ENDOCRINOL, V177, P161, DOI 10.1016/S0303-7207(01)00452-X; Broome AM, 2004, J INVEST DERMATOL, V122, P29, DOI 10.1046/j.0022-202X.2003.22105.x; Candi E, 2004, BIOCHEM J, V381, P313, DOI 10.1042/BJ20031474; Casadio R, 1999, EUR J BIOCHEM, V262, P672, DOI 10.1046/j.1432-1327.1999.00437.x; CHAKRAVARTY R, 1990, BIOCHEM J, V271, P25, DOI 10.1042/bj2710025; CHAKRAVARTY R, 1989, J BIOL CHEM, V264, P625; CLINE PR, 1983, CANCER RES, V43, P3203; Dashti SR, 2001, J BIOL CHEM, V276, P27214, DOI 10.1074/jbc.M100465200; Dashti SR, 2001, J BIOL CHEM, V276, P8059, DOI 10.1074/jbc.C000862200; Deucher A, 2000, INT J ONCOL, V17, P1195; ECKERT RL, 1993, J INVEST DERMATOL, V100, P613, DOI 10.1111/1523-1747.ep12472288; ECKERT RL, 1989, PHYSIOL REV, V69, P1316, DOI 10.1152/physrev.1989.69.4.1316; Eckert RL, 1997, PHYSIOL REV, V77, P397, DOI 10.1152/physrev.1997.77.2.397; GOLDSMITH LA, 1975, J INVEST DERMATOL, V64, P316, DOI 10.1111/1523-1747.ep12512262; GORODESKI GI, 1990, J CLIN ENDOCR METAB, V70, P1624, DOI 10.1210/jcem-70-6-1624; Green H, 1980, Harvey Lect, V74, P101; GREEN H, 1982, MOL CELL BIOL, V2, P1115, DOI 10.1128/MCB.2.9.1115; GREENBERG CS, 1991, FASEB J, V5, P3071, DOI 10.1096/fasebj.5.15.1683845; HENNINGS H, 1981, BIOCHEM BIOPH RES CO, V102, P739, DOI 10.1016/S0006-291X(81)80194-5; HUBER M, 1995, SCIENCE, V267, P525, DOI 10.1126/science.7824952; Kalinin AE, 2002, BIOESSAYS, V24, P789, DOI 10.1002/bies.10144; KASTURI L, 1993, EXP CELL RES, V205, P84, DOI 10.1006/excr.1993.1061; KIM SY, 1995, J BIOL CHEM, V270, P18026, DOI 10.1074/jbc.270.30.18026; Kuramoto N, 2002, J CLIN INVEST, V109, P243, DOI 10.1172/JCI13563; LaCelle PT, 1998, SKIN PHARMACOL APPL, V11, P214, DOI 10.1159/000029830; Lambert A, 2000, SKIN PHARMACOL APPL, V13, P17, DOI 10.1159/000029905; LIEW FM, 1992, EXP CELL RES, V202, P310, DOI 10.1016/0014-4827(92)90080-R; Lorand L, 2003, NAT REV MOL CELL BIO, V4, P140, DOI 10.1038/nrm1014; Matsuki M, 1998, P NATL ACAD SCI USA, V95, P1044, DOI 10.1073/pnas.95.3.1044; MENON GK, 1985, J INVEST DERMATOL, V84, P508, DOI 10.1111/1523-1747.ep12273485; MICHEL S, 1992, J INVEST DERMATOL, V98, P364, DOI 10.1111/1523-1747.ep12499806; Nemes Z, 1999, EXP MOL MED, V31, P5, DOI 10.1038/emm.1999.2; Nemes Z, 1999, J BIOL CHEM, V274, P11013, DOI 10.1074/jbc.274.16.11013; Nemes Z, 1999, P NATL ACAD SCI USA, V96, P8402, DOI 10.1073/pnas.96.15.8402; OGAWA H, 1976, J BIOL CHEM, V251, P7281; Oliverio S, 1997, MOL CELL BIOL, V17, P6040, DOI 10.1128/MCB.17.10.6040; PHILLIPS MA, 1993, BIOCHEMISTRY-US, V32, P11057, DOI 10.1021/bi00092a015; Polakowska RR, 1999, J CELL BIOCHEM, V73, P355; RICE RH, 1977, CELL, V11, P417, DOI 10.1016/0092-8674(77)90059-9; RICE RH, 1990, BIOCHEM J, V265, P351, DOI 10.1042/bj2650351; RICE RH, 1979, CELL, V18, P681, DOI 10.1016/0092-8674(79)90123-5; Robinson NA, 1996, J INVEST DERMATOL, V107, P101, DOI 10.1111/1523-1747.ep12298323; Rossi A, 1998, J INVEST DERMATOL, V110, P34, DOI 10.1046/j.1523-1747.1998.00071.x; Singh US, 2003, J BIOL CHEM, V278, P391, DOI 10.1074/jbc.M206361200; Smethurst PA, 1996, BIOCHEM J, V313, P803, DOI 10.1042/bj3130803; Steinert PM, 1996, J BIOL CHEM, V271, P26242, DOI 10.1074/jbc.271.42.26242; Steinert PM, 1999, MOL BIOL CELL, V10, P4247, DOI 10.1091/mbc.10.12.4247; Sturniolo MT, 2003, J BIOL CHEM, V278, P48066, DOI 10.1074/jbc.M307215200; WERTZ PW, 1989, J INVEST DERMATOL, V92, P109, DOI 10.1111/1523-1747.ep13071317; Zhang JW, 1998, J BIOL CHEM, V273, P2288, DOI 10.1074/jbc.273.4.2288	54	31	31	2	11	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 21	2005	24	18					2963	2972		10.1038/sj.onc.1208392	http://dx.doi.org/10.1038/sj.onc.1208392			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	919WY	15846304				2022-12-17	WOS:000228649500005
J	Wang, YA; Zhang, ZQ; Lubet, R; You, M				Wang, YA; Zhang, ZQ; Lubet, R; You, M			Tobacco smoke-induced lung tumorigenesis in mutant A/J mice with alterations in K-ras, p53, or Ink4a/Arf	ONCOGENE			English	Article						tobacco smoke; A/J mice; transgene; lung tumorigenesis; K-ras; p53; Ink4a/Arf	CIGARETTE-SMOKE; P16(INK4A) INACTIVATION; PROTEIN ACCUMULATION; ONCOGENE ACTIVATION; CANCER; TUMORS; MUTATIONS; MOUSE; GENE; 4-(METHYLNITROSAMINO)-1-(3-PYRIDYL)-1-BUTANONE	A/J mice with genetic alterations in K-ras, p53, or Ink4a/Arf were employed to investigate whether mice carrying these germline mutations would be susceptible to tobacco smoke-induced lung tumorigenesis. Transgenic mice of both genders and their wild-type littermates were exposed to environmental cigarette smoke for 6 months, followed by recovery in air for 5 months. A significant increase of lung tumor multiplicity was observed in K-ras, p53, or Ink4a/Arf mutant mice when compared with wild-type mice. Furthermore, an additive effect was observed between the mice with a mutant p53 transgene and an Ink4A/Arf deletion during tobacco smoke-induced lung tumorigenesis. Sequence analysis of the K-ras gene indicated that the mutations had occurred at either codon 12/13 or 61 in both spontaneously occurring (air control) and tobacco smoke-induced lung tumors. K-ras mutations were found in 62% of the tumors from air-control animals and 83% in those exposed to tobacco smoke. The mutation spectrum found in tumors from mice exposed to tobacco smoke is somewhat similar to that in tumors from air-control mice. In addition, we identified three novel mutations at codon 12: GGT (Gly)-> TTT (Phe), ATT (Ile), and CTT (Leu). These findings provide evidence that K-ras, p53, and Ink4a/Arf mutations play a role in tobacco smoke-related lung carcinogenesis. The similarity of the mutation spectra in the K-ras oncogene observed in tobacco smoke-induced tumors, as compared to spontaneous tumors, suggests that tobacco smoke enhances lung tumorigenesis primarily through promoting spontaneously occurring K-ras mutations.	Washington Univ, Sch Med, Dept Surg, Siteman Canc Ctr, St Louis, MO 63110 USA; NCI, Rockville, MD 20892 USA	Siteman Cancer Center; Washington University (WUSTL); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	You, M (corresponding author), Washington Univ, Sch Med, Dept Surg, Siteman Canc Ctr, 660 S Euclid Ave, St Louis, MO 63110 USA.	youm@msnotes.wustl.edu			NATIONAL CANCER INSTITUTE [R01CA058554] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA58554, N01CN-35117] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bardeesy N, 2002, MOL CELL BIOL, V22, P635, DOI 10.1128/MCB.22.2.635-643.2002; CARBONE D, 1992, AM J MED, V93, P13; CHEN B, 1993, CARCINOGENESIS, V14, P1603, DOI 10.1093/carcin/14.8.1603; CHIBA I, 1990, ONCOGENE, V5, P1603; D'Agostini F, 2001, INT J ONCOL, V18, P607; De Flora S, 2003, CANCER RES, V63, P793; DEVEREUX TR, 1991, CARCINOGENESIS, V12, P299, DOI 10.1093/carcin/12.2.299; FONTANINI G, 1994, J PATHOL, V174, P23, DOI 10.1002/path.1711740105; Gazzeri S, 1998, ONCOGENE, V16, P497, DOI 10.1038/sj.onc.1201559; Hamada K, 1998, GENE CHROMOSOME CANC, V22, P232, DOI 10.1002/(SICI)1098-2264(199807)22:3<232::AID-GCC9>3.0.CO;2-X; Hecht SS, 1999, JNCI-J NATL CANCER I, V91, P1194, DOI 10.1093/jnci/91.14.1194; HERZOG CR, 1993, MOL CARCINOGEN, V8, P202, DOI 10.1002/mc.2940080311; Hursting SD, 2001, TOXICOL PATHOL, V29, P137, DOI 10.1080/019262301301418946; HUSGAFVELPURSIAINEN K, 1993, INT J CANCER, V53, P250, DOI 10.1002/ijc.2910530213; Hwang SJ, 2003, HUM GENET, V113, P238, DOI 10.1007/s00439-003-0968-7; Kamb A, 1994, Nat Genet, V8, P23; Kinoshita I, 1996, CANCER RES, V56, P5557; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; MARCHETTI A, 1993, CANCER RES, V53, P4665; MATZINGER SA, 1995, CARCINOGENESIS, V16, P2487, DOI 10.1093/carcin/16.10.2487; MERLO A, 1995, NAT MED, V1, P692; MINNA JD, 1993, CHEST S, V103, P449; RODENHUIS S, 1992, CANCER RES, V52, pS2665; RODENHUIS S, 1988, CANCER RES, V48, P5738; RODENHUIS S, 1990, AM REV RESPIR DIS, V142, P27; RONAI ZA, 1993, CARCINOGENESIS, V14, P2419, DOI 10.1093/carcin/14.11.2419; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHAPIRO GI, 1995, CANCER RES, V55, P6200; SLEBOS RJC, 1991, J NATL CANCER I, V83, P1024, DOI 10.1093/jnci/83.14.1024; SOZZI G, 1992, CANCER RES, V52, P6079; TAKAHASHI T, 1991, ONCOGENE, V6, P1775; TEAGUE SV, 1994, INHAL TOXICOL, V6, P79, DOI 10.3109/08958379409029697; TOP B, 1995, INT J CANCER, V64, P83, DOI 10.1002/ijc.2910640203; Wang XW, 1997, J CELL PHYSIOL, V173, P247, DOI 10.1002/(SICI)1097-4652(199711)173:2<247::AID-JCP30>3.0.CO;2-A; Wang Y, 2003, CANCER RES, V63, P4389; WIETHEGE T, 1995, J CANCER RES CLIN, V121, P371, DOI 10.1007/BF01225691; Witschi H, 2002, TOXICOL SCI, V68, P322, DOI 10.1093/toxsci/68.2.322; WITSCHI H, 1995, FUND APPL TOXICOL, V26, P32, DOI 10.1006/faat.1995.1072; Witschi H, 2000, EXP LUNG RES, V26, P743, DOI 10.1080/01902140150216792; You M, 1998, HEMATOL ONCOL CLIN N, V12, P1037, DOI 10.1016/S0889-8588(05)70040-X; YOU M, 1989, P NATL ACAD SCI USA, V86, P3070, DOI 10.1073/pnas.86.9.3070; YOU M, 1992, P NATL ACAD SCI USA, V89, P5804, DOI 10.1073/pnas.89.13.5804; Zhang ZQ, 2001, NAT GENET, V29, P25, DOI 10.1038/ng721; Zhang ZQ, 2003, P NATL ACAD SCI USA, V100, P12642, DOI 10.1073/pnas.2133947100; Zhang ZQ, 2000, CANCER RES, V60, P901; Zhang ZQ, 2002, CANCER RES, V62, P3024	46	31	32	2	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 21	2005	24	18					3042	3049		10.1038/sj.onc.1208390	http://dx.doi.org/10.1038/sj.onc.1208390			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	919WY	15846305				2022-12-17	WOS:000228649500013
J	Ingley, E; McCarthy, DJ; Pore, JR; Sarna, MK; Adenan, AS; Wright, MJ; Erber, W; Tilbrook, PA; Klinken, SP				Ingley, E; McCarthy, DJ; Pore, JR; Sarna, MK; Adenan, AS; Wright, MJ; Erber, W; Tilbrook, PA; Klinken, SP			Lyn deficiency reduces GATA-1, EKLF and STAT5, and induces extramedullary stress erythropoiesis	ONCOGENE			English	Article						erythropoiesis; erythropoietin; Lyn; STAT5; GATA-1; EKLF	TRANSCRIPTION FACTOR; DNA-BINDING; ERYTHROID-DIFFERENTIATION; TYROSINE PHOSPHORYLATION; CELL-LINES; PHOSPHATIDYLINOSITOL 3-KINASE; STAT5A(-/-)5B(-/-) MICE; RECEPTOR; PROLIFERATION; ACTIVATION	In vitro studies have implicated the Lyn tyrosine kinase in erythropoietin signaling. In this study, we show that J2E erythroid cells lacking Lyn have impaired signaling and reduced levels of transcription factors STAT5a, EKLF and GATA-1. Since mice lacking STAT5, EKLF or GATA-1 have red cell abnormalities, this study also examined the erythroid compartment of Lyn(-/-) mice. Significantly, STAT5, EKLF and GATA-1 levels were appreciably lower in Lyn(-/-) erythroblasts, and the phenotype of Lyn(-/-) animals was remarkably similar to GATA-1(low) animals. Although young adult Lyn-deficient mice had normal hematocrits, older mice developed anemia. Grossly enlarged erythroblasts and florid erythrophagocytosis were detected in the bone marrow of mice lacking Lyn. Markedly elevated erythroid progenitors and precursor levels were observed in the spleens, but not bone marrow, of Lyn(-/-) animals indicating that extramedullary erythropoiesis was occurring. These data indicate that Lyn(-/-) mice display extramedullary stress erythropoiesis to compensate for intrinsic and extrinsic erythroid defects.	Univ Western Australia, Western Australian Inst Med Res, Lab Canc Med, Perth, WA 6000, Australia; Univ Western Australia, Med Res Ctr, Perth, WA 6000, Australia; Univ Western Australia, Queen Elizabeth II Med Ctr, PathCtr, Nedlands, WA, Australia	University of Western Australia; University of Western Australia; University of Western Australia	Klinken, SP (corresponding author), Univ Western Australia, Western Australian Inst Med Res, Lab Canc Med, Level 6,MRF Bldg,Rear 50 Murray St, Perth, WA 6000, Australia.	pklinken@waimr.uwa.edu.au	Sarna, Mohinder/Q-7834-2016; Sarna, Mohinder/GYR-3271-2022; Sarna, Mohinder/AAO-9343-2020; Ingley, Evan/C-2401-2013	Sarna, Mohinder/0000-0002-2448-1588; Sarna, Mohinder/0000-0002-2448-1588; Ingley, Evan/0000-0002-8112-9134				Arai A, 2001, J BIOL CHEM, V276, P33282, DOI 10.1074/jbc.M102924200; Bao HF, 1999, BLOOD, V93, P3757, DOI 10.1182/blood.V93.11.3757.411a34_3757_3773; Bauer A, 1999, GENE DEV, V13, P2996, DOI 10.1101/gad.13.22.2996; Brunati AM, 2000, BLOOD, V96, P1550, DOI 10.1182/blood.V96.4.1550.h8001550_1550_1557; BUSFIELD SJ, 1992, BLOOD, V80, P412; CARROLL MP, 1991, J BIOL CHEM, V266, P14964; Chan VWF, 1997, IMMUNITY, V7, P69, DOI 10.1016/S1074-7613(00)80511-7; Chin H, 1998, BLOOD, V91, P3734; Coghill E, 2001, BLOOD, V97, P1861, DOI 10.1182/blood.V97.6.1861; Corey SJ, 1999, BLOOD, V93, P1, DOI 10.1182/blood.V93.1.1; DAMEN JE, 1993, BLOOD, V81, P3204; DAMEN JE, 1995, EMBO J, V14, P5557, DOI 10.1002/j.1460-2075.1995.tb00243.x; Gobert S, 1996, EMBO J, V15, P2434, DOI 10.1002/j.1460-2075.1996.tb00601.x; GOUILLEUX F, 1995, EMBO J, V14, P2005, DOI 10.1002/j.1460-2075.1995.tb07192.x; Gregory RC, 1998, BLOOD, V92, P1104, DOI 10.1182/blood.V92.4.1104.416k38_1104_1118; Harashima A, 2002, BLOOD, V100, P4440, DOI 10.1182/blood-2002-03-0864; Harder KW, 2001, IMMUNITY, V15, P603, DOI 10.1016/S1074-7613(01)00208-4; Heyworth C, 2002, EMBO J, V21, P3770, DOI 10.1093/emboj/cdf368; HIBBS ML, 1995, CELL, V83, P301, DOI 10.1016/0092-8674(95)90171-X; Ingley E, 2001, J BIOL CHEM, V276, P43428, DOI 10.1074/jbc.M106645200; Ingley E, 2000, J BIOL CHEM, V275, P7887, DOI 10.1074/jbc.275.11.7887; Iwatsuki K, 1997, J BIOL CHEM, V272, P8149, DOI 10.1074/jbc.272.13.8149; Kirito K, 1998, BLOOD, V92, P462, DOI 10.1182/blood.V92.2.462.414k15_462_471; Klingmuller U, 1996, P NATL ACAD SCI USA, V93, P8324, DOI 10.1073/pnas.93.16.8324; KLINKEN SP, 1988, P NATL ACAD SCI USA, V85, P8506, DOI 10.1073/pnas.85.22.8506; KLINKEN SP, 1987, J IMMUNOL, V139, P3091; KLINKEN SP, 1990, LEUKEMIA, V4, P24; KRYSTAL G, 1983, EXP HEMATOL, V11, P649; Kubota Y, 2001, EMBO J, V20, P5666, DOI 10.1093/emboj/20.20.5666; KULESSA H, 1995, GENE DEV, V9, P1250, DOI 10.1101/gad.9.10.1250; Lecoq-Lafon C, 1999, BLOOD, V93, P2578, DOI 10.1182/blood.V93.8.2578.408k24_2578_2585; McDevitt MA, 1997, P NATL ACAD SCI USA, V94, P6781, DOI 10.1073/pnas.94.13.6781; MCLEOD DL, 1974, BLOOD, V44, P517, DOI 10.1182/blood.V44.4.517.517; MILLER IJ, 1993, MOL CELL BIOL, V13, P2776, DOI 10.1128/MCB.13.5.2776; Neubauer H, 1998, CELL, V93, P397, DOI 10.1016/S0092-8674(00)81168-X; NISHIZUMI H, 1995, IMMUNITY, V3, P549, DOI 10.1016/1074-7613(95)90126-4; NUEZ B, 1995, NATURE, V375, P316, DOI 10.1038/375316a0; Oda A, 1998, BLOOD, V92, P443, DOI 10.1182/blood.V92.2.443.414k25_443_451; OHASHI T, 1995, BLOOD, V85, P1454, DOI 10.1182/blood.V85.6.1454.bloodjournal8561454; Okutani Y, 2001, ONCOGENE, V20, P6643, DOI 10.1038/sj.onc.1204807; Parganas E, 1998, CELL, V93, P385, DOI 10.1016/S0092-8674(00)81167-8; Penta K, 1995, J BIOL CHEM, V270, P31282, DOI 10.1074/jbc.270.52.31282; PERKINS AC, 1995, NATURE, V375, P318; PEVNY L, 1991, NATURE, V349, P257, DOI 10.1038/349257a0; RAMSAY RG, 1992, J BIOL CHEM, V267, P5656; Rylski M, 2003, MOL CELL BIOL, V23, P5031, DOI 10.1128/MCB.23.14.5031-5042.2003; Sarna MK, 2003, ONCOGENE, V22, P3221, DOI 10.1038/sj.onc.1206381; Satterthwaite AB, 1998, J EXP MED, V188, P833, DOI 10.1084/jem.188.5.833; Socolovsky M, 1999, CELL, V98, P181, DOI 10.1016/S0092-8674(00)81013-2; Socolovsky M, 2001, BLOOD, V98, P3261, DOI 10.1182/blood.V98.12.3261; Spadaccini A, 1998, J BIOL CHEM, V273, P23793, DOI 10.1074/jbc.273.37.23793; Teglund S, 1998, CELL, V93, P841, DOI 10.1016/S0092-8674(00)81444-0; Tilbrook PA, 1996, J BIOL CHEM, V271, P3453; Tilbrook PA, 1997, EMBO J, V16, P1610, DOI 10.1093/emboj/16.7.1610; Tilbrook PA, 2001, CANCER RES, V61, P2453; Tilbrook PA, 1996, CELL GROWTH DIFFER, V28, P175; TSAI SF, 1989, NATURE, V339, P446, DOI 10.1038/339446a0; Vannucchi AM, 2001, BLOOD, V97, P3040, DOI 10.1182/blood.V97.10.3040; WAKAO H, 1995, EMBO J, V14, P2527, DOI 10.1002/j.1460-2075.1995.tb07250.x; WEISS MJ, 1994, GENE DEV, V8, P1184, DOI 10.1101/gad.8.10.1184; Whyatt D, 2000, NATURE, V406, P519, DOI 10.1038/35020086; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; WU H, 1995, CELL, V83, P59, DOI 10.1016/0092-8674(95)90234-1; Yamaguchi Y, 1998, BLOOD, V91, P450, DOI 10.1182/blood.V91.2.450.450_450_457	64	31	34	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 13	2005	24	3					336	343		10.1038/sj.onc.1208199	http://dx.doi.org/10.1038/sj.onc.1208199			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	887CH	15516974				2022-12-17	WOS:000226279700005
J	Lim, MA; Yang, L; Zheng, Y; Wu, H; Dong, LQ; Liu, F				Lim, MA; Yang, L; Zheng, Y; Wu, H; Dong, LQ; Liu, F			Roles of PDK-1 and PKN in regulating cell migration and cortical actin formation of PTEN-knockout cells	ONCOGENE			English	Article						PTEN; cortical actin; Rho; Rac; PKN; PDK-1; cell migration	TUMOR-SUPPRESSOR GENE; PROTEIN-KINASE-C; ZIPPER-LIKE SEQUENCES; PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHOINOSITIDE 3-KINASE; CATALYTIC DOMAIN; PUTATIVE TARGET; PROSTATE-CANCER; HUMAN BRAIN; ACTIVATION	Mutations in the tumor suppressor protein PTEN (phosphatase and tensin homologue deleted on chromosome 10) enhance cell migration, yet the underlying molecular mechanisms remain largely uncharacterized. Loss of PTEN in mouse embryonic fibroblasts (MEFs) correlates with striking cortical actin accumulation. However, how loss of PTEN leads to cortical actin formation and whether the presence of cortical actin contributes to the increased cell migration are unclear. Here we show that overexpression of dominant-negative forms of (DN) PTEN, RhoA or its kinase-dead (KD) effector, PKN, inhibited cortical actin formation, indicating that cortical actin of Pten(-/-) MEFs is mediated by the PTEN/Rho/PKN pathway. However, neither DN RhoA nor KD PKN inhibited the enhanced migration of Pten(-/-) cells, in contrast to the inhibitory effect of DN Rac. In agreement with the previous observation that DN Akt inhibits migration of Pten(-/-) cells, we demonstrate here that overexpression of KD PDK-1, the Akt kinase, reduces Pten(-/-) cell migration. Furthermore, overexpression of DN forms of Akt, Rac, or PDK-1, all of which inhibit migration of Pten(-/-) cells, had no effect on cortical actin accumulation. Our findings suggest that PDK-1/Akt signaling pathway plays a major role in regulating cell migration induced by PTEN deficiency.	Univ Texas, Hlth Sci Ctr, Dept Pharmacol, San Antonio, TX 78229 USA; Childrens Hosp Res Fdn, Div Expt Hematol, Cincinnati, OH 45229 USA; Univ Calif Los Angeles, Sch Med, Dept Mol & Med Pharmacol, Los Angeles, CA USA; Univ Texas, Hlth Sci Ctr, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA; Univ Texas, Hlth Sci Ctr, Dept Biochem, San Antonio, TX 78229 USA	University of Texas System; University of Texas Health San Antonio; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation; University System of Ohio; University of Cincinnati; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio	Liu, F (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Pharmacol, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.	liuf@uthscsa.edu	Zheng, Yi/J-7235-2015	Zheng, Yi/0000-0001-7089-6074	NIDDK NIH HHS [DK56166] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK056166] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alessi DR, 1997, CURR BIOL, V7, P776, DOI 10.1016/S0960-9822(06)00336-8; Amano M, 1996, SCIENCE, V271, P648, DOI 10.1126/science.271.5249.648; Amano M, 1997, SCIENCE, V275, P1308, DOI 10.1126/science.275.5304.1308; Anderson KE, 1998, CURR BIOL, V8, P684, DOI 10.1016/S0960-9822(98)70274-X; Balendran A, 1999, CURR BIOL, V9, P393, DOI 10.1016/S0960-9822(99)80186-9; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARSAGI D, 1986, SCIENCE, V233, P1061, DOI 10.1126/science.3090687; BERNARD O, 1994, CELL GROWTH DIFFER, V5, P1159; Burridge K, 2004, CELL, V116, P167, DOI 10.1016/S0092-8674(04)00003-0; Cairns P, 1998, ONCOGENE, V16, P3215, DOI 10.1038/sj.onc.1201855; Celebi JT, 2000, J MED GENET, V37, P653, DOI 10.1136/jmg.37.9.653; Dahia PLM, 2000, ENDOCR-RELAT CANCER, V7, P115, DOI 10.1677/erc.0.0070115; Davies MA, 2002, CLIN CANCER RES, V8, P1904; Dong LQ, 1999, J BIOL CHEM, V274, P8117, DOI 10.1074/jbc.274.12.8117; Dong LQ, 2000, P NATL ACAD SCI USA, V97, P5089, DOI 10.1073/pnas.090491897; Filippa N, 2000, MOL CELL BIOL, V20, P5712, DOI 10.1128/MCB.20.15.5712-5721.2000; Frame MC, 2002, CURR OPIN GENET DEV, V12, P36, DOI 10.1016/S0959-437X(01)00261-1; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Furnari FB, 1997, P NATL ACAD SCI USA, V94, P12479, DOI 10.1073/pnas.94.23.12479; Hahn M, 1999, CLIN CANCER RES, V5, P2431; Han JW, 1998, SCIENCE, V279, P558, DOI 10.1126/science.279.5350.558; Higuchi M, 2001, CURR BIOL, V11, P1958, DOI 10.1016/S0960-9822(01)00599-1; Hwang PH, 2001, CANCER LETT, V172, P83, DOI 10.1016/S0304-3835(01)00632-2; Lemmon MA, 2000, BIOCHEM J, V350, P1, DOI 10.1042/0264-6021:3500001; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Li R, 1999, J BIOL CHEM, V274, P29648, DOI 10.1074/jbc.274.42.29648; Liliental J, 2000, CURR BIOL, V10, P401, DOI 10.1016/S0960-9822(00)00417-6; Lu Y, 1999, GENE DEV, V13, P1168, DOI 10.1101/gad.13.9.1168; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Maruta H, 1999, MICROSC RES TECHNIQ, V47, P61; Mertens F, 1997, CANCER RES, V57, P2765; MUKAI H, 1994, BIOCHEM BIOPH RES CO, V199, P897, DOI 10.1006/bbrc.1994.1313; MUKAI H, 1994, BIOCHEM BIOPH RES CO, V204, P348, DOI 10.1006/bbrc.1994.2466; MUSACCHIO A, 1993, TRENDS BIOCHEM SCI, V18, P343, DOI 10.1016/0968-0004(93)90071-T; Nakanishi K, 1999, CLIN EXP METASTAS, V17, P507, DOI 10.1023/A:1006685218766; NOBES CD, 1995, J CELL SCI, V108, P225; Ojaniemi M, 1997, J BIOL CHEM, V272, P25993, DOI 10.1074/jbc.272.41.25993; PALMER RH, 1995, EUR J BIOCHEM, V227, P344, DOI 10.1111/j.1432-1033.1995.tb20395.x; Raftopoulou M, 2004, DEV BIOL, V265, P23, DOI 10.1016/j.ydbio.2003.06.003; Rameh LE, 1999, J BIOL CHEM, V274, P8347, DOI 10.1074/jbc.274.13.8347; Reid T, 1996, J BIOL CHEM, V271, P13556, DOI 10.1074/jbc.271.23.13556; Riento K, 2003, NAT REV MOL CELL BIO, V4, P446, DOI 10.1038/nrm1128; RIJKEN PJ, 1991, J CELL SCI, V100, P491; Risinger JI, 1997, CANCER RES, V57, P4736; Scita G, 2000, EMBO J, V19, P2393, DOI 10.1093/emboj/19.11.2393; Sliva D, 2002, J BIOL CHEM, V277, P3150, DOI 10.1074/jbc.M109579200; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710; Takahashi M, 1998, P NATL ACAD SCI USA, V95, P11566, DOI 10.1073/pnas.95.20.11566; Tsakiridis T, 1999, MICROSC RES TECHNIQ, V47, P79, DOI 10.1002/(SICI)1097-0029(19991015)47:2<79::AID-JEMT1>3.0.CO;2-S; Vanhaesebroeck B, 2001, ANNU REV BIOCHEM, V70, P535, DOI 10.1146/annurev.biochem.70.1.535; Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561; Vara JAF, 2004, CANCER TREAT REV, V30, P193, DOI 10.1016/j.ctrv.2003.07.007; Wang SI, 1997, CANCER RES, V57, P4183; Watanabe G, 1996, SCIENCE, V271, P645, DOI 10.1126/science.271.5249.645; WENNSTROM S, 1994, CURR BIOL, V4, P385, DOI 10.1016/S0960-9822(00)00087-7; Wick MJ, 2000, J BIOL CHEM, V275, P40400, DOI 10.1074/jbc.M003937200; Zeng X, 2002, CANCER RES, V62, P3538; Zheng DQ, 2000, J BIOL CHEM, V275, P24565, DOI 10.1074/jbc.M002646200	60	31	34	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 16	2004	23	58					9348	9358		10.1038/sj.onc.1208147	http://dx.doi.org/10.1038/sj.onc.1208147			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	880BT	15531926				2022-12-17	WOS:000225764100006
J	Mancini, A; Koch, A; Whetton, AD; Tamura, T				Mancini, A; Koch, A; Whetton, AD; Tamura, T			The M-CSF receptor substrate and interacting protein FMIP is governed in its subcellular localization by protein kinase C-mediated phosphorylation, and thereby potentiates M-CSF-mediated differentiation	ONCOGENE			English	Article						Fms tyrosine kinase; serine phosphorylation; nuclear localization signal; macrophage differentiation; M-CSF-mediated signaling	STIMULATING FACTOR-RECEPTOR; BINDING-SITE; ACTIVATION; MUTATION; MURINE; OSTEOPETROSIS; GRANULOCYTE; SIGNAL; ALPHA; CELLS	Macrophage colony-stimulating factor (M-CSF or CSF-1) and its cognate receptor, the tyrosine kinase c-fms, are essential for monocyte and macrophage development. We have recently identified an Fms-interacting protein (FMIP) that binds transiently to the cytoplasmic domain of activated Fms molecules and is phosphorylated on tyrosine by Fms tyrosine kinase. FMIP is a substrate not only for Fms but also for protein kinase C (PKC). Mutagenesis reveals that this occurs on serines 5 and 6. Adjacent to these sites is a nuclear localization signal (NLS). We show that this NLS is essential for the predominantly nuclear localization of FMIP. Generation of phosphomimetic substitutions on serine residues 5 and 6 confirms that PKC-mediated phosphorylation on this site leads to translocation of FMIP to the cytosol. Furthermore, the mutant FMIP (FMIPSS5,6AA) was detected abundantly in the nucleus even in the presence of activated PKCalpha. Wild-type FMIP and FMIPSS5,6AA inhibited M-CSF-mediated survival signaling, while FMIPSS5,6EE-expressing cells survived and differentiated into macrophages more efficiently than wild-type cells in the presence of M-CSF or TPA. We conclude M-CSF-mediated activation of PKCalpha can potentiate FMIP action to initiate survival/differentiation signaling.	Hannover Med Sch, Inst Biochem, D-30623 Hannover, Germany; Univ Manchester, Dept Biomol Sci, Manchester M60 1QD, Lancs, England; Univ Manchester, Christie Hosp, Fac Med, Manchester M20 9BX, Lancs, England	Hannover Medical School; University of Manchester; Christie NHS Foundation Trust; Christie Hospital; University of Manchester	Tamura, T (corresponding author), Hannover Med Sch, Inst Biochem, OE 4310,Carl Neuberg Str 1, D-30623 Hannover, Germany.	tamura.teruko@mh-hannover.de		WHETTON, ANTHONY D/0000-0002-1098-3878				Bourette RP, 1998, EMBO J, V17, P7273, DOI 10.1093/emboj/17.24.7273; Bourette RP, 1997, EMBO J, V16, P5880, DOI 10.1093/emboj/16.19.5880; COURTNEIDGE SA, 1993, EMBO J, V12, P943, DOI 10.1002/j.1460-2075.1993.tb05735.x; Dai XM, 2002, BLOOD, V99, P111, DOI 10.1182/blood.V99.1.111; DATTA R, 1992, BLOOD, V79, P904; Friedman AD, 2002, ONCOGENE, V21, P3377, DOI 10.1038/sj.onc.1205324; GLINIAK BC, 1990, CELL, V63, P1073, DOI 10.1016/0092-8674(90)90510-L; HEYWORTH CM, 1992, BLOOD, V80, P2230; MACIEJEWSKI PM, 1995, J BIOL CHEM, V270, P27661, DOI 10.1074/jbc.270.46.27661; Mancini A, 1997, ONCOGENE, V15, P1565, DOI 10.1038/sj.onc.1201518; Mancini A, 2002, J BIOL CHEM, V277, P14635, DOI 10.1074/jbc.M109214200; MARKS SC, 1976, J HERED, V67, P11, DOI 10.1093/oxfordjournals.jhered.a108657; MORRISON P, 1993, J BIOL CHEM, V268, P15536; NAKANO T, 1994, SCIENCE, V265, P1098, DOI 10.1126/science.8066449; Novak U, 1996, ONCOGENE, V13, P2607; Petrovick HS, 1998, MOL CELL BIOL, V18, P3915, DOI 10.1128/MCB.18.7.3915; Pierce A, 1998, J CELL BIOL, V140, P1511, DOI 10.1083/jcb.140.6.1511; REEDIJK M, 1992, EMBO J, V11, P1365, DOI 10.1002/j.1460-2075.1992.tb05181.x; Tagoh H, 2002, GENE DEV, V16, P1721, DOI 10.1101/gad.222002; Tamura T, 1999, ONCOGENE, V18, P6488, DOI 10.1038/sj.onc.1203062; TROULIARIS S, 1995, J VIROL, V69, P6010, DOI 10.1128/JVI.69.10.6010-6020.1995; VANDERGEER P, 1993, EMBO J, V12, P5161, DOI 10.1002/j.1460-2075.1993.tb06211.x; Wagner S, 2000, EXP CELL RES, V258, P204, DOI 10.1006/excr.2000.4925; WAYS DK, 1991, BLOOD, V78, P2633; WHETTON AD, 1994, J CELL BIOL, V125, P651, DOI 10.1083/jcb.125.3.651; XIE YG, 1993, HUM MOL GENET, V2, P1361; YOSHIDA H, 1990, NATURE, V345, P442, DOI 10.1038/345442a0; Zhang DE, 1996, CURR TOP MICROBIOL, V211, P137	28	31	33	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 26	2004	23	39					6581	6589		10.1038/sj.onc.1207841	http://dx.doi.org/10.1038/sj.onc.1207841			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	849IB	15221008				2022-12-17	WOS:000223530800005
J	Wada, O; Oishi, H; Takada, I; Yanagisawa, J; Yano, T; Kato, S				Wada, O; Oishi, H; Takada, I; Yanagisawa, J; Yano, T; Kato, S			RETRACTED: BRCA1 function mediates a TRAP/DRIP complex through direct interaction with TRAP220 (Retracted article. See vol. 33, pg. 804, 2014)	ONCOGENE			English	Article; Retracted Publication						BRCA1; TRAP220; breast cancer	ESTROGEN-RECEPTOR; NUCLEAR RECEPTOR; BREAST-CANCER; DNA-REPAIR; TRANSCRIPTIONAL ACTIVATION; OVARIAN-CANCER; PROTEIN; GENE; SUSCEPTIBILITY; COACTIVATOR	Breast cancer susceptibility gene 1 (BRCA1) is a tumor suppressor gene mutated in a high percentage of hereditary breast and ovarian cancers. The multifunctional BRCA1 protein acts on cell cycle control, exerting several highly specialized DNA repair processes through diverse domains. Gene regulation through its C-terminal domain (BRCT) is indispensable for BRCA1-mediated tumor suppression, suggesting the possibility that the BRCT domain interacts with co-regulator complexes. Using a biochemical approach with HeLa S3 nuclear extracts, we isolated BRCT-associated complexes and identified one of the purified components as TRAP220. We then performed interaction studies in vivo (co-immunoprecipitation) and in vitro (glutathione S-transferase pull-down assays) and showed that BRCT directly interacted with TRAP220. This in vitro interaction was completely abolished by BRCT point mutations typical of those found in patients with BRCA1 that lack transactivation function. BRCA1 transactivation function was dependent on TRAP220 expression level in a transient expression assay. Moreover, a cell survival assay showed that antisense TRAP220 expression to disrupt endogenous TRAP220 expression significantly reduced the survival rate potentiated by BRCA1 after DNA damage. These results suggested that a TRAP220 complex play an important role as putative co-activator complexes in BRCA1-mediated tumor suppression.	Univ Tokyo, Inst Mol & Cellular Biol, Bunkyo Ku, Tokyo 1130034, Japan; Univ Tokyo, Dept Obstet & Gynecol, Bunkyo Ku, Tokyo 1138655, Japan; Japan Sci & Technol, SORST, Kawaguchi, Saitama 3320012, Japan	University of Tokyo; University of Tokyo; Japan Science & Technology Agency (JST)	Yano, T (corresponding author), Univ Tokyo, Inst Mol & Cellular Biol, Bunkyo Ku, Yayoi 1-1-1, Tokyo 1130034, Japan.	uskato@mail.ecc.u-tokyo.ac.jp	Oishi, Hajime/GRX-5428-2022					Anderson SE, 1998, NAT GENET, V19, P254, DOI 10.1038/930; Bochar DA, 2000, CELL, V102, P257, DOI 10.1016/S0092-8674(00)00030-1; Callebaut I, 1997, FEBS LETT, V400, P25, DOI 10.1016/S0014-5793(96)01312-9; Cantor SB, 2001, CELL, V105, P149, DOI 10.1016/S0092-8674(01)00304-X; Chapman MS, 1996, NATURE, V382, P678, DOI 10.1038/382678a0; Fan S, 1999, SCIENCE, V284, P1354, DOI 10.1126/science.284.5418.1354; Fondell JD, 1996, P NATL ACAD SCI USA, V93, P8329, DOI 10.1073/pnas.93.16.8329; Fondell JD, 1999, P NATL ACAD SCI USA, V96, P1959, DOI 10.1073/pnas.96.5.1959; Freedman LP, 1999, CELL, V97, P5, DOI 10.1016/S0092-8674(00)80708-4; FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630; Greenman J, 1998, GENE CHROMOSOME CANC, V21, P244, DOI 10.1002/(SICI)1098-2264(199803)21:3<244::AID-GCC9>3.0.CO;2-#; Gu W, 1999, MOL CELL, V3, P97, DOI 10.1016/S1097-2765(00)80178-1; Humphrey JS, 1997, P NATL ACAD SCI USA, V94, P5820, DOI 10.1073/pnas.94.11.5820; Ito M, 1999, MOL CELL, V3, P361, DOI 10.1016/S1097-2765(00)80463-3; Kawai H, 2002, ONCOGENE, V21, P7730, DOI 10.1038/sj.onc.1205971; Kitagawa H, 2003, CELL, V113, P905, DOI 10.1016/S0092-8674(03)00436-7; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Miyake T, 2000, J BIOL CHEM, V275, P40169, DOI 10.1074/jbc.M007138200; Monteiro ANA, 1996, P NATL ACAD SCI USA, V93, P13595, DOI 10.1073/pnas.93.24.13595; Moynahan ME, 1999, MOL CELL, V4, P511, DOI 10.1016/S1097-2765(00)80202-6; Ohtake F, 2003, NATURE, V423, P545, DOI 10.1038/nature01606; Pao GM, 2000, P NATL ACAD SCI USA, V97, P1020, DOI 10.1073/pnas.97.3.1020; Rachez C, 1999, NATURE, V398, P824, DOI 10.1038/19783; Scully R, 1999, MOL CELL, V4, P1093, DOI 10.1016/S1097-2765(00)80238-5; Venkitaraman AR, 2002, CELL, V108, P171, DOI 10.1016/S0092-8674(02)00615-3; Watanabe M, 2001, EMBO J, V20, P1341, DOI 10.1093/emboj/20.6.1341; Yanagisawa J, 2002, MOL CELL, V9, P553, DOI 10.1016/S1097-2765(02)00478-1; Yarden RI, 1999, P NATL ACAD SCI USA, V96, P4983, DOI 10.1073/pnas.96.9.4983; Yu X, 1998, J BIOL CHEM, V273, P25388, DOI 10.1074/jbc.273.39.25388; Zhang HB, 1998, ONCOGENE, V16, P1713, DOI 10.1038/sj.onc.1201932; Zheng L, 2001, P NATL ACAD SCI USA, V98, P9587, DOI 10.1073/pnas.171174298; Zhong Q, 1999, SCIENCE, V285, P747, DOI 10.1126/science.285.5428.747; Zhu YJ, 1999, P NATL ACAD SCI USA, V96, P10848, DOI 10.1073/pnas.96.19.10848	34	31	32	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 5	2004	23	35					6000	6005		10.1038/sj.onc.1207786	http://dx.doi.org/10.1038/sj.onc.1207786			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	841OV	15208681				2022-12-17	WOS:000222941100015
J	Duxbury, MS; Ito, H; Benoit, E; Zinner, MJ; Ashley, SW; Whang, EE				Duxbury, MS; Ito, H; Benoit, E; Zinner, MJ; Ashley, SW; Whang, EE			Overexpression of CEACAM6 promotes insulin-like growth factor I-induced pancreatic adenocarcinoma cellular invasiveness	ONCOGENE			English	Article						pancreatic adenocarcinoma; cancer; CEACAM6; insulin-like growth factor I; IGF-I invasion; Akt; Src; MMP-2	PAROXYSMAL-NOCTURNAL HEMOGLOBINURIA; TUMOR-NECROSIS-FACTOR; REACTING ANTIGEN NCA; FACTOR RECEPTOR; CANCER CELLS; CARCINOMA-CELLS; IGF-I; MATRIX METALLOPROTEINASE-2; ANTIBODY BY114; FAMILY-MEMBERS	Carcinoembryonic antigen-related cell adhesion molecule 6 (CEACAM6) is a glycosylphosphatidylinositol-linked immunoglobulin superfamily member that is overexpressed in a variety of human cancers. We have recently reported that suppression of CEACAM6 expression impairs pancreatic adenocarcinoma progression in vivo. In order to characterize the mechanisms through which CEACAM6 influences the malignant phenotype, CEA-CAM6-overexpressing Capan2 pancreatic adenocarcinoma cells were established by stable transfection. We determined the effect of CEACAM6 overexpression on cellular invasiveness towards insulin-like growth factor I (IGF-I), a peptide of critical importance in pancreatic cancer malignant cellular behavior and tumor progression. IGF-I-induced cellular invasiveness and IGF-IR expression were significantly increased in clones overexpressing CEACAM6. Using inhibitory anti-IGF-IR antibody, a requirement for IGF-IR signaling in the enhanced invasiveness towards IGF-I induced by CEACAM6 overexpression was confirmed. CEACAM6-overexpressing clones exhibited increased Akt and c-Src kinase activities, as well as higher levels of matrix metalloproteinase-2 (MMP-2) expression and activity in the presence of IGF-I. While Akt kinase is both necessary and sufficient to induce IGF-IR upregulation, c-Sre kinase activity is necessary, but alone is insufficient to upregulate IGF-IR expression. CEACAM6 is an important determinant of pancreatic adenocarcinoma malignant cellular behavior and, together with its downstream targets, warrants further investigation as a therapeutic target in this disease.	Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Surg, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School	Whang, EE (corresponding author), Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Surg, 75 Francis St, Boston, MA 02115 USA.	ewhang1@partners.org						BASERGA R, 1994, CELL PROLIFERAT, V27, P63, DOI 10.1111/j.1365-2184.1994.tb01406.x; BERGMANN U, 1995, CANCER RES, V55, P2007; BERROZPE G, 1994, INT J CANCER, V58, P185, DOI 10.1002/ijc.2910580207; Brodt P, 2001, J BIOL CHEM, V276, P33608, DOI 10.1074/jbc.M102754200; Burfeind P, 1996, P NATL ACAD SCI USA, V93, P7263, DOI 10.1073/pnas.93.14.7263; Datta K, 2000, J BIOL CHEM, V275, P20700, DOI 10.1074/jbc.M909970199; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; Dunn SE, 1998, CANCER RES, V58, P3353; Duxbury MS, 2004, ONCOGENE, V23, P465, DOI 10.1038/sj.onc.1207036; Ellenrieder V, 1999, ANN ONCOL, V10, P46, DOI 10.1023/A:1008380501633; Flossmann-Kast BBM, 1998, CANCER RES, V58, P3551; Gardner-Thorpe J, 2002, BIOCHEM BIOPH RES CO, V293, P391, DOI 10.1016/S0006-291X(02)00237-1; Guirouilh J, 2000, INT J ONCOL, V17, P777; HASEGAWA T, 1993, BRIT J CANCER, V67, P58, DOI 10.1038/bjc.1993.9; Ilantzis C, 2002, NEOPLASIA, V4, P151, DOI 10.1038/sj.neo.7900201; Ito H, 2003, SURGERY, V134, P221, DOI 10.1067/msy.2003.224; Jiang TY, 2003, J BIOL CHEM, V278, P15789, DOI 10.1074/jbc.M212525200; KALEKO M, 1990, MOL CELL BIOL, V10, P464, DOI 10.1128/MCB.10.2.464; KALTHOFF H, 1993, ONCOGENE, V8, P289; KLEINMAN HK, 1982, BIOCHEMISTRY-US, V21, P6188, DOI 10.1021/bi00267a025; KLEINMAN HK, 1986, BIOCHEMISTRY-US, V25, P312, DOI 10.1021/bi00350a005; KODERA Y, 1993, BRIT J CANCER, V68, P130, DOI 10.1038/bjc.1993.300; Kuroki M, 2001, J LEUKOCYTE BIOL, V70, P543; Lazar-Molnar E, 2000, CYTOKINE, V12, P547, DOI 10.1006/cyto.1999.0614; Li SL, 2000, CANCER IMMUNOL IMMUN, V49, P243, DOI 10.1007/s002620000115; LOHR M, 1994, BRIT J CANCER, V69, P144, DOI 10.1038/bjc.1994.24; Long L, 1998, CANCER RES, V58, P3243; LONG L, 1994, CANCER RES, V54, P3732; Long L, 1998, EXP CELL RES, V238, P116, DOI 10.1006/excr.1997.3814; MACAULAY VM, 1992, BRIT J CANCER, V65, P311, DOI 10.1038/bjc.1992.65; MAYNE KM, 1993, BRIT J HAEMATOL, V83, P30, DOI 10.1111/j.1365-2141.1993.tb04627.x; Mira E, 1999, ENDOCRINOLOGY, V140, P1657, DOI 10.1210/en.140.4.1657; Murphy LO, 2001, BRIT J CANCER, V84, P926, DOI 10.1054/bjoc.2001.1698; Naumann M, 1996, GASTROENTEROLOGY, V110, P1215, DOI 10.1053/gast.1996.v110.pm8613012; Ordonez C, 2000, CANCER RES, V60, P3419; Ouban A, 2003, HUM PATHOL, V34, P803, DOI 10.1016/S0046-8177(03)00291-0; Park BK, 2001, CANCER RES, V61, P7647; PIETRZKOWSKI Z, 1993, CANCER RES, V53, P1102; Prisco M, 1997, MOL CELL BIOL, V17, P1084, DOI 10.1128/MCB.17.3.1084; RAITANO AB, 1990, PANCREAS, V5, P267, DOI 10.1097/00006676-199005000-00005; RESNICOFF M, 1994, CANCER RES, V54, P2218; Scholzel S, 2000, AM J PATHOL, V156, P595, DOI 10.1016/S0002-9440(10)64764-5; SELL C, 1995, CANCER RES, V55, P303; Shanmugathasan M, 2000, PATHOL INT, V50, P273, DOI 10.1046/j.1440-1827.2000.01047.x; Sipos B, 2003, VIRCHOWS ARCH, V442, P444, DOI 10.1007/s00428-003-0784-4; SKUBITZ KM, 1995, J IMMUNOL, V155, P5382; Sonenberg N, 1998, CURR OPIN CELL BIOL, V10, P268, DOI 10.1016/S0955-0674(98)80150-6; STRACKE ML, 1989, J BIOL CHEM, V264, P21544; Streuli CH, 1999, J MAMMARY GLAND BIOL, V4, P183, DOI 10.1023/A:1018729308878; Tanno S, 2001, CANCER RES, V61, P589; Tooze JA, 1995, EXP HEMATOL, V23, P1484; Valentinis, 1997, BIOCHIM BIOPHYS ACTA, V1332, P105; Wu YL, 1996, J CELL PHYSIOL, V168, P499, DOI 10.1002/(SICI)1097-4652(199609)168:3<499::AID-JCP2>3.0.CO;2-K; Wu YP, 2002, CANCER RES, V62, P1030; Yawata A, 1998, ONCOGENE, V16, P2681, DOI 10.1038/sj.onc.1201792; Yoon A, 2001, MOL CELL BIOCHEM, V223, P1, DOI 10.1023/A:1017549222677; Zeng HY, 2003, BIOCHEM BIOPH RES CO, V302, P46, DOI 10.1016/S0006-291X(03)00107-4; Zhang DL, 2003, ONCOGENE, V22, P974, DOI 10.1038/sj.onc.1206197	58	31	33	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 29	2004	23	34					5834	5842		10.1038/sj.onc.1207775	http://dx.doi.org/10.1038/sj.onc.1207775			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	837KW	15208677				2022-12-17	WOS:000222629800013
J	Giampieri, S; Garcia-Escudero, R; Green, J; Storey, A				Giampieri, S; Garcia-Escudero, R; Green, J; Storey, A			Human papillomavirus type 77 E6 protein selectively inhibits p53-dependent transcription of proapoptotic genes following UV-B irradiation	ONCOGENE			English	Article						p53; apoptosis; transcriptional activation; HPV; UV-B	TUMOR-SUPPRESSOR PROTEIN; NONMELANOMA SKIN-CANCER; EPIDERMODYSPLASIA-VERRUCIFORMIS; P53-INDUCED APOPTOSIS; E6 PROTEINS; P53 MUTANTS; HPV TYPES; ACTIVATION; PROMOTERS; DEFINES	DNA damage, such as that elicited by UV-B, can induce either a cell cycle arrest or apoptosis that can be signalled by the p53 protein through the activation of a number of downstream cellular target genes. In contrast to oncogenic anogenital human papillomaviruses (HPVs), which mediate proteolytic degradation of p53, the E6 protein of cutaneous HPVs, such as HPV 77, do not promote p53 degradation. We have previously shown, however, that expression of HPV 77 E6 can effectively block UV-induced apoptosis in cells that have UY-activated p53. Here, we report that expression of the E6 protein from the cutaneous HPV 77 attenuates the UY-induced transactivation of p53-regulated proapoptotic genes Fas, PUMAbeta, Apaf-1, PIG3. This inhibition of p53-activation of proapoptotic genes by HPV77 E6 is exerted selectively, as the increased expression of p53 target genes involved in cell cycle arrest or regulatory functions regulation, such as p21 and Hdm2, is unaffected. Our data suggest that HPV 77 E6 may play an important role in specifically deregulating p53-dependent transactivation of proapoptotic genes upon UV-B irradiation.	Canc Res UK, Skin Tumour Lab, London E1 2AT, England	Cancer Research UK	Storey, A (corresponding author), Canc Res UK, Skin Tumour Lab, 2 Newark St, London E1 2AT, England.	alan.storey@cancer.org.uk	Garcia-Escudero, Ramon/A-2735-2012	Garcia-Escudero, Ramon/0000-0001-5640-6542; Storey, Alan/0000-0003-2001-9772; Giampieri, Silvia/0000-0001-5484-3140; Green, Judith/0000-0001-6825-9404				Appella E, 2001, EUR J BIOCHEM, V268, P2764, DOI 10.1046/j.1432-1327.2001.02225.x; Campomenosi P, 2001, ONCOGENE, V20, P3573, DOI 10.1038/sj.onc.1204468; de Villiers EM, 1999, SEMIN CANCER BIOL, V9, P413, DOI 10.1006/scbi.1999.0145; Delius H, 1998, VIROLOGY, V240, P359, DOI 10.1006/viro.1997.8943; Harwood CA, 2000, J MED VIROL, V61, P289, DOI 10.1002/1096-9071(200007)61:3&lt;289::AID-JMV2&gt;3.0.CO;2-Z; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Jackson S, 2000, GENE DEV, V14, P3065, DOI 10.1101/gad.182100; Jackson S, 2000, ONCOGENE, V19, P592, DOI 10.1038/sj.onc.1203339; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Ludwig RL, 1996, MOL CELL BIOL, V16, P4952; Malanchi I, 2002, ONCOGENE, V21, P5665, DOI 10.1038/sj.onc.1205617; Mantovani F, 2001, ONCOGENE, V20, P7874, DOI 10.1038/sj.onc.1204869; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Orth G, 2001, J VIROL, V75, P4952, DOI 10.1128/JVI.75.10.4952-4953.2001; ORTH G, 1986, CIBA F SYMP, V120, P157; Pluquet O, 2001, CANCER LETT, V174, P1, DOI 10.1016/S0304-3835(01)00698-X; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Purdie KJ, 1999, EMBO J, V18, P5359, DOI 10.1093/emboj/18.19.5359; Rapp B, 1997, J VIROL, V71, P6956, DOI 10.1128/JVI.71.9.6956-6966.1997; Rowan S, 1996, EMBO J, V15, P827, DOI 10.1002/j.1460-2075.1996.tb00418.x; Samuels-Lev Y, 2001, MOL CELL, V8, P781, DOI 10.1016/S1097-2765(01)00367-7; Scolnick DM, 1997, CANCER RES, V57, P3693; Sesto A, 2002, P NATL ACAD SCI USA, V99, P2965, DOI 10.1073/pnas.052678999; STEGER G, 1992, ARCH VIROL, V125, P355, DOI 10.1007/BF01309654; STOREY A, 1995, ONCOGENE, V11, P653; Storey A, 2002, TRENDS MOL MED, V8, P417, DOI 10.1016/S1471-4914(02)02387-0; Surentheran T, 1998, J CLIN PATHOL, V51, P606, DOI 10.1136/jcp.51.8.606; Vousden KH, 2002, BBA-REV CANCER, V1602, P47, DOI 10.1016/S0304-419X(02)00035-5; Wattre P, 1996, ANN BIOL CLIN-PARIS, V54, P189; Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097-2765(01)00213-1	32	31	33	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 29	2004	23	34					5864	5870		10.1038/sj.onc.1207711	http://dx.doi.org/10.1038/sj.onc.1207711			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	837KW	15077176				2022-12-17	WOS:000222629800017
J	Sgarbanti, M; Arguello, M; tenOever, BR; Battistini, A; Lin, RT; Hiscott, J				Sgarbanti, M; Arguello, M; tenOever, BR; Battistini, A; Lin, RT; Hiscott, J			A requirement for NF-kappa B induction in the production of replication-competent HHV-8 virions	ONCOGENE			English	Article						HHV8; NF-kappa B; herpesvirus; lytic infection	SARCOMA-ASSOCIATED HERPESVIRUS; PRIMARY EFFUSION LYMPHOMA; PROTEIN-COUPLED RECEPTOR; ENDOTHELIAL-CELLS; GENE-EXPRESSION; HUMAN-HERPESVIRUS-8 INFECTION; DNA-SEQUENCES; IKK-GAMMA; KINASE; ALPHA	The gammaherpesvirus human herpesvirus 8 (HHV-8) infects endothelial and B-lymphoid cells and is responsible for the development of Kaposi's sarcoma and primary effusion lymphoma (PEL). In the present study, we demonstrate that the activation of the NF-kappaB pathway during HHV-8 lytic replication is required for the generation of replication-competent virions capable of initiating a de novo infection of endothelial cells. In the HHV-8-positive PEL cell line BCBL-1, tetradecanoyl phorbol acetate (TPA) induction of the lytic cycle activates the NF-kappaB pathway, and this activation requires the induction of the IKKbeta component of the classical IkappaB kinase (IKK) complex. To further investigate the role of NF-kappaB activation in HHV-8 lytic replication, the NF-kappaB super-repressor IkappaBalpha-2NDelta4 was introduced into BCBL-1 cells by retroviral transduction. Expression of IkappaBalpha-2NDelta4 completely abolished NF-kappaB activity, as demonstrated by the loss of NF-kappaB DNA-binding activity and the absence of expression of the endogenous, NF-kappaB-regulated IkappaBalpha gene. NF-kappaB blockade dramatically impaired the ability of HHV-8 to produce infectious particles capable of initiating an effective de novo infection of endothelial EA.hy926 cells, as demonstrated by the lack of viral protein production in the target cells. Diminished infectivity did not appear to be caused by a reduction in virus titer, as demonstrated by equivalent viral DNA content in the supernatant of TPA-stimulated BCBL-1 and BCBL-1/2N4 cells. Although the viral and/or cellular products affected by NF-kappaB inactivation remain to be fully characterized, these data demonstrate an unexpected role for NF-kappaB induction during lytic reactivation in the production of replication-competent HHV-8 virions.	McGill Univ, Jewish Gen Hosp, Lady Davis Inst Med Res, Terry Fox Mol Oncol Grp, Montreal, PQ H3T 1E2, Canada; McGill Univ, Dept Microbiol, Montreal, PQ H3T 1E2, Canada; McGill Univ, Dept Immunol, Montreal, PQ H3T 1E2, Canada; McGill Univ, Dept Med, Montreal, PQ H3T 1E2, Canada; Ist Super Sanita, Virol Lab, I-00161 Rome, Italy	Lady Davis Institute; McGill University; McGill University; McGill University; McGill University; Istituto Superiore di Sanita (ISS)	Lin, RT (corresponding author), McGill Univ, Jewish Gen Hosp, Lady Davis Inst Med Res, Terry Fox Mol Oncol Grp, 3755 Cote Ste Catherine Rd, Montreal, PQ H3T 1E2, Canada.	john.hiscott@mcgill.ca	SGARBANTI, MARCO/C-2962-2016; Lin, Rongtuan/A-1442-2008; BATTISTINI, ANGELA/C-2944-2016	SGARBANTI, MARCO/0000-0002-0433-5110; Lin, Rongtuan/0000-0002-2238-3503; 				ANTOINE N, 1994, CANCER RES, V54, P2073; Arguello M, 2003, ONCOGENE, V22, P964, DOI 10.1038/sj.onc.1206270; Arvanitakis L, 1996, BLOOD, V88, P2648, DOI 10.1182/blood.V88.7.2648.bloodjournal8872648; Asou H, 1998, BLOOD, V91, P2475, DOI 10.1182/blood.V91.7.2475.2475_2475_2481; Bais C, 1998, NATURE, V391, P86, DOI 10.1038/34193; Beauparlant P, 1996, J BIOL CHEM, V271, P10690, DOI 10.1074/jbc.271.18.10690; Brown HJ, 2003, J VIROL, V77, P8532, DOI 10.1128/JVI.77.15.8532-8540.2003; Cannon M, 2003, J VIROL, V77, P57, DOI 10.1128/JVI.77.1.57-67.2003; Carbone A, 2000, LEUKEMIA, V14, P1301, DOI 10.1038/sj.leu.2401802; CESARMAN E, 1995, BLOOD, V86, P2708, DOI 10.1182/blood.V86.7.2708.bloodjournal8672708; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; Chatterjee M, 2002, SCIENCE, V298, P1432, DOI 10.1126/science.1074883; Chiou CJ, 2002, J VIROL, V76, P3421, DOI 10.1128/JVI.76.7.3421-3439.2002; Ciufo DM, 2001, J VIROL, V75, P5614, DOI 10.1128/JVI.75.12.5614-5626.2001; Curreli F, 2002, J VIROL, V76, P5208, DOI 10.1128/JVI.76.10.5208-5219.2002; Delhase M, 1999, SCIENCE, V284, P309, DOI 10.1126/science.284.5412.309; DiDonato J, 1996, MOL CELL BIOL, V16, P1295; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Drexler HG, 1998, LEUKEMIA, V12, P1507, DOI 10.1038/sj.leu.2401160; EDGELL CJ, 1983, P NATL ACAD SCI-BIOL, V80, P3734, DOI 10.1073/pnas.80.12.3734; Flore O, 1998, NATURE, V394, P588, DOI 10.1038/29093; Gaidano G, 1997, BLOOD, V89, P3755; Guo HG, 2003, J VIROL, V77, P2631, DOI 10.1128/JVI.77.4.2631-2639.2003; Gurer C, 2002, J VIROL, V76, P4666, DOI 10.1128/JVI.76.9.4666-4670.2002; Gwack Y, 2001, J VIROL, V75, P1909, DOI 10.1128/JVI.75.4.1909-1917.2001; Harhaj EW, 2000, ONCOGENE, V19, P1448, DOI 10.1038/sj.onc.1203445; Hiscott J, 2001, J CLIN INVEST, V107, P143, DOI 10.1172/JCI11918; Hu YL, 1999, SCIENCE, V284, P316, DOI 10.1126/science.284.5412.316; Ishii T, 2001, ONCOGENE, V20, P1900, DOI 10.1038/sj.onc.1204267; Jenner RG, 2001, J VIROL, V75, P891, DOI 10.1128/JVI.75.2.891-902.2001; Jones KD, 1999, BLOOD, V94, P2871; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Keller SA, 2000, BLOOD, V96, P2537; Kwon H, 1998, J BIOL CHEM, V273, P7431, DOI 10.1074/jbc.273.13.7431; Lagunoff M, 2002, J VIROL, V76, P2440, DOI 10.1128/JVI.76.5.2440-2448.2002; LEBAIL O, 1993, EMBO J, V12, P5043, DOI 10.1002/j.1460-2075.1993.tb06197.x; Lin RT, 2001, ONCOGENE, V20, P800, DOI 10.1038/sj.onc.1204163; Lin RT, 1996, MOL CELL BIOL, V16, P1401; Liu L, 2002, J BIOL CHEM, V277, P13745, DOI 10.1074/jbc.M110480200; Matolcsy A, 1998, AM J PATHOL, V153, P1609, DOI 10.1016/S0002-9440(10)65749-5; Means RE, 2002, EMBO J, V21, P1638, DOI 10.1093/emboj/21.7.1638; Miller G, 1997, J VIROL, V71, P314, DOI 10.1128/JVI.71.1.314-324.1997; Monini P, 1999, BLOOD, V93, P4044; Montaner S, 2001, CANCER RES, V61, P2641; Moore PS, 1996, J VIROL, V70, P549, DOI 10.1128/JVI.70.1.549-558.1996; Moses AV, 1999, J VIROL, V73, P6892, DOI 10.1128/JVI.73.8.6892-6902.1999; Nador RG, 1996, BLOOD, V88, P645, DOI 10.1182/blood.V88.2.645.bloodjournal882645; Nicholas J, 1997, J VIROL, V71, P1963, DOI 10.1128/JVI.71.3.1963-1974.1997; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Pati S, 2001, J VIROL, V75, P8660, DOI 10.1128/JVI.75.18.8660-8673.2001; Renne R, 1996, NAT MED, V2, P342, DOI 10.1038/nm0396-342; Rothwarf DM, 1998, NATURE, V395, P297, DOI 10.1038/26261; Sakurada S, 2001, J VIROL, V75, P7717, DOI 10.1128/JVI.75.16.7717-7722.2001; Sarid R, 1999, ADV VIRUS RES, V52, P139, DOI 10.1016/S0065-3527(08)60299-7; Schwarz M, 2001, J IMMUNOL, V167, P505, DOI 10.4049/jimmunol.167.1.505; Smit MJ, 2002, J VIROL, V76, P1744, DOI 10.1128/JVI.76.4.1744-1752.2002; SOULIER J, 1995, BLOOD, V86, P1276, DOI 10.1182/blood.V86.4.1276.bloodjournal8641276; Sun R, 1999, J VIROL, V73, P2232, DOI 10.1128/JVI.73.3.2232-2242.1999; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; Sun SC, 2000, AIDS RES HUM RETROV, V16, P1591, DOI 10.1089/08892220050193001; Webb JH, 1999, FEBS LETT, V444, P136, DOI 10.1016/S0014-5793(99)00025-3; Yang TY, 2000, J EXP MED, V191, P445, DOI 10.1084/jem.191.3.445; Yu YM, 1999, J GEN VIROL, V80, P83, DOI 10.1099/0022-1317-80-1-83; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7	64	31	32	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 29	2004	23	34					5770	5780		10.1038/sj.onc.1207707	http://dx.doi.org/10.1038/sj.onc.1207707			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	837KW	15235582				2022-12-17	WOS:000222629800006
J	Stove, C; Vanrobaeys, F; Devreese, B; Van Beeumen, J; Mareel, M; Bracke, M				Stove, C; Vanrobaeys, F; Devreese, B; Van Beeumen, J; Mareel, M; Bracke, M			Melanoma cells secrete follistatin, an antagonist of activin-mediated growth inhibition	ONCOGENE			English	Article						follistatin; activin; Smad; melanoma; growth; apoptosis	MESSENGER-RIBONUCLEIC-ACID; FOLLICULAR-FLUID; BINDING PROTEIN; FACTOR SYSTEM; FACTOR-BETA; EXPRESSION; MORPHOGENESIS; LINE; FSH; PROLIFERATION	Using a proteomic approach to screen for new growth factors released by melanoma cells, we identified follistatin as a major heparin-binding factor in medium conditioned by the Bowes melanoma cell line. Since follistatin is primarily studied in relation to its neutralization of activin, a member of the transforming growth factor-beta family of ligands, the expression and function of this receptor system was investigated in a panel of melanoma cell lines and melanocytes. All cell lines expressed activin receptors and showed phosphorylation of Smad signal transduction molecules upon treatment with activin. Secretion of follistatin, either native or after retroviral transduction, efficiently prevented Smad activation or activation of an activin-responsive luciferase reporter construct. In melanocytes, activin treatment led to growth inhibition and induction of apoptosis. These effects were counteracted by cotreatment with follistatin. In summary, we characterized the activin-activin receptor system in melanocytes and melanoma cell lines and found that secretion of follistatin by melanoma cells may represent an effective way to circumvent activin's negative regulatory effects.	Ghent Univ Hosp, Dept Radiotherapy & Nucl Med, Expt Cancerol Lab, B-9000 Ghent, Belgium; Univ Ghent, Lab Prot Biochem & Prot Engn, B-9000 Ghent, Belgium	Ghent University; Ghent University Hospital; Ghent University	Bracke, M (corresponding author), Ghent Univ Hosp, Dept Radiotherapy & Nucl Med, Expt Cancerol Lab, De Pintelaan 185, B-9000 Ghent, Belgium.	brackemarc@hotmail.com	Devreese, Bart/K-2841-2019; Stove, Christophe/B-6057-2008; Devreese, Bart/B-2011-2009	Devreese, Bart/0000-0002-9764-2581; Stove, Christophe/0000-0001-7126-348X; Devreese, Bart/0000-0002-9764-2581				Alanko T, 2000, J INVEST DERMATOL, V115, P286, DOI 10.1046/j.1523-1747.2000.00045.x; Ball EMA, 2001, DEV BIOL, V238, P1, DOI 10.1006/dbio.2001.0399; Bartkova J, 1996, CANCER RES, V56, P5475; Beer HD, 2000, J INVEST DERM SYMP P, V5, P34, DOI 10.1046/j.1087-0024.2000.00009.x; Berking C, 2001, CANCER RES, V61, P8306; Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; Chen YG, 2002, EXP BIOL MED, V227, P75, DOI 10.1177/153537020222700201; Cho SH, 2003, J IMMUNOL, V170, P4045, DOI 10.4049/jimmunol.170.8.4045; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Delbaere A, 1999, ENDOCRINOLOGY, V140, P2463, DOI 10.1210/en.140.6.2463; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Devreese B, 2002, J CHROMATOGR A, V976, P113, DOI 10.1016/S0021-9673(02)01153-6; deWinter JP, 1996, MOL CELL ENDOCRINOL, V116, P105, DOI 10.1016/0303-7207(95)03705-5; ESCH FS, 1987, MOL ENDOCRINOL, V1, P849, DOI 10.1210/mend-1-11-849; Gray PC, 2003, P NATL ACAD SCI USA, V100, P5193, DOI 10.1073/pnas.0531290100; Gullick WJ, 2001, BREAST CANCER RES, V3, P390, DOI 10.1186/bcr328; Gumienny TL, 2002, TRENDS ENDOCRIN MET, V13, P295, DOI 10.1016/S1043-2760(02)00615-X; Hager JW, 2002, RAPID COMMUN MASS SP, V16, P512, DOI 10.1002/rcm.607; Hashimoto O, 1997, J BIOL CHEM, V272, P13835, DOI 10.1074/jbc.272.21.13835; Hempen PM, 2003, CANCER RES, V63, P994; Innis CA, 2003, J BIOL CHEM, V278, P39969, DOI 10.1074/jbc.M211284200; INOUYE S, 1991, ENDOCRINOLOGY, V129, P815, DOI 10.1210/endo-129-2-815; Knight PG, 1996, FRONT NEUROENDOCRIN, V17, P476, DOI 10.1006/frne.1996.0013; Lazar-Molnar E, 2000, CYTOKINE, V12, P547, DOI 10.1006/cyto.1999.0614; LING N, 1986, NATURE, V321, P779, DOI 10.1038/321779a0; Liu QY, 1996, CANCER RES, V56, P1155; Luisi S, 2001, EUR J ENDOCRINOL, V145, P225, DOI 10.1530/eje.0.1450225; Massague J, 2000, GENE DEV, V14, P627; Meier F., 1998, FRONT BIOSCI J VIS L, V3, P1005, DOI [10.2741/a341, DOI 10.2741/A341]; MICHEL U, 1992, ENDOCRINOLOGY, V130, P3684, DOI 10.1210/en.130.6.3684; Munz B, 1999, EMBO J, V18, P5205, DOI 10.1093/emboj/18.19.5205; NAKAMURA T, 1990, SCIENCE, V247, P836, DOI 10.1126/science.2106159; Risbridger GP, 2001, ENDOCR REV, V22, P836, DOI 10.1210/er.22.6.836; ROBERTSON DM, 1987, BIOCHEM BIOPH RES CO, V149, P744, DOI 10.1016/0006-291X(87)90430-X; Rodeck U, 1999, CANCER RES, V59, P547; RODECK U, 1994, CANCER RES, V54, P575; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; Sandra K, 2004, J AM SOC MASS SPECTR, V15, P413, DOI 10.1016/j.jasms.2003.11.003; Schneyer AL, 1996, ENDOCRINOLOGY, V137, P240, DOI 10.1210/en.137.1.240; SCHNEYER AL, 1994, ENDOCRINOLOGY, V135, P667, DOI 10.1210/en.135.2.667; Shellman YG, 2000, J INVEST DERMATOL, V114, P1200, DOI 10.1046/j.1523-1747.2000.00988.x; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; SHIMASAKI S, 1988, P NATL ACAD SCI USA, V85, P4218, DOI 10.1073/pnas.85.12.4218; Sidis Y, 2002, ENDOCRINOLOGY, V143, P1613, DOI 10.1210/en.143.5.1613; Sidis Y, 2001, J BIOL CHEM, V276, P17718, DOI 10.1074/jbc.M100736200; Stove C, 2003, J INVEST DERMATOL, V121, P802, DOI 10.1046/j.1523-1747.2003.12522.x; Stove V, 2003, BLOOD, V102, P2925, DOI 10.1182/blood-2003-03-0833; TANO M, 1995, MOL CELL ENDOCRINOL, V109, P167, DOI 10.1016/0303-7207(95)03499-W; Tuveson DA, 2003, CANCER CELL, V4, P95, DOI 10.1016/S1535-6108(03)00189-2; UENO N, 1987, P NATL ACAD SCI USA, V84, P8282, DOI 10.1073/pnas.84.23.8282; VALE W, 1986, NATURE, V321, P776, DOI 10.1038/321776a0; Wang QF, 2000, ENDOCRINOLOGY, V141, P3183, DOI 10.1210/en.141.9.3183; Wankell M, 2001, J ENDOCRINOL, V171, P385, DOI 10.1677/joe.0.1710385; Wankell M, 2001, EMBO J, V20, P5361, DOI 10.1093/emboj/20.19.5361; Welt C, 2002, EXP BIOL MED, V227, P724, DOI 10.1177/153537020222700905; Willert Jennifer, 2002, BMC Dev Biol, V2, P8, DOI 10.1186/1471-213X-2-8	56	31	33	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 8	2004	23	31					5330	5339		10.1038/sj.onc.1207699	http://dx.doi.org/10.1038/sj.onc.1207699			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	835NX	15064726	Green Published			2022-12-17	WOS:000222491600008
J	Zanier, R; Briot, D; du Villard, JAD; Sarasin, A; Rosselli, F				Zanier, R; Briot, D; du Villard, JAD; Sarasin, A; Rosselli, F			Fanconi anemia C gene product regulates expression of genes involved in differentiation and inflammation	ONCOGENE			English	Article						Fanconi anemia; leukemia; gene expression; microarray; DNA repair	NECROSIS-FACTOR-ALPHA; CELL MYELOPROLIFERATIVE DISORDER; HEMATOPOIETIC STEM-CELLS; MYELOID-LEUKEMIA CELLS; GROWTH-FACTOR; PROTEIN; COMPLEMENTATION; TRANSCRIPTION; INTERACTS; RECEPTOR	Loss of Fanconi anemia ( FA) proteins activity by recessive inherited mutations in one of the FA genes leads to a disease characterized by bone marrow failure, myeloid leukemia and DNA damage hypersensitivity. The aim of this work was to improve our understanding of the FA syndrome de. ning the transcription profile of the FA complementation group C (FANCC)-deficient cells in comparison to their ectopically corrected counterpart using oligonucleotide microarrays. In this way, 49 RNAs have been isolated, which showed a consistent differential pattern of expression among FANCC mutated and corrected cells. The observed specific changes in gene expression suggest that FANCC regulates specifically myeloid differentiation and unmasks a previously unsuspected anti-inflammatory role for the FA proteins. In spite of the DNA damage hypersensitivity of the syndrome, no gene coding for a protein directly involved in DNA repair/damage response was found to be deregulated in our analysis. This observation suggests that FANCC does not directly control genes involved in DNA repair at the transcriptional level, but does not exclude a regulation at the translational or post-translational level, or by protein/protein interactions. The potential role of the differentially expressed genes in FA phenotype as well as a functional- and cellular-based clustering of the identified genes are presented and discussed.	Inst Gustave Roussy, CNRS, UPR 2169, F-94805 Villejuif, France	Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy	Rosselli, F (corresponding author), Inst Gustave Roussy, CNRS, UPR 2169, 39 Rue Camille Desmoulins, F-94805 Villejuif, France.	rosselli@igr.fr	Filippo, Rosselli/AAO-6393-2020	Filippo, Rosselli/0000-0003-1080-5745				Ahmad SI, 2002, BIOESSAYS, V24, P439, DOI 10.1002/bies.10082; Alter BP, 1996, AM J HEMATOL, V53, P99, DOI 10.1002/(SICI)1096-8652(199610)53:2<99::AID-AJH7>3.3.CO;2-M; BEDFORD FK, 1993, NUCLEIC ACIDS RES, V21, P1245, DOI 10.1093/nar/21.5.1245; Benezra M, 2003, J BIOL CHEM, V278, P26333, DOI 10.1074/jbc.M303076200; Coller HA, 2000, P NATL ACAD SCI USA, V97, P3260, DOI 10.1073/pnas.97.7.3260; Curtis DJ, 2000, EXP HEMATOL, V28, P1250, DOI 10.1016/S0301-472X(00)00537-3; D'Andrea AD, 2003, NAT REV CANCER, V3, P23, DOI 10.1038/nrc970; Dolis D, 1997, BIOPHYS CHEM, V68, P221, DOI 10.1016/S0301-4622(97)00048-3; Folias A, 2002, HUM MOL GENET, V11, P2591, DOI 10.1093/hmg/11.21.2591; Grompe M, 2001, HUM MOL GENET, V10, P2253, DOI 10.1093/hmg/10.20.2253; Hanada T, 2002, CYTOKINE GROWTH F R, V13, P413, DOI 10.1016/S1359-6101(02)00026-6; Hansen GM, 1999, ONCOGENE, V18, P6531, DOI 10.1038/sj.onc.1203023; Hashimoto S, 1999, BLOOD, V94, P845, DOI 10.1182/blood.V94.3.845.415k09_845_852; Hoatlin ME, 1999, BLOOD, V94, P3737, DOI 10.1182/blood.V94.11.3737.423k39_3737_3747; HROMAS R, 1993, BIOCHEM BIOPH RES CO, V195, P976, DOI 10.1006/bbrc.1993.2140; Jobin C, 1999, J IMMUNOL, V163, P3474; Joenje H, 2001, NAT REV GENET, V2, P446, DOI 10.1038/35076590; Karanu FN, 2000, J EXP MED, V192, P1365, DOI 10.1084/jem.192.9.1365; Lehnert M, 1996, EUR J CANCER, V32A, P912, DOI 10.1016/0959-8049(96)00069-X; Li PX, 2000, J BIOL CHEM, V275, P20127, DOI 10.1074/jbc.M909580199; Li QT, 2002, NAT REV IMMUNOL, V2, P725, DOI 10.1038/nri910; Li YL, 1997, J CLIN INVEST, V100, P2873, DOI 10.1172/JCI119836; LINDSELL CE, 1995, CELL, V80, P909, DOI 10.1016/0092-8674(95)90294-5; MACDONALD D, 1995, LEUKEMIA, V9, P1628; MANFIOLETTI G, 1995, BLOOD, V85, P1237, DOI 10.1182/blood.V85.5.1237.bloodjournal8551237; Mills JC, 2001, NAT CELL BIOL, V3, pE175, DOI 10.1038/35087108; Orkin SH, 2000, NAT REV GENET, V1, P57, DOI 10.1038/35049577; Otsuki T, 2001, HUM MOL GENET, V10, P2651, DOI 10.1093/hmg/10.23.2651; Pallis M, 2000, BLOOD, V95, P2897, DOI 10.1182/blood.V95.9.2897.009k14_2897_2904; Pang QS, 2001, BLOOD, V97, P1644, DOI 10.1182/blood.V97.6.1644; Pang QS, 2001, EMBO J, V20, P4478, DOI 10.1093/emboj/20.16.4478; Popovici C, 1999, BLOOD, V93, P1381, DOI 10.1182/blood.V93.4.1381.404k30_1381_1389; Popovici C, 1998, P NATL ACAD SCI USA, V95, P5712, DOI 10.1073/pnas.95.10.5712; Reber M, 2001, MECH DEVELOP, V100, P75, DOI 10.1016/S0925-4773(00)00493-7; ROSSELLI F, 1994, BLOOD, V83, P1216; Rousset S, 2002, PHOTOCHEM PHOTOBIOL, V75, P159, DOI 10.1562/0031-8655(2002)075<0159:MAIFAF>2.0.CO;2; Ruppitsch W, 1997, HUM GENET, V99, P710, DOI 10.1007/s004390050437; Schreuder H, 1997, NATURE, V386, P194, DOI 10.1038/386194a0; SCHULTZ JC, 1993, AM J HEMATOL, V42, P196, DOI 10.1002/ajh.2830420211; STRATHDEE CA, 1992, NATURE, V356, P763, DOI 10.1038/356763a0; Sullivan DM, 1996, INVEST OPHTH VIS SCI, V37, P766; Sun ZX, 2001, GENE DEV, V15, P3217, DOI 10.1101/gad946701; Tohda S, 2001, LEUKEMIA LYMPHOMA, V42, P467, DOI 10.3109/10428190109064603; TRONCHE F, 1992, BIOESSAYS, V14, P579, DOI 10.1002/bies.950140902; Walker L, 2001, STEM CELLS, V19, P543, DOI 10.1634/stemcells.19-6-543; WALSH CE, 1994, J CLIN INVEST, V94, P1440, DOI 10.1172/JCI117481; Ward PA, 2002, MOL CELL BIOCHEM, V234, P225, DOI 10.1023/A:1015944709177; Xie Y, 2000, BRIT J HAEMATOL, V111, P1057, DOI 10.1111/j.1365-2141.2000.02450.x; Zhang F, 1999, CARCINOGENESIS, V20, P445, DOI 10.1093/carcin/20.3.445	49	31	32	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 24	2004	23	29					5004	5013		10.1038/sj.onc.1207677	http://dx.doi.org/10.1038/sj.onc.1207677			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	831ZX	15077170				2022-12-17	WOS:000222237300006
J	Guerrero, C; Martin-Encabo, S; Fernandez-Medarde, A; Santos, E				Guerrero, C; Martin-Encabo, S; Fernandez-Medarde, A; Santos, E			C3G-mediated suppression of oncogene-induced focus formation in fibroblasts involves inhibition of ERK activation, cyclin A expression and alterations of anchorage-independent growth	ONCOGENE			English	Article						C3G; Ras; focus formation; anchorage-independent growth; transformation suppression	EXCHANGE FACTOR C3G; HEMATOPOIETIC-CELL ADHESION; NUCLEOTIDE-RELEASING FACTOR; ADAPTER PROTEIN CRKL; SMALL GTPASE RAP1; R-RAS; FOCAL ADHESIONS; KINASE; PHOSPHORYLATION; RECEPTOR	We showed previously that exogenous overexpression of C3G, a guanine nucleotide releasing factor (GEF) for Rap1 and R-Ras proteins, blocks the focus-forming activity of cotransfected, activated, sis, ras and v-raf oncogenes in NIH 3T3 cells. In this report, we show that C3G also interferes with dbl and R-Ras focus-forming activity and demonstrate that the transformation suppressor ability of C3G maps to its Crk-binding region (SH3-b domain). Using full-length C3G and C3GDeltaCat mutant, lacking catalytic domain, we showed here that overexpression of cotransfected C3G or C3GDeltaCat inhibited oncogenic Hras(lys12)-mediated phosphorylation of ERK, without altering Ras and Raf-1 kinase activation. We also showed that, overexpressed C3G and C3GDeltaCat inhibited the viability of oncogenic Ras-induced colonies in soft agar, indicating that C3G interferes with the anchorage-independent growth of Ras-transformed cells in a Rap1-independent manner. Consistent with both observations, overexpression of exogenous C3G and C3GDeltaCat also caused downregulation of Ras-induced cyclin A expression. Altogether, our results indicate that C3G interferes with at least two separate aspects of oncogenic transformation-cell cycle progression and loss of contact inhibition-and that these inhibitory effects probably account for its transformation suppressor activity.	Univ Salamanca, CSIC, Ctr Invest Canc, IBMCC, Salamanca 37007, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigacion del Cancer (CIC); CSIC-USAL - Instituto de Biologia Molecular y Celular del Cancer de Salamanca (IBMCC); University of Salamanca	Santos, E (corresponding author), Univ Salamanca, CSIC, Ctr Invest Canc, IBMCC, Campus Miguel de Unamuno, Salamanca 37007, Spain.	esantos@usal.es	Guerrero, Carmen/F-1776-2010; Fernández-Medarde, Alberto/B-3839-2017	Guerrero, Carmen/0000-0002-8747-6831; Fernández-Medarde, Alberto/0000-0002-1230-5501				Abassi YA, 2002, EMBO J, V21, P4571, DOI 10.1093/emboj/cdf446; Arai A, 1999, BLOOD, V93, P3713, DOI 10.1182/blood.V93.11.3713.411a36_3713_3722; Arai A, 2001, J BIOL CHEM, V276, P10453, DOI 10.1074/jbc.M004627200; BENITO M, 1991, SCIENCE, V253, P565, DOI 10.1126/science.1857988; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; de Jong R, 1998, ONCOGENE, V17, P2805, DOI 10.1038/sj.onc.1202207; Dhillon AS, 2002, MOL CELL BIOL, V22, P3237, DOI 10.1128/MCB.22.10.3237-3246.2002; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; EVA A, 1985, NATURE, V316, P273, DOI 10.1038/316273a0; Gotoh T, 1997, J BIOL CHEM, V272, P18602, DOI 10.1074/jbc.272.30.18602; GOTOH T, 1995, MOL CELL BIOL, V15, P6746; GUADAGNO TM, 1993, SCIENCE, V262, P1572, DOI 10.1126/science.8248807; Guerrero C, 1998, ONCOGENE, V16, P613, DOI 10.1038/sj.onc.1201569; Guerrero C, 2002, AM J PHYSIOL-LUNG C, V282, pL1099, DOI 10.1152/ajplung.00178.2001; Hamad NM, 2002, GENE DEV, V16, P2045, DOI 10.1101/gad.993902; Howe A, 1998, CURR OPIN CELL BIOL, V10, P220, DOI 10.1016/S0955-0674(98)80144-0; Ishimaru S, 1999, EMBO J, V18, P145, DOI 10.1093/emboj/18.1.145; Kang JS, 1996, MOL CELL BIOL, V16, P3370; KNUDSEN BS, 1994, J BIOL CHEM, V269, P32781; LACAL JC, 1986, P NATL ACAD SCI USA, V83, P5400, DOI 10.1073/pnas.83.15.5400; Li LM, 2002, MOL CELL BIOL, V22, P1203, DOI 10.1128/MCB.22.4.1203-1217.2002; MARAIS R, 1995, EMBO J, V14, P3136, DOI 10.1002/j.1460-2075.1995.tb07316.x; MATTER ML, 1994, J CELL BIOL, V124, P1083, DOI 10.1083/jcb.124.6.1083; McLeod SJ, 1998, J BIOL CHEM, V273, P29218, DOI 10.1074/jbc.273.44.29218; MIKI T, 1989, GENE, V83, P137, DOI 10.1016/0378-1119(89)90411-3; Mochizuki N, 2000, J BIOL CHEM, V275, P12667, DOI 10.1074/jbc.275.17.12667; Ohba Y, 2000, J BIOL CHEM, V275, P20020, DOI 10.1074/jbc.M000981200; Ohba Y, 2001, EMBO J, V20, P3333, DOI 10.1093/emboj/20.13.3333; PaasinenSohns A, 1997, ONCOGENE, V15, P1953, DOI 10.1038/sj.onc.1201366; Peeper DS, 1997, NATURE, V386, P177, DOI 10.1038/386177a0; Quilliam LA, 2002, PROG NUCLEIC ACID RE, V71, P391, DOI 10.1016/S0079-6603(02)71047-7; Reedquist KA, 1998, J BIOL CHEM, V273, P4944, DOI 10.1074/jbc.273.9.4944; Renshaw MW, 1997, EMBO J, V16, P5592, DOI 10.1093/emboj/16.18.5592; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; SAEZ R, 1994, ONCOGENE, V9, P2977; Sakkab D, 2000, J BIOL CHEM, V275, P10772, DOI 10.1074/jbc.275.15.10772; SAKODA T, 1992, ONCOGENE, V7, P1705; Schulze A, 1996, MOL CELL BIOL, V16, P4632; SOZERI O, 1992, ONCOGENE, V7, P2259; Takuwa N, 2001, MOL CELL ENDOCRINOL, V177, P25, DOI 10.1016/S0303-7207(01)00439-7; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; Uemura N, 1999, J BIOL CHEM, V274, P37525, DOI 10.1074/jbc.274.53.37525; Voss AK, 2003, DEVELOPMENT, V130, P355, DOI 10.1242/dev.00217; Yam CH, 2002, CELL MOL LIFE SCI, V59, P1317, DOI 10.1007/s00018-002-8510-y; Yang JJ, 1998, MOL CELL BIOL, V18, P2586, DOI 10.1128/MCB.18.5.2586; Yokote K, 1998, ONCOGENE, V16, P1229, DOI 10.1038/sj.onc.1201641; York RD, 1998, NATURE, V392, P622, DOI 10.1038/33451; Zhu T, 1998, J BIOL CHEM, V273, P33864, DOI 10.1074/jbc.273.50.33864	48	31	32	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 17	2004	23	28					4885	4893		10.1038/sj.onc.1207622	http://dx.doi.org/10.1038/sj.onc.1207622			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	830EK	15077165	Green Submitted			2022-12-17	WOS:000222104200009
J	Adachi, H; Majima, S; Kon, S; Kobayashi, T; Kajino, K; Mitani, H; Hirayama, Y; Shiina, H; Igawa, M; Hino, O				Adachi, H; Majima, S; Kon, S; Kobayashi, T; Kajino, K; Mitani, H; Hirayama, Y; Shiina, H; Igawa, M; Hino, O			Niban gene is commonly expressed in the renal tumors: a new candidate marker for renal carcinogenesis	ONCOGENE			English	Article						Niban; Tsc2 mutant (Eker) rats; multistep renal carcinogenesis; tumor marker; human renal cell carcinoma	EKER RAT MODEL; EMBRYONIC LETHALITY; PREDISPOSING GENE; TSC2 MUTATION; CELL-GROWTH; COMPLEX; CARCINOMA; PATHWAY; TARGET	Functional inactivation of tuberous sclerosis 2 gene (Tsc2) leads to renal carcinogenesis in the hereditary renal carcinoma Eker rat models. Recent studies revealed a role of tuberin, a TSC2 product, in suppressing the p70 S6 kinase (p70S6K) activity via inhibition of mammalian target of rapamycin (mTOR). Phosphorylated S6 protein, a substrate of p70S6K, was expressed in the early lesions in Eker rats, and this expression was suppressed by the treatment of rapamycin, an inhibitor of mTOR. We previously isolated the novel gene Niban expressed in renal carcinogenesis of Eker rats. In this study, we demonstrated that the expression of Niban was detected from early preneoplastic lesions in Eker rats. Interestingly, in contrast to the phosphorylated S6 protein, the expression of Niban was unchanged and early lesions still remained even after treatment with rapamycin. These results might suggest the existence of another pathway independent of mTOR-S6K pathway in Tsc2 mutant renal carcinogenesis. In addition, Nib an was also expressed in other renal carcinoma models, including Tsc1 and Tsc2 knockout mice, and various types of human renal cell carcinomas. Thus, Nib an was commonly expressed in renal carcinomas and might be a new marker for renal carcinogenesis.	Japanese Fdn Canc Res, Inst Canc, Dept Expt Pathol, Toshima Ku, Tokyo 1708455, Japan; Shimane Univ, Sch Med, Dept Urol, Izumo, Shimane 6938501, Japan; Immunobiol Labs Co Ltd, Fujioka, Gunma 3750005, Japan	Japanese Foundation for Cancer Research; Shimane University; Immuno-Biological Laboratories Co. Ltd.	Hino, O (corresponding author), Japanese Fdn Canc Res, Inst Canc, Dept Expt Pathol, Toshima Ku, 1-37-1 Kami Ikebukuro, Tokyo 1708455, Japan.	ohino@ims.u-tokyo.ac.jp	Kon, Shigeyuki/A-3809-2012					Dan HC, 2002, J BIOL CHEM, V277, P35364, DOI 10.1074/jbc.M205838200; EKER R, 1961, NATURE, V189, P858, DOI 10.1038/189858b0; Gao XS, 2002, NAT CELL BIOL, V4, P699, DOI 10.1038/ncb847; Gao XS, 2001, GENE DEV, V15, P1383, DOI 10.1101/gad.901101; HINO O, 1993, P NATL ACAD SCI USA, V90, P327, DOI 10.1073/pnas.90.1.327; HINO O, 1994, BIOCHEM BIOPH RES CO, V203, P1302, DOI 10.1006/bbrc.1994.2324; Hino O, 2003, CANCER SCI, V94, P142, DOI 10.1111/j.1349-7006.2003.tb01410.x; Hino O, 2001, JPN J CANCER RES, V92, P1147, DOI 10.1111/j.1349-7006.2001.tb02133.x; Inoki K, 2002, NAT CELL BIOL, V4, P648, DOI 10.1038/ncb839; Kenerson HL, 2002, CANCER RES, V62, P5645; Kobayashi T, 1999, CANCER RES, V59, P1206; KOBAYASHI T, 1995, NAT GENET, V9, P70, DOI 10.1038/ng0195-70; Kobayashi T, 2003, P JPN ACAD B-PHYS, V79, P22, DOI 10.2183/pjab.79B.22; Kobayashi T, 2001, P NATL ACAD SCI USA, V98, P8762, DOI 10.1073/pnas.151033798; Kon S, 2000, J CELL BIOCHEM, V77, P487; KUBO Y, 1995, CANCER RES, V55, P989; Majima S, 2000, JPN J CANCER RES, V91, P869, DOI 10.1111/j.1349-7006.2000.tb01027.x; Manning BD, 2002, MOL CELL, V10, P151, DOI 10.1016/S1097-2765(02)00568-3; Okimoto K, 2000, JPN J CANCER RES, V91, P1096, DOI 10.1111/j.1349-7006.2000.tb00890.x; Potter CJ, 2001, CELL, V105, P357, DOI 10.1016/S0092-8674(01)00333-6; Takahashi R, 1999, EXP ANIM TOKYO, V48, P255, DOI 10.1538/expanim.48.255; Tapon N, 2001, CELL, V105, P345, DOI 10.1016/S0092-8674(01)00332-4; YEUNG RS, 1994, P NATL ACAD SCI USA, V91, P11413, DOI 10.1073/pnas.91.24.11413	23	31	34	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 22	2004	23	19					3495	3500		10.1038/sj.onc.1207468	http://dx.doi.org/10.1038/sj.onc.1207468			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	814LA	14990989				2022-12-17	WOS:000220975000025
J	Chumakov, AM; Kubota, T; Walter, S; Koeffler, HP				Chumakov, AM; Kubota, T; Walter, S; Koeffler, HP			Identification of murine and human XCP1 genes as C/EBP-epsilon-dependent members of FIZZ/Resistin gene family	ONCOGENE			English	Article						C/EBP; resistin; transcriptional regulation; myeloid; chemotaxis; defensin; innate immunity	BINDING-PROTEIN-EPSILON; MYELOID TRANSCRIPTION FACTOR; CELL-LINE; EXPRESSION; DEFENSINS; LEUKEMIA; RESISTIN; DIFFERENTIATION; MYB; CHEMOKINES	The CCAAT enhancer binding protein epsilon (C/EBP-epsilon) transcription factor is expressed predominantly in granulocytes. Mice with a disruption of the C/EBP-epsilon gene fail to produce mature granulocytes and eosinophils. Cells derived from the peritoneal exudates of C/EBP-epsilon -/- mice lack the expression of a number of chemokines and chemokine receptor genes. We have found a novel C/EBP-epsilon dependent promyelocyte-specific gene, mXCP1. mXCP1 belongs to a family of XCP/FIZZ/Resistin genes, which includes four murine genes and two human genes, hXCP1 and hXCP2. These genes have four exons and encode short secreted proteins sharing a ten-cysteine motif. Murine mXCP1, mXCP2 and mXCP3 genes map to murine chromosome 16 and mXCP4 is positioned on chromosome 8; the hXCP1 and hXCP2 genes are located at homologous regions of chromosomes 3 and 19. Introduction of an inducible C/EBP-epsilon gene into the NIH3T3 and myeloid cells from C/EBP-epsilon-null mice line revealed that the conditional expression of C/EBP-epsilon induced mXCP1. The HXCP1 gene was identified as a C/EBP-epsilon-dependent regulatory homologue of mXCP1. The expression data for other members of XCP/FIZZ gene family are presented. Further studies indicate that XCP1 is a secreted protein that is chemotactic to myeloid cells from C/EBP-epsilon-null mice and is able to interact directly with alpha-defensin.	Univ Calif Los Angeles, Sch Med,Burns & Allen Res Inst, Cedars Sinai Med Ctr, Div Hematol Oncol, Los Angeles, CA 90048 USA; Kochi Med Sch, Dept Med, Kochi 783, Japan	Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Kochi University	Chumakov, AM (corresponding author), Univ Calif Los Angeles, Sch Med,Burns & Allen Res Inst, Cedars Sinai Med Ctr, Div Hematol Oncol, Davis Bldg 5022,8700 Beverly Blvd, Los Angeles, CA 90048 USA.	achumakov@hotmail.com	Chumakov, Alexey/N-1541-2014	Chumakov, Alexey/0000-0003-2733-3166				ALTSCHUL SF, 1994, NAT GENET, V6, P119, DOI 10.1038/ng0294-119; Altschul SF, 1996, METHOD ENZYMOL, V266, P460; Antonson P, 1996, GENOMICS, V35, P30, DOI 10.1006/geno.1996.0319; BACON KB, 1988, BRIT J PHARMACOL, V95, P966, DOI 10.1111/j.1476-5381.1988.tb11727.x; Banerjee RR, 2001, J BIOL CHEM, V276, P25970, DOI 10.1074/jbc.M103109200; Broxmeyer HE, 1999, ANN NY ACAD SCI, V872, P142, DOI 10.1111/j.1749-6632.1999.tb08460.x; CHUMAKOV A, 1993, GENE, V131, P231, DOI 10.1016/0378-1119(93)90298-H; Chumakov AM, 1997, MOL CELL BIOL, V17, P1375, DOI 10.1128/MCB.17.3.1375; Dieu MC, 1998, J EXP MED, V188, P373, DOI 10.1084/jem.188.2.373; Ganz T, 1999, SCIENCE, V286, P420, DOI 10.1126/science.286.5439.420; GRIGNANI F, 1993, CELL, V74, P423, DOI 10.1016/0092-8674(93)80044-F; Gropp R, 1999, HUM GENE THER, V10, P957, DOI 10.1089/10430349950018355; Hartman HB, 2002, J BIOL CHEM, V277, P19754, DOI 10.1074/jbc.M201451200; Haugen F, 2001, FEBS LETT, V507, P105, DOI 10.1016/S0014-5793(01)02968-4; Herwig S, 1996, BLOOD, V87, P350, DOI 10.1182/blood.V87.1.350.bloodjournal871350; Holcomb IN, 2000, EMBO J, V19, P4046, DOI 10.1093/emboj/19.15.4046; HUTTNER KM, 1994, GENOMICS, V19, P448, DOI 10.1006/geno.1994.1093; Ichinose M, 1996, IMMUNOPHARMACOLOGY, V35, P103, DOI 10.1016/S0162-3109(96)00118-X; Kinoshita K, 2000, MOL CELL BIOL, V20, P4680, DOI 10.1128/MCB.20.13.4680-4690.2000; KOEFFLER HP, 1978, SCIENCE, V200, P1153, DOI 10.1126/science.306682; Kubota T, 2000, BLOOD, V96, P3953, DOI 10.1182/blood.V96.12.3953.h8003953_3953_3957; LANOTTE M, 1991, BLOOD, V77, P1080; LECLAIR KP, 1992, P NATL ACAD SCI USA, V89, P8145, DOI 10.1073/pnas.89.17.8145; Lekstrom-Himes J, 1998, J BIOL CHEM, V273, P28545, DOI 10.1074/jbc.273.44.28545; Lekstrom-Himes J, 1999, BLOOD, V93, P3096; Lekstrom-Himes JA, 1999, J EXP MED, V189, P1847, DOI 10.1084/jem.189.11.1847; Masera RG, 1996, REGUL PEPTIDES, V62, P13, DOI 10.1016/0167-0115(95)00150-6; Mink S, 1996, MOL CELL BIOL, V16, P1316; Morosetti R, 1997, BLOOD, V90, P2591, DOI 10.1182/blood.V90.7.2591.2591_2591_2600; NESS SA, 1993, GENE DEV, V7, P749, DOI 10.1101/gad.7.5.749; Park DJ, 1999, J CLIN INVEST, V103, P1399, DOI 10.1172/JCI2887; POLI V, 1990, CELL, V63, P643, DOI 10.1016/0092-8674(90)90459-R; Savage DB, 2001, DIABETES, V50, P2199, DOI 10.2337/diabetes.50.10.2199; SCOTT LM, 1992, BLOOD, V80, P1725; SELSTED ME, 1992, J CELL BIOL, V118, P929, DOI 10.1083/jcb.118.4.929; Steppan CM, 2001, NATURE, V409, P307, DOI 10.1038/35053000; Steppan CM, 2001, P NATL ACAD SCI USA, V98, P502, DOI 10.1073/pnas.98.2.502; Taupin DR, 2000, P NATL ACAD SCI USA, V97, P799, DOI 10.1073/pnas.97.2.799; Verbeek W, 1999, BLOOD, V93, P3327, DOI 10.1182/blood.V93.10.3327; Verbeek W, 1999, BLOOD, V94, P3141, DOI 10.1182/blood.V94.9.3141.421k41_3141_3150; WILLIAMS SC, 1991, GENE DEV, V5, P1553, DOI 10.1101/gad.5.9.1553; Yamanaka R, 1997, P NATL ACAD SCI USA, V94, P6462, DOI 10.1073/pnas.94.12.6462; Yamanaka R, 1997, P NATL ACAD SCI USA, V94, P13187, DOI 10.1073/pnas.94.24.13187; Yang D, 1999, SCIENCE, V286, P525, DOI 10.1126/science.286.5439.525; YOUNT NY, 1995, J IMMUNOL, V155, P4476; Zhang DE, 1997, P NATL ACAD SCI USA, V94, P569, DOI 10.1073/pnas.94.2.569	46	31	36	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 22	2004	23	19					3414	3425		10.1038/sj.onc.1207126	http://dx.doi.org/10.1038/sj.onc.1207126			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	814LA	15064728				2022-12-17	WOS:000220975000016
J	Chipitsyna, G; Slonina, D; Siddiqui, K; Peruzzi, F; Skorski, T; Reiss, K; Sawaya, BE; Khalili, K; Amini, S				Chipitsyna, G; Slonina, D; Siddiqui, K; Peruzzi, F; Skorski, T; Reiss, K; Sawaya, BE; Khalili, K; Amini, S			HIV-1 Tat increases cell survival in response to cisplatin by stimulating Rad51 gene expression	ONCOGENE			English	Article						HIV-1; Tat; DNA repair	IMMUNODEFICIENCY-VIRUS TYPE-1; TNF-ALPHA; CHECKPOINT ACTIVATION; DNA-REPAIR; PROTEIN; TRANSCRIPTION; REPLICATION; P53; SYSTEM; DAMAGE	Tat is an early regulatory protein of human immunodeficiency virus type 1, which plays a central role in the pathogenesis of AIDS by stimulating transcription of the viral genome and impairing several important cellular pathways during the progression of the disease. Here, we investigated the effect of Tat on cell response to DNA damage. Our results indicate that Tat production causes a noticeable increase in the survival rate of PC12 cells upon their treatment with genotoxic agents. Single-cell gel electrophoresis studies revealed reduced DNA breakage in PC12-Tat cells upon cisplatin treatment relative to the control cells. Furthermore, cytogenetic data exhibited less chromosomal damage in Tat-producing cells after recovery from cisplatin treatment, corroborating electrophoretic data. Examination of several proteins involved in the control of DNA repair showed elevated levels of Rad51, a key regulator of homologous recombination in cells expressing Tat. On the other hand, the level of Ku70, one of the components of the nonhomologous end-joining repair pathway, was slightly decreased in cells expressing Tat. Using a fluorescence-based assay, we demonstrated that repair of DNA double-strand breaks via homologous recombination is increased in Tat-producing cells. The results from in vitro nonhomologous end-joining assay revealed a reduced ability of protein extract from PC12-Tat cells compared to PC12 cells in rejoining linearized DNA. These observations ascribe a new role for Tat in host genomic integrity, perhaps by affecting the expression of genes involved in DNA repair.	Temple Univ, Coll Sci & Technol, Ctr Neurovirol & Canc Biol, Philadelphia, PA 19122 USA; Coll Sci & Technol, Ctr Biotechnol, Dept Biol, Philadelphia, PA 19122 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Amini, S (corresponding author), Temple Univ, Coll Sci & Technol, Ctr Neurovirol & Canc Biol, 1900 N 12th St,015-96, Philadelphia, PA 19122 USA.	shohreh.amini@temple.edu	Peruzzi, Francesca/M-9804-2014	Slonina, Dorota/0000-0003-1225-2355	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS040673] Funding Source: NIH RePORTER; NINDS NIH HHS [R01 NS040673-02] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Aguilera A, 2001, TRENDS GENET, V17, P318, DOI 10.1016/S0168-9525(01)02309-5; Barboric M, 2001, MOL CELL, V8, P327, DOI 10.1016/S1097-2765(01)00314-8; Baumann P, 1998, P NATL ACAD SCI USA, V95, P14066, DOI 10.1073/pnas.95.24.14066; Bennasser Y, 2002, VIROLOGY, V303, P174, DOI 10.1006/viro.2002.1676; Berkhout B, 2002, J NEUROVIROL, V8, P134, DOI 10.1080/13550280290101102; Brown KD, 2003, NAT GENET, V33, P80, DOI 10.1038/ng1052; BUONAGURO L, 1992, J VIROL, V66, P7159, DOI 10.1128/JVI.66.12.7159-7167.1992; Chen PQ, 1997, J BIOL CHEM, V272, P22385, DOI 10.1074/jbc.272.36.22385; Clark E, 2000, J VIROL, V74, P5040, DOI 10.1128/JVI.74.11.5040-5052.2000; Douek DC, 2003, ANNU REV IMMUNOL, V21, P265, DOI 10.1146/annurev.immunol.21.120601.141053; DUAN LX, 1994, J VIROL, V68, P4302, DOI 10.1128/JVI.68.7.4302-4313.1994; Esposito G, 2002, J BIOL CHEM, V277, P50348, DOI 10.1074/jbc.M207170200; Featherstone C, 1999, MUTAT RES-DNA REPAIR, V434, P3, DOI 10.1016/S0921-8777(99)00006-3; Gonzalez E, 2001, J IMMUNOL, V166, P4560, DOI 10.4049/jimmunol.166.7.4560; GREEN MHL, 1994, MUTAT RES-DNAGING G, V316, P91, DOI 10.1016/0921-8734(94)90011-6; Kai M, 2003, GENE DEV, V17, P64, DOI 10.1101/gad.1043203; Kashanchi F, 2000, J VIROL, V74, P652, DOI 10.1128/JVI.74.2.652-660.2000; Kundu M, 1998, J BIOL CHEM, V273, P8130, DOI 10.1074/jbc.273.14.8130; Lambotte O, 2003, BRAIN PATHOL, V13, P95, DOI 10.1111/j.1750-3639.2003.tb00010.x; Lee SH, 2002, MOL CELLS, V13, P159; LI CJ, 1995, P NATL ACAD SCI USA, V92, P5461, DOI 10.1073/pnas.92.12.5461; Liang Chen, 2002, AIDS Reviews, V4, P41; Magnusson KP, 2000, GENE, V246, P247, DOI 10.1016/S0378-1119(00)00068-8; Mahieux R, 2001, J VIROL, V75, P1736, DOI 10.1128/JVI.75.4.1736-1743.2001; McCloskey TW, 1997, J IMMUNOL, V158, P1014; Persaud D, 2003, J VIROL, V77, P1659, DOI 10.1128/JVI.77.3.1659-1665.2003; Peruzzi F, 2002, J NEUROVIROL, V8, P91, DOI 10.1080/13550280290167885; Phimister EG, 2003, NEW ENGL J MED, V348, P643, DOI 10.1056/NEJMcibr035051; Pierce AJ, 1999, GENE DEV, V13, P2633, DOI 10.1101/gad.13.20.2633; Rappaport J, 1999, J LEUKOCYTE BIOL, V65, P458, DOI 10.1002/jlb.65.4.458; RAUTONEN N, 1994, AIDS, V8, P1504, DOI 10.1097/00002030-199410000-00023; Reynolds L, 2003, P NATL ACAD SCI USA, V100, P1615, DOI 10.1073/pnas.252770699; Sawaya BE, 2000, J BIOL CHEM, V275, P35209, DOI 10.1074/jbc.M005197200; Sawaya BE, 1998, J NEUROIMMUNOL, V87, P33, DOI 10.1016/S0165-5728(98)00044-7; Sengupta S, 2003, EMBO J, V22, P1210, DOI 10.1093/emboj/cdg114; Shi B, 1998, J NEUROVIROL, V4, P281, DOI 10.3109/13550289809114529; SINGH NP, 1994, INT J RADIAT BIOL, V66, P23, DOI 10.1080/09553009414550911; Venkitaraman AR, 2002, CELL, V108, P171, DOI 10.1016/S0092-8674(02)00615-3	38	31	33	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 8	2004	23	15					2664	2671		10.1038/sj.onc.1207417	http://dx.doi.org/10.1038/sj.onc.1207417			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	810OZ	14755242				2022-12-17	WOS:000220714900008
J	Wang, SH; Mezosi, E; Wolf, JM; Cao, ZY; Utsugi, S; Gauger, PG; Doherty, GM; Baker, JR				Wang, SH; Mezosi, E; Wolf, JM; Cao, ZY; Utsugi, S; Gauger, PG; Doherty, GM; Baker, JR			IFN gamma sensitization to TRAIL-induced apoptosis in human thyroid carcinoma cells by upregulating Bak expression	ONCOGENE			English	Article						Bak; thyroid cancer; apoptosis; IFN gamma; TRAIL	FAS-MEDIATED APOPTOSIS; INTERFERON-GAMMA; FOLLICULAR CELLS; CYTOCHROME-C; BCL-2 FAMILY; CANCER-CELLS; DEATH; LIGAND; PATHWAY; RELEASE	TRAIL preferentially induces apoptosis in tumor cells and virus-infected cells. Unlike other tumor necrosis factor family members, TRAIL does not kill cells from most normal tissues and has thus been proposed as a promising new cancer treatment. Our study demonstrated that IFNgamma combined with TRAIL can trigger apoptosis in vitro in several resistant thyroid tumor cell lines, such as thyroid anaplastic carcinoma cells (ARO cells), while either agent alone exerts only a minimal effect. We further tested this effect on a mouse thyroid tumor model, when in vivo tumor growth was also significantly inhibited by this combination. The mechanism of how IFNgamma sensitized thyroid carcinoma cells to TRAIL-induced apoptosis was investigated by screening global gene alterations in ARO cells treated with IFNgamma. Microarray data revealed that a proapoptotic gene, Bak, is markedly upregulated by IFNgamma, and this was confirmed by RNase protection assay. Western blot analysis also showed a significant increase in Bak at the protein level. Upregulation of Bak and sensitization for apoptosis by IFNgamma was blocked by overexpression of antisense Bak in ARO cells. Furthermore, overexpression of Bak sensitized ARO cell to TRAIL-induced apoptosis without the need for IFNgamma pretreatment. This suggests that Bak is a regulatory molecule involved in IFNgamma-facilitated TRAIL-mediated apoptosis in thyroid cancer cells.	Univ Michigan, Med Ctr, Dept Med, Ann Arbor, MI 48109 USA; Univ Michigan, Med Ctr, Dept Surg, Ann Arbor, MI 48109 USA; Univ Michigan, Med Ctr, Ctr Biol Nanotechnol, Ann Arbor, MI USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Baker, JR (corresponding author), Univ Michigan, Med Ctr, Dept Med, Ann Arbor, MI 48109 USA.	jbakerjr@umich.edu	Gauger, Paul/W-8176-2019	Doherty, Gerard/0000-0002-1685-9552	NIDDK NIH HHS [P60DK20572, DK58771] Funding Source: Medline; PHS HHS [R01 A137141] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P60DK020572] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ain KB, 1998, THYROID, V8, P715, DOI 10.1089/thy.1998.8.715; Ain KB, 2000, THYROID, V10, P587, DOI 10.1089/thy.2000.10.587; Beatty GL, 2001, IMMUNOL RES, V24, P201, DOI 10.1385/IR:24:2:201; Bonavida B, 1999, INT J ONCOL, V15, P793; Braga-Basaria M, 2003, J CLIN ENDOCR METAB, V88, P1947, DOI 10.1210/jc.2002-021863; Bretz JD, 1999, J BIOL CHEM, V274, P23627, DOI 10.1074/jbc.274.33.23627; Bretz JD, 1999, J BIOL CHEM, V274, P25433, DOI 10.1074/jbc.274.36.25433; Caturegli P, 2000, P NATL ACAD SCI USA, V97, P1719, DOI 10.1073/pnas.020522597; de Metz J, 2000, THYROID, V10, P87, DOI 10.1089/thy.2000.10.87; Egle A, 1996, EUR J IMMUNOL, V26, P3119, DOI 10.1002/eji.1830261244; FISHER DE, 1994, CELL, V78, P539, DOI 10.1016/0092-8674(94)90518-5; Fulda S, 2002, ONCOGENE, V21, P2295, DOI 10.1038/sj.onc.1205255; Jelinek DF, 1997, J CLIN INVEST, V99, P447, DOI 10.1172/JCI119179; Kandasamy K, 2003, CANCER RES, V63, P1712; Kayagaki N, 1999, J IMMUNOL, V162, P2639; KILLINGER WA, 1992, ANN THORAC SURG, V53, P472, DOI 10.1016/0003-4975(92)90271-5; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kroemer G, 2001, B ACAD NAT MED PARIS, V185, P1135, DOI 10.1016/S0001-4079(19)34476-0; Kumar-Sinha C, 2002, J BIOL CHEM, V277, P575, DOI 10.1074/jbc.M107795200; Langaas V, 2001, ANTICANCER RES, V21, P3733; LEE YS, 1988, CANCER RES, V48, P559; Mitsiades N, 2000, CANCER RES, V60, P4122; Newton K, 1998, CURR OPIN GENET DEV, V8, P68, DOI 10.1016/S0959-437X(98)80064-6; Ossina NK, 1997, J BIOL CHEM, V272, P16351, DOI 10.1074/jbc.272.26.16351; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; Poulaki V, 2002, AM J PATHOL, V161, P643, DOI 10.1016/S0002-9440(10)64220-4; Ruiz-Ruiz C, 2002, BIOCHEM J, V365, P825, DOI 10.1042/BJ20020184; Sato K, 2001, EUR J IMMUNOL, V31, P3138, DOI 10.1002/1521-4141(200111)31:11<3138::AID-IMMU3138>3.0.CO;2-B; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; Shin EC, 2001, CANCER IMMUNOL IMMUN, V50, P23, DOI 10.1007/s002620000166; Simonian PL, 1997, ONCOGENE, V15, P1871, DOI 10.1038/sj.onc.1201350; Strasser A, 2000, ANNU REV BIOCHEM, V69, P217, DOI 10.1146/annurev.biochem.69.1.217; Sundararajan R, 2001, J BIOL CHEM, V276, P45120, DOI 10.1074/jbc.M106386200; Voigt W, 2000, CLIN CANCER RES, V6, P2087; Wang SH, 1999, ENDOCRINOLOGY, V140, P1649, DOI 10.1210/en.140.4.1649; Wang SH, 2002, J IMMUNOL, V168, P2470, DOI 10.4049/jimmunol.168.5.2470; Wang SH, 2001, THYROID, V11, P725, DOI 10.1089/10507250152484556; Yano H, 1996, J HEPATOL, V25, P454, DOI 10.1016/S0168-8278(96)80204-2; Yeung SCJ, 2000, CANCER RES, V60, P650	39	31	34	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 29	2004	23	4					928	935		10.1038/sj.onc.1207213	http://dx.doi.org/10.1038/sj.onc.1207213			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	767UV	14647456				2022-12-17	WOS:000188486600008
J	Denys, H; Jadidizadeh, A; Nik, SA; Van Dam, K; Aerts, S; Alman, BA; Cassiman, JJ; Tejpar, S				Denys, H; Jadidizadeh, A; Nik, SA; Van Dam, K; Aerts, S; Alman, BA; Cassiman, JJ; Tejpar, S			Identification of IGFBP-6 as a significantly downregulated gene by beta-catenin in desmoid tumors	ONCOGENE			English	Article						beta-catenin; IGFBP-6; expression profile; desmoid; target genes	AGGRESSIVE FIBROMATOSIS; CELL-PROLIFERATION; EXPRESSION; MUTATIONS; BINDING; CANCER; ACTIVATION; TARGET	Desmoid tumors (aggressive fibromatosis) are locally invasive soft tissue tumors in which beta-catenin-mediated TCF-3-dependent transcription is activated. To provide more insight into the pathophysiology of these tumors, expression profiles were generated using oligonucleotide arrays (Affymetrix). In total, 69 differentially expressed genes were identified in desmoids compared to normal fibroblasts (fascia) from the same patients. The differential expression of a selection of genes was confirmed using RT-PCR and Northern blotting. We further evaluated the insulin-like growth factor-binding protein 6 (IGFBP-6), a gene that was consistently downregulated in all desmoids tested. Promotor studies and electromobility shift assays revealed two functional beta-catenin/TCF-responsive elements in the human IGFBP-6 promoter. These findings suggest that IGFBP-6 is directly downregulated by the beta-catenin/TCF complex in desmoid tumors, and imply a role for the IGF axis in the proliferation of desmoid tumors.	Catholic Univ Louvain, Ctr Human Genet, B-3000 Louvain, Belgium; Univ Louvain, Dept Elect Engn, B-3001 Heverlee, Belgium; Hosp Sick Children, Program Dev Biol, Toronto, ON M5G 1X8, Canada; Univ Toronto, Toronto, ON M5G 1X8, Canada	Universite Catholique Louvain; Universite Catholique Louvain; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto	Tejpar, S (corresponding author), Catholic Univ Louvain, Ctr Human Genet, Campus Gasthuisberg,Herestr 49, B-3000 Louvain, Belgium.	Sabine.Tejpar@med.kuleuven.ac.be	Aerts, Stein/A-1100-2009; Nik, Saeid Amini/B-6640-2014	Aerts, Stein/0000-0002-8006-0315; Nik, Saeid Amini/0000-0002-9185-9456				Albuquerque C, 2002, HUM MOL GENET, V11, P1549, DOI 10.1093/hmg/11.13.1549; Alman BA, 1997, AM J PATHOL, V151, P329; Bach LA, 1999, HORM METAB RES, V31, P226, DOI 10.1055/s-2007-978723; Bauer A, 2000, EMBO J, V19, P6121, DOI 10.1093/emboj/19.22.6121; Brannon M, 1997, GENE DEV, V11, P2359, DOI 10.1101/gad.11.18.2359; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; Cheon SS, 2002, P NATL ACAD SCI USA, V99, P6973, DOI 10.1073/pnas.102657399; Cui HM, 2002, CANCER RES, V62, P6442; CULLEN KJ, 1992, MOL ENDOCRINOL, V6, P91, DOI 10.1210/me.6.1.91; DEMOOR CH, 1995, BIOCHEM J, V307, P225, DOI 10.1042/bj3070225; Eccles DM, 1996, AM J HUM GENET, V59, P1193; Fujita M, 2000, CANCER RES, V60, P6683; Gat U, 1998, CELL, V95, P605, DOI 10.1016/S0092-8674(00)81631-1; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Hecht A, 2000, EMBO REP, V1, P24, DOI 10.1093/embo-reports/kvd012; Kielman MF, 2002, NAT GENET, V32, P594, DOI 10.1038/ng1045; Kim EJ, 2002, J CELL PHYSIOL, V190, P92, DOI 10.1002/jcp.10045; Li C, 1998, AM J PATHOL, V153, P709, DOI 10.1016/S0002-9440(10)65614-3; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Poon R, 2001, ONCOGENE, V20, P451, DOI 10.1038/sj.onc.1204107; ROGHANI M, 1991, GROWTH REGULAT, V1, P125; Roose J, 1999, BBA-REV CANCER, V1424, pM23, DOI 10.1016/S0304-419X(99)00026-8; Roose J, 1998, NATURE, V395, P608, DOI 10.1038/26989; Saito T, 2001, J PATHOL, V195, P222, DOI 10.1002/path.942; SINGH P, 1994, AM J PHYSIOL-GASTR L, V267, pG608, DOI 10.1152/ajpgi.1994.267.4.G608; Tejpar S, 1999, ONCOGENE, V18, P6615, DOI 10.1038/sj.onc.1203041; Tejpar S, 2001, BRIT J CANCER, V85, P98, DOI 10.1054/bjoc.2001.1857; Zhang L, 1997, SCIENCE, V276, P1268, DOI 10.1126/science.276.5316.1268	28	31	34	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 22	2004	23	3					654	664		10.1038/sj.onc.1207160	http://dx.doi.org/10.1038/sj.onc.1207160			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	765VK	14737101				2022-12-17	WOS:000188304900004
J	Liu, YN; Kang, BB; Chen, JH				Liu, YN; Kang, BB; Chen, JH			Transcriptional regulation of human osteopontin promoter by C/EBP alpha and AML-1 in metastatic cancer cells	ONCOGENE			English	Article						gene expression; metastasis; OPN; C/EBP alpha; AML-1	BINDING; EXPRESSION; PROTEINS; FUSION; DOMAIN	Osteopontin (OPN) is a secreted glycoprotein produced by osteoclasts, macrophages, T cells, hematopoietic cells, and vascular smooth muscle cells. It contributes to macrophage homing and cellular immunity. It also mediates neovascularization, inhibits apoptosis, and plays important roles in extracellular matrix remodeling and angiogenesis. These properties are also characteristics of metastatic cancer cells. Consequently, the OPN gene was found to be upregulated among various metastatic cancer cells. This suggests that OPN is involved in tumor metastasis. How the OPN gene is upregulated in metastatic cancer cells remains to be illustrated. Thus, we investigated the transcriptional activation of the OPN promoter in the human metastatic cancer cell line A2058. We cloned the OPN promoter, and serial deletion analysis of the OPN promoter showed that the region between -170 and -127 may act as an enhancer to control the OPN gene in metastatic tumor cells. This region was found to contain overlapped AML-1 and C/EBP binding site motifs. Gel-mobility-shift assays using the A2058 nuclear extract and AML-1a or C/EBPalpha (CCAAT/enhancer binding protein alpha) recombinant protein indicated that these two transcription factors can bind to the overlapped AML-1/C/EBP binding site motifs on the OPN regulatory sequence from -147 to -127. Surprisingly, the gel-shift experiments did not show supershift complex formation between AML-1 and C/EBPalpha. Functional analysis showed that the C/EBPalpha was more potent than the complex of AML-1 and its cofactor CBFbeta to upregulate the OPN promoter. In addition, AML-1 and C/EBPalpha did not exhibit transactivation additively or synergistically. Our results suggest that AML-1 and C/EBPalpha play an important role in the upregulation of the OPN gene in metastatic tumor cells.	Tzu Chi Univ, Grad Inst Mol & Cell Biol, Hualien, Taiwan; Tzu Chi Univ, Grad Inst Human Genet, Hualien, Taiwan; Tzu Chi Univ, Coll Med, Dept Med Technol, Hualien, Taiwan	Tzu Chi University; Tzu Chi University; Tzu Chi University	Chen, JH (corresponding author), Tzu Chi Univ, Grad Inst Mol & Cell Biol, 701 Chung Yang Rd Sec 3, Hualien, Taiwan.	jhc@mail.tcu.edu.tw						ANNA T, 1998, INT J CANCER, V77, P82; Baiker A, 2000, NAT CELL BIOL, V2, P182, DOI 10.1038/35004061; BROWN LF, 1994, AM J PATHOL, V145, P610; Chabas D, 2001, SCIENCE, V294, P1731, DOI 10.1126/science.1062960; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; Crawford HC, 1998, CANCER RES, V58, P5206; DIPAK PR, 2002, BIOCHEM J, V365, P561; DONGYAN W, 2000, ONCOGENE, V19, P5801; FUMIYUKI T, 2002, INT J CANCER, V98, P707; Gang X, 2001, AM J KIDNEY DIS, V37, P374, DOI 10.1053/ajkd.2001.21316; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HELMUT P, 2003, NAT REV MOL CELL BIO, V4, P33; JOHN DD, 1983, NUCLEIC ACIDS RES, V11, P1475; Kaartinen MT, 1999, J BIOL CHEM, V274, P1729, DOI 10.1074/jbc.274.3.1729; LEVANON D, 1994, GENOMICS, V23, P425, DOI 10.1006/geno.1994.1519; LIU P, 1993, SCIENCE, V261, P1041, DOI 10.1126/science.8351518; Lorsbach RB, 2001, INT J HEMATOL, V74, P258, DOI 10.1007/BF02982058; Lund AH, 2002, CANCER CELL, V1, P213, DOI 10.1016/S1535-6108(02)00049-1; MEYERS S, 1995, MOL CELL BIOL, V15, P1974; MEYERS S, 1993, MOL CELL BIOL, V13, P6336, DOI 10.1128/MCB.13.10.6336; Mignatti P, 1996, ENZYME PROTEIN, V49, P117, DOI 10.1159/000468621; MIKALA E, 2002, NAT REV CANCER, V2, P163; MIYOSHI H, 1995, NUCLEIC ACIDS RES, V23, P2762, DOI 10.1093/nar/23.14.2762; Nau GJ, 1999, INFECT IMMUN, V67, P4223, DOI 10.1128/IAI.67.8.4223-4230.1999; PER A, 1995, BIOCHEM BIOPH RES CO, V215, P106; Petrovick HS, 1998, MOL CELL BIOL, V18, P3915, DOI 10.1128/MCB.18.7.3915; Rittling SR, 2002, J BIOL CHEM, V277, P9175, DOI 10.1074/jbc.M109028200; Rudland PS, 2002, CANCER RES, V62, P3417; Sato M, 1998, ONCOGENE, V17, P1517, DOI 10.1038/sj.onc.1202064; Shi XM, 2001, J BIOL CHEM, V276, P850, DOI 10.1074/jbc.M005955200; Sporn MB, 1996, LANCET, V347, P1377, DOI 10.1016/S0140-6736(96)91015-6; SUBHA P, 2001, J BIOL CHEM, V276, P44926; Tomizawa M, 2002, INT J MOL MED, V9, P597; Weber GF, 2001, BBA-REV CANCER, V1552, P61, DOI 10.1016/S0304-419X(01)00037-3; Weber GF, 1996, SCIENCE, V271, P509, DOI 10.1126/science.271.5248.509; Zhang DE, 1996, MOL CELL BIOL, V16, P1231	38	31	34	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 8	2004	23	1					278	288		10.1038/sj.onc.1207022	http://dx.doi.org/10.1038/sj.onc.1207022			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	761HK	14712233				2022-12-17	WOS:000187895300029
J	Perkins, ND				Perkins, ND			Oncogenes, tumor suppressors and p52 NF-kappa B	ONCOGENE			English	Editorial Material						NF-kappa B2; Lyt-10; NIK; IKK; P53; cyclin D1	HUMAN-IMMUNODEFICIENCY-VIRUS; DNA-BINDING; CYCLIN D1; TRANSCRIPTIONAL ACTIVATION; NF-KAPPA-B2 P100; IKK-ALPHA; T-CELLS; EXPRESSION; BCL-3; GENE	A role for the p52 NF-kappaB subunit in tumorigenesis has been steadily emerging since its discovery as a gene associated with chromosomal translocations in B- and T-cell lymphomas. Now Eliopoulos and co-workers have extended these studies to examine the effect of the Epstein - Barr virus (EBV)-encoded latent infection membrane protein 1 (LMP1) on p52. They find that LMP1 stimulates the processing of p100 to p52 NF-kappaB. Moreover, nuclear p52 is also associated with LMP1 expression in tumor tissue biopsies. They also demonstrate that the pathway leading to p100/p52 processing is distinct from that engaged by LMP1 to activate other NF-kappaB subunits through IkappaBalpha degradation. A clearer picture is now developing of the important role that p52 NF-kappaB plays during normal cell growth and how subverting its function can contribute to oncogenesis.	Univ Dundee, Sch Life Sci, Div Gene Regulat & Express, Dundee DD1 5EH, Scotland	University of Dundee	Perkins, ND (corresponding author), Univ Dundee, Sch Life Sci, Div Gene Regulat & Express, MSI WTB Complex,Dow St, Dundee DD1 5EH, Scotland.	n.d.perkins@dundee.ac.uk						Baldwin AS, 2001, J CLIN INVEST, V107, P241, DOI 10.1172/JCI11991; BOURS V, 1993, CELL, V72, P729, DOI 10.1016/0092-8674(93)90401-B; BOURS V, 1992, MOL CELL BIOL, V12, P685, DOI 10.1128/MCB.12.2.685; Budunova IV, 1999, ONCOGENE, V18, P7423, DOI 10.1038/sj.onc.1203104; Cao YX, 2001, CELL, V107, P763, DOI 10.1016/S0092-8674(01)00599-2; CHANG CC, 1995, MOL CELL BIOL, V15, P5180; Ciana P, 1997, ONCOGENE, V14, P1805, DOI 10.1038/sj.onc.1201015; Cogswell PC, 2000, ONCOGENE, V19, P1123, DOI 10.1038/sj.onc.1203412; Coope HJ, 2002, EMBO J, V21, P5375, DOI 10.1093/emboj/cdf542; Dejardin E, 2002, IMMUNITY, V17, P525, DOI 10.1016/S1074-7613(02)00423-5; DUCKETT CS, 1993, MOL CELL BIOL, V13, P1315, DOI 10.1128/MCB.13.3.1315; FRACCHIOLLA NS, 1993, ONCOGENE, V8, P2839; FUJITA T, 1992, GENE DEV, V6, P775, DOI 10.1101/gad.6.5.775; Garg A, 2002, LEUKEMIA, V16, P1053, DOI 10.1038/sj.leu.2402482; Heusch M, 1999, ONCOGENE, V18, P6201, DOI 10.1038/sj.onc.1203022; Ishikawa H, 1997, J EXP MED, V186, P999, DOI 10.1084/jem.186.7.999; Jol H, 2000, ONCOGENE, V19, P841, DOI 10.1038/sj.onc.1203392; Kayagaki N, 2002, IMMUNITY, V17, P515, DOI 10.1016/S1074-7613(02)00425-9; LAHERTY CD, 1992, J BIOL CHEM, V267, P24157; LIPTAY S, 1994, MOL CELL BIOL, V14, P7695, DOI 10.1128/MCB.14.12.7695; Mayo MW, 1997, SCIENCE, V278, P1812, DOI 10.1126/science.278.5344.1812; McFarland EDC, 1999, ONCOGENE, V18, P6959, DOI 10.1038/sj.onc.1203217; McKeithan TW, 1997, GENE CHROMOSOME CANC, V20, P64, DOI 10.1002/(SICI)1098-2264(199709)20:1<64::AID-GCC10>3.0.CO;2-F; Mordmuller B, 2003, EMBO REP, V4, P82, DOI 10.1038/embor710; Mosialos G, 1997, SEMIN CANCER BIOL, V8, P121, DOI 10.1006/scbi.1997.0063; Muller JR, 2003, J BIOL CHEM, V278, P12006, DOI 10.1074/jbc.M210768200; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; NERI A, 1991, CELL, V67, P1075, DOI 10.1016/0092-8674(91)90285-7; NOLAN GP, 1993, MOL CELL BIOL, V13, P3557, DOI 10.1128/MCB.13.6.3557; Perkins ND, 2000, TRENDS BIOCHEM SCI, V25, P434, DOI 10.1016/S0968-0004(00)01617-0; PERKINS ND, 1994, MOL CELL BIOL, V14, P6570, DOI 10.1128/MCB.14.10.6570; Reuther JY, 1998, GENE DEV, V12, P968, DOI 10.1101/gad.12.7.968; Rocha S, 2003, MOL CELL BIOL, V23, P4713, DOI 10.1128/MCB.23.13.4713-4727.2003; Saccani S, 2003, MOL CELL, V11, P1563, DOI 10.1016/S1097-2765(03)00227-2; SCHMID RM, 1991, NATURE, V352, P733, DOI 10.1038/352733a0; Senftleben U, 2001, SCIENCE, V293, P1495, DOI 10.1126/science.1062677; THAKUR S, 1994, ONCOGENE, V9, P2335; Viatour P, 2003, LEUKEMIA, V17, P1349, DOI 10.1038/sj.leu.2402982; Wang YQ, 2002, NAT CELL BIOL, V4, P888, DOI 10.1038/ncb872; WEINSTATSASLOW D, 1995, NAT MED, V1, P1257, DOI 10.1038/nm1295-1257; Westerheide SD, 2001, MOL CELL BIOL, V21, P8428, DOI 10.1128/MCB.21.24.8428-8436.2001; Xiao GT, 2001, EMBO J, V20, P6805, DOI 10.1093/emboj/20.23.6805	43	31	34	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 23	2003	22	48					7553	7556		10.1038/sj.onc.1207139	http://dx.doi.org/10.1038/sj.onc.1207139			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	735KQ	14576816				2022-12-17	WOS:000186113000001
J	Simeone, AM; Broemeling, LD; Rosenblum, J; Tari, AM				Simeone, AM; Broemeling, LD; Rosenblum, J; Tari, AM			HER2/neu reduces the apoptotic effects of N-(4-hydroxyphenyl)retinamide (4-HPR) in breast cancer cells by decreasing nitric oxide production	ONCOGENE			English	Article						HER2/neu; 4-HPR (fenretinide); nitric oxide; all-trans retinoic acid; breast cancer	TRANS-RETINOIC ACID; MONOCLONAL-ANTIBODY; PHASE-II; PROGNOSTIC INDICATOR; GROWTH-INHIBITION; SYNTHASE ACTIVITY; TUMOR-CELLS; EXPRESSION; TRASTUZUMAB; FENRETINIDE	The retinoid N-(4-hydroxyphenyl) retinamide (4-HPR also known as fenretinide) is a potent inducer of apoptosis in breast cancer cells. We observed a 4.5-fold reduction in 4-HPR- mediated apoptosis in MCF-7 breast cancer cells transfected with HER2/neu (MCF-7/HER2) as compared with the parental MCF-7 (MCF-7/WT) cells. Blocking HER2/neu with trastuzumab (Herceptin(TM)) led to a sixfold increase in 4-HPR- induced apoptosis in HER2/neuoverexpressing cells. These data indicate that HER2/neu reduces the sensitivity of breast cancer cells to 4-HPR. We showed previously that nitric oxide ( NO) is essential for 4-HPR to induce apoptosis in breast cancer cells. The inhibitory effects of the 4-HPR and trastuzumab combination correlated with the amount of NO produced in HER2/neu-overexpressing cells. When a NO synthase ( NOS) inhibitor was used to block NO production, decreased apoptosis by the 4-HPR and trastuzumab combination was observed. Furthermore, 4-HPR-mediated NOSII expression was lower in MCF-7/HER2 than MCF-7/WT cells, but was increased by trastuzumab in HER2/neu-overexpressing cells. Here we report the novel findings that HER2/neu reduces the ability of 4-HPR to induce apoptosis in breast cancer cells, and that one mechanism by which HER2/neu increases the resistance of breast cancer cells to 4-HPR is by decreasing NOSII-mediated NO production.	Univ Texas, MD Anderson Canc Ctr, Dept Bioimmunotherapy, Sect Immunobiol & Drug Carriers,Unit 422, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Biostat, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Tari, AM (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Bioimmunotherapy, Sect Immunobiol & Drug Carriers,Unit 422, 1515 Holcombe Blvd, Houston, TX 77030 USA.	atari@mdanderson.org						Adami A, 1998, LIFE SCI, V63, P2097, DOI 10.1016/S0024-3205(99)80006-X; Baselga J, 1998, CANCER RES, V58, P2825; BENZ CC, 1992, BREAST CANCER RES TR, V24, P85, DOI 10.1007/BF01961241; Binder C, 1999, LAB INVEST, V79, P1703; Burke HB, 1998, CANCER-AM CANCER SOC, V82, P874, DOI 10.1002/(SICI)1097-0142(19980301)82:5<874::AID-CNCR11>3.0.CO;2-Y; Burstein HJ, 2001, J CLIN ONCOL, V19, P2722, DOI 10.1200/JCO.2001.19.10.2722; CARTER P, 1992, P NATL ACAD SCI USA, V89, P4285, DOI 10.1073/pnas.89.10.4285; Cobleigh MA, 1999, J CLIN ONCOL, V17, P2639, DOI 10.1200/JCO.1999.17.9.2639; Colomer R, 2000, CLIN CANCER RES, V6, P2356; COSTA A, 1989, EUR J CANCER CLIN ON, V25, P805, DOI 10.1016/0277-5379(89)90124-7; Decensi A, 2000, J CELL BIOCHEM, P84; DONG ZY, 1994, CANCER RES, V54, P789; DuenasGonzalez A, 1997, MODERN PATHOL, V10, P645; Esteva FJ, 2002, J CLIN ONCOL, V20, P1800, DOI 10.1200/JCO.2002.07.058; Fanjul AN, 1996, J BIOL CHEM, V271, P22441, DOI 10.1074/jbc.271.37.22441; FORMELLI F, 1993, J CLIN ONCOL, V11, P2036, DOI 10.1200/JCO.1993.11.10.2036; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; Haffty BG, 1996, INT J RADIAT ONCOL, V35, P751, DOI 10.1016/0360-3016(96)00150-2; Herbert BS, 1999, NUTR CANCER, V34, P121, DOI 10.1207/S15327914NC3402_1; HUDZIAK RM, 1989, MOL CELL BIOL, V9, P1165, DOI 10.1128/MCB.9.3.1165; Jinno H, 1999, CARCINOGENESIS, V20, P229, DOI 10.1093/carcin/20.2.229; Kalivendi SV, 2001, J BIOL CHEM, V276, P47266, DOI 10.1074/jbc.M106829200; Kazmi SMI, 1996, CANCER RES, V56, P1056; LI LM, 1991, CANCER RES, V51, P2531; Lu YH, 2001, JNCI-J NATL CANCER I, V93, P1852, DOI 10.1093/jnci/93.24.1852; Mangelsdorf David J., 1994, P319; Mangiarotti R, 1998, BRIT J CANCER, V77, P186, DOI 10.1038/bjc.1998.32; Martin JHJ, 2000, ONCOL REP, V7, P219; MEHTA RG, 1991, EUR J CANCER, V27, P138, DOI 10.1016/0277-5379(91)90471-O; MODIANO MR, 1990, INVEST NEW DRUG, V8, P317; MOON RC, 1979, CANCER RES, V39, P1339; Pegram MD, 1998, J CLIN ONCOL, V16, P2659, DOI 10.1200/JCO.1998.16.8.2659; PIETRAS RJ, 1994, ONCOGENE, V9, P1829; Pietras RJ, 1999, CANCER RES, V59, P1347; Rao GN, 1999, BREAST CANCER RES TR, V58, P241; Reveneau S, 1999, LAB INVEST, V79, P1215; Seidman AD, 2001, J CLIN ONCOL, V19, P2587, DOI 10.1200/JCO.2001.19.10.2587; SHEIKH MS, 1995, CARCINOGENESIS, V16, P2477, DOI 10.1093/carcin/16.10.2477; Simeone AM, 2002, MOL CANCER THER, V1, P1009; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Sliwkowski MX, 1999, SEMIN ONCOL, V26, P60; Tan M, 1997, CANCER RES, V57, P1199; TANDON AK, 1989, J CLIN ONCOL, V7, P1120, DOI 10.1200/JCO.1989.7.8.1120; Tari AM, 1999, ONCOGENE, V18, P1325, DOI 10.1038/sj.onc.1202422; Tari AM, 2002, ONCOGENE, V21, P5224, DOI 10.1038/sj.onc.1205660; THOMSEN LL, 1995, BRIT J CANCER, V72, P41, DOI 10.1038/bjc.1995.274; Toma S, 1998, ANTICANCER RES, V18, P935; Toma S, 1997, INT J CANCER, V70, P619, DOI 10.1002/(SICI)1097-0215(19970304)70:5<619::AID-IJC21>3.0.CO;2-6; Tschugguel W, 1999, BREAST CANCER RES TR, V56, P145; Umansky V, 2000, INT J ONCOL, V16, P109; Vakkala M, 2000, CLIN CANCER RES, V6, P2408; Veronesi U, 1999, J NATL CANCER I, V91, P1847, DOI 10.1093/jnci/91.21.1847; Vogel CL, 2002, J CLIN ONCOL, V20, P719, DOI 10.1200/JCO.2002.20.3.719; Wang TTY, 1996, CANCER LETT, V107, P65, DOI 10.1016/0304-3835(96)04344-3; Wilcken NRC, 1996, CELL GROWTH DIFFER, V7, P65; Witters LM, 1997, BREAST CANCER RES TR, V42, P1, DOI 10.1023/A:1005798224288; WRIGHT C, 1989, CANCER RES, V49, P2087; XIE KP, 1995, J EXP MED, V181, P1333, DOI 10.1084/jem.181.4.1333; Yu DH, 1996, ONCOGENE, V13, P1359	61	31	31	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 2	2003	22	43					6739	6747		10.1038/sj.onc.1206786	http://dx.doi.org/10.1038/sj.onc.1206786			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	729XA	14555987				2022-12-17	WOS:000185799300009
J	Joerges, C; Kuntze, I; Herzinge, T				Joerges, C; Kuntze, I; Herzinge, T			Induction of a caffeine-sensitive S-phase cell cycle checkpoint by psoralen plus ultraviolet A radiation	ONCOGENE			English	Article						cell cycle; keratinocytes; psoralens; replication checkpoint; ultraviolet radiation	DNA-DAMAGE CHECKPOINT; INTERSTRAND CROSS-LINKS; IRRADIATED HELA-CELLS; ATAXIA-TELANGIECTASIA; SACCHAROMYCES-CEREVISIAE; DEPENDENT KINASES; G(1)/S TRANSITION; MAMMALIAN-CELLS; G(2) CHECKPOINT; PROTEIN-KINASE	Induction of interstrand crosslinks (ICLs) in chromosomal DNA is considered a major reason for the antiproliferative effect of psoralen plus ultraviolet A ( PUVA). It is unclear as to whether PUVA-induced cell cycle arrest is caused by ICLs mechanically stalling replication forks or by triggering cell cycle checkpoints. Cell cycle checkpoints serve to maintain genomic stability by halting cell cycle progression to prevent replication of damaged DNA templates or segregation of broken chromosomes. Here, we show that HaCaT keratinocytes treated with PUVA arrest with S-phase DNA content. Cells that had completed DNA replication were not perturbed by PUVA and passed through mitosis. Cells treated with PUVA during G1-phase continued traversing G1 until arresting in early S-phase. PUVA induced rapid phosphorylation of the Chk1 checkpoint kinase at Ser345 and a concomitant decrease in Cdc25A levels. Chk1 phosphorylation, decrease of Cdc25 A levels and S-phase arrest were abolished by caffeine, demonstrating that active checkpoint signaling rather than passive mechanical blockage by ICLs causes the PUVA-induced replication arrest. Overexpression of Cdc25A only partially overrode the S-phase arrest, suggesting that additional signaling events implement PUVA-induced S-phase arrest.	Univ Munich, Klin & Poliklin Dermatol & Allergol, D-80337 Munich, Germany	University of Munich	Herzinge, T (corresponding author), Univ Munich, Klin & Poliklin Dermatol & Allergol, Frauenlobstr 9-11, D-80337 Munich, Germany.	Thomas.Herzinger@lrz.uni-muenchen.de						Akkari YMN, 2000, MOL CELL BIOL, V20, P8283, DOI 10.1128/MCB.20.21.8283-8289.2000; Bentley NJ, 1996, EMBO J, V15, P6641, DOI 10.1002/j.1460-2075.1996.tb01054.x; Blasina A, 1999, CURR BIOL, V9, P1135, DOI 10.1016/S0960-9822(99)80486-2; Blasina A, 1999, CURR BIOL, V9, P1, DOI 10.1016/S0960-9822(99)80041-4; Blomberg I, 1999, MOL CELL BIOL, V19, P6183; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; BUSSE PM, 1977, RADIAT RES, V71, P666, DOI 10.2307/3574634; BUSSE PM, 1978, RADIAT RES, V76, P292, DOI 10.2307/3574780; Chaturvedi P, 1999, ONCOGENE, V18, P4047, DOI 10.1038/sj.onc.1202925; Cimprich KA, 1996, P NATL ACAD SCI USA, V93, P2850, DOI 10.1073/pnas.93.7.2850; COHEN SR, 1981, J INVEST DERMATOL, V76, P409, DOI 10.1111/1523-1747.ep12520956; DEANDRADE HHR, 1989, MOL GEN GENET, V217, P419; Diffley JFX, 1998, CURR BIOL, V8, pR771, DOI 10.1016/S0960-9822(07)00483-6; Dronkert MLG, 2001, MUTAT RES-DNA REPAIR, V486, P217, DOI 10.1016/S0921-8777(01)00092-1; Esashi F, 1999, MOL CELL, V4, P167, DOI 10.1016/S1097-2765(00)80364-0; Falck J, 2002, NAT GENET, V30, P290, DOI 10.1038/ng845; Falck J, 2001, NATURE, V410, P842, DOI 10.1038/35071124; Feijoo C, 2001, J CELL BIOL, V154, P913, DOI 10.1083/jcb.200104099; Furnari B, 1999, MOL BIOL CELL, V10, P833, DOI 10.1091/mbc.10.4.833; GALAKTIONOV K, 1991, CELL, V67, P1181, DOI 10.1016/0092-8674(91)90294-9; Gaspprro F. P., 1988, PSORALEN DNA PHOTOBI, V1, P5; GUNTHER EJ, 1995, CANCER RES, V55, P1283; Guo ZJ, 2000, GENE DEV, V14, P2745, DOI 10.1101/gad.842500; Hall-Jackson CA, 1999, ONCOGENE, V18, P6707, DOI 10.1038/sj.onc.1203077; HAMLIN JL, 1992, BIOESSAYS, V14, P651, DOI 10.1002/bies.950141002; Hekmat-Nejad M, 2000, CURR BIOL, V10, P1565, DOI 10.1016/S0960-9822(00)00855-1; Henzinger T, 1998, J BIOL CHEM, V273, P14958, DOI 10.1074/jbc.273.24.14958; HERZINGER T, 1995, ONCOGENE, V11, P2151; HOFFMANN I, 1994, EMBO J, V13, P4302, DOI 10.1002/j.1460-2075.1994.tb06750.x; JACHYMCZYK WJ, 1981, MOL GEN GENET, V182, P196, DOI 10.1007/BF00269658; JINNO S, 1994, EMBO J, V13, P1549, DOI 10.1002/j.1460-2075.1994.tb06417.x; Liu QH, 2000, GENE DEV, V14, P1448; LJUNGGREN B, 1980, J INVEST DERMATOL, V74, P59, DOI 10.1111/1523-1747.ep12514621; Luftl M, 1998, J INVEST DERMATOL, V111, P399, DOI 10.1046/j.1523-1747.1998.00316.x; MAGANASCHWENCKE N, 1982, P NATL ACAD SCI-BIOL, V79, P1722, DOI 10.1073/pnas.79.6.1722; Mailand N, 2000, SCIENCE, V288, P1425, DOI 10.1126/science.288.5470.1425; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; MENIEL V, 1995, MUTAT RES-FUND MOL M, V329, P121, DOI 10.1016/0027-5107(95)00023-C; Molinari M, 2000, EMBO REP, V1, P71, DOI 10.1093/embo-reports/kvd018; Nurse P, 1997, CELL, V91, P865, DOI 10.1016/S0092-8674(00)80476-6; ORREN DK, 1995, MOL CELL BIOL, V15, P3722; PAINTER RB, 1980, P NATL ACAD SCI-BIOL, V77, P7315, DOI 10.1073/pnas.77.12.7315; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; RAO PN, 1970, NATURE, V225, P159, DOI 10.1038/225159a0; SADHU K, 1990, P NATL ACAD SCI USA, V87, P5139, DOI 10.1073/pnas.87.13.5139; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; Sarkaria JN, 1999, CANCER RES, V59, P4375; SCHLEGEL R, 1986, SCIENCE, V232, P1264, DOI 10.1126/science.2422760; SEBASTIAN B, 1993, P NATL ACAD SCI USA, V90, P3521, DOI 10.1073/pnas.90.8.3521; Sexl V, 1999, ONCOGENE, V18, P573, DOI 10.1038/sj.onc.1202362; TOBEY RA, 1975, NATURE, V254, P245, DOI 10.1038/254245a0; Tominaga K, 1999, J BIOL CHEM, V274, P31463, DOI 10.1074/jbc.274.44.31463; VARGA JM, 1982, CANCER RES, V42, P2223; WANG YY, 1988, MOL CELL BIOL, V8, P196, DOI 10.1128/MCB.8.1.196; Weinert T, 1998, CELL, V94, P555, DOI 10.1016/S0092-8674(00)81597-4; Zhao H, 2001, MOL CELL BIOL, V21, P4129, DOI 10.1128/MCB.21.13.4129-4139.2001; Zhao S, 2000, NATURE, V405, P473, DOI 10.1038/35013083; Zhou BBS, 2000, J BIOL CHEM, V275, P10342, DOI 10.1074/jbc.275.14.10342	58	31	33	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 18	2003	22	40					6119	6128		10.1038/sj.onc.1206613	http://dx.doi.org/10.1038/sj.onc.1206613			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	724UZ	13679850				2022-12-17	WOS:000185506200001
J	Yustein, JT; Xia, L; Kahlenburg, JM; Robinson, D; Templeton, D; Kung, HJ				Yustein, JT; Xia, L; Kahlenburg, JM; Robinson, D; Templeton, D; Kung, HJ			Comparative studies of a new subfamily of human Ste20-like kinases: homodimerization, subcellular localization, and selective activation of MKK3 and p38	ONCOGENE			English	Article						Ste20 kinase; TAO; p38 MAPK	EPIDERMAL-GROWTH-FACTOR; N-TERMINAL KINASE; HEMATOPOIETIC PROGENITOR KINASE-1; SIGNAL-REGULATED KINASE; GERMINAL CENTER KINASE; PROTEIN-KINASE; PAK-FAMILY; MOLECULAR-CLONING; ADAPTER PROTEINS; COILED COILS	The Sterile-20 or Ste20 family of serine/threonine kinases is a group of signaling molecules whose physiological roles within mammalian cells are just starting to be elucidated. Here, in this report we present the characterization of three human Ste20-like kinases with greater than 90% similarity within their catalytic domains that de. ne a novel subfamily of Ste20s. Members of this kinase family include rat thousand and one (TAO1) and chicken KFC ( kinase from chicken). For the lack of a consensus nomenclature in the literature, in this report, we shall call this family hKFC ( for their homology to chicken KFC) and the three members hKFC-A, hKFC-B, and hKFC-C, respectively. These kinases have many similarities including an aminoterminal kinase domain, a serine-rich region, and a coiled-coil configuration within the C-terminus. All three kinases are able to activate the p38 MAP kinase pathway through the specific activation of the upstream MKK3 kinase. We also offer evidence, both theoretical and biochemical, showing that these kinases can undergo self-association. Despite these similarities, these kinases differ in tissue distribution, apparent subcellular localization, and feature structural differences largely within the carboxyl-terminal sequence.	Univ Calif Davis, Med Ctr, Ctr Canc, Sacramento, CA 95817 USA; Case Western Reserve Univ, Dept Mol Biol & Microbiol, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Pathol, Cleveland, OH 44106 USA; Univ Virginia, Dept Pathol, Charlottesville, VA 22908 USA	University of California System; University of California Davis; Case Western Reserve University; Case Western Reserve University; University of Virginia	Kung, HJ (corresponding author), Univ Calif Davis, Med Ctr, Ctr Canc, 4645 2nd Ave, Sacramento, CA 95817 USA.	hkung@ucdavis.edu	Templeton, Dennis J/F-7695-2011; Kung, Hsing-Jien/C-7651-2013		NATIONAL CANCER INSTITUTE [U01CA057179, R37CA039207, R01CA057179, R37CA046613, R01CA039207, R01CA046613] Funding Source: NIH RePORTER; NCI NIH HHS [CA39207, CA57179, CA46613] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Assefa Z, 1997, J INVEST DERMATOL, V108, P886, DOI 10.1111/1523-1747.ep12292595; Becker E, 2000, MOL CELL BIOL, V20, P1537, DOI 10.1128/MCB.20.5.1537-1545.2000; Bost F, 1999, MOL CELL BIOL, V19, P1938; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; Brown JL, 1996, CURR BIOL, V6, P598, DOI 10.1016/S0960-9822(02)00546-8; CHAREST DL, 1993, MOL CELL BIOL, V13, P4679, DOI 10.1128/MCB.13.8.4679; Chen Z, 1999, J BIOL CHEM, V274, P28803, DOI 10.1074/jbc.274.40.28803; Chung CY, 1999, J CELL BIOL, V147, P559, DOI 10.1083/jcb.147.3.559; CREASY CL, 1995, J BIOL CHEM, V270, P21695, DOI 10.1074/jbc.270.37.21695; Creasy CL, 1995, GENE, V167, P303, DOI 10.1016/0378-1119(95)00653-2; Dan I, 2000, FEBS LETT, V469, P19, DOI 10.1016/S0014-5793(00)01247-3; Dan I, 2001, TRENDS CELL BIOL, V11, P220, DOI 10.1016/S0962-8924(01)01980-8; Eby JJ, 1998, CURR BIOL, V8, P967, DOI 10.1016/S0960-9822(98)00398-4; Endo J, 2000, FEBS LETT, V468, P234, DOI 10.1016/S0014-5793(00)01219-9; Enslen H, 2000, EMBO J, V19, P1301, DOI 10.1093/emboj/19.6.1301; Fanger GR, 1997, CURR OPIN GENET DEV, V7, P67, DOI 10.1016/S0959-437X(97)80111-6; Frost JA, 1996, MOL CELL BIOL, V16, P3707, DOI 10.1128/mcb.16.7.3707; Geng Y, 1996, J CLIN INVEST, V98, P2425, DOI 10.1172/JCI119056; HATZ P, 1994, J BIOL CHEM, V269, P16802; Holly SP, 1999, J CELL BIOL, V147, P845, DOI 10.1083/jcb.147.4.845; Hu MCT, 1996, GENE DEV, V10, P2251, DOI 10.1101/gad.10.18.2251; Hutchison M, 1998, J BIOL CHEM, V273, P28625, DOI 10.1074/jbc.273.44.28625; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Kyriakis JM, 1996, BIOESSAYS, V18, P567, DOI 10.1002/bies.950180708; Ling P, 1999, MOL CELL BIOL, V19, P1359; Ling P, 2001, J BIOL CHEM, V276, P18908, DOI 10.1074/jbc.M101485200; Lu HT, 1999, EMBO J, V18, P1845, DOI 10.1093/emboj/18.7.1845; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; Moore TM, 2000, J BIOL CHEM, V275, P4311, DOI 10.1074/jbc.275.6.4311; Moriguchi T, 1996, J BIOL CHEM, V271, P13675, DOI 10.1074/jbc.271.23.13675; Oehrl W, 1998, ONCOGENE, V17, P1893, DOI 10.1038/sj.onc.1202108; Parrini MC, 2002, MOL CELL, V9, P73, DOI 10.1016/S1097-2765(01)00428-2; Paul A, 1997, CELL SIGNAL, V9, P403, DOI 10.1016/S0898-6568(97)00042-9; PERALDI P, 1993, ENDOCRINOLOGY, V132, P2578, DOI 10.1210/en.132.6.2578; POMBO CM, 1995, NATURE, V377, P750, DOI 10.1038/377750a0; Rousseau S, 1997, ONCOGENE, V15, P2169, DOI 10.1038/sj.onc.1201380; Su YC, 1997, EMBO J, V16, P1279, DOI 10.1093/emboj/16.6.1279; Takekawa M, 1997, EMBO J, V16, P4973, DOI 10.1093/emboj/16.16.4973; Tassi E, 1999, J BIOL CHEM, V274, P33287, DOI 10.1074/jbc.274.47.33287; Tibbles LA, 1996, EMBO J, V15, P7026, DOI 10.1002/j.1460-2075.1996.tb01094.x; Wolf E, 1997, PROTEIN SCI, V6, P1179, DOI 10.1002/pro.5560060606; Wysk M, 1999, P NATL ACAD SCI USA, V96, P3763, DOI 10.1073/pnas.96.7.3763; Xing J, 1998, MOL CELL BIOL, V18, P1946, DOI 10.1128/MCB.18.4.1946; Yoneda T, 2001, J BIOL CHEM, V276, P13935, DOI 10.1074/jbc.M010677200; Yustein JT, 2000, ONCOGENE, V19, P710, DOI 10.1038/sj.onc.1203342; Zanke BW, 1996, CURR BIOL, V6, P606, DOI 10.1016/S0960-9822(02)00547-X; Zanke BW, 1996, J BIOL CHEM, V271, P29876, DOI 10.1074/jbc.271.47.29876; Zhou GS, 1999, J BIOL CHEM, V274, P13133, DOI 10.1074/jbc.274.19.13133	49	31	36	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 18	2003	22	40					6129	6141		10.1038/sj.onc.1206605	http://dx.doi.org/10.1038/sj.onc.1206605			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	724UZ	13679851				2022-12-17	WOS:000185506200002
J	Schmidt-Ullrich, RK				Schmidt-Ullrich, RK			Molecular targets in radiation oncology - Overview	ONCOGENE			English	Editorial Material						DNA damage; cell survival; signal transduction			Virginia Commonwealth Univ, Dept Radiat Oncol, Richmond, VA 23284 USA	Virginia Commonwealth University	Schmidt-Ullrich, RK (corresponding author), Virginia Commonwealth Univ, Dept Radiat Oncol, Med Coll Virginia Campus, Richmond, VA 23284 USA.								0	31	31	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 1	2003	22	37					5730	5733		10.1038/sj.onc.1206662	http://dx.doi.org/10.1038/sj.onc.1206662			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	717JV	12947382				2022-12-17	WOS:000185086100002
J	He, JQ; Xu, HG; Xu, XX; Hall, RA				He, JQ; Xu, HG; Xu, XX; Hall, RA			Cell cycle-dependent phosphorylation of Disabled-2 by cdc2	ONCOGENE			English	Article						tumor suppressor; cdk; receptor; cancer; kinase; phosphatase	EPITHELIAL OVARIAN-CANCER; TUMOR-SUPPRESSOR GENE; PROTEIN-PHOSPHORYLATION; BINDING PARTNER; PROSTATE-CANCER; OKADAIC ACID; MYOSIN-VI; DOC-2/DAB2; KINASE; MOUSE	Disabled-2 (Dab2; also known as p96 and DOC-2) is a signal transduction protein that has been implicated in the control of cell growth. Dab2 is known to be a phosphoprotein, but little is known about the kinases that phosphorylate Dab2. We have found that Dab2 phosphorylation is markedly increased during the mitosis phase of the cell cycle. This phosphorylation is blocked by roscovitine, a selective inhibitor of cyclin-dependent kinases. Dab2 robustly coimmunoprecipitates from cells with the cyclin-dependent kinase cdc2, and purified cdc2 can phosphorylate purified Dab2 fusion proteins in vitro on multiple sites. Cellular phosphorylation of Dab2 by cdc2 promotes the association of Dab2 with Pir1 a peptidylprolyl isomerase that regulates the rate of Dab2 dephosphorylation. These findings reveal that Dab2 is differentially phosphorylated during the cell cycle by cdc2 and provide a potential feedback mechanism by which Dab2 inhibition of cell growth and proliferation may be regulated.	Emory Univ, Sch Med, Dept Pharmacol, Atlanta, GA 30322 USA; Fox Chase Canc Ctr, Ovarian Canc Program, Div Med Sci, Philadelphia, PA 19111 USA	Emory University; Fox Chase Cancer Center	Hall, RA (corresponding author), Emory Univ, Sch Med, Dept Pharmacol, 5113 Rollins Res Ctr,1510 Clifton Rd, Atlanta, GA 30322 USA.			Hall, Randy/0000-0002-8318-8728	NCI NIH HHS [R01-CA-75389, R01-CA-79716] Funding Source: Medline; NHLBI NIH HHS [R01-HL-64713] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA079716, R01CA075389] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL064713] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ajiro K, 1996, J BIOL CHEM, V271, P13197, DOI 10.1074/jbc.271.22.13197; Albertsen HM, 1996, GENOMICS, V33, P207, DOI 10.1006/geno.1996.0185; Endicott JA, 1999, CURR OPIN STRUC BIOL, V9, P738, DOI 10.1016/S0959-440X(99)00038-X; Fazili Z, 1999, ONCOGENE, V18, P3104, DOI 10.1038/sj.onc.1202649; Ferrell JE, 2002, CURR OPIN CELL BIOL, V14, P140, DOI 10.1016/S0955-0674(02)00314-9; Fulop V, 1998, ONCOGENE, V17, P419, DOI 10.1038/sj.onc.1201955; GERTLER FB, 1989, CELL, V58, P103, DOI 10.1016/0092-8674(89)90407-8; HAYSTEAD TAJ, 1989, NATURE, V337, P78, DOI 10.1038/337078a0; He JQ, 2001, J BIOL CHEM, V276, P26814, DOI 10.1074/jbc.M101820200; He JQ, 2001, J BIOL CHEM, V276, P41559, DOI 10.1074/jbc.M106859200; Hocevar BA, 2001, EMBO J, V20, P2789, DOI 10.1093/emboj/20.11.2789; Holmes JK, 1996, J BIOL CHEM, V271, P25240, DOI 10.1074/jbc.271.41.25240; Howell BW, 1997, EMBO J, V16, P121, DOI 10.1093/emboj/16.1.121; Howell BW, 1997, NATURE, V389, P733, DOI 10.1038/39607; Inoue A, 2002, BIOCHEM BIOPH RES CO, V292, P300, DOI 10.1006/bbrc.2002.6636; Keshvara L, 2002, J NEUROSCI, V22, P4869, DOI 10.1523/JNEUROSCI.22-12-04869.2002; Keshvara L, 2001, J BIOL CHEM, V276, P16008, DOI 10.1074/jbc.M101422200; Kishimoto T, 1997, Prog Cell Cycle Res, V3, P241; Kwon YG, 1997, P NATL ACAD SCI USA, V94, P2168, DOI 10.1073/pnas.94.6.2168; Lu KP, 2002, TRENDS CELL BIOL, V12, P164, DOI 10.1016/S0962-8924(02)02253-5; MOK SC, 1994, GYNECOL ONCOL, V52, P247, DOI 10.1006/gyno.1994.1040; Mok SC, 1998, ONCOGENE, V16, P2381, DOI 10.1038/sj.onc.1201769; Morris SM, 2002, TRAFFIC, V3, P331, DOI 10.1034/j.1600-0854.2002.30503.x; Morris SM, 2001, TRAFFIC, V2, P111, DOI 10.1034/j.1600-0854.2001.020206.x; Sheldon M, 1997, NATURE, V389, P730, DOI 10.1038/39601; Sheng ZJ, 2000, ONCOGENE, V19, P4847, DOI 10.1038/sj.onc.1203853; SHETTY KTV, 1995, J NEUROCHEM, V64, P2681; Smith ER, 2001, J BIOL CHEM, V276, P47303, DOI 10.1074/jbc.M106158200; SUGANUMA M, 1990, CANCER RES, V50, P3521; Tseng CP, 1999, J BIOL CHEM, V274, P31981, DOI 10.1074/jbc.274.45.31981; Verdecia MA, 2000, NAT STRUCT BIOL, V7, P639, DOI 10.1038/77929; Wang SC, 2001, ONCOGENE, V20, P6960, DOI 10.1038/sj.onc.1204873; Wang Z, 2002, J BIOL CHEM, V277, P12622, DOI 10.1074/jbc.M110568200; Ware ML, 1997, NEURON, V19, P239, DOI 10.1016/S0896-6273(00)80936-8; XU XX, 1995, J BIOL CHEM, V270, P14184, DOI 10.1074/jbc.270.23.14184; Xu XX, 1998, ONCOGENE, V16, P1561, DOI 10.1038/sj.onc.1201678; Zhou J, 2001, J BIOL CHEM, V276, P27793, DOI 10.1074/jbc.M102803200; ZIEVE GW, 1980, EXP CELL RES, V126, P397, DOI 10.1016/0014-4827(80)90279-7	38	31	35	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 17	2003	22	29					4524	4530		10.1038/sj.onc.1206767	http://dx.doi.org/10.1038/sj.onc.1206767			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	699JX	12881709				2022-12-17	WOS:000184054700008
J	Ho, SM; Lau, KM; Mok, SCH; Syed, V				Ho, SM; Lau, KM; Mok, SCH; Syed, V			Profiling follicle stimulating hormone-induced gene expression changes in normal and malignant human ovarian surface epithelial cells	ONCOGENE			English	Article						cDNA microarray; hormonal carcinogenesis; gene expression; GTPase activating protein (rap1GAP); neogenin; restin	REED-STERNBERG CELLS; HEAT-SHOCK PROTEINS; LUTEINIZING-HORMONE; CDNA MICROARRAY; CALORIC RESTRICTION; HODGKINS-DISEASE; BREAST-CANCER; RNA HELICASES; RECEPTOR; GONADOTROPINS	Epidemiological data have implicated the pituitary gonadotropin follicle stimulating hormone (FSH) as both a risk factor for and a protective agent against epithelial ovarian cancer. Yet, little is known about how this hormone could play such opposing roles in ovarian carcinogenesis. Complementary DNA microarrays containing 2400 named genes were used to examine FSH-induced gene expression changes in ovarian cancer (OC) and immortalized normal human ovarian surface epithelial (HOSE) cell lines. Two-way t-statistics analyses of array data identified two distinct sets of FSH-regulated genes in HOSE and in established OC cell lines established from patients (OVCA cell tines). Among the HOSE cell lines, FSH increased expression of 57% of the 312 genes and downregulated 43%. In contrast, FSH diminished expression of 92% of the 177 genes in the OVCA cell lines. All but 18 of the genes affected by FSH in HOSE cell lines were different from those altered in OVCA cell lines. Among the 18 overlapping genes, nine genes exhibited the same direction of change following FSH challenge, while the other nine showed discordance in response between HOSE and OVCA cell tines. The FSH-induced differential expression of seven out of nine genes was confirmed by real-time RT-PCR. Gene-specific antisense otigonuleotides (ODNs) were used to inhibit the expression of genes encoding GTPase activating protein (rap1GAP), neogenin, and restin in HOSE and OVCA cells. Antisense ODNs to neogenin and restin, but not an antisense ODN to rap1GAP, were effective in inhibiting OVCA cell growth, diminishing proliferating cell nuclear antigen expression, and increasing caspase 3 activities. Furthermore, the ODN to rap1GAP was further shown to be ineffective in altering migration properties of OVCA cell lines. HOSE cell proliferation was not affected by treatment with any of the antisense ODNs. In summary, gene profiling data reveal for the first time that FSH may exert different biological actions on OVCA cells than on HOSE cells, by differential regulation of a set of putative oncogenes/tumor suppressors. Specifically, neogenin and restin were found to exhibit proproliferation/survival action on OC cells.	Univ Massachusetts, Sch Med, Dept Surg, Worcester, MA 01605 USA; Univ Massachusetts, Sch Med, Dept Cell Biol & Physiol, Worcester, MA 01605 USA; Harvard Univ, Brigham & Womens Hosp,Sch Med, Dept Obstet Gynecol & Reprod Biol, Lab Gynecol Oncol, Boston, MA 02115 USA	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Syed, V (corresponding author), Univ Massachusetts, Sch Med, Dept Surg, 364 Plantat St,5th Floor, Worcester, MA 01605 USA.	Viqar.Syed@umassmed.edu			NATIONAL CANCER INSTITUTE [R01CA094221, R03CA091250] Funding Source: NIH RePORTER; NCI NIH HHS [CA091250, CA94221] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ala-Fossi SL, 1999, ANTICANCER RES, V19, P4289; ALTSCHULER DL, 1995, J BIOL CHEM, V270, P10373, DOI 10.1074/jbc.270.18.10373; Auersperg N, 2001, ENDOCR REV, V22, P255, DOI 10.1210/er.22.2.255; BAST RC, 1981, J CLIN INVEST, V68, P1331, DOI 10.1172/JCI110380; BILBE G, 1992, EMBO J, V11, P2103, DOI 10.1002/j.1460-2075.1992.tb05269.x; Callow ME, 2000, APPL ENVIRON MICROB, V66, P3249, DOI 10.1128/AEM.66.8.3249-3254.2000; Cao SX, 2001, P NATL ACAD SCI USA, V98, P10630, DOI 10.1073/pnas.191313598; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; Conroy SE, 1996, BRIT J CANCER, V74, P717, DOI 10.1038/bjc.1996.427; Cramer DW, 1998, FERTIL STERIL, V70, P371, DOI 10.1016/S0015-0282(98)00153-8; Dujardin D, 1998, J CELL BIOL, V141, P849, DOI 10.1083/jcb.141.4.849; Emons G, 1996, CANCER, V78, P1452; ERICKSON GF, 1994, ENDOCRINOLOGY, V134, P1365, DOI 10.1210/en.134.3.1365; Feeley KM, 2001, HISTOPATHOLOGY, V38, P87, DOI 10.1046/j.1365-2559.2001.01042.x; Fuller-Pace Frances V., 1994, Trends in Cell Biology, V4, P271, DOI 10.1016/0962-8924(94)90210-0; FUQUA SAW, 1994, BREAST CANCER RES TR, V32, P67, DOI 10.1007/BF00666207; GILLETT WR, 1991, HUM REPROD, V6, P645, DOI 10.1093/oxfordjournals.humrep.a137398; GODWIN AK, 1993, CANCER-AM CANCER SOC, V71, P530; Halperin R, 1999, INT J GYNECOL CANCER, V9, P502, DOI 10.1046/j.1525-1438.1999.99075.x; HAMILTON TC, 1992, CURR PROB CANCER, V16, P5, DOI 10.1016/0147-0272(92)90047-R; HEIZISOUER KJ, 1995, JAMA-J AM MED ASSOC, V274, P1926; HILLIKER C, 1994, CYTOGENET CELL GENET, V65, P172, DOI 10.1159/000133625; Hofstra LS, 1999, ANTICANCER RES, V19, P3627; Holschneider CH, 2000, SEMIN SURG ONCOL, V19, P3, DOI 10.1002/1098-2388(200007/08)19:1<3::AID-SSU2>3.0.CO;2-S; Hough CD, 2001, CANCER RES, V61, P3869; Ismail RS, 2000, CANCER RES, V60, P6744; Itoh K, 1999, NAT MED, V5, P221, DOI 10.1038/5587; Ivarsson K, 2001, HUM REPROD, V16, P18, DOI 10.1093/humrep/16.1.18; Konishi I, 1999, ONCOLOGY-BASEL, V57, P45, DOI 10.1159/000055274; Lau KM, 1999, P NATL ACAD SCI USA, V96, P5722, DOI 10.1073/pnas.96.10.5722; Lee CK, 1999, SCIENCE, V285, P1390, DOI 10.1126/science.285.5432.1390; Lee HM, 2001, MECH AGEING DEV, V122, P355, DOI 10.1016/S0047-6374(00)00254-2; Li M, 1996, J BIOL CHEM, V271, P11059, DOI 10.1074/jbc.271.19.11059; Mandai M, 1997, EUR J CANCER, V33, P1501, DOI 10.1016/S0959-8049(97)00166-4; MARIMOTO RI, 1994, BIOL HEAT SHOCK PROT; Markert JM, 2001, PHYSIOL GENOMICS, V5, P21, DOI 10.1152/physiolgenomics.2001.5.1.21; Mathew A, 1998, MOL CELL BIOL, V18, P5091, DOI 10.1128/MCB.18.9.5091; Meyerhardt JA, 1997, ONCOGENE, V14, P1129, DOI 10.1038/sj.onc.1200935; Mukherjee A, 1998, MOL ENDOCRINOL, V12, P785, DOI 10.1210/me.12.6.785; Oliver C.J., 1998, FRONT BIOSCI, V3, P961; Ono K, 2000, CANCER RES, V60, P5007; Parrott JA, 2001, MOL CELL ENDOCRINOL, V172, P213, DOI 10.1016/S0303-7207(00)00340-3; PIERRE P, 1992, CELL, V70, P887, DOI 10.1016/0092-8674(92)90240-D; RAO BR, 1991, ENDOCR REV, V12, P14, DOI 10.1210/edrv-12-1-14; Rauh-Adelmann C, 2000, MOL CARCINOGEN, V28, P236, DOI 10.1002/1098-2744(200008)28:4<236::AID-MC6>3.0.CO;2-H; Rickard JE, 1996, TRENDS CELL BIOL, V6, P178, DOI 10.1016/0962-8924(96)10017-9; Risch HA, 1998, JNCI-J NATL CANCER I, V90, P1774, DOI 10.1093/jnci/90.23.1774; Sassone-Corsi P, 1998, INT J BIOCHEM CELL B, V30, P27, DOI 10.1016/S1357-2725(97)00093-9; SCHMID SR, 1992, MOL MICROBIOL, V6, P283, DOI 10.1111/j.1365-2958.1992.tb01470.x; Schummer M, 1999, GENE, V238, P375, DOI 10.1016/S0378-1119(99)00342-X; Shridhar V, 2001, CANCER RES, V61, P5895; Shushan A, 1996, FERTIL STERIL, V65, P13, DOI 10.1016/S0015-0282(16)58020-0; Syed V, 2001, CANCER RES, V61, P6768; Syed V, 2002, JNCI-J NATL CANCER I, V94, P617; TSAO SW, 1995, EXP CELL RES, V218, P499, DOI 10.1006/excr.1995.1184; Tsukamoto N, 1999, J BIOL CHEM, V274, P18463, DOI 10.1074/jbc.274.26.18463; Venema J, 1997, MOL CELL BIOL, V17, P3398, DOI 10.1128/MCB.17.6.3398; VIELMETTER J, 1994, J CELL BIOL, V127, P2009, DOI 10.1083/jcb.127.6.2009; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; Wang C, 2000, J PHARMACOL EXP THER, V294, P287; Wang K, 1999, GENE, V229, P101, DOI 10.1016/S0378-1119(99)00035-9; Wani MA, 1997, SOMAT CELL MOLEC GEN, V23, P123, DOI 10.1007/BF02679971; Welsh JB, 2001, P NATL ACAD SCI USA, V98, P1176, DOI 10.1073/pnas.98.3.1176; WERA S, 1994, BIOCHEM J, V311, P17; WHITTEMORE AS, 1992, AM J EPIDEMIOL, V136, P1184, DOI 10.1093/oxfordjournals.aje.a116427; Yang YH, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.4.e15; Zheng WX, 1996, AM J PATHOL, V148, P47; Zheng WX, 2000, GYNECOL ONCOL, V76, P80, DOI 10.1006/gyno.1999.5628	68	31	32	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 3	2003	22	27					4243	4256		10.1038/sj.onc.1206437	http://dx.doi.org/10.1038/sj.onc.1206437			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	698CJ	12833147	Bronze			2022-12-17	WOS:000183979800011
J	Flinterman, M; Gaken, J; Farzaneh, F; Tavassoli, M				Flinterman, M; Gaken, J; Farzaneh, F; Tavassoli, M			E1A-mediated suppression of EGFR expression and induction of apoptosis in head and neck squamous carcinoma cell lines	ONCOGENE			English	Article						E1A; EGFR; PML; apoptosis; head and neck cancer; gene therapy	GROWTH-FACTOR RECEPTOR; PROMYELOCYTIC LEUKEMIA PROTEIN; TUMOR SUPPRESSION; ADENOVIRUS-5 E1A; NUCLEAR-BODIES; CANCER CELLS; IN-VIVO; P53; PML; TRANSCRIPTION	Previous studies have shown early region 1A (E1A) gene to inhibit the proliferation of tumour cells with wild-type, but not mutant, p53. E1A has also been shown to downregulate c-erb-B-2/neu expression, resulting in inhibition of growth in c-erb-B-2/neu overexpressing tumour cells. In this study, we have investigated the effect of E1A expression on four head and neck squamous cell carcinoma (HNSCC) cell lines that do not overexpress c-erb-B-2/neu. Cell cycle and Western blot analysis show E1A-mediated induction of apoptosis in all cell lines examined. This induction of apoptosis was independent of the p53 status as it occurred in the cell lines with wildtype, mutated or deleted p53. However, there was no evidence of E1A-induced apoptosis in a p53(+ve) normal human fibroblast cell line, 1BR3. Analysis of apoptosis in the SCC cell lines demonstrated E1A-mediated downregulation of EGFR, which was overexpressed in each of these cell lines. Overexpression of an exogenously introduced EGFR, under the control of an E1A-insensitive heterologous promoter, blocked E1A induction of apoptosis in these cells. Therefore, E1A-mediated downregulation of EGFR expression appears to be the cause, rather than a consequence of E1A-induced apoptosis in these SCC cell lines. Previous studies have shown downregulation of EGFR expression by PML. Interestingly, E1A expression in the HNSCC cells altered the pattern of PML distribution and induced the level of PML protein, thus suggesting that E1A-mediated downregulation of EGFR may occur via direct or indirect interactions with PML. These findings demonstrate a novel pathway by which E1A can induce apoptosis and identify EGFR as a potential target for the development of therapeutic strategies against epithelial malignancies, the majority of which have abnormal EGFR expression.	Kings Coll London, Dept Oral Med & Pathol, Head & Neck Oncol Grp, Rayne Inst, London SE5 9NU, England; Kings Coll London, Guys Kings & St Thomas Sch Med, Rayne Inst, Dept Mol Med, London SE5 9NU, England	University of London; King's College London; University of London; King's College London	Tavassoli, M (corresponding author), Kings Coll London, Dept Oral Med & Pathol, Head & Neck Oncol Grp, Rayne Inst, 123 Coldharbour Lane, London SE5 9NU, England.	mahvash.tavassoli@kcl.ac.uk	Farzaneh, Farzin/B-4902-2009	Farzaneh, Farzin/0000-0002-9275-2415				AKUSJARVI G, 1979, J MOL BIOL, V134, P143, DOI 10.1016/0022-2836(79)90417-0; Alcalay M, 1998, MOL CELL BIOL, V18, P1084, DOI 10.1128/MCB.18.2.1084; Averbuch SD, 2002, CLIN CANCER RES, V8, P1; BORRELLI E, 1984, NATURE, V312, P608, DOI 10.1038/312608a0; BRANTON PE, 1984, BIOCHIM BIOPHYS ACTA, V780, P67, DOI 10.1016/0304-419X(84)90007-6; Chang JY, 1996, ONCOGENE, V13, P1405; Chang JY, 1997, ONCOGENE, V14, P561, DOI 10.1038/sj.onc.1200861; CHIOU SK, 1994, MOL CELL BIOL, V14, P2556, DOI 10.1128/MCB.14.4.2556; Davies DE, 1996, BIOCHEM PHARMACOL, V51, P1101, DOI 10.1016/0006-2952(95)02232-5; de Melker AA, 2001, J CELL SCI, V114, P2167; de Stanchina E, 1998, GENE DEV, V12, P2434, DOI 10.1101/gad.12.15.2434; DEGROOT R, 1991, MOL CELL BIOL, V11, P192, DOI 10.1128/MCB.11.1.192; Duque PM, 1999, CANCER GENE THER, V6, P554, DOI 10.1038/sj.cgt.7700077; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; FAHA B, 1993, J VIROL, V67, P2456, DOI 10.1128/JVI.67.5.2456-2465.1993; FERGUSON B, 1985, MOL CELL BIOL, V5, P2653, DOI 10.1128/MCB.5.10.2653; Fogal V, 2000, EMBO J, V19, P6185, DOI 10.1093/emboj/19.22.6185; FRISCH SM, 1995, CANCER RES, V55, P5551; Frisch SM, 2002, NAT REV MOL CELL BIO, V3, P441, DOI 10.1038/nrm827; FRY DW, 1994, SCIENCE, V265, P1093, DOI 10.1126/science.8066447; Graham F L, 1991, Methods Mol Biol, V7, P109, DOI 10.1385/0-89603-178-0:109; Grooteclaes ML, 2000, ONCOGENE, V19, P3823, DOI 10.1038/sj.onc.1203721; He YK, 1998, JNCI-J NATL CANCER I, V90, P1080, DOI 10.1093/jnci/90.14.1080; IMPERIALE MJ, 1984, MOL CELL BIOL, V4, P867, DOI 10.1128/MCB.4.5.867; IRISH JC, 1993, LARYNGOSCOPE, V103, P42; ISHII S, 1985, P NATL ACAD SCI USA, V82, P4920, DOI 10.1073/pnas.82.15.4920; Jensen K, 2001, ONCOGENE, V20, P7223, DOI 10.1038/sj.onc.1204765; Lee WP, 1999, MOL CELL BIOL, V19, P8075; Lill NL, 2000, J BIOL CHEM, V275, P367, DOI 10.1074/jbc.275.1.367; LOWE SW, 1994, P NATL ACAD SCI USA, V91, P2026, DOI 10.1073/pnas.91.6.2026; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; LudesMeyers JH, 1996, MOL CELL BIOL, V16, P6009; Mal A, 1996, NATURE, V380, P262, DOI 10.1038/380262a0; Maul GG, 1995, J CELL BIOCHEM, V59, P498, DOI 10.1002/jcb.240590410; Mymryk JS, 1996, ONCOGENE, V13, P1581; Nishi H, 2001, J BIOL CHEM, V276, P41717, DOI 10.1074/jbc.M101241200; Prudenziati M, 2000, INT J CANCER, V88, P943, DOI 10.1002/1097-0215(20001215)88:6<943::AID-IJC17>3.0.CO;2-F; RUSCH V, 1993, CANCER RES, V53, P2379; Saha V, 1998, J CELL BIOCHEM, P264, DOI 10.1002/(SICI)1097-4644(1998)72:30/31+<264::AID-JCB32>3.0.CO;2-U; SALOMON DS, 1995, BREAST CANCER RES TR, V33, P103, DOI 10.1007/BF00682718; Sartor M, 1999, BRIT J CANCER, V80, P79, DOI 10.1038/sj.bjc.6690505; SASSONECORSI P, 1987, P NATL ACAD SCI USA, V84, P6430, DOI 10.1073/pnas.84.18.6430; Sheikh MS, 1997, ONCOGENE, V15, P1095, DOI 10.1038/sj.onc.1201264; STEIN R, 1984, MOL CELL BIOL, V4, P2792, DOI 10.1128/MCB.4.12.2792; STEIN RW, 1990, J VIROL, V64, P4421, DOI 10.1128/JVI.64.9.4421-4427.1990; Tavassoli M, 2002, CARCINOGENESIS, V23, P1569, DOI 10.1093/carcin/23.10.1569; TEODORO JG, 1995, ONCOGENE, V11, P467; Thomas A, 1998, GENE DEV, V12, P1975, DOI 10.1101/gad.12.13.1975; Tian XX, 1999, BRIT J CANCER, V81, P994, DOI 10.1038/sj.bjc.6690798; Vallian S, 1997, EXP CELL RES, V237, P371, DOI 10.1006/excr.1997.3801; Vallian S, 1998, MOL CELL BIOL, V18, P7147, DOI 10.1128/MCB.18.12.7147; WEIS K, 1994, CELL, V76, P345, DOI 10.1016/0092-8674(94)90341-7; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; Woodburn JR, 1999, PHARMACOL THERAPEUT, V82, P241, DOI 10.1016/S0163-7258(98)00045-X; Wu WS, 2001, MOL CELL BIOL, V21, P2259, DOI 10.1128/MCB.21.7.2259-2268.2001; YAN DH, 1991, ONCOGENE, V6, P343; Yeudall WA, 1997, MOL CARCINOGEN, V18, P89, DOI 10.1002/(SICI)1098-2744(199702)18:2<89::AID-MC4>3.0.CO;2-L; YU DH, 1995, ONCOGENE, V11, P1383	58	31	31	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 3	2003	22	13					1965	1977		10.1038/sj.onc.1206190	http://dx.doi.org/10.1038/sj.onc.1206190			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	662UR	12673202	Bronze			2022-12-17	WOS:000181967700007
J	Chen, QH; Lin, J; Jinno, S; Okayama, H				Chen, QH; Lin, J; Jinno, S; Okayama, H			Overexpression of Cdk6-cyclin D3 highly sensitizes cells to physical and chemical transformation	ONCOGENE			English	Article						Cdk6; cyclin D3; BALB/c3T3; C3H10T1/2; 3-methylcholanthrene/ultraviolet-induced transformation	CYCLIN-DEPENDENT KINASE-6; RETINOBLASTOMA PROTEIN; REGULATORY MECHANISMS; CDK INHIBITORS; CANCER; EXPRESSION; D1; PHOSPHORYLATION; COMPLEX; E-CDK2	Virtually all mammalian cells express two seemingly redundant cyclin-D-dependent kinases (Cdk4 and Cdk6) and three partner cyclins (D1, D2 and D3) essential for the G(1)-S transition, with predominant expression of Cdk4 and D1 in mesenchymal cells and Cdk6 and D3 in hematopoietic cells. We recently found two novel functions for Cdk6 executed in fibroblasts although unlike Cdk4 it is dispensable for their proliferation. In the rat fibroblast NRK-49F cells, oncogenic stimulation recruits Cdk6 to participate in a step of the cell cycle start that seems to be critical for anchorage-independent S-phase onset. Among the kinase-D-type cyclin combinations, the Cdk6-cyclin-D3 complex has a unique ability to evade inhibition by cyclin-dependent kinase inhibitors and thereby control the cell's proliferative competence under growth-suppressive conditions. We describe here that 2-5-fold overexpression of both Cdk6 and D3 enhances by 5 x 10(3)-10(6) -fold the susceptibility of the BALB/c3T3 and C3HIOT1/2 mouse fibroblast lines to ultraviolet irradiation- as well as 3-methylcholanthrene-induced transformation. This result suggests that deregulated expression of Cdk6 and cyclinD3 may predispose cells to malignant transformation, supporting the recent finding that cyclin D3 activated by chromosomal rearrangement is the causative gene of non-Hodgkin B lymphoma, in which Cdk6 is the major partner kinase.	Univ Tokyo, Grad Sch Med, Dept Biochem & Mol Biol, Bunkyo Ku, Tokyo 1130033, Japan	University of Tokyo	Okayama, H (corresponding author), Univ Tokyo, Grad Sch Med, Dept Biochem & Mol Biol, Bunkyo Ku, Hongo, Tokyo 1130033, Japan.	okayama@m.u-tokyo.ac.jp						Bartkova J, 1998, ONCOGENE, V17, P1027, DOI 10.1038/sj.onc.1202016; Cenciarelli C, 1999, MOL CELL BIOL, V19, P5203; Chilosi M, 1998, AM J PATHOL, V152, P209; Corcoran MM, 1999, ONCOGENE, V18, P6271, DOI 10.1038/sj.onc.1203033; Costello JF, 1997, CANCER RES, V57, P1250; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; Easton J, 1998, CANCER RES, V58, P2624; Ebert MPA, 2001, J CANCER RES CLIN, V127, P449, DOI 10.1007/s004320100235; Fang F, 1996, SCIENCE, V271, P499, DOI 10.1126/science.271.5248.499; Hall M, 1996, ADV CANCER RES, V68, P67, DOI 10.1016/S0065-230X(08)60352-8; Henzinger T, 1998, J BIOL CHEM, V273, P14958, DOI 10.1074/jbc.273.24.14958; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; JIANG W, 1993, P NATL ACAD SCI USA, V90, P9026, DOI 10.1073/pnas.90.19.9026; Jinno S, 1999, ONCOGENE, V18, P565, DOI 10.1038/sj.onc.1202347; Jinno S, 2002, ONCOGENE, V21, P1777, DOI 10.1038/sj.onc.1205249; Jinno S, 1999, P NATL ACAD SCI USA, V96, P13197, DOI 10.1073/pnas.96.23.13197; Kakunaga T, 1985, IARC Sci Publ, V67, P55; KAKUNAGA T, 1980, SCIENCE, V209, P505, DOI 10.1126/science.7394516; Kawada M, 1997, ONCOGENE, V15, P629, DOI 10.1038/sj.onc.1201228; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; LEBWOHL DE, 1994, ONCOGENE, V9, P1925; Lien HC, 2000, LAB INVEST, V80, P893, DOI 10.1038/labinvest.3780093; Lin J, 2001, ONCOGENE, V20, P2000, DOI 10.1038/sj.onc.1204375; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; Okayama H, 1996, ADV CANCER RES, V69, P17, DOI 10.1016/S0065-230X(08)60859-3; Park DS, 1998, J CELL BIOL, V143, P457, DOI 10.1083/jcb.143.2.457; PINES J, 1995, SEMIN CANCER BIOL, V6, P63, DOI 10.1006/scbi.1995.0009; REZNIKOFF CA, 1973, CANCER RES, V33, P3231; ROBELS AI, 1995, CARCINOGENESIS, V16, P781, DOI 10.1093/carcin/16.4.781; Rogatsky I, 1997, MOL CELL BIOL, V17, P3181, DOI 10.1128/MCB.17.6.3181; SCHAUER IE, 1994, P NATL ACAD SCI USA, V91, P7827, DOI 10.1073/pnas.91.16.7827; Shaughnessy J, 2001, BLOOD, V98, P217, DOI 10.1182/blood.V98.1.217; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Sonoki T, 2001, BLOOD, V98, P2837, DOI 10.1182/blood.V98.9.2837; Timmermann S, 1997, CELL GROWTH DIFFER, V8, P361; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; Wang J, 1996, CELL GROWTH DIFFER, V7, P1471; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Zhu XY, 1996, J CELL BIOL, V133, P391, DOI 10.1083/jcb.133.2.391	39	31	33	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 20	2003	22	7					992	1001		10.1038/sj.onc.1206193	http://dx.doi.org/10.1038/sj.onc.1206193			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	644PB	12592386				2022-12-17	WOS:000180926100005
J	Wang, XH; Jin, DY; Wong, HL; Feng, HC; Wong, YC; Tsao, SW				Wang, XH; Jin, DY; Wong, HL; Feng, HC; Wong, YC; Tsao, SW			MAD2-induced sensitization to vincristine is associated with mitotic arrest and Raf/Bcl-2 phosphorylation in nasopharyngeal carcinoma cells	ONCOGENE			English	Article						MA132; Bcl-2; vincristine; Raf; nasopharyngeal carcinoma	SPINDLE ASSEMBLY CHECKPOINT; PROTEIN-KINASE; MAP KINASE; PROMOTING COMPLEX; GROWTH ARREST; HUMAN CANCERS; APOPTOSIS; BCL-2; DEATH; MAD2	Mitotic arrest deficient 2 (MAD2) is thought to be a key component of the mitotic checkpoint, which ensures accurate chromosome segregation. Reduced expression of MAD2 protein is associated with mitotic checkpoint abrogation and chromosomal instability in certain types of human cancers. To explore the possibility of developing a novel strategy for the treatment of cancer based on selective killing of mitotic checkpoint-defective or -competent cells, here we have investigated the effect of MAD2 expression on cellular sensitivity to checkpoint-targeting anticancer drugs. We reintroduced MAD2 protein in a mitotic checkpoint-defective nasopharyngeal carcinoma cell tine, CNE2, using an inducible expression vector. We found that overexpression of MAD2 led to an increased sensitivity to vincristine, which was accompanied by increased mitotic index and G2/M cell cycle arrest. In addition, increased phosphorylation of Raf, MEK1/2 and Bcl-2 was observed in MAD2-overexpressing cells in response to vincristine. Furthermore, inhibition of phosphorylation of MEK1/2 by its inhibitor PD098059 led to reduced sensitivity to vincristine, which was associated with decreased Bcl-2 phosphorylation. Our data suggest a role for MAD2 in the sensitization of cancer cells to certain mitotic checkpoint-targeting anticancer drugs.	Univ Hong Kong, Dept Anat, Hong Kong, Hong Kong, Peoples R China; Dept Biochem, Hong Kong, Hong Kong, Peoples R China	University of Hong Kong	Tsao, SW (corresponding author), Univ Hong Kong, Dept Anat, 21 Sassoon Rd,1st Floor,Fac Med Bldg,Lab Block, Hong Kong, Hong Kong, Peoples R China.		Feng, Huichen/F-5502-2011	Feng, Huichen/0000-0003-3069-8174				Amon A, 1999, CURR OPIN GENET DEV, V9, P69, DOI 10.1016/S0959-437X(99)80010-0; Blagosklonny MV, 1997, CANCER RES, V57, P130; Bricker K.S., 1978, Kasetsart University Fisheries Research Bulletin, V10, P1; Cahill DP, 1998, NATURE, V392, P300, DOI 10.1038/32688; Dimmeler S, 1999, J EXP MED, V189, P1815, DOI 10.1084/jem.189.11.1815; Dobles M, 2000, CELL, V101, P635, DOI 10.1016/S0092-8674(00)80875-2; Fan MY, 2000, CANCER RES, V60, P6403; HALDAR S, 1995, P NATL ACAD SCI USA, V92, P4507, DOI 10.1073/pnas.92.10.4507; Hayne C, 2000, J BIOL CHEM, V275, P31876, DOI 10.1074/jbc.M002766200; Huang STJ, 2002, FASEB J, V16, DOI 10.1096/fj.01-0852com; Huang Y, 1999, ONCOGENE, V18, P3431, DOI 10.1038/sj.onc.1202685; Jin DY, 1998, CELL, V93, P81, DOI 10.1016/S0092-8674(00)81148-4; Jordan MA, 1996, CANCER RES, V56, P816; Kallio M, 1998, J CELL BIOL, V141, P1393, DOI 10.1083/jcb.141.6.1393; Kasai T, 2002, J BIOL CHEM, V277, P5187, DOI 10.1074/jbc.M110295200; LAIRD AD, 1995, J BIOL CHEM, V270, P26742, DOI 10.1074/jbc.270.45.26742; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Li Y, 1996, SCIENCE, V274, P246, DOI 10.1126/science.274.5285.246; Lovric J, 1996, ONCOGENE, V12, P1109; Minn AJ, 1996, GENE DEV, V10, P2621, DOI 10.1101/gad.10.20.2621; MINSHULL J, 1994, CELL, V79, P475, DOI 10.1016/0092-8674(94)90256-9; Pennisi E, 1998, SCIENCE, V279, P477, DOI 10.1126/science.279.5350.477; SHERWOOD SW, 1994, EXP CELL RES, V215, P373, DOI 10.1006/excr.1994.1354; Srivastava RK, 1998, MOL CELL BIOL, V18, P3509, DOI 10.1128/MCB.18.6.3509; Stadheim TA, 2001, CANCER RES, V61, P1533; Takahashi T, 1999, ONCOGENE, V18, P4295, DOI 10.1038/sj.onc.1202807; Takenaka K, 1997, J CELL BIOL, V136, P1091, DOI 10.1083/jcb.136.5.1091; Takenaka K, 1998, SCIENCE, V280, P599, DOI 10.1126/science.280.5363.599; Wahl AF, 1996, NAT MED, V2, P72, DOI 10.1038/nm0196-72; Wang TH, 1999, J BIOL CHEM, V274, P8208, DOI 10.1074/jbc.274.12.8208; Wang XH, 1999, INT J ONCOL, V15, P1097; Wang XH, 1998, CANCER RES, V58, P5019; Wang XH, 2002, CANCER RES, V62, P1662; Wang XH, 2000, CARCINOGENESIS, V21, P2293, DOI 10.1093/carcin/21.12.2293; Wang XM, 1997, J CELL BIOL, V137, P433, DOI 10.1083/jcb.137.2.433; Wassmann K, 2001, CURR OPIN GENET DEV, V11, P83, DOI 10.1016/S0959-437X(00)00161-1; Yamamoto K, 1999, MOL CELL BIOL, V19, P8469; Yeung K, 1999, NATURE, V401, P173, DOI 10.1038/43686; Zhang YK, 2001, MOL CELL BIOL, V21, P5190, DOI 10.1128/MCB.21.15.5190-5199.2001	39	31	34	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 9	2003	22	1					109	116		10.1038/sj.onc.1206069	http://dx.doi.org/10.1038/sj.onc.1206069			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	631KL	12527913				2022-12-17	WOS:000180166900012
J	Senga, T; Iwamoto, T; Humphrey, SE; Yokota, T; Taparowsky, EJ; Hamaguchi, M				Senga, T; Iwamoto, T; Humphrey, SE; Yokota, T; Taparowsky, EJ; Hamaguchi, M			Stat3-dependent induction of BATF in M1 mouse myeloid leukemia cells	ONCOGENE			English	Article						IL-6/LIF; gp130; Stat3; BATF; AP-1	CYTOKINE RECEPTOR GP130; C-MYC; B-ATF; STAT3; SIGNALS; DIFFERENTIATION; TRANSCRIPTION; ACTIVATION; PROTEIN; FAMILY	Stat3 mediates cellular responses associated with proliferation, survival and differentiation, but the mechanisms underlying the diverse effects of this signaling molecule remain unknown. M1 mouse myeloid leukemia cells arrest growth and differentiate into macrophages following treatment with interleukin 6 (IL-6) or leukemia inhibitory factor (LIF), and recent studies have shown that Stat3 plays a central role in this process. Utilizing representational difference analysis, we demonstrate that expression of the mouse BATF gene is upregulated as an early response to IL-6/LIF stimulation and Stat3 activation in this cell system. Immunoblots using antibodies to BATF detected an increase in BATF protein in response to LIF/IL-6 stimulation. BATF is a member of the AP-1 family of basic leucine zipper transcription factors and functions to inhibit the transcriptional and biological functions of AP-1 activity in mammalian cells. BATF forms complexes with c-Jun in M1. cells and forced expression of BATF in the absence of Stat3 signaling results in a reduced rate of cellular growth. These results indicate that Stat3 mediates cellular growth by modulating AP-1 activity through the induction of BATF.	Nagoya Univ, Sch Med, Dept Mol Pathogenesis, Showa Ku, Nagoya, Aichi 4668550, Japan; Nagoya Univ, Sch Med, Radioisotope Res Ctr, Med Div,Showa Ku, Nagoya, Aichi 4668550, Japan; Kanazawa Univ, Grad Sch Med Sci, Div Stem Cell Biol, Kanazawa, Ishikawa 9208640, Japan; Purdue Univ, Dept Biol Sci, W Lafayette, IN 47907 USA	Nagoya University; Nagoya University; Kanazawa University; Purdue University System; Purdue University; Purdue University West Lafayette Campus	Hamaguchi, M (corresponding author), Nagoya Univ, Sch Med, Dept Mol Pathogenesis, Showa Ku, 65 Tsurumai, Nagoya, Aichi 4668550, Japan.	mhamagu@tsuru.med.nagoya-u.ac.jp	Yokota, Takashi/J-8483-2015; Yokota, Takashi/F-6021-2011		NATIONAL CANCER INSTITUTE [R01CA078264] Funding Source: NIH RePORTER; NCI NIH HHS [CA78264] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aronheim A, 1997, MOL CELL BIOL, V17, P3094, DOI 10.1128/MCB.17.6.3094; Bellido T, 1998, J BIOL CHEM, V273, P21137, DOI 10.1074/jbc.273.33.21137; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Dorsey MJ, 1995, ONCOGENE, V11, P2255; Echlin DR, 2000, ONCOGENE, V19, P1752, DOI 10.1038/sj.onc.1203491; Fukada T, 1996, IMMUNITY, V5, P449, DOI 10.1016/S1074-7613(00)80501-4; Fukada T, 1998, EMBO J, V17, P6670, DOI 10.1093/emboj/17.22.6670; Hirano T, 2000, ONCOGENE, V19, P2548, DOI 10.1038/sj.onc.1203551; HUBANK M, 1994, NUCLEIC ACIDS RES, V22, P5640, DOI 10.1093/nar/22.25.5640; Kitamura T, 2000, METH MOL B, V134, P143; LISITSYN N, 1993, SCIENCE, V259, P946, DOI 10.1126/science.8438152; LORD KA, 1993, MOL CELL BIOL, V13, P841, DOI 10.1128/MCB.13.2.841; Masuhara M, 1997, BIOCHEM BIOPH RES CO, V239, P439, DOI 10.1006/bbrc.1997.7484; Matsuda T, 1999, EMBO J, V18, P4261, DOI 10.1093/emboj/18.15.4261; O'Farrell AM, 2000, J IMMUNOL, V164, P4607, DOI 10.4049/jimmunol.164.9.4607; Ohtani T, 2000, IMMUNITY, V12, P95, DOI 10.1016/S1074-7613(00)80162-4; SELVAKUMARAN M, 1992, MOL CELL BIOL, V12, P2493, DOI 10.1128/MCB.12.6.2493; Senga T, 2001, J BIOL CHEM, V276, P32678, DOI 10.1074/jbc.M105749200; Shimozaki K, 1997, J BIOL CHEM, V272, P25184, DOI 10.1074/jbc.272.40.25184; Shirogane T, 1999, IMMUNITY, V11, P709, DOI 10.1016/S1074-7613(00)80145-4; Takahashi-Tezuka M, 1998, MOL CELL BIOL, V18, P4109, DOI 10.1128/MCB.18.7.4109; Williams KL, 2001, EUR J IMMUNOL, V31, P1620, DOI 10.1002/1521-4141(200105)31:5<1620::AID-IMMU1620>3.0.CO;2-3	22	31	32	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 21	2002	21	53					8186	8191		10.1038/sj.onc.1205918	http://dx.doi.org/10.1038/sj.onc.1205918			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	615DW	12444555				2022-12-17	WOS:000179231400013
J	Bierkamp, C; Kowalski-Chauvel, A; Dehez, S; Fourmy, D; Pradayrol, L; Seva, C				Bierkamp, C; Kowalski-Chauvel, A; Dehez, S; Fourmy, D; Pradayrol, L; Seva, C			Gastrin mediated cholecystokinin-2 receptor activation induces loss of cell adhesion and scattering in epithelial MDCK cells	ONCOGENE			English	Article						epithelial cells; cell adhesion; Gastrin; CCK-2R; catenin; migration; cancer	CADHERIN-CATENIN COMPLEX; HEPATOCYTE GROWTH-FACTOR; HUMAN COLORECTAL-CANCER; RHO-FAMILY GTPASES; PHOSPHATIDYLINOSITOL 3-KINASE; TYROSINE PHOSPHORYLATION; B/GASTRIN RECEPTOR; P120 CATENIN; BETA-CATENIN; PROTEIN INTERACTIONS	The presence of gastrin and CCK-2/gastrin receptors in human preneoplastic and neoplastic lesions of pancreas and colon suggests a role in cancer development. Gastrin's growth-promoting action has been established, but a role in cellular morphogenetic processes promoting tumor invasion has been elusive. Our aim was (i) to investigate whether activation of the CCK-2R affects cellular morphology, intercellular adhesion and motility, as crucial parameters of epithelial differentiation, and (ii) to identify the signaling pathways and mechanisms implicated. Madin-Darby Canine Kidney (MDCK) cells were chosen to generate an epithelial non-tumorigenic model system expressing human CCK-2R. Epithelial differentiation and motility were analysed upon CCK-2R activation using immunocytochemistry and invasion assays. The functionality of adhesion complexes and activity of signaling proteins was determined with biochemical techniques. CCK-2R activation induced cell dissociation and enhanced invasion, preceded by decreased membrane localization of adherens junction molecules and nuclear accumulation of beta-catenin. Concomitantly, and requiring the activation of several signaling pathways, catenins were shifted from the cytoskeletal to the cytoplasmic fraction, suggesting the detachment of the cytoskeleton from the adherens complex. These data represent the first evidence for the CCK-2R, regulating cell-cell and cell-substrate adhesion and support a role for CCK-2R in the progression of carcinoma.	CHU Rangueil, Inst Louis Bugnard, Dept Biol & Pathol Digest, INSERM,U531, F-31403 Toulouse, France	CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm)	Bierkamp, C (corresponding author), CHU Rangueil, Inst Louis Bugnard, Dept Biol & Pathol Digest, INSERM,U531, 1 Av Jean Poulhes, F-31403 Toulouse, France.		SEVA, Catherine/O-9166-2014; Kowalski-Chauvel, Aline/O-9212-2014; Fourmy, Daniel/AAE-3703-2019	SEVA, Catherine/0000-0002-4265-7372; Fourmy, Daniel/0000-0001-9910-4827				Aberle H, 1996, J CELL BIOCHEM, V61, P514, DOI 10.1002/(SICI)1097-4644(19960616)61:4<514::AID-JCB4>3.0.CO;2-R; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Anastasiadis PZ, 2000, NAT CELL BIOL, V2, P637, DOI 10.1038/35023588; BEHRENS J, 1989, J CELL BIOL, V108, P2435, DOI 10.1083/jcb.108.6.2435; BEHRENS J, 1993, J CELL BIOL, V120, P757, DOI 10.1083/jcb.120.3.757; Ben-Ze'ev A, 2000, EXP CELL RES, V261, P75, DOI 10.1006/excr.2000.5045; BIRCHMEIER W, 1994, BBA-REV CANCER, V1198, P11, DOI 10.1016/0304-419X(94)90003-5; Caplin M, 2000, BRIT J SURG, V87, P1035, DOI 10.1046/j.1365-2168.2000.01488.x; Chen HC, 1998, J BIOL CHEM, V273, P25777, DOI 10.1074/jbc.273.40.25777; Clerc P, 2002, GASTROENTEROLOGY, V122, P428, DOI 10.1053/gast.2002.30984; Daniel JM, 1997, BIOESSAYS, V19, P883, DOI 10.1002/bies.950191008; Daulhac L, 1999, J BIOL CHEM, V274, P20657, DOI 10.1074/jbc.274.29.20657; Daulhac L, 1999, FEBS LETT, V445, P251, DOI 10.1016/S0014-5793(99)00129-5; Ding WQ, 2002, CANCER RES, V62, P947; Emami S, 2001, FASEB J, V15, P351, DOI 10.1096/fj.00-0355com; Espada J, 1999, J CELL BIOL, V146, P967, DOI 10.1083/jcb.146.5.967; Grosheva I, 2001, J CELL SCI, V114, P695; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; Hellmich MR, 2000, J BIOL CHEM, V275, P32122, DOI 10.1074/jbc.M005754200; HINCK L, 1994, J CELL BIOL, V125, P1327, DOI 10.1083/jcb.125.6.1327; Hirata M, 1996, FEBS LETT, V383, P241, DOI 10.1016/0014-5793(96)00245-1; Hollande F, 2001, J BIOL CHEM, V276, P40402, DOI 10.1074/jbc.M105090200; Jawhari AU, 1999, J PATHOL, V189, P180, DOI 10.1002/(SICI)1096-9896(199910)189:2<180::AID-PATH414>3.0.CO;2-2; Khwaja A, 1998, J BIOL CHEM, V273, P18793, DOI 10.1074/jbc.273.30.18793; Koh TJ, 2000, J CLIN INVEST, V106, P533, DOI 10.1172/JCI9476; KowalskiChauvel A, 1996, J BIOL CHEM, V271, P26356, DOI 10.1074/jbc.271.42.26356; Miyazaki Y, 1999, GASTROENTEROLOGY, V116, P78, DOI 10.1016/S0016-5085(99)70231-3; Nollet F, 1999, Mol Cell Biol Res Commun, V2, P77, DOI 10.1006/mcbr.1999.0155; Noren NK, 2000, J CELL BIOL, V150, P567, DOI 10.1083/jcb.150.3.567; Owens DW, 2000, MOL BIOL CELL, V11, P51, DOI 10.1091/mbc.11.1.51; Ozawa M, 1998, J BIOL CHEM, V273, P6166, DOI 10.1074/jbc.273.11.6166; Potempa S, 1998, MOL BIOL CELL, V9, P2185, DOI 10.1091/mbc.9.8.2185; REHFELD JF, 1994, ADV CANCER RES, V63, P295, DOI 10.1016/S0065-230X(08)60403-0; Rosin-Arbesfeld R, 2001, EMBO J, V20, P5929, DOI 10.1093/emboj/20.21.5929; Rozengurt E, 2001, ANNU REV PHYSIOL, V63, P49, DOI 10.1146/annurev.physiol.63.1.49; Saillan-Barreau C, 1998, GASTROENTEROLOGY, V115, P988, DOI 10.1016/S0016-5085(98)70271-9; Schmitz F, 2001, EUR J CLIN INVEST, V31, P812, DOI 10.1046/j.1365-2362.2001.00870.x; SEVA C, 1990, DIGESTION, V46, P166, DOI 10.1159/000200381; Skoudy A, 1996, INT J CANCER, V68, P14, DOI 10.1002/(SICI)1097-0215(19960927)68:1<14::AID-IJC3>3.0.CO;2-#; Smith AM, 2000, ALIMENT PHARM THERAP, V14, P1231, DOI 10.1046/j.1365-2036.2000.00842.x; Smith AM, 2000, GUT, V47, P820, DOI 10.1136/gut.47.6.820; Steinberg MS, 1999, CURR OPIN CELL BIOL, V11, P554, DOI 10.1016/S0955-0674(99)00027-7; Taniguchi T, 1996, ONCOGENE, V12, P1357; Thorburn CM, 1998, GASTROENTEROLOGY, V115, P275, DOI 10.1016/S0016-5085(98)70193-3; Thoreson MA, 2000, J CELL BIOL, V148, P189, DOI 10.1083/jcb.148.1.189; Todisco A, 2001, AM J PHYSIOL-GASTR L, V280, pG298, DOI 10.1152/ajpgi.2001.280.2.G298; Torres M, 1997, P NATL ACAD SCI USA, V94, P901, DOI 10.1073/pnas.94.3.901; Varner JA, 1996, CURR OPIN CELL BIOL, V8, P724, DOI 10.1016/S0955-0674(96)80115-3; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; Wang TC, 2000, GASTROENTEROLOGY, V118, P36, DOI 10.1016/S0016-5085(00)70412-4; Watson SA, 2000, CANCER RES, V60, P5902; Watson SA, 2001, CANCER RES, V61, P625; WEIDNER KM, 1993, J CELL BIOL, V121, P145, DOI 10.1083/jcb.121.1.145	53	31	32	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 31	2002	21	50					7656	7670		10.1038/sj.onc.1205999	http://dx.doi.org/10.1038/sj.onc.1205999			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	606VW	12400008				2022-12-17	WOS:000178756200005
J	Santos, J; Montagutelli, X; Acevedo, A; Lopez, P; Vaquero, C; Fernandez, M; Arnau, MR; Szatanik, M; Salido, E; Guenet, JL; Fernandez-Piqueras, J				Santos, J; Montagutelli, X; Acevedo, A; Lopez, P; Vaquero, C; Fernandez, M; Arnau, MR; Szatanik, M; Salido, E; Guenet, JL; Fernandez-Piqueras, J			A new locus for resistance to gamma-radiation-induced thymic lymphoma identified using inter-specific consomic and inter-specific recombinant congenic strains of mice	ONCOGENE			English	Article						mouse thymic lymphomas; tumor resistance genes; inter-specific consomic (ICS); recombinant congenic (IRCS) strains	SUSCEPTIBILITY; TUMORS; MOUSE; GENE; IRRADIATION; SUPPRESSOR; MUTATION; MODELS	Mice of the C57BL/6J inbred strain develop thymic lymphomas at very high frequency after acute gamma-irradiation, while mice of several inbred strains derived from the wild progenitor of the Mus spretus species and their F1 hybrids with C57BL/6J appear extremely resistant. Analysis of the genetic determinism of the gamma-radiation-induced thymic lymphoma (RITL) resistance with the help of inter-specific consomic strains (ICS), which carry a single introgressed Mus spretus chromosome on a C57BL/6J genetic background, provide significant evidence for the existence of a thymic lymphoma resistance (Tlyr1) locus on chromosome 19. The subsequent analysis of the backcross progeny resulting from a cross between consomic mice heterozygous for the Mus spretus chromosome 19 and C57BL/6J mice, together with the study of inter-specific recombinant congenic strains (IRCS), suggest that this Tlyr1 locus maps within the D19Mit60-D19Mit40 chromosome interval. In addition to the discovery of a new locus controlling RITL development, our study emphasizes the value of ICS and IRCS for the genetic analysis of cancer predisposition.	Univ Autonoma Madrid, Fac Ciencias, Dept Biol, Lab Genet Mol Humana, E-28049 Madrid, Spain; Inst Pasteur, Unite Genet Mammiferes, F-75724 Paris, France; Univ La Laguna, Fac Med, Dept Anat Patol, Tenerife 38071, Spain	Autonomous University of Madrid; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Universidad de la Laguna	Santos, J (corresponding author), Univ Autonoma Madrid, Fac Ciencias, Dept Biol, Lab Genet Mol Humana, E-28049 Madrid, Spain.		Salido, Eduardo C/I-2232-2015; Arozena, Abraham Acevedo/L-6584-2018; Santos, Javier/ABF-5755-2021; Arnau Diaz-Llanos, Maria Rosa/L-8442-2018	Salido, Eduardo C/0000-0001-9599-9854; Arozena, Abraham Acevedo/0000-0001-6127-7116; Santos, Javier/0000-0002-4168-6251; Arnau Diaz-Llanos, Maria Rosa/0000-0002-2941-1626				Angel JM, 2002, MOL CARCINOGEN, V33, P105, DOI 10.1002/mc.10026; ANGEL JM, 1993, MOL CARCINOGEN, V7, P151, DOI 10.1002/mc.2940070305; Balmain A, 1998, TRENDS GENET, V14, P139, DOI 10.1016/S0168-9525(98)01422-X; LANDER E, 1995, NAT GENET, V11, P241, DOI 10.1038/ng1195-241; Manenti G, 1996, NAT GENET, V12, P455, DOI 10.1038/ng0496-455; Matin A, 1999, NAT GENET, V23, P237, DOI 10.1038/13874; Mori N, 2000, J RADIAT RES, V41, P367, DOI 10.1269/jrr.41.367; NAGASE H, 1995, NAT GENET, V10, P424, DOI 10.1038/ng0895-424; Nagase H, 1999, P NATL ACAD SCI USA, V96, P15032, DOI 10.1073/pnas.96.26.15032; NEWCOMB EW, 1988, CANCER RES, V48, P5514; OKUMOTO M, 1989, J RADIAT RES, V30, P135, DOI 10.1269/jrr.30.135; OKUMOTO M, 1990, CANCER RES, V50, P3848; Podsypanina K, 1999, P NATL ACAD SCI USA, V96, P1563, DOI 10.1073/pnas.96.4.1563; RICHIE ER, 1985, CANCER RES, V45, P2802; Saito Y, 2001, ONCOGENE, V20, P5243, DOI 10.1038/sj.onc.1204675; Santos J, 2001, ONCOGENE, V20, P2186, DOI 10.1038/sj.onc.1204297; Shibahara K, 1995, GENE, V166, P297, DOI 10.1016/0378-1119(95)00607-9; Suzuki A, 1998, CURR BIOL, V8, P1169, DOI 10.1016/S0960-9822(07)00488-5; Szymanska H, 1999, INT J CANCER, V83, P674, DOI 10.1002/(SICI)1097-0215(19991126)83:5<674::AID-IJC18>3.0.CO;2-M; WATANABEFUKUNAG.R, 1992, NATURE, V356, P317; Wielowieyski A, 1999, MAMM GENOME, V10, P623, DOI 10.1007/s003359901057; YAMADA Y, 1994, J EXP MED, V180, P2155, DOI 10.1084/jem.180.6.2155; Yang HS, 2001, ONCOGENE, V20, P669, DOI 10.1038/sj.onc.1204137; Zhang SL, 2001, MOL CELL BIOL, V21, P310, DOI 10.1128/MCB.21.1.310-318.2001	24	31	33	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 26	2002	21	43					6680	6683		10.1038/sj.onc.1205846	http://dx.doi.org/10.1038/sj.onc.1205846			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	597BM	12242666	Bronze			2022-12-17	WOS:000178202300014
J	Blanchard, F; Kinzie, E; Wang, YP; Duplomb, L; Godard, A; Held, WA; Asch, BB; Baumann, H				Blanchard, F; Kinzie, E; Wang, YP; Duplomb, L; Godard, A; Held, WA; Asch, BB; Baumann, H			FR901228, an inhibitor of histone deacetylases, increases the cellular responsiveness to IL-6 type cytokines by enhancing the expression of receptor proteins	ONCOGENE			English	Article						cytokine receptor; inflammatory mediators; signal transduction; gene regulation; cytotoxicity	BREAST-CANCER CELLS; ONCOSTATIN-M; DNA METHYLATION; BINDING-PROTEIN; UP-REGULATION; TRANSCRIPTIONAL REPRESSION; GELSOLIN EXPRESSION; TARGETED DISRUPTION; GROWTH-INHIBITION; SIGNAL TRANSDUCER	The related members of the interleukin-6 (IL-6) family of cytokines, leukemia inhibitory factor (LIF), oncostatin M (OSM) and IL-6 are inflammatory mediators that control differentiated cell functions as well as proliferation. The cellular responsiveness to these cytokines is largely determined by the expression of the appropriate receptor proteins. The receptor expression profile for each cell type is established during differentiation and is often altered during oncogenic transformation. Since inhibition of histone deacetylases (HDAC) has the potential to re-activate epigenetically silenced genes, we asked whether inhibition of HDAC enhances the expression of IL-6 cytokine receptors and, thus, increase desirable cytokine responses. We demonstrate that treatment with FR901228 (FR), an HDAC inhibitor, increases the responsiveness to LIF in different cell types, including normal fibroblasts, epithelial cells, macrophages and splenocytes, as well as various tumor cell lines. Depending on the cell type, FR treatment also enhances the responsiveness to OSM and IL-6. These effects involve a transcriptional induction of the cytokine receptor subunits LIFRalpha, OSMRbeta, gp130, or the transcription factor STAT3. FR-specific induction of LIFRalpha occurs independently of de noro protein synthesis and cell proliferation and is mediated in part by the CBP/p300 coactivator. Chromatin immunoprecipitation experiments indicate that the expression of LIFRalpha. and gp130 genes correlates with the level of acetylated histone 3 associated with the receptor promoter regions. The FR-stimulated expression of IL-6-type cytokine receptors in certain tumor cells also provided improved conditions for suppression of cell growth by taking advantage of the growth inhibitory effect of these cytokines.	INSERM, U463, Inst Biol, F-44035 Nantes 01, France; Roswell Pk Canc Inst, Dept Mol & Cellular Biol, Buffalo, NY 14263 USA; Roswell Pk Canc Inst, Div Expt Pathol, Buffalo, NY 14263 USA	Institut National de la Sante et de la Recherche Medicale (Inserm); Roswell Park Cancer Institute; Roswell Park Cancer Institute	Blanchard, F (corresponding author), INSERM, U463, Inst Biol, 9 Quai Moncousu, F-44035 Nantes 01, France.		Blanchard, Frederic/K-8018-2015; Blanchard, Frederic/AAS-1930-2021	Blanchard, Frederic/0000-0003-1055-2573; Blanchard, Frederic/0000-0003-1055-2573; Duplomb, Laurence/0000-0002-5715-3759	NATIONAL CANCER INSTITUTE [P30CA016056, R01CA068612, R01CA085580] Funding Source: NIH RePORTER; NCI NIH HHS [CA 16056, CA 68612, CA 85580] Funding Source: Medline; NIDDK NIH HHS [DK 38866] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANTEQUERA F, 1990, CELL, V62, P503, DOI 10.1016/0092-8674(90)90015-7; Archer SY, 1998, P NATL ACAD SCI USA, V95, P6791, DOI 10.1073/pnas.95.12.6791; Armenante F, 1999, BIOCHEM BIOPH RES CO, V258, P644, DOI 10.1006/bbrc.1999.0566; Auernhammer CJ, 2000, ENDOCR REV, V21, P313, DOI 10.1210/er.21.3.313; Avantaggiati ML, 1997, CELL, V89, P1175, DOI 10.1016/S0092-8674(00)80304-9; BAJAJ P, 1993, CANCER LETT, V71, P143, DOI 10.1016/0304-3835(93)90109-M; Barasch J, 1999, CELL, V99, P377, DOI 10.1016/S0092-8674(00)81524-X; BAUMANN H, 1994, IMMUNOL TODAY, V15, P74, DOI 10.1016/0167-5699(94)90137-6; Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X; Bellido T, 1998, J BIOL CHEM, V273, P21137, DOI 10.1074/jbc.273.33.21137; BHUYAN BK, 1992, CANCER RES, V52, P5687; Birger Y, 1999, NATURE, V397, P84, DOI 10.1038/16291; Blanchard F, 2001, J BIOL CHEM, V276, P47038, DOI 10.1074/jbc.M107971200; Blanchard F, 1998, J BIOL CHEM, V273, P20886, DOI 10.1074/jbc.273.33.20886; Blanchard F, 2000, J BIOL CHEM, V275, P28793, DOI 10.1074/jbc.M003986200; BREITMAN TR, 1990, CANCER RES, V50, P6268; Byrd JC, 1999, BLOOD, V94, P1401, DOI 10.1182/blood.V94.4.1401.416k30_1401_1408; CAMERON DJ, 1980, J IMMUNOL, V124, P708; Chen B, 2000, CANCER RES, V60, P3290; Douglas AM, 1997, ONCOGENE, V14, P661, DOI 10.1038/sj.onc.1200882; Gadient RA, 1999, STEM CELLS, V17, P127, DOI 10.1002/stem.170127; Giraud S, 2002, J BIOL CHEM, V277, P8004, DOI 10.1074/jbc.M111486200; Grenier A, 1999, BLOOD, V93, P1413, DOI 10.1182/blood.V93.4.1413.404k06_1413_1421; Heinrich PC, 1998, BIOCHEM J, V334, P297, DOI 10.1042/bj3340297; HOSHIKAWA Y, 1994, EXP CELL RES, V214, P189, DOI 10.1006/excr.1994.1248; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; Kang SH, 1999, ONCOGENE, V18, P7280, DOI 10.1038/sj.onc.1203146; Kantarjian HM, 1997, LEUKEMIA, V11, P1617, DOI 10.1038/sj.leu.2400796; Karpf AR, 1999, P NATL ACAD SCI USA, V96, P14007, DOI 10.1073/pnas.96.24.14007; Kim H, 1999, MOL CELL BIOL, V19, P5326; Klausen P, 2000, ONCOGENE, V19, P3675, DOI 10.1038/sj.onc.1203707; Klouche M, 1999, J IMMUNOL, V163, P4583; Kortylewski M, 1999, ONCOGENE, V18, P3742, DOI 10.1038/sj.onc.1202708; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; LI E, 1993, COLD SPRING HARB SYM, V58, P297, DOI 10.1101/SQB.1993.058.01.035; Lindberg RA, 1998, MOL CELL BIOL, V18, P3357, DOI 10.1128/MCB.18.6.3357; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Magdinier F, 2001, P NATL ACAD SCI USA, V98, P4990, DOI 10.1073/pnas.101617298; Melki JR, 1999, CANCER RES, V59, P3730; Mielnicki LM, 1999, EXP CELL RES, V249, P161, DOI 10.1006/excr.1999.4461; Momparler RL, 1997, ANTI-CANCER DRUG, V8, P358, DOI 10.1097/00001813-199704000-00008; Mosley B, 1996, J BIOL CHEM, V271, P32635, DOI 10.1074/jbc.271.51.32635; NAIR BC, 1992, SCIENCE, V255, P1432; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; Ng HH, 1999, CURR OPIN GENET DEV, V9, P158, DOI 10.1016/S0959-437X(99)80024-0; OBrien CA, 1997, J BIOL CHEM, V272, P15003, DOI 10.1074/jbc.272.23.15003; Okamoto H, 1997, ARTHRITIS RHEUM, V40, P1096, DOI 10.1002/art.1780400614; RICHARDS CD, 1994, CYTOKINE, V6, P40, DOI 10.1016/1043-4666(94)90006-X; Rountree MR, 2001, ONCOGENE, V20, P3156, DOI 10.1038/sj.onc.1204339; Sandor V, 2000, BRIT J CANCER, V83, P817, DOI 10.1054/bjoc.2000.1327; Shin JY, 2000, CANCER RES, V60, P262; Thibault A, 1998, TUMORI, V84, P87, DOI 10.1177/030089169808400120; Vo N, 2001, J BIOL CHEM, V276, P13505, DOI 10.1074/jbc.R000025200; Wang YP, 2000, J BIOL CHEM, V275, P25273, DOI 10.1074/jbc.M002296200; Wang ZY, 1997, J BIOL CHEM, V272, P27957, DOI 10.1074/jbc.272.44.27957; WARE CB, 1995, DEVELOPMENT, V121, P1283; Weidle UH, 2000, ANTICANCER RES, V20, P1471; Wong HR, 1997, AM J PHYSIOL-LUNG C, V273, pL1, DOI 10.1152/ajplung.1997.273.1.L1; Xiao HY, 2000, J BIOL CHEM, V275, P1371, DOI 10.1074/jbc.275.2.1371; Yoshida K, 1996, P NATL ACAD SCI USA, V93, P407, DOI 10.1073/pnas.93.1.407	60	31	31	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 12	2002	21	41					6264	6277		10.1038/sj.onc.1205777	http://dx.doi.org/10.1038/sj.onc.1205777			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	590NM	12214267				2022-12-17	WOS:000177829000003
J	Morris, M; Hepburn, P; Wynford-Thomas, D				Morris, M; Hepburn, P; Wynford-Thomas, D			Sequential extension of proliferative lifespan in human fibroblasts induced by over-expression of CDK4 or 6 and loss of p53 function	ONCOGENE			English	Article						senescence; CDK4; CDK6; p53; fibroblast	HUMAN-DIPLOID FIBROBLASTS; KINASE INHIBITOR P16; TUMOR-SUPPRESSOR; REPLICATIVE SENESCENCE; DNA-SYNTHESIS; GENE-TRANSFER; HUMAN-CELLS; RB; IMMORTALIZATION; P21	Replicative senescence is thought to be a significant barrier to human tumorigenesis, which in human fibroblasts, and many other cell types, can be overcome experimentally by combined loss of function of p53 and Rb 'pathways'. To avoid the confounding pleiotropic effects of HPVE7 frequently used in such studies, here we have employed retroviral vectors over-expressing CDK4 or CDK6 as a more representative model of naturally-occurring mutations targeting the Rb pathway. We show that these can extend fibroblast lifespan by similar to10 population doublings, ending in a viable senescence-like state which contrasts with the apoptotic end-stage seen with E7. Compared with 'normal' senescence, this growth arrest was, in most cases, not accompanied by any further increase in p21(Wafl) levels but with up to a 19-fold increase in p16(Ink4a). Surprisingly however, this could not explain arrest, since expression of mutant CDK4 and/or CDK6, incapable of binding p16(Ink4a) did not confer any greater lifespan extension than the wild-type CDKs. Subsequent abrogation of p53 function by a second vector, encoding HPVE6, downregulated p21(Wafl) and conferred a second lifespan extension, ending in a crisis-like state, consistent with full escape from senescence. These data: (i) point to a back-up 'senescence' mechanism distinct from induction of p21(wafl) or p16(Ink4a) and (ii) provide an in vitro model of clonal evolution through successive dysfunction of Rb and p53 pathways in a relevant human cell context.	Cardiff Univ, Dept Pathol, Canc Res Campaign Labs, Cardiff CF14 4XN, S Glam, Wales	Cardiff University	Wynford-Thomas, D (corresponding author), Cardiff Univ, Dept Pathol, Canc Res Campaign Labs, Heath Pk, Cardiff CF14 4XN, S Glam, Wales.	KingTD@Cardiff.ac.uk	Morris, Mark/C-6413-2008	Morris, Mark/0000-0002-0700-355X				Alcorta DA, 1996, P NATL ACAD SCI USA, V93, P13742, DOI 10.1073/pnas.93.24.13742; Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; Berube NG, 1998, AM J HUM GENET, V62, P1015, DOI 10.1086/301848; Bond J, 1996, ONCOGENE, V13, P2097; BOND JA, 1994, ONCOGENE, V9, P1885; BOND JA, 1995, CANCER RES, V55, P2404; Bond JA, 1999, MOL CELL BIOL, V19, P3103; Bringold F, 2000, EXP GERONTOL, V35, P317, DOI 10.1016/S0531-5565(00)00083-8; Brown JP, 1997, SCIENCE, V277, P831, DOI 10.1126/science.277.5327.831; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; Costello JF, 1997, CANCER RES, V57, P1250; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; Dimri GP, 2000, MOL CELL BIOL, V20, P273, DOI 10.1128/MCB.20.1.273-285.2000; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Dunham MA, 2000, NAT GENET, V26, P447, DOI 10.1038/82586; Funk JO, 1997, GENE DEV, V11, P2090, DOI 10.1101/gad.11.16.2090; Gire V, 1998, MOL CELL BIOL, V18, P1611, DOI 10.1128/MCB.18.3.1611; Grignani F, 1998, CANCER RES, V58, P14; HALBERT CL, 1991, J VIROL, V65, P473, DOI 10.1128/JVI.65.1.473-478.1991; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hara E, 1996, MOL CELL BIOL, V16, P859; HARA E, 1991, BIOCHEM BIOPH RES CO, V179, P528, DOI 10.1016/0006-291X(91)91403-Y; Harbour JW, 1999, CELL, V98, P859, DOI 10.1016/S0092-8674(00)81519-6; Jones CJ, 2000, MOL CELL BIOL, V20, P5690, DOI 10.1128/MCB.20.15.5690-5699.2000; Jones DL, 1997, GENE DEV, V11, P2101, DOI 10.1101/gad.11.16.2101; Kanoe H, 1998, ANTICANCER RES, V18, P2317; LI Y, 1994, CANCER RES, V54, P6078; Mailand N, 2000, SCIENCE, V288, P1425, DOI 10.1126/science.288.5470.1425; Mitra J, 1999, MOL CELL BIOL, V19, P3916; MORGENBESSER SD, 1994, NATURE, V371, P72, DOI 10.1038/371072a0; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Morisaki H, 1999, EXP CELL RES, V253, P503, DOI 10.1006/excr.1999.4698; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; Ohtani N, 2001, NATURE, V409, P1067, DOI 10.1038/35059131; PAN HC, 1994, GENE DEV, V8, P1285, DOI 10.1101/gad.8.11.1285; Parry D, 1999, MOL CELL BIOL, V19, P1775; PARRY D, 1995, EMBO J, V14, P503, DOI 10.1002/j.1460-2075.1995.tb07026.x; Pilotti S, 1998, J PATHOL, V185, P188; Reddel RR, 2000, CARCINOGENESIS, V21, P477, DOI 10.1093/carcin/21.3.477; Reis RM, 2000, AM J PATHOL, V156, P425, DOI 10.1016/S0002-9440(10)64746-3; Ruas M, 1998, BBA-REV CANCER, V1378, pF115, DOI 10.1016/S0304-419X(98)00017-1; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Sherr CJ, 2000, CURR OPIN GENET DEV, V10, P94, DOI 10.1016/S0959-437X(99)00038-6; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Stein GH, 1999, MOL CELL BIOL, V19, P2109; Tao WK, 1999, P NATL ACAD SCI USA, V96, P6937, DOI 10.1073/pnas.96.12.6937; Webley K, 2000, MOL CELL BIOL, V20, P2803, DOI 10.1128/MCB.20.8.2803-2808.2000; Wei WY, 1999, EXP CELL RES, V253, P519, DOI 10.1006/excr.1999.4665; WOLFEL T, 1995, SCIENCE, V269, P1281, DOI 10.1126/science.7652577; Wright WE, 2000, NAT MED, V6, P849, DOI 10.1038/78592; WRIGHT WE, 1989, MOL CELL BIOL, V9, P3088, DOI 10.1128/MCB.9.7.3088; Wunder JS, 1999, ONCOGENE, V18, P783, DOI 10.1038/sj.onc.1202346; WynfordThomas D, 1997, EUR J CANCER, V33, P716, DOI 10.1016/S0959-8049(97)00064-6; WynfordThomas D, 1996, BIOL SIGNAL, V5, P139	54	31	31	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 20	2002	21	27					4277	4288		10.1038/sj.onc.1205492	http://dx.doi.org/10.1038/sj.onc.1205492			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	562AA	12082615				2022-12-17	WOS:000176174200010
J	Neve, RM; Ylstra, B; Chang, CH; Albertson, DG; Benz, CC				Neve, RM; Ylstra, B; Chang, CH; Albertson, DG; Benz, CC			ErbB2 activation of ESX gene expression	ONCOGENE			English	Article						ErbB2; ESX; breast cancer; Ets	ETS TRANSCRIPTION FACTOR; GENOMIC ORGANIZATION; ELF3; DIFFERENTIATION; AMPLICON; PROMOTER; TISSUES; CANCER; FAMILY; CELLS	Various members of the Ets multigene family exhibit diverse roles in development, cell differentiation, tissue-specific gene expression and human malignancy. In the search for Ets factors involved in mammary gland development and malignancy, ESX was found to be upregulated in a subset of breast tumours and cell lines. We report the transcriptional regulation of ESX in epithelial breast cancer cells. Transient reporter assays using the ESX promoter show that ESX transcription is regulated by ErbB receptor signalling. In cell lines and in 45 primary ductal breast cancers we show that ESX transcript expression significantly correlates with ErbB2 transcript levels. Moreover, expression of ErbB2 in cells upregulates ESX promoter activity while inhibition of ErbB2 or its downstream signaling pathways decrease both ESX promoter activity and endogenous ESX protein levels. These results indicate that the ESX promoter represents a transcriptional target of ErbB2, and ESX expression may represent a downstream mediator of ErbB2 signaling and ErbB2-induced gene expression.	Buck Inst Age Res, Novato, CA 94945 USA; Univ Calif San Francisco, Canc Res Inst, San Francisco, CA 94143 USA	Buck Institute for Research on Aging; University of California System; University of California San Francisco	Benz, CC (corresponding author), Buck Inst Age Res, 8001 Redwood Blvd, Novato, CA 94945 USA.		Ylstra, Bauke/D-2906-2012	Ylstra, Bauke/0000-0001-9479-3010	NATIONAL CANCER INSTITUTE [R01CA036773, P01CA044768] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA 44768, R01 CA 36773] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Albertson DG, 2000, NAT GENET, V25, P144, DOI 10.1038/75985; Andreoli JM, 1997, NUCLEIC ACIDS RES, V25, P4287, DOI 10.1093/nar/25.21.4287; Brembeck FH, 2000, ONCOGENE, V19, P1941, DOI 10.1038/sj.onc.1203441; Chang CH, 1999, ONCOGENE, V18, P3682, DOI 10.1038/sj.onc.1202674; Chang CH, 1997, ONCOGENE, V14, P1617, DOI 10.1038/sj.onc.1200978; Collins C, 2001, GENOME RES, V11, P1034, DOI 10.1101/gr.GR1743R; Godfrey TE, 2000, J MOL DIAGN, V2, P84, DOI 10.1016/S1525-1578(10)60621-6; Khwaja A, 1999, NATURE, V401, P33, DOI 10.1038/43354; Lane HA, 2000, MOL CELL BIOL, V20, P3210, DOI 10.1128/MCB.20.9.3210-3223.2000; Neve R, 1998, FASEB J, V12, P1541, DOI 10.1096/fasebj.12.14.1541; Neve RM, 2000, ONCOGENE, V19, P1647, DOI 10.1038/sj.onc.1203470; Neve RM, 2001, BIOCHEM BIOPH RES CO, V280, P274, DOI 10.1006/bbrc.2000.4104; NG AYN, 2002, IN PRESS GASTROENTER; Oettgen P, 1999, GENOMICS, V55, P358, DOI 10.1006/geno.1998.5681; RUDDERS S, 2000, J BIOL CHEM, V17, P17; Scott GK, 2000, ONCOGENE, V19, P6490, DOI 10.1038/sj.onc.1204041; Shridhar V, 2001, CANCER RES, V61, P5895; Tymms MJ, 1997, ONCOGENE, V15, P2449, DOI 10.1038/sj.onc.1201427; Yoshida N, 2000, MECH DEVELOP, V97, P27, DOI 10.1016/S0925-4773(00)00419-6	19	31	33	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 30	2002	21	24					3934	3938		10.1038/sj.onc.1205503	http://dx.doi.org/10.1038/sj.onc.1205503			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	556KD	12032832				2022-12-17	WOS:000175847200013
J	Palmero, I; Murga, M; Zubiaga, A; Serrano, M				Palmero, I; Murga, M; Zubiaga, A; Serrano, M			Activation of ARF by oncogenic stress in mouse fibroblasts is independent of E2F1 and E2F2	ONCOGENE			English	Article						ARF; p53; E2F; tumour suppressor; oncogene	THYMIC NEGATIVE SELECTION; TUMOR-SUPPRESSOR; DNA-DAMAGE; TRANSCRIPTION FACTOR; INK4A LOCUS; S-PHASE; P53-DEPENDENT APOPTOSIS; CELLULAR PROLIFERATION; GROWTH-CHARACTERISTICS; UV-IRRADIATION	The ARF tumour suppressor protein (p14(ARF) in human and p19(ARF) in mouse) is a major mediator of the activation of p53 in response to oncogenic stress. Little is known about the signalling pathways connecting oncogenic stimuli to the activation of ARF. Regulation of ARF occurs primarily at the transcriptional level and several modulators of ARF transcription have been identified. Notably, ectopic expression of E2F1 upregulates ARF transcriptionally, and both E2F1 and ARF have been implicated in apoptosis and cell-cycle arrest. We have used primary mouse fibroblasts deficient for E2F1, E2F2, or both to determine the possible role of these E2F proteins as upstream regulators of ARF in response to oncogenic stimuli and other stresses. In particular, we have studied the effects of oncogenic Ras and the viral oncoprotein E1A on ARF levels, neoplastic transformation, and sensitization to apoptosis. We have also examined the behaviour of the E2F-deficient MEFs with respect to immortalization and sensitivity to DNA damage. None of the ARF-mediated responses that we have analysed is significantly affected in E2F1(-/-), E2F2(-/-) or E2F1/2(-/-) MEFs, and ARF is upregulated normally in all cases. Taken together, our results indicate that the activation of ARF in response to oncogenic stress can occur by E2F1- and E2F2-independent mechanisms. This challenges previous suggestions implicating E2F factors as key mediators in the activation of ARF by oncogenic stress.	CSIC, Natl Biotechnol Ctr, Dept Immunol & Oncol, E-28049 Madrid, Spain; Univ Basque Country, Fac Sci, Dept Anim Biol & Genet, E-48080 Bilbao, Spain; Univ Salamanca, CSIC, Inst Mol & Cellular Biol Canc, E-37007 Salamanca, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); University of Basque Country; Consejo Superior de Investigaciones Cientificas (CSIC); University of Salamanca	Serrano, M (corresponding author), CSIC, Natl Biotechnol Ctr, Dept Immunol & Oncol, Campus Cantoblanco, E-28049 Madrid, Spain.		zubiaga, ana/S-3457-2019; Palmero, Ignacio/B-4346-2013; Serrano, Manuel/H-2634-2015	zubiaga, ana/0000-0002-2132-9708; Serrano, Manuel/0000-0001-7177-9312				AMRTELLI F, 2001, P NATL ACAD SCI USA, V98, P4455; Ashcroft M, 1999, ONCOGENE, V18, P7637, DOI 10.1038/sj.onc.1203012; Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; Blattner C, 1999, MOL CELL BIOL, V19, P3704; BRUMMELKAMP TR, 2001, J BIOL CHEM, V17, P17; Dannenberg JH, 2000, GENE DEV, V14, P3051, DOI 10.1101/gad.847700; de Stanchina E, 1998, GENE DEV, V12, P2434, DOI 10.1101/gad.12.15.2434; DeGregori J, 1997, P NATL ACAD SCI USA, V94, P7245, DOI 10.1073/pnas.94.14.7245; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; Dimri GP, 2000, MOL CELL BIOL, V20, P273, DOI 10.1128/MCB.20.1.273-285.2000; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Eymin B, 2001, ONCOGENE, V20, P1033, DOI 10.1038/sj.onc.1204220; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; Garcia I, 2000, CELL GROWTH DIFFER, V11, P91; Harbour JW, 2000, GENE DEV, V14, P2393, DOI 10.1101/gad.813200; HARVEY M, 1993, ONCOGENE, V8, P2457; Hofferer M, 1999, NUCLEIC ACIDS RES, V27, P491, DOI 10.1093/nar/27.2.491; Hsieh JK, 2002, MOL CELL BIOL, V22, P78, DOI 10.1128/MCB.22.1.78-93.2002; Huang YY, 1997, CANCER RES, V57, P3640; Humbert PO, 2000, GENE DEV, V14, P690; Inoue K, 1999, P NATL ACAD SCI USA, V96, P3993, DOI 10.1073/pnas.96.7.3993; Inoue K, 2000, GENE DEV, V14, P1797; Irwin M, 2000, NATURE, V407, P645, DOI 10.1038/35036614; Ishida S, 2001, MOL CELL BIOL, V21, P4684, DOI 10.1128/MCB.21.14.4684-4699.2001; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Jacobs JJL, 2000, NAT GENET, V26, P291, DOI 10.1038/81583; Jacobs JJL, 1999, NATURE, V397, P164, DOI 10.1038/16476; Jones SN, 1996, P NATL ACAD SCI USA, V93, P14106, DOI 10.1073/pnas.93.24.14106; Kamijo T, 1999, CANCER RES, V59, P2217; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Khan SH, 2000, P NATL ACAD SCI USA, V97, P3266, DOI 10.1073/pnas.050560997; KOWALIK TF, 1995, J VIROL, V69, P2491, DOI 10.1128/JVI.69.4.2491-2500.1995; Kowalik TF, 1998, CELL GROWTH DIFFER, V9, P113; Krimpenfort P, 2001, NATURE, V413, P83, DOI 10.1038/35092584; Leone G, 2001, MOL CELL, V8, P105, DOI 10.1016/S1097-2765(01)00275-1; Lin WC, 2001, GENE DEV, V15, P1833; Lissy NA, 2000, NATURE, V407, P642, DOI 10.1038/35036608; Llanos S, 2001, NAT CELL BIOL, V3, P445, DOI 10.1038/35074506; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; Maestro R, 1999, GENE DEV, V13, P2207, DOI 10.1101/gad.13.17.2207; Meng RD, 1999, INT J ONCOL, V14, P5; Moroni MC, 2001, NAT CELL BIOL, V3, P552, DOI 10.1038/35078527; Muller H, 2001, GENE DEV, V15, P267, DOI 10.1101/gad.864201; Murga M, 2001, IMMUNITY, V15, P959, DOI 10.1016/S1074-7613(01)00254-0; Palmero I, 1997, ONCOGENE, V15, P495, DOI 10.1038/sj.onc.1201212; Palmero I, 2001, METHOD ENZYMOL, V333, P247; Palmero I, 1998, NATURE, V395, P125, DOI 10.1038/25870; Pan HC, 1998, MOL CELL, V2, P283, DOI 10.1016/S1097-2765(00)80273-7; Pantoja C, 1999, ONCOGENE, V18, P4974, DOI 10.1038/sj.onc.1202880; Peeper DS, 2001, NAT CELL BIOL, V3, P198, DOI 10.1038/35055110; Phillips AC, 1999, MOL CELL, V4, P771, DOI 10.1016/S1097-2765(00)80387-1; Phillips AC, 1997, GENE DEV, V11, P1853, DOI 10.1101/gad.11.14.1853; Prives C, 1998, CELL, V95, P5, DOI 10.1016/S0092-8674(00)81774-2; Radfar A, 1998, P NATL ACAD SCI USA, V95, P13194, DOI 10.1073/pnas.95.22.13194; Rempel RE, 2000, MOL CELL, V6, P293, DOI 10.1016/S1097-2765(00)00030-7; Robertson KD, 1998, MOL CELL BIOL, V18, P6457, DOI 10.1128/MCB.18.11.6457; Ruas M, 1998, BBA-REV CANCER, V1378, pF115, DOI 10.1016/S0304-419X(98)00017-1; Sage J, 2000, GENE DEV, V14, P3037, DOI 10.1101/gad.843200; Serrano M, 2000, CARCINOGENESIS, V21, P865, DOI 10.1093/carcin/21.5.865; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; Serrano M, 1997, EXP CELL RES, V237, P7, DOI 10.1006/excr.1997.3824; Sharpless NE, 2001, NATURE, V413, P86, DOI 10.1038/35092592; Sharpless NE, 1999, CURR OPIN GENET DEV, V9, P22, DOI 10.1016/S0959-437X(99)80004-5; Sherr CJ, 2000, CELL, V102, P407, DOI 10.1016/S0092-8674(00)00046-5; Sherr CJ, 2000, CURR OPIN GENET DEV, V10, P94, DOI 10.1016/S0959-437X(99)00038-6; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; Sherr CJ, 2001, NAT REV MOL CELL BIO, V2, P731, DOI 10.1038/35096061; Sherr CJ, 2001, CELL, V106, P531, DOI 10.1016/S0092-8674(01)00486-X; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299; Tolbert D, 2002, MOL CELL BIOL, V22, P370, DOI 10.1128/MCB.22.1.370-377.2002; Trimarchi JM, 2002, NAT REV MOL CELL BIO, V3, P11, DOI 10.1038/nrm714; Vigo E, 1999, MOL CELL BIOL, V19, P6379; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Weinberg RA, 1997, CELL, V88, P573, DOI 10.1016/S0092-8674(00)81897-8; Weitzman JB, 2000, MOL CELL, V6, P1109, DOI 10.1016/S1097-2765(00)00109-X; Woods DB, 2001, EXP CELL RES, V264, P56, DOI 10.1006/excr.2000.5141; Wu L, 1997, MOL MED, V3, P441, DOI 10.1007/BF03401691; Wu LZ, 2001, NATURE, V414, P457, DOI 10.1038/35106593; Yamasaki L, 1996, CELL, V85, P537, DOI 10.1016/S0092-8674(00)81254-4; Zhu JW, 1999, CELL GROWTH DIFFER, V10, P829; Zhu JW, 2001, MOL CELL BIOL, V21, P8547, DOI 10.1128/MCB.21.24.8547-8564.2001; Ziebold U, 2001, GENE DEV, V15, P386, DOI 10.1101/gad.858801; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424; Zindy F, 1997, ONCOGENE, V15, P203, DOI 10.1038/sj.onc.1201178	88	31	31	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 2	2002	21	19					2939	2947		10.1038/sj/onc/1205371	http://dx.doi.org/10.1038/sj/onc/1205371			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	546FM	12082524				2022-12-17	WOS:000175262700001
J	Janz, C; Susse, S; Wiesmuller, L				Janz, C; Susse, S; Wiesmuller, L			p53 and recombination intermediates: role of tetramerization at DNA junctions in complex formation and exonucleolytic degradation	ONCOGENE			English	Article						exonuclease; genomic stability; mispairing; oligomerization; protein-DNA complex formation; tumor suppressor	INTRACHROMOSOMAL HOMOLOGOUS RECOMBINATION; BINDING DOMAIN PEPTIDES; HOLLIDAY JUNCTIONS; HUMAN RAD51; PROTEIN; REPLICATION; INSTABILITY; DAMAGE; OLIGOMERIZATION; INACTIVATION	Heteroduplex joints represent intermediates of Rad51-dependent recombination processes, which are recognized by p53 with extremely high affinities, in a manner independent of the DNA sequence content. To determine the structural elements required for complex formation, we monitored DNA-binding by protection against restriction endonuclease cleavage. We show that wild-type (wt) p53 interacts with heteroduplex joints in the proximity of the flexible junction. Association of p53 within this junction region was also observed with preformed Rad51-heteroduplex complexes, whereas SSB counteracted p53 binding. At a distance of 31 bp from the junction p53 established very few contacts with the heteroduplex, despite the presence of an A - G mismatch. Consistently, p53-dependent exonucleolytic degradation decreased when we raised the distance between the junction and the heteroduplex terminus by 27 bp. Different from the cancer-related mutant p53(273H), which did not recognize the junction, tetramerization defective p53-1262 was protection competent but displayed reduced complex stability in gel shifts. Moreover, p53-1262 performed exonucleolytic activities towards ssDNA like wtp53, but reduced degradation of heteroduplex joints. These results suggest that during recombination wild-type p53, as a tetramer, stably binds to strand transfer regions, enabling the protein to exonucleolytically correct heteroduplex intermediates early after strand invasion.	Univ Ulm, Frauenklin & Poliklin, D-89075 Ulm, Germany	Ulm University	Wiesmuller, L (corresponding author), Univ Ulm, Frauenklin & Poliklin, Prittwitzstr 43, D-89075 Ulm, Germany.	Lisa.Wiesmueller@medizin.uni-ulm.de						Ahrendt SA, 2000, CANCER RES, V60, P2488; Albrechtsen N, 1999, ONCOGENE, V18, P7706, DOI 10.1038/sj.onc.1202952; Atz J, 2000, J CELL BIOCHEM, V76, P572, DOI 10.1002/(SICI)1097-4644(20000315)76:4<572::AID-JCB6>3.0.CO;2-6; Bakhanashvili M, 2001, EUR J BIOCHEM, V268, P2047, DOI 10.1046/j.1432-1327.2001.02075.x; BALAGURUMOORTHY P, 1995, P NATL ACAD SCI USA, V92, P8591, DOI 10.1073/pnas.92.19.8591; Baumann P, 1998, TRENDS BIOCHEM SCI, V23, P247, DOI 10.1016/S0968-0004(98)01232-8; Bertrand P, 1997, ONCOGENE, V14, P1117, DOI 10.1038/sj.onc.1200931; Blander G, 1999, J BIOL CHEM, V274, P29463, DOI 10.1074/jbc.274.41.29463; Chene P, 1999, J MOL BIOL, V288, P891, DOI 10.1006/jmbi.1999.2738; Chene P, 1999, J MOL BIOL, V286, P1269, DOI 10.1006/jmbi.1999.2563; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; Cleaver JE, 1999, CANCER RES, V59, P1102; Constantinou A, 2000, EMBO REP, V1, P80, DOI 10.1093/embo-reports/kvd004; Dasika GK, 1999, ONCOGENE, V18, P7883, DOI 10.1038/sj.onc.1203283; Dudenhoffer C, 1999, ONCOGENE, V18, P5773, DOI 10.1038/sj.onc.1202964; Dudenhoffer C, 1998, MOL CELL BIOL, V18, P5332, DOI 10.1128/MCB.18.9.5332; Flores-Rozas H, 2000, TRENDS BIOCHEM SCI, V25, P196, DOI 10.1016/S0968-0004(00)01568-1; Gebow D, 2000, MOL CELL BIOL, V20, P4028, DOI 10.1128/MCB.20.11.4028-4035.2000; Haber JE, 1999, TRENDS BIOCHEM SCI, V24, P271, DOI 10.1016/S0968-0004(99)01413-9; Honma M, 1997, MUTAT RES-FUND MOL M, V374, P89, DOI 10.1016/S0027-5107(96)00223-0; Huang P, 1998, ONCOGENE, V17, P261, DOI 10.1038/sj.onc.1201946; ISHIZAKI K, 1994, INT J CANCER, V58, P254, DOI 10.1002/ijc.2910580218; Janus F, 1999, MOL CELL BIOL, V19, P2155; JAYARAMAN L, 1995, CELL, V81, P1021, DOI 10.1016/S0092-8674(05)80007-8; Jean D, 1997, NUCLEIC ACIDS RES, V25, P4004, DOI 10.1093/nar/25.20.4004; Kuhn C, 1999, ONCOGENE, V18, P769, DOI 10.1038/sj.onc.1202327; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LEE S, 1995, CELL, V81, P1013, DOI 10.1016/S0092-8674(05)80006-6; Lee SM, 1997, J BIOL CHEM, V272, P7532, DOI 10.1074/jbc.272.11.7532; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Mekeel KL, 1997, ONCOGENE, V14, P1847, DOI 10.1038/sj.onc.1201143; MEYN MS, 1994, INT J RADIAT BIOL, V66, pS141; Mummenbrauer T, 1996, CELL, V85, P1089, DOI 10.1016/S0092-8674(00)81309-4; Nagaich AK, 1999, P NATL ACAD SCI USA, V96, P1875, DOI 10.1073/pnas.96.5.1875; Nagaich AK, 1997, J BIOL CHEM, V272, P14830, DOI 10.1074/jbc.272.23.14830; Nagaich AK, 1997, J BIOL CHEM, V272, P14842, DOI 10.1074/jbc.272.23.14842; Palecek E, 1997, ONCOGENE, V15, P2201, DOI 10.1038/sj.onc.1201398; Pham P, 2001, NATURE, V409, P366, DOI 10.1038/35053116; Saintigny Y, 1999, ONCOGENE, V18, P3553, DOI 10.1038/sj.onc.1202941; Schwartz JL, 1999, RADIAT RES, V151, P385, DOI 10.2307/3579824; SHAKKED Z, 2000, J BIOMOL STRUCT DYN; Skalski V, 2000, ONCOGENE, V19, P3321, DOI 10.1038/sj.onc.1203649; STENGER JE, 1994, EMBO J, V13, P6011, DOI 10.1002/j.1460-2075.1994.tb06947.x; Susse S, 2000, ONCOGENE, V19, P4500, DOI 10.1038/sj.onc.1203809; Tarunina M, 1996, ONCOGENE, V13, P589; TOKINO T, 1994, HUM MOL GENET, V3, P1537, DOI 10.1093/hmg/3.9.1537; Wiesmuller L, 1996, J VIROL, V70, P737; Willers H, 2000, ONCOGENE, V19, P632, DOI 10.1038/sj.onc.1203142; Wold MS, 1997, ANNU REV BIOCHEM, V66, P61, DOI 10.1146/annurev.biochem.66.1.61; XIA F, 1994, MOL CELL BIOL, V14, P5850, DOI 10.1128/MCB.14.9.5850; Zotchev SB, 2000, NUCLEIC ACIDS RES, V28, P4005, DOI 10.1093/nar/28.20.4005	51	31	32	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 28	2002	21	14					2130	2140		10.1038/sj.onc.1205292	http://dx.doi.org/10.1038/sj.onc.1205292			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	533XJ	11948396				2022-12-17	WOS:000174555300002
J	Ueda, C; Akasaka, T; Kurata, M; Maesako, Y; Nishikori, M; Ichinohasama, R; Imada, K; Uchiyama, T; Ohno, H				Ueda, C; Akasaka, T; Kurata, M; Maesako, Y; Nishikori, M; Ichinohasama, R; Imada, K; Uchiyama, T; Ohno, H			The gene for interleukin-21 receptor is the partner of BCL6 in t(3;16)(q27;p11), which is recurrently observed in diffuse large B-cell lymphoma	ONCOGENE			English	Article						BCL6 gene; non-immunoglobulin gene; t(3;16)(q27;p11) translocation; interleukin-21 receptor gene; diffuse large B-cell lymphoma	GERMINAL-CENTER FORMATION; NON-HODGKINS-LYMPHOMA; FINGER ENCODING GENE; POZ DOMAIN; BETA-CHAIN; TRANSCRIPTIONAL REPRESSION; LAZ3/BCL6 ONCOPROTEIN; TRANSLOCATION; PROTEIN; DIFFERENTIATION	BCL6 translocation affecting the chromosomal band 3q27 can involve a number of non-immunoglobulin (non-IG) gene loci as partners. We report here that the gene for interleukin-21 receptor (IL-21R) is the partner of BCL6 in t(3;16)(q27;p11) translocation. The two breakpoints on 16p11 of a lymphoma cell line YM and case no. 1012 with diffuse large B-cell lymphoma, both of which carried t(3;16), were localized within the similar to27-kb intron I of IL-21R. As a result of t(3;16), the promoter region of IL-21R was substituted for the regulatory sequences of BCL6 in the same transcriptional orientation. Reverse transcriptase-mediated polymerase chain reaction revealed chimeric mRNA consisting of two noncoding exons 1a/1b of IL-21R and coding exons of BCL6 in both lymphoma cells. Fluorescence in situ chromosomal hybridization of YM metaphase cells revealed fusion signals that contained both the BCL6 and IL-21R sequences on the der(3)t(3;16) chromosome. IL-21R was actively transcribed in YM cells, while BCL6 that was under the control of the IL-21R promoter was only moderately expressed at the mRNA and protein level. We constructed expression plasmid of BCL6 that followed the promoter sequences of IL-21R. COS-7 cells transiently transfected with the plasmid expressed high level Bcl-6 protein and displayed nuclear staining with a characteristic punctate pattern by immunofluorescence, indicating that expression of BCL6 can be enhanced by t(3;16). This study added to the list of non-IG partners of BCL6 translocations a new class of gene, i.e. cytokine receptor gene, the expression of which is closely associated with lymphoid cells.	Kyoto Univ, Fac Med, Dept Internal Med, Sakyo Ku, Kyoto 6068507, Japan; Tohoku Univ, Sch Dent, Dept Oral Pathol, Aoba Ku, Sendai, Miyagi 9808575, Japan	Kyoto University; Tohoku University	Ohno, H (corresponding author), Kyoto Univ, Fac Med, Dept Internal Med, Sakyo Ku, Div 1,54 Shogoin Kawaramachi, Kyoto 6068507, Japan.			Imada, Kazunori/0000-0002-0945-0513				Akasaka H, 2000, CANCER RES, V60, P2335; Akasaka T, 1997, CANCER RES, V57, P7; Albagli O, 1996, BIOCHEM BIOPH RES CO, V220, P911, DOI 10.1006/bbrc.1996.0505; BARDWELL VJ, 1994, GENE DEV, V8, P1664, DOI 10.1101/gad.8.14.1664; BASTARD C, 1994, BLOOD, V83, P2423; CATTORETTI G, 1995, BLOOD, V86, P45, DOI 10.1182/blood.V86.1.45.bloodjournal86145; Chang CC, 1996, P NATL ACAD SCI USA, V93, P6947, DOI 10.1073/pnas.93.14.6947; DALLERY E, 1995, ONCOGENE, V10, P2171; Dhordain P, 1997, P NATL ACAD SCI USA, V94, P10762, DOI 10.1073/pnas.94.20.10762; Dhordain P, 1998, NUCLEIC ACIDS RES, V26, P4645, DOI 10.1093/nar/26.20.4645; Dhordain P, 1995, ONCOGENE, V11, P2689; Fukuda T, 1997, J EXP MED, V186, P439, DOI 10.1084/jem.186.3.439; Galiegue-Zouitina S, 1999, GENE CHROMOSOME CANC, V26, P97, DOI 10.1002/(SICI)1098-2264(199910)26:2<97::AID-GCC1>3.0.CO;2-9; Galieque-Zouitina S, 1996, LEUKEMIA, V10, P579; Han SH, 1997, SCIENCE, V278, P301, DOI 10.1126/science.278.5336.301; HATAKEYAMA M, 1989, SCIENCE, V244, P551, DOI 10.1126/science.2785715; Hosokawa Y, 2000, BLOOD, V95, P2719; Huynh KD, 1998, ONCOGENE, V17, P2473, DOI 10.1038/sj.onc.1202197; Ichinohasama R, 1998, CANCER GENET CYTOGEN, V103, P133, DOI 10.1016/S0165-4608(97)00390-7; KERCKAERT JP, 1993, NAT GENET, V5, P66, DOI 10.1038/ng0993-66; Kikuchi M, 2000, ONCOGENE, V19, P4941, DOI 10.1038/sj.onc.1203864; Kuppers R, 1999, NEW ENGL J MED, V341, P1520; Lin JX, 1997, MOL CELL BIOL, V17, P3714, DOI 10.1128/MCB.17.7.3714; MIKI T, 1994, BLOOD, V83, P26; OHASHI K, 1995, BIOCHEM BIOPH RES CO, V214, P461, DOI 10.1006/bbrc.1995.2309; Ohno H, 1997, LEUKEMIA LYMPHOMA, V27, P53, DOI 10.3109/10428199709068271; ONIZUKA T, 1995, BLOOD, V86, P28, DOI 10.1182/blood.V86.1.28.bloodjournal86128; Ozaki K, 2000, P NATL ACAD SCI USA, V97, P11439, DOI 10.1073/pnas.200360997; Parrish-Novak J, 2000, NATURE, V408, P57, DOI 10.1038/35040504; Shaffer AL, 2000, IMMUNITY, V13, P199, DOI 10.1016/S1074-7613(00)00020-0; Willis TG, 2000, BLOOD, V96, P808, DOI 10.1182/blood.V96.3.808.015k30_808_822; Wong CW, 1998, J BIOL CHEM, V273, P27695, DOI 10.1074/jbc.273.42.27695; Xu WS, 2000, GENE CHROMOSOME CANC, V27, P69, DOI 10.1002/(SICI)1098-2264(200001)27:1<69::AID-GCC9>3.0.CO;2-5; Ye BH, 1997, NAT GENET, V16, P161, DOI 10.1038/ng0697-161; YE BH, 1993, SCIENCE, V262, P747, DOI 10.1126/science.8235596; Yonetani N, 1998, ONCOGENE, V17, P971, DOI 10.1038/sj.onc.1202027; Yoshida S, 1999, ONCOGENE, V18, P7994, DOI 10.1038/sj.onc.1203293; ZOLA H, 1991, IMMUNOLOGY, V72, P167	38	31	34	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 17	2002	21	3					368	376		10.1038/sj.onc.1205099	http://dx.doi.org/10.1038/sj.onc.1205099			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	512FV	11821949	Green Submitted			2022-12-17	WOS:000173311200005
J	Nakamura, T; Komiya, M; Gotoh, N; Koizumi, S; Shibuya, M; Mori, N				Nakamura, T; Komiya, M; Gotoh, N; Koizumi, S; Shibuya, M; Mori, N			Discrimination between phosphotyrosine-mediated signaling properties of conventional and neuronal Shc adapter molecules	ONCOGENE			English	Article						Shc family; NGF; Trk; tyrosine kinase; Ras; Erk	NERVE GROWTH-FACTOR; PROTEIN-KINASE ACTIVATION; PC12 CELLS; TYROSINE PHOSPHORYLATION; TRANSDUCTION PATHWAYS; BINDING DOMAIN; ROADS LEAD; CRK-II; N-SHC; RAS	The phosphotyrosine (pTyr) adapter Shc/ShcA is a major connector in various tyrosine kinase signalings following a variety of stimulation such as growth factor/neurotrophin, as well as in those following calcium influx and integrin activation. As in other tissues, Shc has been implicated in neuronal signalings; however, recent evidence suggests that N-Shc/ShcC and Sck/ShcB would take over most of the roles of Shc in mature central neurons, and switching phenomena between Shc and N-Shc expression were observed in several neuronal paradigms. Little is, however, known as to the signal-output differences between Shc and N-Shc. Here we determined the efficacy of Shc and N-Shc toward Erk activation in NGF-treated PC12 cells, and found that N-Shc transduced Grb2/Sos/Ras-dependent Erk activation less efficiently than Shc. This was mainly because N-Shc has only one high-affinity Grb2-binding site, whereas Shc has two such sites. Phosphopeptide mapping revealed that N-Shc has novel tyrosine-phosphorylation sites at Y259/Y260 and Y286; in vivo-phosphorylation of these tyrosines was demonstrated by site-specific anti-pTyr antibodies. Phosphorylated Y286 bound to several proteins, of which one was Crk. The pY221/pY222 site, corresponding to one of the Grb2-binding sites of Shc, also preferentially bound to Crk. The phosphorylation-dependent interaction between N-Shc and Crk was demonstrated in vitro and in vivo. These results indicate that N-Shc has specific features of signal-output, and further suggest that the switching between Shc and N-Shc during neural development and regeneration would lead to differentiation of downstream signalings.	Natl Inst Longev Sci, Dept Mol Genet, Aichi 4748522, Japan; JST, Program Protecting Brain, CREST, Aichi 4748522, Japan; Sumitomo Elect Ind Ltd, Biomed R&D Dept, Sakae Ku, Yokohama, Kanagawa 2448588, Japan; Univ Tokyo, Inst Med Sci, Dept Genet, Minato Ku, Tokyo 1080071, Japan; Novartis, Takarazuka Res Inst, Takarazuka, Hyogo 6658666, Japan	Japan Science & Technology Agency (JST); Sumitomo Electric Industries; University of Tokyo; Novartis	Mori, N (corresponding author), Natl Inst Longev Sci, Dept Mol Genet, Gengo 36-3, Aichi 4748522, Japan.	morinos@nils.go.jp	GOTOH, Noriko/D-8430-2015	Gotoh, Noriko/0000-0003-3733-260X				ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; Bonfini L, 1996, TRENDS BIOCHEM SCI, V21, P257, DOI 10.1016/0968-0004(96)10033-5; BOURNE HR, 1995, NATURE, V376, P727, DOI 10.1038/376727a0; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; Busca R, 2000, EMBO J, V19, P2900, DOI 10.1093/emboj/19.12.2900; Conti L, 1997, P NATL ACAD SCI USA, V94, P8185, DOI 10.1073/pnas.94.15.8185; El-Shemerly MYM, 1997, J BIOL CHEM, V272, P30599, DOI 10.1074/jbc.272.49.30599; Escalante M, 2000, J BIOL CHEM, V275, P24787, DOI 10.1074/jbc.M000711200; Gotoh N, 1996, EMBO J, V15, P6197, DOI 10.1002/j.1460-2075.1996.tb01008.x; Gotoh N, 1997, MOL CELL BIOL, V17, P1824, DOI 10.1128/MCB.17.4.1824; Harmer SL, 1997, MOL CELL BIOL, V17, P4087, DOI 10.1128/MCB.17.7.4087; Hashimoto A, 1999, J BIOL CHEM, V274, P20139, DOI 10.1074/jbc.274.29.20139; HASHIMOTO Y, 1994, ONCOGENE, V9, P869; HAUSER CA, 1995, METHOD ENZYMOL, V255, P395; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; Ichiba T, 1997, J BIOL CHEM, V272, P22215, DOI 10.1074/jbc.272.35.22215; Iwasaki Y, 1997, BIOCHEMISTRY-US, V36, P2694, DOI 10.1021/bi962057x; Kao SC, 2001, J BIOL CHEM, V276, P18169, DOI 10.1074/jbc.M008870200; Kojima T, 2001, BIOCHEM BIOPH RES CO, V284, P1039, DOI 10.1006/bbrc.2001.5080; Lai KMV, 2000, GENE DEV, V14, P1132; Luschnig S, 2000, MOL CELL, V5, P231, DOI 10.1016/S1097-2765(00)80419-0; Matsuda M, 1996, CELL SIGNAL, V8, P335, DOI 10.1016/0898-6568(96)00067-8; MATSUDA M, 1994, MOL CELL BIOL, V14, P5495, DOI 10.1128/MCB.14.8.5495; Migliaccio E, 1999, NATURE, V402, P309, DOI 10.1038/46311; MIKI H, 1994, J BIOL CHEM, V269, P5489; Minichiello L, 1998, NEURON, V21, P335, DOI 10.1016/S0896-6273(00)80543-7; Nakamura T, 1996, ONCOGENE, V13, P1111; Nakamura T, 1998, J BIOL CHEM, V273, P6960, DOI 10.1074/jbc.273.12.6960; Nakashima N, 1999, J BIOL CHEM, V274, P3001, DOI 10.1074/jbc.274.5.3001; OBERMEIER A, 1994, EMBO J, V13, P1585, DOI 10.1002/j.1460-2075.1994.tb06421.x; OBryan JP, 1996, P NATL ACAD SCI USA, V93, P2729, DOI 10.1073/pnas.93.7.2729; OBryan JP, 1996, J BIOL CHEM, V271, P11787, DOI 10.1074/jbc.271.20.11787; Okabayashi Y, 1996, J BIOL CHEM, V271, P5265; Pawson T, 1999, CELL, V97, P675, DOI 10.1016/S0092-8674(00)80779-5; Pelicci G, 1996, ONCOGENE, V13, P633; Ribon V, 1996, J BIOL CHEM, V271, P7375, DOI 10.1074/jbc.271.13.7375; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; Sakai R, 2000, NEURON, V28, P819, DOI 10.1016/S0896-6273(00)00156-2; Shields JM, 2000, TRENDS CELL BIOL, V10, P147, DOI 10.1016/S0962-8924(00)01740-2; SIMCOX ME, 1994, STRATEGIES, V7, P68; STEPHENS RM, 1994, NEURON, V12, P691, DOI 10.1016/0896-6273(94)90223-2; Tanabe K, 1998, MOL BRAIN RES, V53, P291, DOI 10.1016/S0169-328X(97)00264-7; Tanaka S, 1997, P NATL ACAD SCI USA, V94, P2356, DOI 10.1073/pnas.94.6.2356; Thomas D, 1997, J BIOL CHEM, V272, P22293, DOI 10.1074/jbc.272.35.22293; Torres M, 1996, ONCOGENE, V12, P77; vanderGeer P, 1996, CURR BIOL, V6, P1435, DOI 10.1016/S0960-9822(96)00748-8; vanderGeer P, 1996, P NATL ACAD SCI USA, V93, P963, DOI 10.1073/pnas.93.3.963; Wary KK, 1998, CELL, V94, P625, DOI 10.1016/S0092-8674(00)81604-9; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; Yamashita S, 2000, J BIOL CHEM, V275, P25488, DOI 10.1074/jbc.M003414200; York RD, 1998, NATURE, V392, P622, DOI 10.1038/33451; Zwartkruis FJT, 1998, EMBO J, V17, P5905, DOI 10.1093/emboj/17.20.5905	52	31	33	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 3	2002	21	1					22	31		10.1038/sj.onc.1205019	http://dx.doi.org/10.1038/sj.onc.1205019			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	505AD	11791173				2022-12-17	WOS:000172887800003
J	Garkavtsev, IV; Kley, N; Grigorian, IA; Gudkov, AV				Garkavtsev, IV; Kley, N; Grigorian, IA; Gudkov, AV			The Bloom syndrome protein interacts and cooperates with p53 in regulation of transcription and cell growth control	ONCOGENE			English	Article						Bloom syndrome; BLM protein; p53; interaction; two-hydrid system; transactivation	GENE; HELICASES; RADIATION	Bloom syndrome is an autosomal recessive disorder associated with mutations in BLM gene encoding protein that belongs to the family of DNA helicases. It is characterized by predisposition to cancer, immunodeficiency, high sensitivity to UV and genomic instability of somatic cells. Here we show physical and functional cooperation between BLM and p53 proteins. Ectopic expression of BLM causes anti-proliferative effect in p53 wild type, but not in p53-deficient cells; p53-mediated transactivation is attenuated in primary fibroblasts from Bloom syndrome patients. BLM and p53 proteins physically interact in the cells as demonstrated in yeast and mammalian two-hybrid systems; interaction sites are mapped to 237-272 aa residues of BML and 285-340 aa of P53. Ectopic expression of the fragment of wild type BML containing p53-interactive domain suppresses p53-mediated transcription and interferes with p53-mediated growth inhibition. These observations indicate that BLM might be an important component of p53 function and suggest that Bloom Syndrome phenotype may in part be the result of the deregulation of the p53 tumor suppressor pathway.	Cleveland Clin Fdn, Dept Mol Biol, Lerner Res Inst, Cleveland, OH 44195 USA; GPC Biotech Inc, Waltham, MA 02451 USA; Univ Illinois, Dept Pharmacokinet & Pharmacodynam, Chicago, IL 60607 USA	Cleveland Clinic Foundation; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Garkavtsev, IV (corresponding author), Cleveland Clin Fdn, Dept Mol Biol, Lerner Res Inst, Cleveland, OH 44195 USA.			Gudkov, Andrei/0000-0003-2548-0154	NCI NIH HHS [CA75179] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA075179] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akashi M, 1998, CLIN OBSTET GYNECOL, V41, P172, DOI 10.1097/00003081-199803000-00024; EL DW, 1993, CELL, V75, P817; ELLIS NA, 1994, AM J HUM GENET, V55, P453; ELLIS NA, 1995, CELL, V83, P655, DOI 10.1016/0092-8674(95)90105-1; Garkavtsev I, 1998, NATURE, V391, P295, DOI 10.1038/34675; GERMAN J, 1993, MEDICINE, V72, P393, DOI 10.1097/00005792-199311000-00003; Komarova EA, 1997, EMBO J, V16, P1391, DOI 10.1093/emboj/16.6.1391; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; Mohaghegh P, 2001, NUCLEIC ACIDS RES, V29, P2843, DOI 10.1093/nar/29.13.2843; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Morozov V, 1997, TRENDS BIOCHEM SCI, V22, P417, DOI 10.1016/S0968-0004(97)01128-6; Ossovskaya VS, 1996, P NATL ACAD SCI USA, V93, P10309, DOI 10.1073/pnas.93.19.10309; Prives C, 1999, J PATHOL, V187, P112; Spillare EA, 1999, GENE DEV, V13, P1355, DOI 10.1101/gad.13.11.1355; Wallace-Brodeur RR, 1999, CELL MOL LIFE SCI, V55, P64, DOI 10.1007/s000180050270; Wang XW, 2001, J BIOL CHEM, V276, P32948, DOI 10.1074/jbc.M103298200	16	31	32	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 13	2001	20	57					8276	8280		10.1038/sj.onc.1205120	http://dx.doi.org/10.1038/sj.onc.1205120			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	498KC	11781842				2022-12-17	WOS:000172507800011
J	Leonard, JR; D'Sa, C; Klocke, BJ; Roth, KA				Leonard, JR; D'Sa, C; Klocke, BJ; Roth, KA			Neural precursor cell apoptosis and glial tumorigenesis following transplacental ethyl-nitrosourea exposure	ONCOGENE			English	Article						p53; astrocytoma; Bcl-X-L; programmed cell death	CENTRAL-NERVOUS-SYSTEM; BCL-X; NEUROGENIC TUMORS; BRAIN-TUMORS; STEM-CELLS; DEATH; P53; NEURONS; MICE; BAX	Neural precursor cells (NPCs) populate the embryonic ventricular zone and persist in the subependymal zone of the adult brain. We hypothesized that hereditary and/or acquired mutations in apoptosis-associated genes, such as p53 and caspases, may protect NPCs from DNA damage-induced death and predispose them to subsequent neoplastic transformation. To test this hypothesis, we exposed NPCs from wild-type and targeted gene-disrupted mouse embryos (p53, caspase-9, caspase-3, and bax mutants) to ethyl-nitrosourea (ENU), a known DNA mutagen and neural carcinogen, and measured NPC viability. We found that ENU produced caspase-3 activation and apoptotic NPC death 6-24 h after administration both in vivo and in vitro. This effect was critically dependent on p53 and caspase-9 expression. The long-term effect of intrauterine ENU exposure was examined in control and p53-deficient mice. High grade glial tumors were found in 60% of p53(-/-) young adult mice exposed to ENU on gestational day 12.5 but not in p53(+/-) or P53(+/+) littermates or in untreated p53-deficient mice. All the tumors were located supratentorially and possessed strong immunoreactivity for glial fibrillary acidic protein and the anti-apoptotic molecule Bcl-X-L. These results suggest that intrauterine exposure of NPCs to certain DNA damaging agents may synergistically interact with specific genetic abnormalities (e.g. p53 deficiency) to produce glial neoplasms in the adult brain.	Washington Univ, Sch Med, Dept Pathol & Immunol, Div Neuropathol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Neurol Surg, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	Roth, KA (corresponding author), Washington Univ, Sch Med, Dept Pathol & Immunol, Div Neuropathol, 660 S Euclid Ave,Box 8118, St Louis, MO 63110 USA.	kroth@pathology.wustl.edu		Roth, Kevin/0000-0002-0643-995X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007296] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK07296] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aloyz RS, 1998, J CELL BIOL, V143, P1691, DOI 10.1083/jcb.143.6.1691; Armstrong RC, 1997, J NEUROSCI, V17, P553; BILZER T, 1989, NEUROTOXICOL TERATOL, V11, P551, DOI 10.1016/0892-0362(89)90036-6; Bruggers CS, 1999, J PEDIAT HEMATOL ONC, V21, P19, DOI 10.1097/00043426-199901000-00005; D'Sa-Eipper C, 2000, DEV NEUROSCI-BASEL, V22, P116, DOI 10.1159/000017433; D'Sa-Eipper C, 2001, DEVELOPMENT, V128, P137; DIWAN BA, 1974, CANCER RES, V34, P764; Doetsch F, 1999, CELL, V97, P703, DOI 10.1016/S0092-8674(00)80783-7; DOLE M, 1994, CANCER RES, V54, P3253; DOLE MG, 1995, CANCER RES, V55, P2576; DRUCKREY H, 1966, NATURE, V210, P1378, DOI 10.1038/2101378a0; Eves EM, 1996, J NEUROCHEM, V67, P1908; Frank KM, 1998, NATURE, V396, P173, DOI 10.1038/24172; Haydar TF, 2000, J NEUROSCI, V20, P5764, DOI 10.1523/JNEUROSCI.20-15-05764.2000; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Johansson CB, 1999, CELL, V96, P25, DOI 10.1016/S0092-8674(00)80956-3; Johnson MD, 1998, J NEUROSCI RES, V54, P721, DOI 10.1002/(SICI)1097-4547(19981215)54:6<721::AID-JNR1>3.0.CO;2-1; Johnson MD, 1999, J NEUROSCI, V19, P2996; Kleihues P., 2000, PATHOLOGY GENETICS T, P29; Klein MA, 2000, ONCOGENE, V19, P5329, DOI 10.1038/sj.onc.1203941; Krajewski S, 1997, AM J PATHOL, V150, P805; Liu R, 1999, AM J PATHOL, V155, P1861, DOI 10.1016/S0002-9440(10)65505-8; McKay R, 1997, SCIENCE, V276, P66, DOI 10.1126/science.276.5309.66; MOTOYAMA N, 1995, SCIENCE, V267, P1506, DOI 10.1126/science.7878471; Oda H, 1997, CANCER RES, V57, P646; Oppenheim RW, 2001, J NEUROSCI, V21, P4752, DOI 10.1523/JNEUROSCI.21-13-04752.2001; Rao MS, 1999, ANAT RECORD, V257, P137; Roth KA, 2000, P NATL ACAD SCI USA, V97, P466, DOI 10.1073/pnas.97.1.466; SCHLEGEL J, 1994, EXP TOXICOL PATHOL, V45, P455, DOI 10.1016/S0940-2993(11)80504-X; Shindler KS, 1997, J NEUROSCI, V17, P3112; Srinivasan A, 1998, CELL DEATH DIFFER, V5, P1004, DOI 10.1038/sj.cdd.4400449; Stiles CD, 1998, BBA-REV CANCER, V1377, pR1, DOI 10.1016/S0304-419X(97)00030-9; TIMME TL, 1994, BIOTECHNIQUES, V17, P460; Watanabe K, 1997, CLIN CANCER RES, V3, P523; Wechsler W, 1979, Natl Cancer Inst Monogr, P219; WECHSLER W, 1969, ANN NY ACAD SCI, V159, P360, DOI 10.1111/j.1749-6632.1969.tb48291.x; Zaidi AU, 2001, J NEUROSCI, V21, P169, DOI 10.1523/JNEUROSCI.21-01-00169.2001; Zheng TS, 1998, P NATL ACAD SCI USA, V95, P13618, DOI 10.1073/pnas.95.23.13618	38	31	32	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 13	2001	20	57					8281	8286		10.1038/sj.onc.1205024	http://dx.doi.org/10.1038/sj.onc.1205024			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	498KC	11781843				2022-12-17	WOS:000172507800012
J	Wang, TT; Fan, LQ; Watanabe, Y; McNeill, P; Fanger, GR; Persing, DH; Reed, SG				Wang, TT; Fan, LQ; Watanabe, Y; McNeill, P; Fanger, GR; Persing, DH; Reed, SG			L552S, an alternatively spliced isoform of XAGE-1, is over-expressed in lung adenocarcinoma	ONCOGENE			English	Article						tumor antigen; lung adenocarcinoma; lung squamous cell carcinoma (LSCC); XAGE-1; cancer testis antigen	CYTOLYTIC T-LYMPHOCYTES; CANCER/TESTIS ANTIGENS; INSITU HYBRIDIZATION; HUMAN-MELANOMA; GENES; IDENTIFICATION; SARCOMA; FAMILY; CANCER	Using a combination of cDNA subtraction and microarray analysis, we report here the identification and characterization of L552S, an over-expressed, alternatively spliced isoform of XAGE-1 in lung adenocarcinoma. Real-time RT-PCR analysis shows that L552S is expressed at levels greater than 10-fold in 12 of 25 lung adenocarcinoma tumors compared with the highest expression level found in all normal tissues tested. L552S is expressed in both early and late stages of lung adenocarcinoma, but it was not detected in large cell carcinoma, small cell carcinoma, or atypical lung neuroendocrine carcinoid. The full-length cDNA for L552S comprises 770 bp and encodes a polypeptide of 160 amino acids. C-terminal 94 amino acids of L552S are identical to a cancer testis antigen, XAGE-1, found in Ewing's sarcoma. Genomic sequence analysis has revealed that L552S and XAGE-1 are alternatively spliced isoforms, and expression of both L552S and XAGE-1 isoforms are present in lung adenocarcinoma. Immunohistochemistry analysis using affinity purified L552S polyclonal antibodies demonstrated specific nuclear staining in 10 of 12 lung adenocarcinoma samples. Furthermore, antibody responses to recombinant L552S protein were observed in seven of 17 lung pleural effusion fluids of lung cancer patients. These results strongly imply that L552S protein is immunogenic and suggest that it might have use as a vaccine target for lung cancer.	Corixa Corp, Dept Tumor Antigen Discovery, Seattle, WA 98104 USA; Univ Washington, Dept Pathobiol, Seattle, WA 98195 USA	Corixa; University of Washington; University of Washington Seattle	Wang, TT (corresponding author), Corixa Corp, Dept Tumor Antigen Discovery, 1124 Columbia St, Seattle, WA 98104 USA.							BOEL P, 1995, IMMUNITY, V2, P167, DOI 10.1016/S1074-7613(95)80053-0; Brinckerhoff LH, 2000, CURR OPIN ONCOL, V12, P163, DOI 10.1097/00001622-200003000-00012; Brinkmann U, 1999, CANCER RES, V59, P1445; Chen YT, 1999, CANCER J SCI AM, V5, P16; Chen YT, 1998, P NATL ACAD SCI USA, V95, P6919, DOI 10.1073/pnas.95.12.6919; HENG HHQ, 1993, CHROMOSOMA, V102, P325, DOI 10.1007/BF00661275; HENG HHQ, 1992, P NATL ACAD SCI USA, V89, P9509, DOI 10.1073/pnas.89.20.9509; Jungbluth AA, 2000, BRIT J CANCER, V83, P493, DOI 10.1054/bjoc.2000.1291; Liu XF, 2000, CANCER RES, V60, P4752; Martelange V, 2000, CANCER RES, V60, P3848; Robbins PF, 1996, CURR OPIN IMMUNOL, V8, P628, DOI 10.1016/S0952-7915(96)80078-1; Tureci O, 1996, CANCER RES, V56, P4766; Tureci O, 1998, P NATL ACAD SCI USA, V95, P5211, DOI 10.1073/pnas.95.9.5211; VANDENEYNDE B, 1995, J EXP MED, V182, P689, DOI 10.1084/jem.182.3.689; VANDERBRUGGEN P, 1991, SCIENCE, V254, P1643, DOI 10.1126/science.1840703; Wang T, 2000, ONCOGENE, V19, P1519, DOI 10.1038/sj.onc.1203457; Yoshimatsu T, 1998, J SURG ONCOL, V67, P126	17	31	37	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 22	2001	20	53					7699	7709		10.1038/sj.onc.1204939	http://dx.doi.org/10.1038/sj.onc.1204939			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	492HE	11753648				2022-12-17	WOS:000172161700001
J	Chen, WY; Palanisamy, N; Schmidt, H; Teruya-Feldstein, J; Jhanwar, SC; Zelenetz, AD; Houldsworth, J; Chaganti, RSK				Chen, WY; Palanisamy, N; Schmidt, H; Teruya-Feldstein, J; Jhanwar, SC; Zelenetz, AD; Houldsworth, J; Chaganti, RSK			Deregulation of FCGR2B expression by 1q21 rearrangements in follicular lymphomas	ONCOGENE			English	Article						FCGR2B; 1q21; follicular lymphoma; translocation	FC-GAMMA-RIIB; NON-HODGKINS-LYMPHOMA; B-CELLS; CHROMOSOMAL-ABNORMALITIES; CYTOGENETIC ANALYSIS; NEGATIVE REGULATION; MALIGNANT-LYMPHOMA; PROTEIN P62(DOK); RECEPTOR; TRANSLOCATIONS	We report here the molecular cloning and characterization of a t(1;14)(q21;q32) in a follicular lymphoma (FL) with an unusual BCL2 aberration. Fluorescence in situ hybridization (FISH) and Southern blot analysis of tumor cells identified the translocation breakpoint within the 5' switch region of IGHG (S gamma). We cloned the chimeric breakpoint region approximately 1.5 kbp downstream from the HindIII site of 5'S gamma2 on chromosome 14q32 and identified a 360-bp novel segment with homology to the CpG island clone 11h8. Two BAC clones containing this sequence were isolated and mapped to 1q21 by FISH. BAC 342/P13 contained sequences homologous to Fc gamma receptors 2A, 3A, 2B, 3B, and a heat shock protein gene HSP70B. The translocation brought the S gamma2 region of a productive IGH allele 20 similar to 30 kbp upstream of FCGR2B. As a result of the translocation, the b2 isoform of FCGR2B was overexpressed in the tumor. Screening of a panel of 76 B-cell lymphomas with 1q21-23 cytogenetic aberrations by Southern blot analysis using breakpoint probes identified an additional FL with a t(14;18)(q32;q21) and a breakpoint in the FCGR2B region. These results suggest that FCGR2B may be deregulated by 1q21 aberration in BCL2 rearranged FLs and possibly play a role in their progression.	Mem Sloan Kettering Canc Ctr, Cell Biol Program, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center	Chaganti, RSK (corresponding author), Mem Sloan Kettering Canc Ctr, Cell Biol Program, 1275 York Ave, New York, NY 10021 USA.		Palanisamy, Nallasivam/ABC-8844-2020	Palanisamy, Nallasivam/0000-0002-0633-9772	NCI NIH HHS [CA-80814, CA-66999, CA-34775] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA080814, R01CA066999, R01CA034775] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bergsagel PL, 1996, P NATL ACAD SCI USA, V93, P13931, DOI 10.1073/pnas.93.24.13931; Bolland S, 1998, IMMUNITY, V8, P509, DOI 10.1016/S1074-7613(00)80555-5; BROOKS DG, 1989, J EXP MED, V170, P1369, DOI 10.1084/jem.170.4.1369; BUDDE P, 1994, J BIOL CHEM, V269, P30636; Callanan MB, 2000, P NATL ACAD SCI USA, V97, P309, DOI 10.1073/pnas.97.1.309; Chaganti RSK, 2000, SEMIN HEMATOL, V37, P396; Chaganti SR, 1998, GENE CHROMOSOME CANC, V23, P328, DOI 10.1002/(SICI)1098-2264(199812)23:4<328::AID-GCC8>3.0.CO;2-M; Cigudosa JC, 1999, GENE CHROMOSOME CANC, V25, P123, DOI 10.1002/(SICI)1098-2264(199906)25:2<123::AID-GCC8>3.0.CO;2-4; Daeron M, 1997, ANNU REV IMMUNOL, V15, P203, DOI 10.1146/annurev.immunol.15.1.203; Dalla-Favera R, 1999, CURR TOP MICROBIOL, V246, P257; Dyomin VG, 2000, BLOOD, V95, P2666; Hatzivassiliou G, 2001, IMMUNITY, V14, P277, DOI 10.1016/S1074-7613(01)00109-1; Metes D, 1998, BLOOD, V91, P2369, DOI 10.1182/blood.V91.7.2369.2369_2369_2380; OFFIT K, 1991, BLOOD, V77, P1508; Ono M, 1996, NATURE, V383, P263, DOI 10.1038/383263a0; Pearse RN, 1999, IMMUNITY, V10, P753, DOI 10.1016/S1074-7613(00)80074-6; QIU WQ, 1990, SCIENCE, V248, P732, DOI 10.1126/science.2139735; RAO PH, 1993, GENOMICS, V16, P426, DOI 10.1006/geno.1993.1206; Ravetch JV, 2000, SCIENCE, V290, P84, DOI 10.1126/science.290.5489.84; SARMAY G, 1995, EUR J IMMUNOL, V25, P262, DOI 10.1002/eji.1830250143; Tamir I, 2000, IMMUNITY, V12, P347, DOI 10.1016/S1074-7613(00)80187-9; TILLY H, 1994, BLOOD, V84, P1043; TWEEDDALE ME, 1987, BLOOD, V69, P1307; Willis TG, 1998, BLOOD, V91, P1873, DOI 10.1182/blood.V91.6.1873.1873_1873_1881; Willis TG, 2000, BLOOD, V96, P808, DOI 10.1182/blood.V96.3.808.015k30_808_822; WITZ IP, 1992, IMMUNOL RES, V11, P283, DOI 10.1007/BF02919134; Yamanashi Y, 2000, GENE DEV, V14, P11; Zusman T, 1996, INT J CANCER, V68, P219, DOI 10.1002/(SICI)1097-0215(19961009)68:2<219::AID-IJC14>3.0.CO;2-5	28	31	31	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 15	2001	20	52					7686	7693		10.1038/sj.onc.1204989	http://dx.doi.org/10.1038/sj.onc.1204989			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	491TC	11753646				2022-12-17	WOS:000172124100011
J	Prathapam, T; Kuhne, C; Banks, L				Prathapam, T; Kuhne, C; Banks, L			The HPV-16 E7 oncoprotein binds Skip and suppresses its transcriptional activity	ONCOGENE			English	Article						human papillomavirus (HPV); oncoproteins; E7; Skip; SNW	HUMAN PAPILLOMAVIRUS TYPE-16; RETINOBLASTOMA GENE-PRODUCT; MUTATIONAL ANALYSIS; HUMAN KERATINOCYTES; PROTEIN; CELLS; IDENTIFICATION; IMMORTALIZATION; TRANSACTIVATION; ADENOVIRUS-E1A	E7 is the major transforming protein of human papillomavirus (HPV), which is implicated in the development of cervical cancer. The transforming activity of E7 has been attributed in part to its interaction with the retinoblastoma (Rb) tumour suppressor; however, the Rb interaction alone is not sufficient for transformation by E7. In a screen for cellular targets of HPV E7, we identified the Ski interacting protein, Skip, as a new interacting partner of E7. We show that HPV-16 E7 associates with Skip via sequences in its carboxy terminal region, and the evolutionarily conserved proline rich sequences (PRS) of the SNW domain of Skip. E7 functionally targets Skip in vivo and inhibits its transcriptional activation activity. Two transformation defective mutants of E7 were identified that failed both to bind Skip and to inhibit its transcriptional activity. These results suggest that inhibition of Skip function may contribute to cell transformation by HPV-16 E7.	Int Ctr Genet Engn & Biotechnol, I-34012 Trieste, Italy	International Center for Genetic Engineering & Biotechnology (ICGEB)	Banks, L (corresponding author), Int Ctr Genet Engn & Biotechnol, Padriciano 99, I-34012 Trieste, Italy.							ANDROPHY EJ, 1987, EMBO J, V6, P989, DOI 10.1002/j.1460-2075.1987.tb04849.x; BANKS L, 1990, ONCOGENE, V5, P1383; BANKS L, 1987, J GEN VIROL, V68, P1351, DOI 10.1099/0022-1317-68-5-1351; BARBOSA MS, 1990, EMBO J, V9, P153, DOI 10.1002/j.1460-2075.1990.tb08091.x; Baudino TA, 1998, J BIOL CHEM, V273, P16434, DOI 10.1074/jbc.273.26.16434; Caldeira S, 2000, ONCOGENE, V19, P821, DOI 10.1038/sj.onc.1203375; CHELLAPPAN S, 1992, P NATL ACAD SCI USA, V89, P4549, DOI 10.1073/pnas.89.10.4549; Dahl R, 1998, ONCOGENE, V16, P1579, DOI 10.1038/sj.onc.1201687; DURFEE T, 1993, GENE DEV, V7, P55; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; EDMONDS C, 1989, J VIROL, V63, P2650, DOI 10.1128/JVI.63.6.2650-2656.1989; HAWLEYNELSON P, 1989, EMBO J, V8, P3905, DOI 10.1002/j.1460-2075.1989.tb08570.x; JansenDurr P, 1996, TRENDS GENET, V12, P270, DOI 10.1016/0168-9525(96)81455-7; JEWERS RJ, 1992, J VIROL, V66, P1329, DOI 10.1128/JVI.66.3.1329-1335.1992; Kuhne C, 1998, J BIOL CHEM, V273, P34302, DOI 10.1074/jbc.273.51.34302; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MASSIMI P, 1997, J GEN VIROL, V78, P2601; MUNGER K, 1989, J VIROL, V63, P4417; MURTHY SCS, 1985, P NATL ACAD SCI USA, V82, P2230, DOI 10.1073/pnas.82.8.2230; PHELPS WC, 1988, CELL, V53, P539, DOI 10.1016/0092-8674(88)90570-3; PIM D, 1994, ONCOGENE, V9, P1869; Prathapam T, 2001, NUCLEIC ACIDS RES, V29, P3469, DOI 10.1093/nar/29.17.3469; QUIN XQ, 1992, GENE DEV, V6, P953; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SMOTKIN D, 1986, P NATL ACAD SCI USA, V83, P4680, DOI 10.1073/pnas.83.13.4680; STAVNEZER E, 1981, J VIROL, V39, P920, DOI 10.1128/JVI.39.3.920-934.1981; STOREY A, 1988, EMBO J, V7, P1815, DOI 10.1002/j.1460-2075.1988.tb03013.x; Tokitou F, 1999, J BIOL CHEM, V274, P4485, DOI 10.1074/jbc.274.8.4485; WATANABE S, 1990, J VIROL, V64, P207, DOI 10.1128/JVI.64.1.207-214.1990; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; Zhou SF, 2000, J VIROL, V74, P1939, DOI 10.1128/JVI.74.4.1939-1947.2000; ZURHAUSEN H, 1987, PAPOVAVIRIDAE PAPILL, P245	32	31	32	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 15	2001	20	52					7677	7685		10.1038/sj.onc.1204960	http://dx.doi.org/10.1038/sj.onc.1204960			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	491TC	11753645				2022-12-17	WOS:000172124100010
J	Kucharczak, J; Pannequin, J; Camby, I; Decaestecker, C; Kiss, R; Martinez, J				Kucharczak, J; Pannequin, J; Camby, I; Decaestecker, C; Kiss, R; Martinez, J			Gastrin induces over-expression of genes involved in human U373 glioblastoma cell migration	ONCOGENE			English	Article						glioblastoma; proliferation; migration; gastrin; gene overexpression	CALCIUM-BINDING PROTEINS; GLIOMA-CELLS; EXTRACELLULAR-MATRIX; ASTROCYTIC TUMORS; RHO; MODULATION; KINASE; FIBROBLASTS; INCREASES; INVASION	Astrocytic tumors are the most common and the most malignant primary tumors of the central nervous system. We had previously observed that gastrin could significantly modulate both cell proliferation and migration of astrocytoma cells. We have investigated in the present study which genes could be targeted by gastrin in tumor astrocyte migration. Using a subtractive hybridization PCR technique we have cloned genes differentially overexpressed in human astrocytoma U373 cells treated or not with gastrin. We found about 70 genes overexpressed by gastrin. Among the genes overexpressed by gastrin, we paid particular attention to tenascin-C, S100A6 and MLCK genes because their direct involvement in cell migration features. Their gastrin-induced overexpression was quantitatively determined by competitive RT-PCR technique. We also showed by means of a reporter gene system that S100A6 and tenascin-C respective promoters were upregulated after gastrin treatment. These data show that gastrin-mediated effects in glioblastoma cells occur through activation of a number of genes involved in cell migration and suggest that gastrin could be a target in new therapeutic strategies against malignant gliomas.	Univ Montpellier I, Fac Pharm, LAPP, CNRS,UMR 5810, F-34060 Montpellier, France; Univ Montpellier 2, Fac Pharm, LAPP, CNRS,UMR 5810, F-34060 Montpellier, France; Free Univ Brussels, Fac Med, Lab Histopathol, B-1050 Brussels, Belgium	Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; Universite Libre de Bruxelles; Vrije Universiteit Brussel	Martinez, J (corresponding author), Univ Montpellier I, Fac Pharm, LAPP, CNRS,UMR 5810, 15 Av C Flahault, F-34060 Montpellier, France.	martinez@colombes.pharma.univ-montpl.fr	Martinez, Jean/R-9421-2019	Martinez, Jean/0000-0002-9267-4621; Decaestecker, Christine/0000-0002-5495-1931; pannequin, julie/0000-0002-9956-373X; KUCHARCZAK, Jerome/0000-0001-7722-8490				Aspenstrom P, 1999, CURR OPIN CELL BIOL, V11, P95, DOI 10.1016/S0955-0674(99)80011-8; ASTRUC ME, 1995, ENDOCRINOLOGY, V136, P824, DOI 10.1210/en.136.3.824; Burg MA, 1997, EXP CELL RES, V235, P254, DOI 10.1006/excr.1997.3674; Camby I, 1996, J NATL CANCER I, V88, P594, DOI 10.1093/jnci/88.9.594; Camby I, 1999, BRAIN PATHOL, V9, P1; CAMBY I, 1994, J NEURO-ONCOL, V20, P67, DOI 10.1007/BF01057963; Camby I, 2001, BRAIN PATHOL, V11, P12; ChrzanowskaWodnicka M, 1996, J CELL BIOL, V133, P1403, DOI 10.1083/jcb.133.6.1403; De Hauwer C, 1998, J NEUROBIOL, V37, P373, DOI 10.1002/(SICI)1097-4695(19981115)37:3<373::AID-NEU3>3.0.CO;2-H; De la Fuente M, 1998, NEUROPEPTIDES, V32, P225, DOI 10.1016/S0143-4179(98)90041-5; Decaestecker C, 1998, BRAIN PATHOL, V8, P29; DelaFuente M, 1997, J ENDOCRINOL, V153, P475, DOI 10.1677/joe.0.1530475; Donato R, 1999, BBA-MOL CELL RES, V1450, P191, DOI 10.1016/S0167-4889(99)00058-0; Enam SA, 1998, NEUROSURGERY, V42, P599, DOI 10.1097/00006123-199803000-00030; GHERZI R, 1995, J BIOL CHEM, V270, P3429, DOI 10.1074/jbc.270.7.3429; Giese A, 1996, J CELL SCI, V109, P2161; Giese A, 1996, NEUROSURGERY, V38, P755, DOI 10.1227/00006123-199604000-00026; GIESE A, 1994, CANCER RES, V54, P3897; Gillespie GY, 1999, CANCER RES, V59, P2076; Gladson CL, 1999, J NEUROPATH EXP NEUR, V58, P1029, DOI 10.1097/00005072-199910000-00001; GOECKELER ZM, 1995, J CELL BIOL, V130, P613, DOI 10.1083/jcb.130.3.613; Golitsina NL, 1996, BIOCHEM BIOPH RES CO, V220, P360, DOI 10.1006/bbrc.1996.0410; Kleihues P, 2000, PATHOLOGY GENETICS T; Klemke RL, 1998, J CELL BIOL, V140, P961, DOI 10.1083/jcb.140.4.961; KRUCZYNSKI A, 1995, INT J ONCOL, V6, P473; LAMB NJC, 1988, J CELL BIOL, V106, P1955, DOI 10.1083/jcb.106.6.1955; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; Legler JM, 1999, JNCI-J NATL CANCER I, V91, P1382, DOI 10.1093/jnci/91.16.1382; Machesky LM, 1999, P NATL ACAD SCI USA, V96, P3739, DOI 10.1073/pnas.96.7.3739; Maekawa M, 1999, SCIENCE, V285, P895, DOI 10.1126/science.285.5429.895; Mettouchi A, 1997, MOL CELL BIOL, V17, P3202, DOI 10.1128/MCB.17.6.3202; REHFELD JF, 1994, ADV CANCER RES, V63, P295, DOI 10.1016/S0065-230X(08)60403-0; Sasaki H, 1998, CANCER, V82, P1921, DOI 10.1002/(SICI)1097-0142(19980515)82:10<1921::AID-CNCR16>3.0.CO;2-V; Schafer BW, 1996, TRENDS BIOCHEM SCI, V21, P134, DOI 10.1016/0968-0004(96)10020-7; SEUFFERLEIN T, 1995, CELL GROWTH DIFFER, V6, P383; Stepan VM, 1999, AM J PHYSIOL-GASTR L, V276, pG1363, DOI 10.1152/ajpgi.1999.276.6.G1363; TAKENAGA K, 1994, CELL STRUCT FUNCT, V19, P133, DOI 10.1247/csf.19.133; Taniguchi T, 1996, ONCOGENE, V12, P1357; Tapon N, 1997, CURR OPIN CELL BIOL, V9, P86, DOI 10.1016/S0955-0674(97)80156-1; Treasurywala S, 1998, GLIA, V24, P236, DOI 10.1002/(SICI)1098-1136(199810)24:2<236::AID-GLIA8>3.3.CO;2-1; VANDENHEUVEL JP, 1993, BIOTECHNIQUES, V14, P395; Waterman-Storer CM, 1999, CURR OPIN CELL BIOL, V11, P61, DOI 10.1016/S0955-0674(99)80008-8; Zhang H, 1998, J NEUROSCI, V18, P2370; [No title captured]	44	31	33	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 25	2001	20	48					7021	7028		10.1038/sj.onc.1204882	http://dx.doi.org/10.1038/sj.onc.1204882			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	485DY	11704826				2022-12-17	WOS:000171739300005
J	Skapek, SX; Lin, SCJ; Jablonski, MM; McKeller, RN; Tan, M; Hu, NP; Lee, EYHP				Skapek, SX; Lin, SCJ; Jablonski, MM; McKeller, RN; Tan, M; Hu, NP; Lee, EYHP			Persistent expression of cyclin D1 disrupts normal photoreceptor differentiation and retina development	ONCOGENE			English	Article						cyclin D1; retina; RB; photoreceptors; retinoblastoma	RETINOBLASTOMA PROTEIN; CELL-CYCLE; TARGETED DISRUPTION; ECTOPIC EXPRESSION; VERTEBRATE RETINA; MICE DEFICIENT; MOUSE RETINA; MUTANT MICE; GENE; PATHWAY	The differentiation of neuronal cells in the developing mammalian retina is closely coupled to cell cycle arrest and proceeds in a highly organized manner. Cyclin D1, which regulates cell proliferation in many cells, also drives the proliferation of photoreceptor progenitors. In the mouse retina, cyclin D1 protein normally decreases as photoreceptors mature. To study the importance of the down-regulation of cyclin D1 during photoreceptor development, we generated a transgenic mouse in which cyclin D1 was persistently expressed in developing photoreceptor cells. We observed numerous abnormalities in both photoreceptors and other nonphotoreceptor cells in the retina of these transgenic mice. In particular, we observed delayed opsin expression in developing photoreceptors and alterations in their number and morphology in the mature retina. These alterations were accompanied by disorganization of the inner nuclear and plexiform layers. The expression of cyclin D1 caused excess photoreceptor cell proliferation and apoptosis. Loss of the p53 tumor suppressor gene decreased cyclin D1-induced apoptosis and led to microscopic hyperplasia in the retina. These findings are distinct from other mouse models in which the retinoblastoma gene pathway is disrupted and suggest that the IRBP-cyclin D1 mouse model may recapitulate an early step in the development of retinoblastoma.	St Jude Childrens Res Hosp, Dept Hematol Oncol, Memphis, TN 38105 USA; Univ Texas, Hlth Sci Ctr, Dept Mol Med, San Antonio, TX 78245 USA; Univ Tennessee, Dept Ophthalmol, Memphis, TN 38163 USA; Univ Tennessee, Dept Anat & Neurobiol, Memphis, TN 38163 USA; St Jude Childrens Res Hosp, Dept Biostat, Memphis, TN 38105 USA	St Jude Children's Research Hospital; University of Texas System; University of Texas Health San Antonio; University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center; St Jude Children's Research Hospital	Skapek, SX (corresponding author), St Jude Childrens Res Hosp, Dept Hematol Oncol, 332 N Lauderdale St, Memphis, TN 38105 USA.	steve.skapek@stjude.org						Cepko CL, 1996, P NATL ACAD SCI USA, V93, P589, DOI 10.1073/pnas.93.2.589; CHANG GQ, 1993, NEURON, V11, P595, DOI 10.1016/0896-6273(93)90072-Y; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; DiCiommo D, 2000, SEMIN CANCER BIOL, V10, P255, DOI 10.1006/scbi.2000.0326; DIGGLE P, 1994, ANAL LONGITUNDINAL D, P63; DOBASHI Y, 1995, J BIOL CHEM, V270, P23031, DOI 10.1074/jbc.270.39.23031; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; Dyer MA, 2000, DEVELOPMENT, V127, P3593; Dynlacht BD, 1997, NATURE, V389, P149, DOI 10.1038/38225; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Harbour JW, 2000, GENE DEV, V14, P2393, DOI 10.1101/gad.813200; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HOWES KA, 1994, INVEST OPHTH VIS SCI, V35, P342; HOWES KA, 1994, GENE DEV, V8, P1300, DOI 10.1101/gad.8.11.1300; Humphries MM, 1997, NAT GENET, V15, P216, DOI 10.1038/ng0297-216; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; LEE EYHP, 1994, GENE DEV, V8, P2008, DOI 10.1101/gad.8.17.2008; Lee MH, 1996, GENE DEV, V10, P1621, DOI 10.1101/gad.10.13.1621; Levine EM, 2000, DEV BIOL, V219, P299, DOI 10.1006/dbio.2000.9622; Lin SCJ, 1996, SEMIN CANCER BIOL, V7, P279, DOI 10.1006/scbi.1996.0036; LIN SCJ, 2001, IN PRESS ONCOGENE; Ma CY, 1998, P NATL ACAD SCI USA, V95, P9938, DOI 10.1073/pnas.95.17.9938; Morrow EM, 1998, J NEUROSCI, V18, P3738; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; Ohnuma S, 1999, CELL, V99, P499, DOI 10.1016/S0092-8674(00)81538-X; Poluha W, 1996, MOL CELL BIOL, V16, P1335; RAO SS, 1994, MOL CELL BIOL, V14, P5259, DOI 10.1128/MCB.14.8.5259; Reh TA, 1998, J NEUROBIOL, V36, P206, DOI 10.1002/(SICI)1097-4695(199808)36:2<206::AID-NEU8>3.3.CO;2-4; RILEY DJ, 1994, ANNU REV CELL BIOL, V10, P1, DOI 10.1146/annurev.cb.10.110194.000245; Robanus-Maandag E, 1998, GENE DEV, V12, P1599, DOI 10.1101/gad.12.11.1599; Ross ME, 1996, TRENDS NEUROSCI, V19, P62, DOI 10.1016/0166-2236(96)89622-6; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; SICINSKI P, 1995, CELL, V82, P621, DOI 10.1016/0092-8674(95)90034-9; SKAPEK SX, 1995, SCIENCE, V267, P1022, DOI 10.1126/science.7863328; TURNER DL, 1990, NEURON, V4, P833, DOI 10.1016/0896-6273(90)90136-4; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; YOUNG RW, 1984, J COMP NEUROL, V229, P362, DOI 10.1002/cne.902290307; YOUNG RW, 1985, ANAT REC, V212, P199, DOI 10.1002/ar.1092120215	44	31	33	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 11	2001	20	46					6742	6751		10.1038/sj.onc.1204876	http://dx.doi.org/10.1038/sj.onc.1204876			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	482AA	11709709				2022-12-17	WOS:000171551600011
J	Jiang, M; Axe, T; Holgate, R; Rubbi, CP; Okorokov, AL; Mee, T; Milner, J				Jiang, M; Axe, T; Holgate, R; Rubbi, CP; Okorokov, AL; Mee, T; Milner, J			p53 binds the nuclear matrix in normal cells: binding involves the proline-rich domain of p53 and increases following genotoxic stress	ONCOGENE			English	Article						p53; nuclear matrix; proline-rich domain; DNA damage; SV40 large T	LARGE T-ANTIGEN; HYDROPHOBIC AMINO-ACIDS; A MOUSE CELLS; TERMINAL DOMAIN; DNA-BINDING; TRANSCRIPTIONAL COACTIVATOR; CELLULAR PROTEIN-P53; PROTEOLYTIC CLEAVAGE; FUNCTIONAL DOMAIN; GROWTH ARREST	The tumour suppressor p53 is a multifunctional protein important for the maintenance of genomic integrity. It is able to form molecular complexes with different DNA targets and also with cellular proteins involved in DNA transcription and DNA repair. In mammalian cells the biochemical processing of DNA occurs on a nuclear substructure termed the nuclear matrix. Previously Deppert and co-workers have identified p53 in association with the nuclear matrix in viral- and non-viral transformed cell lines. In the present study we demonstrate, for the first time, that p53 is bound to the nuclear matrix in primary cultures of normal mammalian cells and that this binding increases following DNA damage. Analysis of cell lines expressing structural mutants of p53 revealed that association with the nuclear matrix is independent of the tertiary and quaternary structure of p53. However, the proline-rich domain towards the N-terminus of p53 (residues 67 to 98) appeared important for binding to the nuclear matrix. This was demonstrated by TET-ON regulated expression of p53-derived constructs in p53(-/-) murine embryonic fibroblasts (MEF p53(-/-)). The proline-rich domain of p53 has potential for SH3 protein-protein interaction, and has a role in p53-mediated apoptosis and possibly base excision repair of DNA damage. We discuss our observations in relation to the ability of p53 to facilitate DNA repair and also review evidence indicating that matrix-bound p53 in SV40-transformed cells may facilitate the transforming potential of SV40 large T antigen.	Univ York, Dept Biol, YCR P53 Res Grp, York YO10 5DD, N Yorkshire, England	University of York - UK	Milner, J (corresponding author), Univ York, Dept Biol, YCR P53 Res Grp, York YO10 5DD, N Yorkshire, England.			Okorokov, Andrei/0000-0003-2477-3254; Jiang, Ming/0000-0003-3361-9881				Avantaggiati ML, 1996, EMBO J, V15, P2236, DOI 10.1002/j.1460-2075.1996.tb00577.x; BEREZNEY R, 1974, BIOCHEM BIOPH RES CO, V60, P1410, DOI 10.1016/0006-291X(74)90355-6; Berezney R, 1995, INT REV CYTOL, V162A, P1; Boulikas T, 1995, INT REV CYTOL, V162A, P279; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; Cook Peter R., 2001, EMBO Reports, V2, P14, DOI 10.1093/embo-reports/kve011; COOK PR, 1991, CELL, V66, P627, DOI 10.1016/0092-8674(91)90109-C; DEPPERT W, 1986, MOL CELL BIOL, V6, P2233, DOI 10.1128/MCB.6.6.2233; DEPPERT W, 1989, ONCOGENE, V4, P1103; Deppert W, 2000, CRIT REV EUKAR GENE, V10, P45; Deppert W, 1995, INT REV CYTOL, V162A, P485; DEPPERT W, 1990, ONCOGENE, V5, P1701; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DUTTA A, 1993, NATURE, V365, P79, DOI 10.1038/365079a0; Eckner R, 1996, MOL CELL BIOL, V16, P3454; Gorina S, 1996, SCIENCE, V274, P1001, DOI 10.1126/science.274.5289.1001; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Jackson DA, 1995, INT REV CYTOL, V162A, P125; Jimenez GS, 1999, ONCOGENE, V18, P7656, DOI 10.1038/sj.onc.1203013; Kennedy BK, 2000, GENE DEV, V14, P2855, DOI 10.1101/gad.842600; Klotzsche O, 1998, ONCOGENE, V16, P3423, DOI 10.1038/sj.onc.1202155; Leveillard T, 1996, EMBO J, V15, P1615, DOI 10.1002/j.1460-2075.1996.tb00506.x; Lill NL, 1997, NATURE, V387, P823, DOI 10.1038/42981; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; LIN JY, 1995, ONCOGENE, V10, P2387; Ljungman M, 2000, NEOPLASIA, V2, P208, DOI 10.1038/sj.neo.7900073; LU H, 1995, P NATL ACAD SCI USA, V92, P5154, DOI 10.1073/pnas.92.11.5154; MANCINI MA, 1994, P NATL ACAD SCI USA, V91, P418, DOI 10.1073/pnas.91.1.418; May P, 1999, ONCOGENE, V18, P7621, DOI 10.1038/sj.onc.1203285; Mee T, 1999, BRIT J CANCER, V81, P212, DOI 10.1038/sj.bjc.6690679; MILNER J, 1991, MOL CELL BIOL, V11, P12, DOI 10.1128/MCB.11.1.12; MILNER J, 1993, ONCOGENE, V8, P2001; MITTNACHT S, 1991, CELL, V65, P381, DOI 10.1016/0092-8674(91)90456-9; Molinari M, 1996, ONCOGENE, V13, P2077; Nickerson JA, 1997, P NATL ACAD SCI USA, V94, P4446, DOI 10.1073/pnas.94.9.4446; Offer H, 2001, CANCER RES, V61, P88; Offer H, 1999, FEBS LETT, V450, P197, DOI 10.1016/S0014-5793(99)00505-0; Okorokov AL, 1997, EMBO J, V16, P6008, DOI 10.1093/emboj/16.19.6008; PARDOLL DM, 1980, EXP CELL RES, V128, P466, DOI 10.1016/0014-4827(80)90083-X; Peden KWC, 1998, VIRUS GENES, V16, P153, DOI 10.1023/A:1007941622680; PEDEN KWC, 1989, VIROLOGY, V168, P13, DOI 10.1016/0042-6822(89)90398-X; PENMAN S, 1995, P NATL ACAD SCI USA, V92, P5251, DOI 10.1073/pnas.92.12.5251; Ruaro EM, 1997, P NATL ACAD SCI USA, V94, P4675, DOI 10.1073/pnas.94.9.4675; Rubbi CP, 2000, ONCOGENE, V19, P85, DOI 10.1038/sj.onc.1203378; Sakamuro D, 1997, ONCOGENE, V15, P887, DOI 10.1038/sj.onc.1201263; Spector D. L., 1998, CELLS LAB MANUAL; SPECTOR DL, 1993, ANNU REV CELL BIOL, V9, P265, DOI 10.1146/annurev.cb.09.110193.001405; STAUFENBIEL M, 1983, CELL, V33, P173, DOI 10.1016/0092-8674(83)90346-X; STEINMEYER K, 1990, ONCOGENE, V5, P1691; Stenoien D, 1998, J CELL BIOCHEM, V70, P213, DOI 10.1002/(SICI)1097-4644(19980801)70:2<213::AID-JCB7>3.0.CO;2-R; Stratling WH, 1999, CRIT REV EUKAR GENE, V9, P311, DOI 10.1615/CritRevEukarGeneExpr.v9.i3-4.150; Venot C, 1998, EMBO J, V17, P4668, DOI 10.1093/emboj/17.16.4668; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Walker KK, 1996, P NATL ACAD SCI USA, V93, P15335, DOI 10.1073/pnas.93.26.15335; WANG XW, 1995, NAT GENET, V10, P188, DOI 10.1038/ng0695-188; Will K, 1998, J CELL BIOCHEM, V69, P260, DOI 10.1002/(SICI)1097-4644(19980601)69:3<260::AID-JCB4>3.0.CO;2-P; ZERRAHN J, 1992, ONCOGENE, V7, P1371; Zhou JM, 2001, EMBO J, V20, P914, DOI 10.1093/emboj/20.4.914	58	31	32	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 6	2001	20	39					5449	5458		10.1038/sj.onc.1204705	http://dx.doi.org/10.1038/sj.onc.1204705			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	468WL	11571642				2022-12-17	WOS:000170781100005
J	Benaud, CM; Dickson, RB				Benaud, CM; Dickson, RB			Adhesion-regulated G1 cell cycle arrest in epithelial cells requires the downregulation of c-Myc	ONCOGENE			English	Article						adhesion; c-Myc; cell cycle; p27	GROWTH-FACTOR-BETA; RETINOBLASTOMA PROTEIN; KINASE-ACTIVITY; FUNCTIONAL INACTIVATION; DEPENDENT EXPRESSION; NEGATIVE REGULATORS; SIGNAL-TRANSDUCTION; GENE-EXPRESSION; CDK COMPLEXES; MESSENGER-RNA	Adhesion to the extracellular matrix is required for the expression and activation of the cyclin-cyclin-dependent kinase (CDK) complexes, and for G1 phase progression of non-transformed cells. However, in non-adherent cells no molecular mechanism has yet been proposed for the cell adhesion-dependent up-regulation of the p27 cyclin-dependent kinase inhibitor (CKI), and the associated inhibition of cyclin E-CDK2. We now show that in epithelial cells the expression of c-Myc is tightly regulated by cell-substrate adhesion. When deprived of adhesion, two independently derived mammary epithelial cell lines, 184AlN4 and MCF-10A, rapidly decrease their level of c-Myc mRNA and protein. This decrease in levels of c-Myc correlates with G1 phase arrest, as indicated by hypophosphorylation of pRb and inhibition of the activity of the cyclin E-CDK2 complex. In 184AlN4 cells, cell-substrate adhesion is required for the suppression of p27, and induction of cyclin E, E2F-1, but not cyclins D1 and D3. Enforced expression of c-Myc in non-adherent 184AIN4 and MCF-10A cells reverses the adhesion-dependent inhibition of cell cycle progression. Restoration of c-Myc in non-adherent cells induces the expression of E2F-1, and hyperphosphorylation of pRb in response to EGF treatment. In addition, expression of c-Myc results in the anchorage-independent activation of the CDK2 complex, the associated upregulation of cyclin E, and the destabilization and degradation of p27 by the ubiquitin-proteasome pathway. Our study thus suggests that c-Myc is the link between cell adhesion and the regulation of p27 and cyclin ECDK2. Furthermore, we describe a role for c-Myc in adhesion-mediated regulation of E2F-1.	Georgetown Univ, Med Ctr, Dept Cell Biol, Vincent T Lombardi Canc Ctr, Washington, DC 20007 USA; Georgetown Univ, Med Ctr, Dept Oncol, Vincent T Lombardi Canc Ctr, Washington, DC 20007 USA	Georgetown University; Georgetown University	Dickson, RB (corresponding author), Georgetown Univ, Med Ctr, Dept Cell Biol, Vincent T Lombardi Canc Ctr, 3970 Reservoir Rd NW, Washington, DC 20007 USA.	dicksonr@gunet.georgetown.edu	Benaud, Christelle/M-1178-2018		NIA NIH HHS [R01 AG1496] Funding Source: Medline	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ALEXANDROW MG, 1995, CANCER RES, V55, P1452; BARRETT JF, 1995, J BIOL CHEM, V270, P15923, DOI 10.1074/jbc.270.27.15923; Black AR, 1999, GENE, V237, P281, DOI 10.1016/S0378-1119(99)00305-4; Bohmer RM, 1996, MOL BIOL CELL, V7, P101; Bouchard C, 1999, EMBO J, V18, P5321, DOI 10.1093/emboj/18.19.5321; Brown JR, 1998, MOL CELL BIOL, V18, P5609, DOI 10.1128/MCB.18.9.5609; Carstens CP, 1996, EXP CELL RES, V229, P86, DOI 10.1006/excr.1996.0346; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; Dike LE, 1996, J CELL SCI, V109, P2855; DIKE LE, 1988, P NATL ACAD SCI USA, V85, P6792, DOI 10.1073/pnas.85.18.6792; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Fang F, 1996, SCIENCE, V271, P499, DOI 10.1126/science.271.5248.499; Flinn EM, 1998, MOL CELL BIOL, V18, P5961, DOI 10.1128/MCB.18.10.5961; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; GUADAGNO TM, 1993, SCIENCE, V262, P1572, DOI 10.1126/science.8248807; GUADAGNO TM, 1991, J CELL BIOL, V115, P1419, DOI 10.1083/jcb.115.5.1419; Guo QB, 1998, P NATL ACAD SCI USA, V95, P9172, DOI 10.1073/pnas.95.16.9172; HANSON KD, 1994, MOL CELL BIOL, V14, P5748, DOI 10.1128/MCB.14.9.5748; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; HATAKEYAMA M, 1994, GENE DEV, V8, P1759, DOI 10.1101/gad.8.15.1759; HEIKKILA R, 1987, NATURE, V328, P445, DOI 10.1038/328445a0; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; Howe AK, 1998, J BIOL CHEM, V273, P27268, DOI 10.1074/jbc.273.42.27268; JANSENDURR P, 1993, P NATL ACAD SCI USA, V90, P3685, DOI 10.1073/pnas.90.8.3685; JOHNSON DG, 1994, GENE DEV, V8, P1514, DOI 10.1101/gad.8.13.1514; KUMATORI A, 1991, BIOCHEM BIOPH RES CO, V178, P480, DOI 10.1016/0006-291X(91)90132-Q; Leone G, 1999, P NATL ACAD SCI USA, V96, P6626, DOI 10.1073/pnas.96.12.6626; Liao DJ, 2000, ONCOGENE, V19, P1307, DOI 10.1038/sj.onc.1203430; Lin TH, 1997, J BIOL CHEM, V272, P8849; Lundberg AS, 1998, MOL CELL BIOL, V18, P753, DOI 10.1128/MCB.18.2.753; MATSUHISA T, 1981, EXP CELL RES, V135, P393, DOI 10.1016/0014-4827(81)90176-2; Muller D, 1997, ONCOGENE, V15, P2561, DOI 10.1038/sj.onc.1201440; Nass SJ, 1998, CLIN CANCER RES, V4, P1813; Nijjar T, 1999, CANCER RES, V59, P5112; Novak A, 1998, P NATL ACAD SCI USA, V95, P4374, DOI 10.1073/pnas.95.8.4374; Ohtani K, 1995, P NATL ACAD SCI USA, V92, P12146, DOI 10.1073/pnas.92.26.12146; OTSUKA H, 1976, J CELL PHYSIOL, V87, P213, DOI 10.1002/jcp.1040870209; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; Perez-Roger I, 1999, EMBO J, V18, P5310, DOI 10.1093/emboj/18.19.5310; PerezRoger I, 1997, ONCOGENE, V14, P2373, DOI 10.1038/sj.onc.1201197; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; Roovers K, 1999, MOL BIOL CELL, V10, P3197, DOI 10.1091/mbc.10.10.3197; Rudolph B, 1996, EMBO J, V15, P3065, DOI 10.1002/j.1460-2075.1996.tb00669.x; Salghetti SE, 1999, EMBO J, V18, P717, DOI 10.1093/emboj/18.3.717; Schulze A, 1996, MOL CELL BIOL, V16, P4632; Sears R, 1997, MOL CELL BIOL, V17, P5227, DOI 10.1128/MCB.17.9.5227; Sears R, 1999, MOL CELL, V3, P169, DOI 10.1016/S1097-2765(00)80308-1; SEJERSEN T, 1985, J CELL PHYSIOL, V125, P465, DOI 10.1002/jcp.1041250315; SHERR CJ, 1995, P ASSOC AM PHYSICIAN, V107, P181; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; SOULE HD, 1990, CANCER RES, V50, P6075; SPENCER CA, 1991, ADV CANCER RES, V56, P1; STAMPFER MR, 1993, EXP CELL RES, V208, P175, DOI 10.1006/excr.1993.1236; STAMPFER MR, 1985, P NATL ACAD SCI USA, V82, P2394, DOI 10.1073/pnas.82.8.2394; STEINER P, 1995, EMBO J, V14, P4814, DOI 10.1002/j.1460-2075.1995.tb00163.x; THOMPSON CB, 1985, NATURE, V314, P363, DOI 10.1038/314363a0; VALVERIUS EM, 1990, J CELL PHYSIOL, V145, P207, DOI 10.1002/jcp.1041450204; VINDELOV LL, 1983, CYTOMETRY, V3, P323, DOI 10.1002/cyto.990030503; Vlach J, 1996, EMBO J, V15, P6595, DOI 10.1002/j.1460-2075.1996.tb01050.x; ZerfassThome K, 1997, MOL CELL BIOL, V17, P407, DOI 10.1128/MCB.17.1.407; Zhu XY, 1996, J CELL BIOL, V133, P391, DOI 10.1083/jcb.133.2.391	64	31	32	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 27	2001	20	33					4554	4567		10.1038/sj.onc.1204609	http://dx.doi.org/10.1038/sj.onc.1204609			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	456GN	11494151				2022-12-17	WOS:000170074900013
J	Kim, MY; Park, E; Park, JH; Park, DH; Moon, WS; Cho, BH; Shin, HS; Kim, DG				Kim, MY; Park, E; Park, JH; Park, DH; Moon, WS; Cho, BH; Shin, HS; Kim, DG			Expression profile of nine novel genes differentially expressed in hepatitis B virus-associated hepatocellular carcinomas	ONCOGENE			English	Article						HCC; HBV; genes; DD-PCR; hepatocarcinogenesis	SECRETORY-TRYPSIN-INHIBITOR; SERUM ALPHA-FETOPROTEIN; MESSENGER-RNA; FACTOR-II; TUMOR-MARKER; LIVER; H19; PROTEINS; CLONING; DNA	Chronic hepatitis B virus (HBV) infection is known to be one of the major causes in the development of hepatocellular carcinoma (HCC), although the biomolecular mechanism(s) involved remain unclear. To identify the cellular gene(s) involved in HBV-associated hepatocarcinogenesis, we used the mRNA differential display method and examined three paired tumor and nontumor tissues, all of which had chromosomally integrated HBV-DNA through chronic infection. Using 240 different combinations of three one-base anchored oligo-dT primers and 80 arbitrary 13-mers, genes decreased or increased in expression more than twofold between each tumor tissue and its paired nontumor tissue were identified. Twenty-nine known genes and four novel genes were differentially over-expressed in the HCC tumor tissues. In contrast, 27 known genes and five novel genes were under-expressed in those tumor tissues. The nucleotide sequences of the nine novel gene fragments were determined and their expression patterns were examined in 40 HCC samples. HA61T2, PT18, HG63T1, and HG57T1 were preferentially over-expressed in 32 cases (80%, P<0.001), 24 cases (60%), 23 cases (57.5%) and 22 cases (55%) of the 40 tumor tissues, respectively. There was an increased frequency of HG57T1 over-expression in HCC patients with HBV-positive serology and low serum alpha-feto protein (AFP) levels (P<0.05). DNT10, PTB, PT19, ENT25 and HA6T4 were under-expressed in 26 cases (65%), 23 cases (57.5%), 21 cases (53%), 20 cases (50%) and 18 cases (45%) of the 40 tumor samples, respectively. There was a strong correlation of DNT10 under-expression with high serum AFP level in HCC patients, irrespective of HBV serology (P<0.01). HA6T4 was preferentially under-expressed in HCC tumors in patients with HBV-positive serology and high serum AFP levels (P<0.05). Thus, the functional analyses of the known and novel genes identified in this study should prove valuable to further understand the mechanism(s) of hepatocarcinogenesis.	Chonbuk Natl Univ, Med Sch & Hosp, Res Inst Clin Med, Div GI & Hepatol,Dept Internal Med, Chonju 561712, Chonbuk, South Korea; Chonbuk Natl Univ, Med Sch & Hosp, Dept Anat Pathol, Chonju 561712, Chonbuk, South Korea; Chonbuk Natl Univ, Med Sch & Hosp, Dept Gen Surg, Chonju 561712, Chonbuk, South Korea; Pohang Univ Sci & Technol, Dept Life Sci, Pohang 790784, Kyungpuk, South Korea	Jeonbuk National University; Jeonbuk National University; Jeonbuk National University; Pohang University of Science & Technology (POSTECH)	Kim, DG (corresponding author), Chonbuk Natl Univ, Med Sch & Hosp, Res Inst Clin Med, Div GI & Hepatol,Dept Internal Med, Chonju 561712, Chonbuk, South Korea.							ADAMS MD, 1993, NAT GENET, V4, P373, DOI 10.1038/ng0893-373; AKSOY S, 1994, J BIOL CHEM, V269, P14835; Ariel I, 1998, J CLIN PATHOL-MOL PA, V51, P21, DOI 10.1136/mp.51.1.21; BARNARD GF, 1992, CANCER RES, V52, P3067; BARNARD GF, 1993, CANCER RES, V53, P4048; Bayati N, 1998, AM J GASTROENTEROL, V93, P2452, DOI 10.1111/j.1572-0241.1998.00703.x; Buendia M A, 1992, Semin Cancer Biol, V3, P309; CAIRO G, 1993, EXP CELL RES, V206, P255, DOI 10.1006/excr.1993.1145; CARIANI E, 1988, CANCER RES, V48, P6844; CASELMANN WH, 1990, P NATL ACAD SCI USA, V87, P2970, DOI 10.1073/pnas.87.8.2970; CHEN DS, 1979, CANCER-AM CANCER SOC, V44, P984, DOI 10.1002/1097-0142(197909)44:3<984::AID-CNCR2820440328>3.0.CO;2-6; CHEN PJ, 1989, GASTROENTEROLOGY, V96, P527, DOI 10.1016/0016-5085(89)91581-3; DeRisi J, 1996, NAT GENET, V14, P457; HSIA CC, 1994, J MED VIROL, V44, P67, DOI 10.1002/jmv.1890440113; Hu RH, 1999, J FORMOS MED ASSOC, V98, P85; HUANG LR, 1995, CANCER RES, V55, P4717; KEKULE AS, 1990, NATURE, V343, P457, DOI 10.1038/343457a0; Kim DG, 1999, HEPATOLOGY, V29, P1091, DOI 10.1002/hep.510290414; Kim KS, 1997, CANCER LETT, V119, P143, DOI 10.1016/S0304-3835(97)00264-4; KOSHY R, 1981, J GEN VIROL, V57, P95, DOI 10.1099/0022-1317-57-1-95; LASSERRE C, 1992, CANCER RES, V52, P5089; LAURENCE C, 1994, GASTROENTEROLOGY, V106, P1312; LAWSON D, 1975, CANCER RES, V35, P156; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; LIANG P, 1994, NUCLEIC ACIDS RES, V22, P5763, DOI 10.1093/nar/22.25.5763; LUGASSY C, 1987, J INFECT DIS, V155, P64, DOI 10.1093/infdis/155.1.64; MATSUNO T, 1992, CANCER RES, V52, P1192; Montalto G, 1998, ONCOLOGY-BASEL, V55, P421, DOI 10.1159/000011889; MURATA A, 1988, LIFE SCI, V43, P1233, DOI 10.1016/0024-3205(88)90213-5; NISHIYAMA M, 1992, BIOCHEM BIOPH RES CO, V183, P280, DOI 10.1016/0006-291X(92)91640-C; OHMACHI Y, 1993, INT J CANCER, V55, P728, DOI 10.1002/ijc.2910550505; Okamura A, 1998, JPN J CANCER RES, V89, P649, DOI 10.1111/j.1349-7006.1998.tb03267.x; PENG SY, 1993, HEPATOLOGY, V17, P35, DOI 10.1016/0270-9139(93)90188-S; RAINIER S, 1995, CANCER RES, V55, P1836; Ross JA, 1999, CANCER, V85, P1389, DOI 10.1002/(SICI)1097-0142(19990315)85:6<1389::AID-CNCR24>3.3.CO;2-M; ROTHSTEIN JL, 1993, METHOD ENZYMOL, V225, P587; SCHEUER PJ, 1991, J HEPATOL, V13, P372, DOI 10.1016/0168-8278(91)90084-O; Scuric Z, 1998, HEPATOLOGY, V27, P943, DOI 10.1002/hep.510270408; Sohda T, 1998, J HUM GENET, V43, P49, DOI 10.1007/s100380050036; SPANDAU DF, 1988, J VIROL, V62, P427, DOI 10.1128/JVI.62.2.427-434.1988; SU TS, 1989, CANCER RES, V49, P1773; TIMBLIN C, 1990, NUCLEIC ACIDS RES, V18, P1587, DOI 10.1093/nar/18.6.1587; Trautwein C, 1996, GASTROENTEROLOGY, V110, P1854, DOI 10.1053/gast.1996.v110.pm8964411; TWU JS, 1987, J VIROL, V61, P3448, DOI 10.1128/JVI.61.11.3448-3453.1987; Wake N, 1998, INT J GYNECOL OBSTET, V60, pS1, DOI 10.1016/S0020-7292(96)02403-4; WENGER RH, 1995, J BIOL CHEM, V270, P27865, DOI 10.1074/jbc.270.46.27865; ZEMEL S, 1992, NAT GENET, V2, P61, DOI 10.1038/ng0992-61; ZHANG X, 1994, CANCER RES, V54, P4177	48	31	31	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 27	2001	20	33					4568	4575		10.1038/sj.onc.1204626	http://dx.doi.org/10.1038/sj.onc.1204626			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	456GN	11494152				2022-12-17	WOS:000170074900014
J	Giorgetti-Peraldi, S; Murdaca, J; Mas, JC; Van Obberghen, E				Giorgetti-Peraldi, S; Murdaca, J; Mas, JC; Van Obberghen, E			The adapter protein, Grb10, is a positive regulator of vascular endothelial growth factor signaling	ONCOGENE			English	Article						Grb10; VEGF receptor; KDR; angiogenesis	INSULIN-RECEPTOR SUBSTRATE-1; TYROSINE KINASE; FLK-1/KDR ACTIVATION; PLECKSTRIN HOMOLOGY; BINDING-PROTEIN; NITRIC-OXIDE; SH2 DOMAINS; I RECEPTOR; ANGIOGENESIS; CELLS	Vascular endothelial growth factor (VEGF) is an important regulator of vasculogenesis and angiogenesis. Activation of VEGF receptors leads to the recruitment of SH2 containing proteins which link the receptors to the activation of signaling pathways. Here we report that Grb10, an adapter protein of which the biological role remains unknown, is tyrosine phosphorylated in response to VEGF in endothelial cells (HUVEC) and in 293 cells expressing the VEGF receptor KDR, An intact SH2 domain is required for Grb10 tyrosine phosphorylation in response to VEGF, and this phosphorylation is mediated in part through the activation of Src, In HUVEC, VEGF increases Grb10 mRNA level. Expression of Grb10 in HUVEC or in KDR expressing 293 cells results in an increase in the amount and in the tyrosine phosphorylation of KDR, In 293 cells, this is correlated with the activation of signaling molecules, such as MAP kinase, By expressing mutants of Grb10, we found that the positive action of Grb10 is independent of its SH2 domain. Moreover, these Grb10 effects on KDR seem to be specific since Grb10 has no effect on the insulin receptor, and Grb2, another adapter protein, does not mimic the effect of Grb10 on KDR, In conclusion, we propose that VEGF up-regulates Grb10 level, which in turn increases KDR molecules, suggesting that Grb10 could be involved in a positive feedback loop in VEGF signaling.	Fac Med Nice, IFR 50, INSERM, U145, F-06107 Nice 2, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur	Giorgetti-Peraldi, S (corresponding author), Fac Med Nice, IFR 50, INSERM, U145, Ave Valombrose, F-06107 Nice 2, France.			Giorgetti-Peraldi, Sophie/0000-0002-2751-2618				Abedi H, 1997, J BIOL CHEM, V272, P15442, DOI 10.1074/jbc.272.24.15442; Bai RY, 1998, ONCOGENE, V17, P941, DOI 10.1038/sj.onc.1202024; BARBIERI B, 1981, P SOC EXP BIOL MED, V168, P204; Carmeliet P, 2000, NAT MED, V6, P389, DOI 10.1038/74651; Dong LQ, 1997, J BIOL CHEM, V272, P29104, DOI 10.1074/jbc.272.46.29104; DOUGHERVERMAZEN M, 1994, BIOCHEM BIOPH RES CO, V205, P728, DOI 10.1006/bbrc.1994.2726; Eliceiri BP, 1999, MOL CELL, V4, P915, DOI 10.1016/S1097-2765(00)80221-X; Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; Frantz JD, 1997, J BIOL CHEM, V272, P2659, DOI 10.1074/jbc.272.5.2659; Gerber HP, 1998, J BIOL CHEM, V273, P30336, DOI 10.1074/jbc.273.46.30336; GUSTAFSON TA, 1995, MOL CELL BIOL, V15, P2500; He H, 1999, J BIOL CHEM, V274, P25130, DOI 10.1074/jbc.274.35.25130; He WM, 1998, J BIOL CHEM, V273, P6860, DOI 10.1074/jbc.273.12.6860; Hiratsuka S, 1998, P NATL ACAD SCI USA, V95, P9349, DOI 10.1073/pnas.95.16.9349; Langlais P, 2000, ONCOGENE, V19, P2895, DOI 10.1038/sj.onc.1203616; Morrione A, 1997, J BIOL CHEM, V272, P26382, DOI 10.1074/jbc.272.42.26382; Morrione A, 1999, J BIOL CHEM, V274, P24094, DOI 10.1074/jbc.274.34.24094; Moutoussamy S, 1998, J BIOL CHEM, V273, P15906, DOI 10.1074/jbc.273.26.15906; Nantel A, 1998, J BIOL CHEM, V273, P10475, DOI 10.1074/jbc.273.17.10475; Neufeld G, 1999, FASEB J, V13, P9, DOI 10.1096/fasebj.13.1.9; OOI J, 1995, ONCOGENE, V10, P1621; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; Shen BQ, 1999, J BIOL CHEM, V274, P33057, DOI 10.1074/jbc.274.46.33057; Stein E, 1996, J BIOL CHEM, V271, P23588, DOI 10.1074/jbc.271.38.23588; Takahashi T, 1999, ONCOGENE, V18, P2221, DOI 10.1038/sj.onc.1202527; TARTAREDECKERT S, 1995, J BIOL CHEM, V270, P23456, DOI 10.1074/jbc.270.40.23456; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; Wang J, 1999, MOL CELL BIOL, V19, P6217; Wu LW, 2000, J BIOL CHEM, V275, P5096, DOI 10.1074/jbc.275.7.5096	31	31	33	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 5	2001	20	30					3959	3968		10.1038/sj.onc.1204520	http://dx.doi.org/10.1038/sj.onc.1204520			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	449JM	11494124				2022-12-17	WOS:000169681500004
J	Grange, T; Cappabianca, L; Flavin, M; Sassi, H; Thomassin, H				Grange, T; Cappabianca, L; Flavin, M; Sassi, H; Thomassin, H			In vivo analysis of the model tyrosine aminotransferase gene reveals multiple sequential steps in glucocorticoid receptor action	ONCOGENE			English	Review						chromatin; DNA methylation; transcription; liver nuclear receptor	TRANSCRIPTION FACTORS; DNA DEMETHYLATION; RESPONSE ELEMENT; GLYCOSYLASE ACTIVITY; CHROMATIN STRUCTURE; DEPENDENT ENHANCER; STEROID-RECEPTORS; HORMONE-RECEPTOR; NUCLEAR FACTOR; MMTV PROMOTER	We are studying the mechanisms of transcriptional activation by nuclear receptors and we focus our studies on the glucocorticoid regulation of the model tyrosine aminotransferase gene. Rather than using in vitro biochemical approaches, we determine the actual events occurring in the cells, Our experimental approaches include genomic footprinting, chromatin immunoprecipitation, in situ hybridization and transgenic mice. Our results show that the glucocorticoid receptor uses a dynamic multistep mechanism to recruit successively accessory DNA binding proteins that assist in the activation process. Chromatin is first remodelled, DNA is then demethylated, and the synthesis of an accessory factor is induced, Efficient transcription induction is finally achieved upon the formation of a 'stable' multiprotein complex interacting with the regulatory element. We discuss: the relative contribution of histone acetyltransferases and ATP-dependent remodelling machines to the chromatin remodelling event; the nature of the remodelled state; the contribution of regulated DNA demethylation to gene memory during development; the mechanisms of regulated DNA demethylation; the dynamics of protein recruitment at regulatory elements; tbe control of the frequency of transcription pulses and the control levels of the cell-type specificity of the glucocorticoid response.	Univ Paris 06, CNRS, Inst Jacques Monod, F-75251 Paris 05, France; Univ Paris 07, CNRS, Inst Jacques Monod, F-75251 Paris 05, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite	Grange, T (corresponding author), Univ Paris 06, CNRS, Inst Jacques Monod, Tour 43,2 Pl Jussieu, F-75251 Paris 05, France.			Grange, Thierry/0000-0001-8700-3092; cappabianca, lucia/0000-0002-9112-1750; THOMASSIN, Helene/0000-0003-4613-5587				ADLER AJ, 1992, P NATL ACAD SCI USA, V89, P11660, DOI 10.1073/pnas.89.24.11660; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BECKER P, 1984, EMBO J, V3, P2015, DOI 10.1002/j.1460-2075.1984.tb02084.x; BECKER PB, 1986, NATURE, V324, P686, DOI 10.1038/324686a0; BEERMANN F, 1993, MECH DEVELOP, V42, P59, DOI 10.1016/0925-4773(93)90098-I; Bhattacharya SK, 1999, NATURE, V397, P579, DOI 10.1038/17533; Bird AP, 1999, CELL, V99, P451, DOI 10.1016/S0092-8674(00)81532-9; BRESNICK EH, 1992, NUCLEIC ACIDS RES, V20, P273, DOI 10.1093/nar/20.2.273; Chen HW, 1999, CELL, V98, P675, DOI 10.1016/S0092-8674(00)80054-9; Chen YH, 2000, J BIOL CHEM, V275, P27366; Chuang LSH, 1997, SCIENCE, V277, P1996, DOI 10.1126/science.277.5334.1996; Dilworth FJ, 2000, MOL CELL, V6, P1049, DOI 10.1016/S1097-2765(00)00103-9; ESPINAS ML, 1994, MOL CELL BIOL, V14, P4116, DOI 10.1128/MCB.14.6.4116; ESPINAS ML, 1995, MOL CELL BIOL, V15, P5346; FRAGOSO G, 1995, GENE DEV, V9, P1933, DOI 10.1101/gad.9.15.1933; Fryer CJ, 1998, NATURE, V393, P88, DOI 10.1038/30032; Glass CK, 2000, GENE DEV, V14, P121; GRANGE T, 1989, NUCLEIC ACIDS RES, V17, P8695, DOI 10.1093/nar/17.21.8695; GRANGE T, 1991, NUCLEIC ACIDS RES, V19, P131, DOI 10.1093/nar/19.1.131; GRANNER DK, 1983, MOL CELL BIOCHEM, V53-4, P113; Hsieh CL, 1999, MOL CELL BIOL, V19, P46; JANTZEN HM, 1987, CELL, V49, P29, DOI 10.1016/0092-8674(87)90752-5; Jost J. P., 1996, Epigenetic mechanisms of gene regulation., P109; Kingston RE, 1999, GENE DEV, V13, P2339, DOI 10.1101/gad.13.18.2339; Knutti D, 2000, MOL CELL BIOL, V20, P2411, DOI 10.1128/MCB.20.7.2411-2422.2000; LEE DY, 1993, CELL, V72, P73, DOI 10.1016/0092-8674(93)90051-Q; Lemon B, 2000, GENE DEV, V14, P2551, DOI 10.1101/gad.831000; LIN ECC, 1957, BIOCHIM BIOPHYS ACTA, V26, P85, DOI 10.1016/0006-3002(57)90057-4; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; McNally JG, 2000, SCIENCE, V287, P1262, DOI 10.1126/science.287.5456.1262; Mink S, 1997, MOL CELL BIOL, V17, P6609, DOI 10.1128/MCB.17.11.6609; MUCHARDT C, 1993, EMBO J, V12, P4279, DOI 10.1002/j.1460-2075.1993.tb06112.x; Newlands S, 1998, GENE DEV, V12, P2748, DOI 10.1101/gad.12.17.2748; Ng HH, 1999, NAT GENET, V23, P58, DOI 10.1038/12659; NIGHTINGALE K, 1995, J BIOL CHEM, V270, P4197, DOI 10.1074/jbc.270.9.4197; NISHIO Y, 1993, MOL CELL BIOL, V13, P1854, DOI 10.1128/MCB.13.3.1854; Reichardt HM, 1998, CELL, V93, P531, DOI 10.1016/S0092-8674(00)81183-6; REIK A, 1991, EMBO J, V10, P2569, DOI 10.1002/j.1460-2075.1991.tb07797.x; RIGAUD G, 1991, CELL, V67, P977, DOI 10.1016/0092-8674(91)90370-E; Robyr D, 2000, MOL ENDOCRINOL, V14, P329, DOI 10.1210/me.14.3.329; ROUX J, 1995, DNA CELL BIOL, V14, P385, DOI 10.1089/dna.1995.14.385; Sassi H, 1998, P NATL ACAD SCI USA, V95, P5621, DOI 10.1073/pnas.95.10.5621; SASSI H, 1995, P NATL ACAD SCI USA, V92, P7197, DOI 10.1073/pnas.92.16.7197; SCHULE R, 1988, SCIENCE, V242, P1418, DOI 10.1126/science.3201230; SCHUTZ G, 1986, ANN NY ACAD, V478, P93; Schwarz S, 1997, NUCLEIC ACIDS RES, V25, P5052, DOI 10.1093/nar/25.24.5052; Shiau AK, 1998, CELL, V95, P927, DOI 10.1016/S0092-8674(00)81717-1; Sugiyama T, 1998, MOL ENDOCRINOL, V12, P1487, DOI 10.1210/me.12.10.1487; Swisher JFA, 1998, NUCLEIC ACIDS RES, V26, P5573, DOI 10.1093/nar/26.24.5573; THOMASSIN H, 2001, IN PRESS EMBO J; Tomkins G M, 1971, Adv Cell Biol, V2, P299; Tronche F, 1998, CURR OPIN GENET DEV, V8, P532, DOI 10.1016/S0959-437X(98)80007-5; TRUSS M, 1995, EMBO J, V14, P1737, DOI 10.1002/j.1460-2075.1995.tb07163.x; Wade PA, 1999, NAT GENET, V23, P62, DOI 10.1038/12664; Walsh CP, 1999, GENE DEV, V13, P26, DOI 10.1101/gad.13.1.26; Weiss A, 1996, CELL, V86, P709, DOI 10.1016/S0092-8674(00)80146-4; WIJGERDE M, 1995, NATURE, V377, P209, DOI 10.1038/377209a0; WILKS A, 1984, NUCLEIC ACIDS RES, V12, P1163, DOI 10.1093/nar/12.2.1163; Wolffe AP, 1999, P NATL ACAD SCI USA, V96, P5894, DOI 10.1073/pnas.96.11.5894; Wong JM, 1997, EMBO J, V16, P3158, DOI 10.1093/emboj/16.11.3158; Workman JL, 1998, ANNU REV BIOCHEM, V67, P545, DOI 10.1146/annurev.biochem.67.1.545; Wurtz JM, 1996, NAT STRUCT BIOL, V3, P206; ZARET KS, 1984, CELL, V38, P29, DOI 10.1016/0092-8674(84)90523-3; Zhu B, 2000, NUCLEIC ACIDS RES, V28, P4157, DOI 10.1093/nar/28.21.4157; Zhu B, 2000, P NATL ACAD SCI USA, V97, P5135, DOI 10.1073/pnas.100107597	65	31	34	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 28	2001	20	24					3028	3038		10.1038/sj.onc.1204327	http://dx.doi.org/10.1038/sj.onc.1204327			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	442WT	11420718				2022-12-17	WOS:000169308500006
J	Mitin, N; Kudla, AJ; Konieczny, SF; Taparowsky, EJ				Mitin, N; Kudla, AJ; Konieczny, SF; Taparowsky, EJ			Differential effects of Ras signaling through NF kappa B on skeletal myogenesis	ONCOGENE			English	Article						Ras; myogenesis; NF kappa B; signal transduction	ACTIVATED PROTEIN-KINASE; CELL-CYCLE PROGRESSION; ONCOGENIC RAS; TRANSCRIPTIONAL ACTIVITY; MUSCLE DIFFERENTIATION; MAP KINASE; 3T3 CELLS; INHIBITION; GROWTH; TRANSFORMATION	Oncogenic Ras (H-Ras G12V) inhibits skeletal myogenesis through multiple signaling pathways. Previously, we demonstrated that the major downstream effecters of Ras (i.e., MEK/MAPK, RalGDS and Rac/Rho) play a minor, if any, role in the differentiation-defective phenotype of Ras myoblasts, Recently, NF kappaB, another Ras signaling target, has been shown to inhibit myogenesis presumably by stimulating cyclin D1 accumulation and cell cycle progression. In this study, we address the involvement of NF kappaB activation in the Ras-induced inhibition of myogenesis, Using H-Ras G12V and three G12V effector-loop variants, we detect high levels of NF kappaB transcriptional activity in C3H10T1/2-MyoD cells treated with differentiation medium. Myogenesis is blocked by all Ras proteins tested, yet only in the case of H-Ras G12V are cyclin D1 levels increased and cell cycle progression maintained, Expression of I kappaB alpha SR, an inhibitor of NF kappaB, does not reverse the differentiation-defective phenotype of Ras expressing cultures, but does induce differentiation in cultures treated with tumor necrosis factor (TNF alpha) or in cultures expressing the RelA/p65 subunit of NF kappaB, These data confirm that NF kappaB is a target of Ras and suggest that the cellular actions of NF kappaB require additional signals that are discriminated by the Ras effector-loop variants. Results with I kappaB alpha SR convincingly demonstrate that H-Ras G12V does not rely on NF kappaB activity to block myogenesis, an observation that continues to implicate another unidentified signaling pathway(s) in the inhibition of skeletal myogenesis by Ras.	Purdue Univ, Dept Biol Sci, W Lafayette, IN 47907 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus	Taparowsky, EJ (corresponding author), Purdue Univ, Dept Biol Sci, W Lafayette, IN 47907 USA.		Mitin, Natalia/E-8043-2012		NCI NIH HHS [T32 CA09634] Funding Source: Medline; NIAMS NIH HHS [AR41115-07] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009634] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aktas H, 1997, MOL CELL BIOL, V17, P3850, DOI 10.1128/MCB.17.7.3850; ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; Anrather J, 1999, J BIOL CHEM, V274, P13594, DOI 10.1074/jbc.274.19.13594; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Bargou RC, 1997, J CLIN INVEST, V100, P2961, DOI 10.1172/JCI119849; BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; BEG AA, 1992, GENE DEV, V6, P1899, DOI 10.1101/gad.6.10.1899; Bennett AM, 1997, SCIENCE, V278, P1288, DOI 10.1126/science.278.5341.1288; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; DOBROWOLSKI S, 1994, MOL CELL BIOL, V14, P5441, DOI 10.1128/MCB.14.8.5441; Dorman CM, 1999, ONCOGENE, V18, P5167, DOI 10.1038/sj.onc.1202907; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FERAMISCO JR, 1984, CELL, V38, P109, DOI 10.1016/0092-8674(84)90531-2; Finco TS, 1997, J BIOL CHEM, V272, P24113, DOI 10.1074/jbc.272.39.24113; Gille H, 1999, J BIOL CHEM, V274, P22033, DOI 10.1074/jbc.274.31.22033; GOSSETT LA, 1988, J CELL BIOL, V106, P2127, DOI 10.1083/jcb.106.6.2127; Grumont RJ, 1998, J EXP MED, V187, P663, DOI 10.1084/jem.187.5.663; Guttridge DC, 1999, MOL CELL BIOL, V19, P5785; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; Hinz M, 1999, MOL CELL BIOL, V19, P2690; Hitomi M, 1999, MOL CELL BIOL, V19, P4623; HOLLENBERG SM, 1993, P NATL ACAD SCI USA, V90, P8028, DOI 10.1073/pnas.90.17.8028; Jol H, 2000, ONCOGENE, V19, P841, DOI 10.1038/sj.onc.1203392; Joneson T, 1996, SCIENCE, V271, P810, DOI 10.1126/science.271.5250.810; Kaliman P, 1996, J BIOL CHEM, V271, P19146, DOI 10.1074/jbc.271.32.19146; Karin M, 1999, ONCOGENE, V18, P6867, DOI 10.1038/sj.onc.1203219; KONG YF, 1995, MOL CELL BIOL, V15, P5205; KONIECZNY SF, 1989, ONCOGENE, V4, P473; LASSAR AB, 1989, CELL, V58, P659, DOI 10.1016/0092-8674(89)90101-3; May MJ, 1997, SEMIN CANCER BIOL, V8, P63, DOI 10.1006/scbi.1997.0057; Mayo MW, 1997, SCIENCE, V278, P1812, DOI 10.1126/science.278.5344.1812; Meriane M, 2000, MOL BIOL CELL, V11, P2513, DOI 10.1091/mbc.11.8.2513; Miller MJ, 1997, J BIOL CHEM, V272, P5600, DOI 10.1074/jbc.272.9.5600; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; Norris JL, 1999, J BIOL CHEM, V274, P13841, DOI 10.1074/jbc.274.20.13841; OLSON EN, 1987, MOL CELL BIOL, V7, P2104, DOI 10.1128/MCB.7.6.2104; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Pinset C, 1997, CR ACAD SCI III-VIE, V320, P367, DOI 10.1016/S0764-4469(97)85024-X; PRENDERGAST GC, 1995, ONCOGENE, V10, P2289; Ramocki MB, 1998, J BIOL CHEM, V273, P17696, DOI 10.1074/jbc.273.28.17696; Ramocki MB, 1997, MOL CELL BIOL, V17, P3547, DOI 10.1128/MCB.17.7.3547; RAO SS, 1994, MOL CELL BIOL, V14, P5259, DOI 10.1128/MCB.14.8.5259; ROBBINS DJ, 1992, P NATL ACAD SCI USA, V89, P6924, DOI 10.1073/pnas.89.15.6924; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; SKAPEK SX, 1995, SCIENCE, V267, P1022, DOI 10.1126/science.7863328; Takano H, 1998, MOL CELL BIOL, V18, P1580, DOI 10.1128/MCB.18.3.1580; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; Trent JC, 1996, EMBO J, V15, P4497, DOI 10.1002/j.1460-2075.1996.tb00827.x; VAIDYA TB, 1991, J CELL BIOL, V114, P809, DOI 10.1083/jcb.114.4.809; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Wang J, 1996, SCIENCE, V273, P359, DOI 10.1126/science.273.5273.359; Weyman CM, 1997, ONCOGENE, V14, P697, DOI 10.1038/sj.onc.1200874; White MA, 1996, J BIOL CHEM, V271, P16439, DOI 10.1074/jbc.271.28.16439; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; Wu ZG, 2000, MOL CELL BIOL, V20, P3951, DOI 10.1128/MCB.20.11.3951-3964.2000; Zabludoff SD, 1998, CELL GROWTH DIFFER, V9, P1; Zetser A, 1999, J BIOL CHEM, V274, P5193, DOI 10.1074/jbc.274.8.5193; Zhang JM, 1999, EMBO J, V18, P926, DOI 10.1093/emboj/18.4.926	60	31	32	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 15	2001	20	11					1276	1286		10.1038/sj.onc.1204223	http://dx.doi.org/10.1038/sj.onc.1204223			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	411JM	11313872				2022-12-17	WOS:000167495000002
J	McCormick, F				McCormick, F			ONYX-015 selectivity and the p14ARF pathway	ONCOGENE			English	Article						p53; ONYX-015; adenovirus; p14ARF	TUMOR-CELLS; P53 STATUS; ADENOVIRUS MUTANT; MESSENGER-RNA; REPLICATION; PROTEIN; INFECTION; INDUCTION; P19(ARF); EFFICACY	ONYX-015, dl1520, is an adenovirus that lacks the E1B 55K gene and therefore lacks the capacity to neutralize p53 during infection. This virus induces high levels of p53 and fails to grow efficiently in primary epithelial cells. However, it does replicate in many tumor cells, including those expressing wild-type p53. In these cells, ONYX-015 fails to induce active p53. This is because the pathway from Ela to p53 is disrupted through loss of p14ARF. We propose that high levels of Mdm2 activity resulting from loss of p14ARF, and high levels of Mdm2 protein resulting from activated Ras prevent accumulation of functional p53 during infection of tumor cells that retain wild-type p53.	Univ Calif San Francisco, Ctr Comprehens Canc, Inst Canc Res, San Francisco, CA 94115 USA	University of California System; University of California San Francisco; UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer Center	McCormick, F (corresponding author), Univ Calif San Francisco, Ctr Comprehens Canc, Inst Canc Res, 2340 Sutter St, San Francisco, CA 94115 USA.							BABISS LE, 1985, MOL CELL BIOL, V5, P2552, DOI 10.1128/MCB.5.10.2552; BELTZ GA, 1979, J MOL BIOL, V131, P353, DOI 10.1016/0022-2836(79)90081-0; Bischoff JR, 1996, SCIENCE, V274, P373, DOI 10.1126/science.274.5286.373; Chiou SK, 1997, J VIROL, V71, P3515, DOI 10.1128/JVI.71.5.3515-3525.1997; de Stanchina E, 1998, GENE DEV, V12, P2434, DOI 10.1101/gad.12.15.2434; Goodrum FD, 1998, J VIROL, V72, P9479, DOI 10.1128/JVI.72.12.9479-9490.1998; Harada JN, 1999, J VIROL, V73, P5333, DOI 10.1128/JVI.73.7.5333-5344.1999; Heise C, 1997, NAT MED, V3, P639, DOI 10.1038/nm0697-639; Howley P M, 1989, Princess Takamatsu Symp, V20, P199; Khuri FR, 2000, NAT MED, V6, P879, DOI 10.1038/78638; Ries S, 2000, CELL, V103, P321, DOI 10.1016/S0092-8674(00)00123-9; Ries SJ, 2000, NAT MED, V6, P1128, DOI 10.1038/80466; Rothmann T, 1998, J VIROL, V72, P9470, DOI 10.1128/JVI.72.12.9470-9478.1998; Rubenwolf S, 1997, J VIROL, V71, P1115, DOI 10.1128/JVI.71.2.1115-1123.1997; SARNOW P, 1984, J VIROL, V49, P692, DOI 10.1128/JVI.49.3.692-700.1984; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Turnell AS, 1999, J VIROL, V73, P2074, DOI 10.1128/JVI.73.3.2074-2083.1999; Wildner O, 1999, GENE THER, V6, P57, DOI 10.1038/sj.gt.3300810	19	31	34	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 27	2000	19	56					6670	6672		10.1038/sj.onc.1204096	http://dx.doi.org/10.1038/sj.onc.1204096			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	415CY	11426653				2022-12-17	WOS:000167704000014
J	Doucet, C; Jasmin, C; Azzarone, B				Doucet, C; Jasmin, C; Azzarone, B			Unusual interleukin-4 and-13 signaling in human normal and tumor lung fibroblasts	ONCOGENE			English	Article						lung fibroblasts; myofibroblasts; IL-4/IL-13; signal transduction	INSULIN-RECEPTOR SUBSTRATE-1; ACTIVATED PROTEIN-KINASE; TYROSINE PHOSPHORYLATION; CELLS; TRANSDUCTION; IL-13; CHAIN; EXPRESSION; PATHWAYS; INVOLVEMENT	IL-4 and IL-13 act on human lung fibroblasts through specific receptors differing in their composition. Indeed, the gammac chain is constitutively expressed in tumor lung myofibroblast but not in normal cells, Here, we have analysed the signal transduction induced by IL-4 and IL-13 in both cell types, in order to better understand the molecular mechanisms underlying tumor stromal development. The IL-4R alpha chain is constitutively phosphorylated and pre-associated with the JAK1 protein in both cell types. In normal cells, we detected the activation of the classic IRS-2 or JAK1/STAT6 pathways, the phosphorylation of JAK2, while Tyk2 was constitutively phosphorylated and not modified by both cytokines, In addition to these pathways, in lung tumor myofibroblasts, IL-4 and IL-13 induced the phosphorylation of JAK3 and increased the phosphorylation of Tyk2, Interestingly, in both cell types IL-4 and IL-13 triggered an unusual pattern of STAT1 and STAT3 activation. These events probably correspond to a tissue-specific signaling important for the immunoregulatory functions of airways fibroblasts, Indeed, the inflammatory-like pattern of STATs signaling triggered by IL-4 and IL-13 in these cells may favor the homing of inflammatory and/or metastatic cells. In lung myofibroblasts, these properties could be modified through the different pattern of JAK activation.	Hop Paul Brousse, INSERM U268, F-94807 Villejuif, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Paul-Brousse - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm)	Azzarone, B (corresponding author), Hop Paul Brousse, INSERM U506, 16 Av PV Couturier, F-94807 Villejuif, France.		Azzarone, Bruno/AAH-9251-2019	Azzarone, Bruno/0000-0002-5962-3849				Aman MJ, 1996, J BIOL CHEM, V271, P29265, DOI 10.1074/jbc.271.46.29265; Aringer M, 1999, IMMUNOLOGIST, V7, P139; AZZARONE B, 1984, J CELL BIOL, V98, P1133, DOI 10.1083/jcb.98.3.1133; Brouty-Boye D, 2000, EUR J IMMUNOL, V30, P914, DOI 10.1002/1521-4141(200003)30:3<914::AID-IMMU914>3.0.CO;2-D; Callard RE, 1996, IMMUNOL TODAY, V17, P108, DOI 10.1016/0167-5699(96)80600-1; Chen XH, 1997, J BIOL CHEM, V272, P6556, DOI 10.1074/jbc.272.10.6556; Chuang LM, 1997, BIOCHEM BIOPH RES CO, V235, P317, DOI 10.1006/bbrc.1997.6771; Chuang LM, 1996, J BIOCHEM-TOKYO, V120, P111; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Demoulin JB, 1998, CYTOKINES CELL MOL T, V4, P243; Doucet C, 1998, INT IMMUNOL, V10, P1421, DOI 10.1093/intimm/10.10.1421; Doucet C, 1998, J CLIN INVEST, V101, P2129, DOI 10.1172/JCI741; Goebeler M, 1997, IMMUNOLOGY, V91, P450, DOI 10.1046/j.1365-2567.1997.00263.x; GUSCHIN D, 1995, EMBO J, V14, P1421, DOI 10.1002/j.1460-2075.1995.tb07128.x; IDZERDA RL, 1990, J EXP MED, V171, P861, DOI 10.1084/jem.171.3.861; IHLE JN, 1995, TRENDS GENET, V11, P69, DOI 10.1016/S0168-9525(00)89000-9; JOHNSTON JA, 1995, J BIOL CHEM, V270, P28527, DOI 10.1074/jbc.270.48.28527; LEFORT S, 1995, FEBS LETT, V366, P122, DOI 10.1016/0014-5793(95)00512-8; MINTY A, 1993, NATURE, V362, P248, DOI 10.1038/362248a0; Murata T, 1998, INT IMMUNOL, V10, P1103, DOI 10.1093/intimm/10.8.1103; Murata T, 1995, J BIOL CHEM, V270, P30829, DOI 10.1074/jbc.270.51.30829; Obiri NI, 1997, J BIOL CHEM, V272, P20251, DOI 10.1074/jbc.272.32.20251; PAUL WE, 1991, BLOOD, V77, P1859; ROLLING C, 1995, ONCOGENE, V10, P1757; Rolling C, 1996, FEBS LETT, V393, P53, DOI 10.1016/0014-5793(96)00835-6; SAPPINO AP, 1990, LAB INVEST, V63, P144; Schiemann WP, 1997, J BIOL CHEM, V272, P16631, DOI 10.1074/jbc.272.26.16631; SCHMITTGRAFF A, 1994, VIRCHOWS ARCH, V425, P3, DOI 10.1007/BF00193944; Schnyder B, 1996, BIOCHEM J, V315, P767, DOI 10.1042/bj3150767; SIRONI M, 1994, BLOOD, V84, P1913; SMEZBERTLING C, 1995, J BIOL CHEM, V270, P966; Smith RS, 1997, AM J PATHOL, V151, P317; SUN XJ, 1995, NATURE, V377, P173, DOI 10.1038/377173a0; Takeda K, 1996, J IMMUNOL, V157, P3220; TEPPER RI, 1990, CELL, V62, P457, DOI 10.1016/0092-8674(90)90011-3; WELHAM MJ, 1995, J BIOL CHEM, V270, P12286, DOI 10.1074/jbc.270.20.12286; Wery S, 1996, J BIOL CHEM, V271, P8529, DOI 10.1074/jbc.271.15.8529; WITTHUHN BA, 1994, NATURE, V370, P153, DOI 10.1038/370153a0	38	31	31	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 30	2000	19	51					5898	5905		10.1038/sj.onc.1203933	http://dx.doi.org/10.1038/sj.onc.1203933			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	378CA	11127821				2022-12-17	WOS:000165563100009
J	Amanullah, A; Liebermann, DA; Hoffman, B				Amanullah, A; Liebermann, DA; Hoffman, B			p53-independent apoptosis associated with c-Myc-mediated block in myeloid cell differentiation	ONCOGENE			English	Article						myeloid; c-myc; p53; differentiation; apoptosis	LEUKEMIA INHIBITORY FACTOR; TERMINAL DIFFERENTIATION; GROWTH-INHIBITION; DEATH; EXPRESSION; BCL-2; GENE; PROTOONCOGENES; REGULATORS; ARREST	Previously we have shown that deregulated expression of c-myc in M1 myeloid leukemic cells blocked IL-6-induced differentiation and its associated growth arrest; however, the cells proliferated at a significantly reduced rate compared to untreated cells. The basis for the increased doubling time of IL-6-treated M1myc cells was found to be due to the induction of a p53-independent apoptotic pathway. The apoptotic response was not completely penetrant; in the same population of cells both proliferation and apoptosis were continuously ongoing, Down-regulation of Bcl-2 was insufficient to account for the apoptotic response, since deregulated expression of Bcl-2 delayed, but did not block, the onset of apoptosis, Furthermore, our results indicated that the IL-6-induced partial hypophosphorylation of the retinoblastoma gene product (Rb), observed in M1myc cells, was not responsible for the apoptotic response. Finally, the findings in M1 cells were extended to myeloid cells derived from the bone marrow of wild type and p53-deficient mice, where the deregulated expression of c-myc was also shown to block terminal differentiation and induce apoptosis independent of p53, These findings provide new insights into how myc participates in the neoplastic process, and how additional mutations can promote more aggressive tumors.	Temple Univ, Sch Med, Dept Biochem, Fels Inst Canc Res & Mol Biol, Philadelphia, PA 19140 USA; Univ Penn, Cell & Mol Biol Grad Grp, Philadelphia, PA 19104 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; University of Pennsylvania	Liebermann, DA (corresponding author), Temple Univ, Sch Med, Dept Biochem, Fels Inst Canc Res & Mol Biol, 3307 N Broad St, Philadelphia, PA 19140 USA.				NCI NIH HHS [IROI CA81168] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA081168] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABDOLLAHI A, 1991, ONCOGENE, V6, P165; ABDOLLAHI A, 1991, CELL GROWTH DIFFER, V2, P401; ASKEW DS, 1991, ONCOGENE, V6, P1915; BISSONNETTE RP, 1992, NATURE, V359, P552, DOI 10.1038/359552a0; Chao DT, 1998, ANNU REV IMMUNOL, V16, P395, DOI 10.1146/annurev.immunol.16.1.395; Eilers M, 1999, MOL CELLS, V9, P1; EVAN GI, 1993, CURR OPIN GENET DEV, V3, P44, DOI 10.1016/S0959-437X(05)80339-9; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Facchini LM, 1998, FASEB J, V12, P633, DOI 10.1096/fasebj.12.9.633; FANIDI A, 1992, NATURE, V359, P554, DOI 10.1038/359554a0; FREYTAG SO, 1988, MOL CELL BIOL, V8, P1614, DOI 10.1128/MCB.8.4.1614; Graf T, 1992, CURR OPIN GENET DEV, V2, P249, DOI 10.1016/S0959-437X(05)80281-3; HAWLEY RG, 1994, ANN NY ACAD SCI, V716, P327, DOI 10.1111/j.1749-6632.1994.tb21724.x; Hoffman B, 1998, ONCOGENE, V17, P3351, DOI 10.1038/sj.onc.1202592; HOFFMANLIEBERMANN B, 1991, MOL CELL BIOL, V11, P2375, DOI 10.1128/MCB.11.5.2375; HOFFMANLIEBERMANN B, 1991, ONCOGENE, V6, P903; Hueber AO, 1997, SCIENCE, V278, P1305, DOI 10.1126/science.278.5341.1305; Kagaya S, 1997, MOL CELL BIOL, V17, P6736, DOI 10.1128/MCB.17.11.6736; KRISHNARAJU K, 1995, MOL CELL BIOL, V15, P5499; LIEBERMANN DA, 1989, ONCOGENE, V4, P583; LIEBERMANN DA, 1995, ONCOGENE, V11, P199; LIEBERMANN DA, 1994, STEM CELLS, V12, P352, DOI 10.1002/stem.5530120402; LORD KA, 1990, CELL GROWTH DIFFER, V1, P637; LORD KA, 1993, MOL CELL BIOL, V13, P841, DOI 10.1128/MCB.13.2.841; MEIKRANTZ W, 1995, J CELL BIOCHEM, V58, P160, DOI 10.1002/jcb.240580205; Nesbit CE, 1999, ONCOGENE, V18, P3004, DOI 10.1038/sj.onc.1202746; OLTVAI ZN, 1994, CELL, V79, P189, DOI 10.1016/0092-8674(94)90188-0; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; PACKHAM G, 1995, BBA-REV CANCER, V1242, P11, DOI 10.1016/0304-419X(94)00015-T; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; PELLICER A, 1978, CELL, V14, P133, DOI 10.1016/0092-8674(78)90308-2; PETER M, 1994, CELL, V79, P181, DOI 10.1016/0092-8674(94)90186-4; Prendergast GC, 1999, ONCOGENE, V18, P2967, DOI 10.1038/sj.onc.1202727; Schmidt EV, 1999, ONCOGENE, V18, P2988, DOI 10.1038/sj.onc.1202751; SELVAKUMARAN M, 1993, BLOOD, V81, P2257; SELVAKUMARAN M, 1992, MOL CELL BIOL, V12, P2493, DOI 10.1128/MCB.12.6.2493; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SHI YF, 1992, SCIENCE, V257, P212, DOI 10.1126/science.1378649; SPENCER CA, 1991, ADV CANCER RES, V56, P1; TSUJIMOTO Y, 1986, P NATL ACAD SCI USA, V83, P5214, DOI 10.1073/pnas.83.14.5214; Wang RX, 1998, ONCOGENE, V17, P1503, DOI 10.1038/sj.onc.1202059; YMER S, 1985, NATURE, V317, P255, DOI 10.1038/317255a0; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; Zamzami N, 1998, ONCOGENE, V16, P2265, DOI 10.1038/sj.onc.1201989	44	31	32	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 15	2000	19	26					2967	2977		10.1038/sj.onc.1203638	http://dx.doi.org/10.1038/sj.onc.1203638			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	323TQ	10871848				2022-12-17	WOS:000087581400003
J	Kajino, S; Suganuma, M; Teranishi, F; Takahashi, N; Tetsuka, T; Ohara, H; Itoh, M; Okamoto, T				Kajino, S; Suganuma, M; Teranishi, F; Takahashi, N; Tetsuka, T; Ohara, H; Itoh, M; Okamoto, T			Evidence that de novo protein synthesis is dispensable for anti-apoptotic effects of NF-kappa B	ONCOGENE			English	Article						carcinogenesis; NF-kappa B; apoptosis; TNF-alpha; cycloheximide	RHEUMATOID SYNOVIAL FIBROBLASTS; INDUCED CELL-DEATH; TUMOR PROMOTER; INHIBITION; ACTIVATION; ALPHA; INDUCTION; CANCER; AUROTHIOGLUCOSE; SUPPRESSION	The transcription factor NF-kappa B is a positive transcription factor for a number of genes and has been recognized as an anti-apoptotic regulator. However, the mechanism by which NF-kappa B blocks apoptosis is still controversial. Here, we demonstrate the evidence that NF-kappa B could attenuate the TNF-alpha-induced apoptosis without de novo protein synthesis using human pancreatic cancer cell lines, MIA PaCa-2 and Capan-2, The TNF-alpha-induced apoptosis was blocked by IL-1 beta, a potent inducer of NF-kappa B activation. This inhibitory effect of IL-1 beta was evident when cells were treated with protein synthesis inhibitors such as cycloheximide (CHS). Moreover, NF-kappa B decoy oligonucleotides could not block the anti-apoptotic effect of IL-1 beta at doses sufficient to block the NF-kappa B-dependent transcription induced by IL-1 beta, To confirm the role of NF-kappa B in blocking apoptosis we generated stable cell Lines expressing I kappa B Delta N, a highly stable form of I kappa B alpha, a cytoplasmic inhibitor of NF-kappa B. In these stable transfectants, the antiapoptotic effect of IL-1 beta was totally abolished, indicating that the anti-apoptotic action of IL-1 beta could be ascribed to the NF-kappa B action. These findings show that ne novo protein synthesis is dispensable for anti-apoptotic effects of NF-kappa B and support the possibility that NF-kappa B could exert its anti-apoptotic action through protein-protein interaction.	Nagoya City Univ, Sch Med, Dept Mol Genet, Mizuho Ku, Nagoya, Aichi 4678601, Japan; Nagoya City Univ, Sch Med, Dept Internal Med 1, Nagoya, Aichi 4678601, Japan	Nagoya City University; Nagoya City University	Okamoto, T (corresponding author), Nagoya City Univ, Sch Med, Dept Mol Genet, Mizuho Ku, 1 Kawasumi, Nagoya, Aichi 4678601, Japan.							Baeuerle PA, 1998, CELL, V95, P729, DOI 10.1016/S0092-8674(00)81694-3; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; Chu ZL, 1997, P NATL ACAD SCI USA, V94, P10057, DOI 10.1073/pnas.94.19.10057; FUJIKI H, 1987, ADV CANCER RES, V49, P223, DOI 10.1016/S0065-230X(08)60799-X; Gilmore TD, 1996, ONCOGENE, V13, P1367; KOMORI A, 1993, CANCER RES, V53, P1982; KOPP E, 1994, SCIENCE, V265, P956, DOI 10.1126/science.8052854; Krappmann D, 1999, ONCOGENE, V18, P943, DOI 10.1038/sj.onc.1202351; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; MARX J, 1995, SCIENCE, V270, P232, DOI 10.1126/science.270.5234.232; Mori T, 2000, FEBS LETT, V465, P124, DOI 10.1016/S0014-5793(99)01726-3; Morishita R, 1997, NAT MED, V3, P894, DOI 10.1038/nm0897-894; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Okamoto T, 1997, CURR TOP CELL REGUL, V35, P149, DOI 10.1016/S0070-2137(97)80006-4; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; Sakurada S, 1996, INT IMMUNOL, V8, P1483, DOI 10.1093/intimm/8.10.1483; Saliou C, 1999, FREE RADICAL BIO MED, V26, P174, DOI 10.1016/S0891-5849(98)00212-3; Sato T, 1998, AIDS RES HUM RETROV, V14, P293, DOI 10.1089/aid.1998.14.293; SUGANUMA M, 1988, P NATL ACAD SCI USA, V85, P1768, DOI 10.1073/pnas.85.6.1768; Suganuma M, 1996, CANCER RES, V56, P3711; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Traber KE, 1999, INT IMMUNOL, V11, P143, DOI 10.1093/intimm/11.2.143; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; Visconti R, 1997, ONCOGENE, V15, P1987, DOI 10.1038/sj.onc.1201373; Wang CY, 1999, NAT MED, V5, P412, DOI 10.1038/7410; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Wu MX, 1998, SCIENCE, V281, P998, DOI 10.1126/science.281.5379.998; Yang JP, 1999, ONCOGENE, V18, P5177, DOI 10.1038/sj.onc.1202904; Yoshida S, 1999, INT IMMUNOL, V11, P151, DOI 10.1093/intimm/11.2.151	33	31	33	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 27	2000	19	18					2233	2239		10.1038/sj.onc.1203560	http://dx.doi.org/10.1038/sj.onc.1203560			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	312ZP	10822373				2022-12-17	WOS:000086974100008
J	Kaida, A; Ariumi, Y; Ueda, Y; Lin, JY; Hijikata, M; Ikawa, S; Shimotohno, K				Kaida, A; Ariumi, Y; Ueda, Y; Lin, JY; Hijikata, M; Ikawa, S; Shimotohno, K			Functional impairment of p73 and p51, the p53-related proteins, by the human T-cell leukemia virus type 1 Tax oncoprotein	ONCOGENE			English	Article						Tax; HTLV-1; p53; p73; p51; CBP	HUMAN PAPILLOMAVIRUS TYPE-16; TRANSCRIPTIONAL ACTIVATION; RAT FIBROBLASTS; TRANSACTIVATION; DOMAIN; INHIBITION; HOMOLOG; E6; TRANSFORMATION; INACTIVATION	We have previously demonstrated that the human T-cell leukemia virus type 1 (HTLV-1) Tax oncoprotein represses the trans-activation function of p53 tumor suppressor protein. Recently, several proteins with sequence homology to p53 have been identified. In this study, we demonstrated that Tax represses the transactivation functions of p73 alpha, p73 beta, and p51A, the p53-related proteins, as well as p53, Moreover, a mutant Tax of coactivator CBP-binding site (K88A), which activated NF-kappa B but not CREB pathway, could not repress the p73 nor p51 trans-activation functions, indicating that CBP-binding domain of Tax is essential for the suppression of their functions. Using proteins of Gal4-fused N-terminal region of p73 and p51, we showed that Tax-mediated inactivation of p73 or p51 requires for their N-terminal trans-activation domains. Furthermore, only the putative N-terminal trans-activation domains of them did not have enough transcriptional activities and their adjacent regions are essential for their full transactivation, suggesting the existence of their second transactivation subdomains. Thus, HTLV-1 Tax inactivated the p53-related proteins through their N-terminal transactivation domains.	Kyoto Univ, Dept Viral Oncol, Inst Virus Res, Sakyo Ku, Kyoto 6068507, Japan; Tohoku Univ, Dept Cell Biol, Inst Dev Aging & Canc, Sendai, Miyagi 9800872, Japan	Kyoto University; Tohoku University	Shimotohno, K (corresponding author), Kyoto Univ, Dept Viral Oncol, Inst Virus Res, Sakyo Ku, Kyoto 6068507, Japan.		Ariumi, Yasuo/F-5804-2013; 井川, 俊太郎/L-5911-2015; Ueda, Yoshihide/S-7620-2016	Ueda, Yoshihide/0000-0003-3196-3494				Akagi T, 1997, FEBS LETT, V406, P263, DOI 10.1016/S0014-5793(97)00280-9; Akagi T, 1997, ONCOGENE, V14, P2071, DOI 10.1038/sj.onc.1201045; BARGONETTI J, 1992, GENE DEV, V6, P1886, DOI 10.1101/gad.6.10.1886; Cereseto A, 1996, BLOOD, V88, P1551, DOI 10.1182/blood.V88.5.1551.bloodjournal8851551; CHANG J, 1995, J BIOL CHEM, V270, P25014, DOI 10.1074/jbc.270.42.25014; De Laurenzi V, 1998, J EXP MED, V188, P1763, DOI 10.1084/jem.188.9.1763; Dobner T, 1996, SCIENCE, V272, P1470, DOI 10.1126/science.272.5267.1470; Harrod R, 1998, MOL CELL BIOL, V18, P5052, DOI 10.1128/MCB.18.9.5052; Higashino F, 1998, P NATL ACAD SCI USA, V95, P15683, DOI 10.1073/pnas.95.26.15683; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Kao SY, 1999, J VIROL, V73, P4299, DOI 10.1128/JVI.73.5.4299-4304.1999; KIYONO T, 1994, J VIROL, V68, P4656, DOI 10.1128/JVI.68.7.4656-4661.1994; Marin MC, 1998, MOL CELL BIOL, V18, P6316, DOI 10.1128/MCB.18.11.6316; Matsumoto K, 1997, J VIROL, V71, P4445, DOI 10.1128/JVI.71.6.4445-4451.1997; Miyake H, 1999, VIROLOGY, V253, P155, DOI 10.1006/viro.1998.9500; Mulloy JC, 1998, J VIROL, V72, P8852, DOI 10.1128/JVI.72.11.8852-8860.1998; Osada M, 1998, NAT MED, V4, P839, DOI 10.1038/nm0798-839; Pise-Masison CA, 1998, J VIROL, V72, P1165, DOI 10.1128/JVI.72.2.1165-1170.1998; Pise-Masison CA, 1998, J VIROL, V72, P6348, DOI 10.1128/JVI.72.8.6348-6355.1998; Rosin O, 1998, J BIOL CHEM, V273, P6698, DOI 10.1074/jbc.273.12.6698; Roth J, 1998, J VIROL, V72, P8510, DOI 10.1128/JVI.72.11.8510-8516.1998; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SEGAWA K, 1993, ONCOGENE, V8, P543; Senoo M, 1998, BIOCHEM BIOPH RES CO, V248, P603, DOI 10.1006/bbrc.1998.9013; Steegenga WT, 1999, MOL CELL BIOL, V19, P3885; Trink B, 1998, NAT MED, V4, P747, DOI 10.1038/nm0798-747; Ueda Y, 1999, ONCOGENE, V18, P4993, DOI 10.1038/sj.onc.1202817; Venot C, 1999, ONCOGENE, V18, P2405, DOI 10.1038/sj.onc.1202539; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; Yamaoka S, 1996, EMBO J, V15, P873, DOI 10.1002/j.1460-2075.1996.tb00422.x; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; YEW PR, 1994, GENE DEV, V8, P190, DOI 10.1101/gad.8.2.190; YEW PR, 1992, NATURE, V357, P82, DOI 10.1038/357082a0	34	31	31	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 10	2000	19	6					827	830		10.1038/sj.onc.1203387	http://dx.doi.org/10.1038/sj.onc.1203387			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	281ZV	10698501				2022-12-17	WOS:000085192100013
J	Loging, WT; Reisman, D				Loging, WT; Reisman, D			Inhibition of the putative tumor suppressor gene TIMP-3 by tumor-derived p53 mutants and wild type p53	ONCOGENE			English	Article						mutant p53; gene expression; TIMP-3; tumor suppressor	MOUSE-TISSUE INHIBITOR; TATA-BINDING PROTEIN; CELL-CYCLE ARREST; TRANSCRIPTIONAL REPRESSION; MATRIX METALLOPROTEINASES; GROWTH-FACTOR; FUNCTION MUTATIONS; MOLECULAR-CLONING; CARCINOMA-CELLS; DNA-ELEMENTS	The p53 gene is a tumor suppressor that regulates the expression of genes required for cell cycle arrest or apoptosis. Mutations in p53 have been observed in over 60% of all human cancers. Certain classes of mutant p53 proteins maintain some of their activities or acquire novel activities and thus may contribute to the transformed phenotype. By carrying out an analysis of differential gene expression using cDNA expression arrays, we compared the expression patterns of cells expressing no p53 to isogenic lines expressing the codon 248 Arg to Trp mutant p53 allele (R248W). In this report, we show that the R248W and D281G p53 mutants, two of the more commonly occurring mutations, as well as wild type p53, repress transcription of the tissue inhibitor of metalloproteinases type 3 (TIMP3) gene by greater than tenfold. TIMP3 expression has been observed to be repressed in many tumors and its reduced expression is thought to contribute to tumor metastasis and invasiveness by allowing increased activity of metalloproteinases in the extracellular matrix. Since mutant forms of p53 tend to be expressed at greatly elevated levels in many human tumors, the retention of their ability to repress TIMP3 illustrate one mechanism by which mutant forms of the p53 gene may contribute to tumorigenesis.	Univ S Carolina, Dept Biol Sci, Columbia, SC 29208 USA	University of South Carolina; University of South Carolina System; University of South Carolina Columbia	Reisman, D (corresponding author), Univ S Carolina, Dept Biol Sci, Columbia, SC 29208 USA.							AGOFF SN, 1993, SCIENCE, V259, P84, DOI 10.1126/science.8418500; Ahonen M, 1998, CANCER RES, V58, P2310; AnandApte B, 1996, BIOCHEM CELL BIOL, V74, P853, DOI 10.1139/o96-090; Andreu T, 1998, J BIOL CHEM, V273, P13848, DOI 10.1074/jbc.273.22.13848; Avantaggiati ML, 1997, CELL, V89, P1175, DOI 10.1016/S0092-8674(00)80304-9; Baker AH, 1998, J CLIN INVEST, V101, P1478, DOI 10.1172/JCI1584; Balint E, 1996, CANCER RES, V56, P1648; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; BenEzra D, 1997, INVEST OPHTH VIS SCI, V38, P2433; Bian JH, 1996, CARCINOGENESIS, V17, P1805, DOI 10.1093/carcin/17.9.1805; Bian JH, 1996, CARCINOGENESIS, V17, P2559, DOI 10.1093/carcin/17.12.2559; Blandino G, 1999, ONCOGENE, V18, P477, DOI 10.1038/sj.onc.1202314; Brooks PC, 1996, CELL, V85, P683, DOI 10.1016/S0092-8674(00)81235-0; Budde A, 1999, ONCOGENE, V18, P1119, DOI 10.1038/sj.onc.1202402; Cairns CA, 1998, EMBO J, V17, P3112, DOI 10.1093/emboj/17.11.3112; Chan EC, 1998, BBA-MOL BASIS DIS, V1407, P200, DOI 10.1016/S0925-4439(98)00041-6; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; DEB S, 1992, J VIROL, V66, P6164, DOI 10.1128/JVI.66.10.6164-6170.1992; Di Como CJ, 1999, MOL CELL BIOL, V19, P1438; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Elkeles A, 1999, MOL CELL BIOL, V19, P2594; Farmer G, 1996, NUCLEIC ACIDS RES, V24, P4281, DOI 10.1093/nar/24.21.4281; Farmer G, 1996, MOL CELL BIOL, V16, P4295; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Foley J, 1996, CANCER RES, V56, P4056; Frazier MW, 1998, MOL CELL BIOL, V18, P3735, DOI 10.1128/MCB.18.7.3735; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GERWIN BI, 1992, P NATL ACAD SCI USA, V89, P2759, DOI 10.1073/pnas.89.7.2759; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; Gomez DE, 1997, EUR J CELL BIOL, V74, P111; Gu W, 1997, NATURE, V387, P819, DOI 10.1038/42972; Gualberto A, 1998, P NATL ACAD SCI USA, V95, P5166, DOI 10.1073/pnas.95.9.5166; GUALBERTO A, 1995, MOL CELL BIOL, V15, P3450; HARVEY DM, 1991, GENE DEV, V5, P2375, DOI 10.1101/gad.5.12b.2375; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; Hiraoka N, 1998, CELL, V95, P365, DOI 10.1016/S0092-8674(00)81768-7; HORIKOSHI N, 1995, MOL CELL BIOL, V15, P227, DOI 10.1128/MCB.15.1.227; HSIAO M, 1994, AM J PATHOL, V145, P702; HSIAO M, 1995, MOL CARCINOGEN, V13, P112, DOI 10.1002/mc.2940130208; Hussain SP, 1998, CANCER RES, V58, P4023; JACKSON P, 1993, ONCOGENE, V8, P589; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Kim HT, 1997, BIOCHEM J, V324, P547, DOI 10.1042/bj3240547; Kinzler KW, 1998, COLORECTAL TUMORS GE, P565; LECO KJ, 1994, J BIOL CHEM, V269, P9352; Lee KC, 1999, MOL CELL BIOL, V19, P1279; LEVINE AJ, 1994, BRIT J CANCER, V69, P409, DOI 10.1038/bjc.1994.76; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Li RZ, 1998, ONCOGENE, V16, P3269, DOI 10.1038/sj.onc.1201867; LILL J, 1995, ONCOGENE, V10, P2387; LU H, 1995, P NATL ACAD SCI USA, V92, P5154, DOI 10.1073/pnas.92.11.5154; LudesMeyers JH, 1996, MOL CELL BIOL, V16, P6009; MACK DH, 1993, NATURE, V363, P281, DOI 10.1038/363281a0; MIYASHITA T, 1995, CELL, V80, P293; Muller BF, 1996, ONCOGENE, V12, P1941; Murphy M, 1996, GENE DEV, V10, P2971, DOI 10.1101/gad.10.23.2971; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; Pennie WD, 1999, CELL GROWTH DIFFER, V10, P279; Prives C, 1998, CELL, V95, P5, DOI 10.1016/S0092-8674(00)81774-2; RAGIMOV N, 1993, ONCOGENE, V8, P1183; Rowan S, 1996, EMBO J, V15, P827, DOI 10.1002/j.1460-2075.1996.tb00418.x; Ryan KM, 1998, MOL CELL BIOL, V18, P3692, DOI 10.1128/MCB.18.7.3692; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; Schwartz D, 1998, SEMIN CANCER BIOL, V8, P325, DOI 10.1006/scbi.1998.0095; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SHAULSKY G, 1991, CANCER RES, V51, P5232; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; SHOHAT O, 1987, ONCOGENE, V1, P277; Smith MR, 1997, CYTOKINE, V9, P770, DOI 10.1006/cyto.1997.0233; SUBLER MA, 1992, J VIROL, V66, P4757, DOI 10.1128/JVI.66.8.4757-4762.1992; SUN Y, 1993, P NATL ACAD SCI USA, V90, P2827, DOI 10.1073/pnas.90.7.2827; SUN Y, 1994, CANCER RES, V54, P1139; SUN Y, 1995, J BIOL CHEM, V270, P19312, DOI 10.1074/jbc.270.33.19312; THUT CJ, 1995, SCIENCE, V267, P100, DOI 10.1126/science.7809597; Ueno H, 1997, CANCER RES, V57, P2055; VAN MEIR EG, 1994, CANCER RES, V54, P649; VASSALLI JD, 1994, NATURE, V370, P14, DOI 10.1038/370014a0; Wang QJ, 1997, MOL CELL BIOL, V17, P389, DOI 10.1128/MCB.17.1.389; Werb Z, 1997, CELL, V91, P439, DOI 10.1016/S0092-8674(00)80429-8; Will K, 1998, P NATL ACAD SCI USA, V95, P13681, DOI 10.1073/pnas.95.23.13681; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705; XIAO H, 1994, MOL CELL BIOL, V14, P7103; YEW PR, 1994, GENE DEV, V8, P190, DOI 10.1101/gad.8.2.190; Yu Q, 1999, GENE DEV, V13, P35, DOI 10.1101/gad.13.1.35	90	31	31	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 9	1999	18	52					7608	7615		10.1038/sj.onc.1203135	http://dx.doi.org/10.1038/sj.onc.1203135			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	263HQ	10602522				2022-12-17	WOS:000084119600024
J	Wu, Y; Ma, GZ; Lu, D; Lin, F; Xu, HJ; Liu, JX; Arlinghaus, RB				Wu, Y; Ma, GZ; Lu, D; Lin, F; Xu, HJ; Liu, JX; Arlinghaus, RB			Bcr: a negative regulator of the Bcr-Abl oncoprotein	ONCOGENE			English	Article						Bcr; Bcr-Abl; Bcr-Abl inhibitor; tyrosine kinase	TYROSINE PHOSPHORYLATION; CELL-LINES; C-ABL; KINASE; SEQUENCES; PROTEIN; ACTIVATION; ONCOGENE; DOMAIN; EXPRESSION	Chronic myelogenous leukemia is typically characterized by the presence of the Philadelphia chromosome (Ph) in which 5' portions of the BCR gene are fused to a large portion of the ABL gene. Our studies and those of others indicate that Bcr sequences within the Bcr-Abl oncoprotein are critically involved in activating the Abl tyrosine kinase and actively participate in the oncogenic response, which is generated by the Bcr-Abl oncoprotein, We investigated the role of the Bcr protein in the oncogenic effects of Bcr-Abl. Reduction of the level of the Bcr protein by incubating cells with a 3' BCR anti-sense oligodeoxynucleotide increased the growth rate and survival of hematopoietic cell lines expressing Bcr-Abl. Also, enforced expression of Bcr in Bcr-Abl cell lines strongly reduced transformation efficiency. Induction of Bcr expression drastically reduced the phosphotyrosine content of Bcr-Abl in Rat-1 fibroblasts transformed by P185 BCR-ABL and in hematopoietic cells expressing P210 Bcr-Abl within days following induction of Bcr. Rat-1/P185 cells maintained for three weeks after Bcr induction had dramatically reduced amounts of phosphotyrosine proteins compared to cells in which Bcr expression was repressed by the addition of Tet. In contrast Bcr expression did not decrease the phosphotyrosine content of either v-Src or activated Neu tyrosine kinase. Importantly, the phosphotyrosine content of total P160 BCR (induced plus endogenous) was strongly reduced by inducing expression of Bcr, indicating that the induced Bcr protein was not a target of the tyrosine kinase activity of Bcr-Abl but instead functioned as an inhibitor of Bcr-Abl, These results show that the Bcr protein can function as a negative regulator of Bcr-Abl, but that the inhibitory effects of Bcr are dependent on achieving an elevated level of Bcr expression relative to Bcr-Abl.	Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Mol Therapeut, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Arlinghaus, RB (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, 1515 Holcombe Blvd, Houston, TX 77030 USA.				NCI NIH HHS [CA49639, CA65611, CA16672] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA065611, P01CA049639, P30CA016672] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CHUANG TH, 1995, P NATL ACAD SCI USA, V92, P10282, DOI 10.1073/pnas.92.22.10282; DIEKMANN D, 1991, NATURE, V351, P400, DOI 10.1038/351400a0; GARCIA R, 1991, ONCOGENE, V6, P1983; Hu SX, 1997, CANCER RES, V57, P3339; HUNG MC, 1989, P NATL ACAD SCI USA, V86, P2545, DOI 10.1073/pnas.86.8.2545; Li JZ, 1996, J BIOL CHEM, V271, P32930, DOI 10.1074/jbc.271.51.32930; Liu JX, 1996, CANCER RES, V56, P5120; Liu JX, 1996, MOL CELL BIOL, V16, P998; LIU JX, 1993, ONCOGENE, V8, P101; LU D, 1993, BLOOD, V82, P1257; Ma GZ, 1997, ONCOGENE, V14, P2367, DOI 10.1038/sj.onc.1201053; MARU Y, 1995, MOL CELL BIOL, V15, P835; MCWHIRTER JR, 1993, MOL CELL BIOL, V13, P7587, DOI 10.1128/MCB.13.12.7587; MCWHIRTER JR, 1991, MOL CELL BIOL, V11, P1553, DOI 10.1128/MCB.11.3.1553; MULLER AJ, 1992, MOL CELL BIOL, V12, P5087, DOI 10.1128/MCB.12.11.5087; MULLER AJ, 1991, MOL CELL BIOL, V11, P1785, DOI 10.1128/MCB.11.4.1785; NAUMOVSKI L, 1988, CANCER RES, V48, P2876; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/0092-8674(93)90689-N; PENDERGAST AM, 1991, CELL, V66, P161, DOI 10.1016/0092-8674(91)90148-R; PUIL L, 1994, EMBO J, V13, P764, DOI 10.1002/j.1460-2075.1994.tb06319.x; RON D, 1991, NEW BIOL, V3, P372; SIRARD C, 1994, BLOOD, V83, P1575; VARMUS HE, 1981, VIROLOGY, V108, P28, DOI 10.1016/0042-6822(81)90525-0; Voncken JW, 1998, ONCOGENE, V16, P2029, DOI 10.1038/sj.onc.1201730; VONCKEN JW, 1995, CELL, V80, P719, DOI 10.1016/0092-8674(95)90350-X; Wu Y, 1998, ONCOGENE, V16, P141, DOI 10.1038/sj.onc.1201524	26	31	32	0	6	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 5	1999	18	31					4416	4424		10.1038/sj.onc.1202828	http://dx.doi.org/10.1038/sj.onc.1202828			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	222YT	10442632				2022-12-17	WOS:000081813500003
J	Yang, HK; Kang, SH; Kim, YS; Won, K; Bang, YJ; Kim, SJ				Yang, HK; Kang, SH; Kim, YS; Won, K; Bang, YJ; Kim, SJ			Truncation of the TGF-beta type II receptor gene results in insensitivity to TGF-beta in human gastric cancer cells	ONCOGENE			English	Article						transforming growth factor-beta; cancer; mutation; carcinogenesis; receptor	MICROSATELLITE INSTABILITY; COLORECTAL CANCERS; GROWTH-INHIBITION; MUTATIONS; COLON; EXPRESSION; KINASE	The transforming growth factor-beta (TGF-beta receptor system has been implicated in the development of resistance to the growth-inhibitory effects of TGF-beta. It has been reported that resistance to TGF-beta correlates with inactivation of the TGF-beta type II receptor (RII). In the present report, we examine the genetic changes in the TGF-beta RII gene of human gastric cancer cell lines, SNU-5 and SNU-668, which we had previously reported to express truncated TGF-beta RII transcripts. By independent PCR and Southern hybridization analysis of genomic DNA, we found that the genomic sequence of TGF-beta RII is truncated after exon 2 in SNU-5 and after exon 3 in SNU-668. This was confirmed by sequencing the TGF-beta RII cDNA cloned from a SNU-5 cDNA library. Predicted TGF-beta RII protein of SNU-5 cells based on sequencing data contains only a part of extracellular domain of TGF-beta RII. We demonstrate that cotransfection of 3TP-Lux and wild type TGF-beta RII restores the TGF-beta responsiveness in SNU-5 cells, suggesting that genetic changes in the TGF-beta RII gene of SNU-5 cells are responsible for the loss of sensitivity to TGF-beta. This is the first report demonstrating that truncation of the TGF-beta RII gene is an alternative mechanism to inactivate the TGF-beta signal transduction pathways.	NCI, Lab Cell Regulat & Carcinogenesis, Bethesda, MD 20892 USA; Seoul Natl Univ, Coll Med, Canc Res Ctr, Seoul, South Korea	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Seoul National University (SNU)	Kim, SJ (corresponding author), NCI, Lab Cell Regulat & Carcinogenesis, Bethesda, MD 20892 USA.		Yang, Han-Kwang/J-2767-2012; Bang, Yung Jue/J-2759-2012	Bang, Yung Jue/0000-0001-6000-4597				BIOBIN GP, 1996, LAB INVEST, V74, P513; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; GARRIGUEANTAR L, 1995, CANCER RES, V55, P3892; HAHM KB, IN PRESS; INAGAKI M, 1993, P NATL ACAD SCI USA, V90, P5359, DOI 10.1073/pnas.90.11.5359; Kim David H., 1996, Journal of Biomedical Science, V3, P143, DOI 10.1007/BF02253095; KIMCHI A, 1988, SCIENCE, V240, P196, DOI 10.1126/science.2895499; LIN HY, 1994, CELL MOL BIOL, V40, P337; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; LIU B, 1995, NAT GENET, V9, P48, DOI 10.1038/ng0195-48; Lu SL, 1996, CANCER RES, V56, P4595; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; Markowitz Sanford D., 1996, Cytokine and Growth Factor Reviews, V7, P93, DOI 10.1016/1359-6101(96)00001-9; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MYEROFF LL, 1995, CANCER RES, V55, P5545; Ohue M, 1996, INT J CANCER, V68, P203, DOI 10.1002/(SICI)1097-0215(19961009)68:2<203::AID-IJC11>3.0.CO;2-B; Park JG, 1997, INT J CANCER, V70, P443, DOI 10.1002/(SICI)1097-0215(19970207)70:4<443::AID-IJC12>3.0.CO;2-G; PARK KC, 1994, P NATL ACAD SCI USA, V91, P8772, DOI 10.1073/pnas.91.19.8772; PARSONS R, 1995, CANCER RES, V55, P5548; PEPTIN MC, 1996, BIOCHEM BIOPH RES CO, V220, P289; Renault B, 1996, HUM GENET, V98, P601, DOI 10.1007/s004390050267; Roberts AB, 1990, HDB EXPT PHARM, V95, P419; SPORN MB, 1985, NATURE, V313, P747; SUN LZ, 1994, J BIOL CHEM, V269, P26449; Takenoshita S, 1997, ONCOGENE, V14, P1255, DOI 10.1038/sj.onc.1200938; WANG J, 1995, J BIOL CHEM, V270, P22044, DOI 10.1074/jbc.270.37.22044; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0	28	31	33	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 1	1999	18	13					2213	2219		10.1038/sj.onc.1202535	http://dx.doi.org/10.1038/sj.onc.1202535			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	182YE	10327067	Bronze			2022-12-17	WOS:000079525100005
J	Morimoto, AM; Berson, AE; Fujii, GH; Teng, DHF; Tavtigian, SV; Bookstein, R; Steck, PA; Bolen, JB				Morimoto, AM; Berson, AE; Fujii, GH; Teng, DHF; Tavtigian, SV; Bookstein, R; Steck, PA; Bolen, JB			Phenotypic analysis of human glioma cells expressing the MMAC1 tumor suppressor phosphatase	ONCOGENE			English	Article						MMAC1/PTEN; tumor suppressor; phosphatase	GERMLINE MUTATIONS; GENE; PTEN; PROTEINS; BREAST; CANCER	MMAC1, also known as PTEN or TEP-1, was recently identified as a gene commonly mutated in a variety of human neoplasias, Sequence analysis revealed that MMAC1 harbored sequences similar to those found in several protein phosphatases, Subsequent studies demonstrated that MMAC1 possessed in vitro enzymatic activity similar to that exhibited by dual specificity phosphatases, To characterize the potential cellular functions of MMAC1, we expressed wild-type and several mutant variants of MMAC1 in the human glioma cell line, U373, that lacks endogenous expression. While expression of wild-type MMAC1 in these cells significantly reduced their growth rate and saturation density, expression of enzymatically inactive MMAC1 significantly enhanced growth in soft agar, Our observations indicate that while wild-type MMAC1 exhibits activities compatible with its proposed role as a tumor suppressor, cellular expression of MMAC1 containing mutations in the catalytic domain may yield protein products that enhance transformation characteristics.	DNAX Res Inst Mol & Cellular Biol Inc, Dept Cell Signaling, Palo Alto, CA 94304 USA; Myriad Genet Inc, Salt Lake City, UT 84108 USA; Canji Inc, San Diego, CA 92121 USA; Univ Texas, MD Anderson Cancer Ctr, Dept Neurooncol, Houston, TX 77030 USA	Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.; Myriad Genetics, Inc; University of Texas System; UTMD Anderson Cancer Center	Morimoto, AM (corresponding author), DNAX Res Inst Mol & Cellular Biol Inc, Dept Cell Signaling, Palo Alto, CA 94304 USA.							BAKER BW, 1992, NUCLEIC ACIDS RES, V20, P5234, DOI 10.1093/nar/20.19.5234; Cheney IW, 1998, CANCER RES, V58, P2331; Furnari FB, 1997, P NATL ACAD SCI USA, V94, P12479, DOI 10.1073/pnas.94.23.12479; Guldberg P, 1997, CANCER RES, V57, P3660; Kong DH, 1997, NAT GENET, V17, P143, DOI 10.1038/ng1097-143; Li DM, 1997, CANCER RES, V57, P2124; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Liaw D, 1997, NAT GENET, V16, P64, DOI 10.1038/ng0597-64; Marsh DJ, 1997, NAT GENET, V16, P333, DOI 10.1038/ng0897-333; Myers MP, 1997, P NATL ACAD SCI USA, V94, P9052, DOI 10.1073/pnas.94.17.9052; Neel BG, 1997, CURR OPIN CELL BIOL, V9, P193, DOI 10.1016/S0955-0674(97)80063-4; Onishi M, 1996, EXP HEMATOL, V24, P324; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Pullen N, 1998, SCIENCE, V279, P707, DOI 10.1126/science.279.5351.707; Saras J, 1996, TRENDS BIOCHEM SCI, V21, P455, DOI 10.1016/S0968-0004(96)30044-3; SHIOZAKI K, 1995, NATURE, V378, P739, DOI 10.1038/378739a0; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; Tamura M, 1998, SCIENCE, V280, P1614, DOI 10.1126/science.280.5369.1614; Teng DHF, 1997, CANCER RES, V57, P5221	21	31	33	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 11	1999	18	6					1261	1266		10.1038/sj.onc.1202441	http://dx.doi.org/10.1038/sj.onc.1202441			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	165FW	10022807				2022-12-17	WOS:000078510900001
J	Saxena, A; Shriml, LM; Dean, M; Ali, IU				Saxena, A; Shriml, LM; Dean, M; Ali, IU			Comparative molecular genetic profiles of anaplastic astrocytomas glioblastomas multiforme and their subsequent recurrences	ONCOGENE			English	Article						malignant gliomas; recurrence; genetic profiles	TUMOR-SUPPRESSOR GENE; MALIGNANT BRAIN-TUMORS; GROWTH-FACTOR RECEPTOR; TISSUE INHIBITOR; GELATINASE-A; P53; GLIOMAS; PROGRESSION; EXPRESSION; MUTATION	Malignant glial tumors (anaplastic astrocytomas and glioblastomas multiforme) arise mostly either from the progression of low grade precursor lesions or rapidly in a de novo fashion and contain distinct genetic alterations. There is, however, a third subset of malignant gliomas in which genetic lesions remain to be identified, Following surgical resection, all gliomas appear to have an inherent tendency to recur, Comparative molecular analysis of ten primary malignant gliomas (three anaplastic astrocytomas and seven glioblastomas multiforme) with their recurrences identified two distinct subgroups of recurrent tumors. In one group, primary tumors harbored genetic aberrations frequently associated with linear progression or ne novo formation pathways of glial tumorigenesis and maintained their genetic profiles upon recurrence. In the other subset with no detectable known genetic mutations at first presentation, the recurrent tumors sustained specific abnormalities associated with pathways of linear progression or ne novo formation. These included loss of genes on chromosomes 17 and 10, mutations in the p53 gene, homozygous deletion of the DMBTA1 and p16 and/or p15 genes and amplification and/or overexpression of CDK4 and alpha form of the PDGF receptor. Recurrent tumors from both groups also displayed an abnormal expression profile of the metalloproteinase, gel A, and its inhibitor, TIMP-2, consistent with their highly invasive behavior, Delineation of the molecular differences between malignant glioblastomas and their subsequent recurrences may have important implications for the development of rational clinical approaches for this neoplasm that remains refractory to existing therapeutic modalities.	NCI, Chemoprevent Branch, NIH, Bethesda, MD 20892 USA; NINCDS, Surg Neurol Branch, NIH, Bethesda, MD 20892 USA; NCI, Lab Genom Divers, NIH, Frederick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Ali, IU (corresponding author), NCI, Chemoprevent Branch, NIH, Bethesda, MD 20892 USA.		Dean, Michael C/G-8172-2012; Dean, Michael/R-7501-2019	Dean, Michael C/0000-0003-2234-0631; 	NATIONAL CANCER INSTITUTE [ZIABC005652, Z01BC005652] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BERKMAN RA, 1992, J NEUROSURG, V77, P432, DOI 10.3171/jns.1992.77.3.0432; Berns EMJJ, 1998, BRIT J CANCER, V77, P1130, DOI 10.1038/bjc.1998.187; Brachmann RK, 1996, P NATL ACAD SCI USA, V93, P4091, DOI 10.1073/pnas.93.9.4091; CHO Y, 1994, SCIENCE, V265, P1994; Erber R, 1998, ONCOGENE, V16, P1671, DOI 10.1038/sj.onc.1201690; FLEMING TP, 1992, CANCER RES, V52, P4550; GUTIERREZ MI, 1994, HUM MOL GENET, V3, P2247, DOI 10.1093/hmg/3.12.2247; HAYASHI Y, 1991, BIOCHEM BIOPH RES CO, V180, P1145, DOI 10.1016/S0006-291X(05)81186-6; Hermanson M, 1996, CANCER RES, V56, P164; KERN SE, 1991, ONCOGENE, V6, P131; Kleihues P, 1993, HISTOLOGICAL TYPING; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Louis DN, 1997, BRAIN PATHOL, V7, P755, DOI 10.1111/j.1750-3639.1997.tb01062.x; LOUIS DN, 1995, TRENDS GENET, V11, P412, DOI 10.1016/S0168-9525(00)89125-8; MIKKELSEN T, 1995, J NEUROSURG, V83, P285, DOI 10.3171/jns.1995.83.2.0285; Mollenhauer J, 1997, NAT GENET, V17, P32, DOI 10.1038/ng0997-32; MORSE RP, 1994, J NEURO-ONCOL, V21, P151, DOI 10.1007/BF01052899; NAKAGAWA T, 1994, J NEUROSURG, V81, P69, DOI 10.3171/jns.1994.81.1.0069; NEMETH JA, 1993, EXP CELL RES, V207, P376, DOI 10.1006/excr.1993.1204; PRUCHON E, 1994, CANCER GENET CYTOGEN, V76, P85, DOI 10.1016/0165-4608(94)90454-5; RAJAN B, 1994, EUR J CANCER, V30A, P1809, DOI 10.1016/0959-8049(94)00248-4; Reifenberger J, 1996, J NEUROPATH EXP NEUR, V55, P822, DOI 10.1097/00005072-199607000-00007; RITTER AM, 1994, NEUROSURGERY, V35, P192, DOI 10.1227/00006123-199408000-00003; ROLLEY N, 1995, ONCOGENE, V11, P763; Rosenberg JE, 1996, ONCOGENE, V13, P2483; SAXENA A, 1995, INT J ONCOL, V7, P469; Saxena A, 1996, ONCOGENE, V13, P661; SAXENA A, 1992, CANCER RES, V52, P6716; SIDRANSKY D, 1992, NATURE, V355, P846, DOI 10.1038/355846a0; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; STETLERSTEVENSON WG, 1992, FEBS LETT, V296, P231, DOI 10.1016/0014-5793(92)80386-U; VONDEIMLING A, 1993, BRAIN PATHOL, V3, P19; Yamamoto M, 1996, CANCER RES, V56, P384; YAMAMOTO M, 1994, J NEURO-ONCOL, V22, P139, DOI 10.1007/BF01052889; YONG WH, 1995, J NEUROPATH EXP NEUR, V54, P622, DOI 10.1097/00005072-199509000-00002	35	31	33	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 11	1999	18	6					1385	1390		10.1038/sj.onc.1202440	http://dx.doi.org/10.1038/sj.onc.1202440			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	165FW	10022821				2022-12-17	WOS:000078510900015
J	Dunn, J; Garde, J; Dolan, K; Gosney, JR; Sutton, R; Meltzer, SJ; Field, JK				Dunn, J; Garde, J; Dolan, K; Gosney, JR; Sutton, R; Meltzer, SJ; Field, JK			Multiple target sites of allelic imbalance on chromosome 17 in Barrett's oesophageal cancer	ONCOGENE			English	Article						Barrett's adenocarcinoma; deletion mapping; chromosome 17; target regions	TUMOR-SUPPRESSOR GENE; EPITHELIAL OVARIAN-TUMORS; HUMAN BREAST CARCINOMAS; ESOPHAGEAL ADENOCARCINOMA; PROGNOSTIC VALUE; PROSTATE-CANCER; P53 MUTATIONS; FREQUENT LOSS; HETEROZYGOSITY; REGIONS	Twelve Barrett's adenocarcinomas have been analysed for the occurrence of allelic imbalance (LOH) on chromosome 17 using 41 microsatellite markers. This study provides evidence for 13 minimal regions of LOH, six on 17p and seven on 17q. Four of these centre in the vicinity of the known tumour suppressor genes (TSGs) TP53 (17p13.1), NF1 (17q11.2), BRCA1 (17q21.1), and a putative TSG (17p13.3), The tumours all displayed relatively small regions of LOH (1-10 cM), and in several tumours extensive regions of LOH were detected. One tumour displayed only two very small regions of LOH; 17p11.2 and 17p13.1. The frequency of allelic imbalance has been calculated based on the LOH encompassing only one minimal region, and based on all the LOH observations. By both evaluations the highest LOH frequencies were found for regions II (p53), III (17p13.1 centromeric to p53), IV (17p12), V (17p11.2) and VII (NF1, 17q11.2). Our data supports the existence of multiple TSGs on chromosome 17 and challenges the view that p53 is the sole target of LOH on 17p in Barrett's adenocarcinoma.	Univ Liverpool, Mol Genet & Oncol Grp, Liverpool L69 3BX, Merseyside, England; Thameside Gen Hosp, Dept Surg, Ashton Under Lyne OL6 9RW, Greater Manches, England; Univ Liverpool, Dept Pathol, Liverpool L69 3BX, Merseyside, England; Univ Liverpool, Dept Surg, Liverpool L69 3BX, Merseyside, England; Univ Maryland, Baltimore, MD 21201 USA; Vet Affairs Hosp, Baltimore, MD 21201 USA	University of Liverpool; University of Liverpool; University of Liverpool; University System of Maryland; University of Maryland Baltimore	Field, JK (corresponding author), Univ Liverpool, Mol Genet & Oncol Grp, Liverpool L69 3BX, Merseyside, England.		Sutton, Robert/I-3587-2016; Field, John K./AAD-5674-2020	Sutton, Robert/0000-0001-6600-562X; Field, John K./0000-0003-3951-6365				ABERLE H, 1995, P NATL ACAD SCI USA, V92, P6384, DOI 10.1073/pnas.92.14.6384; ALESSANDRA V, 1995, CANCER RES, V55, P2645; ALKASSPOOLES M, 1993, INT J CANCER, V54, P213, DOI 10.1002/ijc.2910540209; ATKIN NB, 1989, CANCER GENET CYTOGEN, V37, P229, DOI 10.1016/0165-4608(89)90053-8; Audrezet MP, 1996, HUM MUTAT, V7, P109, DOI 10.1002/(SICI)1098-1004(1996)7:2<109::AID-HUMU4>3.0.CO;2-7; Barrett MT, 1996, ONCOGENE, V12, P1873; Barrett MT, 1996, ONCOGENE, V13, P1867; BLOUNT PL, 1993, P NATL ACAD SCI USA, V90, P3221, DOI 10.1073/pnas.90.8.3221; BLOUNT PL, 1994, CANCER RES, V54, P2292; CAMERON AJ, 1995, GASTROENTEROLOGY, V109, P1541, DOI 10.1016/0016-5085(95)90642-8; CAMERON AJ, 1993, ENDOSCOPY, V25, P635, DOI 10.1055/s-2007-1010420; CAMERON AJ, 1992, GASTROENTEROLOGY, V103, P1241, DOI 10.1016/0016-5085(92)91510-B; Campomenosi P, 1996, CANCER EPIDEM BIOMAR, V5, P559; CASSON AG, 1994, AM J SURG, V167, P52, DOI 10.1016/0002-9610(94)90053-1; Chekmareva MA, 1997, PROSTATE, V33, P271; COGEN PH, 1992, AM J HUM GENET, V50, P584; CORNELIS RS, 1993, ONCOGENE, V8, P781; CORNELIS RS, 1994, CANCER RES, V54, P4200; CROPP CS, 1993, CANCER RES, V53, P5617; FENNERTY MB, 1993, ALIMENT PHARM THER, V7, P339; FILIPE MI, 1993, ENDOSCOPY, V25, P637, DOI 10.1055/s-2007-1010421; FLEJOU JF, 1994, PATHOL RES PRACT, V190, P1141, DOI 10.1016/S0344-0338(11)80440-1; FONG KM, 1995, CANCER RES, V55, P4268; FUTREAL PA, 1992, CANCER RES, V52, P2624; Galipeau PC, 1996, P NATL ACAD SCI USA, V93, P7081, DOI 10.1073/pnas.93.14.7081; GAO X, 1995, ONCOGENE, V11, P1241; GLEESON CM, 1995, CANCER RES, V55, P3406; Gonzalez MV, 1997, J CLIN PATHOL, V50, P212, DOI 10.1136/jcp.50.3.212; GREENWALD BD, 1992, INT J ONCOL, V1, P271; Gullick W J, 1990, Int J Cancer Suppl, V5, P55; HARRIS CC, 1993, NEW ENGL J MED, V329, P1318, DOI 10.1056/NEJM199310283291807; HUANG Y, 1993, CANCER RES, V53, P1889; HUANG Y, 1992, CANCER RES, V52, P6525; Kelsell DP, 1996, HUM MOL GENET, V5, P857, DOI 10.1093/hmg/5.6.857; Kerangueven F, 1997, ONCOGENE, V14, P339, DOI 10.1038/sj.onc.1200818; KIRCHWEGER R, 1994, INT J CANCER, V56, P193, DOI 10.1002/ijc.2910560208; KNUDSON AG, 1993, P NATL ACAD SCI USA, V90, P10914, DOI 10.1073/pnas.90.23.10914; KRISHNADATH KK, 1995, EUR J GASTROEN HEPAT, V7, P81; MORI T, 1994, CANCER RES, V54, P1638; NAGAI MA, 1995, CANCER RES, V55, P112; NAKAMURA T, 1994, CANCER-AM CANCER SOC, V73, P1785, DOI 10.1002/1097-0142(19940401)73:7<1785::AID-CNCR2820730703>3.0.CO;2-0; NEIDERACHER D, 1997, GENES CHROM CANC, V18, P181; NESHAT K, 1994, GASTROENTEROLOGY, V106, P1589, DOI 10.1016/0016-5085(94)90415-4; Phelan CM, 1998, CANCER RES, V58, P1004; PHILLIPS N, 1993, INT J CANCER, V54, P85, DOI 10.1002/ijc.2910540115; PIERETTI M, 1995, HUM PATHOL, V26, P393, DOI 10.1016/0046-8177(95)90139-6; Plummer SJ, 1997, ONCOGENE, V14, P2339, DOI 10.1038/sj.onc.1201073; RISK JM, 1994, NAT GENET, V8, P319, DOI 10.1038/ng1294-319; SAITO H, 1993, CANCER RES, V53, P3382; SATO T, 1992, CANCER RES, V52, P1643; SAUNTER ER, 1995, J SURG ONCOL, V58, P269; SAXENA A, 1992, CANCER RES, V52, P6716; SCHULTZ DC, 1996, CANCER RES, V56, P2002; SEIZINGER BR, 1993, NAT GENET, V3, P97, DOI 10.1038/ng0293-97; Stein Hubert J., 1993, Dysphagia, V8, P276, DOI 10.1007/BF01354551; SWIFT A, 1995, BRIT J CANCER, V71, P995, DOI 10.1038/bjc.1995.191; VONBREVERN M, 1998, IN PRESS ONCOGENE; WALES MM, 1995, NAT MED, V1, P570, DOI 10.1038/nm0695-570; Wang TH, 1996, J FORMOS MED ASSOC, V95, P509; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; Wertheim I, 1996, ONCOGENE, V12, P2147; White GRM, 1996, BRIT J CANCER, V74, P863, DOI 10.1038/bjc.1996.449; WRIGHT TA, 1994, EUR J GASTROEN HEPAT, V6, P656, DOI 10.1097/00042737-199408000-00003	63	31	32	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 28	1999	18	4					987	993		10.1038/sj.onc.1202371	http://dx.doi.org/10.1038/sj.onc.1202371			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	165FT	10023674				2022-12-17	WOS:000078510600015
J	Ferrier, R; Nougarede, R; Doucet, S; Kahn-Perles, B; Imbert, J; Mathieu-Mahul, D				Ferrier, R; Nougarede, R; Doucet, S; Kahn-Perles, B; Imbert, J; Mathieu-Mahul, D			Physical interaction of the bHLH LYL1 protein and NF-kappa B1 p105	ONCOGENE			English	Article						bHLH; LYL1; NF-kappa b	NF-KAPPA-B; T-CELL LEUKEMIA; LOOP-HELIX PROTEINS; ACUTE LYMPHOBLASTIC-LEUKEMIA; DNA-BINDING PROPERTIES; SCL GENE-PRODUCT; TRANSGENIC MICE; ERYTHROID-DIFFERENTIATION; HEMATOPOIETIC LINEAGES; ENHANCER-BINDING	The LYL1 gene was first identified upon the molecular characterization of the t(7;9)(q35;p13) translocation associated with some human T-cell acute leukemias (T-ALLs), In adult tissues, LYL1 expression is restricted to hematopoietic cells with the notable exclusion of the T cell lineage. LYL1 encodes a basic helix-loop-helix (bHLH) protein highly related to TAL-1, whose activation is also associated with a high proportion of human T-ALLs. A yeast two-hybrid system was used to identify proteins that specifically interact with LYL1 and might mediate its activities. We found that p105, the precursor of NF-kappa B1 p50, was the major LYL1-interacting protein in this system. The association between LYL1 and p105 was confirmed both in vitro and in vivo in mammalian cells. Biochemical studies indicated that the interaction was mediated by the bHLH motif of LYL1 and the ankyrin-like motifs of p105. Ectopic expression of LYL1 in a human T cell line caused a significant decrease in NF-kappa B-dependent transcription, associated with a reduced level of NF-kappa B1 proteins.	Inst Genet Mol, UMR 5535, F-34293 Montpellier, France; Inst J Paoli I Calmettes, INSERM, U119, F-13009 Marseille, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Montpellier; Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Institut Paoli-Calmette (IPC)	Mathieu-Mahul, D (corresponding author), Inst Genet Mol, UMR 5535, 1919 Route Mende, F-34293 Montpellier, France.		Imbert, Jean/G-3248-2013; Imbert, Jean/AAG-1165-2020; Mathieu, Daniele/G-6092-2012; Kahn-Perlès, Brigitte/M-3513-2016	Imbert, Jean/0000-0002-0478-9593; Imbert, Jean/0000-0002-0478-9593; Kahn-Perlès, Brigitte/0000-0001-5673-5901				ABBADIE C, 1993, CELL, V75, P899, DOI 10.1016/0092-8674(93)90534-W; APLAN PD, 1992, EMBO J, V11, P4073, DOI 10.1002/j.1460-2075.1992.tb05500.x; BAER R, 1993, SEMIN CANCER BIOL, V4, P341; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Baichwal V. R., 1997, CURR BIOL, V7, P94; BAIN G, 1994, CELL, V79, P885, DOI 10.1016/0092-8674(94)90077-9; BASH RO, 1995, BLOOD, V86, P666, DOI 10.1182/blood.V86.2.666.bloodjournal862666; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BEGLEY CG, 1989, P NATL ACAD SCI USA, V86, P10128, DOI 10.1073/pnas.86.24.10128; BERNARD O, 1990, GENE CHROMOSOME CANC, V1, P194, DOI 10.1002/gcc.2870010303; BERNARD O, 1991, ONCOGENE, V6, P1477; Boothby MR, 1997, J EXP MED, V185, P1897, DOI 10.1084/jem.185.11.1897; BROWN L, 1990, EMBO J, V9, P3343, DOI 10.1002/j.1460-2075.1990.tb07535.x; Carrasco D, 1996, EMBO J, V15, P3640, DOI 10.1002/j.1460-2075.1996.tb00733.x; CHANG CC, 1995, MOL CELL BIOL, V15, P5180; CHEN Q, 1990, EMBO J, V9, P415, DOI 10.1002/j.1460-2075.1990.tb08126.x; Condorelli GL, 1997, MOL CELL BIOL, V17, P2954, DOI 10.1128/MCB.17.5.2954; Condorelli GL, 1996, CANCER RES, V56, P5113; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FINCH E, 1995, ADDICT RES, V3, P63, DOI 10.3109/16066359509005223; FUJIMOTO K, 1995, GENE, V165, P183, DOI 10.1016/0378-1119(95)00507-3; Gilmore TD, 1996, ONCOGENE, V13, P1367; GOLDFARB AN, 1992, BLOOD, V80, P2658; GREEN AR, 1991, ONCOGENE, V6, P475; GREEN AR, 1991, EMBO J, V10, P4153, DOI 10.1002/j.1460-2075.1991.tb04993.x; Grilli M, 1996, SCIENCE, V274, P1383, DOI 10.1126/science.274.5291.1383; Grimm S, 1996, J CELL BIOL, V134, P13, DOI 10.1083/jcb.134.1.13; HSU HL, 1994, P NATL ACAD SCI USA, V91, P3181, DOI 10.1073/pnas.91.8.3181; HSU HL, 1994, P NATL ACAD SCI USA, V91, P5947, DOI 10.1073/pnas.91.13.5947; HSU HL, 1991, MOL CELL BIOL, V11, P3037, DOI 10.1128/MCB.11.6.3037; HSU HL, 1994, MOL CELL BIOL, V14, P1256, DOI 10.1128/MCB.14.2.1256; KALLIANPUR AR, 1994, BLOOD, V83, P1200; KANG SM, 1992, SCIENCE, V256, P1452, DOI 10.1126/science.1604322; Kelliher MA, 1996, EMBO J, V15, P5160, DOI 10.1002/j.1460-2075.1996.tb00900.x; KLEIN ES, 1993, GENE DEV, V7, P55, DOI 10.1101/gad.7.1.55; LEROYVIARD K, 1995, EMBO J, V14, P2341, DOI 10.1002/j.1460-2075.1995.tb07229.x; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; MacKichan ML, 1996, J BIOL CHEM, V271, P6084, DOI 10.1074/jbc.271.11.6084; Mahajan MA, 1996, ONCOGENE, V12, P2343; MELLENTIN JD, 1989, CELL, V58, P77, DOI 10.1016/0092-8674(89)90404-2; MIGLIAZZA A, 1994, BLOOD, V84, P3850, DOI 10.1182/blood.V84.11.3850.bloodjournal84113850; Miyamoto A, 1996, MOL CELL BIOL, V16, P2394; MOUTHON MA, 1993, BLOOD, V81, P647; MUNOZ E, 1994, J VIROL, V68, P8035; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; Ono Y, 1997, J BIOL CHEM, V272, P4576, DOI 10.1074/jbc.272.7.4576; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; Porcher C, 1996, CELL, V86, P47, DOI 10.1016/S0092-8674(00)80076-8; PULFORD K, 1995, BLOOD, V85, P675, DOI 10.1182/blood.V85.3.675.bloodjournal853675; ROBB L, 1995, P NATL ACAD SCI USA, V92, P7075, DOI 10.1073/pnas.92.15.7075; Robb L, 1996, EMBO J, V15, P4123, DOI 10.1002/j.1460-2075.1996.tb00787.x; Rousset R, 1996, NATURE, V381, P328, DOI 10.1038/381328a0; SHIVDASANI RA, 1995, NATURE, V373, P432, DOI 10.1038/373432a0; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TEN RM, 1992, EMBO J, V11, P195, DOI 10.1002/j.1460-2075.1992.tb05042.x; VALGEARCHER VE, 1994, P NATL ACAD SCI USA, V91, P8617, DOI 10.1073/pnas.91.18.8617; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; VISVADER J, 1991, ONCOGENE, V6, P187; WADMAN I, 1994, EMBO J, V13, P4831, DOI 10.1002/j.1460-2075.1994.tb06809.x; Wadman IA, 1997, EMBO J, V16, P3145, DOI 10.1093/emboj/16.11.3145; XIA Y, 1994, ONCOGENE, V9, P1437; XIA Y, 1991, P NATL ACAD SCI USA, V88, P11416, DOI 10.1073/pnas.88.24.11416	62	31	33	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 28	1999	18	4					995	1005		10.1038/sj.onc.1202374	http://dx.doi.org/10.1038/sj.onc.1202374			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	165FT	10023675				2022-12-17	WOS:000078510600016
J	Kuhn, C; Muller, F; Melle, C; Nasheuer, HP; Janus, F; Deppert, W; Grosse, F				Kuhn, C; Muller, F; Melle, C; Nasheuer, HP; Janus, F; Deppert, W; Grosse, F			Surface plasmon resonance measurements reveal stable complex formation between p53 and DNA polymerase alpha	ONCOGENE			English	Article						DNA replication; DNA repair; protein-protein interactions; biomolecular interaction analysis (BIA); BIAcore	REPLICATION PROTEIN-A; SV40 T-ANTIGEN; SV40-TRANSFORMED CELLS; IN-VITRO; BINDING; DOMAINS; SUBUNIT; PRIMASE; EXPRESSION; ACTIVATION	Surface plasmon resonance measurements were used for detecting and quantifying protein-protein interactions detecting and quantifying protein-protein interactions between the tumorsuppressor protein p53, the SV40 large T antigen (T-ag), the cellular DNA polymerase alpha-primase complex (pol-prim), and the cellular single-strand DNA binding protein RPA, Highly purified p53 protein bound to immobilized T-ag with an apparent binding constant of 2 x 10(8) M-1. Binding of p53 to RPA was in the same order of magnitude with a binding constant of 4 x 10(8) M-1, when RPA was coupled to the sensor chip via its smallest subunit, and 1 x 10(8) M-1, when RPA,vas coupled via its p70 subunit, Furthermore, p53 bound human DNA polymerase a-primase complex (pol-prim) with a K-A value of 1 x 10(10) M-1. Both the p68 subunit and the p180 subunit of pol-prim could interact with p53 displaying binding constants of 2 x 10(10) M-1 and 5 x 10(9) M-1, respectively, Complex formation was also observed with a p180/p68 heterodimer, and again with a binding constant similar. Hence, there was no synergistic effect when p53 bound to higher order complexes of pol-prim. A truncated form of p53, consisting of amino acids 1-320, bound pol-prim by four orders of magnitude less efficiently, Therefore, an intact C-terminus of p53 seems to be important for efficient binding to pol-prim. It was also tried to measure complex formation between p53, pol-prim, and T-ag. However there was no evidence for the existence of a ternary complex consisting of T-ag, pol-prim, and p53.	Inst Mol Biotechnol, Abt Biochem, D-07745 Jena, Germany; Univ Hamburg, Heinrich Pette Inst Expt Virol & Immunol, Abt Tumorvirol, D-20251 Hamburg, Germany	Heinrich Pette Institute; University of Hamburg	Grosse, F (corresponding author), Inst Mol Biotechnol, Abt Biochem, Beutenbergstr 11, D-07745 Jena, Germany.			Melle, Christian/0000-0002-1870-9419; Nasheuer, Heinz Peter/0000-0002-9218-9079				Agarwal ML, 1998, J BIOL CHEM, V273, P1, DOI 10.1074/jbc.273.1.1; Anderson ME, 1997, MOL CELL BIOL, V17, P6255, DOI 10.1128/MCB.17.11.6255; Boulikas T, 1996, ANTICANCER RES, V16, P693; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAITHWAITE AW, 1987, NATURE, V329, P458, DOI 10.1038/329458a0; COLLINS KL, 1993, EMBO J, V12, P4555, DOI 10.1002/j.1460-2075.1993.tb06144.x; COX LS, 1995, BIOESSAYS, V17, P501, DOI 10.1002/bies.950170606; DORNREITER I, 1990, EMBO J, V9, P3329, DOI 10.1002/j.1460-2075.1990.tb07533.x; DORNREITER I, 1992, EMBO J, V11, P769, DOI 10.1002/j.1460-2075.1992.tb05110.x; DUTTA A, 1993, NATURE, V365, P79, DOI 10.1038/365079a0; Ford JM, 1997, J BIOL CHEM, V272, P28073, DOI 10.1074/jbc.272.44.28073; Fortunato EA, 1998, J VIROL, V72, P2033, DOI 10.1128/JVI.72.3.2033-2039.1998; GANNON J V, 1990, New Biologist, V2, P84; GANNON JV, 1987, NATURE, V329, P456, DOI 10.1038/329456a0; HE ZG, 1993, CELL, V73, P1223, DOI 10.1016/0092-8674(93)90650-F; HENRICKSEN LA, 1994, J BIOL CHEM, V269, P11121; HOCHULI E, 1987, J CHROMATOGR, V411, P371, DOI 10.1016/S0021-9673(00)93988-8; JAYARAMAN L, 1995, CELL, V81, P1021, DOI 10.1016/S0092-8674(05)80007-8; Kernohan NM, 1996, J BIOL CHEM, V271, P4954; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LEE S, 1995, CELL, V81, P1013, DOI 10.1016/S0092-8674(05)80006-6; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LI R, 1993, CELL, V73, P1207, DOI 10.1016/0092-8674(93)90649-B; Li R, 1998, MOL CELL BIOL, V18, P1296, DOI 10.1128/MCB.18.3.1296; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; MELENDY T, 1993, J BIOL CHEM, V268, P3389; MOAREFI IF, 1993, J VIROL, V67, P4992, DOI 10.1128/JVI.67.8.4992-5002.1993; Mummenbrauer T, 1996, CELL, V85, P1089, DOI 10.1016/S0092-8674(00)81309-4; SCHMIEG FI, 1988, VIROLOGY, V164, P132, DOI 10.1016/0042-6822(88)90628-9; STADLBAUER F, 1994, EUR J BIOCHEM, V222, P781, DOI 10.1111/j.1432-1033.1994.tb18925.x; Stadlbauer F, 1996, MOL CELL BIOL, V16, P94; TANAKA S, 1982, J BIOL CHEM, V257, P8386; Wang XW, 1997, J CELL PHYSIOL, V173, P247, DOI 10.1002/(SICI)1097-4652(199711)173:2<247::AID-JCP30>3.0.CO;2-A; WANG Y, 1993, GENE DEV, V7, P2575, DOI 10.1101/gad.7.12b.2575; Warbrick E, 1996, CURR BIOL, V6, P1057, DOI 10.1016/S0960-9822(02)70663-5; WILCOCK D, 1991, NATURE, V349, P429, DOI 10.1038/349429a0	37	31	31	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 21	1999	18	3					769	774		10.1038/sj.onc.1202327	http://dx.doi.org/10.1038/sj.onc.1202327			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	163FW	9989827				2022-12-17	WOS:000078394400022
J	Scotlandi, K; Manara, MC; Serra, M; Benini, S; Maurici, D; Caputo, A; De Giovanni, C; Lollini, PL; Nanni, P; Picci, P; Campanacci, M; Baldini, N				Scotlandi, K; Manara, MC; Serra, M; Benini, S; Maurici, D; Caputo, A; De Giovanni, C; Lollini, PL; Nanni, P; Picci, P; Campanacci, M; Baldini, N			The expression of P-glycoprotein is causally related to a less aggressive phenotype in human osteosarcoma cells	ONCOGENE			English	Article						MDR1 gene; tumorigenicity; metastasis; osteosarcoma; P-glycoprotein	MULTIDRUG-RESISTANCE; TUMOR PROGRESSION; COMPLEMENTARY-DNA; MDR PROTEIN; GENE; ESTABLISHMENT; AMPLIFICATION; BEHAVIOR; GROWTH; LINES	The relationship between P-glycoprotein expression and malignancy is controversial. We have recently found that, in osteosarcoma, multidrug resistance (MDR) is associated with a less aggressive behavior, both in vitro and in clinical settings. In this study, we evaluated whether P-glycoprotein overexpression has a cause-effect relationship with the reduced metastatic potential of MDR cells, or rather reflects a more complex phenotype, MDR1 gene-transfected osteosarcoma cell clones, showing different levels of P-glycoprotein expression, were analysed for their in vitro characteristics and their tumorigenic and metastatic ability in athymic mice. Apart from the different levels of P-glycoprotein, no significant change in the expression of surface antigens or in the differentiative features were observed in the MDR1 gene transfectants compared to the parental cell lines or control clones, obtained by transfection with neo gene alone. In contrast to controls, however, MDR1 transfectants showed a significantly lower ability to grow in semi-solid medium and were completely unable to grow and give lung metastases in athymic mice. These findings indicate that P-glycoprotein overexpression is causally associated with a low malignant potential of osteosarcoma cells, and open new insights on the role and functions of P-glycoprotein activity.	Istituti Ortopedici Rizzoli, Lab Ricerca Oncol, I-40136 Bologna, Italy; Univ Ferrara, Dipartimento Med Sperimentale & Diagnost, I-44100 Ferrara, Italy; Univ Bologna, Ist Cancerol, I-40126 Bologna, Italy	University of Ferrara; University of Bologna	Baldini, N (corresponding author), Istituti Ortopedici Rizzoli, Lab Ricerca Oncol, I-40136 Bologna, Italy.		Caputo, Antonella/ABE-7851-2020; Serra, Massimo/J-4878-2016; De Giovanni, Carla/B-1312-2009; Baldini, Nicola/J-4806-2016; Lollini, Pier Luigi/A-7644-2008; Scotlandi, Katia/J-9009-2016; Manara, Maria Cristina/K-3366-2018; Picci, Piero/J-5979-2016; BENINI, STEFANIA/D-1804-2019	Caputo, Antonella/0000-0002-1241-0299; Serra, Massimo/0000-0003-0742-1177; Baldini, Nicola/0000-0003-2228-3833; Lollini, Pier Luigi/0000-0003-1702-4108; Scotlandi, Katia/0000-0001-6114-9499; Manara, Maria Cristina/0000-0001-5686-720X; DE GIOVANNI, CARLA/0000-0003-4388-4988; Nanni, Patrizia/0000-0001-5319-0803; Picci, Piero/0000-0002-8519-4101; BENINI, STEFANIA/0000-0003-0958-9088				Baldini N, 1997, NAT MED, V3, P378, DOI 10.1038/nm0497-378; BALDINI N, 1995, NEW ENGL J MED, V333, P1380, DOI 10.1056/NEJM199511233332103; BASHIR I, 1994, INT J CANCER, V57, P719, DOI 10.1002/ijc.2910570519; BENARD J, 1989, INT J CANCER, V43, P471, DOI 10.1002/ijc.2910430322; BIEDLER JL, 1994, CANCER METAST REV, V13, P191, DOI 10.1007/BF00689636; BIEDLER JL, 1975, J NATL CANCER I, V55, P671, DOI 10.1093/jnci/55.3.671; BRADLEY G, 1992, CANCER RES, V52, P5154; BRADLEY G, 1994, CANCER METAST REV, V13, P223, DOI 10.1007/BF00689638; CHAN HSL, 1990, J CLIN ONCOL, V8, P689, DOI 10.1200/JCO.1990.8.4.689; CHAN HSL, 1991, NEW ENGL J MED, V325, P1608, DOI 10.1056/NEJM199112053252304; Chan HSL, 1997, J NATL CANCER I, V89, P1706, DOI 10.1093/jnci/89.22.1706; CHEN CJ, 1986, CELL, V47, P381, DOI 10.1016/0092-8674(86)90595-7; FOOTE SJ, 1989, CELL, V57, P921, DOI 10.1016/0092-8674(89)90330-9; GOLDSTEIN LJ, 1989, J NATL CANCER I, V81, P116, DOI 10.1093/jnci/81.2.116; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; HABU S, 1981, J IMMUNOL, V127, P34; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; Hoffman MM, 1996, J GEN PHYSIOL, V108, P295, DOI 10.1085/jgp.108.4.295; Kerbel R. S., 1993, P583; LINCKE CR, 1990, CANCER RES, V50, P1779; MIRSKI SEL, 1987, CANCER RES, V47, P2594; MURPHY LD, 1990, BIOCHEMISTRY-US, V29, P10351, DOI 10.1021/bi00497a009; PASTAN I, 1988, P NATL ACAD SCI USA, V85, P4486, DOI 10.1073/pnas.85.12.4486; PINEDO HM, 1995, NEW ENGL J MED, V333, P1417, DOI 10.1056/NEJM199511233332111; RIORDAN JR, 1989, SCIENCE, V245, P1066; RODAN SB, 1987, CANCER RES, V47, P4961; Roepe PD, 1996, J BIOENERG BIOMEMBR, V28, P541, DOI 10.1007/BF02110444; Scotlandi K, 1996, CANCER RES, V56, P2434; SERRA M, 1993, ANTICANCER RES, V13, P323; THOMAS PM, 1995, SCIENCE, V268, P426, DOI 10.1126/science.7716548; UEDA K, 1987, P NATL ACAD SCI USA, V84, P3004, DOI 10.1073/pnas.84.9.3004	31	31	32	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 21	1999	18	3					739	746		10.1038/sj.onc.1202330	http://dx.doi.org/10.1038/sj.onc.1202330			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	163FW	9989824				2022-12-17	WOS:000078394400019
J	Wang, XL; Uzawa, K; Imai, FL; Tanzawa, H				Wang, XL; Uzawa, K; Imai, FL; Tanzawa, H			Localization of a novel tumor suppressor gene associated with human oral cancer on chromosome 4q25	ONCOGENE			English	Article						chromosome 4; loss of heterozygosity (LOH); oral carcinoma; tumor suppressor gene (TSG)	SQUAMOUS-CELL CARCINOMA; LONG ARM; ALLELOTYPE ANALYSIS; CERVICAL-CARCINOMA; BLADDER-CARCINOMA; HEAD; HETEROZYGOSITY; DELETION; REGIONS	Recent cytogenetic and molecular studies with highly polymorphic microsatellite markers have implicated allele loss involving chromosome 4 in several human cancers, which suggests the presence of multiple tumor suppressor gene (TSG) loci, However, there has been no detailed analysis of loss of heterozygosity (LOH) on chromosome 4 in oral squamous cell carcinoma (OSCC). To determine the location of a putative TSG associated with OSCC on chromosome 4, polymerase chain reaction (PCR) analysis of microsatellite polymorphisms corresponding to 17 loci was performed to screen 32 patients with OSCC. LOH was observed in the majority of the tumors (75%) in at least one of the loci. The loci on the long arm exhibited a significantly higher frequency of deletions (66%) than those of the short arm (25%). Among the loci tested, frequent LOH was centered at D4S1573 on 4q25, which represents a region of about 4 centimorgans (cM), However, no commonly deleted regions were found on the short arm of the chromosome, We detected microsatellite instability (MI) in 31% of the cases. MI was also observed more frequently on the long arm (28%) than the short arm (6%), Thus, our data indicate that alterations of chromosome 4 regions, especially the long arm, are associated with OSCC tumorigenesis and that the 4q25 region may harbor at least one putative TSG.	Chiba Univ, Sch Med, Dept Oral Surg, Chuo Ku, Chiba 2608670, Japan	Chiba University	Tanzawa, H (corresponding author), Chiba Univ, Sch Med, Dept Oral Surg, Chuo Ku, 1-8-1 Inohana, Chiba 2608670, Japan.			Uzawa, Katsuhiro/0000-0002-7036-0859				AHSEE KW, 1994, CANCER RES, V54, P1617; Chou YHW, 1998, CANCER LETT, V123, P1, DOI 10.1016/S0304-3835(97)00276-0; ELDER PA, 1994, ONCOGENE, V9, P3433; ELNAGGAR AK, 1995, CANCER RES, V55, P2656; GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; Hammoud ZT, 1996, CANCER RES, V56, P4499; Hampton GM, 1996, P NATL ACAD SCI USA, V93, P6704, DOI 10.1073/pnas.93.13.6704; Larson AA, 1996, CANCER RES, V56, P1426; Leon M, 1996, ANTICANCER RES, V16, P349; MARSHALL CJ, 1991, CELL, V64, P313, DOI 10.1016/0092-8674(91)90641-B; MITRA AB, 1994, CANCER RES, V54, P4481; NAWROZ H, 1994, CANCER RES, V54, P1152; Ohta M, 1996, CELL, V84, P587, DOI 10.1016/S0092-8674(00)81034-X; PARKIN DM, 1993, INT J CANCER, V54, P594, DOI 10.1002/ijc.2910540413; Pershouse MA, 1997, ONCOGENE, V14, P369, DOI 10.1038/sj.onc.1200836; POLASCIK TJ, 1995, CANCER RES, V55, P5396; Shridhar V, 1997, ONCOGENE, V15, P2727, DOI 10.1038/sj.onc.1201448; Uzawa K, 1996, INT J CANCER, V67, P510, DOI 10.1002/(SICI)1097-0215(19960807)67:4<510::AID-IJC8>3.3.CO;2-R; VANDYKE DL, 1994, GENE CHROMOSOME CANC, V9, P192, DOI 10.1002/gcc.2870090308; Wang XL, 1998, INT J CANCER, V75, P671, DOI 10.1002/(SICI)1097-0215(19980302)75:5<671::AID-IJC2>3.3.CO;2-6; Wang XL, 1997, INT J ONCOL, V10, P535; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741	22	31	33	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 21	1999	18	3					823	825		10.1038/sj.onc.1202318	http://dx.doi.org/10.1038/sj.onc.1202318			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	163FW	9989834				2022-12-17	WOS:000078394400029
J	Penna, D; Schmidt, A; Beermann, F				Penna, D; Schmidt, A; Beermann, F			Tumors of the retinal pigment epithelium metastasize to inguinal lymph nodes and spleen in tyrosinase-related protein 1 SV40 T antigen transgenic mice	ONCOGENE			English	Article						metastasis; pigmentation; retinal pigment epithelium; transgenic mice; TRP-1; tyrosinase	MALIGNANT SKIN MELANOMA; FUSION GENE; MOUSE; PROMOTER; EXPRESSION; ADENOCARCINOMA; MELANOCYTES; HYPERPLASIA; ACTIVATION; SURVIVAL	The pigment epithelium of the retina (RPE) is derived from the optic cup and is essential for function and development of the eye. We produced a transgenic mouse line that expresses simian virus (SV40) transforming sequences under control of the 1.4 kb tyrosinase-related protein 1 (TRP-1) promoter, targeting expression of T antigen (Tag) to the RPE. In transgenic embryos, RPE cells proliferated in the anterior part of the eye and near the optic nerve. This resulted in formation of tumors, which were pigmented and of epithelial origin. In 3 months-old mice, pigmented cells were detected in spleen and inguinal lymph nodes. In spleen, tyrosinase, TRP-1 and SV40 Tag were expressed and tyrosinase was enzymatically active, Pigmented regions were positive for an epithelial marker, cytokeratin. Cell lines were established from tumor and metastases and kept in culture for more than 2 months. These were pigmented, and maintained expression of tyrosinase, TRP-1, cytokeratin and SV40 Tag. This demonstrates that RPE tumor cells metastasize to lymph node and spleen. In conclusion, the metastasis from TRP-1/Tag RPE tumors towards spleen and lymph nodes serves as potential tool to investigate biology and metastasis of tumors derived from the pigment epithelium.	Swiss Inst Expt Canc Res, CH-1066 Epalinges, Switzerland	Swiss Institute Experimental Cancer Research	Beermann, F (corresponding author), Swiss Inst Expt Canc Res, Chemin Boveresses 155, CH-1066 Epalinges, Switzerland.							ALBERT DM, 1972, ARCH OPHTHALMOL-CHIC, V88, P70; ANAND R, 1994, INVEST OPHTH VIS SCI, V35, P3533; BEERMANN F, 1993, MECH DEVELOP, V42, P59, DOI 10.1016/0925-4773(93)90098-I; BEERMANN F, 1992, P NATL ACAD SCI USA, V89, P2809, DOI 10.1073/pnas.89.7.2809; BRADL M, 1991, P NATL ACAD SCI USA, V88, P164, DOI 10.1073/pnas.88.1.164; CABLE J, 1995, MECH DEVELOP, V50, P139, DOI 10.1016/0925-4773(94)00331-G; Carbone M, 1997, ONCOGENE, V15, P1877, DOI 10.1038/sj.onc.1201375; CHAR D, 1994, MALIGNANT MELANOMA, P343; Chin L, 1997, GENE DEV, V11, P2822, DOI 10.1101/gad.11.21.2822; delMarmol V, 1996, FEBS LETT, V381, P165, DOI 10.1016/0014-5793(96)00109-3; Ewald D, 1996, SCIENCE, V273, P1384, DOI 10.1126/science.273.5280.1384; FAN JT, 1995, AM J OPHTHALMOL, V119, P243, DOI 10.1016/S0002-9394(14)73887-5; FIDLER IJ, 1990, CANCER RES, V50, P6130; FIERS W, 1978, NATURE, V273, P113, DOI 10.1038/273113a0; Frayer W C, 1966, Trans Am Ophthalmol Soc, V64, P586; GARNER A, 1970, BRIT J OPHTHALMOL, V54, P715, DOI 10.1136/bjo.54.11.715; Greer CH, 1952, T OPHTHAL SOC UK, V72, P265; HUDSPETH AJ, 1973, INVEST OPHTH VISUAL, V12, P354; IWAMOTO T, 1991, EMBO J, V10, P3167, DOI 10.1002/j.1460-2075.1991.tb04878.x; JACKSON IJ, 1991, NUCLEIC ACIDS RES, V19, P3799, DOI 10.1093/nar/19.14.3799; KLEINSZANTO A, 1991, P NATL ACAD SCI USA, V88, P169, DOI 10.1073/pnas.88.1.169; LOEFFLER KU, 1996, GRAEFES ARCH CLIN EX, V234, P70; LOWINGS P, 1992, MOL CELL BIOL, V12, P3653, DOI 10.1128/MCB.12.8.3653; MACARTHUR H, 1984, J VIROL, V52, P483, DOI 10.1128/JVI.52.2.483-491.1984; MCKAY BS, 1994, EXP CELL RES, V213, P85, DOI 10.1006/excr.1994.1176; MINTZ B, 1992, P NATL ACAD SCI USA, V89, P11421, DOI 10.1073/pnas.89.23.11421; MINTZ B, 1993, P NATL ACAD SCI USA, V90, P8822, DOI 10.1073/pnas.90.19.8822; MINTZ B, 1993, P NATL ACAD SCI USA, V90, P8817, DOI 10.1073/pnas.90.19.8817; POWELL MB, 1995, MOL CARCINOGEN, V12, P82, DOI 10.1002/mc.2940120205; RAYMOND SM, 1995, CURR BIOL, V5, P1286, DOI 10.1016/S0960-9822(95)00255-7; REICHMANN E, 1992, CELL, V71, P1103, DOI 10.1016/S0092-8674(05)80060-1; ROBINSON W, 1987, BASIC CLIN ASPECTS M, P155; SCHMIDT A, 1994, P NATL ACAD SCI USA, V91, P4756, DOI 10.1073/pnas.91.11.4756; SHIELDS JA, 1994, ARCH OPHTHALMOL-CHIC, V112, P650, DOI 10.1001/archopht.1994.01090170094029; SINGH S, 1994, EPITHELIAL CELL BIOL, V3, P79; STEEL KP, 1992, DEVELOPMENT, V115, P1111; STEINBERG RH, 1979, RETINA PIGMENTED EPI, V1, P32; Tief K, 1997, PIGM CELL RES, V10, P153; Tief K, 1996, EUR J BIOCHEM, V241, P12, DOI 10.1111/j.1432-1033.1996.0012t.x; Tief K, 1996, DEV DYNAM, V205, P445, DOI 10.1002/(SICI)1097-0177(199604)205:4<445::AID-AJA8>3.0.CO;2-I; Zhao SL, 1997, INT REV CYTOL, V171, P225; Zhu H, 1998, J INVEST DERMATOL, V110, P247, DOI 10.1046/j.1523-1747.1998.00133.x	42	31	31	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 19	1998	17	20					2601	2607		10.1038/sj.onc.1202196	http://dx.doi.org/10.1038/sj.onc.1202196			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	139YN	9840923				2022-12-17	WOS:000077058900007
J	Rieger, J; Stander, M; Loschmann, PA; Heneka, M; Dichgans, J; Klockgether, T; Weller, M				Rieger, J; Stander, M; Loschmann, PA; Heneka, M; Dichgans, J; Klockgether, T; Weller, M			Synthesis and biological effects of NO in malignant glioma cells: modulation by cytokines including CD95L and TGF-beta, dexamethasone, and p53 gene transfer	ONCOGENE			English	Article						nitric oxide; glioma; CD 95 ligand; p53	NITRIC-OXIDE SYNTHASE; WILD-TYPE P53; ANTIBODY-MEDIATED APOPTOSIS; TUMOR-NECROSIS-FACTOR; TATA-BINDING PROTEIN; GROWTH-FACTOR-BETA; GLIAL-CELLS; ENDOTHELIAL-CELLS; BCL-2 EXPRESSION; L-ARGININE	Nitric oxide (NO) is thought to play an important role in neurotransmission, inflammation, and regulation of cell death in the mammalian brain. Here, we examined the synthesis and biological effects of NO in human malignant glioma cells. Exposure to cytokines such as interferon (IFN)-gamma, tumor necrosis factor (TNF)-alpha or interleukin (IL)-1 beta and lipopolysaccharide (LPS) induced NO synthesis in rat C6 and A172 human glioma cells, but not in LN-229, T98G or LN-18 human malignant glioma cells. Induced release of NO involved enhanced expression of inducible NO synthase (iNOS). Failure to detect NO release in the latter cell lines was not overcome by neutralization of endogenous TGF-beta or by coexposure to cytokines, LPS, and antioxidants. Apoptosis induced by CD95 ligand (CD95L) did not involve NO formation. Neither NOS inhibitors nor NO donators modulated CD95L-induced apoptosis. Dexamethasone (DEX)-mediated protection of glioma cells from CD95L-induced apoptosis was also independent of DEX effects on NO metabolism. DEX inhibited not only cytokine/ LPS-evoked NO release but also attenuated the toxicity of NO in three of five cell lines. Forced expression of temperature-sensitive p53 val(135) in C6 cells in either mutant or wild-type conformation inhibited cytokine/LPS-induced NO synthesis. Further, accumulation of p53 in both mutant or wild-type conformation protected glioma cells from the toxicity of exogenous NO, consistent with a gain of p53 function associated with p53 accumulation. We conclude that resistance to NO-dependent immune defense mechanisms may contribute to the malignant progression of human cancers with p53 alterations, notably those associated with the accumulation of mutant p53 protein.	Univ Tubingen, Sch Med, Dept Neurol, Mol Neurooncol Lab, D-72074 Tubingen, Germany; Univ Tubingen, Sch Med, Dept Neurol, Neuropharmacol Lab, D-72074 Tubingen, Germany	Eberhard Karls University of Tubingen; Eberhard Karls University of Tubingen	Weller, M (corresponding author), Univ Tubingen, Sch Med, Dept Neurol, Mol Neurooncol Lab, D-72074 Tubingen, Germany.		Heneka, Michael/E-8072-2015	Heneka, Michael/0000-0003-4996-1630; Weller, Michael/0000-0002-1748-174X				ALBINA JE, 1993, J IMMUNOL, V150, P5080; ASAI A, 1994, J NEURO-ONCOL, V19, P259, DOI 10.1007/BF01053280; BERNATOWICZ A, 1995, J NEUROIMMUNOL, V60, P53, DOI 10.1016/0165-5728(95)00053-5; BIANCO FJ, 1995, AM J PATHOL, V146, P75; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; Calmels S, 1997, CANCER RES, V57, P3365; COBBS CS, 1995, CANCER RES, V55, P727; Dimmeler S, 1997, J EXP MED, V185, P601, DOI 10.1084/jem.185.4.601; Ellie E, 1995, NEUROREPORT, V7, P294, DOI 10.1097/00001756-199512290-00070; EWEN ME, 1995, GENE DEV, V9, P204, DOI 10.1101/gad.9.2.204; FEHSEL K, 1995, J IMMUNOL, V155, P2858; FEINSTEIN DL, 1994, J NEUROCHEM, V62, P315; Forrester K, 1996, P NATL ACAD SCI USA, V93, P2442, DOI 10.1073/pnas.93.6.2442; FUJISAWA H, 1995, J NEUROCHEM, V64, P85; Fukuo K, 1996, HYPERTENSION, V27, P823, DOI 10.1161/01.HYP.27.3.823; HARVEY M, 1995, NAT GENET, V9, P305, DOI 10.1038/ng0395-305; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; Ho YS, 1996, MOL CARCINOGEN, V16, P20, DOI 10.1002/(SICI)1098-2744(199605)16:1<20::AID-MC4>3.3.CO;2-I; HORIKOSHI N, 1995, MOL CELL BIOL, V15, P227, DOI 10.1128/MCB.15.1.227; Kawase M, 1996, BRAIN RES, V738, P319, DOI 10.1016/S0006-8993(96)00924-9; KILBOURN RG, 1990, J NATL CANCER I, V82, P772, DOI 10.1093/jnci/82.9.772; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LIU X, 1993, MOL CELL BIOL, V13, P3291, DOI 10.1128/MCB.13.6.3291; MARLETTA MA, 1988, BIOCHEMISTRY-US, V27, P8706, DOI 10.1021/bi00424a003; MESSMER UK, 1994, FEBS LETT, V355, P23; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MURATA J, 1995, INT J CANCER, V62, P743, DOI 10.1002/ijc.2910620616; MURPHY S, 1993, TRENDS NEUROSCI, V16, P323, DOI 10.1016/0166-2236(93)90109-Y; RADOMSKI MW, 1990, P NATL ACAD SCI USA, V87, P10043, DOI 10.1073/pnas.87.24.10043; RENSINGEHL A, 1995, EUR J IMMUNOL, V25, P2253, DOI 10.1002/eji.1830250821; Roth W, 1997, CANCER IMMUNOL IMMUN, V44, P55, DOI 10.1007/s002620050355; RYAN JJ, 1994, P NATL ACAD SCI USA, V91, P5878, DOI 10.1073/pnas.91.13.5878; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SIMMONS ML, 1993, EUR J NEUROSCI, V5, P825, DOI 10.1111/j.1460-9568.1993.tb00934.x; SIMMONS ML, 1992, J NEUROCHEM, V59, P597; STUEHR DJ, 1989, J EXP MED, V169, P1543, DOI 10.1084/jem.169.5.1543; TREPEL M, 1997, J NEUROONCOL; TREPEL M, 1997, IN PRESS LEUKEMIA; TREPEL M, 1996, J NEUROONCOL, V30, P95; VAN MEIR EG, 1994, CANCER RES, V54, P649; VIGNE P, 1993, BRAIN RES, V606, P332, DOI 10.1016/0006-8993(93)91003-B; VODOVOTZ Y, 1993, J EXP MED, V178, P605, DOI 10.1084/jem.178.2.605; Wagenknecht B, 1997, FEBS LETT, V409, P17, DOI 10.1016/S0014-5793(97)00468-7; WAGENKNECHT B, 1997, CELL PHYSIOL BIOCHEM, V19, P459; Weller M, 1997, NEUROL RES, V19, P459; Weller M, 1995, BRAIN RES REV, V21, P128, DOI 10.1016/0165-0173(95)00010-0; Weller M, 1997, INT J CANCER, V73, P707, DOI 10.1002/(SICI)1097-0215(19971127)73:5<707::AID-IJC16>3.3.CO;2-5; WELLER M, 1994, J CLIN INVEST, V94, P954, DOI 10.1172/JCI117462; Weller M, 1997, NEUROLOGY, V48, P1704, DOI 10.1212/WNL.48.6.1704; WELLER M, 1995, CANCER RES, V55, P2936; WELLER M, 1995, J CLIN INVEST, V95, P2633, DOI 10.1172/JCI117965; WU CC, 1995, P NATL ACAD SCI USA, V92, P3473, DOI 10.1073/pnas.92.8.3473; YONEHARA S, 1989, J EXP MED, V169, P1747, DOI 10.1084/jem.169.5.1747	53	31	32	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 5	1998	17	18					2323	2332		10.1038/sj.onc.1202154	http://dx.doi.org/10.1038/sj.onc.1202154			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	134BQ	9811463				2022-12-17	WOS:000076723300006
J	Oh, Y; Proctor, ML; Fan, YH; Su, LK; Hong, WK; Fong, KM; Sekido, YS; Gazdar, DF; Minna, JD; Mao, L				Oh, Y; Proctor, ML; Fan, YH; Su, LK; Hong, WK; Fong, KM; Sekido, YS; Gazdar, DF; Minna, JD; Mao, L			TSG101 is not mutated in lung cancer but a shortened transcript is frequently expressed in small cell lung cancer	ONCOGENE			English	Article						non-small cell lung cancer; tumor suppressor	HUMAN BREAST-CANCER; P53 MUTATIONS; FHIT GENE; HETEROZYGOSITY; TUMORS; LINES; PHOSPHOPROTEIN; ONCOPROTEIN-18; CHROMOSOME-11; ABNORMALITIES	TSG101 is a candidate tumor suppressor gene whose deletion in NIH3T3 cells leads to spontaneous lung metastases in nude mice. Aberrant transcripts of TSG101 have been identified in 47% of primary breast carcinomas, without evidence of intragenic deletions at the TSG101 locus on 11p15, To investigate the possible role of TSG101 in lung cancer, which often shows 11p allele loss, we performed transcript analysis and mutational analysis of TSG101 in lung cancer cell lines. Reverse transcriptase RT-PCR and Northern analysis detected a common TSG101 transcript, shortened because of an internal deletion, which was expressed simultaneously with the wild-type transcript in 89% of small cell lung cancer (SCLC) lines. In contrast, the wild-type transcript was expressed alone in normal tissues, primary non-small cell lung cancer (NSCLC) specimens, and the majority of NSCLC cell lines. Sequence of the shortened SCLC transcript was identical to that of the most common aberrant transcript identified in breast cancer, consisting of a deletion of exons 2-4 and part of 1 and 5, Southern analysis of SCLC lines expressing the shortened transcript did not detect any intragenic deletions, Single strand conformational polymorphism (SSCP) analysis and direct sequencing of TSG101 cDNAs also identified no mutations or deletions. These results suggest that TSG101 is not mutated in lung cancer but that aberrant splicing of TSG101 occurs in SCLC.	Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Surg, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75235 USA; Univ Texas, MD Anderson Cancer Ctr, Dept Tumor Biol, Houston, TX 77030 USA; Univ Texas, MD Anderson Cancer Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX 77030 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Minna, JD (corresponding author), Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.		Mao, Li/C-7570-2011; Fong, Kwun M/G-6369-2010	Mao, Li/0000-0001-7263-3358; Fong, Kwun/0000-0002-6507-1403; Sekido, Yoshitaka/0000-0002-2428-3848	NCI NIH HHS [5T32CA66187-03, CA 16672, P50 CA70907] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA066187, P50CA070907, P30CA016672] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams MD, 1996, CURR OPIN CELL BIOL, V8, P331, DOI 10.1016/S0955-0674(96)80006-8; BEPLER G, 1994, P NATL ACAD SCI USA, V91, P5513, DOI 10.1073/pnas.91.12.5513; COOK RM, 1993, CURR PROB CANCER, V17, P71; DAMICO D, 1992, ONCOGENE, V7, P339; DEVESA SS, 1991, CANCER EPIDEM BIOMAR, V1, P29; DiPaolo G, 1996, J CELL BIOL, V133, P1383, DOI 10.1083/jcb.133.6.1383; DOYE V, 1990, J BIOL CHEM, V265, P11650; Druck T, 1997, CANCER RES, V57, P504; FONG KM, 1994, GENE CHROMOSOME CANC, V10, P183, DOI 10.1002/gcc.2870100306; Fong KM, 1997, CANCER RES, V57, P2256; GRATIOTDEANS J, 1992, J CLIN INVEST, V90, P1576, DOI 10.1172/JCI116026; GUDMUNDSSON J, 1995, BRIT J CANCER, V72, P696, DOI 10.1038/bjc.1995.396; HAILAT N, 1990, ONCOGENE, V5, P1615; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; IIZUKA M, 1995, GENE CHROMOSOME CANC, V13, P40; Kim SK, 1997, CANCER RES, V57, P400; Koonin EV, 1997, NAT GENET, V16, P330, DOI 10.1038/ng0897-330; KOPPEL J, 1993, FEBS LETT, V331, P65, DOI 10.1016/0014-5793(93)80298-9; Kornblihtt AR, 1996, FASEB J, V10, P248, DOI 10.1096/fasebj.10.2.8641558; Lee MP, 1997, CANCER RES, V57, P3131; Li LM, 1996, CELL, V85, P319, DOI 10.1016/S0092-8674(00)81111-3; Li LM, 1997, CELL, V88, P143, DOI 10.1016/S0092-8674(00)81866-8; Liang H., 1997, Proceedings of the American Association for Cancer Research Annual Meeting, V38, P68; MAO L, 1994, CANCER RES, V54, P1634; Mao L, 1996, CANCER RES, V56, P5128; MARKLUND U, 1993, J BIOL CHEM, V268, P15039; MATTHEWS MJ, 1973, CANCER CHEMOTH REP 3, V4, P63; MILLER CW, 1992, CANCER RES, V52, P1695; Parker SL, 1996, CA-CANCER J CLIN, V46, P5, DOI 10.3322/canjclin.46.1.5; Petersen I, 1997, BRIT J CANCER, V75, P79, DOI 10.1038/bjc.1997.13; Roberts GC, 1996, EMBO J, V15, P6301, DOI 10.1002/j.1460-2075.1996.tb01020.x; ROOS G, 1993, LEUKEMIA, V7, P1538; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; RYGAARD K, 1992, CANCER RES, V50, P5312; Sigalas I, 1996, NAT MED, V2, P912, DOI 10.1038/nm0896-912; Sozzi G, 1996, CELL, V85, P17, DOI 10.1016/S0092-8674(00)81078-8; Steiner P, 1997, NAT GENET, V16, P332, DOI 10.1038/ng0897-332; Sundareshan TS, 1996, CANCER GENET CYTOGEN, V91, P53, DOI 10.1016/S0165-4608(96)00031-3; VIRMANI AK, 1998, IN PRESS GEN CHROM C; West CA, 1996, BONE, V19, P41, DOI 10.1016/8756-3282(96)00105-6; WINQVIST R, 1995, CANCER RES, V55, P2660	41	31	32	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 3	1998	17	9					1141	1148		10.1038/sj.onc.1202029	http://dx.doi.org/10.1038/sj.onc.1202029			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	114FL	9764824				2022-12-17	WOS:000075598400009
J	Yuan, J; Tirabassi, RS; Bush, AB; Cole, MD				Yuan, J; Tirabassi, RS; Bush, AB; Cole, MD			The C-elegans MDL-1 and MXL-1 proteins can functionally substitute for vertebrate MAD and MAX	ONCOGENE			English	Article						C-elegans; MAD; MAX	NEMATODE CAENORHABDITIS-ELEGANS; TRANSCRIPTIONAL REPRESSION; HISTONE DEACETYLASE; MYC-MAX; ONCOGENIC ACTIVITY; CELL-GROWTH; N-COR; COMPLEX; TRANSFORMATION; GENE	The genes of the myc/max/mad family play an important role in controlling cell proliferation and differentiation. We have identified the first homologues of the mad and max genes in the nematode C. elegans, which we have named mdl-1 and mxl-1 respectively. Like the vertebrate MAD proteins, MDL-1 binds an E-box DNA sequence (CACGTG) when dimerized with MXL-1. However, unlike vertebrate MAX, MXL-1 can not form homodimers and bind to DNA alone. Promoter fusions to a GFP reporter suggest that these genes are coexpressed in posterior intestinal and post-mitotic neuronal cells during larval development. The coexpression in the posterior intestinal cells occurs before their final division at the end of the L1 stage and persists afterwards, demonstrating that mad and max expression can be correlated directly to the cell cycle state of an individual cell type. These data also show that mxl-1 is an obligate partner for mdl-1 in vivo and in vitro and indicate that these genes may play an important role in post-embryonic development. Finally, MDL-1 can suppress activated c-MYC/RAS-induced focus formation in a rat embryo fibroblast transformation assay. Like the vertebrate MAD protein, MDL-1 activity in suppressing transformation is dependent on a functional SIN3 interaction domain.	Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA	Princeton University	Cole, MD (corresponding author), Merck & Co Inc, Dept Bioinformat, POB 2000,RY80A-1, Rahway, NJ 07065 USA.				NCI NIH HHS [CA55248] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA055248] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; AMATI B, 1993, CELL, V72, P233, DOI 10.1016/0092-8674(93)90663-B; AMBROS V, 1984, SCIENCE, V226, P409, DOI 10.1126/science.6494891; ARMAND P, 1994, MOL CELL BIOL, V13, P383; AYER DE, 1995, CELL, V80, P767, DOI 10.1016/0092-8674(95)90355-0; AYER DE, 1993, GENE DEV, V7, P2110, DOI 10.1101/gad.7.11.2110; AYER DE, 1993, CELL, V72, P1; BERBERICH S, 1992, ONCOGENE, V7, P775; BERBERICH SJ, 1992, GENE DEV, V6, P166, DOI 10.1101/gad.6.2.166; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BROUGH DE, 1995, MOL CELL BIOL, V15, P1536; CERNI C, 1995, ONCOGENE, V11, P587; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; EAGLE LR, 1995, NAT GENET, V9, P249, DOI 10.1038/ng0395-249; EVAN GI, 1993, CURR OPIN GENET DEV, V3, P44, DOI 10.1016/S0959-437X(05)80339-9; FIRE A, 1986, EMBO J, V5, P2673, DOI 10.1002/j.1460-2075.1986.tb04550.x; Gallant P, 1996, SCIENCE, V274, P1523, DOI 10.1126/science.274.5292.1523; Hassig CA, 1997, CELL, V89, P341, DOI 10.1016/S0092-8674(00)80214-7; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; HURLIN PJ, 1995, EMBO J, V14, P5646, DOI 10.1002/j.1460-2075.1995.tb00252.x; Hurlin PJ, 1997, GENE DEV, V11, P44, DOI 10.1101/gad.11.1.44; Kadosh D, 1997, CELL, V89, P365, DOI 10.1016/S0092-8674(00)80217-2; Kipreos ET, 1996, CELL, V85, P829, DOI 10.1016/S0092-8674(00)81267-2; KOSKINEN PJ, 1994, CELL GROWTH DIFFER, V5, P313; KOSKINEN PJ, 1995, CELL GROWTH DIFFER, V6, P623; KRAUSE M, 1987, CELL, V49, P753, DOI 10.1016/0092-8674(87)90613-1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; LAHOZ EG, 1994, P NATL ACAD SCI USA, V91, P5503, DOI 10.1073/pnas.91.12.5503; MADURO M, 1995, GENETICS, V141, P977; Meroni G, 1997, EMBO J, V16, P2892, DOI 10.1093/emboj/16.10.2892; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; RUVKUN G, 1989, NATURE, V338, P313, DOI 10.1038/338313a0; SchreiberAgus N, 1997, P NATL ACAD SCI USA, V94, P1235, DOI 10.1073/pnas.94.4.1235; SCHREIBERAGUS N, 1995, CELL, V80, P777, DOI 10.1016/0092-8674(95)90356-9; SCHREIBERAGUS N, 1994, ONCOGENE, V9, P3167; SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012-1606(77)90158-0; SULSTON JE, 1983, DEV BIOL, V100, P64, DOI 10.1016/0012-1606(83)90201-4; Wood WB., 1988, NEMATODE CAENORHABDI; WORMAN HJ, 1988, P NATL ACAD SCI USA, V85, P8531, DOI 10.1073/pnas.85.22.8531; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A; Zhang Y, 1997, CELL, V89, P357, DOI 10.1016/S0092-8674(00)80216-0	44	31	39	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 3	1998	17	9					1109	1118		10.1038/sj.onc.1202036	http://dx.doi.org/10.1038/sj.onc.1202036			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	114FL	9764821				2022-12-17	WOS:000075598400006
J	Santos, J; Herranz, M; Perez de Castro, I; Pellicer, A; Fernandez-Piqueras, J				Santos, J; Herranz, M; Perez de Castro, I; Pellicer, A; Fernandez-Piqueras, J			A new candidate site for a tumor suppressor gene involved in mouse thymic lymphomagenesis is located on the distal part of chromosome 4	ONCOGENE			English	Article						mouse thymic lymphomas; gamma-irradiation; loss of heterozygosity; microsatellites; distal chromosome 4 region; tumor suppressor genes	ALLELIC LOSS; INTESTINAL NEOPLASIA; MAJOR MODIFIER; HETEROZYGOSITY; NEUROBLASTOMA; ABNORMALITIES; DELETION; REGION; 1P36; PHEOCHROMOCYTOMAS	In a previous work we provided preliminary evidence of the existence of a putative tumor suppressor gene region on the distal part of chromosome 4 in gamma-radiation-induced T-cell lymphomas of (C57BL/6JxRF/J) Fl hybrid mice. This region, named as TLSR2 (Thymic Lymphoma Suppressor Region 2), was located centered at D4Mit54. A more detailed allelotype analysis in the mentioned tumors with new informative microsatellites on distal chromosome 4 region, as well as in thymic lymphomas induced with gamma-rays in Fl hybrids generated from reciprocal crosses between the strains C57BL/6J and BALB/cJ, and having in mind the new map position of D4Mit205b, allowed us to confirm the existence of TLSR2 and to define it more precisely as centered at D4Mit205b, In addition, we identified a new candidate region, named as TLSR3 (Thymic Lymphoma Suppressor Re,Region 3), located between the Mom-l locus and D4Mit68, as the site of another putative tumor suppressor region involved in thymic lymphomagenesis.	Univ Autonoma Madrid, Fac Ciencias, Lab Genet Mol Humana, Dept Biol, E-28049 Madrid, Spain; NYU, Med Ctr, Kaplan Comprehens Canc Ctr, New York, NY 10016 USA	Autonomous University of Madrid; New York University	Fernandez-Piqueras, J (corresponding author), Univ Autonoma Madrid, Fac Ciencias, Lab Genet Mol Humana, Dept Biol, E-28049 Madrid, Spain.		MARTINEZ, ANTONIO PELLICER/C-4832-2015; de Castro, Ignacio Pérez/A-6260-2012; Santos, Javier/ABF-5755-2021	de Castro, Ignacio Pérez/0000-0002-8822-8274; Santos, Javier/0000-0002-4168-6251; Pellicer, Angel/0000-0002-5062-0692				ABBOTT CM, 1994, MAMM GENOME, V5, pS51; BARDI G, 1993, CANCER RES, V53, P1895; BELLO MJ, 1994, INT J CANCER, V57, P172, DOI 10.1002/ijc.2910570207; BELLO MJ, 1994, GENE CHROMOSOME CANC, V9, P296, DOI 10.1002/gcc.2870090411; BIECHE I, 1994, CANCER RES, V54, P4274; CHENG NC, 1995, ONCOGENE, V10, P291; DIETRICH WF, 1993, CELL, V75, P631, DOI 10.1016/0092-8674(93)90484-8; DING SF, 1992, BRIT J CANCER, V65, P809, DOI 10.1038/bjc.1992.173; DOVE WF, 1994, COLD SPRING HARB SYM, V59, P501, DOI 10.1101/SQB.1994.059.01.055; FONG CT, 1992, CANCER RES, V52, P1780; HERZOG CR, 1995, ONCOGENE, V11, P1811; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; KHOSLA S, 1991, J CLIN INVEST, V87, P1691, DOI 10.1172/JCI115186; MACPHEE M, 1995, CELL, V81, P957, DOI 10.1016/0092-8674(95)90015-2; Malumbres M, 1997, ONCOGENE, V14, P1361, DOI 10.1038/sj.onc.1200969; MATHEW S, 1994, CANCER RES, V54, P6265; Mock BA, 1996, MAMM GENOME, V6, pS73; MOLEY JF, 1992, CANCER RES, V52, P770; QUELLE DE, 1995, ONCOGENE, V11, P635; Radany EH, 1997, P NATL ACAD SCI USA, V94, P8664, DOI 10.1073/pnas.94.16.8664; Santos J, 1996, ONCOGENE, V12, P669; SCHLEIERMACHER G, 1994, GENE CHROMOSOME CANC, V10, P275, DOI 10.1002/gcc.2870100409; SIMON D, 1991, ONCOGENE, V6, P765; SOKOVA OI, 1992, CANCER GENET CYTOGEN, V58, P24, DOI 10.1016/0165-4608(92)90128-U; SREEKANTAIAH C, 1993, AM J PATHOL, V142, P293; TAKEDA O, 1994, GENE CHROMOSOME CANC, V10, P30, DOI 10.1002/gcc.2870100106; Zhuang SM, 1996, CANCER RES, V56, P3338	27	31	31	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 20	1998	17	7					925	929		10.1038/sj.onc.1202009	http://dx.doi.org/10.1038/sj.onc.1202009			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	111QH	9780010				2022-12-17	WOS:000075448800015
J	Zhang, N; Chen, P; Gatei, M; Scott, S; Khanna, KK; Lavin, MF				Zhang, N; Chen, P; Gatei, M; Scott, S; Khanna, KK; Lavin, MF			An anti-sense construct of full-length ATM cDNA imposes a radiosensitive phenotype on normal cells	ONCOGENE			English	Article						ataxia-telangiectasia; ATM; anti-sense cDNA; radiosensitivity; cell cycle	ATAXIA-TELANGIECTASIA CELLS; CYCLE CHECKPOINT PATHWAY; ABL TYROSINE KINASE; IONIZING-RADIATION; DNA-SYNTHESIS; GENE-PRODUCT; C-ABL; DEFICIENT MICE; PROTEIN; DAMAGE	The cloning of a full-length cDNA for the gene (ATM) mutated in the human genetic disorder ataxia-telangiectasia (A-T) has been described recently. This cDNA, as well as a fragment representing a functional region from ATM, are capable of rescuing various aspects of the radiosensitive phenotype in A-T cells. We have subcloned full-length ATM cDNA in the opposite orientation in an EBV-based vector under the control of an inducible promoter to determine whether this anti-sense construct might sensitize control lymphoblastoid cells to ionizing radiation, The effectiveness of expression of this construct in control cells was monitored by loss of ATM protein which was evident over a period 6-12 h after induction. Under these conditions radiosensitivity was enhanced approximately threefold in control cells, approaching the degree of radiosensitivity observed in A-T cells. Expression of the anti-sense construct also increased the number of radiation-induced chromosomal breaks and led to the appearance of radioresistant DNA synthesis in these cells. Abrogation of the G1/S checkpoint was evident from the loss of the p53 response and that of its downstream effector, p21/WAF1, post-irradiation. The extent of accumulation of transfected cells in G2/M phase at 24 h post-irradiation was similar to that observed in A-T cells and the induction of stress-activated protein kinase by ionizing radiation was prevented by antisense ATM cDNA expression. These data demonstrate that full-length ATM anti-sense cDNA, by reducing the amount of ATM protein, is effective in imposing a series of known defects characteristic of the A-T phenotype, This inducible system provides an experimental model to further investigate mechanisms underlying radiosensitivity and cell cycle control.	Queensland Canc Fund, Res Labs, Brisbane, Qld 4029, Australia; Queensland Inst Med Res, Dept Surg, Brisbane, Qld 4029, Australia	Cancer Council Queensland; QIMR Berghofer Medical Research Institute	Lavin, MF (corresponding author), Queensland Canc Fund, Res Labs, PO Royal Brisbane Hosp, Brisbane, Qld 4029, Australia.		Khanna, Kum Kum/I-1747-2013; Lavin, Martin F/F-5961-2014	Lavin, Martin F/0000-0002-5940-4769; Khanna, Kum Kum/0000-0001-8650-5381				ALKHODAIRY F, 1994, MOL BIOL CELL, V5, P147, DOI 10.1091/mbc.5.2.147; AURIAS A, 1980, MUTAT RES, V69, P369, DOI 10.1016/0027-5107(80)90101-3; Barlow C, 1996, CELL, V86, P159, DOI 10.1016/S0092-8674(00)80086-0; Baskaran R, 1997, NATURE, V387, P516, DOI 10.1038/387516a0; Beamish H, 1996, J BIOL CHEM, V271, P20486, DOI 10.1074/jbc.271.34.20486; BEAMISH H, 1994, INT J RADIAT BIOL, V65, P175, DOI 10.1080/09553009414550211; BODER E, 1985, ATAXIA TELANGIECTASI, V19, P1; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; Brown KD, 1997, P NATL ACAD SCI USA, V94, P1840, DOI 10.1073/pnas.94.5.1840; Byrd PJ, 1996, HUM MOL GENET, V5, P145, DOI 10.1093/hmg/5.1.145; CANMAN CE, 1994, CANCER RES, V54, P5054; Chen P, 1996, INT J RADIAT BIOL, V69, P385, DOI 10.1080/095530096145940; CHEN P, 1994, CANCER GENET CYTOGEN, V76, P43, DOI 10.1016/0165-4608(94)90069-8; CHEN PC, 1978, NATURE, V274, P484, DOI 10.1038/274484a0; COLE J, 1988, INT J RADIAT BIOL, V54, P929, DOI 10.1080/09553008814552331; COQUERELLE TM, 1987, INT J RADIAT BIOL, V51, P209, DOI 10.1080/09553008714550711; CORNFORTH MN, 1985, SCIENCE, V227, P1589, DOI 10.1126/science.3975628; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Elson A, 1996, P NATL ACAD SCI USA, V93, P13084, DOI 10.1073/pnas.93.23.13084; FORAY N, 1997, IN PRESS INT J RAD B; GATTI RA, 1988, NATURE, V336, P577, DOI 10.1038/336577a0; Gilad S, 1996, HUM MOL GENET, V5, P433, DOI 10.1093/hmg/5.4.433; GREENWELL PW, 1995, CELL, V82, P823, DOI 10.1016/0092-8674(95)90479-4; HARI KL, 1995, CELL, V82, P815, DOI 10.1016/0092-8674(95)90478-6; HARTLEY KO, 1995, CELL, V82, P849, DOI 10.1016/0092-8674(95)90482-4; HOULDSWORTH J, 1980, NUCLEIC ACIDS RES, V8, P3709, DOI 10.1093/nar/8.16.3709; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Khanna KK, 1997, J BIOL CHEM, V272, P9489; KHANNA KK, 1995, ONCOGENE, V11, P609; KHANNA KK, 1993, ONCOGENE, V8, P3307; KHARBANDA S, 1995, NATURE, V376, P785, DOI 10.1038/376785a0; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Lakin ND, 1996, ONCOGENE, V13, P2707; LAVIN MF, 1992, CANCER GENET CYTOGEN, V60, P183, DOI 10.1016/0165-4608(92)90014-Y; Lavin MF, 1997, ANNU REV IMMUNOL, V15, P177, DOI 10.1146/annurev.immunol.15.1.177; LAVIN MF, 1988, MUTAT RES, V193, P193, DOI 10.1016/0167-8817(88)90030-2; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MCFARLIN DE, 1972, MEDICINE, V51, P281, DOI 10.1097/00005792-197207000-00002; MEYN MS, 1993, SCIENCE, V260, P1327, DOI 10.1126/science.8493577; Morgan SE, 1997, MOL CELL BIOL, V17, P2020, DOI 10.1128/MCB.17.4.2020; NAGASAWA H, 1983, MUTAT RES, V109, P297, DOI 10.1016/0027-5107(83)90054-4; PAINTER RB, 1980, P NATL ACAD SCI-BIOL, V77, P7315, DOI 10.1073/pnas.77.12.7315; PAINTER RB, 1986, INT J RADIAT BIOL, V49, P771; PANDITA TK, 1992, RADIAT RES, V130, P94, DOI 10.2307/3578485; ROSIN MP, 1986, HUM GENET, V74, P335, DOI 10.1007/BF00280482; RUDOLPH NS, 1989, MUTAT RES, V211, P19, DOI 10.1016/0027-5107(89)90103-6; SANFORD KK, 1990, CHROMOSOMAL ABERRATI, P113; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; SAVITSKY K, 1995, HUM MOL GENET, V4, P2025, DOI 10.1093/hmg/4.11.2025; SCOTT D, 1994, INT J RADIAT BIOL, V66, pS157, DOI 10.1080/09553009414551991; SCOTT D, 1982, INT J RADIAT BIOL, V42, P679, DOI 10.1080/09553008214551661; Sedgwick R, 1991, HDB CLIN NEUROLOGY, P347; Shafman T, 1997, NATURE, V387, P520, DOI 10.1038/387520a0; SHAFMAN TD, 1995, CANCER RES, V55, P3242; SHILOH Y, 1986, LANCET, V1, P689; TAYLOR AMR, 1975, NATURE, V258, P427, DOI 10.1038/258427a0; TAYLOR AMR, 1982, ATAXIA TELANGIECTASI, P53; Telatar M, 1996, AM J HUM GENET, V59, P40; Uziel T, 1996, GENOMICS, V33, P317, DOI 10.1006/geno.1996.0201; VOUSDEN KH, 1993, J GEN VIROL, V74, P803, DOI 10.1099/0022-1317-74-5-803; Watters D, 1997, ONCOGENE, V14, P1911, DOI 10.1038/sj.onc.1201037; Xu Y, 1996, GENE DEV, V10, P2401, DOI 10.1101/gad.10.19.2401; ZAMPETTIBOSSELER F, 1981, INT J RADIAT BIOL, V39, P547, DOI 10.1080/09553008114550651; Zhang N, 1997, P NATL ACAD SCI USA, V94, P8021, DOI 10.1073/pnas.94.15.8021; Ziv Y, 1997, ONCOGENE, V15, P159, DOI 10.1038/sj.onc.1201319; ZIV Y, 1995, SOMAT CELL MOLEC GEN, V21, P99, DOI 10.1007/BF02255785	66	31	33	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 20	1998	17	7					811	818		10.1038/sj.onc.1202007	http://dx.doi.org/10.1038/sj.onc.1202007			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	111QH	9779997				2022-12-17	WOS:000075448800002
J	Kisielewski, AE; Xiao, GH; Liu, SC; Klein-Szanto, AJP; Novara, M; Sina, J; Bleicher, K; Yeung, RS; Goodrow, TL				Kisielewski, AE; Xiao, GH; Liu, SC; Klein-Szanto, AJP; Novara, M; Sina, J; Bleicher, K; Yeung, RS; Goodrow, TL			Analysis of the FHIT gene and its product in squamous cell carcinomas of the head and neck	ONCOGENE			English	Article						FHIT; squamous carcinogenesis; RT-PCR; westerns	TUMOR-SUPPRESSOR GENE; ALLELIC LOSS; LUNG-CANCER; 3P14.2; LINES; AMPLIFICATION; ONCOGENE; SITE; ALLELOTYPE; DELETIONS	The FHIT gene has been implicated as a tumor suppressor gene in human malignancies. To determine if FHIT alterations play a role in human squamous cell carcinogenesis of the head and neck (HNSCC), we examined the gene and its product by RT-PCR, SSCP, Northern, Southern, and Western blot analysis in primary HNSCC and/or HNSCC cell lines. Three of 32 tumor samples lacked detectable expression of FHIT by RT-PCR but showed amplification of a control gene of similar size. One of 29 primary tumors and 2/9 HNSCC cell lines exhibited aberrant transcripts generated by RT-PCR methods using one set of 40 cycles of amplification. FHIT mRNA expression was absent in seven HNSCC cell lines but detectable in primary keratinocytes by Northern analysis. Using specific polyclonal antiserum to the full-length I;HIT protein in immunoblot analyses, 4/9 cell lines analysed showed no expression of pFhit, two exhibited low levels of expression, and three expressed a putative truncated pFhit. One of 15 tumors analysed also exhibited an overexpressed truncated protein. PCR/SSCP and Southern analysis of one cell line DNA that expressed a truncated protein indicated that it sustained homozygous loss of FHIT exon 5. Our results suggest that alterations in FHIT at the DNA, RNA, and protein levels exist at a low but significant frequency in HNSCCs. Further studies regarding the potential biological activity of FHIT are needed to clarify the role of this gene in HIVSCC tumorigenesis.	Fox Chase Canc Ctr, Dept Pathol, Philadelphia, PA 19111 USA; Fox Chase Canc Ctr, Div Basic Sci, Philadelphia, PA 19111 USA; Merck & Co Inc, Dept Genet Toxicol, West Point, PA 19486 USA	Fox Chase Cancer Center; Fox Chase Cancer Center; Merck & Company	Goodrow, TL (corresponding author), Fox Chase Canc Ctr, Dept Pathol, Philadelphia, PA 19111 USA.		Klein-Szanto, A./E-6218-2010		NCI NIH HHS [CA61889, CA06927] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA006927, R29CA061889, R01CA061889] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AHSEE KW, 1994, CANCER RES, V54, P1617; Barnes LD, 1996, BIOCHEMISTRY-US, V35, P11529, DOI 10.1021/bi961415t; BARTKOVA J, 1995, CANCER RES, V55, P949; BERENSON JR, 1989, ONCOGENE, V4, P1111; BRACHMAN DG, 1994, SEMIN ONCOL, V21, P320; Druck T, 1997, CANCER RES, V57, P504; Fong KM, 1997, CANCER RES, V57, P2256; Gemma A, 1997, CANCER RES, V57, P1435; Hendricks DT, 1997, CANCER RES, V57, P2112; JOVANOVIC A, 1993, J ORAL PATHOL MED, V22, P459, DOI 10.1111/j.1600-0714.1993.tb00125.x; Kastury K, 1996, CANCER RES, V56, P978; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; LAMMIE GA, 1991, ONCOGENE, V6, P439; LATIF F, 1992, CANCER RES, V52, P1451; LI XH, 1994, J NATL CANCER I, V86, P1524, DOI 10.1093/jnci/86.20.1524; Mao L, 1996, CANCER RES, V56, P5128; Mau S, 1996, CANCER RES, V56, P5484; MERRITT WD, 1990, ARCH OTOLARYNGOL, V116, P1394; NAWROZ H, 1994, CANCER RES, V54, P1152; Negrini M, 1996, CANCER RES, V56, P3173; Ohta M, 1996, CELL, V84, P587, DOI 10.1016/S0092-8674(00)81034-X; Sakata K, 1996, J ORAL PATHOL MED, V25, P302, DOI 10.1111/j.1600-0714.1996.tb00266.x; Sambrook J., 1989, MOL CLONING LAB MANU, V2nd; SCHUURING E, 1992, ONCOGENE, V7, P355; SOMERS KD, 1990, ONCOGENE, V5, P915; Sozzi G, 1996, CANCER RES, V56, P2472; Sozzi G, 1996, CELL, V85, P17, DOI 10.1016/S0092-8674(00)81078-8; Thiagalingam S, 1996, CANCER RES, V56, P2936; Virgilio L, 1996, P NATL ACAD SCI USA, V93, P9770, DOI 10.1073/pnas.93.18.9770; VOKES EE, 1993, NEW ENGL J MED, V328, P184, DOI 10.1056/NEJM199301213280306; Waber PG, 1996, ONCOGENE, V12, P365; Xiao GH, 1997, AM J PATHOL, V151, P1541; Yanagisawa K, 1996, CANCER RES, V56, P5579; ZHANG SY, 1994, CANCER RES, V54, P5050	34	31	41	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 9	1998	17	1					83	91		10.1038/sj.onc.1201910	http://dx.doi.org/10.1038/sj.onc.1201910			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZY936	9671317				2022-12-17	WOS:000074677800010
J	Dono, R; James, D; Zeller, R				Dono, R; James, D; Zeller, R			A GR-motif functions in nuclear accumulation of the large FGF-2 isoforms and interferes with mitogenic signalling	ONCOGENE			English	Article						fibroblast growth factor; FGF2; NLS; nuclear retention; mitotic arrest; proliferation	FIBROBLAST GROWTH-FACTOR; TRANSLOCATION SEQUENCE; BIOLOGICAL-ACTIVITY; ENDOTHELIAL-CELLS; MESSENGER-RNA; FACTOR FAMILY; FACTOR-II; LOCALIZATION; BFGF; EXPRESSION	Nuclear translocation has been documented for members of the fibroblast growth factor (FGF) family in addition to their roles as extra-cellular signalling molecules. Fusing different parts of the chicken FGF-2. open reading frame to pyruvate kinase shows that direct nuclear accumulation is mediated by the amino-termini of the two leucine initiated FGF-2 isoforms (Leu-isoforms; 21.5 and 20.0 kDa), An evolutionarily conserved glycine-arginine (GR)-motif is present in the 21.5 kDa Leu-isoform and a shorter GR-repeat in the 20.0 kDa Leu-isoform, whereas no such repeats are present in the 18.5 kDa FGF-2 isoform (Met-isoform), Expression in NIH3T3 fibroblasts shows that the 21.5 kDa Leu-isoform is predominantly nuclear, whereas the Met-isoform is predominantly cytoplasmic. Most importantly, insertion of the GR-motif into the Met-isoform results in a protein with characteristics similar to the Leu-isoforms, as shown by nuclear accumulation of the chimeric M-GR-protein. Furthermore, only NIH3T3 fibroblasts expressing the Met-isoform proliferate under serum starvation conditions, whereas cells expressing either the M-GR- Or Leu-isoforms stay growth arrested. These studies show that the GR-signal mediates nuclear translocation of endogenous Leu-isoforms and blocks their mitogenic activity.	European Mol Biol Lab, D-69117 Heidelberg, Germany	European Molecular Biology Laboratory (EMBL)	Zeller, R (corresponding author), European Mol Biol Lab, Meyerhofstr 1, D-69117 Heidelberg, Germany.		James, Dominic/G-6435-2016; DONO, ROSANNA/I-7821-2016; Zeller, Rolf/C-2610-2013	James, Dominic/0000-0002-0452-2178; Zeller, Rolf/0000-0002-3186-7403				ABRAHAM JA, 1986, SCIENCE, V233, P545, DOI 10.1126/science.2425435; BALDIN V, 1990, EMBO J, V9, P1511, DOI 10.1002/j.1460-2075.1990.tb08269.x; BIKFALVI A, 1995, J CELL BIOL, V129, P233, DOI 10.1083/jcb.129.1.233; Borja AZM, 1996, DEV BIOL, V180, P680, DOI 10.1006/dbio.1996.0337; BOUCHE G, 1987, P NATL ACAD SCI USA, V84, P6770, DOI 10.1073/pnas.84.19.6770; BUGLER B, 1991, MOL CELL BIOL, V11, P573, DOI 10.1128/MCB.11.1.573; COUDERC B, 1991, CELL REGUL, V2, P709, DOI 10.1091/mbc.2.9.709; DINGWALL C, 1988, J CELL BIOL, V107, P841, DOI 10.1083/jcb.107.3.841; DONO R, 1994, DEV BIOL, V163, P316, DOI 10.1006/dbio.1994.1151; FELDMAN B, 1995, SCIENCE, V267, P246, DOI 10.1126/science.7809630; FLORKIEWICZ RZ, 1989, P NATL ACAD SCI USA, V86, P3978, DOI 10.1073/pnas.86.11.3978; FRIESEL RE, 1995, FASEB J, V9, P919, DOI 10.1096/fasebj.9.10.7542215; GHISOLFI L, 1992, J BIOL CHEM, V267, P2955; GOMEZPINILLA F, 1992, J NEUROSCI, V12, P345; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GUALANDRIS A, 1994, J CELL PHYSIOL, V161, P149, DOI 10.1002/jcp.1041610118; HEBERT JM, 1994, CELL, V78, P1017, DOI 10.1016/0092-8674(94)90276-3; HEBERT JM, 1990, DEV BIOL, V138, P454, DOI 10.1016/0012-1606(90)90211-Z; IMAMURA T, 1990, SCIENCE, V249, P1567, DOI 10.1126/science.1699274; Joy A, 1997, ONCOGENE, V14, P171, DOI 10.1038/sj.onc.1200823; KIEFER P, 1994, EMBO J, V13, P4126, DOI 10.1002/j.1460-2075.1994.tb06730.x; LIN Y, 1996, J BIOL CHEM, V271, P5303; Maher PA, 1996, J CELL BIOL, V134, P529, DOI 10.1083/jcb.134.2.529; MASON IJ, 1994, CELL, V78, P547, DOI 10.1016/0092-8674(94)90520-7; MIGNATTI P, 1992, J CELL PHYSIOL, V151, P81, DOI 10.1002/jcp.1041510113; MIYAMOTO M, 1993, MOL CELL BIOL, V13, P4251, DOI 10.1128/MCB.13.7.4251; Moffett J, 1996, P NATL ACAD SCI USA, V93, P2470, DOI 10.1073/pnas.93.6.2470; MUESCH A, 1990, TRENDS BIOCHEM SCI, V15, P86, DOI 10.1016/0968-0004(90)90186-F; Nigg EA, 1997, NATURE, V386, P779, DOI 10.1038/386779a0; POWELL PP, 1991, J CELL PHYSIOL, V148, P202, DOI 10.1002/jcp.1041480204; PRESTA M, 1993, GROWTH FACTORS, V9, P269, DOI 10.3109/08977199308991587; QUARTO N, 1991, CELL REGUL, V2, P699, DOI 10.1091/mbc.2.9.699; QUARTO N, 1991, J CELL PHYSIOL, V147, P311, DOI 10.1002/jcp.1041470217; RIESE J, 1995, MECH DEVELOP, V49, P13, DOI 10.1016/0925-4773(94)00296-Y; ROGELJ S, 1989, J CELL BIOL, V109, P823, DOI 10.1083/jcb.109.2.823; SCHMIDTZACHMANN MS, 1993, J CELL SCI, V105, P799; SCHMIDTZACHMANN MS, 1993, CELL, V74, P493, DOI 10.1016/0092-8674(93)80051-F; SHERMAN L, 1993, DEVELOPMENT, V118, P1313; SHIURBA RA, 1991, DEVELOPMENT, V113, P487; SIOMI H, 1995, J CELL BIOL, V129, P511; Smallwood PM, 1996, P NATL ACAD SCI USA, V93, P9850, DOI 10.1073/pnas.93.18.9850; TESSLER S, 1990, J CELL PHYSIOL, V145, P310, DOI 10.1002/jcp.1041450216; TRUMPP A, 1992, GENE DEV, V6, P14, DOI 10.1101/gad.6.1.14; WIEDLOCHA A, 1994, CELL, V76, P1039, DOI 10.1016/0092-8674(94)90381-6; WOODWARD WR, 1992, J NEUROSCI, V12, P142; Yamasaki M, 1996, J BIOL CHEM, V271, P15918, DOI 10.1074/jbc.271.27.15918; ZAGZAG D, 1990, CANCER RES, V50, P7393; ZHANG JD, 1991, P NATL ACAD SCI USA, V88, P3446, DOI 10.1073/pnas.88.8.3446; ZHU X, 1991, SCIENCE, V251, P90, DOI 10.1126/science.1702556; ZUNIGA A, 1993, DEV BIOL, V157, P110, DOI 10.1006/dbio.1993.1116	50	31	32	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 23	1998	16	16					2151	2158		10.1038/sj.onc.1201746	http://dx.doi.org/10.1038/sj.onc.1201746			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZJ077	9572496				2022-12-17	WOS:000073177200013
J	Wise, SC; Burmeister, LA; Zhou, XF; Bubulya, A; Oberfield, JL; Birrer, MJ; Shemshedini, L				Wise, SC; Burmeister, LA; Zhou, XF; Bubulya, A; Oberfield, JL; Birrer, MJ; Shemshedini, L			Identification of domains of c-Jun mediating androgen receptor transactivation	ONCOGENE			English	Article						c-Jun; androgen receptor; transactivation	ACTIVATED PROTEIN-KINASES; MAMMARY-TUMOR VIRUS; NUCLEAR RECEPTORS; TRANSCRIPTIONAL ACTIVATION; GLUCOCORTICOID RECEPTOR; ESTROGEN-RECEPTOR; RESPONSE ELEMENT; AP-1 ACTIVITY; FUNCTION AF-2; IN-VITRO	The proto-oncoprotein c-Jun, when complexed with c-Fos, forms the climeric complex identified as AP-1 which regulates transcription directly by binding to AP-1-responsive genes. We have previously reported an indirect mechanism by which c-Jun is able to regulate transcription by stimulating androgen receptor transactivation in the absence of c-Fos or any apparent DNA binding. A series of c-Jun mutants were tested in order to characterize the domains of c-Jun responsible for this effect. The studies reported here indicate that functional bZIP region and a portion of the N-terminal activation functions is necessary for c-Jun stimulation of androgen receptor transactivation. Testing c-Jun/v-Jun chimeras, we show that v-Jun is unable to stimulate androgen receptor transactivation and the effect is dependent on the c-Jun activation functions, c-Jun exhibits a bell-shaped activity on androgen receptor-mediated transactivation which appears to be distinct from c-Jun's transactivation ability. A c-Jun mutant deficient in transactivation is able to stimulate androgen receptor activity. These results indicate that c-Jun's transactivation ability can be separated from c-Jun's ability to stimulate the androgen receptor transactivation.	Univ Toledo, Dept Biol, Toledo, OH 43606 USA; NCI, Dept Cell & Canc Biol, Div Clin Sci, Rockville, MD 20850 USA	University System of Ohio; University of Toledo; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Shemshedini, L (corresponding author), Univ Toledo, Dept Biol, Toledo, OH 43606 USA.							ADLER AJ, 1992, P NATL ACAD SCI USA, V89, P11660, DOI 10.1073/pnas.89.24.11660; ALANI R, 1991, MOL CELL BIOL, V11, P6286, DOI 10.1128/MCB.11.12.6286; ANGEL P, 1989, New Biologist, V1, P35; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; ARCHER TK, 1994, MOL ENDOCRINOL, V8, P568, DOI 10.1210/me.8.5.568; ARRIZA JL, 1987, SCIENCE, V237, P268, DOI 10.1126/science.3037703; Bannister AJ, 1995, ONCOGENE, V11, P2509; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; BOHMANN D, 1989, CELL, V59, P709, DOI 10.1016/0092-8674(89)90017-2; BOS TJ, 1990, GENE DEV, V4, P1677, DOI 10.1101/gad.4.10.1677; Brown PH, 1996, CELL GROWTH DIFFER, V7, P1013; BROWN PH, 1994, ONCOGENE, V9, P791; Bubulya A, 1996, J BIOL CHEM, V271, P24583, DOI 10.1074/jbc.271.40.24583; CAVAILLES V, 1995, EMBO J, V14, P3741, DOI 10.1002/j.1460-2075.1995.tb00044.x; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; CHANG CS, 1988, SCIENCE, V240, P324, DOI 10.1126/science.3353726; Claessens F, 1996, J BIOL CHEM, V271, P19013, DOI 10.1074/jbc.271.32.19013; Claret FX, 1996, NATURE, V383, P453, DOI 10.1038/383453a0; DENG TL, 1992, P NATL ACAD SCI USA, V89, P8572, DOI 10.1073/pnas.89.18.8572; DOUCAS V, 1991, EMBO J, V10, P2237, DOI 10.1002/j.1460-2075.1991.tb07760.x; DURAND B, 1994, EMBO J, V13, P5370, DOI 10.1002/j.1460-2075.1994.tb06872.x; FRANKLIN CC, 1995, BIOCHEM J, V305, P967, DOI 10.1042/bj3050967; Gill G, 1992, CURR OPIN GENET DEV, V2, P236, DOI 10.1016/S0959-437X(05)80279-5; GRONEMEYER H, 1987, EMBO J, V6, P3985, DOI 10.1002/j.1460-2075.1987.tb02741.x; HAM J, 1988, NUCLEIC ACIDS RES, V16, P5263, DOI 10.1093/nar/16.12.5263; Hong H, 1996, P NATL ACAD SCI USA, V93, P4948, DOI 10.1073/pnas.93.10.4948; JENSTER G, 1995, J BIOL CHEM, V270, P7341, DOI 10.1074/jbc.270.13.7341; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KASTNER P, 1995, CELL, V83, P859, DOI 10.1016/0092-8674(95)90202-3; KUROKAWA R, 1995, NATURE, V377, P451, DOI 10.1038/377451a0; LEDOUARIN B, 1995, EMBO J, V14, P2020, DOI 10.1002/j.1460-2075.1995.tb07194.x; Lee JS, 1996, MOL CELL BIOL, V16, P4312; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MARODER M, 1993, MOL ENDOCRINOL, V7, P570, DOI 10.1210/me.7.4.570; Martin ML, 1996, MOL CELL BIOL, V16, P2110; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; NAKAE K, 1995, J BIOL CHEM, V270, P23795, DOI 10.1074/jbc.270.40.23795; OEHLER T, 1993, ONCOGENE, V8, P1141; ONATE SA, 1995, SCIENCE, V270, P1354; PFAHL M, 1993, ENDOCR REV, V14, P651, DOI 10.1210/er.14.5.651; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; Sato N, 1997, J BIOL CHEM, V272, P17485, DOI 10.1074/jbc.272.28.17485; SCARLETT CO, 1995, MOL ENDOCRINOL, V9, P413, DOI 10.1210/me.9.4.413; SCHUTTE J, 1989, CELL, V59, P987, DOI 10.1016/0092-8674(89)90755-1; SHEMSHEDINI L, 1991, EMBO J, V10, P3839, DOI 10.1002/j.1460-2075.1991.tb04953.x; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; SMEAL T, 1989, GENE DEV, V3, P2091, DOI 10.1101/gad.3.12b.2091; THUMMEL CS, 1995, CELL, V83, P871, DOI 10.1016/0092-8674(95)90203-1; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; VOGT PK, 1990, ADV CANCER RES, V55, P2; Yeh SY, 1996, P NATL ACAD SCI USA, V93, P5517, DOI 10.1073/pnas.93.11.5517	55	31	33	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 16	1998	16	15					2001	2009		10.1038/sj.onc.1201697	http://dx.doi.org/10.1038/sj.onc.1201697			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZH166	9591784				2022-12-17	WOS:000073079400012
J	Rudra-Ganguly, N; Zheng, JP; Hoang, AT; Roy-Burman, P				Rudra-Ganguly, N; Zheng, JP; Hoang, AT; Roy-Burman, P			Downregulation of human FGF8 activity by antisense constructs in murine fibroblastic and human prostatic carcinoma cell systems	ONCOGENE			English	Article						FGF8; antisense RNA; prostate cancer cells; retroviral vector	INDUCED GROWTH-FACTOR; BREAST-CANCER CELLS; MOLECULAR-CLONING; BONE FIBROBLASTS; FACTOR-VIII; ANDROGEN; GENE; EXPRESSION; FAMILY; MAINTENANCE	Previously, we described cloning of three alternatively spliced mRNA forms of human FGF8, a, b, and e, of which the b form is the major expressed species in both normal and tumor prostatic epithelial cells. In this report, we describe construction and overexpression of sense and antisense sequences of either the full length FGF8b coding region (215-amino acids or 215aa), 103aa N-terminal part or a smaller N-terminal region (34aa), each including the 23aa putative signal peptide domain, via a retrovirus system. While the morphologic transforming activities of the sense 215aa and 103aa constructs were similar in NIH3T3 cells, 103aa displayed reduced soft agar clonogenic activity, The 34aa construct was practically inert in these assays, although its expression could mimic the ability of 215aa or 103aa in conferring cell growth under reduced serum condition. Overexpression of any of the three constructs in antisense orientation, however, was similarly effective in reversing the morphology and anchorage-independent growth property of FGF8b-transfected NIH3T3 cells, The expression of the antisense 215aa construct significantly reduced the growth rate of the human prostatic carcinoma DU145 cells and inhibited their soft agar clonogenic activity and in vivo tumorigenicity in nude mice, Taken together, these results identify N-terminal portions of FGF8 protein isoform for having the domains necessary for one or more of the biologic effects examined, and suggest that low levels of FGF8 expressed in prostatic epithelial cells may contribute significantly to their growth and tumorigenic properties.	Univ So Calif, Sch Med, Dept Pathol, Los Angeles, CA 90033 USA; Univ So Calif, Sch Med, Dept Biochem & Mol Biol, Los Angeles, CA 90033 USA	University of Southern California; University of Southern California	Roy-Burman, P (corresponding author), Univ So Calif, Sch Med, Dept Pathol, 2011 Zonal Ave,HMR 212, Los Angeles, CA 90033 USA.				NATIONAL CANCER INSTITUTE [R01CA059705, T32CA009320] Funding Source: NIH RePORTER; NCI NIH HHS [T32-CA09320, CA59705] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; Blunt AG, 1997, J BIOL CHEM, V272, P3733, DOI 10.1074/jbc.272.6.3733; Coulier F, 1997, J MOL EVOL, V44, P43, DOI 10.1007/PL00006120; Crossley PH, 1996, CELL, V84, P127, DOI 10.1016/S0092-8674(00)80999-X; CROSSLEY PH, 1995, DEVELOPMENT, V121, P439; FREYTAG SO, 1994, GENE DEV, V8, P1654, DOI 10.1101/gad.8.14.1654; Gemel J, 1996, GENOMICS, V35, P253, DOI 10.1006/geno.1996.0349; Ghosh AK, 1996, CELL GROWTH DIFFER, V7, P1425; Gibson I, 1996, CANCER METAST REV, V15, P287, DOI 10.1007/BF00046343; GLEAVE M, 1991, CANCER RES, V51, P3753; GLEAVE ME, 1992, J UROLOGY, V147, P1151, DOI 10.1016/S0022-5347(17)37506-7; HEIKINHEIMO M, 1994, MECH DEVELOP, V48, P129, DOI 10.1016/0925-4773(94)90022-1; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; JUNKER U, 1994, ANTISENSE RES DEV, V4, P165, DOI 10.1089/ard.1994.4.165; KOBAYASHI M, 1995, ANTISENSE RES DEV, V5, P141, DOI 10.1089/ard.1995.5.141; KOUHARA H, 1994, ONCOGENE, V9, P455; Leung HY, 1996, ONCOGENE, V12, P1833; LORENZI MV, 1995, ONCOGENE, V10, P2051; MACARTHUR CA, 1995, DEVELOPMENT, V121, P3603; MACARTHUR CA, 1995, CELL GROWTH DIFFER, V6, P817; MACARTHUR CA, 1995, J VIROL, V69, P2501, DOI 10.1128/JVI.69.4.2501-2507.1995; MAHMOOD R, 1995, CURR BIOL, V5, P797, DOI 10.1016/S0960-9822(95)00157-6; MASON IJ, 1994, CELL, V78, P547, DOI 10.1016/0092-8674(94)90520-7; OHUCHI H, 1994, BIOCHEM BIOPH RES CO, V204, P882, DOI 10.1006/bbrc.1994.2542; Payson RA, 1996, ONCOGENE, V13, P47; TANAKA A, 1995, FEBS LETT, V363, P226, DOI 10.1016/0014-5793(95)00324-3; TANAKA A, 1992, P NATL ACAD SCI USA, V89, P8928, DOI 10.1073/pnas.89.19.8928; Verdier AS, 1997, GENOMICS, V40, P151, DOI 10.1006/geno.1996.4492; WHITE RA, 1995, GENOMICS, V30, P109, DOI 10.1006/geno.1995.0020; YAN GC, 1992, MOL ENDOCRINOL, V6, P2123, DOI 10.1210/me.6.12.2123	30	31	32	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 19	1998	16	11					1487	1492		10.1038/sj.onc.1201652	http://dx.doi.org/10.1038/sj.onc.1201652			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZC383	9525747				2022-12-17	WOS:000072572400012
J	Rampalli, AM; Gao, CY; Chauthaiwale, VM; Zelenka, PS				Rampalli, AM; Gao, CY; Chauthaiwale, VM; Zelenka, PS			pRb and p107 regulate E2F activity during lens fiber cell differentiation	ONCOGENE			English	Article						differentiation; cell cycle; tumor suppressors; lens; E2F; transcription factors	TRANSCRIPTION FACTOR E2F; B-MYB TRANSCRIPTION; RETINOBLASTOMA PROTEIN; CYCLE REGULATION; IN-VIVO; TRANSGENIC MICE; FACTOR DRTF1/E2F; GENE FAMILY; MOUSE LENS; EXPRESSION	During growth arrest and differentiation, activity of the E2F family of transcription factors is inhibited by interactions with pRb and the related proteins, p107 and p130. To determine which members of the E2F and pRb families may contribute to growth arrest as lens epithelial cells differentiate into fiber cells, we examined the expression of individual E2F species and characterized the E2F protein complexes formed in rat lens epithelia and fibers. RT/PCR detected all five known members of the E2F family in lens epithelial cells, but only E2F-1, E2F-3, and E2F-5 in fiber cells. Proteins extracted from lens epithelia of newborn rats formed at least two specific complexes with an E2F consensus oligonucleotide. Proteins from lens fiber cells formed three specific complexes, one of which comigrated with an epithelial cell complex. Incubation of epithelial and fiber cell extracts with an antibody specific for p107 demonstrated that two fiber cell complexes and one epithelial cell complex contained p107. Although the remaining fiber cell complex did not react with antibodies to pRb or p130 in this assay, a strong reaction with pRb antibody was observed when the electromobility shifted complexes were subsequently immunoblotted (shift/Western assay). Immunocytochemistry confirmed that pRb protein is present in the nuclei of both epithelial cells and fiber cells. Immunoblotting of whole cell extracts with pRb antibody showed multiple, phosphorylated forms of pRb in the epithelial cells, but predominantly hypophosphorylated pRb in the fiber cells. None of the complexes formed with E2F were recognized exclusively by the p130 antibody, although the previously identified p107 complexes reacted weakly. The absence of p130/E2F complexes was correlated with the presence of multiple ubiquitinated forms of p130, especially in the fiber cells. Thus, although p130/E2F complexes are implicated in the terminal differentiation of many cell types, in differentiating lens fiber cells pRb and p107 seem to be the primary regulators of E2F activity.	NEI, Mol & Dev Biol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI)	Zelenka, PS (corresponding author), NEI, Mol & Dev Biol Lab, NIH, Bethesda, MD 20892 USA.							ADNANE J, 1995, J BIOL CHEM, V270, P8837, DOI 10.1074/jbc.270.15.8837; BANDARA LR, 1994, EMBO J, V13, P3104, DOI 10.1002/j.1460-2075.1994.tb06609.x; BASSNETT S, 1992, DEV DYNAM, V194, P85, DOI 10.1002/aja.1001940202; BEIJERSBERGEN RL, 1994, GENE DEV, V8, P2680, DOI 10.1101/gad.8.22.2680; BREMNER R, 1995, MOL CELL BIOL, V15, P3256; Campanero MR, 1997, P NATL ACAD SCI USA, V94, P2221, DOI 10.1073/pnas.94.6.2221; CAO L, 1992, NATURE, V355, P176, DOI 10.1038/355176a0; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; COBRINIK D, 1993, GENE DEV, V7, P2392, DOI 10.1101/gad.7.12a.2392; Cobrinik D, 1996, GENE DEV, V10, P1633, DOI 10.1101/gad.10.13.1633; CORBEIL HB, 1995, ONCOGENE, V11, P909; DALTON S, 1992, EMBO J, V11, P1797, DOI 10.1002/j.1460-2075.1992.tb05231.x; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; DEMCZUK S, 1993, P NATL ACAD SCI USA, V90, P2574, DOI 10.1073/pnas.90.7.2574; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; FRIDOVICHKEIL JL, 1993, CELL GROWTH DIFFER, V4, P679; Fromm L, 1996, ONCOGENE, V12, P69; FROMM L, 1994, MOL CELL BIOL, V14, P6743, DOI 10.1128/MCB.14.10.6743; GALLANT P, 1992, J CELL BIOL, V117, P213, DOI 10.1083/jcb.117.1.213; GAO CY, 1995, DEV BIOL, V169, P185, DOI 10.1006/dbio.1995.1136; GINSBERG D, 1994, GENE DEV, V8, P2665, DOI 10.1101/gad.8.22.2665; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HEIBERT SW, 1989, P NATL ACAD SCI USA, V86, P3594; HENGLEIN B, 1994, P NATL ACAD SCI USA, V91, P5490, DOI 10.1073/pnas.91.12.5490; HERZINGER T, 1995, ONCOGENE, V10, P2079; HEY HY, 1997, IN PRESS DEV DYNAM; HIJMANS EM, 1995, MOL CELL BIOL, V15, P3082; HOWES KA, 1994, GENE DEV, V8, P1300, DOI 10.1101/gad.8.11.1300; Hurford RK, 1997, GENE DEV, V11, P1447, DOI 10.1101/gad.11.11.1447; Ikeda M, 1996, P NATL ACAD SCI USA, V93, P3215, DOI 10.1073/pnas.93.8.3215; IKEDA MA, 1993, MOL CELL BIOL, V13, P7029, DOI 10.1128/MCB.13.11.7029; ITOH A, 1995, CELL MOL BIOL RES, V41, P147; IVEYHOYLE M, 1993, MOL CELL BIOL, V13, P7802, DOI 10.1128/MCB.13.12.7802; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; JIANG HP, 1994, ONCOGENE, V9, P3397; KIESS M, 1995, CELL GROWTH DIFFER, V6, P1287; KUWABARA T, 1974, INVEST OPHTH VISUAL, V13, P973; LAM EWF, 1995, GENE, V160, P277, DOI 10.1016/0378-1119(95)00184-8; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; LEE EYHP, 1994, GENE DEV, V8, P2008, DOI 10.1101/gad.8.17.2008; LEES E, 1992, GENE DEV, V6, P1874, DOI 10.1101/gad.6.10.1874; LEES JA, 1993, MOL CELL BIOL, V13, P7813, DOI 10.1128/MCB.13.12.7813; LI Y, 1993, GENE DEV, V7, P2366, DOI 10.1101/gad.7.12a.2366; MAHON KA, 1987, SCIENCE, V235, P1622, DOI 10.1126/science.3029873; MEANS AL, 1992, MOL CELL BIOL, V12, P1054, DOI 10.1128/MCB.12.3.1054; MORGENBESSER SD, 1994, NATURE, V371, P72, DOI 10.1038/371072a0; MULLER H, 1994, P NATL ACAD SCI USA, V91, P2945, DOI 10.1073/pnas.91.8.2945; NEVINS JR, 1992, SCIENCE, V258, P424; Ohtani K, 1995, P NATL ACAD SCI USA, V92, P12146, DOI 10.1073/pnas.92.26.12146; ORMONDROYD E, 1995, ONCOGENE, V11, P1437; PAN HC, 1994, GENE DEV, V8, P1285, DOI 10.1101/gad.8.11.1285; PAN HC, 1995, GENE DEV, V9, P2157, DOI 10.1101/gad.9.17.2157; PEARSON BE, 1991, MOL CELL BIOL, V11, P2181; PERSONS BJ, 1970, EXP EYE RES, V9, P144, DOI 10.1016/S0014-4835(70)80069-0; PIATIGORSKY J, 1992, ADV DEV BIOCH, V1, P211; RINAUDO JAS, 1992, EXP CELL RES, V199, P147, DOI 10.1016/0014-4827(92)90472-K; Sambrook J, 1989, MOL CLONING LAB MANU; SARDET C, 1995, P NATL ACAD SCI USA, V92, P2403, DOI 10.1073/pnas.92.6.2403; SELLERS WR, 1995, P NATL ACAD SCI USA, V92, P11544, DOI 10.1073/pnas.92.25.11544; SHIN EK, 1995, MOL CELL BIOL, V15, P2252; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; TOMMASI S, 1995, MOL CELL BIOL, V15, P6901; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VAIRO G, 1995, GENE DEV, V9, P869, DOI 10.1101/gad.9.7.869; VRENSEN GFJM, 1991, EXP EYE RES, V52, P647, DOI 10.1016/0014-4835(91)90017-9; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WEINTRAUB SJ, 1995, NATURE, V375, P812, DOI 10.1038/375812a0; Wells JM, 1997, J BIOL CHEM, V272, P4483, DOI 10.1074/jbc.272.7.4483; Yamasaki L, 1996, CELL, V85, P537, DOI 10.1016/S0092-8674(00)81254-4; YEE AS, 1989, MOL CELL BIOL, V9, P578, DOI 10.1128/MCB.9.2.578; Zhang PM, 1997, NATURE, V387, P151, DOI 10.1038/387151a0; ZHANG YH, 1995, ONCOGENE, V10, P2085; Zwicker J, 1996, SCIENCE, V271, P1595, DOI 10.1126/science.271.5255.1595	73	31	31	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 22	1998	16	3					399	408		10.1038/sj.onc.1201546	http://dx.doi.org/10.1038/sj.onc.1201546			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YT262	9467965				2022-12-17	WOS:000071582100012
J	Eiriksdottir, G; Barkardottir, RB; Agnarsson, BA; Johannesdottir, G; Olafsdottir, K; Egilsson, V; Ingvarsson, S				Eiriksdottir, G; Barkardottir, RB; Agnarsson, BA; Johannesdottir, G; Olafsdottir, K; Egilsson, V; Ingvarsson, S			High incidence of loss of heterozygosity at chromosome 17p13 in breast tumours from BRCA2 mutation carriers	ONCOGENE			English	Article						breast cancer; chromosome 17p13; TP53, BRCA2 carriers; LOH	P53 GENE-MUTATIONS; SUPPRESSOR GENE; CANCER PATIENTS; OVARIAN-CANCER; CARCINOMAS; LINKAGE; TP53; IMMUNOHISTOCHEMISTRY; PATHOLOGY; PROGNOSIS	Breast tumours from BRCA1 and BRCA2 mutation carriers are genetically instable and display specific patterns of chromosomal aberrations, suggestive of distinct genetic pathways in tumour progression, The frequency of abnormalities affecting chromosome 17p and the TP53 gene was determined in 27 breast tumours from 26 female patients carrying the Icelandic BRCA2 founder mutation (999del5), Loss of heterozygosity (LOH) was detected in 23 of the 27 tumours (85%), The majority of tumours manifesting LOH had lost a large region on 17p, although a more restricted loss, including the TP53 locus was seen in a few tumours. Positive p53 immunostaining was observed in 18 of 26 tumours (69%), However, mutations in the TP53 gene were detected in only three tumours (11%), including a missense (codon 139) and a nonsense mutation (codon 306) in two tumours with moderate p53 expression and a frameshift deletion (codon 182) in a tumour with no detectable p53 expression, Positive p53 immunostaining, mainly weak, was observed in 16 of the 24 tumours (66%) without TP53 mutation, The high frequency of LOH at chromosome 17p13 suggests that one or more genes from this region are involved in the development of BRCA2-induced breast cancer. The frequent finding of weak overexpression of, presumably wild type p53 protein, suggests an alternative mechanism of TP53 involvement specific to these tumours.	Univ Iceland, Dept Pathol, IS-121 Reykjavik, Iceland; Natl Hosp Iceland, IS-121 Reykjavik, Iceland	University of Iceland; Landspitali National University Hospital	Barkardottir, RB (corresponding author), Univ Iceland, Dept Pathol, POB 1465, IS-121 Reykjavik, Iceland.		Ingvarsson, Sigurdur/E-7448-2011	Ingvarsson, Sigurdur/0000-0003-4125-1714				BERGH J, 1995, NAT MED, V1, P1029, DOI 10.1038/nm1095-1029; BHARGAVA V, 1994, MODERN PATHOL, V7, P361; CORNELIS RS, 1994, CANCER RES, V54, P4200; COX LS, 1995, EMBO J, V14, P2099, DOI 10.1002/j.1460-2075.1995.tb07201.x; DENG G, 1994, CANCER RES, V54, P499; EASTON DF, 1993, AM J HUM GENET, V52, P678; ELNAGGAR AK, 1995, INT J CANCER, V64, P196, DOI 10.1002/ijc.2910640309; ELSTON CW, 1987, DIAGNOSTIC HISTOPATH, P300; FISHER CJ, 1994, BRIT J CANCER, V69, P26, DOI 10.1038/bjc.1994.4; FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630; Gretarsdottir S, 1996, BRIT J CANCER, V74, P555, DOI 10.1038/bjc.1996.400; GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; HALL PA, 1994, J PATHOL, V172, P1, DOI 10.1002/path.1711720103; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; IGGO R, 1990, LANCET, V335, P675, DOI 10.1016/0140-6736(90)90801-B; JACQUEMIER J, 1994, BRIT J CANCER, V69, P846, DOI 10.1038/bjc.1994.164; Johannesdottir G, 1996, CANCER RES, V56, P3663; Johannsson OT, 1997, EUR J CANCER, V33, P362, DOI 10.1016/S0959-8049(96)00469-8; JONES MH, 1992, GENE CHROMOSOME CANC, V5, P89, DOI 10.1002/gcc.2870050113; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; Lakhani SR, 1997, LANCET, V349, P1505; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LYNCH HT, 1990, BREAST CANCER RES TR, V15, P63, DOI 10.1007/BF01810778; Marcus JN, 1996, CANCER-AM CANCER SOC, V77, P697, DOI 10.1002/(SICI)1097-0142(19960215)77:4<697::AID-CNCR16>3.0.CO;2-W; MERLO GR, 1994, CANCER GENET CYTOGEN, V76, P106, DOI 10.1016/0165-4608(94)90458-8; NEWMAN B, 1988, P NATL ACAD SCI USA, V85, P3044, DOI 10.1073/pnas.85.9.3044; RUNNEBAUM IB, 1991, P NATL ACAD SCI USA, V88, P10657, DOI 10.1073/pnas.88.23.10657; SAITOH S, 1994, ONCOGENE, V9, P2869; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Sharan SK, 1997, NATURE, V386, P804, DOI 10.1038/386804a0; Sjogren S, 1996, J NATL CANCER I, V88, P173, DOI 10.1093/jnci/88.3-4.173; Sobol H, 1997, INT J ONCOL, V10, P349; Soddu S, 1996, MOL CELL BIOL, V16, P487; Teng DHF, 1996, NAT GENET, V13, P241, DOI 10.1038/ng0696-241; Tirkkonen M, 1997, CANCER RES, V57, P1222; UMEKITA Y, 1994, JPN J CANCER RES, V85, P825, DOI 10.1111/j.1349-7006.1994.tb02954.x; VIGNAL A, 1993, METHODS MOL GENETICS, V1, P211; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; WOOSTER R, 1994, SCIENCE, V265, P2088, DOI 10.1126/science.8091231; YANDELL DW, 1993, DIAGN MOL PATHOL, V2, P1	42	31	33	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 8	1998	16	1					21	26		10.1038/sj.onc.1201509	http://dx.doi.org/10.1038/sj.onc.1201509			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YP056	9467939	Green Published			2022-12-17	WOS:000071236800003
J	Darby, TG; Meissner, J; Ruhlmann, A; Mueller, WH; Scheibe, RJ				Darby, TG; Meissner, J; Ruhlmann, A; Mueller, WH; Scheibe, RJ			Functional interference between retinoic acid or steroid hormone receptors and the oncoprotein Fli-1	ONCOGENE			English	Article						cross-talk; Fli-1; hormone nuclear receptors; repression; erythroleukemia	HUMAN GLUCOCORTICOID RECEPTOR; PROVIRAL INTEGRATION SITE; ONCOGENE FAMILY MEMBER; MURINE LEUKEMIA-VIRUS; ETS GENE FAMILY; A-I GENE; THYROID-HORMONE; DNA-BINDING; TRANSCRIPTIONAL ACTIVATION; CELL-DIFFERENTIATION	The Fli-1 protein is a member of the ets proto-oncogene family, whose overexpression is a consequence of Friend murine leukemia virus (F-MuLV) integration in Friend erythroleukemic cells. We present evidence that Fli-1 and the retinoic acid receptor (RAR alpha) can reciprocally repress one another's transcriptional activation. Overexpression of Fli-1 inhibits the retinoic acid-induced activation of genes carrying a functional retinoic acid response element (RARE), Conversely, RAR alpha is able to repress Fli-1-mediated transcriptional activation. Transfection analysis of RAR alpha and Fli-1 mutants in cultured cells demonstrate that the DNA binding domain of RAR alpha and the N-terminal region of Fli-1 are required for repression, Gel retardation analysis demonstrates that RAR alpha cannot bind to the Fli-1 binding site in the E74 promoter and the expression of Fli-1 does not affect RAR alpha binding to DIVA, Furthermore, the data suggest an indirect interaction between Fli-1 and RAR alpha mediated by a 'bridging' factor(s) present in nuclear extracts from RM10 erythroleukemia cells, Fli-1 also interferes with the action of receptors for thyroid or glucocorticoid hormone in several hematopoietic cell lines, The RA-induced differentiation and decrease of cell proliferation was blocked in myeloblastic leukemia HL-60 cells overexpressing the N-terminal region of Fli-1 at physiological concentrations of RA. These data suggest that accumulation of Fli-1 can oppose the transcriptional activity of hormone receptors in hematopoietic cells.	Hannover Med Sch, Zentrum Biochem, Dept Clin Chem, D-30623 Hannover, Germany; Hannover Med Sch, Zentrum Biochem, Inst Physiol, D-30623 Hannover, Germany; Max Delbruck Zentrum, Berlin, Germany; Hannover Med Sch, Inst Mol Biol, D-30623 Hannover, Germany	Hannover Medical School; Hannover Medical School; Helmholtz Association; Max Delbruck Center for Molecular Medicine; Hannover Medical School	Scheibe, RJ (corresponding author), Hannover Med Sch, Zentrum Biochem, Dept Clin Chem, D-30623 Hannover, Germany.							BAILLY RA, 1994, MOL CELL BIOL, V14, P3230, DOI 10.1128/MCB.14.5.3230; Bassuk AG, 1997, ADV IMMUNOL, V64, P65, DOI 10.1016/S0065-2776(08)60887-1; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BENDAVID Y, 1991, GENE DEV, V5, P908, DOI 10.1101/gad.5.6.908; BENDAVID Y, 1991, CELL, V66, P831, DOI 10.1016/0092-8674(91)90428-2; BENDAVID Y, 1990, P NATL ACAD SCI USA, V87, P1332, DOI 10.1073/pnas.87.4.1332; Blomhoff R., 1994, VITAMIN A HLTH DIS; BRAND N, 1988, NATURE, V332, P850, DOI 10.1038/332850a0; BREITMAN TR, 1980, P NATL ACAD SCI-BIOL, V77, P2936, DOI 10.1073/pnas.77.5.2936; CELADA A, 1992, J IMMUNOL, V148, P1102; CHAMBON P, 1991, FAMILY RETINOIC ACID; Chambon Pierre, 1994, Seminars in Cell Biology, V5, P115, DOI 10.1006/scel.1994.1015; Chesnut JD, 1996, J IMMUNOL METHODS, V193, P17, DOI 10.1016/0022-1759(96)00032-4; DAMM K, 1989, NATURE, V339, P593, DOI 10.1038/339593a0; DARROW AL, 1990, MOL CELL BIOL, V10, P5883, DOI 10.1128/MCB.10.11.5883; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; DELGADO MD, 1994, ONCOGENE, V9, P1723; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; DETHE H, 1991, RETINOIC ACID RECEPT; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; GAUTHIER JM, 1993, EMBO J, V12, P5089, DOI 10.1002/j.1460-2075.1993.tb06203.x; GIGUERE V, 1986, CELL, V46, P645, DOI 10.1016/0092-8674(86)90339-9; GILL G, 1988, NATURE, V334, P721, DOI 10.1038/334721a0; GLASS CK, 1991, REGULATION GNEE TRAN; GOLAY J, 1988, CELL, V55, P1147, DOI 10.1016/0092-8674(88)90259-0; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GREEN S, 1988, TRENDS GENET, V4, P309, DOI 10.1016/0168-9525(88)90108-4; HAGMAN J, 1994, CURR OPIN IMMUNOL, V6, P222, DOI 10.1016/0952-7915(94)90095-7; HO IC, 1990, SCIENCE, V250, P814, DOI 10.1126/science.2237431; HOFFMANN B, 1990, MOL ENDOCRINOL, V4, P1727, DOI 10.1210/mend-4-11-1727; HOLLENBERG SM, 1985, NATURE, V318, P635, DOI 10.1038/318635a0; HROMAS R, 1993, BLOOD, V82, P2998; HROMAS R, 1993, BIOCHIM BIOPHYS ACTA, V1172, P155, DOI 10.1016/0167-4781(93)90283-J; JANKNECHT R, 1993, BIOCHIM BIOPHYS ACTA, V1155, P346, DOI 10.1016/0304-419X(93)90014-4; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; KARIN M, 1984, NATURE, V308, P513, DOI 10.1038/308513a0; Kastner P, 1994, ROLE NUCL RETINOIC A; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; KLEMSZ MJ, 1993, J BIOL CHEM, V268, P5769; LADIAS JAA, 1991, SCIENCE, V251, P561, DOI 10.1126/science.1899293; LEID M, 1992, TRENDS BIOCHEM SCI, V17, P427, DOI 10.1016/0968-0004(92)90014-Z; LEIDEN JM, 1994, CURR OPIN IMMUNOL, V6, P231, DOI 10.1016/0952-7915(94)90096-5; LEPRINCE D, 1983, NATURE, V306, P395, DOI 10.1038/306395a0; LESSNICK SL, 1995, ONCOGENE, V10, P423; LI JP, 1990, NATURE, V343, P762, DOI 10.1038/343762a0; LI JP, 1991, J VIROL, V65, P2408, DOI 10.1128/JVI.65.5.2408-2414.1991; LINNEY E, 1992, CURR TOP DEV BIOL, V27, P309, DOI 10.1016/S0070-2153(08)60538-4; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; MANGELSDORF DJ, 1994, RETINOID RECEPTORS R; MAO XH, 1994, J BIOL CHEM, V269, P18216; MAY WA, 1993, P NATL ACAD SCI USA, V90, P5752, DOI 10.1073/pnas.90.12.5752; METZ T, 1991, CELL, V66, P95, DOI 10.1016/0092-8674(91)90142-L; MEYER ME, 1989, CELL, V57, P433, DOI 10.1016/0092-8674(89)90918-5; MOREAUGACHELIN F, 1989, ONCOGENE, V4, P1449; MOREAUGACHELIN F, 1988, NATURE, V331, P277, DOI 10.1038/331277a0; NAGAYA T, 1993, J BIOL CHEM, V268, P15766; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; NUNN MF, 1983, NATURE, V306, P391, DOI 10.1038/306391a0; NUNN MF, 1989, J VIROL, V63, P398, DOI 10.1128/JVI.63.1.398-402.1989; PAHL HL, 1993, J BIOL CHEM, V268, P5014; PAUL R, 1991, J VIROL, V65, P464, DOI 10.1128/JVI.65.1.464-467.1991; PFAHL M, 1991, MOL MECH RETINOIC AC; Rao G, 1997, ONCOGENE, V14, P123, DOI 10.1038/sj.onc.1200807; RAO VN, 1993, ONCOGENE, V8, P2167; REDDY ESP, 1987, P NATL ACAD SCI USA, V84, P6131, DOI 10.1073/pnas.84.17.6131; ROTTMAN JN, 1991, MOL CELL BIOL, V11, P3814, DOI 10.1128/MCB.11.7.3814; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAP J, 1986, NATURE, V324, P635, DOI 10.1038/324635a0; SCHEIBE RJ, 1992, J BIOL CHEM, V267, P17611; SCHEIBE RJ, 1991, J CELL BIOL, V113, P1173, DOI 10.1083/jcb.113.5.1173; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SCHROEDER C, 1992, ONCOGENE, V7, P217; SCHUETZE S, 1993, MOL CELL BIOL, V13, P5670, DOI 10.1128/MCB.13.9.5670; SETH A, 1992, CELL GROWTH DIFFER, V3, P327; SETH A, 1990, ONCOGENE, V5, P1761; SHYAM E, 1990, CANCER RES, V50, P5013; SIDDIQUE HR, 1993, ONCOGENE, V8, P1751; SPORN MB, 1994, RETINOIDS; SUCOV HM, 1990, P NATL ACAD SCI USA, V87, P5392, DOI 10.1073/pnas.87.14.5392; URNESS LD, 1990, CELL, V63, P47, DOI 10.1016/0092-8674(90)90287-O; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; Watson DK, 1997, ONCOGENE, V14, P213, DOI 10.1038/sj.onc.1200839; WEINBERGER C, 1986, NATURE, V324, P641, DOI 10.1038/324641a0; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZHANG LQ, 1993, ONCOGENE, V8, P1621; ZHANG LQ, 1995, MOL CELL BIOL, V15, P6961	88	31	32	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 18	1997	15	25					3067	3082		10.1038/sj.onc.1201503	http://dx.doi.org/10.1038/sj.onc.1201503			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YL559	9444955				2022-12-17	WOS:000070968000007
J	Takemura, M; Kitagawa, T; Izuta, S; Wasa, J; Takai, A; Akiyama, T; Yoshida, S				Takemura, M; Kitagawa, T; Izuta, S; Wasa, J; Takai, A; Akiyama, T; Yoshida, S			Phosphorylated retinoblastoma protein stimulates DNA polymerase alpha	ONCOGENE			English	Article						Rb protein; DNA polymerase alpha; protein-protein interaction; DNA replication; phosphorylation	HUMAN CYCLIN-E; T-ANTIGEN; TRANSCRIPTION FACTOR; GENE-PRODUCT; SV40 ORIGIN; CALF THYMUS; REPLICATION INVITRO; CELL-CYCLE; RB PROTEIN; IN-VITRO	Human retinoblastoma (Rb) protein, immunopurified from an extract of recombinant baculovirus infected cells, stimulated 10-100-fold the activity of DNA polymerase alpha from calf thymus or human HeLa cells, Purified Rb protein is composed of two electrophoretically distinguishable forms, i.e., partially phosphorylated and under-phosphorylated forms. Dephosphorylation of Rb protein by protein phosphatase 2A largely diminished its stimulatory effect, On the other hand, a hyperphosphorylated Rb protein, obtained from insect cells overexpressing Rb protein, cyclin E and cyclin-dependent kinase 2 simultaneously, stimulated DNA polymerase alpha more strongly than the singly-expressed Rb protein. These results indicate that the phosphorylation is crucial for the stimulation, Rb protein isolated from human Burkitt lymphoma Raji cells also stimulated DNA polymerase alpha. In contrast, Rb protein did not affect eukaryotic DNA primase or Klenow fragment of Escherichia coli DNA polymerase I, By immunoprecipitation using anti-DNA polymerase alpha antibody, Rb protein in nuclear extract of Raji cells was coprecipitated with DNA polymerase alpha, This result indicates that DNA polymerase alpha exists as a complex containing phosphorylated Rb protein in cells. DNA polymerase alpha specifically bound to a purified Rb protein-immobilized Sepharose column. Rb protein also bound to DNA polymerase alpha trapped to anti-DNA polymerase a antibody-Sepharose column, suggesting the direct association of these two proteins, These observations suggest a new function of phosphorylated Rb protein in the regulation of DNA replication.	NAGOYA UNIV,SCH MED,DIS MECHANISM & CONTROL RES INST,CANC CELL BIOL LAB,NAGOYA,AICHI 466,JAPAN; KUMAMOTO UNIV,FAC SCI,DEPT BIOL SCI,KUMAMOTO 860,JAPAN; NAGOYA UNIV,SCH MED,DEPT PHYSIOL,NAGOYA,AICHI 466,JAPAN; OSAKA UNIV,MICROBIAL DIS RES INST,SUITA,OSAKA 565,JAPAN	Nagoya University; Kumamoto University; Nagoya University; Osaka University								AKIYAMA T, 1992, P NATL ACAD SCI USA, V89, P7900, DOI 10.1073/pnas.89.17.7900; ALBERTS AS, 1993, P NATL ACAD SCI USA, V90, P388, DOI 10.1073/pnas.90.2.388; AMIN AA, 1994, J BIOL CHEM, V269, P7735; BAGCHI S, 1991, CELL, V65, P1063, DOI 10.1016/0092-8674(91)90558-G; CAVANAUGH AH, 1995, NATURE, V374, P177, DOI 10.1038/374177a0; CAVENEE WK, 1983, NATURE, V305, P779, DOI 10.1038/305779a0; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; COLLINS KL, 1991, MOL CELL BIOL, V11, P2108, DOI 10.1128/MCB.11.4.2108; DEAN FB, 1987, P NATL ACAD SCI USA, V84, P16, DOI 10.1073/pnas.84.1.16; DODSON M, 1987, SCIENCE, V238, P964, DOI 10.1126/science.2823389; DORNREITER I, 1990, EMBO J, V9, P3329, DOI 10.1002/j.1460-2075.1990.tb07533.x; DORNREITER I, 1992, EMBO J, V11, P769, DOI 10.1002/j.1460-2075.1992.tb05110.x; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; FURUICHI Y, 1993, BIOSCI BIOTECH BIOCH, V57, P147, DOI 10.1271/bbb.57.147; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HOROWITZ JM, 1989, SCIENCE, V243, P937, DOI 10.1126/science.2521957; HURWITZ J, 1990, J BIOL CHEM, V265, P18043; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; KELLY TJ, 1988, J BIOL CHEM, V263, P17889; Kitagawa M, 1996, EMBO J, V15, P7060, DOI 10.1002/j.1460-2075.1996.tb01097.x; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE EYHP, 1988, SCIENCE, V241, P218, DOI 10.1126/science.3388033; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; LEE WH, 1994, COLD SPRING HARB SYM, V59, P97, DOI 10.1101/SQB.1994.059.01.013; LEE WH, 1987, NATURE, V329, P642, DOI 10.1038/329642a0; MURAKAMI Y, 1992, P NATL ACAD SCI USA, V89, P952, DOI 10.1073/pnas.89.3.952; NAKAMURA H, 1984, EXP CELL RES, V151, P123, DOI 10.1016/0014-4827(84)90362-8; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; SAVOYSKY E, 1992, BIOCHEM BIOPH RES CO, V187, P697, DOI 10.1016/0006-291X(92)91251-K; SAVOYSKY E, 1993, ONCOGENE, V8, P319; SIMBULAN CMG, 1993, J BIOL CHEM, V268, P93; SIMBULAN CMG, 1994, BIOCHEMISTRY-US, V33, P9007, DOI 10.1021/bi00196a019; SMALE ST, 1986, MOL CELL BIOL, V6, P4077, DOI 10.1128/MCB.6.11.4077; STILLMAN B, 1989, ANNU REV CELL BIOL, V5, P197; SUZUKI M, 1994, J BIOL CHEM, V269, P10225; TAKEMURA M, 1994, BIOCHEM BIOPH RES CO, V199, P46, DOI 10.1006/bbrc.1994.1191; TAMAI K, 1988, BIOCHIM BIOPHYS ACTA, V950, P263, DOI 10.1016/0167-4781(88)90122-4; TANG A, 1988, SCIENCE, V242, P263, DOI 10.1126/science.3175651; TSURIMOTO T, 1990, NATURE, V346, P534, DOI 10.1038/346534a0; TUNG HYL, 1984, EUR J BIOCHEM, V138, P635, DOI 10.1111/j.1432-1033.1984.tb07962.x; WAGA S, 1994, NATURE, V369, P207, DOI 10.1038/369207a0; WANG NP, 1990, CELL GROWTH DIFFER, V1, P429; WANG TSF, 1991, ANNU REV BIOCHEM, V60, P513, DOI 10.1146/annurev.biochem.60.1.513; YOKOTA J, 1988, ONCOGENE, V3, P471; YOSHIDA S, 1974, BIOCHIM BIOPHYS ACTA, V353, P463, DOI 10.1016/0005-2787(74)90052-5; YOSHIDA S, 1989, J BIOCHEM-TOKYO, V106, P389, DOI 10.1093/oxfordjournals.jbchem.a122863	50	31	31	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 13	1997	15	20					2483	2492		10.1038/sj.onc.1201431	http://dx.doi.org/10.1038/sj.onc.1201431			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YE963	9395244				2022-12-17	WOS:A1997YE96300010
J	Gallo, R; Provenzano, C; Carbone, R; DiFiore, PP; Castellani, L; Falcone, G; Alema, S				Gallo, R; Provenzano, C; Carbone, R; DiFiore, PP; Castellani, L; Falcone, G; Alema, S			Regulation of the tyrosine kinase substrate Eps8 expression by growth factors, v-Src and terminal differentiation	ONCOGENE			English	Article						tyrosine kinase; Eps8; Shc; differentiation; signal transduction	QUAIL MYOTUBES; CONSTITUTIVE PHOSPHORYLATION; HIGH-EFFICIENCY; SHC PROTEINS; TRANSFORMATION; DOMAIN; CELLS; FIBROBLASTS; ONCOGENES; MUSCLE	SH3-containing proteins are involved in signal transduction by a number of growth factor receptors and in the organization of the cytoskeleton. The recently identified Eps8 protein, which contains an SH3 domain, is coupled functionally and physically to the EGFR and is tyrosine phosphorylated by this receptor and other receptors as well,Here, we examined the regulation of eps8 expression in response to mitogenic or differentiative signals, We show that Eps8 is expressed at low levels in resting fibroblasts, but its expression is strongly induced during activation by serum, phorbol esters and the v-src oncogene, Conversely, expression of Eps8, but not of other EGFR substrates such as She or Eps15, is virtually extinguished in non-proliferating, terminally differentiated murine myogenic cells, The putative role of Eps8 protein as a v-Src substrate was analysed in murine fibroblasts and in quail myogenic cells expressing a temperature-sensitive variant of the tyrosine kinase, Tyrosine phosphorylation of Eps8 was detected only at the permissive temperature, A non-myristylated, transformation-defective mutant of v-Src did not phosphorylate Eps8, whereas it phosphorylated She. Together, these findings indicate that Eps8 may be a critical substrate of v-Src, They further establish Eps8 as an example of a signal transducer whose expression senses the balance between growth and differentiation and might, therefore, be involved in the determination of the phenotype.	CNR, IST BIOL CELLULARE, I-00137 ROME, ITALY; EUROPEAN INST ONCOL, I-20141 MILAN, ITALY; UNIV BARI, IST MICROBIOL, I-70124 BARI, ITALY; UNIV ROMA TOR VERGATA, DIPARTIMENTO MED SPERIMENTALE & SCI BIOCHIM, I-00133 ROME, ITALY	Consiglio Nazionale delle Ricerche (CNR); IRCCS European Institute of Oncology (IEO); Universita degli Studi di Bari Aldo Moro; University of Rome Tor Vergata			Falcone, Germana/A-3735-2016; Di Fiore, Pier Paolo/K-2130-2012	Di Fiore, Pier Paolo/0000-0002-2252-0950; Castellani, Loriana/0000-0002-8519-3504; Alema, Stefano/0000-0002-9869-6354; Falcone, Germana/0000-0002-3508-7623	Telethon [800] Funding Source: Medline	Telethon(Fondazione Telethon)		ALEMA S, 1987, ADV CANCER RES, V49, P1, DOI 10.1016/S0065-230X(08)60792-7; ALEMA S, 1985, NATURE, V316, P557, DOI 10.1038/316557a0; ALEMA S, 1994, SEMIN CANCER BIOL, V5, P147; BOETTIGER D, 1989, CURR TOP MICROBIOL, V147, P31; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; CASTAGNINO P, 1995, ONCOGENE, V10, P723; CASTELLANI L, 1995, J CELL BIOL, V130, P871, DOI 10.1083/jcb.130.4.871; Castellani L, 1996, J CELL SCI, V109, P1335; CATLING AD, 1993, ONCOGENE, V8, P1875; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; FALCONE G, 1991, MOL CELL BIOL, V11, P3331, DOI 10.1128/MCB.11.6.3331; FALCONE G, 1992, ONCOGENE, V7, P1913; FAZIOLI F, 1993, EMBO J, V12, P3799, DOI 10.1002/j.1460-2075.1993.tb06058.x; FAZIOLI F, 1993, MOL CELL BIOL, V13, P5814, DOI 10.1128/MCB.13.9.5814; FINCHAM VJ, 1995, ONCOGENE, V10, P2247; HJELLE B, 1988, P NATL ACAD SCI USA, V85, P4355, DOI 10.1073/pnas.85.12.4355; KAMPS MP, 1986, CELL, V45, P105, DOI 10.1016/0092-8674(86)90542-8; KARLSSON T, 1995, ONCOGENE, V10, P1475; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIPSICH L, 1984, MOL CELL BIOL, V4, P1420, DOI 10.1128/MCB.4.7.1420; Matoskova B, 1996, ONCOGENE, V12, P2679; MATOSKOVA B, 1995, MOL CELL BIOL, V15, P3805; MCGLADE J, 1992, P NATL ACAD SCI USA, V89, P8869, DOI 10.1073/pnas.89.19.8869; Migliaccio E, 1997, EMBO J, V16, P706, DOI 10.1093/emboj/16.4.706; OKAMURA H, 1995, J BIOL CHEM, V270, P26613, DOI 10.1074/jbc.270.44.26613; PARSONS JT, 1989, CURR TOP MICROBIOL, V147, P79; PELICCI G, 1995, ONCOGENE, V11, P899; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VERDERAME MF, 1995, MOL BIOL CELL, V6, P953, DOI 10.1091/mbc.6.8.953; WONG WT, 1994, ONCOGENE, V9, P3057; WU H, 1991, MOL CELL BIOL, V11, P5113, DOI 10.1128/MCB.11.10.5113; WU H, 1993, J CELL BIOL, V120, P1417, DOI 10.1083/jcb.120.6.1417; WYKE JA, 1987, BIOCHIM BIOPHYS ACTA, V907, P47, DOI 10.1016/0304-419X(87)90018-7	34	31	31	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 16	1997	15	16					1929	1936		10.1038/sj.onc.1201344	http://dx.doi.org/10.1038/sj.onc.1201344			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YA872	9365239				2022-12-17	WOS:A1997YA87200007
J	Munoz, R; Klingenberg, O; Wiedlocha, A; Rapak, A; Falnes, PO; Olsnes, S				Munoz, R; Klingenberg, O; Wiedlocha, A; Rapak, A; Falnes, PO; Olsnes, S			Effect of mutation of cytoplasmic receptor domain and of genistein on transport of acidic fibroblast growth factor into cells	ONCOGENE			English	Article						acidic fibroblast growth factor; receptor mutant; genistein; farnesylation	NUCLEAR TRANSLOCATION SEQUENCE; TYROSINE KINASE-ACTIVITY; FACTOR-I; SIGNAL-TRANSDUCTION; DIPHTHERIA-TOXIN; BALB/C 3T3; PRELAMIN-A; FGF; INTERNALIZATION; LOCALIZATION	Acidic fibroblast growth factor (aFGF) binds to specific transmembrane receptors and is partly transported to a nuclear location, To study this transport we made a kinase-negative mutant of FGF receptor 4 as well as one where the major part of the cytoplasmic receptor domain was deleted, and expressed them in U2OSDr1 cells that lack functional FGF receptors. All receptors mediated endocytic uptake of aFGF. Translocation of the growth factor across cellular membranes was assayed using aFGF with a C-terminal CAAX-motif, which signals addition of a farnesyl group onto the protein once in the cytosol. CAAX-tagged aFGF was farnesylated when incubated with cells containing wild-type or kinase-negative receptors. It was not farnesylated in cells expressing the,deleted receptor, or when the incubation was in the presence of genistein, aFGF incubated with cells transfected with wild-type or kinase-negative receptors, but not with the deleted receptor, was partly recovered from the nuclear fraction in the absence, but not in the presence of genistein. The data indicate that the cytoplasmic receptor domain, but not the active kinase, is required for transport of the growth factor into cells, and that genistein inhibits the process.	NORWEGIAN RADIUM HOSP,INST CANC RES,N-0310 OSLO,NORWAY	University of Oslo			Falnes, Pål Ø./AAA-4581-2020; Rapak, Andrzej/ABE-6262-2021	Rapak, Andrzej/0000-0003-4897-0287; Falnes, Pal/0000-0001-8114-6025; Munoz, Raquel/0000-0001-9861-0349				AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; Bonnet H, 1996, J BIOL CHEM, V271, P24781, DOI 10.1074/jbc.271.40.24781; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; CAO Y, 1993, J CELL SCI, V104, P77; Casey PJ, 1996, J BIOL CHEM, V271, P5289, DOI 10.1074/jbc.271.10.5289; CHANG CP, 1993, J BIOL CHEM, V268, P19312; CHELLAIAH AT, 1994, J BIOL CHEM, V269, P11620; CRUMLEY G, 1991, ONCOGENE, V6, P2255; DUNN WA, 1980, J BIOL CHEM, V255, P5971; FALLON RJ, 1994, J BIOL CHEM, V269, P11011; FALNES PO, 1995, BIOCHEMISTRY-US, V34, P11152, DOI 10.1021/bi00035a021; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; HILL T, 1990, SCIENCE, V248, P1661; HOU JZ, 1991, SCIENCE, V251, P665, DOI 10.1126/science.1846977; IMAMURA T, 1994, EXP CELL RES, V215, P363, DOI 10.1006/excr.1994.1353; IMAMURA T, 1990, SCIENCE, V249, P1567, DOI 10.1126/science.1699274; IMAMURA T, 1992, J BIOL CHEM, V267, P5676; JACKSON A, 1992, P NATL ACAD SCI USA, V89, P10691, DOI 10.1073/pnas.89.22.10691; JOHNSON DE, 1990, MOL CELL BIOL, V10, P4728, DOI 10.1128/MCB.10.9.4728; JOHNSON DE, 1991, MOL CELL BIOL, V11, P4627, DOI 10.1128/MCB.11.9.4627; Johnston CL, 1995, J BIOL CHEM, V270, P30643, DOI 10.1074/jbc.270.51.30643; KIEFER P, 1994, EMBO J, V13, P4126, DOI 10.1002/j.1460-2075.1994.tb06730.x; KOROMA BM, 1994, BIOCHEM PHARMACOL, V48, P809, DOI 10.1016/0006-2952(94)90060-4; LANDGREN E, 1995, ONCOGENE, V10, P2027; LINASSIER C, 1990, BIOCHEM PHARMACOL, V39, P187, DOI 10.1016/0006-2952(90)90664-7; LOMAZE C, 1993, MOL BIOL CELL, V4, P715; LUTZ RJ, 1992, P NATL ACAD SCI USA, V89, P3000, DOI 10.1073/pnas.89.7.3000; Maher PA, 1996, J CELL BIOL, V134, P529, DOI 10.1083/jcb.134.2.529; MASON IJ, 1994, CELL, V78, P547, DOI 10.1016/0092-8674(94)90520-7; Pintucci G, 1996, MOL BIOL CELL, V7, P1249, DOI 10.1091/mbc.7.8.1249; PRUDOVSKY I, 1994, J BIOL CHEM, V269, P31720; RIESE J, 1995, MECH DEVELOP, V49, P13, DOI 10.1016/0925-4773(94)00296-Y; ROBINSON M S, 1992, Trends in Cell Biology, V2, P293, DOI 10.1016/0962-8924(92)90118-7; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SINENSKY M, 1994, J CELL SCI, V107, P61; SORKIN A, 1993, ONCOGENE, V8, P3021; SORKIN A, 1991, J BIOL CHEM, V266, P8355; SORKIN A, 1993, SCIENCE, V261, P612, DOI 10.1126/science.8342026; SOROKIN A, 1994, J BIOL CHEM, V269, P17056; Stachowiak MK, 1996, MOL BIOL CELL, V7, P1299, DOI 10.1091/mbc.7.8.1299; Stachowiak MK, 1996, MOL BRAIN RES, V38, P161, DOI 10.1016/0169-328X(96)00010-1; TROWBRIDGE IS, 1991, CURR OPIN CELL BIOL, V3, P634; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; Vainikka S, 1996, J BIOL CHEM, V271, P1270, DOI 10.1074/jbc.271.3.1270; Vera JC, 1996, J BIOL CHEM, V271, P8719, DOI 10.1074/jbc.271.15.8719; Wiedlocha A, 1995, J BIOL CHEM, V270, P30680, DOI 10.1074/jbc.270.51.30680; WIEDLOCHA A, 1994, CELL, V76, P1039, DOI 10.1016/0092-8674(94)90381-6; Wiedlocha A, 1996, MOL CELL BIOL, V16, P270; WIEDLOCHA A, 1992, EMBO J, V11, P4835, DOI 10.1002/j.1460-2075.1992.tb05589.x; ZHAN X, 1992, BIOCHEM BIOPH RES CO, V188, P982, DOI 10.1016/0006-291X(92)91328-N; ZHAN X, 1993, J BIOL CHEM, V268, P9611	53	31	33	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 31	1997	15	5					525	536		10.1038/sj.onc.1201226	http://dx.doi.org/10.1038/sj.onc.1201226			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XN255	9247306	Green Published			2022-12-17	WOS:A1997XN25500004
J	Coopersmith, CM; Gordon, JI				Coopersmith, CM; Gordon, JI			gamma-ray-induced apoptosis in transgenic mice with proliferative abnormalities in their intestinal epithelium: Re-entry of villus enterocytes into the cell cycle does not affect their radioresistance but enhances the radiosensitivity of the crypt by inducing p53	ONCOGENE			English	Article						radiation; apoptosis; cell cycle; intestinal epithelium; transgenic mice; p53	MOUSE SMALL-INTESTINE; RADIATION-INDUCED APOPTOSIS; BCL-2 HOMOLOG BAK; IN-VIVO; TUMOR-ANTIGEN; T-ANTIGEN; DIFFERENTIATION PROGRAMS; CHROMOSOMAL BREAKPOINT; GASTROINTESTINAL-TRACT; DNA FRAGMENTATION	The radiosensitivity of proliferating crypt epithelial cells makes the gut a major limiting factor in the use of radiotherapy for treatment of abdominal cancers, As post-mitotic epithelial cells migrate from mouse small intestinal crypts to the base of adjacent villi, they rapidly lose their ability to undergo apoptosis in response to ionizing irradiation (IR), To determine whether this radioresistance reflects withdrawal from the cell cycle, we used a lineage-specific promoter to direct expression of wild type Simian virus 40 T antigen (SV40 TAgWt) to villus, but not crypt, enterocytes in FVB/N transgenic mice, SV40 TAgWt induced, pRB-dependent, re-entry into the cell cycle is not associated with the acquisition of IR-stimulated apoptosis 4 h or 24 h after 6 Gy or 12 Gy of gamma-irradiation, Coexpression of SV40 TAgWt and K-ras(Val12) produces dysplasia in cycling villus enterocytes but no shift towards apoptotic responsiveness to IR, These findings suggest that the radioresistance of villus enterocytes is not simply due to their cell cycle arrest and may be a reflection of their microenvironment, Remarkably, reentry of villus enterocytes to the cell cycle increases the radiosensitivity of the crypt epithelium without changing Bcl-2, Bcl-x(L), Bak, or Bar expression, This effect is only manifest after IR and, based upon results obtained with mutant SV40 TAgs, depends upon reaching a critical level of proliferation in villus enterocytes, Like the normal crypt response to IR, the villus-derived enhancement of IR-stimulated crypt apoptosis is associated with an induction of p53 and Raf-l, and is dependent upon p53, Unlike the normal crypt response to IR, the p53 induction involves cells distributed throughout the crypt and the apoptotic response is not confined to the lower half of the crypt, These results indicate that signals initiated by cycling enterocytes can be transmitted to the crypt epithelium to induce p53 and influence their IR-induced apoptosis, Understanding the underlying signaling pathways may provide clues about how to modify a normal crypt's radiosensitivity for therapeutic benefit.	WASHINGTON UNIV,SCH MED,DEPT MOL BIOL & PHARMACOL,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT SURG,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL)					NIDDK NIH HHS [DK30292] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK030292, R37DK030292] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAKHSHI A, 1985, CELL, V41, P899, DOI 10.1016/S0092-8674(85)80070-2; BJERKNES M, 1981, AM J ANAT, V160, P51, DOI 10.1002/aja.1001600105; Blagosklonny MV, 1996, CANCER RES, V56, P1851; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; Bry L, 1996, P NATL ACAD SCI USA, V93, P1161, DOI 10.1073/pnas.93.3.1161; CALVERT R, 1990, ANAT REC, V227, P199, DOI 10.1002/ar.1092270208; CHANDRASEKARAN C, 1993, P NATL ACAD SCI USA, V90, P8871, DOI 10.1073/pnas.90.19.8871; Chandrasekaran C, 1996, J BIOL CHEM, V271, P28414, DOI 10.1074/jbc.271.45.28414; Chen CY, 1996, J BIOL CHEM, V271, P2376, DOI 10.1074/jbc.271.5.2376; CHEN JD, 1992, ONCOGENE, V7, P1167; CHENG H, 1974, AM J ANAT, V141, P537, DOI 10.1002/aja.1001410407; CHENG H, 1974, AM J ANAT, V141, P461, DOI 10.1002/aja.1001410403; CHENG H, 1974, AM J ANAT, V141, P481, DOI 10.1002/aja.1001410404; CHENG H, 1974, AM J ANAT, V141, P503, DOI 10.1002/aja.1001410405; CHENG H, 1974, AM J ANAT, V141, P521, DOI 10.1002/aja.1001410406; CHITTENDEN T, 1995, NATURE, V374, P733, DOI 10.1038/374733a0; CHWALINSKI S, 1988, CELL TISSUE KINET, V21, P317, DOI 10.1111/j.1365-2184.1988.tb00790.x; CLARKE AR, 1994, ONCOGENE, V9, P1767; CLEARY ML, 1985, P NATL ACAD SCI USA, V82, P7439, DOI 10.1073/pnas.82.21.7439; COHN SM, 1992, J CELL BIOL, V119, P27, DOI 10.1083/jcb.119.1.27; COOPERSMITH CM, 1997, IN PRESS J CELL BIOL; DEWEY WC, 1995, INT J RADIAT ONCOL, V33, P781, DOI 10.1016/0360-3016(95)00214-8; FALK P, 1994, AM J PHYSIOL, V266, pG987, DOI 10.1152/ajpgi.1994.266.6.G987; FARROW SN, 1995, NATURE, V374, P731, DOI 10.1038/374731a0; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Gajewski TF, 1996, CELL, V87, P589, DOI 10.1016/S0092-8674(00)81377-X; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; HALL PA, 1994, J CELL SCI, V107, P3569; HAUFT SM, 1992, J CELL BIOL, V117, P825, DOI 10.1083/jcb.117.4.825; Hermiston ML, 1996, GENE DEV, V10, P985, DOI 10.1101/gad.10.8.985; HERMISTON ML, 1995, J CELL BIOL, V129, P489, DOI 10.1083/jcb.129.2.489; Kasid U, 1996, NATURE, V382, P813, DOI 10.1038/382813a0; KIEFER MC, 1995, NATURE, V374, P736, DOI 10.1038/374736a0; KIM SH, 1994, P NATL ACAD SCI USA, V91, P6914, DOI 10.1073/pnas.91.15.6914; KIM SH, 1993, J CELL BIOL, V123, P877, DOI 10.1083/jcb.123.4.877; Kitada S, 1996, ONCOGENE, V12, P187; KNUDSON CM, 1995, SCIENCE, V270, P96, DOI 10.1126/science.270.5233.96; KRAJEWSKI S, 1994, AM J PATHOL, V145, P1323; KRAJEWSKI S, 1994, CANCER RES, V54, P5501; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOEFFLER M, 1993, J THEOR BIOL, V160, P471, DOI 10.1006/jtbi.1993.1031; MCCALLUM DE, IN PRESS ONCOGENE; MERRITT AJ, 1995, J CELL SCI, V108, P2261; MERRITT AJ, 1994, CANCER RES, V54, P614; MOTOYAMA N, 1995, SCIENCE, V267, P1506, DOI 10.1126/science.7878471; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; OREN M, 1981, MOL CELL BIOL, V1, P101, DOI 10.1128/MCB.1.2.101; PIPAS JM, 1983, MOL CELL BIOL, V3, P203, DOI 10.1128/MCB.3.2.203; POTTEN CS, 1990, INT J RADIAT BIOL, V58, P925, DOI 10.1080/09553009014552281; POTTEN CS, 1990, DEVELOPMENT, V110, P1001; POTTEN CS, 1994, INT J RADIAT BIOL, V65, P71, DOI 10.1080/09553009414550101; POTTEN CS, 1992, CANCER METAST REV, V11, P179, DOI 10.1007/BF00048063; Pullan S, 1996, J CELL SCI, V109, P631; REICH NC, 1983, MOL CELL BIOL, V3, P2143, DOI 10.1128/MCB.3.12.2143; RUOSLAHTI E, 1994, CELL, V77, P477, DOI 10.1016/0092-8674(94)90209-7; SCHMIDT GH, 1985, CELL, V40, P425, DOI 10.1016/0092-8674(85)90156-4; SELLINS KS, 1987, J IMMUNOL, V139, P3199; SRINIVASAN A, 1989, J VIROL, V63, P5459, DOI 10.1128/JVI.63.12.5459-5463.1989; STEPHENS L C, 1989, Cancer Bulletin (Houston), V41, P106; TSUJIMOTO Y, 1985, SCIENCE, V229, P1390, DOI 10.1126/science.3929382; WANG HG, 1994, ONCOGENE, V9, P2751; WRIGHT NA, 1982, CELL TISSUE KINET, V15, P595, DOI 10.1111/j.1365-2184.1982.tb01066.x; WRIGHT NA, 1984, BIOL EPITHELIAL CELL, P843; Wyllie A H, 1980, Int Rev Cytol, V68, P251; Zhan QM, 1996, ONCOGENE, V13, P2287	66	31	31	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 10	1997	15	2					131	141		10.1038/sj.onc.1201176	http://dx.doi.org/10.1038/sj.onc.1201176			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XK372	9244349				2022-12-17	WOS:A1997XK37200002
J	Charlesworth, A; Rozengurt, E				Charlesworth, A; Rozengurt, E			Bombesin and neuromedin B stimulate the activation of p42(mapk) and p74(raf-1) via a protein kinase C-independent pathway in Rat-1 cells	ONCOGENE			English	Article						p21(ras); G(q); neuropeptide; MAP kinases; signal transduction	SWISS 3T3 CELLS; GASTRIN-RELEASING PEPTIDE; MAP KINASE; LUNG-CANCER; RECEPTOR; GROWTH; RAS; PHOSPHORYLATION; IDENTIFICATION; FIBROBLASTS	The mechanisms by which seven transmembrane receptors activate p42(mapk)/p44(mapk) are not well defined although p21(ras)- and protein kinase C (PKC)-dependent pathways have been implicated, typically for G(i)- and G(q)-coupled receptors, respectively, Here, we demonstrate that in Rat-1 cells transfected with the G(q)-coupled bombesin/gastrin releasing peptide receptor, bombesin stimulated activation of p42(mapk) that was not inhibited by the specific PKC inhibitor GF 109203X or by down regulation of phorbol ester-sensitive PKC isoforms, In addition, bombesin rapidly stimulated p74(raf-1) activity that was also independent of PKC activity and insensitive to inhibition by pertussis toxin, Furthermore, addition of neuromedin B to Rat-l cells transfected with the neuromedin B preferring receptor also activated p42(mapk) and p74(raf-1) in a PKC-independent and pertussis toxin-insensitive manner, Finally we show that addition of bombesin to Rat-1 cells stimulated the GTP loading of p21(ras). Our results reveal a novel PKC-independent pathway in the action of G(q)-coupled receptors and stress the importance of cell context in defining the signal transduction pathway(s) that link specific receptors to the activation of the mitogen-activated protein kinase cascade.	IMPERIAL CANC RES FUND, LONDON WC2A 3PX, ENGLAND	Cancer Research UK								ALBLAS J, 1993, J BIOL CHEM, V268, P22235; ALESSI DR, 1994, EMBO J, V13, P1610, DOI 10.1002/j.1460-2075.1994.tb06424.x; ASHKENAZI A, 1987, SCIENCE, V238, P672, DOI 10.1126/science.2823384; BASU TN, 1992, NATURE, V356, P713, DOI 10.1038/356713a0; BATTEY JF, 1991, P NATL ACAD SCI USA, V88, P395, DOI 10.1073/pnas.88.2.395; CARNEY DN, 1987, CANCER RES, V47, P821; Charlesworth A, 1996, ONCOGENE, V12, P1337; COFFER A, 1990, FEBS LETT, V263, P80, DOI 10.1016/0014-5793(90)80710-Z; CORJAY MH, 1991, J BIOL CHEM, V266, P18771; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; CUTTITTA F, 1985, NATURE, V316, P823, DOI 10.1038/316823a0; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; HAWES BE, 1995, J BIOL CHEM, V270, P17148, DOI 10.1074/jbc.270.29.17148; HIGGINS TE, 1992, P NATL ACAD SCI USA, V89, P4240, DOI 10.1073/pnas.89.10.4240; HOWE LR, 1993, J BIOL CHEM, V268, P20717; KOCH WJ, 1994, P NATL ACAD SCI USA, V91, P12706, DOI 10.1073/pnas.91.26.12706; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; LACH EB, 1995, CELL GROWTH DIFFER, V6, P1427; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MATTINGLEY RR, 1995, MOL CELL BIOL, V14, P8623; OFFERMANNS S, 1994, FEBS LETT, V349, P201, DOI 10.1016/0014-5793(94)00667-9; PANG L, 1993, BIOCHEM J, V289, P283, DOI 10.1042/bj2890283; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; ROZENGURT E, 1983, P NATL ACAD SCI-BIOL, V80, P2936, DOI 10.1073/pnas.80.10.2936; ROZENGURT E, 1992, Current Opinion in Cell Biology, V4, P161, DOI 10.1016/0955-0674(92)90027-A; RUSSELL M, 1994, MOL CELL BIOL, V14, P2343, DOI 10.1128/MCB.14.4.2343; SATOH T, 1990, P NATL ACAD SCI USA, V87, P5993, DOI 10.1073/pnas.87.15.5993; SCHLAEPFER DD, 1994, NATURE, V372, P786; SETHI T, 1992, CANCER RES, V52, pS2737; SEUFFERLEIN T, 1995, CELL GROWTH DIFFER, V6, P383; Seufferlein T, 1996, J BIOL CHEM, V271, P21471, DOI 10.1074/jbc.271.35.21471; SEUFFERLEIN T, 1995, J BIOL CHEM, V270, P1; SOZERI O, 1992, ONCOGENE, V7, P2259; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; vanBiesen T, 1996, J BIOL CHEM, V271, P1266, DOI 10.1074/jbc.271.3.1266; VANCORVEN EJ, 1993, P NATL ACAD SCI USA, V90, P1257, DOI 10.1073/pnas.90.4.1257; WADA E, 1991, NEURON, V6, P421, DOI 10.1016/0896-6273(91)90250-4; Wan Y, 1996, NATURE, V380, P541, DOI 10.1038/380541a0; WINITZ S, 1993, J BIOL CHEM, V268, P19196; WITHERS DJ, 1995, J BIOL CHEM, V270, P21411, DOI 10.1074/jbc.270.36.21411; WU J, 1993, P NATL ACAD SCI USA, V90, P173, DOI 10.1073/pnas.90.1.173; YEO EJ, 1995, J BIOL CHEM, V270, P3980, DOI 10.1074/jbc.270.8.3980; ZACHARY I, 1985, P NATL ACAD SCI USA, V82, P7616, DOI 10.1073/pnas.82.22.7616; ZACHARY I, 1987, J BIOL CHEM, V262, P3947	46	31	31	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 15	1997	14	19					2323	2329		10.1038/sj.onc.1201075	http://dx.doi.org/10.1038/sj.onc.1201075			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WY883	9178908				2022-12-17	WOS:A1997WY88300009
J	Husson, H; Mograbi, B; SchmidAntomarchi, H; Fischer, S; Rossi, B				Husson, H; Mograbi, B; SchmidAntomarchi, H; Fischer, S; Rossi, B			CSF-1 stimulation induces the formation of a multiprotein complex including CSF-1 receptor, c-Cbl, PI 3-kinase, Crk-II and Grb2	ONCOGENE			English	Article						Colony Stimulating Factor-1; c-Cbl; c-Crk-II; phosphatidylinositol 3-kinase; Grb2; multimolecular complex	PROTEIN-TYROSINE KINASE; GROWTH-FACTOR RECEPTOR; CELL ANTIGEN RECEPTOR; INSULIN-RECEPTOR; SH3 DOMAIN; PHOSPHATIDYLINOSITOL 3'-KINASE; SIGNAL-TRANSDUCTION; 2-HYBRID SYSTEM; JURKAT CELLS; V-CRK	Recently c-Cbl has been reported to be phosphorylated upon CSF-1 stimulation. The product of the c-cbl protooncogene (c-Cbl) is a 120 kDa protein harboring several docking sites for Src homology 2 (SH2) domain containing proteins and proline-rich regions that have been shown to allow its constitutive association with the SH3 domains of Grb2, We demonstrate here that CSF-1 exposure of stable transfectant CHO cells expressing the CSF-1 receptor induced the sustained tyrosine phosphorylation of c-Cbl and its subsequent association with Crk-II and the p85 kDa subunit of the PI 3-kinase, while it constitutively associates with Grb2, We demonstrate by in vitro experiments that these associations require the SH2 domain of Crk-II and both the C- and N-terminal SH2 domains of the p85 subunit of the PI 3-kinase, c-Cbl is the major PI 3-kinase-containing protein in c-Fms expressing CHO cells upon CSF-1 stimulation, Thus c-Cbl behaves as a core protein, allowing the formation of a quaternary complex including, Crk-II, PI 3-kinase and Grb2, We provide evidence that this multiprotein complex can interact with the tyrosine phosphorylated CSF-1 receptor through the unoccupied SH2 domain of Grb2.	FAC MED,INSERM U364,F-06107 NICE,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm)			Mograbi, Baharia/N-5531-2018; Mograbi, Baharia/Q-7953-2019	Mograbi, Baharia/0000-0002-1025-3429				BACKER JM, 1993, J BIOL CHEM, V268, P8204; BEITNERJOHNSON D, 1995, J BIOL CHEM, V270, P5187, DOI 10.1074/jbc.270.10.5187; BIRGE RB, 1992, J BIOL CHEM, V267, P10588; BIRGE RB, 1993, MOL CELL BIOL, V13, P4648, DOI 10.1128/MCB.13.8.4648; BLAKE TJ, 1993, EMBO J, V12, P2017, DOI 10.1002/j.1460-2075.1993.tb05851.x; Buday L, 1996, J BIOL CHEM, V271, P6159, DOI 10.1074/jbc.271.11.6159; CRAPARO A, 1995, J BIOL CHEM, V270, P15639, DOI 10.1074/jbc.270.26.15639; DONOVAN JA, 1994, J BIOL CHEM, V269, P22921; FAUX MC, 1986, CELL, V85, P9; FELLER SM, 1995, ONCOGENE, V10, P1465; Fournel M, 1996, J EXP MED, V183, P301, DOI 10.1084/jem.183.1.301; Fukazawa T, 1996, J BIOL CHEM, V271, P14554, DOI 10.1074/jbc.271.24.14554; GALISTEO ML, 1995, J BIOL CHEM, V270, P20242, DOI 10.1074/jbc.270.35.20242; HEMPSTEAD BL, 1994, MOL CELL BIOL, V14, P1964, DOI 10.1128/MCB.14.3.1964; KARNITZ LM, 1994, J EXP MED, V179, P1799, DOI 10.1084/jem.179.6.1799; KIM TJ, 1995, J BIOL CHEM, V270, P27504, DOI 10.1074/jbc.270.46.27504; KUHNE MR, 1994, J BIOL CHEM, V269, P15833; LAMOTHE B, 1995, FEBS LETT, V373, P51, DOI 10.1016/0014-5793(95)01011-3; LANGDON WY, 1989, P NATL ACAD SCI USA, V86, P1168, DOI 10.1073/pnas.86.4.1168; LEE AWM, 1992, CURR TOP CELL REGUL, V32, P73; LEE CH, 1993, P NATL ACAD SCI USA, V90, P11713, DOI 10.1073/pnas.90.24.11713; LIU XQ, 1993, MOL CELL BIOL, V13, P5225, DOI 10.1128/MCB.13.9.5225; MEISNER H, 1995, J BIOL CHEM, V270, P25332, DOI 10.1074/jbc.270.43.25332; MEISNER H, 1995, MOL CELL BIOL, V15, P3571; MOTTO DG, 1994, J BIOL CHEM, V269, P21608; ODAI H, 1995, J BIOL CHEM, V270, P10800, DOI 10.1074/jbc.270.18.10800; ONEILL TJ, 1994, MOL CELL BIOL, V14, P6433, DOI 10.1128/MCB.14.10.6433; Panchamoorthy G, 1996, J BIOL CHEM, V271, P3187, DOI 10.1074/jbc.271.6.3187; PRASAD KVS, 1993, MOL CELL BIOL, V13, P7708, DOI 10.1128/MCB.13.12.7708; PRUETT W, 1995, MOL CELL BIOL, V15, P1778; RAMOSMORALES F, 1994, ONCOGENE, V9, P1917; Reedquist KA, 1996, J BIOL CHEM, V271, P8435, DOI 10.1074/jbc.271.14.8435; REEDQUIST KA, 1994, P NATL ACAD SCI USA, V91, P4135, DOI 10.1073/pnas.91.10.4135; Ribon V, 1996, J BIOL CHEM, V271, P7375, DOI 10.1074/jbc.271.13.7375; RIVEROLEZCANO OM, 1994, J BIOL CHEM, V269, P17363; Sambrook J, 1989, MOL CLONING LAB MANU; Sattler M, 1996, ONCOGENE, V12, P839; SCHMIDANTOMARCH.H, 1995, EUR J IMMUNOL, V26, P717; Schnyder B, 1996, BIOCHEM J, V315, P767, DOI 10.1042/bj3150767; SHERR CJ, 1990, LYMPHOKINE RES, V9, P543; Smit L, 1996, ONCOGENE, V13, P381; STANLEY ER, 1981, J IMMUNOL METHODS, V42, P253, DOI 10.1016/0022-1759(81)90156-3; STANLEY ER, 1994, CYTOKINE HDB, P387; Sun XJ, 1996, J BIOL CHEM, V271, P10583, DOI 10.1074/jbc.271.18.10583; TAICHMAN R, 1993, J BIOL CHEM, V268, P20031; TANAKA S, 1995, J BIOL CHEM, V270, P14347, DOI 10.1074/jbc.270.24.14347; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; VANDERGEER P, 1993, EMBO J, V12, P5161, DOI 10.1002/j.1460-2075.1993.tb06211.x; Wang Y, 1996, J BIOL CHEM, V271, P17, DOI 10.1074/jbc.271.1.17; Wymann MP, 1996, MOL CELL BIOL, V16, P1722	50	31	31	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY 15	1997	14	19					2331	2338		10.1038/sj.onc.1201074	http://dx.doi.org/10.1038/sj.onc.1201074			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WY883	9178909				2022-12-17	WOS:A1997WY88300010
J	Ivanchuk, SM; Eng, C; Cavenee, WK; Mulligan, LM				Ivanchuk, SM; Eng, C; Cavenee, WK; Mulligan, LM			The expression of RET and its multiple splice forms in developing human kidney	ONCOGENE			English	Article						RET; kidney; alternative splicing	GROWTH-FACTOR RECEPTORS; ADULT-RAT TISSUES; TYROSINE KINASE; PROTO-ONCOGENE; PROTOONCOGENE PRODUCT; MESSENGER-RNA; CELL-LINE; VARIANTS; TRANSFORMATION; SPECIFICITY	A series of inductive events between two different cell groups, the ureteric bud epithelium and metanephric mesenchyme, gives rise to the functional mammalian kidney, These reciprocal inductive interactions involve a number of molecules, one of which is the RET receptor tyrosine kinase, The phenotype of mice lacking functional RET includes kidney agenesis or severe dysgenesis, indicating a requirement for RET in kidney organogenesis, To investigate RET expression in human kidney development, we used a semi-quantitative RT-PCR-based strategy to examine a panel of kidney RNA samples ranging from 8-24 weeks gestational age, We found RET expression was highest earlier in development (14 weeks) with expression decreasing through to 24 weeks gestation, While three alternative RET transcripts generated by exon skipping at the 5' end of the gene were all detected throughout kidney development, expression of one transcript, RET2/6, where exon 2 was spliced to exon 6, varied relative to full length RET during this period, Levels of RET2/6 were highest at the earliest age of fetal kidney examined (8 weeks) and decreased relative to all other RET transcripts to low adult levels, The period of high expression coincides with a period of rapid bud bifurcation, Thus, it is possible that RET2/6 has a role in the early growth and differentiation of the human kidney.	QUEENS UNIV,DEPT PATHOL,KINGSTON,ON K7L 3N6,CANADA; QUEENS UNIV,DEPT PAEDIAT,KINGSTON,ON K7L 3N6,CANADA; HARVARD UNIV,SCH MED,DEPT MED,DANA FARBER CANC INST,DIV CANC EPIDEMIOL & CONTRO,BOSTON,MA 02115; LUDWIG INST CANC RES,SAN DIEGO BRANCH,LA JOLLA,CA 92093	Queens University - Canada; Queens University - Canada; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Ludwig Institute for Cancer Research				Eng, Charis/0000-0002-3693-5145				ASAI N, 1995, MOL CELL BIOL, V15, P1613; AVANTAGGIATO V, 1994, CELL GROWTH DIFFER, V5, P305; BARD JBL, 1994, MECH DEVELOP, V48, P3, DOI 10.1016/0925-4773(94)00273-8; BEVILACQUA A, 1988, P NATL ACAD SCI USA, V85, P831, DOI 10.1073/pnas.85.3.831; BRACEY LT, 1987, P NATL ACAD SCI USA, V84, P9020, DOI 10.1073/pnas.84.24.9020; BUNONE G, 1995, EXP CELL RES, V217, P92, DOI 10.1006/excr.1995.1067; CALIFANO D, 1995, ONCOGENE, V11, P107; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; Durbec PL, 1996, DEVELOPMENT, V122, P349; ENG C, 1997, IN PRESS HUM MUTAT; GRIECO M, 1990, CELL, V60, P557, DOI 10.1016/0092-8674(90)90659-3; Hellmich HL, 1996, MECH DEVELOP, V54, P95, DOI 10.1016/0925-4773(95)00464-5; Jing SQ, 1996, CELL, V85, P1113, DOI 10.1016/S0092-8674(00)81311-2; KREIDBERG JA, 1993, CELL, V74, P679, DOI 10.1016/0092-8674(93)90515-R; KWOK JBJ, 1993, ONCOGENE, V8, P2575; LEONG SS, 1983, ADV THYROID NEOPLASI, P95; LORENZO MJ, 1995, ONCOGENE, V10, P1377; MCDONALD FJ, 1994, DEV GENET, V15, P148, DOI 10.1002/dvg.1020150205; MIKI T, 1992, P NATL ACAD SCI USA, V89, P246, DOI 10.1073/pnas.89.1.246; Moore MW, 1996, NATURE, V382, P76, DOI 10.1038/382076a0; MORRISON C, 1994, BBA-GENE STRUCT EXPR, V1219, P493, DOI 10.1016/0167-4781(94)90076-0; MULLIGAN LM, 1993, NATURE, V363, P458, DOI 10.1038/363458a0; MYERS SM, 1995, ONCOGENE, V11, P2039; NAKAMURA T, 1994, J PATHOL, V172, P255, DOI 10.1002/path.1711720305; ORRURTREGER A, 1993, DEV BIOL, V158, P475, DOI 10.1006/dbio.1993.1205; PACHNIS V, 1993, DEVELOPMENT, V119, P1005; Pichel JG, 1996, NATURE, V382, P73, DOI 10.1038/382073a0; POTTER EL, 1972, NORMAL ABNORMAL DEV, V1; ROTHENPIELER UW, 1993, DEVELOPMENT, V119, P711; Sanchez MP, 1996, NATURE, V382, P70, DOI 10.1038/382070a0; SANTORO M, 1990, ONCOGENE, V5, P1595; SANTORO M, 1993, CELL GROWTH DIFFER, V4, P77; Saxen L., 1987, ORGANOGENESIS KIDNEY; SCHUCHARDT A, 1994, NATURE, V367, P380, DOI 10.1038/367380a0; Schuchardt A, 1996, DEVELOPMENT, V122, P1919; SHI DL, 1994, DEV BIOL, V164, P173, DOI 10.1006/dbio.1994.1189; STARK K, 1994, NATURE, V372, P679, DOI 10.1038/372679a0; TAHIRA T, 1988, BIOCHEM BIOPH RES CO, V153, P1290, DOI 10.1016/S0006-291X(88)81368-8; TAHIRA T, 1990, ONCOGENE, V5, P97; TAKAHASHI M, 1988, ONCOGENE, V3, P571; Treanor JJS, 1996, NATURE, V382, P80, DOI 10.1038/382080a0; TSUZUKI T, 1995, ONCOGENE, V10, P191; YAYON A, 1992, EMBO J, V11, P1885, DOI 10.1002/j.1460-2075.1992.tb05240.x	43	31	31	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 17	1997	14	15					1811	1818		10.1038/sj.onc.1201016	http://dx.doi.org/10.1038/sj.onc.1201016			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WW166	9150387				2022-12-17	WOS:A1997WW16600007
J	Jiang, HP; Lin, JJ; Tao, J; Fisher, PB				Jiang, HP; Lin, JJ; Tao, J; Fisher, PB			Suppression of human ribosomal protein L23A expression during cell growth inhibition by interferon-beta	ONCOGENE			English	Article						interferon-beta; melanoma differentiation associated gene-20 (mda-20); ribosomal protein L23a; cell growth inhibition; antisense transcripts	BOVINE SEMINAL RIBONUCLEASE; DOUBLE-STRANDED-RNA; C-MYC GENE; MESSENGER-RNAS; TRANSCRIPTIONAL ACTIVATION; ORNITHINE DECARBOXYLASE; 2-5A-DEPENDENT RNASE; DIFFERENTIATION; CLEAVAGE; SITE	Interferons inhibit cell growth in normal and tumor-derived cells. The molecular basis of interferons antiproliferative activity remains to be defined. Using subtraction hybridization, a human melanoma differentiation associated gene, mda-20, has been identified that is down-regulated by treatment with interferon. Sequence analysis indicates that mda-20 is human ribosomal protein L23a (rp L23a). The mRNA levels of rp L23a and growth are diminished in a variety of human tumor cell lines following treatment with human fibroblast interferon, interferon-beta (IFN-beta). Expression of rp L23a is also reduced in human melanoma cells treated with human leukocyte (IFN-alpha) and immune (IFN-gamma) interferons, but not by growth inhibition resulting from serum starvation. These findings suggest that growth suppression alone is not sufficient to reduce rp L23a expression. Instead, reduced rp L23a mRNA results from biochemical changes mediated by interferons. Ectopic expression of an antisense rp L23a sequence in human HeLa cervical carcinoma cells results in a reduction in colony formation indicating a direct antiproliferative effect by inhibiting rp L23a expression. The mechanism underlying inhibition in rp L23a expression in IFN-beta-treated cells may involve antisense rp L23a RNA. These results suggest that rp L23a may be one of the target molecules involved in mediating growth inhibition by interferon.	COLUMBIA UNIV COLL PHYS & SURG,COLUMBIA PRESBYTERIAN MED CTR,DEPT PATHOL,NEW YORK,NY 10032; COLUMBIA UNIV COLL PHYS & SURG,COLUMBIA PRESBYTERIAN MED CTR,DEPT UROL,NEW YORK,NY 10032	Columbia University; NewYork-Presbyterian Hospital; Columbia University; NewYork-Presbyterian Hospital					NCI NIH HHS [CA35675] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA035675] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABDOLLAHI A, 1991, CELL GROWTH DIFFER, V2, P401; AGRAWAL MG, 1987, J BIOL CHEM, V262, P4868; BELHUMEUR P, 1993, MOL CELL BIOL, V13, P2846, DOI 10.1128/MCB.13.5.2846; BIRNBAUM M, 1990, DIFFERENTIATION, V45, P138, DOI 10.1111/j.1432-0436.1990.tb00467.x; CAFFARELLI E, 1984, EMBO J, V6, P3493; CELANO P, 1992, J BIOL CHEM, V267, P15092; CHAN YL, 1995, BBA-GENE STRUCT EXPR, V1260, P113, DOI 10.1016/0167-4781(94)00193-7; CHATTERJEE D, 1992, CANCER CHEMOTH PHARM, V30, P12, DOI 10.1007/BF00686479; CHIANG MY, 1991, J BIOL CHEM, V266, P18162; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; ELBARADI TTAL, 1985, EMBO J, V4, P2101, DOI 10.1002/j.1460-2075.1985.tb03898.x; FISHER PB, 1985, J INTERFERON RES, V5, P11, DOI 10.1089/jir.1985.5.11; FISHER PB, 1985, PHARMACOL THERAPEUT, V27, P143, DOI 10.1016/0163-7258(85)90067-1; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GARBE C, 1993, J INVEST DERMATOL, V100, pS239; *GEN COMP GROUP, 1991, PROGR MAN; GIOVANELLA BC, 1976, J NATL CANCER I, V56, P1131, DOI 10.1093/jnci/56.6.1131; GREINER JW, 1985, PHARMACOL THERAPEUT, V31, P209, DOI 10.1016/0163-7258(85)90023-3; GUTTERMAN JU, 1994, P NATL ACAD SCI USA, V91, P1198, DOI 10.1073/pnas.91.4.1198; HARELBELLAN A, 1988, J IMMUNOL, V141, P1012; HASSEL BA, 1993, EMBO J, V12, P3297, DOI 10.1002/j.1460-2075.1993.tb05999.x; HUNTER T, 1993, NATURE, V366, P114, DOI 10.1038/366114a0; JACOBS FA, 1985, EUR J BIOCHEM, V150, P255, DOI 10.1111/j.1432-1033.1985.tb09015.x; Jiang Hongping, 1993, Molecular and Cellular Differentiation, V1, P41; Jiang Hongping, 1993, Molecular and Cellular Differentiation, V1, P285; Jiang Hongping, 1993, Molecular and Cellular Differentiation, V1, P197; JIANG HP, 1995, ONCOGENE, V11, P1179; Jiang HP, 1995, ONCOGENE, V11, P2477; Jiang HP, 1996, P NATL ACAD SCI USA, V93, P9160, DOI 10.1073/pnas.93.17.9160; JIANG HP, 1995, ONCOGENE, V10, P1855; KAO HT, 1983, MOL CELL BIOL, V3, P2058, DOI 10.1128/MCB.3.11.2058; KHOCHBIN S, 1989, EMBO J, V8, P4107, DOI 10.1002/j.1460-2075.1989.tb08595.x; KRYSTAL G, 1988, MOL CELL BIOL, V8, P3373, DOI 10.1128/MCB.8.8.3373; LEGHA SS, 1989, SEMIN ONCOL, V16, P34; LEVY S, 1991, P NATL ACAD SCI USA, V88, P3319, DOI 10.1073/pnas.88.8.3319; MAGER WH, 1988, BIOCHIM BIOPHYS ACTA, V949, P1, DOI 10.1016/0167-4781(88)90048-6; MEYUHAS O, 1987, MOL CELL BIOL, V7, P2691, DOI 10.1128/MCB.7.8.2691; OVERMAN PF, 1993, SOMAT CELL MOLEC GEN, V19, P347, DOI 10.1007/BF01232747; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PESTKA S, 1987, ANNU REV BIOCHEM, V56, P727, DOI 10.1146/annurev.bi.56.070187.003455; ROMEO G, 1989, TRENDS GENET, V5, P19, DOI 10.1016/0168-9525(89)90007-3; SCHEIN CH, 1995, BIOCHEM J, V307, P123, DOI 10.1042/bj3070123; SCHEIN CH, 1990, FEBS LETT, V270, P229, DOI 10.1016/0014-5793(90)81275-S; SEKAR V, 1983, BIOCHEM BIOPH RES CO, V114, P950, DOI 10.1016/0006-291X(83)90652-6; SEN GC, 1992, J BIOL CHEM, V267, P5017; SHEETS MD, 1990, NUCLEIC ACIDS RES, V18, P5799, DOI 10.1093/nar/18.19.5799; SILVERMAN RH, 1994, J INTERFERON RES, V14, P101, DOI 10.1089/jir.1994.14.101; SREEVALSAN T, 1980, J CELL PHYSIOL, V104, P1, DOI 10.1002/jcp.1041040102; SUZUKI K, 1993, J BIOL CHEM, V268, P2755; SZYSZKA R, 1989, J BIOL CHEM, V264, P3827; VESTER B, 1984, J MOL BIOL, V179, P431, DOI 10.1016/0022-2836(84)90074-3; WAGNER M, 1985, MOL CELL BIOL, V5, P3560, DOI 10.1128/MCB.5.12.3560; ZHOU AM, 1993, CELL, V72, P753, DOI 10.1016/0092-8674(93)90403-D; ZOON KC, 1986, P NATL ACAD SCI USA, V83, P8226, DOI 10.1073/pnas.83.21.8226	55	31	35	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 30	1997	14	4					473	480		10.1038/sj.onc.1200858	http://dx.doi.org/10.1038/sj.onc.1200858			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WE364	9053844				2022-12-17	WOS:A1997WE36400010
J	DeCesare, D; Palazzolo, M; Blasi, F				DeCesare, D; Palazzolo, M; Blasi, F			Functional characterization of COM, a DNA region required for cooperation between AP-1 sites in urokinase gene transcription	ONCOGENE			English	Article						urokinase; enhancer; transcription	PLASMINOGEN-ACTIVATOR GENE; COLONY-STIMULATING FACTOR; REGULATORY ELEMENT; PHORBOL-ESTER; HMG DOMAIN; ENHANCER; INDUCTION; CELLS; INTERLEUKIN-3; EXPRESSION	The inducible uPA enhancer contains two phorbol ester responsive elements: the combined PEA3/AP-1(A) and a downstream AP-1(A) site. The integrity of all three sites is essential for enhancer activity, The interposed 74 bp long DNA region (COM, Cooperation Mediator) is in turn required for the synergistic action of the PEA3/AP-1 and AP-1 sites, Here we present a characterization of the COM sequence: our results show that COM and COM-binding proteins (UEF, Urokinase Enhancer Factors) may play a structural role in the induction of the uPA enhancer by phorbol-myristate-acetate (TPA), (1) COM has a bipartite structure (uCOM and dCOM) and each half contributes by about 50% to the COM-mediated TPA induction, (2) COM function is strictly dependent on its position, but not on its orientation and neither the entire COM nor individual UEF-binding sites can directly transactivate a test promoter, (3) The requirement for COM in TPA-induction is partly eliminated by the deletion of COM sequence, However, also in the COM-deleted enhancer, integrity of the PEA3/AP-1, and AP-1, sites is essential for enhancer function, We conclude that COM and COM-binding proteins provide a structural surface which facilitates the cooperation between the transactivator proteins bound at the PEA3/AP-1, and AP-1, sites, Sequences homologous to uCOM are found in the promoters of other inducible genes, coding for proteases, cytokines and chemokines: for example, in the promoter of the MIP1 alpha/LD78 chemokine gene, a 15/18 nucleotides identity is found in a region mediating positive and negative functions in TPA induction. Thus, COM-like elements represent a general enhancer function which, although lacking an intrinsic transactivating capacity, modulates the synergism between transcription factors bound to distant sites.	UNIV MILAN,DIPARTIMENTO GENET & BIOL MICRORGAN,I-20133 MILAN,ITALY; SAN RAFFAELE SCI INST,DIBIT,I-20132 MILAN,ITALY	University of Milan				Blasi, Francesco/0000-0001-9406-1784				BAGGIOLINI M, 1994, ADV IMMUNOL, V55, P97; BERTHELSEN J, 1996, J BIOL CHEM, V272, P3822; BESSER D, 1996, IN PRESS FIBRINOLYSI; Blasi F, 1990, Semin Cancer Biol, V1, P117; CARMELIET P, 1994, NATURE, V368, P419, DOI 10.1038/368419a0; CHU G, 1987, NUCLEIC ACIDS RES, V15, P1311, DOI 10.1093/nar/15.3.1311; DANO K, 1985, ADV CANCER RES, V44, P139, DOI 10.1016/S0065-230X(08)60028-7; DECESARE D, 1995, ONCOGENE, V11, P365; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; GIESE K, 1995, GENE DEV, V9, P995, DOI 10.1101/gad.9.8.995; GROSSCHEDL R, 1994, TRENDS GENET, V10, P94, DOI 10.1016/0168-9525(94)90232-1; HERR W, 1986, CELL, V45, P461, DOI 10.1016/0092-8674(86)90332-6; LEE JS, 1993, NUCLEIC ACIDS RES, V21, P3365, DOI 10.1093/nar/21.15.3365; LEE KAW, 1988, GENE ANAL TECH, V5, P22, DOI 10.1016/0735-0651(88)90023-4; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MATHEYPREVOT B, 1990, P NATL ACAD SCI USA, V87, P5046, DOI 10.1073/pnas.87.13.5046; MIYATAKE S, 1985, EMBO J, V4, P2561, DOI 10.1002/j.1460-2075.1985.tb03971.x; NERLOV C, 1991, ONCOGENE, V6, P1583; NERLOV C, 1992, EMBO J, V11, P4573, DOI 10.1002/j.1460-2075.1992.tb05559.x; NEUMANN JR, 1987, BIOTECHNIQUES, V5, P444; NOMIYAMA H, 1993, MOL CELL BIOL, V13, P2787, DOI 10.1128/MCB.13.5.2787; OKUDA A, 1990, EMBO J, V9, P1131, DOI 10.1002/j.1460-2075.1990.tb08219.x; Resnati M, 1996, EMBO J, V15, P1572, DOI 10.1002/j.1460-2075.1996.tb00502.x; RORTH P, 1990, NUCLEIC ACIDS RES, V18, P5009, DOI 10.1093/nar/18.17.5009; Sambrook J, 1989, MOL CLONING LAB MANU; SHOEMAKER SG, 1990, P NATL ACAD SCI USA, V87, P9650, DOI 10.1073/pnas.87.24.9650; SIRUMCONNOLLY K, 1991, NUCLEIC ACIDS RES, V19, P335, DOI 10.1093/nar/19.2.335; STACEY KJ, 1995, MOL CELL BIOL, V15, P3430; Thanos D, 1995, CELL, V83, P1091, DOI 10.1016/0092-8674(95)90136-1; THANOS D, 1992, CELL, V71, P777, DOI 10.1016/0092-8674(92)90554-P; TIJAN R, 1994, CELL, V77, P5; TRAVIS A, 1991, GENE DEV, V5, P880, DOI 10.1101/gad.5.5.880; VERDE P, 1988, NUCLEIC ACIDS RES, V16, P10699, DOI 10.1093/nar/16.22.10699; WOLFFE AP, 1994, TRENDS BIOCHEM SCI, V19, P240, DOI 10.1016/0968-0004(94)90148-1	34	31	31	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 19	1996	13	12					2551	2562						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VZ654	9000129				2022-12-17	WOS:A1996VZ65400005
J	Brizzi, MF; Dentelli, P; Lanfrancone, L; Rosso, A; Pelicci, PG; Pegoraro, L				Brizzi, MF; Dentelli, P; Lanfrancone, L; Rosso, A; Pelicci, PG; Pegoraro, L			Discrete protein interactions with the Grb2/c-Cbl complex in SCF- and TPO-mediated myeloid cell proliferation	ONCOGENE			English	Article						c-Cbl; thrombopoietin; stem cell factor; cell proliferation; signal transduction	COLONY-STIMULATING FACTOR; GROWTH-FACTOR RECEPTOR; SRC HOMOLOGY-3 DOMAIN; C-CBL PROTOONCOGENE; TYROSINE PHOSPHORYLATION; HEMATOPOIETIC-CELLS; ANTIGEN RECEPTOR; SH3 DOMAINS; SIGNAL-TRANSDUCTION; MOLECULAR-CLONING	Hemopoietic cell proliferation is mediated by nontyrosine and tyrosine kinases that signal via uncommon and common sets of downstream effector molecules including the Grb2/c-Chl. In the present study we evaluated tyrosine phosphorylation of c-Cbl and the interaction of the Grb2/c-Cbl complex with signaling proteins upon activation of non-tyrosine (c-Mpl) and tyrosine kinase (c-Kit) receptors leading to myeloid cell proliferation. By using the growth factor dependent M-07e cell line, we found that both c-Mpl and c-Kit ligands, namely: SCF and TPO, induce c-Cbl tyrosine phosphorylation. In these cells the adaptor protein Grb2 constitutively binds a substantial fraction of c-Cbl through the N-terminal SH3 domain. In vitro experiments showed that the stable Grb2/c-Cbl complex interacts, through the Grb2 SH2 domain, with the SCF-activated c-Kit. By contrast stimulation with TPO leads to the formation of a Grb2 complex containing JAK2. In vitro and in vivo experiments support the hypothesis that Grb2 mediates the association of c-Kit with c-Cbl. Moreover we found that, upon SCF stimulation, the Grb2/c-Cbl complex recruits She, probably via Grb2. By contrast the Ras exchanger factor (Sos1) was not detected in anti-c-Cbl immunoprecipitates suggesting that Grb2/Sos1 and Grb2/c-Cbl are present in different complexes. Taken together our results demonstrate that c-Cbl plays an important role in coupling both tyrosine and non-tyrosine kinase receptors to downstream effector molecules and that different signaling molecules interact with Grb2/c-Cbl complex when non-tyrosine or tyrosine kinase receptors are activated.	UNIV TURIN,DIPARTIMENTO MED INTERNA,I-10126 TURIN,ITALY; IST EUROPEO ONCOL,DIPARTIMENTO ONCOL SPERIMENTALE,I-20141 MILAN,ITALY	University of Turin; IRCCS European Institute of Oncology (IEO)			Pelicci, Pier Giuseppe/AAL-6572-2020; Lanfrancone, Luisa/AAC-8671-2019; Brizzi, Maria Felice/J-7882-2016	Lanfrancone, Luisa/0000-0002-4523-3815; 				AVANZI GC, 1990, J CELL PHYSIOL, V145, P458, DOI 10.1002/jcp.1041450310; BLAKE TJ, 1991, ONCOGENE, V6, P653; BLECHMAN JM, 1993, J BIOL CHEM, V268, P4399; BOWTELL DDL, 1995, ONCOGENE, V11, P1561; BRIZZI MF, 1994, J BIOL CHEM, V269, P31680; BROUDY VC, 1995, BLOOD, V85, P1719, DOI 10.1182/blood.V85.7.1719.bloodjournal8571719; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CUTLER RL, 1993, J BIOL CHEM, V268, P21463; DEJONG R, 1995, J BIOL CHEM, V270, P21468, DOI 10.1074/jbc.270.37.21468; DONOVAN JA, 1994, J BIOL CHEM, V269, P22921; GALISTEO ML, 1995, J BIOL CHEM, V270, P20242, DOI 10.1074/jbc.270.35.20242; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; GURNEY AL, 1995, P NATL ACAD SCI USA, V92, P5292, DOI 10.1073/pnas.92.12.5292; HUANG E, 1990, CELL, V63, P225, DOI 10.1016/0092-8674(90)90303-V; JONGEWARD GD, 1995, GENETICS, V139, P1553; KAUSHANSKY K, 1994, NATURE, V369, P568, DOI 10.1038/369568a0; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; LANFRANCONE L, 1995, ONCOGENE, V10, P907; LANGDON WY, 1989, P NATL ACAD SCI USA, V86, P1168, DOI 10.1073/pnas.86.4.1168; LEV S, 1992, J BIOL CHEM, V267, P10866; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LIU L, 1994, MOL CELL BIOL, V14, P6926, DOI 10.1128/MCB.14.10.6926; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MARCILLA A, 1995, J BIOL CHEM, V270, P9115, DOI 10.1074/jbc.270.16.9115; MATUOKA K, 1992, P NATL ACAD SCI USA, V89, P9015, DOI 10.1073/pnas.89.19.9015; MEISNER H, 1995, J BIOL CHEM, V270, P25332, DOI 10.1074/jbc.270.43.25332; MEISNER H, 1995, MOL CELL BIOL, V15, P3571; MIKI H, 1994, J BIOL CHEM, V269, P5489; MIYAZAWA K, 1991, EXP HEMATOL, V19, P1110; Montrucchio G, 1996, BLOOD, V87, P2762, DOI 10.1182/blood.V87.7.2762.bloodjournal8772762; MOTTO DG, 1994, J BIOL CHEM, V269, P21608; MU SX, 1995, BLOOD, V86, P4532, DOI 10.1182/blood.V86.12.4532.bloodjournal86124532; MYERS M, 1995, TRENDS BIOCHEM SCI, V19, P289; ODAI H, 1995, J BIOL CHEM, V270, P10800, DOI 10.1074/jbc.270.18.10800; PANCHAMOORTHY G, 1994, MOL CELL BIOL, V14, P6372, DOI 10.1128/MCB.14.9.6372; Panchamoorthy G, 1996, J BIOL CHEM, V271, P3187, DOI 10.1074/jbc.271.6.3187; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; QIU F, 1988, EMBO J, V7, P1003, DOI 10.1002/j.1460-2075.1988.tb02907.x; QUELLE FW, 1994, MOL CELL BIOL, V14, P4335, DOI 10.1128/MCB.14.7.4335; REEDQUIST KA, 1994, P NATL ACAD SCI USA, V91, P4135, DOI 10.1073/pnas.91.10.4135; REIF K, 1994, J BIOL CHEM, V269, P14081; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SASAKI K, 1995, BIOCHEM BIOPH RES CO, V216, P338, DOI 10.1006/bbrc.1995.2629; SKODA RC, 1993, EMBO J, V12, P2645, DOI 10.1002/j.1460-2075.1993.tb05925.x; TANAKA S, 1995, J BIOL CHEM, V270, P14347, DOI 10.1074/jbc.270.24.14347; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; TAUCHI T, 1994, J EXP MED, V179, P167, DOI 10.1084/jem.179.1.167; TORTOLANI PJ, 1995, BLOOD, V85, P3444, DOI 10.1182/blood.V85.12.3444.bloodjournal85123444; VIGON I, 1993, ONCOGENE, V8, P2607; VIGON I, 1992, P NATL ACAD SCI USA, V89, P5640, DOI 10.1073/pnas.89.12.5640; WANG XY, 1995, J BIOL CHEM, V270, P27999; WILLIAMS DE, 1990, CELL, V63, P167, DOI 10.1016/0092-8674(90)90297-R; YARDEN Y, 1987, EMBO J, V6, P3341, DOI 10.1002/j.1460-2075.1987.tb02655.x; YOON CH, 1995, SCIENCE, V269, P1102, DOI 10.1126/science.7652556; ZSEBO KM, 1990, CELL, V63, P195, DOI 10.1016/0092-8674(90)90300-4	55	31	33	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 21	1996	13	10					2067	2076						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VV145	8950973				2022-12-17	WOS:A1996VV14500003
J	Spitkovsky, D; Aengeneyndt, F; Braspenning, J; Doeberitz, MV				Spitkovsky, D; Aengeneyndt, F; Braspenning, J; Doeberitz, MV			p53-independent growth regulation of cervical cancer cells by the papillomavirus E6 oncogene	ONCOGENE			English	Article						p53; low risk and high risk HPV E6; p21 dexamethasone; transactivation; growth arrest	P53 PROTEIN; CELLULAR-RESPONSE; CARCINOMA CELLS; DNA DAMAGE; E7; ONCOPROTEINS; SUPPRESSION; EXPRESSION; APOPTOSIS; INDUCTION	Growth of cervical carcinoma cells depends on continuous expression of high risk type human papillomavirus oncogenes E6 and E7, E6 destabilizes p53, a tumor-suppressive transcription factor, which activates expression of the inhibitor of cell cycle progression p21 and other genes, E6-mediated p53 degradation can therefore result in cell cycle deregulation, It has, however, not yet been determined whether p53 inactivation is sufficient to provoke cell cycle progression in established cervical carcinoma cells, Moreover, it has not yet been clarified whether E6 confers additional p53-independent growth stimuli in cancer cells, To address these questions, we analysed p53 functions in SW 756 cervical cancer cells in which the expression of endogenous HPV 18 E6-E7 genes be downregulated by dexamethasone. This results significantly increased p53 levels and sequent cell cycle arrest in the G(1) phase, Surprisingly, p53 activities were suppressed rather than enhanced in these cervical cancer cells, However, if high risk papillomavirus type 16 E6 genes, including a mutant which does not degrade p53, were expressed in dexamethasone-treated SW 756 cells with suppressed endogenous HPV type 18 E6-E7 expression, the cells reentered the cell cycle even in the absence of a cooperating viral E7 gene, In contrast, the non oncogenic papillomavirus type 6 E6 gene did not release the cells from growth arrest under these conditions, These data indicate that suppression of p53 functions is not sufficient to provoke cell cycle progression in E6-E7-depleted cervical cancer cells and point to a p53-independent mitotic activity to oncogenic papillomavirus type E6 genes in cervical carcinoma cells.	UNIV HEIDELBERG, DIV MOL DIAGNOST & THERAPY, DEPT SURG, D-69120 HEIDELBERG, GERMANY; DEUTSCH KREBSFORSCHUNGSZENTRUM, FSP6 ANGEW TUMORVIROL, D-69120 HEIDELBERG, GERMANY	Ruprecht Karls University Heidelberg; Helmholtz Association; German Cancer Research Center (DKFZ)								BUTZ K, 1995, ONCOGENE, V10, P927; CHEN JJ, 1995, SCIENCE, V269, P529, DOI 10.1126/science.7624774; CROOK T, 1994, CELL, V79, P817, DOI 10.1016/0092-8674(94)90071-X; DOEBERITZ MV, 1988, CANCER RES, V48, P3780; DOEBERITZ MV, 1991, P NATL ACAD SCI USA, V88, P1411, DOI 10.1073/pnas.88.4.1411; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FRAKER PJ, 1995, METHOD CELL BIOL, V46, P57; FRITSCHE M, 1993, ONCOGENE, V8, P307; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HAVRE PA, 1995, CANCER RES, V55, P4420; KASTAN MB, 1991, CANCER RES, V51, P6304; KESSIS TD, 1993, P NATL ACAD SCI USA, V90, P3988, DOI 10.1073/pnas.90.9.3988; Klingelhutz AJ, 1996, NATURE, V380, P79, DOI 10.1038/380079a0; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; MASUDA H, 1987, P NATL ACAD SCI USA, V84, P7716, DOI 10.1073/pnas.84.21.7716; MIETZ JA, 1992, EMBO J, V11, P5013, DOI 10.1002/j.1460-2075.1992.tb05608.x; MULLER M, 1992, VIROLOGY, V187, P508; MUNGER K, 1992, CANCER SURV, V12, P197; SCHAUB LBO, 1995, MOL CELL BIOL, V15, P3032; SEDMAN SA, 1991, J VIROL, V65, P4860, DOI 10.1128/JVI.65.9.4860-4866.1991; SEEDORF K, 1987, EMBO J, V6, P139, DOI 10.1002/j.1460-2075.1987.tb04731.x; SEYLER FH, 1991, NUCLEIC ACIDS RES, V19, P5080; VONKNEBEL M, 1992, INT J CANCER, V51, P831, DOI 10.1002/ijc.2910510527; VONKNEBELDOEBERITZ M, 1994, J VIROL, V68, P2811, DOI 10.1128/JVI.68.5.2811-2821.1994; ZHAN QM, 1994, CANCER RES, V54, P2755; ZHAN QM, 1994, ONCOGENE, V9, P3743; ZURHAUSEN H, 1994, ANNU REV MICROBIOL, V48, P427, DOI 10.1146/annurev.micro.48.1.427	29	31	33	1	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 5	1996	13	5					1027	1035						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VG766	8806692				2022-12-17	WOS:A1996VG76600016
J	Wang, L; Li, WD; Wang, XQ; Zhang, CL; Zhang, T; Mao, XZ; Wu, M				Wang, L; Li, WD; Wang, XQ; Zhang, CL; Zhang, T; Mao, XZ; Wu, M			Genetic alterations on chromosomes 3 and 9 of esophageal cancer tissues from China	ONCOGENE			English	Article						tumor suppressor genes; esophageal cancer; loss of heterozygosity; microsatellite; genetic instability	SQUAMOUS-CELL CARCINOMA; HETEROZYGOSITY; ADENOCARCINOMA; HOMOLOG; LUNG	In previous studies, we had demonstrated that allelic losses in esophageal cancer (EC) tissues are frequently involved in chromosomes 3 and 9 acid that EC patients and their blood relatives have low capacity to repair damaged DNA and showed genetic instability. To better define the deleted chromosomal loci and understand the genetic instability in EC tissues, we selected 12 microsatellite markers (D3S1232, D3S1238, D3S1289, D3S1480, D3S647, D3S966, D3S1317, D3S659, D9S156, D9S171, D9S176 and GSN) to examine 36 paired EC tissues for loss of heterozygosity (LOH) and microsatellite instability (MIN) on chromosomes 3 and 9. The frequent LOH was found at D9S156(9p21), D3S647(3p23) and D3S1480(3p14.2), implying the possible existence of tumor suppressor genes near the deleted loci. Higher LOH incidence at D9S156 (9/18) and D3S1480 (8/19) was observed in EC tissues from Beijing, a low EC area. More frequent LOH at D3S647 (6/14) was found in EC tissues from Yangquan, a high EC area, This geographic difference of LOH occurrence was indicative of genetic heterogeneity in the etiology of EC. 24 of 36 (66.7%) EC tissues showed MIN at one or more chromosomal loci. The putative EC suppressor genes on chromosomes 3 and 9 and the molecular basis of the genetic instability associated with EC remain to be elucidated.	CHINESE ACAD MED SCI,INST CANC,NATL LAB MOLEC ONCOL,BEIJING 100021,PEOPLES R CHINA; BEIJING UNION MED COLL,BEIJING 100021,PEOPLES R CHINA; CANC INST HOSP,YANGQUAN,SHANXI,PEOPLES R CHINA	Chinese Academy of Medical Sciences - Peking Union Medical College; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College				Li, Wei-Dong/0000-0003-0521-7412				ALLTONEN LA, 1993, SCIENCE, V260, P177; AOLI T, 1994, GENES CHROMOSOM CANC, V10, P177; BOYNTON RF, 1991, CANCER RES, V51, P5766; BOYNTON RF, 1992, P NATL ACAD SCI USA, V89, P3385, DOI 10.1073/pnas.89.8.3385; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; CAIRNS P, 1994, SCIENCE, V265, P415, DOI 10.1126/science.8023167; CARTER CL, 1992, J NATL CANCER I, V84, P771, DOI 10.1093/jnci/84.10.771; CHENG JQ, 1994, CANCER RES, V54, P5547; COLEMAN A, 1994, CANCER RES, V54, P344; DIAZ MO, 1990, NEW ENGL J MED, V322, P77, DOI 10.1056/NEJM199001113220202; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; GIANI C, 1994, CANCER RES, V54, P6338; HU N, 1992, INT J EPIDEMIOL, V21, P877, DOI 10.1093/ije/21.5.877; HUANG DP, 1994, CANCER RES, V54, P4003; HUANG Y, 1992, CANCER RES, V52, P6525; HUSSUSSIAN CJ, 1994, NAT GENET, V8, P15, DOI 10.1038/ng0994-15; KAMB A, 1994, NAT GENET, V8, P22, DOI 10.1038/ng0994-22; KAMB A, 1994, SCIENCE, V264, P236; KEEN AJ, 1994, ONCOGENE, V9, P2083; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; Li J Y, 1982, Natl Cancer Inst Monogr, V62, P113; LI WB, 1994, PROG NATURAL SCI, V5, P602; LOEB LA, 1994, CANCER RES, V54, P5059; LUBINSKI J, 1994, CANCER RES, V54, P3710; MELTZER SJ, 1994, CANCER RES, V54, P3379; MERLO A, 1994, CANCER RES, V54, P640; MITRA S, 1993, PROG NUCLEIC ACID RE, V44, P109, DOI 10.1016/S0079-6603(08)60218-4; MORI T, 1994, CANCER RES, V54, P3396; NICOLAIDES NC, 1994, NATURE, V371, P75, DOI 10.1038/371075a0; OGASAWARA S, 1995, CANCER RES, V55, P891; OLOPADE OL, 1994, CANCER RES, V54, P5547; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; PARSONS R, 1993, CELL, V75, P1227, DOI 10.1016/0092-8674(93)90331-J; Sambrook J., 1989, MOL CLONING LAB MANU; SHIBAGAKI I, 1994, CANCER RES, V54, P2996; SPRUCK CH, 1994, NATURE, V370, P183, DOI 10.1038/370183a0; Su Y A, 1988, Proc Chin Acad Med Sci Peking Union Med Coll, V3, P84; TARMIN L, 1994, CANCER RES, V54, P6094; TSUCHIYA E, 1992, CANCER RES, V52, P2478; VANDERRIET P, 1994, CANCER RES, V54, P1156; WANGPENG J, 1990, CANCER GENET CYTOGEN, V45, P101; Weber J, 1989, AM J HUM GENET, V44, P338; WU DF, 1988, NATL MED J CHINA, V68, P128; WU M, 1989, GENETIC EPIDEMIOLOGY, P188; YANG CS, 1980, CANCER RES, V40, P2633; YOKOYAMA S, 1992, CANCER RES, V52, P873; ZHU D, 1994, CHINESE J MED GENET, V11, P354	47	31	38	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB 1	1996	12	3					699	703						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TV597	8637728				2022-12-17	WOS:A1996TV59700028
J	Hodge, DR; Robinson, L; Watson, D; Lautenberger, J; Zhang, XK; Venanzoni, M; Seth, A				Hodge, DR; Robinson, L; Watson, D; Lautenberger, J; Zhang, XK; Venanzoni, M; Seth, A			Interaction of ETS-1 and ERGB/FLI-1 proteins with DNA is modulated by spacing between multiple binding sites as well as phosphorylation	ONCOGENE			English	Article						ETS-1,ERGB FL1-1; transcription factors; HIV-1 enhancer; transactivation; EBS palindrome; Cam-KII phosphorylation site	TRANSCRIPTION; COMPLEX; FAMILY; GENE; IDENTIFICATION; PROTOONCOGENE; ACTIVATION; MECHANISM; SEQUENCES; ONCOGENE	ETS is a family of transcription factors that contain a highly conserved ETS DNA binding domain. Various members of the ETS family are expressed in cells of hematopoietic lineage. ETS-1, ETS-2 and ERGB/FLI-1 are expressed at high levels in T-lymphocytes. HIV-1 infects T-cells and it has been shown that its LTR contains binding sites for various transcription factors. In this study we show that the HIV-1 core enhancer is directly regulated by ERGB/FLI-1 protein positively, as well as, negatively, depending upon the presence or absence of accessory factors in different cell types. In addition, we show that the ETS-1 transactivation activity is enhanced upon dephosphorylation of the Calmodulin-dependant Protein Kinase II phosphorylation site located in exon VII. Finally, we demonstrate that the spacing two EBS cores in palindromic or direct play a crucial role in binding of ETS proteins to DNA.	UNIV TORONTO, DEPT PATHOL, TORONTO, ON M5S 1B2, CANADA; UNIV TORONTO, MRC, PERIODONTAL PHYSIOL GRP, TORONTO, ON M5S 1B2, CANADA; WOMENS COLL HOSP, MOLEC PATHOL LAB, TORONTO, ON M5S 1B2, CANADA; NCI, MOLEC ONCOL LAB, FREDERICK, MD 21702 USA; PROGRAM RESOURCES INC DYNCORP, FREDERICK, MD 21702 USA; MED UNIV S CAROLINA, CTR MOLEC & STRUCT BIOL, CHARLESTON, SC 29425 USA	University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; Womens College Hospital; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Medical University of South Carolina								ASCIONE R, 1992, INT J ONCOL, V1, P631; BENDAVID Y, 1991, GENE DEV, V5, P908, DOI 10.1101/gad.5.6.908; BOULUKOS KE, 1988, EMBO J, V7, P697, DOI 10.1002/j.1460-2075.1988.tb02865.x; BROWN TA, 1992, GENE DEV, V6, P2502, DOI 10.1101/gad.6.12b.2502; CULLEN BR, 1992, AIDS RES HUM RETROV, V8, P387, DOI 10.1089/aid.1992.8.387; CULLEN BR, 1992, MICROBIOL REV, V56, P375, DOI 10.1128/MMBR.56.3.375-394.1992; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; DALTON S, 1993, PHILOS T ROY SOC B, V340, P325, DOI 10.1098/rstb.1993.0074; EISENBEIS CF, 1993, MOL CELL BIOL, V13, P6452, DOI 10.1128/MCB.13.10.6452; FISHER RJ, 1994, PROTEIN SCI, V3, P257; FLEISCHMAN LF, 1993, ONCOGENE, V8, P771; GOEBL MG, 1990, CELL, V61, P1165, DOI 10.1016/0092-8674(90)90676-6; HODGE DR, 1993, MIAMI SHORT REP, V3, P32; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; JANKNECHT R, 1994, ONCOGENE, V9, P1273; KOIZUMI S, 1990, ONCOGENE, V5, P675; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAMARCO K, 1991, SCIENCE, V253, P789, DOI 10.1126/science.1876836; PAPAS TS, 1991, SER SYMP AD, V4, P211; POPOVIC M, 1984, SCIENCE, V224, P497, DOI 10.1126/science.6200935; RABAULT B, 1994, J BIOL CHEM, V269, P28143; SETH A, 1993, ONCOGENE, V8, P1783; SETH A, 1989, ONCOGENE RES, V5, P61; SETH A, 1993, AIDS RES HUM RETROV, V9, P1017, DOI 10.1089/aid.1993.9.1017; SETH A, 1994, ONCOGENE, V9, P469; SETH A, 1990, ONCOGENE, V5, P1761; THOMPSON CB, 1992, MOL CELL BIOL, V12, P1043, DOI 10.1128/MCB.12.3.1043; VENANZONI MC, 1996, IN PRESS ONCOGENE; WATSON DK, 1992, CELL GROWTH DIFFER, V3, P705; WATSON DK, 1988, P NATL ACAD SCI USA, V85, P7862, DOI 10.1073/pnas.85.21.7862; WATSON DK, 1986, P NATL ACAD SCI USA, V83, P1792, DOI 10.1073/pnas.83.6.1792	31	31	31	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 4	1996	12	1					11	18						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TQ014	8552380				2022-12-17	WOS:A1996TQ01400002
J	West, MJ; Sullivan, NF; Willis, AE				West, MJ; Sullivan, NF; Willis, AE			Translational upregulation of the c-myc oncogene in Bloom's syndrome cell lines	ONCOGENE			English	Article						c-myc; Bloom's syndrome; translation; eIF-4E; eIF-2 alpha	DNA LIGASE-I; 5' UNTRANSLATED REGION; HEAVY-CHAIN LOCUS; MESSENGER-RNA; MALIGNANT TRANSFORMATION; ERYTHROLEUKEMIA-CELLS; SYNDROME LYMPHOCYTES; SYNDROME FIBROBLASTS; INCREASED EXPRESSION; BURKITTS-LYMPHOMA	Previous studies have shown a constitutive increase in the levels of c-myc protein in cell lines derived from patients with the cancer-prone disorder Bloom's Syndrome (BS), We report here that this overexpression results from a specific increase in the translation of the c-myc mRNA and is not the result of either a chromosomal translocation involving the c-myc locus or an amplification of this gene, We also did not detect any increase in the stability of the c-myc protein or any significant increases in the levels of c-myc mRNA expressed in BS cells compared to control cell Lines, Overall, there is a 39-80% increase in the association of the c-myc mRNA with polysomes in BS cell lines, Since, in some cases, overexpression of the c-myc protein has been shown to increase levels of the translation initiation factors eIF-4E and eIF-2 alpha, which may themselves play a role in malignant conversion, we have also examined the levels of these proteins in BS cells and found them to be either comparable or lower than those in control cell lines, These data suggest that if c-myc does contribute to the cancer predisposition phenotype in BS then it does not appear to act via an eIF-4E and eIF-2 alpha mediated pathway.	UNIV LEICESTER, DEPT BIOCHEM, LEICESTER LE1 7RH, LEICS, ENGLAND; NUVENTURES LTD, NEWCASTLE UPON TYNE NE2 4HE, TYNE & WEAR, ENGLAND	University of Leicester				Willis, Anne/0000-0002-1470-8531; West, Michelle/0000-0002-9497-9365				BARNES DE, 1992, CELL, V69, P495, DOI 10.1016/0092-8674(92)90450-Q; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; BENTLEY DL, 1986, NATURE, V321, P702, DOI 10.1038/321702a0; BERNHEIM A, 1981, CANCER GENET CYTOGEN, V3, P307, DOI 10.1016/0165-4608(81)90039-X; CHAGANTI RS, 1974, P NATL ACAD SCI USA, V71, P4508, DOI 10.1073/pnas.71.11.4508; CHAN JYH, 1988, J BIOL CHEM, V263, P18231; CHAN JYH, 1987, NATURE, V325, P357, DOI 10.1038/325357a0; COLLINS S, 1982, NATURE, V298, P679, DOI 10.1038/298679a0; DALLAFAVERA R, 1982, NATURE, V299, P61; DARVEAU A, 1985, P NATL ACAD SCI USA, V82, P2315, DOI 10.1073/pnas.82.8.2315; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; GERMAN J, 1989, CLIN GENET, V35, P57; GERMAN J, 1994, P NATL ACAD SCI USA, V91, P6669, DOI 10.1073/pnas.91.14.6669; GERMAN J, 1977, AM J HUM GENET, V29, P553; GERMAN J, 1983, CHROMOSOME MUTATION; HANN SR, 1992, GENE DEV, V6, P1229, DOI 10.1101/gad.6.7.1229; HANN SR, 1984, MOL CELL BIOL, V4, P2486, DOI 10.1128/MCB.4.11.2486; HERRICK DJ, 1994, MOL CELL BIOL, V14, P2119, DOI 10.1128/MCB.14.3.2119; ISHIZAKI K, 1981, MUTAT RES, V80, P213, DOI 10.1016/0027-5107(81)90189-5; KEREKATTE V, 1995, INT J CANCER, V64, P27, DOI 10.1002/ijc.2910640107; KINGSTON RE, 1984, NATURE, V312, P280, DOI 10.1038/312280a0; KOROMILAS AE, 1992, SCIENCE, V257, P1685, DOI 10.1126/science.1382315; KREPINSKY AB, 1979, HUM GENET, V50, P151, DOI 10.1007/BF00390236; KURIHARA T, 1987, MUTAT RES, V184, P147, DOI 10.1016/0167-8817(87)90071-X; LANDERS JE, 1994, ONCOGENE, V9, P2745; LAZARISKARATZAS A, 1990, NATURE, V345, P544, DOI 10.1038/345544a0; LAZARUS P, 1992, ONCOGENE, V7, P1037; LUSCHER B, 1988, MOL CELL BIOL, V8, P2504; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; MCDANIEL LD, 1992, P NATL ACAD SCI USA, V89, P7968, DOI 10.1073/pnas.89.17.7968; MILTENBERGER RJ, 1995, MOL CELL BIOL, V15, P2527; MIYAGI Y, 1995, CANCER LETT, V91, P247, DOI 10.1016/0304-3835(95)03737-H; MOORE JP, 1987, ONCOGENE RES, V2, P65; NERI A, 1988, P NATL ACAD SCI USA, V85, P2748, DOI 10.1073/pnas.85.8.2748; PARKIN N, 1988, MOL CELL BIOL, V8, P2875, DOI 10.1128/MCB.8.7.2875; PELICCI PG, 1986, P NATL ACAD SCI USA, V83, P2984, DOI 10.1073/pnas.83.9.2984; PROKIPCAK RD, 1994, J BIOL CHEM, V269, P9261; REISMAN D, 1993, CELL GROWTH DIFFER, V4, P57; ROSENWALD IB, 1993, MOL CELL BIOL, V13, P7358, DOI 10.1128/MCB.13.12.7358; ROSENWALD IB, 1993, P NATL ACAD SCI USA, V90, P6175, DOI 10.1073/pnas.90.13.6175; ROWE M, 1989, J VIROL, V63, P1031, DOI 10.1128/JVI.63.3.1031-1039.1989; SAITO H, 1983, P NATL ACAD SCI-BIOL, V80, P7476, DOI 10.1073/pnas.80.24.7476; SCHWAB M, 1986, MOL CELL BIOL, V6, P2752, DOI 10.1128/MCB.6.7.2752; SEABRIGH.M, 1971, LANCET, V2, P971; SHINDO H, 1993, ACTA NEUROPATHOL, V86, P345, DOI 10.1007/BF00369446; SHIRAMIZU B, 1991, BLOOD, V77, P1516; SPOTTS GD, 1990, MOL CELL BIOL, V10, P3952, DOI 10.1128/MCB.10.8.3952; SULLIVAN NF, 1988, CURR TOP MICROBIOL, V141, P208; SULLIVAN NF, 1989, ONCOGENE, V4, P1509; SULLIVAN NF, 1989, ONCOGENE, V4, P1497; TAUB R, 1982, P NATL ACAD SCI-BIOL, V79, P7837, DOI 10.1073/pnas.79.24.7837; THEODORAKIS NG, 1988, J BIOL CHEM, V263, P14579; WARREN ST, 1981, P NATL ACAD SCI-BIOL, V78, P3133, DOI 10.1073/pnas.78.5.3133; WATSON RJ, 1988, MOL CELL BIOL, V8, P3938, DOI 10.1128/MCB.8.9.3938; WATT R, 1983, P NATL ACAD SCI-BIOL, V80, P6307, DOI 10.1073/pnas.80.20.6307; WATT RA, 1985, MOL CELL BIOL, V5, P448, DOI 10.1128/MCB.5.3.448; WEI YF, 1995, MOL CELL BIOL, V15, P3206; WILLIS AE, 1987, NATURE, V325, P355, DOI 10.1038/325355a0; WILLIS AE, 1987, P NATL ACAD SCI USA, V84, P8016, DOI 10.1073/pnas.84.22.8016; YANG SW, 1992, P NATL ACAD SCI USA, V89, P2227, DOI 10.1073/pnas.89.6.2227; ZECH L, 1976, INT J CANCER, V17, P47, DOI 10.1002/ijc.2910170108	61	31	31	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 21	1995	11	12					2515	2524						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TP188	8545108				2022-12-17	WOS:A1995TP18800007
J	Nguyen, HQ; Selvakumaran, M; Liebermann, DA; Hoffman, B				Nguyen, HQ; Selvakumaran, M; Liebermann, DA; Hoffman, B			Blocking c-Myc and Max expression inhibits proliferation and induces differentiation of normal and leukemic myeloid cells	ONCOGENE			English	Note						c-myc; max; myeloid differentiation	IMMEDIATE EARLY RESPONSE; DNA-BINDING; TERMINAL DIFFERENTIATION; ONCOGENE EXPRESSION; GROWTH ARREST; PROTEIN; LINE; APOPTOSIS; HL-60; AMPLIFICATION	Given the central role c-Myc plays in growth control, differentiation and apoptosis, understanding how c-Myc functions will increase our understanding about normal cell development, and how alterations in these processes can lead to malignancy, C-Myc is a negative regulator of terminal myeloid differentiation; therefore, it was of interest to determine what effect blocking c-MSc expression would have on proliferation and differentiation, Tn this work we showed that blocking expression of either c-Myc or Max, its molecular partner, in myeloblastic leukemia M1 cells activated the differentiation program in the absence of an exogenous source of differentiation inducer; the cells assumed an intermediate stage myeloid morphology. Moreover, when both c-Myc and Max expression were concommitantly blocked, many of the cells underwent terminal differentiation, Finally, extending these studies to myeloblast enriched normal bone marrow (BM) cells has shown that blocking expression of either c-Myc or Max accelerated GM-CSF-induced differentiation along both the granulocytic and monocytic lineages, Thus, it can be concluded that blocking either c-Myc or Max expression in myeloid cells at specific stages of development activates and accelerates the terminal differentiation program.	TEMPLE UNIV,SCH MED,FELS INST CANC RES & MOLEC BIOL,PHILADELPHIA,PA 19140	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University					NATIONAL CANCER INSTITUTE [R01CA051162, R01CA043618, P30CA012227] Funding Source: NIH RePORTER; NCI NIH HHS [1RO1CA51162, 5 P30 CA12227, 1RO1CA43618] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ASKEW DS, 1991, ONCOGENE, V6, P1915; AYER DE, 1995, CELL, V80, P767, DOI 10.1016/0092-8674(95)90355-0; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; COLLINS S, 1982, NATURE, V298, P679, DOI 10.1038/298679a0; COPPOLA JA, 1986, NATURE, V320, P760, DOI 10.1038/320760a0; DALLAFAVERA R, 1982, NATURE, V299, P61; DMITROVSKY E, 1986, NATURE, V322, P748, DOI 10.1038/322748a0; EVAN GI, 1993, CURR OPIN GENET DEV, V3, P44, DOI 10.1016/S0959-437X(05)80339-9; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FREYTAG SO, 1988, MOL CELL BIOL, V8, P1614, DOI 10.1128/MCB.8.4.1614; GERWIRTZ AM, 1988, SCIENCE, V242, P180; HOFFMANLIEBERMANN B, 1991, MOL CELL BIOL, V11, P2375, DOI 10.1128/MCB.11.5.2375; HOLT JT, 1988, MOL CELL BIOL, V8, P963, DOI 10.1128/MCB.8.2.963; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LIEBERMANN D, 1981, INT J CANCER, V28, P285, DOI 10.1002/ijc.2910280306; LIEBERMANN DA, 1989, ONCOGENE, V4, P583; LORD KA, 1990, ONCOGENE, V5, P387; LORD KA, 1990, CELL GROWTH DIFFER, V1, P637; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; NGUYEN HQ, 1993, CELL, V72, P197, DOI 10.1016/0092-8674(93)90660-I; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; PROCHOWNIK EV, 1986, NATURE, V322, P848, DOI 10.1038/322848a0; SCHNEIDER MD, 1987, MOL CELL BIOL, V7, P1973, DOI 10.1128/MCB.7.5.1973; SELVAKUMARAN M, 1993, BLOOD, V81, P2257; SELVAKUMARAN M, 1994, MOL CELL BIOL, V14, P2352, DOI 10.1128/MCB.14.4.2352; SHI YF, 1992, SCIENCE, V257, P212, DOI 10.1126/science.1378649; WICKSTROM EL, 1988, P NATL ACAD SCI USA, V85, P1028, DOI 10.1073/pnas.85.4.1028	29	31	31	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 7	1995	11	11					2439	2444						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TK702	8570196				2022-12-17	WOS:A1995TK70200029
J	PERREM, K; RAYNER, J; VOSS, T; STURZBECHER, H; JACKSON, P; BRAITHWAITE, A				PERREM, K; RAYNER, J; VOSS, T; STURZBECHER, H; JACKSON, P; BRAITHWAITE, A			P53 REPRESSES SV40 TRANSCRIPTION BY PREVENTING FORMATION OF TRANSCRIPTION COMPLEXES	ONCOGENE			English	Article						P53; SV40; GENE REPRESSION	WILD-TYPE P53; HUMAN PAPILLOMAVIRUS TYPE-16; HUMAN HSP70 PROMOTER; BINDING PROTEIN; CHLORAMPHENICOL ACETYLTRANSFERASE; NEGATIVE REGULATION; DNA-REPLICATION; MAMMALIAN-CELLS; GENE-PRODUCT; MUTANT P53	There is now much evidence to suggest that the p53 tumour suppressor protein functions to monitor the integrity of the genome. When DNA damage is detected, p53 suppresses cell growth to allow repair or directs the cell into apoptosis. The mechanism of action of p53 is as yet unclear but recent evidence has accumulated to suggest that p53 might act by regulating gene expression. Consistent with this model, p53 can both activate and repress a number of viral and cellular promoters. p53 has also been shown to bind to the CCAAT-binding Factor and TATA-binding protein (TBP), and there is direct evidence that p53 represses in vitro transcription by preventing TBP from binding DNA. We now provide evidence that p53 can repress transcription from the SV40 promoter by disrupting DNA/protein complexes involving transcription factor Sp1.	AUSTRALIAN NATL UNIV, JOHN CURTIN SCH MED RES, DIV CELL BIOL, CELL TRANSFORMAT GRP, CANBERRA, ACT 2601, AUSTRALIA; UNIV HAMBURG, HEINRICH PETTE INST EXPTL VIROL & IMMUNOL, D-20251 HAMBURG, GERMANY	Australian National University; John Curtin School of Medical Research; Heinrich Pette Institute; University of Hamburg								AGOFF SN, 1993, SCIENCE, V259, P84, DOI 10.1126/science.8418500; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BARGONETTI J, 1991, CELL, V65, P1083, DOI 10.1016/0092-8674(91)90560-L; BIENZTADMOR B, 1985, EMBO J, V4, P3209, DOI 10.1002/j.1460-2075.1985.tb04067.x; BORELLINI F, 1993, J BIOL CHEM, V268, P7923; BRAITHWAITE AW, 1987, NATURE, V329, P458, DOI 10.1038/329458a0; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; CHIU R, 1987, NATURE, V329, P648, DOI 10.1038/329648a0; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; COHEN DR, 1994, P NATL ACAD SCI USA, V91, P4372, DOI 10.1073/pnas.91.10.4372; DONEHOWER LA, 1993, BIOCHIM BIOPHYS ACTA, V1155, P181, DOI 10.1016/0304-419X(93)90004-V; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HARPER JW, 1993, CELL, V75, P805; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HOPPESEYLER F, 1993, J VIROL, V67, P3111, DOI 10.1128/JVI.67.6.3111-3117.1993; JACKSON P, 1994, BIOCHEM BIOPH RES CO, V203, P133, DOI 10.1006/bbrc.1994.2159; JACKSON P, 1993, ONCOGENE, V8, P589; JACKSON P, 1995, IN PRESS GENE EXPRES, V5; JENKINS JR, 1985, NATURE, V317, P816, DOI 10.1038/317816a0; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KLEY N, 1992, NUCLEIC ACIDS RES, V20, P4083, DOI 10.1093/nar/20.15.4083; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LEHMAN TA, 1991, CANCER RES, V51, P4090; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MITCHELL PJ, 1987, CELL, V50, P847, DOI 10.1016/0092-8674(87)90512-5; MIYASHITA T, 1994, CANCER RES, V54, P3131; NABEL GJ, 1988, SCIENCE, V239, P1299, DOI 10.1126/science.2830675; PAULY M, 1992, NUCLEIC ACIDS RES, V20, P975, DOI 10.1093/nar/20.5.975; QUITSCHKE WW, 1989, J BIOL CHEM, V264, P9539; RAGIMOV N, 1993, ONCOGENE, V8, P1183; RAY A, 1988, P NATL ACAD SCI USA, V85, P6701, DOI 10.1073/pnas.85.18.6701; SANTHANAM U, 1991, P NATL ACAD SCI USA, V88, P7605, DOI 10.1073/pnas.88.17.7605; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SHEN YQ, 1994, P NATL ACAD SCI USA, V91, P8940, DOI 10.1073/pnas.91.19.8940; SHIIO Y, 1992, P NATL ACAD SCI USA, V89, P5206, DOI 10.1073/pnas.89.12.5206; SLEIGH MJ, 1986, ANAL BIOCHEM, V156, P251, DOI 10.1016/0003-2697(86)90180-6; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STURZBECHER HW, 1988, ONCOGENE, V3, P405; STURZBECHER HW, 1992, ONCOGENE, V7, P1513; STURZBECHER HW, 1988, CANCER CELL, V6, P159; SUBLER MA, 1992, J VIROL, V66, P4757, DOI 10.1128/JVI.66.8.4757-4762.1992; TOOZE J, 1980, DNA TUMOR VIRUSES 2; TRUANT R, 1993, J BIOL CHEM, V268, P2284; UEDA T, 1994, P NATL ACAD SCI USA, V91, P10680, DOI 10.1073/pnas.91.22.10680; VOUSDEN K, 1993, FASEB J, V7, P872, DOI 10.1096/fasebj.7.10.8393818; WU BJ, 1986, P NATL ACAD SCI USA, V83, P629, DOI 10.1073/pnas.83.3.629	57	31	31	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 5	1995	11	7					1299	1307						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RY967	7478550				2022-12-17	WOS:A1995RY96700010
J	HERZINGER, T; WOLF, DA; EICK, D; KIND, P				HERZINGER, T; WOLF, DA; EICK, D; KIND, P			THE PRB-RELATED PROTEIN P130 IS A POSSIBLE EFFECTOR OF TRANSFORMING GROWTH-FACTOR-BETA-1 INDUCED CELL-CYCLE ARREST IN KERATINOCYTES	ONCOGENE			English	Article						GROWTH CONTROL; TUMOR SUPPRESSOR GENES	RETINOBLASTOMA GENE-PRODUCT; TRANSCRIPTION FACTOR E2F; HUMAN MYC PROMOTER; TGF-BETA; C-MYC; TRANS-ACTIVATION; DEPENDENT KINASE; DIRECT BINDING; INHIBITION; P107	Transforming growth factor beta 1 (TGF-beta 1) is known to inhibit epithelial cell growth by inducing a G1 cell cycle arrest. We have studied the effect of TGF-beta 1 on protein binding to a transcription factor E2F consensus element in extracts from early passage human keratinocytes (HFKs) and a permanent human keratinocyte cell line (HaCaT). Treatment of these cells with TGF-beta 1 resulted in the formation of a DNA binding complex between the pRb-related protein p130 and E2F. Formation of the E2F-p130 complex correlated with inhibition of cell cycle progression in G1 and suppression of the E2F-regulated cdc2 gene. While p130 mRNA and protein levels were not influenced by TGF-beta 1, the activity of cyclin-dependent kinase 2 (Cdk2) towards p130 in vitro was inhibited. The results identify p130 as a downstream target of TGF-beta 1 and a possible mediator of the G1 cell cycle arrest.	GSF FORSCHUNGSZENTRUM UNWELT & GESUNDHEIT,INST KLIN MOLEK BIOL & TUMORGENET,D-81377 MUNICH,GERMANY; UNIV MUNICH,DERMATOL KLIN & POLIKLIN,MOLEK PATHOL ABT,D-80337 MUNICH,GERMANY	Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; University of Munich			Wolf, Dieter/AAE-5890-2021	Wolf, Dieter/0000-0002-3761-1070				BAGCHI S, 1991, CELL, V65, P1063, DOI 10.1016/0092-8674(91)90558-G; BANDARA LR, 1991, NATURE, V351, P494, DOI 10.1038/351494a0; CAO L, 1992, NATURE, V355, P176, DOI 10.1038/355176a0; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHITTENDEN T, 1993, MOL CELL BIOL, V13, P3975, DOI 10.1128/MCB.13.7.3975; COBRINIK D, 1993, GENE DEV, V7, P2392, DOI 10.1101/gad.7.12a.2392; COFFEY RJ, 1988, MOL CELL BIOL, V8, P3088, DOI 10.1128/MCB.8.8.3088; DALTON S, 1992, EMBO J, V11, P1797, DOI 10.1002/j.1460-2075.1992.tb05231.x; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DEVOTO SH, 1992, CELL, V68, P167, DOI 10.1016/0092-8674(92)90215-X; DOU QP, 1994, J BIOL CHEM, V269, P1306; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; DYNLACHT BD, 1994, GENE DEV, V8, P1772, DOI 10.1101/gad.8.15.1772; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; EWEN ME, 1993, CELL, V74, P1009, DOI 10.1016/0092-8674(93)90723-4; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; GAZIN C, 1984, EMBO J, V3, P383, DOI 10.1002/j.1460-2075.1984.tb01816.x; GIORDANO A, 1991, ONCOGENE, V6, P481; HAMEL PA, 1992, MOL CELL BIOL, V12, P3431, DOI 10.1128/MCB.12.8.3431; HANNON GJ, 1993, GENE DEV, V7, P2378, DOI 10.1101/gad.7.12a.2378; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HELIN K, 1993, MOL CELL BIOL, V13, P6501, DOI 10.1128/MCB.13.10.6501; HIEBERT SW, 1989, P NATL ACAD SCI USA, V86, P3594, DOI 10.1073/pnas.86.10.3594; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HU Q, 1992, MOL CELL BIOL, V12, P971, DOI 10.1128/MCB.12.3.971; KATO J, 1993, GENE DEV, V7, P331; KOFF A, 1993, SCIENCE, V260, P536, DOI 10.1126/science.8475385; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; LATHANGUE NB, 1994, TRENDS BIOCHEM SCI, V19, P108, DOI 10.1016/0968-0004(94)90202-X; LEES E, 1992, GENE DEV, V6, P1874, DOI 10.1101/gad.6.10.1874; LI Y, 1993, GENE DEV, V7, P2366, DOI 10.1101/gad.7.12a.2366; MASSAGUE J, 1992, CANCER SURV, V12, P81; MAYOL X, 1993, ONCOGENE, V8, P2561; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; MISSERO C, 1991, P NATL ACAD SCI USA, V88, P3489, DOI 10.1073/pnas.88.8.3489; MUDRYJ M, 1991, CELL, V65, P1243, DOI 10.1016/0092-8674(91)90019-U; ONG G, 1991, ONCOGENE, V6, P761; PAGANO M, 1992, ONCOGENE, V7, P1681; PIETENPOL JA, 1991, P NATL ACAD SCI USA, V88, P10227, DOI 10.1073/pnas.88.22.10227; PIETENPOL JA, 1990, CELL, V61, P777, DOI 10.1016/0092-8674(90)90188-K; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; SCHWARZ JK, 1993, EMBO J, V12, P1013, DOI 10.1002/j.1460-2075.1993.tb05742.x; SHIPLEY GD, 1986, CANCER RES, V46, P2068; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; SLINGERLAND JM, 1994, MOL CELL BIOL, V14, P3683, DOI 10.1128/MCB.14.6.3683; THALMEIER K, 1989, GENE DEV, V3, P527, DOI 10.1101/gad.3.4.527; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; WHYTE P, 1988, J VIROL, V62, P257, DOI 10.1128/JVI.62.1.257-265.1988; WOLF DA, 1995, ONCOGENE, V10, P2067; WOLF DA, 1993, MOL ENDOCRINOL, V7, P924, DOI 10.1210/me.7.7.924; ZAMANIAN M, 1993, MOL BIOL CELL, V4, P389, DOI 10.1091/mbc.4.4.389; ZENTELLA A, 1991, MOL CELL BIOL, V11, P4952, DOI 10.1128/MCB.11.10.4952; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111	54	31	31	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JUN 1	1995	10	11					2079	2084						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RB703	7784052				2022-12-17	WOS:A1995RB70300002
J	BOGENMANN, E; TORRES, M; MATSUSHIMA, H				BOGENMANN, E; TORRES, M; MATSUSHIMA, H			CONSTITUTIVE N-MYC GENE-EXPRESSION INHIBITS TRKA MEDIATED NEURONAL DIFFERENTIATION	ONCOGENE			English	Article						N-MYC; TRKA; DIFFERENTIATION; NEURONAL CELLS; CELL CYCLE	NERVE GROWTH-FACTOR; TYROSINE PROTEIN-KINASE; NEUROBLASTOMA CELL-LINE; AFFINITY NGF RECEPTOR; CLASS-I GENE; PC12 CELLS; NEUROTROPHIC FACTOR; C-MYC; MONOCLONAL-ANTIBODIES; MESSENGER-RNA	The effect of constitutively expressed N-myc gene on nerve growth factor (NGF) induced neuronal differentiation was investigated, B104, a rat central nervous system-derived cell line and its N-myc gene expressing derivative lines (C6, C7) (Bernards et al., 1986), were stably transfected with the trkA proto-oncogene and independent clones for each cell line were analysed. NGF induced phosphorylation of the trkA receptor, activated a cascade of cellular intermediaries such as phospholipase C gamma 1 and ERK proteins, and stimulated c-fos gene transcription in all trk-A-expressing clones. NGF-mediated neuronal differentiation was observed solely in trkA-expressing B104-derived clones and was characterized by reduced cell growth, activation of NGF-regulated genes, and downregulation of the endogenous low-affinity NGF receptor gene (gp75(NGFR)). NO such phenotypical changes occurred in trkA-expressing C6 or C7-derived clones following NGF treatment. These results are consistent with the hypothesis that constitutive expression of N-myc inhibits exit from cell cycle and blocks neuronal cell differentiation.	UNIV SO CALIF,SCH PHARM,LOS ANGELES,CA 90089; CALTECH,DIV BIOL 14775,PASADENA,CA 91125; JIKEI UNIV,SCH MED,DEPT PEDIAT,MINATO KU,TOKYO 105,JAPAN	University of Southern California; California Institute of Technology; Jikei University	BOGENMANN, E (corresponding author), CHILDRENS HOSP LOS ANGELES,RES INST,DIV HEMATOL ONCOL,4650 SUNSET BLVD,LOS ANGELES,CA 90027, USA.				NINDS NIH HHS [NS25795] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS025795] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AKESON R, 1990, MOL CELL BIOL, V10, P2012, DOI 10.1128/MCB.10.5.2012; BERKEMEIER LR, 1991, NEURON, V7, P857, DOI 10.1016/0896-6273(91)90287-A; BERNARDS R, 1986, CELL, V47, P667, DOI 10.1016/0092-8674(86)90509-X; BERNARDS R, 1991, EMBO J, V10, P1119, DOI 10.1002/j.1460-2075.1991.tb08052.x; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; CARDO CC, 1991, CELL, V66, P173; CHAO MV, 1992, NEURON, V9, P583, DOI 10.1016/0896-6273(92)90023-7; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COLE MD, 1991, CELL, V65, P715, DOI 10.1016/0092-8674(91)90377-B; COWAN NJ, 1983, MOL CELL BIOL, V3, P1738, DOI 10.1128/MCB.3.10.1738; CURRAN T, 1982, J VIROL, V44, P674, DOI 10.1128/JVI.44.2.674-682.1982; DOBROWSKY RT, 1994, SCIENCE, V265, P1596, DOI 10.1126/science.8079174; DOHERTY P, 1988, NEUROSCI LETT, V92, P222, DOI 10.1016/0304-3940(88)90065-1; EAGER KB, 1991, ONCOGENE, V6, P819; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; ERNFORS P, 1988, NEURON, V1, P983, DOI 10.1016/0896-6273(88)90155-9; FELTNER DE, 1989, J IMMUNOL, V143, P4292; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; GOMEZ N, 1990, FEBS LETT, V271, P119, DOI 10.1016/0014-5793(90)80386-W; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; GROSS N, 1990, CANCER RES, V50, P7532; HEMPSTEAD BL, 1991, NATURE, V350, P678, DOI 10.1038/350678a0; HEMPSTEAD BL, 1989, SCIENCE, V243, P373, DOI 10.1126/science.2536190; HOLT JT, 1988, MOL CELL BIOL, V8, P963, DOI 10.1128/MCB.8.2.963; IBANEZ CF, 1992, CELL, V69, P329, DOI 10.1016/0092-8674(92)90413-7; IKENAKA K, 1990, J BIOL CHEM, V265, P19782; JING SQ, 1992, NEURON, V9, P1067, DOI 10.1016/0896-6273(92)90066-M; JOHNSON D, 1986, CELL, V47, P545, DOI 10.1016/0092-8674(86)90619-7; KADESCH T, 1993, CELL GROWTH DIFFER, V4, P49; KAPLAN DR, 1991, NATURE, V350, P158, DOI 10.1038/350158a0; KIM UH, 1991, J BIOL CHEM, V266, P1359; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; KLEIN R, 1991, CELL, V66, P395, DOI 10.1016/0092-8674(91)90628-C; KLEIN R, 1989, EMBO J, V8, P3701, DOI 10.1002/j.1460-2075.1989.tb08545.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMBALLE F, 1993, EMBO J, V12, P3083, DOI 10.1002/j.1460-2075.1993.tb05977.x; LAMBALLE F, 1991, CELL, V66, P967, DOI 10.1016/0092-8674(91)90442-2; LEE KF, 1992, CELL, V69, P737, DOI 10.1016/0092-8674(92)90286-L; LEONARD DGB, 1987, MOL CELL BIOL, V7, P3156, DOI 10.1128/MCB.7.9.3156; LO LC, 1991, DEV BIOL, V145, P139, DOI 10.1016/0012-1606(91)90220-W; LOEB DM, 1991, CELL, V66, P961, DOI 10.1016/0092-8674(91)90441-Z; LOEB DM, 1993, J NEUROSCI, V13, P2919; MACHIDA CM, 1989, NEURON, V2, P1587, DOI 10.1016/0896-6273(89)90047-0; MACLEOD AR, 1981, EUR J BIOCHEM, V119, P353, DOI 10.1111/j.1432-1033.1981.tb05615.x; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; MATSUSHIMA H, 1992, INT J CANCER, V51, P250, DOI 10.1002/ijc.2910510214; MATSUSHIMA H, 1993, MOL CELL BIOL, V13, P7447, DOI 10.1128/MCB.13.12.7447; MATSUSHIMA H, 1990, MOL CELL BIOL, V10, P5015, DOI 10.1128/MCB.10.9.5015; MEAKIN SO, 1992, TRENDS NEUROSCI, V15, P323, DOI 10.1016/0166-2236(92)90047-C; MEAKIN SO, 1992, P NATL ACAD SCI USA, V89, P2374, DOI 10.1073/pnas.89.6.2374; MILLER FD, 1991, J CELL BIOL, V112, P303, DOI 10.1083/jcb.112.2.303; NAKAGAWARA A, 1992, CANCER RES, V52, P1364; NAKAGAWARA A, 1993, NEW ENGL J MED, V328, P847, DOI 10.1056/NEJM199303253281205; NEGRONI A, 1991, CELL GROWTH DIFFER, V2, P511; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PRENDERGAST GC, 1990, MOL CELL BIOL, V10, P1265, DOI 10.1128/MCB.10.3.1265; RUDKIN BB, 1989, EMBO J, V8, P3319, DOI 10.1002/j.1460-2075.1989.tb08493.x; RUSTGI AK, 1991, NATURE, V352, P541, DOI 10.1038/352541a0; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SCHUBERT D, 1974, NATURE, V249, P224, DOI 10.1038/249224a0; SCHWAB M, 1983, NATURE, V305, P245, DOI 10.1038/305245a0; SCHWAB M, 1984, P NATL ACAD SCI-BIOL, V81, P4940, DOI 10.1073/pnas.81.15.4940; SCHWAB M, 1985, NATURE, V316, P160, DOI 10.1038/316160a0; SEEGER RC, 1982, ANN INTERN MED, V97, P873, DOI 10.7326/0003-4819-97-6-873; SQUINTO SP, 1991, CELL, V65, P885, DOI 10.1016/0092-8674(91)90395-F; STEPHENS RM, 1994, NEURON, V12, P691, DOI 10.1016/0896-6273(94)90223-2; SUGIO K, 1991, CANCER, V67, P1384, DOI 10.1002/1097-0142(19910301)67:5<1384::AID-CNCR2820670518>3.0.CO;2-7; SUZUKI T, 1993, J NATL CANCER I, V85, P377, DOI 10.1093/jnci/85.5.377; THIELE CJ, 1988, EXP CELL BIOL, V56, P321; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; TORRES M, 1993, J IMMUNOL, V150, P1563; VANDERGEER P, 1994, ANN REV CELL BIOL, V100, P251; VANTVEER LJ, 1993, EMBO J, V12, P195, DOI 10.1002/j.1460-2075.1993.tb05645.x; VERDI JM, 1994, NEURON, V12, P733, DOI 10.1016/0896-6273(94)90327-1; VETTER ML, 1991, P NATL ACAD SCI USA, V88, P5650, DOI 10.1073/pnas.88.13.5650; WESKAMP G, 1991, NEURON, V6, P649, DOI 10.1016/0896-6273(91)90067-A; WHITESELL L, 1991, MOL CELL BIOL, V11, P1360, DOI 10.1128/MCB.11.3.1360; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; ZANCA DM, 1989, MOL CELL BIOL, V9, P24; ZANCA DM, 1986, NATURE, V319, P743	82	31	31	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	MAY 18	1995	10	10					1915	1925						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QZ926	7761093				2022-12-17	WOS:A1995QZ92600005
J	BUSHEL, P; KIM, JH; CHANG, W; CATINO, JJ; RULEY, HE; KUMAR, CC				BUSHEL, P; KIM, JH; CHANG, W; CATINO, JJ; RULEY, HE; KUMAR, CC			2 SERUM RESPONSE ELEMENTS MEDIATE TRANSCRIPTIONAL REPRESSION OF HUMAN SMOOTH-MUSCLE ALPHA-ACTIN PROMOTER IN RAS-TRANSFORMED CELLS	ONCOGENE			English	Article						ALPHA-ACTIN PROMOTER; SRES; RAS-ONCOGENE; REPRESSION	C-FOS; FIBROBLAST CELLS; GENE-EXPRESSION; ACTIVATION; CDNA; ONCOGENES; PROTEIN; YY1; TUMORIGENICITY; SUPPRESSION	The mechanism by which activated uas expression leads to repression genes specific actin filament proteins not understood, However, these changes associated with loss of organized actin filaments, are necessary to maintain the transformed phenotype. The human smooth muscle (sm) alpha-actin promoter is repressed in ras-transformed fibroblast cells and derepressed in revertant cell lines. In this study, we demonstrate that two serum response elements (SREs) present in the alpha-actin promoter are required for transcriptional repression in ras-transformed cells and the two SREs act synergistically to repress heterologous promoters in a ras-transformation dependent manner, Serum response factor (SRF), which can bind to the sm alpha-actin SREs, restores alpha-actin promoter activity in ras-transformed cells. c-Fos, c-Jun and YY1 also repress alpha-actin promoter through SREs, suggesting that these transcription factors may play a role in repressing alpha-actin promoter in uas-transformed cells.	SCHERING PLOUGH CORP, RES INST, DEPT TUMOR BIOL, KENILWORTH, NJ 07033 USA; MIT, CTR CANC RES, DEPT BIOL, CAMBRIDGE, MA 02139 USA	Merck & Company; Schering Plough Corporation; Massachusetts Institute of Technology (MIT)			Kim, Jae-Hong/B-2530-2009; Chang, Wen/AAA-5076-2021	Kim, Jae-Hong/0000-0002-8019-0208; Chang, Wen/0000-0003-3369-083X	NCI NIH HHS [R01CA40602] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA040602] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BASSIN RH, 1987, ADV VIRAL ONCOL, V6, P103; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BLANK RS, 1992, J BIOL CHEM, V267, P984; CARROLL SL, 1988, MOL CELL BIOL, V8, P241, DOI 10.1128/MCB.8.1.241; CARROLL SL, 1986, J BIOL CHEM, V261, P8955; FERNANDEZ JLR, 1992, J CELL BIOL, V119, P427, DOI 10.1083/jcb.119.2.427; FOSTER DN, 1992, J BIOL CHEM, V267, P11995; FUKUMOTO Y, 1990, J BIOL CHEM, V265, P774; GAFFNEY DF, 1985, NUCLEIC ACIDS RES, V13, P7847, DOI 10.1093/nar/13.21.7847; GLUCK U, 1993, P NATL ACAD SCI USA, V90, P383, DOI 10.1073/pnas.90.2.383; GUALBERTO A, 1992, MOL CELL BIOL, V12, P4209, DOI 10.1128/MCB.12.9.4209; GUTMAN A, 1991, MOL CELL BIOL, V11, P5381, DOI 10.1128/MCB.11.10.5381; HARIHARAN N, 1991, P NATL ACAD SCI USA, V88, P9799, DOI 10.1073/pnas.88.21.9799; HERRLICH P, 1989, TRENDS GENET, V5, P112, DOI 10.1016/0168-9525(89)90041-3; IMLER JL, 1988, NATURE, V332, P275, DOI 10.1038/332275a0; JOHANSEN FE, 1993, MOL CELL BIOL, V13, P4640, DOI 10.1128/MCB.13.8.4640; KIM JH, 1993, BIOCHEM BIOPH RES CO, V190, P1115, DOI 10.1006/bbrc.1993.1165; KONIG H, 1989, EMBO J, V8, P2559, DOI 10.1002/j.1460-2075.1989.tb08394.x; KUMAR CC, 1992, CANCER RES, V52, P6877; KUMAR CC, 1992, CELL GROWTH DIFFER, V3, P1; KUMAR CC, 1991, EXP BIOL M, P47; LEAVITT J, 1985, NATURE, V316, P840, DOI 10.1038/316840a0; LEE TC, 1992, P NATL ACAD SCI USA, V89, P9814, DOI 10.1073/pnas.89.20.9814; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MIN BH, 1990, J BIOL CHEM, V265, P16667; NORMAN C, 1988, CELL, V55, P989, DOI 10.1016/0092-8674(88)90244-9; PIETTE J, 1988, P NATL ACAD SCI USA, V85, P3401, DOI 10.1073/pnas.85.10.3401; POLLACK R, 1984, ADV VIRAL ONCOL, V4, P3; PRASAD GL, 1993, P NATL ACAD SCI USA, V90, P7039, DOI 10.1073/pnas.90.15.7039; QURESHI SA, 1992, J BIOL CHEM, V267, P17635; REDDY S, 1990, J BIOL CHEM, V265, P1683; RIVERA V M, 1990, New Biologist, V2, P751; RIVERA VM, 1990, GENE DEV, V4, P255, DOI 10.1101/gad.4.2.255; SASSONECORSI P, 1988, NATURE, V334, P314, DOI 10.1038/334314a0; SCHONTHAL A, 1988, CELL, V54, P325, DOI 10.1016/0092-8674(88)90195-X; SHI Y, 1991, CELL, V67, P377, DOI 10.1016/0092-8674(91)90189-6; Treisman R, 1990, Semin Cancer Biol, V1, P47; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WASYLYK C, 1988, EMBO J, V7, P2475, DOI 10.1002/j.1460-2075.1988.tb03094.x	39	31	35	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 6	1995	10	7					1361	1370						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QR651	7731687				2022-12-17	WOS:A1995QR65100013
J	YATES, KE; LYNCH, MR; WONG, SG; SLAMON, DJ; GASSON, JC				YATES, KE; LYNCH, MR; WONG, SG; SLAMON, DJ; GASSON, JC			HUMAN C-FES IS A NUCLEAR TYROSINE KINASE	ONCOGENE			English	Note						C-FES; TYROSINE KINASE; NUCLEAR LOCALIZATION; HEMATOPOIESIS	SIGNAL-TRANSDUCTION; GROWTH-HORMONE; GENE-PRODUCT; FPS-GENE; PROTEIN; PHOSPHORYLATION; JAK2; DNA; ERYTHROPOIETIN; LOCALIZATION	FES is a non-receptor protein tyrosine kinase expressed in hematopoietic progenitors and differentiated myeloid cells. It has recently been implicated in granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-3 (IL-3) and erythropoietin signal transduction. To better understand the role played by FES in normal and neoplastic hematopoiesis, we used cell fractionation techniques to examine the subcellular localization of FES in myeloid cells and cell lines. FES was observed in the nuclear, granular and plasma membrane fractions of primary human neutrophils and the myeloid leukemia cell line, HL-60. The nuclear localization was confirmed by immunocytochemistry of neutrophils.	UNIV CALIF LOS ANGELES, SCH MED, DEPT BIOL CHEM, LOS ANGELES, CA 90024 USA; UNIV CALIF LOS ANGELES, SCH MED, INST MOLEC BIOL, LOS ANGELES, CA 90024 USA; UNIV CALIF LOS ANGELES, SCH MED, DEPT MED, DIV HEMATOL ONCOL, LOS ANGELES, CA 90024 USA; UNIV CALIF LOS ANGELES, SCH MED, JONSSON COMPREHENS CANC CTR, LOS ANGELES, CA 90024 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA					NATIONAL CANCER INSTITUTE [R01CA040163] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA40163, CA09056] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; BAZAN JF, 1989, BIOCHEM BIOPH RES CO, V164, P788, DOI 10.1016/0006-291X(89)91528-3; BROOKSWILSON AR, 1989, MOL CELL BIOL, V9, P2214, DOI 10.1128/MCB.9.5.2214; CARE A, 1994, ONCOGENE, V9, P739; DHUT S, 1991, ONCOGENE, V6, P1459; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; FERRARI S, 1985, BRIT J HAEMATOL, V59, P21, DOI 10.1111/j.1365-2141.1985.tb02959.x; FOSTER DA, 1983, J VIROL, V48, P744, DOI 10.1128/JVI.48.3.744-751.1983; GANZ T, 1985, J CLIN INVEST, V76, P1427, DOI 10.1172/JCI112120; GREER P, 1994, MOL CELL BIOL, V14, P6755, DOI 10.1128/MCB.14.10.6755; HANAZONO Y, 1993, BLOOD, V81, P3193; HANAZONO Y, 1993, EMBO J, V12, P1641, DOI 10.1002/j.1460-2075.1993.tb05809.x; HAO QL, 1991, MOL CELL BIOL, V11, P1180, DOI 10.1128/MCB.11.2.1180; HARPUR AG, 1992, ONCOGENE, V7, P1347; HAZAN B, 1993, CELL GROWTH DIFFER, V4, P443; KHAN KD, 1993, P NATL ACAD SCI USA, V90, P6806, DOI 10.1073/pnas.90.14.6806; KOTANIDES H, 1993, SCIENCE, V262, P1265, DOI 10.1126/science.7694370; LANFRANCONE L, 1989, INT J CANCER, P35; LARNER AC, 1993, SCIENCE, V261, P1730, DOI 10.1126/science.8378773; MORLA AO, 1988, MOL CELL BIOL, V8, P2214, DOI 10.1128/MCB.8.5.2214; PELLMAN D, 1985, NATURE, V314, P374, DOI 10.1038/314374a0; QUELLE FW, 1994, MOL CELL BIOL, V14, P4335, DOI 10.1128/MCB.14.7.4335; ROEBROEK AJM, 1985, EMBO J, V4, P2897, DOI 10.1002/j.1460-2075.1985.tb04020.x; SAWYERS CL, 1994, CELL, V77, P121, DOI 10.1016/0092-8674(94)90240-2; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; SILVENNOINEN O, 1993, SCIENCE, V261, P1736, DOI 10.1126/science.8378775; SLAMON DJ, 1984, SCIENCE, V224, P256, DOI 10.1126/science.6538699; SMITHGALL TE, 1988, J BIOL CHEM, V263, P15050; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; TOWLER DA, 1988, ANNU REV BIOCHEM, V57, P69, DOI 10.1146/annurev.bi.57.070188.000441; TSYGANKOV AY, 1993, STEM CELLS, V11, P371, DOI 10.1002/stem.5530110504; VANETTEN RA, 1989, CELL, V58, P669, DOI 10.1016/0092-8674(89)90102-5; Warren L, 1974, Methods Enzymol, V31, P156; WATLING D, 1993, NATURE, V366, P166, DOI 10.1038/366166a0; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; WONG GG, 1985, SCIENCE, V228, P810, DOI 10.1126/science.3923623; YOUNG JC, 1984, J VIROL, V52, P913, DOI 10.1128/JVI.52.3.913-918.1984	37	31	31	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 16	1995	10	6					1239	1242						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QN353	7700650				2022-12-17	WOS:A1995QN35300027
J	BERBERICH, S; COLE, M				BERBERICH, S; COLE, M			THE MDM-2 ONCOGENE IS TRANSLOCATED AND OVEREXPRESSED IN A MURINE PLASMACYTOMA CELL-LINE EXPRESSING WILD-TYPE P53	ONCOGENE			English	Note							C-MYC; BURKITT-LYMPHOMA; GENE; PROTEIN; MUTATION; REQUIRES; TUMORS; RAS	The cellular p53 protein has been demonstrated to possess growth-inhibitory activity. Recent work suggests that the murine double minute gene (mdm-2) encodes a protein that may function as a cellular regulator or mediator of p53 function. We were interested in determining if the mdm-2 gene was overexpressed in mouse tumor cells, in particular mouse plasmacytomas that harbor wild type-p53 protein. A novel chromosomal translocation of the mdm-2 gene was detected in the SP2 cell line, that is derived from plasmacytoma MOPC21. The translocation results in a head-to-head arrangement of the mdm-2 gene (chromosome 10) with the immunoglobulin CK gene (chromosome 6), analogous to the translocations that activate the c-mye gene in murine plasmacytomas. Based on Northern blot analysis, the translocation induces a 10-fold elevation of mdm-2 RNA. Primer extension assays demonstrate that the 5' end of the mdm-2 RNA from the translocated gene is colinear with the 5' mdm-2 mRNA from an unrearranged gene, suggesting that the mRNA and encoded protein are unaltered. This chromosomal translocation represents the first example in which mdm-2 overexpression is activated by a genetic alteration other than gene amplification.	WRIGHT STATE UNIV,KETTERING MED CTR,CLIN MOLEC GENET LAB,DAYTON,OH 45435; PRINCETON UNIV,DEPT MOLEC BIOL,PRINCETON,NJ 08544	Wright State University Dayton; Princeton University	BERBERICH, S (corresponding author), WRIGHT STATE UNIV,DEPT BIOCHEM & MOLEC BIOL,DAYTON,OH, USA.							BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BAUMBACH WR, 1987, MOL CELL BIOL, V7, P664, DOI 10.1128/MCB.7.2.664; BERBERICH S, 1992, ONCOGENE, V7, P775; BERBERICH SJ, 1992, GENE DEV, V6, P166, DOI 10.1101/gad.6.2.166; CAHILLYSNYDER L, 1987, SOMAT CELL MOLEC GEN, V13, P235, DOI 10.1007/BF01535205; COPPOLA JA, 1986, NATURE, V320, P760, DOI 10.1038/320760a0; COWAN NJ, 1974, J MOL BIOL, V90, P691, DOI 10.1016/0022-2836(74)90533-6; FAKHARZADEH SS, 1991, EMBO J, V10, P1565, DOI 10.1002/j.1460-2075.1991.tb07676.x; GAIDANO G, 1991, P NATL ACAD SCI USA, V88, P5413, DOI 10.1073/pnas.88.12.5413; GUTIERREZ MI, 1992, CANCER RES, V52, P1032; HINDS P, 1989, J VIROL, V63, P739, DOI 10.1128/JVI.63.2.739-746.1989; LADANYI M, 1993, CANCER RES, V53, P16; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LEACH FS, 1993, CANCER RES, V53, P2231; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LINIAL M, 1985, SCIENCE, V230, P1126, DOI 10.1126/science.2999973; LU X, 1992, CELL, V70, P153, DOI 10.1016/0092-8674(92)90541-J; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; PERLMUTTER RM, 1984, NATURE, V307, P473, DOI 10.1038/307473a0; WIMAN KG, 1991, ONCOGENE, V6, P1633; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126	22	31	31	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1994	9	5					1469	1472						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NH401	8152809				2022-12-17	WOS:A1994NH40100020
J	XIA, Y; HWANG, L; COBB, MH; BAER, R				XIA, Y; HWANG, L; COBB, MH; BAER, R			PRODUCTS OF THE TAL2 ONCOGENE IN LEUKEMIC T-CELLS - BHLH PHOSPHOPROTEINS WITH DNA-BINDING ACTIVITY	ONCOGENE			English	Article							ACUTE LYMPHOBLASTIC-LEUKEMIA; LOOP-HELIX PROTEIN; GLUTATHIONE-S-TRANSFERASE; CHROMOSOMAL TRANSLOCATION; ESCHERICHIA-COLI; ENHANCER-BINDING; GENE; MOTIF; PURIFICATION; MYOD	The TAL2 gene is activated as a result of the (7;9) (q34;q32) translocation, a chromosome defect found in the malignant cells of some patients with T-cell acute lymphoblastic leukemia (T-ALL). TAL2 potentially encodes a basic helix-loop-helix motif that is highly related to those specified by TAL1 and LYL1, distinct genes that have also been implicated in T-ALL. In this report we show that leukemic cells bearing the (7;9) (q34;q32) translocation express a TAL2 gene product of 108 amino acids. In leukemic cells this product exists in both a phosphorylated (pp13(TAL2)) and an unphosphorylated (p12(TAL2)) form. Serine residue 100 is the major site of TAL2 phosphorylation in vivo, and it serves as an effective in vitro substrate for mitogen-activated protein (MAP) kinases such as ERK1. TAL2 polypeptides interact in vivo with the E2A gene products (E47 and E12) to form bHLH heterodimers that bind DNA in a sequence-specific manner. The TAL2 polypeptides do not bind DNA by themselves, however, suggesting that their functional properties may be contingent upon association with other bHLH proteins. Taken together, the properties of TAL2 evaluated here broadly resemble those described previously for TAL1, and therefore support the idea that both proteins promote T-ALL by a common mechanism.	UNIV TEXAS,SOUTHWESTERN MED CTR,DEPT MICROBIOL,DALLAS,TX 75235; UNIV TEXAS,SOUTHWESTERN MED CTR,DEPT PHARMACOL,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas				Cobb, Melanie/0000-0003-0833-5473	NCI NIH HHS [CA44016] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA044016] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; APLAN PD, 1992, BLOOD, V79, P1327; BAER R, 1993, SEMIN CANCER BIOL, V4, P341; BASH RO, 1993, BLOOD, V81, P2110; BEGLEY CG, 1989, P NATL ACAD SCI USA, V86, P10128, DOI 10.1073/pnas.86.24.10128; BERNARD O, 1992, J EXP MED, V176, P919, DOI 10.1084/jem.176.4.919; BERNARD O, 1991, ONCOGENE, V6, P1477; BLACKWELL TK, 1990, SCIENCE, V250, P1104, DOI 10.1126/science.2174572; BOULTON TG, 1991, BIOCHEMISTRY-US, V30, P278, DOI 10.1021/bi00215a038; BOULTON TG, 1990, SCIENCE, V249, P64, DOI 10.1126/science.2164259; BRENNAN TJ, 1991, P NATL ACAD SCI USA, V88, P5675, DOI 10.1073/pnas.88.13.5675; BROWN L, 1990, EMBO J, V9, P3343, DOI 10.1002/j.1460-2075.1990.tb07535.x; CARROLL AJ, 1990, BLOOD, V76, P1220; CHAKRABORTY T, 1992, J BIOL CHEM, V267, P17498; CHEN Q, 1990, EMBO J, V9, P415, DOI 10.1002/j.1460-2075.1990.tb08126.x; CHEN Q, 1990, J EXP MED, V172, P1403, DOI 10.1084/jem.172.5.1403; CHENG JT, 1993, MOL CELL BIOL, V13, P801, DOI 10.1128/MCB.13.2.801; CHENG JT, 1993, ONCOGENE, V8, P677; COBB MH, 1991, CELL REGUL, V2, P965, DOI 10.1091/mbc.2.12.965; DANG CV, 1991, MOL CELL BIOL, V11, P954, DOI 10.1128/MCB.11.2.954; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DAVIS RL, 1990, CELL, V60, P733, DOI 10.1016/0092-8674(90)90088-V; FERREDAMARE AR, 1993, NATURE, V363, P38, DOI 10.1038/363038a0; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FINGER LR, 1989, P NATL ACAD SCI USA, V86, P5039, DOI 10.1073/pnas.86.13.5039; FINKEL T, 1993, J BIOL CHEM, V268, P5; FITZGERALD TJ, 1991, BLOOD, V78, P2686; GOLEMIS EA, 1992, MOL CELL BIOL, V12, P3006, DOI 10.1128/MCB.12.7.3006; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HSU HL, 1991, MOL CELL BIOL, V11, P3037, DOI 10.1128/MCB.11.6.3037; HSU HL, 1994, MOL CELL BIOL, V14, P1256, DOI 10.1128/MCB.14.2.1256; HSU HL, 1994, UNPUB; HSU HL, 1994, IN PRESS P NATL ACAD, V91; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; JEN Y, 1992, GENE DEV, V6, P1466, DOI 10.1101/gad.6.8.1466; JONSSON OG, 1991, J CLIN INVEST, V87, P2029, DOI 10.1172/JCI115232; KADESCH T, 1993, CELL GROWTH DIFFER, V4, P49; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; MELLENTIN JD, 1989, CELL, V58, P77, DOI 10.1016/0092-8674(89)90404-2; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; RABBITTS TH, 1991, CELL, V67, P641, DOI 10.1016/0092-8674(91)90057-6; REYNOLDS TC, 1987, CELL, V50, P107, DOI 10.1016/0092-8674(87)90667-2; SADOWSKI I, 1989, NUCLEIC ACIDS RES, V17, P7539, DOI 10.1093/nar/17.18.7539; SADOWSKI I, 1988, NATURE, V335, P559; SANGER F, 1980, J MOL BIOL, V143, P161, DOI 10.1016/0022-2836(80)90196-5; SHORT JM, 1988, NUCLEIC ACIDS RES, V16, P7583, DOI 10.1093/nar/16.15.7583; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SMITH SD, 1988, BLOOD, V71, P395; TYCKO B, 1989, J EXP MED, V169, P369, DOI 10.1084/jem.169.2.369; VORONOVA A, 1990, P NATL ACAD SCI USA, V87, P4722, DOI 10.1073/pnas.87.12.4722; WESTBROOK CA, 1987, P NATL ACAD SCI USA, V84, P251, DOI 10.1073/pnas.84.1.251; XIA Y, 1991, P NATL ACAD SCI USA, V88, P11416, DOI 10.1073/pnas.88.24.11416; XIA Y, 1992, GENE CHROMOSOME CANC, V4, P211, DOI 10.1002/gcc.2870040304	54	31	32	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1994	9	5					1437	1446						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NH401	8152805				2022-12-17	WOS:A1994NH40100016
J	CHAN, TA; CHU, CA; RAUEN, KA; KROIHER, M; TATAREWICZ, SM; STEELE, RE				CHAN, TA; CHU, CA; RAUEN, KA; KROIHER, M; TATAREWICZ, SM; STEELE, RE			IDENTIFICATION OF A GENE ENCODING A NOVEL PROTEIN-TYROSINE KINASE CONTAINING SH2 DOMAINS AND ANKYRIN-LIKE REPEATS	ONCOGENE			English	Note							POLYMERASE CHAIN-REACTION; BUDDING STRAIN L4; DROSOPHILA-MELANOGASTER; DEVELOPMENTAL MECHANISMS; SEQUENCE-ANALYSIS; NERVOUS-SYSTEM; LEUKEMIA-CELLS; DNA-SEQUENCE; SRC GENE; HYDRA	Using the polymerase chain reaction with primers corresponding to conserved regions in the kinase domain of protein-tyrosine kinases, we amplified segments of several protein-tyrosine kinase genes from Hydra vulgaris, a member of the ancient metazoan phylum Cnidaria. Characterization of cDNA clones for one of these genes, HTK16, revealed that it encodes a non-receptor protein-tyrosine kinase with two SH2 domains but no SH3 domain. In this regard the predicted HTK16 protein resembles two mammalian non-receptor protein-tyrosine kinases, the products of the ZAP-70 and syk genes. However, the HTK16 protein contains five ankyrin-like repeats, a structural motif which has not previously been found in protein-tyrosine kinases. The HTK16 protein also contains a potential tyrosine phosphorylation site in its carboxyl-terminal tail which resembles the phosphorylation site in members of the src family. RNA hybridization analysis indicates that the HTK16 gene is expressed in epithelial cells, cells which also express the Hydra homologue of the src protein. Our finding of the HTK16 gene in Hydra indicates that diversification of genes encoding non-receptor protein-tyrosine kinases was a very early event in metazoan evolution.	UNIV CALIF IRVINE, DEPT BIOL CHEM, IRVINE, CA 92717 USA; UNIV CALIF IRVINE, CTR DEV BIOL, IRVINE, CA 92717 USA	University of California System; University of California Irvine; University of California System; University of California Irvine			Chan, Timothy A/ABD-5850-2021		NATIONAL CENTER FOR RESEARCH RESOURCES [R01RR009755] Funding Source: NIH RePORTER; NCRR NIH HHS [R01 RR09755-01] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BLANK V, 1992, TRENDS BIOCHEM SCI, V17, P135, DOI 10.1016/0968-0004(92)90321-Y; Bode H.R., 1983, P291; BODE HR, 1978, PROG BIOPHYS MOL BIO, V33, P189; BOLEN JB, 1993, ONCOGENE, V8, P2025; BOSCH TCG, 1989, MOL CELL BIOL, V9, P4141, DOI 10.1128/MCB.9.10.4141; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; Cooper J.A, 1990, PEPT PROT PHOSPH, P85; COOPER JA, 1986, MOL CELL BIOL, V6, P4467, DOI 10.1128/MCB.6.12.4467; DAVID CN, 1973, ROUX ARCH DEV BIOL, V171, P259, DOI 10.1007/BF00577724; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FIRMBACHKRAFT I, 1990, ONCOGENE, V5, P1329; GODDARD JM, 1986, P NATL ACAD SCI USA, V83, P2172, DOI 10.1073/pnas.83.7.2172; GREGORY RJ, 1987, MOL CELL BIOL, V7, P2119, DOI 10.1128/MCB.7.6.2119; GRIMMELIKHUIJZEN CJP, 1982, HISTOCHEMISTRY, V73, P499, DOI 10.1007/BF00493364; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HENIKOFF S, 1987, METHOD ENZYMOL, V155, P156; HENKEMEYER MJ, 1988, MOL CELL BIOL, V8, P843, DOI 10.1128/MCB.8.2.843; HOLSTEIN TW, 1990, NATURE, V346, P21, DOI 10.1038/346021b0; HUANG CC, 1985, J MOL BIOL, V181, P175, DOI 10.1016/0022-2836(85)90083-X; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.bi.54.070185.004341; KAMB A, 1989, P NATL ACAD SCI USA, V86, P4372, DOI 10.1073/pnas.86.12.4372; KATZEN AL, 1991, MOL CELL BIOL, V11, P226, DOI 10.1128/MCB.11.1.226; KHANDJIAN EW, 1987, BIO-TECHNOL, V5, P165, DOI 10.1038/nbt0287-165; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LAI C, 1991, NEURON, V6, P691, DOI 10.1016/0896-6273(91)90167-X; LENHOFF H M, 1970, Laboratory Animals (London), V4, P139, DOI 10.1258/002367770781036463; LUX SE, 1990, NATURE, V344, P36, DOI 10.1038/344036a0; MACAULEY A, 1990, New Biologist, V2, P828; MANO H, 1990, ONCOGENE, V5, P1781; MARCK C, 1988, NUCLEIC ACIDS RES, V16, P1829, DOI 10.1093/nar/16.5.1829; MESMASSON AM, 1986, P NATL ACAD SCI USA, V83, P9768, DOI 10.1073/pnas.83.24.9768; MUSTELIN T, 1993, TRENDS BIOCHEM SCI, V18, P215, DOI 10.1016/0968-0004(93)90192-P; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; OTTILIE S, 1992, ONCOGENE, V7, P1625; PARTANEN J, 1990, P NATL ACAD SCI USA, V87, P8913, DOI 10.1073/pnas.87.22.8913; PAWSON T, 1989, MOL CELL BIOL, V9, P5722, DOI 10.1128/MCB.9.12.5722; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; RAMAKRISHNAN L, 1989, BIOCHIM BIOPHYS ACTA, V989, P209, DOI 10.1016/0304-419X(89)90043-7; ROEBROEK AJM, 1985, EMBO J, V4, P2897, DOI 10.1002/j.1460-2075.1985.tb04020.x; ROEHL H, 1993, NATURE, V364, P632, DOI 10.1038/364632a0; RUBIN DI, 1982, DEV BIOL, V89, P332, DOI 10.1016/0012-1606(82)90322-0; Sambrook J., 1989, MOL CLONING LAB MANU; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SHISHIDO E, 1991, FEBS LETT, V289, P235, DOI 10.1016/0014-5793(91)81078-M; SHORT JM, 1992, METHOD ENZYMOL, V216, P495; SHORT JM, 1988, NUCLEIC ACIDS RES, V16, P7583, DOI 10.1093/nar/16.15.7583; SHTIVELMAN E, 1986, CELL, V47, P277, DOI 10.1016/0092-8674(86)90450-2; TAKANO J, 1984, J EMBRYOL EXP MORPH, V80, P155; TAKANO J, 1983, J EMBRYOL EXP MORPH, V78, P141; TAKEYA T, 1983, CELL, V32, P881, DOI 10.1016/0092-8674(83)90073-9; TANIGUCHI T, 1991, J BIOL CHEM, V266, P15790; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; WEISS A, 1993, CELL, V73, P209, DOI 10.1016/0092-8674(93)90221-B; WILKS AF, 1989, P NATL ACAD SCI USA, V86, P1603, DOI 10.1073/pnas.86.5.1603; YAMADA N, 1993, BIOCHEM BIOPH RES CO, V192, P231, DOI 10.1006/bbrc.1993.1404; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303	60	31	34	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	1994	9	4					1253	1259						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NC048	8134129				2022-12-17	WOS:A1994NC04800031
J	SACHSE, R; MURAKAMI, Y; SHIRAISHI, M; HAYASHI, K; SEKIYA, T				SACHSE, R; MURAKAMI, Y; SHIRAISHI, M; HAYASHI, K; SEKIYA, T			DNA ABERRATIONS AT THE RETINOBLASTOMA GENE LOCUS IN HUMAN SQUAMOUS-CELL CARCINOMAS OF THE LUNG	ONCOGENE			English	Article							POLYMERASE CHAIN-REACTION; SUSCEPTIBILITY GENE; OSTEO-SARCOMA; SEQUENCE POLYMORPHISMS; PROTEIN EXPRESSION; POINT MUTATIONS; HUMAN GENOME; SHORT ARM; RB GENE; HETEROZYGOSITY	We detected DNA aberrations at the RB locus in surgical specimens of human primary non-small cell lung carcinoma by single-strand conformation polymorphism analysis of polymerase chain reaction products amplified from regions of exons 2 to 27 including parts of the flanking intron sequences. Detection of nucleotide sequence polymorphism revealed loss of heterozygosity in six of eight informative cases among 13 squamous cell carcinomas analysed. In two of the six cases, mutations in the remaining allele were detected. In 25 adenocarcinomas analysed, no loss of heterozygosity was observed in 16 informative cases and a point mutation was detected in one of the uniformative cases. In one of three adenosquamous carcinomas analysed, a point mutation was detected and one adenoid cystic carcinoma analysed showed allelic loss of the RB gene. Our results indicated that loss of heterozygosity at the RB locus is frequent in squamous cell carcinomas of the lung,:but not in adenocarcinomas. In the squamous cell carcinomas with allelic loss, mutations of the RB gene in the remaining alleles were found in one third of the tumors.	NATL CANC CTR,RES INST,DIV ONCOGENE,CHUO KU,TOKYO 104,JAPAN	National Cancer Center - Japan								BARKER D, 1982, CYTOGENET CELL GENET, V32, P253; BARKER D, 1984, CELL, V36, P131, DOI 10.1016/0092-8674(84)90081-3; BLIN N, 1976, NUCLEIC ACIDS RES, V3, P2303, DOI 10.1093/nar/3.9.2303; BORG A, 1992, CANCER RES, V52, P2991; BRAUCH H, 1987, NEW ENGL J MED, V317, P1109, DOI 10.1056/NEJM198710293171803; BROWN AG, 1993, NAT GENET, V3, P67, DOI 10.1038/ng0193-67; CAIRNS P, 1991, ONCOGENE, V6, P2305; COOPER DN, 1984, HUM GENET, V66, P1, DOI 10.1007/BF00275182; COOPER DN, 1985, HUM GENET, V69, P201, DOI 10.1007/BF00293024; FRIEND SH, 1987, P NATL ACAD SCI USA, V84, P9059, DOI 10.1073/pnas.84.24.9059; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; FUNG YKT, 1987, SCIENCE, V236, P1657, DOI 10.1126/science.2885916; HANSEN MF, 1985, P NATL ACAD SCI USA, V82, P6216, DOI 10.1073/pnas.82.18.6216; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; HAYASHI K, 1989, NUCLEIC ACIDS RES, V17, P3605, DOI 10.1093/nar/17.9.3605; HAYASHI K, 1992, GENET ANAL-BIOMOL E, V9, P73, DOI 10.1016/1050-3862(92)90001-L; HENSEL CH, 1990, CANCER RES, V50, P3067; HOROWITZ JM, 1989, SCIENCE, V243, P937, DOI 10.1126/science.2521957; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; ISHIKAWA J, 1991, CANCER RES, V51, P5736; KISHIMOTO Y, 1992, CANCER RES, V52, P4799; KISHIMOTO Y, 1992, HUM GENET, V88, P487, DOI 10.1007/BF00219333; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; LEE EYHP, 1988, SCIENCE, V241, P218, DOI 10.1126/science.3388033; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; MASHIYAMA S, 1991, TECHNIQUE, V2, P304; MCGEE TL, 1989, GENE, V80, P119, DOI 10.1016/0378-1119(89)90256-4; MORI N, 1990, ONCOGENE, V5, P1713; MORI N, 1989, CANCER RES, V49, P5130; MURAKAMI Y, 1991, CANCER RES, V51, P5520; NAYLOR SL, 1987, NATURE, V329, P451, DOI 10.1038/329451a0; Nei M., 1987, MOL EVOLUTIONARY GEN; ORITA M, 1990, GENOMICS, V8, P271, DOI 10.1016/0888-7543(90)90282-Y; ORITA M, 1989, P NATL ACAD SCI USA, V86, P2766, DOI 10.1073/pnas.86.8.2766; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; REISSMANN PT, 1993, ONCOGENE, V8, P1913; REISSMANN PT, 1989, ONCOGENE, V4, P839; SACHSE R, 1992, JPN J CANCER RES, V83, P1299, DOI 10.1111/j.1349-7006.1992.tb02762.x; SHIRAISHI M, 1989, CANCER RES, V49, P6474; SUZUKI Y, 1991, ANAL BIOCHEM, V192, P82, DOI 10.1016/0003-2697(91)90188-Y; SUZUKI Y, 1990, ONCOGENE, V5, P1037; TANG A, 1988, SCIENCE, V242, P263, DOI 10.1126/science.3175651; TOGUCHIDA J, 1988, CANCER RES, V48, P3939; TSUCHIYA E, 1992, CANCER RES, V52, P2478; VARLEY JM, 1989, ONCOGENE, V4, P725; WESTON A, 1989, P NATL ACAD SCI USA, V86, P5099, DOI 10.1073/pnas.86.13.5099; XU HJ, 1991, CANCER RES, V51, P2735; YANDELL DW, 1989, AM J HUM GENET, V45, P547; YANDELL DW, 1989, NEW ENGL J MED, V321, P1689, DOI 10.1056/NEJM198912213212501; YOKOTA J, 1987, P NATL ACAD SCI USA, V84, P9252, DOI 10.1073/pnas.84.24.9252; YOKOTA J, 1988, ONCOGENE, V3, P471; YOKOYAMA S, 1992, CANCER RES, V52, P873	52	31	34	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1994	9	1					39	47						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW247	8302602				2022-12-17	WOS:A1994MW24700006
J	SCHUERMANN, M; HENNIG, G; MULLER, R				SCHUERMANN, M; HENNIG, G; MULLER, R			TRANSCRIPTIONAL ACTIVATION AND TRANSFORMATION BY CHIMERIC FOS-ESTROGEN RECEPTOR PROTEINS - ALTERED PROPERTIES AS A CONSEQUENCE OF GENE FUSION	ONCOGENE			English	Article							C-FOS; V-FOS; CELLULAR-TRANSFORMATION; GLUCOCORTICOID RECEPTOR; NEGATIVE REGULATOR; BINDING DOMAINS; AUTO-REGULATION; PROTO-ONCOGENE; JUN; TRANSACTIVATION	We have generated a series of conditionally active Fos and FosB proteins by fusion with a C-terminal fragment of the human estrogen receptor (ER) which harbours the ligand binding site and the overlapping hormone-inducible transactivation domain TAF-2. The chimaeric Fos-ER proteins showed estrogen-inducible activation of TRE (TPA-responsive element)-directed trapscription and hormone-dependent transformation of fibroblasts. These properties of the fusion proteins were independent of the transregulatory and transforming properties of their normal non-fused counterparts c-Fos, v-Fos, FosB-L and FosB-S. Thus c-Fos-ER and FosB-S-ER were strong transforming proteins in the presence of hormone, although c-Fos and FosB-S possess only marginal oncogenic properties. In addition, all fusion proteins showed increased transactivation in the presence of estrogen, again most noticeable in the case of c-Fos-ER and FosB-S-ER. The ER-fusion thus basically eliminated the differences in the transactivating potential seen among the various native Fos proteins. Our data therefore provide evidence: (i) that the hormone binding domain of the human estrogen receptor, apart from delivering hormonal control to a heterologous protein, can have profound effects on the activity of certain transcription factors, particularly on proteins with weak oncogenic and/or transregulatory potential, and (ii) that the transforming potential of c-Fos and FosB-S can be dramatically elevated by increasing their transactivating properties.	PHILIPPS UNIV MARBURG,INST MOLEK BIOL & TUMORFORSCH,EMIL MANNKOPFF STR 2,D-35037 MARBURG,GERMANY	Philipps University Marburg			Müller, Rolf/L-4997-2016	Müller, Rolf/0000-0003-3339-4248				ADAMKIEWICZ J, 1990, ONCOGENE, V5, P525; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; Ausubel F., 1992, MOL REPROD DEV, DOI DOI 10.1002/MRD.1080010210; BARBER JR, 1987, MOL CELL BIOL, V7, P2201, DOI 10.1128/MCB.7.6.2201; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BURK O, 1991, EMBO J, V10, P3713, DOI 10.1002/j.1460-2075.1991.tb04939.x; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; DOBRZANSKI P, 1991, MOL CELL BIOL, V11, P5470, DOI 10.1128/MCB.11.11.5470; EILERS M, 1989, NATURE, V340, P66, DOI 10.1038/340066a0; GIUS D, 1990, MOL CELL BIOL, V10, P4243, DOI 10.1128/MCB.10.8.4243; HAVARSTEIN LS, 1992, P NATL ACAD SCI USA, V89, P618, DOI 10.1073/pnas.89.2.618; JENUWEIN T, 1987, CELL, V48, P647, DOI 10.1016/0092-8674(87)90243-1; JOOSS K, 1992, ONCOGENE, V7, P1933; KONIG H, 1989, EMBO J, V8, P2559, DOI 10.1002/j.1460-2075.1989.tb08394.x; KUMAR V, 1986, EMBO J, V5, P2231, DOI 10.1002/j.1460-2075.1986.tb04489.x; KUMAR V, 1988, CELL, V55, P145, DOI 10.1016/0092-8674(88)90017-7; LUCIBELLO F, 1989, CELL, V59, P9989; LUCIBELLO F C, 1991, Critical Reviews in Oncogenesis, V2, P259; LUCIBELLO FC, 1990, EMBO J, V9, P2827, DOI 10.1002/j.1460-2075.1990.tb07471.x; LUCIBELLO FC, 1991, NEW BIOL, V3, P671; MILLER AD, 1984, CELL, V36, P51; MUMBERG D, 1991, GENE DEV, V5, P1212, DOI 10.1101/gad.5.7.1212; NAKABEPPU Y, 1991, CELL, V64, P751, DOI 10.1016/0092-8674(91)90504-R; NEUBERG M, 1991, ONCOGENE, V6, P1325; NISHINA H, 1990, P NATL ACAD SCI USA, V87, P3619, DOI 10.1073/pnas.87.9.3619; OLIVIERO S, 1992, GENE DEV, V6, P1799, DOI 10.1101/gad.6.9.1799; PICARD D, 1988, CELL, V54, P1073, DOI 10.1016/0092-8674(88)90122-5; SASSONECORSI P, 1988, NATURE, V334, P314, DOI 10.1038/334314a0; SCHUERMANN M, 1989, CELL, V56, P507, DOI 10.1016/0092-8674(89)90253-5; SCHUERMANN M, 1991, ONCOGENE, V6, P567; SETOYAMA C, 1986, P NATL ACAD SCI USA, V83, P3213, DOI 10.1073/pnas.83.10.3213; SUPERTIFURGA G, 1991, P NATL ACAD SCI USA, V88, P5114, DOI 10.1073/pnas.88.12.5114; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; TORA L, 1989, EMBO J, V8, P1981, DOI 10.1002/j.1460-2075.1989.tb03604.x; TORA L, 1989, CELL, V59, P447; TRATNER I, 1992, MOL CELL BIOL, V12, P998, DOI 10.1128/MCB.12.3.998; UMEK RM, 1991, SCIENCE, V251, P288, DOI 10.1126/science.1987644; VERRIER B, 1986, EMBO J, V5, P913, DOI 10.1002/j.1460-2075.1986.tb04303.x; WEBSTER NJG, 1988, CELL, V54, P199, DOI 10.1016/0092-8674(88)90552-1; WISDOM R, 1992, GENE DEV, V6, P667, DOI 10.1101/gad.6.4.667; YEN J, 1991, P NATL ACAD SCI USA, V88, P5077, DOI 10.1073/pnas.88.12.5077; ZERIAL M, 1989, EMBO J, V8, P805, DOI 10.1002/j.1460-2075.1989.tb03441.x	43	31	31	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1993	8	10					2781	2790						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LX343	8378087				2022-12-17	WOS:A1993LX34300020
J	FLEISCHMAN, LF; PILARO, AM; MURAKAMI, K; KONDOH, A; FISHER, RJ; PAPAS, TS				FLEISCHMAN, LF; PILARO, AM; MURAKAMI, K; KONDOH, A; FISHER, RJ; PAPAS, TS			C-ETS-1-PROTEIN IS HYPERPHOSPHORYLATED DURING MITOSIS	ONCOGENE			English	Article							LONG TERMINAL REPEAT; NUCLEAR-ENVELOPE BREAKDOWN; LEUKEMIA-VIRUS HTLV-1; PROTEIN KINASE-II; V-ETS ONCOGENE; DIFFERENTIAL PHOSPHORYLATION; TRANSCRIPTIONAL ACTIVATORS; C-ETS-1 PROTOONCOGENE; MAMMALIAN-CELLS; DNA-BINDING	The ets-1 and ets-2 proto-oncogene products can serve as transcription factors and become phosphorylated in response to Ca2+-mediated signals. We have examined expression of Ets proteins during the cell cycle in cells svnchronized by centrifugal elutriation or nocodazole-induced mitotic block. Both methods revealed the presence of a hyperphosphorylated isoform of Ets-1 during the mitotic phase. This isoform showed a characteristic mobility shift and was observed during mitosis in each of four cell lines (three human T-cell lines and a human astrocytoma) that express ets-1. In elutriated cells, only a small portion of the Ets-1 in cells from the G2/M fractions was hyperphosphorylated, while in nocodazole-arrested cells more of the Ets-1 was shifted. When cells were released from nocodazole arrest, this isoform disappeared within 1-2h as cells completed mitosis and entered G1. This suggests that hyperphosphorylated Ets-1 is present transiently during early mitosis, before or around the time of the metaphase-anaphase transition. Exposure of unsynchronized cells to okadaic acid resulted in a dramatic hyperphosphorylation of virtually all Ets-1, suggesting that changes in cellular phosphatase activity are important for cell cycle regulation of Ets-1. Hyperphosphorylated Ets-1 appears to arise from multiple phosphorylations on serine in the exon 7-encoded domain of the protein and did not appear to alter sequence-specific DNA-binding activity. Although enhanced phosphorylation of Ets-2 was detected in nocodazole-arrested cells, no Ets-2 hyperphosphorylation was seen.	NCI,EXPTL IMMUNOL LAB,FREDERICK,MD 21702; DYNCORP,PROGRAM RESOURCES INC,FREDERICK CANC RES & DEV CTR,FREDERICK,MD 21702	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	FLEISCHMAN, LF (corresponding author), NCI,MOLEC ONCOL LAB,FREDERICK,MD 21702, USA.		Fisher, Robert/B-1431-2009					AMOUYEL P, 1988, BRAIN RES, V447, P149, DOI 10.1016/0006-8993(88)90976-6; BAITINGER C, 1990, J CELL BIOL, V111, P1763, DOI 10.1083/jcb.111.5.1763; BENDAVID Y, 1991, GENE DEV, V5, P908, DOI 10.1101/gad.5.6.908; BHAT NK, 1990, P NATL ACAD SCI USA, V87, P3723, DOI 10.1073/pnas.87.10.3723; BHAT NK, 1989, J IMMUNOL, V142, P672; BHAT NK, 1987, P NATL ACAD SCI USA, V84, P3163; BOSSELUT R, 1990, EMBO J, V9, P3137, DOI 10.1002/j.1460-2075.1990.tb07511.x; BOULUKOS KE, 1989, MOL CELL BIOL, V9, P5718, DOI 10.1128/MCB.9.12.5718; BOULUKOS KE, 1990, GENE DEV, V4, P401, DOI 10.1101/gad.4.3.401; BRAUTIGAN DL, 1990, NATURE, V344, P74, DOI 10.1038/344074a0; BURTIS KC, 1990, CELL, V61, P85, DOI 10.1016/0092-8674(90)90217-3; CHEN JH, 1985, MOL CELL BIOL, V5, P2993, DOI 10.1128/MCB.5.11.2993; CHEN ZQ, 1990, SCIENCE, V250, P1416, DOI 10.1126/science.2255913; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; CYERT MS, 1989, CELL, V57, P891, DOI 10.1016/0092-8674(89)90325-5; FISHER RJ, 1991, ONCOGENE, V6, P2249; FISHER RJ, 1992, J BIOL CHEM, V267, P17957; FUJIWARA S, 1988, ONCOGENE, V2, P99; FUJIWARA S, 1990, MOL CELL BIOL, V10, P1249, DOI 10.1128/MCB.10.3.1249; FUJIWARA S, 1988, MOL CELL BIOL, V8, P4700, DOI 10.1128/MCB.8.11.4700; GHYSDAEL J, 1986, P NATL ACAD SCI USA, V83, P1714, DOI 10.1073/pnas.83.6.1714; GOLAY J, 1988, CELL, V55, P1147, DOI 10.1016/0092-8674(88)90259-0; GUNTHER CV, 1990, GENE DEV, V4, P667, DOI 10.1101/gad.4.4.667; HO IC, 1990, SCIENCE, V250, P814, DOI 10.1126/science.2237431; KAO JPY, 1990, J CELL BIOL, V111, P183, DOI 10.1083/jcb.111.1.183; KIPREOS ET, 1990, SCIENCE, V248, P217, DOI 10.1126/science.2183353; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; KOIZUMI S, 1990, ONCOGENE, V5, P675; LINDWALL G, 1984, J BIOL CHEM, V259, P5301; MARTIN ME, 1988, P NATL ACAD SCI USA, V85, P5839, DOI 10.1073/pnas.85.16.5839; OHTA Y, 1990, P NATL ACAD SCI USA, V87, P5341, DOI 10.1073/pnas.87.14.5341; PETER M, 1990, CELL, V61, P591, DOI 10.1016/0092-8674(90)90471-P; POGNONEC P, 1988, EMBO J, V7, P977, DOI 10.1002/j.1460-2075.1988.tb02904.x; PRESCOTT DM, 1962, EXP CELL RES, V26, P260, DOI 10.1016/0014-4827(62)90176-3; RAO VN, 1987, SCIENCE, V237, P635, DOI 10.1126/science.3299708; RAO VN, 1989, SCIENCE, V244, P66, DOI 10.1126/science.2539641; SACCHI N, 1988, LEUKEMIA, V2, P12; SCHWORER CM, 1986, J BIOL CHEM, V261, P8581; SETH A, 1989, P NATL ACAD SCI USA, V86, P7833, DOI 10.1073/pnas.86.20.7833; SHENOY S, 1989, CELL, V57, P763, DOI 10.1016/0092-8674(89)90791-5; STEINER B, 1990, EMBO J, V9, P3539, DOI 10.1002/j.1460-2075.1990.tb07563.x; STEINHARDT RA, 1988, NATURE, V332, P364, DOI 10.1038/332364a0; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WASYLYK C, 1989, EMBO J, V8, P3371, DOI 10.1002/j.1460-2075.1989.tb08500.x; WATSON D K, 1990, Critical Reviews in Oncogenesis, V1, P409; WATSON DK, 1985, P NATL ACAD SCI USA, V82, P7294, DOI 10.1073/pnas.82.21.7294; YAMASHITA K, 1990, EMBO J, V9, P4331, DOI 10.1002/j.1460-2075.1990.tb07882.x; YUAN CC, 1989, J VIROL, V63, P205, DOI 10.1128/JVI.63.1.205-215.1989; ZIEVE GW, 1980, EXP CELL RES, V126, P397, DOI 10.1016/0014-4827(80)90279-7	49	31	32	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1993	8	3					771	780						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN008	8437861				2022-12-17	WOS:A1993KN00800030
J	KASTELEIN, RA; SHANAFELT, AB				KASTELEIN, RA; SHANAFELT, AB			GM-CSF RECEPTOR - INTERACTIONS AND ACTIVATION	ONCOGENE			English	Review							COLONY-STIMULATING FACTOR; EXPRESSION CLONING; GROWTH-HORMONE; GENE FAMILY; GRANULOCYTE; INTERLEUKIN-3; BINDING; SUBUNIT; RECONSTITUTION; MOLECULE				KASTELEIN, RA (corresponding author), DNAX RES INST MOLEC & CELLULAR BIOL INC, MOLEC & CELLULAR BIOL RES INST, DEPT MOLEC BIOL, PALO ALTO, CA 94304 USA.							ABDELMEGUID SS, 1987, P NATL ACAD SCI USA, V84, P6434, DOI 10.1073/pnas.84.18.6434; BAZAN JF, 1990, IMMUNOL TODAY, V11, P350, DOI 10.1016/0167-5699(90)90139-Z; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; CUNNINGHAM BC, 1991, SCIENCE, V254, P821, DOI 10.1126/science.1948064; DAVIS S, 1991, SCIENCE, V253, P59, DOI 10.1126/science.1648265; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; DIEDERICHS K, 1991, SCIENCE, V254, P1779, DOI 10.1126/science.1837174; ELLIOTT MJ, 1989, BLOOD, V74, P2349; GEARING DP, 1992, SCIENCE, V255, P1434, DOI 10.1126/science.1542794; GEARING DP, 1989, EMBO J, V8, P3667, DOI 10.1002/j.1460-2075.1989.tb08541.x; GORMAN DM, 1990, P NATL ACAD SCI USA, V87, P5459, DOI 10.1073/pnas.87.14.5459; HARA T, 1992, EMBO J, V11, P1875, DOI 10.1002/j.1460-2075.1992.tb05239.x; HAYASHIDA K, 1990, P NATL ACAD SCI USA, V87, P9655, DOI 10.1073/pnas.87.24.9655; Heyworth CM, 1990, GROWTH FACTORS, V2, P197, DOI 10.3109/08977199009071506; IMLER JL, 1992, EMBO J, V11, P2047, DOI 10.1002/j.1460-2075.1992.tb05262.x; ITOH N, 1990, SCIENCE, V247, P324, DOI 10.1126/science.2404337; KAUSHANSKY K, 1989, P NATL ACAD SCI USA, V86, P1213, DOI 10.1073/pnas.86.4.1213; KITAMURA T, 1991, CELL, V66, P1165, DOI 10.1016/0092-8674(91)90039-2; KITAMURA T, 1991, P NATL ACAD SCI USA, V88, P5082, DOI 10.1073/pnas.88.12.5082; LONGMORE GD, 1991, CELL, V67, P1089, DOI 10.1016/0092-8674(91)90286-8; LOPEZ AF, 1992, EMBO J, V11, P909, DOI 10.1002/j.1460-2075.1992.tb05129.x; MEROPOL NJ, 1992, J BIOL CHEM, V267, P14266; METCALF D, 1986, BLOOD, V67, P257; MURAKAMI M, 1991, P NATL ACAD SCI USA, V88, P11349, DOI 10.1073/pnas.88.24.11349; PARK LS, 1992, P NATL ACAD SCI USA, V89, P4295, DOI 10.1073/pnas.89.10.4295; Parry D A, 1991, J Mol Recognit, V4, P63, DOI 10.1002/jmr.300040205; SCHEFFLER JE, 1991, IN PRESS BIOCHEMISTR; SHANAFELT AB, 1991, EMBO J, V10, P4105, DOI 10.1002/j.1460-2075.1991.tb04987.x; SHANAFELT AB, 1992, IN PRESS J BIOL CHEM; SMITH LJ, 1992, J MOL BIOL, V224, P899, DOI 10.1016/0022-2836(92)90457-U; TAVERNIER J, 1991, CELL, V66, P1175, DOI 10.1016/0092-8674(91)90040-6; WANG HM, 1992, J BIOL CHEM, V267, P979; YOSHIMURA A, 1990, NATURE, V348, P647, DOI 10.1038/348647a0; ZURAWSKI SM, 1989, EMBO J, V8, P2583, DOI 10.1002/j.1460-2075.1989.tb08397.x	34	31	33	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	1993	8	2					231	236						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN006	8426734				2022-12-17	WOS:A1993KN00600001
J	MARCELLE, C; EICHMANN, A				MARCELLE, C; EICHMANN, A			MOLECULAR-CLONING OF A FAMILY OF PROTEIN-KINASE GENES EXPRESSED IN THE AVIAN EMBRYO	ONCOGENE			English	Article							GROWTH-FACTOR RECEPTOR; POLYMERASE CHAIN-REACTION; TYROSINE KINASE; C-KIT; W-LOCUS; DEVELOPMENTAL EXPRESSION; PHOSPHOTYROSINE ANTIBODY; SIGNAL TRANSDUCTION; MOUSE DEVELOPMENT; EYE DEVELOPMENT	We have used the polymerase chain reaction (PCR) technique to clone kinase-related sequences from avian blastula, neural crest and neural tube mRNA. Twenty-three distinct protein kinase (PK) sequences were amplified, of which eight are identical to previously described PK genes. The cloned molecules fall into three classes: growth factor receptor tyrosine kinases (RTKs), cytosolic tyrosine kinases and serine/threonine kinases. Among the cloned RTKs were the insulin-like growth factor type I receptor, platelet-derived growth factor receptor alpha, the CEK1 fibroblast growth factor (FGF) receptor as well as the avian homolog of a recently cloned PCR fragment related to the eph/elk/eck family, tyro-5. Furthermore, we cloned a novel FGF receptor-like molecule as well as two novel putative RTKs related to the vascular endothelial growth factor (VEGF) receptor. The pattern of expression of the PCR clones was examined by Northern blot analysis of adult tissues: each molecule recognized one or more transcripts of various sizes, suggesting that PK genes may play regulatory roles both in early development and in adult regulation of tissue function. Together with recent studies, this survey confirms the hypothesis that PKs may play important roles in early vertebrate development.			MARCELLE, C (corresponding author), INST EMBRYOL, CNRS, 49BIS, AVE BELLE GABRIELLE, F-94736 NOGENT SUR MARNE, FRANCE.							ADAMSON ED, 1987, DEVELOPMENT, V99, P449; BAKER NE, 1989, NATURE, V340, P150, DOI 10.1038/340150a0; BASLER K, 1988, TRENDS GENET, V4, P74, DOI 10.1016/0168-9525(88)90044-3; BELYAVSKY A, 1989, NUCLEIC ACIDS RES, V17, P2919, DOI 10.1093/nar/17.8.2919; BERNARDS A, 1991, ONCOGENE, V6, P1185; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHABOT B, 1988, NATURE, V335, P88, DOI 10.1038/335088a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; CHOU YH, 1991, P NATL ACAD SCI USA, V88, P4897, DOI 10.1073/pnas.88.11.4897; DESSEN P, 1990, CABIOS, V6, P335; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; DIONNE CA, 1990, EMBO J, V9, P2685, DOI 10.1002/j.1460-2075.1990.tb07454.x; ERLICH H, 1989, PCR TECHNOLOGY PRINC, P3; FIRMBACHKRAFT I, 1990, ONCOGENE, V5, P1329; GEISSLER EN, 1988, CELL, V55, P185, DOI 10.1016/0092-8674(88)90020-7; GREGORY RJ, 1987, MOL CELL BIOL, V7, P2119, DOI 10.1128/MCB.7.6.2119; HAFEN E, 1987, SCIENCE, V236, P55, DOI 10.1126/science.2882603; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HANKS SK, 1987, P NATL ACAD SCI USA, V84, P388, DOI 10.1073/pnas.84.2.388; HAO QL, 1989, MOL CELL BIOL, V9, P1587, DOI 10.1128/MCB.9.4.1587; HIRAI H, 1987, SCIENCE, V238, P1717, DOI 10.1126/science.2825356; HOLTZMAN DA, 1987, P NATL ACAD SCI USA, V84, P8325, DOI 10.1073/pnas.84.23.8325; HOUSSAINT E, 1990, P NATL ACAD SCI USA, V87, P8180, DOI 10.1073/pnas.87.20.8180; IRIE K, 1991, CELL, V65, P785, DOI 10.1016/0092-8674(91)90386-D; JOHNSON DE, 1990, MOL CELL BIOL, V10, P4728, DOI 10.1128/MCB.10.9.4728; KATAMINE S, 1988, MOL CELL BIOL, V8, P259, DOI 10.1128/MCB.8.1.259; KEEGAN K, 1991, P NATL ACAD SCI USA, V88, P1095, DOI 10.1073/pnas.88.4.1095; KIMELMAN D, 1987, CELL, V51, P869, DOI 10.1016/0092-8674(87)90110-3; KLEIN R, 1990, DEVELOPMENT, V109, P845; KORNBLUTH S, 1988, MOL CELL BIOL, V8, P5541, DOI 10.1128/MCB.8.12.5541; KROLEWSKI JJ, 1990, ONCOGENE, V5, P277; KRUH GD, 1986, SCIENCE, V234, P1545, DOI 10.1126/science.3787260; LAI C, 1991, NEURON, V6, P691, DOI 10.1016/0896-6273(91)90167-X; LEE PL, 1989, SCIENCE, V245, P57, DOI 10.1126/science.2544996; LEHNER CF, 1990, EMBO J, V9, P3573, DOI 10.1002/j.1460-2075.1990.tb07568.x; LETWIN K, 1988, ONCOGENE, V3, P621; LINDBERG RA, 1990, MOL CELL BIOL, V10, P6316, DOI 10.1128/MCB.10.12.6316; LORINCZ AT, 1984, NATURE, V307, P183, DOI 10.1038/307183a0; MAHLER PA, 1988, J BIOL CHEM, V106, P1747; Maniatis T, 1989, MOL CLONING; MANSUKHANI A, 1990, P NATL ACAD SCI USA, V87, P4378, DOI 10.1073/pnas.87.11.4378; MARTINZANCA D, 1990, GENE DEV, V4, P683, DOI 10.1101/gad.4.5.683; MATHEWS LS, 1991, CELL, V65, P973, DOI 10.1016/0092-8674(91)90549-E; MATSUI T, 1989, SCIENCE, V243, P800, DOI 10.1126/science.2536956; MITRANI E, 1990, CELL, V63, P495, DOI 10.1016/0092-8674(90)90446-L; MULLER R, 1984, CURR TOP MICROBIOL, V112, P73; ORRURTREGER A, 1990, DEVELOPMENT, V109, P911; PARTANEN J, 1990, P NATL ACAD SCI USA, V87, P8913, DOI 10.1073/pnas.87.22.8913; PARTANEN J, 1991, EMBO J, V10, P1347, DOI 10.1002/j.1460-2075.1991.tb07654.x; PASQUALE EB, 1990, P NATL ACAD SCI USA, V87, P5812, DOI 10.1073/pnas.87.15.5812; PASQUALE EB, 1989, P NATL ACAD SCI USA, V86, P5449, DOI 10.1073/pnas.86.14.5449; PAWSON T, 1990, TRENDS GENET, V6, P350, DOI 10.1016/0168-9525(90)90276-C; RAZ V, 1991, ONCOGENE, V6, P753; REID HH, 1990, P NATL ACAD SCI USA, V87, P1596, DOI 10.1073/pnas.87.4.1596; REITH AD, 1990, GENE DEV, V4, P390, DOI 10.1101/gad.4.3.390; ROEBROEK AJM, 1985, EMBO J, V4, P2897, DOI 10.1002/j.1460-2075.1985.tb04020.x; RUBIN GM, 1989, CELL, V57, P519, DOI 10.1016/0092-8674(89)90120-7; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SCHEJTER ED, 1989, CELL, V56, P1093, DOI 10.1016/0092-8674(89)90642-9; SCHWARTZBERG PL, 1991, CELL, V65, P1165, DOI 10.1016/0092-8674(91)90012-N; SHIBUYA M, 1990, ONCOGENE, V5, P519; SHTIVELMAN E, 1986, CELL, V47, P277, DOI 10.1016/0092-8674(86)90450-2; SMITH EA, 1991, P NATL ACAD SCI USA, V88, P4811, DOI 10.1073/pnas.88.11.4811; SMITH JC, 1990, NATURE, V345, P729, DOI 10.1038/345729a0; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; SPRENGER F, 1989, NATURE, V338, P478, DOI 10.1038/338478a0; STEPHENSON DA, 1991, P NATL ACAD SCI USA, V88, P6, DOI 10.1073/pnas.88.1.6; SUDOL M, 1988, NUCLEIC ACIDS RES, V16, P9876, DOI 10.1093/nar/16.20.9876; TAKEYA T, 1983, CELL, V32, P881, DOI 10.1016/0092-8674(83)90073-9; TERMAN BI, 1991, ONCOGENE, V6, P1677; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; WILKS AF, 1989, GENE, V85, P67, DOI 10.1016/0378-1119(89)90465-4; WILKS AF, 1991, MOL CELL BIOL, V11, P2057, DOI 10.1128/MCB.11.4.2057; WILKS AF, 1989, P NATL ACAD SCI USA, V86, P1603, DOI 10.1073/pnas.86.5.1603	78	31	37	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	1992	7	12					2479	2487						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KA856	1281306				2022-12-17	WOS:A1992KA85600013
J	WONG, WY; HAVARSTEIN, LS; MORGAN, IM; VOGT, PK				WONG, WY; HAVARSTEIN, LS; MORGAN, IM; VOGT, PK			C-JUN CAUSES FOCUS FORMATION AND ANCHORAGE-INDEPENDENT GROWTH IN CULTURE BUT IS NONTUMORIGENIC	ONCOGENE			English	Note							CHICKEN-EMBRYO FIBROBLASTS; DNA-BINDING ACTIVITY; ONCOGENE JUN; AP-1; FOS; TRANSFORMATION; ENCODES; PROTEIN; MEMBER; FAMILY	The RCAS retroviral vector was used to express chicken and mouse cellular Jun proteins in chicken embryo fibroblasts. Both mouse and chicken proteins induced foci of transformed cells with low to moderate efficiency compared with viral Jun, but were as effective as the viral protein in promoting anchorage-independent growth. Viral Jun and a recombinant between viral and cellular Jun induced tumors in 1-day-old chicks; the cellular Jun proteins were uniformly non-tumorigenic.	NORRIS CANC CTR,LOS ANGELES,CA 90033; UNIV SO CALIF,SCH MED,DEPT MICROBIOL,LOS ANGELES,CA 90033; UNIV SO CALIF,LOS ANGELES CTY MED CTR,DEPT PEDIAT,1129 N STATE ST,LOS ANGELES,CA 90033	University of Southern California; University of Southern California			Vogt, Peter K./R-7547-2019	Vogt, Peter K./0000-0002-4519-7500; Havarstein, Leiv Sigve/0000-0001-8250-4322	NCI NIH HHS [CA 42564] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA042564] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; BALL AR, 1988, COLD SPRING HARB SYM, V53, P687, DOI 10.1101/SQB.1988.053.01.078; BERGER I, 1991, ONCOGENE, V6, P561; BISTER K, 1977, VIROLOGY, V82, P431, DOI 10.1016/0042-6822(77)90017-4; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BOS TJ, 1990, GENE DEV, V4, P1677, DOI 10.1101/gad.4.10.1677; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; CASTELLAZZI M, 1990, ONCOGENE, V5, P1285; CAVALIERI F, 1985, VIROLOGY, V143, P680, DOI 10.1016/0042-6822(85)90412-X; CHENG YC, 1987, J BIOL CHEM, V262, P2187; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; KAWAI S, 1984, MOL CELL BIOL, V4, P1172, DOI 10.1128/MCB.4.6.1172; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; NISHIMURA T, 1988, ONCOGENE, V3, P659; RANSONE LJ, 1990, P NATL ACAD SCI USA, V87, P3806, DOI 10.1073/pnas.87.10.3806; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; SUZUKI T, 1991, JPN J CANCER RES, V82, P58, DOI 10.1111/j.1349-7006.1991.tb01746.x; Vogt P K, 1990, Adv Cancer Res, V55, P1, DOI 10.1016/S0065-230X(08)60466-2	22	31	31	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1992	7	10					2077	2080						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JP424	1408150				2022-12-17	WOS:A1992JP42400025
J	LANDESMAN, Y; PAGANO, M; DRAETTA, G; ROTTER, V; FUSENIG, NE; KIMCHI, A				LANDESMAN, Y; PAGANO, M; DRAETTA, G; ROTTER, V; FUSENIG, NE; KIMCHI, A			MODIFICATIONS OF CELL-CYCLE CONTROLLING NUCLEAR PROTEINS BY TRANSFORMING GROWTH-FACTOR-BETA IN THE HACAT KERATINOCYTE CELL-LINE	ONCOGENE			English	Note							RETINOBLASTOMA GENE-PRODUCT; TRANSCRIPTION FACTOR; INHIBITION; PROLIFERATION; EXPRESSION; SUPPRESSION; KINASE		WEIZMANN INST SCI,DEPT MOLEC GENET & VIROL,IL-76100 REHOVOT,ISRAEL; GERMAN CANC RES CTR,EUROPEAN MOLEC BIOL LAB,DIFFERENTIAT PROGRAM,W-6900 HEIDELBERG,GERMANY; GERMAN CANC RES CTR,INST BIOCHEM,DIV DIFFERENTIAT & CARCINOGENESIS INVITRO,W-6900 HEIDELBERG,GERMANY; WEIZMANN INST SCI,DEPT CELL BIOL,IL-76100 REHOVOT,ISRAEL	Weizmann Institute of Science; European Molecular Biology Laboratory (EMBL); Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ); Weizmann Institute of Science				pagano, michele/0000-0003-3210-2442				BANDARA LR, 1991, NATURE, V352, P249, DOI 10.1038/352249a0; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; BOYD FT, 1989, J BIOL CHEM, V264, P2272; CAO L, 1992, NATURE, V355, P176, DOI 10.1038/355176a0; COFFEY RJ, 1988, MOL CELL BIOL, V8, P3088, DOI 10.1128/MCB.8.8.3088; DEVOTO SH, 1992, CELL, V68, P167, DOI 10.1016/0092-8674(92)90215-X; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; GIORDANO A, 1989, CELL, V58, P981, DOI 10.1016/0092-8674(89)90949-5; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HARRIS N, 1986, MOL CELL BIOL, V6, P4650, DOI 10.1128/MCB.6.12.4650; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; LAIHO M, 1991, J BIOL CHEM, V266, P9108; LIKE B, 1986, J BIOL CHEM, V261, P3426; MARSHALL CJ, 1991, CELL, V64, P313, DOI 10.1016/0092-8674(91)90641-B; MOSES HL, 1990, CELL, V63, P245, DOI 10.1016/0092-8674(90)90155-8; MUDRYJ M, 1991, CELL, V65, P1243, DOI 10.1016/0092-8674(91)90019-U; NIELSENHAMILTON M, 1990, CURR TOP DEV BIOL, V24, P95; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PIETENPOL JA, 1991, P NATL ACAD SCI USA, V88, P10227, DOI 10.1073/pnas.88.22.10227; PIETENPOL JA, 1990, CELL, V61, P777, DOI 10.1016/0092-8674(90)90188-K; PIETENPOL JA, 1990, P NATL ACAD SCI USA, V87, P3758, DOI 10.1073/pnas.87.10.3758; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; RESNITZKY D, 1992, P NATL ACAD SCI USA, V89, P402, DOI 10.1073/pnas.89.1.402; RESNITZKY D, 1991, CELL GROWTH DIFFER, V2, P33; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SHIPLEY GD, 1986, CANCER RES, V46, P2068; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; TIEFENBRUN N, 1991, ONCOGENE, V6, P1001; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; WANG J, 1990, NATURE, V343, P555, DOI 10.1038/343555a0; YARDEN A, 1986, SCIENCE, V234, P1419, DOI 10.1126/science.3097823; ZENTELLA A, 1991, MOL CELL BIOL, V11, P4952, DOI 10.1128/MCB.11.10.4952	33	31	31	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1992	7	8					1661	1665						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JE813	1385861				2022-12-17	WOS:A1992JE81300026
J	SHARIF, M; PRIVALSKY, ML				SHARIF, M; PRIVALSKY, ML			V-ERBA AND C-ERBA PROTEINS ENHANCE TRANSCRIPTIONAL ACTIVATION BY C-JUN	ONCOGENE			English	Article							RETINOIC ACID RECEPTOR; THYROID-HORMONE RECEPTORS; GLUCOCORTICOID RECEPTOR; RESPONSE ELEMENT; NEGATIVE REGULATION; ONCOGENE PROTEIN; OSTEOCALCIN GENE; BINDING DOMAIN; BETA-GENE; TATA BOX	The ability of different transcription factors to interact with one another is an important means by which the eucaryotic cell can integrate separate growth and differentiation signals into a coherent response. We report here an analysis of the interactions of transcription factors that are also the products of oncogenes: the erbA, jun and fos proteins. We demonstrate that the c-jun polypeptide can functionally interact with the c-erbA protein (thyroid hormone receptor) to yield an enhanced activity greater than that of either factor individually. Although the avian erythroblastosis v-erbA allele is generally thought to act as a transcriptional repressor in vertebrate cells, we also report the existence of promoter contexts where v-erbA, as well as c-erbA, can serve as 'co-activators' of c-jun function. V-erbA appears to augment retinoic acid receptor function in the same context. Our results suggest that v-erbA may have unanticipated positive effect on transcription in the neoplastic cell in addition to the repressor functions previously characterized.	UNIV CALIF DAVIS, DEPT MICROBIOL, DAVIS, CA 95616 USA	University of California System; University of California Davis					NCI NIH HHS [CA53394, CA38823] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA053394, R01CA053394, R01CA038823] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AUWERX J, 1991, CELL, V64, P983, DOI 10.1016/0092-8674(91)90322-P; BAICHWAL VR, 1990, CELL, V63, P815, DOI 10.1016/0092-8674(90)90147-7; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BOUCHER P, 1990, ONCOGENE, V5, P1303; BRAND N, 1988, NATURE, V332, P850, DOI 10.1038/332850a0; BRUGGEMEIER U, 1991, CELL, V64, P565, DOI 10.1016/0092-8674(91)90240-Y; CHATTERJEE VKK, 1989, P NATL ACAD SCI USA, V86, P9114, DOI 10.1073/pnas.86.23.9114; CORDINGLEY MG, 1987, CELL, V48, P261, DOI 10.1016/0092-8674(87)90429-6; CRONE DE, 1990, J BIOL CHEM, V265, P10851; DAMM K, 1989, NATURE, V339, P593, DOI 10.1038/339593a0; DARLING DS, 1989, MOL ENDOCRINOL, V3, P1359, DOI 10.1210/mend-3-9-1359; DAYTON AI, 1984, P NATL ACAD SCI-BIOL, V81, P4495, DOI 10.1073/pnas.81.14.4495; DESBOIS C, 1991, CELL, V67, P731, DOI 10.1016/0092-8674(91)90068-A; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FORMAN B M, 1990, New Biologist, V2, P587; FORREST D, 1990, ONCOGENE, V5, P309; GAUB MP, 1990, CELL, V63, P1267, DOI 10.1016/0092-8674(90)90422-B; GLASS CK, 1990, BIOCHIM BIOPHYS ACTA, V1032, P157, DOI 10.1016/0304-419X(90)90002-I; GRAF T, 1983, CELL, V34, P7, DOI 10.1016/0092-8674(83)90130-7; GREEN S, 1988, TRENDS GENET, V4, P309, DOI 10.1016/0168-9525(88)90108-4; HOFFMANN B, 1990, MOL ENDOCRINOL, V4, P1727, DOI 10.1210/mend-4-11-1727; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; JONES KA, 1985, CELL, V42, P559, DOI 10.1016/0092-8674(85)90113-8; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MARTINEZ E, 1991, MOL CELL BIOL, V11, P2937, DOI 10.1128/MCB.11.6.2937; MUNOZ A, 1988, EMBO J, V7, P155, DOI 10.1002/j.1460-2075.1988.tb02795.x; OWEN TA, 1990, P NATL ACAD SCI USA, V87, P9990, DOI 10.1073/pnas.87.24.9990; PATHAK BG, 1990, GENOMICS, V8, P641, DOI 10.1016/0888-7543(90)90250-X; PRIVALSKY ML, 1990, CELL, V63, P1277, DOI 10.1016/0092-8674(90)90423-C; SAP J, 1989, NATURE, V340, P242, DOI 10.1038/340242a0; SAP J, 1986, NATURE, V324, P635, DOI 10.1038/324635a0; SCHULE R, 1990, CELL, V61, P497, DOI 10.1016/0092-8674(90)90531-I; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; SHARIF M, 1991, CELL, V66, P885, DOI 10.1016/0092-8674(91)90435-2; STEIN GS, 1989, CONNECT TISSUE RES, V20, P3, DOI 10.3109/03008208909049996; STRAHLE U, 1988, EMBO J, V7, P3389, DOI 10.1002/j.1460-2075.1988.tb03212.x; SUCOV HM, 1990, P NATL ACAD SCI USA, V87, P5392, DOI 10.1073/pnas.87.14.5392; Vogt P K, 1990, Adv Cancer Res, V55, P1, DOI 10.1016/S0065-230X(08)60466-2; WEINBERGER C, 1986, NATURE, V324, P641, DOI 10.1038/324641a0; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V; ZENKE M, 1990, CELL, V61, P1035, DOI 10.1016/0092-8674(90)90068-P	42	31	31	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	1992	7	5					953	960						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HP642	1349165				2022-12-17	WOS:A1992HP64200015
J	BERANGER, F; TAVITIAN, A; DEGUNZBURG, J				BERANGER, F; TAVITIAN, A; DEGUNZBURG, J			POSTTRANSLATIONAL PROCESSING AND SUBCELLULAR-LOCALIZATION OF THE RAS-RELATED RAP2 PROTEIN	ONCOGENE			English	Article							GTP-BINDING PROTEIN; GAMMA SUBUNITS CONTAIN; NUCLEAR-ENVELOPE; ENDOPLASMIC-RETICULUM; CATALYTIC DOMAIN; PLASMA-MEMBRANE; MEVALONIC ACID; GENE-PRODUCT; LAMIN B; P21	The ras-related rap2 gene encodes a 21 kDa GTP-binding protein that exhibits many structural similarities with Ras proteins. In particular, it contains a C-terminal CAAX sequence (C, cysteine; A, aliphatic residue; X, any amino acid) which has been shown to direct the post-translational modifications responsible for membrane binding of Ras proteins and nuclear lamins. We have generated cell lines overexpressing the Rap2 protein as well as specific anti-Rap2 antibodies and show that the protein is tightly associated with cellular membranes. Similarly to Ras proteins, the Rap2 protein is synthesized as a soluble and hydrophilic precursor that is processed to the mature hydrophobic membrane-bound form. During its maturation, the Rap2 protein is modified by the attachment of both palmitate and polyisoprenoid groups, as is also the case for H- and N-Ras proteins. Subcellular fractionation by sucrose density centrifugation as well as indirect immunofluorescence experiments show that the Rap2 protein is localized in a low-density compartment that morphologically overlaps with the endoplasmic reticulum, whereas Ras proteins are associated with the plasma membrane. In spite of similar post-translational modifications by palmitoylation and polyisoprenylation, Ras and Rap2 proteins are thus located on distinct subcellular structures.			BERANGER, F (corresponding author), FAC MED LARIBOISIERE,INSERM,U248,10 AVE VERDUN,F-75010 PARIS,FRANCE.		Beranger, Florence/R-7581-2019					ADARI H, 1988, SCIENCE, V240, P518, DOI 10.1126/science.2833817; BALCH WE, 1990, TRENDS BIOCHEM SCI, V15, P473, DOI 10.1016/0968-0004(90)90301-Q; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BECK LA, 1988, J CELL BIOL, V107, P1307, DOI 10.1083/jcb.107.4.1307; BERANGER F, 1991, P NATL ACAD SCI USA, V88, P1606, DOI 10.1073/pnas.88.5.1606; BERGER M, 1984, J BIOL CHEM, V259, P7245; BORDIER C, 1981, J BIOL CHEM, V256, P1604; BUSS JE, 1986, MOL CELL BIOL, V6, P116, DOI 10.1128/MCB.6.1.116; CALES C, 1988, NATURE, V332, P548, DOI 10.1038/332548a0; CASEY PJ, 1989, P NATL ACAD SCI USA, V86, P8323, DOI 10.1073/pnas.86.21.8323; CHARDIN P, 1991, CANCER CELL-MON REV, V3, P117; CHARDIN P, 1986, EMBO J, V5, P2203, DOI 10.1002/j.1460-2075.1986.tb04485.x; CHAVRIER P, 1990, CELL, V62, P317, DOI 10.1016/0092-8674(90)90369-P; DARCHEN F, 1990, P NATL ACAD SCI USA, V87, P5692, DOI 10.1073/pnas.87.15.5692; DEGUNZBURG J, 1989, P NATL ACAD SCI USA, V86, P4007; DEVOS AM, 1988, SCIENCE, V239, P888, DOI 10.1126/science.2448879; FARNSWORTH CC, 1990, SCIENCE, V247, P320, DOI 10.1126/science.2296721; FUKADA Y, 1990, NATURE, V346, P658, DOI 10.1038/346658a0; FURTH ME, 1982, J VIROL, V43, P294, DOI 10.1128/JVI.43.1.294-304.1982; GOUD B, 1990, NATURE, V345, P553, DOI 10.1038/345553a0; GOUD B, 1988, CELL, V53, P753, DOI 10.1016/0092-8674(88)90093-1; GUTIERREZ L, 1989, EMBO J, V8, P1093, DOI 10.1002/j.1460-2075.1989.tb03478.x; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HOLTZ D, 1989, CELL, V59, P969, DOI 10.1016/0092-8674(89)90753-8; HORI Y, 1991, ONCOGENE, V6, P515; JACKSON JH, 1990, P NATL ACAD SCI USA, V87, P3042, DOI 10.1073/pnas.87.8.3042; JIMENEZ B, 1991, IN PRESS INT J CANCE; JOHN J, 1988, J BIOL CHEM, V263, P11792; KAWATA M, 1990, P NATL ACAD SCI USA, V87, P8960, DOI 10.1073/pnas.87.22.8960; KHOSRAVIFAR R, 1991, IN PRESS P NATL ACAD; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAI RK, 1990, P NATL ACAD SCI USA, V87, P7673, DOI 10.1073/pnas.87.19.7673; LOUVARD D, 1982, J CELL BIOL, V92, P92, DOI 10.1083/jcb.92.1.92; LOWE DG, 1987, CELL, V48, P137, DOI 10.1016/0092-8674(87)90364-3; MALTESE WA, 1989, J BIOL CHEM, V264, P18168; MALTESE WA, 1990, J BIOL CHEM, V265, P2148; MIZOGUCHI A, 1990, J BIOL CHEM, V265, P11872; MUMBY SM, 1990, P NATL ACAD SCI USA, V87, P5873, DOI 10.1073/pnas.87.15.5873; PAI EF, 1989, NATURE, V341, P209, DOI 10.1038/341209a0; PIZON V, 1988, NUCLEIC ACIDS RES, V16, P7719, DOI 10.1093/nar/16.15.7719; PIZON V, 1988, ONCOGENE, V3, P201; RILLING HC, 1990, SCIENCE, V247, P318, DOI 10.1126/science.2296720; SCHAFER WR, 1989, SCIENCE, V245, P379, DOI 10.1126/science.2569235; SHIH C, 1982, CELL, V29, P161, DOI 10.1016/0092-8674(82)90100-3; SIGAL IS, 1986, P NATL ACAD SCI USA, V83, P4725, DOI 10.1073/pnas.83.13.4725; SMITH DE, 1984, J CELL BIOL, V99, P20, DOI 10.1083/jcb.99.1.20; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; TUCKER J, 1986, EMBO J, V5, P1351, DOI 10.1002/j.1460-2075.1986.tb04366.x; VANDERSLUIJS P, 1991, IN PRESS P NATL ACAD; VAUX D, 1990, NATURE, V345, P495, DOI 10.1038/345495a0; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; VONMOLLARD F, 1990, P NATL ACAD SCI USA, V87, P5692; WILLINGHAM MC, 1980, CELL, V19, P1005, DOI 10.1016/0092-8674(80)90091-4; WILLUMSEN BM, 1986, MOL CELL BIOL, V6, P2646, DOI 10.1128/MCB.6.7.2646; WILLUMSEN BM, 1984, NATURE, V310, P583, DOI 10.1038/310583a0; WOLDA SL, 1988, J BIOL CHEM, V263, P5997; WORMAN HJ, 1988, P NATL ACAD SCI USA, V85, P8531, DOI 10.1073/pnas.85.22.8531; YAMANE HK, 1990, P NATL ACAD SCI USA, V87, P5868, DOI 10.1073/pnas.87.15.5868; YAMANE HK, 1991, P NATL ACAD SCI USA, V88, P286, DOI 10.1073/pnas.88.1.286	61	31	32	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1991	6	10					1835	1842						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX118	1923507				2022-12-17	WOS:A1991GX11800016
J	MORRIS, CM; HAO, QL; HEISTERKAMP, N; FITZGERALD, PH; GROFFEN, J				MORRIS, CM; HAO, QL; HEISTERKAMP, N; FITZGERALD, PH; GROFFEN, J			LOCALIZATION OF THE TRK PROTOONCOGENE TO HUMAN-CHROMOSOME BANDS 1Q23-1Q24	ONCOGENE			English	Note							DIFFERENT CELLULAR SEQUENCES; RECEPTOR KINASE DOMAIN; BIOCHEMICAL-CHARACTERIZATION; ACTIVATION; RECOMBINATION; GENE; MAPS	A FER-related sequence isolated from a human genomic library was found to be homologous to TRK. In situ hybridization of a 0.92 kb probe, isolated from this sequence, localized the TRK gene to the long arm of chromosome 1 within bands 1q23-1q24. This is a significantly more proximal location of TRK than the 1q32-1q41 site published recently (Miozzo et al., 1990).	CHILDRENS HOSP LOS ANGELES,DEPT PATHOL,MOLEC DIAG SECT,LOS ANGELES,CA	Children's Hospital Los Angeles	MORRIS, CM (corresponding author), CHRISTCHURCH HOSP,CYTOGENET & MOLEC ONCOL UNIT,CHRISTCHURCH,NEW ZEALAND.		Heisterkamp, Nora/C-1698-2012; Morris, Christine/G-1690-2011	Heisterkamp, Nora/0000-0003-2769-2273; 	NCI NIH HHS [1RO-CA47456] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA047456, R55CA047456] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BONGARZONE I, 1989, ONCOGENE, V4, P1457; COULIER F, 1989, MOL CELL BIOL, V9, P15, DOI 10.1128/MCB.9.1.15; HAO QL, 1989, MOL CELL BIOL, V9, P1587, DOI 10.1128/MCB.9.4.1587; KOZMA SC, 1988, EMBO J, V7, P147, DOI 10.1002/j.1460-2075.1988.tb02794.x; MARTINZANCA D, 1989, MOL CELL BIOL, V9, P24, DOI 10.1128/MCB.9.1.24; MARTINZANCA D, 1986, NATURE, V319, P743, DOI 10.1038/319743a0; MIOZZO M, 1990, ONCOGENE, V5, P1411; MITRA G, 1987, P NATL ACAD SCI USA, V84, P6707, DOI 10.1073/pnas.84.19.6707; MORRIS C, 1990, CYTOGENET CELL GENET, V53, P196, DOI 10.1159/000132929; MORRIS CM, 1987, LEUKEMIA RES, V11, P163, DOI 10.1016/0145-2126(87)90022-1; OLAH E, 1989, CANCER GENET CYTOGEN, V43, P179, DOI 10.1016/0165-4608(89)90029-0; OSKAM R, 1988, P NATL ACAD SCI USA, V85, P2964, DOI 10.1073/pnas.85.9.2964; TRENT JM, 1989, CYTOGENET CELL GENET, V51, P533, DOI 10.1159/000132807	13	31	31	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1991	6	6					1093	1095						3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GU622	1829807				2022-12-17	WOS:A1991GU62200030
J	ANDRES, AC; BCHINI, O; SCHUBAUR, B; DOLDER, B; LEMEUR, M; GERLINGER, P				ANDRES, AC; BCHINI, O; SCHUBAUR, B; DOLDER, B; LEMEUR, M; GERLINGER, P			H-RAS INDUCED TRANSFORMATION OF MAMMARY EPITHELIUM IS FAVORED BY INCREASED ONCOGENE EXPRESSION OR BY INHIBITION OF MAMMARY REGRESSION	ONCOGENE			English	Article							MILK PROTEIN GENE; HUMAN-BREAST CANCER; TRANSGENIC MICE; HYBRID GENE; MOUSE; PROMOTER; CELLS; ACTIVATION; INDUCTION; TUMORS	The promoter of the mammary specific murine whey acidic protein gene was used to direct Ha-ras expression in different lines of transgenic mice. We found that this promoter contains a tissue specific enhancer which directed expression in both orientations albeit to different levels. We used this feature to generate low and high ras expressing transgenic lines. The reversed orientation led to a weak expression in lines 3 and 58 and to a tumor frequency of 2%. In contrast, 72% of mice from line 25 showing high ras expression developed mammary tumors. Nulliparity is one risk factor for human breast cancer, suggesting a protective effect of post-lactational mammary regression. In order to investigate the effect of post-lactational regression, the low tumor frequency lines were crossed with mice expressing ubiquitously the human growth hormone gene, which induces permanent development of the mammary epithelium. Indeed, mammary tumors were observed in 76% of double transgenic females. Thus, the tumorigenic potential of the ras oncogene in mammary cells in vivo correlates with the level of its expression and with the developmental history of the mammary gland. Transformation coincides with the escape of oncogene expression from the regulation of the Wap promoter and the extinction of endogenous Wap gene expression.	FAC MED STRASBOURG, INST CHIM BIOL,INSERM,CNRS, GENET MOLEC EUCARYOTES LAB,11 RUE HUMANN, F-67085 STRASBOURG, FRANCE; FAC MED STRASBOURG, INST CHIM BIOL, INSERM, UNITE 184 BIOL MOLEC & GENIE GENET, F-67085 STRASBOURG, FRANCE	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	GERLINGER, P (corresponding author), FAC MED STRASBOURG, INST CHIM BIOL,INSERM,CNRS, GENET MOLEC EUCARYOTES LAB, 11 RUE HUMANN, F-67085 STRASBOURG, FRANCE.							ADNANE J, 1989, ONCOGENE, V4, P1389; ANDRES AC, 1987, P NATL ACAD SCI USA, V84, P1299, DOI 10.1073/pnas.84.5.1299; ANDRES AC, 1988, GENE DEV, V2, P1486, DOI 10.1101/gad.2.11.1486; ASHLEY RL, 1980, CANCER RES, V40, P4232; BALL RK, 1988, MOL ENDOCRINOL, V2, P133, DOI 10.1210/mend-2-2-133; BARBACID M, 1986, CARCINOGENESIS, V7, P1037, DOI 10.1093/carcin/7.7.1037; BCHINI O, 1991, IN PRESS ENDOCRINOLO, V128; BOS JL, 1989, CANCER RES, V49, P4682; BOUKAMP P, 1990, CANCER RES, V50, P2840; BOYLE P, 1988, BAILLIERE CLIN ONCOL, P1; CALLAHAN R, 1989, JNCI-J NATL CANCER I, V81, P1780, DOI 10.1093/jnci/81.23.1780; CAMPBELL SM, 1984, NUCLEIC ACIDS RES, V12, P8685, DOI 10.1093/nar/12.22.8685; CAPON DJ, 1983, NATURE, V302, P33, DOI 10.1038/302033a0; CARDIFF RD, 1988, ONCOGENE, V3, P205; CHEN LH, 1989, CELL REGUL, V1, P45, DOI 10.1091/mbc.1.1.45; CHOWCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156; CLAIR T, 1987, CANCER RES, V47, P5290; DANDEKAR S, 1986, MOL CELL BIOL, V6, P4104, DOI 10.1128/MCB.6.11.4104; DEMBINSKI TC, 1985, CANCER RES, V45, P3083; DENOTO FM, 1981, NUCLEIC ACIDS RES, V9, P3719, DOI 10.1093/nar/9.15.3719; DOPPLER W, 1989, P NATL ACAD SCI USA, V86, P104, DOI 10.1073/pnas.86.1.104; DUBOULE D, 1989, EMBO J, V8, P1497, DOI 10.1002/j.1460-2075.1989.tb03534.x; HOBBS AA, 1982, J BIOL CHEM, V17, P8389; JAGGI R, 1986, EMBO J, V5, P2609, DOI 10.1002/j.1460-2075.1986.tb04541.x; Korenman S. G., 1981, Banbury Report, V8, P71; KRAUS MH, 1984, P NATL ACAD SCI-BIOL, V81, P5384, DOI 10.1073/pnas.81.17.5384; KUMAR R, 1990, SCIENCE, V248, P1101, DOI 10.1126/science.2188364; LATHE R, 1987, GENE, V57, P193, DOI 10.1016/0378-1119(87)90122-3; LIPSETT MB, 1960, CANCER RES, V20, P1172; LUBON H, 1987, NUCLEIC ACIDS RES, V15, P2103, DOI 10.1093/nar/15.5.2103; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MEDINA D, 1973, METHOD CANCER RES, V7, P353; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MIYAMOTO S, 1990, CANCER RES, V50, P6010; MIYAMOTO S, 1990, MOL CELL BIOL, V10, P1593, DOI 10.1128/MCB.10.4.1593; PALMITER RD, 1982, CELL, V29, P701, DOI 10.1016/0092-8674(82)90186-6; PITTIUS CW, 1988, MOL ENDOCRINOL, V2, P1027, DOI 10.1210/mend-2-11-1027; REDMOND SMS, 1988, ONCOGENE, V2, P259; RUSSO J, 1989, DEV ONCOL, V58, P133; SASSONECORSI P, 1989, MOL CELL BIOL, V9, P3174, DOI 10.1128/MCB.9.8.3174; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; SCHOENENBERGER CA, 1990, DEV BIOL, V139, P327, DOI 10.1016/0012-1606(90)90302-Y; SCHOENENBERGER CA, 1988, EMBO J, V7, P169, DOI 10.1002/j.1460-2075.1988.tb02797.x; SCHONTHAL A, 1988, CELL, V54, P325, DOI 10.1016/0092-8674(88)90195-X; SCHUH AC, 1990, NATURE, V346, P756, DOI 10.1038/346756a0; SUKUMAR S, 1983, NATURE, V306, P658, DOI 10.1038/306658a0; TANAKA T, 1986, CANCER RES, V46, P1465; Vonderhaar B K, 1988, Cancer Treat Res, V40, P251	48	31	32	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	1991	6	5					771	779						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GT825	2052356				2022-12-17	WOS:A1991GT82500013
J	SCHUERMANN, M; JOOSS, K; MULLER, R				SCHUERMANN, M; JOOSS, K; MULLER, R			FOSB IS A TRANSFORMING GENE ENCODING A TRANSCRIPTIONAL ACTIVATOR	ONCOGENE			English	Article							DNA-BINDING PROTEINS; JUN PROTO-ONCOGENE; C-FOS; LEUCINE ZIPPER; CYCLIC-AMP; V-FOS; NEGATIVE REGULATOR; MOUSE FIBROBLASTS; MAMMALIAN-CELLS; GROWTH-FACTORS	The fosB gene encodes a nuclear protein that shows a high degree of homology with c-Fos in several of the known functionally crucial domains, e.g., the leucine zipper and the DNA-binding site, but shows considerable divergence in other regions. Here, we report that FosB, when placed under the control of a constitutive promoter, exhibits clear transforming properties in focus assays using mouse NIH3T3 or rat 208F fibroblasts. The transforming potential of FosB is considerably stronger than that of a corresponding c-fos construct and resembles that of viral fos genes. Using chimeric fos/fosB constructs we show that the C-terminal half of FosB is responsible for these stronger transforming properties, apparently by giving rise to significantly higher levels of protein as compared with the corresponding c-fos sequence. Surprisingly, substitution of the N-terminus of Fos with that of FosB decreases its transforming potential. These differences in the transforming potential are not related to DNA or protein expression, but rather seem to reflect differences in the molecular function(s) encoded in the N-terminal halves of Fos and FosB protein. Both, fosB- and v-fos transformed cells show increased expression of a number of endogenous genes, including c-jun, transin, alpha-1(III) collagen and tissue plasminogen activator. Transactivation by FosB and v-fos of the c-jun and alpha-1(III) collagen gene promoters and of a 3 x TRE-tk chimeric promoter could be shown in transient CAT assays. v-Fos, but not FosB-transformed cells, also show elevated levels of urokinase and plasminogen activator inhibitor mRNAs, pointing to potential differences in the gene regulatory properties of the two Fos family members.			SCHUERMANN, M (corresponding author), UNIV MARBURG, INST MOLEK BIOL & TUMORFORSCH, EMIL MANNKOPFF STR 2, W-3550 MARBURG, GERMANY.		Müller, Rolf/L-4997-2016	Müller, Rolf/0000-0003-3339-4248				ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BARBER JR, 1987, MOL CELL BIOL, V7, P2201, DOI 10.1128/MCB.7.6.2201; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; CLERC RG, 1988, GENE DEV, V2, P1570, DOI 10.1101/gad.2.12a.1570; COHEN DR, 1988, MOL CELL BIOL, V8, P2063, DOI 10.1128/MCB.8.5.2063; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; CURRAN T, 1982, VIROLOGY, V116, P221, DOI 10.1016/0042-6822(82)90415-9; DONY C, 1987, NATURE, V328, P711, DOI 10.1038/328711a0; FRANZA BR, 1988, SCIENCE, V239, P1150, DOI 10.1126/science.2964084; GENTZ R, 1989, SCIENCE, V243, P1695, DOI 10.1126/science.2494702; GONZALEZ GA, 1989, NATURE, V337, P749, DOI 10.1038/337749a0; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; HE CS, 1989, P NATL ACAD SCI USA, V86, P2632, DOI 10.1073/pnas.86.8.2632; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; HOEFFLER JP, 1988, SCIENCE, V242, P1430, DOI 10.1126/science.2974179; JENUWEIN T, 1987, CELL, V48, P647, DOI 10.1016/0092-8674(87)90243-1; JENUWEIN T, 1985, CELL, V41, P629, DOI 10.1016/S0092-8674(85)80035-0; KEMP BE, 1977, J BIOL CHEM, V252, P4888; KERR LD, 1988, SCIENCE, V242, P1424, DOI 10.1126/science.2462278; KONIG H, 1989, EMBO J, V8, P2559, DOI 10.1002/j.1460-2075.1989.tb08394.x; KOUZARIDES T, 1988, NATURE, V336, P646, DOI 10.1038/336646a0; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LEE WMF, 1988, MOL CELL BIOL, V8, P5521, DOI 10.1128/MCB.8.12.5521; LIAU G, 1985, J BIOL CHEM, V260, P531; LUCIBELLO FC, 1988, ONCOGENE, V3, P43; LUCIBELLO FC, 1990, EMBO J, V9, P2827, DOI 10.1002/j.1460-2075.1990.tb07471.x; LUCIBELLO FC, 1989, CELL, V59, P999, DOI 10.1016/0092-8674(89)90756-3; MAEKAWA T, 1989, EMBO J, V8, P2023, DOI 10.1002/j.1460-2075.1989.tb03610.x; MATRISIAN LM, 1985, EMBO J, V4, P1435, DOI 10.1002/j.1460-2075.1985.tb03799.x; MATRISIAN LM, 1990, TRENDS GENET, V6, P121, DOI 10.1016/0168-9525(90)90126-Q; MATSUI M, 1990, ONCOGENE, V5, P249; MEIJLINK F, 1985, P NATL ACAD SCI USA, V82, P4987, DOI 10.1073/pnas.82.15.4987; MILLER AD, 1984, CELL, V36, P51; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MULLER MM, 1988, NATURE, V336, P544, DOI 10.1038/336544a0; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; NEUBERG M, 1989, NATURE, V338, P589, DOI 10.1038/338589a0; NEUBERG M, 1989, NATURE, V341, P243, DOI 10.1038/341243a0; PRENDERGAST GC, 1989, MOL CELL BIOL, V9, P124, DOI 10.1128/MCB.9.1.124; RANSONE LJ, 1989, GENE DEV, V3, P770, DOI 10.1101/gad.3.6.770; REDEMANNFIBI B, 1991, IN PRESS DIFFERENTIA; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; RYSECK RP, 1988, NATURE, V334, P535, DOI 10.1038/334535a0; SASSONECORSI P, 1988, NATURE, V336, P692, DOI 10.1038/336692a0; SASSONECORSI P, 1988, CELL, V54, P553, DOI 10.1016/0092-8674(88)90077-3; SCHEIDEREIT C, 1988, NATURE, V336, P551, DOI 10.1038/336551a0; SCHOLER HR, 1989, EMBO J, V8, P2551, DOI 10.1002/j.1460-2075.1989.tb08393.x; SCHONTHAL A, 1988, CELL, V54, P325, DOI 10.1016/0092-8674(88)90195-X; SCHREIBER E, 1988, EMBO J, V7, P4221, DOI 10.1002/j.1460-2075.1988.tb03319.x; SCHUERMANN M, 1989, CELL, V56, P507, DOI 10.1016/0092-8674(89)90253-5; SCHUERMANN M, 1990, NUCLEIC ACIDS RES, V18, P4945, DOI 10.1093/nar/18.16.4945; SCHUTTE J, 1989, CELL, V59, P987, DOI 10.1016/0092-8674(89)90755-1; SETOYAMA C, 1986, P NATL ACAD SCI USA, V83, P3213, DOI 10.1073/pnas.83.10.3213; SETOYAMA C, 1986, BIOCHEM BIOPH RES CO, V136, P1042, DOI 10.1016/0006-291X(86)90438-9; STAUDT LM, 1988, SCIENCE, V241, P577, DOI 10.1126/science.3399892; STURM RA, 1988, GENE DEV, V2, P1582, DOI 10.1101/gad.2.12a.1582; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; VANBEVEREN C, 1983, CELL, V32, P1241, DOI 10.1016/0092-8674(83)90306-9; VERRIER B, 1986, EMBO J, V5, P913, DOI 10.1002/j.1460-2075.1986.tb04303.x; WASYLYK C, 1988, EMBO J, V7, P2475, DOI 10.1002/j.1460-2075.1988.tb03094.x; WILKINSON DG, 1989, DEVELOPMENT, V106, P465; XI H, 1989, NATURE, V340, P35, DOI 10.1038/340035a0; ZERIAL M, 1989, EMBO J, V8, P805, DOI 10.1002/j.1460-2075.1989.tb03441.x	73	31	31	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	1991	6	4					567	576						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FR939	1903195				2022-12-17	WOS:A1991FR93900010
J	WILDENHAIN, Y; PAWSON, T; BLACKSTEIN, ME; ANDRULIS, IL				WILDENHAIN, Y; PAWSON, T; BLACKSTEIN, ME; ANDRULIS, IL			P185NEU IS PHOSPHORYLATED ON TYROSINE IN HUMAN PRIMARY BREAST-TUMORS WHICH OVEREXPRESS NEU/ERBB-2	ONCOGENE			English	Article									MT SINAI HOSP, RES INST, 600 UNIV AVE, TORONTO M5G 1X5, ONTARIO, CANADA; MT SINAI HOSP, DEPT MED, TORONTO M5G 1X5, ONTARIO, CANADA; UNIV TORONTO, DEPT MED GENET, TORONTO M5G 1X5, ONTARIO, CANADA; UNIV TORONTO, DEPT ANAT, TORONTO M5G 1X5, ONTARIO, CANADA	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University of Toronto			Andrulis, Irene L./E-7267-2013					ALITALO K, 1986, ADV CANCER RES, V47, P235, DOI 10.1016/S0065-230X(08)60201-8; BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BARGMANN CI, 1988, EMBO J, V7, P2043, DOI 10.1002/j.1460-2075.1988.tb03044.x; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; HUNG MC, 1989, P NATL ACAD SCI USA, V86, P2545, DOI 10.1073/pnas.86.8.2545; KAMPS MP, 1988, ONCOGENE, V2, P305; KING CR, 1988, EMBO J, V7, P1647, DOI 10.1002/j.1460-2075.1988.tb02991.x; LEE J, 1989, EMBO J, V8, P167, DOI 10.1002/j.1460-2075.1989.tb03361.x; LEHVASLAIHO H, 1989, EMBO J, V8, P159, DOI 10.1002/j.1460-2075.1989.tb03360.x; LETWIN K, 1988, ONCOGENE, V3, P621; SCHECHTER AL, 1984, NATURE, V312, P513, DOI 10.1038/312513a0; SEGATTO O, 1988, MOL CELL BIOL, V8, P5570, DOI 10.1128/MCB.8.12.5570; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; STERN DF, 1988, EMBO J, V7, P995, DOI 10.1002/j.1460-2075.1988.tb02906.x; STERN DF, 1988, MOL CELL BIOL, V8, P3969, DOI 10.1128/MCB.8.9.3969; WEINER DB, 1989, NATURE, V339, P230, DOI 10.1038/339230a0; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0	20	31	32	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1990	5	6					879	883						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DP553	1694290				2022-12-17	WOS:A1990DP55300014
J	ITOH, M; INOUE, J; TOYOSHIMA, H; AKIZAWA, T; HIGASHI, M; YOSHIDA, M				ITOH, M; INOUE, J; TOYOSHIMA, H; AKIZAWA, T; HIGASHI, M; YOSHIDA, M			HTLV-1-REX AND HIV-1-REV ACT THROUGH SIMILAR MECHANISMS TO RELIEVE SUPPRESSION OF UNSPLICED RNA EXPRESSION	ONCOGENE			English	Article									JAPANESE FDN CANC RES,INST CANC,DEPT VIRAL ONCOL,KAMI IKEBUKURO,TOSHIMA KU,TOKYO 170,JAPAN	Japanese Foundation for Cancer Research								CULLEN BR, 1988, J VIROL, V62, P2498, DOI 10.1128/JVI.62.7.2498-2501.1988; FEINBERG MB, 1986, CELL, V46, P807, DOI 10.1016/0092-8674(86)90062-0; FELBER BK, 1989, P NATL ACAD SCI USA, V86, P1495, DOI 10.1073/pnas.86.5.1495; FUJISAWA J, 1985, P NATL ACAD SCI USA, V82, P2277, DOI 10.1073/pnas.82.8.2277; FUJISAWA J, 1986, EMBO J, V5, P713, DOI 10.1002/j.1460-2075.1986.tb04272.x; HADZOPOULOUCLADARAS M, 1989, J VIROL, V63, P1265, DOI 10.1128/JVI.63.3.1265-1274.1989; HAHN BH, 1984, NATURE, V312, P166, DOI 10.1038/312166a0; HIDAKA M, 1988, EMBO J, V7, P519, DOI 10.1002/j.1460-2075.1988.tb02840.x; INOUE J, 1987, P NATL ACAD SCI USA, V84, P3653, DOI 10.1073/pnas.84.11.3653; INOUE JI, 1986, FEBS LETT, V209, P187, DOI 10.1016/0014-5793(86)81108-5; KIYOKAWA T, 1985, P NATL ACAD SCI USA, V82, P8359, DOI 10.1073/pnas.82.24.8359; KNIGHT DM, 1987, SCIENCE, V236, P837, DOI 10.1126/science.3033827; MALIM MH, 1989, NATURE, V338, P254, DOI 10.1038/338254a0; OHTA M, 1988, J VIROL, V62, P4445, DOI 10.1128/JVI.62.12.4445-4451.1988; RIMSKY L, 1988, NATURE, V335, P738, DOI 10.1038/335738a0; ROSEN CA, 1988, P NATL ACAD SCI USA, V85, P2071, DOI 10.1073/pnas.85.7.2071; ROSENBLATT JD, 1988, SCIENCE, V240, P916, DOI 10.1126/science.2834826; SADAIE MR, 1988, SCIENCE, V239, P910, DOI 10.1126/science.3277284; SEIKI M, 1985, SCIENCE, V228, P1532, DOI 10.1126/science.2990031; SEIKI M, 1988, P NATL ACAD SCI USA, V85, P7124, DOI 10.1073/pnas.85.19.7124; SEIKI M, 1983, P NATL ACAD SCI-BIOL, V80, P3618, DOI 10.1073/pnas.80.12.3618; SEIKI M, 1986, EMBO J, V5, P561, DOI 10.1002/j.1460-2075.1986.tb04247.x; SIOMI H, 1988, CELL, V55, P197, DOI 10.1016/0092-8674(88)90043-8; SODROSKI J, 1986, NATURE, V321, P412, DOI 10.1038/321412a0; STINSKI MF, 1983, J VIROL, V46, P1; TERWILLIGER E, 1988, J VIROL, V62, P655, DOI 10.1128/JVI.62.2.655-658.1988; YOSHIDA M, 1988, CONTROL OF HUMAN RETROVIRUS GENE EXPRESSION, P251	27	31	32	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1989	4	11					1275	1279						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AX659	2682457				2022-12-17	WOS:A1989AX65900001
J	DUDEK, H; REDDY, EP				DUDEK, H; REDDY, EP			IDENTIFICATION OF 2 TRANSLATIONAL PRODUCTS FOR C-MYB	ONCOGENE			English	Article											DUDEK, H (corresponding author), WISTAR INST,3601 SPRUCE ST,PHILADELPHIA,PA 19104, USA.		Reddy, E. Premkumar/F-6233-2011		NATIONAL CANCER INSTITUTE [R01CA044463] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007229] Funding Source: NIH RePORTER; NCI NIH HHS [1RO1 CA 44463] Funding Source: Medline; NIGMS NIH HHS [5T32 GM 07229] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANFOSSI G, 1989, P NATL ACAD SCI USA, V86, P3379, DOI 10.1073/pnas.86.9.3379; BADING H, 1987, ONCOGENE, V1, P395; BADING H, 1988, ONCOGENE, V3, P257; BALUDA MA, 1961, VIROLOGY, V15, P185, DOI 10.1016/0042-6822(61)90234-3; BENDER TP, 1987, SCIENCE, V237, P1473, DOI 10.1126/science.3498214; BENDER TP, 1986, P NATL ACAD SCI USA, V83, P3204, DOI 10.1073/pnas.83.10.3204; BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; BOYLE WJ, 1983, P NATL ACAD SCI-BIOL, V80, P2834, DOI 10.1073/pnas.80.10.2834; BOYLE WJ, 1984, P NATL ACAD SCI-BIOL, V81, P4265, DOI 10.1073/pnas.81.14.4265; CHALLBERG MD, 1979, P NATL ACAD SCI USA, V76, P655, DOI 10.1073/pnas.76.2.655; GEORGE DG, 1986, NUCLEIC ACIDS RES, V14, P11, DOI 10.1093/nar/14.1.11; GERONDAKIS S, 1986, MOL CELL BIOL, V6, P3677, DOI 10.1128/MCB.6.11.3677; GONDA TJ, 1985, EMBO J, V4, P2003, DOI 10.1002/j.1460-2075.1985.tb03884.x; KLEMPNAUER KH, 1984, CELL, V37, P537, DOI 10.1016/0092-8674(84)90384-2; KLEMPNAUER KH, 1986, EMBO J, V5, P1903, DOI 10.1002/j.1460-2075.1986.tb04443.x; KLEMPNAUER KH, 1983, CELL, V33, P345, DOI 10.1016/0092-8674(83)90416-6; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LAVU S, 1986, NUCLEIC ACIDS RES, V14, P5309, DOI 10.1093/nar/14.13.5309; MOELLING K, 1985, CELL, V40, P983, DOI 10.1016/0092-8674(85)90358-7; Moscovici C, 1975, Curr Top Microbiol Immunol, V71, P79; MUSHINSKI JF, 1983, SCIENCE, V220, P795, DOI 10.1126/science.6687762; PAIGE CJ, 1978, J IMMUNOL, V121, P641; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PELLICI PG, 1984, SCIENCE, V224, P1117; PETERS CWB, 1987, EMBO J, V6, P3085, DOI 10.1002/j.1460-2075.1987.tb02616.x; RAMSAY RG, 1986, P NATL ACAD SCI USA, V83, P6849, DOI 10.1073/pnas.83.18.6849; REDDY EP, 1988, ONCOGENE HDB, P327; ROSSON D, 1987, P NATL ACAD SCI USA, V84, P3171, DOI 10.1073/pnas.84.10.3171; ROSSON D, 1986, NATURE, V319, P604, DOI 10.1038/319604a0; RUSHLOW KE, 1982, SCIENCE, V216, P1421, DOI 10.1126/science.6283631; RUTHER U, 1983, EMBO J, V2, P1791, DOI 10.1002/j.1460-2075.1983.tb01659.x; SHEINESS D, 1984, MOL CELL BIOL, V4, P1206, DOI 10.1128/MCB.4.7.1206; SHENONG GLC, 1987, EMBO J, V6, P4035, DOI 10.1002/j.1460-2075.1987.tb02748.x; SHENONG GLC, 1984, SCIENCE, V226, P1077, DOI 10.1126/science.6093260; SHENONG GLC, 1986, MOL CELL BIOL, V6, P380, DOI 10.1128/MCB.6.2.380; WEINSTEIN Y, 1986, P NATL ACAD SCI USA, V83, P5010, DOI 10.1073/pnas.83.14.5010; WEINSTEIN Y, 1987, J VIROL, V61, P2339, DOI 10.1128/JVI.61.7.2339-2343.1987; WESTIN EH, 1982, P NATL ACAD SCI-BIOL, V79, P2194, DOI 10.1073/pnas.79.7.2194	40	31	31	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1989	4	9					1061	1066						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AM531	2674850				2022-12-17	WOS:A1989AM53100001
J	KATZAV, S; MARTINZANCA, D; BARBACID, M; HEDGE, AM; ISFORT, R; IHLE, JN				KATZAV, S; MARTINZANCA, D; BARBACID, M; HEDGE, AM; ISFORT, R; IHLE, JN			THE TRK ONCOGENE ABROGATES GROWTH-FACTOR REQUIREMENTS AND TRANSFORMS HEMATOPOIETIC-CELLS	ONCOGENE			English	Article									NCI, FREDERICK CANC RES FACIL, BRI BASIC RES PROGRAM, MOLEC MECHANISMS LEUKEMOGENESIS SECT, FREDERICK, MD 21701 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	KATZAV, S (corresponding author), NCI, FREDERICK CANC RES FACIL, DEV ONCOL SECT, FREDERICK, MD 21701 USA.				NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NCI [N01CO074101] Funding Source: NIH RePORTER; NCI NIH HHS [N01-CO-74101, P30 CA21765] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		COOK WD, 1987, MOL CELL BIOL, V7, P2631, DOI 10.1128/MCB.7.7.2631; COOK WD, 1985, CELL, V41, P677, DOI 10.1016/S0092-8674(85)80048-9; COULIER F, 1989, MOL CELL BIOL, V9, P15, DOI 10.1128/MCB.9.1.15; DALEY GQ, 1988, P NATL ACAD SCI USA, V85, P9312, DOI 10.1073/pnas.85.23.9312; DEXTER TM, 1980, J EXP MED, V152, P1036, DOI 10.1084/jem.152.4.1036; FRACKELTON AR, 1983, MOL CELL BIOL, V3, P1343, DOI 10.1128/MCB.3.8.1343; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HAPEL AJ, 1986, LYMPHOKINE RES, V5, P249; HARIHARAN IK, 1988, IN PRESS ONCOGENE RE, V3; Ihle J N, 1989, Year Immunol, V5, P59; IHLE JN, 1982, J IMMUNOL, V129, P1377; ISFORT R, 1988, J BIOL CHEM, V263, P19203; ISFORT RJ, 1988, P NATL ACAD SCI USA, V85, P7982, DOI 10.1073/pnas.85.21.7982; JHAPPAN C, 1986, J VIROL, V60, P750, DOI 10.1128/JVI.60.2.750-753.1986; KOZMA SC, 1988, EMBO J, V7, P147, DOI 10.1002/j.1460-2075.1988.tb02794.x; LANG RA, 1985, CELL, V43, P531, DOI 10.1016/0092-8674(85)90182-5; MANN R, 1983, CELL, V33, P153, DOI 10.1016/0092-8674(83)90344-6; MARTINZANCA D, 1989, MOL CELL BIOL, V9, P24, DOI 10.1128/MCB.9.1.24; MARTINZANCA D, 1986, NATURE, V319, P743, DOI 10.1038/319743a0; MATHEYPREVOT B, 1986, MOL CELL BIOL, V6, P4133, DOI 10.1128/MCB.6.11.4133; MITRA G, 1987, P NATL ACAD SCI USA, V84, P6707, DOI 10.1073/pnas.84.19.6707; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; OSKAM R, 1988, P NATL ACAD SCI USA, V85, P2964, DOI 10.1073/pnas.85.9.2964; OVERELL RW, 1987, MOL CELL BIOL, V7, P3394, DOI 10.1128/MCB.7.10.3394; PIERCE JH, 1985, CELL, V41, P685, DOI 10.1016/S0092-8674(85)80049-0; PIERCE JH, 1988, SCIENCE, V239, P628, DOI 10.1126/science.3257584; PULCIANI S, 1982, NATURE, V300, P539, DOI 10.1038/300539a0; WATSON JD, 1987, J IMMUNOL, V139, P123; WHEELER EF, 1987, MOL CELL BIOL, V7, P1673, DOI 10.1128/MCB.7.5.1673	29	31	31	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	1989	4	9					1129	1135						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AM531	2674855				2022-12-17	WOS:A1989AM53100012
J	LUBBERT, M; MILLER, CW; KAHAN, J; KOEFFLER, HP				LUBBERT, M; MILLER, CW; KAHAN, J; KOEFFLER, HP			EXPRESSION, METHYLATION AND CHROMATIN STRUCTURE OF THE P53-GENE IN UNTRANSFORMED AND HUMAN T-CELL LEUKEMIA-VIRUS TYPE-I-TRANSFORMED HUMAN LYMPHOCYTE-T	ONCOGENE			English	Article									UNIV CALIF LOS ANGELES,DEPT MED,DIV HEMATOL ONCOL,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles					NATIONAL CANCER INSTITUTE [R01CA033936, R01CA026038, U01CA043277] Funding Source: NIH RePORTER; NCI NIH HHS [CA33936, CA26038, CA43277] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARBIERI R, 1987, BIOCHEM BIOPH RES CO, V145, P96, DOI 10.1016/0006-291X(87)91292-7; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P51; BRAITHWAITE AW, 1987, NATURE, V329, P458, DOI 10.1038/329458a0; CHEN ISY, 1983, P NATL ACAD SCI-BIOL, V80, P7006, DOI 10.1073/pnas.80.22.7006; CRAWFORD L, 1983, INT REV EXP PATHOL, V25, P1; CRAWFORD LV, 1981, P NATL ACAD SCI-BIOL, V78, P41, DOI 10.1073/pnas.78.1.41; DELEO AB, 1979, P NATL ACAD SCI USA, V76, P2420, DOI 10.1073/pnas.76.5.2420; DEPPERT W, 1987, MOL CELL BIOL, V7, P4453, DOI 10.1128/MCB.7.12.4453; DOERFLER W, 1983, ANNU REV BIOCHEM, V52, P93, DOI 10.1146/annurev.bi.52.070183.000521; DONY C, 1985, NATURE, V317, P636, DOI 10.1038/317636a0; DYSON PJ, 1985, EMBO J, V4, P2885, DOI 10.1002/j.1460-2075.1985.tb04018.x; EISSENBERG JC, 1985, ANNU REV GENET, V19, P485, DOI 10.1146/annurev.genet.19.1.485; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; Favaloro J, 1980, Methods Enzymol, V65, P718; FEINBERG AP, 1983, NATURE, V301, P89, DOI 10.1038/301089a0; FEINBERG AP, 1983, BIOCHEM BIOPH RES CO, V111, P47, DOI 10.1016/S0006-291X(83)80115-6; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; Gluzman Y, 1980, Cold Spring Harb Symp Quant Biol, V44 Pt 1,, P293; GOELZ SE, 1985, SCIENCE, V228, P187, DOI 10.1126/science.2579435; HARDY KJ, 1985, P NATL ACAD SCI USA, V82, P8173, DOI 10.1073/pnas.82.23.8173; HARLOW E, 1985, MOL CELL BIOL, V5, P1601, DOI 10.1128/MCB.5.7.1601; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HARRIS N, 1986, MOL CELL BIOL, V6, P4650, DOI 10.1128/MCB.6.12.4650; JAY G, 1981, P NATL ACAD SCI-BIOL, V78, P2932, DOI 10.1073/pnas.78.5.2932; JENKINS JR, 1984, NATURE, V312, P651, DOI 10.1038/312651a0; KESHET I, 1986, CELL, V44, P535, DOI 10.1016/0092-8674(86)90263-1; KOEFFLER HP, 1984, BLOOD, V64, P482; KOEFFLER HP, 1986, P NATL ACAD SCI USA, V83, P4035, DOI 10.1073/pnas.83.11.4035; KOEFFLER HP, 1985, BLOOD, V65, P484; LAEMMLI UK, 1970, J MOL BIOL, V98, P680; LAMB P, 1986, MOL CELL BIOL, V6, P1379, DOI 10.1128/MCB.6.5.1379; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; LUBBERT M, 1988, J EXP MED, V167, P873, DOI 10.1084/jem.167.3.873; MERCER WE, 1982, P NATL ACAD SCI-BIOL, V79, P6309, DOI 10.1073/pnas.79.20.6309; MILLS FC, 1983, NATURE, V306, P809, DOI 10.1038/306809a0; MILNER J, 1984, NATURE, V310, P143, DOI 10.1038/310143a0; MILNER J, 1981, VIROLOGY, V112, P785, DOI 10.1016/0042-6822(81)90327-5; MIYOSHI I, 1981, NATURE, V294, P700; OREN M, 1981, MOL CELL BIOL, V1, P101, DOI 10.1128/MCB.1.2.101; OREN M, 1982, MOL CELL BIOL, V2, P443, DOI 10.1128/MCB.2.4.443; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; PONTE P, 1983, MOL CELL BIOL, V3, P1783, DOI 10.1128/MCB.3.10.1783; POPOVIC M, 1983, SCIENCE, V219, P856, DOI 10.1126/science.6600519; REED JC, 1986, P NATL ACAD SCI USA, V83, P3982, DOI 10.1073/pnas.83.11.3982; REICH NC, 1983, MOL CELL BIOL, V3, P2143, DOI 10.1128/MCB.3.12.2143; REICH NC, 1984, NATURE, V308, P199, DOI 10.1038/308199a0; ROTTER V, 1981, J VIROL, V38, P336, DOI 10.1128/JVI.38.1.336-346.1981; ROTTER V, 1983, P NATL ACAD SCI-BIOL, V80, P2613, DOI 10.1073/pnas.80.9.2613; ROVINSKI B, 1987, MOL CELL BIOL, V7, P847, DOI 10.1128/MCB.7.2.847; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SHIMADA T, 1985, J BIOL CHEM, V260, P2468; SIDELL N, 1988, CANCER RES, V48, P2226; SIEBENLIST U, 1984, CELL, V37, P381, DOI 10.1016/0092-8674(84)90368-4; STORB U, 1983, P NATL ACAD SCI-BIOL, V80, P6642, DOI 10.1073/pnas.80.21.6642; TRATNER I, 1987, MOL CELL BIOL, V7, P1856, DOI 10.1128/MCB.7.5.1856; VANDERPLOEG LHT, 1980, CELL, V19, P947, DOI 10.1016/0092-8674(80)90086-0; YAMAMOTO N, 1982, SCIENCE, V217, P737, DOI 10.1126/science.6980467; ZANTEMA A, 1985, MOL CELL BIOL, V5, P3084, DOI 10.1128/MCB.5.11.3084	60	31	31	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1989	4	5					643	651						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	U7688	2657579				2022-12-17	WOS:A1989U768800016
J	KAWAKAMI, Y; FURUE, M; KAWAKAMI, T				KAWAKAMI, Y; FURUE, M; KAWAKAMI, T			IDENTIFICATION OF FYN-ENCODED PROTEINS IN NORMAL HUMAN-BLOOD CELLS	ONCOGENE			English	Note									NCI,CELLULAR & MOLEC BIOL LAB,BETHESDA,MD 20892; NCI,DERMATOL BRANCH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Kawakami, Toshiaki/O-1616-2015					AZARNIA R, 1988, SCIENCE, V239, P398, DOI 10.1126/science.2447651; BARNEKOW A, 1986, EMBO J, V5, P701, DOI 10.1002/j.1460-2075.1986.tb04270.x; BISHOP JM, 1987, SCIENCE, V235, P305, DOI 10.1126/science.3541204; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; COTTON PC, 1983, MOL CELL BIOL, V3, P1157, DOI 10.1128/MCB.3.6.1157; FULTS DW, 1985, MOL CELL BIOL, V5, P27, DOI 10.1128/MCB.5.1.27; GILMORE TD, 1986, CELL, V44, P791, DOI 10.1016/0092-8674(86)90845-7; GOLDEN A, 1986, P NATL ACAD SCI USA, V83, P852, DOI 10.1073/pnas.83.4.852; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; HUNTER T, 1987, CELL, V50, P823, DOI 10.1016/0092-8674(87)90509-5; JACOBS C, 1983, CANCER RES, V43, P1696; JULIUS MH, 1973, EUR J IMMUNOL, V3, P645, DOI 10.1002/eji.1830031011; KAWAKAMI T, 1986, MOL CELL BIOL, V6, P4195, DOI 10.1128/MCB.6.12.4195; KAWAKAMI T, 1988, P NATL ACAD SCI USA, V85, P3870, DOI 10.1073/pnas.85.11.3870; KITAMURA N, 1982, NATURE, V297, P205, DOI 10.1038/297205a0; LEVY BT, 1984, DEV BIOL, V104, P9, DOI 10.1016/0012-1606(84)90031-9; Maniatis T., 1982, MOL CLONING; MARTH JD, 1988, NATURE, V332, P171, DOI 10.1038/332171a0; NAHARRO G, 1984, SCIENCE, V223, P63, DOI 10.1126/science.6318314; POPESCU NC, 1987, ONCOGENE, V1, P449; SEMBA K, 1986, P NATL ACAD SCI USA, V83, P5459, DOI 10.1073/pnas.83.15.5459; SORGE LK, 1984, CELL, V36, P249, DOI 10.1016/0092-8674(84)90218-6; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350	25	31	32	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1989	4	3					389	391						3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	U5676	2649850				2022-12-17	WOS:A1989U567600017
J	PORTELLA, G; FERULANO, G; SANTORO, M; GRIECO, M; FUSCO, A; VECCHIO, G				PORTELLA, G; FERULANO, G; SANTORO, M; GRIECO, M; FUSCO, A; VECCHIO, G			THE KIRSTEN MURINE SARCOMA-VIRUS INDUCES RAT-THYROID CARCINOMAS INVIVO	ONCOGENE			English	Article									FAC MED & CHIRURG CATANZARO,IST ONCOL CLIN & SPERIMENTALE,CATANZARO,ITALY; FAC MED & CHIRURG NAPOLI 2,DIPARTIMENTO BIOL & PATOL & CELLULARE & MOLEC,NAPOLI,ITALY; FAC MED & CHIRURG NAPOLI 2,IST CHIRURG GEN & SCI GASTROENTEROL,NAPOLI,ITALY	Magna Graecia University of Catanzaro; University of Naples Federico II; University of Naples Federico II	PORTELLA, G (corresponding author), FAC MED & CHIRURG NAPOLI 2,CNR,CTR ENDOCRINOL 8 ONCOL SPERIMENTALE,NAPOLI,ITALY.		Portella, Giuseppe/AFU-6826-2022	PORTELLA, Giuseppe/0000-0001-8276-9769; Fusco, Alfredo/0000-0003-3332-5197; Grieco, Michele/0000-0002-4212-7814				AARONSON SA, 1983, CANCER RES, V43, P1; ADAMS SL, 1977, P NATL ACAD SCI USA, V74, P3399, DOI 10.1073/pnas.74.8.3399; AMBESIIMPIOMBATO FS, 1980, P NATL ACAD SCI-BIOL, V77, P3455, DOI 10.1073/pnas.77.6.3455; AUERSPERG N, 1977, INT J CANCER, V19, P81, DOI 10.1002/ijc.2910190112; BALMAIN A, 1983, NATURE, V303, P72, DOI 10.1038/303072a0; BALMAIN A, 1984, NATURE, V307, P658, DOI 10.1038/307658a0; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BOS JL, 1987, NATURE, V327, P293, DOI 10.1038/327293a0; BROWN K, 1986, CELL, V46, P447, DOI 10.1016/0092-8674(86)90665-3; COLLETTA G, 1986, SCIENCE, V233, P458, DOI 10.1126/science.3726540; COLLETTA G, 1983, MOL CELL BIOL, V3, P2099, DOI 10.1128/MCB.3.11.2099; DER CJ, 1982, P NATL ACAD SCI-BIOL, V79, P3637, DOI 10.1073/pnas.79.11.3637; DILAURO R, 1982, GENE, V19, P117, DOI 10.1016/0378-1119(82)90196-2; ELLIS RW, 1981, NATURE, V292, P506, DOI 10.1038/292506a0; FURTH ME, 1982, J VIROL, V43, P294, DOI 10.1128/JVI.43.1.294-304.1982; FUSCO A, 1985, J VIROL, V56, P284, DOI 10.1128/JVI.56.1.284-292.1985; FUSCO A, 1982, CANCER RES, V42, P618; FUSCO A, 1987, NATURE, V328, P170, DOI 10.1038/328170a0; FUSCO A, 1987, MOL CELL BIOL, V7, P3365, DOI 10.1128/MCB.7.9.3365; KONIG MP, 1981, ADV THYROID NEOPLASI, P177; MACPHERSON I, 1964, VIROLOGY, V23, P291, DOI 10.1016/0042-6822(64)90301-0; Maniatis T., 1982, MOL CLONING; PULCIANI S, 1982, NATURE, V300, P539, DOI 10.1038/300539a0; ROWE WP, 1970, VIROLOGY, V42, P1136, DOI 10.1016/0042-6822(70)90362-4; ROYBURMAN P, 1975, J GEN VIROL, V28, P193, DOI 10.1099/0022-1317-28-2-193; SUAREZ HG, 1988, ONCOGENE, V2, P403; VARMUS HE, 1984, ANNU REV GENET, V18, P553; WEISS R, 1982, RNA TUMOR VIRUSES, P209; WOLLMAN SH, 1963, RECENT PROG HORM RES, V19, P579; YUSPA SH, 1985, NATURE, V314, P459, DOI 10.1038/314459a0	30	31	32	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1989	4	2					181	188						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	U5675	2538791				2022-12-17	WOS:A1989U567500009
J	WARD, JM; PERANTONI, AO; SANTOS, E				WARD, JM; PERANTONI, AO; SANTOS, E			COMPARATIVE IMMUNOHISTOCHEMICAL REACTIVITY OF MONOCLONAL AND POLYCLONAL ANTIBODIES TO H-RAS P21 IN NORMAL AND NEOPLASTIC TISSUES OF RODENTS AND HUMANS	ONCOGENE			English	Article									NIAID,MOLEC MICROBIOL LAB,BETHESDA,MD 20892; NCI,FREDERICK CANC RES FACIL,DIV CANC ETIOL,COMPARAT CARCINOGENESIS LAB,DEV BIOL WORKING GRP,FREDERICK,MD 21701	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	WARD, JM (corresponding author), NCI,FREDERICK CANC RES FACIL,TUMOR PATHOL & PATHOGENESIS SECT,BLDG 538,RM 205,FREDERICK,MD 21701, USA.				NCI NIH HHS [N01-CO-74102] Funding Source: Medline; OFFICE OF THE DIRECTOR, NCI [N01CO074102] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AGNANTIS NJ, 1986, ANTICANCER RES, V6, P1157; ALLEN DC, 1987, J CLIN PATHOL, V40, P157, DOI 10.1136/jcp.40.2.157; AOKI I, 1987, ACTA PATHOL JAPON, V37, P1903; AUGENLICHT LH, 1987, CANCER RES, V47, P3763; BACKER JM, 1986, P NATL ACAD SCI USA, V83, P6357, DOI 10.1073/pnas.83.17.6357; BACKER JM, 1986, BIOCHEM BIOPH RES CO, V135, P316, DOI 10.1016/0006-291X(86)90979-4; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BIZUB D, 1987, ONCOGENE, V1, P131; BOS JL, 1987, NATURE, V327, P293, DOI 10.1038/327293a0; BROWN K, 1986, CELL, V46, P447, DOI 10.1016/0092-8674(86)90665-3; CANDLISH W, 1986, J PATHOL, V150, P163, DOI 10.1002/path.1711500303; CARNEY WP, 1986, P NATL ACAD SCI USA, V83, P7485, DOI 10.1073/pnas.83.19.7485; CHESA PG, 1987, P NATL ACAD SCI USA, V84, P3234, DOI 10.1073/pnas.84.10.3234; CIOCCA DR, 1983, J HISTOCHEM CYTOCHEM, V31, P691, DOI 10.1177/31.5.6341459; CLAIR T, 1987, CANCER RES, V47, P5290; CLARK R, 1985, P NATL ACAD SCI USA, V82, P5280, DOI 10.1073/pnas.82.16.5280; CZERNIAK B, 1987, CANCER, V60, P2432, DOI 10.1002/1097-0142(19871115)60:10<2432::AID-CNCR2820601014>3.0.CO;2-1; CZERNIAK B, 1987, AM J PATHOL, V126, P411; EMBLETON MJ, 1988, BRIT J CANCER, V57, P48, DOI 10.1038/bjc.1988.7; FORRESTER K, 1987, NATURE, V327, P298, DOI 10.1038/327298a0; FROMOWITZ FB, 1987, HUM PATHOL, V18, P1268, DOI 10.1016/S0046-8177(87)80412-4; FUJITA J, 1988, J NATL CANCER I, V80, P37, DOI 10.1093/jnci/80.1.37; FURTH ME, 1987, ONCOGENE, V1, P47; FURTH ME, 1982, J VIROL, V43, P294, DOI 10.1128/JVI.43.1.294-304.1982; GALAND P, 1988, INT J CANCER, V41, P155, DOI 10.1002/ijc.2910410127; GALLICK GE, 1985, P NATL ACAD SCI USA, V82, P1795, DOI 10.1073/pnas.82.6.1795; GASTL G, 1986, IMMUNOCYTOCHEMISTRY, P273; GAY NJ, 1983, NATURE, V301, P262, DOI 10.1038/301262a0; GHOSH AK, 1986, J CLIN PATHOL, V39, P428, DOI 10.1136/jcp.39.4.428; HABIB NA, 1986, INT SURG, V71, P182; HAND PH, 1987, J NATL CANCER I, V79, P59; HAND PH, 1984, P NATL ACAD SCI-BIOL, V81, P5227, DOI 10.1073/pnas.81.16.5227; HAND PH, 1985, MONOCLONAL ANTIBODIE, V27, P23; JOHNSON TL, 1987, CANCER, V59, P107, DOI 10.1002/1097-0142(19870101)59:1<107::AID-CNCR2820590123>3.0.CO;2-U; JOHNSON TL, 1987, AM J PATHOL, V127, P60; KANAI T, 1987, JPN J CANCER RES, V78, P1314; KERR IB, 1985, BRIT J CANCER, V52, P695, DOI 10.1038/bjc.1985.245; KUZUMAKI N, 1986, J NATL CANCER I, V77, P1273; LACAL JC, 1984, P NATL ACAD SCI-BIOL, V81, P5305, DOI 10.1073/pnas.81.17.5305; LANZA G, 1988, HISTOPATHOLOGY, V12, P595, DOI 10.1111/j.1365-2559.1988.tb01984.x; LEE I, 1987, VIRCHOWS ARCH B, V53, P146, DOI 10.1007/BF02890237; LOKE SL, 1988, AM J PATHOL, V131, P29; LUNDY J, 1986, J CLIN ONCOL, V4, P1321, DOI 10.1200/JCO.1986.4.9.1321; MCKENZIE KJ, 1987, HUM PATHOL, V18, P1282, DOI 10.1016/S0046-8177(87)80414-8; MELTZER SJ, 1987, GASTROENTEROLOGY, V92, P1174, DOI 10.1016/S0016-5085(87)91074-2; MIZUKAMI Y, 1988, CANCER, V61, P873, DOI 10.1002/1097-0142(19880301)61:5<873::AID-CNCR2820610504>3.0.CO;2-W; MONNAT M, 1987, INT J CANCER, V40, P293, DOI 10.1002/ijc.2910400302; NONOMURA A, 1987, LIVER, V7, P142; NONOMURA A, 1987, AM J GASTROENTEROL, V82, P512; OHUCHI N, 1987, CANCER RES, V47, P1413; OHUCHI N, 1986, CANCER RES, V46, P2511; OLDSTONE MBA, 1987, CELL, V50, P819, DOI 10.1016/0092-8674(87)90507-1; PELLING JC, 1987, CARCINOGENESIS, V8, P1481, DOI 10.1093/carcin/8.10.1481; PULCIANI S, 1985, CELL, V48, P1023; QUAIFE CJ, 1987, CELL, V48, P1023, DOI 10.1016/0092-8674(87)90710-0; REYNOLDS SH, 1986, P NATL ACAD SCI USA, V83, P33, DOI 10.1073/pnas.83.1.33; RICHMOND RE, 1988, J HISTOCHEM CYTOCHEM, V36, P179, DOI 10.1177/36.2.3121722; ROBINSON A, 1986, BRIT J CANCER, V54, P877, DOI 10.1038/bjc.1986.256; RODENBURG CJ, 1988, ARCH PATHOL LAB MED, V112, P151; SAMOWITZ WS, 1988, LAB INVEST, V58, pA81; SAMOWITZ WS, 1988, HUM PATHOL, V19, P127, DOI 10.1016/S0046-8177(88)80339-3; SANTOS E, 1988, J BIOL CHEM, V263, P9853; SANTOS E, 1982, NATURE, V298, P243; SHIRATORI Y, 1987, CANCER RES, V47, P6806; SIGAL IS, 1986, P NATL ACAD SCI USA, V83, P4725, DOI 10.1073/pnas.83.13.4725; SORRENTINO V, 1989, IN PRESS ONCOGENE; SRINIVASAPPA J, 1986, J VIROL, V57, P397, DOI 10.1128/JVI.57.1.397-401.1986; STOWERS SJ, 1988, CARCINOGENESIS, V9, P271, DOI 10.1093/carcin/9.2.271; SUKUMAR S, 1986, MOL CELL BIOL, V6, P2716, DOI 10.1128/MCB.6.7.2716; TAHARA E, 1986, JPN J CANCER RES, V77, P517; TANAKA T, 1988, CANCER RES, V48, P1030; TANAKA T, 1986, MOL CELL BIOCHEM, V70, P97; TANAKA T, 1987, MOL CELL BIOCHEM, V75, P23, DOI 10.1007/BF00231605; TANAKA T, 1985, P NATL ACAD SCI USA, V82, P3400, DOI 10.1073/pnas.82.10.3400; TANAKA T, 1986, CANCER RES, V46, P1465; THOR A, 1986, LAB INVEST, V55, P603; THOR A, 1984, NATURE, V311, P562, DOI 10.1038/311562a0; TOKSOZ D, 1987, ONCOGENE, V1, P409; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; ULSH LS, 1984, MOL CELL BIOL, V4, P1647, DOI 10.1128/MCB.4.8.1647; VIOLA MV, 1985, J EXP MED, V161, P1213, DOI 10.1084/jem.161.5.1213; VIOLA MV, 1986, NEW ENGL J MED, V314, P133, DOI 10.1056/NEJM198601163140301; WARD JM, 1988, JPN J CANCER RES, V79, P152, DOI 10.1111/j.1349-7006.1988.tb01570.x; WARD JM, 1986, CARCINOGENESIS, V7, P645, DOI 10.1093/carcin/7.4.645; WILLIAMS ARW, 1985, BRIT J CANCER, V52, P687, DOI 10.1038/bjc.1985.244; WILLINGHAM MC, 1983, EXP CELL RES, V149, P141, DOI 10.1016/0014-4827(83)90387-7; WILLINGHAM MC, 1980, CELL, V19, P1005, DOI 10.1016/0092-8674(80)90091-4; WILSON MJ, 1986, FASEB J, V45, P1707; WONG G, 1986, CANCER RES, V46, P6029; YASUI W, 1987, ACTA PATHOL JAPON, V37, P1731; YOSHIDA K, 1988, CANCER RES, V48, P5503; ZARBL H, 1985, NATURE, V315, P382, DOI 10.1038/315382a0	92	31	32	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1989	4	2					203	213						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	U5675	2648257				2022-12-17	WOS:A1989U567500012
J	TENDIJKE, P; VANKESSEL, AHMG; FOULKES, JG; LEBEAU, MM				TENDIJKE, P; VANKESSEL, AHMG; FOULKES, JG; LEBEAU, MM			TRANSFORMING GROWTH-FACTOR TYPE-BETA-3 MAPS TO HUMAN CHROMOSOME-14, REGION Q23-Q24	ONCOGENE			English	Article									ONCOGENE SCI INC,350 COMMUN DR,MANHASSET,NY 11030; ERASMUS UNIV,DEPT CELL BIOL & GENET,3000 DR ROTTERDAM,NETHERLANDS; UNIV CHICAGO,JOINT SECT HEMATOL ONCOL,CHICAGO,IL 60637	Erasmus University Rotterdam; University of Chicago			Dijke, Peter ten/AAG-4660-2021; van Kessel, Ad Geurts/A-2810-2010	Dijke, Peter ten/0000-0002-7234-342X; 				ASSOIAN RK, 1983, J BIOL CHEM, V258, P7155; BARTON DE, 1987, CYTOGENET CELL GENET, V46, P578; BLOOMFIELD CD, 1987, CYTOGENET CELL GENET, V46, P344, DOI 10.1159/000132485; CATE RL, 1986, CELL, V45, P685, DOI 10.1016/0092-8674(86)90783-X; CHEIFETZ S, 1987, CELL, V48, P409, DOI 10.1016/0092-8674(87)90192-9; DEMARTIN R, 1987, EMBO J, V6, P3673, DOI 10.1002/j.1460-2075.1987.tb02700.x; DERYNCK R, 1986, J BIOL CHEM, V261, P4377; DERYNCK R, 1987, NUCLEIC ACIDS RES, V15, P3187, DOI 10.1093/nar/15.7.3187; DERYNCK R, 1985, NATURE, V316, P701, DOI 10.1038/316701a0; FUJII D, 1986, SOMAT CELL MOLEC GEN, V12, P281, DOI 10.1007/BF01570787; HANKS SK, 1988, P NATL ACAD SCI USA, V85, P79, DOI 10.1073/pnas.85.1.79; IKEDA T, 1987, BIOCHEMISTRY-US, V26, P2406, DOI 10.1021/bi00383a002; JAKOWLEW SB, 1988, MOL ENDOCRINOL, V2, P747, DOI 10.1210/mend-2-8-747; LEBEAU MM, 1984, NATURE, V312, P70, DOI 10.1038/312070a0; LING N, 1986, NATURE, V321, P779, DOI 10.1038/321779a0; MADISEN L, 1988, DNA-J MOLEC CELL BIO, V7, P1, DOI 10.1089/dna.1988.7.1; MANIATIS T, 1980, ANNU REV GENET, V14, P145, DOI 10.1146/annurev.ge.14.120180.001045; MASON AJ, 1985, NATURE, V318, P659, DOI 10.1038/318659a0; MASSAGUE J, 1987, CELL, V49, P437, DOI 10.1016/0092-8674(87)90443-0; NEDWIN GE, 1985, NUCLEIC ACIDS RES, V13, P6381; OHTA M, 1987, NATURE, V329, P539, DOI 10.1038/329539a0; OWERBACH D, 1981, P NATL ACAD SCI-BIOL, V78, P3123, DOI 10.1073/pnas.78.5.3123; ROPERS HH, 1987, CYTOGENET CELL GENET, V46, P243; ROSA F, 1988, SCIENCE, V239, P783, DOI 10.1126/science.3422517; SEYEDIN SM, 1986, J BIOL CHEM, V261, P5693; SEYEDIN SM, 1987, J BIOL CHEM, V262, P1946; SHARPLES K, 1987, DNA-J MOLEC CELL BIO, V6, P239, DOI 10.1089/dna.1987.6.239; SPORN MB, 1987, J CELL BIOL, V105, P1039, DOI 10.1083/jcb.105.3.1039; TENDIJKE P, 1988, P NATL ACAD SCI USA, V85, P4715; TENDIJKE P, 1988, IN PRESS BIOTECHNOLO; VANKESSEL AG, 1983, P NATL ACAD SCI USA, V80, P3728; VANOBBERGHENSCHILLING E, 1987, MOL ENDOCRINOL, V1, P693, DOI 10.1210/mend-1-10-693; WRANN M, 1987, EMBO J, V6, P1633, DOI 10.1002/j.1460-2075.1987.tb02411.x	33	31	33	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1988	3	6					721	724						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	R6460	2577876				2022-12-17	WOS:A1988R646000016
J	Qiu, YF; Yang, Y; Yang, RY; Liu, CX; Hsu, JM; Jiang, Z; Sun, LL; Wei, YK; Li, CW; Yu, DH; Zhang, J; Hung, MC				Qiu, Yufan; Yang, Yi; Yang, Riyao; Liu, Chunxiao; Hsu, Jung-Mao; Jiang, Zhou; Sun, Linlin; Wei, Yongkun; Li, Chia-Wei; Yu, Dihua; Zhang, Jin; Hung, Mien-Chie			Activated T cell-derived exosomal PD-1 attenuates PD-L1-induced immune dysfunction in triple-negative breast cancer	ONCOGENE			English	Article							TUMOR-INFILTRATING LYMPHOCYTES; EXTRACELLULAR VESICLES; EXPRESSION; BIOLOGY	Programmed cell death 1 (PD-1) is widely expressed in tumor-infiltrating lymphocytes (TILs) of triple-negative breast cancer (TNBC). As a dominant inhibitory immune checkpoint (ICP) receptor, cell surface PD-1 is well-known to transduce negative signaling of effector T cell activity during cell-cell contact. However, despite its well-documented inhibitory effects, higher PD-1 expression in TILs is significantly associated with longer survival in TNBC patients. This phenomenon raises an interesting question whether PD-1 harbors positive activity to enhance anti-tumor immunity. Here, we show that PD-1 is secreted in an exosomal form by activated T cells and can remotely interact with either cell surface or exosomal programmed death-ligand 1 (PD-L1), induce PD-L1 internalization via clathrin-mediated endocytosis, and thereby prevent subsequent cellular PD-L1: PD-1 interaction, restoring tumor surveillance through attenuating PD-L1-induced suppression of tumor-specific cytotoxic T cell activity. Our results, through revealing an anti-PD-L1 function of exosomal PD-1, provide a positive role to enhance cytotoxic T cell activity and a potential therapeutic strategy of modifying the exosome surface with membrane-bound inhibitory ICP receptors to attenuate the suppressive tumor immune microenvironment.	[Qiu, Yufan; Zhang, Jin] Tianjin Med Univ Canc Inst & Hosp, Treatment & Res Ctr, Dept Breast Canc Prevent 3, Tianjin, Peoples R China; [Qiu, Yufan; Zhang, Jin] Tianjin Med Univ Canc Inst & Hosp, Minist Educ, Key Lab Breast Canc Prevent & Therapy, Tianjin, Peoples R China; [Qiu, Yufan; Zhang, Jin] Tianjin Med Univ Canc Inst & Hosp, Tianjins Clin Res Ctr Canc, Tianjin, Peoples R China; [Qiu, Yufan; Zhang, Jin] Tianjin Med Univ Canc Inst & Hosp, Key Lab Canc Prevent & Therapy, Tianjin, Peoples R China; [Qiu, Yufan; Zhang, Jin] Tianjin Med Univ Canc Inst & Hosp, Natl Clin Res Ctr Canc, Tianjin, Peoples R China; [Qiu, Yufan; Yang, Yi; Yang, Riyao; Liu, Chunxiao; Hsu, Jung-Mao; Jiang, Zhou; Sun, Linlin; Wei, Yongkun; Li, Chia-Wei; Yu, Dihua; Hung, Mien-Chie] Univ Texas MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA; [Qiu, Yufan; Zhang, Jin] Tianjin Med Univ, Tianjin, Peoples R China; [Yang, Yi] Third Mil Med Univ, Southwest Hosp, Inst Pathol & Southwest Canc Ctr, Army Med Univ, Chongqing, Peoples R China; [Hsu, Jung-Mao; Hung, Mien-Chie] China Med Univ, Grad Inst Biomed Sci & Res Ctr Mol Med, Taichung 406, Taiwan; [Sun, Linlin] Tianjin Med Univ Gen Hosp, Lung Canc Inst, Tianjin Key Lab Lung Canc Metastasis & Tumor Micr, Tianjin, Peoples R China; [Li, Chia-Wei] Acad Sinica, Inst Biomed Sci, Taipei, Taiwan; [Hung, Mien-Chie] Asia Univ, Dept Biotechnol, Taichung 413, Taiwan	Tianjin Medical University; Tianjin Medical University; Tianjin Medical University; Tianjin Medical University; Tianjin Medical University; University of Texas System; UTMD Anderson Cancer Center; Tianjin Medical University; Army Medical University; China Medical University Taiwan; Tianjin Medical University; Academia Sinica - Taiwan; Asia University Taiwan	Zhang, J (corresponding author), Tianjin Med Univ Canc Inst & Hosp, Treatment & Res Ctr, Dept Breast Canc Prevent 3, Tianjin, Peoples R China.; Zhang, J (corresponding author), Tianjin Med Univ Canc Inst & Hosp, Minist Educ, Key Lab Breast Canc Prevent & Therapy, Tianjin, Peoples R China.; Zhang, J (corresponding author), Tianjin Med Univ Canc Inst & Hosp, Tianjins Clin Res Ctr Canc, Tianjin, Peoples R China.; Zhang, J (corresponding author), Tianjin Med Univ Canc Inst & Hosp, Key Lab Canc Prevent & Therapy, Tianjin, Peoples R China.; Zhang, J (corresponding author), Tianjin Med Univ Canc Inst & Hosp, Natl Clin Res Ctr Canc, Tianjin, Peoples R China.; Hung, MC (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA.; Zhang, J (corresponding author), Tianjin Med Univ, Tianjin, Peoples R China.; Hung, MC (corresponding author), China Med Univ, Grad Inst Biomed Sci & Res Ctr Mol Med, Taichung 406, Taiwan.; Hung, MC (corresponding author), Asia Univ, Dept Biotechnol, Taichung 413, Taiwan.	zhangjin@tjmuch.com; mhung@cmu.edu.tw	Hsu, Jung-Mao/AAC-9527-2019; Jiang, Zhou/ABF-2435-2021; Li, Chia-Wei/AAC-8660-2019; Hung, Mien-Chie/ABD-5911-2021; Yang, Riyao/R-7593-2019	Jiang, Zhou/0000-0003-4247-2949; Li, Chia-Wei/0000-0002-2531-2866; Hung, Mien-Chie/0000-0003-4317-4740; Yang, Riyao/0000-0002-0278-4385; Qiu, Yufan/0000-0002-6791-9957	National Institutes of Health CCSG [CA016672]; Cancer Prevention and Research Institute of Texas [RP160710]; MD Anderson-China Medical University Sister Institution Fund; Ministry of Science and Technology in Taiwan [MOST 109-2327-B-039-003, MOST 109-2314-B-001-008]; Patel Memorial Breast Cancer Endowment Fund; National Natural Science Foundation of China [81672623]; Science and Technology Support Program of Tianjin, China [19YFZCSY0030]; China Scholarship Council [201906940042]	National Institutes of Health CCSG(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Cancer Prevention and Research Institute of Texas; MD Anderson-China Medical University Sister Institution Fund; Ministry of Science and Technology in Taiwan(Ministry of Science and Technology, Taiwan); Patel Memorial Breast Cancer Endowment Fund; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Science and Technology Support Program of Tianjin, China; China Scholarship Council(China Scholarship Council)	This work was funded in part by the following: grants from the National Institutes of Health CCSG CA016672; Cancer Prevention and Research Institute of Texas (RP160710); The MD Anderson-China Medical University Sister Institution Fund; Ministry of Science and Technology in Taiwan (MOST 109-2327-B-039-003 to MCH, MOST 109-2314-B-001-008 to CWL); Patel Memorial Breast Cancer Endowment Fund; The National Natural Science Foundation of China (No. 81672623); The Science and Technology Support Program of Tianjin, China (No. 19YFZCSY0030); The China Scholarship Council Award to YQ (No. 201906940042). We would like to thank the scientific editors in the Research Medical Library at MD Anderson Cancer Center for editorial assistance.	Bastos N, 2018, SEMIN CELL DEV BIOL, V78, P13, DOI 10.1016/j.semcdb.2017.08.009; Beit-Yannai E, 2018, J CELL MOL MED, V22, P2001, DOI 10.1111/jcmm.13479; Blanchard N, 2002, J IMMUNOL, V168, P3235, DOI 10.4049/jimmunol.168.7.3235; Burugu S, 2017, ANN ONCOL, V28, P2977, DOI 10.1093/annonc/mdx557; Burugu S, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2018.1502128; Calvo V, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21072631; Chen L, 2019, MED SCI MONITOR, V25, P4877, DOI 10.12659/MSM.917058; Datar I, 2019, CLIN CANCER RES, V25, P4663, DOI 10.1158/1078-0432.CCR-18-4142; Diskin B, 2020, NAT IMMUNOL, V21, P442, DOI 10.1038/s41590-020-0620-x; Dong HD, 2002, NAT MED, V8, P793, DOI 10.1038/nm730; Fernandez-Poma SM, 2017, CANCER RES, V77, P3672, DOI 10.1158/0008-5472.CAN-17-0236; Freeman GJ, 2000, J EXP MED, V192, P1027, DOI 10.1084/jem.192.7.1027; Gros A, 2014, J CLIN INVEST, V124, P2246, DOI [10.1172/JC173639, 10.1172/JCI73639]; Gutierrez-Vazquez C, 2013, IMMUNOL REV, V251, P125, DOI 10.1111/imr.12013; Ha D, 2016, ACTA PHARM SIN B, V6, P287, DOI 10.1016/j.apsb.2016.02.001; Harano K, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0204513; Kalluri R, 2020, SCIENCE, V367, P640, DOI 10.1126/science.aau6977; Kalluri R, 2016, J CLIN INVEST, V126, P1208, DOI 10.1172/JCI81135; Latchman YE, 2004, P NATL ACAD SCI USA, V101, P10691, DOI 10.1073/pnas.0307252101; Lehmann BD, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0157368; Li CL, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12574; Liu CX, 2021, J HEPATOL, V74, P907, DOI 10.1016/j.jhep.2020.09.030; Loi S, 2014, ANN ONCOL, V25, P1544, DOI 10.1093/annonc/mdu112; Lotvall J, 2014, J EXTRACELL VESICLES, V3, DOI 10.3402/jev.v3.26913; Lu J, 2018, IMMUNOL RES, V66, P313, DOI 10.1007/s12026-018-9000-0; Luan X, 2017, ACTA PHARMACOL SIN, V38, P754, DOI 10.1038/aps.2017.12; Maia J, 2018, FRONT CELL DEV BIOL, V6, DOI 10.3389/fcell.2018.00018; Pardoll D, 2015, SEMIN ONCOL, V42, P523, DOI 10.1053/j.seminoncol.2015.05.003; Pardoll DM, 2012, NAT REV CANCER, V12, P252, DOI 10.1038/nrc3239; Pegtel DM, 2019, ANNU REV BIOCHEM, V88, P487, DOI 10.1146/annurev-biochem-013118-111902; Poggio M, 2019, CELL, V177, P414, DOI 10.1016/j.cell.2019.02.016; Pruneri G, 2016, ANN ONCOL, V27, P249, DOI 10.1093/annonc/mdv571; Ren XY, 2018, CANCER BIOL THER, V19, P373, DOI 10.1080/15384047.2018.1423919; Ruivo CF, 2017, CANCER RES, V77, P6480, DOI 10.1158/0008-5472.CAN-17-0994; Seo N, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-02865-1; Sharma P, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-019-56542-4; Theodoraki MN, 2018, CLIN CANCER RES, V24, P896, DOI 10.1158/1078-0432.CCR-17-2664; Thery Clotilde, 2006, Curr Protoc Cell Biol, VChapter 3, DOI 10.1002/0471143030.cb0322s30; Tucci M, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2017.1387706; Vader P, 2016, ADV DRUG DELIVER REV, V106, P148, DOI 10.1016/j.addr.2016.02.006; Ventimiglia LN, 2016, FRONT CELL DEV BIOL, V4, DOI 10.3389/fcell.2016.00084; Wang JL, 2014, MOL MED REP, V9, P125, DOI 10.3892/mmr.2013.1759; Wang XC, 2019, J MED GENET, V56, P29, DOI 10.1136/jmedgenet-2018-105439; Whiteside TL, 2016, J CLIN INVEST, V126, P1216, DOI 10.1172/JCI81136; Xie FT, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1074-3; Yang JT, 2019, BIOMED RES INT, V2019, DOI 10.1155/2019/6387924; Yang RY, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-21099-2; Yeong J, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0499-y	48	30	31	10	28	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 5	2021	40	31					4992	5001		10.1038/s41388-021-01896-1	http://dx.doi.org/10.1038/s41388-021-01896-1		JUN 2021	10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TV5MG	34172932	hybrid, Green Published			2022-12-17	WOS:000667016100002
J	Lequeux, A; Noman, MZ; Xiao, MLN; Van Moer, K; Hasmim, M; Benoit, A; Bosseler, M; Viry, E; Arakelian, T; Berchem, G; Chouaib, S; Janji, B				Lequeux, Audrey; Noman, Muhammad Zaeem; Xiao, Malina; Van Moer, Kris; Hasmim, Meriem; Benoit, Alice; Bosseler, Manon; Viry, Elodie; Arakelian, Tsolere; Berchem, Guy; Chouaib, Salem; Janji, Bassam			Targeting HIF-1 alpha transcriptional activity drives cytotoxic immune effector cells into melanoma and improves combination immunotherapy	ONCOGENE			English	Article							HYPOXIA; SUSCEPTIBILITY; OPPORTUNITIES; AUTOPHAGY; THERAPY; BIOLOGY; GROWTH; LYSIS	Hypoxia is a key factor responsible for the failure of therapeutic response in most solid tumors and promotes the acquisition of tumor resistance to various antitumor immune effectors. Reshaping the hypoxic immune suppressive tumor microenvironment to improve cancer immunotherapy is still a relevant challenge. We investigated the impact of inhibiting HIF-1 alpha transcriptional activity on cytotoxic immune cell infiltration into B16-F10 melanoma. We showed that tumors expressing a deleted form of HIF-1 alpha displayed increased levels of NK and CD8(+) effector T cells in the tumor microenvironment, which was associated with high levels of CCL2 and CCL5 chemokines. We showed that combining acriflavine, reported as a pharmacological agent preventing HIF-1 alpha/HIF-1 beta dimerization, dramatically improved the benefit of cancer immunotherapy based on TRP-2 peptide vaccination and anti-PD-1 blocking antibody. In melanoma patients, we revealed that tumors exhibiting high CCL5 are less hypoxic, and displayed high NK, CD3(+), CD4(+) and CD8(+) T cell markers than those having low CCL5. In addition, melanoma patients with high CCL5 in their tumors survive better than those having low CCL5. This study provides the pre-clinical proof of concept for a novel triple combination strategy including blocking HIF-1 alpha transcription activity along vaccination and PD-1 blocking immunotherapy.	[Lequeux, Audrey; Noman, Muhammad Zaeem; Xiao, Malina; Van Moer, Kris; Hasmim, Meriem; Benoit, Alice; Bosseler, Manon; Viry, Elodie; Arakelian, Tsolere; Berchem, Guy; Janji, Bassam] Luxembourg Inst Hlth LIH, Dept Oncol, Tumor Immunotherapy & Microenvironm TIME Grp, Luxembourg, Luxembourg; [Berchem, Guy] Ctr Hosp Luxembourg, Dept Hematooncol, Luxembourg, Luxembourg; [Chouaib, Salem] Gustave Roussy, Integrat Tumor Immunol & Genet Oncol, INSERM, UMR 1186, Villejuif, France; [Chouaib, Salem] Gulf Med Univ, Thumbay Res Inst Precis Med, Ajman, U Arab Emirates	Luxembourg Institute of Health; Luxembourg Hospital Center; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; UNICANCER; Gustave Roussy	Janji, B (corresponding author), Luxembourg Inst Hlth LIH, Dept Oncol, Tumor Immunotherapy & Microenvironm TIME Grp, Luxembourg, Luxembourg.	bassam.janji@lih.lu	Berchem, Guy/C-9364-2014	Berchem, Guy/0000-0003-0157-2257; Arakelian, Tsolere/0000-0002-0079-9268	Luxembourg Institute of Health; FNRS Televie [7.4535.16, 7.6505.18, 7.4606.18]; Luxembourg National Research Fund [C18/BM/12670304/COMBATIC, PRIDE15/10675146/CANBIO]; Fondation Cancer, Luxembourg [FC/2018/06]; Kriibskrank Kanner Foundation, Luxembourg (2019); Janssen Cilag Pharma; Roche Pharma, Action LIONS Vaincre le Cancer Luxembourg; Sheik Hamdan Bin Rashid Al Maktoum Foundation, United Arab Emirates	Luxembourg Institute of Health; FNRS Televie(Fonds de la Recherche Scientifique - FNRS); Luxembourg National Research Fund(Luxembourg National Research Fund); Fondation Cancer, Luxembourg; Kriibskrank Kanner Foundation, Luxembourg (2019); Janssen Cilag Pharma; Roche Pharma, Action LIONS Vaincre le Cancer Luxembourg; Sheik Hamdan Bin Rashid Al Maktoum Foundation, United Arab Emirates	We thank Dr Anne Largeot from Tumor Stroma interactions group (Luxembourg Institute of Health) for her technical assistance. This work was supported by Luxembourg Institute of Health and grants from FNRS Televie (grants 7.4535.16, 7.6505.18 and no7.4606.18); Luxembourg National Research Fund (C18/BM/12670304/COMBATIC and PRIDE15/10675146/CANBIO); Fondation Cancer, Luxembourg (FC/2018/06); Kriibskrank Kanner Foundation, Luxembourg (2019); Janssen Cilag Pharma; Roche Pharma, Action LIONS Vaincre le Cancer Luxembourg and Sheik Hamdan Bin Rashid Al Maktoum Foundation, United Arab Emirates.	Baginska J, 2013, P NATL ACAD SCI USA, V110, P17450, DOI 10.1073/pnas.1304790110; Barsoum IB, 2014, CANCER RES, V74, P665, DOI 10.1158/0008-5472.CAN-13-0992; Berchem G, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2015.1062968; BOTTAZZI B, 1992, J IMMUNOL, V148, P1280; Brown CE, 2007, J IMMUNOL, V179, P3332, DOI 10.4049/jimmunol.179.5.3332; Burke JD, 2019, SEMIN IMMUNOL, V43, DOI 10.1016/j.smim.2019.05.002; Chouaib S, 2017, ONCOGENE, V36, P439, DOI 10.1038/onc.2016.225; Colliez F, 2017, FRONT ONCOL, V7, DOI 10.3389/fonc.2017.00010; Deng J, 2019, CANCER IMMUNOL RES, V7, P1079, DOI 10.1158/2326-6066.CIR-18-0507; Hugo W, 2016, CELL, V165, P35, DOI 10.1016/j.cell.2016.02.065; Jayaprakash P, 2018, J CLIN INVEST, V128, P5137, DOI 10.1172/JCI96268; Lee K, 2009, P NATL ACAD SCI USA, V106, P17910, DOI 10.1073/pnas.0909353106; Lequeux A, 2019, CANCER LETT, V458, P13, DOI 10.1016/j.canlet.2019.05.021; McKeown SR, 2014, BRIT J RADIOL, V87, DOI 10.1259/bjr.20130676; Messai Y, 2016, EUR UROL, V70, P623, DOI 10.1016/j.eururo.2015.11.029; Noman MZ, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aax7881; Noman MZ, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8091083; Noman MZ, 2014, J EXP MED, V211, P781, DOI 10.1084/jem.20131916; Noman MZ, 2012, CANCER RES, V72, P4629, DOI 10.1158/0008-5472.CAN-12-1383; Noman MZ, 2011, CANCER RES, V71, P5976, DOI 10.1158/0008-5472.CAN-11-1094; Scharping NE, 2017, CANCER IMMUNOL RES, V5, P9, DOI 10.1158/2326-6066.CIR-16-0103; Scholz CC, 2013, CURR OPIN PHARMACOL, V13, P646, DOI 10.1016/j.coph.2013.04.009; Semenza GL, 2010, ONCOGENE, V29, P625, DOI 10.1038/onc.2009.441; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Semenza GL, 2012, TRENDS PHARMACOL SCI, V33, P207, DOI 10.1016/j.tips.2012.01.005; Shannon AM, 2003, CANCER TREAT REV, V29, P297, DOI 10.1016/S0305-7372(03)00003-3; Span PN, 2015, SEMIN NUCL MED, V45, P101, DOI 10.1053/j.semnuclmed.2014.10.002; Stathopoulos GT, 2008, JNCI-J NATL CANCER I, V100, P1464, DOI 10.1093/jnci/djn325; Zhang HF, 2008, P NATL ACAD SCI USA, V105, P19579, DOI 10.1073/pnas.0809763105; Zhang HM, 2015, P NATL ACAD SCI USA, V112, pE6215, DOI 10.1073/pnas.1520032112	30	30	31	2	12	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 15	2021	40	28					4725	4735		10.1038/s41388-021-01846-x	http://dx.doi.org/10.1038/s41388-021-01846-x		JUN 2021	11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TK8LG	34155342	hybrid, Green Published			2022-12-17	WOS:000664006400003
J	Zhu, YZ; Dalrymple, SL; Coleman, I; Zheng, SL; Xu, JF; Hooper, JE; Antonarakis, ES; De Marzo, AM; Meeker, AK; Nelson, PS; Isaacs, WB; Denmeade, SR; Luo, J; Brennen, WN; Isaacs, JT				Zhu, Yezi; Dalrymple, Susan L.; Coleman, Ilsa; Zheng, S. Lilly; Xu, Jianfeng; Hooper, Jody E.; Antonarakis, Emmanuel S.; De Marzo, Angelo M.; Meeker, Alan K.; Nelson, Peter S.; Isaacs, William B.; Denmeade, Samuel R.; Luo, Jun; Brennen, W. Nathaniel; Isaacs, John T.			Role of androgen receptor splice variant-7 (AR-V7) in prostate cancer resistance to 2nd-generation androgen receptor signaling inhibitors	ONCOGENE			English	Article							ABIRATERONE; THERAPY; GROWTH; GENE; ENZALUTAMIDE; ANTIANDROGEN; PROGRESSION; EXPRESSION; APOPTOSIS; INDUCE	The role of truncated androgen receptor splice variant-7 (AR-V7) in prostate cancer biology is an unresolved question. Is it simply a marker of resistance to 2nd-generation androgen receptor signaling inhibitors (ARSi) like abiraterone acetate (Abi) and enzalutamide (Enza) or a functional driver of lethal resistance via its ligand-independent transcriptional activity? To resolve this question, the correlation between resistance to ARSi and genetic chances and expression of full length AR (AR-FL) vs. AR-V7 were evaluated in a series of independent patient-derived xenografts (PDXs). While all PDXs lack PTEN expression, there is no consistent requirement for mutation inTP53, RB1, BRCA2, PIK3CA, or MSH2, or expression of SOX2 or ERG and ARSi resistance. Elevated expression of AR-FL alone is sufficient for Abi but not Enza resistance, even if AR-FL is gain-of-function (GOF) mutated. Enza resistance is consistently correlated with enhanced AR-V7 expression. In vitro and in vivo growth responses of Abi-/Enza-resistant LNCaP-95 cells in which CRISPR-Cas9 was used to knockout AR-FL or AR-V7 alone or in combination were evaluated. Combining these growth responses with RNAseq analysis demonstrates that both AR-FL- and AR-V7-dependent transcriptional complementation are needed for Abi/Enza resistance.	[Zhu, Yezi; Antonarakis, Emmanuel S.; De Marzo, Angelo M.; Meeker, Alan K.; Isaacs, William B.; Denmeade, Samuel R.; Luo, Jun; Brennen, W. Nathaniel; Isaacs, John T.] Johns Hopkins Univ, Sch Med, James Buchanan Brady Urol Inst, Dept Urol, Baltimore, MD 21205 USA; [Dalrymple, Susan L.; Antonarakis, Emmanuel S.; De Marzo, Angelo M.; Meeker, Alan K.; Isaacs, William B.; Denmeade, Samuel R.; Luo, Jun; Brennen, W. Nathaniel; Isaacs, John T.] Johns Hopkins Univ, Sch Med, Sidney Kimmel Comprehens Canc Ctr SKCCC, Dept Oncol, Baltimore, MD 21205 USA; [Coleman, Ilsa] Fred Hutchinson Canc Res Ctr, Div Human Biol, Seattle, WA 98109 USA; [Zheng, S. Lilly; Xu, Jianfeng] North Shore Univ Hlth Syst, Program Personalized Canc Care, Evanston, IL USA; [Hooper, Jody E.; De Marzo, Angelo M.; Meeker, Alan K.] Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21205 USA; [Nelson, Peter S.] Univ Washington, Dept Med & Urol, Seattle, WA 98195 USA	Johns Hopkins University; Johns Hopkins University; Fred Hutchinson Cancer Center; Johns Hopkins University; University of Washington; University of Washington Seattle	Isaacs, JT (corresponding author), Johns Hopkins Univ, Sch Med, James Buchanan Brady Urol Inst, Dept Urol, Baltimore, MD 21205 USA.; Isaacs, JT (corresponding author), Johns Hopkins Univ, Sch Med, Sidney Kimmel Comprehens Canc Ctr SKCCC, Dept Oncol, Baltimore, MD 21205 USA.	isaacjo@jhmi.edu		, Jody/0000-0002-8209-3559	Department of Defense Prostate Cancer Research Program [W81XWH1810349, W81XWH-17-1-0528, W81XWH-18-2-0015]; NIH Prostate SPOREs [P50 CA058236]; Pathology Core from the Prostate SPORE [P50 CA058236, P50 CA097186, W81XWH-18-1-0347, P01 CA163227]; Emerson Collective Cancer Research Fund [643396]; Allegheny Health Network-Johns Hopkins University Cancer Research Fund [R01 CA185297]; SKCCC CCSG [P30 CA006973]	Department of Defense Prostate Cancer Research Program(United States Department of Defense); NIH Prostate SPOREs(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Pathology Core from the Prostate SPORE; Emerson Collective Cancer Research Fund; Allegheny Health Network-Johns Hopkins University Cancer Research Fund; SKCCC CCSG	We are grateful to the patients and their families who participated in the Legacy Gift Rapid Autopsy program at Hopkins. We would like to acknowledge the Department of Defense Prostate Cancer Research Program W81XWH1810349 (JTI), W81XWH-17-1-0528 (WNB), W81XWH-18-2-0015 (AMM) and NIH Prostate SPOREs P50 CA058236 (JTI), Pathology Core from the Prostate SPORE P50 CA058236 (AMM) and P50 CA097186 (PSN), W81XWH-18-1-0347 (PSN), P01 CA163227 (PSN), Emerson Collective Cancer Research Fund [643396, (WNB)], Allegheny Health Network-Johns Hopkins University Cancer Research Fund (WNB), R01 CA185297 (JL and ESA). Also, we wish to thank the Cell Imaging Facility, Animal Core Facility, Tissue Histology Core, Genetic Resource Core, Cytogenetics Core Facility, and the Autopsy Core from the CCSG Grant supported by the SKCCC CCSG (P30 CA006973) for their services and assistance.	Ajiboye AS, 2017, PROSTATE, V77, P829, DOI 10.1002/pros.23323; Antonarakis ES, 2014, NEW ENGL J MED, V371, P1028, DOI 10.1056/NEJMoa1315815; Bellur S, 2019, HUM PATHOL, V85, P313, DOI 10.1016/j.humpath.2018.11.016; BERCHEM GJ, 1995, CANCER RES, V55, P735; Chen CD, 2004, NAT MED, V10, P33, DOI 10.1038/nm972; Chen EJ, 2015, CLIN CANCER RES, V21, P1273, DOI 10.1158/1078-0432.CCR-14-1220; Dehm SM, 2008, CANCER RES, V68, P5469, DOI 10.1158/0008-5472.CAN-08-0594; Esquenet M, 1997, J STEROID BIOCHEM, V62, P391, DOI 10.1016/S0960-0760(97)00054-X; Guo YP, 1999, CANCER RES, V59, P1366; Guo ZY, 2009, CANCER RES, V69, P2305, DOI 10.1158/0008-5472.CAN-08-3795; HOROSZEWICZ JS, 1983, CANCER RES, V43, P1809; Hu R, 2012, CANCER RES, V72, P3457, DOI 10.1158/0008-5472.CAN-11-3892; Hu R, 2009, CANCER RES, V69, P16, DOI 10.1158/0008-5472.CAN-08-2764; Huang YT, 2021, ASIAN J CONTROL, V23, P1693, DOI 10.1002/asjc.2326; Isaacs JT, 2018, AM J CLIN EXP UROL, V6, P55; Isaacs JT, 2012, PROSTATE, V72, P1491, DOI 10.1002/pros.22504; JENSTER G, 1993, BIOCHEM J, V293, P761, DOI 10.1042/bj2930761; Karan D, 2001, CLIN CANCER RES, V7, P3472; Kurita T, 2001, CELL DEATH DIFFER, V8, P192, DOI 10.1038/sj.cdd.4400797; KYPRIANOU N, 1990, CANCER RES, V50, P3748; Lam HM, 2017, CLIN CANCER RES, V23, P2301, DOI 10.1158/1078-0432.CCR-16-2054; Leach FS, 2000, J UROLOGY, V164, P1830, DOI 10.1016/S0022-5347(05)67115-7; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Li YM, 2013, CANCER RES, V73, P483, DOI 10.1158/0008-5472.CAN-12-3630; Lin XH, 2001, AM J PATHOL, V159, P1815, DOI 10.1016/S0002-9440(10)63028-3; Litvinov IV, 2003, J CLIN ENDOCR METAB, V88, P2972, DOI 10.1210/jc.2002-022038; Liu LL, 2014, ONCOGENE, V33, P3140, DOI 10.1038/onc.2013.284; Lu CX, 2020, PROSTATE CANCER P D, V23, P381, DOI 10.1038/s41391-020-0217-3; Moll JM, 2019, PROSTATE, V79, P937, DOI 10.1002/pros.23799; Mostaghel EA, 2019, CLIN CANCER RES, V25, P426, DOI 10.1158/1078-0432.CCR-18-1431; Mostaghel EA, 2017, CLIN CANCER RES, V23, P4592, DOI 10.1158/1078-0432.CCR-16-2245; Naidu C Kumaraswamy, 2016, Asian Pac J Cancer Prev, V17, P2199; Pflug BR, 1999, PROSTATE, V40, P269, DOI 10.1002/(SICI)1097-0045(19990901)40:4<269::AID-PROS9>3.0.CO;2-6; Quigley DA, 2018, CELL, V174, P758, DOI 10.1016/j.cell.2018.06.039; Sedelaar JPM, 2009, PROSTATE, V69, P1724, DOI 10.1002/pros.21028; Sharp A, 2016, CLIN CANCER RES, V22, P4280, DOI 10.1158/1078-0432.CCR-16-1137; Takeda DY, 2018, CELL, V174, P422, DOI 10.1016/j.cell.2018.05.037; Tan J, 1997, MOL ENDOCRINOL, V11, P450, DOI 10.1210/me.11.4.450; Teply BA, 2018, LANCET ONCOL, V19, P76, DOI 10.1016/S1470-2045(17)30906-3; Tombal B, 2002, CELL DEATH DIFFER, V9, P561, DOI 10.1038/sj.cdd.4400999; Tran C, 2009, SCIENCE, V324, P787, DOI 10.1126/science.1168175; Vander Griend DJ, 2010, PROSTATE, V70, P90, DOI 10.1002/pros.21043; VELDSCHOLTE J, 1990, BIOCHEM BIOPH RES CO, V173, P534, DOI 10.1016/S0006-291X(05)80067-1; VISAKORPI T, 1995, NAT GENET, V9, P401, DOI 10.1038/ng0495-401; Viswanathan SR, 2018, CELL, V174, P433, DOI 10.1016/j.cell.2018.05.036; Yang YC, 2016, CLIN CANCER RES, V22, P4466, DOI 10.1158/1078-0432.CCR-15-2901; Zhang Q, 2005, MOL ENDOCRINOL, V19, P2390, DOI 10.1210/me.2005-0096	47	30	30	2	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 5	2020	39	45					6935	6949		10.1038/s41388-020-01479-6	http://dx.doi.org/10.1038/s41388-020-01479-6		SEP 2020	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ON7IM	32989253	Green Accepted			2022-12-17	WOS:000573446900002
J	Tian, YR; Ma, RR; Sun, YJ; Liu, HT; Zhang, H; Sun, YY; Liu, L; Li, YH; Song, L; Gao, P				Tian, Yaru; Ma, Ranran; Sun, Yujing; Liu, Haiting; Zhang, Hui; Sun, Yiyuan; Liu, Lei; Li, Yuhong; Song, Lin; Gao, Peng			SP1-activated long noncoding RNA lncRNA GCMA functions as a competing endogenous RNA to promote tumor metastasis by sponging miR-124 and miR-34a in gastric cancer	ONCOGENE			English	Article							MESENCHYMAL TRANSITIONS; RESISTANCE; CARCINOMA; INSIGHTS; SNAIL; EMT	Long noncoding RNAs (lncRNAs) were demonstrated to play important roles in gene regulation and cancer progression. However, the functional roles of lncRNAs and the detailed mechanisms underlying gastric cancer (GC) progression remain largely unclear. Here, we identified a novel cancer-related lncRNA, termed lncRNA GCMA (Gastric Cancer metastasis-associated lncRNA), which was upregulated in GC tissues with lymph node metastasis (LNM) compared with tissues without LNM. High expression of GCMA was significantly associated with poor prognosis of patients with GC. Luciferase assays, bioinformatics analyses and chromatin immunoprecipitation (ChIP) assays indicated that SP1 transcription factor directly bound to the GCMA promoter region and activated its transcription. Functionally, upregulation of GCMA dramatically promoted GC cells proliferation, migration and invasion in vitro, whereas knockdown of GCMA elicited the opposite function. Consistently, stable knockdown of GCMA inhibited tumor proliferation, invasion and metastasis in vivo. Mechanistically, by using bioinformatics analyses, RNA binding protein immunoprecipitation (RIP) assays, luciferase assays and western-blot assays, GCMA was demonstrated to function as a competing endogenous RNA (ceRNA) via competitively absorbing miR-124 and miR-34a to upregulate slug and snail, thereby induced epithelial-mesenchymal transition (EMT) and GC cell metastasis in vitro and in vivo. Collectively, these results demonstrate that GCMA functions as an oncogenic lncRNA that may serve as a potential prognostic biomarker for GC and shed new lights on targeted therapy of GC in the future.	[Tian, Yaru; Ma, Ranran; Sun, Yujing; Liu, Haiting; Zhang, Hui; Sun, Yiyuan; Liu, Lei; Li, Yuhong; Song, Lin; Gao, Peng] Shandong Univ, Cheeloo Coll Med, Minist Educ, Key Lab Expt Teratol, Jinan, Peoples R China; [Tian, Yaru; Ma, Ranran; Sun, Yujing; Liu, Haiting; Zhang, Hui; Sun, Yiyuan; Liu, Lei; Li, Yuhong; Song, Lin; Gao, Peng] Shandong Univ, Cheeloo Coll Med, Dept Pathol, Sch Basic Med Sci, Jinan, Peoples R China; [Ma, Ranran; Sun, Yujing; Liu, Haiting; Zhang, Hui; Sun, Yiyuan; Liu, Lei; Gao, Peng] Shandong Univ, Cheeloo Coll Med, Qilu Hosp, Dept Pathol, Jinan, Peoples R China; [Li, Yuhong] Peoples Hosp Liaocheng, Dept Pathol, Liaocheng, Shandong, Peoples R China; [Song, Lin] Shandong Univ, Shandong Prov Hosp, Cheeloo Coll Med, Dept Pathol, Jinan, Peoples R China	Shandong University; Shandong University; Shandong University; Shandong First Medical University & Shandong Academy of Medical Sciences; Shandong University	Gao, P (corresponding author), Shandong Univ, Cheeloo Coll Med, Minist Educ, Key Lab Expt Teratol, Jinan, Peoples R China.; Gao, P (corresponding author), Shandong Univ, Cheeloo Coll Med, Dept Pathol, Sch Basic Med Sci, Jinan, Peoples R China.; Gao, P (corresponding author), Shandong Univ, Cheeloo Coll Med, Qilu Hosp, Dept Pathol, Jinan, Peoples R China.	gaopeng@sdu.edu.cn			National Natural Science Foundation of China [81672842, 81872362]; Taishan Scholars Program of Shandong Province [ts201511096]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Taishan Scholars Program of Shandong Province	This study was supported by the National Natural Science Foundation of China (Grant nos. 81672842 and 81872362), the Taishan Scholars Program of Shandong Province (Grant no. ts201511096).	Bolos V, 2003, J CELL SCI, V116, P499, DOI 10.1242/jcs.00224; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Chu PC, 2018, ONCOGENE, V37, P3440, DOI 10.1038/s41388-018-0222-3; De Craene B, 2013, NAT REV CANCER, V13, P97, DOI 10.1038/nrc3447; Fang XY, 2015, CANCER LETT, V356, P357, DOI 10.1016/j.canlet.2014.11.005; Fatica A, 2014, NAT REV GENET, V15, P7, DOI 10.1038/nrg3606; Gao HY, 2017, ONCOTARGETS THER, V10, P205, DOI 10.2147/OTT.S116178; Gao P, 2009, J PATHOL, V218, P192, DOI 10.1002/path.2523; Gibb EA, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-38; Gupta GP, 2006, CELL, V127, P679, DOI 10.1016/j.cell.2006.11.001; Gupta PB, 2005, NAT GENET, V37, P1047, DOI 10.1038/ng1634; Hansen BC, 2017, FASEB J, V31, P4216, DOI 10.1096/fj.201601250R; Hu XT, 2020, J CANCER, V11, P229, DOI 10.7150/jca.35537; Jang E, 2016, BIOMATERIALS, V105, P12, DOI 10.1016/j.biomaterials.2016.07.036; Jung HY, 2019, NAT CELL BIOL, V21, P359, DOI 10.1038/s41556-019-0291-8; Kallen AN, 2013, MOL CELL, V52, P101, DOI 10.1016/j.molcel.2013.08.027; Kim WY, 2014, EXP MOL MED, V46, DOI 10.1038/emm.2014.1; Liu HT, 2018, CANCER RES, V78, P5877, DOI 10.1158/0008-5472.CAN-18-1011; Lu YY, 2017, NAT MED, V23, P1331, DOI 10.1038/nm.4424; McLean MIH, 2014, NAT REV GASTRO HEPAT, V11, P664, DOI 10.1038/nrgastro.2014.143; Mercer TR, 2009, NAT REV GENET, V10, P155, DOI 10.1038/nrg2521; Murray-Stewart T, 2016, ONCOGENE, V35, P5480, DOI 10.1038/onc.2016.91; Nguyen DX, 2009, NAT REV CANCER, V9, P274, DOI 10.1038/nrc2622; Puisieux A, 2014, NAT CELL BIOL, V16, P488, DOI 10.1038/ncb2976; Qian YW, 2017, HEPATOLOGY, V66, P1165, DOI 10.1002/hep.29296; Salmena L, 2011, CELL, V146, P353, DOI 10.1016/j.cell.2011.07.014; Schirle NT, 2014, SCIENCE, V346, P608, DOI 10.1126/science.1258040; Sheng Y, 2016, GYNECOL ONCOL, V140, P145, DOI 10.1016/j.ygyno.2015.11.017; Shi DB, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1125-z; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; Song YX, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00304-1; Thomson DW, 2016, NAT REV GENET, V17, P272, DOI 10.1038/nrg.2016.20; Tsai CY, 2014, CLIN CANCER RES, V20, P2276, DOI 10.1158/1078-0432.CCR-13-1221; Wang KC, 2011, MOL CELL, V43, P904, DOI 10.1016/j.molcel.2011.08.018; Wapinski O, 2011, TRENDS CELL BIOL, V21, P354, DOI 10.1016/j.tcb.2011.04.001; Wilusz JE, 2009, GENE DEV, V23, P1494, DOI 10.1101/gad.1800909; Xing AY, 2015, J PATHOL, V236, P53, DOI 10.1002/path.4495; Yuan JH, 2014, CANCER CELL, V25, P666, DOI 10.1016/j.ccr.2014.03.010; Zhang K, 2014, GENE, V547, P1, DOI 10.1016/j.gene.2014.06.043	39	30	31	1	13	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 18	2020	39	25					4854	4868		10.1038/s41388-020-1330-4	http://dx.doi.org/10.1038/s41388-020-1330-4		MAY 2020	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LZ3HT	32439864				2022-12-17	WOS:000534735300002
J	Pancholi, S; Ribas, R; Simigdala, N; Schuster, E; Nikitorowicz-Buniak, J; Ressa, A; Gao, Q; Leal, MF; Bhamra, A; Thornhill, A; Morisset, L; Montaudon, E; Sourd, L; Fitzpatrick, M; Altelaar, M; Johnston, SR; Marangoni, E; Dowsett, M; Martin, LA				Pancholi, Sunil; Ribas, Ricardo; Simigdala, Nikiana; Schuster, Eugene; Nikitorowicz-Buniak, Joanna; Ressa, Anna; Gao, Qiong; Leal, Mariana Ferreira; Bhamra, Amandeep; Thornhill, Allan; Morisset, Ludivine; Montaudon, Elodie; Sourd, Laura; Fitzpatrick, Martin; Altelaar, Maarten; Johnston, Stephen R.; Marangoni, Elisabetta; Dowsett, Mitch; Martin, Lesley-Ann			Tumour kinome re-wiring governs resistance to palbociclib in oestrogen receptor positive breast cancers, highlighting new therapeutic modalities	ONCOGENE			English	Article							DEPENDENT KINASE 4/6; CELL-CYCLE; ADJUVANT TAMOXIFEN; TRANSCRIPTION; DEPRIVATION; INHIBITION; CYCLIN-D1; CDK7; AMPLIFICATION; TARGET	Combination of CDK4/6 inhibitors and endocrine therapy improves clinical outcome in advanced oestrogen receptor (ER)-positive breast cancer, however relapse is inevitable. Here, we show in model systems that other than loss of RB1 few gene-copy number (CN) alterations are associated with irreversible-resistance to endocrine therapy and subsequent secondary resistance to palbociclib. Resistance to palbociclib occurred as a result of tumour cell re-wiring leading to increased expression of EGFR, MAPK, CDK4, CDK2, CDK7, CCNE1 and CCNE2. Resistance altered the ER genome wide-binding pattern, leading to decreased expression of 'classical' oestrogen-regulated genes and was accompanied by reduced sensitivity to fulvestrant and tamoxifen. Persistent CDK4 blockade decreased phosphorylation of tuberous sclerosis complex 2 (TSC2) enhancing EGFR signalling, leading to the re-wiring of ER. Kinome-knockdown confirmed dependency on ERBB-signalling and G2/M-checkpoint proteins such as WEE1, together with the cell cycle master regulator, CDK7. Noteworthy, sensitivity to CDK7 inhibition was associated with loss of ER and RB1 CN. Overall, we show that resistance to CDK4/6 inhibitors is dependent on kinase re-wiring and the redeployment of signalling cascades previously associated with endocrine resistance and highlights new therapeutic networks that can be exploited upon relapse after CDK4/6 inhibition.	[Pancholi, Sunil; Ribas, Ricardo; Simigdala, Nikiana; Schuster, Eugene; Nikitorowicz-Buniak, Joanna; Leal, Mariana Ferreira; Dowsett, Mitch; Martin, Lesley-Ann] Inst Canc Res, Breast Canc Now Toby Robins Res Ctr, London SW7 3RP, England; [Ressa, Anna; Fitzpatrick, Martin; Altelaar, Maarten] Univ Utrecht, Bijvoet Ctr Biomol Res, Biomol Mass Spectrometry & Prote, NL-3584 CH Utrecht, Netherlands; [Ressa, Anna; Fitzpatrick, Martin; Altelaar, Maarten] Univ Utrecht, Utrecht Inst Pharmaceut Sci, NL-3584 CH Utrecht, Netherlands; [Gao, Qiong] Inst Canc Res, Bioinformat Cofacil, CRUK, Sutton SM2 5NG, Surrey, England; [Bhamra, Amandeep] Inst Canc Res, Prote Unit, Sutton SW7 3RP, Surrey, England; [Thornhill, Allan] Inst Canc Res, Ctr Canc Imaging, Sutton SM2 5NG, Surrey, England; [Morisset, Ludivine; Montaudon, Elodie; Sourd, Laura; Marangoni, Elisabetta] Inst Curie, Dept Translat Res, Paris, France; [Johnston, Stephen R.] Royal Marsden Hosp, Breast Unit, London SW3 6JJ, England; [Dowsett, Mitch] Royal Marsden Hosp, Ralph Lauren Ctr Breast Canc Res, London SW3 6JJ, England	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; Utrecht University; Utrecht University; University of London; Institute of Cancer Research - UK; University of London; Institute of Cancer Research - UK; University of London; Institute of Cancer Research - UK; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Royal Marsden NHS Foundation Trust; Royal Marsden NHS Foundation Trust	Martin, LA (corresponding author), Inst Canc Res, Breast Canc Now Toby Robins Res Ctr, London SW7 3RP, England.	lesley-ann.martin@icr.ac.uk	Marangoni, Elisabetta/GSO-3945-2022	Marangoni, Elisabetta/0000-0002-3337-6448; Gao, Qiong/0000-0002-0406-1594; Pancholi, Sunil/0000-0002-0880-1588; Schuster, Eugene/0000-0001-5076-2810; Ribas, Ricardo/0000-0002-8134-0036	Pfizer; NHS; Breast Cancer Now; Walk the Walk; Proteins@Work - Netherlands Organisation for Scientific Research (NWO) as part of the National Roadmap Large-scale Research Facilities of the Netherlands [184.032.201]; HighThroughput Genomics Group at the Wellcome Trust Centre for Human Genetics (Wellcome Trust) [090532/Z/09/Z]; Arthur Foundation	Pfizer(Pfizer); NHS; Breast Cancer Now; Walk the Walk; Proteins@Work - Netherlands Organisation for Scientific Research (NWO) as part of the National Roadmap Large-scale Research Facilities of the Netherlands(Netherlands Organization for Scientific Research (NWO)); HighThroughput Genomics Group at the Wellcome Trust Centre for Human Genetics (Wellcome Trust); Arthur Foundation	We also would like to thank Pfizer, for academic funding and NHS funding to the Royal Marsden Hospital's NIHR Biomedical Research Centre. This work was also supported by Breast Cancer Now, working in partnership with Walk the Walk; Proteins@Work, financed by the Netherlands Organisation for Scientific Research (NWO) as part of the National Roadmap Large-scale Research Facilities of the Netherlands (project number 184.032.201); HighThroughput Genomics Group at the Wellcome Trust Centre for Human Genetics (funded by Wellcome Trust grant reference 090532/Z/09/Z) for the generation of the Sequencing data and The Arthur Foundation.	Asghar U, 2015, NAT REV DRUG DISCOV, V14, P130, DOI 10.1038/nrd4504; Bhat-Nakshatri P, 2008, MOL CELL BIOL, V28, P7487, DOI 10.1128/MCB.00799-08; Bhinge K, 2017, ONCOTARGET, V8, P27155, DOI 10.18632/oncotarget.15676; Bosco EE, 2007, J CLIN INVEST, V117, P218, DOI 10.1172/JCI28803; Brough R, 2011, CANCER DISCOV, V1, P260, DOI 10.1158/2159-8290.CD-11-0107; Chandarlapaty S, 2011, CANCER CELL, V19, P58, DOI 10.1016/j.ccr.2010.10.031; De Falco G, 2000, ONCOGENE, V19, P373, DOI 10.1038/sj.onc.1203305; de Leeuw R, 2018, CLIN CANCER RES, V24, P4201, DOI 10.1158/1078-0432.CCR-18-0410; DICKSON C, 1995, CANCER LETT, V90, P43, DOI 10.1016/0304-3835(94)03676-A; Finn RS, 2016, NEW ENGL J MED, V375, P1925, DOI 10.1056/NEJMoa1607303; Fisher RP, 2005, J CELL SCI, V118, P5171, DOI 10.1242/jcs.02718; Fry DW, 2004, MOL CANCER THER, V3, P1427; Gao Q, 2014, CLIN CANCER RES, V20, P2485, DOI 10.1158/1078-0432.CCR-13-2602; GILLETT C, 1994, CANCER RES, V54, P1812; Goel S, 2016, CANCER CELL, V29, P255, DOI 10.1016/j.ccell.2016.02.006; Goetz MP, 2017, J CLIN ONCOL, V35, P3638, DOI 10.1200/JCO.2017.75.6155; Grinstein E, 2002, ONCOGENE, V21, P1485, DOI 10.1038/sj.onc.1205211; Halaban R, 1998, INT J MOL MED, V1, P419; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Herrera-Abreu MT, 2016, CANCER RES, V76, P2301, DOI 10.1158/0008-5472.CAN-15-0728; Hortobagyi GN, 2016, NEW ENGL J MED, V375, P1738, DOI 10.1056/NEJMoa1609709; Jansen VM, 2017, CANCER RES, V77, P2488, DOI 10.1158/0008-5472.CAN-16-2653; Jirstrom K, 2005, CANCER RES, V65, P8009, DOI 10.1158/0008-5472.CAN-05-0746; Kettner NM, 2019, CLIN CANCER RES, V25, P3996, DOI 10.1158/1078-0432.CCR-18-3274; Kwiatkowski N, 2014, NATURE, V511, P616, DOI 10.1038/nature13393; Li B, 2017, CANCER RES, V77, P3834, DOI 10.1158/0008-5472.CAN-16-2546; Lundgren K, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3161; Lupien M, 2010, GENE DEV, V24, P2219, DOI 10.1101/gad.1944810; Ma CX, 2017, CLIN CANCER RES, V23, P4055, DOI 10.1158/1078-0432.CCR-16-3206; Martin M, 2017, NAT COMMUN, V8, DOI [10.1038/ncomms15127, 10.1038/s41467-017-01864-y]; Matheson CJ, 2016, TRENDS PHARMACOL SCI, V37, P872, DOI 10.1016/j.tips.2016.06.006; Michaloglou C, 2018, MOL CANCER THER, V17, P908, DOI 10.1158/1535-7163.MCT-17-0537; Miller TW, 2011, CANCER DISCOV, V1, P338, DOI 10.1158/2159-8290.CD-11-0101; Morandi A, 2013, CANCER RES, V73, P3783, DOI 10.1158/0008-5472.CAN-12-4265; Musgrove EA, 2011, NAT REV CANCER, V11, P558, DOI 10.1038/nrc3090; Narasimha AM, 2014, ELIFE, V3, DOI 10.7554/eLife.02872; O'Leary B, 2018, CANCER DISCOV, V8, P1390, DOI 10.1158/2159-8290.CD-18-0264; Patani N, 2014, MOL CELL ENDOCRINOL, V382, P683, DOI 10.1016/j.mce.2013.09.038; Patel H, 2018, MOL CANCER THER, V17, P1156, DOI 10.1158/1535-7163.MCT-16-0847; Paternot S, 2010, CELL CYCLE, V9, P689, DOI 10.4161/cc.9.4.10611; Raaijmakers LM, 2015, J PROTEOME RES, V14, P4332, DOI 10.1021/acs.jproteome.5b00529; Ressa A, 2019, J PROTEOME RES, V18, P576, DOI 10.1021/acs.jproteome.8b00576; Ribas R, 2015, MOL CANCER THER, V14, P2035, DOI 10.1158/1535-7163.MCT-15-0143; Rondon-Lagos M, 2014, MOL CYTOGENET, V7, DOI 10.1186/1755-8166-7-8; Rudas M, 2008, CLIN CANCER RES, V14, P1767, DOI 10.1158/1078-0432.CCR-07-4122; Rudolph JD, 2016, CELL SYST, V3, P585, DOI 10.1016/j.cels.2016.11.005; Schmidt D, 2009, METHODS, V48, P240, DOI 10.1016/j.ymeth.2009.03.001; Shaw AS, 2014, MOL CELL BIOL, V34, P1538, DOI 10.1128/MCB.00057-14; Simigdala N, 2016, BREAST CANCER RES, V18, DOI 10.1186/s13058-016-0713-5; Smith EJ, 1998, CELL GROWTH DIFFER, V9, P297; Stark R., 2011, R PACKAGE VERSION, V100, P1; Turner NC, 2015, NEW ENGL J MED, V373, P209, DOI 10.1056/NEJMoa1505270; Witzel II, 2010, BIOCHEM SOC T, V38, P217, DOI 10.1042/BST0380217; Yang C, 2017, ONCOGENE, V36, P2255, DOI 10.1038/onc.2016.379; Zacharek SJ, 2005, CANCER RES, V65, P11354, DOI 10.1158/0008-5472.CAN-05-2236; Zhou HJ, 2013, NAT PROTOC, V8, P461, DOI 10.1038/nprot.2013.010	56	30	30	2	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 18	2020	39	25					4781	4797		10.1038/s41388-020-1284-6	http://dx.doi.org/10.1038/s41388-020-1284-6		APR 2020	17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LZ3HT	32307447	Green Published, hybrid			2022-12-17	WOS:000527477100001
J	Dellle Cave, D; Di Guida, M; Costa, V; Sevillano, M; Ferrante, L; Heeschen, C; Corona, M; Cucciardi, A; Lonardo, E				Dellle Cave, Donatella; Di Guida, Martina; Costa, Valerio; Sevillano, Marta; Ferrante, Luigi; Heeschen, Christopher; Corona, Marco; Cucciardi, Antonio; Lonardo, Enza			TGF-beta 1 secreted by pancreatic stellate cells promotes stemness and tumourigenicity in pancreatic cancer cells through L1CAM downregulation	ONCOGENE			English	Article							DUCTAL ADENOCARCINOMA; ADHESION MOLECULE; PROGNOSTIC VALUE; UP-REGULATION; SELF-RENEWAL; EXPRESSION; L1; PROTEIN; PROVIDES; BINDING	Pancreatic stellate cells (PSCs) secrete high levels of transforming growth factor-beta 1 (TGF-beta 1) that contributes to the development of pancreatic ductal adenocarcinoma (PDAC). TGF-beta 1 modulates the expression of L1 cell adhesion molecule (L1CAM), but its role in tumour progression still remains controversial. To clarify L1 function in PDAC and cellular phenotypes, we performed L1CAM cell sorting, silencing and overexpression in several primary pancreatic cancer cells. PSCs silenced for TGF-beta 1 were used for crosstalk experiments. We found that TGF-beta 1 secreted by PSCs negatively regulates L1CAM expression, through canonical TGF-beta-Smad2/3 signalling, leading to a more aggressive PDAC phenotype. Cells with reduced expression of L1CAM harboured enhanced stemness potential and tumourigenicity. Inactivation of TGF-beta 1 signalling in PSCs strongly reduced the aggressiveness of PDAC cells. Our data provide functional proof and mechanistic insights for the tumour-suppressive function of L1CAM via reducing stemness. Rescuing L1CAM expression in cancer cells through targeting of TGF-beta 1 reverses stemness and bears the potential to improve the still miserable prognosis of PDAC patients.	[Dellle Cave, Donatella; Di Guida, Martina; Costa, Valerio; Ferrante, Luigi; Corona, Marco; Cucciardi, Antonio; Lonardo, Enza] CNR, Inst Genet & Biophys Adriano Buzzati Traverso IGB, Via Pietro Castellino 111, I-80131 Naples, Italy; [Sevillano, Marta] Barcelona Inst Sci & Technol, IRB, Barcelona, Spain; [Heeschen, Christopher; Lonardo, Enza] CNIO, Spanish Natl Canc Res Ctr, Madrid, Spain	Consiglio Nazionale delle Ricerche (CNR); Istituto di Genetica e Biofisica "Adriano Buzzati-Traverso" (IGB-CNR); Barcelona Institute of Science & Technology; Institute for Research in Biomedicine - IRB Barcelona; Centro Nacional de Investigaciones Oncologicas (CNIO)	Lonardo, E (corresponding author), CNR, Inst Genet & Biophys Adriano Buzzati Traverso IGB, Via Pietro Castellino 111, I-80131 Naples, Italy.; Lonardo, E (corresponding author), CNIO, Spanish Natl Canc Res Ctr, Madrid, Spain.	enza.lonardo@igb.cnr.it	Delle Cave, Donatella/AAM-2941-2021; Costa, Valerio/K-4505-2016	Delle Cave, Donatella/0000-0002-4019-2778; Costa, Valerio/0000-0002-7294-6933; SEVILLANO, MARTA/0000-0001-5761-0879; Lonardo, Enza/0000-0001-6654-1043; corona, marco/0000-0002-3727-6444	Marie Curie IF (H2020MSCA-IF-2015) [703753]; my first AIRC grant (MFAG-2017) [20206]; POR Campania FESR 2014/2020 (Project SATIN)	Marie Curie IF (H2020MSCA-IF-2015); my first AIRC grant (MFAG-2017); POR Campania FESR 2014/2020 (Project SATIN)	This work was supported by the: Marie Curie IF (H2020MSCA-IF-2015, #703753) to EL, my first AIRC grant (MFAG-2017, #20206) to EL and POR Campania FESR 2014/2020 (Project SATIN) to EL and VC.	Altevogt P, 2016, INT J CANCER, V138, P1565, DOI 10.1002/ijc.29658; Aponte PM, 2017, STEM CELLS INT, V2017, DOI 10.1155/2017/5619472; Apte MV, 2004, PANCREAS, V29, P179, DOI 10.1097/00006676-200410000-00002; Bachem MG, 2008, LANGENBECK ARCH SURG, V393, P891, DOI 10.1007/s00423-008-0279-5; Ben QW, 2010, ANN SURG ONCOL, V17, P2213, DOI 10.1245/s10434-010-0955-x; Bergmann F, 2010, ONCOL REP, V24, P909, DOI 10.3892/or_00000936; Er EE, 2019, NAT CELL BIOL, V21, P408, DOI 10.1038/s41556-018-0257-2; Feig C, 2012, CLIN CANCER RES, V18, P4266, DOI 10.1158/1078-0432.CCR-11-3114; Foucher ED, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01044; Geismann C, 2011, INT J ONCOL, V38, P257, DOI 10.3892/ijo_00000846; Geismann C, 2009, CANCER RES, V69, P4517, DOI 10.1158/0008-5472.CAN-08-3493; Haspel J, 2003, FRONT BIOSCI-LANDMRK, V8, pS1210, DOI 10.2741/1108; He J, 2018, ONCOTARGET, V9, P1326, DOI 10.18632/oncotarget.19847; Hwang RF, 2008, CANCER RES, V68, P918, DOI 10.1158/0008-5472.CAN-07-5714; Javle M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085942; Jones S, 2008, SCIENCE, V321, P1801, DOI 10.1126/science.1164368; Kaifi JT, 2006, ANTICANCER RES, V26, P1167; Kaifi JT, 2006, WORLD J GASTROENTERO, V12, P94, DOI 10.3748/wjg.v12.i1.94; Kiefel H, 2012, CARCINOGENESIS, V33, P1919, DOI 10.1093/carcin/bgs220; Kim HS, 2012, INT J CLIN EXP PATHO, V5, P754; KOWITZ A, 1993, CLIN EXP METASTAS, V11, P419, DOI 10.1007/BF00132985; Phi LTH, 2018, STEM CELLS INT, V2018, DOI 10.1155/2018/5416923; Li XP, 2015, INT J CLIN EXP PATHO, V8, P12084; Locke M, 2005, CANCER RES, V65, P8944, DOI 10.1158/0008-5472.CAN-05-0931; Lonardo E, 2015, JOVE-J VIS EXP, DOI 10.3791/52801; Lonardo E, 2012, CELL CYCLE, V11, P1282, DOI 10.4161/cc.19679; Lonardo E, 2011, CELL STEM CELL, V9, P433, DOI 10.1016/j.stem.2011.10.001; Garcia-Heredia JM, 2017, CLIN CANCER RES, V23, P3871, DOI 10.1158/1078-0432.CCR-16-2358; Marzoq AJ, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-41740-x; Miranda-Lorenzo I, 2014, NAT METHODS, V11, P1161, DOI [10.1038/NMETH.3112, 10.1038/nmeth.3112]; Mizukami T, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-687; Moulla A, 2013, POL J PATHOL, V64, P180, DOI 10.5114/PJP.2013.38135; Na'ara S, 2019, ONCOGENE, V38, P596, DOI 10.1038/s41388-018-0458-y; Pechriggl EJ, 2017, J HISTOCHEM CYTOCHEM, V65, P21, DOI 10.1369/0022155416677241; Roa-Pena L, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-47519-4; Rubio-Viqueira B, 2006, CLIN CANCER RES, V12, P4652, DOI 10.1158/1078-0432.CCR-06-0113; Schirmer U, 2018, BMC CANCER, V18, DOI 10.1186/s12885-018-4928-y; Schroder C, 2009, ONCOL REP, V22, P1109, DOI 10.3892/or_00000543; Shen W, 2017, CELL BIOSCI, V7, DOI 10.1186/s13578-017-0168-0; Soovares P, 2017, GYNECOL ONCOL, V146, P615, DOI 10.1016/j.ygyno.2017.06.010; Tang DY, 2015, EXP CELL RES, V330, P336, DOI [10.1016/j.yexcr.10.021, 10.1016/j.yexcr.2014.10.021]; Tsutsumi S, 2011, J SURG ONCOL, V103, P669, DOI 10.1002/jso.21880; Uhlen M, 2010, NAT BIOTECHNOL, V28, P1248, DOI 10.1038/nbt1210-1248; Valiente M, 2014, CELL, V156, P1002, DOI 10.1016/j.cell.2014.01.040; Valle S, 2018, CANCERS, V10, DOI 10.3390/cancers10020033; Wachowiak R, 2007, ANN SURG ONCOL, V14, P3575, DOI 10.1245/s10434-007-9608-0	46	30	31	2	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2020	39	21					4271	4285		10.1038/s41388-020-1289-1	http://dx.doi.org/10.1038/s41388-020-1289-1		APR 2020	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LQ2DH	32291413	Green Published, hybrid			2022-12-17	WOS:000526237900002
J	Sun, CY; Li, X; Guo, ES; Li, N; Zhou, B; Lu, H; Huang, J; Xia, M; Shan, WY; Wang, BB; Li, KZ; Weng, DH; Xu, XY; Gao, QL; Wang, SX; Hu, JB; Lu, YL; Mills, GB; Chen, G				Sun, Chaoyang; Li, Xi; Guo, Ensong; Li, Na; Zhou, Bo; Lu, Hao; Huang, Jia; Xia, Meng; Shan, Wanying; Wang, Beibei; Li, Kezhen; Weng, Danhui; Xu, Xiaoyan; Gao, Qinglei; Wang, Shixuan; Hu, Junbo; Lu, Yiling; Mills, Gordon B.; Chen, Gang			MCP-1/CCR-2 axis in adipocytes and cancer cell respectively facilitates ovarian cancer peritoneal metastasis	ONCOGENE			English	Article							MONOCYTE CHEMOATTRACTANT PROTEIN-1; CHEMOTACTIC PROTEIN-1; GENE-EXPRESSION; LIGAND 2; METFORMIN; RECEPTOR; GROWTH; OBESITY; CCL2; IDENTIFICATION	Ovarian cancer selective metastasizes to the omentum contributing to the poor prognosis associated with ovarian cancer. However, the mechanism underlining this propensity and therapeutic approaches to counter this process has not been fully elucidated. Here, we show that MCP-1 produced by omental adipocytes binding to its cognate receptor CCR-2 on ovarian cancer cells facilitates migration and omental metastasis by activating the PI3K/AKT/mTOR pathway and its downstream effectors HIF-1 alpha and VEGF-A in cell lines, xenografts, and transgenic murine models. MCP-1 antibody significantly decreased tumor burden and increased survival of mice in vivo. Interestingly, metformin decreased omental metastasis at least partially by inhibiting MCP-1 secretion from adipocytes independent of direct effects on cancer cells. Together this suggests a novel target of MCP-1/CCR-2 axis that could benefit ovarian cancer patients.	[Sun, Chaoyang; Li, Xi; Guo, Ensong; Li, Na; Zhou, Bo; Lu, Hao; Huang, Jia; Xia, Meng; Shan, Wanying; Wang, Beibei; Li, Kezhen; Weng, Danhui; Xu, Xiaoyan; Gao, Qinglei; Wang, Shixuan; Hu, Junbo; Chen, Gang] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Gynecol & Obstet, Wuhan 430030, Hubei, Peoples R China; [Li, Na] Peter MacCallum Canc Ctr, Canc Genet Lab, Melbourne, Vic 3000, Australia; [Zhou, Bo] Wuhan Univ, Dept Gynecol Oncol, Zhongnan Hosp, Wuhan 430071, Hubei, Peoples R China; [Lu, Hao; Xia, Meng] Cent Hosp Wuhan, Dept Gynecol & Obstet, Wuhan 430030, Hubei, Peoples R China; [Hu, Junbo] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Gastrointestinal Surg, Wuhan 430030, Hubei, Peoples R China; [Lu, Yiling; Mills, Gordon B.] Univ Texas MD Anderson Canc Ctr, Dept Syst Biol, Houston, TX 77030 USA	Huazhong University of Science & Technology; Peter Maccallum Cancer Center; Wuhan University; Huazhong University of Science & Technology; University of Texas System; UTMD Anderson Cancer Center	Chen, G (corresponding author), Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Gynecol & Obstet, Wuhan 430030, Hubei, Peoples R China.	gumpc@126.com	chaoyang, sun/HCH-0905-2022	Chen, Gang/0000-0002-8320-6594; Mills, Gordon/0000-0002-0144-9614; Sun, Chaoyang/0000-0003-2469-1638	National Key R&D Program of China [2016YFC1303100]; National Basic Research Program of China (973 Program) [2015CB553903]; Nature and Science Foundation of China [81272859, 81572569, 81402163, 81402164, 81501530, 81671394, 81370469]; International S&T Cooperation Program of China [2013DFA31400]; NIH [P50CA217685]; Ovarian Cancer Research Foundation	National Key R&D Program of China; National Basic Research Program of China (973 Program)(National Basic Research Program of China); Nature and Science Foundation of China(National Natural Science Foundation of China (NSFC)); International S&T Cooperation Program of China; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Ovarian Cancer Research Foundation	This study was supported by the National Key R&D Program of China (2016YFC1303100), the National Basic Research Program of China (973 Program, 2015CB553903), Nature and Science Foundation of China (81272859, 81572569, 81402163, 81402164, 81501530, 81671394, and 81370469), the International S&T Cooperation Program of China (No. 2013DFA31400). GBM has support from NIH P50CA217685, Ovarian Cancer Research Foundation, and a kind gift from the Adelson Medical Research Fund.	Al-Wahab Z, 2015, ONCOTARGET, V6, P10908, DOI 10.18632/oncotarget.3434; Algire C, 2012, CANCER PREV RES, V5, P536, DOI 10.1158/1940-6207.CAPR-11-0536; Amano SU, 2014, CELL METAB, V19, P162, DOI 10.1016/j.cmet.2013.11.017; Bae HS, 2014, J OVARIAN RES, V7, DOI 10.1186/1757-2215-7-41; Baldan V, 2015, BRIT J CANCER, V112, P1510, DOI 10.1038/bjc.2015.96; Banerjee S, 2013, CLIN CANCER RES, V19, P961, DOI 10.1158/1078-0432.CCR-12-2243; Bell D, 2011, NATURE, V474, P609, DOI 10.1038/nature10166; Broek IV, 2003, BRIT J CANCER, V88, P855, DOI 10.1038/sj.bjc.6600833; Castadot P, 2005, Cancer Radiother, V9, P183, DOI 10.1016/j.canrad.2005.03.001; Fang WB, 2012, J BIOL CHEM, V287, P36593, DOI 10.1074/jbc.M112.365999; Furukawa S, 2013, ANTICANCER RES, V33, P4785; Giuliani M, 2017, MINERVA GINECOL, V8; Guru SK, 2015, CANCER RES, V75, P2886, DOI 10.1158/0008-5472.CAN-14-2312; He YY, 2007, HUM REPROD, V22, P2733, DOI 10.1093/humrep/dem208; Hoy AJ, 2017, TRENDS MOL MED, V23, P381, DOI 10.1016/j.molmed.2017.02.009; Kojima R, 2010, J IMMUNOL, V184, P5253, DOI 10.4049/jimmunol.0901298; Li XG, 2017, GUT, V66, P157, DOI 10.1136/gutjnl-2015-310514; Lim MC, 2009, GYNECOL ONCOL, V112, P28, DOI 10.1016/j.ygyno.2008.09.046; Liu GX, 2013, TUMOR BIOL, V34, P2741, DOI 10.1007/s13277-013-0827-7; Lu CH, 2016, EUR J PHARMACOL, V789, P60, DOI 10.1016/j.ejphar.2016.07.012; MANOME Y, 1995, CANCER IMMUNOL IMMUN, V41, P227; Milliken D, 2002, CLIN CANCER RES, V8, P1108; Mizutani K, 2009, ANTICANCER RES, V29, P3109; Naora H, 2005, NAT REV CANCER, V5, P355, DOI 10.1038/nrc1611; Nieman KM, 2011, NAT MED, V17, P1498, DOI 10.1038/nm.2492; Pequeux C, 2012, CANCER RES, V72, P3010, DOI 10.1158/0008-5472.CAN-11-3768; Pienta KJ, 2013, INVEST NEW DRUG, V31, P760, DOI 10.1007/s10637-012-9869-8; Rattan R, 2011, NEOPLASIA, V13, P483, DOI 10.1593/neo.11148; Robinson E, 2014, BIOCHEM SOC T, V42, P125, DOI 10.1042/BST20130203; Rodriguez GM, 2018, CANCERS, V10, DOI 10.3390/cancers10080242; Romero IL, 2015, CLIN CANCER RES, V21, P680, DOI 10.1158/1078-0432.CCR-14-2198; Shen H, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1250-8; Sica A, 2000, J IMMUNOL, V164, P733, DOI 10.4049/jimmunol.164.2.733; Sierra-Filardi E, 2014, J IMMUNOL, V192, P3858, DOI 10.4049/jimmunol.1302821; Sikka A, 2012, CELL CYCLE, V11, P1374, DOI 10.4161/cc.19798; Tabuso M, 2017, WORLD J GASTROENTERO, V23, P5829, DOI 10.3748/wjg.v23.i32.5829; TARIN D, 1984, CANCER RES, V44, P3584; Teng PN, 2014, BRIT J CANCER, V110, P123, DOI 10.1038/bjc.2013.687; Torre LA, 2018, CA-CANCER J CLIN, V68, P284, DOI 10.3322/caac.21456; Tsuyada A, 2012, CANCER RES, V72, P2768, DOI 10.1158/0008-5472.CAN-11-3567; Visser M, 1999, JAMA-J AM MED ASSOC, V282, P2131, DOI 10.1001/jama.282.22.2131; Wang Y, 2018, CAN RESPIR J, V2018, DOI 10.1155/2018/8354892; Wang YX, 2019, J CELL PHYSL, P8; Wojnarowicz P, 2012, ONCOGENESIS, V1, DOI 10.1038/oncsis.2012.25; Xu TP, 2014, J HEMATOL ONCOL, V7, DOI 10.1186/s13045-014-0063-7; Xu XJ, 2012, J LIPID RES, V53, P792, DOI 10.1194/jlr.P022905; Yang HS, 2011, INT J GYNECOL CANCER, V21, P1525, DOI 10.1097/IGC.0b013e31822eb5f8; Yu HD, 2019, J CLIN INVEST, V129, P2485, DOI 10.1172/JCI125646; Yumimoto K, 2019, CANCER SCI, V110, P2090, DOI 10.1111/cas.14075; Zhang J, 2010, JNCI-J NATL CANCER I, V102, P522, DOI 10.1093/jnci/djq044	50	30	31	3	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2020	39	8					1681	1695		10.1038/s41388-019-1090-1	http://dx.doi.org/10.1038/s41388-019-1090-1			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN6CG	31705064	Green Accepted			2022-12-17	WOS:000514923000005
J	Sun, BW; Mason, S; Wilson, RC; Hazard, SE; Wang, YB; Fang, R; Wang, QW; Yeh, ES; Yang, MX; Roberts, TM; Zhao, JJ; Wang, Q				Sun, Bowen; Mason, Seth; Wilson, Robert C.; Hazard, Starr E.; Wang, Yubao; Fang, Rong; Wang, Qiwei; Yeh, Elizabeth S.; Yang, Meixiang; Roberts, Thomas M.; Zhao, Jean J.; Wang, Qi			Inhibition of the transcriptional kinase CDK7 overcomes therapeutic resistance in HER2-positive breast cancers	ONCOGENE			English	Article							TRASTUZUMAB RESISTANCE; MEDIATES RESISTANCE; TERMINAL DOMAIN; RECEPTOR; ACTIVATION; LAPATINIB; TUMORS; EXPRESSION; MUTATIONS; PATHWAY	Resistance of breast cancer to human epidermal growth factor receptor 2 (HER2) inhibitors involves reprogramming of the kinome through HER2/HER3 signaling via the activation of multiple tyrosine kinases and transcriptional upregulation. The heterogeneity of induced kinases prevents kinase targeting by a single kinase inhibitor and presents a major challenge to the treatment of therapeutically recalcitrant HER2-positive breast cancers (HER2+ BCs). As a result, there is a critical need for effective treatment that attacks the aberrant kinome activation associated with resistance to HER2-targeted therapy. Here, we describe a novel treatment strategy that targets cyclin-dependent kinase 7 (CDK7) in HER2 inhibitor-resistant (HER2iR) breast cancer. We show that both HER2 inhibitor-sensitive (HER2iS) and HER2iR breast cancer cell lines exhibit high sensitivity to THZ1, a newly identified covalent inhibitor of the transcription regulatory kinase CDK7. CDK7 promotes cell cycle progression through inhibition of transcription, rather than via direct phosphorylation of classical CDK targets. The transcriptional kinase activity of CDK7 is regulated by HER2, and by the receptor tyrosine kinases activated in response to HER2 inhibition, as well as by the downstream SHP2 and PI3K/AKT pathways. A low dose of THZ1 displayed potent synergy with the HER2 inhibitor lapatinib in HER2iR BC cells in vitro. Dual HER2 and CDK7 inhibition induced tumor regression in two HER2iR BC xenograft models in vivo. Our data support the utilization of CDK7 inhibition as an additional therapeutic avenue that blocks the activation of genes engaged by multiple HER2iR kinases.	[Sun, Bowen; Yeh, Elizabeth S.; Yang, Meixiang] Jinan Univ, Biomed Translat Res Inst, Affiliated Hosp 1, Guangzhou 510632, Peoples R China; [Sun, Bowen; Yeh, Elizabeth S.; Yang, Meixiang] Jinan Univ, Sch Pharm, Guangzhou 510632, Peoples R China; [Sun, Bowen; Mason, Seth; Wilson, Robert C.; Wang, Qi] Med Univ South Carolina, Dept Pathol & Lab Med, Charleston, SC 29425 USA; [Hazard, Starr E.] Med Univ South Carolina, Computat Biol Resource Ctr, Charleston, SC 29425 USA; [Wang, Yubao; Fang, Rong; Wang, Qiwei; Roberts, Thomas M.; Zhao, Jean J.] Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA; [Wang, Yubao; Fang, Rong; Wang, Qiwei; Roberts, Thomas M.; Zhao, Jean J.] Harvard Med Sch, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA; [Fang, Rong] Ningbo Univ, Sch Med, Zhejiang Prov Key Lab Pathophysiol, Dept Pathol, Ningbo 315211, Peoples R China; [Yeh, Elizabeth S.] Med Univ South Carolina, Dept Cell & Mol Pharmacol & Expt Therapeut, Charleston, SC 29425 USA	Jinan University; Jinan University; Medical University of South Carolina; Medical University of South Carolina; Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; Ningbo University; Medical University of South Carolina	Wang, Q (corresponding author), Med Univ South Carolina, Dept Pathol & Lab Med, Charleston, SC 29425 USA.	wangq@musc.edu	mason, seth/GYU-3141-2022	Hazard, E. Starr/0000-0002-4645-7642; Wang, Qiwei/0000-0003-3897-2529	American Cancer Society [ACS_IRG IRG-97-219-14]; Genomic Shared Resource, Hollings Cancer Center, Medical University of South Carolina [P30 CA138313]; NIH [R01 CA187305, R35 CA210057 CA187918, 1P50CA168504]; Breast Cancer Research Foundation; Rosanna's Rush for Research	American Cancer Society(American Cancer Society); Genomic Shared Resource, Hollings Cancer Center, Medical University of South Carolina; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Breast Cancer Research Foundation; Rosanna's Rush for Research	This work was supported by pilot research funding form an American Cancer Society Institutional Research Grant awarded to the Hollings Cancer Center, Medical University of South Carolina (ACS_IRG IRG-97-219-14, QW); Supported in part by the Genomic Shared Resource, Hollings Cancer Center, Medical University of South Carolina (P30 CA138313); NIH grants R01 CA187305 (ESY), R35 CA210057 CA187918 (TMR and JJZ), 1P50CA168504 (TMR and JJZ); the Breast Cancer Research Foundation (JJZ); Rosanna's Rush for Research (JJZ). We also like to thank Dr Stephen Ethier (Medical University of South Carolina, SC, USA) for providing cell line Sum149.	Akhtar MS, 2009, MOL CELL, V34, P387, DOI 10.1016/j.molcel.2009.04.016; Alexander PB, 2017, J BIOL CHEM, V292, P748, DOI 10.1074/jbc.M116.754960; Bentires-Alj M, 2006, NAT MED, V12, P114, DOI 10.1038/nm1341; Bentires-Alj M, 2004, CANCER RES, V64, P8816, DOI 10.1158/0008-5472.CAN-04-1923; Berns K, 2007, CANCER CELL, V12, P395, DOI 10.1016/j.ccr.2007.08.030; Blackwell KL, 2010, J CLIN ONCOL, V28, P1124, DOI 10.1200/JCO.2008.21.4437; Chen DS, 2002, ONCOGENE, V21, P4921, DOI 10.1038/sj.onc.1205420; Chen YNP, 2016, NATURE, V535, P148, DOI 10.1038/nature18621; Chipumuro E, 2014, CELL, V159, P1126, DOI 10.1016/j.cell.2014.10.024; Chou TC, 2006, PHARMACOL REV, V58, P621, DOI 10.1124/pr.58.3.10; Christensen CL, 2014, CANCER CELL, V26, P909, DOI 10.1016/j.ccell.2014.10.019; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Dueck AC, 2013, CLIN CANCER RES, V19, P5798, DOI 10.1158/1078-0432.CCR-13-0558; Eichhorn PJA, 2008, CANCER RES, V68, P9221, DOI 10.1158/0008-5472.CAN-08-1740; Emery CM, 2009, P NATL ACAD SCI USA, V106, P20411, DOI 10.1073/pnas.0905833106; Ercan D, 2010, ONCOGENE, V29, P2346, DOI 10.1038/onc.2009.526; Glover-Cutter K, 2009, MOL CELL BIOL, V29, P5455, DOI 10.1128/MCB.00637-09; Goel S, 2016, CANCER CELL, V29, P255, DOI 10.1016/j.ccell.2016.02.006; Greulich H, 2005, PLOS MED, V2, P1167, DOI 10.1371/journal.pmed.0020313; Hanker AB, 2017, CLIN CANCER RES, V23, P4323, DOI 10.1158/1078-0432.CCR-16-2287; Hanker AB, 2013, P NATL ACAD SCI USA, V110, P14372, DOI 10.1073/pnas.1303204110; Harrod A, 2017, ONCOGENE, V36, P2286, DOI 10.1038/onc.2016.382; Hellmuth K, 2008, P NATL ACAD SCI USA, V105, P7275, DOI 10.1073/pnas.0710468105; Hynes NE, 2005, NAT REV CANCER, V5, P341, DOI 10.1038/nrc1609; Jeselsohn R, 2018, CANCER CELL, V33, P173, DOI 10.1016/j.ccell.2018.01.004; Julovi SM, 2018, FRONT ENDOCRINOL, V9, DOI 10.3389/fendo.2018.00120; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Kwiatkowski N, 2014, NATURE, V511, P616, DOI 10.1038/nature13393; Larochelle S, 2007, MOL CELL, V25, P839, DOI 10.1016/j.molcel.2007.02.003; Larochelle S, 2012, NAT STRUCT MOL BIOL, V19, P1108, DOI 10.1038/nsmb.2399; Liu PX, 2009, NAT REV DRUG DISCOV, V8, P627, DOI 10.1038/nrd2926; Loi S, 2014, ANN ONCOL, V25, P1544, DOI 10.1093/annonc/mdu112; Lu YH, 2001, JNCI-J NATL CANCER I, V93, P1852, DOI 10.1093/jnci/93.24.1852; Mayer IA, 2014, CLIN CANCER RES, V20, P782, DOI 10.1158/1078-0432.CCR-13-0583; Moasser MM, 2015, JAMA ONCOL, V1, P1154, DOI 10.1001/jamaoncol.2015.2286; Musolino A, 2008, J CLIN ONCOL, V26, P1789, DOI 10.1200/JCO.2007.14.8957; Nagata Y, 2004, CANCER CELL, V6, P117, DOI 10.1016/j.ccr.2004.06.022; Neel BG, 2003, TRENDS BIOCHEM SCI, V28, P284, DOI 10.1016/S0968-0004(03)00091-4; Oliveras-Ferraros C, 2012, CELL CYCLE, V11, P4020, DOI 10.4161/cc.22225; Palancade B, 2003, EUR J BIOCHEM, V270, P3859, DOI 10.1046/j.1432-1033.2003.03794.x; Prahallad A, 2015, CELL REP, V12, P1978, DOI 10.1016/j.celrep.2015.08.037; Rusan M, 2018, CANCER DISCOV, V8, P59, DOI 10.1158/2159-8290.CD-17-0461; Scaltriti M, 2007, J NATL CANCER I, V99, P628, DOI 10.1093/jnci/djk134; Scaltriti M, 2011, P NATL ACAD SCI USA, V108, P3761, DOI 10.1073/pnas.1014835108; Sherr CJ, 2004, GENE DEV, V18, P2699, DOI 10.1101/gad.1256504; Stoeck A, 2014, CANCER DISCOV, V4, P1154, DOI 10.1158/2159-8290.CD-13-0830; Stuhlmiller TJ, 2014, CLIN PHARMACOL THER, V95, P413, DOI 10.1038/clpt.2014.8; Stuhlmiller TJ, 2015, CELL REP, V11, P390, DOI 10.1016/j.celrep.2015.03.037; Wang Q, 2016, ONCOGENE, V35, P3607, DOI 10.1038/onc.2015.406; Wang YB, 2015, CELL, V163, P174, DOI 10.1016/j.cell.2015.08.063; Zhang SQ, 2002, MOL CELL BIOL, V22, P4062, DOI 10.1128/MCB.22.12.4062-4072.2002; Zhuang GL, 2010, CANCER RES, V70, P299, DOI 10.1158/0008-5472.CAN-09-1845	52	30	31	3	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2020	39	1					50	63		10.1038/s41388-019-0953-9	http://dx.doi.org/10.1038/s41388-019-0953-9			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KG3NM	31462705	hybrid, Green Published			2022-12-17	WOS:000509849200005
J	Kim, EH; Jo, Y; Sai, S; Park, MJ; Kim, JY; Kim, JS; Lee, YJ; Cho, JM; Kwak, SY; Baek, JH; Jeong, YK; Song, JY; Yoon, M; Hwang, SG				Kim, Eun Ho; Jo, Yunhui; Sai, Sei; Park, Mung-Jin; Kim, Jeong-Yub; Kim, Jin Su; Lee, Yeon-Joo; Cho, Jae-Min; Kwak, Seo-Young; Baek, Jeong-Hwa; Jeong, Youn Kyoung; Song, Jie-Young; Yoon, Myonggeun; Hwang, Sang-Gu			Tumor-treating fields induce autophagy by blocking the Akt2/miR29b axis in glioblastoma cells	ONCOGENE			English	Article							CANCER; PROLIFERATION; EXPRESSION; SURVIVAL; PATHWAY	Tumor-treating fields (TTFs) - a type of electromagnetic field-based therapy using low-intensity electrical fields - has recently been characterized as a potential anticancer therapy for glioblastoma multiforme (GBM). However, the molecular mechanisms involved remain poorly understood. Our results show that the activation of autophagy contributes to the TTF-induced anti-GBM activity in vitro or in vivo and GBM patient stem cells or primary in vivo culture systems. TTF-treatment upregulated several autophagy-related genes (similar to 2-fold) and induced cytomorphological changes. TTF-induced autophagy in GBM was associated with decreased Akt2 expression, not Akt1 or Akt3, via the mTOR/p70S6K pathway. An Affymetrix GeneChip miRNA 4.0 Array analysis revealed that TTFs altered the expression of many microRNAs (miRNAs). TTF-induced autophagy upregulated miR-29b, which subsequently suppressed the Akt signaling pathway. A luciferase reporter assay confirmed that TTFs induced miR-29b to target Akt2, negatively affecting Akt2 expression thereby triggering autophagy. TTF-induced autophagy suppressed tumor growth in GBM mouse models subjected to TTFs as determined by positron emission tomography and computed tomography (PET-CT). GBM patient stem cells and a primary in vivo culture system with high Akt2 levels also showed TTF-induced inhibition. Taken together, our results identified autophagy as a critical cell death pathway triggered by TTFs in GBM and indicate that TTF is a potential treatment option for GBM.	[Kim, Eun Ho; Jo, Yunhui; Park, Mung-Jin; Kim, Jeong-Yub; Lee, Yeon-Joo; Cho, Jae-Min; Baek, Jeong-Hwa; Song, Jie-Young; Hwang, Sang-Gu] Korea Inst Radiol & Med Sci, Div Radiat Biomed Res, Seoul 01812, South Korea; [Jo, Yunhui; Yoon, Myonggeun] Korea Univ, Dept Bioconvergence Engn, Seoul 02842, South Korea; [Sai, Sei] Natl Inst Radiol Sci, Dept Basic Med Sci Radiat Damages, Chiba, Japan; [Kim, Jin Su] Korea Inst Radiol & Med Sci, Div RI Convergence Res, Seoul 01812, South Korea; [Kwak, Seo-Young] Korea Inst Sci & Technol, Ctr Theragnosis, Biomed Res Inst, Seoul 02792, South Korea; [Jeong, Youn Kyoung] Korea Inst Radiol & Med Sci, Radiat Nonclin Ctr, Div Radiat Res Infrastruct Operat, Seoul 01812, South Korea	Korea Institute of Radiological & Medical Sciences; Korea University; National Institutes for Quantum Science & Technology; Korea Institute of Radiological & Medical Sciences; Korea Institute of Science & Technology (KIST); Korea Institute of Radiological & Medical Sciences	Hwang, SG (corresponding author), Korea Inst Radiol & Med Sci, Div Radiat Biomed Res, Seoul 01812, South Korea.; Yoon, M (corresponding author), Korea Univ, Dept Bioconvergence Engn, Seoul 02842, South Korea.	radioyoon@korea.ac.kr; sgh63@kcch.re.kr	KIM, JIN SU/U-2112-2019; Song, Jie-Young/AAG-6684-2019; Song, Jie-Young/AAH-1254-2019	KIM, JIN SU/0000-0001-8965-9538; Song, Jie-Young/0000-0002-5769-3886; Lee, Yeon-Joo/0000-0002-6605-8761; baeg, jeonghwa/0000-0001-5364-0026	National Research Foundation of Korea (NRF) [NRF-2017R1D1A1B03028923]; Korea Institute of Radiological and Medical Sciences (KIRAMS) - Ministry of Science, ICT (MSIP) Republic of Korea [50531-2018, 50538-2019]	National Research Foundation of Korea (NRF)(National Research Foundation of Korea); Korea Institute of Radiological and Medical Sciences (KIRAMS) - Ministry of Science, ICT (MSIP) Republic of Korea	This work was supported by a National Research Foundation of Korea (NRF) grant (no. NRF-2017R1D1A1B03028923) and a grant from the Korea Institute of Radiological and Medical Sciences (KIRAMS), which was funded by the Ministry of Science, ICT (MSIP) Republic of Korea (50531-2018, 50538-2019).	[Anonymous], 2011, NOVOTTF 100A SYST PR; Bao SD, 2006, NATURE, V444, P756, DOI 10.1038/nature05236; Bodine SC, 2001, NAT CELL BIOL, V3, P1014, DOI 10.1038/ncb1101-1014; Boya P, 2013, NAT CELL BIOL, V15, P713, DOI 10.1038/ncb2788; Constantinescu CC, 2009, PHYS MED BIOL, V54, P2885, DOI 10.1088/0031-9155/54/9/020; Davies AM, 2013, ANN NY ACAD SCI, V1291, P86, DOI 10.1111/nyas.12112; Fohlin H, 2013, EUR J CANCER, V49, P1196, DOI 10.1016/j.ejca.2012.12.006; Ganapathy B, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0155456; Ghobrial IM, 2005, CA-CANCER J CLIN, V55, P178, DOI 10.3322/canjclin.55.3.178; Giladi M, 2017, RADIAT ONCOL, V12, DOI 10.1186/s13014-017-0941-6; Hippert MM, 2006, CANCER RES, V66, P9349, DOI 10.1158/0008-5472.CAN-06-1597; Jeong H, 2014, APPL PHYS LETT, V105, DOI 10.1063/1.4902112; Jo Y, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19113684; Johnson DR, 2012, CANCER-AM CANCER SOC, V118, P5608, DOI 10.1002/cncr.27590; Kessler AF, 2018, CELL DEATH DISCOV, V4, DOI 10.1038/s41420-018-0079-9; Kim EH, 2016, ONCOTARGET, V7, P65125, DOI 10.18632/oncotarget.11372; Kim EH, 2016, ONCOTARGET, V7, P62267, DOI 10.18632/oncotarget.11407; Kirson ED, 2004, CANCER RES, V64, P3288, DOI 10.1158/0008-5472.CAN-04-0083; Kirson ED, 2007, P NATL ACAD SCI USA, V104, P10152, DOI 10.1073/pnas.0702916104; Klionsky DJ, 2016, AUTOPHAGY, V12, P1, DOI 10.1080/15548627.2015.1100356; Kreisberg JI, 2004, CANCER RES, V64, P5232, DOI 10.1158/0008-5472.CAN-04-0272; Li Y, 2016, J ANIM SCI BIOTECHNO, V7, DOI 10.1186/s40104-016-0093-9; Mathew R, 2007, NAT REV CANCER, V7, P961, DOI 10.1038/nrc2254; Mott JL, 2007, ONCOGENE, V26, P6133, DOI 10.1038/sj.onc.1210436; Plastaras JP, 2008, CANCER BIOL THER, V7, P2047, DOI 10.4161/cbt.7.12.7570; Populo H, 2012, INT J MOL SCI, V13, P1886, DOI 10.3390/ijms13021886; Rivas S, 2018, BIOMEDICINES, V6, DOI 10.3390/biomedicines6010029; Sanai N, 2008, NEUROSURGERY, V62, P753, DOI 10.1227/01.neu.0000318159.21731.cf; Schmelzle T, 2000, CELL, V103, P253, DOI 10.1016/S0092-8674(00)00117-3; Stupp R., 2015, JCO, V33, P2000; Stupp R, 2017, JAMA-J AM MED ASSOC, V318, P2306, DOI 10.1001/jama.2017.18718; Stupp R, 2015, JAMA-J AM MED ASSOC, V314, P2535, DOI 10.1001/jama.2015.16669; Stupp R, 2012, EUR J CANCER, V48, P2192, DOI 10.1016/j.ejca.2012.04.011; Toms SA, 2019, J NEURO-ONCOL, V141, P467, DOI 10.1007/s11060-018-03057-z; Tsujimoto Y, 2005, CELL DEATH DIFFER, V12, P1528, DOI 10.1038/sj.cdd.4401777; Walter BA, 2013, J CANCER, V4, P350, DOI 10.7150/jca.6394; Wang Y, 2013, EUR J CELL BIOL, V92, P123, DOI 10.1016/j.ejcb.2012.11.004; Yin J, 2017, CANCER RES, V77, P4973, DOI 10.1158/0008-5472.CAN-17-0388; Yu F, 2007, CELL, V131, P1109, DOI 10.1016/j.cell.2007.10.054	39	30	31	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 26	2019	38	39					6630	6646		10.1038/s41388-019-0882-7	http://dx.doi.org/10.1038/s41388-019-0882-7			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JA5AQ	31375748				2022-12-17	WOS:000487856000005
J	Chen, XH; Mangala, LS; Mooberry, L; Bayraktar, E; Dasari, SK; Ma, SL; Ivan, C; Court, KA; Rodriguez-Aguayo, C; Bayraktar, R; Raut, S; Sabnis, N; Kong, XC; Yang, XB; Lopez-Berestein, G; Lacko, AG; Sood, AK				Chen, Xiuhui; Mangala, Lingegowda S.; Mooberry, Linda; Bayraktar, Emine; Dasari, Santosh K.; Ma, Shaolin; Ivan, Cristina; Court, Karem A.; Rodriguez-Aguayo, Cristian; Bayraktar, Recep; Raut, Sangram; Sabnis, Nirupama; Kong, Xianchao; Yang, Xianbin; Lopez-Berestein, Gabriel; Lacko, Andras G.; Sood, Anil K.			Identifying and targeting angiogenesis-related microRNAs in ovarian cancer	ONCOGENE			English	Article							HIGH-DENSITY-LIPOPROTEIN; ENDOTHELIAL GROWTH-FACTOR; TUMOR-GROWTH; MIR-204; DELIVERY; EXPRESSION; PACLITAXEL; THERAPY; THROMBOSPONDIN-1; IDENTIFICATION	Current anti-angiogenic therapy for cancer is based mainly on inhibition of the vascular endothelial growth factor pathway. However, due to the transient and only modest benefit from such therapy, additional approaches are needed. Deregulation of microRNAs (miRNAs) has been demonstrated to be involved in tumor angiogenesis and offers opportunities for a new therapeutic approach. However, effective miRNA-delivery systems are needed for such approaches to be successful. In this study, miRNA profiling of patient data sets, along with in vitro and in vivo experiments, revealed that miR-204-5p could promote angiogenesis in ovarian tumors through THBS1. By binding with scavenger receptor class B type 1 (SCARB1), reconstituted high-density lipoprotein-nanoparticles (rHDL-NPs) were effective in delivering miR-204-5p inhibitor (miR-204-5p-inh) to tumor sites to suppress tumor growth. These results offer a new understanding of miR-204-5p in regulating tumor angiogenesis.	[Chen, Xiuhui; Mangala, Lingegowda S.; Bayraktar, Emine; Dasari, Santosh K.; Ma, Shaolin; Court, Karem A.; Sood, Anil K.] Univ Texas MD Anderson Canc Ctr, Dept Gynecol Oncol & Reprod Med, Houston, TX 77030 USA; [Chen, Xiuhui; Kong, Xianchao] Harbin Med Univ, Affiliated Hosp 2, Dept Obstet & Gynecol, Harbin, Heilongjiang, Peoples R China; [Mangala, Lingegowda S.; Bayraktar, Emine; Ivan, Cristina; Rodriguez-Aguayo, Cristian; Lopez-Berestein, Gabriel; Sood, Anil K.] Univ Texas MD Anderson Canc Ctr, Ctr RNA Interference & Noncoding RNAs, Houston, TX 77030 USA; [Mooberry, Linda; Raut, Sangram; Sabnis, Nirupama; Lacko, Andras G.] Univ North Texas, Hlth Sci Ctr, Dept Physiol & Anat, Ft Worth, TX USA; [Ivan, Cristina; Rodriguez-Aguayo, Cristian; Bayraktar, Recep; Lopez-Berestein, Gabriel] Univ Texas MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA; [Yang, Xianbin] AM Biotechnol, Houston, TX USA; [Lacko, Andras G.] Univ North Texas, Hlth Sci Ctr, Dept Pediat, Ft Worth, TX USA; [Sood, Anil K.] Univ Texas MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; Harbin Medical University; University of Texas System; UTMD Anderson Cancer Center; University of North Texas System; University of North Texas Denton; University of Texas System; UTMD Anderson Cancer Center; University of North Texas System; University of North Texas Denton; University of Texas System; UTMD Anderson Cancer Center	Mangala, LS; Sood, AK (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Gynecol Oncol & Reprod Med, Houston, TX 77030 USA.; Mangala, LS; Sood, AK (corresponding author), Univ Texas MD Anderson Canc Ctr, Ctr RNA Interference & Noncoding RNAs, Houston, TX 77030 USA.; Sood, AK (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77030 USA.	lsmangala@mdanderson.org; asood@mdanderson.org	Chen, Xiuhui/CAE-9641-2022; Sood, Anoop Kumar/A-7344-2013; Court, Karem A./C-2328-2014; dasari, santosh kumar/V-3867-2019	Sood, Anoop Kumar/0000-0001-5702-4108; Court, Karem A./0000-0002-6334-6960; dasari, santosh kumar/0000-0003-3078-3424; Ivan, Cristina/0000-0002-4848-0168; RODRIGUEZ-AGUAYO, CRISTIAN/0000-0002-7880-7723; Bayraktar, Emine/0000-0002-5189-1507; Bayraktar, Recep/0000-0002-8227-2055	National Institutes of Health [CA016672, UH3TR000943, P50 CA217685, P50 CA098258, R35 CA209904]; Ovarian Cancer Research Fund, Inc.; Blanton-Davis Ovarian Cancer Research Program; American Cancer Society Research Professor Award; Frank McGraw Memorial Chair in Cancer Research; CPRIT [DP150091]; Foundation for Women's Cancer Grant; SPORE in Ovarian Cancer at MD Anderson [P50 CA217685]; NATIONAL CANCER INSTITUTE [R35CA209904, P50CA217685, P50CA098258] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Ovarian Cancer Research Fund, Inc.; Blanton-Davis Ovarian Cancer Research Program; American Cancer Society Research Professor Award(American Cancer Society); Frank McGraw Memorial Chair in Cancer Research; CPRIT; Foundation for Women's Cancer Grant; SPORE in Ovarian Cancer at MD Anderson; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work is supported, in part, by the National Institutes of Health (CA016672, UH3TR000943, P50 CA217685, P50 CA098258, R35 CA209904), Ovarian Cancer Research Fund, Inc. (Program Project Development Grant), Mr. and Mrs. Daniel P. Gordon, The Blanton-Davis Ovarian Cancer Research Program, the American Cancer Society Research Professor Award, and the Frank McGraw Memorial Chair in Cancer Research (AKS) and CPRIT (DP150091; LSM). SKD was supported by Foundation for Women's Cancer Grant, CRA was supported by the P50 CA217685 from the SPORE in Ovarian Cancer at MD Anderson.	Al-Abd AM, 2017, J ADV RES, V8, P591, DOI 10.1016/j.jare.2017.06.006; Armstrong DK, 2006, NEW ENGL J MED, V354, P34, DOI 10.1056/NEJMoa052985; Bell D, 2011, NATURE, V474, P609, DOI 10.1038/nature10166; Cao YH, 2016, CHIN J CANCER, V35, DOI 10.1186/s40880-016-0084-4; Courboulin A, 2011, J EXP MED, V208, P535, DOI 10.1084/jem.20101812; Dey N, 2015, AM J TRANSL RES, V7, P1675; Dunn LL, 2014, DIABETES, V63, P675, DOI 10.2337/db13-0417; Flores-Perez A, 2016, SCI REP-UK, V6, DOI 10.1038/srep34504; Folkman J, 2002, SEMIN ONCOL, V29, P15, DOI 10.1053/sonc.2002.37263; Hausser J, 2014, NAT REV GENET, V15, P599, DOI 10.1038/nrg3765; Huang J, 2010, STEM CELLS, V28, P357, DOI 10.1002/stem.288; Imam JS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052397; Inforzato A, 2010, J BIOL CHEM, V285, P17681, DOI 10.1074/jbc.M109.085639; Jayson GC, 2016, LANCET, V388, P518, DOI 10.1016/S0140-6736(15)01088-0; Johnson R, 2017, BREAST CANCER-TARGET, V9, P383, DOI 10.2147/BCTT.S131038; Kaalund SS, 2014, EPILEPSIA, V55, P2017, DOI 10.1111/epi.12839; Kang Y, 2013, JNCI-J NATL CANCER I, V105, P1485, DOI 10.1093/jnci/djt210; Kuai R, 2017, INT J NANOMED, V12, P6581, DOI 10.2147/IJN.S140591; Kuai R, 2016, ACS NANO, V10, P3015, DOI 10.1021/acsnano.5b07522; Lacko AG, 2015, FRONT PHARMACOL, V6, DOI 10.3389/fphar.2015.00247; Lawler J, 2002, J CELL MOL MED, V6, P1, DOI 10.1111/j.1582-4934.2002.tb00307.x; Lawler PR, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a006627; Lee H, 2016, SCI REP-UK, V6, DOI 10.1038/srep25287; Li Y, 2017, CANCER LETT, V397, P111, DOI 10.1016/j.canlet.2017.03.032; Lu CH, 2010, CANCER CELL, V18, P185, DOI 10.1016/j.ccr.2010.06.016; MacFarlane LA, 2010, CURR GENOMICS, V11, P537, DOI 10.2174/138920210793175895; Mooberry LK, 2016, FRONT PHARMACOL, V7, DOI 10.3389/fphar.2016.00466; Mutharasan RK, 2016, J MATER CHEM B, V4, P188, DOI 10.1039/c5tb01332a; Niu G, 2010, CURR DRUG TARGETS, V11, P1000, DOI 10.2174/138945010791591395; Ohana R, 2015, DEVELOPMENT, V142, P2487, DOI 10.1242/dev.121533; Pecot CV, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3427; Qiu YH, 2013, CELL PHYSIOL BIOCHEM, V32, P1331, DOI 10.1159/000354531; Rajora MA, 2016, FRONT PHARMACOL, V7, DOI 10.3389/fphar.2016.00326; Resovi A, 2014, MATRIX BIOL, V37, P83, DOI 10.1016/j.matbio.2014.01.012; Rodrigueza WV, 1999, J BIOL CHEM, V274, P20344, DOI 10.1074/jbc.274.29.20344; Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73; Shahzad MMK, 2011, NEOPLASIA, V13, P309, DOI 10.1593/neo.101372; Simonsen JB, 2016, NANOMED-NANOTECHNOL, V12, P2161, DOI 10.1016/j.nano.2016.05.009; Son JC, 2017, CANCER INFORM, V16, DOI 10.1177/1176935117702878; Tatiparti K, 2017, NANOMATERIALS-BASEL, V7, DOI 10.3390/nano7040077; Todorova K, 2017, HORM CANCER-US, V8, P28, DOI 10.1007/s12672-016-0279-9; Vickers KC, 2014, J LIPID RES, V55, P4, DOI 10.1194/jlr.R035964; Vickers KC, 2011, NAT CELL BIOL, V13, P423, DOI 10.1038/ncb2210; Wang W, 2014, ONCOL REP, V32, P2127, DOI 10.3892/or.2014.3439; Wang XJ, 2016, BIOMED PHARMACOTHER, V82, P202, DOI 10.1016/j.biopha.2016.04.060; Wu SY, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11169; Xu GL, 2016, MOL ENDOCRINOL, V30, P917, DOI 10.1210/me.2016-1056; Yan HL, 2015, INT J GYNECOL CANCER, V25, P944, DOI 10.1097/IGC.0000000000000456; Yu B, 2013, BLOOD, V121, P136, DOI 10.1182/blood-2012-01-407742; Zhang FR, 2016, EUR J PHARM SCI, V92, P11, DOI 10.1016/j.ejps.2016.06.017; Zhang J, 2012, MODERN PATHOL, V25, P456, DOI 10.1038/modpathol.2011.170; Zhang WC, 2014, TUMOR BIOL, V35, P6235, DOI 10.1007/s13277-014-2202-8; Zhao Y, 2014, BIOCHEM BIOPH RES CO, V454, P183, DOI 10.1016/j.bbrc.2014.10.068	53	30	33	0	8	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 15	2019	38	33					6095	6108		10.1038/s41388-019-0862-y	http://dx.doi.org/10.1038/s41388-019-0862-y			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IR6TP	31289363	Green Accepted			2022-12-17	WOS:000481572400002
J	Knudsen, ES; Kumarasamy, V; Ruiz, A; Sivinski, J; Chung, SJ; Grant, A; Vail, P; Chauhan, SS; Jie, T; Riall, TS; Witkiewicz, AK				Knudsen, Erik S.; Kumarasamy, Vishnu; Ruiz, Amanda; Sivinski, Jared; Chung, Sejin; Grant, Adam; Vail, Paris; Chauhan, Shailender S.; Jie, Tun; Riall, Taylor S.; Witkiewicz, Agnieszka K.			Cell cycle plasticity driven by MTOR signaling: integral resistance to CDK4/6 inhibition in patient-derived models of pancreatic cancer	ONCOGENE			English	Article							BREAST-CANCER; CDK6; PROLIFERATION; COMBINATION; PATHWAY; SENSITIVITY; ABERRATIONS; PROGRESSION; MECHANISMS; SENESCENCE	Pancreatic ductal adenocarcinoma (PDAC), like many KRAS-driven tumors, preferentially loses CDKN2A that encodes an endogenous CDK4/6 inhibitor to bypass the RB-mediated cell cycle suppression. Analysis of a panel of patient-derived cell lines and matched xenografts indicated that many pancreatic cancers have intrinsic resistance to CDK4/6 inhibition that is not due to any established mechanism or published biomarker. Rather, there is a KRAS-dependent rapid adaptive response that leads to the upregulation of cyclin proteins, which participate in functional complexes to mediate resistance. In vivo, the degree of response is associated with the suppression of a gene expression signature that is strongly prognostic in pancreatic cancer. Resistance is associated with an adaptive gene expression signature that is common to multiple kinase inhibitors, but is attenuated with MTOR inhibitors. Combination treatment with MTOR and CDK4/6 inhibitors had potent activity across a large number of patient-derived models of PDAC underscoring the potential clinical efficacy.	[Knudsen, Erik S.; Kumarasamy, Vishnu; Ruiz, Amanda; Chung, Sejin; Grant, Adam; Vail, Paris; Witkiewicz, Agnieszka K.] Roswell Pk Canc Inst, Ctr Personalized Med, Buffalo, NY 14263 USA; [Knudsen, Erik S.; Kumarasamy, Vishnu; Ruiz, Amanda; Chung, Sejin; Grant, Adam; Vail, Paris] Roswell Pk Canc Inst, Dept Mol & Cellular Biol, Buffalo, NY 14263 USA; [Sivinski, Jared] Univ Arizona, Dept Pharmacol, Tucson, AZ USA; [Chauhan, Shailender S.] Univ Arizona, Cellular & Mol Med, Tucson, AZ USA; [Jie, Tun; Riall, Taylor S.] Univ Arizona, Dept Surg, Tucson, AZ USA; [Witkiewicz, Agnieszka K.] Roswell Pk Canc Inst, Dept Pathol, Buffalo, NY 14263 USA	Roswell Park Cancer Institute; Roswell Park Cancer Institute; University of Arizona; University of Arizona; University of Arizona; Roswell Park Cancer Institute	Knudsen, ES; Witkiewicz, AK (corresponding author), Roswell Pk Canc Inst, Ctr Personalized Med, Buffalo, NY 14263 USA.; Knudsen, ES (corresponding author), Roswell Pk Canc Inst, Dept Mol & Cellular Biol, Buffalo, NY 14263 USA.; Witkiewicz, AK (corresponding author), Roswell Pk Canc Inst, Dept Pathol, Buffalo, NY 14263 USA.	Erik.Knudsen@roswellpark.org; Agnieszka.Witkiewicz@roswellpark.org	Kumarasamy, Vishnu/AAV-8896-2021; Chauhan, Shailender Singh/AAM-5269-2020	Chauhan, Shailender Singh/0000-0002-1975-2734; Sivinski, Jared/0000-0003-2696-6279	NCI; NATIONAL CANCER INSTITUTE [R01CA211878] Funding Source: NIH RePORTER	NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	The authors thank all members of the laboratory group and colleagues in the discussion and preparation of this paper. The research was supported by a grant to AKW from the NCI.	Aguirre AJ, 2017, CANCER CELL, V32, P185, DOI 10.1016/j.ccell.2017.07.007; Alexandrov LB, 2013, NATURE, V500, P415, DOI 10.1038/nature12477; Asghar U, 2015, NAT REV DRUG DISCOV, V14, P130, DOI 10.1038/nrd4504; Bartkova J, 2006, NATURE, V444, P633, DOI 10.1038/nature05268; Biankin AV, 2012, NATURE, V491, P399, DOI 10.1038/nature11547; Cheema AR, 2016, SURG CLIN N AM, V96, P1391, DOI 10.1016/j.suc.2016.07.011; Chou A, 2018, GUT, V67, P2142, DOI 10.1136/gutjnl-2017-315144; Collisson EA, 2011, NAT MED, V17, P500, DOI 10.1038/nm.2344; Cowan RW, 2014, CANCER J, V20, P80, DOI 10.1097/PPO.0000000000000011; Driscoll DR, 2016, CANCER RES, V76, P6911, DOI 10.1158/0008-5472.CAN-16-0810; Duncan JS, 2012, CELL, V149, P307, DOI 10.1016/j.cell.2012.02.053; Duronio RJ, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a008904; Franco J, 2016, CELL REP, V14, P979, DOI 10.1016/j.celrep.2015.12.094; Franco J, 2014, ONCOTARGET, V5, P6512, DOI 10.18632/oncotarget.2270; Gao H, 2015, NAT MED, V21, P1318, DOI 10.1038/nm.3954; Gao SQ, 2017, ONCOTARGET, V8, P98233, DOI 10.18632/oncotarget.21004; Gelbert LM, 2014, INVEST NEW DRUG, V32, P825, DOI 10.1007/s10637-014-0120-7; Goel S, 2016, CANCER CELL, V29, P255, DOI 10.1016/j.ccell.2016.02.006; Gong XQ, 2017, CANCER CELL, V32, P761, DOI 10.1016/j.ccell.2017.11.006; Heilmann AM, 2014, CANCER RES, V74, P3947, DOI 10.1158/0008-5472.CAN-13-2923; Herrera-Abreu MT, 2016, CANCER RES, V76, P2301, DOI 10.1158/0008-5472.CAN-15-0728; Johnson GL, 2014, CLIN CANCER RES, V20, P2516, DOI 10.1158/1078-0432.CCR-13-1081; Kleeff J, 2016, NAT REV DIS PRIMERS, V2, DOI 10.1038/nrdp.2016.22; Knudsen ES, 2018, GUT, V67, P508, DOI 10.1136/gutjnl-2016-313133; Knudsen ES, 2017, TRENDS CANCER, V3, P39, DOI 10.1016/j.trecan.2016.11.006; Knudsen ES, 2016, GASTROENTEROLOGY, V150, P48, DOI 10.1053/j.gastro.2015.08.056; Knudsen ES, 1996, J BIOL CHEM, V271, P8313, DOI 10.1074/jbc.271.14.8313; Kozar K, 2004, CELL, V118, P477, DOI 10.1016/j.cell.2004.07.025; Kwong LN, 2012, NAT MED, V18, P1503, DOI 10.1038/nm.2941; Ma XJM, 2009, NAT REV MOL CELL BIO, V10, P307, DOI 10.1038/nrm2672; Malumbres M, 2004, CELL, V118, P493, DOI 10.1016/j.cell.2004.08.002; Ono H, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096060; Ottaiano A, 2017, ACTA ONCOL, V56, P377, DOI 10.1080/0284186X.2017.1288922; Patel P, 2018, MOL CANCER RES, V16, P361, DOI 10.1158/1541-7786.MCR-17-0602; Patnaik A, 2016, CANCER DISCOV, V6, P740, DOI 10.1158/2159-8290.CD-16-0095; Raspe E, 2017, EMBO MOL MED, V9, P1052, DOI 10.15252/emmm.201607084; Rodrik-Outmezguine VS, 2011, CANCER DISCOV, V1, P248, DOI 10.1158/2159-8290.CD-11-0085; Russo AA, 1998, NATURE, V395, P237, DOI 10.1038/26155; SERRANO M, 1995, SCIENCE, V267, P249, DOI 10.1126/science.7809631; Sherr CJ, 2016, CANCER DISCOV, V6, P353, DOI 10.1158/2159-8290.CD-15-0894; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Teh JLF, 2018, CANCER DISCOV, V8, P568, DOI 10.1158/2159-8290.CD-17-0699; Vincent A, 2011, LANCET, V378, P607, DOI 10.1016/S0140-6736(10)62307-0; Witkiewicz AK, 2016, CELL REP, V16, P2017, DOI 10.1016/j.celrep.2016.07.023; Witkiewicz AK, 2015, ONCOTARGET, V6, P15788, DOI 10.18632/oncotarget.3819; Witkiewicz AK, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7744; Witkiewicz AK, 2011, CELL CYCLE, V10, P2497, DOI 10.4161/cc.10.15.16776; Yoshida A, 2016, CANCER RES, V76, P2990, DOI 10.1158/0008-5472.CAN-15-2931; Yuan TL, 2018, CELL REP, V22, P1889, DOI 10.1016/j.celrep.2018.01.051; Zhang JF, 2016, MOL CELL, V62, P929, DOI 10.1016/j.molcel.2016.04.023; 2004, MOL CANC THER, V3, P1427	51	30	30	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 2	2019	38	18					3355	3370		10.1038/s41388-018-0650-0	http://dx.doi.org/10.1038/s41388-018-0650-0			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HW3RI	30696953	Green Accepted			2022-12-17	WOS:000466610000003
J	Laouirem, S; Sannier, A; Norkowski, E; Cauchy, F; Doblas, S; Rautou, PE; Albuquerque, M; Garteiser, P; Sognigbe, L; Raffenne, J; van Beers, BE; Soubrane, O; Bedossa, P; Cros, J; Paradis, V				Laouirem, Samira; Sannier, Aurelie; Norkowski, Emma; Cauchy, Francois; Doblas, Sabrina; Rautou, Pierre Emmanuel; Albuquerque, Miguel; Garteiser, Philippe; Sognigbe, Laura; Raffenne, Jerome; van Beers, Bernard E.; Soubrane, Olivier; Bedossa, Pierre; Cros, Jerome; Paradis, Valerie			Endothelial fatty liver binding protein 4: a new targetable mediator in hepatocellular carcinoma related to metabolic syndrome	ONCOGENE			English	Article							UNITED-STATES; PPAR-GAMMA; CANCER; ADIPOCYTES; DISEASE; OBESITY; PROMOTE; EXPRESSION; METFORMIN; LEPTIN	Metabolic syndrome (MS) is becoming the leading risk factor for hepatocellular carcinoma (HCC). HCC development related to MS may occur in advanced or non-advanced liver fibrosis, suggesting specific molecular pathways. Among these pathways, basal inflammatory state and adipokines production are involved. The aim of this study was to evaluate the role of fatty acid-binding protein 4 (FABP4). In this study, we demonstrate the specific overexpression of FABP4 in human HCC samples from patients with MS compared to other risk factors for chronic liver disease with FABP4 expression restricted to peritumoral endothelial cells. In vitro, glucose, insulin, VEGFA and hypoxia upregulated endothelial FABP4, which was reversed by metformin through mTOR pathway inhibition. FABP4 exerts oncogenic effects on hepatoma cell lines by upregulating the angiogenesis gene signature and pathways involved in the cell cycle, leading to increased cell proliferation and migration, and downregulating HIF1 pathway; effects were reversed in the presence of a specific FABP4 inhibitor (BMS309403). We showed the role of microvesicles as FABP4 vectors between endothelial and tumor cells. In vivo, BMS309403 significantly reduces tumor growth in heterotopic and orthotopic xenografted mice model. In conclusion, this study demonstrates the emerging oncogenic role of liver endothelial cells through FABP4 in HCC related to MS, and highlights new anti-neoplastic mechanism of metformin.	[Laouirem, Samira; Sannier, Aurelie; Norkowski, Emma; Cauchy, Francois; Doblas, Sabrina; Garteiser, Philippe; Sognigbe, Laura; Raffenne, Jerome; van Beers, Bernard E.; Bedossa, Pierre; Cros, Jerome; Paradis, Valerie] INSERM UMR 1149, Ctr Rech Inflammat, Paris, France; [Cauchy, Francois; Soubrane, Olivier] Beaujon Hosp, Hepatobiliary Surg Dept, Clichy, France; [Rautou, Pierre Emmanuel] Beaujon Hosp, Hepatol Dept, 100 Bd Gen Leclerc, F-92110 Clichy, France; [Albuquerque, Miguel; Cros, Jerome; Paradis, Valerie] Beaujon Hosp, Pathol Dept, Clichy, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Beaujon - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Beaujon - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Beaujon - APHP; UDICE-French Research Universities; Universite Paris Cite	Paradis, V (corresponding author), INSERM UMR 1149, Ctr Rech Inflammat, Paris, France.; Paradis, V (corresponding author), Beaujon Hosp, Pathol Dept, Clichy, France.	vparadis@teaser.fr	Paradis, Valerie/X-9097-2019; François, Cauchy/J-7031-2019; Van Beers, Bernard/N-2816-2016; raffenne, jerome/AAD-1601-2020; Soubrane, Olivier/ABB-4434-2021; Cros, Jerome/X-7677-2019; Garteiser, Philippe/P-5719-2017	François, Cauchy/0000-0002-4997-3730; Van Beers, Bernard/0000-0001-6429-1140; raffenne, jerome/0000-0002-5344-5674; Cros, Jerome/0000-0002-4935-3865; Rautou, Pierre-Emmanuel/0000-0001-9567-1859; Garteiser, Philippe/0000-0003-0157-8851	la Ligue Nationale de la Recherche Contre le Cancer; 2la Fondation de la Recherche Medicale	la Ligue Nationale de la Recherche Contre le Cancer; 2la Fondation de la Recherche Medicale	The study was supported by "la Ligue Nationale de la Recherche Contre le Cancer." A. Sannier received a research grant from "2la Fondation de la Recherche Medicale".	Baffy G, 2012, J HEPATOL, V56, P1384, DOI 10.1016/j.jhep.2011.10.027; Bedossa P, 1996, HEPATOLOGY, V24, P289, DOI 10.1002/hep.510240201; Bedossa P, 2012, HEPATOLOGY, V56, P1751, DOI 10.1002/hep.25889; Ben Sahra I, 2011, CANCER RES, V71, P4366, DOI 10.1158/0008-5472.CAN-10-1769; Boord JB, 2004, CIRCULATION, V110, P1492, DOI 10.1161/01.CIR.0000141735.13202.B6; Calle EE, 2003, NEW ENGL J MED, V348, P1625, DOI 10.1056/NEJMoa021423; Cao H, 2006, DIABETES, V55, P1915, DOI 10.2337/db05-1496; Cauchy F, 2017, CLIN SCI, V131, P27, DOI 10.1042/CS20160438; Cauchy F, 2015, GUT, V64, P1498, DOI 10.1136/gutjnl-2015-310069; Chiyonobu N, 2018, AM J PATHOL, V188, P1213, DOI 10.1016/j.ajpath.2018.01.012; Das R, 2001, CLIN CANCER RES, V7, P1706; Dirat B, 2011, CANCER RES, V71, P2455, DOI 10.1158/0008-5472.CAN-10-3323; Eckel RH, 2010, LANCET, V375, P181, DOI 10.1016/S0140-6736(09)61794-3; El-Serag HB, 2001, AM J GASTROENTEROL, V96, P2462, DOI 10.1111/j.1572-0241.2001.04054.x; Elmasri H, 2012, ANGIOGENESIS, V15, P457, DOI 10.1007/s10456-012-9274-0; Ertunc ME, 2015, J LIPID RES, V56, P423, DOI 10.1194/jlr.M055798; Furuhashi M, 2008, NAT REV DRUG DISCOV, V7, P489, DOI 10.1038/nrd2589; Garin-Shkolnik T, 2014, DIABETES, V63, P900, DOI 10.2337/db13-0436; Guaita-Esteruelas S, 2017, MOL CARCINOGEN, V56, P208, DOI 10.1002/mc.22485; Hammamieh Rasha, 2004, J Exp Ther Oncol, V4, P195; Hancke K, 2010, BREAST CANCER RES TR, V119, P367, DOI 10.1007/s10549-009-0577-9; Harjes U, 2014, J BIOL CHEM, V289, P23168, DOI 10.1074/jbc.M114.576512; Herroon MK, 2013, ONCOTARGET, V4, P2108, DOI 10.18632/oncotarget.1482; Hotamisligil GS, 1996, SCIENCE, V274, P1377, DOI 10.1126/science.274.5291.1377; Hu BF, 2015, J HEPATOL, V63, P855, DOI 10.1016/j.jhep.2015.05.030; Queipo-Ortuno MI, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048605; Kaess BM, 2012, J CLIN ENDOCR METAB, V97, pE1943, DOI 10.1210/jc.2012-1458; Kim YC, 2011, J NUTR BIOCHEM, V22, P289, DOI 10.1016/j.jnutbio.2010.02.007; Koh JH, 2009, DIABETES CARE, V32, P147, DOI 10.2337/dc08-1379; Larsson SC, 2007, BRIT J CANCER, V97, P1005, DOI 10.1038/sj.bjc.6603932; Lee D, 2014, ONCOL REP, V31, P1116, DOI 10.3892/or.2014.2975; Lemoinne S, 2015, HEPATOLOGY, V61, P1041, DOI 10.1002/hep.27318; Maeda K, 2005, CELL METAB, V1, P107, DOI 10.1016/j.cmet.2004.12.008; Manabe Y, 2003, J PATHOL, V201, P221, DOI 10.1002/path.1430; Marra F, 2009, HEPATOLOGY, V50, P957, DOI 10.1002/hep.23046; Milner KL, 2009, HEPATOLOGY, V49, P1926, DOI 10.1002/hep.22896; Nieman KM, 2011, NAT MED, V17, P1498, DOI 10.1038/nm.2492; Pais R, 2016, J HEPATOL, V65, P1245, DOI 10.1016/j.jhep.2016.07.033; Paradis V, 2009, HEPATOLOGY, V49, P851, DOI 10.1002/hep.22734; Pelton PD, 1999, BIOCHEM BIOPH RES CO, V261, P456, DOI 10.1006/bbrc.1999.1071; Saavedra P, 2015, BBA-MOL CELL RES, V1853, P2966, DOI 10.1016/j.bbamcr.2015.09.002; Saxena NK, 2007, CANCER RES, V67, P2497, DOI 10.1158/0008-5472.CAN-06-3075; Sharma D, 2010, HEPATOLOGY, V52, P1713, DOI 10.1002/hep.23892; Starley BQ, 2010, HEPATOLOGY, V51, P1820, DOI 10.1002/hep.23594; Thompson KJ, 2017, LIVER INT, DOI [10.1111/liv, DOI 10.1111/LIV]; Wang Y, 2014, J CHEM INF MODEL, V54, P3046, DOI 10.1021/ci500503b; Wang Y, 2017, BIOMED PHARMACOTHER, V85, P272, DOI 10.1016/j.biopha.2016.11.021; Welzel TM, 2011, HEPATOLOGY, V54, P463, DOI 10.1002/hep.24397; Westerbacka J, 2007, DIABETES, V56, P2759, DOI 10.2337/db07-0156; Wong RJ, 2015, GASTROENTEROLOGY, V148, P547, DOI 10.1053/j.gastro.2014.11.039; Xu AM, 2006, CLIN CHEM, V52, P405, DOI 10.1373/clinchem.2005.062463	51	30	30	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 18	2019	38	16					3033	3046		10.1038/s41388-018-0597-1	http://dx.doi.org/10.1038/s41388-018-0597-1			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HU3IV	30575815	Green Published, hybrid			2022-12-17	WOS:000465167600012
J	Chen, CW; Li, YM; Hu, SY; Zhou, W; Meng, YX; Li, ZZ; Zhang, Y; Sun, J; Bob, Z; DePamphilis, ML; Yen, Y; Han, ZY; Zhu, WG				Chen, Chi-Wei; Li, Yongming; Hu, Shuya; Zhou, Wei; Meng, Yunxiao; Li, Zongzhu; Zhang, Yi; Sun, Jing; Bob, Zhou; DePamphilis, Melvin L.; Yen, Yun; Han, Zhiyong; Zhu, Wenge			DHS (trans-4,4 '-dihydroxystilbene) suppresses DNA replication and tumor growth by inhibiting RRM2 (ribonucleotide reductase regulatory subunit M2)	ONCOGENE			English	Article							CHEMOPREVENTIVE AGENT RESVERATROL; CANCER CELL-LINES; TAMOXIFEN RESISTANCE; ENHANCED ANTIOXIDANT; DOWN-REGULATION; GEMCITABINE; ANALOG; DAMAGE; CYCLE; MOUSE	DNA replication machinery is responsible for accurate and efficient duplication of the chromosome. Since inhibition of DNA replication can lead to replication fork stalling, resulting in DNA damage and apoptotic death, inhibitors of DNA replication are commonly used in cancer chemotherapy. Ribonucleotide reductase (RNR) is the rate-limiting enzyme in the biosynthesis of deoxyribonucleoside triphosphates (dNTPs) that are essential for DNA replication and DNA damage repair. Gemcitabine, a nucleotide analog that inhibits RNR, has been used to treat various cancers. However, patients often develop resistance to this drug during treatment. Thus, new drugs that inhibit RNR are needed to be developed. In this study, we identified a synthetic analog of resveratrol (3,5,4'-trihydroxy-trans-stilbene), termed DHS (trans-4,4'-dihydroxystilbene), that acts as a potent inhibitor of DNA replication. Molecular docking analysis identified the RRM2 (ribonucleotide reductase regulatory subunit M2) of RNR as a direct target of DHS. At the molecular level, DHS induced cyclin F-mediated down-regulation of RRM2 by the proteasome. Thus, treatment of cells with DHS reduced RNR activity and consequently decreased synthesis of dNTPs with concomitant inhibition of DNA replication, arrest of cells at S-phase, DNA damage, and finally apoptosis. In mouse models of tumor xenografts, DHS was efficacious against pancreatic, ovarian, and colorectal cancer cells. Moreover, DHS overcame both gemcitabine resistance in pancreatic cancer and cisplatin resistance in ovarian cancer. Thus, DHS is a novel anti-cancer agent that targets RRM2 with therapeutic potential either alone or in combination with other agents to arrest cancer development.	[Chen, Chi-Wei; Li, Yongming; Zhou, Wei; Meng, Yunxiao; Li, Zongzhu; Zhang, Yi; Sun, Jing; Zhu, Wenge] George Washington Univ, Sch Med & Hlth Sci, Dept Biochem & Mol Med, Washington, DC 20052 USA; [Chen, Chi-Wei; Zhou, Wei; Meng, Yunxiao; Li, Zongzhu; Zhang, Yi; Sun, Jing; Zhu, Wenge] George Washington Univ, GW Canc Ctr, Washington, DC 20052 USA; [Li, Yongming] Dalian Med Univ, Coll Basic Med Sci, Dalian, Peoples R China; [Hu, Shuya; Yen, Yun] City Hope Natl Med Ctr, 1500 E Duarte Rd, Duarte, CA 91010 USA; [Zhou, Wei] Zhejiang Univ, Sch Med, Sir Run Run Shaw Hosp, Dept Colorectal Surg, Hangzhou, Zhejiang, Peoples R China; [Bob, Zhou] Lanzhou Univ, State Key Lab Appl Organ Chem, Lanzhou, Gansu, Peoples R China; [DePamphilis, Melvin L.] NICHHD, Bethesda, MD 20892 USA; [Han, Zhiyong] Seton Hall Univ, Dept Med Sci, Hackensack Meridian Sch Med, S Orange, NJ 07079 USA	George Washington University; George Washington University; Dalian Medical University; City of Hope; Zhejiang University; Lanzhou University; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Seton Hall University	Zhu, WG (corresponding author), George Washington Univ, Sch Med & Hlth Sci, Dept Biochem & Mol Med, Washington, DC 20052 USA.; Zhu, WG (corresponding author), George Washington Univ, GW Canc Ctr, Washington, DC 20052 USA.; Han, ZY (corresponding author), Seton Hall Univ, Dept Med Sci, Hackensack Meridian Sch Med, S Orange, NJ 07079 USA.	zhiyong.han@shu.edu; wz6812@gwu.edu	li, yong/HDN-3885-2022	Chen, Chi-Wei/0000-0001-8658-055X	National Institutes of Health [CA177898, CA184717, RSG-13-214-01-DMC]; American Cancer Society; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD000506] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA177898, R01CA184717] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Cancer Society(American Cancer Society); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was partially supported by funding from the National Institutes of Health (CA177898 and CA184717 to WZ). WZ was supported by a Research Scholar Grant, RSG-13-214-01-DMC from the American Cancer Society.	Aye Y, 2015, ONCOGENE, V34, P2011, DOI 10.1038/onc.2014.155; Balan KV, 2006, BIOCHEM PHARMACOL, V72, P573, DOI 10.1016/j.bcp.2006.05.023; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Bikadi Z, 2009, J CHEMINFORMATICS, V1, DOI 10.1186/1758-2946-1-15; Brown VA, 2010, CANCER RES, V70, P9003, DOI 10.1158/0008-5472.CAN-10-2364; Cai YJ, 2004, ANTICANCER RES, V24, P999; Chabes A, 2000, J BIOL CHEM, V275, P17747, DOI 10.1074/jbc.M000799200; Chen CW, 2016, NEOPLASIA, V18, P199, DOI 10.1016/j.neo.2016.02.005; Chen MC, 2015, MOL PHARMACOL, V87, P996, DOI 10.1124/mol.114.094987; Chen W, 2015, ANAL BIOANAL CHEM, V407, P5793, DOI 10.1007/s00216-015-8762-7; Chen ZH, 2004, CARCINOGENESIS, V25, P2005, DOI 10.1093/carcin/bgh183; Chen ZM, 2011, BIOCHEM BIOPH RES CO, V413, P383, DOI 10.1016/j.bbrc.2011.08.111; D'Angiolella V, 2012, CELL, V149, P1023, DOI 10.1016/j.cell.2012.03.043; Fabbrocini G, 2011, AM J CLIN DERMATOL, V12, P133, DOI 10.2165/11530630-000000000-00000; Fan GJ, 2009, BIOORGAN MED CHEM, V17, P2360, DOI 10.1016/j.bmc.2009.02.014; Fang JG, 2002, CHEM-EUR J, V8, P4191, DOI 10.1002/1521-3765(20020916)8:18<4191::AID-CHEM4191>3.0.CO;2-S; Fontecave M, 1998, FEBS LETT, V421, P277, DOI 10.1016/S0014-5793(97)01572-X; Gertz M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049761; Goan YG, 1999, CANCER RES, V59, P4204; Harikumar KB, 2010, INT J CANCER, V127, P257, DOI 10.1002/ijc.25041; Hehlmann R, 2003, LEUKEMIA, V17, P1010, DOI 10.1038/sj.leu.2402951; Hosseini A, 2015, AVICENNA J PHYTOMEDI, V5, P84; Hsieh YY, 2016, CELL DEATH DISCOV, V2, DOI 10.1038/cddiscovery.2016.27; Hu S, 2016, ACTA BIOCH BIOPH SIN, V48, P528, DOI 10.1093/abbs/gmw026; Jafari R, 2014, NAT PROTOC, V9, P2100, DOI 10.1038/nprot.2014.138; Jang MS, 1997, SCIENCE, V275, P218, DOI 10.1126/science.275.5297.218; Jung CP, 2001, CLIN CANCER RES, V7, P2527; Kimura Y, 2008, CANCER SCI, V99, P2083, DOI 10.1111/j.1349-7006.2008.00948.x; Kitao H, 2018, CANCER SCI, V109, P264, DOI 10.1111/cas.13455; Kohnken R, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0446-6; Li GM, 2013, CANCER PREV RES, V6, P27, DOI 10.1158/1940-6207.CAPR-12-0349; Liu J, 2004, NEUROSCI LETT, V363, P257, DOI 10.1016/j.neulet.2004.03.075; Liu XY, 2013, CLIN SCI, V124, P567, DOI 10.1042/CS20120240; LOEWE S, 1953, ARZNEIMITTEL-FORSCH, V3, P285; Lopez-Contreras AJ, 2015, GENE DEV, V29, P690, DOI 10.1101/gad.256958.114; Lu AG, 2012, WORLD J GASTROENTERO, V18, P4704, DOI 10.3748/wjg.v18.i34.4704; Ma LJ, 2015, INT J ONCOL, V47, P1460, DOI 10.3892/ijo.2015.3124; Maccario C, 2012, CARCINOGENESIS, V33, P2172, DOI 10.1093/carcin/bgs244; Minami K, 2015, J PHARMACOL SCI, V127, P319, DOI 10.1016/j.jphs.2015.01.006; Mini E, 2006, ANN ONCOL, V17, pV7, DOI 10.1093/annonc/mdj941; Morikawa T, 2010, HISTOPATHOLOGY, V57, P885, DOI 10.1111/j.1365-2559.2010.03725.x; Morikawa T, 2010, HUM PATHOL, V41, P1742, DOI 10.1016/j.humpath.2010.06.001; Nakano Y, 2007, BRIT J CANCER, V96, P457, DOI 10.1038/sj.bjc.6603559; Nessa MU, 2012, ANTICANCER RES, V32, P53; Nordlund N, 2006, ANNU REV BIOCHEM, V75, P681, DOI 10.1146/annurev.biochem.75.103004.142443; O'Connor MJ, 2015, MOL CELL, V60, P547, DOI 10.1016/j.molcel.2015.10.040; Piotrowska H, 2013, TOXICOL IN VITRO, V27, P2127, DOI 10.1016/j.tiv.2013.09.012; Piotrowska H, 2012, TOXICOL APPL PHARM, V263, P53, DOI 10.1016/j.taap.2012.05.023; Plunkett W, 1995, ANTI-CANCER DRUG, V6, P7, DOI 10.1097/00001813-199512006-00002; PLUNKETT W, 1995, SEMIN ONCOL, V22, P3; Puigvert JC, 2016, FEBS J, V283, P232, DOI 10.1111/febs.13574; Saha B, 2017, ONCOTARGET, V8, P73905, DOI 10.18632/oncotarget.17879; Saiki Y, 2012, BIOCHEM BIOPH RES CO, V421, P98, DOI 10.1016/j.bbrc.2012.03.122; Sale S, 2005, INT J CANCER, V115, P194, DOI 10.1002/ijc.20884; Savio M, 2016, SCI REP-UK, V6, DOI 10.1038/srep19973; Scharadin TM, 2016, CHEM RES TOXICOL, V29, P1843, DOI 10.1021/acs.chemrestox.6b00247; Shah KN, 2015, MOL CANCER THER, V14, P2411, DOI 10.1158/1535-7163.MCT-14-0689; Shah KN, 2014, MOL CANCER RES, V12, P394, DOI 10.1158/1541-7786.MCR-13-0219; SHERMAN PA, 1989, ANAL BIOCHEM, V180, P222, DOI 10.1016/0003-2697(89)90420-X; Shewach DS, 2007, J CLIN ONCOL, V25, P4043, DOI 10.1200/JCO.2007.11.5287; Tanaka H, 2000, NATURE, V404, P42, DOI 10.1038/35003506; THELANDER M, 1985, J BIOL CHEM, V260, P2737; Varoni EM, 2016, FRONT NUTR, V3, DOI 10.3389/fnut.2016.00008; Wang LM, 2012, CHINESE MED J-PEKING, V125, P2151, DOI 10.3760/cma.j.issn.0366-6999.2012.12.013; Yamaguchi T, 2001, CANCER RES, V61, P8256; Zhang J, 2016, GENES-BASEL, V7, DOI 10.3390/genes7080051; Zhou BS, 2013, CANCER RES, V73, P6484, DOI 10.1158/0008-5472.CAN-13-1094; Zhou BS, 1998, BIOCHEM PHARMACOL, V55, P1657, DOI 10.1016/S0006-2952(98)00042-2; Zhou W, 2018, ONCOGENE, V37, P3981, DOI 10.1038/s41388-018-0238-8; Zhu WG, 2007, GENE DEV, V21, P2288, DOI 10.1101/gad.1585607	70	30	30	2	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 28	2019	38	13					2364	2379		10.1038/s41388-018-0584-6	http://dx.doi.org/10.1038/s41388-018-0584-6			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HQ7GN	30518875	Green Accepted			2022-12-17	WOS:000462588000010
J	Zhang, XP; Liu, L; Deng, XZ; Li, D; Cai, HD; Ma, YS; Jia, CY; Wu, B; Fan, YB; Lv, ZW				Zhang, Xiaoping; Liu, Lin; Deng, Xianzhao; Li, Dan; Cai, Haidong; Ma, Yushui; Jia, Chengyou; Wu, Bo; Fan, Youben; Lv, Zhongwei			MicroRNA 483-3p targets Pard3 to potentiate TGF-beta 1-induced cell migration, invasion, and epithelial-mesenchymal transition in anaplastic thyroid cancer cells	ONCOGENE			English	Article							NUCLEOTIDE EXCHANGE FACTOR; LUNG ADENOCARCINOMA; GENE-EXPRESSION; ONCOGENIC ROLE; TIAM1; CARCINOMA; METASTASIS; MIR-483-3P; PROGNOSIS; MIR-21	Anaplastic thyroid cancer (ATC) is associated with poor prognosis and is often untreatable. MicroRNA 483-3p (miR-483) and partitioning-defective 3 (Pard3), a member of the Pard family, have functions and regulatory mechanisms in ATC. The abnormal regulation of miR-483 may play an important role in tumorigenesis, and Par3 is known to regulate cell polarity, cell migration, and cell division. Tumor proliferation promoted by the regulation of miRNA expression can be regulated in thyroid cancer by upregulating transforming growth factor-beta 1 (TGF-beta 1), which is thought to interact with Pard3. When compared with adjacent non-tumor tissues, we found that miR-483 was upregulated and Pard3 was downregulated in 80 thyroid tumor samples. Disease-free survival was decreased when expression of miR-483 was upregulated and Pard3 expression was downregulated. Cell growth, migration, and invasion were induced by overexpression of miR-483. However, knockdown of miR-483 resulted in a loss of cell invasion and viability, both in vitro and in vivo. The expression of Pard3 was increased by the inhibition of miR-483, but TGF-beta 1-induced cell migration and invasion were decreased by miR-483 inhibition. A dual-luciferase reporter assay determined that Pard3 expression was downregulated when targeted with miR483. The epithelial-mesenchymal transition (EMT), as well as Tiam1-Rac signaling, was induced by TGF-beta 1, which was decreased by the overexpression of Pard3. Pard3 decreased the inhibition of EMT and Tiam-Rac1 signaling, which resulted from transfection of ATC cells with miR-483. Overall, the results showed that downregulation of Pard3 resulted in increased cell invasion and EMT in ATC, which was promoted by treatment with miR-483. These findings suggest novel therapeutic targets and treatment strategies for this disease.	[Zhang, Xiaoping; Liu, Lin; Li, Dan; Cai, Haidong; Ma, Yushui; Jia, Chengyou; Lv, Zhongwei] Tongji Univ, Shanghai Peoples Hosp 10, Dept Nucl Med, Shanghai 200072, Peoples R China; [Zhang, Xiaoping; Liu, Lin; Li, Dan; Cai, Haidong; Ma, Yushui; Jia, Chengyou; Lv, Zhongwei] Shanghai Ctr Thyroid Dis, Shanghai 200072, Peoples R China; [Deng, Xianzhao; Wu, Bo; Fan, Youben] Shanghai Jiao Tong Univ, Affiliated Peoples Hosp 6, Dept Gen Surg, Ctr Thyroid, Shanghai 200233, Peoples R China	Tongji University; Shanghai Jiao Tong University	Lv, ZW (corresponding author), Tongji Univ, Shanghai Peoples Hosp 10, Dept Nucl Med, Shanghai 200072, Peoples R China.; Lv, ZW (corresponding author), Shanghai Ctr Thyroid Dis, Shanghai 200072, Peoples R China.; Wu, B; Fan, YB (corresponding author), Shanghai Jiao Tong Univ, Affiliated Peoples Hosp 6, Dept Gen Surg, Ctr Thyroid, Shanghai 200233, Peoples R China.	wubo7421@sohu.com; fanyouben2006@163.com; heyixue163@163.com	Fu, Da/GXF-2656-2022; ma, yushui/HGC-6206-2022; Jia, Chengyou/AAV-1153-2021		National Natural Science Foundation of China [81572626, 81302332, 81371595, 81501505, 81670718]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was funded by the National Natural Science Foundation of China (81572626, 81302332, 81371595, 81501505, and 81670718).	Abue M, 2015, INT J ONCOL, V46, P539, DOI 10.3892/ijo.2014.2743; Ain KB, 1999, SEMIN SURG ONCOL, V16, P64, DOI 10.1002/(SICI)1098-2388(199901/02)16:1<64::AID-SSU10>3.3.CO;2-L; Aranda V, 2008, ONCOGENE, V27, P6878, DOI 10.1038/onc.2008.340; Archibald A, 2015, ONCOGENE, V34, P3199, DOI 10.1038/onc.2014.242; Bonastre E, 2015, CANCER RES, V75, P1287, DOI 10.1158/0008-5472.CAN-14-2444; Cha BK, 2016, ONCOTARGET, V7, P57213, DOI 10.18632/oncotarget.11127; Chen AY, 2009, CANCER-AM CANCER SOC, V115, P3801, DOI 10.1002/cncr.24416; Chen CF, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni178; Cheng Y, 2016, J EXP CLIN CANC RES, V35, DOI 10.1186/s13046-016-0290-6; Cottonham CL, 2010, J BIOL CHEM, V285, P35293, DOI 10.1074/jbc.M110.160069; Cui DM, 2016, INT J BIOCHEM CELL B, V73, P72, DOI 10.1016/j.biocel.2016.02.007; Dong L, 2011, J DENT RES, V90, P804, DOI 10.1177/0022034511401407; Ehtesham Naeim, 2016, Adv Biomed Res, V5, P187, DOI 10.4103/2277-9175.190996; Engers R, 2001, J BIOL CHEM, V276, P41889, DOI 10.1074/jbc.M105049200; Guo XJ, 2016, CLIN EXP MED, V16, P357, DOI 10.1007/s10238-015-0365-2; Hardin H, 2014, AM J PATHOL, V184, P2342, DOI 10.1016/j.ajpath.2014.04.011; Hassan N, 2017, MOL CELL ENDOCRINOL, V456, P36, DOI 10.1016/j.mce.2016.12.011; Hong L, 2010, ANN SURG, V251, P1056, DOI 10.1097/SLA.0b013e3181dd4ea9; Huang YH, 2013, CANCER RES, V73, P2505, DOI 10.1158/0008-5472.CAN-12-2218; Jin J, 2013, ASIAN PAC J CANCER P, V14, P3681, DOI 10.7314/APJCP.2013.14.6.3681; Kitahara CM, 2016, NAT REV ENDOCRINOL, V12, P646, DOI 10.1038/nrendo.2016.110; Li FF, 2014, CELL PHYSIOL BIOCHEM, V34, P2169, DOI 10.1159/000369660; Li HL, 2016, ONCOTARGET, V7, P66267, DOI [10.18632/oncotarget.11411, 10.18632/oncotarget.11728]; Liu L, 2005, WORLD J GASTROENTERO, V11, P705, DOI 10.3748/wjg.v11.i5.705; Liu L, 2018, EXP CELL RES, V362, P532, DOI 10.1016/j.yexcr.2017.12.019; Liu N, 2013, CANCER LETT, V329, P181, DOI 10.1016/j.canlet.2012.10.032; Lu CL, 2015, ONCOTARGET, V6, P24912, DOI 10.18632/oncotarget.4701; Lupini L, 2016, ONCOTARGET, V7, P31361, DOI 10.18632/oncotarget.8913; Ma JJ, 2016, CELL BIOL INT, V40, P448, DOI 10.1002/cbin.10585; Mertens AEE, 2005, J CELL BIOL, V170, P1029, DOI 10.1083/jcb.200502129; Minard ME, 2004, BREAST CANCER RES TR, V84, P21, DOI 10.1023/B:BREA.0000018421.31632.e6; Moriarty CH, 2010, J BIOL CHEM, V285, P20541, DOI 10.1074/jbc.M110.121012; Neff RL, 2008, ENDOCRIN METAB CLIN, V37, P525, DOI 10.1016/j.ecl.2008.02.003; Otsuki Y, 2003, J BIOL CHEM, V278, P5132, DOI 10.1074/jbc.M206733200; Pino MS, 2010, GASTROENTEROLOGY, V138, P1406, DOI 10.1053/j.gastro.2009.12.010; Puppo M, 2016, CELL REP, V16, P967, DOI 10.1016/j.celrep.2016.06.055; Qu XY, 2014, MED ONCOL, V31, DOI 10.1007/s12032-014-0219-x; Smith BR, 2006, THYROID, V16, P109, DOI 10.1089/thy.2006.16.109; Song QC, 2014, CANCER RES, V74, P3031, DOI 10.1158/0008-5472.CAN-13-2193; Stebel A, 2009, ONCOL REP, V21, P217, DOI 10.3892/or_00000211; Sun RW, 2014, ONCOTARGET, V5, P12398, DOI 10.18632/oncotarget.2643; Suzuki A, 2006, J CELL SCI, V119, P979, DOI 10.1242/jcs.02898; VanGuilder HD, 2008, BIOTECHNIQUES, V44, P619, DOI 10.2144/000112776; Veronese A, 2010, CANCER RES, V70, P3140, DOI 10.1158/0008-5472.CAN-09-4456; Warner DR, 2003, FEBS LETT, V539, P167, DOI 10.1016/S0014-5793(03)00155-8; Woodcock SA, 2009, J PROTEOME RES, V8, P5629, DOI 10.1021/pr900716e; Xia X, 2015, ONCOTARGET, V6, P21046, DOI 10.18632/oncotarget.4124; Xu J, 2009, CELL RES, V19, P156, DOI 10.1038/cr.2009.5; Xu Z, 2003, CELL RES, V13, P343, DOI 10.1038/sj.cr.7290179; Xue B, 2013, NAT CELL BIOL, V15, P189, DOI 10.1038/ncb2663; Zhang J, 2014, TUMOR BIOL, V35, P379, DOI 10.1007/s13277-013-1053-z; Zhang K, 2016, ONCOGENE, V35, P1271, DOI 10.1038/onc.2015.184; Zhang KJ, 2016, AM J TRANSL RES, V8, P2196; Zhao Chunling, 2012, BMC Res Notes, V5, P91, DOI 10.1186/1756-0500-5-91; Zhou QY, 2017, CELL SIGNAL, V38, P49, DOI 10.1016/j.cellsig.2017.06.016; Zhou Y, 2013, GENET TEST MOL BIOMA, V17, P470, DOI 10.1089/gtmb.2012.0518; Zhu JH, 2016, TRANSL ONCOL, V9, P592, DOI 10.1016/j.tranon.2016.08.003; Zondag GCM, 2000, J CELL BIOL, V149, P775, DOI 10.1083/jcb.149.4.775	58	30	35	4	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 31	2019	38	5					699	715		10.1038/s41388-018-0447-1	http://dx.doi.org/10.1038/s41388-018-0447-1			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HJ6LI	30171257	Green Published, hybrid			2022-12-17	WOS:000457300300007
J	Castagnino, A; Castro-Castro, A; Irondelle, M; Guichard, A; Lodillinsky, C; Fuhrmann, L; Vacher, S; Aguera-Gonzalez, S; Zagryazhskaya-Masson, A; Romao, M; El Kesrouani, C; Noegel, AA; Dubois, T; Raposo, G; Bear, JE; Clemen, CS; Vincent-Salomon, A; Bieche, I; Chavrier, P				Castagnino, Alessia; Castro-Castro, Antonio; Irondelle, Marie; Guichard, Alan; Lodillinsky, Catalina; Fuhrmann, Laetitia; Vacher, Sophie; Aguera-Gonzalez, Sonia; Zagryazhskaya-Masson, Anna; Romao, Maryse; El Kesrouani, Carole; Noegel, Angelika A.; Dubois, Thierry; Raposo, Graca; Bear, James E.; Clemen, Christoph S.; Vincent-Salomon, Anne; Bieche, Ivan; Chavrier, Philippe			Coronin 1C promotes triple-negative breast cancer invasiveness through regulation of MT1-MMP traffic and invadopodia function	ONCOGENE			English	Article							ACTIN-BINDING; ARP2/3 COMPLEX; MATRIX-METALLOPROTEINASE; MOLECULAR-MECHANISMS; CORTACTIN PROMOTES; EXOSOME SECRETION; INVASION; WASH; METASTASIS; EXPRESSION	Membrane type 1-matrix metalloproteinase (MT1-MMP), a membrane-tethered protease, is key for matrix breakdown during cancer invasion and metastasis. Assembly of branched actin networks by the Arp2/3 complex is required for MT1-MMP traffic and formation of matrix-degradative invadopodia. Contrasting with the well-established role of actin filament branching factor cortactin in invadopodia function during cancer cell invasion, the contribution of coronin-family debranching factors to invadopodia-based matrix remodeling is not known. Here, we investigated the contribution of coronin 1C to the invasive potential of breast cancer cells. We report that expression of coronin 1C is elevated in invasive human breast cancers, correlates positively with MT1-MMP expression in relation with increased metastatic risk and is a new independent prognostic factor in breast cancer. We provide evidence that, akin to cortactin, coronin 1C is required for invadopodia formation and matrix degradation by breast cancer cells lines and for 3D collagen invasion by multicellular spheroids. Using intravital imaging of orthotopic human breast tumor xenografts, we find that coronin 1C accumulates in structures forming in association with collagen fibrils in the tumor microenvironment. Moreover, we establish the role of coronin 1C in the regulation of positioning and trafficking of MT1-MMP-positive endolysosomes. These results identify coronin 1C as a novel player of the multi-faceted mechanism responsible for invadopodia formation, MT1-MMP surface exposure and invasiveness in breast cancer cells.	[Castagnino, Alessia; Castro-Castro, Antonio; Irondelle, Marie; Guichard, Alan; Lodillinsky, Catalina; Aguera-Gonzalez, Sonia; Zagryazhskaya-Masson, Anna; Chavrier, Philippe] PSL Res Univ, CNRS, UMR144, Inst Curie,Membrane & Cytoskeleton Dynam Grp, 26 Rue Ulm, F-75005 Paris, France; [Irondelle, Marie] PSL Res Univ, Cell & Tissue Imaging Facil, Inst Curie, PICT,IBiSA, 26 Rue Ulm, F-75005 Paris, France; [Lodillinsky, Catalina] Univ Buenos Aires, Fac Med, Inst Oncol AH Roffo, Area Invest, San Martin 5481,C1417DTB, Buenos Aires, DF, Argentina; [Lodillinsky, Catalina] Consejo Nacl Invest Cient & Tecn, Buenos Aires, DF, Argentina; [Fuhrmann, Laetitia; El Kesrouani, Carole; Vincent-Salomon, Anne] PSL Res Univ, Inst Curie, Pathol Genet Immunol Dept, 26 Rue Ulm, F-75005 Paris, France; [Vacher, Sophie; Bieche, Ivan] PSL Res Univ, Inst Curie, Dept Genet, Pharmacogenom Unit, 26 Rue Ulm, F-75005 Paris, France; [Romao, Maryse; Raposo, Graca] PSL Res Univ, CNRS, Biogenesis & Funct Lysosome Related Organelles Gr, Inst Curie,UMR144, 26 Rue Ulm, F-75005 Paris, France; [Noegel, Angelika A.; Clemen, Christoph S.] Univ Cologne, Med Fac, Inst Biochem 1, Ctr Biochem, Joseph Stelzmann Str 52, D-50931 Cologne, Germany; [Dubois, Thierry] PSL Res Univ, Inst Curie, Translat Res Dept, Breast Canc Biol Grp, Paris, France; [Bear, James E.] Univ N Carolina, UNC Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27515 USA; [Bear, James E.] Univ N Carolina, Dept Cell Biol & Physiol, Chapel Hill, NC 27515 USA; [Clemen, Christoph S.] Ruhr Univ Bochum, Univ Hosp Bergmannsheil, Heimer Inst Muscle Res, Dept Neurol, Burkle de la Camp Pl 1, D-44789 Bochum, Germany; [Bieche, Ivan] Paris Descartes Univ, Sorbonne Paris Cite, Fac Pharmaceut & Biol Sci, EA7331, 4 Ave Observ, F-75006 Paris, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Sorbonne Universite; Universite Paris Cite; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; University of Buenos Aires; Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Sorbonne Universite; Universite Paris Cite; University of Cologne; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; Ruhr University Bochum; UDICE-French Research Universities; Universite Paris Cite	Chavrier, P (corresponding author), PSL Res Univ, CNRS, UMR144, Inst Curie,Membrane & Cytoskeleton Dynam Grp, 26 Rue Ulm, F-75005 Paris, France.	philippe.chavrier@curie.fr	CHAVRIER, Philippe/AAG-2645-2020; CHAVRIER, Philippe/B-4707-2010	CHAVRIER, Philippe/0000-0002-7351-733X; CHAVRIER, Philippe/0000-0002-7351-733X; Guichard, Alan/0000-0001-8623-9570; Raposo, graca/0000-0001-9590-1298; VACHER, Sophie/0000-0002-0042-6023	French National Research Infrastructure France-BioImaging [ANR10-INBS-04]; Worldwide Cancer Research [16-1235]; EMBO Long Term postdoctoral fellowship; Institut National du Cancer [INCA_6521, INCa PLBIO14-161, INCA_ 6521]; INVADE grant from ITMO Cancer (Call Systems Biology 2012); INCa [INCa PLBIO14-161]; German Research Foundation (DFG) [113/22-2]; Fondation pour la Recherche Medicale (FRM) [DGE20111123020]; Cancerople-IdF [2012-2-EML-04-IC-1]; InCA (Cancer National Institute) [2011-1-LABEL-IC-4]; SiRIC [INCa-DGOS-4654]; 'Equipe labellisee 2015' from 'Ligue Nationale contre le Cancer'	French National Research Infrastructure France-BioImaging; Worldwide Cancer Research; EMBO Long Term postdoctoral fellowship(European Molecular Biology Organization (EMBO)); Institut National du Cancer(Institut National du Cancer (INCA) France); INVADE grant from ITMO Cancer (Call Systems Biology 2012); INCa(Institut National du Cancer (INCA) France); German Research Foundation (DFG)(German Research Foundation (DFG)); Fondation pour la Recherche Medicale (FRM)(Fondation pour la Recherche Medicale); Cancerople-IdF; InCA (Cancer National Institute); SiRIC; 'Equipe labellisee 2015' from 'Ligue Nationale contre le Cancer'	The authors greatly acknowledge the Breast Cancer Study Group and patients of Institut Curie for breast tumor samples. They thank the Cell and Tissue Imaging facility (PICT-IBiSA) and Nikon Imaging Centre, Institut Curie, member of the French National Research Infrastructure France-BioImaging (ANR10-INBS-04) for help with image acquisition and Dr Jakko van Rheenen for help with the mammary window and intravital imaging. AC was supported by a grant from Worldwide Cancer Research (Grant 16-1235 to PC), ACC by an EMBO Long Term postdoctoral fellowship and a grant from 'Institut National du Cancer' (INCA_6521 to PC), AG by INVADE grant from ITMO Cancer (Call Systems Biology 2012) to PC, SAG by a grant from INCa (INCa PLBIO14-161 to PC). and AAN and CSC by a grant from the German Research Foundation (DFG NO 113/22-2). The intravital imaging was supported by the Fondation pour la Recherche Medicale (FRM No DGE20111123020), the Cancerople-IdF (no 2012-2-EML-04-IC-1), InCA (Cancer National Institute, no 2011-1-LABEL-IC-4) and SiRIC (INCa-DGOS-4654). This work was supported by grants from 'Institut National du Cancer' (INCa PLBIO14-161 and INCA_ 6521), Worldwide Cancer Research (Grant 16-1235) and 'Equipe labellisee 2015' from 'Ligue Nationale contre le Cancer' to PC.	Abella JVG, 2016, NAT CELL BIOL, V18, P76, DOI 10.1038/ncb3286; Artym VV, 2006, CANCER RES, V66, P3034, DOI 10.1158/0008-5472.CAN-05-2177; Ayala I, 2008, J CELL SCI, V121, P369, DOI 10.1242/jcs.008037; Behbod F, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2358; Cai L, 2008, CELL, V134, P828, DOI 10.1016/j.cell.2008.06.054; Cai L, 2007, J CELL SCI, V120, P1779, DOI 10.1242/jcs.007641; Cai L, 2007, CELL, V128, P915, DOI 10.1016/j.cell.2007.01.031; Castro-Castro A, 2016, ANNU REV CELL DEV BI, V32, P555, DOI 10.1146/annurev-cellbio-111315-125227; Castro-Castro A, 2012, EUR J CELL BIOL, V91, P950, DOI 10.1016/j.ejcb.2012.07.001; Chan KT, 2012, BIOCHEM J, V444, P89, DOI 10.1042/BJ20120209; Chan KT, 2011, TRENDS CELL BIOL, V21, P481, DOI 10.1016/j.tcb.2011.04.004; Clark ES, 2009, ONCOGENE, V28, P431, DOI 10.1038/onc.2008.389; Clark ES, 2008, EUR J CELL BIOL, V87, P581, DOI 10.1016/j.ejcb.2008.01.008; Derivery E, 2009, DEV CELL, V17, P712, DOI 10.1016/j.devcel.2009.09.010; Eckert MA, 2011, CANCER CELL, V19, P372, DOI 10.1016/j.ccr.2011.01.036; Foger N, 2006, SCIENCE, V313, P839, DOI 10.1126/science.1130563; Gligorijevic B, 2014, PLOS BIOL, V12, DOI 10.1371/journal.pbio.1001995; Gomez TS, 2012, MOL BIOL CELL, V23, P3215, DOI 10.1091/mbc.E12-02-0101; Gomez TS, 2009, DEV CELL, V17, P699, DOI 10.1016/j.devcel.2009.09.009; Holtta-Vuori M, 2012, CIRC RES, V110, P450, DOI 10.1161/CIRCRESAHA.111.256842; Hong NH, 2015, J CELL BIOL, V210, P753, DOI 10.1083/jcb.201412127; Hoshino D, 2013, CELL REP, V5, P1159, DOI 10.1016/j.celrep.2013.10.050; Hotary K, 2006, GENE DEV, V20, P2673, DOI 10.1101/gad.1451806; Humphries CL, 2002, J CELL BIOL, V159, P993, DOI 10.1083/jcb.200206113; Hurbain I, 2017, METHODS MOL BIOL, V1594, P43, DOI 10.1007/978-1-4939-6934-0_4; Juin A, 2012, MOL BIOL CELL, V23, P297, DOI 10.1091/mbc.E11-07-0594; Kirkbride KC, 2012, CYTOSKELETON, V69, P625, DOI 10.1002/cm.21051; Lamprecht MR, 2007, BIOTECHNIQUES, V42, P71, DOI 10.2144/000112257; Leong HS, 2014, CELL REP, V8, P1558, DOI 10.1016/j.celrep.2014.07.050; Linder S, 2011, ANNU REV CELL DEV BI, V27, P185, DOI 10.1146/annurev-cellbio-092910-154216; LISCUM L, 1989, J BIOL CHEM, V264, P11796; Liu CL, 2017, ONCOTARGET, V8, P42043, DOI 10.18632/oncotarget.14927; Lodillinsky C, 2016, ONCOGENE, V35, P344, DOI 10.1038/onc.2015.87; Macpherson IR, 2014, J CELL SCI, V127, P3893, DOI 10.1242/jcs.135947; Mader CC, 2011, CANCER RES, V71, P1730, DOI 10.1158/0008-5472.CAN-10-1432; Marchesin V, 2015, J CELL BIOL, V211, P339, DOI 10.1083/jcb.201506002; Marchesin V, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0121747; McGowan PM, 2008, ANN ONCOL, V19, P1566, DOI 10.1093/annonc/mdn180; Molinie N, 2018, PHYSIOL REV, V98, P215, DOI 10.1152/physrev.00006.2017; Monteiro P, 2013, J CELL BIOL, V203, P1063, DOI 10.1083/jcb.201306162; Mukhejee S, 2004, BBA-MOL CELL BIOL L, V1685, P28, DOI 10.1016/j.bbalip.2004.08.009; Perentes JY, 2011, CANCER RES, V71, P4527, DOI 10.1158/0008-5472.CAN-10-4376; Puthenveedu MA, 2010, CELL, V143, P761, DOI 10.1016/j.cell.2010.10.003; Ren G, 2012, MOL CANCER, V11, DOI 10.1186/1476-4598-11-67; Rosentreter A, 2007, EXP CELL RES, V313, P878, DOI 10.1016/j.yexcr.2006.12.015; Rosse C, 2014, P NATL ACAD SCI USA, V111, pE1872, DOI 10.1073/pnas.1400749111; Rowe RG, 2008, TRENDS CELL BIOL, V18, P560, DOI 10.1016/j.tcb.2008.08.007; Sakurai-Yageta M, 2008, J CELL BIOL, V181, P985, DOI 10.1083/jcb.200709076; Sibarita JB, 2005, ADV BIOCHEM ENG BIOT, V95, P201, DOI 10.1007/b102215; Sinha S, 2016, J CELL BIOL, V214, P197, DOI 10.1083/jcb.201601025; Siton O, 2011, CURR BIOL, V21, P2092, DOI 10.1016/j.cub.2011.11.010; Smith SE, 2017, BREAST CANCER RES, V19, DOI 10.1186/s13058-017-0855-0; Steffen A, 2008, CURR BIOL, V18, P926, DOI 10.1016/j.cub.2008.05.044; Thal DR, 2008, J PATHOL, V214, P415, DOI 10.1002/path.2308; Wang J, 2014, MOL ONCOL, V8, P1690, DOI 10.1016/j.molonc.2014.07.006; Weaver AM, 2001, CURR BIOL, V11, P370, DOI 10.1016/S0960-9822(01)00098-7; Willett R, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01871-z; Wolf K, 2007, NAT CELL BIOL, V9, P893, DOI 10.1038/ncb1616; Wu L, 2010, J EXP CLIN CANC RES, V29, DOI 10.1186/1756-9966-29-17; Yamaguchi H, 2005, J CELL BIOL, V168, P441, DOI 10.1083/jcb.200407076; Yu XZ, 2012, J CELL BIOL, V199, P527, DOI 10.1083/jcb.201203025; Ziemann A, 2013, NEURO-ONCOLOGY, V15, P548, DOI 10.1093/neuonc/nos388	62	30	30	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 13	2018	37	50					6425	6441		10.1038/s41388-018-0422-x	http://dx.doi.org/10.1038/s41388-018-0422-x			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HE0WA	30065298	Green Submitted			2022-12-17	WOS:000452989100004
J	Park, JJ; Park, MH; Oh, EH; Soung, NK; Lee, SJ; Jung, JK; Lee, OJ; Yun, SJ; Kim, WJ; Shin, EY; Kim, EG				Park, Jung-Jin; Park, Mee-Hee; Oh, Eun Hye; Soung, Nak-Kyun; Lee, Soo Jae; Jung, Jae-Kyung; Lee, Ok-Jun; Yun, Seok Joong; Kim, Wun-Jae; Shin, Eun-Young; Kim, Eung-Gook			The p21-activated kinase 4-Slug transcription factor axis promotes epithelial-mesenchymal transition and worsens prognosis in prostate cancer	ONCOGENE			English	Article							SLUG; SNAIL; INVASION; GROWTH; PHOSPHORYLATION; METASTASIS; EXPRESSION; REPRESSOR; OVARIAN; CELLS	Epithelial-mesenchymal transition (EMT) facilitates cancer invasion and metastasis and thus accelerates cancer progression. p21-activated kinase 4 (PAK4) is a critical regulator of prostate cancer (PC) progression. Here, we report that PAK4 activation promotes PC progression through the EMT regulator Slug. We find that phosphorylated PAK4(S474) (pPAK4) levels, an index of PAK4 activation, were tightly associated with Gleason score (p < 0.001), a clinical indicator of PC progression, but not with prostate serum antigen levels or tumor stage. Stable silencing of PAK4 in PC cells reduced their potential for EMT, cellular invasion, and metastasis in vivo. PAK4 bound and directly phosphorylated Slug at two previously unknown sites, S158 and S254, which resulted in its stabilization. The non-phosphorylatable form Slug(S158A/S254A) upregulated transcription of CDH1, which encodes E-cadherin, and thus suppressed EMT and invasion, to a greater extent than did wild-type Slug. The strong EMT inducer TGF-beta elevated pPAK4 and pSlug(S158) levels; PAK4 knockdown or introduction of a dominant-negative form of PAK4 inhibited both TGF-beta-stimulated EMT and an increase in pSlug(S158) levels. Finally, immunohistochemistry revealed a positive correlation between pPAK4 and pSlug(S158) but an inverse correlation between pSlug(S158) and E-cadherin. The results suggest that the PAK4-Slug axis represents a novel pathway that promotes PC progression.	[Park, Jung-Jin; Park, Mee-Hee; Oh, Eun Hye; Shin, Eun-Young; Kim, Eung-Gook] Chungbuk Natl Univ, Coll Med, Dept Biochem, Cheongju 28644, South Korea; [Park, Mee-Hee] KNIH, Korea Ctr Dis Control & Prevent, Div Med Sci Knowledge Management, Osong Eup 28159, Cheongju, South Korea; [Soung, Nak-Kyun] KRIBB, World Class Inst, Ochang Eup 28116, Cheongju, South Korea; [Lee, Soo Jae; Jung, Jae-Kyung] Chungbuk Natl Univ, Coll Pharm, Osong Eup 28160, Cheongju, South Korea; [Lee, Ok-Jun] Chungbuk Natl Univ, Coll Med, Dept Pathol, Cheongju 28644, South Korea; [Yun, Seok Joong; Kim, Wun-Jae] Chungbuk Natl Univ, Coll Med, Dept Urol, Cheongju 28644, South Korea	Chungbuk National University; Korea Centers for Disease Control & Prevention (KCDC); Korea National Institute of Health (KNIH); Korea CDC Center for Biomedical Science; Korea Research Institute of Bioscience & Biotechnology (KRIBB); Chungbuk National University; Chungbuk National University; Chungbuk National University	Shin, EY; Kim, EG (corresponding author), Chungbuk Natl Univ, Coll Med, Dept Biochem, Cheongju 28644, South Korea.	eyshin@chungbuk.ac.kr; egkim@chungbuk.ac.kr		Jung, Jae-Kyung/0000-0002-0490-9663	National Research Foundation of Korea (NRF) grant - Korea government (MSIP) [2017R1A2B3005714, 2015R1A2A2A04004251]; International Science and Business Belt Program through the Ministry of Science, ICT [2017K000490]; Chungbuk National University grant (2015)	National Research Foundation of Korea (NRF) grant - Korea government (MSIP); International Science and Business Belt Program through the Ministry of Science, ICT; Chungbuk National University grant (2015)	This work was supported in part by the National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIP) (2017R1A2B3005714 and 2015R1A2A2A04004251), International Science and Business Belt Program through the Ministry of Science, ICT (2017K000490), and Chungbuk National University grant (2015).	Al-Azayzih A, 2015, BBA-MOL CELL RES, V1853, P1229, DOI 10.1016/j.bbamcr.2015.02.023; Baritaki S, 2009, CANCER RES, V69, P8376, DOI 10.1158/0008-5472.CAN-09-1069; Broster SA, 2015, FUTURE ONCOL, V11, P3197, DOI 10.2217/fon.15.253; Chen MQ, 2006, PROSTATE, V66, P911, DOI 10.1002/pros.20325; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; Dominguez D, 2003, MOL CELL BIOL, V23, P5078, DOI 10.1128/MCB.23.14.5078-5089.2003; Elloul S, 2005, CANCER-AM CANCER SOC, V103, P1631, DOI 10.1002/cncr.20946; Epstein JI, 2016, AM J SURG PATHOL, V40, P244, DOI 10.1097/PAS.0000000000000530; Esposito S, 2015, ONCOTARGET, V6, P17121, DOI 10.18632/oncotarget.2736; Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210; Goc A, 2013, J BIOL CHEM, V288, P3025, DOI 10.1074/jbc.M112.424770; Hemavathy K, 2000, MOL CELL BIOL, V20, P5087, DOI 10.1128/MCB.20.14.5087-5095.2000; Hensel J, 2016, UROLOGY, V92, P6, DOI 10.1016/j.urology.2015.12.039; Kalikin LM, 2003, CANCER BIOL THER, V2, P656; Kao SH, 2014, ONCOGENE, V33, P3172, DOI 10.1038/onc.2013.279; Katsuno Y, 2013, CURR OPIN ONCOL, V25, P76, DOI 10.1097/CCO.0b013e32835b6371; Kim JY, 2012, FEBS J, V279, P2929, DOI 10.1111/j.1742-4658.2012.08674.x; Ko H, 2007, CELLS TISSUES ORGANS, V185, P66, DOI 10.1159/000101305; Kumar R, 2016, ADV CANCER RES, V130, P137, DOI 10.1016/bs.acr.2016.01.002; Kurrey NK, 2009, STEM CELLS, V27, P2059, DOI 10.1002/stem.154; Kurrey NK, 2005, GYNECOL ONCOL, V97, P155, DOI 10.1016/j.ygyno.2004.12.043; Liu YN, 2012, MOL CELL BIOL, V32, P941, DOI 10.1128/MCB.06306-11; Martinez-Estrada OM, 2006, BIOCHEM J, V394, P449, DOI 10.1042/BJ20050591; Mladinich M, 2016, STEM CELLS INT, V2016, DOI 10.1155/2016/5285892; Molina-Ortiz P, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036132; Naber HPH, 2013, BIOCHEM BIOPH RES CO, V435, P58, DOI 10.1016/j.bbrc.2013.04.037; Nakazawa M, 2017, J STEROID BIOCHEM, V166, P84, DOI 10.1016/j.jsbmb.2016.05.007; Nauseef JT, 2011, NAT REV UROL, V8, P428, DOI 10.1038/nrurol.2011.85; NIETO MA, 1994, SCIENCE, V264, P835, DOI 10.1126/science.7513443; Park MH, 2013, ONCOGENE, V32, P2475, DOI 10.1038/onc.2012.255; Rennefahrt UEE, 2007, J BIOL CHEM, V282, P15667, DOI 10.1074/jbc.M700253200; Risolino M, 2014, P NATL ACAD SCI USA, V111, pE3775, DOI 10.1073/pnas.1407074111; Saitoh M, 2016, ONCOGENE, V35, P1049, DOI 10.1038/onc.2015.161; Shih JY, 2005, CLIN CANCER RES, V11, P8070, DOI 10.1158/1078-0432.CCR-05-0687; Slabakova E, 2011, PROSTATE, V71, P1332, DOI 10.1002/pros.21350; Tania M, 2014, TUMOR BIOL, V35, P7335, DOI 10.1007/s13277-014-2163-y; Thakur N, 2014, CELL CYCLE, V13, P2400, DOI 10.4161/cc.29339; Virtakoivu R, 2015, CANCER RES, V75, P2349, DOI 10.1158/0008-5472.CAN-14-2842; Wang C, 2014, ONCOGENE, V33, P3473, DOI 10.1038/onc.2013.300; Wang SP, 2009, NAT CELL BIOL, V11, P694, DOI 10.1038/ncb1875; Wang ZY, 2017, ONCOTARGET, V8, P22563, DOI 10.18632/oncotarget.15124; Wu DW, 2014, ONCOGENE, V33, P1515, DOI 10.1038/onc.2013.107; Wu ZQ, 2012, P NATL ACAD SCI USA, V109, P16654, DOI 10.1073/pnas.1205822109; Yang HW, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-301; Yang HB, 2013, J BIOL CHEM, V288, P8737, DOI 10.1074/jbc.M113.455675; Yang ZB, 2005, CANCER RES, V65, P3179, DOI 10.1158/0008-5472.CAN-04-3480; Zhang KJ, 2011, LAB INVEST, V91, P426, DOI 10.1038/labinvest.2010.201; Zhang LZ, 2004, MOL CELL BIOL, V24, P2169, DOI 10.1128/MCB.24.5.2169-2180.2004; Zhou BHP, 2004, NAT CELL BIOL, V6, P931, DOI 10.1038/ncb1173; Zhu ML, 2010, FASEB J, V24, P769, DOI 10.1096/fj.09-136994	50	30	31	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 20	2018	37	38					5147	5159		10.1038/s41388-018-0327-8	http://dx.doi.org/10.1038/s41388-018-0327-8			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GU2IP	29849120				2022-12-17	WOS:000445093100001
J	Rogers, S; McCloy, RA; Parker, BL; Gallego-Ortega, D; Law, AMK; Chin, VT; Conway, JRW; Fey, D; Millar, EKA; O'Toole, S; Deng, NT; Swarbrick, A; Chastain, PD; Cesare, AJ; Timpson, P; Caldon, CE; Croucher, DR; James, DE; Watkins, DN; Burgess, A				Rogers, Samuel; McCloy, Rachael A.; Parker, Benjamin L.; Gallego-Ortega, David; Law, Andrew M. K.; Chin, Venessa T.; Conway, James R. W.; Fey, Dirk; Millar, Ewan K. A.; O'Toole, Sandra; Deng, Niantao; Swarbrick, Alexander; Chastain, Paul D.; Cesare, Anthony J.; Timpson, Paul; Caldon, C. Elizabeth; Croucher, David R.; James, David E.; Watkins, D. Neil; Burgess, Andrew			MASTL overexpression promotes chromosome instability and metastasis in breast cancer	ONCOGENE			English	Article							PROTEIN PHOSPHATASE 2A; MITOTIC EXIT; GREATWALL KINASE; HUMAN-CELLS; DNA-DAMAGE; EPITHELIAL-CELLS; DEPHOSPHORYLATION; PHOSPHORYLATION; PHENOTYPE; SUBSTRATE	MASTL kinase is essential for correct progression through mitosis, with loss of MASTL causing chromosome segregation errors, mitotic collapse and failure of cytokinesis. However, in cancer MASTL is most commonly amplified and overexpressed. This correlates with increased chromosome instability in breast cancer and poor patient survival in breast, ovarian and lung cancer. Global phosphoproteomic analysis of immortalised breast MCF10A cells engineered to overexpressed MASTL revealed disruption to desmosomes, actin cytoskeleton, PI3K/AKT/mTOR and p38 stress kinase signalling pathways. Notably, these pathways were also disrupted in patient samples that overexpress MASTL. In MCF10A cells, these alterations corresponded with a loss of contact inhibition and partial epithelial-mesenchymal transition, which disrupted migration and allowed cells to proliferate uncontrollably in 3D culture. Furthermore, MASTL overexpression increased aberrant mitotic divisions resulting in increased micronuclei formation. Mathematical modelling indicated that this delay was due to continued inhibition of PP2A-B55, which delayed timely mitotic exit. This corresponded with an increase in DNA damage and delayed transit through interphase. There were no significant alterations to replication kinetics upon MASTL overexpression, however, inhibition of p38 kinase rescued the interphase delay, suggesting the delay was a G2 DNA damage checkpoint response. Importantly, knockdown of MASTL, reduced cell proliferation, prevented invasion and metastasis of MDA-MB-231 breast cancer cells both in vitro and in vivo, indicating the potential of future therapies that target MASTL. Taken together, these results suggest that MASTL overexpression contributes to chromosome instability and metastasis, thereby decreasing breast cancer patient survival.	[Rogers, Samuel; McCloy, Rachael A.; Gallego-Ortega, David; Law, Andrew M. K.; Chin, Venessa T.; Conway, James R. W.; Deng, Niantao; Swarbrick, Alexander; Timpson, Paul; Caldon, C. Elizabeth; Croucher, David R.; Watkins, D. Neil] Garvan Inst Med Res, Kinghorn Canc Ctr, Darlinghurst, NSW 2010, Australia; [Rogers, Samuel; Cesare, Anthony J.] Univ Sydney, Childrens Med Res Inst, Westmead, NSW, Australia; [Parker, Benjamin L.; James, David E.] Univ Sydney, Sch Life & Environm Sci, Charles Perkins Ctr, Sydney, NSW 2006, Australia; [Gallego-Ortega, David; Fey, Dirk] Univ Coll Dublin, Syst Biol Ireland, Dublin 4, Ireland; [Millar, Ewan K. A.] St George Hosp, Dept Anat Pathol, NSW Hlth Pathol, Sydney, NSW 2217, Australia; [Millar, Ewan K. A.] UNSW Sydney, Sch Med Sci, Kensington, NSW 2033, Australia; [Millar, Ewan K. A.] Sydney Western Univ, Sch Med & Hlth Sci, Campbelltown, NSW 2560, Australia; [O'Toole, Sandra] Univ Sydney, Sydney Med Sch, Fisher Rd, Camperdown, NSW 2006, Australia; [O'Toole, Sandra] Royal Prince Alfred Hosp, Dept Tissue Pathol & Diagnost Oncol, Missenden Rd, Camperdown, NSW 2050, Australia; [Deng, Niantao; Swarbrick, Alexander; Caldon, C. Elizabeth; Croucher, David R.; Watkins, D. Neil] UNSW, St Vincents Clin Sch, Fac Med, Darlinghurst, NSW, Australia; [Chastain, Paul D.] Univ Illinois, Coll Med Rockford, Dept Hlth Sci Educ, Rockford, IL 61107 USA; [Croucher, David R.] Univ Coll Dublin, Sch Med & Med Sci, Dublin 4, Ireland; [James, David E.] Univ Sydney, Sch Med, Sydney, NSW 2006, Australia; [Watkins, D. Neil] St Vincents Hosp, Dept Thorac Med, Darlinghurst, NSW 2010, Australia; [Burgess, Andrew] Univ Sydney, ANZAC Res Inst, Sydney, NSW 2139, Australia	Garvan Institute of Medical Research; Children's Medical Research Institute - Australia; University of Sydney; University of Sydney; University College Dublin; St George Hospital; University of New South Wales Sydney; University of Sydney; University of Sydney; University of New South Wales Sydney; University of Illinois System; University of Illinois Chicago; University of Illinois Rockford; University College Dublin; University of Sydney; St Vincents Hospital Sydney; University of Sydney; ANZAC Research Institute	Burgess, A (corresponding author), Univ Sydney, ANZAC Res Inst, Sydney, NSW 2139, Australia.	andrew.burgess@anzac.edu.au	Cesare, Anthony J/F-4691-2010; Gallego-Ortega, David/AAK-9067-2020; Timpson, Paul/A-9429-2016; Swarbrick, Alexander/E-6107-2010; Research Institute, ANZAC/CAE-9030-2022; Burgess, Andrew/H-3339-2019; Cesare, Anthony/N-7415-2019; Chastain, Paul/AAN-2692-2020; Millar, Ewan/ABE-9127-2020	Cesare, Anthony J/0000-0002-0864-1254; Gallego-Ortega, David/0000-0002-2347-7835; Swarbrick, Alexander/0000-0002-3051-5676; Burgess, Andrew/0000-0003-4536-9226; Cesare, Anthony/0000-0002-0864-1254; Chastain, Paul/0000-0001-6782-6788; Millar, Ewan/0000-0002-9778-3253; James, David/0000-0001-5946-5257; McCloy, Rachael/0000-0001-7791-4044; Timpson, Paul/0000-0002-5514-7080; Fey, Dirk/0000-0002-5558-0167; Watkins, Neil/0000-0001-8218-4920; Chin, Venessa/0000-0002-4630-4451; Conway, James/0000-0003-3787-277X; Rogers, Samuel/0000-0002-5345-5741; Deng, Niantao/0000-0001-9717-2236; Croucher, David/0000-0003-4965-8674	NBCF [IIRS-18-103]; CINSW FRL [10/FRL/3-02]; Patricia Helen Guest Fellowship	NBCF; CINSW FRL; Patricia Helen Guest Fellowship	We thank Marcos Malumbres for his insightful comments, Medina Krcic for her assistance, A. Cippioni and C. Ormandy for their generous gifts of the AKT/mTOR MagPix and SILAC reagents. This work was supported by NBCF (IIRS-18-103), CINSW FRL (ID#10/FRL/3-02) and a Patricia Helen Guest Fellowship.	Alvarez-Fernandez, 2017, CELL DEATH DIFFER, P1; Alvarez-Fernandez M, 2013, P NATL ACAD SCI USA, V110, P17374, DOI 10.1073/pnas.1310745110; Bakhoum SF, 2018, NATURE, V553, P467, DOI 10.1038/nature25432; Bettencourt-Dias M, 2004, NATURE, V432, P980, DOI 10.1038/nature03160; Burgess A, 2017, CELL, V169, DOI 10.1016/j.cell.2017.06.003; Burgess A, 2010, P NATL ACAD SCI USA, V107, P12564, DOI 10.1073/pnas.0914191107; Charrasse S, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00339-4; Chin VT, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aai8504; Cundell MJ, 2016, J CELL BIOL, V214, P539, DOI 10.1083/jcb.201606033; Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X; Diril MK, 2016, PLOS GENET, V12, DOI 10.1371/journal.pgen.1006310; Duffy S, 2016, P NATL ACAD SCI USA, V113, P9967, DOI 10.1073/pnas.1611839113; Gharbi-Ayachi A, 2010, SCIENCE, V330, P1673, DOI 10.1126/science.1197048; Gyorffy B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082241; Herrmann D, 2014, CARCINOGENESIS, V35, P1671, DOI 10.1093/carcin/bgu108; Hinchcliffe EH, 2016, NAT CELL BIOL, V18, P668, DOI 10.1038/ncb3348; Kim ES, 2004, INT J ONCOL, V25, P1375; Kim MS, 2003, CANCER RES, V63, P5454; Lemaire M, 2006, CELL CYCLE, V5, P1649, DOI 10.4161/cc.5.15.3006; Lindqvist A, 2004, J CELL SCI, V117, P4979, DOI 10.1242/jcs.01395; Llopis A, 2012, CELL CYCLE, V11, P3627, DOI 10.4161/cc.21917; Lopez-Knowles E, 2010, INT J CANCER, V126, P1121, DOI 10.1002/ijc.24831; McCloy RA, 2015, MOL CELL PROTEOMICS, V14, P2194, DOI 10.1074/mcp.M114.046938; McCloy RA, 2014, CELL CYCLE, V13, P1400, DOI 10.4161/cc.28401; Mochida S, 2010, SCIENCE, V330, P1670, DOI 10.1126/science.1195689; Nagel R, 2015, MOL CANCER THER, V14, P1434, DOI 10.1158/1535-7163.MCT-14-0846; Ocasio CA, 2016, ONCOTARGET, V7, P71182, DOI 10.18632/oncotarget.11511; Peng AM, 2010, CELL CYCLE, V9, P4364, DOI 10.4161/cc.9.21.13632; Pereira B, 2016, NAT COMMUN, V7, P1; Piscitello D, 2017, ONCOGENE, V15, P356; Reinhardt HC, 2007, CANCER CELL, V11, P175, DOI 10.1016/j.ccr.2006.11.024; Rogers S, 2016, J CELL SCI, V129, P1340, DOI 10.1242/jcs.179754; Sansregret L, 2018, NAT REV CLIN ONCOL, V85, P14; Schmitz MHA, 2010, NAT CELL BIOL, V12, P886, DOI 10.1038/ncb2092; Sflomos G, 2016, CANCER CELL, V29, P407, DOI 10.1016/j.ccell.2016.02.002; Tian JJ, 2017, BIOMED PHARMACOTHER, V92, P919, DOI 10.1016/j.biopha.2017.05.118; Vera J, 2015, ELIFE, V4, DOI 10.7554/eLife.10115; Vigneron S, 2009, EMBO J, V28, P2786, DOI 10.1038/emboj.2009.228; Voets E, 2010, CELL CYCLE, V9, P3591, DOI 10.4161/cc.9.17.12832; Wang L, 2014, ONCOTARGET, V5, P11479, DOI 10.18632/oncotarget.2565; Williams BC, 2014, ELIFE, V3, DOI 10.7554/eLife.01695; Wong PY, 2016, SCI REP-UK, V6, DOI 10.1038/srep22230; Xue Y, 2008, MOL CELL PROTEOMICS, V7, P1598, DOI 10.1074/mcp.M700574-MCP200; Young AIJ, 2016, BREAST CANCER RES, V18, DOI 10.1186/s13058-016-0781-6; Zhang CZ, 2015, NATURE, V522, P179, DOI 10.1038/nature14493; Zhuge BZ, 2017, EUR REV MED PHARMACO, V21, P2413	46	30	31	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 16	2018	37	33					4518	4533		10.1038/s41388-018-0295-z	http://dx.doi.org/10.1038/s41388-018-0295-z			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GQ5OV	29743597	Green Published, hybrid			2022-12-17	WOS:000441736700003
J	Duplaquet, L; Kherrouche, Z; Baldacci, S; Jamme, P; Cortot, AB; Copin, MC; Tulasne, D				Duplaquet, Leslie; Kherrouche, Zoulika; Baldacci, Simon; Jamme, Philippe; Cortot, Alexis B.; Copin, Marie-Christine; Tulasne, David			The multiple paths towards MET receptor addiction in cancer	ONCOGENE			English	Review							HEPATOCYTE GROWTH-FACTOR; CELL LUNG-CANCER; TYROSINE KINASE RECEPTOR; FACTOR SCATTER FACTOR; SPLICE-SITE MUTATION; DOMAIN BINDING-SITE; GENE COPY NUMBER; C-MET; ACQUIRED-RESISTANCE; JUXTAMEMBRANE DOMAIN	Targeted therapies against receptor tyrosine kinases (RTKs) are currently used with success on a small proportion of patients displaying clear oncogene activation. Lung cancers with a mutated EGFR provide a good illustration. The efficacy of targeted treatments relies on oncogene addiction, a situation in which the growth or survival of the cancer cells depends on a single deregulated oncogene. MET, a member of the RTK family, is a promising target because it displays many deregulations in a broad panel of cancers. Although clinical trials having evaluated MET inhibitors in large populations have yielded disappointing results, many recent case reports suggest that MET inhibition may be effective in a subset of patients with unambiguous MET activation and thus, most probably, oncogene addiction. Interestingly, preclinical studies have revealed a particularity of MET addiction: it can arise through several mechanisms, and the mechanism involved can differ according to the cancer type. The present review describes the different mechanisms of MET addiction and their consequences for diagnosis and therapeutic strategies. Although in each cancer type MET addiction affects a restricted number of patients, pooling of these patients across all cancer types yields a targetable population liable to benefit from addiction-targeting therapies.	[Duplaquet, Leslie; Kherrouche, Zoulika; Baldacci, Simon; Jamme, Philippe; Cortot, Alexis B.; Copin, Marie-Christine; Tulasne, David] Univ Lille, CNRS, Inst Pasteur Lille, UMR Mech Tumorigenesis & Targeted Therapies M3T 8, F-59000 Lille, France; [Cortot, Alexis B.] Univ Lille, CHU Lille, Thorac Oncol Dept, F-59000 Lille, France; [Copin, Marie-Christine] Univ Lille, CHU Lille, Inst Pathol, Ave Oscar Lambret, F-59000 Lille, France	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Universite de Lille; Universite de Lille - ISITE; CHU Lille; Universite de Lille; Universite de Lille - ISITE; CHU Lille; Universite de Lille	Tulasne, D (corresponding author), Univ Lille, CNRS, Inst Pasteur Lille, UMR Mech Tumorigenesis & Targeted Therapies M3T 8, F-59000 Lille, France.	david.tulasne@ibl.fr	Tulasne, David/A-8705-2008; KHERROUCHE, Zoulika/HHN-0213-2022; Tulasne, David/AAR-5287-2020; Cortot, Alexis B/F-7006-2019; KHERROUCHE, Zoulika/L-6549-2019	Tulasne, David/0000-0002-6764-7242; Cortot, Alexis B/0000-0003-0098-2238; Duplaquet, Leslie/0000-0002-6544-0432; Baldacci, Simon/0000-0003-3610-1316	CNRS; Institut Pasteur de Lille; INSERM; Ligue contre le Cancer, comite Nord; Association pour la Recherche sur le Cancer; Institut National du Cancer; Canceropole Nord-Ouest; Site de Recherche Integree sur le Cancer, SIRIC ONCOLille	CNRS(Centre National de la Recherche Scientifique (CNRS)); Institut Pasteur de Lille; INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission); Ligue contre le Cancer, comite Nord(Ligue nationale contre le cancer); Association pour la Recherche sur le Cancer(Fondation ARC pour la Recherche sur le CancerAustralian Research Council); Institut National du Cancer(Institut National du Cancer (INCA) France); Canceropole Nord-Ouest; Site de Recherche Integree sur le Cancer, SIRIC ONCOLille	This work was supported by the CNRS, the Institut Pasteur de Lille, and INSERM, and by grants from the 'Ligue contre le Cancer, comite Nord', the 'Association pour la Recherche sur le Cancer', the 'Institut National du Cancer', the 'Canceropole Nord-Ouest' and the 'Site de Recherche Integree sur le Cancer, SIRIC ONCOLille'.	Abounader R, 1999, J NATL CANCER I, V91, P1548, DOI 10.1093/jnci/91.18.1548; Abounader R, 2001, FASEB J, V15, P108, DOI 10.1096/fj.01-0421fje; Aebersold DM, 2003, ONCOGENE, V22, P8519, DOI 10.1038/sj.onc.1206968; Apicella M, 2017, ONCOGENE, V36, P1200, DOI 10.1038/onc.2016.283; Asaoka Y, 2010, BIOCHEM BIOPH RES CO, V394, P1042, DOI 10.1016/j.bbrc.2010.03.120; Awad MM, 2016, J CLIN ONCOL, V34, P721, DOI 10.1200/JCO.2015.63.4600; Bahcall M, 2016, CANCER DISCOV, V6, P1334, DOI 10.1158/2159-8290.CD-16-0686; Bao ZS, 2014, GENOME RES, V24, P1765, DOI 10.1101/gr.165126.113; Bardelli A, 2013, CANCER DISCOV, V3, P658, DOI 10.1158/2159-8290.CD-12-0558; Baselga J, 2005, J CLIN ONCOL, V23, P2162, DOI 10.1200/JCO.2005.01.014; Benderra MA, 2016, J THORAC ONCOL, V11, pE21, DOI 10.1016/j.jtho.2015.08.001; Benedettini E, 2010, AM J PATHOL, V177, P415, DOI 10.2353/ajpath.2010.090863; Birchmeier C, 2003, NAT REV MOL CELL BIO, V4, P915, DOI 10.1038/nrm1261; BLADT F, 1995, NATURE, V376, P768, DOI 10.1038/376768a0; Boland JM, 2013, J THORAC ONCOL, V8, P574, DOI 10.1097/JTO.0b013e318287c395; Borowiak M, 2004, P NATL ACAD SCI USA, V101, P10608, DOI 10.1073/pnas.0403412101; Brockmann MA, 2003, CLIN CANCER RES, V9, P4578; Burel-Vandenbos F, 2017, NEUROPATH APPL NEURO, V43, P252, DOI 10.1111/nan.12320; Calvi C, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003228; Cao B, 2001, P NATL ACAD SCI USA, V98, P7443, DOI 10.1073/pnas.131200498; Caparica R, 2017, J THORAC ONCOL, V12, P141, DOI 10.1016/j.jtho.2016.09.116; Cappuzzo F, 2009, J CLIN ONCOL, V27, P1667, DOI 10.1200/JCO.2008.19.1635; Catenacci DVT, 2017, CANCER-AM CANCER SOC, V123, P1061, DOI 10.1002/cncr.30437; Chen HM, 2015, FEBS LETT, V589, P1437, DOI 10.1016/j.febslet.2015.04.032; Chmielowiec J, 2007, J CELL BIOL, V177, P151, DOI 10.1083/jcb.200701086; Choueiri TK, 2013, J CLIN ONCOL, V31, P181, DOI 10.1200/JCO.2012.43.3383; Cloughesy T, 2017, J CLIN ONCOL, V35, P343, DOI 10.1200/JCO.2015.64.7685; COOPER CS, 1986, EMBO J, V5, P2623, DOI 10.1002/j.1460-2075.1986.tb04543.x; COOPER CS, 1984, NATURE, V311, P29, DOI 10.1038/311029a0; Cortot AB, 2017, JNCI-J NATL CANCER I, V109, DOI 10.1093/jnci/djw262; Cortot AB, 2014, EUR RESPIR REV, V23, P356, DOI 10.1183/09059180.00004614; Davies KD, 2017, JCO PRECISION ONCOLO, V1, P1; Dimou A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107677; Dong HJ, 2016, LUNG CANCER, V102, P118, DOI 10.1016/j.lungcan.2016.11.006; Drilon A.R., 2016, J CLIN ONCOL S, V34, DOI DOI 10.1200/JC0.2016.34.15_SUPPL.108; Drilon A, 2017, J THORAC ONCOL, V12, P15, DOI 10.1016/j.jtho.2016.10.014; Durinck S, 2015, NAT GENET, V47, P13, DOI 10.1038/ng.3146; Ellingson BM, 2017, NEURO-ONCOLOGY, V19, P89, DOI 10.1093/neuonc/now187; Engelman JA, 2007, SCIENCE, V316, P1039, DOI 10.1126/science.1141478; Fan YN, 2017, HEPATOLOGY, V66, P1644, DOI 10.1002/hep.29304; Frampton GM, 2015, CANCER DISCOV, V5, P850, DOI 10.1158/2159-8290.CD-15-0285; Funakoshi Y, 2013, INVEST NEW DRUG, V31, P1158, DOI 10.1007/s10637-013-9959-2; Gainor JF, 2016, J THORAC ONCOL, V11, pE83, DOI 10.1016/j.jtho.2016.02.021; GANDINO L, 1994, J BIOL CHEM, V269, P1815; Ghadjar P, 2009, CLIN EXP METASTAS, V26, P809, DOI 10.1007/s10585-009-9280-9; GIORDANO S, 1989, NATURE, V339, P155, DOI 10.1038/339155a0; Graveel C, 2004, P NATL ACAD SCI USA, V101, P17198, DOI 10.1073/pnas.0407651101; Hashigasako A, 2004, J BIOL CHEM, V279, P26445, DOI 10.1074/jbc.M314254200; Heideman DAM, 2001, J PATHOL, V194, P428, DOI 10.1002/path.934; Heist RS, 2016, J THORAC ONCOL, V11, P1242, DOI 10.1016/j.jtho.2016.06.013; Heist RS, 2016, ONCOLOGIST, V21, P481, DOI 10.1634/theoncologist.2015-0510; Huh CG, 2004, P NATL ACAD SCI USA, V101, P4477, DOI 10.1073/pnas.0306068101; Ichimura E, 1996, JPN J CANCER RES, V87, P1063, DOI 10.1111/j.1349-7006.1996.tb03111.x; Ignatius SH, 2017, J THORAC ONCOL, V12, P137, DOI 10.1016/j.jtho.2016.09.119; Jeffers M, 1997, P NATL ACAD SCI USA, V94, P11445, DOI 10.1073/pnas.94.21.11445; Jenkins RW, 2015, CLIN LUNG CANCER, V16, pE101, DOI 10.1016/j.cllc.2015.01.009; Joffre C, 2011, NAT CELL BIOL, V13, P827, DOI 10.1038/ncb2257; Jorge SE, 2015, LUNG CANCER, V90, P369, DOI 10.1016/j.lungcan.2015.10.028; Kim KJ, 2006, CLIN CANCER RES, V12, P1292, DOI 10.1158/1078-0432.CCR-05-1793; Kondo S, 2013, INT J CLIN ONCOL, V18, P207, DOI 10.1007/s10147-011-0361-9; Kong-Beltran M, 2006, CANCER RES, V66, P283, DOI 10.1158/0008-5472.CAN-05-2749; Koochekpour S, 1997, CANCER RES, V57, P5391; Krishnaswamy S, 2009, CLIN CANCER RES, V15, P5714, DOI 10.1158/1078-0432.CCR-09-0070; Kwak Y, 2015, INT J CLIN EXP PATHO, V8, P14932; Lamszus K, 1998, INT J CANCER, V75, P19, DOI 10.1002/(SICI)1097-0215(19980105)75:1<19::AID-IJC4>3.0.CO;2-4; Lapere C, 2017, AM J SURG PATHOL, V41, P414, DOI 10.1097/PAS.0000000000000810; Laterra J, 1997, BIOCHEM BIOPH RES CO, V235, P743, DOI 10.1006/bbrc.1997.6853; Lee J, 2016, CLIN ONCOL-UK, V28, pE35, DOI 10.1016/j.clon.2016.01.009; Lee J, 2015, ONCOTARGET, V6, P28211, DOI 10.18632/oncotarget.4721; Lee JH, 2000, ONCOGENE, V19, P4947, DOI 10.1038/sj.onc.1203874; Lefebvre J, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.377; Lennerz JK, 2011, J CLIN ONCOL, V29, P4803, DOI 10.1200/JCO.2011.35.4928; Li A, 2017, CLIN CANCER RES, V23, P4929, DOI 10.1158/1078-0432.CCR-16-3273; Li YQ, 2015, ONCOTARGET, V6, P13309, DOI 10.18632/oncotarget.3751; Liu XW, 2016, J CLIN ONCOL, V34, P794, DOI 10.1200/JCO.2015.62.0674; Liu YJ, 2014, BRIT J CANCER, V110, P1169, DOI 10.1038/bjc.2014.61; LONGATI P, 1994, ONCOGENE, V9, P49; Lutterbach B, 2007, CANCER RES, V67, P2081, DOI 10.1158/0008-5472.CAN-06-3495; Ma PC, 2003, CANCER RES, V63, P6272; Mahjoubi L, 2016, INVEST NEW DRUG, V34, P397, DOI 10.1007/s10637-016-0332-0; Maina F, 1997, GENE DEV, V11, P3341, DOI 10.1101/gad.11.24.3341; Maina F, 1996, CELL, V87, P531, DOI 10.1016/S0092-8674(00)81372-0; Martens T, 2006, CLIN CANCER RES, V12, P6144, DOI 10.1158/1078-0432.CCR-05-1418; McDermott U, 2010, CANCER RES, V70, P1625, DOI 10.1158/0008-5472.CAN-09-3620; Mendenhall MA, 2015, J THORAC ONCOL, V10, pE33, DOI 10.1097/JTO.0000000000000491; Michieli P, 1999, ONCOGENE, V18, P5221, DOI 10.1038/sj.onc.1202899; Montagne R, 2017, ONCOTARGET, V8, P11268, DOI 10.18632/oncotarget.14499; Nakamura Y, 2007, CANCER SCI, V98, P1006, DOI 10.1111/j.1349-7006.2007.00493.x; Nakayama M, 2013, CYTOKINE, V62, P446, DOI 10.1016/j.cyto.2013.04.006; Noonan SA, 2016, J THORAC ONCOL, V11, P1293, DOI 10.1016/j.jtho.2016.04.033; O'Brien SG, 2003, NEW ENGL J MED, V348, P994, DOI 10.1056/NEJMoa022457; Olivero M, 1996, BRIT J CANCER, V74, P1862, DOI 10.1038/bjc.1996.646; Paik PK, 2015, CANCER DISCOV, V5, P842, DOI 10.1158/2159-8290.CD-14-1467; Park S, 2012, HISTOL HISTOPATHOL, V27, P197, DOI 10.14670/HH-27.197; Park S, 2015, LUNG CANCER, V90, P381, DOI 10.1016/j.lungcan.2015.10.022; Park WS, 1999, CANCER RES, V59, P307; Pelosi G, 2016, J THORAC ONCOL, V11, P718, DOI 10.1016/j.jtho.2016.01.009; Peschard P, 2007, ONCOGENE, V26, P1276, DOI 10.1038/sj.onc.1210201; Peschard P, 2004, J BIOL CHEM, V279, P29565, DOI 10.1074/jbc.M403954200; Peschard P, 2001, MOL CELL, V8, P995, DOI 10.1016/S1097-2765(01)00378-1; PONZETTO C, 1991, ONCOGENE, V6, P553; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; Project, 2016, NAT MED, V22, P1314; Pyo JS, 2016, J GASTRIC CANCER, V16, P141, DOI 10.5230/jgc.2016.16.3.141; Qi J, 2011, CANCER RES, V71, P1081, DOI 10.1158/0008-5472.CAN-10-1623; Raghav K, 2016, ONCOTARGET, V7, P54627, DOI 10.18632/oncotarget.10559; REGECAMBRIN G, 1992, CANCER GENET CYTOGEN, V64, P170, DOI 10.1016/0165-4608(92)90350-H; Rosell R, 2012, LANCET ONCOL, V13, P239, DOI 10.1016/S1470-2045(11)70393-X; Rosen EM, 1996, INT J CANCER, V67, P248, DOI 10.1002/(SICI)1097-0215(19960717)67:2<248::AID-IJC16>3.0.CO;2-7; Scagliotti G, 2015, J CLIN ONCOL, V33, P2667, DOI 10.1200/JCO.2014.60.7317; Schiering N, 2003, P NATL ACAD SCI USA, V100, P12654, DOI 10.1073/pnas.1734128100; Schildhaus HU, 2015, CLIN CANCER RES, V21, P907, DOI 10.1158/1078-0432.CCR-14-0450; SCHMIDT C, 1995, NATURE, V373, P699, DOI 10.1038/373699a0; Schmidt L, 1997, NAT GENET, V16, P68, DOI 10.1038/ng0597-68; Schmidt L, 1998, CANCER RES, V58, P1719; Schmitz K, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120079; Schuller AG, 2015, CLIN CANCER RES, V21, P2811, DOI 10.1158/1078-0432.CCR-14-2685; Shea M, 2016, J THORAC ONCOL, V11, pE81, DOI 10.1016/j.jtho.2016.01.017; Shieh JM, 2013, INT J MED SCI, V10, P988, DOI 10.7150/ijms.5944; Smolen GA, 2006, CANCER RES, V66, P3452, DOI 10.1158/0008-5472.CAN-05-4181; Smolen GA, 2006, P NATL ACAD SCI USA, V103, P2316, DOI 10.1073/pnas.0508776103; Spigel DR, 2017, J CLIN ONCOL, V35, P412, DOI 10.1200/JCO.2016.69.2160; Spoerke JM, 2012, CLIN CANCER RES, V18, P6771, DOI 10.1158/1078-0432.CCR-12-2347; Takayama H, 1997, P NATL ACAD SCI USA, V94, P701, DOI 10.1073/pnas.94.2.701; Tanaka A, 2012, LUNG CANCER, V75, P89, DOI 10.1016/j.lungcan.2011.06.004; Tiedt R, 2011, CANCER RES, V71, P5255, DOI 10.1158/0008-5472.CAN-10-4433; Togashi Y, 2015, LUNG CANCER, V90, P590, DOI 10.1016/j.lungcan.2015.10.020; Tong JH, 2016, CLIN CANCER RES, V22, P3048, DOI 10.1158/1078-0432.CCR-15-2061; Tran TN, 2016, CLIN LUNG CANCER, V17, pe31; Trusolino L, 2016, CANCER DISCOV, V6, P1306, DOI 10.1158/2159-8290.CD-16-1181; Tsuta K, 2012, J THORAC ONCOL, V7, P331, DOI 10.1097/JTO.0b013e318241655f; Tulasne D, 2008, CELL DEATH DIFFER, V15, P427, DOI 10.1038/sj.cdd.4402229; Tyner JW, 2010, CANCER RES, V70, P6233, DOI 10.1158/0008-5472.CAN-10-0429; UEHARA Y, 1995, NATURE, V373, P702, DOI 10.1038/373702a0; Veenstra C, 2016, ONCOTARGET, V7, P37145, DOI 10.18632/oncotarget.9268; Vieira T, 2014, LUNG CANCER, V85, P276, DOI 10.1016/j.lungcan.2014.06.004; Vigna E, 1999, ONCOGENE, V18, P4275, DOI 10.1038/sj.onc.1202791; Vogelstein B, 2013, SCIENCE, V339, P1546, DOI 10.1126/science.1235122; Wang K, 2013, HEPATOLOGY, V58, P706, DOI 10.1002/hep.26402; Wang R, 2001, J CELL BIOL, V153, P1023, DOI 10.1083/jcb.153.5.1023; Waqar SN, 2015, J THORAC ONCOL, V10, pE29, DOI 10.1097/JTO.0000000000000478; Weinstein IB, 2002, SCIENCE, V297, P63, DOI 10.1126/science.1073096; Wen PY, 2011, NEURO-ONCOLOGY, V13, P437, DOI 10.1093/neuonc/noq198; Xie Q, 2012, P NATL ACAD SCI USA, V109, P570, DOI 10.1073/pnas.1119059109; Yeh I, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8174; Yin XL, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0143468; Zhang Y, 2016, J THORAC ONCOL, V11, pE59, DOI 10.1016/j.jtho.2015.12.102; Zhang Y, 2013, CLIN CANCER RES, V19, P1433, DOI 10.1158/1078-0432.CCR-12-2832; Zhao XJ, 2005, CANCER RES, V65, P5561, DOI 10.1158/0008-5472.CAN-04-4603; Zhuang ZP, 1998, NAT GENET, V20, P66, DOI 10.1038/1727	150	30	32	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 14	2018	37	24					3200	3215		10.1038/s41388-018-0185-4	http://dx.doi.org/10.1038/s41388-018-0185-4			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GJ6XB	29551767				2022-12-17	WOS:000435526600002
J	Chu, PC; Lin, PC; Wu, HY; Lin, KT; Wu, C; Bekaii-Saab, T; Lin, YJ; Lee, CT; Lee, JC; Chen, CS				Chu, Po-Chen; Lin, Peng-Chan; Wu, Hsing-Yu; Lin, Kuen-Tyng; Wu, Christina; Bekaii-Saab, Tanios; Lin, Yih-Jyh; Lee, Chung-Ta; Lee, Jeng-Chang; Chen, Ching-Shih			Mutant KRAS promotes liver metastasis of colorectal cancer, in part, by upregulating the MEK-Sp1-DNMT1-miR-137-YB-1-IGF-IR signaling pathway	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; STRONG YB-1 EXPRESSION; I RECEPTOR GENE; GROWTH; MIR-137; CELLS; RESECTION; INVASION; MUTATIONS; SURVIVAL	Although the role of insulin-like growth factor-I receptor (IGF-IR) in promoting colorectal liver metastasis is known, the mechanism by which IGF-IR is upregulated in colorectal cancer (CRC) is not defined. In this study, we obtained evidence that mutant KRAS transcriptionally activates IGF-IR gene expression through Y-box-binding protein (YB)-1 upregulation via a novel MEK-Sp1-DNMT1-miR-137 pathway in CRC cells. The mechanistic link between the tumor suppressive miR-137 and the translational regulation of YB-1 is intriguing because epigenetic silencing of miR-137 represents an early event in colorectal carcinogenesis due to promoter hypermethylation. This proposed signaling axis was further verified by the immunohistochemical evaluations of liver metastases from a cohort of 46 KRAS mutant CRC patients, which showed a significant correlation in the expression levels among Sp1, miR-137, YB-1, and IGF-1R. Moreover, suppression of the expression of YB-1 and IGF-IR via genetic knockdown or the pharmacological inhibition of MEK hampers KRAS-driven colorectal liver metastasis in our animal model studies. From a translational perspective, the identification of this KRAS-driven pathway might provide a mechanistic rationale for the use of a MEK inhibitor as an adjuvant, in combination with standard of care, to prevent the recurrence of colorectal liver metastasis in KRAS mutant CRC patients after receiving liver resection, which warrants further investigation.	[Chu, Po-Chen; Wu, Hsing-Yu; Lin, Kuen-Tyng; Chen, Ching-Shih] Acad Sinica, Inst Biol Chem, Taipei 11529, Taiwan; [Chu, Po-Chen; Chen, Ching-Shih] China Med Univ, Coll Biopharmaceut & Food Sci, Inst New Drug Dev, Taichung 40402, Taiwan; [Lin, Peng-Chan] Natl Cheng Kung Univ, Coll Med, Natl Cheng Kung Univ Hosp, Dept Internal Med, Tainan 70403, Taiwan; [Wu, Hsing-Yu; Chen, Ching-Shih] Natl Taiwan Univ, Coll Life Sci, Inst Biochem Sci, Taipei 10617, Taiwan; [Wu, Christina] Emory Univ, Dept Hematol & Med Oncol, Winship Canc Inst, Atlanta, GA 30322 USA; [Bekaii-Saab, Tanios] Mayo Clin, Canc Ctr, Coll Med & Sci, Phoenix, AZ 85054 USA; [Lin, Yih-Jyh; Lee, Jeng-Chang] Natl Cheng Kung Univ, Natl Cheng Kung Univ Hosp, Coll Med, Dept Surg, Tainan 70403, Taiwan; [Lee, Chung-Ta] Natl Cheng Kung Univ, Natl Cheng Kung Univ Hosp, Coll Med, Dept Pathol, Tainan 70403, Taiwan	Academia Sinica - Taiwan; China Medical University Taiwan; National Cheng Kung University; National Cheng Kung University Hospital; National Taiwan University; Emory University; Mayo Clinic; Mayo Clinic Phoenix; National Cheng Kung University; National Cheng Kung University Hospital; National Cheng Kung University; National Cheng Kung University Hospital	Chen, CS (corresponding author), Acad Sinica, Inst Biol Chem, Taipei 11529, Taiwan.; Chen, CS (corresponding author), China Med Univ, Coll Biopharmaceut & Food Sci, Inst New Drug Dev, Taichung 40402, Taiwan.; Chen, CS (corresponding author), Natl Taiwan Univ, Coll Life Sci, Inst Biochem Sci, Taipei 10617, Taiwan.	cschenibc@gmail.com		Bekaii-Saab, Tanios/0000-0001-7721-1699	Ministry of Science and Technology [MOST 105-2320-B-001-004]; American Cancer Society Seed grant; Paul Calabresi Scholar K12 Training grant; Academia Sinica; Bi-Institutional Collaborative Pancreatic Cancer Research grants from National Cheng Kung University College of Medicine	Ministry of Science and Technology(Ministry of Science, ICT & Future Planning, Republic of Korea); American Cancer Society Seed grant(American Cancer Society); Paul Calabresi Scholar K12 Training grant; Academia Sinica(Academia Sinica - Taiwan); Bi-Institutional Collaborative Pancreatic Cancer Research grants from National Cheng Kung University College of Medicine	This work was supported by the Ministry of Science and Technology grant MOST 105-2320-B-001-004 (P-CC), American Cancer Society Seed grant (CW), Paul Calabresi Scholar K12 Training grant (CW), intramural funding from Academia Sinica (C-SC), Bi-Institutional Collaborative Pancreatic Cancer Research grants from National Cheng Kung University College of Medicine (C-SC).	Adam R, 2009, J CLIN ONCOL, V27, P1829, DOI 10.1200/JCO.2008.19.9273; Ahmed D, 2013, ONCOGENESIS, V2, DOI 10.1038/oncsis.2013.35; Ardito F, 2014, J GASTROINTEST SURG, V18, P1987, DOI 10.1007/s11605-014-2657-3; Balaguer F, 2010, CANCER RES, V70, P6609, DOI 10.1158/0008-5472.CAN-10-0622; Bennouna J, 2011, INVEST NEW DRUG, V29, P1021, DOI 10.1007/s10637-010-9392-8; Brand Toni M, 2012, Small GTPases, V3, P34, DOI 10.4161/sgtp.18751; Brudvik KW, 2015, BRIT J SURG, V102, P1175, DOI 10.1002/bjs.9870; Busch EL, 2014, CANCER EPIDEM BIOMAR, V23, P1164, DOI 10.1158/1055-9965.EPI-14-0017; Cao H, 2015, PATHOL RES PRACT, V211, P557, DOI 10.1016/j.prp.2015.05.010; Chattopadhyay N, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0144825; Chen DL, 2013, CARCINOGENESIS, V34, P803, DOI 10.1093/carcin/bgs400; Chibi M, 2008, J MOL BIOL, V384, P908, DOI 10.1016/j.jmb.2008.09.060; Chu PC, 2016, ONCOGENE, V35, P3897, DOI 10.1038/onc.2015.458; Conlin A, 2005, GUT, V54, P1283, DOI 10.1136/gut.2005.066514; Cui FY, 2016, ONCOL REP, V36, P487, DOI 10.3892/or.2016.4834; de Jong MC, 2009, ANN SURG, V250, P440, DOI 10.1097/SLA.0b013e3181b4539b; Ding CB, 2016, J EXP CLIN CANC RES, V35, DOI 10.1186/s13046-015-0280-0; Ebi H, 2011, J CLIN INVEST, V121, P4311, DOI 10.1172/JCI57909; Ewing GP, 2010, CLIN COLORECTAL CANC, V9, P219, DOI 10.3816/CCC.2010.n.032; Hahn S, 2013, EMBO J, V32, P3079, DOI 10.1038/emboj.2013.236; Huang CC, 2015, ONCOTARGET, V6, P8698, DOI 10.18632/oncotarget.3537; Ishizu K, 2007, BIOL PHARM BULL, V30, P1779, DOI 10.1248/bpb.30.1779; Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104; Kashif M, 2015, SCI REP-UK, V5, DOI 10.1038/srep14118; Kishikawa S, 2002, EUR J BIOCHEM, V269, P2961, DOI 10.1046/j.1432-1033.2002.02972.x; Lai MG, 2015, MOL MED REP, V11, P3301, DOI 10.3892/mmr.2015.3182; Lasham A, 2013, BIOCHEM J, V449, P11, DOI 10.1042/BJ20121323; Lee Michael S, 2014, Gastrointest Cancer Res, V7, pS2; Leonard GD, 2005, J CLIN ONCOL, V23, P2038, DOI 10.1200/JCO.2005.00.349; Leporrier J, 2006, BRIT J SURG, V93, P465, DOI 10.1002/bjs.5278; Li CY, 2015, MOL MED REP, V12, P7072, DOI 10.3892/mmr.2015.4263; Li Z, 2012, J INT MED RES, V40, P1589, DOI 10.1177/147323001204000439; Lievre A, 2006, CANCER RES, V66, P3992, DOI 10.1158/0008-5472.CAN-06-0191; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Luo CL, 2013, J INVEST DERMATOL, V133, P768, DOI 10.1038/jid.2012.357; Lutz M, 2006, FEBS LETT, V580, P3921, DOI 10.1016/j.febslet.2006.06.023; Mahmoudi E, 2017, MOL PSYCHIATR, V22, P44, DOI 10.1038/mp.2016.150; Manfredi S, 2006, ANN SURG, V244, P254, DOI 10.1097/01.sla.0000217629.94941.cf; Mouneimne G, 2009, CANCER CELL, V15, P357, DOI 10.1016/j.ccr.2009.04.006; Nahor I, 2005, GROWTH HORM IGF RES, V15, P388, DOI 10.1016/j.ghir.2005.07.005; Nash GM, 2010, ANN SURG ONCOL, V17, P572, DOI 10.1245/s10434-009-0605-3; Neault M, 2016, CELL REP, V14, P1966, DOI 10.1016/j.celrep.2016.01.068; Okamoto K, 2012, EMBO J, V31, P1752, DOI 10.1038/emboj.2012.25; Passiglia F, 2016, CRIT REV ONCOL HEMAT, V99, P150, DOI 10.1016/j.critrevonc.2015.12.015; Rees M, 2008, ANN SURG, V247, P125, DOI 10.1097/SLA.0b013e31815aa2c2; Sachdev D, 2007, MOL CANCER THER, V6, P1, DOI 10.1158/1535-7163.MCT-06-0080; Samani AA, 2007, ENDOCR REV, V28, P20, DOI 10.1210/er.2006-0001; Shaheen S, 2016, STEM CELL REV REP, V12, P492, DOI 10.1007/s12015-016-9664-6; Shibao K, 1999, INT J CANCER, V83, P732; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Smakman N, 2006, CANCER RES, V66, P5403, DOI 10.1158/0008-5472.CAN-05-4108; Smith AR, 2015, ONCOTARGET, V6, P12558, DOI 10.18632/oncotarget.3726; Van Cutsem E, 2009, NEW ENGL J MED, V360, P1408, DOI 10.1056/NEJMoa0805019; Vigneri PG, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00230; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; Wang H, 2011, CARCINOGENESIS, V32, P1033, DOI 10.1093/carcin/bgr081; Weng WH, 2016, CLIN CANCER RES, V22, P4947, DOI 10.1158/1078-0432.CCR-16-0360; Werner H, 1996, P NATL ACAD SCI USA, V93, P8318, DOI 10.1073/pnas.93.16.8318; Werner H, 2006, TRENDS ENDOCRIN MET, V17, P236, DOI 10.1016/j.tem.2006.06.007; Wu YY, 2014, ANGIOGENESIS, V17, P247, DOI 10.1007/s10456-013-9394-1; Wu Y, 2012, J SURG ONCOL, V105, P724, DOI 10.1002/jso.23030; Yan XB, 2014, INT J CLIN EXP PATHO, V7, P8715; Yang HJ, 2016, ONCOTARGET, V7, P2709, DOI 10.18632/oncotarget.6458; Zhang XM, 2017, ONCOL LETT, V14, P2325, DOI 10.3892/ol.2017.6444; Zhao YJ, 2014, NAT REV CLIN ONCOL, V11, P385, DOI 10.1038/nrclinonc.2014.83; Zhu XL, 2013, ACTA BIOCH BIOPH SIN, V45, P80, DOI 10.1093/abbs/gms099; Zhu YM, 2007, INT J COLORECTAL DIS, V22, P661, DOI 10.1007/s00384-006-0224-4	67	30	30	0	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2018	37	25					3440	3455		10.1038/s41388-018-0222-3	http://dx.doi.org/10.1038/s41388-018-0222-3			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GK7TC	29559746				2022-12-17	WOS:000436411300009
J	Hang, W; Yin, ZX; Liu, G; Zeng, QH; Shen, XF; Sun, QH; Li, DD; Jian, YP; Zhang, YH; Wang, YS; Quan, CS; Zhao, RX; Li, YL; Xu, ZX				Hang, Wei; Yin, Zhi-Xian; Liu, Gang; Zeng, Qinghua; Shen, Xiang-Feng; Sun, Qian-Hui; Li, Dong-Dong; Jian, Yong-Ping; Zhang, Yang-He; Wang, Yi-Shu; Quan, Cheng-Shi; Zhao, Rui-Xun; Li, Yu-Lin; Xu, Zhi-Xiang			Piperlongumine and p53-reactivator APR-246 selectively induce cell death in HNSCC by targeting GSTP1	ONCOGENE			English	Article							MUTANT P53 REACTIVATION; CANCER-CELLS; DOWN-REGULATION; STEM-CELLS; HEAD; DRUG; INHIBITION; CARCINOMA; MECHANISM; APOPTOSIS	TP53 mutations frequently occur in head and neck squamous cell carcinoma (HNSCC) patients without human papillomavirus infection. The recurrence rate for these patients is distinctly high. It has been actively explored to identify agents that target TP53 mutations and restore wild-type (WT) TP53 activities in HNSCC. PRIMA-1 (p53-reactivation and induction of massive apoptosis-1) and its methylated analogue PRIMA-1(Met) (also called APR-246) were found to be able to reestablish the DNA-binding activity of p53 mutants and reinstate the functions of WT p53. Herein we report that piperlongumine (PL), an alkaloid isolated from Piper longum L., synergizes with APR-246 to selectively induce apoptosis and autophagic cell death in HNSCC cells, whereas primary and immortalized mouse embryonic fibroblasts and spontaneously immortalized non-tumorigenic human skin keratinocytes (HaCat) are spared from the damage by the co-treatment. Interestingly, PL-sensitized HNSCC cells to APR-246 are TP53 mutation-independent. Instead, we demonstrated that glutathione S-transferase pi 1 (GSTP1), a GST family member that catalyzes the conjugation of GSH with electrophilic compounds to fulfill its detoxification function, is highly expressed in HNSCC tissues. Administration of PL and APR-246 significantly suppresses GSTP1 activity, resulting in the accumulation of ROS, depletion of GSH, elevation of GSSG, and DNA damage. Ectopic expression of GSTP1 or pre-treatment with antioxidant N-acetyl-L-cysteine (NAC) abrogates the ROS elevation and decreases DNA damage, apoptosis, and autophagic cell death prompted by PL/APR-246. In addition, administration of PL and APR-246 impedes UMSCC10A xenograft tumor growth in SCID mice. Taken together, our data suggest that HNSCC cells are selectively sensitive to the combination of PL and APR-246 due to a remarkably synergistic effect of the co-treatment in the induction of ROS by suppression of GSTP1.	[Hang, Wei; Yin, Zhi-Xian; Liu, Gang] Tianjin Huanhu Hosp, Dept Otorhinolaryngol Head & Neck Surg, Tianjin, Peoples R China; [Zeng, Qinghua; Zhao, Rui-Xun; Xu, Zhi-Xiang] Univ Alabama Birmingham, Ctr Comprehens Canc, Div Hematol & Oncol, Birmingham, AL 35294 USA; [Zeng, Qinghua; Shen, Xiang-Feng; Sun, Qian-Hui; Li, Dong-Dong; Jian, Yong-Ping; Zhang, Yang-He; Wang, Yi-Shu; Quan, Cheng-Shi; Li, Yu-Lin; Xu, Zhi-Xiang] Jilin Univ, Norman Bethune Coll Med, Minist Educ, Key Lab Pathobiol, Changchun, Jilin, Peoples R China	University of Alabama System; University of Alabama Birmingham; Jilin University	Hang, W (corresponding author), Tianjin Huanhu Hosp, Dept Otorhinolaryngol Head & Neck Surg, Tianjin, Peoples R China.	hangwei2627@126.com			National Natural Science Foundation of China [81573087, 81572139, 81772924]; U.S. National Institutes of Health [R01CA133053]; NATIONAL CANCER INSTITUTE [R01CA133053] Funding Source: NIH RePORTER	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported in part by the National Natural Science Foundation of China (Grant Nos: 81573087, 81572139, and 81772924) and the U.S. National Institutes of Health (Grant No: R01CA133053).	Adams DJ, 2012, P NATL ACAD SCI USA, V109, P15115, DOI 10.1073/pnas.1212802109; Agrawal N, 2011, SCIENCE, V333, P1154, DOI 10.1126/science.1206923; Alpay M, 2016, J CANCER RES THER, V12, P556, DOI 10.4103/0973-1482.151936; Basak D, 2016, INT J ONCOL, V48, P1426, DOI 10.3892/ijo.2016.3372; Bentz BG, 2000, LARYNGOSCOPE, V110, P1642, DOI 10.1097/00005537-200010000-00013; Bezerra DP, 2013, EUR J PHARM SCI, V48, P453, DOI 10.1016/j.ejps.2012.12.003; Bharadwaj U, 2015, ONCOGENE, V34, P1341, DOI 10.1038/onc.2014.72; Bykov VJN, 2005, ONCOGENE, V24, P3484, DOI 10.1038/sj.onc.1208419; Bykov VJN, 2002, NAT MED, V8, P282, DOI 10.1038/nm0302-282; Bykov VJN, 2016, FRONT ONCOL, V6, DOI 10.3389/fonc.2016.00021; Bykov VJN, 2014, FEBS LETT, V588, P2622, DOI 10.1016/j.febslet.2014.04.017; Chou TC, 2007, COMPUSYN SOFTWARE DR, P1; Cosenza M, 2017, APOPTOSIS, V22, P827, DOI 10.1007/s10495-017-1364-4; Costa A, 2014, SEMIN CANCER BIOL, V25, P23, DOI 10.1016/j.semcancer.2013.12.007; Deben C, 2016, CANCER LETT, V375, P313, DOI 10.1016/j.canlet.2016.03.017; Fitzgerald AL, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.44; Gersey ZC, 2017, BMC CANCER, V17, DOI 10.1186/s12885-017-3058-2; Glasauer A, 2014, BIOCHEM PHARMACOL, V92, P90, DOI 10.1016/j.bcp.2014.07.017; Harshbarger W, 2017, J BIOL CHEM, V292, P112, DOI 10.1074/jbc.M116.750299; Hientz K, 2017, ONCOTARGET, V8, P8921, DOI 10.18632/oncotarget.13475; Huang BK, 2016, ANTIOXID REDOX SIGN, V24, P924, DOI 10.1089/ars.2015.6482; Huang XM, 2016, CANCER CELL, V30, P940, DOI 10.1016/j.ccell.2016.11.006; Junk DJ, 2008, NEOPLASIA, V10, P450, DOI 10.1593/neo.08120; Jutooru I, 2014, MOL CELL BIOL, V34, P2382, DOI 10.1128/MCB.01602-13; Kim EH, 2011, CANCER PREV RES, V4, P425, DOI 10.1158/1940-6207.CAPR-10-0153; Kim KS, 2006, PIGM CELL RES, V19, P90, DOI 10.1111/j.1600-0749.2005.00281.x; Lambert JMR, 2010, ONCOGENE, V29, P1329, DOI 10.1038/onc.2009.425; Lambert JMR, 2009, CANCER CELL, V15, P376, DOI 10.1016/j.ccr.2009.03.003; Meegan MJ, 2017, EUR J MED CHEM, V125, P453, DOI 10.1016/j.ejmech.2016.09.048; Moreira FD, 2016, SCI REP-UK, V6, DOI 10.1038/srep33646; Patel K, 2015, J PHARM SCI-US, V104, P4417, DOI 10.1002/jps.24637; Peng X, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.417; Pignanelli C, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-01230-4; Prasad S, 2016, CURR PHARM DESIGN, V22, P4151, DOI 10.2174/1381612822666160601103027; Raj L, 2011, NATURE, V475, P231, DOI 10.1038/nature10167; Roh JL, 2014, ONCOTARGET, V5, P9227, DOI 10.18632/oncotarget.2402; Satoh T, 2013, FREE RADICAL BIO MED, V65, P645, DOI 10.1016/j.freeradbiomed.2013.07.022; Shalom-Feuerstein R, 2013, P NATL ACAD SCI USA, V110, P2152, DOI 10.1073/pnas.1201753109; Singh M, 2008, MUTAT RES-FUND MOL M, V638, P184, DOI 10.1016/j.mrfmmm.2007.10.003; Stransky N, 2011, SCIENCE, V333, P1157, DOI 10.1126/science.1208130; Tan JK, 2016, NUTR CANCER, V68, P507, DOI 10.1080/01635581.2016.1153671; Tanaka N, 2015, CLIN CANCER RES, V21, P4831, DOI 10.1158/1078-0432.CCR-15-0279; Tessoulin B, 2014, BLOOD, V124, P1626, DOI 10.1182/blood-2014-01-548800; Trachootham D, 2009, NAT REV DRUG DISCOV, V8, P579, DOI 10.1038/nrd2803; Wang HB, 2017, EUR J MED CHEM, V126, P517, DOI 10.1016/j.ejmech.2016.11.034; Wang Y, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.358; Wang YW, 2016, CANCER PREV RES, V9, P234, DOI 10.1158/1940-6207.CAPR-15-0306; Xi Y, 2015, J CANCER, V6, P327, DOI 10.7150/jca.11185; Xu HG, 2015, ONCOGENE, V34, P3848, DOI 10.1038/onc.2014.315; Xu ZX, 2007, CELL DEATH DIFFER, V14, P1948, DOI 10.1038/sj.cdd.4402207; Yu X, 2012, CANCER CELL, V21, P614, DOI 10.1016/j.ccr.2012.03.042; Zeng Q, 2017, ONCOGENE, V36, P1245, DOI 10.1038/onc.2016.290; Zeng QH, 2016, P NATL ACAD SCI USA, V113, P9333, DOI 10.1073/pnas.1606801113; Zhou G, 2014, MOL CELL, V54, P960, DOI 10.1016/j.molcel.2014.04.024; Zou P, 2016, CANCER LETT, V375, P114, DOI 10.1016/j.canlet.2016.02.058	55	30	30	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2018	37	25					3384	3398		10.1038/s41388-017-0110-2	http://dx.doi.org/10.1038/s41388-017-0110-2			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GK7TC	29348462	Green Accepted			2022-12-17	WOS:000436411300005
J	Dong, L; Yu, L; Bai, CR; Liu, L; Long, H; Shi, L; Lin, ZH				Dong, Ling; Yu, Le; Bai, Chunrong; Liu, Liu; Long, Hua; Shi, Lei; Lin, Zhenghong			USP27-mediated Cyclin E stabilization drives cell cycle progression and hepatocellular tumorigenesis	ONCOGENE			English	Article							BREAST-CANCER; E OVEREXPRESSION; PROGNOSTIC-SIGNIFICANCE; S-PHASE; TRANSCRIPTIONAL ACTIVATION; LUNG-CANCER; PROTEIN; EXPRESSION; PHOSPHORYLATION; AMPLIFICATION	Overexpression of Cyclin E has been seen in many types of cancers. However, the underlying mechanism remains enigmatic. Herein, we identified ubiquitin-specific peptidase 27 (USP27) as a Cyclin E interactor. We found that USP27 promoted Cyclin E stability by negatively regulating its ubiquitination. In addition, suppression of USP27 expression resulted in the inhibition of the growth, migration, and invasion of hepatocellular carcinoma. Furthermore, we detected a positive correlation between USP27 and Cyclin E expression in hepatocellular carcinoma tissues. Finally, we found that USP27 expression is inhibited by 5-fluorouracil (5-FU) treatment and USP27 depletion sensitizes Hep3B cells to 5-FU-induced apoptosis. USP27-mediated Cyclin E stabilization is involved in tumorigenesis, suggesting that targeting USP27 may represent a new therapeutic strategy to treat cancers with aberrant overexpression of Cyclin E protein.	[Dong, Ling; Yu, Le; Bai, Chunrong; Liu, Liu; Long, Hua; Shi, Lei; Lin, Zhenghong] Chongqing Univ, Sch Life Sci, Lab Pathol, Chongqing 401331, Peoples R China	Chongqing University	Lin, ZH (corresponding author), Chongqing Univ, Sch Life Sci, Lab Pathol, Chongqing 401331, Peoples R China.	zhenghonglin@cqu.edu.cn		Lin, Zhenghong/0000-0002-6354-0042	National Natural Science Foundation of China [31571454]; Fundamental Research Funds for the Central Universities [106112017CDJQJ298833]; starting funds of '100 talent scholar program' from Chongqing University	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Fundamental Research Funds for the Central Universities(Fundamental Research Funds for the Central Universities); starting funds of '100 talent scholar program' from Chongqing University	This study was supported by the National Natural Science Foundation of China (Grant Number 31571454 to Z. Lin), the Fundamental Research Funds for the Central Universities (Project Number 106112017CDJQJ298833 to Z. Lin), and the starting funds of '100 talent scholar program' from Chongqing University.	Atanassov BS, 2016, MOL CELL, V62, P558, DOI 10.1016/j.molcel.2016.03.030; Berglund P, 2005, CANCER RES, V65, P9727, DOI 10.1158/0008-5472.CAN-04-3984; Bloom J, 2007, NAT REV MOL CELL BIO, V8, P149, DOI 10.1038/nrm2105; Das T, 2017, NUCLEIC ACIDS RES, V45, P5010, DOI 10.1093/nar/gkx062; Dong YY, 2000, CLIN CANCER RES, V6, P4253; Ear PH, 2013, P NATL ACAD SCI USA, V110, P15716, DOI 10.1073/pnas.1305420110; Erlanson M, 2001, LEUKEMIA LYMPHOMA, V40, P461, DOI 10.3109/10428190109097645; Fukuse T, 2000, CANCER RES, V60, P242; Geng Y, 1996, ONCOGENE, V12, P1173; Huang XD, 2011, MOL CELL, V42, P511, DOI 10.1016/j.molcel.2011.03.027; Hwang HC, 2005, ONCOGENE, V24, P2776, DOI 10.1038/sj.onc.1208613; Iida H, 1997, BLOOD, V90, P3707, DOI 10.1182/blood.V90.9.3707; Keyomarsi K, 2002, NEW ENGL J MED, V347, P1566, DOI 10.1056/NEJMoa021153; KEYOMARSI K, 1993, P NATL ACAD SCI USA, V90, P1112, DOI 10.1073/pnas.90.3.1112; KEYOMARSI K, 1995, ONCOGENE, V11, P941; Koepp DM, 2001, SCIENCE, V294, P173, DOI 10.1126/science.1065203; Lin ZH, 2015, CELL DISCOV, V1, DOI 10.1038/celldisc.2015.28; Lin ZH, 2013, CELL REP, V5, P1639, DOI 10.1016/j.celrep.2013.11.029; Lin ZH, 2012, MOL CELL, V46, P484, DOI 10.1016/j.molcel.2012.03.024; Loog M, 2005, NATURE, V434, P104, DOI 10.1038/nature03329; Luhtala S, 2016, TUMOR BIOL, V37, P9813, DOI 10.1007/s13277-016-4870-z; Minella AC, 2002, CURR BIOL, V12, P1817, DOI 10.1016/S0960-9822(02)01225-3; Moberg KH, 2001, NATURE, V413, P311, DOI 10.1038/35095068; Molendini L, 1998, INT J ONCOL, V12, P1007; Muller-Tidow C, 2001, CANCER RES, V61, P647; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; RESNITZKY D, 1995, MOL CELL BIOL, V15, P4347; Sanchez I, 2005, SEMIN CELL DEV BIOL, V16, P311, DOI 10.1016/j.semcdb.2005.02.007; Santoni-Rugiu E, 2000, MOL CELL BIOL, V20, P3497, DOI 10.1128/MCB.20.10.3497-3509.2000; Schraml P, 2003, J PATHOL, V200, P375, DOI 10.1002/path.1356; Shan J, 2009, MOL CELL, V36, P469, DOI 10.1016/j.molcel.2009.10.018; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Singer JD, 1999, GENE DEV, V13, P2375, DOI 10.1101/gad.13.18.2375; Siu KT, 2012, CELL CYCLE, V11, P57, DOI 10.4161/cc.11.1.18775; Spruck CH, 1999, NATURE, V401, P297, DOI 10.1038/45836; Strohmaier H, 2001, NATURE, V413, P316, DOI 10.1038/35095076; Swaffer MP, 2016, CELL, V167, P1750, DOI 10.1016/j.cell.2016.11.034; Tissier F, 2004, EUR J ENDOCRINOL, V150, P809, DOI 10.1530/eje.0.1500809; Wickliffe K, 2009, CHEM REV, V109, P1537, DOI 10.1021/cr800414e; Wolowiec D, 1996, BRIT J HAEMATOL, V95, P518, DOI 10.1046/j.1365-2141.1996.d01-1930.x; Yasui W, 1996, J Exp Ther Oncol, V1, P88; Yasui W, 1996, VIRCHOWS ARCH, V429, P13	42	30	36	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2018	37	20					2702	2713		10.1038/s41388-018-0137-z	http://dx.doi.org/10.1038/s41388-018-0137-z			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GG2TH	29497124	Green Published, hybrid			2022-12-17	WOS:000432545100007
J	Liu, Y; Zhou, H; Zhu, R; Ding, F; Li, Y; Cao, X; Liu, Z				Liu, Y.; Zhou, H.; Zhu, R.; Ding, F.; Li, Y.; Cao, X.; Liu, Z.			SPSB3 targets SNAIL for degradation in GSK-3 beta phosphorylation-dependent manner and regulates metastasis	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; OVARIAN-CANCER CELLS; C-MYC; PROTEASOMAL DEGRADATION; TRANSCRIPTION FACTORS; UBIQUITIN LIGASE; TUMOR RECURRENCE; PROGRESSION; STABILITY; LINES	Epithelial-mesenchymal transition (EMT) is a process during which normal epithelial cells acquire mesenchymal characteristics. EMT has a critical role in various human diseases especially in cancer. EMT facilitates tumor initiation and progression by mediating cancer cell stemness and motility. Zinc finger transcription factor SNAIL is one of the most important initiators of EMT. Therefore, it is of great significance to understand the regulating mechanism of SNAIL. In this study, we carried out a luciferase-based genome-wide screening using small interfering RNA library against similar to 200 of E3 ligases and ubiquitin-related genes and identified SOCS box protein SPSB3 as a novel E3 ligase component that targets SNAIL into polyubiquitination and degradation in response to GSK-3 beta phosphorylation of SNAIL. Functionally, we observed that SPSB3 overexpression greatly inhibits tumor metastasis by regulating SNAIL degradation both in vitro and in vivo. The expression of SPSB3 and SNAIL are negatively correlated in human esophageal squamous cell carcinoma tissues, and low SPSB3 expression indicates lymph node metastasis. Moreover, high SPSB3 expression indicates good survivals in various kinds of cancer. Collectively, these findings suggest that SPSB3-mediated SNAIL degradation has a vital role in regulating EMT and cancer progression.	[Liu, Y.; Zhou, H.; Zhu, R.; Ding, F.; Li, Y.; Liu, Z.] Chinese Acad Med Sci, Canc Hosp, Natl Canc Ctr, State Key Lab Mol Oncol, Beijing 100021, Peoples R China; [Liu, Y.; Zhou, H.; Zhu, R.; Ding, F.; Li, Y.; Liu, Z.] Peking Union Med Coll, Beijing 100021, Peoples R China; [Cao, X.] Nanjing Med Univ, Nanjing Hosp 1, Dept Surg Oncol, Nanjing, Jiangsu, Peoples R China	Chinese Academy of Medical Sciences - Peking Union Medical College; Cancer Institute & Hospital - CAMS; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; Nanjing Medical University	Liu, Z (corresponding author), Chinese Acad Med Sci, Canc Hosp, Natl Canc Ctr, State Key Lab Mol Oncol, Beijing 100021, Peoples R China.; Liu, Z (corresponding author), Peking Union Med Coll, Beijing 100021, Peoples R China.	liuzh@cicams.ac.cn	Liu, Yongshuo/AGZ-8274-2022; Liu, Yongshuo/GRX-6416-2022	Liu, Yongshuo/0000-0001-8190-0139; Liu, Yongshuo/0000-0001-8190-0139	National Key R&D program of China [2016YFC1302100, 2013CB911004]; National Science Foundation of China [81420108025]; CAMS Initiative for Innovative Medicine [2016-I2M-1-001]	National Key R&D program of China; National Science Foundation of China(National Natural Science Foundation of China (NSFC)); CAMS Initiative for Innovative Medicine	We thank Professor Binhua P Zhou (University of Kentucky College of Medicine, Lexington, KY, USA) for kindly providing the plasmids of WT-GSK-3 beta and KD-GSK-3 beta. This work was supported by grants from the National Key R&D program of China (2016YFC1302100, 2013CB911004), the National Science Foundation of China (81420108025) and CAMS Initiative for Innovative Medicine (2016-I2M-1-001).	Barrallo-Gimeno A, 2005, DEVELOPMENT, V132, P3151, DOI 10.1242/dev.01907; Bastea LI, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030459; Bruyere F, 2010, UROL ONCOL-SEMIN ORI, V28, P591, DOI 10.1016/j.urolonc.2008.11.005; Cardozo T, 2004, NAT REV MOL CELL BIO, V5, P739, DOI 10.1038/nrm1471; De Craene B, 2013, NAT REV CANCER, V13, P97, DOI 10.1038/nrc3447; Diaz VM, 2014, CELL ADHES MIGR, V8, P418, DOI 10.4161/19336918.2014.969998; Du C, 2010, CANCER RES, V70, P7810, DOI 10.1158/0008-5472.CAN-09-4481; Felipe Lima J, 2016, J CLIN MED, V5; Gyorffy B, 2010, BREAST CANCER RES TR, V123, P725, DOI 10.1007/s10549-009-0674-9; Jin Y, 2015, CANCER LETT, V362, P70, DOI 10.1016/j.canlet.2015.03.037; Kurrey NK, 2009, STEM CELLS, V27, P2059, DOI 10.1002/stem.154; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Marino N, 2012, CANCER METAST REV, V31, P593, DOI 10.1007/s10555-012-9374-8; Mei ZC, 2015, J BIOL CHEM, V290, P16202, DOI 10.1074/jbc.M115.645978; Moody SE, 2005, CANCER CELL, V8, P197, DOI 10.1016/j.ccr.2005.07.009; Nishiya T, 2011, J BIOL CHEM, V286, P9009, DOI 10.1074/jbc.M110.190678; Okumura F, 2016, CELL DIV, V11, DOI 10.1186/s13008-016-0016-3; Pantel K, 2004, NAT REV CANCER, V4, P448, DOI 10.1038/nrc1370; Paul I, 2013, ONCOGENE, V32, P1284, DOI 10.1038/onc.2012.144; Peinado H, 2007, NAT REV CANCER, V7, P415, DOI 10.1038/nrc2131; Pon YL, 2008, CANCER RES, V68, P6524, DOI 10.1158/0008-5472.CAN-07-6302; Popov N, 2010, NAT CELL BIOL, V12, P973, DOI 10.1038/ncb2104; Santner SJ, 2001, BREAST CANCER RES TR, V65, P101, DOI 10.1023/A:1006461422273; Sarikas A, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-4-220; SHIMADA Y, 1992, CANCER, V69, P277, DOI 10.1002/1097-0142(19920115)69:2<277::AID-CNCR2820690202>3.0.CO;2-C; Steeg PS, 2016, NAT REV CANCER, V16, P201, DOI 10.1038/nrc.2016.25; Tang Y, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0163324; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Tian YY, 2010, J BIOL CHEM, V285, P7986, DOI 10.1074/jbc.M109.062877; Vinas-Castells R, 2014, NUCLEIC ACIDS RES, V42, P1079, DOI 10.1093/nar/gkt935; Vinas-Castells R, 2010, J BIOL CHEM, V285, P3794, DOI 10.1074/jbc.M109.065995; Wan LL, 2013, NAT MED, V19, P1450, DOI 10.1038/nm.3391; Wang YF, 2013, CURR CANCER DRUG TAR, V13, P963, DOI 10.2174/15680096113136660102; Welcker M, 2004, P NATL ACAD SCI USA, V101, P9085, DOI 10.1073/pnas.0402770101; Wu Y, 2009, CANCER CELL, V15, P416, DOI 10.1016/j.ccr.2009.03.016; Yang ZB, 2005, CANCER RES, V65, P3179, DOI 10.1158/0008-5472.CAN-04-3480; Zhang K, 2012, EMBO J, V31, P29, DOI 10.1038/emboj.2011.357; Zheng HQ, 2014, CANCER CELL, V26, P358, DOI 10.1016/j.ccr.2014.07.022; Zhou BHP, 2004, NAT CELL BIOL, V6, P931, DOI 10.1038/ncb1173; Zhou H, 2017, ONCOGENE, V36, P3312, DOI 10.1038/onc.2016.479	40	30	31	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 8	2018	37	6					768	776		10.1038/onc.2017.370	http://dx.doi.org/10.1038/onc.2017.370			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FV5ND	29059170				2022-12-17	WOS:000424628100008
J	He, Y; Zhao, Y; Wang, L; Bohrer, LR; Pan, Y; Huang, H				He, Y.; Zhao, Y.; Wang, L.; Bohrer, L. R.; Pan, Y.; Huang, H.			LSD1 promotes S-phase entry and tumorigenesis via chromatin co-occupation with E2F1 and selective H3K9 demethylation	ONCOGENE			English	Article							ONCOGENE-INDUCED SENESCENCE; LARGE GENE LISTS; HISTONE DEMETHYLASE; DNA-DAMAGE; CELLULAR SENESCENCE; STRUCTURAL BASIS; PHOSPHORYLATION; TRANSCRIPTION; MECHANISM; COMPLEX	Histone H3 lysine-9 (H3K9) methylation is essential for retinoblastoma protein (RB)-mediated heterochromatin formation, epigenetic silencing of S-phase genes and permanent cell cycle arrest or cellular senescence. Besides as an H3K4 demethylase, lysine-specific demethylase-1 (LSD1) has been shown to promote H3K9 demethylation. However, it is unexplored whether LSD1 has a causal role in regulating cell cycle entry and senescence. Here we demonstrate that genetic depletion or pharmacological inhibition of LSD1 triggers G1 arrest and cellular senescence. Genome-wide chromatin immunoprecipitation-sequencing analysis reveals that LSD1 binding sites overlap significantly with those bound by the S-phase gene transcription factor E2F1. Gene ontology analysis demonstrates that a large portion of E2F1 and LSD1 cotargeted genes are involved in cell cycle and proliferation. Further analyses show that depletion of LSD1 increases the level of H3K9me2 and thereby represses expression of the LSD1-E2F1 cotarget genes, but has no effects on H3K4me2 level in those loci. In contrast, knockdown of the H3K4me2 reader PHF8 decreases the H3K4me2 level at the LSD1-E2F1 cotargeted loci, but this effect is rescued by codepletion of LSD1. Furthermore, the enzymatic activity of LSD1 is essential for H3K9me2 demethylation at cell cycle gene loci. Notably, cotreatment of chemotherapeutic agent camptothecin enhanced LSD1 inhibitor-induced senescence and growth inhibition of cancer cells in vitro and in mice. Our data reveal LSD1 as a molecular rheostat selectively regulating H3K9 demethylation at cell cycle gene loci, thereby representing a key player in oncogenesis and a viable target for cancer therapy.	[He, Y.; Zhao, Y.; Wang, L.; Pan, Y.; Huang, H.] Mayo Clin, Coll Med, Dept Biochem & Mol Biol, 200 First St SW,Gugg 1311B, Rochester, MN 55905 USA; [Bohrer, L. R.] Univ Minnesota, Masonic Canc Ctr, Minneapolis, MN USA; [Wang, L.] Mayo Clin, Coll Med, Div Biomed Stat & Informat, Rochester, MN 55905 USA; [Huang, H.] Mayo Clin, Coll Med, Dept Urol, Rochester, MN 55905 USA; [Huang, H.] Mayo Clin, Coll Med, Canc Ctr, Rochester, MN 55905 USA	Mayo Clinic; University of Minnesota System; University of Minnesota Twin Cities; Mayo Clinic; Mayo Clinic; Mayo Clinic	Huang, H (corresponding author), Mayo Clin, Coll Med, Dept Biochem & Mol Biol, 200 First St SW,Gugg 1311B, Rochester, MN 55905 USA.	huang.haojie@mayo.edu	Zhao, Yu/GQR-1394-2022; zhao, yu/AAD-9494-2021	Wang, Liguo/0000-0003-2072-4826	National Institutes of Health [CA134514, CA130908, CA193239]; Department of Defense [W81XWH-09-1-622]	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Department of Defense(United States Department of Defense)	We thank Binhua Zhou for plasmids. This work was supported in part by grants from the National Institutes of Health (CA134514, CA130908 and CA193239 to HH) and the Department of Defense (W81XWH-09-1-622 to HH).	Adamo A, 2011, NAT CELL BIOL, V13, P652, DOI 10.1038/ncb2246; Bartkova J, 2006, NATURE, V444, P633, DOI 10.1038/nature05268; Ben-Porath I, 2005, INT J BIOCHEM CELL B, V37, P961, DOI 10.1016/j.biocel.2004.10.013; Campisi J, 2011, CURR OPIN GENET DEV, V21, P107, DOI 10.1016/j.gde.2010.10.005; Chau CM, 2008, J VIROL, V82, P3428, DOI 10.1128/JVI.01412-07; Chen SA, 2010, NAT CELL BIOL, V12, P1108, DOI 10.1038/ncb2116; Di Micco R, 2006, NATURE, V444, P638, DOI 10.1038/nature05327; Forneris F, 2007, J BIOL CHEM, V282, P20070, DOI 10.1074/jbc.C700100200; Forneris F, 2006, J BIOL CHEM, V281, P35289, DOI 10.1074/jbc.M607411200; Garcia-Bassets I, 2007, CELL, V128, P505, DOI 10.1016/j.cell.2006.12.038; Gargiulo G, 2013, CANCER CELL, V23, P660, DOI 10.1016/j.ccr.2013.03.030; Gu L, 2015, NAT GENET, V47, P22, DOI 10.1038/ng.3165; Haberle V, 2014, NATURE, V507, P381, DOI 10.1038/nature12974; Heintzman ND, 2007, NAT GENET, V39, P311, DOI 10.1038/ng1966; Hou HF, 2010, CURR OPIN STRUC BIOL, V20, P739, DOI 10.1016/j.sbi.2010.09.006; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Huang DW, 2009, NUCLEIC ACIDS RES, V37, P1, DOI 10.1093/nar/gkn923; Huang HJ, 2006, SCIENCE, V314, P294, DOI 10.1126/science.1130512; Krizhanovsky V, 2008, CELL, V134, P657, DOI 10.1016/j.cell.2008.06.049; Kuppuswamy M, 2008, MOL CELL BIOL, V28, P269, DOI 10.1128/MCB.01077-07; Langmead B, 2012, NAT METHODS, V9, P357, DOI [10.1038/nmeth.1923, 10.1038/NMETH.1923]; Laurent B, 2015, MOL CELL, V57, P957, DOI 10.1016/j.molcel.2015.01.010; Lee MG, 2005, NATURE, V437, P432, DOI 10.1038/nature04021; Liang Y, 2009, NAT MED, V15, P1312, DOI 10.1038/nm.2051; Lim S, 2010, CARCINOGENESIS, V31, P512, DOI 10.1093/carcin/bgp324; Lin AW, 1998, GENE DEV, V12, P3008, DOI 10.1101/gad.12.19.3008; Lin YW, 2010, EMBO J, V29, P1803, DOI 10.1038/emboj.2010.63; Liu W, 2010, NATURE, V466, P508, DOI 10.1038/nature09272; Lowe SW, 2004, NATURE, V432, P307, DOI 10.1038/nature03098; Mallette FA, 2007, GENE DEV, V21, P43, DOI 10.1101/gad.1487307; McLean CY, 2010, NAT BIOTECHNOL, V28, P495, DOI 10.1038/nbt.1630; Meloni AR, 1999, P NATL ACAD SCI USA, V96, P9574, DOI 10.1073/pnas.96.17.9574; Metzger E, 2005, NATURE, V437, P436, DOI 10.1038/nature04020; Metzger E, 2010, NATURE, V464, P792, DOI 10.1038/nature08839; Mohammad HP, 2015, CANCER CELL, V28, P57, DOI 10.1016/j.ccell.2015.06.002; Nair SS, 2010, EMBO REP, V11, P438, DOI 10.1038/embor.2010.62; Narita M, 2003, CELL, V113, P703, DOI 10.1016/S0092-8674(03)00401-X; Nielsen SJ, 2001, NATURE, V412, P561, DOI 10.1038/35087620; Perillo B, 2008, SCIENCE, V319, P202, DOI 10.1126/science.1147674; Schmitt CA, 2002, CELL, V109, P335, DOI 10.1016/S0092-8674(02)00734-1; Sharpless NE, 2015, NAT REV CANCER, V15, P397, DOI 10.1038/nrc3960; Shi YJ, 2004, CELL, V119, P941, DOI 10.1016/j.cell.2004.12.012; Shi YJ, 2003, NATURE, V422, P735, DOI 10.1038/nature01550; Stavropoulos P, 2006, NAT STRUCT MOL BIOL, V13, P626, DOI 10.1038/nsmb1113; Vigo E, 1999, MOL CELL BIOL, V19, P6379; Wang JX, 2007, NATURE, V446, P882, DOI 10.1038/nature05671; Wang Y, 2009, CELL, V138, P660, DOI 10.1016/j.cell.2009.05.050; Yang MJ, 2006, MOL CELL, V23, P377, DOI 10.1016/j.molcel.2006.07.012; Zhang BJ, 2016, NATURE, V537, P553, DOI 10.1038/nature19361; Zhang L, 2006, ONCOGENE, V25, P2615, DOI 10.1038/sj.onc.1209286; Zhang RG, 2005, DEV CELL, V8, P19, DOI 10.1016/j.devcel.2004.10.019; Zhang Y, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-9-r137	52	30	30	2	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 25	2018	37	4					534	543		10.1038/onc.2017.353	http://dx.doi.org/10.1038/onc.2017.353			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FT7KP	28991226				2022-12-17	WOS:000423331600011
J	Conduit, SE; Ramaswamy, V; Remke, M; Watkins, DN; Wainwright, BJ; Taylor, MD; Mitchell, CA; Dyson, JM				Conduit, S. E.; Ramaswamy, V.; Remke, M.; Watkins, D. N.; Wainwright, B. J.; Taylor, M. D.; Mitchell, C. A.; Dyson, J. M.			A compartmentalized phosphoinositide signaling axis at cilia is regulated by INPP5E to maintain cilia and promote Sonic Hedgehog medulloblastoma	ONCOGENE			English	Article							INOSITOL-POLYPHOSPHATE 5-PHOSPHATASE; COUPLED RECEPTOR GPR161; CEREBELLAR DEVELOPMENT; TUMOR-SUPPRESSOR; MOUSE MODEL; PROTEIN TRAFFICKING; TRANSITION ZONE; PATHWAY; GROWTH; CELLS	Sonic Hedgehog (SHH) signaling at primary cilia drives the proliferation and progression of a subset of medulloblastomas, the most common malignant paediatric brain tumor. Severe side effects associated with conventional treatments and resistance to targeted therapies has led to the need for new strategies. SHH signaling is dependent on primary cilia for signal transduction suggesting the potential for cilia destabilizing mechanisms as a therapeutic target. INPP5E is an inositol polyphosphate 5-phosphatase that hydrolyses PtdIns(4,5)P-2 and more potently, the phosphoinositide (PI) 3-kinase product PtdIns(3,4,5)P-3. INPP5E promotes SHH signaling during embryonic development via PtdIns(4,5)P-2 hydrolysis at cilia, that in turn regulates the cilia recruitment of the SHH suppressor GPR161. However, the role INPP5E plays in cancer is unknown and the contribution of PI3-kinase signaling to cilia function is little characterized. Here, we reveal INPP5E promotes SHH signaling in SHH medulloblastoma by negatively regulating a cilia-compartmentalized PI3-kinase signaling axis that maintains primary cilia on tumor cells. Conditional deletion of Inpp5e in a murine model of constitutively active Smoothened-driven medulloblastoma slowed tumor progression, suppressed cell proliferation, reduced SHH signaling and promoted tumor cell cilia loss. PtdIns(3,4,5)P-3, its effector pAKT and the target pGSK3 beta, which when non-phosphorylated promotes cilia assembly/stability, localized to tumor cell cilia. The number of PtdIns(3,4,5)P-3/pAKT/pGSK3 beta-positive cilia was increased in cultured Inpp5e-null tumor cells relative to controls. PI3-kinase inhibition or expression of wild-type, but not catalytically inactive HA-INPP5E partially rescued cilia loss in Inpp5e-null tumor cells in vitro. INPP5E mRNA and copy number were reduced in human SHH medulloblastoma compared to other molecular subtypes and consistent with the murine model, reduced INPP5E was associated with improved overall survival. Therefore our study identifies a compartmentalized PtdIns(3,4,5)P-3/AKT/GSK3 beta signaling axis at cilia in SHH-dependent medulloblastoma that is regulated by INPP5E to maintain tumor cell cilia, promote SHH signaling and thereby medulloblastoma progression.	[Conduit, S. E.; Mitchell, C. A.; Dyson, J. M.] Monash Univ, Dept Biochem & Mol Biol, Canc Program, Monash Biomed Discovery Inst, Clayton, Vic 3800, Australia; [Ramaswamy, V.] Hosp Sick Children, Div Haematol Oncol, Toronto, ON, Canada; [Remke, M.; Taylor, M. D.] Hosp Sick Children, Arthur & Sonia Labatt Brain Tumor Res Ctr, Toronto, ON, Canada; [Watkins, D. N.] Garvan Inst Med Res, Kinghorn Canc Ctr, Darlinghurst, NSW, Australia; [Watkins, D. N.] UNSW, St Vincents Clin Sch, Fac Med, Darlinghurst, NSW, Australia; [Watkins, D. N.] St Vincents Hosp, Dept Thorac Med, Darlinghurst, NSW, Australia; [Wainwright, B. J.] Univ Queensland, Div Mol Genet & Dev, Inst Mol Biosci, Brisbane, Qld, Australia	Monash University; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); Garvan Institute of Medical Research; University of New South Wales Sydney; St Vincents Hospital Sydney; University of Queensland	Mitchell, CA (corresponding author), Monash Univ, Dept Biochem & Mol Biol, Canc Program, Monash Biomed Discovery Inst, Clayton, Vic 3800, Australia.	christina.mitchell@monash.edu		Ramaswamy, Vijay/0000-0002-6557-895X; Wainwright, Brandon/0000-0003-0406-2092; Taylor, Michael/0000-0001-7009-3466	National Health and Medical Research Council [APP1046174]; Australian Postgraduate Award; Alex's Lemonade Stand; CERN foundation; Pediatric Brain Tumor Foundation; National Institutes of Health [R01CA159859, R01CA148699]; NATIONAL CANCER INSTITUTE [R01CA159859, R01CA148699] Funding Source: NIH RePORTER	National Health and Medical Research Council(National Health and Medical Research Council (NHMRC) of Australia); Australian Postgraduate Award(Australian Government); Alex's Lemonade Stand; CERN foundation; Pediatric Brain Tumor Foundation; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This study utilized the Monash Micro Imaging Facility, Monash University, Victoria, Australia and Monash Histology Platform, Department of Anatomy and Developmental Biology, Monash University, Victoria, Australia. This work was funded by a National Health and Medical Research Council project grant (APP1046174). SEC was supported by an Australian Postgraduate Award. VR is supported by a Young Investigator Award from Alex's Lemonade Stand and a Basic Science Fellowship from the CERN foundation. MDT is supported by grants from the Pediatric Brain Tumor Foundation and the National Institutes of Health (R01CA159859 and R01CA148699).	Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Avasthi P, 2012, DIFFERENTIATION, V83, pS30, DOI 10.1016/j.diff.2011.11.015; Bangs FK, 2015, NAT CELL BIOL, V17, P113, DOI 10.1038/ncb3091; Barakat MT, 2013, CARCINOGENESIS, V34, P1382, DOI 10.1093/carcin/bgt041; Berman DM, 2002, SCIENCE, V297, P1559, DOI 10.1126/science.1073733; Bielas SL, 2009, NAT GENET, V41, P1032, DOI 10.1038/ng.423; Casamayor A, 1999, BIOCHEM J, V342, P287, DOI 10.1042/0264-6021:3420287; Castellino RC, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010849; Chavez M, 2015, DEV CELL, V34, P338, DOI 10.1016/j.devcel.2015.06.016; Chen JK, 2002, P NATL ACAD SCI USA, V99, P14071, DOI 10.1073/pnas.182542899; Cho YJ, 2011, J CLIN ONCOL, V29, P1424, DOI 10.1200/JCO.2010.28.5148; Conduit SE, 2012, FEBS LETT, V586, P2846, DOI 10.1016/j.febslet.2012.07.037; Corbit KC, 2005, NATURE, V437, P1018, DOI 10.1038/nature04117; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Crowther AJ, 2016, CANCER RES, V76, P3211, DOI 10.1158/0008-5472.CAN-15-0025; Crowther AJ, 2013, J NEUROSCI, V33, P18098, DOI 10.1523/JNEUROSCI.2602-13.2013; Dussault AA, 2006, BIOL PROCED ONLINE, V8, P1, DOI 10.1251/bpo114; Dyson JM, 2017, J CELL BIOL, V216, P247, DOI 10.1083/jcb.201511055; Elia D, 2007, BBA-MOL CELL RES, V1773, P1438, DOI 10.1016/j.bbamcr.2007.06.006; Eramo MJ, 2016, BIOCHEM SOC T, V44, P240, DOI 10.1042/BST20150214; Franco I, 2014, DEV CELL, V28, P647, DOI 10.1016/j.devcel.2014.01.022; Frew IJ, 2008, EMBO J, V27, P1747, DOI 10.1038/emboj.2008.96; Frick A, 2012, GLIA, V60, P820, DOI 10.1002/glia.22314; Fruman DA, 2014, NAT REV DRUG DISCOV, V13, P140, DOI 10.1038/nrd4204; Garcia-Gonzalo FR, 2015, DEV CELL, V34, P400, DOI 10.1016/j.devcel.2015.08.001; Ge XC, 2015, ELIFE, V4, DOI [10.7554/eLife.07068.001, 10.7554/eLife.07068]; Hakim S, 2016, HUM MOL GENET, V25, P2295, DOI 10.1093/hmg/ddw097; Hammond GRV, 2009, BIOCHEM J, V422, P23, DOI 10.1042/BJ20090428; Hamze-Komaiha O, 2016, CELL REP, V17, P2738, DOI 10.1016/j.celrep.2016.11.033; Han YG, 2009, NAT MED, V15, P1062, DOI 10.1038/nm.2020; Hatton BA, 2006, CANCER RES, V66, P8655, DOI 10.1158/0008-5472.CAN-06-1621; He XL, 2014, NAT MED, V20, P1035, DOI 10.1038/nm.3666; Heine VM, 2010, CANCER RES, V70, P5220, DOI 10.1158/0008-5472.CAN-10-0554; Higginbotham H, 2013, NAT NEUROSCI, V16, P1000, DOI 10.1038/nn.3451; Hoffmeister H, 2011, J CELL BIOL, V192, P631, DOI 10.1083/jcb.201007050; Hou CZ, 2014, DEV BIOL, V395, P167, DOI 10.1016/j.ydbio.2014.07.007; Hsieh AC, 2004, NUCLEIC ACIDS RES, V32, P893, DOI 10.1093/nar/gkh238; Jacoby M, 2009, NAT GENET, V41, P1027, DOI 10.1038/ng.427; Jensen V, 2015, EMBO J, V34, P2537, DOI 10.15252/embj.201488044; Joo W, 2014, SCIENCE, V346, P626, DOI 10.1126/science.1258996; Julian Elaine, 2010, Neural Dev, V5, P27, DOI 10.1186/1749-8104-5-27; Kim J, 2010, NATURE, V464, P1048, DOI 10.1038/nature08895; Kim JC, 2009, NEURON, V63, P305, DOI 10.1016/j.neuron.2009.07.010; Kisseleva MV, 2000, J BIOL CHEM, V275, P20110, DOI 10.1074/jbc.M910119199; Kisseleva MV, 2002, J BIOL CHEM, V277, P6266, DOI 10.1074/jbc.M105969200; Kong AM, 2000, J BIOL CHEM, V275, P24052, DOI 10.1074/jbc.M000874200; Kong AM, 2006, MOL CELL BIOL, V26, P6065, DOI 10.1128/MCB.00203-06; Kool M, 2014, CANCER CELL, V25, P393, DOI 10.1016/j.ccr.2014.02.004; Lam CW, 1999, ONCOGENE, V18, P833, DOI 10.1038/sj.onc.1202360; Larkins CE, 2011, MOL BIOL CELL, V22, P4694, DOI 10.1091/mbc.E10-12-0994; Lee EY, 2010, P NATL ACAD SCI USA, V107, P9736, DOI 10.1073/pnas.1004602107; Lorenz A, 2011, MOL CELL BIOL, V31, P3326, DOI 10.1128/MCB.05718-11; Luo N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066727; Machold R, 2005, NEURON, V48, P17, DOI 10.1016/j.neuron.2005.08.028; Mao J, 2006, CANCER RES, V66, P10171, DOI 10.1158/0008-5472.CAN-06-0657; Matei V, 2005, DEV DYNAM, V234, P633, DOI 10.1002/dvdy.20551; McCubrey JA, 2014, ONCOTARGET, V5, P2881, DOI 10.18632/oncotarget.2037; Metcalfe C, 2013, CANCER RES, V73, P7034, DOI 10.1158/0008-5472.CAN-13-1222; Mukhopadhyay S, 2013, CELL, V152, P210, DOI 10.1016/j.cell.2012.12.026; Nielsen BS, 2015, J CELL SCI, V128, P3543, DOI 10.1242/jcs.173559; Northcott PA, 2012, NATURE, V488, P49, DOI 10.1038/nature11327; Northcott PA, 2011, J CLIN ONCOL, V29, P1408, DOI 10.1200/JCO.2009.27.4324; Ooms LM, 2015, CANCER CELL, V28, P155, DOI 10.1016/j.ccell.2015.07.003; Otero JJ, 2014, DEV BIOL, V385, P328, DOI 10.1016/j.ydbio.2013.10.019; Pal K, 2016, J CELL BIOL, V212, P861, DOI 10.1083/jcb.201506132; Park J, 2015, CELL REP, V13, P2808, DOI 10.1016/j.celrep.2015.12.009; Pei YX, 2012, DEVELOPMENT, V139, P1724, DOI 10.1242/dev.050104; Plotnikova OV, 2015, J CELL SCI, V128, P364, DOI 10.1242/jcs.161323; Poschl J, 2011, ONCOGENE, V30, P4721, DOI 10.1038/onc.2011.173; Pugacheva EN, 2007, CELL, V129, P1351, DOI 10.1016/j.cell.2007.04.035; Ramaswamy S, 1999, P NATL ACAD SCI USA, V96, P2110, DOI 10.1073/pnas.96.5.2110; Read TA, 2009, CANCER CELL, V15, P135, DOI 10.1016/j.ccr.2008.12.016; Remke M, 2011, J CLIN ONCOL, V29, P3852, DOI 10.1200/JCO.2011.36.2798; Rimkus TK, 2016, CANCERS, V8, DOI 10.3390/cancers8020022; Riobo NA, 2006, P NATL ACAD SCI USA, V103, P4505, DOI 10.1073/pnas.0504337103; Rudin CM, 2009, NEW ENGL J MED, V361, P1173, DOI 10.1056/NEJMoa0902903; Saeed H, 2015, BIOGERONTOLOGY, V16, P733, DOI 10.1007/s10522-015-9596-6; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Schuller U, 2008, CANCER CELL, V14, P123, DOI 10.1016/j.ccr.2008.07.005; Spassky N, 2008, DEV BIOL, V317, P246, DOI 10.1016/j.ydbio.2008.02.026; Thoma CR, 2007, NAT CELL BIOL, V9, P588, DOI 10.1038/ncb1579; Vanhaesebroeck B, 2012, NAT REV MOL CELL BIO, V13, P195, DOI 10.1038/nrm3290; Vanner RJ, 2014, CANCER CELL, V26, P33, DOI 10.1016/j.ccr.2014.05.005; Varnai P, 2005, J CELL SCI, V118, P4879, DOI 10.1242/jcs.02606; Wong SY, 2009, NAT MED, V15, P1055, DOI 10.1038/nm.2011; Yang ZJ, 2008, CANCER CELL, V14, P135, DOI 10.1016/j.ccr.2008.07.003; Yee LE, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1005627; Yeh C, 2013, DEV CELL, V26, P358, DOI 10.1016/j.devcel.2013.07.014; Yip SC, 2008, BIOCHEM J, V411, P441, DOI 10.1042/BJ20071179; Yip SC, 2007, J CELL SCI, V120, P3138, DOI 10.1242/jcs.005298; Zhang H., 2015, EVIDENCE BASED COMPL, V2015, P1; Zhu D, 2009, J CELL SCI, V122, P2760, DOI 10.1242/jcs.046276	92	30	30	1	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 26	2017	36	43					5969	5984		10.1038/onc.2017.208	http://dx.doi.org/10.1038/onc.2017.208			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FK9OT	28650469				2022-12-17	WOS:000413841400006
J	Li, H; Xiao, N; Wang, Y; Wang, R; Chen, Y; Pan, W; Liu, D; Li, S; Sun, J; Zhang, K; Sun, Y; Ge, X				Li, H.; Xiao, N.; Wang, Y.; Wang, R.; Chen, Y.; Pan, W.; Liu, D.; Li, S.; Sun, J.; Zhang, K.; Sun, Y.; Ge, X.			Smurf1 regulates lung cancer cell growth and migration through interaction with and ubiquitination of PIPKI gamma	ONCOGENE			English	Article							PHOSPHATIDYLINOSITOL-PHOSPHATE KINASE; I-GAMMA; LIGASE SMURF1; CADHERIN TRAFFICKING; ACQUIRED-RESISTANCE; SPLICE VARIANT; TALIN HEAD; C2 DOMAIN; TARGETS; PHOSPHORYLATION	Type I. phosphatidylinositol phosphate kinase (PIPKI gamma), a phospholipid kinase generating PIP2, is positively expressed in breast cancer tissues, which correlates intimately with the progression of patients. However, little is known about the expression level of PIPKI. in patients with other cancer types as well as their underlying regulation mechanisms. Here, we report that PIPKI. is highly expressed in lung cancer tissues and its expression level is critical for lung cancer cell proliferation, which may serve as a prognostic marker for lung cancer patients. Meanwhile, we show that E3 ubiquitin ligase Smurf1 directly interacts with PIPKI. and targets PIPKI. for ubiquitination and degradation in lung cancer cells. Also, we discover that Smurf1 directly binds to the kinase domain of PIPKI. via its C2 domain while Lysine 255 in PIPKI. acts as the major ubiquitin acceptor site for Smurf1. In addition, we demonstrate that the phosphorylation mimicking mutant of Smurf1, Smurf1 T306D, prevents PIPKI gamma i2 from ubiquitination and subsequent degradation similar to the effect of forskolin-potentiated cAMP formation, suggesting that Thr306 in Smurf1 is critical for its phosphorylation by PKA. Moreover, PKA-Smurf1-PIPKI. signal transduction takes a significant part in lung cancer cell growth and in vivo tumorigenesis. Thus, we propose that the PKA-Smurf1-PIPKI. pathway has an important role in pulmonary tumorigenesis and imposes substantial clinical impact on development of novel diagnostic markers and therapeutic targets for lung cancer treatment.	[Li, H.; Ge, X.] Tongji Univ, Sch Med, Shanghai Peoples Hosp 10, Dept Clin Lab Med, Shanghai 200072, Peoples R China; [Li, H.] Shanghai Jiao Tong Univ, Sch Med, Shanghai Childrens Med Ctr, Key Lab Pediat Hematol & Oncol,Minist Hlth, Shanghai, Peoples R China; [Li, H.; Xiao, N.; Wang, Y.; Chen, Y.; Pan, W.; Liu, D.; Li, S.; Sun, J.; Zhang, K.] East China Normal Univ, Inst Biomed Sci, Shanghai Key Lab Regulatory Biol, Shanghai, Peoples R China; [Li, H.; Xiao, N.; Wang, Y.; Chen, Y.; Pan, W.; Liu, D.; Li, S.; Sun, J.; Zhang, K.] East China Normal Univ, Sch Life Sci, Shanghai, Peoples R China; [Xiao, N.] Shanghai Jiao Tong Univ, Sch Med, Inst Traumat Med, Shanghai Peoples Hosp 9,Dept Burns & Plast Surg, Shanghai, Peoples R China; [Wang, Y.] Tongji Univ, Sch Med, Shanghai Peoples Hosp 10, Dept Hematol, Shanghai, Peoples R China; [Wang, R.] Fudan Univ, Canc Inst, Canc Hosp, Dept Thorac Surg, Shanghai, Peoples R China; [Sun, Y.] Virginia Commonwealth Univ, Sch Dent, Philips Inst Oral Hlth Res, Richmond, VA USA; [Sun, Y.] Virginia Commonwealth Univ, Massey Canc Ctr, Richmond, VA USA	Tongji University; Shanghai Jiao Tong University; East China Normal University; East China Normal University; Shanghai Jiao Tong University; Tongji University; Fudan University; Virginia Commonwealth University; Virginia Commonwealth University	Ge, X (corresponding author), Tongji Univ, Sch Med, Shanghai Peoples Hosp 10, Dept Clin Lab Med, Shanghai 200072, Peoples R China.	gexx0019@163.com			National Basic Research Program of China (973 program) [2012CB910404, 2010CB529704]; National Natural Science Foundation of China [30971521, 81502559, 81500112, 81602515, 81572645, 30800587, 31171338]; Science and Technology Commission of Shanghai Municipality [11DZ2260300]; Science and Technology Commission of Pudong New Area Foundation [PKJ2016-Y37]	National Basic Research Program of China (973 program)(National Basic Research Program of China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Science and Technology Commission of Shanghai Municipality(Science & Technology Commission of Shanghai Municipality (STCSM)); Science and Technology Commission of Pudong New Area Foundation	We thank Dr Dianqing Wu, Jian Luo, Hongrui, Wang, and Lingqiang Zhang for kindly providing reagents. We also appreciate the assistance from other members of the lab. This work was supported by grants from National Basic Research Program of China (973 program 2012CB910404 and 2010CB529704), National Natural Science Foundation of China (30971521, 81502559, 81500112, 81602515, 81572645, 30800587 and 31171338), grant from the Science and Technology Commission of Shanghai Municipality (11DZ2260300) and the Science and Technology Commission of Pudong New Area Foundation (PKJ2016-Y37).	Akieda-Asai S, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011755; Ayoola A, 2012, CANCER INVEST, V30, P433, DOI 10.3109/07357907.2012.666691; Bairstow SF, 2006, J BIOL CHEM, V281, P20632, DOI 10.1074/jbc.M601465200; Blank M, 2012, NAT MED, V18, P227, DOI 10.1038/nm.2596; Cao Y, 2013, CELL MOL LIFE SCI, V70, P2305, DOI 10.1007/s00018-012-1170-7; Chen C, 2015, ONCOGENE, V34, P4635, DOI 10.1038/onc.2014.393; Chen Z, 2016, BIOCHEMISTRY-US, V55, P3658, DOI 10.1021/acs.biochem.6b00448; Cheng PL, 2011, NEURON, V69, P231, DOI 10.1016/j.neuron.2010.12.021; Di Paolo G, 2004, NATURE, V431, P415, DOI 10.1038/nature02896; Di Paolo G, 2002, NATURE, V420, P85, DOI 10.1038/nature01147; Doughman RL, 2003, J MEMBRANE BIOL, V194, P77, DOI 10.1007/s00232-003-2027-7; Giudici ML, 2004, BIOCHEM J, V379, P489, DOI 10.1042/BJ20031394; Goult BT, 2010, EMBO J, V29, P1069, DOI 10.1038/emboj.2010.4; Heck JN, 2007, CRIT REV BIOCHEM MOL, V42, P15, DOI 10.1080/10409230601162752; Hu J, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9205; Huang C, 2009, NAT CELL BIOL, V11, P624, DOI 10.1038/ncb1868; Ishihara H, 1996, J BIOL CHEM, V271, P23611, DOI 10.1074/jbc.271.39.23611; Ishihara H, 1998, J BIOL CHEM, V273, P8741, DOI 10.1074/jbc.273.15.8741; Jafari N, 2016, J BIOL CHEM, V291, P25729, DOI 10.1074/jbc.M116.742742; Kaur A, 2016, NATURE, V532, P250, DOI 10.1038/nature17392; Kavsak P, 2000, MOL CELL, V6, P1365, DOI 10.1016/S1097-2765(00)00134-9; Krauss M, 2003, J CELL BIOL, V162, P113, DOI 10.1083/jcb.200301006; Lee SY, 2005, J CELL BIOL, V168, P789, DOI 10.1083/jcb.200409028; Leslie NR, 2008, ONCOGENE, V27, P5464, DOI 10.1038/onc.2008.243; Li BS, 2015, NAT MED, V21, P563, DOI 10.1038/nm.3840; Li X, 2013, J CELL SCI, V126, P2617, DOI 10.1242/jcs.117044; Ling K, 2003, J CELL BIOL, V163, P1339, DOI 10.1083/jcb.200310067; Ling K, 2002, NATURE, V420, P89, DOI 10.1038/nature01082; Ling K, 2007, J CELL BIOL, V176, P343, DOI 10.1083/jcb.200606023; Ling K, 2006, TRENDS CELL BIOL, V16, P276, DOI 10.1016/j.tcb.2006.03.007; Liu N, 2010, J BIOL CHEM, V285, P18858, DOI 10.1074/jbc.M109.099440; Loijens JC, 1996, J BIOL CHEM, V271, P32937, DOI 10.1074/jbc.271.51.32937; Lu KF, 2008, NAT CELL BIOL, V10, P994, DOI 10.1038/ncb1760; Lu KF, 2011, J BIOL CHEM, V286, P16861, DOI 10.1074/jbc.M110.211979; Maddika S, 2011, NAT CELL BIOL, V13, P728, DOI 10.1038/ncb2240; Nader GPF, 2016, NAT CELL BIOL, V18, P491, DOI 10.1038/ncb3333; Nakayama KI, 2006, NAT REV CANCER, V6, P369, DOI 10.1038/nrc1881; Le OTT, 2015, BBA-MOL CELL RES, V1853, P2432, DOI 10.1016/j.bbamcr.2015.07.001; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Pan J, 2015, ONCOGENE, V34, P3957, DOI 10.1038/onc.2014.327; Pan WJ, 2008, SCIENCE, V321, P1350, DOI 10.1126/science.1160741; Plant PJ, 1997, J BIOL CHEM, V272, P32329, DOI 10.1074/jbc.272.51.32329; Rathert P, 2015, NATURE, V525, P543, DOI 10.1038/nature14898; RECHSTEINER M, 1987, ANNU REV CELL BIOL, V3, P1, DOI 10.1146/annurev.cb.03.110187.000245; Rotin D, 2009, NAT REV MOL CELL BIO, V10, P398, DOI 10.1038/nrm2690; Sahai E, 2007, J CELL BIOL, V176, P35, DOI 10.1083/jcb.200605135; Sangadala S, 2007, J BIOMOL STRUCT DYN, V25, P11, DOI 10.1080/07391102.2007.10507151; Sasaki J, 2005, J EXP MED, V201, P859, DOI 10.1084/jem.20041891; Schill NJ, 2014, J CELL SCI, V127, P2189, DOI 10.1242/jcs.132423; Schill NJ, 2009, BIOCHEM J, V422, P473, DOI 10.1042/BJ20090638; Schill NJ, 2009, BIOCHEM J, V418, P247, DOI 10.1042/BJ20081844; Sun Y, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2471; Suzuki C, 2002, J BIOL CHEM, V277, P39919, DOI 10.1074/jbc.M201901200; Thapa N, 2017, ONCOGENE, V36, P899, DOI 10.1038/onc.2016.267; Wan LX, 2011, MOL CELL, V44, P721, DOI 10.1016/j.molcel.2011.09.024; Wang HR, 2003, SCIENCE, V302, P1775, DOI 10.1126/science.1090772; Wang YF, 2008, P NATL ACAD SCI USA, V105, P14064, DOI 10.1073/pnas.0804139105; Wang YF, 2007, P NATL ACAD SCI USA, V104, P11748, DOI 10.1073/pnas.0700019104; Wang YJ, 2004, J CELL BIOL, V167, P1005, DOI 10.1083/jcb.200408008; Wieffer M, 2012, METHOD CELL BIOL, V108, P209, DOI 10.1016/B978-0-12-386487-1.00011-0; Wiesner S, 2007, CELL, V130, P651, DOI 10.1016/j.cell.2007.06.050; Williamson A, 2013, MOL CELL, V49, P591, DOI 10.1016/j.molcel.2013.01.028; Xia Y, 2011, BIOCHEM BIOPH RES CO, V411, P416, DOI 10.1016/j.bbrc.2011.06.168; Xiao N, 2012, BIOCHEM J, V441, P979, DOI 10.1042/BJ20111358; Xu WW, 2010, IMMUNITY, V33, P340, DOI 10.1016/j.immuni.2010.08.015; Yamaguchi K, 2008, BIOL CHEM, V389, P405, DOI 10.1515/BC.2008.036; Yamashita M, 2005, CELL, V121, P101, DOI 10.1016/j.cell.2005.01.035; Yoon YD, 2012, J BIOL CHEM, V287, P34078, DOI 10.1074/jbc.M112.372789; Yu YL, 2011, J BIOL CHEM, V286, P9657, DOI 10.1074/jbc.M110.185124; Zhu HT, 1999, NATURE, V400, P687, DOI 10.1038/23293	70	30	30	0	19	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 12	2017	36	41					5668	5680		10.1038/onc.2017.166	http://dx.doi.org/10.1038/onc.2017.166			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FJ6DJ	28581524				2022-12-17	WOS:000412843900002
